{"meta":{"query_hash":"9ec9f971cebb","filters":{"topic":"Psoriasis: Treatment and Pathogenesis"},"cohort_total":2393,"direct_labels_cover":8,"predictions_cover":2393,"exported":2393,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9ec9f971cebb","api":"https://metacan.xera.ac/api/v1/cohort?topic=Psoriasis%3A+Treatment+and+Pathogenesis"},"results":[{"id":"W107859310","doi":"","title":"Treatment of severe facial psoriasis with adalimumab.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Dermatology; Psoriatic arthritis; Acitretin; Psoriasis Area and Severity Index; Family history; Body surface area; Disease; Surgery; Internal medicine","score_opus":0.027764377195289687,"score_gpt":0.20528513347572794,"score_spread":0.17752075628043826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W107859310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918389,0.0017891349,0.0000053280864,0.00007165012,0.0004003371,0.00052075944,0.00010742683,0.000061464794,0.0052050333],"genre_scores_gemma":[0.98997957,0.00039063155,0.000058370286,0.000013614345,0.00005457621,0.0008040413,0.00008718482,0.000014433868,0.00859761],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991434,0.00007360919,0.00017581593,0.00022753414,0.000038104183,0.00034149343],"domain_scores_gemma":[0.9995489,0.00005827797,0.00009036673,0.00023360775,0.00003828042,0.00003056457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000033016266,0.00018377852,0.00031686574,0.00007674018,0.00013244973,0.000002529641,0.000090154375,0.00013815932,0.00013894413],"category_scores_gemma":[0.000009303488,0.00012531278,0.00010967162,0.00012439827,0.00014370387,0.00005233287,0.000012648499,0.000032335083,0.00008853321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00206502,0.00095687003,0.12103955,0.000010416951,0.0015308806,0.00008177166,0.0013132734,0.000007095313,0.0010629212,0.00011914896,0.00085509045,0.870958],"study_design_scores_gemma":[0.009474562,0.0006589563,0.856851,0.0000038341223,0.00034922914,0.0005025547,0.00011619271,1.371936e-7,0.06728512,0.00002215809,0.06445699,0.00027925865],"about_ca_topic_score_codex":0.0001365993,"about_ca_topic_score_gemma":0.000039615825,"teacher_disagreement_score":0.8706787,"about_ca_system_score_codex":0.00006319218,"about_ca_system_score_gemma":0.000041033716,"threshold_uncertainty_score":0.5110107},"labels":[],"label_agreement":null},{"id":"W12986567","doi":"10.1177/120347541201600609","title":"Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice","year":2012,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of British Columbia; Dermatrials Research; Hôpital de l'Enfant-Jésus; Institute of Cosmetic and Laser Surgery; University of Toronto; Université Laval; Lynde Centre for Dermatology; McMaster University","funders":"Pfizer Canada; Amgen Canada; Amgen","keywords":"Medicine; Etanercept; Dermatology Life Quality Index; Psoriasis; Quality of life (healthcare); Post-hoc analysis; Internal medicine; Physical therapy; Patient satisfaction; Psoriasis Area and Severity Index; Surgery; Dermatology; Tumor necrosis factor alpha","score_opus":0.04224354705672438,"score_gpt":0.31814824587429,"score_spread":0.27590469881756563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W12986567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965319,0.0018904728,0.000005641069,0.0008526754,0.00050921674,0.00015204352,0.000007947484,0.000003127529,0.00004696513],"genre_scores_gemma":[0.9976773,0.0017492285,0.00013629417,0.0003040675,0.00006989056,0.000002965285,0.0000068395384,0.000008088533,0.000045287637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803716,0.0005307766,0.0010169273,0.00012680668,0.000087443426,0.00020089324],"domain_scores_gemma":[0.9963528,0.0027890997,0.00055993296,0.000097823715,0.00010719604,0.000093159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011127982,0.00016134176,0.0009476489,0.000244358,0.000031684795,0.0000037449752,0.000026717587,0.00014866487,0.000025088817],"category_scores_gemma":[0.0010445139,0.00009474896,0.000067942936,0.00009930677,0.00007712442,0.00018262702,0.000011305509,0.00015194004,0.0000014447447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071905893,0.0004317176,0.8998463,0.000016196893,0.0003426096,0.000028575807,0.0013160837,0.0000036039537,0.00023451941,0.000006388601,0.00016513995,0.09041828],"study_design_scores_gemma":[0.0041810717,0.0012191196,0.9925131,0.00009629184,0.00017594655,0.0002479461,0.00090673484,4.026902e-7,0.00006259746,0.00000867082,0.00048625914,0.0001018399],"about_ca_topic_score_codex":0.00046906006,"about_ca_topic_score_gemma":0.0002446698,"teacher_disagreement_score":0.09266682,"about_ca_system_score_codex":0.000049639864,"about_ca_system_score_gemma":0.00008711709,"threshold_uncertainty_score":0.38637507},"labels":[],"label_agreement":null},{"id":"W144398792","doi":"","title":"Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research","funders":"","keywords":"Clobetasol propionate; Medicine; Shampoo; Psoriasis; Dermatology; Scalp; Quality of life (healthcare); Dermatology Life Quality Index; Pathology","score_opus":0.01991731191660663,"score_gpt":0.2245451303346969,"score_spread":0.20462781841809025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W144398792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663466,0.00088168104,0.000004427724,0.00013212621,0.00037030023,0.0011718493,0.000080895334,0.000048851223,0.00067521224],"genre_scores_gemma":[0.9988965,0.00003317608,0.000036608137,0.00013804066,0.000027692651,0.00037698162,0.00020305808,0.000012796367,0.00027516866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831414,0.00023948819,0.00050959084,0.0003631717,0.0000796164,0.0004939697],"domain_scores_gemma":[0.99928015,0.00008382082,0.00017729943,0.0003201614,0.00008349334,0.000055084514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035891688,0.0002345568,0.00052116654,0.00013534338,0.000059284223,0.000009837532,0.00019728094,0.00021436496,0.00002478247],"category_scores_gemma":[0.00011875881,0.00017011439,0.00010684536,0.00020037025,0.000066326975,0.0001404895,0.000029239674,0.00013790485,0.000016628715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001958858,0.0008259381,0.556269,0.000018601499,0.00022051821,0.0000013831703,0.00010721276,7.961175e-7,0.0013185422,0.00020058123,0.00016120424,0.4389174],"study_design_scores_gemma":[0.004779777,0.00027349926,0.9887899,0.000012617959,0.00006205997,6.1106175e-7,0.000023383634,1.4893648e-7,0.0054068197,0.00007418357,0.00037155388,0.00020544845],"about_ca_topic_score_codex":0.000107370055,"about_ca_topic_score_gemma":0.00007870388,"teacher_disagreement_score":0.43871194,"about_ca_system_score_codex":0.000057391866,"about_ca_system_score_gemma":0.00004204645,"threshold_uncertainty_score":0.69370633},"labels":[],"label_agreement":null},{"id":"W1483348508","doi":"10.1684/ejd.2014.2294","title":"Recommendations for adjunctive basic skin care in patients with psoriasis","year":2014,"lang":"en","type":"review","venue":"European Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine","score_opus":0.0238314868032277,"score_gpt":0.26365041963733665,"score_spread":0.23981893283410896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1483348508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00065078004,0.9955819,0.00014058687,0.000090127,0.0018507359,0.00064609,0.00023406924,0.000013767428,0.0007918898],"genre_scores_gemma":[0.003964031,0.9929308,0.00078876334,0.000074699936,0.00017167104,0.000040620092,0.0017444849,0.00013237528,0.00015253064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560887,0.0025719274,0.001130933,0.00029298963,0.000041063977,0.00035422013],"domain_scores_gemma":[0.9975013,0.00049565337,0.0013992514,0.00027691675,0.0002861363,0.00004072663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026753324,0.00044156128,0.0019885574,0.0005869314,0.000112773814,0.0000127828525,0.00042001976,0.00022205334,0.000083960316],"category_scores_gemma":[0.000094301955,0.00029521482,0.0005214505,0.00019985772,0.00008897698,0.0000803008,0.00005393531,0.00044682686,0.00016592987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003302194,0.00016656313,0.0005498245,0.0010410261,0.001036305,0.000071098155,0.0003554026,2.819372e-7,1.14652885e-7,0.000047335667,0.00499812,0.9914037],"study_design_scores_gemma":[0.0059365234,0.0007823221,0.0007024315,0.0024346702,0.001659769,0.0006871821,0.00008634301,1.541238e-8,0.0000068198324,0.0000042528177,0.9874238,0.00027591307],"about_ca_topic_score_codex":0.0000011817492,"about_ca_topic_score_gemma":0.000010264084,"teacher_disagreement_score":0.9911278,"about_ca_system_score_codex":0.000109159606,"about_ca_system_score_gemma":0.00021609853,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W1485937383","doi":"10.1111/j.1468-3083.2011.04412.x","title":"Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?","year":2012,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Astellas Pharma; Celgene; Pfizer; Genentech; Amgen","keywords":"Medicine; Adalimumab; Ustekinumab; Infliximab; Etanercept; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Clinical trial; Methotrexate; Randomized controlled trial; Intensive care medicine; Dermatology; Disease; Internal medicine; Tumor necrosis factor alpha","score_opus":0.0945180806812629,"score_gpt":0.34455574239945885,"score_spread":0.25003766171819597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1485937383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017109428,0.980122,0.0000057185944,0.00076049706,0.0013616898,0.0004518671,0.00009906326,0.000008455407,0.00008124457],"genre_scores_gemma":[0.019759549,0.979038,0.000080652244,0.0000584393,0.00041783918,0.000004273196,0.00006873239,0.000036116096,0.0005363686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98886484,0.008483127,0.0016555816,0.00044464038,0.00004611134,0.0005057129],"domain_scores_gemma":[0.99452275,0.002029971,0.0028528937,0.0004413048,0.00005243774,0.000100633624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010534388,0.0005205578,0.0033384864,0.00025937415,0.00014948213,0.00001023119,0.00092637487,0.0011399246,0.000038128943],"category_scores_gemma":[0.00018817557,0.00029193299,0.00056376273,0.00014805557,0.0011014538,0.00018949839,0.00070494367,0.0007967148,0.000018684308],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002814752,0.00026112882,0.008482343,0.00069831515,0.004455908,0.000079907826,0.0003415904,1.4195992e-7,0.000019510479,0.00026704563,0.00067658344,0.98443604],"study_design_scores_gemma":[0.0031809222,0.00035987236,0.0049650264,0.0015368917,0.009951756,0.006167236,0.00028237977,1.2935367e-7,0.00019543101,0.0006236805,0.972458,0.00027869505],"about_ca_topic_score_codex":0.000037782782,"about_ca_topic_score_gemma":0.0000056242175,"teacher_disagreement_score":0.9841574,"about_ca_system_score_codex":0.00004300311,"about_ca_system_score_gemma":0.00021356391,"threshold_uncertainty_score":0.99995327},"labels":[],"label_agreement":null},{"id":"W1488327521","doi":"10.4049/jimmunol.184.supp.134.2","title":"IL-27 promotes Tc1 polarization of human CD8 T lymphocytes and enhances their proliferation and effector functions (134.2)","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cytotoxic T cell; Granzyme B; Interleukin 21; IL-2 receptor; CD28; Biology; Cell biology; Granzyme A; CD8; Natural killer T cell; Interleukin 12; Granzyme; ZAP70; T cell; Interleukin 3; Molecular biology; Perforin; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.008980759869396381,"score_gpt":0.2226324386170556,"score_spread":0.2136516787476592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1488327521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114186,0.007525144,0.0000765485,0.00020689263,0.00079437194,0.0001674403,0.00002415866,0.000010450562,0.00005311046],"genre_scores_gemma":[0.99901426,0.0005465405,0.000048109883,0.000014548276,0.0000636982,0.0000040217174,0.000020913154,0.000008589411,0.00027933685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907464,0.00033990576,0.00033222366,0.00008903812,0.000024680901,0.00013951086],"domain_scores_gemma":[0.99904084,0.00029936628,0.00040008497,0.00014141128,0.000106495616,0.00001178594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004708324,0.0001304118,0.00028241897,0.00013086463,0.00025581202,0.000010857534,0.00011205727,0.00019431626,0.00006732604],"category_scores_gemma":[0.000101542246,0.00007633387,0.000048996717,0.000077896686,0.00037453536,0.00012962102,0.00003945519,0.00021749584,0.000010544095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003386219,0.000081758655,0.008940059,0.0000099228155,0.00041148718,5.5068455e-7,0.000983752,2.1201602e-7,0.97412723,0.0001816811,0.000030120838,0.014894594],"study_design_scores_gemma":[0.0016900168,0.0013324703,0.1159605,0.000030014484,0.0002448165,0.0006204866,0.00032590222,0.0000018742502,0.8787737,0.00033258248,0.00060236227,0.00008526989],"about_ca_topic_score_codex":0.000029538862,"about_ca_topic_score_gemma":0.00006129379,"teacher_disagreement_score":0.10702044,"about_ca_system_score_codex":0.000011215958,"about_ca_system_score_gemma":0.000050873135,"threshold_uncertainty_score":0.31128046},"labels":[],"label_agreement":null},{"id":"W1502501296","doi":"10.4049/jimmunol.0802918","title":"IL-27 Regulates Homeostasis of the Intestinal CD4+ Effector T Cell Pool and Limits Intestinal Inflammation in a Murine Model of Colitis","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Cancer Institute; University of Pennsylvania; Crohn's and Colitis Foundation of America; Crohn's and Colitis Foundation; Thomas Jefferson University; Cancer Research Institute; Burroughs Wellcome Fund","keywords":"Inflammation; Biology; Immunology; Immune system; Proinflammatory cytokine; Innate lymphoid cell; Cytokine; T cell; Colitis; Innate immune system; Homeostasis; Effector; Intestinal mucosa; Cell biology; Medicine; Internal medicine","score_opus":0.012296583625769728,"score_gpt":0.2161165471441656,"score_spread":0.20381996351839587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1502501296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249715,0.0063418234,0.00006109899,0.00059275696,0.00020839302,0.00018837687,0.000017755365,0.000005598875,0.00008703871],"genre_scores_gemma":[0.9987597,0.0007739662,0.00025048424,0.000021919572,0.000020534115,0.00000204763,0.0000045543024,0.000007781433,0.00015904414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839705,0.0005889249,0.00065027515,0.00009426259,0.000050488943,0.00021897728],"domain_scores_gemma":[0.9982216,0.0005701159,0.0007741311,0.00023207173,0.00018932759,0.000012755424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061347603,0.00016772671,0.00045202606,0.00020200231,0.00006710554,0.000003729646,0.0003424913,0.00015412626,0.000025192809],"category_scores_gemma":[0.0002761079,0.00009794712,0.000110613015,0.0001970753,0.00034941884,0.000084060666,0.00006926584,0.00031829093,0.0000046594164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023419154,0.00018077188,0.0032814797,0.00002785849,0.00016853638,0.000004213155,0.0012025726,0.0003211204,0.96198165,0.0002657705,0.00006461647,0.030159518],"study_design_scores_gemma":[0.0025086678,0.0015068533,0.24338415,0.00022801812,0.00022197896,0.0007904777,0.00022816697,0.000063515035,0.74962336,0.0013315438,0.000026864247,0.00008641795],"about_ca_topic_score_codex":0.000045194964,"about_ca_topic_score_gemma":0.000031390748,"teacher_disagreement_score":0.24010268,"about_ca_system_score_codex":0.000041306965,"about_ca_system_score_gemma":0.000094258794,"threshold_uncertainty_score":0.39941677},"labels":[],"label_agreement":null},{"id":"W1508752722","doi":"10.1111/bjd.12110","title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Interleukin 17; Internal medicine; Dose; Randomized controlled trial; Gastroenterology; Concomitant; Clinical trial; Plaque psoriasis; Adverse effect; Immunology; Cytokine; Psoriatic arthritis; Pathology","score_opus":0.02137471321531433,"score_gpt":0.28089163570398684,"score_spread":0.25951692248867253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1508752722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738658,0.022684796,0.00007318718,0.0002286662,0.00046714384,0.0024760803,0.000034611832,0.000007623573,0.00016208511],"genre_scores_gemma":[0.9976514,0.0019486131,0.00007707418,0.00003149748,0.000059101065,0.00015639476,0.000016492988,0.00001707427,0.00004238261],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618,0.0017120356,0.0013926177,0.00018970175,0.00009327147,0.0004323663],"domain_scores_gemma":[0.9976708,0.001218495,0.0007301437,0.00019485517,0.00012699173,0.000058660364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009934241,0.000274233,0.0021081187,0.0003548141,0.00019713926,0.000016008433,0.00023552218,0.0002322416,0.0000616924],"category_scores_gemma":[0.000103451785,0.00019813371,0.00033923134,0.00020018185,0.00016636435,0.00015473357,0.00003869944,0.00020058971,0.0000047858266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94736177,0.009339215,0.001603031,0.00002008684,0.0030909507,0.00043768375,0.014837051,0.000041878116,0.00085256516,0.00011627969,0.00008972289,0.02220975],"study_design_scores_gemma":[0.97060263,0.0018033184,0.0010280756,0.00012517003,0.0014407928,0.018557463,0.002233473,0.0000057533257,0.003710361,0.000026102465,0.00029526805,0.00017159882],"about_ca_topic_score_codex":0.00015211677,"about_ca_topic_score_gemma":0.00012221682,"teacher_disagreement_score":0.023785563,"about_ca_system_score_codex":0.00004722632,"about_ca_system_score_gemma":0.00010221981,"threshold_uncertainty_score":0.8079658},"labels":[],"label_agreement":null},{"id":"W1509149404","doi":"10.4049/jimmunol.178.8.5086","title":"IL-28 Elicits Antitumor Responses against Murine Fibrosarcoma","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"In vivo; Cytotoxic T cell; Spleen; Cytokine; Biology; CD8; Immune system; Fibrosarcoma; Interleukin 12; Cancer research; In vitro; Immunology; Molecular biology; Biochemistry","score_opus":0.016516524512669977,"score_gpt":0.25324926215975857,"score_spread":0.2367327376470886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1509149404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750361,0.02129382,0.00015163347,0.00072194723,0.0017444101,0.00011344443,0.000019968833,0.000028700626,0.00088998635],"genre_scores_gemma":[0.99448097,0.002425125,0.00014930806,0.00022816384,0.00014574509,0.0000012616996,0.000011886734,0.000020575013,0.0025369723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998035,0.00062067434,0.0006655998,0.00012213479,0.00005734905,0.0004992206],"domain_scores_gemma":[0.99796295,0.0009355448,0.0005305178,0.00036682183,0.00017814124,0.000026027157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016596112,0.00022054695,0.00044286397,0.00030145876,0.0002772954,0.000008765347,0.0005703903,0.00023537273,0.00022365517],"category_scores_gemma":[0.00023174493,0.00013622649,0.00019272187,0.0002154885,0.00037202032,0.00010615815,0.00010906138,0.00044685518,0.00036125004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058921985,0.00019240868,0.0019492792,0.000004801119,0.0008908607,0.00016601589,0.00060011016,0.0000030174162,0.9448006,0.00025152205,0.0015286336,0.04372054],"study_design_scores_gemma":[0.00447041,0.001748164,0.16104612,0.000073475145,0.00031303463,0.005865007,0.0010330694,3.449903e-7,0.75416905,0.00024969934,0.07077544,0.00025620803],"about_ca_topic_score_codex":0.000024582843,"about_ca_topic_score_gemma":0.000018702218,"teacher_disagreement_score":0.19063158,"about_ca_system_score_codex":0.00005830044,"about_ca_system_score_gemma":0.00010055491,"threshold_uncertainty_score":0.55551547},"labels":[],"label_agreement":null},{"id":"W1514522696","doi":"","title":"Að lifa með psoriasis er að lifa með einkennum sjúkdómsins : líkamleg, andleg og félagsleg líðan einstaklinga með psoriasis","year":2008,"lang":"is","type":"article","venue":"Skemman","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Dermatology; Medicine; Art","score_opus":0.030400055362911124,"score_gpt":0.24235768841565727,"score_spread":0.21195763305274615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1514522696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9119193,0.0346182,0.00016233178,0.0020869295,0.019482873,0.0022219277,0.0023078322,0.0010692563,0.026131375],"genre_scores_gemma":[0.9001045,0.018516984,0.0012495847,0.0010006829,0.004086371,0.0003700866,0.0020741741,0.0005142089,0.07208337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98731065,0.0017870404,0.0027653126,0.0034461971,0.00070924236,0.003981536],"domain_scores_gemma":[0.992583,0.0009853599,0.0013796886,0.0035355126,0.00071885146,0.0007976153],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0014125961,0.002899431,0.0034341002,0.0013449917,0.003601973,0.00024464127,0.0022056445,0.0036164061,0.007395662],"category_scores_gemma":[0.00055384974,0.0028132584,0.0022075947,0.0018592546,0.0016864653,0.0009911155,0.0008274736,0.0020552834,0.010958958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013248792,0.017633807,0.12569484,0.0011569281,0.042757183,0.0074611846,0.05315802,0.00015285463,0.14618386,0.027463622,0.27006403,0.2950249],"study_design_scores_gemma":[0.020020718,0.003161231,0.040494427,0.0006508356,0.006127429,0.001503784,0.0022748034,0.00004067205,0.08475203,0.0010122103,0.8350001,0.0049617584],"about_ca_topic_score_codex":0.0022791375,"about_ca_topic_score_gemma":0.0018970281,"teacher_disagreement_score":0.5649361,"about_ca_system_score_codex":0.00080230075,"about_ca_system_score_gemma":0.0010935395,"threshold_uncertainty_score":0.9983737},"labels":[],"label_agreement":null},{"id":"W1526655047","doi":"10.4049/jimmunol.178.4.2589","title":"IL-23 Is Critical in the Induction but Not in the Effector Phase of Experimental Autoimmune Encephalomyelitis","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":178,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Experimental autoimmune encephalomyelitis; Myelin oligodendrocyte glycoprotein; Immunology; Multiple sclerosis; Myelin; Biology; Effector; Adoptive cell transfer; Encephalomyelitis; T cell; Central nervous system; Immune system; Endocrinology","score_opus":0.02627990822259144,"score_gpt":0.30848322459159316,"score_spread":0.2822033163690017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1526655047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792805,0.017692221,0.000043617823,0.0015777573,0.0009705967,0.00022297507,0.000020951427,0.000004934308,0.00018646369],"genre_scores_gemma":[0.99904543,0.00046076204,0.000025349493,0.00030503416,0.000084644904,0.000009930577,0.000008688944,0.000008986732,0.00005114917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997064,0.0016350708,0.00072104746,0.00011327437,0.00009183468,0.00037480314],"domain_scores_gemma":[0.99740535,0.0018801187,0.00029736912,0.00033666613,0.000071913426,0.0000085631955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029534511,0.00017861044,0.0003880331,0.000226255,0.00014958515,0.00000836051,0.00069600105,0.00024708358,0.0002001928],"category_scores_gemma":[0.00021422072,0.00008816022,0.00015475135,0.00027388355,0.00063943665,0.000117428164,0.00005171469,0.0006531824,0.000054397697],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002488616,0.0008181515,0.0003205314,0.0000043713153,0.00018614905,0.00005905587,0.011987463,4.959465e-7,0.96867627,0.00064424635,0.00014186214,0.01467281],"study_design_scores_gemma":[0.0072478126,0.0030371582,0.18774253,0.000076630735,0.000188129,0.0037664664,0.02618332,0.0000010527624,0.76906216,0.0002321545,0.002309768,0.00015280518],"about_ca_topic_score_codex":0.00024457483,"about_ca_topic_score_gemma":0.000026355494,"teacher_disagreement_score":0.19961408,"about_ca_system_score_codex":0.000069556765,"about_ca_system_score_gemma":0.000059480863,"threshold_uncertainty_score":0.35950693},"labels":[],"label_agreement":null},{"id":"W1530534806","doi":"10.1111/apt.12491","title":"Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease","year":2013,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"UCB Pharma; F. Hoffmann-La Roche; AstraZeneca; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Medicine; Thiopurine methyltransferase; Psoriasis; Inflammatory bowel disease; Skin cancer; Adverse effect; Dermatology; Rash; Incidence (geometry); Cancer; Internal medicine; Disease","score_opus":0.059805856885040067,"score_gpt":0.3472349550690884,"score_spread":0.2874290981840483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1530534806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01768328,0.9786767,7.3947126e-7,0.00043717583,0.00047663497,0.0024138398,0.00024150276,0.000042495496,0.00002765094],"genre_scores_gemma":[0.0015654535,0.9924706,0.000026774811,0.0041167326,0.000025784684,0.0009519741,0.0007563085,0.000043201562,0.00004316892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996676,0.0013294297,0.000992086,0.000507157,0.00004637196,0.00044891323],"domain_scores_gemma":[0.998378,0.0005006521,0.00056108757,0.00043392638,0.00006226303,0.00006410959],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018188865,0.00056849443,0.0015158403,0.00018129099,0.0001317743,0.000009648742,0.00044703198,0.00040283593,0.00083880854],"category_scores_gemma":[6.8374794e-7,0.0004334562,0.00032313843,0.00018483972,0.00056097476,0.00010103918,0.00016297627,0.0004384658,0.0002029589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015688708,0.0016701224,0.004966492,0.009483814,0.02445289,0.00006744482,0.00017077758,7.232649e-7,0.00680213,0.000074726384,0.0028145039,0.9493395],"study_design_scores_gemma":[0.0028481907,0.00014298537,0.0039270855,0.006034467,0.026235297,0.00017274106,0.000026765263,0.0000020341583,0.0018011129,0.00004805588,0.95811224,0.000648998],"about_ca_topic_score_codex":0.000015687667,"about_ca_topic_score_gemma":9.641378e-7,"teacher_disagreement_score":0.95529777,"about_ca_system_score_codex":0.00006254706,"about_ca_system_score_gemma":0.00016772201,"threshold_uncertainty_score":0.9998117},"labels":[],"label_agreement":null},{"id":"W1537640623","doi":"","title":"Effect van behandeling met UVB op psoriasis","year":2004,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.016012021670452185,"score_gpt":0.2572055623118713,"score_spread":0.24119354064141912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1537640623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9655095,0.026218485,0.00089323096,0.00014680119,0.0025994214,0.00062569545,0.0022694948,0.00022173888,0.0015156695],"genre_scores_gemma":[0.97722185,0.009096883,0.0007567651,0.0002468064,0.0009363883,0.00004528415,0.010775638,0.00010168927,0.0008186763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99492675,0.001263082,0.0007482934,0.0016130635,0.00014718866,0.0013016101],"domain_scores_gemma":[0.9963676,0.0010085132,0.00035478154,0.0020168377,0.00004142672,0.0002108488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00154593,0.0009292275,0.0010847847,0.00022973151,0.0012821974,0.00020279907,0.0018795194,0.0005378252,0.00020100974],"category_scores_gemma":[0.000034170982,0.00079076726,0.00021965861,0.00039997985,0.0002922198,0.0005045796,0.0015352896,0.000638755,0.0006574684],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005341227,0.0012482895,0.04896681,0.0024506622,0.0087769,0.0005525627,0.018247453,0.0031588492,0.03520957,0.00068684574,0.001118621,0.8742422],"study_design_scores_gemma":[0.14679468,0.028940003,0.23781389,0.03432656,0.070130266,0.0062298737,0.022962095,0.031606812,0.090577565,0.011358012,0.29633275,0.022927519],"about_ca_topic_score_codex":0.0019509621,"about_ca_topic_score_gemma":0.0021529165,"teacher_disagreement_score":0.85131466,"about_ca_system_score_codex":0.00007071886,"about_ca_system_score_gemma":0.000097640695,"threshold_uncertainty_score":0.9994543},"labels":[],"label_agreement":null},{"id":"W1540837383","doi":"10.1111/j.1468-3083.2010.03637.x","title":"Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers","year":2010,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of British Columbia; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Galderma","keywords":"Psoriasis; Clobetasol propionate; Scalp; Medicine; Shampoo; Dermatology; Hair follicle; Gene expression; Transcriptome; Gene expression profiling; Gene; Internal medicine; Pathology; Biology; Genetics","score_opus":0.012421193648398362,"score_gpt":0.23837578959684205,"score_spread":0.2259545959484437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1540837383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897457,0.00543748,0.00002494923,0.002628201,0.0015910103,0.000231441,0.000020541702,0.000015468826,0.0003052289],"genre_scores_gemma":[0.9978711,0.000786116,0.00076078484,0.00025928442,0.00013370177,0.0000069594817,0.000008095097,0.000025650046,0.00014833204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964579,0.0018885476,0.00091254816,0.0002702828,0.00007506609,0.00039570875],"domain_scores_gemma":[0.99850404,0.0002911253,0.0008609646,0.00020638734,0.00005433121,0.00008313137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007460935,0.00026695535,0.00061670097,0.00027769967,0.00019134038,0.000007259974,0.000591642,0.0003524385,0.000056881338],"category_scores_gemma":[0.00027188324,0.0001748667,0.00023627747,0.0001672171,0.00057752547,0.00015652698,0.00024441734,0.0009025236,0.000022688244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025309161,0.00039345433,0.58268094,0.00014849343,0.00053351035,0.00025656415,0.0005508946,0.000035964185,0.38916996,0.0012632601,0.0015437584,0.020892275],"study_design_scores_gemma":[0.0088249175,0.0001072464,0.54281795,0.00030790735,0.0006522692,0.006331043,0.00018635708,0.00002637273,0.4308418,0.0022519508,0.0072146533,0.00043753907],"about_ca_topic_score_codex":0.0000048218362,"about_ca_topic_score_gemma":0.000004768265,"teacher_disagreement_score":0.04167183,"about_ca_system_score_codex":0.000016104015,"about_ca_system_score_gemma":0.00008029108,"threshold_uncertainty_score":0.7130857},"labels":[],"label_agreement":null},{"id":"W1548178271","doi":"10.1111/j.1468-3083.2011.04033.x","title":"Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting","year":2011,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universität Hamburg; Abbott Laboratories","keywords":"Medicine; Psoriasis; Quality (philosophy); Intensive care medicine; Medical physics; Dermatology","score_opus":0.12007054824233551,"score_gpt":0.3672513233067706,"score_spread":0.24718077506443512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1548178271","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23049544,0.7678471,0.000018739047,0.00028542604,0.00027464936,0.00084705267,0.00010742659,0.000004364826,0.00011975296],"genre_scores_gemma":[0.5298783,0.4696562,0.00018149766,0.000055898356,0.00007234644,0.000032819644,0.000039544466,0.000038181824,0.00004518064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99304163,0.0049502514,0.001518522,0.00022011217,0.000044643963,0.00022481936],"domain_scores_gemma":[0.9940988,0.0011304254,0.004378604,0.00027788014,0.000098214514,0.000016072347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011314073,0.00029897795,0.0015262051,0.00017298365,0.00014040328,0.0000055178916,0.0004662803,0.00030214016,0.0000057441525],"category_scores_gemma":[0.00008262272,0.00012583952,0.0004072827,0.00011608878,0.000535466,0.00009130845,0.00008573929,0.00036025123,4.558337e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024262313,0.00034126843,0.016638208,0.003974811,0.0041652843,0.000054895794,0.006288151,0.000040634623,0.000808039,0.005956378,0.00020384992,0.9591023],"study_design_scores_gemma":[0.014531196,0.005261778,0.038153857,0.0061513875,0.019638728,0.021568136,0.015037161,0.0000019127656,0.012309018,0.0005674903,0.86567056,0.0011088],"about_ca_topic_score_codex":0.00008804774,"about_ca_topic_score_gemma":0.00013717797,"teacher_disagreement_score":0.95799345,"about_ca_system_score_codex":0.00004289554,"about_ca_system_score_gemma":0.00024796554,"threshold_uncertainty_score":0.5131587},"labels":[],"label_agreement":null},{"id":"W1551727579","doi":"10.4049/jimmunol.179.8.5462","title":"Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Heart, Lung, and Blood Institute","keywords":"Receptor; Proinflammatory cytokine; Interleukin 17; Receptor antagonist; Interleukin 1 receptor antagonist; Interleukin; Cell biology; Biology; Antagonist; Interleukin 1 receptor, type II; Immunology; Cytokine; Inflammation; Biochemistry; Interleukin 5","score_opus":0.011809877682000187,"score_gpt":0.24396159741114462,"score_spread":0.23215171972914445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1551727579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818685,0.008687551,0.00039514265,0.0040543876,0.003896502,0.0005350216,0.00010969035,0.000018849258,0.0004343231],"genre_scores_gemma":[0.9902819,0.0015245946,0.00006531992,0.00019510218,0.00011077562,0.000014609541,0.000030389861,0.000030303494,0.0077470355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972624,0.0009950002,0.001079897,0.00016121341,0.0000895662,0.0004119335],"domain_scores_gemma":[0.9963861,0.0010704073,0.0014847992,0.000652094,0.000388334,0.00001828416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032847987,0.00022665599,0.00041057874,0.00013538702,0.00050367345,0.000011340076,0.00094325835,0.0003938307,0.0003768863],"category_scores_gemma":[0.00051388255,0.00011103074,0.0003821622,0.00031965534,0.000648206,0.000095298565,0.0001130618,0.00051800796,0.00022133495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016098401,0.0001629741,0.000126622,0.0000058333744,0.0013283396,0.0000012413954,0.0017854034,0.00000869,0.9739865,0.0012006448,0.006572495,0.013211411],"study_design_scores_gemma":[0.002345958,0.0007686136,0.008107237,0.00004695081,0.00058074744,0.00052696065,0.0017622563,0.0000012542864,0.90976244,0.0012190139,0.074729815,0.00014876232],"about_ca_topic_score_codex":0.000037073863,"about_ca_topic_score_gemma":0.000015526093,"teacher_disagreement_score":0.06815732,"about_ca_system_score_codex":0.000099088444,"about_ca_system_score_gemma":0.00013792777,"threshold_uncertainty_score":0.45277023},"labels":[],"label_agreement":null},{"id":"W1552498041","doi":"10.1111/j.1468-3083.2011.04082.x","title":"Impact of ustekinumab on health‐related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Centre de Recherche Dermatologique du Québec Métropolitain; Guenther Dermatology Research Centre","funders":"","keywords":"Ustekinumab; Psoriasis; Medicine; Dermatology Life Quality Index; Sexual function; Psoriasis Area and Severity Index; Placebo; Quality of life (healthcare); Internal medicine; Severity of illness; Dermatology; Disease; Physical therapy; Pathology; Alternative medicine; Adalimumab","score_opus":0.1610515970460512,"score_gpt":0.3920532647250895,"score_spread":0.2310016676790383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1552498041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933132,0.00501768,0.0000070125193,0.0006838592,0.00035967282,0.00017745388,0.00027204165,0.0000084757585,0.00016061249],"genre_scores_gemma":[0.99899656,0.00072487,0.000051425865,0.00009194996,0.000049090773,6.771741e-7,0.000022908029,0.000015290907,0.000047252943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9813191,0.014869358,0.0032365753,0.00024674326,0.000070256865,0.00025794405],"domain_scores_gemma":[0.9900903,0.0032343513,0.006305631,0.00018697613,0.000101980775,0.00008073935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004623997,0.000251297,0.002200125,0.00016636345,0.00010404013,0.0000019641168,0.00032883487,0.000425506,0.00003062868],"category_scores_gemma":[0.002332994,0.00013959104,0.00034159687,0.000118357944,0.001157318,0.0000625517,0.00010696765,0.00066024176,0.0000021542573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09553576,0.003294412,0.8236292,0.00007066045,0.019083854,0.00006440945,0.007149322,0.000029453982,0.014732882,0.00087655487,0.0029087127,0.03262477],"study_design_scores_gemma":[0.05241315,0.001709924,0.93953836,0.0001593076,0.00073737756,0.0005442648,0.00037687088,0.0000030016008,0.0040061637,0.0003069886,0.0000483902,0.00015622034],"about_ca_topic_score_codex":0.00015622859,"about_ca_topic_score_gemma":0.00001781998,"teacher_disagreement_score":0.11590914,"about_ca_system_score_codex":0.000017392129,"about_ca_system_score_gemma":0.00014166997,"threshold_uncertainty_score":0.56923574},"labels":[],"label_agreement":null},{"id":"W1553367009","doi":"10.1111/j.1542-4758.2011.00616.x","title":"New‐onset psoriasis in a maintenance hemodialysis patient","year":2011,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Hemodialysis; Peritoneal dialysis; Dialysis; Home hemodialysis; Chronic renal failure; Plaque psoriasis; Intensive care medicine; Dermatology; Internal medicine","score_opus":0.020487187503069777,"score_gpt":0.23047317935212325,"score_spread":0.20998599184905348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1553367009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97129357,0.0005077775,0.0015023029,0.00028302864,0.002791581,0.00023825496,0.00014752445,0.00010313888,0.023132844],"genre_scores_gemma":[0.99172825,0.00012426967,0.0029233906,0.00023372413,0.000094169656,0.000085796746,0.0003401269,0.000023155966,0.004447144],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99820536,0.00018251898,0.0005396675,0.0005378412,0.00011745848,0.00041714247],"domain_scores_gemma":[0.99912447,0.00011047229,0.00019987914,0.0003995,0.00011037328,0.00005530772],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022286609,0.0002817637,0.00040788885,0.0005176101,0.00008457065,0.000021596301,0.00045230452,0.00023426011,0.007560955],"category_scores_gemma":[0.00013257406,0.00025872327,0.0003318721,0.000386365,0.00007222795,0.00017577162,0.00011964415,0.00017083892,0.001464696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023085054,0.0015104808,0.31081605,0.00000927879,0.0034150872,0.0001470547,0.009855548,0.000055360826,0.011343719,0.0033405924,0.03166074,0.6255376],"study_design_scores_gemma":[0.02013812,0.0005662956,0.5443419,0.0001737031,0.0013993228,0.00033421416,0.0019248499,0.00025979165,0.29369807,0.008858474,0.12597977,0.0023254512],"about_ca_topic_score_codex":0.0010491573,"about_ca_topic_score_gemma":0.00045712278,"teacher_disagreement_score":0.6232121,"about_ca_system_score_codex":0.00019006101,"about_ca_system_score_gemma":0.000094146766,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W1561358013","doi":"10.1111/j.1468-3083.2011.04409.x","title":"Exploring new concepts in the successful management of psoriasis","year":2012,"lang":"en","type":"editorial","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Disease; Immunology; Pathogenesis; Immune system; Acquired immune system; Systemic inflammation; Inflammation; Dermatology; Intensive care medicine; Pathology","score_opus":0.05146601797081459,"score_gpt":0.28629176813823803,"score_spread":0.23482575016742344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1561358013","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4573386,0.06405594,0.000020242725,0.0034039125,0.47080055,0.00044111616,0.00006521116,0.000013501232,0.0038609214],"genre_scores_gemma":[0.9397967,0.016185114,0.0001003441,0.00009445759,0.04317586,0.0000067801166,0.000018307344,0.000042654487,0.0005797862],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99467856,0.0033250656,0.0012203512,0.00022521906,0.00013907359,0.0004117048],"domain_scores_gemma":[0.9967444,0.0010704971,0.0018291908,0.0002595293,0.000059281683,0.000037080204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012190794,0.00033883765,0.001063999,0.00027797194,0.00010478693,0.000004901897,0.0013595093,0.0006968337,0.000042424574],"category_scores_gemma":[0.00012744463,0.00019948253,0.00032459674,0.00020564612,0.00062773115,0.00014556987,0.00033963815,0.0014059985,0.000018934927],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018066837,0.00064802915,0.044151418,0.0008074503,0.005181965,0.00036879658,0.004567813,0.000015712318,0.0014388791,0.004019008,0.87795985,0.059034422],"study_design_scores_gemma":[0.0056318855,0.00010733027,0.043451548,0.0006550161,0.002119608,0.00228363,0.00072847516,1.3180045e-7,0.005517464,0.0005281962,0.93866056,0.00031612848],"about_ca_topic_score_codex":0.000015450265,"about_ca_topic_score_gemma":0.0000037448933,"teacher_disagreement_score":0.48245808,"about_ca_system_score_codex":0.000025182386,"about_ca_system_score_gemma":0.00007858338,"threshold_uncertainty_score":0.81346613},"labels":[],"label_agreement":null},{"id":"W1572999787","doi":"10.1111/j.1365-2133.2011.10399.x","title":"Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","year":2011,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Cilag; Johnson and Johnson; Abbott Laboratories; Abbott Fund","keywords":"Methotrexate; Medicine; Psoriasis; Dosing; Psoriasis Area and Severity Index; Internal medicine; Placebo; Dose; Champion; Gastroenterology; Surgery; Dermatology","score_opus":0.043282077650785816,"score_gpt":0.28162148791945824,"score_spread":0.23833941026867242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1572999787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987833,0.00055905554,0.00007595898,0.00011571703,0.00018109729,0.00024250922,0.000018659053,0.0000042686397,0.000019434608],"genre_scores_gemma":[0.9995582,0.00002243076,0.00034282077,0.000026021049,0.00001004155,0.0000037664952,0.000003949626,0.000010660308,0.000022121085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590856,0.0028497092,0.0008189448,0.00017670341,0.000060801525,0.00018526235],"domain_scores_gemma":[0.998413,0.0007039679,0.00051515165,0.00016320689,0.00016700738,0.00003763875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008775926,0.00012053459,0.0005993947,0.00022099588,0.00012206896,0.00000951781,0.00018250852,0.00018014874,0.000015511541],"category_scores_gemma":[0.00046034597,0.00009307538,0.00010919159,0.0002778775,0.00011175684,0.00011164917,0.0000613161,0.00029403504,0.0000034548675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060838386,0.00042049,0.98609495,0.000004200684,0.00047020148,0.00009218228,0.0011548967,0.0000026223327,0.000015499703,0.0000047289845,0.00002438319,0.005631998],"study_design_scores_gemma":[0.0062631285,0.0006102319,0.9905565,0.00008542625,0.00057453365,0.0008972556,0.0003537128,3.5623003e-7,0.00047835128,0.00007535756,0.000010456349,0.00009473596],"about_ca_topic_score_codex":0.00009718076,"about_ca_topic_score_gemma":0.0002127306,"teacher_disagreement_score":0.005537262,"about_ca_system_score_codex":0.000021918035,"about_ca_system_score_gemma":0.0000750393,"threshold_uncertainty_score":0.3795504},"labels":[],"label_agreement":null},{"id":"W1575784630","doi":"10.1111/j.1468-3083.2012.04515.x","title":"Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study","year":2012,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research","funders":"Abbott Laboratories; Abbott Fund","keywords":"Adalimumab; Medicine; Psoriasis; Adverse effect; Placebo; Randomized controlled trial; Open label; Internal medicine; Surgery; Dermatology","score_opus":0.057498941496831484,"score_gpt":0.31670504011991774,"score_spread":0.25920609862308625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1575784630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795084,0.01822641,0.000034621255,0.0015333074,0.00017997275,0.00046296933,0.000011382081,0.0000026046937,0.00004032448],"genre_scores_gemma":[0.9978086,0.0017929069,0.0001155504,0.00013376481,0.000024739868,0.000007000057,0.0000024274864,0.000013387275,0.000101632155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699473,0.0019082506,0.0007011627,0.0001552612,0.000046491652,0.00019411983],"domain_scores_gemma":[0.9979627,0.00051170675,0.0012500223,0.00016266183,0.000084569394,0.000028341567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011082912,0.00019196603,0.0010234147,0.00012592887,0.00013276537,0.0000047548237,0.0003180627,0.00014737602,0.000005409545],"category_scores_gemma":[0.00007100924,0.00008984229,0.00011216328,0.00007713018,0.0008094866,0.00010667458,0.00018785012,0.00019749603,3.4447595e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008165085,0.0006460808,0.96774125,0.000031220457,0.0032156962,0.0000062868694,0.001775147,5.4818685e-7,0.003862644,0.0004158957,0.00009059733,0.014049556],"study_design_scores_gemma":[0.021852963,0.00069562724,0.96347326,0.000064979286,0.0019299017,0.002126158,0.0004403406,0.0000010733681,0.009058602,0.00014003522,0.00012313387,0.00009390389],"about_ca_topic_score_codex":0.000012004188,"about_ca_topic_score_gemma":0.0000062091685,"teacher_disagreement_score":0.018300183,"about_ca_system_score_codex":0.000008419624,"about_ca_system_score_gemma":0.000016709108,"threshold_uncertainty_score":0.3663662},"labels":[],"label_agreement":null},{"id":"W1581242854","doi":"10.4049/jimmunol.0803851","title":"Inhibition of ERK MAPK Suppresses IL-23- and IL-1-Driven IL-17 Production and Attenuates Autoimmune Disease","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"MAPK/ERK pathway; Experimental autoimmune encephalomyelitis; Immunology; Innate immune system; Immune system; Cell biology; Biology; Signal transduction","score_opus":0.011273243775981361,"score_gpt":0.2230165687000897,"score_spread":0.21174332492410836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1581242854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643992,0.03195297,0.000016679001,0.0028322593,0.00052363833,0.00016270034,0.00005154262,0.000016059177,0.000044956236],"genre_scores_gemma":[0.9912115,0.00805268,0.00006524332,0.000059833652,0.00006449801,0.0000028277805,0.00003208847,0.000009669344,0.0005016583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99872375,0.0004041764,0.0004538677,0.00014665182,0.000043734664,0.00022781226],"domain_scores_gemma":[0.9989401,0.00016233163,0.00048162587,0.00023839959,0.00015465831,0.000022899536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035648092,0.00018424509,0.00039939344,0.0001688992,0.00019785951,0.00000932294,0.00014355715,0.00015404892,0.000047381563],"category_scores_gemma":[0.00015472135,0.00012250715,0.00008187753,0.00010511173,0.0004473455,0.00018197556,0.00005968238,0.00023936213,0.000012756873],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020870098,0.00022372481,0.0019080145,0.00001754375,0.0005030147,0.000014693208,0.0010089383,0.00001361391,0.97157013,0.00014267207,0.0010648646,0.02144576],"study_design_scores_gemma":[0.002751353,0.0019181885,0.5014156,0.00023042805,0.000984367,0.001485298,0.00080481457,0.0000024291646,0.48491627,0.0020261647,0.003232559,0.00023249103],"about_ca_topic_score_codex":0.000016793048,"about_ca_topic_score_gemma":0.00000677982,"teacher_disagreement_score":0.4995076,"about_ca_system_score_codex":0.000021766593,"about_ca_system_score_gemma":0.00005128703,"threshold_uncertainty_score":0.49956965},"labels":[],"label_agreement":null},{"id":"W1584886566","doi":"","title":"Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"FOXP3; Biology; Immunology; RAR-related orphan receptor gamma; Adoptive cell transfer; Interleukin 17; Interleukin 3; IL-2 receptor; Cell biology; Interleukin 23; Cytokine; Interleukin 21; T cell; Immune system","score_opus":0.010221126697599118,"score_gpt":0.1832323500656521,"score_spread":0.173011223368053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1584886566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340814,0.004374386,0.000016782158,0.0001315101,0.0007215121,0.0007645404,0.00008735018,0.00008611543,0.0004096511],"genre_scores_gemma":[0.98716533,0.00004570149,0.000028687335,0.000038451803,0.000037920585,0.0010455262,0.00026921835,0.000019137207,0.011350044],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99887276,0.00012198108,0.00032130632,0.00030413648,0.000041208637,0.0003386086],"domain_scores_gemma":[0.99930364,0.000054786404,0.00016596093,0.00038217707,0.00006265266,0.000030781182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013670836,0.0001696452,0.00026210683,0.000094567215,0.00008255571,0.000012880036,0.00015396655,0.00014385986,0.00041232468],"category_scores_gemma":[0.000039978346,0.00014428217,0.00010888882,0.00010798901,0.00010929294,0.00017285642,0.000055030363,0.000070798495,0.00015442038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100405996,0.00034916482,0.016292155,0.000040790543,0.00037337295,9.5108203e-7,0.00041968253,0.000015053796,0.49548504,0.000028821098,0.032453693,0.45444086],"study_design_scores_gemma":[0.0007966162,0.000027508178,0.7888834,0.000012487477,0.000093158655,0.0000034318389,0.00004643646,0.000006389689,0.20436099,0.00007597354,0.005539208,0.00015438427],"about_ca_topic_score_codex":0.00015572419,"about_ca_topic_score_gemma":0.0000039310235,"teacher_disagreement_score":0.77259123,"about_ca_system_score_codex":0.000051174637,"about_ca_system_score_gemma":0.000015979385,"threshold_uncertainty_score":0.5883656},"labels":[],"label_agreement":null},{"id":"W1591809044","doi":"10.1111/j.1365-2133.2012.11015.x","title":"A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Pfizer; Amgen","keywords":"Etanercept; Medicine; Psoriasis Area and Severity Index; Psoriasis; Methotrexate; Internal medicine; Placebo; Combination therapy; Adverse effect; Gastroenterology; Randomized controlled trial; Clinical endpoint; Surgery; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.0201933887183919,"score_gpt":0.26993627326028996,"score_spread":0.24974288454189805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1591809044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938502,0.00091817905,0.00036627243,0.00057161076,0.00066122937,0.0033800076,0.00006271151,0.000010414341,0.0001793797],"genre_scores_gemma":[0.99864596,0.000053682517,0.00045023384,0.0002994933,0.000049420647,0.0003313423,0.000026299884,0.00002603422,0.00011751531],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99502987,0.0029291243,0.0011219915,0.00023871765,0.00015879524,0.0005214874],"domain_scores_gemma":[0.99803334,0.00075505464,0.00043959904,0.00022523222,0.0004223966,0.0001243835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016412312,0.0002774674,0.0017157549,0.00043910745,0.00014547908,0.000028450817,0.0003251807,0.00016549186,0.0002477907],"category_scores_gemma":[0.00033664808,0.00019389666,0.00023048981,0.00036400306,0.00007201009,0.00020068556,0.00008374921,0.00029232714,0.00009275458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.970087,0.0016080941,0.010442146,0.00000993136,0.0022454823,0.00012260662,0.0048393793,0.00043521644,0.00024096512,0.000030240677,0.0016563268,0.008282622],"study_design_scores_gemma":[0.9656697,0.00096771994,0.02372416,0.00018971151,0.0013399757,0.0036515018,0.001170511,0.00000318566,0.0026818665,0.000036101905,0.00024915423,0.00031644592],"about_ca_topic_score_codex":0.00015305946,"about_ca_topic_score_gemma":0.0004745477,"teacher_disagreement_score":0.013282013,"about_ca_system_score_codex":0.000064596876,"about_ca_system_score_gemma":0.00010196886,"threshold_uncertainty_score":0.7906876},"labels":[],"label_agreement":null},{"id":"W1592628203","doi":"10.1111/j.1365-2133.2010.10139.x","title":"Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy","year":2010,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Abbott Laboratories","keywords":"Adalimumab; Medicine; Psoriasis; Adverse effect; Internal medicine; Psoriasis Area and Severity Index; Dosing; Surgery; Dermatology; Disease","score_opus":0.00973151097607172,"score_gpt":0.23870295296334362,"score_spread":0.2289714419872719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592628203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638609,0.03355246,0.000371715,0.0006443073,0.00090085965,0.00037523388,0.0002700403,0.000010213928,0.000014230713],"genre_scores_gemma":[0.99500513,0.0037156963,0.0010184412,0.000072441,0.000069017515,0.000022096763,0.000053073632,0.000016958367,0.000027142285],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988048,0.00016427231,0.00047506258,0.0002489757,0.00004380793,0.00026308847],"domain_scores_gemma":[0.999029,0.0003471544,0.00026358344,0.0001392145,0.000097339034,0.0001237451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001158171,0.00018439267,0.0005767851,0.000086368,0.0001879985,0.000025028681,0.00014000485,0.00020103728,0.00003735959],"category_scores_gemma":[0.00013179048,0.00017647703,0.00013355108,0.000058690355,0.00011366324,0.00012411541,0.00003938163,0.00020426755,0.000002515163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029755563,0.0011234066,0.046633903,0.00010421204,0.0047864346,0.0016486875,0.0017931457,0.000027608985,0.06668496,0.00047126,0.0031292373,0.8438416],"study_design_scores_gemma":[0.20282727,0.0055499175,0.4986866,0.0030881206,0.00390432,0.07170486,0.0007042535,0.00009547748,0.17114994,0.006868514,0.03309479,0.0023259267],"about_ca_topic_score_codex":0.00007146385,"about_ca_topic_score_gemma":0.00017024098,"teacher_disagreement_score":0.84151566,"about_ca_system_score_codex":0.000025061381,"about_ca_system_score_gemma":0.00024004214,"threshold_uncertainty_score":0.7196524},"labels":[],"label_agreement":null},{"id":"W1596331316","doi":"10.1111/bcp.12589","title":"A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients","year":2015,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pharmacokinetics; Asthma; Ulcerative colitis; NONMEM; Bioavailability; Population; Elimination rate constant; Gastroenterology; Volume of distribution; Internal medicine; Dosing; Monoclonal antibody; Immunology; Antibody; Pharmacology; Disease","score_opus":0.05835597556917201,"score_gpt":0.4033071487300452,"score_spread":0.3449511731608732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1596331316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915845,0.0048601096,0.000048314443,0.00016370659,0.004941807,0.00036875452,0.00028750498,0.000019435733,0.00015190449],"genre_scores_gemma":[0.99636775,0.0021377592,0.00026301635,0.0004334014,0.0005145973,0.00000788804,0.00015123698,0.000027351954,0.000097001095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460787,0.0022488637,0.0021157807,0.00038835325,0.00015480588,0.00048430133],"domain_scores_gemma":[0.99667215,0.00061757216,0.0013855326,0.00011357101,0.0008591528,0.0003520009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015177343,0.00026947487,0.0014916242,0.00016985457,0.00015163203,0.000025041058,0.00034577772,0.00041308146,0.00043064693],"category_scores_gemma":[0.00030961708,0.00028024506,0.00027807234,0.0001664616,0.00087157614,0.00034312374,0.00011410046,0.0008242851,0.000021374492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009394856,0.005046614,0.7228923,0.000049994364,0.0015665636,0.00032502742,0.0006638631,0.000064517364,0.0041019954,0.000010259517,0.041201305,0.2146827],"study_design_scores_gemma":[0.026502423,0.0072120046,0.95128554,0.00009617352,0.00053301326,0.00077861623,0.00026723565,0.0001909087,0.0033665095,0.000052283594,0.0094316425,0.00028366942],"about_ca_topic_score_codex":0.00029765928,"about_ca_topic_score_gemma":0.00015087437,"teacher_disagreement_score":0.22839321,"about_ca_system_score_codex":0.00005041929,"about_ca_system_score_gemma":0.00033208012,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W1597178328","doi":"10.1111/jdv.12066","title":"Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross‐sectional study","year":2012,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ste. Anne's Hospital","funders":"","keywords":"Medicine; Psoriasis; Infliximab; Weight gain; Internal medicine; Body mass index; Weight change; Weight loss; Methotrexate; Psoriatic arthritis; Risk factor; Cross-sectional study; Gastroenterology; Surgery; Body weight; Obesity; Disease; Dermatology","score_opus":0.03690896554661592,"score_gpt":0.3025646443894252,"score_spread":0.2656556788428093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1597178328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690574,0.0014441352,0.0000054124366,0.00005815378,0.0010483714,0.00040924866,0.00003204819,0.0000027721458,0.00009413054],"genre_scores_gemma":[0.9997496,0.000095640586,0.000030722626,0.000027963764,0.000060644834,0.000005963797,0.0000076161177,0.000011044132,0.000010782899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99493784,0.0037228658,0.00084552256,0.0001301756,0.00012497537,0.00023861998],"domain_scores_gemma":[0.997857,0.0006765371,0.0011870028,0.00009556315,0.00015720585,0.000026702368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021513228,0.00015775432,0.0004221748,0.00022845209,0.0001095751,0.0000021402216,0.00023076001,0.00018937989,0.000027430131],"category_scores_gemma":[0.0007324793,0.00010264704,0.00013814375,0.00008440835,0.00018430613,0.000094339295,0.00008082606,0.0003113171,0.000005158925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083388906,0.0012197862,0.9933123,0.000013489182,0.00061427447,6.047372e-7,0.0012439999,0.00004323831,0.0005301087,0.0001526064,0.000069666225,0.00196605],"study_design_scores_gemma":[0.00987043,0.0001516573,0.9816615,0.000022461234,0.00070909364,0.000057945555,0.00013020338,0.000014012104,0.00686982,0.00018568894,0.00024828184,0.00007891102],"about_ca_topic_score_codex":0.000008711506,"about_ca_topic_score_gemma":0.000004486521,"teacher_disagreement_score":0.011650792,"about_ca_system_score_codex":0.000051054645,"about_ca_system_score_gemma":0.000033809116,"threshold_uncertainty_score":0.4185825},"labels":[],"label_agreement":null},{"id":"W1602706927","doi":"10.1111/j.1365-2249.2011.04382.x","title":"Chemokine CXCL11 links microbial stimuli to intestinal inflammation","year":2011,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Chemokine; Immunology; Inflammation; CXCL11; Biology; Medicine; Chemokine receptor","score_opus":0.08149922873256009,"score_gpt":0.34116291439537616,"score_spread":0.25966368566281606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1602706927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989487,0.0022770087,0.00014003877,0.0002357601,0.0037274275,0.00047891893,0.000020779351,0.00021089688,0.0034221993],"genre_scores_gemma":[0.9950884,0.000061930245,0.0020313337,0.0005189051,0.00025225198,0.000121908546,0.00021929557,0.00004018155,0.0016657943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973154,0.00040618877,0.00097569014,0.0006648286,0.000039030834,0.00059884094],"domain_scores_gemma":[0.9987937,0.00025838244,0.00022933303,0.0005460467,0.000093459545,0.00007907906],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000352303,0.00037647208,0.00062480726,0.00015196792,0.00020319295,0.00001401771,0.0004958152,0.0009762837,0.0035345482],"category_scores_gemma":[0.0002431074,0.00034751493,0.00028581783,0.00018357804,0.0005534377,0.0001265607,0.0003753447,0.0006440749,0.0067046005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023353365,0.0011644508,0.00611955,0.000003790125,0.0005129347,0.000036219775,0.0013104604,3.4647022e-7,0.938557,0.0005990658,0.0017028267,0.04765801],"study_design_scores_gemma":[0.0040338766,0.0026044934,0.037877094,0.000033896762,0.00009912387,0.00014145985,0.0003925796,0.0000010678168,0.9353962,0.00008918275,0.018935084,0.00039596017],"about_ca_topic_score_codex":0.000118775155,"about_ca_topic_score_gemma":0.000012063011,"teacher_disagreement_score":0.04726205,"about_ca_system_score_codex":0.000091235604,"about_ca_system_score_gemma":0.00006944068,"threshold_uncertainty_score":0.99989766},"labels":[],"label_agreement":null},{"id":"W1604305908","doi":"10.1186/s12895-015-0025-y","title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","year":2015,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Viral load; Medicine; Psoriasis; Immunology; Janus kinase inhibitor; Population; Lymphocyte; Internal medicine; Virus; Gastroenterology","score_opus":0.015155513411117994,"score_gpt":0.22293729699267437,"score_spread":0.20778178358155638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1604305908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973817,0.0013797523,0.000033181645,0.000030653668,0.0004532032,0.0003812002,0.00004543031,0.000032438627,0.00026246396],"genre_scores_gemma":[0.99940336,0.000030379542,0.00018295231,0.00006368137,0.000008839702,0.000053862666,0.00018019341,0.000014942227,0.000061782746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987735,0.00032973714,0.0002839238,0.00027568924,0.000052692765,0.00028441745],"domain_scores_gemma":[0.99935937,0.00021207563,0.00013677313,0.00019174376,0.00006264334,0.00003740512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007395418,0.00020549749,0.00043264832,0.00016535507,0.000049820683,0.0000043113296,0.0000930286,0.00027658948,0.000011600171],"category_scores_gemma":[0.00008796734,0.0001667597,0.000041035484,0.00011594353,0.00016553007,0.00007435532,0.000039675895,0.00008034759,0.000077841294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028017967,0.0004289937,0.9890401,0.000072546354,0.000112710455,0.000027520953,0.00047640296,0.0000102968215,0.00073257857,0.001197067,0.00049949443,0.0046004904],"study_design_scores_gemma":[0.026334736,0.0006260355,0.8836216,0.00007570951,0.00014913145,0.000106160514,0.00008453573,0.0000046376676,0.08653769,0.00024964355,0.001915461,0.0002946878],"about_ca_topic_score_codex":0.00010092499,"about_ca_topic_score_gemma":0.0001906892,"teacher_disagreement_score":0.10541853,"about_ca_system_score_codex":0.00007945795,"about_ca_system_score_gemma":0.00016118832,"threshold_uncertainty_score":0.68002635},"labels":[],"label_agreement":null},{"id":"W1607258406","doi":"10.1111/j.2041-1626.2012.00120.x","title":"Markers of potential malignancy in chronic hyperplastic candidiasis","year":2012,"lang":"en","type":"article","venue":"Journal of Investigative and Clinical Dentistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Western University","funders":"","keywords":"Pathology; Biology; Proliferating cell nuclear antigen; Malignancy; Immunohistochemistry; Dysplasia; Hyperplasia; Epithelium; Basal (medicine); Apoptosis; Epithelial dysplasia; Cancer research; Medicine; Endocrinology","score_opus":0.03779605822144946,"score_gpt":0.30954704160466945,"score_spread":0.27175098338322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607258406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865916,0.01171936,0.000028148332,0.00006518681,0.0014029004,0.000057813228,0.000021889671,0.0000026077728,0.00011048656],"genre_scores_gemma":[0.998184,0.0011927524,0.0001919011,0.00003971004,0.00016677623,0.0000016432524,0.000007475489,0.000007407929,0.00020832157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983988,0.00036706685,0.000833229,0.00011098002,0.00005477352,0.00023516394],"domain_scores_gemma":[0.9988309,0.0003785235,0.0005386725,0.0000885471,0.00007307498,0.00009026093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006560556,0.00012782353,0.0004585086,0.000097292526,0.000041107327,0.000006963076,0.00011430895,0.00022757545,0.00018664605],"category_scores_gemma":[0.00035420005,0.00009967946,0.00019055205,0.000111399764,0.0005216291,0.00019267338,0.000042619293,0.00028695542,0.000023739729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077263213,0.000606516,0.83040696,0.000090547364,0.001284362,0.0001643499,0.00023524051,0.000004852533,0.12968,0.00023264313,0.0014317811,0.035090137],"study_design_scores_gemma":[0.0029636798,0.00069560134,0.96144015,0.00024285822,0.0003888388,0.00042223773,0.00029526604,0.0000017361149,0.032851122,0.00029157475,0.00029078487,0.00011614046],"about_ca_topic_score_codex":0.00003171349,"about_ca_topic_score_gemma":0.000023996306,"teacher_disagreement_score":0.13103321,"about_ca_system_score_codex":0.00005086299,"about_ca_system_score_gemma":0.00017393855,"threshold_uncertainty_score":0.40648106},"labels":[],"label_agreement":null},{"id":"W1608594180","doi":"10.1111/j.1468-3083.2011.04225.x","title":"Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open‐label, multicentre, phase IIIb study","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; University of British Columbia; Abbott (Canada); Probity Medical Research","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Plaque psoriasis; Dermatology","score_opus":0.08825053625924434,"score_gpt":0.3294644849332314,"score_spread":0.24121394867398704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1608594180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906265,0.0068218596,0.00003155238,0.0008362742,0.00028423363,0.0011430434,0.000107443964,0.0000034296552,0.00014563222],"genre_scores_gemma":[0.99632865,0.0029904784,0.00045352636,0.000074764765,0.00003268846,0.00001010714,0.0000052567925,0.000018794844,0.00008575619],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613154,0.0020811234,0.0012524326,0.00023795539,0.000052543404,0.0002444028],"domain_scores_gemma":[0.9971482,0.0008133095,0.0015720131,0.0002931317,0.00012337786,0.00004996718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008340408,0.00023964487,0.000964007,0.00015924072,0.0001467792,0.0000028511308,0.00075198116,0.00018311362,0.000018442573],"category_scores_gemma":[0.00013688357,0.00013143926,0.00011255231,0.00010736132,0.00053282455,0.0000909395,0.00016564516,0.00016615348,0.0000012242414],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24182753,0.024513744,0.05732902,0.00010668361,0.011927431,0.000056591725,0.0559837,0.000024031937,0.10619199,0.0017375336,0.00090053363,0.4994012],"study_design_scores_gemma":[0.22782007,0.019331839,0.33288398,0.00021872066,0.00356179,0.0013295665,0.0031055755,0.000013397354,0.39642268,0.00078161835,0.014111864,0.00041888558],"about_ca_topic_score_codex":0.000042372936,"about_ca_topic_score_gemma":0.000017521006,"teacher_disagreement_score":0.4989823,"about_ca_system_score_codex":0.000012223817,"about_ca_system_score_gemma":0.0000528739,"threshold_uncertainty_score":0.53599375},"labels":[],"label_agreement":null},{"id":"W1654452971","doi":"10.1111/j.1468-3083.2011.04305.x","title":"Cost‐effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan‐European analysis","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Scalp; Clobetasol propionate; Population; Dermatology; Surgery; Physical therapy; Environmental health","score_opus":0.043413423672481556,"score_gpt":0.26313708424653115,"score_spread":0.2197236605740496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1654452971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964548,0.0016233686,0.00015502791,0.00013578558,0.00022479235,0.00036303216,0.000020097194,0.000006094481,0.0010169974],"genre_scores_gemma":[0.9995843,0.00016736385,0.00011790641,0.00005806248,0.00001623464,0.000006017343,0.000009469937,0.000019057608,0.000021568409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99104726,0.007498742,0.00081147655,0.0002476107,0.00011239752,0.00028253382],"domain_scores_gemma":[0.9981381,0.00016688924,0.0012217083,0.0001826634,0.00025902526,0.00003160948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019876997,0.00022676578,0.0007934459,0.00040939738,0.00008935734,0.0000028050138,0.00042510984,0.000181433,0.000032434153],"category_scores_gemma":[0.00012643135,0.00013906883,0.00020205397,0.00037063545,0.0005279923,0.00012254385,0.00013033088,0.00040465983,0.000007860675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034314601,0.0004899536,0.9723934,0.00004724856,0.0026918962,0.000024267072,0.0008306227,0.00023189919,0.0013312428,0.00043451076,0.000049418184,0.018044107],"study_design_scores_gemma":[0.0072970465,0.00012962591,0.9776996,0.00013681344,0.0022314424,0.0002843001,0.000055657503,0.00003310407,0.0114815375,0.00042757936,0.00008710788,0.00013623296],"about_ca_topic_score_codex":0.000009091021,"about_ca_topic_score_gemma":0.000008208323,"teacher_disagreement_score":0.017907873,"about_ca_system_score_codex":0.00003463459,"about_ca_system_score_gemma":0.000056827204,"threshold_uncertainty_score":0.5671062},"labels":[],"label_agreement":null},{"id":"W1654464268","doi":"10.1155/2009/514618","title":"Learning the Lessons of Antitumour Necrosis Factor Therapy-Associated Psoriasis","year":2009,"lang":"en","type":"article","venue":"Canadian Journal of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psoriasis; Discontinuation; Medicine; Dermatology; Adverse effect; Necrosis; Internal medicine","score_opus":0.0203114759131784,"score_gpt":0.23459306442144576,"score_spread":0.21428158850826737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1654464268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941349,0.0014646226,0.00002463557,0.0032231659,0.0008614119,0.00008256146,0.000057161105,0.0000071593113,0.00014438825],"genre_scores_gemma":[0.9989053,0.00026296053,0.000020390009,0.00040990656,0.000054791555,9.1132966e-7,0.000015843598,0.000010967244,0.00031890237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836445,0.0005279651,0.00043799047,0.00012906751,0.000039597657,0.0005009374],"domain_scores_gemma":[0.99894786,0.00009754654,0.0005191264,0.0001538272,0.00018048845,0.000101146914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003226965,0.00017457572,0.00046259438,0.00026301722,0.00024084254,0.000015119517,0.00037294533,0.00018022349,0.00034732706],"category_scores_gemma":[0.00013406508,0.00012135721,0.00026128246,0.0001271896,0.00019629787,0.00007181591,0.000008318405,0.00037226104,0.000016447688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016707139,0.0002756384,0.7932402,0.0000045625948,0.0020839055,0.00013719623,0.0030497904,0.00011857548,0.12661745,0.00021557922,0.0056150784,0.06697133],"study_design_scores_gemma":[0.0045191133,0.0061210473,0.9651116,0.00004836278,0.00020871978,0.00047433615,0.0003792499,0.0000012489282,0.013594976,0.00016578514,0.009250284,0.00012527332],"about_ca_topic_score_codex":0.0008883014,"about_ca_topic_score_gemma":0.004703969,"teacher_disagreement_score":0.17187142,"about_ca_system_score_codex":0.00007584101,"about_ca_system_score_gemma":0.00026498284,"threshold_uncertainty_score":0.49488035},"labels":[],"label_agreement":null},{"id":"W1661616496","doi":"10.1111/bjd.12214","title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","year":2013,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":410,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Ustekinumab; Medicine; Mace; Adverse effect; Psoriasis; Population; Internal medicine; Dermatology; Disease; Environmental health","score_opus":0.023963248236928882,"score_gpt":0.2498224002245274,"score_spread":0.2258591519875985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1661616496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28500858,0.7119841,0.000018889214,0.000010787475,0.0009504875,0.0005741097,0.0013911775,0.000006488035,0.00005541639],"genre_scores_gemma":[0.11046624,0.8878542,0.00029015134,0.0000149589805,0.000048941736,0.000024893105,0.0010528933,0.000060848386,0.00018685001],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957407,0.000867892,0.0024118037,0.00040160818,0.00013669986,0.00044131186],"domain_scores_gemma":[0.99640137,0.00047967155,0.002313547,0.00035832805,0.00037725142,0.00006984122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018150549,0.00042439188,0.0035130384,0.00050029985,0.000051625153,0.000017123723,0.0006030554,0.00089584425,0.00016846434],"category_scores_gemma":[0.0001772381,0.0004008566,0.0005399043,0.00030274002,0.00016048517,0.00015757878,0.000115131406,0.0005954527,0.000064047585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048332815,0.0005575969,0.006734433,0.0008403039,0.0023811318,0.0010071165,0.00018901748,0.0000043348527,0.0000033222786,0.000005025147,0.0012476989,0.98219675],"study_design_scores_gemma":[0.1815219,0.0037337118,0.43953976,0.13857387,0.01417061,0.059024032,0.00020450568,7.214443e-7,0.0005944659,0.00011837393,0.15905997,0.003458077],"about_ca_topic_score_codex":0.00025586848,"about_ca_topic_score_gemma":0.00025482354,"teacher_disagreement_score":0.97873867,"about_ca_system_score_codex":0.0000969229,"about_ca_system_score_gemma":0.0005046916,"threshold_uncertainty_score":0.9998443},"labels":[],"label_agreement":null},{"id":"W1701831197","doi":"10.1016/j.smrv.2015.09.003","title":"Psoriasis and sleep disorders: A systematic review","year":2015,"lang":"en","type":"review","venue":"Sleep Medicine Reviews","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mediprobe Research (Canada); Western University","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Insomnia; Metabolic syndrome; Population; Obstructive sleep apnea; Sleep apnea; Restless legs syndrome; Dermatology; Obesity; Internal medicine; Psychiatry","score_opus":0.05768477626681135,"score_gpt":0.33147814692827476,"score_spread":0.2737933706614634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1701831197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.628898e-8,0.98674333,0.000015898717,0.00020565346,0.0016759804,0.009525483,0.000065682405,0.000107151995,0.0016607197],"genre_scores_gemma":[1.4113283e-7,0.99281317,0.0000418636,0.00037305465,0.00029835236,0.002965143,0.0011284658,0.00010305218,0.0022767433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916936,0.003507229,0.0029783158,0.0010084555,0.00015820711,0.0006541997],"domain_scores_gemma":[0.9956578,0.0005785789,0.0019271562,0.0015587966,0.00010918458,0.00016846866],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003814971,0.0013518963,0.013341691,0.00034733585,0.00016633794,0.00001464083,0.0007072005,0.0007166994,0.0007228243],"category_scores_gemma":[0.0017793191,0.00074536336,0.0010965967,0.0007497042,0.00030516696,0.00009838779,0.00019335038,0.00057489105,0.003743327],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000021091985,0.000034947545,3.7725079e-7,0.47443488,0.00082260097,0.0000045303464,0.000044057037,7.0965483e-10,9.2037645e-8,0.00003330973,0.01275952,0.5118636],"study_design_scores_gemma":[0.00044945852,0.00013163779,1.1832322e-7,0.42955282,0.0327234,0.00021031436,0.000011799931,3.7453397e-8,5.35819e-8,0.000018963163,0.5365565,0.0003449014],"about_ca_topic_score_codex":0.00003084599,"about_ca_topic_score_gemma":0.00002240304,"teacher_disagreement_score":0.523797,"about_ca_system_score_codex":0.00016196417,"about_ca_system_score_gemma":0.000109199456,"threshold_uncertainty_score":0.99992317},"labels":[],"label_agreement":null},{"id":"W170763655","doi":"10.4049/jimmunol.178.supp.94.2","title":"Signaling motifs in the IL-17 receptor (94.2)","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Receptor; Biology; Signal transduction; Cell biology; TRIF; Innate immune system; Gene; Downregulation and upregulation; Immune system; Toll-like receptor; Immunology; Computational biology; Genetics","score_opus":0.017937819389024952,"score_gpt":0.24394205497400395,"score_spread":0.226004235584979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W170763655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98091304,0.015084684,0.00022257832,0.001250033,0.0013797882,0.0001259522,0.0000075444,0.000009922627,0.0010064736],"genre_scores_gemma":[0.9979762,0.0006612255,0.0000943444,0.00031774645,0.00013680903,0.000002014966,0.000008492501,0.000011568893,0.0007916193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980462,0.0008298099,0.00057451637,0.00009139878,0.0000533274,0.00040475087],"domain_scores_gemma":[0.99806184,0.0011606924,0.00039402072,0.00028560148,0.000087056105,0.0000107666665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032634048,0.00016103752,0.00031007722,0.00019364365,0.00019745775,0.000008597517,0.0007123718,0.0002300497,0.00038558376],"category_scores_gemma":[0.00012465478,0.00008126537,0.0001446269,0.00023413307,0.0002575107,0.00007709145,0.00004956199,0.0005954853,0.00022506557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020692328,0.00029071048,0.002308357,0.0000035636872,0.0007735713,0.00006417572,0.006698649,0.000028400433,0.93696445,0.0005751661,0.0037719673,0.04645175],"study_design_scores_gemma":[0.010102325,0.0030820286,0.13970773,0.00016530104,0.00078799354,0.007273246,0.023199283,0.0000013062909,0.6042581,0.0019414733,0.20892332,0.0005578861],"about_ca_topic_score_codex":0.00004815897,"about_ca_topic_score_gemma":0.00004329838,"teacher_disagreement_score":0.33270633,"about_ca_system_score_codex":0.00006524345,"about_ca_system_score_gemma":0.00005690456,"threshold_uncertainty_score":0.42218715},"labels":[],"label_agreement":null},{"id":"W1736243164","doi":"10.4049/jimmunol.1301435","title":"SLAM–SAP Signaling Promotes Differentiation of IL-17–Producing T Cells and Progression of Experimental Autoimmune Encephalomyelitis","year":2014,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Child and Family Research Institute","keywords":"Experimental autoimmune encephalomyelitis; Immunology; Cell biology; Biology; Neuroscience; Multiple sclerosis","score_opus":0.010757495731952801,"score_gpt":0.235657528010639,"score_spread":0.22490003227868618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1736243164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773442,0.021594362,0.0001790285,0.00008740528,0.0005685239,0.00015478251,0.000008116642,0.000008652976,0.0000549354],"genre_scores_gemma":[0.99900496,0.0005047975,0.00030511484,0.0000065812837,0.00004335598,0.0000035054732,0.000009082262,0.000011522273,0.00011107737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835575,0.0006252536,0.00063393085,0.00012227645,0.000058125934,0.00020468603],"domain_scores_gemma":[0.9983544,0.00030793226,0.00095725094,0.00022502833,0.00014451839,0.000010904956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007135473,0.00016057349,0.00047803103,0.00014343193,0.00012781446,0.000004854259,0.00023753625,0.00016218025,0.000117277836],"category_scores_gemma":[0.00007300843,0.00010147973,0.00010463063,0.000087355766,0.0003381261,0.00009809903,0.00008992863,0.00019061344,0.000004436918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005613045,0.0001981085,0.00093888934,0.000017049204,0.00041458328,0.0000010133417,0.003458554,0.0000071064746,0.9651599,0.00009791134,0.000020278228,0.02912528],"study_design_scores_gemma":[0.0016238819,0.001590114,0.03615017,0.00017649928,0.00019417459,0.00017112053,0.00071400596,0.0000069353923,0.9590079,0.00013794722,0.00014151321,0.00008573229],"about_ca_topic_score_codex":0.000034028006,"about_ca_topic_score_gemma":0.0000012812907,"teacher_disagreement_score":0.035211276,"about_ca_system_score_codex":0.000021184003,"about_ca_system_score_gemma":0.00003516354,"threshold_uncertainty_score":0.41382232},"labels":[],"label_agreement":null},{"id":"W174219636","doi":"10.4049/jimmunol.186.supp.163.15","title":"IL-13 regulates the in vivo generation of IL-17 producing T cells (163.15)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Neutrophilia; Immunology; Cytokine; Bronchoalveolar lavage; Chemokine; Interleukin 5; Endotype; Eosinophilia; Interleukin 13; Interleukin 17; Medicine; Eosinophil; In vivo; Inflammation; Interleukin 4; Biology; Lung; Interleukin; Asthma; Internal medicine","score_opus":0.02933284586584407,"score_gpt":0.22110134876017176,"score_spread":0.1917685028943277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W174219636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874864,0.010214845,0.000025580648,0.00033262878,0.0013076207,0.00016612004,0.000011936213,0.00000716352,0.00044770853],"genre_scores_gemma":[0.9969545,0.0014712375,0.000104961866,0.000055022603,0.000095755604,0.000004507391,0.000003627272,0.000012507931,0.0012979012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820125,0.00078207935,0.00059971906,0.00011644835,0.000039386912,0.0002611317],"domain_scores_gemma":[0.998625,0.00021967408,0.00061669043,0.0003946453,0.0001356426,0.000008358763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001123333,0.0001581892,0.00035835925,0.00015911738,0.00014446882,0.0000042464194,0.0004728329,0.00019485579,0.0004903192],"category_scores_gemma":[0.00006711736,0.000083406936,0.00011950331,0.0001620659,0.0003244553,0.00009761711,0.00007164146,0.00030830177,0.000041147654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006450256,0.00015340754,0.00086747063,0.000004049783,0.0004872747,0.0000064047285,0.0064939703,0.000036623293,0.98374987,0.0001120128,0.0016765909,0.0057673263],"study_design_scores_gemma":[0.0011330419,0.0005541308,0.019496242,0.000032683565,0.00019862283,0.000370321,0.0008438801,0.0000031239783,0.97497445,0.00030592002,0.0019996713,0.00008790118],"about_ca_topic_score_codex":0.00023246183,"about_ca_topic_score_gemma":0.00013733906,"teacher_disagreement_score":0.01862877,"about_ca_system_score_codex":0.000036063895,"about_ca_system_score_gemma":0.00007432902,"threshold_uncertainty_score":0.5368652},"labels":[],"label_agreement":null},{"id":"W176099508","doi":"10.1177/120347541201600305","title":"Biologic Therapy in Psoriasis: Perspectives on Associated Risks and Patient Management","year":2012,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Clinical Research; University of Calgary; Health Sciences Centre; Sunnybrook Health Science Centre; Foothills Medical Centre; Probity Medical Research","funders":"Pfizer Canada; Amgen Canada; Astellas Pharma; Abbott Canada; Amgen","keywords":"Medicine; Ustekinumab; Adalimumab; Infliximab; Etanercept; Psoriasis; Intensive care medicine; Dermatology; Disease; Internal medicine; Tumor necrosis factor alpha","score_opus":0.09301215965724784,"score_gpt":0.31330355700709833,"score_spread":0.22029139734985048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W176099508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037703227,0.96045995,2.5907636e-7,0.0001016471,0.0011143842,0.00026921034,0.00001337031,0.000009766683,0.00032817002],"genre_scores_gemma":[0.024608016,0.97494894,0.0000053580966,0.000093028546,0.0001555123,0.00001302216,0.000028581853,0.000021732569,0.00012579034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764884,0.0007587186,0.00093017844,0.00024781283,0.00008439653,0.00033005577],"domain_scores_gemma":[0.9971363,0.001621017,0.0009777832,0.00014405868,0.0000635182,0.000057325244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075828825,0.00040449182,0.0022249375,0.0007622215,0.00007924233,0.000008074984,0.00009259503,0.0004388271,0.00012220902],"category_scores_gemma":[0.00015253818,0.00022655651,0.00030547354,0.0001983089,0.00015985999,0.00003858315,0.000027632586,0.00044258297,0.000010308576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022232933,0.00029276422,0.0004744111,0.00030371718,0.0016795604,0.000670485,0.0010334636,5.8731633e-8,0.000003345568,0.00002264504,0.0012569271,0.9940403],"study_design_scores_gemma":[0.0012575799,0.0017323284,0.000660908,0.009806173,0.0020002376,0.0041889986,0.002734668,3.2155427e-8,0.0000036848742,0.000056871857,0.9772038,0.0003547563],"about_ca_topic_score_codex":0.000016656366,"about_ca_topic_score_gemma":0.000002740453,"teacher_disagreement_score":0.99368554,"about_ca_system_score_codex":0.00010091933,"about_ca_system_score_gemma":0.00005363759,"threshold_uncertainty_score":0.9238706},"labels":[],"label_agreement":null},{"id":"W1764867013","doi":"10.1186/s12974-015-0392-7","title":"Interleukin-36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis","year":2015,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada","keywords":"Experimental autoimmune encephalomyelitis; Biology; Microglia; Immunology; Encephalomyelitis; Immune system; CXCL2; Inflammation; Cell biology; Chemokine; Multiple sclerosis; Chemokine receptor","score_opus":0.01930406239422868,"score_gpt":0.2298568527321,"score_spread":0.2105527903378713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1764867013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484885,0.0035445394,0.000005429135,0.00064058,0.0006293326,0.00013675196,0.000027755494,0.000013927326,0.00015281785],"genre_scores_gemma":[0.9991171,0.00017601885,0.00007672013,0.00004243206,0.000080734084,0.0000072398407,0.00002670781,0.000016046619,0.00045705235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998825,0.00021534874,0.0005002455,0.00017390763,0.00006841139,0.00021706424],"domain_scores_gemma":[0.99924767,0.00005884132,0.00039561713,0.00013874336,0.00010892048,0.0000502045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017767977,0.00018196943,0.00030783267,0.00017320487,0.00007354153,0.00005165487,0.00014795401,0.0001303091,0.00006236798],"category_scores_gemma":[0.000049745555,0.00016202347,0.000076893935,0.00007641715,0.000084143125,0.0003466978,0.00004658411,0.00020280157,0.00004236124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005459251,0.00010255917,0.000731305,0.0000054478382,0.00006193839,0.000048411577,0.0025432152,0.0000040751133,0.9859683,0.0000054699317,0.0014358526,0.008547512],"study_design_scores_gemma":[0.0036874274,0.00059332204,0.0127280215,0.000057178713,0.000035557016,0.00031936783,0.0006553756,0.000012788118,0.97170895,0.00006448861,0.009994723,0.00014280569],"about_ca_topic_score_codex":0.00013707709,"about_ca_topic_score_gemma":0.000009421381,"teacher_disagreement_score":0.014259343,"about_ca_system_score_codex":0.00010051823,"about_ca_system_score_gemma":0.00008244706,"threshold_uncertainty_score":0.66071254},"labels":[],"label_agreement":null},{"id":"W1774383972","doi":"10.1111/j.1365-2133.2012.10895.x","title":"The quest for psoriasis susceptibility genes in the postgenome-wide association studies era: charting the road ahead","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Wellcome Trust","keywords":"Psoriasis; Association (psychology); Medicine; Dermatology; Genetics; Biology; Psychology","score_opus":0.02616040516835319,"score_gpt":0.280081891607258,"score_spread":0.2539214864389048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1774383972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83803505,0.14816166,0.000017580856,0.0114247445,0.0019470222,0.00031165834,0.000021762986,0.000008465941,0.00007203583],"genre_scores_gemma":[0.9928358,0.006045118,0.000040699942,0.0006036815,0.00027857974,0.000056235684,0.000011581726,0.000011043284,0.00011723116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970456,0.0015041103,0.00070239545,0.00012594741,0.00007264062,0.0005493494],"domain_scores_gemma":[0.99388427,0.004990239,0.000659942,0.0001730647,0.00027354626,0.000018941671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002570707,0.00014698338,0.0004133715,0.000050649684,0.0009081735,0.00004765347,0.00038907924,0.00019636212,0.000012306822],"category_scores_gemma":[0.0024652402,0.00008458444,0.00022460993,0.0001274151,0.00018621917,0.00016970522,0.000047791265,0.00033975387,0.000022267359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003418661,0.00035438838,0.75965375,0.000029669225,0.0015333432,0.00006919257,0.0055916267,0.0000017082032,0.0019036635,0.00037473923,0.021073256,0.20907278],"study_design_scores_gemma":[0.0037221133,0.00018705834,0.88136435,0.000084620784,0.0005976383,0.011466636,0.01137903,0.0000013795243,0.0068712947,0.0008957982,0.08317631,0.00025379288],"about_ca_topic_score_codex":0.000083734776,"about_ca_topic_score_gemma":0.0011268747,"teacher_disagreement_score":0.20881899,"about_ca_system_score_codex":0.00011891263,"about_ca_system_score_gemma":0.00006586437,"threshold_uncertainty_score":0.69850284},"labels":[],"label_agreement":null},{"id":"W1777365448","doi":"10.1111/j.1365-2133.2012.11142.x","title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Pharmaceuticals; IC Design Education Center; Biogen; Amgen","keywords":"Ustekinumab; Medicine; Psoriasis; Discontinuation; Latent tuberculosis; Concomitant; Internal medicine; Adverse effect; Isoniazid; Tuberculosis; Dermatology; Mycobacterium tuberculosis; Adalimumab; Pathology; Disease","score_opus":0.007895784841891467,"score_gpt":0.20746878040034228,"score_spread":0.19957299555845082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1777365448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373424,0.0053052655,0.000025983607,0.00015663404,0.00044217415,0.00022123462,0.000026005442,0.0000049488854,0.00008348776],"genre_scores_gemma":[0.9977181,0.002093707,0.000065422064,0.00002274767,0.000019007062,0.000011976346,0.0000142428835,0.000010730142,0.000044067416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878746,0.0003140633,0.0004552201,0.000103590275,0.000045477307,0.00029421123],"domain_scores_gemma":[0.999341,0.00015095793,0.00024418818,0.00009476212,0.00012354767,0.00004554843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012745221,0.00013647179,0.0004074559,0.00011723615,0.00015485818,0.000012832986,0.000067225,0.00015047488,0.000023512062],"category_scores_gemma":[0.000033233795,0.000096966665,0.00007451344,0.00011780306,0.000084482854,0.00014920106,0.00002645667,0.00011502933,0.0000084415005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020723476,0.00048075165,0.89013565,0.000008688876,0.0005187133,0.000030131012,0.00034959838,0.000017667864,0.00008103047,0.00003908809,0.00014408957,0.10612225],"study_design_scores_gemma":[0.007529616,0.00045348748,0.9808275,0.00008272107,0.00020145021,0.005941209,0.000058895093,7.5584245e-7,0.0030969782,0.000018289853,0.0016780397,0.000111067544],"about_ca_topic_score_codex":0.00024818443,"about_ca_topic_score_gemma":0.00038381814,"teacher_disagreement_score":0.10601118,"about_ca_system_score_codex":0.0000821564,"about_ca_system_score_gemma":0.000046866124,"threshold_uncertainty_score":0.39541858},"labels":[],"label_agreement":null},{"id":"W1779563191","doi":"10.1111/j.1398-9995.2010.02455.x","title":"CD14+ cell-derived IL-29 modulates proinflammatory cytokine production in patients with allergic airway inflammation","year":2010,"lang":"en","type":"article","venue":"Allergy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"CD14; Immunology; Immune system; Proinflammatory cytokine; Cytokine; Medicine; Allergic inflammation; Inflammation; Tumor necrosis factor alpha; T cell; Allergy; Interleukin; Interleukin 10","score_opus":0.004913834702648635,"score_gpt":0.17792888708082796,"score_spread":0.17301505237817932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1779563191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747187,0.00012136893,0.000003812781,0.00016823526,0.0008817027,0.000527379,0.000013288994,0.00010259756,0.0007097381],"genre_scores_gemma":[0.99747753,0.000047923306,0.0001794238,0.000013137355,0.000108902925,0.00011673941,0.00059549214,0.000031370353,0.0014294945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878305,0.00010181286,0.00030346122,0.0004111818,0.00006433332,0.00033614476],"domain_scores_gemma":[0.9993017,0.000028072653,0.00016843448,0.0003606807,0.00011355753,0.000027579008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012721767,0.00025506612,0.00024129517,0.00016642349,0.00014557716,0.000012973573,0.00014654206,0.00026704188,0.00025372082],"category_scores_gemma":[0.000029981553,0.00020476095,0.000051534065,0.00015871492,0.000089878034,0.00021777424,0.00004095929,0.00023940853,0.00024926546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009532123,0.00049855636,0.046824392,0.000024869796,0.00027898292,0.000007570481,0.000848292,0.00021534807,0.92887276,0.00011765151,0.00040623182,0.020952115],"study_design_scores_gemma":[0.0042345054,0.00027193705,0.42467406,0.000024145807,0.000029958343,0.000005500525,0.000042962296,0.000006521085,0.5598974,0.000054490396,0.010448188,0.0003103214],"about_ca_topic_score_codex":0.000059876485,"about_ca_topic_score_gemma":0.000806072,"teacher_disagreement_score":0.37784967,"about_ca_system_score_codex":0.000036114136,"about_ca_system_score_gemma":0.00005505829,"threshold_uncertainty_score":0.8349909},"labels":[],"label_agreement":null},{"id":"W1809686743","doi":"10.1111/j.1365-2133.2012.10901.x","title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Biotech; Janssen Research and Development","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Dermatology Life Quality Index; Randomized controlled trial; Dosing; Placebo; Internal medicine; Clinical trial; Gastroenterology; Dermatology; Surgery; Disease; Adalimumab","score_opus":0.01753720424858743,"score_gpt":0.24308242075807682,"score_spread":0.2255452165094894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1809686743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947939,0.002104291,0.000051582316,0.00020717598,0.002017708,0.0005105363,0.0002371642,0.000008892705,0.000068772744],"genre_scores_gemma":[0.99920154,0.000104224826,0.00018886916,0.0001858902,0.00013534076,0.000012297013,0.000096072516,0.00002163848,0.000054150223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978556,0.0005365781,0.00084412383,0.00020876367,0.00010347152,0.00045144273],"domain_scores_gemma":[0.99863076,0.00044876934,0.00045360022,0.0002488563,0.00015302551,0.000065002554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019684182,0.00018980574,0.0006710422,0.000109885535,0.00008549389,0.000020746678,0.0003759809,0.00025293563,0.00008576181],"category_scores_gemma":[0.000246073,0.00015374536,0.00013828861,0.00021642656,0.000088825276,0.00021345646,0.00007778602,0.0002901032,0.00007460437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40067863,0.0029920058,0.4795474,0.000017630759,0.002143513,0.00073690474,0.013869233,0.000094959294,0.0005091172,0.00004071635,0.014464526,0.08490533],"study_design_scores_gemma":[0.13273044,0.0005641219,0.8596582,0.00026906485,0.00023208588,0.00201032,0.00016889813,8.524602e-8,0.0031417254,0.000015598684,0.0010036736,0.00020582514],"about_ca_topic_score_codex":0.00025212928,"about_ca_topic_score_gemma":0.00022204817,"teacher_disagreement_score":0.38011074,"about_ca_system_score_codex":0.000048938553,"about_ca_system_score_gemma":0.000111178604,"threshold_uncertainty_score":0.6269554},"labels":[],"label_agreement":null},{"id":"W1810069629","doi":"10.1016/j.jaad.2015.04.023","title":"Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Ottawa; Public Health Ontario; University of Toronto; Women's College Hospital; McMaster University","funders":"","keywords":"Medicine; Ustekinumab; Adalimumab; Etanercept; Infliximab; Adverse effect; Psoriasis; Internal medicine; Incidence (geometry); Discontinuation; Clinical trial; Population; Retrospective cohort study; Confidence interval; Hazard ratio; Dermatology; Disease; Rheumatoid arthritis","score_opus":0.053207852357666036,"score_gpt":0.3817297459648518,"score_spread":0.32852189360718576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1810069629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955706,0.0004086561,0.0000028034053,0.0027677657,0.00049437716,0.00060505257,0.000032567368,0.000003522926,0.00011462819],"genre_scores_gemma":[0.998506,0.00038071434,0.00066876045,0.0003377535,0.00004315147,0.0000160871,0.0000023481498,0.000012707244,0.000032496017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959498,0.0019673724,0.0014234239,0.00021857432,0.00008273333,0.00035807278],"domain_scores_gemma":[0.99619746,0.0008401892,0.0025583105,0.0001590941,0.00017960522,0.0000653454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015554599,0.00018103918,0.0010819711,0.00053258,0.000046347912,0.0000013001485,0.00048765552,0.00019085911,0.0000054669313],"category_scores_gemma":[0.0014642982,0.00012035825,0.00024242171,0.0005345637,0.00039169524,0.000119616365,0.000060398535,0.0005778603,0.0000029669304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062686442,0.00086236146,0.98711085,0.0000041396866,0.0005707475,0.000028169723,0.0013963147,0.000017880775,0.0007874234,0.000033448618,0.00032590522,0.0025941336],"study_design_scores_gemma":[0.011572158,0.0010960577,0.97940546,0.0000467173,0.00015118429,0.0002090372,0.004463879,0.000005727629,0.0014849929,0.00012650334,0.0013275025,0.000110786816],"about_ca_topic_score_codex":0.013529226,"about_ca_topic_score_gemma":0.016586646,"teacher_disagreement_score":0.007705378,"about_ca_system_score_codex":0.00021245354,"about_ca_system_score_gemma":0.00040826813,"threshold_uncertainty_score":0.9930398},"labels":[],"label_agreement":null},{"id":"W1814149022","doi":"10.1111/bjd.14163","title":"Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16–17 years","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Dermatology Life Quality Index; Medicine; Dermatology; Psoriasis; Quality of life (healthcare); Index (typography); Computer science","score_opus":0.028597857370707472,"score_gpt":0.3066605187112383,"score_spread":0.2780626613405308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1814149022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991703,0.0059031826,0.00013713195,0.0010040256,0.00046021282,0.0005742252,0.000119659955,0.000009268458,0.00008932679],"genre_scores_gemma":[0.9992898,0.0002169675,0.000087139255,0.00029572463,0.000016521339,0.000018845754,0.000047099613,0.00002203925,0.000005879953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98723644,0.008037149,0.0035382116,0.000356178,0.0003138285,0.0005181738],"domain_scores_gemma":[0.9935035,0.0016272829,0.0037481275,0.00050198485,0.0004797125,0.00013935688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016822923,0.0003426212,0.0029895194,0.00035438107,0.00010481757,0.000014682168,0.00073369447,0.0006969927,0.000037775255],"category_scores_gemma":[0.0020793888,0.00026270119,0.00029219317,0.00047020844,0.0016851337,0.00018102677,0.0002690385,0.0009261917,0.0000012777533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003988115,0.0014164308,0.98969644,0.000105804174,0.000905194,0.00002880471,0.0012003244,0.000046058627,0.000056808538,0.0005051325,0.000715821,0.0013350906],"study_design_scores_gemma":[0.032721657,0.00013110961,0.96298796,0.00016270953,0.00016189771,0.0012719107,0.0014383801,0.0000069885937,0.0005748322,0.0002719853,0.000037802358,0.00023274955],"about_ca_topic_score_codex":0.0034210035,"about_ca_topic_score_gemma":0.0043241554,"teacher_disagreement_score":0.02873354,"about_ca_system_score_codex":0.00008352647,"about_ca_system_score_gemma":0.0009694704,"threshold_uncertainty_score":0.99998254},"labels":[],"label_agreement":null},{"id":"W1821979477","doi":"10.1371/journal.pone.0134703","title":"First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Novo Nordisk; York University; Wake Forest University; Amgen","keywords":"Tolerability; Medicine; Placebo; Psoriasis Area and Severity Index; Pharmacodynamics; Pharmacokinetics; Internal medicine; Psoriasis; Adverse effect; Randomized controlled trial; Gastroenterology; Pharmacology; Immunology; Pathology","score_opus":0.03412512852354042,"score_gpt":0.2550022592565215,"score_spread":0.22087713073298107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821979477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685353,0.00026746828,0.000018130224,0.000111431786,0.00029538744,0.002041875,0.00005552903,0.000051592124,0.00030508346],"genre_scores_gemma":[0.9976782,0.000055479602,0.00033447507,0.000016163307,0.000058268928,0.00023081589,0.0011344451,0.00003157994,0.00046054044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99805564,0.00044010347,0.0005126925,0.00043954313,0.00014478381,0.00040724047],"domain_scores_gemma":[0.999087,0.00019784554,0.00024171188,0.00029137512,0.00013003273,0.000052069114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005292395,0.0003047392,0.0009914276,0.000285837,0.00010698647,0.00002030919,0.00014716892,0.0002346214,0.00008682111],"category_scores_gemma":[0.000093369,0.000214188,0.000079740494,0.00030089897,0.00013647498,0.00020361248,0.00003273051,0.00019779829,0.00008764357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7589,0.020143287,0.21560569,0.000030773208,0.0011480429,0.000028299477,0.00063550833,0.000023233357,0.002186569,0.000077223995,0.00007084996,0.0011505035],"study_design_scores_gemma":[0.95541334,0.003918831,0.033486854,0.00025737504,0.0005969591,0.0000020101565,0.000041997213,0.00003359308,0.0057189334,0.000107158274,0.00007855274,0.00034437334],"about_ca_topic_score_codex":0.00019367065,"about_ca_topic_score_gemma":0.00029430975,"teacher_disagreement_score":0.19651335,"about_ca_system_score_codex":0.000111016714,"about_ca_system_score_gemma":0.000085013184,"threshold_uncertainty_score":0.8734333},"labels":[],"label_agreement":null},{"id":"W1827903646","doi":"10.1186/1471-5945-7-2","title":"Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series","year":2007,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Center for Research Resources; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Efalizumab; Psoriasis; CD11a; Medicine; Dermatology; CD11c; Immunology; Immune system; Integrin alpha M; Plaque psoriasis; Biology; Phenotype","score_opus":0.021162003274203867,"score_gpt":0.256163776476354,"score_spread":0.23500177320215015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1827903646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896288,0.0075749736,0.00021353665,0.000067314264,0.0009591417,0.00031060725,0.000063169624,0.0001299663,0.0010524747],"genre_scores_gemma":[0.9981271,0.0006514024,0.0004903843,0.000040027233,0.000048945512,0.000041529707,0.00006555609,0.00003274619,0.0005023032],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979858,0.0003435619,0.0005921269,0.00040711797,0.000045000186,0.00062642177],"domain_scores_gemma":[0.9988033,0.0003398074,0.00027709626,0.00043311506,0.00010473815,0.00004194025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019512254,0.00033581833,0.00069188763,0.00027034307,0.00028647023,0.00000870032,0.00021376919,0.00051703583,0.00032291317],"category_scores_gemma":[0.000060199607,0.00029111636,0.00022263717,0.00022815472,0.0003681504,0.00014268325,0.00008243404,0.0001667041,0.00021217018],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074952473,0.0013889266,0.58737713,0.00030848122,0.0033402126,0.012698622,0.007729331,0.000010293954,0.34171364,0.007846089,0.0010501553,0.02904189],"study_design_scores_gemma":[0.0064213886,0.00019680632,0.08763946,0.00003142555,0.00015380996,0.07623305,0.002412977,6.2529125e-7,0.8204113,0.00018479842,0.00590218,0.00041216455],"about_ca_topic_score_codex":0.00016298959,"about_ca_topic_score_gemma":0.0005396391,"teacher_disagreement_score":0.49973765,"about_ca_system_score_codex":0.000035973382,"about_ca_system_score_gemma":0.000091186455,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W1830132041","doi":"10.1007/bf03261868","title":"Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis","year":2012,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of British Columbia; Lynde Centre for Dermatology; University of Toronto; Dermatrials Research","funders":"Pfizer Canada; Amgen Canada; Pfizer; Amgen","keywords":"Medicine; Etanercept; Plaque psoriasis; Health care; Physical therapy; Population; Work productivity; Psoriasis; Productivity; Internal medicine; Environmental health; Dermatology","score_opus":0.07707869048208142,"score_gpt":0.338362433317164,"score_spread":0.26128374283508254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1830132041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90548825,0.0020139813,0.00021121024,0.083534166,0.0007120372,0.006561635,0.0012197968,0.0000782321,0.00018068065],"genre_scores_gemma":[0.97898585,0.0018001115,0.00080608117,0.015936991,0.0003794059,0.0009915753,0.0007925382,0.000055805638,0.00025167334],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977947,0.00010195035,0.0005546126,0.00054590753,0.000021850607,0.0009810036],"domain_scores_gemma":[0.9987748,0.0002631424,0.0003384334,0.00027534252,0.000040361825,0.00030790086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007540807,0.00030572969,0.0006967417,0.00021562148,0.000935191,0.000021868454,0.00008043311,0.00024206145,0.000003994236],"category_scores_gemma":[0.000037837457,0.00028985416,0.000059561324,0.00010312646,0.000045434703,0.00007223878,0.00004699125,0.00012175238,0.000016117088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003583766,0.00067580555,0.062579945,0.0010079569,0.00019835992,1.895492e-8,0.0070848577,0.00005483733,0.000004052175,0.15630698,0.012013835,0.7564896],"study_design_scores_gemma":[0.01092438,0.0022984198,0.454167,0.00008453115,0.00004958903,0.0000043872915,0.0004547075,0.000016506783,0.00014986463,0.003060478,0.5280509,0.0007391965],"about_ca_topic_score_codex":0.00074376847,"about_ca_topic_score_gemma":0.0004740231,"teacher_disagreement_score":0.7557504,"about_ca_system_score_codex":0.00036915418,"about_ca_system_score_gemma":0.0003815699,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W1830479467","doi":"10.1111/j.1365-4632.2010.04512.x","title":"Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studies","year":2010,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Double blind; Placebo; Plaque psoriasis; Randomized controlled trial; Monoclonal antibody; Psoriasis; Dermatology; Monoclonal; Antibody; Internal medicine; Pathology; Immunology","score_opus":0.02345223868321901,"score_gpt":0.3236762313714055,"score_spread":0.3002239926881865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1830479467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881949,0.0066746944,0.00020921224,0.0011740896,0.00232108,0.0010314814,0.00029080219,0.000006497015,0.00009728895],"genre_scores_gemma":[0.9939408,0.004969279,0.00069777755,0.000010652679,0.00013163916,0.000055658624,0.00008760897,0.000013384151,0.000093245275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997639,0.00033503765,0.0015223684,0.00019105544,0.000112365036,0.00020018785],"domain_scores_gemma":[0.99391395,0.0032277454,0.0017241469,0.00019411164,0.00090570556,0.000034341436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041552642,0.00023924094,0.001581661,0.00028003205,0.00008683761,0.000008020713,0.00036074943,0.00020385165,0.000035013498],"category_scores_gemma":[0.00028384523,0.00014032802,0.00042459037,0.000056236815,0.0006489141,0.000094282936,0.000038131733,0.00014813824,0.0000015346824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8943147,0.0011780335,0.0008283694,0.000031303152,0.01330684,0.00016401769,0.0029485195,0.000060752333,0.07350162,0.0038798791,0.000057844867,0.009728134],"study_design_scores_gemma":[0.79818785,0.0017107378,0.0002885874,0.00006909751,0.0018526894,0.013786518,0.0007306163,0.00011321423,0.18144292,0.00084175443,0.0008167738,0.00015926131],"about_ca_topic_score_codex":0.000082423176,"about_ca_topic_score_gemma":0.00015958966,"teacher_disagreement_score":0.10794131,"about_ca_system_score_codex":0.000030367646,"about_ca_system_score_gemma":0.00021023232,"threshold_uncertainty_score":0.57224107},"labels":[],"label_agreement":null},{"id":"W1832791267","doi":"10.1111/ijd.13117","title":"Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis","year":2015,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Tufts Medical Center; Novartis Pharmaceuticals Corporation; Novartis; Amgen","keywords":"Intraclass correlation; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Construct validity; Dermatology Life Quality Index; Physical therapy; Internal medicine; Quality of life (healthcare); Dermatology; Psychometrics; Clinical psychology; Pathology","score_opus":0.048303703591152346,"score_gpt":0.3132335224982294,"score_spread":0.26492981890707706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1832791267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220824,0.0010033569,0.0008218937,0.00031128002,0.00507397,0.00024615816,0.00028201274,0.000008558459,0.00004454212],"genre_scores_gemma":[0.9992288,0.000051036484,0.00016136953,0.00002397779,0.00018096216,0.0000041832054,0.00031633963,0.000015768166,0.000017567892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807274,0.0005143741,0.00074053433,0.00023635595,0.00025695938,0.00017901459],"domain_scores_gemma":[0.9974539,0.00029063926,0.0010742061,0.0004541403,0.000686733,0.00004038174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020702701,0.00018972225,0.0004474297,0.00042070748,0.00007008111,0.000020152485,0.0012276071,0.00015098735,0.00011358038],"category_scores_gemma":[0.00020904289,0.00012309107,0.00009963734,0.00030172223,0.00011345922,0.00036734968,0.00022418193,0.00020078407,0.000017630524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040180963,0.0037335411,0.9644008,0.0000054123548,0.0056426357,0.00008489289,0.0010625953,0.000097419135,0.0028712687,0.000036847672,0.0018110711,0.016235363],"study_design_scores_gemma":[0.29021564,0.0041067884,0.46806562,0.00055200147,0.006942627,0.007072064,0.002709128,0.0003196836,0.20558125,0.0008739076,0.012233799,0.0013274793],"about_ca_topic_score_codex":0.00015967734,"about_ca_topic_score_gemma":0.000048660935,"teacher_disagreement_score":0.49633524,"about_ca_system_score_codex":0.0001613071,"about_ca_system_score_gemma":0.00036977147,"threshold_uncertainty_score":0.5019508},"labels":[],"label_agreement":null},{"id":"W1833097568","doi":"10.3899/jrheum.140954","title":"Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Kwantlen Polytechnic University","funders":"","keywords":"Lupus nephritis; Medicine; Urinary system; Internal medicine; Cytokine; Endocrinology; Nephritis; Immunology; Gastroenterology; Disease","score_opus":0.016689910572271784,"score_gpt":0.230053859457489,"score_spread":0.2133639488852172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1833097568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702184,0.028330624,0.00004847769,0.00062033354,0.0006311235,0.00006453034,0.000006976386,0.000006468839,0.00007302877],"genre_scores_gemma":[0.99243385,0.0071408655,0.00025890817,0.00004857197,0.000009300303,0.0000021371643,0.0000048708894,0.000007717809,0.000093800474],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99890286,0.00045046685,0.00032666084,0.000093472896,0.00003174297,0.00019477747],"domain_scores_gemma":[0.99935824,0.00024104705,0.00020289343,0.000111213536,0.000046763158,0.000039858096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005077169,0.0001231039,0.00035295286,0.00012714112,0.000073684314,0.0000062430963,0.00013646367,0.00016052181,0.000035740293],"category_scores_gemma":[0.00006854255,0.00007490184,0.000029624076,0.0000621929,0.00020010781,0.00009541503,0.0000951255,0.00021833264,0.000010672097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040961853,0.0002969946,0.8515044,0.000032178716,0.0003228821,0.00022179291,0.005676596,0.000009819035,0.103395335,0.00030844027,0.006787158,0.027348245],"study_design_scores_gemma":[0.03125973,0.004740158,0.24533932,0.0006802285,0.00047786772,0.58729583,0.004264461,0.000017117349,0.09819589,0.0077206804,0.01931304,0.00069570536],"about_ca_topic_score_codex":0.00006123369,"about_ca_topic_score_gemma":0.000033891683,"teacher_disagreement_score":0.60616505,"about_ca_system_score_codex":0.000017921104,"about_ca_system_score_gemma":0.000051981828,"threshold_uncertainty_score":0.30544084},"labels":[],"label_agreement":null},{"id":"W1842534514","doi":"10.1016/j.jaad.2015.07.002","title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":224,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Biogen; Janssen Scientific Affairs; Pfizer; Eli Lilly and Company","keywords":"Medicine; Ustekinumab; Placebo; Psoriasis; Dosing; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Gastroenterology; Crossover study; Randomized controlled trial; Randomization; Dermatology; Adalimumab; Pathology","score_opus":0.02644487551324075,"score_gpt":0.2893892750184099,"score_spread":0.2629443995051691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1842534514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958107,0.00022281053,0.000012926942,0.0024585265,0.000364413,0.000998021,0.000058378773,0.0000051626475,0.000069085174],"genre_scores_gemma":[0.99902767,0.000032931017,0.00012032133,0.0006427778,0.000023022267,0.000020830972,0.000002553776,0.000016942624,0.00011292404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99628866,0.0018781417,0.0011252946,0.0002115205,0.00017982395,0.00031655957],"domain_scores_gemma":[0.99752706,0.0002800483,0.0017266601,0.0002676814,0.00011936964,0.00007917133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005636767,0.00023203743,0.0014315988,0.00028075842,0.000052599647,0.0000054181096,0.00075416197,0.0001359239,0.0000043601285],"category_scores_gemma":[0.00036507475,0.0001241392,0.0002342966,0.0004435845,0.0004008168,0.00006520117,0.00017969137,0.0004667721,0.000007718871],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8235777,0.005461383,0.11232854,0.000030823798,0.0028254895,0.00015011212,0.015770858,0.0019054818,0.0050706137,0.00003505024,0.024577277,0.008266647],"study_design_scores_gemma":[0.62895834,0.002993526,0.33113348,0.00045046065,0.0013290783,0.0014114026,0.0044369823,0.000007666934,0.025636569,0.00011384767,0.0030588596,0.00046976478],"about_ca_topic_score_codex":0.00014954605,"about_ca_topic_score_gemma":0.00006965706,"teacher_disagreement_score":0.21880494,"about_ca_system_score_codex":0.000090985435,"about_ca_system_score_gemma":0.00018456292,"threshold_uncertainty_score":0.506225},"labels":[],"label_agreement":null},{"id":"W1858003552","doi":"10.1002/art.39233","title":"Interleukin‐21 Receptor Blockade Inhibits Secondary Humoral Responses and Halts the Progression of Preestablished Disease in the (NZB × NZW)F1 Systemic Lupus Erythematosus Model","year":2015,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phoenix Technologies (Canada); Amgen (Canada)","funders":"Amgen","keywords":"Blockade; Immunology; Medicine; Disease; Systemic lupus erythematosus; Antibody; Receptor; Internal medicine","score_opus":0.017601838771958797,"score_gpt":0.24480436314460696,"score_spread":0.22720252437264815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1858003552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465313,0.050722457,0.000009779663,0.00096679805,0.0007051266,0.0007059244,0.00014046191,0.00005182387,0.00016636112],"genre_scores_gemma":[0.997625,0.001510913,0.00008102435,0.00007262756,0.000010064448,0.00027877875,0.00012450393,0.00002456412,0.00027252774],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698704,0.0013769213,0.0006422206,0.00043678717,0.00009064753,0.0004663984],"domain_scores_gemma":[0.9984574,0.0005534729,0.0002895334,0.00053470145,0.00009723442,0.0000676621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000828968,0.0002952083,0.0006154215,0.00017500858,0.00019605292,0.000032221087,0.00037296768,0.00026428595,0.000043277483],"category_scores_gemma":[0.00032645103,0.00018331941,0.00009751677,0.00019513938,0.00066650496,0.00017729521,0.000191301,0.0002996215,0.000050586965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014490528,0.0015399804,0.7871274,0.00050132803,0.00059355877,0.0003568654,0.049027503,0.000068436544,0.027693717,0.009101113,0.01804185,0.09145776],"study_design_scores_gemma":[0.22163767,0.015231081,0.14268905,0.03308927,0.002210028,0.18558854,0.10157638,0.0026655954,0.19532397,0.036227103,0.054611694,0.009149624],"about_ca_topic_score_codex":0.00013895161,"about_ca_topic_score_gemma":0.00033761538,"teacher_disagreement_score":0.6444383,"about_ca_system_score_codex":0.000027714055,"about_ca_system_score_gemma":0.0002917627,"threshold_uncertainty_score":0.74755484},"labels":[],"label_agreement":null},{"id":"W1870006248","doi":"","title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Discontinuation; Mace; Adverse effect; Psoriasis; Stroke (engine); Internal medicine; Myocardial infarction; Randomized controlled trial; Dermatology; Disease; Infliximab; Percutaneous coronary intervention","score_opus":0.064260563350052,"score_gpt":0.29004928294999893,"score_spread":0.22578871959994695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1870006248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996849,0.00022666242,0.000018522493,0.00021354509,0.001205284,0.0012047315,0.00011137957,0.000033301043,0.00013758069],"genre_scores_gemma":[0.9980054,0.000051277733,0.00024219936,0.00013673217,0.000085085645,0.0009725599,0.00011651035,0.00001543503,0.00037483074],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998224,0.0004304154,0.00052256306,0.0002933184,0.00009408775,0.00043557558],"domain_scores_gemma":[0.99839246,0.0005839951,0.00025185526,0.00064686395,0.00006010861,0.000064699256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009828995,0.00017159272,0.000310782,0.000034818557,0.00011855981,0.000010712444,0.0004605163,0.00015059604,0.000043355438],"category_scores_gemma":[0.00019868734,0.00009173869,0.000098376884,0.00016965061,0.00019364383,0.000076787765,0.00008088461,0.00012417314,0.00005272628],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004942967,0.00044797163,0.17857915,0.00000253309,0.0005157575,0.0000019922236,0.0061543146,8.017726e-7,0.00016194674,0.000061119965,0.00034752412,0.80878395],"study_design_scores_gemma":[0.0024411092,0.00017233589,0.9688813,0.000021297505,0.00010334582,0.0000030479875,0.00041705568,8.7037016e-8,0.01917951,0.0000027689462,0.00865538,0.00012276016],"about_ca_topic_score_codex":0.000075009106,"about_ca_topic_score_gemma":0.00016166648,"teacher_disagreement_score":0.80866116,"about_ca_system_score_codex":0.000031048097,"about_ca_system_score_gemma":0.000048131653,"threshold_uncertainty_score":0.37409952},"labels":[],"label_agreement":null},{"id":"W1877047792","doi":"10.1111/j.1365-2133.2007.08236.x","title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","year":2007,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Abbott Laboratories","keywords":"Adalimumab; Medicine; Psoriasis; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Visual analogue scale; Placebo; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Severity of illness; Psoriatic arthritis; Methotrexate; Dermatology; Physical therapy; Disease; Pathology","score_opus":0.02183459601506674,"score_gpt":0.2774386911100152,"score_spread":0.2556040950949484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1877047792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950758,0.0016186044,0.00003742325,0.00017918453,0.0003742886,0.0021208345,0.0005126993,0.000009115974,0.000072053874],"genre_scores_gemma":[0.9994728,0.00014845726,0.00010292512,0.00010117865,0.0000103779585,0.000028906983,0.00009397063,0.000020280511,0.000021090516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99345523,0.0020735348,0.003684108,0.00028234426,0.00013484004,0.00036996446],"domain_scores_gemma":[0.9937719,0.0023166274,0.0033283127,0.00020244664,0.00026205266,0.00011863132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009052887,0.00030880223,0.004027262,0.0003712214,0.000066783825,0.000009921539,0.00010604872,0.00031391103,0.000052654388],"category_scores_gemma":[0.0010137453,0.00021513061,0.0005452704,0.00015832983,0.00014351748,0.00007114087,0.000019009074,0.0001938505,0.000002098164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91938055,0.0030266854,0.062129978,0.0000072694556,0.0062819384,0.00013504864,0.0010866461,0.00004991285,0.000053972915,0.000008507684,0.000095076684,0.007744432],"study_design_scores_gemma":[0.87441933,0.004387446,0.11956543,0.00017443836,0.00029955557,0.00040597154,0.00012839555,0.0000010458336,0.00039124748,0.00005777915,0.000008219714,0.00016111533],"about_ca_topic_score_codex":0.007558094,"about_ca_topic_score_gemma":0.0015217521,"teacher_disagreement_score":0.05743545,"about_ca_system_score_codex":0.00017264223,"about_ca_system_score_gemma":0.0003394407,"threshold_uncertainty_score":0.9990507},"labels":[],"label_agreement":null},{"id":"W187890988","doi":"","title":"XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Psoriasis; Placebo; Medicine; Psoriasis Area and Severity Index; Placebo group; Internal medicine; Double blind study; Randomized controlled trial; Group B; Double blind; Gastroenterology; Dermatology; Pathology","score_opus":0.04327028975293733,"score_gpt":0.2720589793800247,"score_spread":0.22878868962708737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W187890988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788353,0.0035013412,0.000048797967,0.0002667137,0.0008340797,0.013465044,0.000018656756,0.00003998712,0.0029901194],"genre_scores_gemma":[0.97993857,0.00019858616,0.000023973938,0.000096961136,0.00009215437,0.01713838,0.000032652413,0.000019457097,0.0024592923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99728066,0.00079346716,0.0007592579,0.0004003306,0.000091036934,0.0006752419],"domain_scores_gemma":[0.9980974,0.0011274723,0.00019554317,0.00046950203,0.0000625577,0.00004751188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028716137,0.0003347599,0.0012336968,0.0003379266,0.00013063778,0.000022929184,0.00029170574,0.00019459071,0.000041456235],"category_scores_gemma":[0.00007924118,0.0001903985,0.0003300979,0.0003872811,0.00008578109,0.000057480953,0.000024141651,0.000095287985,0.00007337641],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9225833,0.0029702543,0.0016371396,0.000004028081,0.0018617666,0.000024079009,0.0056034885,0.000035899495,0.00012153376,0.00016734192,0.00012217804,0.064868994],"study_design_scores_gemma":[0.9733213,0.00042015762,0.012810265,0.000005469322,0.00094404095,0.000008200028,0.0014739567,0.0000016168646,0.009425119,0.00006630971,0.0013131078,0.00021042825],"about_ca_topic_score_codex":0.00043034475,"about_ca_topic_score_gemma":0.0010119538,"teacher_disagreement_score":0.06465857,"about_ca_system_score_codex":0.00010657013,"about_ca_system_score_gemma":0.00003237644,"threshold_uncertainty_score":0.77642256},"labels":[],"label_agreement":null},{"id":"W1888848129","doi":"10.1177/1759720x15591801","title":"Atherosclerosis in psoriatic disease: latest evidence and clinical implications","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Musculoskeletal Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Disease; Inflammation; Methotrexate; Observational study; Risk factor; Internal medicine; Population; Atherosclerotic cardiovascular disease; Rheumatoid arthritis; Immunology","score_opus":0.09826791372089386,"score_gpt":0.41706919816370125,"score_spread":0.3188012844428074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1888848129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014444396,0.99585396,0.0000162807,0.00014669614,0.00063940993,0.0014709239,0.0003095001,0.00006965364,0.000049146274],"genre_scores_gemma":[0.012121721,0.9861899,0.000037618323,0.000051399962,0.00009314382,0.0008278375,0.0004087924,0.0000688774,0.00020070434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958454,0.001405538,0.0011035347,0.0009869195,0.0000892885,0.0005693411],"domain_scores_gemma":[0.99730664,0.0011678276,0.0003868973,0.00084779225,0.00005161915,0.0002392168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068501354,0.0006659085,0.0016543793,0.0002663534,0.00010393609,0.000026963093,0.00050914777,0.00036538133,0.0000855671],"category_scores_gemma":[0.00029657778,0.00053001253,0.00057561346,0.0005447419,0.0005010617,0.00036756438,0.00016368354,0.00048436614,0.00029005314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011696545,0.00055734883,0.012330837,0.0029288803,0.00018467882,0.000009575778,0.000022803431,0.0000020185978,4.648204e-7,0.0004766504,0.000015412423,0.9833544],"study_design_scores_gemma":[0.0020136114,0.00018593698,0.11851388,0.011700714,0.0043404736,0.0000050323647,0.000020505639,0.000004623988,6.698969e-8,0.004736181,0.8574671,0.0010118466],"about_ca_topic_score_codex":0.000012224501,"about_ca_topic_score_gemma":0.00004963932,"teacher_disagreement_score":0.98234254,"about_ca_system_score_codex":0.00020521866,"about_ca_system_score_gemma":0.000493311,"threshold_uncertainty_score":0.99971515},"labels":[],"label_agreement":null},{"id":"W1891467571","doi":"","title":"The effect of biologic therapies on the risk of suffering a myocardial infarction (MI) in patients with moderate to severe psoriasis","year":2015,"lang":"en","type":"dissertation","venue":"Memorial University Research Repository (Memorial University)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Confounding; Psoriasis; Myocardial infarction; Internal medicine; Logistic regression; Disease; Risk factor; Physical therapy; Immunology","score_opus":0.014768162684782227,"score_gpt":0.2324791544574714,"score_spread":0.21771099177268916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1891467571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874935,0.000085367814,0.0000011900294,0.000024297073,0.005377644,0.0014371966,0.00015004951,0.00002956226,0.0054011988],"genre_scores_gemma":[0.9931251,0.00017017653,0.0000054480006,0.0000010695513,0.0003596665,0.0000036154368,0.00022732896,0.000025314384,0.006082315],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99335825,0.004835538,0.00028935738,0.00057545525,0.0004171352,0.0005242633],"domain_scores_gemma":[0.9962393,0.0018565825,0.00042066714,0.0006411736,0.00076892844,0.00007334396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015568234,0.0003941734,0.0007056198,0.0008872046,0.0011650933,0.000036829148,0.0009766849,0.0006303662,0.000018858747],"category_scores_gemma":[0.00039636964,0.00025911417,0.00028125398,0.0012162075,0.0004012422,0.00016058823,0.00019840548,0.0008713223,0.000019862755],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7497766,0.00091593375,0.18675153,0.00024511723,0.009467713,0.0002031423,0.008530132,0.0011273698,0.019103482,0.0017637265,0.004013505,0.018101772],"study_design_scores_gemma":[0.08681763,0.051137432,0.5067813,0.0015684197,0.0050047007,0.00001272568,0.032779817,0.000017096125,0.2517251,0.0004096725,0.06081065,0.002935499],"about_ca_topic_score_codex":0.0028585212,"about_ca_topic_score_gemma":0.0013458794,"teacher_disagreement_score":0.6629589,"about_ca_system_score_codex":0.00060897996,"about_ca_system_score_gemma":0.0004666712,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W1892175722","doi":"10.1111/bjd.14018","title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":322,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Janssen Biotech; Allergan; LEO Pharma; Genentech; Celgene; Novartis; Pfizer; ApoPharma; Boehringer Ingelheim; Amgen; AbbVie; Merck; Abbott Laboratories; Eli Lilly and Company","keywords":"Tofacitinib; Janus kinase inhibitor; Placebo; Medicine; Adverse effect; Psoriasis; Internal medicine; Randomized controlled trial; Plaque psoriasis; Gastroenterology; Dermatology; Pathology","score_opus":0.04869677487528288,"score_gpt":0.31686382013012293,"score_spread":0.26816704525484003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1892175722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89344376,0.09621257,0.001090101,0.00077365775,0.004045515,0.002393753,0.0019206567,0.00002791039,0.000092059396],"genre_scores_gemma":[0.99149853,0.006278812,0.00040439895,0.0000533435,0.00075703184,0.00027012618,0.00050983136,0.00003228597,0.00019564209],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927218,0.0035750112,0.0027529784,0.00034541177,0.000111075424,0.0004937213],"domain_scores_gemma":[0.9909625,0.0059790304,0.002150761,0.00034442337,0.00043401192,0.00012928742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024849556,0.00038005598,0.003613719,0.00019038985,0.00022684856,0.0000517182,0.00038232392,0.00040186304,0.000103397775],"category_scores_gemma":[0.001691588,0.00026314054,0.0012067826,0.000104122475,0.00041693271,0.00021703492,0.000025781079,0.00020322576,0.00001818295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7638176,0.001957686,0.000030565123,0.0000072366056,0.0055894023,0.0008169835,0.0011670182,0.000045400317,0.00252511,0.000099767676,0.004622989,0.21932022],"study_design_scores_gemma":[0.9044455,0.0022301525,0.000009226125,0.00010207406,0.0037333907,0.008416018,0.0006252618,0.00007546736,0.055107363,0.00045459167,0.024569554,0.00023139674],"about_ca_topic_score_codex":0.0010293572,"about_ca_topic_score_gemma":0.000809523,"teacher_disagreement_score":0.21908882,"about_ca_system_score_codex":0.00014686963,"about_ca_system_score_gemma":0.0006430022,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W1895427692","doi":"10.1111/j.1365-4632.2010.04660.x","title":"<b>A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis</b>","year":2010,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Université Laval; University of Alberta; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"European Academy of Dermatology and Venereology","keywords":"Medicine; Psoriasis; Medical prescription; Plaque psoriasis; Quality of life (healthcare); Dermatology; Disease; Patient satisfaction; Internal medicine; Surgery; Nursing","score_opus":0.025817997375848587,"score_gpt":0.29554447228164465,"score_spread":0.26972647490579604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1895427692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992105,0.00009087448,0.00005597296,0.005650337,0.0015884347,0.00017099024,0.0002916668,0.000006227566,0.000040460378],"genre_scores_gemma":[0.99880403,0.00006674202,0.000591372,0.00024043418,0.00005447333,0.000015233944,0.00012165046,0.0000126030545,0.000093438466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887425,0.00024773212,0.00037257138,0.00018772761,0.00007635251,0.00024134685],"domain_scores_gemma":[0.99912286,0.00018525592,0.00015372374,0.00010268383,0.0003168883,0.0001185908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014313382,0.00017383357,0.000343729,0.000663701,0.00006786434,0.00002832846,0.00018394875,0.00018065084,0.00009441244],"category_scores_gemma":[0.00008375783,0.00013340547,0.000036858328,0.00011608579,0.00003129023,0.00011637571,0.000027816608,0.00018239548,0.00003856055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008971009,0.0001096942,0.9707955,0.0000013310122,0.00051617477,0.00036238114,0.0006716741,0.00017672952,0.0032725732,0.00009146541,0.00023244503,0.022872921],"study_design_scores_gemma":[0.004423927,0.0002822826,0.9721979,0.000033375327,0.0000619841,0.012363343,0.000097952034,0.000009157668,0.006050737,0.00008259071,0.0042262617,0.00017047374],"about_ca_topic_score_codex":0.042201824,"about_ca_topic_score_gemma":0.7519778,"teacher_disagreement_score":0.709776,"about_ca_system_score_codex":0.00020393364,"about_ca_system_score_gemma":0.0005869978,"threshold_uncertainty_score":0.96417624},"labels":[],"label_agreement":null},{"id":"W1908273569","doi":"10.4049/jimmunol.0900978","title":"Th17 Cells Are the Dominant T Cell Subtype Primed by <i>Shigella flexneri</i> Mediating Protective Immunity","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Shigella flexneri; Biology; Priming (agriculture); Immunology; MHC class II; Interleukin 12; Immune system; Acquired immune system; Shigella; Immunity; T cell; Interleukin 17; Cytotoxic T cell; Microbiology; Bacteria; Genetics; In vitro; Gene","score_opus":0.008529243201153298,"score_gpt":0.21230295581231956,"score_spread":0.20377371261116625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1908273569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98185235,0.012725912,0.000085471955,0.0009118469,0.0033966275,0.00041947406,0.00003657967,0.000020352405,0.00055138196],"genre_scores_gemma":[0.9976097,0.0010618205,0.000052786632,0.00015935494,0.00014431203,0.000017632758,0.000011885652,0.000029820618,0.00091272435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971112,0.0015070633,0.00062420464,0.0001631644,0.00008287058,0.0005115024],"domain_scores_gemma":[0.9965069,0.0012223397,0.0013388384,0.0006369622,0.00026713818,0.000027803915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018316287,0.00030752315,0.0005315623,0.00009405797,0.0007124419,0.000020798554,0.0011511231,0.00043110354,0.00020738585],"category_scores_gemma":[0.0002298994,0.00015421819,0.00019209334,0.00019850711,0.0007094949,0.0001038802,0.0001958344,0.0018114313,0.00024777785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011296911,0.00022784492,0.0003137935,0.0000062853305,0.0005492413,0.00000941375,0.0016879208,0.0000033597032,0.9896576,0.000029804627,0.0014695793,0.0049154786],"study_design_scores_gemma":[0.0021754685,0.00063159794,0.002990334,0.00001842582,0.0003281857,0.0005125311,0.0020936006,9.224379e-7,0.9789443,0.0002346754,0.011892677,0.00017728841],"about_ca_topic_score_codex":0.00020160855,"about_ca_topic_score_gemma":0.00005718335,"teacher_disagreement_score":0.01575731,"about_ca_system_score_codex":0.000048907135,"about_ca_system_score_gemma":0.00017121831,"threshold_uncertainty_score":0.7869868},"labels":[],"label_agreement":null},{"id":"W1909465917","doi":"10.1177/1203475415604322","title":"Predictors of Topical Use in Psoriasis Patients in the REFINE Study","year":2015,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Amgen (Canada); SKiN Health","funders":"Amgen Canada; Amgen","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE","score_opus":0.047780087603215775,"score_gpt":0.2632752384171822,"score_spread":0.21549515081396642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1909465917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745977,0.0012003621,6.9484344e-7,0.00027179217,0.0008588414,0.000105732586,0.0000027336016,0.000002000037,0.00009808742],"genre_scores_gemma":[0.9993845,0.0003448471,0.000004665085,0.0000825546,0.000090579146,0.0000018270041,0.0000057942298,0.0000043430005,0.00008085746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985768,0.00044494437,0.00064737024,0.00008457735,0.000110787776,0.00013549624],"domain_scores_gemma":[0.99835855,0.0011548657,0.0002449312,0.00011136651,0.00010088973,0.000029385666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093449943,0.00010044416,0.0004964635,0.0002701121,0.00001800038,0.000003060183,0.00008941198,0.00008586686,0.000018576002],"category_scores_gemma":[0.0008828,0.000053433858,0.00005572349,0.00017408264,0.00008750648,0.00006152792,0.0000147158735,0.00016675187,0.0000011551352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007420674,0.0006331243,0.9833427,0.0000056963363,0.00010129233,0.00048111455,0.0053155376,0.0000014839972,0.00011702318,0.000004580888,0.0035215677,0.005733808],"study_design_scores_gemma":[0.0038122004,0.0022069733,0.98356235,0.00013448409,0.00017657898,0.00084436836,0.0058987015,3.9302907e-7,0.0001277489,0.000047748956,0.00311259,0.00007586307],"about_ca_topic_score_codex":0.00026627633,"about_ca_topic_score_gemma":0.0002559229,"teacher_disagreement_score":0.005657945,"about_ca_system_score_codex":0.000024865305,"about_ca_system_score_gemma":0.000058359048,"threshold_uncertainty_score":0.21789694},"labels":[],"label_agreement":null},{"id":"W1914487296","doi":"10.1186/1471-5945-6-9","title":"Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence","year":2006,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Efalizumab; Medicine; Discontinuation; Methotrexate; Psoriasis; Plaque psoriasis; Dermatology; Internal medicine; Surgery","score_opus":0.11178013982788167,"score_gpt":0.29296682698034254,"score_spread":0.1811866871524609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1914487296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944875,0.0016953035,0.0011554111,0.000101128484,0.00039065644,0.0014596785,0.000026594815,0.00005747,0.0006262137],"genre_scores_gemma":[0.9968004,0.000006325365,0.00207907,0.000026069647,0.000026100379,0.0005344874,0.00010003364,0.000023495117,0.00040401443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983906,0.00037826228,0.00042714883,0.00041581705,0.000027855496,0.00036027504],"domain_scores_gemma":[0.9991504,0.00020258517,0.00018169254,0.00040500864,0.00003934433,0.000020955054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019335511,0.00021780332,0.000489475,0.00016125257,0.00019035998,0.000027430027,0.0005316047,0.00014625675,0.000016512602],"category_scores_gemma":[0.000021245181,0.00019030044,0.0000383399,0.00012284196,0.000090899775,0.00017796321,0.00017520906,0.00006614354,0.000029589923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043412847,0.012518649,0.71232516,0.00040123504,0.0013986124,0.000054641332,0.02005986,0.00009714359,0.050147727,0.06033005,0.0029781119,0.13534752],"study_design_scores_gemma":[0.11700833,0.009742795,0.5793949,0.00044127455,0.0022208032,0.0012694411,0.055922143,0.0004348932,0.17816488,0.018579159,0.03262976,0.00419165],"about_ca_topic_score_codex":0.00017790921,"about_ca_topic_score_gemma":0.0015086365,"teacher_disagreement_score":0.1329303,"about_ca_system_score_codex":0.000017465663,"about_ca_system_score_gemma":0.000046185683,"threshold_uncertainty_score":0.77602273},"labels":[],"label_agreement":null},{"id":"W1915047740","doi":"10.1684/ejd.2010.1185","title":"Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"European Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Barrie Urology Group","funders":"","keywords":"Medicine; Multicenter study; Placebo; Psoriasis; Double blind; Quality of life (healthcare); Plaque psoriasis; Dermatology; Randomization; Randomized controlled trial; Internal medicine; Physical therapy; Pathology; Alternative medicine","score_opus":0.03980831006728343,"score_gpt":0.2679680252316674,"score_spread":0.228159715164384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1915047740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943435,0.0008786186,0.00002225191,0.000056154324,0.0005211556,0.0016255027,0.000027224687,0.000014040332,0.0025115486],"genre_scores_gemma":[0.99954903,0.00010767083,0.00007781743,0.00005177097,0.00002482674,0.000030935167,0.000035884033,0.000033359633,0.00008871344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992248,0.004846876,0.002089802,0.0002695672,0.00008923431,0.00045650438],"domain_scores_gemma":[0.997221,0.0003789342,0.001602154,0.00030141993,0.00032818917,0.00016830962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014161774,0.00035277338,0.0022527245,0.00072157825,0.00009448884,0.00000889829,0.00039637848,0.00012520877,0.0002698778],"category_scores_gemma":[0.00020734708,0.00024171577,0.0003121396,0.00022282229,0.00022143027,0.00013938242,0.000037327063,0.00032890035,0.000053539352],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72467345,0.0029651888,0.2645264,0.000011198129,0.0024379806,0.0009356004,0.0033893252,0.0000013889195,0.00010455676,0.00002903124,0.000073681906,0.0008522067],"study_design_scores_gemma":[0.9651645,0.0011622935,0.03032914,0.000046572546,0.0006602074,0.00023302452,0.0008348557,0.0000011282716,0.001195091,0.0000023479852,0.00015022377,0.00022061646],"about_ca_topic_score_codex":0.008233071,"about_ca_topic_score_gemma":0.012481469,"teacher_disagreement_score":0.24049106,"about_ca_system_score_codex":0.00006431423,"about_ca_system_score_gemma":0.00028869498,"threshold_uncertainty_score":0.9983712},"labels":[],"label_agreement":null},{"id":"W1919283206","doi":"10.1016/j.jaad.2015.03.049","title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":669,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Ortho-McNeil Pharmaceutical; Janssen Pharmaceuticals; Johnson and Johnson; Janssen Biotech; 3M; Merck Sharp and Dohme; Biogen Idec; Genentech; LEO Pharma; Abbott Laboratories; National Institute for Health and Care Research; Sandoz; Novartis; Celgene; Merck; GlaxoSmithKline; Astellas Pharma US; Galderma; Eli Lilly and Company; Pfizer; Amgen; AbbVie; Society of Daughters of the United States Army; Allergan; Merz Therapeutics","keywords":"Apremilast; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Dermatology; Phosphodiesterase inhibitor; Phosphodiesterase; Internal medicine; Pharmacology; Clinical trial; Psoriatic arthritis; Enzyme","score_opus":0.01953649670246773,"score_gpt":0.30237140756684366,"score_spread":0.28283491086437595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1919283206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931135,0.0008277688,0.000017562546,0.0007702807,0.0007877958,0.0044073565,0.00004897023,0.000005924544,0.00002083804],"genre_scores_gemma":[0.99921274,0.00014454006,0.00026502993,0.00014628409,0.0000717505,0.00011241744,0.0000076534125,0.000021967302,0.000017639988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99069154,0.00559742,0.0027245723,0.00031883363,0.00027112936,0.00039651606],"domain_scores_gemma":[0.99105084,0.0041727386,0.0041776462,0.00027759426,0.0002276471,0.000093524424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026918405,0.00038834263,0.0038365326,0.00040793422,0.000078315985,0.0000093772,0.0005254612,0.00026910327,0.000002998946],"category_scores_gemma":[0.0030244149,0.00020769343,0.00034109745,0.00049483654,0.00078966975,0.00018731174,0.00013835046,0.00059312646,6.3429485e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98371506,0.0018382786,0.001443861,0.000029812933,0.001095188,0.0000073326237,0.003419059,0.00032964608,0.002561916,0.0000144071555,0.00017003677,0.005375386],"study_design_scores_gemma":[0.9755228,0.009210651,0.0013719427,0.00035329026,0.00103743,0.00011875887,0.00047054916,0.00005912252,0.01157455,0.000063404565,0.000025465895,0.00019199926],"about_ca_topic_score_codex":0.00013905583,"about_ca_topic_score_gemma":0.00003208331,"teacher_disagreement_score":0.009012634,"about_ca_system_score_codex":0.000083333776,"about_ca_system_score_gemma":0.0003851081,"threshold_uncertainty_score":0.8469492},"labels":[],"label_agreement":null},{"id":"W1924457352","doi":"10.1111/j.1468-3083.2012.04705.x","title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","year":2012,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Mace; Adverse effect; Internal medicine; Interim analysis; Clinical trial; Incidence (geometry); Population; Surgery; Myocardial infarction","score_opus":0.12957312501059454,"score_gpt":0.414242384369461,"score_spread":0.28466925935886644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924457352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98814005,0.0067637283,0.0001170329,0.0022869613,0.0009806916,0.00091549987,0.0007241653,0.0000034708844,0.00006839428],"genre_scores_gemma":[0.99716455,0.0018997446,0.00028465022,0.00032877526,0.00013835068,0.0000041853637,0.00011579362,0.000015169726,0.000048800375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9728681,0.022338014,0.004010438,0.000422991,0.000086351916,0.00027414778],"domain_scores_gemma":[0.9898268,0.00556667,0.0039299293,0.00050285226,0.00008475039,0.00008897097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012048402,0.00029892745,0.0050301584,0.0003368165,0.00014990178,0.000011650257,0.0011038597,0.00044588078,0.000029725423],"category_scores_gemma":[0.0038290627,0.0001627417,0.0004246678,0.0002063232,0.00087310805,0.0002606831,0.0015299978,0.0005768911,9.328014e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94033104,0.0012968886,0.0088632535,0.000006946302,0.012848243,0.000011736705,0.0013893561,0.000013707963,0.025424492,0.00014326168,0.00030909912,0.009361993],"study_design_scores_gemma":[0.9383336,0.0005127398,0.03980638,0.00020107573,0.015335471,0.0003682793,0.00019861033,0.0004989145,0.0037595802,0.00045508397,0.00032765346,0.00020263743],"about_ca_topic_score_codex":0.00014295436,"about_ca_topic_score_gemma":0.00006605821,"teacher_disagreement_score":0.030943125,"about_ca_system_score_codex":0.000011757215,"about_ca_system_score_gemma":0.00006965407,"threshold_uncertainty_score":0.66364133},"labels":[],"label_agreement":null},{"id":"W1924808736","doi":"10.3899/jrheum.150554","title":"Of Mice and Men: Defining the Role of Interleukin 17 in Rheumatoid Arthritis","year":2015,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Rheumatoid arthritis; Placebo; Rheumatology; Methotrexate; Internal medicine; Population; Arthritis; Psoriasis; Clinical endpoint; Psoriatic arthritis; Immunology; Clinical trial; Pharmacology; Pathology; Alternative medicine","score_opus":0.00991117105318097,"score_gpt":0.21605190485631431,"score_spread":0.20614073380313336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924808736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78133535,0.18179254,0.0000056811746,0.034951974,0.00077350205,0.0001827392,0.000067913024,0.000006336104,0.0008839633],"genre_scores_gemma":[0.9682515,0.028419869,0.00006367435,0.002908979,0.000020850299,0.0000073496362,0.00004202422,0.00003664623,0.0002490733],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970951,0.0012375481,0.0011289035,0.00013944972,0.00008269064,0.00031628806],"domain_scores_gemma":[0.9963838,0.0014316258,0.0016789322,0.0003139066,0.00017672358,0.00001501967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013106613,0.0002728972,0.0012292328,0.00028771686,0.00006423885,0.000005350456,0.0006198646,0.0007097355,0.000089411726],"category_scores_gemma":[0.00017051274,0.0001545974,0.00016793332,0.00012316667,0.00060071953,0.000056613593,0.00014280165,0.0011829104,0.0000160265],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002081622,0.00020659839,0.0751567,0.0001785114,0.003536598,0.000097150834,0.013774197,0.0000117325335,0.0077575943,0.0011945973,0.851964,0.044040684],"study_design_scores_gemma":[0.013277166,0.0023666036,0.003550088,0.0039839097,0.00087957317,0.08257625,0.010780535,0.000009664935,0.021377448,0.009005591,0.85132843,0.0008647643],"about_ca_topic_score_codex":0.0005582956,"about_ca_topic_score_gemma":0.00019804332,"teacher_disagreement_score":0.18691619,"about_ca_system_score_codex":0.000033697004,"about_ca_system_score_gemma":0.00019228442,"threshold_uncertainty_score":0.63042986},"labels":[],"label_agreement":null},{"id":"W1924890477","doi":"10.4049/jimmunol.0902822","title":"Th17 Polarized Cells from Nonobese Diabetic Mice Following Mycobacterial Adjuvant Immunotherapy Delay Type 1 Diabetes","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"NOD mice; Nod; Spleen; Immunology; Adoptive cell transfer; Medicine; Lymph node; Adjuvant; Immunotherapy; Splenocyte; Cytokine; Interleukin 12; Interleukin 17; T cell; Immune system; Diabetes mellitus; Cytotoxic T cell; Autoimmunity; Biology; In vitro; Endocrinology","score_opus":0.007427913875833662,"score_gpt":0.21374488385275447,"score_spread":0.2063169699769208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924890477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96131825,0.021166282,0.00002839353,0.00028727474,0.016869599,0.0001776377,0.000042731986,0.00003096151,0.00007884876],"genre_scores_gemma":[0.99748296,0.001272276,0.00032145798,0.00018654525,0.00033809931,0.0000047767003,0.000046211862,0.00004322817,0.0003044774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99760836,0.00084420363,0.00070914923,0.00019834266,0.0000701845,0.00056975003],"domain_scores_gemma":[0.99766666,0.00096076983,0.00063089945,0.0005500032,0.00015823099,0.00003343883],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086236245,0.000341049,0.00077489094,0.00016840489,0.0003137725,0.00003180979,0.00091534713,0.0005151594,0.0011891874],"category_scores_gemma":[0.00012511629,0.00021780869,0.00038234415,0.00017486098,0.00029171683,0.0001815494,0.00011606896,0.0009350375,0.0005126096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00177935,0.0001813929,0.0024414186,0.000001647416,0.0027646562,0.000018815603,0.000846331,7.7249865e-7,0.97913,0.00001763712,0.00022827505,0.012589674],"study_design_scores_gemma":[0.007413575,0.0010540022,0.034986567,0.000046137688,0.00093002926,0.00016264399,0.00022058465,0.0000016639675,0.9399158,0.0004344438,0.014490171,0.00034438574],"about_ca_topic_score_codex":0.00016375068,"about_ca_topic_score_gemma":0.000043257245,"teacher_disagreement_score":0.039214235,"about_ca_system_score_codex":0.000042599793,"about_ca_system_score_gemma":0.00015655976,"threshold_uncertainty_score":0.99972385},"labels":[],"label_agreement":null},{"id":"W1925087877","doi":"10.1111/j.1468-3083.2011.04332.x","title":"Efficacy and safety of topical WBI‐1001 in patients with mild to moderate psoriasis: results from a randomized double‐blind placebo‐controlled, phase II trial","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Welichem Biotech (Canada); Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Placebo; Randomized controlled trial; Adverse effect; Psoriasis Area and Severity Index; Body surface area; Clinical endpoint; Internal medicine; Dermatology; Pathology","score_opus":0.03312076175434684,"score_gpt":0.264419496675059,"score_spread":0.23129873492071215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1925087877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958957,0.0011873082,0.000035061228,0.0008341011,0.00039650247,0.00091669784,0.000034549725,0.0000049399937,0.0006951501],"genre_scores_gemma":[0.9992455,0.00023987025,0.000230922,0.000112963055,0.00005535423,0.0000080338295,0.000007766609,0.00001333198,0.00008621281],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953916,0.0027053813,0.0013483706,0.00024584506,0.00005801595,0.0002507844],"domain_scores_gemma":[0.9979108,0.0007534309,0.0010713823,0.00014804174,0.000059556194,0.000056763787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091161527,0.00023436517,0.001550419,0.00022976621,0.000118014425,0.0000027854699,0.00031608346,0.00030063765,0.00002220078],"category_scores_gemma":[0.0002670146,0.00013499014,0.00017314099,0.00010470479,0.00056746823,0.000071686634,0.00017320264,0.0004230824,0.0000028410511],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9873412,0.0008941414,0.00543382,0.000007304899,0.0012817689,0.00001824062,0.0020424929,0.000008304319,0.00050170894,0.00038055656,0.00008933446,0.0020011081],"study_design_scores_gemma":[0.96924186,0.0008135125,0.022651013,0.000094305826,0.0007820232,0.000153835,0.00004656317,0.0000033848587,0.0056670234,0.00023240285,0.00018588282,0.00012816764],"about_ca_topic_score_codex":0.000017692913,"about_ca_topic_score_gemma":0.0000070693764,"teacher_disagreement_score":0.018099332,"about_ca_system_score_codex":0.000011118124,"about_ca_system_score_gemma":0.00003945028,"threshold_uncertainty_score":0.55047387},"labels":[],"label_agreement":null},{"id":"W1926302666","doi":"10.4049/jimmunol.0903162","title":"IL-17 Promotes p38 MAPK-Dependent Endothelial Activation Enhancing Neutrophil Recruitment to Sites of Inflammation","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":269,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; Université Laval; Christie (Canada); McGill University Health Centre","funders":"Medical Research Council; McGill University","keywords":"Inflammation; Endothelium; Cytokine; Cell biology; Immunology; Cell adhesion molecule; Chemotaxis; Biology; Intravital microscopy; Tumor necrosis factor alpha; Cancer research; In vivo; Receptor; Endocrinology","score_opus":0.024837539533891232,"score_gpt":0.25624796629778823,"score_spread":0.231410426763897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1926302666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962809,0.00054385123,0.00020363995,0.001097787,0.001248877,0.0004004874,0.000016927344,0.000014664933,0.00019283444],"genre_scores_gemma":[0.9986707,0.00018845744,0.00028014727,0.00004292416,0.00018489435,0.000017321032,0.000015167067,0.000012749056,0.00058763515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985698,0.00036863485,0.0006245898,0.00011411954,0.000073620104,0.00024924724],"domain_scores_gemma":[0.9983634,0.00034565252,0.00071610505,0.00029366312,0.00026209882,0.000019095789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084512285,0.00017260677,0.00035617314,0.00023484876,0.00015077872,0.000008589504,0.00035695068,0.0002458493,0.0003130026],"category_scores_gemma":[0.00021681399,0.00011286733,0.000116168674,0.00012162975,0.00011872229,0.00013761972,0.00008059255,0.00043866647,0.00009489773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011877422,0.0001111536,0.00026452317,0.000006476584,0.00048780712,0.0000027630392,0.0017529869,0.000017736214,0.9648073,0.00026137204,0.00009693487,0.03100322],"study_design_scores_gemma":[0.001381447,0.0009912674,0.010273835,0.00003833842,0.0001640977,0.0002879976,0.00033891242,6.406127e-7,0.98240227,0.00030976703,0.0037135473,0.00009788268],"about_ca_topic_score_codex":0.000046115878,"about_ca_topic_score_gemma":0.00008082655,"teacher_disagreement_score":0.030905338,"about_ca_system_score_codex":0.000052512678,"about_ca_system_score_gemma":0.00009714655,"threshold_uncertainty_score":0.46025962},"labels":[],"label_agreement":null},{"id":"W1931293371","doi":"10.1111/j.1468-3083.2011.03984.x","title":"Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Guenther Dermatology Research Centre; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"","keywords":"Medicine; Infliximab; Psoriasis; Placebo; Randomized controlled trial; Internal medicine; Clinical endpoint; Psoriasis Area and Severity Index; Surgery; Gastroenterology; Dermatology; Pathology; Tumor necrosis factor alpha","score_opus":0.03670318478321744,"score_gpt":0.2581723549905103,"score_spread":0.22146917020729284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1931293371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98959345,0.0060203136,0.000017724247,0.00036365847,0.0003919749,0.00082655996,0.000007814098,0.000008797946,0.002769735],"genre_scores_gemma":[0.998391,0.0010690847,0.00012703391,0.00004279015,0.00005077009,0.000018828008,0.0000018878652,0.000020160145,0.00027847668],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99488205,0.003427489,0.0011424887,0.00020948001,0.000062165855,0.00027632935],"domain_scores_gemma":[0.9974267,0.00059567805,0.0016648398,0.00019309876,0.000077247714,0.000042468193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006957433,0.00030456198,0.0019021917,0.00027397124,0.00012533173,0.0000027220851,0.00039824683,0.00023793435,0.000066000524],"category_scores_gemma":[0.000055346263,0.00015339127,0.00038477842,0.00012206112,0.0009429479,0.00007337071,0.00008660629,0.00027236113,0.000011081173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80562824,0.0015095621,0.17429431,0.000026823182,0.008163857,0.00021319212,0.005109881,0.00000583298,0.0016163464,0.0009902423,0.00009127751,0.002350435],"study_design_scores_gemma":[0.9228837,0.0009069691,0.028482176,0.000058104128,0.0049747517,0.01252447,0.00072039536,0.0000017878813,0.028188877,0.00027555347,0.0007688052,0.00021439909],"about_ca_topic_score_codex":0.000020548885,"about_ca_topic_score_gemma":0.00000740848,"teacher_disagreement_score":0.14581212,"about_ca_system_score_codex":0.000015814869,"about_ca_system_score_gemma":0.000059043894,"threshold_uncertainty_score":0.62551147},"labels":[],"label_agreement":null},{"id":"W1931469350","doi":"10.1684/ejd.2010.0911","title":"Efficacy and safety of etanercept in children and adolescents aged≥8 years with severe plaque psoriasis","year":2010,"lang":"en","type":"article","venue":"European Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexus Clinical Research (Canada)","funders":"Allergan; IC Design Education Center; Astellas Pharma; GlaxoSmithKline; Biogen; LEO Pharma; Galderma","keywords":"Etanercept; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Population; Adverse effect; Surgery; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.005343075049180398,"score_gpt":0.19734018001131567,"score_spread":0.1919971049621353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1931469350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837804,0.0009001715,0.000010389913,0.00012543768,0.00020537506,0.00010167716,0.000013114357,0.0000063658567,0.00025943166],"genre_scores_gemma":[0.9992159,0.00040331754,0.00026571652,0.000035120283,0.00002650155,2.9673993e-7,0.000008725354,0.000016676167,0.000027755514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873704,0.00052265165,0.00038907633,0.00014235485,0.00003043395,0.00017844181],"domain_scores_gemma":[0.9994432,0.000073566094,0.0002813878,0.00012964204,0.00003328662,0.000038973576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020311607,0.00014258969,0.00038048928,0.00017294261,0.000042060976,0.0000059885583,0.00014610226,0.00009160261,0.000042720225],"category_scores_gemma":[0.00003251167,0.00010694417,0.000039664395,0.00007626098,0.00022058081,0.000066691435,0.000051783223,0.0003747743,0.000014536508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00240154,0.00021359042,0.9311488,0.000019936884,0.0004182734,0.0006827601,0.0010995977,0.0000025629108,0.024178851,0.000066536646,0.0003077304,0.039459795],"study_design_scores_gemma":[0.009371362,0.00020576241,0.96232754,0.000085525586,0.0001082008,0.025147501,0.0000532463,1.092469e-7,0.001953095,0.0000053624676,0.0006372232,0.00010509242],"about_ca_topic_score_codex":0.0000061881556,"about_ca_topic_score_gemma":0.000022517697,"teacher_disagreement_score":0.039354704,"about_ca_system_score_codex":0.0000049887367,"about_ca_system_score_gemma":0.000034127523,"threshold_uncertainty_score":0.43610567},"labels":[],"label_agreement":null},{"id":"W1932051732","doi":"10.1111/j.1365-4632.2011.05359.x","title":"Economic burden of moderate to severe plaque psoriasis in Canada","year":2012,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Productivity; Indirect costs; Population; Disease burden; Quality of life (healthcare); Total cost; Demography; Plaque psoriasis; Gerontology; Environmental health; Dermatology; Economic growth; Accounting; Business; Economics","score_opus":0.011170646352529456,"score_gpt":0.2378945197832846,"score_spread":0.22672387343075515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932051732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99183893,0.00090315694,0.00004737877,0.0028004635,0.0037308072,0.00004949338,0.00004579776,0.0000021897838,0.00058180926],"genre_scores_gemma":[0.9994402,0.000091770424,0.00014056177,0.00009795115,0.000114852235,0.000003243822,0.000012722567,0.000006848987,0.00009183227],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905777,0.00011456107,0.00050309725,0.00007345424,0.000046065237,0.00020503167],"domain_scores_gemma":[0.9993666,0.00014560942,0.00027457805,0.00007414536,0.00010073548,0.00003834566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060623057,0.00010030741,0.0003149444,0.00022711641,0.000015175267,0.0000034786224,0.00029526342,0.00009002142,0.00029699886],"category_scores_gemma":[0.000030366316,0.000090217,0.000067937945,0.000034756282,0.000021539552,0.0001261322,0.000045429264,0.00010972491,0.00005780013],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049296967,0.00040339952,0.88122493,0.000028049766,0.0040090894,0.0012974857,0.004656061,0.00504522,0.03148593,0.006491489,0.021445256,0.038983412],"study_design_scores_gemma":[0.021665374,0.00030252483,0.18947409,0.00031286365,0.0003853267,0.09958222,0.0035135816,0.000121350415,0.54747814,0.0011357004,0.13496198,0.001066847],"about_ca_topic_score_codex":0.09398888,"about_ca_topic_score_gemma":0.1300797,"teacher_disagreement_score":0.6917508,"about_ca_system_score_codex":0.00034706865,"about_ca_system_score_gemma":0.0006408187,"threshold_uncertainty_score":0.91204435},"labels":[],"label_agreement":null},{"id":"W1943930704","doi":"10.1111/j.1365-2133.2011.10257.x","title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","year":2011,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ustekinumab; Medicine; Mace; Psoriasis; Placebo; Odds ratio; Internal medicine; Confidence interval; Incidence (geometry); Myocardial infarction; Adverse effect; Stroke (engine); Rate ratio; Clinical trial; Dermatology; Disease; Pathology; Percutaneous coronary intervention","score_opus":0.09309788346243057,"score_gpt":0.3296684587935555,"score_spread":0.2365705753311249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1943930704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755026,0.022264138,0.00013432065,0.000018441442,0.00022604909,0.00017062477,0.0016449101,0.0000035019218,0.00003540396],"genre_scores_gemma":[0.9953559,0.0031574504,0.0011951618,0.000012451392,0.000010312827,0.000001825252,0.00024889637,0.000009963381,0.000008045108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970973,0.00074994937,0.0016080354,0.0002804072,0.000080505866,0.00018381531],"domain_scores_gemma":[0.9979454,0.00024700267,0.0008441476,0.00038673938,0.00053882773,0.000037872313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047198505,0.00016586721,0.0016483106,0.00020310884,0.000051373027,0.0000025895126,0.0003346438,0.00021630236,0.000024111518],"category_scores_gemma":[0.00032411513,0.00013868307,0.00017286527,0.00019944664,0.00030587724,0.0001846722,0.00020006119,0.0002008497,8.189233e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15635116,0.009640298,0.35776007,0.0001911248,0.06289223,0.0018575607,0.0064822854,0.00007676624,0.0020183856,0.00001970875,0.003511092,0.3991993],"study_design_scores_gemma":[0.22936119,0.0076252734,0.67428005,0.0029659264,0.008464505,0.0056156586,0.004781107,0.000019129246,0.06459368,0.00019191594,0.0013345103,0.0007670424],"about_ca_topic_score_codex":0.0009722202,"about_ca_topic_score_gemma":0.00040376972,"teacher_disagreement_score":0.39843228,"about_ca_system_score_codex":0.000015228396,"about_ca_system_score_gemma":0.00012952366,"threshold_uncertainty_score":0.56553316},"labels":[],"label_agreement":null},{"id":"W1948887633","doi":"10.1111/bjd.14068","title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University College of the North","funders":"Pfizer; Merck; Amgen; Abbott Laboratories","keywords":"Medicine; Etanercept; Psoriasis; Adalimumab; Internal medicine; Skin cancer; Population; Cohort; Hazard ratio; Retrospective cohort study; Dermatology; Incidence (geometry); Malignancy; Infliximab; Cumulative incidence; Confidence interval; Cancer; Tumor necrosis factor alpha","score_opus":0.007892005526998097,"score_gpt":0.2158179768008172,"score_spread":0.20792597127381912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948887633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789464,0.0016119998,0.000001095859,0.000033557633,0.00006374543,0.00037418926,0.000011955009,0.0000043695854,0.000004446229],"genre_scores_gemma":[0.9992113,0.0006452532,0.0000100468205,0.000019059462,0.000003141465,0.000012277039,0.0000865113,0.0000067945793,0.000005625989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871314,0.0006003359,0.00037753134,0.00012022557,0.000048323443,0.00014046016],"domain_scores_gemma":[0.9994735,0.00008374234,0.00024225893,0.000055328856,0.00012325874,0.00002188331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015020338,0.000113387985,0.00040382988,0.0002606014,0.000046144618,0.000010004129,0.00004983172,0.000102715116,0.0000018594578],"category_scores_gemma":[0.00005482635,0.00008537379,0.000014087806,0.00022055722,0.00007711626,0.00010017112,0.000020392077,0.00009664892,1.6609201e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004661114,0.0005542868,0.99562746,0.0000085958345,0.00021506412,0.0002468635,0.0016292955,0.0000069459447,0.000021581169,0.0000030974818,0.000026935373,0.0011937306],"study_design_scores_gemma":[0.016505387,0.0007818198,0.9768621,0.00006608946,0.00017292355,0.00467643,0.00071054493,0.0000037347788,0.00007471439,0.00005717792,0.000009546805,0.00007957917],"about_ca_topic_score_codex":0.0048850537,"about_ca_topic_score_gemma":0.0020379084,"teacher_disagreement_score":0.01876544,"about_ca_system_score_codex":0.00001995437,"about_ca_system_score_gemma":0.00001670684,"threshold_uncertainty_score":0.73847723},"labels":[],"label_agreement":null},{"id":"W1958642174","doi":"10.1111/j.1468-3083.2011.04349.x","title":"Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus","year":2011,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Nail (fastener); Dermatology; Acitretin; Onycholysis; Nail disease; Delphi method; Clinical Practice; Disease; Severity of illness; Physical therapy; Internal medicine","score_opus":0.03883756735476328,"score_gpt":0.25454460723101613,"score_spread":0.21570703987625284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958642174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885574,0.00414071,0.00012027476,0.0057203467,0.0006935594,0.0004898768,0.00005059672,0.000007364881,0.00021989488],"genre_scores_gemma":[0.99748486,0.0009834167,0.0010033234,0.0003748325,0.000035486493,0.000023621742,0.000006891145,0.000022029844,0.000065538195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972483,0.0013494237,0.0008297535,0.0002123287,0.000041459552,0.00031872405],"domain_scores_gemma":[0.9982723,0.00060994644,0.00077997375,0.0001942372,0.00010314881,0.000040382423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024776068,0.0002451774,0.0007218324,0.00022713112,0.00017768526,0.0000026421937,0.00039048825,0.00024132225,0.00003117584],"category_scores_gemma":[0.00006396757,0.00013367363,0.00017914281,0.00015705152,0.00045516988,0.00005127318,0.00007139647,0.00020769807,0.0000054425705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029907355,0.0040205326,0.7912316,0.00010498751,0.006389513,0.000082260354,0.018989533,0.00006525736,0.002355993,0.0060830484,0.009391939,0.13137801],"study_design_scores_gemma":[0.04327846,0.0023773478,0.83126384,0.0003063805,0.0019501636,0.0069940337,0.0016316221,0.000015950474,0.051357735,0.0017791636,0.05838355,0.0006617809],"about_ca_topic_score_codex":0.000021100816,"about_ca_topic_score_gemma":0.000025555899,"teacher_disagreement_score":0.13071622,"about_ca_system_score_codex":0.000029265018,"about_ca_system_score_gemma":0.000042324176,"threshold_uncertainty_score":0.5451053},"labels":[],"label_agreement":null},{"id":"W1963835686","doi":"10.2310/7750.2012.11126","title":"Examining the Risk of Cardiovascular Disease in Patients with Psoriasis: A Critical Review","year":2013,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Amgen (Canada)","funders":"Amgen Canada; Amgen","keywords":"Medicine; Psoriasis; Disease; Etiology; Internal medicine; Comorbidity; Epidemiology; Dermatology","score_opus":0.04864237619124212,"score_gpt":0.2689275048615166,"score_spread":0.2202851286702745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963835686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004433153,0.9943874,0.0000032083215,0.00007357852,0.00062893156,0.0004146929,0.000028075296,0.000003644058,0.000027323169],"genre_scores_gemma":[0.0017532535,0.9979094,0.0000096314725,0.000057742403,0.00015259351,0.000020891697,0.000035114826,0.000025277772,0.000036061534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663496,0.0013846114,0.001315725,0.00021594553,0.00019564331,0.0002530895],"domain_scores_gemma":[0.99441594,0.003932708,0.00093921035,0.00039207021,0.00024110622,0.00007898808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014896361,0.0003551632,0.0036136168,0.00029488106,0.00006701268,0.0000052194614,0.00017330103,0.00018899344,0.000128476],"category_scores_gemma":[0.0019353849,0.00015446467,0.0007393029,0.00024587958,0.0003108477,0.00005658601,0.00002989095,0.00049358973,0.0000075540274],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000135495,0.0001169159,0.0043493197,0.010668627,0.004556826,0.0004053163,0.000060942075,5.673365e-7,6.3398694e-8,0.0000024918736,0.002968223,0.97673523],"study_design_scores_gemma":[0.00077607227,0.00046039297,0.0010104566,0.12646884,0.032730144,0.0012469294,0.000050599647,7.211085e-8,2.1820519e-7,0.0000127223275,0.8370108,0.00023278303],"about_ca_topic_score_codex":0.000037774837,"about_ca_topic_score_gemma":8.196089e-7,"teacher_disagreement_score":0.9765024,"about_ca_system_score_codex":0.000030826897,"about_ca_system_score_gemma":0.0002614753,"threshold_uncertainty_score":0.6298886},"labels":[],"label_agreement":null},{"id":"W1964184432","doi":"10.1016/j.jaad.2010.07.026","title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Innovation Initiatives Ontario North; Moncton Hospital; Amgen (Canada); Innovaderm (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Dermatology Life Quality Index; Adverse effect; Psoriasis; Confidence interval; Psoriasis Area and Severity Index; Population; Internal medicine; Quality of life (healthcare); Surgery; Dermatology","score_opus":0.013176974594710403,"score_gpt":0.3136862525341223,"score_spread":0.3005092779394119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964184432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772704,0.0006365029,0.000053432315,0.00078548293,0.00033601394,0.00040244518,0.000049146936,0.0000015610553,0.000008405196],"genre_scores_gemma":[0.99902415,0.0007372899,0.00016207958,0.000028158775,0.000018805731,0.000010551128,0.000003840447,0.0000086353275,0.00000651387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981318,0.0008515793,0.0006919026,0.00011295014,0.0000645386,0.00014719779],"domain_scores_gemma":[0.9968291,0.0010724948,0.001794688,0.00019867007,0.00008997854,0.000015073547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003169512,0.00014270701,0.00079233444,0.000109604,0.00006932344,0.0000015367589,0.00035520244,0.00015598723,0.000008242234],"category_scores_gemma":[0.000062468716,0.000068084715,0.00027162817,0.00017285594,0.00067083264,0.000056135552,0.00003854623,0.00020477615,1.0312904e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012279144,0.00035398826,0.77765423,0.000056273348,0.0004808823,5.567985e-7,0.00028445857,0.000033068776,0.20185094,0.0005246119,0.0000034618006,0.017529596],"study_design_scores_gemma":[0.0023223981,0.0005079433,0.8667033,0.0000577726,0.0004385557,0.0002642081,0.00012699114,0.0000107265,0.1293583,0.00012187633,0.00003895561,0.000049006012],"about_ca_topic_score_codex":0.000111397654,"about_ca_topic_score_gemma":0.00007999146,"teacher_disagreement_score":0.089049,"about_ca_system_score_codex":0.000034592947,"about_ca_system_score_gemma":0.00006246776,"threshold_uncertainty_score":0.2776414},"labels":[],"label_agreement":null},{"id":"W1965004201","doi":"10.3899/jrheum.101122","title":"Psoriasis and Psoriatic Arthritis Video Project 2010: A Report from the GRAPPA Annual Meeting","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Psoriasis; Enthesitis; Psoriasis Area and Severity Index; Rheumatology; Physical therapy; Dermatology; Physical examination; Inter-rater reliability; Severity of illness; Internal medicine; Rating scale","score_opus":0.022159724891518462,"score_gpt":0.23132093114020205,"score_spread":0.2091612062486836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965004201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703958,0.025883626,0.00007546554,0.0005980906,0.0024725397,0.0001994725,0.000038348266,0.000021530132,0.0003150998],"genre_scores_gemma":[0.9903332,0.00893902,0.00037451918,0.000084410516,0.00003836944,0.000010939326,0.000010959498,0.000019269688,0.00018929683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761623,0.0010175809,0.0007904737,0.00017870015,0.00006612582,0.00033091576],"domain_scores_gemma":[0.9973703,0.0011532145,0.0009280788,0.00037200187,0.00014925963,0.000027139444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014344702,0.00022034482,0.00057161227,0.000100224664,0.00034178045,0.000011530598,0.0004088058,0.00022400265,0.00018239897],"category_scores_gemma":[0.00046020705,0.00011485961,0.00015484534,0.0001391755,0.00038019675,0.00012746108,0.00010323807,0.00035784277,0.000051656632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045353705,0.0005367758,0.5774104,0.00003544953,0.007176611,0.00051322713,0.06447533,0.0000015758211,0.0052228193,0.0010212369,0.09116407,0.24790715],"study_design_scores_gemma":[0.02300563,0.0031566853,0.5069322,0.0014226832,0.005389597,0.31680393,0.037205484,0.000008219684,0.022091294,0.019009385,0.06342097,0.0015538804],"about_ca_topic_score_codex":0.0037311292,"about_ca_topic_score_gemma":0.00055522774,"teacher_disagreement_score":0.3162907,"about_ca_system_score_codex":0.000015752963,"about_ca_system_score_gemma":0.00012238584,"threshold_uncertainty_score":0.5640376},"labels":[],"label_agreement":null},{"id":"W1965032245","doi":"10.1016/s0140-6736(12)60642-4","title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Initiatives Ontario North; Dalhousie University; Probity Medical Research","funders":"Celgene","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Tolerability; Internal medicine; Randomized controlled trial; Adverse effect; Clinical endpoint; Clinical trial; Dermatology; Psoriatic arthritis; Alternative medicine","score_opus":0.03543671205202846,"score_gpt":0.27379799004053296,"score_spread":0.23836127798850448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965032245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174887,0.002928156,0.000008000123,0.00041672165,0.0005292783,0.0026996066,0.000047562593,0.0000123025575,0.0016094982],"genre_scores_gemma":[0.9983537,0.0002635942,0.000028188852,0.00008801332,0.00032677638,0.00052732375,0.00002120225,0.000007619592,0.00038356983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99846774,0.00074974686,0.00033561804,0.00011137567,0.000040746785,0.0002947448],"domain_scores_gemma":[0.9983329,0.0010494986,0.00014555843,0.00043663583,0.000022246328,0.000013114068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006384653,0.00015314038,0.0008708472,0.000047323356,0.000059060356,0.0000043998343,0.00025133148,0.00009224164,0.00008168252],"category_scores_gemma":[0.00009280841,0.000068225396,0.00020674214,0.00012083518,0.000055706765,0.000027304453,0.000013494043,0.00005304762,0.00004804569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9697969,0.0015066576,0.0007300334,0.0000065414542,0.0007550557,7.505593e-7,0.009470119,0.000049613816,0.009023509,0.00026126936,0.0009910882,0.007408455],"study_design_scores_gemma":[0.9739372,0.0008057972,0.0051494585,0.000018416926,0.00041560776,0.000005875134,0.0002711545,0.000002918564,0.016188612,0.00004650265,0.003068972,0.00008947064],"about_ca_topic_score_codex":0.000051208925,"about_ca_topic_score_gemma":0.000020942309,"teacher_disagreement_score":0.009198965,"about_ca_system_score_codex":0.000022735967,"about_ca_system_score_gemma":0.000024480703,"threshold_uncertainty_score":0.27821508},"labels":[],"label_agreement":null},{"id":"W1965369309","doi":"10.3899/jrheum.101115","title":"Summary of the International Federation of Psoriasis Associations (IFPA) Meeting: A Report from the GRAPPA 2009 Annual Meeting","year":2011,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Family medicine; Dermatology; Multidisciplinary approach; Political science","score_opus":0.034387054056623775,"score_gpt":0.2761715502904444,"score_spread":0.2417844962338206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965369309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014051824,0.978443,0.000018364726,0.00041119894,0.0052985237,0.00032304827,0.00050801336,0.000008924553,0.00093710126],"genre_scores_gemma":[0.009914467,0.9893436,0.00008268469,0.000020235368,0.000067799105,0.00001245994,0.00018783647,0.000027216129,0.00034373155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952433,0.002202477,0.0020019829,0.00017588433,0.0001471559,0.00022918286],"domain_scores_gemma":[0.9889276,0.0034368352,0.006630847,0.00049661373,0.00049152144,0.000016602671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023898196,0.00030856725,0.0015406278,0.00013949785,0.00032656512,0.000011092385,0.0012700277,0.00052444875,0.00011327955],"category_scores_gemma":[0.0014916657,0.00014443025,0.0008878067,0.00021660475,0.00028850313,0.00008030296,0.00021423098,0.000590986,0.000013876296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018087213,0.0012398163,0.06346756,0.0009793342,0.049833406,0.000033442942,0.011155751,0.000017327931,0.0006338138,0.003005076,0.1419707,0.72585505],"study_design_scores_gemma":[0.002659989,0.00029433495,0.003049889,0.00852036,0.0115225455,0.006166453,0.0015343557,9.829353e-7,0.00068748556,0.00096199615,0.9641595,0.00044214836],"about_ca_topic_score_codex":0.0010363781,"about_ca_topic_score_gemma":0.00048326707,"teacher_disagreement_score":0.8221888,"about_ca_system_score_codex":0.00007499389,"about_ca_system_score_gemma":0.0005092516,"threshold_uncertainty_score":0.58896947},"labels":[],"label_agreement":null},{"id":"W1965433508","doi":"10.1016/j.cca.2014.01.012","title":"Interleukin-17A in lipid metabolism and atherosclerosis","year":2014,"lang":"en","type":"review","venue":"Clinica Chimica Acta","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta; University of Saskatchewan; University of Calgary","funders":"","keywords":"Proinflammatory cytokine; Lipid metabolism; Biology; Cytokine; Interleukin 17; Receptor; Signal transduction; Chemokine; Interleukin; Cell biology; Immune system; Immunology; Inflammation; Endocrinology; Biochemistry","score_opus":0.06035236591429861,"score_gpt":0.3245890015771658,"score_spread":0.2642366356628672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965433508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043470627,0.9915482,4.6225256e-7,0.00008889032,0.0021654728,0.0006408107,0.00017880327,0.00008525916,0.0009450723],"genre_scores_gemma":[0.0022143752,0.9949369,0.00006627067,0.00013047105,0.0003011286,0.00018069019,0.00045879706,0.00009161663,0.0016197496],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618304,0.0010005471,0.0013031699,0.00093724026,0.000038198777,0.0005377935],"domain_scores_gemma":[0.99703825,0.0013826474,0.0006327994,0.0008585942,0.000025942742,0.00006174683],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006656817,0.0007133304,0.0033364124,0.00030948722,0.000108840664,0.000037245176,0.00063399907,0.0014212246,0.0004358762],"category_scores_gemma":[0.0002908568,0.0005402757,0.00077805,0.00022816713,0.00027746582,0.00006738858,0.0003191081,0.0008058551,0.0007612683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004703694,0.00025293513,0.000069220056,0.001309292,0.0008577667,0.000001365789,0.00013129908,2.6136735e-9,0.00022295097,0.00008774193,0.00232254,0.99469787],"study_design_scores_gemma":[0.0012925474,0.000100914265,0.0007564485,0.0035202256,0.0017472621,0.000028701726,0.000008877618,1.1208849e-7,0.00002587798,0.000025774163,0.9920005,0.0004927556],"about_ca_topic_score_codex":0.000016392944,"about_ca_topic_score_gemma":0.000039999864,"teacher_disagreement_score":0.9942051,"about_ca_system_score_codex":0.00005264685,"about_ca_system_score_gemma":0.00012869437,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W1966163121","doi":"10.1111/jdv.12943","title":"Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab","year":2015,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Lynde Centre for Dermatology; Merck Canada Inc. (Canada); Innovaderm (Canada)","funders":"Janssen Biotech; LEO Pharma; AbbVie; Celgene; Novartis; Pfizer; Amgen","keywords":"Adalimumab; Medicine; Infliximab; Etanercept; Psoriasis; Internal medicine; Tumor necrosis factor alpha; Gastroenterology; Surgery; Dermatology","score_opus":0.03392926498281086,"score_gpt":0.26605132690787525,"score_spread":0.2321220619250644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966163121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904208,0.00091030484,0.00006571068,0.0072410027,0.0005736524,0.00037715022,0.00011132705,0.000012027932,0.00028800816],"genre_scores_gemma":[0.99483633,0.00013390336,0.00036078665,0.0014502635,0.00009769077,0.0000068304357,0.0000061942596,0.000041946354,0.003066065],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99528444,0.0031022583,0.0008100529,0.00028752573,0.000085961,0.00042978488],"domain_scores_gemma":[0.9974087,0.0011876427,0.0008298423,0.00024076724,0.0002168045,0.000116256655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010802544,0.00032304344,0.0009396368,0.00030938562,0.00018702973,0.00000934861,0.0006610277,0.00036421872,0.000052440413],"category_scores_gemma":[0.00085171225,0.00016173424,0.00017056879,0.00023109493,0.00050934736,0.00013124074,0.00023613076,0.00042103225,0.000035378653],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6627137,0.0011302903,0.21092409,0.00014639721,0.0038785276,0.00031083057,0.0090637375,0.00007258309,0.016539957,0.0008898363,0.05595101,0.038379025],"study_design_scores_gemma":[0.043676425,0.004522099,0.47193667,0.00041259962,0.0012704736,0.011066502,0.0009033469,0.0000049858772,0.055579208,0.00035535338,0.40952033,0.00075202656],"about_ca_topic_score_codex":0.0000017234818,"about_ca_topic_score_gemma":0.000006605982,"teacher_disagreement_score":0.6190373,"about_ca_system_score_codex":0.000041605177,"about_ca_system_score_gemma":0.00018417445,"threshold_uncertainty_score":0.6595331},"labels":[],"label_agreement":null},{"id":"W1966273028","doi":"10.1016/j.amjmed.2014.08.008","title":"Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities","year":2014,"lang":"en","type":"review","venue":"The American Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health","keywords":"Psoriasis; Medicine; Multidisciplinary approach; Association (psychology); Clinical trial; Comorbidity; Intensive care medicine; Family medicine; Dermatology; Psychiatry; Pathology; Psychotherapist","score_opus":0.08861827673977488,"score_gpt":0.3387796168901894,"score_spread":0.25016134015041447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966273028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012754851,0.99608856,0.0007348762,0.0006570435,0.0006633362,0.0005096651,0.000051989467,0.000010696861,0.000008348565],"genre_scores_gemma":[0.014142246,0.9849311,0.00009851382,0.000060058665,0.00055060675,0.000033161432,0.000033461572,0.00003063867,0.000120206874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99709505,0.0014643585,0.00082447374,0.00021124727,0.0001476813,0.00025718947],"domain_scores_gemma":[0.9872459,0.010047804,0.002190471,0.00032261643,0.00015654937,0.00003663472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049010767,0.0003194276,0.0025171489,0.00012897291,0.00038124775,0.000019981135,0.00037582288,0.00017290837,0.000023698365],"category_scores_gemma":[0.0015499628,0.00014434864,0.0006000574,0.00021299806,0.00041761855,0.000060028367,0.00007330433,0.00042785425,0.000004312911],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004977714,0.0000042748597,0.00008128623,0.00031500906,0.007429441,0.0000022642353,0.0004136562,7.6497696e-7,0.000023446804,0.000036767426,0.00033164557,0.99131167],"study_design_scores_gemma":[0.0054384824,0.0035905412,0.0042137885,0.021559443,0.10443768,0.0015854853,0.002122999,0.000006411904,0.000025775273,0.0008455591,0.8555206,0.00065320334],"about_ca_topic_score_codex":0.00005988817,"about_ca_topic_score_gemma":0.0000025953873,"teacher_disagreement_score":0.99065846,"about_ca_system_score_codex":0.000079248144,"about_ca_system_score_gemma":0.00007546532,"threshold_uncertainty_score":0.5886367},"labels":[],"label_agreement":null},{"id":"W1966688892","doi":"10.12968/pnur.2005.16.12.20135","title":"Managing psoriasis as part of a team","year":2005,"lang":"en","type":"article","venue":"Practice Nursing","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Selkirk College","funders":"","keywords":"Psoriasis; Medicine; Work (physics); Nursing; Dermatology; Engineering","score_opus":0.021020387222386677,"score_gpt":0.29628605813346015,"score_spread":0.27526567091107346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966688892","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41747376,0.024817452,0.00046723158,0.016382033,0.003979392,0.00050429074,0.000022193452,0.00026550778,0.53608817],"genre_scores_gemma":[0.9930997,0.00054225593,0.0023552296,0.00031024325,0.00020415046,0.000013622196,0.000026918591,0.000020407417,0.0034275108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989721,0.00023283986,0.00024413501,0.00022675765,0.000045355537,0.00027882206],"domain_scores_gemma":[0.99904543,0.000403469,0.00021644763,0.00024636157,0.00006707433,0.000021194022],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003197791,0.00013856217,0.00020644406,0.000101439655,0.00015618168,0.00001339173,0.00011843107,0.00013246827,0.00047469183],"category_scores_gemma":[0.00029586887,0.00013277319,0.00008537072,0.0001429716,0.000091398935,0.0003922321,0.000018445486,0.00014175593,0.000984749],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054671883,0.0006124409,0.00024256097,0.0000093853605,0.0003385254,0.0000055415285,0.002423726,0.000014588948,0.031028919,0.0015455041,0.006431208,0.9568009],"study_design_scores_gemma":[0.0019006092,0.00022335065,0.00066076237,0.00018479623,0.0008995402,0.00036502714,0.0032531014,0.000012526055,0.19796222,0.0005811516,0.7937085,0.0002484267],"about_ca_topic_score_codex":0.0000514526,"about_ca_topic_score_gemma":0.000004019099,"teacher_disagreement_score":0.95655245,"about_ca_system_score_codex":0.00007467741,"about_ca_system_score_gemma":0.000043549124,"threshold_uncertainty_score":0.9997931},"labels":[],"label_agreement":null},{"id":"W1966725303","doi":"10.1007/s10227-004-2002-7","title":"Pathogenesis of Psoriasis and Current Challenges","year":2004,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Pathogenesis; Current (fluid); Intensive care medicine; Pathology","score_opus":0.04012616608098008,"score_gpt":0.2610578290259241,"score_spread":0.22093166294494404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966725303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7591935,0.23848683,0.000014703592,0.001177181,0.00096533104,0.000040554496,0.0000055116707,0.0000057091006,0.00011068693],"genre_scores_gemma":[0.8561136,0.14357065,0.000040996638,0.000044986213,0.00018213002,0.0000011015327,0.000003700844,0.0000090175545,0.000033800618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998942,0.00010915052,0.00056407746,0.00013062837,0.00007680723,0.00017733169],"domain_scores_gemma":[0.9986477,0.000653634,0.0004035502,0.00010773064,0.0001293445,0.000058025245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004566824,0.00015929523,0.0007024905,0.00028087827,0.000060683018,0.0000026689443,0.000059320373,0.0001168065,0.00005409147],"category_scores_gemma":[0.00021178156,0.00010592521,0.00012173584,0.00008179408,0.0002077488,0.000053121905,0.000018638795,0.00012259312,0.0000028418356],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063289853,0.0002567738,0.0076626022,0.00020558479,0.0005966381,0.00048552992,0.0023120872,0.0000025044094,0.04124133,0.0003386898,0.0012050256,0.9450603],"study_design_scores_gemma":[0.031452112,0.012418959,0.2513618,0.0114311855,0.009673449,0.17207393,0.017826714,0.0000024025162,0.11916259,0.016742345,0.3552026,0.0026519396],"about_ca_topic_score_codex":0.000015065512,"about_ca_topic_score_gemma":0.0000062735994,"teacher_disagreement_score":0.9424084,"about_ca_system_score_codex":0.000015620899,"about_ca_system_score_gemma":0.00008429406,"threshold_uncertainty_score":0.43195048},"labels":[],"label_agreement":null},{"id":"W1966731684","doi":"10.1590/abd1806-4841.20142613","title":"Anti-TNFα therapy in the management of psoriasis: experience of a state referral center","year":2014,"lang":"en","type":"article","venue":"Anais Brasileiros de Dermatologia","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Adverse effect; Internal medicine; McNemar's test; Adalimumab; Psoriasis Area and Severity Index; Etanercept; Retrospective cohort study; Dyslipidemia; Gastroenterology; Disease; Tumor necrosis factor alpha; Dermatology","score_opus":0.02671658917460087,"score_gpt":0.2695827655066732,"score_spread":0.24286617633207233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966731684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972613,0.00088326255,0.00009446823,0.000064412045,0.00020323973,0.00027449374,0.000026135709,0.000025540901,0.0011671851],"genre_scores_gemma":[0.998573,0.0008665622,0.00013921519,0.00023264633,0.0000058784785,0.00007725255,0.0000423381,0.000010643238,0.000052448944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985135,0.00042560877,0.0004098386,0.0002396925,0.00005930866,0.00035204945],"domain_scores_gemma":[0.9991939,0.00011907594,0.00019435748,0.00044551239,0.000033411117,0.000013752294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026339423,0.00018910237,0.00038884478,0.000108184104,0.00006427614,0.0000081192875,0.0004627521,0.00014190747,0.000063369676],"category_scores_gemma":[0.000011756095,0.0001273424,0.00011722935,0.00022758268,0.00021269372,0.0000724692,0.000054649863,0.00010888544,0.000030390109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019895082,0.00045366655,0.9549663,0.000059100992,0.00023423346,0.000030036455,0.004535194,0.0000046068267,0.012275505,0.0008409338,0.0005595272,0.02584193],"study_design_scores_gemma":[0.0021862718,0.00012844849,0.8997438,0.000056669654,0.00003130737,0.00007211775,0.0012288513,0.0000055654777,0.09529831,0.00013770322,0.000983674,0.00012727108],"about_ca_topic_score_codex":0.000090813235,"about_ca_topic_score_gemma":0.000022654081,"teacher_disagreement_score":0.08302281,"about_ca_system_score_codex":0.000014802289,"about_ca_system_score_gemma":0.000013284791,"threshold_uncertainty_score":0.5192872},"labels":[],"label_agreement":null},{"id":"W1968321227","doi":"10.1016/j.berh.2014.10.010","title":"Genetics of psoriatic arthritis","year":2014,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Health Sciences Centre","funders":"","keywords":"Psoriatic arthritis; Genetics; Genome-wide association study; Gene; Candidate gene; Genetic heterogeneity; Psoriasis; Genetic association; Copy-number variation; Biology; Medicine; Phenotype; Genome; Immunology; Single-nucleotide polymorphism; Genotype","score_opus":0.20657850574225178,"score_gpt":0.5058238894141541,"score_spread":0.29924538367190234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968321227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021358962,0.9924284,0.00003383579,0.00018208721,0.0030226423,0.0012682652,0.00012102754,0.000054984004,0.0026751761],"genre_scores_gemma":[0.00019210433,0.99709475,0.000603011,0.000027851256,0.00013346222,0.00032084397,0.00038523765,0.00010944634,0.0011332908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.974022,0.01940843,0.0037100702,0.0012548873,0.00029831586,0.0013062949],"domain_scores_gemma":[0.9489368,0.04636587,0.0019379292,0.0016925841,0.00089941046,0.00016738474],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.011163398,0.00066231046,0.005594109,0.0006222301,0.00031762285,0.000041425512,0.0013871451,0.0031300045,0.00086775335],"category_scores_gemma":[0.03575588,0.00054645917,0.0012650294,0.0007313056,0.0018852237,0.00014507226,0.00071822386,0.0031511083,0.011795914],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001902345,0.0016847545,0.00008161901,0.0034417778,0.0022330435,0.00006834815,0.00003887105,4.6568836e-8,8.7315794e-7,0.0021183537,0.0063356,0.9838065],"study_design_scores_gemma":[0.0017882587,0.0020856068,0.0000056516988,0.0062846923,0.0017002936,0.0013692593,0.00008909715,5.8014945e-7,0.000006269655,0.00023154615,0.9860318,0.00040696154],"about_ca_topic_score_codex":0.00024165987,"about_ca_topic_score_gemma":0.00006932228,"teacher_disagreement_score":0.9833995,"about_ca_system_score_codex":0.00009052876,"about_ca_system_score_gemma":0.0017942393,"threshold_uncertainty_score":0.9996987},"labels":[],"label_agreement":null},{"id":"W1968358640","doi":"10.1016/j.crohns.2014.06.005","title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience","year":2014,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Ustekinumab; Crohn's disease; Inflammatory bowel disease; Tumor necrosis factor alpha; Tumor necrosis factors; Crohn disease; Adalimumab; Disease; Internal medicine; Gastroenterology","score_opus":0.016904756283040244,"score_gpt":0.248097007957345,"score_spread":0.23119225167430474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968358640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868437,0.011241773,0.00006589298,0.00057098165,0.00058545097,0.00028335743,0.00029141465,0.0000051544857,0.00011224045],"genre_scores_gemma":[0.99543005,0.0031852024,0.00003762484,0.000086212676,0.00010779834,0.000034037195,0.0000044752637,0.000010315267,0.00110428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99909383,0.00012949997,0.0003663296,0.00012807231,0.000056456352,0.00022581438],"domain_scores_gemma":[0.99869585,0.00058138865,0.00032070593,0.0002205541,0.00013839462,0.00004310897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016523837,0.00014917465,0.00033232456,0.000041949177,0.00040791277,0.000016954733,0.00017712123,0.00007107244,0.0000726709],"category_scores_gemma":[0.000047433543,0.00007413296,0.00023273968,0.000057070432,0.00024154357,0.00004925985,0.00001590323,0.000050436127,0.0000029587895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053694393,0.0018197435,0.0032932267,0.00013602876,0.002873288,0.00083767535,0.0058157565,0.000041354837,0.011709984,0.011753297,0.0057790084,0.90224624],"study_design_scores_gemma":[0.0029937718,0.0023920734,0.4829315,0.00006080452,0.00071025215,0.0005404869,0.0007496088,0.000010418951,0.008916157,0.0006578705,0.49988243,0.00015462624],"about_ca_topic_score_codex":0.00007890703,"about_ca_topic_score_gemma":0.000044187815,"teacher_disagreement_score":0.9020916,"about_ca_system_score_codex":0.0000379904,"about_ca_system_score_gemma":0.00004399342,"threshold_uncertainty_score":0.31373766},"labels":[],"label_agreement":null},{"id":"W1968932142","doi":"10.1111/j.1365-2133.2006.07389.x","title":"A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Reliability (semiconductor); Index (typography); Dermatology; Severity of illness; Internal medicine; Physics; Computer science","score_opus":0.021414824926412654,"score_gpt":0.2664604296771659,"score_spread":0.2450456047507532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968932142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928071,0.003487302,0.0019994467,0.00006576909,0.0005226259,0.00057179073,0.00031883232,0.000021195834,0.00020592632],"genre_scores_gemma":[0.99831176,0.000119631724,0.0014182696,0.000022052931,0.00006528486,0.000031174855,0.000015925232,0.0000137180195,0.000002192073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731296,0.00066716864,0.0010805618,0.00042654708,0.00013541187,0.000377318],"domain_scores_gemma":[0.99809265,0.00029802794,0.000943926,0.00020945127,0.0003992297,0.000056713485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006257856,0.000320023,0.0013189616,0.00007640974,0.00020179785,0.00004989447,0.00019950875,0.00027599614,0.0000022059603],"category_scores_gemma":[0.000044979683,0.00032342796,0.0001445923,0.0001602571,0.00038754602,0.00030692574,0.00017551998,0.00023243614,2.3588206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006002979,0.001108598,0.9377816,0.0004197847,0.0010430412,0.00017896014,0.000119574026,0.0000052320015,0.00072072016,0.00026876188,0.00010105136,0.05765242],"study_design_scores_gemma":[0.006575816,0.00057735643,0.98124135,0.00045792165,0.0008509284,0.005762559,0.0020962043,0.00004817569,0.0012186916,0.00089395145,0.000026056265,0.0002509951],"about_ca_topic_score_codex":0.00047721327,"about_ca_topic_score_gemma":0.00070237636,"teacher_disagreement_score":0.057401426,"about_ca_system_score_codex":0.00018527434,"about_ca_system_score_gemma":0.0001500204,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W1968954909","doi":"10.2310/7750.2009.00029","title":"The AWARE Study: Methodology and Baseline Characteristics","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nexus Clinical Research (Canada); Vancouver Coastal Health Research Institute; Innovaderm (Canada); Vancouver Coastal Health; Probity Medical Research; Lynde Centre for Dermatology; University of Toronto; University of British Columbia","funders":"University of Alberta; Astellas Foundation for Research on Metabolic Disorders; Janssen Biotech; University of British Columbia; Amgen; Abbott Laboratories","keywords":"Medicine; Psoriasis; Observational study; Plaque psoriasis; Physical therapy; Demographics; Internal medicine; Dermatology","score_opus":0.05539301469424238,"score_gpt":0.29831242489052306,"score_spread":0.2429194101962807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968954909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97577816,0.017079594,0.00012880465,0.005775752,0.0010837457,0.00008192261,0.0000036575364,0.0000085585625,0.00005977235],"genre_scores_gemma":[0.9898963,0.008624643,0.000038298123,0.0006347903,0.0003106834,7.8490774e-7,0.000005855227,0.000005924718,0.0004827182],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984879,0.00063261564,0.00053302187,0.00010712111,0.00005277473,0.00018657987],"domain_scores_gemma":[0.9952581,0.004124942,0.00032743553,0.0001127028,0.00013161014,0.00004522339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001912148,0.00013505784,0.00058612175,0.00012385081,0.00020896763,0.000009910401,0.000068417234,0.0000950479,0.000049345417],"category_scores_gemma":[0.0010138149,0.00007016078,0.0000644533,0.00007065727,0.00015577005,0.00003452311,0.000012688646,0.0001906821,0.0000027961871],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001271195,0.00017920454,0.030584812,0.000009606628,0.000476693,0.0015123119,0.0012026917,1.7263129e-7,0.006864238,0.000045509267,0.013534968,0.9443186],"study_design_scores_gemma":[0.009585994,0.016323242,0.4089593,0.0007147057,0.0046974067,0.15440127,0.015639914,0.000025974394,0.0028103408,0.002677279,0.38310602,0.0010585571],"about_ca_topic_score_codex":0.000008525982,"about_ca_topic_score_gemma":0.0000057584475,"teacher_disagreement_score":0.94326,"about_ca_system_score_codex":0.000008772287,"about_ca_system_score_gemma":0.000048331025,"threshold_uncertainty_score":0.28610736},"labels":[],"label_agreement":null},{"id":"W1969338238","doi":"10.1136/ebm.14.6.185","title":"Site of psoriasis (scalp or intergluteal/perianal), &gt;=3 affected sites, and nail dystrophy predicted psoriatic arthritis in incident psoriasis","year":2009,"lang":"en","type":"letter","venue":"Evidence-Based Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Scalp; Nail (fastener); Nail disease; Engineering","score_opus":0.026606631615324703,"score_gpt":0.25517504224861237,"score_spread":0.22856841063328767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969338238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6588992,0.13358235,0.00017304222,0.19707064,0.005646491,0.0032151323,0.0008297218,0.00044129055,0.00014213065],"genre_scores_gemma":[0.8304819,0.04500978,0.0009928156,0.10099314,0.0081503345,0.00085038453,0.008702812,0.00036969173,0.0044491393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926429,0.0018709975,0.002208042,0.0015599731,0.00051251973,0.0012055894],"domain_scores_gemma":[0.9942755,0.002659384,0.0013232852,0.0012749673,0.00031253576,0.00015431279],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012097765,0.0013484417,0.003177502,0.0017506628,0.00019090921,0.000037572325,0.0006903325,0.002347037,0.0017537989],"category_scores_gemma":[0.0026857422,0.0010213673,0.00039482725,0.001390831,0.0008913484,0.0003234666,0.00015043216,0.0018597252,0.00009726587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00654889,0.0006441077,0.005968015,0.0017331718,0.0020147278,0.0034690697,0.0021336456,0.00001291745,0.030838126,0.000010361955,0.69563407,0.2509929],"study_design_scores_gemma":[0.08901464,0.031789515,0.2627648,0.085060924,0.012341334,0.001392286,0.0006688901,0.00014372643,0.03408056,0.0004388928,0.47640663,0.0058977627],"about_ca_topic_score_codex":0.0014353648,"about_ca_topic_score_gemma":0.0012645113,"teacher_disagreement_score":0.2567968,"about_ca_system_score_codex":0.0004303074,"about_ca_system_score_gemma":0.0006136482,"threshold_uncertainty_score":0.9999267},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W1969929026","doi":"10.2310/7750.2009.08071","title":"The Burden of Psoriasis in Canada: Insights from the p <u>S</u> oriasis <u>K</u> nowledge <u>IN</u> Canada (SKIN) Survey","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Arthritis Patient Alliance; Université Laval; Guenther Dermatology Research Centre; Lynde Centre for Dermatology","funders":"","keywords":"Psoriasis; Medicine; Body surface area; Dermatology; Psoriatic arthritis; Disease; Demography; Surgery; Internal medicine","score_opus":0.018062329056673487,"score_gpt":0.21546958333573207,"score_spread":0.19740725427905859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969929026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635573,0.030706404,9.296984e-7,0.003246224,0.0022129312,0.00009672158,0.000030806008,0.0000016828001,0.00014699496],"genre_scores_gemma":[0.9939833,0.0052550985,0.000002497753,0.00032343046,0.00030402472,0.000001463064,0.000021251377,0.000008998033,0.00009993718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750465,0.000711671,0.001092519,0.00016640507,0.00018682955,0.00033794867],"domain_scores_gemma":[0.99030226,0.008660745,0.0005432819,0.00024806982,0.0001853195,0.000060300285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008087908,0.00022355554,0.0008960849,0.00013669414,0.0001291874,0.0000065961594,0.00028353187,0.000102670805,0.00007160483],"category_scores_gemma":[0.00080310006,0.00011347092,0.00008944787,0.00033996315,0.00010626397,0.000048160447,0.000020822179,0.00034521628,0.0000011101696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034424467,0.00014781776,0.49873298,0.000023241322,0.001182547,0.0037450402,0.005581539,0.00011101403,0.0031613803,0.000050240647,0.12669253,0.35712922],"study_design_scores_gemma":[0.0023212596,0.00026981367,0.951149,0.0005092188,0.00026489946,0.0014271954,0.0074670385,0.0000151550485,0.0018896624,0.0002786797,0.034113273,0.00029480705],"about_ca_topic_score_codex":0.9973914,"about_ca_topic_score_gemma":0.9994801,"teacher_disagreement_score":0.452416,"about_ca_system_score_codex":0.00046063378,"about_ca_system_score_gemma":0.004740891,"threshold_uncertainty_score":0.8410137},"labels":[],"label_agreement":null},{"id":"W1970846528","doi":"10.1007/s00262-009-0802-8","title":"IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo","year":2009,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"In vivo; Medicine; Proinflammatory cytokine; Immune system; Cytokine; Melanoma; Immunotherapy; Cancer research; Pharmacology; Immunology; Biology; Inflammation","score_opus":0.015989217561995468,"score_gpt":0.25141568541364157,"score_spread":0.2354264678516461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970846528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9367166,0.058188826,0.0000189836,0.0009314672,0.001834,0.00078950124,0.00012605781,0.00027858777,0.0011159695],"genre_scores_gemma":[0.9885682,0.0064530433,0.0001288246,0.0014628287,0.000119440476,0.00025200826,0.00010552913,0.000072236864,0.0028379168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970755,0.00037401356,0.0007251456,0.0007267144,0.000071792965,0.0010268415],"domain_scores_gemma":[0.99865645,0.00012677825,0.00030816693,0.0007791433,0.000096256554,0.00003322204],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002672664,0.0006149103,0.0008830149,0.00043616843,0.00037332025,0.000049671573,0.0006522642,0.0004641144,0.0012768584],"category_scores_gemma":[0.000035264453,0.00056349335,0.00027638883,0.00048103096,0.00049483374,0.0002488301,0.000052105403,0.00055944396,0.00047292546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027983664,0.000603661,0.0053768763,0.000010412825,0.00086871244,0.00013208423,0.0009793071,0.000047111807,0.8983343,0.00032875335,0.0018213958,0.08869897],"study_design_scores_gemma":[0.018545086,0.0009450069,0.25212878,0.00022453425,0.00010743268,0.0002120546,0.00015744673,0.000007874196,0.5210465,0.0002402376,0.20526132,0.0011236743],"about_ca_topic_score_codex":0.0001686977,"about_ca_topic_score_gemma":0.0000846908,"teacher_disagreement_score":0.3772878,"about_ca_system_score_codex":0.0003047995,"about_ca_system_score_gemma":0.00042516092,"threshold_uncertainty_score":0.99968165},"labels":[],"label_agreement":null},{"id":"W1971186170","doi":"10.1067/mjd.2001.112400","title":"Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study","year":2001,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":139,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Randomization; Psoriasis; Randomized controlled trial; Cohort; Surgery; Creatinine; Multicenter trial; Renal function; Cohort study; Internal medicine; Multicenter study; Dermatology","score_opus":0.020096104883756526,"score_gpt":0.30287955544452655,"score_spread":0.28278345056077003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971186170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417764,0.0027799497,0.000113823444,0.0015884846,0.00051728624,0.00074356876,0.000024405064,0.0000054283732,0.000049401693],"genre_scores_gemma":[0.9961988,0.003313689,0.00016637037,0.000082765604,0.00003941141,0.000024610768,0.0000028684335,0.000016447015,0.00015508532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808645,0.00031796674,0.0010398173,0.00017175455,0.00012027049,0.00026374075],"domain_scores_gemma":[0.9975017,0.00032808943,0.0017559788,0.00027274873,0.00011734611,0.000024183144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036552563,0.00020629563,0.0009893285,0.00016911249,0.00008640908,0.0000026040907,0.0008419226,0.00010228917,0.000029172441],"category_scores_gemma":[0.000028820832,0.000116301526,0.00045227708,0.00025148742,0.000646833,0.000051710438,0.00017776202,0.00024731332,0.000002691317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023577535,0.0008847508,0.9489373,0.00006187691,0.0048363814,0.000025013534,0.00024966078,0.000009838714,0.017040392,0.00007783713,0.00093103136,0.024588188],"study_design_scores_gemma":[0.002441542,0.00056715094,0.9433766,0.00013423829,0.0022415568,0.0014036057,0.0016054388,0.0000011377379,0.047189046,0.000036850866,0.00090073154,0.00010208271],"about_ca_topic_score_codex":0.000018860668,"about_ca_topic_score_gemma":0.0000036541194,"teacher_disagreement_score":0.030148653,"about_ca_system_score_codex":0.000032628308,"about_ca_system_score_gemma":0.000031855576,"threshold_uncertainty_score":0.47426385},"labels":[],"label_agreement":null},{"id":"W1971211806","doi":"10.3899/jrheum.090216","title":"Differential Diagnosis of Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Disease; Differential diagnosis; Population; Affect (linguistics); Pathology; Environmental health","score_opus":0.01343201188753156,"score_gpt":0.2507373291912683,"score_spread":0.23730531730373672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971211806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324685,0.0025333082,0.00026766575,0.0017486229,0.0019051533,0.00012531997,0.00006107414,0.000011093309,0.000100913916],"genre_scores_gemma":[0.99750054,0.0016359723,0.0006276943,0.00004820481,0.000022850332,0.000007659438,0.00004232066,0.000008377049,0.00010639426],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828434,0.00021572389,0.0009546697,0.0001484781,0.000079966994,0.00031683585],"domain_scores_gemma":[0.9986287,0.00021656227,0.0007588777,0.00020456436,0.00015196778,0.000039356975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021864919,0.00019764582,0.0007365827,0.0002689967,0.000079757,0.0000057331217,0.00029144785,0.0002005129,0.004205638],"category_scores_gemma":[0.00006810194,0.00015107368,0.00032834982,0.00011136446,0.00009418933,0.00007967112,0.000034097626,0.00016941574,0.00004643347],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017309943,0.0024777956,0.72373456,0.00005296794,0.0029807189,0.00006055495,0.0013801466,0.000007733245,0.02962523,0.00579104,0.08740277,0.14475551],"study_design_scores_gemma":[0.02239657,0.0065583056,0.21071006,0.00033544036,0.0017593283,0.0033397009,0.0010568748,0.0000022675767,0.6710182,0.0033076983,0.07884855,0.0006670396],"about_ca_topic_score_codex":0.000030958046,"about_ca_topic_score_gemma":0.000013891035,"teacher_disagreement_score":0.64139295,"about_ca_system_score_codex":0.000040969968,"about_ca_system_score_gemma":0.00007138522,"threshold_uncertainty_score":0.99670464},"labels":[],"label_agreement":null},{"id":"W1971787050","doi":"10.3899/jrheum.090219","title":"Translational Perspectives on Psoriatic Arthritis","year":2009,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Dental and Craniofacial Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases; U.S. Public Health Service; National Institutes of Health","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Disease; Population; Arthritis; Dermatology; Pathology; Immunology; Environmental health","score_opus":0.025685571424703634,"score_gpt":0.2965811716803986,"score_spread":0.270895600255695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971787050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018060871,0.99660105,0.000042061125,0.00043477683,0.0019112937,0.0004036348,0.00024106517,0.000017544897,0.0001679617],"genre_scores_gemma":[0.000709966,0.99814606,0.00043722254,0.000022688102,0.000068781286,0.000027759168,0.00033159912,0.000032477357,0.00022347251],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967637,0.00072762434,0.0016190517,0.00034086575,0.00012024353,0.00042851781],"domain_scores_gemma":[0.9975403,0.0005757617,0.0014234605,0.0002749148,0.00013475055,0.00005080966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049892144,0.0005334111,0.0027321968,0.00061993144,0.0001563896,0.000017136626,0.0003955889,0.00060206605,0.0028409192],"category_scores_gemma":[0.000072960866,0.00039180892,0.0011676404,0.00016548146,0.00011772416,0.00007582247,0.000021594347,0.000637516,0.0004123544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010974816,0.00046148573,0.000036572575,0.00044309808,0.0027318553,0.00006521036,0.0005603457,6.9245147e-7,8.503311e-7,0.0035193202,0.015066889,0.97700393],"study_design_scores_gemma":[0.002594296,0.000976112,0.000024400171,0.005057038,0.0014135999,0.0052046776,0.0002943648,4.3184997e-8,0.000010431846,0.00026533531,0.98385155,0.0003081366],"about_ca_topic_score_codex":0.000006675441,"about_ca_topic_score_gemma":0.000012112936,"teacher_disagreement_score":0.9766958,"about_ca_system_score_codex":0.00015055729,"about_ca_system_score_gemma":0.0004636291,"threshold_uncertainty_score":0.9998534},"labels":[],"label_agreement":null},{"id":"W1972194503","doi":"10.1016/j.jaad.2007.08.030","title":"From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis","year":2007,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Psoriasis; Foundation (evidence); Dermatology; Vaccination; Family medicine; Immunology","score_opus":0.020526556638649704,"score_gpt":0.29358086557537555,"score_spread":0.27305430893672583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972194503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281317,0.00036864565,0.000049618204,0.006173314,0.00033152473,0.00019581773,0.000037394733,0.000003263723,0.000027263668],"genre_scores_gemma":[0.9992167,0.00017223916,0.00027992117,0.00020496901,0.00009331458,0.000006523213,0.000004701391,0.0000071612444,0.000014466675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986107,0.0003442335,0.0006022929,0.00011645704,0.00014641201,0.00017990636],"domain_scores_gemma":[0.99703515,0.0014815689,0.0012098455,0.00008577527,0.00016630188,0.00002133316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037803565,0.0001259407,0.0004162519,0.00010832813,0.00013980416,0.0000037342859,0.00046123026,0.00016833404,0.000014479722],"category_scores_gemma":[0.0004877882,0.000057955902,0.00013393511,0.00033686342,0.00045897817,0.000061808154,0.00007232886,0.0002805365,7.820582e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008555126,0.00014437662,0.9824447,0.000005002097,0.0004824897,6.936874e-7,0.00028069728,0.000004893426,0.0018736282,0.00019079175,0.00039834093,0.013318841],"study_design_scores_gemma":[0.0027999927,0.00015670792,0.966312,0.00005431541,0.0001975819,0.00012734745,0.0003494351,0.0000020966486,0.02810598,0.0004200197,0.0014104836,0.00006401901],"about_ca_topic_score_codex":0.000059505204,"about_ca_topic_score_gemma":0.000015852109,"teacher_disagreement_score":0.026232352,"about_ca_system_score_codex":0.00004933876,"about_ca_system_score_gemma":0.00009434228,"threshold_uncertainty_score":0.2363373},"labels":[],"label_agreement":null},{"id":"W1972613508","doi":"10.1038/ejhg.2014.172","title":"Fine mapping of eight psoriasis susceptibility loci","year":2014,"lang":"en","type":"article","venue":"European Journal of Human Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Memorial University of Newfoundland; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Krembil Foundation; National Human Genome Research Institute; University of Toronto; Juvenile Diabetes Research Foundation International; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Psoriasis; Genetics; Biology; Computational biology; Evolutionary biology; Medicine; Dermatology","score_opus":0.0268010699597802,"score_gpt":0.23779489386285763,"score_spread":0.21099382390307742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972613508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918052,0.0029116052,0.000778672,0.0000455028,0.00059672364,0.00005919356,0.000012337632,0.000010238273,0.00378051],"genre_scores_gemma":[0.99789673,0.00010141868,0.0009241838,0.000024161658,0.00026613547,2.3789386e-7,0.00001966899,0.000025018353,0.0007424218],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978904,0.0009584112,0.0007187965,0.00015416379,0.0000639935,0.00021420824],"domain_scores_gemma":[0.9987876,0.0000821559,0.00057034596,0.00032308468,0.00019787159,0.000038961847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001126877,0.00016831666,0.0003688428,0.00014647188,0.00012267641,0.000010038818,0.00035589546,0.0000558684,0.0005068264],"category_scores_gemma":[0.00007064365,0.00013739507,0.0002182832,0.000094565956,0.00015669999,0.000033588854,0.00007244948,0.00017793401,0.00012801663],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016966695,0.00039954245,0.038665,0.00006518647,0.00067524624,0.000044872395,0.0016252518,0.000045247318,0.7954511,0.00021912305,0.0053393487,0.1573004],"study_design_scores_gemma":[0.007118323,0.0037610559,0.5362395,0.00015378557,0.0005535548,0.00024068201,0.0003101361,0.0000044158705,0.33635464,0.0004707883,0.1143178,0.0004752861],"about_ca_topic_score_codex":0.0000014838893,"about_ca_topic_score_gemma":0.000005963298,"teacher_disagreement_score":0.49757454,"about_ca_system_score_codex":0.000020002783,"about_ca_system_score_gemma":0.000022474753,"threshold_uncertainty_score":0.5602808},"labels":[],"label_agreement":null},{"id":"W1973354423","doi":"10.1056/nejmoa1314258","title":"Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1964,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Etanercept; Placebo; Dosing; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Dermatology; Clinical trial; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","score_opus":0.0397480406814782,"score_gpt":0.3245614633366991,"score_spread":0.2848134226552209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973354423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875407,0.0046905316,0.00038044667,0.002584533,0.0027156882,0.00015063777,0.000032974516,0.000008929177,0.0018955222],"genre_scores_gemma":[0.99657714,0.00069368334,0.00018494693,0.00008970312,0.0018660525,0.000001362805,0.000038738042,0.000010381027,0.00053800683],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99703884,0.0011071537,0.0013984749,0.00014224314,0.0001000723,0.00021320792],"domain_scores_gemma":[0.9968812,0.0017747894,0.00096714037,0.0001926791,0.00011794255,0.00006627512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051528136,0.0001751633,0.0011502772,0.0003589508,0.000032303502,0.0000027677909,0.00019404989,0.00014522485,0.00035390857],"category_scores_gemma":[0.0024345634,0.000106656276,0.00014067434,0.00017968382,0.00009934031,0.00006414093,0.000015712789,0.00025761366,0.000014294761],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0186871,0.00037984332,0.0012230879,0.000019643545,0.0005428937,0.000082216284,0.002820261,0.00002663759,0.13853346,0.0003815374,0.014844832,0.8224585],"study_design_scores_gemma":[0.71113616,0.005967327,0.0018904941,0.000590279,0.0007661619,0.0007476114,0.00025255824,0.000006321421,0.08858801,0.0019454566,0.18792324,0.00018636102],"about_ca_topic_score_codex":0.0002990473,"about_ca_topic_score_gemma":0.00015384004,"teacher_disagreement_score":0.8222721,"about_ca_system_score_codex":0.00003084905,"about_ca_system_score_gemma":0.00011087913,"threshold_uncertainty_score":0.43493167},"labels":[],"label_agreement":null},{"id":"W1974724279","doi":"10.1159/000130425","title":"Calcipotriol plus Betamethasone Dipropionate Scalp Formulation Is Effective and Well Tolerated in the Treatment of Scalp Psoriasis: A Phase II Study","year":2008,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Quest University Canada; University of British Columbia","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Scalp; Calcipotriol; Betamethasone; Medicine; Psoriasis; Dermatology; Corticosteroid; Surgery; Internal medicine","score_opus":0.022276234462731248,"score_gpt":0.281077922224782,"score_spread":0.25880168776205076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974724279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323916,0.0043072957,0.000029347575,0.00026336295,0.0002302912,0.0017145243,0.000043615997,0.000032272717,0.00014010574],"genre_scores_gemma":[0.9987381,0.00045866903,0.000025535404,0.00008520362,0.000017335573,0.00040439478,0.00012258235,0.000013505404,0.00013466508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806184,0.00075496646,0.00043084266,0.00037354804,0.00005117977,0.00032762377],"domain_scores_gemma":[0.9990568,0.00040247626,0.00016094364,0.00029603436,0.000060942202,0.000022811839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012131562,0.00027727263,0.0006732308,0.0002161578,0.0003256699,0.000004812627,0.00012553037,0.00026914664,0.00006876708],"category_scores_gemma":[0.000021602085,0.00018145764,0.00010495071,0.00029665793,0.0001850274,0.000079532336,0.000034533667,0.00010605868,0.00005031802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012502721,0.038954634,0.4134374,0.000118055716,0.0042713624,0.0014325492,0.26153842,0.000039075432,0.043020204,0.0007296182,0.0016822155,0.22227377],"study_design_scores_gemma":[0.12832919,0.022608142,0.54237306,0.00006349526,0.0017499782,0.0034788763,0.0057845786,0.00036533628,0.27973822,0.00030691564,0.014273721,0.000928482],"about_ca_topic_score_codex":0.00031269327,"about_ca_topic_score_gemma":0.00012949119,"teacher_disagreement_score":0.25575382,"about_ca_system_score_codex":0.00006802505,"about_ca_system_score_gemma":0.000052210402,"threshold_uncertainty_score":0.73996276},"labels":[],"label_agreement":null},{"id":"W1975204978","doi":"10.1073/pnas.0611589104","title":"Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression","year":2007,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Arthritis Foundation","keywords":"Biology; Signal transduction; Receptor; Cell biology; Proinflammatory cytokine; Innate immune system; Gene; Genetics; Inflammation; Immunology","score_opus":0.029139450232654417,"score_gpt":0.2529504995084085,"score_spread":0.22381104927575407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975204978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972372,0.0005094551,0.00002161923,0.0011175392,0.00011610502,0.00014397774,0.000043984634,0.000012042489,0.00079804804],"genre_scores_gemma":[0.99812686,0.000016798445,0.00088889914,0.000054922068,0.00009278409,0.0000068826307,0.000002559005,0.0000031622556,0.00080713787],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99914205,0.000015959995,0.00026377998,0.00021519541,0.00022766227,0.00013538093],"domain_scores_gemma":[0.9994078,0.00014023525,0.00030468352,0.000008272832,0.00012526801,0.000013688964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015972097,0.00009804574,0.000115362585,0.00008620487,0.00048014775,0.000010168811,0.00026446715,0.0001245359,0.00011415469],"category_scores_gemma":[0.000091060174,0.000051658324,0.000061332095,0.0002791686,0.000933292,0.00021609565,0.000047193727,0.0001272887,0.0000025620764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000139152,0.000038427224,0.0055480404,0.00000914609,0.00003306902,3.2929097e-9,0.00027097025,0.00002601907,0.9894962,0.0025622495,0.00081570446,0.0010610403],"study_design_scores_gemma":[0.00026873703,0.00004599619,0.14404087,0.000027614451,0.000022783579,0.000019368626,0.0001802668,0.00001847383,0.84879756,0.0060154353,0.0005083476,0.000054572727],"about_ca_topic_score_codex":0.0000031620498,"about_ca_topic_score_gemma":1.13037196e-7,"teacher_disagreement_score":0.14069864,"about_ca_system_score_codex":0.000021363408,"about_ca_system_score_gemma":0.000019201883,"threshold_uncertainty_score":0.3692957},"labels":[],"label_agreement":null},{"id":"W1975321166","doi":"10.1007/s10227-002-0113-6","title":"Mycophenolate Mofetil (CellCept�) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Vancouver General Hospital; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Medicine; Open label; Psoriasis; Dermatology; Mycophenolate; Clinical trial; Surgery; Internal medicine; Transplantation","score_opus":0.10015512159607844,"score_gpt":0.3576214980133305,"score_spread":0.25746637641725206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975321166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97410226,0.013212459,0.00013152481,0.0006225667,0.009020344,0.00082683546,0.00002126756,0.000018985822,0.002043742],"genre_scores_gemma":[0.98850834,0.0062432406,0.00057512266,0.0006888724,0.0010715518,0.00003632017,0.000024699737,0.00004263508,0.0028092307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971994,0.0005716822,0.0014316387,0.00030859958,0.000095166644,0.00039351464],"domain_scores_gemma":[0.9959965,0.002572468,0.00082759757,0.00021651424,0.0002710803,0.00011585329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023585786,0.00027603877,0.0013335738,0.0002160238,0.00020908752,0.000027764574,0.00021812555,0.00021409873,0.00035798457],"category_scores_gemma":[0.0015410517,0.00018734994,0.00026102297,0.00014499105,0.0002214296,0.00013076418,0.00003577955,0.000313513,0.000020279986],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3488752,0.009031262,0.03886738,0.00018809905,0.006954104,0.0023331323,0.0015960361,0.0000019512515,0.011701524,0.0021127039,0.27068248,0.3076561],"study_design_scores_gemma":[0.48287633,0.016008446,0.00047869308,0.0007866052,0.002320278,0.021945141,0.0011890187,0.000005687514,0.0029084496,0.0042852084,0.466418,0.0007781412],"about_ca_topic_score_codex":0.000015099728,"about_ca_topic_score_gemma":0.0000075366193,"teacher_disagreement_score":0.30687797,"about_ca_system_score_codex":0.00003718078,"about_ca_system_score_gemma":0.00026819657,"threshold_uncertainty_score":0.7639909},"labels":[],"label_agreement":null},{"id":"W1975463338","doi":"10.1016/j.jaad.2006.07.017","title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":517,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Infliximab; Maintenance therapy; Psoriasis; Maintenance dose; Placebo; Randomized controlled trial; Internal medicine; Surgery; Gastroenterology; Chemotherapy; Dermatology; Tumor necrosis factor alpha","score_opus":0.014818830194803984,"score_gpt":0.280921689709543,"score_spread":0.266102859514739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975463338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930457,0.0018715779,0.000047235997,0.004167352,0.00019673973,0.00044359785,0.000035792884,0.000004006926,0.00018798534],"genre_scores_gemma":[0.998795,0.00052837195,0.00023080525,0.00024758032,0.00002781944,0.000020765536,0.0000030284439,0.000012397221,0.00013423986],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99687046,0.0012421788,0.0013419987,0.00015453828,0.00010410079,0.00028674086],"domain_scores_gemma":[0.9964216,0.000816955,0.002454779,0.00020994744,0.00007694629,0.000019799294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002993503,0.00022914489,0.0020685967,0.00024565155,0.000043804357,0.000003676924,0.0005295082,0.00015972412,0.000020088342],"category_scores_gemma":[0.000077634475,0.00012124482,0.000547135,0.00028206938,0.0007924882,0.000047139012,0.00004745822,0.00025220096,0.0000050221993],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49770552,0.0075356616,0.3193004,0.00013724173,0.0065660463,0.00010606686,0.016512142,0.0015168688,0.0930009,0.0063740355,0.032026764,0.019218339],"study_design_scores_gemma":[0.35909927,0.0031999217,0.21227477,0.00055474293,0.0025553403,0.0041910466,0.0049958783,0.00010735005,0.3912501,0.002008832,0.0191185,0.00064422324],"about_ca_topic_score_codex":0.0002627211,"about_ca_topic_score_gemma":0.000022046232,"teacher_disagreement_score":0.2982492,"about_ca_system_score_codex":0.00006670064,"about_ca_system_score_gemma":0.00006873803,"threshold_uncertainty_score":0.49442202},"labels":[],"label_agreement":null},{"id":"W1975592271","doi":"10.1016/j.jaad.2005.10.032","title":"Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Efalizumab; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.006745783155185325,"score_gpt":0.22889915669201263,"score_spread":0.22215337353682732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975592271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994881,0.0008675665,0.000022699982,0.0036436443,0.00018180405,0.00022889355,0.00003118485,0.0000074190243,0.00013581995],"genre_scores_gemma":[0.9991781,0.000078449,0.0002694423,0.0002755606,0.00003543385,0.000008635472,0.00000615201,0.000017234624,0.00013096682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998379,0.00038106702,0.0006210307,0.00017830465,0.000090974354,0.0003496244],"domain_scores_gemma":[0.9986544,0.00011984111,0.000982611,0.00015352857,0.000058866164,0.000030731593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008123044,0.00021857428,0.0007615326,0.00025489237,0.00007503011,0.0000046543473,0.0003846797,0.00014428794,0.000031041098],"category_scores_gemma":[0.000017586592,0.00013196844,0.00015670902,0.0003790902,0.00025845392,0.0000816302,0.000067733985,0.0003071235,0.000023428734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010072841,0.0010926805,0.9506816,0.000035580786,0.0013631447,0.000058948477,0.00037349827,0.0015749305,0.0071579325,0.0005263257,0.008668483,0.018394025],"study_design_scores_gemma":[0.009681186,0.0010218777,0.9298373,0.00012193138,0.0003190604,0.001244058,0.00007237367,0.0000030539102,0.052345835,0.0002921511,0.0048079626,0.00025323062],"about_ca_topic_score_codex":0.00011684704,"about_ca_topic_score_gemma":0.000040049348,"teacher_disagreement_score":0.0451879,"about_ca_system_score_codex":0.00021183612,"about_ca_system_score_gemma":0.0001282302,"threshold_uncertainty_score":0.5381517},"labels":[],"label_agreement":null},{"id":"W1975795171","doi":"10.2165/00128071-200607030-00004","title":"Use of Calcipotriene Cream (Dovonex?? Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex??)","year":2006,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Betamethasone dipropionate; Medicine; Dermatology; Psoriasis; Calcipotriol","score_opus":0.03893121790341279,"score_gpt":0.3272870268135607,"score_spread":0.2883558089101479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975795171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228257,0.0038442048,0.00046163157,0.0017201111,0.001057308,0.00041231565,0.000084636464,0.000026012285,0.000111204216],"genre_scores_gemma":[0.9960449,0.0010305956,0.0021612127,0.00012260956,0.00019606882,0.000025351566,0.000055216573,0.000048736347,0.00031532615],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941443,0.0018224203,0.0026319127,0.00052458775,0.00022923287,0.0006474974],"domain_scores_gemma":[0.9916008,0.0039663846,0.0030872992,0.0007554343,0.0004792248,0.00011084691],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006859637,0.000522574,0.0029756622,0.00030391468,0.00020300919,0.00001963799,0.00051093433,0.00024897407,0.000051812753],"category_scores_gemma":[0.0002967848,0.00030083835,0.0011598155,0.0006729892,0.0021152142,0.00022161404,0.00007843272,0.00042989122,0.000018263725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021343475,0.014329003,0.5911693,0.00006350275,0.028095374,0.0024696465,0.0012954602,0.00054941035,0.07623606,0.0010502068,0.0030645754,0.260334],"study_design_scores_gemma":[0.041454643,0.03721834,0.27823046,0.00031800644,0.0190838,0.012454603,0.0011264274,0.000028211694,0.51149786,0.00043574002,0.09654659,0.0016053565],"about_ca_topic_score_codex":0.0013953161,"about_ca_topic_score_gemma":0.00012327997,"teacher_disagreement_score":0.4352618,"about_ca_system_score_codex":0.000067141336,"about_ca_system_score_gemma":0.00046133832,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W1975941816","doi":"10.1111/jdv.12198","title":"Efficacy of adalimumab across subgroups of patients with moderate‐to‐severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH","year":2013,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Celgene; Pfizer; Eli Lilly and Company; Incyte; Amgen","keywords":"Adalimumab; Medicine; Psoriasis; Clinical endpoint; Placebo; Dermatology Life Quality Index; Post-hoc analysis; Dermatology; Plaque psoriasis; Erythema; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Disease; Pathology","score_opus":0.01061239310158144,"score_gpt":0.2340154822033418,"score_spread":0.22340308910176038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975941816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604005,0.0026452602,0.000014785559,0.0007430563,0.00014041514,0.00022999525,0.00011056657,0.000002943079,0.000072936346],"genre_scores_gemma":[0.9992238,0.00050240743,0.00006566126,0.00008067434,0.000017972081,0.0000021574017,0.000010336574,0.000017186789,0.00007978624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970284,0.0013321354,0.0010664384,0.00020299181,0.00009251305,0.00027752685],"domain_scores_gemma":[0.99715596,0.00042237414,0.0018636177,0.00026722768,0.0002496142,0.000041191986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003620285,0.00023278773,0.001193865,0.00026793795,0.00010519122,0.000002662559,0.0005742468,0.00030394917,0.000051332936],"category_scores_gemma":[0.00010527999,0.00012232209,0.00028346153,0.0004219337,0.0010270659,0.00008834458,0.0002716365,0.0003345394,0.000001614173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012898379,0.00077952247,0.9291838,0.00027097427,0.009595836,0.000007768591,0.0035803556,0.00040021603,0.03349921,0.00048178766,0.00039886523,0.008903279],"study_design_scores_gemma":[0.007909002,0.00067406025,0.9399494,0.00014068883,0.0020245975,0.00037405756,0.00016504014,0.000010946417,0.04839015,0.00005764479,0.00017678877,0.00012762187],"about_ca_topic_score_codex":0.000035344496,"about_ca_topic_score_gemma":0.000035933903,"teacher_disagreement_score":0.01489094,"about_ca_system_score_codex":0.00001791328,"about_ca_system_score_gemma":0.00007710403,"threshold_uncertainty_score":0.498815},"labels":[],"label_agreement":null},{"id":"W1976484071","doi":"10.1016/s0151-9638(11)70066-7","title":"En pratique, comment évaluer les bénéfices thérapeutiques d’un traitement systémique du psoriasis ?","year":2011,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Humanities; Medicine; Political science; Philosophy","score_opus":0.05974049287334451,"score_gpt":0.2935457782871641,"score_spread":0.2338052854138196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976484071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7816793,0.11652574,0.0064553404,0.06913696,0.0041890256,0.0018836365,0.00063121633,0.0012270609,0.01827175],"genre_scores_gemma":[0.9093554,0.06975451,0.007105436,0.011018834,0.00021638967,0.00067883293,0.00034976334,0.00010716305,0.0014136441],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884392,0.0069932626,0.0012433025,0.0010869885,0.00014722512,0.0020900266],"domain_scores_gemma":[0.99561757,0.002284916,0.0006686316,0.00095092657,0.0002584552,0.00021952114],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023744104,0.0011255024,0.0013380103,0.00039576768,0.0006312993,0.00014283502,0.001550306,0.0024420402,0.0019694294],"category_scores_gemma":[0.000638626,0.0010348001,0.0006837605,0.00035935774,0.0009810457,0.000594804,0.00064865325,0.0010887297,0.0005741563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020636157,0.00637033,0.42073315,0.0013843217,0.009787727,0.0049581183,0.022059107,0.00007102537,0.0058486806,0.11455449,0.16637038,0.24579905],"study_design_scores_gemma":[0.0044032307,0.0017049351,0.23159495,0.0007467907,0.002645567,0.005472491,0.005685362,0.00008260112,0.2870662,0.013752262,0.44463474,0.0022108671],"about_ca_topic_score_codex":0.0015465423,"about_ca_topic_score_gemma":0.0005124638,"teacher_disagreement_score":0.28121752,"about_ca_system_score_codex":0.0006074,"about_ca_system_score_gemma":0.0010044681,"threshold_uncertainty_score":0.99921024},"labels":[],"label_agreement":null},{"id":"W1976544953","doi":"10.1073/pnas.1307569110","title":"Langerin <sup>neg</sup> conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"TLR7; Langerin; Psoriasis; Imiquimod; CD11c; Immunology; Interleukin 23; Inflammation; Immune system; Dendritic cell; Medicine; Toll-like receptor; Biology; Interleukin 17; Innate immune system; Phenotype","score_opus":0.02392637541446362,"score_gpt":0.2570702422088321,"score_spread":0.2331438667943685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976544953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995646,0.00016074917,0.0000013737292,0.0026026303,0.000056528705,0.00045292953,0.000038863054,0.000010842166,0.0010300919],"genre_scores_gemma":[0.9984408,0.000024199182,0.000632102,0.00017153718,0.00003893723,0.00008234123,0.0000028842499,0.0000034712905,0.0006037516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903333,0.000020905849,0.00033149225,0.0002176548,0.00020701572,0.00018957564],"domain_scores_gemma":[0.9994147,0.00013582563,0.00022262825,0.000009366097,0.0002003795,0.000017102633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053332123,0.00010309547,0.00016097812,0.00022780095,0.00013041259,0.000016338916,0.0004426461,0.00011374091,0.0000822593],"category_scores_gemma":[0.00020613639,0.00007404543,0.000060016537,0.0004849874,0.00024477462,0.00049657736,0.00008032256,0.00010889449,0.00013230348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026144844,0.000102535276,0.002414831,0.00006460962,0.000032626987,1.1595051e-8,0.0009186343,0.000120234086,0.9842422,0.0076426617,0.0035412244,0.0008943097],"study_design_scores_gemma":[0.00051287963,0.00007042754,0.05125014,0.000116082556,0.000021544609,0.000015919142,0.00055291125,0.0001799015,0.9399571,0.0068135564,0.00040535352,0.000104181425],"about_ca_topic_score_codex":0.000024845302,"about_ca_topic_score_gemma":6.573719e-7,"teacher_disagreement_score":0.048835307,"about_ca_system_score_codex":0.000052975975,"about_ca_system_score_gemma":0.000025163034,"threshold_uncertainty_score":0.3019485},"labels":[],"label_agreement":null},{"id":"W1976786386","doi":"10.3899/jrheum.120818","title":"Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Prologue; Dermatology; Family medicine; Rheumatology; Ustekinumab; Disease; Internal medicine; Adalimumab","score_opus":0.05142548221508472,"score_gpt":0.32731504549662727,"score_spread":0.27588956328154257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976786386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570666,0.04086428,0.00026353108,0.00056184223,0.0008506611,0.00029232053,0.000017354687,0.000005440942,0.00007799556],"genre_scores_gemma":[0.98203796,0.016787332,0.0010295053,0.000013321707,0.000020594725,0.000022924844,0.0000065115655,0.000011870405,0.000069949594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813735,0.0007828515,0.0005001712,0.000103311235,0.00006331153,0.00041302],"domain_scores_gemma":[0.99747664,0.0017166976,0.00039535132,0.0001738799,0.00019224694,0.000045197743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031524482,0.00013259909,0.0005281714,0.00020641783,0.00022152484,0.0000059553836,0.00018284757,0.00020659289,0.00006587617],"category_scores_gemma":[0.00013935058,0.00008404078,0.0000698311,0.000080902115,0.0005186607,0.000115319875,0.000079867656,0.00028422914,0.000006602315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002309644,0.00090532604,0.71774393,0.0002193872,0.0022439163,0.0000026292846,0.0034124025,6.2892786e-7,0.017459136,0.030233867,0.0076591587,0.21780999],"study_design_scores_gemma":[0.03200696,0.014974485,0.82125705,0.00060621585,0.0017952081,0.02726863,0.006221889,0.000023892013,0.01792262,0.030116037,0.047001053,0.000805977],"about_ca_topic_score_codex":0.00007739474,"about_ca_topic_score_gemma":0.00003745606,"teacher_disagreement_score":0.21700402,"about_ca_system_score_codex":0.000017231143,"about_ca_system_score_gemma":0.00005948097,"threshold_uncertainty_score":0.34270838},"labels":[],"label_agreement":null},{"id":"W1976865991","doi":"10.1111/jdv.12934","title":"Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE","year":2015,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Merck Canada Inc. (Canada); Lynde Centre for Dermatology; Moncton Hospital; Amgen (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada); Probity Medical Research","funders":"Pfizer; Amgen","keywords":"Etanercept; Medicine; Dermatology Life Quality Index; Psoriasis; Internal medicine; Randomized controlled trial; Dermatology; Rheumatoid arthritis","score_opus":0.02378567879713218,"score_gpt":0.24451367082407646,"score_spread":0.2207279920269443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976865991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604684,0.0010297449,0.0000032915368,0.0018381699,0.0005237356,0.0001395921,0.000018766277,0.00000610466,0.0003937405],"genre_scores_gemma":[0.9993649,0.000098132776,0.00014258124,0.00025040936,0.000024004124,0.0000017327861,0.00001241423,0.0000139989,0.0000918199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968449,0.00156445,0.0010329747,0.00022011528,0.00007575565,0.00026179367],"domain_scores_gemma":[0.9985564,0.00025447845,0.00092933496,0.00016108932,0.000059598056,0.000039141956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042408257,0.00019758787,0.0006703636,0.00020644342,0.000046395304,0.0000035827209,0.00030837805,0.0002605532,0.0000124691815],"category_scores_gemma":[0.00028874716,0.00011750193,0.00008230765,0.00014209292,0.00025388016,0.00009860795,0.00014274838,0.0005021073,0.0000053461276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002730271,0.0002373732,0.9825501,0.0000047246826,0.000406425,0.00008349883,0.0017851824,0.00001214628,0.00041728,0.000028620603,0.00021172725,0.011532674],"study_design_scores_gemma":[0.016145585,0.00018449695,0.98003954,0.000073769545,0.00011675757,0.00025716476,0.00024417284,0.0000016759549,0.0012397693,0.0002564493,0.0013160574,0.00012455363],"about_ca_topic_score_codex":0.000050031143,"about_ca_topic_score_gemma":0.0000339517,"teacher_disagreement_score":0.013415313,"about_ca_system_score_codex":0.000050720344,"about_ca_system_score_gemma":0.000052726067,"threshold_uncertainty_score":0.47915894},"labels":[],"label_agreement":null},{"id":"W1977350622","doi":"10.1111/bjd.13469","title":"Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up","year":2014,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":203,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Dalhousie University","funders":"Janssen Scientific Affairs","keywords":"Dosing; Medicine; Ustekinumab; Psoriasis; Placebo; Psoriasis Area and Severity Index; Population; Discontinuation; Randomized controlled trial; Adverse effect; Internal medicine; Dermatology; Disease; Alternative medicine","score_opus":0.011009835043840488,"score_gpt":0.22599502152068926,"score_spread":0.21498518647684878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977350622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967757,0.002284622,0.00007590456,0.000054571316,0.00021044457,0.00045918574,0.000102569196,0.0000051060874,0.000031884654],"genre_scores_gemma":[0.9993267,0.0002836579,0.00026391915,0.000043127027,0.000018243767,0.000005036483,0.000030443753,0.000017517297,0.000011351303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982297,0.0005367977,0.00066566415,0.0002478418,0.00008935459,0.00023063365],"domain_scores_gemma":[0.9987184,0.00034018556,0.0005642882,0.00019361959,0.00014952366,0.000033979788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018329281,0.00017851462,0.0007327672,0.00008396817,0.000087621396,0.000016282014,0.00017291181,0.00013596202,0.000007523253],"category_scores_gemma":[0.000091063106,0.00013398466,0.000041846033,0.0001292914,0.00020049744,0.00014537192,0.00006537714,0.00020318352,0.0000010243899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024700701,0.0007445806,0.91087043,0.000016616279,0.0010592226,0.00009167467,0.006303363,0.000020969395,0.00020251259,0.000006770927,0.000099812125,0.05588335],"study_design_scores_gemma":[0.051610366,0.00121588,0.94293284,0.0005032594,0.0004017761,0.0017337236,0.0005387814,6.6398854e-7,0.00086455385,0.000015048185,0.000043954144,0.00013916643],"about_ca_topic_score_codex":0.00037208325,"about_ca_topic_score_gemma":0.0008927943,"teacher_disagreement_score":0.055744186,"about_ca_system_score_codex":0.0000184886,"about_ca_system_score_gemma":0.000057887544,"threshold_uncertainty_score":0.5463736},"labels":[],"label_agreement":null},{"id":"W1978214833","doi":"10.1007/s10227-006-0100-4","title":"Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; Lynde Centre for Dermatology","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Plaque psoriasis; Intensive care medicine; Drug; Biologic Agents; Dermatology; Disease; Pharmacology; Pathology","score_opus":0.027982625513872133,"score_gpt":0.2654800357360675,"score_spread":0.23749741022219537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978214833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97791654,0.015225027,0.00034993535,0.005186579,0.0007975064,0.0001534596,0.0000028012676,0.000011019877,0.0003571607],"genre_scores_gemma":[0.98983926,0.007357353,0.00038937217,0.0006644557,0.00032257804,0.0000036724557,0.000009644383,0.0000117099735,0.0014019314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859023,0.0001891241,0.0007297996,0.0001610816,0.00009011785,0.00023962582],"domain_scores_gemma":[0.9986157,0.00062314863,0.00041128803,0.00017579006,0.00009789148,0.00007620251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055527233,0.00020774652,0.0006329013,0.00021833341,0.00012859586,0.000009834386,0.00016517485,0.00012106222,0.0002470844],"category_scores_gemma":[0.0000894948,0.000109239765,0.0001675963,0.00016333464,0.00010364801,0.000056099718,0.000048914597,0.00018116429,0.000016391185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023524796,0.00015324258,0.009271975,0.00009720505,0.0017974741,0.0009769585,0.006393059,0.000092129514,0.009919008,0.00018265985,0.02431231,0.9444515],"study_design_scores_gemma":[0.04026257,0.019251369,0.11043173,0.025289798,0.01686932,0.16785012,0.047278836,0.00016638446,0.15620166,0.0062923175,0.40471444,0.0053914725],"about_ca_topic_score_codex":0.00006974297,"about_ca_topic_score_gemma":0.00006250473,"teacher_disagreement_score":0.93906003,"about_ca_system_score_codex":0.000050792696,"about_ca_system_score_gemma":0.000072161674,"threshold_uncertainty_score":0.44546682},"labels":[],"label_agreement":null},{"id":"W1978824248","doi":"10.1038/jid.2011.304","title":"A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis","year":2011,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Abbott Laboratories","keywords":"Placebo; Medicine; Adverse effect; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Surgery; Dermatology; Pathology","score_opus":0.03313375104487552,"score_gpt":0.267880182342678,"score_spread":0.23474643129780248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978824248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932631,0.00064183824,0.00006261695,0.0006115189,0.0015741354,0.0021680694,0.000033187804,0.000011902903,0.0016336035],"genre_scores_gemma":[0.9986855,0.00004297451,0.00028974307,0.00034697235,0.000072241324,0.0001739694,0.000008933197,0.000021995738,0.00035767103],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99381316,0.0032363653,0.002148505,0.0002627225,0.000118331765,0.00042092532],"domain_scores_gemma":[0.9964658,0.0007496401,0.002024945,0.00033286426,0.0003419947,0.00008473151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001196943,0.00037561927,0.0031466053,0.00048592885,0.00017227179,0.00001087848,0.0005572629,0.00041380175,0.0003288938],"category_scores_gemma":[0.0010984145,0.0002271397,0.000877009,0.00028457513,0.0009945093,0.00015119747,0.00009768925,0.0004817064,0.000031545984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9359963,0.0012646212,0.00018081708,0.000014774527,0.0023161783,0.000121140205,0.0073833447,0.000009576243,0.04764218,0.0035662304,0.0011561031,0.00034874864],"study_design_scores_gemma":[0.7871357,0.00084218197,0.00022107684,0.00008769107,0.0006787716,0.00076036004,0.0004652901,0.0000053552963,0.2045458,0.0049689775,0.000111279274,0.00017748777],"about_ca_topic_score_codex":0.00009353877,"about_ca_topic_score_gemma":0.00010872239,"teacher_disagreement_score":0.15690361,"about_ca_system_score_codex":0.00007130175,"about_ca_system_score_gemma":0.000434263,"threshold_uncertainty_score":0.9262488},"labels":[],"label_agreement":null},{"id":"W1978855446","doi":"10.1111/jdv.12372","title":"Changes in C‐reactive protein in patients with moderate‐to‐severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy","year":2014,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Etanercept; Adalimumab; Psoriasis; C-reactive protein; Internal medicine; Methotrexate; Psoriasis Area and Severity Index; Psoriatic arthritis; Gastroenterology; Infliximab; Discontinuation; Rheumatoid arthritis; Inflammation; Tumor necrosis factor alpha; Dermatology","score_opus":0.015510631042594309,"score_gpt":0.2466818735983513,"score_spread":0.231171242555757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978855446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173033,0.0002695982,0.00004919219,0.0070696524,0.00015080963,0.00062977703,0.00001536391,0.000007872153,0.000077431265],"genre_scores_gemma":[0.99671584,0.000047599162,0.0008821129,0.0020243432,0.000035921268,0.000036871697,0.0000015206002,0.000035374494,0.00022040996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941899,0.004425036,0.0005709378,0.00032069988,0.0000740172,0.00041940116],"domain_scores_gemma":[0.99893016,0.00034248678,0.00038055234,0.00019210971,0.000074202595,0.00008050664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010056929,0.00030114345,0.0008173981,0.0005740585,0.000069594884,0.00000675119,0.00043402542,0.00027180807,0.000063677995],"category_scores_gemma":[0.00016787517,0.0001781663,0.00007955636,0.00036157403,0.00014683393,0.00007818769,0.00011697727,0.00046450013,0.000023971348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34921363,0.00074829225,0.45229307,0.000030135772,0.000749301,0.00015023982,0.007562099,0.00023577853,0.15577635,0.00006116962,0.00029370526,0.032886237],"study_design_scores_gemma":[0.012802176,0.0012650427,0.89277536,0.00017880349,0.00006308195,0.00056559424,0.00011892361,0.0000022067152,0.087020166,0.00008268804,0.0048374515,0.00028850645],"about_ca_topic_score_codex":0.000011476951,"about_ca_topic_score_gemma":0.00009123769,"teacher_disagreement_score":0.4404823,"about_ca_system_score_codex":0.000048255708,"about_ca_system_score_gemma":0.00005079256,"threshold_uncertainty_score":0.7265411},"labels":[],"label_agreement":null},{"id":"W1979000113","doi":"10.1111/j.1365-2133.2007.08205.x","title":"Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks","year":2007,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Placebo; Internal medicine; Depression (economics); Randomized controlled trial; Clinical trial; Tumor necrosis factor alpha; Dermatology; Pathology; Alternative medicine","score_opus":0.01695004558656602,"score_gpt":0.2591666758012743,"score_spread":0.24221663021470827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979000113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814296,0.008435244,0.0010571362,0.005707284,0.0011465516,0.00178811,0.0003907903,0.000012670367,0.00003265863],"genre_scores_gemma":[0.9791852,0.001448856,0.0006873488,0.017398234,0.0002545597,0.00021400253,0.0003130529,0.00009788108,0.00040086982],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976041,0.00043267076,0.0009758962,0.0003868148,0.00007891643,0.0005216442],"domain_scores_gemma":[0.9972148,0.0015825088,0.0006857714,0.00017451342,0.00028600343,0.00005640246],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002005889,0.00038650993,0.0016035775,0.0007318007,0.000084414314,0.00001442167,0.00028234263,0.0014900219,0.000018473],"category_scores_gemma":[0.00016082161,0.00037248462,0.0003115829,0.00016643052,0.00008371685,0.00006447846,0.000034998222,0.0005180973,0.0000022854583],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037303373,0.0008902661,0.0076382966,0.0020031186,0.0042905686,0.0050103646,0.0023699626,0.000091900205,0.079088375,0.000024885776,0.4572011,0.4040878],"study_design_scores_gemma":[0.04280098,0.005972892,0.014002602,0.004519884,0.0008690649,0.03008841,0.00008351296,0.0000060625794,0.862833,0.00019387435,0.037654717,0.00097497454],"about_ca_topic_score_codex":0.00011671816,"about_ca_topic_score_gemma":0.000091008915,"teacher_disagreement_score":0.78374463,"about_ca_system_score_codex":0.000055267275,"about_ca_system_score_gemma":0.00011225313,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W1979887570","doi":"10.2310/7750.2008.08002","title":"Use of Biologic Therapeutics in Difficult-to-Treat Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Etanercept; Infliximab; Formulary; Randomized controlled trial; Intensive care medicine; Dermatology; Clinical trial; Plaque psoriasis; Surgery; Pharmacology; Disease; Immunology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.058362135002733795,"score_gpt":0.27188108608229455,"score_spread":0.21351895107956076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979887570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048233,0.007183434,0.000011512163,0.0016774148,0.00048270953,0.00007090573,0.0000057410493,0.000007004732,0.00007892492],"genre_scores_gemma":[0.9921578,0.0065990165,0.00006677733,0.00080290926,0.000097256765,6.1587696e-7,0.000007981832,0.0000059300833,0.0002616969],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99879855,0.00017508077,0.00063962676,0.00011816735,0.000057462235,0.00021111996],"domain_scores_gemma":[0.99822223,0.0011870223,0.0002989817,0.00012011095,0.00012839388,0.000043256772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031933215,0.00015944616,0.0007220589,0.00041903323,0.000035675843,0.000004228769,0.00007607581,0.00016356462,0.000067400135],"category_scores_gemma":[0.00027690877,0.000095110445,0.00011064615,0.0002576167,0.00009447386,0.0000532516,0.000009105563,0.00014173277,0.000005080671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025933115,0.0005646968,0.13289863,0.00002902006,0.00036731779,0.001226298,0.0018117226,0.000019720033,0.3888066,0.000066316155,0.008603601,0.46301275],"study_design_scores_gemma":[0.009725658,0.01574527,0.6583679,0.0027498011,0.002725858,0.034255333,0.0031170887,0.0000090934545,0.13450816,0.001411631,0.13593411,0.0014501358],"about_ca_topic_score_codex":0.000034193596,"about_ca_topic_score_gemma":0.000012035131,"teacher_disagreement_score":0.52546924,"about_ca_system_score_codex":0.000021358064,"about_ca_system_score_gemma":0.000046331174,"threshold_uncertainty_score":0.38784912},"labels":[],"label_agreement":null},{"id":"W1979929645","doi":"10.1016/j.jaad.2005.10.029","title":"Relapse, rebound, and psoriasis adverse events: An advisory group report","year":2006,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Royal Victoria Hospital","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Adverse effect; Clinical trial; Disease; Dermatology; Internal medicine; Plaque psoriasis","score_opus":0.027237259942385166,"score_gpt":0.3133963137695004,"score_spread":0.2861590538271152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979929645","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017499164,0.9803879,0.000012576154,0.00039536488,0.0010962064,0.00035113006,0.00007584115,0.000018283356,0.00016351655],"genre_scores_gemma":[0.0033894454,0.99523133,0.00038370685,0.00015018428,0.00016796264,0.000017053013,0.000052578132,0.000059629558,0.00054808613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948363,0.0019986362,0.0021802313,0.00040869944,0.00012798421,0.0004481552],"domain_scores_gemma":[0.9912539,0.00048638682,0.007696588,0.00042177486,0.00007014547,0.000071185845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005034485,0.0005582337,0.003617015,0.00049513986,0.00018061526,0.000004325178,0.000943859,0.00075503084,0.000028779561],"category_scores_gemma":[0.00015734452,0.00035477238,0.0011393018,0.00044560278,0.0010647306,0.00018577659,0.00021191592,0.0012077255,0.000023888999],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047796397,0.0005814535,0.004883415,0.00196128,0.005040729,0.00056776527,0.00012312223,0.0000011037104,0.0002257477,0.00037465774,0.010087949,0.9756748],"study_design_scores_gemma":[0.0009785122,0.0002082871,0.0021451593,0.0012940121,0.004320088,0.08359806,0.00008497249,7.0037395e-8,0.00006258201,0.0002108641,0.90678513,0.0003122455],"about_ca_topic_score_codex":0.00004459945,"about_ca_topic_score_gemma":0.0000052532005,"teacher_disagreement_score":0.97536254,"about_ca_system_score_codex":0.000099090605,"about_ca_system_score_gemma":0.00025952485,"threshold_uncertainty_score":0.99989045},"labels":[],"label_agreement":null},{"id":"W1979989894","doi":"10.1159/000367789","title":"T Helper 17 Cells and Related Cytokines after Allergen Inhalation Challenge in Allergic Asthmatics","year":2014,"lang":"en","type":"article","venue":"International Archives of Allergy and Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunology; Allergen; Peripheral blood mononuclear cell; Medicine; Cytokine; Flow cytometry; Asthma; Allergy; Biology; In vitro","score_opus":0.006535332974691852,"score_gpt":0.20451652432108378,"score_spread":0.19798119134639192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979989894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823639,0.0056465873,0.00012483304,0.0007001607,0.0006522355,0.000114235016,0.000022350954,0.000022841708,0.010352864],"genre_scores_gemma":[0.9909931,0.0065027764,0.00024539934,0.00004018299,0.00002465131,0.000029640601,0.000111028006,0.000013109222,0.0020401322],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989093,0.00018840705,0.00038885532,0.00027677804,0.000034534874,0.00020210037],"domain_scores_gemma":[0.9994312,0.00025155488,0.00014117266,0.00013035054,0.000029112845,0.000016624845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009943683,0.00018468751,0.00027833576,0.0002783215,0.000050596187,0.000006325236,0.00014742826,0.00019620905,0.0003902148],"category_scores_gemma":[0.000030422863,0.00016644262,0.000061676576,0.00004500951,0.00036296144,0.00008984931,0.00014877484,0.00015014473,0.000030259213],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051841503,0.0014540893,0.010085232,0.00007321232,0.007762007,0.00005413561,0.018408818,0.00021991412,0.49871576,0.030501109,0.00022070204,0.42732087],"study_design_scores_gemma":[0.011221439,0.0013728966,0.8296023,0.00029780375,0.00007226846,0.00026186512,0.00083981955,0.0015010323,0.030818142,0.025795288,0.09740033,0.0008167885],"about_ca_topic_score_codex":0.00006510515,"about_ca_topic_score_gemma":0.00017784607,"teacher_disagreement_score":0.8195171,"about_ca_system_score_codex":0.000008672174,"about_ca_system_score_gemma":0.000012309557,"threshold_uncertainty_score":0.6787333},"labels":[],"label_agreement":null},{"id":"W1980098230","doi":"10.1016/j.humimm.2004.04.002","title":"Association of SEEK1 polymorphisms in Crohn's disease","year":2004,"lang":"en","type":"article","venue":"Human Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Arthritis Society","keywords":"Allele; Single-nucleotide polymorphism; Crohn's disease; Genetics; Psoriasis; Biology; Inflammatory bowel disease; Allele frequency; Genotype; Population; Exon; Genetic predisposition; Polymorphism (computer science); Disease; Immunology; Medicine; Gene; Internal medicine","score_opus":0.012659790471144662,"score_gpt":0.23190318169340898,"score_spread":0.21924339122226433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980098230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331754,0.004569709,0.000009807901,0.00032606657,0.0005359656,0.00016790762,0.00003607822,0.000049353457,0.0009875532],"genre_scores_gemma":[0.9953994,0.00010848407,0.000026811733,0.000053844193,0.00002099712,0.000036907713,0.00016400937,0.000014300313,0.0041752057],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99888456,0.00017431866,0.00032757668,0.00023428835,0.000030201212,0.00034907064],"domain_scores_gemma":[0.99940526,0.00006407542,0.00019809141,0.00027604058,0.00004155443,0.000014966751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015501621,0.00015594241,0.0003105538,0.00022685688,0.00010597809,0.000004327806,0.00018115032,0.0002831273,0.0006400913],"category_scores_gemma":[0.00005811169,0.00015486166,0.00010881699,0.0001497718,0.00013114659,0.000067019544,0.000056397457,0.00015469515,0.0004027979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006911839,0.0011440669,0.21844894,0.000016932434,0.00092713826,0.00015106429,0.0012279974,0.000028300256,0.75309706,0.016567865,0.00044075018,0.007258699],"study_design_scores_gemma":[0.0041670892,0.00012269766,0.9562026,0.00002870397,0.00009277388,0.000007628669,0.000051007413,6.314332e-8,0.03462321,0.0029524218,0.0016024221,0.000149356],"about_ca_topic_score_codex":0.0003869212,"about_ca_topic_score_gemma":0.00022627095,"teacher_disagreement_score":0.7377537,"about_ca_system_score_codex":0.00021511703,"about_ca_system_score_gemma":0.00007461148,"threshold_uncertainty_score":0.7008551},"labels":[],"label_agreement":null},{"id":"W1980381087","doi":"10.1016/j.jaad.2014.10.025","title":"WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Multicenter study; Dermatology; Disease; Surgery; Internal medicine; Randomized controlled trial","score_opus":0.013856139154407254,"score_gpt":0.2775879553469565,"score_spread":0.26373181619254926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980381087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731064,0.00076992455,0.00007823371,0.0011789987,0.00014834828,0.00043046064,0.00003359674,0.000008913835,0.00004086619],"genre_scores_gemma":[0.998818,0.00005343625,0.00085036346,0.00016201015,0.000018679617,0.000040226332,0.00000570651,0.0000220988,0.000029473531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765193,0.0006255296,0.0007193968,0.00035021664,0.00021116559,0.00044178165],"domain_scores_gemma":[0.99758404,0.00018368938,0.0016996284,0.00028082816,0.00014295122,0.00010885231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024145008,0.00031517516,0.0009879764,0.00029704437,0.00008707155,0.000014513414,0.00047402066,0.00015015824,0.000009217881],"category_scores_gemma":[0.00012575019,0.00019349021,0.00010890447,0.00052542164,0.0008830496,0.00020646601,0.000098788965,0.0006011984,0.0000012818128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013343071,0.00095760706,0.98386294,0.000031412455,0.00029727168,0.00009765012,0.0005303604,0.000054804612,0.00017460689,0.000035166617,0.00010732713,0.0005078138],"study_design_scores_gemma":[0.023205735,0.00060438935,0.9725797,0.00024558586,0.00022447889,0.00034499614,0.0010470519,0.00001740966,0.0013003377,0.000026617347,0.00019176693,0.00021192807],"about_ca_topic_score_codex":0.000059813778,"about_ca_topic_score_gemma":0.000047873113,"teacher_disagreement_score":0.011283205,"about_ca_system_score_codex":0.00021152111,"about_ca_system_score_gemma":0.0004208268,"threshold_uncertainty_score":0.7890302},"labels":[],"label_agreement":null},{"id":"W1982078500","doi":"10.1007/s00403-010-1033-8","title":"Involvement of IL-17F via the induction of IL-6 in psoriasis","year":2010,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Dermis; Immunohistochemistry; Interleukin 17; Inflammation; Interleukin; Tumor necrosis factor alpha; Biopsy; Immunology; Epidermis (zoology); Messenger RNA; Stimulation; Medicine; Cytokine; Biology; Pathology; Endocrinology; Gene; Anatomy","score_opus":0.05860615583137061,"score_gpt":0.32137781328827214,"score_spread":0.2627716574569015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982078500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957818,0.0005973186,0.000029139503,0.0005761092,0.00019279908,0.00033714046,0.000048419693,0.000008727027,0.0024285698],"genre_scores_gemma":[0.9990823,0.0003897045,0.00029670482,0.000009659931,0.000014190986,0.000051166153,0.00003713139,0.000006367058,0.00011275347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793285,0.0008420909,0.00048552823,0.0002326737,0.00013597404,0.0003708769],"domain_scores_gemma":[0.9975531,0.001784695,0.0001449625,0.00040568726,0.0000851084,0.00002646508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071575295,0.00012113558,0.000371176,0.00030719806,0.000107965134,0.0000033146048,0.0004943336,0.00020555816,0.00019044809],"category_scores_gemma":[0.000433141,0.00007359857,0.00013283649,0.0003426115,0.001378828,0.00004444145,0.00024553708,0.0005480811,0.000026851776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049557665,0.00063695404,0.06222386,0.00005987972,0.00013614619,0.000005859788,0.000994573,0.0000016491585,0.8538861,0.0077259988,0.00013966631,0.07369373],"study_design_scores_gemma":[0.0011908797,0.00028478808,0.27280405,0.00003524297,0.000020819805,0.000025496483,0.00062915497,0.000009679668,0.7133737,0.010003438,0.0015477493,0.000075017386],"about_ca_topic_score_codex":0.00022183004,"about_ca_topic_score_gemma":0.00015384812,"teacher_disagreement_score":0.21058019,"about_ca_system_score_codex":0.0000066646317,"about_ca_system_score_gemma":0.00006778354,"threshold_uncertainty_score":0.5080349},"labels":[],"label_agreement":null},{"id":"W1982840233","doi":"10.2310/7750.2006.00060b","title":"Biologic Therapeutics in the Treatment of Psoriasis. Part 2: Practical Considerations","year":2007,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Proinflammatory cytokine; Biologic Agents; Immunology; Disease; Dermatology; Inflammation; Pathology","score_opus":0.08740100568201346,"score_gpt":0.3231148448372954,"score_spread":0.23571383915528193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982840233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776321,0.016576609,0.000027206499,0.004433028,0.00082324893,0.000097101445,0.0000037419832,0.0000037193606,0.00040326657],"genre_scores_gemma":[0.9857198,0.013348896,0.00006300494,0.00057942455,0.00020269015,0.0000015208509,0.0000065577824,0.0000042704223,0.000073826406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987807,0.00027729513,0.0006302182,0.000080052734,0.00005757736,0.00017412615],"domain_scores_gemma":[0.9929229,0.006538554,0.00032598092,0.000106222884,0.000085101485,0.00002124364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010228965,0.00011638095,0.00047172434,0.00018637619,0.00006711223,0.000003645966,0.000029596105,0.00012460782,0.00013473904],"category_scores_gemma":[0.00027065858,0.000055859826,0.00010934867,0.00010596641,0.00021915165,0.000031417578,0.0000029652292,0.00010814847,0.0000030124238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007445183,0.0078106415,0.28206712,0.0000805844,0.0050933943,0.020977864,0.034017026,0.000009329929,0.09498912,0.004776981,0.048662722,0.49407002],"study_design_scores_gemma":[0.009213155,0.0146870855,0.057063796,0.00047219562,0.0032450377,0.13559128,0.019892523,0.0000031406987,0.033204854,0.005463841,0.7205737,0.0005893517],"about_ca_topic_score_codex":0.000017104581,"about_ca_topic_score_gemma":0.000039292045,"teacher_disagreement_score":0.671911,"about_ca_system_score_codex":0.000021385435,"about_ca_system_score_gemma":0.00008983892,"threshold_uncertainty_score":0.22778976},"labels":[],"label_agreement":null},{"id":"W1984399082","doi":"10.1007/s10227-005-0145-9","title":"Monitoring a Remote Phototherapy Unit Via Telemedicine","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Aberdeen Regional Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Telemedicine; Teledermatology; Referral; Psoriasis; Dermatology; Emergency medicine; Health care; Family medicine","score_opus":0.030123450346156894,"score_gpt":0.2705166052332265,"score_spread":0.2403931548870696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984399082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538877,0.04096815,0.0001454559,0.0029683593,0.0014715701,0.00006829556,0.0000013904164,0.000019244944,0.0004698298],"genre_scores_gemma":[0.97987074,0.016376827,0.00021732615,0.0005435335,0.0015180354,6.6031515e-7,0.0000042523325,0.00001865367,0.001449976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998773,0.00012434261,0.0006230423,0.00012469331,0.000094586154,0.00026037492],"domain_scores_gemma":[0.9984719,0.00083929463,0.00035341954,0.0001322256,0.00012896312,0.000074202355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005683276,0.0001834721,0.00064423156,0.00031889958,0.00010639104,0.0000047373305,0.00008740495,0.0001406551,0.0005206851],"category_scores_gemma":[0.00013819814,0.000119561904,0.00012253004,0.00014522336,0.00014586987,0.000074089854,0.000010061886,0.0002369391,0.000023143863],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069086795,0.00007295073,0.017723948,0.000018254694,0.00048654625,0.0007660716,0.00086313253,0.0000021798032,0.12033804,0.0000028112038,0.006840514,0.85219467],"study_design_scores_gemma":[0.007247138,0.0024276776,0.011969065,0.0020355866,0.001082945,0.087851755,0.0017102766,0.000024569808,0.09679603,0.00034470408,0.7878925,0.00061772624],"about_ca_topic_score_codex":0.00004276445,"about_ca_topic_score_gemma":0.0000057316824,"teacher_disagreement_score":0.851577,"about_ca_system_score_codex":0.000027175689,"about_ca_system_score_gemma":0.00006226015,"threshold_uncertainty_score":0.57011366},"labels":[],"label_agreement":null},{"id":"W1984544062","doi":"10.1007/s10227-004-2004-5","title":"The Use of Alefacept in the Treatment of Psoriasis","year":2004,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Psoriasis; Methotrexate; Dermatology; Skin cancer; PUVA therapy; Melanoma; Tumor necrosis factor alpha; Immunology; Cancer; Internal medicine; Cancer research","score_opus":0.09987180224836265,"score_gpt":0.3094991492859617,"score_spread":0.20962734703759908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984544062","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066111046,0.99182916,0.0000011684548,0.00022417138,0.0010199607,0.00025469103,0.000024500874,0.0000020595583,0.000033159504],"genre_scores_gemma":[0.0010884937,0.99835753,0.0000099335775,0.000022766462,0.00015464007,0.000005583602,0.000022805341,0.000015219323,0.00032301442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973558,0.0006997508,0.0014805299,0.0001295129,0.000112674425,0.00022172886],"domain_scores_gemma":[0.99017197,0.007937386,0.0014803773,0.00028537813,0.0000998875,0.000025011994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006642787,0.0003090924,0.002414293,0.00033352547,0.000079615995,0.000006458236,0.00018455084,0.00028179426,0.00005084185],"category_scores_gemma":[0.0002760578,0.00011934853,0.0007032393,0.0002397011,0.00036371782,0.00003445618,0.000009889026,0.00020802475,0.0000029439202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019359356,0.00027540553,0.00011072906,0.0008160528,0.001272687,0.00046043828,0.0010550029,9.999678e-7,0.000010992468,0.00001871704,0.0028314402,0.99295396],"study_design_scores_gemma":[0.00061021757,0.0009988648,0.000030864376,0.006594534,0.0025148946,0.007035105,0.0002980748,3.0365584e-8,0.000021914446,0.00002917651,0.98177224,0.00009408579],"about_ca_topic_score_codex":0.000093357456,"about_ca_topic_score_gemma":0.000028439572,"teacher_disagreement_score":0.99285984,"about_ca_system_score_codex":0.00006762025,"about_ca_system_score_gemma":0.00034083953,"threshold_uncertainty_score":0.48668918},"labels":[],"label_agreement":null},{"id":"W1984874852","doi":"10.1067/mjd.2003.445","title":"Repeated exposure to blue light does not improve psoriasis","year":2003,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Psoriasis; Medicine; Blue light; Protoporphyrin IX; Photobleaching; Dermatology; Plaque psoriasis; In vivo; Endogeny; Photodynamic therapy; Pathology; Fluorescence; Internal medicine; Optics; Chemistry","score_opus":0.010627363461646529,"score_gpt":0.2530564022201959,"score_spread":0.24242903875854935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984874852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98399234,0.0011674357,0.000030927185,0.013098096,0.001259095,0.00016358588,0.00003298666,0.000014799131,0.00024074642],"genre_scores_gemma":[0.99676186,0.00024167271,0.00041947849,0.0015852377,0.000058468075,0.0000070525857,8.924298e-7,0.000019917316,0.0009053992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976302,0.0008380841,0.0008459916,0.00021324205,0.00008659647,0.00038591828],"domain_scores_gemma":[0.99785864,0.00025432234,0.0014828305,0.0002451515,0.00009478552,0.00006428404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026491433,0.00023625084,0.00088965555,0.00023749053,0.00012564503,0.0000061272217,0.0006048917,0.00023751789,0.000083436615],"category_scores_gemma":[0.00032434697,0.00013179256,0.00038058148,0.0003652678,0.00032532442,0.00007863597,0.000078529316,0.0004580179,0.00005863759],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084319053,0.00016612458,0.015334351,0.000014639774,0.0010598897,0.000027962378,0.0006283362,0.0000089131945,0.96697056,0.0006031031,0.0049125147,0.009430415],"study_design_scores_gemma":[0.0014149118,0.00032108653,0.01063441,0.000028590217,0.0003360701,0.002849816,0.00044050254,1.2684156e-7,0.93103087,0.0001572185,0.052627612,0.0001587899],"about_ca_topic_score_codex":0.000012748691,"about_ca_topic_score_gemma":0.0000025377028,"teacher_disagreement_score":0.047715098,"about_ca_system_score_codex":0.00004295219,"about_ca_system_score_gemma":0.000100083445,"threshold_uncertainty_score":0.53743446},"labels":[],"label_agreement":null},{"id":"W1984934241","doi":"10.2310/7750.2012.12046","title":"Understanding and Assessing Potential Serious Adverse Events: A Practical Approach to Understanding the Benefits and Harm of Psoriasis Treatments","year":2013,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Western University","funders":"","keywords":"Medicine; Psoriasis; Adverse effect; Intensive care medicine; Harm; Dermatology; Pharmacology","score_opus":0.19802695776837653,"score_gpt":0.33876730968757035,"score_spread":0.14074035191919382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984934241","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0103811035,0.9866951,0.0008318676,0.0004140976,0.0009519694,0.0005185437,0.000022051445,0.0000090472,0.00017623087],"genre_scores_gemma":[0.034300767,0.9650709,0.00019074854,0.000058720092,0.00019971574,0.000010660799,0.000026859068,0.000036424946,0.000105172636],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9975421,0.00055054005,0.0010792415,0.00031231952,0.000170052,0.00034574413],"domain_scores_gemma":[0.9961498,0.0022762679,0.0011890722,0.000178857,0.00007144277,0.0001345766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085265294,0.0004569884,0.0022513333,0.00053580315,0.00030044714,0.00002549015,0.000099910074,0.000388655,0.00003959637],"category_scores_gemma":[0.00029362057,0.0002512623,0.0003022731,0.00022812808,0.0002777708,0.00018393516,0.00007334653,0.00040175518,0.0000020461075],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005632511,0.00045253392,0.00055142434,0.0040764255,0.010089621,0.0008075379,0.0021794597,0.000005004553,0.00011606306,0.00070052117,0.003841484,0.9766167],"study_design_scores_gemma":[0.012489599,0.0052338517,0.0006253786,0.09666497,0.10595674,0.43142706,0.05352463,0.000033628105,0.00005257297,0.0027126835,0.28798813,0.0032907703],"about_ca_topic_score_codex":0.000028363205,"about_ca_topic_score_gemma":0.0000019567335,"teacher_disagreement_score":0.9733259,"about_ca_system_score_codex":0.00021282569,"about_ca_system_score_gemma":0.00024116714,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W1985293597","doi":"10.1016/j.annepidem.2007.07.013","title":"Mortality Profiles of Patients with Psoriasis in the Newfoundland and Labrador Founder Population","year":2007,"lang":"en","type":"article","venue":"Annals of Epidemiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Newfoundland and Labrador Centre for Applied Health Research","funders":"","keywords":"Medicine; Founder effect; Psoriasis; Demography; Population; Dermatology; Genetics; Environmental health; Haplotype","score_opus":0.08267119021150217,"score_gpt":0.34086958571529874,"score_spread":0.2581983955037966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985293597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975721,0.0014319586,0.00006821341,0.0002778043,0.00012186845,0.00026010082,0.00004405273,0.0000063948896,0.00021747885],"genre_scores_gemma":[0.9990605,0.00015078217,0.0001676118,0.0003063191,0.000018612454,0.000009978729,0.0002521781,0.0000057370003,0.000028251945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983003,0.0006643507,0.0005151192,0.00020473907,0.000025607753,0.00028989595],"domain_scores_gemma":[0.9976668,0.0016762479,0.00033026392,0.00023068798,0.000081387676,0.000014645328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024476356,0.00012611096,0.00044902685,0.00010277524,0.000047314672,0.000001057188,0.00010607057,0.00019239345,0.000036998725],"category_scores_gemma":[0.00053117657,0.00007413437,0.000055241315,0.0001319022,0.00022278947,0.000060773513,0.00002162687,0.00008508596,0.000002985524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048462802,0.00017367475,0.97952,0.000021356958,0.000166248,8.5033224e-7,0.00024313905,0.0000029856128,0.00010389284,0.0039940174,0.00013567832,0.015153515],"study_design_scores_gemma":[0.0010059157,0.00032686902,0.9947866,0.000016442387,0.0000540542,0.0000025590764,0.00008851815,5.920363e-7,0.00038748322,0.0028117287,0.000447053,0.00007218285],"about_ca_topic_score_codex":0.0033871704,"about_ca_topic_score_gemma":0.003202487,"teacher_disagreement_score":0.015266589,"about_ca_system_score_codex":0.000007168116,"about_ca_system_score_gemma":0.000011842095,"threshold_uncertainty_score":0.5120411},"labels":[],"label_agreement":null},{"id":"W1985447596","doi":"10.1002/eji.200940257","title":"CD161 is a marker of all human IL‐17‐producing T‐cell subsets and is induced by RORC","year":2010,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":361,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research","keywords":"RAR-related orphan receptor gamma; Biology; CD8; T-cell receptor; Orphan receptor; C-C chemokine receptor type 6; Cytotoxic T cell; Retinoic acid; T cell; Interleukin 17; Cell biology; Immunology; Molecular biology; Transcription factor; Cytokine; FOXP3; Immune system; Genetics; Cell culture; Gene; In vitro","score_opus":0.016372923968904197,"score_gpt":0.2288458564220238,"score_spread":0.2124729324531196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985447596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881994,0.006853753,0.000005962973,0.00050242204,0.0010486646,0.00009448262,0.000047645368,0.000015014549,0.0032326237],"genre_scores_gemma":[0.99615765,0.00046377498,0.00017311296,0.0003426164,0.000077145,9.733816e-7,0.00002357978,0.0000403142,0.0027208242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978904,0.00067889394,0.0007258913,0.00029078376,0.0000504981,0.0003635356],"domain_scores_gemma":[0.9985334,0.00009776839,0.0007413266,0.0004094038,0.00016774848,0.000050307543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089056685,0.00026488688,0.000518856,0.00022850663,0.00014766952,0.00001507916,0.00041382678,0.00019089083,0.0013651516],"category_scores_gemma":[0.00007862745,0.00022038553,0.00017068075,0.00010073612,0.0002670233,0.00011821799,0.00013862348,0.00070114,0.0001525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002961637,0.00020459495,0.0024875116,0.000010823191,0.00073206367,0.00005501112,0.0022094517,4.0145306e-8,0.9651224,0.00001621867,0.014057327,0.01480841],"study_design_scores_gemma":[0.0046374984,0.001396659,0.09029423,0.000047738748,0.00030993557,0.0009264456,0.0002739867,1.6494843e-7,0.8131501,0.000041129806,0.08862955,0.00029257813],"about_ca_topic_score_codex":0.000029039142,"about_ca_topic_score_gemma":0.0000057203843,"teacher_disagreement_score":0.1519723,"about_ca_system_score_codex":0.000016386717,"about_ca_system_score_gemma":0.000053393975,"threshold_uncertainty_score":0.9995477},"labels":[],"label_agreement":null},{"id":"W1985886453","doi":"10.1016/j.jaad.2011.06.035","title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Hyperlipidemia; Diabetes mellitus; Framingham Risk Score; Internal medicine; Population; Blood pressure; Risk factor; Disease; Endocrinology; Dermatology","score_opus":0.01704995357881962,"score_gpt":0.22461067678834515,"score_spread":0.20756072320952554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985886453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980336,0.0013148874,0.000038534035,0.00024081551,0.00009541372,0.00019106056,0.00003877042,0.0000033969975,0.00004356417],"genre_scores_gemma":[0.99881715,0.00071603607,0.00037039988,0.000065747205,0.0000046952778,0.000004563658,0.0000013693026,0.000012682036,0.000007337104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985348,0.0005193056,0.00048603243,0.00015744539,0.00008268247,0.00021975789],"domain_scores_gemma":[0.99868494,0.00017976802,0.00088043284,0.00015867181,0.00005666008,0.000039520175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011135508,0.00018718204,0.00092853495,0.00023133199,0.000055518365,0.0000017810479,0.0002472412,0.00011890548,0.000013671841],"category_scores_gemma":[0.000040404608,0.00010922558,0.00025009835,0.0002573928,0.0003364271,0.000069413596,0.000075487194,0.00021540213,0.0000020519844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014895262,0.00031813787,0.98720676,0.000012189981,0.0036033406,0.0000048765537,0.0011479071,0.00013450203,0.00015969345,0.000036815276,0.00009423068,0.0057920003],"study_design_scores_gemma":[0.003223766,0.00055657484,0.9533513,0.000048574075,0.0010236535,0.00013881641,0.0004502608,4.96992e-7,0.040717293,0.00017606409,0.00019196216,0.00012121552],"about_ca_topic_score_codex":0.00034527265,"about_ca_topic_score_gemma":0.000010794635,"teacher_disagreement_score":0.0405576,"about_ca_system_score_codex":0.000044724587,"about_ca_system_score_gemma":0.00004489213,"threshold_uncertainty_score":0.44540897},"labels":[],"label_agreement":null},{"id":"W1985924058","doi":"10.1016/s0149-2918(00)83065-9","title":"A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis","year":2000,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Western University","funders":"Allergan","keywords":"Mometasone furoate; Medicine; Tazarotene; Tolerability; Psoriasis; Dermatology; Corticosteroid; Moisturizer; Calcipotriol; Erythema; Pharmacology; Adverse effect; Internal medicine","score_opus":0.15036461694942313,"score_gpt":0.39854128326357696,"score_spread":0.24817666631415383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985924058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810143,0.0150334425,0.00007520466,0.0005039957,0.0010604463,0.00089300796,0.00022768402,0.000050788713,0.0011411322],"genre_scores_gemma":[0.9843493,0.013230578,0.00064545363,0.00022683102,0.00014111011,0.00012179651,0.00020707215,0.000044893317,0.0010329747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505126,0.0014135722,0.0019229364,0.00072142005,0.00021015556,0.00068062724],"domain_scores_gemma":[0.99458176,0.0034178824,0.0006507359,0.0011634933,0.000112706606,0.00007344987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095561973,0.0005586091,0.0016461429,0.00014776112,0.00018246524,0.000021031816,0.00074227777,0.00062430813,0.00050078303],"category_scores_gemma":[0.000079455116,0.0003913419,0.0006113445,0.00059969013,0.0006796868,0.000098113305,0.00005579991,0.00041204118,0.00018454064],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029804438,0.019668486,0.015317002,0.00006049466,0.0052030366,0.00005665677,0.010769816,0.00088830147,0.016561992,0.0004993172,0.00035221264,0.9008182],"study_design_scores_gemma":[0.13948214,0.088595234,0.11489336,0.0005132598,0.00977125,0.0000837664,0.008891162,0.0013595944,0.20871507,0.0006573716,0.42433503,0.0027027545],"about_ca_topic_score_codex":0.00033172854,"about_ca_topic_score_gemma":0.00014749482,"teacher_disagreement_score":0.8981155,"about_ca_system_score_codex":0.00020686131,"about_ca_system_score_gemma":0.00021489455,"threshold_uncertainty_score":0.99985385},"labels":[],"label_agreement":null},{"id":"W1986268987","doi":"10.1016/j.jdermsci.2008.07.009","title":"Development of an in vitro psoriatic skin model by tissue engineering","year":2008,"lang":"en","type":"article","venue":"Journal of Dermatological Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Involucrin; Psoriasis; Dermis; Immunohistochemistry; Loricrin; Pathology; Epidermis (zoology); Filaggrin; Human skin; Medicine; Keratinocyte; Extracellular matrix; Dermatology; In vitro; Chemistry; Biology; Anatomy; Atopic dermatitis; Cell biology","score_opus":0.020236044544093678,"score_gpt":0.24465667198223828,"score_spread":0.22442062743814462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986268987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764615,0.0007315122,0.0013363454,0.000032645006,0.00014677447,0.00004532396,0.0000029515709,0.0000063289485,0.00005195824],"genre_scores_gemma":[0.9799189,0.000040178064,0.019992959,0.000020454483,0.0000051677134,0.0000019439412,0.000002255401,0.000002488291,0.00001565873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990543,0.000040295625,0.0004500029,0.00011958998,0.00009535393,0.0002404688],"domain_scores_gemma":[0.99957776,0.000050259398,0.00018886037,0.00007989104,0.000057753918,0.00004549714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003441605,0.00009399635,0.00028426573,0.00014802547,0.00009650964,0.0000047460426,0.0003321406,0.00009200641,0.000017729788],"category_scores_gemma":[0.00008247203,0.00006438842,0.000036690395,0.00026821438,0.00017015416,0.000204985,0.000038484977,0.00011840376,0.000009165967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005762477,0.00020639606,0.0005811843,0.000004277256,0.000012866816,0.000042492815,0.0006033538,0.000290956,0.9874078,0.000026112399,0.000034485296,0.010732434],"study_design_scores_gemma":[0.0006954706,0.000057312718,0.010359609,0.000013507005,0.000008752064,0.00087924616,0.00004315314,0.0005608793,0.9869189,0.000028774492,0.0003499629,0.00008441233],"about_ca_topic_score_codex":0.0000017340043,"about_ca_topic_score_gemma":8.278303e-7,"teacher_disagreement_score":0.018656613,"about_ca_system_score_codex":0.000051735722,"about_ca_system_score_gemma":0.00017068008,"threshold_uncertainty_score":0.26256835},"labels":[],"label_agreement":null},{"id":"W1986597285","doi":"10.3315/jdcr.2014.1170","title":"Pustular psoriasis complicated with acute generalized exanthematous pustulosis","year":2014,"lang":"en","type":"article","venue":"Journal of Dermatological Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Alberta","funders":"","keywords":"Medicine; Psoriasis; Pustular psoriasis; Dermatology; Generalized pustular psoriasis; Acute generalized exanthematous pustulosis; Acitretin; Discontinuation; Pustulosis; Toxic epidermal necrolysis; Surgery; Osteomyelitis","score_opus":0.019562640381056085,"score_gpt":0.24907800736536448,"score_spread":0.22951536698430838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986597285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949745,0.0018474725,0.0012209519,0.00043901685,0.000581046,0.00020643654,0.000011072694,0.00007102091,0.0006485138],"genre_scores_gemma":[0.9977751,0.00015316004,0.001581116,0.0001928216,0.00006883788,0.000017913799,0.000031121708,0.000024227553,0.00015570565],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9975411,0.00046914764,0.0010982375,0.00032954972,0.00013239542,0.00042952885],"domain_scores_gemma":[0.997641,0.00024204694,0.0012560729,0.0004344258,0.00030679622,0.00011965647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160686,0.0003392119,0.0010312888,0.00017940761,0.00025781512,0.000035201367,0.000134939,0.00036369092,0.0002929482],"category_scores_gemma":[0.0001411201,0.00020045601,0.00034471575,0.00024022601,0.00018390155,0.00013522,0.000059958387,0.00031047684,0.000044745273],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017923334,0.0014541957,0.056002706,0.00006437319,0.0058063352,0.86140937,0.00025860555,0.000045198904,0.04769189,0.000627706,0.010288395,0.0145589],"study_design_scores_gemma":[0.0023331174,0.00044533165,0.0027708395,0.0000421799,0.0012293205,0.9305351,0.000064281274,0.0000061807314,0.04968562,0.0003899633,0.012228263,0.0002698437],"about_ca_topic_score_codex":0.000016462,"about_ca_topic_score_gemma":0.0000051559587,"teacher_disagreement_score":0.0691257,"about_ca_system_score_codex":0.000043609827,"about_ca_system_score_gemma":0.00006612557,"threshold_uncertainty_score":0.8174359},"labels":[],"label_agreement":null},{"id":"W1986727743","doi":"10.6000/1929-5634.2013.02.01.5","title":"Alcohol Consumption in Patients with Psoriasis and its Relationship to Disease Severity","year":2013,"lang":"en","type":"article","venue":"Journal of Nutritional Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Internal medicine; Mean corpuscular volume; Alcohol consumption; Statistical significance; Gastroenterology; Logistic regression; Psoriasis Area and Severity Index; Alcohol; Immunology; Hemoglobin","score_opus":0.04283260414825781,"score_gpt":0.2682371026507411,"score_spread":0.22540449850248326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986727743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968207,0.0018875306,0.000019285526,0.0008073026,0.00015135038,0.00023831359,0.000056662728,0.0000049932232,0.000013872676],"genre_scores_gemma":[0.99905187,0.00019211354,0.00031053848,0.00027931368,0.000034218454,0.00001415114,0.00003894527,0.000007336734,0.00007149321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993645,0.00011725972,0.00023794152,0.00009112985,0.000067295616,0.000121866426],"domain_scores_gemma":[0.99941605,0.00015924805,0.00012019576,0.000058523183,0.00019645436,0.00004955126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010262541,0.0000976222,0.00014962257,0.00015347765,0.00007111773,0.000014434317,0.000060240913,0.00007820117,0.00013572692],"category_scores_gemma":[0.000023365894,0.00007502223,0.000040172938,0.00009177689,0.00003132887,0.00018332708,0.000011179927,0.00012531198,0.00007707392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012387206,0.0006128829,0.9926864,0.000015474348,0.00017277742,0.000003310202,0.000096238815,0.0000062588842,0.0009499853,0.00033151297,0.00017664017,0.0037098029],"study_design_scores_gemma":[0.004314853,0.00022755339,0.99285096,0.00007311111,0.0001045901,0.000013702013,0.000017494824,0.000001851377,0.00031487938,0.0010885372,0.0009022437,0.00009024423],"about_ca_topic_score_codex":0.0000016592114,"about_ca_topic_score_gemma":0.0000016977407,"teacher_disagreement_score":0.0036195586,"about_ca_system_score_codex":0.00004696568,"about_ca_system_score_gemma":0.000028336262,"threshold_uncertainty_score":0.30593178},"labels":[],"label_agreement":null},{"id":"W1986938885","doi":"10.1002/eji.200838908","title":"The role of retinoic acid‐related orphan receptor variant 2 and IL‐17 in the development and function of human CD4<sup>+</sup> T cells","year":2009,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Biology; Orphan receptor; Retinoic acid; Cell biology; Interleukin 17; RAR-related orphan receptor gamma; Interleukin 3; T cell; Interleukin 12; Interleukin 21; ZAP70; IL-2 receptor; Cytokine; Immunology; Transcription factor; Cytotoxic T cell; Cell culture; Immune system; In vitro; FOXP3; Genetics; Gene","score_opus":0.00835982430402295,"score_gpt":0.19322307264097227,"score_spread":0.1848632483369493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986938885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98032314,0.017653614,0.0000099912695,0.00020282847,0.0001902834,0.000106566906,0.0000043065206,0.000005219856,0.0015040429],"genre_scores_gemma":[0.9985979,0.00091802824,0.0001117909,0.000031622112,0.000020707917,9.0344713e-7,0.000009661008,0.000009804256,0.00029955228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746686,0.001421165,0.0007286937,0.0001324208,0.000042796382,0.0002080689],"domain_scores_gemma":[0.9990077,0.00016631625,0.0005448711,0.00018484225,0.000082722654,0.000013571028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014999482,0.00015299369,0.00030764556,0.00014422655,0.00020083519,0.000010172072,0.00026438525,0.00009430753,0.000060557326],"category_scores_gemma":[0.000046001445,0.00008962762,0.00006340649,0.00012422464,0.00025499045,0.000056536086,0.000049049082,0.00029782145,0.000016561844],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076651166,0.00016213734,0.0007913156,0.0000039240026,0.00044492335,0.000025882038,0.005931692,0.0000038698004,0.82797325,0.000523535,0.00020244239,0.16317055],"study_design_scores_gemma":[0.0075765396,0.006592373,0.30872917,0.00020231878,0.000361276,0.0010434844,0.0077151484,0.0000024508329,0.5960162,0.0006310866,0.07081452,0.0003153885],"about_ca_topic_score_codex":0.0000032812895,"about_ca_topic_score_gemma":0.0000025866236,"teacher_disagreement_score":0.30793786,"about_ca_system_score_codex":0.00001760316,"about_ca_system_score_gemma":0.00004037265,"threshold_uncertainty_score":0.36549082},"labels":[],"label_agreement":null},{"id":"W1987383335","doi":"10.1007/s10227-006-0102-2","title":"A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto; Mediprobe Research (Canada); Royal Victoria Hospital; Probity Medical Research; Université Laval","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Clinical trial; Dermatology; Plaque psoriasis; Drug; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.09657392485826985,"score_gpt":0.35448349076885105,"score_spread":0.25790956591058123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987383335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005222347,0.99732816,0.000004442062,0.0005832914,0.0010632373,0.0003638087,0.000020137231,0.0000057504544,0.00010893762],"genre_scores_gemma":[0.00012930595,0.9981671,0.000032514687,0.00035981994,0.00038122394,0.0000074879035,0.000012016023,0.000025663277,0.0008848782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957839,0.0011594499,0.0023863178,0.000238872,0.00017880758,0.0002526259],"domain_scores_gemma":[0.9890061,0.0064463653,0.0037614466,0.0004161894,0.00030281328,0.000067080306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025218541,0.00039229146,0.0042758347,0.00019639278,0.00012002427,0.0000059146823,0.00030534668,0.00036320664,0.0003401467],"category_scores_gemma":[0.0019898461,0.00016720618,0.001033903,0.0003156724,0.0003918178,0.00007342629,0.00004234636,0.00075208565,0.00001460997],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016206875,0.00007387503,0.0005198078,0.011992342,0.0013795062,0.00022144438,0.00004273675,1.5183451e-7,0.0000014342824,0.00000583751,0.021403706,0.9641971],"study_design_scores_gemma":[0.00027134301,0.00041411992,0.00003227771,0.2639564,0.007080393,0.018171316,0.00001723646,5.5008197e-8,0.000001943774,0.0000067100477,0.70992017,0.00012804147],"about_ca_topic_score_codex":0.000018689838,"about_ca_topic_score_gemma":0.000012357375,"teacher_disagreement_score":0.96406907,"about_ca_system_score_codex":0.000044239303,"about_ca_system_score_gemma":0.0008234131,"threshold_uncertainty_score":0.68184704},"labels":[],"label_agreement":null},{"id":"W1988013022","doi":"10.1111/cea.12341","title":"<scp>IL</scp>‐21 receptor signalling partially mediates Th2‐mediated allergic airway responses","year":2014,"lang":"en","type":"article","venue":"Clinical & Experimental Allergy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute","keywords":"Immunology; Cytokine; House dust mite; Immunoglobulin E; Immune system; Receptor; Allergen; Sensitization; Interleukin 10; Medicine; Interleukin 13; Allergic response; Interleukin 4; Biology; Allergy; Antibody; Internal medicine","score_opus":0.03686400377645017,"score_gpt":0.3056772526979715,"score_spread":0.26881324892152136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988013022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823648,0.009644907,0.00006581707,0.00035321992,0.0036744438,0.0003588157,0.00008114751,0.00036768126,0.0030892005],"genre_scores_gemma":[0.98777574,0.001324677,0.00042877896,0.00096321816,0.00071313296,0.00018995773,0.00078961876,0.00008539386,0.0077295047],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950223,0.0016536032,0.0012834892,0.0010013413,0.00015589499,0.0008833579],"domain_scores_gemma":[0.9936348,0.0050794575,0.00038892834,0.0005668936,0.00009503408,0.00023486878],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010743089,0.00058628473,0.00093556975,0.00013018992,0.0003811774,0.00004857915,0.00062407757,0.00084018754,0.0016850496],"category_scores_gemma":[0.0014593805,0.00049702125,0.00056296395,0.0001999043,0.0005941756,0.00016210167,0.0002754517,0.0004413434,0.006226953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016489584,0.0030572107,0.0042632227,0.000012888712,0.002086289,0.000038934373,0.0012837215,0.000022506658,0.9342133,0.0010593815,0.040740114,0.011573483],"study_design_scores_gemma":[0.005630269,0.0023424358,0.0045043887,0.000058186062,0.00008375995,0.00001526675,0.00085999485,0.0000364451,0.5489319,0.00013657442,0.43702972,0.00037104837],"about_ca_topic_score_codex":0.000039534687,"about_ca_topic_score_gemma":0.000033884637,"teacher_disagreement_score":0.39628962,"about_ca_system_score_codex":0.00006572631,"about_ca_system_score_gemma":0.00012141261,"threshold_uncertainty_score":0.9997482},"labels":[],"label_agreement":null},{"id":"W1988157050","doi":"10.3899/jrheum.081304","title":"Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis","year":2009,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Rheumatoid arthritis; Monocyte; Immunology; Interleukin; Interleukin 17; Interleukin 20; Interleukin 4; Interleukin 19; Synovial membrane; Cytokine; Interleukin 5","score_opus":0.014925469176685484,"score_gpt":0.24479298125993618,"score_spread":0.22986751208325068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988157050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027765,0.008351879,0.000148226,0.00028557156,0.00071531313,0.00015206943,0.000029168874,0.000014141928,0.000025980358],"genre_scores_gemma":[0.9824964,0.017107677,0.0002548079,0.00007230638,0.0000069958483,0.0000034523046,0.00001264533,0.0000156665,0.00003009583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971935,0.0006821182,0.0014490262,0.00019080698,0.00007188279,0.0004126498],"domain_scores_gemma":[0.9980142,0.00025642803,0.0012033503,0.0003708057,0.00010578946,0.00004942359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007990827,0.0002665833,0.0009253887,0.00029808216,0.00011300982,0.000008227618,0.0005216898,0.00032140542,0.00016824747],"category_scores_gemma":[0.00009662278,0.00017539885,0.0001967772,0.00014362285,0.00022305534,0.00018884618,0.000061857754,0.00035324576,0.000031462754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003938842,0.0006299716,0.071118794,0.00001804721,0.00025705172,0.000121750985,0.006567775,0.00000676233,0.8436734,0.00012994093,0.00069712714,0.07284055],"study_design_scores_gemma":[0.010959414,0.004204241,0.05706012,0.0013141197,0.00013132888,0.03178136,0.0023782386,0.000041243595,0.887983,0.0021250455,0.001506311,0.0005155272],"about_ca_topic_score_codex":0.00013843364,"about_ca_topic_score_gemma":0.00022709792,"teacher_disagreement_score":0.07232502,"about_ca_system_score_codex":0.000046002544,"about_ca_system_score_gemma":0.00012191938,"threshold_uncertainty_score":0.71525574},"labels":[],"label_agreement":null},{"id":"W1988845586","doi":"10.1016/j.jaad.2003.10.497","title":"A new anti-psoriatic ointment yields high efficacy irrespective of initial disease levels","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Galderma","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Plaque psoriasis; Dermatology; Betamethasone dipropionate; Disease; Betamethasone","score_opus":0.022601719317820998,"score_gpt":0.30690558313449534,"score_spread":0.28430386381667433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988845586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605347,0.002162857,0.00031518802,0.01055831,0.0006321112,0.00017043488,0.0000474376,0.000008908179,0.000051287636],"genre_scores_gemma":[0.9986338,0.00026993995,0.00064426404,0.00029596043,0.00009336156,0.0000022575668,0.0000018710084,0.000014543102,0.000043995078],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99823785,0.00040035587,0.000805808,0.00016155772,0.00010585875,0.0002885459],"domain_scores_gemma":[0.9974861,0.00033096346,0.0018663582,0.00017649528,0.0000631153,0.00007695249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114124596,0.00021088532,0.00094184413,0.00022300342,0.00007754478,0.0000033502768,0.0005465303,0.00014682775,0.00008829226],"category_scores_gemma":[0.0001873003,0.00014120154,0.00041127007,0.0003023091,0.0005897842,0.00008453518,0.00010770057,0.00038513457,0.000023482107],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020349722,0.0061222813,0.078130156,0.00031324552,0.019313097,0.0006979004,0.0071881316,0.0017900083,0.59341955,0.04001471,0.013488736,0.21917245],"study_design_scores_gemma":[0.00843882,0.0007443196,0.6176087,0.00019550258,0.001259022,0.0020802845,0.00025892977,3.7864206e-7,0.36219615,0.0055896887,0.0013957209,0.00023248272],"about_ca_topic_score_codex":0.00008885777,"about_ca_topic_score_gemma":0.000001851145,"teacher_disagreement_score":0.53947854,"about_ca_system_score_codex":0.00007136224,"about_ca_system_score_gemma":0.00037147792,"threshold_uncertainty_score":0.57580316},"labels":[],"label_agreement":null},{"id":"W1989223663","doi":"10.1007/s12016-012-8303-5","title":"The Genetics of Psoriasis and Psoriatic Arthritis","year":2012,"lang":"en","type":"review","venue":"Clinical Reviews in Allergy & Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Genetics; Genetic association; Biology; Genetic predisposition; Genome-wide association study; Candidate gene; Immunology; Atopic dermatitis; Disease; Human leukocyte antigen; Gene; Medicine; Genotype; Single-nucleotide polymorphism; Pathology; Antigen","score_opus":0.10367765271551505,"score_gpt":0.3715692466531016,"score_spread":0.26789159393758655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989223663","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013535313,0.9924042,0.0000038806656,0.000042786163,0.005702756,0.0012962706,0.000039550225,0.000024711066,0.0003504622],"genre_scores_gemma":[0.00003910412,0.99796224,0.00014809823,0.000039047973,0.00022895922,0.0004910682,0.0001566182,0.00006584229,0.0008689962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886237,0.005407814,0.004303361,0.00075395795,0.00005567015,0.0008554948],"domain_scores_gemma":[0.99158216,0.004960582,0.0019328331,0.0013979771,0.000068421105,0.000058033624],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034513727,0.0007726298,0.005441755,0.00019612964,0.00019801749,0.000015397974,0.0009618645,0.0019786533,0.00026588948],"category_scores_gemma":[0.0014217441,0.00048376867,0.0013282399,0.00037403646,0.0013344527,0.000049810587,0.00049503526,0.0011734163,0.00091163866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046498946,0.0002399651,0.000041207455,0.00087904773,0.001821735,0.000004826799,0.000039888477,1.1279025e-8,0.0000017550582,0.0010250988,0.00044982502,0.99545014],"study_design_scores_gemma":[0.0012421514,0.0003058676,0.00037078248,0.004624225,0.000996051,0.000110884874,0.000015323772,5.591567e-8,0.0000032558062,0.0001743717,0.991767,0.00039005198],"about_ca_topic_score_codex":0.000022772607,"about_ca_topic_score_gemma":0.00015332896,"teacher_disagreement_score":0.9950601,"about_ca_system_score_codex":0.000062917155,"about_ca_system_score_gemma":0.00022377231,"threshold_uncertainty_score":0.99986625},"labels":[],"label_agreement":null},{"id":"W1989230651","doi":"10.1159/000051583","title":"Pharmacoeconomic Evaluation of Calcipotriol (Daivonex&lt;sup&gt;®&lt;/sup&gt;/Dovonex&lt;sup&gt;®&lt;/sup&gt;) and UVB Phototherapy in the Treatment of Psoriasis: A Markov Model for The Netherlands","year":2001,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Calcipotriol; Psoriasis; Dermatology; Dithranol; Clinical trial; Tazarotene; Internal medicine","score_opus":0.03645147457789816,"score_gpt":0.2949461869963617,"score_spread":0.25849471241846356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989230651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95529354,0.037359465,0.0005716011,0.0014076323,0.0005274258,0.0034380814,0.00057567336,0.000075680444,0.0007509001],"genre_scores_gemma":[0.9809871,0.014609142,0.00029438038,0.00051342713,0.00015873802,0.0021117737,0.00050245645,0.00009878914,0.0007241983],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9943772,0.0017563775,0.0015119402,0.0010040604,0.00021943125,0.0011310134],"domain_scores_gemma":[0.99605215,0.0017424779,0.0007155744,0.001115663,0.00028473034,0.00008941613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001411307,0.0008970718,0.0016355598,0.000532768,0.00047335908,0.000040555795,0.0007805106,0.00089567073,0.0005903296],"category_scores_gemma":[0.00008218067,0.0006190934,0.00058815995,0.00043042045,0.0006255189,0.00022881466,0.00008086988,0.00026903496,0.0000785175],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028340211,0.01189797,0.042106155,0.0005722214,0.01803985,0.00021570998,0.08238866,0.02250795,0.29769948,0.003596127,0.036859836,0.45577583],"study_design_scores_gemma":[0.13575527,0.005013329,0.020266915,0.00029973185,0.012198036,0.0044557755,0.004158391,0.5010884,0.102782816,0.004194578,0.20623863,0.0035481688],"about_ca_topic_score_codex":0.00018860483,"about_ca_topic_score_gemma":0.0006804214,"teacher_disagreement_score":0.47858042,"about_ca_system_score_codex":0.0002572455,"about_ca_system_score_gemma":0.00038274223,"threshold_uncertainty_score":0.99962604},"labels":[],"label_agreement":null},{"id":"W1989702104","doi":"10.1016/j.jaad.2011.06.041","title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University; Probity Medical Research","funders":"","keywords":"Ustekinumab; Medicine; Placebo; Psoriasis; Internal medicine; Population; Epidemiology; Confidence interval; Clinical trial; Randomized controlled trial; Dermatology; Disease; Pathology","score_opus":0.07938100106568033,"score_gpt":0.36741952211894696,"score_spread":0.28803852105326666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989702104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997776,0.00093332643,0.000041479627,0.0002597101,0.00016898947,0.00024678608,0.0005519496,0.0000028115178,0.000018952887],"genre_scores_gemma":[0.998728,0.00071154855,0.00043098006,0.00006935844,0.000017498043,0.0000043376144,0.000014045773,0.000008956065,0.00001526874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99589545,0.0013095429,0.0022781016,0.00024234256,0.000086192646,0.000188352],"domain_scores_gemma":[0.9948185,0.0008285618,0.003968964,0.00020573015,0.00012313774,0.000055117638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045362557,0.00020335373,0.001928054,0.00024885032,0.00011358619,0.0000015630216,0.0002830827,0.00021280137,0.000044989458],"category_scores_gemma":[0.00043149127,0.00013023909,0.00021793685,0.00028125843,0.0008242011,0.00012351113,0.00021988031,0.0002565889,2.9543642e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05770299,0.0030023083,0.8739751,0.000019854495,0.0037685428,0.00000909384,0.008036993,0.000019680196,0.036037497,0.000023563274,0.00018027301,0.017224122],"study_design_scores_gemma":[0.023649871,0.003001701,0.80800104,0.00029411074,0.0013207032,0.000091941954,0.0004282088,0.000002686996,0.16293064,0.00008974783,0.00003708269,0.00015229266],"about_ca_topic_score_codex":0.00048197762,"about_ca_topic_score_gemma":0.00003806593,"teacher_disagreement_score":0.12689313,"about_ca_system_score_codex":0.000014667205,"about_ca_system_score_gemma":0.00007996659,"threshold_uncertainty_score":0.5310996},"labels":[],"label_agreement":null},{"id":"W1990009757","doi":"10.1186/cc10609","title":"IL-17A rs1974226 GG genotype is associated with increased susceptibility to Gram-positive infection and mortality of severe sepsis","year":2012,"lang":"en","type":"article","venue":"Critical Care","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Sepsis; Medicine; Genotype; Gram; Host response; Immunology; Genetics; Biology; Bacteria; Gene; Immune system","score_opus":0.02237983267926645,"score_gpt":0.2858974781935606,"score_spread":0.26351764551429413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990009757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677306,0.00096689624,0.000031578416,0.000059519734,0.00020155433,0.0002515103,0.00093751383,0.000047008823,0.00073136744],"genre_scores_gemma":[0.99929017,0.000008862321,0.000060023413,0.00017318208,0.000030961244,0.000023495122,0.00034506677,0.0000129096115,0.00005533209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988451,0.0003023526,0.00017987241,0.000269544,0.000053951004,0.0003491997],"domain_scores_gemma":[0.9990375,0.0002956981,0.00003850293,0.00021780796,0.00031711918,0.000093363116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017561381,0.00017903905,0.00031703213,0.000050229,0.0001524878,0.000009374809,0.000050606133,0.0002703047,0.00029299135],"category_scores_gemma":[0.00038595818,0.00014827945,0.00007676482,0.00016585286,0.00023186178,0.00010761968,0.000052504478,0.00010862202,0.000039251918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024166975,0.00027614506,0.97878057,0.00007592272,0.00031702107,0.0000035392416,0.0022014584,2.3082144e-7,0.014718618,0.000302798,0.00017437825,0.0029076405],"study_design_scores_gemma":[0.0007646957,0.0004569008,0.9504625,0.000041478863,0.0005749544,0.000010894572,0.0005613499,2.401859e-7,0.046721637,0.00007401186,0.00014531937,0.00018597614],"about_ca_topic_score_codex":0.0008337359,"about_ca_topic_score_gemma":0.00059424376,"teacher_disagreement_score":0.03200302,"about_ca_system_score_codex":0.00009632393,"about_ca_system_score_gemma":0.00003959828,"threshold_uncertainty_score":0.604666},"labels":[],"label_agreement":null},{"id":"W1990088027","doi":"10.3899/jrheum.150257","title":"Screening for Psoriatic Arthritis in People with Psoriasis","year":2015,"lang":"en","type":"editorial","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Dermatology; Subclinical infection; Asymptomatic; Rheumatology; Arthritis; Disease; Enthesopathy; Internal medicine","score_opus":0.01431467451813066,"score_gpt":0.2471403298556225,"score_spread":0.23282565533749186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990088027","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12216054,0.036594525,0.0010016367,0.00042002916,0.83873093,0.0006908315,0.0002727288,0.00003067015,0.00009812372],"genre_scores_gemma":[0.5274713,0.11994535,0.009312404,0.00022405943,0.3297062,0.00076995423,0.0033945437,0.0011104855,0.008065728],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716306,0.00080774777,0.0010657572,0.00023777326,0.00016824405,0.0005574491],"domain_scores_gemma":[0.993729,0.0038223506,0.0014828412,0.0003676735,0.0005513916,0.000046764566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021537903,0.00042430393,0.0016941361,0.00039299802,0.00015864629,0.000018247736,0.0006944409,0.0011508717,0.00007656621],"category_scores_gemma":[0.0011537136,0.00026081532,0.0002331939,0.00023576836,0.0001871907,0.00011042571,0.00006925507,0.0009650228,0.00003934491],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055552493,0.00013966493,0.0032089227,0.00008412002,0.0015908907,0.000016425045,0.001579636,0.000037007518,0.000028671533,0.000049672537,0.9594568,0.028252913],"study_design_scores_gemma":[0.027682038,0.003320466,0.00046419,0.0016013011,0.0017562745,0.0047820606,0.0014283161,0.000005174259,0.00020844626,0.00081078924,0.9572559,0.00068503845],"about_ca_topic_score_codex":0.00056416227,"about_ca_topic_score_gemma":0.0032409963,"teacher_disagreement_score":0.50902474,"about_ca_system_score_codex":0.00011816821,"about_ca_system_score_gemma":0.0008519043,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W1992622835","doi":"10.2310/7750.2008.07069","title":"Efficacy of a Day-Care Program in the Treatment of Psoriasis","year":2008,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Retrospective cohort study; Plaque psoriasis; Population; Dermatology; Surgery; Internal medicine","score_opus":0.03449395301791336,"score_gpt":0.2739845122490617,"score_spread":0.23949055923114831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992622835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630306,0.03585524,0.000001468968,0.00028634214,0.00039195968,0.00016614428,0.000005057132,0.0000041297567,0.00025909883],"genre_scores_gemma":[0.98220223,0.017514043,0.000032626955,0.00003424928,0.00011791684,0.000004864927,0.0000122084475,0.0000062754716,0.00007557542],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99879724,0.00024276372,0.0006330511,0.00008847788,0.00008359775,0.00015485467],"domain_scores_gemma":[0.9976584,0.0016679829,0.00040326378,0.00014144262,0.000106684754,0.000022261273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025994866,0.00013467755,0.00070824305,0.00024575958,0.000050740433,0.00000121517,0.000083980056,0.00010214119,0.00005599675],"category_scores_gemma":[0.0001380711,0.00006857631,0.00020351094,0.00017785469,0.00025460366,0.000025534328,0.000004675405,0.00007948518,0.0000014180418],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024373275,0.002621457,0.13079093,0.000079135585,0.0010031826,0.0024669496,0.044513494,0.0000045434176,0.008020511,0.000022094575,0.0036626768,0.8043777],"study_design_scores_gemma":[0.032486685,0.041727465,0.48770675,0.0022558377,0.0042666206,0.06476879,0.032308158,0.000003211445,0.053092927,0.00019455476,0.28035164,0.0008373773],"about_ca_topic_score_codex":0.000053164535,"about_ca_topic_score_gemma":0.000011006747,"teacher_disagreement_score":0.8035403,"about_ca_system_score_codex":0.000021243968,"about_ca_system_score_gemma":0.000089136985,"threshold_uncertainty_score":0.27964607},"labels":[],"label_agreement":null},{"id":"W1992644783","doi":"10.2310/7750.2008.07080","title":"Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research","funders":"","keywords":"Medicine; Infliximab; Psoriasis; Dermatology; Pustular psoriasis; Psoriatic arthritis; Ankylosing spondylitis; Rheumatoid arthritis; Arthritis; Disease; Adalimumab; Spondylitis; Surgery; Immunology; Internal medicine","score_opus":0.019125019732479435,"score_gpt":0.23592421371592637,"score_spread":0.21679919398344694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992644783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847612,0.014184223,0.000006157946,0.0004322397,0.0003574398,0.00006513438,0.000021046639,0.000008664661,0.0001639143],"genre_scores_gemma":[0.99211496,0.0075366665,0.000034912486,0.000060890572,0.00010510507,9.632059e-7,0.000019969644,0.0000041291887,0.00012243178],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989898,0.00008312504,0.0005146217,0.00012359415,0.000082274484,0.00020654745],"domain_scores_gemma":[0.99890214,0.000387984,0.00043206516,0.00012503035,0.00010169862,0.000051089577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017876826,0.00018446104,0.00073802203,0.00026434794,0.00007437055,0.0000035255387,0.0000646434,0.00009734604,0.00011070954],"category_scores_gemma":[0.000052721385,0.000105885716,0.00011348637,0.00011726921,0.00012549592,0.00006397249,0.0000052981977,0.00010206712,0.0000036237843],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02154097,0.0016799258,0.15978289,0.00019476078,0.0041050017,0.011438623,0.007173912,0.00003071671,0.24100178,0.00005109327,0.008272694,0.5447276],"study_design_scores_gemma":[0.033574224,0.04164766,0.08185222,0.004388009,0.007529048,0.24836577,0.0052228887,0.000004416371,0.47131115,0.00037791027,0.10401588,0.001710805],"about_ca_topic_score_codex":0.000020723503,"about_ca_topic_score_gemma":0.0000036100864,"teacher_disagreement_score":0.5430168,"about_ca_system_score_codex":0.000031677664,"about_ca_system_score_gemma":0.00008804476,"threshold_uncertainty_score":0.4317894},"labels":[],"label_agreement":null},{"id":"W1993178599","doi":"10.2310/7750.2009.00026","title":"Practical Aspects of Prescribing a Biologic","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Biologic Agents; Intensive care medicine; Psoriasis; Dermatology; Disease; Pathology","score_opus":0.10204938992966,"score_gpt":0.33723139154681736,"score_spread":0.23518200161715735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993178599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005416751,0.9969765,0.000009529935,0.00026123694,0.0010723252,0.0001461507,0.000009727148,0.000009619326,0.0009732448],"genre_scores_gemma":[0.0013251638,0.9978903,0.00005893899,0.00007240506,0.00035861542,0.000001733131,0.00003348501,0.000016614993,0.00024272659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974832,0.0005717348,0.0013922425,0.00019426888,0.000086847846,0.00027172454],"domain_scores_gemma":[0.9938979,0.0039743367,0.0017471684,0.00018128031,0.00013840795,0.000060884515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008437139,0.0003442864,0.0033845694,0.00052425684,0.000057983172,0.0000051105035,0.000118747135,0.00052679423,0.00019762904],"category_scores_gemma":[0.001211982,0.000192049,0.0006075295,0.00018831009,0.0002241159,0.000051176492,0.000024191922,0.00049970456,0.000012778959],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013309685,0.00013358892,0.000026153983,0.0014521385,0.0011263347,0.0024433006,0.000068497335,3.067708e-8,0.000098309814,0.000109191,0.015260691,0.9791487],"study_design_scores_gemma":[0.00029946436,0.0008510887,0.000007371749,0.012267212,0.0034160765,0.06481508,0.00006200487,4.073968e-8,0.000035989506,0.00014084911,0.9179343,0.0001705402],"about_ca_topic_score_codex":0.000006580614,"about_ca_topic_score_gemma":0.0000011509144,"teacher_disagreement_score":0.9789781,"about_ca_system_score_codex":0.00003429803,"about_ca_system_score_gemma":0.00047114512,"threshold_uncertainty_score":0.7831531},"labels":[],"label_agreement":null},{"id":"W1993243930","doi":"10.1097/01.asw.0000429778.10020.67","title":"A Review of the Clinical Variants and the Management of Psoriasis","year":2013,"lang":"en","type":"review","venue":"Advances in Skin & Wound Care","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine","score_opus":0.03160510421387834,"score_gpt":0.3498774234840129,"score_spread":0.31827231927013455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993243930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027695733,0.9938893,0.0000018263465,0.0000206266,0.0014818532,0.0019462793,0.00009715656,0.000005466143,0.0025298367],"genre_scores_gemma":[0.000087203334,0.99876755,0.00010339028,0.00006550921,0.000037874204,0.00042383233,0.00006644997,0.000018328841,0.00042985028],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970638,0.0011999159,0.0010993802,0.0003673085,0.00006250016,0.00020710172],"domain_scores_gemma":[0.99765605,0.00064807705,0.0008258299,0.00078494713,0.00007393759,0.00001117019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006422707,0.00032038274,0.001889447,0.000047605274,0.00007096561,0.000005024098,0.0006220691,0.0002903554,0.0001159237],"category_scores_gemma":[0.000058205904,0.000149496,0.0006477066,0.0003036174,0.00058226514,0.000060801154,0.00028474256,0.00028499612,0.000029132241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022750231,0.000040282244,0.000041056195,0.06044586,0.000630338,0.0000016800476,0.00009284325,6.336687e-8,2.9649252e-8,0.0009871694,0.0002085065,0.93752944],"study_design_scores_gemma":[0.0011370806,0.00003765607,0.00010194509,0.075528055,0.0027161774,0.000018611074,0.00019893509,9.9343795e-9,0.0000018752278,0.00015807513,0.9199665,0.00013504432],"about_ca_topic_score_codex":0.000022704773,"about_ca_topic_score_gemma":0.00002220343,"teacher_disagreement_score":0.9373944,"about_ca_system_score_codex":0.000036858084,"about_ca_system_score_gemma":0.00006719049,"threshold_uncertainty_score":0.609627},"labels":[],"label_agreement":null},{"id":"W1993456571","doi":"10.6000/1929-6029.2014.03.03.3","title":"Comparative Risk-Benefit Analysis of Different Classes of Biologic Agents in Patients with Psoriasis: A Case Study on the Pros and Cons of Mixed Treatment Comparison in Synthesizing Complex Evidence Networks","year":2014,"lang":"en","type":"article","venue":"International Journal of Statistics in Medical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Placebo; Adverse effect; Internal medicine; Randomization; Biologic Agents; Ustekinumab; Arthritis; Rheumatology; TNF inhibitor; Randomized controlled trial; Tumor necrosis factor alpha; Immunology; Alternative medicine; Etanercept; Disease; Infliximab; Pathology","score_opus":0.18773638305101512,"score_gpt":0.4383742288688274,"score_spread":0.25063784581781223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993456571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987429,0.00020824737,0.00046325804,0.000047701113,0.00007828758,0.00032707248,0.00012386992,6.7730423e-7,0.000008019623],"genre_scores_gemma":[0.9994671,0.00035265367,0.0001251198,0.0000037041677,0.000008118523,0.00001789497,0.00001999417,0.0000033979602,0.0000020324167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964885,0.0018790074,0.0008523196,0.00015346639,0.00045913117,0.00016757309],"domain_scores_gemma":[0.9876844,0.011093612,0.00056005776,0.00011470567,0.0005133224,0.000033867338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019249048,0.00011842987,0.0007206944,0.00070938404,0.000035030633,0.0000075694575,0.00028525147,0.00008146511,0.00006757638],"category_scores_gemma":[0.0018795584,0.00006467156,0.00004679026,0.0003545233,0.00042875056,0.000026347283,0.00007189767,0.000353778,3.3320578e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021102726,0.0032517405,0.9748276,0.000008472035,0.0018349343,0.000108422544,0.0018311085,0.0006446719,0.000058547514,0.0003748645,0.000014006378,0.0149353435],"study_design_scores_gemma":[0.0034237006,0.003257397,0.98649335,0.00041294584,0.00021481185,0.000007864559,0.0024777446,0.0032326926,0.00032119898,0.00010816882,0.0000022356207,0.000047892707],"about_ca_topic_score_codex":0.0011364912,"about_ca_topic_score_gemma":0.007272462,"teacher_disagreement_score":0.014887451,"about_ca_system_score_codex":0.00013763945,"about_ca_system_score_gemma":0.000072711795,"threshold_uncertainty_score":0.40582043},"labels":[],"label_agreement":null},{"id":"W1994132766","doi":"10.2310/7750.2006.00070","title":"Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis","year":2007,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; University of Victoria; Mediprobe Research (Canada); University of Toronto; University of British Columbia; Sunnybrook Health Science Centre","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Psoriasis Area and Severity Index; Secukinumab; Rheumatoid arthritis; Dosing; Ustekinumab; Erythema; Plaque psoriasis; Dermatology Life Quality Index; Internal medicine; Adalimumab","score_opus":0.01958180936552655,"score_gpt":0.2543829953005602,"score_spread":0.23480118593503363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994132766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733074,0.024983127,0.00002640932,0.0005720318,0.00048556313,0.00010207961,0.000002868701,0.0000023721739,0.00051819],"genre_scores_gemma":[0.976083,0.023581026,0.00007104531,0.00009946803,0.00008318636,8.119365e-7,0.000004016546,0.00000601435,0.00007146093],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986764,0.00015252922,0.00080145296,0.00009504089,0.00009865703,0.00017590854],"domain_scores_gemma":[0.99703175,0.002336314,0.0004294652,0.000118801996,0.00005717486,0.00002648391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014617565,0.00012329819,0.0006084168,0.0002895202,0.000037383892,0.0000023512534,0.00008472328,0.00010237396,0.000081044745],"category_scores_gemma":[0.0001131946,0.00007334473,0.00009468006,0.00017344957,0.00019933067,0.00003415542,0.000014685581,0.00013956877,0.0000011799319],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027609156,0.00043282344,0.01763152,0.00026585898,0.0012449471,0.002911234,0.006107686,0.0000033327758,0.007236918,0.00048152608,0.004028933,0.9568943],"study_design_scores_gemma":[0.03875312,0.0069400473,0.7057687,0.011420881,0.0054610274,0.08060242,0.04977912,0.0000051913457,0.027749995,0.0028169686,0.06954686,0.0011556911],"about_ca_topic_score_codex":0.000034472312,"about_ca_topic_score_gemma":0.000020909732,"teacher_disagreement_score":0.9557386,"about_ca_system_score_codex":0.000010022766,"about_ca_system_score_gemma":0.000024832201,"threshold_uncertainty_score":0.29909113},"labels":[],"label_agreement":null},{"id":"W1994529307","doi":"10.1152/ajpregu.00540.2013","title":"Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response","year":2014,"lang":"en","type":"article","venue":"American Journal of Physiology-Regulatory, Integrative and Comparative Physiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Inflammation; Interleukin 23; HEK 293 cells; Proinflammatory cytokine; Chemistry; In vivo; Cytokine; Receptor; Pharmacology; Cell biology; Immunology; Interleukin 17; Biology; Biochemistry","score_opus":0.02485374147178303,"score_gpt":0.25133862422617037,"score_spread":0.22648488275438733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994529307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99697566,0.0013470403,0.0003028966,0.00016349556,0.00071346556,0.0002818732,0.00009216782,0.000013694484,0.000109695124],"genre_scores_gemma":[0.99828047,0.00012403085,0.000988406,0.00020141427,0.00023943417,0.000017581486,0.000025134386,0.00002211226,0.00010143424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99425566,0.0038405613,0.00088590116,0.00045994122,0.000095645635,0.0004623081],"domain_scores_gemma":[0.99456656,0.002341864,0.0019852917,0.00046054425,0.00057803484,0.00006771524],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00081415253,0.0005229967,0.0014130755,0.00016714336,0.0005450164,0.000013461531,0.00065702334,0.00015042095,0.00008764605],"category_scores_gemma":[0.00018920832,0.00027778832,0.00047622717,0.00034915164,0.005059891,0.00011977211,0.00019427369,0.0006152052,0.000018650164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004903608,0.00024855,0.001977726,0.000008735334,0.0009046221,5.1352885e-7,0.0031212918,0.00016504295,0.98486596,0.0024945056,0.00046591,0.00084350683],"study_design_scores_gemma":[0.0022488025,0.0029316542,0.4183829,0.00023321921,0.00023687299,0.00011164231,0.014340543,0.000052821004,0.5509273,0.00078934984,0.009308215,0.00043667745],"about_ca_topic_score_codex":0.000086955195,"about_ca_topic_score_gemma":0.000024455925,"teacher_disagreement_score":0.4339387,"about_ca_system_score_codex":0.00009752165,"about_ca_system_score_gemma":0.00026105787,"threshold_uncertainty_score":0.99996746},"labels":[],"label_agreement":null},{"id":"W1995845116","doi":"10.1080/09546630510011801","title":"Evaluation of the efficacy of topical caffeine in the treatment of psoriasis vulgaris","year":2005,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Caffeine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Dermatology; Pathology","score_opus":0.05697133314208078,"score_gpt":0.3086893164628903,"score_spread":0.2517179833208095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995845116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907665,0.0071560713,0.0000066046355,0.0009746812,0.0002317863,0.0004313184,0.00002050874,0.000002812059,0.00040967332],"genre_scores_gemma":[0.99876785,0.0009400199,0.00013992372,0.000017176664,0.000051542866,0.000022340897,0.0000067710325,0.000004533369,0.000049810642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99747837,0.0011497173,0.0008522892,0.00012315296,0.00022272233,0.00017376305],"domain_scores_gemma":[0.99821717,0.00061363133,0.00066573865,0.00029407992,0.00019107282,0.000018294817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004826603,0.00018803825,0.0006574699,0.000094211326,0.000053165677,0.0000030330532,0.00024352518,0.00018287779,0.00014953951],"category_scores_gemma":[0.00012344829,0.00007708158,0.000489922,0.00017566977,0.0001716845,0.000039976556,0.000015667132,0.0000728808,0.0000058770042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018504134,0.024741517,0.29366377,0.00002457082,0.003553987,0.000050366878,0.00878342,0.0007295546,0.030254712,0.0008411967,0.00024644256,0.63526005],"study_design_scores_gemma":[0.016169686,0.003823031,0.6165259,0.00006194609,0.0026226784,0.00048099135,0.0005952201,0.00002384151,0.35604492,0.00023080615,0.0033142236,0.00010678513],"about_ca_topic_score_codex":0.000041381183,"about_ca_topic_score_gemma":0.000058951817,"teacher_disagreement_score":0.6351533,"about_ca_system_score_codex":0.00024336968,"about_ca_system_score_gemma":0.00012213683,"threshold_uncertainty_score":0.3143296},"labels":[],"label_agreement":null},{"id":"W1996190935","doi":"10.1046/j.1468-3083.17.s2.3.x","title":"Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis","year":2003,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Placebo; Psoriasis; Adverse effect; Internal medicine; Psoriasis Area and Severity Index; Clinical trial; Gastroenterology; Dermatology; Pathology","score_opus":0.01923045553152288,"score_gpt":0.2943934389556732,"score_spread":0.27516298342415035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996190935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997879,0.0009294131,0.000017222706,0.00048011506,0.00024865172,0.00033599156,0.000033591983,0.0000024048993,0.0000736074],"genre_scores_gemma":[0.9996295,0.00015066493,0.00012616256,0.000032324224,0.000014943366,0.0000014429611,0.0000036480872,0.000012519743,0.000028771221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99173516,0.006091474,0.0016774288,0.00020982887,0.00007994621,0.00020613818],"domain_scores_gemma":[0.9974002,0.0005630632,0.0016698963,0.00021092959,0.000115913936,0.00003997434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016176087,0.00018116721,0.00090256106,0.0002810596,0.000042271568,0.0000010479529,0.0003367062,0.0002721541,0.000017955106],"category_scores_gemma":[0.0005111642,0.00012199285,0.00014122567,0.00022167421,0.0005026725,0.00005665359,0.000075029886,0.0004000508,0.0000022718666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07049272,0.006034503,0.8895944,0.000091670365,0.0017212606,0.0000706217,0.002623888,0.0001064806,0.020617759,0.00016555915,0.0004195178,0.008061615],"study_design_scores_gemma":[0.03736852,0.005730923,0.89399624,0.00015217767,0.000482826,0.0005079337,0.0003666547,8.3970684e-7,0.059607573,0.0000362056,0.0016137288,0.0001364104],"about_ca_topic_score_codex":0.000004366053,"about_ca_topic_score_gemma":0.000014734096,"teacher_disagreement_score":0.038989812,"about_ca_system_score_codex":0.00001849816,"about_ca_system_score_gemma":0.00013522308,"threshold_uncertainty_score":0.4974724},"labels":[],"label_agreement":null},{"id":"W1996351781","doi":"10.2310/7750.2006.00072","title":"Practical Considerations for the Initiation and Maintenance of Etanercept in the Treatment of Psoriasis","year":2007,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Lynde Centre for Dermatology; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Dosing; Dermatology; Intensive care medicine; Tumor necrosis factor alpha; Internal medicine","score_opus":0.06880761970566739,"score_gpt":0.31746918539814056,"score_spread":0.24866156569247316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996351781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467106,0.008286176,0.00034855885,0.006017935,0.00036742137,0.00017907906,0.000008388633,0.0000013271264,0.000120087425],"genre_scores_gemma":[0.99123025,0.008318665,0.00013521197,0.00017868905,0.00008985089,0.0000030442518,0.0000031818176,0.000003128926,0.000037958995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991918,0.00012290153,0.00048162095,0.000055103206,0.000045893103,0.000102660284],"domain_scores_gemma":[0.98692864,0.012539523,0.00033271709,0.00007095147,0.00011576264,0.000012374916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095322134,0.000073548705,0.00033104586,0.00011080191,0.00006402864,0.00000247778,0.00001936573,0.00006674339,0.000032987653],"category_scores_gemma":[0.00074651605,0.000032823777,0.00007164401,0.00006399409,0.0001968842,0.000032449592,0.0000023189057,0.000058263366,1.843585e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015160481,0.0038926275,0.12821005,0.0002975515,0.0044998066,0.0030910992,0.07958637,0.000025959242,0.10110786,0.011388076,0.06298207,0.58975804],"study_design_scores_gemma":[0.035000645,0.029088764,0.32414493,0.0019454452,0.010792318,0.18811835,0.11627879,0.00008674885,0.08906371,0.015554744,0.18891773,0.0010078206],"about_ca_topic_score_codex":0.000028336186,"about_ca_topic_score_gemma":0.00007469893,"teacher_disagreement_score":0.58875024,"about_ca_system_score_codex":0.000012487662,"about_ca_system_score_gemma":0.000065001674,"threshold_uncertainty_score":0.13385147},"labels":[],"label_agreement":null},{"id":"W1996677715","doi":"10.2310/7750.2012.12036","title":"One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population","year":2013,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; Hôpital de l'Enfant-Jésus; Institute of Cosmetic and Laser Surgery; Université Laval; Lynde Centre for Dermatology; Amgen (Canada); SKiN Health; University of British Columbia","funders":"Pfizer Canada; Amgen Canada; Amgen","keywords":"Medicine; Etanercept; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Clinical endpoint; Plaque psoriasis; Internal medicine; Population; Quality of life (healthcare); Open label; Body surface area; Surgery; Randomized controlled trial; Dermatology","score_opus":0.07198932471620476,"score_gpt":0.32127664003229606,"score_spread":0.2492873153160913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996677715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493504,0.0027856247,0.000013730138,0.0005747806,0.00033412172,0.001314066,0.000017190452,0.0000015169583,0.00002391865],"genre_scores_gemma":[0.9988407,0.0009244236,0.000051277082,0.000045866116,0.00004052335,0.0000353754,0.000011562807,0.000009989706,0.000040274546],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99841684,0.0005960924,0.0005877397,0.00013163501,0.00007146003,0.0001962322],"domain_scores_gemma":[0.9949616,0.0043531395,0.0003164045,0.00013283743,0.00018309763,0.00005289895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013156092,0.00013956314,0.0006730315,0.00018941154,0.00014882779,0.000012632783,0.00009916838,0.000078789984,0.00004252155],"category_scores_gemma":[0.00032982405,0.00007327394,0.000049579197,0.00011569629,0.00006894598,0.00006607543,0.00001552916,0.00007127531,6.013773e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028212998,0.0044250772,0.31770453,0.00018428048,0.002842386,0.000059311904,0.016260743,0.00046024722,0.03657247,0.000043912572,0.00020424588,0.5930298],"study_design_scores_gemma":[0.046054956,0.05041034,0.8725517,0.00228777,0.0035130135,0.0012322702,0.016678965,0.0010149315,0.004325452,0.00045040576,0.000920288,0.0005599111],"about_ca_topic_score_codex":0.05918435,"about_ca_topic_score_gemma":0.021551877,"teacher_disagreement_score":0.5924699,"about_ca_system_score_codex":0.00010709246,"about_ca_system_score_gemma":0.00011894241,"threshold_uncertainty_score":0.99630225},"labels":[],"label_agreement":null},{"id":"W1997158650","doi":"10.1073/pnas.1100667108","title":"Regulation of type 17 helper T-cell function by nitric oxide during inflammation","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"Aryl hydrocarbon receptor; Experimental autoimmune encephalomyelitis; Nitric oxide; Inflammation; Immunology; Nitric oxide synthase; Autoimmune disease; Interleukin 17; Receptor; Autoimmunity; Pathogenesis; Chemistry; T cell; Biology; Cell biology; Immune system; Endocrinology; Biochemistry; Transcription factor; Antibody; Gene","score_opus":0.03306215582147709,"score_gpt":0.23714079847338498,"score_spread":0.2040786426519079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997158650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941385,0.00038510514,7.8362416e-7,0.000060695813,0.000030000503,0.00010418079,0.000007706827,0.000008499482,0.0052645416],"genre_scores_gemma":[0.9985094,0.000034224777,0.0001661232,0.000011017052,0.000015974623,0.0000045756874,0.0000014395522,0.0000023973655,0.0012548151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993873,0.000009660081,0.0002443871,0.00012823162,0.00014379101,0.000086619366],"domain_scores_gemma":[0.9993221,0.000034976845,0.00041925447,0.00000737547,0.00021004687,0.0000062517524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041573498,0.00006563504,0.00010283248,0.00014602175,0.00012589751,0.0000027416627,0.00021668787,0.00011350041,0.000075477634],"category_scores_gemma":[0.00008623108,0.000045614932,0.00004592798,0.00044458135,0.00025516088,0.0002797219,0.000037686124,0.00005703207,0.0000067421224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009346466,0.000038274993,0.012935474,0.000027851616,0.000023773715,5.444469e-10,0.00012840929,0.000006186866,0.9841704,0.0017756611,0.00039404133,0.0004064768],"study_design_scores_gemma":[0.00020065441,0.000031685566,0.32207644,0.000017554592,0.000024832352,0.0000015097781,0.000059217447,0.0000061986734,0.6748583,0.0026282137,0.00006435481,0.000031062376],"about_ca_topic_score_codex":0.00000946793,"about_ca_topic_score_gemma":3.6811453e-8,"teacher_disagreement_score":0.3093121,"about_ca_system_score_codex":0.00001749995,"about_ca_system_score_gemma":0.00001399465,"threshold_uncertainty_score":0.1860123},"labels":[],"label_agreement":null},{"id":"W1997189639","doi":"10.1111/j.1365-2133.2009.09238.x","title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","year":2009,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Library science; Art; Art history; Classics; Computer science","score_opus":0.012791580294271805,"score_gpt":0.24806132362284522,"score_spread":0.23526974332857342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997189639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955433,0.0021567706,0.000060790175,0.0012184397,0.0004435725,0.0002965871,0.000052936826,0.000036050642,0.00019153678],"genre_scores_gemma":[0.9975287,0.000523064,0.00093235134,0.00034326312,0.00007240602,0.000008859613,0.000038392023,0.000027764178,0.0005252265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972892,0.00096651196,0.00078417506,0.00036257057,0.00010087086,0.0004966861],"domain_scores_gemma":[0.9985705,0.00024037632,0.00046266033,0.00026124605,0.0003311487,0.00013406319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001951549,0.0003114758,0.0009079095,0.00019670755,0.00026318256,0.000041495703,0.0002462177,0.00041006156,0.0001685569],"category_scores_gemma":[0.000088646906,0.00023930249,0.00019485503,0.00019779925,0.0001249823,0.00018397992,0.00002348091,0.00037441088,0.00007591524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23773347,0.0055785473,0.3634108,0.000030306017,0.004735346,0.026580423,0.0018288663,0.00015323241,0.0044441745,0.000027716287,0.007907472,0.34756964],"study_design_scores_gemma":[0.03087308,0.007286347,0.86535037,0.00036503802,0.00066762505,0.08032299,0.00025161906,5.5366394e-7,0.00660433,0.000035145502,0.0077118548,0.0005310699],"about_ca_topic_score_codex":0.000016884243,"about_ca_topic_score_gemma":0.00009564444,"teacher_disagreement_score":0.50193954,"about_ca_system_score_codex":0.00010508499,"about_ca_system_score_gemma":0.00021435771,"threshold_uncertainty_score":0.97584724},"labels":[],"label_agreement":null},{"id":"W1997237519","doi":"10.1111/jdv.12909","title":"Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review","year":2014,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Centre Hospitalier de l’Université de Montréal; Innovaderm (Canada); Centre hospitalier universitaire de Québec; University of British Columbia; University of Toronto; Western University; Hôpital du Sacré-Cœur de Montréal; Lynde Centre for Dermatology; University of Alberta; Université de Montréal; Hôpital Saint-Luc","funders":"Sanofi","keywords":"Medicine; Adalimumab; Ustekinumab; Etanercept; Psoriasis; Placebo; Randomized controlled trial; Depression (economics); Internal medicine; Beck Depression Inventory; Physical therapy; Clinical trial; Dermatology; Anxiety; Psychiatry; Tumor necrosis factor alpha; Alternative medicine","score_opus":0.011939223124890748,"score_gpt":0.2652383911809469,"score_spread":0.2532991680560561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997237519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016632631,0.98171425,0.000001619931,0.000069283415,0.0003767023,0.0010169127,0.000025727719,0.000005506965,0.00015737147],"genre_scores_gemma":[0.060064103,0.93967164,0.00000538889,0.00012566139,0.000030067707,0.000018367798,0.000015469843,0.000033724686,0.000035549416],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98346484,0.013978021,0.0019148742,0.0002741738,0.00007470052,0.00029337252],"domain_scores_gemma":[0.993115,0.0017987897,0.0046884622,0.00030224517,0.00006362752,0.000031879237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013383905,0.0005034215,0.0052666953,0.00036092656,0.00006174079,0.0000021278324,0.0008440254,0.0006552595,0.00000858141],"category_scores_gemma":[0.00057119183,0.00023052047,0.00060332165,0.00022510217,0.0005101489,0.000036382247,0.00017661306,0.0009211441,0.000019831146],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011608585,0.00044366485,0.038556334,0.8036056,0.0076099387,0.00008656565,0.0000815252,0.0000021271032,0.0000070361602,0.00044831898,0.00062219286,0.14737582],"study_design_scores_gemma":[0.010632707,0.002499165,0.0062910444,0.9038297,0.034512643,0.007751266,0.000005435129,1.8075936e-7,0.0004112844,0.000052314113,0.033265676,0.0007485817],"about_ca_topic_score_codex":5.769535e-7,"about_ca_topic_score_gemma":2.322736e-7,"teacher_disagreement_score":0.14662725,"about_ca_system_score_codex":0.000029110082,"about_ca_system_score_gemma":0.00005077806,"threshold_uncertainty_score":0.9400352},"labels":[],"label_agreement":null},{"id":"W1998000193","doi":"10.1038/nm1651","title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","year":2007,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1735,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta; Université de Montréal; Hôpital Notre-Dame","funders":"Canadian Institutes of Health Research","keywords":"Blood–brain barrier; Inflammation; Central nervous system; Multiple sclerosis; Immunology; Granzyme; Biology; Pathogenesis; Granzyme A; In vivo; Medicine; Neuroscience; Immune system; Granzyme B; T cell; CD8; Perforin","score_opus":0.006146394405878335,"score_gpt":0.24515487064111682,"score_spread":0.2390084762352385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998000193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985399,0.011067979,0.00004122132,0.00053941546,0.0010578211,0.0003246961,0.000013969919,0.0001291952,0.0014266925],"genre_scores_gemma":[0.99723107,0.0000411058,0.000041621737,0.00012013585,0.0005811197,0.000009940547,0.00032486432,0.000015772443,0.0016343974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989224,0.00010339344,0.00028523515,0.00026941506,0.00006868602,0.0003508648],"domain_scores_gemma":[0.999476,0.00009556741,0.00012693743,0.00019043418,0.000056854675,0.000054191627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044608666,0.00020309334,0.00028006692,0.00014306168,0.00023475196,0.000007472335,0.00009015869,0.00059100625,0.00008111522],"category_scores_gemma":[0.000105684725,0.0001418388,0.00004273182,0.00013247854,0.00014207435,0.00007250008,0.000024975823,0.00026431322,0.000022542054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014977879,0.00003519968,0.0052199205,0.00010091352,0.00024210096,0.00007512464,0.0013153083,3.8094453e-7,0.9345028,0.00324415,0.00066642126,0.054447938],"study_design_scores_gemma":[0.010980156,0.0008695386,0.4486917,0.0005652025,0.0009437712,0.0008245181,0.001199387,0.000005316881,0.51072925,0.00019978646,0.024551481,0.0004399187],"about_ca_topic_score_codex":0.00006139094,"about_ca_topic_score_gemma":0.0000802021,"teacher_disagreement_score":0.44347176,"about_ca_system_score_codex":0.00008320832,"about_ca_system_score_gemma":0.000021861162,"threshold_uncertainty_score":0.57840186},"labels":[],"label_agreement":null},{"id":"W1998652494","doi":"10.1016/j.jaad.2014.07.046","title":"Assessing adherence with phototherapy protocols","year":2014,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Centre for Advancing Health Outcomes; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Medicine; MEDLINE; Dermatology; Intensive care medicine","score_opus":0.0289464904360851,"score_gpt":0.3254488855279885,"score_spread":0.2965023950919034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998652494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955689,0.0003418521,0.00037492768,0.0024212222,0.00010844176,0.00076068373,0.0000025993286,0.000009866556,0.00041151152],"genre_scores_gemma":[0.9981579,0.00004160987,0.0009575584,0.00065947504,0.0000331372,0.000078204896,4.033111e-7,0.0000128557585,0.00005885096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985095,0.0006222984,0.0004600777,0.000115371695,0.000064844804,0.00022788015],"domain_scores_gemma":[0.99778754,0.00025607517,0.0017549085,0.00013600667,0.000041825733,0.000023639574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016452685,0.00014826952,0.0006257678,0.00010354042,0.00009241072,0.000009320699,0.00050634186,0.00010683925,0.000040568106],"category_scores_gemma":[0.000048145343,0.00008038542,0.00015562483,0.00021518598,0.00069204194,0.00012867927,0.00003533675,0.00034194952,0.000011245497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014593194,0.00026435743,0.14231032,0.000038453236,0.00088623347,0.000011522299,0.00030691177,0.00001330035,0.7578779,0.00049980695,0.0016149583,0.09471696],"study_design_scores_gemma":[0.0039510303,0.0009929974,0.14290674,0.00027356963,0.00023287,0.008472997,0.00027977274,0.0000051303114,0.8103478,0.0004142247,0.031901274,0.00022160931],"about_ca_topic_score_codex":0.000008632553,"about_ca_topic_score_gemma":7.6725024e-7,"teacher_disagreement_score":0.09449535,"about_ca_system_score_codex":0.0000144933565,"about_ca_system_score_gemma":0.00009351005,"threshold_uncertainty_score":0.3278022},"labels":[],"label_agreement":null},{"id":"W1999075488","doi":"10.1007/s10227-006-0104-0","title":"Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; University of Calgary; University of Manitoba; Sunnybrook Health Science Centre; Université Laval; Lynde Centre for Dermatology; Queen Elizabeth II Health Sciences Centre; University of Toronto; Dalhousie University; University Health Network; University of British Columbia; Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Adverse effect; Intensive care medicine; Drug; Disease; Clinical trial; Dermatology; Plaque psoriasis; Pharmacology; Internal medicine","score_opus":0.06254265068135623,"score_gpt":0.3123617089270362,"score_spread":0.24981905824567996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999075488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015303395,0.99671286,0.00009205398,0.00025427333,0.0006244914,0.0005182148,0.00003903499,0.000011389208,0.0002173524],"genre_scores_gemma":[0.0006550918,0.99743783,0.00041380053,0.00008347731,0.0004523966,0.000055827673,0.00006657109,0.000045876117,0.00078912],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792063,0.00022917747,0.0010902013,0.0002886244,0.00007561619,0.00039576893],"domain_scores_gemma":[0.99723125,0.0017154469,0.0006726178,0.0001771409,0.000118433956,0.000085130334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038248734,0.00052300305,0.0032752652,0.00075737643,0.00009591289,0.0000249771,0.0001136453,0.0003546412,0.00008245242],"category_scores_gemma":[0.00005063649,0.00028894757,0.00040682108,0.00020767532,0.00007415445,0.000096099386,0.000013277802,0.00021569806,0.000007957679],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013043294,0.000114589486,0.000009394013,0.00084699434,0.0013193103,0.00087246945,0.0006124453,0.00004078823,0.0000060419106,0.000018337407,0.0024831041,0.9923722],"study_design_scores_gemma":[0.001835927,0.0020567088,9.2999096e-7,0.010356994,0.0026985547,0.020516632,0.00072127837,0.0000012460707,0.000006887574,0.000028870762,0.96145004,0.00032592966],"about_ca_topic_score_codex":0.000033734843,"about_ca_topic_score_gemma":0.00007329404,"teacher_disagreement_score":0.99204624,"about_ca_system_score_codex":0.00019641101,"about_ca_system_score_gemma":0.0007435232,"threshold_uncertainty_score":0.99995625},"labels":[],"label_agreement":null},{"id":"W1999262129","doi":"10.3899/jrheum.120823","title":"Psoriasis and Psoriatic Arthritis Video Project: An Update from the GRAPPA 2011 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dactylitis; Psoriasis; Psoriatic arthritis; Psoriasis Area and Severity Index; Enthesitis; Dermatology; Rheumatology; Physical therapy; Severity of illness; Internal medicine","score_opus":0.014531861853846154,"score_gpt":0.2369562165168686,"score_spread":0.22242435466302246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999262129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9419395,0.05433911,0.000053036776,0.0009912187,0.0023640841,0.00016254345,0.00006879389,0.000019862333,0.000061882696],"genre_scores_gemma":[0.98557436,0.013830603,0.00023985544,0.00017128105,0.000088121764,0.000007907353,0.000021670547,0.000020352316,0.000045847646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724406,0.0015028112,0.00058995484,0.00013651233,0.00006478817,0.00046186103],"domain_scores_gemma":[0.9977323,0.0011818293,0.0006098983,0.0003222054,0.00010591541,0.00004786451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015493085,0.00022687201,0.0005236042,0.00009431738,0.0004123337,0.000016692005,0.0004233449,0.00022140892,0.00023930767],"category_scores_gemma":[0.0001809357,0.00012023437,0.000113268245,0.00009806268,0.0003098312,0.0003235095,0.000096042,0.00034814197,0.0001481322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026092606,0.0006351985,0.55488557,0.00002507984,0.0038418137,0.000016004193,0.04089058,0.0000041480434,0.0062493044,0.002805266,0.047109764,0.34092802],"study_design_scores_gemma":[0.036431298,0.004352931,0.5238834,0.0011992308,0.0076440764,0.07348919,0.063888915,0.000025183272,0.026543647,0.014351693,0.24558657,0.0026038385],"about_ca_topic_score_codex":0.0012275209,"about_ca_topic_score_gemma":0.00031466017,"teacher_disagreement_score":0.3383242,"about_ca_system_score_codex":0.00001688303,"about_ca_system_score_gemma":0.000067501984,"threshold_uncertainty_score":0.49030152},"labels":[],"label_agreement":null},{"id":"W1999694298","doi":"10.1016/j.annder.2013.09.323","title":"L’ustekinumab améliore les capacités physiques, la qualité de vie globale et celle liée aux problèmes articulaires et cutanés ainsi que la productivité au travail chez des patients présentant une arthrite psoriasique active","year":2013,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.030265445166653384,"score_gpt":0.30033344028255793,"score_spread":0.27006799511590457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999694298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584138,0.017457522,0.0004906083,0.013766676,0.0009063628,0.0018611646,0.0005973893,0.0005787573,0.0059277434],"genre_scores_gemma":[0.9693108,0.023512932,0.0023426851,0.0016779315,0.00014526623,0.0009613075,0.00061181316,0.00013860548,0.0012986518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98371243,0.011121397,0.0010978032,0.0013792755,0.00021568824,0.0024733744],"domain_scores_gemma":[0.9951109,0.002411718,0.0007283649,0.00093703414,0.00052051456,0.00029146764],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016787531,0.0013226194,0.0015022501,0.000306097,0.0007138278,0.00024551764,0.0008276432,0.0022144741,0.00014058819],"category_scores_gemma":[0.001589078,0.0012053774,0.0006367139,0.00063560205,0.00294538,0.001137341,0.0004165372,0.0014859949,0.00033250978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021844765,0.009868293,0.44677398,0.001930277,0.004964734,0.0020560406,0.06403325,0.000454848,0.058742378,0.02806228,0.049739465,0.33119],"study_design_scores_gemma":[0.0060553546,0.0015476194,0.58965534,0.0014410102,0.0010697785,0.0041433144,0.013561865,0.00006788263,0.28471506,0.024873279,0.07035762,0.00251185],"about_ca_topic_score_codex":0.00974599,"about_ca_topic_score_gemma":0.009915492,"teacher_disagreement_score":0.32867813,"about_ca_system_score_codex":0.0010516112,"about_ca_system_score_gemma":0.0034976897,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W2000142077","doi":"10.1067/mjd.2003.130","title":"Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis","year":2003,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Betamethasone dipropionate; Medicine; Psoriasis; Dermatology; Betamethasone; Combination therapy; Onset of action; Pharmacology; Internal medicine","score_opus":0.02503805519354295,"score_gpt":0.29499881826161783,"score_spread":0.26996076306807487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000142077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498785,0.003924679,0.000010911629,0.00079287984,0.00007616012,0.00016520993,0.000025846506,0.0000010022427,0.00001544685],"genre_scores_gemma":[0.99674875,0.003066853,0.000142099,0.000019410312,0.0000036432834,0.00000285242,0.0000014175147,0.000005018786,0.000009933092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819356,0.00084819656,0.0006833469,0.00008920462,0.000069193105,0.00011649378],"domain_scores_gemma":[0.9972463,0.0007179954,0.0018569969,0.00010351917,0.00006214568,0.000013043576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024065455,0.000115226794,0.00076432945,0.00022196496,0.000028698547,8.7840607e-7,0.00014762479,0.00011890086,0.000005193621],"category_scores_gemma":[0.000112040114,0.00006669202,0.00014201162,0.00027436722,0.0008090053,0.00004697364,0.000016570717,0.00012723489,1.7435183e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032299664,0.002643309,0.53625166,0.0001287592,0.0017796454,0.0000064959845,0.0061921016,0.000012986594,0.38907382,0.0014464573,0.00007244013,0.059162367],"study_design_scores_gemma":[0.0036228062,0.0010725579,0.55574954,0.000042720596,0.00038096542,0.0005376744,0.0005283121,9.705278e-7,0.43749958,0.0003054284,0.00021674158,0.000042702097],"about_ca_topic_score_codex":0.00010185191,"about_ca_topic_score_gemma":0.0000037159605,"teacher_disagreement_score":0.059119664,"about_ca_system_score_codex":0.000017810708,"about_ca_system_score_gemma":0.000046039037,"threshold_uncertainty_score":0.29808137},"labels":[],"label_agreement":null},{"id":"W2000223123","doi":"10.3899/jrheum.111246","title":"Global Partnering Opportunities and Challenges of Psoriasis and Psoriatic Arthritis in Latin America: A Report from the GRAPPA 2010 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Dactylitis; Medicine; Enthesitis; Latin Americans; Psoriasis; Rheumatology; Family medicine; Dermatology; Internal medicine","score_opus":0.04147638579112378,"score_gpt":0.24852649814312924,"score_spread":0.20705011235200546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000223123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8442313,0.15327463,0.000010939214,0.0016133358,0.00066953443,0.00006869894,0.00003160573,0.000005450396,0.00009453443],"genre_scores_gemma":[0.8967431,0.10307069,0.000114911665,0.000022446455,0.000020395139,0.0000037512111,0.0000041594444,0.00000673606,0.000013783597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826676,0.0006810913,0.0006392848,0.000095703675,0.00004906167,0.00026811098],"domain_scores_gemma":[0.9980024,0.0010068453,0.00072656834,0.00017236437,0.000059775484,0.000032056338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010524552,0.00015132815,0.00055751443,0.00006104724,0.00010954924,0.000004948102,0.0001504918,0.00013695093,0.000024116518],"category_scores_gemma":[0.00024993217,0.00008929097,0.000059045065,0.00007525854,0.0003888605,0.00012117213,0.00008797039,0.00015655832,0.0000019357685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049034617,0.00013145129,0.7352118,0.000032342796,0.0008803426,0.00003923701,0.014119811,0.0000037800085,0.000467796,0.0014173412,0.0008040498,0.2464017],"study_design_scores_gemma":[0.00436238,0.0004840302,0.91328335,0.00057135907,0.00058530574,0.021840334,0.048239958,0.0000044215644,0.00059916585,0.0018789456,0.007839409,0.00031131812],"about_ca_topic_score_codex":0.0010431092,"about_ca_topic_score_gemma":0.0005268767,"teacher_disagreement_score":0.24609038,"about_ca_system_score_codex":0.0000127724725,"about_ca_system_score_gemma":0.00004297094,"threshold_uncertainty_score":0.36411798},"labels":[],"label_agreement":null},{"id":"W2000342864","doi":"10.2310/7750.2010.09063","title":"Psoriasis and Multiple Sclerosis: Is There a Link?","year":2010,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care","funders":"","keywords":"Psoriasis; Medicine; Multiple sclerosis; Cochrane Library; Dermatology; Population; Immunology; Meta-analysis; Internal medicine","score_opus":0.07254919817218239,"score_gpt":0.28240953098014765,"score_spread":0.20986033280796526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000342864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057130205,0.9910039,0.0000018112567,0.00046484408,0.0024287864,0.0001798998,0.000043187047,0.000015224662,0.00014936813],"genre_scores_gemma":[0.0011590174,0.9967587,0.00002927618,0.00020078896,0.0009758633,0.000004940232,0.000035107805,0.00004531164,0.00079099316],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777883,0.0003213322,0.0011812091,0.00028797932,0.00009971385,0.00033090386],"domain_scores_gemma":[0.9952606,0.003091204,0.0011423259,0.00025475177,0.00013663755,0.00011450052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071497355,0.0004919716,0.0030974557,0.0004989085,0.00016332054,0.00001989557,0.00015993626,0.0009173938,0.00038258903],"category_scores_gemma":[0.00048144223,0.00028994257,0.0005655156,0.00016560165,0.00030613272,0.000063789514,0.000044045595,0.0008691477,0.00003097728],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009213053,0.00004549718,0.00026192775,0.0012976386,0.0010868465,0.00045817017,0.00028925354,6.1479537e-9,0.000075893375,0.0000032736011,0.012977289,0.9834121],"study_design_scores_gemma":[0.0006361899,0.00024825134,0.000040840587,0.012213949,0.0033958117,0.020037727,0.00010568314,9.666174e-8,0.000024976534,0.000031105516,0.9630111,0.00025430627],"about_ca_topic_score_codex":0.000023246588,"about_ca_topic_score_gemma":0.000007701972,"teacher_disagreement_score":0.98315775,"about_ca_system_score_codex":0.000023623918,"about_ca_system_score_gemma":0.00023780906,"threshold_uncertainty_score":0.9999553},"labels":[],"label_agreement":null},{"id":"W2001020066","doi":"10.2310/7750.2010.09039","title":"Psoriasis Care: New and Emerging Pharmacologic Trends","year":2010,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma; Amgen","keywords":"Medicine; Psoriasis; Intensive care medicine; Dermatology","score_opus":0.048044593721489844,"score_gpt":0.3230931864136608,"score_spread":0.27504859269217097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001020066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015662761,0.9926495,0.0000021666497,0.00034494273,0.004826178,0.00009548047,0.000014658152,0.000017709708,0.00048311203],"genre_scores_gemma":[0.00029898854,0.9957219,0.000032622997,0.00012343063,0.0014132626,0.0000035365108,0.000063546475,0.00003481633,0.0023079473],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785787,0.000313038,0.0011136075,0.0002765341,0.00009162169,0.000347336],"domain_scores_gemma":[0.99677116,0.0017219239,0.0010912599,0.00016610386,0.0001002956,0.00014923459],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047968424,0.00048750572,0.0029770576,0.00089313695,0.00015287203,0.00001471513,0.00015309108,0.00066539965,0.00075711205],"category_scores_gemma":[0.00021219067,0.0002951597,0.00052973616,0.00025752003,0.00020335538,0.000062764506,0.000042151085,0.0008294335,0.00001299539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008148471,0.000026274867,0.000062469175,0.0008917606,0.0008664808,0.0010145025,0.00038278382,2.1110493e-8,0.0000771191,0.0000042915335,0.032844063,0.96374875],"study_design_scores_gemma":[0.000658968,0.00027596898,0.000009335283,0.0029465384,0.0055551357,0.028971244,0.0001631976,2.8866381e-8,0.000015665679,0.000014403204,0.9611428,0.0002467606],"about_ca_topic_score_codex":0.000024378674,"about_ca_topic_score_gemma":0.000007230306,"teacher_disagreement_score":0.963502,"about_ca_system_score_codex":0.000038734976,"about_ca_system_score_gemma":0.00034891607,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W2001025619","doi":"10.1016/j.cyto.2008.07.065","title":"25 Role of Syk in IL-4-induced human neutrophils","year":2008,"lang":"en","type":"article","venue":"Cytokine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"","keywords":"Syk; Chemistry; Immunology; Cell biology; Biology; Signal transduction","score_opus":0.02393522397176491,"score_gpt":0.239721349332064,"score_spread":0.21578612536029906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001025619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473506,0.0012340837,9.869206e-7,0.000043234155,0.00017846334,0.00012303736,0.000038633363,0.000033584358,0.0036129158],"genre_scores_gemma":[0.9988334,0.00008470509,0.000020034062,0.00002588232,0.000039583436,0.000017816848,0.000093698494,0.00001202345,0.0008728477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992454,0.0000800006,0.00023591574,0.00018889362,0.000022307142,0.00022745875],"domain_scores_gemma":[0.9996053,0.000035065026,0.000075806645,0.00024210032,0.000027466305,0.00001427228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000654726,0.00013089401,0.00028154347,0.0001334122,0.00008734226,0.0000013762972,0.00013742267,0.00016846629,0.00025754157],"category_scores_gemma":[0.000012819389,0.00011636394,0.000078317076,0.0001508187,0.00007706311,0.00004101576,0.000037249603,0.000100997284,0.00019696722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006622422,0.00020617839,0.024900777,0.0000047848503,0.000067518195,0.00002751816,0.00033660044,0.0000012796246,0.9696613,0.0005899976,0.00017521184,0.003962638],"study_design_scores_gemma":[0.0019946361,0.000226339,0.25721604,0.000016280586,0.000031807733,0.00005427512,0.000055339515,3.9081903e-7,0.734952,0.00017204072,0.0051606256,0.000120263656],"about_ca_topic_score_codex":0.00017752017,"about_ca_topic_score_gemma":0.0000492582,"teacher_disagreement_score":0.23470931,"about_ca_system_score_codex":0.000025161084,"about_ca_system_score_gemma":0.000025801499,"threshold_uncertainty_score":0.4745184},"labels":[],"label_agreement":null},{"id":"W2001467013","doi":"10.1111/j.1468-3083.2009.03221.x","title":"Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial","year":2009,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research; Western University","funders":"University of California, San Francisco; LEO Pharma; University of Sheffield","keywords":"Calcipotriol; Scalp; Medicine; Betamethasone dipropionate; Betamethasone; Psoriasis; Dermatology; Quality of life (healthcare); Randomized controlled trial; Surgery; Internal medicine","score_opus":0.015627777923780686,"score_gpt":0.25255241881348667,"score_spread":0.236924640889706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001467013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947999,0.0022294235,0.000044733664,0.0013672919,0.00017452495,0.0009634459,0.0000091694865,0.000007829099,0.00040367237],"genre_scores_gemma":[0.9993901,0.00017675928,0.00012323112,0.00017170647,0.000039999748,0.000007794896,0.0000073082424,0.0000128249385,0.00007027216],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99201775,0.0057275975,0.0016725545,0.0002037185,0.00010651184,0.0002718563],"domain_scores_gemma":[0.9962784,0.001050322,0.0023273476,0.00014929191,0.00014731202,0.000047336787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014857512,0.00026780274,0.002568431,0.00029159177,0.00009419901,0.0000035392673,0.0003011351,0.00031253454,0.000024089688],"category_scores_gemma":[0.00049510185,0.00013242352,0.00034961282,0.00022428385,0.0006200926,0.00010606136,0.000046290184,0.00043743412,0.0000023314078],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7626785,0.00052282924,0.23106717,0.000017568578,0.0012757158,0.000008049393,0.00015864904,0.000021941225,0.00049389905,0.0008172774,0.0000361795,0.0029022326],"study_design_scores_gemma":[0.64759856,0.00039143546,0.34954,0.00006677644,0.0005674981,0.0001309601,0.000016336939,0.000002949771,0.0012912058,0.0002378407,0.00004541211,0.00011102976],"about_ca_topic_score_codex":0.000007818805,"about_ca_topic_score_gemma":0.0000034514558,"teacher_disagreement_score":0.11847284,"about_ca_system_score_codex":0.000018389801,"about_ca_system_score_gemma":0.00007173235,"threshold_uncertainty_score":0.5400075},"labels":[],"label_agreement":null},{"id":"W2001731626","doi":"10.1111/1756-185x.12647","title":"Which is worse in psoriasis - skin or joints?","year":2015,"lang":"en","type":"editorial","venue":"International Journal of Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Psoriatic arthritis; Psoriasis; Embarrassment; Disease; Population; Physical therapy; Clinical psychology; Internal medicine; Dermatology; Psychology; Environmental health","score_opus":0.017221961249226474,"score_gpt":0.29026768439785955,"score_spread":0.27304572314863307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001731626","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028760618,0.008982627,0.00001605505,0.00043569287,0.9590951,0.00020248495,0.0018561255,0.000025335672,0.0006259702],"genre_scores_gemma":[0.25533524,0.022763602,0.00067883194,0.00029638,0.6875511,0.00015105367,0.004767308,0.00030140273,0.028155081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997126,0.00033020493,0.0013080237,0.00030485206,0.00061324204,0.00031770434],"domain_scores_gemma":[0.9952813,0.0012546184,0.0013128978,0.00028032975,0.0017679014,0.000102986196],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055982557,0.00042353998,0.0009620609,0.00078857277,0.00004540365,0.00009705333,0.0011060813,0.00063951075,0.0031558655],"category_scores_gemma":[0.00393262,0.00030960081,0.00038847022,0.00023042591,0.00008575199,0.00029529855,0.0001424849,0.0005650989,0.00051013986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023873742,0.00072943734,0.0006977572,0.000054179993,0.0026216828,0.00017101555,0.0006284108,0.000007773603,0.000011200685,0.00001215293,0.95332,0.039358985],"study_design_scores_gemma":[0.012125791,0.0005558905,0.0029062813,0.0033978615,0.0012052748,0.00022668575,0.0006381196,0.000004978863,0.00023923849,0.0012445109,0.9768141,0.00064129266],"about_ca_topic_score_codex":0.00015923446,"about_ca_topic_score_gemma":0.0002207636,"teacher_disagreement_score":0.27154398,"about_ca_system_score_codex":0.00043984043,"about_ca_system_score_gemma":0.0017338395,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W2001961359","doi":"10.3899/jrheum.140178","title":"Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Epidemiology; Data science; Informatics; Health informatics; MEDLINE; Comparative effectiveness research; Medical record; Health care; Disease; Database; Alternative medicine; Public health; Pathology; Computer science; Surgery; Dermatology","score_opus":0.060755495644239606,"score_gpt":0.34840782361243394,"score_spread":0.28765232796819434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001961359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95897496,0.038203757,0.0001729722,0.0016947736,0.00068750593,0.00019351277,0.000032956257,0.000007104567,0.000032450294],"genre_scores_gemma":[0.98201,0.017610364,0.00022052768,0.00003873094,0.000045084947,0.000007198926,0.000014765083,0.00001690374,0.00003643473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924676,0.0057273433,0.0007527336,0.00024294118,0.00016187665,0.0006475299],"domain_scores_gemma":[0.98928154,0.009617832,0.00036924038,0.0004170904,0.00027040252,0.000043881617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013295432,0.00017289752,0.0006143641,0.00029508787,0.0007313968,0.00003082402,0.00035775438,0.00018451766,0.000038148242],"category_scores_gemma":[0.0015940159,0.00009666792,0.000062709056,0.00033694645,0.00067671173,0.0001615728,0.0003417357,0.00090624584,0.0000100437255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058741536,0.00012759004,0.9639791,0.000015305997,0.0005242068,0.00007830884,0.0036975986,0.000025018051,0.00041980407,0.0006680508,0.004537272,0.025340302],"study_design_scores_gemma":[0.024270415,0.0014438785,0.81254834,0.0030704853,0.00081537844,0.051277652,0.044147525,0.0011105727,0.0009519154,0.0153618045,0.043997213,0.0010048338],"about_ca_topic_score_codex":0.006412501,"about_ca_topic_score_gemma":0.0035360847,"teacher_disagreement_score":0.1514308,"about_ca_system_score_codex":0.000030265172,"about_ca_system_score_gemma":0.00008867847,"threshold_uncertainty_score":0.9693826},"labels":[],"label_agreement":null},{"id":"W2002327634","doi":"10.3899/jrheum.100293","title":"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus","year":2010,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Serositis; Lupus nephritis; Immunology; Pathogenesis; Internal medicine; Cytokine; Lupus erythematosus; Interleukin; Systemic lupus erythematosus; Nephritis; Interleukin 17; Disease; Antibody","score_opus":0.009380575987566772,"score_gpt":0.228745200390258,"score_spread":0.21936462440269122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002327634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943732,0.0032317345,0.000047443526,0.0012308001,0.000884669,0.00017338649,0.000017963393,0.0000063000507,0.000034482167],"genre_scores_gemma":[0.9983019,0.0013947602,0.000022748281,0.000017610368,0.0000069021767,0.000005814179,0.000001976699,0.000008632956,0.0002396365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988228,0.00043251138,0.00041019858,0.00010731611,0.000037237816,0.00018992748],"domain_scores_gemma":[0.99826777,0.0009785328,0.00042477148,0.00021659838,0.00006600456,0.00004634478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078180386,0.00013818467,0.0003909581,0.00013030083,0.00014460752,0.000009428159,0.00019793861,0.00014911681,0.000012610246],"category_scores_gemma":[0.00027740514,0.00007420545,0.000058579884,0.00008897634,0.00025424827,0.00008161625,0.000081364706,0.00029492695,0.000007643446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061150366,0.00014900253,0.7100394,0.00008910707,0.00044057073,0.000018498396,0.003584982,0.000012771822,0.26429415,0.0018935256,0.0014114175,0.011951566],"study_design_scores_gemma":[0.011168215,0.0015137789,0.87590176,0.0011086308,0.0009524674,0.07538847,0.0033812344,0.00006735856,0.019009521,0.0066351197,0.0042899814,0.00058346207],"about_ca_topic_score_codex":0.00007262836,"about_ca_topic_score_gemma":0.0004921682,"teacher_disagreement_score":0.24528462,"about_ca_system_score_codex":0.00001631464,"about_ca_system_score_gemma":0.000060819693,"threshold_uncertainty_score":0.30260104},"labels":[],"label_agreement":null},{"id":"W2003027167","doi":"10.1007/s13555-014-0043-4","title":"Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy","year":2014,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Medicine; Discontinuation; Psoriasis; Dermatology Life Quality Index; Adalimumab; Psoriasis Area and Severity Index; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Placebo; Severity of illness; Physical therapy; Disease; Dermatology","score_opus":0.020566537768950222,"score_gpt":0.26867663484768733,"score_spread":0.2481100970787371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003027167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856119,0.012559429,0.00014657814,0.0007136065,0.00029487346,0.00037424828,0.000089175745,0.000024452522,0.00018574194],"genre_scores_gemma":[0.99804026,0.0013745994,0.00009026656,0.00031548942,0.000010241034,0.000045796696,0.000053639043,0.000015330696,0.000054389366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766594,0.00090531877,0.00082893873,0.0002831907,0.000053415402,0.00026320442],"domain_scores_gemma":[0.9986511,0.0003363752,0.00054138637,0.00028575258,0.00013680203,0.00004857485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003587181,0.00021578795,0.00096736074,0.00016258456,0.00008556975,0.0000018669904,0.000117933996,0.0003081472,0.0001773605],"category_scores_gemma":[0.000050022187,0.00016768421,0.00014837433,0.00019351122,0.00037955976,0.000047271275,0.000025024268,0.00011064739,0.00001247421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026492923,0.0019841609,0.6347383,0.00017903038,0.0045006694,0.000007134831,0.013991814,0.000012302201,0.13367297,0.0126431445,0.00033366258,0.17144388],"study_design_scores_gemma":[0.011442126,0.0017506168,0.7515524,0.00005955397,0.00005358861,0.00008119832,0.0004908072,0.0000022326726,0.22928452,0.00300331,0.0019200465,0.0003596204],"about_ca_topic_score_codex":0.00046722722,"about_ca_topic_score_gemma":0.000094089046,"teacher_disagreement_score":0.17108427,"about_ca_system_score_codex":0.000009376957,"about_ca_system_score_gemma":0.00009493195,"threshold_uncertainty_score":0.68379635},"labels":[],"label_agreement":null},{"id":"W2003059802","doi":"10.1111/jdv.12677","title":"Adalimumab retreatment successfully restores clinical response and health‐related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption","year":2014,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"AbbVie","keywords":"Medicine; Adalimumab; Psoriasis; Regimen; Psoriasis Area and Severity Index; Quality of life (healthcare); Dosing; Severity of illness; Dermatology Life Quality Index; Internal medicine; Surgery; Drug withdrawal; Drug; Disease; Dermatology; Pharmacology","score_opus":0.056016352291885306,"score_gpt":0.3229741263617203,"score_spread":0.266957774069835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003059802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885115,0.0027565735,0.000026809175,0.008200578,0.00024033913,0.000189757,0.00001042406,0.0000055728856,0.00005843035],"genre_scores_gemma":[0.9984177,0.00080593367,0.00009822601,0.00059035484,0.000018896859,0.0000015235728,0.0000035363773,0.000014763694,0.000049072827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.989372,0.00877893,0.0013416276,0.00022372644,0.0000611809,0.00022251166],"domain_scores_gemma":[0.99772096,0.00063688884,0.0013451269,0.00015660607,0.00007397786,0.000066433015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002236533,0.00018939018,0.00095050904,0.00021038967,0.00009826157,0.000003486366,0.00024748367,0.00027252443,0.0000094032275],"category_scores_gemma":[0.0002854184,0.00011745523,0.00010499622,0.00012705322,0.00042939544,0.000073845375,0.000111077796,0.00040744405,0.0000026086407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02665336,0.00029868638,0.9606366,0.000027688997,0.00055143,0.000004287756,0.00066739874,0.000036699617,0.00025304707,0.00043566452,0.0003393306,0.010095785],"study_design_scores_gemma":[0.011146612,0.000823137,0.98619545,0.00012201392,0.00006161101,0.00022900561,0.00005789602,0.0000028297657,0.00055905705,0.00032131924,0.0003770031,0.00010406763],"about_ca_topic_score_codex":0.000030334475,"about_ca_topic_score_gemma":0.000026628139,"teacher_disagreement_score":0.025558827,"about_ca_system_score_codex":0.00002919969,"about_ca_system_score_gemma":0.000077898665,"threshold_uncertainty_score":0.47896853},"labels":[],"label_agreement":null},{"id":"W2004570679","doi":"10.1067/mjd.2001.117850","title":"The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody","year":2001,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Internal medicine; Gastroenterology; White blood cell; Surgery; Immunology; Pathology","score_opus":0.017956186068602137,"score_gpt":0.28486302243096984,"score_spread":0.26690683636236767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004570679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836938,0.003386613,0.0001266335,0.012205736,0.00025045697,0.00019804646,0.000020029445,0.0000073721476,0.000111359775],"genre_scores_gemma":[0.99406236,0.0045335577,0.0004453733,0.00031569236,0.000067772155,0.000004429365,0.000002166521,0.000017345266,0.00055127667],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983643,0.00034649987,0.0006616826,0.00016621035,0.0000978024,0.00036345367],"domain_scores_gemma":[0.9979393,0.00034928593,0.0013513725,0.0002150949,0.000080380436,0.00006455449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000103366794,0.00024178058,0.00092003593,0.0001527312,0.00017999811,0.0000071546688,0.00054552784,0.00012604888,0.00002626829],"category_scores_gemma":[0.000027329028,0.000116914714,0.00031233212,0.0003985806,0.00051873847,0.00006932344,0.00004714791,0.00019962458,0.000016089176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022222634,0.0017200891,0.4920667,0.000027583668,0.009736653,0.00015097925,0.0031191243,0.001058796,0.2905341,0.00088284526,0.011591504,0.16688895],"study_design_scores_gemma":[0.011832755,0.004463391,0.3695811,0.00016247312,0.0019499671,0.032886814,0.0012379668,0.000017032518,0.43811843,0.00073501613,0.13846901,0.0005460395],"about_ca_topic_score_codex":0.00010742484,"about_ca_topic_score_gemma":0.000013616528,"teacher_disagreement_score":0.16634291,"about_ca_system_score_codex":0.00004980485,"about_ca_system_score_gemma":0.00019414649,"threshold_uncertainty_score":0.47676438},"labels":[],"label_agreement":null},{"id":"W2004774344","doi":"10.1016/j.chom.2008.09.009","title":"Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine","year":2008,"lang":"en","type":"article","venue":"Cell Host & Microbe","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1748,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Howard Hughes Medical Institute","keywords":"Biology; FOXP3; Lamina propria; Immunology; RAR-related orphan receptor gamma; Cellular differentiation; Microbiology; Cell biology; Immunity; Gut flora; Inflammation; Cell; Intestinal mucosa; Effector; Immune system; Epithelium; Internal medicine","score_opus":0.01989031726558024,"score_gpt":0.19411463535177653,"score_spread":0.1742243180861963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004774344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911018,0.0058124736,0.000011800918,0.00024439933,0.0007417545,0.0005206406,0.00013416276,0.000015043848,0.0014179475],"genre_scores_gemma":[0.9959017,0.00064196036,0.000065657136,0.00010549727,0.000051470888,0.000015789736,0.00007631901,0.000020279736,0.0031213332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837065,0.0004844695,0.00045375648,0.00033687346,0.00004291125,0.00031132135],"domain_scores_gemma":[0.99844265,0.0003630222,0.00030835287,0.0008001844,0.00007644248,0.000009328409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000363401,0.00024925172,0.00033780193,0.00008306031,0.00024210395,0.000008991341,0.0006708888,0.00015920954,0.0001670495],"category_scores_gemma":[0.000030109733,0.00012640328,0.00022393434,0.00035960096,0.00038222884,0.00003123695,0.00014869269,0.00025830095,0.00007509816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007106649,0.00035289195,0.010893983,0.000025637673,0.00005988771,0.0000025832717,0.0044727423,0.0000063486395,0.97791815,0.000009453992,0.005472952,0.0007142795],"study_design_scores_gemma":[0.0008149853,0.000057844427,0.11735346,0.000056135403,0.00008451162,0.000041047922,0.00029260872,5.685316e-7,0.8699599,0.000005562759,0.011212782,0.00012058417],"about_ca_topic_score_codex":0.00022056761,"about_ca_topic_score_gemma":0.00010467783,"teacher_disagreement_score":0.107958265,"about_ca_system_score_codex":0.000034696703,"about_ca_system_score_gemma":0.000048151833,"threshold_uncertainty_score":0.5154576},"labels":[],"label_agreement":null},{"id":"W2005063145","doi":"10.1159/000018309","title":"Calcipotriol Cream Combined with Twice Weekly Broad-Band UVB Phototherapy: A Safe, Effective and UVB-Sparing Antipsoriatric Combination Treatment","year":2000,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Probity Medical Research; Hôpital de l'Enfant-Jésus; Women's College Hospital; University of Toronto","funders":"","keywords":"Calcipotriol; Medicine; Erythema; Dermatology; Psoriasis; Cumulative dose; Skin type; Ultraviolet therapy; Broad band; Prospective cohort study; Internal medicine","score_opus":0.007162276871311988,"score_gpt":0.21994819765907056,"score_spread":0.21278592078775857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005063145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870559,0.004978574,0.000021427033,0.00033053345,0.00027612702,0.0010751303,0.00003617417,0.00012238376,0.00610378],"genre_scores_gemma":[0.9955868,0.0012444854,0.00005893613,0.00014706697,0.000025524232,0.00030496047,0.00019525869,0.000035881134,0.0024011026],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981262,0.00046044114,0.00032288925,0.0005377262,0.00004441651,0.0005082951],"domain_scores_gemma":[0.9990544,0.00038936263,0.00014121477,0.00030621633,0.00005419038,0.000054644253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008102552,0.00041341977,0.0007066191,0.0002231416,0.00035499356,0.000025737601,0.00012435745,0.0003848889,0.00059335085],"category_scores_gemma":[0.000010270451,0.00031940645,0.00009631379,0.00027090678,0.00021866497,0.00012166849,0.000016849355,0.00014759591,0.00039552822],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034902245,0.008265213,0.29599884,0.00025716468,0.008404862,0.00089123467,0.009281722,0.000034661545,0.1280348,0.0026472057,0.0030562903,0.50822574],"study_design_scores_gemma":[0.07214914,0.01358217,0.33135858,0.00012367743,0.0016815918,0.004900402,0.00036939167,0.000053985248,0.4847503,0.00039315855,0.0891415,0.0014960864],"about_ca_topic_score_codex":0.0004304357,"about_ca_topic_score_gemma":0.00017136618,"teacher_disagreement_score":0.50672966,"about_ca_system_score_codex":0.00008657137,"about_ca_system_score_gemma":0.000057949856,"threshold_uncertainty_score":0.9999258},"labels":[],"label_agreement":null},{"id":"W2005618682","doi":"10.1016/j.jaad.2003.10.548","title":"Oral tazarotene improves scalp psoriasis","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Tazarotene; Medicine; Psoriasis; Placebo; Dermatology; Scalp; Pathology","score_opus":0.014579817447976245,"score_gpt":0.26943845640454794,"score_spread":0.2548586389565717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005618682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98359406,0.002845356,0.000068603724,0.012461745,0.00071475055,0.00013732043,0.0000117307045,0.000013401895,0.00015300549],"genre_scores_gemma":[0.99753433,0.00051019574,0.00089418713,0.0008292749,0.00006807662,0.0000047866224,0.0000013520896,0.000016356546,0.00014144578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824286,0.00039352322,0.0007823403,0.00015192543,0.000082596685,0.0003467551],"domain_scores_gemma":[0.99777603,0.00017287796,0.001780342,0.00016430845,0.00006495754,0.00004145982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019643345,0.00021037734,0.001021994,0.00020633529,0.00011817857,0.0000051437955,0.000689691,0.00020271046,0.00003818522],"category_scores_gemma":[0.00012994645,0.00012717798,0.0005132006,0.0003257147,0.0009082994,0.00010931165,0.000110682275,0.00047017724,0.000048812155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003085012,0.0005910094,0.018149927,0.00003431463,0.0028515118,0.000052666288,0.00050858804,0.000061153834,0.8920625,0.002062243,0.0049898652,0.07555124],"study_design_scores_gemma":[0.01102195,0.00052574015,0.110840976,0.000084886895,0.0009873796,0.013027756,0.00041685684,7.702516e-7,0.8430063,0.0036101213,0.016183717,0.00029351073],"about_ca_topic_score_codex":0.000044302953,"about_ca_topic_score_gemma":0.000002614464,"teacher_disagreement_score":0.09269105,"about_ca_system_score_codex":0.000053898573,"about_ca_system_score_gemma":0.00014510368,"threshold_uncertainty_score":0.51861674},"labels":[],"label_agreement":null},{"id":"W2005900651","doi":"10.1371/journal.pone.0027629","title":"Interleukin-19: A Constituent of the Regulome That Controls Antigen Presenting Cells in the Lungs and Airway Responses to Microbial Products","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; York University; National Institute of Environmental Health Sciences; Flight Attendant Medical Research Institute; American Heart Association","keywords":"CD11c; Bronchoalveolar lavage; Biology; Immunology; Extracellular; Cytokine; Immune system; Dendritic cell; Interleukin 4; Tumor necrosis factor alpha; Inflammation; Molecular biology; Medicine; Lung; Cell biology; Internal medicine; Phenotype","score_opus":0.05535491326090313,"score_gpt":0.2209820809265593,"score_spread":0.16562716766565616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005900651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636745,0.001240559,0.0000011440554,0.0005666,0.00016823907,0.000979118,0.000075841075,0.0000144099395,0.0005866253],"genre_scores_gemma":[0.9974846,0.00008391738,0.00016284229,0.00019929014,0.000024504941,0.00005543182,0.000005852596,0.000008946924,0.001974588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875915,0.00047151165,0.00021993599,0.00025354122,0.00005039092,0.0002454929],"domain_scores_gemma":[0.9992176,0.00021984479,0.000120519355,0.0003760721,0.00004958173,0.000016334325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040047598,0.00014154114,0.00027886964,0.00008664898,0.0001106492,0.000011464095,0.00029834616,0.00009571312,0.000044688863],"category_scores_gemma":[0.00019450097,0.00008310515,0.00005073754,0.00013930087,0.0002503559,0.00004907896,0.0001310181,0.00011447985,0.0000321394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007482271,0.0006698994,0.0786069,0.000040983803,0.00032049563,0.000007920074,0.005948304,6.100787e-8,0.9130582,0.00008357502,0.0003119503,0.00020347956],"study_design_scores_gemma":[0.0010375809,0.000112813555,0.0923218,0.00013206764,0.00016146952,0.00001860744,0.00037890617,2.0629854e-7,0.9051195,0.000020515687,0.0006041218,0.00009244425],"about_ca_topic_score_codex":0.00020521686,"about_ca_topic_score_gemma":0.00009530029,"teacher_disagreement_score":0.013714893,"about_ca_system_score_codex":0.000016277841,"about_ca_system_score_gemma":0.00005769644,"threshold_uncertainty_score":0.338893},"labels":[],"label_agreement":null},{"id":"W2005983782","doi":"10.1016/j.cjca.2014.11.013","title":"The Fire Within Psoriatic Patients: Overlap Between Inflammatory and Cardiovascular Diseases","year":2014,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Psoriatic arthritis; Internal medicine","score_opus":0.00908640177976387,"score_gpt":0.18287622517797653,"score_spread":0.17378982339821267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005983782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48861197,0.36547878,0.00013031208,0.10378602,0.035552993,0.0017185676,0.0024443867,0.00007078872,0.002206191],"genre_scores_gemma":[0.9393326,0.002604334,0.000021103417,0.03496325,0.02051573,0.000053923864,0.0011979328,0.00017206055,0.0011390598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968557,0.0014148093,0.00068392855,0.0003085137,0.00009400144,0.00064308767],"domain_scores_gemma":[0.99776196,0.0007188385,0.00051518145,0.0005637898,0.00027116638,0.0001690802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005896084,0.0004073423,0.0014011774,0.00023006047,0.00050455093,0.000049863076,0.0005128302,0.0012189472,0.000014464438],"category_scores_gemma":[0.00039396604,0.00027988266,0.00086183334,0.00007565737,0.00062023854,0.0000681274,0.000033961067,0.0012041639,0.000054986664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032203763,9.728138e-7,0.110654116,0.00005185955,0.0096285725,0.00032281547,0.00010128033,0.000029878764,0.0000017304959,0.000022911247,0.84975475,0.029398888],"study_design_scores_gemma":[0.0012187473,0.00022244228,0.055673394,0.000067498106,0.0027006976,0.0002496005,0.000036290414,1.0363484e-7,0.0000069872117,0.00019239953,0.9393593,0.00027254887],"about_ca_topic_score_codex":0.0003230215,"about_ca_topic_score_gemma":0.00015907994,"teacher_disagreement_score":0.45072064,"about_ca_system_score_codex":0.00015320707,"about_ca_system_score_gemma":0.0009218153,"threshold_uncertainty_score":0.9999653},"labels":[],"label_agreement":null},{"id":"W2007128909","doi":"10.1016/j.jval.2013.03.1151","title":"Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Psoriatic arthritis; Dermatology Life Quality Index; Placebo; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Psoriasis; Physical therapy; Arthritis; Etanercept; Rheumatoid arthritis; Dermatology","score_opus":0.04403238897080384,"score_gpt":0.3055460466635542,"score_spread":0.26151365769275037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007128909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811781,0.0012645829,0.0000025106287,0.00023200783,0.00074874226,0.016259175,0.00016550219,0.000029702564,0.0001196898],"genre_scores_gemma":[0.99787265,0.00015676997,0.000015826476,0.000020271378,0.000008121718,0.0015181049,0.0002450309,0.00002656787,0.000136679],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9900194,0.0050097327,0.0037936016,0.0005059039,0.00022615868,0.00044519687],"domain_scores_gemma":[0.99009955,0.005319886,0.0034581085,0.00081725453,0.00024801856,0.00005720273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023700346,0.00038125922,0.002579367,0.00028687654,0.000117965305,0.000007775884,0.00019948873,0.00021533607,0.00009805411],"category_scores_gemma":[0.004517693,0.00023309543,0.00038522773,0.00032548344,0.00016431932,0.00006655166,0.000050742914,0.00024569425,0.000024981648],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9571363,0.009993199,0.008999869,0.00016209736,0.001890497,0.000030039342,0.004845524,0.000086332504,0.0022983605,0.000013983708,0.00046666336,0.014077157],"study_design_scores_gemma":[0.9563799,0.01554159,0.000889223,0.00026860583,0.00033829283,0.00002378196,0.0004203863,0.00014066609,0.025762716,0.00002748693,0.00002713032,0.00018024218],"about_ca_topic_score_codex":0.020043124,"about_ca_topic_score_gemma":0.00008918624,"teacher_disagreement_score":0.023464356,"about_ca_system_score_codex":0.00010369443,"about_ca_system_score_gemma":0.00017645782,"threshold_uncertainty_score":0.9864825},"labels":[],"label_agreement":null},{"id":"W2007200101","doi":"10.1016/j.clim.2014.06.006","title":"Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes","year":2014,"lang":"en","type":"review","venue":"Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Ustekinumab; Medicine; Immunology; Type 1 diabetes; Psoriasis; Interleukin 23; Secretion; Monoclonal antibody; Disease; Type 2 diabetes; Blockade; Monoclonal; Diabetes mellitus; Interleukin 17; Antibody; Cytokine; Internal medicine; Endocrinology; Tumor necrosis factor alpha; Receptor","score_opus":0.11466244844011708,"score_gpt":0.40902976763958043,"score_spread":0.29436731919946335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007200101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012329929,0.97820616,0.00008411719,0.00043796914,0.017428318,0.0020655016,0.00015292625,0.00017821473,0.00021380931],"genre_scores_gemma":[0.000114053895,0.98288465,0.00020799729,0.0008642046,0.002492929,0.00032613915,0.0018494294,0.00014657201,0.011114039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98955786,0.0044561047,0.0033312156,0.0014030173,0.0000646037,0.0011871873],"domain_scores_gemma":[0.98605114,0.0105852205,0.0015926417,0.0014571089,0.00021757754,0.00009632386],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0033877343,0.0009787583,0.004764119,0.00015063568,0.0005317326,0.00005264785,0.0016820008,0.004095431,0.001210202],"category_scores_gemma":[0.0033539007,0.00059361546,0.0033771824,0.00029590147,0.001305269,0.000060956274,0.0004116793,0.001892418,0.0049652494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005027058,0.00040088143,0.000099592995,0.00017270123,0.0071447473,0.0000057466864,0.000019093583,1.5558831e-7,0.000029165942,0.00017696881,0.057411563,0.9340367],"study_design_scores_gemma":[0.0034477655,0.0031606713,0.00015338146,0.0005553747,0.0031095878,0.000044893717,0.0000174919,0.0000010823591,0.000013695199,0.0005166166,0.9883633,0.0006160983],"about_ca_topic_score_codex":0.000030468078,"about_ca_topic_score_gemma":0.00000562735,"teacher_disagreement_score":0.9334206,"about_ca_system_score_codex":0.000049112088,"about_ca_system_score_gemma":0.00095325516,"threshold_uncertainty_score":0.9997028},"labels":[],"label_agreement":null},{"id":"W2007939198","doi":"10.2310/7750.2009.08082","title":"Update on Intralesional Steroid: Focus on Dermatoses","year":2010,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Medicine; Dermatology; Psoriasis; Alopecia areata; Food and drug administration; Triamcinolone acetonide; Surgery","score_opus":0.04312898939655487,"score_gpt":0.29401649618909625,"score_spread":0.2508875067925414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007939198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042390716,0.9912015,0.0000013132561,0.00067291176,0.0032761937,0.00014148102,0.000036298705,0.0000138287505,0.00041739407],"genre_scores_gemma":[0.0010662588,0.99706,0.000009793826,0.00039022998,0.0007954012,0.000004659111,0.000086781205,0.00003748987,0.0005494052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779457,0.00039287907,0.0011296681,0.0002423769,0.00011936969,0.00032115393],"domain_scores_gemma":[0.9952688,0.0032677578,0.0010443304,0.00023704197,0.00008513658,0.00009688344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049043616,0.00047962394,0.0026448655,0.00069020066,0.00012491169,0.000012329768,0.00018291816,0.0006463518,0.00048557247],"category_scores_gemma":[0.0002707198,0.00026782067,0.00057112885,0.000098679106,0.0002026548,0.000041668573,0.000023585088,0.0009959956,0.00017411193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025284625,0.00012082094,0.00001847605,0.0005450356,0.0006434787,0.001875476,0.00004309695,4.5947328e-8,0.0000426397,0.00005144832,0.03743883,0.9589678],"study_design_scores_gemma":[0.00040292914,0.00055157364,0.000006888309,0.010336658,0.0013622111,0.036314834,0.000018074623,1.884452e-8,0.00006481913,0.00009069682,0.95063215,0.00021911388],"about_ca_topic_score_codex":0.0000033042215,"about_ca_topic_score_gemma":0.0000035356543,"teacher_disagreement_score":0.9587487,"about_ca_system_score_codex":0.000037273705,"about_ca_system_score_gemma":0.00027219215,"threshold_uncertainty_score":0.9999774},"labels":[],"label_agreement":null},{"id":"W2008064568","doi":"10.2147/ptt.s74906","title":"Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study","year":2014,"lang":"en","type":"article","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Disease; Medicine; Ethnography; Dermatology; Internal medicine; History","score_opus":0.014067794272409485,"score_gpt":0.23797462818869777,"score_spread":0.2239068339162883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008064568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960903,0.0016241922,0.000027346377,0.00014603061,0.0005476611,0.0012918013,0.00006572573,0.00012383609,0.000083125444],"genre_scores_gemma":[0.99873644,0.00024472573,0.0001502,0.00026670058,0.000066748275,0.0002525854,0.00012624206,0.00005079064,0.00010554818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774784,0.0004223795,0.00041054442,0.0008212229,0.00013070961,0.00046729692],"domain_scores_gemma":[0.9987343,0.00009650137,0.00020390692,0.0005794362,0.000154097,0.00023178842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002386474,0.0004934548,0.00059366954,0.00021830054,0.00049621094,0.000083457555,0.00014680752,0.000150625,0.0000645253],"category_scores_gemma":[0.00003877161,0.00033125957,0.00009206266,0.00019460428,0.000118056305,0.0002499129,0.000065380365,0.00013238702,0.000009734424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029004703,0.0008929689,0.77890986,0.000005973768,0.0011529031,0.000008318647,0.0050856657,0.000016046708,0.00007622042,0.00002846604,0.00007228277,0.21085082],"study_design_scores_gemma":[0.0108448975,0.0026412718,0.9803299,0.000020386307,0.00028071023,0.0000022947884,0.00079755945,0.000008991777,0.00024011651,0.00020864696,0.0040949513,0.00053028745],"about_ca_topic_score_codex":0.0003532506,"about_ca_topic_score_gemma":0.00008832299,"teacher_disagreement_score":0.21032053,"about_ca_system_score_codex":0.000014262569,"about_ca_system_score_gemma":0.00002055946,"threshold_uncertainty_score":0.99991393},"labels":[],"label_agreement":null},{"id":"W2008716526","doi":"10.1016/j.jaad.2006.05.027","title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":507,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Adalimumab; Open label; Psoriasis; Randomized controlled trial; Double blind; Dermatology; Surgery; Internal medicine; Placebo; Alternative medicine; Tumor necrosis factor alpha","score_opus":0.03691857886856944,"score_gpt":0.3417004839563627,"score_spread":0.3047819050877933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008716526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846525,0.0004726679,0.000012574313,0.0043202657,0.0003633664,0.0063299197,0.000011783135,0.000006381275,0.00001776451],"genre_scores_gemma":[0.99869627,0.00006536621,0.00032883673,0.00044814037,0.000041068077,0.00022346115,0.0000021952603,0.000019391,0.00017529653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9924652,0.004963103,0.0017924686,0.00033134766,0.00012462844,0.00032324027],"domain_scores_gemma":[0.99609244,0.0016939477,0.0017936293,0.00022125774,0.0001264898,0.00007224815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015560281,0.0003122254,0.0035521935,0.0003759581,0.00011902514,0.000019738596,0.00048856944,0.00017556617,0.000007674055],"category_scores_gemma":[0.0002601653,0.00016103222,0.0002436966,0.00033789992,0.00031651216,0.00010457971,0.00017540502,0.00029760067,0.000007560131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96346074,0.004191141,0.027391836,0.0000017932892,0.0015243867,0.000022240722,0.00027133705,0.00006142422,0.00042787736,0.000015215755,0.00033942363,0.002292601],"study_design_scores_gemma":[0.93912554,0.0063799536,0.052159432,0.000043388958,0.0010394271,0.00018485427,0.00017419028,0.0000026371301,0.00050209847,0.00004111503,0.00018252342,0.00016486291],"about_ca_topic_score_codex":0.00016291038,"about_ca_topic_score_gemma":0.000038672086,"teacher_disagreement_score":0.024767596,"about_ca_system_score_codex":0.0000781554,"about_ca_system_score_gemma":0.00018567218,"threshold_uncertainty_score":0.65667033},"labels":[],"label_agreement":null},{"id":"W2008807002","doi":"10.2165/00002018-200831080-00008","title":"Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis","year":2008,"lang":"en","type":"article","venue":"Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Genentech; Abbott Laboratories","keywords":"Efalizumab; Medicine; Psoriasis; Placebo; Internal medicine; Dermatology; Plaque psoriasis; Surgery; Pathology","score_opus":0.010667903469793037,"score_gpt":0.20868609147315725,"score_spread":0.1980181880033642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008807002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655896,0.0004215262,0.000046058554,0.00012979875,0.0002712426,0.00048956566,0.00022128689,0.000037867783,0.0018236776],"genre_scores_gemma":[0.9975976,0.00034162437,0.0002234084,0.0001231855,0.000015706504,0.00002721148,0.00025454635,0.0000230177,0.00139372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872315,0.00020897728,0.0003544679,0.00032259003,0.00006545112,0.0003253488],"domain_scores_gemma":[0.99933296,0.00009473463,0.00010281016,0.00034311932,0.00009489251,0.0000314962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013342485,0.00023210814,0.0004232144,0.00013348841,0.00015924816,0.0000025752508,0.00017595117,0.00013788401,0.0003054602],"category_scores_gemma":[0.0000140012135,0.00017480232,0.0000817181,0.00028551873,0.00007871801,0.00008480778,0.000040103725,0.000108461245,0.00014697056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06374462,0.002078626,0.7425572,0.00002577963,0.001115153,0.00002893066,0.012218375,0.0009744548,0.0016248224,0.00043854868,0.0022949101,0.17289853],"study_design_scores_gemma":[0.017453749,0.00047592522,0.9596504,0.00004667122,0.000034901142,0.000011274376,0.0001150437,0.0000019135719,0.012733319,0.00003208577,0.009109561,0.00033513852],"about_ca_topic_score_codex":0.0002253265,"about_ca_topic_score_gemma":0.000111114365,"teacher_disagreement_score":0.21709315,"about_ca_system_score_codex":0.00007490484,"about_ca_system_score_gemma":0.00007314556,"threshold_uncertainty_score":0.7128232},"labels":[],"label_agreement":null},{"id":"W2008995310","doi":"10.6000/1927-5951.2014.04.02.9","title":"Response to Ustekinumab in a Patient with Severe Psoriasis when Adalimumab Dose Escalation Fails","year":2014,"lang":"en","type":"article","venue":"Journal of Pharmacy and Nutrition Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adalimumab; Ustekinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Tolerability; Dermatology; Internal medicine; Adverse effect; Disease","score_opus":0.025223814153381315,"score_gpt":0.28611376182423215,"score_spread":0.26088994767085083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008995310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963455,0.000935107,0.00013959286,0.0020146426,0.00026944946,0.00016215966,0.000008217022,0.000006534044,0.00011878245],"genre_scores_gemma":[0.9985148,0.00012917302,0.0010363875,0.0002253354,0.00004362465,0.0000107192745,0.0000020957264,0.0000035250507,0.00003438287],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878603,0.00047221905,0.0003101429,0.00015746779,0.00010143635,0.00017268621],"domain_scores_gemma":[0.9993263,0.00027542247,0.00019996562,0.000055684523,0.00009644793,0.000046178426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010163814,0.000104703075,0.00019985127,0.0003520471,0.00016635015,0.000046856938,0.00011361497,0.000042870623,0.00009372921],"category_scores_gemma":[0.000077579876,0.00007167379,0.000043536173,0.00027474904,0.00009932457,0.00046161024,0.000019033245,0.0000952112,0.000012602789],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07577651,0.0018994737,0.036762588,0.00007810879,0.00022210213,0.0001329417,0.010863267,0.00020257705,0.3566588,0.00031331318,0.0040782113,0.5130121],"study_design_scores_gemma":[0.10714457,0.024759647,0.10600248,0.0017702801,0.00060654874,0.00775671,0.011116899,0.00027789222,0.40379986,0.004361356,0.33093673,0.0014670276],"about_ca_topic_score_codex":0.000022602697,"about_ca_topic_score_gemma":0.000019815565,"teacher_disagreement_score":0.5115451,"about_ca_system_score_codex":0.00003503505,"about_ca_system_score_gemma":0.000059934147,"threshold_uncertainty_score":0.29227725},"labels":[],"label_agreement":null},{"id":"W2009152675","doi":"10.2298/mpns0404171b","title":"Heredity of psoriasis","year":2004,"lang":"en","type":"article","venue":"Medicinski pregled","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Proband; Medicine; Heredity; Penetrance; Genetic predisposition; First-degree relatives; Disease; Epidemiology; Family aggregation; Family history; Dermatology; Genetics; Internal medicine; Phenotype; Mutation; Gene; Biology","score_opus":0.016501396187612892,"score_gpt":0.2396511155483401,"score_spread":0.2231497193607272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009152675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98642296,0.0040233685,0.0002343482,0.0003291544,0.0018952991,0.00022498687,0.000028749737,0.00009111752,0.006749992],"genre_scores_gemma":[0.99821186,0.00010939736,0.00019912068,0.00007252383,0.000102854894,0.000021328238,0.000072218245,0.000012272387,0.0011984109],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913704,0.00008398138,0.0002672581,0.00021429361,0.00005420328,0.00024324376],"domain_scores_gemma":[0.9994094,0.000084914864,0.000111197645,0.00031197708,0.000054378426,0.000028127997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016706774,0.00015185455,0.00033732128,0.00008706694,0.000073753276,0.000002072926,0.00017709944,0.00019825506,0.0007821519],"category_scores_gemma":[0.00010387998,0.00011682849,0.00010840074,0.00015232372,0.0001790649,0.000047111917,0.000035934278,0.000103282626,0.0003680355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001242368,0.0018711833,0.02171012,0.00017023011,0.0022602123,0.00009011074,0.0064632623,0.000037356323,0.67275405,0.006956915,0.008189473,0.27825472],"study_design_scores_gemma":[0.01370706,0.00069597794,0.04103965,0.00019175715,0.0004823182,0.000080009486,0.00043482863,3.6349914e-7,0.9236816,0.002278273,0.01712376,0.00028439978],"about_ca_topic_score_codex":0.00018248624,"about_ca_topic_score_gemma":0.00004534104,"teacher_disagreement_score":0.2779703,"about_ca_system_score_codex":0.000040829134,"about_ca_system_score_gemma":0.000079760015,"threshold_uncertainty_score":0.8564015},"labels":[],"label_agreement":null},{"id":"W2010532625","doi":"10.1074/jbc.m111.304949","title":"Interleukin (IL)-23 Suppresses IL-10 in Inflammatory Bowel Disease","year":2011,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Inflammatory bowel disease; Immune system; Pathogenesis; Lamina propria; Immunology; Intestinal mucosa; Biology; Interleukin; Inflammation; Cytokine; Medicine; Pathology; Epithelium; Disease; Internal medicine","score_opus":0.027204578462267037,"score_gpt":0.23117574717440914,"score_spread":0.2039711687121421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010532625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499,0.002918747,0.0000045623588,0.00005578963,0.00026233328,0.000050756727,0.000049196835,0.000019004312,0.0016495954],"genre_scores_gemma":[0.9982699,0.00035602946,0.00006882221,0.000042488544,0.00010397692,0.0000072560983,0.000042118605,0.0000078201065,0.0011015994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988489,0.00011108763,0.0005436105,0.00018558875,0.000036972593,0.00027381736],"domain_scores_gemma":[0.9992635,0.000114113886,0.00030014737,0.0001719511,0.00007008046,0.000080207625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024626023,0.00019295899,0.00030457386,0.000049626164,0.000041607447,0.000008915589,0.00033652488,0.00033004253,0.0028591547],"category_scores_gemma":[0.0002457051,0.00012788981,0.00021405847,0.000060172308,0.0001895207,0.000074345466,0.00008217678,0.00030202567,0.00013986805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028057955,0.00070731784,0.22347628,0.000055379733,0.00024945426,0.0006481979,0.00022222419,0.0000012037245,0.7657016,0.000024207086,0.0023104846,0.0037978706],"study_design_scores_gemma":[0.002101943,0.0002781694,0.24575794,0.000111031004,0.000087785804,0.00025261915,0.00022725973,4.1985314e-7,0.7372064,0.00052035745,0.013190322,0.00026575362],"about_ca_topic_score_codex":0.0000033967399,"about_ca_topic_score_gemma":0.0000013505806,"teacher_disagreement_score":0.028495198,"about_ca_system_score_codex":0.00004857515,"about_ca_system_score_gemma":0.00007003749,"threshold_uncertainty_score":0.99805236},"labels":[],"label_agreement":null},{"id":"W2010719421","doi":"10.1007/s10227-005-0121-4","title":"Safe Psoriasis Control: A New Outcome Measure for the Composite Assessment of the Efficacy and Safety of Psoriasis Treatment","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Clinical endpoint; Safety profile; Clinical trial; Patient-reported outcome; Quality of life (healthcare); Intensive care medicine; Adverse effect; Internal medicine; Dermatology","score_opus":0.03297616383954409,"score_gpt":0.2878567824449184,"score_spread":0.2548806186053743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010719421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94657415,0.036887657,0.00060838764,0.013352766,0.0016399029,0.0006438893,0.00006554444,0.0000078155535,0.00021987606],"genre_scores_gemma":[0.99429786,0.004426403,0.00017758463,0.00023835467,0.00037088248,0.0000047616054,0.000004807777,0.000013163999,0.00046615687],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822694,0.00026332482,0.0010241594,0.0001396902,0.00013446141,0.00021144173],"domain_scores_gemma":[0.99347,0.00519846,0.00086204254,0.0002290153,0.00018169181,0.00005880494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085533236,0.00022446702,0.0010770846,0.00013000207,0.00018025604,0.0000056038257,0.00013734592,0.00013623982,0.00007053933],"category_scores_gemma":[0.0002853732,0.0001009368,0.00035241427,0.000110196605,0.0002521259,0.000043311353,0.000018880497,0.00013717281,5.135023e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009381422,0.0007067506,0.17167921,0.00010721173,0.0072034886,0.00004187831,0.0022298957,0.00015350374,0.040882982,0.000278767,0.008978677,0.7583562],"study_design_scores_gemma":[0.069625504,0.007728015,0.53796816,0.0018804569,0.021631647,0.011633595,0.002127912,0.00012312405,0.020428965,0.00030525844,0.3256965,0.0008508572],"about_ca_topic_score_codex":0.00007221178,"about_ca_topic_score_gemma":0.000040075593,"teacher_disagreement_score":0.75750536,"about_ca_system_score_codex":0.00005470372,"about_ca_system_score_gemma":0.00019567783,"threshold_uncertainty_score":0.41160834},"labels":[],"label_agreement":null},{"id":"W2010996659","doi":"10.1016/j.vetimm.2011.08.021","title":"Induction, regulation and physiological role of IL-17 secreting helper T-cells isolated from PBMC, thymus, and lung lymphocytes of young pigs","year":2011,"lang":"en","type":"article","venue":"Veterinary Immunology and Immunopathology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Chongqing University of Arts and Sciences","keywords":"Biology; Peripheral blood mononuclear cell; Immunology; Molecular biology; Transforming growth factor; Recombinant DNA; Interleukin 21; T cell; In vitro; Gene; Cell biology; Immune system; Genetics","score_opus":0.021539068520488872,"score_gpt":0.21827615664733357,"score_spread":0.1967370881268447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010996659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439718,0.054890703,0.00003344946,0.00001330136,0.0005168912,0.0002251517,0.00010668979,0.000050710267,0.00019127878],"genre_scores_gemma":[0.9928373,0.0062758583,0.00047066595,0.000018228093,0.0000209397,0.000030355692,0.00018871059,0.00002204592,0.00013588346],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978285,0.00064626714,0.0005893778,0.00054078235,0.000027878343,0.00036722136],"domain_scores_gemma":[0.99894243,0.00017754707,0.00040425078,0.00035942407,0.000093008166,0.000023325532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000249211,0.00034393673,0.0007291906,0.0002026563,0.00024285562,0.000006118599,0.0001657048,0.00076876726,0.00025739262],"category_scores_gemma":[0.00004431721,0.0003052105,0.000075461925,0.00012309955,0.0012931983,0.00019014928,0.0003118293,0.00023784129,0.000009128647],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022342382,0.00016939301,0.011427416,0.000026328744,0.0004918864,0.000016630458,0.0042523253,2.4361117e-7,0.96487504,0.0002586846,0.0000081337785,0.016239677],"study_design_scores_gemma":[0.0028953082,0.0035414929,0.6086258,0.00008361015,0.00031371397,0.0015943862,0.0021810196,0.000020211332,0.37902778,0.0011251819,0.00023173123,0.00035974607],"about_ca_topic_score_codex":0.0003572048,"about_ca_topic_score_gemma":0.0000041449634,"teacher_disagreement_score":0.5971984,"about_ca_system_score_codex":0.000020512294,"about_ca_system_score_gemma":0.00003119601,"threshold_uncertainty_score":0.99994},"labels":[],"label_agreement":null},{"id":"W2012114706","doi":"10.1111/j.1365-2249.2009.04037.x","title":"Translational Mini-Review Series on Th17 Cells: Function and regulation of human T helper 17 cells in health and disease","year":2009,"lang":"en","type":"review","venue":"Clinical & Experimental Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":274,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Disease; Function (biology); Series (stratigraphy); Cell biology; Human disease; Biology; Computational biology; Medicine; Internal medicine","score_opus":0.07645446842964479,"score_gpt":0.3882415689592604,"score_spread":0.31178710052961556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012114706","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046268846,0.9931815,0.0000011627885,0.0001754231,0.0007066849,0.0010623094,0.0001249366,0.000026696744,0.00009435972],"genre_scores_gemma":[0.0031606122,0.9940314,0.000034433084,0.00033734692,0.000052993437,0.00011216833,0.0013103588,0.000029091329,0.00093156105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959518,0.0013597469,0.001637523,0.0006869975,0.000050538914,0.0003134243],"domain_scores_gemma":[0.9984542,0.00038482947,0.0006804756,0.0003709111,0.000024413603,0.00008513628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044762582,0.00047408938,0.0021382307,0.0001818557,0.00014863366,0.0000076158144,0.00014536377,0.00062489393,0.00029816336],"category_scores_gemma":[0.00003356258,0.0003966168,0.0003816048,0.00012706067,0.0006906703,0.00009372907,0.00006214934,0.0003863947,0.000050479634],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011865463,0.0021338784,0.00011641215,0.0055537447,0.00082550314,0.000008384957,0.00020185075,1.9121377e-7,0.0042474065,0.0016999977,0.0020401163,0.981986],"study_design_scores_gemma":[0.0042054895,0.006359187,0.003599086,0.02091949,0.0010094655,0.00004366745,0.00014202663,2.0408646e-7,0.0010777119,0.00037948208,0.9615181,0.00074609503],"about_ca_topic_score_codex":0.00001668094,"about_ca_topic_score_gemma":0.0000050657854,"teacher_disagreement_score":0.98123986,"about_ca_system_score_codex":0.00005210814,"about_ca_system_score_gemma":0.00022077707,"threshold_uncertainty_score":0.99984854},"labels":[],"label_agreement":null},{"id":"W2012154624","doi":"10.1007/s00403-009-0961-7","title":"Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab","year":2009,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University; University of Windsor; Innovaderm (Canada)","funders":"","keywords":"Psoriasis Area and Severity Index; Medicine; Placebo; Psoriasis; Pharmacodynamics; Gastroenterology; Internal medicine; Randomized controlled trial; Pharmacokinetics; Randomization; Body surface area; Immunology; Pathology","score_opus":0.07611136627480423,"score_gpt":0.39382316862847017,"score_spread":0.3177118023536659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012154624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740273,0.022577958,0.00001790058,0.00022219274,0.00005865711,0.0022212043,0.00014573651,0.000020874515,0.0007081749],"genre_scores_gemma":[0.9755187,0.023813922,0.00033474877,0.0000042401107,0.000014495096,0.00007228197,0.00012302304,0.000011846383,0.00010672072],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99568343,0.001791283,0.0013116576,0.0005031624,0.0001842594,0.00052619283],"domain_scores_gemma":[0.98982656,0.009041721,0.0005309729,0.00032744178,0.00019519319,0.000078139856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079671026,0.0003533865,0.0026952934,0.0005209107,0.00018168168,0.000008239365,0.00027932468,0.00018687395,0.00001973516],"category_scores_gemma":[0.00056857965,0.00022908869,0.00031528276,0.00021097911,0.0024529337,0.000050466104,0.00013683255,0.00021510446,0.0000027114772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7050182,0.0019123501,0.00036686956,0.0001201359,0.002785067,0.0001016054,0.002715938,0.000016429487,0.26330018,0.00205156,0.000007456335,0.021604149],"study_design_scores_gemma":[0.805938,0.0038719308,0.0019138473,0.00015595253,0.00071753474,0.0003453581,0.0004603232,0.000121795485,0.18384181,0.0024203318,0.000016547907,0.00019654019],"about_ca_topic_score_codex":0.00010594329,"about_ca_topic_score_gemma":0.000015423575,"teacher_disagreement_score":0.100919776,"about_ca_system_score_codex":0.00001903995,"about_ca_system_score_gemma":0.000109703666,"threshold_uncertainty_score":0.93419653},"labels":[],"label_agreement":null},{"id":"W2012715950","doi":"10.1016/j.jaad.2010.12.005","title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":177,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Placebo; Internal medicine; Open label; Clinical trial; Randomized controlled trial; Severity of illness; Surgery; Dermatology; Disease","score_opus":0.027432609005187077,"score_gpt":0.2852208799279339,"score_spread":0.2577882709227468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012715950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980544,0.00012836007,0.0000064595124,0.00011011046,0.00012133571,0.00095103664,0.000617437,0.0000046888154,0.0000062018726],"genre_scores_gemma":[0.9991365,0.000034545996,0.00055660727,0.000156727,0.000011908166,0.000008548451,0.00005949532,0.000021452764,0.000014185396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978017,0.0006440119,0.00091696886,0.0003103092,0.000088454944,0.0002385116],"domain_scores_gemma":[0.9976479,0.00032713616,0.0015959822,0.00023682155,0.00013856812,0.000053599113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015228434,0.00021905002,0.0010493222,0.00016084495,0.000062043466,0.000006603385,0.0005329437,0.00015223121,0.000009828361],"category_scores_gemma":[0.00010037987,0.00014553315,0.00005427073,0.00018293595,0.00020535052,0.00017760706,0.00017421503,0.00020947789,0.0000015512899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.094774276,0.0034891202,0.8828347,0.00000409408,0.0008624427,0.000008875982,0.0024899982,0.0000030747847,0.0020078504,0.0000016894102,0.00021290239,0.013310984],"study_design_scores_gemma":[0.050000936,0.0036742128,0.94218147,0.00012210959,0.0004358703,0.000016245085,0.00014475969,0.0000011462282,0.0032277799,0.000033383396,0.000015153949,0.00014695512],"about_ca_topic_score_codex":0.00066379405,"about_ca_topic_score_gemma":0.000064162596,"teacher_disagreement_score":0.059346754,"about_ca_system_score_codex":0.00003527286,"about_ca_system_score_gemma":0.000042244264,"threshold_uncertainty_score":0.59346694},"labels":[],"label_agreement":null},{"id":"W2012980289","doi":"10.1067/mjd.2002.127247","title":"A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis","year":2002,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":347,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Tolerability; Psoriasis Area and Severity Index; Psoriasis; Placebo; Plaque psoriasis; Adverse effect; Dermatology; Surgery; Anesthesia; Internal medicine","score_opus":0.030223057427708658,"score_gpt":0.320761134649429,"score_spread":0.29053807722172037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012980289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942122,0.0032609233,0.000008174032,0.0005676509,0.00012263958,0.0017841758,0.000014897078,0.000004134236,0.000025174344],"genre_scores_gemma":[0.99954647,0.00027685464,0.00007453653,0.000027435399,0.00001530464,0.000027491493,0.0000015946872,0.000012489952,0.000017806755],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956502,0.0020661105,0.0016502475,0.00020581485,0.0001588619,0.00026877847],"domain_scores_gemma":[0.9942528,0.0015554136,0.003828302,0.00018731758,0.00014294802,0.00003320678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000918264,0.00024993115,0.0028181989,0.00030341544,0.0000667659,0.000003044982,0.00036776898,0.0001465111,0.00007356216],"category_scores_gemma":[0.00024984713,0.00014616361,0.00027981037,0.00030605786,0.0012190473,0.000091959795,0.00007548052,0.0004005421,0.0000012324894],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8848609,0.0034889132,0.095601544,0.00004216086,0.0029779735,0.0000036175743,0.0019529815,0.00013353497,0.0033620412,0.000014381263,0.0000625334,0.007499467],"study_design_scores_gemma":[0.96262574,0.0026326943,0.022814734,0.000112553615,0.0016936605,0.00015264518,0.00052598625,0.000041978885,0.009239443,0.000015779075,0.000012911741,0.00013185912],"about_ca_topic_score_codex":0.00006077417,"about_ca_topic_score_gemma":0.000012155942,"teacher_disagreement_score":0.077764906,"about_ca_system_score_codex":0.000050106933,"about_ca_system_score_gemma":0.00009473923,"threshold_uncertainty_score":0.5960379},"labels":[],"label_agreement":null},{"id":"W2014181447","doi":"10.1038/labinvest.2012.69","title":"Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact","year":2012,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Crosstalk; Pathological; Cell; In vitro; Pathology; Cell biology; Immunology; Biology; Medicine; Chemistry; Physics; Genetics; Optics","score_opus":0.0186873692104899,"score_gpt":0.23780496976121498,"score_spread":0.2191176005507251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014181447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945777,0.0044299946,0.0000042343777,0.00004758584,0.00021390099,0.0002473207,0.0002525572,0.00003035716,0.00019636122],"genre_scores_gemma":[0.99890655,0.000056040193,0.00051646424,0.00012418478,0.000053057625,0.000048248803,0.00023720498,0.000011694885,0.000046552035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984326,0.00053426,0.0003886999,0.00027367304,0.000053682572,0.00031708923],"domain_scores_gemma":[0.9992363,0.00032797185,0.00015630192,0.00015293146,0.000057043053,0.000069483445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005264346,0.00020126063,0.00038962814,0.00017616936,0.00008520789,0.000013691496,0.000094950694,0.00030004847,0.00003126245],"category_scores_gemma":[0.00011947381,0.00017837394,0.00003359749,0.00036775638,0.00013877382,0.00024445713,0.00005350813,0.00012732808,0.00003938964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010679,0.00009553635,0.48699424,0.000020328123,0.000009070598,0.0000022450586,0.00084946054,0.0000022469908,0.51109016,0.00003106102,0.000036107784,0.0007627456],"study_design_scores_gemma":[0.001205155,0.00006452094,0.46694595,0.000021211239,0.000021663573,7.6753986e-7,0.00012289648,9.3952025e-7,0.53132886,0.000038841143,0.00014538606,0.00010382638],"about_ca_topic_score_codex":0.00010511297,"about_ca_topic_score_gemma":0.000026353866,"teacher_disagreement_score":0.020238679,"about_ca_system_score_codex":0.000086459135,"about_ca_system_score_gemma":0.000116208015,"threshold_uncertainty_score":0.72738785},"labels":[],"label_agreement":null},{"id":"W2014539367","doi":"10.1159/000316179","title":"Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy","year":2010,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Nail (fastener); Dermatology; Nail disease; Disease; Quality of life (healthcare); Anxiety; Internal medicine; Psychiatry","score_opus":0.018837060520599018,"score_gpt":0.23395866547082567,"score_spread":0.21512160495022664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014539367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354607,0.0020706507,0.00001077195,0.00053449126,0.00035809257,0.00040602536,0.000028561295,0.000051992985,0.0029933224],"genre_scores_gemma":[0.9962941,0.0027724078,0.00028958474,0.00008569947,0.000012018638,0.00016252932,0.0000640221,0.000013670871,0.00030599203],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990514,0.00011015652,0.0002071643,0.00032604174,0.000021781589,0.00028343932],"domain_scores_gemma":[0.9994148,0.00009619214,0.00011420655,0.00032517037,0.000025534528,0.000024065208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004306097,0.00024212692,0.00037784988,0.000122883,0.00010791122,0.000005098783,0.00011868841,0.00022999158,0.00014853125],"category_scores_gemma":[0.000002102276,0.00015064752,0.00006277255,0.00009839439,0.00025049743,0.000027510947,0.000030907464,0.0000882041,0.0000925095],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038362436,0.0023531327,0.13698067,0.000091601985,0.005493241,0.00036083005,0.0014086609,0.000001046759,0.12015098,0.0710966,0.00060707255,0.6576199],"study_design_scores_gemma":[0.021551255,0.004376056,0.08800473,0.000046617704,0.00046922854,0.0012740162,0.0005432138,0.0000016977882,0.80138457,0.0013157087,0.08045551,0.0005774107],"about_ca_topic_score_codex":0.00006371717,"about_ca_topic_score_gemma":0.00009461168,"teacher_disagreement_score":0.6812336,"about_ca_system_score_codex":0.000013462737,"about_ca_system_score_gemma":0.000019791518,"threshold_uncertainty_score":0.6143228},"labels":[],"label_agreement":null},{"id":"W2015529970","doi":"10.1111/pde.12545","title":"Successful Treatment of Severe Psoriasis in an Adolescent with Ustekinumab","year":2015,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Ustekinumab; Methotrexate; Dermatology; Refractory (planetary science); Quality of life (healthcare); Disease; Adalimumab; Internal medicine","score_opus":0.025455113279531174,"score_gpt":0.25226230895921314,"score_spread":0.22680719567968197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015529970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99277747,0.005358882,0.00001905774,0.00012351183,0.00056058256,0.0003160083,0.000040109197,0.0000563691,0.00074800214],"genre_scores_gemma":[0.99882555,0.00047173907,0.0001632564,0.000029808258,0.000077186676,0.00007038757,0.00014626348,0.000021570837,0.00019425602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839604,0.00034314606,0.00040025802,0.000371628,0.00005394616,0.00043497345],"domain_scores_gemma":[0.99917287,0.00009632254,0.00018914182,0.00036976353,0.000100828394,0.000071053466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000072526585,0.00027401917,0.0006055989,0.00033188265,0.00004494477,0.000006346449,0.00019273353,0.0003038066,0.00009245493],"category_scores_gemma":[0.000016778797,0.00020599896,0.00007219961,0.00035954732,0.00009293398,0.00012568948,0.000030072628,0.00008371814,0.00016956234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010086002,0.0013708996,0.98683673,0.00003350165,0.000112999674,0.00018791376,0.0010829336,0.000033761175,0.00011270413,0.0000952641,0.00057671097,0.008548],"study_design_scores_gemma":[0.0701596,0.00688456,0.8596441,0.00004460542,0.0022737002,0.006437659,0.004272341,0.000024390381,0.025991932,0.0003317517,0.02219111,0.0017442419],"about_ca_topic_score_codex":0.00025580006,"about_ca_topic_score_gemma":0.0005076316,"teacher_disagreement_score":0.1271926,"about_ca_system_score_codex":0.0001148122,"about_ca_system_score_gemma":0.0002796591,"threshold_uncertainty_score":0.8400394},"labels":[],"label_agreement":null},{"id":"W2016060866","doi":"10.1165/rcmb.2012-0267oc","title":"IL-17A Mediates a Selective Gene Expression Profile in Asthmatic Human Airway Smooth Muscle Cells","year":2014,"lang":"en","type":"article","venue":"American Journal of Respiratory Cell and Molecular Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Asthma and Lung UK","keywords":"Signal transduction; Gene expression; Biology; Chemokine; Ribosomal s6 kinase; Proinflammatory cytokine; Cell biology; Gene; Immunology; Regulation of gene expression; Inflammation; Genetics","score_opus":0.006135536558250154,"score_gpt":0.22813055772486654,"score_spread":0.22199502116661637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016060866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953469,0.0033114285,0.0006073435,0.000037632482,0.0002024597,0.00013368433,0.000013610578,0.000011111498,0.00033582633],"genre_scores_gemma":[0.99854285,0.000099964505,0.00085483264,0.00037981282,0.00004531123,0.000014357256,0.000012359048,0.000019456134,0.00003107368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979234,0.0009942512,0.0004387992,0.00027020948,0.00003902098,0.00033432254],"domain_scores_gemma":[0.9990338,0.00014251603,0.00050443574,0.00017348323,0.00008091831,0.000064858534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040393605,0.00022108114,0.0005365782,0.00027092174,0.00009868368,0.000007757296,0.0001838697,0.00015885022,0.00004638863],"category_scores_gemma":[0.000039210357,0.00016876684,0.00011713675,0.00017817432,0.00036952342,0.000043479788,0.000055678785,0.00024709787,0.000021652331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001114637,0.00012973248,0.0027829949,0.00000864785,0.000051698527,0.000023663053,0.0003079536,0.0000041430303,0.947164,0.000022746766,0.0001457116,0.049247216],"study_design_scores_gemma":[0.0018747993,0.0034905402,0.0050451374,0.000031878535,0.000058297042,0.000017739983,0.00024791554,0.000001072193,0.97647095,0.00014605057,0.012413683,0.00020193022],"about_ca_topic_score_codex":0.00003210626,"about_ca_topic_score_gemma":0.000008513707,"teacher_disagreement_score":0.049045287,"about_ca_system_score_codex":0.000030524297,"about_ca_system_score_gemma":0.0000674918,"threshold_uncertainty_score":0.6882112},"labels":[],"label_agreement":null},{"id":"W2016610378","doi":"10.2310/7750.2009.00030","title":"Efficacy Outcomes in Patients Using Alefacept in the AWARE Study","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; University of Toronto; Vancouver Coastal Health Research Institute; Nexus Clinical Research (Canada); University of British Columbia","funders":"University of British Columbia; University of Alberta; Astellas Pharma; Abbott Canada","keywords":"Medicine; Psoriasis; Observational study; Clearance; Body surface area; Plaque psoriasis; Regimen; Clinical trial; Psoriasis Area and Severity Index; Internal medicine; Dermatology; Surgery; Urology","score_opus":0.03439403477348725,"score_gpt":0.28603122600306097,"score_spread":0.25163719122957373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016610378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997097,0.0015662786,0.0000014635948,0.0007119535,0.00042452844,0.0001518487,0.0000011644823,0.0000028952168,0.00004288164],"genre_scores_gemma":[0.9993205,0.00017815863,0.0000032026192,0.00039926765,0.000047477726,3.6141415e-7,0.000003712688,0.000004087831,0.00004321428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878836,0.00032496988,0.00053197914,0.00009327097,0.000082558014,0.00017887476],"domain_scores_gemma":[0.9987944,0.0008356832,0.00020737185,0.000101228215,0.000043159514,0.000018167153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006026459,0.0001263288,0.0005415379,0.0003021824,0.000053897424,0.0000051458132,0.00008872857,0.0000737543,0.000040205392],"category_scores_gemma":[0.00021353328,0.000066370274,0.00007416889,0.00015301503,0.00004491381,0.00004864216,0.000007137389,0.0001937938,0.0000023136547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004560658,0.0010443504,0.9524883,0.000002884331,0.00008896599,0.00081835996,0.0037799089,0.000006600978,0.00022781621,0.0000010459672,0.0006701265,0.04041557],"study_design_scores_gemma":[0.0034810689,0.0011305333,0.99107313,0.000116272466,0.00012483553,0.00077893515,0.0028014104,0.0000012339185,0.00002931757,0.000025194671,0.00035272288,0.0000853379],"about_ca_topic_score_codex":0.000037444894,"about_ca_topic_score_gemma":0.000020582047,"teacher_disagreement_score":0.04033023,"about_ca_system_score_codex":0.000024947038,"about_ca_system_score_gemma":0.000035098903,"threshold_uncertainty_score":0.27065012},"labels":[],"label_agreement":null},{"id":"W2016936721","doi":"10.1586/edm.12.77","title":"Molecular mechanisms in psoriasis: historical perspective and current pathogenesis","year":2013,"lang":"en","type":"article","venue":"Expert Review of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Psoriasis; Pathogenesis; Perspective (graphical); Current (fluid); Dermatology; Immunology","score_opus":0.013744547258682295,"score_gpt":0.2716510600628251,"score_spread":0.2579065128041428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016936721","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04804719,0.9459668,0.00033693897,0.003617348,0.00089815113,0.0006351122,0.000006941662,0.00003432306,0.00045723098],"genre_scores_gemma":[0.73792475,0.25919446,0.0010695233,0.00084846513,0.000026511381,0.0007609031,0.000049190232,0.00003375416,0.00009244937],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824846,0.00048547657,0.000517832,0.00038459,0.000045236513,0.00031842355],"domain_scores_gemma":[0.99924093,0.00010262409,0.00017129484,0.0002989343,0.00014799538,0.00003823193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009177228,0.00024869456,0.00082236837,0.00015636193,0.0000494107,0.0000035619064,0.00017531886,0.00019754366,0.000405824],"category_scores_gemma":[0.00012562968,0.0002039733,0.00014002116,0.0002454639,0.00008460307,0.00007634367,0.00008193715,0.00012881008,0.00017929793],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014209513,0.0022663423,0.0044281897,0.004063096,0.00089317677,0.00032688837,0.0031980781,2.643875e-7,0.4041748,0.065251075,0.037299655,0.47795635],"study_design_scores_gemma":[0.013533667,0.0009174709,0.020469591,0.009364119,0.0010063867,0.0077567925,0.0031325016,0.000012514188,0.5077844,0.012518682,0.42029607,0.0032077762],"about_ca_topic_score_codex":0.000250017,"about_ca_topic_score_gemma":0.000007847482,"teacher_disagreement_score":0.6898775,"about_ca_system_score_codex":0.00015037565,"about_ca_system_score_gemma":0.000062819505,"threshold_uncertainty_score":0.83177894},"labels":[],"label_agreement":null},{"id":"W2017054987","doi":"10.3899/jrheum.140175","title":"GRAPPA 2013 Basic/Translational/Clinical Science Update: Comorbidity Monitoring","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Comorbidity; Psoriatic arthritis; Psoriasis; MEDLINE; Clinical Practice; Intensive care medicine; Disease; Physical therapy; Internal medicine; Dermatology","score_opus":0.031829426420836804,"score_gpt":0.2953795532623052,"score_spread":0.2635501268414684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017054987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911193,0.0023406919,0.0006501395,0.0015769971,0.004008668,0.00006261381,0.0000040385025,0.000015946935,0.00022159913],"genre_scores_gemma":[0.99692017,0.0026048003,0.00029748082,0.000045787794,0.00003767911,0.000001290517,0.0000031550107,0.0000084193125,0.00008119973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980939,0.00074883,0.00063339237,0.0001358986,0.00008583956,0.00030215268],"domain_scores_gemma":[0.99803656,0.00097238546,0.00046468186,0.00027073294,0.00021108451,0.000044555592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030930866,0.00013628996,0.00041771933,0.00014586751,0.0003668044,0.000011539388,0.0006305375,0.00015799871,0.00017028858],"category_scores_gemma":[0.00023250609,0.00008396646,0.00014764414,0.00018752563,0.0008781732,0.00014850075,0.00005758841,0.0003576066,0.0003064562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005616266,0.00023279544,0.9259345,0.000010961485,0.00045508813,0.0000035279086,0.00045436976,0.00005093221,0.0146351755,0.0037270135,0.0056426995,0.048291318],"study_design_scores_gemma":[0.008823957,0.0012793802,0.83116746,0.00022327335,0.0009431944,0.013908239,0.0005466153,0.00008044676,0.04646795,0.009043225,0.08686481,0.0006514743],"about_ca_topic_score_codex":0.000087800094,"about_ca_topic_score_gemma":0.000014822854,"teacher_disagreement_score":0.09476706,"about_ca_system_score_codex":0.000016267726,"about_ca_system_score_gemma":0.00013964903,"threshold_uncertainty_score":0.39389765},"labels":[],"label_agreement":null},{"id":"W2017480010","doi":"10.1111/jdv.12177","title":"Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study","year":2013,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Quality of life (healthcare); Dermatology Life Quality Index; Psoriasis; Placebo; Physical therapy; Psoriatic arthritis; Work productivity; Randomized controlled trial; Severity of illness; Internal medicine; Productivity; Alternative medicine; Dermatology; Nursing","score_opus":0.028383320793183855,"score_gpt":0.29311438830241565,"score_spread":0.2647310675092318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017480010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989844,0.0037908158,0.000037198828,0.0041436087,0.00027614116,0.001753691,0.00007262876,0.000006793425,0.000020697596],"genre_scores_gemma":[0.99925715,0.00042943622,0.00009521677,0.000084610205,0.000032504053,0.000025627987,0.000004224152,0.0000143363095,0.000056905326],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918581,0.0063014864,0.0012277247,0.00031804419,0.000052982887,0.0002416183],"domain_scores_gemma":[0.9951494,0.002582088,0.0019501154,0.00016932239,0.00007213277,0.00007698746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013581971,0.00026035472,0.0019401568,0.00015947408,0.00014700233,0.000004288353,0.00016782047,0.00020340469,0.0000045922493],"category_scores_gemma":[0.000632185,0.00016219655,0.0002003106,0.00010686063,0.00044700011,0.00007839622,0.00011461599,0.00024060706,0.0000012512987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79492134,0.00712249,0.038568508,0.0003538604,0.011078082,0.000019317058,0.013907481,0.00006734052,0.04083089,0.0002964952,0.00088526716,0.09194892],"study_design_scores_gemma":[0.56499684,0.0025130329,0.3650915,0.0002333106,0.0013171248,0.00040350654,0.0002574085,0.000014169772,0.06347369,0.0013073478,0.00010106224,0.0002910061],"about_ca_topic_score_codex":0.00018443396,"about_ca_topic_score_gemma":0.000010004432,"teacher_disagreement_score":0.326523,"about_ca_system_score_codex":0.000022973354,"about_ca_system_score_gemma":0.000057244633,"threshold_uncertainty_score":0.6614183},"labels":[],"label_agreement":null},{"id":"W2017539130","doi":"10.4103/0019-5154.62751","title":"Genetics of psoriasis and psoriatic arthritis","year":2010,"lang":"en","type":"article","venue":"Indian Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Heritability; Genetics; Dermatology; Medicine; Biology","score_opus":0.007831443341163168,"score_gpt":0.22240607880517885,"score_spread":0.21457463546401567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017539130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853123,0.011714315,0.000026210295,0.00042926476,0.0022373153,0.00006627979,0.00001974035,0.0000064005576,0.00018818426],"genre_scores_gemma":[0.9974971,0.001521478,0.0008091641,0.000042593103,0.00007636324,0.0000020202388,0.000005277433,0.000011458481,0.000034576788],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891233,0.0001529682,0.00056041713,0.00010969254,0.000036664773,0.00022791729],"domain_scores_gemma":[0.9989989,0.00019182876,0.000472355,0.00016449911,0.00012226829,0.000050174775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012889503,0.00013767225,0.00048658246,0.0002532766,0.000067884685,0.0000069330176,0.000181206,0.00032128667,0.00023313158],"category_scores_gemma":[0.00009814321,0.00011787941,0.00011281488,0.00009400905,0.0002664704,0.00006831871,0.00003029495,0.0003030707,0.000036943726],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035833154,0.00033396462,0.14308117,0.00007736885,0.0013756121,0.0014952103,0.0034752046,0.0000010478126,0.21690078,0.0018188277,0.0019565478,0.62912595],"study_design_scores_gemma":[0.011897095,0.0008233143,0.084192514,0.00012805873,0.0005944352,0.14066567,0.00079396775,0.0000014526355,0.72051954,0.0033097952,0.03661219,0.00046195774],"about_ca_topic_score_codex":0.000005568044,"about_ca_topic_score_gemma":0.000041755433,"teacher_disagreement_score":0.62866396,"about_ca_system_score_codex":0.0000053314952,"about_ca_system_score_gemma":0.000119331344,"threshold_uncertainty_score":0.4806983},"labels":[],"label_agreement":null},{"id":"W2017768069","doi":"10.1016/j.jaci.2010.12.1117","title":"TH17 cytokines induce human airway smooth muscle cell migration","year":2011,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Manitoba; Christie (Canada)","funders":"Canadian Institutes of Health Research; McGill University Health Centre; Genentech; McGill University; GlaxoSmithKline","keywords":"MAPK/ERK pathway; Cell biology; Signal transduction; Cytokine; Cell migration; p38 mitogen-activated protein kinases; Kinase; Immunology; Receptor; Biology; Cancer research; Medicine; Cell; Internal medicine; Biochemistry","score_opus":0.045558068389464364,"score_gpt":0.2863839730092165,"score_spread":0.24082590461975212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017768069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801047,0.0075018816,0.000037900834,0.00020694562,0.0017047334,0.00006609111,0.000004500758,0.000018895527,0.0024485993],"genre_scores_gemma":[0.9922338,0.0059743314,0.00021172035,0.00013841232,0.00015148701,0.0000030397402,0.00001501835,0.000015124797,0.0012570436],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980567,0.00047278704,0.00093731494,0.00022382036,0.00003576308,0.00027359027],"domain_scores_gemma":[0.99868494,0.0002383165,0.00065746554,0.00022356585,0.00015291301,0.00004281075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051513937,0.00019928583,0.0005187714,0.00013503601,0.00019430787,0.00000949322,0.0002714589,0.0006074205,0.000769679],"category_scores_gemma":[0.00008059269,0.000150072,0.00027196365,0.00008080624,0.00036235186,0.00015646496,0.00007838079,0.0005063228,0.00010373143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004483839,0.0060571088,0.052869905,0.000021255712,0.009245005,0.00028794265,0.0036806765,0.0000011910593,0.58656096,0.003783436,0.0061609196,0.32684773],"study_design_scores_gemma":[0.006705921,0.0051839324,0.8711851,0.000046504265,0.0004140196,0.00019664287,0.0007184599,5.170983e-7,0.03771702,0.0013092337,0.07618752,0.00033507965],"about_ca_topic_score_codex":0.000092808375,"about_ca_topic_score_gemma":0.00019779538,"teacher_disagreement_score":0.81831527,"about_ca_system_score_codex":0.0000159139,"about_ca_system_score_gemma":0.00006334764,"threshold_uncertainty_score":0.8427445},"labels":[],"label_agreement":null},{"id":"W2017932566","doi":"10.3109/09546634.2013.865009","title":"The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials","year":2013,"lang":"en","type":"review","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":261,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Clinical trial; Surrogate endpoint; Internal medicine; Dermatology; Immunology; Psoriatic arthritis","score_opus":0.3175616168721397,"score_gpt":0.490082295512084,"score_spread":0.1725206786399443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017932566","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011922158,0.9792568,0.00018107954,0.00074967375,0.0029289206,0.0043595624,0.0004380293,0.00003513327,0.00012864156],"genre_scores_gemma":[0.0013637005,0.99335515,0.003099809,0.00010020841,0.0002751407,0.0014433649,0.00017987506,0.000036203593,0.00014653025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9801594,0.011866655,0.006292042,0.0006566793,0.00022223344,0.0008030013],"domain_scores_gemma":[0.98182184,0.012437032,0.0046530105,0.0005950455,0.0002804864,0.00021257707],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009112358,0.0009797831,0.0069476073,0.00015416436,0.00041260495,0.00013921468,0.0007340197,0.0016545287,0.000083919396],"category_scores_gemma":[0.004438059,0.00045782744,0.0039499006,0.00029759848,0.000345815,0.00014959832,0.00014468575,0.00078095985,0.00007811054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044150098,0.0012055152,0.0016177777,0.00044084192,0.0041912617,0.0001006664,0.000027644739,0.0000034808465,0.0000035565145,0.00037754784,0.0032600998,0.9883301],"study_design_scores_gemma":[0.02317476,0.005023003,0.0030358916,0.005254388,0.016792435,0.0046739397,0.0001820301,0.00004876215,0.00007918467,0.0039909505,0.93645406,0.0012905925],"about_ca_topic_score_codex":0.000017870381,"about_ca_topic_score_gemma":0.000019242778,"teacher_disagreement_score":0.9870395,"about_ca_system_score_codex":0.0013262271,"about_ca_system_score_gemma":0.0020241446,"threshold_uncertainty_score":0.99978733},"labels":[],"label_agreement":null},{"id":"W2018438415","doi":"10.1016/j.jaad.2005.10.054","title":"Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Psoriasis; Placebo; Randomized controlled trial; Open label; Dermatology; Internal medicine; Alternative medicine; Tumor necrosis factor alpha","score_opus":0.015428633258825881,"score_gpt":0.28942460871081427,"score_spread":0.2739959754519884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018438415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923977,0.0004989131,0.000016348715,0.003583176,0.00040326646,0.0028885014,0.00006094204,0.000007908997,0.0001432141],"genre_scores_gemma":[0.99817735,0.000039434864,0.000462387,0.0005615219,0.000068103094,0.00026970555,0.000005255531,0.000026538588,0.0003896796],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921866,0.0054060486,0.0015508616,0.0002751664,0.00013642712,0.00044488953],"domain_scores_gemma":[0.9950635,0.002430299,0.0021269938,0.00022349256,0.00010247975,0.000053250384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094203267,0.00036540264,0.0030736835,0.0005697026,0.000097316646,0.000019087456,0.0007088937,0.00021296981,0.00006482742],"category_scores_gemma":[0.00041219947,0.0002010528,0.00038027143,0.0004268926,0.00068863964,0.00012787839,0.00015302026,0.00034632723,0.000023739945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98512965,0.0013490816,0.005848868,0.0000032286791,0.0010771578,0.00007361631,0.00037915763,0.000012377925,0.0025183514,0.00004006489,0.00045057182,0.0031178477],"study_design_scores_gemma":[0.9629439,0.0034878124,0.025722485,0.00006684201,0.00082576205,0.0005339774,0.00010517163,0.000001236676,0.0034752267,0.00009848834,0.0025189484,0.00022012775],"about_ca_topic_score_codex":0.00017082108,"about_ca_topic_score_gemma":0.000049820716,"teacher_disagreement_score":0.022185756,"about_ca_system_score_codex":0.00015659878,"about_ca_system_score_gemma":0.00029622024,"threshold_uncertainty_score":0.8198695},"labels":[],"label_agreement":null},{"id":"W2019217317","doi":"10.1046/j.1523-1747.2003.12040.x","title":"Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study","year":2003,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":385,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Skin cancer; Incidence (geometry); Population; Prospective cohort study; Internal medicine; Dermatology; Cohort; Basal cell carcinoma; Cohort study; Cancer; Surgery; Gastroenterology; Basal cell","score_opus":0.011344830806819037,"score_gpt":0.2211599671607557,"score_spread":0.20981513635393667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019217317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983057,0.0006107322,0.000006476731,0.000038507555,0.00021355995,0.00041770464,0.000028058099,0.000008268677,0.0003710177],"genre_scores_gemma":[0.9994893,0.00010204924,0.00024925725,0.000032091473,0.000007253031,0.000022703129,0.000013482012,0.000015651056,0.00006821986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99723166,0.0013485618,0.0008456484,0.00020479968,0.00008795205,0.00028137147],"domain_scores_gemma":[0.99786747,0.0003117514,0.0011480984,0.00019438071,0.0004310586,0.000047262864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037434397,0.0002516873,0.00090345263,0.00037949058,0.000070157446,0.0000042881848,0.00017075661,0.00017928274,0.00006574578],"category_scores_gemma":[0.00055672927,0.00017319736,0.000111732144,0.00041818988,0.00042236052,0.00013031357,0.000019405643,0.00027629742,0.00001538389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043494653,0.0010906139,0.99016666,0.000011169005,0.001351011,0.00015901019,0.0013979472,0.000010732962,0.004797784,0.00017578139,0.00024295908,0.0001613648],"study_design_scores_gemma":[0.0060694725,0.0010617189,0.7765671,0.000043033288,0.0004503155,0.00031136093,0.00093881576,1.5596932e-7,0.21407145,0.00017871486,0.00018055186,0.00012731442],"about_ca_topic_score_codex":0.00013183821,"about_ca_topic_score_gemma":0.00013976831,"teacher_disagreement_score":0.21359958,"about_ca_system_score_codex":0.000059113438,"about_ca_system_score_gemma":0.0001789025,"threshold_uncertainty_score":0.7062783},"labels":[],"label_agreement":null},{"id":"W2020502963","doi":"10.2165/00128071-200405020-00001","title":"Fixed-Dose Combination Therapy for Psoriasis","year":2004,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"LEO Pharma","keywords":"Medicine; Psoriasis; Pharmacotherapy; Combination therapy; Fixed-dose combination; Dermatology; Pharmacology; Internal medicine","score_opus":0.0788575514855078,"score_gpt":0.4060985113205483,"score_spread":0.32724095983504053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020502963","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013750399,0.99217486,0.00023584232,0.00038858934,0.004983069,0.00064843026,0.00008267915,0.00002752635,0.00008397794],"genre_scores_gemma":[0.0020120787,0.9962543,0.00070719264,0.00022457479,0.00028733563,0.00007136738,0.00019809764,0.00006486739,0.00018015601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937952,0.0019213746,0.0033177799,0.00041156175,0.00007311691,0.00048092374],"domain_scores_gemma":[0.9898756,0.004702875,0.0046052346,0.00039756403,0.00032250973,0.00009619117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009415277,0.00053062435,0.005673704,0.0003799315,0.00012994447,0.000015848724,0.00068341667,0.00087178266,0.00011142694],"category_scores_gemma":[0.00071589474,0.00037195112,0.0027682309,0.00031625136,0.0007899383,0.00008696424,0.00004880985,0.00081623,0.00020752977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044588192,0.0006771129,0.00012669152,0.0005000198,0.002934413,0.00006557731,0.00003658611,1.8490383e-7,8.6928543e-7,0.00063718273,0.001501761,0.9930737],"study_design_scores_gemma":[0.0062501617,0.0026738264,0.00012941699,0.0015180801,0.0021187915,0.0032830664,0.000044880253,8.066444e-8,0.000017940545,0.00032115853,0.9833112,0.00033141492],"about_ca_topic_score_codex":0.00001211316,"about_ca_topic_score_gemma":0.0000022925758,"teacher_disagreement_score":0.9927423,"about_ca_system_score_codex":0.000073290765,"about_ca_system_score_gemma":0.0013542868,"threshold_uncertainty_score":0.9998732},"labels":[],"label_agreement":null},{"id":"W2020659835","doi":"10.1097/mop.0b013e328362c3f6","title":"New therapies under development for psoriasis treatment","year":2013,"lang":"en","type":"review","venue":"Current Opinion in Pediatrics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Géomatique du Québec","funders":"","keywords":"Medicine; Psoriasis; Janus kinase; Clinical trial; Adverse effect; Mechanism (biology); Apremilast; Intensive care medicine; Bioinformatics; Pharmacology; Dermatology; Immunology; Cytokine; Internal medicine; Psoriatic arthritis","score_opus":0.14611951085000408,"score_gpt":0.36784336622768027,"score_spread":0.2217238553776762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020659835","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013166785,0.9729673,0.00060779613,0.000020120346,0.023711197,0.002381416,0.00017751569,0.00008073816,0.000040695297],"genre_scores_gemma":[0.0000010447282,0.9895255,0.0010585987,0.000003006891,0.0014784317,0.0019917027,0.003795628,0.00007606609,0.0020700325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736905,0.000232744,0.0009861798,0.0007173243,0.00006968788,0.0006249892],"domain_scores_gemma":[0.9983637,0.0006030298,0.00047991282,0.00041904583,0.0000638225,0.00007049321],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017925748,0.0008181723,0.001620497,0.00060539535,0.00016855671,0.000044121705,0.00036821447,0.00074851484,0.0003534597],"category_scores_gemma":[0.000032091742,0.0005983041,0.0006305597,0.00042695782,0.000032855158,0.00008018225,0.00007898332,0.00023876125,0.0011553809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001671899,0.0002828712,0.00010067886,0.0035186172,0.00035992466,1.497078e-7,0.0002556532,4.116151e-7,1.243605e-7,0.00024109361,0.019423036,0.9758007],"study_design_scores_gemma":[0.0019529051,0.00014654928,0.000059056983,0.0011701975,0.00074761023,0.0000068825443,0.00003206995,8.498951e-8,0.000004459474,0.000106432184,0.995191,0.00058277766],"about_ca_topic_score_codex":0.000024808362,"about_ca_topic_score_gemma":0.000005963339,"teacher_disagreement_score":0.9757679,"about_ca_system_score_codex":0.00059141306,"about_ca_system_score_gemma":0.0012723964,"threshold_uncertainty_score":0.99964684},"labels":[],"label_agreement":null},{"id":"W2020672548","doi":"10.12968/bjon.2010.19.19.79279","title":"Teens with chronic skin: are we speaking their language?","year":2010,"lang":"en","type":"article","venue":"British Journal of Nursing","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Feeling; Coping (psychology); Anticipation (artificial intelligence); Psychology; Developmental psychology; Medicine; Quarter (Canadian coin); Health professionals; Qualitative research; Pediatrics; Psychiatry; Social psychology; Health care","score_opus":0.015541282608909282,"score_gpt":0.2503601364936417,"score_spread":0.23481885388473242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020672548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970585,0.026392315,0.000105148094,0.00033405243,0.0014055724,0.00006357122,0.00001861409,0.000020154066,0.001075591],"genre_scores_gemma":[0.99835527,0.0004406933,0.00037290415,0.000025487429,0.0004613363,9.635688e-7,0.000008209634,0.000020740388,0.00031440824],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992669,0.00007910669,0.00022083202,0.00012253398,0.00004226591,0.00026834288],"domain_scores_gemma":[0.99942166,0.000057220102,0.00029191904,0.00011175035,0.0000853459,0.000032109427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016600301,0.00012432608,0.00026068196,0.00008495871,0.00019267284,0.000046594454,0.00016228291,0.0001373778,0.00028230148],"category_scores_gemma":[0.000020638452,0.00010558762,0.00011467607,0.00009068176,0.00013621105,0.00013885237,0.000009778309,0.00044903686,0.00002242866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111519235,0.00017694184,0.0016425974,0.000008093471,0.00021376157,0.000600359,0.0013801935,0.000003483991,0.121985614,0.000013155566,0.0012940323,0.8725703],"study_design_scores_gemma":[0.013705809,0.0016008201,0.30098802,0.010465424,0.0010318079,0.23999155,0.012159343,0.0000066263124,0.36211205,0.00034733847,0.056521572,0.0010696643],"about_ca_topic_score_codex":0.000037170932,"about_ca_topic_score_gemma":0.00041112656,"teacher_disagreement_score":0.8715006,"about_ca_system_score_codex":0.00006389372,"about_ca_system_score_gemma":0.00007517426,"threshold_uncertainty_score":0.43057382},"labels":[],"label_agreement":null},{"id":"W2020906240","doi":"10.1038/ng.689","title":"Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2","year":2010,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":362,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Single-nucleotide polymorphism; Psoriasis; Biology; Genome-wide association study; Locus (genetics); Genetics; Psoriatic arthritis; Genetic association; Disease; SNP; Genotype; Gene; Immunology; Internal medicine; Medicine","score_opus":0.008799259409241606,"score_gpt":0.24551446979487454,"score_spread":0.23671521038563292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020906240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985,0.0036388661,0.0000043115783,0.0002070183,0.004999661,0.00058925065,0.0001096859,0.000111827714,0.00048940914],"genre_scores_gemma":[0.9908853,0.00013863322,0.000094901894,0.0001257841,0.0002410862,0.000041776155,0.0002136484,0.00002855104,0.008230282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982677,0.0002561405,0.0003487522,0.00054039084,0.00012559658,0.00046141905],"domain_scores_gemma":[0.9985568,0.000353985,0.00020717083,0.00063699693,0.00020177366,0.000043254742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058315473,0.00028714727,0.00034697138,0.00010842362,0.00034887483,0.000037996975,0.0003286038,0.0012319621,0.00090883876],"category_scores_gemma":[0.00043488713,0.00025654517,0.0001772253,0.00020775612,0.000069442096,0.00005018576,0.00013524598,0.0008255198,0.00074139965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012774814,0.00052156183,0.8015159,0.000008414398,0.00054049335,0.000008490644,0.0010085824,0.0000022611855,0.18980359,0.0000044694925,0.0023564764,0.004102037],"study_design_scores_gemma":[0.0018950219,0.00021039828,0.87962997,0.0000022484394,0.00041361316,0.000005697888,0.00024187563,3.3947242e-7,0.08883153,0.00012545036,0.028372264,0.00027159808],"about_ca_topic_score_codex":0.000022588616,"about_ca_topic_score_gemma":0.0030792572,"teacher_disagreement_score":0.10097206,"about_ca_system_score_codex":0.000184874,"about_ca_system_score_gemma":0.000055812157,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W2021667566","doi":"10.1097/mib.0b013e3182802a76","title":"IL-25 Downregulates Th1/Th17 Immune Response in an IL-10–Dependent Manner in Inflammatory Bowel Disease","year":2013,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China","keywords":"Lamina propria; Inflammatory bowel disease; Tumor necrosis factor alpha; Immunology; T helper cell; Interleukin; T cell; Flow cytometry; Immune system; Interleukin 17; Intestinal mucosa; Ulcerative colitis; Medicine; Cytokine; Internal medicine; Pathology; Disease","score_opus":0.008995084923342781,"score_gpt":0.22426047272843921,"score_spread":0.21526538780509644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021667566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888245,0.0077860286,0.0000010565994,0.0003130555,0.00068192487,0.0013077313,0.0005793015,0.00030997302,0.00019644358],"genre_scores_gemma":[0.99394333,0.00022274085,0.000015078905,0.00013955212,0.00011294049,0.0010758722,0.0006238783,0.000097169155,0.003769433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495786,0.0015530898,0.0011524307,0.001009209,0.00017982443,0.0011475999],"domain_scores_gemma":[0.99740374,0.00042550356,0.0003156785,0.0013524521,0.00015014678,0.0003524958],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00058209855,0.00078977103,0.00063398894,0.00078743976,0.00028720545,0.00015007408,0.00077382074,0.00048342836,0.003327204],"category_scores_gemma":[0.00029164704,0.000730626,0.0003482561,0.00023967827,0.000443287,0.0011357157,0.00028675795,0.00037006722,0.0035849859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015808193,0.0019274676,0.88438845,0.00022665548,0.00039223064,0.0019652033,0.0012043027,0.00052899536,0.08334169,0.00051322003,0.0021089665,0.0075946534],"study_design_scores_gemma":[0.004644424,0.00018231716,0.9876819,0.0002102849,0.00016902624,0.000013615492,0.0005628409,0.00004670204,0.002351363,0.00074241444,0.0025383541,0.0008567424],"about_ca_topic_score_codex":0.00018047242,"about_ca_topic_score_gemma":0.00024132393,"teacher_disagreement_score":0.10329349,"about_ca_system_score_codex":0.0002854043,"about_ca_system_score_gemma":0.000411637,"threshold_uncertainty_score":0.99951446},"labels":[],"label_agreement":null},{"id":"W2021674244","doi":"10.1038/ni1439","title":"The adaptor Act1 is required for interleukin 17–dependent signaling associated with autoimmune and inflammatory disease","year":2007,"lang":"en","type":"article","venue":"Nature Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":604,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Ubiquitin ligase; Experimental autoimmune encephalomyelitis; Inflammation; Signal transducing adaptor protein; Immunology; Signal transduction; Biology; Cell biology; Immune system; Ubiquitin; Gene","score_opus":0.008614561718123904,"score_gpt":0.23422580435540222,"score_spread":0.2256112426372783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021674244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94306123,0.053813696,0.00011681932,0.0006533881,0.0011716916,0.00066256715,0.00014416424,0.00014196553,0.00023447968],"genre_scores_gemma":[0.9947861,0.00030096274,0.000058131576,0.00035005252,0.000060266822,0.00009406991,0.00024184783,0.000038334143,0.0040702713],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998263,0.00018951512,0.0003873177,0.0004273883,0.000059963353,0.0006728437],"domain_scores_gemma":[0.9979539,0.001148479,0.00027636875,0.00041579994,0.00016659856,0.000038840637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073906843,0.00032394132,0.00036273646,0.00012788823,0.00065447215,0.00003267816,0.00033371616,0.0008853217,0.000046577636],"category_scores_gemma":[0.0003207439,0.00021344176,0.0001263993,0.00013207922,0.00040617093,0.000101047335,0.00010549007,0.00062939315,0.000020864765],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02279461,0.0005004473,0.010821319,0.000042804764,0.0082054045,0.00018632252,0.0018051951,0.0000028960703,0.87625635,0.005850878,0.004589186,0.0689446],"study_design_scores_gemma":[0.021115849,0.0021271512,0.43543923,0.00039594504,0.0016384836,0.00020406998,0.0019540347,0.000013671569,0.3670805,0.0016495353,0.16687354,0.0015079834],"about_ca_topic_score_codex":0.000010562778,"about_ca_topic_score_gemma":0.00010455453,"teacher_disagreement_score":0.50917584,"about_ca_system_score_codex":0.00013014827,"about_ca_system_score_gemma":0.00012257356,"threshold_uncertainty_score":0.87039024},"labels":[],"label_agreement":null},{"id":"W2021710624","doi":"10.1038/nrrheum.2011.169","title":"Genetics of susceptibility and treatment response in psoriatic arthritis","year":2011,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Arthritis Society","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Disease; Candidate gene; Genome-wide association study; Immunology; Arthritis; Inflammatory arthritis; Genetic predisposition; Bioinformatics; Genetics; Gene; Single-nucleotide polymorphism; Biology; Genotype; Internal medicine","score_opus":0.040792306074588114,"score_gpt":0.3150444648058217,"score_spread":0.2742521587312336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021710624","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003045902,0.99372935,0.0000016726982,0.0000098184255,0.0009637419,0.0019952687,0.0001603122,0.000025759533,0.000068145724],"genre_scores_gemma":[0.0007560095,0.9982251,0.00014645347,0.000008644365,0.0000109700895,0.00037244472,0.00025601877,0.000045862398,0.0001785178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270207,0.0041157496,0.0018341852,0.0008243413,0.000031032036,0.0004926309],"domain_scores_gemma":[0.9969283,0.001040505,0.001020934,0.0009149309,0.000049505572,0.000045860274],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011141306,0.0007869764,0.0059662764,0.00044577508,0.000060154263,0.0000051973934,0.00032341896,0.0028472242,0.00029731935],"category_scores_gemma":[0.00040712752,0.00055116165,0.00070855493,0.00036052504,0.00031114195,0.00003342421,0.00010724774,0.0007159786,0.00026231195],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024666783,0.0002497628,0.00035953673,0.004892221,0.00042999233,0.00001581829,0.00016760937,5.5760494e-9,0.000004426165,0.0002263591,0.00015459664,0.993253],"study_design_scores_gemma":[0.0013491891,0.0005760622,0.0002549136,0.0093739815,0.0009525327,0.000757814,0.000009013543,5.2709456e-8,0.000021649652,0.00005649088,0.986269,0.00037930603],"about_ca_topic_score_codex":0.00006877283,"about_ca_topic_score_gemma":0.0003558735,"teacher_disagreement_score":0.99287367,"about_ca_system_score_codex":0.00015995264,"about_ca_system_score_gemma":0.00030863404,"threshold_uncertainty_score":0.999694},"labels":[],"label_agreement":null},{"id":"W2022258009","doi":"10.3899/jrheum.101124","title":"Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Pathogenesis; Dermatology; Comorbidity; Arthritis; Intensive care medicine; Physical therapy; Internal medicine","score_opus":0.03757908501458412,"score_gpt":0.25842277366660804,"score_spread":0.22084368865202392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022258009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79972243,0.19823474,0.000024835861,0.0003890782,0.0010980172,0.0003468902,0.00008625119,0.000007154591,0.00009060738],"genre_scores_gemma":[0.9084844,0.090861894,0.00047810856,0.00003226514,0.000041024636,0.00005032279,0.000014941981,0.000014537865,0.000022532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969398,0.0016948603,0.00067162915,0.00021941845,0.00010636933,0.0003679685],"domain_scores_gemma":[0.99790144,0.0011863147,0.0003889854,0.0003161622,0.00017999738,0.00002707925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002952975,0.00018682147,0.0005772594,0.0001645339,0.00040244308,0.000015504098,0.00026795306,0.00017860002,0.000025991425],"category_scores_gemma":[0.00017513693,0.00010854526,0.00015615218,0.00015544251,0.00065972423,0.00009261156,0.00011386619,0.00026679534,0.000003248515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076149423,0.00041232724,0.16488782,0.00017167912,0.013765009,0.0011162579,0.06257779,0.0000053635413,0.0009875521,0.0038229742,0.014666331,0.72997195],"study_design_scores_gemma":[0.033712726,0.0043386114,0.3508011,0.0016687276,0.0052915607,0.06079849,0.29860726,0.00000545409,0.007566182,0.030392013,0.20537591,0.0014419418],"about_ca_topic_score_codex":0.0013048577,"about_ca_topic_score_gemma":0.00057671044,"teacher_disagreement_score":0.72853,"about_ca_system_score_codex":0.000020373818,"about_ca_system_score_gemma":0.000062898274,"threshold_uncertainty_score":0.44263473},"labels":[],"label_agreement":null},{"id":"W2023039127","doi":"10.1016/j.jaad.2011.07.034","title":"Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology","funders":"","keywords":"Medicine; Etanercept; Scalp; Placebo; Dermatology Life Quality Index; Psoriasis; Internal medicine; Randomized controlled trial; Adverse effect; Surgery; Clinical endpoint; Dermatology; Gastroenterology; Tumor necrosis factor alpha; Pathology","score_opus":0.03386156533134699,"score_gpt":0.27507144587953,"score_spread":0.241209880548183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023039127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957181,0.0006043632,0.00011081221,0.0012873441,0.00025031163,0.0016222926,0.000012578084,0.000011639762,0.0003825351],"genre_scores_gemma":[0.9986442,0.00017386478,0.00047746883,0.00038323583,0.000029802046,0.00009524217,0.0000014146635,0.000025524063,0.00016928658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961196,0.0016682877,0.0014225785,0.0002512786,0.00015694633,0.000381279],"domain_scores_gemma":[0.99600935,0.0005436496,0.002947256,0.00026507044,0.00016340664,0.000071271075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006310207,0.0003438524,0.0027964462,0.00043536187,0.00012279047,0.000005678688,0.0007899425,0.0001980781,0.000100086036],"category_scores_gemma":[0.000071513714,0.00018908594,0.0004918462,0.00042937367,0.0006847784,0.00011554385,0.00013844333,0.00048403654,0.000017072553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9719665,0.0011184523,0.0070497217,0.000021196869,0.006776359,0.000027161152,0.005878926,0.00013363526,0.00519201,0.00022278265,0.00048200772,0.0011312499],"study_design_scores_gemma":[0.9203738,0.0017558641,0.0025014316,0.00010518654,0.0036122177,0.0027406043,0.004834579,0.000008661761,0.06332151,0.00023566696,0.00019410951,0.00031639196],"about_ca_topic_score_codex":0.00019213241,"about_ca_topic_score_gemma":0.000043312997,"teacher_disagreement_score":0.058129497,"about_ca_system_score_codex":0.000038201946,"about_ca_system_score_gemma":0.0001417195,"threshold_uncertainty_score":0.7710701},"labels":[],"label_agreement":null},{"id":"W2023850571","doi":"10.1038/psp.2013.22","title":"Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis","year":2013,"lang":"en","type":"article","venue":"CPT Pharmacometrics & Systems Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Pfizer","keywords":"Tofacitinib; Janus kinase inhibitor; Medicine; Psoriasis; Pharmacokinetics; Clinical trial; Placebo; Population; Pharmacology; Plaque psoriasis; Internal medicine; Covariate; Dosing; Dermatology; Rheumatoid arthritis; Statistics; Pathology; Mathematics","score_opus":0.03613601634449804,"score_gpt":0.30933716649492865,"score_spread":0.2732011501504306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023850571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590135,0.033575274,0.000018396388,0.00022554162,0.0039965576,0.0024440964,0.0005626555,0.000058529422,0.00010544929],"genre_scores_gemma":[0.99096906,0.0072244178,0.00004068514,0.00012993453,0.00029048754,0.0007893198,0.00017511807,0.000052259154,0.00032873458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936917,0.0032908132,0.001299044,0.00069174025,0.0001831698,0.000843521],"domain_scores_gemma":[0.9965354,0.0019309421,0.0006377256,0.00047899553,0.00027442267,0.00014250126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013300906,0.0006222661,0.0012022525,0.0016159636,0.00017668647,0.0000363636,0.000620508,0.00041741884,0.0008340318],"category_scores_gemma":[0.00006185883,0.0004684704,0.00022876401,0.0019287491,0.00047976227,0.0002824064,0.0000935111,0.00033577933,0.00009087227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030623209,0.0041644983,0.009222901,0.0002082471,0.0009819536,0.00010549195,0.0024235433,0.00012170014,0.91505396,0.000050615457,0.0032491093,0.061355654],"study_design_scores_gemma":[0.03538133,0.006254511,0.0183979,0.000055685592,0.0015590144,0.00027581074,0.0010707224,0.00048299658,0.8324315,0.00002014752,0.103361934,0.0007084476],"about_ca_topic_score_codex":0.0009353866,"about_ca_topic_score_gemma":0.000016496728,"teacher_disagreement_score":0.100112826,"about_ca_system_score_codex":0.0003284515,"about_ca_system_score_gemma":0.00023785522,"threshold_uncertainty_score":0.9997767},"labels":[],"label_agreement":null},{"id":"W2024540441","doi":"10.1089/vim.2008.0014","title":"Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling","year":2008,"lang":"en","type":"article","venue":"Viral Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Multiple Sclerosis Society","keywords":"Central nervous system; Coronavirus; Neuroscience; Biology; Signal transduction; Immunology; Neuroinflammation; Virology; Medicine; Coronavirus disease 2019 (COVID-19); Inflammation; Cell biology; Disease; Pathology; Infectious disease (medical specialty)","score_opus":0.0444133331523505,"score_gpt":0.2453639375782666,"score_spread":0.2009506044259161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024540441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964405,0.0007754354,0.00014839735,0.00003757825,0.0017501191,0.00061692944,0.00007693153,0.00004808684,0.000106049934],"genre_scores_gemma":[0.9990988,0.000039407987,0.000027758644,0.000040217335,0.000036316957,0.000076365795,0.000027787715,0.00002006526,0.00063330954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977124,0.0011209312,0.00044804413,0.0003095147,0.0000716536,0.00033749457],"domain_scores_gemma":[0.9990406,0.0001392839,0.00036745143,0.00037246812,0.00006839627,0.000011781754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027220137,0.00022540164,0.00040034097,0.00014875011,0.00033303397,0.0000039200277,0.00018180291,0.0003815803,0.000027415947],"category_scores_gemma":[0.00006124527,0.00017165352,0.0002994656,0.0001445321,0.00017591724,0.0000717382,0.00007289157,0.00022297841,0.00006646052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037191766,0.00021063846,0.0054282234,0.000017359778,0.0004929502,0.000014789851,0.0015374018,0.00010458833,0.98567694,0.00007958713,0.000024208173,0.0026941535],"study_design_scores_gemma":[0.0021462217,0.0010885864,0.09289642,0.000048120964,0.00014662878,0.000092575036,0.00012261323,0.000012774493,0.9031683,0.00000625668,0.00013645017,0.0001350166],"about_ca_topic_score_codex":0.000970095,"about_ca_topic_score_gemma":0.00004369166,"teacher_disagreement_score":0.08746819,"about_ca_system_score_codex":0.00019538376,"about_ca_system_score_gemma":0.00012254275,"threshold_uncertainty_score":0.6999827},"labels":[],"label_agreement":null},{"id":"W2024626717","doi":"10.2310/7750.2014.13191","title":"Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada","year":2014,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Plaque psoriasis; Infliximab; Placebo; Odds ratio; Meta-analysis; Internal medicine; Adverse effect; Clinical trial; Dermatology; Pathology; Tumor necrosis factor alpha; Alternative medicine","score_opus":0.09961051167293497,"score_gpt":0.31082471846107984,"score_spread":0.21121420678814487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024626717","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054784876,0.99773514,0.000015108339,0.00012457308,0.0011059005,0.00029740523,0.00013285757,0.000002588172,0.00003854798],"genre_scores_gemma":[0.0015708957,0.9973046,0.000020898606,0.00007973369,0.00031515816,0.00003228338,0.00025222197,0.000027717066,0.0003964658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965089,0.00059738744,0.0021194073,0.00026297203,0.00011741254,0.0003939246],"domain_scores_gemma":[0.99079704,0.0065189917,0.0022211045,0.00026582103,0.00013079062,0.000066260596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009690637,0.000470979,0.010303693,0.00088196975,0.000058961068,0.0000036638958,0.00017663688,0.00033580817,0.0003622205],"category_scores_gemma":[0.00019564145,0.00027197032,0.0024608811,0.00059632346,0.00008258485,0.00002775929,0.000018286673,0.0002469835,0.0000012916701],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019510264,0.00006716817,0.0002632036,0.0019109484,0.4313791,0.0004199747,0.00005471888,0.000047693815,0.0000021771593,0.000012166895,0.018771755,0.54687595],"study_design_scores_gemma":[0.00041867662,0.0002375542,0.000014593054,0.0009233532,0.47060403,0.00087045383,0.000020688585,0.000001109083,0.000002163109,0.000015361275,0.5267404,0.00015163608],"about_ca_topic_score_codex":0.04413731,"about_ca_topic_score_gemma":0.15574403,"teacher_disagreement_score":0.5467243,"about_ca_system_score_codex":0.00037621986,"about_ca_system_score_gemma":0.0020995366,"threshold_uncertainty_score":0.99997324},"labels":[],"label_agreement":null},{"id":"W2024643527","doi":"10.1007/s10227-005-0117-0","title":"Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Genentech","keywords":"Efalizumab; Medicine; Adverse effect; Placebo; Psoriasis; Clinical trial; Incidence (geometry); Dermatology; Internal medicine; Plaque psoriasis; Pathology; Alternative medicine","score_opus":0.07264368308476009,"score_gpt":0.34332635255601374,"score_spread":0.27068266947125363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024643527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002821059,0.9948696,0.0000021889073,0.00022024871,0.0012161472,0.00051186595,0.00026208407,0.000004235219,0.000092600574],"genre_scores_gemma":[0.00039452434,0.99810773,0.000035149085,0.0001810986,0.000520121,0.0000055830715,0.0005533615,0.000031382253,0.0001710686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941926,0.0009220556,0.0040103984,0.00036706653,0.0001983313,0.00030956935],"domain_scores_gemma":[0.9941595,0.0019296387,0.0029182888,0.00059559033,0.00029680226,0.000100146994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002285417,0.00044327165,0.006290298,0.00042273116,0.000053691492,0.0000022626416,0.00036388962,0.0004442956,0.0002796692],"category_scores_gemma":[0.00076216756,0.00025630448,0.00043016867,0.00032391062,0.00017918866,0.00009294797,0.000118626216,0.00055709895,0.0000062999575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018104807,0.00033974362,0.00060331647,0.01516085,0.0016035952,0.00017962861,0.000051006522,0.0000013373035,1.7726248e-7,0.0000027348524,0.02560463,0.9546425],"study_design_scores_gemma":[0.0018597564,0.0013453851,0.00009619178,0.18062842,0.002901437,0.001558345,0.00001010828,1.2763084e-7,7.6404416e-7,0.0000017331483,0.81139666,0.00020109362],"about_ca_topic_score_codex":0.000014998019,"about_ca_topic_score_gemma":0.00002638692,"teacher_disagreement_score":0.9544414,"about_ca_system_score_codex":0.00007982537,"about_ca_system_score_gemma":0.0011813868,"threshold_uncertainty_score":0.9999889},"labels":[],"label_agreement":null},{"id":"W2025042808","doi":"10.1016/j.jval.2013.03.1158","title":"Improvements In Productivity At Paid Work And Within Household, And Increased Participation In Daily Activities After 24 Weeks Of Certolizumab Pegol Treatment Of Patients With Psoriatic Arthritis: Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study","year":2013,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Certolizumab pegol; Presenteeism; Medicine; Placebo; Work productivity; Absenteeism; Psoriatic arthritis; Productivity; Bristol-Myers; Randomized controlled trial; Internal medicine; Physical therapy; Arthritis; Rheumatoid arthritis; Adalimumab; Alternative medicine; Psychology","score_opus":0.030234618528876364,"score_gpt":0.26830918071231474,"score_spread":0.23807456218343837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025042808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897017,0.0016773522,7.197711e-7,0.000054058186,0.000105067294,0.008345031,0.000104389044,0.000007728862,0.000003935305],"genre_scores_gemma":[0.9977823,0.00018753082,0.00005055881,0.000002510284,0.0000056312915,0.0018767266,0.00005457183,0.000014587638,0.00002560412],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99654925,0.0015634965,0.0011356466,0.00038016573,0.0000887399,0.000282679],"domain_scores_gemma":[0.99835753,0.0005880029,0.00072513113,0.0002483071,0.000044992383,0.000036053763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006768937,0.00024008637,0.0013983898,0.00033508163,0.00003564208,0.00000611711,0.000043137075,0.000103506274,0.00001022519],"category_scores_gemma":[0.00009998063,0.00017251696,0.00004697891,0.00022452233,0.00015261062,0.00014641623,0.000029029658,0.000075824595,4.335326e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6780735,0.0076950938,0.29453206,0.0001100983,0.0002716218,0.000005214484,0.011695445,0.000044443812,0.0003999126,0.0000020930433,0.000001081183,0.0071694497],"study_design_scores_gemma":[0.7634392,0.004255837,0.2279962,0.00024430506,0.00011132766,0.0000012615806,0.00047308378,0.000034751225,0.0033080052,0.000022949745,4.007205e-7,0.00011272639],"about_ca_topic_score_codex":0.014810302,"about_ca_topic_score_gemma":0.0042555747,"teacher_disagreement_score":0.08536566,"about_ca_system_score_codex":0.00014520716,"about_ca_system_score_gemma":0.00012219811,"threshold_uncertainty_score":0.9917502},"labels":[],"label_agreement":null},{"id":"W2025490383","doi":"10.1111/j.1365-2133.2008.08927.x","title":"A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial","year":2008,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma","keywords":"Calcipotriol; Betamethasone dipropionate; Scalp; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Betamethasone; Double blind; Surgery; Internal medicine; Placebo","score_opus":0.04040179878295714,"score_gpt":0.2816668870223897,"score_spread":0.24126508823943255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025490383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791402,0.015438521,0.0006422814,0.0003232478,0.00041930954,0.003945368,0.00006066464,0.0000044489007,0.000025914705],"genre_scores_gemma":[0.99703723,0.0023051,0.00022047463,0.000015260091,0.00006200836,0.00026183398,0.000034884226,0.000013198227,0.000050015384],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99723643,0.0008586696,0.0013295042,0.00016565618,0.00013648067,0.0002732744],"domain_scores_gemma":[0.9954809,0.0023772786,0.0015634138,0.00016257433,0.000385968,0.000029899878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045185414,0.00020887413,0.0019989228,0.0001835533,0.00014289253,0.0000069278103,0.00027944645,0.00023120726,0.000021407315],"category_scores_gemma":[0.00017665616,0.00012053523,0.0005671523,0.00023176822,0.0002911224,0.000121358906,0.000016223074,0.00015719327,0.0000010255633],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97546846,0.0012416706,0.00063326303,0.000024878838,0.0025297224,0.000069354755,0.0038209294,0.00009293923,0.0011675023,0.00009758481,0.00007659095,0.014777103],"study_design_scores_gemma":[0.9638343,0.0016816182,0.0028691026,0.00015135192,0.0014904549,0.0034588964,0.0005651126,0.00007708536,0.025576964,0.00007083352,0.00012017392,0.00010413111],"about_ca_topic_score_codex":0.00045399863,"about_ca_topic_score_gemma":0.00027763753,"teacher_disagreement_score":0.024409462,"about_ca_system_score_codex":0.000061320185,"about_ca_system_score_gemma":0.0003460657,"threshold_uncertainty_score":0.49152842},"labels":[],"label_agreement":null},{"id":"W2025589393","doi":"10.1159/000182207","title":"Active Psoriasis Unassociated with Proteinuria","year":2008,"lang":"en","type":"article","venue":"˜The œNephron journals/Nephron journals","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Memorial University of Newfoundland","funders":"","keywords":"Proteinuria; Medicine; Psoriasis; Titer; Internal medicine; Gastroenterology; Dermatology; Immunology; Kidney; Antibody","score_opus":0.02909359044765884,"score_gpt":0.25580725173053637,"score_spread":0.22671366128287754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025589393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671783,0.023358105,0.00041807574,0.0028206485,0.0015843828,0.0013067063,0.00014910148,0.00023738158,0.002947304],"genre_scores_gemma":[0.98113954,0.005179314,0.00030178498,0.0009020266,0.0009022862,0.00017782627,0.00005958107,0.00015199142,0.011185643],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99413115,0.0017971902,0.0012769961,0.0007241601,0.00050104014,0.0015694484],"domain_scores_gemma":[0.99609953,0.00049135945,0.0016001695,0.0008761663,0.0006634531,0.00026929445],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001566315,0.00091569277,0.0012141726,0.0004973143,0.0026195513,0.0001780284,0.0010435242,0.0007192656,0.0067032287],"category_scores_gemma":[0.0001121691,0.0005749794,0.0006290006,0.0010261093,0.00063232036,0.000700308,0.00013827192,0.0016891927,0.0015372364],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01423189,0.0036731653,0.040051367,0.00007598248,0.025285784,0.0032764613,0.018059492,0.00035106388,0.4932865,0.0002052425,0.15474069,0.24676238],"study_design_scores_gemma":[0.035448063,0.0039306898,0.39449742,0.0012918155,0.0036764413,0.036307927,0.0051326584,0.000022285598,0.15271,0.0016790502,0.3617623,0.00354136],"about_ca_topic_score_codex":0.00013566477,"about_ca_topic_score_gemma":0.00019985842,"teacher_disagreement_score":0.35444605,"about_ca_system_score_codex":0.00051659776,"about_ca_system_score_gemma":0.0006019341,"threshold_uncertainty_score":0.99967015},"labels":[],"label_agreement":null},{"id":"W2025692360","doi":"10.1159/000246851","title":"Long-Term Use of Topical Calcipotriol in Chronic Plaque Psoriasis","year":2009,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Calcipotriol; Medicine; Psoriasis; Tolerability; Plaque psoriasis; Psoriasis Area and Severity Index; Dermatology; Prospective cohort study; Dithranol; Surgery; Adverse effect; Internal medicine","score_opus":0.026207253351737743,"score_gpt":0.26721661385256085,"score_spread":0.2410093605008231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025692360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962871,0.0022001853,0.00010461453,0.00041971751,0.00041435496,0.000189815,0.000017778004,0.000041470135,0.0003249667],"genre_scores_gemma":[0.99905,0.00025976897,0.000060582483,0.0001422251,0.000028210316,0.000017346918,0.00010621024,0.000007876912,0.00032778626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987076,0.00023679294,0.00038889723,0.00026054634,0.000023920677,0.00038223475],"domain_scores_gemma":[0.99938446,0.0001791756,0.0000980202,0.00028932755,0.000025958772,0.000023031796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004165093,0.00017769812,0.00046665073,0.00018287203,0.00004657203,0.0000048696697,0.0001687073,0.0004419835,0.0002553499],"category_scores_gemma":[0.00003669316,0.0001593189,0.000110666086,0.00015158839,0.0001248126,0.00008447577,0.00003262787,0.00016117984,0.0001762303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000756089,0.0007146824,0.7091806,0.000064494845,0.00035646048,0.0008398303,0.0010025206,0.000019504432,0.18539192,0.008351167,0.001966739,0.091356],"study_design_scores_gemma":[0.0031359065,0.0002428864,0.8109687,0.00003385392,0.00007754571,0.0008246949,0.000016537457,0.0000053793606,0.18123183,0.00013197937,0.0031322823,0.00019839949],"about_ca_topic_score_codex":0.0000719002,"about_ca_topic_score_gemma":0.00030511068,"teacher_disagreement_score":0.10178811,"about_ca_system_score_codex":0.00008657234,"about_ca_system_score_gemma":0.00010204654,"threshold_uncertainty_score":0.6496836},"labels":[],"label_agreement":null},{"id":"W2026049639","doi":"10.7439/ijbr.v5i4.567","title":"Lipid profile and its relationship to Oxidant and Antioxidant status in Psoriatic Arthritis","year":2014,"lang":"en","type":"article","venue":"International Journal of Biomedical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Malondialdehyde; Psoriatic arthritis; Medicine; Lipid peroxidation; Glutathione peroxidase; Superoxide dismutase; Dyslipidemia; Oxidative stress; Psoriasis; Antioxidant; Glutathione reductase; Arthritis; Internal medicine; Lipid profile; Endocrinology; Cholesterol; Immunology; Biochemistry; Chemistry; Disease","score_opus":0.041842729187018174,"score_gpt":0.35000170364904754,"score_spread":0.30815897446202933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026049639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269176,0.0030988099,0.00012152471,0.0030431435,0.0006829131,0.00012214293,0.000026633832,0.0000050268427,0.00020805543],"genre_scores_gemma":[0.99763614,0.001476105,0.00030404702,0.00004732776,0.00019287996,0.0000094697,0.000012115337,0.00000668063,0.00031520796],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984433,0.0004260532,0.00039446793,0.00015723993,0.00028990582,0.00028900316],"domain_scores_gemma":[0.99845046,0.0009493301,0.00008441576,0.00006298138,0.00032517588,0.00012765672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019088436,0.000080231424,0.00018912298,0.0007387951,0.00007040868,0.000035030716,0.00018579626,0.00012318451,0.00017060062],"category_scores_gemma":[0.002683988,0.00006281119,0.000032446074,0.00021595138,0.00014943459,0.00010355284,0.000113730435,0.00034855164,0.00009205248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010057498,0.0004793834,0.034050595,0.000026257225,0.0002744513,0.00019848191,0.0012136126,9.961419e-7,0.13761371,0.0053916816,0.0027036683,0.8170414],"study_design_scores_gemma":[0.00864029,0.0020898422,0.8907735,0.00080142164,0.000026640664,0.0010450449,0.000460444,0.00010363289,0.0147155635,0.0030359114,0.07806966,0.00023805402],"about_ca_topic_score_codex":0.00003926495,"about_ca_topic_score_gemma":0.000026455094,"teacher_disagreement_score":0.8567229,"about_ca_system_score_codex":0.00007190658,"about_ca_system_score_gemma":0.00011714604,"threshold_uncertainty_score":0.32131785},"labels":[],"label_agreement":null},{"id":"W2026261818","doi":"10.1016/j.jaad.2006.09.002","title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Allergan; 3M; Astellas Pharma US; Amgen; Biogen; Abbott Laboratories","keywords":"Medicine; Etanercept; Discontinuation; Clinical endpoint; Psoriasis; Randomized controlled trial; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Surgery; Internal medicine; Dermatology","score_opus":0.04710496800482027,"score_gpt":0.33180287935337477,"score_spread":0.2846979113485545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026261818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99067193,0.0045580934,0.0000085407455,0.002900316,0.0006068611,0.000818095,0.000025114708,0.0000032284343,0.0004078167],"genre_scores_gemma":[0.9960701,0.0034668571,0.00015241985,0.00012090402,0.000055866807,0.00003191503,0.000004011988,0.000011997024,0.0000859309],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99564403,0.0024543698,0.0014103748,0.00014486352,0.00009891175,0.0002474625],"domain_scores_gemma":[0.9948626,0.0017503479,0.0030811136,0.00022192967,0.0000700493,0.000013945708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005443769,0.00022949703,0.0020683317,0.00023060024,0.000050215844,0.000005331396,0.001008827,0.0001850764,0.000038692953],"category_scores_gemma":[0.00010653111,0.00011352216,0.0005032101,0.00035541318,0.0012339448,0.00006544896,0.0000535006,0.00023532358,0.0000031398051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9175541,0.0035548836,0.0018902753,0.000008297761,0.0022787526,0.0000188043,0.0015550579,0.0000071608047,0.033867624,0.0005465279,0.0010232796,0.03769528],"study_design_scores_gemma":[0.9149018,0.0042090025,0.0030933837,0.000045719025,0.00081809785,0.00084048463,0.00096733536,0.0000026094285,0.06975817,0.0003967986,0.004831793,0.00013479417],"about_ca_topic_score_codex":0.0004519767,"about_ca_topic_score_gemma":0.000021779664,"teacher_disagreement_score":0.037560485,"about_ca_system_score_codex":0.00004350561,"about_ca_system_score_gemma":0.000096004034,"threshold_uncertainty_score":0.46292993},"labels":[],"label_agreement":null},{"id":"W2026687111","doi":"10.1007/s10875-012-9828-3","title":"Glucocorticoid Receptor-Beta Up-Regulation and Steroid Resistance Induction by IL-17 and IL-23 Cytokine Stimulation in Peripheral Mononuclear Cells","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada)","funders":"National Plan for Science, Technology and Innovation; Canadian Institutes of Health Research","keywords":"Dexamethasone; Glucocorticoid receptor; Glucocorticoid; Endocrinology; Peripheral blood mononuclear cell; Interleukin 17; Internal medicine; Cytokine; Interleukin; Medicine; Biology; Immunology; In vitro; Biochemistry","score_opus":0.03174977455880341,"score_gpt":0.3002122914244146,"score_spread":0.2684625168656112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026687111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862089,0.010199454,0.000088805915,0.00045747714,0.0027583179,0.00017641258,0.000023998045,0.000011458771,0.000075150594],"genre_scores_gemma":[0.99457157,0.002895196,0.0003513885,0.00007144098,0.00018951266,0.000003372277,0.000045167457,0.000018229632,0.0018541196],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975248,0.0007051727,0.0011822729,0.00022017738,0.000054259224,0.00031331944],"domain_scores_gemma":[0.99844074,0.00044477844,0.00078934,0.00017514109,0.000102743994,0.000047248348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010037078,0.00018918677,0.0006365368,0.00014392876,0.00008789125,0.00001670813,0.000104187864,0.0005627732,0.00017671764],"category_scores_gemma":[0.00013807672,0.00016239051,0.00010851569,0.00011172295,0.00025334614,0.00043624983,0.000055611537,0.00049792347,0.000041975745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046325102,0.0004982189,0.101932764,0.000016127005,0.0005619867,0.0000027621134,0.000626323,0.000019309628,0.82307845,0.000127172,0.002718824,0.06578556],"study_design_scores_gemma":[0.008924909,0.001285927,0.90188825,0.000077314835,0.00024261717,0.000108725595,0.00033572098,0.000012149768,0.03692539,0.00017439252,0.04975154,0.00027306812],"about_ca_topic_score_codex":0.000011800245,"about_ca_topic_score_gemma":0.0000131245,"teacher_disagreement_score":0.7999555,"about_ca_system_score_codex":0.00006107678,"about_ca_system_score_gemma":0.00003924619,"threshold_uncertainty_score":0.6622093},"labels":[],"label_agreement":null},{"id":"W2026774405","doi":"10.3899/jrheum.090213","title":"What's New in Laboratory Research?","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Epidermis (zoology); Keratinocyte; Medicine; Immunology; Effector; Immune system; Integrin; Cell biology; Pathogenesis; Cancer research; Biology; Receptor; Cell culture; Internal medicine; Genetics","score_opus":0.03168500837421118,"score_gpt":0.3168695978845745,"score_spread":0.28518458951036335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026774405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593145,0.023751749,0.000027985514,0.014193091,0.0024055953,0.00017068228,0.000010234703,0.000011305744,0.00011481454],"genre_scores_gemma":[0.9930357,0.005592085,0.0005136328,0.00018676456,0.0000339835,0.0000034853163,0.00002222029,0.000008755491,0.0006033761],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979746,0.0005764216,0.00070301065,0.00016700568,0.00009551405,0.0004834641],"domain_scores_gemma":[0.9990495,0.0002512683,0.00025513288,0.00020189432,0.00018321796,0.00005902305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013349525,0.00014659321,0.0004624884,0.0005540092,0.000090535184,0.000028064793,0.00030449417,0.00021245603,0.0013886476],"category_scores_gemma":[0.000118094074,0.000119067445,0.00010198298,0.0003009252,0.000089478504,0.00034082195,0.000035782217,0.0004426987,0.00020147003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020196962,0.0015981267,0.16347641,0.000027454862,0.00083509804,0.0005575047,0.0056046373,0.000017210092,0.037375443,0.010393062,0.58932614,0.18876922],"study_design_scores_gemma":[0.020047244,0.0042076358,0.077332914,0.0006181705,0.00014130508,0.0028065313,0.008146436,0.000001264511,0.064009316,0.00980436,0.81235987,0.00052493566],"about_ca_topic_score_codex":0.0000670035,"about_ca_topic_score_gemma":0.00014741549,"teacher_disagreement_score":0.22303376,"about_ca_system_score_codex":0.000118762866,"about_ca_system_score_gemma":0.00037580202,"threshold_uncertainty_score":0.99952424},"labels":[],"label_agreement":null},{"id":"W2027016939","doi":"10.1097/00000372-200006000-00013","title":"Histopathology of Psoriasis Treated With Zinc Pyrithione","year":2000,"lang":"en","type":"article","venue":"American Journal of Dermatopathology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Psoriasis; Histopathology; Medicine; Seborrheic dermatitis; Dermatology; Dandruff; Pathogenesis; Cytokine; Pathology; Immunology; Shampoo","score_opus":0.007011949983650793,"score_gpt":0.2146995517797156,"score_spread":0.2076876017960648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027016939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537385,0.0021117073,0.00012372747,0.0003246209,0.0002613855,0.000104851846,0.000029312665,0.00003068378,0.0016398588],"genre_scores_gemma":[0.9970913,0.0005717828,0.0013191288,0.00020879696,0.00005341117,0.000008355646,0.000020210387,0.00003116115,0.0006958696],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977403,0.00069102546,0.0008155701,0.00025620396,0.0000765106,0.00042034575],"domain_scores_gemma":[0.99827754,0.00019290896,0.00090003794,0.00034808833,0.0002199445,0.00006149457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030362242,0.00028957354,0.0011186941,0.00034380067,0.00009842491,0.000004636439,0.00033936993,0.00017462453,0.0010192776],"category_scores_gemma":[0.0000325796,0.00021314353,0.00022673215,0.00041337198,0.0011490075,0.00011693231,0.000023281467,0.00028690632,0.0001500472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005014442,0.0009736571,0.33913064,0.00002305785,0.00062812376,0.0021065501,0.0018340647,0.00004033399,0.11172038,0.00027131467,0.0009909967,0.53726643],"study_design_scores_gemma":[0.016529897,0.018287124,0.46561632,0.00022861052,0.0024857973,0.2567899,0.0021930458,0.0000033660745,0.18849817,0.000306056,0.047864743,0.0011969891],"about_ca_topic_score_codex":0.00004873044,"about_ca_topic_score_gemma":0.000008895832,"teacher_disagreement_score":0.53606945,"about_ca_system_score_codex":0.000048640515,"about_ca_system_score_gemma":0.000118392374,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W2028187033","doi":"10.3899/jrheum.090214","title":"Clinical Aspects and Comorbidities of Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dyslipidemia; Disease; Metabolic syndrome; Dermatology; Depression (economics); Type 2 diabetes; Diabetes mellitus; Abdominal obesity; Stroke (engine); Obesity; Internal medicine; Endocrinology","score_opus":0.02412554104787581,"score_gpt":0.29523873175192444,"score_spread":0.27111319070404866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028187033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990205,0.006127606,0.0000842085,0.0017535016,0.0014512236,0.00009362628,0.000041702468,0.000008313848,0.00023482738],"genre_scores_gemma":[0.9952427,0.0034501727,0.0010836156,0.00008210204,0.000022234819,0.0000013936062,0.000022030254,0.000005731353,0.00008998966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982519,0.00029995598,0.0010332065,0.00013463483,0.00005388126,0.00022638908],"domain_scores_gemma":[0.99863833,0.0003526646,0.00069331226,0.00015370108,0.0001226712,0.00003930238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006520463,0.00014952818,0.00073747936,0.00016817698,0.0000691568,0.0000050450835,0.0001657899,0.0001906737,0.0006061381],"category_scores_gemma":[0.00009782943,0.00011445917,0.00019599129,0.00006265388,0.00020089466,0.000070970105,0.000033164702,0.00018733006,0.00001519364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001543791,0.0013237988,0.7590032,0.000056554563,0.0025171342,0.0000950518,0.0012687797,0.0000020258094,0.005181772,0.020913541,0.06724572,0.1408486],"study_design_scores_gemma":[0.03165727,0.013214221,0.716712,0.0004402535,0.0017028077,0.011840373,0.0035224543,0.0000032991675,0.07332616,0.015307022,0.13151921,0.0007549357],"about_ca_topic_score_codex":0.000026870715,"about_ca_topic_score_gemma":0.000021215443,"teacher_disagreement_score":0.14009367,"about_ca_system_score_codex":0.000018480228,"about_ca_system_score_gemma":0.000083234525,"threshold_uncertainty_score":0.66367865},"labels":[],"label_agreement":null},{"id":"W2028648418","doi":"10.1111/bjd.13551","title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","year":2014,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Tofacitinib; Medicine; Randomized controlled trial; Dermatology; Psoriasis; Surgery; Internal medicine","score_opus":0.006669906811866754,"score_gpt":0.22138959867279262,"score_spread":0.21471969186092588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028648418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98135155,0.013816291,0.0003402139,0.0007861973,0.001433008,0.0016458948,0.000020621103,0.000020695647,0.000585523],"genre_scores_gemma":[0.99740064,0.0015838599,0.00019517005,0.00015424332,0.00013374507,0.00021829511,0.000021605163,0.00002092702,0.00027149302],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99597937,0.0019529983,0.0012597389,0.0002860759,0.00007264471,0.00044915135],"domain_scores_gemma":[0.9981471,0.0009548304,0.0005472702,0.00014331713,0.00012337051,0.000084126696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078686234,0.0002793246,0.0026325847,0.000300405,0.00013940889,0.000049425245,0.00018070058,0.00038187995,0.0001680038],"category_scores_gemma":[0.00056434673,0.00024138876,0.00037789802,0.00011900456,0.00018827748,0.00012896542,0.00004556318,0.00032639076,0.00003957437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9701722,0.00036425903,0.0004852717,0.000017186161,0.0013603672,0.00101308,0.0002783093,0.000023029646,0.00050865236,0.0004341751,0.0008462467,0.02449719],"study_design_scores_gemma":[0.958167,0.00064616953,0.0003279886,0.0001930419,0.00047048024,0.03624046,0.000061078325,0.000029542283,0.0017444241,0.00048372534,0.0014097248,0.00022635749],"about_ca_topic_score_codex":0.00009377204,"about_ca_topic_score_gemma":0.00027427485,"teacher_disagreement_score":0.035227377,"about_ca_system_score_codex":0.00008753797,"about_ca_system_score_gemma":0.00022999992,"threshold_uncertainty_score":0.98435473},"labels":[],"label_agreement":null},{"id":"W2028737081","doi":"10.1016/j.cyto.2012.07.002","title":"IL-6 activates STAT5 in T cells","year":2012,"lang":"en","type":"article","venue":"Cytokine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"STAT5; Cell biology; Chemistry; Biology; Signal transduction","score_opus":0.01798860383305353,"score_gpt":0.23777071347815307,"score_spread":0.21978210964509953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028737081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939563,0.0021411963,0.00001169631,0.00006865925,0.0008348289,0.00009962177,0.00006348876,0.000042812942,0.0027813793],"genre_scores_gemma":[0.996627,0.00011303596,0.000073468225,0.00006343578,0.000070774455,0.000019654555,0.000092278235,0.000011368504,0.0029290402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993099,0.00007523948,0.00012331031,0.00012221093,0.000014437264,0.0003549099],"domain_scores_gemma":[0.9996978,0.00007983697,0.00003640623,0.00015518133,0.000010281893,0.000020509071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000110021814,0.000115949166,0.00016134807,0.00007810735,0.000044932647,0.0000036702536,0.0000819489,0.00012503893,0.00085728604],"category_scores_gemma":[0.000012851273,0.000094986,0.000043103657,0.00010839873,0.000039504277,0.000100013465,0.000032252065,0.000086910826,0.0016404976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102849386,0.00025750548,0.041088045,0.0000055525284,0.00006912674,0.0000043856335,0.00046386404,0.0000010304203,0.9324136,0.00022572519,0.0023573101,0.023011036],"study_design_scores_gemma":[0.0010169673,0.000044253997,0.07333875,0.0000086713435,0.000023947201,0.000008795394,0.00007923492,1.7354888e-7,0.82004327,0.0000361777,0.10528877,0.000110976674],"about_ca_topic_score_codex":0.00004446858,"about_ca_topic_score_gemma":0.000012099853,"teacher_disagreement_score":0.11237028,"about_ca_system_score_codex":0.000032981075,"about_ca_system_score_gemma":0.000012104001,"threshold_uncertainty_score":0.99913687},"labels":[],"label_agreement":null},{"id":"W2028782256","doi":"10.3899/jrheum.090210","title":"Immunopathogenesis of Psoriasis and Pharmacological Perspectives","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Intensive care medicine; Dermatology","score_opus":0.013492257397386583,"score_gpt":0.26679673615384775,"score_spread":0.25330447875646117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028782256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747953,0.022549806,0.00010175513,0.0016062421,0.0006431657,0.00013990978,0.00004093025,0.000011765271,0.00011115245],"genre_scores_gemma":[0.99296814,0.0056277127,0.0012400179,0.000045681143,0.000015868516,0.0000043507785,0.000011742883,0.000006870754,0.000079585094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983653,0.00030932037,0.00077491667,0.00018916707,0.00006776179,0.00029353474],"domain_scores_gemma":[0.99880946,0.0002140051,0.0006094975,0.0001327677,0.00019235384,0.000041922052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049097894,0.00020542371,0.0007099055,0.000245256,0.000106704196,0.0000063720313,0.00021639469,0.00018548318,0.0009120284],"category_scores_gemma":[0.00007668933,0.000153555,0.00020692732,0.00011719924,0.00019605563,0.000095126146,0.000043544635,0.00017098873,0.0000131466495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040313113,0.00266989,0.18119875,0.000054100736,0.004241656,0.00013497935,0.006530963,0.000008355798,0.654922,0.009559835,0.016996615,0.119651526],"study_design_scores_gemma":[0.03090572,0.01152088,0.34680358,0.00024375344,0.0032204718,0.014726657,0.016770834,0.0000048933503,0.54120046,0.0028379336,0.030780932,0.0009839003],"about_ca_topic_score_codex":0.000014047593,"about_ca_topic_score_gemma":0.000003070467,"teacher_disagreement_score":0.16560481,"about_ca_system_score_codex":0.000045055098,"about_ca_system_score_gemma":0.00007436259,"threshold_uncertainty_score":0.99860716},"labels":[],"label_agreement":null},{"id":"W2028836969","doi":"10.3899/jrheum.140180","title":"Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Outreach; Dermatology; Rheumatology; Family medicine; Medical education; Internal medicine; Medical physics","score_opus":0.009484108868532681,"score_gpt":0.23195889401650807,"score_spread":0.2224747851479754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028836969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97731775,0.014411999,0.00013980453,0.0061633056,0.001679384,0.00009534017,0.000060489303,0.000011011926,0.00012088701],"genre_scores_gemma":[0.9870515,0.012213585,0.0002644004,0.00029828164,0.00008081884,0.0000063916186,0.000040001996,0.000014387585,0.00003066272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99725574,0.0017562136,0.00052646396,0.00014536135,0.000058798367,0.00025741896],"domain_scores_gemma":[0.99633676,0.002632411,0.000586684,0.00025382967,0.00015139053,0.00003894189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010918623,0.00018514963,0.0004265876,0.00007846191,0.00041286464,0.000019261406,0.00039189402,0.00015657362,0.00030498946],"category_scores_gemma":[0.00032201814,0.00010285618,0.000086949934,0.00009395854,0.00035867462,0.00023485256,0.000061286155,0.00028262156,0.00010489829],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026117016,0.0009060061,0.41873652,0.000037292346,0.005591966,0.000008246075,0.045184847,0.00006044093,0.004615602,0.033237815,0.066528834,0.42248073],"study_design_scores_gemma":[0.023443852,0.0032672312,0.7073887,0.0010629763,0.0029138,0.018357098,0.028895095,0.00009469817,0.005214622,0.104709916,0.10313788,0.0015141107],"about_ca_topic_score_codex":0.0005428358,"about_ca_topic_score_gemma":0.00041633434,"teacher_disagreement_score":0.42096663,"about_ca_system_score_codex":0.000013643343,"about_ca_system_score_gemma":0.0000853345,"threshold_uncertainty_score":0.41943535},"labels":[],"label_agreement":null},{"id":"W2029128580","doi":"10.1111/exd.12710","title":"Evidence that a neutrophil–keratinocyte crosstalk is an early target of <scp>IL</scp>‐17A inhibition in psoriasis","year":2015,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Barrie Urology Group; AV&R (Canada); Innovation Initiatives Ontario North; Moncton Hospital; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada); Probity Medical Research","funders":"Cilag; LEO Pharma; AbbVie; Biogen Idec; Medac; Celgene; Novartis Pharma; Novartis; Novartis Institutes for BioMedical Research; Amgen; Pfizer; Kyowa Hakko Kirin; Eli Lilly and Company; Merck; GlaxoSmithKline","keywords":"Psoriasis; Secukinumab; CXCL1; Interleukin 17; Immunology; Medicine; Cytokine; Keratinocyte; Chemokine; Interleukin 8; Chemotaxis; CD11c; Internal medicine; Inflammation; Biology; Receptor; In vitro; Psoriatic arthritis","score_opus":0.059179566207339926,"score_gpt":0.2885891891835427,"score_spread":0.22940962297620276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029128580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98011845,0.017548982,0.00003761471,0.00013408232,0.0008967465,0.00036568215,0.0000835921,0.0000769402,0.00073792954],"genre_scores_gemma":[0.99850523,0.00012470549,0.00037259466,0.00024612935,0.00004076637,0.00013557242,0.0001634563,0.00003157171,0.0003799438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977755,0.0005339507,0.0005132482,0.0005441788,0.000092839524,0.00054027105],"domain_scores_gemma":[0.99894255,0.00017331503,0.00029731743,0.00042272813,0.000074620024,0.00008945309],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014901554,0.00034724272,0.0006031652,0.00024861266,0.000118703334,0.000027100894,0.00021021633,0.00044034419,0.00014475422],"category_scores_gemma":[0.00007484248,0.00033687794,0.00013212481,0.00023323056,0.00034704953,0.0005663495,0.00013744079,0.00018971045,0.00033800874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050163217,0.0010342344,0.09492679,0.000026840295,0.00017797788,0.00033802498,0.016533365,0.000009151586,0.8818068,0.0006629051,0.0033421505,0.00064012717],"study_design_scores_gemma":[0.0035137373,0.00061104,0.017390333,0.000057906214,0.000034341883,0.0005916905,0.0029139994,0.000007841995,0.97309864,0.00017495448,0.0014559609,0.00014957719],"about_ca_topic_score_codex":0.00038707178,"about_ca_topic_score_gemma":0.000032967124,"teacher_disagreement_score":0.091291815,"about_ca_system_score_codex":0.000113840295,"about_ca_system_score_gemma":0.00011920971,"threshold_uncertainty_score":0.9999083},"labels":[],"label_agreement":null},{"id":"W2029285596","doi":"10.2217/14622416.9.2.195","title":"Psoriatic Arthritis: Genetic Susceptibility and Pharmacogenetics","year":2008,"lang":"en","type":"review","venue":"Pharmacogenomics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Pharmacogenetics; Medicine; Arthritis; Blockade; Disease; Tumor necrosis factor alpha; Etiology; Immunology; Inflammatory arthritis; Pathogenesis; Bioinformatics; Gene; Internal medicine; Biology; Genetics; Genotype; Receptor","score_opus":0.04551782348808525,"score_gpt":0.3091116498139086,"score_spread":0.26359382632582334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029285596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030388434,0.99199384,0.00001635968,0.0000067657197,0.0023963363,0.0013608924,0.00083955366,0.00014492987,0.00020244667],"genre_scores_gemma":[0.0002984294,0.9972637,0.00035005686,0.00007028553,0.00041529373,0.00023749121,0.000686114,0.00015284249,0.0005257729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963332,0.0006610539,0.001096948,0.0010545372,0.00006905283,0.0007852259],"domain_scores_gemma":[0.99838895,0.00032707927,0.0005023176,0.0005806011,0.00006635591,0.00013469666],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018010284,0.001005562,0.0022142562,0.00026091846,0.00037406842,0.00003687152,0.0004940159,0.0006729214,0.0006401018],"category_scores_gemma":[0.000030419118,0.0009335703,0.0006894739,0.00025142633,0.00035479994,0.00006246732,0.0002616523,0.00056735135,0.0015329957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033343007,0.00016991462,0.000034004108,0.0015666487,0.0016955717,0.00008480701,0.000110884066,8.5070184e-7,0.0002449758,0.0000064401734,0.0016919591,0.9943606],"study_design_scores_gemma":[0.002031138,0.0000815419,0.000024142737,0.00065073336,0.0034040434,0.0017929953,0.000008900348,0.0000021926967,0.00040642763,0.000023769599,0.9907194,0.00085475354],"about_ca_topic_score_codex":0.00002024491,"about_ca_topic_score_gemma":0.000007957741,"teacher_disagreement_score":0.99350584,"about_ca_system_score_codex":0.00017596954,"about_ca_system_score_gemma":0.00038938865,"threshold_uncertainty_score":0.9993115},"labels":[],"label_agreement":null},{"id":"W2029548961","doi":"10.1111/jdv.12174","title":"Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two‐stage qualitative and quantitative study","year":2013,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma; University of Pennsylvania","keywords":"Psychosocial; Medicine; Medical prescription; Feeling; Thematic analysis; Psoriasis; Social support; Qualitative research; Family medicine; Clinical psychology; Psychiatry; Nursing; Psychology","score_opus":0.04022761123985095,"score_gpt":0.32076705672190114,"score_spread":0.2805394454820502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029548961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997806,0.00095078954,0.000013294324,0.0005976787,0.00018772186,0.00027519563,0.000019418487,0.0000039781517,0.00014588202],"genre_scores_gemma":[0.9994506,0.00006833186,0.0002531563,0.000108954366,0.000016490318,0.0000060728494,0.000004576127,0.000010764138,0.00008104664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644744,0.0025541638,0.0005552066,0.00017075392,0.0000691072,0.00020332998],"domain_scores_gemma":[0.9986987,0.0004289115,0.00069776777,0.00005741703,0.00008555299,0.0000316569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063608936,0.00017244779,0.00045283113,0.00027420756,0.00014075707,0.000010643403,0.00020873059,0.00011165613,0.000033073604],"category_scores_gemma":[0.00010321033,0.00011344827,0.000037629026,0.00014476584,0.00062661467,0.00020698954,0.00014762486,0.00040437636,0.0000065195445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061755546,0.0003712558,0.97131187,0.000019491592,0.0005815814,0.000011133787,0.022013009,0.0000010021594,0.00054068066,0.0012621969,0.00013540588,0.0031348148],"study_design_scores_gemma":[0.008573086,0.00050458976,0.98143727,0.0000433339,0.00018279438,0.0002704469,0.007982312,7.708699e-7,0.0002541413,0.00056615693,0.00007181516,0.000113294154],"about_ca_topic_score_codex":0.00001952073,"about_ca_topic_score_gemma":0.000014507736,"teacher_disagreement_score":0.014030698,"about_ca_system_score_codex":0.000009419708,"about_ca_system_score_gemma":0.000028263225,"threshold_uncertainty_score":0.46262863},"labels":[],"label_agreement":null},{"id":"W2030117347","doi":"10.1086/378076","title":"CARD15: a Pleiotropic Autoimmune Gene That Confers Susceptibility to Psoriatic Arthritis","year":2003,"lang":"en","type":"article","venue":"The American Journal of Human Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Psoriatic arthritis; Proband; Immunology; Odds ratio; Allele; Medicine; Genetic predisposition; Genetics; Gene; Disease; Biology; Internal medicine; Mutation","score_opus":0.020848177449632136,"score_gpt":0.25554274738933386,"score_spread":0.23469456993970172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030117347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905049,0.007928192,0.0002327331,0.00020695044,0.00069689064,0.00019666838,0.000017787554,0.000016343052,0.0001995379],"genre_scores_gemma":[0.9976364,0.0009225065,0.00075639255,0.00024225382,0.000079578625,0.000006420488,0.0000061123524,0.0000252359,0.00032509473],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980441,0.00075646583,0.0005058519,0.00019581978,0.00010070465,0.0003970653],"domain_scores_gemma":[0.9986052,0.00013020214,0.0005409803,0.0005116278,0.00014597,0.000066024186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005223717,0.00023372173,0.00061900757,0.00012574754,0.000290036,0.00002725454,0.00042346548,0.000059268976,0.0003162171],"category_scores_gemma":[0.000060605555,0.00016546668,0.00024666608,0.00019984963,0.00045321594,0.00003052126,0.00004708539,0.0002382658,0.00010834038],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000572359,0.00046489012,0.036445927,0.000012703015,0.002224496,0.00008223753,0.0057703536,0.00023544923,0.67785835,0.0007404773,0.002034058,0.2735587],"study_design_scores_gemma":[0.0072923517,0.011180809,0.5393355,0.00013021701,0.0013077633,0.0017725027,0.0063938345,0.000002145884,0.3955801,0.0018980943,0.03410833,0.0009983262],"about_ca_topic_score_codex":0.00004945835,"about_ca_topic_score_gemma":0.0000513488,"teacher_disagreement_score":0.5028896,"about_ca_system_score_codex":0.00008246655,"about_ca_system_score_gemma":0.00013038969,"threshold_uncertainty_score":0.67475355},"labels":[],"label_agreement":null},{"id":"W2030345324","doi":"10.1002/eji.201040804","title":"IL‐27 increases the proliferation and effector functions of human naïve CD8<sup>+</sup> T lymphocytes and promotes their development into Tc1 cells","year":2010,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":137,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Cytotoxic T cell; Biology; Interleukin 21; IL-2 receptor; Granzyme B; CD8; Interleukin 12; Cell biology; Cytokine; Natural killer T cell; T cell; Molecular biology; ZAP70; Immunology; Immune system; Biochemistry; In vitro","score_opus":0.009573890312203086,"score_gpt":0.20266761838287933,"score_spread":0.19309372807067623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030345324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99324375,0.0057597663,0.000033142263,0.00011920013,0.0004505316,0.00020001993,0.0000164723,0.000015860378,0.00016127963],"genre_scores_gemma":[0.99901885,0.0002602657,0.00028802207,0.00003053977,0.00008555125,0.0000052705263,0.0000299222,0.000020912685,0.00026067908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981204,0.0009616496,0.0005150121,0.00017053142,0.0000350922,0.00019728135],"domain_scores_gemma":[0.9988927,0.0003266818,0.00040275068,0.00019697606,0.00015311022,0.000027730008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083071936,0.0002089591,0.00034512507,0.00016523911,0.00038927977,0.000024622148,0.00019257257,0.00009786901,0.00008652554],"category_scores_gemma":[0.00012736008,0.00012672938,0.000075179836,0.00007829278,0.00045928604,0.00010261851,0.00011690982,0.0002968453,0.000056029254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031220715,0.00017900446,0.006475048,0.000019565343,0.00073797,0.000013926767,0.003434897,0.00000156046,0.94261706,0.000061149025,0.00021656652,0.045931067],"study_design_scores_gemma":[0.0044494905,0.0021838618,0.13533159,0.000107532025,0.00028258233,0.0013919097,0.0011965581,0.0000031767913,0.83476007,0.0000594147,0.019975353,0.00025846154],"about_ca_topic_score_codex":0.000018145556,"about_ca_topic_score_gemma":0.000019561592,"teacher_disagreement_score":0.12885654,"about_ca_system_score_codex":0.000021453248,"about_ca_system_score_gemma":0.00009688607,"threshold_uncertainty_score":0.5167874},"labels":[],"label_agreement":null},{"id":"W2030458038","doi":"10.1007/s10227-005-0116-1","title":"Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Adverse effect; Plaque psoriasis; Internal medicine; Randomized controlled trial; Dermatology; Severity of illness; Clinical trial; Gastroenterology; Pathology","score_opus":0.06949153664816805,"score_gpt":0.3514986361385988,"score_spread":0.28200709949043073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030458038","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.062190667,0.9325533,0.000010576277,0.000104446626,0.0027763492,0.002077544,0.00021240904,0.000012654012,0.000062048464],"genre_scores_gemma":[0.0069398675,0.9904309,0.00002590611,0.000032703538,0.0017137767,0.000038872106,0.0006380609,0.000049268856,0.00013064493],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9838905,0.005848515,0.009043588,0.00050382625,0.00026324225,0.00045033064],"domain_scores_gemma":[0.93218076,0.05892472,0.008099035,0.00042932728,0.0002420809,0.00012409991],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010729931,0.00077039003,0.020103801,0.00085523084,0.00007419981,0.000011799248,0.00028042027,0.0009771852,0.00032300502],"category_scores_gemma":[0.0077346377,0.00039124285,0.0023496065,0.00025769972,0.00053001026,0.00008151739,0.000028692295,0.0009345079,0.000010493737],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44983375,0.00068741967,0.000059740054,0.00021286978,0.006346817,0.00029098365,0.00010412605,8.836432e-7,3.301301e-7,0.0000013162926,0.0023396937,0.5401221],"study_design_scores_gemma":[0.70347303,0.0016192391,0.000024320932,0.019884568,0.016572993,0.00041641292,0.000019288964,0.0000010020236,0.0000013176923,0.000010793889,0.25767034,0.00030670394],"about_ca_topic_score_codex":0.00006769163,"about_ca_topic_score_gemma":0.00009401803,"teacher_disagreement_score":0.53981537,"about_ca_system_score_codex":0.00013263698,"about_ca_system_score_gemma":0.0011172117,"threshold_uncertainty_score":0.99985397},"labels":[],"label_agreement":null},{"id":"W2030919445","doi":"10.1038/jid.2011.376","title":"TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis","year":2011,"lang":"en","type":"review","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":173,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Arthritis Society; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs","keywords":"Medicine; Psoriasis; Etanercept; Tumor necrosis factor alpha; Immunology; Rheumatoid arthritis; Psoriatic arthritis; Arthritis; Internal medicine","score_opus":0.05464714558623123,"score_gpt":0.27855815113815396,"score_spread":0.22391100555192273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030919445","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.104364075,0.89344984,0.000007656183,0.00045703046,0.00083242083,0.0005777407,0.00019661985,0.000028432554,0.00008619805],"genre_scores_gemma":[0.010603238,0.9868376,0.00063293346,0.00044846063,0.0001229111,0.00015465583,0.00016568541,0.00015588033,0.00087863137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923256,0.0045155804,0.0017972962,0.00051191566,0.0001059372,0.00074367085],"domain_scores_gemma":[0.99456835,0.001357673,0.003082242,0.00043503128,0.00036074506,0.00019595555],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00086254044,0.00084636186,0.004145664,0.0016098865,0.00013788218,0.00001782717,0.00075527915,0.0013763515,0.00017046585],"category_scores_gemma":[0.001479453,0.00059754855,0.0006075873,0.0010141628,0.0006277962,0.00013588124,0.00012868625,0.0011669875,0.00030693164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02555553,0.006152007,0.008837232,0.00461675,0.064456046,0.042084243,0.023448192,0.000017716115,0.021354033,0.0012458715,0.044797666,0.7574347],"study_design_scores_gemma":[0.008413651,0.0018426613,0.00881982,0.019104028,0.0058842404,0.022490544,0.00039140586,9.798861e-8,0.039689735,0.00029628453,0.8914546,0.0016129417],"about_ca_topic_score_codex":0.000029098084,"about_ca_topic_score_gemma":0.000103746264,"teacher_disagreement_score":0.8466569,"about_ca_system_score_codex":0.00038758395,"about_ca_system_score_gemma":0.001377277,"threshold_uncertainty_score":0.99992007},"labels":[],"label_agreement":null},{"id":"W2031165393","doi":"10.2310/7750.2009.08083","title":"The Burden of Psoriasis and Barriers to Satisfactory Care: Results from a Canadian Patient Survey","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Lakehead University","funders":"EMD Serono","keywords":"Psoriasis; Medicine; Unemployment; Population; Family medicine; Demography; Psychiatry; Environmental health; Dermatology","score_opus":0.015151116875304911,"score_gpt":0.22702192323383952,"score_spread":0.2118708063585346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031165393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758612,0.020049537,8.3644716e-7,0.0027735657,0.0008976086,0.00007701346,0.00015659831,0.0000030522638,0.00018061629],"genre_scores_gemma":[0.996458,0.0029269578,0.000011769483,0.00035773535,0.00014156976,5.212823e-7,0.000030882293,0.000005785615,0.00006677954],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987101,0.0002899763,0.0005767281,0.00012625125,0.00007814086,0.00021883447],"domain_scores_gemma":[0.9968968,0.002263441,0.00028269898,0.00014421695,0.00018463923,0.00022820012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053666165,0.00013470244,0.0004725228,0.0002010221,0.0001834106,0.000008001064,0.000074466836,0.00011627763,0.000043560998],"category_scores_gemma":[0.0016580074,0.00007984891,0.00006599438,0.00010409583,0.0001208839,0.00002901117,0.000009072158,0.00012637777,0.0000017835321],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047419816,0.000021724276,0.047011506,0.000010998085,0.00086283125,0.0007733069,0.03442024,0.000012984947,0.009742315,0.000011159125,0.09012945,0.8122615],"study_design_scores_gemma":[0.006799949,0.006654261,0.55048496,0.0012347954,0.0013089203,0.0045412476,0.040251385,0.0000033670094,0.008221948,0.00040706634,0.37920675,0.0008853282],"about_ca_topic_score_codex":0.052581582,"about_ca_topic_score_gemma":0.016233372,"teacher_disagreement_score":0.81137615,"about_ca_system_score_codex":0.000043513297,"about_ca_system_score_gemma":0.0003287639,"threshold_uncertainty_score":0.95372736},"labels":[],"label_agreement":null},{"id":"W2032132548","doi":"10.1046/j.1468-3083.17.s2.4.x","title":"Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis","year":2003,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical trial; Body surface area; Dermatology; Internal medicine; Randomized controlled trial; Surgery; Pathology","score_opus":0.02010016712135707,"score_gpt":0.29285495982258564,"score_spread":0.27275479270122854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032132548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980082,0.0007957849,0.000013807409,0.00044918383,0.00026020192,0.00032999425,0.000041417698,0.0000024000528,0.00009904372],"genre_scores_gemma":[0.9996447,0.00014785505,0.00010521691,0.000032016862,0.000015638703,0.0000013263398,0.0000034870914,0.000012627685,0.000037157395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922259,0.0055965087,0.0016866022,0.00020495904,0.00007534714,0.00021072055],"domain_scores_gemma":[0.9972711,0.00061516574,0.0017630077,0.0001982939,0.00011285333,0.00003954151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014636002,0.00017971973,0.00090804463,0.00028129912,0.000044557542,0.000001009155,0.00033296214,0.0002643254,0.000017331695],"category_scores_gemma":[0.0004451908,0.00012179683,0.00012062641,0.00021130989,0.0004977239,0.000051536368,0.00007224255,0.00039976923,0.0000024507349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09772679,0.0083078975,0.8522527,0.0000988251,0.0017253514,0.000090751026,0.0045099626,0.00010240868,0.022159752,0.00018014606,0.00047420055,0.012371176],"study_design_scores_gemma":[0.036639374,0.0075571383,0.8940488,0.00014897397,0.0004383738,0.00070444884,0.00043592643,6.332801e-7,0.05862877,0.000039401417,0.0012215937,0.00013656066],"about_ca_topic_score_codex":0.0000051693996,"about_ca_topic_score_gemma":0.000018628347,"teacher_disagreement_score":0.061087422,"about_ca_system_score_codex":0.000019755582,"about_ca_system_score_gemma":0.00015044339,"threshold_uncertainty_score":0.49667308},"labels":[],"label_agreement":null},{"id":"W2032332028","doi":"10.1001/jama.2010.1162","title":"Early-Onset Obesity and Risk for Psoriatic ArthritisOBESITY AND RISK FOR PSORIATIC ARTHRITIS","year":2010,"lang":"en","type":"letter","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Body mass index; Obesity; Family history; Odds ratio; Risk factor; Body surface area; Internal medicine; Dermatology","score_opus":0.009632709486884081,"score_gpt":0.21734824014824955,"score_spread":0.20771553066136547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032332028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94258636,0.024600115,0.00032570612,0.010453255,0.0037784763,0.0026397416,0.015417655,0.00014299309,0.000055709934],"genre_scores_gemma":[0.5038613,0.2980343,0.018391607,0.08707211,0.027512237,0.009937722,0.031647988,0.001201383,0.022341305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694,0.0005075608,0.000583286,0.0010357306,0.00007607819,0.0008573202],"domain_scores_gemma":[0.99649113,0.0019988064,0.0006336632,0.0006351415,0.00017182191,0.00006945857],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006745328,0.0007100097,0.0012091958,0.00020507463,0.00091104116,0.00015300134,0.0002688293,0.0039577684,0.00013483247],"category_scores_gemma":[0.00070386496,0.00067740976,0.00037480643,0.000085795866,0.00031589938,0.00017770802,0.000114847884,0.0021323941,0.000114937306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005947379,0.00016433028,0.049381826,0.00038146498,0.0019690478,0.00004065354,0.00042907594,7.1407264e-8,0.00015286064,0.000039470196,0.48772046,0.459126],"study_design_scores_gemma":[0.01707061,0.0011141468,0.16536054,0.00026610648,0.0030759685,0.00020272621,0.000032967986,0.000007065937,0.0013359236,0.005481437,0.8049507,0.0011017838],"about_ca_topic_score_codex":0.00080321135,"about_ca_topic_score_gemma":0.00091247575,"teacher_disagreement_score":0.4580242,"about_ca_system_score_codex":0.0000399906,"about_ca_system_score_gemma":0.00010543142,"threshold_uncertainty_score":0.9995677},"labels":[],"label_agreement":null},{"id":"W2032434473","doi":"10.2165/00128071-200708020-00005","title":"Placebo Response in Two Long-Term Randomized Psoriasis Studies that were Negative for Rosiglitazone","year":2007,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Rosiglitazone; Psoriasis; Placebo; Placebo response; Pharmacotherapy; Randomized controlled trial; Term (time); Internal medicine; Dermatology; Alternative medicine; Pathology; Receptor","score_opus":0.061996705573639385,"score_gpt":0.41234882713377624,"score_spread":0.35035212156013684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032434473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98668844,0.00579943,0.0018622864,0.0024318427,0.0025305154,0.00058062124,0.000017761475,0.000020735779,0.00006839332],"genre_scores_gemma":[0.99572897,0.0017777317,0.0016136224,0.00049396104,0.00015022859,0.000039906972,0.000009132848,0.000026307463,0.00016011117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9918467,0.004570135,0.0025434445,0.0003448014,0.00008173027,0.00061318744],"domain_scores_gemma":[0.95434034,0.043054886,0.001964259,0.00025547092,0.00028964548,0.000095408584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074604684,0.00032601767,0.0033599355,0.0004257536,0.000114574446,0.000009148532,0.00035428553,0.00022565207,0.000049549966],"category_scores_gemma":[0.0066541745,0.0002342446,0.0009399063,0.00022842587,0.0021191917,0.00013080986,0.00007058596,0.0005356659,0.000041387368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75936145,0.0005051346,0.13628256,0.000017875824,0.0032815258,0.0005313077,0.0010725738,0.0000037189614,0.00048779705,0.0002256363,0.0004663205,0.09776407],"study_design_scores_gemma":[0.6499374,0.004231721,0.3100588,0.00030201054,0.0018352665,0.0041722953,0.0057449844,0.0000037903014,0.018322041,0.0014540561,0.0032438494,0.00069379434],"about_ca_topic_score_codex":0.000022014885,"about_ca_topic_score_gemma":0.00013723866,"teacher_disagreement_score":0.17377625,"about_ca_system_score_codex":0.00006974788,"about_ca_system_score_gemma":0.00023448015,"threshold_uncertainty_score":0.9552218},"labels":[],"label_agreement":null},{"id":"W2033040352","doi":"10.1007/s10227-006-0101-3","title":"Efalizumab, a reversible T-cell modulator for psoriasis","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; Dalhousie University; Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Efalizumab; Psoriasis; Medicine; Monoclonal antibody; Immunology; Monoclonal; CD8; Pharmacology; Antibody; Plaque psoriasis; Immune system","score_opus":0.055928440063620286,"score_gpt":0.30188778319375703,"score_spread":0.24595934313013673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033040352","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029984943,0.9959995,0.000024716057,0.00024545813,0.0027330287,0.00034543473,0.000058905513,0.000015748923,0.00027736186],"genre_scores_gemma":[0.00010532587,0.9934661,0.0001248646,0.00016177187,0.0014362137,0.000015569232,0.00010669993,0.000053182608,0.00453031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975225,0.00027348188,0.0014184818,0.0002853371,0.00009881155,0.00040139988],"domain_scores_gemma":[0.99500126,0.0030438222,0.0014190723,0.00025017175,0.00018602282,0.00009965186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077672576,0.00049125863,0.0035182836,0.00067666115,0.00014501589,0.0000115384,0.0001985736,0.00064024475,0.00034748137],"category_scores_gemma":[0.00033340722,0.00031416933,0.0011137242,0.00019611695,0.00013887427,0.00007007492,0.000027114567,0.00036794879,0.00003694628],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019284309,0.00009212056,0.0000069221414,0.0026269662,0.0010218727,0.00028615823,0.00009211783,1.8108416e-7,0.000022372655,0.000008837053,0.1278116,0.867838],"study_design_scores_gemma":[0.0009853694,0.00041504813,6.732346e-7,0.006325792,0.00526322,0.013320518,0.000054977238,2.0842846e-7,0.000019841782,0.000031525997,0.9733113,0.00027151062],"about_ca_topic_score_codex":0.0000109189405,"about_ca_topic_score_gemma":0.0000024180856,"teacher_disagreement_score":0.8675665,"about_ca_system_score_codex":0.000093304945,"about_ca_system_score_gemma":0.0004432074,"threshold_uncertainty_score":0.99993104},"labels":[],"label_agreement":null},{"id":"W2033415744","doi":"10.3899/jrheum.090225","title":"Multidisciplinary Focus on Cyclosporin A","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dactylitis; Psoriasis; Psoriatic arthritis; Combination therapy; Internal medicine; Randomized controlled trial; Oncology; Pharmacology; Dermatology; Enthesitis","score_opus":0.01384003475660558,"score_gpt":0.263609168737106,"score_spread":0.2497691339805004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033415744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875778,0.0022655446,0.00013927098,0.0055190623,0.0011766606,0.00017610163,0.000022517184,0.000030471485,0.003092587],"genre_scores_gemma":[0.9973483,0.0003676338,0.0008471321,0.00005882608,0.000017792121,0.000004113617,0.000016968444,0.000014394498,0.0013248518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877715,0.00014719005,0.00054954225,0.00015833422,0.00005544145,0.0003123235],"domain_scores_gemma":[0.9992059,0.000108622866,0.0004011752,0.00019263489,0.000050078077,0.00004158193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002533328,0.00018678352,0.00045208013,0.00023662747,0.00009988024,0.000005226421,0.00021047707,0.00015858517,0.0021966645],"category_scores_gemma":[0.00002981776,0.00013830673,0.00018880423,0.00008224857,0.000054725966,0.000049846167,0.00002693773,0.00018668255,0.00045376868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053437334,0.0049868766,0.38031203,0.000029457917,0.0028786077,0.00087214157,0.0023261784,0.0000408912,0.041243657,0.04275492,0.20371985,0.31549168],"study_design_scores_gemma":[0.04463781,0.021169549,0.44129583,0.00062004034,0.0010026405,0.018223062,0.0024325587,0.000007195203,0.219786,0.01820631,0.23114672,0.0014722794],"about_ca_topic_score_codex":0.000013542474,"about_ca_topic_score_gemma":0.00001432522,"teacher_disagreement_score":0.31401938,"about_ca_system_score_codex":0.00005339343,"about_ca_system_score_gemma":0.000051574163,"threshold_uncertainty_score":0.99871546},"labels":[],"label_agreement":null},{"id":"W2033881749","doi":"10.1016/j.jaad.2014.08.039","title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","year":2014,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amgen","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Internal medicine; Dermatology Life Quality Index; Placebo; Interim analysis; Clinical trial; Gastroenterology; Dermatology","score_opus":0.012164301127651758,"score_gpt":0.2660242826918065,"score_spread":0.25385998156415474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033881749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943522,0.0024757623,0.00014682827,0.0024621838,0.0002260364,0.00019104073,0.00006551432,0.000003657372,0.00007678196],"genre_scores_gemma":[0.9981232,0.0009900492,0.0006043866,0.00012940992,0.000039350907,0.0000060038583,0.0000022686534,0.000012717365,0.00009258009],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99835354,0.00042240394,0.00082745403,0.00013598528,0.000045767614,0.00021487074],"domain_scores_gemma":[0.9970846,0.0008247818,0.0018366986,0.00015673166,0.00006756221,0.000029610554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018378207,0.00017713118,0.0010777997,0.00015887046,0.000051130166,0.0000013736587,0.000278002,0.00016237385,0.000024131272],"category_scores_gemma":[0.00012452046,0.0001098966,0.00039003915,0.00012566063,0.0007717648,0.000042072214,0.000055831428,0.00013516002,0.0000020397586],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031693682,0.0015832118,0.21662967,0.00028587363,0.008128924,0.0000066403886,0.0026182476,0.00005528942,0.33324027,0.0023602855,0.0021507815,0.4012471],"study_design_scores_gemma":[0.01533929,0.0033628345,0.48848277,0.00014811687,0.0022521692,0.0020688502,0.00031237915,0.000009929608,0.446594,0.00061683124,0.040556777,0.00025602744],"about_ca_topic_score_codex":0.0000260714,"about_ca_topic_score_gemma":0.0000025862107,"teacher_disagreement_score":0.40099108,"about_ca_system_score_codex":0.00003222197,"about_ca_system_score_gemma":0.000064384294,"threshold_uncertainty_score":0.44814533},"labels":[],"label_agreement":null},{"id":"W2033978760","doi":"10.1001/archdermatol.2009.347","title":"Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis","year":2010,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Adalimumab; Medicine; Psoriasis; Internal medicine; Titer; Psoriasis Area and Severity Index; Gastroenterology; Dermatology; Antibody; Immunology; Tumor necrosis factor alpha","score_opus":0.010020221381026782,"score_gpt":0.2573756866100511,"score_spread":0.24735546522902432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033978760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985092,0.00022156845,0.000049634105,0.00015328382,0.0002308025,0.00020173058,0.000046399626,0.000009983378,0.0005773641],"genre_scores_gemma":[0.9988453,0.00029470105,0.0006334336,0.000026101723,0.0000043053383,0.0000073003876,0.00017556206,0.0000057837874,0.00000755323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893004,0.00022937053,0.00046928317,0.00017144556,0.000024988136,0.00017487443],"domain_scores_gemma":[0.99906844,0.0004618709,0.00025266534,0.00017104133,0.000027207243,0.000018762146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005941286,0.00011847391,0.00038981898,0.00016359676,0.00003856278,0.0000019272775,0.00011553581,0.00014826945,0.000013569104],"category_scores_gemma":[0.000048383845,0.00008951021,0.00005410241,0.000057816585,0.00084119046,0.00008055948,0.00004423064,0.00014936055,0.0000048745173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009210005,0.00036494085,0.9306402,0.000040305727,0.0001570749,0.000008190019,0.00048054708,5.2439384e-7,0.03985904,0.0011741364,0.000013078682,0.026340948],"study_design_scores_gemma":[0.0060969153,0.00032013105,0.93059075,0.000050091337,0.00006882049,0.000084167135,0.00012854427,0.00000629884,0.061891105,0.00040159572,0.00024902224,0.00011255011],"about_ca_topic_score_codex":0.000032581705,"about_ca_topic_score_gemma":0.00014383373,"teacher_disagreement_score":0.026228398,"about_ca_system_score_codex":0.0000018817798,"about_ca_system_score_gemma":0.000048587448,"threshold_uncertainty_score":0.36501205},"labels":[],"label_agreement":null},{"id":"W2034554277","doi":"10.2310/7750.2006.00073","title":"Challenges and Solutions in Selecting Systemic Antipsoriatic Agents","year":2007,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Clinical Research","funders":"","keywords":"Medicine; Systemic therapy; Psoriasis; Intensive care medicine; Quality (philosophy); Quality of life (healthcare); Selection (genetic algorithm); Risk analysis (engineering); Dermatology; Nursing","score_opus":0.06084656755319063,"score_gpt":0.27501120229953363,"score_spread":0.214164634746343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034554277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8708129,0.12735292,0.000019274252,0.00051967485,0.00078596605,0.000048332276,5.5564965e-7,0.0000068843706,0.00045351067],"genre_scores_gemma":[0.9674151,0.032225307,0.000014428903,0.00006551547,0.00016202373,5.310848e-7,0.0000018871359,0.0000069105326,0.00010827392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998931,0.00013032861,0.0005271168,0.00010636869,0.00004974504,0.00025547735],"domain_scores_gemma":[0.9982021,0.0013826021,0.00025317082,0.000060511207,0.000060040642,0.000041581297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014681132,0.000112120484,0.00047514465,0.00038297096,0.0000825743,0.0000031414208,0.000037024212,0.000119762866,0.000019112478],"category_scores_gemma":[0.00032827916,0.00008005812,0.000049592963,0.0000957419,0.00007448829,0.00005281255,0.000012536512,0.00016441241,0.0000028439351],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000886785,0.00024092541,0.112682804,0.00032150737,0.00081609696,0.0043681962,0.009990151,0.0000035621667,0.04493779,0.00021968536,0.0035723036,0.8219602],"study_design_scores_gemma":[0.010872256,0.0028040411,0.47758248,0.0089685125,0.001870073,0.43159598,0.035522718,0.000031998563,0.0045971684,0.0014564296,0.023539087,0.0011592618],"about_ca_topic_score_codex":0.000017211947,"about_ca_topic_score_gemma":0.00005293603,"teacher_disagreement_score":0.82080096,"about_ca_system_score_codex":0.000027977025,"about_ca_system_score_gemma":0.000040427673,"threshold_uncertainty_score":0.32646754},"labels":[],"label_agreement":null},{"id":"W2034585843","doi":"10.1001/jama.290.23.3073","title":"Efalizumab for Patients With Moderate to Severe Plaque Psoriasis","year":2003,"lang":"en","type":"article","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":397,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Placebo; Adverse effect; Severity of illness; Internal medicine; Dermatology; Plaque psoriasis; Randomized controlled trial; Visual analogue scale; Surgery; Pathology","score_opus":0.01132498776174481,"score_gpt":0.21921148491514844,"score_spread":0.20788649715340363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034585843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939707,0.00018885068,0.0006028115,0.00021040117,0.00062596257,0.0006682689,0.00024639908,0.00006048508,0.0034261467],"genre_scores_gemma":[0.99281675,0.000009882297,0.0015015588,0.00033484405,0.00003613038,0.0002134143,0.00024229809,0.000026160944,0.004818985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991326,0.0000903329,0.00014095957,0.00028523454,0.000029249308,0.00032165166],"domain_scores_gemma":[0.9994726,0.00010113197,0.00005082238,0.00022488821,0.00011616004,0.000034349872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007667108,0.00017943818,0.0002163117,0.00006477591,0.00017644011,0.000022053653,0.000097624696,0.00018683469,0.00023167662],"category_scores_gemma":[0.00007043295,0.00013471967,0.00006586137,0.00010414566,0.000021519174,0.00008540535,0.000014320981,0.0000605313,0.0003581655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036744878,0.0035620958,0.1745169,0.00016271847,0.0043823053,0.000031483556,0.0048952936,0.00036960538,0.0077058226,0.02518145,0.16399242,0.57845503],"study_design_scores_gemma":[0.06818766,0.0038383065,0.08247609,0.000116189214,0.0006532359,0.000058939793,0.00043023785,0.0000056536646,0.105063155,0.0016139304,0.73609394,0.0014626655],"about_ca_topic_score_codex":0.000015515629,"about_ca_topic_score_gemma":0.000020898331,"teacher_disagreement_score":0.57699233,"about_ca_system_score_codex":0.000043198543,"about_ca_system_score_gemma":0.000044580538,"threshold_uncertainty_score":0.5493709},"labels":[],"label_agreement":null},{"id":"W2034868754","doi":"10.1016/j.jaad.2010.04.040","title":"Immune response to pneumococcal polysaccharide vaccine in adults with chronic plaque psoriasis treated with alefacept","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Astellas Pharma","keywords":"Medicine; Plaque psoriasis; Psoriasis; Immune system; Dermatology; Immunology","score_opus":0.01081404379905381,"score_gpt":0.23785209298034796,"score_spread":0.22703804918129414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034868754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938953,0.0012921583,0.000020965836,0.004317233,0.00009985576,0.00029926543,0.000017560978,0.000014632077,0.000043028933],"genre_scores_gemma":[0.99903065,0.00026049282,0.0003250336,0.00020784026,0.000023840053,0.000018536428,0.0000014877941,0.000028144654,0.00010399757],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975695,0.00086826825,0.00077888515,0.00023988675,0.00008248666,0.00046099292],"domain_scores_gemma":[0.99807143,0.00027366783,0.001279954,0.00024125201,0.00006887426,0.00006482363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002421168,0.00029669452,0.0010485527,0.000473987,0.00007600266,0.0000030998892,0.0006621437,0.0001888497,0.00010068191],"category_scores_gemma":[0.000057147314,0.00016786692,0.00016907461,0.00068645267,0.00036919644,0.000110197,0.00008734703,0.0005485207,0.000030179091],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119165085,0.00050099724,0.2860709,0.000031597203,0.0014593146,0.00025885965,0.0024545083,0.00003168495,0.582846,0.00005056122,0.00032696998,0.006803519],"study_design_scores_gemma":[0.005984675,0.002027611,0.65382284,0.0002383089,0.00024780375,0.007089898,0.0004244354,8.609651e-7,0.32930627,0.000012447094,0.000658681,0.00018614421],"about_ca_topic_score_codex":0.000277887,"about_ca_topic_score_gemma":0.000081075144,"teacher_disagreement_score":0.36775196,"about_ca_system_score_codex":0.00011527479,"about_ca_system_score_gemma":0.00020790233,"threshold_uncertainty_score":0.68454146},"labels":[],"label_agreement":null},{"id":"W2035145633","doi":"10.1159/000329527","title":"IL-17A and IL-17F Expression in B Lymphocytes","year":2011,"lang":"en","type":"article","venue":"International Archives of Allergy and Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Plan for Science, Technology and Innovation; Canadian Institutes of Health Research; King Saud University","keywords":"Interleukin 17; Biology; Cytokine; CD19; Immunology; Interleukin; Molecular biology; CD3; Flow cytometry; Immune system; CD8","score_opus":0.014228323895313944,"score_gpt":0.2173065504739149,"score_spread":0.20307822657860095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035145633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829333,0.0071672904,0.000060415914,0.00008310772,0.0004787557,0.00006739233,0.00004276527,0.000016797112,0.009150201],"genre_scores_gemma":[0.99220943,0.006186993,0.0005639927,0.0000311746,0.00001440094,0.000017977058,0.0000650082,0.000007787998,0.0009032443],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992407,0.00010485679,0.00023719064,0.00022872652,0.000019771767,0.00016875596],"domain_scores_gemma":[0.9995559,0.00020535116,0.00009507146,0.00011422691,0.000016853513,0.000012582609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047369726,0.00013391014,0.0002025941,0.0002221538,0.000051910334,0.000003335661,0.00018060098,0.000121204546,0.0003113418],"category_scores_gemma":[0.000035202287,0.00011482838,0.00004403491,0.000031290958,0.000360516,0.00008029995,0.0001730043,0.00008990316,0.000018102139],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026094697,0.00040670636,0.02169276,0.00000956605,0.0012069604,0.000021405585,0.0058736578,0.0000010547701,0.7654732,0.009961331,0.000053855296,0.19269004],"study_design_scores_gemma":[0.003452378,0.0003585999,0.6655823,0.00008658226,0.00001446187,0.00012499528,0.0005353248,0.000011070134,0.30877277,0.0070441123,0.013830697,0.00018670774],"about_ca_topic_score_codex":0.00023131991,"about_ca_topic_score_gemma":0.00009953271,"teacher_disagreement_score":0.64388955,"about_ca_system_score_codex":0.000007991003,"about_ca_system_score_gemma":0.000019867466,"threshold_uncertainty_score":0.46825653},"labels":[],"label_agreement":null},{"id":"W2036443896","doi":"10.1016/s0031-9384(00)00290-0","title":"The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization","year":2000,"lang":"en","type":"article","venue":"Physiology & Behavior","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Mount Saint Vincent University","funders":"Mount Saint Vincent University","keywords":"Psychosocial; Feeling; Psoriasis; Quality of life (healthcare); Psychology; Clinical psychology; Disease; Gerontology; Medicine; Psychiatry; Social psychology; Psychotherapist; Internal medicine","score_opus":0.023825159495040455,"score_gpt":0.31940036168353986,"score_spread":0.2955752021884994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036443896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829656,0.0009007271,0.0000010527614,0.00003181396,0.00018690938,0.00022083794,0.00022517961,0.000021543801,0.00011538167],"genre_scores_gemma":[0.9992467,0.00034342767,0.000013141706,0.000010098923,0.00006222992,0.00005364098,0.000098312914,0.00000975806,0.0001626741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99881035,0.00040579698,0.00032673235,0.00020955235,0.000035519246,0.00021203983],"domain_scores_gemma":[0.9992305,0.00023321486,0.00020177917,0.00024702935,0.00006467468,0.000022824346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014562825,0.00016039406,0.00043057106,0.00002857973,0.00017558417,0.0000038735297,0.00014978294,0.00017082368,0.0003094506],"category_scores_gemma":[0.000035849753,0.000105807696,0.00020869766,0.00010888564,0.00045287018,0.000051396604,0.000030307368,0.000100457226,0.000041666262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001375604,0.0008840501,0.11486169,0.00001695534,0.00047957455,2.4624723e-7,0.00066059985,0.000004082782,0.7387408,0.00030635236,0.0004621473,0.1422079],"study_design_scores_gemma":[0.0012767642,0.00023213355,0.9876633,0.000006567149,0.0001689958,0.0000018483995,0.000043728614,0.0000015017957,0.01003514,0.00034617982,0.00012297691,0.00010083883],"about_ca_topic_score_codex":0.00021785276,"about_ca_topic_score_gemma":0.000021486998,"teacher_disagreement_score":0.87280166,"about_ca_system_score_codex":0.000015903683,"about_ca_system_score_gemma":0.00005546441,"threshold_uncertainty_score":0.43147126},"labels":[],"label_agreement":null},{"id":"W2036488279","doi":"10.1016/j.jaad.2004.09.029","title":"Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial","year":2005,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Randomized controlled trial; Dermatology; Plaque psoriasis; Internal medicine; Pathology","score_opus":0.01780253160628653,"score_gpt":0.29822210374410896,"score_spread":0.2804195721378224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036488279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96941894,0.01571281,0.000057233716,0.012842885,0.0010472966,0.0006607821,0.00010806831,0.000024046381,0.00012794169],"genre_scores_gemma":[0.99207294,0.006092423,0.0003407583,0.0006846908,0.00055867335,0.000029651286,0.000015991125,0.000025055147,0.0001798195],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953222,0.0019752053,0.0018479715,0.00028854376,0.00012542486,0.00044065664],"domain_scores_gemma":[0.99401563,0.0015323939,0.0040288595,0.0002955848,0.00007124269,0.000056309655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005872948,0.0003457908,0.0022351318,0.00024378505,0.00015102736,0.000010512658,0.00087867485,0.00033348158,0.0001017824],"category_scores_gemma":[0.00030227745,0.00020548547,0.0009727365,0.0002548146,0.0012188915,0.0001587844,0.00008703046,0.0006853723,0.000032040218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76057017,0.0006152425,0.000010230031,0.0000034007276,0.0029854353,0.000012116581,0.0005988682,0.0000056721215,0.13129477,0.00012946308,0.004301974,0.09947268],"study_design_scores_gemma":[0.7504944,0.00071044505,0.00025291918,0.00004274218,0.00069362257,0.0009754902,0.0001409893,0.000013749886,0.22337551,0.00042093906,0.022691263,0.000187924],"about_ca_topic_score_codex":0.000100307974,"about_ca_topic_score_gemma":0.0000062583167,"teacher_disagreement_score":0.09928475,"about_ca_system_score_codex":0.000100913065,"about_ca_system_score_gemma":0.00030259116,"threshold_uncertainty_score":0.8379454},"labels":[],"label_agreement":null},{"id":"W2037236355","doi":"10.1586/edm.12.37","title":"Psoriasis: why does it come with a greater risk of heart attack and stroke?","year":2012,"lang":"en","type":"article","venue":"Expert Review of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Stroke (engine); Psoriasis; Cardiology; Dermatology","score_opus":0.017999850733083304,"score_gpt":0.27871404730751015,"score_spread":0.26071419657442685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037236355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51491976,0.48148865,0.000028539143,0.0021281799,0.0004950662,0.00037657903,0.00007615215,0.000024404477,0.00046264275],"genre_scores_gemma":[0.8906722,0.106652975,0.0009188597,0.0012949923,0.000042350253,0.00009337015,0.000049222173,0.000020494577,0.00025550628],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983933,0.00053361314,0.00047235578,0.00021456342,0.00004145099,0.00034473374],"domain_scores_gemma":[0.99904954,0.0001775573,0.0002899963,0.00037147544,0.000070319526,0.000041118932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016026649,0.00023612608,0.0009802462,0.00008403772,0.00006621498,0.0000021326475,0.00013031099,0.00018755297,0.00053441763],"category_scores_gemma":[0.00004723862,0.00013426486,0.00014052841,0.00009135505,0.00029207722,0.000106167885,0.000060367594,0.00010374258,0.000063541425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056725525,0.00061811664,0.8765141,0.003963439,0.0026639353,0.000021243084,0.0031651845,6.8870705e-8,0.016597841,0.00032891004,0.08444824,0.011111666],"study_design_scores_gemma":[0.003975089,0.00037582644,0.026919326,0.0028412687,0.0011357917,0.0035815295,0.0005639552,3.4254936e-7,0.19793457,0.000011480669,0.76215845,0.000502367],"about_ca_topic_score_codex":0.00006617095,"about_ca_topic_score_gemma":0.000019077885,"teacher_disagreement_score":0.8495948,"about_ca_system_score_codex":0.000008999117,"about_ca_system_score_gemma":0.00002488974,"threshold_uncertainty_score":0.5851498},"labels":[],"label_agreement":null},{"id":"W2037356704","doi":"10.3899/jrheum.110278","title":"Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Enthesitis; Dactylitis; Psoriatic arthritis; Observational study; Physical therapy; Randomized controlled trial; Psoriasis; Internal medicine; Rheumatology; Construct validity; Clinical trial; Disease; Surgery; Dermatology; Patient satisfaction","score_opus":0.03220250874909466,"score_gpt":0.2467839209550077,"score_spread":0.21458141220591304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037356704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966635,0.0015711813,0.00019432398,0.00015292408,0.0011180263,0.00020051519,0.000020432004,0.000003475962,0.00007562604],"genre_scores_gemma":[0.9989186,0.00040877284,0.00045316343,0.000016404934,0.000017764321,0.0000066173334,0.0000054988745,0.000009552961,0.00016363827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846447,0.00036240518,0.0008313753,0.00010722453,0.000049258415,0.00018528935],"domain_scores_gemma":[0.99817884,0.00033990393,0.0010714292,0.00024182827,0.00013613614,0.00003187031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008330839,0.0001407169,0.0004896943,0.000100783276,0.00013403094,0.000002552883,0.000272284,0.00012627184,0.00028489632],"category_scores_gemma":[0.00029924966,0.000080282756,0.00014517785,0.00007962718,0.00030640818,0.00006336665,0.00009601948,0.00014598663,0.000004583455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056650944,0.002469771,0.6540313,0.00047448935,0.0070446404,0.00012297473,0.032982,0.000001835222,0.023642128,0.0046198084,0.008512065,0.20944808],"study_design_scores_gemma":[0.0072644604,0.0007105415,0.94085556,0.0005141491,0.0007160754,0.0101293195,0.001460034,0.0000023794203,0.018527096,0.0039977194,0.015531156,0.00029153537],"about_ca_topic_score_codex":0.000032837783,"about_ca_topic_score_gemma":0.00026519984,"teacher_disagreement_score":0.2868243,"about_ca_system_score_codex":0.00002145973,"about_ca_system_score_gemma":0.00020986322,"threshold_uncertainty_score":0.32738358},"labels":[],"label_agreement":null},{"id":"W2037691975","doi":"10.1007/s00403-006-0707-8","title":"The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients","year":2006,"lang":"en","type":"review","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Psoriasis; Medicine; Exacerbation; Psoriatic arthritis; Concomitant; Comorbidity; Disease; Methotrexate; Intensive care medicine; Internal medicine; Dermatology","score_opus":0.0914265840378175,"score_gpt":0.38057215896359764,"score_spread":0.28914557492578014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037691975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009879983,0.98672384,0.000021840056,0.00008290138,0.00008827728,0.0019560081,0.0008904625,0.000006185406,0.00035051457],"genre_scores_gemma":[0.030122453,0.96866745,0.000047960133,0.0000035962937,0.000009362821,0.00044908086,0.00044450304,0.000013545832,0.00024207898],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99744755,0.0010508023,0.0007129011,0.0002801267,0.00013885136,0.00036975148],"domain_scores_gemma":[0.9850972,0.013809164,0.00050285505,0.00045582192,0.00010556289,0.000029356377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056230614,0.00021300772,0.00087958446,0.00010120917,0.0003577339,0.000010905206,0.00062600203,0.00015181505,0.000008556764],"category_scores_gemma":[0.00032061915,0.00009857758,0.00045415133,0.00017340183,0.0011125309,0.00001943204,0.00024235672,0.00020954593,0.0000021165608],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030020534,0.00039610115,0.041830864,0.0019468851,0.0014472387,0.000002119872,0.000035439072,8.4058705e-8,0.0000029706487,0.005174831,0.00018689848,0.94867635],"study_design_scores_gemma":[0.0047268486,0.00073150883,0.7319993,0.0030802002,0.0019728474,0.0000042536412,0.00008138489,0.0000028465565,0.00020577745,0.005921862,0.2508888,0.00038443113],"about_ca_topic_score_codex":0.0000058209944,"about_ca_topic_score_gemma":0.000006197094,"teacher_disagreement_score":0.94829196,"about_ca_system_score_codex":0.000014375958,"about_ca_system_score_gemma":0.000077421995,"threshold_uncertainty_score":0.40991664},"labels":[],"label_agreement":null},{"id":"W2037862910","doi":"10.3899/jrheum.120237","title":"Metabolic Syndrome in Patients with Psoriatic Disease","year":2012,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung, and Blood Institute; University of Pennsylvania; Genentech; Celgene; National Institutes of Health; Pfizer; Amgen","keywords":"Medicine; Metabolic syndrome; Psoriasis; Dyslipidemia; Disease; Insulin resistance; Obesity; Internal medicine; Diabetes mellitus; Intensive care medicine; Dermatology; Endocrinology","score_opus":0.008137942195595547,"score_gpt":0.22007392674916507,"score_spread":0.21193598455356952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037862910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907347,0.007244023,0.00003216892,0.00036596996,0.0013493974,0.00020392661,0.000044850047,0.0000076188753,0.0000173277],"genre_scores_gemma":[0.9992275,0.00023076814,0.0003213415,0.0000396105,0.000009160227,0.000017019847,0.000079669466,0.000014716901,0.000060217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984693,0.000254838,0.0005966806,0.000117947064,0.00008193467,0.00047931416],"domain_scores_gemma":[0.9991415,0.00010483973,0.00040667213,0.00018026042,0.00007593848,0.00009080147],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035738858,0.00019226449,0.00056271063,0.00029046784,0.00006245946,0.000005275528,0.00017607176,0.00009519832,0.0011179551],"category_scores_gemma":[0.000044977107,0.00013116881,0.00010726742,0.00013697437,0.000066508765,0.00021547524,0.000037827842,0.00016974844,0.00012235311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075978326,0.00094630534,0.9928836,0.00001635342,0.000622045,0.000020742784,0.00027216534,0.0000030756892,0.000015925383,0.0009810899,0.001216272,0.0022625953],"study_design_scores_gemma":[0.007942362,0.00036827833,0.980347,0.00005737767,0.00032602655,0.0003257077,0.000100384146,1.6102942e-7,0.00020772626,0.00006228312,0.010114712,0.00014803001],"about_ca_topic_score_codex":0.000024015702,"about_ca_topic_score_gemma":0.000016226433,"teacher_disagreement_score":0.012536694,"about_ca_system_score_codex":0.000053673844,"about_ca_system_score_gemma":0.000077025084,"threshold_uncertainty_score":0.99979514},"labels":[],"label_agreement":null},{"id":"W2037898655","doi":"10.1097/01.mjt.0000174350.82270.da","title":"A Report on Three Recent Clinical Trials Using Mahonia aquifolium 10% Topical Cream and a Review of the Worldwide Clinical Experience With Mahonia aquifolium for the Treatment of Plaque Psoriasis","year":2005,"lang":"en","type":"review","venue":"American Journal of Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Dermatology; Placebo; Clinical trial; Quality of life (healthcare); Plaque psoriasis; Observational study; Surgery; Internal medicine; Alternative medicine; Pathology","score_opus":0.25700794254951226,"score_gpt":0.4736207341609644,"score_spread":0.21661279161145214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037898655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047305874,0.9905814,0.00016585115,0.0008039702,0.0016934528,0.0018794659,0.000113703514,0.000007320023,0.000024244933],"genre_scores_gemma":[0.00040421498,0.996805,0.001313612,0.0003843466,0.00069642277,0.00008839916,0.000014856247,0.000056040917,0.00023707928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904581,0.0035414714,0.0048885928,0.00049165613,0.00021676125,0.00040344681],"domain_scores_gemma":[0.98159826,0.008010637,0.008837628,0.0010939703,0.0003750301,0.000084495194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041741948,0.0006430233,0.005794235,0.00012640774,0.00016981486,0.00001774677,0.0007142232,0.0003814636,0.0001072249],"category_scores_gemma":[0.00068970403,0.0002767656,0.002595535,0.00040537756,0.0014230876,0.000042489635,0.00006748212,0.000514005,0.0000031189904],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020971028,0.0011353961,0.0008473025,0.00067442784,0.006360505,0.000018921726,0.000112756265,8.306583e-7,0.0000061824558,0.000020177107,0.0001541273,0.9885723],"study_design_scores_gemma":[0.0024824657,0.008000204,0.00051789836,0.0138204,0.01762261,0.0012145048,0.00009153673,0.0000013396098,0.00006546413,0.000013972371,0.9558872,0.0002824072],"about_ca_topic_score_codex":0.000029902494,"about_ca_topic_score_gemma":0.000028458997,"teacher_disagreement_score":0.9882899,"about_ca_system_score_codex":0.00018026993,"about_ca_system_score_gemma":0.0010519531,"threshold_uncertainty_score":0.99996847},"labels":[],"label_agreement":null},{"id":"W2038309633","doi":"10.1038/ng.693","title":"Genome-wide association analysis identifies three psoriasis susceptibility loci","year":2010,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":336,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Human Genome Research Institute; Canadian Institutes of Health Research","keywords":"Biology; Genome-wide association study; Psoriasis; Genetics; Genetic association; Meta-analysis; Single-nucleotide polymorphism; Genotype; Internal medicine; Gene; Immunology; Medicine","score_opus":0.008543461758992255,"score_gpt":0.24153603719323627,"score_spread":0.232992575434244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038309633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911501,0.004470781,0.00012904241,0.00029517143,0.0027083417,0.00022066954,0.00020026902,0.0001008056,0.000724836],"genre_scores_gemma":[0.9954454,0.00021976231,0.0005036697,0.000168424,0.00022908224,0.000018731878,0.000960081,0.000020231553,0.0024346327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984724,0.00013710349,0.00033504146,0.00050400454,0.00011620223,0.0004352696],"domain_scores_gemma":[0.99843,0.00034048,0.00023427278,0.00068669376,0.0002681734,0.000040363342],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053363066,0.00026005146,0.00040972274,0.0002316668,0.0002606729,0.00004876699,0.00034976887,0.0015429514,0.0014716572],"category_scores_gemma":[0.0004640179,0.00023574507,0.0003821509,0.000646519,0.00008028924,0.000057175228,0.000088868175,0.0008538748,0.00045940388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005055683,0.00011788413,0.9074234,0.000007468957,0.0026936291,0.000002754713,0.00016492222,0.000013969959,0.08123009,0.000022984133,0.0015629408,0.0067094085],"study_design_scores_gemma":[0.0007082013,0.000042202173,0.92073154,0.0000011414986,0.0021709986,0.0000016837366,0.00004354365,0.000004321045,0.052817777,0.00055820565,0.02268343,0.00023695202],"about_ca_topic_score_codex":0.000037296253,"about_ca_topic_score_gemma":0.0057219886,"teacher_disagreement_score":0.028412314,"about_ca_system_score_codex":0.00010394327,"about_ca_system_score_gemma":0.00005640289,"threshold_uncertainty_score":0.99975324},"labels":[],"label_agreement":null},{"id":"W2038389900","doi":"10.1016/j.jdds.2014.03.005","title":"Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)","year":2015,"lang":"en","type":"article","venue":"Journal of Dermatology & Dermatologic Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Adalimumab; Depression (economics); Medicine; Suicidal ideation; Observational study; Internal medicine; Psoriasis Area and Severity Index; Dermatology; Poison control; Tumor necrosis factor alpha","score_opus":0.08598141975115373,"score_gpt":0.3211789754228176,"score_spread":0.23519755567166387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038389900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98189765,0.0140944095,0.00025598996,0.00054979074,0.0020738023,0.0006999148,0.0003606958,0.00002151894,0.000046201454],"genre_scores_gemma":[0.9978324,0.0013766529,0.00019328822,0.000065461405,0.00004390678,0.00012555819,0.00029460015,0.000024302879,0.000043815166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550927,0.0013079189,0.0022383754,0.00027935396,0.0002740274,0.0003910457],"domain_scores_gemma":[0.9900008,0.00499815,0.003610777,0.00041011482,0.00091737485,0.000062825624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087074697,0.0003793881,0.0018796431,0.00036762567,0.00015566594,0.000008600912,0.00034954317,0.0005144568,0.000100427766],"category_scores_gemma":[0.000612569,0.00024364676,0.0007298424,0.0003444892,0.00026771493,0.00022144162,0.00004346982,0.00018047668,0.0000024175658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021934218,0.009101326,0.8970578,0.00006692502,0.0057340097,0.0000841457,0.0009442793,0.00006313604,0.0037881697,0.00009046667,0.07616626,0.0047100973],"study_design_scores_gemma":[0.03508142,0.004315576,0.77765274,0.0004460123,0.0066382224,0.0033667174,0.0073226364,0.00016444983,0.14685726,0.0010273417,0.016327534,0.0008000853],"about_ca_topic_score_codex":0.000045249006,"about_ca_topic_score_gemma":0.000012902946,"teacher_disagreement_score":0.1430691,"about_ca_system_score_codex":0.00014906503,"about_ca_system_score_gemma":0.0005657265,"threshold_uncertainty_score":0.9935627},"labels":[],"label_agreement":null},{"id":"W2038777577","doi":"10.3899/jrheum.120247","title":"Soluble Biomarkers May Differentiate Psoriasis from Psoriatic Arthritis","year":2012,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Western Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Osteoprotegerin; Cartilage oligomeric matrix protein; Internal medicine; Biomarker; Psoriasis Area and Severity Index; Oncology; Immunology; Pathology; Osteoarthritis; Receptor; Activator (genetics)","score_opus":0.01602058053847506,"score_gpt":0.24432964115819233,"score_spread":0.22830906061971729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038777577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9596547,0.026099512,0.00039333611,0.0010515968,0.012318504,0.00019338225,0.00015077602,0.000030521656,0.00010765971],"genre_scores_gemma":[0.99416053,0.0035175083,0.0016454742,0.00006618123,0.00010515426,0.00002231435,0.00023264014,0.000029600676,0.00022057447],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724734,0.00052112667,0.0011115754,0.0002217383,0.00011451267,0.000783709],"domain_scores_gemma":[0.9982477,0.00038642195,0.00082280324,0.0003148311,0.00010760163,0.000120647754],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061986037,0.00033554598,0.00087613787,0.00028885063,0.0002079083,0.000021622984,0.00034179873,0.00025700423,0.00773026],"category_scores_gemma":[0.0000788104,0.00027102252,0.00037099354,0.00013237467,0.00013438634,0.00027535472,0.00010517607,0.00025674654,0.00056236965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010102264,0.0012088495,0.77514535,0.00002836657,0.008291884,0.000032119187,0.0017111113,0.000001923131,0.011770047,0.0015981897,0.09091082,0.1082911],"study_design_scores_gemma":[0.07101841,0.001992153,0.20359312,0.00075538264,0.0041945283,0.005551585,0.0043198136,0.000008711076,0.22844636,0.0033917115,0.47468626,0.0020419438],"about_ca_topic_score_codex":0.0003946094,"about_ca_topic_score_gemma":0.00012728573,"teacher_disagreement_score":0.5715522,"about_ca_system_score_codex":0.00010361321,"about_ca_system_score_gemma":0.00008493533,"threshold_uncertainty_score":0.9999742},"labels":[],"label_agreement":null},{"id":"W2038794565","doi":"10.1016/j.bbi.2014.03.004","title":"Participation of interleukin 17A in neuroimmune interactions","year":2014,"lang":"en","type":"article","venue":"Brain Behavior and Immunity","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Crohn's and Colitis Foundation of Canada","keywords":"Neuroscience; Multiple sclerosis; Interleukin 17; Axon; Central nervous system; Inflammation; Cytokine; Neuroinflammation; Immune system; Microglia; Nervous system; Neuropathology; Immunology; Biology; Medicine; Pathology; Disease","score_opus":0.02971645263837286,"score_gpt":0.2941865803148681,"score_spread":0.26447012767649525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038794565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985076,0.00031582947,0.000028471659,0.00009720802,0.00033772193,0.0001378489,0.000013851455,0.000021326387,0.0005401125],"genre_scores_gemma":[0.9991403,0.0000260442,0.000026249772,0.00004012867,0.0000070361784,0.00005329466,0.00009437105,0.000007773197,0.0006047666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905455,0.00039337517,0.0002586102,0.00012501887,0.000016593349,0.00015182783],"domain_scores_gemma":[0.99941844,0.00023148596,0.00008239304,0.00022752196,0.000027351536,0.000012836705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023088939,0.000106322084,0.00019898865,0.00012579693,0.00008531995,0.00000674267,0.00009287504,0.00008234061,0.00018369926],"category_scores_gemma":[0.00011348236,0.00009864799,0.00005064531,0.00010861238,0.00010228137,0.00009365602,0.000056832203,0.0001624372,0.000028664575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015498603,0.0006793733,0.14033139,0.000011534565,0.000030447065,0.0000015657696,0.0011928533,9.301743e-7,0.6433316,0.00047282872,0.0001528035,0.21363968],"study_design_scores_gemma":[0.0011334999,0.00018729377,0.92727596,0.000024868777,0.000061924795,0.00001099263,0.00016768393,0.0000038668654,0.068709575,0.0000356574,0.0023000624,0.00008860288],"about_ca_topic_score_codex":0.00048761923,"about_ca_topic_score_gemma":0.0002464962,"teacher_disagreement_score":0.78694457,"about_ca_system_score_codex":0.000015016181,"about_ca_system_score_gemma":0.000009815681,"threshold_uncertainty_score":0.40227485},"labels":[],"label_agreement":null},{"id":"W2038882458","doi":"10.1097/der.0000000000000056","title":"Patch Test Results in Psoriasis Patients on Biologics","year":2014,"lang":"en","type":"article","venue":"Dermatitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Etanercept; Dermatology; Ustekinumab; Infliximab; Psoriatic arthritis; Patch test; Internal medicine; Allergy; Rheumatoid arthritis; Immunology; Disease","score_opus":0.013092109663950835,"score_gpt":0.21901434641468615,"score_spread":0.20592223675073532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038882458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98326415,0.00013931844,0.000014771929,0.00075492624,0.000997883,0.00020942836,0.0005294142,0.00008247278,0.01400763],"genre_scores_gemma":[0.99707246,0.00012050869,0.00006228124,0.0010273717,0.000041010717,0.00003694886,0.0009908882,0.000011682067,0.0006368258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988323,0.00023143875,0.00032501825,0.00027463,0.000033953926,0.00030266625],"domain_scores_gemma":[0.99903405,0.0005159678,0.00010615489,0.00028519036,0.00003853755,0.000020100917],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016446832,0.00017925796,0.00024165542,0.00012482567,0.00010003317,0.000011599429,0.00015631483,0.00024184193,0.00011218292],"category_scores_gemma":[0.00045898466,0.00014615805,0.000063984866,0.0001533916,0.00005298969,0.00005482667,0.000036280206,0.00012072822,0.0019675633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009072284,0.00083143404,0.685335,0.000015074401,0.000071271235,0.000011052116,0.0006156799,0.0000059087356,0.00072616676,0.0005496112,0.04747077,0.2642773],"study_design_scores_gemma":[0.0041979547,0.00044582583,0.8724925,0.00003970906,0.000020020201,0.000004631678,0.000025288806,0.000006227218,0.01121992,0.00025901067,0.11109201,0.00019692612],"about_ca_topic_score_codex":0.00016573802,"about_ca_topic_score_gemma":0.00020620917,"teacher_disagreement_score":0.2640804,"about_ca_system_score_codex":0.00004103985,"about_ca_system_score_gemma":0.000010772724,"threshold_uncertainty_score":0.9988095},"labels":[],"label_agreement":null},{"id":"W2040528185","doi":"10.2310/7750.2011.10080","title":"Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations","year":2011,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Université de Sherbrooke","funders":"Galderma","keywords":"Medicine; Psoriasis; Adverse effect; Dermatology; Calcineurin; Concomitant; Topical agents; Plaque psoriasis; Biologic Agents; Intensive care medicine; Surgery; Pharmacology; Internal medicine; Disease","score_opus":0.21492820650867245,"score_gpt":0.35134858676584874,"score_spread":0.1364203802571763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040528185","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034187264,0.99442846,0.0000049090067,0.00075691857,0.0009973163,0.00026926302,0.000014998593,0.0000045004126,0.000104897736],"genre_scores_gemma":[0.0017595309,0.9975469,0.000029937491,0.00019357722,0.00023365449,0.00002043126,0.00007859683,0.000011488195,0.00012584709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970676,0.001290201,0.0012092185,0.00017041883,0.000058504986,0.00020411098],"domain_scores_gemma":[0.9917835,0.0069600036,0.00090998976,0.0002428134,0.000078233126,0.000025473193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010138805,0.00031255945,0.002173377,0.000470853,0.000063576095,0.000005427022,0.00021258944,0.00036572045,0.0003550345],"category_scores_gemma":[0.00037489602,0.00013587614,0.0005932593,0.00022042997,0.00022156132,0.000039272138,0.000010272701,0.00028009835,0.0000056569033],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020491499,0.00023921714,0.00044889978,0.00026928337,0.00056314387,0.00042646696,0.00045265237,3.8724945e-8,0.000016914466,0.000022146587,0.0025019401,0.9948544],"study_design_scores_gemma":[0.00057564233,0.0018961477,0.00008693614,0.0077706403,0.001102576,0.0024569451,0.00015969962,2.5722583e-8,0.00001991346,0.000056421628,0.98574954,0.00012551348],"about_ca_topic_score_codex":0.00007552927,"about_ca_topic_score_gemma":0.000016157268,"teacher_disagreement_score":0.99472886,"about_ca_system_score_codex":0.000055939156,"about_ca_system_score_gemma":0.00029569745,"threshold_uncertainty_score":0.5540868},"labels":[],"label_agreement":null},{"id":"W2041325459","doi":"10.1111/jdv.12555","title":"A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (<scp>REFINE</scp>)","year":2014,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Merck Canada Inc. (Canada); Lynde Centre for Dermatology; Moncton Hospital; Amgen (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada); Probity Medical Research","funders":"Astellas Pharma; Pfizer; Eli Lilly and Company; Incyte; Amgen","keywords":"Etanercept; Medicine; Clinical endpoint; Randomized controlled trial; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Body surface area; Confidence interval; Surgery; Gastroenterology; Dermatology; Rheumatoid arthritis","score_opus":0.020609265804763396,"score_gpt":0.26908514774791686,"score_spread":0.24847588194315345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041325459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082726,0.00064894045,0.00013896756,0.00631571,0.00045651817,0.0010611727,0.000013995717,0.000011513773,0.0005258994],"genre_scores_gemma":[0.9979917,0.00017317887,0.00019219474,0.001220058,0.00007958454,0.0000140522625,0.0000045826337,0.000032020365,0.00029263232],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9893803,0.008167259,0.0013771653,0.0004202694,0.00017570832,0.00047930164],"domain_scores_gemma":[0.9963767,0.002181801,0.0008717307,0.0003087846,0.00014682597,0.00011414771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020416027,0.0004170732,0.0017311939,0.00030685886,0.0002517055,0.000015287484,0.000705134,0.0003216693,0.000020402784],"category_scores_gemma":[0.0008891711,0.00023432754,0.00019325841,0.00025878288,0.0005485501,0.000098597906,0.00039565202,0.00084084517,0.000024266243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50197357,0.003981508,0.41212708,0.00020075057,0.007941303,0.00014891039,0.032522243,0.0044428096,0.010944189,0.0024001165,0.0041518034,0.019165713],"study_design_scores_gemma":[0.24396302,0.0020193444,0.74014974,0.00024038393,0.0019697398,0.001872206,0.0017860983,0.000052257114,0.003017941,0.00027764298,0.0043190625,0.0003325716],"about_ca_topic_score_codex":0.00003580003,"about_ca_topic_score_gemma":0.000031623116,"teacher_disagreement_score":0.32802266,"about_ca_system_score_codex":0.000043747033,"about_ca_system_score_gemma":0.000089246285,"threshold_uncertainty_score":0.95556},"labels":[],"label_agreement":null},{"id":"W2041435794","doi":"10.1089/jir.2010.0083","title":"Interleukin-23-Induced Interleukin-23 Receptor Subunit Expression Is Mediated by the Janus Kinase/Signal Transducer and Activation of Transcription Pathway in Human CD4 T Cells","year":2010,"lang":"en","type":"article","venue":"Journal of Interferon & Cytokine Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; STAT4; Janus kinase; STAT1; Signal transduction; IL-2 receptor; Biology; ZAP70; Common gamma chain; STAT3; T cell; STAT protein; JAK-STAT signaling pathway; Molecular biology; Receptor; stat; Interleukin-21 receptor; Immune system; Immunology; Tyrosine kinase; Biochemistry","score_opus":0.04505741519750242,"score_gpt":0.30582143547328755,"score_spread":0.26076402027578516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041435794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752986,0.00048323686,0.0000632884,0.00075691426,0.00054861937,0.0003655746,0.00009181698,0.0000105640165,0.00015010968],"genre_scores_gemma":[0.9989126,0.00019709497,0.000026302723,0.000033398814,0.00011811439,0.00002360447,0.000099056895,0.000033011038,0.000556856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968792,0.0011066186,0.0009469757,0.0003145701,0.00028081532,0.00047179777],"domain_scores_gemma":[0.99819666,0.0005423808,0.00039414503,0.00029399613,0.0004946034,0.000078213336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002128129,0.00028083194,0.00052243605,0.000728053,0.00019030675,0.000047522008,0.0005523649,0.00044583384,0.0009991078],"category_scores_gemma":[0.00009644052,0.00018731975,0.00019329025,0.0003703151,0.00031555258,0.000331021,0.0000728666,0.001731545,0.000036323243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029237862,0.00047708763,0.00045485777,0.000042341664,0.00016193741,0.0000096252625,0.004006483,4.975496e-7,0.97457355,0.000015140477,0.0028660528,0.014468647],"study_design_scores_gemma":[0.0033641164,0.0023851246,0.0012928776,0.00042936925,0.000031431908,0.000059439684,0.0014483158,0.0000043407713,0.9866706,0.000044039592,0.0041131373,0.00015719452],"about_ca_topic_score_codex":0.00017882031,"about_ca_topic_score_gemma":0.00015107641,"teacher_disagreement_score":0.014311452,"about_ca_system_score_codex":0.00014497305,"about_ca_system_score_gemma":0.00012360251,"threshold_uncertainty_score":0.9999141},"labels":[],"label_agreement":null},{"id":"W2041516336","doi":"10.3899/jrheum.140179","title":"GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual Meeting","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Inflammatory arthritis; Arthritis; MEDLINE; Medical physics; Intensive care medicine; Physical therapy; Internal medicine","score_opus":0.01612319114682563,"score_gpt":0.2456432679126144,"score_spread":0.22952007676578878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041516336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826472,0.006253443,0.0002947186,0.008693726,0.0017603717,0.0001343582,0.00007474653,0.000023828597,0.00011761567],"genre_scores_gemma":[0.9906156,0.008448465,0.00031972243,0.00029981814,0.00004165502,0.000009421333,0.00009948109,0.000017899298,0.00014795747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969566,0.0019927132,0.000562682,0.00014452919,0.000043555396,0.00029993398],"domain_scores_gemma":[0.9972829,0.0015469383,0.00061641383,0.00040324475,0.00011589486,0.000034603752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009972876,0.0002144157,0.00045129584,0.00008191412,0.00047818664,0.000015322232,0.00052536896,0.00016550867,0.0003821861],"category_scores_gemma":[0.0000985834,0.000103497005,0.00016368099,0.00010510906,0.00021460523,0.0001417484,0.000049632603,0.0002201799,0.00026191844],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030115512,0.0013572614,0.2357537,0.000010849291,0.006746056,0.000012067791,0.019926012,0.000118523756,0.010741605,0.0060469937,0.15049055,0.5657848],"study_design_scores_gemma":[0.015240439,0.0045214077,0.038109634,0.0003099026,0.0030338767,0.008534907,0.013203302,0.000070965,0.012691574,0.016792335,0.8866074,0.0008842674],"about_ca_topic_score_codex":0.0015465732,"about_ca_topic_score_gemma":0.0009121851,"teacher_disagreement_score":0.7361168,"about_ca_system_score_codex":0.00003315562,"about_ca_system_score_gemma":0.00005267133,"threshold_uncertainty_score":0.42204854},"labels":[],"label_agreement":null},{"id":"W2042087858","doi":"10.1016/j.cyto.2007.07.032","title":"27 Effects of IL-17 On Effector and Regultory T Cell Subsets","year":2007,"lang":"en","type":"article","venue":"Cytokine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Effector; T cell; Cell biology; Immunology; Biology; Immune system","score_opus":0.007025056071684047,"score_gpt":0.21425646235566798,"score_spread":0.20723140628398393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042087858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172294,0.004221387,0.000021272628,0.000021461947,0.00083745935,0.00022533022,0.000043394768,0.00003914733,0.0028676162],"genre_scores_gemma":[0.9954799,0.00010198077,0.00004246892,0.00006002992,0.000054161603,0.000007058552,0.000075287666,0.000014011139,0.0041651255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992852,0.0000833388,0.00015315347,0.00021077092,0.000026893727,0.00024060385],"domain_scores_gemma":[0.9992172,0.00043536103,0.000078640696,0.00021912612,0.000022825732,0.00002684321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019083718,0.00015808948,0.00025248618,0.000098083925,0.000058639776,0.0000025735037,0.00007861271,0.00019159236,0.00007787294],"category_scores_gemma":[0.000038578433,0.00012677856,0.00006504424,0.000078866135,0.0001050024,0.00002403236,0.000027831005,0.000086985034,0.0002411341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004891931,0.00020911326,0.005368401,0.000099463636,0.00010091574,0.000035203382,0.00017367583,2.4220006e-7,0.96981394,0.00008116523,0.0044338927,0.01919479],"study_design_scores_gemma":[0.002423026,0.0005570947,0.10702259,0.000046890185,0.00009188936,0.000012020048,0.000011450286,1.04423606e-7,0.8730393,0.000014550255,0.016670285,0.000110800735],"about_ca_topic_score_codex":0.000011216105,"about_ca_topic_score_gemma":0.000009257522,"teacher_disagreement_score":0.10165419,"about_ca_system_score_codex":0.000020141471,"about_ca_system_score_gemma":0.000010601077,"threshold_uncertainty_score":0.5169879},"labels":[],"label_agreement":null},{"id":"W2042638001","doi":"10.1016/j.jaad.2010.02.060","title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Etanercept; Randomized controlled trial; Psoriasis; Dermatology; Physical therapy; Surgery; Internal medicine; Tumor necrosis factor alpha","score_opus":0.012531557788304871,"score_gpt":0.26473916223222793,"score_spread":0.25220760444392304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042638001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950535,0.00036213023,0.000007901713,0.0013933394,0.0012587776,0.0017033337,0.00009397713,0.000014980474,0.00011204613],"genre_scores_gemma":[0.99894255,0.00038799728,0.00022806127,0.00015545882,0.000083814666,0.00006663704,0.0000298619,0.000023983088,0.00008163788],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949184,0.0016696829,0.0025347224,0.00030294806,0.00016879298,0.00040544418],"domain_scores_gemma":[0.9890037,0.0040920395,0.006472644,0.00026969076,0.00009877309,0.00006313306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004071109,0.00040363148,0.0038328543,0.0004739441,0.00011778145,0.000010103857,0.00039230016,0.0003023514,0.000052585976],"category_scores_gemma":[0.00116733,0.00020491607,0.0009001622,0.00031569556,0.0006225166,0.00013111725,0.000056298435,0.0006392093,0.0000070718174],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9297357,0.0025786834,0.05757236,0.0000031946772,0.003458595,0.000036347094,0.000820293,0.000007041474,0.0014700145,0.000014915245,0.00013153309,0.0041713035],"study_design_scores_gemma":[0.96874785,0.0014325468,0.023603003,0.00002096784,0.002996101,0.00016990339,0.00016227654,0.0000027907633,0.0023653312,0.000101800084,0.00019748292,0.00019993228],"about_ca_topic_score_codex":0.00015369855,"about_ca_topic_score_gemma":0.00007970575,"teacher_disagreement_score":0.039012145,"about_ca_system_score_codex":0.000059952163,"about_ca_system_score_gemma":0.00026760693,"threshold_uncertainty_score":0.8356235},"labels":[],"label_agreement":null},{"id":"W2042990407","doi":"10.3899/jrheum.101118","title":"Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire and the Role of Dermatologists: A Report from the GRAPPA 2009 Annual Meeting: Table 1.","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Arthritis; Dermatology; Inflammatory arthritis; Arthropathy; Physical therapy; Internal medicine; Alternative medicine; Pathology; Osteoarthritis","score_opus":0.014707734060716024,"score_gpt":0.22710981853377332,"score_spread":0.2124020844730573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042990407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8771266,0.12127649,0.00017294213,0.0006754346,0.00039266763,0.00019517391,0.000019153185,0.000008131462,0.00013341555],"genre_scores_gemma":[0.9930441,0.0066610286,0.0002103925,0.000033473072,0.000010690119,0.0000105512445,0.0000094230145,0.0000079843985,0.000012394222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973296,0.0016319205,0.00065609487,0.00011879605,0.000078668316,0.0001849102],"domain_scores_gemma":[0.99731946,0.0011733039,0.0010004778,0.0002479162,0.00023983498,0.000019035155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025332514,0.00014457552,0.00045606235,0.000053008396,0.00030764175,0.000008490756,0.00022977355,0.00015055244,0.000052699277],"category_scores_gemma":[0.0007562139,0.00006847419,0.000074332114,0.00009335179,0.00075437763,0.00010387182,0.000070845635,0.00021708742,0.0000035644662],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008607257,0.00022795658,0.6957491,0.00002469381,0.0035713806,0.000042540774,0.027400449,0.000017909602,0.0016462643,0.005354644,0.0032541335,0.25410363],"study_design_scores_gemma":[0.06410641,0.0019303192,0.58915883,0.0024348504,0.009202669,0.14531307,0.054770116,0.00056812086,0.024896717,0.09864763,0.007933893,0.0010373726],"about_ca_topic_score_codex":0.0026102504,"about_ca_topic_score_gemma":0.00051099906,"teacher_disagreement_score":0.25306627,"about_ca_system_score_codex":0.0000088205115,"about_ca_system_score_gemma":0.00008271419,"threshold_uncertainty_score":0.3945935},"labels":[],"label_agreement":null},{"id":"W2043309765","doi":"10.3899/jrheum.140881","title":"Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group","year":2014,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Nail (fastener); Dermatology; Nail disease","score_opus":0.027273351829140258,"score_gpt":0.28320700390437664,"score_spread":0.2559336520752364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043309765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009928687,0.99140304,0.00021106152,0.00037275717,0.0037857534,0.0038924357,0.00014915202,0.000039721977,0.000046817637],"genre_scores_gemma":[0.00011936712,0.9967437,0.000048958016,0.00022448687,0.000056299825,0.0009578376,0.0002199778,0.00011841163,0.0015109596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98885846,0.006282183,0.0033993076,0.00044386758,0.00017612359,0.0008400658],"domain_scores_gemma":[0.9865829,0.0060744504,0.005669675,0.0013359183,0.00025666764,0.0000804428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0041935593,0.0011213166,0.0080586,0.00027001172,0.00063905126,0.000038102495,0.002190021,0.0009867746,0.00013985265],"category_scores_gemma":[0.00084711896,0.00049259246,0.0026924908,0.00055757584,0.0003845762,0.0000920488,0.00014214093,0.0008278435,0.00051909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042991914,0.0004328467,0.00002653034,0.39495465,0.030887445,0.000008375117,0.0003455322,1.3494811e-7,0.0000017403951,0.00043233778,0.14395411,0.4285264],"study_design_scores_gemma":[0.002302149,0.0006070409,0.0000014748334,0.2793324,0.067183934,0.010902784,0.00009687944,7.8583746e-8,0.000002945685,0.00016215927,0.6389373,0.00047085507],"about_ca_topic_score_codex":0.000046630794,"about_ca_topic_score_gemma":0.000016784239,"teacher_disagreement_score":0.4949832,"about_ca_system_score_codex":0.00019425407,"about_ca_system_score_gemma":0.0002484735,"threshold_uncertainty_score":0.9997526},"labels":[],"label_agreement":null},{"id":"W2044248453","doi":"10.1089/jir.2012.0058","title":"Engagement of CD14 Sensitizes Primary Monocytes to IFN-γ to Produce IL-12/23p40 and IL-23 Through p38 Mitogen-Activated Protein Kinase and Independent of the Janus Kinase/Signal Transducers and Activators of Transcription Signaling","year":2013,"lang":"en","type":"article","venue":"Journal of Interferon & Cytokine Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"p38 mitogen-activated protein kinases; CD14; Janus kinase; Kinase; stat; Cell biology; JAK-STAT signaling pathway; Signal transduction; STAT protein; Interleukin 12; Biology; Chemistry; Protein kinase A; Molecular biology; Immune system; STAT3; Immunology; Tyrosine kinase; In vitro; Biochemistry","score_opus":0.05125649423373745,"score_gpt":0.2910697597288573,"score_spread":0.23981326549511983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044248453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99638003,0.001200307,0.000103081584,0.00083854486,0.00013236143,0.0012409715,0.0000674137,0.0000053225735,0.00003197267],"genre_scores_gemma":[0.99921274,0.00020786806,0.00032296998,0.000021360733,0.000043524597,0.00003681065,0.00000511026,0.000021991122,0.00012763868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973557,0.0009823053,0.0007150144,0.00031166393,0.00028013627,0.00035516304],"domain_scores_gemma":[0.99856824,0.00026384185,0.000313438,0.00022431753,0.0005428148,0.000087366156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001327639,0.00023811788,0.0005942773,0.00039894896,0.00014333277,0.000025578003,0.00022897868,0.00016208639,0.00005898501],"category_scores_gemma":[0.00013511325,0.00016301464,0.00012267077,0.0002902338,0.00029419185,0.00023188858,0.00013612646,0.0005002492,0.0000017850014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004908409,0.00026077926,0.0009552162,0.00025993664,0.0005638559,0.0000074123595,0.0065445155,0.000016458409,0.96927434,0.000012775168,0.00011738873,0.017078921],"study_design_scores_gemma":[0.0021206515,0.0033473575,0.02072183,0.0006779359,0.0001018161,0.000057926485,0.0026378206,0.0000017015944,0.9699516,0.000050806626,0.00020023464,0.00013026167],"about_ca_topic_score_codex":0.00035401952,"about_ca_topic_score_gemma":0.000023698884,"teacher_disagreement_score":0.019766614,"about_ca_system_score_codex":0.00011356906,"about_ca_system_score_gemma":0.00014719965,"threshold_uncertainty_score":0.66475445},"labels":[],"label_agreement":null},{"id":"W2045113343","doi":"10.1038/ng.311","title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways","year":2009,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1396,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Toronto","funders":"National Center for Research Resources; Foundation for the National Institutes of Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Human Genome Research Institute; National Institutes of Health; National Heart, Lung, and Blood Institute","keywords":"Psoriasis; Biology; Genetics; Single-nucleotide polymorphism; Genome-wide association study; Genetic association; Gene; Epistasis; Immune system; Genetic predisposition; Immunology; Genotype","score_opus":0.007429858098225966,"score_gpt":0.21244382661875544,"score_spread":0.20501396852052947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045113343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826751,0.015454051,0.00002820857,0.00026161398,0.0003047775,0.00021276996,0.0001580161,0.00003561881,0.0008698892],"genre_scores_gemma":[0.99595606,0.0012319279,0.00093168975,0.00024393381,0.00007675436,0.000005899388,0.00018572084,0.000013960378,0.001354069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990529,0.00010982534,0.00022085737,0.00026617362,0.000071973605,0.0002782671],"domain_scores_gemma":[0.9992742,0.00011771982,0.00021826144,0.00022126074,0.00013984388,0.000028721195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020279373,0.00019038553,0.00030930308,0.000091276226,0.00010202056,0.000010680676,0.0001248637,0.00069967535,0.000033811917],"category_scores_gemma":[0.000072576506,0.0001538253,0.000060467377,0.00017285967,0.000041644693,0.00003038063,0.000022478558,0.00025403738,0.000023266566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000507023,0.0003220973,0.4806135,0.000043344335,0.0009826684,0.000014825142,0.0011305992,0.000019087316,0.43889403,0.0004700681,0.00316756,0.07383519],"study_design_scores_gemma":[0.0018516969,0.0006166921,0.83557796,0.0000265903,0.00033221924,0.000016051557,0.000063598694,8.1677314e-7,0.15104574,0.00041576778,0.009823499,0.0002293374],"about_ca_topic_score_codex":0.0000024738056,"about_ca_topic_score_gemma":0.000022953758,"teacher_disagreement_score":0.35496446,"about_ca_system_score_codex":0.000064761865,"about_ca_system_score_gemma":0.000047828875,"threshold_uncertainty_score":0.62728137},"labels":[],"label_agreement":null},{"id":"W2045382888","doi":"10.1016/j.neubiorev.2013.01.021","title":"Interleukin-17 in post-stroke neurodegeneration","year":2013,"lang":"en","type":"review","venue":"Neuroscience & Biobehavioral Reviews","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto; Toronto General Hospital; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Toronto Rehabilitation Institute; Heart and Stroke Foundation of Canada","keywords":"Stroke (engine); Neurodegeneration; Inflammation; Dementia; Neuroscience; Medicine; Neuroinflammation; Interleukin; Immunology; Cytokine; Psychology; Disease; Internal medicine","score_opus":0.12170117229321795,"score_gpt":0.3553889915759716,"score_spread":0.23368781928275364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045382888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016997611,0.9921762,0.0000041014455,0.0000033172382,0.0031086497,0.0025161987,0.00022712344,0.000071296134,0.00019339309],"genre_scores_gemma":[0.00005764539,0.99015677,0.00005685387,0.00026325937,0.00006882885,0.0010316665,0.00040059755,0.000053511394,0.00791089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957662,0.00082457915,0.0013677651,0.0011969829,0.00009951563,0.00074495113],"domain_scores_gemma":[0.99826026,0.000008802758,0.0007135743,0.0008830925,0.000058984526,0.000075283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049978757,0.00085154345,0.0022635187,0.00053328095,0.0001900053,0.00011633394,0.00095353706,0.00061352894,0.00062376965],"category_scores_gemma":[0.00017166077,0.0006007525,0.00086395786,0.000626559,0.00026215258,0.00033055886,0.00022228106,0.00067687815,0.0030343542],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000036991541,0.00017625402,0.00006052632,0.00037045678,4.047941e-7,0.000022050172,0.000021848306,3.7950628e-8,0.011537237,0.000008214298,0.0018153145,0.98598397],"study_design_scores_gemma":[0.00023182186,0.00028295995,0.00014427962,0.0014312877,0.0004978948,0.00013944414,0.000004433989,2.3352423e-7,0.00009239032,7.492053e-7,0.9966963,0.0004781868],"about_ca_topic_score_codex":0.000096029245,"about_ca_topic_score_gemma":0.0000671387,"teacher_disagreement_score":0.994881,"about_ca_system_score_codex":0.00014919078,"about_ca_system_score_gemma":0.00023649697,"threshold_uncertainty_score":0.9996444},"labels":[],"label_agreement":null},{"id":"W2046182548","doi":"10.1007/s10227-005-0103-6","title":"Safety and Efficacy of a Milk-derived Extract in the Treatment of Plaque Psoriasis:An Open-label Study","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Psoriasis; Tolerability; Adverse effect; Plaque psoriasis; Open label; Internal medicine; Dermatology","score_opus":0.04918904075310129,"score_gpt":0.30560736263385324,"score_spread":0.256418321880752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046182548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98426473,0.014278323,0.000003108251,0.0007722073,0.00022894479,0.00031853287,0.000008792207,0.0000026684174,0.00012271825],"genre_scores_gemma":[0.98729795,0.012343222,0.000048200305,0.000075048345,0.00012031748,0.0000036826705,0.000008472025,0.000008827907,0.00009425867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982291,0.0004987351,0.00087183743,0.00014610584,0.00008426508,0.0001699492],"domain_scores_gemma":[0.9971493,0.002044135,0.00050496095,0.00018740025,0.000074484655,0.000039734463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008586555,0.00017939594,0.00094127166,0.00022594596,0.00007122729,0.0000064292217,0.00015566479,0.00010221032,0.00007495442],"category_scores_gemma":[0.00011441302,0.000096309755,0.000058375143,0.00012378127,0.0001631844,0.000094666626,0.000016089614,0.00011039245,0.0000010323309],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019469947,0.021131309,0.053173672,0.000044399898,0.002048599,0.0014866008,0.040894203,0.000011010814,0.07918659,0.000037370988,0.0010917622,0.7814245],"study_design_scores_gemma":[0.17306867,0.10490322,0.49592224,0.0019266591,0.007377026,0.04147513,0.06151462,0.00003434749,0.031998865,0.0002593169,0.08021572,0.001304169],"about_ca_topic_score_codex":0.00015894361,"about_ca_topic_score_gemma":0.00016525868,"teacher_disagreement_score":0.7801204,"about_ca_system_score_codex":0.000026508975,"about_ca_system_score_gemma":0.000085852385,"threshold_uncertainty_score":0.3927398},"labels":[],"label_agreement":null},{"id":"W2046506588","doi":"10.1139/y07-084","title":"XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.","year":2007,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université du Québec; Université Laval","funders":"","keywords":"Psoriasis; Medicine; Splenocyte; Concanavalin A; In vivo; Pharmacology; In vitro; Hematology; Immune system; Internal medicine; Immunology; Chemistry; Biotechnology; Biology; Biochemistry","score_opus":0.015158811212046944,"score_gpt":0.24977968702196135,"score_spread":0.23462087580991442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046506588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939054,0.0010583746,0.000008662562,0.003687893,0.0005252097,0.00065373717,0.000102770166,0.0000015972628,0.000056311746],"genre_scores_gemma":[0.9987242,0.000115603936,0.0001802069,0.00036815615,0.000348273,0.000005845369,0.000011986138,0.000009512847,0.00023616683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985888,0.00021725593,0.0006152287,0.00020685108,0.000039959246,0.00033190136],"domain_scores_gemma":[0.99882257,0.0001745343,0.00056903757,0.000090743546,0.0002332684,0.0001098235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062481244,0.00015273431,0.00060467876,0.0002826832,0.00010725136,0.0000027094557,0.00012502894,0.00014656682,0.0020279149],"category_scores_gemma":[0.00006812448,0.000111187546,0.00006641506,0.0002509471,0.00027087648,0.0000703006,0.000011198639,0.0002529198,5.2568964e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016870536,0.00021628932,0.00062345754,0.00010718836,0.00059562596,0.0000029453863,0.0019097052,0.00008474395,0.9649307,0.00019536838,0.0038522128,0.010611203],"study_design_scores_gemma":[0.005264852,0.0028151195,0.03965987,0.00008505194,0.00017203475,0.000037640002,0.000111844914,0.0000067925544,0.94806564,0.00016906051,0.0035067347,0.0001053606],"about_ca_topic_score_codex":0.001951807,"about_ca_topic_score_gemma":0.0053689955,"teacher_disagreement_score":0.03903641,"about_ca_system_score_codex":0.00005296766,"about_ca_system_score_gemma":0.0007000817,"threshold_uncertainty_score":0.9988844},"labels":[],"label_agreement":null},{"id":"W2046880604","doi":"10.1371/journal.pone.0013676","title":"cis-Urocanic Acid Attenuates Acute Dextran Sodium Sulphate-Induced Intestinal Inflammation","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Fondation pour la Recherche Médicale","keywords":"Colitis; FOXP3; IL-2 receptor; Immunology; Lipopolysaccharide; Chemistry; Pharmacology; CXCL1; Oxazolone; Immune system; Medicine; T cell; Chemokine","score_opus":0.0322306736521352,"score_gpt":0.22808077361931756,"score_spread":0.19585009996718236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046880604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978041,0.00023453966,0.000015625212,0.0004876132,0.00042575639,0.0002732464,0.00003478925,0.0001786419,0.0005456647],"genre_scores_gemma":[0.99770087,0.00004888258,0.0004988147,0.00004897455,0.0001641546,0.00007507558,0.00037234512,0.000025778778,0.0010650773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989266,0.00008664184,0.00026334377,0.00030187433,0.000058793434,0.0003627855],"domain_scores_gemma":[0.9993056,0.00009593523,0.00012085437,0.00032450532,0.000113783084,0.000039291117],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014632438,0.00022260226,0.0002920232,0.000111500136,0.00019798033,0.000025166923,0.00022912498,0.00027280505,0.00045962378],"category_scores_gemma":[0.000098910714,0.00020039907,0.000080932055,0.0001364298,0.00007541025,0.00015166868,0.000050577833,0.00032848684,0.0020279875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016219752,0.00042919768,0.0040717428,0.000016653672,0.00082117284,0.000014007353,0.00034548435,3.296121e-8,0.9821516,0.00011684441,0.000060041286,0.011810979],"study_design_scores_gemma":[0.0013758461,0.00028109146,0.010704234,0.0000430803,0.00064905954,0.00004255557,0.000049483577,0.000005981008,0.98633814,0.00013351014,0.00015910048,0.00021793484],"about_ca_topic_score_codex":0.000034799206,"about_ca_topic_score_gemma":0.00018834777,"teacher_disagreement_score":0.011593044,"about_ca_system_score_codex":0.000023034861,"about_ca_system_score_gemma":0.00005630054,"threshold_uncertainty_score":0.9987491},"labels":[],"label_agreement":null},{"id":"W2047011925","doi":"10.1111/bjd.13235","title":"Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age","year":2014,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Astellas Pharma; LEO Pharma; Galderma; Dermira; Celgene; Amgen; Pfizer; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Medicine; Dermatology; Calcipotriol; Scalp; Psoriasis","score_opus":0.013583323941817375,"score_gpt":0.24151719145665604,"score_spread":0.22793386751483866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047011925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869287,0.0124347145,0.00003235152,0.00008970928,0.0002045888,0.00020928742,0.000038136848,0.0000023126609,0.00006022714],"genre_scores_gemma":[0.99469423,0.0051261205,0.000094253206,0.000020456602,0.000016635857,0.000003863629,0.000013747882,0.000009022066,0.000021650596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979053,0.0007681879,0.0008902639,0.0001447561,0.00006551535,0.00022593483],"domain_scores_gemma":[0.99881816,0.00040189124,0.0005446458,0.0001535445,0.000058916,0.000022852895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029074174,0.0001338009,0.00089853286,0.00023308363,0.000029592817,0.000003963514,0.00020846825,0.0002282188,0.00001703161],"category_scores_gemma":[0.00012497473,0.000114729206,0.00016700475,0.00014683626,0.00029040733,0.000048632344,0.000026857238,0.00015485084,0.0000018138263],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043706233,0.0038994905,0.31862456,0.0001826001,0.0007392058,0.0016116777,0.0048411335,0.000047494414,0.01624218,0.00017369461,0.00018345528,0.6490839],"study_design_scores_gemma":[0.017786259,0.00062111346,0.9643336,0.00047681012,0.00021364912,0.0046539116,0.00022829654,0.000003160483,0.010529481,0.00008075551,0.0009687822,0.000104176324],"about_ca_topic_score_codex":0.00041207552,"about_ca_topic_score_gemma":0.0004821203,"teacher_disagreement_score":0.6489797,"about_ca_system_score_codex":0.000040075087,"about_ca_system_score_gemma":0.00006185684,"threshold_uncertainty_score":0.46785212},"labels":[],"label_agreement":null},{"id":"W2047034520","doi":"10.1046/j.1523-1747.2003.12152.x","title":"Resetting the Research Agenda for Psoriasis","year":2003,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Alternative medicine; Randomized controlled trial; Clinical trial; Quarter (Canadian coin); Family medicine; Dermatology; Surgery; Pathology; History","score_opus":0.13161491522978577,"score_gpt":0.3409582630752898,"score_spread":0.20934334784550404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047034520","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027398411,0.015998567,0.00007931271,0.9483544,0.0054753046,0.0009379622,0.00023085673,0.000023420118,0.0015017729],"genre_scores_gemma":[0.020278653,0.0012917395,0.0038216792,0.9493697,0.0060534184,0.0005196664,0.00084883615,0.00032163694,0.017494665],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922247,0.0049756207,0.0011982177,0.00040113722,0.00020255827,0.0009977523],"domain_scores_gemma":[0.9903449,0.006299338,0.0014029267,0.0005016022,0.0014059071,0.000045329143],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002241628,0.00045208397,0.0011451388,0.0006763736,0.000793208,0.000049393613,0.001015335,0.0018097444,0.00019151092],"category_scores_gemma":[0.0035002192,0.00028763083,0.00061293156,0.00042533007,0.0020090502,0.00011936361,0.00010417679,0.0040851687,0.00019283287],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114762544,0.00003508367,0.00006126582,0.00009863243,0.0016137769,0.0005451811,0.0009181296,6.7497626e-7,0.008403807,0.00037978773,0.9867272,0.0011017477],"study_design_scores_gemma":[0.0015163401,0.0002741024,0.00006338811,0.00011858985,0.00040634786,0.0043214904,0.00064275385,3.1934232e-7,0.14647356,0.0050875,0.8408723,0.00022331919],"about_ca_topic_score_codex":0.000021235664,"about_ca_topic_score_gemma":0.000011172262,"teacher_disagreement_score":0.14585485,"about_ca_system_score_codex":0.00016179131,"about_ca_system_score_gemma":0.0009882415,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W2047351371","doi":"10.2310/7750.2009.08088","title":"Cost Comparison of Psoriasis Treatments","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Élisabeth Bruyère Hospital; University of Ottawa","funders":"EMD Serono; LEO Pharma; Australian Government; Amgen","keywords":"Medicine; Psoriasis; Infliximab; Plaque psoriasis; Body surface area; Dermatology; Psoriasis Area and Severity Index; Surgery; Internal medicine; Disease","score_opus":0.053959586453887806,"score_gpt":0.3079754591531861,"score_spread":0.25401587269929826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047351371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972705,0.024473757,0.000027124112,0.00097531884,0.0009585869,0.00007810754,0.000006370616,0.000008403713,0.00076732325],"genre_scores_gemma":[0.9963368,0.0027990192,0.00004891358,0.00017209342,0.00014935933,6.868687e-7,0.000014668161,0.000006160894,0.0004722536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879056,0.00012397316,0.0007176838,0.00010092036,0.00008027809,0.00018660045],"domain_scores_gemma":[0.99840546,0.0007519061,0.00055423984,0.00011404103,0.00012258504,0.000051778276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028182773,0.00015424007,0.0008886069,0.00026054814,0.00006626052,0.0000031024213,0.00007255078,0.00013073992,0.00021344797],"category_scores_gemma":[0.00016492365,0.0000997103,0.0001613568,0.00011946769,0.000117053016,0.00005175345,0.0000062346776,0.00012266284,0.000008344796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017257133,0.0007631004,0.08003229,0.00002676829,0.0013333521,0.0005604011,0.002164451,0.000004216691,0.04838338,0.000058255588,0.046200085,0.818748],"study_design_scores_gemma":[0.027795324,0.026243553,0.25690147,0.0038142188,0.013810349,0.06320883,0.011327117,0.00002329692,0.28514853,0.0028322793,0.30707985,0.0018151874],"about_ca_topic_score_codex":0.000014731064,"about_ca_topic_score_gemma":0.0000023017992,"teacher_disagreement_score":0.8169328,"about_ca_system_score_codex":0.000022552977,"about_ca_system_score_gemma":0.00005718989,"threshold_uncertainty_score":0.4066068},"labels":[],"label_agreement":null},{"id":"W2047363745","doi":"10.1016/j.clinre.2013.12.008","title":"Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations","year":2014,"lang":"en","type":"article","venue":"Clinics and Research in Hepatology and Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Tehran University of Medical Sciences and Health Services; University of Tehran","keywords":"Single-nucleotide polymorphism; Genotype; Ulcerative colitis; Medicine; Allele; Allele frequency; Inflammatory bowel disease; Locus (genetics); Disease; Genetics; Immunology; Biology; Internal medicine; Gene","score_opus":0.08141179416096803,"score_gpt":0.352895777031877,"score_spread":0.271483982870909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047363745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966266,0.0004275033,0.000007390497,0.0015642844,0.00060940086,0.0005895998,0.000024773091,0.00001352558,0.0001369285],"genre_scores_gemma":[0.99900365,0.00033144138,0.00006952805,0.00022011572,0.000035841487,0.00013539694,0.00006331697,0.000015418682,0.00012528355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941811,0.003688215,0.0006556857,0.0006258387,0.00004566864,0.00080347847],"domain_scores_gemma":[0.9988154,0.00074282836,0.00008924597,0.00023619387,0.00005319109,0.00006310433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021034635,0.00020873855,0.00063420786,0.00078754243,0.00016210954,0.000017184799,0.00017676012,0.0003852984,0.000057078254],"category_scores_gemma":[0.00021023511,0.00019174081,0.000043334145,0.00026233788,0.0007135296,0.000075742275,0.00021675503,0.00076956005,0.00003872625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023758174,0.0011462145,0.9844768,0.000010183405,0.000048774902,0.00008601206,0.0014720873,0.000001215075,0.0003879007,0.0005977748,0.00008649028,0.009310743],"study_design_scores_gemma":[0.0069142524,0.0039482913,0.9851366,0.00005206602,0.000014125958,0.00007716678,0.0009105811,0.000074842246,0.00004288143,0.0018393395,0.0008769431,0.0001128612],"about_ca_topic_score_codex":0.00073696586,"about_ca_topic_score_gemma":0.053479053,"teacher_disagreement_score":0.052742086,"about_ca_system_score_codex":0.00007309009,"about_ca_system_score_gemma":0.000037526843,"threshold_uncertainty_score":0.9637925},"labels":[],"label_agreement":null},{"id":"W2047891261","doi":"10.1100/tsw.2007.275","title":"Biological Functions of Interleukin-21 and Its Role in Inflammation","year":2007,"lang":"en","type":"review","venue":"The Scientific World JOURNAL","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Inflammation; Immunology; Rheumatoid arthritis; Cytokine; Innate lymphoid cell; Interleukin 9; Medicine; Interleukin; Immunity; Arthritis; Disease; Immune system; Internal medicine","score_opus":0.06556705866234305,"score_gpt":0.30224549969603637,"score_spread":0.23667844103369332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047891261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010687171,0.9859068,0.0000049065184,0.000039497405,0.002401409,0.00026135315,0.000036773505,0.000009804649,0.00065233186],"genre_scores_gemma":[0.0055278107,0.9795881,0.00001217573,0.0000036533709,0.00013814472,0.000014072757,0.00011034863,0.0000105778545,0.01459514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982176,0.0005458657,0.0006697868,0.00023769114,0.00005361251,0.0002754382],"domain_scores_gemma":[0.9989397,0.00030104019,0.00046208236,0.0002024109,0.00007142611,0.00002334017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021042852,0.00020882541,0.000636691,0.0007859996,0.00035531897,0.00006164483,0.00031097926,0.00020586539,0.00043141394],"category_scores_gemma":[0.00006172127,0.000112078735,0.00024710526,0.0007268693,0.00028268227,0.00007268033,0.000095377785,0.000535933,0.00025778508],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027169142,0.00004219935,0.000047397578,0.00012772139,0.00016468372,0.0000056215126,0.00018822505,4.7809505e-7,0.0007688148,0.00018580514,0.00046768517,0.9979742],"study_design_scores_gemma":[0.00032011172,0.000039715705,0.00020787679,0.0014947586,0.00029886662,0.0004057374,0.00009528483,4.870563e-7,0.000254778,0.00014433349,0.99661666,0.00012138247],"about_ca_topic_score_codex":0.0000031954198,"about_ca_topic_score_gemma":0.00011327572,"teacher_disagreement_score":0.9978528,"about_ca_system_score_codex":0.00006527118,"about_ca_system_score_gemma":0.00011720226,"threshold_uncertainty_score":0.47236803},"labels":[],"label_agreement":null},{"id":"W2048616749","doi":"10.2310/7750.2008.07079","title":"Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics","year":2008,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research","funders":"","keywords":"Psoriasis Area and Severity Index; Medicine; Psoriasis; Clinical trial; Severity of illness; Plaque psoriasis; Dermatology; Physical therapy; Internal medicine","score_opus":0.1151131709890265,"score_gpt":0.29623656383067737,"score_spread":0.18112339284165085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048616749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928495,0.0034973156,0.0010716203,0.0014238155,0.00096610695,0.00009499545,0.0000082401475,0.0000070972023,0.00008129808],"genre_scores_gemma":[0.9884773,0.011003066,0.00018590581,0.000058135272,0.00016687022,0.0000012410333,0.000010492536,0.000006829173,0.000090148584],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9990471,0.00012852238,0.00047686137,0.00012277214,0.000060203984,0.00016452049],"domain_scores_gemma":[0.99814785,0.0012114795,0.00039590275,0.00007219279,0.00012483029,0.000047747028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005373352,0.00012698174,0.00056273345,0.0001954078,0.00015540102,0.0000026624673,0.000030706262,0.00017564098,0.00004878418],"category_scores_gemma":[0.00042985,0.00008433446,0.00010622418,0.00007619752,0.0003492796,0.000070491726,0.000012266136,0.00014166585,3.522242e-7],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027428932,0.0018993281,0.42269585,0.0007262517,0.0066530113,0.0031537975,0.022090843,0.000015268683,0.22651684,0.0018451586,0.15367743,0.13329731],"study_design_scores_gemma":[0.019301329,0.013640047,0.067664504,0.0022711814,0.0056388504,0.7080246,0.06548157,0.00012662639,0.038679868,0.011002488,0.066339284,0.0018296528],"about_ca_topic_score_codex":0.000016463155,"about_ca_topic_score_gemma":0.0000034670659,"teacher_disagreement_score":0.7048708,"about_ca_system_score_codex":0.000045591776,"about_ca_system_score_gemma":0.00009619394,"threshold_uncertainty_score":0.34390593},"labels":[],"label_agreement":null},{"id":"W2048694434","doi":"10.3899/jrheum.160112","title":"Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","year":2016,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Krembil Foundation; University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Rubric; Family medicine; Dermatology; Physical therapy; Medical physics; Psychology","score_opus":0.03159590693635607,"score_gpt":0.3146197089475408,"score_spread":0.28302380201118477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048694434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98507833,0.01188158,0.00014736333,0.0019330339,0.00055219163,0.00029987068,0.00005971958,0.0000034004372,0.000044498975],"genre_scores_gemma":[0.99076253,0.008719784,0.0003986362,0.000008401545,0.00001073248,0.000013683902,0.0000012801585,0.000009776103,0.000075201235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788725,0.0010366241,0.0005927972,0.000120120894,0.000084040475,0.0002791493],"domain_scores_gemma":[0.99617344,0.002592564,0.00064665265,0.00021476643,0.00034962624,0.000022958588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002949126,0.00012035332,0.00051474717,0.00014168672,0.00019800988,0.0000035266962,0.00028617668,0.00017503148,0.000017823095],"category_scores_gemma":[0.00041676944,0.000054236694,0.00008926201,0.00011721819,0.0008517946,0.000072106704,0.00013015102,0.00018693072,9.5271247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034941523,0.00059688784,0.54034346,0.00027173053,0.0026882403,0.000003088488,0.0039352146,0.0000017290702,0.12638837,0.018281411,0.007974124,0.29602158],"study_design_scores_gemma":[0.05757045,0.020495431,0.6744911,0.004337896,0.0021078333,0.016213158,0.0119009875,0.00002256939,0.12024448,0.06589345,0.02580429,0.00091835664],"about_ca_topic_score_codex":0.00007413335,"about_ca_topic_score_gemma":0.00009644939,"teacher_disagreement_score":0.29510322,"about_ca_system_score_codex":0.000017471784,"about_ca_system_score_gemma":0.00010479894,"threshold_uncertainty_score":0.31384727},"labels":[],"label_agreement":null},{"id":"W2049222887","doi":"10.1111/pde.12437","title":"Rituximab Induced Psoriasis in an Infant","year":2014,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Rituximab; Psoriasis; CD20; Monoclonal antibody; Immunology; Monoclonal; Dermatology; Antibody","score_opus":0.0153949452228112,"score_gpt":0.2450891268754122,"score_spread":0.229694181652601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049222887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946498,0.0013159802,0.000053534655,0.00024727854,0.0015126135,0.00018714822,0.000011192643,0.0001285053,0.0018939096],"genre_scores_gemma":[0.9989845,0.00015717029,0.00012914363,0.000229195,0.00017164434,0.000076177865,0.00012111035,0.00002267313,0.00010835786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979297,0.0005933526,0.00043291168,0.00043810988,0.000036726415,0.00056920445],"domain_scores_gemma":[0.99909526,0.00026620668,0.00013192224,0.0004143708,0.000043761473,0.000048459016],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020852123,0.00025075735,0.0005595636,0.0004382155,0.00011402003,0.000012748799,0.00029804496,0.00051024737,0.00029353888],"category_scores_gemma":[0.000115811876,0.00023156374,0.00008651158,0.00036055272,0.000054019514,0.00014991184,0.00007181929,0.00024226002,0.0017061773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025898902,0.0010209552,0.94164747,0.000042622083,0.000088928864,0.00008948025,0.0007838505,0.000002650279,0.00618332,0.0025419686,0.0020850995,0.04525467],"study_design_scores_gemma":[0.0282486,0.0007806821,0.89191306,0.0000124984645,0.00070491666,0.001683376,0.0002915072,0.00007035356,0.029076595,0.0021693325,0.04352806,0.0015210321],"about_ca_topic_score_codex":0.0001491175,"about_ca_topic_score_gemma":0.00024203293,"teacher_disagreement_score":0.04973442,"about_ca_system_score_codex":0.000029888295,"about_ca_system_score_gemma":0.00007718411,"threshold_uncertainty_score":0.9990711},"labels":[],"label_agreement":null},{"id":"W2049798709","doi":"10.1111/j.0366-077x.2004.05950.x","title":"The use of ciclosporin in psoriasis: a clinical review","year":2004,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Ciclosporin; Psoriasis; Skin cancer; Dermatology; Adverse effect; Quality of life (healthcare); Population; Disease; Malignancy; Clinical trial; PUVA therapy; Intensive care medicine; Internal medicine; Cancer; Transplantation","score_opus":0.09772538025185368,"score_gpt":0.35004147090312127,"score_spread":0.2523160906512676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049798709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016145803,0.9967041,0.0000055748624,0.00015588653,0.0023476395,0.00051402225,0.000068620335,0.0000081520875,0.00003453994],"genre_scores_gemma":[0.000070211354,0.9993755,0.0001238879,0.00007490932,0.000078224955,0.000028957436,0.00005322954,0.000035127567,0.00015993892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270105,0.0026415484,0.0038613754,0.00027832648,0.00007890345,0.00043878428],"domain_scores_gemma":[0.9945919,0.0018404694,0.00292745,0.000375649,0.00021568169,0.00004888486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094489154,0.00035850808,0.004133549,0.00020374215,0.00010217465,0.000022698308,0.00071526226,0.00091780437,0.00007954053],"category_scores_gemma":[0.001112013,0.00026761164,0.0015768791,0.0003542643,0.00040053265,0.000119511446,0.00010207029,0.001179844,0.000082830215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053305703,0.00024981855,0.0001631169,0.006371678,0.0011248586,0.0027611998,0.000008460137,8.8509054e-8,1.5040612e-7,0.00007918216,0.0083568925,0.98083127],"study_design_scores_gemma":[0.001353878,0.000084040694,0.00016339599,0.08438222,0.0018917937,0.11140718,0.000005694158,7.2346844e-9,0.0000032602316,0.000037796046,0.8005023,0.00016841205],"about_ca_topic_score_codex":0.00007261182,"about_ca_topic_score_gemma":0.0001217748,"teacher_disagreement_score":0.9806628,"about_ca_system_score_codex":0.00008082201,"about_ca_system_score_gemma":0.0010940026,"threshold_uncertainty_score":0.9999776},"labels":[],"label_agreement":null},{"id":"W2049915900","doi":"10.1159/000155642","title":"A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp Psoriasis","year":2008,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Thornhill Medical (Canada); Health Sciences Centre; Moncton Hospital","funders":"LEO Pharma","keywords":"Calcipotriol; Scalp; Medicine; Betamethasone dipropionate; Psoriasis; Dermatology; Betamethasone; Adverse effect; Corticosteroid; Surgery; Internal medicine","score_opus":0.02313363758946562,"score_gpt":0.2608614042814614,"score_spread":0.23772776669199575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049915900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969474,0.0019652536,0.000021143996,0.00012909151,0.000102208825,0.0007108665,0.000014259488,0.0000052449177,0.00010454011],"genre_scores_gemma":[0.9993272,0.00055123697,0.00002707863,0.000015363847,0.000003131953,0.000022634018,0.000015359297,0.0000055824153,0.000032407068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876004,0.00043784303,0.00042460585,0.0001784878,0.000048288097,0.00015075548],"domain_scores_gemma":[0.99917156,0.00030046297,0.00021234821,0.00027616697,0.000031452153,0.000008030845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015879699,0.0001238961,0.00039375524,0.00009776115,0.00010411893,0.0000012660511,0.00016019323,0.00012656272,0.000009728145],"category_scores_gemma":[0.000018637453,0.000072781375,0.00005550937,0.00019521783,0.00025827702,0.00003448579,0.000110185174,0.000082387676,0.0000014144106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070494635,0.001008479,0.9673571,0.00011481234,0.0005529061,0.000035571567,0.0064426595,0.000006243526,0.0021379224,0.0010176555,0.000014637317,0.020607075],"study_design_scores_gemma":[0.005514701,0.00015687213,0.98410845,0.000035028865,0.0002437742,0.00027367775,0.00057339465,0.0000027565518,0.008960165,0.00003709532,0.00003168766,0.00006242282],"about_ca_topic_score_codex":0.00006096265,"about_ca_topic_score_gemma":0.000068964124,"teacher_disagreement_score":0.020544652,"about_ca_system_score_codex":0.000008168164,"about_ca_system_score_gemma":0.000012479929,"threshold_uncertainty_score":0.29679382},"labels":[],"label_agreement":null},{"id":"W2050106566","doi":"10.1111/j.1365-2133.2008.08680.x","title":"A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index","year":2008,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"U.S. Food and Drug Administration","keywords":"Psoriasis; Medicine; Index (typography); Library science; Family medicine; Dermatology; Computer science","score_opus":0.043202111919481895,"score_gpt":0.28073312112201226,"score_spread":0.23753100920253037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050106566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563026,0.0016060915,0.00115418,0.0001630923,0.0006949152,0.00057575334,0.000080904436,0.000006783588,0.00008803347],"genre_scores_gemma":[0.9984973,0.0003387201,0.00095145823,0.000046911962,0.000032012653,0.000048563346,0.000009981058,0.000014378803,0.000060685983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782956,0.0004922552,0.0010949344,0.00023547845,0.00008063501,0.00026712794],"domain_scores_gemma":[0.99823433,0.0003981799,0.0007729376,0.00022626821,0.00033425682,0.000034034652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006058568,0.00019308602,0.00085205055,0.00012012779,0.00018302727,0.000014099678,0.00029298698,0.00020765042,0.00010091429],"category_scores_gemma":[0.0001427008,0.0001527955,0.00015329331,0.00011648163,0.00037436222,0.00016307623,0.00012043361,0.0002549608,0.0000016436612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021811943,0.005036149,0.9124631,0.0001797109,0.003386646,0.0005288737,0.0062999246,0.000012715655,0.013894285,0.00004849859,0.003579503,0.052389394],"study_design_scores_gemma":[0.015313811,0.0015278409,0.9194692,0.00016947709,0.0005914336,0.035810016,0.003253035,0.000015993848,0.022459649,0.00004865494,0.0011101268,0.00023075861],"about_ca_topic_score_codex":0.00012581325,"about_ca_topic_score_gemma":0.00007261277,"teacher_disagreement_score":0.052158635,"about_ca_system_score_codex":0.000037664282,"about_ca_system_score_gemma":0.00019900154,"threshold_uncertainty_score":0.623082},"labels":[],"label_agreement":null},{"id":"W2050172669","doi":"10.1016/j.jaad.2004.04.012","title":"Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":608,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Inter-rater reliability; Cronbach's alpha; Concordance; Severity of illness; Clinical trial; Physical therapy; Dermatology; Psychometrics; Internal medicine; Rating scale; Statistics; Clinical psychology","score_opus":0.024617126348465305,"score_gpt":0.3342530989070339,"score_spread":0.3096359725585686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050172669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924634,0.0017447775,0.0006983503,0.0035669224,0.0005391098,0.00031277805,0.0001257729,0.000032565007,0.0005163296],"genre_scores_gemma":[0.99385333,0.00037276323,0.0051262192,0.0005030166,0.00009590898,0.000014673184,0.0000042504344,0.000019991003,0.000009868553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968042,0.0010269472,0.00093488465,0.00041925072,0.00027505387,0.00053966517],"domain_scores_gemma":[0.996625,0.00031452216,0.0025226907,0.00026261777,0.00016887605,0.00010629264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005239523,0.0004481968,0.0014269438,0.00011822015,0.00034282784,0.00003278525,0.0005332733,0.0002922063,0.000007448517],"category_scores_gemma":[0.000059575174,0.00030315222,0.0002505495,0.0006200821,0.0010215876,0.00031098785,0.00024051154,0.0005874772,0.000003122513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023423596,0.00065194553,0.8819236,0.00025848235,0.0058457763,0.000100946934,0.00038528343,0.00025928204,0.0059715654,0.009107665,0.00039529777,0.092757784],"study_design_scores_gemma":[0.009857432,0.00092869095,0.96374774,0.00038120325,0.0026868135,0.013900426,0.002557807,0.00005841126,0.0030667821,0.0018437624,0.00050071464,0.00047020163],"about_ca_topic_score_codex":0.0001827983,"about_ca_topic_score_gemma":0.00001956488,"teacher_disagreement_score":0.092287585,"about_ca_system_score_codex":0.0005067247,"about_ca_system_score_gemma":0.00046570675,"threshold_uncertainty_score":0.99994206},"labels":[],"label_agreement":null},{"id":"W2050181345","doi":"10.1016/j.annder.2013.09.212","title":"Cancers survenus dans le programme de développement clinique sur le traitement du psoriasis par l’ustekinumab : rapport final portant sur un suivi de cinq ans","year":2013,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Disease","score_opus":0.07928627684238518,"score_gpt":0.29400037955717057,"score_spread":0.2147141027147854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050181345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380138,0.018137883,0.0040068873,0.03483061,0.0017470606,0.0016092107,0.00040688954,0.00048840366,0.00075923454],"genre_scores_gemma":[0.9699114,0.01743986,0.0048480597,0.0025713479,0.00019024551,0.0015906832,0.0007072172,0.00012911447,0.002612084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9881338,0.0040569818,0.0016600717,0.0013042301,0.00020084908,0.004644058],"domain_scores_gemma":[0.99569845,0.0015084714,0.00085632555,0.0009927403,0.000410568,0.00053343584],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0040671877,0.0011877817,0.0015645105,0.00032671576,0.0008499757,0.00016336027,0.0012146313,0.0019244022,0.00053461175],"category_scores_gemma":[0.0011267569,0.0012047656,0.0008347464,0.00052604836,0.0011144383,0.00046052935,0.00034991148,0.001037975,0.0002180458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069615134,0.002914792,0.81071913,0.00040655257,0.003191303,0.0038499057,0.006513304,0.00039083042,0.008817249,0.001230351,0.08001125,0.081259154],"study_design_scores_gemma":[0.008606397,0.0012712156,0.80300146,0.0003061609,0.00097154785,0.0054206075,0.006133666,0.00038413837,0.11232496,0.0034096437,0.05626967,0.0019005481],"about_ca_topic_score_codex":0.016409017,"about_ca_topic_score_gemma":0.008642509,"teacher_disagreement_score":0.10350771,"about_ca_system_score_codex":0.001994597,"about_ca_system_score_gemma":0.014088246,"threshold_uncertainty_score":0.9993713},"labels":[],"label_agreement":null},{"id":"W2050501917","doi":"10.1111/jdv.12996","title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Plaque psoriasis; Dermatology; Scalp; Psoriasis; Nail (fastener); Psoriatic arthritis; Secukinumab","score_opus":0.017956625286759696,"score_gpt":0.24744523857170717,"score_spread":0.22948861328494746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050501917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962144,0.0023487224,0.000008966588,0.0008379222,0.000195236,0.00024982402,0.000011286508,0.0000026808382,0.00013098413],"genre_scores_gemma":[0.9995862,0.00022256405,0.000058608595,0.000056458528,0.000027706295,0.0000033683696,0.0000034387656,0.00001184034,0.000029814326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980112,0.0009020617,0.0006464235,0.000160206,0.000054630607,0.00022552533],"domain_scores_gemma":[0.9989864,0.00013023143,0.0006920039,0.00010062531,0.00005067547,0.000040024035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004245659,0.00016652247,0.00060965406,0.00024991337,0.000044140164,0.0000020321625,0.00021906846,0.00019287651,0.0000070782708],"category_scores_gemma":[0.00005262611,0.00009637926,0.00005124361,0.00014289653,0.0005257207,0.000080655445,0.000103296894,0.0003867964,0.0000014864205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12007136,0.0021012009,0.8058448,0.000098629615,0.0009699603,0.00013176903,0.0015436172,0.000052646465,0.0036995849,0.0006110628,0.00048723255,0.06438815],"study_design_scores_gemma":[0.36097053,0.004835782,0.60904294,0.000318075,0.0005129898,0.0018936667,0.0002646807,0.000004954311,0.019588571,0.00033560413,0.0019432218,0.00028899667],"about_ca_topic_score_codex":0.0000126205005,"about_ca_topic_score_gemma":0.00003225202,"teacher_disagreement_score":0.24089918,"about_ca_system_score_codex":0.00003608305,"about_ca_system_score_gemma":0.00011780058,"threshold_uncertainty_score":0.39302325},"labels":[],"label_agreement":null},{"id":"W2050528164","doi":"10.3899/jrheum.090228","title":"Biologic Therapies for Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Efalizumab; Psoriasis; Etanercept; Adalimumab; Infliximab; Quality of life (healthcare); Tumor necrosis factor alpha; Disease; Dermatology; Biologic Agents; Intensive care medicine; Immunology; Internal medicine","score_opus":0.020519365660394664,"score_gpt":0.2689313349519948,"score_spread":0.24841196929160012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050528164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744103,0.012327295,0.0018484007,0.008006649,0.0028019447,0.000365131,0.000096498436,0.000032180396,0.00011162997],"genre_scores_gemma":[0.99413747,0.0012717585,0.003932409,0.00025135346,0.000034395125,0.000017119262,0.00007248696,0.000009027929,0.00027395482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985766,0.00017082032,0.0006759251,0.00016447471,0.000038637107,0.00037353893],"domain_scores_gemma":[0.99885017,0.0002944135,0.00050286227,0.0001676771,0.0001550486,0.000029844365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004986217,0.0001997143,0.00057758606,0.00020006495,0.00015598924,0.000010111445,0.00027193502,0.00021486223,0.0008243222],"category_scores_gemma":[0.000080990765,0.00013793645,0.00030942107,0.00008041394,0.00007934569,0.000075889395,0.000017312224,0.00012640042,0.000050775605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049602753,0.001983487,0.15386063,0.000059111426,0.0056404592,0.00004802082,0.0031288245,0.000013473888,0.08611538,0.031442028,0.27709725,0.43565103],"study_design_scores_gemma":[0.025166634,0.011172278,0.039896775,0.0001313472,0.0009711144,0.0045959647,0.0025949688,0.000003140419,0.10046271,0.023786765,0.7904368,0.0007815126],"about_ca_topic_score_codex":0.0000073200627,"about_ca_topic_score_gemma":0.000008289523,"teacher_disagreement_score":0.5133395,"about_ca_system_score_codex":0.000044378405,"about_ca_system_score_gemma":0.000069136426,"threshold_uncertainty_score":0.902575},"labels":[],"label_agreement":null},{"id":"W2050760905","doi":"10.1038/mt.2012.127","title":"Inducible IL10+ Suppressor B Cells Inhibit CNS Inflammation and T Helper 17 Polarization","year":2012,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; McGill University","funders":"Canadian Institutes of Health Research; McGill University; Georgia Cancer Coalition","keywords":"Suppressor; Inflammation; Interleukin 10; Biology; Immunology; Cancer research; Immune system; Gene; Genetics","score_opus":0.014129940489620704,"score_gpt":0.2255329825036124,"score_spread":0.21140304201399168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050760905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989813,0.008298505,0.0004802489,0.00017505308,0.00035107095,0.00025126463,0.000016392129,0.000050742314,0.0005637159],"genre_scores_gemma":[0.9975076,0.00027609366,0.00014868112,0.00020312809,0.00005830594,0.000031830376,0.00021667028,0.00002111359,0.0015366102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921966,0.00016247825,0.00014203855,0.0001746945,0.000033208784,0.0002679418],"domain_scores_gemma":[0.9996535,0.000023788542,0.0000630714,0.00020034952,0.000031072574,0.000028187495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001463827,0.00015268897,0.00014284602,0.00008597881,0.0001233939,0.000017757959,0.00006546219,0.00022352723,0.00029386178],"category_scores_gemma":[0.0000075087846,0.0001323988,0.00005089183,0.00009634969,0.00005689316,0.0001629086,0.000024500327,0.000083843355,0.00022195681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007184098,0.00007615857,0.0032314043,0.0000035908595,0.00013725947,0.0000016087725,0.0009137986,0.000002260118,0.9764225,0.00042640665,0.0001741824,0.01853901],"study_design_scores_gemma":[0.0013319788,0.00007532794,0.0067769187,0.000007184435,0.00003563799,0.000011126536,0.00005049133,0.0000011990016,0.96515715,0.00008171974,0.026325418,0.00014581824],"about_ca_topic_score_codex":0.000024701374,"about_ca_topic_score_gemma":0.0000019746353,"teacher_disagreement_score":0.026151234,"about_ca_system_score_codex":0.000015863065,"about_ca_system_score_gemma":0.000012838903,"threshold_uncertainty_score":0.5399066},"labels":[],"label_agreement":null},{"id":"W2050849983","doi":"10.3109/09546634.2011.607795","title":"A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept","year":2011,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Guenther Dermatology Research Centre; Innovaderm (Canada); Mediprobe Research (Canada); Lynde Centre for Dermatology","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Dermatology; Combination therapy; Ultraviolet b; Randomized controlled trial; Internal medicine; Tumor necrosis factor alpha","score_opus":0.03614645644071029,"score_gpt":0.2553173164820604,"score_spread":0.2191708600413501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050849983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997654,0.00054741144,0.000038569917,0.00013498194,0.00011935699,0.0013745409,0.000016822563,0.000008994111,0.000105295985],"genre_scores_gemma":[0.9992954,0.00020173067,0.00027240976,0.000045102057,0.000007520679,0.000098561206,0.0000066541415,0.000016516322,0.000056115325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533683,0.0028642025,0.0010834831,0.00028206184,0.00016771347,0.00026570924],"domain_scores_gemma":[0.99806494,0.0006866736,0.0006822017,0.00032433553,0.00017050865,0.000071350565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010216014,0.00034641993,0.0015437584,0.00028948853,0.000082772145,0.000014208935,0.00021813225,0.00018596959,0.00019804684],"category_scores_gemma":[0.00006688975,0.0001710887,0.00023699316,0.00016238258,0.0002480119,0.00012211145,0.000047466943,0.00016067369,0.000005396978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46347997,0.0075925826,0.49929398,0.000010220096,0.001287905,0.00008367867,0.020216629,0.00001740004,0.0010304475,0.00004049856,0.0000094353445,0.006937268],"study_design_scores_gemma":[0.18116534,0.008107583,0.80241597,0.00008117777,0.00062621955,0.00007220456,0.0017136673,0.0000045741344,0.005552492,0.000061147344,0.000025693198,0.00017390386],"about_ca_topic_score_codex":0.000062850835,"about_ca_topic_score_gemma":0.00005009397,"teacher_disagreement_score":0.303122,"about_ca_system_score_codex":0.00009400122,"about_ca_system_score_gemma":0.000040258117,"threshold_uncertainty_score":0.69767946},"labels":[],"label_agreement":null},{"id":"W2050985326","doi":"10.1007/s12016-012-8306-2","title":"Cytokine-Based Therapy in Psoriasis","year":2012,"lang":"en","type":"review","venue":"Clinical Reviews in Allergy & Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Regional Municipality of Waterloo","funders":"","keywords":"Psoriasis; Cytokine; Medicine; Immunology; Immunopathology; Dermatology","score_opus":0.16273729906234793,"score_gpt":0.3961267258155396,"score_spread":0.23338942675319166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050985326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020561666,0.9899695,0.0000064743363,0.000071097,0.006401557,0.0022716161,0.00005560105,0.00008461573,0.00093394],"genre_scores_gemma":[0.00006154143,0.99502224,0.00017292741,0.0003208873,0.0003200559,0.0017621508,0.0010558579,0.00013718718,0.0011471421],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9823887,0.009354338,0.005269182,0.0014386437,0.000069358524,0.0014798057],"domain_scores_gemma":[0.9927703,0.0034653887,0.0017040998,0.0019226394,0.00005835916,0.00007919197],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00424339,0.0013783481,0.008634584,0.00084317115,0.000102034566,0.000016729604,0.0015535188,0.0040611313,0.0024498117],"category_scores_gemma":[0.0010356344,0.0010162012,0.0026895807,0.001017233,0.0006496354,0.00010463198,0.00028518712,0.0024573777,0.0076433253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022227113,0.0014236452,0.0002435714,0.0007863826,0.0011366518,0.00004135874,0.000028845398,1.4074645e-7,0.000006422549,0.00024062398,0.0006381226,0.995232],"study_design_scores_gemma":[0.004084006,0.00049755763,0.00080917013,0.0061982963,0.00040611904,0.000048560854,0.000005736099,9.436578e-8,0.0000073521837,0.00004534732,0.9870661,0.00083167903],"about_ca_topic_score_codex":0.000094329014,"about_ca_topic_score_gemma":0.0002636975,"teacher_disagreement_score":0.99440026,"about_ca_system_score_codex":0.00030922843,"about_ca_system_score_gemma":0.00055756385,"threshold_uncertainty_score":0.9998967},"labels":[],"label_agreement":null},{"id":"W2051073361","doi":"10.3899/jrheum.091462","title":"Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences","year":2010,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of Manitoba; Toronto Western Hospital; Research Manitoba; University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"","keywords":"Inference; Phylogenetic tree; Predictability; Clade; Robustness (evolution); Evolutionary biology; Computational biology; Covariance; Biology; False discovery rate; Machine learning; Artificial intelligence; Computer science; Statistics; Genetics; Gene; Mathematics","score_opus":0.017589017433937808,"score_gpt":0.2580237409942766,"score_spread":0.2404347235603388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051073361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14524837,0.8522281,0.0000025044567,0.00006487201,0.0010273075,0.00032611948,0.0010876679,0.000010506977,0.0000045676125],"genre_scores_gemma":[0.009774318,0.9894905,0.000111496316,0.000013124502,0.00002315135,0.000054690474,0.0004528584,0.000034378772,0.00004548002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959965,0.0010381858,0.0021380642,0.00033220975,0.00008577782,0.00040928385],"domain_scores_gemma":[0.9952673,0.0015828079,0.0025738324,0.00033036308,0.00015880378,0.00008690371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004717893,0.0005876196,0.003813774,0.00048549898,0.0001519122,0.000013704317,0.00038779914,0.00086257065,0.00033513326],"category_scores_gemma":[0.00016460799,0.0004051699,0.0005570298,0.00010435977,0.0008238731,0.00008407973,0.00025105514,0.00056156446,0.0000123628415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037649146,0.00051461457,0.06867853,0.014074162,0.0056310794,0.000110158166,0.00076580845,4.0928494e-8,0.0008905147,0.0012894891,0.0012200234,0.9064491],"study_design_scores_gemma":[0.0043640994,0.0013440117,0.018609094,0.006715427,0.0067471494,0.0042997864,0.0008220782,2.9829263e-7,0.00008635917,0.00079726096,0.9553252,0.0008892324],"about_ca_topic_score_codex":0.000044890145,"about_ca_topic_score_gemma":0.000025916303,"teacher_disagreement_score":0.9541052,"about_ca_system_score_codex":0.000031947373,"about_ca_system_score_gemma":0.00035331308,"threshold_uncertainty_score":0.99984},"labels":[],"label_agreement":null},{"id":"W2051641690","doi":"10.1111/j.1365-2133.2007.08025.x","title":"Inhibition of tumour necrosis factor-? secretion from EpiDerm<sup>TM</sup>tissues by a novel small molecule, UTL-5d","year":2007,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Psoriasis; Lotion; Tumor necrosis factor alpha; Epidermis (zoology); Secretion; Necrosis; Cell; Medicine; Cancer research; In vitro; Pharmacology; Chemistry; Immunology; Pathology; Internal medicine; Biochemistry","score_opus":0.017621404559757834,"score_gpt":0.22872303095357402,"score_spread":0.2111016263938162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051641690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738723,0.018602137,0.005888065,0.00024573336,0.00043388622,0.00016161577,0.00055874535,0.000030934047,0.00020660463],"genre_scores_gemma":[0.9971979,0.0012355748,0.00076014665,0.00016299411,0.00007235344,0.000004650272,0.00041642095,0.000031844047,0.0001180631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765646,0.0003102318,0.0011607677,0.0002850115,0.00009034525,0.00049715926],"domain_scores_gemma":[0.9982696,0.00036660585,0.00084459735,0.00015973418,0.0002761293,0.00008332634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002413654,0.00026886782,0.0008385234,0.00024555018,0.00014823972,0.000026317466,0.00023373998,0.00057444343,0.000379987],"category_scores_gemma":[0.00016975786,0.00030077633,0.00027161028,0.00018186422,0.00021760544,0.00019738368,0.000060055027,0.0003890155,0.000050779592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050889613,0.0005901782,0.009516451,0.00003177871,0.00063386036,0.0015243504,0.0006324191,0.0000039916113,0.9613907,0.00003895967,0.004130841,0.020997588],"study_design_scores_gemma":[0.0061669042,0.00029170746,0.03875149,0.00034956922,0.0003308451,0.0332969,0.0005054063,0.0000061602827,0.91640157,0.00025871024,0.0032843626,0.00035635525],"about_ca_topic_score_codex":0.0008375536,"about_ca_topic_score_gemma":0.0002195751,"teacher_disagreement_score":0.044989098,"about_ca_system_score_codex":0.000062983454,"about_ca_system_score_gemma":0.000090121335,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W2051720298","doi":"10.1007/s10227-001-0129-3","title":"Nonpsoriatic Uses of Calcipotriol","year":2002,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre","funders":"","keywords":"Calcipotriol; Medicine; Calcitriol; Vitamin D and neurology; Dermatology; Pharmacology; Psoriasis; Endocrinology","score_opus":0.07635486608260113,"score_gpt":0.30549462883523865,"score_spread":0.22913976275263753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051720298","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009176554,0.99624443,0.0000035811088,0.00006551243,0.002227393,0.0001428731,0.000023925068,0.000007615702,0.00036699141],"genre_scores_gemma":[0.0005319131,0.99766713,0.0000147798055,0.000039748124,0.00046797472,0.0000031401385,0.000029514833,0.00002904844,0.001216745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732566,0.00044419186,0.0016863829,0.00017374322,0.00010727194,0.00026276594],"domain_scores_gemma":[0.9937642,0.0039497446,0.0018581179,0.00021265473,0.00015170616,0.000063545165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056531926,0.00037915408,0.0039809435,0.0006930926,0.000060645303,0.0000044057883,0.00016224575,0.0004751845,0.00077572453],"category_scores_gemma":[0.0005652042,0.00022219442,0.0007522918,0.00023222307,0.00022538792,0.000042266525,0.000024286679,0.00037943004,0.000033300155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058798112,0.000098695346,0.00006469727,0.0034539662,0.0016734119,0.0009040679,0.00020085943,6.296229e-8,0.000021461103,0.000009350909,0.025469687,0.96804494],"study_design_scores_gemma":[0.000383205,0.00037978208,0.0000046874234,0.014479954,0.0047903527,0.022509327,0.00007028171,6.136749e-8,0.000013839629,0.000019436771,0.95716983,0.0001792476],"about_ca_topic_score_codex":0.00001597406,"about_ca_topic_score_gemma":0.0000017814474,"teacher_disagreement_score":0.9678657,"about_ca_system_score_codex":0.00003632673,"about_ca_system_score_gemma":0.00021805275,"threshold_uncertainty_score":0.9060825},"labels":[],"label_agreement":null},{"id":"W2051723090","doi":"10.3899/jrheum.130456","title":"Psoriasis Outcome Measures: A Report from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Metabolic syndrome; Disease; Depression (economics); Obesity; Alcohol consumption; Physical therapy; Dermatology; Internal medicine","score_opus":0.0234936582403639,"score_gpt":0.24755663047582,"score_spread":0.2240629722354561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051723090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978018,0.014547674,0.00019795343,0.0038252731,0.0027777068,0.00019798346,0.0000252272,0.000025645826,0.00038454126],"genre_scores_gemma":[0.9976488,0.0011113515,0.00014326166,0.00021037222,0.000046667406,0.000012445604,0.000013590213,0.000020132577,0.0007933983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716073,0.001169549,0.0010206624,0.00015318462,0.000098079254,0.00039782078],"domain_scores_gemma":[0.9963108,0.0018051508,0.0010606897,0.000488654,0.0002966869,0.000038054703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016086488,0.0002338842,0.00061846006,0.00008414879,0.00036805152,0.000018175222,0.00070475455,0.00025771992,0.0007621597],"category_scores_gemma":[0.0005922166,0.00011068179,0.00027326975,0.00013728114,0.00029216844,0.00020260176,0.00009984343,0.0004478368,0.0006336807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005753601,0.00018606446,0.81974137,0.000008374265,0.003106237,0.000057251073,0.005280949,0.000010943808,0.00837349,0.0002478615,0.12786356,0.03454852],"study_design_scores_gemma":[0.0128541,0.000981613,0.56463856,0.0004173929,0.0042121336,0.11270424,0.022143608,0.000006459715,0.010337428,0.010146608,0.2603064,0.0012514669],"about_ca_topic_score_codex":0.0025339546,"about_ca_topic_score_gemma":0.00028026119,"teacher_disagreement_score":0.2551028,"about_ca_system_score_codex":0.000029502966,"about_ca_system_score_gemma":0.00008608505,"threshold_uncertainty_score":0.83451146},"labels":[],"label_agreement":null},{"id":"W2053127888","doi":"10.1056/nejmoa1315231","title":"Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Amgen","keywords":"Medicine; Psoriatic arthritis; Monoclonal antibody; Monoclonal; Ixekizumab; Immunology; Arthritis; Antibody; Dermatology; Secukinumab","score_opus":0.014039691405010728,"score_gpt":0.26419101783173465,"score_spread":0.25015132642672394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053127888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98588,0.009458939,0.00032910702,0.0015070463,0.0020762275,0.00007454926,0.0000037898,0.00001320049,0.0006571245],"genre_scores_gemma":[0.99609613,0.0017110516,0.00023736102,0.00021988423,0.001458881,8.750152e-7,0.000038721646,0.000013983033,0.00022309739],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984541,0.00041661237,0.0005936263,0.00016271407,0.00009587793,0.0002770806],"domain_scores_gemma":[0.9991041,0.0002490292,0.00029107984,0.00017988167,0.000081090024,0.000094853756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011141625,0.000181896,0.00062037376,0.0002789665,0.0000623864,0.000007157838,0.00020083945,0.0001483284,0.00063063856],"category_scores_gemma":[0.00026314287,0.00012601489,0.000072557195,0.0001530341,0.00010813693,0.00013890366,0.000016317925,0.00029809988,0.000042790085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006047917,0.00019361914,0.03881032,0.000009701283,0.00018142449,0.00014827716,0.0013888807,0.00002251057,0.06864411,0.00047294766,0.00204499,0.8874784],"study_design_scores_gemma":[0.23209494,0.009012009,0.5794929,0.0011231769,0.00042981966,0.005667735,0.0004619849,0.000035179415,0.010754363,0.0045168446,0.1558752,0.0005357878],"about_ca_topic_score_codex":0.00017552983,"about_ca_topic_score_gemma":0.00012533322,"teacher_disagreement_score":0.8869426,"about_ca_system_score_codex":0.00002551016,"about_ca_system_score_gemma":0.00008840517,"threshold_uncertainty_score":0.690505},"labels":[],"label_agreement":null},{"id":"W2053423099","doi":"10.2310/7750.2009.08068","title":"Work-Related Lost Productivity and Its Economic Impact on Canadian Patients with Moderate to Severe Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Lynde Centre for Dermatology; University of Toronto; Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre","funders":"Amgen Canada","keywords":"Psoriasis; Medicine; Productivity; Work productivity; Population; Demography; Dermatology; Environmental health","score_opus":0.011413114752858763,"score_gpt":0.21950783516782793,"score_spread":0.20809472041496918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053423099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949276,0.0017892654,4.409853e-7,0.0022851818,0.0004958602,0.00014269278,0.000023228342,0.0000057752804,0.0003299787],"genre_scores_gemma":[0.99887526,0.00029199617,0.0000042862475,0.00033013726,0.00010593889,6.301505e-7,0.00001634169,0.000010372847,0.0003650371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905795,0.000102488346,0.0003257234,0.00018282673,0.000049120736,0.00028186708],"domain_scores_gemma":[0.99916,0.00025637046,0.00019533971,0.000101795515,0.000096948985,0.0001895644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025511815,0.000204185,0.0005580841,0.0003729215,0.00011451712,0.0000112092375,0.000048419584,0.00012259929,0.00017086687],"category_scores_gemma":[0.00009001939,0.0001223365,0.00006169928,0.000108306485,0.00004079664,0.00008872258,0.000005017223,0.00017300255,0.000027103959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0249457,0.0004903582,0.4669492,0.000034866152,0.0030044247,0.0020246685,0.0034045817,0.0009670886,0.0015247014,0.000056804227,0.05747741,0.43912017],"study_design_scores_gemma":[0.007817584,0.010389671,0.95697016,0.0012675256,0.0010786941,0.011187321,0.0002107932,0.000010891431,0.001963756,0.000270198,0.007848144,0.000985259],"about_ca_topic_score_codex":0.0005190969,"about_ca_topic_score_gemma":0.00058523036,"teacher_disagreement_score":0.49002096,"about_ca_system_score_codex":0.00013706739,"about_ca_system_score_gemma":0.0002423763,"threshold_uncertainty_score":0.49887374},"labels":[],"label_agreement":null},{"id":"W2053528201","doi":"10.1111/jdv.12272","title":"Increased expression of <scp>IL</scp>‐17A and limited involvement of <scp>IL</scp>‐23 in patients with palmo‐plantar (<scp>PP</scp>) pustular psoriasis or <scp>PP</scp> pustulosis; results from a randomised controlled trial","year":2013,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Windsor Clinical Research; Dalhousie University; Innovaderm (Canada)","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Ustekinumab; Placebo; Psoriasis; Internal medicine; Pustulosis; Dermatology; Gastroenterology; Disease; Pathology","score_opus":0.014113659528431454,"score_gpt":0.21441690747392753,"score_spread":0.20030324794549606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053528201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869858,0.008913892,0.000014169505,0.00023569001,0.0007811782,0.002224486,0.00035203228,0.00002905809,0.00046371468],"genre_scores_gemma":[0.994422,0.004110446,0.0002916202,0.0002951998,0.00018103838,0.00007021986,0.00015209016,0.00007585451,0.00040149942],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9879797,0.0067776996,0.0032291582,0.000762636,0.00032204998,0.0009287441],"domain_scores_gemma":[0.9841076,0.0101321535,0.004650575,0.00052467553,0.00035979605,0.00022518638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018593121,0.0008357457,0.003164159,0.00066613045,0.00028517275,0.000024294748,0.0010406914,0.0011322272,0.000013748871],"category_scores_gemma":[0.0048596393,0.0005259953,0.000529032,0.00044749683,0.0011209964,0.0002821172,0.0004927362,0.001199627,0.000021351047],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14413577,0.0051756734,0.62836283,0.00042270863,0.009601572,0.00035314471,0.007726622,0.00010284416,0.16998352,0.0001612621,0.031847816,0.0021262057],"study_design_scores_gemma":[0.56604415,0.0016038723,0.27343673,0.0006677451,0.002379023,0.00053192605,0.0016206612,0.000028675595,0.14851901,0.00028688286,0.004750758,0.0001306104],"about_ca_topic_score_codex":0.000104708466,"about_ca_topic_score_gemma":0.000019918369,"teacher_disagreement_score":0.42190835,"about_ca_system_score_codex":0.00005248093,"about_ca_system_score_gemma":0.00017843276,"threshold_uncertainty_score":0.99971914},"labels":[],"label_agreement":null},{"id":"W2053531292","doi":"10.1111/j.1529-8019.2008.00235.x","title":"Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis","year":2008,"lang":"en","type":"article","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Probity Medical Research","funders":"Merck KGaA","keywords":"Medicine; Efalizumab; Plaque psoriasis; Psoriasis; Dermatology; Dermatologic agents; PUVA therapy","score_opus":0.01978578425018108,"score_gpt":0.2375135563121972,"score_spread":0.21772777206201613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053531292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938518,0.003777872,0.00006454876,0.00019428482,0.0004368127,0.0014081121,0.00006298118,0.00009771141,0.00010587857],"genre_scores_gemma":[0.9973556,0.0014042135,0.00007516519,0.0004953097,0.00002352708,0.0001913479,0.00019307705,0.000040854804,0.00022090074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979606,0.00031080886,0.0004777651,0.00055122597,0.00009988036,0.00059969793],"domain_scores_gemma":[0.9989435,0.0001503938,0.00016672978,0.0005618538,0.0001099935,0.000067535744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008056581,0.00044746345,0.0007685108,0.00029304437,0.00018871864,0.000011058564,0.00041400513,0.00035282204,0.00034072102],"category_scores_gemma":[0.000014211542,0.0003169774,0.00013852933,0.00042824604,0.00012600177,0.000106542015,0.000046087225,0.0001737042,0.00024764068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021145616,0.0015968407,0.89562434,0.000017961269,0.00083071366,0.0000987857,0.0045543713,0.0003128642,0.0034368066,0.00006000457,0.001407727,0.07091396],"study_design_scores_gemma":[0.02662037,0.0020151313,0.90978116,0.00005896657,0.00002140494,0.00008926611,0.000036221878,0.0000012920469,0.059817396,0.000017621654,0.0010802073,0.00046097144],"about_ca_topic_score_codex":0.000080964004,"about_ca_topic_score_gemma":0.000080261154,"teacher_disagreement_score":0.070452996,"about_ca_system_score_codex":0.00011365447,"about_ca_system_score_gemma":0.00012862428,"threshold_uncertainty_score":0.99992824},"labels":[],"label_agreement":null},{"id":"W2053548435","doi":"10.1111/exd.12242","title":"Psoriatic keratinocytes are resistant to tumor necrosis factor alpha's induction of m<scp>RNA</scp> for the <scp>NMDA</scp>‐<scp>R</scp>2<scp>C</scp> subunit","year":2013,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bishop's University","funders":"","keywords":"NMDA receptor; Tumor necrosis factor alpha; Psoriasis; Keratinocyte; In vitro; Molecular biology; Messenger RNA; Biology; RNA; Chemistry; Cancer research; Immunology; Receptor; Biochemistry; Gene","score_opus":0.02242052475672388,"score_gpt":0.2540396724913424,"score_spread":0.23161914773461853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053548435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698764,0.019842723,0.00014139868,0.00024974378,0.0042090737,0.0030749687,0.0006875204,0.00031382832,0.0016043568],"genre_scores_gemma":[0.9849976,0.00034242216,0.0007206045,0.0008523268,0.00033199653,0.0026483734,0.00063496036,0.00019346291,0.009278257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9939398,0.0008808536,0.0015782594,0.0013721415,0.00028073977,0.0019481734],"domain_scores_gemma":[0.99051654,0.0063901874,0.0011454566,0.0012582884,0.00039764692,0.00029190237],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030341928,0.0012460707,0.001763668,0.00056703854,0.0012023189,0.0001831317,0.0011668275,0.0010412541,0.00017622334],"category_scores_gemma":[0.0021426375,0.0010206561,0.0006851414,0.00067278894,0.00069528946,0.00056315033,0.00046660684,0.0006037947,0.0015437279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051936666,0.0011351589,0.0074466206,0.00015677972,0.0017267265,0.000046166915,0.01520931,0.000010588532,0.8101366,0.00085798296,0.16234626,0.00087588193],"study_design_scores_gemma":[0.004035869,0.0008314276,0.016501417,0.000095965945,0.00035105675,0.0003972173,0.032412663,0.000022935383,0.8401515,0.00021052486,0.10486245,0.0001269649],"about_ca_topic_score_codex":0.0006852681,"about_ca_topic_score_gemma":0.00013680663,"teacher_disagreement_score":0.057483803,"about_ca_system_score_codex":0.000352931,"about_ca_system_score_gemma":0.0003085438,"threshold_uncertainty_score":0.99923366},"labels":[],"label_agreement":null},{"id":"W2053633009","doi":"10.1371/journal.pone.0045706","title":"IL-27-Induced Gene Expression Is Downregulated in HIV-Infected Subjects","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada; Queen's University; Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Peripheral blood mononuclear cell; Immunology; Downregulation and upregulation; Biology; Immune system; Flow cytometry; Gene expression; Cytokine; Pathogenesis; Lentivirus; Gene; Human immunodeficiency virus (HIV); Viral disease; In vitro","score_opus":0.03940096797592821,"score_gpt":0.225922181814522,"score_spread":0.1865212138385938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053633009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967165,0.001590105,0.0000033167246,0.00008435861,0.0002868945,0.0003161744,0.000061018214,0.00013131923,0.000810293],"genre_scores_gemma":[0.99653965,0.000116193616,0.00031978686,0.00007523785,0.00008424705,0.00004926198,0.0003337426,0.000025965555,0.0024558902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986758,0.00022012631,0.00024329443,0.00026627354,0.00005523569,0.0005392674],"domain_scores_gemma":[0.9993965,0.00008716243,0.00008872433,0.00033429635,0.000045646666,0.000047651225],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014629753,0.00022040337,0.0003521741,0.00017067589,0.00009551205,0.0000078085,0.00012814305,0.00037979995,0.0013934338],"category_scores_gemma":[0.00004741809,0.00019165344,0.000067455374,0.0002426181,0.000033581382,0.00014847716,0.00006382525,0.00016787482,0.0032306465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018445861,0.002059694,0.08240952,0.00001539571,0.00028724648,0.000004652782,0.0007377686,1.2064928e-7,0.91287965,0.000012416635,0.0005010387,0.0009080212],"study_design_scores_gemma":[0.0019984152,0.00008620293,0.11406702,0.00009036687,0.00015680549,0.000006349972,0.00002614638,0.000001327666,0.8830662,0.00001399181,0.00028799314,0.00019920271],"about_ca_topic_score_codex":0.000042429885,"about_ca_topic_score_gemma":0.000010384104,"teacher_disagreement_score":0.0316575,"about_ca_system_score_codex":0.00006007989,"about_ca_system_score_gemma":0.000027033619,"threshold_uncertainty_score":0.9995194},"labels":[],"label_agreement":null},{"id":"W2054496321","doi":"10.1046/j.1468-3083.2000.00134.x","title":"Quality of life of psoriasis patients","year":2000,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Psoriasis; Medicine; Quality of life (healthcare); Context (archaeology); Disease; Gerontology; Socialization; Dermatology; Psychology; Developmental psychology; Nursing","score_opus":0.0279421862173735,"score_gpt":0.25686378712024344,"score_spread":0.22892160090286995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054496321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9173011,0.013837105,0.000005125361,0.064151816,0.0015777781,0.00019797197,0.00021227731,0.00000824723,0.002708583],"genre_scores_gemma":[0.97670126,0.0025027548,0.00006545815,0.019735573,0.00035458614,0.0000013679938,0.000040241597,0.000041287683,0.00055748626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99192494,0.0052692574,0.0020986185,0.00024848542,0.000113534545,0.00034513458],"domain_scores_gemma":[0.9947318,0.00073374,0.0040801275,0.00027791166,0.00014291277,0.000033505286],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00064667256,0.000355934,0.0018272543,0.00034450702,0.00008645302,0.0000018109547,0.00093209173,0.0013656075,0.00016529497],"category_scores_gemma":[0.000272748,0.00024125063,0.0006046628,0.00014338123,0.0012461788,0.0000609655,0.0002155022,0.0016308179,0.000018965487],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00236694,0.0006069527,0.411516,0.0009168514,0.005971293,0.00008566406,0.00065193017,0.000007518223,0.005216369,0.00036923488,0.54856396,0.023727296],"study_design_scores_gemma":[0.009375977,0.00026815105,0.44684625,0.0003869232,0.001873216,0.002181662,0.000046143803,2.5454278e-7,0.021923183,0.0010935118,0.5154878,0.0005169452],"about_ca_topic_score_codex":0.000009792894,"about_ca_topic_score_gemma":7.9830266e-7,"teacher_disagreement_score":0.05940015,"about_ca_system_score_codex":0.000014694495,"about_ca_system_score_gemma":0.000102763566,"threshold_uncertainty_score":0.99993086},"labels":[],"label_agreement":null},{"id":"W2054546707","doi":"10.1016/j.clim.2009.03.068","title":"OR.56. Preferential Recruitment of IL-17 and IFN-γ Co-expressing CD4+T Lymphocytes Into the Central Nervous System","year":2009,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Central nervous system; Biology; Cell biology; Immunology; Neuroscience","score_opus":0.08190505372609269,"score_gpt":0.34399888508596527,"score_spread":0.2620938313598726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054546707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826604,0.0133771105,0.000050000548,0.00034227665,0.0018921869,0.0005825338,0.00004071638,0.000105662504,0.0009491017],"genre_scores_gemma":[0.9962023,0.0018355425,0.00017509618,0.0001654016,0.00015382434,0.000049031725,0.00011868569,0.000016522334,0.0012835911],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969736,0.0009713317,0.0009659993,0.0004913948,0.000047028974,0.00055068126],"domain_scores_gemma":[0.99803007,0.0008625588,0.00040052104,0.000593262,0.00007072584,0.000042870943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004743606,0.00030276092,0.0007793931,0.000074786105,0.0003264723,0.000022818153,0.00041591513,0.0006612277,0.0001435078],"category_scores_gemma":[0.0001655179,0.00018563861,0.00028105953,0.00010819885,0.0008386869,0.00007532455,0.00013647263,0.00030062126,0.00009212454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055887955,0.0011975222,0.008473045,0.000048119255,0.0028139378,0.00004387615,0.0020148484,0.0000024635747,0.11206626,0.0025703404,0.00242951,0.8627513],"study_design_scores_gemma":[0.025098948,0.0088780075,0.6414677,0.00058941636,0.0025864271,0.00067740004,0.003736022,0.000029293644,0.17901762,0.00077011116,0.13600028,0.0011487694],"about_ca_topic_score_codex":0.00009939994,"about_ca_topic_score_gemma":0.000028875387,"teacher_disagreement_score":0.8616025,"about_ca_system_score_codex":0.00008616025,"about_ca_system_score_gemma":0.00014799843,"threshold_uncertainty_score":0.7570123},"labels":[],"label_agreement":null},{"id":"W2054573088","doi":"10.3899/jrheum.090822","title":"Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis","year":2010,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Disease; Population; Metabolic syndrome; Risk factor; Internal medicine; Incidence (geometry); Epidemiology; Dermatology; Obesity; Environmental health","score_opus":0.011152886625613161,"score_gpt":0.21916953218123267,"score_spread":0.2080166455556195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054573088","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41246337,0.586719,0.0000031118761,0.000004409851,0.0005057751,0.00024012859,0.00005756023,0.000004181766,0.0000024956032],"genre_scores_gemma":[0.026953457,0.97292084,0.000021754458,0.0000019218617,0.0000092403825,0.00001018618,0.000038241058,0.00003225955,0.000012092284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972709,0.0014013716,0.0007222681,0.00022897682,0.00007653819,0.00029993683],"domain_scores_gemma":[0.99781626,0.0007730976,0.000876367,0.0003923786,0.00007261044,0.00006928898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067068706,0.00041547132,0.0023219218,0.0002880065,0.00015500546,0.000013760971,0.00024756385,0.00045437834,0.000028906506],"category_scores_gemma":[0.00021111453,0.00021452805,0.00035644663,0.0001377273,0.00031922653,0.000078682184,0.00007510352,0.0008186115,0.000010792879],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002255762,0.000083864856,0.14869495,0.0004590395,0.004701332,0.000010133836,0.0002246999,6.825464e-7,4.641204e-8,0.000016920787,0.0000300814,0.8455527],"study_design_scores_gemma":[0.016370855,0.0013826342,0.13679858,0.011753594,0.04376318,0.0046529383,0.00021232694,3.6586437e-7,0.0000030080428,0.00026857283,0.78356314,0.0012308036],"about_ca_topic_score_codex":0.00021681971,"about_ca_topic_score_gemma":0.00008933329,"teacher_disagreement_score":0.84432185,"about_ca_system_score_codex":0.000027737238,"about_ca_system_score_gemma":0.00014477604,"threshold_uncertainty_score":0.87482},"labels":[],"label_agreement":null},{"id":"W2054717635","doi":"10.1111/bjd.12266","title":"A randomized phase 2a efficacy and safety trial of the topical <scp>J</scp> anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","year":2013,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Université de Montréal; Innovaderm (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Adverse effect; Tolerability; Discontinuation; Erythema; Dermatology; Psoriasis; Plaque psoriasis; Randomized controlled trial; Clinical endpoint; Internal medicine; Pharmacology; Rheumatoid arthritis","score_opus":0.013713880296584411,"score_gpt":0.24996373882449766,"score_spread":0.23624985852791325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054717635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795782,0.017567575,0.000017923037,0.0006009454,0.00082855346,0.0011795985,0.000060822855,0.000004725782,0.00016164318],"genre_scores_gemma":[0.99418324,0.005453621,0.000033078322,0.000051849493,0.00011753355,0.000067509965,0.000015668971,0.000009320973,0.00006818815],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664974,0.0017395285,0.0010861538,0.00016268341,0.00007518381,0.00028670198],"domain_scores_gemma":[0.99681586,0.0022077337,0.00064460543,0.00019939382,0.00009917362,0.000033242948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031726848,0.0001911611,0.0011484736,0.000112301335,0.00010667755,0.00001740091,0.00025730339,0.0002820897,0.00006890875],"category_scores_gemma":[0.00042556963,0.00011839041,0.0003986624,0.000137482,0.000523259,0.00008471482,0.000031671792,0.00021067882,0.000005767252],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3373156,0.017377045,0.0025988277,0.00015446387,0.0041276375,0.0017620015,0.0075460426,0.000007828573,0.024177188,0.0009779556,0.0063831317,0.59757227],"study_design_scores_gemma":[0.93334913,0.0017572059,0.003027251,0.00015818718,0.0005463238,0.011973143,0.00042766478,0.0000033311508,0.04040528,0.00018385107,0.008094735,0.000073902185],"about_ca_topic_score_codex":0.00016393285,"about_ca_topic_score_gemma":0.00007105982,"teacher_disagreement_score":0.59749836,"about_ca_system_score_codex":0.00004598302,"about_ca_system_score_gemma":0.00016364933,"threshold_uncertainty_score":0.48278207},"labels":[],"label_agreement":null},{"id":"W2055496440","doi":"10.1016/j.jaad.2003.10.229","title":"Alefacept in combination with methotrexate for treatment of active psoriatic arthritis: rationale and design of a randomized, double-blind, placebo-controlled study","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Methotrexate; Psoriasis; Placebo; Arthritis; Psoriasis Area and Severity Index; Internal medicine; Population; Dermatology; Randomization; Randomized controlled trial; Surgery; Gastroenterology; Pathology","score_opus":0.02895944336610945,"score_gpt":0.29690023631253243,"score_spread":0.267940792946423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055496440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913151,0.0029167677,0.0014974714,0.0011887581,0.0000682836,0.0029885275,0.000015291365,0.0000024295325,0.000007315266],"genre_scores_gemma":[0.99713457,0.0009981282,0.0016449302,0.000022779339,0.000007631578,0.00016045348,0.0000025112822,0.000009182883,0.000019830153],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975421,0.0011868681,0.00092616334,0.00012544934,0.000070772905,0.00014865388],"domain_scores_gemma":[0.9957351,0.0015492983,0.002514499,0.00007788997,0.00010648101,0.000016712138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004900059,0.00016815789,0.0019902077,0.0002893251,0.000045666748,0.000002215914,0.00014294259,0.000092283735,0.000004989809],"category_scores_gemma":[0.00010981929,0.00009726697,0.00023418639,0.00018593147,0.000528606,0.00007965111,0.000015084721,0.00009057863,3.7834945e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9646339,0.0019772153,0.001655407,0.000021809103,0.004687356,0.0000059509925,0.0042199036,0.0010591538,0.011583691,0.00048674343,0.000009248005,0.009659636],"study_design_scores_gemma":[0.8914484,0.0026779012,0.0027695931,0.00008304708,0.0014702881,0.00049150997,0.0019680017,0.0000160164,0.09788981,0.0010806647,0.000012717223,0.00009206639],"about_ca_topic_score_codex":0.000048088546,"about_ca_topic_score_gemma":0.000015278374,"teacher_disagreement_score":0.08630612,"about_ca_system_score_codex":0.000050668972,"about_ca_system_score_gemma":0.00014559645,"threshold_uncertainty_score":0.3966432},"labels":[],"label_agreement":null},{"id":"W2056089951","doi":"10.1016/j.jep.2013.10.034","title":"Picea mariana polyphenolic extract inhibits phlogogenic mediators produced by TNF-α-activated psoriatic keratinocytes: Impact on NF-κB pathway","year":2013,"lang":"en","type":"article","venue":"Journal of Ethnopharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Géomatique du Québec; Université Laval; Centre hospitalier de l'Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Tumor necrosis factor alpha; Psoriasis; Keratinocyte; Pharmacology; Chemistry; Polyphenol; Viability assay; Propidium iodide; Biochemistry; Biology; Immunology; Antioxidant; Programmed cell death; Apoptosis","score_opus":0.015427342673620212,"score_gpt":0.2772154351518781,"score_spread":0.26178809247825785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056089951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863781,0.006814286,0.000008460533,0.0010749131,0.004693825,0.0006731427,0.00008423391,0.00006484735,0.00020824226],"genre_scores_gemma":[0.9971334,0.0005136316,0.00006832203,0.0007309407,0.00053674984,0.0000700542,0.00006772179,0.00006533742,0.0008138774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963119,0.0010244874,0.0011475822,0.0004712333,0.00015726163,0.0008875613],"domain_scores_gemma":[0.99708366,0.00080784067,0.001217917,0.00033339666,0.00035024426,0.00020692611],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00062541896,0.0006033263,0.0010311367,0.0005002488,0.00026296754,0.000042237956,0.0005173289,0.00067304977,0.0057639503],"category_scores_gemma":[0.00028696898,0.00043180038,0.000460155,0.0004276536,0.00018792499,0.00041456646,0.000072786446,0.0010388334,0.0011614101],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012232121,0.0008228056,0.0011116032,0.000016829461,0.0020809178,0.00006218235,0.0005206051,0.00002125793,0.92568,0.000012119341,0.03176049,0.036688007],"study_design_scores_gemma":[0.0073464816,0.0022231066,0.0069505167,0.00004044635,0.000498425,0.0001345169,0.00014262712,0.000008149647,0.9791361,0.000095101874,0.003008769,0.00041573975],"about_ca_topic_score_codex":0.000117688825,"about_ca_topic_score_gemma":0.000005040145,"teacher_disagreement_score":0.053456154,"about_ca_system_score_codex":0.00033437708,"about_ca_system_score_gemma":0.00047090996,"threshold_uncertainty_score":0.9998134},"labels":[],"label_agreement":null},{"id":"W2056361036","doi":"10.1001/jama.2011.1211","title":"Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events","year":2011,"lang":"en","type":"review","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":286,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Medicine; Ustekinumab; Etanercept; Infliximab; Adalimumab; Internal medicine; Psoriatic arthritis; Placebo; Randomized controlled trial; Psoriasis; Golimumab; Mace; Myocardial infarction; Tumor necrosis factor alpha; Arthritis; Immunology; Pathology; Percutaneous coronary intervention","score_opus":0.05131386266000487,"score_gpt":0.27884436229443454,"score_spread":0.22753049963442967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056361036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037561206,0.9964014,0.00003227543,0.00002371025,0.0009515744,0.0011505799,0.0008534424,0.000070540416,0.00014085029],"genre_scores_gemma":[0.0002215265,0.9946661,0.000058070305,0.000009221251,0.0005968668,0.00060106115,0.0017151114,0.000044934535,0.0020870885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979857,0.00062770373,0.00041111987,0.0005244002,0.00003388331,0.00041714933],"domain_scores_gemma":[0.99857426,0.00058637,0.0003674239,0.00038582017,0.00006324139,0.000022891474],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00068592397,0.00044966707,0.0018671348,0.0001431205,0.00019415004,0.000018503584,0.00024125759,0.0016106821,0.0001205367],"category_scores_gemma":[0.00010904641,0.000323513,0.0011887471,0.000108311346,0.000040711384,0.00006706093,0.00007020059,0.00023760111,0.00025658016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014245454,0.000023661329,0.00054724026,0.0012243338,0.017792206,7.6668783e-7,0.000069083624,1.2583215e-8,0.0000024873796,0.00004877806,0.0011250547,0.97915214],"study_design_scores_gemma":[0.0015560709,0.00020006153,0.00092293107,0.0007921375,0.0094801225,0.000010606675,0.000009465108,1.1662572e-8,0.000036213194,0.0001607489,0.9865002,0.00033142997],"about_ca_topic_score_codex":0.000046532685,"about_ca_topic_score_gemma":0.000009336973,"teacher_disagreement_score":0.98537517,"about_ca_system_score_codex":0.00024036394,"about_ca_system_score_gemma":0.00011642614,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W2057766882","doi":"10.2310/7750.2007.00036","title":"Alefacept is Safe and Efficacious in the Treatment of Palmar Plantar Pustulosis","year":2007,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"","keywords":"Medicine; Psoriasis; Pustulosis; Palmoplantar pustulosis; Psoriasis Area and Severity Index; Dermatology; Itching; Surgery","score_opus":0.023957610786133232,"score_gpt":0.256506291734706,"score_spread":0.23254868094857278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057766882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96424526,0.033833783,0.000005275519,0.0011766899,0.00034597676,0.00008807738,0.000008842235,0.0000025590264,0.00029356085],"genre_scores_gemma":[0.9712917,0.028130364,0.000015857006,0.00025223778,0.00010999279,9.23381e-7,0.0000072062694,0.000005963816,0.00018570528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998949,0.00012511952,0.0005519866,0.00010301361,0.00007210891,0.00019879002],"domain_scores_gemma":[0.9974478,0.002100886,0.0002687985,0.00010493197,0.000043003733,0.000034593784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006584456,0.00014654438,0.0005817193,0.00025434795,0.000059913873,0.000002814506,0.000056991586,0.000120218894,0.00011317646],"category_scores_gemma":[0.000058797676,0.00007600175,0.000102088496,0.00010720929,0.00017337305,0.000024652296,0.0000052476435,0.00009583355,0.0000027749616],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049259444,0.0011625304,0.38543397,0.00007929832,0.0013368094,0.005229635,0.026689546,0.0000013991192,0.019520069,0.00003305606,0.013798876,0.5417889],"study_design_scores_gemma":[0.015245844,0.01446126,0.31382388,0.0012321136,0.003185001,0.09920761,0.023571044,0.0000032842606,0.05864064,0.00038433276,0.46945155,0.0007934458],"about_ca_topic_score_codex":0.0000771773,"about_ca_topic_score_gemma":0.000048997408,"teacher_disagreement_score":0.5409954,"about_ca_system_score_codex":0.000021717144,"about_ca_system_score_gemma":0.000030674146,"threshold_uncertainty_score":0.30992615},"labels":[],"label_agreement":null},{"id":"W2058130577","doi":"10.1186/2051-1426-2-s2-p36","title":"P62. Effectiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Melatonin; Proinflammatory cytokine; Cancer research; Cytokine; Medicine; Apoptosis; Breast cancer; Biology; Immunology; Cancer; Internal medicine; Inflammation","score_opus":0.006679934714977232,"score_gpt":0.25558503115788644,"score_spread":0.2489050964429092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058130577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927644,0.07019625,0.00032344603,0.00010268723,0.00082446676,0.00032679277,0.0005093474,0.0000051139673,0.00006786354],"genre_scores_gemma":[0.9846331,0.014941334,0.00005476458,0.00003547421,0.00006662737,0.000068499656,0.000006083917,0.000025528423,0.0001686034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871045,0.0002963171,0.0005366664,0.00016097736,0.000056478646,0.00023908695],"domain_scores_gemma":[0.9984812,0.0004748523,0.0005800543,0.00013881945,0.00030520954,0.000019824045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065746735,0.00020117899,0.00073776033,0.00013340062,0.000073286414,0.000005643442,0.00016951209,0.0001934035,0.00016043043],"category_scores_gemma":[0.00001747939,0.00015363585,0.0002200241,0.000102620426,0.00016409531,0.00011335571,0.000011839725,0.00013031258,5.4738e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065953694,0.00022882214,0.066610366,0.00024057779,0.00096523145,4.6639263e-7,0.00036375897,0.000047682097,0.8698854,0.00020292054,0.000046652192,0.05481279],"study_design_scores_gemma":[0.017158829,0.0006842448,0.27658275,0.00049058924,0.00022842594,0.000030276984,0.000060903625,0.000013374391,0.70181054,0.00042487137,0.0023360737,0.00017914921],"about_ca_topic_score_codex":0.0012422651,"about_ca_topic_score_gemma":0.00019006417,"teacher_disagreement_score":0.20997237,"about_ca_system_score_codex":0.00007145927,"about_ca_system_score_gemma":0.00011563265,"threshold_uncertainty_score":0.6265088},"labels":[],"label_agreement":null},{"id":"W2058368385","doi":"10.3899/jrheum.080739","title":"Sonographic Monitoring of Psoriatic Plaque","year":2009,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dermatology; Psoriatic arthritis; Psoriasis","score_opus":0.014832873607224385,"score_gpt":0.2403027026593414,"score_spread":0.22546982905211702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058368385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883204,0.009521392,0.000114142626,0.000533093,0.0013135022,0.000057017074,0.0000022342942,0.0000097452275,0.00012847736],"genre_scores_gemma":[0.99619234,0.003545243,0.00017005324,0.000016738688,0.000012287575,6.9153685e-7,0.000001225081,0.0000056858316,0.000055737863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988435,0.0003356604,0.0005128071,0.0000615807,0.000037668553,0.00020878341],"domain_scores_gemma":[0.99878734,0.0003533319,0.0005665834,0.00018301592,0.00009235256,0.000017382597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004898675,0.00011996956,0.0004381764,0.00017405105,0.00009298729,0.0000027253218,0.00031250558,0.00015373623,0.000060462167],"category_scores_gemma":[0.00006440603,0.00007298148,0.0001519794,0.00014518427,0.000119153505,0.00006112236,0.000016192142,0.00020655489,0.00003074596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024768633,0.0006049222,0.7505724,0.000050987215,0.0023022087,0.000019390809,0.0045255604,0.000069877555,0.11752216,0.004815429,0.002640048,0.1144002],"study_design_scores_gemma":[0.014618637,0.0054328605,0.67106616,0.0008147742,0.0022415332,0.028901774,0.0037393158,0.00000666155,0.25270602,0.014201034,0.005582988,0.00068821193],"about_ca_topic_score_codex":0.000030557687,"about_ca_topic_score_gemma":0.00000367082,"teacher_disagreement_score":0.13518386,"about_ca_system_score_codex":0.000012878725,"about_ca_system_score_gemma":0.000050483046,"threshold_uncertainty_score":0.29760984},"labels":[],"label_agreement":null},{"id":"W2058457431","doi":"10.1038/cr.2008.320","title":"IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling","year":2008,"lang":"en","type":"article","venue":"Cell Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research; National Natural Science Foundation of China; University of Toronto; Strong","keywords":"Biology; Homomeric; Receptor; Signal transduction; Cell biology; Interleukin-1 receptor; Interleukin 17; Interleukin; Cytokine; Immunology; Gene; Genetics","score_opus":0.07077401208897091,"score_gpt":0.3073263865449594,"score_spread":0.2365523744559885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058457431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670363,0.0053150556,0.000014449225,0.00035711026,0.0004230523,0.0005791058,0.00024228783,0.00010278908,0.0062624873],"genre_scores_gemma":[0.92951626,0.003967592,0.0005097156,0.00011981978,0.00023546362,0.00013879735,0.0003741619,0.000069780384,0.06506839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967122,0.0006910846,0.00039136436,0.00079000444,0.00024362918,0.0011716892],"domain_scores_gemma":[0.997189,0.0016270374,0.00011724311,0.0005474266,0.00034094325,0.00017836949],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00093139237,0.0003980218,0.0005336108,0.00042595956,0.00088281796,0.000065565866,0.00047984702,0.00042920554,0.0038657547],"category_scores_gemma":[0.00023218128,0.000279065,0.00010278818,0.00052415987,0.0008432601,0.00021602486,0.00027613205,0.0007838844,0.0016533503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004274405,0.00069715705,0.004974279,0.0001251202,0.0005497702,0.00047935153,0.005235541,0.0000070451883,0.8809547,0.000045025867,0.079200216,0.023457415],"study_design_scores_gemma":[0.0035786543,0.0017088554,0.001977781,0.00014246393,0.00007948121,0.00017868084,0.0015290215,0.000006119622,0.77327895,0.000051561656,0.21699601,0.00047242962],"about_ca_topic_score_codex":0.00017181662,"about_ca_topic_score_gemma":0.00010750759,"teacher_disagreement_score":0.13779579,"about_ca_system_score_codex":0.00012094259,"about_ca_system_score_gemma":0.00034605354,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W2058496878","doi":"10.1016/j.sder.2005.01.005","title":"Potential future therapies for psoriasis","year":2005,"lang":"en","type":"review","venue":"Seminars in Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine","score_opus":0.03196763355397156,"score_gpt":0.29660028210445827,"score_spread":0.26463264855048674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058496878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031698562,0.9941601,0.0000042471606,0.00038344858,0.004054256,0.00068830163,0.00013205438,0.000056818673,0.0002037468],"genre_scores_gemma":[0.000070104885,0.9926066,0.00006945682,0.00014344823,0.0019119575,0.00021019958,0.0010912799,0.000068384645,0.0038285963],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976433,0.00029950106,0.00082890334,0.00060579303,0.00006395619,0.0005585675],"domain_scores_gemma":[0.99702775,0.0022180786,0.0003205213,0.00034595528,0.000041631105,0.000046073983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052439776,0.0006339158,0.0027426132,0.0005695521,0.00016647614,0.000010737866,0.00018149236,0.0010313649,0.00039901974],"category_scores_gemma":[0.0001249861,0.00043601968,0.00054394087,0.0002481932,0.00023779509,0.000038755923,0.00003909684,0.00035027362,0.000040951636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010889298,0.00006506262,0.000030240564,0.0017574786,0.000569025,0.00026398688,0.00036542982,6.223825e-8,0.000006124564,0.000024943252,0.035064567,0.9617442],"study_design_scores_gemma":[0.00046776357,0.0001412304,0.0000034670682,0.007404498,0.0015938325,0.003495201,0.00040442444,1.8741338e-7,0.0000031784332,0.00005399013,0.9860311,0.00040112325],"about_ca_topic_score_codex":0.000023929388,"about_ca_topic_score_gemma":0.00002522711,"teacher_disagreement_score":0.96134305,"about_ca_system_score_codex":0.00006807308,"about_ca_system_score_gemma":0.00014926629,"threshold_uncertainty_score":0.99980915},"labels":[],"label_agreement":null},{"id":"W2059731285","doi":"10.1016/j.jval.2012.03.552","title":"PSY18 Economic Burden of Psoriasis (PSO) and Obesity in Patients With Psoriasis in the United States","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Poisson regression; Body mass index; Obesity; Psoriasis; Comorbidity; Psoriatic arthritis; Demography; Internal medicine; Population; Environmental health","score_opus":0.021890551546225996,"score_gpt":0.24641965959571305,"score_spread":0.22452910804948706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059731285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968598,0.0019397475,0.0000013142409,0.00027637574,0.00029345934,0.00049188186,0.000079096775,0.0000095753385,0.000048741615],"genre_scores_gemma":[0.9987487,0.00080773263,0.00007361818,0.00009185278,0.000028383543,0.000030489293,0.00018758001,0.000011696368,0.000019938645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802774,0.0008522639,0.0004323484,0.00020751939,0.000037707487,0.0004424276],"domain_scores_gemma":[0.9991794,0.00036520514,0.00017486863,0.00023417055,0.000016607171,0.000029706744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094894535,0.00016594962,0.00036418546,0.0003499785,0.0000615132,0.0000052690834,0.00014458894,0.00013506034,0.00003605497],"category_scores_gemma":[0.00002712294,0.000116798816,0.000027160135,0.00029870312,0.00008417929,0.00010036206,0.000032109143,0.00016559157,0.000021568063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037763128,0.0003986809,0.98479664,0.000054635333,0.000042773412,9.148181e-7,0.009079023,0.0005661713,0.000009476895,0.00034550845,0.00007567822,0.004252858],"study_design_scores_gemma":[0.0044459742,0.00037323608,0.99238247,0.00009347122,0.000020362555,0.0000033741194,0.0012524027,0.000036409776,0.00015961411,0.00013368356,0.00097051513,0.0001284951],"about_ca_topic_score_codex":0.034151018,"about_ca_topic_score_gemma":0.00089499773,"teacher_disagreement_score":0.03325602,"about_ca_system_score_codex":0.00015505595,"about_ca_system_score_gemma":0.0000770754,"threshold_uncertainty_score":0.9722807},"labels":[],"label_agreement":null},{"id":"W2060078400","doi":"10.2310/7750.2008.07055","title":"Efficacy and Tolerability of Topical Tacrolimus Ointment for the Treatment of Male Genital Psoriasis","year":2008,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Tolerability; Tacrolimus; Psoriasis; Dermatology; Sex organ; Topical agents; Adverse effect; Pharmacology; Surgery; Transplantation","score_opus":0.040550159987044275,"score_gpt":0.2649739492069857,"score_spread":0.2244237892199414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060078400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97621727,0.0224113,0.000039683313,0.00055967056,0.00052317104,0.00017836674,0.00001515328,0.000002590237,0.000052799714],"genre_scores_gemma":[0.98717535,0.012260152,0.000062116014,0.000026002757,0.00016043716,0.0000049091364,0.0000049411574,0.00000557489,0.0003005351],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901515,0.00009143909,0.00058929843,0.00010317722,0.00005878833,0.0001421223],"domain_scores_gemma":[0.9967904,0.002621379,0.0003177722,0.00012573213,0.000108620414,0.000036095847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022203877,0.00012926431,0.0006898127,0.0000830492,0.0001008671,0.0000013735196,0.00004910653,0.00009090797,0.00008676462],"category_scores_gemma":[0.0001473186,0.00006684737,0.00018240296,0.00005005297,0.00038005903,0.000022435244,0.000008164369,0.000050304323,4.775346e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01273595,0.0027906287,0.20921625,0.00018720773,0.004062895,0.0008074707,0.011760558,0.000011147781,0.06666198,0.000103254046,0.0052756295,0.686387],"study_design_scores_gemma":[0.03973244,0.063255794,0.43486732,0.00070727174,0.008226499,0.13284625,0.006727605,0.00002939599,0.1716598,0.00061455223,0.14041637,0.0009166905],"about_ca_topic_score_codex":0.0000363726,"about_ca_topic_score_gemma":0.000005802596,"teacher_disagreement_score":0.68547034,"about_ca_system_score_codex":0.00002257917,"about_ca_system_score_gemma":0.00006217514,"threshold_uncertainty_score":0.27259567},"labels":[],"label_agreement":null},{"id":"W2060086598","doi":"10.1159/000323408","title":"Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial","year":2011,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); Probity Medical Research; Dalhousie University","funders":"LEO Pharma","keywords":"Medicine; Calcipotriol; Betamethasone dipropionate; Psoriasis; Randomized controlled trial; Adverse effect; Regimen; Dermatology; Betamethasone; Clinical trial; Corticosteroid; Surgery; Internal medicine","score_opus":0.025069061503398913,"score_gpt":0.25645839261755876,"score_spread":0.23138933111415985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060086598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034613,0.0024849616,0.00017574821,0.00038782577,0.00072784285,0.0054064454,0.00003246332,0.00006216906,0.0003763986],"genre_scores_gemma":[0.99741906,0.00020994735,0.00027797645,0.00025058218,0.00003940165,0.0015049842,0.00012494969,0.000031369134,0.00014175051],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99378365,0.0036161784,0.0012895162,0.0006110715,0.00010808616,0.0005914704],"domain_scores_gemma":[0.99627626,0.0024437471,0.00060659886,0.00046766884,0.0001352389,0.00007051179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001083988,0.0004627374,0.0033883373,0.00018518289,0.00022711516,0.000019817362,0.00027887375,0.00047524725,0.0001297618],"category_scores_gemma":[0.0002948221,0.00022795978,0.00032166843,0.00018275854,0.0015700861,0.00009473193,0.00010873489,0.00043642966,0.000080461185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9494753,0.0010872331,0.042522177,0.000012061785,0.0026601548,0.00006397312,0.0012637593,0.0000017679743,0.000010840794,0.0008497324,0.00012520437,0.0019277796],"study_design_scores_gemma":[0.97151494,0.0011140114,0.024340944,0.000035886784,0.0016008563,0.00008862123,0.00017920394,0.000067435714,0.00032545434,0.00017152332,0.00025748776,0.00030366008],"about_ca_topic_score_codex":0.0004609842,"about_ca_topic_score_gemma":0.00023067552,"teacher_disagreement_score":0.0220396,"about_ca_system_score_codex":0.000047283535,"about_ca_system_score_gemma":0.00015060803,"threshold_uncertainty_score":0.929593},"labels":[],"label_agreement":null},{"id":"W2060546762","doi":"10.1001/archderm.143.6.719","title":"Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis","year":2007,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":321,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Dalhousie University","funders":"Amgen","keywords":"Etanercept; Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Internal medicine; Randomized controlled trial; Surgery; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.006874321831855182,"score_gpt":0.22223136281131853,"score_spread":0.21535704097946334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060546762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706465,0.0010442118,0.00017614558,0.000054439817,0.00010535026,0.0002304455,0.00004892955,0.000009623494,0.0012661837],"genre_scores_gemma":[0.99919903,0.00017201876,0.00043781643,0.000013163697,0.000003946207,0.000002400051,0.000109658526,0.000011355344,0.000050583938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987491,0.00018134531,0.00053450966,0.00022181627,0.000035271358,0.00027800494],"domain_scores_gemma":[0.99862725,0.00078374305,0.0002914473,0.00024505737,0.000029075498,0.000023457318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000066749155,0.0001667482,0.0005869995,0.000285436,0.000034619363,8.303508e-7,0.00016023059,0.00014678054,0.000039415503],"category_scores_gemma":[0.000033176053,0.00013520109,0.000071317154,0.00011788032,0.00057191815,0.00004197256,0.00007178741,0.000101063146,0.000004681252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062150373,0.00059710606,0.9373078,0.00009646905,0.00033368098,0.000013756333,0.0013172943,0.0000011498737,0.015049049,0.00045539826,0.0000065787717,0.03860672],"study_design_scores_gemma":[0.007865899,0.00042192324,0.9497116,0.0000731492,0.000119805285,0.00006691403,0.000083022285,2.736129e-7,0.041410875,0.00004003711,0.000097276,0.00010918784],"about_ca_topic_score_codex":0.000049298735,"about_ca_topic_score_gemma":0.000115522154,"teacher_disagreement_score":0.03849753,"about_ca_system_score_codex":0.0000051642455,"about_ca_system_score_gemma":0.000034446002,"threshold_uncertainty_score":0.551334},"labels":[],"label_agreement":null},{"id":"W2060607284","doi":"10.1371/journal.pone.0114604","title":"IL-17 Enhances Chemotaxis of Primary Human B Cells during Asthma","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada); McGill University","funders":"National Plan for Science, Technology and Innovation; King Saud University","keywords":"Chemotaxis; Immunology; COPD; Inflammation; Asthma; Interleukin 17; Cytokine; Medicine; Lung; Mediator; In vitro; Infiltration (HVAC); Biology; Receptor; Internal medicine","score_opus":0.02068315282587271,"score_gpt":0.20169185152003177,"score_spread":0.18100869869415906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060607284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912023,0.00070462894,0.000004996821,0.000030064173,0.00008891258,0.00012568448,0.000030253192,0.000052845444,0.007760294],"genre_scores_gemma":[0.9899928,0.00009302632,0.00031974906,0.000026948046,0.00006736262,0.000018214345,0.00007504815,0.000013550628,0.009393325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992375,0.00008384176,0.00020463372,0.00021118228,0.000042234846,0.00022064902],"domain_scores_gemma":[0.999502,0.00006144485,0.000117394375,0.0002643132,0.000038745766,0.000016113223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010522912,0.00013432787,0.00034698626,0.00006159607,0.00011976475,0.00000426603,0.00014951064,0.00013888137,0.0004854977],"category_scores_gemma":[0.000014444378,0.00012248593,0.000074512536,0.00006218422,0.000091156726,0.000047403802,0.000052636507,0.00008033911,0.00034785728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064048785,0.0008654848,0.0017210662,0.00010944414,0.00043455348,0.0000010356798,0.00017495867,1.6792879e-7,0.99440503,0.000041341606,0.00012155568,0.002061306],"study_design_scores_gemma":[0.00095210614,0.00018924804,0.029611174,0.000079419566,0.00012003364,0.0000015468303,0.000014842247,2.436891e-7,0.968297,0.000043392745,0.00057111663,0.0001198719],"about_ca_topic_score_codex":0.000022280017,"about_ca_topic_score_gemma":0.000010418741,"teacher_disagreement_score":0.027890109,"about_ca_system_score_codex":0.000021765889,"about_ca_system_score_gemma":0.000011407287,"threshold_uncertainty_score":0.53158593},"labels":[],"label_agreement":null},{"id":"W2060836363","doi":"10.1007/s40273-014-0244-9","title":"Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis","year":2014,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; AbbVie Canada; Michael Smith Health Research BC; Pfizer","keywords":"Medicine; MEDLINE; Time horizon; Health economics; Health care; Health administration; Cost effectiveness; Economic evaluation; Public health; Risk analysis (engineering); Nursing; Business; Pathology","score_opus":0.12097548477240598,"score_gpt":0.43272456523198516,"score_spread":0.31174908045957916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060836363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003277156,0.9898436,0.00008604174,0.0000024127735,0.0009697349,0.007050013,0.0018560365,0.00002179022,0.00013756726],"genre_scores_gemma":[0.00003868416,0.99460894,0.000056917863,0.000031010713,0.00004726951,0.0033298158,0.0015815814,0.00006276084,0.00024303135],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963164,0.0011127219,0.0018107368,0.0004474397,0.00002643977,0.00028631042],"domain_scores_gemma":[0.9947269,0.0021888183,0.0023552228,0.0005675726,0.00012870945,0.000032769316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093435036,0.0005851115,0.006847958,0.00024885437,0.00005661238,0.0000050534495,0.00045135067,0.00032336437,0.00016025502],"category_scores_gemma":[0.00016076952,0.00043817208,0.0020370735,0.00014174126,0.0000823037,0.00005366059,0.000056859488,0.00010243534,0.0001416332],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047346057,0.00016159347,0.0000014726659,0.82443595,0.014368326,3.9297387e-7,0.000007540954,6.241539e-7,0.00009245956,0.000047381054,0.00026046933,0.16057646],"study_design_scores_gemma":[0.0026217573,0.00020910785,0.0000011978169,0.6415924,0.12718548,0.000030066476,0.000004901109,0.0000018044416,0.007368973,0.000016261227,0.22046375,0.00050434313],"about_ca_topic_score_codex":0.000018105547,"about_ca_topic_score_gemma":7.768233e-7,"teacher_disagreement_score":0.22020328,"about_ca_system_score_codex":0.0001858392,"about_ca_system_score_gemma":0.00018212409,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2061084002","doi":"10.1001/archdermatol.2010.384","title":"Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet","year":2010,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Adalimumab; Medicine; Psoriasis; Plaque psoriasis; Placebo; Randomized controlled trial; Adverse effect; Internal medicine; Surgery; Dermatology; Disease; Pathology","score_opus":0.010780354092859263,"score_gpt":0.23366209531017862,"score_spread":0.22288174121731935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061084002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682736,0.001052955,0.00010763992,0.00061002374,0.00030728747,0.0004293298,0.000214933,0.000008581693,0.00044186236],"genre_scores_gemma":[0.99874556,0.00021895829,0.0006125743,0.000016863152,0.000014596353,0.00007072834,0.00003641133,0.000010746526,0.00027358576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991923,0.0001038222,0.00028788942,0.00018914358,0.000017518509,0.00020930287],"domain_scores_gemma":[0.99900466,0.00047789887,0.00016434802,0.0003070593,0.000025513007,0.000020526137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000022264101,0.0001506652,0.00047385666,0.00009523178,0.00008247036,0.0000016065377,0.00016296677,0.00013565859,0.000024820203],"category_scores_gemma":[0.00002406852,0.0001007235,0.00014209964,0.00005305966,0.00032310883,0.0000217231,0.000058298087,0.00004005247,0.0000025057877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028700698,0.0005008315,0.02772604,0.00018419536,0.0011816092,0.000003307086,0.0041047316,0.000024540748,0.87890136,0.009101006,0.00028077283,0.07512156],"study_design_scores_gemma":[0.006561091,0.0007918087,0.015401278,0.00002830234,0.0002288407,0.00029010186,0.000076723016,0.000029240551,0.97131264,0.0016677292,0.0034986162,0.000113610644],"about_ca_topic_score_codex":0.000066256434,"about_ca_topic_score_gemma":0.00038486684,"teacher_disagreement_score":0.092411324,"about_ca_system_score_codex":0.0000058818546,"about_ca_system_score_gemma":0.00010259024,"threshold_uncertainty_score":0.4107385},"labels":[],"label_agreement":null},{"id":"W2061898955","doi":"10.1159/000084753","title":"A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity","year":2005,"lang":"en","type":"review","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Alberta","funders":"","keywords":"Calcipotriol; Psoriasis; Psoriasis Area and Severity Index; Betamethasone dipropionate; Medicine; Post-hoc analysis; Severity of illness; Dermatology; Clinical trial; Internal medicine","score_opus":0.03156849247277451,"score_gpt":0.3073143497789704,"score_spread":0.2757458573061959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061898955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013775546,0.98118573,0.000025688107,0.0000807392,0.0005242315,0.0030233392,0.001256943,0.00006067671,0.000067091394],"genre_scores_gemma":[0.035499603,0.96120125,0.0002438013,0.000014256616,0.00012551312,0.0009718363,0.0016895013,0.00006618275,0.00018803071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946236,0.002521252,0.0012495212,0.0009767164,0.000075218595,0.0005537058],"domain_scores_gemma":[0.99601066,0.001823795,0.0011428961,0.0007440606,0.00018175271,0.00009686322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033025068,0.0008774947,0.0044370787,0.0004482484,0.00016330031,0.000010039071,0.0002581773,0.0005607567,0.00008711],"category_scores_gemma":[0.00026709458,0.00065073353,0.0007185253,0.00028519725,0.00063736143,0.00008782748,0.00012575806,0.00025615527,0.000031593183],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009009358,0.00088479114,0.0009059189,0.005291957,0.0038265418,0.00013481523,0.00041958856,5.460872e-7,0.000073100935,0.00014619956,0.000094912044,0.9873207],"study_design_scores_gemma":[0.0072457236,0.00080874306,0.00048576258,0.002690774,0.012435122,0.0014304253,0.00008182237,0.000005054446,0.003152553,0.00005165499,0.9707681,0.00084424706],"about_ca_topic_score_codex":0.00024833757,"about_ca_topic_score_gemma":0.00006270884,"teacher_disagreement_score":0.9864764,"about_ca_system_score_codex":0.00016580713,"about_ca_system_score_gemma":0.0004787654,"threshold_uncertainty_score":0.9995944},"labels":[],"label_agreement":null},{"id":"W2062156425","doi":"10.1111/jcpt.12044","title":"Biological treatments for moderate-to-severe psoriasis: indirect comparison","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Pharmacy and Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Etanercept; Infliximab; Adalimumab; Psoriasis; Clinical trial; Placebo; Randomized controlled trial; Internal medicine; Dermatology; Disease; Rheumatoid arthritis; Pathology; Alternative medicine","score_opus":0.1947639593448097,"score_gpt":0.42278789237691977,"score_spread":0.22802393303211008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062156425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99096036,0.0054530133,0.0003497872,0.0008570616,0.0016810263,0.00045038864,0.00003418701,0.000018495444,0.00019565277],"genre_scores_gemma":[0.99391633,0.0029092787,0.0010189062,0.0013557326,0.00030286243,0.000023101595,0.000015810758,0.000015494214,0.00044250477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796593,0.00038728974,0.0010962082,0.00021148474,0.000049708906,0.00028940136],"domain_scores_gemma":[0.99794364,0.001140536,0.00048970466,0.00011929253,0.00019899232,0.00010780611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006227378,0.00021840604,0.00083162746,0.00008385604,0.00014228614,0.000033046148,0.00019409267,0.00021963923,0.00022358734],"category_scores_gemma":[0.00009131522,0.00013850574,0.00033354096,0.00007894248,0.00010210164,0.00012718262,0.00003464832,0.00028811142,0.0001245423],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006346893,0.0015167963,0.11429821,0.00001003068,0.004706162,0.0000056751737,0.0003612553,0.000012938928,0.008488786,0.000079853904,0.0033514386,0.86082196],"study_design_scores_gemma":[0.06653271,0.009750838,0.21180984,0.00014230363,0.004821853,0.00034591247,0.0005636397,0.0003522136,0.06771108,0.007813299,0.6290835,0.0010728012],"about_ca_topic_score_codex":0.0000068658082,"about_ca_topic_score_gemma":0.0000011251572,"teacher_disagreement_score":0.85974914,"about_ca_system_score_codex":0.000016846641,"about_ca_system_score_gemma":0.000062475556,"threshold_uncertainty_score":0.56481},"labels":[],"label_agreement":null},{"id":"W2062348457","doi":"10.1111/bjd.12583","title":"The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials","year":2013,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ustekinumab; Medicine; Etanercept; Adalimumab; Psoriasis; Clinical trial; Infliximab; Clinical study design; Research design; Intensive care medicine; Disease; Medical physics; Internal medicine; Dermatology; Rheumatoid arthritis","score_opus":0.2213100421307294,"score_gpt":0.46960002834956105,"score_spread":0.24828998621883164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062348457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.111579135,0.87962496,0.0012481112,0.000041921867,0.0012358478,0.0040812967,0.0021799167,0.0000053488816,0.0000034702264],"genre_scores_gemma":[0.23188138,0.7672058,0.00023107183,0.00000783692,0.0000620893,0.0003703156,0.00020416392,0.000019273644,0.000018123294],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98077583,0.013320046,0.0051526623,0.00030019673,0.00009963571,0.00035159697],"domain_scores_gemma":[0.9500136,0.04230669,0.0069275023,0.00029832032,0.00040696305,0.000046963836],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0057349266,0.00043150724,0.009481273,0.00018024436,0.00020037933,0.000045294455,0.00058184715,0.00043048122,0.000041850893],"category_scores_gemma":[0.012072404,0.0002141501,0.0021538737,0.00015948186,0.0009842012,0.0000795023,0.00009205704,0.00022956416,0.000002517099],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022522025,0.0004354637,0.0023629915,0.0018538624,0.013455334,0.000022067226,0.00019908848,8.473967e-7,0.00009130757,0.00006584072,0.00026470303,0.95872647],"study_design_scores_gemma":[0.6105787,0.014783228,0.07266954,0.032364126,0.2088752,0.026018888,0.0017811388,0.0000072784824,0.010778186,0.002009672,0.017537458,0.0025965818],"about_ca_topic_score_codex":0.00013802103,"about_ca_topic_score_gemma":0.00016982296,"teacher_disagreement_score":0.9561299,"about_ca_system_score_codex":0.00004182888,"about_ca_system_score_gemma":0.00025743202,"threshold_uncertainty_score":0.9962493},"labels":[],"label_agreement":null},{"id":"W2062523779","doi":"10.1159/000233234","title":"Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis","year":2009,"lang":"en","type":"review","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"Abbott Laboratories","keywords":"Etanercept; Infliximab; Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Meta-analysis; Internal medicine; Randomized controlled trial; Dermatology Life Quality Index; Relative risk; Dermatology; Tumor necrosis factor alpha; Confidence interval","score_opus":0.0662432849259815,"score_gpt":0.3253446383323664,"score_spread":0.25910135340638485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062523779","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016309064,0.9901949,0.00012042729,0.000115664916,0.00013482894,0.008084492,0.0012264384,0.000059472968,0.000047471523],"genre_scores_gemma":[0.00025682998,0.9924314,0.00015458898,0.00025025575,0.000009203558,0.0038421538,0.0013877703,0.000052024854,0.0016157432],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948326,0.0016518004,0.0020619067,0.00087158824,0.000056895922,0.0005252236],"domain_scores_gemma":[0.9963287,0.001102561,0.0013290998,0.0010253304,0.00014112842,0.00007318268],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00031232,0.0009516797,0.01788326,0.00067293475,0.0001387601,0.000015727106,0.00045146936,0.00090284884,0.00008826155],"category_scores_gemma":[0.00013768286,0.00061882654,0.0037559497,0.0006442859,0.00006238566,0.00004974856,0.000075424934,0.00016092481,0.00020196679],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056497254,0.00014498382,6.189173e-7,0.5043228,0.48978934,0.000021544543,0.00008005555,0.0000013884805,0.0000012090749,0.00019596191,0.0007533683,0.004632189],"study_design_scores_gemma":[0.0010357717,0.000109920664,5.7035805e-7,0.018843396,0.96378857,0.002399711,0.0000121748135,3.4539065e-7,0.000018835835,0.000012362782,0.013321332,0.00045703692],"about_ca_topic_score_codex":0.000017236407,"about_ca_topic_score_gemma":0.000012734692,"teacher_disagreement_score":0.48547944,"about_ca_system_score_codex":0.00007781967,"about_ca_system_score_gemma":0.00015557598,"threshold_uncertainty_score":0.9996263},"labels":[],"label_agreement":null},{"id":"W2062882203","doi":"10.1016/j.cyto.2009.07.456","title":"IL-23 induced signaling and IL-23 receptor expression in human CD4 T cells","year":2009,"lang":"en","type":"article","venue":"Cytokine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cell biology; Molecular biology; Cancer research; Biology; Chemistry","score_opus":0.021665305985266097,"score_gpt":0.2490785206893126,"score_spread":0.22741321470404652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062882203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975801,0.0010259643,0.000010982586,0.00011582519,0.00034977664,0.00019435669,0.000054537704,0.0000638261,0.00060464925],"genre_scores_gemma":[0.99773884,0.00010727318,0.00017357622,0.00010633269,0.00008569352,0.000014515746,0.0002744739,0.000014434197,0.0014848369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892724,0.00014308695,0.0002532023,0.00033176164,0.000030473893,0.00031425458],"domain_scores_gemma":[0.99958456,0.000063915744,0.00008501192,0.0002119409,0.000023299763,0.000031281095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015466644,0.00020424041,0.00029149317,0.00014304245,0.00016087861,0.000014190168,0.00012190751,0.00029209026,0.00027807022],"category_scores_gemma":[0.000017158189,0.00017569527,0.000054877426,0.00013436952,0.000042884334,0.0000818846,0.000041234092,0.00017366423,0.00024731178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011875512,0.00014575024,0.0010210479,0.000006052763,0.00002563266,0.000012639592,0.000384529,0.000001598118,0.9828942,0.000046768902,0.0010904408,0.014252583],"study_design_scores_gemma":[0.00203486,0.00030779757,0.009178439,0.000084278305,0.00003020565,0.0000080259815,0.0000912808,5.272801e-7,0.9816753,0.00014597818,0.0062464303,0.00019686697],"about_ca_topic_score_codex":0.000016728998,"about_ca_topic_score_gemma":0.0000095730675,"teacher_disagreement_score":0.014055715,"about_ca_system_score_codex":0.000035042493,"about_ca_system_score_gemma":0.000015968051,"threshold_uncertainty_score":0.7164645},"labels":[],"label_agreement":null},{"id":"W2063627867","doi":"10.1016/j.jaad.2007.09.010","title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","year":2007,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":883,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Adalimumab; Psoriasis; Randomized controlled trial; Dermatology; Physical therapy; Internal medicine; Tumor necrosis factor alpha","score_opus":0.020117108803110594,"score_gpt":0.3155302584066383,"score_spread":0.2954131496035277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063627867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98210925,0.004259493,0.0024156761,0.007368771,0.001247863,0.0024271375,0.000032501335,0.000014710294,0.00012461047],"genre_scores_gemma":[0.9960901,0.00067895616,0.0006356506,0.0019647833,0.00021349925,0.000096638716,0.0000029004814,0.000023632867,0.00029384665],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99641997,0.0011016396,0.001701984,0.00020027069,0.00010429372,0.0004718414],"domain_scores_gemma":[0.994337,0.0024292774,0.0028497276,0.00016773185,0.00014761208,0.00006862148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001616573,0.00029288675,0.0032487223,0.0003312408,0.00016608913,0.000008602555,0.00059665914,0.0002422782,0.00004286249],"category_scores_gemma":[0.00045463728,0.00016383994,0.0013978306,0.00026038397,0.0005126483,0.000079101424,0.000049781018,0.00035785147,0.000009241886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94926476,0.0004568581,0.00003244973,0.000005686779,0.0034403075,0.000007845746,0.00041819646,0.000018127748,0.022617778,0.00040666375,0.0032567512,0.020074572],"study_design_scores_gemma":[0.9226432,0.0009687091,0.00004693119,0.000029228891,0.0008975187,0.0014165028,0.00025916868,0.000008753441,0.065768406,0.0006949211,0.007096897,0.00016975446],"about_ca_topic_score_codex":0.000014219476,"about_ca_topic_score_gemma":0.00000209789,"teacher_disagreement_score":0.043150626,"about_ca_system_score_codex":0.00004251195,"about_ca_system_score_gemma":0.00015819503,"threshold_uncertainty_score":0.6681199},"labels":[],"label_agreement":null},{"id":"W2064542056","doi":"10.1111/pde.12351","title":"A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics","year":2014,"lang":"en","type":"review","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Acitretin; Psoriasis; Pustular psoriasis; Methotrexate; Dermatology; Systemic therapy; Pediatrics; Generalized pustular psoriasis; MEDLINE; Surgery; Internal medicine; Cancer","score_opus":0.019979658200436255,"score_gpt":0.2938574759461936,"score_spread":0.27387781774575737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064542056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011217459,0.99196863,0.00024078778,0.000043906042,0.0017296275,0.0054770024,0.00036071517,0.000068931186,0.00009915505],"genre_scores_gemma":[0.00006289101,0.9931404,0.00009205742,0.00005970579,0.00020893115,0.0047454066,0.0013874832,0.00007496965,0.00022816268],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99328405,0.0018591166,0.0034405754,0.000675618,0.000102299,0.00063832325],"domain_scores_gemma":[0.9925058,0.0035624693,0.0026635535,0.0009998336,0.00021271071,0.000055650828],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011665461,0.00069270417,0.007497657,0.0011641094,0.0000927851,0.000006495933,0.00086841884,0.0013527257,0.000065854074],"category_scores_gemma":[0.0013150392,0.00054399925,0.0012107533,0.0011316668,0.00008668626,0.00004732332,0.00011267883,0.00036189167,0.00049227796],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000052603323,0.00012085375,0.00006988451,0.9881634,0.0007033325,0.000012361564,0.000045008048,4.7044516e-8,1.3630115e-7,0.00033990355,0.0030986727,0.007441127],"study_design_scores_gemma":[0.0025170343,0.00013425347,0.0000046768464,0.65745014,0.12402889,0.0045345463,0.000055613717,9.503753e-7,0.000002863839,0.00006859315,0.20997916,0.0012232467],"about_ca_topic_score_codex":0.0000123140035,"about_ca_topic_score_gemma":0.0000047774724,"teacher_disagreement_score":0.33071324,"about_ca_system_score_codex":0.00012979168,"about_ca_system_score_gemma":0.00080497056,"threshold_uncertainty_score":0.99994373},"labels":[],"label_agreement":null},{"id":"W2064761712","doi":"10.1111/j.1468-3083.2009.03416.x","title":"Adenosine deaminase activity, trypsin inhibitory capacity and total antioxidant capacity in psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Children's Hospital Research Institute of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Antioxidant capacity; Psoriasis; Adenosine deaminase; Antioxidant; Trypsin; Internal medicine; Gastroenterology; Endocrinology; Enzyme; Immunology; Adenosine; Biochemistry; Oxidative stress; Chemistry","score_opus":0.02713003508645927,"score_gpt":0.23523032525060186,"score_spread":0.20810029016414258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064761712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902422,0.004806518,0.000012325373,0.0039629,0.00044468525,0.000098160424,0.000011677575,0.000008524236,0.0004130324],"genre_scores_gemma":[0.99886745,0.0006236268,0.000110587745,0.00023337523,0.00007975376,6.4426644e-7,7.2964866e-7,0.00001028698,0.000073541225],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99689114,0.0019636159,0.0005821646,0.00021089474,0.000047443435,0.0003047502],"domain_scores_gemma":[0.99898535,0.00020644192,0.00061160687,0.00011661009,0.00003335347,0.000046627625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053104764,0.00022213146,0.00064960367,0.00024790378,0.00013581323,0.000005018648,0.0002461503,0.00035202567,0.000012330408],"category_scores_gemma":[0.00011765179,0.0001581986,0.00013555681,0.0001409596,0.00069784484,0.00014250934,0.000113801536,0.0007170198,0.0000057703232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014303852,0.00083594094,0.3455967,0.00008485767,0.00053552614,0.00027826976,0.0013492693,0.00001247993,0.5937833,0.0031550543,0.0013628725,0.051575314],"study_design_scores_gemma":[0.0029850905,0.00011479877,0.85938406,0.000083157414,0.00017654005,0.015000436,0.000043455388,0.0000026235505,0.12040185,0.00087232015,0.0007882172,0.00014745859],"about_ca_topic_score_codex":0.000010077189,"about_ca_topic_score_gemma":0.0000057239517,"teacher_disagreement_score":0.5137873,"about_ca_system_score_codex":0.000024216044,"about_ca_system_score_gemma":0.000028502673,"threshold_uncertainty_score":0.64511514},"labels":[],"label_agreement":null},{"id":"W2065380322","doi":"10.1016/j.clinthera.2005.12.007","title":"An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"IC Design Education Center; Biogen","keywords":"Medicine; Psoriasis; Tolerability; Clinical trial; Adverse effect; Incidence (geometry); Internal medicine; Plaque psoriasis; Population; Psoriasis Area and Severity Index; Dermatology; Surgery","score_opus":0.2201283353892288,"score_gpt":0.4562995894410747,"score_spread":0.23617125405184589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065380322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06379784,0.9300734,0.000052090672,0.000021053102,0.0010055725,0.0018760909,0.0030623546,0.000025455429,0.00008616149],"genre_scores_gemma":[0.008401055,0.9877394,0.00019407608,0.000069797185,0.00008059558,0.00004009933,0.0029794686,0.00006504637,0.00043049277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98729736,0.0060737585,0.005321535,0.0007366265,0.00014883289,0.00042186302],"domain_scores_gemma":[0.9896989,0.005250487,0.003361933,0.0011455928,0.00047506945,0.000068012494],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0039176866,0.0007231442,0.008921754,0.00094408833,0.000055018216,0.000009787523,0.0008943398,0.0016410085,0.0005566054],"category_scores_gemma":[0.0005333433,0.00049342186,0.002584028,0.0013070402,0.00040107276,0.00006785769,0.00008287487,0.0005635391,0.000012053524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021610835,0.0015551465,0.028047165,0.00021143495,0.022200547,8.0861207e-7,0.00067872123,0.000011517816,0.000055785385,0.000010455621,0.000041138035,0.9450262],"study_design_scores_gemma":[0.01657335,0.005692661,0.075617455,0.008000521,0.060689125,0.0000017494797,0.0005805227,0.000022302565,0.0013872895,0.000022612334,0.82982004,0.0015923482],"about_ca_topic_score_codex":0.000080088794,"about_ca_topic_score_gemma":0.0001926175,"teacher_disagreement_score":0.9434338,"about_ca_system_score_codex":0.00009078832,"about_ca_system_score_gemma":0.00032253467,"threshold_uncertainty_score":0.99975175},"labels":[],"label_agreement":null},{"id":"W2066002096","doi":"10.1016/j.jaad.2009.11.012","title":"Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Ustekinumab; Psoriasis; Psoriasis Area and Severity Index; Dosing; Body mass index; Placebo; Weight loss; Overweight; Internal medicine; Crossover study; Gastroenterology; Obesity; Dermatology; Infliximab; Disease","score_opus":0.01383228764558732,"score_gpt":0.27610456426620683,"score_spread":0.2622722766206195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066002096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939358,0.00006770221,0.00004010408,0.005405558,0.00011662252,0.0003206303,0.0000883826,0.0000014004005,0.000023767492],"genre_scores_gemma":[0.9992309,0.000043097698,0.00053289166,0.00014908859,0.000012888291,0.0000059275985,0.0000050369435,0.0000076480965,0.000012474346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989844,0.0002510011,0.0004903067,0.00009003362,0.000046821402,0.0001374547],"domain_scores_gemma":[0.99794346,0.0007919844,0.001048992,0.0001040146,0.000092831906,0.000018686596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001621959,0.00011202453,0.00046419265,0.0001524474,0.00007757317,0.0000022341474,0.00021910672,0.00008401154,0.000019411045],"category_scores_gemma":[0.00012808183,0.000057026442,0.000115856514,0.00018320227,0.0002550742,0.00005688217,0.000033948672,0.00025369742,6.8666515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045959227,0.0018113389,0.7823124,0.000055169447,0.0034597013,0.0000013364058,0.003415169,0.0007185956,0.11042643,0.0028086107,0.005162234,0.043869812],"study_design_scores_gemma":[0.0071431985,0.00089311175,0.95842385,0.00011093914,0.00020873176,0.00017751397,0.00014932961,0.000009111825,0.031855367,0.00024716434,0.00067784055,0.00010384579],"about_ca_topic_score_codex":0.000012838133,"about_ca_topic_score_gemma":0.0000064925216,"teacher_disagreement_score":0.17611147,"about_ca_system_score_codex":0.000021416503,"about_ca_system_score_gemma":0.000079894555,"threshold_uncertainty_score":0.23254707},"labels":[],"label_agreement":null},{"id":"W2066541194","doi":"10.2310/7750.2009.00023","title":"Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of British Columbia; Innovaderm (Canada)","funders":"Genentech; LEO Pharma; Abbott Laboratories","keywords":"Medicine; Psoriasis; Etanercept; Ustekinumab; Efalizumab; Adalimumab; Infliximab; Psoriatic arthritis; Adverse effect; Dermatology; Methotrexate; Biologic Agents; Rheumatoid arthritis; Acitretin; Disease; Pharmacology; Immunology; Internal medicine; Plaque psoriasis","score_opus":0.08341096772902548,"score_gpt":0.32096492018312617,"score_spread":0.2375539524541007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066541194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0455769,0.95319337,0.0000012889268,0.00007832101,0.0007036151,0.00030118023,0.000056212786,0.0000023194232,0.000086823675],"genre_scores_gemma":[0.022873802,0.97668976,0.000005659601,0.00003574448,0.00013190617,0.000005504921,0.000094131894,0.000009431291,0.00015405011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970461,0.0008358026,0.0016444416,0.00017529033,0.00010377589,0.0001945737],"domain_scores_gemma":[0.99585634,0.002247068,0.0016103633,0.00016864979,0.00008491245,0.000032690587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008483882,0.000322212,0.002882506,0.0004885252,0.000050459956,0.0000030198946,0.00013540321,0.00034079736,0.0001034056],"category_scores_gemma":[0.00012164317,0.00015563224,0.00051945756,0.00018958155,0.00022687775,0.000024746532,0.00001039377,0.0001564072,0.0000023149105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035727312,0.00042890108,0.0019898098,0.0018336634,0.0015994457,0.0006544997,0.00051534834,2.7155875e-7,0.000022134105,0.000022792907,0.001970158,0.9906057],"study_design_scores_gemma":[0.0024089378,0.0027546703,0.0014613114,0.019371819,0.00523829,0.032056246,0.0005180987,2.3378135e-7,0.000013119911,0.000069751375,0.93586934,0.00023818407],"about_ca_topic_score_codex":0.000023055083,"about_ca_topic_score_gemma":0.0000033237336,"teacher_disagreement_score":0.99036753,"about_ca_system_score_codex":0.000061073704,"about_ca_system_score_gemma":0.00015672496,"threshold_uncertainty_score":0.6346498},"labels":[],"label_agreement":null},{"id":"W2067113873","doi":"10.1073/pnas.1206048110","title":"MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; York University","keywords":"Cell biology; PI3K/AKT/mTOR pathway; T cell; Cell growth; Cellular differentiation; Signal transduction; Innate lymphoid cell; Biology; Innate immune system; Immune system; Chemistry; Immunology","score_opus":0.01793658038798776,"score_gpt":0.25951356675565296,"score_spread":0.2415769863676652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067113873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307156,0.00011875712,0.00001217324,0.005748571,0.00003313684,0.0005743499,0.00003296869,0.000013184499,0.00039530013],"genre_scores_gemma":[0.99712646,0.000011354009,0.0008489924,0.0006139007,0.000064531625,0.000058817513,0.0000032958728,0.0000051379748,0.0012675321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990267,0.000014093742,0.00025768892,0.00028848718,0.00022446798,0.0001885233],"domain_scores_gemma":[0.99937445,0.00006768117,0.00022917755,0.000009717827,0.0002918758,0.000027088621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005809952,0.00011790054,0.00014533615,0.00017761916,0.00033375234,0.00004557108,0.0003097789,0.00014546822,0.000048407914],"category_scores_gemma":[0.00012765374,0.00008352543,0.00004015728,0.0004420175,0.00018998605,0.0005290824,0.00010948923,0.00010165171,0.0000136416675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031697575,0.00004902918,0.0021754955,0.000034906127,0.000022549604,1.9099307e-9,0.0013436588,0.000014304886,0.9896166,0.00032717327,0.0045196856,0.0018649434],"study_design_scores_gemma":[0.00024992204,0.000103835686,0.006260191,0.00006933591,0.000019751275,0.000001931095,0.00046262515,0.000050826628,0.98964703,0.00220878,0.00082785083,0.0000979394],"about_ca_topic_score_codex":0.00001647266,"about_ca_topic_score_gemma":7.303787e-8,"teacher_disagreement_score":0.00513467,"about_ca_system_score_codex":0.000032037424,"about_ca_system_score_gemma":0.000030036996,"threshold_uncertainty_score":0.34060684},"labels":[],"label_agreement":null},{"id":"W2067318974","doi":"10.1007/s00403-015-1549-z","title":"Omentin-1 plasma levels and omentin-1 expression are decreased in psoriatic lesions of psoriasis patients","year":2015,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Natural Science Foundation of Guangdong Province","keywords":"Psoriasis; Medicine; Pathogenesis; Psoriasis Area and Severity Index; Adipokine; Internal medicine; Immunohistochemistry; Genotype; Allele; Endocrinology; Gastroenterology; Dermatology; Obesity; Leptin; Gene; Biology","score_opus":0.10412822578980829,"score_gpt":0.33051280732181604,"score_spread":0.22638458153200774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067318974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963928,0.0012003443,0.000016867032,0.00013200853,0.00011362801,0.00040949538,0.000105110514,0.00001661083,0.001613131],"genre_scores_gemma":[0.9988219,0.00021083457,0.0005905949,0.000008535241,0.0000072040625,0.000062149855,0.00007438402,0.000010990192,0.00021339493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708515,0.0012657172,0.0005370991,0.00037202012,0.00020510564,0.00053488003],"domain_scores_gemma":[0.9973807,0.0018889178,0.00019128402,0.00030176615,0.00012066415,0.00011666594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005028419,0.00018370741,0.00053802005,0.00048022575,0.000120317774,0.000009478319,0.0003308944,0.0001961356,0.00007369286],"category_scores_gemma":[0.0013580321,0.00013585805,0.00009207339,0.0002987115,0.0006050181,0.000081998915,0.0003975326,0.00026328056,0.000036887257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016545566,0.0019790707,0.8890377,0.00014406444,0.00015027433,0.000032101932,0.0017028339,0.0000029317996,0.0658799,0.0007989499,0.0006042515,0.038013328],"study_design_scores_gemma":[0.0076768273,0.00041977284,0.7748808,0.00026811418,0.000033912722,0.000013046769,0.0010982039,0.000018263707,0.21099535,0.0038241926,0.0005982082,0.00017329179],"about_ca_topic_score_codex":0.00004385887,"about_ca_topic_score_gemma":0.000017674025,"teacher_disagreement_score":0.14511545,"about_ca_system_score_codex":0.000019515719,"about_ca_system_score_gemma":0.00008689526,"threshold_uncertainty_score":0.554013},"labels":[],"label_agreement":null},{"id":"W2067605344","doi":"10.3899/jrheum.110899","title":"Quality of Life in Patients with Immune-Mediated Inflammatory Diseases","year":2011,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Abbott Canada; Michael Smith Health Research BC; Child and Family Research Institute; Pfizer; Amgen","keywords":"Medicine; Quality of life (healthcare); Disease; Clinical trial; Physical therapy; Health related quality of life; Intensive care medicine; Inclusion (mineral); Internal medicine; Nursing","score_opus":0.02585812383046983,"score_gpt":0.2753751350440754,"score_spread":0.2495170112136056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067605344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07681967,0.92112786,0.0000036690794,0.000012959234,0.00083025,0.0005579094,0.0006217797,0.0000091081865,0.000016797809],"genre_scores_gemma":[0.01840414,0.9803312,0.000073020405,0.0000074473323,0.0000080884565,0.00004582104,0.0010603172,0.00003922232,0.000030745905],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471074,0.0012951518,0.0031941936,0.0002664129,0.00011047103,0.00042304114],"domain_scores_gemma":[0.9944769,0.0006106338,0.0041941144,0.00040411617,0.00023990386,0.000074309755],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063176337,0.0005037714,0.004008105,0.0006558068,0.000052282136,0.000004532028,0.0005119486,0.0005312694,0.0011314828],"category_scores_gemma":[0.00023695102,0.0003303992,0.00063965324,0.00020563757,0.00023475183,0.0001027888,0.0001141422,0.00045569698,0.000071060094],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014677432,0.0015325623,0.872269,0.005185019,0.005107947,0.000016963393,0.00023741131,2.3812035e-7,0.0000012900139,0.0002562414,0.0015013199,0.1124243],"study_design_scores_gemma":[0.017647296,0.0016102402,0.19485831,0.009208855,0.002617551,0.00014314528,0.00016843627,1.7658385e-8,0.000011738255,0.00003878728,0.7729002,0.00079540827],"about_ca_topic_score_codex":0.000108111286,"about_ca_topic_score_gemma":0.000073120544,"teacher_disagreement_score":0.7713989,"about_ca_system_score_codex":0.0001268892,"about_ca_system_score_gemma":0.00082964776,"threshold_uncertainty_score":0.9999148},"labels":[],"label_agreement":null},{"id":"W2067727557","doi":"10.1007/s10067-014-2743-7","title":"Prevalence of cardiovascular risk factors in patients with psoriatic arthritis","year":2014,"lang":"en","type":"article","venue":"Clinical Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Diabetes mellitus; Epidemiology; Psoriasis; Depression (economics); Obesity; Population; Rheumatology; Arthritis; Immunology; Endocrinology","score_opus":0.013325310347876283,"score_gpt":0.24210662218150852,"score_spread":0.22878131183363223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067727557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950979,0.0034623733,0.00015058856,0.000008210852,0.0008724965,0.00023910412,0.000046055357,0.00002944934,0.00009387073],"genre_scores_gemma":[0.9969686,0.0027966914,0.0001080644,0.000007732071,0.000005964776,0.000017464152,0.000046165598,0.000014617034,0.000034681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722975,0.0012225896,0.00076690625,0.0004145903,0.000052902247,0.0003132355],"domain_scores_gemma":[0.99776644,0.0013015337,0.00029861534,0.0005285427,0.00007164265,0.000033212167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006956033,0.00019010007,0.0009498341,0.00008969531,0.000053605578,0.000002318893,0.0002155145,0.0003904682,0.00016367676],"category_scores_gemma":[0.0011342387,0.00014099859,0.0002864688,0.0001171294,0.00036544693,0.000046843255,0.000052885804,0.0002448943,0.00013273384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024779866,0.0003760933,0.9257323,0.000041834643,0.00074623397,9.4467003e-7,0.00007443646,0.000015956146,0.0000014574266,0.00019220724,0.00004330205,0.07252743],"study_design_scores_gemma":[0.007253122,0.00085065677,0.989914,0.00010372796,0.00025587546,0.0000034537163,0.000016617709,0.0000029346897,0.00022405598,0.0001623203,0.001057559,0.00015568115],"about_ca_topic_score_codex":0.00020542384,"about_ca_topic_score_gemma":0.00003401559,"teacher_disagreement_score":0.07237174,"about_ca_system_score_codex":0.000012345001,"about_ca_system_score_gemma":0.000036156463,"threshold_uncertainty_score":0.57497555},"labels":[],"label_agreement":null},{"id":"W2068089617","doi":"10.1016/j.jaad.2013.12.036","title":"Interleukin 17A: Toward a new understanding of psoriasis pathogenesis","year":2014,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":332,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada); Dermatrials Research; Centre de Recherche Dermatologique du Québec Métropolitain; Lynde Centre for Dermatology","funders":"","keywords":"Psoriasis; Medicine; Immunology; Pathogenesis; Cytokine; Proinflammatory cytokine; Immune system; Inflammation; Chemokine; Interleukin 17","score_opus":0.07583151560383232,"score_gpt":0.3313353460327577,"score_spread":0.2555038304289254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068089617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022048177,0.99459404,0.00041082708,0.0010873451,0.0011951913,0.0003009391,0.00007515876,0.000012605994,0.00011909697],"genre_scores_gemma":[0.02054603,0.9784984,0.00035813113,0.00014383417,0.00016454315,0.000006804285,0.000008503515,0.0000595895,0.00021415786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948989,0.001833777,0.0023494929,0.00030764693,0.00014281091,0.0004673809],"domain_scores_gemma":[0.98973316,0.0010935807,0.008690813,0.0003408189,0.00006475793,0.000076845026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041630285,0.0005718502,0.0053907903,0.0007108954,0.000086962566,0.0000069025264,0.0015664547,0.0007035528,0.0000787933],"category_scores_gemma":[0.00023244103,0.00035537186,0.0022581324,0.0006785393,0.00096707593,0.00007327739,0.00027005104,0.0009080192,0.000033429027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040973205,0.00018141101,0.00048221112,0.003517031,0.006856775,0.000028832634,0.00040933958,0.00000151701,0.0010542956,0.0011528886,0.012789587,0.9731164],"study_design_scores_gemma":[0.0017255805,0.00035605062,0.00020349055,0.0055445023,0.008537279,0.011225442,0.00036518325,2.3607386e-7,0.0025326938,0.0006784032,0.96837604,0.00045510047],"about_ca_topic_score_codex":0.000030751922,"about_ca_topic_score_gemma":0.0000022032877,"teacher_disagreement_score":0.97266126,"about_ca_system_score_codex":0.00021209981,"about_ca_system_score_gemma":0.00059578154,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W2068567051","doi":"10.1046/j.1365-2036.2004.01819.x","title":"Monitoring methotrexate‐induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","year":2004,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Methotrexate; Psoriasis; Cirrhosis; Liver biopsy; Biopsy; Gastroenterology; Cumulative dose; Internal medicine; Fibrosis; Hepatic fibrosis; Dermatology","score_opus":0.031709774280325946,"score_gpt":0.27361313867565334,"score_spread":0.2419033643953274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068567051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925366,0.002458185,0.000005966949,0.000328532,0.0037558204,0.0006820819,0.00009452121,0.000109639244,0.000028624518],"genre_scores_gemma":[0.997139,0.00076094177,0.00051343103,0.0009432177,0.00019097704,0.00013971493,0.00017346871,0.000055503406,0.00008377002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783456,0.00044046203,0.00041467277,0.000541988,0.00009067529,0.00067761744],"domain_scores_gemma":[0.9991983,0.00016355944,0.00023260213,0.0002748916,0.000080070626,0.000050530994],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000163334,0.0004672944,0.0005151911,0.00023130087,0.00026370687,0.000019271924,0.00030654308,0.00033166283,0.00032199355],"category_scores_gemma":[4.851046e-7,0.00039828086,0.00010834043,0.00032588252,0.00016423326,0.00022300135,0.00009029763,0.00032210123,0.00018705444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052073104,0.002066696,0.4671095,0.00004123646,0.013608116,0.0000776802,0.0022224577,0.00019175936,0.500319,0.0000101405685,0.000033694134,0.009112387],"study_design_scores_gemma":[0.015693897,0.00092724524,0.3105814,0.000079248886,0.006568849,0.0000084199455,0.0004407426,0.0000015668357,0.6648793,0.000029473482,0.0003382023,0.00045165044],"about_ca_topic_score_codex":0.00040813282,"about_ca_topic_score_gemma":0.00007196339,"teacher_disagreement_score":0.16456029,"about_ca_system_score_codex":0.0002774016,"about_ca_system_score_gemma":0.000075868935,"threshold_uncertainty_score":0.99984694},"labels":[],"label_agreement":null},{"id":"W2068953765","doi":"10.1111/j.1365-4632.2009.04012.x","title":"Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis","year":2009,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.025386493197776375,"score_gpt":0.2838506729306866,"score_spread":0.25846417973291025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068953765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942417,0.0017754973,0.00012252007,0.0031540862,0.0002503034,0.00019947052,0.0000338018,0.0000030872914,0.00021950646],"genre_scores_gemma":[0.9977977,0.0017543825,0.000191778,0.00018379762,0.000020950729,0.0000032873118,0.000023809558,0.0000036382087,0.000020644968],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99904794,0.00021629414,0.00045628485,0.00009811119,0.000058642763,0.00012273707],"domain_scores_gemma":[0.999145,0.0002490349,0.0003227518,0.00009803527,0.00016907272,0.000016126713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006548121,0.00012721519,0.00041416966,0.0001895418,0.000027863647,0.0000057473867,0.00025282663,0.000093162205,0.000021894923],"category_scores_gemma":[0.000012680057,0.000070306894,0.000075475844,0.00008235851,0.00009234066,0.000043543336,0.0000095686555,0.00006538603,0.000003029282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10059487,0.009964545,0.24641106,0.000016223408,0.0062773563,0.0018829843,0.023377895,0.0017548408,0.072804466,0.0071835155,0.0011376599,0.5285946],"study_design_scores_gemma":[0.06552154,0.010280932,0.65567106,0.00021949451,0.00036067097,0.03890075,0.0015996359,0.000050271257,0.17635538,0.0012451231,0.049270503,0.0005246722],"about_ca_topic_score_codex":0.000019682348,"about_ca_topic_score_gemma":0.00003190917,"teacher_disagreement_score":0.5280699,"about_ca_system_score_codex":0.00003544914,"about_ca_system_score_gemma":0.00004877669,"threshold_uncertainty_score":0.2867032},"labels":[],"label_agreement":null},{"id":"W2069236338","doi":"10.1111/bjd.13745","title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"U.S. Food and Drug Administration; Astellas Pharma","keywords":"Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Dosing; Adverse effect; Body surface area; Internal medicine; Clinical endpoint; Dermatology Life Quality Index; Clinical trial; Gastroenterology; Randomized controlled trial; Janus kinase; Urology; Cytokine; Dermatology; Pathology","score_opus":0.026855971073515394,"score_gpt":0.28088120055266036,"score_spread":0.25402522947914496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069236338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935749,0.0012638522,0.00047928243,0.00028601766,0.00062281726,0.0036454184,0.000048940587,0.000009812541,0.00006893949],"genre_scores_gemma":[0.99947387,0.00003752519,0.0001683893,0.00006750356,0.000048850583,0.000116347255,0.00003354308,0.000022352027,0.00003160795],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964709,0.0014462838,0.0012330381,0.00030016352,0.00019129478,0.0003582927],"domain_scores_gemma":[0.99806195,0.0005264151,0.0005095358,0.00019376593,0.00058525056,0.00012306812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013477303,0.0002803851,0.001513604,0.00035785243,0.00014942796,0.000047470265,0.00023086015,0.00018823367,0.000023702929],"category_scores_gemma":[0.00039884786,0.00020345513,0.0001545792,0.00028821113,0.00015713897,0.00018946751,0.0000931701,0.0003035726,0.000012998179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9746612,0.0048656194,0.0063219015,0.000008928287,0.0014264449,0.00022677529,0.0023526598,0.00041888285,0.00035059973,0.00001947589,0.00018435834,0.009163186],"study_design_scores_gemma":[0.9853927,0.002118518,0.0062675574,0.00015237421,0.0010386733,0.0030682292,0.00051878125,0.000024312789,0.0011251826,0.000023321341,0.000050203238,0.00022015549],"about_ca_topic_score_codex":0.00023251775,"about_ca_topic_score_gemma":0.00034690232,"teacher_disagreement_score":0.010731523,"about_ca_system_score_codex":0.00007678141,"about_ca_system_score_gemma":0.0002606599,"threshold_uncertainty_score":0.82966596},"labels":[],"label_agreement":null},{"id":"W2071306106","doi":"10.2310/7750.2006.00060a","title":"Biologic Therapeutics in the Treatment of Psoriasis. Part 1: Review","year":2007,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre; Dalhousie University","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Etanercept; Adalimumab; Infliximab; Dermatology; Biosimilar; Clinical trial; Immunology; Biologic Agents; Proinflammatory cytokine; Daclizumab; Plaque psoriasis; Tumor necrosis factor alpha; Monoclonal antibody; Inflammation; Pathology; Internal medicine; Antibody; Rheumatoid arthritis","score_opus":0.15106736347777644,"score_gpt":0.3572197791623919,"score_spread":0.20615241568461545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071306106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050547044,0.9972152,8.911683e-7,0.00034619748,0.0013203934,0.00037253817,0.000016396789,0.0000041494686,0.00021877498],"genre_scores_gemma":[0.00006859923,0.99878055,0.000006204506,0.00046981353,0.00037345113,0.000010790294,0.000065899454,0.000016341713,0.00020832395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966854,0.00094712997,0.0018093131,0.00017730107,0.00009904748,0.00028182165],"domain_scores_gemma":[0.9931721,0.004940049,0.0014859333,0.00027874878,0.00009381629,0.00002931512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016975629,0.0004031713,0.003703907,0.00042875795,0.00005003516,0.0000032051653,0.00019926952,0.0003915206,0.00014956533],"category_scores_gemma":[0.00014411929,0.00016904133,0.00077994866,0.00034529142,0.00023752505,0.000020872065,0.000008257277,0.0002737771,0.000009771307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073199735,0.00027883868,0.00009434343,0.003274536,0.0009958982,0.00075785327,0.00022244774,1.3112092e-8,0.000003322751,0.000008388227,0.0052287905,0.98906237],"study_design_scores_gemma":[0.00036468095,0.00112143,0.000009973748,0.025603872,0.004454352,0.01121785,0.0000995876,6.204018e-9,0.000004481223,0.000018797879,0.9569735,0.00013145401],"about_ca_topic_score_codex":0.000011895337,"about_ca_topic_score_gemma":0.0000064297524,"teacher_disagreement_score":0.98893094,"about_ca_system_score_codex":0.000057805497,"about_ca_system_score_gemma":0.00020568447,"threshold_uncertainty_score":0.6893306},"labels":[],"label_agreement":null},{"id":"W2071343804","doi":"10.1056/nejmoa062382","title":"A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":785,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Monoclonal antibody; Monoclonal; Immunology; Interleukin 23; Ixekizumab; Interleukin; Interleukin 2; Dermatology; Antibody; Cytokine; Secukinumab; Psoriatic arthritis","score_opus":0.032647876164843576,"score_gpt":0.31457699936906935,"score_spread":0.2819291232042258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071343804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97764933,0.01596048,0.001972157,0.0013141402,0.0023932538,0.00025217075,0.00001577822,0.000008290506,0.0004344117],"genre_scores_gemma":[0.993831,0.0012244716,0.00022348906,0.0000644788,0.0022766858,0.0000028089212,0.000037812395,0.000012900962,0.002326355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989164,0.00007646074,0.000596369,0.00010826455,0.00007296978,0.00022951994],"domain_scores_gemma":[0.9984598,0.0007778527,0.0004245068,0.00016418425,0.00012163204,0.00005198577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083397963,0.00017102467,0.0004976645,0.00016989135,0.00011854008,0.0000030833976,0.00018068177,0.00010681272,0.00022368644],"category_scores_gemma":[0.00007287552,0.00008311569,0.00020419473,0.00007966479,0.00015191743,0.000035582296,0.000008041048,0.00009629933,0.000005264161],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037662862,0.00046563172,0.009697237,0.000014903994,0.0020057007,0.000054525084,0.0043240627,0.0000049009013,0.21835884,0.0004142998,0.0051813493,0.7557123],"study_design_scores_gemma":[0.1662412,0.022912184,0.07319113,0.0002754228,0.002767139,0.0013109952,0.0014606727,0.0000024922792,0.12410964,0.00088380213,0.60661095,0.00023438981],"about_ca_topic_score_codex":0.00013775821,"about_ca_topic_score_gemma":0.00015489626,"teacher_disagreement_score":0.75547785,"about_ca_system_score_codex":0.000051867435,"about_ca_system_score_gemma":0.000059885835,"threshold_uncertainty_score":0.33893594},"labels":[],"label_agreement":null},{"id":"W2071374810","doi":"10.1016/j.jaad.2010.04.004","title":"Long-term etanercept in pediatric patients with plaque psoriasis","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Etanercept; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Placebo; Internal medicine; Interim analysis; Dermatology Life Quality Index; Clinical endpoint; Randomized controlled trial; Plaque psoriasis; Dermatology; Tumor necrosis factor alpha","score_opus":0.007928751217707723,"score_gpt":0.24474649434592544,"score_spread":0.2368177431282177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071374810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969836,0.00041541326,0.000006240524,0.00179793,0.00056710106,0.0001298406,0.000013958308,0.0000066592743,0.000079269565],"genre_scores_gemma":[0.99917847,0.0002654534,0.00018174689,0.00023831961,0.00006626186,0.000003708332,0.0000034790733,0.0000157325,0.00004680833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851227,0.00033286837,0.00061193155,0.000151334,0.00008452012,0.0003070953],"domain_scores_gemma":[0.99806374,0.00024316448,0.0014378596,0.00015645321,0.00006250857,0.000036295365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012797977,0.00019061973,0.0006748818,0.00031561893,0.00006270371,0.0000038801913,0.0005862105,0.00022135537,0.00007604335],"category_scores_gemma":[0.00006579767,0.00011321736,0.00017588976,0.0003952794,0.0004964398,0.00010197645,0.0000725551,0.0008438139,0.000023919185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067999144,0.00025613286,0.9847674,0.0000135388755,0.00019192245,0.00001687855,0.0001519736,0.0000026087723,0.0064107873,0.000047050256,0.000528541,0.00693321],"study_design_scores_gemma":[0.0028145954,0.00017245226,0.98292685,0.000016425893,0.00026432436,0.0010678482,0.000030563668,1.4555224e-7,0.012061781,0.00004029685,0.00048402135,0.00012069884],"about_ca_topic_score_codex":0.0000103477705,"about_ca_topic_score_gemma":0.000024639887,"teacher_disagreement_score":0.006812511,"about_ca_system_score_codex":0.0000226591,"about_ca_system_score_gemma":0.00009300174,"threshold_uncertainty_score":0.46168697},"labels":[],"label_agreement":null},{"id":"W2071780577","doi":"10.1016/j.jaad.2010.01.030","title":"Efficacy and safety of ABT-874, a monoclonal anti–interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Dosing; Internal medicine; Dose; Gastroenterology; Surgery; Dermatology; Pathology","score_opus":0.04806543979036704,"score_gpt":0.34248805588444153,"score_spread":0.2944226160940745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071780577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812162,0.01335654,0.00012731201,0.002715566,0.0004407946,0.001925644,0.00020695238,0.0000048893003,0.00000610443],"genre_scores_gemma":[0.9868868,0.01194229,0.0008760286,0.000057240377,0.000074101,0.00005681883,0.000023640798,0.000019386964,0.000063697495],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970168,0.0006751787,0.0016723311,0.0002459249,0.00010607445,0.00028371692],"domain_scores_gemma":[0.99267554,0.003005769,0.0038481357,0.00026612863,0.00015651404,0.00004788497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005719329,0.00033123157,0.002493139,0.00020991075,0.00020876399,0.0000075435046,0.00050983217,0.00022264698,0.000023197796],"category_scores_gemma":[0.00029739153,0.00017873634,0.000445467,0.00018442556,0.0019033625,0.000124942,0.0001328754,0.00024583002,3.5154363e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53016144,0.009704694,0.0006195648,0.00005378461,0.0052629337,0.000006588594,0.0014838659,0.000009359655,0.4140121,0.0003386953,0.0002944907,0.03805247],"study_design_scores_gemma":[0.7192338,0.015284742,0.004628409,0.00018990065,0.0038727745,0.0011898612,0.00044422114,0.000095738294,0.25228631,0.00019860489,0.0023876785,0.00018791846],"about_ca_topic_score_codex":0.000109311324,"about_ca_topic_score_gemma":0.000013200555,"teacher_disagreement_score":0.18907237,"about_ca_system_score_codex":0.000045490986,"about_ca_system_score_gemma":0.00024028598,"threshold_uncertainty_score":0.7288656},"labels":[],"label_agreement":null},{"id":"W2071911850","doi":"10.1038/nrrheum.2009.76","title":"Targeted therapy for psoriatic arthritis","year":2009,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Rehabilitation Institute","funders":"","keywords":"Psoriatic arthritis; Medicine; Tumor necrosis factor alpha; Psoriasis; Arthritis; Tumor necrosis factor α; Dermatology; Oncology; Internal medicine","score_opus":0.030897267188517166,"score_gpt":0.32079052409107744,"score_spread":0.2898932569025603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071911850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000031098352,0.98954666,0.00004868974,0.00006960296,0.0045461054,0.0051183957,0.00031168986,0.0001662181,0.00018952841],"genre_scores_gemma":[0.0000054927455,0.99202335,0.00040342743,0.00021177452,0.00011083777,0.0020378765,0.004126076,0.000107402906,0.0009737769],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945011,0.0015872937,0.0018534085,0.0010910126,0.000051505303,0.00091564184],"domain_scores_gemma":[0.99653834,0.000938556,0.0013634599,0.0009919296,0.00010827623,0.000059424303],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007817814,0.0012107464,0.0077025266,0.00039571527,0.00027081487,0.000024667748,0.00077623397,0.004975797,0.00058364536],"category_scores_gemma":[0.00043338264,0.0008361726,0.002399926,0.0004678041,0.0001301872,0.00006846525,0.00005158062,0.001393095,0.0020126742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004361817,0.00014702581,0.0000015806663,0.004794785,0.0009894157,0.0000071882787,0.000022538747,5.5333396e-9,0.0000015261228,0.0010144856,0.040456794,0.952521],"study_design_scores_gemma":[0.0019172477,0.00029023454,0.00000254238,0.010965063,0.0010850242,0.00099351,0.0000022086783,6.216763e-8,0.000012117146,0.00024468362,0.98376894,0.00071836356],"about_ca_topic_score_codex":0.0000062114686,"about_ca_topic_score_gemma":0.000013343227,"teacher_disagreement_score":0.9518027,"about_ca_system_score_codex":0.00010330787,"about_ca_system_score_gemma":0.00032341463,"threshold_uncertainty_score":0.9994089},"labels":[],"label_agreement":null},{"id":"W2073059673","doi":"10.1016/j.jval.2012.03.538","title":"PSY4 Prevalence of Autoimmune Diseases and Other Comorbidities in Patients With Psoriasis in the United States","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Psoriatic arthritis; Comorbidity; Ankylosing spondylitis; Psoriasis; Internal medicine; Rheumatoid arthritis; McNemar's test; Population; Immunology","score_opus":0.028100096501049172,"score_gpt":0.25833581647333254,"score_spread":0.23023571997228337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073059673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888967,0.010267808,9.485376e-7,0.00012671408,0.00013637797,0.0003627365,0.00017964318,0.000008662159,0.000020367319],"genre_scores_gemma":[0.9987299,0.00092148694,0.000026636195,0.00015368497,0.0000072734724,0.00003617416,0.000079848345,0.000008306341,0.00003672002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985324,0.0007449851,0.00027493393,0.00011887685,0.000040148487,0.00028861623],"domain_scores_gemma":[0.999365,0.00032470474,0.000113592425,0.00016755855,0.000014031452,0.000015141592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040596444,0.000111113644,0.0002178636,0.0001950929,0.000043216205,0.0000031727438,0.00010058853,0.000058573758,0.000034713215],"category_scores_gemma":[0.000028216491,0.000071071016,0.000015570948,0.00026783414,0.000114728806,0.00006579356,0.000019372197,0.00009294921,0.000004352266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026226486,0.00055915635,0.9906937,0.00017470871,0.00002064093,5.7111333e-7,0.006439475,0.00008104208,0.000008122032,0.0002992039,0.00003725965,0.0014238548],"study_design_scores_gemma":[0.002107464,0.00026263023,0.9958541,0.00019929663,0.00001578656,0.0000015046049,0.0007198321,0.000009029204,0.00004923535,0.00007053355,0.00063837157,0.00007223051],"about_ca_topic_score_codex":0.007869799,"about_ca_topic_score_gemma":0.00010343327,"teacher_disagreement_score":0.009833127,"about_ca_system_score_codex":0.000042686825,"about_ca_system_score_gemma":0.000041056854,"threshold_uncertainty_score":0.99873686},"labels":[],"label_agreement":null},{"id":"W2073293328","doi":"10.1111/j.1540-9740.2004.02992.x","title":"The Role of Fish Oils in Psoriasis","year":2004,"lang":"en","type":"article","venue":"SKINmed Dermatology for the Clinician","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The King's University; Queen's University; University of Alberta","funders":"","keywords":"Queen (butterfly); Medicine; Fish <Actinopterygii>; Citation; Library science","score_opus":0.015628571873420562,"score_gpt":0.26761449230634987,"score_spread":0.25198592043292933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073293328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739536,0.011337616,0.00007348521,0.009395263,0.0026013907,0.0008673163,0.00011574561,0.00005131413,0.0016042858],"genre_scores_gemma":[0.99806243,0.0007276357,0.0000630455,0.00056713825,0.00004921985,0.00021332274,0.0000467832,0.000018382385,0.0002520648],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844885,0.00021565918,0.0005986067,0.00023473812,0.000031263848,0.00047091252],"domain_scores_gemma":[0.99688673,0.0023045526,0.00025007452,0.00049052364,0.000050975603,0.000017155859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043288086,0.00017948858,0.00039752488,0.000077418525,0.00038217433,0.000007622136,0.00050837087,0.0003554592,0.000030608084],"category_scores_gemma":[0.00029895722,0.0001049332,0.00025908666,0.00017061399,0.0004717905,0.00003981066,0.00006163952,0.0001965525,0.000118501725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051725055,0.0017231763,0.06554945,0.000081914994,0.004148645,0.00007535733,0.0064378693,0.000112902795,0.0259029,0.10216017,0.0092474185,0.7793877],"study_design_scores_gemma":[0.013418037,0.00033950794,0.03454569,0.000071187285,0.0005999441,0.00041388435,0.0034013297,0.000009819718,0.5114181,0.069252916,0.36610228,0.00042726984],"about_ca_topic_score_codex":0.00008874647,"about_ca_topic_score_gemma":0.0012731166,"teacher_disagreement_score":0.7789604,"about_ca_system_score_codex":0.000031117776,"about_ca_system_score_gemma":0.000097795135,"threshold_uncertainty_score":0.42790517},"labels":[],"label_agreement":null},{"id":"W2073893218","doi":"10.1016/j.jval.2011.08.1494","title":"PSS29 Treatment Patterns of Psoriasis Patients and Trends Over Time","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Psoriasis; Medicine; Body mass index; Psoriasis Area and Severity Index; Population; Dermatology; Internal medicine; Body surface area; Retrospective cohort study","score_opus":0.03972298619910637,"score_gpt":0.25619942129535445,"score_spread":0.2164764350962481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073893218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972688,0.0013617096,0.0000017965522,0.000039058265,0.00032197294,0.00016760961,0.0001953919,0.000020931846,0.000622717],"genre_scores_gemma":[0.99785477,0.0006648778,0.00009113482,0.00004318406,0.000013641077,0.000023259501,0.00011945409,0.000012952285,0.0011767239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988579,0.00025788264,0.0003386303,0.00023823434,0.000027761636,0.00027956066],"domain_scores_gemma":[0.9995463,0.00006994851,0.00014795958,0.0001861679,0.00001536311,0.000034282093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013396244,0.00015862334,0.00034045597,0.00019774436,0.000052509797,0.0000019133804,0.00006636666,0.00012444018,0.0006518639],"category_scores_gemma":[0.000008238338,0.00012705296,0.00006238136,0.00010904703,0.000036498794,0.000042422063,0.000023861172,0.000047855516,0.00006290784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025294579,0.00096682756,0.75711185,0.000037010075,0.00015216669,0.00000368291,0.0035780563,0.0000014942915,0.00030156894,0.00020914446,0.00015583399,0.23722944],"study_design_scores_gemma":[0.004003467,0.0015063991,0.9887239,0.00005126401,0.00004294396,0.0000045601537,0.000040149982,0.0000055583273,0.004270703,0.00006869707,0.0011602644,0.00012213526],"about_ca_topic_score_codex":0.010111196,"about_ca_topic_score_gemma":0.00010740152,"teacher_disagreement_score":0.2371073,"about_ca_system_score_codex":0.000094553696,"about_ca_system_score_gemma":0.000037580015,"threshold_uncertainty_score":0.9964806},"labels":[],"label_agreement":null},{"id":"W2074241528","doi":"10.3899/jrheum.130457","title":"Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Comorbidity; Dermatology; Internal medicine; Arthritis; Physical therapy","score_opus":0.01060149992089085,"score_gpt":0.2064056208232058,"score_spread":0.19580412090231494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074241528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86850995,0.1293352,0.000081098995,0.00058909424,0.0011974465,0.0001567375,0.00003778786,0.000009472564,0.00008323184],"genre_scores_gemma":[0.98393196,0.015758028,0.00013056023,0.00003499483,0.000032296168,0.000010353225,0.00001266725,0.000013515375,0.00007563725],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977357,0.0010199685,0.000776805,0.00012507808,0.00008831961,0.00025412618],"domain_scores_gemma":[0.99725956,0.0013217309,0.00076104497,0.00040387452,0.00022801194,0.000025767595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012473798,0.00018071968,0.0007710871,0.00007294739,0.00021217414,0.000011033293,0.0003251923,0.00017666142,0.00020555136],"category_scores_gemma":[0.00028517487,0.000097010605,0.00029559495,0.000093385046,0.00045758073,0.00016575861,0.000086016036,0.00024917026,0.000035652512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014004894,0.00051360135,0.39515275,0.00012591478,0.039149914,0.00020090704,0.032386556,0.000084334584,0.009884706,0.0014398124,0.115609206,0.4040518],"study_design_scores_gemma":[0.027901715,0.0022110103,0.53168595,0.0022807429,0.012199868,0.19283128,0.07036483,0.000019267989,0.02968694,0.024793427,0.104329914,0.0016950734],"about_ca_topic_score_codex":0.0037661104,"about_ca_topic_score_gemma":0.00015691972,"teacher_disagreement_score":0.40235674,"about_ca_system_score_codex":0.000011500817,"about_ca_system_score_gemma":0.000063262814,"threshold_uncertainty_score":0.56932575},"labels":[],"label_agreement":null},{"id":"W2074687456","doi":"10.1159/000095037","title":"A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis","year":2006,"lang":"en","type":"review","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Population; Skin cancer; Placebo; Dermatology; Internal medicine; Clinical trial; Malignancy; Cancer; Gastroenterology; Plaque psoriasis; Pathology","score_opus":0.2664707127899108,"score_gpt":0.4162623924972009,"score_spread":0.14979167970729007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074687456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010894943,0.99185103,0.000045698,0.00011036027,0.002773783,0.003322454,0.0014635584,0.000106551524,0.0002176276],"genre_scores_gemma":[0.000017639859,0.9932219,0.00024605545,0.00013394673,0.00021359006,0.0015438278,0.0036144531,0.000094137125,0.0009144611],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9870318,0.0061251773,0.005143929,0.0008949821,0.000056217472,0.0007478976],"domain_scores_gemma":[0.98993057,0.005604571,0.0032735434,0.00092717435,0.00021246319,0.000051684732],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022843692,0.00088742236,0.01103491,0.0003289661,0.00017551854,0.000009766629,0.00068496325,0.0022142725,0.0002523838],"category_scores_gemma":[0.0020724474,0.0006653215,0.0041815094,0.00032347807,0.00032257117,0.00006120017,0.00015348983,0.00042488362,0.0002632593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031651263,0.000431641,0.00007554475,0.26955444,0.005359097,0.00008117768,0.000020570356,3.554036e-8,0.00003588587,0.001064376,0.060823463,0.6622373],"study_design_scores_gemma":[0.0031183162,0.00011345144,0.000029149869,0.050147142,0.008613247,0.0013188178,0.0000059197587,4.908771e-8,0.00036127184,0.000048155827,0.93572605,0.00051841454],"about_ca_topic_score_codex":0.000029667393,"about_ca_topic_score_gemma":0.000016291622,"teacher_disagreement_score":0.8749026,"about_ca_system_score_codex":0.000073389936,"about_ca_system_score_gemma":0.00060354406,"threshold_uncertainty_score":0.9995798},"labels":[],"label_agreement":null},{"id":"W2075016651","doi":"10.1159/000066440","title":"A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet&lt;sup&gt;TM&lt;/sup&gt;) Is an Effective Once-Daily Treatment for Psoriasis vulgaris","year":2002,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Calcipotriol; Betamethasone dipropionate; Betamethasone; Medicine; Psoriasis; Dermatology; Corticosteroid; Combination therapy; Adverse effect; Pharmacology; Surgery; Internal medicine","score_opus":0.02767437267886239,"score_gpt":0.26313999789651094,"score_spread":0.23546562521764855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075016651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771232,0.010763443,0.00425616,0.0015305879,0.001351008,0.0027866277,0.00055894646,0.0003919337,0.0012381142],"genre_scores_gemma":[0.9878493,0.00076119875,0.0018979837,0.00043896885,0.00025409518,0.0014353782,0.0011106658,0.0001012441,0.0061511765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621516,0.00066647615,0.0007716598,0.0011014953,0.00010387729,0.0011413258],"domain_scores_gemma":[0.9976143,0.00084631215,0.00035829033,0.0008164253,0.00018793375,0.00017668582],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016659059,0.0007859626,0.0012772394,0.00042623805,0.00063883397,0.000046430167,0.0003778683,0.0011156261,0.001654222],"category_scores_gemma":[0.00010773245,0.0006699568,0.0005518101,0.00038870279,0.00016325011,0.00037618424,0.00008174546,0.0002220907,0.0014507361],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029563664,0.0024977755,0.010101011,0.00014107193,0.0054090945,0.00021422248,0.016311575,0.00009204989,0.05560828,0.004975715,0.03869789,0.86299497],"study_design_scores_gemma":[0.03609023,0.004557076,0.011539661,0.00008814286,0.0031841306,0.0018111744,0.0003823281,0.002069181,0.33235034,0.0022774986,0.6037193,0.0019309269],"about_ca_topic_score_codex":0.0002998341,"about_ca_topic_score_gemma":0.00023589822,"teacher_disagreement_score":0.861064,"about_ca_system_score_codex":0.0003195228,"about_ca_system_score_gemma":0.00010369009,"threshold_uncertainty_score":0.99957514},"labels":[],"label_agreement":null},{"id":"W2075382650","doi":"10.1016/j.jaad.2009.08.040","title":"Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Guenther Dermatology Research Centre; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"","keywords":"Adalimumab; Medicine; Etanercept; Adverse effect; Confidence interval; Internal medicine; Psoriasis; Surgery; Gastroenterology; Dermatology; Tumor necrosis factor alpha","score_opus":0.00841022388969352,"score_gpt":0.2526636037709236,"score_spread":0.2442533798812301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075382650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968708,0.00014180614,0.000008090235,0.0025393902,0.00014771284,0.00021491648,0.00004958065,0.00000432351,0.000023376058],"genre_scores_gemma":[0.9992421,0.00006586808,0.00035738762,0.00026674493,0.0000148090885,0.0000025655115,0.0000024371625,0.000015749463,0.00003231658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978832,0.00092506805,0.00066953385,0.00017657207,0.00009090278,0.0002547427],"domain_scores_gemma":[0.99803513,0.0005712674,0.0010591435,0.00019923405,0.00007241666,0.0000628062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003012784,0.00019370158,0.00083674904,0.00032321346,0.00006316269,0.000003167197,0.00040394155,0.00021366813,0.000040172035],"category_scores_gemma":[0.000164186,0.00012303381,0.00009352799,0.00022111317,0.0007246633,0.00010591648,0.000079352,0.0005748686,0.000002608933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041127693,0.00036470493,0.83195466,0.000013010309,0.00045745613,0.000009853857,0.0017682913,0.000020819018,0.10308415,0.00006457368,0.0003753436,0.020759426],"study_design_scores_gemma":[0.0058002863,0.00086396665,0.9626384,0.000053995893,0.00014407089,0.00041879085,0.00024924063,6.66572e-7,0.027973717,0.000022265915,0.0017098569,0.00012479317],"about_ca_topic_score_codex":0.000046127556,"about_ca_topic_score_gemma":0.000050594652,"teacher_disagreement_score":0.13068366,"about_ca_system_score_codex":0.000028169521,"about_ca_system_score_gemma":0.000100462144,"threshold_uncertainty_score":0.50171727},"labels":[],"label_agreement":null},{"id":"W207589287","doi":"","title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Observational study; Psoriatic arthritis; Adverse effect; Disease registry; Overweight; Internal medicine; Epidemiology; Myocardial infarction; Etanercept; Disease; Body mass index; Dermatology; Rheumatoid arthritis","score_opus":0.04204460406498329,"score_gpt":0.24570346073847946,"score_spread":0.20365885667349617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W207589287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893938,0.0023637807,0.00015199737,0.000051810293,0.0004372599,0.0025529645,0.004976594,0.0000338306,0.000038009257],"genre_scores_gemma":[0.9945839,0.0001514491,0.0001788813,0.000014059145,0.000027303973,0.0022369388,0.0011117836,0.00001779529,0.0016778971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985599,0.00022669496,0.00042072323,0.0003654604,0.000082104554,0.0003451172],"domain_scores_gemma":[0.9983042,0.00037336638,0.0007409237,0.00028274502,0.00022769585,0.00007105361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028956603,0.00024487413,0.00044721438,0.00012606841,0.00010406987,0.000009670397,0.00017870021,0.00016042995,0.000046078545],"category_scores_gemma":[0.0004698204,0.00015250556,0.00009602978,0.00012312747,0.00019327085,0.00013380805,0.000052549916,0.000052766085,0.0000020597008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058141135,0.0013426298,0.9329839,0.00021872461,0.0011757701,0.0000036070473,0.00009717928,0.000002450556,0.000030162364,0.000008999825,0.0012029256,0.004792553],"study_design_scores_gemma":[0.0119137345,0.00060384365,0.9829246,0.000271225,0.00056788715,0.000006537778,0.00010222404,0.0000063317916,0.00307544,0.000020560406,0.00034250904,0.00016513508],"about_ca_topic_score_codex":0.00002680152,"about_ca_topic_score_gemma":0.000019150817,"teacher_disagreement_score":0.04994071,"about_ca_system_score_codex":0.000097188895,"about_ca_system_score_gemma":0.000069746486,"threshold_uncertainty_score":0.6218996},"labels":[],"label_agreement":null},{"id":"W2076138863","doi":"10.1074/jbc.m110.112599","title":"Interleukin-27 Induces a STAT1/3- and NF-κB-dependent Proinflammatory Cytokine Profile in Human Monocytes","year":2010,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Universiti Sains Malaysia","keywords":"Chemokine; Proinflammatory cytokine; Cytokine; Cell biology; Monocyte; Innate immune system; Acquired immune system; Immunology; NF-κB; Immune system; Biology; Signal transduction; Inflammation","score_opus":0.020842581186734505,"score_gpt":0.25274599810200593,"score_spread":0.23190341691527142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076138863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975027,0.0012930679,0.000001427038,0.000083147585,0.00025258848,0.000099017,0.000023462835,0.000016948108,0.00072766014],"genre_scores_gemma":[0.998943,0.00011913636,0.00012798385,0.000019860483,0.00013436776,0.000009630339,0.000026316033,0.000007795712,0.00061195873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893826,0.00007324545,0.00048799845,0.00020930558,0.000041012314,0.0002501735],"domain_scores_gemma":[0.99932253,0.000106502666,0.000325524,0.000131223,0.00006329421,0.000050932646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003725247,0.00019150606,0.00037957955,0.000057527122,0.000066602726,0.00001835395,0.0002235056,0.00044514646,0.00062068435],"category_scores_gemma":[0.00012873343,0.0001252037,0.000095022486,0.000059027363,0.00020260176,0.00007219589,0.000091033115,0.00067913684,0.000015922134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024801248,0.0001972793,0.03315737,0.000022199778,0.00009234729,0.000090053414,0.00013265468,1.6158623e-7,0.9612996,0.000016399974,0.00009527033,0.0046486743],"study_design_scores_gemma":[0.0016112829,0.00026407038,0.024615932,0.000041730098,0.000028402896,0.00051970215,0.00022825073,2.289639e-7,0.97079486,0.00021931426,0.0015277262,0.0001485242],"about_ca_topic_score_codex":0.0000066305815,"about_ca_topic_score_gemma":0.000007720215,"teacher_disagreement_score":0.009495258,"about_ca_system_score_codex":0.000044289816,"about_ca_system_score_gemma":0.00007140574,"threshold_uncertainty_score":0.67960584},"labels":[],"label_agreement":null},{"id":"W2076285889","doi":"10.1159/000198155","title":"Fine Structural Changes in the Liver of Methotrexate-Treated Psoriatics","year":2009,"lang":"en","type":"article","venue":"Digestion","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; St. Michael's Hospital","funders":"","keywords":"Pleomorphism (cytology); Pathology; Ultrastructure; Colchicine; Hyperplasia; Microfilament; Gigantism; Cytoplasm; Methotrexate; Glycogen; Biopsy; Cytoplasmic inclusion; Biology; Cell; Internal medicine; Medicine; Endocrinology; Biochemistry; Immunohistochemistry; Cytoskeleton","score_opus":0.021953718985654427,"score_gpt":0.25542466436154276,"score_spread":0.23347094537588833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076285889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737966,0.0015885833,0.00000976111,0.00033888267,0.00015728206,0.00013844081,0.000019114494,0.000019027208,0.0003492427],"genre_scores_gemma":[0.9993544,0.0001183835,0.000073201634,0.00004177323,0.000024612644,0.0000063208304,0.00018337293,0.0000030312374,0.00019487855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994422,0.0001929491,0.00011500053,0.000100600446,0.000023363922,0.00012586574],"domain_scores_gemma":[0.9996644,0.000105147985,0.00006855582,0.00013126887,0.00002599135,0.000004591962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013587734,0.000090043824,0.00013430936,0.00006808316,0.000043886565,0.000003924679,0.00009036175,0.00011031751,0.00007181166],"category_scores_gemma":[0.00004071978,0.0000567165,0.0000328314,0.00014636737,0.000029132922,0.000032570424,0.000005977567,0.00006446713,0.000024778958],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005204052,0.00029098164,0.062020704,0.000018679135,0.00015289392,0.000026479365,0.0052143885,0.000037582704,0.27906924,0.005898372,0.00048736262,0.6462629],"study_design_scores_gemma":[0.00089613616,0.0002958959,0.8701399,0.000020517433,0.00008756215,0.000016276317,0.00008090733,0.000011707917,0.12731327,0.0004787011,0.00057507795,0.00008406268],"about_ca_topic_score_codex":0.0001033153,"about_ca_topic_score_gemma":0.000210524,"teacher_disagreement_score":0.8081192,"about_ca_system_score_codex":0.000014131873,"about_ca_system_score_gemma":0.0000068674713,"threshold_uncertainty_score":0.23128319},"labels":[],"label_agreement":null},{"id":"W2077277924","doi":"10.1016/j.jaad.2005.10.061","title":"A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis","year":2006,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Body surface area; Internal medicine; Calcineurin; Creatinine; Renal function; Plaque psoriasis; Randomized controlled trial; Clinical endpoint; Gastroenterology; Adverse effect; Urology; Dermatology; Pathology; Transplantation","score_opus":0.013288853269379763,"score_gpt":0.27992318773841834,"score_spread":0.26663433446903856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077277924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490523,0.0017839414,0.000026911815,0.001194901,0.00046359547,0.00151057,0.000025121286,0.0000063100733,0.0000833936],"genre_scores_gemma":[0.9993145,0.00028099996,0.000108655506,0.000073827636,0.000075662334,0.00005372532,0.000008894022,0.000018438615,0.00006529865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99631894,0.0013567035,0.0016433722,0.00018513424,0.00013581668,0.0003600084],"domain_scores_gemma":[0.99487764,0.00089846854,0.003924804,0.00017209914,0.00009841335,0.000028589282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048217614,0.00027786614,0.0024844883,0.00042435597,0.00005908815,0.0000043703963,0.00050589466,0.00022480557,0.000040239294],"category_scores_gemma":[0.0000991563,0.00015790427,0.0006094276,0.00032444505,0.0009683418,0.00010850994,0.000058263762,0.00045977873,0.0000062378476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9831007,0.0018133649,0.0088200765,0.000020172749,0.0015586058,0.000007582254,0.00012940243,0.000045720804,0.0024765285,0.00010292406,0.00027863178,0.0016462993],"study_design_scores_gemma":[0.97377807,0.0009820175,0.00201567,0.00008042054,0.0010289652,0.00015370069,0.000042324842,0.0000066051966,0.02115619,0.000049597376,0.00056785427,0.0001385556],"about_ca_topic_score_codex":0.00014439574,"about_ca_topic_score_gemma":0.000021354757,"teacher_disagreement_score":0.018679662,"about_ca_system_score_codex":0.000083259925,"about_ca_system_score_gemma":0.00017858502,"threshold_uncertainty_score":0.64391494},"labels":[],"label_agreement":null},{"id":"W2078226469","doi":"10.1111/bjd.12517","title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","year":2013,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Janus kinase inhibitor; Medicine; Psoriasis; Placebo; Internal medicine; Gastroenterology; Ruxolitinib; Hematology; Pharmacology; Immunology; Myelofibrosis; Bone marrow; Pathology; Rheumatoid arthritis","score_opus":0.011939957086453021,"score_gpt":0.2302836348210307,"score_spread":0.2183436777345777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078226469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374014,0.0045559243,0.000009677275,0.00015017,0.00078755,0.0003768523,0.00007977103,0.000018635574,0.00028130476],"genre_scores_gemma":[0.99889344,0.00073067617,0.0001491212,0.00002151412,0.000028963777,0.000041701616,0.000025998925,0.000019156665,0.00008940192],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721384,0.0009762974,0.0010485755,0.00024657857,0.00008682569,0.0004279038],"domain_scores_gemma":[0.99799824,0.00076870224,0.0008033275,0.00021751037,0.00013853634,0.00007366821],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016424041,0.00029903906,0.0013979711,0.0002633672,0.00010545466,0.000014331819,0.00024042338,0.00043720967,0.00038743883],"category_scores_gemma":[0.0002191738,0.00024795267,0.000532602,0.000117102005,0.000320474,0.00012411285,0.00004535522,0.00024235435,0.000078306635],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008749991,0.004225218,0.16961624,0.00064380234,0.0058457684,0.012234636,0.0009659757,0.00003251017,0.2640868,0.00019877026,0.0032054568,0.5301948],"study_design_scores_gemma":[0.011271937,0.003654425,0.02483693,0.00035803928,0.00044827157,0.055176653,0.00011040648,8.7713175e-7,0.9034882,0.000061012423,0.0003861954,0.0002070267],"about_ca_topic_score_codex":0.00018537998,"about_ca_topic_score_gemma":0.00001762435,"teacher_disagreement_score":0.63940144,"about_ca_system_score_codex":0.000056232093,"about_ca_system_score_gemma":0.00006096682,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W2078488737","doi":"10.4137/cmped.s8045","title":"Treatment of Childhood Psoriasis with Phototherapy and Photochemotherapy","year":2013,"lang":"en","type":"article","venue":"Clinical Medicine Insights Pediatrics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Psoriasis; Modalities; Medicine; Treatment modality; Therapeutic modalities; Dermatology; Pediatrics; Surgery; Physical therapy","score_opus":0.025847450157466798,"score_gpt":0.28871011134988217,"score_spread":0.26286266119241536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078488737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97961646,0.017103244,0.000036359084,0.0005427625,0.00070300075,0.00086217077,0.000010009549,0.000056778437,0.0010691866],"genre_scores_gemma":[0.9666431,0.030965105,0.0003822096,0.00032280345,0.0006657772,0.00013189724,0.00005403539,0.0000342067,0.0008008526],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983597,0.00018050047,0.00069167005,0.0004303891,0.00007416491,0.0002635993],"domain_scores_gemma":[0.9980593,0.0010227337,0.00030536173,0.00039076948,0.00013065278,0.00009118479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010760176,0.00031138293,0.0008076997,0.00015882925,0.00009357003,0.0000061665974,0.00013066363,0.00032984602,0.00076373015],"category_scores_gemma":[0.00007814689,0.00016777916,0.00011810496,0.00026179847,0.00052969885,0.00007087346,0.0000139957965,0.000120636425,0.00009166514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001214304,0.0042713755,0.2322714,0.00005595056,0.001647957,0.000029458057,0.00627245,4.9683945e-7,0.0085529275,0.0003040629,0.0048414213,0.7405382],"study_design_scores_gemma":[0.08545738,0.049698934,0.7207513,0.0001330336,0.002574492,0.00021003795,0.0016031227,0.0000098037635,0.038687762,0.0021297196,0.09750206,0.0012423521],"about_ca_topic_score_codex":0.00019484377,"about_ca_topic_score_gemma":0.000015895543,"teacher_disagreement_score":0.73929584,"about_ca_system_score_codex":0.000021880482,"about_ca_system_score_gemma":0.00007546361,"threshold_uncertainty_score":0.836231},"labels":[],"label_agreement":null},{"id":"W2078674248","doi":"10.2310/7750.2014.14038","title":"Interleukin-17 Antagonists in the Treatment of Psoriasis","year":2015,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriasis; Dermatology; Interleukin; Interleukin 17; Immunology; Cytokine","score_opus":0.07979066944694684,"score_gpt":0.32904698960807605,"score_spread":0.2492563201611292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078674248","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004963134,0.99263024,6.173167e-7,0.00019244815,0.0016028603,0.00022320537,0.000026480717,0.000003917137,0.00035712196],"genre_scores_gemma":[0.0010194785,0.99784034,0.000007109539,0.00004688689,0.00041216201,0.000009206305,0.00006487957,0.000019325556,0.0005805893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973345,0.0007033323,0.0014225767,0.00017422785,0.00011799719,0.00024741393],"domain_scores_gemma":[0.9958098,0.002544254,0.0012212151,0.00025922156,0.000120238656,0.000045283785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000992204,0.00038352673,0.0032909978,0.0005942171,0.00004529266,0.000007092903,0.00020667596,0.00034881575,0.00010633428],"category_scores_gemma":[0.00014185483,0.0001760925,0.0006113474,0.00024285312,0.00022687133,0.000034501023,0.000012091249,0.00024395183,0.000009501901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020090633,0.0003216567,0.00013456083,0.00066340377,0.00096576643,0.0017385841,0.0016004473,6.0191205e-8,0.000006989086,0.0000060782395,0.019839019,0.97452253],"study_design_scores_gemma":[0.00074185774,0.0014115984,0.000010662799,0.004760129,0.0025378515,0.021709621,0.00048097823,2.6801965e-8,0.000009302247,0.000030161716,0.9681746,0.00013323457],"about_ca_topic_score_codex":0.00004844533,"about_ca_topic_score_gemma":0.000018677481,"teacher_disagreement_score":0.9743893,"about_ca_system_score_codex":0.00011396039,"about_ca_system_score_gemma":0.0003897951,"threshold_uncertainty_score":0.71808434},"labels":[],"label_agreement":null},{"id":"W2078817323","doi":"10.3899/jrheum.120257","title":"The Inhibitor of Costimulation of T Cells: Abatacept","year":2012,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Abatacept; CD80; Medicine; Psoriasis; CD28; Immunology; T cell; Inflammation; Immune system; Arthritis; Psoriatic arthritis; Cytotoxic T cell; Cancer research; CD40; Rituximab; Antibody; Biology","score_opus":0.035617001673973234,"score_gpt":0.2985976284885972,"score_spread":0.262980626814624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078817323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014200417,0.9942289,0.000037846115,0.00005628201,0.0035563817,0.0004012005,0.0002646397,0.0000040280734,0.000030651645],"genre_scores_gemma":[0.007988931,0.99138165,0.00019813709,0.0000023450862,0.000034666635,0.000016673619,0.00018489617,0.000024399777,0.00016832056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964793,0.00074106525,0.002198039,0.00014167589,0.00009661148,0.00034332552],"domain_scores_gemma":[0.99437386,0.0012217353,0.0038136048,0.00033552074,0.0002219862,0.000033274886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009844609,0.00032890827,0.0021228667,0.00026383903,0.00011276228,0.0000048225706,0.00044402422,0.00048325452,0.0006393342],"category_scores_gemma":[0.00006276088,0.00018992556,0.00078715116,0.00014049294,0.00023896387,0.000067551795,0.00010074937,0.0003364506,0.0000612299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002168669,0.00042648832,0.0013901378,0.0033406748,0.0045086322,0.0000047572203,0.00033120712,0.0000017709417,0.00021378456,0.0006275793,0.014770432,0.97416764],"study_design_scores_gemma":[0.0012311727,0.00036229135,0.000027941083,0.0020597808,0.0027001153,0.00061395613,0.000117267424,1.0615098e-7,0.0017238996,0.000021959997,0.990999,0.00014252382],"about_ca_topic_score_codex":0.000021725371,"about_ca_topic_score_gemma":0.000016007247,"teacher_disagreement_score":0.97622854,"about_ca_system_score_codex":0.00008160822,"about_ca_system_score_gemma":0.00028992273,"threshold_uncertainty_score":0.77449393},"labels":[],"label_agreement":null},{"id":"W2079077914","doi":"10.1111/j.1572-0241.2007.01660.x","title":"<i>ATG16L1</i>and<i>IL23R</i>Are Associated With Inflammatory Bowel Diseases but Not With Celiac Disease in The Netherlands","year":2008,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"","keywords":"ATG16L1; Medicine; Inflammatory bowel disease; Odds ratio; Single-nucleotide polymorphism; Ulcerative colitis; Crohn's disease; Gastroenterology; Case-control study; Internal medicine; Allele; Immunology; Disease; Genotype; Genetics; Gene; Biology","score_opus":0.007850727638738553,"score_gpt":0.1953497742131483,"score_spread":0.18749904657440974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079077914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967921,0.0008953706,0.00003620095,0.0019530277,0.00009227927,0.00014574481,0.00006292621,0.000013189025,0.000009187049],"genre_scores_gemma":[0.99761844,0.00043490666,0.00001620378,0.0017395633,0.0000641853,0.000019844232,0.000015991145,0.000019901041,0.00007097566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978265,0.0011374496,0.00033264584,0.00017905638,0.00010059833,0.0004237576],"domain_scores_gemma":[0.99846786,0.00033381933,0.0007748216,0.00026960007,0.00008561063,0.00006827247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157734,0.00024221145,0.00054267957,0.000116719435,0.00021718912,0.000010940138,0.0003988648,0.00003910383,0.000015761821],"category_scores_gemma":[0.000045681758,0.00011170246,0.0001056369,0.0001404086,0.0013726243,0.00008127193,0.000041442596,0.00035337717,0.0000058324094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027936142,0.000252044,0.96859276,0.0000034029445,0.0005417645,0.0006062125,0.0008319765,0.00007468459,0.00038659998,0.000004340895,0.00037826732,0.00039179958],"study_design_scores_gemma":[0.0035962823,0.0057642125,0.98756754,0.000059777594,0.0003887742,0.0013551954,0.0008672861,0.0000022479687,0.00006578089,0.000011809949,0.00022763383,0.00009347927],"about_ca_topic_score_codex":0.000033206088,"about_ca_topic_score_gemma":0.00014224555,"teacher_disagreement_score":0.024339858,"about_ca_system_score_codex":0.00003306412,"about_ca_system_score_gemma":0.000082699866,"threshold_uncertainty_score":0.5057491},"labels":[],"label_agreement":null},{"id":"W2079101710","doi":"10.1111/j.1365-2133.2009.09116.x","title":"Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial","year":2009,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"LEO Pharma","keywords":"Calcipotriol; Scalp; Medicine; Betamethasone; Betamethasone dipropionate; Dermatology; Adverse effect; Randomized controlled trial; Psoriasis; Randomization; Surgery; Internal medicine","score_opus":0.014460332997114416,"score_gpt":0.25436953819956776,"score_spread":0.23990920520245335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079101710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741073,0.021176336,0.0006560565,0.00051362626,0.00032493993,0.003105537,0.000031690826,0.000010548353,0.00007393025],"genre_scores_gemma":[0.9958484,0.0036443705,0.00024999963,0.00003140347,0.00005551815,0.000080703794,0.000055061497,0.0000112789485,0.000023234443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952731,0.0021596197,0.0018373372,0.0002317838,0.00014472965,0.00035343596],"domain_scores_gemma":[0.99630004,0.0018191801,0.0014096156,0.00018049,0.0002461574,0.000044492703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008310759,0.00028537196,0.002973653,0.00031835496,0.00015605036,0.000018091183,0.00019644904,0.00033563864,0.000026808077],"category_scores_gemma":[0.0002904189,0.00018372638,0.0004952486,0.00024314696,0.00036581114,0.00013739931,0.000012904943,0.0002095008,0.0000017952209],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93851185,0.0018689777,0.00038471314,0.000018848043,0.0012748427,0.00020306773,0.0013486884,0.00005826886,0.002296017,0.00018150646,0.00005026886,0.053802926],"study_design_scores_gemma":[0.9702832,0.0026847597,0.014372439,0.00025794748,0.0016824603,0.006638624,0.00019517375,0.000112057256,0.003293,0.00017945285,0.00012873737,0.00017211722],"about_ca_topic_score_codex":0.00016441486,"about_ca_topic_score_gemma":0.000118376905,"teacher_disagreement_score":0.05363081,"about_ca_system_score_codex":0.00009021144,"about_ca_system_score_gemma":0.00019092031,"threshold_uncertainty_score":0.7492144},"labels":[],"label_agreement":null},{"id":"W2079525680","doi":"10.1067/mjd.2000.108320","title":"Tazarotene combination treatments in psoriasis","year":2000,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Tazarotene; Medicine; Tolerability; Psoriasis; Dermatology; Clinical efficacy; Plaque psoriasis; Potency; Combination therapy; Clinical trial; Adjunctive treatment; Pharmacology; Adverse effect; Surgery; Internal medicine","score_opus":0.03183543854003123,"score_gpt":0.3219527245661909,"score_spread":0.29011728602615966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079525680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014894023,0.98329264,0.0000011053977,0.00068150554,0.00051451,0.00036177042,0.000054506974,0.0000075583644,0.00019237176],"genre_scores_gemma":[0.007917222,0.9914761,0.00005906247,0.000099540746,0.000042515825,0.000021016313,0.000018825065,0.000032489246,0.0003331899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610084,0.0016343391,0.0015869413,0.00022773261,0.00008992006,0.00036024902],"domain_scores_gemma":[0.9953677,0.0004445751,0.003910273,0.00021355471,0.00003252778,0.000031355372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019168363,0.0004180419,0.0033055726,0.0006725094,0.000069690934,0.0000046352657,0.0008850048,0.00054009253,0.00009746119],"category_scores_gemma":[0.000060185837,0.00025457994,0.0010378344,0.0006785668,0.0005145266,0.00007967253,0.000082076695,0.0008163703,0.000080260164],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016488846,0.000359858,0.00062058214,0.00037034944,0.0017490195,0.000034734672,0.00006650724,8.9796805e-7,0.000048354184,0.00006357797,0.0013993869,0.99512184],"study_design_scores_gemma":[0.0024817844,0.00023425724,0.0021857787,0.0025075492,0.0037058,0.009280253,0.000037702528,1.571546e-7,0.00062739203,0.00022864665,0.97842646,0.00028419695],"about_ca_topic_score_codex":0.000026787196,"about_ca_topic_score_gemma":0.0000016954378,"teacher_disagreement_score":0.99483764,"about_ca_system_score_codex":0.00016050349,"about_ca_system_score_gemma":0.00024542637,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W2080126086","doi":"10.3899/jrheum.130451","title":"GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venerology Meeting, Verona, 2012: A Meeting Report","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Psoriatic arthritis; Plaque psoriasis; Presentation (obstetrics); Family medicine; Library science; Surgery","score_opus":0.013624631692496975,"score_gpt":0.23083844896832456,"score_spread":0.2172138172758276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080126086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718096,0.011153856,0.00008347711,0.014703198,0.0007468778,0.00029224722,0.0000046646487,0.000017134606,0.0011889136],"genre_scores_gemma":[0.99656886,0.0025462105,0.00016570221,0.0003504278,0.000020117623,0.000011482369,0.000004713885,0.00002645285,0.00030601872],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99570394,0.0024459949,0.0010806789,0.00021025857,0.00007248407,0.000486619],"domain_scores_gemma":[0.9974966,0.0008492443,0.0011593791,0.0002923484,0.00013855036,0.000063887775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016710636,0.00025381852,0.0007265077,0.0001805583,0.00027001853,0.000009322918,0.0006238206,0.0002522024,0.0001151695],"category_scores_gemma":[0.00020768338,0.00014163354,0.0001528812,0.00014629983,0.0004610474,0.00009368528,0.00025948766,0.00044472225,0.00019620964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019736877,0.00055205746,0.54524875,0.00017142498,0.0049148486,0.0002748799,0.0112155145,0.00066532195,0.27197674,0.0022470106,0.13211422,0.02864554],"study_design_scores_gemma":[0.010304592,0.0015693188,0.15614876,0.0007563236,0.0027580387,0.52260286,0.0039547733,0.0000449221,0.059259247,0.0029759654,0.23845787,0.0011673181],"about_ca_topic_score_codex":0.0002779752,"about_ca_topic_score_gemma":0.000057465866,"teacher_disagreement_score":0.52232796,"about_ca_system_score_codex":0.000020754627,"about_ca_system_score_gemma":0.00005067638,"threshold_uncertainty_score":0.5775648},"labels":[],"label_agreement":null},{"id":"W2080237150","doi":"10.1111/bjd.13814","title":"Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Dosing; Randomized controlled trial; Interleukin 17; Internal medicine; Dermatology; Cytokine; Psoriatic arthritis","score_opus":0.01857271942566301,"score_gpt":0.2995247510734746,"score_spread":0.2809520316478116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080237150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98219603,0.008200681,0.0001798582,0.0033727784,0.003935269,0.0019198545,0.000059720838,0.000016484433,0.00011932333],"genre_scores_gemma":[0.9987035,0.00031366138,0.000121516365,0.00016543832,0.00020082157,0.0001990613,0.000028073408,0.000022850347,0.00024510827],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98767424,0.009109713,0.0021087164,0.00035081897,0.00014196453,0.00061457884],"domain_scores_gemma":[0.996177,0.002338327,0.0009104038,0.00025280277,0.00020821829,0.00011325566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004428375,0.00031882472,0.0022379872,0.00057222164,0.00013833266,0.00011138695,0.0003299927,0.0004422373,0.000029018096],"category_scores_gemma":[0.004150757,0.00023065764,0.00057462096,0.00030926144,0.0002293701,0.00022940725,0.00005082356,0.00048176755,0.000028809996],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9636871,0.0010894039,0.000029679606,0.000002326483,0.00070135423,0.0076218285,0.0016224318,0.00007562303,0.003769846,0.000017068418,0.0011478766,0.020235466],"study_design_scores_gemma":[0.9704822,0.0017520977,0.00022422538,0.00010489027,0.00047198447,0.018297533,0.0016051459,0.000028881715,0.004534053,0.00015786766,0.0021261664,0.00021498486],"about_ca_topic_score_codex":0.0002861259,"about_ca_topic_score_gemma":0.00029631273,"teacher_disagreement_score":0.020020481,"about_ca_system_score_codex":0.0002900097,"about_ca_system_score_gemma":0.0010200525,"threshold_uncertainty_score":0.94059455},"labels":[],"label_agreement":null},{"id":"W2080248549","doi":"10.1111/j.1572-0241.2007.01661.x","title":"Association Between Genetic Variants in the<i>IL</i>-<i>23R</i>Gene and Early-Onset Crohn's Disease: Results From a Case-Control and Family-Based Study Among Canadian Children","year":2008,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill Genome Centre; British Columbia Children's Hospital; Children's Hospital of Eastern Ontario; McGill University Health Centre; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Single-nucleotide polymorphism; SNP; Case-control study; Medicine; Genetic association; Genetics; Logistic regression; Genotype; Transmission disequilibrium test; Linkage disequilibrium; Gene; Odds ratio; Biology; Internal medicine","score_opus":0.008123531101491705,"score_gpt":0.2030071832296586,"score_spread":0.1948836521281669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080248549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968751,0.00061088474,0.000023343768,0.0009030223,0.00010578918,0.00035052223,0.0011241455,0.000005410443,0.0000017650021],"genre_scores_gemma":[0.999097,0.00010320358,0.000051034363,0.00060166384,0.00008574951,0.000012650196,0.000027068858,0.000013153137,0.000008471948],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965725,0.00219676,0.00049053656,0.00023482114,0.00007351525,0.00043185183],"domain_scores_gemma":[0.99820226,0.0005890978,0.00079859706,0.00024990243,0.000054064032,0.00010605636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007314226,0.00020292735,0.00057155034,0.00020077075,0.0002770431,0.000019409106,0.0002576716,0.00006126627,0.000004321039],"category_scores_gemma":[0.00010671932,0.000133023,0.00008042546,0.0001238683,0.00034847454,0.000053669606,0.000025955625,0.0003116745,0.0000031093316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044887364,0.00011120912,0.99020344,3.7490327e-7,0.00094318687,0.0018414664,0.0010691951,0.000014352004,0.00009009014,4.886916e-8,0.00011320491,0.001124667],"study_design_scores_gemma":[0.0067700557,0.0027480894,0.98824257,0.000008662908,0.0007877854,0.0010489636,0.00029038917,0.000002585456,0.0000053845224,0.000010168017,0.000010033283,0.00007534096],"about_ca_topic_score_codex":0.049267646,"about_ca_topic_score_gemma":0.022067316,"teacher_disagreement_score":0.027200328,"about_ca_system_score_codex":0.00007177166,"about_ca_system_score_gemma":0.00009672163,"threshold_uncertainty_score":0.9957774},"labels":[],"label_agreement":null},{"id":"W2080445759","doi":"10.1016/j.jval.2012.08.1361","title":"PMS6 Anti-Tumour Necrosis Factor (TNF) Drugs for the Treatment of Psoriatic Arthritis (PsA)","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Golimumab; Adalimumab; Medicine; Psoriatic arthritis; Etanercept; Infliximab; Internal medicine; Psoriasis; Oncology; Psoriasis Area and Severity Index; Meta-analysis; Tumor necrosis factor alpha; Rheumatoid arthritis; Physical therapy; Dermatology","score_opus":0.04878508233628078,"score_gpt":0.28875065714799253,"score_spread":0.23996557481171174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080445759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92922926,0.06638049,0.00007328674,0.00076838804,0.0019831893,0.0011021429,0.00037892733,0.000032094344,0.00005224431],"genre_scores_gemma":[0.98574436,0.0131164305,0.00027284925,0.00008956094,0.00013414997,0.00022893408,0.00007640573,0.00002164118,0.00031568506],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834824,0.00031706027,0.00047512894,0.00020723758,0.00004194337,0.00061037706],"domain_scores_gemma":[0.99857587,0.0008346778,0.0002230146,0.00029076106,0.000028316506,0.000047339792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035919354,0.0002065713,0.0004892883,0.00010035042,0.00021040336,0.000006750559,0.00012916545,0.00014569737,0.00014655537],"category_scores_gemma":[0.000038251495,0.00013905749,0.00018146158,0.00015342681,0.00007333049,0.00006855379,0.000013605185,0.00006359437,0.000077048295],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004378159,0.0032735202,0.07440105,0.00023745983,0.00078347087,0.0000020261807,0.024682898,0.0001729623,0.0074053486,0.0022309106,0.0013056172,0.8850669],"study_design_scores_gemma":[0.025405321,0.0064034495,0.65311277,0.000528039,0.00045903798,0.00007358182,0.0029065346,0.00019596175,0.13539058,0.00075714826,0.17381047,0.00095712236],"about_ca_topic_score_codex":0.0034155163,"about_ca_topic_score_gemma":0.00007059838,"teacher_disagreement_score":0.8841098,"about_ca_system_score_codex":0.00016602689,"about_ca_system_score_gemma":0.00012778625,"threshold_uncertainty_score":0.56706},"labels":[],"label_agreement":null},{"id":"W2080564104","doi":"10.1177/12034754020060s302","title":"Pathophysiology of Psoriasis: Science behind Therapy","year":2002,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Psoriasis; Pathophysiology; Dermatology; Pathology","score_opus":0.06307052042947793,"score_gpt":0.303484449103759,"score_spread":0.24041392867428107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080564104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052521033,0.9916343,0.0000013899868,0.00007212207,0.0026224882,0.00015547093,0.000017533786,0.000007693127,0.00023687676],"genre_scores_gemma":[0.0011542747,0.9978474,0.000018140052,0.000080258564,0.00046521323,0.0000042192178,0.000016707378,0.000025690828,0.00038812394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972644,0.00041501064,0.0015078603,0.00028570226,0.0001539024,0.00037314056],"domain_scores_gemma":[0.99535537,0.0021074465,0.0018865947,0.0002945843,0.00027729172,0.00007872163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010811801,0.00040955227,0.003590744,0.0010413871,0.00013522731,0.000006800951,0.00032949986,0.00044252077,0.00042621477],"category_scores_gemma":[0.000425665,0.0002351884,0.0006348103,0.00035533108,0.0010502634,0.00007866914,0.00003984104,0.00042780206,0.000019174899],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108076965,0.000117933996,0.000025426514,0.0007552001,0.0006832387,0.0004342067,0.00029790486,5.354663e-8,0.0005828673,0.000009881081,0.0050522913,0.9919329],"study_design_scores_gemma":[0.00060591026,0.00089309324,0.000015628582,0.0067507806,0.0014754741,0.012837143,0.00008900154,7.623125e-8,0.00011004169,0.000111543784,0.9768759,0.00023542668],"about_ca_topic_score_codex":0.0000108175855,"about_ca_topic_score_gemma":6.430542e-7,"teacher_disagreement_score":0.9916975,"about_ca_system_score_codex":0.00004265077,"about_ca_system_score_gemma":0.0004940303,"threshold_uncertainty_score":0.9590705},"labels":[],"label_agreement":null},{"id":"W2081011313","doi":"10.1034/j.1600-0536.2001.440204.x","title":"Results of a quality of life questionnaire in a patch test clinic population","year":2001,"lang":"en","type":"article","venue":"Contact Dermatitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Patch test; Test (biology); Medicine; Population; Quality of life (healthcare); Quality (philosophy); Patch testing; Family medicine; Dermatology; Contact dermatitis; Environmental health; Allergy; Immunology; Nursing; Biology","score_opus":0.030825594126596974,"score_gpt":0.29251026972307265,"score_spread":0.2616846755964757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081011313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965721,0.0019072595,0.000023636629,0.00026330812,0.00021886085,0.00017231182,0.00014700656,0.000022323962,0.00067321147],"genre_scores_gemma":[0.9990605,0.00033713062,0.000026259382,0.00008214487,0.000013257538,0.000014837246,0.00023832815,0.000005982489,0.00022155953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860704,0.0003054261,0.0007756495,0.00014187105,0.000032812113,0.00013720528],"domain_scores_gemma":[0.99903136,0.00031051543,0.000361494,0.00021538703,0.00006531683,0.000015941276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003040325,0.000101422265,0.0003719307,0.000099281155,0.00003060795,0.000002607069,0.00008324337,0.000173005,0.0001128758],"category_scores_gemma":[0.00077015447,0.000095136566,0.00008528748,0.0001579527,0.000033166503,0.00008933724,0.000017212144,0.000069991154,0.00006944541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022355991,0.00026255668,0.9756643,0.000049426006,0.00005483008,0.000004933342,0.0005628528,7.104533e-7,0.0068439166,0.00008739946,0.00029191092,0.015953576],"study_design_scores_gemma":[0.003535467,0.00013957718,0.9924628,0.00017160847,0.00002481049,0.000008412251,0.000070083726,0.00000284258,0.0029219592,0.00013885708,0.00043660254,0.00008698706],"about_ca_topic_score_codex":0.0069183176,"about_ca_topic_score_gemma":0.0039129443,"teacher_disagreement_score":0.016798465,"about_ca_system_score_codex":0.000030103827,"about_ca_system_score_gemma":0.00004605401,"threshold_uncertainty_score":0.9996947},"labels":[],"label_agreement":null},{"id":"W2081016717","doi":"10.1016/j.jaad.2009.09.014","title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":216,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Ustekinumab; Dermatology Life Quality Index; Psoriasis; Anxiety; Quality of life (healthcare); Placebo; Depression (economics); Hospital Anxiety and Depression Scale; Randomized controlled trial; Internal medicine; Physical therapy; Dermatology; Psychiatry; Disease; Alternative medicine; Pathology; Nursing","score_opus":0.013777554518188496,"score_gpt":0.2760983433877126,"score_spread":0.2623207888695241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081016717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655443,0.00056763686,0.000017092018,0.0005303343,0.00040512206,0.0017243049,0.00015699572,0.0000069562466,0.000037117377],"genre_scores_gemma":[0.99947345,0.00012482762,0.0001830644,0.00008751502,0.000032654898,0.00004170123,0.000016783377,0.000019387988,0.000020596399],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945946,0.0017505905,0.0028357361,0.00032233444,0.00018307623,0.0003136837],"domain_scores_gemma":[0.9915779,0.001777128,0.0060701617,0.00028009582,0.00020684807,0.00008785703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010575919,0.00032717566,0.003485925,0.0003617405,0.000076020886,0.0000070158185,0.00053595594,0.0004223322,0.000018445258],"category_scores_gemma":[0.00071695435,0.00018861688,0.00042452235,0.00034133843,0.0009793825,0.0001341092,0.000117903845,0.0007439135,0.0000012925508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9509975,0.00096841704,0.010552435,0.000015436011,0.0027059196,0.0000015301133,0.0009210005,0.000040164057,0.029582482,0.000037744005,0.00006792932,0.004109496],"study_design_scores_gemma":[0.9558956,0.0006872082,0.014720921,0.000085136635,0.000908873,0.00005532368,0.00022618874,0.000016214735,0.027070971,0.00012789771,0.000016685486,0.00018899111],"about_ca_topic_score_codex":0.00044113336,"about_ca_topic_score_gemma":0.000035792193,"teacher_disagreement_score":0.0048981416,"about_ca_system_score_codex":0.000019137908,"about_ca_system_score_gemma":0.0002256901,"threshold_uncertainty_score":0.7691573},"labels":[],"label_agreement":null},{"id":"W2081258574","doi":"10.3899/jrheum.090223","title":"Traditional Systemic Treatment of Psoriasis","year":2009,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Acitretin; Psoriasis; Methotrexate; Systemic therapy; Dermatology; Disease; Intensive care medicine; Systemic disease; Psoriatic arthritis; Internal medicine; Cancer","score_opus":0.026003490571205375,"score_gpt":0.2511219939900832,"score_spread":0.22511850341887785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081258574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988481,0.007888217,0.00019703477,0.0012310138,0.0016796902,0.00019338177,0.00014384332,0.000012867575,0.00017297381],"genre_scores_gemma":[0.9969849,0.0019252251,0.00073878217,0.000027991473,0.000031419437,0.000008473523,0.000099290766,0.000008030953,0.00017585867],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827117,0.00021944314,0.0009925404,0.00015235167,0.000080458885,0.00028402655],"domain_scores_gemma":[0.9986772,0.00020428507,0.00074739096,0.00018775424,0.00014241716,0.00004097778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022867798,0.00021312834,0.00078363286,0.00026897548,0.000083131425,0.0000047451813,0.00018621792,0.0001808015,0.001261351],"category_scores_gemma":[0.000023284172,0.00015622888,0.00035550765,0.000100914345,0.000082912105,0.000077373756,0.00000798685,0.000081036545,0.000053595293],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065618483,0.012779305,0.33622223,0.00018512714,0.012815347,0.00038343924,0.007650912,0.000116886484,0.16644461,0.044943955,0.08511461,0.32678172],"study_design_scores_gemma":[0.08309676,0.048427206,0.14802158,0.0010170309,0.004528604,0.07521939,0.0051566632,0.000010694783,0.48123446,0.009975713,0.1417267,0.0015852002],"about_ca_topic_score_codex":0.000025071886,"about_ca_topic_score_gemma":0.000007514117,"teacher_disagreement_score":0.32519653,"about_ca_system_score_codex":0.00014289166,"about_ca_system_score_gemma":0.00014955961,"threshold_uncertainty_score":0.9996516},"labels":[],"label_agreement":null},{"id":"W2081479967","doi":"10.1111/j.1365-2133.2008.08962.x","title":"Economic evaluation of systemic therapies for moderate to severe psoriasis","year":2008,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Infliximab; Etanercept; Efalizumab; Ciclosporin; Psoriasis; Psoriasis Area and Severity Index; Confidence interval; Quality-adjusted life year; Methotrexate; Internal medicine; Cost effectiveness; Transplantation; Dermatology; Rheumatoid arthritis; Tumor necrosis factor alpha","score_opus":0.030662793363812158,"score_gpt":0.26129945777624486,"score_spread":0.2306366644124327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081479967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97591734,0.021791903,0.00043797313,0.00020312222,0.0011163907,0.00031506614,0.00008637976,0.00000878263,0.00012301972],"genre_scores_gemma":[0.99771637,0.0016498701,0.00036141416,0.00004559161,0.000059778165,0.00003363591,0.000020467278,0.000014056537,0.0000988082],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9986364,0.00037390448,0.00060040347,0.00013509094,0.000048307804,0.0002058479],"domain_scores_gemma":[0.998911,0.00016348869,0.0004116526,0.00010621385,0.00038024609,0.000027402028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033674724,0.00011592723,0.0005356963,0.00015113696,0.00013937062,0.000007121218,0.00016831221,0.00018597287,0.00013264202],"category_scores_gemma":[0.00007922359,0.00012255952,0.00018819637,0.00004658923,0.000069552385,0.0001285786,0.000016793101,0.00008059174,0.000041098465],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009609562,0.0012143163,0.048669003,0.0003472484,0.011263975,0.0010265227,0.013768843,0.004023078,0.15000263,0.0014856324,0.077629924,0.6809593],"study_design_scores_gemma":[0.03346061,0.00090369117,0.03477404,0.0006908839,0.0019109123,0.7404744,0.0020477485,0.000113122194,0.17764182,0.0015438569,0.005717867,0.00072106585],"about_ca_topic_score_codex":0.000037141985,"about_ca_topic_score_gemma":0.00004839187,"teacher_disagreement_score":0.73944783,"about_ca_system_score_codex":0.00007073365,"about_ca_system_score_gemma":0.00030034274,"threshold_uncertainty_score":0.4997832},"labels":[],"label_agreement":null},{"id":"W2082013793","doi":"10.1016/j.jval.2011.01.006","title":"Cost Utility Analysis Based on a Head-to-Head Phase 3 Trial Comparing Ustekinumab and Etanercept in Patients with Moderate-to-Severe Plaque Psoriasis: A Canadian Perspective","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Ustekinumab; Etanercept; Medicine; Psoriasis; Clinical trial; Randomized controlled trial; Population; Physical therapy; Dermatology; Internal medicine; Infliximab; Disease; Environmental health","score_opus":0.08889802513076007,"score_gpt":0.3092991665688152,"score_spread":0.22040114143805511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082013793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635756,0.00012103933,0.000084623774,0.00024761888,0.00022848403,0.002171989,0.00032839156,0.000027060589,0.00043322623],"genre_scores_gemma":[0.99885726,0.00000764925,0.0002730295,0.00046179435,0.000016251006,0.0001791497,0.0001636118,0.000020257366,0.000021011376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99711114,0.0009053525,0.00048534418,0.0007120383,0.000081530736,0.00070460734],"domain_scores_gemma":[0.9989866,0.0001461168,0.000119457596,0.00039410286,0.00008627883,0.0002674366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005668869,0.00031053656,0.0008082742,0.0011952275,0.00021106495,0.00001731045,0.00015096692,0.00020425858,0.0001309498],"category_scores_gemma":[0.00007434177,0.00027354722,0.00007854383,0.0010422275,0.000053661952,0.00006684788,0.000023475044,0.00028985494,0.000035933703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23896632,0.0037728227,0.7130259,0.000045681605,0.00074318197,0.00005317373,0.023480427,0.01069178,0.000007871391,0.00022748557,0.000081328864,0.008904008],"study_design_scores_gemma":[0.1429919,0.0058183107,0.84374666,0.00022130748,0.00026955816,0.0000035348921,0.0015154692,0.004619985,0.00008193387,0.00005990678,0.00013444347,0.0005370209],"about_ca_topic_score_codex":0.5634032,"about_ca_topic_score_gemma":0.56964856,"teacher_disagreement_score":0.13072072,"about_ca_system_score_codex":0.001046632,"about_ca_system_score_gemma":0.0007155838,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W2082686341","doi":"10.2165/00002018-200629010-00004","title":"Fulfilling an Unmet Need in Psoriasis","year":2006,"lang":"en","type":"review","venue":"Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Efalizumab; Etanercept; Adalimumab; Infliximab; Rheumatoid arthritis; Methotrexate; Dermatology; Psoriatic arthritis; Acitretin; Immunology; Ciclosporin; Population; Tumor necrosis factor alpha; Transplantation; Internal medicine","score_opus":0.031329017145245386,"score_gpt":0.29074359468332905,"score_spread":0.25941457753808367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082686341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020988313,0.9934833,0.000012343754,0.000017736047,0.0017319751,0.00063505414,0.00053727685,0.0001243751,0.0032480368],"genre_scores_gemma":[0.00011478674,0.98809624,0.0001379616,0.000021993315,0.00022093333,0.00011909109,0.0063227094,0.000079145975,0.0048871366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663794,0.0010239644,0.0009594324,0.0007191767,0.000050612758,0.0006088914],"domain_scores_gemma":[0.9985037,0.0003914684,0.0003523687,0.0006834868,0.00003151333,0.00003744814],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058915734,0.0006652316,0.0020877295,0.00045422572,0.00017338223,0.000020516085,0.00047539297,0.0008946158,0.00044254816],"category_scores_gemma":[0.00003296007,0.00054588437,0.0006047756,0.0005402933,0.000082018014,0.00010688927,0.00008664742,0.0004975634,0.0012138396],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000463617,0.00019927956,0.000051298073,0.0007928994,0.0003222944,0.000029920775,0.0001313046,0.000003098103,0.0000050328495,0.0002061408,0.0010442823,0.99716806],"study_design_scores_gemma":[0.0010363363,0.000032663203,0.00010849804,0.0015060542,0.0009958204,0.000043909127,0.000058412676,3.969055e-7,0.000023645804,0.00004173375,0.99559355,0.000558992],"about_ca_topic_score_codex":0.0005093252,"about_ca_topic_score_gemma":0.00040448894,"teacher_disagreement_score":0.9966091,"about_ca_system_score_codex":0.00022234656,"about_ca_system_score_gemma":0.000188302,"threshold_uncertainty_score":0.9996993},"labels":[],"label_agreement":null},{"id":"W2083502021","doi":"10.1111/jdv.12118","title":"A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis","year":2013,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":146,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute for Health and Care Research","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis; Consensus conference; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.018976310717006735,"score_gpt":0.24011096736160484,"score_spread":0.2211346566445981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083502021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901417,0.0010799569,0.0001504632,0.007170529,0.00016313563,0.00028286863,0.000005572743,0.0000036678991,0.0010021012],"genre_scores_gemma":[0.9981981,0.0006813669,0.0007546022,0.00022772366,0.000017783148,0.000007589877,0.0000032144749,0.000008722572,0.00010091789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788344,0.0011963381,0.0005740533,0.00014871398,0.000037738268,0.00015970689],"domain_scores_gemma":[0.99919796,0.00016873267,0.0004684887,0.00011238821,0.000032663353,0.000019745672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036122085,0.00014422284,0.00038457106,0.00014081976,0.00009877963,0.0000044088715,0.00017171173,0.00014161131,0.000015200871],"category_scores_gemma":[0.000015347185,0.00008118656,0.0000791928,0.00009869847,0.00021986123,0.000034903474,0.000042359734,0.0001901371,0.000004503454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019862546,0.005921826,0.3851663,0.0013263873,0.02124796,0.0060596587,0.041191272,0.099629305,0.06295908,0.048371445,0.007903689,0.30036053],"study_design_scores_gemma":[0.03393657,0.0015231816,0.7274543,0.0011939344,0.0032495637,0.13719161,0.004258388,0.00059600425,0.07766503,0.006635302,0.00533555,0.0009605719],"about_ca_topic_score_codex":0.000009482588,"about_ca_topic_score_gemma":0.0000014525677,"teacher_disagreement_score":0.342288,"about_ca_system_score_codex":0.000014135668,"about_ca_system_score_gemma":0.000014705352,"threshold_uncertainty_score":0.3310692},"labels":[],"label_agreement":null},{"id":"W2083524155","doi":"10.2310/7750.2008/08070","title":"Targeting the Interleukin-12/23 Cytokine Family in the Treatment of Psoriatic Disease","year":2008,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Abbott Laboratories","keywords":"Ustekinumab; Medicine; Psoriasis; Immunology; Psoriatic arthritis; Placebo; Cytokine; Adverse effect; Interleukin 23; Disease; Ixekizumab; Interleukin; Internal medicine; Secukinumab; Adalimumab; Pathology; Alternative medicine","score_opus":0.05127968610392212,"score_gpt":0.28872900460876155,"score_spread":0.23744931850483944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083524155","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010496579,0.987437,0.0000021261442,0.0003236406,0.0012977847,0.00033449882,0.000029083472,0.000004484198,0.00007479218],"genre_scores_gemma":[0.0048840214,0.9941072,0.000004119513,0.000117296644,0.0005352414,0.000017731341,0.00008537368,0.000022732194,0.0002263119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969524,0.00096672564,0.0014853913,0.00018201536,0.00013386655,0.00027957596],"domain_scores_gemma":[0.99327,0.0050840923,0.0012496787,0.00027861595,0.000070349546,0.000047293845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006221281,0.000407614,0.0024024614,0.0003826244,0.00012153693,0.0000069588887,0.0002514082,0.00019869131,0.000044627584],"category_scores_gemma":[0.0003240238,0.00016017661,0.00071581063,0.00022031808,0.0002888681,0.000032949665,0.000015778385,0.0003056676,0.000008587484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003330284,0.00040634934,0.00032076825,0.00086390955,0.0012814486,0.0034853024,0.0019905695,9.819861e-7,0.0000238685,0.00000772543,0.014545731,0.9767403],"study_design_scores_gemma":[0.0006496235,0.00067700597,0.00009972503,0.0051746084,0.0025204874,0.008395955,0.00052622694,3.685984e-7,0.0000027139722,0.000023287652,0.98178387,0.00014612896],"about_ca_topic_score_codex":0.000040501738,"about_ca_topic_score_gemma":0.0000065101426,"teacher_disagreement_score":0.9765942,"about_ca_system_score_codex":0.00008011395,"about_ca_system_score_gemma":0.0003383024,"threshold_uncertainty_score":0.65318125},"labels":[],"label_agreement":null},{"id":"W2084396922","doi":"10.1159/000090653","title":"Low Levels of Emotional Awareness Predict a Better Response to Dermatological Treatment in Patients with Psoriasis","year":2006,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Société Française de Dermatologie et de Pathologie Sexuellement Transmissible; University of Arizona","keywords":"Psoriasis; Dermatological diseases; Medicine; Dermatology","score_opus":0.012889962403078522,"score_gpt":0.2289955924147959,"score_spread":0.21610563001171737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084396922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978832,0.00011310502,0.00017784807,0.0005961506,0.00025989529,0.00047272723,0.0003178748,0.000048559992,0.00013064759],"genre_scores_gemma":[0.99893695,0.0000023625466,0.00028435365,0.00014468333,0.000014693416,0.00013131762,0.00031061308,0.000017660184,0.00015739245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804807,0.0005754646,0.00046780737,0.00039420038,0.000063807136,0.00045067098],"domain_scores_gemma":[0.9991437,0.00031519635,0.00012782514,0.00029409814,0.000086447966,0.000032736967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076976314,0.0002854468,0.0006081993,0.00032077509,0.00008713709,0.00000546911,0.00016462489,0.00033699407,0.00023675465],"category_scores_gemma":[0.000031147785,0.00020870016,0.00009473223,0.0002531668,0.00015734762,0.0000629222,0.00004584617,0.00008107714,0.00016584426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042198002,0.0013837512,0.98710614,0.000015964339,0.00018121768,0.00012862602,0.00017133552,0.000036579142,0.0023815401,0.00015005058,0.000487931,0.0037370813],"study_design_scores_gemma":[0.007526031,0.00047293256,0.9388289,0.00003302247,0.00006904831,0.00020155603,0.000021013844,0.0000017788886,0.051031515,0.00006153004,0.0015548783,0.00019779561],"about_ca_topic_score_codex":0.00010531409,"about_ca_topic_score_gemma":0.00014055765,"teacher_disagreement_score":0.048649974,"about_ca_system_score_codex":0.00009233781,"about_ca_system_score_gemma":0.0001334182,"threshold_uncertainty_score":0.85105455},"labels":[],"label_agreement":null},{"id":"W2084538530","doi":"10.3899/jrheum.120468","title":"Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"CXCR5; BCL6; Interleukin 21; Immunology; Germinal center; Medicine; T cell; B cell; Antibody; Immune system","score_opus":0.009000275959761814,"score_gpt":0.20533516278226038,"score_spread":0.19633488682249856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084538530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773591,0.0210825,0.00010342526,0.00010742695,0.0009794441,0.000114238144,0.0000071361446,0.0000079761,0.00023874277],"genre_scores_gemma":[0.9979531,0.0014329004,0.000059974573,0.000019809371,0.000006251918,0.0000048511642,0.000005528776,0.000012336675,0.00050524547],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99873847,0.0004498334,0.00041616085,0.000076518736,0.000027705848,0.0002913204],"domain_scores_gemma":[0.99891865,0.00047891706,0.00037522422,0.00014929847,0.000046798225,0.00003107978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047477015,0.0001531563,0.00039866226,0.00014866426,0.00009913467,0.000007621226,0.00016158019,0.0001491905,0.00008279976],"category_scores_gemma":[0.00001620371,0.00008625268,0.000046412893,0.00009081604,0.00013969201,0.00012159484,0.000034572717,0.00025068285,0.00007113712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008474888,0.00022842194,0.9624287,0.00005854837,0.00018224331,0.000012442434,0.008108013,0.000022067426,0.026182352,0.00030050843,0.0013190451,0.00031020775],"study_design_scores_gemma":[0.029571602,0.0030399172,0.029854447,0.0014890919,0.0019034086,0.74792904,0.027195325,0.000043164113,0.15373863,0.0005301158,0.0035764799,0.001128754],"about_ca_topic_score_codex":0.000060869166,"about_ca_topic_score_gemma":0.00008438045,"teacher_disagreement_score":0.9325742,"about_ca_system_score_codex":0.000029824765,"about_ca_system_score_gemma":0.00004298825,"threshold_uncertainty_score":0.35172823},"labels":[],"label_agreement":null},{"id":"W2084768692","doi":"10.1111/j.1365-2133.1975.tb03119.x","title":"The effect of the activity of psoriasis on the response to autologous ground skin extract","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Stimulant; Medicine; Inhibitory postsynaptic potential; DNA synthesis; Dermatology; Pharmacology; DNA; Internal medicine; Chemistry; Biochemistry","score_opus":0.007098427813098961,"score_gpt":0.2267103106540354,"score_spread":0.21961188284093644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084768692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917855,0.0037848423,0.000029572433,0.0026807606,0.0011220383,0.0002775954,0.000031498956,0.000007265188,0.00028088473],"genre_scores_gemma":[0.99943745,0.00013188805,0.000015103267,0.000056401364,0.000043339474,0.000013179154,0.0000013825851,0.000012859222,0.00028840356],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99548346,0.0034196586,0.0005574363,0.00013956502,0.000094374285,0.00030549482],"domain_scores_gemma":[0.9942966,0.0045643076,0.0006854609,0.00032543266,0.000108857304,0.00001934824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010103495,0.00016932467,0.00053920207,0.00008594275,0.00037332866,0.000018275885,0.00058428146,0.00023637532,0.000043302887],"category_scores_gemma":[0.0006732515,0.00009059065,0.00037498528,0.00020405046,0.00041088153,0.000052717704,0.000072622,0.00036182988,0.000019951483],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032424215,0.00091818965,0.031864025,0.000058949292,0.002145325,0.0011215471,0.00055004563,0.000054558423,0.40016887,0.0010055664,0.036994763,0.49269396],"study_design_scores_gemma":[0.0023337256,0.00080315524,0.4201086,0.00011747545,0.0002450988,0.024911214,0.00006207813,5.9159555e-7,0.54109085,0.00016729695,0.010052971,0.00010694347],"about_ca_topic_score_codex":0.00021824607,"about_ca_topic_score_gemma":0.00019935859,"teacher_disagreement_score":0.492587,"about_ca_system_score_codex":0.000038631737,"about_ca_system_score_gemma":0.00010064455,"threshold_uncertainty_score":0.36941794},"labels":[],"label_agreement":null},{"id":"W2084817509","doi":"10.1016/s0140-6736(08)60593-0","title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Alberta; Lynde Centre for Dermatology; Innovation Initiatives Ontario North; Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Plaque psoriasis; Body surface area; Internal medicine; Clinical endpoint; Gastroenterology; Adverse effect; Nephrotoxicity; Clinical trial; Toxicity; Dermatology","score_opus":0.049314623224433446,"score_gpt":0.303236361154231,"score_spread":0.25392173792979755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084817509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175894,0.0023876978,0.000008822996,0.00021624618,0.00052729575,0.0038197816,0.00003325286,0.00006183245,0.0011861395],"genre_scores_gemma":[0.997595,0.00038108567,0.000022559992,0.000063221785,0.0002015647,0.00052790414,0.000054793432,0.000018606986,0.001135227],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978686,0.0006951286,0.00060508953,0.0003110962,0.00006872297,0.0004513669],"domain_scores_gemma":[0.9981028,0.0009297486,0.00026205138,0.00063669484,0.000044337532,0.000024382307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007648108,0.00027303663,0.0013503424,0.00013507048,0.00018675435,0.00000800892,0.0004550929,0.00016446685,0.0002705318],"category_scores_gemma":[0.00010729669,0.00016947601,0.00021352872,0.0002297173,0.00014645014,0.00006047485,0.000061245555,0.0002386182,0.00018381115],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9703469,0.003785525,0.0044701896,0.000009515181,0.0015144948,0.000054803153,0.009827912,0.00004887243,0.0060817185,0.000051047296,0.0014701539,0.0023388169],"study_design_scores_gemma":[0.9848473,0.0003734252,0.0036370156,0.000027318743,0.00049353694,0.000029652401,0.0008073932,0.000013010857,0.008566566,0.000009972977,0.0010141479,0.00018063997],"about_ca_topic_score_codex":0.0002767365,"about_ca_topic_score_gemma":0.00018158027,"teacher_disagreement_score":0.014500369,"about_ca_system_score_codex":0.000033218585,"about_ca_system_score_gemma":0.000067453395,"threshold_uncertainty_score":0.69110316},"labels":[],"label_agreement":null},{"id":"W2085498159","doi":"10.2310/7750.2010.10013","title":"Long-Term Prognosis and Comorbidities Associated with Psoriasis in the Newfoundland and Labrador Founder Population","year":2011,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Population; Comorbidity; Cohort; Disease; Observational study; Cohort study; Pediatrics; Internal medicine; Dermatology; Environmental health","score_opus":0.04564059094135802,"score_gpt":0.2473669184304617,"score_spread":0.20172632748910369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085498159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231845,0.006745661,0.000004725656,0.0004708783,0.00024300329,0.00009744735,0.0000029402681,0.0000058860296,0.00011098691],"genre_scores_gemma":[0.99689007,0.0027135233,0.000013072294,0.00018238432,0.00007197864,0.0000031467857,0.000017967983,0.000007999105,0.00009985188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991302,0.00022687402,0.0003237336,0.000104057275,0.000059658145,0.00015547962],"domain_scores_gemma":[0.9986216,0.00096998824,0.00026028138,0.00006192187,0.0000582094,0.000028034689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005224147,0.00013440324,0.00041422236,0.00017949817,0.00010796504,0.000013896114,0.00004321584,0.000106130705,0.000053587388],"category_scores_gemma":[0.00012797539,0.00007040882,0.00003305997,0.00009738939,0.00019237355,0.000098940145,0.000009370741,0.00013968766,4.6871347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044826884,0.000090320675,0.9688373,0.000021442806,0.00028788927,0.0005076006,0.0034718527,5.1269456e-8,0.00011158642,0.000033595188,0.00036396543,0.025826091],"study_design_scores_gemma":[0.0012395093,0.00056454266,0.98924243,0.00029639676,0.0003666625,0.006823704,0.0010154998,5.722001e-7,0.000034859146,0.00021020482,0.0001112691,0.00009432098],"about_ca_topic_score_codex":0.00042738154,"about_ca_topic_score_gemma":0.0012141423,"teacher_disagreement_score":0.02573177,"about_ca_system_score_codex":0.000018625493,"about_ca_system_score_gemma":0.000024933785,"threshold_uncertainty_score":0.28711885},"labels":[],"label_agreement":null},{"id":"W2085690242","doi":"10.1007/s00403-013-1404-z","title":"Psoriatic keratinocytes prime neutrophils for an overproduction of superoxide anions","year":2013,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"Canadian Institutes of Health Research; Université Laval","keywords":"Superoxide; Keratinocyte; Immunology; Neutrophile; Psoriasis; Priming (agriculture); In vitro; Neutrophil extracellular traps; Chemistry; Medicine; Inflammation; Biology; Biochemistry; Enzyme","score_opus":0.07971368720763411,"score_gpt":0.3406097757170314,"score_spread":0.2608960885093973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085690242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624133,0.0012665404,0.00019795258,0.00045406361,0.00011409873,0.0008779799,0.00005215157,0.00004554767,0.00075034227],"genre_scores_gemma":[0.9968877,0.00023749383,0.0022249494,0.000012003386,0.00003149128,0.0002314476,0.00013581027,0.000014580229,0.00022454324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980747,0.0006942432,0.0003796103,0.00032326035,0.000081844766,0.00044632005],"domain_scores_gemma":[0.9976762,0.0016595643,0.00008724543,0.00037221596,0.00015592911,0.000048863294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000255938,0.0001342145,0.00037051766,0.00020620055,0.00016737176,0.000012118443,0.00031293783,0.00014155937,0.00015249089],"category_scores_gemma":[0.00053390115,0.00009726718,0.00013682988,0.0001583764,0.0006241797,0.0001437751,0.00010236412,0.0001736044,0.000050188824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034451392,0.0005891592,0.008170846,0.000067536035,0.00014772623,0.0000010124692,0.000411164,0.0000029411697,0.93807065,0.007268893,0.00047475196,0.044450827],"study_design_scores_gemma":[0.0014668284,0.0012110757,0.19144392,0.000036818,0.00003927945,0.000038903792,0.00032511333,0.000069197304,0.78854966,0.015951665,0.00073291693,0.00013462553],"about_ca_topic_score_codex":0.00012733578,"about_ca_topic_score_gemma":0.000008390069,"teacher_disagreement_score":0.18327308,"about_ca_system_score_codex":0.00000844511,"about_ca_system_score_gemma":0.00006484839,"threshold_uncertainty_score":0.39664403},"labels":[],"label_agreement":null},{"id":"W2086014388","doi":"10.2310/7750.2009.00022","title":"Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research","funders":"Abbott Canada; Abbott Laboratories; Abbott Fund","keywords":"Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Adverse effect; Internal medicine; Clinical trial; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.07662719507908018,"score_gpt":0.32188847996869346,"score_spread":0.2452612848896133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086014388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041052006,0.9571643,5.199644e-7,0.0004282079,0.00084343384,0.00033313225,0.00010307607,0.000005526157,0.000069797345],"genre_scores_gemma":[0.006041149,0.9932359,0.000011882771,0.00005086857,0.0004430281,0.0000054346083,0.000108706656,0.000016224101,0.00008680489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967232,0.0007239427,0.0018925974,0.00027545326,0.00012415893,0.00026064913],"domain_scores_gemma":[0.98854727,0.00966563,0.0013707958,0.00027774394,0.00009756287,0.000041003124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008734631,0.00047266515,0.0038744374,0.0004113194,0.00009773664,0.0000072403004,0.00014959933,0.00034853668,0.000018951583],"category_scores_gemma":[0.0005007503,0.00022150467,0.00044184952,0.00020481666,0.0002798468,0.000037969516,0.000015945867,0.00027396408,0.000002752282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019502386,0.0003682672,0.00007403998,0.00031847897,0.0033179757,0.0013757601,0.0022503922,2.1471195e-7,0.000009282069,0.000005052131,0.0017555308,0.98857474],"study_design_scores_gemma":[0.007798286,0.004065463,0.0007733405,0.019562155,0.01266694,0.010261781,0.0013999284,1.2428194e-7,0.000011027933,0.00016310079,0.94294655,0.00035130454],"about_ca_topic_score_codex":0.00007458597,"about_ca_topic_score_gemma":0.00008787785,"teacher_disagreement_score":0.98822343,"about_ca_system_score_codex":0.00007719073,"about_ca_system_score_gemma":0.00018331043,"threshold_uncertainty_score":0.9032698},"labels":[],"label_agreement":null},{"id":"W2086591847","doi":"10.1080/09546630902984596","title":"Efalizumab discontinuation: A practical strategy","year":2009,"lang":"en","type":"review","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Efalizumab; Medicine; Discontinuation; Psoriasis; Plaque psoriasis; Dermatology; Progressive multifocal leukoencephalopathy; Monoclonal; Pharmacology; Monoclonal antibody; Immunology; Surgery; Multiple sclerosis; Antibody","score_opus":0.12147682256946304,"score_gpt":0.37707455563146003,"score_spread":0.25559773306199696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086591847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018315349,0.9970115,0.000031559386,0.00023312727,0.000598788,0.0004931505,0.000062591935,0.000032953198,0.0013532079],"genre_scores_gemma":[0.00065871584,0.997517,0.00039311821,0.000028211774,0.00016508492,0.000041886895,0.00019869763,0.00002359327,0.00097372866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965674,0.0010438513,0.0015030041,0.00033772035,0.0001059149,0.00044209455],"domain_scores_gemma":[0.99721766,0.000682733,0.0015818425,0.0003149916,0.00010963605,0.000093142844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019283469,0.000680234,0.0032809456,0.00023255535,0.00013985284,0.00005453854,0.0002656697,0.0009357973,0.00050532445],"category_scores_gemma":[0.000103676866,0.0003523555,0.0016672065,0.00019676104,0.00011606669,0.00014638156,0.00003362378,0.00044581998,0.0005951055],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001097074,0.0017092216,0.000016038117,0.0001693217,0.0023997526,0.0020321538,0.00002690604,3.2074257e-7,0.0000014735639,0.0004892037,0.0020905954,0.9909553],"study_design_scores_gemma":[0.0020826228,0.0022538216,0.000058387694,0.0014393164,0.0057040555,0.024799801,0.000031661275,9.0807994e-8,0.000040263847,0.00015089179,0.9631257,0.00031335143],"about_ca_topic_score_codex":0.0000020814773,"about_ca_topic_score_gemma":0.000001858413,"teacher_disagreement_score":0.99064195,"about_ca_system_score_codex":0.00034977542,"about_ca_system_score_gemma":0.00057489274,"threshold_uncertainty_score":0.99989283},"labels":[],"label_agreement":null},{"id":"W2086611890","doi":"10.1016/j.jaci.2005.10.025","title":"IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts","year":2006,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada)","funders":"","keywords":"Proinflammatory cytokine; Lung; Cell biology; Cancer research; Biology; Immunology; Medicine; Inflammation; Internal medicine","score_opus":0.012293732905358304,"score_gpt":0.2622913682128852,"score_spread":0.2499976353075269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086611890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97995543,0.018662242,0.000015586113,0.00036756415,0.00069296407,0.00009051289,0.0000045104543,0.0000071457666,0.00020404963],"genre_scores_gemma":[0.9961522,0.003098006,0.00010141433,0.000022899458,0.00010945664,0.0000035973683,0.000007291141,0.000009653795,0.00049547653],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979206,0.00053526385,0.0011277741,0.00015511738,0.000039273404,0.00022198592],"domain_scores_gemma":[0.99826145,0.00074627186,0.000684558,0.00019246171,0.0001007446,0.000014482414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058921485,0.00015514434,0.0005194411,0.000113664115,0.000081946,0.000006012671,0.0002452385,0.0004055733,0.000114560615],"category_scores_gemma":[0.000112758935,0.00009262704,0.00021371857,0.000089291105,0.00047130653,0.0000996715,0.00009323579,0.0003700976,0.00000854285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066022226,0.0016317144,0.14653246,0.000040674746,0.003034238,0.000108275606,0.00048346998,0.000108831075,0.798528,0.002574542,0.003688291,0.036667254],"study_design_scores_gemma":[0.005251356,0.000981604,0.8897839,0.00023205353,0.00013301335,0.00028672608,0.0002468149,0.000005137824,0.0917192,0.0015987279,0.009596994,0.0001644631],"about_ca_topic_score_codex":0.000034185665,"about_ca_topic_score_gemma":0.00009604545,"teacher_disagreement_score":0.74325144,"about_ca_system_score_codex":0.0000143639745,"about_ca_system_score_gemma":0.00006634307,"threshold_uncertainty_score":0.3777221},"labels":[],"label_agreement":null},{"id":"W2086846524","doi":"10.1016/j.jneuroim.2013.10.006","title":"IL-25 prevents T cell-mediated neurotoxicity by decreasing LFA-1 expression","year":2013,"lang":"en","type":"article","venue":"Journal of Neuroimmunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Multiple Sclerosis Society of Canada; University of Alberta","keywords":"Neuroprotection; Neurotoxicity; Multiple sclerosis; Immune system; Immunology; T cell; Neuroinflammation; Cytokine; Medicine; Mechanism (biology); Cell adhesion molecule; Inflammation; Pharmacology; Toxicity; Internal medicine","score_opus":0.013594711674452024,"score_gpt":0.22581639537289142,"score_spread":0.21222168369843938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086846524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239916,0.004554222,0.000064221094,0.00033915605,0.0017584764,0.00030451582,0.000029074954,0.000042391664,0.00050878775],"genre_scores_gemma":[0.9971163,0.0008559155,0.00015770823,0.0002743707,0.00005626734,0.000018931873,0.000041990203,0.000035478108,0.0014429956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755746,0.0008471072,0.00073448557,0.0002834716,0.00007800924,0.0004994554],"domain_scores_gemma":[0.9982284,0.00044237514,0.0007635695,0.00034006193,0.00016297618,0.000062660416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019584048,0.0002991652,0.0005538209,0.00023751652,0.00020214623,0.00002823334,0.0004960227,0.00038211318,0.0010738884],"category_scores_gemma":[0.00022839324,0.00023720242,0.00023565418,0.00016952881,0.00016030786,0.00031963186,0.00012989526,0.0005915002,0.00065779523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002659627,0.00051858585,0.0034344445,0.000008417089,0.00013926647,0.00004885076,0.00010330309,0.0000011870253,0.97569245,0.000003913006,0.011599317,0.008184284],"study_design_scores_gemma":[0.0065944013,0.0020634262,0.21615793,0.00008988999,0.00021465661,0.0017202311,0.00014287571,0.000004539109,0.71863985,0.00021455539,0.053737316,0.00042032776],"about_ca_topic_score_codex":0.000037098573,"about_ca_topic_score_gemma":6.857679e-7,"teacher_disagreement_score":0.25705263,"about_ca_system_score_codex":0.0000474855,"about_ca_system_score_gemma":0.00007459468,"threshold_uncertainty_score":0.99983925},"labels":[],"label_agreement":null},{"id":"W2086861262","doi":"10.1111/j.1365-2133.2006.07237.x","title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dermatology Life Quality Index; Infliximab; Psoriasis; Medicine; Maintenance therapy; Placebo; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Regimen; Psoriasis Area and Severity Index; Physical therapy; Surgery; Dermatology; Chemotherapy; Pathology; Tumor necrosis factor alpha","score_opus":0.007955155368587987,"score_gpt":0.21694139133958537,"score_spread":0.20898623597099739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086861262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523026,0.0024686574,0.000086043794,0.00017108109,0.00024370145,0.0017324408,0.00001243026,0.0000050426756,0.000050357117],"genre_scores_gemma":[0.9992472,0.00033076497,0.00014512554,0.00007426462,0.000021440348,0.00013053487,0.000013470106,0.000011255519,0.000025955143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972589,0.0009595858,0.0012625753,0.00018493632,0.000080902646,0.00025309395],"domain_scores_gemma":[0.99851096,0.00027267842,0.0008648622,0.00008874017,0.00023450897,0.00002822412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057929644,0.000177141,0.0018657489,0.00025421297,0.000042992273,0.000015191679,0.00009322704,0.000187722,0.000016486947],"category_scores_gemma":[0.00016143826,0.00012722812,0.00011358611,0.0001487704,0.00015355689,0.00013619146,0.00001515484,0.00020469955,7.859424e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94924706,0.00097096135,0.041090365,0.0000115760495,0.00050068024,0.000059093672,0.00014815187,0.000039413455,0.0004002348,0.00005972073,0.000049653077,0.0074230726],"study_design_scores_gemma":[0.907151,0.0010366219,0.08993243,0.00013150927,0.00007100626,0.000499439,0.000099039156,0.0000015452035,0.00079230923,0.0001373838,0.000012687186,0.00013505029],"about_ca_topic_score_codex":0.0006323143,"about_ca_topic_score_gemma":0.0007304081,"teacher_disagreement_score":0.04884206,"about_ca_system_score_codex":0.000039402727,"about_ca_system_score_gemma":0.00016145821,"threshold_uncertainty_score":0.51882124},"labels":[],"label_agreement":null},{"id":"W2087453345","doi":"10.14740/cr363w","title":"Interleukin 17A in Patients With Stable Coronary Artery Disease: Are There Differences According to Gender?","year":2014,"lang":"en","type":"article","venue":"Cardiology Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Coronary artery disease; Myocardial infarction; Stimulus (psychology); Internal medicine; Interleukin 17; Cardiology; Stimulation; Prospective cohort study; Inflammation; Gastroenterology","score_opus":0.054013850531821075,"score_gpt":0.28748790722349676,"score_spread":0.2334740566916757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087453345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963069,0.0011835656,0.00006595753,0.00011353695,0.0003418881,0.00048942864,0.00007169282,0.00003966952,0.0013873657],"genre_scores_gemma":[0.99871784,0.000039396113,0.000017264098,0.000055517903,0.000069513284,0.00020324912,0.0001482346,0.000022569415,0.00072639016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968801,0.0014881081,0.00019976994,0.0005516793,0.00009767874,0.0007826676],"domain_scores_gemma":[0.9987597,0.00047901648,0.000043100114,0.00047308198,0.00015731598,0.00008778291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067618955,0.00021085243,0.00055103545,0.00032072858,0.00022968663,0.000021075966,0.00037877855,0.00021058401,0.0001112792],"category_scores_gemma":[0.0001571024,0.00015179806,0.000074588555,0.0002786297,0.00026199184,0.00007803686,0.00022604794,0.00038294823,0.00046679567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014996727,0.00009154488,0.9861079,0.000017947217,0.00026768702,0.000067170375,0.00014648316,0.000011131397,0.0005634866,0.00008667443,0.00087859516,0.010261751],"study_design_scores_gemma":[0.0017454742,0.00047387986,0.9950634,0.00005841808,0.000030963096,0.0000088428915,0.0007325875,0.0000016561282,0.00014739281,0.00017375321,0.0013856896,0.00017794783],"about_ca_topic_score_codex":0.000023345683,"about_ca_topic_score_gemma":0.00003821748,"teacher_disagreement_score":0.010083803,"about_ca_system_score_codex":0.0001064585,"about_ca_system_score_gemma":0.00007305848,"threshold_uncertainty_score":0.6190145},"labels":[],"label_agreement":null},{"id":"W2087818439","doi":"10.2310/7750.2011.10067","title":"Support Needed to Involve Psoriasis Patients in Treatment Decisions: Survey of Dermatologists","year":2011,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Windsor Clinical Research; University of Windsor; University of Ottawa; University of British Columbia; Memorial University of Newfoundland","funders":"Canadian Dermatology Foundation; Dermatology Foundation","keywords":"Medicine; Generalizability theory; Psoriasis; Disease; Family medicine; Dermatology; Pathology","score_opus":0.087718382542064,"score_gpt":0.27973190526103425,"score_spread":0.19201352271897026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087818439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958895,0.0025980182,0.000011395759,0.00017177314,0.0009820373,0.00012801416,0.000037503727,0.000005168669,0.00017662787],"genre_scores_gemma":[0.9954781,0.003973443,0.00009458053,0.00024228547,0.00002905906,0.000002561721,0.000082342754,0.000010730892,0.00008692597],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981389,0.0003467508,0.0010038653,0.00017846681,0.00008984063,0.00024219709],"domain_scores_gemma":[0.99683756,0.0020997832,0.0004596631,0.00025919688,0.00026068962,0.000083089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008156436,0.0001888517,0.0009595074,0.0005618967,0.000040047515,0.0000024382487,0.0001692986,0.000161224,0.00020682208],"category_scores_gemma":[0.0014949531,0.00012071017,0.00009139454,0.00026228122,0.000117110874,0.00007223332,0.00004199295,0.000092662296,0.000013733546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002483244,0.00071247586,0.88356364,0.00001140162,0.00042296533,0.00068664766,0.002870472,4.8067056e-7,0.0006340914,0.0000035986209,0.016671117,0.091939844],"study_design_scores_gemma":[0.006058975,0.0044870456,0.96574765,0.00058108446,0.0005678681,0.0036934605,0.0019174621,0.0000012002024,0.010761629,0.0001388418,0.0056825243,0.0003622709],"about_ca_topic_score_codex":0.0023012573,"about_ca_topic_score_gemma":0.0008208838,"teacher_disagreement_score":0.091577575,"about_ca_system_score_codex":0.000042329262,"about_ca_system_score_gemma":0.0001592694,"threshold_uncertainty_score":0.49224177},"labels":[],"label_agreement":null},{"id":"W2087950211","doi":"10.1016/j.jval.2011.08.1478","title":"PSS13 Economic Burden of Psoriasis and Diabetes in Patients With Psoriasis in the United States","year":2011,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Psoriasis; Medicine; Diabetes mellitus; Population; Internal medicine; Dermatology; Endocrinology; Environmental health","score_opus":0.026312052098932743,"score_gpt":0.22934285807486096,"score_spread":0.2030308059759282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087950211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806786,0.0010293176,3.5466059e-7,0.00014583764,0.00017873633,0.00043138347,0.00007056089,0.000009422867,0.000066534],"genre_scores_gemma":[0.9990049,0.0006174439,0.000083889194,0.00007502795,0.000010732709,0.000042271873,0.00013967523,0.000011989296,0.0000140722495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983103,0.00064931373,0.00042846534,0.00023684376,0.000028823057,0.00034625153],"domain_scores_gemma":[0.9992807,0.00029388414,0.000167269,0.00022282658,0.000016247095,0.000019104307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005969762,0.00015548254,0.00035075523,0.00039227874,0.0000435518,0.000004342373,0.00015760862,0.000114403934,0.00004662409],"category_scores_gemma":[0.000022862758,0.00010734989,0.000025028958,0.00027633645,0.000096375516,0.00006295463,0.00002762965,0.00013438922,0.000014065089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032544616,0.0002472775,0.9817141,0.00005146349,0.00005696195,0.000001591503,0.011343366,0.0002917288,0.000013377776,0.00028810615,0.00004013842,0.0056264405],"study_design_scores_gemma":[0.0044820895,0.0007355583,0.99199903,0.00012212471,0.000021381607,9.416321e-7,0.0012671032,0.000072672636,0.00044193654,0.0004136244,0.00031113267,0.00013238774],"about_ca_topic_score_codex":0.041395165,"about_ca_topic_score_gemma":0.0012610891,"teacher_disagreement_score":0.040134076,"about_ca_system_score_codex":0.00008693117,"about_ca_system_score_gemma":0.00007120964,"threshold_uncertainty_score":0.9649883},"labels":[],"label_agreement":null},{"id":"W2088155036","doi":"10.1111/j.1365-2133.2008.08771.x","title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","year":2008,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Etanercept; Medicine; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Surgery; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.013127596193070683,"score_gpt":0.23315935662622386,"score_spread":0.22003176043315317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088155036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946431,0.002139728,0.00016847352,0.00034749391,0.00026466078,0.0022750685,0.000026890528,0.000009923596,0.00012469568],"genre_scores_gemma":[0.9984063,0.00054972013,0.00057608925,0.00015899492,0.000017710097,0.00007756274,0.000043185522,0.000021101285,0.00014935418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99706775,0.0010619155,0.0011617987,0.00030110547,0.000109612076,0.0002977912],"domain_scores_gemma":[0.9980918,0.00041175948,0.000867093,0.00014437322,0.0004172109,0.0000677355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031644147,0.0002639407,0.002295126,0.00021939808,0.0001665483,0.000034083692,0.00020927699,0.0003093834,0.00006508763],"category_scores_gemma":[0.00013665832,0.00020225495,0.00009635645,0.0001745543,0.00024180875,0.00022427892,0.000040101986,0.0002750588,0.000008098889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99132526,0.0015787648,0.0017348462,0.000012523859,0.00082493963,0.0011892449,0.000453738,0.0000235039,0.0005806786,0.000011038626,0.000557214,0.0017082394],"study_design_scores_gemma":[0.9650125,0.002778389,0.004997657,0.00032736023,0.00042568025,0.023832573,0.00009295811,0.000019395244,0.0022000745,0.000016196615,0.00006487856,0.00023233466],"about_ca_topic_score_codex":0.00007909977,"about_ca_topic_score_gemma":0.00014229298,"teacher_disagreement_score":0.026312765,"about_ca_system_score_codex":0.00002998852,"about_ca_system_score_gemma":0.00035665676,"threshold_uncertainty_score":0.8247717},"labels":[],"label_agreement":null},{"id":"W2088569180","doi":"10.1038/jid.2012.163","title":"Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial","year":2012,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amgen","keywords":"Psoriasis; Medicine; Placebo; Randomized controlled trial; Antibody response; Clinical trial; Internal medicine; Pharmacology; Antibody; Immunology; Pathology; Alternative medicine","score_opus":0.03603419821464761,"score_gpt":0.31141154483526073,"score_spread":0.27537734662061314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088569180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8112722,0.0014777884,0.00009090399,0.17679869,0.0046560536,0.004422008,0.0011363345,0.00004293428,0.000103088554],"genre_scores_gemma":[0.74285644,0.00094735075,0.0053430824,0.23602673,0.006909023,0.0012133187,0.003344625,0.0003595755,0.00299986],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.97088385,0.021720316,0.004667781,0.0010880445,0.00030871504,0.0013312801],"domain_scores_gemma":[0.9799585,0.014315542,0.003832522,0.0008096004,0.00071084825,0.00037304123],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.005687262,0.0012857142,0.008262978,0.0016499527,0.00022920898,0.00007506381,0.00092877826,0.003050933,0.0002793045],"category_scores_gemma":[0.009006888,0.0008302137,0.001239281,0.000598587,0.0011518936,0.00034585083,0.00016098052,0.003732167,0.00047836688],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6853742,0.000597265,0.00006080074,0.000017449833,0.0038899262,0.0017533648,0.0019420601,0.000021963953,0.012419281,0.0000038915523,0.29366106,0.0002587268],"study_design_scores_gemma":[0.89561236,0.004181361,0.00014522887,0.00063199265,0.0021214637,0.0013206367,0.00016295505,0.0000036314425,0.028169418,0.00008451237,0.06665503,0.0009113859],"about_ca_topic_score_codex":0.00007593936,"about_ca_topic_score_gemma":0.000042189316,"teacher_disagreement_score":0.227006,"about_ca_system_score_codex":0.0002582181,"about_ca_system_score_gemma":0.0017944204,"threshold_uncertainty_score":0.99998945},"labels":[],"label_agreement":null},{"id":"W2088712063","doi":"10.1186/2051-1426-1-s1-p146","title":"Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Ovarian cancer; Nitric oxide; Endogeny; Cancer; Cancer research; Nitric oxide synthase; Ascites; RAR-related orphan receptor gamma; Cancer cell; Medicine; Chemistry; Cell biology; Immunology; Biology; Internal medicine; Immune system","score_opus":0.03533179665720833,"score_gpt":0.2758429772357749,"score_spread":0.24051118057856657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088712063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615107,0.037151422,0.000009385244,0.000097660966,0.00043655385,0.00060948316,0.00015710885,0.0000054420957,0.000022229302],"genre_scores_gemma":[0.97882396,0.020472003,0.00021756871,0.0000383358,0.000018279961,0.0002482647,0.0000039575707,0.00002122764,0.0001564115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853843,0.0001852969,0.0005931369,0.00023417966,0.0000676349,0.0003813254],"domain_scores_gemma":[0.9989429,0.00021437107,0.0005385027,0.00013015859,0.00014394749,0.000030118154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004831985,0.0002268701,0.0006129015,0.00021504865,0.00012689282,0.000015948643,0.00013983705,0.0002207182,0.00033672497],"category_scores_gemma":[0.000014769057,0.00018841751,0.00008919842,0.00019468856,0.00013076226,0.00020788782,0.000026920025,0.00020814824,8.1120464e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000938016,0.00030002705,0.057575967,0.00005747619,0.00049011724,0.0000013833859,0.0018572093,0.000012731927,0.8334671,0.0000028514855,0.000038787166,0.105258286],"study_design_scores_gemma":[0.004447088,0.00010941044,0.2575284,0.00014002757,0.000043144664,0.0000036922213,0.00017405149,0.0000029957566,0.73643446,0.00006016339,0.00090498617,0.00015159078],"about_ca_topic_score_codex":0.016393585,"about_ca_topic_score_gemma":0.0056815287,"teacher_disagreement_score":0.19995241,"about_ca_system_score_codex":0.00039796502,"about_ca_system_score_gemma":0.0004099889,"threshold_uncertainty_score":0.99015635},"labels":[],"label_agreement":null},{"id":"W2088802427","doi":"10.1016/j.jaad.2009.05.042","title":"A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Placebo; Monoclonal antibody; Interferon alfa; Double blind; Monoclonal; Internal medicine; Placebo-controlled study; Interferon; Antibody; Dermatology; Immunology; Gastroenterology; Alpha interferon; Pathology; Alternative medicine","score_opus":0.020838323158465445,"score_gpt":0.32371114343321705,"score_spread":0.3028728202747516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088802427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951848,0.0015767512,0.000027355958,0.0012254108,0.00061233673,0.0012886726,0.000017790133,0.000010856434,0.00005607146],"genre_scores_gemma":[0.9991902,0.00039063816,0.00012583433,0.00007743822,0.00009900238,0.000050507213,0.000006848601,0.000029158096,0.000030381561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99569273,0.0017212322,0.0016192832,0.00030851975,0.0001792991,0.0004789252],"domain_scores_gemma":[0.99523336,0.0008973209,0.0033459668,0.00032186616,0.00012856296,0.00007294739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001022092,0.00038879973,0.0030998576,0.0006565278,0.00010255907,0.000008932087,0.0009831715,0.0002946514,0.000085200365],"category_scores_gemma":[0.00012075549,0.00022497546,0.00046718842,0.00048350153,0.0014497291,0.0002103793,0.000113818576,0.0011506772,0.0000064351307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81276727,0.0026994182,0.026363557,0.000025499921,0.003145493,0.000067409455,0.0013246164,0.00004901672,0.15064749,0.00010151193,0.00006978778,0.0027389575],"study_design_scores_gemma":[0.8997946,0.0028377485,0.0042743552,0.00009077974,0.0015532882,0.0043445155,0.0010663457,0.000029981633,0.08555785,0.00006141003,0.00014266974,0.00024645685],"about_ca_topic_score_codex":0.00024748666,"about_ca_topic_score_gemma":0.00022870974,"teacher_disagreement_score":0.087027356,"about_ca_system_score_codex":0.000043758966,"about_ca_system_score_gemma":0.00031783717,"threshold_uncertainty_score":0.9174233},"labels":[],"label_agreement":null},{"id":"W2089797941","doi":"10.1016/j.bbmt.2009.12.456","title":"Patients With Cutaneous Graft Versus Host Disease Exhibit Reduced Production Of IL-17","year":2010,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pathogenesis; Medicine; Graft-versus-host disease; Immunology; Peripheral blood mononuclear cell; Ionomycin; Disease; Pathology; Internal medicine; Stimulation; Biology; In vitro","score_opus":0.006880622190508948,"score_gpt":0.20328217195629578,"score_spread":0.19640154976578683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089797941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980426,0.0003469008,0.0000060218326,0.000056974535,0.0008237891,0.0002537382,0.0003572612,0.000021747415,0.00009096686],"genre_scores_gemma":[0.9982396,0.00030636488,0.0001437682,0.000004875351,0.00002506796,0.00001608192,0.0011497107,0.000007890238,0.00010663406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993515,0.000063895866,0.00018706436,0.00023594277,0.000023619092,0.0001380059],"domain_scores_gemma":[0.9995692,0.000064119966,0.00013548724,0.00013143133,0.000074818876,0.000024981573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000052230946,0.00013131187,0.00019501243,0.000080860584,0.00007122648,0.0000017280291,0.000055456294,0.00015555862,0.0000388311],"category_scores_gemma":[0.00001770835,0.00010161027,0.000040446153,0.00006078613,0.00025560596,0.000050965762,0.000004915313,0.000078369805,0.000003063309],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005248898,0.00030837336,0.077503264,0.00007437032,0.00028088843,0.0000036394795,0.00023860582,4.4615263e-7,0.9123156,0.00016044982,0.000016323662,0.0038491364],"study_design_scores_gemma":[0.007180451,0.0014165004,0.21984968,0.000049738348,0.0016151305,0.00004572408,0.000035761284,1.8241123e-7,0.7692817,0.000058305883,0.000269908,0.00019693885],"about_ca_topic_score_codex":0.0000338399,"about_ca_topic_score_gemma":0.00009026351,"teacher_disagreement_score":0.14303392,"about_ca_system_score_codex":0.000001995075,"about_ca_system_score_gemma":0.00003100094,"threshold_uncertainty_score":0.41435465},"labels":[],"label_agreement":null},{"id":"W2090871631","doi":"10.4137/cmped.s13775","title":"Erratum for “Treatment of Childhood Psoriasis with Phototherapy and Photochemotherapy”","year":2014,"lang":"en","type":"erratum","venue":"Clinical Medicine Insights Pediatrics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology; University hospital; Sick child; Family medicine; Pediatrics","score_opus":0.03106225794730494,"score_gpt":0.3054717594930776,"score_spread":0.27440950154577265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090871631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23519282,0.53896093,0.0011282894,0.0029922666,0.178606,0.013772693,0.0012746034,0.0006037309,0.02746864],"genre_scores_gemma":[0.0527265,0.6181262,0.0024125776,0.0029158157,0.046256177,0.0020768996,0.010569012,0.00087025936,0.26404655],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641,0.00034353344,0.0014852049,0.0010823128,0.00015123366,0.00052767945],"domain_scores_gemma":[0.9950938,0.002350179,0.0012191918,0.0008696248,0.0003235542,0.00014362817],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00039692648,0.00089241454,0.0027272524,0.0003934621,0.00019578994,0.000011341896,0.00033978376,0.0020720274,0.00018139133],"category_scores_gemma":[0.00032515978,0.00052593375,0.00044587877,0.0003161412,0.00087327167,0.000044355882,0.000031723477,0.00042455894,0.000022456834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002533487,0.0023599707,0.0029718713,0.00041697387,0.0029994475,0.000017772212,0.001974811,2.2467586e-7,0.00019376558,0.00013708866,0.86607164,0.12032292],"study_design_scores_gemma":[0.024220249,0.022058116,0.003910398,0.0002808067,0.0037622396,0.000036645826,0.00013350538,0.0000026343494,0.0006255763,0.00065278425,0.94362843,0.000688621],"about_ca_topic_score_codex":0.00006983549,"about_ca_topic_score_gemma":0.000079495774,"teacher_disagreement_score":0.23657791,"about_ca_system_score_codex":0.000061515595,"about_ca_system_score_gemma":0.00044254577,"threshold_uncertainty_score":0.9997192},"labels":[],"label_agreement":null},{"id":"W2093738326","doi":"10.3899/jrheum.101119","title":"Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Epidemiology; Population; Dermatology; Arthritis; Physical therapy; Family medicine; Internal medicine; Environmental health","score_opus":0.04404283781201571,"score_gpt":0.25931399978279884,"score_spread":0.21527116197078314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093738326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772941,0.015771605,0.0015387794,0.0013848853,0.0031983738,0.00016254942,0.00005036452,0.00003522989,0.00056410476],"genre_scores_gemma":[0.9953463,0.0019062101,0.002107809,0.00028346648,0.00006989097,0.000009580301,0.00002767818,0.000026616806,0.00022242604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949538,0.0027650984,0.0014094292,0.00023791961,0.00006348801,0.00057024596],"domain_scores_gemma":[0.99179864,0.0056222193,0.0017334104,0.000589075,0.00021669261,0.000039939066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041601392,0.00029384726,0.0009097298,0.00011100964,0.00044826686,0.0000052597698,0.0008486381,0.0003881224,0.00050986436],"category_scores_gemma":[0.0022143924,0.00015206612,0.0003446637,0.00017878404,0.00049499614,0.00013323915,0.00015036855,0.0006091449,0.00014316473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060922666,0.00023311804,0.87141323,0.000008115225,0.0046543377,0.00018897478,0.008459833,0.00001805277,0.0015679679,0.001329044,0.039473042,0.06656202],"study_design_scores_gemma":[0.017562034,0.0025963162,0.72153896,0.0005996393,0.0053363377,0.12463238,0.014973391,0.000019656269,0.009723638,0.015593288,0.08603189,0.0013924389],"about_ca_topic_score_codex":0.0022686175,"about_ca_topic_score_gemma":0.0002481057,"teacher_disagreement_score":0.14987424,"about_ca_system_score_codex":0.000022847797,"about_ca_system_score_gemma":0.00010614038,"threshold_uncertainty_score":0.62010765},"labels":[],"label_agreement":null},{"id":"W2093785176","doi":"10.1182/blood-2009-04-216085","title":"Evidence for a cross-talk between human neutrophils and Th17 cells","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":761,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Università degli Studi di Verona; Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona; Associazione Italiana per la Ricerca sul Cancro","keywords":"CCL20; C-C chemokine receptor type 6; Chemokine; Interleukin 17; Immunology; Chemotaxis; Tumor necrosis factor alpha; Biology; CCR2; CXCL16; Chemokine receptor; Cell biology; Cytokine; Inflammation; Receptor","score_opus":0.05511394460269681,"score_gpt":0.308155979884125,"score_spread":0.2530420352814282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093785176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148375,0.007559636,0.000014974056,0.0001121189,0.00012290377,0.00028228856,0.000067370995,0.0000544542,0.00030248784],"genre_scores_gemma":[0.99815506,0.0001776003,0.00013629175,0.00007062485,0.00012629342,0.00002395359,0.00006491515,0.000008710539,0.0012365448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992515,0.000046414734,0.00015995612,0.00026404034,0.000016828393,0.00026130446],"domain_scores_gemma":[0.9995196,0.00016878148,0.000062330946,0.00019618006,0.000029457631,0.000023665883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011522286,0.00014154092,0.00021281408,0.00004385844,0.00025369038,0.000027724975,0.0001237001,0.00016866905,0.000042985397],"category_scores_gemma":[0.000021618964,0.0001215554,0.000082919076,0.000047183912,0.00007424139,0.000103257844,0.000021463633,0.00006144271,0.000044163942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079085214,0.00023553666,0.030394053,0.000017371434,0.00022282744,0.000008874374,0.00017699519,2.1493776e-7,0.9541185,0.00029397022,0.00027042252,0.014182152],"study_design_scores_gemma":[0.004061205,0.000855617,0.34717596,0.00005074032,0.00047189198,0.000022571177,0.00001092844,5.8351098e-8,0.6434155,0.00070764025,0.003036717,0.00019117026],"about_ca_topic_score_codex":0.0000138724845,"about_ca_topic_score_gemma":0.0000035909768,"teacher_disagreement_score":0.3167819,"about_ca_system_score_codex":0.0000061998066,"about_ca_system_score_gemma":0.000013973556,"threshold_uncertainty_score":0.49568853},"labels":[],"label_agreement":null},{"id":"W2094634198","doi":"10.3899/jrheum.100146","title":"Frequency and Phenotype of T Helper 17 Cells in Peripheral Blood and Synovial Fluid of Patients with Reactive Arthritis","year":2010,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Medicine; Flow cytometry; Immunology; Synovial fluid; Cytokine; Interleukin 21; Arthritis; T cell; Pathology; Immune system; Biology; In vitro","score_opus":0.004026153636335397,"score_gpt":0.18476946176702005,"score_spread":0.18074330813068465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094634198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695075,0.00254894,0.000004820678,0.00004448239,0.0002614702,0.00009342518,0.000027842503,0.00000190963,0.00006634212],"genre_scores_gemma":[0.9987511,0.0010293858,0.00017989628,0.000008076675,0.0000031741654,0.0000011628289,0.000003621398,0.000007120297,0.000016455278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999209,0.00018013321,0.00035771308,0.00008048541,0.000032384334,0.00014030084],"domain_scores_gemma":[0.9991675,0.00020802839,0.00037950044,0.00011099829,0.000117000825,0.000016959244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021723734,0.000110286266,0.00043316235,0.000092139875,0.00004110021,0.000001783892,0.00010089615,0.0001493726,0.00009417024],"category_scores_gemma":[0.00003765942,0.000067053,0.000031488456,0.00005744762,0.00047765707,0.00006920379,0.000026998945,0.00021699737,0.0000011319274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011661032,0.00026819392,0.6465864,0.000016147242,0.0003330043,0.0000044188055,0.0021929028,6.0439214e-7,0.34573346,0.00021667231,0.00003058196,0.0034515064],"study_design_scores_gemma":[0.017646864,0.0034788502,0.7960114,0.00025897202,0.00050579046,0.002777493,0.0010150089,8.9060364e-7,0.17708358,0.000830037,0.00013026639,0.00026084587],"about_ca_topic_score_codex":0.00023838422,"about_ca_topic_score_gemma":0.00042724906,"teacher_disagreement_score":0.16864987,"about_ca_system_score_codex":0.0000045432853,"about_ca_system_score_gemma":0.000050933835,"threshold_uncertainty_score":0.2734342},"labels":[],"label_agreement":null},{"id":"W2095107490","doi":"10.1007/s10227-005-0035-1","title":"Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel","year":2004,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Guenther Dermatology Research Centre; Université Laval; University of Manitoba; University of British Columbia; Probity Medical Research; University of Calgary; Innovaderm (Canada); University Health Network; Dalhousie University; Western University; University of Toronto; Lynde Centre for Dermatology; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psoriasis; Quality of life (healthcare); Clinical trial; Panel discussion; Intensive care medicine; Disease; Dermatology; Internal medicine; Nursing","score_opus":0.04447640236346012,"score_gpt":0.2637940386200915,"score_spread":0.21931763625663137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095107490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888082,0.006248889,0.000019394902,0.002623114,0.001527907,0.0001769823,0.0000139203485,0.000005980038,0.00057562435],"genre_scores_gemma":[0.9971935,0.0016820603,0.00033230253,0.00051758037,0.000089690526,0.000004359083,0.000006362639,0.000011841215,0.00016231577],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838483,0.00020309121,0.0008468343,0.0001662815,0.00011698442,0.00028197136],"domain_scores_gemma":[0.9985348,0.00039398135,0.0005399782,0.00021143361,0.00021706501,0.00010274709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005505699,0.00021354429,0.0007564878,0.0003422811,0.00018522728,0.000005768444,0.00019195188,0.00018280756,0.00008644236],"category_scores_gemma":[0.0002451646,0.000121199315,0.00020368487,0.00026023615,0.0002421928,0.000026708514,0.000038780458,0.00018159885,0.0000038774597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011207607,0.001515749,0.08037676,0.0011079202,0.016243804,0.007816627,0.055696618,0.0011858576,0.1498691,0.0031612068,0.06394992,0.60786885],"study_design_scores_gemma":[0.057329506,0.014910666,0.118808545,0.041870616,0.012494772,0.10305187,0.17503643,0.00006127335,0.32614905,0.027708935,0.117163174,0.005415159],"about_ca_topic_score_codex":0.011194399,"about_ca_topic_score_gemma":0.0052843057,"teacher_disagreement_score":0.60245365,"about_ca_system_score_codex":0.0001141394,"about_ca_system_score_gemma":0.0002944786,"threshold_uncertainty_score":0.9953901},"labels":[],"label_agreement":null},{"id":"W2095273564","doi":"10.1111/jdv.12210","title":"Factors influencing seasonal patterns of relapse in anti‐<scp>TNF</scp> psoriatic responders after temporary drug discontinuation","year":2013,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canada's Michael Smith Genome Sciences Centre","keywords":"Medicine; Discontinuation; Drug; Tumor necrosis factor alpha; Psoriasis; Internal medicine; Pharmacology; Immunology","score_opus":0.017700943385415537,"score_gpt":0.22878811725361556,"score_spread":0.21108717386820003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095273564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634125,0.008023886,0.0000050329895,0.027107146,0.0009992697,0.00021250798,0.00006277647,0.000008752265,0.00016808358],"genre_scores_gemma":[0.9899894,0.00066272356,0.00001852567,0.00815638,0.00024073517,0.0000040370214,0.000046613804,0.000049916078,0.000831657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313927,0.0044984394,0.0014725807,0.00032190248,0.00011547744,0.0004523096],"domain_scores_gemma":[0.9960529,0.0010772345,0.002526125,0.00023393384,0.000074007556,0.000035794485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006359815,0.00044830827,0.0013197873,0.0006206416,0.00008885971,0.0000084128005,0.000716125,0.0011245199,0.000047336438],"category_scores_gemma":[0.00026326612,0.000296955,0.0003895162,0.00016056836,0.0005450209,0.00021432602,0.00027120605,0.002295609,0.000017070584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013005451,0.00010576096,0.9253086,0.00025949528,0.0010055858,0.0002987966,0.0018739635,0.000006516128,0.0022095137,0.000035581415,0.06782507,0.0009410587],"study_design_scores_gemma":[0.0025585736,0.00006421456,0.94822687,0.0006516888,0.0006853058,0.0019662734,0.00042797896,0.0000012562249,0.008719779,0.00034059273,0.036160294,0.0001971807],"about_ca_topic_score_codex":0.000023374605,"about_ca_topic_score_gemma":0.0000042350202,"teacher_disagreement_score":0.031664778,"about_ca_system_score_codex":0.000040111325,"about_ca_system_score_gemma":0.00009786307,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W2095312613","doi":"10.2310/7750.2006.00014","title":"Efalizumab in the Treatment of Psoriasis","year":2006,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Mediprobe Research (Canada); Sunnybrook Health Science Centre","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Plaque psoriasis; Clinical trial; Randomized controlled trial; Internal medicine","score_opus":0.05736309729129946,"score_gpt":0.3074424336461156,"score_spread":0.25007933635481616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095312613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043293578,0.99375314,9.571183e-7,0.00012728185,0.0011517026,0.00021223786,0.000021908558,0.0000036011372,0.000399801],"genre_scores_gemma":[0.0009696735,0.9980084,0.000006119633,0.000029459896,0.00040954235,0.000009554925,0.000069004214,0.000018602186,0.00047968386],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974039,0.00066097506,0.001437418,0.00015895597,0.000100295445,0.00023843745],"domain_scores_gemma":[0.9948771,0.0036326605,0.0011697519,0.00022828153,0.000067939836,0.000024264467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058257434,0.00035978935,0.0030584317,0.00060603,0.000051954725,0.0000050921676,0.00016066658,0.00035141874,0.00010094332],"category_scores_gemma":[0.000099872166,0.0001642561,0.0007144309,0.00026627188,0.00018554363,0.000026298634,0.0000069409216,0.00020159213,0.0000072685903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011217281,0.0003477045,0.00014690985,0.00085924426,0.00075634697,0.0014210794,0.00048675976,1.3370901e-7,0.0000042930137,0.000012629686,0.009718282,0.98613447],"study_design_scores_gemma":[0.0007128877,0.00094098656,0.0000313205,0.0041955067,0.0029992603,0.01587022,0.00016318263,2.2835668e-8,0.000007538011,0.00003229611,0.9749211,0.00012566395],"about_ca_topic_score_codex":0.0001118184,"about_ca_topic_score_gemma":0.00002565761,"teacher_disagreement_score":0.98600876,"about_ca_system_score_codex":0.00007387253,"about_ca_system_score_gemma":0.00022569064,"threshold_uncertainty_score":0.6698169},"labels":[],"label_agreement":null},{"id":"W2096567616","doi":"10.1164/rccm.201410-1861oc","title":"IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke–induced Lymphoid Neogenesis","year":2015,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"COPD; Medicine; Interleukin 17; Neogenesis; Lung; Immunology; Obstructive lung disease; Pathology; Internal medicine; Inflammation","score_opus":0.024674768666054853,"score_gpt":0.28823013149251675,"score_spread":0.2635553628264619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096567616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.949645,0.047413442,0.000021367501,0.0022148665,0.00037681652,0.00014099714,0.000114834394,0.000011253425,0.00006146726],"genre_scores_gemma":[0.9974409,0.00015296786,0.000013633148,0.0021456585,0.00017182025,0.000013574098,0.000013915589,0.000016367587,0.000031172956],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983236,0.00041629362,0.00047654222,0.0002999862,0.00011850375,0.00036507763],"domain_scores_gemma":[0.9985515,0.0004130468,0.0001403627,0.00017608948,0.0003705908,0.00034839616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039422794,0.00024590132,0.0006649573,0.00029225927,0.00009816646,0.000011098849,0.00013598494,0.000098542405,0.000094543895],"category_scores_gemma":[0.00067195593,0.00018646513,0.00006581872,0.0003335808,0.0008966254,0.000105784886,0.000057169556,0.00021832855,0.0000034010643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005422557,0.00018249077,0.3747614,0.00011698131,0.0005271704,0.0018588344,0.0037276896,0.0000024976916,0.13415271,0.0005252026,0.00058144284,0.47814104],"study_design_scores_gemma":[0.012428787,0.01478499,0.8304927,0.00076179986,0.0018615758,0.000696834,0.03403604,0.0000043124396,0.058305185,0.0005333488,0.04521448,0.0008799905],"about_ca_topic_score_codex":0.000114399874,"about_ca_topic_score_gemma":0.000014392245,"teacher_disagreement_score":0.47726104,"about_ca_system_score_codex":0.00018631156,"about_ca_system_score_gemma":0.0003038899,"threshold_uncertainty_score":0.7603827},"labels":[],"label_agreement":null},{"id":"W2097935815","doi":"10.1056/nejmoa1010858","title":"A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Methotrexate; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Surgery; Dermatology","score_opus":0.03962854020416268,"score_gpt":0.24207024753002349,"score_spread":0.2024417073258608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097935815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620736,0.0007365708,0.00015422575,0.00011643959,0.0010097177,0.00022300122,0.0000024439469,0.000010674644,0.001539551],"genre_scores_gemma":[0.99832755,0.000059233953,0.00077832513,0.000047338755,0.0004929525,0.000003018103,0.000015559945,0.00001689105,0.0002591187],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986668,0.00029760425,0.0004970171,0.00015993982,0.00011755687,0.00026104177],"domain_scores_gemma":[0.99903023,0.00016760359,0.00044429145,0.00015756689,0.0001276586,0.00007265662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006310184,0.00020677602,0.00069256854,0.0002744467,0.000050843704,0.0000042412908,0.00017453684,0.00009698065,0.00044880263],"category_scores_gemma":[0.00008421248,0.000109442415,0.00005075646,0.00020373674,0.00011015951,0.00011058264,0.000015746444,0.00028618172,0.000011976417],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38681963,0.0009890011,0.39548308,0.000014018982,0.001245254,0.00022796175,0.0061801123,0.0000094945935,0.00038576004,0.0000758677,0.0007866797,0.20778315],"study_design_scores_gemma":[0.69652706,0.013707956,0.28360152,0.00032674934,0.00060734135,0.00020881041,0.00019123135,4.6587343e-7,0.0010403326,0.00009622072,0.0035294886,0.0001628068],"about_ca_topic_score_codex":0.0003515838,"about_ca_topic_score_gemma":0.00033275614,"teacher_disagreement_score":0.3097074,"about_ca_system_score_codex":0.00003967419,"about_ca_system_score_gemma":0.000103238046,"threshold_uncertainty_score":0.4914074},"labels":[],"label_agreement":null},{"id":"W2098835966","doi":"10.1111/j.1365-2133.2005.06948.x","title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","year":2005,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Etanercept; Dermatology Life Quality Index; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Physical therapy; Surgery; Dermatology; Tumor necrosis factor alpha; Pathology; Nursing","score_opus":0.01380888393346637,"score_gpt":0.25708492088982243,"score_spread":0.24327603695635605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098835966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040926,0.007157025,0.00012175561,0.00044852993,0.0007275071,0.0007683143,0.000085683,0.000013311395,0.0002686461],"genre_scores_gemma":[0.99722934,0.0018835666,0.0005065727,0.00009556563,0.000047036443,0.000029973227,0.00004786178,0.000017869503,0.00014224535],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963092,0.0006746572,0.0023876417,0.00020431902,0.00012662489,0.00029752747],"domain_scores_gemma":[0.9960075,0.00051446684,0.0028025992,0.00022541563,0.00040609698,0.000043898544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005251244,0.00023081986,0.0021128128,0.0002358793,0.000073816416,0.000009164939,0.00019789017,0.00026155202,0.00018587291],"category_scores_gemma":[0.0002811492,0.00017556881,0.0005771256,0.0001376512,0.0003539777,0.00012710433,0.000028943734,0.00020934873,0.0000041728304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7146586,0.0022108627,0.00027254276,0.0000098421,0.0056011574,0.00055913144,0.00078557275,0.0000037237182,0.017819792,0.00001778624,0.0011791325,0.25688183],"study_design_scores_gemma":[0.8571948,0.0018951084,0.00027586427,0.000078713354,0.00085415755,0.012843803,0.00022541138,0.0000012117299,0.12436951,0.000026482934,0.0020803774,0.00015459451],"about_ca_topic_score_codex":0.00015624489,"about_ca_topic_score_gemma":0.00005280273,"teacher_disagreement_score":0.25672725,"about_ca_system_score_codex":0.000025416686,"about_ca_system_score_gemma":0.00019589317,"threshold_uncertainty_score":0.7159489},"labels":[],"label_agreement":null},{"id":"W2100107304","doi":"10.1016/j.jaad.2014.10.026","title":"Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis","year":2014,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amgen","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Discontinuation; Psoriatic arthritis; Secukinumab; Placebo; Internal medicine; Dermatology; Pathology","score_opus":0.008354940819251108,"score_gpt":0.23906012908527388,"score_spread":0.23070518826602276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100107304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975393,0.00016615372,0.00008259912,0.0018000774,0.000076460215,0.00023558536,0.000055658176,0.0000034754057,0.000040706345],"genre_scores_gemma":[0.99924916,0.00007639585,0.0004878408,0.00013152597,0.000010434261,0.0000034198868,0.0000058625706,0.000012339383,0.000023015447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833727,0.00046237072,0.0007523052,0.00015322216,0.00008030361,0.00021450335],"domain_scores_gemma":[0.9981979,0.00037586995,0.0011220648,0.00014867826,0.000109556466,0.0000459061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011788653,0.00017230434,0.00091320294,0.00029385957,0.000057368354,0.0000019248625,0.00030584558,0.00013209252,0.000011136752],"category_scores_gemma":[0.00014549887,0.00010853377,0.000095145,0.00042022622,0.0003344138,0.000058566784,0.00008255007,0.00022004501,0.0000028853526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013222641,0.000690287,0.9422645,0.000056942255,0.0005537294,0.0000022201805,0.0011955802,0.0014066905,0.024693059,0.00042387823,0.00055547385,0.0149350185],"study_design_scores_gemma":[0.0058216574,0.00049555564,0.9655426,0.000106751264,0.00021490961,0.00017912756,0.00010310028,0.0000048851807,0.026957227,0.000063535255,0.00039423833,0.00011637165],"about_ca_topic_score_codex":0.00005934611,"about_ca_topic_score_gemma":0.00001763066,"teacher_disagreement_score":0.023278162,"about_ca_system_score_codex":0.000028984396,"about_ca_system_score_gemma":0.000045473957,"threshold_uncertainty_score":0.44258785},"labels":[],"label_agreement":null},{"id":"W2102143593","doi":"10.4049/jimmunol.1003715","title":"TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Multiple Sclerosis Society","keywords":"Effector; Phenotype; TLR2; Stimulation; Function (biology); Cell biology; Biology; Neuroscience; Gene; Genetics; Signal transduction","score_opus":0.012795602616161278,"score_gpt":0.21607694169714545,"score_spread":0.20328133908098417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102143593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99137723,0.007134954,0.00010450161,0.000040300034,0.0009385791,0.00019319986,0.0000037038274,0.000019703824,0.00018780821],"genre_scores_gemma":[0.9991793,0.00019091113,0.00013670525,0.000036897505,0.000057286812,0.000005223616,0.000012959564,0.000018124683,0.00036257968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986371,0.00065017527,0.00031381086,0.00014081637,0.000041726882,0.00021636928],"domain_scores_gemma":[0.9988635,0.00020854047,0.00050125015,0.00025010944,0.00015694356,0.000019635434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031416462,0.00019648878,0.0003369645,0.00014973305,0.00030917572,0.000006962025,0.00019856424,0.0002164092,0.00022641203],"category_scores_gemma":[0.000018056426,0.0001152369,0.00006932345,0.00008727182,0.00043095337,0.00015192051,0.000055837532,0.00027857823,0.00004957675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049107424,0.00012109536,0.0017136002,0.00000871329,0.0013718592,0.000009777689,0.005488473,0.000007760033,0.9791649,0.00021405924,0.00023721685,0.0067518284],"study_design_scores_gemma":[0.005086842,0.0055563017,0.40283823,0.00009111574,0.0012799833,0.000463422,0.0012643595,0.0000013930049,0.58136165,0.0011782687,0.00064102234,0.00023741035],"about_ca_topic_score_codex":0.00007596288,"about_ca_topic_score_gemma":0.000019663486,"teacher_disagreement_score":0.40112463,"about_ca_system_score_codex":0.000042550284,"about_ca_system_score_gemma":0.000050553128,"threshold_uncertainty_score":0.46992245},"labels":[],"label_agreement":null},{"id":"W2102417014","doi":"10.1159/000149970","title":"Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus","year":2008,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"LEO Pharma","keywords":"Infliximab; Medicine; Psoriasis; Dermatology; Expert opinion; Delphi method; MEDLINE; Delphi; Alternative medicine; Intensive care medicine; Family medicine; Internal medicine; Disease; Pathology","score_opus":0.044891892441980025,"score_gpt":0.2771967326334308,"score_spread":0.23230484019145078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102417014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97281086,0.015734173,0.0013300682,0.0072051645,0.0011204326,0.001204252,0.00018034509,0.00011791188,0.00029676556],"genre_scores_gemma":[0.9944263,0.0025927147,0.0009186478,0.000291509,0.00003986159,0.0008468587,0.00044813176,0.00003196702,0.00040399106],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838454,0.0002740409,0.0004748613,0.00035445165,0.000031755313,0.0004803822],"domain_scores_gemma":[0.99783266,0.0012788256,0.0002537308,0.00049204146,0.00010971618,0.00003302386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039092774,0.00031761767,0.00066378823,0.0001519105,0.0005079446,0.000004779166,0.00021797184,0.00031989618,0.00019576875],"category_scores_gemma":[0.000027009675,0.00019959739,0.00020300467,0.00015767213,0.0006875659,0.000041951207,0.000031897463,0.00007528395,0.000081517755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012180832,0.007426721,0.58700925,0.0002188523,0.01731961,0.0016995291,0.022515183,0.000014515012,0.03841962,0.016027072,0.075583555,0.22158524],"study_design_scores_gemma":[0.044694215,0.0030515299,0.1026727,0.00009022566,0.002020674,0.079923995,0.0016141903,0.000031951033,0.36390027,0.0001989764,0.4005129,0.0012883549],"about_ca_topic_score_codex":0.0001197662,"about_ca_topic_score_gemma":0.00024433274,"teacher_disagreement_score":0.48433656,"about_ca_system_score_codex":0.00004918203,"about_ca_system_score_gemma":0.00012019289,"threshold_uncertainty_score":0.81393456},"labels":[],"label_agreement":null},{"id":"W2102889851","doi":"10.1038/ng.2467","title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","year":2012,"lang":"en","type":"review","venue":"Nature Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1047,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital; University of Toronto; Centre for Addiction and Mental Health","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Human Genome Research Institute; National Institute for Health and Care Research; Canadian Institutes of Health Research; Versus Arthritis; Medical Research Council; Wellcome Trust","keywords":"Biology; Genome-wide association study; Innate immune system; Psoriasis; Genetics; Candidate gene; Genetic architecture; Immunology; Immune system; Gene; Computational biology; Phenotype; Single-nucleotide polymorphism; Genotype","score_opus":0.022818241077731772,"score_gpt":0.2848450931229573,"score_spread":0.2620268520452255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102889851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042650034,0.9927503,0.0000070466276,0.000016649272,0.0016561155,0.0007085209,0.00038512936,0.000023775548,0.00018746301],"genre_scores_gemma":[0.058552805,0.93943244,0.00006630175,0.0000061173205,0.0001998361,0.000023390405,0.0008544605,0.00003597993,0.0008286944],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974254,0.0007974557,0.001000661,0.00035245583,0.00010053345,0.00032352944],"domain_scores_gemma":[0.9969773,0.0002839791,0.0011635983,0.001340986,0.0002008752,0.000033240747],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006201837,0.00043641846,0.0012708413,0.00015248705,0.00012908339,0.000008934606,0.000843181,0.0020975096,0.0001881306],"category_scores_gemma":[0.00008183845,0.00027600164,0.0006090352,0.00041942645,0.00022575236,0.000035023568,0.00017199096,0.0008207958,0.00012497987],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031810865,0.00019045135,0.00016530773,0.0011839744,0.001065773,2.173736e-7,0.00034131182,2.5873217e-7,0.002267614,0.00035487907,0.000442345,0.993956],"study_design_scores_gemma":[0.000311971,0.00006299841,0.0010937941,0.00030662998,0.0041352473,0.000012281115,0.000045606357,1.0899475e-7,0.034301404,0.0003505007,0.9591382,0.00024123417],"about_ca_topic_score_codex":0.000056189565,"about_ca_topic_score_gemma":0.00005735653,"teacher_disagreement_score":0.9937148,"about_ca_system_score_codex":0.000065983426,"about_ca_system_score_gemma":0.0002777194,"threshold_uncertainty_score":0.99996924},"labels":[],"label_agreement":null},{"id":"W2103067301","doi":"10.3899/jrheum.140169","title":"GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Venereology; Psoriatic arthritis; Medicine; Dermatology; Psoriasis; Family medicine; Library science","score_opus":0.012787580229973722,"score_gpt":0.2360266766175406,"score_spread":0.22323909638756687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103067301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759,0.0068341875,0.00026629955,0.014165717,0.0013367338,0.0001990626,0.0000074675386,0.000013934441,0.0012766289],"genre_scores_gemma":[0.9960682,0.0030974704,0.00011797174,0.00030602823,0.000025382999,0.0000048158045,0.000005439078,0.000023864255,0.00035082034],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519485,0.0030519916,0.0010445415,0.0002092409,0.000068619906,0.0004307263],"domain_scores_gemma":[0.997183,0.0011135605,0.0011961538,0.00031835388,0.00013094312,0.0000579651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021460485,0.00024831752,0.0007913894,0.00016801957,0.00026788126,0.000007370398,0.0006114349,0.00023971435,0.000057410056],"category_scores_gemma":[0.00027786984,0.00013907989,0.00014548293,0.00014211469,0.0006413296,0.00005150419,0.00021967429,0.00042347546,0.00010106193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027863923,0.0003937955,0.7624275,0.00017678406,0.0033838493,0.00025525916,0.0076831994,0.0002460848,0.11858128,0.007945021,0.07858319,0.017537605],"study_design_scores_gemma":[0.0068510524,0.0007488092,0.048544638,0.00045192603,0.0017366131,0.34644756,0.0015317628,0.00002794582,0.040872335,0.0014211247,0.5506761,0.0006901276],"about_ca_topic_score_codex":0.00015836602,"about_ca_topic_score_gemma":0.00015555185,"teacher_disagreement_score":0.7138829,"about_ca_system_score_codex":0.000018911234,"about_ca_system_score_gemma":0.000051763116,"threshold_uncertainty_score":0.5671513},"labels":[],"label_agreement":null},{"id":"W2103499669","doi":"10.3109/09546634.2012.713458","title":"Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial","year":2012,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Adalimumab; Psoriasis; Polysomnography; Obstructive sleep apnea; Randomized controlled trial; Placebo; Sleep apnea; Internal medicine; Psoriasis Area and Severity Index; Anesthesia; Apnea; Dermatology; Tumor necrosis factor alpha","score_opus":0.009382823303474402,"score_gpt":0.2342899557498504,"score_spread":0.224907132446376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103499669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441075,0.002364366,0.000012418489,0.00004995908,0.00067541114,0.0023318357,0.000015151746,0.000008722179,0.00013135714],"genre_scores_gemma":[0.9994385,0.00010856164,0.00016905996,0.000018349743,0.000026244985,0.0002015374,0.000013579549,0.000010780782,0.000013347543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962909,0.0021849584,0.00089441036,0.00017474902,0.000111555455,0.00034342252],"domain_scores_gemma":[0.9954654,0.0033891313,0.00086414866,0.00014176256,0.000069183625,0.00007036901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006287076,0.000361272,0.0027855954,0.0002225008,0.00006217617,0.0000085577285,0.00009067371,0.00025152383,0.000032902957],"category_scores_gemma":[0.000330207,0.0001609675,0.0005435169,0.00010510757,0.00021548024,0.00011020669,0.00001809106,0.00015015906,0.000008499804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8997007,0.0021214285,0.077632934,0.000010101347,0.003657883,0.000028729242,0.0002855479,0.000014949376,0.00003664835,0.00006214497,0.000004626077,0.01644433],"study_design_scores_gemma":[0.9556906,0.012390848,0.020973885,0.000042157073,0.002114014,0.000098021155,0.00004637386,0.0000029928212,0.008447831,0.000032230815,0.000016557015,0.00014445082],"about_ca_topic_score_codex":0.0000068497498,"about_ca_topic_score_gemma":8.90556e-7,"teacher_disagreement_score":0.05665905,"about_ca_system_score_codex":0.00011321314,"about_ca_system_score_gemma":0.00001777595,"threshold_uncertainty_score":0.6564064},"labels":[],"label_agreement":null},{"id":"W2103750969","doi":"10.1111/jdv.12751","title":"Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (<scp>JUNCTURE</scp>)","year":2014,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Secukinumab; Medicine; Placebo; Psoriasis Area and Severity Index; Adverse effect; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.009028260821662588,"score_gpt":0.2390158899966629,"score_spread":0.22998762917500032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103750969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901223,0.0060139624,0.000081940096,0.0012673908,0.00069819286,0.00073929166,0.000012355277,0.000007432142,0.0010571392],"genre_scores_gemma":[0.9988179,0.0007514021,0.000050678264,0.0001323964,0.00007602304,0.0000070161113,0.0000056940776,0.000013074845,0.00014580305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.989433,0.008358567,0.0016521728,0.00023014541,0.00006593307,0.0002601752],"domain_scores_gemma":[0.9945045,0.0035056123,0.0017465625,0.00014929741,0.000053326527,0.000040712614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029980673,0.0002535389,0.002115507,0.00017610413,0.00010079566,0.000004962433,0.0003389151,0.00043502208,0.000015091307],"category_scores_gemma":[0.001991063,0.00015229169,0.00037650482,0.00010659689,0.0010516518,0.00007276986,0.00011430734,0.0005302897,0.0000032500961],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.941503,0.0007651817,0.02800536,0.00009338434,0.002119022,0.000018351138,0.001103284,0.0000191315,0.013757566,0.0037265732,0.0013512973,0.00753784],"study_design_scores_gemma":[0.94276357,0.0003404129,0.03259254,0.00007617034,0.0009856141,0.002161485,0.00007635577,0.000017055021,0.014400574,0.0011341145,0.00534771,0.00010440369],"about_ca_topic_score_codex":0.000005361191,"about_ca_topic_score_gemma":0.000004767511,"teacher_disagreement_score":0.008695616,"about_ca_system_score_codex":0.000015894779,"about_ca_system_score_gemma":0.00006842137,"threshold_uncertainty_score":0.62102747},"labels":[],"label_agreement":null},{"id":"W2104297249","doi":"10.1007/s13555-015-0076-3","title":"Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study","year":2015,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Varsinais-Suomen Sairaanhoitopiiri","keywords":"Psoriasis; Medicine; Quarter (Canadian coin); Quality of life (healthcare); Physical therapy; Nursing; Dermatology","score_opus":0.017903952037004626,"score_gpt":0.2444107126873785,"score_spread":0.22650676065037387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104297249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863025,0.012846149,2.9249563e-7,0.00013049228,0.00015245951,0.00033167936,0.000031575728,0.000042195847,0.00016266818],"genre_scores_gemma":[0.9986517,0.00094679417,0.00000410418,0.00017051151,0.000013555536,0.000039410636,0.000028583896,0.000012731919,0.00013264126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899167,0.00031664077,0.00018691366,0.00028300783,0.00003827013,0.00018349799],"domain_scores_gemma":[0.9995034,0.00009695887,0.00008986388,0.00022804676,0.000044907443,0.000036839254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008422948,0.0001975361,0.00035474618,0.00011512459,0.00014137062,0.0000056975196,0.000091161804,0.00020984662,0.000016782937],"category_scores_gemma":[0.000014558012,0.00014996155,0.000037231264,0.000068200316,0.00019654975,0.000042452528,0.00003782068,0.00009498814,0.00007647495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050005987,0.0011781233,0.934188,0.000031103475,0.0009319678,0.00011602999,0.014028251,0.00005399023,0.0058274,0.00090599945,0.0011888715,0.03654963],"study_design_scores_gemma":[0.010702626,0.0025002202,0.91403717,0.00006133638,0.00010755332,0.0003425291,0.000825304,9.789823e-7,0.0675956,0.00032012127,0.0031940844,0.00031246198],"about_ca_topic_score_codex":0.000056139623,"about_ca_topic_score_gemma":0.000024822384,"teacher_disagreement_score":0.0617682,"about_ca_system_score_codex":0.000021596456,"about_ca_system_score_gemma":0.000023058,"threshold_uncertainty_score":0.6115254},"labels":[],"label_agreement":null},{"id":"W2104401957","doi":"10.1097/mib.0b013e3182a85709","title":"Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients","year":2013,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":203,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"FOXP3; Immunology; Medicine; Immune system; Inflammatory bowel disease; Peripheral blood mononuclear cell; Population; Regulatory T cell; T cell; RAR-related orphan receptor gamma; IL-2 receptor; Biology; Internal medicine; In vitro; Disease","score_opus":0.008650069151674737,"score_gpt":0.20004633061029783,"score_spread":0.1913962614586231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104401957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521506,0.0012016178,0.00006592843,0.0000036572396,0.00032620036,0.0014369987,0.0015865569,0.000103556464,0.000060426828],"genre_scores_gemma":[0.9992108,0.00004691207,0.00008938971,0.000024987236,0.00009242135,0.00016583678,0.00023071544,0.000081900325,0.000057065383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958429,0.0006419922,0.0014177704,0.0010258545,0.00031007797,0.000761447],"domain_scores_gemma":[0.9961454,0.0011796714,0.0014071342,0.0005953116,0.00035455733,0.0003179076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040451312,0.00071428024,0.00083216967,0.0004375765,0.00039971998,0.000062370375,0.00025870153,0.00044827582,0.00016198745],"category_scores_gemma":[0.00030339675,0.0007379764,0.00026939777,0.00016201238,0.0008334286,0.0008892772,0.00035814356,0.00032578714,0.000014052667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037564567,0.00023252566,0.6248888,0.0014663957,0.00025338924,0.00002049936,0.0006871891,0.00032093856,0.37074298,0.000017836554,0.00006557565,0.00092826545],"study_design_scores_gemma":[0.0034617484,0.00013515702,0.90302753,0.001027263,0.000839647,0.0000030980523,0.00037213272,0.00019415688,0.09019213,0.00012808613,0.000013512688,0.0006055435],"about_ca_topic_score_codex":0.00010303197,"about_ca_topic_score_gemma":0.000008014475,"teacher_disagreement_score":0.28055084,"about_ca_system_score_codex":0.00015176788,"about_ca_system_score_gemma":0.00030344256,"threshold_uncertainty_score":0.9995071},"labels":[],"label_agreement":null},{"id":"W2104805649","doi":"10.4049/jimmunol.1300828","title":"Toll IL-1R8/Single Ig IL-1–Related Receptor Regulates Psoriasiform Inflammation through Direct Inhibition of Innate IL-17A Expression by γδ T Cells","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Inflammation; Psoriasis; Immunology; Interleukin 17; Receptor; Innate lymphoid cell; Toll-like receptor; Infiltration (HVAC); Cytokine; In vivo; Psoriatic arthritis; Medicine; Biology; Innate immune system; Immune system; Internal medicine","score_opus":0.009778273171470661,"score_gpt":0.20550652532512706,"score_spread":0.1957282521536564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104805649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878261,0.007863496,0.000052064297,0.00068595493,0.0020754077,0.0003730509,0.00009069098,0.00004417916,0.0009890547],"genre_scores_gemma":[0.9943725,0.0034418954,0.00023645943,0.000038255504,0.00009141293,0.000015998095,0.00015234298,0.00003462216,0.0016165428],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716306,0.00093082554,0.0011752385,0.00020018505,0.00010063767,0.00043007883],"domain_scores_gemma":[0.99719524,0.00043435104,0.0015634637,0.0004012263,0.00038020662,0.00002552621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006670723,0.00032682563,0.0006737065,0.00020852155,0.00025368575,0.000018881343,0.00037272606,0.0006058598,0.0010490578],"category_scores_gemma":[0.0001146971,0.00021418746,0.00022715142,0.0002596691,0.0003851052,0.00058556156,0.000117222015,0.00045182862,0.0004220984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008441452,0.00023421798,0.000055173226,0.000015346399,0.00065904506,0.0000022553734,0.0023578554,0.00002067551,0.97007203,0.00008227482,0.008274463,0.017382532],"study_design_scores_gemma":[0.0027744945,0.0011014815,0.0008588512,0.00018471487,0.00023795372,0.00015621327,0.0007599477,0.0000022159593,0.97794014,0.0011440425,0.014632433,0.00020753457],"about_ca_topic_score_codex":0.00013220582,"about_ca_topic_score_gemma":0.000005320389,"teacher_disagreement_score":0.017174996,"about_ca_system_score_codex":0.00012166912,"about_ca_system_score_gemma":0.00006139455,"threshold_uncertainty_score":0.9998641},"labels":[],"label_agreement":null},{"id":"W2105090944","doi":"10.1089/jir.2013.0154","title":"Interleukin-27 Mediates Inflammation During Chronic Disease","year":2014,"lang":"en","type":"review","venue":"Journal of Interferon & Cytokine Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Immunology; Multiple sclerosis; Inflammatory bowel disease; Medicine; Rheumatoid arthritis; Proinflammatory cytokine; Ulcerative colitis; Inflammation; Pathogenesis; Cytokine; Psoriasis; Disease; Immune system; Pathology","score_opus":0.0700899636131175,"score_gpt":0.3764607952134155,"score_spread":0.306370831600298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105090944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010018799,0.98722744,0.000017095483,0.00012668787,0.001815362,0.0004959192,0.000059690705,0.000024633004,0.00021436076],"genre_scores_gemma":[0.013388595,0.9816387,0.0000104920055,0.0000027364383,0.0018101058,0.000052447725,0.0001839131,0.000080768856,0.002832189],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471277,0.0021391935,0.0016606444,0.00040720252,0.0003023602,0.0007778498],"domain_scores_gemma":[0.9966003,0.00095380197,0.0010874139,0.0005615684,0.0006270379,0.00016989102],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023643223,0.000530805,0.002026458,0.0016359446,0.00021006023,0.00008881169,0.0010891338,0.0005545541,0.0009706234],"category_scores_gemma":[0.0006943995,0.00036439626,0.0010387717,0.00042079174,0.00025878858,0.00022066872,0.00037407395,0.0019342024,0.001641807],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00098159,0.00016936995,0.000030207135,0.011029942,0.0020547349,0.00026316033,0.00013766593,0.0000023175012,0.0042213835,0.000057840072,0.00397198,0.9770798],"study_design_scores_gemma":[0.0014968581,0.0015610026,0.000058089026,0.021144876,0.00095226086,0.00051587675,0.000034293513,8.8176563e-7,0.0026357076,0.00003950601,0.97123396,0.00032671072],"about_ca_topic_score_codex":0.000010762997,"about_ca_topic_score_gemma":0.00001630508,"teacher_disagreement_score":0.9767531,"about_ca_system_score_codex":0.0012013441,"about_ca_system_score_gemma":0.000984552,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W2105190398","doi":"10.1136/ard.2010.147421","title":"IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients","year":2011,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University Health Network; Toronto Western Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Krembil Foundation; University of Toronto; Arthritis Society","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Genetic marker; Immunology; Gene; Genetics","score_opus":0.03751114802023366,"score_gpt":0.2430001526999564,"score_spread":0.20548900467972273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105190398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988666,0.0076253167,0.000022970142,0.00019932562,0.0012230114,0.0007311832,0.0011154461,0.000042929227,0.00037382153],"genre_scores_gemma":[0.9967588,0.0010420433,0.00012732926,0.00031461255,0.000023994486,0.00022253665,0.0001184989,0.00003109672,0.001361074],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985335,0.00019441087,0.0005038015,0.00028320754,0.00008424463,0.0004008716],"domain_scores_gemma":[0.99860823,0.0001799369,0.0003887933,0.00059334293,0.00016018566,0.00006952977],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014758769,0.00026453743,0.00046390024,0.00009177908,0.00022070791,0.000011314442,0.00041803316,0.0001380155,0.0013647969],"category_scores_gemma":[0.0003672139,0.00018570115,0.0005297316,0.00014414261,0.00022024498,0.00013501804,0.00010032194,0.000049403363,0.000115305076],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001275047,0.0027014504,0.14744651,0.0002882749,0.004212564,0.0000020605792,0.0033752797,8.2209135e-7,0.00022568501,0.0006228122,0.06353473,0.7763148],"study_design_scores_gemma":[0.003488758,0.00029742697,0.95274305,0.00040042892,0.00069822534,0.0000029341732,0.00013000383,0.000005939236,0.035908427,0.004992534,0.0010021869,0.0003300889],"about_ca_topic_score_codex":0.00020133532,"about_ca_topic_score_gemma":0.000012401717,"teacher_disagreement_score":0.80529654,"about_ca_system_score_codex":0.000011406622,"about_ca_system_score_gemma":0.0000668017,"threshold_uncertainty_score":0.9995481},"labels":[],"label_agreement":null},{"id":"W2105758861","doi":"10.1345/aph.1m151","title":"Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis","year":2009,"lang":"en","type":"review","venue":"Annals of Pharmacotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Secukinumab; Psoriasis Area and Severity Index; Adverse effect; Clinical trial; Psoriasis; Etanercept; Dermatology Life Quality Index; Dermatology; Adalimumab; Internal medicine; Psoriatic arthritis; Disease","score_opus":0.09313564293242937,"score_gpt":0.38346372820593533,"score_spread":0.29032808527350595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105758861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012703455,0.994669,0.000010131374,0.00012476672,0.0007287797,0.00149687,0.0011230675,0.00006257514,0.0005144319],"genre_scores_gemma":[0.0006550207,0.99511486,0.000060071907,0.00020119238,0.00026849002,0.00026451555,0.000509923,0.00009364267,0.0028322684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969376,0.00053374475,0.0011334557,0.00066674885,0.000094170005,0.0006343113],"domain_scores_gemma":[0.997996,0.00022901106,0.0008086637,0.0006372082,0.00024511988,0.00008401015],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013394408,0.0009056969,0.0032006379,0.00047755358,0.00010050718,0.000011142344,0.0004919346,0.00067584415,0.0012794817],"category_scores_gemma":[0.000008537291,0.0006848134,0.001443844,0.0004153557,0.00009735142,0.0000809414,0.000023957828,0.00016786715,0.00036830624],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007343919,0.0009513056,0.0000026546222,0.0013656811,0.004772458,0.000012677403,0.00026404578,0.000011982174,0.0035371773,0.000091562615,0.0054323045,0.9828237],"study_design_scores_gemma":[0.0034258768,0.0020502252,0.0000032821656,0.0021885757,0.0013649927,0.000039399816,0.000008023316,7.469013e-7,0.1101079,0.000032674703,0.8802603,0.0005180025],"about_ca_topic_score_codex":0.00013362257,"about_ca_topic_score_gemma":0.000020811172,"teacher_disagreement_score":0.98230577,"about_ca_system_score_codex":0.00014008793,"about_ca_system_score_gemma":0.00046883238,"threshold_uncertainty_score":0.9996335},"labels":[],"label_agreement":null},{"id":"W2105825555","doi":"10.1126/scisignal.2000066","title":"IL-17 Receptor Signaling Inhibits C/EBPβ by Sequential Phosphorylation of the Regulatory 2 Domain","year":2009,"lang":"en","type":"article","venue":"Science Signaling","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; McMaster University; Hamilton Health Sciences","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Canadian Institutes of Health Research","keywords":"Phosphorylation; Transcription factor; Cell biology; Signal transduction; Receptor; Chemistry; Biology; Cancer research; Gene; Biochemistry","score_opus":0.012289774264235385,"score_gpt":0.2308615684292343,"score_spread":0.21857179416499892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105825555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964421,0.0014591899,0.00022468554,0.0001666805,0.0007723489,0.00020574174,0.000036875586,0.000042994485,0.00064938073],"genre_scores_gemma":[0.99870276,0.000009945279,0.00041511926,0.00011114707,0.000049084432,0.0000050307403,0.000027066995,0.0000073739425,0.00067248143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985867,0.00014926279,0.00032738774,0.00037809784,0.00016409437,0.00039444814],"domain_scores_gemma":[0.999257,0.000063244595,0.00023808029,0.00029874162,0.000111033885,0.000031842195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055403,0.00016566897,0.00019770795,0.00010643114,0.000648125,0.000028849654,0.000433909,0.00014493184,0.0003160975],"category_scores_gemma":[0.00005744051,0.00012207699,0.00012263042,0.0005629964,0.00057746825,0.00022992223,0.000055120712,0.00013695158,0.000047522208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047919584,0.00004986938,0.00034376816,0.0000027123215,0.000019964418,3.1737363e-7,0.000621781,0.00010392151,0.99021465,0.0005978531,0.0005853435,0.007411915],"study_design_scores_gemma":[0.0005324962,0.00009041877,0.00086921523,0.00006376023,0.00003451718,0.0000052490013,0.00020963159,0.000005960723,0.99591714,0.00090925716,0.0012174078,0.0001449427],"about_ca_topic_score_codex":0.000016781358,"about_ca_topic_score_gemma":0.0000012765065,"teacher_disagreement_score":0.007266972,"about_ca_system_score_codex":0.00010239711,"about_ca_system_score_gemma":0.00019203893,"threshold_uncertainty_score":0.49849194},"labels":[],"label_agreement":null},{"id":"W2106171751","doi":"10.1111/j.1365-2133.2004.05986.x","title":"Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris","year":2004,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Calcipotriol; Medicine; Betamethasone dipropionate; Psoriasis; Betamethasone; Dermatology; Psoriasis Area and Severity Index; Internal medicine","score_opus":0.013239316774461081,"score_gpt":0.23853204966403918,"score_spread":0.2252927328895781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106171751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741768,0.023909228,0.000112405876,0.0007391433,0.0003838965,0.00045622006,0.000052106814,0.000018462371,0.00015171566],"genre_scores_gemma":[0.9919695,0.0065952893,0.0011183193,0.000036834466,0.000036365105,0.000035134926,0.000035886813,0.00002973057,0.00014288504],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975085,0.000424022,0.0010453196,0.00037872136,0.00011399852,0.0005294331],"domain_scores_gemma":[0.998479,0.0003064992,0.0007117744,0.00023902397,0.00016443928,0.000099279845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019504548,0.00035513428,0.0012178418,0.0003634332,0.00013646748,0.000020565967,0.00020343314,0.00033892778,0.00008797312],"category_scores_gemma":[0.000081597675,0.0002989165,0.00022421229,0.00025511225,0.00037354598,0.00014165633,0.00005773789,0.00030580332,0.000020718286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00950146,0.007855401,0.031066636,0.00014405586,0.006409494,0.017695688,0.0046557686,0.00029965542,0.033409625,0.0009855173,0.0005971772,0.8873795],"study_design_scores_gemma":[0.16434418,0.01684744,0.16234086,0.00216598,0.002859961,0.2138185,0.0019416618,0.000004011999,0.4214345,0.0007950261,0.012100261,0.0013476337],"about_ca_topic_score_codex":0.0009126027,"about_ca_topic_score_gemma":0.00056502747,"teacher_disagreement_score":0.88603187,"about_ca_system_score_codex":0.0003133407,"about_ca_system_score_gemma":0.00035094813,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W2106296241","doi":"10.1186/1710-1492-9-23","title":"IL-17-producing peripheral blood CD177+ neutrophils increase in allergic asthmatic subjects","year":2013,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional","keywords":"Immunology; Asthma; Medicine; Allergy; Population; CD8; Immune system","score_opus":0.01598384206443089,"score_gpt":0.2551507314883943,"score_spread":0.2391668894239634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106296241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98146456,0.014518957,0.000009547126,0.0010170633,0.0011544073,0.00045921686,0.000011478411,0.00011850483,0.0012462481],"genre_scores_gemma":[0.9894348,0.005950232,0.00027764312,0.0006795281,0.00016823024,0.00016994092,0.000146974,0.00004713874,0.0031255584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957009,0.0011593044,0.0011601275,0.0009797243,0.000057526504,0.00094243063],"domain_scores_gemma":[0.9980789,0.00074052205,0.00028075883,0.000701956,0.000097609394,0.00010028076],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00056362536,0.00050279277,0.0009917592,0.00021234408,0.00024943775,0.00004518601,0.00040843242,0.00089616835,0.0029452567],"category_scores_gemma":[0.00027441708,0.00043810674,0.00027737606,0.00025530986,0.0006456534,0.00025710545,0.0002926026,0.0007392189,0.00095968356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046259407,0.010086199,0.07537516,0.000092447066,0.017526587,0.0012215755,0.0038589302,0.00005627807,0.24074587,0.005425837,0.008272197,0.63271296],"study_design_scores_gemma":[0.013441736,0.0026206602,0.9539994,0.00011417641,0.00012848723,0.00073998596,0.0006340002,0.00003302173,0.0020224773,0.0012535758,0.024096558,0.00091591716],"about_ca_topic_score_codex":0.0020282008,"about_ca_topic_score_gemma":0.00085987366,"teacher_disagreement_score":0.87862426,"about_ca_system_score_codex":0.00004084933,"about_ca_system_score_gemma":0.000108521075,"threshold_uncertainty_score":0.9998182},"labels":[],"label_agreement":null},{"id":"W2107258238","doi":"10.3899/jrheum.131250","title":"Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11","year":2014,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Medicine; Observational study; Psoriasis; Enthesitis; Randomized controlled trial; Physical therapy; Internal medicine; Quality of life (healthcare); Rheumatology; Clinical trial; Disease; Arthritis; Dermatology","score_opus":0.024440568825366087,"score_gpt":0.2794089736149098,"score_spread":0.2549684047895437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107258238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28974172,0.7080993,0.0001677953,0.000082568484,0.0012281132,0.00060144387,0.00006756287,0.0000051126963,0.0000064101055],"genre_scores_gemma":[0.11256094,0.8868693,0.00019316537,0.00000832385,0.00001735943,0.000053875683,0.000027204538,0.000037362774,0.00023246146],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958688,0.0014844738,0.0019188931,0.0002549294,0.0001240195,0.0003488772],"domain_scores_gemma":[0.9928679,0.0018241549,0.004442248,0.0006125589,0.00019450083,0.00005865259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018161167,0.00042279763,0.0028628903,0.00023961566,0.0002774147,0.0000062985823,0.0004893308,0.0004342479,0.000065089334],"category_scores_gemma":[0.0007224606,0.00023547378,0.00067004346,0.00017527859,0.00036863046,0.00006522896,0.00020779332,0.00033514109,0.000007975827],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012755973,0.00022666795,0.0012889849,0.0037553243,0.0025633313,0.000014690228,0.0005360007,0.000001551011,0.000083713654,0.00012766253,0.00056982646,0.98955667],"study_design_scores_gemma":[0.008200999,0.00065820734,0.006802502,0.024026033,0.0058844066,0.029172305,0.00011607678,0.0000043534983,0.0007779398,0.000785082,0.9227831,0.00078899733],"about_ca_topic_score_codex":0.000040334748,"about_ca_topic_score_gemma":0.0002570092,"teacher_disagreement_score":0.9887676,"about_ca_system_score_codex":0.00009529904,"about_ca_system_score_gemma":0.00088015344,"threshold_uncertainty_score":0.9602342},"labels":[],"label_agreement":null},{"id":"W2107375357","doi":"10.1093/rheumatology/ker349","title":"Differences in body mass index among individuals with PsA, psoriasis, RA and the general population","year":2011,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia; SKiN Health","funders":"Canadian Institutes of Health Research; Child and Family Research Institute","keywords":"Medicine; Psoriasis; Body mass index; Population; Index (typography); Internal medicine; Dermatology; Environmental health","score_opus":0.017898055496389433,"score_gpt":0.2215830207907455,"score_spread":0.20368496529435606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107375357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971486,0.0012161486,0.000026952592,0.00005207634,0.00023322545,0.00030928274,0.000022255927,0.000031392556,0.00096009305],"genre_scores_gemma":[0.9986165,0.0001428204,0.00014173635,0.000046454315,0.000043439733,0.000066038476,0.00009591064,0.000011899504,0.00083520374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893105,0.0003173828,0.0002004486,0.00025135378,0.000043902786,0.00025586807],"domain_scores_gemma":[0.9995684,0.000082547565,0.00010816361,0.00020616174,0.000016483733,0.000018226245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002605943,0.00017675811,0.00029633215,0.00009238708,0.00012435019,0.000021750444,0.00015632159,0.0002005864,0.00014307823],"category_scores_gemma":[0.00001538194,0.000103482955,0.000041321455,0.00012242456,0.00020177179,0.000117270305,0.00004323445,0.00013987577,0.000026387414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037725872,0.000055295004,0.9941283,0.000004056822,0.00020577543,0.0000058807086,0.0010968372,4.2451757e-7,0.0003748469,0.0010472848,0.00004156712,0.0026624722],"study_design_scores_gemma":[0.004278493,0.000094449984,0.9928836,0.000019700932,0.00011290626,0.000010921311,0.0001677718,0.00000872642,0.0012182418,0.00089779455,0.00015939171,0.0001479526],"about_ca_topic_score_codex":0.001751159,"about_ca_topic_score_gemma":0.00065532204,"teacher_disagreement_score":0.0039012341,"about_ca_system_score_codex":0.000015125891,"about_ca_system_score_gemma":0.000013482773,"threshold_uncertainty_score":0.42199123},"labels":[],"label_agreement":null},{"id":"W2107730744","doi":"10.1136/ard.2004.033217","title":"Psoriasis: epidemiology, clinical features, and quality of life","year":2005,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Epidemiology; Disease; Psychosocial; Dermatology; Quality of life (healthcare); Pathology; Psychiatry","score_opus":0.28487102146392945,"score_gpt":0.4508351941802997,"score_spread":0.16596417271637026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107730744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018061025,0.99515676,0.0000011233141,0.00025383104,0.00081400963,0.0005777137,0.0012290888,0.000024832385,0.00013653755],"genre_scores_gemma":[0.0016558192,0.997049,0.000040324285,0.0001813955,0.000075168515,0.000060710307,0.00021886149,0.000026170757,0.0006925806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99191946,0.004860323,0.002391722,0.0004226189,0.00006218786,0.0003437007],"domain_scores_gemma":[0.9897753,0.0066659786,0.002414751,0.0009646911,0.000091678696,0.00008761296],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019892403,0.00044956306,0.0042226757,0.000101996025,0.00010301126,0.0000045044217,0.00064987165,0.00065933634,0.00015800064],"category_scores_gemma":[0.007028593,0.00025269564,0.0019034332,0.00015617268,0.0007917029,0.000047041278,0.0002639442,0.00027052886,0.00005312677],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009558019,0.0004041954,0.0012622422,0.0065004043,0.003429407,1.738783e-7,0.00002361642,1.9774998e-7,8.594449e-8,0.0010034023,0.013598352,0.97368234],"study_design_scores_gemma":[0.0016692642,0.0002391047,0.08376278,0.019665372,0.007886483,0.00002425476,0.000069710746,1.7243165e-7,0.0000067243814,0.0012879719,0.8847347,0.0006534734],"about_ca_topic_score_codex":0.000110166955,"about_ca_topic_score_gemma":0.000014450974,"teacher_disagreement_score":0.9730289,"about_ca_system_score_codex":0.000008310619,"about_ca_system_score_gemma":0.00032227705,"threshold_uncertainty_score":0.99999255},"labels":[],"label_agreement":null},{"id":"W2107768865","doi":"10.1016/j.jaad.2009.07.032","title":"The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis","year":2010,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Clinical Research","funders":"","keywords":"Medicine; Psoriasis; Plaque psoriasis; Adverse effect; Safety profile; Dermatology; Internal medicine; Clinical trial; Psoriasis Area and Severity Index","score_opus":0.008885098678193015,"score_gpt":0.26615299882690063,"score_spread":0.2572679001487076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107768865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904401,0.0013209358,0.000049657276,0.0074397977,0.00016489747,0.00047703824,0.000095865966,0.000004872465,0.0000068675713],"genre_scores_gemma":[0.9988578,0.0005305449,0.00037352793,0.00003632793,0.000022388615,0.000017094984,0.0000044731382,0.000013888393,0.0001439582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833286,0.0006106169,0.0005996966,0.0001308761,0.000068981586,0.00025694526],"domain_scores_gemma":[0.9960547,0.001992341,0.0015922128,0.00016700722,0.000153175,0.000040562572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039401825,0.00017044268,0.0007690711,0.000116793955,0.00015933444,0.000002672094,0.00029288154,0.0001801949,0.000010576599],"category_scores_gemma":[0.0006242364,0.0000853426,0.00019799983,0.00019188905,0.00083781616,0.000036689693,0.00004253489,0.00016490587,4.8628556e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02618817,0.00042576678,0.029091123,0.000030417812,0.0019150642,0.0000049568343,0.00086738815,0.00002217845,0.9130559,0.00011343263,0.00088168215,0.027403902],"study_design_scores_gemma":[0.007753202,0.00341155,0.11551394,0.0001045472,0.0007302917,0.0007281687,0.0012515361,0.00001993437,0.85057837,0.000058947368,0.01970462,0.00014491274],"about_ca_topic_score_codex":0.000020144791,"about_ca_topic_score_gemma":0.000028031427,"teacher_disagreement_score":0.08642282,"about_ca_system_score_codex":0.000072781506,"about_ca_system_score_gemma":0.0002633354,"threshold_uncertainty_score":0.34801704},"labels":[],"label_agreement":null},{"id":"W2107774951","doi":"10.2310/7750.2008.08012","title":"Nail Psoriasis and Biologics","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Infliximab; Psoriatic arthritis; Placebo; Nail (fastener); Psoriasis Area and Severity Index; Clinical trial; Nail disease; Plaque psoriasis; Internal medicine; Pathology; Tumor necrosis factor alpha; Alternative medicine","score_opus":0.06080249670349511,"score_gpt":0.30059206865496146,"score_spread":0.23978957195146636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107774951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012917136,0.9962486,0.0000026666191,0.00024180315,0.0017403783,0.00012783385,0.000015735133,0.000014768147,0.00031652208],"genre_scores_gemma":[0.00022067499,0.9980905,0.000027528538,0.00018855695,0.0006422316,0.00000232546,0.000052557207,0.000021208178,0.0007544115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776393,0.00043325865,0.0011768531,0.0002492325,0.00007091516,0.00030578606],"domain_scores_gemma":[0.99597055,0.00256287,0.0010989218,0.00017760569,0.00010450404,0.00008555341],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000784757,0.00044507673,0.003333898,0.0005542369,0.000119842145,0.000012066518,0.00013097044,0.00066145184,0.00015567531],"category_scores_gemma":[0.00047262758,0.0002497109,0.00046341127,0.0001797362,0.00026379884,0.0000466929,0.000029065079,0.0004719282,0.000017955732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007183542,0.000043440814,0.00004735396,0.0008476735,0.00080220465,0.0010397283,0.00007814884,1.15385514e-8,0.000010684828,0.000016268234,0.019752473,0.97729015],"study_design_scores_gemma":[0.00033531364,0.00051757647,0.000015920923,0.0063369884,0.002876629,0.045619003,0.00006408955,2.08651e-8,0.0000036939814,0.00009803493,0.94391495,0.00021780112],"about_ca_topic_score_codex":0.000007446457,"about_ca_topic_score_gemma":0.0000015952448,"teacher_disagreement_score":0.97707236,"about_ca_system_score_codex":0.00003324713,"about_ca_system_score_gemma":0.00020164484,"threshold_uncertainty_score":0.9999955},"labels":[],"label_agreement":null},{"id":"W2108046961","doi":"10.1016/j.jaad.2003.10.010","title":"Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Plaque psoriasis; Internal medicine; Randomized controlled trial; Cohort; Dermatology; Surgery; Pathology","score_opus":0.012879503249499737,"score_gpt":0.278769773733461,"score_spread":0.2658902704839613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108046961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538696,0.0009759089,0.00016473372,0.0018741644,0.00012976062,0.0008549257,0.0005855946,0.0000044032954,0.00002354242],"genre_scores_gemma":[0.99872774,0.0005296552,0.00047854983,0.00018895676,0.000015568241,0.000010305224,0.000026722139,0.000013610832,0.000008904781],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953517,0.0018945718,0.0021562208,0.000214471,0.00011540986,0.00026762532],"domain_scores_gemma":[0.9941553,0.0016495939,0.0038612322,0.00017533373,0.00011036856,0.00004818036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010141453,0.00023833306,0.0032013045,0.00029257388,0.000053039177,0.0000027356784,0.00034074724,0.00020282071,0.000014628299],"category_scores_gemma":[0.00078757375,0.00014020917,0.000289439,0.00030456806,0.00051353633,0.00007969199,0.00008320675,0.0003146844,0.0000014240068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96654636,0.0012334539,0.011814974,0.000019177218,0.004376128,0.0000128257825,0.0018471084,0.00032028923,0.01091419,0.00015524054,0.00015404621,0.0026061996],"study_design_scores_gemma":[0.8264585,0.0006753429,0.08627126,0.00034655645,0.001956728,0.00022195917,0.0002512369,0.00000400157,0.08306597,0.00037870684,0.00017023,0.00019948898],"about_ca_topic_score_codex":0.00017581401,"about_ca_topic_score_gemma":0.000014291018,"teacher_disagreement_score":0.14008784,"about_ca_system_score_codex":0.000043145617,"about_ca_system_score_gemma":0.000154691,"threshold_uncertainty_score":0.5717564},"labels":[],"label_agreement":null},{"id":"W2108615089","doi":"10.1067/mai.2001.117929","title":"IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines","year":2001,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":949,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada); Cegep de Sainte Foy","funders":"Medical Research Council Canada; Canadian Lung Association; Medical Research Council; Canadian Thoracic Society","keywords":"Bronchoalveolar lavage; Cytokine; Immunocytochemistry; Immunology; Medicine; Sputum; Chemokine; Eosinophil; Interleukin 8; Peripheral blood mononuclear cell; Interleukin 5; Interleukin; Pathology; Asthma; Inflammation; In vitro; Biology; Lung; Internal medicine","score_opus":0.02676230942960233,"score_gpt":0.2977832038162598,"score_spread":0.27102089438665744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108615089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927304,0.004699546,0.0000080123655,0.0014824272,0.00058972643,0.00013709682,0.0000075864973,0.0000125612605,0.00033264916],"genre_scores_gemma":[0.9940611,0.0043995725,0.00016455588,0.00040531452,0.00018248642,0.000006169213,0.0000112929765,0.000014615989,0.0007548556],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99776614,0.0004735945,0.0010516127,0.0003153209,0.000046424575,0.00034690203],"domain_scores_gemma":[0.99878997,0.00042821438,0.0004052906,0.00020518375,0.00010033432,0.0000709963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000646899,0.0002338545,0.0007257009,0.00026079614,0.00015270492,0.00001883347,0.00022460285,0.00047338012,0.00028020074],"category_scores_gemma":[0.000266658,0.00018399562,0.00013994658,0.0001651587,0.00030737525,0.0001677958,0.00013386388,0.0004893623,0.00003417461],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014682476,0.0043782922,0.17789686,0.000048536,0.008796727,0.00062208576,0.0038057533,0.00001198957,0.44036508,0.0011098117,0.009947031,0.33833537],"study_design_scores_gemma":[0.008459736,0.0054774093,0.9187095,0.00020941325,0.00016206662,0.0012260011,0.00043663493,0.0000012089396,0.0064725364,0.0007449095,0.057753965,0.00034659944],"about_ca_topic_score_codex":0.00010656086,"about_ca_topic_score_gemma":0.0004160854,"teacher_disagreement_score":0.74081266,"about_ca_system_score_codex":0.000023336064,"about_ca_system_score_gemma":0.00007326876,"threshold_uncertainty_score":0.7503123},"labels":[],"label_agreement":null},{"id":"W2109041707","doi":"10.1136/annrheumdis-2012-201299","title":"Obesity and the risk of psoriatic arthritis: a population-based study","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of British Columbia","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Medicine; Psoriatic arthritis; Obesity; Psoriasis; Population; Environmental health; Internal medicine; Dermatology","score_opus":0.020786116741324932,"score_gpt":0.25965122072503694,"score_spread":0.238865103983712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109041707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97515154,0.0238055,0.00000640625,0.00013370624,0.00024606055,0.0004890157,0.00013157088,0.000011982775,0.000024242145],"genre_scores_gemma":[0.9993402,0.00048869837,0.000010226317,0.000039461254,0.0000098972605,0.000042589974,0.000015145254,0.000006222016,0.00004761135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985516,0.0008368868,0.00030390386,0.00008910665,0.000058431324,0.00016007469],"domain_scores_gemma":[0.9984469,0.0007891756,0.0003343363,0.00036421957,0.000043977583,0.000021389826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004566877,0.000115306975,0.0003361805,0.000034459652,0.00017565873,0.0000054727425,0.00016432018,0.00003880524,0.00008195678],"category_scores_gemma":[0.0005335179,0.0000583301,0.0001768983,0.00009380886,0.00014962006,0.00005979676,0.000051348234,0.00004199771,0.000012024842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027210152,0.0012000026,0.9516192,0.000053969594,0.00086648867,8.3266116e-8,0.0009288418,0.000014311365,0.000007215919,0.0005498363,0.00019012517,0.044297818],"study_design_scores_gemma":[0.0024135262,0.00006893016,0.994197,0.00012341721,0.0006619667,8.207807e-7,0.00042887207,0.00000922043,0.0004996817,0.0015218804,0.000011148224,0.00006350611],"about_ca_topic_score_codex":0.0005402893,"about_ca_topic_score_gemma":0.00003650009,"teacher_disagreement_score":0.044234313,"about_ca_system_score_codex":0.0000032593784,"about_ca_system_score_gemma":0.000022688106,"threshold_uncertainty_score":0.23786324},"labels":[],"label_agreement":null},{"id":"W2109774695","doi":"10.1111/j.1365-4632.2012.05707.x","title":"Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis","year":2013,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Adalimumab; Dermatology; Psoriasis; Pustulosis; Generalized pustular psoriasis; Rheumatoid arthritis; Methotrexate; Etanercept; Psoriatic arthritis; Pustular psoriasis; Arthritis; Infliximab; Surgery; Tumor necrosis factor alpha; Immunology","score_opus":0.012561822031661247,"score_gpt":0.24409552309862392,"score_spread":0.23153370106696267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109774695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97766316,0.012964989,0.0008158767,0.0033842237,0.004665727,0.00026202187,0.000031050913,0.000027913184,0.00018504147],"genre_scores_gemma":[0.994958,0.0038971934,0.0004814264,0.0002896837,0.000099290206,0.00005866331,0.000103721184,0.00002297737,0.00008905486],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853927,0.00015573409,0.000705346,0.00017517265,0.00010001857,0.0003244856],"domain_scores_gemma":[0.9987078,0.0002988578,0.0004380033,0.00013009622,0.00038015193,0.000045137884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008167304,0.00020937342,0.00048249835,0.00026504928,0.00011806569,0.00004565007,0.00049879,0.00023666755,0.00043349882],"category_scores_gemma":[0.00006798228,0.00017505718,0.0004563421,0.000057563764,0.00007309777,0.0003035896,0.000041215673,0.0001628651,0.00021003454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032575354,0.0016310256,0.37716183,0.00003135241,0.018039357,0.0039072065,0.0024112584,0.000018965839,0.17731398,0.004255857,0.077541746,0.33442986],"study_design_scores_gemma":[0.052951336,0.0009433998,0.031298675,0.00045243834,0.00025859426,0.19571532,0.0013611561,0.0000675146,0.43773443,0.0066848854,0.27132708,0.0012051921],"about_ca_topic_score_codex":0.000044684468,"about_ca_topic_score_gemma":0.000011377974,"teacher_disagreement_score":0.34586316,"about_ca_system_score_codex":0.000050442835,"about_ca_system_score_gemma":0.00012182735,"threshold_uncertainty_score":0.7138625},"labels":[],"label_agreement":null},{"id":"W2110092116","doi":"10.1200/jco.2011.40.0655","title":"Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Rash; Internal medicine; Nausea; Adverse effect; Surgery; Gastroenterology","score_opus":0.12199987148998305,"score_gpt":0.4138951775415325,"score_spread":0.29189530605154945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110092116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964232,0.00045943834,0.000029556708,0.00033027542,0.002181583,0.0003291665,0.0000113977385,0.00000739167,0.00022799242],"genre_scores_gemma":[0.9991813,0.000018617311,0.0002801503,0.00011378587,0.00017509011,0.00001110391,0.0000070775977,0.000013670718,0.00019921522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608475,0.0018753186,0.0013913023,0.00017939278,0.00008733353,0.0003818771],"domain_scores_gemma":[0.9966928,0.0014685537,0.0013780121,0.0001943045,0.00015854418,0.000107819316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028429406,0.00019790161,0.0014107443,0.00018954033,0.00010001259,0.000006437067,0.0002243827,0.00026516756,0.0002754516],"category_scores_gemma":[0.0006836668,0.00012292081,0.00024937038,0.00015269623,0.00020306741,0.0002885807,0.0000893156,0.00072109717,0.00007094092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015928872,0.042353302,0.66288877,0.0000037232514,0.001461063,0.000090603215,0.0009120134,7.9227664e-7,0.00016835141,0.000009010825,0.00041727914,0.27576622],"study_design_scores_gemma":[0.056424752,0.0728998,0.85597765,0.000021219508,0.00081877806,0.00005085778,0.0003125768,4.1601146e-7,0.00027990388,0.000018700732,0.013056857,0.00013849273],"about_ca_topic_score_codex":0.00003148557,"about_ca_topic_score_gemma":0.00014431297,"teacher_disagreement_score":0.27562773,"about_ca_system_score_codex":0.00012389028,"about_ca_system_score_gemma":0.00039905906,"threshold_uncertainty_score":0.5012565},"labels":[],"label_agreement":null},{"id":"W2110717830","doi":"10.1016/j.jval.2014.08.1633","title":"Impact of Biologics Use on Depression and Anxiety Frequency and Health Care Resource Utilization In Psoriasis: An Analysis Using the Quebec Provincial Drug Reimbursement Program Database","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Université de Montréal","funders":"","keywords":"Medicine; Psoriasis; Reimbursement; Depression (economics); Anxiety; Database; Quality of life (healthcare); Health care; Internal medicine; Psychiatry; Dermatology","score_opus":0.06619317030901606,"score_gpt":0.3472439568685518,"score_spread":0.28105078655953575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110717830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302083,0.005598266,0.000078595425,0.000095591226,0.00006918987,0.0009581008,0.0001482749,0.00002621019,0.0000049550085],"genre_scores_gemma":[0.9974899,0.0010109073,0.000701714,0.00007795198,0.000024273857,0.000032594442,0.00064736954,0.000010729774,0.0000045248034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967741,0.0019053572,0.00048598932,0.0004360855,0.000055989356,0.00034250395],"domain_scores_gemma":[0.99905604,0.00014196258,0.00032728756,0.00038485517,0.00003603479,0.000053803426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012988813,0.00019055084,0.00042075338,0.00029386027,0.00021680405,0.00001896417,0.0001024828,0.00013113511,0.0000038822213],"category_scores_gemma":[0.00008006701,0.00012469916,0.000061821294,0.0004509492,0.000097331606,0.000113294096,0.000051214454,0.00016652774,2.6792208e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024245099,0.00033559944,0.8407717,0.00008540074,0.00008815634,7.8312314e-7,0.0045976355,0.001457606,0.00042340963,0.00015981136,0.000014138009,0.15182333],"study_design_scores_gemma":[0.0017494778,0.001335606,0.99140275,0.00023467609,0.00012221668,0.000005998136,0.0015942476,0.0027640352,0.00040290508,0.000034025514,0.00017918681,0.00017490685],"about_ca_topic_score_codex":0.2268864,"about_ca_topic_score_gemma":0.042502586,"teacher_disagreement_score":0.18438382,"about_ca_system_score_codex":0.00034048338,"about_ca_system_score_gemma":0.00029838286,"threshold_uncertainty_score":0.97496927},"labels":[],"label_agreement":null},{"id":"W2111022239","doi":"10.3899/jrheum.100259","title":"Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis","year":2010,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Novo Nordisk","keywords":"Medicine; Rheumatoid arthritis; Radiography; Internal medicine; Interleukin; Immunopathology; Arthritis; Autoimmune disease; Disease; Interleukin 4; Immunology; Gastroenterology; Surgery; Cytokine","score_opus":0.004247602756758495,"score_gpt":0.18141618207768612,"score_spread":0.1771685793209276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111022239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979383,0.001293981,0.0000103719785,0.0001233705,0.00013303122,0.00031679843,0.00015197523,0.00002280863,0.000009391086],"genre_scores_gemma":[0.9982121,0.0016153066,0.000043457985,0.000029231807,0.000002677448,0.00001305814,0.000043646898,0.00003185018,0.000008692436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793434,0.00083397835,0.00039173648,0.00025189933,0.000108210595,0.00047981532],"domain_scores_gemma":[0.9979323,0.00065458746,0.00079724635,0.00027057182,0.00018801773,0.0001572667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049845275,0.0003413105,0.0007961076,0.0003620251,0.00021769397,0.000029984738,0.00018733667,0.00022090945,0.000030297591],"category_scores_gemma":[0.00016960409,0.00019380818,0.000054972465,0.00029327074,0.0007696827,0.00024295918,0.000052413496,0.000655941,0.0000034511093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01490946,0.00046939676,0.9795706,0.000014813307,0.0008706072,0.000054650416,0.00052798324,7.905218e-7,0.00093391404,0.000025885573,0.00003612133,0.0025857226],"study_design_scores_gemma":[0.016493004,0.001824552,0.97924966,0.00049324293,0.0002000268,0.0009211142,0.00017551887,0.000002378622,0.00029442005,0.00005165719,0.000047667112,0.0002467324],"about_ca_topic_score_codex":0.001614861,"about_ca_topic_score_gemma":0.0076122773,"teacher_disagreement_score":0.005997416,"about_ca_system_score_codex":0.000034364784,"about_ca_system_score_gemma":0.0001736755,"threshold_uncertainty_score":0.79032683},"labels":[],"label_agreement":null},{"id":"W2111247729","doi":"10.1016/j.jaad.2011.07.040","title":"Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis","year":2011,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Tolerability; Adverse effect; Internal medicine; Population; Cumulative incidence; Incidence (geometry); Placebo; Surgery; Dermatology; Cohort; Pathology; Tumor necrosis factor alpha","score_opus":0.023749187184791385,"score_gpt":0.2864853932099048,"score_spread":0.2627362060251134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111247729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19239822,0.80651397,0.000016554135,0.000080220845,0.00015479539,0.00046930925,0.0003285496,0.0000060816938,0.00003233123],"genre_scores_gemma":[0.111804835,0.8878326,0.00013431939,0.000038645165,0.000015053385,0.0000093461085,0.00009959338,0.000031399137,0.00003422932],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956141,0.0016051986,0.0020251505,0.00030596188,0.000100484314,0.00034911482],"domain_scores_gemma":[0.9950588,0.00036233533,0.004132632,0.00027676625,0.00012289525,0.00004657638],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028286796,0.0004991074,0.004778593,0.0009814323,0.0000620121,0.0000035221924,0.00078545115,0.00053570623,0.000108266184],"category_scores_gemma":[0.00006170489,0.00026859326,0.0008553329,0.0012710909,0.0011594781,0.000086601525,0.00015187543,0.0009329043,0.000003566923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019126518,0.0004016202,0.35637265,0.0010150934,0.014161593,0.0000148155095,0.00019560591,0.0000011862838,0.000020233027,0.00004975079,0.00007952954,0.6257753],"study_design_scores_gemma":[0.0036174904,0.00078376295,0.8520115,0.0055881185,0.03741804,0.0019525475,0.00014047227,2.848672e-7,0.00033825423,0.00001690362,0.09743319,0.0006994438],"about_ca_topic_score_codex":0.000023711851,"about_ca_topic_score_gemma":0.000016651355,"teacher_disagreement_score":0.6250758,"about_ca_system_score_codex":0.00008275353,"about_ca_system_score_gemma":0.00023688676,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W2111269206","doi":"10.4049/jimmunol.1101592","title":"Human CD90 Identifies Th17/Tc17 T Cell Subsets That Are Depleted in HIV-Infected Patients","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre hospitalier universitaire Sainte-Justine","keywords":"CD90; Human immunodeficiency virus (HIV); Virology; Immunology; Biology; Microbiology; Cell; Genetics","score_opus":0.026707362612440777,"score_gpt":0.22127405628624022,"score_spread":0.19456669367379945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111269206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156314,0.005805896,0.000010680572,0.000063179046,0.0012813162,0.00017412998,0.00002133438,0.000024484567,0.0010558565],"genre_scores_gemma":[0.9987596,0.0003944705,0.000020065818,0.000055632165,0.00002528569,0.000005528826,0.00003436106,0.000023065397,0.000681964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978458,0.00091711327,0.0005948663,0.00015291185,0.000057124773,0.0004321663],"domain_scores_gemma":[0.9984382,0.00016259815,0.0008375796,0.00037000948,0.00017192791,0.000019718547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004700767,0.00025249374,0.00050582306,0.0003363473,0.00022988823,0.000009605056,0.000614289,0.00032348765,0.0006224667],"category_scores_gemma":[0.000057498102,0.0001660249,0.00017073913,0.00018371487,0.00027415963,0.00016856208,0.00012201419,0.0004940877,0.00034628628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021361785,0.0016062561,0.585776,0.000019830683,0.0013145922,0.000108796805,0.007358501,0.0000022479326,0.39554074,0.000111411675,0.0032066763,0.0028187945],"study_design_scores_gemma":[0.004416673,0.00046793162,0.82825226,0.000049981187,0.00023186562,0.00015266227,0.0008953367,1.3275978e-7,0.16451441,0.00038183352,0.00047158555,0.00016534467],"about_ca_topic_score_codex":0.00013022161,"about_ca_topic_score_gemma":0.00017593456,"teacher_disagreement_score":0.24247628,"about_ca_system_score_codex":0.000068328736,"about_ca_system_score_gemma":0.000042447384,"threshold_uncertainty_score":0.68155736},"labels":[],"label_agreement":null},{"id":"W2111469026","doi":"10.1001/archderm.141.12.1580","title":"Relationship Between Smoking and the Clinical Severity of Psoriasis","year":2005,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ministero della Salute","keywords":"Medicine; Psoriasis; Odds ratio; Body mass index; Confounding; Confidence interval; Psoriasis Area and Severity Index; Internal medicine; Severity of illness; Dermatology","score_opus":0.040216547640550306,"score_gpt":0.29895977331789064,"score_spread":0.2587432256773403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111469026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176973,0.0028730864,0.00014123722,0.0018154028,0.0001464496,0.00012730529,0.000027664382,0.000014962492,0.0030841832],"genre_scores_gemma":[0.9989341,0.00017618759,0.0006357905,0.000048272126,0.000033178014,0.0000073417036,0.000029596828,0.000005712264,0.00012983693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840367,0.00077874627,0.00049141335,0.00015274866,0.00001929968,0.00015412956],"domain_scores_gemma":[0.9943354,0.00519117,0.00022441323,0.00022175466,0.000012697503,0.000014531853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018615596,0.0000975565,0.00043935815,0.000075889126,0.00010018152,0.0000016313652,0.00015922614,0.00015624723,0.000021831618],"category_scores_gemma":[0.00024153617,0.0000673084,0.0001386139,0.000055304405,0.001140714,0.000037488528,0.00008693103,0.00016448043,0.00001295222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029382776,0.00004835067,0.9345223,0.000017116201,0.00027872832,0.0000011280841,0.0007616497,3.7322806e-7,0.00014332484,0.011724896,0.00013166644,0.05207668],"study_design_scores_gemma":[0.0039254706,0.000034275232,0.9798698,0.000012457206,0.00029025844,0.0001244112,0.00008659613,0.0000031238044,0.0064953147,0.0052363817,0.003853232,0.00006870904],"about_ca_topic_score_codex":0.000020141146,"about_ca_topic_score_gemma":0.00001579169,"teacher_disagreement_score":0.05200797,"about_ca_system_score_codex":0.000001924291,"about_ca_system_score_gemma":0.000031048923,"threshold_uncertainty_score":0.42030084},"labels":[],"label_agreement":null},{"id":"W2111608103","doi":"10.1590/abd1806-4841.20153038","title":"Psoriasis: classical and emerging comorbidities","year":2015,"lang":"en","type":"review","venue":"Anais Brasileiros de Dermatologia","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":376,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Inflammatory bowel disease; Disease; Comorbidity; Depression (economics); Dermatology; Intensive care medicine; Psychiatry; Internal medicine","score_opus":0.06285823579085517,"score_gpt":0.32113567735887033,"score_spread":0.25827744156801513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111608103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002092525,0.9946745,0.000015307362,0.000048401373,0.0011587356,0.00049086043,0.00029483897,0.00026758353,0.0009572627],"genre_scores_gemma":[0.001982881,0.99514085,0.0000925381,0.0001110395,0.0001188615,0.00023948491,0.0010803875,0.000079499965,0.0011544285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968695,0.00084689434,0.0007310228,0.0006879037,0.000073395706,0.00079128286],"domain_scores_gemma":[0.998401,0.0004554412,0.0004027542,0.000558255,0.00007003201,0.00011252625],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031511683,0.00079343736,0.002493808,0.0003134989,0.00028897493,0.000069719026,0.00046695536,0.0014810606,0.00017690026],"category_scores_gemma":[0.00012554693,0.00063091196,0.00047443277,0.00026830068,0.00043074318,0.00012418783,0.00024253303,0.00062973687,0.00092103385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022108035,0.00010786132,0.0037620428,0.0023666662,0.0011664182,0.00024184411,0.0002287659,5.0807998e-8,0.000004702485,0.00058371,0.062821284,0.92869455],"study_design_scores_gemma":[0.00077173335,0.00006898154,0.001153333,0.0013346049,0.0020966455,0.0029287434,0.00016647864,8.8835446e-7,0.00004459684,0.000095187555,0.9906862,0.00065261935],"about_ca_topic_score_codex":0.00003240728,"about_ca_topic_score_gemma":0.000018217785,"teacher_disagreement_score":0.92804193,"about_ca_system_score_codex":0.00014245007,"about_ca_system_score_gemma":0.00035352085,"threshold_uncertainty_score":0.9998569},"labels":[],"label_agreement":null},{"id":"W2111624359","doi":"10.3899/jrheum.100041","title":"Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis","year":2010,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Rheumatoid arthritis; Malignancy; Skin cancer; Basal cell carcinoma; Methotrexate; Cancer; Arthritis; Population; Oncology; Internal medicine; Basal cell","score_opus":0.01697146005047637,"score_gpt":0.26638798824239274,"score_spread":0.24941652819191637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111624359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12747155,0.8694293,0.0000080817745,0.00007014145,0.0024451767,0.0004946858,0.00003545595,0.00001807389,0.000027519887],"genre_scores_gemma":[0.03853981,0.9611798,0.00008356393,0.000016951919,0.000021760028,0.000030539777,0.00004091191,0.000044881137,0.000041789757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957826,0.001603332,0.0017278116,0.00031513002,0.00007062649,0.0005004923],"domain_scores_gemma":[0.9963581,0.0014480083,0.0017369351,0.0003131396,0.00008976487,0.000054059266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010582221,0.00057446305,0.0028376577,0.00048235612,0.00023431661,0.000029132205,0.00041357707,0.0010217732,0.0001798692],"category_scores_gemma":[0.0002069723,0.0003815529,0.0002718508,0.00022083875,0.00043267244,0.00013484964,0.00013804862,0.0012548513,0.0000672554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015496106,0.00009725528,0.00077576144,0.00051215,0.00060875533,0.000085633386,0.00033012734,3.99837e-7,0.00007394453,0.00023072519,0.00018640577,0.9969439],"study_design_scores_gemma":[0.006757649,0.0007743718,0.00041137953,0.014692795,0.0012485492,0.31335682,0.00017219997,0.000001954553,0.000057815163,0.0012476661,0.66048574,0.000793056],"about_ca_topic_score_codex":0.000117193114,"about_ca_topic_score_gemma":0.0002028206,"teacher_disagreement_score":0.99615085,"about_ca_system_score_codex":0.000056642148,"about_ca_system_score_gemma":0.0002417014,"threshold_uncertainty_score":0.9998636},"labels":[],"label_agreement":null},{"id":"W2111980183","doi":"10.4049/jimmunol.170.10.4886","title":"Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment","year":2003,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":530,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cell biology; Signal transduction; STAT1; Chemistry; Biology","score_opus":0.027012210444021162,"score_gpt":0.26692335257398603,"score_spread":0.23991114212996487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111980183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938133,0.004332877,0.0005894789,0.000063750296,0.00073210313,0.00024125417,0.000030606698,0.000005089915,0.00019157727],"genre_scores_gemma":[0.9989606,0.00036510953,0.00053006475,0.000008515852,0.00004850467,0.000006904982,0.000013413315,0.000013577912,0.00005332228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982622,0.0005815119,0.00079036196,0.00008742891,0.000052393767,0.000226054],"domain_scores_gemma":[0.9975523,0.00051529176,0.0014395261,0.00018733146,0.00029788358,0.000007663307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074451516,0.0001441026,0.00048254355,0.00015041747,0.00012780841,0.0000020688447,0.00020117497,0.00020123519,0.00006021555],"category_scores_gemma":[0.00018784919,0.00010418182,0.00016834744,0.00013308408,0.00021364151,0.0001507227,0.000034254288,0.00021919436,0.0000017694534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019396103,0.00025597966,0.00079189346,0.00003604554,0.0012508873,4.881446e-7,0.0035624797,0.00013119733,0.9835019,0.0008383048,0.000017598126,0.007673595],"study_design_scores_gemma":[0.0030521054,0.0009230508,0.0036465426,0.000095137,0.0003134916,0.00013374364,0.0042772954,6.0363453e-7,0.98541987,0.001437174,0.00062439655,0.000076615666],"about_ca_topic_score_codex":0.0000416639,"about_ca_topic_score_gemma":0.0000019178485,"teacher_disagreement_score":0.0075969794,"about_ca_system_score_codex":0.00006827003,"about_ca_system_score_gemma":0.00012281377,"threshold_uncertainty_score":0.42484114},"labels":[],"label_agreement":null},{"id":"W2111992170","doi":"10.4049/jimmunol.1002306","title":"Inflammatory Cytokines IL-32 and IL-17 Have Common Signaling Intermediates despite Differential Dependence on TNF-Receptor 1","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Lung Association Saskatchewan; University of Manitoba","funders":"","keywords":"Receptor; Differential (mechanical device); Tumor necrosis factor alpha; Chemistry; Immunology; Medicine; Physics; Biochemistry","score_opus":0.01975511958181102,"score_gpt":0.22472291295326624,"score_spread":0.2049677933714552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111992170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285305,0.0052070054,0.000083553176,0.000107655746,0.001420034,0.0001232464,0.00002870776,0.000022177115,0.00015457965],"genre_scores_gemma":[0.9977555,0.0016249428,0.00007321045,0.00007900447,0.00011574678,0.000005861346,0.000011829764,0.000020518692,0.00031334357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982626,0.00065004616,0.0005361921,0.00015043348,0.000053325628,0.00034743868],"domain_scores_gemma":[0.9985398,0.0005145654,0.00055138493,0.00025900098,0.00010555566,0.000029707542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042522326,0.00026520225,0.00047028717,0.00020566018,0.00024265463,0.000013092845,0.0004855712,0.00028807163,0.0007079399],"category_scores_gemma":[0.000072971125,0.00016495508,0.00013740343,0.00005237342,0.0005132107,0.00012570995,0.00014471546,0.00051430403,0.00010601676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004470123,0.00021510183,0.018312149,0.000010874736,0.0015537476,0.000041464038,0.0042384723,0.0000030143497,0.93434936,0.00017512412,0.00031247252,0.03631808],"study_design_scores_gemma":[0.0038986078,0.0029397705,0.14563964,0.00019023447,0.0006390446,0.0012351811,0.0013800103,0.0000029829614,0.84012914,0.00054965407,0.0030470348,0.00034870178],"about_ca_topic_score_codex":0.00005153335,"about_ca_topic_score_gemma":0.000044204357,"teacher_disagreement_score":0.12732749,"about_ca_system_score_codex":0.000039041217,"about_ca_system_score_gemma":0.00004288812,"threshold_uncertainty_score":0.7751446},"labels":[],"label_agreement":null},{"id":"W2112629007","doi":"10.1007/s00403-006-0660-6","title":"The long-term efficacy and safety of new biological therapies for psoriasis","year":2006,"lang":"en","type":"review","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Probity Medical Research","funders":"","keywords":"Efalizumab; Etanercept; Medicine; Psoriasis; Infliximab; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Dermatology; Plaque psoriasis; Disease; Tumor necrosis factor alpha","score_opus":0.1448395228925136,"score_gpt":0.39690683258300447,"score_spread":0.25206730969049085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112629007","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003801932,0.99327236,0.00007383458,0.0001257355,0.00013467307,0.0017115007,0.0002469601,0.000025526268,0.0006074853],"genre_scores_gemma":[0.003872989,0.9941567,0.000248969,0.0000037245763,0.000053532964,0.00018360064,0.00042804796,0.000023516548,0.0010288951],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958236,0.0018378944,0.0009502486,0.00054120284,0.000111107336,0.00073589577],"domain_scores_gemma":[0.9785232,0.020489004,0.000346284,0.0005086428,0.00007138538,0.00006147343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070125004,0.00040268293,0.0018399116,0.0002448104,0.00047792867,0.00002329975,0.0008868607,0.00062435516,0.000041752624],"category_scores_gemma":[0.0007828483,0.00019624163,0.0006588009,0.00025158873,0.0023281588,0.00002498143,0.0004137335,0.0005081848,0.00002141418],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077294745,0.00021879592,0.0008286549,0.0014583946,0.0008994924,0.000006963934,0.00008967476,3.1065973e-8,0.00009122515,0.003620051,0.000618119,0.99139565],"study_design_scores_gemma":[0.002795529,0.0008530662,0.016195286,0.002120651,0.00049725635,0.00015719651,0.000042027492,2.0898378e-7,0.00052170345,0.0033108578,0.9731622,0.00034405384],"about_ca_topic_score_codex":0.000018002387,"about_ca_topic_score_gemma":0.000010157392,"teacher_disagreement_score":0.9910516,"about_ca_system_score_codex":0.000013877687,"about_ca_system_score_gemma":0.00022604277,"threshold_uncertainty_score":0.85781986},"labels":[],"label_agreement":null},{"id":"W2114649991","doi":"10.4049/jimmunol.0902796","title":"IL-23 Receptor Regulates Unconventional IL-17–Producing T Cells That Control Bacterial Infections","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Allergy and Infectious Diseases; U.S. Public Health Service; National Institutes of Health; Deutsche Forschungsgemeinschaft; Ellison Medical Foundation; Multiple Sclerosis Society; National Multiple Sclerosis Society","keywords":"Intracellular; Effector; Intracellular parasite; Biology; Immune system; Cell biology; Interleukin 17; Inflammation; Microbiology; Immunology","score_opus":0.010414309889175343,"score_gpt":0.21554303002607778,"score_spread":0.20512872013690242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114649991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98371834,0.0013416848,0.00007040163,0.0010740713,0.013313963,0.00016995003,0.00009074194,0.000029696514,0.00019114734],"genre_scores_gemma":[0.9957255,0.00045312237,0.00010309792,0.00007692949,0.0005372248,0.0000075158814,0.00004957964,0.000020870111,0.003026146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982984,0.0006113843,0.00050962484,0.00016286582,0.000053647444,0.00036408898],"domain_scores_gemma":[0.9982398,0.00053709844,0.000615137,0.00037318398,0.00020913908,0.000025653195],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009866987,0.00022410449,0.0004358769,0.00018656229,0.00039770757,0.000020220483,0.00040473312,0.00036249607,0.0032376759],"category_scores_gemma":[0.00012987039,0.00014616842,0.00026346234,0.00011968749,0.00042468903,0.00016754694,0.00006260751,0.0007188195,0.0005497096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010975464,0.00021878688,0.0013456933,0.0000028887291,0.0013193114,0.000003801922,0.00035931292,0.000010507292,0.9856804,0.00018381301,0.005224714,0.0045532132],"study_design_scores_gemma":[0.0057869693,0.0009908796,0.035398107,0.00003445259,0.00063308206,0.0017265665,0.00022984199,8.1159914e-7,0.85791373,0.00055607985,0.0964896,0.0002398899],"about_ca_topic_score_codex":0.00004725727,"about_ca_topic_score_gemma":0.00004970674,"teacher_disagreement_score":0.1277667,"about_ca_system_score_codex":0.00004300468,"about_ca_system_score_gemma":0.00014046693,"threshold_uncertainty_score":0.9976735},"labels":[],"label_agreement":null},{"id":"W2114677349","doi":"10.1016/j.jaad.2008.01.006","title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","year":2008,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":431,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Medicine; Psoriasis; Foundation (evidence); Disease; Intensive care medicine; Population; MEDLINE; Dermatology; Family medicine; Pathology; Environmental health","score_opus":0.13592852914850512,"score_gpt":0.4088836466374366,"score_spread":0.2729551174889315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114677349","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026787806,0.9850797,0.000086207736,0.008904456,0.0020440826,0.0006351138,0.00043353922,0.000016565433,0.000121551464],"genre_scores_gemma":[0.0013704409,0.9955011,0.0021320463,0.0004376832,0.00027993164,0.00003174568,0.0000728996,0.00003350212,0.00014065289],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958382,0.0016452636,0.0018666995,0.00026608168,0.00011395929,0.00026977982],"domain_scores_gemma":[0.9892855,0.005236323,0.00511365,0.0001392425,0.00018247038,0.0000427892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004864154,0.00035709227,0.0024880148,0.0004436388,0.0003040632,0.000009426266,0.00047138645,0.00048253374,0.0000281538],"category_scores_gemma":[0.0007837544,0.00024166786,0.0010955525,0.00026357613,0.0011895826,0.000056551336,0.000090017376,0.0007885429,0.000015351574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039226367,0.00014142417,0.00016561996,0.00027536438,0.0026135468,0.000003480882,0.000053898453,8.8105975e-7,0.0000049848854,0.0009081106,0.052713003,0.94272745],"study_design_scores_gemma":[0.0015674744,0.0003223943,0.0004552464,0.0011190597,0.0016146022,0.0070280833,0.000096875985,0.0000014093752,0.000054952714,0.0002856863,0.9872458,0.00020844504],"about_ca_topic_score_codex":0.0000064487217,"about_ca_topic_score_gemma":0.0000013552689,"teacher_disagreement_score":0.94251895,"about_ca_system_score_codex":0.00006827327,"about_ca_system_score_gemma":0.0004009666,"threshold_uncertainty_score":0.98549294},"labels":[],"label_agreement":null},{"id":"W2114701953","doi":"10.1016/j.ajhg.2012.03.013","title":"Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis","year":2012,"lang":"en","type":"review","venue":"The American Journal of Human Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":357,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; Dana Foundation; Canadian Institutes of Health Research; National Institutes of Health; National Human Genome Research Institute; University of Toronto; Eunice Kennedy Shriver National Institute of Child Health and Human Development; University of Michigan","keywords":"Psoriasis; Missense mutation; Biology; Genetics; Transcriptome; Mutation; Cancer research; Gene; Gene expression; Immunology","score_opus":0.05434381234687968,"score_gpt":0.3187818959993689,"score_spread":0.2644380836524892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114701953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38497615,0.6145785,0.0000010183802,0.000007588026,0.00022334751,0.00014858328,0.000028261993,0.0000024445278,0.00003410758],"genre_scores_gemma":[0.33307868,0.6666003,0.00010147258,0.00000956556,0.0001314236,0.0000054549346,0.000020201907,0.00002963144,0.000023277438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964645,0.0017025184,0.0011933632,0.00019585769,0.000073531184,0.00037026318],"domain_scores_gemma":[0.99734426,0.00031231597,0.0018130407,0.00042624655,0.00005197657,0.00005219281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097532995,0.00035486967,0.0022909695,0.00043356942,0.00008847967,0.000011434182,0.00052487006,0.00018858309,0.000039583534],"category_scores_gemma":[0.000020998426,0.00024005504,0.00027838987,0.000289779,0.0004424137,0.000062904444,0.000109013774,0.00048560105,0.0000045790775],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009203301,0.00020206161,0.0058517507,0.00036427748,0.00047762517,0.000035872792,0.0012323896,0.000004132093,0.00059854117,0.000045015524,0.000021648215,0.9910747],"study_design_scores_gemma":[0.018492289,0.019488797,0.41210955,0.037466317,0.03464478,0.015004665,0.009275766,0.000007792824,0.004833919,0.001412062,0.44155645,0.0057075834],"about_ca_topic_score_codex":0.000090455294,"about_ca_topic_score_gemma":0.00009761879,"teacher_disagreement_score":0.98536706,"about_ca_system_score_codex":0.00007854062,"about_ca_system_score_gemma":0.00012277457,"threshold_uncertainty_score":0.97891605},"labels":[],"label_agreement":null},{"id":"W2114814856","doi":"10.2310/7750.2009.00021","title":"Biologics in the Treatment of Psoriasis: Clinical and Economic Overview","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"Abbott Laboratories; Abbott Fund","keywords":"Ustekinumab; Medicine; Adalimumab; Infliximab; Psoriasis; Etanercept; Psoriasis Area and Severity Index; Efalizumab; Dermatology; Randomized controlled trial; Plaque psoriasis; Internal medicine; Disease; Tumor necrosis factor alpha","score_opus":0.13384459456858502,"score_gpt":0.36746058593198916,"score_spread":0.23361599136340414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114814856","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017042622,0.98130083,2.4305558e-7,0.00023091178,0.0010925742,0.0002158244,0.0000195894,0.0000030494184,0.00009434874],"genre_scores_gemma":[0.0010439848,0.9982835,0.000008674467,0.0001045902,0.00043606208,0.000004441588,0.000029919964,0.000010499056,0.00007830016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666214,0.0010370621,0.0018510558,0.00020349764,0.00004320497,0.00020301154],"domain_scores_gemma":[0.99364877,0.004831705,0.001242217,0.00020641959,0.0000326634,0.000038220416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013594703,0.00033828113,0.0035983508,0.00033242992,0.00004403342,0.000005751752,0.00013916433,0.00046890284,0.000059627062],"category_scores_gemma":[0.0001489458,0.0001533693,0.0006256669,0.00009760363,0.00031060394,0.000027273702,0.000010204469,0.0002498788,0.000006141196],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011683634,0.00021896172,0.001042498,0.00046306374,0.0007099342,0.00046635847,0.00019169542,4.627639e-8,6.8923475e-7,0.000029754161,0.0022100077,0.99455017],"study_design_scores_gemma":[0.00077822205,0.0021209354,0.00030214436,0.0042050336,0.002563957,0.011109533,0.00013200435,5.9348633e-8,9.4782456e-7,0.00010339808,0.9785516,0.00013215213],"about_ca_topic_score_codex":0.000027639133,"about_ca_topic_score_gemma":0.000016772163,"teacher_disagreement_score":0.994418,"about_ca_system_score_codex":0.000040974315,"about_ca_system_score_gemma":0.000232431,"threshold_uncertainty_score":0.6254218},"labels":[],"label_agreement":null},{"id":"W2115206201","doi":"10.2310/7750.2014.13151","title":"Think beyond the Skin","year":2015,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Dermatrials Research; Child and Family Research Institute; Lynde Centre for Dermatology; University of Toronto; St. Joseph’s Healthcare Hamilton; University of British Columbia; Memorial University of Newfoundland","funders":"Merck Canada; Valeant Pharmaceuticals International","keywords":"Medicine; Psoriasis; Rheumatoid arthritis; Psoriasis Area and Severity Index; Dermatology; Dermatology Life Quality Index; Psoriatic arthritis; Quality of life (healthcare); Intensive care medicine; Internal medicine","score_opus":0.03278514995451424,"score_gpt":0.25164085693513993,"score_spread":0.2188557069806257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115206201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94725364,0.04026492,0.00001563323,0.00717219,0.002507753,0.00005162579,0.0000023796197,0.000009837685,0.0027220405],"genre_scores_gemma":[0.9941139,0.0020704903,0.000019587113,0.0012808063,0.00051964255,5.8706235e-7,0.0000058389223,0.000008799183,0.001980332],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991052,0.00018972646,0.00038249866,0.000076668686,0.00007940441,0.00016647717],"domain_scores_gemma":[0.99834365,0.0010881315,0.00025448433,0.00012023996,0.00013553085,0.000057959107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009155274,0.00011449516,0.00039980182,0.00012249302,0.00009074882,0.000006764217,0.00009675803,0.00010048592,0.00015220734],"category_scores_gemma":[0.00035019565,0.0000549184,0.000102788064,0.00009128373,0.00019356645,0.00005077598,0.00001656558,0.00018084886,0.000030101548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010951059,0.00013827786,0.009379555,0.00001806242,0.00095332717,0.0019654282,0.009656844,0.0000035299925,0.0061856727,0.00029047442,0.7671923,0.20312141],"study_design_scores_gemma":[0.0038041363,0.0017461301,0.004809286,0.0002733206,0.0012356525,0.10692031,0.012486604,0.0000036340277,0.0048771976,0.0054198056,0.8580397,0.0003842662],"about_ca_topic_score_codex":0.000023471539,"about_ca_topic_score_gemma":0.0000058259825,"teacher_disagreement_score":0.20273714,"about_ca_system_score_codex":0.000016193382,"about_ca_system_score_gemma":0.0001148978,"threshold_uncertainty_score":0.22395073},"labels":[],"label_agreement":null},{"id":"W2116526448","doi":"10.2310/7750.2011.10066","title":"Canadian Guidelines for the Management of Plaque Psoriasis: Overview","year":2011,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Probity Medical Research; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Scalp; Plaque psoriasis","score_opus":0.11613844297127882,"score_gpt":0.29889666331523934,"score_spread":0.18275822034396053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116526448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5363095,0.43191165,0.00032812773,0.018021164,0.008592098,0.00074787025,0.000075958174,0.000020291367,0.0039933305],"genre_scores_gemma":[0.8989828,0.09625628,0.0006572841,0.0015649154,0.00042681122,0.000013840951,0.000014733871,0.000022708977,0.002060632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901485,0.000056811485,0.0006058,0.00008264069,0.00004971547,0.00019015066],"domain_scores_gemma":[0.99863696,0.0005780673,0.0003244403,0.00013263655,0.00027626986,0.000051612977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070935563,0.000119468896,0.00044198902,0.00017566775,0.00009569449,0.0000022341076,0.00011936978,0.00008589043,0.0003432238],"category_scores_gemma":[0.000101489655,0.00006356164,0.00015523621,0.000083773186,0.00008813095,0.000031523425,0.000010710515,0.00007039223,0.0000039526785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016902379,0.00013836096,0.0072040902,0.00043525783,0.006266155,0.0010924865,0.0024669534,0.0000027807139,0.0012129586,0.0019099402,0.34741762,0.63016313],"study_design_scores_gemma":[0.0036217056,0.001270893,0.0096267,0.002425804,0.005003052,0.012164794,0.0070195207,0.0000060552807,0.0044652163,0.0022675116,0.95173144,0.00039727686],"about_ca_topic_score_codex":0.003463763,"about_ca_topic_score_gemma":0.0014475944,"teacher_disagreement_score":0.62976587,"about_ca_system_score_codex":0.00002133058,"about_ca_system_score_gemma":0.00011345372,"threshold_uncertainty_score":0.52361965},"labels":[],"label_agreement":null},{"id":"W2116954175","doi":"10.1093/infdis/jiu144","title":"Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Biology; Human cytomegalovirus; Interleukin 28B; Viral replication; Single-nucleotide polymorphism; SNP; Peripheral blood mononuclear cell; Virology; Immunology; Virus; Gene; Genotype; Genetics; In vitro","score_opus":0.004926634265542882,"score_gpt":0.1914045688807336,"score_spread":0.18647793461519072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116954175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958441,0.0022982215,0.00046349852,0.000012639677,0.00068028056,0.00009619094,0.000007733148,0.00003292472,0.0005643713],"genre_scores_gemma":[0.99941456,0.00026568983,0.000003785829,0.00003389896,0.00011312362,0.0000041488947,0.000008331062,0.000015408365,0.00014106382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989767,0.00039701935,0.00033409504,0.00008240676,0.00005988117,0.00014991475],"domain_scores_gemma":[0.9989396,0.00016490527,0.00051966956,0.00019547514,0.00015586363,0.000024494326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002972875,0.00014947381,0.0002900866,0.00019352025,0.00017435245,0.000009461648,0.00010387879,0.00007476317,0.0000852811],"category_scores_gemma":[0.000048118225,0.00008871537,0.00015526915,0.00014506739,0.00013901698,0.00018441923,0.000028637773,0.00015837788,0.000030602558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007913655,0.0009518404,0.50320584,0.00015072613,0.00272414,0.000007251265,0.00046678638,0.00074222515,0.4293546,0.00012527154,0.00027919537,0.054078456],"study_design_scores_gemma":[0.0032649215,0.0017370486,0.9580021,0.0001089321,0.0010482398,0.0004715482,0.000044120312,8.8063183e-7,0.034225844,0.00015331723,0.00082043477,0.00012259741],"about_ca_topic_score_codex":0.00008511349,"about_ca_topic_score_gemma":0.000028012877,"teacher_disagreement_score":0.45479628,"about_ca_system_score_codex":0.00009428016,"about_ca_system_score_gemma":0.000065486354,"threshold_uncertainty_score":0.36177078},"labels":[],"label_agreement":null},{"id":"W2116956799","doi":"10.1016/s0140-6736(08)60725-4","title":"Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1865,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Internal medicine; Randomization; Randomized controlled trial; Intention-to-treat analysis; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.03512843593995436,"score_gpt":0.26493493718177374,"score_spread":0.2298065012418194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116956799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432564,0.0005152328,0.000005900259,0.00012112421,0.00042390625,0.003414759,0.00033374454,0.000042473835,0.00081722013],"genre_scores_gemma":[0.9978598,0.00016535983,0.000060878618,0.000038548296,0.00024225612,0.00019724919,0.00095759,0.000023633283,0.00045469403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976799,0.0005800234,0.0007848447,0.00044086188,0.00010017221,0.0004141981],"domain_scores_gemma":[0.9980273,0.0008687102,0.00044270905,0.00057068135,0.000059034228,0.00003153253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005785024,0.00033373077,0.0013964556,0.00013360832,0.00023748711,0.000015250625,0.00036903273,0.00022965568,0.000065103486],"category_scores_gemma":[0.00009316697,0.00020024835,0.00015015529,0.00014184351,0.0002948742,0.00008466474,0.000087225046,0.0002764864,0.000030532337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98309773,0.00094606867,0.009174861,0.0000067388414,0.0011766758,0.000012920456,0.002622243,0.0000128298325,0.0016324029,0.00003200585,0.00040691512,0.00087858306],"study_design_scores_gemma":[0.9242233,0.0013287015,0.07190811,0.00009832269,0.0003439263,0.000007872626,0.000060356473,0.0000019865233,0.0013803203,0.000026671742,0.00040768538,0.00021275737],"about_ca_topic_score_codex":0.00043526018,"about_ca_topic_score_gemma":0.00027965877,"teacher_disagreement_score":0.06273325,"about_ca_system_score_codex":0.00004133862,"about_ca_system_score_gemma":0.00006924486,"threshold_uncertainty_score":0.81658906},"labels":[],"label_agreement":null},{"id":"W2117002365","doi":"10.1136/annrheumdis-2013-203771","title":"Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Health and Medical Research Council; Versus Arthritis; Medical Research Council; State Government of Victoria; Australian Government","keywords":"Interleukin 17; Glycoprotein 130; Medicine; T cell; Arthritis; Immunology; Molecular biology; Cytokine; Internal medicine; Interleukin 6; Biology; Immune system","score_opus":0.02369706498808092,"score_gpt":0.25759801512165653,"score_spread":0.23390095013357562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117002365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436265,0.0039114603,0.0000036354913,0.0007154432,0.00017450514,0.0005151551,0.00021559448,0.000016808313,0.00008474807],"genre_scores_gemma":[0.9986977,0.00050560804,0.000018109246,0.00017510747,0.000004822889,0.00010048825,0.000014975862,0.000013472443,0.00046973064],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984684,0.00051445037,0.00049243396,0.00018956848,0.000085971806,0.00024920492],"domain_scores_gemma":[0.99863815,0.00056697516,0.00025781698,0.00034634463,0.00014737165,0.000043357548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027324216,0.00016812359,0.00039967723,0.00016236724,0.00006390226,0.000009530905,0.00028174772,0.000101674246,0.00080904097],"category_scores_gemma":[0.00044555432,0.00012364186,0.00017587112,0.00020582323,0.00010227046,0.00013192285,0.00010623501,0.00007611091,0.00024731847],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070049064,0.002512063,0.08087923,0.00032298474,0.003058883,0.00001844416,0.012260648,0.000535509,0.5385346,0.00025345877,0.012080578,0.34253874],"study_design_scores_gemma":[0.0017545954,0.00025044882,0.74212277,0.0012220249,0.00010643097,0.000006103432,0.0012083105,0.000012110955,0.25160092,0.0011222711,0.00035820567,0.00023584127],"about_ca_topic_score_codex":0.0003071504,"about_ca_topic_score_gemma":0.00002381749,"teacher_disagreement_score":0.6612435,"about_ca_system_score_codex":0.00001718576,"about_ca_system_score_gemma":0.000104177525,"threshold_uncertainty_score":0.88584316},"labels":[],"label_agreement":null},{"id":"W2117031417","doi":"10.3899/jrheum.111242","title":"Genetics of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting: Figure 1.","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Immunology; Allele; Genome-wide association study; Human leukocyte antigen; Disease; Candidate gene; Genetics; Gene; Biology; Genotype; Single-nucleotide polymorphism; Internal medicine; Antigen","score_opus":0.013216355214363184,"score_gpt":0.2292552880651009,"score_spread":0.21603893285073772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117031417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88009876,0.116474465,0.000048998525,0.00077479007,0.0023634518,0.00010761443,0.00004829391,0.000007809557,0.000075834665],"genre_scores_gemma":[0.98471534,0.0147917885,0.00022593254,0.000052235384,0.000056275512,0.0000036710765,0.000013319062,0.000014612959,0.00012679344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979652,0.0007576219,0.000778725,0.00010403079,0.000072317154,0.0003220846],"domain_scores_gemma":[0.9971849,0.0012547965,0.0010216461,0.00034570912,0.00015328349,0.000039690596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012398388,0.00018398926,0.0005650982,0.00006809704,0.00018154214,0.0000057206,0.00033087254,0.00024640988,0.00014975897],"category_scores_gemma":[0.00033262046,0.00009925879,0.00014151316,0.00010397938,0.0003663378,0.000086969034,0.00008323415,0.00029385556,0.000028907798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010359742,0.000359755,0.8552669,0.000026673042,0.0031916474,0.000029606043,0.014096567,0.0000067480287,0.010960353,0.00046836972,0.03627679,0.078280576],"study_design_scores_gemma":[0.014841073,0.0017972833,0.7208517,0.0008865617,0.0050471006,0.09832551,0.017597698,0.0000062627205,0.04622326,0.005617196,0.08784334,0.0009629739],"about_ca_topic_score_codex":0.00033798357,"about_ca_topic_score_gemma":0.0000869796,"teacher_disagreement_score":0.13441521,"about_ca_system_score_codex":0.0000107952665,"about_ca_system_score_gemma":0.000067981615,"threshold_uncertainty_score":0.40476558},"labels":[],"label_agreement":null},{"id":"W2117178293","doi":"10.1358/dot.2004.40.11.872578","title":"Efalizumab: Advancing psoriasis management with a novel, targetedT-cell modulator","year":2004,"lang":"en","type":"review","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Psoriasis; Medicine; Pathogenesis; Monoclonal antibody; Immunology; Clinical trial; Monoclonal; Dermatology; Antibody; Plaque psoriasis; Pathology","score_opus":0.013235696228063943,"score_gpt":0.24904233892696076,"score_spread":0.2358066426988968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117178293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015855882,0.9925759,0.0001360633,0.00001135569,0.0009832344,0.001147415,0.0007360142,0.00010397591,0.0041474937],"genre_scores_gemma":[0.0005797456,0.99074477,0.002013124,0.000017220884,0.00006781987,0.0002566464,0.00087279966,0.00011931345,0.0053285374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975169,0.00014794002,0.0007749234,0.00076652714,0.0001421217,0.0006515971],"domain_scores_gemma":[0.9981795,0.00012973252,0.00070724543,0.00082861795,0.00009950004,0.000055433597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003006564,0.0007923865,0.0021128822,0.00039836287,0.00014619372,0.000014998725,0.0005578967,0.0005957403,0.00034455617],"category_scores_gemma":[0.000013284327,0.0005777818,0.0006787325,0.0003967317,0.00012555801,0.000091618014,0.00016618421,0.0002949635,0.0003024563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012549796,0.00066063984,0.000004567117,0.019140149,0.0032565894,0.000043279724,0.00025944033,0.00002053885,0.000096284115,0.0006294167,0.001050805,0.9747128],"study_design_scores_gemma":[0.0029380142,0.00020247723,0.0000053862395,0.0097890375,0.004191254,0.00005151217,0.000090691705,1.3451779e-7,0.000980658,0.000025872805,0.9810862,0.0006387805],"about_ca_topic_score_codex":0.00008005888,"about_ca_topic_score_gemma":0.000007887474,"teacher_disagreement_score":0.98003536,"about_ca_system_score_codex":0.0003479577,"about_ca_system_score_gemma":0.0003158697,"threshold_uncertainty_score":0.99966735},"labels":[],"label_agreement":null},{"id":"W2118058941","doi":"10.1111/j.1365-4632.2007.03158.x","title":"Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb study","year":2007,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Genentech; Abbott Laboratories","keywords":"Medicine; Efalizumab; Dermatology; Psoriasis; Multicenter study; Open label; Plaque psoriasis; Clinical trial; Surgery; Internal medicine; Randomized controlled trial","score_opus":0.032016500715600915,"score_gpt":0.34767670709023435,"score_spread":0.31566020637463343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118058941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048793,0.00035499627,0.0026235466,0.00079491,0.004858426,0.0003941472,0.00037187888,0.0000195843,0.00009457013],"genre_scores_gemma":[0.9975293,0.000038480066,0.0012689765,0.0004988381,0.0001901045,0.000013621764,0.00040041163,0.000025113573,0.0000351366],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788874,0.00038283467,0.0008992086,0.00034108612,0.00018366452,0.00030449172],"domain_scores_gemma":[0.99822617,0.00043872016,0.00046572974,0.00019578898,0.00058123074,0.00009238117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017853196,0.00026156957,0.0005217607,0.00038810994,0.00015153605,0.000087659544,0.0012108802,0.00017292945,0.00058007456],"category_scores_gemma":[0.00009459796,0.00022905726,0.000093780334,0.000104692626,0.00006466871,0.00054652523,0.00013833289,0.00024547282,0.00011604871],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059267726,0.039319616,0.38829875,0.0000050218296,0.020455742,0.0056061256,0.07217221,0.000016347056,0.1458433,0.0004240563,0.001994198,0.2665969],"study_design_scores_gemma":[0.28419843,0.012963612,0.32370418,0.00040547174,0.0017805541,0.0019003906,0.01708518,0.00004300112,0.331316,0.001966382,0.02307512,0.0015617005],"about_ca_topic_score_codex":0.0006212527,"about_ca_topic_score_gemma":0.0003624193,"teacher_disagreement_score":0.2650352,"about_ca_system_score_codex":0.00014820081,"about_ca_system_score_gemma":0.00006293872,"threshold_uncertainty_score":0.9340684},"labels":[],"label_agreement":null},{"id":"W2118943255","doi":"10.3899/jrheum.140104","title":"Tuberculosis Reactivation Risk in Dermatology","year":2014,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Etanercept; Tuberculosis; Adalimumab; Disease; Latent tuberculosis; Dermatology; Immunology; Risk factor; Mycobacterium tuberculosis; Tumor necrosis factor alpha; Internal medicine; Pathology","score_opus":0.02113490415681214,"score_gpt":0.291019926504318,"score_spread":0.2698850223475059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118943255","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026024322,0.9939832,0.00009727854,0.00026167362,0.0023730386,0.00047312054,0.00011489428,0.000016624024,0.000077740115],"genre_scores_gemma":[0.0026566545,0.9963482,0.00029354476,0.000019124767,0.000027671185,0.0000743118,0.0004445993,0.000047586465,0.000088286295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938119,0.0024795507,0.0026620259,0.0003825349,0.0000851569,0.00057884294],"domain_scores_gemma":[0.99472195,0.0014059948,0.0032823887,0.00041687413,0.00012330944,0.00004948568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011145826,0.00058224896,0.0041940343,0.0011700774,0.000114321054,0.000012563265,0.0005122786,0.0011290567,0.0008750011],"category_scores_gemma":[0.00032853105,0.0004350219,0.0009060653,0.00030287172,0.00013076229,0.00010858952,0.000105338004,0.0010160166,0.0003767073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011752274,0.0003668354,0.011231494,0.0026412958,0.003028189,0.00009482564,0.00019654931,0.0000010317785,0.0000055474516,0.0004616737,0.018063948,0.9637911],"study_design_scores_gemma":[0.0022923923,0.00022348756,0.00017172647,0.003292094,0.002010238,0.010513038,0.00006367078,3.16606e-7,0.00004903461,0.0001323481,0.98092175,0.00032993284],"about_ca_topic_score_codex":0.00015731258,"about_ca_topic_score_gemma":0.0001672694,"teacher_disagreement_score":0.96346116,"about_ca_system_score_codex":0.0002854058,"about_ca_system_score_gemma":0.0003524193,"threshold_uncertainty_score":0.99981016},"labels":[],"label_agreement":null},{"id":"W2120096107","doi":"10.1016/j.rdc.2015.07.002","title":"Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis","year":2015,"lang":"en","type":"review","venue":"Rheumatic Disease Clinics of North America","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Epigenetics; Genome-wide association study; Genetics; Gene; Genetic architecture; Copy-number variation; Psoriasis; Genetic association; Psoriatic arthritis; Candidate gene; Disease; Major histocompatibility complex; Genetic predisposition; Medicine; Computational biology; Biology; Genome; Immunology; Phenotype; Single-nucleotide polymorphism; Genotype","score_opus":0.03252364130476305,"score_gpt":0.3077579741057637,"score_spread":0.2752343328010007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120096107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026869856,0.96989864,0.00002387451,0.000007911121,0.0006616931,0.0011257887,0.0012883645,0.000033487035,0.00009036568],"genre_scores_gemma":[0.013622391,0.98510534,0.0004453339,0.000017829256,0.00004404693,0.00016140704,0.0004664567,0.00008010179,0.000057069305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960252,0.00071492256,0.0019180491,0.00072793284,0.00015560926,0.00045830655],"domain_scores_gemma":[0.99606407,0.0009711003,0.0017387028,0.00075795,0.00017644634,0.0002917537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026201014,0.0007230907,0.0034853723,0.00031491037,0.000089948284,0.000015483183,0.00037609544,0.00026822978,0.00016854194],"category_scores_gemma":[0.00040105055,0.00063287024,0.0005354172,0.00038156417,0.00075188756,0.000048088616,0.00022405652,0.0002213493,0.00010439103],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007534897,0.00034062445,0.0011281767,0.009031382,0.0017515701,0.000017792561,0.000110616675,0.0000020997188,3.9500705e-7,0.000008728168,0.00016822475,0.98736507],"study_design_scores_gemma":[0.00815141,0.001867364,0.024478609,0.02188015,0.032473978,0.00015149543,0.00011478182,0.000035729376,0.000008011681,0.0011005676,0.90741974,0.002318162],"about_ca_topic_score_codex":0.00003118821,"about_ca_topic_score_gemma":0.00001429776,"teacher_disagreement_score":0.98504686,"about_ca_system_score_codex":0.000031045096,"about_ca_system_score_gemma":0.0007921667,"threshold_uncertainty_score":0.9996123},"labels":[],"label_agreement":null},{"id":"W2120182890","doi":"10.1016/j.jdcr.2014.09.002","title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report","year":2014,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"University of Connecticut; Eli Lilly and Company","keywords":"Psoriasis; Medicine; Disease; Psoriatic arthritis; Secukinumab; Ustekinumab; Dyslipidemia; Dermatology; Internal medicine; Immunology; Adalimumab","score_opus":0.021779075063008392,"score_gpt":0.2579939865623472,"score_spread":0.2362149114993388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120182890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97601634,0.020955123,0.00017461837,0.0001420563,0.0013612431,0.001127838,0.0000453689,0.000060981325,0.00011640129],"genre_scores_gemma":[0.99496984,0.0034155052,0.00018699984,0.00003538043,0.00011090083,0.00054075354,0.00010233004,0.000020948812,0.0006173077],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9983782,0.00019242705,0.0006527784,0.00045012022,0.00003365857,0.00029281946],"domain_scores_gemma":[0.9978613,0.0007916189,0.00052290614,0.0006905913,0.00009811829,0.00003546484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005799707,0.00027364635,0.0005438765,0.00007246741,0.00035501702,0.000015717083,0.00003486587,0.00022427659,0.000060594637],"category_scores_gemma":[0.00016630652,0.00016145453,0.00024048825,0.00009977387,0.0001733943,0.000039552247,0.000016761667,0.000046772882,0.0000046494033],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057786354,0.0008785273,0.004080504,0.000022645669,0.0014871063,0.23261988,0.0008449634,0.0000032401636,0.0034584168,0.00022092056,0.00043254514,0.75537336],"study_design_scores_gemma":[0.0052807713,0.0034127317,0.0016232744,0.000022243286,0.00051968143,0.9133534,0.00036134047,0.000013107135,0.031023774,0.0007114496,0.043420434,0.0002578058],"about_ca_topic_score_codex":0.0005243738,"about_ca_topic_score_gemma":0.0001595254,"teacher_disagreement_score":0.75511557,"about_ca_system_score_codex":0.00003252544,"about_ca_system_score_gemma":0.000047399477,"threshold_uncertainty_score":0.6583924},"labels":[],"label_agreement":null},{"id":"W2120361989","doi":"10.1136/ard.2004.031765","title":"Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations","year":2005,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Memorial University of Newfoundland","funders":"Canadian Institutes of Health Research; Arthritis Society","keywords":"Psoriatic arthritis; Linkage disequilibrium; Medicine; Odds ratio; Population; Psoriasis; SNP; Internal medicine; Allele; Genome-wide association study; Immunology; Single-nucleotide polymorphism; Genetics; Haplotype; Genotype; Biology","score_opus":0.02684029313695235,"score_gpt":0.2803873358360567,"score_spread":0.25354704269910433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120361989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911166,0.0063847336,0.0000012471944,0.0016143328,0.0001551785,0.00014766146,0.00030643496,0.00000646276,0.00026736286],"genre_scores_gemma":[0.99901915,0.00042655473,0.00002297532,0.000053346346,0.000008661508,0.000013155139,0.000052831154,0.0000049330133,0.00039836724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928063,0.00015524785,0.0002806096,0.000085343985,0.000036573827,0.00016156529],"domain_scores_gemma":[0.99943435,0.00015347442,0.00019149053,0.00015127144,0.00004132895,0.000028108228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014356717,0.00007923529,0.00021651876,0.00008593073,0.00007375071,0.0000049695286,0.00008907768,0.000041001083,0.00014578941],"category_scores_gemma":[0.00034081165,0.00006111855,0.000075105876,0.000113665235,0.00004519967,0.000063127394,0.000019719831,0.000031569987,0.000015984559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003257508,0.00023548039,0.63292867,0.000051422227,0.0003261738,5.9056356e-7,0.00059032766,0.000065201864,0.00008701428,0.0013001804,0.003092525,0.36128983],"study_design_scores_gemma":[0.0008397914,0.000019740592,0.9957303,0.00020498701,0.00010551978,0.00000174746,0.00006393616,0.000026770547,0.00067103107,0.001823912,0.0004429992,0.000069295405],"about_ca_topic_score_codex":0.01749022,"about_ca_topic_score_gemma":0.13086928,"teacher_disagreement_score":0.36280158,"about_ca_system_score_codex":0.00002812358,"about_ca_system_score_gemma":0.00007354482,"threshold_uncertainty_score":0.9890524},"labels":[],"label_agreement":null},{"id":"W2121615696","doi":"10.1155/2013/980419","title":"Promising New Treatments for Psoriasis","year":2013,"lang":"en","type":"review","venue":"The Scientific World JOURNAL","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Université Laval","keywords":"Psoriasis; Medicine; Methotrexate; Dermatology; Disease; Population; Quality of life (healthcare); Clinical trial; Intensive care medicine; Immunology; Internal medicine","score_opus":0.08908814688070928,"score_gpt":0.32548941766043743,"score_spread":0.23640127077972817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121615696","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004979146,0.9834098,0.0000441715,0.00015250524,0.013796442,0.0017409881,0.00011274914,0.000045307945,0.00064822723],"genre_scores_gemma":[0.0000032878438,0.66051924,0.00034723387,0.000011359123,0.0006366103,0.00013668762,0.00022312658,0.000046943136,0.3380755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972322,0.00052482483,0.0008125123,0.0005592838,0.000109077555,0.00076207914],"domain_scores_gemma":[0.99779856,0.00044783545,0.0008383635,0.0006981585,0.0001238683,0.00009320209],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011762555,0.0005749216,0.0012965782,0.0005696353,0.002047884,0.0006375931,0.0009890039,0.000271202,0.0017820474],"category_scores_gemma":[0.000074623684,0.0002971546,0.0012890885,0.0006807659,0.0002654717,0.00016440006,0.00010255084,0.000502403,0.0029383479],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018426883,0.00007052989,9.757215e-7,0.00017979283,0.0017113895,0.0000031594443,0.00013068176,1.5233661e-7,0.000049748283,0.00006846711,0.13131623,0.8664504],"study_design_scores_gemma":[0.0011373395,0.000059107904,0.000002874909,0.0019951363,0.005610956,0.00048894185,0.000024805442,1.9324969e-7,0.00013210559,0.000581098,0.9896685,0.0002989366],"about_ca_topic_score_codex":0.000015277412,"about_ca_topic_score_gemma":0.000022798824,"teacher_disagreement_score":0.8661515,"about_ca_system_score_codex":0.0002335135,"about_ca_system_score_gemma":0.0007951485,"threshold_uncertainty_score":0.9999481},"labels":[],"label_agreement":null},{"id":"W2121623213","doi":"10.1016/j.jaad.2015.06.038","title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis; Observational study; Medical prescription; Confidence interval; Population; Adverse effect; Internal medicine; Dermatology; Disease; Pharmacology","score_opus":0.024680481966402493,"score_gpt":0.28335760386240566,"score_spread":0.25867712189600317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121623213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98622125,0.0019660885,0.00012485503,0.010736984,0.00022440139,0.00022526289,0.00036339302,0.00000773766,0.00012999335],"genre_scores_gemma":[0.99761254,0.0003096312,0.0012428368,0.0003153262,0.00007490658,0.000010780881,0.000016849752,0.000016866745,0.0004002399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762994,0.0009661078,0.0007754532,0.00021914634,0.00010753038,0.00030180535],"domain_scores_gemma":[0.9963377,0.0012135293,0.0018597887,0.0003266257,0.00020173982,0.00006062249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000426491,0.00022645216,0.0011773026,0.00016154515,0.00009706423,0.000007863261,0.00072568905,0.00017219837,0.00008070005],"category_scores_gemma":[0.00042379776,0.00013077055,0.0006196094,0.00051477726,0.00034100073,0.000053893014,0.000102468424,0.00019151164,0.000012095948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058319356,0.0010878254,0.71477354,0.00006138865,0.045271132,0.000032442393,0.005926054,0.0033022186,0.045828868,0.00047306766,0.09248243,0.032441705],"study_design_scores_gemma":[0.036230758,0.0038047794,0.5704532,0.00028910182,0.01589202,0.002352705,0.014086835,0.00024148154,0.23987544,0.0019118497,0.11341871,0.0014430963],"about_ca_topic_score_codex":0.00026339764,"about_ca_topic_score_gemma":0.00003577898,"teacher_disagreement_score":0.19404657,"about_ca_system_score_codex":0.00008446799,"about_ca_system_score_gemma":0.00016587788,"threshold_uncertainty_score":0.53326684},"labels":[],"label_agreement":null},{"id":"W2121627842","doi":"10.1378/chest.12-0598","title":"T Helper 17 Cells in Airway Diseases","year":2013,"lang":"en","type":"review","venue":"CHEST Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada); McGill University","funders":"","keywords":"Medicine; COPD; Immunology; Asthma; Airway; Immune system; Inflammation; Lung; Proinflammatory cytokine; Interleukin 17; Internal medicine","score_opus":0.04090317263607348,"score_gpt":0.282439769883912,"score_spread":0.24153659724783852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121627842","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017604907,0.99648094,0.0000034362818,0.000019007972,0.002036455,0.00031698387,0.000112291,0.000022832892,0.0008320168],"genre_scores_gemma":[0.00002470325,0.984634,0.00004635088,0.000024670464,0.0003619823,0.00007447894,0.00019205487,0.000044166012,0.014597619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981723,0.0004095695,0.00060683175,0.00029400442,0.000039717204,0.00047758792],"domain_scores_gemma":[0.9990402,0.00019383607,0.00037469048,0.0002786857,0.00003865575,0.00007396273],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016584796,0.000457296,0.0013849542,0.00029374045,0.000154872,0.000050312367,0.0003921326,0.0006149623,0.0038121217],"category_scores_gemma":[0.000029830231,0.00030720676,0.000670888,0.00016122546,0.00011612283,0.00010339713,0.00006721894,0.0007019177,0.00512853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008539715,0.0001764247,0.00004742395,0.0011937798,0.00042574725,0.00010087735,0.00006271861,1.5268424e-7,0.00005539747,0.000005046074,0.02155387,0.97637004],"study_design_scores_gemma":[0.0005908596,0.0000568061,0.000084372405,0.0029142455,0.0010141018,0.00053612055,0.000028056738,1.9901268e-8,0.00009072902,0.00001894024,0.9943534,0.00031235776],"about_ca_topic_score_codex":0.000008153533,"about_ca_topic_score_gemma":0.000004338256,"teacher_disagreement_score":0.97605765,"about_ca_system_score_codex":0.00015438063,"about_ca_system_score_gemma":0.00029360125,"threshold_uncertainty_score":0.999938},"labels":[],"label_agreement":null},{"id":"W2121976840","doi":"10.1186/cc10515","title":"IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis","year":2011,"lang":"en","type":"article","venue":"Critical Care","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; National Sanitarium Association; Heart and Stroke Foundation of Canada","keywords":"Sepsis; Medicine; Single-nucleotide polymorphism; Odds ratio; Cohort; Genotype; Septic shock; Internal medicine; SNP; Immunology; Biology; Genetics; Gene","score_opus":0.03234445705530698,"score_gpt":0.27604340814196854,"score_spread":0.24369895108666156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121976840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980253,0.00025937564,0.00023675576,0.000029882238,0.00018175087,0.00023136265,0.00035297725,0.000033550386,0.0006490409],"genre_scores_gemma":[0.9994999,0.000006569194,0.00019531402,0.000088322864,0.000013703328,0.00002281388,0.00012321629,0.000008797407,0.000041327636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991102,0.00021487696,0.00016797369,0.00028190372,0.000037220998,0.00018780993],"domain_scores_gemma":[0.99933064,0.000118307784,0.000038310136,0.00017689737,0.00029596995,0.000039893013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008026186,0.00012994863,0.00022182254,0.000043615026,0.00010088854,0.00000663621,0.000041522,0.00019186,0.00033964516],"category_scores_gemma":[0.00017840175,0.00011084622,0.000052277708,0.0001170562,0.00014388817,0.00005634376,0.00003198695,0.00007408597,0.000018785433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000336542,0.00030957063,0.9653841,0.00009420283,0.00043645047,0.000007738904,0.011102386,8.471293e-7,0.015718274,0.00035182777,0.000069373644,0.0061886837],"study_design_scores_gemma":[0.0006303833,0.000662961,0.97022825,0.000034875215,0.00044097137,0.000007863544,0.00032346032,9.466741e-7,0.02724092,0.00029122396,0.000008563305,0.0001295477],"about_ca_topic_score_codex":0.00074119755,"about_ca_topic_score_gemma":0.00054111716,"teacher_disagreement_score":0.011522648,"about_ca_system_score_codex":0.000057320565,"about_ca_system_score_gemma":0.00002865211,"threshold_uncertainty_score":0.45201775},"labels":[],"label_agreement":null},{"id":"W2122643788","doi":"10.4081/reumatismo.2007.1s.85","title":"BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS","year":2011,"lang":"en","type":"article","venue":"Reumatismo","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Disease; Quality of life (healthcare); Intensive care medicine; Arthritis; Psoriasis; Dermatology; Immunology; Internal medicine","score_opus":0.04423652660104984,"score_gpt":0.23115980723623525,"score_spread":0.1869232806351854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122643788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659456,0.02674346,0.00005948164,0.000017157263,0.00062228617,0.00016426775,0.000031277,0.00006263503,0.0063538556],"genre_scores_gemma":[0.99066055,0.00824982,0.00052565255,0.000033062734,0.000011964545,0.000027612317,0.0000416071,0.000009487203,0.00044024247],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925965,0.00013634072,0.0002419174,0.00015616814,0.000018071307,0.00018784114],"domain_scores_gemma":[0.9995213,0.00006318257,0.0001247503,0.00025091897,0.000028144103,0.000011686356],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012361698,0.00012434152,0.0002653256,0.00006600859,0.000057779365,0.0000020672337,0.00014477447,0.00016549298,0.0024301696],"category_scores_gemma":[0.000023384131,0.000093441515,0.00009172663,0.000090354275,0.00009895581,0.00004329476,0.000022221726,0.000055822067,0.00061865675],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001336725,0.00025215468,0.007450629,0.000008464826,0.00037065274,0.000005738958,0.0016268676,8.993562e-8,0.049188554,0.003924307,0.000718461,0.9363204],"study_design_scores_gemma":[0.005608347,0.0013472671,0.29148662,0.00015094689,0.000062832325,0.00009262653,0.00030132988,9.2385824e-7,0.6785023,0.008004964,0.014009381,0.00043243606],"about_ca_topic_score_codex":0.00013579443,"about_ca_topic_score_gemma":0.000010260165,"teacher_disagreement_score":0.935888,"about_ca_system_score_codex":0.00000828423,"about_ca_system_score_gemma":0.000018754161,"threshold_uncertainty_score":0.99848175},"labels":[],"label_agreement":null},{"id":"W2124390485","doi":"10.1016/j.jaci.2015.01.033","title":"Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis","year":2015,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Psoriasis; Mast cell; Atopic dermatitis; Immunology; Cytokine; Interleukin 33; T cell; Skin biopsy; Medicine; Biology; Interleukin; Pathology; Biopsy; Immune system","score_opus":0.021312610107481852,"score_gpt":0.26150585366322415,"score_spread":0.2401932435557423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124390485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945459,0.0037364042,0.0000037127797,0.00044061375,0.0009927719,0.00011911063,0.00001075049,0.000008730258,0.00014205258],"genre_scores_gemma":[0.99810994,0.0010709254,0.00013773769,0.00015000835,0.00007253045,0.0000038775584,0.000013200104,0.0000136083945,0.00042817937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982683,0.0004349879,0.00074249646,0.00023696474,0.00005159684,0.00026564897],"domain_scores_gemma":[0.9989084,0.00013761513,0.00053932355,0.00017542153,0.000175115,0.00006413195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040354836,0.00019155968,0.0006000079,0.00014741397,0.00009497308,0.000014160892,0.00015606287,0.0003704045,0.000083297164],"category_scores_gemma":[0.00008953251,0.00013853745,0.00008301111,0.00009013815,0.0003619709,0.00014376336,0.0000798736,0.00041807204,0.000020781026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018444689,0.001533245,0.943497,0.00001605892,0.0045906096,0.00012280406,0.0006651398,0.0000031747393,0.0007352161,0.0002521324,0.0026389644,0.044101197],"study_design_scores_gemma":[0.013253588,0.00252087,0.973823,0.00006699675,0.00015682697,0.00008528858,0.00045275362,1.812937e-7,0.00061350985,0.00020470186,0.008656978,0.00016530615],"about_ca_topic_score_codex":0.00003763862,"about_ca_topic_score_gemma":0.00019382099,"teacher_disagreement_score":0.04393589,"about_ca_system_score_codex":0.000033924178,"about_ca_system_score_gemma":0.00006733671,"threshold_uncertainty_score":0.5649393},"labels":[],"label_agreement":null},{"id":"W2124838161","doi":"10.2310/7750.2006.00052","title":"Are Narrow-Band Ultraviolet B Home Units a Viable Option for Continuous or Maintenance Therapy of Photoresponsive Diseases?","year":2006,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Élisabeth Bruyère Hospital; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Family medicine","score_opus":0.025000193657102047,"score_gpt":0.2450627852789512,"score_spread":0.22006259162184916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124838161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731148,0.025424538,0.000044132816,0.000388037,0.0006905079,0.00018641676,0.0001089184,0.000008707567,0.000033945184],"genre_scores_gemma":[0.9937111,0.00444191,0.000020503194,0.00021752167,0.00022464589,0.000008079133,0.000047391317,0.000014812141,0.0013140234],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998866,0.00014005159,0.00056936906,0.00012740231,0.00006759482,0.00022953599],"domain_scores_gemma":[0.9968575,0.001657625,0.0008719537,0.00010303224,0.0004678142,0.00004204288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031081133,0.00017035089,0.0007939034,0.00021986681,0.00008895673,0.000005319478,0.0000688873,0.00012889919,0.00009744346],"category_scores_gemma":[0.000410549,0.00010099967,0.00013781874,0.00015268012,0.00019218867,0.000065738306,0.000003767732,0.00009288262,0.0000012131768],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059844427,0.00090054784,0.13595195,0.0002407496,0.0013957317,0.003294676,0.0009815472,0.0000270516,0.63269484,0.00013587718,0.13937739,0.025155209],"study_design_scores_gemma":[0.044876367,0.015011267,0.16947283,0.00610183,0.0029698308,0.05899063,0.0096697295,0.000017499846,0.26704502,0.004233912,0.41979733,0.00181373],"about_ca_topic_score_codex":0.00004197201,"about_ca_topic_score_gemma":0.000011677606,"teacher_disagreement_score":0.36564982,"about_ca_system_score_codex":0.000021356616,"about_ca_system_score_gemma":0.00012970812,"threshold_uncertainty_score":0.4118647},"labels":[],"label_agreement":null},{"id":"W2124887300","doi":"10.6000/1929-6029.2014.03.02.1","title":"Biologic Therapy for Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis: Systematic Review with Pairwise and Network Meta-Analysis","year":2014,"lang":"en","type":"article","venue":"International Journal of Statistics in Medical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Golimumab; Psoriasis; Placebo; Internal medicine; Adverse effect; Meta-analysis; Randomized controlled trial; Infliximab; Ustekinumab; Etanercept; Psoriasis Area and Severity Index; Arthritis; Physical therapy; Rheumatoid arthritis; Dermatology; Alternative medicine; Pathology","score_opus":0.10216470467691911,"score_gpt":0.3950385845504263,"score_spread":0.29287387987350716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124887300","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035807252,0.4754141,0.450517,0.027045239,0.0025351257,0.0066784956,0.001693924,0.000047978632,0.00026088383],"genre_scores_gemma":[0.78749424,0.17991589,0.026484024,0.003395124,0.00049498584,0.00091294566,0.00022637322,0.00004887321,0.0010275177],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99621266,0.0016765939,0.0009301475,0.0002459308,0.00058776286,0.0003468816],"domain_scores_gemma":[0.9919332,0.0063575027,0.0003140621,0.00017363229,0.0011003116,0.000121266734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075259106,0.0001753625,0.0014314369,0.00040951057,0.000096442265,0.000047059115,0.0005229734,0.0001492874,0.0007475034],"category_scores_gemma":[0.0062525007,0.000093789175,0.00021030605,0.0004149638,0.00014573509,0.00005727336,0.00006474413,0.00037847526,0.000016315935],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026548596,0.0019731093,0.0016845473,0.018411947,0.56671023,0.001882457,0.001652346,0.0015432005,0.00010487234,0.03615849,0.049959365,0.2933708],"study_design_scores_gemma":[0.12671968,0.057187803,0.009238526,0.16163447,0.38898394,0.010351229,0.002695332,0.012856909,0.0016360912,0.17148608,0.051389676,0.005820282],"about_ca_topic_score_codex":0.000032940396,"about_ca_topic_score_gemma":0.0003182435,"teacher_disagreement_score":0.751687,"about_ca_system_score_codex":0.00007032204,"about_ca_system_score_gemma":0.00024056654,"threshold_uncertainty_score":0.8184638},"labels":[],"label_agreement":null},{"id":"W2125383321","doi":"10.1189/jlb.0810456","title":"The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity","year":2011,"lang":"en","type":"article","venue":"Journal of Leukocyte Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"National Natural Science Foundation of China; National Science Foundation","keywords":"Lamina propria; Biology; Intraepithelial lymphocyte; Cytotoxicity; Inflammatory bowel disease; Immunology; Interleukin 15; Lymphocyte; Inflammation; Cancer research; Interleukin; Disease; Immune system; Pathology; Cytokine; Epithelium; In vitro; Medicine","score_opus":0.015136319091792805,"score_gpt":0.2277437835315318,"score_spread":0.212607464439739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125383321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910195,0.010223549,0.0000058079017,0.000048695667,0.0002813392,0.0002615117,0.00003436089,0.000011286466,0.000031502346],"genre_scores_gemma":[0.9976318,0.002038,0.00013498696,0.000020011554,0.00006478198,0.000016658054,0.000005783328,0.000013480474,0.00007452269],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976827,0.0010671038,0.00070618617,0.00020759324,0.000046234007,0.0002901777],"domain_scores_gemma":[0.99841005,0.0005432991,0.0006417974,0.00021288896,0.00011431621,0.0000776608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010797252,0.00022261858,0.0004101185,0.00022672638,0.0001560545,0.000010212499,0.00022615732,0.00028205937,0.000018483292],"category_scores_gemma":[0.00048014676,0.00013572788,0.00009285397,0.000062834406,0.0007192446,0.000106002575,0.00012605234,0.00021770937,0.0000049667565],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0127910515,0.00013052997,0.3090347,0.000047437374,0.00013427946,0.00008362328,0.0010297281,1.8484653e-7,0.669316,0.0002636344,0.000023246572,0.0071456],"study_design_scores_gemma":[0.003098369,0.00056981,0.58801115,0.000118430886,0.00007934571,0.0001501246,0.0001827222,0.0000021167546,0.40652272,0.00059181015,0.00054749695,0.00012588716],"about_ca_topic_score_codex":0.0000452076,"about_ca_topic_score_gemma":0.000051246294,"teacher_disagreement_score":0.27897644,"about_ca_system_score_codex":0.00006573145,"about_ca_system_score_gemma":0.00037180417,"threshold_uncertainty_score":0.55348223},"labels":[],"label_agreement":null},{"id":"W2125574991","doi":"10.2340/00015555-1895","title":"Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden","year":2015,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Cilag; Sveriges Kommuner och Landsting; Västerbotten Läns Landsting; LEO Pharma; Pfizer","keywords":"Psoriasis; Resource (disambiguation); Dermatology; Medicine; Business; Computer science","score_opus":0.023180284227758415,"score_gpt":0.21625669271062856,"score_spread":0.19307640848287014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125574991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819183,0.0005030963,0.000002041389,0.0006187594,0.00018459714,0.00027814045,0.000022184444,0.00002435048,0.00017500439],"genre_scores_gemma":[0.9992982,0.00003103119,0.000077351775,0.00014710902,0.000033330216,0.00006609882,0.0001799033,0.000009150458,0.00015783057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998594,0.0004979717,0.00029837032,0.00027724257,0.00004943499,0.00028300757],"domain_scores_gemma":[0.9992535,0.00015503568,0.00014467782,0.0003669541,0.00006103223,0.000018814328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025837752,0.00017865928,0.00029679047,0.00013243468,0.000039345134,0.0000090237945,0.00021377568,0.00024536048,0.00006965109],"category_scores_gemma":[0.00017360118,0.0000978977,0.000044503133,0.00029817503,0.00019093648,0.00011974317,0.00009315515,0.00016357131,0.000037847458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022282214,0.00032019435,0.9914801,0.000004045051,0.00006629983,0.000009524096,0.0005049789,0.000028418755,0.00048633775,0.000058712634,0.0023112628,0.00250188],"study_design_scores_gemma":[0.0028415082,0.00027893917,0.969143,0.000014009638,0.000041823016,0.000016234419,0.00029332473,9.030851e-7,0.0032069767,0.000090726426,0.02392062,0.00015193896],"about_ca_topic_score_codex":0.000106205094,"about_ca_topic_score_gemma":0.00016159544,"teacher_disagreement_score":0.02233713,"about_ca_system_score_codex":0.00005544016,"about_ca_system_score_gemma":0.000029189352,"threshold_uncertainty_score":0.39921522},"labels":[],"label_agreement":null},{"id":"W2125750090","doi":"10.1159/000077660","title":"T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action","year":2004,"lang":"en","type":"review","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Genentech","keywords":"Efalizumab; Psoriasis; Medicine; Immune system; Immunology; Monoclonal antibody; Pathogenesis; Clinical trial; Inflammation; Plaque psoriasis; Antibody; Pathology","score_opus":0.03942388968389858,"score_gpt":0.2882956257899326,"score_spread":0.24887173610603402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125750090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030143087,0.9895201,0.006871433,0.000033982906,0.0008723202,0.0020088586,0.00030303438,0.000034293735,0.00005457892],"genre_scores_gemma":[0.015437537,0.9819714,0.00024123846,0.0000032329592,0.000042773063,0.00089163997,0.0010847397,0.0000521933,0.0002752529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831337,0.0002735939,0.0006560328,0.00038789638,0.000041410516,0.0003277124],"domain_scores_gemma":[0.99793196,0.00057477865,0.00088453,0.00051162526,0.000081159385,0.000015963891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00005950325,0.0004792487,0.0017968825,0.00022193462,0.00014042406,0.0000038370717,0.00022381672,0.00080540695,0.000077315424],"category_scores_gemma":[0.000005902559,0.00027496027,0.0005922179,0.0001857504,0.00016737636,0.00003945785,0.000017017164,0.00009888628,0.000044500095],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044000603,0.000908225,0.000004107572,0.0075366534,0.00364517,0.000010182445,0.00022843428,0.00004231542,0.0005456246,0.0044627,0.0001246273,0.98205197],"study_design_scores_gemma":[0.007988885,0.0030760118,0.000011389323,0.0018342403,0.009534622,0.001076229,0.00009032896,0.000010508339,0.04869689,0.00050320354,0.9266983,0.00047933872],"about_ca_topic_score_codex":0.00008904771,"about_ca_topic_score_gemma":0.000068301226,"teacher_disagreement_score":0.9815726,"about_ca_system_score_codex":0.00030032132,"about_ca_system_score_gemma":0.0005414924,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W2125761434","doi":"10.1097/shk.0b013e3181d67041","title":"DIFFERENTIAL EFFECTS OF IL-17 PATHWAY IN DISSEMINATED CANDIDIASIS AND ZYMOSAN-INDUCED MULTIPLE ORGAN FAILURE","year":2010,"lang":"en","type":"article","venue":"Shock","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Zymosan; Differential (mechanical device); Medicine; Immunology; Biology; Genetics; Physics","score_opus":0.005467266300921182,"score_gpt":0.20660167970907964,"score_spread":0.20113441340815846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125761434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985882,0.00022209733,0.000005493702,0.000042390577,0.0006830009,0.00026540644,0.0000618279,0.000034873836,0.00009668467],"genre_scores_gemma":[0.9993192,0.00001987503,0.000043210723,0.0000083210125,0.000028504666,0.000021655476,0.00014323153,0.000016803408,0.00039919416],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999156,0.00009205052,0.00019314168,0.0002613696,0.000027245365,0.00027021926],"domain_scores_gemma":[0.9993819,0.00025847068,0.00007465807,0.00022679329,0.000026536618,0.000031630825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043754007,0.0001917462,0.00032223508,0.000110462264,0.00007440636,0.0000089806845,0.000115638795,0.00034475923,0.00022350613],"category_scores_gemma":[0.00011331572,0.0001563726,0.000060110335,0.00013318355,0.00007496104,0.000053534848,0.000056424717,0.00021901062,0.000025059353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010987974,0.00014511916,0.040911533,0.000034001416,0.00009821256,0.00001506487,0.00057384203,3.8328746e-8,0.932818,0.000032959066,0.0001642258,0.025097134],"study_design_scores_gemma":[0.0025564684,0.00013380518,0.13258179,0.000033619846,0.000051253275,0.000013267969,0.000111755915,0.0000024111343,0.8638101,0.00002217751,0.0005366333,0.00014672842],"about_ca_topic_score_codex":0.00031324377,"about_ca_topic_score_gemma":0.0027821609,"teacher_disagreement_score":0.091670245,"about_ca_system_score_codex":0.000012625248,"about_ca_system_score_gemma":0.000032104766,"threshold_uncertainty_score":0.63766897},"labels":[],"label_agreement":null},{"id":"W2126057417","doi":"10.2310/7750.2009.00027","title":"Psoriatic Nail Disease: Quality of Life and Treatment","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Mediprobe Research (Canada); Sunnybrook Health Science Centre","funders":"Abbott Laboratories","keywords":"Medicine; Psoriasis; Etanercept; Psoriatic arthritis; Dermatology; Infliximab; Onycholysis; Adalimumab; Nail disease; Nail (fastener); Efalizumab; Clinical trial; Disease; Plaque psoriasis; Internal medicine; Rheumatoid arthritis","score_opus":0.08378408996342748,"score_gpt":0.329641257855253,"score_spread":0.24585716789182552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126057417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009491831,0.989139,0.0000015192725,0.0002293067,0.0008240019,0.000183693,0.000043997945,0.0000075076064,0.00007914374],"genre_scores_gemma":[0.00261013,0.99631524,0.000010186362,0.00007193529,0.0003633268,0.0000040560826,0.000064862674,0.000018395474,0.00054187403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971317,0.0006631299,0.0016593699,0.00021206819,0.00010398233,0.00022974347],"domain_scores_gemma":[0.9948958,0.0029406652,0.0016769947,0.00022215307,0.00010284493,0.00016150739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006733315,0.00040804307,0.0039915997,0.00039288859,0.00007325335,0.000006146087,0.00008967771,0.0002933927,0.00012522435],"category_scores_gemma":[0.00067249907,0.00023100027,0.00059723854,0.00012979371,0.00021608557,0.000039411712,0.000015513851,0.00019503087,0.0000053403755],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034218995,0.00016881038,0.00032639102,0.0023161075,0.0016444044,0.0003740765,0.000118561176,4.5235144e-8,0.000008321135,0.000019683846,0.0030301085,0.9916513],"study_design_scores_gemma":[0.0010486848,0.0008100427,0.0004306644,0.00815022,0.0053088064,0.00313376,0.00007174756,5.7585748e-8,0.0000023740943,0.00008270828,0.98071074,0.000250172],"about_ca_topic_score_codex":0.000027209408,"about_ca_topic_score_gemma":0.000004549043,"teacher_disagreement_score":0.99140114,"about_ca_system_score_codex":0.000053742166,"about_ca_system_score_gemma":0.0005422942,"threshold_uncertainty_score":0.94199175},"labels":[],"label_agreement":null},{"id":"W2126197815","doi":"10.4049/jimmunol.174.6.3534","title":"The IL-27 Receptor Chain WSX-1 Differentially Regulates Antibacterial Immunity and Survival during Experimental Tuberculosis","year":2005,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":278,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Immunology; Mycobacterium tuberculosis; Inflammation; Proinflammatory cytokine; Biology; Immunity; Macrophage; Cytokine; T cell; Tumor necrosis factor alpha; Tuberculosis; Microbiology; Medicine; In vitro","score_opus":0.009760600568225714,"score_gpt":0.2225567857034287,"score_spread":0.212796185135203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126197815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708931,0.024502665,0.0000038426806,0.0012788154,0.0030461445,0.00013828462,0.000021025166,0.000020421965,0.000095704585],"genre_scores_gemma":[0.9920954,0.006567601,0.000033608758,0.000022157126,0.0002975699,0.0000037235575,0.000013820065,0.000021570328,0.0009445521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975291,0.0012892561,0.0005639463,0.00013729307,0.00006042355,0.00042001935],"domain_scores_gemma":[0.99860424,0.0004907437,0.00042869002,0.00036104454,0.00009045439,0.00002482833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008010711,0.00025624898,0.00043122948,0.000093775954,0.0008483898,0.00003751382,0.0005214134,0.0002326522,0.00032528036],"category_scores_gemma":[0.000070787595,0.0001403451,0.00016574068,0.000085149455,0.0005925252,0.00014626257,0.0002221097,0.00042306105,0.00007391369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030513513,0.00017917732,0.00063458626,0.000002931052,0.0012889452,0.000002655602,0.0014513925,0.0000014294028,0.98326284,0.0001435418,0.00017173451,0.009809432],"study_design_scores_gemma":[0.003818687,0.00062788784,0.09395082,0.000032354623,0.00023361304,0.00082597503,0.0018340349,6.520039e-7,0.89102924,0.000038337,0.007418187,0.0001902189],"about_ca_topic_score_codex":0.0000553518,"about_ca_topic_score_gemma":0.00003786572,"teacher_disagreement_score":0.093316235,"about_ca_system_score_codex":0.00007749665,"about_ca_system_score_gemma":0.000052636417,"threshold_uncertainty_score":0.65252143},"labels":[],"label_agreement":null},{"id":"W2126375175","doi":"10.2310/7750.2008.07060","title":"ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study","year":2008,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Alberta; Mediprobe Research (Canada); Sunnybrook Health Science Centre; Dalhousie University","funders":"","keywords":"Medicine; Placebo; Quality of life (healthcare); Randomized controlled trial; Surgery; Pathology; Alternative medicine","score_opus":0.04968443599187423,"score_gpt":0.2979457931064615,"score_spread":0.2482613571145873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126375175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811411,0.016232545,0.000019688265,0.0006908693,0.0010826587,0.00042777284,0.00005473726,0.000011970571,0.00033865788],"genre_scores_gemma":[0.9949234,0.0037164236,0.000021928856,0.00019959467,0.00030347458,0.000007197726,0.000034681565,0.000011111721,0.0007822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956291,0.0014921791,0.0022927395,0.00019807216,0.00016735098,0.00022055837],"domain_scores_gemma":[0.9859141,0.011888107,0.0016444665,0.00022163092,0.00023823345,0.000093425006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003286584,0.00023979036,0.003181827,0.00030390866,0.00018551621,0.0000030059252,0.000112991365,0.0001609801,0.00032092576],"category_scores_gemma":[0.0057966243,0.00014173042,0.00047777218,0.000118693235,0.00039963666,0.000063222695,0.000026495416,0.00022694464,0.0000051701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9506742,0.002044937,0.003563391,0.000012201341,0.0041194097,0.0011409074,0.006844617,0.0000024446367,0.008744692,0.0000046988584,0.015264147,0.0075843744],"study_design_scores_gemma":[0.98617864,0.0027930224,0.00086679275,0.00018119007,0.0016641525,0.00222907,0.002739417,0.000004521772,0.0009141974,0.00009685525,0.0021088573,0.00022331405],"about_ca_topic_score_codex":0.00038793441,"about_ca_topic_score_gemma":0.000021053453,"teacher_disagreement_score":0.03550443,"about_ca_system_score_codex":0.00001614222,"about_ca_system_score_gemma":0.00022440981,"threshold_uncertainty_score":0.69395196},"labels":[],"label_agreement":null},{"id":"W2126457303","doi":"10.1111/j.1365-2133.2010.09707.x","title":"Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis","year":2010,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Abbott Laboratories","keywords":"Psoriasis; Medicine; Risk factor; Necrosis; Oncology; Dermatology; Internal medicine","score_opus":0.027893241891942245,"score_gpt":0.3084209535246435,"score_spread":0.28052771163270124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126457303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06741128,0.92943215,0.000008039446,0.00004699296,0.001453272,0.00051615055,0.0010040718,0.000006086531,0.00012196035],"genre_scores_gemma":[0.043646432,0.9557381,0.00025173975,0.0000081134,0.00007594264,0.000046491205,0.00014781099,0.000036094323,0.00004922569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956818,0.0013163075,0.0021557843,0.00029754467,0.00011767989,0.00043084862],"domain_scores_gemma":[0.99524444,0.0009679471,0.0031546254,0.00037993558,0.00021220672,0.00004082229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002930854,0.00048375435,0.0036916821,0.00045032063,0.00012269219,0.000026108006,0.000722504,0.0010024002,0.00016972481],"category_scores_gemma":[0.00007983459,0.00034980557,0.0013900489,0.00029824182,0.00028425682,0.000088116765,0.00004071026,0.0007529658,0.000011909392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051460887,0.0014973156,0.0031704647,0.0007413387,0.0015054927,0.0008748709,0.0002615615,2.4132342e-7,0.00016372447,0.000051929102,0.00023230456,0.9914493],"study_design_scores_gemma":[0.005762702,0.0012887461,0.018599499,0.0046780226,0.005942503,0.08945236,0.0001788421,2.2451509e-7,0.0017506134,0.0001096356,0.8717194,0.00051740184],"about_ca_topic_score_codex":0.000315541,"about_ca_topic_score_gemma":0.00037519124,"teacher_disagreement_score":0.99093187,"about_ca_system_score_codex":0.00011012102,"about_ca_system_score_gemma":0.0005466208,"threshold_uncertainty_score":0.9998954},"labels":[],"label_agreement":null},{"id":"W2126689331","doi":"10.1016/j.jaad.2012.10.055","title":"OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis","year":2013,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Novartis; Amgen","keywords":"Medicine; Etanercept; Postmarketing surveillance; Observational study; Psoriasis; Interim analysis; Interim; Dermatology; Adverse effect; Clinical trial; Pharmacology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.05944239180353295,"score_gpt":0.3224240746200683,"score_spread":0.26298168281653533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126689331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909601,0.0027362993,0.00021205128,0.005432247,0.00023307264,0.0002725935,0.00011644512,0.00000461418,0.000032575994],"genre_scores_gemma":[0.9971622,0.0011215878,0.001296872,0.00019116912,0.000048273738,0.000018271667,0.000020454067,0.00001218392,0.00012894203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764675,0.00068475615,0.0011884971,0.00015606909,0.000088902765,0.00023499681],"domain_scores_gemma":[0.99476624,0.0013637074,0.0033322757,0.0002919896,0.0002158989,0.0000298818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029777072,0.0001981165,0.0011150902,0.0001826823,0.00011320001,0.0000043438918,0.00071570126,0.00016557336,0.000105884654],"category_scores_gemma":[0.00015868251,0.000107645035,0.0008405315,0.00044175613,0.0007488718,0.000112429814,0.00004707616,0.00016501808,0.0000025699435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059217606,0.0017518546,0.54078543,0.00010492513,0.027027383,0.0000038069736,0.002682062,0.0004594206,0.33282244,0.0008524509,0.0025067846,0.08508166],"study_design_scores_gemma":[0.0024387178,0.0010744246,0.9011934,0.000048478858,0.004674876,0.0005143039,0.0021628335,0.00009471732,0.08101894,0.00024435986,0.0063776756,0.0001572959],"about_ca_topic_score_codex":0.00014955302,"about_ca_topic_score_gemma":0.000011718817,"teacher_disagreement_score":0.36040792,"about_ca_system_score_codex":0.000049694983,"about_ca_system_score_gemma":0.000101245416,"threshold_uncertainty_score":0.4389637},"labels":[],"label_agreement":null},{"id":"W2126861266","doi":"10.1034/j.1600-0781.2002.180208_2.x","title":"002
Multiple exposures to blue light does not improve psoriasis in patients with elevated endogenous levels of protoporphyrin IX","year":2002,"lang":"en","type":"article","venue":"Photodermatology Photoimmunology & Photomedicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Protoporphyrin IX; Psoriasis; Erythema; Medicine; In vivo; Photobleaching; Endogeny; Photodynamic therapy; Blue light; Dermatology; Pathology; Gastroenterology; Internal medicine; Fluorescence; Chemistry","score_opus":0.016935216692116492,"score_gpt":0.21137994729732118,"score_spread":0.19444473060520467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126861266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99072045,0.0018044037,0.000013258035,0.00040431,0.0013794915,0.004473377,0.0006338136,0.00020839805,0.00036249933],"genre_scores_gemma":[0.99614775,0.00013927242,0.00014636606,0.0006393241,0.000033722168,0.0018368117,0.00021949202,0.000101013095,0.0007362464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949022,0.0006302896,0.0015735202,0.0012142393,0.00020842273,0.001471334],"domain_scores_gemma":[0.9970364,0.0005165863,0.00068578,0.0012717601,0.000371709,0.00011776505],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036596623,0.00092702336,0.0020782114,0.0011814458,0.00026142836,0.000011154496,0.0008496777,0.00094908144,0.0022934016],"category_scores_gemma":[0.00027591342,0.00066354085,0.00021414478,0.00095675455,0.00079313514,0.00018432508,0.00024001316,0.00073124527,0.0004166423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003955804,0.0019542538,0.16070439,0.000086172586,0.0012137162,0.00015530246,0.0037816907,0.000002986232,0.82351553,0.000016533812,0.00019862337,0.004414993],"study_design_scores_gemma":[0.020772686,0.0021472787,0.12111651,0.00013446444,0.00027030788,0.00022607436,0.00038855957,0.000008274903,0.85189074,0.000018656321,0.0023976248,0.0006288071],"about_ca_topic_score_codex":0.00060922053,"about_ca_topic_score_gemma":0.00025821835,"teacher_disagreement_score":0.039587885,"about_ca_system_score_codex":0.00016812194,"about_ca_system_score_gemma":0.0000906737,"threshold_uncertainty_score":0.9995816},"labels":[],"label_agreement":null},{"id":"W2127549800","doi":"10.1348/014466502163949","title":"Psychological stress, distress and disability in patients with psoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia","year":2002,"lang":"en","type":"article","venue":"British Journal of Clinical Psychology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":241,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alexithymia; Coping (psychology); Psychology; Psoriasis; Anxiety; Clinical psychology; Toronto Alexithymia Scale; Distress; Worry; Psychiatry; Explained variation; Personality; Hospital Anxiety and Depression Scale; Medicine","score_opus":0.03988646810994479,"score_gpt":0.34005314567106726,"score_spread":0.3001666775611225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127549800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535006,0.0033882805,0.000021945665,0.0005951461,0.00030873943,0.00021662383,0.000072432194,0.0000031285017,0.00004365245],"genre_scores_gemma":[0.99685234,0.0028781968,0.0000766218,0.00012498478,0.000037229092,0.0000057811912,0.00001740353,0.000004362093,0.0000030579247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735993,0.0012527287,0.00091189396,0.00025465118,0.000053201496,0.00016759108],"domain_scores_gemma":[0.9985069,0.00084124145,0.0004147625,0.000118238204,0.000088453606,0.000030381518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010692477,0.00011048554,0.00050493726,0.00004583424,0.000072794064,0.000014247471,0.00009640838,0.0002989184,0.00006214649],"category_scores_gemma":[0.00052034797,0.00008169894,0.000048597718,0.00009955016,0.00086917327,0.000066124885,0.000020149697,0.00038361634,9.426781e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010935923,0.0013728832,0.89712185,0.000009203805,0.000060749662,0.0000258788,0.00024105559,5.496311e-7,0.000030319,0.000056819274,0.00013262492,0.0998545],"study_design_scores_gemma":[0.011513662,0.0009587284,0.9861949,0.00017070571,0.000066773224,0.00044528738,0.00016651502,0.0000015758076,0.0000021711526,0.0003320909,0.00005937267,0.00008821705],"about_ca_topic_score_codex":0.00004932755,"about_ca_topic_score_gemma":0.00025195302,"teacher_disagreement_score":0.09976628,"about_ca_system_score_codex":0.000010459073,"about_ca_system_score_gemma":0.0000051801894,"threshold_uncertainty_score":0.33315864},"labels":[],"label_agreement":null},{"id":"W2127834887","doi":"10.1056/nejmoa1109017","title":"Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":929,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Placebo; Psoriasis; Internal medicine; Randomization; Gastroenterology; Body surface area; Clinical endpoint; Dose-ranging study; Interleukin 17; Randomized controlled trial; Immunology; Cytokine; Double blind; Pathology","score_opus":0.02568001421573626,"score_gpt":0.29810644341533243,"score_spread":0.2724264291995962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127834887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755125,0.012570027,0.0012098302,0.0018158505,0.008065401,0.00020007785,0.000029708259,0.000026276975,0.0005703317],"genre_scores_gemma":[0.9871441,0.0006774374,0.0007836824,0.0002874018,0.007783644,0.0000031618847,0.00015376948,0.000025889576,0.0031408805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986097,0.00019740233,0.0005371073,0.00014339578,0.00008485146,0.000427492],"domain_scores_gemma":[0.99874574,0.00034585444,0.00037417051,0.00019747872,0.00016147469,0.00017528664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010817233,0.00022230226,0.00060318684,0.00020912413,0.00011723798,0.000007512256,0.00023679616,0.00017307165,0.0013679324],"category_scores_gemma":[0.000234435,0.00012732072,0.00015305114,0.00010473684,0.000104681356,0.00025515462,0.000017226737,0.00020424821,0.000051483876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022628605,0.0003994878,0.029045304,0.000024317982,0.00083872234,0.000012109092,0.0031168635,0.0000023017003,0.35513464,0.00025080217,0.06660109,0.5423115],"study_design_scores_gemma":[0.07709754,0.0041793045,0.02650673,0.0002054049,0.0009161087,0.0013190757,0.00060252554,0.000001312953,0.03834253,0.00020429809,0.8503525,0.00027261316],"about_ca_topic_score_codex":0.00005008868,"about_ca_topic_score_gemma":0.000012061549,"teacher_disagreement_score":0.7837515,"about_ca_system_score_codex":0.000047668324,"about_ca_system_score_gemma":0.00007963355,"threshold_uncertainty_score":0.999545},"labels":[],"label_agreement":null},{"id":"W2128314829","doi":"10.1186/1471-5945-6-8","title":"Evaluation of efalizumab using safe psoriasis control","year":2006,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Psoriasis; Dermatology; Medicine; Plaque psoriasis","score_opus":0.03732343796800558,"score_gpt":0.27775104957932,"score_spread":0.24042761161131443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128314829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603415,0.006617683,0.001965782,0.000049458442,0.0009813742,0.00035554293,0.000048838276,0.000044612472,0.0039025338],"genre_scores_gemma":[0.9991637,0.000009789994,0.00044047314,0.000028144155,0.00004481275,0.000038728504,0.00010583746,0.000014488995,0.00015403797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979356,0.000994603,0.00043076056,0.00024515545,0.00008842256,0.00030548277],"domain_scores_gemma":[0.99900925,0.000213086,0.00023086295,0.0002756929,0.00025900314,0.000012082665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042541214,0.00017536819,0.00043003206,0.00015968717,0.00011065958,0.0000043739315,0.0001310254,0.0003178384,0.0006061281],"category_scores_gemma":[0.00008998587,0.0001606915,0.00014081394,0.00013109691,0.0001407301,0.00006108084,0.000022712647,0.00006435726,0.00022632559],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00169123,0.0014695534,0.39747676,0.00016155305,0.0023128523,0.00004404571,0.00040437782,0.002534872,0.51269513,0.016932465,0.007566582,0.056710564],"study_design_scores_gemma":[0.055461727,0.00025901292,0.26556963,0.00008303926,0.009047793,0.0036320258,0.0003433497,0.0037778344,0.6382473,0.0075110416,0.014965022,0.001102239],"about_ca_topic_score_codex":0.00030191004,"about_ca_topic_score_gemma":0.00019529233,"teacher_disagreement_score":0.13190714,"about_ca_system_score_codex":0.000069583104,"about_ca_system_score_gemma":0.0002534501,"threshold_uncertainty_score":0.66366774},"labels":[],"label_agreement":null},{"id":"W2128484342","doi":"10.2340/00015555-1810","title":"Genotype–Phenotype Correlations in a Prospective Cohort Study of Paediatric Plaque Psoriasis: Lack of Correlation Between HLA-C*06 and Family History of Psoriasis","year":2014,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Psoriasis; Medicine; Family history; Prospective cohort study; Correlation; Cohort; Heritability; Single-nucleotide polymorphism; Genotype; Internal medicine; Human leukocyte antigen; Dermatology; Immunology; Genetics; Gene; Biology; Antigen","score_opus":0.023268909698359624,"score_gpt":0.23637903404548016,"score_spread":0.21311012434712054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128484342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944247,0.0026647625,0.000082040504,0.000021589067,0.00042737057,0.0008406911,0.00004479802,0.00003358134,0.0014604422],"genre_scores_gemma":[0.9991359,0.0002246922,0.000105995154,0.00001567505,0.000035849356,0.00007959451,0.00013474963,0.00001768858,0.00024982475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789166,0.0006113071,0.000773913,0.00038660446,0.00009324198,0.00024327026],"domain_scores_gemma":[0.99809843,0.0006926983,0.00065814564,0.000374368,0.00014758854,0.000028742816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042100425,0.00024980123,0.0008289108,0.00033619523,0.00005978924,0.0000023013115,0.00017106823,0.00039660643,0.000057567755],"category_scores_gemma":[0.00021006638,0.0002206574,0.00009364808,0.00032668878,0.00021978609,0.000100501304,0.00009564836,0.00019791823,0.000020124286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026374232,0.00055182196,0.9877335,0.000037041264,0.00042462003,0.000002214238,0.0027814086,0.000079101694,0.0052672992,0.0003885095,0.0004929897,0.0019777918],"study_design_scores_gemma":[0.003227155,0.00057934993,0.9929984,0.000025391197,0.0005967161,0.0000062429,0.00053661445,0.000036355512,0.0009758938,0.00033109437,0.0004969814,0.00018979989],"about_ca_topic_score_codex":0.00043631042,"about_ca_topic_score_gemma":0.000104989056,"teacher_disagreement_score":0.005264946,"about_ca_system_score_codex":0.00016018974,"about_ca_system_score_gemma":0.000121489946,"threshold_uncertainty_score":0.8998148},"labels":[],"label_agreement":null},{"id":"W2128642890","doi":"10.1111/cei.12691","title":"Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg17) cells in type 1 diabetes in non-obese diabetic mice","year":2015,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"NOD mice; Adoptive cell transfer; Immunology; Interleukin 17; Biology; Nod; Autoimmunity; Transdifferentiation; IL-2 receptor; T cell; Cell biology; Immune system; Endocrinology; Diabetes mellitus; Stem cell","score_opus":0.031827395350622255,"score_gpt":0.3221941125698793,"score_spread":0.29036671721925705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128642890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96444374,0.032249644,2.5102023e-7,0.000038838185,0.0021482252,0.00050720933,0.000013639747,0.000030909905,0.0005675261],"genre_scores_gemma":[0.99771285,0.00023301154,0.00011705808,0.00009844263,0.000054511012,0.00007916273,0.00010199325,0.000035295438,0.0015676453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967917,0.00087085087,0.001036938,0.0006724712,0.000055016135,0.0005730175],"domain_scores_gemma":[0.9985877,0.0004186939,0.00030125372,0.00053480675,0.000105400446,0.000052099524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006963202,0.00033449684,0.00091111875,0.00023293683,0.000042362124,0.000007514738,0.00040512744,0.00055257464,0.000314037],"category_scores_gemma":[0.00021167203,0.0003102255,0.00015636858,0.0003479473,0.00066786207,0.00014707627,0.00030634386,0.00044515505,0.0004086461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011712132,0.002008968,0.11632889,0.0000105498675,0.00033418363,0.000013336849,0.004608749,0.0000067882534,0.87054133,0.000021009077,0.00078525126,0.004169727],"study_design_scores_gemma":[0.0045274966,0.0021856492,0.11175013,0.00015114427,0.000054507494,0.000006035711,0.0034095102,0.0000061176056,0.87642425,0.00011262589,0.0010722573,0.0003002827],"about_ca_topic_score_codex":0.00017720593,"about_ca_topic_score_gemma":0.00007200233,"teacher_disagreement_score":0.033269122,"about_ca_system_score_codex":0.00018661657,"about_ca_system_score_gemma":0.00015230419,"threshold_uncertainty_score":0.999935},"labels":[],"label_agreement":null},{"id":"W2128802200","doi":"10.4049/jimmunol.1301360","title":"T Cell–Derived IL-17 Mediates Epithelial Changes in the Airway and Drives Pulmonary Neutrophilia","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; York University; GlaxoSmithKline; Concern Foundation","keywords":"Neutrophilia; Immunology; Respiratory epithelium; Inflammation; Lung; Proinflammatory cytokine; Cytokine; Interleukin 17; Medicine; Asthma; Pathogenesis; Biology; Internal medicine","score_opus":0.009822738544848969,"score_gpt":0.20447880189469003,"score_spread":0.19465606334984106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128802200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592904,0.03343601,0.0000032576045,0.0060868138,0.00068230653,0.00021316303,0.000011518602,0.000008577776,0.0002679461],"genre_scores_gemma":[0.9881417,0.010908976,0.000024571475,0.00029160542,0.00011678597,0.00001832288,0.000007674156,0.0000120591885,0.0004782666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981972,0.00096968014,0.00034077736,0.000114753864,0.00004223255,0.00033535142],"domain_scores_gemma":[0.9987493,0.00059651886,0.00031771846,0.00024970382,0.0000720197,0.000014702326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055122434,0.00019520511,0.00035205157,0.0001561449,0.00019676884,0.000014716584,0.0005378286,0.00020938776,0.00033273528],"category_scores_gemma":[0.000041061,0.00009591318,0.0000790946,0.000113590264,0.0004858343,0.0001093467,0.00009557084,0.00042580147,0.00013371457],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035580245,0.0001531006,0.0015942355,0.0000047495823,0.00023330656,0.000026461143,0.0037198644,0.0000023092564,0.97471964,0.000046659068,0.00084401114,0.018299837],"study_design_scores_gemma":[0.0054689506,0.002922951,0.5112594,0.000080639235,0.00059413014,0.0040228153,0.013063267,0.00000493044,0.44680178,0.0024709576,0.012853827,0.00045637618],"about_ca_topic_score_codex":0.00011488328,"about_ca_topic_score_gemma":0.000042751126,"teacher_disagreement_score":0.52791786,"about_ca_system_score_codex":0.000018810502,"about_ca_system_score_gemma":0.00003510641,"threshold_uncertainty_score":0.39112258},"labels":[],"label_agreement":null},{"id":"W2129777700","doi":"10.1111/jdv.12046","title":"Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study","year":2012,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":211,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Psoriasis Area and Severity Index; Adverse effect; Psoriasis; Placebo; Population; Internal medicine; Randomized controlled trial; Clinical trial; Dermatology; Disease; Adalimumab","score_opus":0.02111987263224534,"score_gpt":0.26119187618601464,"score_spread":0.2400720035537693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129777700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979991,0.0005470715,0.000011102907,0.00047296807,0.00028829408,0.0005955684,0.000015028985,0.0000028566612,0.00006806453],"genre_scores_gemma":[0.9996225,0.00002134882,0.000039739654,0.0001990365,0.000032610198,0.000008441255,0.0000037707432,0.000015815041,0.000056738416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972133,0.001660275,0.0006052704,0.00014850932,0.000053933825,0.00031870228],"domain_scores_gemma":[0.9990156,0.0003358555,0.00041686097,0.00014920335,0.000046976435,0.000035499073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005967871,0.00017320874,0.00056547706,0.00028382233,0.00006024469,0.0000028658449,0.0004484601,0.00015657004,0.000011004346],"category_scores_gemma":[0.000090170965,0.000098600605,0.00009204334,0.00023313117,0.00013934303,0.000072451345,0.000101431804,0.0002932286,0.000006556808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049943854,0.0007622961,0.98302877,0.0000141282435,0.00031027943,0.000011192068,0.0053417124,0.000038031634,0.00043516347,0.00004919531,0.00030775185,0.0047070673],"study_design_scores_gemma":[0.010786221,0.0003363226,0.9854009,0.0000520977,0.00022966204,0.00037774778,0.00024731987,2.3070271e-7,0.0021889794,0.000012904267,0.00026954708,0.00009803536],"about_ca_topic_score_codex":0.000006550892,"about_ca_topic_score_gemma":0.00001368861,"teacher_disagreement_score":0.005791836,"about_ca_system_score_codex":0.00002012638,"about_ca_system_score_gemma":0.000021283498,"threshold_uncertainty_score":0.40208158},"labels":[],"label_agreement":null},{"id":"W2130435008","doi":"10.1152/ajplung.00111.2013","title":"Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis","year":2013,"lang":"en","type":"article","venue":"American Journal of Physiology-Lung Cellular and Molecular Physiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Interleukin 17; Inflammation; Apoptosis; Alveolar macrophage; Immunology; Gene knockdown; Proinflammatory cytokine; Interleukin; Cytokine; Medicine; Chemistry; Macrophage; In vitro","score_opus":0.005813716791606712,"score_gpt":0.20600144404607038,"score_spread":0.20018772725446365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130435008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948647,0.0042747636,0.000050992312,0.00014396093,0.00036997083,0.00023077722,0.000008657378,0.000014190313,0.000042007367],"genre_scores_gemma":[0.99822885,0.0010718112,0.00037407508,0.0001075684,0.000093511415,0.000013733182,0.000058276826,0.000027610346,0.000024552515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980149,0.0005804323,0.0005990514,0.00036869387,0.00006304926,0.0003738186],"domain_scores_gemma":[0.9984026,0.00010662006,0.0008574506,0.00026627886,0.00029360765,0.000073444724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016028287,0.0003159441,0.0008059506,0.00022534867,0.00016523509,0.000008533283,0.00021001548,0.00023800456,0.00010801201],"category_scores_gemma":[0.00003759235,0.0002649053,0.00019031914,0.00021216829,0.0005616779,0.000118740376,0.0001234453,0.0002764486,0.00001033873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024815463,0.00010737801,0.0003007106,0.000037496968,0.0005718329,0.0000025808301,0.00036893322,0.000023474679,0.98058575,0.00003297836,0.00011494803,0.017605748],"study_design_scores_gemma":[0.0010734067,0.0024782007,0.053962696,0.000034102097,0.0003997076,0.000043322005,0.0002960754,0.0000213998,0.9409466,0.0003198916,0.00018380152,0.00024080534],"about_ca_topic_score_codex":0.00013867453,"about_ca_topic_score_gemma":7.015446e-7,"teacher_disagreement_score":0.053661987,"about_ca_system_score_codex":0.000023305423,"about_ca_system_score_gemma":0.00007023648,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W2130746889","doi":"10.2310/7750.2006.00049","title":"XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study","year":2006,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Placebo group; Randomized controlled trial; Placebo-controlled study; Double blind study; Gastroenterology; Double blind; Dermatology; Pathology","score_opus":0.035835063305072835,"score_gpt":0.2795273246596686,"score_spread":0.2436922613545958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130746889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789287,0.01719076,0.0000163902,0.0012453268,0.0008097531,0.001319066,0.0000044367016,0.000006484898,0.00047910368],"genre_scores_gemma":[0.9961489,0.0025932037,0.000013551207,0.00014307177,0.00031623157,0.00008419633,0.0000095973155,0.000012615379,0.00067866145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719214,0.0008901627,0.0013222292,0.00017845006,0.00014335943,0.00027367988],"domain_scores_gemma":[0.9953267,0.0037372038,0.0005611974,0.00019610644,0.00014001539,0.000038783404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019370484,0.00026996515,0.002155422,0.0005243658,0.00009583192,0.000012097599,0.00012236631,0.00012510552,0.000071792165],"category_scores_gemma":[0.00013371314,0.00012936763,0.00033545206,0.00023935708,0.00012934936,0.000047207857,0.000007960851,0.00012661418,0.000005851383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9737025,0.002128163,0.004094854,0.000012717844,0.0016771769,0.0009370206,0.0055925543,0.000110231165,0.0011373512,0.000042244577,0.003223534,0.0073416573],"study_design_scores_gemma":[0.98125184,0.003537583,0.00050001254,0.00018595737,0.0025901531,0.0023491685,0.004490649,0.000008655039,0.0015498229,0.00024300998,0.0030742632,0.00021887582],"about_ca_topic_score_codex":0.00046869103,"about_ca_topic_score_gemma":0.0002098575,"teacher_disagreement_score":0.017220192,"about_ca_system_score_codex":0.000040674055,"about_ca_system_score_gemma":0.000096378775,"threshold_uncertainty_score":0.5275459},"labels":[],"label_agreement":null},{"id":"W2131020062","doi":"10.1111/j.1365-2133.2006.07585.x","title":"Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen","keywords":"Etanercept; Psoriasis; Medicine; Pharmacokinetics; Internal medicine; Dermatology; Pharmacology; Tumor necrosis factor alpha","score_opus":0.018106902793602615,"score_gpt":0.29266588155561674,"score_spread":0.2745589787620141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131020062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859644,0.01314696,0.000025618632,0.00015069282,0.00030887892,0.00017351062,0.000053414446,0.000005641187,0.00017087483],"genre_scores_gemma":[0.99855334,0.0007612534,0.00054330134,0.000023150269,0.000031153933,0.0000033722404,0.000027037828,0.000012947597,0.000044449513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976721,0.0005231163,0.0012854596,0.00020250988,0.00007252345,0.00024432005],"domain_scores_gemma":[0.9984824,0.0003184512,0.00088387995,0.00009239087,0.00018605003,0.000036802998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020841809,0.00016403274,0.0010643284,0.00016803051,0.000056337623,0.000008440159,0.00014498032,0.0002578884,0.000049141054],"category_scores_gemma":[0.00006070761,0.00015376593,0.0000880099,0.00011915636,0.0005069081,0.00011473624,0.000046607118,0.0003040657,0.0000022551587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001235618,0.00087083987,0.9519946,0.00006639999,0.0002508018,0.00011787007,0.000114758885,0.0000027390747,0.0032512725,0.000032262305,0.0010776682,0.04098517],"study_design_scores_gemma":[0.012210085,0.00070710666,0.97578156,0.00024289609,0.00030445826,0.0031878161,0.00017138083,0.000004154636,0.006311755,0.000039399685,0.00089940795,0.0001399758],"about_ca_topic_score_codex":0.00019141939,"about_ca_topic_score_gemma":0.00013253735,"teacher_disagreement_score":0.040845193,"about_ca_system_score_codex":0.000008787807,"about_ca_system_score_gemma":0.00007468681,"threshold_uncertainty_score":0.62703925},"labels":[],"label_agreement":null},{"id":"W2131963153","doi":"10.1186/s12931-014-0145-7","title":"Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD","year":2014,"lang":"en","type":"article","venue":"Respiratory Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University; St. Joseph’s Healthcare Hamilton; McGill University Health Centre","funders":"Fundamental Research Funds for the Central Universities; McGill University Health Centre; McMaster University; Canada Research Chairs; McGill University","keywords":"COPD; Lung; Downregulation and upregulation; Western blot; Immune system; Medicine; Immunology; Parenchyma; Inflammation; Pathology; Andrology; Biology; Chemistry; Internal medicine; Biochemistry","score_opus":0.10496332511792747,"score_gpt":0.36644165900512365,"score_spread":0.2614783338871962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131963153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995662,0.0016883943,0.0005541651,0.00012799152,0.00009300229,0.00068368105,0.00043879176,0.000041945157,0.0007100738],"genre_scores_gemma":[0.99804235,0.000012490995,0.00008105187,0.00003767423,0.000109261,0.00035147447,0.000500464,0.00002695835,0.0008383087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831015,0.0005357333,0.00029025617,0.0003769336,0.00009576844,0.00039116375],"domain_scores_gemma":[0.99832666,0.0006222073,0.00011101855,0.00058918586,0.0003091688,0.000041742285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084132067,0.00014514115,0.00026763944,0.00019010765,0.0004400144,0.000017806422,0.00027613377,0.00024088843,0.00017491746],"category_scores_gemma":[0.000093125775,0.00012131545,0.00005444219,0.00020819744,0.00022459537,0.000083452884,0.000055478777,0.00015572568,0.000038103426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038401378,0.00013987433,0.11073663,0.00003800257,0.0002647899,8.0818734e-7,0.00026549966,0.000005035879,0.8432657,0.0022047462,0.0047839764,0.037910905],"study_design_scores_gemma":[0.0024272846,0.0008863881,0.44658563,0.00005795969,0.00007318189,0.0000019604884,0.000058352616,0.0000031013644,0.49929422,0.0005705483,0.04987983,0.00016155704],"about_ca_topic_score_codex":0.00010600126,"about_ca_topic_score_gemma":0.00010242639,"teacher_disagreement_score":0.3439715,"about_ca_system_score_codex":0.00005471754,"about_ca_system_score_gemma":0.000086955464,"threshold_uncertainty_score":0.49471003},"labels":[],"label_agreement":null},{"id":"W2132182554","doi":"10.3899/jrheum.130463","title":"Psoriasis and Psoriatic Arthritis Video Project: An Update from the 2012 GRAPPA Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Arthritis; Physical therapy; Medical physics; Internal medicine","score_opus":0.010896518405310914,"score_gpt":0.2253822659575318,"score_spread":0.21448574755222088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132182554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96495074,0.030942336,0.000054687098,0.0021207589,0.001527749,0.0002624776,0.000051279472,0.000022004171,0.00006797477],"genre_scores_gemma":[0.9866941,0.012610854,0.00026384235,0.0002293463,0.000052416442,0.000017612378,0.000021854477,0.000020996104,0.00008900713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973757,0.0013694548,0.00063563423,0.00017091988,0.00006492633,0.00038333074],"domain_scores_gemma":[0.99760616,0.0012327123,0.0006123073,0.00034011315,0.00016881133,0.000039871633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009066787,0.00023313168,0.0005407833,0.0000975612,0.0004083254,0.000033731594,0.00048496338,0.00022342049,0.0004654927],"category_scores_gemma":[0.00019000642,0.00012152477,0.000111793765,0.00013216572,0.00034038138,0.0004040405,0.000097356155,0.00035610815,0.00022730834],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015202897,0.00047077687,0.14043541,0.000028088158,0.0041264864,0.00002344284,0.023414839,0.000009667062,0.011569893,0.0018451825,0.11849142,0.6980645],"study_design_scores_gemma":[0.050548118,0.006974588,0.47410148,0.0020273793,0.006914671,0.07014638,0.07773733,0.00011196699,0.021673473,0.058446664,0.22791547,0.003402479],"about_ca_topic_score_codex":0.0028966533,"about_ca_topic_score_gemma":0.00064434914,"teacher_disagreement_score":0.69466203,"about_ca_system_score_codex":0.000015235935,"about_ca_system_score_gemma":0.000077603014,"threshold_uncertainty_score":0.5096819},"labels":[],"label_agreement":null},{"id":"W2132800651","doi":"10.1093/hmg/dds344","title":"Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis","year":2012,"lang":"en","type":"article","venue":"Human Molecular Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health","funders":"King's College London; Medical Research Council; National Institute for Health and Care Research; Wellcome Trust","keywords":"Biology; Linkage disequilibrium; Psoriasis; Genetics; Major histocompatibility complex; Single-nucleotide polymorphism; Allele; Human leukocyte antigen; Haplotype; Locus (genetics); Genetic association; Genome-wide association study; Immunology; Immune system; Gene; Genotype; Antigen","score_opus":0.03994678534483245,"score_gpt":0.2693160518826858,"score_spread":0.22936926653785336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132800651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984736,0.0018718508,0.01189335,0.000024147326,0.0001504754,0.00034232,0.00035228624,0.00008053042,0.0005490396],"genre_scores_gemma":[0.99337435,0.000004476734,0.0006545043,0.000090140435,0.000040683262,0.00006221795,0.005312856,0.00003005701,0.00043069807],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984461,0.00018718676,0.0003549023,0.00038145756,0.00012704256,0.0005032912],"domain_scores_gemma":[0.9989572,0.00007430505,0.00022257614,0.0005170689,0.00016560964,0.000063238134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024615132,0.00030297955,0.0004652146,0.0002064157,0.00038450805,0.000028694934,0.00023919006,0.00023154126,0.0017321882],"category_scores_gemma":[0.000028545937,0.0002758212,0.0002819545,0.0003909985,0.0003019296,0.0000574605,0.00007592922,0.00013521525,0.00014292402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010375441,0.001574226,0.3613592,0.000016777167,0.012845165,0.000012517918,0.0004936164,0.0002642059,0.6186249,0.002726228,0.0012272705,0.00075210066],"study_design_scores_gemma":[0.0020333019,0.00012166015,0.9659901,0.000006160099,0.0038412933,0.000008727029,0.00005285422,0.000019903746,0.026390053,0.00041623684,0.00076769403,0.00035196065],"about_ca_topic_score_codex":0.00007168407,"about_ca_topic_score_gemma":0.0006260323,"teacher_disagreement_score":0.60463095,"about_ca_system_score_codex":0.000121725294,"about_ca_system_score_gemma":0.00003389624,"threshold_uncertainty_score":0.9999694},"labels":[],"label_agreement":null},{"id":"W2132923004","doi":"10.1111/bjd.13013","title":"Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)","year":2014,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Janssen Biotech; Janssen Scientific Affairs","keywords":"Medicine; Psoriasis; Disease; Patient registry; Prospective cohort study; Baseline (sea); Longitudinal study; Internal medicine; Physical therapy; Pediatrics; Dermatology; Pathology","score_opus":0.00590134978092694,"score_gpt":0.188536144276712,"score_spread":0.18263479449578507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132923004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989102,0.009586213,0.00018087689,0.000106755244,0.00040347475,0.00032636177,0.00025252148,0.000011986784,0.000029779243],"genre_scores_gemma":[0.9986068,0.0007087121,0.00027450974,0.00006217419,0.000028269207,0.000024711113,0.00018803657,0.000020303885,0.00008648297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982365,0.0005362422,0.00062554097,0.00024962347,0.000071924456,0.00028016831],"domain_scores_gemma":[0.9985852,0.00025793482,0.0006196098,0.0001873747,0.00021849536,0.00013138822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011758752,0.00022575165,0.00071205763,0.00024753995,0.00005847758,0.00000893932,0.00012788741,0.00013224185,0.00006216015],"category_scores_gemma":[0.00024452712,0.00020375717,0.0001574302,0.0000990818,0.0002648395,0.00009764152,0.000020125699,0.00015009516,0.0000026769846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006377344,0.0017667551,0.9643161,0.00006270682,0.00032880995,0.0006632049,0.00008972541,0.000002291521,0.00008620028,0.000014708144,0.00033416066,0.025957959],"study_design_scores_gemma":[0.020046266,0.00032878574,0.9741634,0.00023684157,0.00058276486,0.0003325815,0.00002115395,0.00003238773,0.0001776559,0.000018166316,0.0038703342,0.0001896217],"about_ca_topic_score_codex":0.000041782536,"about_ca_topic_score_gemma":0.000087865534,"teacher_disagreement_score":0.025768336,"about_ca_system_score_codex":0.00014688392,"about_ca_system_score_gemma":0.0003013182,"threshold_uncertainty_score":0.83089757},"labels":[],"label_agreement":null},{"id":"W2132938540","doi":"10.4049/jimmunol.175.1.404","title":"Role of IL-17A, IL-17F, and the IL-17 Receptor in Regulating Growth-Related Oncogene-α and Granulocyte Colony-Stimulating Factor in Bronchial Epithelium: Implications for Airway Inflammation in Cystic Fibrosis","year":2005,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":395,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Heart, Lung, and Blood Institute","keywords":"Cystic fibrosis; Granulocyte colony-stimulating factor receptor; Inflammation; Epithelium; Respiratory epithelium; Granulocyte colony-stimulating factor; Interleukin 17; Immunology; Granulocyte; Medicine; Airway; Receptor; Cancer research; Biology; Internal medicine; Pathology","score_opus":0.009079376718189737,"score_gpt":0.23033427683169722,"score_spread":0.22125490011350749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132938540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867692,0.010709119,0.000044653043,0.0016209827,0.0001332282,0.0005855191,0.00009166592,0.0000074452496,0.000038160524],"genre_scores_gemma":[0.99806356,0.0012927449,0.00043629916,0.000018412476,0.000039057046,0.00004739643,0.000023871791,0.000016219345,0.00006242045],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976201,0.0008302301,0.0010477254,0.00015992696,0.000037235386,0.00030479726],"domain_scores_gemma":[0.9969743,0.0019563586,0.00075480214,0.00018723968,0.000113933325,0.000013390025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012120084,0.0001964898,0.00056698115,0.00031591623,0.00017080762,0.000009563874,0.00023121091,0.00029263855,0.000027591042],"category_scores_gemma":[0.00039865193,0.0001299924,0.00009126859,0.00025186012,0.00037208167,0.00015930139,0.00007545697,0.00034759904,0.000003225992],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037232076,0.0000905129,0.030582115,0.00001692579,0.00024061487,3.8989015e-7,0.0057458906,0.0006279731,0.8666354,0.00069912325,0.0000127669255,0.09162511],"study_design_scores_gemma":[0.02636908,0.0011922285,0.78461206,0.00034888412,0.00034960595,0.00031652412,0.0017154845,0.00056932896,0.17809273,0.005029555,0.0010452474,0.00035928155],"about_ca_topic_score_codex":0.00024667394,"about_ca_topic_score_gemma":0.0005382539,"teacher_disagreement_score":0.7540299,"about_ca_system_score_codex":0.00012312387,"about_ca_system_score_gemma":0.00007283298,"threshold_uncertainty_score":0.5300936},"labels":[],"label_agreement":null},{"id":"W2134587254","doi":"10.1097/mpg.0b013e31828390ba","title":"Infliximab‐Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With IL‐23 Receptor Polymorphisms","year":2012,"lang":"en","type":"article","venue":"Journal of Pediatric Gastroenterology and Nutrition","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; McMaster Children's Hospital","funders":"","keywords":"Medicine; Psoriasis; Infliximab; Inflammatory bowel disease; Internal medicine; Dermatology; Gastroenterology; Disease; Tumor necrosis factor alpha; Psoriasis Area and Severity Index","score_opus":0.009192514295440463,"score_gpt":0.21419617212289785,"score_spread":0.2050036578274574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134587254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902884,0.0078633595,0.000048650112,0.00066732866,0.00081138493,0.0002335387,0.00007227214,0.000011529632,0.0000035559328],"genre_scores_gemma":[0.9860236,0.012414026,0.0002693478,0.00006754813,0.0011126207,0.000025230584,0.000046447105,0.000014479017,0.000026725822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984492,0.00032321046,0.00047432425,0.00020516852,0.000088684246,0.00045939954],"domain_scores_gemma":[0.9989906,0.00013398398,0.0005441398,0.00008232303,0.000097224685,0.0001517281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005223259,0.00022566214,0.00039991428,0.00056168245,0.00016469574,0.000021168069,0.000068414185,0.000292422,0.000024902785],"category_scores_gemma":[0.000077836565,0.00018618988,0.000078957535,0.00017493934,0.00006888423,0.0004296995,0.0000441994,0.00032759827,0.0000060497446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005250221,0.000746593,0.9895194,0.00005639672,0.00018308677,0.000025727071,0.00029655345,6.6329466e-7,0.00090067607,0.00002148378,0.00069909875,0.002300065],"study_design_scores_gemma":[0.010133202,0.0018539216,0.98590666,0.00001910874,0.0011398835,0.00028950864,0.00017555867,0.0000010982068,0.00019729859,0.00006922668,0.00008687812,0.00012763051],"about_ca_topic_score_codex":0.0000105853815,"about_ca_topic_score_gemma":0.00002085347,"teacher_disagreement_score":0.0048829806,"about_ca_system_score_codex":0.00007795874,"about_ca_system_score_gemma":0.000038807877,"threshold_uncertainty_score":0.7592603},"labels":[],"label_agreement":null},{"id":"W2135176969","doi":"10.3899/jrheum.080458","title":"Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis","year":2008,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Alberta; Memorial University of Newfoundland","funders":"","keywords":"Single-nucleotide polymorphism; Medicine; Haplotype; Psoriasis; Psoriatic arthritis; SNP; Genetic association; Allele; Immunology; Genotype; Genetics; Biology; Gene","score_opus":0.010082637219889654,"score_gpt":0.20560583248181857,"score_spread":0.1955231952619289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135176969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947808,0.0032558455,0.00015711157,0.00051923783,0.0010401986,0.00007686937,0.000012069159,0.000008852559,0.00014903465],"genre_scores_gemma":[0.9932478,0.005753015,0.00020346118,0.000024697769,0.00000953129,0.0000021263738,0.000007951401,0.000010299704,0.00074110023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985614,0.0005812665,0.00051893276,0.00007251653,0.000060626902,0.00020528014],"domain_scores_gemma":[0.99809045,0.0005607951,0.0009981989,0.00015038581,0.00018352272,0.000016652508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057135767,0.00012018425,0.0004978452,0.00010931839,0.00011713164,0.000002067158,0.00022093368,0.0001749495,0.00036607825],"category_scores_gemma":[0.00017931667,0.00007126592,0.000092133705,0.00012169785,0.00013825044,0.000077887446,0.000022893537,0.00020221286,0.00014191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055214125,0.00078994146,0.8421356,0.00005329674,0.00753065,0.000049690836,0.010780138,0.000030072262,0.04239012,0.0010210266,0.0529321,0.03676595],"study_design_scores_gemma":[0.06908853,0.015173901,0.4886774,0.0024487784,0.003911282,0.15999904,0.005815493,0.000015130582,0.20519732,0.0025720159,0.045446374,0.0016547285],"about_ca_topic_score_codex":0.00008199825,"about_ca_topic_score_gemma":0.000090031775,"teacher_disagreement_score":0.3534582,"about_ca_system_score_codex":0.000053790194,"about_ca_system_score_gemma":0.0001097996,"threshold_uncertainty_score":0.40083003},"labels":[],"label_agreement":null},{"id":"W2136517791","doi":"10.1016/j.jaad.2015.04.011","title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":206,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Secukinumab; Plaque psoriasis; Randomized controlled trial; Regimen; Double blind; Psoriasis; Dermatology; Surgery; Placebo; Alternative medicine","score_opus":0.0436581266930141,"score_gpt":0.31966165566413257,"score_spread":0.27600352897111846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136517791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97468495,0.001152947,0.00038242695,0.018415483,0.0028886276,0.001909013,0.000074189666,0.000029892104,0.0004624773],"genre_scores_gemma":[0.9966475,0.00023604551,0.0010187537,0.00096181,0.00024928252,0.00016534443,0.0000125044,0.000037835583,0.00067097635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964515,0.0011446119,0.0012735686,0.00035676037,0.00017020603,0.0006033822],"domain_scores_gemma":[0.99600476,0.0009255727,0.0023246761,0.00031149914,0.0002793815,0.00015411525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081710715,0.0004341628,0.0023530847,0.00027627771,0.00017003065,0.000021892347,0.0008713719,0.0004072129,0.000024494662],"category_scores_gemma":[0.0005633459,0.00027521185,0.0010264316,0.00034587036,0.00062463694,0.0001705657,0.00017386011,0.0005826481,0.000048860536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9761262,0.00026150787,0.000076868964,0.000016897018,0.0032276122,0.00002527326,0.0012635405,0.00007602323,0.0010852519,0.0010251356,0.015502954,0.0013127519],"study_design_scores_gemma":[0.93723065,0.001987332,0.000033288445,0.0001012385,0.0016388029,0.0033649253,0.0013810056,0.000016144299,0.038942996,0.00093931146,0.014027055,0.00033728228],"about_ca_topic_score_codex":0.00015352272,"about_ca_topic_score_gemma":0.00001664894,"teacher_disagreement_score":0.038895566,"about_ca_system_score_codex":0.00022805756,"about_ca_system_score_gemma":0.0004638816,"threshold_uncertainty_score":0.99997},"labels":[],"label_agreement":null},{"id":"W2136749841","doi":"10.3899/jrheum.090066","title":"Th17 Transcription Factor RORC2 Is Inversely Correlated with FOXP3 Expression in the Joints of Children with Juvenile Idiopathic Arthritis","year":2009,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"FOXP3; Medicine; Peripheral blood mononuclear cell; Synovial fluid; IL-2 receptor; Arthritis; Internal medicine; Flow cytometry; Immunology; Endocrinology; Interleukin 17; Molecular biology; T cell; Cytokine; Biology; Pathology; Immune system; In vitro","score_opus":0.012149899416098614,"score_gpt":0.20747161329307942,"score_spread":0.1953217138769808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136749841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244136,0.0061984323,0.00015040231,0.000773856,0.00016405739,0.00020459747,0.000015973354,0.000009586883,0.000041721003],"genre_scores_gemma":[0.99773765,0.0020432412,0.0000444849,0.00012116039,0.000004083726,0.0000026160458,0.000008898654,0.000009799432,0.000028048687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983181,0.00071204576,0.0005359078,0.00011558458,0.00008349746,0.00023490161],"domain_scores_gemma":[0.9989488,0.0001074477,0.0006183609,0.00022242546,0.00008485355,0.000018085966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047539602,0.00018207364,0.00055335974,0.000141496,0.0001162326,0.000005833697,0.00031237502,0.00020808644,0.0000960208],"category_scores_gemma":[0.000021956357,0.00008350007,0.00009043458,0.00018332926,0.00017365691,0.00012148638,0.000008868065,0.00040593746,0.00001626708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013012113,0.0013214244,0.5916041,0.000035642162,0.0013414416,0.00007188182,0.042685643,0.000087517,0.30252445,0.00023648044,0.0028180536,0.044261243],"study_design_scores_gemma":[0.021470644,0.008013682,0.773485,0.0018639183,0.00060211855,0.036289472,0.0028099767,0.0000071429854,0.15411538,0.0005751665,0.0003322589,0.00043522567],"about_ca_topic_score_codex":0.00011273628,"about_ca_topic_score_gemma":0.00014768553,"teacher_disagreement_score":0.18188089,"about_ca_system_score_codex":0.000022887283,"about_ca_system_score_gemma":0.00008976148,"threshold_uncertainty_score":0.34050342},"labels":[],"label_agreement":null},{"id":"W2137061095","doi":"10.1001/archdermatol.2012.36","title":"A Patient Decision Aid for Psoriasis Based on Current Clinical Practice Guidelines","year":2012,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Psoriasis; CLARITY; Psoriasis Area and Severity Index; Clinical Practice; Private practice; Evidence-based medicine; Adverse effect; Alternative medicine; Dermatology; Family medicine; Pathology; Internal medicine","score_opus":0.05766886907086166,"score_gpt":0.37360197963115205,"score_spread":0.3159331105602904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137061095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8663122,0.041280672,0.053191163,0.0069873063,0.019006351,0.0023450272,0.0005280479,0.00021178633,0.010137439],"genre_scores_gemma":[0.93160397,0.0005594401,0.06633309,0.0009288612,0.00014578467,0.00014061492,0.00021850293,0.000025702482,0.000044051063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978802,0.0005025829,0.0008542293,0.00028585497,0.000048045673,0.00042904707],"domain_scores_gemma":[0.9936474,0.0054254783,0.00036624877,0.00038561417,0.00011853388,0.00005675209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020733952,0.00020855223,0.00048793165,0.00017708003,0.000115094816,0.0000032709802,0.00017949658,0.000179812,0.000048350634],"category_scores_gemma":[0.0025891177,0.00016418408,0.00032281093,0.00006991641,0.0001844869,0.000086737986,0.000067631896,0.0001446502,0.00013450132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004586377,0.001987547,0.029637754,0.000039103103,0.00023521022,0.0000051324946,0.0003408601,0.000010571596,0.00082704815,0.0024272327,0.012519833,0.94738334],"study_design_scores_gemma":[0.0061607626,0.00065626745,0.0061286944,0.00009286052,0.00036200343,0.00017232013,0.00012681453,0.000097013304,0.01783935,0.0005786355,0.96755165,0.0002336299],"about_ca_topic_score_codex":0.000004314565,"about_ca_topic_score_gemma":0.0000021234976,"teacher_disagreement_score":0.9550318,"about_ca_system_score_codex":0.0000074116865,"about_ca_system_score_gemma":0.00008177136,"threshold_uncertainty_score":0.66952324},"labels":[],"label_agreement":null},{"id":"W2137297208","doi":"10.1016/j.clindermatol.2007.11.001","title":"Monitoring biologics for the treatment of psoriasis","year":2008,"lang":"en","type":"review","venue":"Clinics in Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Etanercept; Efalizumab; Psoriasis; Infliximab; Adalimumab; Disease; Internal medicine; Dermatology","score_opus":0.13440729044574612,"score_gpt":0.38479813532450086,"score_spread":0.25039084487875474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137297208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075643125,0.99206537,0.000021163336,0.000027887101,0.005373433,0.0014199143,0.00021257561,0.000036073052,0.000087134],"genre_scores_gemma":[0.0002304527,0.9976902,0.00018135963,0.000008320587,0.00016336037,0.0010634987,0.00025694654,0.000043088523,0.00036274834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997084,0.0005376708,0.0013551832,0.00050650124,0.000024445219,0.00049215544],"domain_scores_gemma":[0.991541,0.0069322856,0.0007313672,0.00071512314,0.00006206037,0.000018164634],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00014181895,0.0005334967,0.0028106365,0.00024707548,0.00017421601,0.000004181279,0.0005302131,0.0015750868,0.00002483057],"category_scores_gemma":[0.00017434554,0.0003137267,0.0011565572,0.00025296642,0.00037295246,0.000020090296,0.000055874127,0.00023718794,0.00011754178],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006301768,0.00044163794,0.0012598776,0.0006366368,0.0012585894,0.000027951239,0.0001617195,5.2622937e-7,0.0000010272539,0.00015290508,0.00031316542,0.99568295],"study_design_scores_gemma":[0.0016227628,0.00037834528,0.00007320672,0.00059654354,0.0012855364,0.0005243828,0.000051380004,4.927182e-7,0.00016134595,0.00008280486,0.99497205,0.00025113247],"about_ca_topic_score_codex":0.000014464891,"about_ca_topic_score_gemma":0.000010478539,"teacher_disagreement_score":0.99543184,"about_ca_system_score_codex":0.00011654234,"about_ca_system_score_gemma":0.0002941085,"threshold_uncertainty_score":0.99993145},"labels":[],"label_agreement":null},{"id":"W2137323340","doi":"10.1186/1477-7525-11-82","title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","year":2013,"lang":"en","type":"article","venue":"Health and Quality of Life Outcomes","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Celgene","keywords":"Apremilast; Medicine; Placebo; Minimal clinically important difference; Dermatology Life Quality Index; Psoriasis; Quality of life (healthcare); Visual analogue scale; Randomized controlled trial; Internal medicine; Physical therapy; Dermatology; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.053390834004827845,"score_gpt":0.33993608928871355,"score_spread":0.2865452552838857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137323340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902768,0.0011509227,0.000005607133,0.0009544993,0.0002096114,0.0069992943,0.00036767812,0.000018060611,0.00001748389],"genre_scores_gemma":[0.99719036,0.00015656775,0.00017026112,0.0010907404,0.0000095758705,0.0010544932,0.00022288956,0.0000132019,0.00009189871],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99387777,0.0027704998,0.0023127017,0.00048118606,0.00015350532,0.00040433553],"domain_scores_gemma":[0.9965153,0.0017558688,0.0009897434,0.0005109371,0.000099672114,0.00012853341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001654667,0.00038959595,0.0030741654,0.0001884617,0.000108182794,0.000020844214,0.00012531958,0.00011886313,0.00002233486],"category_scores_gemma":[0.00044675017,0.0001998648,0.00019300087,0.00015431264,0.00010234585,0.00013906596,0.000026194079,0.00009425248,0.000003734733],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40008232,0.01000646,0.523305,0.000036890935,0.001405507,0.0000059734953,0.049461555,0.00001065119,0.00012961453,0.0000112862135,0.000036558275,0.015508199],"study_design_scores_gemma":[0.7378526,0.005231773,0.24071045,0.00004997267,0.0001755319,9.759463e-7,0.015398985,0.000008488132,0.0002986542,0.00003922944,0.000024073654,0.00020929924],"about_ca_topic_score_codex":0.047509175,"about_ca_topic_score_gemma":0.008194921,"teacher_disagreement_score":0.33777022,"about_ca_system_score_codex":0.00006337473,"about_ca_system_score_gemma":0.00022055584,"threshold_uncertainty_score":0.9588335},"labels":[],"label_agreement":null},{"id":"W2137807405","doi":"10.3899/jrheum.111245","title":"Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Biogen; Pfizer","keywords":"Medicine; Psoriasis; Epidemiology; Comorbidity; Dermatology; Internal medicine","score_opus":0.02173072284205035,"score_gpt":0.2378418976836459,"score_spread":0.21611117484159553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137807405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89772034,0.098678425,0.00046793954,0.00046131466,0.0024793802,0.00011820831,0.00004199732,0.0000069228895,0.00002549854],"genre_scores_gemma":[0.9917551,0.007838308,0.00024835102,0.000045314846,0.000044836943,0.0000060997195,0.000015483896,0.000013072269,0.000033385015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956099,0.0027615747,0.0010133444,0.0001320156,0.000063305626,0.00041986696],"domain_scores_gemma":[0.9965437,0.0020224364,0.00092059514,0.0003724668,0.000108180124,0.0000326053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053772097,0.00019236736,0.0010225932,0.000116264426,0.00015217134,0.0000019971665,0.00032933056,0.0002949582,0.000048356233],"category_scores_gemma":[0.0006861842,0.00010488823,0.00030887136,0.00010332954,0.00044370984,0.00011151828,0.000119126766,0.0003781834,0.000009527553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001558546,0.00034336367,0.9418731,0.00004169602,0.007695696,0.00012013473,0.012988729,0.00014879472,0.010795505,0.0016361632,0.0039255773,0.018872723],"study_design_scores_gemma":[0.012940765,0.0012042085,0.7576439,0.00061546214,0.00645269,0.13707452,0.035017103,0.000016795764,0.021306776,0.015131595,0.011707553,0.00088865345],"about_ca_topic_score_codex":0.0022227885,"about_ca_topic_score_gemma":0.000079904035,"teacher_disagreement_score":0.1842292,"about_ca_system_score_codex":0.000017712742,"about_ca_system_score_gemma":0.000055441615,"threshold_uncertainty_score":0.4277218},"labels":[],"label_agreement":null},{"id":"W2138522708","doi":"10.1111/pde.12072","title":"Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States","year":2013,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Valeant Pharmaceuticals International; Amgen; Pfizer; National Institutes of Health; Galderma; Northwestern University","keywords":"Medicine; Psoriasis; Scalp; Dermatology; Family history; Odds ratio; Alopecia areata; Nail (fastener); Severity of illness; Confidence interval; Surgery; Internal medicine","score_opus":0.031193017835895114,"score_gpt":0.3008481266883539,"score_spread":0.2696551088524588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138522708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682695,0.0010732019,0.000010992693,0.0002964541,0.00060056744,0.0008806614,0.00008873192,0.000023987988,0.00019846232],"genre_scores_gemma":[0.99782103,0.0014560393,0.000089830275,0.00007855782,0.000079532176,0.00013936023,0.00025476195,0.000011672729,0.00006923258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99648786,0.0015316239,0.0012922797,0.0002947225,0.00006497317,0.00032854077],"domain_scores_gemma":[0.99662566,0.0022443635,0.00051644584,0.00041485365,0.00017646996,0.00002222446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052328507,0.00018941172,0.00049495004,0.00055966474,0.000064788714,0.000005850417,0.00038663097,0.00023445918,0.000090532485],"category_scores_gemma":[0.00033108736,0.0001315571,0.00012729903,0.00077858183,0.00011460338,0.00007518498,0.00007169597,0.00022548261,0.00024105723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024809578,0.0022433596,0.9869021,0.00003911135,0.00014898578,0.00005072517,0.0035670707,0.000008632993,0.000017907169,0.000031869917,0.006105578,0.00063656166],"study_design_scores_gemma":[0.008253816,0.00037773032,0.98547757,0.0000024618375,0.00071496563,0.000065586064,0.0043279584,0.00001783329,0.00007874007,0.00009008053,0.00045453696,0.00013874857],"about_ca_topic_score_codex":0.0011428699,"about_ca_topic_score_gemma":0.00015469629,"teacher_disagreement_score":0.008005721,"about_ca_system_score_codex":0.000009420212,"about_ca_system_score_gemma":0.00007381131,"threshold_uncertainty_score":0.5364743},"labels":[],"label_agreement":null},{"id":"W2138647255","doi":"10.1016/s0140-6736(14)62113-9","title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":394,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Tofacitinib; Placebo; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Janus kinase inhibitor; Population; Randomized controlled trial; Surgery; Dermatology; Rheumatoid arthritis","score_opus":0.07837364539587272,"score_gpt":0.32449581759472496,"score_spread":0.24612217219885224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138647255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903549,0.000606904,0.00007621714,0.000866037,0.0027883532,0.001924178,0.00028145825,0.000103189464,0.0029987742],"genre_scores_gemma":[0.99590755,0.00014260116,0.000077866105,0.00020559254,0.0010040994,0.0005685528,0.0001978429,0.000025843196,0.001870056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796855,0.000596897,0.00037895804,0.00037623165,0.0000720273,0.00060736114],"domain_scores_gemma":[0.99868166,0.00048151362,0.00011083657,0.0006064395,0.000048757574,0.00007077777],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088319095,0.00030731419,0.00088202424,0.00008798633,0.00014748833,0.000039072165,0.00045460486,0.0002869068,0.0006318605],"category_scores_gemma":[0.00030155247,0.00019339827,0.00012814932,0.0002371365,0.00008793283,0.00009696746,0.00008575715,0.0003052508,0.00094385643],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9699939,0.00028829472,0.00006524039,0.000012026901,0.00033126163,0.000038870272,0.0017865428,0.00013569563,0.002866484,0.00005149778,0.012280234,0.012149945],"study_design_scores_gemma":[0.9570472,0.0018989971,0.00011109854,0.000041288848,0.00018761275,0.000029006818,0.00037112794,0.00007221795,0.007665079,0.00007625255,0.032165486,0.00033459842],"about_ca_topic_score_codex":0.0001600439,"about_ca_topic_score_gemma":0.0007287245,"teacher_disagreement_score":0.019885253,"about_ca_system_score_codex":0.00020635019,"about_ca_system_score_gemma":0.00041432484,"threshold_uncertainty_score":0.999834},"labels":[],"label_agreement":null},{"id":"W2139218479","doi":"10.1185/03007995.2010.507492","title":"Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis","year":2010,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Discontinuation; Tumor necrosis factor alpha; Clinical trial; Psoriatic arthritis; Systemic inflammatory response syndrome; Sepsis; Internal medicine; Arthritis; Etiology; Placebo; Dermatology; Pathology","score_opus":0.2546228500833358,"score_gpt":0.4820121677577306,"score_spread":0.2273893176743948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139218479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04686648,0.949159,0.000004614287,0.000020116051,0.0024889275,0.0012720156,0.00012064754,0.000021843962,0.00004634599],"genre_scores_gemma":[0.00039878636,0.99773085,0.00009894324,0.0000017472914,0.00024021172,0.00068392884,0.0005833268,0.000032249245,0.00022998327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948184,0.0015149731,0.0015468949,0.0007632189,0.00042219574,0.00093433884],"domain_scores_gemma":[0.9974447,0.0014212594,0.0003185721,0.00036930025,0.00013752353,0.00030863847],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041403254,0.00040809132,0.0018730799,0.0007106018,0.00020866824,0.000023356168,0.0005783762,0.0011912682,0.00093607994],"category_scores_gemma":[0.0027911905,0.0002857714,0.00027472124,0.00055203645,0.00072657096,0.000055571036,0.00045633616,0.002783285,0.0003335215],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008082923,0.0006618799,0.00028734407,0.0048743295,0.00013710027,0.000005925891,0.00020978549,1.2055454e-10,0.000037485446,0.00005248377,0.0002761423,0.9933767],"study_design_scores_gemma":[0.0013099521,0.0002955133,0.000332927,0.017831406,0.000028748358,0.0000122281535,0.00003920063,1.4743405e-7,0.000105122366,0.000024813402,0.9797651,0.00025484402],"about_ca_topic_score_codex":0.000017176815,"about_ca_topic_score_gemma":0.000036155026,"teacher_disagreement_score":0.99312186,"about_ca_system_score_codex":0.00016271256,"about_ca_system_score_gemma":0.0023990204,"threshold_uncertainty_score":0.9999772},"labels":[],"label_agreement":null},{"id":"W2141045409","doi":"10.1111/j.1365-2133.2009.09491.x","title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","year":2009,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Ustekinumab; Psoriasis; Medicine; Quality of life (healthcare); Phoenix; Dermatology; Dermatologic agents; Physical therapy; Internal medicine; Disease; Pathology; Nursing","score_opus":0.0183358813007874,"score_gpt":0.24431816057660868,"score_spread":0.2259822792758213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141045409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913857,0.0049907444,0.000017448336,0.0019398881,0.00078310276,0.0004915482,0.00030089694,0.000012670001,0.000078006444],"genre_scores_gemma":[0.99892473,0.00019484186,0.00013745273,0.0005180733,0.000044165175,0.0000056169583,0.00013136657,0.000012323771,0.000031414595],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960065,0.0013481773,0.0018953991,0.00025845476,0.000108592845,0.00038288397],"domain_scores_gemma":[0.9976234,0.00048434568,0.0013475784,0.00024261263,0.00022998563,0.00007208518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048529,0.00020156274,0.0011006721,0.00012584534,0.00014103822,0.00002128442,0.00034752922,0.0003018833,0.00003591774],"category_scores_gemma":[0.00053738814,0.00015638427,0.00016170702,0.00022828883,0.00010321738,0.00014188951,0.00003194986,0.00040966697,0.000013492373],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.683747,0.0042008534,0.058090493,0.000029616169,0.0022895618,0.00041271822,0.0047983704,0.00010826975,0.0012812916,0.0001333229,0.015304582,0.22960392],"study_design_scores_gemma":[0.2318222,0.0019652026,0.7623614,0.00028371825,0.000116296644,0.00112924,0.00033523,0.0000010813604,0.0010427277,0.00031746607,0.00036511334,0.00026031473],"about_ca_topic_score_codex":0.0014913348,"about_ca_topic_score_gemma":0.00070292887,"teacher_disagreement_score":0.7042709,"about_ca_system_score_codex":0.000055933688,"about_ca_system_score_gemma":0.0003852959,"threshold_uncertainty_score":0.63771653},"labels":[],"label_agreement":null},{"id":"W2142056570","doi":"10.1503/cmaj.1031335","title":"Psoriasis and the new biologic agents: interrupting a T-AP dance","year":2004,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Biogen; Amgen","keywords":"Psoriasis; Immune system; T cell; Immunology; Monoclonal antibody; Cytokine; Medicine; Antibody; Biology","score_opus":0.027751243300796088,"score_gpt":0.28405861555259326,"score_spread":0.25630737225179717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142056570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004450162,0.99247056,0.00001848769,0.0034424583,0.0029816183,0.00027900632,0.00006500121,0.000018726141,0.0006796406],"genre_scores_gemma":[0.00009330464,0.99451935,0.000028174321,0.0012440546,0.0010828477,0.000024191248,0.000094283314,0.000022959148,0.0028908509],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997108,0.0011086572,0.00074080046,0.00027818859,0.00016458084,0.00059977884],"domain_scores_gemma":[0.99788797,0.00072237477,0.0007355438,0.00015708542,0.0000889556,0.00040808972],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019767322,0.0003377377,0.0011389817,0.00020808067,0.0005357431,0.00009420595,0.0004810992,0.0014267224,0.0025525768],"category_scores_gemma":[0.0021940516,0.00019673222,0.00046077545,0.00023544092,0.0001492387,0.00006091147,0.00004978373,0.0014670246,0.000601964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007977298,0.000009037921,0.000050355546,0.00012081167,0.0010747276,0.00007723728,0.00021241281,5.5192427e-8,5.8646904e-8,0.00024884858,0.023425119,0.97477335],"study_design_scores_gemma":[0.002159059,0.0000318185,0.000048889236,0.002976824,0.000792912,0.00121275,0.00008771492,2.2660527e-7,2.3953004e-7,0.00018154793,0.9923129,0.00019510063],"about_ca_topic_score_codex":0.0023270077,"about_ca_topic_score_gemma":0.0063520935,"teacher_disagreement_score":0.97457826,"about_ca_system_score_codex":0.0011880007,"about_ca_system_score_gemma":0.0047510182,"threshold_uncertainty_score":0.99986964},"labels":[],"label_agreement":null},{"id":"W2142329760","doi":"10.1111/bjd.12632","title":"Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from <scp>PHOENIX</scp> 1","year":2013,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Moncton Hospital","funders":"Celgene; Janssen Research and Development; Pfizer; Amgen","keywords":"Ustekinumab; Medicine; Psoriasis; Dermatology; Nail (fastener); Placebo; Dosing; Psoriasis Area and Severity Index; Randomized controlled trial; Nail disease; Surgery; Internal medicine; Disease; Pathology","score_opus":0.006298647247534306,"score_gpt":0.18957286171401702,"score_spread":0.1832742144664827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142329760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942711,0.0035201316,0.000031501982,0.0002996133,0.0008534668,0.00042548636,0.00037273916,0.000026644608,0.00019931702],"genre_scores_gemma":[0.99847174,0.00018956658,0.00036334214,0.00025670996,0.000062493746,0.000038683585,0.00024922812,0.000034584922,0.00033365586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976128,0.000406357,0.00090347114,0.00038875703,0.00010703351,0.0005815933],"domain_scores_gemma":[0.99834347,0.0003560012,0.00049505115,0.00027068472,0.00036075877,0.00017404534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000094318624,0.00029321466,0.00071773276,0.00025742888,0.0001486041,0.000078401674,0.0003777835,0.00030490325,0.00009127174],"category_scores_gemma":[0.00039572603,0.00027297297,0.00014347993,0.00020406893,0.00011382564,0.0004171625,0.00008173229,0.00038784268,0.00029710022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01117532,0.003893855,0.50737077,0.00007155186,0.0029171028,0.006186083,0.003399361,0.00018824638,0.0040424345,0.000042858675,0.103938416,0.35677397],"study_design_scores_gemma":[0.02463073,0.0003547147,0.9647808,0.00032953423,0.00023674531,0.0021982759,0.00030161534,0.0000055913356,0.0034062357,0.0003074294,0.0032301666,0.00021817144],"about_ca_topic_score_codex":0.00076027185,"about_ca_topic_score_gemma":0.00024703197,"teacher_disagreement_score":0.45741,"about_ca_system_score_codex":0.00007045359,"about_ca_system_score_gemma":0.00020189006,"threshold_uncertainty_score":0.9999722},"labels":[],"label_agreement":null},{"id":"W2142359268","doi":"10.2147/tcrm.2007.3.2.245","title":"The safety of etanercept for the treatment of plaque psoriasis","year":2007,"lang":"en","type":"article","venue":"Therapeutics and Clinical Risk Management","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Western University","funders":"","keywords":"Etanercept; Medicine; Psoriasis; Tumor necrosis factor alpha; Immunology; Adverse effect; Immune system; Cytokine; Pharmacology","score_opus":0.04419726128517241,"score_gpt":0.33547815017991833,"score_spread":0.2912808888947459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142359268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91305095,0.06486846,0.009877712,0.0014051863,0.0029342277,0.0031891034,0.0002900271,0.000048210262,0.0043361313],"genre_scores_gemma":[0.76053655,0.23700905,0.00028992866,0.00007032676,0.00005760873,0.00003291809,0.000015434882,0.000011880506,0.0019762802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879336,0.00014908238,0.0006053844,0.0001843514,0.0000415919,0.00022622335],"domain_scores_gemma":[0.99595934,0.003317065,0.00028028968,0.0003830922,0.000044359884,0.000015831214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013159213,0.0001429655,0.00028798237,0.000025438936,0.00029709295,0.0000064774567,0.00018440661,0.000121224024,0.00002674481],"category_scores_gemma":[0.0000120531495,0.000067933346,0.0002660604,0.00006937506,0.00034153264,0.00001005723,0.00003307739,0.000060395854,0.000007747399],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023409969,0.0004991908,0.006108976,0.0000087449025,0.0037570747,5.446269e-7,0.00027980283,0.0000030508108,0.00006898068,0.0087993825,0.00007475436,0.9780585],"study_design_scores_gemma":[0.0065725246,0.0025999164,0.14651807,0.00001473495,0.003648422,0.0000013706341,0.0015437909,0.000028319722,0.0031307982,0.0023287595,0.83346844,0.0001448833],"about_ca_topic_score_codex":0.00004124222,"about_ca_topic_score_gemma":0.00012482992,"teacher_disagreement_score":0.9779136,"about_ca_system_score_codex":0.000017445856,"about_ca_system_score_gemma":0.000009806687,"threshold_uncertainty_score":0.27702415},"labels":[],"label_agreement":null},{"id":"W2143716911","doi":"10.4049/jimmunol.1000148","title":"Distinct Roles of IL-23 and IL-17 in the Development of Psoriasis-Like Lesions in a Mouse Model","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Interleukin 17; Psoriasis; Interleukin 23; Genetically modified mouse; Cytokine; Immune system; Immunology; Transgene; Interleukin 12; Interleukin; In vivo; Chemistry; Biology; Molecular biology; In vitro; Biochemistry; Cytotoxic T cell","score_opus":0.03586547536677869,"score_gpt":0.24203216939246716,"score_spread":0.20616669402568846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143716911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942821,0.004991242,0.000095154566,0.00009346489,0.00014370974,0.00012179789,0.00002932976,0.000002987566,0.00024017278],"genre_scores_gemma":[0.9982919,0.00086351566,0.0005497433,0.000021193504,0.0000065562267,0.0000065629265,0.0000054605744,0.000008151121,0.0002469057],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983979,0.0005314219,0.00071933225,0.00008931451,0.000042820084,0.0002192377],"domain_scores_gemma":[0.99890393,0.0003097156,0.00047400332,0.00023386993,0.0000694644,0.00000900323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010092553,0.00014726513,0.00042286536,0.00021961395,0.00007938132,0.0000017789182,0.00045000558,0.00016990761,0.000030903237],"category_scores_gemma":[0.00005875308,0.00008008693,0.00007393719,0.00012673916,0.00031379444,0.000058112335,0.000078653095,0.00027861143,0.000005777295],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005265261,0.0016507807,0.017718833,0.000032071803,0.0013186239,0.00001835454,0.102180995,0.000054403565,0.809182,0.0012421212,0.00027654736,0.061060026],"study_design_scores_gemma":[0.0083767185,0.0013175631,0.5573863,0.00020768923,0.00044868342,0.000443751,0.017967654,0.000019285659,0.409864,0.0025467642,0.0010851574,0.0003364504],"about_ca_topic_score_codex":0.00007001502,"about_ca_topic_score_gemma":0.00077641517,"teacher_disagreement_score":0.5396674,"about_ca_system_score_codex":0.000026780297,"about_ca_system_score_gemma":0.00013026687,"threshold_uncertainty_score":0.32658502},"labels":[],"label_agreement":null},{"id":"W2145148829","doi":"10.3899/jrheum.120208","title":"Cytokine Secretion by Pathogen Recognition Receptor-stimulated Dendritic Cells in Rheumatoid Arthritis and Ankylosing Spondylitis","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Secretion; Medicine; Tumor necrosis factor alpha; Immunology; Receptor; Cytokine; Rheumatoid arthritis; Ankylosing spondylitis; TLR2; Monocyte; Dendritic cell; Interleukin; Internal medicine; Immune system; TLR4","score_opus":0.012237803631620634,"score_gpt":0.21718575954873692,"score_spread":0.2049479559171163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145148829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9599713,0.0381791,0.00012474314,0.00018559892,0.0010946608,0.00014483648,0.00024333858,0.000017261471,0.000039138475],"genre_scores_gemma":[0.96401626,0.035499867,0.00014710396,0.000042195323,0.000011041436,0.000004636751,0.00022678002,0.00001965478,0.000032484102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997671,0.0010375411,0.0006709231,0.00012450937,0.00005173959,0.00044425912],"domain_scores_gemma":[0.9987437,0.0005585542,0.00041992735,0.0001355915,0.00008813778,0.000054080523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010783339,0.00020215395,0.00050968555,0.00020182542,0.00015272485,0.000011243679,0.0001343136,0.0002976568,0.0005901064],"category_scores_gemma":[0.00011729268,0.00015493506,0.000077091536,0.00016383885,0.00018514461,0.00024924395,0.000039577168,0.00031847565,0.00012545894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017670633,0.00040574346,0.12628001,0.000043418007,0.0004204142,0.000017024155,0.00344017,0.0000062384506,0.74504656,0.00010444793,0.003099535,0.11936938],"study_design_scores_gemma":[0.048947565,0.004076028,0.07551385,0.0057701077,0.0010360784,0.15073264,0.0074918345,0.000088277855,0.61218536,0.003695724,0.08768262,0.002779934],"about_ca_topic_score_codex":0.00015756775,"about_ca_topic_score_gemma":0.0000385727,"teacher_disagreement_score":0.15071562,"about_ca_system_score_codex":0.000056936547,"about_ca_system_score_gemma":0.000033459364,"threshold_uncertainty_score":0.64612514},"labels":[],"label_agreement":null},{"id":"W2146310816","doi":"10.1159/000096069","title":"Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris","year":2006,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg","funders":"","keywords":"Calcipotriol; Medicine; Betamethasone dipropionate; Betamethasone; Dermatology; Psoriasis; Internal medicine","score_opus":0.03526425378347577,"score_gpt":0.28754232649991535,"score_spread":0.2522780727164396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146310816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891437,0.005394773,0.0000112591715,0.0003393995,0.00048671075,0.003425574,0.00017400888,0.000033895885,0.0009906251],"genre_scores_gemma":[0.9983937,0.00036006808,0.00007142854,0.000011094853,0.00006419571,0.0004705453,0.00034732444,0.000028718314,0.00025290452],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99502045,0.0016861799,0.0018921606,0.000686647,0.0001499801,0.00056455727],"domain_scores_gemma":[0.99623424,0.001561168,0.000951417,0.0010391477,0.00018725698,0.000026794303],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006053708,0.0004954639,0.0018241707,0.0004823582,0.0001515581,0.000007781667,0.00046618248,0.00031330506,0.000048551723],"category_scores_gemma":[0.0000832469,0.00033115543,0.00038239796,0.00072056206,0.00042004042,0.00007389015,0.00006487489,0.00020339341,0.000026906147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6489467,0.09614914,0.0855443,0.00029725552,0.007097291,0.0005713743,0.037233733,0.0006887811,0.08328428,0.0019290408,0.0012849367,0.036973175],"study_design_scores_gemma":[0.64445686,0.0037192102,0.066421285,0.00006560856,0.0018528865,0.0004597002,0.0017267923,0.000007792055,0.27256283,0.00015523327,0.008061715,0.000510085],"about_ca_topic_score_codex":0.0055931075,"about_ca_topic_score_gemma":0.0017341957,"teacher_disagreement_score":0.18927856,"about_ca_system_score_codex":0.000074376425,"about_ca_system_score_gemma":0.00013417297,"threshold_uncertainty_score":0.99991405},"labels":[],"label_agreement":null},{"id":"W2146480859","doi":"10.1016/j.ad.2011.03.022","title":"Epidemiology and quality of life of patients with psoriasis in Chile","year":2011,"lang":"en","type":"article","venue":"Actas Dermo-Sifiliográficas","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Psoriasis; Medicine; Epidemiology; Observational study; Disease; Quality of life (healthcare); Dermatology Life Quality Index; Family history; Dermatology; Body surface area; Diabetes mellitus; Internal medicine; Psoriasis Area and Severity Index; Cross-sectional study; Severity of illness; Pathology","score_opus":0.06511043132688288,"score_gpt":0.27085740957799065,"score_spread":0.20574697825110777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146480859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557734,0.002523611,0.000016741948,0.000029334982,0.0001811572,0.00029993514,0.00018222172,0.0000217943,0.0011678644],"genre_scores_gemma":[0.9988712,0.00024676244,0.0005439081,0.00006168686,0.00000973109,0.000029242592,0.00016099631,0.000016841997,0.000059648868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977552,0.0006839745,0.0007803062,0.00037980248,0.00004236066,0.0003583371],"domain_scores_gemma":[0.9983264,0.00064650393,0.0004680888,0.0004194376,0.000090341346,0.00004922645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056787604,0.00023175865,0.00084840535,0.0002855907,0.000050554278,9.573904e-7,0.0001847472,0.00030322344,0.00042584725],"category_scores_gemma":[0.00038426532,0.00017718163,0.00010907407,0.00030670973,0.00040238997,0.000086722954,0.00007190984,0.00013787787,0.000022571174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015795032,0.00067314,0.98658305,0.000052129995,0.0003792315,0.0000014561983,0.0008088635,3.3168206e-7,0.0021978372,0.0009371673,0.00012453007,0.006662726],"study_design_scores_gemma":[0.0035370293,0.00041125555,0.9830884,0.000025396304,0.000102518774,0.000002587635,0.00016749176,3.8113888e-7,0.012049573,0.00023061667,0.00020936865,0.0001754292],"about_ca_topic_score_codex":0.0008535091,"about_ca_topic_score_gemma":0.00018161863,"teacher_disagreement_score":0.009851736,"about_ca_system_score_codex":0.000013208652,"about_ca_system_score_gemma":0.000043177606,"threshold_uncertainty_score":0.7225258},"labels":[],"label_agreement":null},{"id":"W2146526013","doi":"","title":"Can nicotine use alleviate symptoms of psoriasis?","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Psoriasis; Medicine; Nicotine; Dermatology; Psychiatry","score_opus":0.02817985728552968,"score_gpt":0.21558010625291382,"score_spread":0.18740024896738414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146526013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923067,0.0037328226,0.0000042585148,0.00013395866,0.0020942388,0.00037430393,0.0000695408,0.00006252107,0.0012216497],"genre_scores_gemma":[0.99312717,0.00010737736,0.00002700477,0.00007388454,0.00012614275,0.0003996618,0.000106448126,0.000017356913,0.0060149436],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988532,0.00013999378,0.00024022558,0.00016014623,0.0000319008,0.000574513],"domain_scores_gemma":[0.99936855,0.00012875056,0.0001261786,0.00028433072,0.000037719557,0.000054452536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002499988,0.00015933624,0.00027286657,0.00008738097,0.000060857456,0.000006503884,0.00013775284,0.0001692859,0.00013798696],"category_scores_gemma":[0.00008454509,0.00013022959,0.000118636184,0.00011932242,0.00007676732,0.0001350745,0.00005238879,0.00007510594,0.00013256424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026745631,0.00060544757,0.456238,0.000023902416,0.0012153963,0.0000014707178,0.00055613794,8.151613e-7,0.008325241,0.0013120413,0.0035409466,0.52791315],"study_design_scores_gemma":[0.0015659579,0.000035295972,0.87813324,0.0000050109034,0.0002232353,0.000015647971,0.000023467666,7.4226335e-8,0.08111257,0.00002864442,0.03869794,0.00015893912],"about_ca_topic_score_codex":0.00012396238,"about_ca_topic_score_gemma":0.000022792687,"teacher_disagreement_score":0.5277542,"about_ca_system_score_codex":0.00003200475,"about_ca_system_score_gemma":0.00001250378,"threshold_uncertainty_score":0.5310608},"labels":[],"label_agreement":null},{"id":"W2146724716","doi":"10.3899/jrheum.120234","title":"Th17 and Interleukin 23 in the Pathogenesis of Psoriatic Arthritis and Spondyloarthritis","year":2012,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Interleukin 23; Pathogenesis; Immunology; Interleukin 17; Psoriasis; Immune system; Arthritis; Interleukin; Disease; Cytokine; Pathology","score_opus":0.027980881996088332,"score_gpt":0.2781737554364335,"score_spread":0.2501928734403452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146724716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04195371,0.9561948,0.0000046748737,0.00013910611,0.00096951245,0.00045325808,0.0002666556,0.000003753305,0.000014538169],"genre_scores_gemma":[0.030733572,0.96881604,0.00018602774,0.00001680516,0.00002608855,0.000054551536,0.000111903035,0.000024957832,0.000030064262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616945,0.0013586567,0.0017207434,0.00024366337,0.00008623874,0.0004212517],"domain_scores_gemma":[0.99725103,0.0009341083,0.0014295289,0.00027904983,0.00006365489,0.00004261324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014320321,0.00042505984,0.0024901067,0.0004944813,0.00008521235,0.000015322987,0.00034342203,0.000472571,0.00030433104],"category_scores_gemma":[0.00008030245,0.00027112922,0.0003595627,0.00017147884,0.0002689711,0.00007510447,0.0001221503,0.00042345145,0.00001968396],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006229911,0.00018761768,0.0044090357,0.0016311958,0.0008319969,0.0000713295,0.0010036487,2.364842e-8,0.000011335698,0.00046760368,0.00075037585,0.9905735],"study_design_scores_gemma":[0.003429216,0.0006876243,0.002029232,0.008097312,0.002096471,0.023176642,0.00083024375,6.178906e-8,0.00002667321,0.00014173816,0.95915127,0.00033354212],"about_ca_topic_score_codex":0.000053558353,"about_ca_topic_score_gemma":0.00022210946,"teacher_disagreement_score":0.99024,"about_ca_system_score_codex":0.000045860794,"about_ca_system_score_gemma":0.00014475767,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W2146843653","doi":"10.1111/j.1365-2133.2005.06688.x","title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","year":2005,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":692,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"SAINT; Medicine; Library science; Family medicine; Art history; Art","score_opus":0.006313327572443979,"score_gpt":0.26180500052152084,"score_spread":0.2554916729490769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146843653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97352046,0.023470629,0.000038261136,0.00025607285,0.0010554485,0.0013667721,0.000026281074,0.000008244384,0.0002578361],"genre_scores_gemma":[0.9957143,0.0039962656,0.00009002224,0.00000955438,0.0000924994,0.000033794782,0.000016371816,0.00000857884,0.000038630238],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951937,0.0024792955,0.001839481,0.0001702144,0.00007016003,0.0002471165],"domain_scores_gemma":[0.997555,0.00095055904,0.0012287952,0.000111308735,0.00011675672,0.000037577156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011974509,0.00019847517,0.0031177711,0.00021983853,0.000053910313,0.000007834468,0.00014811703,0.00035389044,0.000103926395],"category_scores_gemma":[0.00058263086,0.00016851984,0.00049182656,0.00015842979,0.0003820897,0.000114516,0.000030313768,0.00018983212,0.000003495604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88214004,0.0009221508,0.0001338852,0.00002401169,0.0012848933,0.00019853874,0.00015720911,0.0000093908675,0.0050641433,0.00006511379,0.00022608726,0.10977452],"study_design_scores_gemma":[0.95561403,0.0011417477,0.00041981807,0.00017430983,0.0012122893,0.03271232,0.000051398787,0.000005045636,0.008331115,0.000043262837,0.00018468972,0.000109972425],"about_ca_topic_score_codex":0.000083833365,"about_ca_topic_score_gemma":0.000052234354,"teacher_disagreement_score":0.10966455,"about_ca_system_score_codex":0.0000419588,"about_ca_system_score_gemma":0.00012069766,"threshold_uncertainty_score":0.68720394},"labels":[],"label_agreement":null},{"id":"W2147796654","doi":"10.2174/1874279300903010050","title":"Successful Treatment of Psoriasis-like Lesions in HIV Infected Patients in Uganda with Chloroquine","year":2009,"lang":"en","type":"article","venue":"The Open Infectious Diseases Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Psoriasis; Chloroquine; Human immunodeficiency virus (HIV); Traditional medicine; Dermatology; Internal medicine; Immunology; Malaria","score_opus":0.011448058563937427,"score_gpt":0.25271458043461525,"score_spread":0.24126652187067782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147796654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655265,0.0011134851,0.000006436791,0.00013427049,0.00031297092,0.00062438153,0.00006889074,0.000019134806,0.0011677742],"genre_scores_gemma":[0.9986086,0.00089247705,0.000008001267,0.000058047233,0.000039179155,0.000042195523,0.00010239855,0.000014009018,0.00023508265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855256,0.00039362255,0.00042595543,0.00021318153,0.00006553136,0.00034915388],"domain_scores_gemma":[0.9991676,0.00014077088,0.00026792623,0.00027367513,0.00009527142,0.000054762426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013754946,0.00025153175,0.00046582674,0.00025595073,0.00025529528,0.00005826049,0.00032543644,0.00009938956,0.00036122592],"category_scores_gemma":[0.000037067155,0.00014494867,0.00011454563,0.00043556016,0.000095146584,0.00025214412,0.000047125308,0.00015395608,0.00003724285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017232609,0.0039643906,0.9403641,0.0000032821301,0.00023534296,0.000040147937,0.0005715408,0.00013735823,0.00029369493,0.00005680622,0.00017172303,0.052438308],"study_design_scores_gemma":[0.016364047,0.0026340194,0.978285,0.00009764611,0.0002617962,0.00010616453,0.00013115305,0.0000017200033,0.0009337936,0.0003490924,0.0006536216,0.00018191584],"about_ca_topic_score_codex":0.0005519474,"about_ca_topic_score_gemma":0.0011881733,"teacher_disagreement_score":0.05225639,"about_ca_system_score_codex":0.00020636091,"about_ca_system_score_gemma":0.00017495696,"threshold_uncertainty_score":0.5910835},"labels":[],"label_agreement":null},{"id":"W2147939477","doi":"10.2174/187152809787582507","title":"The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders","year":2009,"lang":"en","type":"review","venue":"Inflammation & Allergy - Drug Targets","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":358,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; Queen's University","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Immune system; Biology; Proinflammatory cytokine; Cell biology; Immunology; Inflammation","score_opus":0.01465498676103584,"score_gpt":0.24943009094451568,"score_spread":0.23477510418347985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147939477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009184449,0.98770034,0.00002024172,0.0001837983,0.0008589805,0.00097271334,0.00004398503,0.00009423016,0.00094127504],"genre_scores_gemma":[0.002825792,0.9947158,0.000032028838,0.000005174634,0.00010658704,0.00025811637,0.0008632776,0.000038773444,0.0011544343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969789,0.0007190714,0.0013866764,0.00042332665,0.00009588899,0.00039614906],"domain_scores_gemma":[0.99797434,0.0004286474,0.0010099446,0.00045791492,0.00010465986,0.000024477295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006276722,0.00055619504,0.0011793211,0.0004546166,0.00033320358,0.000040989802,0.0002735471,0.00058295723,0.000038983362],"category_scores_gemma":[0.0001499709,0.00040555903,0.0003241862,0.0003523528,0.000192576,0.00024504206,0.000090982714,0.00033482056,0.000100125464],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049482835,0.00003977268,0.00009712575,0.0006207586,0.00054974057,0.000001908029,0.00053021335,0.00003298517,0.0002473433,0.0007089338,0.00032017718,0.99680156],"study_design_scores_gemma":[0.00092760567,0.000054409084,0.008897266,0.0012631791,0.00023185449,0.000011590059,0.000043018346,0.000005580445,0.0002534027,0.00046726948,0.9874735,0.00037133624],"about_ca_topic_score_codex":0.00025576417,"about_ca_topic_score_gemma":0.00163865,"teacher_disagreement_score":0.9964302,"about_ca_system_score_codex":0.00010723611,"about_ca_system_score_gemma":0.00017185333,"threshold_uncertainty_score":0.9998396},"labels":[],"label_agreement":null},{"id":"W2148793188","doi":"10.4049/jimmunol.0901528","title":"Loss of CD4+ T Cell IL-6R Expression during Inflammation Underlines a Role for IL-6 <i>Trans</i> Signaling in the Local Maintenance of Th17 Cells","year":2010,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"Cell biology; CD28; Biology; T cell; Effector; IL-2 receptor; Signal transduction; ZAP70; Cytokine; Population; Immunology; Immune system; Medicine","score_opus":0.008012781372952955,"score_gpt":0.21169993754790076,"score_spread":0.20368715617494781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148793188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946943,0.0024566718,0.0016782178,0.00027928542,0.0005722569,0.00023804736,0.000029365632,0.000004684337,0.000047184327],"genre_scores_gemma":[0.99903595,0.000552943,0.00022884949,0.00001652035,0.00006117942,0.000008401609,0.0000069925277,0.00001230622,0.00007684777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848473,0.00041873372,0.0006905689,0.000095838346,0.000053028307,0.00025709486],"domain_scores_gemma":[0.99810064,0.00070072827,0.00076331134,0.00024813158,0.00017871908,0.000008499482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000987591,0.00015522253,0.0003884683,0.0001346515,0.00011585898,0.000004005493,0.00051780016,0.0002496173,0.00003556345],"category_scores_gemma":[0.000046638113,0.00008534741,0.00017324515,0.00011491757,0.00034776956,0.00009559312,0.000038651877,0.00040590545,0.0000036288882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020995156,0.00014241156,0.00033205937,0.000041742675,0.00012747677,0.00000393121,0.0031877917,0.00033770376,0.9906639,0.00008542958,0.000025273845,0.0029527885],"study_design_scores_gemma":[0.0029738138,0.0004020635,0.0023917612,0.00009889913,0.00013523507,0.00018089692,0.002614037,0.0000075190433,0.9897782,0.0006821116,0.00065502163,0.000080419224],"about_ca_topic_score_codex":0.00003336698,"about_ca_topic_score_gemma":0.00004442332,"teacher_disagreement_score":0.004341673,"about_ca_system_score_codex":0.000017590042,"about_ca_system_score_gemma":0.00006638181,"threshold_uncertainty_score":0.34803665},"labels":[],"label_agreement":null},{"id":"W2149566497","doi":"10.1056/nejmoa0810652","title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":851,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ustekinumab; Medicine; Etanercept; Psoriasis; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Secukinumab; Dermatology; Clearance; Gastroenterology; Adalimumab; Randomized controlled trial; Tumor necrosis factor alpha; Psoriatic arthritis; Urology","score_opus":0.02972773026265618,"score_gpt":0.3047776721716203,"score_spread":0.2750499419089641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149566497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268067,0.0024352022,0.0007697114,0.0015527217,0.002026487,0.00015361763,0.000015433076,0.0000062324893,0.00035993208],"genre_scores_gemma":[0.9969305,0.00010842585,0.0011966517,0.000086578395,0.00086805737,0.000002105646,0.0000136788585,0.000010657057,0.0007833775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991232,0.00007037031,0.00046920497,0.00011340069,0.000059928898,0.00016390666],"domain_scores_gemma":[0.9989512,0.0003880561,0.0002858437,0.00012225754,0.00016911486,0.00008350991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047908613,0.00013713556,0.0006048034,0.00015608323,0.00006616149,0.0000038751386,0.00012472483,0.00015188617,0.00030953303],"category_scores_gemma":[0.00026038772,0.0000877085,0.0000659407,0.000074379335,0.000089836954,0.00004736132,0.000016268394,0.00022708485,0.0000049848068],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005161859,0.00013668987,0.014638457,0.000035965928,0.00046192147,0.000008435629,0.004220865,0.000027563961,0.34685296,0.0003719448,0.015368787,0.6127146],"study_design_scores_gemma":[0.2977571,0.014099241,0.051536307,0.0005769746,0.0027972248,0.0035659173,0.002543539,0.000073784264,0.21481775,0.0028176648,0.40874436,0.0006701651],"about_ca_topic_score_codex":0.00004145953,"about_ca_topic_score_gemma":0.000096171214,"teacher_disagreement_score":0.6120444,"about_ca_system_score_codex":0.000008570104,"about_ca_system_score_gemma":0.00006393724,"threshold_uncertainty_score":0.35766488},"labels":[],"label_agreement":null},{"id":"W2149827116","doi":"10.1001/archderm.143.2.223","title":"Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions","year":2007,"lang":"en","type":"review","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":326,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; SKiN Health; University of British Columbia; Vancouver General Hospital; Western University","funders":"Child and Family Research Institute","keywords":"Medicine; Psoriasis; Etanercept; Psoriatic arthritis; Infliximab; Adalimumab; Immunology; Arthritis; Tumor necrosis factor alpha; Exacerbation; Dermatology; Alpha interferon; Rheumatoid arthritis; Interferon","score_opus":0.01421573516114932,"score_gpt":0.2534251725536917,"score_spread":0.23920943739254236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149827116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022185553,0.9750289,0.000016150634,0.0000347721,0.00031078546,0.000963452,0.00073255994,0.000045501336,0.0006823788],"genre_scores_gemma":[0.03802592,0.9578868,0.00015047778,0.000025059271,0.0000063246553,0.00015144766,0.0036183752,0.000047609818,0.00008799493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970126,0.00071787304,0.0010934459,0.00054868596,0.000054651628,0.0005727174],"domain_scores_gemma":[0.9976444,0.00122384,0.00066624343,0.00038337026,0.000028589682,0.000053518517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000062274215,0.00058661855,0.0025620603,0.0008116119,0.00013179088,0.000008809753,0.0003001125,0.000694702,0.00007078718],"category_scores_gemma":[0.00005655574,0.00045012866,0.0002686438,0.0002992945,0.0007642452,0.00008320733,0.00012426893,0.00038617486,0.00005679288],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012143809,0.000648489,0.028579427,0.003748432,0.0016587671,0.000095196556,0.0003639794,8.369724e-8,0.0000062225336,0.0005497237,0.001999025,0.9622292],"study_design_scores_gemma":[0.009366826,0.00038167826,0.010683468,0.006051351,0.0023264927,0.0018171304,0.00012702985,2.4601422e-7,0.00032928566,0.00033599848,0.9674873,0.0010932055],"about_ca_topic_score_codex":0.00005324184,"about_ca_topic_score_gemma":0.000043134114,"teacher_disagreement_score":0.96548826,"about_ca_system_score_codex":0.000021264414,"about_ca_system_score_gemma":0.00013651169,"threshold_uncertainty_score":0.999795},"labels":[],"label_agreement":null},{"id":"W2150055807","doi":"","title":"Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Psoriasis; Medical prescription; Family medicine; Population; Health care; Body surface area; Dermatology; Internal medicine; Nursing","score_opus":0.04311280845698937,"score_gpt":0.27818585949737346,"score_spread":0.2350730510403841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150055807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884736,0.0033093535,0.00030159042,0.0006968344,0.0014588471,0.0017882334,0.00016896118,0.000044745997,0.0037578153],"genre_scores_gemma":[0.9954018,0.0000276989,0.00032627338,0.001046876,0.00016577341,0.0023392155,0.000031090818,0.000021786082,0.0006394702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987625,0.00026128435,0.00021065159,0.00019781289,0.000053559543,0.0005141907],"domain_scores_gemma":[0.99909467,0.0003210624,0.00017578369,0.00029113563,0.000085976135,0.00003135525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006283727,0.00015419602,0.00021009253,0.000046372515,0.0001870046,0.000012549195,0.00020239034,0.00009948839,0.000005311283],"category_scores_gemma":[0.00016236224,0.000113164424,0.00012172643,0.00011164829,0.00001988413,0.00020770631,0.00008729673,0.00008346028,0.000029260775],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094809994,0.0002941582,0.0039725606,0.00003983299,0.0007596354,2.548763e-7,0.0021656258,0.00017454835,0.021285465,0.0008850912,0.0008746206,0.9686001],"study_design_scores_gemma":[0.0073196157,0.00020579422,0.5420442,0.000110636356,0.0022062922,0.00003371207,0.007747564,0.000110932735,0.38257492,0.0015186731,0.0552509,0.00087671337],"about_ca_topic_score_codex":0.00006877095,"about_ca_topic_score_gemma":0.000007258768,"teacher_disagreement_score":0.96772337,"about_ca_system_score_codex":0.000047287835,"about_ca_system_score_gemma":0.00002051104,"threshold_uncertainty_score":0.46147114},"labels":[],"label_agreement":null},{"id":"W2150859319","doi":"10.1136/bmjopen-2013-004179","title":"Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil","year":2014,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Medicine; Government (linguistics); Family medicine; Psoriasis; Pharmacy; Alternative medicine; Pathology; Dermatology","score_opus":0.29980027734320003,"score_gpt":0.4275264178423343,"score_spread":0.12772614049913428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150859319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434227,0.000055563956,0.000030580257,0.0012405996,0.00022901493,0.002658788,0.000040850464,0.00000868589,0.0013936756],"genre_scores_gemma":[0.9924533,0.00002621585,0.0013686034,0.0025078629,0.00003792612,0.0009905247,0.00004958022,0.000008576237,0.0025574246],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99841505,0.00060367194,0.00042033705,0.00028434145,0.000036043806,0.00024053126],"domain_scores_gemma":[0.99910414,0.00031819748,0.00007357359,0.00043556854,0.00004713686,0.00002140833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084477355,0.00014342411,0.00034617246,0.00011118005,0.000041990716,0.000025984024,0.00068667077,0.00014446767,0.00027684768],"category_scores_gemma":[0.00079643354,0.0000857927,0.000053758475,0.0003178307,0.00003297089,0.00007768018,0.00028378773,0.000058241272,0.0005213173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030659277,0.0006488899,0.34023508,0.00002136115,0.000092364935,0.000030095274,0.003197464,0.00017819756,0.04389407,0.00088424736,0.08857205,0.51918024],"study_design_scores_gemma":[0.0049703275,0.0018929028,0.7818696,0.00025636502,0.000049693477,0.00002508248,0.00042211334,0.000009554149,0.021753484,0.00024241532,0.18806967,0.0004388057],"about_ca_topic_score_codex":0.0027124442,"about_ca_topic_score_gemma":0.0020049936,"teacher_disagreement_score":0.5187414,"about_ca_system_score_codex":0.000019813191,"about_ca_system_score_gemma":0.000030128202,"threshold_uncertainty_score":0.6700653},"labels":[],"label_agreement":null},{"id":"W2152106583","doi":"10.1111/j.1610-0387.2006.06111.x","title":"CLinical Experience Acquired with Raptiva<sup>®</sup> (CLEAR) trial in patients with moderate‐to‐severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo‐controlled trial","year":2006,"lang":"en","type":"article","venue":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Efalizumab; Medicine; Psoriasis Area and Severity Index; Placebo; Clinical trial; Open label; Plaque psoriasis; Psoriasis; Randomized controlled trial; Internal medicine; Adverse effect; Refractory (planetary science); Dermatology","score_opus":0.02832144192445271,"score_gpt":0.30369505824993187,"score_spread":0.2753736163254792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152106583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921771,0.0004971696,0.00023708817,0.00047159925,0.0010549458,0.00487278,0.00019359557,0.00010549648,0.00039021825],"genre_scores_gemma":[0.9950937,0.00020336374,0.0017103739,0.00017642092,0.00048049344,0.0009325282,0.0007593583,0.00007938488,0.00056439044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9921743,0.002304191,0.0026678636,0.00136141,0.00038390735,0.0011083134],"domain_scores_gemma":[0.996636,0.00095231336,0.0010179637,0.0008185282,0.00031415763,0.0002610365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009172754,0.0009641847,0.0021388247,0.00072766904,0.0003487849,0.0002325276,0.0008720838,0.0008852084,0.00026020728],"category_scores_gemma":[0.00022179834,0.0006463721,0.0003772968,0.00043343822,0.00027868495,0.0010496584,0.00011652634,0.0007341878,0.00012403047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9461401,0.010351667,0.03245037,0.0000025732695,0.0014135272,0.0005483859,0.0032513407,0.0016400655,0.00014423851,0.00001450863,0.0005330254,0.0035102111],"study_design_scores_gemma":[0.9727601,0.009003925,0.0123209,0.00013861989,0.0005004935,0.00014796006,0.0012319124,0.00053065666,0.0010920104,0.0000734746,0.0013533162,0.00084663735],"about_ca_topic_score_codex":0.0003664452,"about_ca_topic_score_gemma":0.00035765805,"teacher_disagreement_score":0.026620006,"about_ca_system_score_codex":0.00031142405,"about_ca_system_score_gemma":0.00044347427,"threshold_uncertainty_score":0.99959874},"labels":[],"label_agreement":null},{"id":"W2152237795","doi":"10.2174/187152808785748155","title":"Therapeutic Benefits of Regulating Inflammation in Autoimmunity","year":2008,"lang":"en","type":"review","venue":"Inflammation & Allergy - Drug Targets","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunology; Autoimmunity; Immune system; Innate lymphoid cell; Inflammation; Experimental autoimmune encephalomyelitis; Biology; Innate immune system; Acquired immune system; Cytokine; T cell; Regulatory T cell; IL-2 receptor","score_opus":0.035080977259388954,"score_gpt":0.26932948573769755,"score_spread":0.23424850847830858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152237795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009889229,0.9872389,0.000010697596,0.000042139163,0.00068937975,0.0008963421,0.000057803027,0.00012152397,0.001053977],"genre_scores_gemma":[0.003912867,0.99183524,0.000121846984,0.000005004817,0.00013597356,0.00024484238,0.00251769,0.00006872438,0.0011578226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606436,0.0010631726,0.00179444,0.00047630648,0.00012749557,0.00047423918],"domain_scores_gemma":[0.9971792,0.00046897668,0.0014954577,0.00066416804,0.00016376594,0.000028416274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004565322,0.00066386827,0.0017946231,0.00071858964,0.00023380309,0.000016646978,0.00046431946,0.00085863017,0.00031109338],"category_scores_gemma":[0.000111977584,0.00059597386,0.0005230026,0.00051711814,0.00014582029,0.0002742355,0.00012690375,0.00047876773,0.00035070733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041431715,0.00006933878,0.00003980111,0.0011510308,0.0008021032,0.0000049302594,0.0013824857,0.0002326233,0.000209727,0.0008803068,0.00010142162,0.9950848],"study_design_scores_gemma":[0.0014948288,0.00005150765,0.0016033988,0.0046904115,0.00028880584,0.00007431076,0.00006390885,0.000015379825,0.0031347035,0.00018028519,0.9877006,0.00070189114],"about_ca_topic_score_codex":0.00015280145,"about_ca_topic_score_gemma":0.00025687244,"teacher_disagreement_score":0.9943829,"about_ca_system_score_codex":0.00021230534,"about_ca_system_score_gemma":0.0002946628,"threshold_uncertainty_score":0.99964917},"labels":[],"label_agreement":null},{"id":"W2152565098","doi":"10.1517/14656566.6.13.2327","title":"Alefacept: an expert review concerning the treatment of psoriasis","year":2005,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Mediprobe Research (Canada); Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Clinical trial; Plaque psoriasis; Topical agents; Intensive care medicine; Internal medicine","score_opus":0.12976649526910297,"score_gpt":0.4289530562968752,"score_spread":0.2991865610277722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152565098","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000066348625,0.9923009,0.000006302714,0.00031784977,0.00453114,0.00210424,0.00020958025,0.00012090806,0.00040239535],"genre_scores_gemma":[0.0000024475908,0.9929606,0.00007811908,0.0013936117,0.0015513193,0.0014859316,0.0010192974,0.0001326629,0.0013760385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604714,0.0015113213,0.001016102,0.00079103734,0.00012664785,0.0005077424],"domain_scores_gemma":[0.99769014,0.00043792807,0.0007511198,0.0009889142,0.00006225198,0.000069638205],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002673881,0.0009949108,0.0024523677,0.00016842918,0.00028438395,0.00001850685,0.0006918698,0.00047543022,0.00596357],"category_scores_gemma":[0.000008101354,0.00055954047,0.001262226,0.00026600788,0.00019059738,0.000099368706,0.000021032582,0.0002393833,0.00062108523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012257765,0.0009913783,5.013393e-7,0.000444532,0.0016872206,0.0000024624117,0.001276885,2.5765206e-7,0.00026838508,0.000037274494,0.021765208,0.97340333],"study_design_scores_gemma":[0.0023165517,0.0011185912,5.253495e-7,0.0074792006,0.00023712199,0.00004238519,0.000050264433,3.8068384e-7,0.0022054166,0.0000010668316,0.98602456,0.000523942],"about_ca_topic_score_codex":0.000058834834,"about_ca_topic_score_gemma":0.000001939209,"teacher_disagreement_score":0.97287935,"about_ca_system_score_codex":0.00026109183,"about_ca_system_score_gemma":0.00018466548,"threshold_uncertainty_score":0.9996856},"labels":[],"label_agreement":null},{"id":"W2152633345","doi":"10.1016/j.ajhg.2014.07.002","title":"Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes","year":2014,"lang":"en","type":"article","venue":"The American Journal of Human Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":218,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of General Medical Sciences; National Institutes of Health; Japan Science and Technology Agency; Canadian Institutes of Health Research; Japan Science Society; Krembil Foundation; Arthritis Society; Japan Society for the Promotion of Science; Doris Duke Charitable Foundation; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Helene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust; Arthritis Foundation","keywords":"Psoriasis; Major histocompatibility complex; Histocompatibility; Medicine; Dermatology; Computational biology; Immunology; Human leukocyte antigen; Biology; Antigen","score_opus":0.05990541690726462,"score_gpt":0.32074603278494895,"score_spread":0.2608406158776843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152633345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773115,0.0013622507,0.000057877318,0.00039552784,0.00020204068,0.000104614235,0.000013088121,0.000006651895,0.00012677666],"genre_scores_gemma":[0.99919367,0.00011610506,0.00035232346,0.000104839535,0.00012241912,0.0000022752652,0.000009457798,0.000009023079,0.000089882684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813235,0.0008904375,0.00062024663,0.00012808347,0.000046956822,0.00018194002],"domain_scores_gemma":[0.99846303,0.00051358546,0.00071415625,0.00018067923,0.00009976893,0.000028769447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011780186,0.00011662936,0.00047554832,0.0000958877,0.00017367883,0.000010372941,0.00022744946,0.000049843635,0.000060538932],"category_scores_gemma":[0.00013922175,0.000082636194,0.00011091809,0.00012891971,0.00028295565,0.000023123896,0.000050073686,0.00021935548,0.000016970338],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022480162,0.00038071643,0.78578544,0.0000084931635,0.00052892644,0.000004372688,0.0015785919,0.000026038928,0.03057779,0.00038075456,0.00095087657,0.17955321],"study_design_scores_gemma":[0.0013240671,0.00079136767,0.994282,0.00001332042,0.00013591265,0.000021948923,0.00018139284,0.000020465342,0.0006676677,0.00056345423,0.0019016224,0.00009675311],"about_ca_topic_score_codex":0.000029865661,"about_ca_topic_score_gemma":0.00015147089,"teacher_disagreement_score":0.2084966,"about_ca_system_score_codex":0.00004347904,"about_ca_system_score_gemma":0.000032499232,"threshold_uncertainty_score":0.3369806},"labels":[],"label_agreement":null},{"id":"W2152976783","doi":"10.1056/nejmoa030002","title":"A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":580,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Immunology; Pharmacology; Plaque psoriasis; Pathology","score_opus":0.020678053063598698,"score_gpt":0.24537759749365937,"score_spread":0.22469954443006068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152976783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245596,0.034509346,0.022932354,0.0028746675,0.010470896,0.00056989584,0.0000657514,0.00004680349,0.003970714],"genre_scores_gemma":[0.9919273,0.0004681988,0.002480325,0.0002279983,0.001228394,0.0000058481296,0.000038301998,0.00002556963,0.0035980358],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998798,0.00013986301,0.00052555866,0.00016194809,0.000078527744,0.00029610426],"domain_scores_gemma":[0.9988121,0.00039645072,0.00035751605,0.00016663202,0.0001698694,0.000097432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000719072,0.00021159618,0.0005443881,0.00019135146,0.00010363345,0.0000051442685,0.00016134782,0.00019052812,0.00054192863],"category_scores_gemma":[0.00037195487,0.00013917458,0.0001532976,0.00013202125,0.000073159594,0.00006858231,0.000008023248,0.00019702544,0.000019985058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003671833,0.0005233074,0.0020545428,0.000054795288,0.0011759325,0.000059864116,0.0020242874,0.000061332874,0.78192157,0.0023347847,0.06549786,0.14061987],"study_design_scores_gemma":[0.19696984,0.0028045787,0.0012584524,0.00014030017,0.0008614252,0.0018146723,0.00028442152,0.0000047555022,0.14750351,0.0013545891,0.64673907,0.00026439194],"about_ca_topic_score_codex":0.00004417985,"about_ca_topic_score_gemma":0.000017374672,"teacher_disagreement_score":0.6344181,"about_ca_system_score_codex":0.000043043994,"about_ca_system_score_gemma":0.00017401965,"threshold_uncertainty_score":0.59337384},"labels":[],"label_agreement":null},{"id":"W2154234582","doi":"10.1046/j.1365-2133.2002.04967.x","title":"Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial","year":2002,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Calcipotriol; Betamethasone dipropionate; Medicine; Psoriasis; Psoriasis Area and Severity Index; Betamethasone; Randomized controlled trial; Adverse effect; Dermatology; Corticosteroid; Surgery; Internal medicine","score_opus":0.06992348893430708,"score_gpt":0.32695770503985633,"score_spread":0.2570342161055492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154234582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971141,0.02484285,0.00013771713,0.00077158085,0.00045557736,0.0025449882,0.000040943127,0.0000070738834,0.000058283353],"genre_scores_gemma":[0.98726535,0.012123496,0.0002991915,0.000055201872,0.00006335717,0.000068872745,0.000018704799,0.000015614865,0.000090223926],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99392605,0.0025668151,0.0027206263,0.00031685602,0.00014465516,0.0003250168],"domain_scores_gemma":[0.9926531,0.00515414,0.0016066424,0.0002395317,0.00025568297,0.000090913905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012278423,0.0002854966,0.003087417,0.00034721315,0.00010683307,0.000019357778,0.0002974582,0.00041129568,0.00007687531],"category_scores_gemma":[0.0008888481,0.00020197245,0.00043700275,0.00035951732,0.000487758,0.00012274948,0.000048349324,0.00028654886,0.0000032653832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9155763,0.0032947282,0.0016667705,0.000039571245,0.0019499653,0.00021295607,0.003148668,0.000007155491,0.0009881905,0.00009250869,0.00021656966,0.07280664],"study_design_scores_gemma":[0.9818488,0.0036618242,0.0051837172,0.00024757558,0.0017512543,0.0032003256,0.0004024373,0.00004166258,0.0026499154,0.000052177744,0.0007826557,0.00017767432],"about_ca_topic_score_codex":0.00059333147,"about_ca_topic_score_gemma":0.00024297075,"teacher_disagreement_score":0.07262897,"about_ca_system_score_codex":0.00003908996,"about_ca_system_score_gemma":0.0001365302,"threshold_uncertainty_score":0.8236198},"labels":[],"label_agreement":null},{"id":"W2154831158","doi":"10.2310/7750.2010.09066","title":"Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population","year":2010,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Epidemiology; Population; Overweight; Dyslipidemia; Dermatology; Body surface area; Plaque psoriasis; Obesity; Internal medicine; Environmental health","score_opus":0.0321533463166618,"score_gpt":0.27505896894099624,"score_spread":0.24290562262433443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154831158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434847,0.001955763,0.00001080614,0.0018698222,0.0015702132,0.00008270489,0.000016036209,0.000003882876,0.00014232862],"genre_scores_gemma":[0.99875265,0.00046480834,0.00009273176,0.00036481285,0.00014145224,0.0000018422766,0.000035695215,0.000009710375,0.00013632131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982476,0.00040740008,0.00084157207,0.00013521977,0.0000418647,0.0003263419],"domain_scores_gemma":[0.9968942,0.002355289,0.00035559642,0.0001252867,0.0001279632,0.00014168161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019105643,0.0001432453,0.00089835684,0.00073563925,0.00005618841,0.0000011298557,0.000080067024,0.0002784945,0.00022273549],"category_scores_gemma":[0.0019465885,0.00010424747,0.00009386714,0.00018262863,0.00008351723,0.0000516061,0.000009072546,0.00029229178,0.0000057514326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009458196,0.000047333127,0.9677897,0.000019744113,0.00015805807,0.00031165252,0.0004647391,0.00003524305,0.0056328126,0.00014036456,0.0028867975,0.021567753],"study_design_scores_gemma":[0.0021090498,0.0006043675,0.9759544,0.00032135638,0.00020317496,0.010833879,0.0002951338,0.000028138056,0.0012148332,0.0011881536,0.006950352,0.00029712182],"about_ca_topic_score_codex":0.079258814,"about_ca_topic_score_gemma":0.16198698,"teacher_disagreement_score":0.08272817,"about_ca_system_score_codex":0.000039352795,"about_ca_system_score_gemma":0.00024012744,"threshold_uncertainty_score":0.9268725},"labels":[],"label_agreement":null},{"id":"W2154955762","doi":"10.1007/s10227-006-0103-1","title":"Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches","year":2005,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Guenther Dermatology Research Centre; University of Calgary; University of Manitoba; Sunnybrook Health Science Centre; Probity Medical Research; University of British Columbia; University Health Network; Dalhousie University; University of Toronto; Université Laval; Lynde Centre for Dermatology; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Psoriasis; Etanercept; Infliximab; Efalizumab; Intensive care medicine; Biologic Agents; Clinical trial; Position paper; Disease; Ustekinumab; Plaque psoriasis; Dermatology; Pathology; Immunology","score_opus":0.14258398993935872,"score_gpt":0.3278647980418575,"score_spread":0.18528080810249875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154955762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001273614,0.9956126,0.00019939766,0.0008930078,0.0009422143,0.00078337506,0.0001150173,0.000012255048,0.00016849136],"genre_scores_gemma":[0.0011288457,0.99348754,0.0043207454,0.00014460915,0.00023366182,0.000092576935,0.0003871613,0.00002862974,0.0001762148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695307,0.00048191362,0.0019293965,0.00028433464,0.000089212466,0.0002620964],"domain_scores_gemma":[0.99566,0.0019587819,0.0019637183,0.00019113629,0.00014674413,0.00007958929],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010101973,0.00040821737,0.0027593721,0.0005859033,0.00014958413,0.00001099962,0.00017432273,0.0003945667,0.00008049699],"category_scores_gemma":[0.00018151425,0.0002515843,0.0004964533,0.00024012625,0.00009986746,0.000054974706,0.00007062116,0.00024341454,0.0000050708672],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035014385,0.00014277168,0.000009583419,0.0021795419,0.0023317246,0.000072419214,0.00054126105,0.0000045140578,0.000006318959,0.00011370976,0.010233882,0.98401415],"study_design_scores_gemma":[0.00082248764,0.0007425776,0.0000013664245,0.012345958,0.0030236652,0.0022847303,0.0008899171,7.407772e-7,0.000024279418,0.00031188034,0.9792684,0.00028401465],"about_ca_topic_score_codex":0.0000066758807,"about_ca_topic_score_gemma":0.0000030007825,"teacher_disagreement_score":0.98373014,"about_ca_system_score_codex":0.000069228845,"about_ca_system_score_gemma":0.00014461947,"threshold_uncertainty_score":0.9999936},"labels":[],"label_agreement":null},{"id":"W2156148414","doi":"10.1016/j.jaad.2013.12.018","title":"Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","year":2014,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":511,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Dermatology; Multinational corporation; Family medicine","score_opus":0.017635775911214853,"score_gpt":0.2849447469926242,"score_spread":0.26730897108140933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156148414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921955,0.0017988817,0.000071930386,0.005231989,0.00023168224,0.00023460771,0.00018351362,0.0000025662093,0.0000493493],"genre_scores_gemma":[0.9980627,0.000716888,0.0009629688,0.00018922224,0.00002590754,0.000009417242,0.000021138609,0.000007954996,0.000003816457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959321,0.0024934649,0.0010509073,0.00017191531,0.00017884494,0.00017278605],"domain_scores_gemma":[0.9945928,0.0026632776,0.0024067957,0.00021490647,0.00010716607,0.000015073993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009629027,0.00016225434,0.0006476154,0.00014018199,0.00009536313,0.000005078131,0.00046841128,0.00009986922,0.000011359216],"category_scores_gemma":[0.0002816833,0.00008824892,0.00018015894,0.0003093667,0.0004660131,0.000053894408,0.00007190568,0.00028676385,6.916061e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002358724,0.0011069358,0.87504363,0.0000610742,0.00259293,0.0000067569376,0.0051902905,0.00059588504,0.0019333753,0.004703584,0.00095961144,0.10544719],"study_design_scores_gemma":[0.0033895206,0.0001844545,0.9906967,0.00013534918,0.00023896551,0.000060804985,0.0025716524,0.000058837577,0.0018443707,0.000515657,0.0002241667,0.00007951661],"about_ca_topic_score_codex":0.00059429544,"about_ca_topic_score_gemma":0.00006467365,"teacher_disagreement_score":0.11565306,"about_ca_system_score_codex":0.00003763109,"about_ca_system_score_gemma":0.00005299054,"threshold_uncertainty_score":0.35986865},"labels":[],"label_agreement":null},{"id":"W2156475253","doi":"10.1111/bjd.13004","title":"Long‐term efficacy and safety of infliximab maintenance therapy in patients with plaque‐type psoriasis in real‐world practice","year":2014,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Schering-Plough","keywords":"Art history; Art; Medicine; Humanities","score_opus":0.008659925112616014,"score_gpt":0.23623426742092551,"score_spread":0.2275743423083095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156475253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537635,0.0033861948,0.000020998421,0.00027200062,0.0003001161,0.00020003671,0.0000100128755,0.0000062551203,0.0004280566],"genre_scores_gemma":[0.9938764,0.0056938026,0.00022651331,0.00010850556,0.000015647329,0.0000033726403,0.000020528274,0.000014994982,0.00004021271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817026,0.0006247696,0.0006789569,0.00017961166,0.000056789835,0.00028964045],"domain_scores_gemma":[0.99850136,0.0005292816,0.00058228,0.00013228784,0.00022417823,0.00003062557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028057507,0.00015567256,0.00062588364,0.00027354877,0.00004770692,0.00001108206,0.00016536798,0.00018042827,0.00003591983],"category_scores_gemma":[0.00022332596,0.00014111893,0.000045603836,0.0002484486,0.00017523335,0.00022053866,0.000031148156,0.00030201004,0.0000050107415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010316207,0.0008156755,0.8570729,0.000019668045,0.00026168156,0.0004494142,0.00029729493,0.0000043863856,0.00023710694,0.00012406525,0.00020702634,0.13019457],"study_design_scores_gemma":[0.025366701,0.00064945023,0.9658239,0.00032581066,0.000059742328,0.0045893155,0.000036490666,3.585367e-7,0.001197785,0.000029264565,0.0017844323,0.00013676363],"about_ca_topic_score_codex":0.00018578685,"about_ca_topic_score_gemma":0.00078907947,"teacher_disagreement_score":0.13005781,"about_ca_system_score_codex":0.000039388553,"about_ca_system_score_gemma":0.00008175981,"threshold_uncertainty_score":0.5754663},"labels":[],"label_agreement":null},{"id":"W2156822431","doi":"10.1016/j.jval.2014.03.1654","title":"Characteristics Of Chronic Plaque Psoriasis In Canada: A Retrospective Database Study","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Novartis (Canada); Lawson Health Research Institute","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Infliximab; Acitretin; Ustekinumab; Etanercept; Dermatology; Palmoplantar pustulosis; Retrospective cohort study; Plaque psoriasis; Methotrexate; Internal medicine; Etretinate; Database; Disease; Rheumatoid arthritis","score_opus":0.0229398275402995,"score_gpt":0.2518703270930761,"score_spread":0.2289304995527766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156822431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711156,0.0010523633,0.000013128337,0.00015283663,0.0008348983,0.0005074746,0.00024500757,0.000010677426,0.00007205464],"genre_scores_gemma":[0.99931175,0.00034745762,0.000029301784,0.000051008,0.000047995676,0.00004177752,0.00011107993,0.000012544168,0.00004706526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979457,0.0007724517,0.00055112806,0.0003005555,0.000053214753,0.00037692726],"domain_scores_gemma":[0.99915224,0.00022476584,0.00022329003,0.00034197795,0.000027837767,0.000029890787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007436371,0.0001515627,0.0005268669,0.00015556088,0.00005319954,0.0000022065965,0.00015175586,0.00007392299,0.00006931476],"category_scores_gemma":[0.00012866364,0.000143676,0.000027627962,0.00025209293,0.00003122022,0.000037413345,0.000045072793,0.00020459983,0.000017106986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020603141,0.00071647164,0.9821575,0.00011176844,0.000076061086,0.000025320602,0.0011431669,0.000053091797,0.0006704252,0.0006167773,0.00020654836,0.014016823],"study_design_scores_gemma":[0.0029937376,0.00074606785,0.99406284,0.00012674341,0.000018950355,0.000007491015,0.00033733156,0.000104465675,0.00080295297,0.00003890521,0.00062904274,0.00013146653],"about_ca_topic_score_codex":0.93626946,"about_ca_topic_score_gemma":0.88731444,"teacher_disagreement_score":0.048955027,"about_ca_system_score_codex":0.0015264577,"about_ca_system_score_gemma":0.0017669074,"threshold_uncertainty_score":0.58589375},"labels":[],"label_agreement":null},{"id":"W2157527537","doi":"10.1177/1203475415597094","title":"A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris","year":2015,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lakeridge Health; Guenther Dermatology Research Centre","funders":"LEO Pharma","keywords":"Medicine; Psoriasis; Betamethasone dipropionate; Calcipotriol; Urinary calcium; Internal medicine; Calcium metabolism; Vitamin D and neurology; Calcium; Endocrinology; Gastroenterology; Dermatology","score_opus":0.04228327600292078,"score_gpt":0.2684339423861145,"score_spread":0.22615066638319373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157527537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942556,0.0048847,0.000054011653,0.00024348756,0.00030800153,0.00017700363,0.00003993269,0.0000045793304,0.000032692493],"genre_scores_gemma":[0.99892646,0.0007349282,0.000086527645,0.00009201413,0.00007295046,0.000002188059,0.000029586265,0.000014847847,0.000040469924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987123,0.00012931622,0.0005935716,0.00018347643,0.00014190454,0.0002394358],"domain_scores_gemma":[0.9977009,0.0011019185,0.00051661127,0.00012185369,0.00044086858,0.000117811556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005007242,0.0002366042,0.0009463852,0.00043818617,0.00006524949,0.000009444732,0.000042255488,0.00018443428,0.000024890622],"category_scores_gemma":[0.00057953276,0.00014033537,0.0000796709,0.00016935883,0.0002081548,0.00011928623,0.000019819227,0.00019323148,0.0000013551387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025352204,0.0009715926,0.7883148,0.00011737526,0.001697483,0.0003614926,0.005652469,0.00002446103,0.014332728,0.000012303498,0.0043107043,0.15885237],"study_design_scores_gemma":[0.037732422,0.026262477,0.9073364,0.002213805,0.0022156958,0.0065787784,0.0024813167,0.00004736722,0.012012882,0.00013888879,0.0020408682,0.0009390609],"about_ca_topic_score_codex":0.0003165717,"about_ca_topic_score_gemma":0.000023792407,"teacher_disagreement_score":0.15791331,"about_ca_system_score_codex":0.00005335661,"about_ca_system_score_gemma":0.00012384496,"threshold_uncertainty_score":0.57227105},"labels":[],"label_agreement":null},{"id":"W2158223524","doi":"10.3899/jrheum.140177","title":"The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A Novel Index to Measure All Non-plaque Psoriasis Subsets","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Psoriatic arthritis; Psoriasis Area and Severity Index; Nail disease; Nail (fastener); Plaque psoriasis; Scalp; Severity of illness; Internal medicine","score_opus":0.014818815241077457,"score_gpt":0.22796641607428825,"score_spread":0.2131476008332108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158223524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888352,0.0013055858,0.0023123904,0.0027406386,0.0040059485,0.00037779287,0.000044586082,0.000041366835,0.0003364679],"genre_scores_gemma":[0.99726564,0.0014401433,0.00015616477,0.00064560707,0.00008640997,0.000018575967,0.00002230507,0.000048526865,0.0003166244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961722,0.0012997914,0.001115629,0.00032853248,0.00021306345,0.00087081536],"domain_scores_gemma":[0.9959492,0.0018570685,0.0009450148,0.0007408565,0.00034950994,0.00015835624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023693703,0.00050853036,0.0010573633,0.0003120862,0.00078318024,0.000051812105,0.001355244,0.0005759707,0.000108927066],"category_scores_gemma":[0.00029993907,0.00029060175,0.00036067519,0.00035149627,0.00044322578,0.00015105044,0.00020953099,0.0008204487,0.0005445096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023489509,0.0012058296,0.6930986,0.0001056098,0.010207258,0.00006978305,0.010365732,0.00067179726,0.07917973,0.0015110914,0.098364405,0.081730664],"study_design_scores_gemma":[0.05296683,0.0036605136,0.42448914,0.0013065194,0.0048511564,0.07835368,0.0045097503,0.0006117895,0.046454184,0.0023721245,0.37734976,0.003074548],"about_ca_topic_score_codex":0.0009376295,"about_ca_topic_score_gemma":0.0018275051,"teacher_disagreement_score":0.27898538,"about_ca_system_score_codex":0.000107282234,"about_ca_system_score_gemma":0.00018899301,"threshold_uncertainty_score":0.99995464},"labels":[],"label_agreement":null},{"id":"W2158357844","doi":"10.1155/2011/913802","title":"Platelet-Activating Factor Induces Th17 Cell Differentiation","year":2011,"lang":"en","type":"article","venue":"Mediators of Inflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Platelet-activating factor; RAR-related orphan receptor gamma; Mediator; Cell biology; Interleukin 17; Immunology; Inflammation; Biology; Monocyte; Chemistry; Immune system","score_opus":0.0217887871191323,"score_gpt":0.2120984524044585,"score_spread":0.1903096652853262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158357844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735665,0.00023280112,0.0000983902,0.000009526681,0.000637761,0.0001586588,0.000018102623,0.00005180282,0.0014362914],"genre_scores_gemma":[0.9994369,0.000042480377,0.00015087183,0.0000033880553,0.000057016365,0.00002085873,0.00016768719,0.0000103198445,0.00011046809],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992882,0.000088171924,0.00029333812,0.00013637402,0.000044106506,0.00014982958],"domain_scores_gemma":[0.9993892,0.00008174476,0.0003226833,0.00013454689,0.00005688695,0.0000149513935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086664564,0.000126749,0.00017375634,0.00012421254,0.00007487621,0.00000451513,0.0000982955,0.00019154362,0.00060244725],"category_scores_gemma":[0.000063148334,0.00010623753,0.00005884154,0.00008553958,0.000036067235,0.00019119322,0.000022118638,0.00007741277,0.00014119361],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078951896,0.000066483815,0.016243793,0.000029625518,0.00008533172,7.596538e-7,0.0049360674,5.4614355e-7,0.89679474,0.000117654265,0.000032275773,0.08161375],"study_design_scores_gemma":[0.0006705611,0.00005906519,0.15565574,0.000011734644,0.00001365335,7.5927545e-7,0.00020950582,0.0000019667104,0.8430481,0.00007788808,0.0001642206,0.000086778135],"about_ca_topic_score_codex":0.000046905727,"about_ca_topic_score_gemma":0.000008455249,"teacher_disagreement_score":0.13941196,"about_ca_system_score_codex":0.000023341798,"about_ca_system_score_gemma":0.000023579352,"threshold_uncertainty_score":0.65963745},"labels":[],"label_agreement":null},{"id":"W2158451924","doi":"10.1136/ard.2004.030775","title":"Genetic epidemiology of psoriasis and psoriatic arthritis","year":2005,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":236,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Proband; Epidemiology; Human leukocyte antigen; Population; Immunology; Dermatology; Genetics; Antigen; Pathology; Biology; Mutation; Environmental health","score_opus":0.08897557196478321,"score_gpt":0.3433414651356648,"score_spread":0.2543658931708816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158451924","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026225355,0.99510187,0.0000040773884,0.000087575354,0.00068354944,0.0006498073,0.0007684965,0.00002180935,0.000060278824],"genre_scores_gemma":[0.0030812775,0.9961538,0.00010770598,0.00004950818,0.0000525568,0.000118752694,0.00009358263,0.000036625446,0.00030619706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961891,0.0015108002,0.0014654624,0.00037855137,0.00005875889,0.00039733236],"domain_scores_gemma":[0.9953452,0.0022365046,0.0014739814,0.0008134845,0.000076385484,0.000054490876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000383035,0.0004741869,0.0030879304,0.00017415339,0.00010647714,0.0000035720846,0.0005382659,0.00039442512,0.00030987224],"category_scores_gemma":[0.0011884185,0.00029528746,0.0011093477,0.00021167824,0.0004949168,0.000044030545,0.00019827326,0.0001399922,0.00008462797],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019515865,0.00019149361,0.00024016491,0.005339904,0.002026169,8.264553e-7,0.00006131543,0.000001115456,1.7170447e-7,0.00031077102,0.0017029875,0.99010557],"study_design_scores_gemma":[0.0024837472,0.0005356786,0.026702696,0.06609456,0.016523661,0.00025702646,0.00010971528,0.0000030104159,0.000045271725,0.0062150746,0.8797563,0.0012732722],"about_ca_topic_score_codex":0.000059911457,"about_ca_topic_score_gemma":0.000009416718,"teacher_disagreement_score":0.9888323,"about_ca_system_score_codex":0.000012057827,"about_ca_system_score_gemma":0.00018644975,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W2158567115","doi":"10.1164/rccm.201410-1782oc","title":"Innate Lymphoid Cells Are the Predominant Source of IL-17A during the Early Pathogenesis of Acute Respiratory Distress Syndrome","year":2015,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Queen's University; Public Health Agency; Queen's University Belfast","keywords":"Innate lymphoid cell; ARDS; Immunology; Medicine; Pathogenesis; Lung; Cytokine; Innate immune system; Intensive care; Biology; Immune system; Internal medicine","score_opus":0.014662645013961053,"score_gpt":0.2546303901979746,"score_spread":0.23996774518401356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158567115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97536874,0.023508273,0.000040245017,0.000347561,0.00040163798,0.00012943087,0.00015557946,0.000007403285,0.000041137402],"genre_scores_gemma":[0.9993788,0.00016159151,0.000015124679,0.00026018693,0.0001153267,0.000008739569,0.0000021470455,0.000019383306,0.000038713533],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976331,0.000890641,0.0007550249,0.00020413655,0.00021462882,0.00030245815],"domain_scores_gemma":[0.9976402,0.00062410213,0.0006536806,0.0003691072,0.0005878096,0.00012512098],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0008135834,0.00023935395,0.00080176967,0.0001387493,0.00018284518,0.000007699238,0.00039275008,0.00010259996,0.000028597693],"category_scores_gemma":[0.00032594672,0.00012191047,0.00017217148,0.00029037846,0.003007131,0.00007712023,0.00009371739,0.00025853855,0.0000033431709],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004934967,0.00034744904,0.20916568,0.00037816633,0.001838289,0.0010043138,0.0130969,0.000014194022,0.67337286,0.00019586264,0.00046171894,0.09518962],"study_design_scores_gemma":[0.012469669,0.025772145,0.5065185,0.0015799854,0.005528689,0.0032773896,0.10220671,0.0000010335782,0.32447627,0.00010263596,0.017323824,0.0007431303],"about_ca_topic_score_codex":0.0000564277,"about_ca_topic_score_gemma":0.000005032929,"teacher_disagreement_score":0.34889656,"about_ca_system_score_codex":0.00004719918,"about_ca_system_score_gemma":0.00013171049,"threshold_uncertainty_score":0.9997061},"labels":[],"label_agreement":null},{"id":"W2159011171","doi":"10.1016/j.jaad.2005.10.028","title":"Long-term management of plaque psoriasis with continuous efalizumab therapy","year":2006,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Term (time)","score_opus":0.026313459963280234,"score_gpt":0.3065750847279561,"score_spread":0.28026162476467587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159011171","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02743304,0.970924,0.000025046345,0.0003320173,0.0004148561,0.0005380203,0.000078092555,0.000011265648,0.00024362955],"genre_scores_gemma":[0.013055483,0.986116,0.00021633825,0.00006983742,0.00006057335,0.000022725779,0.000020183,0.00005293902,0.00038591964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963947,0.001073828,0.0016888907,0.00027971578,0.00014144114,0.00042143103],"domain_scores_gemma":[0.9921462,0.0003494221,0.0070451177,0.00034554818,0.000079277175,0.00003444332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019225923,0.0005514871,0.0041514705,0.00040745962,0.00008164248,0.0000058235055,0.0012694797,0.00046237343,0.000053507832],"category_scores_gemma":[0.000008105716,0.00030002196,0.0011738893,0.0005021018,0.0010960553,0.000059118614,0.00013569923,0.0007283868,0.000018879979],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093727134,0.0004225313,0.0029594616,0.0025254963,0.011253941,0.00018483943,0.000056853987,0.0000013577312,0.00007925404,0.00022451261,0.0032664621,0.978088],"study_design_scores_gemma":[0.0057719667,0.00086286897,0.009880818,0.008703928,0.010154524,0.02828527,0.000095052914,3.733152e-8,0.0031118025,0.00006107215,0.93243396,0.0006386878],"about_ca_topic_score_codex":0.00001980813,"about_ca_topic_score_gemma":0.0000017481567,"teacher_disagreement_score":0.97744936,"about_ca_system_score_codex":0.00007337027,"about_ca_system_score_gemma":0.00017986611,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W2159244051","doi":"10.1517/14740338.2014.942219","title":"Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil","year":2014,"lang":"en","type":"article","venue":"Expert Opinion on Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Medicine; Psoriasis; Adalimumab; Etanercept; Adverse effect; Infliximab; Discontinuation; Odds ratio; Internal medicine; Efalizumab; Intensive care medicine; Dermatology; Rheumatoid arthritis; Disease","score_opus":0.020439595718758717,"score_gpt":0.2603271935728105,"score_spread":0.23988759785405175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159244051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99730307,0.00044675937,0.000027053671,0.00024328334,0.0008670788,0.0005234938,0.00011622609,0.000019381088,0.00045362677],"genre_scores_gemma":[0.99921304,0.00029622283,0.0000944017,0.00006737846,0.000014040602,0.00006804413,0.00015428953,0.000007827318,0.00008477234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987772,0.00036821465,0.00040269393,0.0002498301,0.000045116813,0.00015695827],"domain_scores_gemma":[0.99898684,0.00032845815,0.00033819693,0.00027101606,0.000059667036,0.000015833772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029269376,0.00013634267,0.00028189013,0.000050887422,0.000107455686,0.0000010610174,0.00007196464,0.00016082879,0.00003637892],"category_scores_gemma":[0.00034200982,0.00008314828,0.00009246547,0.000115689865,0.00013251898,0.000040831994,0.000036873713,0.00007995962,9.83745e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007658828,0.0062008766,0.73490655,0.00009403616,0.001913987,0.000008233149,0.022310441,0.00016160712,0.0860205,0.0038178733,0.0075823376,0.12932475],"study_design_scores_gemma":[0.003116189,0.0005847232,0.941997,0.00022729964,0.000017575152,0.000012023841,0.0005257915,0.00000902007,0.036624916,0.00023771323,0.016466696,0.00018107356],"about_ca_topic_score_codex":0.00018860542,"about_ca_topic_score_gemma":0.0000583558,"teacher_disagreement_score":0.20709045,"about_ca_system_score_codex":0.00004571569,"about_ca_system_score_gemma":0.000032116073,"threshold_uncertainty_score":0.33906886},"labels":[],"label_agreement":null},{"id":"W2159969811","doi":"10.3899/jrheum.131292","title":"Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lupus nephritis; Urinary system; Immunology; Internal medicine; Proteinuria; Renal function; Nephritis; Kidney; Gastroenterology; Kidney disease; Disease","score_opus":0.013407876243313162,"score_gpt":0.22067678135853214,"score_spread":0.20726890511521898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159969811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970606,0.00067982404,0.0005276102,0.00034928488,0.00086980924,0.00018300337,0.0000135582495,0.000026524493,0.0002898181],"genre_scores_gemma":[0.9988894,0.0000999213,0.00014492404,0.000029830833,0.000010089261,0.0000082697825,0.0000057896304,0.000021141099,0.00079062197],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9978165,0.0012554538,0.00038406855,0.00013913914,0.000055911045,0.00034893124],"domain_scores_gemma":[0.9984356,0.0005495695,0.000627721,0.0002585423,0.00008883391,0.000039707105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084613555,0.00022182708,0.0005649981,0.00017775394,0.0002432123,0.000011429861,0.00037191034,0.00022868894,0.00035076652],"category_scores_gemma":[0.00011410404,0.00013045664,0.00011465997,0.00013343019,0.000275772,0.00014287843,0.000075621865,0.00047051228,0.00015422965],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017845906,0.0012056683,0.28590888,0.0001360974,0.0041108485,0.00022720204,0.0028304667,0.000025670075,0.58851975,0.002304688,0.0038539905,0.09303081],"study_design_scores_gemma":[0.041988965,0.017759923,0.14559218,0.002644297,0.002351054,0.48076847,0.0017197779,0.000070855516,0.27794576,0.0024236564,0.024929456,0.0018055949],"about_ca_topic_score_codex":0.00022272136,"about_ca_topic_score_gemma":0.0000643598,"teacher_disagreement_score":0.4805413,"about_ca_system_score_codex":0.000052218067,"about_ca_system_score_gemma":0.00009426557,"threshold_uncertainty_score":0.5319867},"labels":[],"label_agreement":null},{"id":"W2160316669","doi":"10.1016/j.amjmed.2007.06.020","title":"Smoking and the Risk of Psoriasis in Women: Nurses’ Health Study II","year":2007,"lang":"en","type":"article","venue":"The American Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":184,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; Vancouver General Hospital","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; University of Utah","keywords":"Medicine; Psoriasis; Prospective cohort study; Relative risk; Confidence interval; Incidence (geometry); Internal medicine; Risk factor; Dermatology","score_opus":0.011311036401557801,"score_gpt":0.2842227243656863,"score_spread":0.2729116879641285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160316669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861212,0.009230445,0.000027666594,0.0038488796,0.000505674,0.00018004178,0.000002351477,0.000003141847,0.000080649275],"genre_scores_gemma":[0.9971484,0.0021508525,0.000016199094,0.00048365176,0.00012690316,0.0000027208814,4.2771015e-7,0.0000066064085,0.00006424857],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980231,0.00097338017,0.00059066125,0.00008440783,0.00008722084,0.0002412095],"domain_scores_gemma":[0.99764144,0.0009380916,0.0011488928,0.00018681813,0.00005301249,0.000031734235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006642374,0.000112606365,0.0006884779,0.00016705769,0.00016486911,0.00000141539,0.00021751472,0.000021599904,0.00003886501],"category_scores_gemma":[0.0002278188,0.000047286998,0.000052256266,0.00032658823,0.0011771582,0.000023029323,0.00003524977,0.00029501368,8.151115e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008474393,0.00037605313,0.10319033,0.0000048487896,0.0012625356,0.00001988497,0.0916276,0.0000049767814,0.00082064356,0.00008207381,0.00044989484,0.79368675],"study_design_scores_gemma":[0.022558546,0.011564989,0.7969445,0.00015154474,0.0005078027,0.00034613465,0.16525844,6.447795e-7,0.00033990396,0.00040357566,0.0018344586,0.00008946198],"about_ca_topic_score_codex":0.0007744194,"about_ca_topic_score_gemma":0.0000625954,"teacher_disagreement_score":0.7935973,"about_ca_system_score_codex":0.0000558029,"about_ca_system_score_gemma":0.00004963332,"threshold_uncertainty_score":0.43372884},"labels":[],"label_agreement":null},{"id":"W2160339193","doi":"10.3899/jrheum.101120","title":"Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting: Table 1.","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Multidisciplinary approach","score_opus":0.022192331321040155,"score_gpt":0.24320553896830416,"score_spread":0.221013207647264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160339193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98882455,0.007952325,0.000026666658,0.0020837188,0.0004787447,0.00019946649,0.000049261245,0.000006432296,0.00037882023],"genre_scores_gemma":[0.9977869,0.0017113424,0.00024100207,0.00012665636,0.000007022166,0.000004883156,0.0000016401231,0.000015623444,0.00010495949],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99687517,0.0014540949,0.0010693388,0.00013115871,0.000092191614,0.00037806443],"domain_scores_gemma":[0.9961349,0.0010251725,0.0022929586,0.00031377914,0.0002020979,0.000031109208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095164834,0.0002093367,0.0009539552,0.00016593045,0.00015946236,0.0000014216341,0.0010964294,0.00016980969,0.000055778753],"category_scores_gemma":[0.00027593403,0.00010039371,0.00025507432,0.00039550077,0.00101791,0.00005256793,0.00024853807,0.00034099742,0.000009187765],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043364633,0.0006233459,0.81047165,0.00013781914,0.0031774123,0.0000068761055,0.018624779,0.00006888101,0.12766406,0.0024217989,0.024024924,0.008441956],"study_design_scores_gemma":[0.0029699302,0.0011712464,0.117027245,0.0006492971,0.0014313775,0.009806348,0.0126902405,0.000004994413,0.8403127,0.00094907836,0.01265247,0.00033505436],"about_ca_topic_score_codex":0.0008574193,"about_ca_topic_score_gemma":0.00013461662,"teacher_disagreement_score":0.71264863,"about_ca_system_score_codex":0.000016164644,"about_ca_system_score_gemma":0.00011383701,"threshold_uncertainty_score":0.40939364},"labels":[],"label_agreement":null},{"id":"W2160630176","doi":"10.1001/archdermatol.2011.1410","title":"Consensus Guidelines for the Management of Plaque Psoriasis","year":2012,"lang":"en","type":"article","venue":"Archives of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ustekinumab; Psoriasis; Plaque psoriasis; Dermatology; Tumor necrosis factor alpha; Internal medicine; Infliximab","score_opus":0.04781214168223819,"score_gpt":0.2978862464901789,"score_spread":0.25007410480794073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160630176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91002417,0.055732425,0.0055844863,0.010161929,0.003551146,0.0016019965,0.00039472512,0.000080659906,0.012868448],"genre_scores_gemma":[0.9925704,0.0008778254,0.0057136156,0.00008847628,0.00002930407,0.00008235061,0.00004647261,0.000010751179,0.0005807777],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907106,0.00011243494,0.00038808936,0.00011800031,0.000019015648,0.00029137262],"domain_scores_gemma":[0.9984008,0.0010797644,0.00018347804,0.00027721046,0.000043912558,0.0000148096715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007872338,0.00012589658,0.0003038658,0.000074404474,0.000087354834,9.909826e-7,0.00021515676,0.00008369787,0.000052200834],"category_scores_gemma":[0.00003404676,0.00008336503,0.00016130423,0.00005091519,0.0003284065,0.000016814342,0.00007506095,0.000042573618,0.000027216247],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004033487,0.00126689,0.07148225,0.0011456659,0.015227558,0.00002449539,0.0042986455,0.00003853677,0.11359337,0.26400098,0.05459728,0.47029084],"study_design_scores_gemma":[0.008675013,0.0001996984,0.057085894,0.00013782697,0.0020890108,0.0011436047,0.002897614,0.00003501914,0.6568172,0.0041467007,0.26636714,0.00040532293],"about_ca_topic_score_codex":0.000016210912,"about_ca_topic_score_gemma":0.0000043456766,"teacher_disagreement_score":0.5432238,"about_ca_system_score_codex":0.000002330898,"about_ca_system_score_gemma":0.000017106093,"threshold_uncertainty_score":0.33995274},"labels":[],"label_agreement":null},{"id":"W2161415751","doi":"10.3899/jrheum.141271","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Amgen","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Tolerability; Placebo; Adverse effect; Rheumatology; Clinical endpoint; Methotrexate; Randomized controlled trial; Pathology","score_opus":0.030449429821718433,"score_gpt":0.2976582989393441,"score_spread":0.26720886911762565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161415751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993591,0.003663823,0.00004126076,0.0018336293,0.00018209277,0.00065586815,0.0000074960367,0.000007936149,0.000016875154],"genre_scores_gemma":[0.9988589,0.0008829027,0.00014880697,0.00005832302,0.0000026044108,0.000010574689,0.0000010940777,0.00001551774,0.000021223335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99344915,0.005217477,0.0007189439,0.000211113,0.000103571714,0.0002997288],"domain_scores_gemma":[0.99723005,0.0017878972,0.00028432207,0.00039164667,0.00020807088,0.00009800555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007022099,0.00021316936,0.0008004745,0.00026081534,0.00013043647,0.000013893105,0.0003350523,0.000086980566,0.000013494447],"category_scores_gemma":[0.0008797308,0.00011206876,0.000037589278,0.00030932197,0.0002705862,0.000095148745,0.00017148642,0.00024555673,0.000011316397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15679903,0.0018796695,0.56943953,0.000021856311,0.0012190046,0.00009335998,0.14060019,0.0003683921,0.010768246,0.0002464352,0.00022262306,0.11834164],"study_design_scores_gemma":[0.032246634,0.022890802,0.8973737,0.00048115235,0.00028893256,0.01617482,0.023857797,0.0000085322035,0.005203449,0.0006736271,0.00040367225,0.00039688032],"about_ca_topic_score_codex":0.0007829416,"about_ca_topic_score_gemma":0.002875808,"teacher_disagreement_score":0.32793415,"about_ca_system_score_codex":0.00004298807,"about_ca_system_score_gemma":0.0002015189,"threshold_uncertainty_score":0.45700315},"labels":[],"label_agreement":null},{"id":"W2163031644","doi":"10.1016/j.jaad.2008.04.027","title":"A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial","year":2008,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Betamethasone dipropionate; Medicine; Scalp; Betamethasone; Dermatology; Psoriasis; Randomized controlled trial; Corticosteroid; Surgery; Internal medicine","score_opus":0.03481588415778829,"score_gpt":0.2963953368776418,"score_spread":0.2615794527198535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163031644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976433,0.0046150223,0.000059465972,0.00323717,0.00016316553,0.0021078866,0.000012550961,0.0000032303215,0.000037184338],"genre_scores_gemma":[0.9979748,0.0016652682,0.000114724964,0.00007969649,0.00004768087,0.00007195992,0.0000026062892,0.000009753064,0.000033523473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963833,0.0018681294,0.0011920022,0.00015170306,0.00016123637,0.00024361443],"domain_scores_gemma":[0.9943321,0.0022999903,0.0030686872,0.00016271182,0.000105011,0.000031553456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055579207,0.0002327535,0.0024759397,0.0002330301,0.00012401257,0.0000035256205,0.00039055935,0.00015803885,0.000007562454],"category_scores_gemma":[0.00013835337,0.00009610989,0.0004939797,0.00041956734,0.0013522259,0.000096321535,0.00003671912,0.0002708991,8.773805e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9843152,0.0004945615,0.0016893788,0.0000086277,0.0024258352,0.000006260998,0.005826796,0.00008223686,0.002098712,0.0002502973,0.000046488254,0.002755563],"study_design_scores_gemma":[0.95606464,0.0010616471,0.0052515077,0.000053976957,0.0016706185,0.000989879,0.0007826408,0.00005691821,0.033756863,0.00012079351,0.00010218587,0.00008832672],"about_ca_topic_score_codex":0.00021521223,"about_ca_topic_score_gemma":0.000016997732,"teacher_disagreement_score":0.03165815,"about_ca_system_score_codex":0.00005477046,"about_ca_system_score_gemma":0.00020102286,"threshold_uncertainty_score":0.49823326},"labels":[],"label_agreement":null},{"id":"W2163232748","doi":"10.1111/j.1365-2133.2007.08315.x","title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","year":2007,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":722,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Abbott Laboratories","keywords":"Champion; SAINT; Medicine; Nice; Humanities; Library science; Art; Political science; Art history; Law","score_opus":0.011530061312799737,"score_gpt":0.2450423416198201,"score_spread":0.23351228030702037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163232748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933129,0.004087202,0.00009668258,0.00019364353,0.00040664306,0.0016592045,0.00008829239,0.000008132154,0.00014733204],"genre_scores_gemma":[0.99922484,0.00041744031,0.00017239893,0.000052632153,0.000023582734,0.00001611763,0.000054703854,0.000012136807,0.000026165717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943991,0.0032229386,0.0017133438,0.0002454362,0.00011200336,0.0003072101],"domain_scores_gemma":[0.99081886,0.0073022526,0.0013855394,0.00017688816,0.00027609986,0.000040368763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001638291,0.00023905859,0.0025307622,0.00017808539,0.00015817882,0.000017713573,0.00023367493,0.00019921482,0.00003682058],"category_scores_gemma":[0.0006437183,0.00015630647,0.00017687882,0.0001724863,0.00034509005,0.00010298362,0.00005107426,0.00036170817,0.0000044111835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9453474,0.0015188551,0.03739752,0.0000035364328,0.003468962,0.00035527657,0.004623429,0.000012706552,0.00005827999,0.000017799202,0.00024514156,0.0069510443],"study_design_scores_gemma":[0.67430085,0.00059025,0.32139874,0.00012386643,0.0007423407,0.00080802257,0.0012320795,0.0000014181641,0.00055065856,0.000022678461,0.00011028746,0.0001188297],"about_ca_topic_score_codex":0.0005064841,"about_ca_topic_score_gemma":0.0012480041,"teacher_disagreement_score":0.2840012,"about_ca_system_score_codex":0.000029654806,"about_ca_system_score_gemma":0.00007121718,"threshold_uncertainty_score":0.6373993},"labels":[],"label_agreement":null},{"id":"W2164214226","doi":"10.1111/j.1468-3083.2007.02534.x","title":"Psoriasis: consensus on topical therapies","year":2008,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Medicine; Consensus conference; Psoriasis; Family medicine; Alternative medicine; MEDLINE; Dermatology; Pathology; Internal medicine","score_opus":0.030575454888843716,"score_gpt":0.24952175534235474,"score_spread":0.21894630045351102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164214226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806726,0.0074013043,0.0000059278027,0.008343686,0.0008112491,0.00006061474,0.000004669836,0.000009895518,0.0026900345],"genre_scores_gemma":[0.99753344,0.0010889469,0.000078418,0.00064500823,0.000108672815,7.290308e-7,7.8750827e-7,0.000011497536,0.0005324763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973969,0.0016994532,0.0005134754,0.0001348256,0.000040502367,0.00021483643],"domain_scores_gemma":[0.9989899,0.00033352367,0.00049579167,0.00011722113,0.000035580288,0.0000280219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002489058,0.00015907404,0.0004650744,0.00012124722,0.00019833221,0.0000015403062,0.0003377199,0.00024522518,0.000047923273],"category_scores_gemma":[0.000102236605,0.00009607882,0.0001823543,0.00007226968,0.0009137399,0.000025561523,0.00008602729,0.0004700058,0.000042847314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033535608,0.00075509155,0.82976335,0.00006440017,0.0034588245,0.00093319867,0.0032421255,0.000020982945,0.052470632,0.024333173,0.040169444,0.041435227],"study_design_scores_gemma":[0.0068853805,0.00028939324,0.7250645,0.00009750112,0.0004368395,0.07858343,0.00020752408,0.0000014218527,0.07738751,0.002147104,0.10861107,0.00028834032],"about_ca_topic_score_codex":0.0000012109894,"about_ca_topic_score_gemma":4.0930254e-7,"teacher_disagreement_score":0.10469885,"about_ca_system_score_codex":0.0000087036515,"about_ca_system_score_gemma":0.000032204505,"threshold_uncertainty_score":0.39179802},"labels":[],"label_agreement":null},{"id":"W2164218337","doi":"10.1111/j.1365-4632.2006.02777.x","title":"Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial","year":2006,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Western University","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Tolerability; Internal medicine; Randomized controlled trial; Incidence (geometry); Dermatology; Gastroenterology; Plaque psoriasis; Pathology","score_opus":0.0058412472123271645,"score_gpt":0.24775964514819127,"score_spread":0.2419183979358641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164218337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900621,0.0024155527,0.0012927931,0.0020705014,0.0020159327,0.0012231759,0.000048428697,0.000011050776,0.00086043007],"genre_scores_gemma":[0.99896127,0.00023144502,0.00020119867,0.00005151078,0.00018645452,0.0001012208,0.00005449773,0.000013849675,0.00019856864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973145,0.0006518956,0.0014701991,0.00018355284,0.00013093583,0.00024892963],"domain_scores_gemma":[0.99783146,0.00066057366,0.0009401974,0.00011944555,0.0004186887,0.000029622095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026148694,0.00022688083,0.0016190183,0.00053176045,0.00003748933,0.000011670416,0.00034555735,0.00021559518,0.00017950777],"category_scores_gemma":[0.00013728003,0.00015456733,0.00036934385,0.00010933642,0.00012950077,0.00012957437,0.000034751887,0.00020135105,0.000021575102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9898498,0.0008554344,0.0002504742,0.000010416478,0.001994392,0.0007604425,0.0002968163,0.00051020714,0.001151855,0.0021180345,0.00031136992,0.0018907322],"study_design_scores_gemma":[0.9818602,0.000686128,0.00006988354,0.00022463087,0.00026695826,0.007711885,0.000053078413,0.00006470645,0.007795938,0.0003774017,0.0007424328,0.00014673093],"about_ca_topic_score_codex":0.00012493336,"about_ca_topic_score_gemma":0.00035817813,"teacher_disagreement_score":0.00889912,"about_ca_system_score_codex":0.00014656445,"about_ca_system_score_gemma":0.00038548606,"threshold_uncertainty_score":0.63030726},"labels":[],"label_agreement":null},{"id":"W2164460355","doi":"10.3899/jrheum.101377","title":"Natural Killer-22 Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Are an Innate Source of Interleukin 22 and Tumor Necrosis Factor-α","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Nanfang Hospital","keywords":"Perforin; Interleukin 21; Tumor necrosis factor alpha; Granzyme; Immunology; Granzyme B; Medicine; Interleukin 12; Granzyme A; Cytokine; Natural killer cell; Lymphokine-activated killer cell; Janus kinase 3; Interleukin 15; Synovial fluid; Interleukin; Cytotoxic T cell; Biology; Immune system; T cell; CD8; In vitro; Pathology","score_opus":0.009774630541842686,"score_gpt":0.19572852420658773,"score_spread":0.18595389366474505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164460355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648523,0.0026322664,0.000015218243,0.00003567583,0.0005965214,0.00017438893,0.000031659423,0.0000057796256,0.000023259809],"genre_scores_gemma":[0.99854034,0.0013231356,0.000055677356,0.000033504028,0.0000023776408,0.0000033008487,0.0000083278,0.000015516403,0.00001783261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980044,0.0008015874,0.00071440946,0.0001333149,0.00007901355,0.00026727063],"domain_scores_gemma":[0.9981829,0.0003434368,0.0010190397,0.0002607484,0.00016923329,0.000024636545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043468934,0.00021494148,0.00069814496,0.00019857414,0.00009219925,0.000005655428,0.00046637387,0.00013597675,0.00013994217],"category_scores_gemma":[0.000056491997,0.00011226726,0.00009348897,0.00014449061,0.0005068621,0.00013698147,0.000070960414,0.00032343125,0.0000053745857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005217722,0.00079058146,0.9499356,0.000046712263,0.0006295135,0.00001546004,0.018789986,0.000003305862,0.015083172,0.0001228774,0.0003390987,0.009025972],"study_design_scores_gemma":[0.012279068,0.0038877986,0.9114138,0.0007547711,0.00017849395,0.0037350433,0.0070571434,0.0000056375443,0.059584983,0.0002350673,0.0004832469,0.00038496853],"about_ca_topic_score_codex":0.00052740576,"about_ca_topic_score_gemma":0.00033202153,"teacher_disagreement_score":0.044501808,"about_ca_system_score_codex":0.000016778877,"about_ca_system_score_gemma":0.000049624774,"threshold_uncertainty_score":0.4578126},"labels":[],"label_agreement":null},{"id":"W2165238384","doi":"10.3899/jrheum.130452","title":"GRAPPA Trainees Symposium 2012: A Report from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Rheumatology; Dermatology; Family medicine; Plaque psoriasis; Medical physics; Internal medicine; Physical therapy","score_opus":0.010270790651308693,"score_gpt":0.2170923346695888,"score_spread":0.2068215440182801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165238384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97152674,0.018975649,0.00013111027,0.00638546,0.0021192073,0.0002195961,0.000041134994,0.00002742526,0.0005736736],"genre_scores_gemma":[0.99598795,0.0021874749,0.000117969306,0.0001947204,0.00005260684,0.000015334172,0.000035777306,0.00002296263,0.0013852266],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975302,0.0009487378,0.00083969184,0.00016398073,0.000077662175,0.0004396984],"domain_scores_gemma":[0.9968836,0.0014940532,0.00092678244,0.0004342079,0.00021897731,0.00004239164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010783118,0.0002528706,0.00057684653,0.00009635837,0.0003583963,0.00001857524,0.0006588906,0.00026644292,0.00092531776],"category_scores_gemma":[0.00014866969,0.00012445172,0.00026258465,0.0001387402,0.00037972888,0.00027798963,0.00009044198,0.00043348316,0.00041019206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001072396,0.000481648,0.23740321,0.00002187144,0.005627118,0.00014152392,0.015910616,0.00003147392,0.09539426,0.00073560356,0.620829,0.022351291],"study_design_scores_gemma":[0.01688232,0.0021030165,0.2976514,0.0008191198,0.005070064,0.22918007,0.030751595,0.00001871314,0.028135572,0.017074568,0.37037125,0.0019423045],"about_ca_topic_score_codex":0.0014725011,"about_ca_topic_score_gemma":0.0002135639,"teacher_disagreement_score":0.25045773,"about_ca_system_score_codex":0.000020226531,"about_ca_system_score_gemma":0.000090108326,"threshold_uncertainty_score":0.99998796},"labels":[],"label_agreement":null},{"id":"W2165319493","doi":"10.1016/j.jaad.2003.10.519","title":"Quality of life effect of oral tazarotene in patients with moderate to severe psoriasis as measured by the 12-item psoriasis quality of life questionnaire (PQOL-12)","year":2004,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Tazarotene; Medicine; Psoriasis; Placebo; Quality of life (healthcare); Plaque psoriasis; Dermatology; Internal medicine; Physical therapy; Pathology; Nursing","score_opus":0.0192783328908954,"score_gpt":0.2842970265607068,"score_spread":0.2650186936698114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165319493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940627,0.0011733166,0.00008109011,0.0038098246,0.00023173963,0.0004860341,0.00012142916,0.000008503383,0.00002533524],"genre_scores_gemma":[0.9991474,0.0001247362,0.00018934532,0.00045886918,0.000018711236,0.00001445232,0.000006991115,0.000023254122,0.000016208756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99299765,0.0039796093,0.0020459904,0.00026975328,0.0003257792,0.00038119213],"domain_scores_gemma":[0.99409515,0.0007864591,0.0043901172,0.00036708932,0.0002657376,0.000095439034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013571223,0.00036049067,0.00230797,0.00025218626,0.00009868563,0.0000040927735,0.00081268867,0.00032160766,0.000014976779],"category_scores_gemma":[0.0013480006,0.0002059071,0.00045124002,0.0005296368,0.0009794879,0.00013441827,0.00012587823,0.00053624186,0.000003926737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028173223,0.0008413791,0.9289171,0.00019918801,0.0021742948,0.0000016418799,0.0010295,0.0006008119,0.031167582,0.00017789404,0.0006116873,0.0061056986],"study_design_scores_gemma":[0.011773166,0.0014281154,0.8538396,0.00022261617,0.00037848068,0.0000853678,0.0002649112,0.0000010778494,0.1314191,0.00027696264,0.00007873816,0.00023187338],"about_ca_topic_score_codex":0.0012814351,"about_ca_topic_score_gemma":0.0000993042,"teacher_disagreement_score":0.10025153,"about_ca_system_score_codex":0.000096519376,"about_ca_system_score_gemma":0.00033360018,"threshold_uncertainty_score":0.83966476},"labels":[],"label_agreement":null},{"id":"W2167305078","doi":"10.1111/j.1365-2133.2012.11168.x","title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","year":2012,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Janus kinase inhibitor; Medicine; Placebo; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Dose-ranging study; Internal medicine; Gastroenterology; Randomized controlled trial; Clinical endpoint; Dermatology; Double blind; Pathology","score_opus":0.01880262927208139,"score_gpt":0.28178375465673705,"score_spread":0.2629811253846557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167305078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96964025,0.028108673,0.000025024758,0.00008263102,0.0005624724,0.0014478796,0.000056014138,0.0000076018405,0.00006944862],"genre_scores_gemma":[0.9980169,0.0016837635,0.00008854909,0.000021030666,0.00006165983,0.00007027048,0.000027393384,0.000013818213,0.000016632406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99483234,0.003192,0.001339614,0.0001655388,0.00008247451,0.00038801716],"domain_scores_gemma":[0.9976089,0.001284548,0.0007646217,0.00018296688,0.000104209204,0.000054773685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012122432,0.0002425595,0.0019740646,0.00027145102,0.00011906469,0.000014895763,0.0001877996,0.00019864655,0.00006895574],"category_scores_gemma":[0.00022037102,0.00017461936,0.00033138884,0.0001514118,0.0002765612,0.00019536243,0.000019960453,0.00016959196,0.0000026549408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71243215,0.026125781,0.022401344,0.000037826012,0.0040075253,0.0016496099,0.019498805,0.000005336264,0.007326217,0.00012200839,0.00008861818,0.2063048],"study_design_scores_gemma":[0.95557064,0.0020854182,0.010978653,0.000112226786,0.0017404838,0.015605697,0.0037695551,0.0000038836524,0.009412089,0.000026338652,0.00051731366,0.00017768602],"about_ca_topic_score_codex":0.00016034723,"about_ca_topic_score_gemma":0.00009771683,"teacher_disagreement_score":0.24313852,"about_ca_system_score_codex":0.000031168438,"about_ca_system_score_gemma":0.0000832758,"threshold_uncertainty_score":0.7120771},"labels":[],"label_agreement":null},{"id":"W2167573905","doi":"10.1016/j.clinthera.2005.09.007","title":"Incidence of infection during efalizumab therapy for psoriasis: Analysis of the clinical trial experience","year":2005,"lang":"en","type":"review","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Dalhousie University","funders":"Genentech","keywords":"Efalizumab; Medicine; Psoriasis; Placebo; Incidence (geometry); Clinical trial; Adverse effect; Internal medicine; Randomized controlled trial; Immunology; Plaque psoriasis; Pathology","score_opus":0.27534577022948004,"score_gpt":0.4846407011721711,"score_spread":0.20929493094269108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167573905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11574934,0.8778932,0.000059545375,0.000012483215,0.0042013368,0.0018579508,0.00016936944,0.000031344673,0.000025433112],"genre_scores_gemma":[0.012646398,0.9859699,0.000091806956,0.000056478588,0.00050387345,0.00029499162,0.00010055796,0.000042169388,0.00029379816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99288255,0.002319195,0.0036602584,0.0006824627,0.000110105626,0.0003454313],"domain_scores_gemma":[0.99145633,0.0043938723,0.0026870843,0.0012250443,0.00020353016,0.00003412979],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018593185,0.00048174747,0.0038378548,0.000236994,0.00017003172,0.0000112153975,0.00074916525,0.0016306668,0.00011314418],"category_scores_gemma":[0.0005031048,0.00029279038,0.005903472,0.0009788304,0.00075476285,0.000055158234,0.00013639814,0.0005675515,0.000012506028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056960243,0.0010490438,0.00254804,0.0002730098,0.014731066,2.9636465e-7,0.00012069346,0.0000021096612,0.0000078913345,0.000045673787,0.000014649651,0.9755115],"study_design_scores_gemma":[0.02622962,0.0016335257,0.008196642,0.0010609571,0.03326081,0.000005750141,0.000021977221,0.0000048000784,0.0001860945,0.00003600958,0.9289055,0.00045829976],"about_ca_topic_score_codex":0.000015246968,"about_ca_topic_score_gemma":0.000026876662,"teacher_disagreement_score":0.9750532,"about_ca_system_score_codex":0.000055920187,"about_ca_system_score_gemma":0.0003675346,"threshold_uncertainty_score":0.99995244},"labels":[],"label_agreement":null},{"id":"W2168384861","doi":"10.1016/j.jaut.2009.12.001","title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","year":2009,"lang":"en","type":"review","venue":"Journal of Autoimmunity","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":518,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Epidemiology; Incidence (geometry); Obesity; Demography; Dermatology; Internal medicine","score_opus":0.03600848533808458,"score_gpt":0.2795983337620942,"score_spread":0.2435898484240096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168384861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.078775354,0.92011756,0.0000035027945,0.000012466134,0.0006734067,0.00019638143,0.0001767708,0.000007934058,0.000036628862],"genre_scores_gemma":[0.013939252,0.98557216,0.00010266498,0.000010743621,0.000054956214,0.0000031311183,0.00017883485,0.000022747297,0.000115491304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966139,0.0013993006,0.0014335325,0.00020700721,0.000056014735,0.0002902055],"domain_scores_gemma":[0.9965513,0.0010935756,0.001971527,0.00030108858,0.000030112722,0.000052444007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090304686,0.00046177063,0.0031722304,0.00035280042,0.00015635088,0.000009836383,0.00026816563,0.00076389353,0.00014100164],"category_scores_gemma":[0.00024282662,0.00033233446,0.0005508819,0.000097333745,0.0003721732,0.000110949615,0.00010993354,0.00075221923,0.000007828629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040132825,0.00018203977,0.0003203661,0.0005522562,0.0013125164,0.000014802351,0.00023548982,1.0419559e-7,0.0000635564,0.000030608826,0.00012831822,0.9971198],"study_design_scores_gemma":[0.0027104216,0.0018116381,0.022932589,0.0056319674,0.005228143,0.002876385,0.00036224042,2.7885113e-7,0.0001227485,0.00036262002,0.95738596,0.00057500246],"about_ca_topic_score_codex":0.000032686235,"about_ca_topic_score_gemma":0.0000030261397,"teacher_disagreement_score":0.9965448,"about_ca_system_score_codex":0.000074370255,"about_ca_system_score_gemma":0.0001230941,"threshold_uncertainty_score":0.99991286},"labels":[],"label_agreement":null},{"id":"W2168503185","doi":"10.1056/nejmoa066886","title":"Etanercept Treatment for Children and Adolescents with Plaque Psoriasis","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":388,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexus Clinical Research (Canada); Dalhousie University","funders":"National Psoriasis Foundation; Amgen","keywords":"Etanercept; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Tumor necrosis factor alpha; Internal medicine","score_opus":0.017998479829523132,"score_gpt":0.2390666548705623,"score_spread":0.22106817504103918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168503185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909685,0.0069875773,0.00025421506,0.0010199018,0.00046707413,0.00020891486,0.000015195652,0.000010322971,0.00006826521],"genre_scores_gemma":[0.9944761,0.003163725,0.00027366503,0.000089855814,0.0010707914,0.0000033513968,0.00003266564,0.000013520477,0.0008763479],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99928147,0.00007693568,0.0002704578,0.00013259055,0.00005304029,0.00018548625],"domain_scores_gemma":[0.99945825,0.00009545502,0.00019681129,0.00010075464,0.00007023938,0.000078491044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015506531,0.00017764975,0.00043947902,0.000117157004,0.0001212061,0.000002473525,0.00007668086,0.00009431491,0.00007151859],"category_scores_gemma":[0.00003321637,0.000093653354,0.00005998419,0.00005802665,0.00013467844,0.000050424966,0.0000064574638,0.00009343899,0.000005017114],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011690854,0.00038777225,0.23924604,0.000020211804,0.0018071374,0.00019053546,0.0045773783,0.000009106404,0.010969218,0.00004814686,0.012207196,0.7188464],"study_design_scores_gemma":[0.34665215,0.017352311,0.5581316,0.00060523517,0.0018206761,0.022160454,0.00021964268,8.4379946e-7,0.010906057,0.00011666638,0.04171056,0.00032381446],"about_ca_topic_score_codex":0.0001003818,"about_ca_topic_score_gemma":0.000044189535,"teacher_disagreement_score":0.7185226,"about_ca_system_score_codex":0.000033349344,"about_ca_system_score_gemma":0.00008575407,"threshold_uncertainty_score":0.38190728},"labels":[],"label_agreement":null},{"id":"W2168911501","doi":"10.1016/s0140-6736(05)67763-x","title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","year":2005,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1069,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"Amgen","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Etanercept; Psoriasis; Internal medicine; Depression (economics); Physical therapy; Beck Depression Inventory; Adverse effect; Clinical endpoint; Randomized controlled trial; Clinical trial; Psychiatry; Rheumatoid arthritis; Anxiety; Dermatology","score_opus":0.07492228636010856,"score_gpt":0.36006008215133556,"score_spread":0.285137795791227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168911501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990179,0.0049325363,0.000016324946,0.0009504968,0.00075294566,0.0019986802,0.000019915986,0.000047805937,0.0011022848],"genre_scores_gemma":[0.9959582,0.0015955351,0.000075069576,0.00026443021,0.00062045874,0.00025576874,0.000050067934,0.000013370549,0.0011671168],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979809,0.00070683856,0.00060599874,0.00033276327,0.00004327893,0.00033020735],"domain_scores_gemma":[0.99819285,0.001199597,0.00018859931,0.00036438956,0.000018804798,0.000035747515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015072479,0.0002304206,0.0012160587,0.000072903356,0.00016111945,0.000029495037,0.00019123901,0.0002961892,0.00017610179],"category_scores_gemma":[0.00018011333,0.00012865206,0.00015262893,0.000069772745,0.00015252692,0.000081053266,0.00006554735,0.00027962506,0.000038013783],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9405784,0.0003739217,0.009819446,0.0000045539527,0.00054479274,0.0000048861607,0.00041101465,0.000002406097,0.00053720985,0.000040042745,0.0013455264,0.04633782],"study_design_scores_gemma":[0.9898465,0.00020657608,0.005972351,0.000023760973,0.0004400196,0.000011604664,0.000082138526,0.000024406758,0.00046061393,0.000034362492,0.0027403913,0.00015725261],"about_ca_topic_score_codex":0.000038565435,"about_ca_topic_score_gemma":0.00017170564,"teacher_disagreement_score":0.04926814,"about_ca_system_score_codex":0.000015472746,"about_ca_system_score_gemma":0.000028310396,"threshold_uncertainty_score":0.52462786},"labels":[],"label_agreement":null},{"id":"W2169005742","doi":"10.1111/j.1365-2133.2011.10280.x","title":"Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course","year":2011,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Institute for Health and Care Research","keywords":"Life course approach; Psoriasis; Medicine; Course (navigation); Disease; Perception; Gerontology; Psychology; Dermatology; Internal medicine; Developmental psychology; Neuroscience","score_opus":0.01610294237770836,"score_gpt":0.2565166595212557,"score_spread":0.2404137171435473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169005742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97130275,0.025778031,0.000025547959,0.00076551037,0.0013320989,0.0004701093,0.000086529566,0.00001983599,0.0002196085],"genre_scores_gemma":[0.9976588,0.0018521885,0.00008719476,0.00022614928,0.00003766623,0.0000317535,0.000041098203,0.000024084009,0.000041079067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99682766,0.0010287239,0.0013180755,0.00024333574,0.00012713445,0.00045508778],"domain_scores_gemma":[0.9982289,0.00015563158,0.000989804,0.00024553636,0.00024497308,0.00013514109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033444725,0.0002614436,0.0007278698,0.00013657763,0.0001644075,0.000012507941,0.0003273774,0.00028808785,0.000707163],"category_scores_gemma":[0.00011388399,0.00021578562,0.00035748226,0.00019303142,0.00039263052,0.00019564846,0.00007875409,0.000407904,0.00006729769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014185952,0.024262046,0.6980264,0.00023686596,0.013969096,0.0075675356,0.056344096,0.000215432,0.003168574,0.0011055187,0.034682307,0.14623617],"study_design_scores_gemma":[0.0079824515,0.0010186231,0.97118014,0.000326242,0.001567109,0.007821251,0.007758833,0.000014701829,0.0010693028,0.0005030194,0.00045654632,0.0003017797],"about_ca_topic_score_codex":0.00026191547,"about_ca_topic_score_gemma":0.00006722464,"teacher_disagreement_score":0.27315372,"about_ca_system_score_codex":0.000060618513,"about_ca_system_score_gemma":0.0004883294,"threshold_uncertainty_score":0.8799482},"labels":[],"label_agreement":null},{"id":"W2169051031","doi":"10.3899/jrheum.111027","title":"Increased Serum Interleukin 22 in Patients with Rheumatoid Arthritis and Correlation with Disease Activity","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universidade Federal de Pernambuco; Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Ionomycin; Peripheral blood mononuclear cell; Gastroenterology; Rheumatoid factor; Immunology; Serology; Interleukin; Endocrinology; Cytokine; Antibody; In vitro; Stimulation","score_opus":0.005630189289668725,"score_gpt":0.19298267379239423,"score_spread":0.1873524845027255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169051031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959368,0.0033816334,0.000107228625,0.00011726822,0.00025879664,0.00014893344,0.000013981566,0.000008505029,0.00002685537],"genre_scores_gemma":[0.99888265,0.0010151706,0.000033865406,0.000020817519,0.0000027627839,0.000004176285,0.000011071951,0.000012218343,0.00001727348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988311,0.0005146802,0.00025593347,0.00008424996,0.000048538986,0.0002655243],"domain_scores_gemma":[0.9990894,0.00028336226,0.00036618943,0.00014065985,0.000063838685,0.000056509376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003707035,0.0001536967,0.00035054862,0.00013156979,0.00010019302,0.0000059038603,0.000104220664,0.000094790805,0.000085082655],"category_scores_gemma":[0.000047788562,0.00008528855,0.000030936262,0.00009899146,0.00018775719,0.00025594755,0.00003191854,0.00022604283,0.00001803368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006606963,0.00028895386,0.977738,0.0000079780175,0.00019484089,0.0000032322528,0.00057886733,0.0000057527973,0.00007299699,0.00007845875,0.000073250834,0.014350663],"study_design_scores_gemma":[0.0064442493,0.0005507909,0.9911822,0.00022507102,0.00006932824,0.0008937137,0.00013321641,0.0000029585751,0.00022807659,0.00003107127,0.00013047234,0.000108870845],"about_ca_topic_score_codex":0.00014514835,"about_ca_topic_score_gemma":0.00016041618,"teacher_disagreement_score":0.014241792,"about_ca_system_score_codex":0.00003598956,"about_ca_system_score_gemma":0.000060196908,"threshold_uncertainty_score":0.34779662},"labels":[],"label_agreement":null},{"id":"W2169202162","doi":"10.1186/1745-6215-15-294","title":"Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial","year":2014,"lang":"en","type":"article","venue":"Trials","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Guangzhou University; Chengdu University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; China Academy of Chinese Medical Sciences; Simon Fraser University; Guangdong Provincial Hospital of Traditional Chinese Medicine; Chengdu University; China-Japan Friendship Hospital; Shanghai University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Guangzhou University of Chinese Medicine; Sun Yat-sen University; RMIT University","keywords":"Calcipotriol; Medicine; Psoriasis; Betamethasone; Randomized controlled trial; Placebo; Dermatology; Psoriasis Area and Severity Index; Clinical trial; Betamethasone dipropionate; Internal medicine; Alternative medicine; Pathology","score_opus":0.056840422493918,"score_gpt":0.3855697643317018,"score_spread":0.3287293418377838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169202162","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17752597,0.00029981075,0.0029332847,0.0005444054,0.0013449495,0.8169343,0.00009903168,0.00014707311,0.0001711952],"genre_scores_gemma":[0.11920245,0.000012395638,0.00058188767,0.000080563404,0.00082057295,0.87735003,0.00014569715,0.00006476576,0.0017416184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9903814,0.00552578,0.0024584387,0.00085080136,0.00015335926,0.00063018687],"domain_scores_gemma":[0.97133225,0.02621362,0.0014833465,0.0005663776,0.000300622,0.00010380982],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.016427524,0.00077658804,0.0079636555,0.0003194349,0.0004528549,0.00004491176,0.00025982133,0.00040877133,0.00036310745],"category_scores_gemma":[0.013498969,0.00038605937,0.0008992184,0.00021169415,0.00034581436,0.00008242852,0.0000540939,0.00015624423,0.000015631938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9723412,0.0017794621,0.00009633961,0.00008020517,0.006716954,0.0000016260153,0.0010651015,0.0000018426476,0.00216407,0.00032871976,0.0013677524,0.014056754],"study_design_scores_gemma":[0.95297116,0.033248987,0.00005199638,0.000081133374,0.006219264,0.0000063861316,0.00022260078,0.00003860806,0.0016370113,0.00079790206,0.004303951,0.00042100763],"about_ca_topic_score_codex":0.000174319,"about_ca_topic_score_gemma":0.00010840859,"teacher_disagreement_score":0.06041576,"about_ca_system_score_codex":0.000058556805,"about_ca_system_score_gemma":0.00013017801,"threshold_uncertainty_score":0.99985915},"labels":[],"label_agreement":null},{"id":"W2169340184","doi":"10.1111/jgh.12674","title":"Smoking behaviour modifies <i>IL23r</i>‐associated disease risk in patients with Crohn's disease","year":2014,"lang":"en","type":"article","venue":"Journal of Gastroenterology and Hepatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Health and Medical Research Council","keywords":"Single-nucleotide polymorphism; Haplotype; Odds ratio; SNP; Medicine; Genotype; Case-control study; Allele; Risk factor; Gastroenterology; Minor allele frequency; Crohn's disease; Disease; Internal medicine; Genetics; Immunology; Biology; Gene","score_opus":0.0059384557568024935,"score_gpt":0.19622865428337177,"score_spread":0.19029019852656928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169340184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981921,0.00059865403,0.000112892085,0.00034208095,0.0005174264,0.00013241207,0.000076619035,0.000014432012,0.000013391001],"genre_scores_gemma":[0.9993028,0.0001661447,0.00003997632,0.00033236342,0.000030337964,0.000010039207,0.0000638346,0.000016902575,0.000037599875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778885,0.0009009197,0.00050373137,0.0002686819,0.00005889779,0.00047890435],"domain_scores_gemma":[0.9988141,0.00014715768,0.0005964874,0.00018065285,0.00013125881,0.00013032272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039180616,0.00024861944,0.00063221087,0.00028720492,0.00015997785,0.000010600199,0.00017328342,0.00019438294,0.000053921412],"category_scores_gemma":[0.00016796905,0.00018828582,0.00012069303,0.000066075125,0.0003099932,0.00013307903,0.00006017074,0.00041924306,0.0000062076124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014151844,0.00068557955,0.98308074,0.000009254085,0.00034861077,0.00018035613,0.000097348384,0.000017773147,0.00001229533,0.00005181199,0.00015026152,0.001214146],"study_design_scores_gemma":[0.01004969,0.0016814063,0.98699933,0.000046496094,0.0006418734,0.00003932587,0.000021837415,0.000011473118,0.000011672131,0.00024920888,0.00013632016,0.00011138568],"about_ca_topic_score_codex":0.00003623644,"about_ca_topic_score_gemma":0.00021114042,"teacher_disagreement_score":0.004102154,"about_ca_system_score_codex":0.00004824969,"about_ca_system_score_gemma":0.000050677,"threshold_uncertainty_score":0.7678073},"labels":[],"label_agreement":null},{"id":"W2169787227","doi":"10.1111/j.1365-2133.2006.07344.x","title":"CLinical experience acquired with the efalizumab (Raptiva<sup>®</sup>) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","year":2006,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Plaque psoriasis; Psoriasis; Placebo; Medicine; Randomized controlled trial; Clinical trial; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.011873326462174835,"score_gpt":0.25914505403540095,"score_spread":0.2472717275732261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169787227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311477,0.0006670333,0.00037920813,0.0007965499,0.00152963,0.0030169564,0.00021371112,0.000025421012,0.00025673688],"genre_scores_gemma":[0.99821204,0.0001246837,0.0002594554,0.0001792753,0.00042440818,0.00032207463,0.000253251,0.000031283707,0.00019351309],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99387777,0.0026485396,0.0022498341,0.00050226256,0.00023241267,0.0004891969],"domain_scores_gemma":[0.9958913,0.0021480746,0.0012732367,0.00027642515,0.00033319765,0.00007780072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008591064,0.00036939853,0.0020926138,0.00024102932,0.00023418921,0.00010073268,0.0006088612,0.00044637593,0.00016633084],"category_scores_gemma":[0.00056270114,0.00024705785,0.00042938828,0.00018811734,0.00045677478,0.00029493144,0.00007118979,0.00045858807,0.000023984825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9850542,0.0023847169,0.00049892074,0.0000013304622,0.0015909398,0.0008684023,0.0008828568,0.00025045782,0.0000094698435,0.000029667599,0.0027509844,0.005678038],"study_design_scores_gemma":[0.9929559,0.0020418644,0.0005784842,0.00014840715,0.00045552786,0.0018947349,0.00041655972,0.00006773863,0.00013186107,0.000057161764,0.00095697655,0.00029475777],"about_ca_topic_score_codex":0.00042335145,"about_ca_topic_score_gemma":0.00029648526,"teacher_disagreement_score":0.00790171,"about_ca_system_score_codex":0.00007614113,"about_ca_system_score_gemma":0.0003129631,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W2169804509","doi":"10.1586/14737167.2014.933671","title":"The economic burden of psoriasis: a systematic literature review","year":2014,"lang":"en","type":"review","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Indirect costs; Medicine; Systematic review; Economic cost; MEDLINE; Business; Economics; Political science; Dermatology; Accounting","score_opus":0.04387184782459543,"score_gpt":0.47216852535200154,"score_spread":0.42829667752740613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169804509","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012929756,0.98942655,8.518284e-7,0.00056705665,0.0021473377,0.0065133623,0.00037883085,0.000028975095,0.000935725],"genre_scores_gemma":[0.0000014867337,0.99258745,0.00003547573,0.00038949816,0.00030674457,0.0026183138,0.0004894255,0.00011587884,0.0034557593],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9873219,0.006340198,0.0043385476,0.0008914997,0.0001891155,0.000918723],"domain_scores_gemma":[0.9889731,0.0057424796,0.0025432638,0.0022450048,0.00038952427,0.00010666192],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009448667,0.0009790458,0.00937466,0.00045852704,0.0003205045,0.000056687455,0.0028443844,0.0005513647,0.0008147821],"category_scores_gemma":[0.0009227188,0.0005578183,0.0032592649,0.0004461185,0.00044447614,0.000133807,0.0005721969,0.0010967327,0.0019336165],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010673343,0.00003120827,4.541821e-7,0.62871665,0.0025046987,0.000003050398,0.0000677839,6.8373055e-8,0.0000037126822,0.00025801922,0.0391652,0.3292385],"study_design_scores_gemma":[0.00030901816,0.00004581535,9.572285e-8,0.45061576,0.0014305431,0.000053515716,0.000014160846,5.972156e-7,0.000020525189,0.000006090358,0.547264,0.00023991537],"about_ca_topic_score_codex":0.00005600645,"about_ca_topic_score_gemma":0.0000049265554,"teacher_disagreement_score":0.5080988,"about_ca_system_score_codex":0.0006027176,"about_ca_system_score_gemma":0.00092600595,"threshold_uncertainty_score":0.9996873},"labels":[],"label_agreement":null},{"id":"W2171309002","doi":"10.1016/j.jaad.2010.03.009","title":"Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study","year":2011,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Adalimumab; Etanercept; Psoriasis; Psoriasis Area and Severity Index; Methotrexate; Internal medicine; Dermatology; Clinical endpoint; Infliximab; Clinical trial; Tumor necrosis factor alpha","score_opus":0.05221773961470023,"score_gpt":0.33484986160342134,"score_spread":0.2826321219887211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171309002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962125,0.00009539552,0.00016323147,0.0017522653,0.00016917742,0.0013246908,0.00025324375,0.000012025486,0.000017472956],"genre_scores_gemma":[0.9857526,0.000033157885,0.012923072,0.0011307334,0.000022159826,0.000030591164,0.000005597137,0.00003594433,0.00006615253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965977,0.0016825381,0.00088714797,0.00037962204,0.00009500431,0.0003579795],"domain_scores_gemma":[0.9969306,0.0012375003,0.0012935151,0.00030143355,0.00012097845,0.00011596676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071429956,0.00028938704,0.0010715206,0.00025582843,0.00021264768,0.000015692329,0.0010057745,0.000119396005,0.000027541566],"category_scores_gemma":[0.00037061336,0.00016553857,0.00006927693,0.00036505196,0.00018025334,0.0001793254,0.00021878211,0.00028738478,0.0000053294316],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8038779,0.004195064,0.031214908,0.000006918506,0.0028503553,0.000034821293,0.018401043,0.000010208929,0.09005953,0.00001135516,0.0007459456,0.048591927],"study_design_scores_gemma":[0.07037689,0.020429183,0.8648632,0.000120416225,0.0011662837,0.0005986248,0.003089498,0.0000027614594,0.0343244,0.000054905413,0.004501169,0.0004726294],"about_ca_topic_score_codex":0.00026346953,"about_ca_topic_score_gemma":0.00005404892,"teacher_disagreement_score":0.8336483,"about_ca_system_score_codex":0.00004642684,"about_ca_system_score_gemma":0.00011873816,"threshold_uncertainty_score":0.67504674},"labels":[],"label_agreement":null},{"id":"W2171889601","doi":"10.1016/s0140-6736(15)60125-8","title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":831,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Institute for Health and Care Research; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Clinical trial; Blinding; Interleukin 17; Physical therapy; Dermatology; Psoriatic arthritis; Cytokine; Tumor necrosis factor alpha; Secukinumab; Pathology; Alternative medicine","score_opus":0.11490206835391355,"score_gpt":0.35665395981763115,"score_spread":0.24175189146371762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171889601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99405676,0.001406746,0.000113362075,0.00057617895,0.00037898356,0.00094884605,0.0013190046,0.000038128677,0.0011619712],"genre_scores_gemma":[0.99777454,0.00010351047,0.00041464515,0.00012996786,0.00020047283,0.00006380998,0.0003353686,0.000018415416,0.0009592585],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973425,0.0012410383,0.00064951536,0.00035788424,0.00008359047,0.00032545047],"domain_scores_gemma":[0.99710923,0.0019051571,0.0003373112,0.00053241814,0.000066041626,0.00004982023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016298785,0.00026221294,0.0016365403,0.00008315462,0.00008123971,0.000025785905,0.0002758461,0.000158949,0.00011366708],"category_scores_gemma":[0.0007386482,0.00014006294,0.00007301883,0.00020768734,0.000107810185,0.00008269056,0.00006271729,0.00017391007,0.00006903315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9234532,0.000383154,0.002743824,0.000012831589,0.0008480287,0.000019646819,0.008392278,0.0015310253,0.008095528,0.000038170874,0.015750147,0.03873218],"study_design_scores_gemma":[0.91172326,0.0019643076,0.002257967,0.00019307809,0.0008062695,0.000031319403,0.0023612774,0.0002313191,0.067544475,0.0005313086,0.01184326,0.0005121517],"about_ca_topic_score_codex":0.0009592567,"about_ca_topic_score_gemma":0.0013445361,"teacher_disagreement_score":0.05944895,"about_ca_system_score_codex":0.00005255992,"about_ca_system_score_gemma":0.00014023794,"threshold_uncertainty_score":0.57116014},"labels":[],"label_agreement":null},{"id":"W2172257129","doi":"10.1016/s0140-6736(05)67566-6","title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","year":2005,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1045,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Probity Medical Research","funders":"","keywords":"Infliximab; Psoriasis; Medicine; Psoriasis Area and Severity Index; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Dermatology; Surgery; Randomized controlled trial; Tumor necrosis factor alpha; Pathology","score_opus":0.06806402176190217,"score_gpt":0.3177268351608078,"score_spread":0.24966281339890561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172257129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902326,0.002388707,0.0002040132,0.0037758593,0.00087418605,0.002014787,0.000101009566,0.00007522764,0.00033360772],"genre_scores_gemma":[0.99374634,0.0007217893,0.0004204758,0.0007906977,0.0013452503,0.0005794445,0.000101125945,0.000019891204,0.002274956],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989432,0.00010018681,0.00023146805,0.00029621832,0.00003268948,0.00039625043],"domain_scores_gemma":[0.99934983,0.00011895173,0.000102619946,0.0003423893,0.00005814803,0.000028053437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031184134,0.0002006051,0.00040867433,0.000054427874,0.0002719862,0.00003905226,0.00020074334,0.0001696844,0.000093229144],"category_scores_gemma":[0.000026225001,0.00012747858,0.000077274584,0.000099192155,0.00008681079,0.0001192584,0.00003206262,0.00012837422,0.00007715068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8012349,0.0004446721,0.00003161569,0.000006147694,0.00041091154,8.189887e-7,0.0018518412,0.00004896985,0.00898652,0.00062995096,0.0106950365,0.17565864],"study_design_scores_gemma":[0.8427601,0.00073004776,0.00014049107,0.00002215152,0.0001329876,0.00002482624,0.0002793405,0.0000706748,0.028153732,0.00022716704,0.12721561,0.00024286707],"about_ca_topic_score_codex":0.00004381059,"about_ca_topic_score_gemma":0.00007003425,"teacher_disagreement_score":0.17541577,"about_ca_system_score_codex":0.00003454432,"about_ca_system_score_gemma":0.000033338798,"threshold_uncertainty_score":0.51984257},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2174794845","doi":"10.1177/1203475415616073","title":"Psoriasis and Smoking","year":2015,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Centre Hospitalier de l’Université de Montréal; Memorial University of Newfoundland; Centre hospitalier universitaire de Québec; University of British Columbia; University of Toronto; Western University; Hôpital du Sacré-Cœur de Montréal; Lynde Centre for Dermatology; University of Alberta; Université de Montréal; Hôpital Notre-Dame; Hôpital Saint-Luc","funders":"","keywords":"Psoriasis; Medicine; Relative risk; Dermatology; MEDLINE; Internal medicine; Confidence interval","score_opus":0.07577581062414974,"score_gpt":0.3131464595589141,"score_spread":0.2373706489347644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2174794845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011159452,0.9957227,0.0000020030081,0.00012908326,0.0025047234,0.000107298234,0.000013052035,0.0000111613745,0.00039404928],"genre_scores_gemma":[0.00024900062,0.9981485,0.000013024572,0.00007428673,0.0006773568,0.0000028965005,0.000036775218,0.000030107383,0.00076803606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979864,0.00038793244,0.0010555051,0.00020534651,0.00010001511,0.00026480222],"domain_scores_gemma":[0.9966186,0.0019475837,0.0010179139,0.00015954755,0.00015172434,0.00010460879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011404122,0.00037768943,0.003121827,0.000561177,0.00009124795,0.000012505964,0.00010840839,0.00048755234,0.0001417792],"category_scores_gemma":[0.00041098046,0.00022398135,0.00034402247,0.00015818322,0.00020959308,0.000057202436,0.000038575596,0.00043264145,0.0000117661275],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005877936,0.000025628964,0.00009347185,0.0012673698,0.0011284848,0.001078385,0.00017782424,1.2760946e-8,0.0000034128818,0.000009100412,0.029821573,0.96633595],"study_design_scores_gemma":[0.0003997569,0.00023029263,0.0000049858972,0.007814039,0.0039908933,0.052397028,0.00011912473,2.3977483e-8,0.0000017722946,0.000059751368,0.93479794,0.00018436523],"about_ca_topic_score_codex":0.000012585271,"about_ca_topic_score_gemma":0.0000016587426,"teacher_disagreement_score":0.9661516,"about_ca_system_score_codex":0.00004759277,"about_ca_system_score_gemma":0.00031640037,"threshold_uncertainty_score":0.9133695},"labels":[],"label_agreement":null},{"id":"W2176753380","doi":"10.1016/j.ajhg.2015.10.019","title":"Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture","year":2015,"lang":"en","type":"review","venue":"The American Journal of Human Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":322,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital; University of Toronto","funders":"National Center for Research Resources; National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriasis; Genetic architecture; Psoriatic arthritis; Genome-wide association study; Dermatology; Association (psychology); Genetic association; Medicine; Genetics; Biology; Genotype; Psychology; Gene; Single-nucleotide polymorphism; Quantitative trait locus","score_opus":0.0257946088666563,"score_gpt":0.2726901896241581,"score_spread":0.2468955807575018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176753380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39875415,0.6007715,0.000009756425,0.000017776352,0.00012893882,0.00017766087,0.00012477317,0.0000035778191,0.000011851876],"genre_scores_gemma":[0.122253634,0.87731814,0.00013554844,0.000020826312,0.000101718586,0.000010490579,0.000053736047,0.000029799347,0.000076117685],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959422,0.0018496237,0.001432187,0.00026589434,0.00015567165,0.00035442383],"domain_scores_gemma":[0.9941348,0.0012994462,0.0039034216,0.00041548468,0.00019193052,0.000054960743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080947287,0.00044479713,0.0037420404,0.0008846847,0.0001036395,0.000026940585,0.000596363,0.00022214762,0.000043874457],"category_scores_gemma":[0.00015807681,0.0002731401,0.0006984609,0.0009328013,0.00033541114,0.000016742848,0.00009161589,0.00048768055,0.000005171677],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004425015,0.00008266425,0.008872411,0.00016466905,0.008557723,0.000022185159,0.0013421777,0.000027063088,0.00005629808,0.0000018818711,0.00003114539,0.9807975],"study_design_scores_gemma":[0.006963139,0.01569342,0.49668446,0.01265662,0.19604531,0.0030196328,0.004332466,0.0000085245765,0.00015105472,0.0050548585,0.2554008,0.0039896932],"about_ca_topic_score_codex":0.000033114768,"about_ca_topic_score_gemma":0.00010510503,"teacher_disagreement_score":0.97680783,"about_ca_system_score_codex":0.0001828878,"about_ca_system_score_gemma":0.00018062165,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W2190836745","doi":"10.1016/j.jaad.2015.09.001","title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma; Janssen Pharmaceuticals; Les Laboratories Pierre Fabre; Celgene; Amgen; Pfizer; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Scalp; Nail (fastener); Randomized controlled trial; Randomization; Internal medicine; Dermatology; Psoriasis Area and Severity Index; Surgery; Psoriatic arthritis; Pathology","score_opus":0.02141852448562145,"score_gpt":0.29201591086730627,"score_spread":0.27059738638168485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2190836745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944888,0.0028987273,0.000011808909,0.0012670574,0.00024089101,0.000973711,0.00008155335,0.000007120495,0.000030360718],"genre_scores_gemma":[0.9989828,0.00033801424,0.0003684743,0.00018323622,0.000033226777,0.000024371993,0.000008808399,0.000016720152,0.00004436908],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936068,0.0034387365,0.002238076,0.00026014904,0.00014767773,0.0003085382],"domain_scores_gemma":[0.9939901,0.0017833035,0.0037096934,0.0001751244,0.00021073586,0.00013099963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019651426,0.00033543157,0.004957602,0.00030530168,0.00006175055,0.000011161112,0.0002925925,0.00021185864,0.0000035637445],"category_scores_gemma":[0.001646544,0.00017152695,0.00028602107,0.00030496466,0.0010251858,0.0001742274,0.00010136985,0.00032069295,0.0000012663676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9350522,0.0014799598,0.031374272,0.00002849992,0.0016434365,0.000019404428,0.0023087582,0.000020218211,0.0064738523,0.00003683924,0.001259886,0.020302663],"study_design_scores_gemma":[0.94069314,0.0025566213,0.01723937,0.0002487116,0.00214286,0.0006776273,0.001143215,0.000008862959,0.03461865,0.000071903145,0.0003365136,0.00026255075],"about_ca_topic_score_codex":0.00007842947,"about_ca_topic_score_gemma":0.000012361298,"teacher_disagreement_score":0.0281448,"about_ca_system_score_codex":0.00003700721,"about_ca_system_score_gemma":0.00012981586,"threshold_uncertainty_score":0.6994666},"labels":[],"label_agreement":null},{"id":"W2204505485","doi":"10.1016/j.jaad.2015.08.030","title":"Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study","year":2015,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Public Health Ontario; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Ustekinumab; Psoriasis; Adalimumab; Infliximab; Etanercept; Psoriasis Area and Severity Index; Dermatology; Internal medicine; Clinical trial; Disease; Tumor necrosis factor alpha","score_opus":0.07845842287127083,"score_gpt":0.377885283379961,"score_spread":0.29942686050869016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2204505485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96386075,0.001097045,0.0000019308425,0.032765888,0.0005831979,0.0013726706,0.00026412855,0.000002962213,0.00005140879],"genre_scores_gemma":[0.9909847,0.002469016,0.000133574,0.006132195,0.00013188653,0.000047041452,0.0000273598,0.000028124443,0.000046131303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9851867,0.011223286,0.0024945969,0.00036918654,0.00022346132,0.0005027876],"domain_scores_gemma":[0.9898097,0.004789238,0.004674069,0.00041068575,0.0002567884,0.000059513382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022406687,0.000434567,0.0031567055,0.0010662265,0.000044561173,0.0000042626316,0.0010949209,0.0010480077,0.000008870969],"category_scores_gemma":[0.00068654044,0.0002557773,0.0005433979,0.0008997739,0.00091984746,0.00011379613,0.00010108858,0.0021110193,0.0000030031547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008487221,0.0014397429,0.9556961,0.00010748708,0.0048056734,0.00039268078,0.0018082343,0.00024364737,0.0014090234,0.000024655199,0.022784758,0.0028007997],"study_design_scores_gemma":[0.008170166,0.0045188204,0.9250187,0.00050485355,0.0040653436,0.002466594,0.0012056844,0.0000036215338,0.004994902,0.00019052047,0.04839667,0.00046411087],"about_ca_topic_score_codex":0.026095374,"about_ca_topic_score_gemma":0.0038231357,"teacher_disagreement_score":0.030677361,"about_ca_system_score_codex":0.0003459721,"about_ca_system_score_gemma":0.0010256274,"threshold_uncertainty_score":0.99998945},"labels":[],"label_agreement":null},{"id":"W2209763605","doi":"10.1136/annrheumdis-2015-eular.3592","title":"SAT0560 Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Current Status of Observations","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Manitoba","funders":"","keywords":"Medicine; Ustekinumab; Adalimumab; Etanercept; Infliximab; Psoriatic arthritis; Internal medicine; Psoriasis; Hazard ratio; Incidence (geometry); Population; Cohort; Cumulative incidence; Proportional hazards model; Cohort study; Disease; Rheumatoid arthritis; Immunology; Confidence interval; Environmental health","score_opus":0.12902274584544143,"score_gpt":0.36466315501737656,"score_spread":0.23564040917193513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2209763605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325246,0.0054459902,0.0000075416274,0.00022836296,0.00042536322,0.0004884662,0.000101908496,0.000009340763,0.000040559906],"genre_scores_gemma":[0.9985459,0.0012628296,0.000010338342,0.000016528616,0.000007990342,0.0000767767,0.000041536656,0.0000055393884,0.000032604727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870557,0.000531857,0.0003346548,0.00014113812,0.00010072287,0.00018606304],"domain_scores_gemma":[0.99902016,0.00020151459,0.0002787507,0.00037190766,0.00009894936,0.000028746828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034434753,0.00012533074,0.00025540363,0.000060638766,0.00009020401,0.0000056011218,0.00017690336,0.00003907143,0.000011516775],"category_scores_gemma":[0.00024840835,0.00007343527,0.00009403461,0.00020518292,0.00009501199,0.000090133,0.00008136112,0.00007096547,0.000003082709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008853869,0.0015190089,0.95550656,0.000066325025,0.00028996915,4.2409408e-7,0.0010984108,0.000033133747,0.000019111843,0.00015313065,0.0006756294,0.04054976],"study_design_scores_gemma":[0.0011903502,0.00021912274,0.9957409,0.00015195552,0.00025280198,0.0000030552626,0.0010005125,0.0000057785464,0.0000901131,0.0010591837,0.0002182225,0.0000680214],"about_ca_topic_score_codex":0.0008678238,"about_ca_topic_score_gemma":0.00019844521,"teacher_disagreement_score":0.040481735,"about_ca_system_score_codex":0.000022879642,"about_ca_system_score_gemma":0.00014898651,"threshold_uncertainty_score":0.29946035},"labels":[],"label_agreement":null},{"id":"W2212760020","doi":"10.1080/21645515.2015.1081322","title":"A systematic review on the efficacy and safety of Infliximab in patients with psoriasis","year":2015,"lang":"en","type":"review","venue":"Human Vaccines & Immunotherapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Peking University; University of Lethbridge","keywords":"Infliximab; Psoriasis; Medicine; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Psoriatic arthritis; Meta-analysis; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.03789805417563061,"score_gpt":0.2927388868412876,"score_spread":0.25484083266565705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2212760020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010412184,0.994237,3.972516e-7,0.000017396565,0.0001676763,0.0043009003,0.00008101245,0.000028511615,0.00012589301],"genre_scores_gemma":[0.00040131607,0.9983655,0.0000057056577,0.0001246363,0.00001731614,0.00030761378,0.00031148855,0.00008116905,0.0003852181],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966363,0.0011396686,0.0013824455,0.00039954847,0.00011036986,0.00033172526],"domain_scores_gemma":[0.99692035,0.0007359133,0.0010939434,0.0010722212,0.00015839422,0.000019171881],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007356472,0.0006931665,0.0034404607,0.00022702347,0.00014567429,0.000017879478,0.00052317826,0.00037688226,0.000104128725],"category_scores_gemma":[0.000073141855,0.00035106315,0.00027959555,0.00038912645,0.00009459946,0.000043977747,0.00008360589,0.00036935485,0.00008177436],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086372066,0.0013769224,0.00029780777,0.6565501,0.008606691,0.000004184893,0.0006592016,2.6264763e-7,0.0000030766569,0.00085822074,0.00028886233,0.33049095],"study_design_scores_gemma":[0.009057775,0.0012407376,0.0011299504,0.7146644,0.0142365685,0.000023647048,0.000037282494,4.5282057e-8,0.000005549998,0.000023864339,0.2587831,0.0007970558],"about_ca_topic_score_codex":0.000012314416,"about_ca_topic_score_gemma":0.000009980789,"teacher_disagreement_score":0.32969388,"about_ca_system_score_codex":0.000114944545,"about_ca_system_score_gemma":0.00011015896,"threshold_uncertainty_score":0.99989414},"labels":[],"label_agreement":null},{"id":"W2213602427","doi":"10.1177/1203475415586332","title":"The Relationship of Obesity With the Severity of Psoriasis","year":2015,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Body mass index; Obesity; Psoriasis Area and Severity Index; Systemic inflammation; Internal medicine; Adipokine; Disease; Dermatology; Inflammation; Insulin resistance","score_opus":0.06840376014098393,"score_gpt":0.29808462564457056,"score_spread":0.22968086550358663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2213602427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010562074,0.98799795,0.0000043963164,0.0003652674,0.00069721614,0.00015872884,0.000018702009,0.0000031296418,0.00019251052],"genre_scores_gemma":[0.009860963,0.989279,0.00000772662,0.000017877159,0.00017449811,0.0000028964112,0.00001578126,0.0000136105455,0.0006276654],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781454,0.0007975553,0.00097438716,0.00010714697,0.00014146915,0.00016488993],"domain_scores_gemma":[0.9886596,0.008800741,0.0019085216,0.00026763714,0.0003263101,0.000037186062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020812734,0.00023369127,0.0019399445,0.00016551565,0.00015719108,0.000004115118,0.0002066535,0.00026117705,0.000029389845],"category_scores_gemma":[0.00073184853,0.00008700961,0.00035689384,0.00023511787,0.0005594243,0.00003234298,0.000025961208,0.0004117075,0.0000028097402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038375932,0.00007863901,0.0030031991,0.0013216034,0.001819294,0.00013043536,0.00043824012,1.9330768e-7,0.0000032648493,0.000077979064,0.025886517,0.9668569],"study_design_scores_gemma":[0.0003564515,0.00038774445,0.00045925094,0.005032371,0.004080623,0.011778957,0.00037452884,3.430303e-8,0.000009110834,0.000116410585,0.9772942,0.000110308094],"about_ca_topic_score_codex":0.000025282732,"about_ca_topic_score_gemma":0.000015646416,"teacher_disagreement_score":0.96674657,"about_ca_system_score_codex":0.000029003872,"about_ca_system_score_gemma":0.0005323324,"threshold_uncertainty_score":0.35481492},"labels":[],"label_agreement":null},{"id":"W221516563","doi":"10.1074/jbc.c600256200","title":"Act1 Adaptor Protein Is an Immediate and Essential Signaling Component of Interleukin-17 Receptor","year":2006,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Signal transducing adaptor protein; Cell biology; Signal transduction; Proinflammatory cytokine; Biology; Receptor; Chemokine; SOCS3; Inflammation; Immunology; STAT3; Genetics","score_opus":0.019661853618939847,"score_gpt":0.23178078422341022,"score_spread":0.21211893060447037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W221516563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974397,0.002018483,0.000026635189,0.00010750767,0.00013048355,0.00007019191,0.000070287744,0.000010167341,0.00012658966],"genre_scores_gemma":[0.99888045,0.00008340056,0.00039228747,0.000020128418,0.0002396477,0.0000033983029,0.00007028269,0.0000064116593,0.0003039792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899346,0.00009238617,0.00050562876,0.00017110596,0.000045600675,0.00019184162],"domain_scores_gemma":[0.999212,0.00007262517,0.00047686117,0.000103504775,0.00009348916,0.000041491498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023056267,0.00016417341,0.00039355882,0.000029699793,0.000056342833,0.000009775596,0.0001734898,0.00031562112,0.0006568094],"category_scores_gemma":[0.00003220166,0.00010922742,0.00015111404,0.00004697397,0.00019382391,0.00005454688,0.00004741363,0.00020939796,0.000005523066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069712364,0.00031180924,0.0022672191,0.000022077797,0.0001378983,0.0000123602285,0.00005227907,8.7681303e-7,0.99449784,0.0000061480728,0.000406023,0.0015883642],"study_design_scores_gemma":[0.0012824663,0.00037849587,0.0025147088,0.00006752608,0.0000560257,0.000098284414,0.0001302584,8.66672e-7,0.993841,0.00009058216,0.0014196315,0.000120137505],"about_ca_topic_score_codex":0.000014159413,"about_ca_topic_score_gemma":4.4165014e-7,"teacher_disagreement_score":0.0019350824,"about_ca_system_score_codex":0.00002971936,"about_ca_system_score_gemma":0.000032938406,"threshold_uncertainty_score":0.71916026},"labels":[],"label_agreement":null},{"id":"W2224097706","doi":"10.1007/s40257-015-0161-5","title":"Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials","year":2015,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Adalimumab; Psoriasis; Placebo; Internal medicine; Psoriasis Area and Severity Index; Adverse effect; Post-hoc analysis; Clinical trial; Discontinuation; Population; Dermatology; Rheumatoid arthritis","score_opus":0.11885768880016609,"score_gpt":0.3976571667334317,"score_spread":0.27879947793326565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224097706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99403584,0.00072168006,0.00007493443,0.0017212827,0.001373879,0.0016320669,0.00038097348,0.000023781173,0.000035577323],"genre_scores_gemma":[0.99780697,0.00047398522,0.0006104587,0.0006230959,0.0001610822,0.000045503806,0.00017409853,0.000042094394,0.00006269082],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9761924,0.012935322,0.009165968,0.00078992144,0.00031706947,0.0005992766],"domain_scores_gemma":[0.96137226,0.028456446,0.0076814634,0.0008756099,0.0012577226,0.00035647504],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010940213,0.00053940667,0.009402485,0.0012190313,0.00007776739,0.000026752925,0.00086738693,0.00068873574,0.000089411275],"category_scores_gemma":[0.0153714605,0.0003208893,0.0016645333,0.001536384,0.0006950695,0.00014864848,0.0001105031,0.0008219621,0.000056287117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74724215,0.0019804535,0.14656188,0.0000031990733,0.018462958,0.00011655716,0.0006944092,0.000075263306,0.00010933026,0.0000051574016,0.0002332951,0.08451535],"study_design_scores_gemma":[0.5477309,0.017722057,0.4245068,0.00020692367,0.0077430094,0.00007234379,0.0006384336,0.000014447805,0.00029216195,0.0000071346367,0.00066796277,0.00039781161],"about_ca_topic_score_codex":0.00028284712,"about_ca_topic_score_gemma":0.00072464364,"teacher_disagreement_score":0.27794492,"about_ca_system_score_codex":0.000083169674,"about_ca_system_score_gemma":0.0012544391,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2230886991","doi":"10.1016/j.annder.2015.10.109","title":"Effets de l’aprémilast sur le prurit chez des patients atteints de psoriasis en plaques modéré à sévère : résultats des études ESTEEM 1 et 2 de phase 3","year":2015,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.07426033661388794,"score_gpt":0.3273378915377232,"score_spread":0.25307755492383527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230886991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95551157,0.035111483,0.0016085089,0.0034148544,0.0009248445,0.0007803558,0.00076936895,0.0006287984,0.0012502286],"genre_scores_gemma":[0.9689416,0.015572603,0.010178811,0.0023483615,0.00016937728,0.00037793547,0.00070116646,0.0001541911,0.0015559158],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9877889,0.0063010063,0.0010690369,0.001160121,0.00020673251,0.003474159],"domain_scores_gemma":[0.99427956,0.0031605808,0.00054110854,0.0008481564,0.0005500515,0.00062055956],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002767363,0.0012619941,0.0014727247,0.00042916674,0.00064326,0.00020221954,0.0013522019,0.0024079967,0.00012698615],"category_scores_gemma":[0.00499232,0.0012693425,0.00058820983,0.0005099628,0.0018339424,0.00086821354,0.0006024414,0.0011129178,0.00045942483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031184787,0.008595903,0.8283041,0.00091645075,0.0029613955,0.0036348084,0.020123612,0.00093191775,0.01524197,0.0020608355,0.03126343,0.08284709],"study_design_scores_gemma":[0.035921197,0.0042487774,0.41476777,0.0017129903,0.0024858615,0.008521307,0.0063792276,0.00055514526,0.41838703,0.019849842,0.08356093,0.0036099367],"about_ca_topic_score_codex":0.0014295799,"about_ca_topic_score_gemma":0.002006615,"teacher_disagreement_score":0.41353634,"about_ca_system_score_codex":0.0020185169,"about_ca_system_score_gemma":0.0050809686,"threshold_uncertainty_score":0.99897563},"labels":[],"label_agreement":null},{"id":"W2231288659","doi":"10.1016/j.annder.2015.10.104","title":"Ixekizumab dans le traitement du psoriasis en plaques modéré à sévère : résultats à 60 semaines d’une étude de phase 3, en double aveugle, avec une phase d’induction suivie d’une phase de re-randomisation (UNCOVER-1)","year":2015,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Ixekizumab; Gynecology; Psoriasis; Secukinumab; Dermatology","score_opus":0.05384061089742038,"score_gpt":0.32926707850923764,"score_spread":0.27542646761181727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231288659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9283039,0.016926356,0.016631383,0.031039638,0.0024230666,0.0016543184,0.0009152311,0.00071608543,0.0013899978],"genre_scores_gemma":[0.974828,0.014827101,0.003310414,0.0013030366,0.00065628893,0.0007997458,0.0025581324,0.0001543946,0.001562862],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9893381,0.0044732904,0.0016754024,0.0014581492,0.0003094454,0.0027455897],"domain_scores_gemma":[0.99498683,0.0020042271,0.0009477564,0.0010562561,0.00045418774,0.0005507364],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0034392052,0.0014265624,0.0019088117,0.0006166605,0.0008764308,0.00020841774,0.0011129311,0.002390709,0.00018191786],"category_scores_gemma":[0.0015920156,0.0014262212,0.0007818082,0.0011232987,0.0009832447,0.0011537081,0.00031268282,0.0011264352,0.00026864832],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070627466,0.033689182,0.011856984,0.0012783486,0.010024071,0.01679313,0.18171646,0.011853327,0.20576724,0.005755641,0.11604235,0.3345958],"study_design_scores_gemma":[0.24775404,0.0067837895,0.0053382115,0.00070934556,0.0050104694,0.014106183,0.045578167,0.0058562225,0.5403103,0.0133629395,0.11156531,0.0036249913],"about_ca_topic_score_codex":0.0044426373,"about_ca_topic_score_gemma":0.0039355136,"teacher_disagreement_score":0.33454308,"about_ca_system_score_codex":0.0020480973,"about_ca_system_score_gemma":0.0031559076,"threshold_uncertainty_score":0.9998484},"labels":[],"label_agreement":null},{"id":"W2237180614","doi":"10.1016/s0140-6736(16)00048-9","title":"Ixekizumab for psoriasis – Authors' reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Psoriasis; Scopus; Ixekizumab; Medicine; Psychosocial; Depression (economics); Etanercept; Disease; Psychiatry; Immunology; MEDLINE; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis; Secukinumab","score_opus":0.03980343883148937,"score_gpt":0.269108292380619,"score_spread":0.22930485354912963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2237180614","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005773142,0.004310792,0.00012151896,0.97862524,0.0074003474,0.0007981776,0.0026372992,0.0002462988,0.0052830055],"genre_scores_gemma":[0.0010130424,0.00064578693,0.00023507905,0.71653813,0.03738973,0.0008312138,0.0026731268,0.00013983606,0.24053404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792814,0.00036843415,0.0003059038,0.00051836466,0.000051079893,0.00082805404],"domain_scores_gemma":[0.99752116,0.000779747,0.00025191368,0.0013645843,0.000070113536,0.000012459661],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046820557,0.00040615103,0.0008871636,0.00007879251,0.00032223266,0.000031333686,0.0009099777,0.0010759579,0.0007443119],"category_scores_gemma":[0.00012229943,0.00021571416,0.00036516535,0.00007251524,0.000171127,0.000040711497,0.000089337045,0.0006601767,0.002092167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035653758,0.000010131106,0.000025613326,0.000049408223,0.0007914383,0.00001687501,0.000111298636,3.2104712e-8,0.00055695703,0.00018293147,0.94172025,0.056178525],"study_design_scores_gemma":[0.0028402745,0.00011944883,0.00014693635,0.000080210455,0.00048450255,0.000051093128,0.0000082704955,9.625952e-8,0.0027944935,0.0018645604,0.99129385,0.00031627103],"about_ca_topic_score_codex":0.000026569478,"about_ca_topic_score_gemma":0.000005297155,"teacher_disagreement_score":0.2620871,"about_ca_system_score_codex":0.00006220752,"about_ca_system_score_gemma":0.000066897,"threshold_uncertainty_score":0.9986848},"labels":[],"label_agreement":null},{"id":"W2238151847","doi":"10.1016/j.jaad.2015.09.056","title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novartis Pharmaceuticals Corporation; Pfizer; Amgen; Abbott Laboratories","keywords":"Medicine; Etanercept; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Severity of illness; Dermatology","score_opus":0.007268308609013646,"score_gpt":0.2422221157195497,"score_spread":0.23495380711053607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238151847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552274,0.0019168967,0.00002341464,0.002322236,0.000055997272,0.0001249407,0.000021089521,0.0000031611562,0.000009499889],"genre_scores_gemma":[0.99705493,0.0027375077,0.00005759383,0.00010296294,0.00001531755,8.261343e-7,7.3243353e-7,0.0000097612365,0.00002033762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998721,0.0003684586,0.00052015693,0.00013945707,0.00004951496,0.00020141999],"domain_scores_gemma":[0.99861336,0.00018301512,0.0010464838,0.000101522346,0.000024954472,0.00003065159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011734751,0.00015220577,0.0006989834,0.00017472383,0.000038541406,0.000001671626,0.00025141315,0.0001343035,0.000011227276],"category_scores_gemma":[0.000040813782,0.00007656417,0.000084725005,0.00014510576,0.0010116198,0.00006952431,0.0000803752,0.00021554,0.0000018433286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002412805,0.000113361966,0.93538004,0.000015141997,0.0003767721,0.000006695451,0.00013462528,6.473109e-7,0.02845944,0.000035204135,0.000045260473,0.033020005],"study_design_scores_gemma":[0.005567549,0.00019701589,0.96024597,0.00028991577,0.00020661109,0.0055582593,0.000028485074,6.215377e-8,0.027749896,0.000019914549,0.000051467312,0.00008487233],"about_ca_topic_score_codex":0.000016935957,"about_ca_topic_score_gemma":0.0000056610565,"teacher_disagreement_score":0.03293513,"about_ca_system_score_codex":0.00001898294,"about_ca_system_score_gemma":0.00004262249,"threshold_uncertainty_score":0.37273553},"labels":[],"label_agreement":null},{"id":"W2257545295","doi":"10.1016/j.jaad.2015.12.017","title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Innovaderm (Canada); Probity Medical Research","funders":"Medac; Janssen Scientific Affairs; Eli Lilly and Company; Galderma; Incyte; Dermira; University of Connecticut; Celgene; Amgen; Pfizer; GlaxoSmithKline; Abbott Laboratories","keywords":"Ustekinumab; Medicine; Adalimumab; Etanercept; Infliximab; Psoriasis; Internal medicine; Observational study; Psoriasis Area and Severity Index; Body surface area; Odds ratio; Dermatology; Tumor necrosis factor alpha","score_opus":0.09110685648330386,"score_gpt":0.3823672007373807,"score_spread":0.2912603442540768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257545295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605864,0.0008188468,0.00009359877,0.0012056738,0.00023229246,0.0009553984,0.0006079628,0.000004492645,0.000023101235],"genre_scores_gemma":[0.99860865,0.0008034289,0.0003974528,0.000019186791,0.000033809785,0.00007749352,0.000010200786,0.00000955523,0.0000402447],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967025,0.0015753917,0.001069091,0.00028964362,0.00010470249,0.0002586756],"domain_scores_gemma":[0.991371,0.005440646,0.0027862203,0.00022385418,0.00015427306,0.000024027066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006908333,0.00024654993,0.001361174,0.00019716924,0.00011274416,0.0000035444373,0.00039972435,0.00012220744,0.000007754036],"category_scores_gemma":[0.0001725491,0.00011762205,0.00027973714,0.0003481848,0.0006847316,0.00007849611,0.00008029958,0.00016623417,5.3484655e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077322056,0.0016100889,0.96166,0.000020719806,0.002690832,0.000005280783,0.00088883925,0.00001093937,0.02287232,0.0003285354,0.00012465792,0.0020555404],"study_design_scores_gemma":[0.011308206,0.0014765841,0.94199854,0.00013912722,0.00064046524,0.00006346507,0.0008617717,0.000004453874,0.04260955,0.00047682383,0.00031854562,0.00010246472],"about_ca_topic_score_codex":0.0003171718,"about_ca_topic_score_gemma":0.00013324196,"teacher_disagreement_score":0.019737229,"about_ca_system_score_codex":0.0001596683,"about_ca_system_score_gemma":0.00015526923,"threshold_uncertainty_score":0.4796488},"labels":[],"label_agreement":null},{"id":"W2259186441","doi":"10.1586/14737167.2016.1133301","title":"Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis","year":2015,"lang":"en","type":"review","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Secukinumab; Ustekinumab; Medicine; Etanercept; Psoriasis; Plaque psoriasis; Dermatology; Quality of life (healthcare); Cost effectiveness; Intensive care medicine; Internal medicine; Psoriatic arthritis; Adalimumab; Tumor necrosis factor alpha","score_opus":0.125425104094077,"score_gpt":0.5415789431220314,"score_spread":0.41615383902795433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259186441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003649529,0.9881549,0.000006015837,0.00064788887,0.0018076195,0.00652582,0.0020906327,0.000024344785,0.00070631265],"genre_scores_gemma":[0.0000036121849,0.9936531,0.000597784,0.0011797595,0.0002888836,0.0018993153,0.0009516202,0.00012899513,0.0012969056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914184,0.0025267475,0.0038601805,0.0012274337,0.00013109349,0.00083610014],"domain_scores_gemma":[0.99376404,0.0030007951,0.0012546444,0.0012027157,0.0005211095,0.00025670198],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008652098,0.0008741494,0.008620329,0.0004963634,0.00014653962,0.00002282054,0.0013033492,0.0006597289,0.0012385052],"category_scores_gemma":[0.0006729368,0.00067973475,0.002093167,0.00023048797,0.0004026862,0.0001497684,0.00064955506,0.00075726,0.000670924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012727713,0.00012610889,0.00001959877,0.19254503,0.0018589653,0.0000019487907,0.000038329294,1.203739e-7,0.0000019133533,0.00014792536,0.112743065,0.6923897],"study_design_scores_gemma":[0.0019778244,0.00024359819,0.0000022382737,0.11117409,0.0012381435,0.000043286407,0.000012914525,0.0000014773674,0.00004179209,0.00003194873,0.88473094,0.00050173496],"about_ca_topic_score_codex":0.000083727406,"about_ca_topic_score_gemma":0.000010263676,"teacher_disagreement_score":0.77198786,"about_ca_system_score_codex":0.00042195347,"about_ca_system_score_gemma":0.001812329,"threshold_uncertainty_score":0.9996745},"labels":[],"label_agreement":null},{"id":"W2259478424","doi":"10.1016/j.atherosclerosis.2015.04.187","title":"HLA-Class I genes are associated with a higher burden of atherosclerosis in patients with psoriatic disease","year":2015,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Human leukocyte antigen; Psoriasis; Medicine; Disease; Inflammation; Immunology; Phenotype; Gene; Antigen; Internal medicine; Genetics; Biology","score_opus":0.024429690111078785,"score_gpt":0.20680075013412863,"score_spread":0.18237106002304984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259478424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761856,0.0008141186,0.0000060225216,0.00012713388,0.00031741775,0.0005560758,0.00029002567,0.00009589412,0.00017476245],"genre_scores_gemma":[0.99836534,0.00005950286,0.00006777023,0.000062428044,0.00003146501,0.00015519647,0.00024246213,0.00007864781,0.0009371577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794656,0.00033197636,0.0004265341,0.00053718407,0.0001994758,0.0005582803],"domain_scores_gemma":[0.9984855,0.00013951275,0.00044600104,0.00054882374,0.000254542,0.00012563927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022206033,0.00044093255,0.00067683565,0.00016032379,0.00010413158,0.000022867996,0.00031051153,0.00026493854,0.00018008656],"category_scores_gemma":[0.00007114073,0.00031588183,0.000118715776,0.00054674386,0.000232612,0.00017934544,0.00007171352,0.00015316448,0.00010471895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011406168,0.0011129816,0.9917337,0.000019454954,0.0006188332,0.000001787163,0.00078499457,0.00012587316,0.0023285248,0.00003921963,0.00031208154,0.0017819796],"study_design_scores_gemma":[0.011984894,0.0008214864,0.98324585,0.00041450522,0.00043370316,2.0413376e-7,0.00022961543,0.0000059601734,0.0020193958,0.000030498499,0.0003980451,0.0004158674],"about_ca_topic_score_codex":0.00032850058,"about_ca_topic_score_gemma":0.00016414434,"teacher_disagreement_score":0.010844277,"about_ca_system_score_codex":0.00018909898,"about_ca_system_score_gemma":0.000109419576,"threshold_uncertainty_score":0.9999293},"labels":[],"label_agreement":null},{"id":"W2261560227","doi":"10.4049/jimmunol.1500437","title":"Cooperation between IL-7 Receptor and Integrin α2β1 (CD49b) Drives Th17-Mediated Bone Loss","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Centre Hospitalier Universitaire de Québec; Université Laval","keywords":"Osteoclast; Cell biology; Integrin; CD49b; PI3K/AKT/mTOR pathway; Protein kinase B; MAPK/ERK pathway; Cytokine; Receptor; Chemistry; Cancer research; Signal transduction; Biology; Immunology; T cell; Interleukin 21; Biochemistry","score_opus":0.023715167169564403,"score_gpt":0.24294056162394992,"score_spread":0.21922539445438552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261560227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97980815,0.016822655,0.00015046608,0.0017034614,0.0011703807,0.00011926159,0.000028308314,0.000021269574,0.00017605611],"genre_scores_gemma":[0.9961396,0.0025751246,0.00012517496,0.00007393322,0.00015325617,0.0000032036028,0.00005375234,0.000015150553,0.0008608252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982762,0.00081904256,0.0004831681,0.00011428132,0.000044190063,0.00026316126],"domain_scores_gemma":[0.9987019,0.00046225268,0.00036974053,0.00020107339,0.00022808812,0.000036973463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009248109,0.0001849894,0.00044833325,0.0001535847,0.00015288348,0.000013353848,0.00026792637,0.00029021065,0.00012357377],"category_scores_gemma":[0.00029715136,0.00011106945,0.00007217089,0.00013809271,0.00042136756,0.00015019262,0.00009107109,0.00042497247,0.00026238858],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035947855,0.00026098595,0.028179275,0.00000907551,0.003043606,0.000036949677,0.007168915,0.000012037498,0.88359416,0.00065748545,0.008929504,0.06451325],"study_design_scores_gemma":[0.02898849,0.010336021,0.1843651,0.00026220598,0.0023491771,0.00694055,0.008443617,0.0000055454234,0.49088436,0.00205246,0.26423484,0.0011376264],"about_ca_topic_score_codex":0.00004488558,"about_ca_topic_score_gemma":0.000012617228,"teacher_disagreement_score":0.3927098,"about_ca_system_score_codex":0.000059686245,"about_ca_system_score_gemma":0.00010634548,"threshold_uncertainty_score":0.45292807},"labels":[],"label_agreement":null},{"id":"W2262165924","doi":"10.1136/annrheumdis-2015-eular.2000","title":"SAT0559 Malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"","keywords":"Cognition; Medicine; Audiology; Comprehension; Cognitive psychology; Psychology; Psychiatry","score_opus":0.15537927818480918,"score_gpt":0.3572144170035453,"score_spread":0.2018351388187361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262165924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804182,0.018102245,0.0000069071707,0.00041198634,0.000323536,0.0004302073,0.00022179884,0.000009097721,0.00007603538],"genre_scores_gemma":[0.99843454,0.0013275347,0.0000295163,0.000027735121,0.000008110217,0.000073844254,0.000037226913,0.0000062496374,0.00005526077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858296,0.00050982396,0.0003893135,0.00016156478,0.00011870958,0.00023765609],"domain_scores_gemma":[0.9987442,0.0003387089,0.0002847958,0.00047627298,0.00012264679,0.000033413162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004175461,0.0001462896,0.00031890118,0.000059586826,0.00009907586,0.000012109218,0.0003086525,0.00004044388,0.00001719188],"category_scores_gemma":[0.0003365673,0.00008217585,0.00011022445,0.00021017028,0.00019527184,0.000092917275,0.000112773574,0.000074164345,0.000003336717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001093122,0.001717906,0.9610548,0.00010498103,0.00038629698,0.0000015251688,0.0026058138,0.000017539494,0.00006952064,0.00092973927,0.002732701,0.030269882],"study_design_scores_gemma":[0.0010737607,0.0001986888,0.9916453,0.00020287979,0.00027780925,0.00000313667,0.004600525,0.000004005703,0.00021300683,0.0012466299,0.0004508841,0.00008341718],"about_ca_topic_score_codex":0.0003716731,"about_ca_topic_score_gemma":0.00009555431,"teacher_disagreement_score":0.030590475,"about_ca_system_score_codex":0.000016987451,"about_ca_system_score_gemma":0.00020051672,"threshold_uncertainty_score":0.3351034},"labels":[],"label_agreement":null},{"id":"W2263144298","doi":"10.1111/ijd.13236","title":"Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials","year":2016,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"Novartis Pharmaceuticals Corporation; Pfizer; Tufts Medical Center; Eli Lilly and Company; Amgen","keywords":"Medicine; Secukinumab; Itching; Placebo; Dermatology; Randomized controlled trial; Psoriasis; Clinical trial; Physical therapy; Alternative medicine; Surgery; Internal medicine; Psoriatic arthritis","score_opus":0.0335983227720286,"score_gpt":0.35784562277628895,"score_spread":0.32424730000426033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263144298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901612,0.0027317493,0.0016307405,0.0014313508,0.0033050429,0.00045916782,0.000097765034,0.000011474142,0.00017152196],"genre_scores_gemma":[0.99883926,0.00055798073,0.00026374575,0.000065897,0.0001373435,0.000016296586,0.00002156233,0.00001305867,0.00008486954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98971766,0.005064598,0.0046125157,0.00023971862,0.00015529501,0.00021020841],"domain_scores_gemma":[0.9806059,0.012828153,0.0054903817,0.00018535391,0.00083441654,0.000055816923],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004612314,0.00023017288,0.002498239,0.00041351057,0.000038594964,0.000009942733,0.0003152052,0.00029377406,0.00007785289],"category_scores_gemma":[0.014617952,0.00013109333,0.00090517686,0.00005715175,0.00046966484,0.00014048214,0.000073495015,0.00017357057,0.0000043553046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5719035,0.000991894,0.0033233394,0.000013042527,0.0131829,0.00031681257,0.00055504474,0.0000012187504,0.067691796,0.000887421,0.0005786639,0.34055433],"study_design_scores_gemma":[0.9120853,0.0009528455,0.00020838394,0.00023666555,0.0014382091,0.0048186835,0.00012816528,0.000028869244,0.07701754,0.0015295629,0.0013871408,0.0001686215],"about_ca_topic_score_codex":0.0000220182,"about_ca_topic_score_gemma":0.0000047710846,"teacher_disagreement_score":0.3403857,"about_ca_system_score_codex":0.000027687984,"about_ca_system_score_gemma":0.00021498126,"threshold_uncertainty_score":0.9936823},"labels":[],"label_agreement":null},{"id":"W2263474571","doi":"10.1016/j.jval.2015.03.1051","title":"Cost-effectiveness of Secukinumab compared to current treatments for the treatment of moderate to severe plaque Psoriasis in Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Secukinumab; Ustekinumab; Medicine; Etanercept; Adalimumab; Infliximab; Ixekizumab; Psoriasis; Quality-adjusted life year; Cost effectiveness; Dermatology; Internal medicine; Psoriatic arthritis; Disease; Tumor necrosis factor alpha","score_opus":0.12951627574653257,"score_gpt":0.33807852997998106,"score_spread":0.20856225423344849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2263474571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944813,0.004615832,0.00017590229,0.00034847346,0.000941218,0.003679952,0.0007630413,0.000006944507,0.000020495225],"genre_scores_gemma":[0.99814904,0.00044255267,0.00014894486,0.000048148326,0.000011756136,0.0010306351,0.00012255154,0.000014372743,0.00003199387],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9980635,0.0007754954,0.00045874176,0.00027752313,0.00006008315,0.0003646771],"domain_scores_gemma":[0.9985718,0.0008674708,0.00013591105,0.00027321881,0.000075995944,0.0000755922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048517602,0.00020377208,0.0006222573,0.00014362435,0.000048718022,0.0000029280188,0.0001362183,0.0000568791,0.000005655185],"category_scores_gemma":[0.000038366186,0.00014425063,0.0000649491,0.0002640671,0.000017564122,0.000025782248,0.00002037312,0.000048274233,0.000005416891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030750481,0.005740536,0.17219749,0.0006510691,0.0015533433,0.000019833671,0.03210027,0.43186575,0.0014112272,0.0011593585,0.0015340219,0.3210166],"study_design_scores_gemma":[0.12534219,0.01808875,0.6423878,0.0029480462,0.0006876939,0.00006467909,0.008389001,0.004067683,0.14730808,0.0013946678,0.04766734,0.0016540439],"about_ca_topic_score_codex":0.82466334,"about_ca_topic_score_gemma":0.5918488,"teacher_disagreement_score":0.47019035,"about_ca_system_score_codex":0.0022568041,"about_ca_system_score_gemma":0.0020597174,"threshold_uncertainty_score":0.5901464},"labels":[],"label_agreement":null},{"id":"W2266212047","doi":"10.7554/elife.10087","title":"The NFκB-inducing kinase is essential for the developmental programming of skin-resident and IL-17-producing γδ T cells","year":2015,"lang":"en","type":"article","venue":"eLife","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"European Commission; Universität Zürich; Yale University; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Developmental biology; Cell biology; Kinase; Biology; NF-κB; Signal transduction","score_opus":0.02801303591470131,"score_gpt":0.2571590350454822,"score_spread":0.2291459991307809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266212047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990716,0.0071147555,0.00013948602,0.0003512731,0.000980804,0.0005548472,0.000031972562,0.000024104871,0.00008676494],"genre_scores_gemma":[0.99653834,0.0002048533,0.0008170966,0.00009580571,0.00015047588,0.00010029373,0.000023803177,0.000016825485,0.0020525015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990571,0.000079190766,0.00025033174,0.00025207302,0.000063557614,0.0002977535],"domain_scores_gemma":[0.9992294,0.00030802988,0.00012783894,0.00021345213,0.00009298001,0.000028356806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063229294,0.00014982834,0.00017373687,0.000033652464,0.00047719592,0.00003461634,0.00017785773,0.000093898765,0.00002078007],"category_scores_gemma":[0.00009576812,0.00008750526,0.000074984215,0.00007055094,0.00014668355,0.00005204278,0.00010568282,0.00008082649,0.000029085055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086312497,0.00022739892,0.0064650583,0.00006617023,0.0015340468,0.000009036812,0.03174473,0.000017469612,0.49037305,0.00030640053,0.04032026,0.42807326],"study_design_scores_gemma":[0.0013388456,0.000101493046,0.002920207,0.000026872545,0.00015533845,0.000018729368,0.003469703,0.000005485444,0.9078228,0.000024485482,0.08398439,0.00013166177],"about_ca_topic_score_codex":0.00020123749,"about_ca_topic_score_gemma":0.0000933295,"teacher_disagreement_score":0.4279416,"about_ca_system_score_codex":0.000034630626,"about_ca_system_score_gemma":0.00011758249,"threshold_uncertainty_score":0.36702535},"labels":[],"label_agreement":null},{"id":"W2268073391","doi":"10.1111/pde.12782","title":"Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series","year":2016,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriasis; Adverse effect; Retrospective cohort study; Population; Sample size determination; Referral; Disease; Severity of illness; Internal medicine; Pediatrics; Dermatology","score_opus":0.012975507774910508,"score_gpt":0.23301935994841283,"score_spread":0.2200438521735023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268073391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124223,0.0047093276,0.0001643963,0.00080383226,0.0013385277,0.0004894273,0.0003737769,0.00013582046,0.0007426507],"genre_scores_gemma":[0.993674,0.0030214472,0.00026212636,0.000034392142,0.00028287197,0.000206839,0.000026552607,0.000033865756,0.0024579498],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99792457,0.00028769535,0.0005455092,0.00057160953,0.00005367368,0.0006169362],"domain_scores_gemma":[0.998753,0.0002868588,0.00024195726,0.00047196427,0.0001608144,0.00008539185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000063504354,0.00039317846,0.00078758586,0.00043936746,0.00019362576,0.000008139375,0.00017138163,0.00038568772,0.00037213403],"category_scores_gemma":[0.00009022793,0.00026333565,0.00020893173,0.00046865732,0.00008395733,0.00015488704,0.00007209461,0.00006109675,0.0010280285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030049603,0.0013129322,0.9459189,0.00010728003,0.0010025715,0.005920308,0.0027691296,0.000006185766,0.0037787163,0.002260253,0.008371462,0.025547288],"study_design_scores_gemma":[0.07473432,0.012974813,0.19091482,0.00004544106,0.012397446,0.44490093,0.0017761161,0.0000057068996,0.20720747,0.005250291,0.0444262,0.0053664497],"about_ca_topic_score_codex":0.00008147815,"about_ca_topic_score_gemma":0.00007462493,"teacher_disagreement_score":0.7550041,"about_ca_system_score_codex":0.00014412323,"about_ca_system_score_gemma":0.0001731864,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W2271791365","doi":"10.1007/s11136-015-1224-z","title":"Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice","year":2016,"lang":"en","type":"article","venue":"Quality of Life Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Schering-Plough","keywords":"Dermatology Life Quality Index; Medicine; Psoriasis; Infliximab; Internal medicine; Quality of life (healthcare); Psoriasis Area and Severity Index; Plaque psoriasis; Observational study; Physical therapy; Dermatology; Disease","score_opus":0.1392719225380195,"score_gpt":0.4097923883786874,"score_spread":0.2705204658406679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271791365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565214,0.001277994,0.000001372076,0.0013312731,0.00015074573,0.00094863435,0.00011428961,0.000018337154,0.00050522655],"genre_scores_gemma":[0.99784887,0.0013365997,0.000082313556,0.00003847207,0.000014042672,0.000044538534,0.00006792691,0.000025581025,0.0005416855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899242,0.0065262076,0.0019448083,0.000475979,0.00044242374,0.0006863677],"domain_scores_gemma":[0.99431795,0.00321139,0.0010555339,0.0006522715,0.0006750455,0.00008783956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0084132245,0.00023262357,0.0011141782,0.00076552015,0.0001032393,0.0000057374355,0.00037725287,0.0002806256,0.00018951038],"category_scores_gemma":[0.0024350556,0.00016633484,0.00009757529,0.0010763184,0.00039357113,0.00025483235,0.00013728303,0.00039125688,0.000035295005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0297794,0.002897084,0.9135852,0.0004001648,0.00066572585,0.0000013497685,0.0022542558,0.0000018223385,0.030831732,0.0008169459,0.00007556234,0.018690798],"study_design_scores_gemma":[0.021544592,0.0020295389,0.95600575,0.00030279544,0.000009255313,1.8236729e-7,0.00057900907,1.3402942e-7,0.019083163,0.0001116705,0.00015605675,0.00017786652],"about_ca_topic_score_codex":0.033080727,"about_ca_topic_score_gemma":0.0031873467,"teacher_disagreement_score":0.042420577,"about_ca_system_score_codex":0.00023217306,"about_ca_system_score_gemma":0.00072791916,"threshold_uncertainty_score":0.9733581},"labels":[],"label_agreement":null},{"id":"W2281561883","doi":"","title":"Кловейт в терапии стероидчувствительных дерматозов","year":2014,"lang":"ru","type":"article","venue":"Российский журнал кожных и венерических болезней","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Exacerbation; Medicine; Drug; Subclinical infection; Medical prescription; Corticosteroid; Psoriasis; Fluticasone propionate; Budesonide; Drug class; Dermatology; Pharmacology; Internal medicine","score_opus":0.013777620759284714,"score_gpt":0.22561620782656427,"score_spread":0.21183858706727957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281561883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6715612,0.06807196,0.0026950317,0.007716432,0.033961806,0.0043548006,0.0027542938,0.0025541764,0.20633034],"genre_scores_gemma":[0.91431713,0.0034158726,0.0008835864,0.0029199466,0.002804795,0.00031306036,0.0017917578,0.00046125427,0.073092595],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9871612,0.0025792266,0.0025324707,0.0032041217,0.000589056,0.003933885],"domain_scores_gemma":[0.9924182,0.0014348719,0.0012981216,0.003638625,0.00052008114,0.00069009204],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0022161931,0.0026321982,0.0029930626,0.0010686192,0.0018548683,0.00038160605,0.0024264397,0.0030722325,0.014313522],"category_scores_gemma":[0.0007303209,0.0025601005,0.0017119898,0.0014822923,0.0013893796,0.0007026236,0.0009477684,0.0019078435,0.043467928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028970472,0.004173483,0.016824486,0.0007835078,0.006881741,0.00040714722,0.003630882,0.00008920048,0.09403002,0.027211262,0.2246634,0.61840785],"study_design_scores_gemma":[0.011984596,0.0021682763,0.028788755,0.000641597,0.0028747234,0.00052234577,0.000908249,0.00017166883,0.04304752,0.0024129339,0.9029142,0.003565115],"about_ca_topic_score_codex":0.0005560125,"about_ca_topic_score_gemma":0.00032835602,"teacher_disagreement_score":0.6782508,"about_ca_system_score_codex":0.00051450427,"about_ca_system_score_gemma":0.0006128161,"threshold_uncertainty_score":0.9994446},"labels":[],"label_agreement":null},{"id":"W2281809067","doi":"10.3899/jrheum.150406","title":"Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?","year":2016,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Population; Cohort; Productivity; Demography; Health care; Total cost; Internal medicine; Environmental health; Dermatology","score_opus":0.02247332966328869,"score_gpt":0.2625477691952815,"score_spread":0.2400744395319928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281809067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917713,0.0033727465,0.00018863496,0.003152781,0.0008572206,0.00047573622,0.00015062047,0.000010350874,0.000020654894],"genre_scores_gemma":[0.9970616,0.0023376164,0.0001324532,0.0002163158,0.000018234017,0.000045047505,0.000026806332,0.00002252889,0.0001394135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763453,0.0006589507,0.00094043167,0.00022214682,0.00008019675,0.00046376884],"domain_scores_gemma":[0.9976148,0.00145737,0.0005612856,0.00022844435,0.00009645179,0.00004163258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001572243,0.0002472911,0.00081141386,0.0003208331,0.000114391594,0.000012486798,0.0002679276,0.00029574256,0.00030988592],"category_scores_gemma":[0.00032017502,0.00015462366,0.00013073064,0.00015644377,0.00011930875,0.00014892826,0.000044783497,0.00018104374,0.000056621895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016345502,0.00020297518,0.969536,0.000023047085,0.000440023,0.00000847781,0.0011086527,0.000007025387,0.0031534832,0.00013967555,0.0021157593,0.0216303],"study_design_scores_gemma":[0.09723722,0.002715852,0.8514347,0.002506493,0.0014466144,0.005293232,0.005516297,0.00009997682,0.019666744,0.005276031,0.007274782,0.0015320533],"about_ca_topic_score_codex":0.0030335954,"about_ca_topic_score_gemma":0.0046609025,"teacher_disagreement_score":0.11810133,"about_ca_system_score_codex":0.0001959532,"about_ca_system_score_gemma":0.00011357489,"threshold_uncertainty_score":0.630537},"labels":[],"label_agreement":null},{"id":"W2283622962","doi":"10.1016/j.jaad.2016.01.013","title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Plaque psoriasis; Open label; Term (time); Psoriasis; Dermatology; Randomized controlled trial; Internal medicine","score_opus":0.058195940204066335,"score_gpt":0.36216570395143804,"score_spread":0.3039697637473717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283622962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96571356,0.028257128,0.000058048598,0.0034137226,0.00045492486,0.0017988685,0.00029335776,0.000008654501,0.0000017272218],"genre_scores_gemma":[0.9776186,0.021945827,0.000108229186,0.0000866742,0.00009954749,0.000059133254,0.0000127773355,0.000020742928,0.0000484682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962319,0.0015491416,0.0014117629,0.00038267858,0.00009027105,0.00033421462],"domain_scores_gemma":[0.99297774,0.0040942403,0.0024165553,0.00032487704,0.0001257175,0.00006086805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064347545,0.00036833945,0.0023298124,0.00014187476,0.0002857541,0.000014240377,0.0005438777,0.00016985317,0.000008999311],"category_scores_gemma":[0.00027307923,0.00016262173,0.00021726737,0.00012637839,0.0018433888,0.00018723118,0.00019891628,0.00017086606,0.0000012880273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49543044,0.0058871508,0.018690597,0.000040769704,0.011786103,0.0000738251,0.0040962333,0.0000017025119,0.10452094,0.000042684638,0.0002978899,0.35913166],"study_design_scores_gemma":[0.7634673,0.007871425,0.12701234,0.00041638812,0.0050185593,0.0011737978,0.00089046854,0.0000035347668,0.09339092,0.0001243644,0.00032684495,0.00030403578],"about_ca_topic_score_codex":0.00006289658,"about_ca_topic_score_gemma":0.000047309317,"teacher_disagreement_score":0.35882765,"about_ca_system_score_codex":0.00008370391,"about_ca_system_score_gemma":0.00010270151,"threshold_uncertainty_score":0.6792042},"labels":[],"label_agreement":null},{"id":"W2284160709","doi":"","title":"A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.","year":2012,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Clinical endpoint; Randomized controlled trial; Dermatology; Clinical trial; Psoriasis Area and Severity Index; Clinical efficacy; Surgery; Internal medicine","score_opus":0.02076778508727218,"score_gpt":0.24022128311433597,"score_spread":0.2194534980270638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284160709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986302,0.0036138,0.00006143275,0.0001501272,0.00016104235,0.009625063,0.00003782691,0.000020292813,0.000028394237],"genre_scores_gemma":[0.99312514,0.0001682122,0.000051200786,0.000041703322,0.000013407699,0.0059673884,0.000022955499,0.000018193552,0.0005918075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980108,0.0010432359,0.00042151936,0.00021543918,0.000054106255,0.00025489877],"domain_scores_gemma":[0.9981064,0.0012725856,0.00029678553,0.00016075776,0.00012225939,0.000041168074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017773826,0.00020197083,0.0009902836,0.00016352734,0.00011400906,0.000012852996,0.00005707679,0.00012058446,0.000013101792],"category_scores_gemma":[0.00018876677,0.00013336804,0.00008572339,0.000099999466,0.00009728528,0.000106501226,0.000008945198,0.00004313792,5.53499e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.955108,0.0013706567,0.0063347276,0.000014228338,0.0017607192,2.7419372e-7,0.007117267,0.000005790726,0.012185605,0.000031618936,0.000053121705,0.016017988],"study_design_scores_gemma":[0.75878364,0.0011927938,0.18092038,0.000011808906,0.00042199943,0.000012067606,0.00062196155,0.000008317017,0.057737846,0.00003696328,0.00008392455,0.0001683087],"about_ca_topic_score_codex":0.000032486827,"about_ca_topic_score_gemma":0.000024784835,"teacher_disagreement_score":0.19632436,"about_ca_system_score_codex":0.00001610058,"about_ca_system_score_gemma":0.00002171118,"threshold_uncertainty_score":0.5438591},"labels":[],"label_agreement":null},{"id":"W2285826736","doi":"10.1136/annrheumdis-2015-eular.2852","title":"THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Psoriasis; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Dermatology Life Quality Index; Rheumatology; Dermatology; Placebo; Ustekinumab; Randomized controlled trial; Adalimumab; Disease; Pathology","score_opus":0.029915895439353496,"score_gpt":0.268604237032849,"score_spread":0.23868834159349553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285826736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881232,0.0070687286,7.154091e-7,0.000969868,0.0009266618,0.0010968505,0.0016966152,0.000035751462,0.00008165886],"genre_scores_gemma":[0.9989531,0.0003012856,0.000013782681,0.00007378471,0.00010147128,0.00009674327,0.0003355381,0.000022505765,0.00010180649],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997511,0.0009119298,0.0006408322,0.00037791525,0.00021645703,0.0003418128],"domain_scores_gemma":[0.9979128,0.00052211626,0.00047305663,0.00083871605,0.00019116938,0.00006211068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039733204,0.0003064969,0.00054041715,0.000070046655,0.00017756091,0.000035494122,0.0006631261,0.0000993589,0.00007373567],"category_scores_gemma":[0.00054167194,0.00015588726,0.00015503308,0.0003285632,0.00018006423,0.00014970575,0.00011278023,0.00013161016,0.000057269608],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020194989,0.013896872,0.06247795,0.000044197033,0.005179698,0.000019911222,0.040940296,0.00016444313,0.00004894468,0.0000948526,0.03591728,0.82102054],"study_design_scores_gemma":[0.066349335,0.0032510092,0.881793,0.0012662826,0.0013832009,0.000002758821,0.039693855,0.000010522032,0.0021407816,0.0021215228,0.0012738063,0.0007138845],"about_ca_topic_score_codex":0.0008067615,"about_ca_topic_score_gemma":0.0002128206,"teacher_disagreement_score":0.82030666,"about_ca_system_score_codex":0.000021674161,"about_ca_system_score_gemma":0.00015992325,"threshold_uncertainty_score":0.63568985},"labels":[],"label_agreement":null},{"id":"W2287696128","doi":"10.1016/j.humimm.2012.07.223","title":"97-P","year":2012,"lang":"en","type":"article","venue":"Human Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Single-nucleotide polymorphism; Genotyping; Genotype; Univariate analysis; Allele; Fibrosis; Medicine; Internal medicine; Gastroenterology; Pathology; Biology; Gene; Multivariate analysis; Genetics","score_opus":0.03224582366340462,"score_gpt":0.25649408554447006,"score_spread":0.22424826188106545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287696128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540399,0.023498297,0.00001861473,0.0000680728,0.0021723793,0.00012563467,0.000009680578,0.00018158773,0.019885851],"genre_scores_gemma":[0.9824076,0.0000774595,0.000052991614,0.00011020144,0.00012563035,0.000045722492,0.00015919989,0.000020680282,0.017000508],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877226,0.00019258272,0.00020718014,0.00018562458,0.00001681015,0.0006255516],"domain_scores_gemma":[0.99945277,0.000063096566,0.000076429824,0.000361595,0.000025096673,0.000021023387],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015448156,0.00017356945,0.00024850675,0.000120698925,0.00030700237,0.0000062114964,0.00020584046,0.00030696107,0.004851335],"category_scores_gemma":[0.000018212939,0.00016241176,0.000104734725,0.00008496821,0.00021123921,0.0001153494,0.00008628212,0.00017182504,0.014822828],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011040578,0.0005103952,0.03421248,0.0000064874102,0.0008962652,0.000005930182,0.001135011,1.18275786e-7,0.83643764,0.034780998,0.004477575,0.08742669],"study_design_scores_gemma":[0.0027217288,0.00029829488,0.36322352,0.000010589845,0.00018059438,0.00022991507,0.00026380157,4.1890285e-8,0.17093955,0.00056482677,0.46115902,0.0004080946],"about_ca_topic_score_codex":0.000052367068,"about_ca_topic_score_gemma":0.000008216085,"teacher_disagreement_score":0.6654981,"about_ca_system_score_codex":0.000038766862,"about_ca_system_score_gemma":0.000013915319,"threshold_uncertainty_score":0.99605834},"labels":[],"label_agreement":null},{"id":"W2293694143","doi":"10.1139/cjpp-2015-0483","title":"Paeoniflorin suppresses inflammatory response in imiquimod-induced psoriasis-like mice and peripheral blood mononuclear cells (PBMCs) from psoriasis patients","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Physiology and Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Peripheral blood mononuclear cell; Imiquimod; Paeoniflorin; Medicine; Immunology; Immune system; Tumor necrosis factor alpha; CD11c; Infiltration (HVAC); Inflammation; Cytokine; Chemistry; In vitro","score_opus":0.010377287920613968,"score_gpt":0.21815203957566215,"score_spread":0.2077747516550482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293694143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354655,0.0022509114,0.0000019638833,0.00039032474,0.0033671174,0.0001933481,0.00021537989,0.000010183618,0.00002420908],"genre_scores_gemma":[0.99843806,0.00074314274,0.00004367772,0.00034755925,0.0002373316,0.000015858403,0.00001529323,0.000026867257,0.00013219535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972114,0.0012362738,0.0005342837,0.00038925654,0.000033315086,0.00059547334],"domain_scores_gemma":[0.9983738,0.00078775216,0.00030410397,0.00015181657,0.00012906517,0.0002534699],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035179168,0.00031836386,0.0005988844,0.00035182587,0.00020741031,0.000011722577,0.00026658454,0.00049992185,0.001975732],"category_scores_gemma":[0.00006454465,0.00024617137,0.000104890976,0.00008096455,0.00039482053,0.00022231789,0.00005194082,0.0003414039,0.00003569444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004652639,0.00012122406,0.02288236,0.000016781947,0.0006167043,0.00013010913,0.0011346414,0.000004002562,0.96416664,0.000012923031,0.0014273,0.0048347004],"study_design_scores_gemma":[0.01592294,0.0015303047,0.31027612,0.00006218538,0.00044858136,0.000086036925,0.00018532426,0.000001580654,0.6626501,0.00045503752,0.007957032,0.0004247601],"about_ca_topic_score_codex":0.001025891,"about_ca_topic_score_gemma":0.0015314369,"teacher_disagreement_score":0.30151653,"about_ca_system_score_codex":0.000092596245,"about_ca_system_score_gemma":0.00044244016,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W2301023649","doi":"10.1111/jdv.13614","title":"Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council","year":2016,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Systemic therapy; Topical agents; Internal medicine","score_opus":0.13021997312421185,"score_gpt":0.3547782450982474,"score_spread":0.22455827197403555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301023649","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017639916,0.9758466,0.000013458139,0.0039555705,0.0013757044,0.00051139743,0.00026292683,0.000004178098,0.00039028574],"genre_scores_gemma":[0.048105747,0.950268,0.000023555967,0.000051070714,0.00020591031,0.000024294759,0.000013009046,0.00002757258,0.001280848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993944,0.0037420704,0.0016419237,0.0002268178,0.00016155382,0.000283639],"domain_scores_gemma":[0.9943758,0.002631373,0.0022818134,0.0002814571,0.00040069764,0.000028846092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018427909,0.0002939886,0.0015110772,0.000268041,0.00015954571,0.000005505408,0.00094233255,0.0005866401,0.00005353234],"category_scores_gemma":[0.00041103215,0.00013914156,0.00071095774,0.00017465757,0.0013049124,0.00003855613,0.00012442576,0.0003797922,0.00001006103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012000134,0.0004946729,0.0009306351,0.00055342383,0.0058909524,0.0000084534395,0.00076628424,2.9288879e-7,0.007490806,0.0034738907,0.017112415,0.96207815],"study_design_scores_gemma":[0.0029787668,0.00020905248,0.00031457722,0.00053949986,0.000961506,0.0021398268,0.00007736676,2.0086526e-7,0.0074311956,0.00048777342,0.98474485,0.00011539055],"about_ca_topic_score_codex":0.000005690671,"about_ca_topic_score_gemma":0.0000014763847,"teacher_disagreement_score":0.9676324,"about_ca_system_score_codex":0.00010795402,"about_ca_system_score_gemma":0.0003223915,"threshold_uncertainty_score":0.5674028},"labels":[],"label_agreement":null},{"id":"W2303023444","doi":"10.1111/bjd.13488","title":"Psoriasis and the risk of myocardial infarction: A population-based cohort study","year":2014,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Medicine; Psoriasis; Myocardial infarction; Cohort; Population; Cohort study; Internal medicine; Cardiology; Dermatology; Environmental health","score_opus":0.027905989915151225,"score_gpt":0.2522783611410862,"score_spread":0.22437237122593498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303023444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844253,0.00019773368,0.0000872572,0.0003697335,0.00011256118,0.0006509193,0.000011568527,0.000013562357,0.00011414279],"genre_scores_gemma":[0.99964654,0.00019837132,0.0000275966,0.000008657095,0.000030365725,0.0000064299297,0.000019252177,0.0000061748465,0.000056628585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99698704,0.0023329356,0.00013891661,0.00020943438,0.00014140067,0.0001902643],"domain_scores_gemma":[0.99792874,0.0013469367,0.00011524982,0.00043882037,0.00015046485,0.000019760806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023136947,0.000098175755,0.0002769447,0.00013106609,0.0005165824,0.0000073215983,0.00028899353,0.000085975036,0.00009819709],"category_scores_gemma":[0.00017612669,0.00006355112,0.00012010515,0.00020056214,0.0006526521,0.000063593856,0.00013594065,0.00020466483,0.000043091186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013428832,0.00016818676,0.9778334,0.000014018981,0.000810645,8.992127e-7,0.011471843,0.000034864814,0.00018009356,0.00023341378,0.00026261943,0.007647137],"study_design_scores_gemma":[0.0045314906,0.00027050474,0.9838086,0.000013513682,0.00033048142,0.000001317319,0.008596344,0.00003832103,0.00031164012,0.00020812394,0.0018269543,0.000062727806],"about_ca_topic_score_codex":0.00050804,"about_ca_topic_score_gemma":0.00003468912,"teacher_disagreement_score":0.0075844093,"about_ca_system_score_codex":0.00003423627,"about_ca_system_score_gemma":0.000033057087,"threshold_uncertainty_score":0.39731863},"labels":[],"label_agreement":null},{"id":"W2304028829","doi":"10.1016/j.jaad.2016.02.1164","title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Celgene","keywords":"Apremilast; Medicine; Psoriasis; Dermatology; Phase (matter); Pharmacology; Internal medicine","score_opus":0.042796572009189,"score_gpt":0.3684748574190304,"score_spread":0.3256782854098414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304028829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544907,0.0012481757,0.000016922817,0.000930048,0.00027964613,0.0015608615,0.00050847547,0.0000037995057,0.000003012496],"genre_scores_gemma":[0.9980282,0.0014745733,0.00024532512,0.00010177077,0.00006387179,0.000041177245,0.000022039367,0.00001837491,0.000004668871],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9861067,0.008964414,0.00381011,0.00046606275,0.0002597743,0.00039296757],"domain_scores_gemma":[0.9844422,0.010189167,0.004747035,0.00043109554,0.000113761576,0.000076778844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034495739,0.0004306063,0.0036562874,0.0005944331,0.000103484075,0.000008019258,0.00054569874,0.0003076606,0.0000073515744],"category_scores_gemma":[0.0018309401,0.00019615878,0.00046500843,0.00091136055,0.0007851908,0.00015883052,0.00011191266,0.0003623579,2.7946618e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67366076,0.008796572,0.11916057,0.000038350427,0.0052214134,0.000016779046,0.0080208,0.0000894572,0.018095385,0.0000074035897,0.00007772181,0.16681477],"study_design_scores_gemma":[0.61722744,0.034132104,0.27944726,0.0008171689,0.008936411,0.00008664815,0.0013981103,0.00005765082,0.0573295,0.00008866127,0.00009624926,0.00038279418],"about_ca_topic_score_codex":0.00037731885,"about_ca_topic_score_gemma":0.00017251435,"teacher_disagreement_score":0.16643198,"about_ca_system_score_codex":0.000078123,"about_ca_system_score_gemma":0.00017372644,"threshold_uncertainty_score":0.7999123},"labels":[],"label_agreement":null},{"id":"W2304037606","doi":"10.3899/jrheum.150126","title":"A Comprehensive Assessment Tool for Psoriasis — An Unmet Need: Report from the GRAPPA 2014 Annual Meeting","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Plaque psoriasis; Dermatology; Psoriatic arthritis; Psoriasis Area and Severity Index; Severity of illness; Internal medicine","score_opus":0.028556443213636894,"score_gpt":0.28943511070884215,"score_spread":0.2608786674952053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304037606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805356,0.0051455256,0.0014961173,0.0019021374,0.0028787025,0.00029750273,0.00011835656,0.000022229055,0.00008584116],"genre_scores_gemma":[0.9967808,0.0005925326,0.0020206606,0.00023640286,0.00007531896,0.000020342168,0.00010698671,0.00002469772,0.00014222166],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723667,0.0013250704,0.0008140367,0.00018202577,0.00009401356,0.00034818344],"domain_scores_gemma":[0.9958124,0.0020938914,0.0010340469,0.0004638108,0.00054698857,0.00004882681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018728502,0.00022978628,0.0006446587,0.000086472144,0.00031279802,0.000018057945,0.00057306315,0.00022564382,0.00006358683],"category_scores_gemma":[0.00030195832,0.00012170696,0.00021770775,0.00010613257,0.00023514488,0.00014813773,0.00009044827,0.00030554898,0.000037889713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057139713,0.0007879519,0.5488676,0.000030118132,0.007364471,0.0001315752,0.018137261,0.0002249551,0.015043319,0.001545703,0.36395115,0.03820196],"study_design_scores_gemma":[0.03448642,0.0056954124,0.19387835,0.0003587507,0.0049785776,0.07869554,0.09597514,0.00010219983,0.00876368,0.018064696,0.5574571,0.0015441397],"about_ca_topic_score_codex":0.0008045764,"about_ca_topic_score_gemma":0.000097599,"teacher_disagreement_score":0.35498923,"about_ca_system_score_codex":0.000052709293,"about_ca_system_score_gemma":0.00026329077,"threshold_uncertainty_score":0.4963066},"labels":[],"label_agreement":null},{"id":"W2308193643","doi":"10.1007/s40257-016-0187-3","title":"Cognitive Impairment in Patients with Psoriasis: A Cross-Sectional Study Using the Montreal Cognitive Assessment","year":2016,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bozok Üniversitesi","keywords":"Psoriasis; Medicine; Montreal Cognitive Assessment; Odds ratio; Internal medicine; Cognition; Cross-sectional study; Beck Depression Inventory; Physical therapy; Psychiatry; Dementia; Disease; Dermatology; Pathology; Anxiety","score_opus":0.03376329744548311,"score_gpt":0.3681341402364533,"score_spread":0.3343708427909702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308193643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980011,0.00009311045,0.0002954554,0.00018536726,0.0007999148,0.00048389385,0.00005679495,0.000009430607,0.00007494755],"genre_scores_gemma":[0.9995489,0.000036443147,0.000075114214,0.00018785936,0.00007779055,0.000024138215,0.000009062877,0.00001721738,0.000023437822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99547434,0.0021843049,0.0014773046,0.00032353707,0.00014907776,0.00039141616],"domain_scores_gemma":[0.99457896,0.003329063,0.0013549931,0.00015338844,0.00051727437,0.00006631129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089245645,0.0002434449,0.00093469716,0.00016818772,0.00015098344,0.000016982644,0.00023674198,0.0001402161,0.0001092583],"category_scores_gemma":[0.00031043217,0.000116675496,0.0002408174,0.0002218678,0.0011287705,0.00015148902,0.00007162178,0.0004145765,0.000028326855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007875336,0.0028332719,0.9457283,0.0000014647363,0.0016403998,0.00012032976,0.000254638,0.0000013531378,0.000010834657,0.0000083607765,0.000017142545,0.041508585],"study_design_scores_gemma":[0.024394289,0.005949207,0.966973,0.00007927025,0.0003927371,0.00036533774,0.001577067,8.506332e-7,0.000057339308,0.000028585633,0.000029112183,0.00015321361],"about_ca_topic_score_codex":0.00012852006,"about_ca_topic_score_gemma":0.00009988623,"teacher_disagreement_score":0.04135537,"about_ca_system_score_codex":0.00007672764,"about_ca_system_score_gemma":0.0003830236,"threshold_uncertainty_score":0.47578886},"labels":[],"label_agreement":null},{"id":"W2313941233","doi":"10.3899/jrheum.111347","title":"Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR Registry","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Psoriasis; Rituximab; Rheumatoid arthritis; Internal medicine; Incidence (geometry); Psoriatic arthritis; Rheumatology; Discontinuation; Dermatology; Surgery; Lymphoma","score_opus":0.034147785562755606,"score_gpt":0.2671057613158487,"score_spread":0.23295797575309307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313941233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89271873,0.10566625,0.00022434517,0.00030006407,0.00061267416,0.00018094912,0.00028070682,0.0000076119836,0.000008691525],"genre_scores_gemma":[0.9752696,0.023996651,0.00058524706,0.000020871788,0.000026799258,0.0000043495547,0.000049720846,0.000014775346,0.00003199754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998252,0.00047057966,0.00076149986,0.0001449305,0.0000663937,0.00030460968],"domain_scores_gemma":[0.99599123,0.0019867725,0.0012022735,0.00065999967,0.00012454853,0.000035150304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010960478,0.0001852585,0.00066992524,0.00006091449,0.00021775196,0.000005429148,0.0008551513,0.00019928296,0.0000696621],"category_scores_gemma":[0.000572639,0.00010812916,0.00010457593,0.00008964638,0.00035753206,0.00020950176,0.0002017676,0.00022821194,0.000005277223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002096164,0.0002955908,0.93944097,0.000056251265,0.0016230508,0.0000014966361,0.0062564774,0.0000037585773,0.015907716,0.00010476319,0.0075088805,0.026704857],"study_design_scores_gemma":[0.02239821,0.00085700763,0.8504523,0.001678821,0.000546293,0.013472336,0.0055059264,0.000012416723,0.098343715,0.002222229,0.004028471,0.0004822747],"about_ca_topic_score_codex":0.0013631537,"about_ca_topic_score_gemma":0.0003099378,"teacher_disagreement_score":0.0889887,"about_ca_system_score_codex":0.000012560777,"about_ca_system_score_gemma":0.00013519918,"threshold_uncertainty_score":0.44093794},"labels":[],"label_agreement":null},{"id":"W2317308047","doi":"10.2310/7750.2009.08066","title":"A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Family medicine","score_opus":0.03455336826606173,"score_gpt":0.289557736026198,"score_spread":0.25500436776013624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317308047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996886,0.0008749245,0.0000030012184,0.0011928919,0.00059999956,0.00019108319,0.00012471274,0.0000064240558,0.00012094988],"genre_scores_gemma":[0.9986452,0.0003255173,0.000020601092,0.0006221632,0.0001111084,0.0000012394481,0.00006542248,0.000011694248,0.00019708612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982184,0.00045815785,0.00069760036,0.00015442062,0.00012093107,0.0003504866],"domain_scores_gemma":[0.997935,0.00087761116,0.00027251517,0.00019986536,0.0004701177,0.00024487864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000964991,0.00022233793,0.0007754495,0.00044509047,0.00013090015,0.00001063031,0.00015847455,0.00013886858,0.00014637096],"category_scores_gemma":[0.0006638679,0.0001210719,0.00019424272,0.00028884978,0.00004918277,0.00005419344,0.0000136775725,0.00016935544,0.000009047012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059866155,0.00066766836,0.8174623,0.000017226788,0.001955339,0.00048441582,0.0043770387,0.00017279816,0.001925922,0.0000023685222,0.07925421,0.08769409],"study_design_scores_gemma":[0.0015499718,0.0031492442,0.99201065,0.0002050368,0.00034321746,0.0011381762,0.00019175911,0.000009082659,0.00028718277,0.000044738095,0.00087966793,0.00019129507],"about_ca_topic_score_codex":0.015823927,"about_ca_topic_score_gemma":0.011575393,"teacher_disagreement_score":0.17454833,"about_ca_system_score_codex":0.00013116852,"about_ca_system_score_gemma":0.0004914763,"threshold_uncertainty_score":0.9907298},"labels":[],"label_agreement":null},{"id":"W2317828523","doi":"10.2147/ptt.s85330","title":"Management of scalp psoriasis: current perspectives","year":2016,"lang":"en","type":"review","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SKiN Health","funders":"","keywords":"Psoriasis; Scalp; Current (fluid); Dermatology; Medicine; Engineering; Electrical engineering","score_opus":0.03440615871811137,"score_gpt":0.3066513171424867,"score_spread":0.27224515842437536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317828523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011221355,0.99426323,0.000032785483,0.000026327842,0.0028324695,0.0010684067,0.0003767197,0.00008513704,0.0012027238],"genre_scores_gemma":[0.00031306164,0.99733996,0.00010825794,0.000005052143,0.000289663,0.00036137472,0.0001718752,0.000085779284,0.0013249784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997105,0.0004679162,0.0008186605,0.00092271157,0.00010300966,0.00058268436],"domain_scores_gemma":[0.99837625,0.00022008223,0.000610066,0.0006326167,0.00009763474,0.00006335934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003607541,0.0008569985,0.002239808,0.00033878427,0.00021595154,0.000025258929,0.0004426259,0.00052095787,0.00084003725],"category_scores_gemma":[0.000010358503,0.0005275764,0.00086746574,0.00024668875,0.00027397054,0.00009659697,0.0001378377,0.00024506665,0.0003133594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001309981,0.0004415774,0.000009469327,0.002134404,0.004752207,0.00000852512,0.00036263236,6.569912e-9,0.000008724692,0.004912484,0.0005878858,0.98665106],"study_design_scores_gemma":[0.0026186137,0.00019638888,0.00007026848,0.0057258294,0.0013151866,0.000023214265,0.00018762652,1.897393e-8,0.00011878318,0.00037964003,0.98878664,0.0005777991],"about_ca_topic_score_codex":0.000010286325,"about_ca_topic_score_gemma":7.592434e-7,"teacher_disagreement_score":0.98819876,"about_ca_system_score_codex":0.000077472694,"about_ca_system_score_gemma":0.0000771192,"threshold_uncertainty_score":0.9997176},"labels":[],"label_agreement":null},{"id":"W2319342693","doi":"10.1136/annrheumdis-2013-eular.308","title":"OP0103 Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Rheumatoid arthritis; Clinical endpoint; Psoriasis; Adverse effect; Rheumatology; Randomized controlled trial; Immunology","score_opus":0.02035229992375236,"score_gpt":0.26873687599887963,"score_spread":0.24838457607512726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319342693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923779,0.0063269953,0.0000039969354,0.00023320486,0.00022031588,0.0005563386,0.00011978562,0.000027071095,0.00013442744],"genre_scores_gemma":[0.99816924,0.0014349292,0.00004049748,0.00005807065,0.000009860106,0.000040380695,0.00009055708,0.000019458017,0.00013700449],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846005,0.00037700636,0.00047368612,0.00023900588,0.00008868101,0.00036159332],"domain_scores_gemma":[0.99860865,0.00029921974,0.00032605868,0.00061059714,0.000110440764,0.00004504876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001647396,0.00022041825,0.0005767301,0.00012704432,0.00008588191,0.000014660545,0.0003866926,0.00009404943,0.00042596136],"category_scores_gemma":[0.00019814615,0.00014040305,0.00017331606,0.00027464138,0.00027523597,0.00020983293,0.00007354466,0.00007073939,0.00008666343],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094609265,0.0073426026,0.27944344,0.0007699712,0.002364758,0.000014366692,0.0027258892,0.00022067405,0.024114113,0.0014451772,0.0033536141,0.67725927],"study_design_scores_gemma":[0.0028903582,0.0004053967,0.96934116,0.0010080506,0.00014982176,0.000011659902,0.00025621825,0.000011529223,0.02435758,0.001341666,0.000029729594,0.00019683105],"about_ca_topic_score_codex":0.0008420926,"about_ca_topic_score_gemma":0.000071159,"teacher_disagreement_score":0.6898977,"about_ca_system_score_codex":0.000006554646,"about_ca_system_score_gemma":0.00009335302,"threshold_uncertainty_score":0.572547},"labels":[],"label_agreement":null},{"id":"W2320126037","doi":"10.3899/jrheum.120822","title":"GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Medical physics; Index (typography); Physical therapy; Internal medicine; Arthritis; Computer science; World Wide Web","score_opus":0.020434715898210047,"score_gpt":0.25802347005579684,"score_spread":0.2375887541575868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320126037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726897,0.022795364,0.00013514645,0.0013913816,0.0023865951,0.00020617008,0.00003489438,0.000024745286,0.00033598943],"genre_scores_gemma":[0.99772763,0.0012145805,0.000101459715,0.00014121327,0.000057619138,0.00000954295,0.000020837706,0.000023001272,0.00070410856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966972,0.0017128988,0.00080408383,0.00014730025,0.00009661469,0.0005419195],"domain_scores_gemma":[0.99653906,0.0016981058,0.0010814241,0.00047427104,0.00017038445,0.00003677217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026685125,0.00024789124,0.0005464482,0.0001511129,0.00039373818,0.000010469304,0.000584101,0.00030591126,0.00029815373],"category_scores_gemma":[0.00034558572,0.00012230643,0.00024320702,0.00017591834,0.00034816083,0.00018784005,0.00012371581,0.00054389844,0.0001954434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021955618,0.00022458521,0.9012122,0.0000062665713,0.0017915858,0.000048028713,0.0085835615,0.0000024920403,0.0046748165,0.0002543808,0.07567669,0.005329802],"study_design_scores_gemma":[0.007714102,0.0007272304,0.5883905,0.00026370827,0.0021378647,0.12680605,0.017851707,0.0000029878443,0.009399428,0.0023595896,0.24354996,0.00079683797],"about_ca_topic_score_codex":0.0015530464,"about_ca_topic_score_gemma":0.00016041774,"teacher_disagreement_score":0.31282172,"about_ca_system_score_codex":0.000030444564,"about_ca_system_score_gemma":0.00016919445,"threshold_uncertainty_score":0.49875116},"labels":[],"label_agreement":null},{"id":"W2320645779","doi":"10.3899/jrheum.140170","title":"GRAPPA Trainees Symposium 2013: A Report from the GRAPPA 2013 Annual Meeting","year":2014,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Plaque psoriasis; Rheumatology; Dermatology; Family medicine; Medical physics; Internal medicine","score_opus":0.009396109398033002,"score_gpt":0.21666010590894025,"score_spread":0.20726399651090724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320645779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779547,0.009618117,0.000328429,0.00914852,0.0023246156,0.00013632023,0.000033286433,0.000028497305,0.0004275215],"genre_scores_gemma":[0.9955592,0.0035225297,0.000121054654,0.00020114605,0.000061805804,0.0000064636533,0.000029367133,0.000021930662,0.00047646344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972062,0.001325784,0.000817977,0.00017560816,0.000079314246,0.00039509984],"domain_scores_gemma":[0.99642456,0.0019272309,0.0009702018,0.00046490045,0.00017612419,0.00003701047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018042247,0.00024808192,0.00060962554,0.00009427532,0.00037885105,0.000013968364,0.00068060646,0.00025715766,0.00019375684],"category_scores_gemma":[0.00022680017,0.00012429735,0.00026408676,0.00012782037,0.00037902955,0.00010057059,0.0000855143,0.0004154232,0.00016861204],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002485716,0.00054467126,0.3272062,0.000033227778,0.0062642545,0.00014540824,0.020893743,0.00016887765,0.07499943,0.0017158899,0.54174715,0.023795426],"study_design_scores_gemma":[0.015180764,0.0023157238,0.090091564,0.00073891424,0.0043493574,0.15250066,0.014180928,0.00006039969,0.020774689,0.0128328595,0.6854743,0.001499851],"about_ca_topic_score_codex":0.0018500811,"about_ca_topic_score_gemma":0.0004572557,"teacher_disagreement_score":0.23711462,"about_ca_system_score_codex":0.000017240944,"about_ca_system_score_gemma":0.00007115586,"threshold_uncertainty_score":0.5068699},"labels":[],"label_agreement":null},{"id":"W2323267995","doi":"10.3899/jrheum.130455","title":"Dermatology Screening Tools: Project Update from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Cohort; Dermatology; Cohort study; Medical physics; Internal medicine","score_opus":0.02163272701443461,"score_gpt":0.24018352156059988,"score_spread":0.21855079454616527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323267995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729785,0.019528901,0.000563094,0.0049827294,0.0013560278,0.00027893367,0.000048621634,0.000031484396,0.00023172237],"genre_scores_gemma":[0.99664444,0.0021534716,0.0005203777,0.0004261475,0.00003095258,0.000016945543,0.00003468525,0.000022849434,0.00015016092],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99686015,0.0016625578,0.00074856397,0.00015720699,0.00006540567,0.0005061387],"domain_scores_gemma":[0.99616945,0.0024481283,0.0007850675,0.00036249915,0.00020660729,0.000028238812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007134934,0.00025326427,0.0006069088,0.00011490517,0.00044873255,0.000028425427,0.00082482735,0.00028543218,0.00064502977],"category_scores_gemma":[0.00026632956,0.0001263867,0.00020307563,0.00016882228,0.00039476954,0.00037302868,0.00015745913,0.0005166203,0.00059249625],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017531244,0.00032356946,0.35653272,0.000027582877,0.0060994145,0.00005835236,0.011370437,0.0000349318,0.017626513,0.0018722339,0.3863676,0.21793354],"study_design_scores_gemma":[0.022788588,0.0015723897,0.22525065,0.0010206151,0.0045458716,0.14175303,0.04623174,0.00008931123,0.034211796,0.010046083,0.5103294,0.0021604884],"about_ca_topic_score_codex":0.0017146615,"about_ca_topic_score_gemma":0.00019579822,"teacher_disagreement_score":0.21577305,"about_ca_system_score_codex":0.000016289163,"about_ca_system_score_gemma":0.00009617338,"threshold_uncertainty_score":0.7615538},"labels":[],"label_agreement":null},{"id":"W2323304856","doi":"10.1097/00000372-200104000-00019","title":"Letter regarding “Histopathology of Psoriasis Treated With Zinc Pyrithione”","year":2001,"lang":"en","type":"article","venue":"American Journal of Dermatopathology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Clobetasol propionate; Dermatology; Psoriasis; Medicine; Plaque psoriasis; Product (mathematics); Mathematics","score_opus":0.009951708003691436,"score_gpt":0.22408335402656432,"score_spread":0.21413164602287288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323304856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99471384,0.001548057,0.0008797875,0.0009454387,0.0005414796,0.0001101745,0.000014364019,0.00003367965,0.0012131488],"genre_scores_gemma":[0.99697727,0.00040369495,0.0014075747,0.00068786053,0.00011776836,0.00000907468,0.000015740454,0.000036621273,0.00034441194],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.997563,0.00073802535,0.00084054255,0.00028689211,0.000086812746,0.000484712],"domain_scores_gemma":[0.9977411,0.00023691755,0.0012955972,0.00037050797,0.00029497838,0.00006092476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039898476,0.0003143,0.0011550355,0.00050533534,0.000123117,0.000006941932,0.00035024332,0.00018911874,0.00015850541],"category_scores_gemma":[0.000067444074,0.00023141994,0.00026200956,0.00047822643,0.0009991336,0.00015253041,0.00004969866,0.00034298009,0.00006423802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033971104,0.00050169573,0.7498638,0.000018295597,0.00057009957,0.0042219805,0.0012330288,0.000023199667,0.15451446,0.00026543275,0.0026047644,0.0827861],"study_design_scores_gemma":[0.015369975,0.010771688,0.30529445,0.00028161128,0.0022681598,0.39503458,0.002349526,0.000003338359,0.16265668,0.00023158483,0.10455328,0.0011851199],"about_ca_topic_score_codex":0.00003667742,"about_ca_topic_score_gemma":0.000011107298,"teacher_disagreement_score":0.44456938,"about_ca_system_score_codex":0.00006144524,"about_ca_system_score_gemma":0.00009102438,"threshold_uncertainty_score":0.9437031},"labels":[],"label_agreement":null},{"id":"W2323608499","doi":"10.3899/jrheum.140880","title":"Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review","year":2014,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Disease; Population; Arthritis; Intensive care medicine; Internal medicine","score_opus":0.010310815926604464,"score_gpt":0.24908064470155997,"score_spread":0.2387698287749555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323608499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008820608,0.9886227,0.00005077654,0.000019112926,0.0003503496,0.0020636292,0.00006395975,0.0000039469383,0.0000048770416],"genre_scores_gemma":[0.0065596644,0.9932323,0.00006271069,0.000010266978,0.000004520075,0.000048542573,0.000036184276,0.000031998254,0.000013812887],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9948426,0.0020958567,0.0025671173,0.00016319905,0.00007996458,0.00025125605],"domain_scores_gemma":[0.99153066,0.0033725677,0.0044387435,0.00041060182,0.00022625951,0.00002119964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017688101,0.00039173866,0.0063400767,0.0002900141,0.000055404707,0.0000030644503,0.0004409772,0.00033622643,0.000022270642],"category_scores_gemma":[0.00051359984,0.00019511234,0.0004878134,0.00020917531,0.00025268938,0.000043643297,0.00004409727,0.0002448592,0.0000047559565],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009211942,0.00030368246,0.0007467328,0.5419647,0.0059274654,6.953416e-7,0.00049787574,3.807372e-7,2.7728115e-7,0.0003249205,0.00005774114,0.44925433],"study_design_scores_gemma":[0.011226014,0.0027221988,0.0004935952,0.9581929,0.016332898,0.0013893667,0.000082391474,2.0793317e-7,0.000004011233,0.000068486326,0.009138803,0.00034913296],"about_ca_topic_score_codex":0.000018714685,"about_ca_topic_score_gemma":0.000019429084,"teacher_disagreement_score":0.4489052,"about_ca_system_score_codex":0.000035307916,"about_ca_system_score_gemma":0.0001451222,"threshold_uncertainty_score":0.795645},"labels":[],"label_agreement":null},{"id":"W2323903826","doi":"10.1016/j.jaad.2016.02.1221","title":"Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent","year":2016,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Tumor necrosis factor alpha; Tumor necrosis factor α; Necrosis; Tumor necrosis factors; Dermatology; Internal medicine","score_opus":0.020563300929828776,"score_gpt":0.2829021297591856,"score_spread":0.26233882882935683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323903826","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33539096,0.66250324,0.0000023793357,0.00009985773,0.00009298267,0.0017431182,0.00015694914,0.0000060462294,0.0000044651383],"genre_scores_gemma":[0.12854138,0.8711866,0.00002260162,0.00008785027,0.000012802939,0.0000524435,0.000017125867,0.000056141347,0.000023017197],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9928108,0.0028281151,0.0032562313,0.00036339488,0.00025649226,0.00048495524],"domain_scores_gemma":[0.98459744,0.0009770734,0.013625218,0.000527752,0.00020973507,0.00006277155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027975393,0.0007762631,0.009769353,0.0005746443,0.000052214844,0.000004503982,0.001190885,0.00032893714,0.000050445986],"category_scores_gemma":[0.00017901324,0.00032168487,0.0012818925,0.0007349844,0.00083830324,0.00007991816,0.00010599346,0.0006011684,0.000006611919],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030835557,0.004186317,0.085281976,0.67361575,0.030116713,0.00005870166,0.00045720662,5.246768e-7,0.00050062616,0.000031132717,0.00053771253,0.20212977],"study_design_scores_gemma":[0.009779932,0.0026946233,0.0643662,0.8985555,0.01346542,0.0018820327,0.00003752106,4.7198714e-8,0.0033027597,0.0000038061896,0.005179,0.0007331466],"about_ca_topic_score_codex":0.000018004028,"about_ca_topic_score_gemma":9.049921e-7,"teacher_disagreement_score":0.22493973,"about_ca_system_score_codex":0.00012443303,"about_ca_system_score_gemma":0.0002769567,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W2323925800","doi":"10.1111/jdv.13611","title":"Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":242,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Adalimumab; Discontinuation; Etanercept; Psoriasis; Hazard ratio; Infliximab; Internal medicine; Proportional hazards model; Confidence interval; Disease; Dermatology; Rheumatoid arthritis","score_opus":0.02220654482873743,"score_gpt":0.25711842298768806,"score_spread":0.23491187815895062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323925800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990616,0.004348891,0.00004138996,0.0040092277,0.00033540858,0.00016571357,0.00039210697,0.0000048787606,0.00008633676],"genre_scores_gemma":[0.9980865,0.0015726314,0.00010742956,0.000111440335,0.00004769598,0.0000025308993,0.000017091641,0.000014333616,0.00004035163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558276,0.0028454147,0.00093752437,0.00027457334,0.000089234345,0.00027051024],"domain_scores_gemma":[0.9965385,0.0012434619,0.0017663252,0.00031062405,0.000099637604,0.000041443145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008880273,0.00023813025,0.0007286279,0.00011949635,0.00010470424,0.000003269906,0.000573881,0.00022301105,0.0000173004],"category_scores_gemma":[0.00023751102,0.000107706015,0.00015399932,0.00013615181,0.0010676365,0.00007446065,0.00015291167,0.00037707938,0.0000010205986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054580406,0.0003407807,0.9873237,0.000021122547,0.0005551807,0.00002293432,0.00014401725,0.0000031034997,0.002240724,0.00034237315,0.0003482552,0.0031997457],"study_design_scores_gemma":[0.011818613,0.00014063077,0.98157203,0.00022309701,0.00024875646,0.00008041531,0.000081830374,8.491006e-7,0.004340305,0.00033398592,0.0010431051,0.00011638026],"about_ca_topic_score_codex":0.000018196488,"about_ca_topic_score_gemma":0.00002191538,"teacher_disagreement_score":0.007470448,"about_ca_system_score_codex":0.000017846427,"about_ca_system_score_gemma":0.00010361766,"threshold_uncertainty_score":0.43921238},"labels":[],"label_agreement":null},{"id":"W2324386707","doi":"10.3899/jrheum.130454","title":"Outcome Measures for Psoriasis Severity: A Report from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Outcome (game theory); Rheumatology; Physical therapy; Family medicine; Internal medicine; Dermatology","score_opus":0.0251462582446179,"score_gpt":0.25657309479819396,"score_spread":0.23142683655357604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324386707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819255,0.010036053,0.00063531334,0.0041767005,0.0026617178,0.00034503147,0.00006267709,0.000023105147,0.0001338894],"genre_scores_gemma":[0.99791056,0.00065117853,0.00038537334,0.00022974265,0.000053521773,0.000032113276,0.000020762858,0.000021360518,0.0006953773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777037,0.0007338698,0.00089633913,0.00014845024,0.00007421726,0.00037673727],"domain_scores_gemma":[0.996139,0.002205538,0.0008961852,0.00038633117,0.00034087125,0.000032058797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015945461,0.00021435604,0.00060914253,0.00006981897,0.0003889449,0.000017518754,0.0005683808,0.00024402337,0.00029878478],"category_scores_gemma":[0.0006655919,0.00010540664,0.00030149284,0.00009454391,0.0002302056,0.00018078367,0.0000764054,0.00030132572,0.00015176622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001301604,0.00022076278,0.724409,0.000019696558,0.004218565,0.000024755567,0.004899381,0.000010372064,0.008398356,0.00032188097,0.19367342,0.06250226],"study_design_scores_gemma":[0.017185524,0.0013219574,0.43858156,0.00036886756,0.005315284,0.07315735,0.017074246,0.000017503711,0.014435174,0.021215461,0.40997618,0.0013508837],"about_ca_topic_score_codex":0.0015267354,"about_ca_topic_score_gemma":0.00026673134,"teacher_disagreement_score":0.2858274,"about_ca_system_score_codex":0.000026269578,"about_ca_system_score_gemma":0.000080182814,"threshold_uncertainty_score":0.42983577},"labels":[],"label_agreement":null},{"id":"W2325176118","doi":"10.3899/jrheum.111244","title":"Comorbidities of Psoriatic Arthritis — Metabolic Syndrome and Prevention: A Report from the GRAPPA 2010 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Metabolic syndrome; Psoriasis; Comorbidity; Incidence (geometry); Coronary artery disease; Population; Inflammatory arthritis; Depression (economics); Disease; Arthritis; Internal medicine; Physical therapy; Intensive care medicine; Dermatology; Obesity; Environmental health","score_opus":0.01573268658994016,"score_gpt":0.23564156304798453,"score_spread":0.21990887645804438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325176118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87687486,0.12070567,0.00004907574,0.00039023443,0.0017807406,0.000093332834,0.000041759733,0.0000067648675,0.000057528494],"genre_scores_gemma":[0.9889074,0.010696635,0.00014692219,0.000022347904,0.000024301446,0.0000044268304,0.0000147035835,0.000009563019,0.00017367474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980992,0.000855822,0.00067128264,0.00007529965,0.000057129288,0.00024124469],"domain_scores_gemma":[0.9977517,0.00096299173,0.00093128695,0.00023363493,0.00009550666,0.000024872175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013290896,0.00013974619,0.0005826713,0.000064197324,0.00018333762,0.000005024953,0.00022703702,0.00013862741,0.00014545742],"category_scores_gemma":[0.00019316097,0.000076132914,0.00013536321,0.00008296718,0.00034901543,0.00014237924,0.00006912216,0.0002167146,0.000017093926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010346398,0.00053715135,0.8635221,0.00005518253,0.008265538,0.00008456701,0.02279374,0.000004939871,0.007099362,0.0032562052,0.02538565,0.06796089],"study_design_scores_gemma":[0.0062608337,0.0008542117,0.66989374,0.0006691435,0.0028711841,0.2681486,0.011619311,0.0000010464394,0.009384758,0.00672044,0.023164652,0.00041204743],"about_ca_topic_score_codex":0.0005802298,"about_ca_topic_score_gemma":0.000105513245,"teacher_disagreement_score":0.26806405,"about_ca_system_score_codex":0.000006057735,"about_ca_system_score_gemma":0.00005233542,"threshold_uncertainty_score":0.310461},"labels":[],"label_agreement":null},{"id":"W2325250307","doi":"10.1136/annrheumdis-2013-eular.1989","title":"SAT0264 Ustekinumab Improves Physical Function, Quality of Life and Work Productivity of Patients With Active Psoriatic Arthritis who were NaÏVe To MTX, Despite MTX Therapy or Previously Treated with Anti-Tnf: Results from Psummit I and Psummit II","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Dermatology Life Quality Index; Ustekinumab; Quality of life (healthcare); Internal medicine; Placebo; Physical therapy; Rheumatology; Psoriasis; Minimal clinically important difference; Arthritis; Randomized controlled trial; Infliximab; Disease; Dermatology; Pathology; Alternative medicine","score_opus":0.021773344829550335,"score_gpt":0.2437459372954986,"score_spread":0.22197259246594825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325250307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943618,0.0026957158,0.000003408872,0.00027648744,0.00006462968,0.0014980069,0.0010656867,0.000022445134,0.000011789944],"genre_scores_gemma":[0.9988239,0.00070852455,0.00004285003,0.000046190125,0.00001563026,0.00010983252,0.00011097633,0.000021879616,0.00012023646],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981485,0.00047002872,0.0005354934,0.0004429624,0.00014122631,0.00026178185],"domain_scores_gemma":[0.9975847,0.0005533484,0.00075015466,0.0006822046,0.0003476937,0.00008190459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013770492,0.00032005954,0.0009353684,0.000070130875,0.00016784106,0.000018215436,0.00020309318,0.000089992245,0.000034080025],"category_scores_gemma":[0.0005291217,0.00017141085,0.00011315003,0.00026684676,0.00039000963,0.00024890047,0.00011384046,0.000075358774,0.0000035171267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03435247,0.003732601,0.3052361,0.0003120786,0.0050365557,4.350018e-7,0.004574807,0.00001273888,0.0014469689,0.000028588396,0.0011878941,0.6440788],"study_design_scores_gemma":[0.00588625,0.0022156807,0.97992533,0.0008534979,0.00030597713,3.195274e-7,0.00033161283,0.0000011892165,0.0099673895,0.00027080454,0.00002436661,0.00021756884],"about_ca_topic_score_codex":0.0008493153,"about_ca_topic_score_gemma":0.000107242406,"teacher_disagreement_score":0.67468923,"about_ca_system_score_codex":0.000009227683,"about_ca_system_score_gemma":0.00009116463,"threshold_uncertainty_score":0.6989932},"labels":[],"label_agreement":null},{"id":"W2326643498","doi":"10.1056/nejmoa1503824","title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":806,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Dalhousie University; Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Psoriasis; Dermatology; Ixekizumab; Internal medicine; Secukinumab; Psoriatic arthritis; Disease; Infliximab","score_opus":0.07908791848008138,"score_gpt":0.32409912824797255,"score_spread":0.24501120976789115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326643498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96786577,0.028349351,0.00008125661,0.0012760271,0.0015004126,0.000083189276,0.0000014717501,0.000010814816,0.0008317068],"genre_scores_gemma":[0.9975757,0.00058718136,0.00018510234,0.000072767776,0.0009059533,0.0000016551867,0.000008376014,0.0000104916535,0.0006527458],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998889,0.00020984578,0.0004616051,0.00012196452,0.00010218322,0.00021536398],"domain_scores_gemma":[0.9991025,0.00021164071,0.00028326915,0.00012691288,0.00019211881,0.00008357081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086587487,0.00016763296,0.0006830383,0.00025131198,0.000040411003,0.000004001442,0.00014096487,0.000072976196,0.000060434057],"category_scores_gemma":[0.00026721333,0.00009455631,0.000040047802,0.00018814002,0.0001332998,0.00009817274,0.000020476527,0.0002392634,0.000016932527],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020879898,0.0011022142,0.069597945,0.000046716286,0.0026939157,0.0012847574,0.026771886,0.00016885115,0.009233616,0.00022662898,0.03412835,0.8338652],"study_design_scores_gemma":[0.845829,0.015737165,0.0071217963,0.0012104661,0.0012017613,0.0055416976,0.009994206,0.000008478719,0.006849364,0.0007928218,0.1053467,0.0003665164],"about_ca_topic_score_codex":0.00012794662,"about_ca_topic_score_gemma":0.00027844656,"teacher_disagreement_score":0.8334987,"about_ca_system_score_codex":0.00008716136,"about_ca_system_score_gemma":0.00015360676,"threshold_uncertainty_score":0.38558945},"labels":[],"label_agreement":null},{"id":"W2328070819","doi":"10.3899/jrheum.120231","title":"New Insights into the Concept of Psoriatic Disease","year":2012,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Disease; Pathological; Process (computing); Intensive care medicine; Pathology; Computer science","score_opus":0.028232733783913815,"score_gpt":0.2908156844559647,"score_spread":0.26258295067205084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328070819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034704164,0.99432266,0.00012664912,0.00029488426,0.0043374365,0.0004863515,0.000055865352,0.000007889528,0.000021216787],"genre_scores_gemma":[0.0029025641,0.9959579,0.0002901064,0.000020004083,0.00009353009,0.000027619377,0.0002332484,0.00003395507,0.00044107673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634385,0.0010304038,0.0018876537,0.00021369307,0.000113873735,0.00041052626],"domain_scores_gemma":[0.99589115,0.0007761118,0.0025869608,0.0004973802,0.00012640803,0.000121956866],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043169633,0.00048251147,0.002522716,0.00030797836,0.00014409248,0.0000091875345,0.00076665415,0.00041385513,0.0023855325],"category_scores_gemma":[0.0000898686,0.0002593667,0.0010283983,0.00018769174,0.0002178933,0.000093529525,0.00015128152,0.000474934,0.00018361703],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011862868,0.0002300069,0.00045251625,0.0015350357,0.0046961308,0.000020162905,0.0021103641,4.0522062e-7,0.000002321962,0.0032099753,0.026692415,0.960932],"study_design_scores_gemma":[0.001481739,0.00021213632,0.000043226642,0.0021827132,0.0066821426,0.0005192537,0.00015502707,3.4858918e-8,0.00004748297,0.00027876973,0.9881811,0.00021637221],"about_ca_topic_score_codex":0.00010084631,"about_ca_topic_score_gemma":0.000036129917,"teacher_disagreement_score":0.96148866,"about_ca_system_score_codex":0.00011772902,"about_ca_system_score_gemma":0.0009922249,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W2328123966","doi":"10.1097/mib.0000000000000757","title":"Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease","year":2016,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Inflammatory bowel disease; Internal medicine; Incidence (geometry); Ulcerative colitis; Gastroenterology; Disease; Crohn's disease; Tumor necrosis factor alpha; Immunology","score_opus":0.012352254774737628,"score_gpt":0.24184622674566178,"score_spread":0.22949397197092414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328123966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996535,0.0014291905,0.0000036201043,0.00005258946,0.00044799634,0.00077443547,0.0006518441,0.000072988274,0.000032354914],"genre_scores_gemma":[0.9965189,0.0028659683,0.000011016124,0.00006562737,0.000043891712,0.000120200835,0.00018034196,0.0000396345,0.00015441647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977004,0.0003563399,0.0007944206,0.0005795522,0.00014419676,0.00042509925],"domain_scores_gemma":[0.9985567,0.00020415556,0.00039898636,0.00055010704,0.00012332307,0.00016678205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022492665,0.00039357092,0.00048337068,0.00018283515,0.000109427834,0.000020008105,0.00027975312,0.00020509075,0.00013757969],"category_scores_gemma":[0.000068076915,0.00026526384,0.00013518627,0.00009967639,0.00042639818,0.00031822964,0.00012950027,0.00010650277,0.000071428316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033989346,0.0008075596,0.93035036,0.00012573936,0.0005536064,0.000069521215,0.00006150548,1.5750162e-7,0.00063425326,0.00010802643,0.00034872544,0.063541576],"study_design_scores_gemma":[0.00872909,0.0002718756,0.98867583,0.0004077221,0.00021543932,4.9287956e-7,0.000034383007,3.121134e-7,0.00044499506,0.000048508493,0.0008049353,0.00036643274],"about_ca_topic_score_codex":0.0000070416527,"about_ca_topic_score_gemma":0.0000053044064,"teacher_disagreement_score":0.06317514,"about_ca_system_score_codex":0.000050253213,"about_ca_system_score_gemma":0.00010896668,"threshold_uncertainty_score":0.99998},"labels":[],"label_agreement":null},{"id":"W2329324114","doi":"10.1136/annrheumdis-2012-eular.3259","title":"SAT0312 Psoriasis and psoriatic arthritis among natives and mestizos from the andean mountains region of peru","year":2012,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Epidemiology; Ethnic group; Psoriasis; Population; Demography; Disease; Internal medicine; Dermatology; Environmental health","score_opus":0.03100127219215618,"score_gpt":0.25696159930774115,"score_spread":0.22596032711558497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329324114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93163913,0.067070566,0.0000065800746,0.0004524335,0.00026761694,0.00025934615,0.00021119947,0.000015001111,0.00007814646],"genre_scores_gemma":[0.9918497,0.007853719,0.00001725535,0.00007125576,0.000031664902,0.000024994975,0.000033871398,0.000011953132,0.00010555046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882877,0.00041620262,0.00030513565,0.00015503386,0.000066198176,0.000228633],"domain_scores_gemma":[0.99846876,0.00079317135,0.00029587408,0.00034425434,0.000054419503,0.00004354893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001935072,0.00017904719,0.0003816644,0.000044210425,0.00020146294,0.000013095848,0.00018520607,0.00008274608,0.00006448508],"category_scores_gemma":[0.00035146996,0.00010092697,0.00013635319,0.000101475795,0.00055525574,0.00017217813,0.00011115514,0.00005970202,0.0000049334258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026532848,0.0004808188,0.5457821,0.00012012712,0.0018125579,0.0000010926061,0.008022249,0.0000017417742,0.0003483628,0.0021489023,0.003505923,0.43751082],"study_design_scores_gemma":[0.0009720769,0.00007633687,0.98976755,0.00042854907,0.0004169285,0.000008063852,0.0015784603,0.000004713704,0.0039853044,0.0024695299,0.00016727253,0.00012522383],"about_ca_topic_score_codex":0.00043881172,"about_ca_topic_score_gemma":0.000046488298,"teacher_disagreement_score":0.44398546,"about_ca_system_score_codex":0.0000051975626,"about_ca_system_score_gemma":0.000022175078,"threshold_uncertainty_score":0.41156825},"labels":[],"label_agreement":null},{"id":"W2330298529","doi":"10.3899/jrheum.101123","title":"Current Challenges in the Genetics of Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Genome-wide association study; Medicine; Disease; Genetics; Human genetics; Epistasis; Medical genetics; Gene; Internal medicine; Biology; Dermatology; Single-nucleotide polymorphism; Genotype","score_opus":0.04327692130174259,"score_gpt":0.2513472408839821,"score_spread":0.20807031958223948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330298529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7366972,0.2611466,0.00001552625,0.0005635332,0.0012922828,0.0001071446,0.000017744958,0.000003964212,0.00015600574],"genre_scores_gemma":[0.90557826,0.094293416,0.00006505562,0.000018593237,0.000021136633,0.000006041879,0.0000048535794,0.000008240224,0.0000043899868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99733573,0.001411501,0.0008206093,0.00011265081,0.00007284353,0.00024667958],"domain_scores_gemma":[0.99725217,0.0013013241,0.000928545,0.0003915894,0.0001136192,0.000012757535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001788405,0.00015534661,0.00045006073,0.00007183326,0.00011337189,0.0000031965697,0.0006373595,0.00013710256,0.00006165049],"category_scores_gemma":[0.00024737182,0.000071347764,0.00014030775,0.000105945466,0.00026270983,0.000042717078,0.00006083485,0.00035469607,0.000018917397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030265036,0.0011936888,0.24991754,0.000044939763,0.002491759,0.00016602433,0.1164488,0.0000124843755,0.0012393198,0.0023378318,0.006353887,0.6167672],"study_design_scores_gemma":[0.018388433,0.003153576,0.77466893,0.001901025,0.0025376524,0.048401415,0.07891291,0.000008414733,0.009713163,0.023359127,0.038106762,0.00084862235],"about_ca_topic_score_codex":0.00033623938,"about_ca_topic_score_gemma":0.0007722141,"teacher_disagreement_score":0.61591864,"about_ca_system_score_codex":0.000009849519,"about_ca_system_score_gemma":0.00007866663,"threshold_uncertainty_score":0.29094774},"labels":[],"label_agreement":null},{"id":"W2331337690","doi":"10.3899/jrheum.150627","title":"Translational Research in Psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Translational research; Psoriasis; Public health; Psychological intervention; Bioinformatics; Immunology; Pathology","score_opus":0.08589113358059447,"score_gpt":0.3430655183616144,"score_spread":0.25717438478101995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331337690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863806,0.005168433,0.00012832283,0.005599743,0.0019349243,0.00016438303,0.000029162025,0.000007927675,0.0005864979],"genre_scores_gemma":[0.9983071,0.00028651935,0.0010987101,0.00002312056,0.000022965569,0.00001289028,0.00004397778,0.000009682943,0.00019503589],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978598,0.0007294446,0.00072168774,0.0001485294,0.0001438936,0.00039667357],"domain_scores_gemma":[0.998939,0.00037443452,0.00019961911,0.0001418813,0.00028859993,0.000056486777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024241407,0.00012328262,0.00040409202,0.00059718324,0.000071088696,0.000008402954,0.00025136108,0.00018917513,0.0008085652],"category_scores_gemma":[0.00009814075,0.00009940425,0.000107247724,0.0002629758,0.00013420769,0.000110120585,0.000036746085,0.00035939494,0.00020501553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020412067,0.0009394516,0.8494469,0.000027098908,0.0007477003,0.00016895069,0.004298766,0.000061341765,0.0017440573,0.008988808,0.09988097,0.03165473],"study_design_scores_gemma":[0.06129075,0.004083386,0.09183418,0.00041002274,0.00030071812,0.011183814,0.012372512,0.000018394197,0.026734902,0.034010604,0.7569377,0.000823057],"about_ca_topic_score_codex":0.00013297118,"about_ca_topic_score_gemma":0.00019439308,"teacher_disagreement_score":0.7576127,"about_ca_system_score_codex":0.00010779967,"about_ca_system_score_gemma":0.0003522711,"threshold_uncertainty_score":0.8853222},"labels":[],"label_agreement":null},{"id":"W2331921205","doi":"10.1097/01.jdn.0000350422.93121.b2","title":"The Dermatology Nurse's Role in Effective Home Phototherapy","year":2009,"lang":"en","type":"article","venue":"Journal of the Dermatology Nurses’ Association","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Dermatology; Medicine","score_opus":0.0030946228838215836,"score_gpt":0.22818458852771545,"score_spread":0.22508996564389386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331921205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752066,0.0063251555,0.000009906429,0.013292444,0.0040355595,0.00037204052,0.0000075319635,0.000019976967,0.00073078665],"genre_scores_gemma":[0.99813026,0.00035321247,0.000013390553,0.0005923537,0.000068491885,0.000017833632,0.0000056928907,0.000012065667,0.0008066963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970533,0.001609976,0.0006231683,0.00015194573,0.00009727105,0.0004643161],"domain_scores_gemma":[0.9974325,0.000999295,0.0011390145,0.00023863287,0.00016759911,0.000023000952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004948034,0.00020950002,0.00053124194,0.00016768624,0.00038009105,0.000024775518,0.0004802608,0.0005173143,0.000025970898],"category_scores_gemma":[0.00028647328,0.00012382648,0.00030738866,0.00028251772,0.000107214335,0.00014668929,0.000015289163,0.0005416382,0.00007649452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021416538,0.0011311196,0.7712707,0.000009057601,0.002107709,0.00016463565,0.0057092574,0.000039948158,0.07825323,0.0026521732,0.03033324,0.10618727],"study_design_scores_gemma":[0.006473855,0.00025383796,0.86659724,0.000056214325,0.00031833592,0.0038629046,0.000888974,0.000013662265,0.08348757,0.0076640663,0.03013943,0.00024389026],"about_ca_topic_score_codex":0.000011846492,"about_ca_topic_score_gemma":0.000065610715,"teacher_disagreement_score":0.105943374,"about_ca_system_score_codex":0.00040190638,"about_ca_system_score_gemma":0.000098394594,"threshold_uncertainty_score":0.50494975},"labels":[],"label_agreement":null},{"id":"W2332001784","doi":"10.3899/jrheum.120253","title":"Ustekinumab for Psoriasis and Psoriatic Arthritis","year":2012,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Clinical trial; Plaque psoriasis; Arthritis; Internal medicine; Disease; Adalimumab","score_opus":0.03984757902511951,"score_gpt":0.30028989926483923,"score_spread":0.2604423202397197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332001784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027005104,0.9921376,0.00015771759,0.00013325115,0.005882177,0.0008883754,0.0004944077,0.000015911237,0.000020492163],"genre_scores_gemma":[0.00044178285,0.9971286,0.0013852424,0.000015825824,0.00012492463,0.00018628687,0.00039271542,0.00006263398,0.00026198273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964257,0.000547804,0.0019366886,0.00032514773,0.00007607171,0.00068858627],"domain_scores_gemma":[0.9963651,0.0010292751,0.0020426277,0.00031542004,0.00015527556,0.000092319264],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00094829785,0.0006045488,0.0035245782,0.00049581064,0.00020247915,0.000024135077,0.00036045068,0.0008145174,0.0011175751],"category_scores_gemma":[0.00011820872,0.00044924777,0.0009412383,0.0001241724,0.00014636139,0.00013002077,0.00010755925,0.00040861103,0.000110063294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009809383,0.00018535339,0.00019669735,0.0033248132,0.0038769792,0.000011571616,0.00018670189,3.364251e-8,0.0000011984213,0.00079922256,0.015221092,0.97609824],"study_design_scores_gemma":[0.00405634,0.00053065375,0.00001139991,0.0032638523,0.005633761,0.008637835,0.00010749637,6.013016e-8,0.000018932536,0.00013963149,0.9772365,0.00036350026],"about_ca_topic_score_codex":0.000017440429,"about_ca_topic_score_gemma":0.000029445797,"teacher_disagreement_score":0.9757348,"about_ca_system_score_codex":0.00013544285,"about_ca_system_score_gemma":0.00030244968,"threshold_uncertainty_score":0.9997959},"labels":[],"label_agreement":null},{"id":"W2332152821","doi":"10.3899/jrheum.101113","title":"Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","year":2011,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Family medicine; Dermatology; Rheumatology; Outreach; Internal medicine; Physical therapy","score_opus":0.0642433752203398,"score_gpt":0.316796021334647,"score_spread":0.2525526461143072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332152821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792726,0.019068139,0.00031606018,0.00027707816,0.0005432026,0.00031172935,0.000021599966,0.000006262425,0.00018330065],"genre_scores_gemma":[0.9824002,0.015762737,0.0017168063,0.000012911372,0.000008655246,0.000021118187,0.0000047380995,0.000011453722,0.00006137655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982735,0.00068363827,0.0005338775,0.00013298169,0.000057781184,0.00031821977],"domain_scores_gemma":[0.99805546,0.0010746717,0.00041315128,0.0001853532,0.00023796536,0.0000333792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022581834,0.00013381052,0.00053681596,0.00022628973,0.00020580074,0.00000538175,0.00022135413,0.00020575091,0.00006417133],"category_scores_gemma":[0.00014649154,0.00008544285,0.00007076347,0.000115512295,0.00060048385,0.000074889576,0.00007365675,0.00028063575,0.0000032583073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067427126,0.0014845715,0.45406997,0.00033906384,0.004109404,0.000019135234,0.008856741,7.1448505e-7,0.0212267,0.05330087,0.007572544,0.44227758],"study_design_scores_gemma":[0.04227901,0.033261262,0.71089774,0.0009965077,0.0020356367,0.03088656,0.008524168,0.000039787916,0.029984688,0.1208922,0.01923964,0.0009627911],"about_ca_topic_score_codex":0.00013973592,"about_ca_topic_score_gemma":0.00009417329,"teacher_disagreement_score":0.4413148,"about_ca_system_score_codex":0.000013030051,"about_ca_system_score_gemma":0.00007730734,"threshold_uncertainty_score":0.34842584},"labels":[],"label_agreement":null},{"id":"W2332295706","doi":"10.3899/jrheum.150629","title":"Psoriatic Disease: Clinical Staging","year":2015,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Psoriasis; Psoriatic arthritis; Dermatology; Intensive care medicine; Pathology","score_opus":0.04629560538133127,"score_gpt":0.31983860406934606,"score_spread":0.2735429986880148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332295706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97957534,0.008892844,0.0006113113,0.0034191292,0.007141321,0.000161967,0.000046923727,0.000024244046,0.00012694881],"genre_scores_gemma":[0.9974693,0.0007748873,0.001056235,0.0001237248,0.000056442917,0.000007729213,0.000059517693,0.00001533907,0.00043680822],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976764,0.00057382684,0.0011254612,0.00017877718,0.00009324651,0.00035229718],"domain_scores_gemma":[0.99844617,0.00029751225,0.0006464854,0.00023904855,0.00020853092,0.00016224642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013796681,0.00018082526,0.00061550643,0.0001669354,0.0000816878,0.000011858648,0.00028376433,0.00014430445,0.0008376177],"category_scores_gemma":[0.00034583476,0.00013726232,0.00026023097,0.00008762636,0.0001307145,0.00011484476,0.00007650628,0.0002537214,0.0003169534],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009807043,0.00049256615,0.8308347,0.000019656458,0.0011710026,0.00011443976,0.00042770672,0.000009471542,0.00006993784,0.0015484907,0.14565298,0.018678373],"study_design_scores_gemma":[0.03253048,0.0025147938,0.12674417,0.0002529445,0.0016981323,0.0026048669,0.0027652588,0.0000182753,0.001565627,0.0042291726,0.8243726,0.0007036995],"about_ca_topic_score_codex":0.000021531445,"about_ca_topic_score_gemma":0.000010607323,"teacher_disagreement_score":0.7040905,"about_ca_system_score_codex":0.000077224206,"about_ca_system_score_gemma":0.00039280465,"threshold_uncertainty_score":0.9171327},"labels":[],"label_agreement":null},{"id":"W2332346805","doi":"10.1136/annrheumdis-2014-eular.1499","title":"AB0752 Efficacy and Safety of Brodalumab over One Year in Patients with Psoriatic Arthritis with and without Prior Exposure to A Biologic","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Université Laval","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Internal medicine; Rheumatology; Psoriasis; Ustekinumab; Enthesitis; Placebo; Arthritis; Surgery; Adalimumab; Dermatology; Rheumatoid arthritis; Pathology","score_opus":0.012049945015239644,"score_gpt":0.2263392746583248,"score_spread":0.21428932964308514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332346805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99731743,0.0019001899,0.000006833895,0.000087531065,0.00003683815,0.00050696905,0.00010067599,0.000010117834,0.000033414493],"genre_scores_gemma":[0.99944216,0.00029179148,0.000117933814,0.00006379354,0.0000034851078,0.000020179968,0.000018469571,0.000010291142,0.00003191522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991301,0.00019212291,0.00025521155,0.00019179432,0.000059061047,0.00017171062],"domain_scores_gemma":[0.999293,0.00016847884,0.00017850507,0.00027153405,0.00005379972,0.000034627254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011944829,0.00014943304,0.00041810604,0.0000669129,0.00005775529,0.000006341927,0.00010888749,0.000057625173,0.000036171637],"category_scores_gemma":[0.00016408406,0.00008487404,0.000034555575,0.000118791475,0.000184905,0.000048855778,0.000059943603,0.000039950864,0.000004261359],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031323656,0.0006885593,0.83734363,0.00013017865,0.00043235515,1.4567031e-7,0.0005030351,0.0000115416515,0.00009435462,0.00016780989,0.000049599967,0.15744641],"study_design_scores_gemma":[0.0064548748,0.0014703715,0.9901366,0.0009876646,0.0001268464,9.124966e-7,0.00005191939,9.548118e-7,0.00048571415,0.00013709185,0.000031345433,0.00011567173],"about_ca_topic_score_codex":0.000049675582,"about_ca_topic_score_gemma":0.00004108908,"teacher_disagreement_score":0.15733074,"about_ca_system_score_codex":0.0000041597714,"about_ca_system_score_gemma":0.000024723866,"threshold_uncertainty_score":0.3461063},"labels":[],"label_agreement":null},{"id":"W2332775026","doi":"10.2310/7750.2009.00032","title":"Update on Alefacept Safety","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nexus Clinical Research (Canada); Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Psoriasis; Dosing; Observational study; Incidence (geometry); Clinical trial; Dermatology; Surgery; Internal medicine","score_opus":0.018287662208451145,"score_gpt":0.24506949769188618,"score_spread":0.22678183548343503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332775026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96830195,0.015978806,0.000037480902,0.010566506,0.0016438433,0.00006217013,0.0000061877995,0.000019068055,0.0033840036],"genre_scores_gemma":[0.9889482,0.007231205,0.000017748867,0.0023747727,0.0002801243,2.3952373e-7,0.00001361685,0.0000065323775,0.0011275272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904615,0.000120284305,0.0004655618,0.00010589274,0.000064782595,0.00019731902],"domain_scores_gemma":[0.9988972,0.00061518274,0.0002583715,0.00010940037,0.00006817495,0.0000516849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039309054,0.00014364724,0.00052646786,0.00021426642,0.00009384204,0.0000042371034,0.00006610832,0.00011883349,0.0005534167],"category_scores_gemma":[0.00015588,0.000089731235,0.0001256647,0.00008415644,0.00008631464,0.00004472887,0.0000052454625,0.0001816046,0.000053292253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028376568,0.00023436992,0.0033655285,0.000012209727,0.000454072,0.00237742,0.0005712908,0.0000056204094,0.021235153,0.00031653527,0.16307186,0.80551827],"study_design_scores_gemma":[0.003915557,0.0042874813,0.020683143,0.0007551056,0.0007331649,0.04164216,0.0006419864,0.000002378186,0.00962818,0.0014508008,0.91579354,0.00046650777],"about_ca_topic_score_codex":0.00000303044,"about_ca_topic_score_gemma":0.0000010186837,"teacher_disagreement_score":0.8050518,"about_ca_system_score_codex":0.000019000034,"about_ca_system_score_gemma":0.00004601353,"threshold_uncertainty_score":0.6059525},"labels":[],"label_agreement":null},{"id":"W2333448314","doi":"10.3899/jrheum.120825","title":"Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists’ Perspective: A Report from the GRAPPA 2011 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Dermatology; Perspective (graphical); Family medicine","score_opus":0.07650818437017448,"score_gpt":0.3035074491672533,"score_spread":0.22699926479707883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333448314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92247874,0.073169075,0.000025967987,0.0021750592,0.0017839771,0.00019847408,0.000039471186,0.000017206186,0.00011205714],"genre_scores_gemma":[0.98071516,0.018930368,0.00016125452,0.000035309113,0.00008139288,0.000024327064,0.000011832057,0.000019058201,0.000021317353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99499756,0.0030790453,0.00086673803,0.00023735846,0.00014834465,0.00067092763],"domain_scores_gemma":[0.994033,0.0045770756,0.0006019343,0.00043903623,0.00028539222,0.000063579224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038743585,0.00024058022,0.0007138953,0.00020750664,0.00046333944,0.000020550957,0.00047906375,0.0002488736,0.00012480978],"category_scores_gemma":[0.0014184588,0.00014367244,0.0001283424,0.00022537411,0.0005905833,0.00038990474,0.00021225263,0.0009226458,0.00007612161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008421235,0.00023096777,0.9481441,0.0000073070614,0.0008352359,0.00011971783,0.030566094,0.0000014065112,0.0011250827,0.0007565747,0.0026439563,0.014727458],"study_design_scores_gemma":[0.0049714525,0.0002151711,0.8902616,0.0004190976,0.00038639584,0.022025533,0.065248124,0.0000023673776,0.003859772,0.0073972903,0.0048489,0.00036428613],"about_ca_topic_score_codex":0.01476553,"about_ca_topic_score_gemma":0.0016124098,"teacher_disagreement_score":0.058236428,"about_ca_system_score_codex":0.000106582665,"about_ca_system_score_gemma":0.00013050127,"threshold_uncertainty_score":0.99179524},"labels":[],"label_agreement":null},{"id":"W2333653704","doi":"10.3899/jrheum.130458","title":"Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting","year":2013,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Malignancy; Dermatology; Comorbidity; Internal medicine; Immunology","score_opus":0.009844498094048217,"score_gpt":0.21889443483273321,"score_spread":0.209049936738685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333653704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935142,0.062341284,0.00003268035,0.0010322572,0.0011012182,0.00018623797,0.000028785322,0.000015196684,0.00012037518],"genre_scores_gemma":[0.9804069,0.019282468,0.00010325449,0.000056597222,0.000020394651,0.000011832416,0.000010395234,0.000011029378,0.000097170574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789745,0.0008826717,0.0007969817,0.0001244248,0.000055585766,0.00024286845],"domain_scores_gemma":[0.99641454,0.0020692437,0.0010660643,0.00024265601,0.00018306472,0.00002444894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010082065,0.00018707,0.00068058155,0.0000824592,0.00027732324,0.000014744771,0.00022141445,0.00021404574,0.0002069051],"category_scores_gemma":[0.0003592434,0.00010058934,0.00009706346,0.000088363064,0.0006328761,0.00018260934,0.00011492105,0.00028872254,0.00001695392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009138739,0.0004202715,0.7068278,0.00006656411,0.005252959,0.000069137044,0.018648837,0.000011239475,0.014041403,0.0012205068,0.036797184,0.2157302],"study_design_scores_gemma":[0.00996762,0.0018061276,0.86818457,0.00064781914,0.0016151523,0.0671796,0.017463269,0.000009997236,0.0039782356,0.014921479,0.013703886,0.000522248],"about_ca_topic_score_codex":0.0036078463,"about_ca_topic_score_gemma":0.00039510254,"teacher_disagreement_score":0.21520796,"about_ca_system_score_codex":0.000015269754,"about_ca_system_score_gemma":0.000069295544,"threshold_uncertainty_score":0.54540086},"labels":[],"label_agreement":null},{"id":"W2334337629","doi":"10.1136/annrheumdis-2014-eular.1174","title":"SAT0404 Fifty-Two Week Clinical Response to Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Rheumatology; Adverse effect; Psoriasis; Placebo; Psoriasis Area and Severity Index; Rheumatoid arthritis; Immunology; Pathology","score_opus":0.03669345411588095,"score_gpt":0.3284316581926772,"score_spread":0.2917382040767963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334337629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520767,0.0022112534,0.000029510273,0.0012676873,0.0004946927,0.0004963443,0.00016864178,0.000052496976,0.00007169059],"genre_scores_gemma":[0.99831015,0.0007550305,0.0001054602,0.0004709279,0.0000338802,0.00004171778,0.00007163739,0.000029639694,0.00018155253],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996073,0.0022046997,0.000708298,0.0004234934,0.000117117685,0.00047339406],"domain_scores_gemma":[0.99731785,0.0012676454,0.00029627286,0.0009046981,0.00009963714,0.000113891154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011729288,0.00028816,0.0007629775,0.00016856537,0.00015634033,0.000026804128,0.0005122677,0.00012583655,0.00014149939],"category_scores_gemma":[0.0013656715,0.00019333861,0.00024293481,0.00034121925,0.00027247623,0.00015320072,0.00011592293,0.00012932677,0.00019441498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01282095,0.005720143,0.28548208,0.00022560194,0.0013636064,0.000035397054,0.0018755394,0.00026150994,0.00499187,0.00089377485,0.004213328,0.6821162],"study_design_scores_gemma":[0.004403178,0.0017458915,0.9868353,0.0010114241,0.0001732894,0.00002010357,0.00019985558,0.00002166391,0.003530019,0.0009211939,0.00082614674,0.00031190657],"about_ca_topic_score_codex":0.000249,"about_ca_topic_score_gemma":0.00026941707,"teacher_disagreement_score":0.70135325,"about_ca_system_score_codex":0.000011448384,"about_ca_system_score_gemma":0.00015804496,"threshold_uncertainty_score":0.788412},"labels":[],"label_agreement":null},{"id":"W2334546249","doi":"10.2310/7750.2009.00031","title":"Patterns of Combination Therapy with Alefacept for the Treatment of Psoriasis in Canada in the AWARE Study","year":2009,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health Research Institute; Innovaderm (Canada); Probity Medical Research; University of Toronto; Nexus Clinical Research (Canada); University of British Columbia","funders":"LEO Pharma; Galderma; Janssen Biotech; Astellas Pharma; University of British Columbia; University of Alberta; Abbott Canada","keywords":"Medicine; Concomitant; Discontinuation; Psoriasis; Population; Observational study; Dermatology; Combination therapy; Clinical trial; Plaque psoriasis; Internal medicine","score_opus":0.02696615080495873,"score_gpt":0.2538744705991516,"score_spread":0.22690831979419285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334546249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921491,0.0058300453,0.000008909471,0.0014897243,0.0001936723,0.00031146314,0.0000082488605,6.626879e-7,0.000008131374],"genre_scores_gemma":[0.9946273,0.005190582,0.0000013960889,0.00010524361,0.000029546014,0.000006640053,0.000005491101,0.0000032457312,0.00003054341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916637,0.00017445811,0.00041444204,0.0000629659,0.00007559864,0.00010616871],"domain_scores_gemma":[0.99792755,0.0016020042,0.00029193112,0.00009747963,0.00007185085,0.000009181837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035248423,0.000097918964,0.00044440723,0.00011610306,0.000033797787,0.0000014602737,0.000068947484,0.000032551947,0.000018890714],"category_scores_gemma":[0.00002482337,0.00003997687,0.000052148716,0.000098121025,0.000028392948,0.00001885601,0.0000012179548,0.00005328631,3.419385e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002265955,0.0013794095,0.72410417,0.000011088442,0.00042549442,0.00025362562,0.009006562,0.00001877011,0.00055097253,0.000007185087,0.00054206303,0.2614347],"study_design_scores_gemma":[0.011099142,0.015583319,0.93469214,0.00025149668,0.0004136046,0.0011438107,0.03114523,0.0000071385657,0.0027932785,0.000058749087,0.002685531,0.0001265469],"about_ca_topic_score_codex":0.04494465,"about_ca_topic_score_gemma":0.13156602,"teacher_disagreement_score":0.26130813,"about_ca_system_score_codex":0.000050850253,"about_ca_system_score_gemma":0.00018887028,"threshold_uncertainty_score":0.9614152},"labels":[],"label_agreement":null},{"id":"W2334991599","doi":"10.1136/annrheumdis-2013-eular.2012","title":"SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Discontinuation; Adverse effect; Psoriasis; Population; Internal medicine; Dermatology; Rheumatoid arthritis","score_opus":0.043655645000211914,"score_gpt":0.29381732660925947,"score_spread":0.25016168160904756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334991599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438775,0.0035243202,0.000009910138,0.00010380644,0.0006234257,0.001066213,0.00023608904,0.00002386508,0.000024652598],"genre_scores_gemma":[0.99848264,0.0009024664,0.00018745588,0.000044631674,0.000016042017,0.00011526499,0.00017255568,0.000019829627,0.000059106787],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99785066,0.00045996477,0.0010014392,0.00023993842,0.00017158671,0.00027641325],"domain_scores_gemma":[0.9972838,0.0010047216,0.00082705385,0.00060583354,0.00023484348,0.000043731154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026922234,0.00021884475,0.0006658479,0.000047365203,0.00013953535,0.000013022967,0.0005260679,0.00011930789,0.000328811],"category_scores_gemma":[0.00044200744,0.0001245999,0.00033292975,0.00018390085,0.0003719202,0.00010972856,0.00020641884,0.000088464585,0.000046508136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003383325,0.00087362755,0.3901808,0.000056161705,0.0015546757,2.8442005e-7,0.0006112247,0.0000015688072,0.000011114403,0.000020151532,0.00049896055,0.6058531],"study_design_scores_gemma":[0.0034271723,0.00026993066,0.99294764,0.0011605232,0.00038027685,5.431277e-7,0.00016474734,0.00000104497,0.0011747195,0.00021570185,0.00011484427,0.0001428771],"about_ca_topic_score_codex":0.00024860975,"about_ca_topic_score_gemma":0.00008116103,"teacher_disagreement_score":0.6057102,"about_ca_system_score_codex":0.0000130898725,"about_ca_system_score_gemma":0.00014291672,"threshold_uncertainty_score":0.5081036},"labels":[],"label_agreement":null},{"id":"W2335158544","doi":"10.1177/1203475415584511","title":"Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept","year":2015,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); Centre de Recherche Dermatologique du Québec Métropolitain; Memorial University of Newfoundland; Probity Medical Research; Merck Canada Inc. (Canada); Université de Sherbrooke","funders":"Amgen Canada; Amgen","keywords":"Medicine; Etanercept; Psoriasis; Psoriatic arthritis; Body surface area; Psoriasis Area and Severity Index; Plaque psoriasis; Surgery; Internal medicine; Dermatology; Rheumatoid arthritis","score_opus":0.025290437281649487,"score_gpt":0.24190831616136083,"score_spread":0.21661787887971135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335158544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959358,0.002116514,0.00008630636,0.00043634663,0.0007406195,0.00013137779,0.0000099174995,0.0000075825574,0.00053555274],"genre_scores_gemma":[0.99793077,0.0008454559,0.00012708975,0.00018785892,0.00008363266,0.0000023348164,0.000024931276,0.000014199619,0.000783746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888897,0.00011143937,0.0005108242,0.0001393021,0.00014034439,0.00020911683],"domain_scores_gemma":[0.9989095,0.00022188628,0.0003352048,0.00014320742,0.00027719312,0.00011301732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003218357,0.00017847566,0.00064330833,0.00024284219,0.00004685893,0.0000052487417,0.00008973581,0.000097911696,0.000113715796],"category_scores_gemma":[0.000038911265,0.00010922319,0.000076450146,0.00013765162,0.000084777006,0.00006882237,0.000025841913,0.00010854863,0.000011441977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021846445,0.0009422683,0.64670986,0.0003319136,0.004820856,0.0045992476,0.0046175956,0.00014971364,0.0011799767,0.00006846777,0.047857232,0.26687646],"study_design_scores_gemma":[0.06209043,0.024843795,0.77610224,0.011685651,0.0112113245,0.045804635,0.009168801,0.000009499203,0.013615545,0.0007671078,0.04166086,0.0030401335],"about_ca_topic_score_codex":0.0000117073905,"about_ca_topic_score_gemma":0.0000068696254,"teacher_disagreement_score":0.26383632,"about_ca_system_score_codex":0.000033349545,"about_ca_system_score_gemma":0.00006201437,"threshold_uncertainty_score":0.44539925},"labels":[],"label_agreement":null},{"id":"W2337006501","doi":"10.1136/annrheumdis-2015-eular.3489","title":"OP0175 Two-Year Clinical Response to Brodalumab, An Anti-IL-17 Receptor Antibody, in Patients with Psoriatic Arthritis","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Psoriasis; Rheumatology; Psoriasis Area and Severity Index; Placebo; Rheumatoid arthritis; Immunology; Gastroenterology; Pathology","score_opus":0.04251572921150886,"score_gpt":0.3289120101862254,"score_spread":0.28639628097471653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337006501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966221,0.0008755511,0.000003354612,0.0007214892,0.0006628763,0.00058467925,0.00043087205,0.00003674333,0.00006232586],"genre_scores_gemma":[0.9989017,0.00022316973,0.00012672483,0.00023818371,0.00002306758,0.00003104653,0.00017899141,0.000024791305,0.00025232797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971351,0.0013785948,0.0006276002,0.0003452478,0.00014336722,0.00037006842],"domain_scores_gemma":[0.9982557,0.00038105302,0.00027390604,0.0007421501,0.00020035163,0.00014681298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082809525,0.00023617834,0.0006044918,0.0001349144,0.000092338654,0.000021527449,0.00045039138,0.00011041189,0.00016307343],"category_scores_gemma":[0.0011745176,0.00014377556,0.00016793291,0.00028751115,0.00020424667,0.00017765348,0.00012455051,0.00010065407,0.00026400745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01288026,0.003788835,0.8465822,0.00004026509,0.0006416879,0.0000047516314,0.0009543398,0.00006898673,0.00016906748,0.00011744431,0.014296155,0.12045603],"study_design_scores_gemma":[0.007252395,0.0015944785,0.9881339,0.0005767342,0.00010633993,0.0000016051424,0.0003603738,0.000002079407,0.00053479424,0.00023401939,0.0009650005,0.0002382437],"about_ca_topic_score_codex":0.0001162781,"about_ca_topic_score_gemma":0.00004352188,"teacher_disagreement_score":0.14155176,"about_ca_system_score_codex":0.000020154486,"about_ca_system_score_gemma":0.00020159999,"threshold_uncertainty_score":0.5862997},"labels":[],"label_agreement":null},{"id":"W2337341101","doi":"10.2340/00015555-2360","title":"Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Medac; LEO Pharma; Galderma; Les Laboratories Pierre Fabre; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Teva Pharmaceutical Industries; Eli Lilly and Company","keywords":"Medicine; Apremilast; Visual analogue scale; Psoriasis; Quality of life (healthcare); Placebo; Dermatology; Severity of illness; Internal medicine; Dermatology Life Quality Index; Plaque psoriasis; Physical therapy; Alternative medicine; Pathology; Psoriatic arthritis","score_opus":0.00693561421531896,"score_gpt":0.20323091068542257,"score_spread":0.1962952964701036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337341101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987659,0.00012981285,0.000049026108,0.000097993136,0.00006560306,0.0007319983,0.000072849674,0.000015713878,0.00007113597],"genre_scores_gemma":[0.9994698,0.000056634544,0.00009699459,0.00014753814,0.000003867831,0.00010790127,0.000035868816,0.000015279253,0.000066073684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982143,0.0005251558,0.00047893423,0.00037221963,0.00007431447,0.00033506606],"domain_scores_gemma":[0.9988336,0.00054441136,0.0002862389,0.0002582094,0.000031561216,0.000046008452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026816613,0.00026533997,0.0006136203,0.00016687077,0.000041581672,0.000004147446,0.00015181396,0.00021389448,0.000018212206],"category_scores_gemma":[0.000112697555,0.00014689527,0.000038680486,0.00017300004,0.00012526523,0.00009623189,0.00008037037,0.00010107275,0.000004349281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009238188,0.0009789157,0.9593626,0.00012806887,0.0002405785,0.000009224521,0.00047047567,0.00003274532,0.014118308,0.00008930873,0.000065759814,0.0152657805],"study_design_scores_gemma":[0.013162029,0.001225333,0.94399756,0.0003962676,0.000039273455,0.0000021765825,0.000051385217,0.0000020363702,0.040777966,0.00006170846,0.000039174774,0.00024505684],"about_ca_topic_score_codex":0.00019878826,"about_ca_topic_score_gemma":0.0002992758,"teacher_disagreement_score":0.026659658,"about_ca_system_score_codex":0.00004761607,"about_ca_system_score_gemma":0.000044447486,"threshold_uncertainty_score":0.5990215},"labels":[],"label_agreement":null},{"id":"W2338499894","doi":"10.17352/2455-8605.000007","title":"Psoriasis with Onychodystrophy in a 7-Year-Old Boy","year":2015,"lang":"en","type":"article","venue":"International Journal of Dermatology and Clinical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; BP (Canada); University of Calgary; University of Alberta","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Nail (fastener); Nail disease; Disease; Population; Pathology","score_opus":0.11216426873835679,"score_gpt":0.42879139831518837,"score_spread":0.3166271295768316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338499894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120086,0.0013226859,0.000039651062,0.0050873132,0.0010731317,0.0000754148,0.0000066114153,0.000005393971,0.0011889057],"genre_scores_gemma":[0.9982483,0.0007555695,0.000288319,0.000100481266,0.00013100359,0.0000046573305,0.0000070566784,0.0000075087796,0.00045710363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784154,0.0009092535,0.0006078945,0.0001799928,0.00019862122,0.00026269708],"domain_scores_gemma":[0.9978698,0.000999854,0.00017373431,0.00011429581,0.00075168075,0.00009067307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014862977,0.00009771272,0.00034106302,0.00037942705,0.000043521846,0.000023522269,0.00038308493,0.00026260017,0.00007072792],"category_scores_gemma":[0.0010208869,0.00006814361,0.00008504583,0.00015036049,0.00035055133,0.0001301691,0.000097771335,0.0007439027,0.00011822757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076368363,0.0007282873,0.9470042,0.0000046753885,0.0009764491,0.00201939,0.00030136624,0.0000020316124,0.00024194426,0.002710461,0.0050405585,0.03333381],"study_design_scores_gemma":[0.065768376,0.0051670102,0.7923788,0.0004968169,0.00027977108,0.026122442,0.006055457,0.000025161364,0.0059425742,0.014481138,0.08267331,0.0006091737],"about_ca_topic_score_codex":0.00004508724,"about_ca_topic_score_gemma":0.000067090776,"teacher_disagreement_score":0.15462543,"about_ca_system_score_codex":0.000050036164,"about_ca_system_score_gemma":0.00026245997,"threshold_uncertainty_score":0.32319283},"labels":[],"label_agreement":null},{"id":"W2339202777","doi":"10.1177/1203475416631329","title":"MACEs Not Associated With the Use of Biologic Therapy for Psoriasis in Real-World Clinical Practice","year":2016,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Psoriasis; Cohort; Adverse effect; Internal medicine; Cohort study; Medical record; Retrospective cohort study; Disease; Dermatology","score_opus":0.12843470086284256,"score_gpt":0.3418190549777474,"score_spread":0.21338435411490483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339202777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874234,0.0026557585,0.000023525883,0.009078346,0.00059062167,0.00015230446,0.000016551869,0.0000060608754,0.00005339855],"genre_scores_gemma":[0.9734382,0.024684241,0.00008120631,0.00088573684,0.00015873623,0.0000049888113,0.000005919351,0.0000099609815,0.00073098415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99821615,0.00065847405,0.0007415813,0.0001262313,0.00006740543,0.00019015638],"domain_scores_gemma":[0.96982694,0.02883717,0.00093837094,0.00011786626,0.000253226,0.00002643491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019976771,0.00013418407,0.0007045578,0.00018951754,0.000057619218,0.000004340313,0.00008492761,0.00014448307,0.00005034214],"category_scores_gemma":[0.0031925591,0.000050071896,0.00014056842,0.00015494853,0.00032575763,0.00009777187,0.000009170855,0.00013544262,0.0000010429595],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023224466,0.00070951006,0.44248405,0.000015750065,0.0027482763,0.00053951005,0.0006353168,0.0000019000522,0.021257065,0.00010868094,0.044272527,0.46400297],"study_design_scores_gemma":[0.019129263,0.011636603,0.36578563,0.0019774253,0.001942822,0.004510286,0.0014301757,0.0000025500497,0.009676168,0.0002847635,0.583053,0.0005712945],"about_ca_topic_score_codex":0.00007706348,"about_ca_topic_score_gemma":0.00020208789,"teacher_disagreement_score":0.5387805,"about_ca_system_score_codex":0.000020258865,"about_ca_system_score_gemma":0.000105851155,"threshold_uncertainty_score":0.3822022},"labels":[],"label_agreement":null},{"id":"W2339999281","doi":"10.3899/jrheum.150641","title":"New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol","year":2015,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Certolizumab pegol; Medicine; Psoriatic arthritis; Psoriasis; Rheumatoid arthritis; Tumor necrosis factor alpha; Arthritis; Oncology; Immunology; Internal medicine; Adalimumab","score_opus":0.09187653286900763,"score_gpt":0.31585251805428133,"score_spread":0.2239759851852737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339999281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006194493,0.99288905,0.00015811546,0.0004975668,0.0029033744,0.0019384951,0.0009753906,0.000009795594,0.000008790679],"genre_scores_gemma":[0.001997693,0.99608856,0.0008261133,0.0000038499443,0.000071714,0.0003322195,0.0003687388,0.00005632872,0.00025479676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99588597,0.00058321905,0.0024281899,0.00037203563,0.00011946227,0.0006111059],"domain_scores_gemma":[0.99575377,0.0011561495,0.0024169942,0.00047798865,0.00011124133,0.00008383311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002818384,0.00069121964,0.0041549285,0.0004881868,0.00011973214,0.000020983549,0.0005983716,0.00049825676,0.00041167933],"category_scores_gemma":[0.000066505665,0.0004008899,0.0013300226,0.00020498998,0.00014314572,0.00008048078,0.00005478323,0.0002804334,0.000033491262],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040176176,0.00076413486,0.0003692652,0.0011714641,0.004143365,0.000060170885,0.0012499518,8.629296e-7,0.0000028054737,0.00036540622,0.0055855615,0.98588526],"study_design_scores_gemma":[0.009781876,0.0024100114,0.000024032866,0.0020461387,0.002842699,0.006373071,0.00041964583,0.0000010189735,0.00018763456,0.00020892954,0.9753664,0.0003385407],"about_ca_topic_score_codex":0.0002979745,"about_ca_topic_score_gemma":0.00026016912,"teacher_disagreement_score":0.9855467,"about_ca_system_score_codex":0.00047034543,"about_ca_system_score_gemma":0.0014651256,"threshold_uncertainty_score":0.9998443},"labels":[],"label_agreement":null},{"id":"W2341013428","doi":"10.3899/jrheum.150638","title":"Concept of Remission in Chronic Plaque Psoriasis","year":2015,"lang":"en","type":"review","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Ustekinumab; Methotrexate; Dermatology; Acitretin; Psoriatic arthritis; Psoriasis Area and Severity Index; Etanercept; Body surface area; Population; Disease; Rheumatoid arthritis; Adalimumab; Immunology; Internal medicine","score_opus":0.04035226263113693,"score_gpt":0.3243175583472769,"score_spread":0.28396529571613993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341013428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072876783,0.9960108,0.000018545616,0.00010282861,0.0023791478,0.0004580559,0.00022649199,0.000007991328,0.00006739289],"genre_scores_gemma":[0.0009689226,0.9980201,0.0002512152,0.0000046176865,0.00003996442,0.000029248456,0.00039501322,0.00003669679,0.00025422915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954611,0.0010600464,0.002585831,0.00029995415,0.00011819117,0.00047489823],"domain_scores_gemma":[0.99616224,0.00044448546,0.0027491874,0.00037500233,0.00020213008,0.00006698539],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010948572,0.0004975787,0.0039619463,0.0007248962,0.000046815134,0.000005448467,0.0005869362,0.0009404815,0.0015421781],"category_scores_gemma":[0.0001105155,0.00035500692,0.0007340844,0.0002729399,0.0001806614,0.00007699534,0.00013400607,0.0006526104,0.00008112636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019793336,0.00029725773,0.0005004463,0.003068155,0.002105981,0.00009594215,0.0004321953,0.0000036273536,0.000029569754,0.00028892967,0.046404775,0.94657516],"study_design_scores_gemma":[0.0039716903,0.0007456382,0.000008430771,0.008305675,0.0012024946,0.0027094705,0.00013941582,1.6061776e-7,0.00035623854,0.00007337488,0.98222554,0.0002618657],"about_ca_topic_score_codex":0.00009040575,"about_ca_topic_score_gemma":0.000064566666,"teacher_disagreement_score":0.9463133,"about_ca_system_score_codex":0.0007626572,"about_ca_system_score_gemma":0.002077643,"threshold_uncertainty_score":0.9998902},"labels":[],"label_agreement":null},{"id":"W2341637852","doi":"10.1177/1203475416631328","title":"Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Adalimumab; Dermatology; Acitretin; Ustekinumab; Infliximab; Combination therapy; Etanercept; Psoriasis Area and Severity Index; Thalidomide; Adverse effect; Methotrexate; Internal medicine; Psoriatic arthritis; Rheumatoid arthritis","score_opus":0.036885696148977666,"score_gpt":0.24973653946963542,"score_spread":0.21285084332065776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341637852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908057,0.007846167,0.0001632407,0.0007588712,0.00025589066,0.00013027167,0.00001970629,0.0000027202007,0.000017442051],"genre_scores_gemma":[0.992976,0.0065288087,0.000058714897,0.00002036198,0.00006468577,0.000005337163,0.0000041982103,0.00000975635,0.0003320993],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922574,0.00008925951,0.0004409048,0.00007930368,0.000044262983,0.00012055697],"domain_scores_gemma":[0.99752504,0.0018396977,0.00042118283,0.00008213483,0.00011535232,0.000016616073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017925315,0.00011377492,0.000588588,0.0002450726,0.000020358664,0.0000013273988,0.000031537114,0.00008573632,0.000068528796],"category_scores_gemma":[0.00006732894,0.000053113443,0.0000879167,0.0000663293,0.00015295822,0.00006218035,0.0000026350353,0.000020621754,4.270304e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008440765,0.0010826542,0.13168617,0.00011150925,0.0017808424,0.0001008392,0.0025997348,0.0000056504273,0.34590682,0.00018321854,0.0016868718,0.50641495],"study_design_scores_gemma":[0.05444669,0.054713536,0.053536758,0.007464125,0.0027562454,0.008791997,0.0024796058,0.000011080392,0.60094655,0.0012251639,0.2127682,0.0008600564],"about_ca_topic_score_codex":0.000053171894,"about_ca_topic_score_gemma":0.000068871894,"teacher_disagreement_score":0.50555485,"about_ca_system_score_codex":0.000050536994,"about_ca_system_score_gemma":0.00008818588,"threshold_uncertainty_score":0.21659033},"labels":[],"label_agreement":null},{"id":"W2342481736","doi":"10.3899/jrheum.150127","title":"The Psoriasis Symptom Inventory: An Effective Patient-reported Outcome Measure of Psoriasis Severity","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Amgen","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Clinical trial; Psoriatic arthritis; Severity of illness; Clinical Practice; Physical therapy; Dermatology; Internal medicine","score_opus":0.03096180944977835,"score_gpt":0.26269844585804053,"score_spread":0.23173663640826217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342481736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895507,0.0054988815,0.000058136975,0.00040280024,0.0039339205,0.00031936256,0.000014099591,0.00002473573,0.0001973597],"genre_scores_gemma":[0.99935263,0.00041402166,0.000040989355,0.00004057401,0.000019980267,0.000013805331,0.000008409579,0.000022259408,0.00008735323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99544,0.0026891015,0.001129173,0.00017317107,0.00016984326,0.0003987229],"domain_scores_gemma":[0.9960151,0.0009834723,0.0016665377,0.0005779397,0.0006681455,0.00008884604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026857855,0.0002788535,0.00083798985,0.00014566258,0.00031145892,0.000012476855,0.0006382072,0.0003274795,0.000038823742],"category_scores_gemma":[0.001034706,0.00014651047,0.0002795395,0.00023417883,0.00047988858,0.00016715586,0.000101766724,0.000417619,0.000043821845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005889805,0.0005662739,0.8886281,0.000027645052,0.004559807,0.00002113245,0.008477756,0.000029080238,0.002843155,0.0007620636,0.004584471,0.08361067],"study_design_scores_gemma":[0.059965014,0.019951658,0.62424946,0.00073256274,0.012760147,0.06033221,0.03950091,0.00007118624,0.10120676,0.0150132105,0.06359161,0.0026252833],"about_ca_topic_score_codex":0.00040290933,"about_ca_topic_score_gemma":0.00019845285,"teacher_disagreement_score":0.2643787,"about_ca_system_score_codex":0.00010297575,"about_ca_system_score_gemma":0.00020226614,"threshold_uncertainty_score":0.5974524},"labels":[],"label_agreement":null},{"id":"W2342639218","doi":"10.1371/journal.pone.0154433","title":"HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Maple Leaf Medical Clinic; Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research; Canadian Foundation for AIDS Research","keywords":"Coinfection; Hepatitis C virus; Immunology; Virology; Hepatitis C; CD8; Viral load; Biology; Virus; Medicine; Immune system","score_opus":0.021465615709319274,"score_gpt":0.18613256213188734,"score_spread":0.16466694642256807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2342639218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960283,0.00046041823,0.000069452915,0.0005961374,0.00055093924,0.0011478077,0.00052397273,0.00020918397,0.00041375778],"genre_scores_gemma":[0.98866194,0.00017723006,0.00011579604,0.00009920912,0.0002475782,0.00015777389,0.00013055062,0.00006390302,0.010346028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972165,0.00049109507,0.00048592468,0.0009239116,0.00013296347,0.0007496078],"domain_scores_gemma":[0.9984548,0.00034646492,0.00039906707,0.0005737144,0.00017739017,0.0000485457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053066073,0.00042687982,0.00076499465,0.00024548027,0.0002449485,0.00003322841,0.00019046105,0.00036181326,0.00025064612],"category_scores_gemma":[0.00015208474,0.00031107044,0.000110158144,0.0002738437,0.00015563075,0.00022710278,0.000048367896,0.00029987935,0.0011462832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008846828,0.0019801457,0.04102304,0.000043587006,0.00085618446,0.0000373912,0.0005306452,0.000010720876,0.95067877,0.0000091454895,0.00072934583,0.0032163484],"study_design_scores_gemma":[0.0067806314,0.00046504926,0.04441405,0.0007423296,0.00043915358,0.0000047208378,0.00007886855,0.0000055062683,0.9456442,0.000015461412,0.0009410241,0.00046897895],"about_ca_topic_score_codex":0.00011072379,"about_ca_topic_score_gemma":0.00024263977,"teacher_disagreement_score":0.00993227,"about_ca_system_score_codex":0.0003406963,"about_ca_system_score_gemma":0.00007939737,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W2343061795","doi":"10.1164/rccm.201509-1751oc","title":"IL-25 Receptor Expression on Airway Dendritic Cells after Allergen Challenge in Subjects with Asthma","year":2015,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Plasmacytoid dendritic cell; Medicine; Immunology; Sputum; TLR9; Allergen; Thymic stromal lymphopoietin; Toll-like receptor; Cytokine; Immune system; Dendritic cell; Allergy; Innate immune system; Biology; Pathology; Gene expression","score_opus":0.018532059961497833,"score_gpt":0.2658234944677391,"score_spread":0.24729143450624128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343061795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775967,0.020321619,0.000023711798,0.00083078013,0.0005310076,0.00008705447,0.0000132016785,0.000009781572,0.0005861151],"genre_scores_gemma":[0.9986957,0.00025578236,0.00010702436,0.00064940343,0.00021886911,0.000012831455,0.000003947536,0.00001753006,0.00003892181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99846125,0.00051006424,0.00036098,0.00022741717,0.00013980061,0.00030050427],"domain_scores_gemma":[0.9989574,0.0003358333,0.000115435716,0.00016104282,0.00024275432,0.00018755012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003581291,0.0002119348,0.0005302916,0.000177245,0.000053680866,0.000005505672,0.00011765974,0.00010441983,0.000186021],"category_scores_gemma":[0.00019996286,0.00013311906,0.000053106472,0.00015259667,0.00073337613,0.000088709705,0.000024726598,0.00033031023,0.000025941481],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035708465,0.0018563753,0.06349998,0.00038451838,0.0005899088,0.005542659,0.034238927,0.000013118979,0.22309795,0.00073283724,0.008642529,0.6256927],"study_design_scores_gemma":[0.03840224,0.21889418,0.057575375,0.0063108928,0.0008603912,0.0010167711,0.13455763,8.077002e-7,0.24914809,0.00020269002,0.2911652,0.001865739],"about_ca_topic_score_codex":0.000012178692,"about_ca_topic_score_gemma":0.000025083225,"teacher_disagreement_score":0.623827,"about_ca_system_score_codex":0.00006056437,"about_ca_system_score_gemma":0.00010212533,"threshold_uncertainty_score":0.54284376},"labels":[],"label_agreement":null},{"id":"W2343167356","doi":"10.3899/jrheum.160114","title":"International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update","year":2016,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Psoriasis; Outcome (game theory); Alternative medicine; Family medicine; Dermatology; Disease; Clinical Practice; MEDLINE; Internal medicine; Pathology","score_opus":0.030821376754203853,"score_gpt":0.2837591273498798,"score_spread":0.2529377505956759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343167356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98010117,0.00046162572,0.0022480148,0.013754936,0.0027024099,0.000206109,0.000045251003,0.00003529049,0.0004452118],"genre_scores_gemma":[0.9980141,0.0004912288,0.00014308853,0.0011038391,0.000016410611,0.000017929937,0.000012136114,0.000021644988,0.0001796309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978264,0.00070406386,0.00080832874,0.0001878823,0.00010277203,0.00037058324],"domain_scores_gemma":[0.997959,0.0007963883,0.00056861044,0.0003556857,0.00020318876,0.0001171224],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055084005,0.00025672998,0.00066472444,0.00028349113,0.0001611539,0.000011166498,0.00080032856,0.00016753984,0.00072200457],"category_scores_gemma":[0.0005472605,0.00012705673,0.00016212164,0.000100561236,0.00021608232,0.00016823938,0.00011464821,0.0001820988,0.0014221603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072767264,0.0006346619,0.8824111,0.000020084131,0.0038573167,0.00010581564,0.003043145,0.000021529468,0.010449202,0.019763276,0.004894305,0.06752279],"study_design_scores_gemma":[0.043179624,0.002248175,0.6832519,0.00041701325,0.0039093606,0.03295789,0.0043897755,0.000006446404,0.024203366,0.037916847,0.16520339,0.0023161788],"about_ca_topic_score_codex":0.000024413494,"about_ca_topic_score_gemma":0.000038199196,"teacher_disagreement_score":0.19915922,"about_ca_system_score_codex":0.00006949093,"about_ca_system_score_gemma":0.00013433794,"threshold_uncertainty_score":0.9993554},"labels":[],"label_agreement":null},{"id":"W2343403807","doi":"10.1016/j.jid.2016.02.035","title":"011 The spectrum of mild-to-severe psoriasis vulgaris is defined by a constant genomic response to inflammation, but with key differences in immune regulatory genes","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Inflammation; Immune system; Medicine; Immunology; Disease; Pathology","score_opus":0.01554637250642433,"score_gpt":0.21213453844376978,"score_spread":0.19658816593734546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343403807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768105,0.0029849366,0.00011524491,0.01936473,0.00023671037,0.0003164291,0.00011768233,0.000009827481,0.00004389944],"genre_scores_gemma":[0.9984697,0.00020007802,0.0005577809,0.00040067694,0.000024023751,0.000027869839,0.000004358195,0.000018364279,0.000297118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970312,0.0012520219,0.0009934416,0.00025143902,0.000100880294,0.00037098592],"domain_scores_gemma":[0.99742573,0.0010758184,0.0008355895,0.00032649425,0.0002482238,0.000088120876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005554159,0.00029194757,0.00082768383,0.00043775878,0.00013101927,0.000010332658,0.00043891778,0.00022945885,0.00013842965],"category_scores_gemma":[0.00040475844,0.00015427684,0.00012626975,0.00033751587,0.0008370396,0.00011875984,0.00008360964,0.00018799845,0.000070207774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004720484,0.00007474323,0.05508762,0.000011681327,0.00066895736,0.000045327197,0.0037381637,0.000002384456,0.93173367,0.0005953098,0.0022159931,0.0011056773],"study_design_scores_gemma":[0.003015539,0.0005891978,0.20288119,0.00016416835,0.00012182636,0.000832228,0.00075956335,2.7040352e-7,0.7887675,0.0009332258,0.001749947,0.00018534416],"about_ca_topic_score_codex":0.00008357257,"about_ca_topic_score_gemma":0.00011409443,"teacher_disagreement_score":0.14779358,"about_ca_system_score_codex":0.00011761854,"about_ca_system_score_gemma":0.0004690964,"threshold_uncertainty_score":0.62912273},"labels":[],"label_agreement":null},{"id":"W2344644734","doi":"10.3899/jrheum.160115","title":"Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting","year":2016,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Psoriasis Area and Severity Index; Dermatology; Nail disease; Quality of life (healthcare); Severity of illness; Disease; Physical therapy; Internal medicine; Nursing","score_opus":0.014417776417567165,"score_gpt":0.25596245196559947,"score_spread":0.2415446755480323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344644734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875141,0.005064539,0.0001451115,0.0042240634,0.0025761535,0.00019771363,0.000098753226,0.000008967576,0.0001706434],"genre_scores_gemma":[0.99844825,0.0011629413,0.00011836651,0.000107546046,0.000019343539,0.000006233987,0.000005168293,0.000013262146,0.00011886883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969695,0.0015777694,0.00090997835,0.00014442,0.00012127949,0.00027704905],"domain_scores_gemma":[0.9950151,0.0023546633,0.0016812729,0.00056169933,0.00036475767,0.00002253466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007449121,0.00019839298,0.0005530139,0.000053272088,0.0002716518,0.0000048464617,0.0006524221,0.0001716812,0.0001571808],"category_scores_gemma":[0.00023063201,0.00006917133,0.00028738746,0.00012719363,0.00042020282,0.000066750705,0.00019396041,0.000256081,0.000021889284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014394084,0.0004730328,0.7690409,0.000019546733,0.005462981,0.00005508721,0.007498935,0.000029059545,0.09595459,0.0010474375,0.07362663,0.045352392],"study_design_scores_gemma":[0.012563722,0.0017089549,0.7210865,0.0012722852,0.0028487812,0.03422327,0.01614465,0.0000053685403,0.063210994,0.004646115,0.14159304,0.0006962976],"about_ca_topic_score_codex":0.000563546,"about_ca_topic_score_gemma":0.000096547556,"teacher_disagreement_score":0.06796642,"about_ca_system_score_codex":0.000044685978,"about_ca_system_score_gemma":0.0001831766,"threshold_uncertainty_score":0.28207248},"labels":[],"label_agreement":null},{"id":"W2345166439","doi":"10.3899/jrheum.160119","title":"GRAPPA 2015 Research and Education Project Reports","year":2016,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute for Health and Care Research","keywords":"Medicine; Psoriatic arthritis; Delphi method; Delphi; Psoriasis; Medical physics; Physical therapy; Medical education; Dermatology","score_opus":0.0408537466667672,"score_gpt":0.32893192026966245,"score_spread":0.2880781736028952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345166439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850063,0.010937555,0.000027377768,0.0023861385,0.0011008759,0.00011969746,0.0000018024235,0.0000069460675,0.0004133574],"genre_scores_gemma":[0.9928577,0.0043112445,0.00004527308,0.000016725366,0.000010860267,0.0000060581824,0.0000015857619,0.0000071611494,0.0027433776],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986542,0.00065011956,0.0003439354,0.00009302173,0.00004484137,0.00021389061],"domain_scores_gemma":[0.99860424,0.0006247309,0.00029649757,0.00020368761,0.00025321144,0.000017630875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001617366,0.00008106265,0.00022357075,0.0002135944,0.0001628952,0.000005146977,0.00014088617,0.00012579943,0.00008429196],"category_scores_gemma":[0.00022887514,0.000036290705,0.000039497452,0.00011220069,0.000355313,0.00007655445,0.000047720598,0.00015275697,0.000052787134],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014822745,0.00049726764,0.42740494,0.00003205465,0.0007934695,0.000033606135,0.0021613871,8.131453e-8,0.09937044,0.0034661538,0.23657459,0.22818373],"study_design_scores_gemma":[0.007102511,0.0045102583,0.09917359,0.00096926413,0.000571801,0.36705306,0.0049151783,2.3294025e-7,0.06655743,0.06607864,0.3824672,0.00060081953],"about_ca_topic_score_codex":0.00013677536,"about_ca_topic_score_gemma":0.000030498584,"teacher_disagreement_score":0.36701944,"about_ca_system_score_codex":0.000025865258,"about_ca_system_score_gemma":0.00029889317,"threshold_uncertainty_score":0.1479892},"labels":[],"label_agreement":null},{"id":"W2345886165","doi":"10.4236/jcdsa.2016.62009","title":"Plaque Psoriasis: Understanding Risk Factors of This Inflammatory Skin Pathology","year":2016,"lang":"en","type":"article","venue":"Journal of Cosmetics Dermatological Sciences and Applications","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Psoriasis; Dermatology; Medicine; Disease; Pathology; Epidermis (zoology); Anatomy","score_opus":0.03879617041448071,"score_gpt":0.26409695598767585,"score_spread":0.22530078557319513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345886165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808537,0.001663789,0.016105736,0.00046686435,0.00016908825,0.00013220122,0.000032907006,0.000011635094,0.0005641175],"genre_scores_gemma":[0.9966161,0.002760448,0.00053177984,0.000023074892,0.0000234698,0.000008691764,0.0000013311463,0.000003272142,0.000031826727],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99890727,0.00019130364,0.00047539265,0.00015562489,0.00007155445,0.00019884859],"domain_scores_gemma":[0.9983732,0.00080818654,0.00059015444,0.00010710799,0.00007480105,0.00004656855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004323701,0.00011845069,0.00031389942,0.00013742581,0.0002836015,0.000012932967,0.00025223836,0.0001696548,0.00010873313],"category_scores_gemma":[0.00009032222,0.000060160233,0.00011138882,0.0001929327,0.0008625311,0.00009733984,0.000051197105,0.000108244414,0.000011884563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023063637,0.00079464546,0.50793993,0.00005131557,0.0006613133,0.000037005997,0.0019318789,0.000026249154,0.08348782,0.32710204,0.0020920865,0.07564506],"study_design_scores_gemma":[0.011067629,0.0033862914,0.28317276,0.0004014321,0.0019542254,0.004749449,0.014445985,0.000032242533,0.28249562,0.31071258,0.08603247,0.0015493013],"about_ca_topic_score_codex":0.0000023710734,"about_ca_topic_score_gemma":0.0000023828904,"teacher_disagreement_score":0.2247672,"about_ca_system_score_codex":0.000029024197,"about_ca_system_score_gemma":0.00005327525,"threshold_uncertainty_score":0.31780317},"labels":[],"label_agreement":null},{"id":"W2346598705","doi":"10.1177/1203475416648323","title":"A Review of Psoriasis, Therapies, and Suicide","year":2016,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Depression (economics); Psychiatry; Anxiety; Suicidal ideation; Dermatology; Poison control; Suicide prevention; Medical emergency","score_opus":0.05162497318336843,"score_gpt":0.31265980637575846,"score_spread":0.26103483319239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346598705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000107326174,0.9979341,0.000002680923,0.0004550159,0.0011062521,0.0001959041,0.00003369348,0.000006343386,0.00015870912],"genre_scores_gemma":[0.000024885858,0.9987523,0.000013821586,0.00031819806,0.0003379759,0.000004807225,0.000028911565,0.00002717665,0.0004919453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737483,0.0005460164,0.0015616064,0.0001942891,0.00008691278,0.00023635893],"domain_scores_gemma":[0.9943948,0.0033543701,0.0017936614,0.00021855558,0.00017262179,0.00006602351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011881165,0.00037992842,0.0040975926,0.0004032747,0.000054207336,0.0000034560135,0.00013348994,0.00033504603,0.0004610123],"category_scores_gemma":[0.0005868865,0.00018713859,0.00054124877,0.00014988189,0.00029314568,0.000045907633,0.00003057219,0.00026395594,0.000010142662],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058179783,0.00003088106,0.000038948852,0.028234065,0.0014270222,0.00026034465,0.000053138807,3.030839e-10,0.000026046486,0.000014757009,0.032566413,0.9372902],"study_design_scores_gemma":[0.000274409,0.00020659427,0.000003683006,0.23658195,0.0024248934,0.018660123,0.00001834151,1.1790082e-9,0.0000054219186,0.000033035158,0.7416642,0.00012737424],"about_ca_topic_score_codex":0.000010473466,"about_ca_topic_score_gemma":0.0000012781215,"teacher_disagreement_score":0.9371628,"about_ca_system_score_codex":0.000025745452,"about_ca_system_score_gemma":0.0003012501,"threshold_uncertainty_score":0.76312906},"labels":[],"label_agreement":null},{"id":"W2347070017","doi":"10.1371/journal.pone.0155215","title":"Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris","year":2016,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Palmoplantar pustulosis; Gene expression; Gene expression profiling; Gene; Microarray; DNA microarray; Microarray analysis techniques; Biology; Medicine; Cancer research; Genetics; Immunology","score_opus":0.02488117723051589,"score_gpt":0.20699759191186184,"score_spread":0.18211641468134596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2347070017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999274,0.0030998462,0.00014655017,0.00069264864,0.00029114596,0.00080595404,0.0047151474,0.00016743432,0.00008851187],"genre_scores_gemma":[0.99596137,0.0003862749,0.001793643,0.00018542074,0.00007101956,0.0002097781,0.0010796593,0.00007583485,0.00023702944],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971744,0.0004686785,0.0005527202,0.0009646183,0.00026152228,0.0005781022],"domain_scores_gemma":[0.99780345,0.0006515631,0.00036787186,0.00086985895,0.00012772203,0.00017954229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017226559,0.0005482235,0.0009512041,0.00028630754,0.00025923798,0.000023263683,0.0003516217,0.0004458878,0.00043048634],"category_scores_gemma":[0.00030974965,0.00039527312,0.00020551607,0.00024165495,0.00016169022,0.000112642396,0.00013075686,0.000173261,0.00014440573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017340414,0.0015957892,0.23576847,0.00008897461,0.001410702,0.00009012976,0.00023163647,0.0000048546262,0.75729936,0.00001769236,0.00027019685,0.0014881549],"study_design_scores_gemma":[0.0039230543,0.00041253882,0.058902007,0.0010334274,0.0018301537,0.000004435641,0.0001726929,0.000008123287,0.93298143,0.000077089426,0.00015198655,0.0005030491],"about_ca_topic_score_codex":0.00013865935,"about_ca_topic_score_gemma":0.000015633732,"teacher_disagreement_score":0.17686646,"about_ca_system_score_codex":0.0000774229,"about_ca_system_score_gemma":0.000053165037,"threshold_uncertainty_score":0.9998499},"labels":[],"label_agreement":null},{"id":"W2351033811","doi":"10.1177/1203475416650430","title":"Do Biologics Protect Patients With Psoriasis From Myocardial Infarction? A Retrospective Cohort","year":2016,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Myocardial infarction; Retrospective cohort study; Cohort; Internal medicine; Plaque psoriasis; Dermatology","score_opus":0.012190038943648026,"score_gpt":0.2168360125583816,"score_spread":0.20464597361473358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2351033811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527496,0.0020621794,0.000059275128,0.00072368555,0.0013846408,0.00018448275,0.000050298797,0.000017459914,0.0002430358],"genre_scores_gemma":[0.9971981,0.002005856,0.00003773888,0.00014523072,0.00041469527,0.000007091299,0.000021037515,0.000013345122,0.00015688982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874306,0.00022121858,0.0004726664,0.00021097073,0.00012327297,0.00022879777],"domain_scores_gemma":[0.9980174,0.0009808694,0.0004722916,0.00015340147,0.00031877722,0.00005729755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004020655,0.00020301074,0.00074682746,0.00021038012,0.000114245755,0.000007328973,0.00007580505,0.00019198567,0.00038474036],"category_scores_gemma":[0.00050980574,0.000092662645,0.00013025553,0.00012579325,0.00025018075,0.000091083464,0.000018111854,0.00016081924,0.00001673501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001893031,0.00008929316,0.9399341,0.0000033238496,0.0014002247,0.00012569567,0.00019363091,9.927496e-8,0.0034794286,0.000010522102,0.004818084,0.04805259],"study_design_scores_gemma":[0.00386984,0.0021382498,0.9756111,0.0004032591,0.0007856683,0.00116884,0.00018344253,5.450494e-8,0.0012296687,0.00059801026,0.013761999,0.0002498896],"about_ca_topic_score_codex":0.000046578916,"about_ca_topic_score_gemma":0.0000065722957,"teacher_disagreement_score":0.047802698,"about_ca_system_score_codex":0.000072402385,"about_ca_system_score_gemma":0.00008177345,"threshold_uncertainty_score":0.4212637},"labels":[],"label_agreement":null},{"id":"W2355597624","doi":"10.1016/j.jid.2016.04.032","title":"The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"National Center for Advancing Translational Sciences","keywords":"Gene; Psoriasis; Immune system; Genetics; Biology; Computational biology; Immunology","score_opus":0.017699652671943667,"score_gpt":0.21523683347759173,"score_spread":0.19753718080564805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2355597624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902047,0.0052555115,0.00007511767,0.005025957,0.00021090143,0.00020844756,0.00012653277,0.000007072758,0.000069990434],"genre_scores_gemma":[0.99855167,0.00066938286,0.0003020594,0.0001427207,0.000019734778,0.000017310931,0.000010607772,0.000016245753,0.00027028672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774027,0.0006800103,0.0009455442,0.0002052747,0.00011078319,0.0003181193],"domain_scores_gemma":[0.9973277,0.00084868784,0.0012451273,0.00029189466,0.00023212173,0.000054504606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029109788,0.00026519236,0.00086506,0.0002578719,0.00013035358,0.0000065115364,0.00037721655,0.0002696696,0.00004775889],"category_scores_gemma":[0.00013359947,0.00014042013,0.00013923831,0.0002704227,0.00081027416,0.00014263502,0.000064678214,0.00018370821,0.0000076400265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012520934,0.00017900101,0.08696413,0.000024316061,0.0007845815,0.000013132527,0.0013493832,0.0000019258741,0.89998513,0.00072549103,0.0020351557,0.006685662],"study_design_scores_gemma":[0.0024073597,0.0005564252,0.12194066,0.00021135635,0.00008986355,0.00027314565,0.0005499541,4.963622e-7,0.8711043,0.0011360977,0.0015794465,0.00015087737],"about_ca_topic_score_codex":0.00017930704,"about_ca_topic_score_gemma":0.00017567385,"teacher_disagreement_score":0.034976527,"about_ca_system_score_codex":0.0000731273,"about_ca_system_score_gemma":0.00026392625,"threshold_uncertainty_score":0.5726167},"labels":[],"label_agreement":null},{"id":"W2383568726","doi":"10.3899/jrheum.150128","title":"Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Rheumatology; Dermatology; Alternative medicine; Clinical Practice; Physical therapy; Medical physics; Intensive care medicine; Internal medicine; Family medicine; Pathology","score_opus":0.01503336346572946,"score_gpt":0.2427858569585679,"score_spread":0.22775249349283846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2383568726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848934,0.010524924,0.00008890978,0.00305069,0.0011276515,0.00014620168,0.000027334907,0.000013118576,0.00012777396],"genre_scores_gemma":[0.998815,0.00038858457,0.000431674,0.00013909253,0.000019291076,0.0000066211715,0.00000828328,0.000014350754,0.00017712693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979586,0.0008174139,0.0006956671,0.00015883107,0.00006294437,0.00030654925],"domain_scores_gemma":[0.99786305,0.0011422369,0.0005682933,0.00028961617,0.00008633881,0.00005047267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018685493,0.00019356958,0.0006052744,0.00013294589,0.00013790264,0.000011766063,0.00034853426,0.00017394045,0.000025103145],"category_scores_gemma":[0.00073716,0.00009665479,0.0000975361,0.00011879533,0.0001467378,0.00009490164,0.00011656309,0.00028334008,0.00003899841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066158996,0.0000847387,0.9720658,0.000003921156,0.00044963058,0.00011185164,0.008728988,0.000012098351,0.001536316,0.000052283052,0.0077793193,0.008513442],"study_design_scores_gemma":[0.018833384,0.0015043088,0.8162371,0.00033603716,0.0012238509,0.07548783,0.042042673,0.000016670543,0.005326017,0.0053309095,0.032794192,0.00086703623],"about_ca_topic_score_codex":0.0028577014,"about_ca_topic_score_gemma":0.0005243424,"teacher_disagreement_score":0.15582873,"about_ca_system_score_codex":0.000035353176,"about_ca_system_score_gemma":0.000117896845,"threshold_uncertainty_score":0.43200088},"labels":[],"label_agreement":null},{"id":"W2391966097","doi":"","title":"Etanercept in the treatment of palmoplantar pustulosis.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Etanercept; Medicine; Palmoplantar pustulosis; Placebo; Erythema; Psoriasis; Internal medicine; Dermatology; Randomized controlled trial; Psoriasis Area and Severity Index; Pathology; Rheumatoid arthritis","score_opus":0.03764906935991232,"score_gpt":0.214138824775701,"score_spread":0.17648975541578868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2391966097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913699,0.0043428815,6.616732e-7,0.00015356304,0.00025234488,0.0004795135,0.000033158667,0.000015802805,0.003352155],"genre_scores_gemma":[0.9951363,0.0019838144,0.000007657217,0.000050871375,0.000026433718,0.0009219012,0.000066577246,0.000005586321,0.0018008322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992483,0.00016101493,0.0001665902,0.00014136142,0.000025660567,0.00025702748],"domain_scores_gemma":[0.9995853,0.00012949332,0.000049765797,0.00021531423,0.000009951343,0.000010212727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010298762,0.00011269033,0.00020257481,0.00006724472,0.00007185475,0.0000018063744,0.0001253379,0.0000966522,0.00007100163],"category_scores_gemma":[0.000009187772,0.0000655256,0.00009200823,0.00012250252,0.00009692002,0.000024262148,0.0000064599667,0.00003743605,0.00007150827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005061655,0.002619536,0.46063265,0.000011065455,0.00055769173,0.00016790011,0.0090606855,0.0000038791736,0.0021786895,0.00020355023,0.0033190902,0.5207391],"study_design_scores_gemma":[0.001641252,0.00012158072,0.95113987,0.0000015374437,0.00007238689,0.0001259553,0.00018691542,8.327124e-8,0.013842783,0.00002037013,0.032773167,0.000074093026],"about_ca_topic_score_codex":0.00015996002,"about_ca_topic_score_gemma":0.000084505635,"teacher_disagreement_score":0.520665,"about_ca_system_score_codex":0.000035889356,"about_ca_system_score_gemma":0.000011471838,"threshold_uncertainty_score":0.26720563},"labels":[],"label_agreement":null},{"id":"W2395273197","doi":"10.1177/1203475416651605","title":"The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis","year":2016,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Secukinumab; Ixekizumab; Psoriasis; Medicine; Pathogenesis; Interleukin 17; Interleukin 23; Immunology; Dermatology; Interleukin; Psoriatic arthritis; Cytokine","score_opus":0.03013245956767451,"score_gpt":0.2798331892835766,"score_spread":0.24970072971590207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395273197","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022186907,0.97495615,0.000002507904,0.00068906235,0.0010587245,0.00065912073,0.0003567955,0.0000031308764,0.000087613415],"genre_scores_gemma":[0.009151833,0.9899964,0.000008214763,0.000040350827,0.00044192807,0.00005362671,0.000028546296,0.000030035355,0.00024909567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664533,0.0007635763,0.0018343172,0.00024511063,0.00018192781,0.00032972507],"domain_scores_gemma":[0.98189664,0.015216963,0.0022186437,0.00044231952,0.00018288431,0.00004252842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016708061,0.00047593596,0.0027141834,0.0004067463,0.0001881171,0.000008229337,0.00030855,0.00038963914,0.0000374993],"category_scores_gemma":[0.0003479093,0.00016948296,0.00086842035,0.00023016898,0.0005478008,0.00003608115,0.000024654322,0.00019089786,0.0000013986127],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010374802,0.00025992672,0.00018051403,0.0004918324,0.0020027102,0.00006121918,0.000792696,4.5643992e-7,0.00030502025,0.000079067526,0.0044686077,0.99032044],"study_design_scores_gemma":[0.0012467385,0.0018421741,0.00007905741,0.004815093,0.0036896227,0.001577692,0.00092736684,2.5568355e-7,0.0006411531,0.0001812999,0.9848334,0.00016612899],"about_ca_topic_score_codex":0.000046633562,"about_ca_topic_score_gemma":0.000034051645,"teacher_disagreement_score":0.9901543,"about_ca_system_score_codex":0.00005274657,"about_ca_system_score_gemma":0.00025637957,"threshold_uncertainty_score":0.6911315},"labels":[],"label_agreement":null},{"id":"W2395341313","doi":"10.1016/j.jval.2016.03.520","title":"The Impact of Plaque Psoriasis Severity on Work Productivity and Daily Activities","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Vancouver Coastal Health; Novartis (Canada)","funders":"","keywords":"Psoriasis; Medicine; Presenteeism; Psoriasis Area and Severity Index; Interquartile range; Severity of illness; Activities of daily living; Depression (economics); Absenteeism; Physical therapy; Internal medicine; Psychology; Dermatology","score_opus":0.029818509174328312,"score_gpt":0.2788996319676803,"score_spread":0.24908112279335198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2395341313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540037,0.0024609957,0.000004874273,0.0012390137,0.0003983229,0.0002789116,0.000068923975,0.000020516942,0.00012808663],"genre_scores_gemma":[0.9981265,0.0012343682,0.000018139719,0.000011513466,0.00004012445,0.000024391951,0.0000036412962,0.0000088984625,0.0005324171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851483,0.0006863367,0.00021946769,0.00023448942,0.00003119977,0.00031369104],"domain_scores_gemma":[0.9985901,0.00094019284,0.00014552377,0.00028554338,0.000014824244,0.000023814246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007166542,0.00013898316,0.0002669749,0.00006892209,0.00017816994,0.000005528226,0.000093766335,0.00010538803,0.000023378001],"category_scores_gemma":[0.00012441754,0.00006913375,0.000066800654,0.00013297363,0.00017546218,0.00006595282,0.000031573607,0.00010359244,0.000018192999],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003380898,0.00054466503,0.4156147,0.000064200656,0.00036881902,0.0000038089104,0.002092286,0.000046482393,0.011347959,0.0011373253,0.00243636,0.5629625],"study_design_scores_gemma":[0.0019041486,0.00090712676,0.9756521,0.00021765968,0.000013673894,0.000019330202,0.00011520635,0.0000011624253,0.018637452,0.0008867834,0.0014926713,0.00015266008],"about_ca_topic_score_codex":0.0022964969,"about_ca_topic_score_gemma":0.00009195718,"teacher_disagreement_score":0.5628098,"about_ca_system_score_codex":0.00014637974,"about_ca_system_score_gemma":0.0001757536,"threshold_uncertainty_score":0.34716317},"labels":[],"label_agreement":null},{"id":"W2397615067","doi":"10.1016/j.jaad.2016.03.026","title":"Clinical meaningfulness of complete skin clearance in psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Quality of life (healthcare); Severity of illness; Dermatology; Internal medicine","score_opus":0.032898005873031634,"score_gpt":0.3138636616375706,"score_spread":0.28096565576453897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397615067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243903,0.0012416276,0.00008325344,0.0055045923,0.000523983,0.00008055894,0.00002416007,0.0000044283383,0.00009839366],"genre_scores_gemma":[0.9986158,0.00072102365,0.000263942,0.00027789362,0.00004551124,0.0000021390306,3.4809193e-7,0.000011452062,0.0000618925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970441,0.0011685499,0.0012979688,0.00015074396,0.0000728707,0.00026577985],"domain_scores_gemma":[0.9963588,0.0009520154,0.0024297275,0.00016940144,0.00006277001,0.000027295933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046681945,0.00015002259,0.0011210961,0.00019721896,0.000037736656,0.0000011660716,0.00068586506,0.00019150788,0.000053044758],"category_scores_gemma":[0.00024972289,0.000081596496,0.0003962237,0.00028873127,0.0012786848,0.00007555148,0.00010245773,0.00034935315,0.00002361167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041777124,0.0005085009,0.62596804,0.000038849346,0.0011857646,0.000027468486,0.00036867632,0.000006112732,0.14325565,0.0014969774,0.0034538647,0.21951234],"study_design_scores_gemma":[0.004545598,0.00028766482,0.84152687,0.00021806714,0.00020897061,0.0018062628,0.00018103862,9.569139e-7,0.13739166,0.0008314713,0.012854415,0.00014701403],"about_ca_topic_score_codex":0.000021430695,"about_ca_topic_score_gemma":0.000005059933,"teacher_disagreement_score":0.21936534,"about_ca_system_score_codex":0.000025802172,"about_ca_system_score_gemma":0.00007531146,"threshold_uncertainty_score":0.47113678},"labels":[],"label_agreement":null},{"id":"W2401171230","doi":"10.1016/j.jval.2016.03.490","title":"Assessing Severity In Psoriasis: Correlation Of Different Measures (Pasi, Bsa, And Iga) In A Canadian Real-World Setting","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovaderm (Canada); Novartis (Canada)","funders":"","keywords":"Psoriasis; Psoriasis Area and Severity Index; Medicine; Rank correlation; Spearman's rank correlation coefficient; Severity of illness; Correlation; Observational study; Internal medicine; Body surface area; Dermatology","score_opus":0.039772160177721824,"score_gpt":0.28787270484287375,"score_spread":0.2481005446651519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2401171230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966189,0.0015227726,0.000012040807,0.0008255152,0.00037053332,0.00028726034,0.000029936085,0.000012137537,0.0003208844],"genre_scores_gemma":[0.99913615,0.000591273,0.000085666295,0.000043968328,0.000016823968,0.000021405052,0.000020276404,0.000010047575,0.00007441718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979479,0.00081019715,0.0004966376,0.00025648327,0.000039189246,0.00044961888],"domain_scores_gemma":[0.9992491,0.00036618402,0.00016510423,0.00014418413,0.000019281539,0.000056165078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010200036,0.00013726966,0.00036361063,0.00053179346,0.00007023715,0.0000076293395,0.00006679064,0.0001545263,0.000019278035],"category_scores_gemma":[0.00013617812,0.000107097985,0.00002772102,0.00024980615,0.000048743404,0.00011827548,0.000019193129,0.00014196677,0.00000496149],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070804716,0.000056295212,0.9077537,0.00005049522,0.000014703037,0.0000073188294,0.0010532483,0.000026829894,0.0014717686,0.00044075574,0.000021167814,0.08903292],"study_design_scores_gemma":[0.0017888205,0.00006676857,0.9953355,0.0006937736,0.000008063618,0.0000062513627,0.00020847605,0.00006691551,0.0010356362,0.0005483788,0.00013325467,0.00010811793],"about_ca_topic_score_codex":0.5652125,"about_ca_topic_score_gemma":0.7496735,"teacher_disagreement_score":0.18446101,"about_ca_system_score_codex":0.00063079677,"about_ca_system_score_gemma":0.00043547503,"threshold_uncertainty_score":0.43768278},"labels":[],"label_agreement":null},{"id":"W2409969130","doi":"10.1007/978-3-319-19530-8_2","title":"GRAPPA Historical Perspective","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Perspective (graphical); Alternative medicine; Family medicine; Dermatology; Medical physics; Medical education; Physical therapy; Pathology; Computer science; Artificial intelligence","score_opus":0.022157681949745486,"score_gpt":0.2235446726087227,"score_spread":0.20138699065897722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409969130","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020197063,0.016057352,0.00005308011,0.00052128,0.0020146961,0.00017210655,0.00008590918,0.00014952826,0.98092586],"genre_scores_gemma":[0.0019074106,0.00074321363,0.00003373596,0.000082512684,0.00020074587,0.000015236421,0.000056469034,0.000046043613,0.9969146],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990163,0.000027336955,0.00020516761,0.00046347015,0.000032280488,0.0002554309],"domain_scores_gemma":[0.99931043,0.000104534134,0.00011297995,0.0003469932,0.00009881777,0.000026222298],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0000526857,0.00036253105,0.0004553873,0.00015577383,0.00010937682,0.0000045249926,0.00017517134,0.00084175117,0.013543653],"category_scores_gemma":[0.000011493202,0.00024027811,0.00033875005,0.000011706361,0.00010374719,0.000029168634,0.000057622357,0.0001816063,0.013007176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012293577,0.000038037535,0.00001351416,0.00000409589,0.0010074674,0.000032147193,0.00008595244,3.0461662e-9,0.0020845896,0.8620668,0.09625936,0.038285106],"study_design_scores_gemma":[0.0007968905,0.00014767196,0.000026481555,0.000034136014,0.00028578428,0.000045893885,0.000012859223,2.5617997e-9,0.0012010111,0.025951266,0.9711505,0.00034745957],"about_ca_topic_score_codex":0.00004786093,"about_ca_topic_score_gemma":0.000027043678,"teacher_disagreement_score":0.87489116,"about_ca_system_score_codex":0.0008261629,"about_ca_system_score_gemma":0.000070388574,"threshold_uncertainty_score":0.9877613},"labels":[],"label_agreement":null},{"id":"W2411825127","doi":"10.1097/00000372-200104000-00018","title":"Letter regarding “Histopathology of Psoriasis Treated With Zinc Pyrithione”","year":2001,"lang":"en","type":"letter","venue":"American Journal of Dermatopathology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dermatopathology; Histopathology; Zinc; Dermatology; Psoriasis; Product (mathematics); Medicine; Pathology; Chemistry; Mathematics; Organic chemistry","score_opus":0.01101672399827048,"score_gpt":0.22116619228268863,"score_spread":0.21014946828441816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411825127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8181507,0.006951658,0.0008246366,0.16695122,0.0035196985,0.00055440085,0.00024848833,0.00012564941,0.0026735717],"genre_scores_gemma":[0.6225207,0.002646273,0.004134816,0.35865137,0.0048678303,0.00009359686,0.0008334952,0.00051044754,0.0057415008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99480474,0.0018026284,0.0016293009,0.00062258786,0.00019418098,0.0009465368],"domain_scores_gemma":[0.9942496,0.00055700913,0.0037894035,0.00078986736,0.0005511928,0.00006294929],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000497231,0.0008266832,0.002979485,0.0011953342,0.00016446081,0.000015709547,0.0008231807,0.0011996926,0.0002803718],"category_scores_gemma":[0.000091729555,0.00062416604,0.0006894541,0.00061133725,0.0018898854,0.00015903355,0.000103031525,0.0022292405,0.00011943723],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002207142,0.00038444417,0.08581427,0.00013530435,0.002051889,0.036797658,0.0009242833,0.000009838864,0.016867846,0.000029573415,0.8149664,0.039811376],"study_design_scores_gemma":[0.004306524,0.0037748434,0.004536503,0.00031742096,0.0024340637,0.18099017,0.00024390122,2.8445297e-7,0.010254918,0.00005272907,0.7922731,0.0008155337],"about_ca_topic_score_codex":0.000067308436,"about_ca_topic_score_gemma":0.000008090303,"teacher_disagreement_score":0.19563001,"about_ca_system_score_codex":0.00015991737,"about_ca_system_score_gemma":0.00025095543,"threshold_uncertainty_score":0.999621},"labels":[],"label_agreement":null},{"id":"W2411836947","doi":"10.1136/annrheumdis-2015-eular.2265","title":"THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Clinical endpoint; Placebo; Placebo-controlled study; Internal medicine; Psoriasis Area and Severity Index; Regimen; Dactylitis; Dosing; Enthesitis; Randomized controlled trial; Gastroenterology; Rheumatoid arthritis; Psoriasis; Immunology; Double blind; Pathology","score_opus":0.038396197517986244,"score_gpt":0.3107881325951577,"score_spread":0.27239193507717147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411836947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746075,0.021036768,0.000007072398,0.000089477304,0.00047199382,0.0036181093,0.000113458285,0.000021745014,0.000033871533],"genre_scores_gemma":[0.99911416,0.0005826449,0.000023641103,0.000022563863,0.00002453183,0.00012526574,0.000022596632,0.000022137669,0.000062457555],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99722004,0.0011491919,0.0008662349,0.00030682285,0.00012911927,0.0003285724],"domain_scores_gemma":[0.99771094,0.0008501308,0.0008103338,0.0004078758,0.00015512967,0.000065594075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006348104,0.0003261535,0.001591392,0.00019687306,0.00010977194,0.00002634861,0.00025496757,0.00012582084,0.00002254995],"category_scores_gemma":[0.0004142691,0.0002110241,0.00034548083,0.00019932343,0.00027431935,0.00016702175,0.00011818209,0.00010942139,0.0000031316233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84319335,0.003942596,0.00029792168,0.00012447462,0.004052343,0.000020230415,0.013810915,0.000040499322,0.0015564349,0.000053287164,0.000026152922,0.13288179],"study_design_scores_gemma":[0.97968686,0.001408785,0.0002533476,0.00082782196,0.0019409569,0.00004153479,0.010310739,0.00033115363,0.0044542034,0.00045897768,0.000005503435,0.00028011724],"about_ca_topic_score_codex":0.00045092934,"about_ca_topic_score_gemma":0.00008136137,"teacher_disagreement_score":0.1364935,"about_ca_system_score_codex":0.000031358733,"about_ca_system_score_gemma":0.00015988368,"threshold_uncertainty_score":0.86053133},"labels":[],"label_agreement":null},{"id":"W2411996261","doi":"10.1080/17425255.2016.1194394","title":"Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Drug Metabolism & Toxicology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Pharmacogenomics; Medicine; Psoriatic arthritis; Psoriasis; Pharmacogenetics; Disease; Intensive care medicine; Personalized medicine; Clinical trial; Adverse effect; Precision medicine; Bioinformatics; Pharmacology; Internal medicine; Dermatology; Pathology","score_opus":0.05894967176582562,"score_gpt":0.34760396465932103,"score_spread":0.2886542928934954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411996261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005878936,0.9835581,4.906985e-7,0.00055210234,0.012872798,0.0017127072,0.00035597142,0.000085666994,0.0002742271],"genre_scores_gemma":[0.000069999296,0.99540967,0.00004517746,0.0000886752,0.0025519738,0.0011756042,0.000257947,0.00011809293,0.000282833],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955142,0.0013219779,0.0008665613,0.0013898071,0.000072302704,0.00083513686],"domain_scores_gemma":[0.9983753,0.00047309004,0.00047142166,0.0004992035,0.00004100536,0.00013999756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028980523,0.0012160788,0.0028532885,0.0006703597,0.00019416667,0.00002442251,0.00033479623,0.0009266957,0.00023141573],"category_scores_gemma":[0.000020492449,0.00083485205,0.0003847988,0.00017150301,0.0002679215,0.00009085046,0.00018986079,0.00044068205,0.00021024584],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001695305,0.00059817877,0.0000036703748,0.00048422618,0.0008264288,0.000015180907,0.001323564,3.2762664e-8,0.00016843175,0.0015498212,0.00051436404,0.99434656],"study_design_scores_gemma":[0.0052663977,0.00023139954,0.00009322102,0.00094343704,0.00038002437,0.00014568429,0.00008216714,1.8630953e-7,0.0006549022,0.00006615264,0.9913762,0.00076019287],"about_ca_topic_score_codex":0.000006733089,"about_ca_topic_score_gemma":0.000011382263,"teacher_disagreement_score":0.99358636,"about_ca_system_score_codex":0.00021395735,"about_ca_system_score_gemma":0.00021448231,"threshold_uncertainty_score":0.9994102},"labels":[],"label_agreement":null},{"id":"W2412621561","doi":"10.1136/annrheumdis-2015-eular.1339","title":"AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Adalimumab; Psoriatic arthritis; Internal medicine; Psoriasis; Gastroenterology; Psoriasis Area and Severity Index; Quartile; Placebo; Body mass index; Arthritis; Rheumatoid arthritis; Immunology; Pathology","score_opus":0.027472200514693155,"score_gpt":0.2565416920185186,"score_spread":0.22906949150382547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2412621561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448705,0.0040749656,0.0000038745334,0.00054918654,0.00017775605,0.0005351956,0.00007894969,0.000019942374,0.00007307759],"genre_scores_gemma":[0.9993923,0.00014088796,0.000015203949,0.00013425527,0.0000034470308,0.00007499763,0.00005755959,0.000014595176,0.00016679981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838316,0.0007212666,0.00037365482,0.00018730368,0.000091820446,0.00024276033],"domain_scores_gemma":[0.9990579,0.00029993794,0.00015924369,0.00034756315,0.00009098794,0.00004435508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030124778,0.00016530325,0.00032576954,0.00019147858,0.000044514087,0.000008155985,0.00019148832,0.00007892115,0.0000622041],"category_scores_gemma":[0.00034350972,0.00010572797,0.00006969031,0.0004060903,0.00006557347,0.00010869903,0.00004178656,0.00005962408,0.00008813423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016418142,0.0018918831,0.8117225,0.0000457481,0.00045292612,0.0000073432916,0.0029321134,0.00036067519,0.00012679954,0.00022966093,0.0011853755,0.1646268],"study_design_scores_gemma":[0.0043093534,0.00046297375,0.9923153,0.00058674155,0.00006182215,0.0000012092946,0.00014410894,0.0000074259124,0.0008919867,0.00091240247,0.00017162284,0.00013506526],"about_ca_topic_score_codex":0.00018675497,"about_ca_topic_score_gemma":0.00011946049,"teacher_disagreement_score":0.18059276,"about_ca_system_score_codex":0.00003872204,"about_ca_system_score_gemma":0.00009829886,"threshold_uncertainty_score":0.43114617},"labels":[],"label_agreement":null},{"id":"W2413352053","doi":"10.2310/7750.2013.13052","title":"Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study","year":2013,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovaderm (Canada)","funders":"Pfizer","keywords":"Medicine; Psoriasis; Retrospective cohort study; Myocardial infarction; Cohort; Cohort study; Internal medicine; Emergency medicine; Surgery; Dermatology","score_opus":0.006555782814184588,"score_gpt":0.2041547781312512,"score_spread":0.19759899531706662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413352053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770975,0.00092056947,8.69556e-7,0.00012192427,0.00068323273,0.0003120062,0.000010292401,0.0000032454066,0.0002380971],"genre_scores_gemma":[0.999183,0.00060444523,0.000005489115,0.000047164143,0.00008481455,0.000007673085,0.000010693277,0.000008642211,0.000048077804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878687,0.00025821663,0.000503535,0.00012395413,0.00010480211,0.00022264103],"domain_scores_gemma":[0.99874467,0.00034036848,0.00041767376,0.000106476684,0.00031456043,0.00007625929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005899858,0.00013428852,0.0006789115,0.00051278557,0.0000633033,0.0000043315977,0.000049740545,0.00010215285,0.00018579469],"category_scores_gemma":[0.00032884063,0.00008452868,0.00008082572,0.000189412,0.00009976697,0.00008967337,0.000006768535,0.00020023614,0.0000054319803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038408322,0.00017566382,0.98872524,0.0000044854505,0.0010537754,0.00008028599,0.00093122653,0.000001911244,0.00007874273,0.0000014156809,0.001598273,0.006964917],"study_design_scores_gemma":[0.001748464,0.0012831432,0.99482733,0.00008401012,0.00047658154,0.00026652095,0.0007989898,3.925886e-7,0.00002573974,0.000035485155,0.00037308084,0.000080272475],"about_ca_topic_score_codex":0.086606756,"about_ca_topic_score_gemma":0.020460192,"teacher_disagreement_score":0.06614657,"about_ca_system_score_codex":0.00010440374,"about_ca_system_score_gemma":0.00017101158,"threshold_uncertainty_score":0.9974139},"labels":[],"label_agreement":null},{"id":"W2413805145","doi":"","title":"Pityriasis rubra pilaris.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Pityriasis rubra pilaris; Dermatology; Medicine; Psoriasis","score_opus":0.0211524280212186,"score_gpt":0.2068180488520401,"score_spread":0.1856656208308215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413805145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624144,0.0059610484,0.000044896187,0.0020623158,0.0013349265,0.00065639307,0.00007691642,0.0002731309,0.027175967],"genre_scores_gemma":[0.980307,0.000106641965,0.00010133065,0.00045801137,0.00017258387,0.00076274225,0.00006623425,0.000014318611,0.018011125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990514,0.000087395616,0.00016365825,0.0002325602,0.000025126212,0.00043984124],"domain_scores_gemma":[0.99958295,0.000061650455,0.000052385192,0.00024775017,0.000021760536,0.00003349244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018353763,0.00014204468,0.00018144227,0.00007694735,0.00012746098,0.000014590692,0.00016081223,0.00017423178,0.0005675204],"category_scores_gemma":[0.00004067884,0.00012132479,0.00010340192,0.00010659969,0.00005807276,0.00010223314,0.000043160326,0.000095899704,0.0019003028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007644849,0.0001703221,0.0056010955,0.0000029199591,0.000239211,0.0000034751297,0.0001109359,0.0000012747877,0.0017885712,0.0005166082,0.018278964,0.97321016],"study_design_scores_gemma":[0.0014034121,0.000017148348,0.40710986,0.0000015449419,0.000112421105,0.000024248842,0.000022459779,2.9174942e-7,0.053528465,0.00007153736,0.53753674,0.00017189526],"about_ca_topic_score_codex":0.00004471729,"about_ca_topic_score_gemma":0.000034355195,"teacher_disagreement_score":0.97303826,"about_ca_system_score_codex":0.00004786471,"about_ca_system_score_gemma":0.000017611677,"threshold_uncertainty_score":0.9988768},"labels":[],"label_agreement":null},{"id":"W2414322210","doi":"10.1136/annrheumdis-2015-eular.4179","title":"SAT0566 Impact of Disease Management by Rheumatologists and Dermatologists on Patients' Attitude Toward Medication in Psoriatic Arthritis: Results from the Global Align Study","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Disease; Rheumatology; Psoriasis; Rheumatoid arthritis; Physical therapy; Dermatology","score_opus":0.03953200847345099,"score_gpt":0.30642019330252945,"score_spread":0.26688818482907845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414322210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532003,0.010829177,0.00000404949,0.0006836467,0.00023935945,0.00084025296,0.0019925195,0.000019890798,0.00007105735],"genre_scores_gemma":[0.99775434,0.0017200431,0.000007582825,0.00007725314,0.0000032935072,0.00007301004,0.00034649737,0.000007551885,0.000010423785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792105,0.000737113,0.00064125797,0.00029015105,0.0001732655,0.0002371752],"domain_scores_gemma":[0.9983414,0.00044037297,0.00046211146,0.0006008211,0.000075409116,0.00007992836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031603346,0.0002263188,0.00044665523,0.000043057906,0.000071728005,0.000014629253,0.00043043893,0.000066313194,0.000012400521],"category_scores_gemma":[0.00082337944,0.00012513052,0.00015310131,0.00016968475,0.00027062674,0.00007370045,0.00016381653,0.000053340664,0.000017502633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024461516,0.0033897308,0.91353595,0.00006173859,0.0013998223,0.0000048365578,0.0012913801,0.00004758364,0.0000010649288,0.00032095253,0.014931014,0.062569745],"study_design_scores_gemma":[0.005402186,0.00032745829,0.99019796,0.0005092562,0.00024189304,8.83922e-7,0.00065240375,0.000007022444,0.00005386405,0.0024528045,0.00003130287,0.0001229561],"about_ca_topic_score_codex":0.0012418531,"about_ca_topic_score_gemma":0.00008770077,"teacher_disagreement_score":0.07666199,"about_ca_system_score_codex":0.000043451524,"about_ca_system_score_gemma":0.00007933328,"threshold_uncertainty_score":0.51026744},"labels":[],"label_agreement":null},{"id":"W2416438187","doi":"10.1136/annrheumdis-2015-eular.1847","title":"THU0417 Improvements in Extra-Articular Manifestations of Psoriatic Arthritis Over 96 Weeks of Certolizumab Pegol Treatment","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Dactylitis; Psoriatic arthritis; Psoriasis; Certolizumab pegol; Enthesitis; Psoriasis Area and Severity Index; Internal medicine; Clinical endpoint; Placebo; Placebo-controlled study; Surgery; Dermatology; Gastroenterology; Clinical trial; Double blind; Etanercept; Rheumatoid arthritis; Pathology","score_opus":0.04890140752926477,"score_gpt":0.29021960478177783,"score_spread":0.24131819725251305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416438187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98926353,0.009125568,0.000008565864,0.00026391548,0.00027298267,0.00046066998,0.00038199383,0.000010894788,0.00021184723],"genre_scores_gemma":[0.99834174,0.0011707919,0.000027863853,0.000013840019,0.000005520565,0.00007642624,0.00006361533,0.000012178941,0.0002880407],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866766,0.00024399451,0.00059741543,0.0001632931,0.00010070731,0.0002269089],"domain_scores_gemma":[0.9988336,0.00017329118,0.00039868764,0.00044532816,0.000107882435,0.000041227257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074578216,0.0001790461,0.0004696463,0.00010722032,0.000041649433,0.0000045463444,0.00020559641,0.00007060863,0.00016676301],"category_scores_gemma":[0.0001791573,0.00012255104,0.0002521475,0.00015592929,0.00014705448,0.00009227258,0.000050585568,0.000031206448,0.000020051624],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019607958,0.013199028,0.117822304,0.00089365785,0.0061300835,0.00010078968,0.011080348,0.00025992573,0.012706211,0.0042196023,0.004144908,0.82748234],"study_design_scores_gemma":[0.023822844,0.003055704,0.70466226,0.002498008,0.0020429112,0.00011681302,0.0038581064,0.00014417613,0.23895893,0.019628663,0.0005108382,0.000700736],"about_ca_topic_score_codex":0.00063731737,"about_ca_topic_score_gemma":0.00010608132,"teacher_disagreement_score":0.82678163,"about_ca_system_score_codex":0.000026580927,"about_ca_system_score_gemma":0.00014300083,"threshold_uncertainty_score":0.49974865},"labels":[],"label_agreement":null},{"id":"W2417066645","doi":"10.1021/acs.jmedchem.5b00597","title":"Discovery of 1-{4-[3-Fluoro-4-((3 <i>S</i> ,6 <i>R</i> )-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C (RORc or RORγ) Inverse Agonist","year":2015,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Center for Research Resources; National Institutes of Health","keywords":"RAR-related orphan receptor gamma; Chemistry; Orphan receptor; ADME; Potency; Agonist; Stereochemistry; Inverse agonist; Pharmacology; Retinoic acid; Receptor; Nuclear receptor; Selectivity; In vitro; Biochemistry","score_opus":0.017614457176327473,"score_gpt":0.23919563628038246,"score_spread":0.22158117910405498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417066645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684908,0.026072169,0.00005321494,0.0010068543,0.001875693,0.0003406198,0.00020330826,0.0000690141,0.0018883386],"genre_scores_gemma":[0.97223246,0.0060950047,0.002279717,0.00033906108,0.00070655916,0.000027496963,0.00032141578,0.0001253175,0.017872995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99536145,0.0006325673,0.001875938,0.00074465387,0.00050508673,0.0008803198],"domain_scores_gemma":[0.9947317,0.0005208207,0.002809905,0.0006008827,0.0009507253,0.00038593914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023842352,0.0007961047,0.001837879,0.00026238695,0.00027469522,0.00005883294,0.0006967858,0.0010611711,0.0007015113],"category_scores_gemma":[0.0017492886,0.0006024686,0.00048528917,0.000829325,0.0010215269,0.0005478469,0.00020546762,0.0012964673,0.00010898262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060491706,0.0005833994,0.0045312583,0.0003235462,0.00131477,0.00018367919,0.00092627795,0.0000020973926,0.9247639,0.000005603367,0.05644318,0.00487307],"study_design_scores_gemma":[0.008902847,0.0016618691,0.00040066493,0.0008458832,0.0010471864,0.0020255484,0.0019490519,0.000002154533,0.9592506,0.00010579209,0.023185382,0.00062301714],"about_ca_topic_score_codex":0.00015832284,"about_ca_topic_score_gemma":0.000026149342,"teacher_disagreement_score":0.03448666,"about_ca_system_score_codex":0.00039560304,"about_ca_system_score_gemma":0.0016223256,"threshold_uncertainty_score":0.99964267},"labels":[],"label_agreement":null},{"id":"W2418506270","doi":"10.1056/nejmoa1512711","title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":838,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Etanercept; Placebo; Plaque psoriasis; Clinical trial; Interleukin 17; Dermatology; Internal medicine; Tumor necrosis factor alpha; Alternative medicine; Secukinumab; Inflammation; Psoriatic arthritis; Pathology","score_opus":0.044715934339980265,"score_gpt":0.3116114006828535,"score_spread":0.2668954663428732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418506270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864787,0.004582148,0.000890937,0.0056451196,0.001758746,0.00017581193,0.000044304925,0.000007273546,0.000416975],"genre_scores_gemma":[0.99637777,0.001016872,0.00016013329,0.00010977518,0.0009583548,0.0000027527021,0.000008538206,0.000011647097,0.0013541452],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778706,0.0005985123,0.0011588824,0.00013902585,0.000091808746,0.00022472061],"domain_scores_gemma":[0.9978675,0.0011630318,0.0005850453,0.00016243954,0.00013300066,0.000088942434],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291133,0.00017407387,0.0011111387,0.00040364361,0.000029179533,0.0000022747947,0.00018587985,0.00015624573,0.0011833385],"category_scores_gemma":[0.0014372084,0.00008566388,0.00013257099,0.00016701863,0.00007234942,0.00008632321,0.000017990566,0.00013721632,0.000031582535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014960859,0.000279166,0.00073358597,0.000009463402,0.00037634635,0.00008240342,0.0010692914,0.0000084505555,0.20425485,0.00012292773,0.009539811,0.76856285],"study_design_scores_gemma":[0.65947384,0.009185801,0.0027493448,0.001539438,0.0007290127,0.0012671321,0.00031155112,0.000001199107,0.21728173,0.002183668,0.10498442,0.00029286768],"about_ca_topic_score_codex":0.00009079771,"about_ca_topic_score_gemma":0.000058108104,"teacher_disagreement_score":0.76826996,"about_ca_system_score_codex":0.000048894653,"about_ca_system_score_gemma":0.00016976621,"threshold_uncertainty_score":0.9997297},"labels":[],"label_agreement":null},{"id":"W2418887226","doi":"","title":"A review of biologic treatments for psoriasis with emphasis on infliximab.","year":2007,"lang":"en","type":"review","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Infliximab; Distress; Biosimilar; Quality of life (healthcare); Disease; Intensive care medicine; Psychosocial; Biologic Agents; Dermatology; Internal medicine; Psychiatry; Nursing","score_opus":0.10552433453342977,"score_gpt":0.3240848983738192,"score_spread":0.21856056384038944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418887226","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033147964,0.99032867,0.0000072596717,0.000015647638,0.00063342944,0.0065864976,0.0009539249,0.00007221296,0.0013691873],"genre_scores_gemma":[0.0000112664175,0.9780385,0.00010720946,0.00017809674,0.00008467877,0.017063929,0.0020228766,0.00006794625,0.0024254927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99730366,0.0003232112,0.0008917763,0.0006918158,0.000057873738,0.00073168165],"domain_scores_gemma":[0.9975508,0.0007471549,0.00085995236,0.0006779931,0.000109486056,0.00005464745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005970266,0.000753759,0.0029575608,0.00036574772,0.000104456165,0.0000070525425,0.00038956443,0.0007324436,0.000086289736],"category_scores_gemma":[0.00017070973,0.0004429085,0.0010389391,0.00047423638,0.00014523379,0.00003817063,0.000045405108,0.00017054641,0.00012304065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002678479,0.0003724053,0.000029630874,0.02534141,0.0041914675,0.0000058223113,0.000007393714,1.0306916e-8,1.9691196e-7,0.00004936923,0.0017091434,0.9680253],"study_design_scores_gemma":[0.0018190661,0.00049821334,0.00021877013,0.022413524,0.009227712,0.00005773928,0.0000028101665,1.5303787e-9,0.00009248432,0.000006072415,0.9652609,0.00040266724],"about_ca_topic_score_codex":0.000015827209,"about_ca_topic_score_gemma":0.0000076264946,"teacher_disagreement_score":0.96762264,"about_ca_system_score_codex":0.0001874498,"about_ca_system_score_gemma":0.000116595365,"threshold_uncertainty_score":0.9998023},"labels":[],"label_agreement":null},{"id":"W2441495064","doi":"10.15761/god.1000160","title":"HLA-Cw6 status predicts efficacy of biologic treatments in psoriasis patients","year":2016,"lang":"en","type":"article","venue":"Global Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Immunology; Human leukocyte antigen; Medicine; Computational biology; Biology; Antigen","score_opus":0.012164953204283038,"score_gpt":0.24004704805349408,"score_spread":0.22788209484921104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2441495064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369025,0.0015913113,0.000013957292,0.00012321648,0.0011604014,0.0003787191,0.0010576657,0.00007269681,0.0019117794],"genre_scores_gemma":[0.99881667,0.00048654393,0.00006016124,0.00005973753,0.000012182761,0.000048196896,0.00033411573,0.000010338157,0.00017203431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978382,0.00040711623,0.00053983903,0.0004422245,0.000046421384,0.0007262034],"domain_scores_gemma":[0.99905956,0.00024542,0.00021848838,0.00035378922,0.0000708031,0.00005191374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005748375,0.0002962181,0.00060111453,0.00013545658,0.000061014623,0.0000030607357,0.00024054616,0.0004767597,0.00026998532],"category_scores_gemma":[0.00017379365,0.00019047757,0.00014357822,0.000269441,0.00026715494,0.00008397417,0.00010294539,0.000059494447,0.00073342276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006608426,0.00085926603,0.9225129,0.000009970744,0.00036062291,0.0000333086,0.00006389818,5.37422e-7,0.003070629,0.0005636421,0.00097293436,0.07089145],"study_design_scores_gemma":[0.013919145,0.00035838404,0.96628904,0.00004099707,0.00013247518,0.000072420335,0.000019700807,1.8301367e-7,0.013623634,0.00032733488,0.0050221216,0.00019454841],"about_ca_topic_score_codex":0.00019357704,"about_ca_topic_score_gemma":0.00012194101,"teacher_disagreement_score":0.070696905,"about_ca_system_score_codex":0.0001718778,"about_ca_system_score_gemma":0.0000915385,"threshold_uncertainty_score":0.942691},"labels":[],"label_agreement":null},{"id":"W2460580996","doi":"","title":"Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Betamethasone dipropionate; Calcipotriol; Psoriasis; Medicine; Clinical trial; Dermatology; Pharmacology; Internal medicine","score_opus":0.02415093073561197,"score_gpt":0.2388475814581522,"score_spread":0.21469665072254024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460580996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841551,0.011883053,0.0013799331,0.00008728812,0.00020570793,0.0019616212,0.00012477445,0.000011126459,0.00019134798],"genre_scores_gemma":[0.99641395,0.0009185453,0.00018252835,0.000005910027,0.000009204667,0.0020726484,0.00006363251,0.0000086121145,0.00032500015],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992182,0.000115334966,0.00029465495,0.00017331427,0.00003420757,0.00016427918],"domain_scores_gemma":[0.9988777,0.0005066671,0.00027730846,0.00022817822,0.00009663496,0.000013501716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002735016,0.00011557874,0.00030395755,0.00006397043,0.00006591588,0.0000020735722,0.00007843508,0.00010714932,0.0000057843736],"category_scores_gemma":[0.00007848062,0.00007675686,0.00009644785,0.00012775742,0.00014663587,0.00003502567,0.000008302165,0.00002315036,9.3759115e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042693413,0.0010137075,0.019225568,0.00006870145,0.00074419484,1.16712535e-7,0.00072935235,0.0000054656807,0.031628862,0.00849684,0.00004284968,0.9376174],"study_design_scores_gemma":[0.006454252,0.0004913115,0.32488328,0.000007761771,0.0006721106,0.0000037248178,0.00017382149,0.00001317737,0.65158886,0.000907284,0.014691271,0.00011316895],"about_ca_topic_score_codex":0.00009259898,"about_ca_topic_score_gemma":0.000018772094,"teacher_disagreement_score":0.93750423,"about_ca_system_score_codex":0.000031550917,"about_ca_system_score_gemma":0.000019025454,"threshold_uncertainty_score":0.31300542},"labels":[],"label_agreement":null},{"id":"W2462932618","doi":"","title":"Duration of remission of biologic agents for chronic plaque psoriasis.","year":2007,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Infliximab; Efalizumab; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Clinical trial; Randomized controlled trial; Internal medicine; Plaque psoriasis; Dermatology; Tumor necrosis factor alpha","score_opus":0.03556328970419666,"score_gpt":0.25307542087124335,"score_spread":0.2175121311670467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2462932618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950352,0.0019116466,0.00054992863,0.0000537774,0.00081669906,0.0008099445,0.000060966602,0.00002626406,0.00073557685],"genre_scores_gemma":[0.99796087,0.00015813693,0.0001165959,0.000012472241,0.000056730823,0.00023504038,0.00019486417,0.0000073593023,0.0012579181],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991484,0.00005345269,0.00034611166,0.0001612675,0.000021688715,0.0002690693],"domain_scores_gemma":[0.9993691,0.00016531681,0.00023508682,0.00015430093,0.000058358557,0.000017853714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052382343,0.000100309655,0.00021996847,0.000095024996,0.00004978617,0.0000013277809,0.00010226002,0.00022132201,0.00005018716],"category_scores_gemma":[0.00012295859,0.00007785306,0.00010621397,0.00009943434,0.00006169138,0.000036632537,0.000019904974,0.00003775457,0.00000769117],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001199155,0.00024719117,0.018473322,0.00008981063,0.00032735063,0.0000012600059,0.00013517622,0.0000029149808,0.3317339,0.00082936604,0.0014386949,0.6455218],"study_design_scores_gemma":[0.0015935713,0.00012176173,0.34740046,0.000008727831,0.00007077729,0.0000034392253,0.000020115838,5.450822e-7,0.6394508,0.00012145663,0.011141345,0.000067029825],"about_ca_topic_score_codex":0.000021647678,"about_ca_topic_score_gemma":0.000030988478,"teacher_disagreement_score":0.6454548,"about_ca_system_score_codex":0.000052909443,"about_ca_system_score_gemma":0.000023683122,"threshold_uncertainty_score":0.31747556},"labels":[],"label_agreement":null},{"id":"W2463021530","doi":"10.1177/1203475416655705","title":"2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009","year":2016,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Plaque psoriasis; Addendum; Psoriasis; Dermatology","score_opus":0.10182479379072755,"score_gpt":0.33658557039483145,"score_spread":0.23476077660410388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463021530","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000137688785,0.9858399,0.000041870404,0.009241707,0.0038401308,0.0005623092,0.00019707423,0.0000039167085,0.00025934566],"genre_scores_gemma":[0.000052816653,0.9926719,0.000052830033,0.0005368617,0.0014960279,0.000037239683,0.000025922669,0.000026740867,0.00509966],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978363,0.00020712202,0.0013107529,0.00018071434,0.00010850688,0.0003566396],"domain_scores_gemma":[0.99525493,0.0029810432,0.00091189187,0.0003341385,0.0004197716,0.00009819549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015028858,0.0003313412,0.0016972573,0.00041362236,0.00025756643,0.0000100245625,0.00037808545,0.00028117534,0.00029612187],"category_scores_gemma":[0.00033343688,0.000120747194,0.0005916436,0.00017322529,0.00014692145,0.0000254448,0.000033736254,0.00018823564,0.00003739833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008052733,0.000007654937,0.000001848925,0.00046589904,0.00175211,0.00010424027,0.00004160559,1.3203062e-7,0.000001144334,0.000032665183,0.41030914,0.587203],"study_design_scores_gemma":[0.00032332595,0.00020063702,0.0000031900574,0.013666329,0.0036131637,0.0025180893,0.000143968,5.309982e-8,0.000004086308,0.000033012322,0.9793622,0.00013197777],"about_ca_topic_score_codex":0.0014059207,"about_ca_topic_score_gemma":0.0026884032,"teacher_disagreement_score":0.58707106,"about_ca_system_score_codex":0.00007525102,"about_ca_system_score_gemma":0.00062693015,"threshold_uncertainty_score":0.49239278},"labels":[],"label_agreement":null},{"id":"W2463397294","doi":"10.1177/1203475416658004","title":"Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction","year":2016,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Myocardial infarction; Methotrexate; Incidence (geometry); Comorbidity; Population; Internal medicine; Psoriatic arthritis; Dermatology","score_opus":0.02166041346546222,"score_gpt":0.2386238150843728,"score_spread":0.2169634016189106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463397294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996679,0.0021180282,0.000019337906,0.00054525357,0.00042121534,0.000081330145,0.000016160442,0.000007871328,0.00011176807],"genre_scores_gemma":[0.99345225,0.006066328,0.000034920668,0.0000891203,0.00010015549,0.0000018013662,0.00001160112,0.000009782672,0.0002340472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877065,0.0003580837,0.00050112454,0.00014264391,0.0000507485,0.00017674912],"domain_scores_gemma":[0.99776727,0.0012867419,0.0005543652,0.00009591591,0.00024506217,0.000050673356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051504327,0.00016956714,0.00069323654,0.00026799095,0.00006269163,0.0000031596512,0.000041430052,0.00015081473,0.000058586636],"category_scores_gemma":[0.0003904495,0.000078491576,0.00008833439,0.000096246964,0.00027617905,0.000070741815,0.000013054774,0.000084442414,0.0000016327068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061040777,0.00014858623,0.49239182,0.000028521587,0.0017529574,0.00019385999,0.00054461835,4.1676918e-7,0.24204692,0.000013571765,0.002825699,0.25394893],"study_design_scores_gemma":[0.026026782,0.01645757,0.70645034,0.0026800365,0.0052947956,0.014897821,0.001427554,0.0000019795514,0.19391376,0.0007422654,0.031036362,0.0010707324],"about_ca_topic_score_codex":0.000039858518,"about_ca_topic_score_gemma":0.0000037519637,"teacher_disagreement_score":0.25287822,"about_ca_system_score_codex":0.000018778968,"about_ca_system_score_gemma":0.000048257272,"threshold_uncertainty_score":0.32007936},"labels":[],"label_agreement":null},{"id":"W2465970507","doi":"10.1016/j.clindermatol.2016.07.006","title":"Psoriasis in adults and children: Kids are not just little people","year":2016,"lang":"en","type":"article","venue":"Clinics in Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Psoriasis; Medicine; Psychosocial; Presentation (obstetrics); Population; Disease; Pediatrics; Intensive care medicine; Psychiatry; Dermatology; Surgery; Pathology","score_opus":0.017726842485054854,"score_gpt":0.2671119005339196,"score_spread":0.24938505804886474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465970507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344116,0.0031272639,0.000009959739,0.0016529785,0.0010978724,0.00023220081,0.0000840746,0.000045783734,0.00030869676],"genre_scores_gemma":[0.9966963,0.0024101501,0.000059090904,0.00030163923,0.000040214287,0.00005922106,0.000048661615,0.000019625873,0.0003650843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810916,0.00034699772,0.00056500896,0.0004909592,0.000025357156,0.0004624948],"domain_scores_gemma":[0.998615,0.00079223624,0.00016688365,0.0003600239,0.00003228433,0.00003354884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020553454,0.00022614555,0.00058810285,0.00024234304,0.00006817779,0.000005670079,0.0002133786,0.00063643523,0.0001737369],"category_scores_gemma":[0.0003033169,0.00017193417,0.000079048325,0.00018937496,0.00021197906,0.000083080515,0.00012890255,0.0002077482,0.0004614402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043985655,0.00023132302,0.96477044,0.000020405128,0.00006880952,0.000051176386,0.00047900787,1.8365282e-7,0.00033243673,0.00066527026,0.0008137461,0.032127336],"study_design_scores_gemma":[0.008567565,0.00009145203,0.9832618,0.00014578368,0.00004294,0.0004502316,0.00022375431,0.0000017349907,0.0042008027,0.00042319726,0.0023183452,0.00027239224],"about_ca_topic_score_codex":0.00007040105,"about_ca_topic_score_gemma":0.0013942998,"teacher_disagreement_score":0.031854942,"about_ca_system_score_codex":0.000036080055,"about_ca_system_score_gemma":0.00005696319,"threshold_uncertainty_score":0.7011272},"labels":[],"label_agreement":null},{"id":"W2468986879","doi":"","title":"Topical treatment of psoriasis in children.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Treatment modality; Modalities; Therapeutic modalities; Topical agents; First line; Intensive care medicine; Surgery; Physical therapy; Internal medicine","score_opus":0.02626444030818241,"score_gpt":0.20848490125385796,"score_spread":0.18222046094567557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468986879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904367,0.0053351535,0.0000012097425,0.00014155773,0.00030204852,0.00041520013,0.000021861224,0.000025229036,0.0033210753],"genre_scores_gemma":[0.9947119,0.0005734744,0.000018552853,0.0000149765665,0.000041139203,0.0005880715,0.000026232412,0.0000064620695,0.0040192017],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992765,0.00007666641,0.00018426194,0.00017288503,0.000018488587,0.00027117127],"domain_scores_gemma":[0.9997052,0.00004638415,0.000043552343,0.00017791314,0.000008984496,0.000017945433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042930325,0.00011170011,0.00022807792,0.00009315227,0.00002666618,0.000002682447,0.000075501775,0.00013018797,0.00041563093],"category_scores_gemma":[0.000015709893,0.00008769951,0.000092173934,0.00011231581,0.000048339818,0.000029300636,0.0000115250195,0.00003115682,0.0001222473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040375566,0.0005629868,0.31300932,0.0000013524312,0.00016959777,0.0000026089638,0.00014165547,4.6100186e-7,0.00017409865,0.00012625728,0.00022339495,0.6855479],"study_design_scores_gemma":[0.002845186,0.0000987542,0.97295725,0.0000016073329,0.000062863015,0.000017900933,0.000011548577,4.0114196e-7,0.018254476,0.000032976488,0.0056327735,0.00008425632],"about_ca_topic_score_codex":0.000095631985,"about_ca_topic_score_gemma":0.000024461255,"teacher_disagreement_score":0.68546367,"about_ca_system_score_codex":0.000052029085,"about_ca_system_score_gemma":0.0000031160273,"threshold_uncertainty_score":0.4550867},"labels":[],"label_agreement":null},{"id":"W2469341543","doi":"10.3899/jrheum.150125","title":"Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Concomitant; Dermatology; Arthritis; Physical therapy; Surgery; Internal medicine","score_opus":0.021808868644309233,"score_gpt":0.24190037840429265,"score_spread":0.22009150975998343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469341543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94802934,0.047617506,0.00035907832,0.0013454171,0.0018317484,0.00015232648,0.000009692015,0.000015442693,0.00063947524],"genre_scores_gemma":[0.9925006,0.0068692183,0.00041791782,0.000059705857,0.000012058413,0.00000632225,0.000013864939,0.000011822998,0.00010847631],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99769485,0.0008926181,0.00093681883,0.00012075634,0.00009173292,0.000263212],"domain_scores_gemma":[0.997394,0.0007363691,0.0012443083,0.00042871016,0.00016638407,0.000030199384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015680753,0.00016990701,0.0005786079,0.00006451129,0.00013393039,0.000007037905,0.0005546322,0.00015407547,0.00007388156],"category_scores_gemma":[0.00017243499,0.00008895408,0.00016546751,0.000113573624,0.00032208365,0.00005926074,0.00011656806,0.0002261651,0.00010618791],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034276878,0.000736813,0.64451873,0.00011457425,0.013139093,0.0011694711,0.010468648,0.00013210639,0.002863936,0.00517962,0.22222623,0.096023075],"study_design_scores_gemma":[0.054145604,0.0026902438,0.17458779,0.004865419,0.010443761,0.41920894,0.06799204,0.000044013384,0.04710754,0.06599634,0.15086055,0.002057763],"about_ca_topic_score_codex":0.00049270235,"about_ca_topic_score_gemma":0.00008832001,"teacher_disagreement_score":0.46993095,"about_ca_system_score_codex":0.000023726425,"about_ca_system_score_gemma":0.00008477522,"threshold_uncertainty_score":0.3627442},"labels":[],"label_agreement":null},{"id":"W2469489436","doi":"","title":"The IMPACT Programme in Psoriasis: Phase I - where we are now and future directions","year":2015,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Disease; Overweight; Physical therapy; Psychology; Obesity; Dermatology; Pathology","score_opus":0.08924501889422057,"score_gpt":0.3185071587454897,"score_spread":0.22926213985126911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469489436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9693405,0.022526883,0.0000033007948,0.0073522474,0.00018923965,0.0003974575,0.000022729688,0.000028389839,0.00013923194],"genre_scores_gemma":[0.9699625,0.029159755,0.000032425512,0.000004881475,0.000111510446,0.000011042402,0.000022293003,0.00001345749,0.00068217394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841344,0.0007049383,0.000108249245,0.00022643771,0.0000986401,0.00044831654],"domain_scores_gemma":[0.9990437,0.00031158575,0.000067647736,0.00035046606,0.00015741968,0.00006919273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091990887,0.00013085903,0.00019431034,0.00014536848,0.000514176,0.000025725294,0.00034951812,0.00014716647,0.00005545868],"category_scores_gemma":[0.000045515364,0.0000811293,0.00009093283,0.00035293828,0.0005404186,0.00015223207,0.00017074765,0.00033367414,0.00013326001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051691676,0.0017643098,0.074689284,0.00009755392,0.0012307863,0.00013961803,0.13849808,0.0000056916833,0.0025206655,0.00026159186,0.040258963,0.73536426],"study_design_scores_gemma":[0.0059466152,0.00066628214,0.048302043,0.00009738289,0.00006816562,0.000031010746,0.19009249,0.000011556584,0.0006867493,0.0003403331,0.7535981,0.00015928473],"about_ca_topic_score_codex":0.00006181049,"about_ca_topic_score_gemma":0.00044584234,"teacher_disagreement_score":0.735205,"about_ca_system_score_codex":0.00013440715,"about_ca_system_score_gemma":0.00010822125,"threshold_uncertainty_score":0.3954678},"labels":[],"label_agreement":null},{"id":"W2470286754","doi":"10.3945/ajcn.116.139444","title":"Lifestyle intervention in psoriasis: a new avenue for treatment?","year":2016,"lang":"en","type":"letter","venue":"American Journal of Clinical Nutrition","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Intervention (counseling); Intensive care medicine; Dermatology; Psychiatry","score_opus":0.04592181955502767,"score_gpt":0.35182519462647177,"score_spread":0.3059033750714441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470286754","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29010975,0.020593584,0.0016311416,0.66766346,0.016316662,0.0021468797,0.0013162213,0.00007252743,0.00014974497],"genre_scores_gemma":[0.45201957,0.0650472,0.010866705,0.28127512,0.15626606,0.0011714062,0.005831647,0.00071560824,0.026806673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966702,0.0007650391,0.0017817939,0.00033165826,0.000069779904,0.0003815274],"domain_scores_gemma":[0.9958355,0.0015952076,0.0021230862,0.00023886132,0.00015472155,0.000052617608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065650017,0.00031438257,0.001495226,0.00035573982,0.0000458626,0.000016767763,0.0002593598,0.0007477372,0.00010827764],"category_scores_gemma":[0.00031941355,0.00022785991,0.0013881053,0.00014241227,0.00022375997,0.00012372051,0.000017185113,0.00053498015,0.00009288872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020812436,0.00055568287,0.0011258123,0.000032817254,0.00086735823,0.00006255803,0.000040351195,7.0590374e-8,0.00009335162,0.0000047988447,0.39728013,0.5978558],"study_design_scores_gemma":[0.019388339,0.013092871,0.001404706,0.0011095111,0.0006710077,0.00014010523,0.000053387932,1.3871677e-7,0.0004619198,0.0012036975,0.9622367,0.0002376289],"about_ca_topic_score_codex":0.00005259642,"about_ca_topic_score_gemma":0.000029738323,"teacher_disagreement_score":0.59761816,"about_ca_system_score_codex":0.0001575535,"about_ca_system_score_gemma":0.00020345715,"threshold_uncertainty_score":0.9291858},"labels":[],"label_agreement":null},{"id":"W2485786533","doi":"10.1016/b978-1-4832-2950-8.50076-8","title":"‘PUSTULAR’ PSORIASIS: PLATES LXXV, LXXVI","year":2013,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut d'Histoire de l'Amérique Française","funders":"","keywords":"Pustular psoriasis; Dermatology; Psoriasis; Medicine","score_opus":0.01671502793545067,"score_gpt":0.21934178811191135,"score_spread":0.2026267601764607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485786533","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015271258,0.02312688,8.1595624e-7,0.000062251376,0.0032071501,0.0009809575,0.00025634625,0.00027661005,0.97056186],"genre_scores_gemma":[0.0032756485,0.00082865614,0.00010482233,0.00023688604,0.00047050364,0.00021190174,0.00060182204,0.00018491632,0.99408484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742424,0.000106011445,0.0007216214,0.00090860884,0.000108277374,0.00073121657],"domain_scores_gemma":[0.9981425,0.00017257055,0.00043321587,0.0010183395,0.00014546375,0.00008794496],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020078842,0.0009975972,0.0012109694,0.00029052058,0.00032451007,0.000055633813,0.00056690193,0.0017263611,0.008895946],"category_scores_gemma":[0.0000219039,0.00085601554,0.00064565573,0.000017985278,0.0003117666,0.00007310713,0.00021610809,0.0007037152,0.028308243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084269865,0.000039916547,0.00001504422,0.000053499647,0.0020811677,0.000053238688,0.00025004378,1.5065116e-7,0.0013449293,0.0045869034,0.0046046185,0.9868862],"study_design_scores_gemma":[0.0014595641,0.00020840118,0.000059803537,0.0002939365,0.0010681278,0.00011085949,0.000021604767,1.8936193e-7,0.0034429145,0.0051587597,0.9872893,0.00088651874],"about_ca_topic_score_codex":0.0000045385887,"about_ca_topic_score_gemma":0.000021427613,"teacher_disagreement_score":0.9859997,"about_ca_system_score_codex":0.000114988856,"about_ca_system_score_gemma":0.0001400081,"threshold_uncertainty_score":0.9995696},"labels":[],"label_agreement":null},{"id":"W2497655497","doi":"10.1177/1352458516658559","title":"Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment","year":2016,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Natalizumab; Multiple sclerosis; Medicine; Peripheral blood mononuclear cell; Immunology; Discontinuation; Progressive multifocal leukoencephalopathy; Interleukin 17; Cytokine; Internal medicine; Biology; In vitro","score_opus":0.04912672049802235,"score_gpt":0.22933993576441605,"score_spread":0.1802132152663937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2497655497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268234,0.0057629854,0.000044400433,0.0000823667,0.00050872576,0.0003073041,0.00049185404,0.000035072844,0.000084959385],"genre_scores_gemma":[0.99592,0.0029051332,0.00073364825,0.000011746511,0.000080752165,0.000039929953,0.00003439688,0.000036368587,0.0002380119],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745053,0.0004054674,0.00094093534,0.00047032634,0.0001291953,0.0006035358],"domain_scores_gemma":[0.9980918,0.00056439877,0.0005977337,0.00049269985,0.00017768591,0.00007566728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050772587,0.00039007966,0.000801191,0.00038316514,0.0002223134,0.00001779121,0.00034904442,0.0003048834,0.00041408002],"category_scores_gemma":[0.00031689284,0.00026581684,0.0003984199,0.00028759157,0.00019213308,0.00028901544,0.000100100915,0.00013518178,0.000064345884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008069981,0.0005832042,0.20656766,0.000010529216,0.00030270437,0.0000026584955,0.0008273364,0.000021787753,0.616973,0.0000049765094,0.00007044685,0.17382872],"study_design_scores_gemma":[0.009650297,0.0003346024,0.40476596,0.00039732308,0.000092647795,0.000042943204,0.00023362397,0.000014956064,0.5836754,0.000035780602,0.0005642422,0.00019221219],"about_ca_topic_score_codex":0.0010240693,"about_ca_topic_score_gemma":0.00087248394,"teacher_disagreement_score":0.1981983,"about_ca_system_score_codex":0.0005155044,"about_ca_system_score_gemma":0.00016982308,"threshold_uncertainty_score":0.9999794},"labels":[],"label_agreement":null},{"id":"W2503219031","doi":"10.1016/j.jaad.2016.06.012","title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Medicine; Tofacitinib; Plaque psoriasis; Psoriasis; Internal medicine; Term (time); Cardiology; Dermatology","score_opus":0.013382230975705947,"score_gpt":0.25176488473306263,"score_spread":0.23838265375735668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503219031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683213,0.00222261,0.00009100215,0.00025661668,0.00013734694,0.00028399122,0.0001689606,0.0000046166824,0.0000027263593],"genre_scores_gemma":[0.99874896,0.0010887255,0.000045376797,0.00007877472,0.000008911056,0.00000309823,0.000008355865,0.000015324678,0.0000024851413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788064,0.00094566715,0.000488083,0.00029484482,0.00016261818,0.00022813161],"domain_scores_gemma":[0.9976872,0.00092958583,0.00083994283,0.0004595524,0.00004238729,0.0000413101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029783667,0.00025074827,0.0014465065,0.00026645715,0.000063670974,0.0000027323892,0.0003547717,0.00015776794,0.0000044690373],"category_scores_gemma":[0.00022328433,0.00011866405,0.0003492771,0.00013942333,0.0005752905,0.000096612384,0.00010850758,0.00026222927,8.886167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002648027,0.0003679398,0.9524052,0.000039496746,0.0038274769,0.000025528934,0.00006624503,0.000014104236,0.0014096105,0.0000043694504,0.00003679197,0.039155208],"study_design_scores_gemma":[0.018879607,0.000693121,0.94118583,0.00022023362,0.0014668627,0.00010134771,0.000023808703,0.0000011355377,0.037107237,0.0000068200998,0.00018241767,0.00013156289],"about_ca_topic_score_codex":0.000040032573,"about_ca_topic_score_gemma":0.0000014835142,"teacher_disagreement_score":0.039023645,"about_ca_system_score_codex":0.00002191173,"about_ca_system_score_gemma":0.00003475795,"threshold_uncertainty_score":0.48389795},"labels":[],"label_agreement":null},{"id":"W2507796609","doi":"10.1016/j.jid.2016.06.077","title":"060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Placebo; Adverse effect; Psoriasis; Internal medicine; Secukinumab; Dermatology; Psoriatic arthritis","score_opus":0.05319128426273027,"score_gpt":0.3155931721780265,"score_spread":0.26240188791529623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507796609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959293,0.00031898762,0.00036911498,0.00083894935,0.00038708796,0.00030028116,0.0017727939,0.0000074688414,0.00007601375],"genre_scores_gemma":[0.9983463,0.00008103832,0.0011377255,0.000132173,0.000022086278,0.000006817759,0.0002122134,0.0000146513885,0.00004696757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99031305,0.0047641187,0.0041516563,0.00034991754,0.000129299,0.00029195476],"domain_scores_gemma":[0.9905075,0.0042970693,0.0037524272,0.00034480623,0.0009899748,0.0001082354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002068274,0.0003007642,0.0033056445,0.00097407086,0.00004202516,0.0000045225547,0.00034715876,0.00048815203,0.00014718698],"category_scores_gemma":[0.0068751746,0.0001639353,0.0005366801,0.00095115334,0.0005915272,0.00016744941,0.000056653356,0.0003028992,0.000016174246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20104076,0.0025616013,0.6187142,0.000030002187,0.067868575,0.00014564945,0.004667712,0.0004657622,0.054233324,0.0005115548,0.0029006992,0.046860166],"study_design_scores_gemma":[0.041433994,0.0012857537,0.7632553,0.00044396127,0.005531089,0.000022887325,0.00037429138,0.000013112002,0.18653208,0.0005283419,0.00032253793,0.00025667687],"about_ca_topic_score_codex":0.00014922435,"about_ca_topic_score_gemma":0.00024001008,"teacher_disagreement_score":0.15960677,"about_ca_system_score_codex":0.00007050167,"about_ca_system_score_gemma":0.00052413176,"threshold_uncertainty_score":0.82307225},"labels":[],"label_agreement":null},{"id":"W2508182513","doi":"10.1111/jdv.13808","title":"Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"National Institutes of Health; Pfizer","keywords":"Tofacitinib; Medicine; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Psoriasis; Janus kinase inhibitor; Placebo; Internal medicine; Plaque psoriasis; Randomized controlled trial; Dermatology; Surgery","score_opus":0.014304655100352299,"score_gpt":0.26121729816183525,"score_spread":0.24691264306148294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508182513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977483,0.00032889048,0.000004074818,0.0009309355,0.00022153344,0.00048388203,0.00019440644,0.0000060002358,0.00008199054],"genre_scores_gemma":[0.9997337,0.000083623905,0.0000193446,0.000072405506,0.000016765876,0.0000062200384,0.0000093098015,0.000016836793,0.000041825526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616325,0.0023620208,0.0008693678,0.0002920696,0.000067783665,0.00024550612],"domain_scores_gemma":[0.99800324,0.00077505334,0.0009303266,0.00019720658,0.00004549533,0.000048693557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033197884,0.000277995,0.0008850162,0.00021320819,0.00007850541,0.0000027777469,0.00019313634,0.00017978952,0.000014608501],"category_scores_gemma":[0.00014802854,0.00012943608,0.00009421921,0.000098873454,0.00024724452,0.00006896197,0.00009834496,0.00020735573,0.0000047700073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032172862,0.0010150006,0.92301214,0.00001293814,0.0015413766,0.000120594676,0.0013057572,0.000020302881,0.0019218879,0.000013733704,0.00010019321,0.038763233],"study_design_scores_gemma":[0.0937497,0.009981043,0.83687,0.00029677348,0.000757771,0.00049222517,0.00010036338,9.593851e-7,0.056824546,0.000046862897,0.00064134505,0.00023840624],"about_ca_topic_score_codex":0.00001864043,"about_ca_topic_score_gemma":0.000017865701,"teacher_disagreement_score":0.086142115,"about_ca_system_score_codex":0.000049811144,"about_ca_system_score_gemma":0.000041365714,"threshold_uncertainty_score":0.52782506},"labels":[],"label_agreement":null},{"id":"W2508963940","doi":"10.1620/tjem.240.47","title":"A Heterodimeric Cytokine, Consisting of IL-17A and IL-17F, Promotes Migration and Capillary-Like Tube Formation of Human Vascular Endothelial Cells","year":2016,"lang":"en","type":"article","venue":"The Tohoku Journal of Experimental Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Angiogenesis; Cell biology; Cytokine; Umbilical vein; Interleukin 8; Chemokine; PI3K/AKT/mTOR pathway; Vascular endothelial growth factor; MAPK/ERK pathway; Biology; Endothelial stem cell; Signal transduction; Chemistry; Immunology; Cancer research; In vitro; Inflammation; Biochemistry; VEGF receptors","score_opus":0.017750770906641355,"score_gpt":0.24923880969340612,"score_spread":0.23148803878676477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508963940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843062,0.014919893,0.000054318196,0.00019703733,0.00026164012,0.00017752475,0.000027602922,0.000004791759,0.000051005427],"genre_scores_gemma":[0.9988954,0.000859453,0.00007236051,0.000032054035,0.000074226686,0.0000039058473,0.000007391588,0.0000084723415,0.0000467066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989812,0.00019216508,0.00051381596,0.00009543324,0.00008176899,0.00013564058],"domain_scores_gemma":[0.9990523,0.00020408702,0.0005147157,0.00012047433,0.000081790145,0.000026650661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041742946,0.00014006697,0.00038742792,0.000104998755,0.00010739077,0.0000029460107,0.00008700687,0.00006756476,0.000076320925],"category_scores_gemma":[0.000048372196,0.000069756745,0.000065059634,0.000052974698,0.0004287483,0.0001222024,0.000035774945,0.00006323291,0.0000015196085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023653806,0.00008172754,0.0007002682,0.00002240712,0.00020068236,0.0000033681156,0.0034891507,1.7586783e-7,0.99131906,0.00004039888,0.00011992433,0.0037862903],"study_design_scores_gemma":[0.0039337096,0.001998367,0.0016634159,0.00027834222,0.00022046662,0.0002845698,0.0015096501,0.0000020621571,0.98964167,0.0000493795,0.00034784203,0.00007053315],"about_ca_topic_score_codex":0.00008957983,"about_ca_topic_score_gemma":0.0000071433947,"teacher_disagreement_score":0.014589243,"about_ca_system_score_codex":0.000022047121,"about_ca_system_score_gemma":0.000014614798,"threshold_uncertainty_score":0.28445974},"labels":[],"label_agreement":null},{"id":"W2510680239","doi":"10.1111/jdv.13918","title":"Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase <scp>III</scp> randomized, controlled trials","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Baxalta; Celgene; Biogen; Amgen; Pfizer; Eli Lilly and Company","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Dermatology Life Quality Index; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Psoriasis Area and Severity Index; Psoriatic arthritis; Physical therapy; Dermatology; Alternative medicine; Pathology; Nursing","score_opus":0.032819225057326575,"score_gpt":0.30237584257435646,"score_spread":0.26955661751702986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510680239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912136,0.0050773835,0.00003651771,0.0016862311,0.0006948285,0.0009806965,0.00008790012,0.0000069536763,0.00021585805],"genre_scores_gemma":[0.9979464,0.0014069452,0.00011028962,0.00021725787,0.000057822454,0.000026512886,0.0000052498845,0.000017578077,0.00021198693],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98403394,0.011968313,0.0032915487,0.00027071682,0.00009943842,0.00033602494],"domain_scores_gemma":[0.9896614,0.0060391957,0.003832529,0.00028124763,0.00013063419,0.000054968466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035524904,0.00036297733,0.003965896,0.000321425,0.00009406433,0.000005637035,0.0004304627,0.0002684473,0.0000056711306],"category_scores_gemma":[0.0021123923,0.00014650209,0.0008146299,0.00013582235,0.0006487329,0.00012419469,0.00007829974,0.0002132259,0.0000025974055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5630001,0.0060417145,0.03851541,0.00006232573,0.01399215,0.00031472082,0.016712878,0.00008827886,0.28454426,0.0009390821,0.0018128891,0.07397622],"study_design_scores_gemma":[0.6590415,0.001202526,0.0048006917,0.00015734606,0.0026225194,0.0020415068,0.0006043572,0.0000060987168,0.32722816,0.0008414583,0.0013211591,0.00013262618],"about_ca_topic_score_codex":0.00002194332,"about_ca_topic_score_gemma":0.000011044665,"teacher_disagreement_score":0.096041456,"about_ca_system_score_codex":0.00002396002,"about_ca_system_score_gemma":0.00007361452,"threshold_uncertainty_score":0.5974182},"labels":[],"label_agreement":null},{"id":"W2512837168","doi":"10.1016/j.jid.2016.06.075","title":"058 Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Placebo; Etanercept; Psoriasis; Internal medicine; Double blind; Dosing; Clinical trial; Dermatology; Secukinumab; Pathology; Tumor necrosis factor alpha","score_opus":0.07545429452531802,"score_gpt":0.3149114856996707,"score_spread":0.23945719117435268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512837168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98983276,0.006027236,0.0004510015,0.0014333946,0.00094590575,0.0006260626,0.0003106316,0.000019513858,0.00035347478],"genre_scores_gemma":[0.99796027,0.0010488871,0.00023743635,0.00018973724,0.000054674383,0.000024359553,0.00008490572,0.000027402297,0.00037232097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99209887,0.0034659465,0.0034143308,0.00035924403,0.00020534205,0.0004562625],"domain_scores_gemma":[0.9861733,0.0062727123,0.005663469,0.00046109324,0.001319015,0.00011040919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002019974,0.000524371,0.0055546113,0.0015506396,0.00010081292,0.000013234989,0.0005698496,0.0006420131,0.00079371146],"category_scores_gemma":[0.0030669668,0.0002812964,0.0020698805,0.0013102551,0.0012342744,0.00027499304,0.00006656952,0.0003309458,0.00004222334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09482188,0.0011319834,0.013427544,0.0000316356,0.06843301,0.00009332887,0.0011868528,0.00013043049,0.80520195,0.0028355496,0.0030160823,0.00968976],"study_design_scores_gemma":[0.12820767,0.0010820378,0.007973074,0.0001724575,0.007080027,0.0002033331,0.0003098761,0.0000034683303,0.8505739,0.00092750974,0.0031855353,0.00028113855],"about_ca_topic_score_codex":0.00011771409,"about_ca_topic_score_gemma":0.00006419526,"teacher_disagreement_score":0.06135298,"about_ca_system_score_codex":0.00014273878,"about_ca_system_score_gemma":0.0010065784,"threshold_uncertainty_score":0.99996394},"labels":[],"label_agreement":null},{"id":"W2512873140","doi":"10.1111/bjd.14965","title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","year":2016,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Immunogenicity; Psoriasis; Psoriasis Area and Severity Index; Monoclonal antibody; Immunology; Cytokine; Interleukin 17; Antibody; Internal medicine; Psoriatic arthritis","score_opus":0.007734141049989083,"score_gpt":0.22355477557271214,"score_spread":0.21582063452272304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512873140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967801,0.0013620225,0.00020395746,0.00035199607,0.0006223932,0.00030016154,0.00018338866,0.000027731921,0.00016827851],"genre_scores_gemma":[0.9990973,0.00015970749,0.00026639327,0.0001293128,0.000057117544,0.0000139912345,0.00007012706,0.000042171996,0.00016388996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997187,0.00049735315,0.0010320935,0.00042926063,0.00012835072,0.0007259247],"domain_scores_gemma":[0.9985798,0.00017247634,0.0005403728,0.00024290869,0.0003622271,0.00010220541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018289416,0.00036821043,0.0010172442,0.00041271944,0.00022970828,0.00004552678,0.00048781722,0.000422345,0.00037320566],"category_scores_gemma":[0.00007169034,0.00030035974,0.00023029675,0.00021979032,0.00020371846,0.000357664,0.00012394848,0.00036233015,0.00011434819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010354821,0.0018475364,0.86396426,0.000039098217,0.0017065152,0.0052831913,0.0005733753,0.000011350454,0.07538267,0.00014417301,0.0034638143,0.03722922],"study_design_scores_gemma":[0.03196553,0.0011663311,0.8684695,0.00082346285,0.00021265881,0.0391778,0.00009355805,6.002936e-7,0.055873655,0.00012901038,0.0014403309,0.0006475711],"about_ca_topic_score_codex":0.00013546257,"about_ca_topic_score_gemma":0.00037518534,"teacher_disagreement_score":0.03658165,"about_ca_system_score_codex":0.00015170555,"about_ca_system_score_gemma":0.00021081962,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W2513795393","doi":"10.1016/j.jid.2016.06.070","title":"053 Evaluation of inflammatory bowel disease in patients with plaque psoriasis studied in phase 3 trials of ixekizumab (UNCOVER Trials): Adjudicated data from the induction period","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ixekizumab; Medicine; Adverse effect; Incidence (geometry); Placebo; Ulcerative colitis; Inflammatory bowel disease; Internal medicine; Psoriasis; Disease; Dermatology; Pathology; Psoriatic arthritis","score_opus":0.11233172994659554,"score_gpt":0.3324804203605718,"score_spread":0.22014869041397625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513795393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939978,0.0024145332,0.000027243366,0.0013275746,0.0005317769,0.00079004536,0.0008995399,0.0000042646716,0.0000071871136],"genre_scores_gemma":[0.9993329,0.00016519545,0.000068494344,0.000038679296,0.000047513324,0.000035002467,0.00029553473,0.000013167978,0.0000034904574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98863643,0.008335539,0.0023162311,0.0002739204,0.00022918786,0.00020867819],"domain_scores_gemma":[0.99280655,0.0024086107,0.0036153586,0.00045949742,0.0006593918,0.000050570263],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051961057,0.00023727168,0.0014578125,0.000379767,0.000055710247,0.0000049952296,0.00042677726,0.00023559172,0.00017453286],"category_scores_gemma":[0.010437092,0.000121397126,0.00014560261,0.00027547995,0.00068317953,0.000400047,0.000089895606,0.00022520732,0.0000076064507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040191907,0.002621063,0.78641015,0.00005409732,0.005036825,0.00005715747,0.004970166,0.00007827454,0.1293998,0.00016813497,0.0033681125,0.027644284],"study_design_scores_gemma":[0.06145489,0.0004798414,0.81898826,0.00047800253,0.001558542,0.0000143407215,0.0005962352,0.0000128526535,0.1147495,0.0013548201,0.00014688418,0.00016580192],"about_ca_topic_score_codex":0.00008514692,"about_ca_topic_score_gemma":0.00017142665,"teacher_disagreement_score":0.03257812,"about_ca_system_score_codex":0.0001379754,"about_ca_system_score_gemma":0.0010200168,"threshold_uncertainty_score":0.9978984},"labels":[],"label_agreement":null},{"id":"W2514982855","doi":"10.1111/jdv.14386","title":"European consensus statement on phenotypes of pustular psoriasis","year":2017,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":440,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute for Health and Care Research; European Academy of Dermatology and Venereology; Psoriasis Association","keywords":"Medicine; Psoriasis; Generalized pustular psoriasis; Dermatology; Phenotype; Pustular psoriasis; Clinical trial; Pathology; Genetics","score_opus":0.0838083635548977,"score_gpt":0.3311105540073089,"score_spread":0.2473021904524112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514982855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058995285,0.9864251,0.0000034971938,0.00069698127,0.0015293884,0.00026795702,0.0000916303,0.000009357643,0.00507658],"genre_scores_gemma":[0.06064686,0.9383237,0.0000617562,0.00008518727,0.00016440882,0.0000019541462,0.000013184759,0.00005827776,0.0006447153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899004,0.0074032797,0.0019320261,0.00031433936,0.000082282175,0.00036768086],"domain_scores_gemma":[0.993545,0.00064678286,0.005240044,0.0004337319,0.00008280909,0.000051617102],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013948358,0.000492426,0.0026406199,0.00037037747,0.00024329309,0.0000068791533,0.0012689251,0.0005141105,0.000047365185],"category_scores_gemma":[0.000297071,0.00029971066,0.00080964155,0.00009120658,0.0012173557,0.000037385707,0.0004009254,0.0010312455,0.000087996596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038972517,0.0003097522,0.0011718407,0.0025573268,0.005495633,0.0003453556,0.00023426377,0.000002984709,0.00019959365,0.0018227411,0.0081850635,0.9792857],"study_design_scores_gemma":[0.0018061019,0.00012922211,0.0015358891,0.002837736,0.0034915167,0.0074744085,0.000024951903,8.1886775e-8,0.00073328585,0.00016176801,0.981556,0.00024905748],"about_ca_topic_score_codex":0.0000024081824,"about_ca_topic_score_gemma":7.0855606e-7,"teacher_disagreement_score":0.9790367,"about_ca_system_score_codex":0.000029990157,"about_ca_system_score_gemma":0.00013395175,"threshold_uncertainty_score":0.9999455},"labels":[],"label_agreement":null},{"id":"W2515018033","doi":"10.1016/j.jid.2016.06.071","title":"054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Dalhousie University","funders":"","keywords":"Ixekizumab; Medicine; Quality of life (healthcare); Internal medicine; Secukinumab","score_opus":0.035331276846548215,"score_gpt":0.29814736614780357,"score_spread":0.26281608930125533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515018033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99046797,0.0029497514,0.00006978377,0.004199182,0.00046183015,0.001330327,0.00042922434,0.000016718099,0.00007519164],"genre_scores_gemma":[0.9986349,0.0003392127,0.00029169128,0.00018769392,0.00003782803,0.000067739915,0.000102829705,0.000020871556,0.000317254],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919477,0.004022477,0.0030970708,0.0003599261,0.00012468112,0.0004481592],"domain_scores_gemma":[0.99239266,0.0028265957,0.004049501,0.000300351,0.0002994923,0.0001313925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012373568,0.00039150703,0.002536191,0.00037174136,0.000089552836,0.0000087240105,0.00021533524,0.00034308413,0.000117225354],"category_scores_gemma":[0.0020758938,0.00020861429,0.00035513978,0.00024158812,0.0010143846,0.00023958425,0.000040419407,0.00021612617,0.000013205485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9152326,0.0016295327,0.0008839206,0.000035849826,0.0037503643,0.00017424356,0.0029713912,0.0000032582911,0.06619809,0.00043027327,0.0005461423,0.008144312],"study_design_scores_gemma":[0.8616348,0.0047039175,0.0013626372,0.00023752847,0.00025402423,0.00007632141,0.00056759093,0.0000030163292,0.1278019,0.0027257323,0.00042535542,0.00020717461],"about_ca_topic_score_codex":0.003112193,"about_ca_topic_score_gemma":0.00047500557,"teacher_disagreement_score":0.061603803,"about_ca_system_score_codex":0.0003603051,"about_ca_system_score_gemma":0.0015874067,"threshold_uncertainty_score":0.8507044},"labels":[],"label_agreement":null},{"id":"W2516241120","doi":"10.1016/j.jid.2016.06.069","title":"052 Efficacy of ixekizumab in moderate-to-severe psoriasis patients who have or have not received prior biologic therapies: An integrated analysis of 3 phase 3 studies","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Placebo; Psoriasis; Medicine; Psoriasis Area and Severity Index; Internal medicine; Plaque psoriasis; Immunology; Secukinumab; Pathology","score_opus":0.061782056428807845,"score_gpt":0.32351102972945084,"score_spread":0.261728973300643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2516241120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714154,0.0010809359,0.00010952311,0.0006681972,0.00025629287,0.00036599586,0.00034732124,0.00001138679,0.000018828638],"genre_scores_gemma":[0.9981012,0.0006024271,0.00080776407,0.00021655402,0.000015213638,0.000021732916,0.000062986095,0.000019380079,0.00015275239],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99568075,0.0017833043,0.0016447877,0.0003832356,0.00010499863,0.00040290467],"domain_scores_gemma":[0.995156,0.0014564461,0.0016737429,0.0003308684,0.0012869238,0.000096001255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004296136,0.00040777176,0.002193429,0.0014039521,0.00009647163,0.000006613196,0.0004282249,0.00040085427,0.00015888156],"category_scores_gemma":[0.0019980979,0.00022193868,0.00035249768,0.00077760435,0.0010185686,0.00024620828,0.00007739068,0.00024107653,0.000010210976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05245023,0.006014804,0.21030949,0.00012272198,0.04606989,0.00025385202,0.051440887,0.00036018013,0.5151817,0.00023379862,0.0015461302,0.11601628],"study_design_scores_gemma":[0.02532331,0.0040249997,0.15540385,0.00042451007,0.0020949026,0.00009395141,0.005887289,0.000037582748,0.8056031,0.00035321427,0.0003453427,0.0004079277],"about_ca_topic_score_codex":0.00005525205,"about_ca_topic_score_gemma":0.00032437965,"teacher_disagreement_score":0.2904214,"about_ca_system_score_codex":0.00015088251,"about_ca_system_score_gemma":0.00029544468,"threshold_uncertainty_score":0.9050397},"labels":[],"label_agreement":null},{"id":"W2517855722","doi":"10.1016/j.jid.2016.06.076","title":"059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Probity Medical Research","funders":"","keywords":"Mace; Medicine; Ixekizumab; Placebo; Internal medicine; Incidence (geometry); Population; Randomized controlled trial; Gastroenterology; Myocardial infarction; Secukinumab; Pathology","score_opus":0.044334275552986815,"score_gpt":0.31402827911991815,"score_spread":0.26969400356693135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517855722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973763,0.000100665675,0.0006009811,0.0007365417,0.00036077292,0.0003336116,0.00038707184,0.000012167139,0.00009189284],"genre_scores_gemma":[0.99788713,0.000045388402,0.0014242086,0.00025198233,0.00003227417,0.00001337668,0.00013873419,0.000019113724,0.00018778506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99170494,0.005199899,0.0022472157,0.00033414946,0.00016126432,0.00035252678],"domain_scores_gemma":[0.9932419,0.0020311077,0.0028859302,0.00025951842,0.0014526319,0.00012888941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002493876,0.00030584572,0.0024418447,0.00076180877,0.00007260718,0.000011081019,0.0002755758,0.00050995825,0.00026851607],"category_scores_gemma":[0.0034053945,0.00015981251,0.00029988636,0.0008355907,0.000291702,0.0003330669,0.000031672007,0.00035615984,0.000032286694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02615293,0.0008195201,0.9425988,0.000010865384,0.012560029,0.000041363124,0.0008523722,0.00021750477,0.0046914006,0.0001484041,0.0010169205,0.01088985],"study_design_scores_gemma":[0.02578702,0.0029352957,0.9128011,0.000250948,0.003910116,0.000054300785,0.00034856398,0.000025034786,0.052018,0.00013027314,0.0013743688,0.0003649772],"about_ca_topic_score_codex":0.00004517652,"about_ca_topic_score_gemma":0.00041347384,"teacher_disagreement_score":0.047326602,"about_ca_system_score_codex":0.00021339719,"about_ca_system_score_gemma":0.0005230381,"threshold_uncertainty_score":0.6516965},"labels":[],"label_agreement":null},{"id":"W2517978134","doi":"10.1016/j.jid.2016.06.073","title":"056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Internal medicine; Plaque psoriasis; Population; Dermatology; Psoriatic arthritis; Pathology; Tumor necrosis factor alpha; Secukinumab","score_opus":0.02718358470953032,"score_gpt":0.26547794785520884,"score_spread":0.23829436314567853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517978134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952532,0.00064847554,0.000039823688,0.0019471715,0.00051594386,0.00017139598,0.001107959,0.000012320523,0.00030367984],"genre_scores_gemma":[0.9989219,0.00021031687,0.00036839486,0.00023143964,0.000061357394,0.0000049642254,0.000052767373,0.000016837364,0.00013203507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997822,0.00066386064,0.0008447366,0.00027576825,0.00007878459,0.00031489038],"domain_scores_gemma":[0.9969658,0.0016321614,0.00080635794,0.0002496884,0.00020833315,0.00013762714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021003706,0.00030120698,0.00090313127,0.00030927363,0.000084272324,0.000007569023,0.00023370991,0.00030244322,0.00016786206],"category_scores_gemma":[0.0005644237,0.00017609198,0.00021542828,0.00014051856,0.0004832528,0.0001285745,0.00005870587,0.00021002225,0.000150856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02283141,0.00028412518,0.01766476,0.000015860032,0.003336869,0.00038451422,0.0057131494,0.000057811172,0.88726485,0.0003051843,0.05520049,0.0069409553],"study_design_scores_gemma":[0.015385127,0.0014050305,0.1501778,0.00033623338,0.00024261457,0.001683084,0.00042721434,0.0000013873351,0.82543004,0.0012575648,0.0033639374,0.00028994362],"about_ca_topic_score_codex":0.00029723393,"about_ca_topic_score_gemma":0.000086101565,"teacher_disagreement_score":0.13251305,"about_ca_system_score_codex":0.000115796276,"about_ca_system_score_gemma":0.00022406502,"threshold_uncertainty_score":0.71808225},"labels":[],"label_agreement":null},{"id":"W2517997451","doi":"10.2217/rme-2016-0037","title":"Tissue-Engineered Human Psoriatic Skin Supplemented with Cytokines as an<i>in Vitro</i>Model to Study Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"Regenerative Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Psoriasis; Transcriptome; Cytokine; Human skin; Tumor necrosis factor alpha; In vivo; Microarray; Immunology; In vitro; Medicine; Gene expression; Biology; Dermatology; Gene; Genetics","score_opus":0.024296127889692556,"score_gpt":0.29228825320162444,"score_spread":0.2679921253119319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517997451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924203,0.0005460664,0.0027471164,0.0020653226,0.00038937785,0.0013884635,0.00013200239,0.000099330704,0.00021199754],"genre_scores_gemma":[0.9932678,0.000039536375,0.00064221397,0.00017508763,0.00028001476,0.00046658667,0.00037814263,0.000053148942,0.0046974868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99758804,0.00047779037,0.00051838986,0.000723646,0.000143528,0.00054858427],"domain_scores_gemma":[0.99889,0.00015577875,0.00012826783,0.0005713982,0.00014618043,0.00010841754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042519416,0.00048677402,0.0007707181,0.00039178604,0.00021302002,0.000009510546,0.0002902167,0.00015320058,0.0008998183],"category_scores_gemma":[0.00008244211,0.00027063396,0.000043788048,0.0004202091,0.00013388175,0.00013723146,0.000055478366,0.00012693174,0.00016800476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013128105,0.0007652917,0.000907726,0.0000078128505,0.00050026405,0.0000697438,0.0052873176,0.000038339607,0.9687407,0.0007499066,0.0013391742,0.020280892],"study_design_scores_gemma":[0.018881882,0.005839692,0.0030933022,0.000116409676,0.00033687582,0.000035849895,0.0013595518,0.000009838633,0.96766156,0.00014203586,0.002084059,0.00043892124],"about_ca_topic_score_codex":0.00038353362,"about_ca_topic_score_gemma":0.0010460783,"teacher_disagreement_score":0.01984197,"about_ca_system_score_codex":0.00013611247,"about_ca_system_score_gemma":0.000067222696,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W2519503335","doi":"10.1111/jdv.13891","title":"The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials","year":2016,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":152,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Anxiety; Observational study; Psychological intervention; Internal medicine; MEDLINE; Systematic review; Psychiatry; Physical therapy; Dermatology","score_opus":0.13560397315939046,"score_gpt":0.39119430731098176,"score_spread":0.25559033415159127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519503335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061286907,0.99216276,0.0000012369372,0.00045418175,0.00039523418,0.0007757955,0.000056762245,0.0000017872246,0.000023562594],"genre_scores_gemma":[0.006133953,0.9936103,0.00002642012,0.00007198043,0.00003521873,0.000010242664,0.0000024757667,0.000014811116,0.00009458618],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9767868,0.018667929,0.0040614307,0.00020731453,0.00008750352,0.00018905569],"domain_scores_gemma":[0.9854501,0.006194512,0.007916573,0.0002261945,0.00018989672,0.000022708202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006828724,0.0002920345,0.004728923,0.00013112393,0.00007725232,0.0000015931646,0.0006152285,0.0003668201,0.000005743037],"category_scores_gemma":[0.0038200244,0.00011255909,0.00056934106,0.00014235606,0.0012531498,0.000054869473,0.00022391598,0.00051298883,0.0000021491733],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054108043,0.00020621868,0.10627116,0.78258514,0.008778446,0.0000074110226,0.0001008894,4.8465e-8,0.0000027278188,0.00095634826,0.00068557035,0.09986496],"study_design_scores_gemma":[0.005172409,0.00030433506,0.07059022,0.8606245,0.022158857,0.0019886987,0.00003553934,4.835987e-8,0.000028918403,0.00028709884,0.03851939,0.00028998964],"about_ca_topic_score_codex":2.0891554e-7,"about_ca_topic_score_gemma":4.1361423e-7,"teacher_disagreement_score":0.099574976,"about_ca_system_score_codex":0.000016504628,"about_ca_system_score_gemma":0.00012265582,"threshold_uncertainty_score":0.46172827},"labels":[],"label_agreement":null},{"id":"W2521243079","doi":"10.1016/j.jaad.2016.08.008","title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":304,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Ustekinumab; Plaque psoriasis; Secukinumab; Dermatology; Psoriasis; Dermatologic agents; Internal medicine; Disease; Adalimumab; Psoriatic arthritis","score_opus":0.01705439731695948,"score_gpt":0.26128476369118464,"score_spread":0.24423036637422516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521243079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419076,0.00010687408,0.000025156518,0.014751692,0.00024980382,0.00046763598,0.00015375036,0.000007701251,0.00004660456],"genre_scores_gemma":[0.9983274,0.000057182224,0.00027741698,0.0011076047,0.00004813489,0.00001217131,9.122551e-7,0.000027657463,0.00014156885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742,0.000813262,0.0009036311,0.00031421942,0.00014965724,0.00039918852],"domain_scores_gemma":[0.997896,0.0007725374,0.0008121682,0.00035541103,0.00009129644,0.00007254161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032363602,0.0002532202,0.000983082,0.0002811412,0.00009507737,0.000008779707,0.0009251197,0.00015676189,0.000045322147],"category_scores_gemma":[0.0002198097,0.00012630702,0.0001693755,0.0005725441,0.00024036579,0.00009238554,0.00025360024,0.0003718152,0.00006617867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15954158,0.0013118125,0.45741838,0.00003194103,0.005068438,0.00015834215,0.08158479,0.0005856543,0.21668123,0.00017872555,0.024160804,0.053278293],"study_design_scores_gemma":[0.01699684,0.0027217998,0.68805295,0.0004654895,0.00045916266,0.001235001,0.013478389,0.0000019628233,0.26988995,0.0001129879,0.006128179,0.0004572888],"about_ca_topic_score_codex":0.0005752944,"about_ca_topic_score_gemma":0.00022091645,"teacher_disagreement_score":0.23063454,"about_ca_system_score_codex":0.00008791998,"about_ca_system_score_gemma":0.0001320845,"threshold_uncertainty_score":0.5150651},"labels":[],"label_agreement":null},{"id":"W2525369337","doi":"","title":"Biomarker discovery in psoriasis using a multiparameter flow cytometry platform","year":2012,"lang":"en","type":"article","venue":"Research Portal (King's College London)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Psoriasis; Flow cytometry; Biomarker; Biomarker discovery; Computational biology; Medicine; Dermatology; Biology; Immunology; Proteomics; Genetics","score_opus":0.08771795181363022,"score_gpt":0.3464480772911941,"score_spread":0.25873012547756385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525369337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873933,0.0055058566,0.00007505033,0.000053691165,0.0014763302,0.000888965,0.00039114107,0.00007226743,0.0041433857],"genre_scores_gemma":[0.9944963,0.0002087054,0.0008469827,0.000044568817,0.00020102218,0.00016182491,0.00023488417,0.000066711305,0.003739013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957713,0.00061121985,0.00064241246,0.0006293402,0.0003228452,0.0020229064],"domain_scores_gemma":[0.99799204,0.00093027105,0.00014028001,0.0006403707,0.00014283627,0.00015419658],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023328539,0.0004219893,0.0006396449,0.0014552592,0.0004806596,0.000079159654,0.00044041374,0.00059907685,0.0010783067],"category_scores_gemma":[0.0004638682,0.00036639645,0.0002941701,0.0018976476,0.00037285383,0.001162278,0.000360016,0.0007033575,0.00067385007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045423056,0.0035548261,0.6678015,0.00021335873,0.0021793663,0.0011498001,0.0017655194,0.00003084667,0.25196606,0.0021379786,0.006753627,0.057904825],"study_design_scores_gemma":[0.031840123,0.0012344044,0.6444575,0.001000735,0.0006047748,0.0019081673,0.0066066524,0.0014352675,0.24506873,0.00079524535,0.061464716,0.0035836883],"about_ca_topic_score_codex":0.00076329533,"about_ca_topic_score_gemma":0.0003880908,"teacher_disagreement_score":0.05471109,"about_ca_system_score_codex":0.00028806404,"about_ca_system_score_gemma":0.00025227797,"threshold_uncertainty_score":0.9998788},"labels":[],"label_agreement":null},{"id":"W2527243486","doi":"10.1016/j.jaad.2016.07.040","title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Tofacitinib; Medicine; Dermatology Life Quality Index; Placebo; Psoriasis; Janus kinase inhibitor; Quality of life (healthcare); Randomized controlled trial; Internal medicine; Psoriasis Area and Severity Index; Clinical trial; Dermatology; Rheumatoid arthritis; Alternative medicine; Pathology; Nursing","score_opus":0.03777943338510351,"score_gpt":0.3214798812904353,"score_spread":0.2837004479053318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527243486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97634506,0.0008076908,0.00009304725,0.020861533,0.00027804173,0.00086582924,0.00073117315,0.000007637408,0.000009986752],"genre_scores_gemma":[0.9983004,0.00037397316,0.000369936,0.0008431141,0.000019899886,0.00001801367,0.000011912706,0.000014697698,0.00004807128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99159354,0.0043316945,0.0033388336,0.00027910777,0.00011572904,0.00034107614],"domain_scores_gemma":[0.9912571,0.0029517645,0.005358956,0.00019617769,0.00011362224,0.00012242296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023602925,0.0002614177,0.0037585015,0.00030998583,0.000068890484,0.0000048986103,0.00034964638,0.00021515359,0.000021278167],"category_scores_gemma":[0.0022316922,0.00013336871,0.00029480492,0.00028247767,0.00047854782,0.000111098074,0.000097086,0.0002706581,0.000004318574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90572965,0.00056923425,0.016571324,0.000028729572,0.0032088263,0.0000037953935,0.0032071779,0.000014939081,0.033778146,0.0001272149,0.0023367153,0.03442425],"study_design_scores_gemma":[0.8157367,0.0014336562,0.11724278,0.0004542029,0.0005585845,0.00012382443,0.000582427,0.0000018361466,0.062130634,0.0007449777,0.0005970522,0.00039330893],"about_ca_topic_score_codex":0.0006438681,"about_ca_topic_score_gemma":0.000027944081,"teacher_disagreement_score":0.10067146,"about_ca_system_score_codex":0.000051276136,"about_ca_system_score_gemma":0.00021543333,"threshold_uncertainty_score":0.5438618},"labels":[],"label_agreement":null},{"id":"W2527420241","doi":"10.1016/j.jdermsci.2016.09.019","title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","year":2016,"lang":"en","type":"article","venue":"Journal of Dermatological Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Medicine; MMP3; Interleukin 17; Dermatology; Immunology; Inflammation; Biology; Gene expression","score_opus":0.016033350295353258,"score_gpt":0.22798310207017186,"score_spread":0.21194975177481862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527420241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967107,0.0003066483,0.00024261525,0.001777892,0.0006004397,0.00011813236,0.00008062501,0.000008470595,0.00015446698],"genre_scores_gemma":[0.99923617,0.00021854434,0.000067764704,0.00024697217,0.000027836515,0.0000042323345,0.0000017177808,0.0000034587817,0.00019330673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987278,0.00019147333,0.0004564369,0.0001756117,0.0001662262,0.0002824241],"domain_scores_gemma":[0.99874586,0.00021885645,0.00062194624,0.0001993257,0.00017019635,0.000043843967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000425117,0.00013271315,0.00033099437,0.00008089119,0.00022440367,0.000014514022,0.0006353362,0.00015586529,0.00027908594],"category_scores_gemma":[0.00020667509,0.000054689503,0.00017684943,0.00032053975,0.0006041075,0.0003079904,0.00008884903,0.00012051369,0.000038277576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014320486,0.00012338682,0.019696552,0.000004338008,0.00005139389,0.000006009603,0.00009000688,6.0862234e-8,0.95627165,0.00012064024,0.00073931017,0.022753445],"study_design_scores_gemma":[0.00118072,0.000112937574,0.06336777,0.00005915956,0.000038873484,0.00041258894,0.000042956457,3.1326636e-7,0.9147241,0.0002248436,0.01975045,0.00008527598],"about_ca_topic_score_codex":0.0000026826995,"about_ca_topic_score_gemma":2.1802282e-7,"teacher_disagreement_score":0.043671217,"about_ca_system_score_codex":0.000049262904,"about_ca_system_score_gemma":0.000119199045,"threshold_uncertainty_score":0.30557954},"labels":[],"label_agreement":null},{"id":"W2529788651","doi":"10.1186/s12895-016-0051-4","title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","year":2016,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Innovaderm (Canada); Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Janus kinase inhibitor; Medicine; Plaque psoriasis; Dermatology; Janus kinase; Randomized controlled trial; Psoriasis; Pharmacology; Clinical trial; Internal medicine; Rheumatoid arthritis","score_opus":0.04656576236925047,"score_gpt":0.32017153205572424,"score_spread":0.27360576968647377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529788651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513113,0.0004791678,0.00083580724,0.00026773065,0.0011604864,0.0017545747,0.00016805252,0.000035716366,0.00016734848],"genre_scores_gemma":[0.9986967,0.00015800573,0.0003986858,0.000015738053,0.0000698441,0.00030092357,0.00009871875,0.000017934875,0.00024344883],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961405,0.0020577656,0.0010769041,0.000361069,0.00006297743,0.00030077633],"domain_scores_gemma":[0.99698156,0.0016267712,0.0006815186,0.00056954153,0.00009940395,0.000041181305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033788744,0.00028155505,0.0012488073,0.0001093971,0.00009811254,0.0000037277916,0.00017612996,0.0003739633,0.00018076542],"category_scores_gemma":[0.00019530165,0.00012829492,0.0004993901,0.00010779993,0.0005180755,0.00009454719,0.000035030844,0.000053250726,0.00003671794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.905959,0.0044191475,0.01218823,0.000025103462,0.0011888689,0.000018815294,0.0004155458,0.0000011174159,0.0116216,0.003066867,0.00009844446,0.060997233],"study_design_scores_gemma":[0.75324094,0.004363525,0.00067140633,0.00003593727,0.0007457648,0.00019618431,0.00006433647,0.000006259413,0.23819923,0.00023388301,0.0020915484,0.00015100163],"about_ca_topic_score_codex":0.000058741432,"about_ca_topic_score_gemma":0.00011577883,"teacher_disagreement_score":0.22657762,"about_ca_system_score_codex":0.00004867692,"about_ca_system_score_gemma":0.00024650787,"threshold_uncertainty_score":0.5231715},"labels":[],"label_agreement":null},{"id":"W2532238474","doi":"10.1111/jdv.14015","title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; Regeneron Pharmaceuticals; UCB Pharma; Medac; LEO Pharma; Eli Lilly and Company; Galderma; Biogen; Celgene; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Apremilast; Placebo; Etanercept; Psoriasis; Randomized controlled trial; Dermatology; Internal medicine; Physical therapy; Psoriatic arthritis; Alternative medicine; Tumor necrosis factor alpha; Pathology","score_opus":0.011074629238026117,"score_gpt":0.2306057609492769,"score_spread":0.21953113171125077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2532238474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919224,0.0024720882,0.00004085235,0.0036187244,0.00038337207,0.0011760666,0.00010516763,0.000006424469,0.0002749416],"genre_scores_gemma":[0.9980257,0.0014803972,0.000083302875,0.00012252817,0.00006470137,0.000013645563,0.000005859147,0.000020051706,0.0001837746],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929323,0.0049825474,0.0013854612,0.0003022863,0.00007636414,0.00032102477],"domain_scores_gemma":[0.99384755,0.0045660287,0.001266674,0.00017821343,0.00007539184,0.00006616465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014348526,0.00030200253,0.0014847021,0.00017379984,0.0002051702,0.00000825567,0.00033658135,0.00031398868,0.0000116629035],"category_scores_gemma":[0.0007264992,0.0001342993,0.00014432297,0.00009412207,0.0010304501,0.00010052127,0.00017107445,0.00041505077,0.000005853373],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98344284,0.0003282554,0.0043659913,0.000008450418,0.001270893,0.00001673885,0.0007953822,0.0000191878,0.0012717245,0.00019139546,0.00039971212,0.007889413],"study_design_scores_gemma":[0.98121214,0.00047773114,0.013419375,0.0002018147,0.0006571371,0.000451237,0.00007076313,0.0000069918274,0.0021184592,0.0003191012,0.0008971779,0.00016809824],"about_ca_topic_score_codex":0.000005933516,"about_ca_topic_score_gemma":0.0000104614965,"teacher_disagreement_score":0.009053383,"about_ca_system_score_codex":0.000016568081,"about_ca_system_score_gemma":0.00005878749,"threshold_uncertainty_score":0.54765666},"labels":[],"label_agreement":null},{"id":"W2533335864","doi":"10.2147/ptt.s87650","title":"Psoriasis in children","year":2016,"lang":"en","type":"review","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Psoriasis; Medicine; Disease; Modalities; Presentation (obstetrics); Population; Psoriatic arthritis; Epidemiology; Treatment modality; Arthritis; Juvenile rheumatoid arthritis; Quality of life (healthcare); Dermatology; Pediatrics; Intensive care medicine; Surgery; Pathology; Immunology; Environmental health","score_opus":0.02497253622087569,"score_gpt":0.27931054303526026,"score_spread":0.25433800681438457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533335864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00074770383,0.9952337,0.000003544613,0.000037676265,0.0016753653,0.0011358175,0.00038032277,0.000103859915,0.0006819661],"genre_scores_gemma":[0.00023041082,0.99660194,0.000040213672,0.000047214497,0.00041009588,0.00039411584,0.00048534645,0.00011125955,0.0016793993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996756,0.00062337884,0.0008063888,0.0009774012,0.000068823974,0.00076797843],"domain_scores_gemma":[0.9985714,0.00032832072,0.0003833469,0.00061476347,0.00003643514,0.000065721695],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041924074,0.00092809525,0.0023899071,0.00051231997,0.0002000896,0.000041690433,0.00043598516,0.0010793584,0.0011706457],"category_scores_gemma":[0.00003316976,0.00057793944,0.00062550657,0.0003033088,0.00016193534,0.00012197214,0.00009896871,0.0003542779,0.00092420453],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007225681,0.00019473607,0.0005769594,0.00019559407,0.0016898301,0.0000068638637,0.00008301357,7.3781568e-9,0.000009956479,0.0003157264,0.00071102293,0.99614406],"study_design_scores_gemma":[0.0035392025,0.00014984224,0.0008257714,0.0016223969,0.00039247397,0.00010519467,0.0000069559446,1.3640465e-8,0.0000711593,0.00028619138,0.9922888,0.00071196206],"about_ca_topic_score_codex":0.000088047535,"about_ca_topic_score_gemma":0.000008823895,"teacher_disagreement_score":0.9954321,"about_ca_system_score_codex":0.00008361264,"about_ca_system_score_gemma":0.000124536,"threshold_uncertainty_score":0.9998537},"labels":[],"label_agreement":null},{"id":"W2535226895","doi":"10.5070/d3229032495","title":"Psoriasis in Latin America","year":2016,"lang":"en","type":"article","venue":"Dermatology Online Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Latin Americans; Psoriasis; Medicine; Scientific literature; Medical literature; Alternative medicine; Family medicine; Dermatology; Pathology; Political science","score_opus":0.017627583636728967,"score_gpt":0.2564658855347983,"score_spread":0.23883830189806934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2535226895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795575,0.0025937723,0.00036474937,0.007029117,0.0013321834,0.00007868265,0.000061573846,0.000047126723,0.0005370189],"genre_scores_gemma":[0.99558413,0.0013819821,0.00085035193,0.00045042014,0.00012703972,0.000009219123,0.000042825613,0.00001920138,0.0015348294],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984572,0.00036867018,0.00046732408,0.00020703698,0.000033682674,0.00046608664],"domain_scores_gemma":[0.9992753,0.00024667825,0.00019696892,0.00018610054,0.000052840478,0.000042080694],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000104466075,0.0001902223,0.0004000813,0.0002960475,0.00013124323,0.0000080291575,0.00022682309,0.00027069967,0.0012166123],"category_scores_gemma":[0.00011647165,0.00011851224,0.00012798613,0.00017328795,0.00016531118,0.00011491568,0.000045678764,0.00026232877,0.0009036209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004439968,0.0007562499,0.31741443,0.0000074509844,0.00046796352,0.0008702571,0.00038444583,0.000001964303,0.071646415,0.0003273384,0.019998385,0.5876811],"study_design_scores_gemma":[0.01872767,0.00034667246,0.49983817,0.00020116515,0.00024205483,0.024415478,0.0005837348,0.000007553102,0.03923521,0.002168538,0.41346592,0.0007678313],"about_ca_topic_score_codex":0.000012204372,"about_ca_topic_score_gemma":0.000059548747,"teacher_disagreement_score":0.5869133,"about_ca_system_score_codex":0.00005571752,"about_ca_system_score_gemma":0.00008622099,"threshold_uncertainty_score":0.9998743},"labels":[],"label_agreement":null},{"id":"W2537338210","doi":"10.1177/1203475416676030","title":"Real-World Experience With Apremilast in Treating Psoriasis","year":2016,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; SKiN Health; University of Manitoba","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Discontinuation; Adverse effect; Dermatology; Nausea; Vomiting; Thalidomide; Clinical trial; Population; Intensive care medicine; Internal medicine; Psoriatic arthritis","score_opus":0.02348461962561104,"score_gpt":0.2573499011079546,"score_spread":0.23386528148234353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537338210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950796,0.0019782227,0.000025837171,0.00088230375,0.00046589843,0.000047452693,0.0000023071925,0.000010225077,0.001508173],"genre_scores_gemma":[0.99431,0.0036708803,0.00006104206,0.000086470944,0.0001753566,0.0000033214471,0.0000017060938,0.000011285527,0.0016799362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888736,0.0001307154,0.0005214887,0.00014549798,0.00007232427,0.00024260147],"domain_scores_gemma":[0.997818,0.0016247183,0.00031773056,0.000115865885,0.00007464886,0.000049068352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034757282,0.00015624907,0.0005678026,0.0003916851,0.0000613708,0.000004155094,0.000070888374,0.000078075034,0.00026901992],"category_scores_gemma":[0.00020255079,0.00007454617,0.00006552228,0.0001991576,0.00019613189,0.00009877501,0.00001126039,0.000100704856,0.000006556718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018987444,0.00011049092,0.61761504,0.000021375561,0.00024298907,0.0022951083,0.0027473145,9.210964e-7,0.076197855,0.00005184132,0.0036060568,0.29521227],"study_design_scores_gemma":[0.034262016,0.008493135,0.47165626,0.019349964,0.0021055469,0.111582465,0.019799123,0.000004573259,0.1565225,0.0009258845,0.17266016,0.0026383789],"about_ca_topic_score_codex":0.00011290505,"about_ca_topic_score_gemma":0.00016138637,"teacher_disagreement_score":0.2925739,"about_ca_system_score_codex":0.00004500074,"about_ca_system_score_gemma":0.00007393903,"threshold_uncertainty_score":0.30399048},"labels":[],"label_agreement":null},{"id":"W2546600532","doi":"10.1111/jdv.14033","title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Universidade Católica de Brasília; Regeneron Pharmaceuticals; Roche; American Society for Parenteral and Enteral Nutrition; Novartis; Merck; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Baxalta; Schering-Plough; AbbVie; Biogen Idec","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Internal medicine; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha; Pathology","score_opus":0.01729171059612685,"score_gpt":0.23998958720637256,"score_spread":0.2226978766102457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546600532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889425,0.006104585,0.00002116742,0.0030780453,0.0004103987,0.00082532456,0.00016701377,0.0000056705376,0.0004453058],"genre_scores_gemma":[0.99699813,0.0020038926,0.00014420578,0.00028738513,0.00005781074,0.000018809367,0.000006732343,0.000021531161,0.00046148378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99447215,0.0034963628,0.0012992125,0.00032189954,0.000080865364,0.0003295409],"domain_scores_gemma":[0.99359274,0.0043310863,0.0016755408,0.00023812475,0.00010961889,0.000052906827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009610186,0.00033970672,0.0019600266,0.00016640534,0.00016166587,0.000013511406,0.0006543212,0.0002613815,0.0000089923615],"category_scores_gemma":[0.0010765801,0.00013789092,0.00019054227,0.00012262752,0.000745652,0.00016666003,0.0002746683,0.00025104298,0.0000052358523],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6851841,0.0020298779,0.18817572,0.00003349352,0.010862717,0.0000732265,0.0042211,0.00003546114,0.012061325,0.0010096607,0.004704874,0.09160842],"study_design_scores_gemma":[0.8390345,0.0007301752,0.13210708,0.000404235,0.0018784294,0.0005305807,0.000217289,0.0000041579383,0.021065893,0.0012384648,0.0026074047,0.00018178727],"about_ca_topic_score_codex":0.000061102,"about_ca_topic_score_gemma":0.000023650078,"teacher_disagreement_score":0.15385038,"about_ca_system_score_codex":0.000033140946,"about_ca_system_score_gemma":0.0000854121,"threshold_uncertainty_score":0.5623029},"labels":[],"label_agreement":null},{"id":"W2549173379","doi":"10.1111/ajd.12548","title":"Survival rates of biological therapies for psoriasis treatment in real‐world clinical practice: A Canadian multicentre retrospective study","year":2016,"lang":"en","type":"article","venue":"Australasian Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Public Health Ontario; Hamilton Health Sciences; University of Toronto; Women's College Hospital; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Ustekinumab; Etanercept; Adalimumab; Infliximab; Internal medicine; Psoriasis; Log-rank test; Survival analysis; Retrospective cohort study; Hazard ratio; Clinical trial; Dermatology; Disease; Confidence interval","score_opus":0.06573943468448674,"score_gpt":0.3640017212925031,"score_spread":0.29826228660801635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549173379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933942,0.00066312467,0.000014931491,0.0034683621,0.0013574642,0.00068331603,0.00009726306,0.000009875401,0.00031145918],"genre_scores_gemma":[0.99820477,0.0008589779,0.00046443494,0.000024639547,0.000088831985,0.00003306836,0.000009999639,0.000016477039,0.00029880076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651456,0.0013703551,0.0012411318,0.00030272387,0.000052800522,0.0005184141],"domain_scores_gemma":[0.9968702,0.0016614663,0.0007995422,0.0002336051,0.000329838,0.00010530094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058919186,0.0002758294,0.0011094058,0.0004569877,0.0000887798,0.000008640033,0.00025877156,0.00034180176,0.00016471733],"category_scores_gemma":[0.0006582838,0.00016104679,0.00032309824,0.00021136779,0.000274719,0.0001683214,0.000018559847,0.00017919448,0.000024164552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021060486,0.0015076274,0.9753554,0.0000045532693,0.001902309,0.00044928383,0.0014318256,2.7705536e-7,0.0012654737,0.000518857,0.00031574088,0.01514261],"study_design_scores_gemma":[0.01602599,0.0033615923,0.96074224,0.000042949185,0.0004706298,0.0007465766,0.006096686,1.6954355e-7,0.004856907,0.00023058562,0.007225056,0.00020061867],"about_ca_topic_score_codex":0.0031190272,"about_ca_topic_score_gemma":0.056573402,"teacher_disagreement_score":0.053454377,"about_ca_system_score_codex":0.00024644437,"about_ca_system_score_gemma":0.0004810048,"threshold_uncertainty_score":0.9606417},"labels":[],"label_agreement":null},{"id":"W2549235269","doi":"10.1016/j.annder.2016.09.643","title":"Rapidité d’action de l’ixékizumab : analyse groupée de 2 essais randomisés de phase 3 (UNCOVER-2 et 3) chez des patients atteints de psoriasis","year":2016,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Gynecology","score_opus":0.05613577750840536,"score_gpt":0.33600756204139726,"score_spread":0.2798717845329919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549235269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95192945,0.016954292,0.02038929,0.006625641,0.0014517283,0.0007092456,0.00072826096,0.0004927923,0.00071929727],"genre_scores_gemma":[0.95116895,0.038604405,0.003795889,0.0033566505,0.0002242364,0.00041096765,0.00046347902,0.00012505015,0.0018503497],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9864359,0.0074968273,0.0011712506,0.0011967676,0.00018345611,0.0035158077],"domain_scores_gemma":[0.9932628,0.004127725,0.00079347636,0.0010148516,0.00033738694,0.000463719],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033326086,0.0011649127,0.0015671105,0.00056951615,0.0007137006,0.00014525115,0.0010888383,0.0025550888,0.00097239466],"category_scores_gemma":[0.004131808,0.0009999941,0.0010372278,0.00059886504,0.0013385246,0.0008014454,0.00035443789,0.0009293019,0.00066794426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009117479,0.0035352586,0.58466697,0.00036915208,0.0037320657,0.001701406,0.0035832988,0.00010753268,0.081699364,0.00051784347,0.028785191,0.28218442],"study_design_scores_gemma":[0.065029725,0.0019810323,0.32537624,0.0009103783,0.0042711548,0.0054601477,0.0020752398,0.00019917419,0.5362217,0.014085767,0.04189935,0.0024900814],"about_ca_topic_score_codex":0.0013724036,"about_ca_topic_score_gemma":0.0010629894,"teacher_disagreement_score":0.45452234,"about_ca_system_score_codex":0.0030306617,"about_ca_system_score_gemma":0.0025528693,"threshold_uncertainty_score":0.9999409},"labels":[],"label_agreement":null},{"id":"W2550215248","doi":"10.1189/jlb.5ru0816-341r","title":"A protective role of IL-37 in cancer: a new hope for cancer patients","year":2016,"lang":"en","type":"review","venue":"Journal of Leukocyte Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Biology; Proinflammatory cytokine; Signal transduction; Cytokine; Cell biology; Cancer research; PI3K/AKT/mTOR pathway; Transcription factor; Receptor; MAPK/ERK pathway; Immunology; Inflammation; Biochemistry; Gene","score_opus":0.03725153619378896,"score_gpt":0.3269268866244373,"score_spread":0.28967535043064835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550215248","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025956242,0.9936425,0.000021311907,0.00004876041,0.0016347526,0.001129349,0.000886174,0.000005813344,0.000035716428],"genre_scores_gemma":[0.0004576074,0.998186,0.00006198233,0.000016489928,0.00035987495,0.00030127386,0.000061417064,0.00003666741,0.0005186757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975402,0.000487521,0.0012071333,0.000308298,0.000034887686,0.00042198005],"domain_scores_gemma":[0.99693155,0.00033400446,0.0022358652,0.00018148335,0.0002710668,0.000046024885],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029588968,0.00041322483,0.0025156452,0.00040683133,0.000045337183,0.000003694053,0.00042418318,0.00091181666,0.0001921717],"category_scores_gemma":[0.0001376406,0.0002459518,0.0007703636,0.00018575981,0.00012062536,0.00006459182,0.00006702462,0.0003397654,0.000022020768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007040972,0.00018016726,0.00055259786,0.0006256215,0.0016332468,0.000002534657,0.000109709115,1.7958403e-7,0.0009687745,0.000041767293,0.00068233843,0.99449897],"study_design_scores_gemma":[0.0037590198,0.0014518199,0.00022271696,0.0060028676,0.00094835367,0.000034604167,0.0000120282,3.2868083e-8,0.0014917307,0.00031307345,0.9855122,0.00025156615],"about_ca_topic_score_codex":0.00043826655,"about_ca_topic_score_gemma":0.00027647382,"teacher_disagreement_score":0.9942474,"about_ca_system_score_codex":0.00051208644,"about_ca_system_score_gemma":0.0017655427,"threshold_uncertainty_score":0.9999993},"labels":[],"label_agreement":null},{"id":"W2550484150","doi":"10.1136/annrheumdis-2016-eular.3590","title":"FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Internal medicine; Placebo; Physical therapy; Gastroenterology; Dermatology; Pathology","score_opus":0.029809757481912204,"score_gpt":0.2868373016328367,"score_spread":0.2570275441509245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550484150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327105,0.0041789026,0.0000076101032,0.0006115324,0.00014336374,0.00071771274,0.0010180683,0.000032076317,0.00001966468],"genre_scores_gemma":[0.9983347,0.0011711012,0.000027346226,0.000039225793,0.000008003361,0.000049366026,0.00021619379,0.000025901505,0.0001281396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976026,0.00064714934,0.0008303953,0.00036103968,0.00013368553,0.00042513083],"domain_scores_gemma":[0.9979496,0.0002973827,0.0008674898,0.00067208975,0.00012498719,0.00008844638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020994361,0.0003317763,0.00092901604,0.00012575825,0.00012154169,0.000007730862,0.0003105068,0.00011837582,0.00011494203],"category_scores_gemma":[0.00007542924,0.00015453623,0.00018999664,0.00021672843,0.0003485871,0.0002016809,0.00005241458,0.00005303703,0.000017499511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043627624,0.004154448,0.8029842,0.00023040248,0.0023832268,0.0000012019982,0.00061615865,0.000024782727,0.0014837292,0.00028372608,0.00013682827,0.18333855],"study_design_scores_gemma":[0.008901869,0.0031783688,0.9816871,0.0007290701,0.00015263013,0.0000013979198,0.000076643286,0.0000024763008,0.004851692,0.00016341275,0.00003659553,0.00021868618],"about_ca_topic_score_codex":0.0021073145,"about_ca_topic_score_gemma":0.0004191987,"teacher_disagreement_score":0.18311988,"about_ca_system_score_codex":0.00007747592,"about_ca_system_score_gemma":0.00051618525,"threshold_uncertainty_score":0.6301804},"labels":[],"label_agreement":null},{"id":"W2550522317","doi":"10.1016/j.annder.2016.09.229","title":"Ixekizumab chez des patients atteints de psoriasis préalablement traités ou non par des biologiques : analyse intégrée de 2 études de phase 3","year":2016,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Gynecology; Medicine; Psoriasis; Secukinumab; Psoriatic arthritis; Immunology","score_opus":0.05436515554745304,"score_gpt":0.33005250274485615,"score_spread":0.2756873471974031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550522317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651197,0.020121142,0.006609653,0.004624843,0.00071854645,0.00079131266,0.0009126639,0.0005275465,0.000574563],"genre_scores_gemma":[0.94654465,0.037813887,0.011508763,0.0019417534,0.00016346868,0.00052541634,0.00038744137,0.00011039815,0.0010042388],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9883453,0.0048163817,0.0013380814,0.0013184007,0.0001555069,0.0040263],"domain_scores_gemma":[0.9951065,0.002318614,0.0006969495,0.0009799672,0.0004274446,0.000470513],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026278107,0.0012979413,0.0015134703,0.0005549465,0.0008092218,0.00013497706,0.0014083063,0.00223875,0.0006611678],"category_scores_gemma":[0.0029248288,0.001030077,0.00081194186,0.0005806706,0.0026846717,0.00060195755,0.0005119583,0.00076309795,0.00047778827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015839037,0.0029548842,0.5317533,0.00031197316,0.0027946425,0.00092910766,0.0034193336,0.000025587682,0.053865094,0.00036317986,0.007968242,0.39403078],"study_design_scores_gemma":[0.009409603,0.0027619493,0.4696783,0.00086200907,0.0020280587,0.0013414251,0.0015411314,0.000045312798,0.486181,0.008387432,0.016232839,0.0015309457],"about_ca_topic_score_codex":0.000898675,"about_ca_topic_score_gemma":0.001277873,"teacher_disagreement_score":0.4323159,"about_ca_system_score_codex":0.0025513754,"about_ca_system_score_gemma":0.0023074434,"threshold_uncertainty_score":0.99997723},"labels":[],"label_agreement":null},{"id":"W2551258084","doi":"10.1136/annrheumdis-2016-eular.4351","title":"FRI0456 Association between Improvement in Enthesopathy and Quality of Life: Results from Anti-Tnf-Naïve Patients with Psoriatic Arthritis in Two Phase 3 Ustekinumab Trials","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Enthesopathy; Medicine; Ustekinumab; Psoriatic arthritis; Internal medicine; Physical therapy; Quality of life (healthcare); Randomization; Post-hoc analysis; Arthritis; Randomized controlled trial; Disease","score_opus":0.052288334874194244,"score_gpt":0.3170246519870126,"score_spread":0.2647363171128183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551258084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99064493,0.0025172902,0.0000053163517,0.00029836094,0.0001672751,0.00065376627,0.0056896294,0.000009600567,0.000013832342],"genre_scores_gemma":[0.99875045,0.00092261,0.000012454254,0.00002677221,0.000014658705,0.00004179786,0.00019145828,0.00001024058,0.000029537408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967017,0.0013016823,0.0013481897,0.0002638344,0.00013970351,0.0002448532],"domain_scores_gemma":[0.99506986,0.00299832,0.0014416532,0.00035135896,0.00010173167,0.000037058253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013305157,0.0001915864,0.0010223257,0.00011198657,0.000043884407,0.000008646972,0.0001750261,0.00008808257,0.00005196884],"category_scores_gemma":[0.0041343444,0.00010684134,0.00014867891,0.00014309718,0.000090329915,0.0001307396,0.00006722653,0.000050019295,0.000006642341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018962821,0.0011973012,0.67446965,0.00005032538,0.00082151685,3.2433215e-7,0.0005736514,0.0000016083811,0.0008400276,0.000027178985,0.00009661642,0.3200255],"study_design_scores_gemma":[0.032038826,0.00029793664,0.9533198,0.0010777191,0.00021106438,3.1609062e-8,0.000120547375,6.7624205e-7,0.011908885,0.0008733004,0.000011838731,0.00013936368],"about_ca_topic_score_codex":0.0014066054,"about_ca_topic_score_gemma":0.00029187772,"teacher_disagreement_score":0.31988612,"about_ca_system_score_codex":0.000040547733,"about_ca_system_score_gemma":0.000081862054,"threshold_uncertainty_score":0.4949495},"labels":[],"label_agreement":null},{"id":"W2551958233","doi":"10.1016/j.jaad.2016.09.026","title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Etanercept; Psoriasis; Adverse effect; Clinical trial; Incidence (geometry); Internal medicine; Psoriatic arthritis; Dermatology","score_opus":0.11210315936177297,"score_gpt":0.3928063394197767,"score_spread":0.28070318005800377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551958233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843718,0.004011556,0.00023112744,0.010682309,0.00026236125,0.0001698348,0.00025541743,0.0000075657967,0.000008040933],"genre_scores_gemma":[0.9953821,0.003773806,0.00039699234,0.0003530857,0.000034829736,0.0000022550685,0.000013723783,0.0000128877755,0.000030337931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943784,0.0032953797,0.0017179389,0.00028944048,0.000067146124,0.00025171498],"domain_scores_gemma":[0.99381924,0.0039972397,0.0017875484,0.0003025795,0.000037137077,0.000056264988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013515315,0.0002316737,0.0022035954,0.0001655193,0.0000640787,0.000007298832,0.0006693277,0.0002508809,0.000042846095],"category_scores_gemma":[0.00078963314,0.0001026817,0.00016674347,0.00015515494,0.0014349706,0.00015336601,0.00025077138,0.00049534906,0.0000044012986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002760742,0.00013068282,0.8699359,0.000005040214,0.0013559826,0.000024016763,0.0000743901,1.8448796e-7,0.0030455352,0.000028565877,0.0010530174,0.12158593],"study_design_scores_gemma":[0.0050617335,0.00018163373,0.9883423,0.00015412776,0.0007597252,0.0015648816,0.00020985349,0.0000013843102,0.0015992053,0.000050962575,0.001940964,0.00013326418],"about_ca_topic_score_codex":0.000035003326,"about_ca_topic_score_gemma":0.00006193023,"teacher_disagreement_score":0.12145267,"about_ca_system_score_codex":0.000024012663,"about_ca_system_score_gemma":0.00009190587,"threshold_uncertainty_score":0.5287209},"labels":[],"label_agreement":null},{"id":"W2552719386","doi":"10.1136/annrheumdis-2016-eular.1843","title":"THU0424 Treatment with Tnf Alpha Blockers Is Associated with Reduced Progression of Atherosclerotic Plaques in Patients with Psoriatic Disease – A Prospective Study","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Waterloo; Women's College Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Psoriasis; Disease; Statin; Gastroenterology; Immunology","score_opus":0.019642548451263387,"score_gpt":0.2591230787110639,"score_spread":0.23948053025980048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552719386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963318,0.0007184202,0.0000011231238,0.00019956607,0.000051349984,0.0022908675,0.0003606695,0.000032275453,0.000013937814],"genre_scores_gemma":[0.99925303,0.00007428808,0.0000133897,0.000014189066,0.0000030348,0.0003728234,0.00003261214,0.000029422248,0.00020718553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984051,0.00037701824,0.00036622002,0.00034763658,0.00018968985,0.00031431593],"domain_scores_gemma":[0.9984526,0.00023921742,0.0005478708,0.00050890836,0.00019111352,0.000060287155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098087956,0.0003279115,0.0005922734,0.000100521705,0.0001061387,0.00000884654,0.00021764796,0.00005438046,0.000064769556],"category_scores_gemma":[0.00010974721,0.00012874977,0.00011238309,0.000278452,0.0002851674,0.00012171194,0.00004244169,0.00003735707,0.0000059623308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006796315,0.009877879,0.95310175,0.00005121186,0.0030032052,0.0000040132145,0.0019524716,0.0000029927735,0.00006693169,0.000012864352,0.000071040246,0.025059314],"study_design_scores_gemma":[0.011932523,0.0066379616,0.9715414,0.0029590416,0.0010382503,4.3113178e-7,0.00037089715,0.0000011217098,0.005187745,0.00012859383,0.0000018226016,0.00020021266],"about_ca_topic_score_codex":0.00006790618,"about_ca_topic_score_gemma":0.0000630156,"teacher_disagreement_score":0.0248591,"about_ca_system_score_codex":0.00007094612,"about_ca_system_score_gemma":0.00018044861,"threshold_uncertainty_score":0.5250263},"labels":[],"label_agreement":null},{"id":"W2553126827","doi":"10.1136/annrheumdis-2016-eular.3192","title":"FRI0471 Certolizumab Pegol for The Treatment of Psoriatic Arthritis: 4-Year Outcomes from The Rapid-Psa Trial","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Certolizumab pegol; Psoriatic arthritis; Adverse effect; Internal medicine; Randomized controlled trial; Placebo; Psoriasis; Surgery; Adalimumab; Arthritis; Rheumatoid arthritis; Dermatology","score_opus":0.05568773566595063,"score_gpt":0.2893052181650443,"score_spread":0.23361748249909364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553126827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393223,0.042896148,0.000043361055,0.010776927,0.0019224307,0.0020583617,0.0028758529,0.0000338493,0.00007076687],"genre_scores_gemma":[0.98846143,0.010287888,0.000014146662,0.0000657486,0.00007231873,0.0004217891,0.000039892013,0.000018610417,0.00061816507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851644,0.00038139807,0.00052011525,0.00020864171,0.000091579415,0.0002818202],"domain_scores_gemma":[0.9939299,0.0046989033,0.00041032681,0.0008536729,0.000081505386,0.000025672545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009439777,0.00024353302,0.0005717279,0.000029669252,0.00026129687,0.000013328695,0.00052561675,0.00008956763,0.0007112885],"category_scores_gemma":[0.00052880676,0.00008334087,0.0008033168,0.00007676319,0.00030948198,0.000059152208,0.000048133224,0.00002541326,0.000064244516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009924635,0.001542923,0.0036172923,0.000030407386,0.0052860174,0.0000010751108,0.0011681438,0.000001431401,0.00025830616,0.00095125457,0.009627372,0.96759117],"study_design_scores_gemma":[0.3052925,0.007979904,0.5079547,0.0026025728,0.010785606,0.000023054397,0.004212759,0.00001760098,0.08164433,0.034603562,0.043562457,0.0013209522],"about_ca_topic_score_codex":0.00020075976,"about_ca_topic_score_gemma":0.000040759154,"teacher_disagreement_score":0.9662702,"about_ca_system_score_codex":0.000015740981,"about_ca_system_score_gemma":0.000092187394,"threshold_uncertainty_score":0.778811},"labels":[],"label_agreement":null},{"id":"W2553129727","doi":"10.1136/annrheumdis-2016-eular.1807","title":"THU0434 Serious Infections in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Etanercept; Ustekinumab; Adalimumab; Psoriatic arthritis; Psoriasis; Infliximab; Internal medicine; Hazard ratio; Observational study; Rheumatoid arthritis; Dermatology; Disease; Confidence interval","score_opus":0.02156932866329865,"score_gpt":0.2789648345852418,"score_spread":0.25739550592194316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2553129727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961149,0.0016976494,0.000008093249,0.000715995,0.00031492286,0.00091808976,0.00012930216,0.000018088405,0.000082933795],"genre_scores_gemma":[0.9985518,0.001030917,0.000012114982,0.000045408848,0.000012375042,0.00025793217,0.0000152099865,0.000013983313,0.000060284474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980629,0.0007224176,0.00047027558,0.00030062726,0.00013718031,0.0003065832],"domain_scores_gemma":[0.99836516,0.0006463334,0.00028283862,0.0006019593,0.00007570168,0.000028016673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037192294,0.0002388808,0.0004354135,0.00013540148,0.00017958887,0.00002646246,0.00031880036,0.00007492776,0.000081774335],"category_scores_gemma":[0.00024201865,0.000110768975,0.000107223845,0.00033524327,0.00020636688,0.00016542242,0.00009233801,0.00009694322,0.00001126876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017914419,0.002565772,0.85404795,0.000031639367,0.00038328493,0.0000042938946,0.0006583417,0.0000041466383,0.0000063519346,0.00018137606,0.0003193183,0.14161839],"study_design_scores_gemma":[0.005221175,0.0005930659,0.9915327,0.0005284519,0.00020552102,0.00000835098,0.00085315725,6.135674e-7,0.000059044272,0.00078931166,0.00005533306,0.00015330885],"about_ca_topic_score_codex":0.00033870045,"about_ca_topic_score_gemma":0.00088584394,"teacher_disagreement_score":0.14146508,"about_ca_system_score_codex":0.000030846277,"about_ca_system_score_gemma":0.00009014058,"threshold_uncertainty_score":0.45170277},"labels":[],"label_agreement":null},{"id":"W2555297192","doi":"10.1136/annrheumdis-2016-eular.1398","title":"THU0430 Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Ixekizumab; Adalimumab; Quality of life (healthcare); Enthesitis; BASDAI; Internal medicine; Dermatology Life Quality Index; Ankylosing spondylitis; Placebo; Psoriasis; Presenteeism; Physical therapy; Arthritis; Rheumatoid arthritis; Immunology; Disease; Absenteeism; Secukinumab; Alternative medicine","score_opus":0.02890524886302692,"score_gpt":0.2673986003624654,"score_spread":0.23849335149943846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555297192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425256,0.0036422778,0.000014892648,0.00040481726,0.00018683852,0.0011159673,0.00035044653,0.000021859181,0.000010315579],"genre_scores_gemma":[0.99904233,0.0006366795,0.000014914821,0.000035410583,0.000009546486,0.00017433689,0.000038328635,0.000016210548,0.000032250784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976548,0.0007866846,0.00062458107,0.00043920657,0.00013752248,0.0003572205],"domain_scores_gemma":[0.9979727,0.00069783995,0.0006620591,0.00048109947,0.00013726215,0.00004900682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025745848,0.00030057193,0.0007703549,0.000105109815,0.00010575843,0.000010202288,0.00022559019,0.00006808328,0.000022661627],"category_scores_gemma":[0.001087105,0.00016075533,0.00015278289,0.0003427098,0.00048554846,0.00037526464,0.00013533038,0.000085442254,0.000007679619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036175568,0.0025214558,0.68481576,0.00045086636,0.00056169817,5.027114e-7,0.0011437641,0.000007737255,0.00016367229,0.00021078956,0.00006376277,0.3064424],"study_design_scores_gemma":[0.004585413,0.00024815457,0.98402363,0.0017214922,0.00011111575,1.6858674e-7,0.00028670067,0.0000015026569,0.0011360499,0.0076687317,0.000003819728,0.00021319823],"about_ca_topic_score_codex":0.00023026881,"about_ca_topic_score_gemma":0.000066068205,"teacher_disagreement_score":0.30622923,"about_ca_system_score_codex":0.00003180719,"about_ca_system_score_gemma":0.00013336101,"threshold_uncertainty_score":0.65554124},"labels":[],"label_agreement":null},{"id":"W2555859840","doi":"10.1136/annrheumdis-2016-eular.3342","title":"FRI0445 Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Internal medicine; Secukinumab; Placebo; Ustekinumab; Arthritis; Clinical endpoint; Gastroenterology; Dermatology; Randomized controlled trial; Rheumatoid arthritis; Adalimumab; Pathology","score_opus":0.022646265567451532,"score_gpt":0.24113012263039724,"score_spread":0.2184838570629457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555859840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97542584,0.022514027,0.000016228898,0.0005661208,0.00028608443,0.00062947307,0.0004447107,0.000028641798,0.00008886915],"genre_scores_gemma":[0.99040246,0.009019685,0.000022292092,0.000016877246,0.000018453016,0.00016567472,0.000023411152,0.000021759843,0.00030937864],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984176,0.00029655086,0.00055296754,0.00028173404,0.0000912638,0.00035987198],"domain_scores_gemma":[0.9984546,0.00038332402,0.0004144097,0.000607423,0.00010047215,0.00003978596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001221309,0.00028399547,0.0006494159,0.000123479,0.000074655974,0.0000057294656,0.00030377513,0.000113207054,0.00023314239],"category_scores_gemma":[0.00016852334,0.00013741197,0.00026987167,0.000188178,0.0002589763,0.00011069428,0.000047987996,0.00003852311,0.00003763918],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002218234,0.0010624289,0.008397027,0.00018886964,0.0014389112,0.000003538124,0.00071392825,0.0000098298315,0.0024987042,0.0002833725,0.00037322505,0.9828119],"study_design_scores_gemma":[0.046589456,0.006137694,0.4593401,0.01622199,0.0013348212,0.000050277187,0.0006730481,0.000021539568,0.46415672,0.002977493,0.0014499035,0.0010469619],"about_ca_topic_score_codex":0.00064080366,"about_ca_topic_score_gemma":0.000957167,"teacher_disagreement_score":0.981765,"about_ca_system_score_codex":0.000066359535,"about_ca_system_score_gemma":0.00025693112,"threshold_uncertainty_score":0.56034976},"labels":[],"label_agreement":null},{"id":"W2556512023","doi":"10.1161/circresaha.116.309637","title":"GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis","year":2016,"lang":"en","type":"article","venue":"Circulation Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health","keywords":"Psoriasis; Medicine; Coronary artery disease; Internal medicine; Cardiology; Subclinical infection; Biomarker; Disease; Population; Fluorodeoxyglucose; Positron emission tomography; Gastroenterology; Radiology; Immunology","score_opus":0.10232313037970012,"score_gpt":0.34051221045516133,"score_spread":0.23818908007546122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556512023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959301,0.002647714,0.00030659704,0.0005244722,0.00011002768,0.00029638698,0.000044083194,0.000013115189,0.00012751619],"genre_scores_gemma":[0.99932575,0.00033112653,0.00002061597,0.000004020141,0.000028368393,0.000047550646,0.00003113098,0.000009086745,0.00020235112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986434,0.0003948839,0.000292784,0.00030224712,0.00013095257,0.0002357128],"domain_scores_gemma":[0.9989238,0.0004728085,0.000045251894,0.0003522832,0.00016689912,0.000039004728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013037551,0.00008776074,0.00020738954,0.0003082512,0.00007707067,0.00000873314,0.000089476576,0.00016638993,0.00019697456],"category_scores_gemma":[0.00045777144,0.00006441999,0.00012596029,0.00030395814,0.00022298224,0.000117216456,0.00005822379,0.000076530865,0.00009844294],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060984126,0.0001392718,0.51554793,0.000044929042,0.00053112785,0.000005500084,0.0002878958,0.000018435661,0.2590427,0.0006138703,0.00009646483,0.22306204],"study_design_scores_gemma":[0.00324717,0.000030344603,0.9863657,0.00006437153,0.000059898124,0.000002427142,0.000027732513,0.00008082372,0.0076303063,0.0004645519,0.0019379505,0.000088745095],"about_ca_topic_score_codex":0.00016979506,"about_ca_topic_score_gemma":0.000015665059,"teacher_disagreement_score":0.47081777,"about_ca_system_score_codex":0.00004828158,"about_ca_system_score_gemma":0.00007748139,"threshold_uncertainty_score":0.26269707},"labels":[],"label_agreement":null},{"id":"W2559903720","doi":"10.1155/2016/2148129","title":"How Does Interleukin-22 Mediate Liver Regeneration and Prevent Injury and Fibrosis?","year":2016,"lang":"en","type":"review","venue":"Journal of Immunology Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centennial College","funders":"University of the Punjab","keywords":"Interleukin 22; Cytokine; Immune system; Immunology; Fibrosis; Interleukin; Regeneration (biology); Inflammation; Interleukin 15; Liver regeneration; Biology; Cancer research; Cell biology; Medicine; Pathology","score_opus":0.054457588978595095,"score_gpt":0.34841177574123006,"score_spread":0.29395418676263496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559903720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074573755,0.9903489,0.0000074375102,0.00046634805,0.0011591044,0.00042525065,0.00008607938,0.00001013788,0.000039393773],"genre_scores_gemma":[0.000979152,0.99105847,0.000061231505,0.000006399078,0.00028975907,0.00005036425,0.00003913112,0.000037596335,0.007477897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954671,0.0027475597,0.0007303846,0.00039149393,0.00012145348,0.00054199103],"domain_scores_gemma":[0.9974272,0.0010782604,0.00071071857,0.00035228507,0.00037397927,0.00005750304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018908979,0.00038705973,0.001531016,0.0009557212,0.00028626155,0.00009254385,0.00043541408,0.0010220598,0.00017818618],"category_scores_gemma":[0.00039748606,0.00020221215,0.00030150154,0.00018691971,0.000807963,0.0002571188,0.000395545,0.001180002,0.00007735592],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027022482,0.00009171342,0.000021918962,0.00082061917,0.001948877,0.000059214308,0.00014009095,1.4963616e-9,0.0066138105,0.00012251288,0.0020333629,0.98787767],"study_design_scores_gemma":[0.0010225547,0.0014116163,0.000120150406,0.0055708713,0.0005791813,0.0016086971,0.00009070141,3.6642398e-8,0.0034270945,0.00022513726,0.9856967,0.00024728515],"about_ca_topic_score_codex":0.000007940328,"about_ca_topic_score_gemma":0.000008896525,"teacher_disagreement_score":0.98763037,"about_ca_system_score_codex":0.00017200565,"about_ca_system_score_gemma":0.00036302226,"threshold_uncertainty_score":0.82459724},"labels":[],"label_agreement":null},{"id":"W2560046656","doi":"10.1016/j.jdcr.2016.05.006","title":"Successful use of secukinumab in pustular psoriasis","year":2016,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Secukinumab; Psoriasis; Dermatology; Plaque psoriasis; Pustular psoriasis; Psoriatic arthritis; Generalized pustular psoriasis","score_opus":0.02240238538059764,"score_gpt":0.24337317832166197,"score_spread":0.22097079294106434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560046656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971979,0.0010919205,0.000041452804,0.000078366545,0.0009153439,0.00020783869,0.000040417082,0.00004352056,0.00038318432],"genre_scores_gemma":[0.9975192,0.00013311816,0.00008796992,0.000017676133,0.000031460015,0.000038187416,0.000026710843,0.000017701597,0.0021279524],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985593,0.00016678266,0.00055906083,0.00036401761,0.00004574232,0.00030507753],"domain_scores_gemma":[0.99884194,0.00021603412,0.0002949268,0.00054660294,0.00007317176,0.000027342763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028617762,0.00018379472,0.00036976355,0.00018314805,0.00005458265,0.000007476543,0.000045693196,0.00025688298,0.0005641557],"category_scores_gemma":[0.00019732681,0.00012341196,0.00013967787,0.00018285833,0.00009411288,0.00018276449,0.00005565846,0.000067420115,0.00006558836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044545322,0.0007046855,0.42167094,0.000052034942,0.0006656079,0.19247639,0.00059861614,0.0000040459263,0.18984881,0.000426146,0.0024518287,0.19065544],"study_design_scores_gemma":[0.0045897774,0.00031378405,0.06312018,0.00021547535,0.00039585348,0.15137444,0.00025412755,6.1644585e-7,0.6956292,0.000786741,0.082664,0.00065584766],"about_ca_topic_score_codex":0.00089829735,"about_ca_topic_score_gemma":0.00030965838,"teacher_disagreement_score":0.50578034,"about_ca_system_score_codex":0.0000643501,"about_ca_system_score_gemma":0.000067992565,"threshold_uncertainty_score":0.61771095},"labels":[],"label_agreement":null},{"id":"W2562079198","doi":"10.1016/j.jaad.2016.10.027","title":"Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Ixekizumab; Psoriasis; Inflammatory bowel disease; Incidence (geometry); Internal medicine; Ulcerative colitis; Randomized controlled trial; Crohn's disease; Maintenance therapy; Adverse effect; Clinical trial; Disease; Immunology; Psoriatic arthritis; Chemotherapy","score_opus":0.017057090672657114,"score_gpt":0.27503765125479906,"score_spread":0.25798056058214197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562079198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948843,0.0015566521,0.00022667626,0.00074884703,0.000078158715,0.001254981,0.001234565,0.000009894084,0.0000059079757],"genre_scores_gemma":[0.99883354,0.0006398214,0.00021246486,0.000044442768,0.000018115677,0.000034562785,0.00017579473,0.000020448751,0.00002081364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992313,0.005018535,0.0019990872,0.00027658013,0.00017398241,0.00021879587],"domain_scores_gemma":[0.98797435,0.003404333,0.0077926503,0.00043384713,0.00030778002,0.00008702401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010270744,0.00029901843,0.0038401461,0.00032261762,0.00005809157,0.00000515776,0.00064531295,0.00013960058,0.00005309556],"category_scores_gemma":[0.0018185413,0.00012212369,0.00030109895,0.00023090586,0.0020875805,0.00036781238,0.00010563445,0.00019342723,9.307176e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6038773,0.00042658823,0.36548728,0.000023316548,0.008075932,0.0000091609245,0.00011704162,0.0000061159167,0.018978687,0.00002165409,0.00022119598,0.0027557628],"study_design_scores_gemma":[0.54860944,0.00049601105,0.41598046,0.00048160463,0.008491911,0.00004516993,0.00020607149,0.000050181152,0.025341708,0.00007531683,0.000033029268,0.00018909037],"about_ca_topic_score_codex":0.00023329291,"about_ca_topic_score_gemma":0.000020110629,"teacher_disagreement_score":0.05526784,"about_ca_system_score_codex":0.000022067896,"about_ca_system_score_gemma":0.00022096094,"threshold_uncertainty_score":0.76917773},"labels":[],"label_agreement":null},{"id":"W2564763984","doi":"10.1016/s0140-6736(16)32574-0","title":"Should methotrexate remain the first-line drug for psoriasis?","year":2016,"lang":"en","type":"letter","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriasis; Methotrexate; Medicine; Psoriasis Area and Severity Index; Dosing; Rheumatoid arthritis; Ulcerative colitis; Dermatology; Pharmacology; Internal medicine; Disease","score_opus":0.06348790335908427,"score_gpt":0.2908936920050368,"score_spread":0.2274057886459525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564763984","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006427949,0.007686117,0.00020011682,0.98165244,0.004098845,0.001058495,0.0017295768,0.00015385958,0.00277773],"genre_scores_gemma":[0.0015895751,0.0024772435,0.0002410243,0.80961144,0.032611646,0.0011325717,0.0016204093,0.00016154446,0.15055455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975366,0.0006663195,0.0003573589,0.0005003978,0.000071294824,0.0008680074],"domain_scores_gemma":[0.9955745,0.0024617757,0.00031314956,0.0015698306,0.00006968496,0.0000110664805],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001231039,0.00049264834,0.0009461621,0.000063310166,0.0005834971,0.000039903967,0.0014023464,0.00084825215,0.00050328363],"category_scores_gemma":[0.00013717708,0.00020484709,0.00043219407,0.000103070546,0.0002681487,0.000040399656,0.00014238793,0.0009237317,0.0010720924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035647873,0.000013340249,0.000040427938,0.00005758381,0.00098925,0.000013152863,0.00024547247,4.81587e-7,0.00038829035,0.000249547,0.97693247,0.020713516],"study_design_scores_gemma":[0.002673339,0.000063458196,0.000113391805,0.00009845156,0.0007140523,0.00003444547,0.00001400708,5.3064514e-7,0.0035371874,0.003577941,0.98886627,0.000306932],"about_ca_topic_score_codex":0.000044697146,"about_ca_topic_score_gemma":0.00009020383,"teacher_disagreement_score":0.17204103,"about_ca_system_score_codex":0.00005489604,"about_ca_system_score_gemma":0.000049937797,"threshold_uncertainty_score":0.9997057},"labels":[],"label_agreement":null},{"id":"W2568858752","doi":"10.1016/j.jaad.2016.11.043","title":"Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Dermatology Life Quality Index; Etanercept; Placebo; Quality of life (healthcare); Psoriasis Area and Severity Index; Randomized controlled trial; Psoriasis; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","score_opus":0.09313924228473613,"score_gpt":0.3864747613679332,"score_spread":0.29333551908319705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568858752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923952,0.001062714,0.000090718226,0.003666862,0.00096950354,0.001152193,0.00016557577,0.000024578836,0.00047265226],"genre_scores_gemma":[0.9984444,0.00043212247,0.00041950116,0.00032894482,0.000146327,0.000024975594,0.000022297161,0.000033843273,0.0001476313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98816514,0.0055660456,0.0050944756,0.00042003233,0.00022157741,0.0005327033],"domain_scores_gemma":[0.97485256,0.00537778,0.018808568,0.0006611574,0.00020991518,0.000089996494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031233435,0.00045743282,0.0067584235,0.00018228294,0.0004526827,0.000045441844,0.0012013881,0.00044161815,0.00006273948],"category_scores_gemma":[0.004940761,0.00025227544,0.001634678,0.00013474989,0.0020595628,0.0002648193,0.00023825782,0.0011159986,0.000018659895],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9325288,0.0006976385,0.03985357,0.000008943984,0.011583009,0.00015488047,0.001744342,0.000036722467,0.0016310144,0.00021426794,0.001346504,0.010200323],"study_design_scores_gemma":[0.95393103,0.0007702693,0.02700376,0.00015518516,0.005331483,0.0017050517,0.0009752914,0.000023423727,0.0076362924,0.00033818165,0.001743037,0.0003869989],"about_ca_topic_score_codex":0.00038192878,"about_ca_topic_score_gemma":0.0000224716,"teacher_disagreement_score":0.021402238,"about_ca_system_score_codex":0.00006340309,"about_ca_system_score_gemma":0.0002311642,"threshold_uncertainty_score":0.99999297},"labels":[],"label_agreement":null},{"id":"W2570141807","doi":"10.1016/j.jaad.2016.11.041","title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":860,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Internal medicine; Placebo; Adverse effect; Surgery; Gastroenterology; Dermatology","score_opus":0.03413351889159199,"score_gpt":0.3233729633831536,"score_spread":0.2892394444915616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570141807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940549,0.00068188744,0.0000958278,0.001851106,0.00017780038,0.0022453219,0.0008734141,0.000005028417,0.000014689848],"genre_scores_gemma":[0.9993049,0.00025116603,0.00020430518,0.00007681593,0.000055412725,0.000034381148,0.000035269924,0.000018248313,0.000019534198],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977421,0.0005646701,0.0009986457,0.00028406078,0.00012674974,0.00028374564],"domain_scores_gemma":[0.9936567,0.0017662264,0.0039120205,0.00040323252,0.00020099677,0.000060802755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024863833,0.00033422885,0.0019356062,0.00009162314,0.00044981457,0.000024905037,0.0006401668,0.00013295109,0.0000040080486],"category_scores_gemma":[0.000071435585,0.00014556856,0.0002029604,0.00008189104,0.0012468571,0.00014604749,0.00008830458,0.00022226541,3.4028884e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97263396,0.0011823619,0.010014719,0.0000063785487,0.0057095205,0.0000046445352,0.0023470388,0.00013458471,0.0032081315,0.00002864628,0.00017497469,0.0045550345],"study_design_scores_gemma":[0.8288165,0.0068659433,0.12835568,0.00013318892,0.0029374103,0.00027661273,0.0012929658,0.000079521174,0.030442145,0.000023823832,0.00054676854,0.00022944443],"about_ca_topic_score_codex":0.00021780738,"about_ca_topic_score_gemma":0.000059511425,"teacher_disagreement_score":0.14381747,"about_ca_system_score_codex":0.00003629472,"about_ca_system_score_gemma":0.0001366968,"threshold_uncertainty_score":0.59361136},"labels":[],"label_agreement":null},{"id":"W2570401170","doi":"10.1007/s40257-016-0246-9","title":"Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)","year":2017,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Etanercept; Plaque psoriasis; Randomized controlled trial; Psoriasis; Pharmacotherapy; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha","score_opus":0.06534057836563588,"score_gpt":0.4286594761625303,"score_spread":0.3633188977968944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570401170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921649,0.0007693544,0.002266195,0.0032841156,0.00074288755,0.0006551763,0.000051588057,0.0000067251844,0.000059076883],"genre_scores_gemma":[0.9953949,0.002229203,0.0016090695,0.00056398736,0.00012886107,0.000015930254,0.000014631815,0.000022873226,0.00002056677],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9807137,0.011680673,0.0064257514,0.0006135544,0.00011196082,0.0004543504],"domain_scores_gemma":[0.9642026,0.030857144,0.0039655822,0.00057013176,0.0001511524,0.00025342716],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013905615,0.00038211496,0.008181487,0.0006261823,0.00015651745,0.000045689358,0.000549446,0.00042461566,0.000082134895],"category_scores_gemma":[0.02079785,0.00029088487,0.00087012764,0.00025040013,0.0009175844,0.00021084401,0.00022044592,0.00082467886,0.000015832298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53357005,0.0006773206,0.048576243,0.0000072811,0.0023203702,0.0002867378,0.0012118194,0.00008561164,0.00088927225,0.00004663362,0.00008735265,0.4122413],"study_design_scores_gemma":[0.844457,0.002274402,0.14542656,0.0004024945,0.0023789061,0.000536521,0.001329562,0.00042870882,0.00083368394,0.0006831823,0.0006644493,0.000584588],"about_ca_topic_score_codex":0.0013077175,"about_ca_topic_score_gemma":0.0007797664,"teacher_disagreement_score":0.41165674,"about_ca_system_score_codex":0.000034954577,"about_ca_system_score_gemma":0.00033085325,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W2575934766","doi":"10.1111/jdv.14128","title":"A randomized, double‐blind, placebo‐controlled, dose‐escalation first‐in‐man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, <scp>AVX</scp>001, in patients with mild to moderate plaque psoriasis","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Placebo; Double blind; Phases of clinical research; Pharmacology; Clinical trial; Internal medicine; Pathology","score_opus":0.03017783277983754,"score_gpt":0.28746147086302093,"score_spread":0.2572836380831834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575934766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496764,0.00057905965,0.000032178905,0.002417355,0.0003187024,0.0014549647,0.000013891377,0.0000043697537,0.00021182682],"genre_scores_gemma":[0.99940974,0.00018487501,0.000043272245,0.00017885983,0.00005236187,0.000023224531,0.0000038273806,0.000017646873,0.00008619189],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99563974,0.0025531042,0.0011122653,0.0002829799,0.000088427565,0.0003234798],"domain_scores_gemma":[0.9972817,0.0012376232,0.0010606642,0.00027547433,0.00007399917,0.000070563365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013400081,0.00027789988,0.0013776553,0.00026797087,0.00032735965,0.00001753893,0.0005525777,0.00022893077,0.0000052567484],"category_scores_gemma":[0.00045997536,0.00015411594,0.00014535291,0.000111612375,0.0005028213,0.0001227824,0.00029030826,0.00054530194,0.0000046831665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52419597,0.0014519767,0.4675328,0.00002415349,0.0009522414,0.00004987608,0.0031594774,0.00031588276,0.0003263942,0.00037207827,0.00015987316,0.0014592457],"study_design_scores_gemma":[0.54911596,0.0003183931,0.44698343,0.00009767212,0.00042757302,0.00021270252,0.0001333118,0.0000150026835,0.0022285315,0.00004813094,0.00033243911,0.00008685633],"about_ca_topic_score_codex":0.000035882083,"about_ca_topic_score_gemma":0.00010885935,"teacher_disagreement_score":0.024919972,"about_ca_system_score_codex":0.00002571543,"about_ca_system_score_gemma":0.000038979266,"threshold_uncertainty_score":0.6284666},"labels":[],"label_agreement":null},{"id":"W2581284434","doi":"10.1155/2017/2405291","title":"Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis","year":2017,"lang":"en","type":"article","venue":"Mediators of Inflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Beijing Municipal Administration of Hospitals; National Natural Science Foundation of China; Beijing Nova Program; Ministry of Science and Technology of the People's Republic of China; National Science Foundation","keywords":"Pathogenesis; Cytokine; Tumor necrosis factor alpha; Immunology; Signal transduction; Immune system; Biology; MAPK/ERK pathway; Psoriasis; Mechanism (biology); Rheumatoid arthritis; Medicine; Cancer research; Cell biology","score_opus":0.007682229887860896,"score_gpt":0.22953222586363442,"score_spread":0.2218499959757735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581284434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99679404,0.0016119112,0.0000135015025,0.00021741145,0.00053697405,0.00020372096,0.000028324326,0.000026860409,0.0005672662],"genre_scores_gemma":[0.99571157,0.003960934,0.00008517462,0.000009835064,0.00003854385,0.000042105963,0.00007085179,0.00001035712,0.0000706101],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991723,0.00008860093,0.00032915222,0.00018167209,0.000047292833,0.0001810343],"domain_scores_gemma":[0.99919456,0.00008322534,0.00034390274,0.00032556854,0.0000316244,0.000021124102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002920698,0.00013982525,0.0003177503,0.00012376126,0.00017053225,0.000020359827,0.00016331079,0.00019516058,0.00007849491],"category_scores_gemma":[0.00019879607,0.00013208413,0.000043350752,0.000040438154,0.00011139826,0.00021705661,0.00006107783,0.00008662908,0.00007120493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047353384,0.00013059752,0.30285797,0.000068197936,0.00021343997,0.000033693963,0.0028424137,0.0000023728269,0.37654704,0.0126421675,0.0001889857,0.30399957],"study_design_scores_gemma":[0.0050340174,0.00017037088,0.3952164,0.00020006373,0.00002369974,0.000035624274,0.00018231921,0.000014280574,0.5930704,0.0048565296,0.00097534177,0.00022094656],"about_ca_topic_score_codex":0.00036383927,"about_ca_topic_score_gemma":0.0005812043,"teacher_disagreement_score":0.30377862,"about_ca_system_score_codex":0.000023888317,"about_ca_system_score_gemma":0.000029637435,"threshold_uncertainty_score":0.5386234},"labels":[],"label_agreement":null},{"id":"W2581410643","doi":"10.1177/0963689718757482","title":"IDO-expressing Fibroblasts Suppress the Development of Imiquimod-induced Psoriasis-like Dermatitis","year":2018,"lang":"en","type":"article","venue":"Cell Transplantation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Imiquimod; Immune system; Medicine; Pathogenesis; Immunology; Interleukin 17; Atopic dermatitis; Interleukin; Cytokine","score_opus":0.020275677352965045,"score_gpt":0.23637833767996108,"score_spread":0.21610266032699604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581410643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356335,0.000298049,0.002676408,0.000033087203,0.0008773338,0.00021993124,0.000042086947,0.000044913177,0.0022448376],"genre_scores_gemma":[0.997909,0.00006399863,0.001296312,0.000040901614,0.00005285358,0.000033574026,0.00029429936,0.000015052354,0.00029400532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900484,0.00016700139,0.00033510107,0.00020640639,0.000052533374,0.00023414583],"domain_scores_gemma":[0.99944574,0.0001361197,0.0001382705,0.00019347892,0.00006990219,0.000016472848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014225813,0.00016532667,0.0001741061,0.00006947596,0.0003333725,0.000014116327,0.00018274858,0.0001584039,0.00023570006],"category_scores_gemma":[0.0000034731695,0.00012265852,0.000065807726,0.00010202913,0.00010098427,0.00011385085,0.000012982274,0.00007648757,0.00019718564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017168603,0.00008200422,0.0009260775,0.00011013476,0.00011651575,0.00000222313,0.014860002,0.0000043298414,0.95924425,0.000017144914,0.00023459442,0.024231054],"study_design_scores_gemma":[0.0013083932,0.00007725442,0.04282574,0.00008712204,0.00014555937,0.00001804503,0.00031680238,0.0000055333535,0.9536136,0.000020900408,0.0014440623,0.0001370151],"about_ca_topic_score_codex":0.000020139567,"about_ca_topic_score_gemma":0.00012213559,"teacher_disagreement_score":0.041899662,"about_ca_system_score_codex":0.00001939117,"about_ca_system_score_gemma":0.000064511965,"threshold_uncertainty_score":0.5001869},"labels":[],"label_agreement":null},{"id":"W2587305350","doi":"10.1111/jdv.14163","title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec; Université Laval; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis; Placebo; Dosing; Maintenance therapy; Clinical trial; Phases of clinical research; Internal medicine; Chemotherapy; Dermatology; Pathology; Secukinumab","score_opus":0.07432504716928887,"score_gpt":0.3566753525540663,"score_spread":0.28235030538477746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587305350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492925,0.0030616864,0.00008032531,0.00083353167,0.00057213515,0.00013237252,0.000029536002,0.0000064731694,0.0003546767],"genre_scores_gemma":[0.99890065,0.0007623689,0.00016134558,0.000066499066,0.000042828477,0.0000015602151,0.000010340442,0.000015554746,0.000038845617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99313956,0.0050840937,0.0012608186,0.00021159544,0.00005158577,0.0002523434],"domain_scores_gemma":[0.9959297,0.0006872712,0.0029476532,0.0002989986,0.00009934854,0.000036984526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019025464,0.00023240142,0.0017476525,0.00058234995,0.00018356257,0.000012071956,0.00076079764,0.00024803067,0.000054880584],"category_scores_gemma":[0.0004807223,0.00013489029,0.00034866115,0.00023082731,0.0009485569,0.00016772964,0.00010567864,0.0004865881,0.000001986099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048574258,0.0016153433,0.5160341,0.000035467165,0.023920452,0.0003652903,0.0028686388,0.00013220748,0.10229525,0.0013952223,0.00026141352,0.3025023],"study_design_scores_gemma":[0.11228447,0.0018785521,0.6614346,0.00036964574,0.010949505,0.004274782,0.0010885545,0.00008763749,0.20133652,0.00037114046,0.0053353687,0.0005892649],"about_ca_topic_score_codex":0.000047319398,"about_ca_topic_score_gemma":0.00005586359,"teacher_disagreement_score":0.30191305,"about_ca_system_score_codex":0.000018382507,"about_ca_system_score_gemma":0.00005579909,"threshold_uncertainty_score":0.55006665},"labels":[],"label_agreement":null},{"id":"W2588014405","doi":"10.1111/bjd.15381","title":"Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab","year":2017,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Etanercept; Dermatology Life Quality Index; Internal medicine; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Confidence interval; Quality of life (healthcare); Visual analogue scale; Severity of illness; Surgery; Gastroenterology; Physical therapy; Randomized controlled trial; Dermatology; Tumor necrosis factor alpha","score_opus":0.024319528757040982,"score_gpt":0.27268119109163624,"score_spread":0.24836166233459525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588014405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974287,0.00040685153,0.000012260901,0.00036577997,0.00039758196,0.0010572895,0.00016448366,0.000006234462,0.00016079904],"genre_scores_gemma":[0.99912506,0.00008401713,0.00021961216,0.00008628315,0.000014475321,0.000041811003,0.000013227447,0.000030318868,0.0003851875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997409,0.00094332866,0.0007835137,0.00035035808,0.00010413669,0.00040965696],"domain_scores_gemma":[0.9982627,0.00021382108,0.0006524507,0.00048857025,0.00027690688,0.00010556497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020985291,0.000284758,0.0011383455,0.00032761844,0.00031054392,0.00009500594,0.00079889235,0.0002389143,0.00012463047],"category_scores_gemma":[0.00017331172,0.00025822214,0.00006616034,0.00011508613,0.00010002865,0.00031732657,0.00022573427,0.00020832058,0.000060034694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089937456,0.010652632,0.8060078,0.00001803082,0.0019145035,0.0041463207,0.0050098705,0.000048564718,0.0015624462,0.000012720444,0.0020659491,0.0786237],"study_design_scores_gemma":[0.06872578,0.006808145,0.9156739,0.0002848919,0.00024835538,0.0038726686,0.0007039325,5.4576486e-7,0.0026581176,0.000014277064,0.00070653815,0.00030282658],"about_ca_topic_score_codex":0.0013406127,"about_ca_topic_score_gemma":0.005736723,"teacher_disagreement_score":0.10966611,"about_ca_system_score_codex":0.00016854302,"about_ca_system_score_gemma":0.00031735018,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W2589532622","doi":"","title":"Dermacase. Can you identify this condition? Guttate psoriasis.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Dermatology; Psoriasis; Computer science; Medicine","score_opus":0.039068101685025954,"score_gpt":0.24026486735493469,"score_spread":0.20119676566990874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589532622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95661414,0.00229161,0.000015461808,0.00026172242,0.0034662187,0.0007691005,0.00029160138,0.00025307984,0.036037087],"genre_scores_gemma":[0.9797683,0.00015006031,0.00003867271,0.00030137223,0.00008270796,0.0013454477,0.00033717035,0.000024212977,0.01795207],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99857384,0.00018220855,0.00027046245,0.00034707203,0.00004004634,0.0005863928],"domain_scores_gemma":[0.9993731,0.000055070188,0.00012075682,0.00033279776,0.000055501925,0.00006280302],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023307477,0.00021915635,0.00025796727,0.00013656846,0.00021718742,0.00001699607,0.00023220872,0.00022588208,0.0026135754],"category_scores_gemma":[0.00004719976,0.00019427302,0.00014576555,0.00014824068,0.00013559102,0.00011935211,0.00005600354,0.00013516631,0.0015235941],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071669114,0.0010680235,0.08335821,0.000051323448,0.0030499538,0.00031609854,0.004120531,3.806015e-7,0.0072062537,0.003231552,0.08174955,0.8151314],"study_design_scores_gemma":[0.002789276,0.000038841757,0.8250428,0.000005725156,0.00041951778,0.00013494483,0.00012609034,1.1723e-7,0.11744354,0.0009953119,0.052657798,0.00034604382],"about_ca_topic_score_codex":0.00035715976,"about_ca_topic_score_gemma":0.000109852386,"teacher_disagreement_score":0.81478536,"about_ca_system_score_codex":0.00005254194,"about_ca_system_score_gemma":0.000027085343,"threshold_uncertainty_score":0.9992538},"labels":[],"label_agreement":null},{"id":"W2590436023","doi":"10.1016/j.jid.2016.11.032","title":"Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Hazard ratio; Major depressive disorder; Depression (economics); Confidence interval; Proportional hazards model; Internal medicine; Population; Immunology; Environmental health","score_opus":0.013107772472675533,"score_gpt":0.235046264938437,"score_spread":0.22193849246576147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590436023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988395,0.00024575088,0.00002807458,0.00004852281,0.00022489112,0.00043968044,0.00012409282,0.00001634041,0.000033122495],"genre_scores_gemma":[0.9993925,0.000011534265,0.0003530664,0.000057339526,0.000019826344,0.000021992328,0.00010837378,0.000026551856,0.000008801656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971447,0.0013934901,0.0007424901,0.00027136537,0.00016567168,0.00028226935],"domain_scores_gemma":[0.9947317,0.00036624144,0.0035990009,0.0004816469,0.0007209139,0.00010050178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034585493,0.00030368802,0.0009365836,0.0002577253,0.00054074795,0.000031252395,0.00038735347,0.00025827173,0.00006021942],"category_scores_gemma":[0.0009528186,0.00020210617,0.000113595765,0.00012586184,0.0004957756,0.00046015417,0.000035907546,0.0003291598,0.0000046912987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013432205,0.0012683524,0.9924318,0.000009536712,0.0018639078,0.0000782125,0.000991226,0.000020765576,0.00039847434,0.000008852235,0.000070671704,0.00151498],"study_design_scores_gemma":[0.017037787,0.0022940182,0.944858,0.0003258931,0.0009777158,0.00003830501,0.00033184767,0.000012810243,0.033722904,0.00018670622,0.000004899605,0.00020912691],"about_ca_topic_score_codex":0.0007231093,"about_ca_topic_score_gemma":0.00095188257,"teacher_disagreement_score":0.047573812,"about_ca_system_score_codex":0.000056995275,"about_ca_system_score_gemma":0.00023982125,"threshold_uncertainty_score":0.82416505},"labels":[],"label_agreement":null},{"id":"W2591549758","doi":"10.1016/j.msard.2017.02.012","title":"Increased incidence and prevalence of psoriasis in multiple sclerosis","year":2017,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; McGill University; University of British Columbia; University of Calgary; University of Manitoba","funders":"Canadian Institutes of Health Research; Dalhousie University; Multiple Sclerosis Society of Canada; Public Health Agency of Canada; Multiple Sclerosis Trust; Multiple Sclerosis Society; European Committee for Treatment and Research in Multiple Sclerosis; Crohn's and Colitis Canada; Dalhousie Medical Research Foundation; Multiple Sclerosis Scientific Research Foundation; U.S. Department of Veterans Affairs; Teva Pharmaceutical Industries; Sanofi; Public Health Agency; National Multiple Sclerosis Society; Michael Smith Health Research BC; Biogen","keywords":"Psoriasis; Medicine; Incidence (geometry); Population; Multiple sclerosis; Cohort; Demography; Medical prescription; Internal medicine; Dermatology; Immunology; Environmental health","score_opus":0.030879322888268362,"score_gpt":0.22577340154250602,"score_spread":0.19489407865423766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591549758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688555,0.011673461,0.0000060062234,0.00016804055,0.00036696,0.00042615298,0.00011514903,0.000042221844,0.00031645072],"genre_scores_gemma":[0.9793849,0.020104421,0.00013143937,0.000017030534,0.000007724965,0.000058656064,0.000028742481,0.000023908866,0.00024315907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983029,0.00019900741,0.0004745799,0.0005606164,0.00006683441,0.000396063],"domain_scores_gemma":[0.9986092,0.0003843182,0.00034948118,0.0005500519,0.000046710862,0.000060234655],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003719963,0.000300177,0.000464351,0.00017879013,0.0006363897,0.00004378396,0.00031530487,0.0004292212,0.00010905543],"category_scores_gemma":[0.000582239,0.0002633656,0.00011163683,0.00012305626,0.0007519879,0.00029321818,0.00021940506,0.00021995784,0.000023944815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031866677,0.00024606206,0.8170633,0.000090307374,0.00017277009,0.0000013434069,0.0007893381,0.000008840253,0.0899011,0.000037701077,0.00004098594,0.09132961],"study_design_scores_gemma":[0.008133809,0.00013801492,0.9765164,0.00043647093,0.00015937052,0.000004664226,0.00027028998,0.00015088244,0.013663159,0.00012578635,0.00010744268,0.00029365835],"about_ca_topic_score_codex":0.0036230483,"about_ca_topic_score_gemma":0.0013520848,"teacher_disagreement_score":0.15945317,"about_ca_system_score_codex":0.00002409302,"about_ca_system_score_gemma":0.000030405077,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W2592535678","doi":"10.1016/j.jid.2017.02.977","title":"TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Université de Montréal; Montreal Heart Institute; Innovaderm (Canada)","funders":"AbbVie Canada","keywords":"Medicine; Adalimumab; Placebo; Clinical endpoint; Psoriasis; Internal medicine; Inflammation; Randomized controlled trial; Tumor necrosis factor alpha; Gastroenterology; Pathology; Dermatology","score_opus":0.010751994532938538,"score_gpt":0.23243417597005472,"score_spread":0.22168218143711618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592535678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970847,0.0005802612,0.000026876362,0.0005089013,0.00035235967,0.0012626906,0.000005858956,0.000009012672,0.00016933946],"genre_scores_gemma":[0.99951285,0.00007304045,0.00020347905,0.000043608467,0.0000301167,0.00007474221,0.000012214226,0.000014416008,0.00003555631],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691373,0.0016467432,0.00087389734,0.00021734416,0.0000920746,0.00025618047],"domain_scores_gemma":[0.9972459,0.0005196637,0.0015952976,0.00028681432,0.00029763157,0.000054670276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092306087,0.00027136048,0.0016241971,0.00031637243,0.0003668477,0.00005987399,0.00026223832,0.00020600109,0.00002445998],"category_scores_gemma":[0.0011990161,0.00017472319,0.00016097698,0.00006492284,0.00092046696,0.00036246926,0.00006485157,0.00030328348,0.000012855703],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30891696,0.0009752577,0.6672793,0.000038482485,0.007031056,0.00021885923,0.0069099357,0.000012340994,0.0040550902,0.00060031394,0.00017395584,0.003788481],"study_design_scores_gemma":[0.6037646,0.0005130897,0.3789014,0.0000670641,0.0008534701,0.00009061339,0.00057820947,0.0000050577746,0.014527515,0.00044622496,0.0000769292,0.00017587523],"about_ca_topic_score_codex":0.000061412145,"about_ca_topic_score_gemma":0.00010983886,"teacher_disagreement_score":0.2948476,"about_ca_system_score_codex":0.000044042557,"about_ca_system_score_gemma":0.00014209557,"threshold_uncertainty_score":0.71250045},"labels":[],"label_agreement":null},{"id":"W2592742793","doi":"10.2147/ppa.s121838","title":"Evaluation of psoriasis patients&amp;rsquo; attitudes toward benefit&amp;ndash;risk and therapeutic trade-offs in their choice of treatments","year":2017,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"Celgene","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.1371396863128506,"score_gpt":0.31876905590983085,"score_spread":0.18162936959698026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592742793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382836,0.0047288425,0.0000063316884,0.000012812273,0.00023065989,0.0006270635,0.00026112478,0.000011790316,0.00029300223],"genre_scores_gemma":[0.99787587,0.001756413,0.00006351207,0.00000810711,0.000008321541,0.00011182306,0.000103101636,0.000010879052,0.00006196027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841845,0.00031825583,0.00043216624,0.00042329982,0.00015001575,0.00025782417],"domain_scores_gemma":[0.9985291,0.00020223355,0.0005785956,0.0004832958,0.00017215536,0.000034671368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003490808,0.00027429592,0.0004367681,0.000109046654,0.00021281307,0.000023232575,0.00023613419,0.00019248137,0.00010860978],"category_scores_gemma":[0.00018668838,0.00020774039,0.00007030784,0.00006932101,0.00024876295,0.0001885748,0.00010548986,0.000117559415,0.000010545823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115284856,0.0003716733,0.56380296,0.00002763402,0.0001818639,7.275494e-8,0.001823616,0.00000295117,0.002902989,0.00002567715,0.0000028144698,0.43074244],"study_design_scores_gemma":[0.003644721,0.00066054065,0.9825731,0.0001866657,0.00045010538,8.3088685e-7,0.000112307716,0.000009300034,0.011261429,0.0007614836,0.00014693727,0.000192617],"about_ca_topic_score_codex":0.0008603496,"about_ca_topic_score_gemma":0.0009266834,"teacher_disagreement_score":0.43054983,"about_ca_system_score_codex":0.000038372975,"about_ca_system_score_gemma":0.000057492663,"threshold_uncertainty_score":0.8471407},"labels":[],"label_agreement":null},{"id":"W2593047881","doi":"10.1111/jdv.14211","title":"Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Dermatology Life Quality Index; Post-hoc analysis; Minimal clinically important difference; Clinical endpoint; Placebo; Hazard ratio; Randomization; Randomized controlled trial; Quality of life (healthcare); Internal medicine; Confidence interval; Pathology; Disease","score_opus":0.055895265232394,"score_gpt":0.3162650381622829,"score_spread":0.2603697729298889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593047881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96735495,0.029288,0.000008975266,0.0017282747,0.00037649894,0.0005858194,0.00015247452,0.0000066248945,0.00049839664],"genre_scores_gemma":[0.98863703,0.010734157,0.00010114346,0.00019767365,0.000042744403,0.000008009669,0.000021568518,0.000021591246,0.00023608474],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9861256,0.0100745,0.0028698505,0.00040824807,0.00008680983,0.00043502156],"domain_scores_gemma":[0.9888514,0.0053644585,0.005319999,0.00031076744,0.000055445485,0.00009789226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005071043,0.00037909212,0.0030897565,0.00031168776,0.00024994317,0.000015581994,0.00042575493,0.0004616066,0.0000066054695],"category_scores_gemma":[0.00446748,0.00023168491,0.00024854025,0.00009987093,0.0012691573,0.00018780722,0.00021747073,0.00058133353,0.0000027417486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14822485,0.0033418045,0.6954913,0.00043451553,0.0114488145,0.00044824023,0.013424601,0.000054157746,0.03448061,0.0013308495,0.002140195,0.08918008],"study_design_scores_gemma":[0.59895205,0.00080247707,0.37300357,0.0004227888,0.0007824319,0.001238359,0.0008486321,0.000024099265,0.017780233,0.0021462091,0.003847671,0.00015148208],"about_ca_topic_score_codex":0.0005697318,"about_ca_topic_score_gemma":0.000093515824,"teacher_disagreement_score":0.4507272,"about_ca_system_score_codex":0.000046736488,"about_ca_system_score_gemma":0.00018443986,"threshold_uncertainty_score":0.9447836},"labels":[],"label_agreement":null},{"id":"W2593514818","doi":"10.3389/fphar.2017.00125","title":"East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis","year":2017,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Government of Canada","keywords":"Psoriasis; Medicine; Inflammation; Population; Immunology; Dermatology","score_opus":0.014723110872764811,"score_gpt":0.25890475390232975,"score_spread":0.24418164302956494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593514818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537534,0.008667155,0.000017519345,0.00041662893,0.003995345,0.00022237834,0.00009920924,0.00003971213,0.001166698],"genre_scores_gemma":[0.99547875,0.0026766693,0.00061524013,0.00008489602,0.00008296293,0.00014231476,0.0000370803,0.000018235527,0.000863836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984551,0.00035519776,0.0003614113,0.00038136565,0.000033703218,0.00041323862],"domain_scores_gemma":[0.9991848,0.00008149064,0.00034764785,0.00029406004,0.000056983044,0.00003504771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003088101,0.00025897808,0.0005802666,0.0002515947,0.00032961843,0.000018470995,0.0003885634,0.00037435812,0.00014008746],"category_scores_gemma":[0.00010222578,0.00023099569,0.000080830614,0.00005519936,0.0008432457,0.00019239039,0.00019567819,0.0002404831,0.000022894881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001439327,0.00032601552,0.69656533,0.00011938921,0.0011288924,0.00016631516,0.0061070765,0.000004755004,0.08240505,0.00011889087,0.013585807,0.19803312],"study_design_scores_gemma":[0.021077251,0.0008202418,0.53099114,0.00011787149,0.0007103825,0.00014735675,0.0040302626,0.000018129886,0.4144679,0.0013683174,0.025330298,0.0009208448],"about_ca_topic_score_codex":0.000030111,"about_ca_topic_score_gemma":0.000037400536,"teacher_disagreement_score":0.33206284,"about_ca_system_score_codex":0.000044093264,"about_ca_system_score_gemma":0.000085795786,"threshold_uncertainty_score":0.9419731},"labels":[],"label_agreement":null},{"id":"W2594248361","doi":"10.1016/b978-0-444-63931-8.00006-0","title":"Bioactive Polyphenols for Diabetes and Inflammation in Psoriasis Disease","year":2017,"lang":"en","type":"book-chapter","venue":"Studies in natural products chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Diabetes mellitus; Polyphenol; Medicine; Psoriasis; Oxidative stress; Inflammation; Antioxidant; Disease; Obesity; Population; Pharmacology; Biology; Traditional medicine; Biochemistry; Immunology; Internal medicine; Environmental health; Endocrinology","score_opus":0.028218642730895346,"score_gpt":0.2729893738121328,"score_spread":0.24477073108123742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594248361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6015404,0.37300244,8.009268e-8,0.0016544526,0.0033295092,0.0019519465,0.0006718125,0.0000821106,0.017767264],"genre_scores_gemma":[0.7593669,0.0056527257,0.000050680115,0.000018995124,0.0005960058,0.0002315973,0.00079335127,0.000047112677,0.23324259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860585,0.000019332578,0.0003223216,0.0006855552,0.000040340085,0.0003266014],"domain_scores_gemma":[0.9989266,0.00018857911,0.00029813955,0.0004273924,0.00014118485,0.000018144774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016234299,0.00043077205,0.00062513596,0.00008834025,0.00018570383,0.00001567081,0.00018718113,0.0003806312,0.0000147617775],"category_scores_gemma":[0.000790728,0.00037252158,0.00008622804,0.000020986552,0.00051225326,0.00010540867,0.00017588765,0.00034896255,0.000010178928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050816145,0.00030852543,0.009846362,0.012274304,0.010619528,0.00017128915,0.0058324207,0.0000021964486,0.5764355,0.0027808018,0.009854969,0.3667925],"study_design_scores_gemma":[0.009979979,0.0001503183,0.007936144,0.0036212269,0.0016009057,0.000014725117,0.000625741,0.0000026869973,0.8756499,0.025091354,0.07273727,0.0025897415],"about_ca_topic_score_codex":0.0000032891514,"about_ca_topic_score_gemma":0.000012527674,"teacher_disagreement_score":0.3673497,"about_ca_system_score_codex":0.00015852001,"about_ca_system_score_gemma":0.00006886778,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W2597104265","doi":"10.5114/ada.2017.65628","title":"The significance of Toll-like receptor (TLR) 2 and 9 gene polymorphisms in psoriasis","year":2017,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Toll-like receptor; Immunology; Dermatology; Receptor; Internal medicine; Innate immune system","score_opus":0.010166002061007977,"score_gpt":0.2500232201488451,"score_spread":0.2398572180878371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597104265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92519087,0.07119817,0.000015375337,0.0014354752,0.0012134055,0.0002138292,0.000016163282,0.000012444991,0.00070426514],"genre_scores_gemma":[0.9658313,0.033457488,0.0001707052,0.000090533875,0.000017505148,0.00008732156,0.000014299476,0.000009547574,0.00032132384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849683,0.00030705496,0.00040121283,0.00036908797,0.000021768616,0.0004040678],"domain_scores_gemma":[0.9986674,0.0006057842,0.00027027822,0.0004116547,0.000023003076,0.0000218605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019725844,0.00019833964,0.00049057044,0.000107050626,0.00040022374,0.000009817095,0.00034336458,0.0003359368,0.000037348796],"category_scores_gemma":[0.00012829632,0.00015027361,0.0000397581,0.000053466832,0.0014625574,0.00017942827,0.0001551365,0.00019266193,0.000015872232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014471984,0.0001945365,0.779405,0.000036793124,0.00024042328,0.00015153426,0.0008045171,0.000006755829,0.025135292,0.010960141,0.00036080403,0.18125701],"study_design_scores_gemma":[0.009815401,0.00035703718,0.74786985,0.000083622916,0.00008816979,0.0014830899,0.0005708539,0.000015655593,0.08306436,0.010081848,0.14591935,0.0006507532],"about_ca_topic_score_codex":0.000102932834,"about_ca_topic_score_gemma":0.001909953,"teacher_disagreement_score":0.18060626,"about_ca_system_score_codex":0.000012413997,"about_ca_system_score_gemma":0.000034163848,"threshold_uncertainty_score":0.612798},"labels":[],"label_agreement":null},{"id":"W2597329772","doi":"10.1111/bjd.15463","title":"Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations","year":2017,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; Dermira; Valeant Pharmaceuticals International; Genentech; Celgene; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Psoriasis; Medicine; Dermatology; Resolution (logic); Computer science; Artificial intelligence","score_opus":0.037536062191523216,"score_gpt":0.2521970647376623,"score_spread":0.21466100254613907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597329772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6493619,0.15968436,0.00061701983,0.16851294,0.010745526,0.0013073825,0.007889393,0.00012198644,0.0017594931],"genre_scores_gemma":[0.90496385,0.042657513,0.008982155,0.03477436,0.00308886,0.00006672301,0.0022738858,0.00028522906,0.0029074093],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690217,0.0009459887,0.0012275726,0.00034913182,0.00009830562,0.00047682654],"domain_scores_gemma":[0.99566686,0.0009772342,0.0025635827,0.00039502335,0.00035532724,0.00004198233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031761115,0.00035268138,0.0014872184,0.0002542873,0.0009997899,0.0001239586,0.00036780955,0.0012861313,0.00026180677],"category_scores_gemma":[0.0006185632,0.00034950674,0.00033101861,0.00005029089,0.0007178444,0.00020773613,0.0001131559,0.0018071239,0.00003262122],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005612634,0.00013774454,0.0037653577,0.00021962206,0.00416068,0.017531626,0.00048433457,0.0000053192493,0.0014050583,0.0001379583,0.94061875,0.030972272],"study_design_scores_gemma":[0.0057869377,0.0003241495,0.011418718,0.0009800673,0.0022636775,0.42469,0.00006627279,0.0000076876795,0.0005430554,0.0016323557,0.55179185,0.0004952554],"about_ca_topic_score_codex":0.0007915334,"about_ca_topic_score_gemma":0.0005095844,"teacher_disagreement_score":0.40715837,"about_ca_system_score_codex":0.000047262176,"about_ca_system_score_gemma":0.00029334924,"threshold_uncertainty_score":0.9998957},"labels":[],"label_agreement":null},{"id":"W2598622099","doi":"10.1111/jdv.14237","title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>‐1, <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3)","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Celgene; Regeneron Pharmaceuticals; Novartis; Amgen; Pfizer; Allergan; Biogen Idec; Eli Lilly and Company; AbbVie; Merck","keywords":"Ixekizumab; Medicine; Placebo; Etanercept; Psoriasis; Palmoplantar pustulosis; Psoriasis Area and Severity Index; Internal medicine; Plaque psoriasis; Dermatology; Gastroenterology; Psoriatic arthritis; Pathology; Tumor necrosis factor alpha; Secukinumab","score_opus":0.029237971730965918,"score_gpt":0.2649287669594539,"score_spread":0.23569079522848796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598622099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340695,0.0031719941,0.00007142608,0.00046908783,0.00059875206,0.0009433317,0.000791922,0.000014930432,0.0005316229],"genre_scores_gemma":[0.9975121,0.0012612669,0.0003507039,0.00042281023,0.00012077177,0.000010522214,0.00008177864,0.000055250515,0.00018478783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99395764,0.0024658276,0.0018594596,0.0007790777,0.00020572195,0.00073230074],"domain_scores_gemma":[0.9922897,0.004135966,0.002615319,0.00054940477,0.0001619273,0.00024765613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016454721,0.00068725063,0.0023447473,0.00047113796,0.0005668637,0.00006135667,0.00087801367,0.000687952,0.0000059508616],"category_scores_gemma":[0.002659512,0.0004928814,0.00019630528,0.00018371493,0.0009066413,0.00036222674,0.0007320133,0.00088688027,0.000018491928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013911106,0.0011784248,0.9403344,0.00019725754,0.0037289388,0.0003069489,0.0076517393,0.0004934778,0.011728678,0.00013047204,0.014998363,0.0053402404],"study_design_scores_gemma":[0.08100983,0.0011021157,0.8793108,0.00065377756,0.0015202513,0.0012023886,0.00092709856,0.000045563185,0.024714114,0.0006292511,0.008661532,0.00022329473],"about_ca_topic_score_codex":0.00011059625,"about_ca_topic_score_gemma":0.00013153706,"teacher_disagreement_score":0.06709872,"about_ca_system_score_codex":0.00005227894,"about_ca_system_score_gemma":0.00012276742,"threshold_uncertainty_score":0.9997523},"labels":[],"label_agreement":null},{"id":"W2599208050","doi":"10.4049/jimmunol.1601366","title":"Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology","year":2017,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Hand and Upper Limb Clinic; Krembil Foundation; Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research; National Institutes of Health; Public Health Agency of Canada","keywords":"Effector; Mechanism (biology); Immunopathology; Immunology; T lymphocyte; Shock (circulatory); Medicine; Biology; Immune system; Philosophy; Epistemology","score_opus":0.014190289986877873,"score_gpt":0.2253027124166198,"score_spread":0.21111242242974193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599208050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723461,0.024863876,0.00021641419,0.00020528353,0.0019261824,0.00028784265,0.000090984286,0.000011607437,0.00005168931],"genre_scores_gemma":[0.99777454,0.0018432364,0.000116902345,0.000008377198,0.000033216733,0.000008046197,0.000025953448,0.000016079191,0.0001736515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982534,0.0005232326,0.0007151426,0.00018263563,0.000060350158,0.000265243],"domain_scores_gemma":[0.9971053,0.0003607678,0.0017595855,0.00055513944,0.00020340864,0.000015800839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001010403,0.00024035868,0.00078170083,0.00017859976,0.00037839226,0.000009651134,0.0004893446,0.00029761143,0.000053262687],"category_scores_gemma":[0.0004983581,0.00016330776,0.0001429781,0.00006328014,0.0011787913,0.0001950084,0.00014327382,0.00022686501,0.000010390753],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017033757,0.000261863,0.0020406232,0.00003854009,0.00096775265,0.000013870565,0.00047471892,0.000002063246,0.97980297,0.000312559,0.000051730778,0.014329955],"study_design_scores_gemma":[0.004890551,0.0023933859,0.11659736,0.00015017652,0.0008323234,0.011471295,0.00028993323,0.0000026548666,0.86251384,0.00048153294,0.00018408646,0.00019287088],"about_ca_topic_score_codex":0.00021992548,"about_ca_topic_score_gemma":0.000024612938,"teacher_disagreement_score":0.11728912,"about_ca_system_score_codex":0.00005960324,"about_ca_system_score_gemma":0.00010562849,"threshold_uncertainty_score":0.6659497},"labels":[],"label_agreement":null},{"id":"W2601521858","doi":"10.1002/psp4.12182","title":"Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight","year":2017,"lang":"en","type":"article","venue":"CPT Pharmacometrics & Systems Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Biotech; Eli Lilly and Company; Galderma; Astellas Pharma; Mylan; UCB Pharma; Regeneron Pharmaceuticals; Genentech; Celgene; Sanofi; Amgen; Pfizer; Meiji Seika Pharma","keywords":"Tofacitinib; Janus kinase inhibitor; Plaque psoriasis; Medicine; Psoriasis; Potency; Body weight; Internal medicine; Psoriasis Area and Severity Index; Population; Pharmacology; Body surface area; Janus kinase; Clinical trial; Dermatology; Chemistry","score_opus":0.0632394518170323,"score_gpt":0.38185053162312693,"score_spread":0.3186110798060946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601521858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98345786,0.008712418,0.00006416512,0.0002355469,0.0044966247,0.0023395235,0.00050877774,0.000049618124,0.00013545758],"genre_scores_gemma":[0.9972733,0.00097305287,0.00019723966,0.00013581853,0.0002625383,0.0008314471,0.00010366634,0.000036102876,0.00018680346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956334,0.0017639745,0.001047077,0.00070147216,0.00013473135,0.0007193291],"domain_scores_gemma":[0.9961444,0.0018494675,0.0009881449,0.00059071544,0.00032558947,0.000101648264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043451143,0.000438356,0.0010758536,0.00065352715,0.0007770499,0.00008681908,0.00093029597,0.0003745269,0.00008951327],"category_scores_gemma":[0.00059916236,0.00033668763,0.00018086436,0.0004868265,0.00080987945,0.00047523185,0.00029415503,0.00042251786,0.000017941691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067555755,0.0009873749,0.054135356,0.00047981806,0.0012753514,0.00005841937,0.0011115965,0.000629386,0.91111887,0.0013122591,0.0010587896,0.021077234],"study_design_scores_gemma":[0.17298742,0.0022623304,0.123368256,0.00025061873,0.0039056153,0.00032596115,0.0006000001,0.007524984,0.6570754,0.00037408224,0.029548908,0.0017764458],"about_ca_topic_score_codex":0.00080871204,"about_ca_topic_score_gemma":0.000016502176,"teacher_disagreement_score":0.25404346,"about_ca_system_score_codex":0.00011432676,"about_ca_system_score_gemma":0.00016763604,"threshold_uncertainty_score":0.9999085},"labels":[],"label_agreement":null},{"id":"W2604523348","doi":"10.1053/j.gastro.2017.03.049","title":"Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study","year":2017,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":277,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Placebo; Medicine; Crohn's disease; Internal medicine; Gastroenterology; Adverse effect; Clinical trial; Cytokine; Clinical endpoint; Confidence interval; Immunology; Disease; Pathology","score_opus":0.01178307712284571,"score_gpt":0.27209361238559865,"score_spread":0.26031053526275294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604523348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833435,0.000054042983,0.000043846638,0.00011023219,0.0002403158,0.0009165222,0.000254006,0.000020562933,0.000026134483],"genre_scores_gemma":[0.9992857,0.0000118134185,0.000053976586,0.00012180436,0.000015942589,0.000044239714,0.00038208018,0.000019782883,0.000064636224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983573,0.00034049523,0.00034027858,0.000488525,0.00004694192,0.00042648788],"domain_scores_gemma":[0.99898326,0.00003124205,0.00020504785,0.00061942596,0.00006617899,0.000094832154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016590116,0.00025895008,0.0005091624,0.00016762713,0.00019777105,0.000019927438,0.00032587358,0.000092762064,0.00003225589],"category_scores_gemma":[0.00004415501,0.00020674015,0.000038041704,0.000036651334,0.00020511252,0.00012215793,0.00018840231,0.00013078525,0.000016701351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06742661,0.004014393,0.91778755,0.000010365241,0.00033022233,0.00008597813,0.0010106016,0.000026700174,0.001397295,0.0000038509124,0.000032191794,0.007874272],"study_design_scores_gemma":[0.0403523,0.005758629,0.9533261,0.000048272952,0.00012118667,0.0000054226857,0.00011725689,0.0000078625735,0.00010461716,0.000003955052,0.00003976746,0.00011463174],"about_ca_topic_score_codex":0.000053330295,"about_ca_topic_score_gemma":0.0006063136,"teacher_disagreement_score":0.03553857,"about_ca_system_score_codex":0.00003075138,"about_ca_system_score_gemma":0.000025686959,"threshold_uncertainty_score":0.84306186},"labels":[],"label_agreement":null},{"id":"W2604967271","doi":"10.1111/jdv.14250","title":"Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Innovaderm (Canada)","funders":"Janssen Biotech; Merck Sharp and Dohme; Allergan; Astellas Pharma; Celgene; Regeneron Pharmaceuticals; Novartis; Amgen; Pfizer; LEO Pharma Research Foundation; Eli Lilly and Company; Johnson and Johnson; AbbVie; Merck; GlaxoSmithKline","keywords":"Medicine; Psoriasis; Dermatology; Body surface area; Surgery","score_opus":0.036488101955308855,"score_gpt":0.2993034730095933,"score_spread":0.26281537105428443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604967271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307793,0.002588213,0.0000023662326,0.003409344,0.00027263057,0.000108483146,0.000018126375,0.0000038285125,0.00051907584],"genre_scores_gemma":[0.99726284,0.0024561388,0.000031243562,0.000091108435,0.000039936967,7.5751876e-7,0.0000011237186,0.000006472798,0.00011039616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997658,0.0012741144,0.000661189,0.00019628875,0.00004845843,0.00016192348],"domain_scores_gemma":[0.9981646,0.00034311815,0.0011180176,0.00028507537,0.000056821536,0.000032388838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003402409,0.00017182516,0.00060836266,0.000066711174,0.00017638977,0.0000045964607,0.0004022794,0.0002696823,0.000006428917],"category_scores_gemma":[0.00027421868,0.00010066102,0.0001374591,0.000029731467,0.0009615075,0.00007623248,0.00009154254,0.0002443424,0.0000020118698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005537431,0.00070562086,0.9277606,0.000040378047,0.00064896815,0.000048473605,0.00058234064,0.000033598313,0.031793736,0.002101224,0.0001337163,0.030613918],"study_design_scores_gemma":[0.004056337,0.0006231511,0.8905767,0.00011668182,0.00010934041,0.0005358057,0.000015697888,0.000001362486,0.10241483,0.0005032771,0.0009772263,0.00006954864],"about_ca_topic_score_codex":0.000012357844,"about_ca_topic_score_gemma":0.0000026840362,"teacher_disagreement_score":0.070621096,"about_ca_system_score_codex":0.000014329385,"about_ca_system_score_gemma":0.000031705884,"threshold_uncertainty_score":0.41048372},"labels":[],"label_agreement":null},{"id":"W2605632483","doi":"","title":"Diagnosis and management of psoriasis.","year":2017,"lang":"en","type":"review","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":412,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa","funders":"","keywords":"Medicine; Psoriasis; Psychosocial; Disease; Intensive care medicine; Acitretin; MEDLINE; Observational study; Dermatology; Psychological intervention; Referral; Clinical trial; Physical therapy; Internal medicine; Psychiatry; Family medicine","score_opus":0.1097961194219535,"score_gpt":0.3045903520668061,"score_spread":0.19479423264485263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605632483","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003611132,0.99282885,3.6246448e-7,0.0000121269995,0.0011169097,0.0016080786,0.00016233962,0.000027461774,0.00420777],"genre_scores_gemma":[0.00007237124,0.9839486,0.00002261214,0.000003846869,0.00004432161,0.009407184,0.00016851899,0.000026982452,0.006305549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987254,0.00015434153,0.00038309238,0.00037065803,0.000028322838,0.0003381949],"domain_scores_gemma":[0.9988061,0.00012675175,0.00044781604,0.00057389645,0.000016942779,0.000028471693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002647682,0.00032115364,0.0013595187,0.00014005048,0.00012060126,0.000016723921,0.00033900785,0.00039753717,0.00005367864],"category_scores_gemma":[0.000023123486,0.00024232513,0.00033984182,0.000060508504,0.00013649755,0.000041572475,0.00018510783,0.000107190994,0.000095473595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000846479,0.00006986726,0.00006700124,0.0071620066,0.002381371,0.000013581686,0.000008252289,1.5674101e-9,1.5003168e-8,0.00019865611,0.0012092078,0.9888816],"study_design_scores_gemma":[0.0005000859,0.000011295715,0.004912174,0.0015718649,0.0042147627,0.000020302845,0.000003688285,7.648608e-10,0.000011924109,0.000020148373,0.9885301,0.00020367609],"about_ca_topic_score_codex":0.000014998961,"about_ca_topic_score_gemma":0.0000035919604,"teacher_disagreement_score":0.9886779,"about_ca_system_score_codex":0.000031053652,"about_ca_system_score_gemma":0.000015431022,"threshold_uncertainty_score":0.9881732},"labels":[],"label_agreement":null},{"id":"W2606034862","doi":"10.1016/j.jid.2017.02.505","title":"485 Genetic signature to assess risk of psoriasis subtypes through machine learning approach","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Genetic architecture; Receiver operating characteristic; Oncology; Discriminative model; Internal medicine; Machine learning; Computer science; Population; Quantitative trait locus; Immunology","score_opus":0.04076731427094829,"score_gpt":0.27456588793233566,"score_spread":0.23379857366138737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606034862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005073,0.005782594,0.0011947555,0.000677961,0.0007552476,0.0001747634,0.00005406113,0.000013568381,0.0012962935],"genre_scores_gemma":[0.98908585,0.00050134404,0.009867299,0.00013710768,0.00007952888,0.000008998924,0.000020519921,0.000022288279,0.00027707708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997619,0.0010217548,0.0006833216,0.00025215614,0.00008763732,0.00033618658],"domain_scores_gemma":[0.99694425,0.00033385598,0.001880173,0.0003851499,0.00038077426,0.00007580801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033746267,0.00028136343,0.00088509143,0.00019541569,0.0004819675,0.000026139107,0.000661233,0.0004139818,0.00009039036],"category_scores_gemma":[0.0013338496,0.00021407784,0.00025268097,0.00011874092,0.0006876731,0.00022025972,0.00013537722,0.0007141787,0.000056602155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011533997,0.0004899573,0.4029415,0.00015653574,0.005249527,0.00032243793,0.0092216665,0.0008601581,0.5640757,0.0025985132,0.0054954244,0.0074351616],"study_design_scores_gemma":[0.0027629815,0.00054002367,0.1914517,0.000083308136,0.0007367774,0.0016829213,0.0005702613,0.00002311139,0.7927347,0.002394158,0.006730167,0.00028988012],"about_ca_topic_score_codex":0.00010745445,"about_ca_topic_score_gemma":0.000026569214,"teacher_disagreement_score":0.22865897,"about_ca_system_score_codex":0.000033963726,"about_ca_system_score_gemma":0.00017390591,"threshold_uncertainty_score":0.87298405},"labels":[],"label_agreement":null},{"id":"W2606035821","doi":"10.1056/nejmoa1607017","title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":511,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Interleukin 23; Gastroenterology; Adverse effect; Interleukin 17; Dermatology; Cytokine; Disease","score_opus":0.04268194601443099,"score_gpt":0.29822357862062016,"score_spread":0.2555416326061892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606035821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961514,0.004469046,0.0021778548,0.01162979,0.015390806,0.00045103295,0.00006069516,0.000028162784,0.0042785862],"genre_scores_gemma":[0.9922108,0.00036152452,0.00066373555,0.00015217165,0.003273308,0.000007235267,0.000025150297,0.000021983482,0.0032840902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886936,0.00009919548,0.00044576108,0.00018565865,0.000089211986,0.0003107963],"domain_scores_gemma":[0.99835706,0.00047347916,0.00048921123,0.00037230065,0.0001831554,0.00012482073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000583987,0.00021778763,0.0005978354,0.00016187457,0.0004151245,0.0000256152,0.0004461273,0.00018690969,0.00048987794],"category_scores_gemma":[0.0007359088,0.00014486516,0.00014165492,0.00004209678,0.00010064353,0.00014463179,0.000040654428,0.00021438104,0.00005176143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05296,0.00012725774,0.0011604541,0.000027424,0.0015746981,0.00012146124,0.002024394,0.00007301016,0.011193499,0.00063356967,0.10763724,0.82246697],"study_design_scores_gemma":[0.42582622,0.007434063,0.006757088,0.00038720336,0.0014434045,0.0012451014,0.0004032952,0.000011208262,0.016267497,0.0016153782,0.5381968,0.00041274633],"about_ca_topic_score_codex":0.00013974533,"about_ca_topic_score_gemma":0.00012519241,"teacher_disagreement_score":0.82205427,"about_ca_system_score_codex":0.00006196528,"about_ca_system_score_gemma":0.00015784439,"threshold_uncertainty_score":0.590743},"labels":[],"label_agreement":null},{"id":"W2606314034","doi":"10.1016/j.jid.2017.02.080","title":"067 Modeling chronic psoriatic inflammation in a 3D reconstructed skin","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Involucrin; Filaggrin; Loricrin; Psoriasis; Immunology; Inflammation; Biology; Keratinocyte; Immune system; Chemokine; Dermis; Cell biology; Pathology; Medicine; Cell culture; Atopic dermatitis","score_opus":0.02872727044082413,"score_gpt":0.2595178918188475,"score_spread":0.23079062137802336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606314034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518377,0.0018562756,0.00019343874,0.0012607479,0.00094443955,0.00013888736,0.0000055670707,0.000011041377,0.0004058187],"genre_scores_gemma":[0.99861246,0.00020537277,0.0009428953,0.000045167104,0.000108590444,0.000010023382,0.000013301962,0.000012554037,0.000049650138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998267,0.00043622468,0.0007874564,0.00016546434,0.00004625005,0.0002976153],"domain_scores_gemma":[0.9982355,0.00013969404,0.001108674,0.00027611843,0.00019706337,0.00004295055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002935659,0.00019381031,0.000571582,0.0003265574,0.0002604651,0.000030659663,0.00037055917,0.00030663266,0.000094631425],"category_scores_gemma":[0.0006038547,0.00016437261,0.00011761097,0.00008080435,0.0004511175,0.00042048044,0.000058935148,0.00038251583,0.00008906838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009135855,0.000265344,0.0569554,0.00021971173,0.0023846533,0.0010054305,0.0075872173,0.0019129866,0.7749583,0.0077842693,0.00096640555,0.1450467],"study_design_scores_gemma":[0.011273041,0.00037129433,0.052131083,0.0005042594,0.0003299824,0.0055895983,0.0005907671,0.0026027744,0.9095536,0.015405587,0.0011588352,0.0004892055],"about_ca_topic_score_codex":0.00005971773,"about_ca_topic_score_gemma":0.00023354236,"teacher_disagreement_score":0.14455749,"about_ca_system_score_codex":0.00014158782,"about_ca_system_score_gemma":0.0004219659,"threshold_uncertainty_score":0.6702921},"labels":[],"label_agreement":null},{"id":"W2606626129","doi":"10.3899/jrheum.161473","title":"Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Western University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Observational study; Task force; Clinical Practice; Task (project management); Physical therapy; Position paper; Alternative medicine; Dermatology; Internal medicine; Pathology; Management","score_opus":0.011967068326185826,"score_gpt":0.2509339675084696,"score_spread":0.23896689918228375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606626129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620196,0.0052972706,0.00009437684,0.028273432,0.0014361504,0.0005703489,0.000039508494,0.00001344278,0.0022558721],"genre_scores_gemma":[0.99633676,0.0011164586,0.00033372338,0.0018519653,0.00004257268,0.00004276953,0.0000064034125,0.000017988725,0.00025138826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828064,0.0006774329,0.00042008798,0.00016611768,0.00006401586,0.00039168188],"domain_scores_gemma":[0.9976065,0.0011366352,0.0005480494,0.00045432127,0.00014666363,0.000107817956],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0008752202,0.00020765809,0.0004364335,0.00014974352,0.0015048765,0.0000717549,0.0004609061,0.00016607635,0.00013156944],"category_scores_gemma":[0.0010949619,0.000120067656,0.00008290709,0.00006873024,0.00016804392,0.00021620569,0.00005732964,0.00028232983,0.00014019501],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004281927,0.00027291893,0.019646622,0.000022191278,0.0025455714,0.00021988462,0.02580948,0.00023159078,0.010494598,0.0069602667,0.023641475,0.9058735],"study_design_scores_gemma":[0.035793867,0.0127809625,0.1670055,0.002945298,0.005676942,0.15064955,0.04398386,0.000053286716,0.030659154,0.006288475,0.54148155,0.00268155],"about_ca_topic_score_codex":0.0210504,"about_ca_topic_score_gemma":0.013105619,"teacher_disagreement_score":0.9031919,"about_ca_system_score_codex":0.00009162252,"about_ca_system_score_gemma":0.0001561263,"threshold_uncertainty_score":0.999795},"labels":[],"label_agreement":null},{"id":"W2606692799","doi":"10.1016/j.jid.2017.02.204","title":"189 Psoriasis age of onset: Effect on treatment outcomes in the PSOLAR registry","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Etanercept; Infliximab; Ustekinumab; Adalimumab; Confidence interval; Odds ratio; Internal medicine; Age of onset; Logistic regression; Methotrexate; Pediatrics; Disease; Dermatology; Rheumatoid arthritis","score_opus":0.03453472273501188,"score_gpt":0.2914062585319386,"score_spread":0.2568715357969267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606692799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456435,0.0008391171,0.0000035769067,0.0027740533,0.000659442,0.00022475909,0.000037391474,0.000005425282,0.0008918647],"genre_scores_gemma":[0.9992273,0.00012775864,0.000088154666,0.00025375275,0.000031178235,0.000020221867,0.000016422257,0.000011478811,0.00022374796],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976544,0.0012209242,0.0006079345,0.00017329745,0.00007382153,0.00026963628],"domain_scores_gemma":[0.9969726,0.0011490224,0.0011860552,0.00058149267,0.00007603672,0.0000347909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043794065,0.00027893131,0.00095846655,0.00020509602,0.00025727676,0.000021109216,0.0006325653,0.0002703818,0.000030704414],"category_scores_gemma":[0.0007031235,0.00014699397,0.0003312746,0.000064761836,0.00094482675,0.00011161773,0.00003754312,0.0003068986,0.00004906264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020001845,0.001614882,0.7929678,0.000083493025,0.0039248597,0.0039273542,0.009133716,0.000009297423,0.16678971,0.0030935358,0.0037873313,0.012667827],"study_design_scores_gemma":[0.005101645,0.001980294,0.4752508,0.000094523624,0.00031262473,0.0014800224,0.00037142192,2.9375644e-7,0.5114533,0.0009910383,0.0028295964,0.00013446563],"about_ca_topic_score_codex":0.00012200218,"about_ca_topic_score_gemma":0.00012364652,"teacher_disagreement_score":0.34466356,"about_ca_system_score_codex":0.000075769545,"about_ca_system_score_gemma":0.00013446037,"threshold_uncertainty_score":0.599424},"labels":[],"label_agreement":null},{"id":"W2606731929","doi":"10.1016/j.jaad.2017.01.052","title":"Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; LEO Pharma; Astellas Pharma; Regeneron Pharmaceuticals; Celgene; GlaxoSmithKline; Biogen; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Apremilast; Tolerability; Psoriasis; Randomized controlled trial; Safety profile; Pooled analysis; Adverse effect; Dermatology; Internal medicine; Meta-analysis; Psoriatic arthritis","score_opus":0.016826691240104122,"score_gpt":0.2979934696584649,"score_spread":0.2811667784183608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606731929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934921,0.0027957133,0.00036364564,0.0016548182,0.00016336818,0.0011014314,0.00041048275,0.0000031895665,0.000015201986],"genre_scores_gemma":[0.99863786,0.00095272204,0.00023770238,0.00007834099,0.000025872663,0.000020204161,0.000021034515,0.000010743558,0.000015549758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945243,0.0025367532,0.0023450863,0.0002518981,0.000094436116,0.00024751484],"domain_scores_gemma":[0.9875861,0.0043657585,0.007576162,0.0002875728,0.00013671369,0.000047736245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020464093,0.00027520963,0.0068774046,0.00029717333,0.00018069748,0.0000129169075,0.00044456602,0.00022152055,0.000028180826],"category_scores_gemma":[0.0019082467,0.00014667826,0.0009221521,0.00013775156,0.001538479,0.00013436926,0.000101388025,0.00027372342,2.7711286e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4116991,0.00038803156,0.56617814,0.000021342616,0.011618504,0.000001894218,0.00018597758,0.000008146313,0.0014865904,0.00002759053,0.000013877333,0.008370822],"study_design_scores_gemma":[0.3520493,0.00030198842,0.6342999,0.00007632233,0.009600473,0.000037513382,0.000061444196,0.000010247671,0.0033034764,0.00011428075,0.000032656837,0.00011245706],"about_ca_topic_score_codex":0.0000675861,"about_ca_topic_score_gemma":0.000029333942,"teacher_disagreement_score":0.06812172,"about_ca_system_score_codex":0.000030271503,"about_ca_system_score_gemma":0.00007262369,"threshold_uncertainty_score":0.5981366},"labels":[],"label_agreement":null},{"id":"W2610587605","doi":"10.3899/jrheum.170149","title":"Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Plaque psoriasis; Dermatology; Disease; Phrase; Pathology; Natural language processing","score_opus":0.015484915503830177,"score_gpt":0.2468474918375257,"score_spread":0.2313625763336955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610587605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758652,0.014873923,0.00009171316,0.004281813,0.0039561545,0.000112367554,0.000039366354,0.000017525259,0.00076197344],"genre_scores_gemma":[0.99702346,0.0018347299,0.00009532585,0.00010484096,0.000071641254,0.0000041742023,0.000009877982,0.000017229188,0.0008387317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980255,0.0007090348,0.00069212075,0.00015437782,0.0000696733,0.00034933773],"domain_scores_gemma":[0.9960839,0.0010810175,0.0017398805,0.0008976732,0.00016822002,0.000029290302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014438726,0.00020562553,0.0005217808,0.000055342705,0.0011504131,0.000032141168,0.001248092,0.00022980275,0.00020260135],"category_scores_gemma":[0.00076687767,0.00009882976,0.00022346385,0.00004297767,0.00050751626,0.00015857483,0.00017738897,0.00038654127,0.00021783082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033697106,0.00029510996,0.7583351,0.000013165938,0.0057842922,0.00027068454,0.008640087,0.000008226313,0.013850432,0.0012776735,0.12710121,0.081054315],"study_design_scores_gemma":[0.013621983,0.00086529687,0.7014798,0.00082977815,0.0036792932,0.08189311,0.00948442,0.0000044314606,0.015814237,0.013633951,0.1577769,0.0009168291],"about_ca_topic_score_codex":0.0022621623,"about_ca_topic_score_gemma":0.0003287295,"teacher_disagreement_score":0.08162243,"about_ca_system_score_codex":0.000022015613,"about_ca_system_score_gemma":0.00015422226,"threshold_uncertainty_score":0.8848164},"labels":[],"label_agreement":null},{"id":"W2610923037","doi":"10.1016/s0140-6736(17)31189-3","title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland; Centre Hospitalier Universitaire Sainte-Justine; Probity Medical Research","funders":"","keywords":"Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Methotrexate; Internal medicine; Adverse effect; Etanercept; Clinical trial; Randomized controlled trial; Dermatology; Disease","score_opus":0.04238407036783415,"score_gpt":0.30119928070151153,"score_spread":0.2588152103336774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610923037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374795,0.0037304694,0.000008601177,0.00028429079,0.00032028495,0.0014495584,0.00014333728,0.000022916533,0.00029257094],"genre_scores_gemma":[0.9982364,0.0011353028,0.00003357955,0.000026645648,0.00026746735,0.00006488814,0.000036397752,0.00002077884,0.00017854675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986737,0.00033878698,0.00027498935,0.00032676253,0.000051374584,0.00033440668],"domain_scores_gemma":[0.99882454,0.00018616638,0.00030989837,0.0006315493,0.000021372653,0.000026472266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053565414,0.00024304578,0.0007074406,0.0000572824,0.00029188636,0.00003477515,0.00035992285,0.00016979473,0.00003499445],"category_scores_gemma":[0.00004333917,0.00015273949,0.00005949863,0.000055536664,0.0003056119,0.00012119214,0.000094711766,0.00021309816,0.000012684427],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97485584,0.00033541335,0.0045133596,0.000026781026,0.00081585255,0.0000045212737,0.00037535836,0.000007862304,0.001448121,0.000048961585,0.00011400688,0.017453894],"study_design_scores_gemma":[0.94859767,0.0011384696,0.046084896,0.00027630216,0.0004383507,0.00003737967,0.000037250717,0.0000023992673,0.0026876614,0.000016686428,0.00048148195,0.00020144526],"about_ca_topic_score_codex":0.00037439092,"about_ca_topic_score_gemma":0.0003251375,"teacher_disagreement_score":0.041571535,"about_ca_system_score_codex":0.000036938105,"about_ca_system_score_gemma":0.00007993275,"threshold_uncertainty_score":0.6228536},"labels":[],"label_agreement":null},{"id":"W2611113224","doi":"10.3899/jrheum.170143","title":"Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Inflammation; Immunology; Interleukin 17; Immunity; Innate immune system; Translational science; Immune system; Pathology","score_opus":0.015722791785106587,"score_gpt":0.25539048082654076,"score_spread":0.23966768904143418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611113224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872029,0.006594755,0.000053959644,0.0045363656,0.0010733748,0.00006319035,0.00002481284,0.000005250908,0.00044543215],"genre_scores_gemma":[0.9988846,0.00078323187,0.0000850805,0.000042471984,0.000019963965,0.0000012848666,0.0000036360213,0.0000051998704,0.00017449766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990293,0.0002343728,0.00035668144,0.00011257847,0.00006514445,0.0002019153],"domain_scores_gemma":[0.9982334,0.0005856483,0.00068882917,0.0003341506,0.00013706928,0.000020904728],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0017164565,0.00010235119,0.00024954558,0.000053501455,0.0013221862,0.000029010673,0.0006046568,0.000092507245,0.000077739925],"category_scores_gemma":[0.00035932494,0.000048859394,0.00007101414,0.00004207723,0.001336714,0.00018400131,0.00007378726,0.00019395885,0.000021988186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066174,0.000066204855,0.9295593,0.000004079807,0.0006712681,0.000046272835,0.005478111,0.0000030058197,0.019618776,0.0009761127,0.006629154,0.036285993],"study_design_scores_gemma":[0.0035456733,0.00017799524,0.9327165,0.00016161373,0.00049864274,0.035020903,0.0019632021,0.0000057720135,0.0051859627,0.0060595674,0.014466054,0.00019812326],"about_ca_topic_score_codex":0.00042499934,"about_ca_topic_score_gemma":0.00010491092,"teacher_disagreement_score":0.03608787,"about_ca_system_score_codex":0.0000069183843,"about_ca_system_score_gemma":0.00020629076,"threshold_uncertainty_score":0.99997795},"labels":[],"label_agreement":null},{"id":"W2611174059","doi":"10.3899/jrheum.170151","title":"Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Delphi method; Psoriatic arthritis; Delphi; Set (abstract data type); MEDLINE; Outcome (game theory); Clinical trial; Medical physics; Family medicine; Dermatology; Pathology; Artificial intelligence","score_opus":0.03027736813001166,"score_gpt":0.28176003903441854,"score_spread":0.2514826709044069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611174059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607913,0.023477672,0.0005177217,0.009444804,0.0049862186,0.00027844537,0.000098986464,0.000020898018,0.00038396363],"genre_scores_gemma":[0.99786353,0.0012259851,0.00017771802,0.00018142645,0.000070883296,0.00001830952,0.000012619353,0.000022431255,0.0004270707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976331,0.000797019,0.0009167609,0.00016921604,0.00008794968,0.00039594495],"domain_scores_gemma":[0.99321723,0.0035286772,0.002079462,0.0008895395,0.00026073577,0.00002437517],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0036522865,0.00023165917,0.0006023792,0.000047185673,0.0020253453,0.000050063158,0.0014703465,0.00022841338,0.000044719225],"category_scores_gemma":[0.0025019534,0.0000948595,0.00035401827,0.000038864917,0.00052261114,0.00014058307,0.00016124369,0.00039267307,0.00006786999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023768006,0.000113196984,0.8597569,0.000013390411,0.00453633,0.000048943224,0.0060220435,0.000020223164,0.0028303624,0.0026762567,0.07214304,0.049462542],"study_design_scores_gemma":[0.018498002,0.0011238424,0.5255569,0.0008863147,0.007164957,0.053593475,0.020296462,0.0000128421925,0.013855588,0.02462601,0.33319607,0.0011894898],"about_ca_topic_score_codex":0.001195474,"about_ca_topic_score_gemma":0.00048414894,"teacher_disagreement_score":0.33419994,"about_ca_system_score_codex":0.000023107332,"about_ca_system_score_gemma":0.00014037872,"threshold_uncertainty_score":0.9992739},"labels":[],"label_agreement":null},{"id":"W2611315837","doi":"10.3899/jrheum.170144","title":"International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Medicine; Guideline; Psoriatic arthritis; Publishing; General partnership; League; Family medicine; Library science; Medical education; Political science; Arthritis; Internal medicine; Pathology; Computer science","score_opus":0.021277620336482644,"score_gpt":0.2777775090017348,"score_spread":0.2564998886652522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611315837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958574,0.002955653,0.0001364539,0.031295925,0.0052110488,0.00011615296,0.00015320902,0.000013806891,0.001543768],"genre_scores_gemma":[0.9912255,0.00714087,0.00021648518,0.000092462156,0.000055606815,0.0000071661584,0.00008566933,0.000010723197,0.0011655655],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987245,0.00041135104,0.000518419,0.00011362481,0.000044018663,0.0001880556],"domain_scores_gemma":[0.99740535,0.00068416726,0.0012308483,0.0005142942,0.00014651628,0.000018809993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068792363,0.00014385501,0.00030368657,0.00004973246,0.0008273218,0.000031137843,0.00080204144,0.00011818021,0.00056305],"category_scores_gemma":[0.00029540466,0.000068545465,0.00015939331,0.000023722412,0.0002500219,0.00014911835,0.00011025523,0.00017189556,0.0001691295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016717602,0.0005235606,0.49683857,0.0000026217813,0.0076827547,0.00014989932,0.0057920218,0.000009306548,0.0048586787,0.0009267531,0.24611495,0.23542912],"study_design_scores_gemma":[0.005124353,0.0003199857,0.063070714,0.00015474448,0.00088374526,0.022010513,0.0024859852,0.000004240767,0.00410581,0.0018949059,0.89971346,0.00023151611],"about_ca_topic_score_codex":0.0013846521,"about_ca_topic_score_gemma":0.0003264378,"teacher_disagreement_score":0.65359855,"about_ca_system_score_codex":0.000048727372,"about_ca_system_score_gemma":0.000101216756,"threshold_uncertainty_score":0.6363174},"labels":[],"label_agreement":null},{"id":"W2611682190","doi":"10.3899/jrheum.170147","title":"Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Clinical Practice; Clinical trial; Physical therapy; Medical physics; Dermatology; Internal medicine","score_opus":0.10223115259379768,"score_gpt":0.4625903315164816,"score_spread":0.36035917892268393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611682190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755,0.0026389211,0.0002922655,0.016032303,0.0047502425,0.0003759967,0.000062020554,0.0000104933715,0.00033777292],"genre_scores_gemma":[0.97512203,0.018885795,0.005353104,0.00035007368,0.00019173237,0.0000056584695,0.000010713111,0.000020401529,0.000060511862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9666033,0.02581956,0.0065241675,0.0004348694,0.00019022962,0.00042792092],"domain_scores_gemma":[0.91312796,0.074717656,0.010644521,0.0010103789,0.00041176876,0.000087736735],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08631446,0.00028139533,0.0024641517,0.000073453746,0.0004558347,0.000041280582,0.00081932155,0.00083319366,0.000067996465],"category_scores_gemma":[0.101611555,0.00014818963,0.0006919406,0.00007091682,0.001667482,0.00038334916,0.00041296225,0.0018563598,0.000014319238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039981892,0.0010128325,0.9324365,0.00000899995,0.0029649409,0.00018916947,0.00035754766,3.7543148e-7,0.000058903002,0.00018901314,0.021586465,0.03719701],"study_design_scores_gemma":[0.009401615,0.0010770083,0.9473594,0.0003181943,0.0026630498,0.01169855,0.0026095298,0.000016553273,0.000047488214,0.000681731,0.023916053,0.00021082963],"about_ca_topic_score_codex":0.0010279239,"about_ca_topic_score_gemma":0.0002749769,"teacher_disagreement_score":0.053475313,"about_ca_system_score_codex":0.000028635675,"about_ca_system_score_gemma":0.00089626503,"threshold_uncertainty_score":0.94083154},"labels":[],"label_agreement":null},{"id":"W2611820913","doi":"10.3899/jrheum.170145","title":"Treatments for Psoriatic Arthritis, a Guide for Patients Written by Fellow Patients: A Report from the GRAPPA 2016 Annual Meeting","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Dermatology; Medical physics; Arthritis; Alternative medicine; Physical therapy; Pathology; Internal medicine","score_opus":0.010044242334790437,"score_gpt":0.24428952692965902,"score_spread":0.2342452845948686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611820913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874447,0.0066009173,0.00024904,0.001025972,0.002735591,0.0008221416,0.0010367875,0.000012550631,0.00007227958],"genre_scores_gemma":[0.9939606,0.0035739078,0.0005043242,0.00013138958,0.00005070102,0.0001133969,0.00050067296,0.000039947783,0.001125038],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979732,0.00034624262,0.0009565061,0.00021836418,0.0000769763,0.0004287114],"domain_scores_gemma":[0.9953165,0.0015156409,0.0020917093,0.0005855854,0.0004537227,0.000036858168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076953636,0.00026490176,0.000650444,0.000048737445,0.0011463743,0.000034019162,0.0007610753,0.00022850178,0.000029371518],"category_scores_gemma":[0.0013011423,0.00014265596,0.00031975872,0.000028793873,0.00021498717,0.00018132135,0.00008959979,0.00014321636,0.0000249059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024500168,0.00081326644,0.5279104,0.000012438128,0.0037852295,0.0000062867234,0.0014480391,7.646543e-7,0.0005014312,0.000041407628,0.35785446,0.10517625],"study_design_scores_gemma":[0.11075561,0.008610763,0.33844593,0.0016044074,0.0075276187,0.0024710959,0.0028455686,0.000013050741,0.006284191,0.008732688,0.51125425,0.0014548419],"about_ca_topic_score_codex":0.00073205854,"about_ca_topic_score_gemma":0.0001614295,"teacher_disagreement_score":0.18946448,"about_ca_system_score_codex":0.000052217747,"about_ca_system_score_gemma":0.0000993339,"threshold_uncertainty_score":0.88171},"labels":[],"label_agreement":null},{"id":"W2612570099","doi":"10.1007/s13671-017-0177-6","title":"Autoimmunity in Psoriasis: Evidence for Specific Autoantigens","year":2017,"lang":"en","type":"article","venue":"Current Dermatology Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Dermira; Regeneron Pharmaceuticals; Georgia Clinical and Translational Science Alliance; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Psoriasis; Medicine; Autoimmunity; Disease; Immunology; Immune system; Dermatology; Pathology","score_opus":0.11282965975236947,"score_gpt":0.3505791612205521,"score_spread":0.23774950146818263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612570099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93679214,0.048783943,0.00020530014,0.000656887,0.012064843,0.00080802926,0.000024997049,0.00012998728,0.00053387793],"genre_scores_gemma":[0.997254,0.0016970539,0.0001288018,0.000020915635,0.00007517432,0.00028135837,0.0001359611,0.000022865062,0.00038384137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776775,0.00021461054,0.00074060203,0.00060761016,0.000044896362,0.00062454026],"domain_scores_gemma":[0.9974111,0.00030966933,0.00068206113,0.0014563358,0.000102701466,0.000038171052],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047149495,0.00030668013,0.0006255769,0.00018494805,0.0008348058,0.000054745444,0.00045464488,0.00035535832,0.00014403672],"category_scores_gemma":[0.00059499894,0.00028524362,0.00023040196,0.00006848954,0.0003849825,0.00029761912,0.00016624434,0.00029001117,0.00018817182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037932798,0.0005996287,0.8179429,0.00015586338,0.0002852241,0.0010401369,0.0006607439,0.000002116751,0.011148997,0.0009957218,0.017271439,0.1495179],"study_design_scores_gemma":[0.002556581,0.000070013324,0.70935,0.0004067206,0.00018891256,0.00485437,0.00007245331,0.000007604678,0.034213647,0.001963265,0.24574913,0.00056733994],"about_ca_topic_score_codex":0.00004564082,"about_ca_topic_score_gemma":0.000056215475,"teacher_disagreement_score":0.22847769,"about_ca_system_score_codex":0.00006475919,"about_ca_system_score_gemma":0.0001544516,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2613045021","doi":"10.4049/jimmunol.194.supp.128.12","title":"Interleukin-17 receptor A (IL-17RA) is a key regulator of type 2 inflammatory responses involved in maintaining immune system homeostasis. (IRC7P.431)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Immunology; Inflammation; Atopic dermatitis; Psoriasis; Immune system; Cytokine; Biology; Innate lymphoid cell; Immunoglobulin E; Innate immune system; Antibody","score_opus":0.02595832513664802,"score_gpt":0.24398917053199454,"score_spread":0.2180308453953465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613045021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502121,0.046876952,0.000013868281,0.00056693854,0.0018539616,0.00021690864,0.000031129235,0.000029217485,0.00019890256],"genre_scores_gemma":[0.9977637,0.0012159261,0.00015392383,0.00005859756,0.00007234684,0.000008156917,0.000014554631,0.00003408495,0.0006787079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958543,0.0020271419,0.0013383196,0.00019024636,0.00010892027,0.00048102735],"domain_scores_gemma":[0.996963,0.0006302884,0.0012742075,0.0005922309,0.00049629615,0.000043944885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028378982,0.00031190776,0.00096663326,0.00060247205,0.000109033994,0.000011169403,0.00076446804,0.00042850582,0.00013726144],"category_scores_gemma":[0.00048269622,0.00021797266,0.0002249792,0.00040472564,0.00046756078,0.00019083312,0.00020721623,0.00058448396,0.00015436624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040680766,0.00037527713,0.012920062,0.000072353716,0.0035771374,0.00013082504,0.019919313,0.00003223627,0.906743,0.0013913348,0.0046361005,0.009521607],"study_design_scores_gemma":[0.022177285,0.008335013,0.06792607,0.0018099088,0.0010831531,0.0034231648,0.0666186,0.000011552077,0.7839187,0.00050796097,0.043287832,0.00090078387],"about_ca_topic_score_codex":0.00013029532,"about_ca_topic_score_gemma":0.00003570111,"teacher_disagreement_score":0.12282431,"about_ca_system_score_codex":0.00040720488,"about_ca_system_score_gemma":0.0005304534,"threshold_uncertainty_score":0.8888667},"labels":[],"label_agreement":null},{"id":"W2613579314","doi":"10.1080/09546634.2017.1329499","title":"What is clearance worth? Patients’ stated risk tolerance for psoriasis treatments","year":2017,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Duke University; Eli Lilly and Company","keywords":"Medicine; Psoriasis; Plaque psoriasis; Regimen; Dermatology; Logistic regression; Surgery; Internal medicine","score_opus":0.03240300307459103,"score_gpt":0.2863386960471726,"score_spread":0.25393569297258156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613579314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848159,0.010850961,0.00005432096,0.00047180447,0.0027082607,0.0005627727,0.00031469585,0.000033515447,0.00018775767],"genre_scores_gemma":[0.9796036,0.018537067,0.0006946277,0.00011242488,0.000076586024,0.00008103941,0.000065273045,0.000023828754,0.000805578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982677,0.00017788858,0.000691812,0.00030792513,0.00009122588,0.000463451],"domain_scores_gemma":[0.99787724,0.00022168344,0.0010768878,0.0004999184,0.00023499047,0.00008930376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011935048,0.00039933788,0.00086228934,0.00008950465,0.0007581934,0.00015479545,0.00039405123,0.00030118437,0.00013537295],"category_scores_gemma":[0.00006916061,0.00024907675,0.00058050716,0.00004939965,0.00017569854,0.0005820362,0.000035787012,0.00013442147,0.00012321753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032630211,0.003061931,0.51436937,0.000022572458,0.0045323456,0.00013881573,0.00075121294,0.00002098778,0.00038140017,0.000047772093,0.0037937693,0.46961683],"study_design_scores_gemma":[0.034006983,0.004423287,0.84847945,0.00019446021,0.002383182,0.00028094937,0.00024045659,0.000017595155,0.0567304,0.0011164121,0.051563397,0.00056343485],"about_ca_topic_score_codex":0.000012988513,"about_ca_topic_score_gemma":0.0000069949183,"teacher_disagreement_score":0.4690534,"about_ca_system_score_codex":0.00018738088,"about_ca_system_score_gemma":0.0000506867,"threshold_uncertainty_score":0.9999961},"labels":[],"label_agreement":null},{"id":"W2617646057","doi":"10.1177/1203475417712499","title":"Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report","year":2017,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Generalized pustular psoriasis; Infliximab; Apremilast; Pustular psoriasis; Disease; Internal medicine; Psoriatic arthritis","score_opus":0.032805024949255246,"score_gpt":0.29383439712897746,"score_spread":0.2610293721797222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617646057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988471,0.0097651845,0.000017698485,0.00042013684,0.0010857247,0.000096577496,0.000008279902,0.0000070140413,0.0001283947],"genre_scores_gemma":[0.9930509,0.0060724956,0.000063093124,0.00004510423,0.00016493103,0.0000020067516,0.000018331668,0.000012646909,0.0005704955],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987379,0.00009711729,0.00067904004,0.00018947349,0.000090268455,0.00020621139],"domain_scores_gemma":[0.9985514,0.00019293476,0.00065248687,0.00038986403,0.00012571018,0.00008756462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007121552,0.00018331077,0.0007315308,0.00018855838,0.0002642675,0.000018715913,0.000117406176,0.00014380354,0.0000869135],"category_scores_gemma":[0.00008165842,0.00012653302,0.00012476751,0.00003832904,0.00028527837,0.00015221119,0.000054189433,0.00013786125,0.0000012026878],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007838508,0.00016291908,0.08424093,0.0001299423,0.002839198,0.6605559,0.0004534824,2.754618e-7,0.0043814573,0.000014853926,0.0011865482,0.24525063],"study_design_scores_gemma":[0.0013061743,0.00068921666,0.0713831,0.00046898445,0.0026352236,0.91924155,0.00040313767,9.865086e-7,0.002273581,0.0000559739,0.0013593769,0.00018267165],"about_ca_topic_score_codex":0.000024070287,"about_ca_topic_score_gemma":0.00001384551,"teacher_disagreement_score":0.25868565,"about_ca_system_score_codex":0.000013522681,"about_ca_system_score_gemma":0.00003351963,"threshold_uncertainty_score":0.5159867},"labels":[],"label_agreement":null},{"id":"W2618122943","doi":"10.1038/ncomms15382","title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","year":2017,"lang":"en","type":"review","venue":"Nature Communications","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":400,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital; University of Toronto","funders":"National Center for Research Resources; European Regional Development Fund; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Medical Research Council; National Institutes of Health; Tartu Ülikool; Heinz Nixdorf Stiftung; Deutsche Forschungsgemeinschaft; Exzellenzclusters Entzündungsforschung; National Research Foundation; King's College London; Psoriasis Association; National Human Genome Research Institute; Wellcome Trust; National Psoriasis Foundation; Helene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust; A. Alfred Taubman Medical Research Institute; Dermatology Foundation; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research; Arthritis National Research Foundation; U.S. Department of Veterans Affairs; Foundation for the National Institutes of Health","keywords":"Psoriasis; Genome-wide association study; Genetic architecture; Heritability; Genetics; Genetic association; Biology; Meta-analysis; Computational biology; Medicine; Quantitative trait locus; Single-nucleotide polymorphism; Immunology; Gene; Genotype; Internal medicine","score_opus":0.12161756025961362,"score_gpt":0.3777229581284424,"score_spread":0.2561053978688288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618122943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013237045,0.98142654,0.00008033141,0.00040495212,0.0006412606,0.0016580733,0.015142225,0.00012779141,0.00050557626],"genre_scores_gemma":[0.0012771068,0.95801604,0.0014357031,0.000110961824,0.00006935553,0.0019349103,0.033528015,0.0000884271,0.0035394595],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.995683,0.0019766795,0.0009350031,0.00071682,0.00008325969,0.00060520024],"domain_scores_gemma":[0.9902751,0.001806267,0.0015836502,0.00604302,0.00023550904,0.000056468223],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007656558,0.00080341223,0.0052044876,0.0006084388,0.0017199949,0.00011397007,0.0037989966,0.003037099,0.00032317007],"category_scores_gemma":[0.0003677703,0.00059846835,0.0060083577,0.0006117306,0.00020911708,0.00007472791,0.00065797043,0.0017842165,0.00018553878],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028398073,0.00088380044,0.000054979395,0.0005411809,0.5743361,0.0000026033808,0.00028416896,3.9154028e-7,0.000012220974,0.0003434084,0.0032571084,0.42025563],"study_design_scores_gemma":[0.00036743193,0.000026792039,0.00040811748,0.00009462891,0.38170734,0.000009910448,0.000006461885,9.0743697e-7,0.0000028372467,0.000047316335,0.6169998,0.00032843603],"about_ca_topic_score_codex":0.000032142947,"about_ca_topic_score_gemma":0.002917391,"teacher_disagreement_score":0.6137427,"about_ca_system_score_codex":0.00011243823,"about_ca_system_score_gemma":0.00019606501,"threshold_uncertainty_score":0.99964666},"labels":[],"label_agreement":null},{"id":"W2618864847","doi":"10.1111/jdv.14313","title":"Phase I randomized study of <scp>KHK</scp>4083, an anti‐<scp>OX</scp>40 monoclonal antibody, in patients with mild to moderate plaque psoriasis","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Kyowa Hakko Kirin","keywords":"Medicine; Monoclonal antibody; Plaque psoriasis; Monoclonal; Antibody; Psoriasis; Immunology","score_opus":0.020971043833649877,"score_gpt":0.2840904797723824,"score_spread":0.2631194359387325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618864847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966287,0.0010649338,0.00004267948,0.00039458298,0.000584463,0.00064386305,0.000042021948,0.00001038572,0.000588384],"genre_scores_gemma":[0.99911845,0.00029169602,0.0001527914,0.00017187519,0.00006971399,0.0000071982004,0.000013597967,0.00003703691,0.00013765144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936834,0.0040089125,0.00129114,0.00039497513,0.00012275556,0.000498801],"domain_scores_gemma":[0.9963553,0.00082056574,0.0021456513,0.0004222675,0.00015521247,0.00010100626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012060547,0.00040602966,0.001831065,0.00045502192,0.0003877146,0.000018671517,0.0011069098,0.00038647844,0.000006184183],"category_scores_gemma":[0.000530086,0.00026143444,0.00022971803,0.00013981579,0.00088020926,0.000274152,0.00034351982,0.00071763323,0.0000101627875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022748265,0.00486601,0.9502899,0.000055243145,0.0027131767,0.00015067669,0.0041357093,0.00015664892,0.01098114,0.00032612166,0.0010614685,0.0025156585],"study_design_scores_gemma":[0.25422898,0.0013146789,0.7079468,0.00016326352,0.0011153002,0.000988237,0.0005730017,0.000028290458,0.03209476,0.00028447335,0.0011201092,0.00014212704],"about_ca_topic_score_codex":0.00002770104,"about_ca_topic_score_gemma":0.000016795331,"teacher_disagreement_score":0.2423431,"about_ca_system_score_codex":0.000017916544,"about_ca_system_score_gemma":0.00006613767,"threshold_uncertainty_score":0.9999838},"labels":[],"label_agreement":null},{"id":"W2619184263","doi":"10.1159/000472149","title":"Glycemic Control in the Treatment of Psoriasis","year":2017,"lang":"en","type":"review","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Psoriasis; Medicine; Immunosuppression; Diabetes mellitus; Glycemic; Type 2 diabetes; Dipeptidyl peptidase-4; Dermatology; Internal medicine; Endocrinology","score_opus":0.06908714579084427,"score_gpt":0.3327043392077005,"score_spread":0.2636171934168562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619184263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031037876,0.9958044,0.0000033530528,0.00008097752,0.0011240975,0.0009940246,0.00023758571,0.000020714446,0.0014244552],"genre_scores_gemma":[0.0041587474,0.99434316,0.0000058661194,0.000033671877,0.000051381696,0.0005525623,0.00045397528,0.000026634103,0.00037400617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737144,0.0010603996,0.00073052855,0.00038025784,0.000030563006,0.0004267927],"domain_scores_gemma":[0.99744874,0.0008460977,0.0006591751,0.0010071745,0.00002523305,0.000013560576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010839017,0.000485436,0.002812626,0.00026969673,0.00014316016,0.000010520526,0.0007041059,0.0009474844,0.000118760756],"category_scores_gemma":[0.000033464363,0.00027513798,0.0007431442,0.00010476677,0.00027515952,0.000031025385,0.000021395192,0.00017976787,0.0006518582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013527162,0.00043818032,0.00013332062,0.00075290183,0.001188407,0.000186988,0.0003337957,3.1381855e-8,0.0000029888708,0.0003959351,0.0006958308,0.99573636],"study_design_scores_gemma":[0.0034494582,0.00026975185,0.00004065597,0.00047686277,0.0023014143,0.0017235223,0.000028579743,1.00006616e-7,0.00002174506,0.000031014977,0.99145156,0.00020535871],"about_ca_topic_score_codex":0.00010588608,"about_ca_topic_score_gemma":0.0000836157,"teacher_disagreement_score":0.99553096,"about_ca_system_score_codex":0.00007244432,"about_ca_system_score_gemma":0.00021826448,"threshold_uncertainty_score":0.9999701},"labels":[],"label_agreement":null},{"id":"W2620586117","doi":"10.1111/jdv.14377","title":"Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis; Dermatology Life Quality Index; Placebo; Etanercept; Internal medicine; Quality of life (healthcare); Dermatology; Secukinumab; Tumor necrosis factor alpha; Pathology; Psoriatic arthritis","score_opus":0.06330163258511776,"score_gpt":0.32777521611422883,"score_spread":0.2644735835291111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620586117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573207,0.0010989233,0.000003491378,0.0014440686,0.0005668785,0.0002451383,0.00039178994,0.0000059011736,0.00051174685],"genre_scores_gemma":[0.99921423,0.00031725212,0.000051314913,0.00004088924,0.000072907605,0.0000027488693,0.000043493877,0.000018281791,0.00023887474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994348,0.0035807902,0.0014491616,0.00026877678,0.000068235626,0.0002850526],"domain_scores_gemma":[0.9959279,0.0013457075,0.0023386027,0.00025712224,0.00007443121,0.000056271256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007482974,0.0002958139,0.0011875668,0.00029642394,0.00029734822,0.000010389427,0.00047907012,0.00034413853,0.000039879487],"category_scores_gemma":[0.0012665818,0.00017632202,0.000470113,0.00006962875,0.00044182132,0.0001257376,0.0001159191,0.00044358932,0.000021320595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04530725,0.0031326562,0.85900116,0.000019382338,0.0045976127,0.00011843989,0.008185886,0.00070015364,0.006006294,0.00048447304,0.002122716,0.070323996],"study_design_scores_gemma":[0.041318674,0.00085695117,0.94804746,0.00013593795,0.0005220343,0.00042885603,0.000097823984,0.000013516485,0.007598266,0.00052319025,0.00028591364,0.00017138003],"about_ca_topic_score_codex":0.00009117249,"about_ca_topic_score_gemma":0.00001801762,"teacher_disagreement_score":0.08904632,"about_ca_system_score_codex":0.000078945035,"about_ca_system_score_gemma":0.00007419054,"threshold_uncertainty_score":0.7190203},"labels":[],"label_agreement":null},{"id":"W2620934892","doi":"10.1097/mop.0000000000000517","title":"Update in the management of pediatric psoriasis","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Pediatrics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Psoriasis; Medicine; Modalities; Disease; Therapeutic modalities; Intensive care medicine; Treatment modality; MEDLINE; Dermatology; Physical therapy; Pathology; Surgery","score_opus":0.14591818336887943,"score_gpt":0.3869949694123423,"score_spread":0.24107678604346286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620934892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056796398,0.9809888,0.0000053019653,0.000013553991,0.01719406,0.0011073938,0.00028100653,0.00001810187,0.000334966],"genre_scores_gemma":[0.000046139263,0.9973258,0.000029997336,0.0000016854224,0.0009066999,0.00035817025,0.0012121965,0.000031385214,0.00008793165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997131,0.00060167274,0.0011253024,0.00054719,0.00012258839,0.0004722687],"domain_scores_gemma":[0.9976791,0.00030377394,0.0009886526,0.00097147276,0.000036867546,0.000020145675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093412475,0.0005100501,0.0013598765,0.00086564856,0.00011640351,0.000027928469,0.0013112681,0.0005198239,0.00006359364],"category_scores_gemma":[0.000039773004,0.00035403256,0.00050757884,0.0008260077,0.00006815174,0.00008040718,0.00025095337,0.0006125036,0.00041074734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013432137,0.0003801165,0.0012913323,0.020478163,0.000108992775,0.0000052503215,0.00009403022,3.5282306e-7,3.6741035e-9,0.00057170645,0.005781081,0.97127557],"study_design_scores_gemma":[0.0010336735,0.000035761746,0.0009812996,0.0017347134,0.0015034279,0.000008947529,0.00003173702,7.619929e-8,8.113688e-8,0.00007452507,0.9942713,0.0003244684],"about_ca_topic_score_codex":0.000010687311,"about_ca_topic_score_gemma":0.0000022200168,"teacher_disagreement_score":0.9884902,"about_ca_system_score_codex":0.00009585684,"about_ca_system_score_gemma":0.00016778607,"threshold_uncertainty_score":0.99989116},"labels":[],"label_agreement":null},{"id":"W2621795952","doi":"10.1177/1203475417712497","title":"Increased Incidence of Critical Illness in Psoriasis","year":2017,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Manitoba Health; University of Manitoba","funders":"Multiple Sclerosis Society; Multiple Sclerosis Society of Canada","keywords":"Medicine; Psoriasis; Incidence (geometry); Population; Cohort; Intensive care unit; Cohort study; Comorbidity; Rate ratio; Standardized mortality ratio; Confidence interval; Proportional hazards model; Internal medicine; Cumulative incidence; Pediatrics; Immunology; Environmental health","score_opus":0.02724957978062647,"score_gpt":0.28843951464313267,"score_spread":0.2611899348625062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621795952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014074,0.006705706,0.0000114881595,0.0014367973,0.0012318948,0.000037755286,0.000004768498,0.000003313514,0.00042754176],"genre_scores_gemma":[0.99778,0.0018415486,0.0000290515,0.000100639736,0.00015258831,0.000001113309,0.0000024413544,0.0000068137383,0.0000857817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988313,0.00017220425,0.00062069885,0.00010802857,0.00007953149,0.00018825234],"domain_scores_gemma":[0.9969907,0.0021252425,0.00046805182,0.0002099309,0.0001567969,0.00004928765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008461069,0.00012278868,0.00071125524,0.0002638313,0.00013812486,0.0000074030218,0.00016145832,0.0001447989,0.00019615695],"category_scores_gemma":[0.003420275,0.00008464592,0.00010411503,0.00005379665,0.0005276414,0.00012019258,0.00003057885,0.00017051,0.0000041888484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003544284,0.00067745906,0.6356613,0.00029817945,0.00055409723,0.007916302,0.003074627,0.0000015796644,0.09354608,0.00053062534,0.008723865,0.2454716],"study_design_scores_gemma":[0.012939511,0.003306886,0.7699574,0.0064537902,0.0023330844,0.06891611,0.006351449,0.00001638141,0.09862592,0.006224866,0.023584597,0.0012899713],"about_ca_topic_score_codex":0.00027834854,"about_ca_topic_score_gemma":0.00004137334,"teacher_disagreement_score":0.24418163,"about_ca_system_score_codex":0.000016438333,"about_ca_system_score_gemma":0.000108732944,"threshold_uncertainty_score":0.40946355},"labels":[],"label_agreement":null},{"id":"W2622966691","doi":"10.1111/jdv.14387","title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Psoriasis; Discontinuation; Retrospective cohort study; Psoriatic arthritis; Cohort; Internal medicine; Dermatology","score_opus":0.013630829294167271,"score_gpt":0.24784718476585627,"score_spread":0.234216355471689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622966691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632365,0.00128125,0.0000023150878,0.0004920847,0.0007596578,0.00024814848,0.000012440744,0.000003902345,0.00087653974],"genre_scores_gemma":[0.9994949,0.00021963219,0.00002633813,0.000052125928,0.00004041878,0.000003900143,9.0320407e-7,0.000015729254,0.00014606767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968158,0.0018069117,0.00083803316,0.00021917475,0.00007007166,0.00025001357],"domain_scores_gemma":[0.99787736,0.00013223037,0.0015859384,0.00028371922,0.00009383677,0.000026898579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000755337,0.00018934907,0.00080320204,0.00022050938,0.00018906027,0.000005969405,0.0006368422,0.00025459746,0.000025542693],"category_scores_gemma":[0.0003110518,0.0001329379,0.00017142095,0.0000726953,0.0006606188,0.00014640391,0.0003186951,0.00057065097,0.000009688564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081397535,0.00037151462,0.994268,0.0000145525055,0.00060018414,0.00006067691,0.0009387024,0.0000010034481,0.0009117379,0.00013480315,0.00011957886,0.0017652465],"study_design_scores_gemma":[0.004691601,0.00017445699,0.9914424,0.000077678545,0.0003340306,0.00043273548,0.00007787366,2.9102662e-7,0.002166791,0.0002856588,0.000211914,0.0001045701],"about_ca_topic_score_codex":0.000030746618,"about_ca_topic_score_gemma":0.000015527388,"teacher_disagreement_score":0.0038776256,"about_ca_system_score_codex":0.000030566862,"about_ca_system_score_gemma":0.0000283824,"threshold_uncertainty_score":0.542105},"labels":[],"label_agreement":null},{"id":"W2623888527","doi":"10.1016/s0140-6736(17)31279-5","title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":556,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Placebo; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Clinical trial; Dermatology; Physical therapy; Gastroenterology; Tumor necrosis factor alpha; Alternative medicine; Pathology","score_opus":0.10436476109237636,"score_gpt":0.36563283276583136,"score_spread":0.261268071673455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623888527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633646,0.012338163,0.00014548014,0.005302125,0.004100666,0.0050145225,0.00707484,0.00015402822,0.0025055632],"genre_scores_gemma":[0.98585063,0.0034410977,0.0005530073,0.00009836382,0.0017439626,0.00046057205,0.00068888726,0.00004634455,0.007117158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99673516,0.0012753934,0.0007484973,0.00057907193,0.00006957939,0.00059232506],"domain_scores_gemma":[0.98708034,0.0104953535,0.0008513285,0.001456023,0.00006868075,0.000048287406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032134186,0.00039855303,0.0020199479,0.000040891482,0.0011126812,0.00014864447,0.00077450747,0.00030314055,0.00033204915],"category_scores_gemma":[0.0048448294,0.00022252047,0.0003268719,0.000039099534,0.00031891474,0.00013428711,0.00011455676,0.00022609583,0.00015654252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90481585,0.00009043929,0.000014667411,0.00001232847,0.0024960868,0.000011780569,0.0006730525,0.000030463334,0.025041489,0.000119859695,0.026482342,0.040211633],"study_design_scores_gemma":[0.8929906,0.00073575106,0.00019437165,0.000059906815,0.0015270029,0.0000087588005,0.00012537307,0.00010827718,0.024029,0.00017962232,0.07973345,0.0003078622],"about_ca_topic_score_codex":0.0004487243,"about_ca_topic_score_gemma":0.0007290863,"teacher_disagreement_score":0.053251114,"about_ca_system_score_codex":0.00007911711,"about_ca_system_score_gemma":0.00016165114,"threshold_uncertainty_score":0.9074121},"labels":[],"label_agreement":null},{"id":"W2624322160","doi":"10.1111/bjd.15723","title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis","year":2017,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Interleukin 17; Monoclonal antibody; Immunology; Clinical trial; Dermatology; Monoclonal; Interleukin; Plaque psoriasis; Antibody; Internal medicine; Cytokine; Secukinumab; Psoriatic arthritis","score_opus":0.09830212884903328,"score_gpt":0.39601046185283323,"score_spread":0.29770833300379995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624322160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2948952,0.7002832,0.00007535076,0.0000255067,0.0024131374,0.000718397,0.0015044074,0.000014870525,0.000069875634],"genre_scores_gemma":[0.10948202,0.8884464,0.00031985377,0.000027306563,0.00022050894,0.000030092606,0.0013386202,0.000072148665,0.00006304822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9891777,0.0053354534,0.0042895228,0.00056942593,0.00012349115,0.0005044244],"domain_scores_gemma":[0.9927028,0.0014780574,0.004677823,0.0005539755,0.00044648955,0.00014086536],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013695299,0.00056692056,0.0074346396,0.00066189346,0.0002141324,0.00007551805,0.000874263,0.0014190621,0.00024382173],"category_scores_gemma":[0.0011636654,0.0004902586,0.0012938931,0.00018886274,0.000284857,0.00033837458,0.00014795864,0.001105855,0.00006248613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001148838,0.0017366601,0.036856517,0.00034559632,0.0039049538,0.0010422502,0.000079185105,0.000002651784,0.0000024444903,0.000007629061,0.0008326951,0.9540406],"study_design_scores_gemma":[0.04675267,0.003927008,0.2005248,0.040255286,0.013814561,0.05715105,0.00010344861,0.0000016636457,0.00011407394,0.00022662591,0.63483965,0.0022891439],"about_ca_topic_score_codex":0.00041211356,"about_ca_topic_score_gemma":0.00043750482,"teacher_disagreement_score":0.9517514,"about_ca_system_score_codex":0.00009624632,"about_ca_system_score_gemma":0.00095396326,"threshold_uncertainty_score":0.99987733},"labels":[],"label_agreement":null},{"id":"W2625079458","doi":"10.1016/j.jval.2016.11.020","title":"Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis","year":2017,"lang":"en","type":"review","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Amgen","keywords":"Psoriasis; Dermatology Life Quality Index; Intraclass correlation; Psoriasis Area and Severity Index; Cronbach's alpha; Medicine; Quality of life (healthcare); Convergent validity; Patient-reported outcome; Severity of illness; Construct validity; Internal medicine; Physical therapy; Dermatology; Psychometrics; Psychology; Clinical psychology; Internal consistency","score_opus":0.10255382474101048,"score_gpt":0.27751853022394274,"score_spread":0.17496470548293225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625079458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032497443,0.9628917,0.000001459197,0.000110061505,0.0010113482,0.0033075265,0.00010042104,0.000024694702,0.000055339486],"genre_scores_gemma":[0.1161523,0.882745,0.000011030873,0.00006843143,0.000052548636,0.0006413082,0.00006564158,0.00007722265,0.00018646277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942187,0.0027341323,0.0011778506,0.0007086624,0.00023598276,0.0009246759],"domain_scores_gemma":[0.9976821,0.00006669897,0.0009559396,0.0011042937,0.0001276685,0.0000632749],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017944896,0.00063549005,0.002138001,0.0004304059,0.00026961355,0.000021174834,0.0008218139,0.0005126735,0.000011934015],"category_scores_gemma":[0.00016575596,0.00038547744,0.00030286337,0.000366275,0.000111286,0.000099920006,0.00017604437,0.00065428106,0.00004959256],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014800007,0.0013669302,0.015222763,0.019152978,0.0016762102,0.000005307717,0.0021423146,0.00030893355,0.000005405146,0.00023595273,0.00042771804,0.9579755],"study_design_scores_gemma":[0.01741275,0.0031369173,0.02110083,0.20969157,0.002076182,0.00004746829,0.00017374901,0.0000132427085,0.0003118733,0.00019519693,0.7429703,0.0028698987],"about_ca_topic_score_codex":0.0032550613,"about_ca_topic_score_gemma":0.0012045042,"teacher_disagreement_score":0.9551056,"about_ca_system_score_codex":0.0016532885,"about_ca_system_score_gemma":0.00311579,"threshold_uncertainty_score":0.9998597},"labels":[],"label_agreement":null},{"id":"W2625513611","doi":"10.1111/jdv.14414","title":"Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2017,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gerontology; Library science; Family medicine","score_opus":0.10927326327233622,"score_gpt":0.32794786725086755,"score_spread":0.21867460397853133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2625513611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8683159,0.014504213,0.0000063070047,0.11614619,0.0005417576,0.00023531872,0.00010500792,0.000002293875,0.00014304293],"genre_scores_gemma":[0.9899839,0.0041597835,0.00008572747,0.0053347494,0.00031898508,0.0000134135025,0.00005572482,0.000014479432,0.000033199827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931532,0.0054818997,0.00080771314,0.00022949731,0.0001240805,0.00020359886],"domain_scores_gemma":[0.9963077,0.0004980493,0.0027283153,0.0002930251,0.0001619746,0.000010986317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015702421,0.00025284875,0.0008178718,0.00023732558,0.00012401247,0.0000071732734,0.0006600706,0.000845493,0.000022680073],"category_scores_gemma":[0.00016652411,0.00014567604,0.00017285199,0.000080212136,0.000527949,0.00008501903,0.000132954,0.0011247941,0.0000010424094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004768416,0.00017153073,0.96475255,0.00009858758,0.0014596721,0.00009209445,0.0008205456,0.0000027501742,0.0064508882,0.0001252291,0.018904727,0.0066445763],"study_design_scores_gemma":[0.002489931,0.00012225931,0.9822047,0.00020356354,0.0009717769,0.001278681,0.000102708225,0.0000026688933,0.0026606154,0.0012756615,0.008559041,0.00012844207],"about_ca_topic_score_codex":0.00002398082,"about_ca_topic_score_gemma":0.000021250116,"teacher_disagreement_score":0.12166807,"about_ca_system_score_codex":0.000023097056,"about_ca_system_score_gemma":0.00010544183,"threshold_uncertainty_score":0.6521216},"labels":[],"label_agreement":null},{"id":"W2672515966","doi":"10.1016/j.jid.2017.05.027","title":"Response to Hjuler et al.","year":2017,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Université de Montréal; Montreal Heart Institute; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Medicine; Adalimumab; Placebo; Dermatology; Inflammation; Ascending aorta; Aorta; Internal medicine; Disease; Pathology; Alternative medicine","score_opus":0.03883189551555337,"score_gpt":0.2889506235301126,"score_spread":0.2501187280145592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2672515966","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10786006,0.002115989,0.000027425709,0.8859136,0.0028538762,0.00022484298,0.00014142792,0.000022875773,0.00083990296],"genre_scores_gemma":[0.012742824,0.00012659814,0.0007911718,0.97883797,0.00032108978,0.000027632372,0.00015153516,0.00007169967,0.0069294632],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950524,0.002958651,0.00089994713,0.00038667629,0.000120982826,0.0005813439],"domain_scores_gemma":[0.99589676,0.0011415278,0.001739642,0.0006367945,0.0004929536,0.00009231607],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007994327,0.00053116196,0.0013814616,0.00070457393,0.00026090574,0.000047494606,0.0009607853,0.001354221,0.00029133415],"category_scores_gemma":[0.0016898132,0.00041957307,0.00043721095,0.000105641455,0.0008390201,0.00019017007,0.00016291742,0.0023933323,0.0013359528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078644365,0.000037150276,0.00011645817,0.00001694433,0.0011720153,0.005354606,0.00058685866,7.824882e-7,0.06957304,0.000038574082,0.92196596,0.0003511466],"study_design_scores_gemma":[0.0015139149,0.0003691949,0.0015262759,0.00019067053,0.0002553593,0.010879152,0.00003652965,5.6785936e-8,0.12173448,0.00048967305,0.86267674,0.00032792328],"about_ca_topic_score_codex":0.000015630036,"about_ca_topic_score_gemma":0.0000062571653,"teacher_disagreement_score":0.09511723,"about_ca_system_score_codex":0.000111159134,"about_ca_system_score_gemma":0.00090257404,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W2697574135","doi":"10.1111/bjd.15750","title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial","year":2017,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":339,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Research and Development","keywords":"Ustekinumab; Medicine; Psoriasis; Double blind; Dermatology; Randomized controlled trial; Randomization; Internal medicine; Alternative medicine; Disease; Pathology; Placebo","score_opus":0.01798615141328034,"score_gpt":0.2754203383737347,"score_spread":0.25743418696045434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2697574135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996523,0.0009675059,0.000017690078,0.0002671234,0.0006196022,0.001313124,0.00017130791,0.0000054245725,0.00011521327],"genre_scores_gemma":[0.9993812,0.0002844869,0.000067185174,0.000027263899,0.000033877775,0.000020350693,0.00002806033,0.000021285388,0.00013628282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957522,0.0019543825,0.0014983054,0.00029029025,0.00013452162,0.00037028774],"domain_scores_gemma":[0.9958613,0.0011997836,0.001988359,0.0005068669,0.00036123852,0.00008244854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013346126,0.00024837052,0.0015371313,0.000249471,0.00030568728,0.000043629912,0.0006267794,0.00035869452,0.0000070462015],"category_scores_gemma":[0.0016950831,0.00018854988,0.00021387766,0.00012032786,0.0006738748,0.0002669844,0.0001419337,0.00036941224,0.0000025259862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9725189,0.0011597573,0.003658433,0.00001588505,0.0006645664,0.00022590396,0.0014402053,0.000008222095,0.0005298173,0.00001968674,0.00028058988,0.019478004],"study_design_scores_gemma":[0.9260177,0.0016289646,0.051325943,0.0004848672,0.00042219984,0.0020685445,0.00020228571,0.0000011702368,0.01722045,0.000027753053,0.00049989234,0.00010024373],"about_ca_topic_score_codex":0.0003627648,"about_ca_topic_score_gemma":0.0003485457,"teacher_disagreement_score":0.04766751,"about_ca_system_score_codex":0.00003840208,"about_ca_system_score_gemma":0.0002163327,"threshold_uncertainty_score":0.76888406},"labels":[],"label_agreement":null},{"id":"W2701201582","doi":"10.1358/dot.2017.53.5.2613690","title":"Brodalumab: The first anti-IL-17 receptor agent for psoriasis","year":2017,"lang":"en","type":"review","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis Area and Severity Index; Psoriasis; Ustekinumab; Psoriatic arthritis; Dermatology; Interleukin 17; Clinical trial; Erythroderma; Immunology; Internal medicine; Adalimumab; Immune system; Disease","score_opus":0.06135471088143997,"score_gpt":0.31812742397030314,"score_spread":0.2567727130888632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2701201582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038754708,0.98936635,0.0000093234,0.00031053196,0.004518044,0.0016661154,0.002116552,0.0000508666,0.0019234829],"genre_scores_gemma":[0.000061551684,0.97845703,0.00008611505,0.000054905177,0.0003625709,0.00059875345,0.0012903801,0.00007357537,0.019015135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778056,0.00028660565,0.0007594603,0.00058914634,0.000067496236,0.00051671517],"domain_scores_gemma":[0.9964186,0.0009035116,0.0011166736,0.001430285,0.00010482273,0.00002613255],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000777735,0.0006085074,0.0021581007,0.00014979062,0.0007130123,0.000039624174,0.0013210607,0.0008230534,0.0005078084],"category_scores_gemma":[0.00021049104,0.00037227658,0.0015829145,0.00009446677,0.00028620203,0.00006739952,0.00019873498,0.00026568543,0.00085485255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034753015,0.0001133031,0.000006157216,0.0022773754,0.0016403765,0.0000010678942,0.00019704913,1.1558528e-7,0.000010407157,0.000115260584,0.1268715,0.86873263],"study_design_scores_gemma":[0.0008680641,0.0001056996,0.000013937313,0.0026928,0.002708789,0.000012323937,0.00003640499,4.9228497e-8,0.00030091513,0.000019577996,0.99286556,0.00037586136],"about_ca_topic_score_codex":0.00007704298,"about_ca_topic_score_gemma":0.000024275892,"teacher_disagreement_score":0.86835676,"about_ca_system_score_codex":0.000093240255,"about_ca_system_score_gemma":0.00020614357,"threshold_uncertainty_score":0.9999231},"labels":[],"label_agreement":null},{"id":"W2731573929","doi":"10.1161/circimaging.112.975730","title":"Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis","year":2012,"lang":"en","type":"article","venue":"Circulation Cardiovascular Imaging","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Psoriasis; Positron emission tomography; Internal medicine; Clinical endpoint; Cardiology; Randomized controlled trial; Nuclear medicine; Tumor necrosis factor alpha; Dermatology","score_opus":0.004242836747541202,"score_gpt":0.18679517112895852,"score_spread":0.18255233438141732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731573929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964351,0.0014796539,0.0003902796,0.000017972936,0.00089864165,0.00064913306,0.000034310066,0.000035494846,0.00005942156],"genre_scores_gemma":[0.99958503,0.0000077897075,0.000023614613,0.000018360695,0.000061862425,0.00004376252,0.00022972147,0.00002488627,0.000004984534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850565,0.000470602,0.0002768494,0.0002647969,0.00017424206,0.00030785298],"domain_scores_gemma":[0.9992332,0.000087459506,0.00018117706,0.00039277988,0.00007753941,0.000027832602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002098471,0.0002285165,0.00036219542,0.00015083427,0.00018712995,0.00002530606,0.000121191435,0.000094355964,0.000012466767],"category_scores_gemma":[0.0000404583,0.00016642276,0.00039531838,0.0003124055,0.000066014356,0.0002818436,0.00002919445,0.00011379523,0.000008158853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027063716,0.00022521535,0.7524166,0.000051754803,0.0006897649,7.449195e-7,0.00030078835,0.00005221925,0.22457127,0.000010401682,0.000038241433,0.021372374],"study_design_scores_gemma":[0.004544602,0.000021917098,0.7649925,0.00008849389,0.00033398237,0.0000024159106,0.000016769052,0.000005173213,0.22950408,0.000005180979,0.0003334468,0.00015146333],"about_ca_topic_score_codex":0.000069316295,"about_ca_topic_score_gemma":9.777284e-7,"teacher_disagreement_score":0.021220911,"about_ca_system_score_codex":0.00011104651,"about_ca_system_score_gemma":0.000024462444,"threshold_uncertainty_score":0.67865235},"labels":[],"label_agreement":null},{"id":"W2735558737","doi":"10.1111/1346-8138.13956","title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Placebo; Dermatology Life Quality Index; Adverse effect; Internal medicine; Psoriasis; Psoriasis Area and Severity Index; Randomized controlled trial; Dermatology; Gastroenterology; Rheumatoid arthritis; Pathology","score_opus":0.03964438293804168,"score_gpt":0.32712794453947586,"score_spread":0.2874835616014342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735558737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878081,0.006190755,0.00028856558,0.0015195518,0.0012991411,0.0026103223,0.00022329063,0.0000056628605,0.000054627904],"genre_scores_gemma":[0.9975303,0.0017262491,0.000052624804,0.000051481926,0.0001468806,0.0002852772,0.00003971113,0.000015710282,0.00015179419],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969629,0.001368411,0.0010979824,0.00016782564,0.00006635144,0.0003365043],"domain_scores_gemma":[0.9931665,0.004742496,0.0013684785,0.0005171672,0.00016931808,0.00003602327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056782184,0.00028871064,0.001965293,0.00017176128,0.00038708802,0.000026040798,0.0005701965,0.0002159519,0.00011836378],"category_scores_gemma":[0.0005153352,0.00013500368,0.00067020406,0.00005755972,0.0002740395,0.0001169804,0.000037773898,0.00012880718,0.000014986581],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98076797,0.0011359883,0.00020369113,0.0000068811255,0.004477675,0.00001912639,0.0034658653,0.00014976322,0.0028397227,0.00003304872,0.0002943467,0.0066059004],"study_design_scores_gemma":[0.9725243,0.0019173347,0.000176298,0.0000351541,0.0029280498,0.00014808968,0.00043869342,0.00012549042,0.020488847,0.00021371867,0.00086389453,0.00014011994],"about_ca_topic_score_codex":0.0004435719,"about_ca_topic_score_gemma":0.00048795764,"teacher_disagreement_score":0.017649125,"about_ca_system_score_codex":0.00009714562,"about_ca_system_score_gemma":0.0001649256,"threshold_uncertainty_score":0.55052906},"labels":[],"label_agreement":null},{"id":"W2735708380","doi":"10.1016/j.jaad.2017.03.026","title":"Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)","year":2017,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Pooled analysis; Randomized controlled trial; Onset of action; Clinical trial; Internal medicine; Meta-analysis","score_opus":0.07260214420150735,"score_gpt":0.3822649441781529,"score_spread":0.30966279997664553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735708380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664204,0.0014952006,0.00009562704,0.028544886,0.00017876564,0.0007342778,0.002516565,0.000006273959,0.000007993946],"genre_scores_gemma":[0.99179214,0.001298407,0.00065868045,0.005059935,0.00012485137,0.000012303754,0.0009696104,0.00004133392,0.000042705848],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98711467,0.008809115,0.0029768867,0.0005343822,0.00021954876,0.0003453965],"domain_scores_gemma":[0.98242384,0.004509115,0.011868929,0.00087552343,0.00026520138,0.000057360146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020003985,0.00051455345,0.0079350965,0.0012257075,0.000079075966,0.000013828593,0.0013800134,0.0006162912,0.00006355953],"category_scores_gemma":[0.0011011447,0.0002885445,0.000742077,0.00062149984,0.0017356924,0.00022419597,0.00022377488,0.0014430876,0.0000016045493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59985065,0.0011707613,0.2127791,0.000094551724,0.10004713,0.00013354057,0.00027683456,0.000081052574,0.0010552325,0.0000015367749,0.04278937,0.04172025],"study_design_scores_gemma":[0.6944333,0.0021975616,0.15646838,0.0009622988,0.12980866,0.00080538023,0.00017345091,0.00028715082,0.0066371793,0.00007296486,0.0071560987,0.0009976022],"about_ca_topic_score_codex":0.000745824,"about_ca_topic_score_gemma":0.000047336376,"teacher_disagreement_score":0.09458263,"about_ca_system_score_codex":0.000039098748,"about_ca_system_score_gemma":0.0002540064,"threshold_uncertainty_score":0.99995667},"labels":[],"label_agreement":null},{"id":"W2735798577","doi":"10.1111/febs.14166","title":"Reciprocal modulation of helper Th1 and Th17 cells by the β2‐adrenergic receptor agonist drug terbutaline","year":2017,"lang":"en","type":"article","venue":"FEBS Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Terbutaline; Reciprocal; Agonist; Chemistry; Pharmacology; Receptor; Internal medicine; Biology; Medicine; Biochemistry","score_opus":0.014196709179356087,"score_gpt":0.2375047873797122,"score_spread":0.2233080782003561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735798577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930237,0.0039351294,0.00007574052,0.0007773244,0.0012941475,0.00009389113,0.00008159697,0.000009180883,0.0007092816],"genre_scores_gemma":[0.99097145,0.0008141937,0.000110054316,0.00004525203,0.00018058199,0.0000046086316,0.000050946797,0.000011438547,0.007811506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992048,0.00016507653,0.00024500414,0.00014560651,0.000045503093,0.000194004],"domain_scores_gemma":[0.99923825,0.0000598106,0.0003440531,0.00026992292,0.000059746508,0.000028192233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033902837,0.0001379724,0.00020511483,0.000035006095,0.0009284003,0.00007686807,0.00025392717,0.00012757728,0.00033977127],"category_scores_gemma":[0.000032222673,0.00008346743,0.000093218,0.00002283157,0.00022519103,0.00013735244,0.00006171984,0.00019175644,0.000056260254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035277507,0.0001315495,0.008138706,0.000008485464,0.00032040154,0.000005093879,0.00070756534,0.00001173475,0.897713,0.00008135034,0.027698632,0.064830676],"study_design_scores_gemma":[0.004649395,0.00034023228,0.070638165,0.00010557563,0.00031447585,0.000500404,0.0003887431,0.000044122247,0.83904535,0.0006135509,0.082998596,0.00036140106],"about_ca_topic_score_codex":0.000069528454,"about_ca_topic_score_gemma":0.000019037461,"teacher_disagreement_score":0.06446927,"about_ca_system_score_codex":0.000020562376,"about_ca_system_score_gemma":0.000030140567,"threshold_uncertainty_score":0.7140598},"labels":[],"label_agreement":null},{"id":"W2737831469","doi":"10.12788/j.sder.2017.026","title":"Highlights of Skin Disease Education Foundation’s 41st Annual Hawaii Dermatology SeminarTM","year":2017,"lang":"en","type":"article","venue":"Seminars in Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Valeant Pharmaceuticals International; Merz Pharmaceuticals; University of Louisville","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Disease; Intensive care medicine; Acne; Pathology","score_opus":0.019211193074154715,"score_gpt":0.26807237662349037,"score_spread":0.24886118354933565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737831469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766256,0.014675289,0.0000038229505,0.0036424599,0.0020443886,0.00018074352,0.00003232717,0.000022983,0.0027723403],"genre_scores_gemma":[0.98995125,0.0062236683,0.000027175367,0.00013097176,0.000113920985,0.000029802066,0.00027663808,0.00001421547,0.003232335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987705,0.00014556284,0.00043178926,0.00031457303,0.000057218585,0.00028040874],"domain_scores_gemma":[0.99833065,0.00075310667,0.00029964614,0.000468565,0.0000840793,0.00006397859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022050209,0.00020427891,0.0005384499,0.0002812949,0.00029400625,0.000008936071,0.00016313209,0.00018479311,0.0002464727],"category_scores_gemma":[0.00035660455,0.00016851508,0.00007263768,0.00007220287,0.00055508845,0.00011910225,0.000054643097,0.000105748004,0.000035561763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011393989,0.0007270334,0.43183905,0.00029355026,0.0002496337,0.0011536226,0.004043222,8.807801e-7,0.0055761705,0.0021022675,0.085332334,0.46754283],"study_design_scores_gemma":[0.004707815,0.0006766402,0.35338777,0.005232852,0.0012688721,0.011364204,0.014212262,0.000008895263,0.029381849,0.004941713,0.5731808,0.001636317],"about_ca_topic_score_codex":0.0002976498,"about_ca_topic_score_gemma":0.00012004549,"teacher_disagreement_score":0.4878485,"about_ca_system_score_codex":0.000033183496,"about_ca_system_score_gemma":0.0002172418,"threshold_uncertainty_score":0.6871846},"labels":[],"label_agreement":null},{"id":"W2737838244","doi":"10.1177/1203475417721424","title":"Treatment of Moderate to Severe Psoriasis With High-Dose (450-mg) Secukinumab: Case Reports of Off-Label Use","year":2017,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Dosing; Adverse effect; Psoriasis Area and Severity Index; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.03801600963425383,"score_gpt":0.26604153865513047,"score_spread":0.22802552902087664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737838244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436986,0.0037760125,0.000008356538,0.0006212045,0.00090326887,0.00016538214,0.000036940633,0.000006986224,0.00011201349],"genre_scores_gemma":[0.99556845,0.0030138497,0.00016998086,0.00005570863,0.00014517533,0.0000038057428,0.000012800138,0.000020501779,0.0010097007],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9983423,0.00013258065,0.0009352167,0.00021653227,0.000119053584,0.0002543209],"domain_scores_gemma":[0.99681723,0.0007318426,0.0014966046,0.00048665854,0.00035870253,0.000108965905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003121573,0.0002685555,0.0012906212,0.00029428102,0.00021045678,0.000014796118,0.000072783776,0.0001632751,0.000081236605],"category_scores_gemma":[0.0003041979,0.0001608456,0.00015168182,0.000075460295,0.00024100764,0.00015413729,0.00002451908,0.00009864301,0.0000019187323],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026445061,0.0021508709,0.09696847,0.00021916279,0.0070039346,0.39661428,0.0066888486,0.000070711416,0.059789345,0.000053132964,0.011162567,0.39283362],"study_design_scores_gemma":[0.009803896,0.008991451,0.011322186,0.0010422397,0.0029605262,0.9159628,0.0009676843,0.000008030723,0.038335674,0.00013154656,0.009981284,0.0004926937],"about_ca_topic_score_codex":0.0007694456,"about_ca_topic_score_gemma":0.00013991131,"teacher_disagreement_score":0.5193485,"about_ca_system_score_codex":0.000044432298,"about_ca_system_score_gemma":0.00018289268,"threshold_uncertainty_score":0.6559093},"labels":[],"label_agreement":null},{"id":"W2743134732","doi":"10.1007/s13555-017-0196-z","title":"Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy","year":2017,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Psoriasis; Calcipotriol; Medicine; Combination therapy; Pharmacology; Fixed-dose combination; Corticosteroid; Dosing; Dermatology; Internal medicine","score_opus":0.029347536833552235,"score_gpt":0.2818068940366248,"score_spread":0.25245935720307255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743134732","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21536331,0.78328645,0.0000056246713,0.00001619489,0.0005291336,0.0007087408,0.000027671953,0.000030470595,0.0000324162],"genre_scores_gemma":[0.07796012,0.9214997,0.000021723736,0.000036473648,0.000015935328,0.00010120922,0.0002259482,0.000039253926,0.00009960695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789536,0.0006974897,0.0005534052,0.0004951272,0.000033636632,0.00032499683],"domain_scores_gemma":[0.9982023,0.0005547557,0.0006876091,0.00046994587,0.000045603585,0.000039758103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018701176,0.0005420425,0.0019665495,0.000281425,0.00040035535,0.00003262753,0.0002038782,0.0009265413,0.000014661516],"category_scores_gemma":[0.000022853315,0.00042568805,0.00018812783,0.000054000106,0.00067907025,0.00013801373,0.000084922074,0.00029545836,0.000012958644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010687141,0.00014131243,0.0017983451,0.0020379527,0.00169221,0.000074086136,0.0003548967,1.5896656e-8,0.001522201,0.00026630476,0.000038719354,0.9919671],"study_design_scores_gemma":[0.020644957,0.0010577132,0.037497193,0.0054847486,0.0018281823,0.00483402,0.00006350206,0.0000037742666,0.010129989,0.00031719694,0.91647154,0.0016671717],"about_ca_topic_score_codex":0.000012749908,"about_ca_topic_score_gemma":0.0000026499526,"teacher_disagreement_score":0.99029994,"about_ca_system_score_codex":0.0000132164705,"about_ca_system_score_gemma":0.00007454127,"threshold_uncertainty_score":0.9998195},"labels":[],"label_agreement":null},{"id":"W2743435786","doi":"10.1111/jdv.14515","title":"Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"LEO Pharma; LEO Pharma Research Foundation","keywords":"Medicine; Psoriasis; Randomized controlled trial; Phase (matter); Dermatology; Physical therapy; Intensive care medicine; Surgery","score_opus":0.06585235734554229,"score_gpt":0.2942708366845995,"score_spread":0.22841847933905723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743435786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401224,0.0027847076,0.000034651468,0.0015610163,0.00034116936,0.0009459434,0.000027831884,0.0000050464837,0.00028737696],"genre_scores_gemma":[0.9991268,0.00052274123,0.00008406308,0.000058796035,0.00006671441,0.00003140982,0.0000065713984,0.000015232695,0.00008768825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959768,0.0025869838,0.0008875531,0.0002269373,0.000077989076,0.00024374177],"domain_scores_gemma":[0.99642366,0.0008538505,0.0023182365,0.00029938266,0.00007514856,0.000029728188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006430775,0.00027547035,0.0012212107,0.000088691515,0.0004639523,0.000012620097,0.00072073564,0.00018431125,0.000015429207],"category_scores_gemma":[0.00017467089,0.00011267758,0.00030686488,0.000030122923,0.0010519832,0.000080712256,0.00013859927,0.0002479613,6.6670924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035828207,0.0015967414,0.9340741,0.000021997637,0.004018154,0.0000075816956,0.0025911476,0.0000015639504,0.0003297653,0.0007272481,0.000073688316,0.020729776],"study_design_scores_gemma":[0.2841329,0.0011676505,0.69325686,0.00006646619,0.002028676,0.00026799415,0.00047317526,0.0000040166083,0.015960751,0.0008056459,0.0016326993,0.00020318867],"about_ca_topic_score_codex":0.0000050737344,"about_ca_topic_score_gemma":0.000010506833,"teacher_disagreement_score":0.24830468,"about_ca_system_score_codex":0.000013706818,"about_ca_system_score_gemma":0.000033491215,"threshold_uncertainty_score":0.45948586},"labels":[],"label_agreement":null},{"id":"W2746922936","doi":"","title":"Psoriasis Treatment Environment in Canada and the latest treatment of Psoriasis","year":2017,"lang":"en","type":"article","venue":"日本皮膚科学会雑誌","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.01694524685737745,"score_gpt":0.21494139592164574,"score_spread":0.1979961490642683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746922936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901934,0.005951591,0.0000011098956,0.0010291457,0.00062023953,0.0004952019,0.0001472941,0.000009632766,0.001552363],"genre_scores_gemma":[0.99019384,0.007251262,0.000034675435,0.000021399315,0.000042839794,0.0001691974,0.000042776814,0.000015256817,0.0022287697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99878615,0.00017280546,0.0003243159,0.000331963,0.00005093539,0.0003338062],"domain_scores_gemma":[0.99867004,0.00026673652,0.00023546786,0.00078246824,0.0000118980715,0.000033414355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011507994,0.00028691124,0.0005562812,0.000051744835,0.0003452626,0.00001934019,0.00022075883,0.0001141624,0.00024353057],"category_scores_gemma":[0.000024428027,0.00016974196,0.00011981247,0.000030097628,0.00025587183,0.00005656529,0.000054697404,0.000045307785,0.000051019568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002050428,0.0009833135,0.40484393,0.000017326955,0.0019034016,0.00009058329,0.002998804,0.000045728255,0.003124487,0.0011113345,0.0003972437,0.5824334],"study_design_scores_gemma":[0.04161131,0.0011526904,0.8155355,0.000043098404,0.0009736261,0.000058067984,0.0008091561,0.000019003483,0.067528695,0.00046177805,0.071278624,0.00052843534],"about_ca_topic_score_codex":0.84506553,"about_ca_topic_score_gemma":0.774101,"teacher_disagreement_score":0.581905,"about_ca_system_score_codex":0.00056044257,"about_ca_system_score_gemma":0.00022649835,"threshold_uncertainty_score":0.6921876},"labels":[],"label_agreement":null},{"id":"W2750070121","doi":"10.1016/j.jval.2017.05.025","title":"Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Etanercept; Adalimumab; Dermatology Life Quality Index; Placebo; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Randomized controlled trial; Erythema; Dermatology; Pathology; Disease; Tumor necrosis factor alpha","score_opus":0.3768532601695033,"score_gpt":0.4339955981307294,"score_spread":0.057142337961226086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750070121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97338754,0.019621586,0.0003222598,0.00019456302,0.00071915326,0.002676601,0.003060272,0.000011206819,0.0000068304394],"genre_scores_gemma":[0.99558264,0.0009100477,0.0026093675,0.000026588532,0.00005305,0.00010655619,0.00068668165,0.000016531767,0.000008552969],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953529,0.0025115306,0.0013424108,0.00042279638,0.00007733544,0.0002930121],"domain_scores_gemma":[0.9941185,0.0034254282,0.001353894,0.0010047404,0.000049823368,0.00004760616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025346796,0.00023699622,0.0024625703,0.00011501732,0.00042049828,0.00003269804,0.00043405133,0.00017186574,0.0000236471],"category_scores_gemma":[0.0005104708,0.00015122666,0.00013662646,0.00005251711,0.0001541839,0.000106313244,0.000103260274,0.00007351888,0.0000017237962],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22546749,0.004792385,0.050179698,0.00018468536,0.0062751714,0.0000023188802,0.082646444,0.012770439,0.004378105,0.00017544009,0.0005324454,0.6125954],"study_design_scores_gemma":[0.7053786,0.013513684,0.058882892,0.0011849581,0.008518906,0.000019884394,0.014336449,0.092968665,0.0988207,0.0013045019,0.003764316,0.0013064393],"about_ca_topic_score_codex":0.016927226,"about_ca_topic_score_gemma":0.0010240718,"teacher_disagreement_score":0.6112889,"about_ca_system_score_codex":0.000068533096,"about_ca_system_score_gemma":0.00019058795,"threshold_uncertainty_score":0.98961914},"labels":[],"label_agreement":null},{"id":"W2751273647","doi":"10.12968/npre.2017.15.9.432","title":"Dermatology prescribing update: Psoriasis","year":2017,"lang":"en","type":"article","venue":"Nurse Prescribing","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Learning Partnership","funders":"","keywords":"Psoriasis; Medicine; Dithranol; Dermatology; Plaque psoriasis; Primary care; Family medicine","score_opus":0.030523865882713185,"score_gpt":0.2681129914306864,"score_spread":0.2375891255479732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751273647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94568646,0.0047515905,0.00022268177,0.0016451707,0.006333827,0.00052204414,0.000081458995,0.00039891567,0.040357877],"genre_scores_gemma":[0.9949679,0.00012548741,0.0004244292,0.00014236469,0.00016385525,0.00007832668,0.0001133142,0.000046593632,0.0039377236],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979391,0.00022659935,0.0003849087,0.0006123095,0.00006490257,0.00077218],"domain_scores_gemma":[0.9980957,0.00010334545,0.00030598592,0.0013508477,0.000082028426,0.00006211564],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020794488,0.00036058517,0.00047877914,0.0001373301,0.0015938008,0.00016303145,0.0008970155,0.00043354012,0.00083791063],"category_scores_gemma":[0.00025453008,0.00033570075,0.00020878435,0.000052513784,0.00030837275,0.00049885135,0.00020486325,0.00029865323,0.0020131448],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011457172,0.0007465895,0.120297946,0.0000990289,0.002066799,0.00042435556,0.0028583794,0.00001934053,0.23859344,0.016203908,0.05100202,0.56654245],"study_design_scores_gemma":[0.010632325,0.00018238228,0.08770238,0.00029319155,0.0011865854,0.0010479535,0.0009528983,0.000073545176,0.6137808,0.0016210813,0.2809688,0.0015580916],"about_ca_topic_score_codex":0.00024105122,"about_ca_topic_score_gemma":0.000065313485,"teacher_disagreement_score":0.5649844,"about_ca_system_score_codex":0.000053766216,"about_ca_system_score_gemma":0.000057608268,"threshold_uncertainty_score":0.9999095},"labels":[],"label_agreement":null},{"id":"W2751529729","doi":"10.1016/j.jid.2017.07.190","title":"193 Integrating health records and genetic signatures to enhance psoriatic arthritis risk assessment","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Medical record; Disease; Receiver operating characteristic; Internal medicine; Diabetes mellitus; Oncology; Dermatology","score_opus":0.016283189410434544,"score_gpt":0.3056521015611786,"score_spread":0.28936891215074406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751529729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97960335,0.01120975,0.0009169245,0.0065820855,0.0011972167,0.00021561488,0.000035824556,0.000012435922,0.00022679153],"genre_scores_gemma":[0.98072755,0.0024097783,0.015858786,0.0007993868,0.000088836,0.000015786823,0.0000062747245,0.000015231174,0.000078371086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977879,0.0008504463,0.00070594595,0.00024699478,0.000060435912,0.00034826522],"domain_scores_gemma":[0.9974312,0.0003133006,0.0016234628,0.00028770888,0.00021152217,0.00013278374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003722225,0.00023528593,0.00072456937,0.00018269333,0.0007258153,0.00006120224,0.0003261697,0.00019778019,0.00004737653],"category_scores_gemma":[0.001001617,0.0001868851,0.00010400923,0.00006195541,0.0004761454,0.00018760971,0.00009968368,0.0005327435,0.000027384844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029477486,0.00026197778,0.08778709,0.000100992926,0.0018431107,0.0005509647,0.0062363255,0.00002350323,0.16532668,0.0019910508,0.020624403,0.71495914],"study_design_scores_gemma":[0.0028956833,0.0018095564,0.63704073,0.00065629673,0.0002173197,0.0035738007,0.00094658544,0.000018606668,0.33680612,0.007710707,0.00787086,0.00045372208],"about_ca_topic_score_codex":0.00017064768,"about_ca_topic_score_gemma":0.000376442,"teacher_disagreement_score":0.7145054,"about_ca_system_score_codex":0.00007213142,"about_ca_system_score_gemma":0.00037237324,"threshold_uncertainty_score":0.7620953},"labels":[],"label_agreement":null},{"id":"W2751640077","doi":"10.1016/j.jaad.2017.07.013","title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Malignancy; Ustekinumab; Odds ratio; Internal medicine; Cancer registry; Risk factor; Cancer; Dermatology; Disease; Adalimumab","score_opus":0.022223092664554342,"score_gpt":0.3001702996194061,"score_spread":0.27794720695485176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751640077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273586,0.0024864294,0.000037009726,0.0037636885,0.00035487255,0.00026897647,0.000056767567,0.000004401099,0.00029200406],"genre_scores_gemma":[0.99709725,0.0023410937,0.00031990084,0.0000606891,0.0000583555,0.00002050832,0.0000017622463,0.000014713061,0.000085723506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971919,0.0012172839,0.0009053523,0.00021065581,0.0001437007,0.00033108657],"domain_scores_gemma":[0.99326706,0.0004918171,0.005533242,0.0006034711,0.000077228346,0.00002716328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045980432,0.00027264436,0.0011726858,0.00017705248,0.0002837338,0.000013795192,0.0013768519,0.00018292709,0.000016822378],"category_scores_gemma":[0.00011001479,0.00013167465,0.00039562967,0.00018179225,0.0011423242,0.0001179223,0.00009112984,0.00046211458,0.000004920237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011125744,0.0004351279,0.9754731,0.000043731347,0.0020713739,0.00008511443,0.00062612974,0.000027571445,0.007412634,0.00045080853,0.00057397987,0.011687845],"study_design_scores_gemma":[0.004235956,0.00075609173,0.9527983,0.00025664025,0.0015418141,0.010469146,0.0014033015,0.0000018645371,0.02707358,0.000194555,0.0011074832,0.00016123096],"about_ca_topic_score_codex":0.00037346702,"about_ca_topic_score_gemma":0.000038718532,"teacher_disagreement_score":0.022674773,"about_ca_system_score_codex":0.00010118976,"about_ca_system_score_gemma":0.00021319212,"threshold_uncertainty_score":0.5369537},"labels":[],"label_agreement":null},{"id":"W2752688736","doi":"10.1111/jdv.14581","title":"Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase <scp>III</scp> trials","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Guenther Dermatology Research Centre; Western University","funders":"Eli Lilly and Company","keywords":"Psoriasis; Ixekizumab; Medicine; Placebo; Psoriasis Area and Severity Index; Dermatology; Dermatology Life Quality Index; Quality of life (healthcare); Internal medicine; Secukinumab; Pathology; Psoriatic arthritis","score_opus":0.07829322909685908,"score_gpt":0.33741251816149587,"score_spread":0.25911928906463677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752688736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950152,0.0021411108,0.000006915749,0.0006517976,0.0007553157,0.00026762742,0.0005027689,0.0000063049038,0.0006529466],"genre_scores_gemma":[0.9988684,0.0008148075,0.000049805665,0.000069101945,0.00008041972,0.0000018480882,0.000019984544,0.000020900681,0.000074721276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99041194,0.006292442,0.0024918546,0.00034314368,0.00011650149,0.00034409267],"domain_scores_gemma":[0.9929199,0.0021091432,0.0043630293,0.00035997693,0.00015234442,0.00009557559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024058856,0.00033619077,0.0020143185,0.0003556033,0.00022960025,0.000010312792,0.0006855644,0.00050631864,0.0000129276905],"category_scores_gemma":[0.0067273113,0.00022304963,0.00044888383,0.00009699509,0.0007179017,0.00015832337,0.00024129954,0.0006204035,0.0000062112417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061039343,0.002641399,0.774029,0.000083754785,0.007977529,0.000073721625,0.007296889,0.00040858524,0.044006344,0.00078563846,0.0038329598,0.097824834],"study_design_scores_gemma":[0.05306532,0.00067942514,0.9128213,0.0001731398,0.00056789187,0.00021839367,0.00015319792,0.0000053098906,0.030493617,0.0012893047,0.00038680917,0.00014630926],"about_ca_topic_score_codex":0.00021533758,"about_ca_topic_score_gemma":0.000027201411,"teacher_disagreement_score":0.13879228,"about_ca_system_score_codex":0.000031590716,"about_ca_system_score_gemma":0.00011014551,"threshold_uncertainty_score":0.90957},"labels":[],"label_agreement":null},{"id":"W2753594593","doi":"10.3899/jrheum.161402","title":"Psoriatic Disease 10 Years Later","year":2017,"lang":"en","type":"editorial","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Immunology; Genetic predisposition; Inflammation; Pathogenesis; Disease; Cytokine; Tumor necrosis factor alpha; Inflammatory bowel disease; Dactylitis; Pathology; Enthesitis","score_opus":0.010565734134200228,"score_gpt":0.24839500911054735,"score_spread":0.23782927497634712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753594593","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07704156,0.021156052,0.000005629329,0.00031381426,0.90096724,0.00013969498,0.00014984825,0.000019136367,0.00020703698],"genre_scores_gemma":[0.43438825,0.09389356,0.00014154181,0.00013869409,0.3677121,0.00005927266,0.0014681608,0.00046382393,0.101734586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978045,0.0007751108,0.00069626333,0.00018425098,0.00013128597,0.00040854342],"domain_scores_gemma":[0.99569666,0.0015753318,0.0016731734,0.0007394835,0.00025535934,0.000059969392],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008955641,0.00034034558,0.0010029132,0.00018449344,0.00027851108,0.000030338668,0.0012699174,0.00097172684,0.0010904623],"category_scores_gemma":[0.0012817895,0.00021097911,0.0003710767,0.000039168197,0.0003677313,0.00009357873,0.00014689688,0.000915308,0.0015293222],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016335665,0.00008007381,0.001012274,0.000046234894,0.0014372814,0.000058149748,0.00025037487,0.0000013004884,0.000044545122,0.000017948676,0.9887695,0.0066487705],"study_design_scores_gemma":[0.0024624937,0.00023916848,0.0012199326,0.00022383306,0.0015711071,0.00056565594,0.000025426194,2.45051e-7,0.00004102996,0.00044167097,0.99298656,0.00022287092],"about_ca_topic_score_codex":0.00007183455,"about_ca_topic_score_gemma":0.000040290342,"teacher_disagreement_score":0.5332551,"about_ca_system_score_codex":0.000057651127,"about_ca_system_score_gemma":0.00062310824,"threshold_uncertainty_score":0.9998227},"labels":[],"label_agreement":null},{"id":"W2753909342","doi":"10.1136/annrheumdis-2017-eular.1719","title":"SAT0463 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Secukinumab; Placebo; Psoriatic arthritis; Discontinuation; Internal medicine; Plaque psoriasis; Randomized controlled trial; Minimal clinically important difference; Physical therapy; TNF inhibitor; Psoriasis; Gastroenterology; Tumor necrosis factor alpha; Arthritis; Adalimumab; Dermatology; Pathology","score_opus":0.047887894986296524,"score_gpt":0.30788697030965284,"score_spread":0.2599990753233563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753909342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674161,0.02895177,3.9218045e-7,0.0017574021,0.00053001096,0.0006197001,0.0007036378,0.000009882408,0.000011094645],"genre_scores_gemma":[0.9916808,0.0077478834,0.000014512912,0.000038411476,0.00008778135,0.00004620702,0.00034582277,0.0000117365735,0.000026837399],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99889016,0.00028284104,0.0002595638,0.00028731153,0.00007615882,0.0002039491],"domain_scores_gemma":[0.9983808,0.00017604488,0.0003662632,0.0009895372,0.00007372797,0.000013650833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011368879,0.00018685863,0.00037172434,0.000033424567,0.00024903487,0.00004019568,0.0005519802,0.00008436701,0.000025892443],"category_scores_gemma":[0.00020996548,0.000101591075,0.000050029954,0.00007572543,0.00032648738,0.00046281828,0.00027726864,0.000103682345,0.0000032178991],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013688513,0.00057922385,0.26496366,0.00012910095,0.0014052975,0.0000058459627,0.0078101074,0.0000018239748,0.000008263257,0.00009928294,0.0016987001,0.72192985],"study_design_scores_gemma":[0.0027478528,0.00010109748,0.9891993,0.0008230971,0.00016197028,0.0000013633954,0.0053479965,6.0922275e-7,0.00019195737,0.0012246292,0.00007852241,0.000121614656],"about_ca_topic_score_codex":0.0002861564,"about_ca_topic_score_gemma":0.0009664518,"teacher_disagreement_score":0.72423565,"about_ca_system_score_codex":0.000018928495,"about_ca_system_score_gemma":0.00006268251,"threshold_uncertainty_score":0.4142764},"labels":[],"label_agreement":null},{"id":"W2754068533","doi":"10.1136/annrheumdis-2017-eular.5163","title":"AB0771 Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the liberate study","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Apremilast; Medicine; Etanercept; Psoriasis; Dermatology; Placebo; Dermatology Life Quality Index; Psoriatic arthritis; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Mucocutaneous zone; Nail disease; Clinical trial; Surgery; Disease; Pathology; Tumor necrosis factor alpha","score_opus":0.03525518595697935,"score_gpt":0.2823813366102179,"score_spread":0.24712615065323856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754068533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967229,0.00032451536,0.0000018747617,0.00040986648,0.00011403584,0.0016113237,0.0006231927,0.000009790946,0.00018249561],"genre_scores_gemma":[0.99917424,0.0002245551,0.000016810738,0.0001064019,0.000008189299,0.000092399714,0.000057385903,0.000018736562,0.00030127598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982002,0.0005431494,0.00050222944,0.0003581607,0.00011991658,0.0002763515],"domain_scores_gemma":[0.9978369,0.0006863447,0.00041292643,0.0009618952,0.000069864276,0.000032097752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017493071,0.00032079485,0.0007577563,0.000061925355,0.0002417006,0.000040393476,0.0005050069,0.000088153975,0.000058156027],"category_scores_gemma":[0.00024838562,0.00015347668,0.00011491024,0.00011546036,0.00015392536,0.00012998354,0.00011429052,0.00008073203,0.000010671414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052945822,0.012485874,0.7812184,0.00008721795,0.0028465756,0.000012370905,0.037348986,0.0005922372,0.00013154099,0.000055949684,0.00053094636,0.11174404],"study_design_scores_gemma":[0.012575206,0.0014974818,0.9822124,0.00066533906,0.0003216745,6.039421e-7,0.0012697871,0.0000067821834,0.0011061163,0.00013145666,0.0000335407,0.00017960228],"about_ca_topic_score_codex":0.001095254,"about_ca_topic_score_gemma":0.000752376,"teacher_disagreement_score":0.20099397,"about_ca_system_score_codex":0.000025489822,"about_ca_system_score_gemma":0.00006016089,"threshold_uncertainty_score":0.62585974},"labels":[],"label_agreement":null},{"id":"W2755130106","doi":"10.1136/annrheumdis-2017-eular.2148","title":"AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Incyte; Valeant Pharmaceuticals International; AbbVie; Celgene; Amgen; Pfizer; Allergan; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Concomitant; Psoriasis; Adalimumab; Placebo; Adverse effect; Internal medicine; Randomized controlled trial; Clinical endpoint; Psoriasis Area and Severity Index; Surgery; Dermatology; Gastroenterology; Rheumatoid arthritis; Pathology","score_opus":0.012470468457135654,"score_gpt":0.24575878918402258,"score_spread":0.23328832072688693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755130106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897945,0.0067993035,0.000004621891,0.0003378603,0.00009780415,0.0026356636,0.00028420956,0.00000724994,0.000038797385],"genre_scores_gemma":[0.99754655,0.0021130436,0.000026518615,0.000025949712,0.000008862222,0.0001958852,0.000043070457,0.00001785776,0.000022270342],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977905,0.0007114593,0.0008611976,0.0002721227,0.00014501499,0.0002196896],"domain_scores_gemma":[0.99591017,0.0020384125,0.0012225132,0.0007012103,0.00009726112,0.000030412706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006256416,0.00027159316,0.0018502137,0.000110750676,0.00020620279,0.000023076267,0.00036169388,0.00009604137,0.000035526486],"category_scores_gemma":[0.00090503186,0.00013348763,0.00023107092,0.000118017204,0.0007969579,0.00013380512,0.00009920788,0.00008758068,8.9074734e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8559024,0.0016879351,0.091801524,0.00008258576,0.0034143352,7.0788644e-7,0.0010487562,0.000015664356,0.0000055233436,0.00002764107,0.000028181934,0.04598478],"study_design_scores_gemma":[0.66570437,0.0005095099,0.33078963,0.0010547545,0.0014630302,5.022722e-7,0.00010848208,0.0000151523745,0.000098114826,0.00013956179,0.000003808068,0.00011308029],"about_ca_topic_score_codex":0.0010906075,"about_ca_topic_score_gemma":0.0009285543,"teacher_disagreement_score":0.2389881,"about_ca_system_score_codex":0.000010852834,"about_ca_system_score_gemma":0.00009747254,"threshold_uncertainty_score":0.54434675},"labels":[],"label_agreement":null},{"id":"W2755163724","doi":"10.1136/annrheumdis-2017-eular.1478","title":"SAT0472 Utilization of the psoriasis epidemiology screening tool to identify signs and symptoms of early psoriatic arthritis among those with psoriasis: analysis from the corrona psoriasis registry","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Horizon Pharma; Pfizer Pharmaceuticals; Janssen Pharmaceuticals; Momenta Pharmaceuticals; Valeant Pharmaceuticals International; Genentech; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Psoriasis; Psoriatic arthritis; Dermatology; Epidemiology; Medicine; Internal medicine","score_opus":0.07103453564537741,"score_gpt":0.323078800177517,"score_spread":0.2520442645321396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755163724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98620534,0.010084043,0.00048261264,0.00073942135,0.0006143638,0.0007513366,0.0010557367,0.000023634439,0.000043516688],"genre_scores_gemma":[0.99770045,0.0016415799,0.00013450433,0.00012401235,0.0000478958,0.00009784207,0.000072303505,0.000028919556,0.00015247753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965148,0.0012073112,0.0011128623,0.00051305204,0.00021961467,0.00043239148],"domain_scores_gemma":[0.9929069,0.002117185,0.0022747822,0.0023387957,0.00029112544,0.00007118777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009250289,0.00039912216,0.0012796037,0.00013946938,0.00075024273,0.00005205196,0.001430644,0.00023370817,0.00011633942],"category_scores_gemma":[0.00351694,0.00021400885,0.0007099381,0.00048577605,0.0011674727,0.00025201193,0.00043794847,0.00015683485,0.0000063896905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068708876,0.00022504762,0.7408432,0.000085022235,0.0068526673,8.250455e-7,0.0013811663,0.0001929922,0.00030940372,0.0003998522,0.00064420555,0.24837855],"study_design_scores_gemma":[0.0014421941,0.00028655544,0.98563206,0.0012324966,0.0046316623,0.000002729801,0.00067428156,0.000041688683,0.004414639,0.0013463948,0.000053006388,0.00024231231],"about_ca_topic_score_codex":0.0038521937,"about_ca_topic_score_gemma":0.0005698222,"teacher_disagreement_score":0.24813622,"about_ca_system_score_codex":0.000013702726,"about_ca_system_score_gemma":0.000103211,"threshold_uncertainty_score":0.8727028},"labels":[],"label_agreement":null},{"id":"W2755164839","doi":"10.1136/annrheumdis-2017-eular.3105","title":"SAT0437 Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior tnf inadequate response","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ixekizumab; Medicine; Psoriatic arthritis; Psoriasis; Mallinckrodt; Placebo; Internal medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Dermatology; Secukinumab; Pathology","score_opus":0.017095471045233863,"score_gpt":0.25304477465024733,"score_spread":0.23594930360501346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755164839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496764,0.0036707711,6.689545e-7,0.0005603108,0.0001348722,0.00040815648,0.00021811886,0.000010666279,0.000028793538],"genre_scores_gemma":[0.9984477,0.0012120866,0.00001767091,0.00004026028,0.0000038503094,0.000041623407,0.000016363983,0.000012334753,0.00020810931],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989572,0.0003036816,0.00023675266,0.00021872109,0.000057078447,0.00022653701],"domain_scores_gemma":[0.99877363,0.00034233433,0.00031514588,0.0004708888,0.00005799158,0.00004000287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015915885,0.00017816074,0.0003440782,0.00007637992,0.00040885,0.000037104,0.00021543991,0.00007671167,0.000020556963],"category_scores_gemma":[0.0006561512,0.000112727656,0.00006337592,0.00004756088,0.00039549283,0.0002025426,0.00015315716,0.000067145695,0.000007729292],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002623421,0.00028381063,0.003217303,0.000046003628,0.0002544763,0.0000016020807,0.0006886252,3.506126e-7,0.000011401543,0.000054041728,0.00011497896,0.992704],"study_design_scores_gemma":[0.0035341133,0.00034040393,0.9922128,0.00067455467,0.00011377616,0.0000025051552,0.00020815017,0.000001959391,0.002062773,0.00065187516,0.00006177845,0.00013535946],"about_ca_topic_score_codex":0.00018894278,"about_ca_topic_score_gemma":0.00010060231,"teacher_disagreement_score":0.9925686,"about_ca_system_score_codex":0.000009765708,"about_ca_system_score_gemma":0.00007123724,"threshold_uncertainty_score":0.45969003},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2755704235","doi":"10.1136/annrheumdis-2017-eular.1580","title":"SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Ixekizumab; Psoriatic arthritis; Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Presenteeism; Placebo; Psoriasis; Internal medicine; Visual analogue scale; Physical therapy; Adalimumab; Tumor necrosis factor alpha; Arthritis; Secukinumab; Absenteeism; Dermatology; Pathology; Alternative medicine; Psychology","score_opus":0.017133957347561166,"score_gpt":0.2559271969964671,"score_spread":0.23879323964890592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755704235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672645,0.0009296323,5.9466674e-7,0.0005999578,0.00033711738,0.0009531454,0.00041201382,0.000023962713,0.000017107282],"genre_scores_gemma":[0.9994247,0.00017706201,0.000014469308,0.00007392772,0.000003838235,0.00010288561,0.000023350485,0.000022564212,0.00015717723],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983265,0.0003616699,0.0005042091,0.00033076762,0.00012131245,0.00035558784],"domain_scores_gemma":[0.99804175,0.0003409521,0.0006874443,0.0007305385,0.00012388367,0.00007543356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012801893,0.0002978755,0.00060663436,0.00013201674,0.00035309664,0.000057358735,0.00032147972,0.00009232125,0.00002660947],"category_scores_gemma":[0.0015095809,0.00018678869,0.0001540331,0.00008968909,0.00021487291,0.00025144298,0.00020608136,0.00008216194,0.000015364505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037737007,0.0006395606,0.18007196,0.000047347763,0.00071437954,0.0000042394463,0.0014509758,0.000002010269,0.00025571164,0.0000059203544,0.00015546197,0.8128787],"study_design_scores_gemma":[0.0034670543,0.00072092627,0.98411846,0.0007118417,0.00015275544,0.0000017170746,0.00016450077,5.8185907e-7,0.010222142,0.00018679685,0.00003062438,0.00022257722],"about_ca_topic_score_codex":0.00041177552,"about_ca_topic_score_gemma":0.000093352864,"teacher_disagreement_score":0.81265616,"about_ca_system_score_codex":0.00002667783,"about_ca_system_score_gemma":0.000088794324,"threshold_uncertainty_score":0.7617022},"labels":[],"label_agreement":null},{"id":"W2755831795","doi":"10.1016/j.jaad.2017.06.153","title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Plaque psoriasis; Psoriasis; Randomized controlled trial; Clinical trial; Dermatology; Internal medicine; Secukinumab; Psoriatic arthritis","score_opus":0.04825524568326119,"score_gpt":0.3700946110253621,"score_spread":0.32183936534210095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755831795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98367095,0.0043925876,0.00033327102,0.0077753537,0.0008450844,0.0025441388,0.0003352956,0.0000038529165,0.00009946139],"genre_scores_gemma":[0.99106985,0.008032365,0.00046726735,0.00012050088,0.00011963409,0.000060331073,0.000004413207,0.000016055488,0.00010956815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99455434,0.001768052,0.0030372313,0.00023960987,0.00011872675,0.0002820539],"domain_scores_gemma":[0.9819274,0.008459236,0.008926509,0.00044924318,0.00019318234,0.00004443687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013329174,0.00029692368,0.0048153135,0.00012487295,0.00023986513,0.0000071802665,0.0007656904,0.00030833585,0.000009959872],"category_scores_gemma":[0.0021949701,0.00014594418,0.0015865654,0.00009272518,0.0022109398,0.00009419271,0.00009170488,0.0002584719,0.0000011364496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96232396,0.0015015649,0.00017448796,0.000023176046,0.007905689,0.000003436128,0.00087727,0.000048480684,0.0029698857,0.00033527188,0.00072915544,0.023107635],"study_design_scores_gemma":[0.9503307,0.0050169043,0.0013791134,0.00011608283,0.004189856,0.00036259147,0.00026933826,0.00002846009,0.0344488,0.00045596936,0.0032694852,0.00013274765],"about_ca_topic_score_codex":0.00007874512,"about_ca_topic_score_gemma":0.0000057749207,"teacher_disagreement_score":0.03147891,"about_ca_system_score_codex":0.000029029117,"about_ca_system_score_gemma":0.00022263433,"threshold_uncertainty_score":0.81463},"labels":[],"label_agreement":null},{"id":"W2755910317","doi":"10.1016/j.jaad.2017.02.051","title":"Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis","year":2017,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Hôpital du Sacré-Cœur de Montréal; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Ankylosing spondylitis; Psoriatic arthritis; Inflammatory bowel disease; Capsule endoscopy; Disease; Dermatology; Population; Internal medicine; Gastroenterology","score_opus":0.024871127265794175,"score_gpt":0.28964748185703637,"score_spread":0.2647763545912422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755910317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9331172,0.0002835754,0.000016436574,0.0648837,0.00039511189,0.0004688005,0.00082020304,0.0000040465893,0.000010887051],"genre_scores_gemma":[0.9846173,0.00013790296,0.0005442011,0.014283074,0.00007472252,0.000017198508,0.000033029115,0.000042934214,0.00024966686],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9970787,0.0008630863,0.0011026297,0.00031440365,0.00019547873,0.00044569187],"domain_scores_gemma":[0.99498624,0.00040012415,0.003805958,0.00046117348,0.00026298405,0.0000835202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012106827,0.0003980795,0.0018804723,0.00068442954,0.00010503073,0.00000976566,0.0011116,0.00045219314,0.000028941142],"category_scores_gemma":[0.0003432285,0.00026649242,0.00038232838,0.00029941715,0.000742173,0.00016283825,0.00025871609,0.001107455,0.000012432593],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023035303,0.0011893826,0.43021187,0.00042293817,0.005658183,0.00082285085,0.001816238,0.00070793746,0.015315989,0.000030165693,0.5155352,0.005253973],"study_design_scores_gemma":[0.0030429792,0.00046796797,0.9584763,0.0008036133,0.001183937,0.00023354431,0.000053777985,6.51695e-7,0.024071153,0.000069324175,0.011249567,0.00034718544],"about_ca_topic_score_codex":0.00023672785,"about_ca_topic_score_gemma":0.000008239117,"teacher_disagreement_score":0.5282644,"about_ca_system_score_codex":0.00007735242,"about_ca_system_score_gemma":0.00029322735,"threshold_uncertainty_score":0.9999787},"labels":[],"label_agreement":null},{"id":"W2756003268","doi":"10.1001/jamadermatol.2017.3029","title":"Safety of Systemic Agents for the Treatment of Pediatric Psoriasis","year":2017,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Pediatric Dermatology Research Alliance","keywords":"Medicine; Psoriasis; Dermatology; Systemic therapy; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.02946837848277884,"score_gpt":0.27351969537490917,"score_spread":0.24405131689213033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756003268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98093295,0.014719803,0.00018819873,0.0005631419,0.0019713505,0.000737977,0.00031536474,0.000020661711,0.00055052276],"genre_scores_gemma":[0.99286383,0.0058935196,0.00006054647,0.000018191737,0.00009862198,0.0001464474,0.000059935574,0.000013559752,0.0008453408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891645,0.00014252856,0.00044004899,0.00020755193,0.000027571892,0.00026585345],"domain_scores_gemma":[0.9979103,0.0006549346,0.0005820016,0.00074096315,0.000096709286,0.000015096589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001037246,0.00017726647,0.00054692605,0.00008206737,0.00038496524,0.000008913326,0.00041405862,0.00030791652,0.000082717095],"category_scores_gemma":[0.00009344152,0.000111984344,0.00026783178,0.000041817497,0.00019674547,0.000057167686,0.000039720846,0.000041155465,0.000059074107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005194777,0.0021873612,0.6319311,0.0005908225,0.0073601375,0.000053988053,0.005228657,0.00001974384,0.025678037,0.010601956,0.014506532,0.29664686],"study_design_scores_gemma":[0.038262736,0.0017217976,0.49431783,0.00008566105,0.0059590144,0.00120955,0.001159417,0.00003579987,0.3019089,0.00044275782,0.15426551,0.000631016],"about_ca_topic_score_codex":0.00011402584,"about_ca_topic_score_gemma":0.000023986588,"teacher_disagreement_score":0.29601583,"about_ca_system_score_codex":0.000031561136,"about_ca_system_score_gemma":0.00006955283,"threshold_uncertainty_score":0.4566589},"labels":[],"label_agreement":null},{"id":"W2756075799","doi":"","title":"The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis.","year":2017,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Medicine; Sex organ; Dermatology; Severity of illness; Reliability (semiconductor); Patient-reported outcome; Quality of life (healthcare); Physical therapy; Internal medicine; Nursing","score_opus":0.07536307365363812,"score_gpt":0.34522193692260156,"score_spread":0.26985886326896347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756075799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779696,0.002280589,0.00043409702,0.0011296321,0.0037120492,0.0020659498,0.00091184466,0.0000240261,0.0016448435],"genre_scores_gemma":[0.9983676,0.00006377472,0.00010506235,0.000050772866,0.00010014618,0.00087240065,0.000020249852,0.000009381816,0.00041063107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854964,0.00025953335,0.00053437374,0.0002135109,0.00007961356,0.00036334505],"domain_scores_gemma":[0.9976249,0.0008587636,0.0005842458,0.00077053555,0.00013670964,0.000024897374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013860841,0.0001624895,0.00041941289,0.000011366904,0.00058954046,0.000028936656,0.00065790454,0.00015436432,0.000005915882],"category_scores_gemma":[0.0004743509,0.00008799316,0.00040830098,0.000037447364,0.000531943,0.000074656695,0.00012262074,0.00011315544,0.0000063236425],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041414247,0.0003085405,0.2764391,0.00002370171,0.0021873463,0.0000010803317,0.000041002986,9.03487e-7,0.00008356436,0.0015628727,0.0010469261,0.7178908],"study_design_scores_gemma":[0.0021786634,0.00008002694,0.9918334,0.000003096653,0.00078903144,0.0000037551283,0.0001122461,0.000006246858,0.0007690939,0.0005800423,0.0035495164,0.000094868745],"about_ca_topic_score_codex":0.000071704955,"about_ca_topic_score_gemma":0.00013490522,"teacher_disagreement_score":0.7177959,"about_ca_system_score_codex":0.000038918515,"about_ca_system_score_gemma":0.000075936325,"threshold_uncertainty_score":0.4534328},"labels":[],"label_agreement":null},{"id":"W2756322479","doi":"10.1136/annrheumdis-2017-eular.1576","title":"OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Psoriasis; Internal medicine; Adalimumab; Ixekizumab; Gastroenterology; Tumor necrosis factor alpha; Clinical endpoint; Surgery; Clinical trial; Immunology; Pathology; Secukinumab","score_opus":0.023090348047180503,"score_gpt":0.28203488290901696,"score_spread":0.25894453486183644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756322479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973819,0.00061999285,4.4677978e-7,0.0002390332,0.000113316884,0.0010735384,0.00056167966,0.0000041462918,0.00000593455],"genre_scores_gemma":[0.9997709,0.0001292523,0.000003831147,0.000013790503,0.0000024192836,0.000033351647,0.0000047586495,0.000009968686,0.000031750806],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986755,0.000505337,0.00037091877,0.00019067476,0.00009031185,0.00016721894],"domain_scores_gemma":[0.9983752,0.00043096323,0.000518205,0.0005454237,0.00009417525,0.00003602728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016475887,0.00016855107,0.00046699203,0.000075062315,0.00022198375,0.0000142380695,0.00029370264,0.00004797314,0.00001541325],"category_scores_gemma":[0.00093936286,0.00009395704,0.00006625913,0.00009264501,0.00026299586,0.00011127767,0.00022135742,0.000055676428,0.0000013355801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045239512,0.0067560747,0.1469686,0.00014135744,0.0011232271,0.0000015772514,0.011535168,0.00000925562,0.0011668277,0.000015634883,0.00009216891,0.7869506],"study_design_scores_gemma":[0.014105373,0.0017193607,0.97254324,0.00093068916,0.00016011986,6.296829e-7,0.00061024976,8.390545e-7,0.009770342,0.000055448134,0.0000060351886,0.000097696764],"about_ca_topic_score_codex":0.00026688096,"about_ca_topic_score_gemma":0.00008971714,"teacher_disagreement_score":0.82557464,"about_ca_system_score_codex":0.000009536087,"about_ca_system_score_gemma":0.00005889123,"threshold_uncertainty_score":0.3831457},"labels":[],"label_agreement":null},{"id":"W2756985120","doi":"10.1016/j.jid.2017.09.021","title":"Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung, and Blood Institute; National Institutes of Health; National Psoriasis Foundation","keywords":"Psoriasis; Medicine; Thrombosis; Dermatology; Interleukin 17; Immunology; Internal medicine; Cytokine","score_opus":0.03950820700915978,"score_gpt":0.2648916327431499,"score_spread":0.22538342573399014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756985120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952206,0.0007322993,0.00008774376,0.0019195935,0.001358317,0.00024405788,0.00016704474,0.000018163975,0.00025218105],"genre_scores_gemma":[0.99880755,0.00017527358,0.0005573158,0.000116829375,0.000074986325,0.000030464624,0.000044387998,0.00001995388,0.00017325819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797326,0.0005805584,0.00087765313,0.00022667502,0.00007717217,0.00026469294],"domain_scores_gemma":[0.9971291,0.00018218682,0.0019205197,0.00034810512,0.0003614524,0.000058653968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022308624,0.00025649084,0.00077323354,0.0002350564,0.00029459773,0.000023206607,0.0002612583,0.00053412415,0.00044123153],"category_scores_gemma":[0.0005720222,0.00018628952,0.00024314637,0.00010429454,0.0010295685,0.00042439497,0.000078495366,0.00039906395,0.00016261313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014530272,0.00028218847,0.011231821,0.000042331278,0.0019791776,0.00020670182,0.0025229068,0.0000025760144,0.97639555,0.00039249856,0.0018142054,0.00367703],"study_design_scores_gemma":[0.003250798,0.00039788353,0.14016946,0.0002073217,0.0004202156,0.00061205105,0.00030835258,0.0000024172705,0.8483833,0.004835355,0.0012443332,0.00016849012],"about_ca_topic_score_codex":0.00012943894,"about_ca_topic_score_gemma":0.000095949494,"teacher_disagreement_score":0.12893763,"about_ca_system_score_codex":0.000058877515,"about_ca_system_score_gemma":0.00020624802,"threshold_uncertainty_score":0.7596666},"labels":[],"label_agreement":null},{"id":"W2758985612","doi":"10.1177/1203475417733414","title":"Acitretin Use in Dermatology","year":2017,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McMaster University; Dermatrials Research; University of Manitoba; Public Health Ontario; University of Toronto; Probity Medical Research; Guenther Dermatology Research Centre; Western University","funders":"","keywords":"Acitretin; Medicine; Psoriasis; Dermatology; Hidradenitis suppurativa; Palmoplantar pustulosis; Pustulosis; Keratolytic; Ichthyosis; Disease; Surgery; Pathology","score_opus":0.12400741611667318,"score_gpt":0.335648241864981,"score_spread":0.2116408257483078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2758985612","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024477162,0.9950699,0.0000010265414,0.00018316714,0.0018917668,0.0001233672,0.000011752701,0.000006779893,0.00026448743],"genre_scores_gemma":[0.0007029221,0.9973769,0.000009817304,0.00006984961,0.00022332833,0.00000426423,0.000046637553,0.000025459623,0.0015407852],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754125,0.00056292803,0.0013121499,0.00020378357,0.00005901337,0.00032088457],"domain_scores_gemma":[0.9946351,0.003450116,0.0015002738,0.00027873844,0.00007847894,0.000057299192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054411526,0.00036575028,0.0037599835,0.00079796056,0.000094587456,0.000016276554,0.00020944074,0.0006433052,0.0002140618],"category_scores_gemma":[0.0010467833,0.00022529424,0.00047718477,0.0000844811,0.00028501786,0.000073750314,0.000037767986,0.000569256,0.00003841273],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009373221,0.00005227559,0.00094412453,0.0012916868,0.0005954793,0.010460024,0.000093688745,2.3499148e-8,0.0000041336734,0.000008681891,0.017909179,0.968547],"study_design_scores_gemma":[0.0003788846,0.000086673586,0.000041285002,0.011100991,0.0012050567,0.08119037,0.000027616652,3.4350258e-8,0.0000026642551,0.00001754828,0.9057831,0.00016578757],"about_ca_topic_score_codex":0.0000429896,"about_ca_topic_score_gemma":0.000030926007,"teacher_disagreement_score":0.96838117,"about_ca_system_score_codex":0.000040743293,"about_ca_system_score_gemma":0.00031067035,"threshold_uncertainty_score":0.9187232},"labels":[],"label_agreement":null},{"id":"W2760576414","doi":"10.1016/j.ijtb.2017.08.027","title":"Interleukin-17 A and F gene polymorphisms affect the risk of tuberculosis: An updated meta-analysis","year":2017,"lang":"en","type":"review","venue":"Indian Journal of Tuberculosis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Allele; Meta-analysis; Tuberculosis; SNP; Medicine; Risk factor; Subgroup analysis; Internal medicine; Single-nucleotide polymorphism; Immunology; Genetics; Genotype; Gene; Biology; Pathology","score_opus":0.071357279050172,"score_gpt":0.3235996977811252,"score_spread":0.2522424187309532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760576414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01850737,0.9785971,0.00000846641,0.00015816755,0.0005329344,0.00054147124,0.0015586618,0.000015881918,0.00007996095],"genre_scores_gemma":[0.029329732,0.9693197,0.00013188373,0.00004784584,0.00015837376,0.00005588738,0.0004366018,0.000076530436,0.00044345856],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933668,0.0033064184,0.0019604217,0.00061329984,0.00019855898,0.00055453775],"domain_scores_gemma":[0.99264735,0.00061431405,0.004714356,0.0015904409,0.00027434799,0.00015919012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023614476,0.0009810068,0.0070454236,0.0014674771,0.00053955306,0.000135616,0.0015903146,0.00097518606,0.0012633203],"category_scores_gemma":[0.0001550372,0.0005286133,0.00802736,0.00063992117,0.00051898946,0.00032234087,0.00020162383,0.0010698418,0.000059509304],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093476796,0.00024332474,0.0004905855,0.00027452072,0.6342189,0.00017844664,0.0006739973,0.0000031819502,0.00006348762,0.0000055586784,0.0008452996,0.36290926],"study_design_scores_gemma":[0.00073911744,0.00059434574,0.0009927545,0.0004132012,0.85972154,0.0022753978,0.00008553474,4.348846e-7,0.0005860123,0.000029172197,0.13402148,0.0005410355],"about_ca_topic_score_codex":0.00035096065,"about_ca_topic_score_gemma":0.0002338257,"teacher_disagreement_score":0.36236823,"about_ca_system_score_codex":0.00010693382,"about_ca_system_score_gemma":0.0002790984,"threshold_uncertainty_score":0.9997165},"labels":[],"label_agreement":null},{"id":"W2763303699","doi":"10.1016/j.jaad.2017.09.060","title":"A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study","year":2017,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Apremilast; Plaque psoriasis; Psoriasis; Multicenter study; Dermatology; Combination therapy; Retrospective cohort study; Internal medicine; Psoriatic arthritis; Randomized controlled trial","score_opus":0.04424193430005016,"score_gpt":0.38726106175395353,"score_spread":0.3430191274539034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763303699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7959405,0.002271322,0.000007861339,0.19994764,0.00074241235,0.0009447183,0.00010597647,0.000003107137,0.00003644261],"genre_scores_gemma":[0.9808491,0.0013796927,0.00022665523,0.01723757,0.00017975265,0.000028971319,0.000010929157,0.00003072617,0.000056593897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996097,0.0016750211,0.0015048357,0.00028073267,0.000106769876,0.00033558308],"domain_scores_gemma":[0.99207914,0.001295392,0.0061235125,0.00026140484,0.00020568066,0.000034883255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006757889,0.00029445082,0.002012193,0.00045493658,0.00013541295,0.000010712216,0.00073290174,0.00076648465,0.000008256062],"category_scores_gemma":[0.0005202745,0.00020842667,0.00037378757,0.00011984042,0.0008315315,0.000117941876,0.000051396346,0.0017654968,0.0000013240412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045734374,0.0012596964,0.85058844,0.00004138077,0.003807059,0.000056410605,0.0022534686,0.0000012300536,0.0007525901,0.0000250532,0.1240575,0.0125837345],"study_design_scores_gemma":[0.018315012,0.0028104854,0.7761916,0.00016852388,0.0010267564,0.0010003631,0.0014213339,0.000009618862,0.002921279,0.00018556576,0.19560951,0.00033994796],"about_ca_topic_score_codex":0.0023824212,"about_ca_topic_score_gemma":0.0007236292,"teacher_disagreement_score":0.18490858,"about_ca_system_score_codex":0.00012526462,"about_ca_system_score_gemma":0.00029774776,"threshold_uncertainty_score":0.84993935},"labels":[],"label_agreement":null},{"id":"W2763398102","doi":"10.1016/j.jaad.2017.08.029","title":"Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research","funders":"","keywords":"Medicine; Adalimumab; Psoriasis; Placebo; Dermatology; Randomized controlled trial; Nail (fastener); Surgery; Internal medicine; Alternative medicine; Pathology; Tumor necrosis factor alpha","score_opus":0.01864386051948098,"score_gpt":0.2980205265829488,"score_spread":0.27937666606346784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763398102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96994704,0.005506563,0.00010316581,0.021561489,0.0009775378,0.0017228454,0.000105432184,0.000007942197,0.00006800444],"genre_scores_gemma":[0.9976867,0.0014228484,0.00017573507,0.00036768042,0.00019218672,0.000064113476,0.0000025900245,0.000020099144,0.00006804381],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704933,0.0010858539,0.0013031024,0.000189098,0.00008788752,0.00028472205],"domain_scores_gemma":[0.98869175,0.0056118206,0.0052327416,0.00034659824,0.000082041995,0.000035025954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008969318,0.0002533155,0.0024463017,0.00009203669,0.00050689594,0.000014672906,0.0010554485,0.00023615913,0.000028141443],"category_scores_gemma":[0.0016035228,0.0001281904,0.0008687465,0.000061114035,0.0020876126,0.00009576836,0.00014421473,0.00038767324,0.0000037273803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9745473,0.00036369372,0.00037162792,0.000012561167,0.0042029284,0.000003310714,0.0004908224,0.0000025412035,0.0033619776,0.0002474096,0.0025145637,0.013881221],"study_design_scores_gemma":[0.97500056,0.0005757282,0.0018968127,0.00008725035,0.0029204253,0.00040867328,0.00020563531,0.000011807535,0.009792646,0.0005347329,0.00843715,0.00012857039],"about_ca_topic_score_codex":0.00007723639,"about_ca_topic_score_gemma":0.000010540773,"teacher_disagreement_score":0.027739681,"about_ca_system_score_codex":0.000019623334,"about_ca_system_score_gemma":0.00011680751,"threshold_uncertainty_score":0.7691896},"labels":[],"label_agreement":null},{"id":"W2763793357","doi":"10.1016/j.jaad.2017.08.024","title":"Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials","year":2017,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Suicidal ideation; Adverse effect; Psychiatry; Psoriasis Area and Severity Index; Clinical trial; Placebo; Internal medicine; Poison control; Dermatology; Injury prevention; Emergency medicine; Pathology","score_opus":0.1410438715761434,"score_gpt":0.4455467596620446,"score_spread":0.3045028880859012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763793357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09267042,0.9052075,0.0000065852455,0.0003194336,0.00091256446,0.0005633823,0.00026594117,0.00000819101,0.00004598934],"genre_scores_gemma":[0.021677468,0.97755045,0.00025241164,0.000025961812,0.0001510451,0.000021121878,0.000021062975,0.000040486426,0.00025997724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98814553,0.006230361,0.0046078996,0.00041958177,0.00016620575,0.00043039725],"domain_scores_gemma":[0.97120917,0.0018417389,0.026069432,0.0006913468,0.00010847684,0.000079823105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014542821,0.00063991465,0.012391955,0.0014100871,0.0001982895,0.0000037136822,0.0015111181,0.0007343324,0.000067402114],"category_scores_gemma":[0.000469479,0.00032682918,0.0066846977,0.0010236877,0.0010176641,0.00008672607,0.00014677632,0.00080612744,0.000019068944],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020704698,0.00089301815,0.034051407,0.0009394079,0.1149081,0.000043065636,0.00008411084,0.0000072508287,0.000046712426,0.000019595165,0.0002811368,0.8466557],"study_design_scores_gemma":[0.008862174,0.0016133745,0.042579696,0.002654173,0.28628945,0.005720947,0.00010987027,6.52307e-7,0.00036416602,0.0000282458,0.65110964,0.000667626],"about_ca_topic_score_codex":0.00004360381,"about_ca_topic_score_gemma":0.000008059699,"teacher_disagreement_score":0.8459881,"about_ca_system_score_codex":0.00013428893,"about_ca_system_score_gemma":0.00061196845,"threshold_uncertainty_score":0.9999184},"labels":[],"label_agreement":null},{"id":"W2764109025","doi":"10.1111/bjd.16050","title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Etanercept; Medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Post-hoc analysis; Dosing; Dermatology; Secukinumab; Tumor necrosis factor alpha; Psoriatic arthritis; Pathology","score_opus":0.0660134355339033,"score_gpt":0.3257095382569747,"score_spread":0.25969610272307136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2764109025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955327,0.038843818,0.00070343935,0.00057296624,0.0028331033,0.00090806745,0.00046890264,0.000030469135,0.00031223803],"genre_scores_gemma":[0.9936848,0.005019035,0.00031096948,0.000052278177,0.00011424593,0.00009617327,0.00014966089,0.00003531913,0.0005374617],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99677116,0.0003711208,0.0016542968,0.00044836153,0.00013833614,0.00061674335],"domain_scores_gemma":[0.9944032,0.0011224173,0.0026600095,0.0006410721,0.0010916323,0.00008170297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043998528,0.00048830296,0.0034605286,0.00066901935,0.0007117775,0.00010357351,0.00075217284,0.0005423175,0.00013852485],"category_scores_gemma":[0.00071146514,0.00041198664,0.0017866312,0.00031583518,0.00050442526,0.00034552664,0.00010414146,0.00026574163,0.000023249386],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11048892,0.005322663,0.049392514,0.0001528561,0.3113245,0.003177389,0.0014098368,0.00043076777,0.0052692173,0.0012375845,0.009991752,0.501802],"study_design_scores_gemma":[0.6363007,0.0058892625,0.10756699,0.0009760024,0.098912,0.022197835,0.002725862,0.00008279525,0.08968754,0.0020511393,0.03172667,0.0018832288],"about_ca_topic_score_codex":0.00058615213,"about_ca_topic_score_gemma":0.0033639069,"teacher_disagreement_score":0.52581173,"about_ca_system_score_codex":0.00023836613,"about_ca_system_score_gemma":0.00047342145,"threshold_uncertainty_score":0.9998332},"labels":[],"label_agreement":null},{"id":"W2765089157","doi":"10.1016/j.jaad.2017.08.051","title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; SKiN Health; Dalhousie University; Probity Medical Research","funders":"Janssen Scientific Affairs; LEO Pharma; Dermira; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Depression (economics); Depressive symptoms; Longitudinal study; Psychiatry; Dermatology; Internal medicine; Pathology; Anxiety","score_opus":0.010845533999091824,"score_gpt":0.2901229953823299,"score_spread":0.27927746138323806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765089157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934825,0.005045399,0.000005300325,0.0009512279,0.00021121604,0.00024843667,0.000013240607,0.0000026519713,0.000040065588],"genre_scores_gemma":[0.99664366,0.003219932,0.000029550765,0.000058685902,0.000017781338,0.00001122699,0.0000012932398,0.000008000775,0.000009881141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976977,0.0012712661,0.00057248416,0.00017732345,0.000069284426,0.00021191036],"domain_scores_gemma":[0.99577373,0.0008675168,0.0030295881,0.00025898096,0.00004482433,0.000025330075],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00041382556,0.00019441228,0.00094441406,0.00010810923,0.0002382101,0.000011296179,0.00064708025,0.00019552857,0.000005653277],"category_scores_gemma":[0.00024561663,0.000090421905,0.00017152459,0.00007125547,0.0027705964,0.000111583846,0.00023040333,0.00044549737,3.7891112e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017204379,0.000057500092,0.97485393,0.000015104723,0.0005655382,0.0000059895856,0.000094231,0.000001625935,0.003491332,0.000034667388,0.000111889465,0.019047765],"study_design_scores_gemma":[0.0077719376,0.00033038497,0.9606871,0.00008982462,0.00022335988,0.0004529054,0.000032862252,0.0000023113898,0.030122159,0.00012562338,0.000082246144,0.00007929916],"about_ca_topic_score_codex":0.00015320502,"about_ca_topic_score_gemma":0.00000908015,"teacher_disagreement_score":0.026630828,"about_ca_system_score_codex":0.000017980105,"about_ca_system_score_gemma":0.00003150129,"threshold_uncertainty_score":0.9999433},"labels":[],"label_agreement":null},{"id":"W2765645961","doi":"10.1016/j.jval.2017.08.2425","title":"Epidemiology of Psoriasis In Colombia: A Governmental Database Analysis","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Epidemiology; Medicine; Psoriasis; Database; Demography; Population; Prevalence; Health care; Pediatrics; Environmental health; Pathology; Dermatology","score_opus":0.07505115506693723,"score_gpt":0.3351063444301166,"score_spread":0.2600551893631794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765645961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916333,0.0059721298,0.000024686138,0.0006869876,0.0005377698,0.00028401523,0.00038640195,0.0000116693,0.00046305955],"genre_scores_gemma":[0.99789506,0.0010497825,0.0004464022,0.000117550175,0.000019215466,0.000035037785,0.00018291721,0.0000085903375,0.000245445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731433,0.0010712821,0.00073681667,0.00037978915,0.00003700236,0.00046075135],"domain_scores_gemma":[0.99796546,0.0006659263,0.0005904404,0.0007280543,0.000014072263,0.000036064906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019418687,0.00015571114,0.0008618182,0.00028382122,0.00016089613,0.0000020333898,0.0003392252,0.00019791581,0.00016020001],"category_scores_gemma":[0.00058956153,0.00014575962,0.00015212552,0.00024046491,0.00017811968,0.00008844724,0.000121498015,0.0001771089,0.000052656585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024221082,0.00033764,0.99212563,0.00004712228,0.00038189313,0.000015853242,0.00023702113,0.00013130097,0.0005757702,0.0012462456,0.00025184828,0.004407447],"study_design_scores_gemma":[0.0025456806,0.00021667319,0.99453086,0.00007061672,0.00013785674,0.000008272373,0.0002445179,0.0001492812,0.0012228868,0.0001582122,0.0005893662,0.00012575692],"about_ca_topic_score_codex":0.05055888,"about_ca_topic_score_gemma":0.0054585673,"teacher_disagreement_score":0.045100313,"about_ca_system_score_codex":0.0003406576,"about_ca_system_score_gemma":0.00013439471,"threshold_uncertainty_score":0.9557635},"labels":[],"label_agreement":null},{"id":"W2765883502","doi":"10.1016/j.jaad.2017.10.012","title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"University of Connecticut; AbbVie; Eli Lilly and Company","keywords":"Medicine; Psoriasis; Cohort; Disease; Dermatology; Comorbidity; Intensive care medicine; Internal medicine","score_opus":0.024647535982479415,"score_gpt":0.270676375239329,"score_spread":0.2460288392568496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765883502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98948085,0.0006821887,0.000009274015,0.0082855,0.00026196626,0.00018831264,0.0010775503,0.0000035411085,0.00001083486],"genre_scores_gemma":[0.9979502,0.001531438,0.000033509743,0.00026550452,0.00005094828,0.0000067533233,0.000058413123,0.000010032153,0.0000931784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984297,0.0004965281,0.0006519008,0.00016018924,0.00006720236,0.0001944895],"domain_scores_gemma":[0.99607104,0.0005787983,0.0028969154,0.00037296262,0.000045266723,0.000035031822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016609364,0.00016832043,0.00065688556,0.000080596365,0.00018478035,0.000013573316,0.00049898616,0.00012152797,0.00001194389],"category_scores_gemma":[0.00031893203,0.00009759659,0.00016997414,0.000071572365,0.0009014863,0.00011913593,0.00008119405,0.00021257192,0.0000018538286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040880744,0.00020229921,0.9491522,0.0000081336175,0.0004741815,0.000021557018,0.0003156601,0.0000065774593,0.042536303,0.000046852856,0.00040935434,0.0027388495],"study_design_scores_gemma":[0.0039359997,0.00011131508,0.9639127,0.00009570261,0.00041034084,0.00010204677,0.000098737095,0.000012403261,0.02591315,0.000039340674,0.005285185,0.00008306055],"about_ca_topic_score_codex":0.0007807595,"about_ca_topic_score_gemma":0.000082686616,"teacher_disagreement_score":0.016623154,"about_ca_system_score_codex":0.000042939308,"about_ca_system_score_gemma":0.00013104772,"threshold_uncertainty_score":0.39798734},"labels":[],"label_agreement":null},{"id":"W2766006797","doi":"10.1016/j.jval.2017.08.2708","title":"Ixekizumab Treatment Leads to Early Improvements in Health-Related Quality of Life Versus Ustekinumab","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Ixekizumab; Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Ustekinumab; Internal medicine; Physical therapy; Placebo; Secukinumab; Disease","score_opus":0.10933141652726085,"score_gpt":0.34734586787121413,"score_spread":0.23801445134395327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766006797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914469,0.0036141996,0.0000030788399,0.0016600708,0.001823408,0.0010189929,0.00012800946,0.00003040709,0.00027494458],"genre_scores_gemma":[0.998357,0.00045123926,0.00011146384,0.000121087294,0.000027052325,0.00008765528,0.00006340178,0.000020629714,0.0007604742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965167,0.00097106287,0.0012848928,0.00046631065,0.00007420195,0.0006868072],"domain_scores_gemma":[0.99805367,0.00023526812,0.0007627474,0.000790398,0.000042709773,0.00011519188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012112132,0.0002572173,0.0008831322,0.00025096862,0.0002859965,0.000014684129,0.00031875,0.00023449372,0.00006992167],"category_scores_gemma":[0.00030418969,0.00023456744,0.00011700071,0.00015862386,0.000086646294,0.000095160416,0.00008132909,0.00016830696,0.00017849822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012510268,0.0031994376,0.6486599,0.0005693977,0.00066847145,0.000027514254,0.012637208,0.00060327386,0.004017594,0.0024913226,0.0004478128,0.3141678],"study_design_scores_gemma":[0.023604726,0.0050737993,0.9670475,0.00025832411,0.000016091566,0.0000021998903,0.0002909446,0.000013133974,0.0021064763,0.00013411474,0.0011740779,0.00027859403],"about_ca_topic_score_codex":0.17275846,"about_ca_topic_score_gemma":0.0052164104,"teacher_disagreement_score":0.31838763,"about_ca_system_score_codex":0.00086833927,"about_ca_system_score_gemma":0.0007199879,"threshold_uncertainty_score":0.95653826},"labels":[],"label_agreement":null},{"id":"W2766032132","doi":"10.1016/j.jaad.2017.10.025","title":"Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Secukinumab; Medicine; Dermatology Life Quality Index; Ustekinumab; Itching; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Quality of life (healthcare); Post-hoc analysis; Internal medicine; Psoriatic arthritis; Disease; Adalimumab","score_opus":0.03770967794458405,"score_gpt":0.34411604359968195,"score_spread":0.30640636565509793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766032132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658364,0.0014850269,0.0000026097493,0.0011196249,0.00033557066,0.0002766198,0.00008809443,0.0000048029706,0.00010398629],"genre_scores_gemma":[0.9997226,0.00015049973,0.000013545328,0.000059704926,0.000023298591,0.0000042978877,0.000003200773,0.000008640101,0.000014194293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945194,0.003767327,0.0011306731,0.00021560701,0.00014854572,0.00021843254],"domain_scores_gemma":[0.9905036,0.0034924394,0.0054094777,0.00046875962,0.000086695756,0.000038991424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007438049,0.00025221638,0.002085273,0.00019024743,0.00025346174,0.000008738009,0.0009936302,0.00018842096,0.0000338811],"category_scores_gemma":[0.0005128804,0.00013638915,0.00057209394,0.00028733243,0.0016981075,0.00008168801,0.00019709159,0.00052936625,0.0000057047223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03855116,0.001041544,0.8936098,0.000033786688,0.042137463,0.000009537695,0.005573851,0.00007543197,0.01160022,0.000245752,0.00050100125,0.0066204537],"study_design_scores_gemma":[0.011813184,0.0037333565,0.9510972,0.000047495916,0.0055173584,0.00006139782,0.0023941037,0.000009504871,0.024998117,0.000057728903,0.00012583031,0.00014473019],"about_ca_topic_score_codex":0.0004861647,"about_ca_topic_score_gemma":0.00003993513,"teacher_disagreement_score":0.05748739,"about_ca_system_score_codex":0.000029333532,"about_ca_system_score_gemma":0.00006662509,"threshold_uncertainty_score":0.6256748},"labels":[],"label_agreement":null},{"id":"W2766123849","doi":"10.1016/j.jval.2017.08.2416","title":"Patient Characteristics and Disease Burden of Psoriasis In Mexico: A Real-World Physician and Patient Survey","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Novartis (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Psoriatic arthritis; Body surface area; Medical prescription; Quality of life (healthcare); Disease burden; Concomitant; Body mass index; Disease; Internal medicine; Dermatology","score_opus":0.03611941783254451,"score_gpt":0.28237981687616465,"score_spread":0.24626039904362013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766123849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963055,0.002025796,6.651807e-7,0.0004051603,0.00037331582,0.00035871894,0.0004241519,0.000008255708,0.0000984346],"genre_scores_gemma":[0.99787605,0.0018127396,0.000031021187,0.000091238515,0.000016421101,0.000025577367,0.00009878733,0.000011556215,0.00003660452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984608,0.0005294547,0.00041908977,0.00027537538,0.000037750873,0.00027750977],"domain_scores_gemma":[0.99899834,0.00019295451,0.00035905832,0.00034759866,0.000028639619,0.00007343274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003319577,0.00015009231,0.00040309588,0.00014371032,0.00015551945,0.000013975531,0.00008599974,0.000069217764,0.0000070534043],"category_scores_gemma":[0.00017696191,0.00013689781,0.00002841832,0.000072988296,0.00012544957,0.000060779614,0.00008825684,0.000100079145,0.000004778416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000494226,0.00024074566,0.85011053,0.00010811676,0.000038761915,0.000014711952,0.0026727912,0.000011048427,0.00024203923,0.0002733979,0.00007475058,0.14571886],"study_design_scores_gemma":[0.0010966683,0.0002482835,0.9972057,0.0002166648,0.000014198646,0.0000010727589,0.00010557692,0.000048227474,0.0002694327,0.00019612628,0.0004826617,0.00011541004],"about_ca_topic_score_codex":0.034340315,"about_ca_topic_score_gemma":0.0016034327,"teacher_disagreement_score":0.14709513,"about_ca_system_score_codex":0.00006302142,"about_ca_system_score_gemma":0.00012829396,"threshold_uncertainty_score":0.9720901},"labels":[],"label_agreement":null},{"id":"W2766193813","doi":"10.1007/s13555-017-0204-3","title":"Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Sex organ; Itching; Psoriasis; Psychosocial; Quality of life (healthcare); Sexual desire; Dermatology; Psychiatry; Human sexuality","score_opus":0.03300738132252601,"score_gpt":0.32895274583850254,"score_spread":0.29594536451597653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766193813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550605,0.0027936941,0.0000014061146,0.00021213939,0.00017483922,0.0003951672,0.00005148353,0.00001522118,0.0008499867],"genre_scores_gemma":[0.9993972,0.00039789538,0.000002811009,0.00002398919,0.0000124528,0.0000528457,0.000012860596,0.000008804172,0.00009113565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987458,0.0006637425,0.00016444486,0.0002172316,0.000025835188,0.0001829227],"domain_scores_gemma":[0.99895114,0.00034999635,0.00020131363,0.00041142467,0.000072799856,0.000013332552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016261211,0.00017635159,0.0003057245,0.000058575853,0.00061310007,0.000016709264,0.00022939063,0.0001275713,0.0001515635],"category_scores_gemma":[0.00006859237,0.00009528576,0.00012880395,0.000028908526,0.0004468089,0.000070991744,0.00003638744,0.00011625582,0.00004663917],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037914703,0.004254484,0.55347717,0.0000046174805,0.006162844,0.000021670121,0.39301887,2.923191e-7,0.0024383941,0.007128059,0.0009301137,0.028772052],"study_design_scores_gemma":[0.0083097145,0.0021778168,0.8966418,0.000009235188,0.00008541334,0.000037707352,0.08396869,6.007928e-7,0.007123488,0.0012523794,0.00018487038,0.00020831304],"about_ca_topic_score_codex":0.00015542172,"about_ca_topic_score_gemma":0.000008944178,"teacher_disagreement_score":0.34316462,"about_ca_system_score_codex":0.000010390456,"about_ca_system_score_gemma":0.000023036617,"threshold_uncertainty_score":0.4715532},"labels":[],"label_agreement":null},{"id":"W2766291043","doi":"10.1111/jdv.14647","title":"Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexus Clinical Research (Canada); SKiN Health; Merck Canada Inc. (Canada); Lynde Centre for Dermatology; Recyc PHP (Canada); Innovation Initiatives Ontario North; Manitoba Beekeepers' Association; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Novo Nordisk; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Novartis; AbbVie; Sanofi; Merck; GlaxoSmithKline; LEO Pharma Research Foundation; Pfizer; Boehringer Ingelheim; Amgen; Eli Lilly and Company; DUSA Pharmaceuticals; Abbott Fund","keywords":"Medicine; Apremilast; Psoriasis; Dermatology; Placebo; Randomized controlled trial; Double blind; Palmoplantar pustulosis; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.0427613775513459,"score_gpt":0.2904193061054218,"score_spread":0.24765792855407592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766291043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846871,0.006793302,0.000073860414,0.0047380724,0.0012310476,0.0017768637,0.00014307551,0.0000070803194,0.0005496367],"genre_scores_gemma":[0.9972647,0.0017549542,0.00010570015,0.00010153766,0.00019328622,0.00005230048,0.00000756068,0.000021127338,0.0004988269],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956093,0.002417351,0.0013209868,0.00028453232,0.00006573132,0.00030210533],"domain_scores_gemma":[0.9943607,0.002791014,0.0022622168,0.00043839053,0.000100932746,0.000046766778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013087858,0.00031263081,0.00180409,0.00014186163,0.0005961137,0.000015801057,0.00092467095,0.00027094278,0.000013548813],"category_scores_gemma":[0.0004090943,0.00015285607,0.000567355,0.000044249497,0.0007069632,0.00007677362,0.0001550575,0.000272586,0.0000097744305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.966385,0.0007698698,0.0124679925,0.000013800925,0.007862327,0.000037365586,0.0035874783,0.00012562507,0.002056638,0.00029784776,0.0011000689,0.005295995],"study_design_scores_gemma":[0.9553325,0.00046594185,0.0154869445,0.00008641171,0.0048758877,0.0013732495,0.0006308872,0.000033133085,0.016211225,0.0006227132,0.0046600993,0.00022100688],"about_ca_topic_score_codex":0.00004930541,"about_ca_topic_score_gemma":0.000029702098,"teacher_disagreement_score":0.014154588,"about_ca_system_score_codex":0.000019247194,"about_ca_system_score_gemma":0.00005617533,"threshold_uncertainty_score":0.6233289},"labels":[],"label_agreement":null},{"id":"W2766482712","doi":"10.1177/1203475417733957","title":"Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices","year":2017,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Queen's University; SKiN Health; University of Manitoba; Probity Medical Research; University of Ottawa","funders":"","keywords":"Medicine; Etanercept; Ustekinumab; Infliximab; Adalimumab; Internal medicine; Survival analysis; Psoriasis; Drug; Retrospective cohort study; Surgery; Dermatology; Pharmacology; Disease; Tumor necrosis factor alpha","score_opus":0.08464347344022534,"score_gpt":0.3219525149018778,"score_spread":0.2373090414616525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766482712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981486,0.015364269,0.000009591541,0.0019064903,0.00081516366,0.00009316686,0.000020638088,0.0000037669095,0.0003008926],"genre_scores_gemma":[0.9908522,0.00868616,0.0000533879,0.000103432896,0.00011014064,0.0000031133904,0.0000119277665,0.0000064923283,0.00017318648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987934,0.00038235527,0.00051529583,0.000080057274,0.00004085539,0.00018799838],"domain_scores_gemma":[0.99465257,0.0033025928,0.0016496894,0.00022491992,0.00014609144,0.000024143916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017308777,0.00012687058,0.00068579696,0.0002085908,0.00032926083,0.000008490381,0.00019560741,0.00016167936,0.00007965073],"category_scores_gemma":[0.0023393598,0.00007952357,0.00015763092,0.000037065493,0.00025093282,0.00011935757,0.00002779372,0.00023883491,0.0000011111124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004834998,0.00096490927,0.8411844,0.00027356256,0.0016962973,0.00035270074,0.009523244,6.7441493e-7,0.05451765,0.0002549743,0.007180538,0.07921607],"study_design_scores_gemma":[0.021702515,0.011257109,0.67406446,0.0032264295,0.0029547357,0.017350433,0.06276491,0.000008967984,0.022727532,0.0053013163,0.17751673,0.001124866],"about_ca_topic_score_codex":0.00023663761,"about_ca_topic_score_gemma":0.00023794518,"teacher_disagreement_score":0.1703362,"about_ca_system_score_codex":0.00001388943,"about_ca_system_score_gemma":0.00007079378,"threshold_uncertainty_score":0.32428768},"labels":[],"label_agreement":null},{"id":"W2766539369","doi":"10.1016/j.jval.2017.08.2989","title":"Assessing the Economic and Humanistic Burden of Psoriatic Arthritis in Brazil","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Novartis (Canada)","funders":"","keywords":"Medicine; Presenteeism; Psoriatic arthritis; Internal medicine; Psoriasis; Absenteeism; Anxiety; Depression (economics); Arthritis; Physical therapy; Dermatology; Psychiatry","score_opus":0.04398812082373241,"score_gpt":0.323395261109215,"score_spread":0.27940714028548264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766539369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761624,0.010227891,0.0000032512148,0.0010755624,0.00050892466,0.00018613711,0.000013364519,0.00000612649,0.00036251455],"genre_scores_gemma":[0.99834335,0.0014199195,0.000050988125,0.000032572672,0.000039678183,0.0000122725105,0.0000074085447,0.0000067052456,0.000087089415],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99903184,0.00027780968,0.000316655,0.00015817305,0.0000131107145,0.00020239648],"domain_scores_gemma":[0.99922895,0.00023569915,0.0002322648,0.00028603282,0.0000054461198,0.000011627794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063894887,0.00008324913,0.00025872883,0.00006661319,0.00026533828,0.00003275446,0.00015093408,0.00007755636,0.000038181854],"category_scores_gemma":[0.00007479013,0.00006633341,0.00002449344,0.000018360248,0.0001358207,0.00009352989,0.000044537992,0.000101254635,0.00002727666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014214721,0.00020593853,0.2407963,0.00040063082,0.00019501286,0.000045843462,0.010965984,0.0012732132,0.0037355593,0.019525928,0.0005205969,0.7221928],"study_design_scores_gemma":[0.0046368926,0.00025732114,0.98448503,0.0006644181,0.000025084899,0.00005993894,0.0008327819,0.00053332985,0.0009572595,0.004911664,0.0024316218,0.00020465955],"about_ca_topic_score_codex":0.015643382,"about_ca_topic_score_gemma":0.0010549907,"teacher_disagreement_score":0.7436887,"about_ca_system_score_codex":0.00008929532,"about_ca_system_score_gemma":0.00016853059,"threshold_uncertainty_score":0.99091154},"labels":[],"label_agreement":null},{"id":"W2766794970","doi":"10.1371/journal.pone.0186823","title":"IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation","year":2017,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"RAR-related orphan receptor gamma; Biology; Immune system; Retinoic acid; Receptor; Immunology; Signal transduction; Orphan receptor; Cancer research; Transcription factor; Cell biology; Cell culture; FOXP3; Gene","score_opus":0.04984994947178485,"score_gpt":0.24575892626018125,"score_spread":0.19590897678839642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766794970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952907,0.0006592031,0.000052090098,0.002652587,0.000060320333,0.00052283204,0.0006444687,0.00003249303,0.00008529507],"genre_scores_gemma":[0.9954831,0.00034070614,0.00011900342,0.0001352076,0.000022202692,0.00019325735,0.0007635909,0.00001649534,0.0029264411],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922806,0.000050358794,0.00020884526,0.0002838178,0.000027284657,0.00020161548],"domain_scores_gemma":[0.9993123,0.00009738351,0.00019499863,0.00031027474,0.00006618338,0.000018879224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118731805,0.00014018682,0.00022423064,0.00008113853,0.0005145037,0.000039162867,0.00009068995,0.00021037187,0.00003601564],"category_scores_gemma":[0.000049797938,0.00014114389,0.000073929295,0.000044768054,0.00006951024,0.0001662337,0.000036893995,0.000091392,0.000046575213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001699749,0.0005904673,0.012878472,0.00002619548,0.0003460393,6.8868644e-8,0.00055267557,2.7749945e-7,0.97961205,0.000012120391,0.004071584,0.0017400526],"study_design_scores_gemma":[0.0019224866,0.0001498308,0.028419573,0.00008124708,0.00022491018,7.5431115e-7,0.0000407271,0.000013177215,0.9673377,0.00004171105,0.0016209722,0.00014688392],"about_ca_topic_score_codex":0.00020926095,"about_ca_topic_score_gemma":0.000014816052,"teacher_disagreement_score":0.015541101,"about_ca_system_score_codex":0.0000652859,"about_ca_system_score_gemma":0.000016629929,"threshold_uncertainty_score":0.575568},"labels":[],"label_agreement":null},{"id":"W2767057806","doi":"10.1016/j.jval.2017.08.2675","title":"Treatment Patterns and Impact of Not Achieving Skin Clearance for Psoriasis Patients In Latin America","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Eli Lilly (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Quality of life (healthcare); Incidence (geometry); Systemic therapy; Groin; Surgery; Internal medicine","score_opus":0.04440911577702839,"score_gpt":0.3167958107092912,"score_spread":0.2723866949322628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767057806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99815524,0.0005221065,0.000013076404,0.00017370342,0.00021778671,0.0005690889,0.00031281007,0.000007587704,0.000028576089],"genre_scores_gemma":[0.9982947,0.0012767824,0.00020156443,0.000022558825,0.000018794599,0.00005957828,0.00005837024,0.000012801395,0.0000548553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988753,0.0001943243,0.00034343218,0.00024612027,0.000022995426,0.00031779738],"domain_scores_gemma":[0.9991545,0.00019652535,0.00031571125,0.00028901533,0.000018257557,0.00002596194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016587287,0.00015195033,0.0004149815,0.00011365849,0.0001555753,0.000009397294,0.00011093496,0.00009705466,0.000012981295],"category_scores_gemma":[0.00007972378,0.00012162299,0.00009268464,0.00004240835,0.000055538225,0.00006374074,0.000029477387,0.00005987956,0.0000057422426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048320263,0.0002887974,0.7799602,0.000050039616,0.00005565522,0.0000010592877,0.0010932055,0.00006286458,0.0001877364,0.000019111718,0.000010498627,0.2177876],"study_design_scores_gemma":[0.0046691867,0.0015111743,0.99240047,0.000118397715,0.000013614629,0.0000012717923,0.000049935665,0.0000698299,0.0008853733,0.000020982112,0.00016816604,0.000091591544],"about_ca_topic_score_codex":0.042940486,"about_ca_topic_score_gemma":0.00072479603,"teacher_disagreement_score":0.21769601,"about_ca_system_score_codex":0.00018826732,"about_ca_system_score_gemma":0.00008042797,"threshold_uncertainty_score":0.96343267},"labels":[],"label_agreement":null},{"id":"W2767077552","doi":"10.1016/j.vhri.2021.05.004","title":"Burden of Disease for Psoriasis in Argentina, Brazil, Colombia, and Mexico","year":2021,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Eli Lilly (Canada)","funders":"Janssen Biotech; Eli Lilly and Company","keywords":"Psoriasis; Disease; Medicine; Geography; Burden of disease; Environmental health; Dermatology; Internal medicine","score_opus":0.04482200382928385,"score_gpt":0.3275858572152577,"score_spread":0.2827638533859738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767077552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9034941,0.086275615,0.000009150419,0.009305197,0.00036151707,0.00039856276,0.00010636662,0.000014173312,0.000035280253],"genre_scores_gemma":[0.988453,0.007997435,0.00065982394,0.0003872163,0.000073046474,0.0001257746,0.00030712216,0.000017223336,0.001979393],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860215,0.00031883267,0.00041123206,0.00031578052,0.00004324627,0.0003087786],"domain_scores_gemma":[0.9992254,0.0003679038,0.00012514809,0.00017053429,0.000060737933,0.000050272596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034167548,0.00013147498,0.000387507,0.00013980144,0.00007083552,0.000005291027,0.00008098789,0.00012302052,0.000058887174],"category_scores_gemma":[0.00013271443,0.00013249181,0.00007550964,0.00018868703,0.00009374537,0.000048245027,0.000037400685,0.000076464974,0.000011050351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009482409,0.0043364945,0.6564259,0.0047316607,0.0010856657,0.00024976785,0.019611822,0.001023344,0.025274212,0.09831857,0.039632473,0.1398277],"study_design_scores_gemma":[0.014296952,0.0009868332,0.46950862,0.0014043755,0.00015146355,0.00005115196,0.0024649624,0.00021865469,0.020542938,0.019541742,0.47012746,0.0007048534],"about_ca_topic_score_codex":0.0020248326,"about_ca_topic_score_gemma":0.0002597082,"teacher_disagreement_score":0.43049496,"about_ca_system_score_codex":0.00005252766,"about_ca_system_score_gemma":0.00024401826,"threshold_uncertainty_score":0.54028594},"labels":[],"label_agreement":null},{"id":"W2767151183","doi":"10.3899/jrheum.161238","title":"CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Dose-ranging study; Rheumatoid arthritis; Placebo; Methotrexate; Internal medicine; Clinical endpoint; Adverse effect; Rheumatology; Pharmacokinetics; Gastroenterology; Randomized controlled trial; Phases of clinical research; Surgery; Clinical trial; Pathology; Double blind","score_opus":0.011774498923605927,"score_gpt":0.2799073730707837,"score_spread":0.2681328741471778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767151183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953358,0.0011519658,0.00044351543,0.0006073214,0.00034940202,0.002005148,0.000021910453,0.000022994645,0.0000619504],"genre_scores_gemma":[0.99906576,0.00027940294,0.00022178754,0.00004033763,0.0000068396457,0.00008274933,0.00001578348,0.000042989723,0.000244364],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99370235,0.003824898,0.0012868823,0.00034430018,0.0001779061,0.0006636586],"domain_scores_gemma":[0.995684,0.0013991662,0.0018234587,0.0007258885,0.00028131343,0.000086116735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053420947,0.0004960259,0.0024774158,0.00064752344,0.0011282065,0.00007205098,0.00092698535,0.00019236126,0.000116339026],"category_scores_gemma":[0.0006398347,0.00027381149,0.00025149435,0.00016538898,0.0005411869,0.0002906177,0.00020139769,0.00054257276,0.000030733536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8633521,0.0019217718,0.116621464,0.000007060134,0.0025896966,0.00018517586,0.006210335,0.000047968744,0.0024602143,0.00004321288,0.00013043606,0.0064305593],"study_design_scores_gemma":[0.93373996,0.011808685,0.048414804,0.0006510794,0.0004785599,0.002384487,0.001181141,0.000013346123,0.0006646042,0.00007004128,0.00016821474,0.00042504896],"about_ca_topic_score_codex":0.00065709697,"about_ca_topic_score_gemma":0.0010566292,"teacher_disagreement_score":0.07038788,"about_ca_system_score_codex":0.00008074401,"about_ca_system_score_gemma":0.00019174026,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W2767153714","doi":"10.1016/j.jval.2017.08.2677","title":"Characteristics of Psoriasis Patients In Latin America","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Demographics; Psoriasis; Scalp; Groin; Dermatology; Surgery; Pediatrics; Demography","score_opus":0.036731974026227215,"score_gpt":0.27956688195942864,"score_spread":0.24283490793320142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767153714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979076,0.00036364625,0.0000033172819,0.00021749084,0.00078105426,0.00021259357,0.00010553387,0.000009306799,0.00039950313],"genre_scores_gemma":[0.9986857,0.000797349,0.00015974077,0.000058531317,0.00001970863,0.000014708453,0.00008654061,0.000009092288,0.00016861132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988572,0.00023760866,0.00042720968,0.00017882942,0.000028527887,0.00027064965],"domain_scores_gemma":[0.99908453,0.00010455304,0.00040669265,0.0003606088,0.000024813753,0.000018799903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002353648,0.000105694024,0.00035670836,0.00012163589,0.00011098268,0.000005758539,0.00019200749,0.00010934657,0.000059322432],"category_scores_gemma":[0.00019456356,0.0000985004,0.00004160551,0.000067422734,0.000081275866,0.00004889174,0.000048140588,0.00010918654,0.00007672032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010937138,0.0003059038,0.87609345,0.00004707953,0.000018145804,0.0000029812643,0.0006911778,0.000005086401,0.00019426583,0.00013820722,0.00009715785,0.12229716],"study_design_scores_gemma":[0.0016661361,0.00020365928,0.9952383,0.000100899415,0.0000061955448,6.01167e-7,0.00003092094,0.000011611866,0.00059375906,0.000076888435,0.0019936312,0.00007736627],"about_ca_topic_score_codex":0.009145459,"about_ca_topic_score_gemma":0.00012844068,"teacher_disagreement_score":0.1222198,"about_ca_system_score_codex":0.00007054749,"about_ca_system_score_gemma":0.00008592111,"threshold_uncertainty_score":0.99745274},"labels":[],"label_agreement":null},{"id":"W2767569616","doi":"10.1016/b978-0-12-810545-0.00005-x","title":"In vitro models of psoriasis","year":2017,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Psoriasis; Pathological; Medicine; Multidisciplinary approach; Pathology; Dermatology; Immunology; Political science","score_opus":0.025804275877213585,"score_gpt":0.2439414398863512,"score_spread":0.2181371640091376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767569616","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006326741,0.009210472,0.0000011655828,0.00002841679,0.0013432093,0.00041762734,0.00029681998,0.000028612405,0.988041],"genre_scores_gemma":[0.022877457,0.00052095763,0.00008818896,0.000051983643,0.00010991768,0.00004598598,0.00015280019,0.00006602854,0.9760867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985444,0.000059565882,0.00053005764,0.0004686518,0.00005973356,0.00033760964],"domain_scores_gemma":[0.9983973,0.00008381937,0.00049233314,0.00093096244,0.00006872514,0.000026884449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020710098,0.00046241275,0.0009986022,0.00027453358,0.00010946763,0.000010478993,0.00047546256,0.0009471578,0.00045714146],"category_scores_gemma":[0.000013247833,0.00042097105,0.00038935346,0.000005178164,0.00025927337,0.00006793677,0.00013765527,0.00035518917,0.00047455204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030646235,0.000029409777,0.0000032894754,0.00005302078,0.0005366974,0.00004165033,0.00028568783,5.3659136e-7,0.0087531,0.0038918508,0.00018790606,0.9859104],"study_design_scores_gemma":[0.0020684043,0.00009332601,0.000021406484,0.00033277454,0.0004985919,0.00003337243,0.0000070341066,8.3406064e-7,0.03972249,0.031049365,0.9256438,0.00052858575],"about_ca_topic_score_codex":0.000007307654,"about_ca_topic_score_gemma":0.00004032794,"teacher_disagreement_score":0.9853818,"about_ca_system_score_codex":0.000063805885,"about_ca_system_score_gemma":0.00012119894,"threshold_uncertainty_score":0.9998242},"labels":[],"label_agreement":null},{"id":"W2767583491","doi":"10.1155/2017/7215072","title":"Contribution of<i>In Vivo</i>and Organotypic 3D Models to Understanding the Role of Macrophages and Neutrophils in the Pathogenesis of Psoriasis","year":2017,"lang":"en","type":"review","venue":"Mediators of Inflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Psoriasis; Immune system; Innate immune system; Pathogenesis; Immunology; Crosstalk; Biology; Inflammation; In vivo; Cell type; Cell biology; Cell","score_opus":0.035531659244266094,"score_gpt":0.2703157277612562,"score_spread":0.23478406851699007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767583491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24236678,0.75638276,0.000052336763,0.000028117875,0.00013641705,0.00082261954,0.00017282815,0.0000032261325,0.000034882618],"genre_scores_gemma":[0.4795594,0.52030927,0.000014870978,0.0000011502793,0.000018898507,0.00004503841,0.000039894214,0.000008421904,0.0000030304732],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823445,0.0005310887,0.00080504856,0.00019113555,0.00007881975,0.00015944865],"domain_scores_gemma":[0.99795014,0.0006272553,0.0010001506,0.0003410406,0.000069276175,0.000012134185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008976593,0.0002210961,0.001087348,0.0003191378,0.00006738978,0.0000066117673,0.0002548257,0.00033044492,0.000007928007],"category_scores_gemma":[0.00018637892,0.00013397585,0.00012670076,0.00020997926,0.00018640737,0.00008677381,0.00006493802,0.00010711496,9.828416e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031931506,0.00012651955,0.0039183097,0.004187784,0.0006512387,0.0000040928267,0.00790128,0.000050831633,0.035264228,0.008865744,0.000007906615,0.93870276],"study_design_scores_gemma":[0.033894878,0.0042724092,0.07486885,0.07021624,0.030172797,0.00029044005,0.02070316,0.00024318547,0.6175644,0.05432432,0.08812066,0.005328664],"about_ca_topic_score_codex":0.0000906265,"about_ca_topic_score_gemma":0.00011112544,"teacher_disagreement_score":0.9333741,"about_ca_system_score_codex":0.000051895015,"about_ca_system_score_gemma":0.00008222986,"threshold_uncertainty_score":0.5463376},"labels":[],"label_agreement":null},{"id":"W2767585845","doi":"10.1016/j.jid.2017.06.031","title":"Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis”","year":2017,"lang":"en","type":"review","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"British Association of Dermatologists; Eli Lilly and Company","keywords":"Psoriasis; Medicine; Meta-analysis; Systematic review; Context (archaeology); Tolerability; Ixekizumab; Adverse effect; MEDLINE; Intensive care medicine; Internal medicine; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.4355963637501712,"score_gpt":0.43796394857987603,"score_spread":0.0023675848297048385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767585845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002390271,0.9943632,0.0000639497,0.0012572819,0.00029429077,0.0036559466,0.0003054526,0.00000651975,0.000029465125],"genre_scores_gemma":[0.00013327802,0.99689007,0.00082078413,0.0007588905,0.000024178902,0.0010558271,0.00025905154,0.000022916034,0.000035028308],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9888733,0.007988912,0.002368255,0.00034988762,0.00013079228,0.00028882513],"domain_scores_gemma":[0.9868964,0.0030956848,0.0082523385,0.00056384725,0.001136732,0.00005497916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004186074,0.00058835355,0.011784687,0.0005411536,0.00026492774,0.000018074374,0.0005089512,0.0005278407,0.00007646428],"category_scores_gemma":[0.0018917215,0.00032882305,0.00344958,0.00033604846,0.00060894736,0.00009106579,0.000049942842,0.0003586387,0.000015303049],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008666595,0.00027765907,0.000003764288,0.16011363,0.8178922,0.000009794114,0.00021134973,0.000014228894,0.000008554271,0.010460402,0.004840064,0.0060816784],"study_design_scores_gemma":[0.0010969178,0.00072377064,0.000006510053,0.025799,0.9032426,0.00036520453,0.000043854307,0.000001935177,0.00011099577,0.0016236211,0.06670566,0.00027995324],"about_ca_topic_score_codex":0.000004432414,"about_ca_topic_score_gemma":0.000008197022,"teacher_disagreement_score":0.13431463,"about_ca_system_score_codex":0.000082746126,"about_ca_system_score_gemma":0.00045566118,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W2768998510","doi":"10.1111/bjd.16140","title":"Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab","year":2017,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"U.S. Food and Drug Administration; Gemeinsame Bundesausschuss; Eli Lilly and Company","keywords":"Secukinumab; Ixekizumab; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.03443892017663107,"score_gpt":0.28688891720687554,"score_spread":0.25244999703024446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768998510","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3260085,0.67218846,0.000015199481,0.000018885934,0.00038640827,0.0009032985,0.00031219982,0.000023941273,0.00014314291],"genre_scores_gemma":[0.50196004,0.4968478,0.00019446384,0.000015035077,0.000038320355,0.00004765644,0.0006721281,0.00011177863,0.00011274605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99561244,0.0011522372,0.0018855265,0.0005245262,0.00016650138,0.0006587455],"domain_scores_gemma":[0.9955799,0.0003754673,0.0030514828,0.0004910263,0.00039669892,0.00010541085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017967043,0.0007321567,0.005914996,0.00086647115,0.00024997664,0.000065191656,0.0008462503,0.0010887499,0.00008334508],"category_scores_gemma":[0.00007578982,0.0005922511,0.00044747264,0.0003675177,0.00023251602,0.00020466605,0.00010456635,0.0010643128,0.000048616228],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006324379,0.0020290283,0.012555836,0.0016802393,0.0043413253,0.002420313,0.0005063901,0.000024446808,9.0737836e-7,0.000008438236,0.0008834346,0.9692253],"study_design_scores_gemma":[0.1258456,0.00886936,0.12914951,0.13480115,0.0202503,0.19759592,0.00043834516,0.0000017578035,0.0009148633,0.000037668116,0.37729272,0.004802793],"about_ca_topic_score_codex":0.0002800252,"about_ca_topic_score_gemma":0.00066231133,"teacher_disagreement_score":0.96442246,"about_ca_system_score_codex":0.00018465014,"about_ca_system_score_gemma":0.0006758371,"threshold_uncertainty_score":0.99965286},"labels":[],"label_agreement":null},{"id":"W2769504915","doi":"10.1016/j.jaad.2017.11.036","title":"Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Probity Medical Research; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Dosing; Clinical endpoint; Retrospective cohort study; Clinical trial; Randomized controlled trial; Dermatology; Discontinuation; Plaque psoriasis; Internal medicine; Surgery; Psoriatic arthritis","score_opus":0.02078974280137467,"score_gpt":0.299219751322203,"score_spread":0.27843000852082833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769504915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636686,0.0002353215,0.0000018283303,0.001709453,0.00092251156,0.00033419608,0.00005549836,0.0000063305642,0.00036801785],"genre_scores_gemma":[0.9993074,0.0003479604,0.00006172757,0.00006784902,0.000041816522,0.0000075553703,0.0000021672797,0.000018973453,0.00014456605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703723,0.0011161435,0.0011217362,0.0002337478,0.00014338414,0.00034777357],"domain_scores_gemma":[0.99480575,0.00029637924,0.004325038,0.00038924156,0.0001477099,0.00003589614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039798414,0.00025052784,0.0013849367,0.00037704688,0.00018269516,0.0000084160665,0.0012011152,0.00012989357,0.000031152606],"category_scores_gemma":[0.00029920472,0.00017505528,0.0003307273,0.00024151076,0.0008802249,0.0001770619,0.0002738621,0.0006242494,0.00000847943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020130079,0.0017221151,0.9876354,0.000015483143,0.00094087987,0.000021036209,0.0015650835,0.0000028604672,0.0030593483,0.0001307617,0.0007190634,0.0021749698],"study_design_scores_gemma":[0.007671228,0.0004008358,0.9736898,0.00007892176,0.00032037104,0.00008708442,0.0012334823,0.0000012255177,0.015746692,0.00014527266,0.00048526315,0.00013982055],"about_ca_topic_score_codex":0.00090319756,"about_ca_topic_score_gemma":0.0005545273,"teacher_disagreement_score":0.013945587,"about_ca_system_score_codex":0.00012423795,"about_ca_system_score_gemma":0.000088886765,"threshold_uncertainty_score":0.71385473},"labels":[],"label_agreement":null},{"id":"W2770411652","doi":"10.1038/s41598-017-16707-5","title":"The Systemic Response to Topical Aldara Treatment is Mediated Through Direct TLR7 Stimulation as Imiquimod Enters the Circulation","year":2017,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Sackler Trust; Wellcome Trust","keywords":"Imiquimod; Psoriasis; TLR7; Medicine; Immune system; Inflammation; Immunology; Stimulation; Toll-like receptor; Endocrinology; Innate immune system","score_opus":0.028991902998798967,"score_gpt":0.28814475610829593,"score_spread":0.259152853109497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770411652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540914,0.00081577577,0.00003569805,0.0026161678,0.009206805,0.00080203125,0.00001397842,0.000058537655,0.0010418519],"genre_scores_gemma":[0.9890002,0.00002599152,0.000012017632,0.0000614873,0.00005254441,0.00011358989,0.000090841655,0.000011203549,0.010632118],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981376,0.00041491265,0.0004057293,0.0005866954,0.00013001767,0.00032507046],"domain_scores_gemma":[0.997481,0.000368535,0.00037264044,0.0016455614,0.000098200115,0.000034054334],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0013321823,0.0001870825,0.00020785184,0.00005309873,0.0031523248,0.00034987155,0.00027325522,0.0001373127,0.00011234694],"category_scores_gemma":[0.00048855133,0.00009945118,0.00015883932,0.00009949317,0.00031017172,0.00014920252,0.00007910621,0.00006136774,0.0004512983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032808,0.00039393143,0.083677135,0.000016172182,0.0012628648,0.00042340145,0.017509604,0.00026536782,0.8179972,0.00026003737,0.021417996,0.053495467],"study_design_scores_gemma":[0.0024818394,0.0006104762,0.32895237,0.00014645512,0.0005664874,0.0011062485,0.00089673884,0.00009246965,0.22026998,0.0019895262,0.44228873,0.00059868075],"about_ca_topic_score_codex":0.0002376326,"about_ca_topic_score_gemma":0.000071030794,"teacher_disagreement_score":0.59772724,"about_ca_system_score_codex":0.00017951928,"about_ca_system_score_gemma":0.00014296202,"threshold_uncertainty_score":0.99814546},"labels":[],"label_agreement":null},{"id":"W2770983814","doi":"10.1007/s00296-017-3895-y","title":"Addressing comorbidities in psoriatic disease","year":2017,"lang":"en","type":"article","venue":"Rheumatology International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Krembil Foundation; Pfizer; AbbVie Canada; Amgen","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Comorbidity; Internal medicine; Depression (economics); Diabetes mellitus; Cohort; Obesity; Blood pressure; Medical record; Metabolic syndrome; Disease; Physical therapy; Dermatology","score_opus":0.054693051917022416,"score_gpt":0.31291720105873594,"score_spread":0.25822414914171354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770983814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702884,0.0012052476,0.000033743905,0.0017302898,0.004695461,0.00008833224,0.00006975095,0.0000413241,0.0051069926],"genre_scores_gemma":[0.9974724,0.00021823467,0.000049828057,0.0000500866,0.000023333789,0.000041661373,0.00018089614,0.000009124414,0.0019544393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992399,0.000081546896,0.00022309832,0.00021106537,0.000035090714,0.00020928205],"domain_scores_gemma":[0.9993486,0.00011639062,0.00017195368,0.0003084435,0.000033595465,0.000021016709],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000111529764,0.00012332345,0.00020519746,0.00012570832,0.00027982166,0.00004532938,0.00046112877,0.000119656936,0.001097077],"category_scores_gemma":[0.0002627278,0.000115501025,0.00006655242,0.000013673162,0.00022085223,0.00017423181,0.00010643759,0.00011355508,0.00063188525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030486874,0.00020505769,0.95256454,0.000017342118,0.0003258612,0.000095267686,0.00031194175,0.0000059436597,0.0006328557,0.020945646,0.003509343,0.021081341],"study_design_scores_gemma":[0.003471216,0.00002167118,0.9798262,0.0001645962,0.000042401018,0.00012589814,0.00010387566,0.00007099904,0.0013466112,0.003579957,0.011025936,0.00022060882],"about_ca_topic_score_codex":0.00021119002,"about_ca_topic_score_gemma":0.00013106741,"teacher_disagreement_score":0.027261699,"about_ca_system_score_codex":0.000044207827,"about_ca_system_score_gemma":0.00005473113,"threshold_uncertainty_score":0.99981606},"labels":[],"label_agreement":null},{"id":"W2772776690","doi":"10.1111/jdv.14738","title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Probity Medical Research; Queen's University","funders":"Galderma; Dermira; Celgene; GlaxoSmithKline; Biogen; Kyowa Hakko Kirin; Eli Lilly and Company; Astellas Pharma; Astellas Pharma US; Amgen","keywords":"Apremilast; Medicine; Psoriasis; Etanercept; Dermatology Life Quality Index; Placebo; Dermatology; Internal medicine; Visual analogue scale; Psoriasis Area and Severity Index; Adverse effect; Psoriatic arthritis; Surgery; Tumor necrosis factor alpha; Pathology","score_opus":0.02100902211503499,"score_gpt":0.25064626129932743,"score_spread":0.22963723918429244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772776690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963237,0.00056208525,0.000007167435,0.0019629903,0.00026984198,0.00042467332,0.00012970995,0.0000055938576,0.0003142063],"genre_scores_gemma":[0.99903333,0.00034093772,0.00006353817,0.00026673585,0.000051435214,0.00000308762,0.000009853146,0.000024504605,0.00020658274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691075,0.001658692,0.00075025397,0.00032912218,0.00007163793,0.0002795231],"domain_scores_gemma":[0.9977096,0.0008589641,0.0009837805,0.00035019798,0.000055893506,0.00004156795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002814658,0.00032094112,0.0010128595,0.00008396696,0.0003707372,0.000016788359,0.0006335266,0.0002560395,0.000033036922],"category_scores_gemma":[0.00017154879,0.00016054428,0.00010743681,0.00007562659,0.00049199647,0.00012750596,0.00024192069,0.00044364206,0.000007987649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023854474,0.00067772495,0.95797133,0.0000070385754,0.0016725952,0.000047456986,0.0066874893,0.000047594447,0.0016764939,0.00005308219,0.00026103228,0.007043705],"study_design_scores_gemma":[0.020275047,0.00061612844,0.970497,0.000184017,0.00058552076,0.00013043763,0.00029832067,0.0000019867177,0.006443404,0.00010306544,0.00070389576,0.0001611698],"about_ca_topic_score_codex":0.00008102557,"about_ca_topic_score_gemma":0.0000893679,"teacher_disagreement_score":0.0125256935,"about_ca_system_score_codex":0.000027686148,"about_ca_system_score_gemma":0.000037508813,"threshold_uncertainty_score":0.6546806},"labels":[],"label_agreement":null},{"id":"W2773144918","doi":"10.1007/s13555-017-0211-4","title":"Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies","year":2017,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Centre de Recherche Dermatologique du Québec Métropolitain; Dalhousie University; Dermatrials Research; Université Laval","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Psoriatic arthritis","score_opus":0.03147621493430002,"score_gpt":0.30312334748383063,"score_spread":0.2716471325495306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773144918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963143,0.0027299502,0.00000482315,0.00027459057,0.000057415178,0.00042318838,0.00016901239,0.0000025211766,0.00002418317],"genre_scores_gemma":[0.9951921,0.004583311,0.000015220973,0.000065469794,0.0000036001015,0.00005905328,0.000071675,0.0000049570617,0.00000462236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985967,0.00055992475,0.00044495804,0.00018572184,0.00004270955,0.00016994958],"domain_scores_gemma":[0.9984313,0.0005482562,0.00046981857,0.0004672149,0.00007491052,0.000008458319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014068167,0.00017291313,0.0009102524,0.00026214623,0.0001049225,0.0000032663056,0.00027913143,0.00007895305,0.0000075965904],"category_scores_gemma":[0.00003100777,0.00009462034,0.0001566824,0.00033036174,0.0004126567,0.000038596136,0.000018796889,0.00005292045,6.5827874e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006526818,0.00349195,0.8910244,0.000019180863,0.00711249,0.000015880722,0.034198612,0.000045921763,0.0007501528,0.00018492609,0.000020055084,0.0566096],"study_design_scores_gemma":[0.01285033,0.0012772909,0.97013694,0.000012297526,0.0008893723,0.000008526712,0.0017199081,0.000010319873,0.012774337,0.000056232082,0.00016546673,0.00009899614],"about_ca_topic_score_codex":0.0005092968,"about_ca_topic_score_gemma":0.002653212,"teacher_disagreement_score":0.07911251,"about_ca_system_score_codex":0.00001112779,"about_ca_system_score_gemma":0.00001952394,"threshold_uncertainty_score":0.38585055},"labels":[],"label_agreement":null},{"id":"W2780430788","doi":"","title":"Update richtlijn psoriasis 2017","year":2017,"lang":"nl","type":"article","venue":"EUR Research Repository (Erasmus University Rotterdam)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.05692717904708562,"score_gpt":0.30276376377877035,"score_spread":0.24583658473168474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2780430788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82932717,0.0041597327,0.000029853016,0.0030510852,0.0071331942,0.0012009444,0.00036570776,0.00019453751,0.15453778],"genre_scores_gemma":[0.7342527,0.0026885692,0.00007311134,0.00005550704,0.00077734055,0.0000076387505,0.000106139494,0.00006174565,0.2619773],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99145967,0.0036446962,0.0005462013,0.0017133584,0.00053659244,0.0020994798],"domain_scores_gemma":[0.99382114,0.0005154414,0.00065292616,0.0038308722,0.00075935095,0.00042024895],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018022602,0.0007582769,0.0009436187,0.0009019228,0.013115683,0.00077976414,0.0038364055,0.0011287306,0.001107632],"category_scores_gemma":[0.00029383693,0.00082105055,0.00063292845,0.00035005398,0.0023168696,0.0011235792,0.0021793498,0.0018453292,0.012365291],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0138642015,0.0032261086,0.08243831,0.00047164073,0.008667204,0.038941544,0.0035977156,0.000011381984,0.16478528,0.005093714,0.6424722,0.03643069],"study_design_scores_gemma":[0.012640726,0.0009987217,0.11495935,0.00036016127,0.00083743886,0.0006558483,0.0014050943,0.000020532932,0.04362967,0.00014137161,0.82308763,0.0012634604],"about_ca_topic_score_codex":0.0030276862,"about_ca_topic_score_gemma":0.00030364172,"teacher_disagreement_score":0.18061543,"about_ca_system_score_codex":0.00077066483,"about_ca_system_score_gemma":0.00074957235,"threshold_uncertainty_score":0.9998055},"labels":[],"label_agreement":null},{"id":"W2781701639","doi":"10.1177/1203475417748886","title":"Management of Common Side Effects of Apremilast","year":2017,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Apremilast; Discontinuation; Nausea; Side effect (computer science); Psoriasis; Intensive care medicine; Diarrhea; Thalidomide; Dermatology; Psychological intervention; Surgery; Internal medicine; Psoriatic arthritis; Psychiatry","score_opus":0.053725406577085945,"score_gpt":0.3159148782274614,"score_spread":0.2621894716503754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781701639","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023923446,0.9943393,0.0000029387688,0.000030587904,0.0017360935,0.00020627637,0.00001258032,0.0000039459055,0.0012759352],"genre_scores_gemma":[0.0043403166,0.9945559,0.00001634001,0.000011780533,0.000140566,0.0000035354053,0.000029572439,0.000021062517,0.0008809275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978988,0.00031047643,0.0013413284,0.00014729273,0.00010150836,0.00020057557],"domain_scores_gemma":[0.99439406,0.0024338488,0.002700464,0.00033147415,0.000095520474,0.00004461353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005886326,0.00031453994,0.0038199075,0.0004184234,0.00006582903,0.0000032873525,0.00023428019,0.00032113117,0.00003824945],"category_scores_gemma":[0.00014954369,0.00019208352,0.0006462216,0.000079116166,0.00028208958,0.00003342508,0.00005435967,0.00026416584,0.000005474252],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107091466,0.0001182796,0.00007211693,0.021238199,0.0030911318,0.0026516533,0.00007063834,4.9961894e-8,0.000056630874,0.000015303454,0.003019507,0.9695594],"study_design_scores_gemma":[0.00065367273,0.0005052899,0.00007365866,0.073880814,0.00804573,0.009541776,0.000052622712,2.3316716e-8,0.00018251594,0.0000383298,0.9068535,0.00017204472],"about_ca_topic_score_codex":0.000014104172,"about_ca_topic_score_gemma":0.0000015680192,"teacher_disagreement_score":0.96938735,"about_ca_system_score_codex":0.000024040577,"about_ca_system_score_gemma":0.00010601582,"threshold_uncertainty_score":0.7832939},"labels":[],"label_agreement":null},{"id":"W2781921947","doi":"10.1016/j.jaad.2018.01.003","title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Secukinumab; Ixekizumab; Medicine; Interleukin 17; Psoriasis; Discontinuation; Psoriasis Area and Severity Index; Dermatology; Internal medicine; Dermatology Life Quality Index; Ustekinumab; Plaque psoriasis; Anakinra; Placebo; Adalimumab; Psoriatic arthritis; Alternative medicine; Cytokine; Pathology; Disease","score_opus":0.011777689674929618,"score_gpt":0.2791067948025814,"score_spread":0.2673291051276518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781921947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974025,0.00042739374,0.000048808608,0.0015358863,0.00015438991,0.00037783894,0.000015832802,0.000004443422,0.000032887558],"genre_scores_gemma":[0.99943954,0.000111254725,0.00024989425,0.00014312373,0.000023279596,0.0000047595677,4.9046724e-7,0.000015921247,0.000011734408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977756,0.0008053997,0.00086715433,0.00020493241,0.00009720405,0.00024969794],"domain_scores_gemma":[0.9977421,0.00031710655,0.0016297182,0.00017285996,0.000107732056,0.000030464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002917885,0.00021343686,0.0010699723,0.00039451127,0.00007931585,0.0000040993414,0.0004407162,0.000114404196,0.000013596074],"category_scores_gemma":[0.000095739764,0.00013314493,0.00010799237,0.0003950239,0.00075905316,0.00008666488,0.00012945308,0.00038809958,0.000001644757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08461088,0.0020742635,0.5918834,0.0000531887,0.0043426207,0.000044744098,0.06399013,0.000021440848,0.23790354,0.00014338206,0.00019761082,0.014734814],"study_design_scores_gemma":[0.014150229,0.0040232074,0.87264794,0.0002735871,0.00035799772,0.001201797,0.019033069,0.0000028685954,0.08784757,0.000049616265,0.0002422731,0.00016984159],"about_ca_topic_score_codex":0.00017602553,"about_ca_topic_score_gemma":0.00013124972,"teacher_disagreement_score":0.28076455,"about_ca_system_score_codex":0.00006673037,"about_ca_system_score_gemma":0.000073430885,"threshold_uncertainty_score":0.5429493},"labels":[],"label_agreement":null},{"id":"W2783133837","doi":"","title":"Serumspiegel-en antistofbepaling bij biologicals voor psoriasis in de dermatologische dagelijkse praktijk.","year":2016,"lang":"nl","type":"article","venue":"Data Archiving and Networked Services (DANS)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.022843459801845926,"score_gpt":0.2627136117554859,"score_spread":0.23987015195363998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2783133837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97392666,0.018509783,0.0009706934,0.0011069945,0.0011212172,0.00053796853,0.0029936533,0.0001935201,0.0006395068],"genre_scores_gemma":[0.96934026,0.025253851,0.0013692743,0.00045572745,0.00037101732,0.00005236992,0.0021784299,0.00006940809,0.0009096759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928433,0.002631624,0.0010227851,0.001701985,0.000107675674,0.0016926335],"domain_scores_gemma":[0.99488634,0.0026600482,0.00046362975,0.0017513866,0.00003887249,0.00019973873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019547998,0.00086370547,0.0011718712,0.0003201554,0.0006280611,0.00011696214,0.0021993804,0.00089015823,0.00020889482],"category_scores_gemma":[0.00015319082,0.0005814589,0.00016080732,0.0004673809,0.00050950004,0.0005429239,0.0018945242,0.00055784825,0.00043192023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001638761,0.00067178445,0.7358563,0.0005038619,0.0015318863,0.000694965,0.00525062,0.00005535635,0.09786324,0.00056833046,0.0019242708,0.15344061],"study_design_scores_gemma":[0.012796735,0.00082059973,0.82829654,0.0060594305,0.001843865,0.0015584728,0.004006485,0.0039961343,0.010652167,0.0013953622,0.12546748,0.0031067324],"about_ca_topic_score_codex":0.0012284821,"about_ca_topic_score_gemma":0.0033683125,"teacher_disagreement_score":0.15033387,"about_ca_system_score_codex":0.00009410433,"about_ca_system_score_gemma":0.00012759394,"threshold_uncertainty_score":0.9996637},"labels":[],"label_agreement":null},{"id":"W2785779242","doi":"10.2196/resprot.8490","title":"Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention","year":2018,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Lilly Deutschland; Eli Lilly and Company","keywords":"Psychosocial; Intervention (counseling); Distress; Psoriasis; Protocol (science); Medicine; Psychology; Clinical psychology; Needs assessment; Psychotherapist; Psychiatry; Nursing; Alternative medicine","score_opus":0.10014878068611524,"score_gpt":0.5029706474404873,"score_spread":0.40282186675437204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785779242","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13836703,0.0000017985368,0.00012600192,0.000011187604,0.000009228962,0.8610433,0.0001530956,0.0000070967612,0.00028131783],"genre_scores_gemma":[0.2854014,3.851012e-8,0.000541541,7.817221e-7,0.000015717977,0.7138998,0.000080166086,0.000009359659,0.00005121915],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982332,0.0006351168,0.0004949935,0.00020980478,0.000167232,0.0002596447],"domain_scores_gemma":[0.9980589,0.0001445365,0.00037521156,0.0002631788,0.0011343735,0.000023802599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088773784,0.00013236835,0.00032876272,0.0001522238,0.00019858283,0.00001094004,0.00024820192,0.00012059812,0.00006995694],"category_scores_gemma":[0.0000388889,0.00007721501,0.00007757023,0.00021552193,0.0008553593,0.00008705824,0.000098084405,0.000108818815,0.0000010849695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12751271,0.01082322,0.35079774,0.0073723174,0.0016408396,3.941477e-7,0.054284506,2.618124e-7,0.011453942,0.0034640334,0.0011451225,0.4315049],"study_design_scores_gemma":[0.08648375,0.031360365,0.62012076,0.003659897,0.000054697037,6.6540974e-7,0.008419417,0.0000026650787,0.2240209,0.00037213095,0.025205458,0.0002992767],"about_ca_topic_score_codex":0.000017888427,"about_ca_topic_score_gemma":0.00012397871,"teacher_disagreement_score":0.43120563,"about_ca_system_score_codex":0.00004464581,"about_ca_system_score_gemma":0.00021390301,"threshold_uncertainty_score":0.31516072},"labels":[],"label_agreement":null},{"id":"W2785965739","doi":"10.36469/9817","title":"Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Astellas Pharma; Mylan; Celgene; Eli Lilly and Company; Valeant Pharmaceuticals International; Pfizer; National Psoriasis Foundation","keywords":"Psoriasis; Tolerability; Medicine; Adverse effect; Logistic regression; Preference; Quality of life (healthcare); Internal medicine; Physical therapy; Statistics; Dermatology","score_opus":0.07272751935305925,"score_gpt":0.3735386163132736,"score_spread":0.30081109696021435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785965739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775714,0.0005937343,0.0000021785472,0.0012317678,0.000069546906,0.00023561092,0.000074033065,5.331665e-7,0.000035434063],"genre_scores_gemma":[0.9837481,0.016125554,0.000027700004,0.000015906833,0.0000048711627,0.000009092704,0.000021229327,0.0000034545462,0.00004413361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983466,0.00057447713,0.0007531529,0.00009640886,0.000040283903,0.00018903005],"domain_scores_gemma":[0.99812895,0.0011349178,0.0005159089,0.00010036454,0.0000994766,0.000020379463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011599063,0.00007929834,0.00037174975,0.0003644977,0.00004792409,0.000004827455,0.000115256626,0.00007685235,0.000012251285],"category_scores_gemma":[0.00009157114,0.00003977341,0.00004930104,0.00011044765,0.00012376372,0.000117361036,0.000015337222,0.00010833807,7.709492e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042429916,0.00026982403,0.9802034,0.000016045073,0.00008991362,0.0000012234378,0.002882435,0.000014346743,0.000019776455,0.00043800025,0.000018224158,0.015622498],"study_design_scores_gemma":[0.0031763765,0.001784523,0.99083644,0.000070885435,0.0000083636205,0.0000021971828,0.0014153607,0.000008137995,0.0009214942,0.0014887436,0.00024859118,0.000038894275],"about_ca_topic_score_codex":0.0010795171,"about_ca_topic_score_gemma":0.0038173208,"teacher_disagreement_score":0.015583604,"about_ca_system_score_codex":0.00015556953,"about_ca_system_score_gemma":0.0002534911,"threshold_uncertainty_score":0.21301545},"labels":[],"label_agreement":null},{"id":"W2789068895","doi":"10.25251/skin.2.supp.4","title":"Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Term (time); Dermatology; Clinical efficacy; Internal medicine; Physics","score_opus":0.04899517628077045,"score_gpt":0.37599208035405723,"score_spread":0.3269969040732868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789068895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99409395,0.0028573985,0.000009101562,0.00035310953,0.0020969089,0.0004346944,0.00011943441,0.000009256863,0.000026150414],"genre_scores_gemma":[0.994324,0.004112081,0.000088379486,0.00013309173,0.0009420916,0.0000022247264,0.000049364637,0.000023281737,0.00032547166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99673253,0.0008172934,0.0017094967,0.0002844732,0.00014702986,0.00030914586],"domain_scores_gemma":[0.99380994,0.004327535,0.0009439155,0.00050662406,0.00032120434,0.00009079792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008944496,0.0002644093,0.0011790761,0.00018752518,0.00009591384,0.0000032325436,0.0003338789,0.00022019168,0.000277026],"category_scores_gemma":[0.0014526478,0.00012570118,0.0001780389,0.00025053998,0.0008516892,0.0000458978,0.00006420112,0.00030907305,0.00005918706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19862837,0.0056907656,0.107711054,0.000014681691,0.007369402,0.0012935995,0.008446081,0.000020464608,0.0009259249,0.00000429537,0.007372333,0.66252303],"study_design_scores_gemma":[0.10463065,0.094757035,0.7885587,0.0015737184,0.0030009768,0.00067286537,0.00036496628,0.0000018535258,0.0011163845,0.000027276257,0.0050168694,0.00027865794],"about_ca_topic_score_codex":0.00011698504,"about_ca_topic_score_gemma":0.0007730796,"teacher_disagreement_score":0.6808477,"about_ca_system_score_codex":0.0001819322,"about_ca_system_score_gemma":0.0002658611,"threshold_uncertainty_score":0.5125945},"labels":[],"label_agreement":null},{"id":"W2789237123","doi":"10.1016/j.jsxm.2017.11.058","title":"039 The Development of a Patient Reported Outcome Measure to Assess Sexual Impacts of Genital Psoriasis: GPSIS","year":2018,"lang":"en","type":"article","venue":"The Journal of Sexual Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Debriefing; Psoriasis; Sex organ; Sexual dysfunction; Clinical psychology; Patient-reported outcome; Medicine; Sexual medicine; Psychology; Reproductive health; Gynecology; Psychiatry; Dermatology; Quality of life (healthcare); Social psychology; Population; Nursing","score_opus":0.08350233544446364,"score_gpt":0.31559864316692343,"score_spread":0.2320963077224598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789237123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509186,0.0018778947,0.00018259579,0.0008520441,0.0015496179,0.00025872223,0.000010050469,0.000008222888,0.00016901115],"genre_scores_gemma":[0.9990237,0.000015139907,0.00028391386,0.00015820525,0.0002791079,0.0000042396523,0.0000062976587,0.000015460391,0.00021397647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974197,0.0004126454,0.001466562,0.00013380319,0.00028204455,0.00028522973],"domain_scores_gemma":[0.9971211,0.00044840586,0.0012813596,0.0003992879,0.0006802737,0.00006956537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002420732,0.00022473035,0.0006521479,0.00018936781,0.00017695151,0.0000030897613,0.000422703,0.00013013846,0.00018668048],"category_scores_gemma":[0.00080444233,0.00009991426,0.000037704885,0.0003254115,0.0003725732,0.00006165104,0.00009123087,0.00023247799,0.000020054013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021776292,0.0002869943,0.012357805,0.000037880927,0.0023414285,0.000014953726,0.03654892,0.000003063753,0.877623,0.000011010359,0.0021754524,0.06642183],"study_design_scores_gemma":[0.008605105,0.028080707,0.27992555,0.00053635176,0.004462194,0.0020665904,0.059266504,0.0000011313913,0.6105686,0.00007693823,0.0059409593,0.00046939592],"about_ca_topic_score_codex":0.00008648966,"about_ca_topic_score_gemma":0.000117393494,"teacher_disagreement_score":0.26756772,"about_ca_system_score_codex":0.000063119514,"about_ca_system_score_gemma":0.00024312269,"threshold_uncertainty_score":0.40743852},"labels":[],"label_agreement":null},{"id":"W2789535269","doi":"10.1111/cei.13116","title":"IL-27: a double agent in the IL-6 family","year":2018,"lang":"en","type":"review","venue":"Clinical & Experimental Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Life Sciences Research Network Wales; Medical Research Council Canada; Versus Arthritis; Arthritis Research UK","keywords":"Immunology; Biology","score_opus":0.15984898576514844,"score_gpt":0.4196639455556228,"score_spread":0.25981495979047436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789535269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008802714,0.9765505,0.0000013439554,0.000053201285,0.009347747,0.0015892055,0.00018330055,0.00009755783,0.0033744045],"genre_scores_gemma":[0.0015948556,0.99270666,0.000039738807,0.00040002316,0.0004086038,0.0008508734,0.0010821908,0.000087540604,0.0028295428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925964,0.002883025,0.0021910928,0.0012463998,0.00008222554,0.0010008481],"domain_scores_gemma":[0.99640363,0.0013102021,0.00070081744,0.0014939848,0.000046015906,0.000045354845],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012367297,0.0009403208,0.0030400683,0.00025982727,0.00027516024,0.000043902724,0.0017238412,0.002324965,0.00084730407],"category_scores_gemma":[0.000084617706,0.0006057317,0.0016228134,0.0004105107,0.0015502668,0.000089141955,0.0005854025,0.0013465467,0.013044429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011057412,0.005157248,0.0000820336,0.00040620076,0.0045137275,0.00029346725,0.0010832195,2.7046196e-8,0.0009778249,0.0013481209,0.028762473,0.9562699],"study_design_scores_gemma":[0.003613728,0.0014871287,0.00013982708,0.0008618132,0.00074405316,0.0002598499,0.00057730556,3.4677626e-8,0.00042057523,0.00003193378,0.99127984,0.00058391865],"about_ca_topic_score_codex":0.00012139911,"about_ca_topic_score_gemma":0.000017362709,"teacher_disagreement_score":0.9625174,"about_ca_system_score_codex":0.00021913704,"about_ca_system_score_gemma":0.00029641902,"threshold_uncertainty_score":0.9996394},"labels":[],"label_agreement":null},{"id":"W2789765710","doi":"10.1177/1203475418758986","title":"Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Infliximab; Psoriasis; Inflammatory bowel disease; Dermatology; Generalized pustular psoriasis; Pyoderma gangrenosum; Disease; Pustular psoriasis; Internal medicine","score_opus":0.013915035079831096,"score_gpt":0.22792451114995954,"score_spread":0.21400947607012843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789765710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887321,0.009439171,0.0000060185644,0.00082797935,0.00075400324,0.00011685843,0.0000074570003,0.000011782866,0.00010461312],"genre_scores_gemma":[0.9976648,0.0013485078,0.000021754977,0.00054299,0.00023574865,0.0000065212166,0.000018304678,0.000018012393,0.000143374],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985172,0.00023876382,0.0006553457,0.00017744751,0.00011994713,0.00029127003],"domain_scores_gemma":[0.99878144,0.0003603977,0.00040721707,0.00016307329,0.00016980719,0.00011809121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035323008,0.0002187784,0.0005808351,0.00035674687,0.00009364319,0.000008573123,0.00008299834,0.0001390959,0.00020130003],"category_scores_gemma":[0.00021187605,0.00013859152,0.00009110974,0.00015528643,0.00022858696,0.00009850724,0.00002038841,0.00019235062,0.000010119264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032765903,0.0014735616,0.3727221,0.00023317011,0.0029572246,0.022415144,0.011162391,0.000011793016,0.24318776,0.00011737398,0.12099241,0.19196118],"study_design_scores_gemma":[0.0663362,0.025416326,0.14921331,0.007974869,0.00609464,0.07369832,0.00985114,0.00007498167,0.1018419,0.0015164617,0.5534957,0.004486171],"about_ca_topic_score_codex":0.000040699455,"about_ca_topic_score_gemma":0.000022751947,"teacher_disagreement_score":0.43250328,"about_ca_system_score_codex":0.000043257,"about_ca_system_score_gemma":0.00017834998,"threshold_uncertainty_score":0.5651598},"labels":[],"label_agreement":null},{"id":"W2790430471","doi":"10.18103/mra.v6i3.1690","title":"Genetics of Psoriatic Arthritis – an update","year":2018,"lang":"en","type":"article","venue":"Medical Research Archives","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Immunology; Pathogenesis; Psoriasis; Allele; Major histocompatibility complex; Arthritis; Medicine; HLA-B27; Inflammatory bowel disease; Human leukocyte antigen; Genetics; Disease; Biology; Antigen; Pathology; Gene","score_opus":0.041959908567875064,"score_gpt":0.3498404184106758,"score_spread":0.30788050984280074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790430471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98157984,0.011031838,0.00035323325,0.00049521145,0.00046035665,0.00020334973,0.000050353847,0.000037377376,0.005788442],"genre_scores_gemma":[0.99165875,0.0065174643,0.00057595083,0.00004557978,0.00025787935,0.000028384353,0.000094598625,0.00001463539,0.0008067482],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751836,0.0011063577,0.00027105946,0.00028907758,0.00024796993,0.000567152],"domain_scores_gemma":[0.9986105,0.000722786,0.000040726165,0.00039144006,0.00008386079,0.000150668],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00093343103,0.00011086375,0.00024133558,0.00021399517,0.00022689257,0.000009357503,0.0004897103,0.00015088209,0.0038420048],"category_scores_gemma":[0.0007057571,0.00008683465,0.00006524849,0.00019699859,0.0021535666,0.000042790416,0.0001933257,0.00030487485,0.00089295115],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023355085,0.0002646389,0.001291057,0.000013026912,0.000117254705,0.00002175437,0.0008256867,4.2012232e-8,0.022882972,0.001710401,0.0012429935,0.9713966],"study_design_scores_gemma":[0.007701266,0.006676851,0.060358603,0.00045420325,0.000071897884,0.00019036708,0.00080050353,0.0002090849,0.57101107,0.030743314,0.32126355,0.0005193013],"about_ca_topic_score_codex":0.00004967292,"about_ca_topic_score_gemma":0.000158715,"teacher_disagreement_score":0.97087735,"about_ca_system_score_codex":0.0000075634803,"about_ca_system_score_gemma":0.000249221,"threshold_uncertainty_score":0.99988496},"labels":[],"label_agreement":null},{"id":"W2790684790","doi":"10.1111/jdv.14913","title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International","keywords":"Medicine; Ustekinumab; Psoriasis; Randomized controlled trial; Placebo; Visual analogue scale; Dermatology Life Quality Index; Ixekizumab; Internal medicine; Dermatology; Physical therapy; Secukinumab; Adalimumab; Psoriatic arthritis; Disease","score_opus":0.020231432584534467,"score_gpt":0.28475968443126637,"score_spread":0.2645282518467319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790684790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884991,0.0076283533,0.000029629113,0.0020734891,0.0003910969,0.00053825544,0.0000071394275,0.000004739967,0.0008281889],"genre_scores_gemma":[0.9985704,0.00066432095,0.000062291634,0.00045606322,0.00008830901,0.000011679807,8.062742e-7,0.000015260059,0.00013088228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99073195,0.0071161953,0.0016309596,0.00019776223,0.00004662495,0.00027651837],"domain_scores_gemma":[0.99677324,0.0015069263,0.0015398125,0.000106733416,0.00004390165,0.000029358667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043586637,0.00022883851,0.0027764707,0.00035648912,0.00007408109,0.0000052316677,0.0002519603,0.00025671654,0.000058573252],"category_scores_gemma":[0.00062257954,0.0001156804,0.00025365746,0.00012822538,0.001108311,0.00006122475,0.000089457135,0.0003851354,0.0000056939625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.570236,0.0012036464,0.2801884,0.00008685848,0.0072131744,0.00019212285,0.003234096,0.0000073288666,0.071237534,0.005667152,0.00061561295,0.06011804],"study_design_scores_gemma":[0.9298802,0.0004581882,0.022387654,0.00025770883,0.0016728683,0.0049142847,0.00021093838,0.000017406684,0.035659272,0.0013875272,0.0028931217,0.00026080295],"about_ca_topic_score_codex":0.000013025284,"about_ca_topic_score_gemma":0.000017053902,"teacher_disagreement_score":0.3596442,"about_ca_system_score_codex":0.000015836193,"about_ca_system_score_gemma":0.000044351968,"threshold_uncertainty_score":0.47173098},"labels":[],"label_agreement":null},{"id":"W2790698850","doi":"10.1177/2040622318759282","title":"Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Chronic Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Dermira; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Eli Lilly and Company; Amgen","keywords":"Psoriasis; Medicine; Pathogenesis; Interleukin 23; Interleukin 17; Immunology; Immune system; Disease; Interleukin; Plaque psoriasis; Dermatology; Cytokine; Pathology","score_opus":0.013224506834935765,"score_gpt":0.28607260919385447,"score_spread":0.2728481023589187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790698850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983796,0.0993077,0.000016538972,0.0002158225,0.00036545214,0.00075750105,0.000056906993,0.000038733637,0.0008617416],"genre_scores_gemma":[0.99270546,0.005684784,0.000022538046,0.00022786784,0.00015262864,0.0005518178,0.00007116538,0.00003361273,0.00055009936],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99745506,0.00068724866,0.00044579763,0.0006721239,0.000078118166,0.00066164474],"domain_scores_gemma":[0.99895185,0.0003594392,0.00012821215,0.00047523723,0.00003112894,0.00005411071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030451122,0.00043952095,0.00046623862,0.00029903193,0.00013376262,0.000026625938,0.00038006745,0.00017327814,0.00018539075],"category_scores_gemma":[0.000031029995,0.00031364174,0.000121223966,0.0004966121,0.00051313377,0.0001812729,0.00007343791,0.00019357396,0.00021837409],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040269503,0.0015074796,0.0373444,0.000049705213,0.0003292349,0.00015564903,0.012015014,0.0000728674,0.0070919385,0.0009069514,0.000019355086,0.93648046],"study_design_scores_gemma":[0.059326973,0.010905137,0.59982,0.0013287549,0.00170742,0.00026988733,0.019023126,0.0006075254,0.093963236,0.04241951,0.1672133,0.0034150782],"about_ca_topic_score_codex":0.00022050615,"about_ca_topic_score_gemma":0.004657493,"teacher_disagreement_score":0.93306535,"about_ca_system_score_codex":0.000882302,"about_ca_system_score_gemma":0.00029722622,"threshold_uncertainty_score":0.9999316},"labels":[],"label_agreement":null},{"id":"W2790907408","doi":"10.1177/247553031700200206","title":"Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data","year":2017,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Itching; Clinical trial; Internal medicine; Dermatology; Severity of illness; Physical therapy; Psoriatic arthritis","score_opus":0.07019014492243286,"score_gpt":0.30813629517120944,"score_spread":0.23794615024877658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790907408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98794097,0.002621157,0.00004019976,0.0010059624,0.004470193,0.0008010884,0.0024636895,0.000054947886,0.00060181896],"genre_scores_gemma":[0.98900884,0.0058262968,0.0007600271,0.0001349739,0.0023312322,0.000029289764,0.00066493463,0.00009597462,0.0011484135],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99444747,0.00089041947,0.0022073153,0.0012557185,0.00038956522,0.00080951396],"domain_scores_gemma":[0.99232644,0.0012819275,0.0032158536,0.0024970633,0.00041677692,0.00026196634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016818764,0.0008709621,0.0022161468,0.00023816653,0.001118369,0.00043636435,0.001198099,0.0007663964,0.00048768878],"category_scores_gemma":[0.00093114877,0.0005525045,0.00045067334,0.000146638,0.00056133175,0.0008185803,0.00027351428,0.00055689557,0.00009557012],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21446544,0.0030255741,0.025750663,0.000015862805,0.022640493,0.0015571315,0.0066065555,0.000004139995,0.000096275224,0.000053599226,0.014136451,0.7116478],"study_design_scores_gemma":[0.7221542,0.025917787,0.1936011,0.0017518632,0.008359642,0.000940019,0.0007216356,0.000026350468,0.002557739,0.00027561255,0.042016715,0.0016773149],"about_ca_topic_score_codex":0.0005692867,"about_ca_topic_score_gemma":0.0005575669,"teacher_disagreement_score":0.7099705,"about_ca_system_score_codex":0.00016775547,"about_ca_system_score_gemma":0.00041408735,"threshold_uncertainty_score":0.9996926},"labels":[],"label_agreement":null},{"id":"W2791358776","doi":"10.1093/jcag/gwy009.090","title":"A90 THREE PATIENTS WITH INFLAMMATORY BOWEL DISEASE DIAGNOSED WHILE BEING TREATED WITH SECUKINUMAB FOR PSORIASIS","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Secukinumab; Medicine; Ustekinumab; Colonoscopy; Inflammatory bowel disease; Psoriasis; Gastroenterology; Internal medicine; Crohn's disease; Adalimumab; Diarrhea; Dermatology; Surgery; Psoriatic arthritis; Disease; Colorectal cancer; Cancer","score_opus":0.005533938742697929,"score_gpt":0.18423062324605471,"score_spread":0.1786966845033568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791358776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977582,0.000022143386,0.00003624657,0.0009883274,0.0005660255,0.00032325528,0.00024334366,0.000006030878,0.000056432833],"genre_scores_gemma":[0.9992163,0.0000046707773,0.00007916974,0.00028938783,0.00011728701,0.000016758968,0.00004815812,0.000019248911,0.00020901771],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875814,0.00024137097,0.00037048163,0.00013689413,0.00009575988,0.0003973746],"domain_scores_gemma":[0.9978231,0.0001226187,0.0010422781,0.00018427745,0.00071922806,0.00010848548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003144349,0.00016444096,0.00032497736,0.00020318422,0.0002644453,0.000012883224,0.00025460028,0.0001484378,0.00006775894],"category_scores_gemma":[0.00015462172,0.00010522799,0.00015343311,0.00008778441,0.000133698,0.000102920974,0.000016619582,0.0001389512,0.000006188427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003748627,0.0000946581,0.9919214,0.000008198938,0.0010633476,0.0000055163405,0.00017091892,0.000013223621,0.000088562694,0.000027024047,0.0025016572,0.00035683907],"study_design_scores_gemma":[0.008858822,0.0022630484,0.98600703,0.0000620946,0.00056617707,0.0000082533425,0.000025401288,0.0000025996615,0.00029911325,0.000051499872,0.0017833364,0.000072621435],"about_ca_topic_score_codex":0.00072494365,"about_ca_topic_score_gemma":0.26187596,"teacher_disagreement_score":0.26115102,"about_ca_system_score_codex":0.0005982384,"about_ca_system_score_gemma":0.00034800934,"threshold_uncertainty_score":0.7515929},"labels":[],"label_agreement":null},{"id":"W2791445493","doi":"10.1093/jcag/gwy008.127","title":"A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN’S PATIENTS REFRACTORY TO ANTI-TNF THERAPY","year":2018,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Ustekinumab; Medicine; Crohn's disease; Refractory (planetary science); Psoriasis; Internal medicine; Adverse effect; Clinical trial; Disease; Adalimumab; Gastroenterology; Immunology","score_opus":0.020197952995637796,"score_gpt":0.27345423818980436,"score_spread":0.25325628519416654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791445493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570155,0.00002103804,0.0000012408224,0.0010222858,0.0028982772,0.00018949651,0.000053111864,0.000002410747,0.00011057128],"genre_scores_gemma":[0.9989304,0.000065530556,0.00003673209,0.00042741242,0.000170791,0.0000017012007,0.000011762086,0.000010365915,0.00034528738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975169,0.0010244527,0.00090662646,0.00013690349,0.000092058835,0.0003231032],"domain_scores_gemma":[0.99763614,0.00016461502,0.0014834325,0.00019160387,0.0004502839,0.000073935495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010928188,0.00012359218,0.00050029915,0.0004981302,0.00008171818,0.0000054431252,0.000301904,0.0002626746,0.000105184066],"category_scores_gemma":[0.00037811877,0.00009545987,0.00022489713,0.00021846744,0.000125252,0.000075478885,0.000028379069,0.00031199123,0.000016246604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018843343,0.00038188443,0.98582166,0.0000024470312,0.00034955342,0.0000023846262,0.00034358294,0.000007698535,0.0014271393,0.0000060723287,0.0042967983,0.0054764445],"study_design_scores_gemma":[0.0059828497,0.0016719127,0.9889186,0.00004549335,0.000052222338,0.000005295607,0.000027574357,3.2834126e-7,0.0010083542,0.0000108339655,0.0022318973,0.000044653232],"about_ca_topic_score_codex":0.0042981384,"about_ca_topic_score_gemma":0.28205588,"teacher_disagreement_score":0.27775773,"about_ca_system_score_codex":0.0007248358,"about_ca_system_score_gemma":0.00031127158,"threshold_uncertainty_score":0.7310447},"labels":[],"label_agreement":null},{"id":"W2791561402","doi":"10.1084/jem.20170369","title":"STAT-3–independent production of IL-17 by mouse innate-like αβ T cells controls ocular infection","year":2018,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Eye Institute; York University; Ludwig Institute for Cancer Research; National Institutes of Health; Harvard University; Brigham and Women's Hospital","keywords":"Immunology; Biology; CD8; Inflammation; T-cell receptor; Transcription factor; Innate immune system; stat; Interleukin 17; Cell biology; T cell; Signal transduction; Immune system; Genetics; Gene","score_opus":0.013414562643693277,"score_gpt":0.2617243672787554,"score_spread":0.24830980463506214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791561402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985046,0.011038285,0.00008508624,0.00031294063,0.0030456225,0.00023656354,0.000011256148,0.000010867788,0.0002133215],"genre_scores_gemma":[0.99692595,0.00057250285,0.000019075094,0.00011648919,0.00033387385,0.0000047944613,0.00001607646,0.000012897937,0.0019983253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988007,0.00029997676,0.0004877195,0.000112475725,0.00011956276,0.00017958891],"domain_scores_gemma":[0.99901474,0.00006699205,0.00052209594,0.00019554325,0.00016865038,0.00003195818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006712796,0.00015990165,0.00035835413,0.000110250876,0.00013108438,0.000002949517,0.00014813164,0.00010231154,0.00055444817],"category_scores_gemma":[0.00003917054,0.00009124364,0.00007775239,0.00010165338,0.00043066073,0.000108867454,0.000030171092,0.00016306115,0.000037507136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014291372,0.00034295258,0.00030605728,0.000004693223,0.00047419034,0.0000026722444,0.0021969979,0.0000025571112,0.9722916,0.000009789274,0.021752961,0.0011864305],"study_design_scores_gemma":[0.0035895666,0.0034624324,0.00042057468,0.00006137458,0.00027652236,0.0001934412,0.0011655346,8.420386e-7,0.97954106,0.000015213318,0.0111961,0.00007735755],"about_ca_topic_score_codex":0.00017593229,"about_ca_topic_score_gemma":0.000008409133,"teacher_disagreement_score":0.011879908,"about_ca_system_score_codex":0.00007827032,"about_ca_system_score_gemma":0.000028577386,"threshold_uncertainty_score":0.60708183},"labels":[],"label_agreement":null},{"id":"W2791647987","doi":"10.1177/1203475418755982","title":"Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Western University; University of Toronto","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Dermatology; Retrospective cohort study; Surgery; Psoriatic arthritis","score_opus":0.02446514151326133,"score_gpt":0.27233930343404733,"score_spread":0.247874161920786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791647987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948902,0.003081881,0.00019421034,0.00055250234,0.0007756649,0.0003512119,0.000017562375,0.00000763107,0.00012909749],"genre_scores_gemma":[0.997863,0.001142804,0.000098944554,0.00019374899,0.00036864108,0.000004806528,0.0000034060781,0.000014708086,0.00030997038],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988563,0.00013174137,0.00057686464,0.00017669807,0.000067976085,0.0001904423],"domain_scores_gemma":[0.99837136,0.0008038624,0.00032813658,0.0001249773,0.00031167574,0.00005998955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000619479,0.00016849706,0.0008013807,0.00022699867,0.00013388033,0.0000055089063,0.00006600309,0.0001036188,0.0000685506],"category_scores_gemma":[0.00029111924,0.000113371076,0.00008409168,0.000116299496,0.0001528915,0.0000484977,0.000016167058,0.00009691767,0.0000019450792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16309744,0.002300359,0.18423337,0.00016570832,0.0091379825,0.00048742324,0.045410275,0.000022256992,0.13002317,0.00016622983,0.05167172,0.41328406],"study_design_scores_gemma":[0.123794906,0.11787497,0.49656495,0.0045658667,0.008526909,0.036379535,0.033057626,0.00006254293,0.075340435,0.0037590712,0.09715781,0.0029153673],"about_ca_topic_score_codex":0.000017247916,"about_ca_topic_score_gemma":0.000015761752,"teacher_disagreement_score":0.4103687,"about_ca_system_score_codex":0.000024528972,"about_ca_system_score_gemma":0.000057979985,"threshold_uncertainty_score":0.46231383},"labels":[],"label_agreement":null},{"id":"W2791839805","doi":"10.1111/jdv.14910","title":"Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized <scp>VOYAGE</scp> 1 trial","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"National Institutes of Health; National Institute for Health and Care Research","keywords":"Medicine; Adalimumab; Psoriasis; Placebo; Randomized controlled trial; Internal medicine; Surgery; Dermatology; Disease","score_opus":0.021936845428191774,"score_gpt":0.24077548794487086,"score_spread":0.2188386425166791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791839805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99443233,0.0022292424,0.000041435855,0.0014168011,0.00049667107,0.0005477322,0.00008689369,0.000014701508,0.0007341625],"genre_scores_gemma":[0.9984419,0.00047568948,0.00014602434,0.00038943757,0.0001498954,0.0000070218325,0.0000121567155,0.000027560995,0.00035036282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934379,0.004415992,0.00139773,0.00031980916,0.00009326683,0.00033532584],"domain_scores_gemma":[0.9946282,0.002930534,0.0019317,0.00027506676,0.0001702643,0.00006423691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089335913,0.0003223385,0.0013229235,0.00016477631,0.00027494287,0.000009914484,0.00044474463,0.00037291236,0.000025256164],"category_scores_gemma":[0.0010518524,0.00015115892,0.00021729287,0.00022036137,0.0015972409,0.0000888762,0.00020292828,0.00044752794,0.000008743621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92901236,0.00047136605,0.018615821,0.000026940019,0.008669573,0.00019211296,0.006473477,0.00003318975,0.018264404,0.00040919404,0.008419733,0.009411814],"study_design_scores_gemma":[0.80532867,0.002604396,0.025970891,0.00036349992,0.0048621194,0.01169327,0.00087657926,0.000019724152,0.13754633,0.0008490167,0.00956771,0.00031777745],"about_ca_topic_score_codex":0.000037109603,"about_ca_topic_score_gemma":0.000013593824,"teacher_disagreement_score":0.12368368,"about_ca_system_score_codex":0.0000133738395,"about_ca_system_score_gemma":0.00008872397,"threshold_uncertainty_score":0.6164082},"labels":[],"label_agreement":null},{"id":"W2792012841","doi":"10.1016/j.jaad.2017.10.011","title":"Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry","year":2017,"lang":"en","type":"editorial","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"University of Connecticut; AbbVie; Eli Lilly and Company","keywords":"Psoriasis; Medicine; Systemic therapy; Cohort; Dermatology; Internal medicine","score_opus":0.019692917563838844,"score_gpt":0.30446377579441486,"score_spread":0.284770858230576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792012841","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043937985,0.0058620754,0.00004027818,0.081569105,0.8663428,0.0005471309,0.0008115145,0.000030136827,0.0008589957],"genre_scores_gemma":[0.45234025,0.0142342765,0.0004623949,0.006095943,0.5211903,0.000094274925,0.00074385747,0.00023301666,0.004605728],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99619216,0.0012544176,0.0013100666,0.00032522346,0.00046758892,0.00045053396],"domain_scores_gemma":[0.9876563,0.0024463853,0.008908115,0.000538591,0.00040538845,0.000045202727],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079436816,0.00047984783,0.0015421167,0.00025845703,0.00066447695,0.000039762323,0.0028927263,0.00096371485,0.00010617127],"category_scores_gemma":[0.0014747395,0.00028569787,0.0008466445,0.00020390119,0.002278218,0.00018431185,0.00034108272,0.0020824396,0.000068703455],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008512122,0.00013280536,0.0012339571,0.000033896064,0.0021300626,0.000011725736,0.00010863061,0.0000040474083,0.00096024486,0.00008175096,0.98570216,0.008749502],"study_design_scores_gemma":[0.0021966402,0.0001501373,0.00407847,0.00014126801,0.001408256,0.0016521375,0.00015537639,8.565158e-7,0.0035741045,0.00073709525,0.98564506,0.00026061435],"about_ca_topic_score_codex":0.00013600166,"about_ca_topic_score_gemma":0.000018614184,"teacher_disagreement_score":0.40840226,"about_ca_system_score_codex":0.00023750076,"about_ca_system_score_gemma":0.00073746825,"threshold_uncertainty_score":0.9999595},"labels":[],"label_agreement":null},{"id":"W2792200490","doi":"10.1111/bjd.16426","title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research; Dalhousie University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Dosing; Psoriasis; Plaque psoriasis; Adverse effect; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Dermatology","score_opus":0.008463195056420257,"score_gpt":0.23560179499714487,"score_spread":0.2271385999407246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792200490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962781,0.0018679334,0.0001781877,0.000061040315,0.0005057416,0.000932735,0.000075330914,0.0000060119005,0.0000948965],"genre_scores_gemma":[0.9993114,0.00028200794,0.00024494558,0.00004089622,0.000033880708,0.000014206286,0.00003114591,0.000019244766,0.000022284989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99682343,0.0009851741,0.0014967576,0.0002478194,0.00009000154,0.0003567934],"domain_scores_gemma":[0.99803734,0.0006096142,0.0008930447,0.00014046124,0.0002666685,0.000052883872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004685813,0.00022868694,0.0020400963,0.0004381239,0.00007418732,0.000014269266,0.00017830756,0.0003312031,0.00009924249],"category_scores_gemma":[0.00030751937,0.00021003872,0.00015581786,0.00024503714,0.00041470394,0.00017689433,0.000054151085,0.00026781502,0.0000030692004],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9582141,0.0021579398,0.0075582536,0.000025974901,0.00071650406,0.0003244096,0.0009558077,0.000008642638,0.0006075268,0.000029070878,0.00021738229,0.029184375],"study_design_scores_gemma":[0.9621144,0.0020522177,0.026047317,0.0005477589,0.00030031198,0.002815415,0.000102019185,0.0000062148047,0.0056458944,0.00006124874,0.000093548544,0.00021367965],"about_ca_topic_score_codex":0.00029588406,"about_ca_topic_score_gemma":0.00027172512,"teacher_disagreement_score":0.028970696,"about_ca_system_score_codex":0.000046049245,"about_ca_system_score_gemma":0.00017634213,"threshold_uncertainty_score":0.856513},"labels":[],"label_agreement":null},{"id":"W2792921896","doi":"10.1111/jdv.14878","title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (<scp>SCULPTURE</scp> Extension Study)","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Probity Medical Research; Innovaderm (Canada)","funders":"Novartis Pharma; Novartis","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Psoriasis; Psoriatic arthritis; Adverse effect; Clinical trial; Internal medicine; Surgery; Dermatology","score_opus":0.011323670330450543,"score_gpt":0.2304250217205764,"score_spread":0.21910135139012588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792921896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774545,0.0009980961,0.0000134950815,0.00034198535,0.00019313619,0.000448766,0.000021427008,0.0000072851035,0.00023037157],"genre_scores_gemma":[0.9992625,0.0001966342,0.00027472945,0.000083162886,0.000033247354,0.0000032960304,0.000005708716,0.000020013367,0.00012071433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732566,0.0013923551,0.0006485088,0.00026526887,0.00005740151,0.00031080647],"domain_scores_gemma":[0.99873513,0.0003330842,0.0006098883,0.0001597141,0.00012174459,0.000040422845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028134513,0.00023959548,0.0007707766,0.00018776265,0.00014455903,0.0000047997173,0.00024160389,0.00022646926,0.000010348773],"category_scores_gemma":[0.0001169976,0.00015000039,0.00007250515,0.00020330903,0.0004923709,0.000100563724,0.00013534447,0.00027089287,0.0000063110538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058148974,0.0014553257,0.9688073,0.00004305094,0.0015533066,0.00008723224,0.005930747,0.00007854878,0.0040923157,0.00054942205,0.0004649805,0.011122871],"study_design_scores_gemma":[0.015412354,0.0015720812,0.96683747,0.00009796659,0.0004296528,0.00083380035,0.0006854652,0.0000025624192,0.01307271,0.00022110011,0.0007344911,0.00010033859],"about_ca_topic_score_codex":0.000020649983,"about_ca_topic_score_gemma":0.000012540096,"teacher_disagreement_score":0.011022532,"about_ca_system_score_codex":0.000037703736,"about_ca_system_score_gemma":0.00006586266,"threshold_uncertainty_score":0.61168385},"labels":[],"label_agreement":null},{"id":"W2793374690","doi":"10.1016/j.jaad.2018.03.008","title":"Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Ixekizumab; Psoriasis; Psoriatic arthritis; Dermatology; Etanercept; Arthritis; Internal medicine; Secukinumab; Tumor necrosis factor alpha","score_opus":0.011637232409715783,"score_gpt":0.3091276638145786,"score_spread":0.29749043140486287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793374690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962368,0.0004579663,0.000014058291,0.002254686,0.0006515661,0.00024628814,0.00007534864,0.0000068213176,0.000056469922],"genre_scores_gemma":[0.9984424,0.00033476876,0.00013549598,0.00097396737,0.000048852704,0.0000075265525,0.000005186138,0.000016431706,0.0000353688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99534875,0.002288843,0.0015987223,0.0002593673,0.00014066769,0.0003636576],"domain_scores_gemma":[0.9956878,0.0015750714,0.0021997825,0.00027298316,0.00020457745,0.000059789574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058455725,0.00028062295,0.0022538379,0.0007547072,0.00007993802,0.000004718412,0.000650676,0.00027664844,0.00006177468],"category_scores_gemma":[0.00093291275,0.00017497774,0.00092282856,0.0009459336,0.0007346761,0.00008164442,0.00011866214,0.00048761262,0.000050393366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017328821,0.0008579551,0.81462765,0.000025863654,0.0064869286,0.000015023781,0.0004667362,0.00006335737,0.0008016521,0.000063004474,0.0012738069,0.1579892],"study_design_scores_gemma":[0.010988368,0.00880629,0.94780755,0.00013622257,0.0022677828,0.00026857326,0.00012842857,0.000008649138,0.028570844,0.00010453732,0.0006480528,0.00026468493],"about_ca_topic_score_codex":0.000054280667,"about_ca_topic_score_gemma":0.000030053101,"teacher_disagreement_score":0.15772451,"about_ca_system_score_codex":0.00005448002,"about_ca_system_score_gemma":0.000077825534,"threshold_uncertainty_score":0.7135385},"labels":[],"label_agreement":null},{"id":"W2793564922","doi":"10.1111/jdv.14926","title":"Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Dosing; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Plaque psoriasis; Internal medicine; Population; Dermatology; Disease","score_opus":0.01301828960695399,"score_gpt":0.23493063478086915,"score_spread":0.22191234517391517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793564922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99732786,0.00033199374,0.0006273569,0.0010288749,0.00020553423,0.00014994005,0.000010535162,0.0000061752758,0.0003117033],"genre_scores_gemma":[0.9987721,0.000055469372,0.00080642,0.0002343155,0.000024226312,0.0000011747572,0.000004212313,0.000017886217,0.00008420079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982152,0.00080479344,0.00053415593,0.00016329318,0.000053543903,0.00022898852],"domain_scores_gemma":[0.9989709,0.00011085058,0.0006568992,0.00012204552,0.00010839481,0.000030911568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021880861,0.00018114816,0.0005640904,0.00024434287,0.000099709505,0.0000036044037,0.00028170686,0.0001795327,0.000025588028],"category_scores_gemma":[0.00003242141,0.00010465326,0.0000621173,0.00017660181,0.00041537578,0.00011044808,0.00009935185,0.00024791513,0.000004677798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004341404,0.00016554123,0.9903764,0.000022237802,0.00046430208,0.000012989858,0.0004897055,0.0014851767,0.00043351663,0.0001372967,0.000089281675,0.0019821445],"study_design_scores_gemma":[0.0075255595,0.00035171755,0.97324926,0.00016516396,0.00024148978,0.000937049,0.000031657408,0.000007814561,0.017217059,0.000046428762,0.00009003844,0.00013677352],"about_ca_topic_score_codex":0.0000038491216,"about_ca_topic_score_gemma":0.000007758424,"teacher_disagreement_score":0.017127154,"about_ca_system_score_codex":0.000017874923,"about_ca_system_score_gemma":0.000041773026,"threshold_uncertainty_score":0.42676362},"labels":[],"label_agreement":null},{"id":"W2793627537","doi":"10.1177/1203475418755998","title":"OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Lynde Centre for Dermatology; Amgen (Canada); Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain; Université de Sherbrooke","funders":"Amgen Canada","keywords":"Medicine; Etanercept; Adverse effect; Incidence (geometry); Psoriasis; Confidence interval; Rate ratio; Internal medicine; Immunology","score_opus":0.025073484909630083,"score_gpt":0.244652012368781,"score_spread":0.21957852745915094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793627537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235684,0.005864648,0.0000026089688,0.00072502386,0.00088529376,0.00006662927,0.000042563075,0.000004329651,0.00005208051],"genre_scores_gemma":[0.9970707,0.0022151358,0.000009589554,0.0003280721,0.00013559987,7.417833e-7,0.00013287643,0.000008416361,0.000098809534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986408,0.00031918546,0.00066408276,0.00010650081,0.00010233297,0.00016710506],"domain_scores_gemma":[0.996435,0.002513504,0.0005546425,0.000120101315,0.00032781233,0.000048939866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029960542,0.00015411891,0.0007684526,0.0001369306,0.00012397768,0.0000050278104,0.00008496964,0.00009733007,0.00019052844],"category_scores_gemma":[0.00031094774,0.00008111919,0.00006583187,0.00015455503,0.00052706583,0.000030956337,0.000020469311,0.00013673454,0.0000013697977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041207173,0.00014904386,0.90242267,0.000024628132,0.0014675052,0.000111947964,0.003972638,0.0000029576106,0.00178643,0.000011442253,0.046937283,0.03899271],"study_design_scores_gemma":[0.031741876,0.0051336884,0.7387749,0.0017437174,0.0064771795,0.0025301557,0.016808603,0.00013507987,0.032226622,0.0008616929,0.16253263,0.0010338493],"about_ca_topic_score_codex":0.22107248,"about_ca_topic_score_gemma":0.05174945,"teacher_disagreement_score":0.16932303,"about_ca_system_score_codex":0.000023327895,"about_ca_system_score_gemma":0.00010921325,"threshold_uncertainty_score":0.96555364},"labels":[],"label_agreement":null},{"id":"W2793685260","doi":"10.1177/247553031600100406","title":"Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept","year":2016,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Etanercept; Itching; Placebo; Psoriasis; Dermatology; Erythema; Internal medicine; Psoriatic arthritis; Tumor necrosis factor alpha; Pathology","score_opus":0.007232418702490851,"score_gpt":0.20826899331836302,"score_spread":0.20103657461587215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793685260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842894,0.0135066,0.0002126097,0.0006187247,0.0008394814,0.0003693237,0.00007944351,0.000018754698,0.000065633816],"genre_scores_gemma":[0.99421996,0.004848836,0.00031633346,0.00020759589,0.00028321327,0.000016732989,0.0000050441618,0.000036092835,0.000066211636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99720335,0.00070249615,0.0010911603,0.00042796638,0.00017234079,0.00040269166],"domain_scores_gemma":[0.99716985,0.0012734815,0.0009907925,0.00023280321,0.00019323183,0.00013983017],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012093206,0.00040606337,0.00097655033,0.0002842925,0.00025649933,0.0000616104,0.00010319618,0.00033680146,0.00012010615],"category_scores_gemma":[0.00048881944,0.00026940196,0.00016519902,0.000095835254,0.00031348277,0.00028613163,0.00006229639,0.00022069123,0.0000038145208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016925839,0.00014696307,0.031847578,0.00005768958,0.0013357775,0.000046607343,0.0021833347,7.0100566e-7,0.005882661,0.00026937856,0.00038850043,0.9561482],"study_design_scores_gemma":[0.17812045,0.030896775,0.66385764,0.009142282,0.0067130225,0.00723603,0.008419698,0.00009560177,0.04424792,0.0083176,0.039214633,0.0037383488],"about_ca_topic_score_codex":0.000056330045,"about_ca_topic_score_gemma":0.000034476365,"teacher_disagreement_score":0.95240986,"about_ca_system_score_codex":0.00003218715,"about_ca_system_score_gemma":0.00005750602,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2793756714","doi":"10.1111/jdv.14868","title":"Shifting the focus – the primary role of <scp>IL</scp>‐23 in psoriasis and other inflammatory disorders","year":2018,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":110,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto; Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Psoriasis; Spondyloarthropathy; Context (archaeology); Immunology; Tumor necrosis factor alpha; Inflammatory bowel disease; Disease; Proinflammatory cytokine; Interleukin 23; Inflammation; Interleukin 17; Arthritis; Internal medicine","score_opus":0.01864517733715582,"score_gpt":0.25272203884677913,"score_spread":0.2340768615096233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793756714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08234053,0.91438574,0.0000015824962,0.000635402,0.00045915067,0.00030379687,0.000027078433,0.0000061461305,0.0018405941],"genre_scores_gemma":[0.07555117,0.9237828,0.000022682976,0.00021176685,0.00019146565,0.000008480553,0.0000031579586,0.000051446183,0.00017702128],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922488,0.0056527047,0.0013893682,0.0002620658,0.000067643945,0.0003794302],"domain_scores_gemma":[0.99508077,0.0021410496,0.0024331317,0.00028036055,0.00003501219,0.000029677223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015840648,0.0004015513,0.0015970017,0.0002647686,0.00022743031,0.000006758467,0.001067163,0.000675198,0.000008511133],"category_scores_gemma":[0.00030613577,0.00019136506,0.0004590815,0.00021358058,0.0018668144,0.000050207676,0.0004850405,0.001174556,0.000017165165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019671433,0.0002495154,0.083790585,0.0025868914,0.0047117276,0.000044390603,0.0037957248,0.0000027140507,0.0004356086,0.003945651,0.0037753098,0.8964652],"study_design_scores_gemma":[0.0012693101,0.000059874932,0.01790275,0.0013731953,0.0017580019,0.0051512225,0.00028473194,4.345891e-7,0.0003522602,0.0013953401,0.97032255,0.00013032233],"about_ca_topic_score_codex":0.0000065426952,"about_ca_topic_score_gemma":0.000014012444,"teacher_disagreement_score":0.96654725,"about_ca_system_score_codex":0.00002092733,"about_ca_system_score_gemma":0.00011090157,"threshold_uncertainty_score":0.7803641},"labels":[],"label_agreement":null},{"id":"W2794845062","doi":"10.1016/j.jaad.2018.03.037","title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":188,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Interleukin 17; Randomized controlled trial; Gastroenterology; Clinical trial; Interleukin; Surgery; Immunology; Inflammation; Cytokine; Pathology","score_opus":0.02089051072143032,"score_gpt":0.2762123065281997,"score_spread":0.2553217958067694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794845062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964531,0.00040473405,0.00007955261,0.0013325672,0.00035779315,0.0011941392,0.00009177059,0.000009221761,0.00007713516],"genre_scores_gemma":[0.99913776,0.00013999085,0.00033234173,0.00018113355,0.00007883308,0.00003230765,0.000024158802,0.000023799328,0.000049667782],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618584,0.001401245,0.0016267627,0.00029479346,0.00015010645,0.00034122932],"domain_scores_gemma":[0.9948557,0.0009432052,0.0038008082,0.00020644125,0.00014425772,0.000049592072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054405787,0.00032734842,0.0022506788,0.0004659931,0.00008268491,0.0000125994275,0.00038933277,0.00024049213,0.00002867935],"category_scores_gemma":[0.00017893456,0.00018281538,0.00025076547,0.00033622514,0.0016169451,0.00020314519,0.000080765094,0.0004347615,0.0000022373197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9868425,0.0009631937,0.0043304963,0.000010591994,0.0022071637,0.0000106178495,0.0015343971,0.000011438282,0.0017792983,0.00006292588,0.00049169234,0.0017556886],"study_design_scores_gemma":[0.9665935,0.0040124706,0.0037118907,0.00020831941,0.0012125963,0.00028987642,0.0004161253,0.000014247124,0.022997422,0.00008171666,0.00027137942,0.0001904296],"about_ca_topic_score_codex":0.00035319242,"about_ca_topic_score_gemma":0.000113044436,"teacher_disagreement_score":0.021218123,"about_ca_system_score_codex":0.00005345377,"about_ca_system_score_gemma":0.00014925444,"threshold_uncertainty_score":0.74549943},"labels":[],"label_agreement":null},{"id":"W2795044792","doi":"10.1016/j.jdcr.2017.11.006","title":"Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series","year":2018,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; NOSM University; Western University; University of Toronto","funders":"","keywords":"Secukinumab; Dosing; Medicine; Psoriasis; Regimen; Maintenance therapy; Dermatology; Surgery; Internal medicine; Chemotherapy; Psoriatic arthritis","score_opus":0.008156284282237239,"score_gpt":0.23080514339138744,"score_spread":0.2226488591091502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795044792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568385,0.00018825888,0.00006912242,0.000041571544,0.0020234995,0.00051186606,0.00007188607,0.000102017795,0.0013079381],"genre_scores_gemma":[0.9977632,0.000048660844,0.0007182453,0.00006728387,0.000117331074,0.000101283236,0.00023573107,0.000031824417,0.00091643614],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99819756,0.00019211574,0.0005831089,0.00057199824,0.000058517606,0.00039668084],"domain_scores_gemma":[0.99869794,0.00004056929,0.00031760902,0.0005003696,0.00040097194,0.000042518648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020012143,0.00028077682,0.00034608424,0.00019426005,0.00027709876,0.00002807816,0.000040161187,0.00030763188,0.00066589174],"category_scores_gemma":[0.00027372007,0.00025093695,0.00011265348,0.00029210089,0.00015123177,0.00030350118,0.000068905276,0.00014341135,0.0000957474],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017934724,0.0019472182,0.38278365,0.000056082303,0.00065479864,0.58056086,0.005977906,0.000088339795,0.0013857391,0.000100743775,0.0021614654,0.022489745],"study_design_scores_gemma":[0.014256629,0.0018048949,0.043666236,0.00019492062,0.00066237623,0.893205,0.0021027022,0.0001589792,0.03620115,0.00012707454,0.0062854416,0.0013346225],"about_ca_topic_score_codex":0.00084156933,"about_ca_topic_score_gemma":0.0019830593,"teacher_disagreement_score":0.3391174,"about_ca_system_score_codex":0.00020832631,"about_ca_system_score_gemma":0.000049132002,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2796762777","doi":"10.1111/jdv.14993","title":"Psoriasis patients’ preference for an aerosol foam topical formulation","year":2018,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Montreal Clinical Research Institute; Guenther Dermatology Research Centre; Thornhill Medical (Canada); Western University; SKiN Health; Queen's University; McMaster University; Dermatrials Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Aerosol; Preference; Meteorology","score_opus":0.046562204864978335,"score_gpt":0.26312829806763816,"score_spread":0.21656609320265982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796762777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8767435,0.002979423,0.00023662625,0.113056205,0.004660364,0.00073346565,0.000174832,0.00002877757,0.0013867855],"genre_scores_gemma":[0.96293616,0.00029853426,0.00035402877,0.033575807,0.0017913916,0.000009309952,0.0001353127,0.000052207706,0.00084723224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964463,0.0019028547,0.0009123711,0.0002915146,0.00006567522,0.00038126894],"domain_scores_gemma":[0.99771637,0.00041692817,0.0014525016,0.00021665615,0.00016609422,0.000031471045],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00034090827,0.00031758263,0.0008146585,0.00018421155,0.00021507569,0.0000075714406,0.000732611,0.00133108,0.000039457456],"category_scores_gemma":[0.00016535689,0.00021037128,0.00031544187,0.000066903354,0.00049342244,0.00012791975,0.00016943827,0.0011192338,0.000018603692],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013991212,0.00031551268,0.080198616,0.0003049221,0.0018936709,0.000034466215,0.00058520166,0.0000017022719,0.0025532257,0.00086662045,0.88440907,0.027437856],"study_design_scores_gemma":[0.0072987797,0.00081139733,0.06676501,0.00020108352,0.0018005364,0.0033506465,0.000022057102,0.000004132394,0.018780742,0.0025561631,0.8979035,0.00050593656],"about_ca_topic_score_codex":0.000001914105,"about_ca_topic_score_gemma":0.0000016587941,"teacher_disagreement_score":0.08619266,"about_ca_system_score_codex":0.000023576087,"about_ca_system_score_gemma":0.000051078856,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2797132528","doi":"10.1016/j.jaad.2018.04.012","title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Clinical trial; Dermatology; Adalimumab; Tumor necrosis factor alpha; Pathology","score_opus":0.04701122508122613,"score_gpt":0.3529104809531127,"score_spread":0.3058992558718866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797132528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9172409,0.05924299,0.00021373124,0.019212281,0.0014727347,0.0022421847,0.0003102044,0.000015179984,0.000049777595],"genre_scores_gemma":[0.97461987,0.024183545,0.00034304365,0.00016794076,0.00035174348,0.00017562485,0.000008940948,0.00002683701,0.00012244983],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99617743,0.0011531325,0.0017613445,0.0003178898,0.00011783794,0.00047237155],"domain_scores_gemma":[0.9907397,0.004747163,0.003920281,0.00032739874,0.00021990562,0.000045525878],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0002961891,0.0004380283,0.0029959378,0.00017391772,0.00032173755,0.000011308293,0.00060895446,0.00026372483,0.000027026994],"category_scores_gemma":[0.00032365945,0.00021345277,0.0009432425,0.00018781515,0.0031062998,0.00013393491,0.00009249966,0.000281157,0.000008396218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9460765,0.0012017601,0.00018905169,0.000033993932,0.016582072,0.000016977365,0.005061728,0.000006059258,0.009668657,0.00020318366,0.004198503,0.016761517],"study_design_scores_gemma":[0.85368866,0.0024577843,0.00014973742,0.00012468293,0.005819882,0.0017133405,0.0021517854,0.00007629856,0.11640857,0.00049121404,0.016701143,0.0002169044],"about_ca_topic_score_codex":0.00023847737,"about_ca_topic_score_gemma":0.000043907716,"teacher_disagreement_score":0.106739916,"about_ca_system_score_codex":0.00013408785,"about_ca_system_score_gemma":0.00018044296,"threshold_uncertainty_score":0.99960667},"labels":[],"label_agreement":null},{"id":"W2797238574","doi":"10.1016/j.jaad.2018.04.013","title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Placebo; Etanercept; Psoriasis Area and Severity Index; Clinical endpoint; Psoriasis; Internal medicine; Adverse effect; Randomized controlled trial; Tumor necrosis factor alpha; Dermatology; Pathology","score_opus":0.037537798279241245,"score_gpt":0.345756602853417,"score_spread":0.3082188045741758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797238574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173904,0.008567054,0.00011854775,0.0055202846,0.0006167141,0.0032188885,0.00014556943,0.000008145606,0.000065770684],"genre_scores_gemma":[0.99491256,0.0044650263,0.00015095362,0.000059866583,0.00014737181,0.00014006077,0.0000044935978,0.000023113513,0.0000965705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99602264,0.0013860872,0.0018199249,0.00025558975,0.00012077947,0.00039495094],"domain_scores_gemma":[0.992339,0.0027891516,0.004323199,0.000321782,0.00018484922,0.000042006006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003948125,0.0003660841,0.002755917,0.0002050876,0.00019634809,0.000007005686,0.00058129086,0.00021773476,0.000029804549],"category_scores_gemma":[0.00021481598,0.00017902191,0.00085544126,0.00021849244,0.002147592,0.00010326888,0.00006652047,0.00024908924,0.000006727478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95831007,0.0030932678,0.0004511109,0.00003316847,0.009248665,0.000012132468,0.0062867454,0.000007525674,0.013312393,0.00008757772,0.00081418385,0.0083431825],"study_design_scores_gemma":[0.9082229,0.006050175,0.0002739366,0.00007176201,0.005580056,0.0021294134,0.00290478,0.000073368574,0.07130894,0.00007936964,0.0031464517,0.00015886058],"about_ca_topic_score_codex":0.00017254616,"about_ca_topic_score_gemma":0.00004146561,"teacher_disagreement_score":0.057996545,"about_ca_system_score_codex":0.00008576604,"about_ca_system_score_gemma":0.00019126818,"threshold_uncertainty_score":0.7912892},"labels":[],"label_agreement":null},{"id":"W2798001650","doi":"10.1111/jdv.14985","title":"Response to ‘Psoriasis patients’ preference for an aerosol foam topical formulation’ by Vender R <i>et al</i>.","year":2018,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Preference","score_opus":0.03894838788157808,"score_gpt":0.2748958025533598,"score_spread":0.23594741467178174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798001650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5722966,0.0014145799,0.0002011439,0.4230277,0.0019327685,0.000521761,0.00028284153,0.000018137021,0.00030447822],"genre_scores_gemma":[0.63698024,0.00019748832,0.00043402944,0.3604517,0.00045795768,0.000017364486,0.00015096799,0.00006691507,0.001243316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942364,0.0039678644,0.0009074218,0.00036661627,0.00008537728,0.00043628504],"domain_scores_gemma":[0.9976398,0.00081502873,0.0010608119,0.00026316865,0.00016611828,0.00005512514],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007441373,0.00035665306,0.0008257425,0.00021098235,0.000209046,0.000010412407,0.00080545014,0.0009125753,0.000036784935],"category_scores_gemma":[0.00033210075,0.00024875664,0.0002762636,0.000089601876,0.00035615504,0.00012414614,0.00022496378,0.0011078026,0.000028175147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024685927,0.00012258602,0.008107788,0.000034288816,0.0005267242,0.0000124923,0.0002850814,8.5741834e-7,0.005983318,0.00007393199,0.97993934,0.002445012],"study_design_scores_gemma":[0.0032207244,0.0005668937,0.013060458,0.00007763611,0.00039238433,0.0010571844,0.000011194932,5.8742484e-7,0.011569509,0.00030374457,0.9694871,0.00025261854],"about_ca_topic_score_codex":0.0000020760747,"about_ca_topic_score_gemma":0.0000012730901,"teacher_disagreement_score":0.064683646,"about_ca_system_score_codex":0.00003156793,"about_ca_system_score_gemma":0.00007296746,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W2799715956","doi":"10.1177/247553031016a00101","title":"Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis","year":2010,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Placebo; Clearance; Psoriasis Area and Severity Index; Internal medicine; Clinical trial; Dermatology; Gastroenterology; Urology; Disease; Pathology; Adalimumab","score_opus":0.014393176712024912,"score_gpt":0.25882682536342416,"score_spread":0.24443364865139924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799715956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579746,0.00013583698,0.00001830586,0.00045515085,0.0021106203,0.0006506507,0.00013259787,0.00007972437,0.00061965815],"genre_scores_gemma":[0.99670136,0.00004060511,0.00074762997,0.00032943,0.000079868994,0.00010494629,0.000073094336,0.00004421656,0.00187882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976211,0.0003957282,0.00053159,0.00069128384,0.000086600456,0.0006736556],"domain_scores_gemma":[0.9987133,0.00038432097,0.00013767363,0.0005409359,0.000114281844,0.00010948106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050281285,0.0003665105,0.00057605875,0.00027179436,0.00021791719,0.000042473428,0.00024452232,0.00047958744,0.00024344424],"category_scores_gemma":[0.00030773107,0.00028903646,0.00010783472,0.00028297043,0.00014710611,0.00018080756,0.00015159791,0.00041074192,0.00027756245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014291923,0.0004859891,0.86755663,0.000010425796,0.00024860233,0.0000091778375,0.00023180177,0.000001892932,0.00055869657,0.0001830653,0.0017462871,0.11467553],"study_design_scores_gemma":[0.013349818,0.0008411312,0.9710629,0.000047107613,0.00014565008,0.00001890601,0.00015721112,0.0000031658894,0.0014832973,0.00017541768,0.012251181,0.00046420094],"about_ca_topic_score_codex":0.00010666313,"about_ca_topic_score_gemma":0.0010925474,"teacher_disagreement_score":0.11421133,"about_ca_system_score_codex":0.00003451365,"about_ca_system_score_gemma":0.00008197725,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W2799853540","doi":"10.1177/247553031016a00102","title":"Cellular Interactions in Vitro: Psoriatic Keratinocytes Enhance T Lymphocyte Survival","year":2010,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Université Laval; Institute for Research in Immunology and Cancer; Hôpital du Saint-Sacrement","funders":"","keywords":"Psoriasis; Propidium iodide; Annexin; In vitro; Flow cytometry; Immunology; Keratinocyte; T lymphocyte; Lymphocyte; Immune system; Cancer research; Apoptosis; Medicine; Biology; Programmed cell death","score_opus":0.012557107677879709,"score_gpt":0.25353054351679266,"score_spread":0.24097343583891295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799853540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795054,0.001522264,0.00018698475,0.00043196153,0.014451009,0.00036175715,0.000080473284,0.00016107585,0.0032990563],"genre_scores_gemma":[0.99585325,0.00012020791,0.00048722286,0.000094422794,0.00028179883,0.00017801797,0.00022921496,0.000040886214,0.0027149995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979419,0.00021998094,0.00050126057,0.0005399623,0.00007239344,0.00072448],"domain_scores_gemma":[0.99884963,0.00028946795,0.00017196943,0.00056766736,0.000068497124,0.000052794396],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030280295,0.00036154856,0.00048203804,0.00025338208,0.00028349386,0.000044302058,0.0003451714,0.00026230377,0.0009601306],"category_scores_gemma":[0.00016081205,0.0003371915,0.00021604274,0.00031844436,0.00011480835,0.00024437372,0.00010145165,0.0004301269,0.0017801849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044931943,0.00031696557,0.0046115834,0.000013438178,0.00018045837,0.000015199028,0.00035404883,0.0000023693333,0.898643,0.0007057188,0.00051314686,0.09419476],"study_design_scores_gemma":[0.0028210857,0.00005990896,0.004851388,0.000026568678,0.00011294278,0.000027592667,0.0003435034,0.000028601551,0.9480856,0.0004044789,0.042845152,0.00039315535],"about_ca_topic_score_codex":0.0004736222,"about_ca_topic_score_gemma":0.0018644611,"teacher_disagreement_score":0.0938016,"about_ca_system_score_codex":0.000114429204,"about_ca_system_score_gemma":0.00010249904,"threshold_uncertainty_score":0.99995315},"labels":[],"label_agreement":null},{"id":"W2799912606","doi":"10.1016/j.jid.2018.03.491","title":"484 Mechanisms in residual plaques in patients with an overall good response to biologics","year":2018,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Université de Montréal","funders":"","keywords":"Psoriasis; Medicine; Immune system; Immunology; Pathology","score_opus":0.018623011659019358,"score_gpt":0.24661339805822452,"score_spread":0.22799038639920516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799912606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981634,0.00012922492,0.00004474865,0.0010269348,0.000283272,0.0002152479,0.000030364641,0.000012438186,0.00009438785],"genre_scores_gemma":[0.9960034,0.000008018606,0.0031051545,0.0007610483,0.000026366313,0.000009389597,0.000026342912,0.000014468429,0.00004579236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99716216,0.0015706825,0.00058594055,0.00024226679,0.00006156332,0.00037739694],"domain_scores_gemma":[0.99882865,0.00028659785,0.00036831392,0.00017998066,0.00025795263,0.000078481076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004961622,0.0002263447,0.00054968585,0.00058503455,0.00007385031,0.00001001668,0.0002727363,0.00031026392,0.000063736006],"category_scores_gemma":[0.00038519668,0.00016132015,0.00004316843,0.000277698,0.00043540803,0.00021850434,0.000056742065,0.0002960222,0.0000641066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04590716,0.0015015822,0.58409846,0.000016119044,0.00054050825,0.00085520773,0.009659885,0.000020990818,0.3477751,0.0062957797,0.0013908803,0.0019383043],"study_design_scores_gemma":[0.005428195,0.005564714,0.65190846,0.00008059896,0.000031255262,0.00023553504,0.00033473287,6.1331144e-7,0.33136734,0.0042504654,0.00060582504,0.00019227272],"about_ca_topic_score_codex":0.000038917293,"about_ca_topic_score_gemma":0.00033335705,"teacher_disagreement_score":0.06780997,"about_ca_system_score_codex":0.00010134426,"about_ca_system_score_gemma":0.00023026172,"threshold_uncertainty_score":0.6578445},"labels":[],"label_agreement":null},{"id":"W2799921227","doi":"10.1016/j.jid.2018.03.756","title":"746 Challenges and opportunities for integrating genetics and health records in risk assessment for psoriasis subtypes","year":2018,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Toronto","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Cohort; Receiver operating characteristic; Comorbidity; Genetic testing; Internal medicine; Oncology; Dermatology","score_opus":0.1207133001315487,"score_gpt":0.3320337930184424,"score_spread":0.2113204928868937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799921227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518779,0.034709055,0.0007614296,0.011543861,0.0005705762,0.0003432842,0.0000676104,0.000007954829,0.0001183525],"genre_scores_gemma":[0.95652765,0.02484285,0.01777478,0.0005952905,0.000119082884,0.000051230993,0.00001920115,0.000017807706,0.000052091393],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985619,0.00043715254,0.0005446751,0.00017469314,0.000024732391,0.00025681665],"domain_scores_gemma":[0.9982937,0.0006211354,0.00067469664,0.00007954633,0.00027253557,0.000058390753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007482044,0.00016983984,0.0005550797,0.00022175272,0.00018289204,0.000011399881,0.00008591249,0.00017474481,0.000005540334],"category_scores_gemma":[0.00023152138,0.00013471318,0.000061547325,0.000036202364,0.00056789705,0.00010067029,0.000031248674,0.00016319359,4.9727487e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010305924,0.00027819842,0.045395844,0.0005348527,0.0019510272,0.000039435232,0.026441013,0.0000013153547,0.015293847,0.03396504,0.00909421,0.8659746],"study_design_scores_gemma":[0.025970677,0.016628189,0.35493302,0.0010810407,0.0010769725,0.0048056,0.06127288,0.00032690415,0.31435633,0.11991407,0.09839649,0.001237824],"about_ca_topic_score_codex":0.00002371612,"about_ca_topic_score_gemma":0.0004965265,"teacher_disagreement_score":0.8647368,"about_ca_system_score_codex":0.00004471723,"about_ca_system_score_gemma":0.0002881746,"threshold_uncertainty_score":0.5493444},"labels":[],"label_agreement":null},{"id":"W2800085437","doi":"10.12968/bjcn.2018.23.5.214","title":"Self-care for older people with psoriasis","year":2018,"lang":"en","type":"article","venue":"British Journal of Community Nursing","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Learning Partnership","funders":"","keywords":"Psoriasis; Medicine; Older people; Incidence (geometry); Primary care; Population; Population ageing; Secondary care; Gerontology; Dermatology; Family medicine; Environmental health","score_opus":0.0156134690110039,"score_gpt":0.26134090981096436,"score_spread":0.24572744079996045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800085437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868456,0.0090003805,0.0011775772,0.00014310959,0.0010818763,0.00020072858,0.000036048248,0.000038045247,0.0014766145],"genre_scores_gemma":[0.99570453,0.00019087922,0.0036550015,0.00006301747,0.00021596876,0.000005666645,0.00004410096,0.000024060027,0.00009677606],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988557,0.00047913892,0.00027765209,0.00006865543,0.000047939164,0.00027090608],"domain_scores_gemma":[0.9986797,0.0002452545,0.0002505222,0.00020528657,0.0005836673,0.00003557899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036964592,0.00013276118,0.00034041802,0.00009698706,0.0011306359,0.00005483779,0.00031560723,0.00014491452,0.00009067822],"category_scores_gemma":[0.000050731564,0.00013141916,0.00014484728,0.00013657506,0.00016915592,0.00017337204,0.000021105072,0.0003776609,0.000014880706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009857543,0.0010905077,0.003151751,0.00008303404,0.0008183913,0.000018901486,0.03823778,0.0000012394873,0.0018441522,0.00006293402,0.00768728,0.9460183],"study_design_scores_gemma":[0.03841148,0.011271009,0.5989932,0.0068736468,0.0039961613,0.0354641,0.09853782,0.000004986869,0.0971,0.0015166518,0.106431656,0.0013993273],"about_ca_topic_score_codex":0.00009235312,"about_ca_topic_score_gemma":0.00036982514,"teacher_disagreement_score":0.94461894,"about_ca_system_score_codex":0.000093676725,"about_ca_system_score_gemma":0.000091959664,"threshold_uncertainty_score":0.8696051},"labels":[],"label_agreement":null},{"id":"W2800454763","doi":"10.1016/j.jid.2018.03.1469","title":"1451 Development of a psoriatic immunocompetent organotypic 3D model as a new promising preclinical tool","year":2018,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Psoriasis; Involucrin; Loricrin; Imiquimod; Immunology; STAT1; Cytokine; Medicine; Inflammation; Western blot; Cancer research; Biology; Keratinocyte; Cell culture; Interferon; Gene","score_opus":0.04593572583007566,"score_gpt":0.2904196774678397,"score_spread":0.24448395163776404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800454763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378633,0.0017960385,0.0023100602,0.0007943484,0.00071107096,0.0002472849,0.0000048073725,0.000018550993,0.00033150366],"genre_scores_gemma":[0.9475486,0.000043733904,0.051451087,0.00039374572,0.00009890854,0.000008572346,0.000011924983,0.00002358712,0.00041980634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740684,0.00042844255,0.0014660342,0.00023578876,0.00009729702,0.00036558017],"domain_scores_gemma":[0.99763435,0.000301752,0.0012299136,0.00023710827,0.0004887781,0.00010808556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039710768,0.00027475285,0.00087444717,0.0002445828,0.00017950844,0.000010891609,0.00036599595,0.000339187,0.00025333534],"category_scores_gemma":[0.00096553063,0.00021481042,0.0001872855,0.00020808486,0.0007431731,0.00016369324,0.00010759687,0.0003337595,0.00024658657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014800184,0.00056183856,0.0024447632,0.00008079047,0.0030232393,0.00006493876,0.015728755,0.000030144065,0.93950844,0.0022740823,0.0041454313,0.030657547],"study_design_scores_gemma":[0.0041948063,0.0005911467,0.0043365676,0.00022289572,0.00034205228,0.001689979,0.0002340844,0.00006835641,0.9797111,0.005199482,0.003163437,0.0002460523],"about_ca_topic_score_codex":0.00000929971,"about_ca_topic_score_gemma":0.000012250264,"teacher_disagreement_score":0.049141027,"about_ca_system_score_codex":0.000089244306,"about_ca_system_score_gemma":0.0029838253,"threshold_uncertainty_score":0.8759715},"labels":[],"label_agreement":null},{"id":"W2800609435","doi":"10.1111/bjd.16737","title":"Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2018,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Psoriasis; Medicine; Cross-sectional study; Socioeconomic status; Correlation; Internal medicine; Dermatology; Environmental health; Pathology; Population","score_opus":0.014122502836669474,"score_gpt":0.2676546408851366,"score_spread":0.2535321380484671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800609435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479014,0.0015855216,0.0001612121,0.0016772592,0.00082712603,0.00024529747,0.0006175674,0.0000048509773,0.00009102346],"genre_scores_gemma":[0.9972827,0.00080607017,0.00013011268,0.0008847551,0.00016733095,0.000017072562,0.0006323574,0.00002233562,0.000057263544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99672323,0.0011162573,0.0012237921,0.00037163135,0.00017436262,0.00039074113],"domain_scores_gemma":[0.9956277,0.0008061306,0.0027716176,0.0002769229,0.0004927362,0.000024915862],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004833076,0.00031271947,0.0015130359,0.00069562986,0.00016806964,0.000046927857,0.00035208248,0.0011038623,0.0002611743],"category_scores_gemma":[0.00007608304,0.00026750445,0.0004543021,0.00029987574,0.0006700616,0.0002137017,0.0000569775,0.0011500398,0.0000034652724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009461293,0.00034712028,0.97447824,0.000074451294,0.006964397,0.00031515775,0.00019613522,0.000026961916,0.00003283385,0.000003513729,0.014305759,0.0023093203],"study_design_scores_gemma":[0.0054898853,0.0003747587,0.98538405,0.00008137179,0.0028215612,0.0031909859,0.000070803544,0.00001068048,0.00013264736,0.000024533321,0.0022094257,0.00020932732],"about_ca_topic_score_codex":0.00026260215,"about_ca_topic_score_gemma":0.000333627,"teacher_disagreement_score":0.012096333,"about_ca_system_score_codex":0.0001602341,"about_ca_system_score_gemma":0.0003758858,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W2801085776","doi":"10.1111/bjd.16724","title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Merck","keywords":"Medicine; Placebo; Adverse effect; Tolerability; Internal medicine; Etanercept; Psoriasis; Gastroenterology; Dermatology; Tumor necrosis factor alpha","score_opus":0.019734505675629236,"score_gpt":0.27073648183936555,"score_spread":0.2510019761637363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801085776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952534,0.019477936,0.022389382,0.0006340108,0.0017243521,0.002140534,0.000671064,0.000019880315,0.00040883286],"genre_scores_gemma":[0.99744743,0.0007978264,0.0012355993,0.000094169176,0.0001044702,0.000082537736,0.00008055248,0.000021448777,0.00013596092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930546,0.0025031636,0.003695977,0.00025748138,0.00010332845,0.00038543178],"domain_scores_gemma":[0.9904863,0.0049538957,0.0030851758,0.00024240752,0.0011685656,0.00006365442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031006988,0.00028106192,0.008952769,0.00085824454,0.00015543748,0.000018071936,0.000384449,0.0004753566,0.0005507606],"category_scores_gemma":[0.0038302578,0.00022813096,0.0028952572,0.00044139044,0.000378451,0.0001069049,0.000045973145,0.0001638045,0.00001224056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8473964,0.00053606543,0.0006641715,0.000047528403,0.10321146,0.00011885798,0.00042090306,0.0001151505,0.012173931,0.00094950094,0.0028936109,0.031472415],"study_design_scores_gemma":[0.8494012,0.00069784984,0.001981644,0.0003047904,0.059369896,0.006658809,0.00018416671,0.00017369125,0.07862711,0.001519587,0.0007057241,0.00037556692],"about_ca_topic_score_codex":0.00009502426,"about_ca_topic_score_gemma":0.00036468523,"teacher_disagreement_score":0.066453174,"about_ca_system_score_codex":0.000034078217,"about_ca_system_score_gemma":0.00028716918,"threshold_uncertainty_score":0.930291},"labels":[],"label_agreement":null},{"id":"W2801086913","doi":"10.1177/247553030713a00101","title":"Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial","year":2007,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Abbott (Canada); Probity Medical Research","funders":"Astellas Pharma","keywords":"Adalimumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Internal medicine; Randomized controlled trial; Clinical trial; Gastroenterology; Tumor necrosis factor alpha; Dermatology; Pathology","score_opus":0.03118195997106565,"score_gpt":0.3004633896999236,"score_spread":0.26928142972885794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801086913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916905,0.000567147,0.00023217438,0.00016971101,0.0014833111,0.005179312,0.00007867395,0.00005701646,0.00054216373],"genre_scores_gemma":[0.99827564,0.00020084843,0.00039258096,0.000076678305,0.00011308788,0.0002976954,0.00019665319,0.000043239637,0.00040354885],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99624646,0.00066637655,0.0014664223,0.0007277265,0.0001319864,0.0007610022],"domain_scores_gemma":[0.9976333,0.001182672,0.00040766035,0.00051273964,0.00013827093,0.00012537705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018755546,0.0005009352,0.0017321497,0.00036599324,0.00016823223,0.000020685222,0.00020442212,0.0004804943,0.00007466198],"category_scores_gemma":[0.00018374826,0.00034785242,0.00032849514,0.00037072855,0.00021301289,0.00012821793,0.00009175461,0.00018277713,0.000060126313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88780046,0.0023287022,0.019575568,0.000011005079,0.0013092795,0.0000063679563,0.0006182828,0.000018771187,0.000023294673,0.00028754384,0.000053914187,0.08796679],"study_design_scores_gemma":[0.9694693,0.0039978693,0.022219177,0.00009154276,0.00074619014,0.000004950715,0.0001809402,0.000002218288,0.0016709523,0.000066269764,0.0011624687,0.00038811474],"about_ca_topic_score_codex":0.0002947405,"about_ca_topic_score_gemma":0.0006168234,"teacher_disagreement_score":0.08757868,"about_ca_system_score_codex":0.00013468064,"about_ca_system_score_gemma":0.00012434175,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W2801390262","doi":"10.1177/1203475418773358","title":"Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Western University; University of Ottawa","funders":"","keywords":"Medicine; Tolerability; Dapsone; Psoriasis; Intensive care medicine; Context (archaeology); Clinical trial; Dermatology; MEDLINE; Adverse effect; Pharmacology; Internal medicine","score_opus":0.06155177064718131,"score_gpt":0.32111777054952445,"score_spread":0.25956599990234314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801390262","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011184122,0.9947178,0.00002982779,0.00010345173,0.002666068,0.0022673847,0.000057604102,0.000022571467,0.000023473773],"genre_scores_gemma":[0.000010464908,0.9964409,0.00004275637,0.00031053604,0.00074143463,0.00025603373,0.00016050464,0.0000777283,0.0019596433],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99492526,0.0011530196,0.0029955427,0.0003629176,0.00014456011,0.00041870147],"domain_scores_gemma":[0.9929673,0.0027523828,0.0033881026,0.0004568943,0.00033630498,0.00009900126],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001736593,0.00072856795,0.009004948,0.0005690749,0.00015682944,0.000015785521,0.00027886784,0.000553359,0.00011914374],"category_scores_gemma":[0.00071414403,0.00039575482,0.0017078061,0.00023696644,0.0001437706,0.0000611826,0.00001896144,0.00022744328,0.000041653886],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021764585,0.00011728474,0.000003420418,0.7759664,0.013812773,0.00051485637,0.0001495143,1.7879254e-8,0.000015011504,0.00000947447,0.048434407,0.16075918],"study_design_scores_gemma":[0.00097496895,0.0005203173,6.103411e-8,0.5630354,0.046643764,0.037480794,0.000040140792,9.673559e-8,0.0000036337794,0.000016525464,0.35103062,0.00025366494],"about_ca_topic_score_codex":0.0000077467585,"about_ca_topic_score_gemma":8.773826e-7,"teacher_disagreement_score":0.3025962,"about_ca_system_score_codex":0.00014118395,"about_ca_system_score_gemma":0.0003657571,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W2801529820","doi":"10.1002/bdd.2130","title":"Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Biopharmaceutics & Drug Disposition","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Astellas Pharma; Kyowa Hakko Kirin","keywords":"Medicine; Pharmacokinetics; Tolerability; Placebo; Psoriasis Area and Severity Index; Area under the curve; Psoriasis; Adverse effect; Body surface area; Gastroenterology; Randomized controlled trial; Internal medicine; Urology; Pharmacology; Anesthesia; Immunology; Pathology","score_opus":0.010222988467584949,"score_gpt":0.25964608578225473,"score_spread":0.24942309731466977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801529820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450874,0.0006112706,0.000064129395,0.000085741405,0.00051056256,0.003838256,0.00014202138,0.000037695227,0.00020155117],"genre_scores_gemma":[0.9989069,0.00025209435,0.000083822044,0.00010643652,0.000053178126,0.00023084912,0.00016430448,0.0000287309,0.00017368466],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976778,0.0007786948,0.00066210434,0.000421458,0.00011634629,0.00034358684],"domain_scores_gemma":[0.9989533,0.00025960113,0.00025755435,0.00021850332,0.00024833242,0.0000627236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054173777,0.00034256213,0.0010663172,0.00027939954,0.00018378384,0.000021218724,0.0001423719,0.00013352877,0.00011148633],"category_scores_gemma":[0.000027618069,0.00025434015,0.00009666571,0.0002657833,0.00020028919,0.000109230394,0.00007125101,0.00014935333,0.000035866367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9492958,0.0031651643,0.026011955,0.000038844733,0.0017117977,0.000006650526,0.004435595,0.000119719756,0.008594361,0.0000785159,0.00009852991,0.006443075],"study_design_scores_gemma":[0.93694377,0.00093819515,0.028080823,0.0000927218,0.0018576706,0.000004864107,0.00047411176,0.00024370535,0.030761857,0.000025112544,0.00017521721,0.00040195553],"about_ca_topic_score_codex":0.000085321284,"about_ca_topic_score_gemma":0.00007543986,"teacher_disagreement_score":0.022167496,"about_ca_system_score_codex":0.00006690053,"about_ca_system_score_gemma":0.00003776896,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W2801709914","doi":"10.1177/247553030915a00201","title":"Clinical Experience with Alefacept in Canadian Patients with Psoriasis: The Amevive Wisdom Acquired from Real-world Evidence (AWARE) Study","year":2009,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovaderm (Canada); University of Toronto; University of Alberta; Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Concomitant; Plaque psoriasis; Observational study; Dermatology; Surgery; Internal medicine","score_opus":0.026658838515447834,"score_gpt":0.29420404816087237,"score_spread":0.26754520964542455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801709914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948028,0.00079855265,0.000013100109,0.00083641807,0.0012038264,0.0016790718,0.000118511976,0.000093144576,0.00045462078],"genre_scores_gemma":[0.99814516,0.00021586979,0.00008140258,0.000573393,0.00012460991,0.00020422215,0.00012937181,0.00003951279,0.00048645886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585956,0.0008478872,0.00079266547,0.0010538234,0.00021249257,0.001233576],"domain_scores_gemma":[0.9975719,0.0005888203,0.00033310533,0.0011411044,0.00017124414,0.00019382048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005477356,0.0005681336,0.00079295476,0.00028323213,0.0005310005,0.00006688916,0.00083844806,0.0002690217,0.00031532842],"category_scores_gemma":[0.00014296302,0.00034862568,0.00015125111,0.0007875906,0.00036960936,0.00042818167,0.000077531375,0.00031908797,0.00022395038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020975305,0.0008613539,0.9525002,0.000002107879,0.00036818796,0.00004690391,0.0053390805,0.000007665004,0.00003169333,0.000043389864,0.00068432855,0.03801753],"study_design_scores_gemma":[0.0067381915,0.0021739525,0.98032236,0.0002223623,0.00034387785,0.0000030732588,0.0067345253,0.0000030010776,0.00033305318,0.00005382054,0.0025783747,0.0004934013],"about_ca_topic_score_codex":0.211883,"about_ca_topic_score_gemma":0.7193323,"teacher_disagreement_score":0.50744927,"about_ca_system_score_codex":0.00030786157,"about_ca_system_score_gemma":0.00040847977,"threshold_uncertainty_score":0.9998966},"labels":[],"label_agreement":null},{"id":"W2802069820","doi":"10.1177/247553030713a00203","title":"Relapse Rate and Duration of Therapeutic Effect of Oral Psoralen plus Ultraviolet a (PUVA) in the Treatment of Plaque-type Psoriasis: Original Data Utilizing Standardized Measures of Effect Duration","year":2007,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; PUVA therapy; Psoriasis; Placebo; Therapeutic effect; Psoralen; Dermatology; Internal medicine; Surgery","score_opus":0.03936084138978593,"score_gpt":0.30366902667587076,"score_spread":0.2643081852860848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802069820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990459,0.007118104,0.00018970508,0.000056988345,0.0006097452,0.0011882235,0.0002743365,0.000018992578,0.00008486517],"genre_scores_gemma":[0.99779284,0.0016377578,0.00011460352,0.000008320072,0.000027543992,0.000039427454,0.00033607316,0.000021985192,0.000021454258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966419,0.001409149,0.000997908,0.00040416847,0.00017001103,0.0003769142],"domain_scores_gemma":[0.99720925,0.0012004981,0.00071532815,0.0007154325,0.0001356278,0.000023874796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031306942,0.00035942465,0.0010474839,0.0002794783,0.000100321864,0.000009027036,0.00032702935,0.00029030294,0.000023071269],"category_scores_gemma":[0.00021206592,0.0002285747,0.00017465383,0.00042347278,0.0002494598,0.00019206069,0.00003713024,0.00011211375,0.0000032567846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041039106,0.00074854016,0.15961386,0.0003902912,0.0019240996,0.000011630397,0.0036641303,0.000018456487,0.5958413,0.000559251,0.000109337445,0.19608001],"study_design_scores_gemma":[0.017415332,0.008183611,0.060296968,0.00023229363,0.0016941464,0.000026407548,0.00084907986,0.00002780129,0.90957236,0.00010068024,0.001369556,0.00023173456],"about_ca_topic_score_codex":0.0005210795,"about_ca_topic_score_gemma":0.00055640127,"teacher_disagreement_score":0.3137311,"about_ca_system_score_codex":0.000088251305,"about_ca_system_score_gemma":0.00010117305,"threshold_uncertainty_score":0.9321006},"labels":[],"label_agreement":null},{"id":"W2802424903","doi":"10.1007/s10620-018-5096-2","title":"Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease","year":2018,"lang":"en","type":"article","venue":"Digestive Diseases and Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Infliximab; Internal medicine; Inflammatory bowel disease; Crohn's disease; Hepatology; Ulcerative colitis; Gastroenterology; Incidence (geometry); Disease; Dermatology","score_opus":0.014354829197009552,"score_gpt":0.2271851495927344,"score_spread":0.21283032039572483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802424903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769574,0.0010169351,0.0000020768657,0.00006993152,0.00012825849,0.00037866842,0.0006278721,0.000046485253,0.000034038952],"genre_scores_gemma":[0.99961275,0.00005429139,0.000007901404,0.00014156863,0.000023167813,0.000041170988,0.00006398374,0.000014265778,0.00004087878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843025,0.00012186066,0.00020735417,0.0006420579,0.00013827755,0.0004601801],"domain_scores_gemma":[0.99917763,0.00016810806,0.00016393389,0.00015956993,0.00011653708,0.00021423021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008428061,0.00030721238,0.00027321442,0.00018379146,0.0007404293,0.00012023305,0.00015189002,0.000054398777,0.000042676165],"category_scores_gemma":[0.00016818533,0.00020577495,0.00004665859,0.00029551482,0.00090322417,0.00038590073,0.00008300694,0.000078463214,0.0000058022724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008316773,0.00025381224,0.9963113,0.000017810009,0.000109248256,0.000046968253,0.00048822333,0.0000018885282,0.00008167355,0.000027906768,0.000018851053,0.0018106358],"study_design_scores_gemma":[0.0023769184,0.00039264144,0.99599886,0.00020134887,0.00020813328,5.315206e-7,0.00021688172,0.000016650923,0.00019910902,0.000041420117,0.000018965029,0.0003285174],"about_ca_topic_score_codex":0.0000707058,"about_ca_topic_score_gemma":0.000019658879,"teacher_disagreement_score":0.0019170382,"about_ca_system_score_codex":0.000044935976,"about_ca_system_score_gemma":0.00017267637,"threshold_uncertainty_score":0.83912593},"labels":[],"label_agreement":null},{"id":"W2802689151","doi":"10.1016/j.jaad.2018.04.043","title":"Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Women's College Hospital; University of Toronto","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Randomized controlled trial; Combination therapy; Dermatology; Internal medicine; Clinical trial; Psoriatic arthritis","score_opus":0.020726983020248026,"score_gpt":0.2901064354930756,"score_spread":0.2693794524728276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802689151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954723,0.002045928,0.00016968635,0.0012921314,0.00017140612,0.0007769406,0.00006198188,0.0000036348204,0.0000060050224],"genre_scores_gemma":[0.99846596,0.00111629,0.0002025199,0.00008915236,0.000021635838,0.00004322001,7.7618006e-7,0.00001698196,0.000043442702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980691,0.0008167596,0.0006899137,0.00014258709,0.0000937218,0.00018790129],"domain_scores_gemma":[0.9965802,0.0006629923,0.0022468618,0.00022977285,0.00026577027,0.000014420398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002737734,0.00018857443,0.00091302407,0.00014983727,0.000064511725,0.0000019366207,0.00039017297,0.00008927677,0.000018214563],"category_scores_gemma":[0.000029483606,0.00009271787,0.00027168784,0.00023071743,0.0012356997,0.00004554676,0.000017737571,0.0001186985,9.1474635e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2424636,0.005610743,0.48217118,0.00002547188,0.009127619,0.000003813633,0.016486367,0.000015702359,0.23300096,0.0001697401,0.00026364345,0.0106611615],"study_design_scores_gemma":[0.016671697,0.009732428,0.6665892,0.00007116841,0.0005250159,0.0001276681,0.0031567146,0.0000122381125,0.30193937,0.000108556495,0.0009717652,0.00009416081],"about_ca_topic_score_codex":0.000039141054,"about_ca_topic_score_gemma":0.00001212791,"teacher_disagreement_score":0.2257919,"about_ca_system_score_codex":0.000060237326,"about_ca_system_score_gemma":0.00007731672,"threshold_uncertainty_score":0.4552987},"labels":[],"label_agreement":null},{"id":"W2802931074","doi":"10.1111/bjd.16736","title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Dermatology; Secukinumab; Pathology; Psoriatic arthritis","score_opus":0.012094035804152687,"score_gpt":0.2528384543173931,"score_spread":0.2407444185132404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802931074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529,0.00211039,0.000120911856,0.000044410415,0.00033928346,0.0018894803,0.000056039364,0.0000073142387,0.00014217371],"genre_scores_gemma":[0.99954444,0.00014895957,0.00014772319,0.000019322664,0.000027466433,0.000043503438,0.000017735874,0.000019443727,0.00003138731],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99698234,0.0009197131,0.0014163782,0.00025133102,0.00010609585,0.00032412767],"domain_scores_gemma":[0.99783325,0.0005613726,0.00087705045,0.00016606598,0.00050084264,0.000061445884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043738715,0.00024293356,0.0021992084,0.00042564332,0.000116735886,0.000014954795,0.00021674042,0.00023194324,0.00009858483],"category_scores_gemma":[0.00018995533,0.00020344814,0.00016944949,0.00022311049,0.00032891505,0.00014852578,0.00006510103,0.000224359,0.000006293742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9615956,0.0042580264,0.008766706,0.000019160352,0.0023463876,0.00032598956,0.0017566698,0.000015953496,0.00020916079,0.000018659772,0.00009383186,0.020593854],"study_design_scores_gemma":[0.976483,0.0024621657,0.012514741,0.0001503422,0.00085179735,0.004493492,0.0004996541,0.0000054513357,0.0022890556,0.000023162895,0.00003553081,0.00019160469],"about_ca_topic_score_codex":0.00013729498,"about_ca_topic_score_gemma":0.00034735634,"teacher_disagreement_score":0.02040225,"about_ca_system_score_codex":0.000027802507,"about_ca_system_score_gemma":0.00013838153,"threshold_uncertainty_score":0.82963747},"labels":[],"label_agreement":null},{"id":"W2803625437","doi":"10.1016/j.jaad.2018.05.032","title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Secukinumab; Psoriatic arthritis","score_opus":0.017638281568883377,"score_gpt":0.26490242844874773,"score_spread":0.24726414687986437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803625437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948281,0.0013259507,0.000025478774,0.0029461326,0.000300551,0.00028773578,0.00015813757,0.0000053666217,0.00012253267],"genre_scores_gemma":[0.9989626,0.00045587023,0.00027189904,0.00012084353,0.000090307396,0.000005370669,0.0000021162189,0.000015776373,0.00007520611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977832,0.00065686705,0.0009506982,0.0002094318,0.000127678,0.0002721474],"domain_scores_gemma":[0.9958435,0.0006208861,0.00297561,0.0003785502,0.0001572518,0.000024149054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018799416,0.00022909134,0.0010671968,0.00009286203,0.00010378815,0.0000028653674,0.0007407058,0.000121300756,0.000022410195],"category_scores_gemma":[0.00009607752,0.000108481494,0.00027860157,0.00034906095,0.0017236293,0.00006443569,0.00007352902,0.00022521433,0.000012780501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11298516,0.006444005,0.640187,0.000043159296,0.019874265,0.000086626365,0.020813404,0.00011039451,0.056547895,0.00071482226,0.010996103,0.13119712],"study_design_scores_gemma":[0.0140138995,0.0058905445,0.800362,0.00017095056,0.0012728422,0.0008486259,0.004370655,0.0000029538148,0.16626412,0.00034266934,0.0062736487,0.00018709664],"about_ca_topic_score_codex":0.0004980344,"about_ca_topic_score_gemma":0.000117665295,"teacher_disagreement_score":0.16017495,"about_ca_system_score_codex":0.00004748542,"about_ca_system_score_gemma":0.00013154163,"threshold_uncertainty_score":0.6350784},"labels":[],"label_agreement":null},{"id":"W2803974737","doi":"10.1093/ibd/izy142","title":"Reversing Ongoing Chronic Intestinal Inflammation and Fibrosis by Sustained Block of IL-12 and IL-23 Using a Vaccine in Mice","year":2018,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Children's Hospital Research Institute of Manitoba","keywords":"Medicine; Interleukin 23; Inflammation; Reversing; Fibrosis; Immunology; Interleukin 17; Internal medicine","score_opus":0.008662123952687045,"score_gpt":0.22396209679940532,"score_spread":0.21529997284671828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803974737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951552,0.004223425,0.000015746196,0.00004154419,0.00011108019,0.00026219946,0.00010288922,0.00004360096,0.000044295328],"genre_scores_gemma":[0.99944276,0.00012823338,0.00011709409,0.000009771605,0.00008347096,0.000012388792,0.000068246816,0.000017890527,0.00012014894],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988542,0.0001537756,0.00036469183,0.0002939935,0.00004166782,0.00029167862],"domain_scores_gemma":[0.99936223,0.00015714909,0.00019648363,0.00015480728,0.00008109228,0.000048239275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011865581,0.00021357893,0.0002654399,0.00019269828,0.00019806175,0.000020518977,0.000082894054,0.00013429408,0.000046447236],"category_scores_gemma":[0.00013546094,0.00021164589,0.000047628626,0.000114880364,0.00020589847,0.00023754539,0.00009424112,0.000078480305,0.000011139877],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090655306,0.00006566235,0.30307573,0.00033034323,0.00014960874,0.000023688937,0.0006975454,0.000008309295,0.68739724,0.00003256839,0.00033474594,0.0069779903],"study_design_scores_gemma":[0.0068898387,0.0005555394,0.7747552,0.0010921924,0.00060257735,0.00010522649,0.001077535,0.00032239358,0.21239527,0.00012180013,0.0014948242,0.0005876135],"about_ca_topic_score_codex":0.000085076324,"about_ca_topic_score_gemma":0.00017093115,"teacher_disagreement_score":0.47500196,"about_ca_system_score_codex":0.00011134671,"about_ca_system_score_gemma":0.00010364134,"threshold_uncertainty_score":0.8630669},"labels":[],"label_agreement":null},{"id":"W2804131537","doi":"10.1111/bjd.16798","title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Plaque psoriasis; Psoriasis; Open label; Dermatology; Term (time); Extension (predicate logic); Internal medicine; Adverse effect; Computer science","score_opus":0.019806568419189007,"score_gpt":0.27153936439104526,"score_spread":0.25173279597185627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804131537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691087,0.0017465247,0.00003007427,0.00009552632,0.00036452085,0.0007706535,0.00003744809,0.000010714589,0.00003364261],"genre_scores_gemma":[0.99946445,0.00018390088,0.000098733144,0.00010029668,0.00003564768,0.0000139927815,0.000052836836,0.000024389965,0.000025775424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775964,0.0006541376,0.0007107479,0.00038389247,0.000065020904,0.00042654722],"domain_scores_gemma":[0.99913657,0.000093518036,0.0002678279,0.00020616363,0.00021819478,0.00007774584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023384712,0.00022581415,0.0007520859,0.00027799944,0.00017614433,0.00006670159,0.00036940165,0.00023684549,0.00008709103],"category_scores_gemma":[0.00005067897,0.00021586157,0.00002279697,0.00021676032,0.00014121927,0.00042076033,0.00015526364,0.00031623596,0.000025847221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012613263,0.005327946,0.88171905,0.0000134255015,0.00024232393,0.0024326802,0.00085087155,0.000009025273,0.00048162753,0.000010297124,0.00012891128,0.09617055],"study_design_scores_gemma":[0.053914137,0.0038860396,0.93266606,0.00033056294,0.000080558864,0.008112288,0.00011293228,0.0000022705121,0.00058402336,0.000010553286,0.000060691873,0.00023986535],"about_ca_topic_score_codex":0.000106477106,"about_ca_topic_score_gemma":0.004158133,"teacher_disagreement_score":0.09593068,"about_ca_system_score_codex":0.00009405522,"about_ca_system_score_gemma":0.00016404015,"threshold_uncertainty_score":0.8802579},"labels":[],"label_agreement":null},{"id":"W2804368428","doi":"10.1177/1203475418773736","title":"Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Western University; SKiN Health; Queen's University; Guenther Dermatology Research Centre; Dermatrials Research","funders":"LEO Pharma; Valeant Pharmaceuticals International","keywords":"Psoriasis; Medicine; Dermatology; Modalities; Topical agents; Family medicine","score_opus":0.023288230978822707,"score_gpt":0.2288084198630532,"score_spread":0.2055201888842305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804368428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877807,0.0084587345,0.0000019584195,0.0010350248,0.0018736249,0.00007976514,0.000012720171,0.0000035752014,0.00075391337],"genre_scores_gemma":[0.9980785,0.00089669885,0.000007538092,0.0003624799,0.00047446508,0.0000016095845,0.000033392756,0.000005920861,0.00013939485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986386,0.0005511545,0.00041799253,0.00012293705,0.00007019922,0.00019913304],"domain_scores_gemma":[0.9983664,0.0010918487,0.00016540488,0.000116608295,0.00019362733,0.00006608267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003164404,0.00012624063,0.00039548025,0.00017042612,0.00013072968,0.0000093332,0.00012253491,0.00014205537,0.00024549424],"category_scores_gemma":[0.00035649256,0.00006389145,0.000060529135,0.00012519209,0.00019614179,0.000051770712,0.000013789265,0.00017702032,0.000016480262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020575948,0.000053992135,0.7963508,0.0000065608774,0.00019564758,0.0002113468,0.0054052225,1.07393625e-7,0.00031446596,0.000016521522,0.011040576,0.18619904],"study_design_scores_gemma":[0.0015939451,0.0009993071,0.91337377,0.00031550752,0.0002119833,0.00036679866,0.0023966753,4.7227505e-7,0.00094334915,0.00042515906,0.07917821,0.00019481567],"about_ca_topic_score_codex":0.030311432,"about_ca_topic_score_gemma":0.10652167,"teacher_disagreement_score":0.18600422,"about_ca_system_score_codex":0.00005796881,"about_ca_system_score_gemma":0.00026206922,"threshold_uncertainty_score":0.9761458},"labels":[],"label_agreement":null},{"id":"W2804416203","doi":"10.1186/s12967-018-1441-7","title":"Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice","year":2018,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Tianjin Medical University; National Natural Science Foundation of China","keywords":"Colitis; Medicine; Ulcerative colitis; Inflammatory bowel disease; Immune system; Inflammation; Pathogenesis; Immunology; Cytokine; Interleukin; Oral administration; Pharmacology; Internal medicine; Disease","score_opus":0.031161371243777478,"score_gpt":0.29357060324968476,"score_spread":0.26240923200590727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804416203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698676,0.009368721,0.00016621444,0.001326742,0.0012027558,0.00009251023,0.000019977546,0.000008260763,0.000828073],"genre_scores_gemma":[0.99786067,0.00007321106,0.0011958613,0.00018069096,0.0004498607,0.0000038845255,0.000032062635,0.000010585967,0.00019318421],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892676,0.00017047544,0.00050267467,0.00011682075,0.00009555699,0.00018772007],"domain_scores_gemma":[0.9993843,0.00017317658,0.0002154868,0.000060030194,0.00013030403,0.000036723246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034815606,0.00013686396,0.0003373737,0.00019374087,0.000094470306,0.0000056521876,0.00012345279,0.000120124016,0.0010897416],"category_scores_gemma":[0.00003845767,0.00010282061,0.000069308924,0.00017862991,0.00026452303,0.00016594063,0.0000070868587,0.00015669817,0.00003172607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012928873,0.00020783884,0.0054234737,0.0000075264875,0.0001740587,0.000036565438,0.0024096067,0.000005584751,0.98265946,0.00019359787,0.0015826441,0.0060067386],"study_design_scores_gemma":[0.015538245,0.0022971982,0.15568095,0.000566145,0.0002599859,0.0004045544,0.0015326441,0.00002522888,0.7970201,0.00072802167,0.025662124,0.00028484204],"about_ca_topic_score_codex":0.00004840929,"about_ca_topic_score_gemma":0.000029865601,"teacher_disagreement_score":0.18563941,"about_ca_system_score_codex":0.000037901253,"about_ca_system_score_gemma":0.00009114682,"threshold_uncertainty_score":0.9998234},"labels":[],"label_agreement":null},{"id":"W2805967746","doi":"10.14715/cmb/2018.64.6.16","title":"Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with colorectal cancer: a meta-analysis","year":2018,"lang":"en","type":"article","venue":"Cellular and Molecular Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Colorectal cancer; Medicine; Meta-analysis; Cytokine; Internal medicine; Interleukin 17; Cochrane Library; Oncology; Immunology; Cancer","score_opus":0.013181180951128276,"score_gpt":0.23171579173894022,"score_spread":0.21853461078781194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805967746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894931,0.009427349,0.00017790742,0.000042859796,0.00011967123,0.0002503295,0.00035442607,0.000013359102,0.00012099974],"genre_scores_gemma":[0.9993677,0.000083387305,0.00011857703,0.00004816376,0.0000065921954,0.000028840466,0.0001510465,0.000013684169,0.00018197372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869525,0.00029799607,0.0002711276,0.00041971754,0.000026476173,0.00028941056],"domain_scores_gemma":[0.99953014,0.000036205045,0.00013662897,0.00018016734,0.0000875421,0.000029333887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012798219,0.00024250323,0.0007966758,0.00018984923,0.00007841694,0.000006204541,0.00009827221,0.0002935597,0.00038321022],"category_scores_gemma":[0.000007095329,0.0001666181,0.00020238478,0.00029061423,0.0004888759,0.000028177668,0.00006887507,0.000088923705,0.0000048426655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042187693,0.00016185932,0.12753107,0.000013424508,0.04908821,0.000011056356,0.00050449965,0.000007716305,0.82001334,0.00026610773,0.000008805156,0.0019720534],"study_design_scores_gemma":[0.003577607,0.0012548431,0.12465174,0.0000048320135,0.035160966,0.000004849723,0.000055566616,0.000011893287,0.8344922,0.00014117488,0.00031622464,0.00032808658],"about_ca_topic_score_codex":0.00021473668,"about_ca_topic_score_gemma":0.00018627611,"teacher_disagreement_score":0.014478898,"about_ca_system_score_codex":0.000013093179,"about_ca_system_score_gemma":0.000030205054,"threshold_uncertainty_score":0.6794489},"labels":[],"label_agreement":null},{"id":"W2806179665","doi":"10.2217/ebo.11.123","title":"Comorbidities of psoriasis: data and implications","year":2011,"lang":"en","type":"other","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Epidemiology; Medicine; Dermatology; Population; Family medicine; Skin cancer; MEDLINE; Cohort study; Cancer; Internal medicine","score_opus":0.0579596610106285,"score_gpt":0.27166768085545373,"score_spread":0.21370801984482524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806179665","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027838876,0.032194518,0.0000691341,0.000049708065,0.0006298248,0.00023268328,0.0046574897,0.00013959376,0.96174866],"genre_scores_gemma":[0.0062254095,0.005565163,0.00051981903,0.000029150811,0.00006539875,0.00002627663,0.0037190448,0.0001241013,0.9837256],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99939555,0.00005078099,0.000148777,0.00027168394,0.000010342724,0.00012285211],"domain_scores_gemma":[0.99893,0.00004417624,0.00013880436,0.0008626074,0.000013673435,0.000010789074],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005466377,0.00016234655,0.00029792,0.00012160842,0.00003268287,0.000002842386,0.00033765993,0.00033236848,0.0113361655],"category_scores_gemma":[0.000010096953,0.00012804235,0.00003143749,0.000040016683,0.00017171512,0.000022734272,0.00018426921,0.000055730252,0.0003548112],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000131254055,0.00007270841,0.0009772418,0.00003463448,0.0007237731,3.9609515e-7,0.00007062783,7.1199635e-10,0.00058424374,0.0043534217,0.96483445,0.028335398],"study_design_scores_gemma":[0.0005394605,0.00004138983,0.0026984315,0.000045446624,0.0003883473,0.000015896772,0.00008565773,3.141471e-8,0.0015575018,0.00019139035,0.99428004,0.0001564004],"about_ca_topic_score_codex":0.0008745795,"about_ca_topic_score_gemma":0.00044802277,"teacher_disagreement_score":0.029445618,"about_ca_system_score_codex":0.0000031614318,"about_ca_system_score_gemma":0.00002953222,"threshold_uncertainty_score":0.9895676},"labels":[],"label_agreement":null},{"id":"W2807342171","doi":"10.1002/cpdd.471","title":"Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis","year":2018,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Pfizer","keywords":"Janus kinase inhibitor; Medicine; Tofacitinib; Dosing; Pharmacokinetics; Psoriasis; Volume of distribution; Renal function; Plaque psoriasis; Internal medicine; Body surface area; Creatinine; Body mass index; Clearance; Gastroenterology; Pharmacology; Urology; Immunology; Rheumatoid arthritis","score_opus":0.01935625667845373,"score_gpt":0.303296412492652,"score_spread":0.28394015581419824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807342171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954042,0.0000842966,0.000021454418,0.0003082769,0.0028826657,0.0008766422,0.00011489174,0.000035150668,0.0002724615],"genre_scores_gemma":[0.99705946,0.00014842558,0.0005710374,0.0010527687,0.00016991312,0.00023595295,0.00024958182,0.000029457595,0.00048337207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968182,0.0005152404,0.0013242615,0.00063175533,0.000080713115,0.0006298683],"domain_scores_gemma":[0.99872655,0.00041116547,0.00029427084,0.00020459338,0.00027225818,0.000091168076],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054698973,0.00035036035,0.00078919565,0.00028500828,0.00008922514,0.0000056797844,0.0003568054,0.00028790248,0.0012111891],"category_scores_gemma":[0.00008316787,0.00030097048,0.00007168879,0.0003781854,0.00031996449,0.000073250194,0.00017271563,0.00039452044,0.00051527156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011202115,0.0035670435,0.7893414,0.00009901635,0.0009792335,0.00006709058,0.0032495137,0.000049267393,0.0053584855,0.000023148807,0.0073794373,0.17868423],"study_design_scores_gemma":[0.024306921,0.0006216537,0.8790224,0.00016285578,0.00014713372,0.000005593285,0.00004895711,0.00001932559,0.078166835,0.000013153161,0.016955554,0.00052957254],"about_ca_topic_score_codex":0.000029745748,"about_ca_topic_score_gemma":0.00020678251,"teacher_disagreement_score":0.17815466,"about_ca_system_score_codex":0.00023405762,"about_ca_system_score_gemma":0.0004325058,"threshold_uncertainty_score":0.99994427},"labels":[],"label_agreement":null},{"id":"W2808209724","doi":"10.1136/annrheumdis-2018-eular.2140","title":"OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Enthesitis; Internal medicine; Placebo; Clinical endpoint; Golimumab; Synovitis; Gastroenterology; Arthritis; Surgery; Rheumatoid arthritis; Randomized controlled trial; Etanercept; Pathology","score_opus":0.017582912759857173,"score_gpt":0.26635962034093,"score_spread":0.24877670758107284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808209724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929907,0.001291565,0.0000022354081,0.000072809555,0.00043333767,0.0010218451,0.004078629,0.00001566789,0.00009326303],"genre_scores_gemma":[0.999142,0.00041566778,0.000021608344,0.000030426467,0.000036134657,0.000037856502,0.00025761884,0.000015721394,0.00004300036],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982568,0.00045212283,0.000600257,0.00032156508,0.00011165454,0.00025758584],"domain_scores_gemma":[0.9981105,0.0007795356,0.00053861673,0.00038372792,0.00014749754,0.000040167877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014498345,0.00023664777,0.0005983029,0.00010910864,0.00011735079,0.000009457173,0.00018525952,0.00012008251,0.00008820124],"category_scores_gemma":[0.0006704841,0.00015576824,0.00012548147,0.00025142496,0.00041188352,0.00014289223,0.000086129585,0.000091355374,0.000011718125],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45023453,0.0071722586,0.004631778,0.00004738391,0.0025554711,0.0000020122372,0.0054353736,0.0000030474891,0.00021300316,0.000053672673,0.0026104422,0.527041],"study_design_scores_gemma":[0.30651772,0.0058975276,0.6625402,0.0018114973,0.00057785463,9.728773e-7,0.00031624438,0.0000062921,0.020815087,0.00096691423,0.00022129851,0.00032840326],"about_ca_topic_score_codex":0.00047091406,"about_ca_topic_score_gemma":0.0001160637,"teacher_disagreement_score":0.6579084,"about_ca_system_score_codex":0.000021524282,"about_ca_system_score_gemma":0.00012937174,"threshold_uncertainty_score":0.63520443},"labels":[],"label_agreement":null},{"id":"W2808543993","doi":"10.3899/jrheum.201668","title":"Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Observational study; Psoriasis; Medicine; Physical therapy; Working group; Randomized controlled trial; Clinical trial; Medical physics; Family medicine; Dermatology; Surgery; Computer science; Pathology","score_opus":0.030145483481970436,"score_gpt":0.2792528666404469,"score_spread":0.24910738315847647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808543993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747845,0.01845529,0.000021736258,0.004503406,0.0015843849,0.000093273506,0.000015775768,0.0000053305384,0.0005363125],"genre_scores_gemma":[0.9976676,0.0016813658,0.00006281496,0.000066638895,0.00004446866,0.0000028004467,0.000008782236,0.000012718952,0.00045279192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953455,0.0032987662,0.00073256507,0.00014697014,0.00013872168,0.0003374927],"domain_scores_gemma":[0.9949505,0.003345355,0.00075469987,0.0005521106,0.0003792737,0.000018071727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003222227,0.00013356644,0.0004355878,0.000050457234,0.0005117429,0.000010604139,0.0007835193,0.00019916208,0.00018578471],"category_scores_gemma":[0.0009442233,0.000060462826,0.00024163017,0.0004022734,0.00053878326,0.00004423376,0.00030635283,0.0007340053,0.000027771173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010910776,0.0002938139,0.8720232,0.000019124267,0.0030220295,0.0003558587,0.013667122,0.000031866435,0.040218644,0.0017709715,0.04340644,0.024099827],"study_design_scores_gemma":[0.007306464,0.00070840924,0.4738326,0.0016858875,0.0016574264,0.15410374,0.050025407,0.0000081231865,0.17740197,0.015881984,0.1167992,0.00058878073],"about_ca_topic_score_codex":0.00054422574,"about_ca_topic_score_gemma":0.0004925751,"teacher_disagreement_score":0.39819062,"about_ca_system_score_codex":0.000027477872,"about_ca_system_score_gemma":0.00024531168,"threshold_uncertainty_score":0.39359644},"labels":[],"label_agreement":null},{"id":"W2808614056","doi":"10.1177/2040622318781760","title":"Ustekinumab in psoriatic arthritis and related phenotypes","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Chronic Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Alberta","funders":"","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Psoriasis; Immunology; Secukinumab; Clinical trial; Tumor necrosis factor alpha; Internal medicine; Infliximab","score_opus":0.024489282211767233,"score_gpt":0.3149809107407573,"score_spread":0.2904916285289901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808614056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019732522,0.9971083,0.0000044931553,0.0000112350735,0.0011049906,0.00084396155,0.00010578304,0.000056909932,0.0005670302],"genre_scores_gemma":[0.0037750297,0.9947316,0.000011629717,0.000018494133,0.00009369255,0.00030080116,0.00030206775,0.000057786478,0.00070891215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99747264,0.00054960203,0.0007025906,0.0006798201,0.000049432587,0.0005459095],"domain_scores_gemma":[0.9988672,0.0003114131,0.0002769415,0.00047424954,0.00001654856,0.00005363662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022458252,0.00053934316,0.0014064705,0.00028660335,0.00008325501,0.000016286667,0.0002872824,0.00039445926,0.00065047917],"category_scores_gemma":[0.000033600787,0.00044502114,0.00021320197,0.00036438616,0.0003644533,0.00018338827,0.000082983745,0.00033874292,0.0004845793],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008874276,0.00011839927,0.0000195405,0.0023196798,0.00023340703,0.000061906416,0.00009089842,0.0000020464136,4.2491033e-7,0.0005079506,0.0000107683045,0.9965462],"study_design_scores_gemma":[0.0028728384,0.00014968262,0.00011685122,0.012641267,0.00087011134,0.000035145593,0.00002042991,0.0000036704782,0.0000015879733,0.0037225508,0.9790427,0.00052313827],"about_ca_topic_score_codex":0.00001191608,"about_ca_topic_score_gemma":0.00014895956,"teacher_disagreement_score":0.9960231,"about_ca_system_score_codex":0.00047354607,"about_ca_system_score_gemma":0.0005670896,"threshold_uncertainty_score":0.99980015},"labels":[],"label_agreement":null},{"id":"W2809920244","doi":"10.1177/1203475418786712","title":"Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Memorial University of Newfoundland","funders":"","keywords":"Medicine; Etanercept; Psoriasis; Ustekinumab; Adalimumab; Psoriatic arthritis; Infliximab; Population; Observational study; Dermatology; Methotrexate; Acitretin; Internal medicine; Disease; Rheumatoid arthritis","score_opus":0.11731895424051458,"score_gpt":0.3134702557675358,"score_spread":0.1961513015270212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809920244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950222,0.0041177045,0.000015006591,0.00023390373,0.00038188646,0.00020175501,0.000014083418,0.0000061543715,0.0000073453443],"genre_scores_gemma":[0.98671,0.012290137,0.0001886992,0.000600968,0.00012397941,0.0000037372058,0.000059734917,0.000009514859,0.00001322757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800533,0.000590626,0.000919558,0.00021087567,0.00007279284,0.00020080124],"domain_scores_gemma":[0.9978652,0.0012866233,0.00044771822,0.000108702385,0.00024304393,0.000048717502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010585195,0.00017319579,0.00070988084,0.0003354856,0.000059655045,0.000008477664,0.00006490811,0.00019509351,0.00004364902],"category_scores_gemma":[0.00042716513,0.0001048874,0.000050344886,0.00023480276,0.00020755973,0.00016511814,0.000013491788,0.0001458471,7.6971247e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005717128,0.00028047693,0.80622745,0.00000564403,0.00011663124,0.00003967239,0.00048726334,0.0000054750667,0.00063676696,0.0000074431896,0.00018866757,0.18628739],"study_design_scores_gemma":[0.005238827,0.0048565543,0.98793703,0.00042646486,0.000026772292,0.0002145077,0.00021336338,0.0000128924285,0.00025650905,0.00019808408,0.00047152318,0.00014744236],"about_ca_topic_score_codex":0.00005453677,"about_ca_topic_score_gemma":0.00013827157,"teacher_disagreement_score":0.18613994,"about_ca_system_score_codex":0.000016535905,"about_ca_system_score_gemma":0.00008983323,"threshold_uncertainty_score":0.42771837},"labels":[],"label_agreement":null},{"id":"W2809929316","doi":"10.3899/jrheum.180134","title":"The Microbiome in Psoriasis and Psoriatic Arthritis: Joints","year":2018,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Microbiome; Dysbiosis; Disease; Immunology; Arthritis; Dermatology; Gut flora; Bioinformatics; Pathology; Biology","score_opus":0.02364563976491065,"score_gpt":0.2711926133403303,"score_spread":0.24754697357541963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809929316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009540291,0.9862895,0.0000037333123,0.00016817832,0.0035673047,0.00034382852,0.00002549248,0.000009599243,0.000052054158],"genre_scores_gemma":[0.0010655576,0.99849236,0.00002807909,0.000018100072,0.000036778936,0.000017671222,0.000013157221,0.000035868685,0.00029240272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995414,0.0022791459,0.0015413618,0.00021257452,0.000051077703,0.00050180196],"domain_scores_gemma":[0.99554145,0.0022782572,0.0016006452,0.00044555435,0.00010110385,0.000032997898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002079097,0.000435923,0.0021479735,0.0003287133,0.00034991704,0.000028900422,0.000766692,0.0006341826,0.00008329875],"category_scores_gemma":[0.0003064687,0.00020880393,0.00039510752,0.00027986622,0.00071903446,0.00006504204,0.00016058068,0.0006855226,0.0003404893],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014640625,0.00006215378,0.00014101139,0.000556055,0.0015136325,0.000015394973,0.00041755755,2.762562e-8,0.000008026196,0.00018545416,0.0054734973,0.99148077],"study_design_scores_gemma":[0.0016716769,0.00027843355,0.00006151446,0.0060872245,0.001273326,0.031145468,0.0001648378,6.900115e-8,0.000015940099,0.0004401586,0.95862734,0.0002339833],"about_ca_topic_score_codex":0.00006856327,"about_ca_topic_score_gemma":0.00025713284,"teacher_disagreement_score":0.9912468,"about_ca_system_score_codex":0.000074509815,"about_ca_system_score_gemma":0.0002771843,"threshold_uncertainty_score":0.85147774},"labels":[],"label_agreement":null},{"id":"W2811367147","doi":"10.1016/j.jval.2018.04.1624","title":"Efficacy of Brodalumab in the Treatment of Moderate-To-Severe Psoriasis: A Network Meta-Analysis","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Ixekizumab; Medicine; Secukinumab; Ustekinumab; Etanercept; Psoriasis Area and Severity Index; Adalimumab; Infliximab; Internal medicine; Randomized controlled trial; Psoriasis; Dermatology; Psoriatic arthritis; Disease; Tumor necrosis factor alpha","score_opus":0.10257215354349344,"score_gpt":0.31986341823037634,"score_spread":0.2172912646868829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811367147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98064965,0.01724283,0.00005291653,0.00064622925,0.00024147348,0.0008467187,0.000081729726,0.000012753655,0.00022569811],"genre_scores_gemma":[0.99836785,0.00059144915,0.00045118327,0.00016612168,0.000057551733,0.000109546534,0.000049766186,0.000010796327,0.0001957249],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9969289,0.0014792646,0.00075915654,0.00034204975,0.000068130896,0.00042251465],"domain_scores_gemma":[0.99846804,0.0006033166,0.00026842207,0.00058089866,0.000052405554,0.000026912612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009251533,0.00021195962,0.0012840637,0.00031610564,0.000092434115,0.0000046194186,0.0002338292,0.00014079708,0.00020673187],"category_scores_gemma":[0.000034790486,0.00013107431,0.0005367398,0.001299839,0.00008849789,0.000026870463,0.000018826333,0.00007034111,0.000048553673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019131256,0.0214492,0.1042532,0.00035230882,0.33859125,0.00006215428,0.12806547,0.2704195,0.00158171,0.010673435,0.0034984283,0.101922095],"study_design_scores_gemma":[0.050795168,0.032196436,0.6585309,0.00025354634,0.19845703,0.00009364887,0.0038734253,0.0020928201,0.021740802,0.004574163,0.025353255,0.0020388076],"about_ca_topic_score_codex":0.008782528,"about_ca_topic_score_gemma":0.0017900397,"teacher_disagreement_score":0.55427766,"about_ca_system_score_codex":0.00010545394,"about_ca_system_score_gemma":0.00014473926,"threshold_uncertainty_score":0.99781805},"labels":[],"label_agreement":null},{"id":"W2831987875","doi":"10.1016/j.jaad.2018.06.057","title":"Psoriasis: Which therapy for which patient","year":2018,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":361,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Johnson and Johnson; Janssen Biotech; MedImmune; Valeant Pharmaceuticals International; AbbVie; Boehringer Ingelheim; AstraZeneca; Novartis; Pfizer","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Disease; Malignancy; Intensive care medicine; Food and drug administration; Quality of life (healthcare); Dermatology; Internal medicine; Pharmacology","score_opus":0.039947038626975656,"score_gpt":0.32888981877310325,"score_spread":0.2889427801461276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2831987875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00410923,0.991613,0.000018525692,0.0014268197,0.0018233616,0.0007458485,0.00015668204,0.000013241398,0.00009331044],"genre_scores_gemma":[0.0036507235,0.9951941,0.00032316416,0.00031678067,0.00026342415,0.00006724781,0.000019645257,0.00006170698,0.00010322689],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958355,0.0014041179,0.0018112363,0.0003273437,0.00010699912,0.0005148155],"domain_scores_gemma":[0.99170405,0.00094022567,0.006644002,0.00034227376,0.00031981812,0.00004961937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003339209,0.00054352166,0.0037005807,0.00039020143,0.0001757527,0.0000087062845,0.0013546305,0.00072772324,0.000053196785],"category_scores_gemma":[0.0002744426,0.000306061,0.0014512701,0.0007590295,0.00058797526,0.00007068636,0.00014589832,0.000806847,0.00005729741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006194341,0.00028379617,0.00013476181,0.00092529115,0.0053980285,0.000003901089,0.00017939653,3.635697e-7,0.00014937864,0.00012481611,0.043449253,0.9487316],"study_design_scores_gemma":[0.0012459691,0.0006337811,0.000101209735,0.0014946868,0.0022643798,0.0050252886,0.00006617114,1.2455216e-7,0.0014195901,0.00011466312,0.9873608,0.00027337056],"about_ca_topic_score_codex":0.000006231855,"about_ca_topic_score_gemma":0.000002581875,"teacher_disagreement_score":0.9484582,"about_ca_system_score_codex":0.00007853953,"about_ca_system_score_gemma":0.00055509555,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W2857965825","doi":"10.1002/art.40657","title":"Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis","year":2018,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"ReumaNederland; National Research Foundation; NYU Langone Medical Center; York University; Arthritis National Research Foundation","keywords":"Arthritis; Inflammatory arthritis; Inflammation; Immunology; Collagen-induced arthritis; Interleukin 17; Biology","score_opus":0.01113461582800139,"score_gpt":0.20874765888388852,"score_spread":0.19761304305588712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2857965825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97952414,0.01783481,0.00006439591,0.000058256996,0.0011044444,0.00038704005,0.00016502979,0.000042801334,0.0008190784],"genre_scores_gemma":[0.9895077,0.009796468,0.0002951369,0.000040035375,0.000012936365,0.000055122156,0.000092374496,0.000027764647,0.00017248212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748176,0.00031668224,0.0011036858,0.00047030157,0.0000641047,0.00056347623],"domain_scores_gemma":[0.99871707,0.00015484012,0.00040686797,0.00052079634,0.00016271522,0.00003768187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034903767,0.00030372423,0.00093462114,0.00036356016,0.00008772102,0.0000050123595,0.00031761624,0.00041001264,0.000764148],"category_scores_gemma":[0.000025581034,0.00031642796,0.00016025054,0.00019979407,0.0007935821,0.00014033644,0.00018665187,0.0001692714,0.0002974685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006002923,0.0010378897,0.05202605,0.00015057958,0.00055536255,0.00007988575,0.003466287,0.000029712966,0.85753405,0.00894714,0.0015708446,0.074001916],"study_design_scores_gemma":[0.008808138,0.0007875259,0.0063621365,0.00070038904,0.00003629813,0.00034410116,0.0005059012,0.000011288513,0.9780229,0.0019385468,0.0020936166,0.0003892134],"about_ca_topic_score_codex":0.00085213786,"about_ca_topic_score_gemma":0.0038255681,"teacher_disagreement_score":0.1204888,"about_ca_system_score_codex":0.000039208255,"about_ca_system_score_gemma":0.00012306384,"threshold_uncertainty_score":0.9999288},"labels":[],"label_agreement":null},{"id":"W28650001","doi":"10.1358/dot.2017.53.5.2613690","title":"子どもの社会性を育むペット飼育 (特集 子どもの社会性を育む)","year":2013,"lang":"en","type":"article","venue":"子どもと発育発達","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01366852841202044,"score_gpt":0.21451340044271686,"score_spread":0.20084487203069643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W28650001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9290751,0.003572603,0.00008568993,0.0006675107,0.0020576527,0.000436419,0.0000322202,0.00032361518,0.06374918],"genre_scores_gemma":[0.95223385,0.00008729992,0.0002665962,0.0004049371,0.00012138344,0.00014847543,0.00014714454,0.000029132285,0.0465612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874467,0.00011541039,0.00024836446,0.00034960412,0.000039288323,0.00050264015],"domain_scores_gemma":[0.99929047,0.000098336386,0.00007642439,0.00041973076,0.00006876525,0.000046296507],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000103566475,0.00024069333,0.00027560274,0.00010725153,0.00020780193,0.00003233885,0.00025250769,0.00027085532,0.012434416],"category_scores_gemma":[0.000034005312,0.00019805122,0.00014665948,0.0001666103,0.000109469926,0.00017206218,0.000072907256,0.00015679176,0.0413815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009929234,0.00047442765,0.026533531,0.000025840878,0.00075225555,0.000025207331,0.0008640295,0.0000037603356,0.34751904,0.0036287755,0.1857956,0.43427825],"study_design_scores_gemma":[0.005410513,0.00049704796,0.21155508,0.000053236003,0.00031834707,0.00022609578,0.0009239965,0.000012354741,0.16673765,0.002779652,0.61034113,0.0011449195],"about_ca_topic_score_codex":0.0004167951,"about_ca_topic_score_gemma":0.000025034848,"teacher_disagreement_score":0.43313333,"about_ca_system_score_codex":0.00005007136,"about_ca_system_score_gemma":0.000042476237,"threshold_uncertainty_score":0.98846835},"labels":[],"label_agreement":null},{"id":"W2883105357","doi":"10.1177/1203475418791114","title":"An Investigation of Comorbid Disease and Health Service Utilization Among Patients With Moderate to Severe Psoriasis in Newfoundland and Labrador","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Comorbidity; Disease; Population; Incidence (geometry); Depression (economics); Inflammatory bowel disease; Internal medicine; Retrospective cohort study; Intensive care medicine; Dermatology","score_opus":0.03203591506727775,"score_gpt":0.26438749772790654,"score_spread":0.23235158266062877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883105357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972292,0.0013571625,0.000022830025,0.0010914468,0.00015021699,0.00012522188,0.000013528999,0.0000039033853,0.0000064842966],"genre_scores_gemma":[0.99847794,0.00067362824,0.00004820102,0.0006695365,0.000059208556,0.0000011828403,0.00004668384,0.000007727951,0.000015916585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991903,0.00015384247,0.00035076,0.00012201653,0.00006088014,0.00012223398],"domain_scores_gemma":[0.99918795,0.00015123397,0.00026754948,0.00007453461,0.00019212236,0.00012660517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031251178,0.00010883927,0.0003777588,0.00022230226,0.000075064534,0.00000728881,0.000028797727,0.00005444601,0.000018083187],"category_scores_gemma":[0.00004044688,0.00007377368,0.000012049271,0.00015591281,0.00013412519,0.00013494185,0.000009474982,0.00006112788,3.3810036e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016998834,0.000055225377,0.97680813,0.00006864632,0.00007117134,0.000024815274,0.0028969774,0.000005599103,0.0003068747,0.0000063664083,0.00031384217,0.01774247],"study_design_scores_gemma":[0.0017536316,0.0011157738,0.99560523,0.00048710953,0.00010527691,0.00019871615,0.00032406402,0.000039487575,0.00009514518,0.000092122056,0.00009610502,0.00008731283],"about_ca_topic_score_codex":0.00072725554,"about_ca_topic_score_gemma":0.0017066789,"teacher_disagreement_score":0.018797128,"about_ca_system_score_codex":0.000021855649,"about_ca_system_score_gemma":0.000092432194,"threshold_uncertainty_score":0.30084032},"labels":[],"label_agreement":null},{"id":"W2885265590","doi":"10.1016/j.cyto.2018.07.028","title":"Type 3 cytokines in liver fibrosis and liver cancer","year":2018,"lang":"en","type":"review","venue":"Cytokine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Debreceni Egyetem; Université de Montréal; Canadian Institutes of Health Research; Canadian Liver Foundation; Public Health Agency; Public Health Agency of Canada; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Liver injury; Medicine; Liver cancer; Inflammation; Immune system; Cancer; Immunology; Chronic liver disease; Fibrosis; Proinflammatory cytokine; Pathogenesis; Liver disease; Wound healing; Cytokine; Pathology; Cirrhosis; Internal medicine","score_opus":0.0490358765895204,"score_gpt":0.2984018881118741,"score_spread":0.24936601152235371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885265590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011337099,0.9964994,6.6569294e-7,0.00000953404,0.0010447864,0.0004408629,0.00036209793,0.000049398546,0.00045954454],"genre_scores_gemma":[0.00022423542,0.9934081,0.000044371907,0.00003125816,0.00027835256,0.00013390437,0.0004719273,0.000052437186,0.0053554582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984012,0.00023196431,0.0003919631,0.0005577351,0.00003060032,0.0003865034],"domain_scores_gemma":[0.9991915,0.00017652595,0.00019330323,0.00034729464,0.00006114852,0.000030194738],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013270177,0.00048427473,0.0013014406,0.00026077143,0.00009388109,0.000017373453,0.00022455219,0.0007340401,0.0015134368],"category_scores_gemma":[0.00003868751,0.00036190677,0.00020101252,0.00035309573,0.00018775988,0.00006362557,0.00015572268,0.00023618918,0.0013213796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006348824,0.00007076584,0.00018602888,0.002323338,0.0004484866,0.000049555576,0.00010120217,2.5691556e-8,0.000092452436,0.000028360157,0.006536689,0.9900996],"study_design_scores_gemma":[0.00056726777,0.0001326912,0.0005515433,0.0037496956,0.0010899893,0.0000920005,0.00000411868,2.3243123e-7,0.0001877707,0.0000053602776,0.9932455,0.0003738538],"about_ca_topic_score_codex":0.0003343015,"about_ca_topic_score_gemma":0.00030015456,"teacher_disagreement_score":0.98972577,"about_ca_system_score_codex":0.00009970989,"about_ca_system_score_gemma":0.00013248924,"threshold_uncertainty_score":0.9998833},"labels":[],"label_agreement":null},{"id":"W2886710556","doi":"10.1111/bjd.17099","title":"Long‐term 52‐week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series","year":2018,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Women's College Hospital; University of Toronto","funders":"","keywords":"Apremilast; Psoriasis; Medicine; Retrospective cohort study; Clinical Practice; Term (time); Series (stratigraphy); Pediatrics; Intensive care medicine; Dermatology; Family medicine; Surgery; Psoriatic arthritis","score_opus":0.030738576802847452,"score_gpt":0.3218042530086166,"score_spread":0.2910656762057691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886710556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8817831,0.02683225,0.00008508693,0.07652199,0.009810197,0.0015872518,0.002773132,0.000044259315,0.00056271604],"genre_scores_gemma":[0.9349688,0.02877521,0.004807654,0.0193215,0.0033618012,0.0003097868,0.0026458774,0.00033540724,0.005473924],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9940283,0.0015972363,0.002917144,0.000584729,0.00011042606,0.0007621665],"domain_scores_gemma":[0.9947879,0.0019598668,0.0023353936,0.0003658346,0.00049626525,0.000054763503],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00048069368,0.00056196435,0.0030333356,0.00084103143,0.00012695434,0.000029755984,0.00034209611,0.002138286,0.00022830798],"category_scores_gemma":[0.0008277383,0.0005452494,0.0009882698,0.0002880061,0.0005153306,0.00031840123,0.00006436678,0.00091616943,0.0000172252],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007973903,0.0044006216,0.4114343,0.00017205239,0.0054369057,0.28445467,0.0013119633,8.361542e-7,0.000031447496,0.000010904968,0.1269655,0.15780689],"study_design_scores_gemma":[0.032047283,0.0027914902,0.25791752,0.00050025835,0.0020090158,0.60338926,0.00038901012,6.4523704e-7,0.00047849253,0.00004303343,0.09986147,0.0005725015],"about_ca_topic_score_codex":0.0003160126,"about_ca_topic_score_gemma":0.0036540006,"teacher_disagreement_score":0.3189346,"about_ca_system_score_codex":0.00042071677,"about_ca_system_score_gemma":0.00029212527,"threshold_uncertainty_score":0.9996999},"labels":[],"label_agreement":null},{"id":"W2887110542","doi":"10.1111/jdv.15203","title":"Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries","year":2018,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Adalimumab; Psoriasis; Adverse effect; Incidence (geometry); MEDLINE; Internal medicine; Dermatology; Disease","score_opus":0.047650653023145736,"score_gpt":0.31506376057707347,"score_spread":0.2674131075539277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887110542","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072276616,0.9962692,0.0000018472064,0.0008748325,0.000800064,0.0006640986,0.000037865804,0.0000040807768,0.0006251917],"genre_scores_gemma":[0.008778939,0.99049973,0.000025077177,0.00012843007,0.00006050245,0.0000069995267,0.000003414299,0.000027909951,0.0004689821],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98398036,0.011696571,0.0036524776,0.00026656696,0.000108309,0.0002957208],"domain_scores_gemma":[0.9895221,0.0018942266,0.00787251,0.00054613996,0.00013728962,0.000027741742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025978973,0.00041749844,0.0045526833,0.00034665977,0.00010386087,0.0000022101437,0.0016751288,0.00052189216,0.000032745444],"category_scores_gemma":[0.0013211698,0.00021147337,0.0010592636,0.00055477035,0.0015216309,0.00007504322,0.00046983096,0.00089755707,0.000011443994],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038221822,0.00018052952,0.0032560641,0.96750486,0.0039084842,0.000046956167,0.0002685763,4.4349508e-7,0.00006209254,0.0020732759,0.003759841,0.018556662],"study_design_scores_gemma":[0.0010811419,0.000084252475,0.0015599083,0.87733096,0.01055391,0.0073744617,0.00003222161,8.4463316e-8,0.00061018544,0.00017535516,0.100938775,0.0002587225],"about_ca_topic_score_codex":0.000010100693,"about_ca_topic_score_gemma":0.000011590052,"teacher_disagreement_score":0.097178936,"about_ca_system_score_codex":0.000054232307,"about_ca_system_score_gemma":0.00027106277,"threshold_uncertainty_score":0.8623634},"labels":[],"label_agreement":null},{"id":"W2887114770","doi":"10.1093/med/9780198737582.003.0009","title":"Psoriasis: skin and nails","year":2018,"lang":"en","type":"book","venue":"Oxford University Press eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Generalized pustular psoriasis; Population; Arthritis; Immunology","score_opus":0.0167224830393357,"score_gpt":0.19933202941185194,"score_spread":0.18260954637251622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887114770","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029703598,0.0016990302,0.000020158071,0.000007834103,0.00089944835,0.0003708693,0.0003913509,0.00014664521,0.99349433],"genre_scores_gemma":[0.00062924845,0.00086074264,0.00008490915,0.00003270562,0.00016329566,0.0000023600294,0.00030920873,0.00003757051,0.99788],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986924,0.00015656836,0.00016448251,0.00056188094,0.000047965237,0.000376684],"domain_scores_gemma":[0.9991035,0.000111054236,0.00019273035,0.00045862753,0.0000799526,0.0000541498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000102347985,0.00041898206,0.00049851515,0.00018067108,0.0003344921,0.000023694962,0.0003772115,0.000989305,0.00016101346],"category_scores_gemma":[0.0000073537794,0.00043463687,0.00018990095,0.000012087917,0.0004340866,0.00006567644,0.00032121458,0.00028730367,0.00003061963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024237076,0.00017489007,0.00009375483,0.00034556413,0.006560567,0.00039517926,0.002317258,2.8539242e-7,0.0011135391,0.15190539,0.5704922,0.26417765],"study_design_scores_gemma":[0.001883279,0.0001815502,0.00007849726,0.00010282438,0.0008490796,0.000038290964,0.000056374203,2.523603e-7,0.0020653794,0.00020185905,0.99412626,0.0004163292],"about_ca_topic_score_codex":0.000042474967,"about_ca_topic_score_gemma":0.000030698826,"teacher_disagreement_score":0.42363405,"about_ca_system_score_codex":0.00013088816,"about_ca_system_score_gemma":0.00015853667,"threshold_uncertainty_score":0.9998105},"labels":[],"label_agreement":null},{"id":"W2887412253","doi":"10.1016/s0140-6736(18)31713-6","title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":662,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"Dermira; Genentech; Celgene; AbbVie; GlaxoSmithKline Australia; Bristol-Myers Squibb; Amgen; Boehringer Ingelheim","keywords":"Medicine; Ustekinumab; Placebo; Psoriasis Area and Severity Index; Internal medicine; Psoriasis; Clinical trial; Randomization; Randomized controlled trial; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.05257706308536371,"score_gpt":0.32006789525900453,"score_spread":0.26749083217364084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887412253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873417,0.0045802617,0.000052771225,0.0009428747,0.0004523095,0.0048452085,0.00091883366,0.000047943307,0.0008180965],"genre_scores_gemma":[0.9967341,0.001355012,0.00023782918,0.00012880299,0.00050780474,0.00028875194,0.00019372957,0.000028394943,0.00052559515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99560463,0.0018546744,0.0013064737,0.00065279036,0.00008150827,0.00049993244],"domain_scores_gemma":[0.9928499,0.0058143362,0.0005675862,0.0006105569,0.00008752284,0.000070098766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033340836,0.00045311247,0.0031959228,0.00019292555,0.0002954866,0.00006360687,0.0002809027,0.0003095127,0.00011556863],"category_scores_gemma":[0.0011033457,0.00027896563,0.00016858146,0.00017527609,0.00033601167,0.00011218133,0.0001226496,0.00025292087,0.000034168355],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9587726,0.00021525774,0.00020218891,0.000011690425,0.0016245564,0.000009011631,0.002812548,0.00004237998,0.018055234,0.00007755677,0.00058754924,0.017589413],"study_design_scores_gemma":[0.98353255,0.0005590736,0.0011946906,0.00011385972,0.0009800562,0.000027660551,0.00017107347,0.00026589257,0.011833069,0.00019375584,0.00082110864,0.0003072113],"about_ca_topic_score_codex":0.0007054163,"about_ca_topic_score_gemma":0.00045133856,"teacher_disagreement_score":0.024759933,"about_ca_system_score_codex":0.000031412383,"about_ca_system_score_gemma":0.000064224274,"threshold_uncertainty_score":0.99996626},"labels":[],"label_agreement":null},{"id":"W2888234487","doi":"10.1177/1203475418795823","title":"Refractory Palmoplantar Pustular Psoriasis Treated With High-Dose Ustekinumab After Initial Failure","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Ustekinumab; Medicine; Refractory (planetary science); Tachyphylaxis; Inflammatory bowel disease; Psoriasis; Dermatology; Plaque psoriasis; Palmoplantar pustulosis; Dosing; Disease; Surgery; Internal medicine; Adalimumab","score_opus":0.015149128167614606,"score_gpt":0.2342160495784384,"score_spread":0.2190669214108238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888234487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928152,0.005009733,0.000012070051,0.0006383285,0.0011341848,0.00009231038,0.000021013388,0.000022535869,0.00025462543],"genre_scores_gemma":[0.9966115,0.001182345,0.000058663132,0.00037223616,0.0011201602,0.0000044599537,0.00004169253,0.00002661299,0.0005823833],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984569,0.00024503758,0.0006018631,0.00021947658,0.00012994824,0.0003467951],"domain_scores_gemma":[0.9983089,0.00067841384,0.0004272569,0.0002055707,0.00028258364,0.000097294534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035441012,0.00029092387,0.0008397518,0.000381093,0.00015018102,0.000012967645,0.00009971848,0.000265908,0.0012325477],"category_scores_gemma":[0.00012005628,0.00017313643,0.00012746976,0.00018193053,0.0004467273,0.00012976563,0.000019308867,0.0002783719,0.00004554055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08360108,0.0016425923,0.25005198,0.00030359978,0.011067724,0.07622302,0.008504057,0.0000025101406,0.094639845,0.0000680519,0.21519624,0.25869933],"study_design_scores_gemma":[0.02429082,0.022138774,0.06817021,0.0035057548,0.008010233,0.25722164,0.005261954,0.0000023708337,0.058476202,0.0003033599,0.5506327,0.0019859516],"about_ca_topic_score_codex":0.000093370385,"about_ca_topic_score_gemma":0.000068313275,"teacher_disagreement_score":0.3354365,"about_ca_system_score_codex":0.00003984776,"about_ca_system_score_gemma":0.00013449656,"threshold_uncertainty_score":0.99968046},"labels":[],"label_agreement":null},{"id":"W2888527569","doi":"10.1016/j.jid.2018.06.003","title":"LB1475 The immune-phenotype of small plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Psoriasis; CD8; Immune system; Medicine; Immunology; Immunohistochemistry; Pathogenesis; Phenotype; Population; T cell; Interferon; Dermatology; Biology","score_opus":0.02905354335253993,"score_gpt":0.24577415358853716,"score_spread":0.21672061023599723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888527569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98796475,0.0056917192,0.00017317697,0.002906041,0.0016297748,0.00013825943,0.000020470361,0.000013136554,0.0014626646],"genre_scores_gemma":[0.99811876,0.00015125262,0.0009377622,0.00038261912,0.00014718794,0.0000058054716,0.000009470776,0.000016276745,0.00023087289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978988,0.00076002,0.00083034055,0.00015054329,0.000055945977,0.00030431527],"domain_scores_gemma":[0.99750626,0.00053954415,0.001060043,0.00028583902,0.00056481565,0.000043486558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037750267,0.00021684855,0.00063650537,0.00018895026,0.0002006952,0.000007748912,0.00050040166,0.000282042,0.00028430615],"category_scores_gemma":[0.0003987097,0.00013373737,0.00024014666,0.00025177188,0.0019938229,0.00009473636,0.00007877277,0.00033105342,0.00019421997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010923286,0.00029438324,0.007195664,0.000045453817,0.002937946,0.00010120626,0.00792571,0.0000049472224,0.9414809,0.019920805,0.012021524,0.0069791293],"study_design_scores_gemma":[0.0018260531,0.0005303963,0.020431368,0.000056000477,0.0003025438,0.0016347867,0.0007884562,0.0000018560888,0.95746815,0.003512539,0.013315544,0.00013227493],"about_ca_topic_score_codex":0.00004597481,"about_ca_topic_score_gemma":0.00004233886,"teacher_disagreement_score":0.016408266,"about_ca_system_score_codex":0.000030987092,"about_ca_system_score_gemma":0.00028549109,"threshold_uncertainty_score":0.7346323},"labels":[],"label_agreement":null},{"id":"W2889154468","doi":"10.1002/acr.23743","title":"Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population‐Based Study","year":2018,"lang":"en","type":"article","venue":"Arthritis Care & Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Hospital; Toronto Western Hospital; Institute for Clinical Evaluative Sciences; McGill University Health Centre; University of Waterloo; Women's College Hospital; University of Toronto","funders":"Canadian Rheumatology Association","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Incidence (geometry); Dermatology; Population; Demography; Environmental health","score_opus":0.03221151651269163,"score_gpt":0.302899648013794,"score_spread":0.2706881315011024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889154468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432904,0.014672653,2.3531321e-7,0.000105928026,0.00013933812,0.00045761437,0.0000462513,0.000005836869,0.00024307074],"genre_scores_gemma":[0.99916583,0.00042594215,0.000019183652,0.000024870895,0.000020945388,0.000136755,0.000036948535,0.000008210976,0.0001612891],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773574,0.0009701861,0.0003366061,0.00037710002,0.00018997704,0.00039038694],"domain_scores_gemma":[0.9990127,0.00043556362,0.000054174823,0.00032182285,0.00014865209,0.000027091553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092015974,0.00013818857,0.00028924647,0.0003801171,0.00021934805,0.000023969049,0.00020760788,0.00010196714,0.00029056842],"category_scores_gemma":[0.00013177887,0.00011621531,0.000024630366,0.00055282237,0.00021170032,0.00009558531,0.00008997244,0.0002895856,0.0000038965754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099494486,0.00010121614,0.77758366,0.000018973175,0.000017350547,0.00004931255,0.009694488,4.0045066e-7,0.000098465884,0.000043601845,0.00008933925,0.2122037],"study_design_scores_gemma":[0.0032091902,0.00074231083,0.9908091,0.00019605632,0.00001324338,0.000017927852,0.0042131804,0.0000013721858,0.0003242099,0.00005817214,0.000309444,0.00010580758],"about_ca_topic_score_codex":0.93389636,"about_ca_topic_score_gemma":0.9991165,"teacher_disagreement_score":0.21322542,"about_ca_system_score_codex":0.00018894095,"about_ca_system_score_gemma":0.00038302978,"threshold_uncertainty_score":0.4739123},"labels":[],"label_agreement":null},{"id":"W2889330860","doi":"10.1136/annrheumdis-2018-eular.2347","title":"THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Ixekizumab; Psoriasis; Adalimumab; Placebo; Secukinumab; Internal medicine; Population; Erythema; Etanercept; Gastroenterology; Tumor necrosis factor alpha; Dermatology; Surgery; Pathology","score_opus":0.016110046367408152,"score_gpt":0.24929206478676103,"score_spread":0.23318201841935288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889330860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963346,0.0017117873,0.0000029762866,0.00067303126,0.00020059361,0.0005861127,0.00044661597,0.000019942647,0.000024306555],"genre_scores_gemma":[0.99916637,0.00041143972,0.00004168072,0.0001371254,0.000010843438,0.00006123934,0.000019738969,0.000019339615,0.0001322021],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99856156,0.00040404504,0.0003318716,0.00030263458,0.00008320102,0.00031670832],"domain_scores_gemma":[0.99891824,0.00040633988,0.00020773713,0.0002972576,0.00011005726,0.00006039456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011713432,0.0002465379,0.00041148748,0.00011418444,0.00023565671,0.000027379521,0.0001645358,0.00009443992,0.000042389293],"category_scores_gemma":[0.0004521209,0.00015889757,0.000077248056,0.00022123338,0.0003605939,0.00021413642,0.00015319054,0.000074378855,0.000021490081],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004425539,0.0004719491,0.0055830725,0.000050799066,0.00033574595,0.0000011446394,0.004991897,6.530471e-7,0.00049037056,0.000036404123,0.0005683175,0.9830441],"study_design_scores_gemma":[0.0027969521,0.0011255984,0.9723969,0.00073560973,0.000096233176,0.0000020046675,0.00058693596,0.0000011109898,0.021334164,0.00062242954,0.00010015112,0.00020189425],"about_ca_topic_score_codex":0.0003367684,"about_ca_topic_score_gemma":0.00014984867,"teacher_disagreement_score":0.9828422,"about_ca_system_score_codex":0.000018614375,"about_ca_system_score_gemma":0.000078749785,"threshold_uncertainty_score":0.6479655},"labels":[],"label_agreement":null},{"id":"W2889338440","doi":"10.1111/bjd.17084","title":"Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma; Mylan; Astellas Pharma; University of Connecticut; Valeant Pharmaceuticals International; National Cancer Institute; AbbVie; Celgene; Biogen; Amgen; Pfizer; Eli Lilly and Company","keywords":"Adalimumab; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Clinical trial; Term (time); Internal medicine; Disease","score_opus":0.04027400225608697,"score_gpt":0.31018953441184344,"score_spread":0.2699155321557565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889338440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950658,0.0017960132,0.00040509715,0.00021849615,0.0015505605,0.00038351168,0.00045684562,0.000011845763,0.0001117925],"genre_scores_gemma":[0.99779916,0.0008833796,0.0006551077,0.00030197098,0.0001457016,0.000008159992,0.00015252344,0.000024981113,0.000029046716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99399924,0.0027950723,0.0023909104,0.00032514022,0.0001000583,0.00038960195],"domain_scores_gemma":[0.99589515,0.0015299903,0.0013112876,0.00022962719,0.0009426219,0.00009134991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051217293,0.0002539469,0.0020110083,0.00023187512,0.00011329354,0.000019508814,0.0003474357,0.0005279768,0.0005007687],"category_scores_gemma":[0.0006583265,0.00022885286,0.00031789465,0.0001835917,0.00034870717,0.00016116361,0.00007831591,0.00040049347,0.000072732866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034500964,0.0015515261,0.8188318,0.000035512712,0.0026172185,0.0013878974,0.0005692822,0.000009081074,0.0007704493,0.000034179833,0.0071951523,0.13249695],"study_design_scores_gemma":[0.039257225,0.001227525,0.9429474,0.00068750035,0.00046601778,0.0058214455,0.00014438054,0.0000017589863,0.008024622,0.0001086597,0.0009936508,0.00031982773],"about_ca_topic_score_codex":0.00023533675,"about_ca_topic_score_gemma":0.0007917105,"teacher_disagreement_score":0.13217713,"about_ca_system_score_codex":0.000047133584,"about_ca_system_score_gemma":0.00022508671,"threshold_uncertainty_score":0.9332349},"labels":[],"label_agreement":null},{"id":"W2890067412","doi":"10.1016/j.jdcr.2018.06.001","title":"Treatment of psoriasis vulgaris using low-dose naltrexone","year":2018,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University","funders":"","keywords":"Psoriasis; Medicine; Presenteeism; Itching; Quality of life (healthcare); Dermatology; Population; Health care; Environmental health; Absenteeism; Nursing","score_opus":0.03101829602201748,"score_gpt":0.279642744318278,"score_spread":0.24862444829626054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890067412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931857,0.002948304,0.00004466907,0.000022006754,0.0018530558,0.00029550924,0.000042075008,0.00006700626,0.0015416634],"genre_scores_gemma":[0.9969658,0.00012718237,0.0004165884,0.000013777584,0.0002212953,0.000028404062,0.00007155873,0.00002644224,0.0021289343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984293,0.00013477077,0.00057983276,0.00044119012,0.00005189628,0.00036299878],"domain_scores_gemma":[0.9986456,0.0000826596,0.0004231917,0.0006549826,0.00014664403,0.000046918958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015334091,0.00027412557,0.0004952519,0.00014989858,0.00024262545,0.000009437227,0.000039220726,0.00026572234,0.00073826476],"category_scores_gemma":[0.00004580717,0.00021979454,0.00023735802,0.0002062724,0.00021108867,0.00007389495,0.000034239423,0.00004838343,0.00012442167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009947025,0.0029768758,0.032666307,0.00007165094,0.0031067573,0.128742,0.0032038528,0.0000075395023,0.5549894,0.00009936271,0.0009986823,0.2721429],"study_design_scores_gemma":[0.002520462,0.0011711703,0.0029369344,0.00004981787,0.0009634533,0.18275884,0.00026488336,0.000010985741,0.7887801,0.0000893547,0.0200847,0.000369298],"about_ca_topic_score_codex":0.0013691402,"about_ca_topic_score_gemma":0.00013083666,"teacher_disagreement_score":0.2717736,"about_ca_system_score_codex":0.00013363575,"about_ca_system_score_gemma":0.0001277246,"threshold_uncertainty_score":0.89629614},"labels":[],"label_agreement":null},{"id":"W2890532892","doi":"10.1016/s0140-6736(18)32167-6","title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":324,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer; Medac; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Ustekinumab; Internal medicine; Placebo; Psoriatic arthritis; Lupus nephritis; Lupus erythematosus; Gastroenterology; Immunology; Arthritis; Disease; Infliximab; Antibody; Pathology","score_opus":0.02245406536625792,"score_gpt":0.2700038569858186,"score_spread":0.24754979161956067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890532892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525756,0.00036722547,0.000002478719,0.000017079275,0.00019058412,0.0036757626,0.00034919294,0.00001691979,0.00012317853],"genre_scores_gemma":[0.99962443,0.00005600635,0.00001476471,0.000009925766,0.00005844066,0.0000806694,0.00007357748,0.000013173727,0.00006899892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983422,0.0005608434,0.00050047564,0.00028845694,0.00006219456,0.00024583843],"domain_scores_gemma":[0.9985646,0.00047266897,0.00040793727,0.0004139424,0.00011588102,0.000024984956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005476771,0.00021156986,0.0010462,0.00009284114,0.000097898956,0.000008695249,0.00015188316,0.00011061816,0.0000074239633],"category_scores_gemma":[0.00007572579,0.00011826506,0.000038595965,0.000113586735,0.00027328773,0.000084276675,0.00005446617,0.00010465025,0.0000044219587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9244752,0.0020605163,0.055260796,0.00003845755,0.0008953515,0.0000031740803,0.011913286,0.0000018436826,0.0024109678,0.000010079945,0.000036265687,0.0028940928],"study_design_scores_gemma":[0.95671767,0.002983811,0.03193567,0.00018682946,0.00047812704,0.000020257065,0.002109554,0.0000063107414,0.005389015,0.0000035544108,0.000036273756,0.0001329083],"about_ca_topic_score_codex":0.000087103035,"about_ca_topic_score_gemma":0.00022408928,"teacher_disagreement_score":0.03224252,"about_ca_system_score_codex":0.000020843661,"about_ca_system_score_gemma":0.000029861063,"threshold_uncertainty_score":0.48227093},"labels":[],"label_agreement":null},{"id":"W2890665672","doi":"10.2196/10815","title":"Patient Perspectives on the Challenges and Responsibilities of Living With Chronic Inflammatory Diseases: Qualitative Study","year":2018,"lang":"en","type":"article","venue":"Journal of Participatory Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canadian Arthritis Patient Alliance; Canadian Society of Intestinal Research; Arthritis Research Centre of Canada; Research Canada; University of British Columbia","funders":"","keywords":"Qualitative research; Toll; Quality of life (healthcare); Medicine; Chronic disease; Disease; Gerontology; Intensive care medicine; Immunology; Nursing; Pathology; Sociology; Social science","score_opus":0.0670956301075145,"score_gpt":0.339782557856216,"score_spread":0.2726869277487015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890665672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95825595,0.040815398,0.0000020751252,0.00043852016,0.00018555757,0.00019240318,0.0000041998073,0.0000058740393,0.00010003041],"genre_scores_gemma":[0.9992046,0.0005455774,0.0000027799008,0.000024571715,0.00015405242,0.000016483727,1.6300156e-7,0.000008642058,0.000043132983],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99777704,0.0014200978,0.00038606266,0.00013508939,0.000110609864,0.00017111957],"domain_scores_gemma":[0.99704003,0.0021128985,0.00035033852,0.00019444547,0.0002661023,0.00003621047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00130607,0.00013588794,0.000355908,0.00012389384,0.00011309018,0.000002144775,0.00008545914,0.000041200463,0.00017853836],"category_scores_gemma":[0.0009948432,0.00006458505,0.000040548137,0.00005720874,0.0010335882,0.00006323096,0.000026512875,0.00013762862,0.000005266632],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018505418,0.00065690686,0.00944258,0.000034463807,0.0011827477,0.000018909068,0.9785037,0.0000015578483,0.0027745657,0.002516914,0.00016100364,0.0028561046],"study_design_scores_gemma":[0.001161837,0.020829631,0.17886713,0.00073526375,0.0004179134,0.000024541392,0.7966874,7.031912e-7,0.00097301725,0.000106876025,0.000120465,0.00007516828],"about_ca_topic_score_codex":0.000009355079,"about_ca_topic_score_gemma":0.000068295834,"teacher_disagreement_score":0.18181625,"about_ca_system_score_codex":0.000060458242,"about_ca_system_score_gemma":0.00013191986,"threshold_uncertainty_score":0.38082987},"labels":[],"label_agreement":null},{"id":"W2890702842","doi":"10.1007/s11136-018-1969-2","title":"Assessment of the Dermatology Life Quality Index (DLQI) in a homogeneous population under lifetime arsenic exposure","year":2018,"lang":"en","type":"article","venue":"Quality of Life Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Xiangya Hospital, Central South University","keywords":"Confirmatory factor analysis; Cronbach's alpha; Dermatology Life Quality Index; Measurement invariance; Population; Quality of Life Research; Reliability (semiconductor); Clinical psychology; Structural equation modeling; Psychology; Medicine; Psychometrics; Public health; Environmental health; Statistics; Dermatology; Mathematics; Pathology","score_opus":0.15376997589658137,"score_gpt":0.42835759723445904,"score_spread":0.2745876213378777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890702842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576646,0.0014541233,0.00006736022,0.0010605311,0.00027242306,0.0004942905,0.000071583025,0.000020536338,0.0007926984],"genre_scores_gemma":[0.9991717,0.000069789,0.00007179328,0.00010360789,0.00006261064,0.00003957991,0.00007035794,0.00001592976,0.00039466342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99038905,0.007178262,0.0011478699,0.00040528807,0.00033252317,0.0005470314],"domain_scores_gemma":[0.9969091,0.0013864209,0.00040163423,0.0008337136,0.00040527526,0.00006389007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004328818,0.000186239,0.0006975793,0.00029502643,0.00024149462,0.000010048801,0.00052324275,0.0004869049,0.0004698662],"category_scores_gemma":[0.0011751354,0.00014251107,0.00020289994,0.0006410455,0.0008867329,0.00006593821,0.00027220466,0.000444729,0.000073737654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048395296,0.00065090286,0.94932,0.00013884391,0.00031379928,0.0000013894776,0.0005274266,0.000015289792,0.04133309,0.0050830483,0.00033518983,0.0017970311],"study_design_scores_gemma":[0.0019734341,0.00020987808,0.9876003,0.000039195755,0.000020049323,0.0000072876055,0.0007516207,0.000012843733,0.007854019,0.0011413493,0.0002531954,0.00013679163],"about_ca_topic_score_codex":0.0049750246,"about_ca_topic_score_gemma":0.0026111908,"teacher_disagreement_score":0.0382803,"about_ca_system_score_codex":0.000114123715,"about_ca_system_score_gemma":0.00063830626,"threshold_uncertainty_score":0.7520782},"labels":[],"label_agreement":null},{"id":"W2890837529","doi":"10.1111/jdv.15242","title":"Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Plaque psoriasis; Psoriasis; Clinical trial; Term (time); Safety profile; Dermatology; Internal medicine; Adverse effect; Psoriatic arthritis; Secukinumab","score_opus":0.03878062737402969,"score_gpt":0.3123729353849405,"score_spread":0.2735923080109108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890837529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99758035,0.0005239955,0.00029047477,0.00061266177,0.00047553022,0.00025057766,0.00014630225,0.000007595461,0.00011250332],"genre_scores_gemma":[0.99904406,0.00013448857,0.0003935708,0.00019952038,0.00009601776,0.0000021317062,0.000055577642,0.000018781213,0.000055865363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9883865,0.008963264,0.0019735747,0.00031558098,0.00007220381,0.00028883616],"domain_scores_gemma":[0.99698746,0.0006805659,0.0018147102,0.0002501401,0.0001941864,0.00007291874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019423,0.00026057582,0.0017361186,0.00044643352,0.00010647522,0.0000050480976,0.00058215,0.00047430786,0.00014258859],"category_scores_gemma":[0.0003886702,0.0001534762,0.00030861556,0.00042839468,0.00073309045,0.00012695354,0.00015085057,0.0005482043,0.00001404243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01221624,0.0004891781,0.9624569,0.000010784174,0.0030424492,0.00002047318,0.000480347,0.000029547567,0.0004122433,0.00009282271,0.00030661156,0.020442432],"study_design_scores_gemma":[0.008857134,0.0004227713,0.9808826,0.00009349626,0.0018030207,0.00018633045,0.000077713936,0.000008766084,0.0070233303,0.000087208886,0.0004019595,0.00015570794],"about_ca_topic_score_codex":0.000026847762,"about_ca_topic_score_gemma":0.00011514748,"teacher_disagreement_score":0.020286724,"about_ca_system_score_codex":0.000022540265,"about_ca_system_score_gemma":0.00009109885,"threshold_uncertainty_score":0.6258578},"labels":[],"label_agreement":null},{"id":"W2891381551","doi":"10.1177/1203475418800947","title":"Prescribing Home Narrowband UVB Phototherapy: A Review of Current Approaches","year":2018,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Vancouver Coastal Health; University of Alberta","funders":"","keywords":"Medicine; Dermatology; Skin type; Erythema; Adverse effect; Reimbursement; Protocol (science); Intensive care medicine; Alternative medicine; Health care","score_opus":0.14884720599022513,"score_gpt":0.32282320314970386,"score_spread":0.17397599715947873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891381551","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033049332,0.99683905,0.0000060949114,0.00009009155,0.00218849,0.00034853577,0.000030070792,0.000008886534,0.00015826928],"genre_scores_gemma":[0.00006170816,0.99885035,0.000013860978,0.0000882463,0.0005991131,0.000011144646,0.00007383681,0.00003741517,0.00026432954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967658,0.0006525271,0.0018836752,0.00026158438,0.00014022698,0.0002962134],"domain_scores_gemma":[0.9956773,0.0014863083,0.0022865408,0.00028732998,0.000189942,0.00007256912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014594626,0.00046456186,0.0044044247,0.0004937892,0.000076779506,0.000005827479,0.00021645511,0.0003208783,0.00041730396],"category_scores_gemma":[0.0003412477,0.00026818036,0.0009161278,0.00024801152,0.00034274784,0.00005492987,0.000031379397,0.00043211257,0.000012640542],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009487583,0.00011039827,0.000029551271,0.060284305,0.0013858483,0.00016190598,0.00017368369,5.532188e-9,0.000017512017,0.0000050861063,0.041381825,0.89635503],"study_design_scores_gemma":[0.00028008388,0.00030945218,9.687203e-7,0.21423645,0.003033787,0.010936728,0.000026640157,3.091353e-8,0.000018471475,0.000017076578,0.77095956,0.00018076066],"about_ca_topic_score_codex":0.0000043635264,"about_ca_topic_score_gemma":8.2476606e-7,"teacher_disagreement_score":0.89617425,"about_ca_system_score_codex":0.000040379167,"about_ca_system_score_gemma":0.00041632945,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W2891620699","doi":"10.1111/bjd.17149","title":"Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Tofacitinib; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Clinical trial; Internal medicine; Rheumatoid arthritis","score_opus":0.023656340273300085,"score_gpt":0.3111337158610936,"score_spread":0.2874773755877935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891620699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946179,0.0025898102,0.00032965984,0.00010918006,0.0007470537,0.00044313484,0.0010870623,0.0000145446365,0.00006170141],"genre_scores_gemma":[0.9985891,0.00048117852,0.00044135546,0.000069740956,0.00012284533,0.00002149665,0.00018050101,0.000024049112,0.00006973316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454004,0.0019651428,0.0024097401,0.0003892488,0.00011658201,0.000579245],"domain_scores_gemma":[0.9965245,0.0006981271,0.001729001,0.00028212383,0.000667356,0.00009885661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015290942,0.00027335863,0.002262016,0.00038519446,0.0001768342,0.00003081049,0.00038621284,0.00057225453,0.00056329835],"category_scores_gemma":[0.00073020736,0.0002433167,0.0005614784,0.000650334,0.00032242888,0.00018536799,0.000078705314,0.00046430458,0.00006550539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432824,0.001167148,0.8444022,0.000027286815,0.009238523,0.00030946737,0.00047955895,0.00008709144,0.0002738961,0.000024917264,0.0014328916,0.1331242],"study_design_scores_gemma":[0.035739098,0.0024789202,0.93656725,0.00033199147,0.0041608787,0.0028332942,0.00026781618,0.000018403296,0.015666848,0.00009746654,0.0013638948,0.00047413955],"about_ca_topic_score_codex":0.00016689891,"about_ca_topic_score_gemma":0.0018587006,"teacher_disagreement_score":0.13265006,"about_ca_system_score_codex":0.00006959613,"about_ca_system_score_gemma":0.00027553152,"threshold_uncertainty_score":0.99221665},"labels":[],"label_agreement":null},{"id":"W2891836054","doi":"10.1111/bjd.17195","title":"Granulocyte–macrophage colony‐stimulating factor ( <scp>GM</scp> ‐ <scp>CSF</scp> ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ <scp>GM</scp> ‐ <scp>CSF</scp> monoclonal antibody","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Dermatrials Research; Probity Medical Research","funders":"Department of Medicine, University of Toronto; University of Toronto; Gentofte Hospital; Takeda Pharmaceutical Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Internal medicine; Granulocyte macrophage colony-stimulating factor; Immunology; Population; Granulocyte colony-stimulating factor; Clinical trial; Monoclonal antibody; Gastroenterology; Randomized controlled trial; Antibody; Pharmacology; Cytokine; Pathology; Chemotherapy","score_opus":0.020038037774897877,"score_gpt":0.27071297728936855,"score_spread":0.2506749395144707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891836054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438727,0.04634135,0.0010969085,0.00008730882,0.0038994108,0.0026633246,0.00025929278,0.00021176315,0.0015679536],"genre_scores_gemma":[0.991538,0.0031963652,0.0015412099,0.0006194828,0.0009286877,0.00015833203,0.00047326184,0.00024952198,0.0012951378],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98498046,0.005717851,0.0045917565,0.0014796908,0.0006238962,0.0026063384],"domain_scores_gemma":[0.9833394,0.009987307,0.0041098585,0.00074986945,0.0013400282,0.00047353303],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0024658667,0.0015771837,0.006182,0.0017257846,0.0016768598,0.00054590957,0.0013620326,0.0020093876,0.0001235026],"category_scores_gemma":[0.00665652,0.0015998669,0.0018105186,0.0011924002,0.0020975268,0.0011707062,0.00030674264,0.002099611,0.00036970468],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045080082,0.0033400436,0.18045948,0.0004453625,0.01371798,0.014993473,0.014987664,0.0004606556,0.74239695,0.00113443,0.018335942,0.005220006],"study_design_scores_gemma":[0.5987388,0.0022582738,0.10500674,0.0024722486,0.004426136,0.09140514,0.0068863346,0.0016743244,0.15532593,0.006927441,0.024203494,0.0006751363],"about_ca_topic_score_codex":0.0005179343,"about_ca_topic_score_gemma":0.00022527797,"teacher_disagreement_score":0.5942308,"about_ca_system_score_codex":0.0004193021,"about_ca_system_score_gemma":0.0008663824,"threshold_uncertainty_score":0.9996976},"labels":[],"label_agreement":null},{"id":"W2892136519","doi":"10.1056/nejmoa1806382","title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":414,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Placebo; Medicine; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Gastroenterology; Clinical endpoint; Tyrosine kinase 2; Clinical trial; Pharmacology; Immunology; Pathology; Receptor; Platelet-derived growth factor receptor","score_opus":0.02193395392893607,"score_gpt":0.28976311251673065,"score_spread":0.2678291585877946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892136519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939419,0.0021220776,0.0001387805,0.0007884546,0.002102189,0.00015031015,0.000008467098,0.00000564454,0.00074216985],"genre_scores_gemma":[0.9965216,0.00031567985,0.000081723905,0.000060917773,0.002719247,0.0000017231696,0.00002109458,0.000007902736,0.0002701198],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99881727,0.00024948633,0.00058588054,0.000107491134,0.000075837415,0.00016403696],"domain_scores_gemma":[0.99903035,0.0002045307,0.00041128136,0.000100695666,0.00020972743,0.00004341777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007866017,0.00012734634,0.00048552128,0.0003245051,0.00003846741,0.0000017919959,0.00006537294,0.00012584719,0.00042505132],"category_scores_gemma":[0.0003698087,0.0000844897,0.00007105043,0.00026572513,0.00017794997,0.00007621119,0.000010846595,0.00018148455,0.000013157058],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15444428,0.0013023891,0.00061192777,0.000012170068,0.00032199064,0.00011647529,0.0029746867,0.0000011491643,0.38924113,0.00013510477,0.009274225,0.44156447],"study_design_scores_gemma":[0.7143036,0.01964415,0.0009642267,0.00023175665,0.0002778579,0.00033587255,0.00014136078,8.3669823e-7,0.25198746,0.00055864075,0.011472287,0.00008193759],"about_ca_topic_score_codex":0.00012560739,"about_ca_topic_score_gemma":0.00009126941,"teacher_disagreement_score":0.55985934,"about_ca_system_score_codex":0.000041142845,"about_ca_system_score_gemma":0.00011856152,"threshold_uncertainty_score":0.4654014},"labels":[],"label_agreement":null},{"id":"W2892208354","doi":"10.4081/monaldi.2018.934","title":"Echocardiographic evaluation of diastolic dysfunction in young and healthy patients with psoriasis: A case-control study","year":2018,"lang":"en","type":"article","venue":"Monaldi Archives for Chest Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Ventricle; Psoriasis; Internal medicine; Cardiology; Diastole; Psoriatic arthritis; Cohort; Risk factor; Incidence (geometry); Disease; Population; Regurgitation (circulation); Case-control study; Blood pressure; Dermatology","score_opus":0.015465408069063633,"score_gpt":0.24880465822601364,"score_spread":0.23333925015695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892208354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606323,0.0010740052,0.00015915367,0.000030003665,0.00020084139,0.001984849,0.00042658174,0.000019431473,0.000041923646],"genre_scores_gemma":[0.9990536,0.000016980128,0.000047917263,0.000018923023,0.00004248052,0.00065703085,0.00013514466,0.000017015522,0.000010927244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986559,0.00043702914,0.00024291652,0.00034692683,0.00007963192,0.00023758422],"domain_scores_gemma":[0.9993236,0.00017983848,0.000120752054,0.00022189683,0.000093879185,0.000060041948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031933544,0.0001770612,0.00026598072,0.0002781978,0.0001675246,0.000006981082,0.00006017941,0.000044596,0.000014598606],"category_scores_gemma":[0.000069792695,0.00014258234,0.00008859407,0.0001597435,0.00020060973,0.000082608436,0.000018676254,0.00005562117,0.0000029035884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008586706,0.0011105206,0.92994165,0.000039262122,0.000479865,0.000007861684,0.0014724544,0.000015375832,0.00013176752,0.000015097306,0.000006687719,0.058192767],"study_design_scores_gemma":[0.018604644,0.001760701,0.9772352,0.00002989319,0.0013057626,0.000008628644,0.00036537024,0.00016973015,0.000052388303,0.00031725052,0.000015299354,0.00013514853],"about_ca_topic_score_codex":0.000090238915,"about_ca_topic_score_gemma":0.00042530222,"teacher_disagreement_score":0.058057617,"about_ca_system_score_codex":0.000021121987,"about_ca_system_score_gemma":0.00007774593,"threshold_uncertainty_score":0.58143395},"labels":[],"label_agreement":null},{"id":"W2893494515","doi":"10.1007/s40257-018-0388-z","title":"Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2018,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"Janssen Scientific Affairs; University of Pennsylvania","keywords":"Medicine; Psoriasis; Etanercept; Infliximab; Adalimumab; Internal medicine; Odds ratio; Confidence interval; Psoriasis Area and Severity Index; Methotrexate; Ustekinumab; Surgery; Dermatology; Rheumatoid arthritis; Disease","score_opus":0.04066805683277146,"score_gpt":0.39020595001039104,"score_spread":0.3495378931776196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893494515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978619,0.0004837025,0.000056922603,0.00039765215,0.00070453715,0.0002940542,0.000040316092,0.0000048649754,0.00015600762],"genre_scores_gemma":[0.9985632,0.0008656077,0.00036181667,0.00008310862,0.00007096938,0.000012628159,0.00001092122,0.0000146575185,0.000017120128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9916146,0.0049744304,0.002671206,0.0003100229,0.00014060977,0.00028916838],"domain_scores_gemma":[0.9856841,0.010552379,0.002991943,0.0005286524,0.00018289067,0.000060040282],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.002560411,0.0003039091,0.0029129009,0.00021331615,0.000052794243,0.0000048011225,0.00040458122,0.00027999535,0.000023408407],"category_scores_gemma":[0.0006319332,0.0001564116,0.0005813235,0.00025217354,0.0027345805,0.00004862191,0.00004557831,0.00041547272,0.0000051902994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070108143,0.0010754152,0.9269936,0.000051423525,0.002132119,0.0002496747,0.0002455913,0.000001225858,0.00014793068,0.00011486729,0.00009712829,0.061880223],"study_design_scores_gemma":[0.01029385,0.04446566,0.93729633,0.00025094426,0.0013584379,0.0027393415,0.0005736433,0.0000011663573,0.0025119877,0.000024534931,0.00034240648,0.00014166525],"about_ca_topic_score_codex":0.0001497238,"about_ca_topic_score_gemma":0.00007474863,"teacher_disagreement_score":0.061738558,"about_ca_system_score_codex":0.000031183223,"about_ca_system_score_gemma":0.00029310558,"threshold_uncertainty_score":0.9999794},"labels":[],"label_agreement":null},{"id":"W2894075989","doi":"10.3390/ijms19102923","title":"The Tissue-Engineered Human Psoriatic Skin Substitute: A Valuable In Vitro Model to Identify Genes with Altered Expression in Lesional Psoriasis","year":2018,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Centre hospitalier universitaire de Québec; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Université Laval","keywords":"Psoriasis; Gene expression profiling; Microarray; Gene; Gene expression; Pathology; Microarray analysis techniques; Human skin; Medicine; Gene chip analysis; DNA microarray; Biology; Dermatology; Genetics","score_opus":0.02672083809661,"score_gpt":0.31943512795577844,"score_spread":0.2927142898591684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894075989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274623,0.0016103449,0.0037794514,0.0004414586,0.0011315648,0.00011840379,0.000006825608,0.00000508774,0.00016059993],"genre_scores_gemma":[0.9946522,0.00006473156,0.004965827,0.00006742214,0.00009542751,0.000013279067,0.0000054967904,0.0000068991444,0.00012868985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987104,0.00014866621,0.00040372874,0.00020614167,0.0002920114,0.00023907727],"domain_scores_gemma":[0.9993266,0.0000919388,0.00019440163,0.00011582098,0.00023976088,0.000031478623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000821737,0.00013263812,0.00018234043,0.00040595682,0.0001788561,0.00008054463,0.000789722,0.00006806085,0.000041099967],"category_scores_gemma":[0.0000733324,0.000083035535,0.00006136756,0.00028371255,0.00020304737,0.00021345523,0.00007749836,0.00011593434,0.000020762558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045394583,0.00010499147,0.00030438512,0.0000012705365,0.000075336495,0.000044949436,0.00047355823,0.0033537664,0.9838247,0.00034712118,0.000108625456,0.010907352],"study_design_scores_gemma":[0.0018553631,0.000311584,0.0070961127,0.000121274774,0.000023700366,0.00011480924,0.00018709997,0.00030013456,0.98812574,0.0011949295,0.00053853495,0.00013070763],"about_ca_topic_score_codex":0.000052098276,"about_ca_topic_score_gemma":0.00012633135,"teacher_disagreement_score":0.010776645,"about_ca_system_score_codex":0.000081070786,"about_ca_system_score_gemma":0.00016044125,"threshold_uncertainty_score":0.3386091},"labels":[],"label_agreement":null},{"id":"W2895378661","doi":"10.1136/annrheumdis-2018-eular.6782","title":"THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Abdominal pain; Inflammatory bowel disease; Exacerbation; Disease","score_opus":0.052684517315116475,"score_gpt":0.3235493271148486,"score_spread":0.2708648097997321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895378661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206984,0.0008314274,0.00006264982,0.000095767595,0.00021753211,0.0013581598,0.0053170184,0.000033053144,0.000014550346],"genre_scores_gemma":[0.99874926,0.00017025793,0.00009286708,0.00010094043,0.00003496375,0.00006154207,0.0006867735,0.000024898905,0.00007848332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610156,0.0017372748,0.001157935,0.0004980474,0.00016000509,0.00034518758],"domain_scores_gemma":[0.99597174,0.0014352441,0.0009696972,0.0011415464,0.0003013601,0.00018040683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010701905,0.0003240942,0.00095210155,0.00007925678,0.00019335067,0.0000196942,0.0006993637,0.00009048936,0.00017419159],"category_scores_gemma":[0.0036729644,0.00019780737,0.00021794264,0.00012217741,0.00038693365,0.0002655233,0.00045261625,0.00009463324,0.000036011923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044566024,0.0009606343,0.94470274,0.00009838129,0.0013874024,0.0000046067257,0.00017890098,0.00001516205,0.000047945516,0.000013964864,0.0019556426,0.0060685794],"study_design_scores_gemma":[0.019893968,0.00036571623,0.9757904,0.001627217,0.0010273331,0.000002216375,0.000058346883,0.0001286773,0.0005544063,0.00032703075,0.00001603718,0.00020868985],"about_ca_topic_score_codex":0.0001788899,"about_ca_topic_score_gemma":0.000087953435,"teacher_disagreement_score":0.031087603,"about_ca_system_score_codex":0.000009446267,"about_ca_system_score_gemma":0.00019400263,"threshold_uncertainty_score":0.806635},"labels":[],"label_agreement":null},{"id":"W2895440481","doi":"10.1038/s41467-018-06672-6","title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Memorial University of Newfoundland; Krembil Foundation; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Krembil Foundation; National Research Foundation; National Psoriasis Foundation; Helene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust; A. Alfred Taubman Medical Research Institute; Dermatology Foundation; Regeneron Pharmaceuticals; Arthritis National Research Foundation; U.S. Department of Veterans Affairs; Foundation for the National Institutes of Health","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Receiver operating characteristic; Oncology; Internal medicine; Computational biology; Dermatology; Biology","score_opus":0.016030692676043935,"score_gpt":0.2730165040049279,"score_spread":0.25698581132888393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895440481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550135,0.009922756,0.00021178789,0.0004072651,0.0009382805,0.0010101635,0.0001620007,0.000052347747,0.0017940725],"genre_scores_gemma":[0.9555456,0.00083122373,0.042766776,0.00013929009,0.000034784927,0.00022773318,0.00029025873,0.00001946599,0.00014483943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982687,0.000489111,0.000537725,0.0003135122,0.0000881004,0.00030285455],"domain_scores_gemma":[0.9977428,0.00027889514,0.00025266665,0.0013127298,0.00037317892,0.000039735274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029548464,0.0002190692,0.00033552476,0.00028732393,0.0003294646,0.0000139593885,0.0008872228,0.0005327846,0.000121800826],"category_scores_gemma":[0.00029443053,0.00020435057,0.0000765015,0.0005563536,0.00014633861,0.00007451993,0.000329135,0.0006614916,0.00013698034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001237967,0.0018846437,0.48945403,0.000023291945,0.00053885585,0.0000013664543,0.00279845,0.000046038884,0.0036056966,0.0010979885,0.004965699,0.49546012],"study_design_scores_gemma":[0.0020566925,0.00023908417,0.9244075,0.0001147036,0.000089338566,0.000001964796,0.0000859554,0.000016399701,0.0058663264,0.000081014034,0.06679458,0.00024646267],"about_ca_topic_score_codex":0.000075296,"about_ca_topic_score_gemma":0.0038178824,"teacher_disagreement_score":0.49521366,"about_ca_system_score_codex":0.00015224221,"about_ca_system_score_gemma":0.00020250474,"threshold_uncertainty_score":0.8333174},"labels":[],"label_agreement":null},{"id":"W2897043380","doi":"10.1111/bjd.17318","title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase <scp>III</scp> trials","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Ortho Dermatologics","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Adverse effect; Psoriasis; Internal medicine; Randomized controlled trial; Psoriatic arthritis; Subgroup analysis; Body surface area; Dermatology; Adalimumab; Meta-analysis; Disease","score_opus":0.016526440334536593,"score_gpt":0.2833830834402225,"score_spread":0.2668566431056859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897043380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99433434,0.003843151,0.00049860054,0.000071333096,0.00032116176,0.00065529725,0.00020018387,0.000008186406,0.00006776924],"genre_scores_gemma":[0.998679,0.00070677686,0.00036395807,0.00004973692,0.000029928402,0.000013850883,0.000057244622,0.000018968773,0.00008055397],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99347264,0.003516314,0.0021968326,0.00029774432,0.00012644615,0.0003900553],"domain_scores_gemma":[0.9934349,0.003939583,0.0017643295,0.00023495845,0.0005465538,0.00007967226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018604026,0.0002626413,0.0036112727,0.0012397557,0.00010753153,0.000018708948,0.0002699348,0.00026537705,0.000056246623],"category_scores_gemma":[0.0027886715,0.0002269551,0.0004201878,0.0008683607,0.0006120186,0.00015304083,0.00006846595,0.00020651938,0.0000047801936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6532732,0.0034201415,0.18216874,0.00007534459,0.025135629,0.00062895514,0.003910601,0.000026379505,0.005778865,0.00023912363,0.0012146354,0.12412839],"study_design_scores_gemma":[0.6902877,0.0018398907,0.26479137,0.00045064348,0.007798893,0.0017793819,0.0002577393,0.0000074225545,0.032071516,0.000059815156,0.0004735267,0.00018212345],"about_ca_topic_score_codex":0.00037663392,"about_ca_topic_score_gemma":0.0004938055,"teacher_disagreement_score":0.12394626,"about_ca_system_score_codex":0.000039721854,"about_ca_system_score_gemma":0.00015082052,"threshold_uncertainty_score":0.92549604},"labels":[],"label_agreement":null},{"id":"W2897116385","doi":"10.1111/bjd.17038","title":"Ixekizumab in genital psoriasis","year":2018,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Ixekizumab; Psoriasis; Dermatology; Medicine; Sex organ; Biology; Psoriatic arthritis; Secukinumab","score_opus":0.013219328369075627,"score_gpt":0.22586833331081116,"score_spread":0.21264900494173553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897116385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54804176,0.13635406,0.00010285798,0.2799861,0.027798982,0.0007902601,0.00073542667,0.00011965114,0.0060708956],"genre_scores_gemma":[0.6697612,0.012855515,0.0011623695,0.28497228,0.01367162,0.00010161216,0.0023531353,0.00047070064,0.014651624],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967224,0.0008571208,0.0012147924,0.00036103567,0.000099235185,0.00074539066],"domain_scores_gemma":[0.9982635,0.0002996447,0.00087219966,0.0002620076,0.00026926387,0.000033407927],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018830768,0.00039289688,0.0013412657,0.0006130846,0.00012973341,0.000046740366,0.00066957937,0.00239774,0.0012014054],"category_scores_gemma":[0.00015975357,0.0004348848,0.00048257664,0.00020425257,0.00035463876,0.00016091502,0.00009413757,0.0021877992,0.0007280924],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015449719,0.00010955175,0.00083579274,0.000043021588,0.00073595176,0.053461924,0.00010687686,9.080504e-8,0.00013538111,0.000003709975,0.8996521,0.044761065],"study_design_scores_gemma":[0.0036204357,0.00015290697,0.0018709652,0.0002626396,0.00031613663,0.3291815,0.000041423253,1.07848116e-7,0.0017762155,0.00017738302,0.6622721,0.00032819554],"about_ca_topic_score_codex":0.000115371935,"about_ca_topic_score_gemma":0.0001368236,"teacher_disagreement_score":0.27571958,"about_ca_system_score_codex":0.000114628754,"about_ca_system_score_gemma":0.00034068822,"threshold_uncertainty_score":0.9998103},"labels":[],"label_agreement":null},{"id":"W2897199008","doi":"10.1111/bjd.17335","title":"Network meta‐analyses of systemic treatments for psoriasis: a critical appraisal","year":2018,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Critical appraisal; Psoriasis; Systemic risk; Systemic therapy; Medicine; Psychology; Dermatology; Internal medicine; Alternative medicine; Economics; Pathology","score_opus":0.07494401286254536,"score_gpt":0.3382779030980835,"score_spread":0.2633338902355381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897199008","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025179038,0.8468709,0.0045810193,0.08423341,0.03395318,0.0015622644,0.0029886072,0.00012106724,0.00051052624],"genre_scores_gemma":[0.82176054,0.024633426,0.014243256,0.09767157,0.030005226,0.001232227,0.0049579046,0.0008748527,0.0046210266],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99528253,0.0014110578,0.0018672339,0.00044843135,0.00013372059,0.00085704227],"domain_scores_gemma":[0.9935671,0.003607919,0.0016378885,0.00034932894,0.0007850798,0.000052668634],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00032355168,0.00055869477,0.003378081,0.00033248487,0.00022586282,0.000038428967,0.00064397743,0.0020851041,0.00037993895],"category_scores_gemma":[0.00071009167,0.0005057761,0.0017987867,0.00017871449,0.0005666396,0.00013511619,0.000072571456,0.00087281695,0.00006565126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046157482,0.00021696977,0.0001388498,0.00037488982,0.05467257,0.004264709,0.0000730292,0.000001792711,0.0007922632,0.000034255096,0.9362814,0.0026877192],"study_design_scores_gemma":[0.009907758,0.0014206535,0.00017649376,0.0018844317,0.14350054,0.4938338,0.00015415883,0.0000014417041,0.010678699,0.0009812838,0.33652335,0.0009373866],"about_ca_topic_score_codex":0.00006796312,"about_ca_topic_score_gemma":0.000012091344,"teacher_disagreement_score":0.82223743,"about_ca_system_score_codex":0.000055237375,"about_ca_system_score_gemma":0.00034497783,"threshold_uncertainty_score":0.9997394},"labels":[],"label_agreement":null},{"id":"W2897664436","doi":"10.3899/jrheum.180566","title":"Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy","year":2018,"lang":"en","type":"letter","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Ankylosing spondylitis; Abatacept; Palmoplantar pustulosis; Psoriasis; Rheumatoid arthritis; Rheumatology; Tocilizumab; Internal medicine; Adalimumab; Etanercept; Adverse effect; Dermatology; Infliximab; Rituximab; Psoriatic arthritis; Tofacitinib; Immunology; Tumor necrosis factor alpha; Lymphoma","score_opus":0.01835998642492456,"score_gpt":0.21033435853672275,"score_spread":0.19197437211179819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897664436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474073,0.007981749,0.0000041307144,0.00620233,0.00036780833,0.00044625602,0.00021808095,0.000019088211,0.000019799993],"genre_scores_gemma":[0.93915945,0.057457153,0.000072136085,0.0028292434,0.000036628364,0.000026689124,0.00031152242,0.00004987693,0.000057319736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959452,0.0017920636,0.0010023474,0.0004188375,0.00013146468,0.0007100504],"domain_scores_gemma":[0.99705786,0.0013741971,0.0010244779,0.00033687832,0.00017001698,0.000036569018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054223964,0.00063996046,0.001850107,0.00062404916,0.00018725762,0.000032204258,0.0004877837,0.0012179072,0.0005412702],"category_scores_gemma":[0.00007400886,0.00029367642,0.0000996311,0.00036076707,0.0009076721,0.00012806887,0.00006650928,0.0013636494,0.00001576427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013927533,0.0002480091,0.9667673,0.000022505712,0.0010441231,0.00029011015,0.0008908449,1.5864639e-7,0.000020329935,0.0000031282111,0.008724306,0.008061638],"study_design_scores_gemma":[0.02860742,0.011617244,0.9159048,0.0028434345,0.00019754926,0.014687142,0.00056444405,6.531466e-7,0.00041717832,0.00009378679,0.024087466,0.0009788646],"about_ca_topic_score_codex":0.0010203681,"about_ca_topic_score_gemma":0.0010621932,"teacher_disagreement_score":0.0508625,"about_ca_system_score_codex":0.00008171521,"about_ca_system_score_gemma":0.00014197695,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W2897757466","doi":"10.1177/2475530318806255","title":"Eight-Patient Case Series of Palmoplantar Pustulosis Treated Successfully With Apremilast","year":2018,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; Trent University; SKiN Health","funders":"","keywords":"Apremilast; Medicine; Psoriatic arthritis; Dermatology; Psoriasis; Population; Ustekinumab; Palmoplantar pustulosis; Internal medicine; Adalimumab; Disease","score_opus":0.009125517270176981,"score_gpt":0.20653983874739915,"score_spread":0.19741432147722215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897757466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897826,0.00791645,0.000052309882,0.000117204654,0.0012322211,0.00019332854,0.00017922503,0.000014569603,0.00051213393],"genre_scores_gemma":[0.99493676,0.003363332,0.0010737242,0.000030070281,0.00037433775,0.000009902269,0.00002096684,0.00002545351,0.00016546772],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981627,0.00025155972,0.0008693573,0.00025089664,0.00012539649,0.00034009854],"domain_scores_gemma":[0.9981675,0.00019544612,0.0008320457,0.0002443681,0.00047195278,0.00008867092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029882934,0.0003144892,0.00078869995,0.0002446518,0.0002902929,0.00003091331,0.00014066033,0.00021645814,0.0005364363],"category_scores_gemma":[0.00006637943,0.0002203059,0.00016533454,0.00025052257,0.00037133816,0.00030340214,0.00004346537,0.00016262245,0.000020967542],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009324969,0.0012794872,0.07150726,0.00017813825,0.0063929236,0.0048443847,0.011308963,0.0000059327713,0.020401591,0.0008289913,0.0075953496,0.866332],"study_design_scores_gemma":[0.03688736,0.039098233,0.030203937,0.0023349582,0.005075118,0.20212118,0.011665577,0.0000097515895,0.6156902,0.0009004849,0.0541409,0.0018723028],"about_ca_topic_score_codex":0.00017034016,"about_ca_topic_score_gemma":0.00046443363,"teacher_disagreement_score":0.8644597,"about_ca_system_score_codex":0.000032548076,"about_ca_system_score_gemma":0.00009291018,"threshold_uncertainty_score":0.8983814},"labels":[],"label_agreement":null},{"id":"W2898213950","doi":"10.1016/j.jaad.2018.10.037","title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine","score_opus":0.03829803433769064,"score_gpt":0.34196070957018015,"score_spread":0.3036626752324895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898213950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233055,0.0036717912,0.00013934266,0.002103291,0.0006409109,0.0010040344,0.00005354228,0.000006047278,0.000050500028],"genre_scores_gemma":[0.99780023,0.0015957342,0.00022621208,0.00008601258,0.000114726354,0.00004971381,0.0000020521563,0.000018538212,0.00010677432],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968389,0.0012127357,0.0013631573,0.00017700587,0.00010108229,0.00030708656],"domain_scores_gemma":[0.9930293,0.0026866975,0.0038245493,0.0002681186,0.00016118064,0.000030147816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005225591,0.0002614582,0.002017819,0.0002551838,0.00019033649,0.0000032534072,0.00066328427,0.00016483259,0.00005560294],"category_scores_gemma":[0.00020503804,0.00013099941,0.000785154,0.00031049017,0.001791929,0.000060229457,0.000056225526,0.00017906088,0.000004363534],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4573505,0.025348537,0.017267467,0.000114291695,0.032202948,0.000021474614,0.02142941,0.000034532477,0.32746792,0.0011400126,0.0059073423,0.111715555],"study_design_scores_gemma":[0.35068327,0.014628909,0.005185137,0.00008956362,0.0062875776,0.0013441285,0.0061126114,0.000021783471,0.60503286,0.0004262898,0.009944836,0.00024304548],"about_ca_topic_score_codex":0.0001007915,"about_ca_topic_score_gemma":0.000008364914,"teacher_disagreement_score":0.2775649,"about_ca_system_score_codex":0.00004677196,"about_ca_system_score_gemma":0.000102378544,"threshold_uncertainty_score":0.6602437},"labels":[],"label_agreement":null},{"id":"W2899058675","doi":"10.11606/issn.2176-7262.v50i6p377-381","title":"Post-inflammatory hyperchromia associated with psoriasis. Case report","year":2018,"lang":"en","type":"article","venue":"Medicina (Ribeirão Preto)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"","keywords":"Psoriasis; Medicine; Disease; Dermatology; Immunology; Pathology","score_opus":0.01360860051490367,"score_gpt":0.2373982791327495,"score_spread":0.22378967861784582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899058675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98782617,0.0012638686,0.00004427353,0.0003237483,0.0020886494,0.00047599064,0.00008140892,0.0003247851,0.0075710914],"genre_scores_gemma":[0.9892336,0.000025611322,0.000098872704,0.00033035275,0.00038497447,0.0000758268,0.00049722526,0.000055982542,0.009297517],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9976933,0.00033855543,0.00051653717,0.00063673593,0.00012947309,0.00068538275],"domain_scores_gemma":[0.99818265,0.0002760545,0.0003052242,0.00074872497,0.00038767682,0.000099640405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079429767,0.0004123778,0.00058157096,0.00016838236,0.0004733253,0.000017331724,0.00024265356,0.00049463945,0.001722192],"category_scores_gemma":[0.0005165553,0.00030183353,0.00012842605,0.00024869395,0.0006569227,0.00014703585,0.00007654128,0.0003101185,0.0008567803],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005455781,0.0019017915,0.16299982,0.00017253227,0.011104123,0.3461245,0.020193527,0.0000022079016,0.23173131,0.0009727466,0.0555139,0.16382776],"study_design_scores_gemma":[0.029969994,0.010015678,0.29193455,0.0010389051,0.0056982706,0.30353653,0.0051234523,0.000017750841,0.25599563,0.00038388936,0.09309696,0.0031883824],"about_ca_topic_score_codex":0.00030826704,"about_ca_topic_score_gemma":0.0007624561,"teacher_disagreement_score":0.16063939,"about_ca_system_score_codex":0.00016311469,"about_ca_system_score_gemma":0.00025413718,"threshold_uncertainty_score":0.9999434},"labels":[],"label_agreement":null},{"id":"W2899230583","doi":"10.1136/annrheumdis-2018-eular.2137","title":"THU0333 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation","funders":"NordForsk; Oak Foundation","keywords":"Medicine; Ixekizumab; Discontinuation; Psoriatic arthritis; Internal medicine; Adverse effect; Placebo; Rheumatology; Psoriasis; Physical therapy; Arthritis; Secukinumab; Dermatology; Alternative medicine","score_opus":0.0212153636489128,"score_gpt":0.2711073827062123,"score_spread":0.24989201905729952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899230583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955587,0.0013419824,0.0000026987718,0.00009664304,0.0001509993,0.0008455125,0.0019167378,0.00001370153,0.00007306612],"genre_scores_gemma":[0.99957603,0.00018423569,0.000017697761,0.000019259438,0.000011652485,0.000023190541,0.00013320381,0.000012635394,0.00002209975],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99868935,0.00027073288,0.00048159974,0.00026188788,0.0000943685,0.00020206017],"domain_scores_gemma":[0.9986137,0.00040015831,0.000362412,0.0004758457,0.00011802208,0.000029859615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001326846,0.0001857502,0.00047175307,0.00007701164,0.000097844655,0.000007648403,0.00022032697,0.00006437411,0.00008769441],"category_scores_gemma":[0.0003287497,0.00011776611,0.00007624532,0.00016961966,0.0003056554,0.00009756371,0.000092336864,0.000059452886,0.000019141615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033577953,0.010204024,0.07054622,0.000043685097,0.0022999765,0.0000025031475,0.005554219,0.0000041155618,0.000035975107,0.00004334811,0.0004603079,0.87722766],"study_design_scores_gemma":[0.029965,0.0022561448,0.9639566,0.0007150749,0.00028057667,3.008043e-7,0.00059826055,0.0000023583523,0.001590125,0.00047153927,0.000030912088,0.00013308517],"about_ca_topic_score_codex":0.0003413281,"about_ca_topic_score_gemma":0.00023543948,"teacher_disagreement_score":0.8934104,"about_ca_system_score_codex":0.000009152892,"about_ca_system_score_gemma":0.000057519046,"threshold_uncertainty_score":0.48023626},"labels":[],"label_agreement":null},{"id":"W2900165792","doi":"","title":"Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Psoriasis; Observational study; Pharmacy; Health plan; Young adult; Retrospective cohort study; Pediatrics; Health care; Demography; Family medicine; Internal medicine; Dermatology","score_opus":0.013800724498990039,"score_gpt":0.22379856474827298,"score_spread":0.20999784024928295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900165792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835277,0.00083689095,0.000010870795,0.0000861524,0.00006072736,0.00052650133,0.000080235346,0.000011104732,0.00003472641],"genre_scores_gemma":[0.99925566,0.00016539983,0.000010184921,0.00012752763,0.000012814482,0.0002413932,0.00012268437,0.0000051261536,0.00005923836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884063,0.00039113907,0.00023140242,0.00022140103,0.000036441525,0.0002789853],"domain_scores_gemma":[0.99953306,0.00008994189,0.000088698675,0.00024263894,0.000031663065,0.00001400824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048493547,0.000116871444,0.00021372401,0.00047296987,0.00004064284,0.0000066360462,0.0001970136,0.00010881613,0.000027114034],"category_scores_gemma":[0.00003968767,0.000081620805,0.000057839534,0.00099844,0.00018771338,0.000034645844,0.000025430898,0.00008548884,0.0000073834753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022592382,0.00022122345,0.98129886,0.0000178589,0.00025734922,0.0000010453151,0.0004525038,0.000011990929,0.000048357466,0.000010787156,0.000058108275,0.017395966],"study_design_scores_gemma":[0.0020053387,0.000044880246,0.9957016,0.000016841263,0.0003730195,0.0000019865345,0.00005611553,0.000015448171,0.0016005699,0.000029521636,0.00007501449,0.00007966342],"about_ca_topic_score_codex":0.0005884876,"about_ca_topic_score_gemma":0.00036680515,"teacher_disagreement_score":0.017316302,"about_ca_system_score_codex":0.00002102249,"about_ca_system_score_gemma":0.000012357948,"threshold_uncertainty_score":0.33284},"labels":[],"label_agreement":null},{"id":"W2900493427","doi":"10.1007/s10067-018-4363-0","title":"Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience","year":2018,"lang":"en","type":"erratum","venue":"Clinical Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Toronto Western Hospital","funders":"","keywords":"Tel aviv; Medicine; Rheumatology; Center (category theory); Psoriasis; Family medicine; Internal medicine; Dermatology; Library science","score_opus":0.03983067049341651,"score_gpt":0.31371299436431777,"score_spread":0.2738823238709013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900493427","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43045688,0.0066776974,0.00009528708,0.00018752704,0.55314714,0.0010273174,0.000107172076,0.00026723466,0.008033775],"genre_scores_gemma":[0.5754603,0.00649382,0.00019203452,0.00079901505,0.0013527039,0.0012842199,0.0022498958,0.00028243146,0.4118856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935066,0.0014386512,0.0023156048,0.0015747634,0.0000953602,0.0010689838],"domain_scores_gemma":[0.99594134,0.0018184617,0.00080376375,0.0011071977,0.00019657158,0.00013263598],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00076474785,0.0007606145,0.0024262643,0.0005204395,0.00018352081,0.00003458027,0.00084551517,0.0032143935,0.001043464],"category_scores_gemma":[0.0028464897,0.00068689644,0.0005765426,0.0004583697,0.00063626387,0.00008953981,0.00035927747,0.0013898703,0.007392672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008953207,0.0009538149,0.09054239,0.000115290706,0.00039838444,0.00006613377,0.0011628913,2.5463936e-7,0.0001123085,0.00004120271,0.893387,0.012325009],"study_design_scores_gemma":[0.008552265,0.002105913,0.002886616,0.004643482,0.00030153044,0.013886447,0.0011346034,0.000012779036,0.00030181423,0.00010370706,0.9646474,0.0014234241],"about_ca_topic_score_codex":0.00018418825,"about_ca_topic_score_gemma":0.00086731085,"teacher_disagreement_score":0.5517944,"about_ca_system_score_codex":0.0002648034,"about_ca_system_score_gemma":0.00032436955,"threshold_uncertainty_score":0.9998697},"labels":[],"label_agreement":null},{"id":"W2900581149","doi":"10.1111/jdv.15369","title":"Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"LEO Pharma","keywords":"Medicine; Psoriasis; Apremilast; Betamethasone dipropionate; Acitretin; Calcipotriol; Methotrexate; Dermatology; Internal medicine; Population; Psoriatic arthritis","score_opus":0.05021722530616508,"score_gpt":0.2970588162189813,"score_spread":0.2468415909128162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900581149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98075235,0.0132783,0.0008466788,0.002907776,0.0013387519,0.0005914016,0.00007304179,0.000020121239,0.00019155873],"genre_scores_gemma":[0.9960932,0.0021295792,0.0008754888,0.00022617845,0.0001902211,0.000020410893,0.00000959189,0.00003578895,0.0004195207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952758,0.0027077077,0.0011890403,0.00030393736,0.0000775701,0.0004459384],"domain_scores_gemma":[0.9961533,0.0016610412,0.0017440965,0.00026338582,0.00012388776,0.0000542899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072089274,0.0003772363,0.0013528464,0.0002335286,0.00035122113,0.00000767463,0.0007018724,0.00044404904,0.00006106467],"category_scores_gemma":[0.00016737345,0.00019283975,0.000414599,0.00023760257,0.0012476672,0.00008077255,0.00014847014,0.0004211492,0.000012893981],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070469975,0.003574874,0.20136008,0.0007168893,0.025509913,0.00020204973,0.03463432,0.00029288948,0.40371108,0.0018726287,0.016331986,0.2413233],"study_design_scores_gemma":[0.021370769,0.0026818977,0.07626291,0.00029663963,0.0051949373,0.0074544363,0.0011254697,0.000083291496,0.840661,0.00047717066,0.043853085,0.0005384002],"about_ca_topic_score_codex":0.000018237663,"about_ca_topic_score_gemma":0.000025330417,"teacher_disagreement_score":0.4369499,"about_ca_system_score_codex":0.00005533629,"about_ca_system_score_gemma":0.0001053822,"threshold_uncertainty_score":0.78637767},"labels":[],"label_agreement":null},{"id":"W2900677307","doi":"10.1177/1203475418814229","title":"Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice","year":2018,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Ixekizumab; Medicine; Erythema; Randomized controlled trial; Psoriasis; Adverse effect; Clinical trial; Psoriasis Area and Severity Index; Internal medicine; Physical therapy; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.050742197539561336,"score_gpt":0.34040015033730675,"score_spread":0.2896579527977454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900677307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98531276,0.004402096,0.00001021399,0.0047952337,0.0023632261,0.00011591125,0.0000067428273,0.000015003057,0.0029788418],"genre_scores_gemma":[0.9836088,0.012710423,0.00013126322,0.0010449772,0.000561184,0.0000011294945,0.00001109583,0.00001720791,0.0019139565],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746627,0.00056207215,0.0013349564,0.00023310124,0.00009789888,0.00030573297],"domain_scores_gemma":[0.99194735,0.00697111,0.0006486465,0.00017633414,0.00016208299,0.00009445334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018565098,0.00022389453,0.0011165637,0.00038671235,0.0001324337,0.000013601855,0.00010057151,0.0001921252,0.0001972935],"category_scores_gemma":[0.0018570924,0.00014711506,0.00014124998,0.0001418633,0.0005565936,0.00013609043,0.000039862298,0.00039027396,0.000021598724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02043532,0.0014607885,0.4338927,0.000057771027,0.0019019495,0.0078005292,0.0027497744,3.7475863e-7,0.0023963714,0.00016563879,0.045332134,0.48380664],"study_design_scores_gemma":[0.011668317,0.0060056993,0.46516246,0.0009869254,0.0013310979,0.035652343,0.0020521272,0.0000033280662,0.0007348294,0.00021671859,0.47565597,0.00053019996],"about_ca_topic_score_codex":0.000186887,"about_ca_topic_score_gemma":0.00027639125,"teacher_disagreement_score":0.48327646,"about_ca_system_score_codex":0.000043046006,"about_ca_system_score_gemma":0.00014398903,"threshold_uncertainty_score":0.5999178},"labels":[],"label_agreement":null},{"id":"W2900923904","doi":"10.12968/indn.2018.11.20","title":"Managing psoriasis – how to answer questions patients ask?","year":2018,"lang":"en","type":"article","venue":"Independent Nurse","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Learning Partnership","funders":"","keywords":"Medicine; Ask price; Psoriasis; Questions and answers; Dermatology; Family medicine; World Wide Web","score_opus":0.012422763415259138,"score_gpt":0.24764130589730834,"score_spread":0.2352185424820492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900923904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973497,0.00042847,0.0003208519,0.0012758687,0.008637049,0.0005305248,0.00010124183,0.00020789495,0.015001142],"genre_scores_gemma":[0.9787195,0.000018546441,0.00023430184,0.00043957337,0.0002707983,0.00008198653,0.00013182219,0.000028519124,0.020074967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871206,0.00014577934,0.00018281686,0.0004368422,0.000082168975,0.00044035635],"domain_scores_gemma":[0.9991886,0.000037645877,0.00007693316,0.00043888166,0.000185264,0.0000726929],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001278059,0.00023901975,0.00022141957,0.00023512295,0.00030777085,0.000043559547,0.00028497333,0.00023772933,0.0007851985],"category_scores_gemma":[0.000055208544,0.00021703985,0.00010614195,0.00021734284,0.00009935412,0.00015064969,0.00006817245,0.00013266892,0.004692899],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059823337,0.0016381006,0.11808598,0.000014252726,0.0007221751,0.000023900346,0.0024560953,0.0000027073295,0.014624231,0.0021049548,0.091807045,0.76792234],"study_design_scores_gemma":[0.0061426368,0.0016044605,0.3847615,0.00017846674,0.0006169104,0.000053877455,0.0016076514,0.0000032403893,0.06668833,0.0013217117,0.5358827,0.0011384877],"about_ca_topic_score_codex":0.00010140196,"about_ca_topic_score_gemma":0.00015834061,"teacher_disagreement_score":0.76678383,"about_ca_system_score_codex":0.000089513334,"about_ca_system_score_gemma":0.000055897268,"threshold_uncertainty_score":0.99608207},"labels":[],"label_agreement":null},{"id":"W2901315913","doi":"10.1136/annrheumdis-2018-eular.2983","title":"AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"Sanofi Genzyme; Allergan; LEO Pharma; Astellas Pharma; Dermira; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Active Biotech; Biogen; Celgene; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Placebo; Internal medicine; Psoriasis; Gastroenterology; Clinical trial; Randomized controlled trial; Dermatology; Pathology","score_opus":0.0742742728827114,"score_gpt":0.389371472254729,"score_spread":0.31509719937201763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901315913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511194,0.002219319,0.0000041301037,0.00038817863,0.0004078528,0.00090968865,0.00089898444,0.00002767926,0.00003219977],"genre_scores_gemma":[0.9989205,0.000151016,0.000012553871,0.00014017725,0.000037502854,0.000053520223,0.00012777229,0.000027856806,0.00052912306],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9930141,0.004635024,0.0013718647,0.00040091632,0.00012637922,0.00045170495],"domain_scores_gemma":[0.9943872,0.0040848944,0.0006992617,0.0006654482,0.00009813006,0.00006507167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026387454,0.0003125113,0.0011497184,0.00018142656,0.00010528307,0.000018146671,0.00045660092,0.00015620643,0.0010561218],"category_scores_gemma":[0.0032536949,0.00019539033,0.00036839972,0.00032513024,0.00049034384,0.00014699047,0.00010496339,0.00014778775,0.00031442504],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14321946,0.030980403,0.21019647,0.00018965654,0.0041733473,0.000015408263,0.0014091542,0.00003104456,0.0022991414,0.0000953465,0.064354524,0.54303604],"study_design_scores_gemma":[0.045199975,0.0025964915,0.9434179,0.00097214873,0.00035661948,0.0000015191224,0.000021389078,0.000018315692,0.0058427216,0.00018565178,0.0010604301,0.00032681972],"about_ca_topic_score_codex":0.0001296688,"about_ca_topic_score_gemma":0.000057432448,"teacher_disagreement_score":0.7332215,"about_ca_system_score_codex":0.000054796008,"about_ca_system_score_gemma":0.00029576718,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W2901523494","doi":"10.1007/s40257-018-0396-z","title":"Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies","year":2018,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Medicine; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Placebo; Quality of life (healthcare); Internal medicine; Minimal clinically important difference; Dermatology; Randomized controlled trial; Disease; Pathology","score_opus":0.03698518268949746,"score_gpt":0.34539625998573364,"score_spread":0.3084110772962362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901523494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98440266,0.0027822994,0.00009614873,0.01143515,0.0006043302,0.0005588081,0.00007174758,0.00001527089,0.000033614],"genre_scores_gemma":[0.9947069,0.001972725,0.00012105109,0.0030398061,0.00006762385,0.00004117499,0.000014065706,0.000020949661,0.000015661375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925611,0.003338287,0.0028845314,0.000586563,0.00012301038,0.0005064946],"domain_scores_gemma":[0.9874306,0.009911392,0.0018356675,0.0004548833,0.00022592154,0.00014159108],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0016797632,0.0004188465,0.0024093792,0.00020192629,0.00023828493,0.0000320207,0.0003018354,0.00028392146,0.000011303848],"category_scores_gemma":[0.0026755042,0.00021857866,0.00014337517,0.00029567588,0.0033009525,0.00015055409,0.00025068672,0.000676181,0.000004266109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09820367,0.0011453462,0.71025866,0.000021572281,0.0067288303,0.0008101888,0.015895851,0.000010562008,0.00028007504,0.00032328797,0.0010015455,0.16532044],"study_design_scores_gemma":[0.24616924,0.009188466,0.70438534,0.00034260855,0.0018350428,0.003927455,0.0261067,0.000112679496,0.0019141794,0.0017342662,0.003084304,0.0011997294],"about_ca_topic_score_codex":0.0011360337,"about_ca_topic_score_gemma":0.0014470966,"teacher_disagreement_score":0.1641207,"about_ca_system_score_codex":0.000030267467,"about_ca_system_score_gemma":0.00021906788,"threshold_uncertainty_score":0.99941146},"labels":[],"label_agreement":null},{"id":"W2901528591","doi":"10.1177/1203475418814234","title":"Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents","year":2018,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Health Sciences Centre; Sunnybrook Health Science Centre; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dosing; Grading (engineering); Methotrexate; Clinical trial; Intensive care medicine; Randomized controlled trial; Ustekinumab; Infliximab; MEDLINE; Dermatology; Surgery; Internal medicine; Tumor necrosis factor alpha","score_opus":0.1636607198195812,"score_gpt":0.3916103064598284,"score_spread":0.22794958664024723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901528591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019395171,0.995569,0.000050825132,0.0002328287,0.0010408368,0.0010236059,0.00009451156,0.000007141224,0.000041759045],"genre_scores_gemma":[0.0006301597,0.99812704,0.00024844313,0.00036440213,0.00022774901,0.00004293002,0.00008042996,0.00003103892,0.00024781242],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626124,0.00044705076,0.0026528835,0.00027965213,0.00011152555,0.00024763332],"domain_scores_gemma":[0.9952822,0.0012870423,0.0025253915,0.00025575268,0.0005882763,0.00006136676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014571727,0.00044661693,0.0049525616,0.00049055985,0.00007011085,0.000004677412,0.00020522378,0.00034125356,0.00009490367],"category_scores_gemma":[0.00029469928,0.00025444885,0.0005416905,0.00019514133,0.00016906034,0.00003337256,0.000038229387,0.00015029985,0.0000025585668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079314754,0.00013689285,0.00010787668,0.09819832,0.0049964325,0.00006847274,0.00033119402,3.2029664e-7,0.00006346872,0.000015718333,0.094307855,0.8009803],"study_design_scores_gemma":[0.00082145055,0.0009989851,0.0000029843238,0.20823227,0.00389399,0.004527518,0.00027285438,6.1772613e-7,0.000029041748,0.000026969396,0.7809735,0.00021980114],"about_ca_topic_score_codex":0.000009837106,"about_ca_topic_score_gemma":0.0000017679921,"teacher_disagreement_score":0.8007605,"about_ca_system_score_codex":0.00003498012,"about_ca_system_score_gemma":0.00014231684,"threshold_uncertainty_score":0.99999076},"labels":[],"label_agreement":null},{"id":"W2902091069","doi":"10.1111/exd.13850","title":"Membrane‐enriched solute carrier family 2 member 1 (<scp>SLC</scp>2A1/<scp>GLUT</scp>1) in psoriatic keratinocytes confers sensitivity to 2‐deoxy‐D‐glucose (2‐<scp>DG</scp>) treatment","year":2018,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Health and Family Planning Commission of Hunan Province; National Natural Science Foundation of China","keywords":"Psoriasis; Glycolysis; Glucose uptake; Glucose transporter; Chemistry; Carbohydrate metabolism; Cancer research; Imiquimod; Keratinocyte; Pharmacology; In vivo; Biochemistry; Cell biology; Biology; Metabolism; Endocrinology; In vitro; Immunology; Insulin; Biotechnology","score_opus":0.023117691183459466,"score_gpt":0.26866479356185907,"score_spread":0.2455471023783996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902091069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97071415,0.009355342,0.000075343094,0.00014173843,0.0036635234,0.0017612143,0.0003606638,0.00038686124,0.013541154],"genre_scores_gemma":[0.98982465,0.00038659116,0.00050296896,0.0013632245,0.0003180801,0.00078237604,0.0007539677,0.00016116639,0.0059069446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99264526,0.0017871683,0.0012744656,0.0017562336,0.00023481931,0.0023020308],"domain_scores_gemma":[0.9957013,0.0021326153,0.0004569402,0.00112572,0.000204283,0.00037910542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00037952105,0.0014292747,0.0020438328,0.0006769784,0.00077166,0.00011379557,0.00053161255,0.0012714037,0.00016427308],"category_scores_gemma":[0.0005040704,0.0013462995,0.0005169807,0.00066755473,0.00084589527,0.0004184656,0.00042419878,0.00047187298,0.003765517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012093393,0.0016776777,0.009492288,0.000040862393,0.0016125523,0.00089302025,0.018024528,0.0000142385725,0.9423736,0.0008994781,0.02318052,0.001670336],"study_design_scores_gemma":[0.007830112,0.0009974501,0.012304573,0.00004793453,0.00032622617,0.0012205763,0.009328218,0.00007416932,0.89164686,0.000042549815,0.07592711,0.00025421486],"about_ca_topic_score_codex":0.0012748955,"about_ca_topic_score_gemma":0.0008027052,"teacher_disagreement_score":0.05274659,"about_ca_system_score_codex":0.0006879455,"about_ca_system_score_gemma":0.0003934031,"threshold_uncertainty_score":0.99984574},"labels":[],"label_agreement":null},{"id":"W2902424295","doi":"10.1016/j.annder.2018.09.150","title":"Interventions dans la pustulose palmoplantaire : revue systématique Cochrane","year":2018,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Humanities; Philosophy; Medicine","score_opus":0.046336218679031135,"score_gpt":0.3385852053012667,"score_spread":0.29224898662223553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902424295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85135365,0.10012408,0.005032904,0.018679768,0.004195149,0.00067406194,0.0008041853,0.0006907844,0.018445425],"genre_scores_gemma":[0.960277,0.023708792,0.0016881857,0.0014574062,0.00028742498,0.00021355723,0.0005278736,0.000073023904,0.011766704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99270684,0.0038654017,0.0009380943,0.0007974792,0.000076097655,0.001616111],"domain_scores_gemma":[0.99614894,0.0020730675,0.00044321688,0.000916286,0.0002473047,0.00017116478],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014575691,0.0007037325,0.0010367783,0.00030893474,0.0005608791,0.000105851046,0.0009502635,0.0019679018,0.0007780551],"category_scores_gemma":[0.0013042466,0.0007017385,0.0007600374,0.00040709216,0.0021342267,0.00030258807,0.00040427042,0.00086154835,0.0025094985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002075027,0.0052197245,0.39269093,0.011100827,0.0064197406,0.021872105,0.022196174,0.00008757112,0.032407988,0.11295966,0.31213734,0.08083292],"study_design_scores_gemma":[0.010400417,0.003793287,0.31205252,0.014814641,0.005293617,0.12323643,0.012839016,0.00024098186,0.19117112,0.022480343,0.29962954,0.004048057],"about_ca_topic_score_codex":0.0002905457,"about_ca_topic_score_gemma":0.00079064927,"teacher_disagreement_score":0.15876314,"about_ca_system_score_codex":0.00042643645,"about_ca_system_score_gemma":0.0008595128,"threshold_uncertainty_score":0.99954337},"labels":[],"label_agreement":null},{"id":"W2902588444","doi":"10.1016/j.annder.2018.09.584","title":"Maintien de la réponse chez des patients souffrant de psoriasis en plaques chronique traités par certolizumab pégol pendant 48 semaines : résultats poolés des études de phase III CIMPASI-1, CIMPASI-2 et CIMPACT","year":2018,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Medicine; Gynecology; Certolizumab pegol; Internal medicine; Tumor necrosis factor alpha","score_opus":0.03479794266752581,"score_gpt":0.33825854630293295,"score_spread":0.30346060363540717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902588444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688643,0.015595268,0.0055571957,0.0043165255,0.00096855575,0.0011550047,0.0012215233,0.00079634093,0.001525292],"genre_scores_gemma":[0.9661825,0.01983854,0.008658544,0.0032534956,0.00030540203,0.00047324537,0.0005385923,0.00020561423,0.00054412516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98099816,0.0112559395,0.0014849405,0.0014075668,0.00023522356,0.0046181567],"domain_scores_gemma":[0.9920879,0.0049386574,0.00076853466,0.0010407886,0.0004947909,0.0006693424],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.0035763273,0.0017182346,0.001982034,0.00068663486,0.0013414937,0.0003356069,0.0016219423,0.0030404464,0.000663056],"category_scores_gemma":[0.0048447275,0.0015935821,0.00095024565,0.0006921635,0.0047903764,0.0008184941,0.00057473127,0.0014772543,0.0002650242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015489943,0.011886082,0.5573126,0.0016544538,0.008498227,0.010163049,0.08122325,0.00021167124,0.12524866,0.004728691,0.07309079,0.1104926],"study_design_scores_gemma":[0.024379104,0.0048472327,0.5972284,0.0013114485,0.0027204005,0.021841902,0.0064215935,0.00059574505,0.296354,0.013599849,0.027650092,0.0030502067],"about_ca_topic_score_codex":0.0020474344,"about_ca_topic_score_gemma":0.0018287097,"teacher_disagreement_score":0.17110534,"about_ca_system_score_codex":0.0025317552,"about_ca_system_score_gemma":0.0048840013,"threshold_uncertainty_score":0.99995863},"labels":[],"label_agreement":null},{"id":"W2902642738","doi":"10.1016/j.annder.2018.09.587","title":"Efficacité et sécurité de l’ixékizumab chez des patients ayant un rhumatisme psoriasique actif : résultats à 3 ans d’une étude de phase 3 (SPIRIT-P1)","year":2018,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.03703868395926451,"score_gpt":0.31952537633022343,"score_spread":0.2824866923709589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902642738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96580976,0.016132304,0.0040939883,0.007850703,0.0018268321,0.0009817533,0.0010104141,0.0007168699,0.0015773833],"genre_scores_gemma":[0.96652347,0.018393723,0.0069994717,0.0056759873,0.00026600662,0.00033639465,0.0008771035,0.00016265662,0.00076518883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9889912,0.004451972,0.0013461746,0.0013706371,0.00019987549,0.0036401146],"domain_scores_gemma":[0.9948244,0.0022972745,0.00075496343,0.0011676294,0.00050615123,0.00044954772],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001766039,0.0013714867,0.0015572347,0.0004536075,0.001066432,0.00019121963,0.0014656584,0.0027730563,0.0008324422],"category_scores_gemma":[0.0021057492,0.0013584297,0.0006865015,0.00082059193,0.0026145887,0.0006229707,0.00052510947,0.0014399745,0.0011722008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052172695,0.014826255,0.5316133,0.00098954,0.005594963,0.005482324,0.03145829,0.00013969107,0.052178256,0.008036119,0.035866346,0.30859765],"study_design_scores_gemma":[0.024561858,0.0049720374,0.4887278,0.0010354341,0.0021412384,0.0068904264,0.0021879568,0.00030934325,0.39200535,0.013629543,0.060658514,0.0028804804],"about_ca_topic_score_codex":0.0010607862,"about_ca_topic_score_gemma":0.002164296,"teacher_disagreement_score":0.3398271,"about_ca_system_score_codex":0.0008344925,"about_ca_system_score_gemma":0.0018040402,"threshold_uncertainty_score":0.99990356},"labels":[],"label_agreement":null},{"id":"W2902697340","doi":"10.1111/bjd.17454","title":"Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <scp>VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development","keywords":"Medicine; Adalimumab; Adverse effect; Randomized controlled trial; Placebo; Clinical trial; Psoriasis; Internal medicine; Dermatology; Pathology; Alternative medicine; Disease","score_opus":0.010887670862251838,"score_gpt":0.23301051871707845,"score_spread":0.2221228478548266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902697340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97534984,0.022537174,0.00026023664,0.00019652268,0.00039256032,0.00066455494,0.00028502278,0.000026022237,0.00028804992],"genre_scores_gemma":[0.9947446,0.003949462,0.00052570575,0.00025086966,0.00006938523,0.0000404643,0.00014009421,0.000037488353,0.00024195912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99514776,0.0020573183,0.0015041665,0.0004973149,0.00017209393,0.00062132603],"domain_scores_gemma":[0.9942826,0.0033633537,0.0011264924,0.00036659976,0.0007825343,0.00007841346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005305239,0.0004648362,0.00279118,0.00041220488,0.00039999618,0.000054639473,0.00045867756,0.0004476337,0.000061256476],"category_scores_gemma":[0.0012975207,0.0003383901,0.00044461002,0.0009164551,0.00090591697,0.00029654513,0.0001556418,0.00041091017,0.000026228054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06584829,0.0032920146,0.7065166,0.00011056838,0.13593757,0.0018622167,0.03312994,0.00019673059,0.0018172811,0.0002084007,0.026557697,0.024522666],"study_design_scores_gemma":[0.42593092,0.0016055834,0.5087288,0.0009394871,0.02342532,0.0045132986,0.00812553,0.000028067083,0.022361854,0.0013734985,0.0025725402,0.0003950928],"about_ca_topic_score_codex":0.0009135108,"about_ca_topic_score_gemma":0.0015115432,"teacher_disagreement_score":0.36008263,"about_ca_system_score_codex":0.00007932816,"about_ca_system_score_gemma":0.00013948802,"threshold_uncertainty_score":0.99990684},"labels":[],"label_agreement":null},{"id":"W2904898191","doi":"10.1080/09546634.2018.1529386","title":"The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment","year":2018,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Galderma; Sun Pharma; Mylan; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Eli Lilly and Company; Pfizer; National Psoriasis Foundation","keywords":"Medicine; Psoriasis; Retrospective cohort study; Biologic Agents; Topical agents; Internal medicine; Cohort; Observational study; Surgery; Dermatology; Disease","score_opus":0.0723164090166498,"score_gpt":0.34736504590440037,"score_spread":0.27504863688775055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904898191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491876,0.0020389017,0.000051858686,0.0004809685,0.00069671887,0.0015880957,0.00015866723,0.000013420297,0.000052585423],"genre_scores_gemma":[0.9972245,0.00061243336,0.0016690248,0.00005296137,0.00005839573,0.0002708764,0.00005229053,0.000010009948,0.000049473445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99787956,0.0006277069,0.00071234576,0.00027968257,0.00016418786,0.00033652943],"domain_scores_gemma":[0.9979261,0.00038662806,0.00060283026,0.00024870728,0.00074690557,0.00008882896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000392741,0.00028169595,0.000616507,0.00010331857,0.0003525634,0.000024905663,0.00015037427,0.0001838927,0.00006724582],"category_scores_gemma":[0.0005522589,0.00011709021,0.00023883992,0.00013715393,0.00019833104,0.00008361571,0.000058950016,0.00006429223,0.000010508836],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014957587,0.0054256096,0.20760067,0.000015526306,0.0024705562,0.000043380765,0.0014067483,0.0000041677617,0.004509374,0.00020883756,0.0010447768,0.76231277],"study_design_scores_gemma":[0.046614446,0.13448404,0.47065532,0.00032052668,0.004648486,0.0009659691,0.0011148282,0.00007694922,0.29062065,0.0015472962,0.048285708,0.0006657564],"about_ca_topic_score_codex":0.000015728305,"about_ca_topic_score_gemma":0.00004784506,"teacher_disagreement_score":0.761647,"about_ca_system_score_codex":0.00039179748,"about_ca_system_score_gemma":0.00012786029,"threshold_uncertainty_score":0.47748},"labels":[],"label_agreement":null},{"id":"W2905218219","doi":"10.1016/j.jdcr.2017.10.009","title":"RETRACTED: Eruptive lentiginosis in resolving psoriatic plaques","year":2018,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Dermatology; Ustekinumab; Treatment modality; Population; Pathology; Surgery; Disease","score_opus":0.01915869829856189,"score_gpt":0.26300715703331107,"score_spread":0.24384845873474917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905218219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98909193,0.0025551757,0.000012882972,0.00006210609,0.0020154675,0.00025019515,0.000015137679,0.00011024285,0.0058868392],"genre_scores_gemma":[0.9975224,0.00010922712,0.00014790578,0.000055837063,0.00019470684,0.00004826009,0.000064740474,0.000020891586,0.0018360124],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983894,0.00016390377,0.00051343127,0.00047118237,0.000052105377,0.00040996744],"domain_scores_gemma":[0.99901366,0.00014028362,0.0002676089,0.00045119354,0.00009432296,0.000032947955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004710577,0.00021748792,0.00033042242,0.00021434962,0.00020250426,0.000022091142,0.000050904226,0.00037445512,0.00060886674],"category_scores_gemma":[0.00022083685,0.00019480611,0.000108465065,0.0002608527,0.00013233727,0.00015361825,0.00005513026,0.00022112798,0.0002699591],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008322961,0.0013388026,0.24282609,0.0001038349,0.0015446005,0.3717243,0.009228431,0.000002399443,0.1532912,0.00039744817,0.018307649,0.20040293],"study_design_scores_gemma":[0.003344922,0.0009925761,0.16677938,0.00043520503,0.0006828015,0.20464054,0.0014766741,0.000010141994,0.5277667,0.0011050826,0.09150555,0.0012604063],"about_ca_topic_score_codex":0.00084136985,"about_ca_topic_score_gemma":0.0008040882,"teacher_disagreement_score":0.3744755,"about_ca_system_score_codex":0.00011107349,"about_ca_system_score_gemma":0.000074466494,"threshold_uncertainty_score":0.7943963},"labels":[],"label_agreement":null},{"id":"W2905794790","doi":"10.1007/s13555-018-0279-5","title":"Clinical Goals and Barriers to Effective Psoriasis Care","year":2018,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université de Sherbrooke; Dermatrials Research; Probity Medical Research","funders":"Cilag; Allergan; Medac; Astellas Pharma; Glenmark Pharmaceuticals; National Psoriasis Foundation; Pfizer; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; University of Connecticut; Eli Lilly and Company; Cardiff University; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Sanofi; GlaxoSmithKline; Galderma; Bristol-Myers Squibb; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Amgen","keywords":"Psoriasis; Pace; Medicine; Disease; Intensive care medicine; Alternative medicine; Business; Family medicine; Dermatology; Pathology","score_opus":0.013536864592358354,"score_gpt":0.2924971744397164,"score_spread":0.27896030984735803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905794790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802159,0.017004719,0.000030112556,0.00044295192,0.0010109552,0.00037176558,0.000026536727,0.000056574958,0.00084048853],"genre_scores_gemma":[0.9962238,0.0018102499,0.00009241926,0.001556043,0.000086435706,0.00006973917,0.000022294264,0.00001285672,0.00012617491],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986802,0.00045786265,0.00020532933,0.00036674156,0.000015250057,0.00027464377],"domain_scores_gemma":[0.9993028,0.00029963627,0.000049998533,0.00018992343,0.00006162128,0.00009603569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012950938,0.00018400763,0.0003798307,0.00008282472,0.00036212802,0.00001039427,0.00008869925,0.00038032926,0.00021777643],"category_scores_gemma":[0.000064890286,0.00014514392,0.000063748426,0.0000808649,0.0004894526,0.000044720677,0.00004482866,0.00011436485,0.0002367664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011281844,0.000041062987,0.49177825,0.000009240335,0.0006515545,0.000022810984,0.0042125667,1.887052e-8,0.0039953403,0.00077211845,0.0017891391,0.49559972],"study_design_scores_gemma":[0.01024244,0.0017863598,0.52453303,0.000032283733,0.00019112321,0.0007191413,0.0018606472,9.0336147e-7,0.12131468,0.0008129285,0.3379486,0.0005578791],"about_ca_topic_score_codex":0.000019131196,"about_ca_topic_score_gemma":0.000027972712,"teacher_disagreement_score":0.49504185,"about_ca_system_score_codex":0.0000067237925,"about_ca_system_score_gemma":0.000029461502,"threshold_uncertainty_score":0.5918797},"labels":[],"label_agreement":null},{"id":"W2906909290","doi":"10.5114/ada.2018.77619","title":"A study of dermoscopic features of nail psoriasis: the pseudo-pseudo-fiber sign","year":2018,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Dermatology; Sign (mathematics); Nail (fastener); Medicine; Mathematics","score_opus":0.011510254684658916,"score_gpt":0.2654726912911937,"score_spread":0.2539624366065348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906909290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742023,0.02219909,0.00001278904,0.0002453359,0.0008086004,0.00038527767,0.000008667414,0.000023427308,0.0021145393],"genre_scores_gemma":[0.9975413,0.0017170497,0.0001391289,0.00011981364,0.000035621248,0.0000869571,0.000010721923,0.000013341435,0.00033607616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789417,0.00073413394,0.0005441964,0.00039730253,0.000040038864,0.00039017026],"domain_scores_gemma":[0.9985461,0.00065719,0.00029078813,0.00040072776,0.00008683046,0.00001834077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017519952,0.000253159,0.00068544736,0.00017821355,0.00017464622,0.0000027449476,0.00035704955,0.00035373282,0.00020241787],"category_scores_gemma":[0.000087742694,0.00017533207,0.00006412184,0.00023287004,0.0012803891,0.000112540794,0.00014241869,0.00022038519,0.000042325646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050261477,0.0044654035,0.651059,0.00026848845,0.0032706812,0.00034439377,0.02792782,0.00003343407,0.018818121,0.012959842,0.0035674216,0.27225927],"study_design_scores_gemma":[0.0215043,0.0050092973,0.8115669,0.0001628507,0.00066576805,0.004316315,0.015369661,0.000005169632,0.10591555,0.007565068,0.027002972,0.0009161878],"about_ca_topic_score_codex":0.000078475976,"about_ca_topic_score_gemma":0.0013915751,"teacher_disagreement_score":0.27134305,"about_ca_system_score_codex":0.000008701582,"about_ca_system_score_gemma":0.000043232063,"threshold_uncertainty_score":0.71498346},"labels":[],"label_agreement":null},{"id":"W2908033840","doi":"10.1177/2475530318818816","title":"Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Research and Development","keywords":"Medicine; Ixekizumab; Psoriasis Area and Severity Index; Meta-analysis; Randomized controlled trial; Internal medicine; Relative risk; Psoriasis; Confidence interval; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.07589645418014619,"score_gpt":0.3256763874813887,"score_spread":0.24977993330124254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908033840","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026374075,0.9934846,0.00028377087,0.00014840228,0.0013770915,0.0037886081,0.000631761,0.000014236259,0.000007797663],"genre_scores_gemma":[0.00037337473,0.99674773,0.00049122033,0.000041484775,0.0008070685,0.0009688662,0.00008785275,0.00006464646,0.00041775455],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99429846,0.0012804135,0.0031206764,0.000598085,0.00018699713,0.0005153933],"domain_scores_gemma":[0.9933047,0.0018172316,0.003552499,0.00073446386,0.00046369902,0.00012736775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016818191,0.0009115504,0.011162358,0.00051393535,0.00054437085,0.000083181374,0.00036625008,0.00055351737,0.00024568822],"category_scores_gemma":[0.00026848738,0.0005013518,0.004097277,0.00081828306,0.00014076986,0.00016660472,0.000056272962,0.00022511106,0.000013303029],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045703977,0.00055519235,0.000001033929,0.1292844,0.5905013,0.000014327276,0.0008317892,0.000013558806,0.0000022073882,0.00010780149,0.0016927521,0.27653858],"study_design_scores_gemma":[0.0041789506,0.0021027254,0.0000029905948,0.024940733,0.86739534,0.00071309664,0.00009936454,0.0000021826827,0.000028947892,0.00008221727,0.09996375,0.0004896763],"about_ca_topic_score_codex":0.00003143909,"about_ca_topic_score_gemma":0.00006710182,"teacher_disagreement_score":0.27689403,"about_ca_system_score_codex":0.00013887582,"about_ca_system_score_gemma":0.00018265819,"threshold_uncertainty_score":0.9997438},"labels":[],"label_agreement":null},{"id":"W2908836806","doi":"10.1136/annrheumdis-2018-eular.3772","title":"OP0130 Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the province of british columbia","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Research Canada; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Population; Dermatology; Environmental health","score_opus":0.011561708438780823,"score_gpt":0.24899515476277337,"score_spread":0.23743344632399255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908836806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556214,0.0021996084,8.372236e-7,0.000029165307,0.00015520689,0.0011004679,0.00093305955,0.0000061689307,0.00001335473],"genre_scores_gemma":[0.99962187,0.000128901,0.000009151621,0.000025498153,0.0000065038525,0.00012279357,0.000031545573,0.000009941504,0.000043819873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983342,0.00065400824,0.0005276361,0.00017534598,0.00012654053,0.00018225033],"domain_scores_gemma":[0.9985984,0.00030109056,0.0005419784,0.00040012418,0.0001459577,0.0000124544995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028020097,0.000109411856,0.0004166592,0.000057260404,0.00007189484,0.0000121183775,0.0003204618,0.00005092315,0.00012448743],"category_scores_gemma":[0.00024489136,0.000085882195,0.00009939455,0.00029719333,0.00016321377,0.00006722412,0.00003413472,0.000056365374,0.0000021983706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030080584,0.0023462619,0.9196267,0.00007578033,0.00028930177,7.3644185e-7,0.0003884675,0.00004958552,0.0000016786838,0.0000030217684,0.0002602018,0.076657474],"study_design_scores_gemma":[0.0037839308,0.00063549407,0.99355865,0.001058154,0.00022256598,1.7888323e-7,0.0003653533,0.000006842792,0.000074717434,0.00020081208,0.000003973992,0.00008932342],"about_ca_topic_score_codex":0.049203433,"about_ca_topic_score_gemma":0.15226996,"teacher_disagreement_score":0.10306652,"about_ca_system_score_codex":0.000012879121,"about_ca_system_score_gemma":0.00012974639,"threshold_uncertainty_score":0.957128},"labels":[],"label_agreement":null},{"id":"W2909090268","doi":"10.1111/bjd.17624","title":"Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"LEO Pharma; Sun Pharma; National Institute for Health and Care Research; Celgene; Pfizer; Eli Lilly and Company","keywords":"Medicine; Ustekinumab; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Adverse effect; Dermatology Life Quality Index; Randomized controlled trial; Plaque psoriasis; Physical therapy; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.011956762107803524,"score_gpt":0.26709302827115905,"score_spread":0.25513626616335555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909090268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687555,0.016013531,0.0016079086,0.001733431,0.0103305625,0.00037752345,0.00015978939,0.00005299606,0.0009688034],"genre_scores_gemma":[0.9977875,0.0004034245,0.0010136956,0.00017645016,0.00019272324,0.000028047798,0.000049779766,0.000034675224,0.0003136993],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99794674,0.00035636194,0.0007811451,0.00027813777,0.000068718444,0.00056887657],"domain_scores_gemma":[0.99750316,0.0016406999,0.00033248117,0.00019343701,0.00026386592,0.00006638309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021614115,0.00022546708,0.00083971885,0.00018356522,0.00016826969,0.000044645723,0.000369564,0.0005116935,0.0008431372],"category_scores_gemma":[0.0006043796,0.00023946117,0.00040410092,0.000106059575,0.00018876289,0.00023041494,0.00005280382,0.0003800762,0.00035643025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020704163,0.0042251097,0.04934589,0.0009665553,0.007895562,0.011797638,0.0023101124,0.000024450783,0.04132341,0.023333834,0.4507653,0.38730794],"study_design_scores_gemma":[0.035236944,0.0017656416,0.014004141,0.00055507396,0.0011700072,0.5604632,0.0010376389,0.000016741216,0.04531488,0.0016166535,0.33790138,0.00091769616],"about_ca_topic_score_codex":0.000026387868,"about_ca_topic_score_gemma":0.000022895283,"teacher_disagreement_score":0.5486656,"about_ca_system_score_codex":0.000043136723,"about_ca_system_score_gemma":0.00021727924,"threshold_uncertainty_score":0.97649425},"labels":[],"label_agreement":null},{"id":"W2909199597","doi":"10.1136/annrheumdis-2018-eular.6751","title":"THU0301 A novel role for the psoriatic arthritis impact of disease questionnaire (PSAID)","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Prom; Internal medicine; Disease; Arthritis; Dermatology","score_opus":0.02872317409925323,"score_gpt":0.2966166982352564,"score_spread":0.26789352413600315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909199597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95928144,0.036857087,0.00027034228,0.0007553803,0.00059352326,0.00073470536,0.0014147477,0.000033354743,0.000059417882],"genre_scores_gemma":[0.99848795,0.0009449607,0.000025300507,0.000076876444,0.000052436117,0.00012106878,0.00003962702,0.000016585316,0.00023516707],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99899167,0.00013259418,0.00037433612,0.0001693555,0.0000683192,0.00026374473],"domain_scores_gemma":[0.99834657,0.00046685323,0.00033781596,0.0005942487,0.00020664299,0.000047853493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018790054,0.0001869614,0.00033274412,0.000048517453,0.00026503863,0.000009766287,0.00040952236,0.000060178696,0.00018596982],"category_scores_gemma":[0.00072815164,0.000096729476,0.00062825135,0.0001454492,0.0004485442,0.00008397808,0.000073959665,0.00003746622,0.000036009442],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037993551,0.003081146,0.04205065,0.00048130626,0.006919967,6.6619225e-7,0.0019361906,0.00013972985,0.0032428354,0.005014419,0.021438494,0.9118952],"study_design_scores_gemma":[0.0028719557,0.0007878902,0.9732649,0.0014222114,0.0012053179,0.000005655986,0.00021849593,0.00023823854,0.008899862,0.010279331,0.0005421416,0.00026404051],"about_ca_topic_score_codex":0.00021994529,"about_ca_topic_score_gemma":0.00002966398,"teacher_disagreement_score":0.9312142,"about_ca_system_score_codex":0.00001123012,"about_ca_system_score_gemma":0.0001817017,"threshold_uncertainty_score":0.39445135},"labels":[],"label_agreement":null},{"id":"W2909753554","doi":"10.3899/jrheum.171228","title":"Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey","year":2019,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; National Health and Nutrition Examination Survey; Psoriasis; Mental health; Depression (economics); Logistic regression; Association (psychology); Cross-sectional study; Population; Psoriatic arthritis; Arthritis; Internal medicine; Psychiatry; Environmental health; Immunology; Pathology","score_opus":0.028588529829779896,"score_gpt":0.257645836198391,"score_spread":0.2290573063686111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909753554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900976,0.007916416,0.000021270058,0.0013716606,0.0001822547,0.00021311683,0.00018745511,0.0000040128616,0.000006250153],"genre_scores_gemma":[0.98935276,0.010184834,0.000050230326,0.000066474444,0.000012194958,0.0000030430353,0.00031075487,0.0000055949904,0.000014112425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794286,0.0013628613,0.0003458418,0.00012382302,0.00007531841,0.00014927676],"domain_scores_gemma":[0.99741024,0.0018800901,0.00047667595,0.00011792338,0.00009817778,0.000016881499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025289287,0.00009043056,0.0003014231,0.00007123535,0.00011218414,0.0000133179465,0.00015750313,0.00010416315,0.00002290426],"category_scores_gemma":[0.00018072047,0.000053165688,0.00001370992,0.00008693646,0.00004921148,0.00015348355,0.000060649276,0.0001837853,0.000008834267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004782739,0.000057374462,0.98514885,0.000010417988,0.00027559034,3.01869e-7,0.0009933148,0.0000010546645,0.000047094458,0.0000106393645,0.0005414535,0.012435619],"study_design_scores_gemma":[0.0041810307,0.0004597882,0.99372274,0.00027720034,0.00003312733,0.00025644593,0.00064779806,0.000010199094,0.00005095868,0.00009207933,0.00021373553,0.000054908665],"about_ca_topic_score_codex":0.002295094,"about_ca_topic_score_gemma":0.0038313856,"teacher_disagreement_score":0.01238071,"about_ca_system_score_codex":0.00008641239,"about_ca_system_score_gemma":0.00008587224,"threshold_uncertainty_score":0.3469511},"labels":[],"label_agreement":null},{"id":"W2910270132","doi":"10.1136/annrheumdis-2018-eular.6758","title":"AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"Merck Sharp and Dohme; EMD Serono; Kyowa Hakko Kirin; Dermira; Meiji Seika Pharma; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; Amgen; Eli Lilly and Company; GlaxoSmithKline; Sun Pharma; Regeneron Pharmaceuticals; American Academy of Dermatology","keywords":"Medicine; Etanercept; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Placebo; Gastroenterology; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.05526279902356336,"score_gpt":0.317720676704457,"score_spread":0.2624578776808936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910270132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970579,0.0016590419,0.0000047644407,0.00026939943,0.0003539806,0.00022855695,0.00009723592,0.00001601746,0.00031308024],"genre_scores_gemma":[0.9987769,0.00016448204,0.000016586639,0.00008428927,0.000016042835,0.000013840964,0.000018897734,0.000010512102,0.00089844124],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99881655,0.00032776358,0.00039316897,0.00016219226,0.00005975448,0.00024055084],"domain_scores_gemma":[0.9988077,0.00045885678,0.00021911733,0.0004277657,0.0000629389,0.000023583234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016915485,0.00014385373,0.00035286884,0.000090975605,0.000069024674,0.000004484092,0.00033103183,0.00008686265,0.0013154829],"category_scores_gemma":[0.00048271366,0.00008491705,0.00020235103,0.00021852441,0.00041635789,0.00005490562,0.00007737112,0.00004464908,0.00014614534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024692433,0.006800457,0.046515517,0.00057253,0.0037856987,0.000018698423,0.0093147205,0.00008346352,0.017701842,0.00239628,0.032307744,0.85581064],"study_design_scores_gemma":[0.0052468926,0.0008227171,0.8146074,0.00082254637,0.00043524773,0.000014409816,0.0006931188,0.0000180337,0.1742439,0.0007369389,0.002050903,0.00030793488],"about_ca_topic_score_codex":0.00012490041,"about_ca_topic_score_gemma":0.000056335015,"teacher_disagreement_score":0.85550267,"about_ca_system_score_codex":0.00000737561,"about_ca_system_score_gemma":0.000106020394,"threshold_uncertainty_score":0.99959743},"labels":[],"label_agreement":null},{"id":"W2910464068","doi":"10.1177/1203475418811347","title":"Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update","year":2019,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Intensive care medicine; Biologic Agents; Rheumatoid arthritis; Bench to bedside; Disease; Alternative medicine; Biosimilar; Inflammatory bowel disease; Dermatology; Immunology; Internal medicine; Pathology; Medical physics","score_opus":0.15783244290585052,"score_gpt":0.37829606974531604,"score_spread":0.22046362683946552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910464068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014980038,0.9945964,0.00005898593,0.0007042956,0.0025065434,0.0004730296,0.00006864779,0.000015686623,0.00007840544],"genre_scores_gemma":[0.00009637766,0.9975146,0.00040656707,0.0005714199,0.00065391476,0.000011753483,0.00043528702,0.000044012515,0.00026604696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976239,0.0003727687,0.0012329259,0.00032520242,0.00011017066,0.0003350111],"domain_scores_gemma":[0.9944685,0.0031544878,0.001485004,0.00026385952,0.0005514833,0.00007666842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000872188,0.00046487869,0.0027822151,0.0005083771,0.00011150079,0.000014821946,0.00014422902,0.00043517462,0.00009638012],"category_scores_gemma":[0.0009796227,0.00023121125,0.00040698258,0.00012603859,0.00012648023,0.00009543279,0.000021359925,0.0003528835,0.000026589083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009096833,0.00016449689,0.00019266139,0.0013188905,0.0014498401,0.00023208954,0.000033266148,3.5004126e-7,0.0000010486959,0.000047617577,0.03481696,0.9608331],"study_design_scores_gemma":[0.0010233639,0.0024423208,0.00000888916,0.0074148956,0.0042095482,0.003284344,0.000085129905,3.590231e-7,0.0000019911506,0.000044354634,0.98121166,0.00027314157],"about_ca_topic_score_codex":0.000003734138,"about_ca_topic_score_gemma":0.0000015360959,"teacher_disagreement_score":0.96055996,"about_ca_system_score_codex":0.000044221266,"about_ca_system_score_gemma":0.00026520883,"threshold_uncertainty_score":0.9428521},"labels":[],"label_agreement":null},{"id":"W2911434758","doi":"10.1111/bjd.17628","title":"Efficacy and safety of mirikizumab ( <scp>LY</scp> 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase <scp>II</scp> study","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Internal medicine; Clinical endpoint; Gastroenterology; Plaque psoriasis; Randomized controlled trial; Surgery; Immunology; Pathology","score_opus":0.013537018109192079,"score_gpt":0.251430133745222,"score_spread":0.2378931156360299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911434758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792091,0.017205518,0.000028023202,0.00019746466,0.0006398617,0.0018327411,0.0005234356,0.0000130706,0.00035078972],"genre_scores_gemma":[0.9946442,0.0046430756,0.00015791714,0.000059445803,0.000048999063,0.00005378628,0.00011687289,0.00002645228,0.000249236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99469054,0.0023709037,0.0018876105,0.00043122718,0.00014254756,0.000477151],"domain_scores_gemma":[0.99280554,0.0053863777,0.0011241175,0.0003952149,0.00021547299,0.0000732663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007090449,0.00038173754,0.0023539402,0.00033981728,0.00016223585,0.000027844311,0.00043333767,0.00039688117,0.000018629362],"category_scores_gemma":[0.0008035417,0.00029702144,0.00036894652,0.00026708425,0.00024058142,0.00014508018,0.000072609364,0.00030661147,0.000023807985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53257644,0.06019588,0.022063607,0.00019681727,0.025723107,0.010170646,0.17076594,0.0004015397,0.031777386,0.00035907564,0.015244441,0.13052513],"study_design_scores_gemma":[0.8994484,0.0049806386,0.027098289,0.00044505682,0.0017362987,0.015664404,0.009681265,0.000016884056,0.035350006,0.00026721694,0.0051639373,0.00014759971],"about_ca_topic_score_codex":0.00053753,"about_ca_topic_score_gemma":0.00029313835,"teacher_disagreement_score":0.36687198,"about_ca_system_score_codex":0.000058233065,"about_ca_system_score_gemma":0.00018731217,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W2912058252","doi":"10.1016/j.jaad.2018.11.057","title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","year":2019,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":924,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Joint (building); MEDLINE; Intensive care medicine","score_opus":0.08478409348539527,"score_gpt":0.3482868694989154,"score_spread":0.2635027760135201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912058252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049553276,0.992535,0.000033918972,0.00084654323,0.0003547256,0.0010013712,0.00023025926,0.0000037749842,0.000039092294],"genre_scores_gemma":[0.0051032268,0.9933743,0.0011892305,0.000062974665,0.000050008668,0.000040926563,0.000013692485,0.000025490814,0.0001401412],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974937,0.00046117298,0.0014904108,0.00022180758,0.00007467611,0.00025822988],"domain_scores_gemma":[0.9934433,0.0007159611,0.0053364886,0.0003073137,0.00017573495,0.000021168433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001713745,0.0004033471,0.0034899712,0.0002552954,0.00008116219,0.0000027608667,0.0006042269,0.00030317233,0.0000072924217],"category_scores_gemma":[0.000038732516,0.00016634828,0.0009904829,0.0002447501,0.0009062805,0.000025943758,0.00011930361,0.00020545762,0.0000021221267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000605679,0.00014481654,0.00068767404,0.003881585,0.0102058,0.0000051625198,0.00023759545,0.0000053600866,0.00010408531,0.00027470282,0.001188749,0.9826588],"study_design_scores_gemma":[0.0021698326,0.0016975773,0.0006530205,0.0023983212,0.014835235,0.0022398296,0.00089721405,4.0166157e-7,0.00258854,0.000042323813,0.9722669,0.0002108021],"about_ca_topic_score_codex":0.00001921681,"about_ca_topic_score_gemma":0.0000027217225,"teacher_disagreement_score":0.982448,"about_ca_system_score_codex":0.00005961237,"about_ca_system_score_gemma":0.000148497,"threshold_uncertainty_score":0.6783486},"labels":[],"label_agreement":null},{"id":"W2912573855","doi":"10.1097/md.0000000000014401","title":"Association of rs2910164 polymorphism in MiR-146a gene with psoriasis susceptibility","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ethica (Canada)","funders":"","keywords":"Odds ratio; Psoriasis; Medicine; Single-nucleotide polymorphism; SNP; Meta-analysis; Confidence interval; Genotype; Etiology; Internal medicine; Subgroup analysis; Bioinformatics; Genetics; Oncology; Gene; Immunology; Biology","score_opus":0.03801630706580292,"score_gpt":0.2902019469369217,"score_spread":0.25218563987111875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912573855","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002057584,0.9946056,0.000005104423,0.00016673695,0.0012894165,0.0008741674,0.00015604876,0.00003131642,0.0008140194],"genre_scores_gemma":[0.00090347993,0.98777086,0.000037502457,0.00002611592,0.00017363476,0.00007722828,0.0013207071,0.000041762374,0.009648723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974476,0.0006280447,0.0008673839,0.00054055173,0.00011408506,0.00040231115],"domain_scores_gemma":[0.99779505,0.00059842906,0.00086633104,0.00062252453,0.00009031964,0.000027362084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087368954,0.00047088714,0.0027758833,0.00039394802,0.000039359675,0.0000023113353,0.00027783922,0.0008584288,0.0012850204],"category_scores_gemma":[0.00019073824,0.0002943628,0.00025624494,0.00050378597,0.00013772084,0.00003867625,0.00004853189,0.00036524067,0.00041285064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018732378,0.00030482563,0.0051248185,0.0051234965,0.0021410664,0.000021061342,0.0003572124,1.871635e-7,0.00047127836,0.000027917524,0.0046138125,0.981627],"study_design_scores_gemma":[0.0042091426,0.0007024002,0.0026749715,0.007334354,0.0049571064,0.000044580964,0.000047926995,6.8869774e-8,0.0002809382,0.000012754818,0.97936857,0.00036721388],"about_ca_topic_score_codex":0.000488288,"about_ca_topic_score_gemma":0.00024642897,"teacher_disagreement_score":0.98125976,"about_ca_system_score_codex":0.0003807358,"about_ca_system_score_gemma":0.00023113689,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W2913107894","doi":"10.1016/j.jaci.2019.01.017","title":"Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept","year":2019,"lang":"en","type":"letter","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Allergan; Novartis; EMD Serono; Language Literacy and Culture, University of Maryland, Baltimore County; LEO Pharma; Biogen; Regeneron Pharmaceuticals; Amgen; Pfizer; Eli Lilly and Company; Valeant Pharmaceuticals International; AbbVie","keywords":"Ustekinumab; Etanercept; Psoriasis; Gene; Medicine; Dermatology; Modulation (music); Biology; Immunology; Cancer research; Computational biology; Tumor necrosis factor alpha; Genetics; Adalimumab; Physics","score_opus":0.036368097346923235,"score_gpt":0.2758517931121152,"score_spread":0.239483695765192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913107894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705329,0.015782101,0.000025539555,0.011082565,0.0022778858,0.00017939803,0.00003610944,0.000008724297,0.00007480668],"genre_scores_gemma":[0.9600287,0.033003926,0.00010792809,0.004644233,0.0009817407,0.00000675005,0.00017689654,0.00004532957,0.0010045099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583256,0.0012590066,0.0020583074,0.00039227176,0.00008916348,0.0003687044],"domain_scores_gemma":[0.99660933,0.0014581867,0.0014588174,0.0002920725,0.00015633613,0.000025279911],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00069926295,0.00039660046,0.0018376085,0.000425833,0.00006391504,0.00001321875,0.00034489034,0.0029784953,0.0001604168],"category_scores_gemma":[0.00014055443,0.0003130536,0.00037912466,0.00009675818,0.0005905691,0.00013703822,0.00008546547,0.0019000501,0.000015071053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006020347,0.0010083247,0.5093596,0.0003794776,0.04834533,0.0007207737,0.0024551153,0.000011774799,0.026607595,0.00013769843,0.030444438,0.37450954],"study_design_scores_gemma":[0.0077176364,0.002356591,0.92079765,0.00030568842,0.0009454021,0.00027296174,0.00015829966,0.0000025411816,0.000540017,0.0004191882,0.06606933,0.0004146969],"about_ca_topic_score_codex":0.000053169766,"about_ca_topic_score_gemma":0.0000654063,"teacher_disagreement_score":0.41143805,"about_ca_system_score_codex":0.000035764155,"about_ca_system_score_gemma":0.00015050345,"threshold_uncertainty_score":0.99993217},"labels":[],"label_agreement":null},{"id":"W2913495210","doi":"10.1177/2050313x19829620","title":"Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report","year":2019,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; University of Toronto; Trent University; SKiN Health","funders":"","keywords":"Acrodermatitis; Medicine; Dermatology; Adalimumab; Surgery; Pathology; Tumor necrosis factor alpha; Internal medicine; Alternative medicine","score_opus":0.011317301401311382,"score_gpt":0.2614664020019277,"score_spread":0.25014910060061635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913495210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820172,0.0013881318,0.000041129035,0.00016364774,0.00040225644,0.0010741582,0.00006719577,0.000060152248,0.0147861205],"genre_scores_gemma":[0.9876046,0.000055516553,0.00018756233,0.00010608995,0.000028067134,0.00008921193,0.00035470625,0.000036035228,0.011538221],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9973437,0.00031067446,0.0010430398,0.00066661055,0.00019332094,0.00044264944],"domain_scores_gemma":[0.99778074,0.00020186593,0.0007457438,0.0009518957,0.00017036537,0.00014937732],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011635865,0.00031901913,0.00085809705,0.000093792674,0.00017133805,0.000043066968,0.00019261579,0.0004115828,0.009192909],"category_scores_gemma":[0.0002260341,0.00022662069,0.0001382255,0.00024412223,0.00025609013,0.00023716725,0.00026638625,0.0002535848,0.00012534631],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025658164,0.00026454352,0.032171313,0.000049400747,0.0005925025,0.9334569,0.00026929736,6.087437e-7,0.0010610601,0.000013022754,0.0009226276,0.030942127],"study_design_scores_gemma":[0.0028404659,0.00035246802,0.0013967883,0.00025720356,0.00032109919,0.96825194,0.00042857163,0.0000020413745,0.012536175,0.000012987274,0.013317991,0.00028229412],"about_ca_topic_score_codex":0.009728837,"about_ca_topic_score_gemma":0.003222659,"teacher_disagreement_score":0.034795,"about_ca_system_score_codex":0.000046956276,"about_ca_system_score_gemma":0.00045272385,"threshold_uncertainty_score":0.99686545},"labels":[],"label_agreement":null},{"id":"W2914070013","doi":"10.1177/1203475418824565","title":"Treating to Target(s) With Interleukin-17 Inhibitors","year":2019,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Western University; University of British Columbia; University of Ottawa; Memorial University of Newfoundland; Probity Medical Research; BC Children's Hospital; University Health Network; University of Toronto; Ottawa Hospital","funders":"Novartis Pharmaceuticals Canada","keywords":"Ixekizumab; Secukinumab; Medicine; Psoriatic arthritis; Psoriasis; Ankylosing spondylitis; Adverse effect; Clinical trial; Dermatology; Placebo; Interleukin 17; Safety profile; Internal medicine; Alternative medicine; Inflammation; Pathology","score_opus":0.04167188102834986,"score_gpt":0.2880805093225169,"score_spread":0.24640862829416704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914070013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002781562,0.99420166,0.000012051836,0.00017350096,0.0017946039,0.00025235538,0.000014915765,0.000013860741,0.0007554616],"genre_scores_gemma":[0.00040875937,0.99403006,0.00007286691,0.00018321922,0.0006575733,0.0000068397007,0.00005835276,0.00004871339,0.0045336145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781847,0.00028149935,0.0011793418,0.00026869314,0.00010852571,0.0003434831],"domain_scores_gemma":[0.99650836,0.0019238144,0.0011094203,0.00022104157,0.0001344992,0.000102853155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054027565,0.00047965805,0.003371953,0.000770776,0.00008565,0.000013835033,0.00015640407,0.00036467606,0.0003276484],"category_scores_gemma":[0.00022570342,0.00025525384,0.00046585637,0.00025820214,0.00011192836,0.000057677058,0.000035510166,0.00046007047,0.000074184565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022387339,0.000051378098,0.00014644401,0.0016846816,0.0014042121,0.002394926,0.00043425657,6.5110504e-7,0.000025384152,0.0000025124934,0.0359132,0.9577185],"study_design_scores_gemma":[0.00036547254,0.0009184205,0.0000027340468,0.023436407,0.002437934,0.047941916,0.00018217106,4.05921e-8,0.000019185023,0.0000039969027,0.9244439,0.00024780826],"about_ca_topic_score_codex":0.000014912224,"about_ca_topic_score_gemma":0.0000045968286,"teacher_disagreement_score":0.95747066,"about_ca_system_score_codex":0.00007913858,"about_ca_system_score_gemma":0.0003691592,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W2914164523","doi":"10.1016/j.jaad.2018.11.058","title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","year":2019,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":486,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Pharmaceuticals; Janssen Biotech; Sandoz; Ortho Dermatologics; LEO Pharma Research Foundation; LEO Pharma; Pfizer; Incyte; Prothena; Novartis Pharmaceuticals Corporation; Dermira; Coherus Biosciences; Valeant Pharmaceuticals International; Janssen Research and Development; XBiotech; UCB; Celgene; Eli Lilly and Company; Allergan; AstraZeneca; Boehringer Ingelheim; Amgen; AbbVie; Sanofi; MedImmune; Merck; National Institutes of Health; Regeneron Pharmaceuticals; Abbott Laboratories","keywords":"Medicine; Psoriasis; Guideline; Intensive care medicine; Population; Disease management; Joint disease; Disease; Dermatology; Alternative medicine; Internal medicine; Pathology; Environmental health","score_opus":0.08175444726901368,"score_gpt":0.3534888795521198,"score_spread":0.2717344322831061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914164523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036502838,0.96096057,0.00005561258,0.0010279341,0.0002927452,0.00093834614,0.00020557494,0.0000028076963,0.000013581309],"genre_scores_gemma":[0.015618206,0.9834244,0.00064460543,0.000050158447,0.000038140213,0.000050424318,0.0000121837475,0.000022079992,0.00013979498],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818385,0.00031880688,0.001053045,0.00018592423,0.00007193901,0.00018646698],"domain_scores_gemma":[0.99635607,0.00042121485,0.002842171,0.00020731012,0.00015090413,0.000022350998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001284176,0.00030702227,0.00252098,0.00025441765,0.00009238041,0.0000039267106,0.00032035998,0.00016743985,0.0000034480647],"category_scores_gemma":[0.000019830379,0.00014211613,0.0004877763,0.00017005908,0.00054777495,0.000031095366,0.000103236554,0.00011867096,9.361826e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067432446,0.00011628918,0.002300842,0.00641979,0.007802445,0.0000044299554,0.0005087963,0.000006063607,0.0001509323,0.00022623222,0.0011723505,0.9806175],"study_design_scores_gemma":[0.0033493477,0.002136394,0.006444253,0.0062657837,0.02012916,0.003211363,0.0030953703,7.9802896e-7,0.003023743,0.000041740437,0.9519749,0.00032711308],"about_ca_topic_score_codex":0.000045427678,"about_ca_topic_score_gemma":0.000007704478,"teacher_disagreement_score":0.9802904,"about_ca_system_score_codex":0.00004472729,"about_ca_system_score_gemma":0.000098502416,"threshold_uncertainty_score":0.57953274},"labels":[],"label_agreement":null},{"id":"W2914339882","doi":"10.3899/jrheum.190119","title":"The Genetics of Psoriasis and Psoriatic Arthritis","year":2019,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Arthritis; Disease; Genome-wide association study; Immunology; Genetic predisposition; Population; Genetics; Internal medicine; Genotype; Single-nucleotide polymorphism; Biology; Gene","score_opus":0.008288332416098007,"score_gpt":0.2152879930253327,"score_spread":0.2069996606092347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914339882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93670934,0.06085096,0.000024035124,0.00049173355,0.0016628392,0.00010412677,0.000005102482,0.0000041280905,0.00014772995],"genre_scores_gemma":[0.95880556,0.04084665,0.000056163524,0.00002197702,0.0000071842364,0.0000013647192,0.0000011559885,0.000008578154,0.00025139254],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872655,0.00045510926,0.00050134404,0.000070700684,0.000043530534,0.00020277438],"domain_scores_gemma":[0.99797285,0.0011252736,0.00053828466,0.00024354423,0.000103863815,0.000016214504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006968619,0.00011446077,0.0004008885,0.000059371898,0.00014056878,0.0000061564997,0.0002916135,0.00013217835,0.000107364336],"category_scores_gemma":[0.00009361365,0.000058200512,0.000092947506,0.00007610859,0.00027260275,0.00003520795,0.000057023542,0.00016857464,0.0000736333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019439327,0.00018357864,0.33971062,0.00006922513,0.0029686522,0.0000059897648,0.003843703,0.000026801446,0.026656143,0.0075733415,0.004492067,0.61252594],"study_design_scores_gemma":[0.05408297,0.011297308,0.40323043,0.001389891,0.004345199,0.08836619,0.016301978,0.000088126566,0.17234111,0.031473063,0.21537346,0.0017102837],"about_ca_topic_score_codex":0.000038436916,"about_ca_topic_score_gemma":0.000043911652,"teacher_disagreement_score":0.61081564,"about_ca_system_score_codex":0.0000092257305,"about_ca_system_score_gemma":0.000057463836,"threshold_uncertainty_score":0.2373348},"labels":[],"label_agreement":null},{"id":"W2914630598","doi":"10.1111/bjd.17738","title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis","year":2019,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Psoriasis; Discontinuation; Meta-analysis; Persistence (discontinuity); Medicine; Drug; Systematic review; Intensive care medicine; Internal medicine; MEDLINE; Pharmacology; Immunology; Biology","score_opus":0.07836011503659017,"score_gpt":0.296998066237931,"score_spread":0.21863795120134083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914630598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009266502,0.9975627,0.0000042061956,0.000024399902,0.0002563237,0.00096798746,0.00021637164,0.000010000752,0.000031371037],"genre_scores_gemma":[0.0076394756,0.9920146,0.000027536465,0.000029469482,0.0000074357476,0.00005568591,0.00009065371,0.000022655795,0.00011249399],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9938197,0.0026531883,0.0027011214,0.0003779119,0.000076498975,0.00037159392],"domain_scores_gemma":[0.9947289,0.0012184462,0.0035172973,0.00031578247,0.00017603984,0.00004350377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007164457,0.0004944428,0.013689699,0.00079664245,0.000065884895,0.000017442031,0.00054207264,0.0007280378,0.00014559453],"category_scores_gemma":[0.00042854922,0.00035580905,0.0031942711,0.0007283466,0.00017932912,0.0001119657,0.000104307925,0.0005689331,0.0000142980625],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001048776,0.00014719465,0.0007349885,0.70105696,0.29088402,0.0002818056,0.00018042553,2.3388364e-7,9.586473e-7,0.000011344893,0.00006875314,0.00662282],"study_design_scores_gemma":[0.0004922209,0.00008314505,0.000081017824,0.07118052,0.9044533,0.021513477,0.0002270347,9.121807e-8,0.000006626635,0.0000042728125,0.001665422,0.0002929129],"about_ca_topic_score_codex":0.00005693832,"about_ca_topic_score_gemma":0.00005094205,"teacher_disagreement_score":0.62987643,"about_ca_system_score_codex":0.00005114776,"about_ca_system_score_gemma":0.0002081802,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W2915850404","doi":"10.1016/j.bpg.2019.02.006","title":"IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?","year":2019,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"Canadian Institutes of Health Research; Canadian Association of Gastroenterology","keywords":"Ustekinumab; Interleukin 23; Interleukin 12; Medicine; Immunology; Crohn's disease; Monoclonal antibody; Immune system; Disease; Internal medicine; Antibody; Interleukin 17; Tumor necrosis factor alpha; Biology; Adalimumab; In vitro","score_opus":0.22379897421202122,"score_gpt":0.48070857355466157,"score_spread":0.25690959934264035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915850404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009061884,0.9821508,0.00071095745,0.0017540891,0.002040006,0.010586299,0.0012540993,0.000050707546,0.00054686127],"genre_scores_gemma":[0.0007355284,0.9857321,0.00071012723,0.00032802342,0.00026177813,0.003049663,0.000788846,0.00009780863,0.008296134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886885,0.006659349,0.0016931278,0.0013461756,0.000262993,0.0013498514],"domain_scores_gemma":[0.98262703,0.014163852,0.0009042355,0.0012408852,0.00088613963,0.0001778525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005641398,0.00060310174,0.002233186,0.00037639018,0.00043551813,0.000060620292,0.0009653902,0.00081005046,0.0002274475],"category_scores_gemma":[0.002739392,0.00037478592,0.001039053,0.000508174,0.0006731,0.00021360823,0.00086334563,0.0017000153,0.0019449897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056585625,0.004041494,0.00013995628,0.006738316,0.010613764,0.0003414498,0.00006601653,0.000009779415,0.0000024350895,0.00041257136,0.018764822,0.9022838],"study_design_scores_gemma":[0.0038053535,0.0068340283,0.00039507775,0.0030124243,0.0072037335,0.00015845346,0.00024476767,0.0000038848707,0.000002348534,0.00006121713,0.9780349,0.0002437745],"about_ca_topic_score_codex":0.00003838011,"about_ca_topic_score_gemma":0.00005743933,"teacher_disagreement_score":0.9592701,"about_ca_system_score_codex":0.00020402794,"about_ca_system_score_gemma":0.00064979447,"threshold_uncertainty_score":0.9998704},"labels":[],"label_agreement":null},{"id":"W2915874484","doi":"10.1016/b0-12-370879-6/00486-5","title":"INTERLEUKINS | IL-17","year":2006,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cytokine; Immunology; Inflammation; Interleukin; Receptor; Biology; Cell biology; Chemistry; Biochemistry","score_opus":0.01492349371997047,"score_gpt":0.22061792914038603,"score_spread":0.20569443542041554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915874484","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030911106,0.0075682783,0.0000021277285,0.00003244758,0.0016435273,0.00040446784,0.0004295245,0.00016774054,0.98944277],"genre_scores_gemma":[0.0021273568,0.00013948082,0.000042402848,0.00020271415,0.00030106414,0.000049691575,0.0009114884,0.00010558269,0.9961202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840987,0.00005095295,0.00047212187,0.00057812314,0.00005583921,0.00043310263],"domain_scores_gemma":[0.9989088,0.00007823335,0.0002641594,0.00065149093,0.00006301233,0.000034264296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000113643284,0.000619662,0.0007214865,0.00020966836,0.0001744782,0.000022750157,0.00035188586,0.0010190749,0.0022718653],"category_scores_gemma":[0.0000054723314,0.00054485135,0.0004738286,0.000009673511,0.00023619905,0.000026147056,0.00013430841,0.00046181917,0.005100893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005868765,0.000023294735,0.000013316987,0.000023166518,0.0006843338,0.00006661412,0.00008687589,1.2464461e-7,0.000833684,0.0022815536,0.018375296,0.97755307],"study_design_scores_gemma":[0.00083338114,0.00012850392,0.00006442387,0.0001973666,0.000528558,0.00008249898,0.000003978064,5.3704444e-8,0.0014379052,0.0020111457,0.99418527,0.0005269305],"about_ca_topic_score_codex":0.0000030690364,"about_ca_topic_score_gemma":0.00007649694,"teacher_disagreement_score":0.9770261,"about_ca_system_score_codex":0.00011119775,"about_ca_system_score_gemma":0.00009300754,"threshold_uncertainty_score":0.9997003},"labels":[],"label_agreement":null},{"id":"W2916050127","doi":"10.1097/01.asw.0000550592.08674.43","title":"Diagnosis and Management of Cutaneous Psoriasis: A Review","year":2019,"lang":"en","type":"review","venue":"Advances in Skin & Wound Care","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Continuing education; Wound care; Nurse practitioners; Disease; Physician assistants; Patient education; MEDLINE; Epidemiology; Intensive care medicine; Family medicine; Health care; Pathology","score_opus":0.02502835719717417,"score_gpt":0.31804613566010714,"score_spread":0.293017778462933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916050127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024765222,0.993973,8.980878e-7,0.0000063539546,0.0012207037,0.002000003,0.0002513453,0.00002301371,0.002499874],"genre_scores_gemma":[0.000050225448,0.99736774,0.0001089676,0.000032964483,0.000031674826,0.0011477529,0.0005285545,0.000043051175,0.0006890762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978862,0.00029987664,0.0007473527,0.0006448358,0.00006862923,0.00035314588],"domain_scores_gemma":[0.998546,0.00030792263,0.00045629602,0.00061878184,0.00005045297,0.000020569101],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012076381,0.0005290323,0.0022555394,0.00016594844,0.000054091575,0.000008397544,0.00037236532,0.00037955554,0.00017516839],"category_scores_gemma":[0.000017345492,0.00042015183,0.00041407792,0.00033992244,0.000119790806,0.00009907924,0.0001721181,0.00023272757,0.0001875177],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011762158,0.000049687216,0.000056105888,0.15252715,0.00044029386,0.000060919076,0.00008639999,3.2563432e-7,3.9971365e-8,0.00013396576,0.00017721788,0.8464561],"study_design_scores_gemma":[0.00043047793,0.00009680453,0.000008790426,0.10122914,0.0033257126,0.00013840522,0.00017721058,4.2737027e-9,0.000005063444,0.000024839499,0.8942236,0.00033997203],"about_ca_topic_score_codex":0.000013959809,"about_ca_topic_score_gemma":0.00004451949,"teacher_disagreement_score":0.89404637,"about_ca_system_score_codex":0.0001347722,"about_ca_system_score_gemma":0.00005377705,"threshold_uncertainty_score":0.99982506},"labels":[],"label_agreement":null},{"id":"W2916063242","doi":"10.1177/1203475418808764","title":"Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users","year":2019,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Toronto","funders":"Janssen Biotech","keywords":"Medicine; Psoriasis; Apremilast; Internal medicine; Dermatology","score_opus":0.0559993676498653,"score_gpt":0.2789077388486327,"score_spread":0.22290837119876739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916063242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98174655,0.01726922,0.0000069821417,0.000069929345,0.00072598545,0.000101587975,0.000021109787,0.0000070117535,0.000051635303],"genre_scores_gemma":[0.9914424,0.008335487,0.000014437986,0.000041756895,0.000048816884,0.0000016635065,0.000034954108,0.000006234847,0.00007423703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987487,0.00034029223,0.0005333508,0.0001621347,0.00006741113,0.0001481062],"domain_scores_gemma":[0.99729455,0.0019161998,0.00050296076,0.000069799964,0.00017934272,0.00003714059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000814617,0.00016281757,0.0008068608,0.0002638642,0.00007116351,0.000005664845,0.00003604855,0.00015946294,0.000047103524],"category_scores_gemma":[0.00026118086,0.000102338294,0.00006170761,0.00009826622,0.00016448076,0.00007048683,0.000019213805,0.00010064719,0.000002895544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059274206,0.00003510602,0.96096504,0.000060631555,0.00060073606,0.000030422125,0.00023173162,0.000004233747,0.027690178,0.000014654753,0.00024601028,0.009528508],"study_design_scores_gemma":[0.0020401715,0.0008600099,0.98516184,0.0004863015,0.00034818766,0.009113035,0.0007689724,0.000009263894,0.00083311246,0.00009732836,0.00013245754,0.00014931333],"about_ca_topic_score_codex":0.00029258034,"about_ca_topic_score_gemma":0.0000428664,"teacher_disagreement_score":0.026857067,"about_ca_system_score_codex":0.00003381625,"about_ca_system_score_gemma":0.00007371097,"threshold_uncertainty_score":0.41732344},"labels":[],"label_agreement":null},{"id":"W2916265300","doi":"","title":"Development and early experiences of a psoriatic arthritis register","year":2000,"lang":"en","type":"article","venue":"Journal of Rheumatology Supplement","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Register (sociolinguistics); Arthritis; Family medicine; Internal medicine; Linguistics","score_opus":0.012966111430536451,"score_gpt":0.23171126495776656,"score_spread":0.21874515352723012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916265300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903792,0.008625698,0.000022109834,0.00021249651,0.0005177521,0.00009919452,0.0000051378465,0.0000055413543,0.00013284925],"genre_scores_gemma":[0.9946986,0.0018242301,0.0029417207,0.00002063288,0.000006846266,0.00001940542,0.0000063762236,0.0000069726375,0.0004752307],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986213,0.00012550464,0.00083111017,0.0001323906,0.000060177783,0.00022950549],"domain_scores_gemma":[0.99930483,0.0000873684,0.0003978818,0.00011884638,0.000058563262,0.000032500826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029557195,0.00014167979,0.0005077866,0.00012960577,0.00009050258,0.0000074651507,0.00014382866,0.00011311598,0.0029115204],"category_scores_gemma":[0.000017751037,0.00010947221,0.00008508544,0.00006246697,0.0001591188,0.00008910363,0.000025250725,0.0000928428,0.000035303685],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012167846,0.0005935383,0.1668653,0.00008111621,0.0019104903,0.00009084405,0.12160557,0.0000014988834,0.0024749667,0.0009851529,0.0074793096,0.69669545],"study_design_scores_gemma":[0.02507077,0.0035953298,0.0952963,0.0010178199,0.00045446825,0.010044556,0.049196992,0.0000011292152,0.1532196,0.00049285416,0.66068673,0.0009234323],"about_ca_topic_score_codex":0.00002789806,"about_ca_topic_score_gemma":0.000026598329,"teacher_disagreement_score":0.695772,"about_ca_system_score_codex":0.000020739779,"about_ca_system_score_gemma":0.00008454047,"threshold_uncertainty_score":0.99799997},"labels":[],"label_agreement":null},{"id":"W2917511848","doi":"10.3899/jrheum.150120","title":"Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Rehabilitation Institute; Toronto Western Hospital","funders":"Amgen","keywords":"Psoriatic arthritis; Dactylitis; Medicine; Psoriasis; Enthesitis; Rheumatology; Family medicine; Dermatology; Alternative medicine; Working group; Medical physics; Physical therapy; Internal medicine; Pathology","score_opus":0.044031542541153525,"score_gpt":0.3185124867341378,"score_spread":0.27448094419298424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917511848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807016,0.017239252,0.0000895742,0.00086305075,0.00067381666,0.00031031328,0.000037156602,0.0000034395287,0.000081744816],"genre_scores_gemma":[0.9945155,0.004774754,0.00061764155,0.000010349839,0.000011850534,0.0000126929945,0.0000030336398,0.000009787958,0.00004439125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774605,0.0011854446,0.0005902658,0.00011485684,0.000097603435,0.00026576346],"domain_scores_gemma":[0.9970558,0.0015831945,0.0006453914,0.00020951268,0.00047355198,0.00003250111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039728153,0.00012059581,0.0005412153,0.00014351578,0.00017484953,0.000004953926,0.00028897283,0.0001786893,0.000008327866],"category_scores_gemma":[0.00045859953,0.000065997614,0.00008103204,0.00012602616,0.0007234556,0.000066291876,0.00013780646,0.00027221674,0.0000010350526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050941627,0.00092013803,0.77518266,0.00038893192,0.0032978673,0.0000048827246,0.012049815,0.000020152176,0.025661925,0.020277549,0.023274459,0.13382748],"study_design_scores_gemma":[0.08549259,0.037958156,0.56910646,0.0031428603,0.0035746095,0.030080086,0.052714653,0.00018348052,0.06936799,0.10431696,0.042681303,0.0013808386],"about_ca_topic_score_codex":0.00015655778,"about_ca_topic_score_gemma":0.000119439355,"teacher_disagreement_score":0.20607617,"about_ca_system_score_codex":0.000018289284,"about_ca_system_score_gemma":0.00015464106,"threshold_uncertainty_score":0.26913047},"labels":[],"label_agreement":null},{"id":"W2917601872","doi":"10.3899/jrheum.111239","title":"Psoriasis and Psoriatic Arthritis Video Project: An Update from the 2010 GRAPPA Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Dactylitis; Psoriatic arthritis; Psoriasis; Enthesitis; Psoriasis Area and Severity Index; Dermatology; Rheumatology; Physical examination; Physical therapy; Internal medicine; Medical physics","score_opus":0.014601623868306922,"score_gpt":0.23805034739387226,"score_spread":0.22344872352556533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917601872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491539,0.04603869,0.000052222666,0.0011548925,0.0032939576,0.0001648694,0.000070679365,0.00002002574,0.000050781367],"genre_scores_gemma":[0.9869193,0.012447852,0.00025281485,0.00017713354,0.0000952852,0.000007843199,0.000022640015,0.00002054917,0.000056569694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728614,0.0014561736,0.00059067714,0.00013612171,0.00006613739,0.00046474035],"domain_scores_gemma":[0.99765515,0.0012519208,0.00060945825,0.00032800497,0.000106918684,0.000048527294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015584644,0.00022766134,0.00052416004,0.00009512676,0.00042526537,0.00001876828,0.0004255279,0.00023588899,0.00015579721],"category_scores_gemma":[0.0002435137,0.000120586716,0.00011335931,0.00013157201,0.00032462832,0.0003249921,0.00009601472,0.00038845255,0.000092902985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025452017,0.00063648476,0.519051,0.000025122034,0.0037665437,0.000016173295,0.040133238,0.0000048812767,0.008631257,0.0023154293,0.050778247,0.3720964],"study_design_scores_gemma":[0.034420878,0.003831745,0.5507827,0.0012586028,0.0069217244,0.071223244,0.058952015,0.00002678153,0.0262392,0.011881209,0.23204117,0.0024207658],"about_ca_topic_score_codex":0.0011434514,"about_ca_topic_score_gemma":0.00036578145,"teacher_disagreement_score":0.36967564,"about_ca_system_score_codex":0.000016676488,"about_ca_system_score_gemma":0.00006906598,"threshold_uncertainty_score":0.49173835},"labels":[],"label_agreement":null},{"id":"W2917779049","doi":"10.3899/jrheum.150133","title":"Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2014 GRAPPA Annual Meeting","year":2015,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Continuing medical education; Dermatology; Family medicine; Medical physics; Medical education; Continuing education","score_opus":0.016430395048027627,"score_gpt":0.24965944616680721,"score_spread":0.2332290511187796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917779049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96366173,0.02989789,0.00006409924,0.0040013813,0.0020349056,0.00009922026,0.00008685196,0.000010907512,0.00014302049],"genre_scores_gemma":[0.9912233,0.008089283,0.00026800018,0.00024043443,0.00007625507,0.000006111892,0.000048034683,0.000014103125,0.00003450053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974818,0.0015357446,0.0005207631,0.00013964549,0.000071462855,0.00025058634],"domain_scores_gemma":[0.9972572,0.0016423464,0.00057083275,0.00024069387,0.00022950444,0.00005944754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012249674,0.00018111839,0.00041568,0.00007965562,0.0002869051,0.00001920495,0.00038740487,0.00015557521,0.00019536454],"category_scores_gemma":[0.0004255244,0.00010062143,0.00007661443,0.00009434548,0.0003575894,0.00027042604,0.000068847505,0.00027688808,0.00013620213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004072312,0.0009313669,0.5672929,0.000022536224,0.005462899,0.000023651302,0.075127505,0.000055791137,0.0020022248,0.015703399,0.14908254,0.18022284],"study_design_scores_gemma":[0.04284859,0.005072657,0.5421131,0.0011367808,0.0041024643,0.040760677,0.115737714,0.000049674916,0.006443985,0.14584985,0.09385046,0.002034022],"about_ca_topic_score_codex":0.00050403026,"about_ca_topic_score_gemma":0.00030217032,"teacher_disagreement_score":0.17818883,"about_ca_system_score_codex":0.000023115042,"about_ca_system_score_gemma":0.00021567033,"threshold_uncertainty_score":0.41032228},"labels":[],"label_agreement":null},{"id":"W2917979966","doi":"10.1016/j.jaad.2019.02.038","title":"Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: A cohort study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Queen's University","funders":"National Institutes of Health; Brown University; National Cancer Institute; Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Psoriasis; Hazard ratio; Psoriatic arthritis; Atopic dermatitis; Proportional hazards model; Cohort; Internal medicine; Cohort study; Confidence interval; Dermatology","score_opus":0.007129921995451364,"score_gpt":0.2375182461267834,"score_spread":0.23038832413133203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917979966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893795,0.0083580855,0.0000017490377,0.0014960158,0.0003550765,0.0003801892,0.000007336687,0.0000060646876,0.000015979824],"genre_scores_gemma":[0.99488413,0.0043833884,0.000020028674,0.0006346986,0.000024977931,0.00001855864,8.1926555e-7,0.0000121128205,0.000021253582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789554,0.0007494253,0.0007882275,0.00018702011,0.0000868613,0.00029290025],"domain_scores_gemma":[0.998461,0.0002574935,0.0010667186,0.0001459549,0.000026850665,0.000041997504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003161421,0.00019349057,0.00094716816,0.00023146922,0.00005838994,0.0000075179673,0.00027209258,0.0001289713,0.00003545443],"category_scores_gemma":[0.000049571518,0.0001414704,0.00008611369,0.00016060598,0.0003600484,0.00012892533,0.00016232899,0.0004099735,0.000012129403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009943206,0.00013600648,0.93776804,0.000033909426,0.00049442536,0.000037441132,0.0016621677,0.0000015346865,0.0013920963,0.000011893383,0.0001704095,0.058192626],"study_design_scores_gemma":[0.0031233015,0.00027121144,0.9898319,0.00009730874,0.000116921656,0.0027612196,0.0016574828,0.000001920816,0.001170318,0.00015252753,0.0006896292,0.00012621027],"about_ca_topic_score_codex":0.000063257416,"about_ca_topic_score_gemma":0.00002549849,"teacher_disagreement_score":0.058066413,"about_ca_system_score_codex":0.000053361284,"about_ca_system_score_gemma":0.000055518503,"threshold_uncertainty_score":0.5768996},"labels":[],"label_agreement":null},{"id":"W2921103104","doi":"10.1177/1203475419833605","title":"Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study","year":2019,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Toronto; Western University; Memorial University of Newfoundland; McMaster University; Queen's University; Université de Sherbrooke; Dermatrials Research; University of Ottawa","funders":"American Academy of Dermatology","keywords":"Checklist; Medicine; Psoriasis; Delphi method; Likert scale; Documentation; Delphi; Population; Family medicine; Dermatology; Physical therapy","score_opus":0.05428009335472437,"score_gpt":0.2902631076750612,"score_spread":0.23598301432033683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921103104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96504223,0.03251534,0.000040303934,0.00019369328,0.0017168861,0.00044287305,0.000012718911,0.0000054061093,0.00003055455],"genre_scores_gemma":[0.99576455,0.003595996,0.00002387087,0.000040006296,0.00022887146,0.0000069678067,0.0000056306594,0.000010354786,0.00032374062],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9987727,0.00017931362,0.00067469367,0.00013016564,0.000058434027,0.0001846973],"domain_scores_gemma":[0.9962686,0.0027608508,0.00060321466,0.00017590346,0.00016594016,0.000025525836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062639575,0.00017099697,0.00086702284,0.00017414136,0.00010037839,0.000004540765,0.000090537804,0.00010909446,0.00007659258],"category_scores_gemma":[0.00014892244,0.00008068675,0.00022788605,0.00009933561,0.000108672306,0.000031118594,0.000010529418,0.00006037322,0.0000032285566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008769836,0.002195389,0.5041281,0.00031040676,0.010747333,0.00060087244,0.013986263,0.000104410065,0.24081638,0.00006740365,0.0037006785,0.21457292],"study_design_scores_gemma":[0.08193621,0.11879036,0.06252954,0.0059435163,0.042812563,0.19279993,0.27561715,0.00047448275,0.055072643,0.0008232725,0.16014919,0.003051142],"about_ca_topic_score_codex":0.00009137006,"about_ca_topic_score_gemma":0.00000778412,"teacher_disagreement_score":0.44159856,"about_ca_system_score_codex":0.000046545556,"about_ca_system_score_gemma":0.000095291834,"threshold_uncertainty_score":0.32903102},"labels":[],"label_agreement":null},{"id":"W2921374616","doi":"10.5070/d3252042888","title":"A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction","year":2019,"lang":"en","type":"article","venue":"Dermatology Online Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Tolerability; Patient satisfaction; Psoriasis; Dermatology; Prospective cohort study; Surgery; Adverse effect; Internal medicine","score_opus":0.015224637202663252,"score_gpt":0.25167995155853856,"score_spread":0.2364553143558753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921374616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942479,0.0027252058,0.00020206039,0.00030055927,0.001897587,0.00029162882,0.00010598768,0.000075669705,0.0001534133],"genre_scores_gemma":[0.99843043,0.00042320654,0.00051955273,0.0001558327,0.00007460078,0.000009264267,0.00009030756,0.000020302585,0.00027648397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852324,0.00024992408,0.0004997178,0.00030259983,0.000049209106,0.00037531563],"domain_scores_gemma":[0.99917805,0.00018142392,0.00026900342,0.0002314507,0.00008382509,0.00005622337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017421434,0.0002517485,0.000579844,0.00017854772,0.00022049555,0.000029757475,0.00014810349,0.00038504475,0.00042932772],"category_scores_gemma":[0.000016396407,0.00020158142,0.00012918162,0.00010958073,0.00013187622,0.00012638031,0.000031364038,0.00042601803,0.0003146994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064661854,0.0005873235,0.6214007,0.00008447507,0.0007319692,0.0000666064,0.0004049842,0.000006920908,0.3380331,0.0003400792,0.00079715525,0.03690006],"study_design_scores_gemma":[0.012128622,0.00048783375,0.9138611,0.0001609245,0.00022113623,0.057722226,0.00066834525,0.000040325118,0.009595878,0.00008171826,0.0046120654,0.0004198119],"about_ca_topic_score_codex":0.00006407009,"about_ca_topic_score_gemma":0.00005584404,"teacher_disagreement_score":0.32843724,"about_ca_system_score_codex":0.000057627396,"about_ca_system_score_gemma":0.000088924535,"threshold_uncertainty_score":0.8220252},"labels":[],"label_agreement":null},{"id":"W2921428590","doi":"10.1177/1203475418792002","title":"Twenty Years Without Treatment: A Presentation of Arthritis Mutilans With Psoriasis","year":2019,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Presentation (obstetrics); Arthritis; Surgery; Internal medicine","score_opus":0.016676814981186436,"score_gpt":0.2424166116518094,"score_spread":0.22573979667062294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921428590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912834,0.0072663897,0.0000117241225,0.00020831185,0.00063506543,0.00011978697,0.000010992683,0.000007302611,0.0004570322],"genre_scores_gemma":[0.9926491,0.006164007,0.000043336597,0.000045569734,0.00010623225,0.000002029905,0.00001984439,0.000011660886,0.0009582138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990803,0.00011674964,0.00043675446,0.000118644,0.00008508811,0.00016244603],"domain_scores_gemma":[0.9988042,0.00050456286,0.00042995278,0.00012248303,0.0000994358,0.0000393745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019320617,0.00013994235,0.00067116384,0.000226378,0.000031266267,0.0000039071924,0.000047436984,0.00009506534,0.0003430898],"category_scores_gemma":[0.000042332525,0.000086767395,0.00011078963,0.00010637998,0.00012325337,0.000072753784,0.0000062496933,0.00007903652,0.000013147959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004063098,0.00036782926,0.6072233,0.00006963883,0.00199435,0.0010267519,0.0037506947,0.000012077256,0.034663867,0.000043750788,0.003281718,0.34350297],"study_design_scores_gemma":[0.06315654,0.041143503,0.3768757,0.007959793,0.007716233,0.13337825,0.01959592,0.000026448037,0.1532007,0.0007242528,0.1941831,0.0020395746],"about_ca_topic_score_codex":0.000085432956,"about_ca_topic_score_gemma":0.000025709873,"teacher_disagreement_score":0.3414634,"about_ca_system_score_codex":0.000021275377,"about_ca_system_score_gemma":0.000090008005,"threshold_uncertainty_score":0.37565926},"labels":[],"label_agreement":null},{"id":"W2921639494","doi":"10.1136/ejhpharm-2019-eahpconf.42","title":"2SPD-002 Comparative efficacy of dimethylfumarate and other treatments for moderate-to-severe chronic plaque psoriasis","year":2019,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acitretin; Methotrexate; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Ustekinumab; Clinical trial; Placebo; Dermatology; Rheumatoid arthritis; Surgery; Adalimumab","score_opus":0.03237178122388199,"score_gpt":0.2828597694627002,"score_spread":0.2504879882388182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921639494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919775,0.0018077759,0.00019002592,0.000055883185,0.00038122575,0.0013214037,0.00027148688,0.00004353672,0.0039511197],"genre_scores_gemma":[0.9802229,0.000058594454,0.00049958355,0.00008401383,0.000027614953,0.0001306938,0.00009997763,0.000023058023,0.018853566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988362,0.00012211276,0.00027205335,0.00041240308,0.000029324368,0.00032788244],"domain_scores_gemma":[0.9991594,0.00035913993,0.0001086104,0.00027993484,0.00005573615,0.000037207563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000095415104,0.00027633455,0.0005688309,0.00010871077,0.00010089895,0.000011528348,0.00012174736,0.00020278386,0.0010075008],"category_scores_gemma":[0.000008765058,0.00020675357,0.00012545937,0.000106559375,0.00006524516,0.00007029947,0.000045586206,0.000057231242,0.0007113303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019584408,0.0026152676,0.039073307,0.00021285487,0.013859232,0.000004242322,0.00807727,0.0008458674,0.8133891,0.009764847,0.008801369,0.08377219],"study_design_scores_gemma":[0.036077417,0.0038261032,0.029715808,0.00010673323,0.0009512107,0.00002397981,0.00043075116,0.00015357544,0.90322405,0.0003247261,0.024378067,0.00078756927],"about_ca_topic_score_codex":0.00012690005,"about_ca_topic_score_gemma":0.00006543708,"teacher_disagreement_score":0.08983491,"about_ca_system_score_codex":0.00006350275,"about_ca_system_score_gemma":0.000060679784,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2922095843","doi":"10.1016/j.jneuroim.2019.03.006","title":"The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks","year":2019,"lang":"en","type":"article","venue":"Journal of Neuroimmunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Abbott Diagnostics; Ministère de la Santé et des Services sociaux","keywords":"Allele; Multiple sclerosis; Genotype; Internal medicine; Medicine; Immunology; Biology; Genetics; Gene","score_opus":0.01476164910115214,"score_gpt":0.21849980032298041,"score_spread":0.20373815122182828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922095843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492407,0.0025245878,0.0000025651022,0.0014945681,0.00058197265,0.00031131128,0.000027379348,0.000006525158,0.0001270345],"genre_scores_gemma":[0.99839306,0.00080575957,0.000016568378,0.00015971708,0.00001277276,0.000009038659,0.000008241334,0.000014316688,0.00058051926],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974506,0.0010106498,0.0007931976,0.00023310995,0.000103546,0.00040888492],"domain_scores_gemma":[0.9970901,0.0013390925,0.0009586069,0.00042377738,0.0001751162,0.000013329986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011511403,0.00019673296,0.0005330337,0.0001508688,0.00011921078,0.000016802851,0.00052991987,0.0003061222,0.00012625351],"category_scores_gemma":[0.00039710954,0.00011179691,0.0001372225,0.00034025975,0.00018590473,0.00015571003,0.000083968494,0.0006353034,0.000056020173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014367617,0.00025515858,0.4962102,0.000005044729,0.00027509383,0.0000058140954,0.0007437081,0.00002886015,0.4971041,0.000020273792,0.0005100413,0.0034049535],"study_design_scores_gemma":[0.0055162827,0.00091473135,0.9771982,0.00004295626,0.00006196693,0.00007041233,0.00046329875,0.000005260333,0.012778734,0.00006112013,0.00278015,0.00010691066],"about_ca_topic_score_codex":0.00030371896,"about_ca_topic_score_gemma":0.0009435042,"teacher_disagreement_score":0.48432538,"about_ca_system_score_codex":0.00015958642,"about_ca_system_score_gemma":0.00012250399,"threshold_uncertainty_score":0.45589456},"labels":[],"label_agreement":null},{"id":"W2922099376","doi":"10.1111/jdv.15400","title":"Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Merck","keywords":"Medicine; Placebo; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Randomized controlled trial; Gastroenterology; Dermatology; Pathology","score_opus":0.02369100495985317,"score_gpt":0.26942692635877286,"score_spread":0.2457359213989197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922099376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849404,0.010923435,0.00016719193,0.0019212596,0.00048722522,0.0011050594,0.000066814326,0.0000058748706,0.0003827101],"genre_scores_gemma":[0.99844986,0.0007651343,0.0001918683,0.00016044825,0.000044571534,0.000011969859,0.000010162143,0.00001926597,0.00034669825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915693,0.005461135,0.0023553397,0.00025933437,0.00007207338,0.0002828627],"domain_scores_gemma":[0.9904027,0.005934779,0.0032744785,0.00020603495,0.00013200972,0.000050015882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003555908,0.00029368332,0.0057343426,0.00060772384,0.000104243125,0.0000038924527,0.00041372175,0.00042611445,0.00008572488],"category_scores_gemma":[0.0013477948,0.00016840262,0.0014304459,0.00019266903,0.00053348514,0.00005850594,0.00015936683,0.0002805643,0.000005637316],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7556192,0.00043923667,0.048227448,0.00019104072,0.07817003,0.000014107639,0.0011614396,0.0007644583,0.10265226,0.0045771496,0.0011819913,0.007001622],"study_design_scores_gemma":[0.7584872,0.000460584,0.07402788,0.0002591177,0.057536732,0.0020428563,0.00012564781,0.00021766826,0.103092164,0.0019908792,0.0013167623,0.00044246062],"about_ca_topic_score_codex":0.000005199985,"about_ca_topic_score_gemma":0.0000072428784,"teacher_disagreement_score":0.025800437,"about_ca_system_score_codex":0.00001596828,"about_ca_system_score_gemma":0.000055595854,"threshold_uncertainty_score":0.686726},"labels":[],"label_agreement":null},{"id":"W2922410885","doi":"10.1016/j.msard.2019.03.009","title":"A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions","year":2019,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Novartis Pharmaceuticals Canada; Novartis Pharma; Mitsubishi Tanabe Pharma Corporation; European Commission; Biogen; Merck; Sanofi; Bayer Schering; Novartis","keywords":"Secukinumab; Medicine; Multiple sclerosis; Rituximab; Psoriasis; Concomitant; Immunology; Ixekizumab; Dermatology; Internal medicine; Antibody; Psoriatic arthritis","score_opus":0.01381924356041253,"score_gpt":0.22112681122446656,"score_spread":0.20730756766405403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922410885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97669023,0.021143513,0.0000050887998,0.00008000089,0.00052230275,0.0011005868,0.00020508024,0.000075306896,0.0001778961],"genre_scores_gemma":[0.99352586,0.005957657,0.00007833395,0.000031144304,0.0000055924324,0.0000976485,0.00013077038,0.000039987426,0.00013301372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979892,0.00030392394,0.0005628162,0.00062566507,0.00005281463,0.00046560468],"domain_scores_gemma":[0.99854285,0.0008066628,0.00021560861,0.00032347275,0.00004225183,0.000069131675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002526821,0.00039958212,0.00078108266,0.00028441296,0.00030048232,0.00003127677,0.00009967557,0.00038291258,0.000086486754],"category_scores_gemma":[0.00011154451,0.00035086088,0.00012637733,0.0002893095,0.00045403058,0.00017968708,0.00012594955,0.00030257716,0.00003465296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013084426,0.0021738182,0.4748456,0.00035392257,0.0015147642,0.00010798336,0.0071452036,0.0000773912,0.42473888,0.00040992541,0.0000990841,0.087224975],"study_design_scores_gemma":[0.12325868,0.00087543024,0.84994274,0.0011813535,0.0008055561,0.000666601,0.0035622094,0.0018703516,0.015979262,0.00048134636,0.00027895803,0.0010975226],"about_ca_topic_score_codex":0.0024284162,"about_ca_topic_score_gemma":0.001184283,"teacher_disagreement_score":0.40875962,"about_ca_system_score_codex":0.00003637735,"about_ca_system_score_gemma":0.000029093608,"threshold_uncertainty_score":0.9998943},"labels":[],"label_agreement":null},{"id":"W2924267060","doi":"10.1080/09546634.2019.1587145","title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","year":2019,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"Janssen Research and Development; Eli Lilly and Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Adverse effect; Dosing; Interim analysis; Internal medicine; Randomized controlled trial; Dermatology; Surgery","score_opus":0.04277174648646291,"score_gpt":0.2797984276950329,"score_spread":0.23702668120856996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924267060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936316,0.00157072,0.000117004674,0.00042905356,0.00029847847,0.0029331986,0.0009460147,0.0000145057065,0.000059443824],"genre_scores_gemma":[0.99877936,0.00013303972,0.0006946493,0.00006767481,0.00003786736,0.00011064772,0.000077271055,0.00001555795,0.000083953455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99790066,0.00036636667,0.0010040401,0.00033993498,0.00011223893,0.0002767505],"domain_scores_gemma":[0.99682796,0.0017530354,0.000810573,0.00034632266,0.00019046097,0.00007166861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000208329,0.0003329859,0.0012373526,0.00007065715,0.0001549365,0.000028912911,0.00020241598,0.00017787635,0.000032543405],"category_scores_gemma":[0.00017072493,0.00015475962,0.00023213288,0.00008727632,0.00006040473,0.000085441185,0.000049435075,0.00011669016,0.000008367087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8797246,0.023171457,0.015358744,0.000023174483,0.014467012,0.00011115555,0.008434759,0.00028084233,0.022659766,0.000087990236,0.00039934437,0.03528115],"study_design_scores_gemma":[0.82140744,0.07207971,0.04811683,0.00034928726,0.0051784553,0.00070808694,0.0035230948,0.000048594342,0.043110996,0.00006475473,0.004790442,0.0006223093],"about_ca_topic_score_codex":0.000038788105,"about_ca_topic_score_gemma":0.000022474604,"teacher_disagreement_score":0.058317166,"about_ca_system_score_codex":0.000073937015,"about_ca_system_score_gemma":0.0000868028,"threshold_uncertainty_score":0.6310914},"labels":[],"label_agreement":null},{"id":"W2925250388","doi":"10.1111/bjd.17918","title":"Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Merck","keywords":"Medicine; Pharmacokinetics; Immunogenicity; Monoclonal; Interleukin 23; Monoclonal antibody; Clinical trial; Internal medicine; Pharmacology; Antibody; Interleukin 17; Immunology; Cytokine","score_opus":0.00609147270162685,"score_gpt":0.2360848474658084,"score_spread":0.22999337476418155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925250388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874614,0.01073233,0.000011372812,0.00023506631,0.00085712055,0.00028479833,0.000030338777,0.0000023492817,0.00038521056],"genre_scores_gemma":[0.9979702,0.001849488,0.000032725296,0.00005434215,0.000010562906,0.0000018319744,0.0000029771636,0.000008053072,0.00006981049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847555,0.00062303833,0.00058077025,0.000099100405,0.00006726242,0.0001542882],"domain_scores_gemma":[0.99791753,0.0009979927,0.0007462967,0.00019340293,0.00013162398,0.000013125106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019408541,0.00011244899,0.00053230196,0.000057213034,0.00006388623,0.0000033935576,0.0003096072,0.00013448279,0.00010813972],"category_scores_gemma":[0.000116534924,0.0000748765,0.00018838035,0.00008754424,0.00029104497,0.00003109642,0.00008287252,0.00024943563,0.000003288524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013063992,0.0010168614,0.08375239,0.00031049663,0.0026807024,0.0001051696,0.00032091668,0.000013573941,0.8623073,0.0013316921,0.001470123,0.04538434],"study_design_scores_gemma":[0.006321726,0.00037673957,0.4802816,0.00038922715,0.0003314404,0.005853846,0.0000476948,0.0000014729973,0.50557154,0.00004707325,0.0007096906,0.00006796733],"about_ca_topic_score_codex":0.000026155281,"about_ca_topic_score_gemma":0.0000040337636,"teacher_disagreement_score":0.3965292,"about_ca_system_score_codex":0.000015072624,"about_ca_system_score_gemma":0.000094258954,"threshold_uncertainty_score":0.30533752},"labels":[],"label_agreement":null},{"id":"W2925273488","doi":"10.5114/dr.2019.83447","title":"The effects of listening to classical music on dehydroepiandrosterone sulfate and subjective anxiety levels in female in-patients with psoriasis","year":2019,"lang":"en","type":"article","venue":"Dermatology Review","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Wojskowy Instytut Medyczny; Uniwersytet Łódzki","keywords":"Dehydroepiandrosterone sulfate; Psoriasis; Anxiety; Active listening; Dehydroepiandrosterone; Medicine; Dermatology; Psychology; Internal medicine; Psychiatry; Hormone; Androgen; Psychotherapist","score_opus":0.009647285047039595,"score_gpt":0.22784612220772862,"score_spread":0.21819883716068902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925273488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97076344,0.027320547,0.0000014605528,0.00024008108,0.00028247078,0.0011954159,0.000009299131,0.000009354499,0.00017795447],"genre_scores_gemma":[0.9957972,0.003531573,0.0000223815,0.00036986178,0.0000028474185,0.000105047686,0.000019192887,0.00001284407,0.00013905723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998499,0.00049876084,0.00033386078,0.00031839148,0.00003771282,0.0003123092],"domain_scores_gemma":[0.99896765,0.0005597371,0.00013173369,0.00028129586,0.00003615379,0.000023426697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017085961,0.00020054389,0.00068664196,0.00009383902,0.000060210474,0.0000044953495,0.00013307907,0.00014737205,0.00001624764],"category_scores_gemma":[0.000102382764,0.00012486718,0.00005429184,0.00025468584,0.00010182798,0.000049307695,0.000063372805,0.00016953815,0.00011027827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005128648,0.00019295528,0.9605093,0.0009756436,0.00015611845,0.000016868204,0.00044794002,5.785945e-7,0.0008508962,0.00020386047,0.00010189218,0.036031086],"study_design_scores_gemma":[0.004652262,0.00056565244,0.9835913,0.002536795,0.00011828201,0.00005917182,0.000023799344,5.997676e-7,0.005135032,0.000012501054,0.0031253693,0.0001792309],"about_ca_topic_score_codex":0.000012637884,"about_ca_topic_score_gemma":0.000115874725,"teacher_disagreement_score":0.035851855,"about_ca_system_score_codex":0.00003226252,"about_ca_system_score_gemma":0.000026020698,"threshold_uncertainty_score":0.5091936},"labels":[],"label_agreement":null},{"id":"W2926710375","doi":"10.3390/ijms20071670","title":"Infiltration of T Cells into a Three-Dimensional Psoriatic Skin Model Mimics Pathological Key Features","year":2019,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Psoriasis; Proinflammatory cytokine; Infiltration (HVAC); Inflammation; Pathological; Phenotype; Pathology; Immunology; Biology; Medicine","score_opus":0.012457197384974849,"score_gpt":0.2530914610152993,"score_spread":0.24063426363032442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926710375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437606,0.0013070673,0.0021410477,0.0002947224,0.0014813498,0.000075670025,0.000011718792,0.000005043903,0.00030729893],"genre_scores_gemma":[0.99208444,0.00004236606,0.007606025,0.00014810289,0.000034345754,0.0000014603127,0.00000799536,0.000004154639,0.00007107776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989804,0.0000970821,0.00037567748,0.00015885137,0.00025994173,0.00012804086],"domain_scores_gemma":[0.99907666,0.00010164794,0.00040192052,0.00008652437,0.00031304947,0.000020185129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045658273,0.00011310862,0.00020842036,0.0002117378,0.000049867383,0.000024930283,0.00051210786,0.00011918931,0.000094648785],"category_scores_gemma":[0.000056506193,0.00008045901,0.00017202864,0.000111099864,0.0001858859,0.00016873128,0.000062920815,0.00012688596,0.000033313438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020066217,0.00018080916,0.0025771628,0.0000043237847,0.00022309677,0.000032195465,0.0003723765,0.016172405,0.9680655,0.0034137324,0.00014370486,0.00861401],"study_design_scores_gemma":[0.0022855375,0.0009821746,0.012227879,0.00011461989,0.00010235947,0.00048474906,0.00015704226,0.002471117,0.96648175,0.014295094,0.00015915591,0.00023853229],"about_ca_topic_score_codex":0.000021658807,"about_ca_topic_score_gemma":0.000011333036,"teacher_disagreement_score":0.013701289,"about_ca_system_score_codex":0.00003261508,"about_ca_system_score_gemma":0.00016853077,"threshold_uncertainty_score":0.3281023},"labels":[],"label_agreement":null},{"id":"W2931858056","doi":"10.1177/1203475419836435","title":"The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review","year":2019,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; Trent University; SKiN Health; University of Toronto","funders":"","keywords":"Medicine; Acrodermatitis; Dermatology; Pustular psoriasis; Psoriasis; Pathology","score_opus":0.16395241918949288,"score_gpt":0.3324645098344342,"score_spread":0.16851209064494133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931858056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009388579,0.989186,4.9331544e-7,0.00031159515,0.00046301354,0.0005621107,0.000044955064,0.0000015437872,0.00004174422],"genre_scores_gemma":[0.00087864185,0.9986524,0.0000073134593,0.00011991806,0.000057188743,0.000010973523,0.000038151655,0.000011840629,0.0002235548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963997,0.0012904365,0.0019005855,0.0001263125,0.0000940108,0.00018893398],"domain_scores_gemma":[0.9887785,0.008142466,0.0025698922,0.0003298492,0.00016269089,0.000016636335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010629611,0.00030159106,0.0036781493,0.00021061389,0.00004121841,0.0000035623139,0.00022573142,0.00022914323,0.00006102833],"category_scores_gemma":[0.00025955422,0.00010961581,0.00078401336,0.00021083017,0.00035669672,0.000031594514,0.000011742251,0.00017475428,0.0000023820457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013965585,0.00021398577,0.00043549103,0.0035330618,0.0012754169,0.00014516123,0.00040671465,7.7749e-8,0.000044063534,0.0000086244,0.0053482605,0.9884495],"study_design_scores_gemma":[0.0005164884,0.0015236903,0.00007436615,0.02643523,0.0015961938,0.003936277,0.0000793849,2.7980493e-8,0.000024548826,0.0000072858393,0.96572,0.000086489286],"about_ca_topic_score_codex":0.00007306479,"about_ca_topic_score_gemma":0.000021960968,"teacher_disagreement_score":0.98836297,"about_ca_system_score_codex":0.00002388411,"about_ca_system_score_gemma":0.00020774276,"threshold_uncertainty_score":0.4470003},"labels":[],"label_agreement":null},{"id":"W2934865518","doi":"10.3899/jrheum.180086","title":"Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis","year":2019,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Quest University Canada; University of British Columbia","funders":"","keywords":"Onycholysis; Medicine; Acrodermatitis; Dermatology; Psoriatic arthritis; Psoriasis; Arthritis; Nail disease; Pathology; Internal medicine","score_opus":0.006303763738087386,"score_gpt":0.20057117542256384,"score_spread":0.19426741168447645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934865518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98882115,0.009047457,0.00011025651,0.0003930964,0.00075991906,0.00013423114,0.000010653655,0.000008539521,0.0007146968],"genre_scores_gemma":[0.99617696,0.003110583,0.00018498985,0.000041294723,0.000004377192,0.0000017971918,0.0000049258897,0.0000121807425,0.00046290547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987245,0.00039149946,0.00053350744,0.00007866338,0.00004978214,0.00022202553],"domain_scores_gemma":[0.99845576,0.0004242168,0.000722021,0.00023201849,0.00014881822,0.000017145103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042180304,0.00013814913,0.0006220257,0.00009525704,0.000060871458,0.0000040450127,0.00029853504,0.00013027157,0.0006774658],"category_scores_gemma":[0.000034173165,0.00007784097,0.00010302111,0.00009355195,0.00019591681,0.00008847937,0.000034193097,0.00018575924,0.00025690914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046038907,0.0006030698,0.7347243,0.00021093921,0.006076404,0.00005770514,0.010423394,0.00009451571,0.05032047,0.0065249973,0.010932617,0.1754277],"study_design_scores_gemma":[0.088903755,0.01573596,0.31246635,0.004650578,0.0036367825,0.22702621,0.013485981,0.000025623654,0.22951607,0.004925475,0.09757589,0.0020513176],"about_ca_topic_score_codex":0.00012028816,"about_ca_topic_score_gemma":0.0001271905,"teacher_disagreement_score":0.42225793,"about_ca_system_score_codex":0.00001338601,"about_ca_system_score_gemma":0.00008264987,"threshold_uncertainty_score":0.74177754},"labels":[],"label_agreement":null},{"id":"W2936229087","doi":"10.1016/j.jid.2019.03.933","title":"857 Psoriasis-related quality-of-life differs by race/ethnicity","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Ethnic group; Dermatology Life Quality Index; Quality of life (healthcare); Logistic regression; Odds ratio; Comorbidity; Demography; Odds; Gerontology; Internal medicine; Dermatology","score_opus":0.031046168222609614,"score_gpt":0.2715835200745004,"score_spread":0.24053735185189076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936229087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989102,0.0065677003,0.000040403665,0.0017078959,0.0015290513,0.0002019601,0.0000605675,0.000021614655,0.00076877367],"genre_scores_gemma":[0.998404,0.00022214995,0.00018804256,0.00047766024,0.00002275528,0.0000046893883,0.000051262272,0.00002171996,0.0006076793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962131,0.0016157537,0.0014454395,0.00024355882,0.000104108476,0.0003780808],"domain_scores_gemma":[0.9970381,0.0009010679,0.0013554803,0.00027497797,0.0003194846,0.000110871595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005262773,0.00029849887,0.0013371632,0.0002501434,0.0000904299,0.0000067470305,0.00038253094,0.0005358087,0.0006071544],"category_scores_gemma":[0.0007088889,0.00023399257,0.00035737525,0.00026598654,0.0007813542,0.00019128689,0.00006611489,0.0005383428,0.00035225743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006667722,0.00028672843,0.08649532,0.00007116522,0.0020406812,0.000022508762,0.0013661667,0.000009066478,0.8907543,0.002433996,0.015161686,0.00069159997],"study_design_scores_gemma":[0.007440887,0.00043246886,0.08733484,0.00008184485,0.00025773552,0.000552551,0.00077543134,0.0000028105508,0.8967559,0.0018759002,0.0041736616,0.00031598125],"about_ca_topic_score_codex":0.000056187237,"about_ca_topic_score_gemma":0.000006748045,"teacher_disagreement_score":0.010988025,"about_ca_system_score_codex":0.000057864658,"about_ca_system_score_gemma":0.00029567076,"threshold_uncertainty_score":0.954194},"labels":[],"label_agreement":null},{"id":"W2937056199","doi":"10.1016/j.cjca.2019.04.007","title":"Role of IL-37 in Cardiovascular Disease Inflammation","year":2019,"lang":"en","type":"review","venue":"Canadian Journal of Cardiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Inflammation; Pathogenesis; Cytokine; Proinflammatory cytokine; Immunology; Disease; Macrophage polarization; Interleukin; Macrophage; Internal medicine; Biology","score_opus":0.023316336339919464,"score_gpt":0.2351533987494407,"score_spread":0.21183706240952122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937056199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008485835,0.99584854,0.000011526608,0.000010276676,0.0015415924,0.00034407896,0.0003203624,0.0000028444085,0.0010721894],"genre_scores_gemma":[0.012533351,0.9866262,0.000008498925,0.0000033520257,0.00042268465,0.000016810865,0.00022318083,0.000030749692,0.00013513486],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973479,0.0010674943,0.0009103119,0.00023278696,0.000046716446,0.0003947989],"domain_scores_gemma":[0.9984973,0.00016457154,0.000559536,0.0004872349,0.00014389982,0.00014745533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006544682,0.000312479,0.0031043063,0.00076924375,0.000039547653,0.000006265106,0.00039251032,0.0006638272,0.000045123303],"category_scores_gemma":[0.00016469264,0.00025865342,0.0019962536,0.00021870363,0.00014543787,0.000064352585,0.000020349167,0.0004172277,0.00014067796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030237983,0.0000021574024,0.0007972909,0.0009845974,0.004902419,0.00015203834,0.00004992784,0.00026919396,0.000015363454,0.000110005414,0.00033784582,0.9923489],"study_design_scores_gemma":[0.000611228,0.00008201843,0.0010799944,0.0014798315,0.004340603,0.0003820292,0.000027470418,9.546974e-8,0.000010698051,0.00007662873,0.9917112,0.00019822891],"about_ca_topic_score_codex":0.0004732556,"about_ca_topic_score_gemma":0.00032755543,"teacher_disagreement_score":0.99215066,"about_ca_system_score_codex":0.0002521895,"about_ca_system_score_gemma":0.0031052523,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W2937112267","doi":"10.1093/rheumatology/kez107.079","title":"263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period","year":2019,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Immunogenicity; Ankylosing spondylitis; Monoclonal antibody; Immunology; Spondylitis; Monoclonal; Dermatology; Arthritis; Antibody","score_opus":0.005673772900500633,"score_gpt":0.21087991424519564,"score_spread":0.205206141344695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937112267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99326164,0.0047109323,0.0000028881063,0.000028539089,0.00034886072,0.0009091328,0.0004782672,0.00008190937,0.0001778242],"genre_scores_gemma":[0.9977798,0.00031821933,0.000087384076,0.000022831633,0.000046097357,0.00006042706,0.0011270035,0.000052631345,0.00050564355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768996,0.00024043568,0.0004917181,0.0007536293,0.00010229953,0.0007219447],"domain_scores_gemma":[0.99914575,0.00005617597,0.0002002847,0.00047112067,0.00006745004,0.000059237525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013047889,0.00050787703,0.00078198174,0.00024958942,0.0003025651,0.00007746442,0.00018375712,0.0002731455,0.0005636676],"category_scores_gemma":[0.000010939474,0.0004434166,0.00015353439,0.00021099563,0.00013415304,0.00027491146,0.00011153384,0.0002078126,0.00014234267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021250516,0.0011779252,0.8881559,0.00010559197,0.0008425451,0.00021926874,0.0029939634,0.0000073761807,0.08615413,0.000070715716,0.000006155207,0.018141406],"study_design_scores_gemma":[0.02144344,0.0018018995,0.9555561,0.0005076281,0.00014178465,0.00016456026,0.00021186797,0.000004614635,0.019126127,0.000028405613,0.00046230876,0.0005512394],"about_ca_topic_score_codex":0.00047377468,"about_ca_topic_score_gemma":0.00032980746,"teacher_disagreement_score":0.06740026,"about_ca_system_score_codex":0.0002661263,"about_ca_system_score_gemma":0.00006946969,"threshold_uncertainty_score":0.99980175},"labels":[],"label_agreement":null},{"id":"W2937526802","doi":"10.1093/rheumatology/kez106.054","title":"055 Can interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?","year":2019,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Rheumatoid arthritis; Medicine; Interleukin 17; Immunology; Interleukin; Immune system; Cytokine","score_opus":0.01197498151110895,"score_gpt":0.21631216987446777,"score_spread":0.20433718836335882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937526802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966294,0.0006523401,0.0000035684293,0.00018527753,0.0005028788,0.0009955083,0.00067930645,0.000084376625,0.0002673144],"genre_scores_gemma":[0.9968569,0.0000969381,0.000085360276,0.00013807426,0.000012734082,0.0001663098,0.0004294589,0.000026804999,0.0021873815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981903,0.00041373319,0.00033134266,0.00050792756,0.00005083658,0.0005058808],"domain_scores_gemma":[0.9991792,0.00016686787,0.000097135264,0.0004605181,0.000043853226,0.00005243614],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021815821,0.00031939012,0.000478774,0.00021594063,0.00007630018,0.000018422685,0.00020828882,0.00024285051,0.00040840192],"category_scores_gemma":[0.000042107084,0.000231414,0.00008505233,0.00021406963,0.000059526916,0.00007137503,0.00006964947,0.000113085545,0.001060745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00869746,0.00076335965,0.9284118,0.0000060937446,0.00037772144,0.00003857511,0.0016227699,0.000013780403,0.018989597,0.000037076883,0.00029187906,0.040749926],"study_design_scores_gemma":[0.011799239,0.0050767483,0.9483205,0.00015836988,0.000023850824,0.00001973265,0.00016658357,6.266004e-7,0.00964877,0.000022586599,0.02440731,0.00035567436],"about_ca_topic_score_codex":0.00031511497,"about_ca_topic_score_gemma":0.000650625,"teacher_disagreement_score":0.04039425,"about_ca_system_score_codex":0.00023757512,"about_ca_system_score_gemma":0.00009059466,"threshold_uncertainty_score":0.99971706},"labels":[],"label_agreement":null},{"id":"W2937688014","doi":"10.1177/1203475419843118","title":"Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis","year":2019,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; NOSM University; Dermatrials Research; Sunnybrook Health Science Centre; Western University; University of Toronto","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Regimen; Psoriasis Area and Severity Index; Dosing; Adverse effect; Clinical trial; Internal medicine; Dermatology; Surgery; Psoriatic arthritis","score_opus":0.026745049249993692,"score_gpt":0.25632074340218164,"score_spread":0.22957569415218795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937688014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741559,0.021303857,0.000042333875,0.0017726792,0.0022476828,0.0003337247,0.00003396548,0.0000070697874,0.00010276714],"genre_scores_gemma":[0.98667467,0.010241001,0.00007739442,0.00027394583,0.00029162134,0.000010834554,0.00001762362,0.000017955475,0.0023949717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882203,0.00010206762,0.00059382827,0.00015409007,0.000083086576,0.00024488542],"domain_scores_gemma":[0.9964479,0.002714375,0.0003779773,0.00020851682,0.00019809308,0.000053129414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033403316,0.00020477528,0.0008664284,0.00020258648,0.000102768005,0.0000062653435,0.00010289112,0.00013615383,0.00027128265],"category_scores_gemma":[0.000106404514,0.00010616472,0.00020221953,0.000114613766,0.000084990716,0.00004541268,0.00001019632,0.00007709532,0.000019135286],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019308796,0.001173212,0.008556626,0.00012502748,0.004590232,0.0003173158,0.0047896868,0.00012031997,0.046339646,0.00023905345,0.03583413,0.87860596],"study_design_scores_gemma":[0.054121446,0.037180882,0.011108287,0.001562719,0.0079282615,0.025307907,0.0066715195,0.00018272517,0.06931363,0.0018285756,0.78339356,0.0014004947],"about_ca_topic_score_codex":0.000054472588,"about_ca_topic_score_gemma":0.000011872165,"teacher_disagreement_score":0.8772055,"about_ca_system_score_codex":0.000044258264,"about_ca_system_score_gemma":0.0001129687,"threshold_uncertainty_score":0.43292716},"labels":[],"label_agreement":null},{"id":"W2937808345","doi":"10.1016/j.jid.2019.03.610","title":"534 Effects on CD3, Treg and TH17 cell numbers in skin biopsies after 16-week mirikizumab treatment, evaluated by an epigenetic assay","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Interleukin 17; Psoriasis; Psoriasis Area and Severity Index; Placebo; CD3; Internal medicine; Immunology; Gastroenterology; Cytokine; Pathology; Immune system; CD8","score_opus":0.013169079394372247,"score_gpt":0.24170725671051818,"score_spread":0.22853817731614592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937808345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071467,0.0072406475,0.0000059715203,0.00057446084,0.00047796647,0.00038064047,0.000041790277,0.0000144556425,0.000549423],"genre_scores_gemma":[0.9982165,0.00040063477,0.00010608998,0.00041491588,0.000024628622,0.00003595284,0.00006812863,0.000028212497,0.00070491177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99665296,0.0019075352,0.0005776644,0.00035237634,0.00007335588,0.0004360972],"domain_scores_gemma":[0.9983508,0.000722149,0.0004893984,0.0002290274,0.00010128014,0.00010735266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026044503,0.00039578287,0.0008565498,0.00036797032,0.000077518846,0.000019728064,0.0001738466,0.0004011311,0.00020225404],"category_scores_gemma":[0.00008394032,0.00029527562,0.00014897452,0.00019633479,0.00040287236,0.00017863336,0.000028996808,0.0002888659,0.00021671182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004951657,0.0026786125,0.20062569,0.00017649568,0.0019652187,0.0010171467,0.009083363,0.000037247883,0.7540848,0.00010519323,0.006782125,0.018492416],"study_design_scores_gemma":[0.008553725,0.003164349,0.102573656,0.000116600735,0.00028409786,0.0009072843,0.00050494145,0.000011560293,0.8808361,0.00048464126,0.0022628626,0.00030015034],"about_ca_topic_score_codex":0.00010476249,"about_ca_topic_score_gemma":0.00014862402,"teacher_disagreement_score":0.12675129,"about_ca_system_score_codex":0.00018288707,"about_ca_system_score_gemma":0.00017558868,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W2937919132","doi":"10.3389/fgene.2019.00304","title":"Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC","year":2019,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Toronto; Krembil Foundation","funders":"National Center for Research Resources; National Research Foundation; National Institutes of Health; National Psoriasis Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Arthritis National Research Foundation","keywords":"Epigenomics; Genome-wide association study; Pharmacogenomics; Biology; Genetics; Computational biology; Psoriatic arthritis; Genetic association; Gene; Arthritis; Single-nucleotide polymorphism; Gene expression; Immunology; DNA methylation; Genotype","score_opus":0.010275473178394048,"score_gpt":0.21054198309018776,"score_spread":0.2002665099117937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937919132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654619,0.024373356,0.0043019103,0.00010727867,0.0027296513,0.0011979914,0.00015174151,0.00001742795,0.0016587522],"genre_scores_gemma":[0.9656196,0.0021781262,0.025738843,0.00014921813,0.00008870262,0.00009727957,0.00018055407,0.000025790505,0.0059218546],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990568,0.00010274721,0.00020761434,0.00031494716,0.000029298624,0.00028858593],"domain_scores_gemma":[0.9995239,0.000079268495,0.00006220304,0.0002618911,0.000047215606,0.000025521329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017231895,0.00018150832,0.00030065665,0.000080840786,0.00009028446,0.000018663224,0.00017660097,0.00015791193,0.000015748477],"category_scores_gemma":[0.000026961814,0.00012886887,0.00004987691,0.00014055397,0.00007424563,0.00002131366,0.000053051903,0.000112482674,0.000054513337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024210503,0.0007414038,0.3519949,0.00015256176,0.000996657,0.00000665611,0.016910579,0.00042743562,0.099854976,0.0005292424,0.21302542,0.31293914],"study_design_scores_gemma":[0.014561594,0.0030185387,0.12987317,0.00016706325,0.00061283825,0.000060060745,0.0132914,0.00081582903,0.6125519,0.0045659323,0.21866372,0.0018179023],"about_ca_topic_score_codex":0.00003117138,"about_ca_topic_score_gemma":0.0000422729,"teacher_disagreement_score":0.512697,"about_ca_system_score_codex":0.000046594916,"about_ca_system_score_gemma":0.000041413354,"threshold_uncertainty_score":0.525512},"labels":[],"label_agreement":null},{"id":"W2938286893","doi":"10.1136/bmjopen-2018-027535","title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry","year":2019,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Novartis","keywords":"Psoriasis; Medicine; Quality of life (healthcare); Dermatology Life Quality Index; Internal medicine; Body surface area; Visual analogue scale; Severity of illness; Clinical trial; Physical therapy; Dermatology","score_opus":0.1257107383605983,"score_gpt":0.4022085455230998,"score_spread":0.2764978071625015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938286893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043,0.00027843195,6.477389e-7,0.00020562297,0.0013763781,0.0050183404,0.0022499103,0.00003107838,0.0004095637],"genre_scores_gemma":[0.9965889,0.00010902135,0.000044138862,0.000073259005,0.000055612847,0.00009078469,0.0026200428,0.000027218312,0.00039104774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938401,0.0026729377,0.001957112,0.0009827046,0.00017274664,0.00037442418],"domain_scores_gemma":[0.9919381,0.0015860336,0.003071501,0.0031211001,0.00019180967,0.00009146588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003172771,0.00034829183,0.0014801014,0.00006548828,0.00016567777,0.000029341396,0.0010277084,0.0002926139,0.00028016017],"category_scores_gemma":[0.0018263317,0.00023659194,0.00023131818,0.00043484423,0.00046585084,0.00028863954,0.0010255898,0.00037404936,0.000049708713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008064081,0.001256185,0.9530144,0.000033964494,0.0020192468,9.975389e-7,0.0003124508,0.0000033475392,0.00005296485,0.000014712277,0.006592146,0.028635554],"study_design_scores_gemma":[0.004706334,0.0009327196,0.9932516,0.00020248207,0.00018462073,0.0000011753527,0.00008185049,0.000001680019,0.00012263181,0.00003931901,0.00022339096,0.00025214744],"about_ca_topic_score_codex":0.058026545,"about_ca_topic_score_gemma":0.0038008208,"teacher_disagreement_score":0.054225724,"about_ca_system_score_codex":0.000091817004,"about_ca_system_score_gemma":0.00051280885,"threshold_uncertainty_score":0.9647939},"labels":[],"label_agreement":null},{"id":"W2939153131","doi":"10.2340/00015555-3195","title":"Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials","year":2019,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; LEO Pharma; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; National Psoriasis Foundation; Valeant Pharmaceuticals International; Endo International; Sanofi; Galderma; Ortho Dermatologics; Eli Lilly and Company; Amgen","keywords":"Secukinumab; Itching; Medicine; Placebo; Psoriasis; Randomized controlled trial; Clinical trial; Pain relief; Dermatology; Physical therapy; Alternative medicine; Surgery; Internal medicine; Psoriatic arthritis","score_opus":0.03243579517012712,"score_gpt":0.29776042570435973,"score_spread":0.2653246305342326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939153131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885943,0.003689524,0.00014471925,0.00033943684,0.00090925896,0.004850923,0.0012152753,0.00011723048,0.0001393506],"genre_scores_gemma":[0.99241906,0.0004467616,0.00070625124,0.00088118087,0.000111626556,0.0004273525,0.004913887,0.00004710896,0.000046789675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9827384,0.013138452,0.001954978,0.0013848236,0.00015326976,0.0006300853],"domain_scores_gemma":[0.9825167,0.015075702,0.00091263413,0.0012855004,0.00008107795,0.00012835895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0057959897,0.00065992476,0.0034240892,0.00019595244,0.00019847065,0.00009362102,0.0006702859,0.00057112554,0.0006431085],"category_scores_gemma":[0.0040169572,0.00041820933,0.0003025011,0.00015642132,0.00016629367,0.00039153657,0.00050208287,0.00046713793,0.00020555888],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7651861,0.001783377,0.08993918,0.000016187245,0.0035098335,0.00004959033,0.00095612294,0.000055332614,0.0009238846,0.000021166872,0.0020909437,0.13546829],"study_design_scores_gemma":[0.9830985,0.001247705,0.007808818,0.00029074552,0.001327477,0.00000821966,0.00032850908,0.0013277101,0.00080537825,0.00051884557,0.0023417743,0.00089628657],"about_ca_topic_score_codex":0.00045669932,"about_ca_topic_score_gemma":0.00009003206,"teacher_disagreement_score":0.21791245,"about_ca_system_score_codex":0.00005843601,"about_ca_system_score_gemma":0.00013838633,"threshold_uncertainty_score":0.99982697},"labels":[],"label_agreement":null},{"id":"W2939591533","doi":"10.1016/j.jid.2019.03.616","title":"540 Rapid response in PASI, sPGA, and BSA measures for patients with moderate-to-severe plaque psoriasis with ixekizumab","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Body surface area; Internal medicine; Mallinckrodt; Etanercept; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha","score_opus":0.013448628006412337,"score_gpt":0.21842897450337723,"score_spread":0.2049803464969649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939591533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474394,0.0016827944,0.00009195392,0.0023561926,0.00022001223,0.0007505427,0.000069621885,0.000011066012,0.00007388553],"genre_scores_gemma":[0.9972125,0.00012475037,0.0015102222,0.00093070744,0.000014289199,0.000042475473,0.000028821325,0.000027408994,0.00010880653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980362,0.00070140755,0.00050718273,0.00029066872,0.00008927507,0.00037523743],"domain_scores_gemma":[0.9981609,0.0006615483,0.00044817,0.00018494789,0.00044970616,0.00009472717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033502575,0.00029714569,0.0007797679,0.00036826232,0.00009925989,0.000013716675,0.0001786097,0.00023415386,0.00004327318],"category_scores_gemma":[0.00026687048,0.00019850896,0.00007048349,0.00020963415,0.00028557252,0.000215532,0.000033225202,0.00027026594,0.0000264856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36520734,0.0017214953,0.50500417,0.0007077803,0.005610303,0.00061788847,0.0130905835,0.00047570342,0.07611321,0.0011688028,0.015950145,0.014332561],"study_design_scores_gemma":[0.05802855,0.0137957055,0.6746941,0.0019069336,0.0007175919,0.0042605167,0.001580271,0.000015208367,0.23592065,0.0011211676,0.006852277,0.0011069982],"about_ca_topic_score_codex":0.0000118010785,"about_ca_topic_score_gemma":0.00004594718,"teacher_disagreement_score":0.3071788,"about_ca_system_score_codex":0.00007434349,"about_ca_system_score_gemma":0.00035541746,"threshold_uncertainty_score":0.8094961},"labels":[],"label_agreement":null},{"id":"W2940671601","doi":"10.1111/jdv.15637","title":"Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Immunogenicity; Psoriasis; Psoriatic arthritis; Psoriasis Area and Severity Index; Monoclonal antibody; Pharmacokinetics; Monoclonal; Immunology; Internal medicine; Antibody; Gastroenterology","score_opus":0.010880054229883123,"score_gpt":0.24964591105737083,"score_spread":0.23876585682748772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2940671601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654037,0.0011815157,0.000003391679,0.0005170358,0.0009591507,0.00024160711,0.000025596131,0.0000113244505,0.0005199939],"genre_scores_gemma":[0.9990834,0.00013124455,0.000029282766,0.00029308334,0.00004722088,0.0000017364184,0.000015536853,0.000026863081,0.0003716187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659824,0.0016587899,0.0009497284,0.00029701146,0.00007218634,0.00042402276],"domain_scores_gemma":[0.9987661,0.00015644713,0.00074630516,0.00020406216,0.0000734243,0.000053645006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043818887,0.0002761514,0.00083327544,0.00039815926,0.000103114784,0.0000070515084,0.000655941,0.00036385359,0.00010670095],"category_scores_gemma":[0.00006582705,0.00020687567,0.00025710947,0.0002382315,0.0002843671,0.000110541594,0.00031007195,0.00061081606,0.0001219388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007641401,0.00021413989,0.8892971,0.000028758652,0.00047369872,0.00006343844,0.00072088774,0.00001341098,0.104780436,0.00022693626,0.00061128766,0.002805753],"study_design_scores_gemma":[0.0059704375,0.00016880977,0.9411004,0.00014495652,0.00015533164,0.0016170477,0.00006018378,0.0000012546702,0.048155673,0.00011560347,0.0023128996,0.0001974068],"about_ca_topic_score_codex":0.00002017869,"about_ca_topic_score_gemma":0.000007495524,"teacher_disagreement_score":0.056624763,"about_ca_system_score_codex":0.000046571444,"about_ca_system_score_gemma":0.000038548005,"threshold_uncertainty_score":0.8436145},"labels":[],"label_agreement":null},{"id":"W2942814639","doi":"10.1002/jcp.28717","title":"Th17 immune response to adipose tissue‐derived mesenchymal stromal cells","year":2019,"lang":"en","type":"article","venue":"Journal of Cellular Physiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research; Université de Montréal","keywords":"Priming (agriculture); Mesenchymal stem cell; Stromal cell; Adipose tissue; Immune system; T cell; Interleukin 17; Cell; Inflammation; Immunology; Immunotherapy; Cell biology; Biology; Cancer research; Chemistry; Endocrinology; Biochemistry","score_opus":0.008754497275568702,"score_gpt":0.22418822636535973,"score_spread":0.21543372908979103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942814639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258995,0.0034595768,0.000090342095,0.0002707286,0.0030469508,0.00025925628,0.000024191053,0.000019775738,0.00023919927],"genre_scores_gemma":[0.9943171,0.00006331301,0.00044472984,0.000118049844,0.00015144724,0.000005069478,0.000027815131,0.000028935705,0.004843538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759614,0.00090723066,0.00063505745,0.00029039764,0.00007395683,0.00049721694],"domain_scores_gemma":[0.99853826,0.00032468943,0.0004590003,0.0004283499,0.00016986331,0.0000798695],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00058982626,0.00028508375,0.0007786674,0.00026579658,0.00009835143,0.000011974162,0.0004634374,0.00032865777,0.002026499],"category_scores_gemma":[0.000060975,0.00022635286,0.00031398787,0.00016190349,0.00009537759,0.00011740483,0.00012063789,0.00033617538,0.0030065426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071171937,0.00022642623,0.00008669823,0.0000116331685,0.0005360759,0.00008209551,0.00042465163,0.000069352776,0.9882034,0.00004298887,0.00075913244,0.002440372],"study_design_scores_gemma":[0.0028075476,0.0029413414,0.02508097,0.00003121045,0.00015842923,0.00016848784,0.00016238069,0.000001499254,0.9421425,0.00007606731,0.026205327,0.00022426527],"about_ca_topic_score_codex":0.000013278253,"about_ca_topic_score_gemma":0.0000010101136,"teacher_disagreement_score":0.046060905,"about_ca_system_score_codex":0.000061909675,"about_ca_system_score_gemma":0.00014356674,"threshold_uncertainty_score":0.9988858},"labels":[],"label_agreement":null},{"id":"W2943808099","doi":"10.1080/09546634.2019.1603361","title":"US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry","year":2019,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Quality of life (healthcare); Clinical endpoint; Internal medicine; Dermatology; Physical therapy; Psoriatic arthritis; Clinical trial","score_opus":0.023680204545905303,"score_gpt":0.27491816307371164,"score_spread":0.25123795852780634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943808099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98369414,0.012897284,0.0001584967,0.00026258323,0.001045618,0.0010740942,0.00056363584,0.000015322807,0.00028885118],"genre_scores_gemma":[0.99442315,0.0046218326,0.00019363692,0.000021574722,0.000086736385,0.00013018164,0.00014952512,0.000018348044,0.00035502986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725753,0.0008476595,0.0010360938,0.0003455928,0.00015054242,0.00036257392],"domain_scores_gemma":[0.9914248,0.0061937775,0.0013363935,0.00075387734,0.00024171187,0.000049457652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039610692,0.0004377324,0.0017530823,0.00018353121,0.00018486296,0.000018076324,0.00046809076,0.00027845852,0.0002442318],"category_scores_gemma":[0.00006391972,0.00018847422,0.0017632516,0.0004944766,0.0002348187,0.000070400914,0.000032600346,0.000113271264,0.000021358808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011740522,0.0050305277,0.8962306,0.00006134937,0.045557033,0.00006149406,0.0010441184,0.0006260093,0.007905358,0.00066837866,0.00030821117,0.030766396],"study_design_scores_gemma":[0.016876223,0.005703397,0.8108932,0.00012310306,0.01901047,0.00011794938,0.0007768782,0.00003214023,0.13584554,0.0004477264,0.009890384,0.0002830222],"about_ca_topic_score_codex":0.0007846642,"about_ca_topic_score_gemma":0.00028967636,"teacher_disagreement_score":0.12794018,"about_ca_system_score_codex":0.000327434,"about_ca_system_score_gemma":0.00013433976,"threshold_uncertainty_score":0.76857555},"labels":[],"label_agreement":null},{"id":"W2943965979","doi":"10.1177/2050313x19845193","title":"Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report","year":2019,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of British Columbia","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Acitretin; Mucocutaneous zone; Dermatology Life Quality Index; Dermatology; Context (archaeology); Body surface area; Psoriasis Area and Severity Index; Hypertriglyceridemia; Human immunodeficiency virus (HIV); Internal medicine; Immunology; Disease","score_opus":0.017646195877097974,"score_gpt":0.27746035606705644,"score_spread":0.25981416018995845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943965979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964366,0.00040476499,0.000012836187,0.00007679536,0.00029556148,0.0014139287,0.000054593882,0.000013922514,0.0012909974],"genre_scores_gemma":[0.99725974,0.00007004417,0.000022830724,0.000053100397,0.000024395,0.0001539994,0.00015754021,0.000018739338,0.0022395933],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980897,0.0003030884,0.0007279829,0.00046855517,0.00014880252,0.00026188855],"domain_scores_gemma":[0.9985421,0.00017181253,0.00039427736,0.00074550265,0.00007065286,0.00007569235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005519835,0.00024044469,0.00066189223,0.00011196323,0.00006601254,0.00001808696,0.00009520435,0.00025416366,0.0016834831],"category_scores_gemma":[0.000087858185,0.00014659844,0.0001240569,0.0002958585,0.00010926451,0.000098829114,0.00008092723,0.000115932926,0.000028184513],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008447479,0.0006260619,0.24097979,0.00002199408,0.0003895259,0.7156463,0.0014833795,0.0000047054746,0.00024791146,0.0000035645485,0.0001225516,0.03962945],"study_design_scores_gemma":[0.0045667314,0.0010885367,0.050735787,0.00018374207,0.00031885467,0.93486637,0.00044427006,0.0000024211192,0.0068373526,0.0000037262216,0.0007566965,0.0001955014],"about_ca_topic_score_codex":0.0067428183,"about_ca_topic_score_gemma":0.004878323,"teacher_disagreement_score":0.21922006,"about_ca_system_score_codex":0.00009111453,"about_ca_system_score_gemma":0.00024833562,"threshold_uncertainty_score":0.9998714},"labels":[],"label_agreement":null},{"id":"W2944669799","doi":"10.1111/jdv.15668","title":"Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Research and Development","keywords":"Medicine; Psoriasis; Selection (genetic algorithm); Phase (matter); Dermatology; Machine learning","score_opus":0.06422691084866118,"score_gpt":0.31386034106018246,"score_spread":0.2496334302115213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944669799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167997,0.005655687,0.000011016627,0.0020780875,0.0003098647,0.00021353098,0.000013342409,0.00000492139,0.000033607354],"genre_scores_gemma":[0.99823993,0.0011125997,0.0003364008,0.00013230511,0.000017782648,0.0000026518646,0.0000016077819,0.000012903452,0.00014381428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99438274,0.0042682313,0.00089115783,0.00019343635,0.0000396425,0.00022480634],"domain_scores_gemma":[0.9980019,0.0011722551,0.00063772633,0.00009728249,0.000058678084,0.00003217553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012327083,0.00017702093,0.00071636616,0.00053302,0.00007386766,0.0000033712315,0.00019388853,0.00026137242,0.000018324134],"category_scores_gemma":[0.00060607336,0.00012888669,0.000090654314,0.00027840325,0.00029637685,0.00015302331,0.0001283253,0.0005486975,0.000009032038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025218584,0.0010436513,0.7085781,0.00009047494,0.0010461407,0.00009587114,0.0046551144,0.00046880063,0.2423038,0.00068536674,0.0006771067,0.015137007],"study_design_scores_gemma":[0.03666839,0.0010429744,0.8854019,0.00032400808,0.0005017686,0.006285455,0.0008287901,0.000037744252,0.06313259,0.00047961707,0.0049788007,0.00031793944],"about_ca_topic_score_codex":0.0000052398923,"about_ca_topic_score_gemma":0.000009655955,"teacher_disagreement_score":0.1791712,"about_ca_system_score_codex":0.000029606152,"about_ca_system_score_gemma":0.000042586944,"threshold_uncertainty_score":0.5255847},"labels":[],"label_agreement":null},{"id":"W2946569503","doi":"10.4088/jcp.18m12462","title":"Risk of Dementia Among Individuals With Psoriasis","year":2019,"lang":"en","type":"article","venue":"The Journal of Clinical Psychiatry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Psoriasis; Dementia; Medicine; Hazard ratio; Vascular dementia; Internal medicine; Incidence (geometry); Diabetes mellitus; Proportional hazards model; Disease; Comorbidity; Dermatology; Confidence interval; Endocrinology","score_opus":0.01983325647076742,"score_gpt":0.29830512561649164,"score_spread":0.2784718691457242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946569503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896792,0.004744225,0.000051519797,0.0003338797,0.00402005,0.00015347637,0.000025107993,0.0000072171665,0.0009852783],"genre_scores_gemma":[0.9974787,0.0009882253,0.00078796933,0.00010246443,0.00023235622,8.95872e-7,0.00000382149,0.000014111863,0.0003914257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99740905,0.0009939346,0.0011796261,0.00012109121,0.00010169013,0.00019462543],"domain_scores_gemma":[0.9964355,0.0011114557,0.0019239443,0.00036896003,0.00012379188,0.000036319205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029594982,0.00015100143,0.0006185183,0.00007767949,0.00007725072,0.0000054154834,0.0004417694,0.00022852176,0.0006265274],"category_scores_gemma":[0.00014424621,0.00007591671,0.00036843948,0.0001371326,0.00023304716,0.00009343451,0.000042870975,0.00051232195,0.00016707863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014290239,0.00037461548,0.98331356,0.000010130581,0.0039404496,6.5038137e-7,0.00014026095,0.000018339175,0.00014318826,0.00011052755,0.0031422223,0.0073770103],"study_design_scores_gemma":[0.005641796,0.0017727963,0.98496884,0.00009795819,0.0027544692,0.00004350797,0.00041015245,4.8273995e-7,0.0006794063,0.0008309634,0.0026938408,0.00010580161],"about_ca_topic_score_codex":0.000021621645,"about_ca_topic_score_gemma":0.000028648454,"teacher_disagreement_score":0.0077994843,"about_ca_system_score_codex":0.0000047138583,"about_ca_system_score_gemma":0.00015073644,"threshold_uncertainty_score":0.68600357},"labels":[],"label_agreement":null},{"id":"W2946605861","doi":"10.2340/00015555-3221","title":"Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study","year":2019,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Medac; Cilag; Astellas Pharma; Regeneron Pharmaceuticals; Biogen; Celgene; Samsung; Valeant Pharmaceuticals International; Sanofi; Universität Zürich; Amgen; Pfizer; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Systemic therapy; Dermatology; Prospective cohort study; Quality of life (healthcare); Internal medicine; Plaque psoriasis","score_opus":0.016714957053171522,"score_gpt":0.26439051062901175,"score_spread":0.24767555357584023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946605861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935025,0.0012729325,0.00003486494,0.0007837038,0.0016468944,0.0024588048,0.00007892338,0.00013091027,0.000090440284],"genre_scores_gemma":[0.99639255,0.00008436465,0.000039224287,0.00060510694,0.00007493125,0.0003627641,0.000043304113,0.000037874717,0.002359857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996778,0.0013096409,0.0005226995,0.000672499,0.00013155943,0.0005855875],"domain_scores_gemma":[0.99821126,0.00059640635,0.00026546774,0.0007795695,0.00010691583,0.00004037917],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076320174,0.00044171253,0.0005932572,0.0001516047,0.00040468396,0.000077417724,0.0006637322,0.0002085788,0.00079168397],"category_scores_gemma":[0.000077610755,0.0002324196,0.00024936005,0.0002577985,0.000100327554,0.0001329232,0.00019011692,0.00025358543,0.0008275214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043230117,0.0024704782,0.6323674,0.000027204496,0.0023321954,0.00004423937,0.008518243,0.000027888575,0.34727946,0.000087193395,0.00047391877,0.0020487956],"study_design_scores_gemma":[0.021207003,0.0013255827,0.8908744,0.00022718924,0.00030552346,0.00023195178,0.0077769114,0.00003728105,0.071183026,0.00007413301,0.005881557,0.00087546295],"about_ca_topic_score_codex":0.00012257535,"about_ca_topic_score_gemma":0.000055255463,"teacher_disagreement_score":0.27609643,"about_ca_system_score_codex":0.000114354014,"about_ca_system_score_gemma":0.000063663196,"threshold_uncertainty_score":0.99995047},"labels":[],"label_agreement":null},{"id":"W2946948895","doi":"10.1016/j.jaad.2019.05.080","title":"Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Maruho; Janssen Biotech; Chugai Pharmaceutical; Ortho Dermatologics; LEO Pharma; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Dermira; Allergan; Regeneron Pharmaceuticals; National Institutes of Health; Vanda Pharmaceuticals; National Psoriasis Foundation; Pfizer; Celgene; Novartis; AbbVie; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Sanofi; MedImmune; Merck; Genentech; Coherus Biosciences; Valeant Pharmaceuticals International; Boehringer Ingelheim; Amgen; Eli Lilly and Company","keywords":"Medicine; Dermatology Life Quality Index; Adalimumab; Interquartile range; Placebo; Psoriasis; Confidence interval; Quality of life (healthcare); Odds ratio; Randomized controlled trial; Psoriasis Area and Severity Index; Internal medicine; Surgery; Dermatology; Pathology","score_opus":0.010844468262028704,"score_gpt":0.2707372972748238,"score_spread":0.2598928290127951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946948895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404,0.0013668612,0.000002315529,0.001601567,0.00025311206,0.0026937658,0.0000029726743,0.0000030573744,0.000036333386],"genre_scores_gemma":[0.99924004,0.00045942536,0.00002558894,0.00017163956,0.000008925329,0.000072334034,7.344978e-7,0.000008970334,0.000012356546],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934881,0.004311936,0.0017569975,0.0001331391,0.0001272716,0.00018260696],"domain_scores_gemma":[0.9940353,0.002310814,0.003416464,0.00017865527,0.000046971,0.000011785689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016829286,0.00018519946,0.0026275562,0.00036527586,0.000030109115,0.0000043288915,0.0003155151,0.00013240313,0.000022190174],"category_scores_gemma":[0.00046548055,0.000089689085,0.0004870975,0.00028882638,0.00034836028,0.0000724303,0.000041746247,0.00032435294,0.000003002659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6646311,0.0006866936,0.31001762,0.000014920303,0.0039139856,0.000013382264,0.00510327,0.000029786264,0.012399242,0.00005817633,0.00004180217,0.003089979],"study_design_scores_gemma":[0.87173736,0.0005522233,0.11732341,0.000039998085,0.0008182149,0.00029238246,0.003738019,0.00000876862,0.00505553,0.00018501157,0.00014802329,0.00010108153],"about_ca_topic_score_codex":0.00009286716,"about_ca_topic_score_gemma":0.000016042788,"teacher_disagreement_score":0.20710617,"about_ca_system_score_codex":0.000021350937,"about_ca_system_score_gemma":0.000065590786,"threshold_uncertainty_score":0.3657415},"labels":[],"label_agreement":null},{"id":"W2947042837","doi":"10.4103/ijd.ijd_475_18","title":"Abnormal Serum Copper and Zinc Levels in Patients with Psoriasis: A Meta-Analysis","year":2019,"lang":"en","type":"article","venue":"Indian Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Medicine; Zinc; Confidence interval; Copper; Internal medicine; Meta-analysis; Gastroenterology; Population; Immunology; Metallurgy","score_opus":0.017311540876178158,"score_gpt":0.2271973929613756,"score_spread":0.20988585208519744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947042837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571294,0.0031503853,0.000007474718,0.0004599601,0.0002683841,0.00015964113,0.000064100954,0.0000062558333,0.00017085696],"genre_scores_gemma":[0.9994852,0.000023824326,0.0001302472,0.0001594143,0.000009291711,0.000005222322,0.000018110295,0.000012592474,0.00015610058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842787,0.0003907105,0.00055950426,0.00020579246,0.00006530875,0.00035081667],"domain_scores_gemma":[0.9990388,0.00014679483,0.00043795814,0.0002048962,0.00012134432,0.000050219223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017522127,0.00022221071,0.0012598621,0.0006971537,0.000056077402,0.000014327469,0.00018928718,0.0002591467,0.0008314032],"category_scores_gemma":[0.000015785941,0.00014797351,0.0003587326,0.0003503628,0.00009937891,0.00021392088,0.00003535726,0.00025898134,0.00011945096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039513694,0.00015866615,0.9395825,0.000012653325,0.05773903,0.00030494097,0.0007553605,0.000013077332,0.00007941065,0.000058535115,0.00009630062,0.0008043831],"study_design_scores_gemma":[0.007364681,0.0004319086,0.95113975,0.000008860885,0.035505638,0.0021985485,0.00025066067,4.1396845e-7,0.0019495053,0.000042362986,0.0008764959,0.00023115463],"about_ca_topic_score_codex":0.000012533514,"about_ca_topic_score_gemma":0.00007927388,"teacher_disagreement_score":0.022233393,"about_ca_system_score_codex":0.000025006839,"about_ca_system_score_gemma":0.00009410206,"threshold_uncertainty_score":0.91032815},"labels":[],"label_agreement":null},{"id":"W2947406345","doi":"10.1097/qad.0000000000002271","title":"The anti-inflammatory IL-37/SIGIRR axis is functionally compromised in HIV infection","year":2019,"lang":"en","type":"article","venue":"AIDS","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Human immunodeficiency virus (HIV); Immunology; Medicine; Inflammation","score_opus":0.009071737758650665,"score_gpt":0.21055542206692823,"score_spread":0.20148368430827757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947406345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372554,0.0009067375,0.000018600645,0.0001717518,0.0014832953,0.00025453712,0.000022410362,0.00005709959,0.003360052],"genre_scores_gemma":[0.98864317,0.00021986858,0.000017263024,0.00013057778,0.000044731456,0.000038216833,0.000083446495,0.000012093827,0.010810631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991604,0.0001497201,0.00019968959,0.00022033096,0.000034218152,0.00023561546],"domain_scores_gemma":[0.9994457,0.00017151401,0.00006762656,0.00026566695,0.000037414888,0.000012072192],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022765438,0.00013815326,0.00017280848,0.00006821897,0.0001667202,0.000015685602,0.00010628329,0.00017822602,0.0009959755],"category_scores_gemma":[0.000015828791,0.00009936601,0.00009920985,0.00013620466,0.00008254475,0.00008501964,0.000036764504,0.00013597192,0.0045739333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021934186,0.00010055596,0.85918164,0.000010820263,0.0002589695,0.000003024375,0.00021315237,0.0000094102425,0.10741802,0.001286925,0.004225181,0.027072934],"study_design_scores_gemma":[0.0025975138,0.00018322903,0.8290181,0.000017397433,0.000043993296,0.000013808308,0.000058604088,0.000005931341,0.027281562,0.00017690624,0.14044356,0.00015934787],"about_ca_topic_score_codex":0.000050900544,"about_ca_topic_score_gemma":0.00002707838,"teacher_disagreement_score":0.13621838,"about_ca_system_score_codex":0.000047101177,"about_ca_system_score_gemma":0.000049031027,"threshold_uncertainty_score":0.99991727},"labels":[],"label_agreement":null},{"id":"W2947756907","doi":"10.1136/annrheumdis-2019-eular.1440","title":"SAT0393 EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Ottawa; University of Toronto; Université de Montréal; University of Saskatchewan; Lakeridge Health; Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"AstraZeneca; Amgen","keywords":"Medicine; Psoriatic arthritis; Ustekinumab; Golimumab; Internal medicine; Infliximab; Dactylitis; Population; Incidence (geometry); Enthesitis; Arthritis; Disease","score_opus":0.01653192858621517,"score_gpt":0.2436608507875698,"score_spread":0.22712892220135464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947756907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912602,0.007182155,0.0000015876672,0.000052093368,0.00018925553,0.0006340895,0.0006049275,0.000008099563,0.00006764905],"genre_scores_gemma":[0.998927,0.00084939,0.000016808093,0.000023627348,0.0000041488884,0.000041758787,0.00008706951,0.000009105354,0.000041077932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892247,0.00029168194,0.00035223755,0.00021692793,0.00006870448,0.00014799065],"domain_scores_gemma":[0.99862623,0.0007169994,0.00027981465,0.00026781048,0.000089352194,0.000019808236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013039209,0.00015215825,0.00044767265,0.000053009393,0.000050507024,0.0000072642624,0.00012761001,0.000086965054,0.00006124172],"category_scores_gemma":[0.00029253511,0.00011213191,0.000085694395,0.00011414807,0.00017122246,0.00011764417,0.000101115074,0.000056725603,0.0000075811035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010910741,0.0003981788,0.9279275,0.00024048513,0.00042499206,3.9941287e-7,0.00050523825,0.000010310219,0.00025914656,0.00057480106,0.000039655613,0.068528235],"study_design_scores_gemma":[0.0049148933,0.00014301643,0.9868496,0.0011690948,0.00008093381,0.0000012394291,0.00010277606,0.000007879415,0.0024744114,0.0041301,0.000018758745,0.00010731921],"about_ca_topic_score_codex":0.0002583567,"about_ca_topic_score_gemma":0.000026663785,"teacher_disagreement_score":0.06842092,"about_ca_system_score_codex":0.000016701306,"about_ca_system_score_gemma":0.00005660438,"threshold_uncertainty_score":0.45726064},"labels":[],"label_agreement":null},{"id":"W2947773178","doi":"10.1016/j.jaad.2019.05.056","title":"Management of pediatric plaque psoriasis using biologics","year":2019,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Nexus Clinical Research (Canada); University of Calgary; Hospital for Sick Children; Université de Montréal; University of Alberta; Sunnybrook Health Science Centre; University of Toronto; SickKids Foundation; Women's College Hospital; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Plaque psoriasis; Quality of life (healthcare); Population; Disease; Dermatology; Intensive care medicine; MEDLINE; Internal medicine","score_opus":0.06962661869359107,"score_gpt":0.34355088271688067,"score_spread":0.2739242640232896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947773178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014978559,0.9830428,0.000020428895,0.00017208955,0.0011899939,0.00038677707,0.0001008317,0.000007112523,0.00010142028],"genre_scores_gemma":[0.004396022,0.99464846,0.00062349567,0.000048652513,0.00010805596,0.000005103062,0.000008375863,0.00003374376,0.00012807891],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618864,0.0012192454,0.0018454808,0.00025730566,0.00010036333,0.00038897592],"domain_scores_gemma":[0.99078476,0.0005308502,0.008280533,0.00030813357,0.00006516134,0.00003056378],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029371394,0.00045053728,0.003868011,0.0005631379,0.00006887015,0.0000032320136,0.0013391407,0.0006182093,0.00003915341],"category_scores_gemma":[0.00003655679,0.00026595467,0.0014950882,0.0007240185,0.00056148064,0.000053544467,0.0003221601,0.0007874371,0.00003865726],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039683448,0.00044054302,0.0029558477,0.012355496,0.013782444,0.000093628805,0.00009583463,0.00001591066,0.00029863924,0.00087546307,0.0034627367,0.96522665],"study_design_scores_gemma":[0.0017297411,0.00030789556,0.0007504701,0.003353649,0.025333483,0.010191347,0.00017264712,5.7970396e-7,0.0009482661,0.00014026099,0.95652914,0.00054249936],"about_ca_topic_score_codex":0.000007924904,"about_ca_topic_score_gemma":1.1426098e-7,"teacher_disagreement_score":0.9646841,"about_ca_system_score_codex":0.00008570002,"about_ca_system_score_gemma":0.00023529113,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W2947828030","doi":"10.1080/09546634.2019.1620502","title":"Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments","year":2019,"lang":"en","type":"editorial","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"LEO Pharma; National Institute for Health and Care Research","keywords":"Medicine; Psoriasis; Plaque psoriasis; Dermatology; Corticosteroid; Population; Disease; Intensive care medicine; Surgery; Internal medicine; Environmental health","score_opus":0.10088429690659054,"score_gpt":0.3779725897040562,"score_spread":0.2770882927974657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947828030","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002473148,0.3577756,0.0005267136,0.008937198,0.6180071,0.0044462136,0.0077116573,0.00002682737,0.00009552191],"genre_scores_gemma":[0.00091735757,0.9128707,0.005080203,0.00028490316,0.07182599,0.0014120407,0.0043618595,0.00007968995,0.0031672423],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609345,0.0003019765,0.0025812755,0.00041604205,0.00022583417,0.00038143207],"domain_scores_gemma":[0.9889768,0.0054525994,0.0028799204,0.00054708356,0.0020840738,0.00005955822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003427853,0.0006473613,0.0023589719,0.00019973754,0.00014582444,0.00001910357,0.0005849731,0.0008217696,0.00023368621],"category_scores_gemma":[0.0012471267,0.0003309883,0.0021354954,0.00011847832,0.00013947723,0.000089622175,0.00003998353,0.00014645247,0.000015947884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002469549,0.00385404,0.00047190144,0.0007476054,0.014157547,0.000009830619,0.00013990859,0.0000040402842,0.00016452807,0.000055688437,0.83352154,0.14440379],"study_design_scores_gemma":[0.014974342,0.007761253,0.00011806021,0.0021147234,0.008000177,0.000098774464,0.00011086782,0.000003617155,0.004960923,0.00008321079,0.96153635,0.00023772728],"about_ca_topic_score_codex":0.000023842054,"about_ca_topic_score_gemma":0.000008502388,"teacher_disagreement_score":0.55509514,"about_ca_system_score_codex":0.00054682,"about_ca_system_score_gemma":0.00043787074,"threshold_uncertainty_score":0.9999142},"labels":[],"label_agreement":null},{"id":"W2947841996","doi":"10.1136/annrheumdis-2019-eular.4603","title":"SAT0369 SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Horizon Pharma; Celgene; Galápagos; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Internal medicine; Rheumatology; Placebo; Ankylosing spondylitis; Clinical trial; Psoriasis; Arthritis; Oncology; Physical therapy; Immunology; Pathology; Alternative medicine","score_opus":0.019037231011136725,"score_gpt":0.25644664402496503,"score_spread":0.2374094130138283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947841996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173094,0.015786534,0.0000031230186,0.00016198397,0.0006982841,0.0008518728,0.00058789586,0.000022368784,0.00015702612],"genre_scores_gemma":[0.9978873,0.0013464673,0.000040587176,0.0000701162,0.000016366812,0.000053857686,0.000053309253,0.000022589407,0.0005094149],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99838,0.0002294233,0.00070821575,0.00025946152,0.00012806758,0.0002948295],"domain_scores_gemma":[0.99798244,0.0003729415,0.00063535216,0.0007871146,0.00017140599,0.000050744402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018964997,0.00025078826,0.0008112409,0.00013193683,0.00006585425,0.0000072597354,0.0004310235,0.00012469885,0.00021957983],"category_scores_gemma":[0.0002816075,0.00017332908,0.00046648172,0.00026113453,0.00016998913,0.00009078289,0.00013908622,0.00006986596,0.00006516857],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028374232,0.0035315894,0.03426857,0.0031517104,0.0056130425,0.0000062168133,0.0064125243,0.00007717728,0.1117127,0.0024097299,0.010895825,0.8190835],"study_design_scores_gemma":[0.010514353,0.00439167,0.5335637,0.009026112,0.001568302,0.000043040254,0.002508606,0.00000839147,0.42957938,0.006091198,0.0017064317,0.0009988546],"about_ca_topic_score_codex":0.0001082788,"about_ca_topic_score_gemma":0.000022545173,"teacher_disagreement_score":0.81808466,"about_ca_system_score_codex":0.000010388419,"about_ca_system_score_gemma":0.000111787806,"threshold_uncertainty_score":0.7068155},"labels":[],"label_agreement":null},{"id":"W2947921920","doi":"10.1159/000499925","title":"Exploration of the Product of the 5-Point Investigator’s Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis","year":2019,"lang":"en","type":"article","venue":"Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Incyte; Dermira; Regeneron Pharmaceuticals; Novartis Pharmaceuticals Corporation; Celgene; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; Allergan; Eli Lilly and Company","keywords":"Medicine; Cutoff; Body surface area; Psoriasis Area and Severity Index; Gastroenterology; Internal medicine; Psoriasis; Dermatology Life Quality Index; Immunology","score_opus":0.017059003839597117,"score_gpt":0.2609197044787536,"score_spread":0.2438607006391565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947921920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953764,0.000073993215,0.00001693136,0.0030002953,0.0003206543,0.00094268995,0.00010560508,0.0000101511105,0.00015327349],"genre_scores_gemma":[0.9996231,0.000005882857,0.00011513135,0.00013527162,0.0000042051647,0.00003705372,0.000027914795,0.0000088545285,0.000042539294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984429,0.00066249387,0.00023684803,0.00033430348,0.00008907273,0.00023437286],"domain_scores_gemma":[0.9990724,0.00012283213,0.0002332345,0.00042719985,0.00009401007,0.00005035489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107006395,0.00018844036,0.00036771363,0.00003178562,0.00007655972,0.0000075651146,0.0001503686,0.00012962913,0.000023082683],"category_scores_gemma":[0.00014526727,0.00011094123,0.0000570526,0.00020666729,0.00022224712,0.00021873902,0.00015893966,0.00014372673,0.000012578309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002746278,0.0005333786,0.99019116,0.000043696375,0.00015553202,0.0000036680376,0.00026271568,0.00008546443,0.004467447,0.0010639348,0.00024965574,0.00019709376],"study_design_scores_gemma":[0.0030144632,0.00021556464,0.9748374,0.00004659839,0.00013470811,0.000038213046,0.00010539033,0.000038757033,0.021110196,0.00023676711,0.000089891815,0.00013204763],"about_ca_topic_score_codex":0.00006498393,"about_ca_topic_score_gemma":0.00006306123,"teacher_disagreement_score":0.016642747,"about_ca_system_score_codex":0.00006501162,"about_ca_system_score_gemma":0.0004993704,"threshold_uncertainty_score":0.4524052},"labels":[],"label_agreement":null},{"id":"W2948138272","doi":"10.1016/j.jid.2019.05.010","title":"Caspase-11–Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis","year":2019,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Science Foundation Ireland","keywords":"Psoriasis; Pyroptosis; Immunology; Innate immune system; Inflammation; Immune system; Inflammasome; Caspase 1; Biology; Caspase; Medicine; Programmed cell death; Apoptosis; Genetics","score_opus":0.03090505595788729,"score_gpt":0.2405978684966653,"score_spread":0.20969281253877803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948138272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71091753,0.005363359,0.00007756227,0.27808884,0.0037466825,0.00079948944,0.00077761797,0.00002607458,0.00020285918],"genre_scores_gemma":[0.70794296,0.00046183105,0.00055035524,0.28764117,0.0010465878,0.000108173146,0.0008312404,0.00016689103,0.0012507903],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99430275,0.0024021957,0.0017680996,0.000504966,0.0001959581,0.00082601426],"domain_scores_gemma":[0.9923387,0.0029642899,0.002746205,0.0007273042,0.0011432361,0.00008027538],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00057067536,0.000780555,0.0023599502,0.00084629236,0.00020290208,0.000025324112,0.0011853764,0.0021798557,0.00014797226],"category_scores_gemma":[0.0010016342,0.0005176653,0.0007533733,0.0005435467,0.00050308224,0.00011826463,0.00019491636,0.0016821271,0.00046022056],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022682492,0.000111618385,0.0024991576,0.00014838071,0.0020505225,0.00072599406,0.00071143056,0.000007912009,0.3317556,0.00006562894,0.66143537,0.0002615419],"study_design_scores_gemma":[0.0032629683,0.0005423779,0.0050564515,0.00024228619,0.0017363263,0.0016580193,0.00031835178,0.0000019577544,0.6762458,0.00024857037,0.31019536,0.00049152295],"about_ca_topic_score_codex":0.000115222516,"about_ca_topic_score_gemma":0.000043958513,"teacher_disagreement_score":0.35124004,"about_ca_system_score_codex":0.0001700073,"about_ca_system_score_gemma":0.0010649677,"threshold_uncertainty_score":0.9997275},"labels":[],"label_agreement":null},{"id":"W2948326073","doi":"10.1111/bjd.17946","title":"Anti‐GM‐CSF therapy in psoriasis","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Itching; Disease; Rheumatoid arthritis; Placebo; Inflammation; Internal medicine; Dermatology; Psoriatic arthritis; Immunology; Pathology; Alternative medicine","score_opus":0.011001263949879712,"score_gpt":0.22774501016155635,"score_spread":0.21674374621167664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948326073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97182447,0.024270268,0.000011952936,0.00039315884,0.001984919,0.00013459912,0.000011885113,0.000014437901,0.0013543201],"genre_scores_gemma":[0.99368,0.005529416,0.0000838966,0.00019840094,0.000046221023,0.0000039147008,0.000014439548,0.000016604621,0.00042709283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984924,0.0003675697,0.0005736622,0.00017151098,0.000044020802,0.00035081455],"domain_scores_gemma":[0.99927425,0.0001518668,0.0002976233,0.00014214678,0.00010643512,0.000027648131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001742873,0.00014668555,0.00063593313,0.00023271375,0.00005593661,0.000020778944,0.00027154913,0.00030771687,0.0010060803],"category_scores_gemma":[0.00004532029,0.00014819943,0.00018566225,0.00016650178,0.00007763917,0.0001779219,0.000029544255,0.00031606978,0.0004800055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007251212,0.0007510657,0.5073131,0.000025060606,0.0008161209,0.005154478,0.0004427024,0.000006915777,0.05332314,0.00027410925,0.009854951,0.4213133],"study_design_scores_gemma":[0.022575922,0.00054916233,0.58450097,0.0002808635,0.00010654752,0.21956286,0.0004399014,0.000001637977,0.09797735,0.0005285104,0.07297987,0.0004964086],"about_ca_topic_score_codex":0.00008459769,"about_ca_topic_score_gemma":0.00005592668,"teacher_disagreement_score":0.4208169,"about_ca_system_score_codex":0.000028324748,"about_ca_system_score_gemma":0.00010423059,"threshold_uncertainty_score":0.99990714},"labels":[],"label_agreement":null},{"id":"W2948755434","doi":"10.1111/dth.12979","title":"A Novel Halobetasol Propionate 0.01%/Tazarotene 0.045% Fixed Combination Treatment for Psoriasis","year":2019,"lang":"en","type":"letter","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Tazarotene; Psoriasis; Dermatology","score_opus":0.04604449796479806,"score_gpt":0.2609826776711557,"score_spread":0.21493817970635762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948755434","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10493301,0.043115497,0.0024814548,0.79880035,0.019784128,0.02064172,0.0066003073,0.0016840838,0.0019594661],"genre_scores_gemma":[0.08224819,0.012790277,0.0030736174,0.71973205,0.0028787039,0.014319008,0.08093662,0.00072625134,0.08329529],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969108,0.00038635885,0.0006579579,0.0010111613,0.000104679624,0.00092901575],"domain_scores_gemma":[0.99766576,0.00070653995,0.0005782319,0.0008498876,0.00017486802,0.000024715684],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014994403,0.0009792602,0.0014000853,0.00030970224,0.00036158375,0.00005839204,0.00053458964,0.0025028295,0.00041333665],"category_scores_gemma":[0.000035584097,0.00070102606,0.0007511757,0.00017129684,0.00015194307,0.00010801417,0.000044381293,0.0005270923,0.0008536729],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001067049,0.0011643308,0.00057193096,0.00015913765,0.0042201392,0.00010054129,0.00039642703,0.0000033363115,0.020984909,0.00026294647,0.8982054,0.07286384],"study_design_scores_gemma":[0.015535265,0.0011705126,0.00046909953,0.000058808975,0.0003951872,0.00035356134,0.00002450951,0.000009454043,0.039257646,0.00031845222,0.9416315,0.00077600416],"about_ca_topic_score_codex":0.000073084615,"about_ca_topic_score_gemma":0.0000070236274,"teacher_disagreement_score":0.08133583,"about_ca_system_score_codex":0.00024901037,"about_ca_system_score_gemma":0.00019092945,"threshold_uncertainty_score":0.9999243},"labels":[],"label_agreement":null},{"id":"W2948881577","doi":"10.1016/j.jaad.2019.05.094","title":"Immunogenicity and skin clearance recapture in clinical studies of brodalumab","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; LEO Pharma; MedImmune; Valeant Pharmaceuticals International; Johnson and Johnson; AbbVie; UCB; Ortho Dermatologics; AstraZeneca; Celgene; Novartis; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Immunogenicity; Pharmacodynamics; Internal medicine; Dermatology; Pharmacokinetics; Immunology; Antibody","score_opus":0.026273331925988894,"score_gpt":0.33084386390404025,"score_spread":0.30457053197805134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948881577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97417116,0.022739844,0.0000011289256,0.0025505521,0.00037458647,0.00010627583,0.000007690361,0.0000024459189,0.00004632903],"genre_scores_gemma":[0.9937846,0.005655876,0.00014355873,0.00030963164,0.000018634384,0.0000010083113,3.3763283e-7,0.0000072649373,0.00007911068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779415,0.00084336987,0.0009933473,0.00013451632,0.00004970171,0.00018493152],"domain_scores_gemma":[0.9974205,0.0005859476,0.0017875329,0.00013640372,0.000054793978,0.00001481138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004163689,0.0001293226,0.0011232126,0.00012564074,0.000028873816,0.0000011416975,0.00036566518,0.00018601908,0.00001437845],"category_scores_gemma":[0.00017086617,0.000082467915,0.000255685,0.0002062659,0.0010583196,0.00005964262,0.0001228532,0.0005206826,0.000008840833],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003231425,0.00029119913,0.8678485,0.00008322752,0.0019853606,0.000011341578,0.0009911334,0.00001149659,0.08077702,0.00031841197,0.001437761,0.043013114],"study_design_scores_gemma":[0.0029683872,0.00033415982,0.9421862,0.00013490375,0.00019538743,0.0019042789,0.00091682957,0.000001301127,0.04818933,0.00035439467,0.0027128526,0.00010201752],"about_ca_topic_score_codex":0.000019666963,"about_ca_topic_score_gemma":0.0000039437964,"teacher_disagreement_score":0.074337654,"about_ca_system_score_codex":0.00001817273,"about_ca_system_score_gemma":0.000053626816,"threshold_uncertainty_score":0.38994226},"labels":[],"label_agreement":null},{"id":"W2949252282","doi":"10.1136/annrheumdis-2019-eular.4166","title":"AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Placebo; Ankylosing spondylitis; Internal medicine; Immune system; Dithranol; Interleukin 17; Psoriasis Area and Severity Index; Arthritis; Interleukin; Gastroenterology; Inflammation; Dermatology; Immunology; Pathology; Cytokine","score_opus":0.05462284286593391,"score_gpt":0.29499905037272445,"score_spread":0.24037620750679053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949252282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521327,0.0010796097,0.0000087138005,0.0003455482,0.0002822017,0.0020407997,0.00096146273,0.00002594749,0.00004241837],"genre_scores_gemma":[0.9991425,0.00022257287,0.000035964316,0.00006209224,0.0000124833305,0.00011090652,0.00021141072,0.000023354738,0.00017871158],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977548,0.00051628187,0.00084590673,0.00046734788,0.00013226086,0.00028336892],"domain_scores_gemma":[0.9980457,0.0006022323,0.00050259236,0.00064732134,0.0001436741,0.000058513968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038618574,0.00031432757,0.00080043863,0.0002116744,0.00008430965,0.000026181195,0.0002524859,0.00012384326,0.00007310669],"category_scores_gemma":[0.00014513453,0.00020164512,0.00015283284,0.00025103777,0.00011434187,0.00020159918,0.00011372978,0.000108095854,0.00003208251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8608351,0.013824248,0.016629841,0.00032013224,0.0043143616,0.00004440145,0.020901546,0.002478637,0.00990356,0.00017034274,0.0017039313,0.06887394],"study_design_scores_gemma":[0.61710304,0.0066944286,0.28978,0.00360164,0.0019476681,0.000048287162,0.0097514875,0.00031786054,0.06800106,0.0016166414,0.00007891635,0.0010589684],"about_ca_topic_score_codex":0.0011012268,"about_ca_topic_score_gemma":0.00026023312,"teacher_disagreement_score":0.27315015,"about_ca_system_score_codex":0.00001847708,"about_ca_system_score_gemma":0.000104615785,"threshold_uncertainty_score":0.82228494},"labels":[],"label_agreement":null},{"id":"W2949395959","doi":"10.1136/annrheumdis-2019-eular.798","title":"FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Dermatology; Arthritis; Rheumatoid arthritis; Psoriasis; Internal medicine","score_opus":0.02667997768072668,"score_gpt":0.28420306581718113,"score_spread":0.25752308813645447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949395959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823634,0.015307406,0.0000016664479,0.00006652684,0.00019234193,0.000352642,0.0016614686,0.000013808299,0.00004071511],"genre_scores_gemma":[0.99864864,0.00076711876,0.00001807808,0.00006072634,0.0000018115935,0.00002862214,0.0004304248,0.000008071323,0.000036495494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867743,0.00028233504,0.00051543844,0.00021766943,0.00009190727,0.00021519321],"domain_scores_gemma":[0.9985154,0.00044727314,0.0004334163,0.00046541286,0.00011838929,0.000020062374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009285114,0.0001881468,0.0008842254,0.00019771022,0.000044174045,0.00000471915,0.00024903615,0.00006667465,0.0005179343],"category_scores_gemma":[0.00017231921,0.000113311864,0.00027216162,0.00044885356,0.00015826049,0.000092164744,0.00007398872,0.000047481408,0.0000443674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000957606,0.002443845,0.9192166,0.0001524929,0.015223459,0.0000025274296,0.001228634,0.0000842168,0.00007720497,0.00012020302,0.00046319817,0.060030013],"study_design_scores_gemma":[0.006723092,0.00029018772,0.98181397,0.00082006806,0.0022486825,4.3315882e-7,0.000847585,0.000014464283,0.00623055,0.0007833572,0.00004332777,0.00018426486],"about_ca_topic_score_codex":0.000091254595,"about_ca_topic_score_gemma":0.00003499444,"teacher_disagreement_score":0.06259739,"about_ca_system_score_codex":0.000008517933,"about_ca_system_score_gemma":0.0000334022,"threshold_uncertainty_score":0.5671018},"labels":[],"label_agreement":null},{"id":"W2949528356","doi":"10.1007/s40257-019-00458-2","title":"Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council","year":2019,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Université Laval; Probity Medical Research","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research; Amgen","keywords":"Psoriasis; Medicine; Pharmacotherapy; Intensive care medicine; Dermatology; Psychiatry","score_opus":0.062405782343731356,"score_gpt":0.3399270085649656,"score_spread":0.27752122622123426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949528356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055433,0.002278644,0.0000029194957,0.0018150087,0.0045637684,0.0004305794,0.000069545225,0.000008375453,0.00027684102],"genre_scores_gemma":[0.9984974,0.00046067964,0.000060148548,0.00078387425,0.00014231216,0.0000068650274,0.0000072903335,0.00001235593,0.000029059765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99196696,0.0044218176,0.0026572174,0.00044107274,0.00024003927,0.00027288805],"domain_scores_gemma":[0.99124265,0.005502247,0.0020002155,0.000664092,0.0005297952,0.00006100412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003677538,0.00023182959,0.0014506271,0.000056832694,0.00008174663,0.000012912319,0.00095359585,0.00027090838,0.00019172009],"category_scores_gemma":[0.003238322,0.00013348462,0.00058575725,0.00022020277,0.0013550994,0.000093096154,0.00030387286,0.00091252424,0.00002696927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017503824,0.0008523468,0.9436614,0.0000070751707,0.0009333772,0.000015795913,0.0020556217,7.045739e-7,0.00002857181,0.000018749146,0.0010189759,0.04965703],"study_design_scores_gemma":[0.0070981407,0.0007171537,0.97257054,0.00005747659,0.00035781955,0.000113470334,0.010208406,0.0000074987724,0.00007792262,0.0001314919,0.008541109,0.000118954966],"about_ca_topic_score_codex":0.00044053863,"about_ca_topic_score_gemma":0.0005945057,"teacher_disagreement_score":0.049538072,"about_ca_system_score_codex":0.000086672575,"about_ca_system_score_gemma":0.0008364444,"threshold_uncertainty_score":0.5443345},"labels":[],"label_agreement":null},{"id":"W2950370118","doi":"10.1177/2050313x19857392","title":"Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report","year":2019,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Dermatology; Psoriasis; Pustular psoriasis; Pustulosis; Immunology; Arthritis","score_opus":0.01993255649021716,"score_gpt":0.2874323661507812,"score_spread":0.2674998096605641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950370118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716162,0.018716086,0.0001223305,0.0004657487,0.0035272418,0.0017705385,0.00003641181,0.00017382864,0.0035716135],"genre_scores_gemma":[0.99215037,0.0003156707,0.00014588365,0.00020272486,0.00037241713,0.0002831409,0.00047459023,0.00008799777,0.005967186],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9946727,0.0007014863,0.0016271153,0.0014867203,0.0004034594,0.0011085309],"domain_scores_gemma":[0.99642336,0.00024791964,0.0007362961,0.0020257374,0.00019174776,0.0003749415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0036031506,0.000591045,0.0011270252,0.0002484527,0.00062868994,0.00015791875,0.00042653596,0.0010444073,0.009438049],"category_scores_gemma":[0.001039808,0.000507731,0.0004051808,0.00054812484,0.00023191104,0.00047530324,0.0008625154,0.00075423275,0.0008482679],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001116054,0.00024326313,0.01091618,0.000088731606,0.0007958007,0.9461406,0.0002548031,0.000004769504,0.0016531211,0.000023609857,0.0023739142,0.037393626],"study_design_scores_gemma":[0.002531224,0.00024059323,0.0002749272,0.0002620952,0.00054003915,0.9251892,0.0005947737,0.000026564667,0.008665116,0.000071210634,0.06104791,0.00055633276],"about_ca_topic_score_codex":0.0033599231,"about_ca_topic_score_gemma":0.0007657234,"teacher_disagreement_score":0.058674,"about_ca_system_score_codex":0.00026859972,"about_ca_system_score_gemma":0.0011239382,"threshold_uncertainty_score":0.99992967},"labels":[],"label_agreement":null},{"id":"W2950469873","doi":"10.1136/annrheumdis-2019-eular.172","title":"AB0745 ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Physical therapy; Psoriasis; Arthritis; Surgery; Dermatology; Pathology","score_opus":0.06153507801289493,"score_gpt":0.38723954002909833,"score_spread":0.3257044620162034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950469873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253637,0.0011089139,0.000004293013,0.000021775912,0.00022769917,0.005144098,0.00093473686,0.000004408146,0.000017690969],"genre_scores_gemma":[0.9995024,0.00018145499,0.000019635221,0.0000025771608,0.000005364511,0.00012917204,0.0001397976,0.000009266957,0.000010333515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99374545,0.004612194,0.0010583096,0.0002557124,0.00018754473,0.00014078645],"domain_scores_gemma":[0.9927822,0.005006622,0.0015254281,0.00047676297,0.00017241288,0.000036626625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021777025,0.00022385322,0.0019519777,0.00010598318,0.000030116898,0.000003779103,0.00012312255,0.00008347911,0.00005332824],"category_scores_gemma":[0.0014633569,0.000114388895,0.00052649167,0.00009847074,0.00024211705,0.00008134542,0.000041502575,0.000043922017,6.891223e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9188705,0.0044179843,0.040221505,0.00009971119,0.003511281,1.3445995e-7,0.00013160362,0.00023919666,0.00026109657,0.000004331966,0.0000054222014,0.03223722],"study_design_scores_gemma":[0.83897537,0.003955506,0.14708513,0.00056457694,0.0048480076,4.351129e-8,0.000016153752,0.001754383,0.0026504092,0.00006389839,2.598657e-7,0.000086240434],"about_ca_topic_score_codex":0.000288137,"about_ca_topic_score_gemma":0.000008100862,"teacher_disagreement_score":0.106863625,"about_ca_system_score_codex":0.000033609074,"about_ca_system_score_gemma":0.0003259695,"threshold_uncertainty_score":0.46646437},"labels":[],"label_agreement":null},{"id":"W2950761310","doi":"10.1186/s12895-019-0087-3","title":"Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America","year":2019,"lang":"en","type":"article","venue":"BMC Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GDI Integrated Facility Services (Canada); Novartis (Canada); University of British Columbia; Lynde Centre for Dermatology; University of Toronto; Queen's University; University of Ottawa; Probity Medical Research","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Observational study; Psoriasis; Population; Dermatology Life Quality Index; Psoriatic arthritis; Quality of life (healthcare); Apremilast; Psoriasis Area and Severity Index; Epidemiology; Physical therapy; Internal medicine; Dermatology; Environmental health","score_opus":0.0076404144922456564,"score_gpt":0.19109756521428564,"score_spread":0.18345715072204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950761310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978939,0.0007175847,0.0003240605,0.000029006738,0.00006643489,0.0007675989,0.00009634037,0.0000051208026,0.0000999016],"genre_scores_gemma":[0.9989784,0.00003886793,0.0007392445,0.00002558124,0.0000025249694,0.000070849856,0.000041984284,0.0000086972905,0.000093880546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991484,0.00018254528,0.00021666249,0.00024710334,0.000031605476,0.00017363662],"domain_scores_gemma":[0.99937487,0.00024035631,0.00015346952,0.00014323497,0.00006987569,0.000018216695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028172879,0.00013727552,0.00039721874,0.00008695283,0.000029392666,0.0000022745078,0.00006111071,0.00009458143,0.000031433],"category_scores_gemma":[0.000027940681,0.00011405987,0.000013446953,0.00012248036,0.00008610115,0.00005027104,0.000034283774,0.00006496669,0.0000032829764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018026322,0.00006482626,0.9946079,0.00008008817,0.00014869061,0.0000037800191,0.00057342986,0.00044818042,0.0013528643,0.00016505776,0.000090745576,0.00066180906],"study_design_scores_gemma":[0.0046000713,0.00030458267,0.98023725,0.000045393204,0.000043180764,0.000050076196,0.00034706737,0.000055166143,0.0140137505,0.00009810642,0.000050482457,0.00015490422],"about_ca_topic_score_codex":0.031471204,"about_ca_topic_score_gemma":0.22624329,"teacher_disagreement_score":0.19477208,"about_ca_system_score_codex":0.00008905816,"about_ca_system_score_gemma":0.0007454332,"threshold_uncertainty_score":0.9749783},"labels":[],"label_agreement":null},{"id":"W2951160933","doi":"10.1136/annrheumdis-2019-eular.3132","title":"AB0740 USE OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS. IMPACTS OF COMBINATION WITH METHOTREXATE","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Osteoporosis Canada; Montreal Clinical Research Institute","funders":"","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Methotrexate; Dermatology; Psoriasis; Arthritis; Immunology","score_opus":0.016975044362148882,"score_gpt":0.23522776407099918,"score_spread":0.2182527197088503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951160933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791193,0.001209157,0.0000028976199,0.000054087,0.00009841687,0.00048811908,0.00019400675,0.0000072702856,0.00003408632],"genre_scores_gemma":[0.9995199,0.00021868871,0.000050060946,0.000019431438,9.0299693e-7,0.000011800735,0.000076179545,0.000012012288,0.00009106295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897563,0.00025719625,0.00036641574,0.00013274603,0.000098193326,0.00016982315],"domain_scores_gemma":[0.9986361,0.000290317,0.0005217067,0.00036860674,0.00016464083,0.000018614372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011685675,0.00014552109,0.0004645076,0.0001114917,0.000022676033,0.0000045835586,0.00015438507,0.000055078268,0.0001027518],"category_scores_gemma":[0.00012711673,0.0000841449,0.00009562739,0.00021724046,0.00009131055,0.0001653266,0.00003524299,0.000041629217,0.000010600307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023356155,0.0021560912,0.93886006,0.00042986075,0.0011266132,6.6519056e-7,0.0007362592,0.000126089,0.00032740599,0.00043789076,0.00019523967,0.053268194],"study_design_scores_gemma":[0.005144511,0.0008264228,0.980036,0.0014391132,0.00016189263,8.4173064e-7,0.00006901741,0.000005746417,0.011881253,0.00031761124,0.000012365885,0.00010522587],"about_ca_topic_score_codex":0.00026374537,"about_ca_topic_score_gemma":0.000052795956,"teacher_disagreement_score":0.053162966,"about_ca_system_score_codex":0.000012702205,"about_ca_system_score_gemma":0.0000644218,"threshold_uncertainty_score":0.34313294},"labels":[],"label_agreement":null},{"id":"W2951304013","doi":"10.1136/annrheumdis-2019-eular.4185","title":"OP0203 CHARACTERIZING THE EPIGENOMIC LANDSCAPE OF PSORIASIS PATIENTS DESTINED TO DEVELOP PSORIATIC ARTHRITIS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Memorial University of Newfoundland; University Health Network","funders":"","keywords":"Psoriasis; Medicine; Epigenomics; DNA methylation; Epigenome; Psoriatic arthritis; Epigenetics; Internal medicine; Oncology; Bioinformatics; Immunology; Genetics; Biology; Gene expression; Gene","score_opus":0.019760450481450392,"score_gpt":0.24042252941687298,"score_spread":0.22066207893542258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951304013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474037,0.002714956,0.0000039479264,0.0005012937,0.00095025415,0.0006451876,0.00027744044,0.000020649015,0.00014591293],"genre_scores_gemma":[0.99872124,0.0005021642,0.000040932136,0.0002370675,0.000015011907,0.00005138352,0.00008371295,0.000018602603,0.0003298916],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859864,0.00028654528,0.00052393274,0.00020600126,0.00009069642,0.00029421135],"domain_scores_gemma":[0.9983479,0.0004328031,0.0003999219,0.000568251,0.00021367078,0.00003745353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022512028,0.00020199532,0.00046421165,0.00007809635,0.00013372986,0.000012660336,0.00051246124,0.00007178547,0.00040446862],"category_scores_gemma":[0.000611858,0.00011798373,0.00019483395,0.00032547492,0.000077516765,0.000076001794,0.00016464107,0.000055345627,0.0003686037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082385156,0.0010150243,0.33868873,0.00036825426,0.0020412842,8.3554255e-7,0.0035521574,0.000039267477,0.006139054,0.0004214994,0.006336182,0.64057386],"study_design_scores_gemma":[0.0014955925,0.00019705163,0.97405857,0.00060871,0.00020040153,0.0000021599953,0.00025147703,0.00000339868,0.021920554,0.00026902367,0.0008061097,0.00018695508],"about_ca_topic_score_codex":0.00005174733,"about_ca_topic_score_gemma":0.000008191212,"teacher_disagreement_score":0.64038694,"about_ca_system_score_codex":0.00000939641,"about_ca_system_score_gemma":0.00010845581,"threshold_uncertainty_score":0.4811237},"labels":[],"label_agreement":null},{"id":"W2952538817","doi":"10.1016/j.jaad.2019.04.073","title":"Validation of the electronic Psoriasis Area and Severity Index application: Establishing measurement equivalence","year":2019,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Janssen UK; Cilag; LEO Pharma; Les Laboratories Pierre Fabre; Janssen Biotech; Novartis; Bausch Health; Celgene; American Academy of Dermatology; Pfizer; Eli Lilly and Company; AbbVie; Sanofi","keywords":"Scopus; Medicine; Psoriasis; Psoriasis Area and Severity Index; Equivalence (formal languages); Patient-reported outcome; MEDLINE; Family medicine; Quality of life (healthcare); Dermatology","score_opus":0.021944010080338364,"score_gpt":0.2521375670072493,"score_spread":0.23019355692691096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952538817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66660833,0.006745838,0.00030187817,0.32472456,0.0008932028,0.00054902025,0.00006541778,0.000010237848,0.000101503785],"genre_scores_gemma":[0.9778302,0.0010037144,0.000029661172,0.020830037,0.00017164367,0.0000104412,0.000006852445,0.000021229056,0.00009624081],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972268,0.0010435137,0.000861696,0.00024195036,0.00025591836,0.00037013736],"domain_scores_gemma":[0.9947673,0.00041574135,0.0042767,0.00034528435,0.00018107495,0.000013908174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050328195,0.00027838198,0.0010229815,0.00017766366,0.00011470462,0.000009025024,0.0011190649,0.00057673163,0.000017915012],"category_scores_gemma":[0.00017987183,0.0001683863,0.00036603725,0.00032212667,0.0007326682,0.00011954722,0.00021870209,0.001783857,0.0000042953448],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012590999,0.0003276973,0.2357206,0.00083925243,0.0069773193,0.000014445309,0.0009070575,0.000081630285,0.17341919,0.00028962974,0.54634744,0.033816632],"study_design_scores_gemma":[0.0037299963,0.00038883,0.12294052,0.0007353304,0.0037526456,0.008766285,0.00028889166,0.000013906929,0.3388629,0.0024460268,0.5173103,0.0007643352],"about_ca_topic_score_codex":0.00004375403,"about_ca_topic_score_gemma":0.000001927726,"teacher_disagreement_score":0.31122184,"about_ca_system_score_codex":0.00014531268,"about_ca_system_score_gemma":0.0003269223,"threshold_uncertainty_score":0.775007},"labels":[],"label_agreement":null},{"id":"W2953210514","doi":"10.1136/annrheumdis-2019-eular.1762","title":"FRI0435 INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Medac; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Placebo; Internal medicine; Psoriasis Area and Severity Index; Psoriasis; Dermatology Life Quality Index; Clinical endpoint; Body surface area; Gastroenterology; Randomized controlled trial; Disease; Immunology; Pathology","score_opus":0.015318172423611946,"score_gpt":0.26945421504190176,"score_spread":0.2541360426182898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953210514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759364,0.00035236994,7.2814703e-7,0.000048946316,0.00011321368,0.0009829542,0.0008964375,0.00000815619,0.0000035645794],"genre_scores_gemma":[0.9995265,0.00018417815,0.000013006357,0.00004621417,0.0000056528706,0.0000319779,0.00017125033,0.0000140919365,0.000007101359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983594,0.0004911788,0.0005836581,0.00025127974,0.00010982271,0.00020465109],"domain_scores_gemma":[0.99836713,0.0005522947,0.00047578773,0.000392796,0.00014894531,0.00006302369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023939552,0.00021213558,0.0006044368,0.00023843706,0.000033803768,0.0000051921866,0.0001960679,0.0000910385,0.000022324735],"category_scores_gemma":[0.0007586966,0.0001424683,0.00010800365,0.00036778205,0.00020124918,0.00013255473,0.000048861104,0.00009362005,0.0000027000503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15315881,0.014501026,0.80290866,0.00038122048,0.00052723836,0.0000027146798,0.00061935926,0.00015778479,0.0005620474,0.00013385335,0.00005796868,0.026989287],"study_design_scores_gemma":[0.046693355,0.0023664767,0.9470224,0.0010029408,0.00021638018,2.365429e-7,0.000051994768,0.000023459013,0.0023056553,0.00015478184,0.0000057505163,0.00015661692],"about_ca_topic_score_codex":0.00008585297,"about_ca_topic_score_gemma":0.000023911793,"teacher_disagreement_score":0.14411367,"about_ca_system_score_codex":0.00001019183,"about_ca_system_score_gemma":0.00014746583,"threshold_uncertainty_score":0.58096886},"labels":[],"label_agreement":null},{"id":"W2953422156","doi":"10.1016/j.jep.2019.112073","title":"Anti-psoriasis effect of water-processed rosin in mice","year":2019,"lang":"en","type":"article","venue":"Journal of Ethnopharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Nanjing University; Nanjing University of Chinese Medicine; Health Research Foundation","keywords":"Psoriasis; Medicine; Imiquimod; In vivo; Pharmacology; Spleen; Inflammation; Dermatology; Immunology; Biology","score_opus":0.010559651094468565,"score_gpt":0.274750058617548,"score_spread":0.26419040752307943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953422156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915926,0.003393054,0.0000033800004,0.0002341744,0.0041918145,0.0002303882,0.000008251368,0.000009419605,0.0003369311],"genre_scores_gemma":[0.9990583,0.00030317236,0.000034985478,0.000080676175,0.00007837289,0.0000064854753,0.00000940149,0.000016821952,0.00041180608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980709,0.00064425525,0.00068073795,0.00018045054,0.000055647142,0.0003680416],"domain_scores_gemma":[0.9987788,0.00052508694,0.0004160274,0.00011500279,0.00013524735,0.000029812303],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009838699,0.0002070832,0.0008750021,0.00040666078,0.000034063287,0.0000047714425,0.00032096225,0.00034380218,0.0012098555],"category_scores_gemma":[0.00005703224,0.00013466459,0.00021151343,0.00019925537,0.000096931995,0.0001690906,0.00005499356,0.00038927412,0.0002808038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021147085,0.00021627286,0.024768563,0.00009994906,0.00045087165,0.00007798601,0.00046766014,0.000051441075,0.9639716,0.0000067068568,0.0003821932,0.0073920195],"study_design_scores_gemma":[0.010396081,0.0015075853,0.014008863,0.000049285747,0.00032230938,0.00007337691,0.000080944155,0.000002110138,0.9717366,0.000029938526,0.0016677777,0.00012514289],"about_ca_topic_score_codex":0.000028358563,"about_ca_topic_score_gemma":0.0000052349783,"teacher_disagreement_score":0.010759699,"about_ca_system_score_codex":0.000054685395,"about_ca_system_score_gemma":0.00007281724,"threshold_uncertainty_score":0.99970317},"labels":[],"label_agreement":null},{"id":"W2953436115","doi":"10.1016/j.jval.2019.04.1774","title":"PSS2 THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada); Health Canada; Vancouver Coastal Health","funders":"","keywords":"Tazarotene; Medicine; Psoriasis; Internal medicine; Randomized controlled trial; Plaque psoriasis; Combination therapy; Meta-analysis; Dermatology; Oncology; Pharmacology","score_opus":0.03505089356395533,"score_gpt":0.2565548362702506,"score_spread":0.22150394270629528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953436115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380946,0.0015539179,0.00028163957,0.0020626083,0.0001435805,0.0020061717,0.000063301624,0.000020942569,0.000058357517],"genre_scores_gemma":[0.9981899,0.000033622746,0.0006196479,0.00041218783,0.00001350703,0.0001594249,0.000057120767,0.000017655637,0.00049692154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976973,0.0010406086,0.00043683583,0.00039734034,0.00009474158,0.00033318828],"domain_scores_gemma":[0.998872,0.00041199007,0.00023485564,0.00034514305,0.00008856136,0.000047474685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044540927,0.00022610901,0.0008224217,0.00016625377,0.00014559546,0.000014572995,0.00014652427,0.00013914455,0.000113056725],"category_scores_gemma":[0.000036794943,0.00013005215,0.0001691643,0.00057630317,0.00006013688,0.00008633363,0.000050495637,0.00015866848,0.00002552323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005202671,0.0010872636,0.80644506,0.000106453524,0.061141144,0.0000027525891,0.015741633,0.095528014,0.00014145135,0.009099218,0.0002973499,0.005206967],"study_design_scores_gemma":[0.0060203266,0.0017787826,0.98212016,0.00008045163,0.007108748,0.0000020789953,0.00019884881,0.00047133098,0.0003406704,0.00086328917,0.00066380634,0.00035148553],"about_ca_topic_score_codex":0.0015663684,"about_ca_topic_score_gemma":0.00034836095,"teacher_disagreement_score":0.1756751,"about_ca_system_score_codex":0.00006681862,"about_ca_system_score_gemma":0.0000664042,"threshold_uncertainty_score":0.5303373},"labels":[],"label_agreement":null},{"id":"W2953600596","doi":"10.1097/mop.0000000000000798","title":"Recommendations for photoprotection in pediatric rheumatology patients","year":2019,"lang":"en","type":"review","venue":"Current Opinion in Pediatrics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Photoprotection; Rheumatology; Internal medicine; MEDLINE; Intensive care medicine","score_opus":0.11952708249659588,"score_gpt":0.3660421266870919,"score_spread":0.24651504419049602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953600596","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016206835,0.9549688,0.00005068765,0.0000140301245,0.041139025,0.0029384529,0.00065734057,0.000042387037,0.000027180306],"genre_scores_gemma":[0.000035725196,0.9882318,0.000048469483,0.0000017972792,0.00030192648,0.0016636918,0.009601557,0.000049634134,0.00006539671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970891,0.0004416098,0.0012307537,0.0006766576,0.000049719973,0.0005121512],"domain_scores_gemma":[0.99808776,0.00075307174,0.0007280604,0.00034089852,0.00006428928,0.000025938925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032079738,0.00048067648,0.0014348876,0.0014925874,0.00008931242,0.000015244626,0.00030932238,0.0009088019,0.0000676363],"category_scores_gemma":[0.00025194557,0.00045032942,0.00040830404,0.0009956476,0.000022334429,0.000096292926,0.00009742211,0.0006010722,0.00044123598],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028419117,0.0005773848,0.01614595,0.020610591,0.000029597033,8.415524e-8,0.00006301908,6.0472166e-7,2.1627846e-8,0.00007264205,0.008156605,0.95431507],"study_design_scores_gemma":[0.002399416,0.00012803973,0.0005950649,0.0013367872,0.00041186583,0.0000050511244,0.000007585918,9.0354837e-7,2.5697926e-7,0.000041260395,0.99464214,0.0004316533],"about_ca_topic_score_codex":0.000021131627,"about_ca_topic_score_gemma":0.000006339861,"teacher_disagreement_score":0.9864855,"about_ca_system_score_codex":0.0002359869,"about_ca_system_score_gemma":0.00034498904,"threshold_uncertainty_score":0.99979484},"labels":[],"label_agreement":null},{"id":"W2953615310","doi":"10.1016/j.cjca.2019.06.021","title":"Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis","year":2019,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Hellenic Atherosclerosis Society","keywords":"Medicine; Secukinumab; Psoriasis; Oxidative stress; Methotrexate; Internal medicine; Malondialdehyde; Cardiology; Pulse wave velocity; Diastole; Gastroenterology; Immunology; Blood pressure; Psoriatic arthritis","score_opus":0.00515757640072248,"score_gpt":0.17926728323823138,"score_spread":0.1741097068375089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953615310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950795,0.0016658321,0.00015558394,0.000042360025,0.0020757392,0.00015888945,0.000009846731,0.0000026808023,0.0008095635],"genre_scores_gemma":[0.99962425,0.00013856264,0.000008695743,0.000047555448,0.00012406647,0.000004344325,0.000021985152,0.0000071077066,0.000023407822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990406,0.00034164096,0.00029762232,0.00010488305,0.000026027616,0.00018921171],"domain_scores_gemma":[0.9995013,0.00012860926,0.00016453187,0.000091818874,0.000065225715,0.000048534774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003345675,0.00010812162,0.00041479542,0.00048263147,0.000032229113,0.000004627051,0.000051660816,0.00024023978,0.000018753237],"category_scores_gemma":[0.00006832898,0.00009354497,0.00015477999,0.000097031574,0.00006568583,0.00009739766,0.0000064376336,0.00016460761,0.000041189473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029351315,0.000049706723,0.47849667,0.0003507766,0.004318364,0.00016973146,0.0034557579,0.002597738,0.24435376,0.003450886,0.0038392572,0.25598222],"study_design_scores_gemma":[0.007778502,0.0023670637,0.93913347,0.00022546599,0.0004298704,0.0002759902,0.0003538942,0.0000024808764,0.03009228,0.0005437685,0.01857981,0.0002174018],"about_ca_topic_score_codex":0.00029337022,"about_ca_topic_score_gemma":0.00032589614,"teacher_disagreement_score":0.4606368,"about_ca_system_score_codex":0.00011085037,"about_ca_system_score_gemma":0.0001533383,"threshold_uncertainty_score":0.38146532},"labels":[],"label_agreement":null},{"id":"W2953837584","doi":"10.1007/s10067-019-04663-6","title":"Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment","year":2019,"lang":"en","type":"review","venue":"Clinical Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Internal medicine; Tumor necrosis factor alpha; Psoriasis; Rheumatology; Obesity; Arthritis; Oncology; Immunology; Adalimumab","score_opus":0.057916646295501896,"score_gpt":0.33548117247229425,"score_spread":0.27756452617679234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953837584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02017058,0.97524655,0.0000022160632,0.000048112284,0.002657815,0.001087545,0.0004067552,0.000051069568,0.0003293287],"genre_scores_gemma":[0.0052016675,0.99314636,0.000027685457,0.000022837383,0.00004688574,0.00014718418,0.0004492471,0.00005309724,0.00090501615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99470973,0.0019395979,0.0019137443,0.0008347095,0.000047854588,0.00055434316],"domain_scores_gemma":[0.99318516,0.0046045007,0.0010885248,0.0010103879,0.000051280145,0.000060157963],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006284747,0.0006611384,0.005125689,0.00014399392,0.00016953266,0.000014583911,0.00047660756,0.0017346896,0.00022262227],"category_scores_gemma":[0.00039264566,0.00039537097,0.0011595311,0.0001427168,0.00079849816,0.000036842277,0.0002203084,0.00048298412,0.0019528961],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041236344,0.00039723364,0.0051183477,0.00087548,0.0025917003,0.000010845788,0.000076575874,2.7101231e-8,0.0000014820121,0.0013040879,0.00032579526,0.9892572],"study_design_scores_gemma":[0.0022342962,0.0008644696,0.0008011303,0.0027657002,0.002981124,0.0006540663,0.000055115426,5.1666024e-7,0.00002128682,0.00034293515,0.9889219,0.00035748162],"about_ca_topic_score_codex":0.000090952766,"about_ca_topic_score_gemma":0.000060805694,"teacher_disagreement_score":0.9888997,"about_ca_system_score_codex":0.00004375363,"about_ca_system_score_gemma":0.00037718535,"threshold_uncertainty_score":0.9998498},"labels":[],"label_agreement":null},{"id":"W2953889774","doi":"10.1136/annrheumdis-2019-215356","title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","year":2019,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Celgene; Novartis Pharmaceuticals Corporation; Pfizer; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Enthesitis; Ankylosing spondylitis; Psoriasis; Disease; Immunology; Interleukin 23; Interleukin 17; Dermatology; Immune system; Pathology","score_opus":0.025860194830817473,"score_gpt":0.2849888468299404,"score_spread":0.25912865199912294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953889774","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048926678,0.9928247,9.707046e-8,0.000097314565,0.00046156862,0.0007189575,0.00089958153,0.0000073816987,0.00009778141],"genre_scores_gemma":[0.0050029582,0.9947081,0.0000024104932,0.000015693531,0.000013326769,0.00007111226,0.000055326833,0.000015083195,0.00011597787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829113,0.00054018176,0.0006278183,0.00022643885,0.00006530753,0.00024913836],"domain_scores_gemma":[0.9970814,0.0018576388,0.00061396457,0.0003708761,0.000051946703,0.000024196177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023319786,0.00027888617,0.0013510772,0.00008069911,0.00011875137,0.000018038363,0.0002694887,0.00014804552,0.000038937098],"category_scores_gemma":[0.0005867802,0.00015620871,0.000286029,0.00012517715,0.0004133192,0.000086443804,0.00013618123,0.00009923551,0.00001203526],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008952758,0.00008554916,0.00012989838,0.0027286534,0.00053488195,7.058123e-7,0.0000991113,1.9357742e-7,9.436503e-7,0.00043804492,0.00018755876,0.99570495],"study_design_scores_gemma":[0.001264506,0.00017228964,0.00088491116,0.017950092,0.0009871353,0.000022202832,0.00038471358,4.660782e-7,0.000051581716,0.0026049535,0.9754591,0.00021805313],"about_ca_topic_score_codex":0.000031277377,"about_ca_topic_score_gemma":0.000052758616,"teacher_disagreement_score":0.99548686,"about_ca_system_score_codex":0.000008353523,"about_ca_system_score_gemma":0.00012077401,"threshold_uncertainty_score":0.6370006},"labels":[],"label_agreement":null},{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","score_opus":0.04080093537706545,"score_gpt":0.28074100667087143,"score_spread":0.23994007129380598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954341438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014439893,0.9755358,0.0000028842808,0.00012538389,0.0009947588,0.0019455948,0.0069248285,0.000014381125,0.00001645456],"genre_scores_gemma":[0.0039767884,0.99407023,0.000023128041,0.000013342367,0.00015612447,0.00030913067,0.0006131505,0.00003559155,0.0008024979],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844193,0.00021443442,0.0006151392,0.00040648188,0.000045797824,0.00027621802],"domain_scores_gemma":[0.99738336,0.0015102754,0.00050217146,0.0005261723,0.000046111214,0.000031942192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021075914,0.00045102165,0.0012530918,0.000118224736,0.00020581321,0.000022455979,0.00018056549,0.00027650248,0.000053718657],"category_scores_gemma":[0.000049875096,0.00022161793,0.0004928327,0.00012496675,0.00039379447,0.000039061353,0.0000767556,0.000080880156,0.00001803585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037854898,0.00023018935,0.00009496553,0.004344025,0.0020018544,0.0000032145792,0.00084337604,4.432663e-8,0.00002975906,0.00022303968,0.00054014474,0.99131083],"study_design_scores_gemma":[0.0016912926,0.000655104,0.00024301124,0.002033919,0.0067084176,0.000036238445,0.00012419373,0.000001035936,0.00023884703,0.00002710742,0.9880186,0.0002222561],"about_ca_topic_score_codex":0.000087559754,"about_ca_topic_score_gemma":0.000025929066,"teacher_disagreement_score":0.99108857,"about_ca_system_score_codex":0.000069698865,"about_ca_system_score_gemma":0.00014463525,"threshold_uncertainty_score":0.90373164},"labels":[],"label_agreement":null},{"id":"W2954444329","doi":"10.1101/681346","title":"Serum Amyloid A Proteins Induce Pathogenic T <sub>H</sub> 17 Cells and Promote Inflammatory Disease","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Alberta Innovates; NYU Langone Medical Center; Damon Runyon Cancer Research Foundation; Howard Hughes Medical Institute","keywords":"Immunology; Interleukin 17; Inflammation; T cell; Cell biology; Cytokine; Biology; RAR-related orphan receptor gamma; Chemistry; FOXP3; Immune system","score_opus":0.009666033555414365,"score_gpt":0.19021373506723877,"score_spread":0.1805477015118244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954444329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822777,0.00984971,0.000061237675,0.00010648169,0.0022651122,0.002986894,0.0019456829,0.00049983955,0.000007333057],"genre_scores_gemma":[0.9970387,0.0011734221,0.00025754818,0.00012943549,0.00028752314,0.0008388029,0.000007506865,0.00020916732,0.000057858822],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957863,0.00050401414,0.0007338903,0.0017649622,0.00016575039,0.00104507],"domain_scores_gemma":[0.99675804,0.000083005325,0.00065502024,0.0019131905,0.00029549559,0.00029527367],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005925985,0.001119332,0.0010049152,0.00039721964,0.0003456371,0.00015654016,0.0006508201,0.0014441762,0.00006591222],"category_scores_gemma":[0.00010535734,0.0011334711,0.00033739812,0.0003098078,0.00027772534,0.00021044178,0.000932821,0.0011046807,0.00085534103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022899361,0.00029569332,0.010930522,0.0006545906,0.00073623157,0.00017662693,0.000028622107,0.000015308678,0.98652864,0.0000556602,0.00027845224,0.00007066412],"study_design_scores_gemma":[0.0015859591,0.0001083565,0.18710895,0.00049871596,0.00060838094,1.1918602e-7,0.0000029294001,0.000012381097,0.8055464,0.0000033314775,0.003435641,0.0010888102],"about_ca_topic_score_codex":0.000013817372,"about_ca_topic_score_gemma":0.0000041448793,"teacher_disagreement_score":0.1809822,"about_ca_system_score_codex":0.00023496842,"about_ca_system_score_gemma":0.0011430425,"threshold_uncertainty_score":0.99992263},"labels":[],"label_agreement":null},{"id":"W2955205003","doi":"10.1016/s0140-6736(19)30952-3","title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":298,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie Deutschland","keywords":"Adalimumab; Medicine; Plaque psoriasis; Psoriasis; Double blind; Internal medicine; Dermatology; Physical therapy; Alternative medicine; Placebo; Disease; Pathology","score_opus":0.027776452468132987,"score_gpt":0.26906986731533666,"score_spread":0.24129341484720368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955205003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905254,0.00021474926,0.000026534706,0.00022835114,0.00059467956,0.0066809794,0.0002050013,0.00007900654,0.0014452826],"genre_scores_gemma":[0.9974848,0.000012831697,0.0000545391,0.00016767449,0.00017586745,0.0009777417,0.00040261456,0.000040032235,0.00068388146],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976153,0.0005766312,0.00047399267,0.0005357498,0.00013982001,0.00065854297],"domain_scores_gemma":[0.998426,0.00035081853,0.00029318602,0.0007812927,0.00009606559,0.000052635372],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003700492,0.0004585079,0.0017670407,0.00016151564,0.00019614765,0.000054615633,0.00050179317,0.00019675738,0.000473118],"category_scores_gemma":[0.00001467028,0.00025198498,0.00015228918,0.00031926724,0.00008323267,0.00015930149,0.00005462341,0.00033115147,0.0005389011],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98829675,0.0013794099,0.0047919317,0.000012075249,0.0014996994,0.0000069842386,0.0009700104,0.0005308214,0.00028167534,0.00007569446,0.0010809508,0.0010739781],"study_design_scores_gemma":[0.9891799,0.0022748937,0.0037203368,0.00007567353,0.00038141388,0.0000085291695,0.00015632622,0.00003124883,0.0026014585,0.000022724718,0.0011497377,0.0003977659],"about_ca_topic_score_codex":0.00013260492,"about_ca_topic_score_gemma":0.00022525073,"teacher_disagreement_score":0.006959402,"about_ca_system_score_codex":0.00011485778,"about_ca_system_score_gemma":0.00014115628,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W2955512364","doi":"10.11606/d.5.2019.tde-04072019-145319","title":"Efeito preventivo e terapêutico do anti IL-17 em modelo experimental de lesão pulmonar induzida pela elastase em camundongos C57B16","year":2019,"lang":"pt","type":"dissertation","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Elastase; Medicine; Chemistry; Molecular biology; Biology; Enzyme","score_opus":0.016064180340776352,"score_gpt":0.2658526872112841,"score_spread":0.24978850687050771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955512364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96369296,0.023752443,0.00045773463,0.000027137667,0.004589389,0.002286618,0.0012759952,0.00020827616,0.0037094238],"genre_scores_gemma":[0.85303605,0.0008789807,0.0003684473,0.00012212258,0.00017355965,0.00043197413,0.011367505,0.00020178867,0.13341959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9935081,0.0012211112,0.0013757693,0.0019063888,0.00022278445,0.0017658225],"domain_scores_gemma":[0.99708915,0.0002858785,0.00083720294,0.0013480312,0.0002164084,0.00022333662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0004593469,0.0017846669,0.001935498,0.00065808406,0.0008177552,0.00025167366,0.0009891036,0.0030170132,0.0060203318],"category_scores_gemma":[0.000032750853,0.0017056275,0.0010875624,0.00038550785,0.00016126053,0.0004259957,0.00025058704,0.0010685957,0.0033098795],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004577405,0.006139593,0.00713789,0.0005820857,0.00811669,0.00036106387,0.033236012,0.000108082226,0.837135,0.00073278527,0.00660365,0.09526974],"study_design_scores_gemma":[0.012689648,0.0023703254,0.014118232,0.0012251103,0.003757784,0.0007218395,0.08458299,0.00040682286,0.8674958,0.00009017461,0.008338447,0.004202833],"about_ca_topic_score_codex":0.00045064153,"about_ca_topic_score_gemma":0.00030713138,"teacher_disagreement_score":0.12971017,"about_ca_system_score_codex":0.0004805667,"about_ca_system_score_gemma":0.00068522664,"threshold_uncertainty_score":0.9994899},"labels":[],"label_agreement":null},{"id":"W2956922241","doi":"10.1111/jdv.15793","title":"Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Medicine; Adalimumab; Placebo; Psoriasis; Dermatology; Nail (fastener); Randomized controlled trial; Internal medicine; Alternative medicine; Pathology","score_opus":0.013741175539809372,"score_gpt":0.2626512666596356,"score_spread":0.24891009111982626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956922241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790115,0.014255786,0.00009100747,0.0024097986,0.0019202165,0.0015119825,0.0000548028,0.000012440776,0.0007325105],"genre_scores_gemma":[0.997267,0.0013619049,0.00013017998,0.00036988396,0.00024460346,0.00001777453,0.000011972056,0.000026364858,0.0005702958],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99430674,0.0037884726,0.001232878,0.0002842984,0.000057203775,0.00033037693],"domain_scores_gemma":[0.99503523,0.0032956689,0.0013969666,0.00017089679,0.000051491457,0.000049718226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013399343,0.0002987678,0.0019174652,0.00017064961,0.00017664483,0.0000081557955,0.00040385872,0.00044957738,0.00013199008],"category_scores_gemma":[0.00043578708,0.00018223292,0.0005177688,0.00006604939,0.0006319742,0.00009453779,0.00015229016,0.00049471855,0.000020624284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9772249,0.0003075283,0.0013288113,0.000027035503,0.0033531962,0.000012892924,0.00035503635,0.0000046910513,0.0061944565,0.0016083025,0.0012638686,0.008319313],"study_design_scores_gemma":[0.9768475,0.0002998039,0.002325378,0.00006928183,0.0019063664,0.0011539183,0.000057171306,0.000015761403,0.0032220802,0.0010645293,0.0128585035,0.00017967503],"about_ca_topic_score_codex":0.0000044921985,"about_ca_topic_score_gemma":0.0000011483971,"teacher_disagreement_score":0.018255565,"about_ca_system_score_codex":0.000014882267,"about_ca_system_score_gemma":0.00005805739,"threshold_uncertainty_score":0.7431243},"labels":[],"label_agreement":null},{"id":"W2957988988","doi":"10.1007/s10875-019-00664-x","title":"Chronic Mucocutaneous Candidiasis in an Adolescent Boy Due to a Novel Mutation in TRAF3IP2","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Chronic mucocutaneous candidiasis; Medicine; Mucocutaneous zone; Immunology; Bronchiectasis; Thrush; Pneumonia; Biology; Internal medicine; Disease","score_opus":0.037527290570323175,"score_gpt":0.33613369444416885,"score_spread":0.2986064038738457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2957988988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260837,0.0032139968,0.000059287202,0.00086795224,0.002844937,0.0003087278,0.000010709329,0.000011487361,0.00007454836],"genre_scores_gemma":[0.9987997,0.00032238406,0.00019303296,0.00027353637,0.00017061303,0.000008711007,0.000018140368,0.000019447156,0.00019448173],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99681264,0.0006776508,0.0016894588,0.00031004593,0.000058100788,0.0004520921],"domain_scores_gemma":[0.9984747,0.00048759257,0.00056466664,0.00029369455,0.00012106904,0.000058267986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011332764,0.00021007538,0.00105927,0.00047421936,0.000030444486,0.000013601897,0.00036569545,0.00059805304,0.00032657033],"category_scores_gemma":[0.0003503764,0.00017797419,0.00024893376,0.0002732801,0.00008056045,0.0001919918,0.000055797238,0.00079814304,0.000518347],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009365116,0.005138206,0.21213749,0.000040045554,0.0010131173,0.0019482994,0.0016118456,0.00059334695,0.21251878,0.00019457651,0.00021141132,0.55522776],"study_design_scores_gemma":[0.018006958,0.0073247277,0.96060264,0.00024548676,0.00013488054,0.0026535394,0.00069940585,0.000023339458,0.0059673004,0.00009994723,0.003922119,0.0003196695],"about_ca_topic_score_codex":0.00013112524,"about_ca_topic_score_gemma":0.0012877713,"teacher_disagreement_score":0.7484651,"about_ca_system_score_codex":0.00022966534,"about_ca_system_score_gemma":0.00038163768,"threshold_uncertainty_score":0.72575766},"labels":[],"label_agreement":null},{"id":"W2960529495","doi":"10.1111/bjd.18333","title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, <scp>BADBIR</scp> )","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Manchester Biomedical Research Centre; NIHR Newcastle Biomedical Research Centre; Medical Research Council; National Institute for Health and Care Research; Psoriasis Association","keywords":"Interquartile range; Medicine; Psoriasis; Concordance; Psoriasis Area and Severity Index; Cohort; Internal medicine; Rank correlation; Severity of illness; Population; Dermatology; Statistics","score_opus":0.02617875109033765,"score_gpt":0.27468237432130155,"score_spread":0.2485036232309639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960529495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224025,0.0051467014,0.000061024435,0.00015044694,0.0011324761,0.0007294971,0.00042095833,0.000027054675,0.000091572554],"genre_scores_gemma":[0.9976956,0.00057036587,0.00094027043,0.00011268804,0.00002894433,0.000017205191,0.00041600005,0.000033475633,0.00018540572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958306,0.001413147,0.0015220811,0.00054340705,0.00016852286,0.00052224577],"domain_scores_gemma":[0.9958547,0.0017553328,0.0015205464,0.0005904673,0.0002207947,0.00005820206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088577386,0.0003139461,0.001548171,0.00037568307,0.00031126503,0.00013708048,0.00071880646,0.00042033187,0.00004904473],"category_scores_gemma":[0.00094680197,0.0003132027,0.00018449662,0.00047138592,0.00009338872,0.00032066117,0.000259993,0.00039184096,0.000023538329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009512416,0.0004400821,0.99212176,0.000016410097,0.0010316173,0.00047519573,0.00021156833,0.00004791536,0.0007103459,0.0000086824075,0.0007229969,0.0041183247],"study_design_scores_gemma":[0.005349056,0.00013221185,0.98824096,0.00016748237,0.0005750726,0.0034446588,0.00061726366,0.000057110672,0.0007559769,0.00009659952,0.00039915266,0.00016445757],"about_ca_topic_score_codex":0.01655088,"about_ca_topic_score_gemma":0.008559837,"teacher_disagreement_score":0.007991043,"about_ca_system_score_codex":0.00021165461,"about_ca_system_score_gemma":0.00015361568,"threshold_uncertainty_score":0.999932},"labels":[],"label_agreement":null},{"id":"W2962722843","doi":"10.3899/jrheum.190114","title":"Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis","year":2019,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Risk stratification; Dermatology; Disease; Biomarker; Internal medicine; Arthritis","score_opus":0.007005272598654517,"score_gpt":0.20336863861204837,"score_spread":0.19636336601339385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962722843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90067154,0.09767003,0.000018316101,0.00019809404,0.0012283948,0.00011779095,0.0000066475827,0.0000072214248,0.0000819806],"genre_scores_gemma":[0.9810605,0.018772746,0.00002557948,0.000028056915,0.000007779963,0.000003123691,0.0000032402484,0.000009933926,0.000089006906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986155,0.00059390167,0.00040624806,0.00010917286,0.000046618836,0.00022855659],"domain_scores_gemma":[0.99903506,0.0004474013,0.00020478827,0.00024373295,0.00004614682,0.000022855262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005385431,0.00013369769,0.00065400405,0.00014942764,0.000059088077,0.0000062422264,0.0001912836,0.00013256267,0.0001931081],"category_scores_gemma":[0.00009561027,0.00008548412,0.00018499473,0.00011065716,0.000116345946,0.000083346094,0.000045962028,0.0001810999,0.00014797217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008427561,0.00017708617,0.7884891,0.00005524552,0.0026887765,0.00003452353,0.0015193145,0.00007239775,0.0010521853,0.00095898175,0.00086924405,0.20324036],"study_design_scores_gemma":[0.04031261,0.0022750413,0.846435,0.0009826123,0.0030453524,0.047277294,0.004498631,0.000022969652,0.0038890096,0.0066143605,0.04363983,0.0010072651],"about_ca_topic_score_codex":0.00015348954,"about_ca_topic_score_gemma":0.000047781443,"teacher_disagreement_score":0.2022331,"about_ca_system_score_codex":0.000020804351,"about_ca_system_score_gemma":0.000051693587,"threshold_uncertainty_score":0.34859413},"labels":[],"label_agreement":null},{"id":"W2964326110","doi":"10.1016/j.mehy.2019.109311","title":"Quantification of randomness (Entropy) as a clinical tool to assess the severity of skin disease","year":2019,"lang":"en","type":"article","venue":"Medical Hypotheses","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa","funders":"","keywords":"Randomness; Psoriasis; Entropy (arrow of time); Disease; Skin lesion; Medicine; Computer science; Mathematics; Dermatology; Statistics; Pathology; Physics","score_opus":0.05306307890017012,"score_gpt":0.3229356353526669,"score_spread":0.26987255645249675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964326110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968534,0.0006019208,0.00027887378,0.00068745547,0.00083014264,0.00043802106,0.00005313746,0.00001765262,0.00023939398],"genre_scores_gemma":[0.9985693,0.00013109487,0.000040588504,0.00020695926,0.000046954265,0.000038207443,0.00003181573,0.000008999824,0.0009260565],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983193,0.0006344295,0.0004928337,0.00023393736,0.00014232907,0.00017713838],"domain_scores_gemma":[0.99745625,0.0018049349,0.00015978898,0.000440756,0.00007832974,0.00005994826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010514864,0.00011736542,0.00041110627,0.000043402146,0.000047118203,0.0000047374187,0.0003504622,0.00017445977,0.001970067],"category_scores_gemma":[0.00239879,0.000069019785,0.00020035806,0.0001331678,0.00026647045,0.000034862285,0.00007358922,0.00012260821,0.0005833055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011867225,0.0030464628,0.4511277,0.00022503284,0.0011649005,0.000021052461,0.00061828736,0.000007217958,0.04152989,0.0076090605,0.0025048312,0.4802783],"study_design_scores_gemma":[0.006442629,0.0003993389,0.8530313,0.0001880475,0.00035796428,0.000015714286,0.00022578302,0.000015128131,0.1096842,0.00068864535,0.02871833,0.00023293718],"about_ca_topic_score_codex":0.000064281085,"about_ca_topic_score_gemma":0.0000091635675,"teacher_disagreement_score":0.48004538,"about_ca_system_score_codex":0.000008942492,"about_ca_system_score_gemma":0.00017427544,"threshold_uncertainty_score":0.99894226},"labels":[],"label_agreement":null},{"id":"W2964703987","doi":"10.1016/j.jaad.2019.04.042","title":"Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Foundation (evidence)","score_opus":0.0316169742257094,"score_gpt":0.3127807220119973,"score_spread":0.2811637477862879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2964703987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854134,0.005201611,0.00017966049,0.008125517,0.0001979108,0.0007161533,0.00009362346,0.000005831224,0.000066327804],"genre_scores_gemma":[0.99065703,0.0058057713,0.003072208,0.00029136243,0.000037978276,0.000035979,0.000007703423,0.000021978385,0.0000700168],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779165,0.00033220713,0.0012325845,0.00021733114,0.00017027094,0.00025597194],"domain_scores_gemma":[0.99510425,0.0005882875,0.0038234927,0.0001674116,0.00028927028,0.000027276943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017136722,0.00026972292,0.0013726702,0.00031488753,0.00009261073,0.0000032348905,0.00042417517,0.00014479876,0.000030044586],"category_scores_gemma":[0.0000368484,0.00014916848,0.00038471798,0.00034638474,0.0012399618,0.000080697086,0.000058532125,0.00015217767,0.0000019833622],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020023,0.0015220264,0.30570397,0.0010344072,0.028238038,0.000009212105,0.0063899374,0.0005639807,0.22090417,0.008062958,0.0035567326,0.40399155],"study_design_scores_gemma":[0.014023649,0.0028212187,0.21264678,0.00030635615,0.0033275334,0.0028118812,0.007619235,0.000052927287,0.7161542,0.0007491437,0.039081685,0.00040538475],"about_ca_topic_score_codex":0.00006496289,"about_ca_topic_score_gemma":0.0000067436886,"teacher_disagreement_score":0.49525005,"about_ca_system_score_codex":0.000067358,"about_ca_system_score_gemma":0.00010582602,"threshold_uncertainty_score":0.60829145},"labels":[],"label_agreement":null},{"id":"W2966010326","doi":"10.1016/j.jaad.2019.04.045","title":"Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study","year":2019,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Samsung Bioepis; Cilag; Janssen Biotech; Beijing Novartis Pharma; Sanofi Genzyme; Merck Sharp and Dohme; Samsung; LEO Pharma; Medac; Mitsubishi Tanabe Pharma Corporation; Almirall; Galderma; Allergan; Tartu Ülikool; National Taiwan University; Sanofi; Kyowa Hakko Kirin; Eli Lilly and Company; National Taiwan University Hospital; Purdue Pharma; Fresenius Medical Care North America; Sun Pharma; Novartis Pharmaceuticals Corporation; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Pfizer; Biogen; Novartis; Celgene; Purdue University; Baxalta; Genentech; Biogen Idec; Novartis Pharma; AbbVie; Boehringer Ingelheim; Amgen; GlaxoSmithKline","keywords":"Medicine; Secukinumab; Psoriasis; Dermatology; Plaque psoriasis; Intensive care medicine; Psoriatic arthritis","score_opus":0.012299822350368085,"score_gpt":0.24611361904426005,"score_spread":0.23381379669389196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966010326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982455,0.00025718485,6.7363635e-7,0.01598381,0.0001920954,0.00093707,0.0001557376,0.0000059181634,0.000012501056],"genre_scores_gemma":[0.9951543,0.00007436077,0.0000967732,0.004533392,0.000036263868,0.000009571168,0.000028574637,0.000039571885,0.000027156935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996368,0.0011636475,0.001486376,0.00039953014,0.0001544501,0.0004279813],"domain_scores_gemma":[0.9947904,0.0015483227,0.00320442,0.00035650574,0.00008131816,0.000019063758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016610805,0.00040909406,0.0017876567,0.00030898346,0.00006851553,0.000012933535,0.0005476105,0.00043245684,0.000004576456],"category_scores_gemma":[0.00022357277,0.00023408806,0.00021984975,0.0003786769,0.0003802266,0.000114193834,0.00018100912,0.0011486836,0.0000026328357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013057765,0.001005243,0.9575793,0.000025917627,0.0034228163,0.00016015454,0.008124378,0.00017474727,0.00025238047,0.0000018223436,0.0019485399,0.014246914],"study_design_scores_gemma":[0.019064546,0.0021559612,0.97254026,0.00018077013,0.0008030417,0.00017729143,0.002734734,0.000002767319,0.0010301969,0.000025541696,0.0009948364,0.0002900516],"about_ca_topic_score_codex":0.0015590978,"about_ca_topic_score_gemma":0.00006816555,"teacher_disagreement_score":0.01496094,"about_ca_system_score_codex":0.00015784975,"about_ca_system_score_gemma":0.00018562224,"threshold_uncertainty_score":0.95458335},"labels":[],"label_agreement":null},{"id":"W2966265540","doi":"10.1186/s13223-019-0359-9","title":"Endogenous stimulation is responsible for the high frequency of IL-17A-producing neutrophils in patients with rheumatoid arthritis","year":2019,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Consejo Nacional de Ciencia y Tecnología; Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional; Instituto Politécnico Nacional","keywords":"Rheumatoid arthritis; Endogeny; Stimulation; Medicine; Immunology; Internal medicine","score_opus":0.018114928425135894,"score_gpt":0.2450177177523745,"score_spread":0.2269027893272386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966265540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99026066,0.007793548,0.00002984238,0.00029712377,0.00080149394,0.00066206255,0.00007051658,0.000019967636,0.000064774285],"genre_scores_gemma":[0.9954023,0.0038443697,0.0002137087,0.000098716024,0.000019893276,0.000049946077,0.00014043186,0.000020688423,0.00020999875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981506,0.0003309747,0.00066164834,0.00046503567,0.000039539747,0.000352215],"domain_scores_gemma":[0.9977741,0.0013310984,0.00027584532,0.00047448656,0.00012824338,0.00001623125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039850973,0.00020559604,0.00054494885,0.000101755126,0.00013764254,0.0000076599945,0.0001924054,0.00036509158,0.00027384286],"category_scores_gemma":[0.00012109114,0.00014229064,0.00011599295,0.0001363945,0.00029185825,0.000089699046,0.00007057656,0.00022306618,0.000062598876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01203568,0.0015342672,0.699174,0.000022456521,0.0039604995,0.0000074714176,0.0010080938,0.000074612704,0.03864162,0.006114591,0.00011534332,0.2373114],"study_design_scores_gemma":[0.011650656,0.002808355,0.97758806,0.0000666248,0.000028346365,0.000015189684,0.00010135534,0.0000044173403,0.004961191,0.00054906175,0.0020372216,0.00018954858],"about_ca_topic_score_codex":0.00043638432,"about_ca_topic_score_gemma":0.00023688367,"teacher_disagreement_score":0.27841407,"about_ca_system_score_codex":0.000018134595,"about_ca_system_score_gemma":0.00008533438,"threshold_uncertainty_score":0.5802444},"labels":[],"label_agreement":null},{"id":"W2967066402","doi":"10.1111/jdv.15862","title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Psoriasis; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Plaque psoriasis; Gastroenterology; Dermatology","score_opus":0.021058167939606725,"score_gpt":0.30064712035991437,"score_spread":0.2795889524203076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967066402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959487,0.0019220577,0.0000263925,0.00078101945,0.00023652797,0.00091044506,0.000041742394,0.0000037021575,0.00012946752],"genre_scores_gemma":[0.9994678,0.00011988592,0.00005045288,0.00025546786,0.000017045379,0.0000054917655,0.000005663338,0.000014433435,0.00006377215],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98589355,0.011213317,0.0022816083,0.0002478197,0.00010214862,0.00026154466],"domain_scores_gemma":[0.99344695,0.0034630117,0.0026722979,0.00020366083,0.00014003398,0.00007405996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003824369,0.00029254155,0.005685289,0.00087122596,0.00004790402,0.0000042003444,0.0003303516,0.0002443789,0.000048819024],"category_scores_gemma":[0.0015706295,0.00014847858,0.00071558426,0.00038113128,0.00028781575,0.000056149394,0.00011258619,0.00034903677,0.0000059750028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56041175,0.00037498292,0.4130136,0.000038983613,0.018966533,0.0000033346632,0.00086346734,0.0014778608,0.0031226114,0.0005141731,0.000085479405,0.0011272262],"study_design_scores_gemma":[0.37154734,0.00043155823,0.6196941,0.00012571372,0.005595491,0.0000551719,0.000060432445,0.000016563736,0.0021917464,0.00011427551,0.000012423647,0.00015515796],"about_ca_topic_score_codex":0.00002522487,"about_ca_topic_score_gemma":0.000006621334,"teacher_disagreement_score":0.20668052,"about_ca_system_score_codex":0.000019442201,"about_ca_system_score_gemma":0.000074986696,"threshold_uncertainty_score":0.60547805},"labels":[],"label_agreement":null},{"id":"W2967315338","doi":"10.1016/j.jaad.2019.08.019","title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"LEO Pharma; Galderma; Dermira; Celgene; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Plaque psoriasis; Apremilast; Pharmacokinetics; Open label; Dermatology; Psoriasis; Adverse effect; Internal medicine","score_opus":0.017765955687691102,"score_gpt":0.29055889634609977,"score_spread":0.27279294065840864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967315338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973405,0.0004151584,0.0000070219585,0.0010107342,0.00018918153,0.0006577415,0.00032348867,0.0000031106078,0.000053075786],"genre_scores_gemma":[0.9990506,0.0003197191,0.0003149177,0.00023476577,0.0000197554,0.0000055863966,0.000008686329,0.0000144638925,0.00003148308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979301,0.00060045975,0.00091268617,0.00023299926,0.00009218441,0.00023158769],"domain_scores_gemma":[0.9977384,0.0003782438,0.0015880032,0.00016708304,0.00008394589,0.000044273576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019993035,0.00020141694,0.00095382775,0.00023125517,0.00004390591,0.0000057576895,0.00061980507,0.00010667251,0.000013653667],"category_scores_gemma":[0.000058493224,0.00012990751,0.000049896276,0.00037907416,0.00014529865,0.0001174268,0.00024665095,0.00036233405,0.0000061188675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07583594,0.0049516796,0.8937401,0.000030208153,0.0012871816,0.00001956322,0.0028338418,0.00024578543,0.010791794,0.000012307327,0.001336348,0.008915224],"study_design_scores_gemma":[0.15184839,0.0037703966,0.81950724,0.00014846801,0.0011755337,0.00029225732,0.0011561196,0.00002360616,0.02072893,0.00006920536,0.0008999486,0.00037990735],"about_ca_topic_score_codex":0.00006345438,"about_ca_topic_score_gemma":0.0000103816155,"teacher_disagreement_score":0.07601244,"about_ca_system_score_codex":0.000028593146,"about_ca_system_score_gemma":0.00008644244,"threshold_uncertainty_score":0.5297475},"labels":[],"label_agreement":null},{"id":"W2967449819","doi":"10.1016/s0140-6736(19)31773-8","title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":376,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Medicine; Clinical endpoint; Psoriasis Area and Severity Index; Internal medicine; Clinical trial; Psoriasis; Population; Randomized controlled trial; Psoriatic arthritis; Dermatology","score_opus":0.044237769727574365,"score_gpt":0.2942113505826859,"score_spread":0.2499735808551115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967449819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807888,0.0016018429,0.000036564936,0.0011290566,0.0047736755,0.007431362,0.00281683,0.000047829162,0.0013740064],"genre_scores_gemma":[0.9923406,0.00056451664,0.00008300025,0.00011174089,0.001655953,0.0015335467,0.0005717196,0.000025408057,0.0031135196],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982818,0.00039562822,0.00051111775,0.00036120275,0.00006189946,0.00038835144],"domain_scores_gemma":[0.9936801,0.004971818,0.00028340876,0.0009690486,0.00007218593,0.000023428489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000471146,0.0002869302,0.0012659876,0.000042945747,0.00021958223,0.000024334839,0.000423056,0.00017915742,0.00041499562],"category_scores_gemma":[0.00022592493,0.00013699157,0.0004656639,0.00009748686,0.00006546464,0.00003684929,0.000025550067,0.00007597786,0.0002879253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9621215,0.00072700024,0.0000044239696,0.0000034010084,0.0035471213,0.0000010919498,0.0024035757,0.00009192483,0.0039924695,0.00010729419,0.0070342007,0.019965997],"study_design_scores_gemma":[0.9259526,0.004029991,0.000027441272,0.000012798778,0.0012684277,0.0000012844216,0.00022255848,0.000092505565,0.015785966,0.00014952841,0.05229895,0.00015794343],"about_ca_topic_score_codex":0.00016315664,"about_ca_topic_score_gemma":0.000071617695,"teacher_disagreement_score":0.04526475,"about_ca_system_score_codex":0.00006406239,"about_ca_system_score_gemma":0.00008029446,"threshold_uncertainty_score":0.5586354},"labels":[],"label_agreement":null},{"id":"W2968595293","doi":"10.14302/issn.2470-5020.jnrt-19-2797","title":"Ultraviolet B Phototherapy Intervention in Patients with Multiple Sclerosis: A Prospective, Randomized Pilot Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Neurological Research And Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; University of Ottawa","funders":"","keywords":"Medicine; Vitamin D and neurology; Randomized controlled trial; Ultraviolet b; Internal medicine; FOXP3; Gastroenterology; Vitamin; Placebo; Immunology; Pathology; Dermatology; Immune system","score_opus":0.059894824227198704,"score_gpt":0.29813789774451455,"score_spread":0.23824307351731583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968595293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955098,0.002504821,0.000005536583,0.00010410128,0.00020925241,0.0015960167,0.0000053120807,0.000007423628,0.000057749698],"genre_scores_gemma":[0.9971536,0.0025362044,0.000022954026,0.00006667979,0.00003292042,0.000061597704,0.0000057465313,0.000010815955,0.000109498484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744946,0.0014470431,0.00040542096,0.0002242564,0.00015580833,0.00031800108],"domain_scores_gemma":[0.9984086,0.0010173144,0.00019373457,0.00011906477,0.00021921463,0.00004206286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016592673,0.00014489617,0.0005660348,0.0002488277,0.00007239413,0.00003135216,0.00016935133,0.00011990416,0.0002526523],"category_scores_gemma":[0.0001975552,0.000076414435,0.00013317223,0.00018657224,0.00024656733,0.00011544618,0.000020692118,0.0005274241,0.00001909156],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7752925,0.002317636,0.1963939,0.000002777418,0.0001851554,0.000007735906,0.00006271828,7.3596357e-7,0.008276662,0.000029584811,0.000015675909,0.017414916],"study_design_scores_gemma":[0.6113179,0.04031959,0.34598094,0.000034476514,0.0000070999413,0.0000062051918,0.000012655403,0.0000012968469,0.0016712346,0.00042626643,0.00016195263,0.00006041729],"about_ca_topic_score_codex":0.000019034092,"about_ca_topic_score_gemma":0.0000052557953,"teacher_disagreement_score":0.16397466,"about_ca_system_score_codex":0.000017964825,"about_ca_system_score_gemma":0.000029255229,"threshold_uncertainty_score":0.31160903},"labels":[],"label_agreement":null},{"id":"W2968760378","doi":"10.1177/2475530319867095","title":"Ixekizumab—An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P","year":2019,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Secukinumab; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology","score_opus":0.008997813675163136,"score_gpt":0.2217314020076513,"score_spread":0.21273358833248815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968760378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930628,0.0025142422,0.000051563275,0.00014592735,0.0009329546,0.0019970078,0.0011118866,0.000022041035,0.00016156975],"genre_scores_gemma":[0.99618626,0.0013408306,0.0011919752,0.00008739697,0.00038078785,0.00014524968,0.00021290939,0.000062290856,0.00039231442],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99719167,0.00045798463,0.0010203959,0.0006588892,0.00014138939,0.00052966626],"domain_scores_gemma":[0.9978687,0.0006880772,0.00065076014,0.0003520325,0.00026416828,0.00017626546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047955217,0.0005491029,0.0012370424,0.00033970762,0.00018954548,0.000086524655,0.00015330913,0.00038057033,0.000097730386],"category_scores_gemma":[0.00011742632,0.0003991832,0.00017500634,0.00020524822,0.00007453166,0.00041999735,0.000036165326,0.00018649029,0.000028046763],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050555285,0.0018132786,0.053788964,0.00004541022,0.0025603028,0.000034109744,0.009556397,0.00017924009,0.0009597837,0.00009226473,0.0012174032,0.87919754],"study_design_scores_gemma":[0.3867499,0.07590477,0.4494081,0.003706865,0.0029908814,0.0002819125,0.0029818944,0.00012326328,0.02851916,0.0015313381,0.044821482,0.0029804155],"about_ca_topic_score_codex":0.0007512447,"about_ca_topic_score_gemma":0.0008511133,"teacher_disagreement_score":0.8762171,"about_ca_system_score_codex":0.0002025722,"about_ca_system_score_gemma":0.0000986171,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W2969285496","doi":"10.1016/j.jid.2020.03.515","title":"506 Predicting the long-term outcomes of biologics in psoriasis patients using machine learning","year":2020,"lang":"en","type":"preprint","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates; University of Alberta","keywords":"Psoriasis; Discontinuation; Medicine; Machine learning; Psoriatic arthritis; Adverse effect; Artificial intelligence; Internal medicine; Algorithm; Computer science; Dermatology","score_opus":0.06414379770166938,"score_gpt":0.28867858520595213,"score_spread":0.22453478750428274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969285496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224293,0.004552041,0.00007586753,0.0009859541,0.0016201136,0.000343268,0.00011043929,0.000018102344,0.000051286523],"genre_scores_gemma":[0.9986147,0.00036112024,0.00057676475,0.00019566127,0.000058526108,0.000009579347,0.00013772395,0.000028504966,0.000017392078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956342,0.0019890636,0.001567429,0.00033109952,0.00010372185,0.00037447023],"domain_scores_gemma":[0.99535614,0.0008756572,0.0031070372,0.0002456197,0.0003591398,0.000056430254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004486591,0.00045759795,0.0015718496,0.0003785938,0.00012979581,0.000015020754,0.00065054203,0.00076052366,0.000033849425],"category_scores_gemma":[0.0016303151,0.000294441,0.00042546194,0.00023787889,0.000774461,0.000091314716,0.00056075555,0.0018586369,0.000009166341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019478927,0.00017046885,0.978576,0.00012289023,0.0015552798,0.000098004544,0.0023455746,0.0002750894,0.015851002,0.00008179248,0.000054182456,0.0006749277],"study_design_scores_gemma":[0.0033041607,0.0003657966,0.8685978,0.0004270767,0.0008233813,0.00039065705,0.00039007203,0.000097482494,0.123751625,0.0014544118,0.000063190484,0.00033433666],"about_ca_topic_score_codex":0.00012061485,"about_ca_topic_score_gemma":0.00005234272,"teacher_disagreement_score":0.10997819,"about_ca_system_score_codex":0.00011338744,"about_ca_system_score_gemma":0.0003539226,"threshold_uncertainty_score":0.99995077},"labels":[],"label_agreement":null},{"id":"W2969477362","doi":"10.1016/j.jid.2019.06.116","title":"LB1143 New insights into the role of T cells in psoriasis: Identification of multi-cytokine producing T cell subsets and a skewed relative contribution of IL17A production by tissue resident CD103+CD8+ T cells","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"CD8; Immunology; Cytokine; Pathogenesis; Population; Biology; Flow cytometry; T cell; Immunophenotyping; Psoriasis; Inflammation; Antigen; Medicine; Immune system","score_opus":0.009195930242590897,"score_gpt":0.22529549886000924,"score_spread":0.21609956861741836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969477362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98571575,0.012471847,0.00009934904,0.00047982988,0.00055854284,0.0006332198,0.000020241438,0.000004886675,0.00001632067],"genre_scores_gemma":[0.99863666,0.00073059084,0.00031602345,0.00001562818,0.000023934736,0.000009284143,0.000032172742,0.000012914004,0.00022277056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970586,0.0010279659,0.0013312533,0.00028435618,0.000102257785,0.00019556699],"domain_scores_gemma":[0.9964121,0.00030171397,0.0024167777,0.00026345393,0.00056610705,0.000039877603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005739888,0.00021301808,0.0007514711,0.00033205736,0.00006432304,0.000005388375,0.00020297123,0.00027197474,0.000015497559],"category_scores_gemma":[0.00034973308,0.00015699054,0.00009025916,0.00034342334,0.00050547393,0.00029169896,0.00005138435,0.00029678878,0.000012908175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003849032,0.00022201797,0.0064368066,0.000080063845,0.00025198152,0.0000034890572,0.019613558,0.00006515466,0.97174317,0.00022935709,0.000414025,0.0005554759],"study_design_scores_gemma":[0.0026873508,0.0002942082,0.013723844,0.00016909529,0.00021529003,0.00006258687,0.0017093641,0.000014895546,0.978588,0.0018495251,0.0005674757,0.000118392105],"about_ca_topic_score_codex":0.00030683848,"about_ca_topic_score_gemma":0.00009034611,"teacher_disagreement_score":0.017904194,"about_ca_system_score_codex":0.000069621805,"about_ca_system_score_gemma":0.0002302033,"threshold_uncertainty_score":0.6401889},"labels":[],"label_agreement":null},{"id":"W2969965480","doi":"10.1016/j.jtauto.2019.100009","title":"The skin microbiome in psoriatic disease: A systematic review and critical appraisal","year":2019,"lang":"en","type":"review","venue":"Journal of Translational Autoimmunity","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Krembil Foundation","keywords":"Psoriasis; Microbiome; Medicine; Psoriatic arthritis; Dermatology; Population; Bioinformatics; Biology; Environmental health","score_opus":0.03634083989992297,"score_gpt":0.3364278534957109,"score_spread":0.30008701359578793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969965480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021328186,0.99728423,0.000015001908,0.00044429768,0.0010726515,0.00094081287,0.00019222761,0.000007352627,0.00002212174],"genre_scores_gemma":[0.000258533,0.99922186,0.000042183143,0.000032322125,0.00003967066,0.00005513997,0.00013924552,0.000025532607,0.00018553833],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9954327,0.0022087297,0.0017909505,0.00018016702,0.00011015793,0.0002772979],"domain_scores_gemma":[0.9922244,0.006385544,0.0008450587,0.00035947183,0.00014219931,0.00004333379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018277217,0.00038913309,0.0026709992,0.00023871852,0.00021299775,0.000041963754,0.00050559826,0.00028419902,0.00007919598],"category_scores_gemma":[0.00093658373,0.00022229987,0.0007817566,0.0002826165,0.00021513278,0.00013523211,0.000039940704,0.0007893747,0.00009131982],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007177166,0.00028524865,0.000009554136,0.89008486,0.0019870931,0.000025223942,0.00013391674,4.529534e-7,0.0000046505966,0.00084752537,0.00025446268,0.106295235],"study_design_scores_gemma":[0.0013578669,0.00013740221,0.00082769926,0.54908365,0.029241145,0.0013515478,0.000029778561,0.0000011615764,6.805151e-7,0.00023560828,0.41724032,0.0004931031],"about_ca_topic_score_codex":0.0000046685527,"about_ca_topic_score_gemma":0.0000042691922,"teacher_disagreement_score":0.41698587,"about_ca_system_score_codex":0.00006888616,"about_ca_system_score_gemma":0.00054822187,"threshold_uncertainty_score":0.9065126},"labels":[],"label_agreement":null},{"id":"W2970968550","doi":"10.1093/ecco-jcc/jjz152","title":"Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Journal of Crohn s and Colitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Inflammatory bowel disease; Psoriasis; Meta-analysis; Association (psychology); Dermatology; Disease; Crohn's disease; Ulcerative colitis; Internal medicine; Ustekinumab; Gastroenterology; Infliximab","score_opus":0.03639815084768477,"score_gpt":0.2972688450430621,"score_spread":0.26087069419537734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970968550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009389889,0.9967429,0.0000032741139,0.0000777625,0.00014208867,0.0007922966,0.001257983,0.0000073223227,0.000037367416],"genre_scores_gemma":[0.00070199696,0.9973224,0.000014973049,0.00005190362,0.000060592964,0.000060597682,0.00004982288,0.000012543337,0.0017251924],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99727815,0.0009431061,0.001110152,0.0003219548,0.00012860059,0.00021803728],"domain_scores_gemma":[0.99711066,0.00058066915,0.0018256087,0.00018769571,0.00018444781,0.00011089722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010323204,0.0003868522,0.004518115,0.00020048271,0.00014768334,0.00008160623,0.00011607083,0.00033538736,0.000105932966],"category_scores_gemma":[0.00020267974,0.00025792373,0.0009977933,0.00020973275,0.00007962228,0.00016492255,0.00007651006,0.00018847531,0.000006900426],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006296447,0.000038006845,0.008111608,0.6674646,0.3085796,0.000029799632,0.000030423378,5.482687e-8,3.481215e-8,0.0001265424,0.00049386953,0.015062445],"study_design_scores_gemma":[0.00027928548,0.00006610999,0.09651037,0.012714259,0.8640459,0.00022674234,0.0000058129604,6.454589e-8,1.0704369e-7,0.000047153615,0.02587624,0.00022792563],"about_ca_topic_score_codex":0.000010443389,"about_ca_topic_score_gemma":0.000008439717,"teacher_disagreement_score":0.6547504,"about_ca_system_score_codex":0.00012060213,"about_ca_system_score_gemma":0.00015124727,"threshold_uncertainty_score":0.9999873},"labels":[],"label_agreement":null},{"id":"W2971667944","doi":"10.1080/1744666x.2019.1648209","title":"An update on generalized pustular psoriasis","year":2019,"lang":"en","type":"review","venue":"Expert Review of Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":221,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Psoriasis; Disease; Formulary; Intensive care medicine; Expert opinion; Dermatology; Internal medicine; Pharmacology","score_opus":0.1149739117403291,"score_gpt":0.4475590101992837,"score_spread":0.33258509845895456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971667944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003477031,0.98601586,0.000008716279,0.00015349797,0.010588844,0.001980593,0.00022847252,0.000120424986,0.00086879585],"genre_scores_gemma":[0.0000028640645,0.99186397,0.00035928018,0.0016590757,0.0005238249,0.00046179062,0.003521321,0.00014071287,0.0014671856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857102,0.0070235454,0.004821872,0.0015183366,0.00012581145,0.0008002075],"domain_scores_gemma":[0.9920042,0.0017428844,0.0027603144,0.0031948264,0.00021382369,0.00008396507],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022034687,0.0012086945,0.011294397,0.00031059494,0.00012558154,0.000013377605,0.0018183979,0.0027428083,0.0042530606],"category_scores_gemma":[0.00094996096,0.0008332799,0.0039946334,0.0004185154,0.0005622214,0.00011513573,0.0002673608,0.001272617,0.009418736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016704622,0.0009114944,0.000004219125,0.013004914,0.0049614566,0.000019020357,0.000013872757,2.9305173e-8,0.000022727756,0.00083882536,0.012905967,0.96715045],"study_design_scores_gemma":[0.0018304865,0.0013208098,0.000012282072,0.046415318,0.003912727,0.00008542314,0.0000054315656,7.947472e-8,0.000060296905,0.000020259055,0.9456372,0.00069967174],"about_ca_topic_score_codex":0.000036596983,"about_ca_topic_score_gemma":0.0000021761682,"teacher_disagreement_score":0.96645075,"about_ca_system_score_codex":0.00007634246,"about_ca_system_score_gemma":0.00056408683,"threshold_uncertainty_score":0.9994118},"labels":[],"label_agreement":null},{"id":"W2971816470","doi":"10.1111/bjd.18484","title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Merck","keywords":"Dosing; Etanercept; Medicine; Plaque psoriasis; Psoriasis; Pharmacology; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.02410772837681473,"score_gpt":0.2871277570869232,"score_spread":0.26302002871010843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971816470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963687,0.034112222,0.00013698157,0.00019506115,0.0005623397,0.00048811964,0.0007757439,0.000013209724,0.000029303606],"genre_scores_gemma":[0.9910905,0.0076695555,0.0007811476,0.00003998368,0.000052056886,0.000012198889,0.0002502358,0.000019920135,0.000084428284],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982743,0.00024241692,0.000853932,0.00032576767,0.00004872398,0.00025481603],"domain_scores_gemma":[0.9979986,0.0008439984,0.0007842852,0.00015626576,0.00016863398,0.00004820423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011456613,0.00025042414,0.0011059911,0.00011535868,0.00014624425,0.000023093437,0.000114811395,0.00022294828,0.000040084884],"category_scores_gemma":[0.00007790023,0.00020832379,0.00010903884,0.00004993716,0.00016449513,0.00015657069,0.000046414385,0.00014211934,0.0000045611623],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.099534,0.0021370891,0.015044612,0.00007759706,0.015265382,0.0013995791,0.012972511,0.000007783305,0.060545165,0.00005285207,0.0011826435,0.79178077],"study_design_scores_gemma":[0.69497657,0.010747732,0.10040578,0.0039059923,0.0072366963,0.055424314,0.011643842,0.000026604845,0.101244934,0.0005321326,0.012638388,0.0012170081],"about_ca_topic_score_codex":0.00045247466,"about_ca_topic_score_gemma":0.00024407676,"teacher_disagreement_score":0.79056376,"about_ca_system_score_codex":0.000059593956,"about_ca_system_score_gemma":0.00006910248,"threshold_uncertainty_score":0.8495198},"labels":[],"label_agreement":null},{"id":"W2971827843","doi":"10.1111/bjd.18483","title":"Weight change in patients with psoriasis using tumour necrosis factor‐α inhibitors","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto; Memorial University of Newfoundland; McGill University","funders":"","keywords":"Psoriasis; Medicine; Necrosis; Tumor necrosis factor alpha; Dermatology; Internal medicine","score_opus":0.013307073982252402,"score_gpt":0.21876449199317632,"score_spread":0.20545741801092393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971827843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941791,0.0036812855,0.000007341869,0.000090878784,0.0016509732,0.0002465797,0.000044204906,0.000012585202,0.00008701219],"genre_scores_gemma":[0.99939114,0.00020743441,0.0001451606,0.00008790142,0.00006164276,0.0000051842285,0.000027660375,0.000025844616,0.0000480119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984739,0.00027309012,0.00055440876,0.00020900833,0.000075196345,0.00041442591],"domain_scores_gemma":[0.9991557,0.00007945643,0.00044302706,0.00012068286,0.00015806091,0.00004309783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007578322,0.00019967204,0.00062989176,0.00029629876,0.000080769016,0.000023325549,0.000202756,0.0002914845,0.00039333792],"category_scores_gemma":[0.000024228213,0.00018765643,0.00013439392,0.00021397385,0.000077762255,0.00033808575,0.00004558377,0.00030947654,0.00008919642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000433618,0.00032806155,0.9708304,0.000018441528,0.00023826318,0.00044844218,0.00029398475,0.0000013033069,0.0024446268,0.000008640204,0.00023698017,0.024717258],"study_design_scores_gemma":[0.010812929,0.0002945645,0.9632912,0.00034485653,0.00012765288,0.008675241,0.00006950413,0.0000013485453,0.014635296,0.000019227633,0.0014509755,0.00027717577],"about_ca_topic_score_codex":0.00024402105,"about_ca_topic_score_gemma":0.00011351581,"teacher_disagreement_score":0.024440082,"about_ca_system_score_codex":0.000077362805,"about_ca_system_score_gemma":0.00008377987,"threshold_uncertainty_score":0.7652407},"labels":[],"label_agreement":null},{"id":"W2971831426","doi":"10.1016/j.jid.2019.07.051","title":"048 Effects on CD3, Treg and TH17 cell numbers in skin biopsies after 16-week mirikizumab treatment, evaluated by an epigenetic assay","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Medicine; Interleukin 17; CD3; Immunology; Cytokine; Skin biopsy; Erythema; Psoriasis Area and Severity Index; T cell; Biopsy; Internal medicine; Gastroenterology; Immune system; CD8","score_opus":0.013169079394372247,"score_gpt":0.24170725671051818,"score_spread":0.22853817731614592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971831426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907356,0.007153522,0.0000060031184,0.0005642131,0.00048318418,0.00038068456,0.00004124424,0.000014433876,0.0006211241],"genre_scores_gemma":[0.99821883,0.0003947961,0.00010503935,0.0004151187,0.000024447503,0.000036003825,0.000068114954,0.000028196502,0.0007094535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99665296,0.0019076911,0.00057767576,0.0003524031,0.00007336428,0.0004359133],"domain_scores_gemma":[0.99835455,0.00071832136,0.0004894457,0.00022902497,0.00010128885,0.00010735891],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002606207,0.00039568043,0.0008563345,0.0003677296,0.000077535355,0.000019728795,0.00017384918,0.0004010245,0.00020176564],"category_scores_gemma":[0.00008462626,0.0002951996,0.00014897707,0.00019634487,0.00040296535,0.00017866645,0.000028995662,0.000288816,0.00021662175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049471613,0.0026952883,0.2036096,0.00017757296,0.0019718076,0.0010074128,0.009127003,0.00003180188,0.7512393,0.00012569188,0.0066479053,0.018419474],"study_design_scores_gemma":[0.008751101,0.0032396838,0.10467341,0.000119235265,0.0002903865,0.0009336623,0.0005147548,0.000011321804,0.87804854,0.0004956572,0.0026155359,0.00030671415],"about_ca_topic_score_codex":0.00010395132,"about_ca_topic_score_gemma":0.00014831028,"teacher_disagreement_score":0.12680925,"about_ca_system_score_codex":0.0001829463,"about_ca_system_score_gemma":0.00017628627,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W2971873891","doi":"10.1186/s12876-019-1067-0","title":"Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report","year":2019,"lang":"en","type":"article","venue":"BMC Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary","funders":"","keywords":"Medicine; Ixekizumab; Plaque psoriasis; Psoriasis; Hepatology; Ustekinumab; Interleukin 23; Blockade; Interleukin 17; Internal medicine; Interleukin; Disease; Immunology; Gastroenterology; Dermatology; Adalimumab; Inflammation; Cytokine; Psoriatic arthritis; Secukinumab","score_opus":0.016614371761332607,"score_gpt":0.24133361104735696,"score_spread":0.22471923928602436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971873891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931738,0.0014919232,0.00035812415,0.0002992845,0.0018659986,0.0024674835,0.00028744582,0.00003965967,0.000016285976],"genre_scores_gemma":[0.99725986,0.000074905736,0.00017277838,0.00014054586,0.000083190964,0.0011904761,0.00016151828,0.000035219666,0.00088150444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975225,0.00028525345,0.00072933704,0.0006706702,0.000050669565,0.0007416164],"domain_scores_gemma":[0.9983582,0.00032420727,0.000307335,0.00085693796,0.00007265962,0.00008064831],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015954959,0.0003883173,0.0006892978,0.00023665829,0.000107213775,0.000010783177,0.00024291084,0.00017793165,0.00020480303],"category_scores_gemma":[0.00003668907,0.00027593196,0.00037719775,0.00011376967,0.00011705895,0.0000478894,0.00007587432,0.000092328075,0.000080889324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057420168,0.00925135,0.8221977,0.00026982545,0.0032155488,0.028384654,0.0065101166,0.0030433561,0.04290642,0.00006747028,0.003301473,0.023431916],"study_design_scores_gemma":[0.07093243,0.05684913,0.7200248,0.00036303594,0.002673608,0.032776754,0.0027109785,0.0005645447,0.04828252,0.00006905906,0.06355327,0.0011998209],"about_ca_topic_score_codex":0.00020672315,"about_ca_topic_score_gemma":0.0027755427,"teacher_disagreement_score":0.10217286,"about_ca_system_score_codex":0.0003114675,"about_ca_system_score_gemma":0.00014538843,"threshold_uncertainty_score":0.9999693},"labels":[],"label_agreement":null},{"id":"W2972256509","doi":"10.1007/s40257-019-00466-2","title":"Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study","year":2019,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bausch Health; Ortho Dermatologics; AstraZeneca; Amgen","keywords":"Medicine; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Tolerability; Psoriasis; Adverse effect; Internal medicine; Quality of life (healthcare); Dermatology","score_opus":0.025764928863366485,"score_gpt":0.3379926812463918,"score_spread":0.3122277523830253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972256509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738574,0.00006549243,0.000022106708,0.00031099305,0.00023524334,0.0019070483,0.000043153334,0.000010806117,0.000019402098],"genre_scores_gemma":[0.99916786,0.000034566154,0.00033107572,0.00028597706,0.0000071493178,0.00004150311,0.000049527534,0.00003331168,0.000049008377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965045,0.00077935646,0.0017023874,0.0004869931,0.00009276719,0.00043402787],"domain_scores_gemma":[0.9972428,0.001003583,0.0011267794,0.00032802467,0.00018890214,0.000109888504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034295654,0.00031766813,0.0020636448,0.00033220925,0.00007507661,0.000021409667,0.00033497054,0.00017512201,0.000033302877],"category_scores_gemma":[0.00017595197,0.00021808122,0.000081511964,0.00034806883,0.00023777808,0.00017844411,0.00014472292,0.00035458637,0.000011562244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08350902,0.009490399,0.80671537,0.0000050995804,0.0011485692,0.00027100486,0.000515755,0.000018623852,0.000014000978,0.000004317437,0.00002769722,0.09828017],"study_design_scores_gemma":[0.13673307,0.039493192,0.82250106,0.00008140373,0.0002644208,0.00025152002,0.00026595738,0.0000026190655,0.000040590916,0.0000035190712,0.00011781753,0.00024480213],"about_ca_topic_score_codex":0.000115559735,"about_ca_topic_score_gemma":0.0002692518,"teacher_disagreement_score":0.098035365,"about_ca_system_score_codex":0.000044768534,"about_ca_system_score_gemma":0.00021688832,"threshold_uncertainty_score":0.8893094},"labels":[],"label_agreement":null},{"id":"W2973074546","doi":"10.1111/bjd.18515","title":"Musculoskeletal ultrasound can improve referrals from dermatology to rheumatology for patients with psoriasis","year":2019,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Rheumatology; Psoriasis; Medicine; Dermatology; Ultrasound; Internal medicine; Medical physics; Radiology","score_opus":0.008778593186146955,"score_gpt":0.22375239530891752,"score_spread":0.21497380212277056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973074546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86898535,0.009019347,0.0004647792,0.09952508,0.013034633,0.002318464,0.006361222,0.00009814728,0.00019296464],"genre_scores_gemma":[0.79834205,0.002789638,0.004378275,0.16777812,0.0021006118,0.00063667377,0.020471128,0.0007687158,0.0027347982],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944853,0.0010257389,0.0018710574,0.00096836395,0.00019180085,0.001457719],"domain_scores_gemma":[0.9939018,0.0024710798,0.0019107299,0.00065536203,0.0009480773,0.00011296332],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00014105796,0.00090889854,0.0032074733,0.00063277234,0.00030238455,0.00008182362,0.0011204459,0.003290529,0.00040270574],"category_scores_gemma":[0.00057054334,0.0008810243,0.00080046465,0.00023899053,0.00035578723,0.00019393592,0.0001365948,0.0020391701,0.00030044554],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013472275,0.00036358854,0.022990342,0.00029109462,0.004963053,0.0031185262,0.00021110209,0.0000010061896,0.0005312264,0.000018373123,0.9498725,0.016291995],"study_design_scores_gemma":[0.020644682,0.0016993723,0.008539402,0.00071422826,0.0027907775,0.10482419,0.00013518558,2.2586592e-7,0.0032436454,0.00030506548,0.855498,0.0016051834],"about_ca_topic_score_codex":0.000493462,"about_ca_topic_score_gemma":0.00041344218,"teacher_disagreement_score":0.10170566,"about_ca_system_score_codex":0.00017777545,"about_ca_system_score_gemma":0.0006088392,"threshold_uncertainty_score":0.999364},"labels":[],"label_agreement":null},{"id":"W2973201597","doi":"10.1136/postgradmedj-2019-136766","title":"Seasonality and global public interest in psoriasis: an infodemiology study","year":2019,"lang":"en","type":"article","venue":"Postgraduate Medical Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Medicine; Seasonality; Psoriatic arthritis; Dermatology; Atopic dermatitis; Ecology","score_opus":0.05858888522888673,"score_gpt":0.3094643967885149,"score_spread":0.2508755115596282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973201597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919934,0.0019113125,0.000014525389,0.0038888955,0.001599246,0.00026284272,0.000021464642,0.0000355005,0.00027279303],"genre_scores_gemma":[0.9989512,0.00028031584,0.000028409851,0.00046478084,0.00012130736,0.00001134693,0.000038183487,0.000010510388,0.00009397746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690497,0.0014752039,0.00056883384,0.00037284777,0.00011587287,0.00056227116],"domain_scores_gemma":[0.9990508,0.00021336103,0.00016152406,0.00024023849,0.00008673464,0.0002473538],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019441799,0.00024161223,0.00051659433,0.000076474134,0.00012457154,0.00004729428,0.00039425836,0.00034261652,0.0010310503],"category_scores_gemma":[0.00058581657,0.00017881647,0.00008571642,0.00020582683,0.00018287674,0.00023982397,0.00015854738,0.00067170965,0.00030873806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032593252,0.00081344397,0.8937406,0.000006014733,0.00024340671,0.00015897947,0.00030361942,1.17145646e-7,0.00012919829,0.0008426811,0.0002143586,0.10322166],"study_design_scores_gemma":[0.006666013,0.0011758168,0.98535836,0.00004368317,0.000075895434,0.002132445,0.0009786192,0.000013505671,0.000025314817,0.0014746257,0.0018473282,0.00020836602],"about_ca_topic_score_codex":0.0001179827,"about_ca_topic_score_gemma":0.001014564,"teacher_disagreement_score":0.1030133,"about_ca_system_score_codex":0.00010871017,"about_ca_system_score_gemma":0.00023852388,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W2975335591","doi":"10.1016/j.ejwf.2019.06.001","title":"Interleukin 17 (IL-17) and interleukin 23 (IL-23) levels are modulated by compressive orthodontic forces in humans","year":2019,"lang":"en","type":"article","venue":"Journal of the World Federation of Orthodontists","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"Medicine; Interleukin 1β; Periodontal fiber; Interleukin; Compression (physics); Dentistry; Orthodontics; Internal medicine; Cytokine; Materials science; Composite material","score_opus":0.020469800865634716,"score_gpt":0.26005095774745596,"score_spread":0.23958115688182124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975335591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951679,0.0020200827,0.00023263939,0.00052097323,0.0011047288,0.00034195677,0.00008223316,0.000010383152,0.00051908003],"genre_scores_gemma":[0.97914183,0.0000633123,0.00032926205,0.0001171832,0.000040345316,0.0000056034805,0.00004901883,0.000020279042,0.020233167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792796,0.0005405866,0.00091980956,0.00024473906,0.00011091783,0.0002559902],"domain_scores_gemma":[0.99801034,0.0002583441,0.0012500959,0.00026738094,0.00017974166,0.00003410934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057747203,0.0002626082,0.00068848085,0.00029257667,0.00017015338,0.00006838153,0.0003154522,0.00017086018,0.0002560693],"category_scores_gemma":[0.00007064719,0.00018723254,0.00023218455,0.00020110872,0.00011262501,0.00028938497,0.0001020831,0.00034707817,0.000015668295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001154131,0.00038562223,0.5036119,0.000089510475,0.0009197097,0.000042248124,0.0016272111,0.00035382487,0.46378902,0.00024034156,0.0222635,0.0055229547],"study_design_scores_gemma":[0.006160432,0.0004753091,0.8492031,0.0011021509,0.00025549185,0.00023317886,0.00044173794,0.000084685475,0.13005778,0.00020767683,0.01138535,0.00039311041],"about_ca_topic_score_codex":0.000040790328,"about_ca_topic_score_gemma":0.0025939927,"teacher_disagreement_score":0.34559116,"about_ca_system_score_codex":0.00009154009,"about_ca_system_score_gemma":0.00005201947,"threshold_uncertainty_score":0.76351213},"labels":[],"label_agreement":null},{"id":"W2976695332","doi":"10.1016/j.jaad.2019.09.042","title":"Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","year":2019,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Merck Sharp and Dohme; Janssen Research and Development; National Institutes of Health; LEO Pharma; Novartis; Valeant Pharmaceuticals International; XBiotech; AbbVie; MedImmune; Merck; School of Public Health, University of California Berkeley; Pfizer; Boehringer Ingelheim; Amgen; UCB; Celgene; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Post-hoc analysis; Post hoc; Psoriasis; Randomized controlled trial; Internal medicine; Dermatology; Physical therapy","score_opus":0.010384056074275607,"score_gpt":0.27071767305180844,"score_spread":0.2603336169775328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976695332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9061743,0.05141849,0.0000031774116,0.04011544,0.00026602737,0.0011049225,0.00090789865,0.000006062603,0.0000036989463],"genre_scores_gemma":[0.9753113,0.013587907,0.00008284686,0.010738422,0.000026206666,0.000023502684,0.00008304232,0.000040207422,0.00010660076],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99273205,0.0038574638,0.0021935403,0.0004371901,0.00023637046,0.000543394],"domain_scores_gemma":[0.9871927,0.004050108,0.008139616,0.0003127502,0.00026249245,0.0000423182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006606777,0.000614094,0.010018814,0.0009782908,0.000091720605,0.000009645936,0.00049537135,0.000578947,0.000016401587],"category_scores_gemma":[0.0005567389,0.00034619772,0.0007613125,0.0006582408,0.0018592617,0.00011111278,0.00016416691,0.0013262857,0.0000018254066],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80536294,0.00081586646,0.028812673,0.0002596083,0.1351712,0.00008044338,0.0011079233,0.00006854301,0.0018281034,0.000008509216,0.02478394,0.0017002173],"study_design_scores_gemma":[0.81878924,0.001513228,0.11812891,0.0005660166,0.048412047,0.0006785126,0.0004951318,0.000007907387,0.0013871876,0.000013795395,0.009359175,0.00064884895],"about_ca_topic_score_codex":0.000056380504,"about_ca_topic_score_gemma":0.0000047965423,"teacher_disagreement_score":0.089316234,"about_ca_system_score_codex":0.000058689282,"about_ca_system_score_gemma":0.0001206844,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W2977074918","doi":"","title":"Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.","year":2016,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Dermatology; Scalp; Medicine; Secukinumab; Nail (fastener); Psoriasis; Alopecia areata; Psoriatic arthritis; Materials science","score_opus":0.019456200542946035,"score_gpt":0.207331633858473,"score_spread":0.18787543331552697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977074918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122864,0.0065440247,0.000003079977,0.00045024152,0.00033647625,0.00055221526,0.00006646447,0.00001641057,0.0008024289],"genre_scores_gemma":[0.9959191,0.0021214222,0.000007930308,0.000035372886,0.00003597576,0.00083040836,0.000020695124,0.000007664301,0.0010214476],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906844,0.0001935039,0.00019043864,0.00020981283,0.000030517185,0.00030729943],"domain_scores_gemma":[0.99940956,0.00025241735,0.00006442252,0.00024289021,0.000013506982,0.000017209017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020415813,0.00014495885,0.00023887004,0.00008041278,0.00005585854,0.000005746178,0.0001177649,0.00012444303,0.000042453117],"category_scores_gemma":[0.00002198417,0.00006824585,0.00006914453,0.00009118712,0.00012081937,0.000045388097,0.000014427817,0.000027590791,0.000031752243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003458279,0.00046408255,0.06275084,0.000007388409,0.0002589021,0.000021383947,0.000987827,8.078444e-8,0.0019736176,0.00032515792,0.00045912794,0.93240577],"study_design_scores_gemma":[0.005955119,0.00023139283,0.88726443,0.00001201049,0.00015994646,0.000073580784,0.00019065881,5.973909e-8,0.04478975,0.00026867047,0.06091402,0.00014038497],"about_ca_topic_score_codex":0.0000970937,"about_ca_topic_score_gemma":0.00011023187,"teacher_disagreement_score":0.9322654,"about_ca_system_score_codex":0.0000442412,"about_ca_system_score_gemma":0.000011104326,"threshold_uncertainty_score":0.2782985},"labels":[],"label_agreement":null},{"id":"W2978323666","doi":"10.14309/00000434-201610001-00662","title":"A Pooled Safety Analysis from the Ustekinumab Crohnʼs Disease and Psoriatic Diseases Phase 2 and 3 Clinical Trial Programs: 2016 ACG Presidential Poster Award","year":2016,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Psoriasis; Clinical trial; Concomitant; Adverse effect; Safety profile; Internal medicine; Incidence (geometry); MedDRA; Randomized controlled trial; Surgery; Disease; Dermatology; Adalimumab; Pharmacovigilance","score_opus":0.01595760640770261,"score_gpt":0.2904053764797509,"score_spread":0.2744477700720483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978323666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068254,0.0019281269,0.00062989374,0.005279516,0.0006488271,0.000352529,0.00046417554,0.000013045912,0.0000013222614],"genre_scores_gemma":[0.9974161,0.0013914624,0.00003442607,0.0005476881,0.0004581871,0.000017101269,0.00004370175,0.000015291851,0.00007605338],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957758,0.00257377,0.0008451152,0.0003174968,0.00008678755,0.00040101103],"domain_scores_gemma":[0.9970989,0.0011759885,0.0010766477,0.00041139158,0.0000916527,0.00014538594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062712905,0.0002548851,0.0009727701,0.00011600129,0.00020045834,0.000040374103,0.00041559487,0.00006179579,0.00014954449],"category_scores_gemma":[0.00022372368,0.000109569475,0.0005074987,0.00013196998,0.0013824415,0.00011989087,0.00016917243,0.00019903248,0.000012860843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48928243,0.00065239327,0.39435226,0.0000021967267,0.013276502,0.000057444275,0.00019541071,6.661638e-7,0.00029284856,0.0000039943748,0.0006703006,0.10121355],"study_design_scores_gemma":[0.09060296,0.019270683,0.86488694,0.000061279505,0.023187596,0.00013523834,0.0002683046,0.0000055902397,0.000016611242,0.00019452017,0.0012187448,0.00015153152],"about_ca_topic_score_codex":0.00009211216,"about_ca_topic_score_gemma":0.00010467332,"teacher_disagreement_score":0.47053468,"about_ca_system_score_codex":0.000033781325,"about_ca_system_score_gemma":0.000104347986,"threshold_uncertainty_score":0.50936633},"labels":[],"label_agreement":null},{"id":"W2978693937","doi":"10.1080/09546634.2019.1656797","title":"Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry","year":2019,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Psoriasis; Demographics; Internal medicine; Logistic regression; Tumor necrosis factor alpha; Body surface area; Dermatology; Physical therapy; Demography","score_opus":0.034188831077173486,"score_gpt":0.2590051900631193,"score_spread":0.2248163589859458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978693937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963697,0.0001538467,0.00003343334,0.0007516328,0.0005012585,0.0007731715,0.00136538,0.000015429658,0.00003612367],"genre_scores_gemma":[0.9986302,0.0001760665,0.00025336436,0.0002986944,0.000026655482,0.000021591832,0.00043076044,0.000019297257,0.00014333097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789834,0.00045879898,0.0007319681,0.00040634873,0.00017019502,0.00033435388],"domain_scores_gemma":[0.99803627,0.00033255687,0.00068382896,0.000713615,0.00016074623,0.000072957846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015558644,0.000336693,0.0008726467,0.0002080065,0.000099852514,0.00003750373,0.0005601438,0.00011948401,0.00015405627],"category_scores_gemma":[0.000053748296,0.00017520205,0.00012581635,0.0004144666,0.000074005824,0.00018405459,0.00012481521,0.00015019036,0.00007299998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009259192,0.0017099538,0.96774244,0.000008141878,0.0008899373,0.000038803995,0.0014577535,0.0001134134,0.014190488,0.000024751567,0.00019228757,0.0043728333],"study_design_scores_gemma":[0.0058526527,0.0015753458,0.97581005,0.00013189316,0.00019811543,0.00002282105,0.0002739174,0.0000060302423,0.014136456,0.000010442928,0.0017739194,0.00020837737],"about_ca_topic_score_codex":0.00020847018,"about_ca_topic_score_gemma":0.00020936487,"teacher_disagreement_score":0.008067585,"about_ca_system_score_codex":0.0001943346,"about_ca_system_score_gemma":0.00011281502,"threshold_uncertainty_score":0.7144532},"labels":[],"label_agreement":null},{"id":"W2979509394","doi":"10.1016/j.isci.2019.10.008","title":"Skin Patterning in Psoriasis by Spatial Interactions between Pathogenic Cytokines","year":2019,"lang":"en","type":"article","venue":"iScience","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Natural Sciences and Engineering Research Council of Canada; Bispebjerg Hospital; Department of Medicine, University of Toronto; Københavns Universitet; University of Alberta","keywords":"Psoriasis; Pathogenesis; Cytokine; Tumor necrosis factor alpha; Disease; Immunology; Lesion; Inflammation; Biology; Medicine; Pathology","score_opus":0.015195905628473933,"score_gpt":0.2530801194182576,"score_spread":0.23788421378978367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979509394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604607,0.00066812924,0.00028670873,0.00013125563,0.001577275,0.00016628327,0.00009854331,0.00003954848,0.0009862103],"genre_scores_gemma":[0.9972631,0.000029064391,0.000048854807,0.000057024452,0.00005618824,0.000024792651,0.00009587223,0.000009264552,0.0024158657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988715,0.00012648755,0.00022787157,0.00038104263,0.000048341328,0.00034472553],"domain_scores_gemma":[0.9994623,0.00016751263,0.000088944114,0.00023743228,0.000022279453,0.000021541693],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002020352,0.00014953557,0.0002137202,0.00013922327,0.000113255286,0.000022469247,0.00027660505,0.0001016227,0.001132687],"category_scores_gemma":[0.000030793857,0.00012986995,0.0000737546,0.00025910157,0.00007677858,0.00019564743,0.00007976796,0.00014778176,0.001784639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021425336,0.00006014677,0.45801872,0.000003770044,0.000026699172,0.0000030834337,0.00047116296,0.000004638575,0.38680977,0.0000119555825,0.00049941515,0.15406922],"study_design_scores_gemma":[0.0017204168,0.00016636666,0.7872942,0.000056993107,0.00005172351,0.000021189524,0.00029105874,0.000017635675,0.17904583,0.000057185443,0.030926848,0.00035056632],"about_ca_topic_score_codex":0.0005640497,"about_ca_topic_score_gemma":0.00024046397,"teacher_disagreement_score":0.3292755,"about_ca_system_score_codex":0.000052508192,"about_ca_system_score_gemma":0.000034871187,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2980198391","doi":"10.5114/ada.2019.87454","title":"Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab","year":2019,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Secukinumab; Adalimumab; Psoriasis; Dermatology; Infliximab; Medicine; Paradoxical reaction; Immunology; Psoriatic arthritis; Pathology; Tumor necrosis factor alpha","score_opus":0.00671683868965513,"score_gpt":0.2398972641719183,"score_spread":0.23318042548226317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980198391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818884,0.015906163,0.00006867956,0.00065075164,0.0005090362,0.0005832784,0.000016797218,0.000049775925,0.00032710697],"genre_scores_gemma":[0.9948591,0.004310134,0.000076189724,0.00018600399,0.000011374585,0.00015201198,0.0003396225,0.000027732678,0.00003781348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970326,0.0008726215,0.0006550114,0.0007628289,0.00008939172,0.0005875863],"domain_scores_gemma":[0.99859744,0.00059077167,0.00031161908,0.00042410262,0.000038949525,0.000037084596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004152241,0.00040797642,0.0009238622,0.00025645416,0.00021817302,0.000014667154,0.00028523785,0.0006171069,0.000015000819],"category_scores_gemma":[0.000044851993,0.00031487222,0.00008999972,0.00042470076,0.00028597473,0.0006865784,0.00007020204,0.0005129139,0.000011478818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010834975,0.0027501136,0.6877399,0.0004048848,0.0023974658,0.00058417954,0.012430566,0.00008459066,0.20932315,0.003363809,0.0004758759,0.069610484],"study_design_scores_gemma":[0.15484205,0.009975888,0.60569406,0.0014475005,0.0026960082,0.019701948,0.041016646,0.0013535233,0.06960029,0.020829681,0.0666317,0.006210716],"about_ca_topic_score_codex":0.00025669902,"about_ca_topic_score_gemma":0.002949028,"teacher_disagreement_score":0.14400707,"about_ca_system_score_codex":0.000046353005,"about_ca_system_score_gemma":0.000043065193,"threshold_uncertainty_score":0.9999303},"labels":[],"label_agreement":null},{"id":"W2980410436","doi":"10.1080/09546634.2019.1679336","title":"Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2","year":2019,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Adalimumab; Psoriasis; Internal medicine; Placebo; Psoriasis Area and Severity Index; Population; Dermatology; Adverse effect; Confidence interval; Gastroenterology; Disease; Pathology","score_opus":0.014621732709655786,"score_gpt":0.23792431000547995,"score_spread":0.22330257729582417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980410436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961402,0.002114811,0.00004162664,0.0004241478,0.00018622878,0.0006731746,0.00035430296,0.00002904131,0.00003646883],"genre_scores_gemma":[0.9983443,0.00033897784,0.00059637276,0.000096818905,0.00003475311,0.000035598307,0.00019514652,0.000023954099,0.00033408226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997428,0.0006726878,0.00072340935,0.00058022223,0.00014036718,0.00045531229],"domain_scores_gemma":[0.9979729,0.0006926145,0.00047813824,0.00045951607,0.00013486348,0.00026194204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019484077,0.00054039015,0.0015418963,0.00040343674,0.0001845286,0.00006198882,0.00017747143,0.00031621556,0.00023591243],"category_scores_gemma":[0.000034661538,0.0003087298,0.00032206264,0.00028139405,0.000111924244,0.00018402054,0.000063755855,0.0001309493,0.00009878914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00641953,0.0015252089,0.96821755,0.0000059679915,0.00971224,0.0001979402,0.00086116133,0.00001311618,0.0028713553,0.000009346797,0.000041930074,0.0101246275],"study_design_scores_gemma":[0.014379579,0.014523215,0.9572893,0.000043444557,0.006927014,0.000109461165,0.00035756023,0.0000047550825,0.0039218077,0.000021041238,0.0020776086,0.00034525167],"about_ca_topic_score_codex":0.00010283286,"about_ca_topic_score_gemma":0.00005580655,"teacher_disagreement_score":0.012998005,"about_ca_system_score_codex":0.00038339576,"about_ca_system_score_gemma":0.000091067515,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W2980603063","doi":"10.1111/bjd.18623","title":"Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Novartis Pharmaceuticals UK Limited","keywords":"Secukinumab; Medicine; Randomized controlled trial; Oncology; Open label; Tumor necrosis factor alpha; Signature (topology); Internal medicine; Necrosis","score_opus":0.018624505448480617,"score_gpt":0.264304644580543,"score_spread":0.24568013913206235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980603063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843494,0.010709807,0.0000367757,0.00010385168,0.0016615052,0.0027494652,0.00026495027,0.000014158991,0.00011002671],"genre_scores_gemma":[0.9984819,0.000749852,0.00023385129,0.00007202655,0.000037728016,0.00006477612,0.00008569103,0.00003169944,0.00024242014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965689,0.0011091514,0.0015367173,0.0003143636,0.00009470686,0.00037613508],"domain_scores_gemma":[0.99670506,0.0009679625,0.0014822449,0.00020879712,0.00059318764,0.000042775162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005911868,0.0002616066,0.00188221,0.00019041779,0.00013858646,0.0000579296,0.00058618747,0.0003403655,0.000072778865],"category_scores_gemma":[0.00048475858,0.0002314899,0.00037706472,0.0001337807,0.00011227802,0.00024278926,0.00011712855,0.00030715717,0.000019614372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6030298,0.022870526,0.056874316,0.0002349633,0.0116986735,0.0006960963,0.00789445,0.000006094906,0.083247125,0.00006578915,0.013040017,0.20034215],"study_design_scores_gemma":[0.9273414,0.00264474,0.0071883453,0.0003306165,0.00059386593,0.0030016426,0.0004871822,0.00000375881,0.055406127,0.00021467889,0.0023955754,0.00039206588],"about_ca_topic_score_codex":0.000133138,"about_ca_topic_score_gemma":0.000042859447,"teacher_disagreement_score":0.3243116,"about_ca_system_score_codex":0.00003675483,"about_ca_system_score_gemma":0.00016404518,"threshold_uncertainty_score":0.9439884},"labels":[],"label_agreement":null},{"id":"W2980666869","doi":"10.1016/j.vhri.2019.08.448","title":"PSY6 HUMANISTIC AND ECONOMIC BURDEN OF DISEASE FOR PSORIASIS IN ARGENTINA, BRAZIL, COLOMBIA AND MEXICO","year":2019,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Medicine; Presenteeism; Latin Americans; Absenteeism; Quality of life (healthcare); Disease burden; Population; Psoriasis; Work productivity; Portuguese; Productivity; Demography; Gerontology; Environmental health; Dermatology; Political science; Psychology; Nursing","score_opus":0.033232608061932734,"score_gpt":0.3130507242685733,"score_spread":0.27981811620664054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980666869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672744,0.029150456,0.0000019023017,0.0024538855,0.00031963325,0.00065684755,0.000101022495,0.000010679876,0.000031124866],"genre_scores_gemma":[0.9952343,0.0033672864,0.00015064255,0.00012282062,0.000042376232,0.00006671758,0.00010677566,0.000013532509,0.0008955498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988736,0.00016189158,0.00036793566,0.0003117819,0.000023359287,0.0002614324],"domain_scores_gemma":[0.99932605,0.0003266726,0.00014252197,0.00014468211,0.000016281567,0.000043818392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031785408,0.00013624332,0.0003878716,0.00015594641,0.000060636354,0.000006771498,0.00007730558,0.00010563985,0.00006515257],"category_scores_gemma":[0.000028478782,0.00013417646,0.00004393296,0.000047316003,0.00010244456,0.00005404022,0.00003196559,0.00006173143,0.000028995739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055890656,0.00069996115,0.8635173,0.0025484627,0.0003976169,0.000012471507,0.006607885,0.0005624154,0.0040112804,0.09327295,0.0064112293,0.016369374],"study_design_scores_gemma":[0.012973361,0.0016675257,0.8330331,0.0008192234,0.00011849592,0.000023051327,0.0009505662,0.00063893467,0.0013257567,0.017181044,0.1306607,0.00060828],"about_ca_topic_score_codex":0.0030014685,"about_ca_topic_score_gemma":0.000258607,"teacher_disagreement_score":0.12424947,"about_ca_system_score_codex":0.00006425376,"about_ca_system_score_gemma":0.00010541211,"threshold_uncertainty_score":0.5471557},"labels":[],"label_agreement":null},{"id":"W2980791844","doi":"10.1016/j.vhri.2019.08.447","title":"PSY5 QUALITY OF LIFE OF INDIVIDUALS WITH PSORIASIS IN LATIN AMERICA","year":2019,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Quality of life (healthcare); Demographics; Internal medicine; Demography; Pediatrics; Dermatology","score_opus":0.0690373693852225,"score_gpt":0.3365973732688915,"score_spread":0.267560003883669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980791844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862388,0.011361565,0.0000030197787,0.0015900858,0.0001512612,0.00038174028,0.000057432488,0.000013138642,0.00020295034],"genre_scores_gemma":[0.9970585,0.0012102517,0.0009740553,0.00020841253,0.000019252053,0.00002554291,0.0000826229,0.0000118732405,0.0004094989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978231,0.0007768588,0.00075696,0.00026479168,0.00009586243,0.00028238675],"domain_scores_gemma":[0.9986187,0.0005403132,0.0004939433,0.00026759086,0.000050166665,0.000029267681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006672895,0.0001509719,0.000726367,0.00024835323,0.000023824254,0.0000018141939,0.00015706598,0.00015014692,0.00015218249],"category_scores_gemma":[0.00007906739,0.00012213382,0.00006531877,0.0003837565,0.00014373867,0.000052514213,0.000028918264,0.00013031576,0.000057910576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007441261,0.00046145593,0.9836717,0.00033602663,0.00013475952,9.692594e-7,0.0039466633,0.00024658508,0.0014353667,0.0031079138,0.00038398342,0.0055304123],"study_design_scores_gemma":[0.0037564633,0.0007634644,0.97922546,0.00041792955,0.000012897821,0.0000024688973,0.0014708285,0.000005398228,0.0023609977,0.0004912742,0.011315003,0.00017782675],"about_ca_topic_score_codex":0.013750928,"about_ca_topic_score_gemma":0.00024692956,"teacher_disagreement_score":0.0135039985,"about_ca_system_score_codex":0.000045637367,"about_ca_system_score_gemma":0.00024670782,"threshold_uncertainty_score":0.99281657},"labels":[],"label_agreement":null},{"id":"W2981098880","doi":"10.1016/j.vhri.2019.08.401","title":"PNS53 DESCRIPTION OF CLINICAL CHARACTERISTICS AND SELF REPORTED WILLINGNESS TO PAY FOR NEW TREATMENTS IN COLOMBIAN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS","year":2019,"lang":"en","type":"article","venue":"Value in Health Regional Issues","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Willingness to pay; Dermatology Life Quality Index; Psoriasis; Internal medicine; Quality of life (healthcare); Psychosocial; Dermatology; Physical therapy; Family medicine; Psychiatry","score_opus":0.05743982690566993,"score_gpt":0.32516108323052406,"score_spread":0.2677212563248541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981098880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491733,0.0024666477,0.000013075581,0.00062397256,0.0005455156,0.0013523251,0.000060084563,0.00001706186,0.0000039947345],"genre_scores_gemma":[0.9935492,0.003731918,0.0018396876,0.00013129224,0.0000520953,0.00007073682,0.00025018206,0.000017871143,0.00035699512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981619,0.00026291446,0.0008440187,0.00039864783,0.000060688388,0.00027181295],"domain_scores_gemma":[0.9989986,0.00031946905,0.0003625568,0.00016841631,0.00007722618,0.00007375388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046520273,0.00017488826,0.000678999,0.00013234062,0.00005134969,0.000008904343,0.000053277705,0.00018907091,0.000008741096],"category_scores_gemma":[0.00010598499,0.00013488308,0.000039317016,0.00014952227,0.000042615076,0.000084068255,0.000019770949,0.00008834481,0.0000062936806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012118709,0.0005602307,0.92695653,0.000121179866,0.00015631095,0.000002867563,0.0013247865,0.000002882343,0.000035868943,0.000117975454,0.000117622614,0.06939186],"study_design_scores_gemma":[0.007878486,0.0022092145,0.9834897,0.00049476925,0.000054855187,0.00000730588,0.00008562084,0.000016219848,0.000062620304,0.00023211505,0.0053308085,0.00013830622],"about_ca_topic_score_codex":0.0018548095,"about_ca_topic_score_gemma":0.00030269547,"teacher_disagreement_score":0.06925356,"about_ca_system_score_codex":0.000060792605,"about_ca_system_score_gemma":0.00016500917,"threshold_uncertainty_score":0.5500372},"labels":[],"label_agreement":null},{"id":"W2981270578","doi":"","title":"Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis.","year":2018,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Waterloo; Actua; Toronto Western Hospital","funders":"","keywords":"Medicine; Synovial fluid; Psoriatic arthritis; Osteoarthritis; Psoriasis; MMP3; Arthritis; Trizol; Internal medicine; Immunology; Gene expression; RNA extraction; Gene; Pathology; Biology","score_opus":0.011991133762547962,"score_gpt":0.20479217965064267,"score_spread":0.1928010458880947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981270578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865281,0.0106476415,0.000014287942,0.00014478595,0.0011779857,0.0009032514,0.00009057213,0.00007043547,0.00042291763],"genre_scores_gemma":[0.99715114,0.00077264913,0.00036804657,0.00013868476,0.00025964074,0.00082683255,0.000054384825,0.00002508972,0.00040352636],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982868,0.00020336502,0.00033168335,0.0005265683,0.0000531753,0.0005984308],"domain_scores_gemma":[0.99943113,0.00009621586,0.00006752976,0.00025575227,0.000044123506,0.00010523566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017950764,0.00026435783,0.00044236775,0.00014745406,0.00021751285,0.000046580208,0.00012447247,0.00022954444,0.00012845204],"category_scores_gemma":[0.00009112366,0.0002508479,0.000046609606,0.00014039653,0.0001975947,0.00010451471,0.0001243114,0.0001076926,0.000047131485],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010639303,0.00023562547,0.012717002,0.000017430357,0.00013683025,0.00014380658,0.0016890056,0.000001036714,0.101714745,0.000036549303,0.0006716928,0.88157237],"study_design_scores_gemma":[0.027797058,0.0016207387,0.43016294,0.00020995586,0.00034985354,0.0029317187,0.00049406395,0.0000055758956,0.51562524,0.00036175226,0.019128395,0.0013127032],"about_ca_topic_score_codex":0.00008316553,"about_ca_topic_score_gemma":0.00043828707,"teacher_disagreement_score":0.88025963,"about_ca_system_score_codex":0.000031671178,"about_ca_system_score_gemma":0.000019376223,"threshold_uncertainty_score":0.9999944},"labels":[],"label_agreement":null},{"id":"W2982284711","doi":"10.1007/s11136-019-02296-5","title":"Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis","year":2019,"lang":"en","type":"article","venue":"Quality of Life Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Psoriasis; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Physical therapy; Clinical trial; Psoriatic arthritis; Immunology; Secukinumab; Alternative medicine; Pathology","score_opus":0.11788134727702153,"score_gpt":0.38653566013328067,"score_spread":0.2686543128562591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982284711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900063,0.00068728544,0.000008454315,0.00061921286,0.00013479755,0.006338122,0.0015779912,0.000017513306,0.00061031483],"genre_scores_gemma":[0.9984012,0.00013496255,0.000020135714,0.00003059023,0.000050419203,0.00036842722,0.0004954788,0.000020670586,0.00047807966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9868535,0.010191097,0.0014945066,0.00060988124,0.00028483276,0.0005661985],"domain_scores_gemma":[0.97549945,0.0229466,0.00048586313,0.00070539606,0.0002583264,0.000104383296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011933446,0.0003683862,0.0030307844,0.00031568768,0.00021123108,0.00004910865,0.00026418056,0.00027932177,0.0002715378],"category_scores_gemma":[0.0039372826,0.00017082308,0.00044085525,0.00025818084,0.00028494807,0.00008549496,0.000069265196,0.00029345675,0.00012338514],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96901256,0.0020079175,0.012270586,0.000010644789,0.003031235,0.0000019911033,0.0021686845,0.000089038345,0.00095414836,0.00012553307,0.0002688015,0.010058832],"study_design_scores_gemma":[0.9014036,0.004821998,0.09013795,0.000089585476,0.00015310843,4.1953257e-7,0.00040619206,0.00004984103,0.0024166943,0.0002764063,0.000030181618,0.00021402212],"about_ca_topic_score_codex":0.008110823,"about_ca_topic_score_gemma":0.00056734035,"teacher_disagreement_score":0.07786737,"about_ca_system_score_codex":0.00018669797,"about_ca_system_score_gemma":0.00034549963,"threshold_uncertainty_score":0.99849427},"labels":[],"label_agreement":null},{"id":"W2982882356","doi":"10.25251/skin.3.supp.36","title":"Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Psoriasis; Plaque psoriasis; Term (time); Internal medicine; Gastroenterology; Dermatology; Adalimumab; Disease","score_opus":0.029787239770012654,"score_gpt":0.29823996114461543,"score_spread":0.2684527213746028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982882356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893037,0.0073276325,0.000022132203,0.0005762492,0.0013988125,0.0008893598,0.0003789561,0.000013799907,0.00008933621],"genre_scores_gemma":[0.9977297,0.0009610716,0.000037888836,0.0000698373,0.0003480079,0.000003115985,0.00052983064,0.00004248911,0.00027803666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99586946,0.0014269232,0.0015610236,0.00039293407,0.00029228433,0.00045739423],"domain_scores_gemma":[0.99385333,0.0031750826,0.0017122946,0.0009664126,0.00018922397,0.00010367318],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009699291,0.00045412948,0.001817219,0.0003252046,0.00011570285,0.000012613486,0.00085141807,0.00021667192,0.00130389],"category_scores_gemma":[0.000552984,0.00024428996,0.00014078636,0.00022469265,0.0003412187,0.00018294428,0.00020258453,0.0004634489,0.000051333274],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37875092,0.00622211,0.30623323,0.00018783324,0.0120786,0.0032414882,0.009118052,0.00008561026,0.14848706,0.000017407898,0.0048545585,0.13072315],"study_design_scores_gemma":[0.5840867,0.029190363,0.31664664,0.004078182,0.014324304,0.019429045,0.0012810454,0.000049954448,0.027898658,0.0002615584,0.0014527191,0.0013008178],"about_ca_topic_score_codex":0.00033498285,"about_ca_topic_score_gemma":0.0002853623,"teacher_disagreement_score":0.2053358,"about_ca_system_score_codex":0.00012588086,"about_ca_system_score_gemma":0.0001754954,"threshold_uncertainty_score":0.99960905},"labels":[],"label_agreement":null},{"id":"W2984127608","doi":"10.25251/skin.3.supp.35","title":"Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Double blinded; Randomized controlled trial; Quality of life (healthcare); Psoriasis; Physical therapy; Surgery; Dermatology; Alternative medicine; Pathology; Nursing","score_opus":0.032285454393292966,"score_gpt":0.30489723420023906,"score_spread":0.2726117798069461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984127608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954482,0.00051986123,0.000020157377,0.0005512821,0.00048129758,0.0029034403,0.000044376975,0.00000806076,0.000023368055],"genre_scores_gemma":[0.9992953,0.00019786948,0.000067667585,0.00015198052,0.000030975065,0.000014596805,0.00003275272,0.000021643893,0.00018723065],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954535,0.0018264115,0.0018166427,0.0003345696,0.00026864134,0.0003002522],"domain_scores_gemma":[0.99486995,0.0028636388,0.0014728067,0.00040141697,0.00030939386,0.00008278703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034392092,0.00032831682,0.00209809,0.00029146226,0.00006257348,0.000009277391,0.0002415666,0.00017266949,0.000038439743],"category_scores_gemma":[0.0007391517,0.00015028668,0.000097242475,0.00021137818,0.00021601348,0.00011326256,0.0000662846,0.00043570696,0.0000036604058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84795535,0.0027789688,0.13642947,0.00001828947,0.0016948294,0.000119821365,0.006309092,0.0001399069,0.00035855395,0.0000017390241,0.000036563957,0.004157437],"study_design_scores_gemma":[0.81893533,0.015150602,0.15807207,0.00045964975,0.0008296122,0.00006496798,0.0058880327,0.000027093594,0.0002861392,0.00006974315,0.0000073647775,0.00020937891],"about_ca_topic_score_codex":0.0010630059,"about_ca_topic_score_gemma":0.0005904361,"teacher_disagreement_score":0.029019978,"about_ca_system_score_codex":0.000060823357,"about_ca_system_score_gemma":0.00019222777,"threshold_uncertainty_score":0.61285126},"labels":[],"label_agreement":null},{"id":"W2984486845","doi":"10.1016/j.autrev.2019.102429","title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","year":2019,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":334,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Allergan; Samsung; Swedish Orphan Biovitrum; Santen; LEO Pharma; Alimera Sciences; Incyte; Cilag; Mylan; Regeneron Pharmaceuticals; Baxalta; Celgene; Biogen; Gilead Sciences; Sanofi; Teva Pharmaceutical Industries; Multiple Sclerosis International Federation; Novartis; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; National Multiple Sclerosis Society","keywords":"Medicine; Ankylosing spondylitis; Psoriatic arthritis; Rheumatology; Psoriasis; Immunology; Context (archaeology); Rheumatoid arthritis; Disease; Interleukin 17; Interleukin 23; Inflammatory bowel disease; Hepatology; Uveitis; Internal medicine; Immune system","score_opus":0.0509616973643908,"score_gpt":0.3308145973401469,"score_spread":0.2798528999757561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984486845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095206866,0.99618167,6.077513e-7,0.00006405545,0.0002653842,0.002237378,0.0000655024,0.000011527739,0.00022179268],"genre_scores_gemma":[0.00088880124,0.99858403,0.000024202844,0.0000575076,0.000007390983,0.00012021555,0.00017035865,0.000028074897,0.00011938645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919774,0.0049379407,0.0022961078,0.00038522022,0.00006346373,0.00033989325],"domain_scores_gemma":[0.9960869,0.0013228175,0.0011950567,0.0013014745,0.000075972406,0.000017761136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026132031,0.0005148307,0.0040350063,0.00023828562,0.000071904324,0.0000128254205,0.0008582113,0.00046599007,0.00020174941],"category_scores_gemma":[0.0018286327,0.00033944624,0.00065437856,0.0005097006,0.0004978687,0.0002999113,0.0004291815,0.0007553859,0.000041380124],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027991302,0.00018159476,0.0004452375,0.06553218,0.00014125291,0.000001063467,0.00027350464,4.5431637e-8,0.00034109718,0.00023112113,0.000091167305,0.9327338],"study_design_scores_gemma":[0.00039441392,0.00010210111,0.00091150054,0.28677398,0.0010514758,0.000022988017,0.00006986442,3.219681e-7,0.000033444834,0.00005385124,0.71033365,0.00025240224],"about_ca_topic_score_codex":0.0004310813,"about_ca_topic_score_gemma":0.00023590535,"teacher_disagreement_score":0.93248135,"about_ca_system_score_codex":0.000111138295,"about_ca_system_score_gemma":0.00027306422,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W2985177726","doi":"10.25251/skin.3.supp.12","title":"An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Psoriasis; Tyrosine-kinase inhibitor; Medicine; Phase (matter); Pharmacology; Quality of life (healthcare); Chemistry; Internal medicine; Dermatology; Cancer; Organic chemistry","score_opus":0.021637576214507306,"score_gpt":0.3057167029094791,"score_spread":0.2840791266949718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985177726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918427,0.0053057303,0.00000846131,0.0004315218,0.0015342977,0.0005890011,0.0001390299,0.0000142368435,0.00013503667],"genre_scores_gemma":[0.9988429,0.00035688482,0.000041700398,0.00012017631,0.00034258055,0.0000039371525,0.00006108634,0.000022565942,0.00020817731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581105,0.0017939111,0.0015969614,0.00027551941,0.00021083468,0.00031175764],"domain_scores_gemma":[0.99636763,0.0013484468,0.0013286563,0.0005492589,0.00032883388,0.00007719416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023145876,0.0002979044,0.0011512466,0.0002643356,0.00008259317,0.0000066455927,0.0004695479,0.000199944,0.00020623858],"category_scores_gemma":[0.0009954617,0.00017139236,0.00012386226,0.00037002243,0.00021996045,0.00012801932,0.00004495204,0.00047965103,0.000026536045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054413624,0.005757739,0.011697106,0.000026751299,0.0015562008,0.0002196479,0.022669028,0.00004748825,0.87856966,0.000013308104,0.0018363358,0.023193104],"study_design_scores_gemma":[0.2712149,0.11089132,0.1315891,0.0015869482,0.004688921,0.0022397535,0.08751549,0.000057047437,0.3839948,0.0015338429,0.0032324996,0.0014553801],"about_ca_topic_score_codex":0.0024833542,"about_ca_topic_score_gemma":0.00063172966,"teacher_disagreement_score":0.49457487,"about_ca_system_score_codex":0.00008562269,"about_ca_system_score_gemma":0.00019795743,"threshold_uncertainty_score":0.69891775},"labels":[],"label_agreement":null},{"id":"W2985715279","doi":"10.25251/skin.3.supp.15","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Disease; Internal medicine","score_opus":0.011130336037182963,"score_gpt":0.27348718798880434,"score_spread":0.2623568519516214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985715279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665062,0.029645918,0.000068916735,0.0011840212,0.00065409415,0.001807305,0.0001177331,0.0000042009688,0.000011638042],"genre_scores_gemma":[0.97747386,0.021693677,0.0000143495845,0.000058946567,0.00014575406,0.0000173913,0.000050235933,0.000015506772,0.00053028954],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809265,0.00073567725,0.0007588361,0.00014521663,0.000081172366,0.00018645164],"domain_scores_gemma":[0.99416274,0.0048874626,0.00053969683,0.00023952834,0.000119498305,0.00005110144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013727776,0.0002258154,0.0010188363,0.00010025436,0.0000986277,0.000004873883,0.00014731995,0.000076464356,0.00013712588],"category_scores_gemma":[0.000492897,0.000099051,0.00009376184,0.00009955133,0.000280008,0.00002652644,0.000017735929,0.00011753325,0.0000029593862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8262022,0.0063676476,0.0025201684,0.00007114744,0.0032290965,0.00014521582,0.012214812,0.00001362251,0.01094925,0.00003139121,0.0013444178,0.13691103],"study_design_scores_gemma":[0.9051995,0.039366536,0.006367724,0.0005677834,0.010500172,0.0020183714,0.006045252,0.00022880215,0.0028475642,0.00015248258,0.026340306,0.00036548407],"about_ca_topic_score_codex":0.00006275055,"about_ca_topic_score_gemma":0.000017199842,"teacher_disagreement_score":0.13654555,"about_ca_system_score_codex":0.000036920494,"about_ca_system_score_gemma":0.000061835206,"threshold_uncertainty_score":0.40391827},"labels":[],"label_agreement":null},{"id":"W2986283446","doi":"10.25251/skin.3.supp.38","title":"Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Nail (fastener); Dermatology; Outcome (game theory); Internal medicine; Infliximab; Tumor necrosis factor alpha; Materials science","score_opus":0.03094004696178332,"score_gpt":0.2977013145001826,"score_spread":0.2667612675383993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986283446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893681,0.0016232056,0.00006977749,0.005178492,0.0021117975,0.00075201556,0.00022663968,0.000015055355,0.000654929],"genre_scores_gemma":[0.9957656,0.00032581846,0.00010435794,0.0002996592,0.00034814747,0.000007615065,0.00006888507,0.000028970684,0.0030509222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967054,0.00088398886,0.0015541634,0.00026074666,0.0001988721,0.00039682045],"domain_scores_gemma":[0.99669,0.0015990753,0.0010148212,0.00045071528,0.00016608484,0.00007930567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009442305,0.00033264753,0.0012923043,0.00025969133,0.000093426694,0.000012063842,0.00045937803,0.00019912259,0.00067567866],"category_scores_gemma":[0.00060379575,0.00016343156,0.00013231902,0.00022048898,0.00008121947,0.00008934942,0.000047045298,0.0004267138,0.00018419493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45776156,0.0019398922,0.0033614535,0.00007523,0.0064146486,0.008692917,0.029325297,0.0011965253,0.27639934,0.00005803592,0.017841674,0.19693342],"study_design_scores_gemma":[0.5484016,0.052193437,0.0032263831,0.00469904,0.008350138,0.11472994,0.017232018,0.00014891704,0.18584138,0.0024677548,0.06023131,0.0024781034],"about_ca_topic_score_codex":0.00051181833,"about_ca_topic_score_gemma":0.00025361349,"teacher_disagreement_score":0.19445531,"about_ca_system_score_codex":0.00013217005,"about_ca_system_score_gemma":0.0001350416,"threshold_uncertainty_score":0.7398207},"labels":[],"label_agreement":null},{"id":"W2986312172","doi":"10.25251/skin.3.supp.39","title":"Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Certolizumab pegol; Placebo; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Dermatology; Adalimumab; Pathology; Alternative medicine","score_opus":0.028946586606599847,"score_gpt":0.2972223779139177,"score_spread":0.2682757913073179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986312172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9210989,0.071719855,0.00011576295,0.0029837207,0.001982027,0.0016649378,0.00020686425,0.00001482035,0.00021313928],"genre_scores_gemma":[0.9838032,0.015318657,0.000073464515,0.00011523019,0.00026286626,0.000011833202,0.00008919304,0.00003233581,0.0002931826],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99546087,0.0016323825,0.0018816617,0.00033352242,0.0002335488,0.00045800093],"domain_scores_gemma":[0.9894268,0.007847318,0.0015848924,0.0008221078,0.00023793931,0.000080927515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018083118,0.0004714509,0.0031211562,0.00034340072,0.00011912549,0.000010296135,0.00084917864,0.00024609722,0.0006445017],"category_scores_gemma":[0.0020764966,0.00024359518,0.00024377414,0.00018076398,0.000620013,0.00018430487,0.00021154166,0.00052836834,0.000031936594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9392323,0.00089561305,0.0010056677,0.00006927414,0.010245815,0.000698123,0.0073253796,0.000032087755,0.019986944,0.000026479935,0.0022620407,0.018220281],"study_design_scores_gemma":[0.96740294,0.0028900772,0.00035947096,0.0012379894,0.006990627,0.007827056,0.008017326,0.00041690888,0.0030957,0.0006407458,0.0008034573,0.00031769593],"about_ca_topic_score_codex":0.00046862836,"about_ca_topic_score_gemma":0.0006016374,"teacher_disagreement_score":0.06270436,"about_ca_system_score_codex":0.000104193714,"about_ca_system_score_gemma":0.000157261,"threshold_uncertainty_score":0.9933523},"labels":[],"label_agreement":null},{"id":"W2986315279","doi":"10.1177/1203475419887731","title":"Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Pityriasis rubra pilaris; Dermatology; Systemic therapy; Refractory (planetary science); Clinical trial; Combination therapy; Disease; Methotrexate; MEDLINE; Intensive care medicine; Randomized controlled trial; Internal medicine; Psoriasis; Cancer","score_opus":0.13352099809453563,"score_gpt":0.31932615255467134,"score_spread":0.1858051544601357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986315279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023400288,0.9946894,0.0000049638793,0.00014096801,0.001301682,0.0014469443,0.00005471654,0.000010127115,0.000011185247],"genre_scores_gemma":[0.0010659469,0.99794495,0.000011746099,0.0003657071,0.00012892077,0.000034201752,0.0000674544,0.00003922598,0.0003418185],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9942813,0.0015190569,0.003403542,0.00031247505,0.00014760348,0.0003360097],"domain_scores_gemma":[0.98867947,0.0072418177,0.0032257736,0.0005119598,0.00026191014,0.00007909542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021716726,0.0005711872,0.009173365,0.0010070454,0.000047316193,0.000008948572,0.00028214147,0.0006150661,0.00010136957],"category_scores_gemma":[0.0024244632,0.00031045298,0.00088521885,0.000501639,0.00010394489,0.00007794164,0.000048880753,0.0005257038,0.000037162863],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022653713,0.00022053982,0.0001869208,0.77783614,0.002416683,0.0008559122,0.00026955636,6.604647e-7,0.000066865396,0.0000035446376,0.005257189,0.21265948],"study_design_scores_gemma":[0.00032916127,0.0008016264,0.0000042145234,0.7409749,0.0048795287,0.0134061985,0.000055579578,6.410294e-8,0.0000040519785,0.000002864386,0.23928511,0.00025668077],"about_ca_topic_score_codex":0.0000429331,"about_ca_topic_score_gemma":0.000007099209,"teacher_disagreement_score":0.23402792,"about_ca_system_score_codex":0.00012156722,"about_ca_system_score_gemma":0.00034914017,"threshold_uncertainty_score":0.99993473},"labels":[],"label_agreement":null},{"id":"W2986619199","doi":"10.1016/j.cjca.2019.11.011","title":"Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?","year":2019,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Psoriasis; Blockade; Interleukin 17; Interleukin; Internal medicine; Dermatology; Inflammation; Cytokine; Receptor","score_opus":0.014913838423823957,"score_gpt":0.24060780443241822,"score_spread":0.22569396600859426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986619199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6347437,0.05987202,0.0007138932,0.16930166,0.123083696,0.0027834328,0.0034088113,0.00006751675,0.006025294],"genre_scores_gemma":[0.91906285,0.0020781392,0.00018727941,0.04084503,0.031216752,0.00006381979,0.0005227121,0.00021044057,0.005812973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99272746,0.0034617642,0.0015892015,0.00082407094,0.00012566199,0.0012718432],"domain_scores_gemma":[0.9971739,0.00046800674,0.000714266,0.0010652546,0.00032837022,0.0002501926],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019536759,0.000657573,0.0030769012,0.0013844025,0.00014709581,0.000044403492,0.0011117973,0.0034075074,0.0001545224],"category_scores_gemma":[0.00062618684,0.00047085647,0.0028264392,0.00019663501,0.00034685424,0.00008360103,0.00008632123,0.003993359,0.0005549674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005024159,0.000010934187,0.037798632,0.000035168465,0.014098102,0.006427729,0.00035551673,0.0015737166,0.00024230294,0.0000022911722,0.8949337,0.044019505],"study_design_scores_gemma":[0.0031487788,0.0005784548,0.015161047,0.00014197986,0.0022444683,0.0014624421,0.00019992031,5.810444e-7,0.0002944272,0.00010437348,0.9761236,0.00053994457],"about_ca_topic_score_codex":0.0050759153,"about_ca_topic_score_gemma":0.003569278,"teacher_disagreement_score":0.2843192,"about_ca_system_score_codex":0.0004921773,"about_ca_system_score_gemma":0.0021311392,"threshold_uncertainty_score":0.99977434},"labels":[],"label_agreement":null},{"id":"W2987175910","doi":"10.25251/skin.3.supp.37","title":"Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Dermatology; Internal medicine; Oncology; Adalimumab; Disease","score_opus":0.038676375836139795,"score_gpt":0.3220570760310816,"score_spread":0.28338070019494177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987175910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795854,0.013946404,0.00013563868,0.0027053703,0.002098683,0.0011262028,0.00024047439,0.000016344307,0.00014545071],"genre_scores_gemma":[0.9963656,0.002167189,0.00014703842,0.000047583268,0.00054334797,0.00001121907,0.00006230647,0.000034003417,0.00062171783],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997393,0.000608121,0.0012815425,0.00022429918,0.00014503629,0.0003479767],"domain_scores_gemma":[0.9926362,0.0053986832,0.0012826428,0.0004261844,0.0001789474,0.000077353616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005621527,0.0003859189,0.002007395,0.00020635236,0.00012241842,0.000009108314,0.0003115982,0.00020150932,0.0010959883],"category_scores_gemma":[0.00056406937,0.00018875851,0.0004337946,0.00010351998,0.00021828103,0.00006033141,0.000027237342,0.00012892301,0.00004040095],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12526841,0.0035656667,0.012179745,0.00011304263,0.023944775,0.0007001122,0.013906574,0.000056646248,0.33872405,0.0004278621,0.0051644873,0.47594863],"study_design_scores_gemma":[0.5755968,0.07733867,0.010468001,0.0013726917,0.03684415,0.028847659,0.0073225964,0.00007369266,0.21499744,0.005583938,0.040213164,0.0013411958],"about_ca_topic_score_codex":0.0002516262,"about_ca_topic_score_gemma":0.00006438011,"teacher_disagreement_score":0.47460744,"about_ca_system_score_codex":0.00008826118,"about_ca_system_score_gemma":0.00012319854,"threshold_uncertainty_score":0.99981713},"labels":[],"label_agreement":null},{"id":"W2987386759","doi":"10.1016/j.jid.2019.09.027","title":"Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Innovaderm (Canada)","funders":"AbbVie","keywords":"Psoriasis; Medicine; Tumor necrosis factor alpha; Immunology; Phenotype; Pathology; Cancer research; Biology; Gene","score_opus":0.017574145875482998,"score_gpt":0.22709766757453145,"score_spread":0.20952352169904845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987386759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969415,0.0016524891,5.175455e-7,0.00020467139,0.00050368713,0.00038574066,0.000010697124,0.0000057162792,0.00029497006],"genre_scores_gemma":[0.9995197,0.00014132503,0.00005970412,0.00021240665,0.000012460736,0.000011812306,0.000013340787,0.00000974679,0.00001950214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781066,0.0010096879,0.0006762561,0.00018916161,0.00006142591,0.00025281598],"domain_scores_gemma":[0.99827456,0.0006936405,0.00069368404,0.0001480959,0.00016416618,0.000025865793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003058859,0.0002049548,0.0006999991,0.00049235247,0.000026649093,0.0000030324272,0.00022514223,0.00028903803,0.0000620284],"category_scores_gemma":[0.00030470474,0.00015062379,0.000105996514,0.00021983584,0.0003572681,0.00012382813,0.000030412637,0.00035750633,0.00007332462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001808582,0.00044867903,0.8972998,0.000035530535,0.00030951144,0.000041953637,0.0030675423,0.000040500672,0.09260723,0.000586684,0.00017493013,0.0035790433],"study_design_scores_gemma":[0.005222426,0.0013233916,0.7128137,0.00014304717,0.000017620136,0.000025715999,0.00032961924,8.674707e-7,0.27914017,0.000762298,0.00011405054,0.00010713197],"about_ca_topic_score_codex":0.000018850342,"about_ca_topic_score_gemma":0.000021290907,"teacher_disagreement_score":0.18653294,"about_ca_system_score_codex":0.000096769494,"about_ca_system_score_gemma":0.00014151064,"threshold_uncertainty_score":0.614226},"labels":[],"label_agreement":null},{"id":"W2988810667","doi":"10.1111/jdv.16077","title":"Safety and efficacy of topical, fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial","year":2019,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Psoriasis; Betamethasone dipropionate; Adverse effect; Scalp; Internal medicine; Vitamin D and neurology; Dermatology","score_opus":0.012726363187107353,"score_gpt":0.25744918661802746,"score_spread":0.2447228234309201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988810667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943115,0.0037770753,0.0000088876095,0.0011673504,0.0002606798,0.00036456477,0.000012630732,0.0000039701404,0.00009334741],"genre_scores_gemma":[0.9986587,0.001079981,0.00004450288,0.00010975905,0.000023612401,0.0000013804034,0.0000066390053,0.000011461883,0.00006395839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976527,0.0011971784,0.00066697475,0.00022032527,0.000059312926,0.00020349305],"domain_scores_gemma":[0.9988584,0.00029138674,0.000654317,0.00010285357,0.000046965066,0.00004610008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039533936,0.00018775149,0.0006792009,0.00017787282,0.00011302651,0.0000037276764,0.00015875699,0.00026011473,0.000013057929],"category_scores_gemma":[0.000121328994,0.00012078241,0.000061489016,0.00009779494,0.0006091381,0.0000901418,0.0001997957,0.00039726176,0.0000015504845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06422433,0.002826233,0.86643255,0.00016094769,0.0008107465,0.000035535435,0.0013941098,0.0000042306606,0.015270467,0.002530502,0.00008882458,0.04622151],"study_design_scores_gemma":[0.118006155,0.0016512156,0.8709553,0.00016422772,0.0003453097,0.0008394642,0.00007191481,0.0000051369766,0.00647419,0.00020931147,0.0011379151,0.00013987701],"about_ca_topic_score_codex":0.0000054910374,"about_ca_topic_score_gemma":0.0000015429133,"teacher_disagreement_score":0.053781826,"about_ca_system_score_codex":0.000013541824,"about_ca_system_score_gemma":0.00003116044,"threshold_uncertainty_score":0.49253637},"labels":[],"label_agreement":null},{"id":"W2990048737","doi":"10.1016/j.annder.2019.09.584","title":"Persistance de l’amélioration clinique du psoriasis génital après un an de traitement par ixékizumab : résultats d’une étude clinique de phase 3 randomisée contrôlée versus placebo chez des patients atteints de psoriasis génital modéré à sévère (IXORA-Q)","year":2019,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Guenther Dermatology Research Centre","funders":"","keywords":"Medicine; Gynecology","score_opus":0.055903628701857506,"score_gpt":0.3081402355912855,"score_spread":0.252236606889428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990048737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97694457,0.0067964327,0.006112263,0.002998433,0.0023234596,0.002452061,0.0012130388,0.00056595966,0.00059380993],"genre_scores_gemma":[0.97754353,0.009771469,0.0075350334,0.0018902803,0.0003655898,0.0009026225,0.0014984948,0.0001861103,0.00030685682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9850057,0.007343927,0.0019203654,0.0017036592,0.00028691773,0.0037394643],"domain_scores_gemma":[0.9920921,0.00429179,0.0011580363,0.0011533418,0.0006428463,0.00066192803],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038314455,0.0015726656,0.002118219,0.00048414723,0.0009588115,0.00025969185,0.0014153139,0.0031119997,0.0004600446],"category_scores_gemma":[0.003239867,0.0016655525,0.0010953186,0.00069753925,0.0014192655,0.001063021,0.0003121702,0.0014853067,0.00041175444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1136254,0.013169731,0.6375972,0.0010206698,0.008008114,0.003795687,0.035222042,0.0019857353,0.03169033,0.0015085916,0.006938124,0.14543836],"study_design_scores_gemma":[0.30318955,0.013779689,0.31629816,0.0013539484,0.007832064,0.0042304834,0.01845247,0.0057409527,0.3005614,0.010224665,0.011947922,0.006388702],"about_ca_topic_score_codex":0.0006635976,"about_ca_topic_score_gemma":0.0014750353,"teacher_disagreement_score":0.32129905,"about_ca_system_score_codex":0.0024700528,"about_ca_system_score_gemma":0.0031042518,"threshold_uncertainty_score":0.99970216},"labels":[],"label_agreement":null},{"id":"W2990350464","doi":"10.3390/pr7120871","title":"Application of an In Vitro Psoriatic Skin Model to Study Cutaneous Metabolization of Tazarotene","year":2019,"lang":"en","type":"article","venue":"Processes","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Centre Hospitalier Universitaire de Québec; Canadian Institutes of Health Research; Université Laval","keywords":"Psoriasis; Tazarotene; Skin equivalent; Dermatology; Dermis; In vivo; Medicine; Keratinocyte; Metabolite; Human skin; In vitro; Epidermis (zoology); Absorption (acoustics); Pharmacology; Pathology; Chemistry; Biology; Biochemistry; Internal medicine; Materials science; Anatomy","score_opus":0.01132210361429889,"score_gpt":0.2512437198522796,"score_spread":0.23992161623798072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990350464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963143,0.0011030433,0.0017175823,0.000008982494,0.00005224587,0.00070003705,0.000025921352,0.0000162279,0.0000616978],"genre_scores_gemma":[0.9989675,0.000045638746,0.00070563494,0.000010278408,0.000006174502,0.000107218635,0.00007513883,0.000009532955,0.00007288042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937063,0.000056827415,0.00023855353,0.00019326931,0.000034586523,0.00010610496],"domain_scores_gemma":[0.9995231,0.000039513703,0.00011994357,0.00019282392,0.000115087074,0.00000951396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090640395,0.0000927637,0.0002547634,0.00012576788,0.000017167671,0.0000022342028,0.00012893586,0.00006745708,0.00001849929],"category_scores_gemma":[0.00004268399,0.000081202284,0.000018749432,0.0003245742,0.000011941189,0.00006952743,0.000021653337,0.000028481112,0.000032837845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071528263,0.0015738866,0.011149652,0.00026811345,0.000116954296,5.709197e-7,0.0033029949,0.003984599,0.9041457,0.00004347887,0.000001530679,0.07469724],"study_design_scores_gemma":[0.0011729369,0.00030408415,0.0035003747,0.000010687191,0.00010854953,0.000004136397,0.00041507639,0.00072120916,0.99331427,0.00031280378,0.000037265116,0.000098598495],"about_ca_topic_score_codex":0.00009229711,"about_ca_topic_score_gemma":0.000054520908,"teacher_disagreement_score":0.089168586,"about_ca_system_score_codex":0.00001000855,"about_ca_system_score_gemma":0.00004869927,"threshold_uncertainty_score":0.3311333},"labels":[],"label_agreement":null},{"id":"W2990393697","doi":"10.1016/j.annder.2019.09.580","title":"Le certolizumab pegol dans le traitement du psoriasis en plaques : résultats d’efficacité sur 2 ans provenant de deux essais de phase 3 (CIMPASI-1 et CIMPASI-2)","year":2019,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Certolizumab pegol; Medicine; Gynecology; Tumor necrosis factor alpha; Internal medicine","score_opus":0.024129766490077312,"score_gpt":0.29009744664036596,"score_spread":0.26596768015028865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990393697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93071234,0.015017328,0.005184442,0.040618025,0.001576896,0.0015747051,0.0012748261,0.0007006782,0.0033407393],"genre_scores_gemma":[0.97659373,0.014456851,0.0023438865,0.002263374,0.00016934339,0.0005737436,0.00087007467,0.00016607792,0.0025629157],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9881427,0.005350189,0.0013637075,0.0014765569,0.00021003778,0.0034567679],"domain_scores_gemma":[0.9944712,0.0029391707,0.0006887143,0.0012318698,0.0002695754,0.00039948095],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014022007,0.0013370182,0.0017868481,0.00045997166,0.0006445209,0.00020987638,0.0015488475,0.0023277265,0.00033453846],"category_scores_gemma":[0.0014380374,0.0013087513,0.0009019312,0.00051790284,0.0008405447,0.00071807945,0.00049154187,0.0012800338,0.00064665976],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009858964,0.020962084,0.34687743,0.0022064042,0.008994494,0.02029186,0.047761455,0.0020482163,0.29337776,0.0403981,0.08676767,0.12045556],"study_design_scores_gemma":[0.041086983,0.0045222766,0.10806337,0.000992363,0.002384734,0.03929366,0.017040407,0.0019656394,0.52748084,0.005569335,0.24749452,0.004105871],"about_ca_topic_score_codex":0.00337144,"about_ca_topic_score_gemma":0.0024543428,"teacher_disagreement_score":0.23881406,"about_ca_system_score_codex":0.0010899678,"about_ca_system_score_gemma":0.0058795926,"threshold_uncertainty_score":0.9999381},"labels":[],"label_agreement":null},{"id":"W2990529092","doi":"10.1016/j.annder.2019.09.564","title":"Constance de la réponse selon les caractéristiques de sévérité de la maladie chez les patients atteints de psoriasis modéré à sévère traités par le guselkumab par rapport au sécukinumab : résultats de l’étude ECLIPSE à la semaine 48","year":2019,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research; Dalhousie University","funders":"","keywords":"Medicine; Gynecology; Secukinumab; Multicenter study; Psoriasis; Dermatology; Randomized controlled trial; Psoriatic arthritis; Surgery","score_opus":0.02230835427809612,"score_gpt":0.28219552853089214,"score_spread":0.259887174252796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990529092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750839,0.013360705,0.0016678438,0.0037627155,0.00067235046,0.00092690595,0.0011124572,0.0006563094,0.0027568522],"genre_scores_gemma":[0.96860886,0.018670257,0.008100522,0.0018360879,0.0002427904,0.00043435214,0.0005821436,0.00020000187,0.00132501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.980337,0.012867136,0.001339615,0.0014305407,0.00021730766,0.0038083987],"domain_scores_gemma":[0.9897988,0.0074083363,0.00087386416,0.0011022367,0.00031385894,0.0005029106],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004843905,0.0014870482,0.0018882642,0.00042316434,0.0010356465,0.00021374506,0.0014558428,0.0043981858,0.0002821781],"category_scores_gemma":[0.0029396212,0.0015588024,0.0008129067,0.00045497232,0.002779936,0.0004507324,0.00042863085,0.0020872601,0.00025988388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024096682,0.0024620867,0.9041098,0.0006592344,0.0023372048,0.0053505227,0.008672642,0.0006263651,0.025586775,0.0018229493,0.02812581,0.017836979],"study_design_scores_gemma":[0.0088032745,0.00059343467,0.7758671,0.00073034054,0.0013900067,0.010419734,0.0033952617,0.00033375854,0.15771784,0.0046756263,0.034132544,0.0019410746],"about_ca_topic_score_codex":0.0024531945,"about_ca_topic_score_gemma":0.0010168295,"teacher_disagreement_score":0.13213107,"about_ca_system_score_codex":0.0016578911,"about_ca_system_score_gemma":0.0069050477,"threshold_uncertainty_score":0.9999339},"labels":[],"label_agreement":null},{"id":"W2990548943","doi":"10.2340/00015555-3375","title":"Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk","year":2019,"lang":"en","type":"review","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Pharmaceuticals; Manchester Biomedical Research Centre; LEO Pharma; LEO Fondet; National Institute for Health and Care Research; Pfizer; LivaNova; UCB Pharma; Regeneron Pharmaceuticals; Les Laboratories Pierre Fabre; Sunovion; Baxalta; Medical Research Council; Celgene; Biogen; Sanofi; Amgen; Galderma; Eli Lilly and Company","keywords":"Psoriasis; Medicine; Disease; Psychosocial; Depression (economics); Comorbidity; Neuroinflammation; Mood; Psychiatry; Mental health; Systemic inflammation; Mechanism (biology); Immunology; Inflammation; Internal medicine","score_opus":0.0821900466478731,"score_gpt":0.2972257346778344,"score_spread":0.2150356880299613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990548943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.052437104,0.9424222,0.000008963041,0.0004889174,0.0022280582,0.0016561366,0.0005800374,0.00013661632,0.000041975152],"genre_scores_gemma":[0.022978943,0.9730091,0.00002493929,0.00003699107,0.0004470358,0.00029604803,0.0029510574,0.000073986565,0.00018191396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948094,0.0021304714,0.0010408927,0.0011777702,0.00015991575,0.00068155024],"domain_scores_gemma":[0.9967141,0.0008800978,0.0009845337,0.0012318754,0.000037828322,0.0001515368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008140081,0.0008769043,0.002490428,0.00018886743,0.0010626556,0.000102811,0.00043568903,0.0008956696,0.000041716467],"category_scores_gemma":[0.00026478205,0.00056012487,0.0010446598,0.00026127612,0.00025762804,0.0002106092,0.00035293095,0.0010495691,0.000060620725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042574233,0.000048734575,0.0062019904,0.0013034885,0.004463719,0.000044549655,0.0005230178,6.1758794e-7,0.0000013239596,0.000028583956,0.0025329087,0.9848085],"study_design_scores_gemma":[0.00079333066,0.000054841265,0.011443775,0.0009247096,0.0047829133,0.00032338005,0.00015947189,3.1599734e-7,0.00000640063,0.000043500164,0.9808987,0.0005686887],"about_ca_topic_score_codex":0.00008731675,"about_ca_topic_score_gemma":0.000008785436,"teacher_disagreement_score":0.9842398,"about_ca_system_score_codex":0.00009708319,"about_ca_system_score_gemma":0.00020783357,"threshold_uncertainty_score":0.99968505},"labels":[],"label_agreement":null},{"id":"W2990759295","doi":"10.1016/j.annder.2019.09.572","title":"Efficacité du guselkumab par rapport au sécukinumab chez les patients atteints de psoriasis en plaques modéré à sévère selon les traitements antérieurs du psoriasis : résultats de l’étude ECLIPSE","year":2019,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Dermatrials Research","funders":"","keywords":"Medicine; Gynecology; Ixekizumab; Secukinumab; Psoriasis; Dermatology; Psoriatic arthritis","score_opus":0.0280483769159782,"score_gpt":0.26814726688667906,"score_spread":0.24009888997070086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990759295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97780514,0.008163524,0.0004790601,0.005432167,0.0033554237,0.0015197047,0.0010517779,0.0007031414,0.001490054],"genre_scores_gemma":[0.97032493,0.022128135,0.0018027432,0.0016500698,0.00066310476,0.00040967064,0.0012987589,0.00021450776,0.0015080463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9867133,0.005317979,0.0017690326,0.0018689687,0.0003435883,0.0039871335],"domain_scores_gemma":[0.9937187,0.0030124858,0.0010592131,0.0012989548,0.00043904048,0.0004715966],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0024320565,0.0017938126,0.0021672572,0.0006292988,0.0011799035,0.00019006255,0.0019459318,0.0036090517,0.00093646673],"category_scores_gemma":[0.0020204035,0.0017883618,0.0010391517,0.00064736983,0.001111489,0.00066316815,0.00067848555,0.0014856467,0.0012855419],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021229605,0.0028594024,0.85206616,0.00055097736,0.003502565,0.0013873698,0.010314453,0.00051420974,0.004791585,0.00039403792,0.027903479,0.09359281],"study_design_scores_gemma":[0.01425174,0.001579811,0.82847047,0.00068373367,0.0022347441,0.002372553,0.004075692,0.0003052618,0.08304112,0.001160788,0.059283428,0.0025406743],"about_ca_topic_score_codex":0.0009754985,"about_ca_topic_score_gemma":0.0006088117,"teacher_disagreement_score":0.09105214,"about_ca_system_score_codex":0.0015878938,"about_ca_system_score_gemma":0.0022077882,"threshold_uncertainty_score":0.9999768},"labels":[],"label_agreement":null},{"id":"W2990766074","doi":"10.1136/bmjopen-2019-032859","title":"Recall of health-related quality of life: how does memory affect the SF-6D in patients with psoriasis or multiple sclerosis? A prospective observational study in Germany","year":2019,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"Universitätsklinikum Hamburg-Eppendorf; Bundesministerium für Bildung und Forschung","keywords":"Medicine; Observational study; Recall; Affect (linguistics); Psoriasis; Quality of life (healthcare); Multiple sclerosis; Health related quality of life; SF-36; Gerontology; Family medicine; Disease; Psychiatry; Internal medicine; Dermatology; Nursing; Cognitive psychology","score_opus":0.1689945227538398,"score_gpt":0.34683091164322105,"score_spread":0.17783638888938125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990766074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986784,0.00010684751,5.1445227e-7,0.0003323045,0.00023391373,0.012342693,0.00010217561,0.000008839577,0.00008874361],"genre_scores_gemma":[0.99824774,0.000004931739,0.00005475047,0.000052432733,0.0000048425723,0.00086818135,0.0000783144,0.00001332213,0.0006754998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969725,0.0017035919,0.00066796446,0.00033076422,0.000103876715,0.00022131829],"domain_scores_gemma":[0.99816114,0.0006253335,0.0006439229,0.0004421035,0.00011263532,0.0000148928775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020340306,0.0001740209,0.00074331387,0.00009179313,0.000065358145,0.000012057187,0.00037883664,0.00012350781,0.00013512454],"category_scores_gemma":[0.0003154426,0.00009053524,0.000055840293,0.00036817158,0.000080282116,0.00017577263,0.0001853146,0.0001377677,0.00001756605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008637682,0.0017902474,0.98277193,0.00005719906,0.0003741769,6.6946814e-7,0.0038514456,0.00001348756,0.0006877699,0.000030809926,0.000055594544,0.0017289896],"study_design_scores_gemma":[0.01744613,0.0011719272,0.97846156,0.00018594536,0.000025709434,3.1741266e-7,0.0018006315,0.0000018386711,0.0007493672,0.000020420175,0.000006366124,0.00012975567],"about_ca_topic_score_codex":0.0035682705,"about_ca_topic_score_gemma":0.007508713,"teacher_disagreement_score":0.0114745125,"about_ca_system_score_codex":0.00008464873,"about_ca_system_score_gemma":0.00028184874,"threshold_uncertainty_score":0.53941816},"labels":[],"label_agreement":null},{"id":"W2991296666","doi":"10.1016/j.det.2019.09.001","title":"Home UV Phototherapy","year":2019,"lang":"en","type":"review","venue":"Dermatologic Clinics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Mylan; Celgene; Samsung; National Psoriasis Foundation; Valeant Pharmaceuticals International; AbbVie; Sanofi; Almirall; Merck; Galderma; Eli Lilly and Company; Sun Pharma; Regeneron Pharmaceuticals; Novartis; Pfizer","keywords":"Medicine; Tolerability; Randomized controlled trial; Dermatology; Alternative medicine; Surgery","score_opus":0.09691848087582133,"score_gpt":0.3537993427803998,"score_spread":0.2568808619045785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991296666","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012319536,0.99200976,0.000006542681,0.000027511356,0.0046065385,0.0009586974,0.00030862205,0.00020978069,0.0017493318],"genre_scores_gemma":[0.000014787014,0.991364,0.00007008591,0.0003752007,0.00007164022,0.00017194296,0.0016601649,0.00007220033,0.0061999517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690896,0.0006767799,0.0010780543,0.00071729335,0.000044853543,0.00057402655],"domain_scores_gemma":[0.99708176,0.0011638175,0.0007292134,0.0009486478,0.00004300706,0.00003358374],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00026770658,0.0007139339,0.0033006023,0.00020532898,0.00014174571,0.00002533734,0.0006810704,0.0020859856,0.0013313594],"category_scores_gemma":[0.000060543745,0.00050086883,0.0013096514,0.00024286825,0.00014574328,0.000045585955,0.00012104587,0.00061816984,0.017131098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020488456,0.00015371402,0.00015364244,0.0023818272,0.001149712,0.000059848968,0.000027779457,4.0385338e-8,5.2568777e-7,0.00017568741,0.010078215,0.98579854],"study_design_scores_gemma":[0.00097583985,0.00009728418,0.00001364352,0.0012563779,0.0016920747,0.0007077632,0.000011616597,1.8995286e-7,0.0000052661817,0.000096902346,0.99458706,0.00055596756],"about_ca_topic_score_codex":0.000003860291,"about_ca_topic_score_gemma":0.0000016973582,"teacher_disagreement_score":0.98524255,"about_ca_system_score_codex":0.000057385005,"about_ca_system_score_gemma":0.00026477652,"threshold_uncertainty_score":0.9997443},"labels":[],"label_agreement":null},{"id":"W2991496398","doi":"10.1007/s13555-019-00340-3","title":"Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure","year":2019,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; Sanofi Genzyme; Genentech; Medac; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; LEO Fondet; Astellas Pharma; Regeneron Pharmaceuticals; Mylan; Eli Lilly and Company; Purdue Pharma; Sun Pharma; Dermira; Purdue University; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Baxalta; Celgene; Pfizer; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Galderma; LEO Pharma; Ortho Dermatologics; Allergan; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Ixekizumab; Psoriasis; Medicine; Dermatology; Psoriatic arthritis","score_opus":0.009983924242019151,"score_gpt":0.21147808006893778,"score_spread":0.20149415582691863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991496398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637043,0.0004978191,0.000008040979,0.00008134428,0.00031589068,0.0011000683,0.0015383335,0.000014799378,0.00007328549],"genre_scores_gemma":[0.99861807,0.0002009349,0.00015757504,0.00014250346,0.0000065820495,0.00010629284,0.000543169,0.000019907182,0.0002049558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872077,0.00015156288,0.00041689488,0.00039197798,0.00004047631,0.0002783108],"domain_scores_gemma":[0.99923164,0.00017087178,0.00015289828,0.00031607968,0.000093761126,0.00003472313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004073018,0.00022251937,0.00058312924,0.00016144385,0.000039582377,0.0000040782697,0.00010998745,0.0002663248,0.000061833416],"category_scores_gemma":[0.000010345745,0.00017318863,0.000075446216,0.00011380171,0.00005478901,0.00005553594,0.000022994003,0.000054419655,0.00002543269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13229549,0.0008464021,0.65633315,0.000022703465,0.0016097631,0.000017572704,0.025553431,0.000117197334,0.0023973156,0.000134595,0.0003702696,0.18030213],"study_design_scores_gemma":[0.057864185,0.004099513,0.881565,0.0001294234,0.00009953794,0.000017382677,0.00066880556,0.0000035216158,0.051812656,0.000096066084,0.0032716535,0.0003722669],"about_ca_topic_score_codex":0.00029574873,"about_ca_topic_score_gemma":0.00013724218,"teacher_disagreement_score":0.22523184,"about_ca_system_score_codex":0.000023761058,"about_ca_system_score_gemma":0.00003198416,"threshold_uncertainty_score":0.70624274},"labels":[],"label_agreement":null},{"id":"W2991659810","doi":"10.1016/j.jaad.2019.11.040","title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development; LEO Pharma; Janssen Scientific Affairs; Janssen Pharmaceuticals; Celgene; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Placebo; Dermatology; Skin cancer; Surgery; Cancer","score_opus":0.03350037897020353,"score_gpt":0.3140369355287464,"score_spread":0.28053655655854287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991659810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167186,0.0015537333,0.000008664478,0.005708514,0.00014145649,0.00048114188,0.0003933893,0.0000032978592,0.000037947768],"genre_scores_gemma":[0.9978855,0.0009277363,0.00052081986,0.00027616043,0.000016973781,0.000004574245,0.0000032786213,0.000011472355,0.00035346343],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995945,0.0022130494,0.0013544315,0.00020897112,0.00008263294,0.00019595455],"domain_scores_gemma":[0.9922125,0.0042753904,0.0031403583,0.00024410641,0.000084803636,0.00004285652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012276495,0.00017457562,0.0017330165,0.00007899067,0.00004196633,0.0000033830354,0.00027206415,0.00013473099,0.000014949154],"category_scores_gemma":[0.00058955856,0.000079887235,0.00019298731,0.00014244711,0.0011995612,0.000036589252,0.00007684208,0.00023338824,0.0000036155927],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39241236,0.0005408878,0.3857057,0.00003802299,0.007755657,0.00007916944,0.0048725484,0.000014084909,0.1461186,0.00019163243,0.0043787146,0.057892635],"study_design_scores_gemma":[0.020263582,0.0054318462,0.89634025,0.00032462602,0.0012133444,0.0019330721,0.0023554172,0.0000016182538,0.055781603,0.000029390289,0.016157623,0.00016759605],"about_ca_topic_score_codex":0.000112415524,"about_ca_topic_score_gemma":0.000012377256,"teacher_disagreement_score":0.5106346,"about_ca_system_score_codex":0.000019949826,"about_ca_system_score_gemma":0.00016412853,"threshold_uncertainty_score":0.4419833},"labels":[],"label_agreement":null},{"id":"W2993441120","doi":"10.25251/skin.3.6.2","title":"Transitioning Between Biologics","year":2019,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Adverse effect; Intensive care medicine; Biologic Agents; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Disease","score_opus":0.014640119302499015,"score_gpt":0.2405203201935189,"score_spread":0.2258802008910199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993441120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878605,0.0065103713,0.00017473557,0.0017500615,0.001327727,0.000113762406,0.000008143099,0.000012278272,0.0022423924],"genre_scores_gemma":[0.99732506,0.00059767143,0.000040154613,0.00019698855,0.00033789407,3.976998e-7,0.000016294936,0.00000880318,0.0014767546],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990299,0.00027177966,0.00037608837,0.00007359155,0.00006086957,0.000187823],"domain_scores_gemma":[0.9987538,0.0006861282,0.00029048728,0.00015941788,0.00008792554,0.000022227505],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000602916,0.00012433206,0.00037003052,0.00008758895,0.00010057473,0.0000025838106,0.00024856656,0.00012888688,0.001097739],"category_scores_gemma":[0.00006657048,0.000060023856,0.0000932572,0.00010831463,0.00015698627,0.00003234027,0.000013390792,0.0002588069,0.00023669064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025565804,0.0002082233,0.04498101,0.000062779094,0.003541962,0.0004563006,0.011117792,0.00017848515,0.668529,0.0005346371,0.014389755,0.2534435],"study_design_scores_gemma":[0.029745152,0.029369451,0.07684063,0.0022542188,0.009644493,0.119167216,0.015760966,0.000013515401,0.28228566,0.009504699,0.42386734,0.0015466477],"about_ca_topic_score_codex":0.000014377905,"about_ca_topic_score_gemma":0.0000024932733,"teacher_disagreement_score":0.4094776,"about_ca_system_score_codex":0.000025618818,"about_ca_system_score_gemma":0.000033547785,"threshold_uncertainty_score":0.9998154},"labels":[],"label_agreement":null},{"id":"W2994983072","doi":"10.1016/j.jconrel.2019.12.016","title":"Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis","year":2019,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Generalitat Valenciana; Ministerio de Ciencia, Innovación y Universidades","keywords":"Psoriasis; Corticosteroid; Medicine; Dermatology; Pharmacology; Conjugate; Chemistry; Internal medicine","score_opus":0.01130798071948525,"score_gpt":0.2364874832926919,"score_spread":0.22517950257320665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994983072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862055,0.0045395936,0.000081569924,0.0006513977,0.0013894757,0.0007701849,0.0000118879,0.000022073518,0.006328309],"genre_scores_gemma":[0.98608387,0.00024869762,0.000279374,0.00041873753,0.00021058317,0.00004017886,0.000010352311,0.000020361718,0.012687843],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982934,0.00029687432,0.0007169918,0.0002367666,0.00009470566,0.0003612382],"domain_scores_gemma":[0.9986954,0.00031941728,0.00039131416,0.00029449188,0.00016142345,0.00013796071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023214129,0.00027901662,0.0010616522,0.00022387455,0.00008297286,0.00003324462,0.00021508412,0.0002123339,0.0006084122],"category_scores_gemma":[0.0001814274,0.00017660462,0.0005890313,0.000118466894,0.000037181337,0.00010235857,0.0000282276,0.0001745709,0.0015073477],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10839092,0.007260571,0.025343116,0.000060414128,0.013769205,0.00040352222,0.0028693413,0.00029225042,0.581067,0.0032062854,0.005670552,0.2516668],"study_design_scores_gemma":[0.46695572,0.03885471,0.036308814,0.0003903924,0.007916742,0.005058337,0.0026670336,0.00010988592,0.19762151,0.0009816035,0.2410756,0.0020596432],"about_ca_topic_score_codex":0.00003744513,"about_ca_topic_score_gemma":0.000002584839,"teacher_disagreement_score":0.3834455,"about_ca_system_score_codex":0.00012562462,"about_ca_system_score_gemma":0.00017926292,"threshold_uncertainty_score":0.9992701},"labels":[],"label_agreement":null},{"id":"W2996552716","doi":"10.1016/j.cell.2019.11.026","title":"Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease","year":2019,"lang":"en","type":"article","venue":"Cell","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":484,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Alberta Innovates; Damon Runyon Cancer Research Foundation; National Multiple Sclerosis Society; Howard Hughes Medical Institute","keywords":"Biology; Interleukin 17; Immunology; Inflammation; Cell biology; RAR-related orphan receptor gamma; Cytokine; Innate lymphoid cell; FOXP3; Acquired immune system; Immune system","score_opus":0.0075697962447836935,"score_gpt":0.19107386234515844,"score_spread":0.18350406610037476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996552716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927227,0.0043180995,0.0000028552972,0.000052335487,0.0005598618,0.00088431063,0.00011632737,0.00007945409,0.0012640939],"genre_scores_gemma":[0.9836257,0.00014963595,0.000052888416,0.000067531306,0.00004114729,0.000070804555,0.00005610888,0.000026256766,0.015909944],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998934,0.00013068355,0.00017578839,0.00038317015,0.000033324293,0.00034307744],"domain_scores_gemma":[0.99939495,0.000033439403,0.00008938754,0.00038751398,0.000026525891,0.00006820718],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012063031,0.00022013014,0.00021618507,0.00006702897,0.00011061643,0.00001783095,0.00014575118,0.00019686313,0.0005244029],"category_scores_gemma":[0.000006506022,0.00018702084,0.00008762182,0.000073142204,0.00006774286,0.00008851132,0.0000966056,0.00014844895,0.002934026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012079512,0.00014425325,0.011436149,0.00009722686,0.00006659187,0.000031551088,0.00030849365,8.906136e-7,0.9829777,0.000027118476,0.00019618409,0.0045930333],"study_design_scores_gemma":[0.002715699,0.00021835588,0.08192236,0.000048463466,0.00016344817,0.00001236256,0.00009369496,0.0000036605147,0.88359356,0.00012375097,0.030717196,0.00038743424],"about_ca_topic_score_codex":0.0000075145513,"about_ca_topic_score_gemma":0.000004210769,"teacher_disagreement_score":0.09938414,"about_ca_system_score_codex":0.000022758568,"about_ca_system_score_gemma":0.00008969112,"threshold_uncertainty_score":0.9978423},"labels":[],"label_agreement":null},{"id":"W2996882089","doi":"10.1016/j.jhep.2019.12.016","title":"IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease","year":2019,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism","keywords":"CXCL1; Tumor necrosis factor alpha; Steatosis; Cancer research; Hepatic stellate cell; Internal medicine; Alcoholic liver disease; Liver injury; Carcinogenesis; Endocrinology; Medicine; Cirrhosis; Chemokine; Biology; Inflammation; Cancer","score_opus":0.014631456511445278,"score_gpt":0.22140542937772184,"score_spread":0.20677397286627655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996882089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9672341,0.031721853,0.0000018921432,0.00014172212,0.00047081948,0.00033246452,0.000013868433,0.000011908633,0.00007137068],"genre_scores_gemma":[0.99887216,0.00073934946,0.00008331815,0.00005828257,0.000019478211,0.0000066804187,0.000018973034,0.000019720472,0.00018203184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790806,0.00053493894,0.00075047923,0.00030467924,0.000060087037,0.00044177548],"domain_scores_gemma":[0.9989265,0.00038475546,0.00036182386,0.00019677366,0.000058783382,0.00007134311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044608445,0.0002691209,0.00074822456,0.0005078462,0.000051653566,0.000013761382,0.00019900083,0.00031668664,0.000583678],"category_scores_gemma":[0.00009018537,0.0002255422,0.00015364357,0.00019920185,0.00013449308,0.00016690271,0.00005760709,0.00039948837,0.00011625804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065000134,0.00022083674,0.96554357,0.000059611237,0.0001722231,0.0021147449,0.00045378046,0.00002306761,0.02731102,0.000048508733,0.000023549657,0.003379109],"study_design_scores_gemma":[0.007991969,0.00067973754,0.9479477,0.00021197252,0.00027472776,0.0017037244,0.00018460437,0.0007423319,0.038908564,0.0006145172,0.00034748562,0.00039268378],"about_ca_topic_score_codex":0.00021355724,"about_ca_topic_score_gemma":0.000073026196,"teacher_disagreement_score":0.031638067,"about_ca_system_score_codex":0.00007454455,"about_ca_system_score_gemma":0.00015541562,"threshold_uncertainty_score":0.9197344},"labels":[],"label_agreement":null},{"id":"W2997875868","doi":"10.1111/bjd.18851","title":"A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Dalhousie University; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Double blinded; Plaque psoriasis; Psoriasis; Randomized controlled trial; Dermatology; Head start; Internal medicine; Placebo; Secukinumab; Pathology","score_opus":0.019551203705524007,"score_gpt":0.26708486217334143,"score_spread":0.2475336584678174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997875868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493074,0.0018635801,0.000086613945,0.00033863776,0.0007480026,0.0017711116,0.00019986604,0.000011787163,0.000049651615],"genre_scores_gemma":[0.9990929,0.00013627957,0.0005199411,0.00006451967,0.00002607935,0.000013785199,0.000067924324,0.000029884313,0.000048680944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954565,0.0017527031,0.0018389948,0.000369711,0.00015798699,0.0004241036],"domain_scores_gemma":[0.996918,0.0013720004,0.0010158616,0.00027234157,0.00031818944,0.00010360533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061431003,0.00031454122,0.002874032,0.00051527837,0.000076376804,0.000023070888,0.00032054618,0.00045181674,0.000108124295],"category_scores_gemma":[0.00029840917,0.00028925997,0.00024325453,0.00024802116,0.00019540393,0.00015564589,0.00009060144,0.00040118414,0.000027370554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9611276,0.0018371182,0.025571574,0.000029312896,0.0011623289,0.00016260425,0.0015235818,0.00015083872,0.0007775465,0.000017633387,0.00028561955,0.0073542385],"study_design_scores_gemma":[0.86134356,0.0029212798,0.12590921,0.00066085317,0.0003960471,0.0016251145,0.00022197764,0.000010586621,0.0063455617,0.000032947442,0.00024641503,0.0002864185],"about_ca_topic_score_codex":0.00057589455,"about_ca_topic_score_gemma":0.0006243638,"teacher_disagreement_score":0.10033763,"about_ca_system_score_codex":0.000069095746,"about_ca_system_score_gemma":0.00031535863,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2998319702","doi":"10.1016/j.jaad.2019.12.038","title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis","year":2019,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Psoriasis Area and Severity Index; Ustekinumab; Secukinumab; Etanercept; Psoriasis; Adalimumab; Infliximab; Cumulative dose; Anakinra; Internal medicine; Dermatology; Psoriatic arthritis; Tumor necrosis factor alpha; Disease","score_opus":0.29854250948539174,"score_gpt":0.4549858454893279,"score_spread":0.15644333600393617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998319702","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018409736,0.97648704,0.00006322205,0.00047323163,0.0006164541,0.00085796963,0.0030676816,0.0000038336143,0.00002082777],"genre_scores_gemma":[0.069953136,0.9290479,0.00055836886,0.000056415178,0.00012675386,0.000027139466,0.000117445714,0.00002758349,0.00008529864],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9906756,0.00320452,0.005189323,0.00040731693,0.00014913295,0.0003740721],"domain_scores_gemma":[0.961723,0.015114623,0.022270048,0.00063629774,0.00021897351,0.00003703304],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00086557027,0.00058527355,0.014297617,0.00035326974,0.00008272227,0.0000028377692,0.0012935105,0.0008770426,0.000059543396],"category_scores_gemma":[0.00036116753,0.0002637461,0.01045666,0.0009038502,0.0013941753,0.000039581308,0.00014350037,0.00054711476,0.0000039991883],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033754176,0.0014437729,0.007792749,0.00042979518,0.68311936,0.0000012089156,0.00042758172,0.00065972854,0.000026432026,0.0002320468,0.003214282,0.29927763],"study_design_scores_gemma":[0.0031064234,0.0020157353,0.0043261694,0.000375503,0.6809134,0.00007569224,0.00019347099,0.00001159936,0.0009224887,0.00015770341,0.30761835,0.00028349785],"about_ca_topic_score_codex":0.00016119565,"about_ca_topic_score_gemma":0.00001911072,"teacher_disagreement_score":0.30440408,"about_ca_system_score_codex":0.00006996992,"about_ca_system_score_gemma":0.00023472197,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W2998523003","doi":"10.1177/1203475419896490","title":"Developing a Patient Charter for People Living With Conditions, Diseases, or Traumas Involving the Skin","year":2019,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Canadian Arthritis Patient Alliance; University of Toronto","funders":"","keywords":"Charter; Medicine; Health care; Government (linguistics); Feeling; Alliance; Hippocratic Oath; Family medicine; Nursing; Psychology; Psychiatry","score_opus":0.05817810966516479,"score_gpt":0.2959640438725851,"score_spread":0.23778593420742034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998523003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036531966,0.99429023,0.000042119995,0.00028167685,0.0011434642,0.0004995726,0.00006453432,0.000009263116,0.000015967558],"genre_scores_gemma":[0.002165484,0.99658144,0.000029227438,0.00024575318,0.00034468813,0.00004725445,0.0001263641,0.00003621276,0.00042357383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982482,0.00031211166,0.0008707527,0.0001955951,0.00008689102,0.00028642488],"domain_scores_gemma":[0.991232,0.0073781465,0.0010239126,0.00017254284,0.0001457722,0.000047643804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038288848,0.00034113278,0.0020827444,0.00029167012,0.00023018314,0.000018750512,0.00012653648,0.00020308327,0.00016912389],"category_scores_gemma":[0.0003598216,0.00014516596,0.00039785894,0.00016063926,0.00010759545,0.00006302052,0.000023072453,0.00025106157,0.000008105208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027186112,0.00008319839,0.00039239213,0.0058924668,0.002349875,0.0002938404,0.0014604077,2.3878644e-7,0.0000037183222,0.000045187186,0.018032454,0.97117436],"study_design_scores_gemma":[0.00046211996,0.0006533975,0.000108404165,0.03270916,0.0047163246,0.018768646,0.0010775337,2.9440596e-7,0.0000017301394,0.000015929589,0.94122547,0.00026097757],"about_ca_topic_score_codex":0.000008290377,"about_ca_topic_score_gemma":0.000022344317,"teacher_disagreement_score":0.9709134,"about_ca_system_score_codex":0.000069558366,"about_ca_system_score_gemma":0.0007216989,"threshold_uncertainty_score":0.5919696},"labels":[],"label_agreement":null},{"id":"W2999017339","doi":"10.29173/hsi215","title":"Does the weather play a role in psoriatic disease?","year":2016,"lang":"en","type":"article","venue":"Health Science Inquiry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Disease; Psoriasis; Geography; Medicine; Dermatology; Internal medicine","score_opus":0.029557746113343237,"score_gpt":0.30288572710525125,"score_spread":0.273327980991908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999017339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98514795,0.0028931967,0.00002658975,0.008620286,0.0026808076,0.0003332118,0.000017026225,0.00004449515,0.00023644502],"genre_scores_gemma":[0.99747455,0.00030076457,0.000022584563,0.0006654991,0.00009488516,0.00007624833,0.0000023848452,0.000006507135,0.001356559],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986812,0.00012472797,0.00022193733,0.00033885465,0.00007244296,0.0005608433],"domain_scores_gemma":[0.99929607,0.00015046011,0.00008701369,0.00037717563,0.000023727944,0.00006556256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008453976,0.00011585537,0.00015249089,0.00012351439,0.00040529188,0.000015439335,0.00039352707,0.000051728384,0.00024307398],"category_scores_gemma":[0.000080555124,0.00004142072,0.000040731236,0.000352496,0.00089533866,0.00015871823,0.00007034392,0.00006842069,0.0006091969],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028466494,0.0003418828,0.35513636,0.000029178998,0.000034187622,0.00001028612,0.010674634,0.0000020768828,0.028021162,0.005617903,0.0018868081,0.5979608],"study_design_scores_gemma":[0.00144605,0.00013328492,0.96925575,0.00014702586,0.000014397229,0.000008796914,0.0010315297,0.000004021662,0.003956175,0.0036745914,0.02013834,0.0001900586],"about_ca_topic_score_codex":0.00010932712,"about_ca_topic_score_gemma":0.00010607008,"teacher_disagreement_score":0.61411935,"about_ca_system_score_codex":0.00012470459,"about_ca_system_score_gemma":0.0004970843,"threshold_uncertainty_score":0.7830197},"labels":[],"label_agreement":null},{"id":"W2999032467","doi":"10.1111/jdv.16187","title":"Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis","year":2020,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Initiatives Ontario North; Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Internal medicine; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Placebo; Arthritis; Gastroenterology; Dermatology; Pathology","score_opus":0.018723276707812878,"score_gpt":0.2714211060891499,"score_spread":0.252697829381337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999032467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913792,0.0052384553,0.000039936716,0.0025900027,0.00012488269,0.0003280757,0.0002877615,0.0000051578795,0.000006531858],"genre_scores_gemma":[0.9987522,0.0007239829,0.000038467388,0.00040432156,0.000033048575,0.000003127453,0.000021609845,0.000018217552,0.000005063647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964023,0.0019992064,0.0010233232,0.00024704894,0.000055653225,0.00027243866],"domain_scores_gemma":[0.99821573,0.0004051139,0.0010845329,0.00009937198,0.000052102467,0.00014313248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040229896,0.00023875941,0.001061072,0.0001275996,0.0001127488,0.0000066071166,0.00021080254,0.00018722752,0.0000107310025],"category_scores_gemma":[0.00040579605,0.00015555434,0.00011077712,0.0001493471,0.00050208915,0.00008252367,0.00015962534,0.00037192943,0.0000015231711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075835414,0.0025318142,0.74853146,0.00033095214,0.0022415458,0.00016451105,0.004388288,0.000029116953,0.017574465,0.00018765451,0.0020259332,0.14615887],"study_design_scores_gemma":[0.13935761,0.003747529,0.82553476,0.0005332215,0.0020533844,0.001469082,0.00020748748,0.000048484442,0.02005975,0.00018991479,0.0061068633,0.00069193525],"about_ca_topic_score_codex":0.0000016527091,"about_ca_topic_score_gemma":8.5344027e-7,"teacher_disagreement_score":0.14546694,"about_ca_system_score_codex":0.000012545261,"about_ca_system_score_gemma":0.000056614375,"threshold_uncertainty_score":0.6343322},"labels":[],"label_agreement":null},{"id":"W2999183880","doi":"10.1177/1203475419897578","title":"Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Psoriasis; Discontinuation; Adverse effect; Population; Cochrane Library; Clinical trial; MEDLINE; Intensive care medicine; Internal medicine; Randomized controlled trial; Dermatology","score_opus":0.03679219203929851,"score_gpt":0.2748122051332955,"score_spread":0.238020013093997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999183880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041937,0.9975174,8.331801e-7,0.00019023471,0.00059941196,0.0011867448,0.000025764763,0.000012328644,0.000047906164],"genre_scores_gemma":[0.00015506841,0.99912924,0.000008100261,0.00018892145,0.00012506559,0.00006345035,0.0001281566,0.000031512347,0.00017049437],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962405,0.0010218319,0.0020234536,0.00029501313,0.0001121639,0.00030701442],"domain_scores_gemma":[0.9953755,0.0022020068,0.0019678085,0.00024279054,0.00012687901,0.00008497363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005373026,0.0005952193,0.0075350367,0.00047825824,0.00005399164,0.000007818531,0.00016690661,0.00033694063,0.0000942334],"category_scores_gemma":[0.00057480414,0.00026956515,0.00058421877,0.00037088888,0.00011231872,0.000047232897,0.000017850747,0.00032679708,0.000034464494],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017271159,0.00024934902,0.00026984562,0.3372857,0.0028711644,0.00257055,0.00014906398,1.9254523e-8,3.894064e-7,0.0000024226201,0.0021574309,0.65427136],"study_design_scores_gemma":[0.0009489379,0.0024534068,0.000007856178,0.57994324,0.012931758,0.0070886738,0.000054106025,1.3349851e-8,3.4940356e-7,0.0000043781392,0.39630967,0.00025758293],"about_ca_topic_score_codex":0.000013232667,"about_ca_topic_score_gemma":0.0000072406992,"teacher_disagreement_score":0.65401375,"about_ca_system_score_codex":0.0001481446,"about_ca_system_score_gemma":0.0003718024,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W2999309611","doi":"10.3899/jrheum.190571","title":"Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Dutch Arthritis Association","keywords":"Rheumatoid arthritis; Psoriasis; Medicine; Interleukin 17; Synovitis; Tumor necrosis factor alpha; Psoriatic arthritis; Receptor; Interleukin; Interleukin 6; Arthritis; Synovial fluid; Immunology; Internal medicine; Cytokine; Pathology; Osteoarthritis","score_opus":0.015178743299768368,"score_gpt":0.2189251489148512,"score_spread":0.20374640561508284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999309611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94580585,0.05174715,0.000053465305,0.0018770165,0.00038715234,0.00008041945,0.000019969611,0.000009987448,0.00001899849],"genre_scores_gemma":[0.9561143,0.04358031,0.000083672414,0.00013753487,0.0000080758955,0.0000034759794,0.0000049174346,0.000010316092,0.00005742374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855965,0.000622461,0.00042598776,0.00015410341,0.000037923222,0.00019985333],"domain_scores_gemma":[0.99908423,0.0005300649,0.00021474756,0.00008079141,0.000039454462,0.000050701285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003980599,0.00015996043,0.000444761,0.00010548224,0.00014303594,0.000015935613,0.00008533116,0.00016159283,0.00020056451],"category_scores_gemma":[0.00017768629,0.00011184662,0.00004093073,0.000065777946,0.00034381522,0.00013453026,0.00009717572,0.0002801322,0.000007727675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017285971,0.00015815873,0.6198854,0.00006956145,0.00043564837,0.00017441153,0.0175686,0.0000072803277,0.20534089,0.0008391565,0.0052753235,0.13295962],"study_design_scores_gemma":[0.04694393,0.0058033434,0.6543512,0.002534428,0.00019481913,0.19320081,0.015763907,0.000064971166,0.03681517,0.0029269885,0.040219367,0.0011810731],"about_ca_topic_score_codex":0.000042924188,"about_ca_topic_score_gemma":0.00010607275,"teacher_disagreement_score":0.1930264,"about_ca_system_score_codex":0.000012011833,"about_ca_system_score_gemma":0.000044439425,"threshold_uncertainty_score":0.45609725},"labels":[],"label_agreement":null},{"id":"W3000234731","doi":"","title":"DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Tazarotene; Medicine; Dermatology; Lotion; Plaque psoriasis; Psoriasis; Clobetasol propionate; Retinoid; Dermatologic agents; Corticosteroid; Pharmacology; Surgery; Antibiotics","score_opus":0.03025818507143531,"score_gpt":0.21526845795395275,"score_spread":0.18501027288251742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000234731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947786,0.00095610885,0.00013942341,0.0019144038,0.00019107385,0.0018994157,0.00006351593,0.00002793346,0.00002955718],"genre_scores_gemma":[0.99753284,0.0003920397,0.0002143977,0.000069744856,0.000038871356,0.0013444484,0.00016804428,0.0000103015145,0.00022932375],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99898875,0.00011762654,0.00029356423,0.00033006913,0.000031117484,0.00023890368],"domain_scores_gemma":[0.9995662,0.000139436,0.000099713565,0.000101030535,0.0000427855,0.00005083628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006192512,0.00015749398,0.00031982406,0.000054136868,0.000051008286,0.000014916071,0.00004613465,0.00019231018,0.0000071333807],"category_scores_gemma":[0.0001204383,0.0001298719,0.000056196892,0.0000718936,0.00008262063,0.00009533836,0.000027040169,0.000051770552,0.0000016848621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036821726,0.0005974764,0.12735452,0.00015891717,0.00021494395,0.0000071703676,0.0011520132,0.0000012229109,0.0059664813,0.0010619422,0.00009381574,0.8597093],"study_design_scores_gemma":[0.014510233,0.0012197347,0.948867,0.000023299921,0.0001518102,0.000016709211,0.000078427016,0.00007953923,0.03059017,0.0001444188,0.0041340394,0.00018460922],"about_ca_topic_score_codex":0.00008053366,"about_ca_topic_score_gemma":0.0000610447,"teacher_disagreement_score":0.8595247,"about_ca_system_score_codex":0.000046255063,"about_ca_system_score_gemma":0.000014929235,"threshold_uncertainty_score":0.5296022},"labels":[],"label_agreement":null},{"id":"W3000407671","doi":"10.1016/j.jid.2020.01.007","title":"Uniting Discovery and Care: The Role of Pharmaceutical Companies in Research, Clinical Studies, and Patient Care","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Pharmaceutical care; Business; Medicine; Patient care; Family medicine; Nursing; Pharmacy","score_opus":0.1935414888341766,"score_gpt":0.40069910850507856,"score_spread":0.20715761967090196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000407671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8634305,0.13406798,8.272206e-7,0.0021956342,0.00011110404,0.00011235062,0.00001500284,0.0000024398182,0.00006416493],"genre_scores_gemma":[0.997353,0.0021674514,0.00010478683,0.00033379247,0.000026256293,0.000003910896,0.000003914434,0.0000057975963,0.0000010970557],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99722147,0.0017974183,0.0005946503,0.00013790435,0.00005616669,0.00019238662],"domain_scores_gemma":[0.99783087,0.0014559774,0.00028018604,0.00006463004,0.00031573317,0.000052624513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026750102,0.00011255903,0.00051219424,0.00008889398,0.00012452662,0.000008407752,0.00011801588,0.00011724169,0.0000026162018],"category_scores_gemma":[0.000828871,0.00007004772,0.000056716974,0.00014557208,0.0022428539,0.00009786577,0.0001658122,0.0005589403,0.0000014768001],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014521275,0.00014344217,0.6297751,0.00036598102,0.0018171885,0.00037513502,0.23360513,0.000009094193,0.0691473,0.004753967,0.000935262,0.05762028],"study_design_scores_gemma":[0.0043621017,0.0017059871,0.052084997,0.00029380716,0.00027422633,0.00092125026,0.4737569,0.000011734968,0.453098,0.0022533482,0.011054436,0.0001832028],"about_ca_topic_score_codex":0.000015667698,"about_ca_topic_score_gemma":0.000026137182,"teacher_disagreement_score":0.57769006,"about_ca_system_score_codex":0.00002402577,"about_ca_system_score_gemma":0.00014256289,"threshold_uncertainty_score":0.82638884},"labels":[],"label_agreement":null},{"id":"W3000494588","doi":"10.5152/eurjrheum.2019.19126","title":"Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry","year":2020,"lang":"en","type":"article","venue":"European Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Patient-reported outcome; Dermatology; Quality of life (healthcare)","score_opus":0.05199080170629532,"score_gpt":0.2629839960731717,"score_spread":0.21099319436687636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000494588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97895354,0.014238335,0.00012937645,0.0014042909,0.0036798578,0.00024555225,0.00029966948,0.000088184526,0.0009612215],"genre_scores_gemma":[0.99309564,0.005064862,0.00028433767,0.0007632523,0.0001628729,0.000006224876,0.0004648823,0.000086061824,0.00007184265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927645,0.0028548562,0.0027007556,0.00077084865,0.00018326053,0.00072583073],"domain_scores_gemma":[0.9960225,0.0004014957,0.002084212,0.0010570848,0.00015883405,0.000275854],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011992102,0.00050910364,0.001500833,0.00031941631,0.00016680395,0.000043511587,0.0013654748,0.00029149008,0.00091742066],"category_scores_gemma":[0.0023142074,0.000469109,0.0003175197,0.00037779572,0.00017928043,0.00035176368,0.0005265232,0.0008419795,0.0011732669],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053960076,0.001471277,0.86403245,0.00012553256,0.0057308627,0.007219722,0.010408974,0.000015453064,0.0022853639,0.00064473355,0.056622338,0.04604729],"study_design_scores_gemma":[0.14074312,0.00817092,0.5281227,0.0034405445,0.00426833,0.014783455,0.01682612,0.00022141497,0.002926883,0.00071838975,0.27522546,0.0045526405],"about_ca_topic_score_codex":0.00033849338,"about_ca_topic_score_gemma":0.00010932481,"teacher_disagreement_score":0.33590972,"about_ca_system_score_codex":0.00007090761,"about_ca_system_score_gemma":0.00035016492,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W3003274437","doi":"10.1016/j.jaad.2020.01.056","title":"Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; MedImmune; Galderma; Ortho Dermatologics; Dermira; DUSA Pharmaceuticals; Vanda Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Kiniksa Pharmaceuticals; AbbVie; Sun Pharma; Regeneron Pharmaceuticals; Abbott Laboratories; Sanofi; Novartis; Pfizer; Amgen","keywords":"Medicine; Double blind; Placebo; Dermatology; Randomized controlled trial; Clinical trial; Internal medicine; Alternative medicine; Pathology","score_opus":0.06953297999972495,"score_gpt":0.37603478330456547,"score_spread":0.3065018033048405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003274437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95979726,0.0036003748,0.0005626405,0.03158648,0.0015265595,0.0028133066,0.00003495602,0.00001837345,0.00006002856],"genre_scores_gemma":[0.99575853,0.0009522503,0.0006635244,0.0018867234,0.0004875934,0.00013901546,0.0000053964354,0.000024649968,0.00008234166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99449295,0.002124301,0.0026521764,0.00024776076,0.00010280384,0.00038002475],"domain_scores_gemma":[0.99151146,0.003340934,0.0047932565,0.00015499911,0.000107511725,0.00009182946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013061968,0.00028550587,0.0034717186,0.00014520099,0.00012351746,0.000009478877,0.0007627126,0.0003162626,0.000049845134],"category_scores_gemma":[0.0014568699,0.00016516975,0.0019112261,0.00024552085,0.0009784794,0.00009082033,0.00008584856,0.00065604184,0.000023827608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9811614,0.0005704596,0.0001369059,0.000027857097,0.0042920327,0.000010121114,0.00030200992,0.000004577869,0.002603559,0.00050133705,0.0042991457,0.0060905875],"study_design_scores_gemma":[0.97610277,0.0015460541,0.000021196625,0.000030000103,0.0029678373,0.0006796264,0.00016778271,0.000037804595,0.0075440374,0.00035719154,0.010388084,0.00015763959],"about_ca_topic_score_codex":0.0000042554134,"about_ca_topic_score_gemma":5.899381e-7,"teacher_disagreement_score":0.035961226,"about_ca_system_score_codex":0.000024001489,"about_ca_system_score_gemma":0.00026393041,"threshold_uncertainty_score":0.6735427},"labels":[],"label_agreement":null},{"id":"W3003414630","doi":"10.25251/skin.4.supp.46","title":"Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Term (time); Randomized controlled trial; Psoriasis; Plaque psoriasis; Internal medicine; Dermatology; Adalimumab; Alternative medicine; Pathology; Disease; Physics","score_opus":0.017923057379120415,"score_gpt":0.28185330641825046,"score_spread":0.26393024903913004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003414630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94491667,0.04990585,0.0004578817,0.0030822346,0.00076187565,0.000709052,0.000057423436,0.00001297512,0.00009604614],"genre_scores_gemma":[0.9920671,0.0072553507,0.00003116397,0.00014186754,0.0003309917,0.000011265871,0.00003747087,0.000019835627,0.000104977335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99632245,0.0013321365,0.00162405,0.00021535445,0.00021113607,0.0002948751],"domain_scores_gemma":[0.9941315,0.0039971694,0.0013251483,0.00029559218,0.00018470777,0.000065905566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007780848,0.00032762857,0.0031343314,0.00037072555,0.00007923176,0.000005062611,0.000457323,0.0001928373,0.0010703902],"category_scores_gemma":[0.0011697966,0.00017654442,0.0006827635,0.0005062169,0.000469249,0.00006106638,0.000062403844,0.00040314105,0.000018146151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90479493,0.00034839395,0.00279513,0.00003101001,0.051805336,0.002534863,0.011833825,0.0002444038,0.011338796,0.000024803303,0.00065171666,0.013596774],"study_design_scores_gemma":[0.93404293,0.0017330853,0.0039849114,0.00043851454,0.05146915,0.0021426335,0.0021764673,0.00016585452,0.0030103829,0.00041469885,0.00012084171,0.00030055383],"about_ca_topic_score_codex":0.00016024055,"about_ca_topic_score_gemma":0.0005223415,"teacher_disagreement_score":0.04715042,"about_ca_system_score_codex":0.00008345892,"about_ca_system_score_gemma":0.00009727266,"threshold_uncertainty_score":0.99984276},"labels":[],"label_agreement":null},{"id":"W3003638259","doi":"10.1080/09546634.2020.1724250","title":"Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Innovaderm (Canada)","funders":"Cilag; LEO Pharma; Bausch Health; Bristol-Myers Squibb; Eli Lilly and Company; Galderma; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Medicine; Psoriasis; Dermatology; Term (time)","score_opus":0.061345816132115996,"score_gpt":0.2869051222724769,"score_spread":0.2255593061403609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003638259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661643,0.0086314045,0.000010323021,0.0034950103,0.00036477266,0.00054146996,0.000088689616,0.00004250159,0.00020937917],"genre_scores_gemma":[0.9820898,0.016861284,0.00012390729,0.00022169479,0.0002066808,0.000035884754,0.00007297333,0.000017942828,0.0003698059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976558,0.0004962779,0.00089936296,0.0004676524,0.000117559764,0.00036331525],"domain_scores_gemma":[0.9983423,0.0006055686,0.00047516453,0.00030025461,0.00009352807,0.00018322034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000055319284,0.00053370907,0.0012224937,0.00011999077,0.00015042053,0.00004344691,0.0001384559,0.00036801994,0.0001243072],"category_scores_gemma":[0.00008124051,0.00029148255,0.0005195547,0.000103819126,0.00018458707,0.00009403072,0.000018929066,0.00012218804,0.000096777025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040899336,0.01923449,0.47917938,0.000024380433,0.0054148533,0.0045140632,0.003005077,0.000016988999,0.02018508,0.0020226673,0.00072098925,0.4247827],"study_design_scores_gemma":[0.043974068,0.11091617,0.5837632,0.00019299038,0.00078609976,0.0023215362,0.00018306072,0.000002410285,0.2320947,0.00013653236,0.025094658,0.0005345586],"about_ca_topic_score_codex":0.000019745547,"about_ca_topic_score_gemma":0.0000055686546,"teacher_disagreement_score":0.42424813,"about_ca_system_score_codex":0.00029732555,"about_ca_system_score_gemma":0.00006827715,"threshold_uncertainty_score":0.99995375},"labels":[],"label_agreement":null},{"id":"W3004396417","doi":"10.1177/1203475420903682","title":"A Brief History of Psoriasis Management in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Intensive care medicine","score_opus":0.02627989625750607,"score_gpt":0.21059410270289014,"score_spread":0.18431420644538407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004396417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957321,0.036321014,0.00000772217,0.0026589655,0.0015877897,0.0000614364,0.000004183939,0.0000034808868,0.0020344],"genre_scores_gemma":[0.9937821,0.0045378744,0.00002201522,0.0010664698,0.00009259782,8.4021207e-7,0.0000040905425,0.000006805698,0.00048721945],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990389,0.00009618845,0.0005528003,0.00009301974,0.00007490244,0.00014418662],"domain_scores_gemma":[0.9991229,0.00040820477,0.0003018896,0.000067207235,0.000048804446,0.000050965333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019843191,0.00010355311,0.00055877666,0.00014543829,0.000012434587,6.784958e-7,0.00006983553,0.000049526716,0.00031432594],"category_scores_gemma":[0.00010139656,0.00007687138,0.00006895359,0.00009358895,0.000066814304,0.000027739576,0.000014455152,0.00011601207,0.0000015276574],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002546625,0.00014972944,0.07158914,0.00032588452,0.001581653,0.011200549,0.0040167207,0.000015046452,0.0119043635,0.00010623234,0.5565054,0.3400587],"study_design_scores_gemma":[0.0049650385,0.00086704304,0.02145962,0.00068916025,0.00094646774,0.005978747,0.0046778354,0.000009926899,0.002232163,0.00008860723,0.9577158,0.0003695828],"about_ca_topic_score_codex":0.04842019,"about_ca_topic_score_gemma":0.019463573,"teacher_disagreement_score":0.40121046,"about_ca_system_score_codex":0.00020125404,"about_ca_system_score_gemma":0.00054641726,"threshold_uncertainty_score":0.99842864},"labels":[],"label_agreement":null},{"id":"W3004911684","doi":"10.1001/jamadermatol.2019.4835","title":"A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents","year":2020,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; LEO Pharma; Galderma; Regeneron Pharmaceuticals; Celgene; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Methotrexate; Psoriasis; Dermatology; Dermatologic agents; Biologic Agents; MEDLINE; Internal medicine; Disease","score_opus":0.03244355478935061,"score_gpt":0.2728204358064183,"score_spread":0.24037688101706767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004911684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973362,0.0008964294,0.000021209924,0.00047455245,0.00018325656,0.00035174852,0.000091905815,0.00007351464,0.00057119096],"genre_scores_gemma":[0.99887735,0.00012533892,0.00020798296,0.00029412078,0.000020559677,0.00004431192,0.0003795665,0.000017849688,0.000032893513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778813,0.0007379714,0.000568079,0.0004367105,0.000046620098,0.00042247292],"domain_scores_gemma":[0.9990621,0.00023753103,0.0003413766,0.00021952268,0.00008975924,0.0000496773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007916407,0.0002880089,0.0009155889,0.00020066016,0.00006839886,0.000006866575,0.0002622234,0.0004815876,0.00019590107],"category_scores_gemma":[0.00012502342,0.00022075392,0.00010291511,0.0005709688,0.00012535835,0.0000912288,0.000086713844,0.00024187387,0.0002246636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016036376,0.00056367164,0.9895173,0.000063066684,0.00020529024,0.00004507357,0.0008365502,0.0000076163064,0.00079000695,0.000032430038,0.00158872,0.004746673],"study_design_scores_gemma":[0.0075474773,0.00067489356,0.9626366,0.000011521374,0.0002813465,0.00002944469,0.00012292332,0.000032912667,0.026255509,0.000014493237,0.0021313403,0.00026156846],"about_ca_topic_score_codex":0.00007763346,"about_ca_topic_score_gemma":0.00004265421,"teacher_disagreement_score":0.026880695,"about_ca_system_score_codex":0.00002951368,"about_ca_system_score_gemma":0.00005199929,"threshold_uncertainty_score":0.90020835},"labels":[],"label_agreement":null},{"id":"W3004913099","doi":"10.1111/jdv.16274","title":"The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry","year":2020,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Merck; AbbVie; Celgene; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Psoriasis; Medicine; Cohort; Odds ratio; Odds; Body surface area; Cohort study; Internal medicine; Cross-sectional study; Quality of life (healthcare); Physical therapy; Dermatology; Logistic regression; Pathology","score_opus":0.024279181702368313,"score_gpt":0.25957366323252823,"score_spread":0.23529448153015992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004913099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840151,0.001472231,0.000003771411,0.013184853,0.00037524404,0.0002868329,0.000017254228,0.000006845693,0.0006378683],"genre_scores_gemma":[0.9968898,0.002274828,0.000033897028,0.0005751168,0.00005580963,0.000011858606,0.000009180037,0.000012438233,0.00013702018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961981,0.002304066,0.0008587397,0.00023021594,0.00014644138,0.00026242368],"domain_scores_gemma":[0.9972004,0.0011002682,0.0014552044,0.00010754593,0.000107356704,0.00002919196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072569103,0.0002183521,0.0004767695,0.00013635469,0.0002378087,0.0000142833305,0.00033625966,0.00018923648,0.000010255647],"category_scores_gemma":[0.0005608809,0.00010959902,0.0001047343,0.00025268155,0.00030061006,0.0001343963,0.000080052705,0.00042416103,0.0000043998634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068028143,0.000184934,0.989194,0.000018635757,0.00044177726,0.0000155579,0.0014670386,0.000013642019,0.0001654474,0.00037660138,0.0006436047,0.00679851],"study_design_scores_gemma":[0.0041906573,0.00018895636,0.98666525,0.000038863258,0.00029676306,0.0002952383,0.00022482144,0.0000048009383,0.0011051142,0.0003004162,0.006576361,0.00011274338],"about_ca_topic_score_codex":0.000022471055,"about_ca_topic_score_gemma":0.000074863434,"teacher_disagreement_score":0.012874752,"about_ca_system_score_codex":0.00010980678,"about_ca_system_score_gemma":0.000066519664,"threshold_uncertainty_score":0.44693187},"labels":[],"label_agreement":null},{"id":"W3004935569","doi":"10.1080/09546634.2020.1720586","title":"Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Plaque psoriasis; Logistic regression; Internal medicine; Demographics; Dermatology; Disease; Adalimumab; Demography","score_opus":0.022571259567142524,"score_gpt":0.23226676470145394,"score_spread":0.2096955051343114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004935569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969427,0.00011929916,0.00008919806,0.0018658562,0.00018544146,0.0006195361,0.00009385334,0.000008539262,0.00007556817],"genre_scores_gemma":[0.99894696,0.00005222,0.00018367682,0.00065610406,0.000020370058,0.000035453097,0.00006969569,0.000011353269,0.000024183688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998083,0.00049390923,0.0007164549,0.00025913937,0.00015316054,0.00029433685],"domain_scores_gemma":[0.99904037,0.00015838217,0.00039472547,0.00020880804,0.00012125913,0.00007648392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015522349,0.00026151817,0.0006654122,0.00021780588,0.00006398212,0.00001773614,0.00028588207,0.00018702897,0.00005289726],"category_scores_gemma":[0.000103487946,0.00014199303,0.00013165492,0.00055358815,0.00004805845,0.00009272773,0.00003848919,0.00016529954,0.00003056435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038121678,0.006398933,0.9132055,0.000042938944,0.00067706825,0.0005560949,0.011750634,0.0020931286,0.010328974,0.00015346085,0.00035129683,0.0163203],"study_design_scores_gemma":[0.013423796,0.0053783203,0.96362865,0.00011195578,0.00018863301,0.00014698708,0.00072145736,0.000010078337,0.013909047,0.000013387291,0.0022217517,0.0002459122],"about_ca_topic_score_codex":0.000015076801,"about_ca_topic_score_gemma":0.000018393712,"teacher_disagreement_score":0.050423183,"about_ca_system_score_codex":0.00019060833,"about_ca_system_score_gemma":0.00009323293,"threshold_uncertainty_score":0.57903075},"labels":[],"label_agreement":null},{"id":"W3005038630","doi":"10.3899/jrheum.200124","title":"Methotrexate in Psoriasis and Psoriatic Arthritis","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Oxford Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Methotrexate; Tolerability; Dermatology; Arthritis; Internal medicine; Adverse effect","score_opus":0.01886145583139694,"score_gpt":0.23691200927073947,"score_spread":0.21805055343934251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005038630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729863,0.022491775,0.00013353257,0.0035806599,0.00060268975,0.00008083351,0.000004819456,0.000010051201,0.00010937211],"genre_scores_gemma":[0.98709613,0.012416971,0.00021388216,0.0002174072,0.000010531508,0.0000021585183,0.0000018796695,0.0000099154695,0.00003111602],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984025,0.00074526866,0.0005009331,0.00010170793,0.000031418553,0.00021817819],"domain_scores_gemma":[0.99890804,0.00058799516,0.0003204791,0.00010628696,0.000042657015,0.000034531335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005808666,0.00013307769,0.0005125058,0.00009658806,0.00007217927,0.0000060460015,0.0002080368,0.000139333,0.00018021172],"category_scores_gemma":[0.00026776505,0.00008558194,0.00007297326,0.0001562545,0.00014021911,0.00007349985,0.000050304312,0.00026223913,0.00008189957],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004056874,0.00026255424,0.26747325,0.000098437355,0.0019824435,0.00013636472,0.021039119,0.00004817604,0.025145862,0.0036740215,0.0072590313,0.66882384],"study_design_scores_gemma":[0.12731047,0.012140036,0.42385203,0.0019169188,0.0044817673,0.13340245,0.023121083,0.00026135042,0.10482474,0.026839694,0.13853529,0.003314163],"about_ca_topic_score_codex":0.000087513625,"about_ca_topic_score_gemma":0.00006963111,"teacher_disagreement_score":0.6655097,"about_ca_system_score_codex":0.000012166815,"about_ca_system_score_gemma":0.00004541454,"threshold_uncertainty_score":0.348993},"labels":[],"label_agreement":null},{"id":"W3005184972","doi":"10.1016/j.jaad.2020.01.072","title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Janssen Biotech; Ortho Dermatologics; LEO Pharma; Sanofi Genzyme; GlaxoSmithKline; Australian Renewable Energy Agency; MedImmune; Kyowa Hakko Kirin; Sun Pharma; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Medac; AbbVie; Novartis; Celgene; Regeneron Pharmaceuticals; University of Connecticut; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Almirall","keywords":"Medicine; Apremilast; Scalp; Placebo; Dermatology; Multicenter study; Double blind; Psoriasis; Randomized controlled trial; Adverse effect; Multicenter trial; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.017344251703946573,"score_gpt":0.27603364919306417,"score_spread":0.25868939748911757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005184972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944545,0.00034892527,0.000023639577,0.0028974412,0.00010545169,0.0020282217,0.00010942968,0.0000028558347,0.000029543053],"genre_scores_gemma":[0.99953204,0.00011676726,0.00012787225,0.00016794102,0.000012136666,0.000016457394,0.0000023564317,0.000013618535,0.000010808005],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99614185,0.0015875114,0.0016813452,0.00021317948,0.00014733833,0.00022878742],"domain_scores_gemma":[0.9952639,0.0010919393,0.0032618786,0.00018911561,0.00014054567,0.000052632207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047981262,0.00024455506,0.0022860705,0.00019506329,0.000057613037,0.000002741872,0.0005357621,0.0001345174,0.0000061886035],"category_scores_gemma":[0.00036230183,0.00012705443,0.00028937327,0.00040202032,0.00072385237,0.0000701427,0.00017290695,0.0003909156,7.638896e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95786077,0.0016296059,0.028185038,0.00003646286,0.0021855321,0.0000029437715,0.0033080843,0.0004891792,0.004694508,0.000010810034,0.00011455138,0.0014825049],"study_design_scores_gemma":[0.9380207,0.0012668709,0.026258036,0.00017813327,0.0011285103,0.00007982094,0.00080479874,0.000034968194,0.03205474,0.0000071259788,0.00004287217,0.00012344477],"about_ca_topic_score_codex":0.000052718187,"about_ca_topic_score_gemma":0.000010737871,"teacher_disagreement_score":0.027360233,"about_ca_system_score_codex":0.000022201992,"about_ca_system_score_gemma":0.00009334968,"threshold_uncertainty_score":0.51811296},"labels":[],"label_agreement":null},{"id":"W3005356559","doi":"10.1177/2050313x20905672","title":"Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report","year":2020,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psoriasis; Regimen; Dosing; Plaque psoriasis; Maintenance dose; Dermatology; Maintenance therapy; Pharmacology; Internal medicine; Chemotherapy","score_opus":0.02648647769300032,"score_gpt":0.28251091187443717,"score_spread":0.25602443418143683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005356559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110323,0.001144508,0.0017984088,0.0014065308,0.0007171333,0.0013369975,0.00006144375,0.000060693597,0.002371053],"genre_scores_gemma":[0.99711883,0.00006920544,0.0012705752,0.00047128057,0.000067780406,0.0001417135,0.00025839853,0.00003068671,0.00057152513],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99718887,0.00035458035,0.0011987978,0.0007344553,0.00015973765,0.00036356942],"domain_scores_gemma":[0.9985609,0.00014125594,0.00041303283,0.00054378435,0.00009656359,0.0002444613],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010910025,0.00026577685,0.00069337053,0.000113264956,0.00013656392,0.00003224022,0.0001661888,0.00045986057,0.003116439],"category_scores_gemma":[0.0015202719,0.0002337375,0.000112778995,0.00045052642,0.00008813465,0.00018797333,0.00034961122,0.0002889782,0.000041704527],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076756644,0.00026983523,0.0008462193,0.0000383234,0.00017317818,0.97022104,0.0009810252,0.0012683326,0.00032353407,0.000010814272,0.0010157464,0.024084391],"study_design_scores_gemma":[0.0032121625,0.00026423088,0.00012951906,0.00015704712,0.0001554196,0.9892165,0.0005645819,0.00038507293,0.0037343155,0.000035567078,0.0018387786,0.00030678394],"about_ca_topic_score_codex":0.0023610264,"about_ca_topic_score_gemma":0.0007663166,"teacher_disagreement_score":0.023777608,"about_ca_system_score_codex":0.000062399035,"about_ca_system_score_gemma":0.0005385783,"threshold_uncertainty_score":0.99779487},"labels":[],"label_agreement":null},{"id":"W3005364164","doi":"10.3899/jrheum.200126","title":"GRAPPA Treatment Recommendations: Updates and Methods","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Medicine; Guideline; Psoriatic arthritis; Medical physics; MEDLINE; Psoriasis; Intensive care medicine; Pathology; Dermatology","score_opus":0.03373392867488933,"score_gpt":0.3046063826926679,"score_spread":0.27087245401777854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005364164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.956821,0.021352433,0.0016917275,0.019150842,0.0006859102,0.00011682369,0.000012133572,0.000019215557,0.00014989088],"genre_scores_gemma":[0.9772015,0.018230733,0.0040366533,0.00035902765,0.000010379676,0.0000045978527,0.00001384818,0.000011188581,0.00013205296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985557,0.0008620385,0.00033959036,0.00008181141,0.000014247014,0.0001465981],"domain_scores_gemma":[0.998841,0.00070172956,0.00028092435,0.00010046522,0.000045064724,0.00003084823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037595816,0.00012088988,0.00036287413,0.00005618718,0.00014119211,0.0000060129487,0.00014893124,0.00009394645,0.00029364612],"category_scores_gemma":[0.000096063246,0.000066481436,0.00007933806,0.00008432547,0.00012825201,0.00005595728,0.000034190874,0.00011370553,0.00006191694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018460945,0.0002855512,0.08150916,0.00002767567,0.0037903641,0.000012432606,0.010633034,0.0000070272067,0.043167338,0.0034700248,0.021310829,0.83394045],"study_design_scores_gemma":[0.017412767,0.007322458,0.0122121945,0.00013958619,0.0032210522,0.030816212,0.0084699,0.000045912926,0.12815712,0.0067198714,0.78475296,0.0007299823],"about_ca_topic_score_codex":0.00004207735,"about_ca_topic_score_gemma":0.00000984205,"teacher_disagreement_score":0.83321047,"about_ca_system_score_codex":0.000014858645,"about_ca_system_score_gemma":0.000037503873,"threshold_uncertainty_score":0.3215219},"labels":[],"label_agreement":null},{"id":"W3006042543","doi":"10.1007/978-3-030-38315-2_4","title":"IL-17 Signaling in the Tumor Microenvironment","year":2020,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Tumor microenvironment; Stromal cell; Extracellular matrix; Metastasis; Cytokine; Tumor progression; Immune system; Cell biology; Cancer research; Chemistry; Biology; Immunology; Cancer","score_opus":0.04526698512076498,"score_gpt":0.3434792591370016,"score_spread":0.2982122740162366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006042543","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011009829,0.99698085,0.000001588609,0.00015801137,0.00055582536,0.00060251163,0.000035850408,0.000012343801,0.0005520256],"genre_scores_gemma":[0.004385747,0.9941659,0.000041521304,0.00052624906,0.00015277641,0.00029945088,0.0003649051,0.000016918346,0.000046505025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798167,0.00055025367,0.000566449,0.0005286164,0.000024609559,0.0003484284],"domain_scores_gemma":[0.99913776,0.00044444986,0.00019890848,0.00019436782,0.0000028284292,0.000021699781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021346495,0.00041826972,0.0013462129,0.00015089134,0.00007079309,0.000003279095,0.00030565693,0.00024499316,0.00019561985],"category_scores_gemma":[0.000027371827,0.00022638222,0.000110066714,0.00018088603,0.00051809725,0.000048914528,0.00010230489,0.000353024,0.000054919055],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060461447,0.000158284,0.00014347523,0.0003576811,0.00009377378,0.000107878535,0.0010920413,9.6650474e-8,0.0046052993,0.0002290458,0.00018680537,0.99296516],"study_design_scores_gemma":[0.0010850002,0.0007124789,0.000008183231,0.0014934875,0.00014600104,0.00022115577,0.0016071588,6.2400964e-8,0.000633019,0.000058064103,0.9938179,0.00021744924],"about_ca_topic_score_codex":0.000034959747,"about_ca_topic_score_gemma":0.00001687707,"teacher_disagreement_score":0.9936311,"about_ca_system_score_codex":0.000074900956,"about_ca_system_score_gemma":0.00002496279,"threshold_uncertainty_score":0.92315996},"labels":[],"label_agreement":null},{"id":"W3006137587","doi":"10.1177/2050313x20904561","title":"Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report","year":2020,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Secukinumab; Medicine; Dermatology; Psoriasis; Etiology; Ustekinumab; Atopic dermatitis; Adverse effect; Tumor necrosis factor alpha; Immunology; Psoriatic arthritis; Pathology; Internal medicine; Adalimumab","score_opus":0.028922534687800122,"score_gpt":0.30904095504578866,"score_spread":0.2801184203579885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006137587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236834,0.00042554675,0.000102947924,0.0010680457,0.0015247662,0.002317805,0.00011369597,0.0000701714,0.0020086872],"genre_scores_gemma":[0.9968864,0.000021054753,0.0001686261,0.000996211,0.00015851649,0.00056175404,0.0006007666,0.000045998182,0.0005607153],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99675214,0.00034041435,0.0011702587,0.0009845813,0.00018181067,0.00057076383],"domain_scores_gemma":[0.99816686,0.00040957902,0.00045587186,0.0006114651,0.0000864855,0.00026976236],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011644686,0.00036467248,0.0007308022,0.00010565887,0.00024954783,0.00004922952,0.00019901905,0.0003765067,0.0016698507],"category_scores_gemma":[0.0024736996,0.0003046069,0.00019365209,0.0002705167,0.00010624833,0.00015543283,0.00026927286,0.00038934476,0.000111685265],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006967062,0.0005699259,0.0047615794,0.00004507818,0.00021706363,0.9369494,0.00063257274,0.0000026699142,0.000053246025,0.000033251734,0.0026985959,0.053339954],"study_design_scores_gemma":[0.010703507,0.0009374555,0.0007206127,0.000247402,0.00028654645,0.9617609,0.00044206544,0.000025600664,0.0029130827,0.00021730096,0.021220941,0.0005246252],"about_ca_topic_score_codex":0.0013822137,"about_ca_topic_score_gemma":0.0015888896,"teacher_disagreement_score":0.05281533,"about_ca_system_score_codex":0.000118155454,"about_ca_system_score_gemma":0.00039397494,"threshold_uncertainty_score":0.9999406},"labels":[],"label_agreement":null},{"id":"W3007162511","doi":"10.1073/pnas.1919893117","title":"Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Research Executive Agency; Canadian Institutes of Health Research; Fondation Leducq; European Commission; Arthritis Research UK; Bayer HealthCare; Cancer Research UK; Ontario Ministry of Economic Development and Innovation; Wellcome Trust; Medical Research Council; Versus Arthritis; Ministero dello Sviluppo Economico; Kennedy Trust for Rheumatology Research; National Institute for Health and Care Research; Genome Canada; Pfizer; Eli Lilly and Company","keywords":"Biology; Demethylase; Effector; Cell biology; Transcription factor; Chromatin; Reprogramming; Histone; Cytokine; Epigenetics; T cell; Immune system; Cell; Immunology; Genetics","score_opus":0.041900855338887426,"score_gpt":0.2861842599851161,"score_spread":0.24428340464622866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007162511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562764,0.0016570849,4.5725795e-7,0.0011012267,0.000034197456,0.0001257531,0.000037765894,0.000015193234,0.0014006789],"genre_scores_gemma":[0.9990197,0.000017489103,0.00021505353,0.00018395315,0.000028175144,0.000010499508,0.0000020128916,0.000003623517,0.00051952386],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926364,0.00001529748,0.00021391557,0.00022221798,0.00015208725,0.00013283218],"domain_scores_gemma":[0.99949837,0.00013751426,0.0002691001,0.000005724959,0.00006731684,0.00002196152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045298797,0.000105915904,0.00016702498,0.00007734388,0.00045498717,0.000009726693,0.00024336565,0.00008847293,0.000030543943],"category_scores_gemma":[0.00016808171,0.00006845027,0.00004993442,0.0002644862,0.00037604113,0.00014134684,0.00007067488,0.00010889561,0.000009824818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003397891,0.000044729208,0.0013358423,0.00002576903,0.000051405117,3.2161576e-9,0.00040575876,0.000002920602,0.993216,0.00072786293,0.0024537889,0.0017019555],"study_design_scores_gemma":[0.00038361351,0.00007957836,0.03173291,0.000022420028,0.000045853056,0.0000021072626,0.0001327988,0.00000237866,0.9635544,0.00025879624,0.00371114,0.000074051095],"about_ca_topic_score_codex":0.0000051883117,"about_ca_topic_score_gemma":4.6758753e-8,"teacher_disagreement_score":0.030397069,"about_ca_system_score_codex":0.000021439027,"about_ca_system_score_gemma":0.000019832598,"threshold_uncertainty_score":0.34994394},"labels":[],"label_agreement":null},{"id":"W3007635773","doi":"10.5114/ada.2019.91420","title":"Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta-analysis of case-control studies","year":2019,"lang":"en","type":"review","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Confidence interval; Triglyceride; Psoriasis; Meta-analysis; Cochrane Library; Apolipoprotein B; Endocrinology; Cholesterol; Immunology","score_opus":0.09331462283396318,"score_gpt":0.36678533841683125,"score_spread":0.27347071558286806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007635773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022689968,0.9928732,0.0000044055996,0.00005551597,0.00015349966,0.004260436,0.0003618885,0.000007236331,0.000014833934],"genre_scores_gemma":[0.048161034,0.9502585,0.00003896379,0.00006464945,0.0000034886045,0.0013776738,0.000051652132,0.000017816657,0.000026246082],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9916798,0.0051886425,0.002033878,0.0006623608,0.00009117578,0.00034413356],"domain_scores_gemma":[0.99568045,0.0019133555,0.0016369652,0.0004782964,0.0002690472,0.000021878397],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017855864,0.00056912063,0.011481003,0.00089671835,0.000053559248,0.0000029260875,0.00017190837,0.0006567199,0.00007323443],"category_scores_gemma":[0.0010041072,0.00039452707,0.00049568684,0.000547925,0.00045229,0.00014824214,0.0001298643,0.00026994996,0.00000437023],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033177963,0.00020272394,0.000513791,0.6048109,0.25841418,0.000063478605,0.00043416672,0.000008436067,5.146784e-7,0.00033447234,0.000005044158,0.1351791],"study_design_scores_gemma":[0.00254795,0.0001719994,0.00028583736,0.01145746,0.9827448,0.0010762834,0.00014136323,0.0000101838905,0.0000052147348,0.00031618215,0.0008461684,0.00039653643],"about_ca_topic_score_codex":0.000050250837,"about_ca_topic_score_gemma":0.0014389219,"teacher_disagreement_score":0.7243306,"about_ca_system_score_codex":0.000047467714,"about_ca_system_score_gemma":0.00009165872,"threshold_uncertainty_score":0.9998507},"labels":[],"label_agreement":null},{"id":"W3008136531","doi":"10.1515/sjpain-2019-0158","title":"The complex experience of psoriasis related skin pain: a qualitative study","year":2020,"lang":"en","type":"article","venue":"Scandinavian Journal of Pain","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Erythema; Qualitative research; Physical therapy","score_opus":0.043819519553731576,"score_gpt":0.3084964024792014,"score_spread":0.2646768829254698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008136531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532485,0.002422531,0.00044814477,0.0009593912,0.0003917397,0.0002598648,0.000020355192,0.0000126866435,0.00016042944],"genre_scores_gemma":[0.999429,0.00006658401,0.000093360155,0.00010407257,0.0000529868,0.0000094447005,0.0000073206875,0.000012278324,0.00022498697],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9937117,0.005040447,0.0007382278,0.00016163006,0.00009950508,0.0002484506],"domain_scores_gemma":[0.9975013,0.00143886,0.00066335674,0.00017138466,0.00016409312,0.000060975326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037533299,0.00017325536,0.00044496503,0.000072396404,0.0002539627,0.000015730167,0.0003925059,0.00007704493,0.00028202726],"category_scores_gemma":[0.0009270571,0.00010969739,0.00022223165,0.00032896086,0.00025582823,0.00007746224,0.000037984053,0.00021959153,0.000025556797],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00249805,0.00077495247,0.045281406,0.000029784735,0.002488089,0.000130119,0.758004,0.000009709085,0.030346181,0.00034288998,0.007379986,0.1527148],"study_design_scores_gemma":[0.009123563,0.010912534,0.049856406,0.00019410765,0.00044057396,0.00010037184,0.90954787,0.000025972406,0.009698491,0.0007584224,0.008917857,0.00042384418],"about_ca_topic_score_codex":0.00002937977,"about_ca_topic_score_gemma":0.000013041555,"teacher_disagreement_score":0.15229097,"about_ca_system_score_codex":0.000038417416,"about_ca_system_score_gemma":0.000053630585,"threshold_uncertainty_score":0.44733295},"labels":[],"label_agreement":null},{"id":"W3008470218","doi":"","title":"Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.","year":2009,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Itching; Psoriatic arthritis; Etiology; Population; Disease; Arthritis; Immunology; Internal medicine","score_opus":0.03449979405312162,"score_gpt":0.2515071622275499,"score_spread":0.21700736817442826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008470218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934374,0.0027739457,0.0008007018,0.00046310568,0.00027718287,0.0012073605,0.00008289764,0.00010763591,0.00084977184],"genre_scores_gemma":[0.9963592,0.00038302125,0.0004659955,0.0008066472,0.000028652163,0.0008285559,0.0001484458,0.000014062488,0.00096536096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834293,0.00024552958,0.00036410324,0.00047889142,0.00007786691,0.0004906555],"domain_scores_gemma":[0.9990742,0.00007723386,0.00013700062,0.00056675234,0.00006777755,0.000077039454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039116587,0.0002584928,0.0004923408,0.00035475462,0.00010376962,0.000021718586,0.00033479964,0.00018628621,0.00018668473],"category_scores_gemma":[0.000011444805,0.00022295555,0.00024372048,0.0006894189,0.00004250186,0.00015423009,0.00001344957,0.000083513776,0.00005071453],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066513955,0.0015257333,0.011404192,0.000043963733,0.006432205,0.000038776132,0.00041744826,0.0028213405,0.0138752805,0.0007804561,0.0010567248,0.9549525],"study_design_scores_gemma":[0.003816736,0.0003365077,0.8579855,0.00005423952,0.0019973486,0.0000046261184,0.00011272323,0.00002781421,0.13355172,0.00021422755,0.0014792883,0.0004192723],"about_ca_topic_score_codex":0.00006420376,"about_ca_topic_score_gemma":0.000025508034,"teacher_disagreement_score":0.9545332,"about_ca_system_score_codex":0.000060296778,"about_ca_system_score_gemma":0.000022649176,"threshold_uncertainty_score":0.90918636},"labels":[],"label_agreement":null},{"id":"W3010084936","doi":"10.1161/atvbaha.119.314008","title":"Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1","year":2020,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; York University","keywords":"Psoriasis; Platelet; Medicine; Pathogenesis; Platelet activation; Disease; Vascular disease; Immunology; Aspirin; Phenotype; Inflammation; Internal medicine; Biology; Gene","score_opus":0.029291436121366757,"score_gpt":0.24176031096120923,"score_spread":0.21246887483984248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010084936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774504,0.00035532034,0.000062623905,0.0007229646,0.00043955274,0.0003930136,0.0000912083,0.00011129556,0.00007900872],"genre_scores_gemma":[0.9973854,0.0015035488,0.00008982271,0.0006875328,0.000072987066,0.00008821926,0.00012219088,0.00004098754,0.000009337857],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99706393,0.0010476713,0.0005052768,0.00074371975,0.000045551256,0.00059387233],"domain_scores_gemma":[0.99908215,0.00026505368,0.00016683413,0.00034608645,0.0000405732,0.000099329714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040845858,0.0004208855,0.00072268816,0.00017104267,0.00021041546,0.00002642697,0.0002588075,0.000624129,0.00033608265],"category_scores_gemma":[0.00007066456,0.00037670945,0.0002090079,0.00027016047,0.00024874645,0.00013643793,0.0001629834,0.00029602548,0.00033729326],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031435097,0.00017957455,0.057676043,0.000019278525,0.00034600144,7.6143044e-7,0.00141705,0.000001644136,0.93781537,0.000031545536,0.000114794064,0.0020836035],"study_design_scores_gemma":[0.005177729,0.0008918246,0.7990668,0.00003045038,0.00011162285,0.0000017577305,0.00021987343,0.0000075997436,0.18641834,0.000021412752,0.0076193395,0.00043328904],"about_ca_topic_score_codex":0.00009452807,"about_ca_topic_score_gemma":0.000026995942,"teacher_disagreement_score":0.751397,"about_ca_system_score_codex":0.000047836416,"about_ca_system_score_gemma":0.00005505987,"threshold_uncertainty_score":0.9998685},"labels":[],"label_agreement":null},{"id":"W3010994301","doi":"10.1038/s41598-020-61981-5","title":"Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV)","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Heritability; Biology; Genetics","score_opus":0.03403750205705872,"score_gpt":0.2411874055482207,"score_spread":0.207149903491162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010994301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98418075,0.005657435,0.000033436958,0.0003272861,0.008539795,0.00063466973,0.00003090139,0.0001887173,0.0004070036],"genre_scores_gemma":[0.9985801,0.00035375275,0.00020937691,0.00004879724,0.000104340805,0.00008798817,0.00011957638,0.000031811964,0.0004642482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957291,0.000452567,0.0011348295,0.0017029243,0.00021178839,0.0007687895],"domain_scores_gemma":[0.9981946,0.00028769032,0.00045760968,0.00077695877,0.00011843402,0.00016474123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010405845,0.00045572585,0.00087284413,0.00024310718,0.0006101209,0.00027155757,0.00025814367,0.0003871015,0.00065212935],"category_scores_gemma":[0.0007958037,0.000412409,0.00020208956,0.0008236118,0.0007636109,0.0003310754,0.00019482085,0.00033744625,0.00012011887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021240939,0.00039172446,0.8021386,0.00013743388,0.00033178084,0.0014538807,0.007487891,0.0000074302325,0.030498082,0.00010186303,0.0020457776,0.15519312],"study_design_scores_gemma":[0.007435217,0.0012273225,0.8071507,0.0007642203,0.0009713448,0.0034626196,0.008037903,0.00028230425,0.12995076,0.0056528514,0.03163174,0.0034330075],"about_ca_topic_score_codex":0.0005186308,"about_ca_topic_score_gemma":0.000988588,"teacher_disagreement_score":0.15176012,"about_ca_system_score_codex":0.000072175564,"about_ca_system_score_gemma":0.00014083843,"threshold_uncertainty_score":0.99983275},"labels":[],"label_agreement":null},{"id":"W3011453881","doi":"10.1111/bjd.19018","title":"Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to &lt; 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"Janssen Research and Development","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Dermatology Life Quality Index; Dosing; Internal medicine; Discontinuation; Gastroenterology; Dermatology; Infliximab; Disease","score_opus":0.03612339614048511,"score_gpt":0.273350417063129,"score_spread":0.23722702092264392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011453881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98928493,0.0064557884,0.000047910595,0.0009079695,0.00049436395,0.0017811027,0.0009825868,0.0000056567933,0.000039690254],"genre_scores_gemma":[0.996547,0.0027898666,0.00019143465,0.00022693981,0.000053424403,0.000055868255,0.00007308349,0.000022741931,0.00003967421],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975975,0.0006674138,0.0010229409,0.00031315023,0.00008760595,0.00031136535],"domain_scores_gemma":[0.99622875,0.0028452014,0.000503665,0.00019671857,0.0001473079,0.00007834997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023053147,0.00021733757,0.0008086388,0.00012701673,0.00012795808,0.00003353795,0.0005691755,0.00016384223,0.00001541215],"category_scores_gemma":[0.00050437864,0.00016501054,0.00012611494,0.00029410698,0.00009263008,0.000079124424,0.00017124582,0.0001388267,0.0000075621797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025591018,0.010150943,0.08706635,0.000054889533,0.006003275,0.0014453144,0.0289514,0.00034390253,0.005981589,0.000019055968,0.039599683,0.7947926],"study_design_scores_gemma":[0.11208627,0.0046567055,0.8511607,0.00016169676,0.0016112572,0.0010694949,0.0020316697,0.000033470733,0.006433595,0.000050008613,0.020490242,0.00021487719],"about_ca_topic_score_codex":0.0004331137,"about_ca_topic_score_gemma":0.0005455077,"teacher_disagreement_score":0.7945777,"about_ca_system_score_codex":0.000042516836,"about_ca_system_score_gemma":0.00010975989,"threshold_uncertainty_score":0.6728934},"labels":[],"label_agreement":null},{"id":"W3012442502","doi":"10.1172/jci126567","title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Krembil Foundation; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Austrian Science Fund; Brigham and Women's Hospital","keywords":"Tyrosine kinase 2; Medicine; Immunology; Immunity; Immune system; Janus kinase; Disease; Ankylosing spondylitis; Biology; Receptor; Cytokine; Internal medicine","score_opus":0.08768227452592112,"score_gpt":0.34968374972924166,"score_spread":0.2620014752033205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012442502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235225,0.0038089124,0.0000055459254,0.0031594108,0.0005220586,0.00009868673,0.000007727854,0.000010906676,0.000034524437],"genre_scores_gemma":[0.9979407,0.0012101273,0.0002835276,0.00026568063,0.00021244808,0.0000022512477,0.000050437764,0.000005866861,0.000028966493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853957,0.00048722886,0.00071171764,0.000118227086,0.00004849533,0.00009473773],"domain_scores_gemma":[0.99909633,0.00022614436,0.00040974846,0.000060777056,0.00010827209,0.000098734985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006104446,0.00008922039,0.00028183762,0.00006484525,0.0000570605,0.000013879051,0.00005415859,0.00013809737,0.00004500533],"category_scores_gemma":[0.0013819527,0.00007013628,0.00007263698,0.00013889969,0.00020390174,0.00021955118,0.000031479587,0.0002914886,0.000019670617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007545066,0.00065421144,0.47239217,0.000110062494,0.00022023551,0.00017260156,0.0019544533,0.000039755476,0.21126097,0.00038056303,0.0028869216,0.30238298],"study_design_scores_gemma":[0.0058857757,0.0018300547,0.9315164,0.0005996376,0.00016742028,0.000048418042,0.0002455895,0.000057483678,0.05365342,0.0033778795,0.0024226983,0.00019523941],"about_ca_topic_score_codex":0.0000049417413,"about_ca_topic_score_gemma":0.000003536554,"teacher_disagreement_score":0.4591242,"about_ca_system_score_codex":0.000009842996,"about_ca_system_score_gemma":0.000106964355,"threshold_uncertainty_score":0.28600746},"labels":[],"label_agreement":null},{"id":"W3012480276","doi":"10.1111/jdv.16366","title":"Comparative 12‐week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real‐world multicenter retrospective study","year":2020,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Secukinumab; Ixekizumab; Medicine; Family medicine; Library science; Ustekinumab; Psoriasis; Dermatology; Adalimumab; Psoriatic arthritis; Internal medicine","score_opus":0.046634290625239945,"score_gpt":0.29616185914182785,"score_spread":0.24952756851658792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012480276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96475434,0.007118218,0.00002128758,0.025160365,0.00082663243,0.0016076053,0.00035856216,0.000010243296,0.00014273354],"genre_scores_gemma":[0.99339783,0.003971423,0.000043503904,0.0021967962,0.00015978268,0.000027237244,0.000020480627,0.000033199125,0.00014974423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930995,0.0047975755,0.0012329203,0.00044111357,0.00008310709,0.0003457976],"domain_scores_gemma":[0.9947469,0.0025516232,0.0023067072,0.00023753729,0.00012201299,0.000035178775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047667648,0.00053885655,0.0024824617,0.0002658937,0.00025405205,0.0000062560607,0.00050415355,0.0005337604,0.000012924607],"category_scores_gemma":[0.00009525679,0.00028849262,0.0004133893,0.00012669823,0.001408624,0.000058792382,0.00022690855,0.0008671804,0.0000017277534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010622469,0.0012901754,0.94213647,0.00047283396,0.020192908,0.00024186798,0.007498962,0.000009666923,0.001241599,0.00022152679,0.011399052,0.004672499],"study_design_scores_gemma":[0.015352678,0.0021036163,0.95187885,0.00018165768,0.004080118,0.0010464088,0.00059413037,0.000005983702,0.0040129228,0.0002752633,0.020185491,0.0002828859],"about_ca_topic_score_codex":0.000038913447,"about_ca_topic_score_gemma":0.000037019352,"teacher_disagreement_score":0.028643481,"about_ca_system_score_codex":0.00006591036,"about_ca_system_score_gemma":0.00005221693,"threshold_uncertainty_score":0.9999567},"labels":[],"label_agreement":null},{"id":"W3012580450","doi":"10.1177/1203475419880181","title":"Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update—Reader Comment","year":2020,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Medical physics; Intensive care medicine","score_opus":0.09461821433735557,"score_gpt":0.31830141490134445,"score_spread":0.22368320056398888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012580450","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011760992,0.0022076836,0.00020209451,0.9827459,0.0025313888,0.00034336807,0.00010702181,0.000027746893,0.000073830335],"genre_scores_gemma":[0.006258891,0.0038185345,0.0011072049,0.98126966,0.005319877,0.000018335795,0.0018327481,0.00007774281,0.00029702543],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99773943,0.0003446164,0.0009888129,0.00035393165,0.00017226065,0.00040096045],"domain_scores_gemma":[0.99555045,0.0025032407,0.0010141169,0.00022409785,0.0006279518,0.00008014041],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042946712,0.00045268604,0.0013663672,0.0003460794,0.00016640182,0.000019806816,0.00015229611,0.00054607994,0.00015904017],"category_scores_gemma":[0.0007806418,0.00025381515,0.00022198171,0.00009235042,0.00019852386,0.000086899774,0.00002486038,0.0008564777,0.000013247149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021522734,0.00013152142,0.0013171368,0.000091029164,0.0012370547,0.0021072668,0.000112366455,7.718302e-7,0.00002877949,0.000010898585,0.96789324,0.024917636],"study_design_scores_gemma":[0.0019423923,0.0037459168,0.00007465973,0.00055887055,0.0013573649,0.0020490142,0.00023873441,0.0000020927978,0.0000758891,0.0001786138,0.98946196,0.00031451767],"about_ca_topic_score_codex":0.000010081738,"about_ca_topic_score_gemma":0.0000016040506,"teacher_disagreement_score":0.02460312,"about_ca_system_score_codex":0.00004756097,"about_ca_system_score_gemma":0.00013073825,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W3012736954","doi":"10.1007/s40257-020-00512-4","title":"Malignancy Rates in Brodalumab Clinical Studies for Psoriasis","year":2020,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics; Amgen","keywords":"Medicine; Ustekinumab; Psoriasis; Internal medicine; Ixekizumab; Psoriasis Area and Severity Index; Dermatology; Secukinumab; Psoriatic arthritis; Adalimumab","score_opus":0.11959967372461948,"score_gpt":0.4233082742569633,"score_spread":0.30370860053234383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012736954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97490865,0.008413526,0.00026588576,0.013184315,0.0028731823,0.00022926295,0.000023470096,0.00002251293,0.000079200065],"genre_scores_gemma":[0.98954463,0.004866052,0.0019017255,0.0031741245,0.00041343295,0.000017780048,0.000011306009,0.000023876857,0.000047082875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99408174,0.0018201818,0.0032156182,0.00038578504,0.000055212346,0.00044149457],"domain_scores_gemma":[0.99139553,0.00633189,0.0016378883,0.00020266094,0.00030673,0.00012532707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010520035,0.0002552977,0.002519749,0.00012721028,0.00007233312,0.0000075332778,0.00042133927,0.00029478065,0.0000615532],"category_scores_gemma":[0.0047289575,0.00019542871,0.0008246223,0.00029497754,0.0010658246,0.00010319822,0.000081580045,0.0005597057,0.00012568504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048114583,0.00070684316,0.5378715,0.000044883065,0.0027675796,0.00035161842,0.0006648893,0.000004882192,0.0003095044,0.00061035773,0.014362732,0.43749377],"study_design_scores_gemma":[0.0631568,0.025719034,0.4917903,0.00042734027,0.002832581,0.0036884432,0.01276625,0.000044229968,0.0074622435,0.002940133,0.387648,0.0015246695],"about_ca_topic_score_codex":0.000008704623,"about_ca_topic_score_gemma":0.000016052114,"teacher_disagreement_score":0.43596908,"about_ca_system_score_codex":0.000017233211,"about_ca_system_score_gemma":0.000287895,"threshold_uncertainty_score":0.79693514},"labels":[],"label_agreement":null},{"id":"W3012801967","doi":"","title":"Diagnostic et prise en charge du psoriasis","year":2017,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Computer science; Medicine; Dermatology","score_opus":0.017978150239063947,"score_gpt":0.23346390980303128,"score_spread":0.21548575956396732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012801967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5387739,0.07123566,0.00001533583,0.022655493,0.02521377,0.0011655106,0.004715841,0.000112660106,0.3361118],"genre_scores_gemma":[0.9157456,0.0064254487,0.00005586818,0.03693773,0.0024075992,0.00016005653,0.0006893534,0.0001334143,0.037444923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970749,0.000512062,0.00033797877,0.0006836625,0.00006717643,0.0013242346],"domain_scores_gemma":[0.9973086,0.00051318534,0.00028552557,0.0013610929,0.00011268766,0.0004188689],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032405282,0.00057213276,0.0006381624,0.00021138546,0.0016704348,0.0002516786,0.000963028,0.000713417,0.00021534208],"category_scores_gemma":[0.00029386723,0.00063752226,0.00034587487,0.0001116291,0.0005202901,0.0004499549,0.000117666656,0.00043586676,0.011080973],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088090936,0.0004762627,0.009229665,0.00011400778,0.001865651,0.00095442036,0.0015932772,0.0000036465558,0.006443745,0.033144906,0.28444484,0.6616415],"study_design_scores_gemma":[0.0018179269,0.00016599918,0.1749487,0.00026631128,0.0005949232,0.000009096994,0.0002618916,0.000004923754,0.001774512,0.00049407047,0.81901264,0.00064896303],"about_ca_topic_score_codex":0.08985157,"about_ca_topic_score_gemma":0.04585634,"teacher_disagreement_score":0.6609925,"about_ca_system_score_codex":0.0005159016,"about_ca_system_score_gemma":0.001069233,"threshold_uncertainty_score":0.99962926},"labels":[],"label_agreement":null},{"id":"W3012827133","doi":"10.1177/1203475419888862","title":"Spesolimab: A Novel Treatment for Pustular Psoriasis","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital; Université Laval","funders":"","keywords":"Medicine; Pustular psoriasis; Generalized pustular psoriasis; Psoriasis; Dermatology; Acrodermatitis; Pathology; Alternative medicine","score_opus":0.06142204986402929,"score_gpt":0.26931394501818107,"score_spread":0.20789189515415177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012827133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9556277,0.026996762,0.0008774679,0.013885134,0.0019271971,0.00027958027,0.00004875176,0.000028701665,0.00032872736],"genre_scores_gemma":[0.99145913,0.0051301736,0.0003057807,0.001412352,0.0011059277,0.000007911251,0.000032752687,0.000024239826,0.000521749],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989402,0.000057814636,0.00054195285,0.00016111661,0.000058231006,0.00024067574],"domain_scores_gemma":[0.99827623,0.0010920728,0.000321352,0.00009074701,0.000120505785,0.000099110184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022636665,0.00019743548,0.00078958616,0.00013954887,0.00009863838,0.000007039118,0.00007177056,0.0001301311,0.0001734074],"category_scores_gemma":[0.0003480472,0.00012522888,0.00026771915,0.00010233879,0.00009637314,0.00005115529,0.000010372925,0.00008885899,0.000011532491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01035824,0.00094966125,0.0102647655,0.00021460737,0.005519744,0.0020497034,0.007431679,0.000016652602,0.27853775,0.00029312048,0.13263395,0.55173016],"study_design_scores_gemma":[0.011403132,0.007016668,0.000848865,0.00028388834,0.0026247432,0.014893919,0.0019284325,0.000025716172,0.023098063,0.00017582488,0.93726254,0.00043823046],"about_ca_topic_score_codex":0.000014889867,"about_ca_topic_score_gemma":0.000002478706,"teacher_disagreement_score":0.80462855,"about_ca_system_score_codex":0.000032539927,"about_ca_system_score_gemma":0.000103364335,"threshold_uncertainty_score":0.5106686},"labels":[],"label_agreement":null},{"id":"W3012841341","doi":"10.1177/1203475419893297","title":"Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update—Author Response","year":2020,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine; Medical physics","score_opus":0.10054043989004437,"score_gpt":0.33512064779973094,"score_spread":0.2345802079096866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012841341","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08311759,0.0022012636,0.00017639704,0.91115004,0.0028058698,0.0003456589,0.00013708688,0.000035354307,0.000030719857],"genre_scores_gemma":[0.022129143,0.0030740148,0.0026345323,0.9589859,0.009517717,0.00003269046,0.0017330026,0.00017076306,0.0017221828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971294,0.00079723273,0.0010676148,0.000402147,0.0001828394,0.00042077474],"domain_scores_gemma":[0.99249786,0.00528276,0.001120334,0.00025380496,0.00075479824,0.00009042636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000976896,0.00046890308,0.0014182959,0.00050460704,0.00018417291,0.000022171515,0.0001665998,0.00067757623,0.00013609286],"category_scores_gemma":[0.0032515612,0.00026700948,0.00024933522,0.00012995553,0.0002244078,0.000100630015,0.000024644598,0.0009395003,0.000016063344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018137908,0.00009838493,0.0008813047,0.00007286424,0.0009974237,0.004288695,0.00012599594,7.504369e-7,0.00014192626,0.0000055171,0.95346195,0.021787297],"study_design_scores_gemma":[0.0020244278,0.0060544694,0.00020338738,0.0006022551,0.0013631054,0.0035399213,0.00021983981,0.0000022384197,0.000126104,0.0001916129,0.98531276,0.000359887],"about_ca_topic_score_codex":0.0000055725104,"about_ca_topic_score_gemma":0.0000012430505,"teacher_disagreement_score":0.060988445,"about_ca_system_score_codex":0.000047445134,"about_ca_system_score_gemma":0.00023635355,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W3012894524","doi":"10.1007/s13555-020-00367-x","title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Guenther Dermatology Research Centre","funders":"Cilag; LEO Pharma; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; Biogen; Pfizer; Incyte; Fresenius Medical Care North America; Sun Pharma; Dermira; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Medac; Baxalta; Hexal AG; Celgene; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Ixekizumab; Medicine; Dosing; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Imputation (statistics); Internal medicine; Randomized controlled trial; Quality of life (healthcare); Tolerability; Adverse effect; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.03507305455433154,"score_gpt":0.2892764760050546,"score_spread":0.25420342145072305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012894524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540812,0.040141564,0.0001135528,0.0029619022,0.00027299055,0.0019107779,0.00038584782,0.00002802962,0.00010415118],"genre_scores_gemma":[0.97878903,0.019533169,0.000052319872,0.0012407872,0.0000437886,0.000099239274,0.0001918761,0.000015836133,0.00003397178],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99554646,0.0026082834,0.001074273,0.00045876802,0.000046847068,0.00026537443],"domain_scores_gemma":[0.99241036,0.0068947733,0.0003883344,0.00022713254,0.00003612004,0.000043288273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008219418,0.00031446968,0.0028205032,0.000060793296,0.00014811265,0.000024955396,0.00014682992,0.00036025702,0.000063383646],"category_scores_gemma":[0.0007817329,0.0001890457,0.00020505484,0.0001289117,0.00035621875,0.00009593211,0.000059310092,0.00019228795,0.00001158683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9421729,0.00023922314,0.0025752026,0.000011497983,0.0033527068,0.000049765604,0.0076645487,0.000011950267,0.003614033,0.00056522636,0.0002895237,0.03945342],"study_design_scores_gemma":[0.976521,0.00029963825,0.013349531,0.000071361166,0.0005792592,0.00008139008,0.00020987041,0.000023640581,0.0063109966,0.0010074673,0.0012772934,0.0002685262],"about_ca_topic_score_codex":0.00013518787,"about_ca_topic_score_gemma":0.00003700644,"teacher_disagreement_score":0.0391849,"about_ca_system_score_codex":0.000007940145,"about_ca_system_score_gemma":0.000056047436,"threshold_uncertainty_score":0.770906},"labels":[],"label_agreement":null},{"id":"W3014699575","doi":"10.1101/2020.04.03.20052191","title":"Risk of aortic aneurysm in patients with psoriasis: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"medRxiv","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Medicine; Psoriasis; Hazard ratio; Internal medicine; Aneurysm; Confidence interval; Cohort study; Cohort; Aortic aneurysm; Cardiology; Observational study; Diabetes mellitus; Surgery; Aorta; Dermatology; Endocrinology","score_opus":0.03280421235352455,"score_gpt":0.2691197102455779,"score_spread":0.23631549789205336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014699575","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043076562,0.99651414,0.000002196106,0.000013649417,0.000047559628,0.0024787777,0.00047225118,0.000021784153,0.000018881641],"genre_scores_gemma":[0.0010750555,0.997698,0.000023368722,0.00003507355,0.0000037314942,0.0006274238,0.00028927947,0.00003581171,0.00021222088],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.995535,0.002153497,0.0013604262,0.00060620793,0.00008568891,0.00025916603],"domain_scores_gemma":[0.9973341,0.00039747404,0.0014333775,0.0007215995,0.000074308526,0.000039119142],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005632797,0.00059648044,0.011006579,0.0003831974,0.00004546454,0.000008126613,0.0003132094,0.00028885086,0.00022558474],"category_scores_gemma":[0.00026341458,0.00032244145,0.0016759014,0.0012636832,0.000081338294,0.000043505817,0.00007329241,0.0002767317,0.00009869584],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017323477,0.00016254143,0.002903067,0.5962479,0.39459538,0.000018455612,0.00005510258,6.444233e-8,6.9040034e-8,0.0000047578137,0.000016902406,0.005978443],"study_design_scores_gemma":[0.00041636295,0.00013610919,0.00071242783,0.011025297,0.9837549,0.000010070226,0.000003837148,5.730502e-8,8.5958277e-7,0.0000015777637,0.0036623802,0.00027617198],"about_ca_topic_score_codex":0.000027848042,"about_ca_topic_score_gemma":0.000025123427,"teacher_disagreement_score":0.5891595,"about_ca_system_score_codex":0.000028647113,"about_ca_system_score_gemma":0.000059273596,"threshold_uncertainty_score":0.99992275},"labels":[],"label_agreement":null},{"id":"W3015065138","doi":"10.1007/s13555-020-00373-z","title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; AstraZeneca; Allergan; Ortho Dermatologics; LEO Pharma; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Novartis Pharmaceuticals Corporation; Dermira; Sun Pharma; Celgene; Sanofi; Galderma; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Genentech; Valeant Pharmaceuticals International; Amgen","keywords":"Secukinumab; Medicine; Disease; Intensive care medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Immunology; Dermatology; Internal medicine","score_opus":0.04918913432521317,"score_gpt":0.2794191380912929,"score_spread":0.23023000376607972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015065138","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010137592,0.997149,7.034439e-7,0.00024637906,0.00019492663,0.001207614,0.000052351064,0.000012882089,0.00012241548],"genre_scores_gemma":[0.0026695759,0.9968738,0.0000147588125,0.000074180076,0.000008436411,0.00024860736,0.00003865193,0.000022995364,0.000048977294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997853,0.00079571584,0.00067804696,0.00038338455,0.000044186745,0.00024566991],"domain_scores_gemma":[0.99851227,0.00038660312,0.00060441426,0.0004353987,0.000042707627,0.000018605044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007513914,0.00041419835,0.0022906873,0.000111009096,0.000077637465,0.0000025509441,0.00021810911,0.00035120765,0.00013946145],"category_scores_gemma":[0.000023730929,0.000214652,0.00032558898,0.00031845836,0.0002156785,0.00004033622,0.000042688465,0.00016012049,0.000028949606],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015229495,0.00022857804,0.00034457826,0.014299913,0.001136557,0.000047879603,0.000633004,6.597876e-8,0.000008610054,0.00009001682,0.00009932943,0.98295915],"study_design_scores_gemma":[0.0013679153,0.00054806744,0.00002752656,0.05234702,0.0008348861,0.0009895546,0.000039268463,2.5162137e-7,0.0005444487,0.0000074532045,0.94308037,0.00021321389],"about_ca_topic_score_codex":0.000049801103,"about_ca_topic_score_gemma":0.000013342054,"teacher_disagreement_score":0.98274595,"about_ca_system_score_codex":0.00004323792,"about_ca_system_score_gemma":0.00023401786,"threshold_uncertainty_score":0.87532544},"labels":[],"label_agreement":null},{"id":"W3015243915","doi":"10.1111/bjd.19132","title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Psoriasis; Dermatology; Pathology","score_opus":0.01067272546066037,"score_gpt":0.2536275253746416,"score_spread":0.24295479991398125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015243915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95976406,0.03886595,0.00017792893,0.00037652548,0.0001724539,0.00049833657,0.00010274921,0.000006794433,0.000035181944],"genre_scores_gemma":[0.9881844,0.011457957,0.00017129343,0.000060467875,0.000030577696,0.000014813085,0.000054898726,0.00001345955,0.000012168161],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718827,0.0008453856,0.0013524479,0.00029323122,0.000069896625,0.00025074184],"domain_scores_gemma":[0.9982941,0.0006155051,0.0007916091,0.00012205848,0.00010882677,0.000067903246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002990704,0.00023622214,0.0024437997,0.0003034481,0.00006251337,0.000018725064,0.00011443156,0.00027448818,0.00011145268],"category_scores_gemma":[0.00021001542,0.00021952113,0.00030904537,0.00035750328,0.00061480846,0.00017835222,0.00007222246,0.00022501292,6.3992496e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.861652,0.0010840072,0.08348046,0.00011586777,0.011916597,0.0022337975,0.0031130603,0.0000016808334,0.00239599,0.00007345306,0.000058107627,0.03387495],"study_design_scores_gemma":[0.87492794,0.00090307684,0.10565089,0.00018761538,0.007861928,0.007183887,0.00014726716,0.000013254823,0.002837214,0.000040627838,0.00004131533,0.00020497697],"about_ca_topic_score_codex":0.00015516407,"about_ca_topic_score_gemma":0.00018329297,"teacher_disagreement_score":0.033669975,"about_ca_system_score_codex":0.000016371856,"about_ca_system_score_gemma":0.00006550463,"threshold_uncertainty_score":0.8951812},"labels":[],"label_agreement":null},{"id":"W3015886911","doi":"10.1111/jdv.16460","title":"Safety in moderate‐to‐severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti‐tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 &amp; VOYAGE 2 trials","year":2020,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Janssen Research and Development","keywords":"Medicine; Latent tuberculosis; Internal medicine; Concomitant; Adalimumab; Adverse effect; Psoriasis; Tuberculosis; Placebo; Isoniazid; Gastroenterology; Dermatology; Mycobacterium tuberculosis; Tumor necrosis factor alpha; Pathology","score_opus":0.028320329105978818,"score_gpt":0.2563176746490313,"score_spread":0.2279973455430525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015886911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001014,0.0019069369,0.000026316293,0.0065057995,0.00013184863,0.0005275372,0.0006843412,0.00001899061,0.00018808994],"genre_scores_gemma":[0.99767417,0.0011164505,0.00025299264,0.00067346165,0.000051345753,0.000006089943,0.00011262411,0.000040923533,0.00007194377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99373716,0.0037666073,0.0014734017,0.0005049629,0.00010193493,0.0004159176],"domain_scores_gemma":[0.997519,0.0008260376,0.001207651,0.00020838047,0.00009407163,0.00014484955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057068537,0.00046915255,0.0017492565,0.0002418545,0.00019643185,0.000014894563,0.00036681286,0.00040148813,0.00003730232],"category_scores_gemma":[0.00028706377,0.00027083582,0.00017820521,0.00029155205,0.00037542803,0.00016047138,0.00016345439,0.00056189264,0.000019016668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075273134,0.0012641961,0.881423,0.00005267857,0.009182491,0.00034656696,0.0030745598,0.00026707482,0.016376132,0.00007399317,0.0016032994,0.011062853],"study_design_scores_gemma":[0.11225494,0.001174104,0.8365585,0.00040642565,0.0050548026,0.0015660512,0.00017450549,0.000021771002,0.03884483,0.00007820939,0.003195426,0.0006703841],"about_ca_topic_score_codex":0.000051156694,"about_ca_topic_score_gemma":0.000026851865,"teacher_disagreement_score":0.044864476,"about_ca_system_score_codex":0.0000495124,"about_ca_system_score_gemma":0.000054273347,"threshold_uncertainty_score":0.99997437},"labels":[],"label_agreement":null},{"id":"W3016397458","doi":"10.1111/bjd.19147","title":"Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; UCB Pharma; Sanofi Genzyme; Genentech; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Coherus Biosciences; Sun Pharma; Dermira; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Medac; Baxalta; Celgene; Pfizer; Biogen; Amgen; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Astellas Pharma US","keywords":"Ixekizumab; Placebo; Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Dermatology; Pathology","score_opus":0.012410969481534086,"score_gpt":0.23847296329299128,"score_spread":0.2260619938114572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016397458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161525,0.012632763,0.0001995482,0.00015539837,0.00054472033,0.004327543,0.00015513215,0.000041357012,0.00032827305],"genre_scores_gemma":[0.99677044,0.0021691176,0.0001939779,0.0001998551,0.00010542127,0.00024988738,0.00011241038,0.00007583179,0.00012308056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99253786,0.0025685534,0.0027776617,0.0007913931,0.00028143992,0.0010430941],"domain_scores_gemma":[0.9914804,0.0058136703,0.0016359391,0.00030246453,0.00046440182,0.00030311817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010175897,0.0007290609,0.0042245993,0.0010474336,0.00023536931,0.00008925174,0.0005961776,0.00071893353,0.000015264819],"category_scores_gemma":[0.002761035,0.0006709135,0.00042167367,0.0010115049,0.00030566685,0.00042058877,0.00020795815,0.0010617936,0.000033163393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8070915,0.014350142,0.10825268,0.0002675968,0.008642781,0.0086352145,0.024212763,0.0010999155,0.0006354129,0.00007957647,0.008266839,0.018465577],"study_design_scores_gemma":[0.9724145,0.0019321153,0.012742717,0.00024402041,0.0013781473,0.0047936765,0.003793664,0.0000476603,0.0017946949,0.000046452467,0.0006727017,0.00013968346],"about_ca_topic_score_codex":0.00015904669,"about_ca_topic_score_gemma":0.00039289636,"teacher_disagreement_score":0.16532296,"about_ca_system_score_codex":0.00010545557,"about_ca_system_score_gemma":0.00044084666,"threshold_uncertainty_score":0.9995742},"labels":[],"label_agreement":null},{"id":"W3016766421","doi":"10.1002/cpt.1852","title":"Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study","year":2020,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"GlaxoSmithKline","keywords":"Placebo; Medicine; Psoriasis; Tolerability; Pharmacology; Pharmacodynamics; Internal medicine; Adverse effect; Randomized controlled trial; Pharmacokinetics; Gastroenterology; Pathology; Immunology","score_opus":0.06489494980480552,"score_gpt":0.37355454547704975,"score_spread":0.3086595956722442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016766421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98086643,0.0004153192,0.00006562979,0.010487972,0.0015091279,0.00645827,0.000049575658,0.000084255225,0.00006344022],"genre_scores_gemma":[0.99040216,0.0001226582,0.00018237015,0.007603356,0.00017562092,0.0012415488,0.000027719167,0.00003848321,0.00020605733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9857273,0.011454214,0.0016327841,0.00066012493,0.000078181714,0.0004474003],"domain_scores_gemma":[0.99127257,0.0076058237,0.0006344553,0.0002288823,0.0001570088,0.000101253776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034385873,0.00038993906,0.0019606824,0.00021329612,0.00011163235,0.00001011559,0.0002735954,0.00045687333,0.0005842456],"category_scores_gemma":[0.0009985891,0.00032294396,0.00042875615,0.00037230403,0.00029871883,0.000096619755,0.00014183098,0.000761123,0.00027699632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5857744,0.0018759248,0.00030263315,0.000007881443,0.0025221216,0.000030475656,0.0036173598,0.000024518858,0.40118918,0.0000031617815,0.00049659977,0.004155701],"study_design_scores_gemma":[0.7525193,0.004717061,0.0008294513,0.00007670314,0.0021986815,0.0000036319514,0.0024097136,0.000079680925,0.23283403,0.000024223153,0.0039234753,0.0003840643],"about_ca_topic_score_codex":0.0000160263,"about_ca_topic_score_gemma":0.000013209873,"teacher_disagreement_score":0.16835517,"about_ca_system_score_codex":0.00008838402,"about_ca_system_score_gemma":0.00018909694,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W3017694991","doi":"10.1093/rheumatology/keaa111.270","title":"P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Internal medicine; Psoriasis Area and Severity Index; Physical therapy; Psoriasis; Surgery; Arthritis; Dermatology; Pathology","score_opus":0.05452408047082669,"score_gpt":0.3585500260172186,"score_spread":0.3040259455463919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017694991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949001,0.00033147685,0.000023808683,0.000022764743,0.00015517599,0.003878462,0.0006554308,0.0000082679735,0.000024504308],"genre_scores_gemma":[0.99933547,0.00003565276,0.00008048165,0.0000042185634,0.000028147639,0.00012800308,0.0003743271,0.000010113951,0.0000035658225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99603325,0.002647685,0.0007136693,0.00034537027,0.00011928422,0.00014072168],"domain_scores_gemma":[0.9973978,0.0015818652,0.0006443064,0.00023759923,0.00009185613,0.00004661612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237759,0.00021021046,0.0012144891,0.000070194736,0.000033132117,0.0000038462545,0.00006996665,0.0001430842,0.000032530752],"category_scores_gemma":[0.00051158364,0.00013745597,0.00021403613,0.000101735495,0.000097561526,0.000063920095,0.000026880869,0.00007595796,7.360405e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91718733,0.0022009388,0.04781106,0.000021328286,0.0015820725,0.00000167709,0.00025252372,0.00009980878,0.010983099,6.797111e-7,0.0000037117327,0.019855775],"study_design_scores_gemma":[0.8955738,0.012253524,0.077578545,0.00005914523,0.0034158784,6.8642656e-8,0.000010804946,0.0015126276,0.009486351,0.0000035345336,0.0000040821674,0.00010163401],"about_ca_topic_score_codex":0.00016073156,"about_ca_topic_score_gemma":0.000017357705,"teacher_disagreement_score":0.02976748,"about_ca_system_score_codex":0.000078066565,"about_ca_system_score_gemma":0.00024890192,"threshold_uncertainty_score":0.5605292},"labels":[],"label_agreement":null},{"id":"W3017958794","doi":"10.7573/dic.2020-2-1","title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","year":2020,"lang":"en","type":"review","venue":"Drugs in Context","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research; Trent University; Western University; SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Ixekizumab; Secukinumab; Exacerbation; Psoriatic arthritis; Inflammatory bowel disease; Ulcerative colitis; Population; Disease; Arthritis; Dermatology; Internal medicine; Immunology","score_opus":0.011589469219921381,"score_gpt":0.23252601206118384,"score_spread":0.22093654284126246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017958794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08956613,0.9074557,4.6189646e-7,0.000021843955,0.0004187256,0.0017409952,0.00035917648,0.00009101447,0.00034599047],"genre_scores_gemma":[0.11047582,0.88365597,0.000012517795,0.0000863419,0.00011024706,0.0009587892,0.0030089752,0.00018910179,0.0015022556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701005,0.0005722999,0.00085539353,0.0008985243,0.00010180035,0.00056191173],"domain_scores_gemma":[0.99856484,0.00024180692,0.00046554295,0.000556854,0.00006837119,0.00010260284],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014152675,0.0008944155,0.001895263,0.00053646904,0.00007727408,0.000030191668,0.0004175184,0.00054192636,0.00016249059],"category_scores_gemma":[0.000046061527,0.00060760544,0.00029664527,0.00052860676,0.00020638699,0.00014215245,0.000115166826,0.00062990125,0.00041959764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016808935,0.00043618958,0.07895577,0.0014279124,0.00084866537,0.00019565632,0.00089118595,8.624951e-7,2.7712332e-7,0.000023792913,0.00054924906,0.91498953],"study_design_scores_gemma":[0.009720252,0.00051634875,0.012901907,0.015587768,0.0015075315,0.0000054700527,0.000196542,3.3551146e-7,0.000015250082,0.0000034987017,0.9584571,0.0010879772],"about_ca_topic_score_codex":0.00013023934,"about_ca_topic_score_gemma":0.00035932436,"teacher_disagreement_score":0.95790786,"about_ca_system_score_codex":0.00040545224,"about_ca_system_score_gemma":0.0004237135,"threshold_uncertainty_score":0.99963754},"labels":[],"label_agreement":null},{"id":"W3018618843","doi":"10.1093/rheumatology/keaa111.254","title":"P261 Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Placebo; Internal medicine; Arthritis; Secukinumab","score_opus":0.01637751115520573,"score_gpt":0.22858805021258294,"score_spread":0.21221053905737722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018618843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966014,0.00032272155,0.000007923522,0.0011220316,0.00028393057,0.0009752777,0.00046877307,0.00008223484,0.00013571732],"genre_scores_gemma":[0.9990047,0.0000061349956,0.000027490094,0.00013034309,0.00009880749,0.00005435109,0.00047193316,0.00003222956,0.00017400812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803483,0.00048894563,0.0003040188,0.00061228435,0.00010729375,0.00045263907],"domain_scores_gemma":[0.998792,0.00045411682,0.00017235077,0.0004447036,0.00006395798,0.000072868235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016884033,0.0003190556,0.00043713753,0.000046221834,0.00021081306,0.00005352447,0.00032652868,0.00012941094,0.00004132188],"category_scores_gemma":[0.00026128994,0.00022235696,0.00008885276,0.00026724683,0.00009732015,0.00018788067,0.00015742429,0.0002873951,0.000066141125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17201012,0.0015440693,0.7770498,0.000012597944,0.001209858,0.00021981145,0.015998209,0.000021657133,0.0010927714,0.00001443816,0.0006426261,0.030184044],"study_design_scores_gemma":[0.040542215,0.0019819592,0.9521383,0.000059589216,0.00041902755,2.6265025e-7,0.002582436,0.000016938342,0.00038654584,0.000004282433,0.001558149,0.00031026037],"about_ca_topic_score_codex":0.00036417568,"about_ca_topic_score_gemma":0.00041795496,"teacher_disagreement_score":0.17508854,"about_ca_system_score_codex":0.000067796784,"about_ca_system_score_gemma":0.00007205093,"threshold_uncertainty_score":0.9067454},"labels":[],"label_agreement":null},{"id":"W3021421518","doi":"10.1080/09546634.2020.1747590","title":"Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"Merck Sharp and Dohme","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Dermatology Life Quality Index; Clinical trial; Placebo; Severity of illness; Plaque psoriasis; Gastroenterology; Quality of life (healthcare); Dermatology; Physical therapy; Pathology","score_opus":0.26164119865088536,"score_gpt":0.3907763029369532,"score_spread":0.12913510428606784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021421518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893887,0.0074843257,0.00022964198,0.0009847209,0.00041974298,0.00056392926,0.00088597817,0.000032425203,0.0000105482995],"genre_scores_gemma":[0.99558073,0.0034682227,0.0005337373,0.00016023201,0.00015175638,0.000016122445,0.000061721476,0.00001698535,0.0000104917135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99590766,0.0019201962,0.0012221714,0.00050207967,0.0001060775,0.00034181983],"domain_scores_gemma":[0.99634475,0.0019876766,0.00096560037,0.0002145346,0.00007513799,0.000412307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028744718,0.0004893447,0.0018384461,0.00008774849,0.00024136997,0.000056008645,0.00011722274,0.00034684705,0.0001562637],"category_scores_gemma":[0.0006733043,0.00028763368,0.00061222905,0.00010338148,0.00025800354,0.0001808083,0.00008219656,0.00020253894,0.0000136067865],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02421431,0.006962169,0.24987605,0.000012881606,0.004621017,0.0014020182,0.00071435753,0.00001144172,0.004758487,0.000011541692,0.0001742344,0.7072415],"study_design_scores_gemma":[0.114136666,0.016216129,0.81499016,0.00019705074,0.009246942,0.0012866182,0.00044689112,0.00060021045,0.03460491,0.00035184243,0.006872207,0.0010503983],"about_ca_topic_score_codex":0.00006920704,"about_ca_topic_score_gemma":0.000008101129,"teacher_disagreement_score":0.70619106,"about_ca_system_score_codex":0.00016007958,"about_ca_system_score_gemma":0.00017822317,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W3022461752","doi":"10.1002/eji.201948435","title":"Pharmacological inhibition of RORC2 enhances human Th17‐Treg stability and function","year":2020,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Bristol-Myers Squibb","keywords":"Biology; Treg cell; Function (biology); Cell biology; Immunology; Immune system; T cell; IL-2 receptor","score_opus":0.03621775840399927,"score_gpt":0.24628570242630207,"score_spread":0.2100679440223028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022461752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076605,0.006953266,0.00023608007,0.00044881162,0.00051317597,0.000078993246,0.000010917587,0.000021233383,0.0009714584],"genre_scores_gemma":[0.9991853,0.0004621257,0.00005705187,0.00013476696,0.000099493125,8.791667e-7,0.000015067211,0.000011151929,0.000034130197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781305,0.001270773,0.0005482853,0.00016609531,0.00003312171,0.00016866201],"domain_scores_gemma":[0.99918693,0.00009574045,0.0004984185,0.000081945036,0.00010793781,0.000028995404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005109307,0.00014193376,0.0003565227,0.00007437618,0.0001084082,0.0000062063605,0.00012639929,0.00007773017,0.0007212474],"category_scores_gemma":[0.00008027623,0.00010903751,0.000118265576,0.00009534963,0.0003138052,0.0001121139,0.000075691365,0.00027552535,0.000057199584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011469959,0.00014994502,0.001400105,0.000011132977,0.00050491263,0.000043592638,0.000655729,6.810226e-7,0.9755048,0.00012532645,0.00033283644,0.020123936],"study_design_scores_gemma":[0.0035417427,0.004339225,0.077533744,0.000027699254,0.00032205178,0.0001491626,0.00054069195,2.8629708e-7,0.9079422,0.00008055018,0.005397894,0.00012477627],"about_ca_topic_score_codex":0.0000021710882,"about_ca_topic_score_gemma":8.683027e-7,"teacher_disagreement_score":0.07613364,"about_ca_system_score_codex":0.000016037653,"about_ca_system_score_gemma":0.000024302391,"threshold_uncertainty_score":0.7897153},"labels":[],"label_agreement":null},{"id":"W3023149225","doi":"10.1016/b978-1-4832-2951-5.50091-5","title":"PSORIASIS","year":2013,"lang":"en","type":"book-chapter","venue":"Elsevier eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut d'Histoire de l'Amérique Française","funders":"","keywords":"Dermatology; Medicine","score_opus":0.017736601541574273,"score_gpt":0.2226631319239252,"score_spread":0.20492653038235092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023149225","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028522263,0.011634799,6.399062e-7,0.000045567736,0.0024822128,0.00059741974,0.00013562571,0.00017498375,0.9846435],"genre_scores_gemma":[0.0010471254,0.00044845315,0.00009615642,0.00021123372,0.00032379176,0.0001172954,0.00034157702,0.00011898402,0.9972954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835414,0.000061772465,0.0004575382,0.00060226856,0.00006398382,0.00046027548],"domain_scores_gemma":[0.99873054,0.00010236425,0.00026965942,0.00075152336,0.00009369429,0.000052202384],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012117242,0.000642119,0.0007723764,0.00018852396,0.00019560475,0.000028374367,0.00036414881,0.0011690197,0.013628212],"category_scores_gemma":[0.000011362037,0.0005469728,0.00046963483,0.000009841621,0.00020469567,0.000037937156,0.00013147404,0.0004422089,0.039090145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033566084,0.00001465617,0.0000058091964,0.00002556211,0.0009559275,0.000020146208,0.0001077463,2.4044326e-8,0.0006768289,0.006391861,0.005486238,0.98628163],"study_design_scores_gemma":[0.0008568634,0.00010217189,0.000047291374,0.0001414883,0.0006169529,0.000054681987,0.0000061470787,3.8674546e-8,0.0015471606,0.0048478716,0.9912283,0.00055104116],"about_ca_topic_score_codex":0.0000019490842,"about_ca_topic_score_gemma":0.000012151146,"teacher_disagreement_score":0.98574203,"about_ca_system_score_codex":0.00007945197,"about_ca_system_score_gemma":0.00009232805,"threshold_uncertainty_score":0.99969816},"labels":[],"label_agreement":null},{"id":"W3024130348","doi":"","title":"A Closer Look at the Data Regarding Suicidal Ideation and Behavior in Psoriasis Patients: The Case of Brodalumab","year":2019,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University; SKiN Health","funders":"","keywords":"Psoriasis; Suicidal ideation; Medicine; Causality (physics); Psychiatry; Clinical trial; Clinical psychology; Psychology; Poison control; Suicide prevention; Dermatology; Medical emergency; Internal medicine","score_opus":0.02576601832975922,"score_gpt":0.2366097024474522,"score_spread":0.21084368411769297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024130348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608207,0.0017235242,5.809082e-7,0.00012367469,0.0004786977,0.0010266308,0.00017754512,0.000009903756,0.00037736347],"genre_scores_gemma":[0.99795043,0.00005760392,0.000004324756,0.00004518183,0.000019125126,0.00041441887,0.00025710944,0.000009163205,0.0012426204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990682,0.00021904439,0.00020872432,0.00025075345,0.000028129392,0.00022513125],"domain_scores_gemma":[0.9990131,0.00023367236,0.00010954852,0.0006021752,0.000030589905,0.000010870767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045939197,0.00010714053,0.00016319237,0.000051320447,0.00011043764,0.000010921621,0.0002119791,0.000103969,0.0000691712],"category_scores_gemma":[0.000090036236,0.00006054531,0.00003647084,0.00010164566,0.00009125478,0.00011671128,0.00024429362,0.00008447662,0.00003313837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029139058,0.0001628936,0.67487884,0.000012981519,0.00013438199,0.000017236012,0.00037150248,9.305378e-7,0.00065157644,0.000088550165,0.00062889134,0.32276082],"study_design_scores_gemma":[0.0025742757,0.000037397844,0.99214023,0.000004541886,0.00026397788,0.0001023462,0.00023818917,0.0000020710445,0.0031540664,0.000022438537,0.0013724522,0.00008800432],"about_ca_topic_score_codex":0.0006326063,"about_ca_topic_score_gemma":0.0015626475,"teacher_disagreement_score":0.32267284,"about_ca_system_score_codex":0.00004294961,"about_ca_system_score_gemma":0.0000106819625,"threshold_uncertainty_score":0.24689661},"labels":[],"label_agreement":null},{"id":"W3024681092","doi":"10.7573/dic.2020-4-10","title":"Psoriasis, biologic therapy, and the pandemic of the 21st century","year":2020,"lang":"en","type":"editorial","venue":"Drugs in Context","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Pandemic; Medicine; Psoriasis; Coronavirus disease 2019 (COVID-19); Intensive care medicine; Coronavirus; Disease; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Immunology; Virology; Infectious disease (medical specialty); Pathology","score_opus":0.017204928679615972,"score_gpt":0.24022682076817975,"score_spread":0.22302189208856377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024681092","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049581703,0.18631804,2.553861e-7,0.00064211624,0.7601641,0.0010145016,0.0006552537,0.000048869362,0.0015751614],"genre_scores_gemma":[0.77746964,0.121260256,0.0000043394793,0.00037120684,0.098599255,0.00021039456,0.000533773,0.00005365871,0.0014974856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759555,0.0010771039,0.0004830775,0.00045200673,0.00008652938,0.00030571775],"domain_scores_gemma":[0.99629897,0.0027236943,0.00039332113,0.00049691304,0.00007151867,0.000015588128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005802357,0.00038176338,0.00081647607,0.000063071646,0.00015763642,0.000015951715,0.00071944104,0.001143966,0.00010102189],"category_scores_gemma":[0.0005054453,0.00018320636,0.00028904865,0.00018495286,0.0008356243,0.000027698357,0.00023911853,0.0008547064,0.00005368345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036070875,0.00017329768,0.003962593,0.00007595605,0.0014691709,0.0000027018002,0.00913365,1.935269e-7,0.0020564427,0.002320277,0.5409441,0.4362545],"study_design_scores_gemma":[0.008352725,0.00009232744,0.00085653336,0.00010201592,0.00015470876,0.0000027487245,0.0018379927,1.6767166e-7,0.0008356865,0.00026437134,0.987286,0.00021476475],"about_ca_topic_score_codex":0.00036816177,"about_ca_topic_score_gemma":0.0002092553,"teacher_disagreement_score":0.7278879,"about_ca_system_score_codex":0.00004661344,"about_ca_system_score_gemma":0.0001781114,"threshold_uncertainty_score":0.8823313},"labels":[],"label_agreement":null},{"id":"W3025029990","doi":"10.1016/j.jaad.2020.05.074","title":"Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment","year":2020,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Hydroxychloroquine; Medicine; Exacerbation; Adverse effect; Dermatology; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.033956187007473985,"score_gpt":0.34790483479555245,"score_spread":0.31394864778807846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025029990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061227,0.9872959,0.00002197435,0.009283313,0.0003385035,0.002771853,0.00020308766,0.000015247986,0.000008885549],"genre_scores_gemma":[0.00029168642,0.9956954,0.00010418751,0.003322659,0.000082654995,0.000337909,0.000022190601,0.000040825675,0.000102452555],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543405,0.0021361606,0.0016858918,0.00033346293,0.00008442389,0.00032598624],"domain_scores_gemma":[0.99114656,0.0031096872,0.00532632,0.0002607689,0.000038873375,0.00011781076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000298132,0.00058783445,0.0071924366,0.00027124633,0.00014883683,0.0000052645437,0.0006345706,0.00037952684,0.000008783805],"category_scores_gemma":[0.0009068066,0.00031280034,0.0015509292,0.00035218537,0.00040106277,0.000039355113,0.00009342855,0.00047178054,0.000026870812],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051651197,0.00024907212,0.000008376451,0.7958639,0.009920374,0.00010724767,0.00015870285,3.44045e-7,0.00005334375,0.00022972259,0.0075711906,0.1853212],"study_design_scores_gemma":[0.0021782608,0.0016730569,0.0000075024186,0.10460376,0.053187877,0.023318976,0.000021634738,4.2885938e-7,0.00017138405,0.000096688025,0.81440127,0.000339159],"about_ca_topic_score_codex":0.0000055795063,"about_ca_topic_score_gemma":5.650936e-7,"teacher_disagreement_score":0.8068301,"about_ca_system_score_codex":0.00029087096,"about_ca_system_score_gemma":0.00053419016,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W3025530165","doi":"10.1007/s13555-020-00383-x","title":"Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Ixekizumab; Dermatology; Nail (fastener); Psoriasis Area and Severity Index; Ustekinumab; Plaque psoriasis; Internal medicine; Secukinumab; Psoriatic arthritis; Disease; Adalimumab","score_opus":0.029726125524352883,"score_gpt":0.266550465056885,"score_spread":0.23682433953253212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025530165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431795,0.0018932971,0.000016018796,0.0014347709,0.00026222778,0.001594116,0.0003584273,0.00007203913,0.000051139432],"genre_scores_gemma":[0.9978261,0.00022396383,0.00010305284,0.0012568566,0.00003079995,0.00016035527,0.00033616534,0.000039230625,0.000023488947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970198,0.0007044139,0.00063057785,0.0009986907,0.00007857729,0.00056793255],"domain_scores_gemma":[0.9989559,0.0003326779,0.00013414024,0.00037031126,0.000064446845,0.00014249209],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014266634,0.00049027224,0.00095398986,0.00024087769,0.00020176473,0.000037065805,0.00022824443,0.00037767235,0.00005095946],"category_scores_gemma":[0.00006933912,0.00040125704,0.00005193504,0.0004993947,0.000107686894,0.00015366013,0.00008888646,0.0003339264,0.00009478485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21607822,0.012197364,0.38077036,0.000025344649,0.0015922796,0.0005493129,0.053480987,0.00008504284,0.00080684153,0.000045472665,0.0006544678,0.33371434],"study_design_scores_gemma":[0.22870106,0.006893374,0.75416064,0.00010397514,0.00015978652,0.00006110446,0.0017950278,0.00003454591,0.0029263757,0.00008453122,0.0041724695,0.00090709754],"about_ca_topic_score_codex":0.0005412949,"about_ca_topic_score_gemma":0.00092666934,"teacher_disagreement_score":0.37339032,"about_ca_system_score_codex":0.00003414817,"about_ca_system_score_gemma":0.000057066205,"threshold_uncertainty_score":0.99984396},"labels":[],"label_agreement":null},{"id":"W3027312170","doi":"10.1016/j.jval.2020.04.1391","title":"PSS2 A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bausch Health (Canada); Health Canada; Vancouver Coastal Health","funders":"","keywords":"Tazarotene; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Psoriasis Area and Severity Index; Dermatology; Internal medicine; Combination therapy","score_opus":0.04641643822411487,"score_gpt":0.24942889753249692,"score_spread":0.20301245930838205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027312170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922144,0.00076595036,0.000101190206,0.0053469404,0.000077720535,0.0012339742,0.00021538754,0.0000095145015,0.000034945777],"genre_scores_gemma":[0.99856997,0.00001702649,0.00039652633,0.00081008725,0.0000088936995,0.00006457078,0.000046857043,0.000012885254,0.00007320802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819165,0.00075856067,0.0004011334,0.0002993826,0.000075115604,0.00027413596],"domain_scores_gemma":[0.9991965,0.00020002326,0.00020785524,0.0002152405,0.00008530185,0.000095061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020841381,0.00017202493,0.00074908795,0.00016126428,0.00012882616,0.0000065577065,0.00013723872,0.00011752106,0.00007262605],"category_scores_gemma":[0.00007029321,0.00010663887,0.00015741937,0.00081505184,0.0000643215,0.000050060058,0.0000363716,0.00012092325,0.0000031114619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023681927,0.00042732063,0.82908714,0.00009454992,0.048256114,0.000002731002,0.023652505,0.08761761,0.00013764993,0.0043534636,0.00035438233,0.0036483537],"study_design_scores_gemma":[0.0028714426,0.00089626806,0.9876036,0.000050689323,0.006597873,5.745821e-7,0.00011911245,0.00052873534,0.0004890933,0.00020849289,0.00042580668,0.00020828538],"about_ca_topic_score_codex":0.048893593,"about_ca_topic_score_gemma":0.028501451,"teacher_disagreement_score":0.15851651,"about_ca_system_score_codex":0.0000756817,"about_ca_system_score_gemma":0.00015962776,"threshold_uncertainty_score":0.98922586},"labels":[],"label_agreement":null},{"id":"W3027629822","doi":"10.14309/crj.0000000000000316","title":"Ixekizumab Associated New-Onset Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"ACG Case Reports Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Exacerbation; Inflammatory bowel disease; Plaque psoriasis; Crohn's disease; Disease; Monoclonal antibody; Post-hoc analysis; Interleukin 17; Dermatology; Immunology; Internal medicine; Inflammation; Secukinumab; Antibody; Psoriatic arthritis","score_opus":0.018659399290614494,"score_gpt":0.23762880523380667,"score_spread":0.21896940594319217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027629822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992462,0.0042893817,0.00004788627,0.0011870924,0.001375209,0.00014792544,0.00004257574,0.00011158321,0.00033637596],"genre_scores_gemma":[0.99725175,0.00020929561,0.000033882046,0.00047088455,0.0002862874,0.0000062898644,0.00011680862,0.000029020423,0.0015957825],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9982696,0.0003081264,0.00061986176,0.0003064358,0.000082271385,0.00041369136],"domain_scores_gemma":[0.9986503,0.000093505594,0.0005444837,0.00025743528,0.00010362044,0.00035062118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037564037,0.0002475078,0.00029326868,0.0000905436,0.0005183867,0.00005664501,0.000082776096,0.00020537134,0.0012967854],"category_scores_gemma":[0.0007237444,0.00021090334,0.00027698558,0.00013192458,0.000064563945,0.00019135633,0.00006378325,0.00048419813,0.00026033117],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072333665,0.0002463923,0.14363226,0.000019364734,0.0016966278,0.6942514,0.0014749353,0.0000347068,0.0042861034,0.000013747127,0.12842245,0.02519867],"study_design_scores_gemma":[0.0047074957,0.00040102747,0.17377418,0.00010536053,0.0014810009,0.7002285,0.0004926852,0.000014799592,0.005575358,0.00047232662,0.11190258,0.0008446522],"about_ca_topic_score_codex":0.000033800545,"about_ca_topic_score_gemma":0.000014767918,"teacher_disagreement_score":0.030141927,"about_ca_system_score_codex":0.00009319562,"about_ca_system_score_gemma":0.00054721977,"threshold_uncertainty_score":0.99961615},"labels":[],"label_agreement":null},{"id":"W3027636528","doi":"10.1016/j.jaad.2020.05.091","title":"Association between psoriasis and risk of dementia: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; McMaster University; Hamilton Health Sciences","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Psoriasis; Dementia; Meta-analysis; Etiology; Systematic review; Association (psychology); MEDLINE; Neuroinflammation; Psychiatry; Dermatology; Disease; Pathology; Psychotherapist; Psychology","score_opus":0.04289654479483503,"score_gpt":0.31919215038933024,"score_spread":0.27629560559449523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027636528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033504545,0.99691314,0.00001214172,0.0017438213,0.000044379354,0.00058755116,0.00035241456,0.000004071582,0.000007438857],"genre_scores_gemma":[0.0017489141,0.99787134,0.00011096202,0.00015063517,0.000015836556,0.000023421078,0.00000897294,0.000017205544,0.000052714367],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99262875,0.004457669,0.0023539732,0.00022896848,0.000121854755,0.00020879133],"domain_scores_gemma":[0.9816033,0.0019647267,0.01610209,0.00019927493,0.00008729291,0.000043270633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087408355,0.0003801159,0.013840678,0.00036037154,0.00007365473,0.0000054215325,0.00053144334,0.00036773275,0.00003493886],"category_scores_gemma":[0.0007021099,0.00020409784,0.0031506093,0.00082187215,0.00029766106,0.000054287142,0.0001682797,0.0006590584,0.000005390252],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001084199,0.00002811524,0.0024147285,0.11740737,0.8724795,0.0000030103113,0.000051599207,6.8577805e-8,0.000002958913,0.000013316416,0.0006211302,0.006967361],"study_design_scores_gemma":[0.00022347059,0.000059801812,0.00035155873,0.0032368498,0.97013867,0.000569279,0.000022604441,4.5744343e-8,0.000034926095,0.000023273504,0.025204265,0.00013526883],"about_ca_topic_score_codex":0.000017437837,"about_ca_topic_score_gemma":0.0000014923357,"teacher_disagreement_score":0.114170514,"about_ca_system_score_codex":0.000043556996,"about_ca_system_score_gemma":0.000085034684,"threshold_uncertainty_score":0.9461211},"labels":[],"label_agreement":null},{"id":"W3030404886","doi":"10.3899/jrheum.200122","title":"Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Medical Research Council; Higher Education Authority; Pfizer; European Commission; Science Foundation Ireland; Newcastle University; Engineering and Physical Sciences Research Council; National Institute for Health and Care Research; Celgene","keywords":"Psoriatic arthritis; Psoriasis; Proteogenomics; Medicine; Precision medicine; Disease; Intensive care medicine; Dermatology; Pathology; Genomics","score_opus":0.020785061837036146,"score_gpt":0.24253860395265503,"score_spread":0.22175354211561887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030404886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602884,0.030758988,0.00024448606,0.0076505383,0.0008372833,0.00009913619,0.0000027214473,0.000010619588,0.00010784895],"genre_scores_gemma":[0.9829403,0.016694672,0.00010211184,0.00020552578,0.000022198166,0.0000019812996,0.000002383868,0.00000972851,0.000021069338],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984547,0.00055475126,0.0006139608,0.00011607355,0.000048785296,0.00021172494],"domain_scores_gemma":[0.9986442,0.00079591677,0.00035618275,0.00011025728,0.00005424281,0.00003925645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006676568,0.00014269075,0.00058597367,0.00012345049,0.000075904536,0.0000043328173,0.00022937552,0.00015390333,0.00024684775],"category_scores_gemma":[0.0005685157,0.000085468455,0.000055552675,0.00016183572,0.00018467975,0.00008242535,0.00006421181,0.00027298756,0.000042545646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038462877,0.00016182671,0.17819566,0.000108353735,0.000966149,0.00009091967,0.0363302,0.000040735144,0.023335697,0.0015428656,0.00931695,0.74606436],"study_design_scores_gemma":[0.1505265,0.022541769,0.5039959,0.006646869,0.0040413295,0.11239245,0.04919664,0.0004712657,0.04497717,0.030203903,0.07201813,0.0029880751],"about_ca_topic_score_codex":0.00014648408,"about_ca_topic_score_gemma":0.000051892086,"teacher_disagreement_score":0.74307626,"about_ca_system_score_codex":0.000017496875,"about_ca_system_score_gemma":0.00004164306,"threshold_uncertainty_score":0.34853023},"labels":[],"label_agreement":null},{"id":"W3031076472","doi":"10.3760/cma.j.issn.1008-6706.2018.12.017","title":"Study on the correlation between serum IL-17 level and sleep-emotion disorder in type 2 diabetes mellitus patients complicated with peripheral neuropathy","year":2018,"lang":"en","type":"article","venue":"Zhongguo jiceng yiyao","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pittsburgh Sleep Quality Index; Peripheral neuropathy; Internal medicine; Hamd; Diabetes mellitus; Depression (economics); Gastroenterology; Type 2 diabetes; Type 2 Diabetes Mellitus; Insomnia; Sleep quality; Endocrinology; Significant difference; Psychiatry","score_opus":0.026345792552288506,"score_gpt":0.23198334939541393,"score_spread":0.20563755684312543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031076472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981065,0.0003197167,0.0000220455,0.0001362499,0.0003486922,0.0006485009,0.000069846006,0.00004956954,0.0002989072],"genre_scores_gemma":[0.99929893,0.000019985599,0.000011436196,0.0000828878,0.000047821202,0.000029028588,0.00019850994,0.000023496637,0.00028789276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987149,0.00037951308,0.00020443821,0.00034752424,0.000057146404,0.0002964786],"domain_scores_gemma":[0.99935776,0.00016630423,0.000102768136,0.00026413705,0.000088096334,0.000020922285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017085532,0.0002166161,0.00023200059,0.00007916311,0.00031434122,0.00002523909,0.000112192014,0.00011548185,0.000107220236],"category_scores_gemma":[0.000033870605,0.00014150755,0.0000257646,0.00026103872,0.00014316833,0.00009238312,0.00004933546,0.000179104,0.00017088233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017115202,0.00041731718,0.9693941,0.0000031774214,0.00014152947,0.0000014733257,0.00171496,0.000010500933,0.000328127,0.00002236897,0.00008628568,0.02770901],"study_design_scores_gemma":[0.002355063,0.0017752105,0.993845,0.000025489193,0.00011802994,0.0000011387154,0.00042783696,0.000025883694,0.0004972605,0.000017422766,0.00074463955,0.00016703429],"about_ca_topic_score_codex":0.000058336413,"about_ca_topic_score_gemma":0.00012544473,"teacher_disagreement_score":0.027541975,"about_ca_system_score_codex":0.000033310815,"about_ca_system_score_gemma":0.000012184399,"threshold_uncertainty_score":0.5770511},"labels":[],"label_agreement":null},{"id":"W3031229361","doi":"10.3760/cma.j.issn.1007-7480.2018.12.008","title":"Levels of peripheral T helper17 cells and serum T helper17-related cytokines in patients with multiple sclerosis: a Meta-analysis","year":2018,"lang":"en","type":"article","venue":"Chin J Rheumatol","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Multiple sclerosis; Internal medicine; Pathogenesis; Gastroenterology; Immunology","score_opus":0.03233736797103943,"score_gpt":0.21929378342380337,"score_spread":0.18695641545276395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031229361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961423,0.002679583,0.000021766506,0.000033425407,0.00015831314,0.00034440824,0.0005138735,0.000040141735,0.00006617759],"genre_scores_gemma":[0.9990679,0.000056642726,0.00020963274,0.000028359242,0.000003971816,0.000042344236,0.00008658,0.000024613939,0.00047993148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840117,0.00024338301,0.00049359235,0.00044860458,0.000069670976,0.000343573],"domain_scores_gemma":[0.99912775,0.00010208395,0.00023115281,0.00038546865,0.000117268704,0.00003626219],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018724687,0.0003241123,0.0011372147,0.00028230133,0.00014851717,0.00001727656,0.00017836136,0.00023081829,0.001137017],"category_scores_gemma":[0.000026395093,0.00022092047,0.00032911115,0.00054396794,0.00029484517,0.00013371596,0.00007085103,0.000114985356,0.0000611186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058915064,0.0006107168,0.90581757,0.000038886872,0.064982615,0.0000022619663,0.003919071,0.000035327914,0.021378417,0.000039761762,0.00006257057,0.002523647],"study_design_scores_gemma":[0.0058625373,0.00038147936,0.9061812,0.00003763818,0.01723218,0.0000043361742,0.00019893011,0.00003949988,0.06962669,0.000019523042,0.00007653324,0.000339432],"about_ca_topic_score_codex":0.00026761065,"about_ca_topic_score_gemma":0.00049841066,"teacher_disagreement_score":0.048248276,"about_ca_system_score_codex":0.000024149234,"about_ca_system_score_gemma":0.00002961021,"threshold_uncertainty_score":0.99977607},"labels":[],"label_agreement":null},{"id":"W3031337347","doi":"10.1371/journal.pone.0233781","title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Inflammatory bowel disease; Meta-analysis; Crohn's disease; Medicine; Disease; Systematic review; Bioinformatics; Immunology; MEDLINE; Internal medicine; Biology","score_opus":0.11757820448241534,"score_gpt":0.2851883883593866,"score_spread":0.16761018387697124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031337347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013624334,0.9953453,0.00008598385,0.000022247346,0.000011188316,0.0032239188,0.001149449,0.000017486964,0.000008213944],"genre_scores_gemma":[0.00019140079,0.9958524,0.00050251797,0.000032182164,0.0000053344334,0.0018925625,0.0011116753,0.000025687323,0.00038621065],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973318,0.0006309181,0.0014612705,0.00035925012,0.00006945291,0.00014732026],"domain_scores_gemma":[0.9975384,0.00035826373,0.0015635462,0.0003783071,0.00011972036,0.00004178734],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004571588,0.00037896074,0.0064976877,0.00024132752,0.000056180346,0.000004698898,0.0001385453,0.00019989055,0.00013619642],"category_scores_gemma":[0.0001886774,0.00025573312,0.0016636077,0.00024984253,0.00006284058,0.000033868935,0.000077200966,0.00011125877,0.000029837478],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015205732,0.00025720563,0.0000030335925,0.6317411,0.36695838,0.0000010887804,0.000059858172,3.667884e-8,0.000015809732,0.0000242353,0.000020352585,0.0009036883],"study_design_scores_gemma":[0.00021589265,0.000041047064,0.000006989524,0.048658617,0.94882077,9.463109e-7,0.000009341323,2.189928e-7,0.00022812303,0.000013697535,0.0018054091,0.00019892055],"about_ca_topic_score_codex":0.0000018863951,"about_ca_topic_score_gemma":0.00000904385,"teacher_disagreement_score":0.5830825,"about_ca_system_score_codex":0.000052269286,"about_ca_system_score_gemma":0.0001799409,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W3031554237","doi":"10.1016/j.jaad.2020.05.105","title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"UCB","keywords":"Medicine; Double blinded; Placebo; Plaque psoriasis; Randomized controlled trial; Blinded study; Dermatology; Psoriasis; Physical therapy; Surgery; Pathology; Alternative medicine","score_opus":0.03360327941764896,"score_gpt":0.2916476084855545,"score_spread":0.25804432906790553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031554237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791924,0.00059159216,0.00037927026,0.015922032,0.00036046034,0.0031302234,0.00036762,0.000022979977,0.000033445507],"genre_scores_gemma":[0.99662936,0.00010678901,0.00096774875,0.0019331379,0.00009540585,0.00013468984,0.00003012968,0.000038727645,0.00006403184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99607843,0.0012550856,0.0015650179,0.00045241023,0.00018394641,0.0004650989],"domain_scores_gemma":[0.9948281,0.0016988287,0.0028283403,0.00025615338,0.0002594415,0.00012915353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000467426,0.0004201302,0.0027807944,0.00023089752,0.00022995163,0.00001900118,0.00068923977,0.00022382468,0.00002277623],"category_scores_gemma":[0.00046988612,0.00024291645,0.0005535195,0.00036440944,0.0003511558,0.00016882122,0.00013476145,0.00051053625,0.00001700393],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9810093,0.0016890815,0.00074390287,0.000011029465,0.0042125797,0.000027846165,0.0020779194,0.00042236695,0.0022908328,0.000018871624,0.0053061256,0.0021901212],"study_design_scores_gemma":[0.9783298,0.003265223,0.0008264471,0.00007439254,0.0026666874,0.0002695895,0.0010817084,0.00008905885,0.011290792,0.00010824617,0.0016761345,0.0003219529],"about_ca_topic_score_codex":0.00008619007,"about_ca_topic_score_gemma":0.00000845603,"teacher_disagreement_score":0.017436963,"about_ca_system_score_codex":0.000049808234,"about_ca_system_score_gemma":0.0001798006,"threshold_uncertainty_score":0.99058455},"labels":[],"label_agreement":null},{"id":"W3032589454","doi":"10.1093/rheumatology/keaa189","title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","year":2020,"lang":"en","type":"review","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Tolerability; Psoriatic arthritis; Adverse effect; Ixekizumab; Discontinuation; Psoriasis; Internal medicine; Clinical trial; Dermatology","score_opus":0.06915195430288312,"score_gpt":0.33464895155482427,"score_spread":0.26549699725194115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032589454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035069925,0.9679364,0.000011060754,0.000040123854,0.0018317269,0.001955743,0.024544418,0.00005125609,0.00012230784],"genre_scores_gemma":[0.0011078486,0.9703724,0.00030098666,0.000057231417,0.00043655332,0.00012515127,0.027482947,0.00008137105,0.000035504127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904892,0.004400049,0.003083919,0.0013846258,0.00014467986,0.0004975706],"domain_scores_gemma":[0.9939318,0.0030586177,0.0014968764,0.0013082176,0.000101663194,0.00010284492],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015547753,0.00078729755,0.0061823223,0.00017250738,0.00011252803,0.000038036458,0.000857074,0.0014041608,0.00031593366],"category_scores_gemma":[0.0014161742,0.00061319786,0.0004870286,0.00031116337,0.00032817136,0.00021595675,0.0004697423,0.000796534,0.00022104119],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020655522,0.00044267482,0.0006056618,0.0006538598,0.0021968097,0.00008748975,0.000106166946,3.99416e-8,6.348498e-7,0.00018758934,0.0006821368,0.99297136],"study_design_scores_gemma":[0.023810603,0.00085385225,0.002268504,0.012897945,0.0037537084,0.000032259042,0.000038196016,6.596643e-7,0.0000063703483,0.00008079102,0.95549685,0.0007602617],"about_ca_topic_score_codex":0.0005211011,"about_ca_topic_score_gemma":0.0012661768,"teacher_disagreement_score":0.9922111,"about_ca_system_score_codex":0.0000613746,"about_ca_system_score_gemma":0.0004110173,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W3032957745","doi":"10.1111/bjd.19075","title":"A study of the drug tildrakizumab for plaque psoriasis","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Plaque psoriasis; Drug; Dermatologic agents; Pharmacology; Antibiotics; Microbiology","score_opus":0.019651180493657584,"score_gpt":0.23760066452775977,"score_spread":0.2179494840341022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032957745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914191,0.0049461015,0.000073394556,0.002025335,0.001003257,0.00037157364,0.000054770746,0.0000105436475,0.00009594539],"genre_scores_gemma":[0.9993491,0.00016094501,0.00008583622,0.00021068155,0.00007048942,0.000014739004,0.00000521711,0.000014265272,0.00008868122],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986033,0.00039189908,0.0006020624,0.00014264365,0.000048149628,0.00021195637],"domain_scores_gemma":[0.9989433,0.0002306661,0.00050882896,0.00012246946,0.00016299014,0.000031687297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010185016,0.00012206294,0.00053347694,0.00005068628,0.0001528468,0.000010629094,0.00040525256,0.00013378436,0.00006942712],"category_scores_gemma":[0.00017330688,0.000100845806,0.00025510456,0.00013384376,0.00009610718,0.00006951329,0.00006519305,0.00020891654,0.000012494616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010690922,0.008680309,0.18209524,0.00041380568,0.013519401,0.0054229493,0.040700696,0.00007062742,0.042834386,0.0012209713,0.3566025,0.3377482],"study_design_scores_gemma":[0.10516629,0.004635177,0.13576831,0.00056271284,0.0049502235,0.23731327,0.025972119,0.0000120251625,0.3604596,0.0009995563,0.122950815,0.0012099115],"about_ca_topic_score_codex":0.00004156555,"about_ca_topic_score_gemma":0.00010337661,"teacher_disagreement_score":0.33653829,"about_ca_system_score_codex":0.000013873238,"about_ca_system_score_gemma":0.00011521513,"threshold_uncertainty_score":0.41123727},"labels":[],"label_agreement":null},{"id":"W3033085996","doi":"","title":"Prostaglandin E2 amplifies IL-17 secretion by gamma delta T cells","year":2018,"lang":"fr","type":"article","venue":"Open Repository and Bibliography (University of Liège)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Secretion; Prostaglandin E2; Delta; Cell biology; Chemistry; Endocrinology; Biology; Physics","score_opus":0.014575086332277864,"score_gpt":0.21606242613209092,"score_spread":0.20148733979981306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033085996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96155083,0.020978365,0.0004908314,0.0018895041,0.0021259508,0.0007625876,0.0011879394,0.000046505815,0.010967456],"genre_scores_gemma":[0.9215911,0.014094862,0.00042349755,0.000046626745,0.00011946962,0.0000016640554,0.00023173896,0.000014369517,0.063476674],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983187,0.0004479904,0.00018760131,0.00056737434,0.00007754794,0.0004008341],"domain_scores_gemma":[0.9988867,0.00010465005,0.0003250687,0.0003695207,0.00020791066,0.00010613645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030881964,0.00029758667,0.00045820765,0.0024113979,0.0011632367,0.00016839156,0.00051048025,0.0005545364,0.0005474739],"category_scores_gemma":[2.8712404e-7,0.00032900434,0.0002426346,0.0034884408,0.0015494367,0.0007686023,0.00035956554,0.00017395773,0.000041785126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016329554,0.00053012633,0.18024193,0.0001511325,0.0014063739,0.000081019214,0.0014988699,2.1072674e-7,0.35546473,0.00032777555,0.45608738,0.002577512],"study_design_scores_gemma":[0.0073981807,0.004658849,0.14767548,0.0007133841,0.002434205,0.00030100808,0.007101227,0.000014109699,0.28729844,0.00028773208,0.54081535,0.0013020261],"about_ca_topic_score_codex":0.0045503564,"about_ca_topic_score_gemma":0.00011841307,"teacher_disagreement_score":0.08472797,"about_ca_system_score_codex":0.000015324582,"about_ca_system_score_gemma":0.000050149163,"threshold_uncertainty_score":0.9999162},"labels":[],"label_agreement":null},{"id":"W3033199158","doi":"10.1093/rheumatology/keaa179","title":"The impact of smoking on prevalence of psoriasis and psoriatic arthritis","year":2020,"lang":"en","type":"review","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Arthritis; Internal medicine","score_opus":0.029608904158828796,"score_gpt":0.29557228690453624,"score_spread":0.26596338274570747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033199158","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002760285,0.9952448,0.0000014154095,0.000012207816,0.0004940216,0.0005443315,0.00060021254,0.000022302771,0.00032039563],"genre_scores_gemma":[0.0064333584,0.9930113,0.000013589076,0.0000037921407,0.00007862706,0.000064881475,0.00008009577,0.0000323933,0.00028197907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981514,0.00050267385,0.00063405425,0.00036428674,0.0000611554,0.0002863905],"domain_scores_gemma":[0.9979233,0.00089022657,0.0006355539,0.00047763457,0.00004355325,0.000029717296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027726908,0.0003934192,0.0015213432,0.00009277371,0.00013047917,0.000013292166,0.00035857368,0.00041722617,0.00010086722],"category_scores_gemma":[0.000176778,0.0002369127,0.0006632631,0.00021282694,0.00018382707,0.00003620194,0.000102122205,0.0002721423,0.000047360347],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067367415,0.000059303973,0.00015371082,0.0025681583,0.0017856429,0.000006698267,0.00013855788,2.2024962e-7,0.000022679933,0.00016956,0.00030528798,0.9947228],"study_design_scores_gemma":[0.002334939,0.0019063768,0.0030863944,0.017170677,0.0050480072,0.00015907937,0.00004089336,8.343496e-7,0.0003898793,0.00021947606,0.96898896,0.0006544695],"about_ca_topic_score_codex":0.00006342277,"about_ca_topic_score_gemma":0.0000049060272,"teacher_disagreement_score":0.9940683,"about_ca_system_score_codex":0.000051061787,"about_ca_system_score_gemma":0.00016532087,"threshold_uncertainty_score":0.96610194},"labels":[],"label_agreement":null},{"id":"W3033338019","doi":"10.1177/1203475420932514","title":"Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Ottawa; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Adverse effect; Clinical trial; Population; Medical record; Headaches; Surgery; Internal medicine","score_opus":0.04159539881819746,"score_gpt":0.2573958441858171,"score_spread":0.21580044536761966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033338019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930586,0.004503182,0.000043001553,0.0017003429,0.00035991383,0.000062446554,0.0000030787176,0.000011765906,0.00025764748],"genre_scores_gemma":[0.99789834,0.0011877001,0.000046959718,0.0005315788,0.00021859432,0.0000022340091,0.000010418437,0.000013310423,0.00009083504],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9988806,0.00012552136,0.0005163707,0.00016438121,0.00007580825,0.00023729453],"domain_scores_gemma":[0.9988971,0.00058348966,0.00029922512,0.00008311885,0.00006327415,0.000073833144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015267012,0.00017398548,0.000604927,0.00017154343,0.000062122075,0.000009128877,0.000081963,0.00010263982,0.00022556674],"category_scores_gemma":[0.0001662783,0.00010941173,0.000076558325,0.00016722227,0.00013498172,0.0001008905,0.000015213759,0.00018035863,0.000006119751],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032062049,0.0002898971,0.83525985,0.00006888706,0.0003781686,0.0071959295,0.01212335,0.0000046593755,0.041809138,0.000006197896,0.0023674816,0.09729024],"study_design_scores_gemma":[0.05821189,0.027296752,0.28133458,0.013184142,0.0031924685,0.3324208,0.035779882,0.00002818646,0.17205717,0.00010784326,0.0726639,0.0037223871],"about_ca_topic_score_codex":0.00001805327,"about_ca_topic_score_gemma":0.00002456499,"teacher_disagreement_score":0.5539253,"about_ca_system_score_codex":0.000029682564,"about_ca_system_score_gemma":0.000055167813,"threshold_uncertainty_score":0.4461681},"labels":[],"label_agreement":null},{"id":"W3034109117","doi":"10.1111/bjd.19072","title":"A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ixekizumab; Psoriasis; Medicine; Dermatology; Secukinumab; Psoriatic arthritis","score_opus":0.0377995545386855,"score_gpt":0.2587733163398282,"score_spread":0.2209737618011427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034109117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755369,0.0197053,0.00024799613,0.003227782,0.00041455982,0.0007629287,0.00005793995,0.000013147629,0.000033485343],"genre_scores_gemma":[0.9973621,0.0021221158,0.000111573456,0.00021335213,0.00007189184,0.00006716722,0.000008850158,0.000013774359,0.000029182787],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851274,0.0004086708,0.0005635242,0.00020300804,0.00004229006,0.00026976335],"domain_scores_gemma":[0.9986109,0.00073421607,0.0003303906,0.00014433125,0.00013477754,0.000045370278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013874118,0.00018762071,0.0007058893,0.000043848187,0.00035435782,0.000031494983,0.00030785182,0.00013390974,0.000023651584],"category_scores_gemma":[0.00007698178,0.000115508745,0.00018898933,0.000118670054,0.00015350865,0.000055539487,0.00005133936,0.00013429111,0.000008948026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01910474,0.0048475857,0.0778958,0.00011368707,0.015235029,0.0016539724,0.062670656,0.00046454,0.0049449215,0.0005618487,0.01635151,0.7961557],"study_design_scores_gemma":[0.16615988,0.035409622,0.22953184,0.000488259,0.011574185,0.21086444,0.0957965,0.00048136522,0.11504292,0.0011854665,0.13117549,0.0022900163],"about_ca_topic_score_codex":0.00010027307,"about_ca_topic_score_gemma":0.000119845135,"teacher_disagreement_score":0.7938657,"about_ca_system_score_codex":0.00002822427,"about_ca_system_score_gemma":0.00006454514,"threshold_uncertainty_score":0.471031},"labels":[],"label_agreement":null},{"id":"W3034204123","doi":"10.1111/bjd.19314","title":"Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira","keywords":"Certolizumab pegol; Medicine; Placebo; Psoriasis; Randomized controlled trial; Plaque psoriasis; Internal medicine; Term (time); Pooled analysis; Gastroenterology; Dermatology; Meta-analysis; Pathology; Alternative medicine; Disease; Adalimumab","score_opus":0.016365935629782575,"score_gpt":0.26628293293723104,"score_spread":0.24991699730744846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034204123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202676,0.07652856,0.0008408962,0.0009265306,0.0005990393,0.0005829059,0.00016850038,0.000019253486,0.00006672333],"genre_scores_gemma":[0.9921883,0.0073215505,0.000113654736,0.000105948544,0.000087678636,0.00003658368,0.00009412382,0.00002108851,0.000031077307],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957768,0.0013363493,0.0020369967,0.00033472033,0.00011324506,0.00040192023],"domain_scores_gemma":[0.99681526,0.0013991185,0.001315911,0.00019126161,0.00019923753,0.000079231184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002474939,0.00030704137,0.0041580726,0.00043896257,0.0000867104,0.000020682632,0.00038607858,0.0003806767,0.00068675895],"category_scores_gemma":[0.0005687058,0.00029212257,0.001149803,0.00044245485,0.00034814765,0.0001741838,0.00009367641,0.00041794154,0.000021293035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81800985,0.0010068992,0.032352015,0.000056410892,0.081062675,0.021549284,0.003151194,0.000054594388,0.00348273,0.00007455392,0.0015603718,0.037639413],"study_design_scores_gemma":[0.94271314,0.00020635666,0.028592357,0.00022403034,0.014832742,0.009503231,0.00050043233,0.0000624188,0.002715523,0.00020319884,0.00010063898,0.00034595898],"about_ca_topic_score_codex":0.00023330028,"about_ca_topic_score_gemma":0.0013259596,"teacher_disagreement_score":0.12470326,"about_ca_system_score_codex":0.00006059132,"about_ca_system_score_gemma":0.00016152968,"threshold_uncertainty_score":0.9999531},"labels":[],"label_agreement":null},{"id":"W3034510222","doi":"10.1111/dth.13800","title":"Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review","year":2020,"lang":"en","type":"review","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Narrative review; Interleukin 23; Immune system; Tumor necrosis factor alpha; Cytokine; Immunology; Cancer research; Interleukin 17; Intensive care medicine","score_opus":0.035654289948374676,"score_gpt":0.3000019041689017,"score_spread":0.26434761422052705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034510222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026194248,0.9944993,0.0000024269661,0.0009742388,0.0006106584,0.00277974,0.00011254177,0.0001821278,0.000577006],"genre_scores_gemma":[0.00070280087,0.99614304,0.000022502487,0.00069768605,0.00009943344,0.0014905458,0.00058974925,0.00009109712,0.00016313916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99531054,0.0017701854,0.0010861937,0.0010581698,0.00009203451,0.0006828453],"domain_scores_gemma":[0.99800205,0.00047721417,0.0007467116,0.00066911103,0.000045689685,0.000059247763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021053708,0.0011947495,0.004030609,0.00034851988,0.00015704152,0.000025951013,0.0006720168,0.0010090122,0.0003926224],"category_scores_gemma":[0.000038535534,0.00072917354,0.00073768984,0.00078836386,0.00021066045,0.000085148444,0.000075108255,0.001007955,0.0012350993],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036302418,0.00017836932,0.0000078769735,0.0035883489,0.0012691214,0.0005286899,0.0005696437,1.5599048e-7,0.000006095075,0.00012802173,0.011073645,0.982287],"study_design_scores_gemma":[0.002572128,0.00091720215,0.000007733226,0.03382361,0.00047559245,0.00090303604,0.00007940159,7.6842e-8,0.0003426359,0.00003737601,0.9600985,0.00074271875],"about_ca_topic_score_codex":0.00003704137,"about_ca_topic_score_gemma":0.00008699673,"teacher_disagreement_score":0.9815443,"about_ca_system_score_codex":0.00061250414,"about_ca_system_score_gemma":0.00067924743,"threshold_uncertainty_score":0.99954253},"labels":[],"label_agreement":null},{"id":"W3034582727","doi":"10.1136/annrheumdis-2020-eular.6013","title":"AB0820 COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Adverse effect; Placebo; Psoriasis Area and Severity Index; Meta-analysis; Dactylitis; Psoriasis; Enthesitis; Rheumatoid arthritis; Physical therapy; Dermatology; Alternative medicine; Pathology","score_opus":0.05957431747440484,"score_gpt":0.27833955742827643,"score_spread":0.2187652399538716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034582727","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37598416,0.62076515,0.00000388296,0.00054948556,0.000038480885,0.0010863777,0.0015406552,0.000012334936,0.00001945421],"genre_scores_gemma":[0.9855501,0.013596875,0.000043229837,0.00030726407,0.0000048229867,0.000059025835,0.00041044218,0.000008289184,0.000019972927],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975376,0.00098162,0.00091487245,0.00028223562,0.00010440246,0.0001792542],"domain_scores_gemma":[0.99756825,0.0009197875,0.0008411363,0.0004828899,0.00014532621,0.000042589945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020521188,0.00024552934,0.0024362546,0.00006074211,0.00005690516,0.00001329188,0.00025957247,0.00006402926,0.000075159696],"category_scores_gemma":[0.00045536697,0.00013066537,0.0005853962,0.0007747078,0.00011047823,0.00008592824,0.00006717093,0.000076716366,0.000009388124],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005589722,0.0033232288,0.025074044,0.06060218,0.87325996,0.0000084935955,0.013784316,0.0018776783,0.0000093290455,0.00035657082,0.010794634,0.005319849],"study_design_scores_gemma":[0.009187688,0.00066405156,0.46214423,0.045261435,0.48128456,0.0000012663826,0.000265465,0.000036775575,0.0002740569,0.0003201725,0.000028219589,0.00053210347],"about_ca_topic_score_codex":0.00003198746,"about_ca_topic_score_gemma":0.00002227271,"teacher_disagreement_score":0.6095659,"about_ca_system_score_codex":0.000004060154,"about_ca_system_score_gemma":0.0000249525,"threshold_uncertainty_score":0.5328379},"labels":[],"label_agreement":null},{"id":"W3035233083","doi":"10.1007/s13555-020-00411-w","title":"Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics","year":2020,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Secukinumab; Ixekizumab; Psoriasis; Ustekinumab; Immunology; Dermatology; Disease; Internal medicine; Adalimumab; Psoriatic arthritis","score_opus":0.02435962657866465,"score_gpt":0.27158581235565776,"score_spread":0.24722618577699312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035233083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3649255,0.6326567,0.00000298329,0.0005924971,0.00013676441,0.0014984636,0.00016180996,0.000019686011,0.000005589814],"genre_scores_gemma":[0.06156364,0.9376111,0.000088984125,0.00031910892,0.00001702664,0.0001618034,0.00012118214,0.00003605202,0.00008110352],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659055,0.001703817,0.0006262647,0.00065382937,0.000046116384,0.00037939879],"domain_scores_gemma":[0.9981893,0.0010605556,0.00022277719,0.0004037912,0.000052647938,0.000070931674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034372267,0.00052034645,0.0017796077,0.00025823052,0.0002196233,0.000016158583,0.00026621931,0.0006713796,0.000025148158],"category_scores_gemma":[0.00017358245,0.00027357458,0.00008174579,0.00042611032,0.0002760578,0.000040475687,0.00015691642,0.00033220678,0.000021759946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023112528,0.00014172362,0.0028708726,0.00032779892,0.0006686032,0.000034721957,0.0012780352,1.6954644e-7,0.0000108843005,0.000045794917,0.000096134194,0.9714127],"study_design_scores_gemma":[0.010086888,0.002590877,0.06474398,0.0010327626,0.000391212,0.00031873668,0.00008492893,7.950657e-8,0.000074057025,0.000011508848,0.9202068,0.00045818152],"about_ca_topic_score_codex":0.000023202358,"about_ca_topic_score_gemma":0.00006499316,"teacher_disagreement_score":0.97095454,"about_ca_system_score_codex":0.000025064635,"about_ca_system_score_gemma":0.00014987738,"threshold_uncertainty_score":0.9999716},"labels":[],"label_agreement":null},{"id":"W3035234370","doi":"10.1016/j.jid.2020.03.083","title":"081 Granzyme K: A potential mediator of psoriasis","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia","funders":"","keywords":"Psoriasis; Granzyme A; Inflammation; Human skin; Erythema; Psoriasis Area and Severity Index; Medicine; Pathology; Keratinocyte; Cytokine; Granzyme B; Immunology; Dermatology; Immune system; Biology; T cell; Cell culture","score_opus":0.02461455669023471,"score_gpt":0.233206827756738,"score_spread":0.2085922710665033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035234370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883052,0.0037861418,0.0002397642,0.0063778916,0.00089817325,0.00010699792,0.000050639253,0.000017060776,0.00021813727],"genre_scores_gemma":[0.99803734,0.00015782866,0.0008506903,0.0007461131,0.00013467617,0.000003982631,0.000019346715,0.000015728587,0.00003427633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811536,0.0005410198,0.0008266778,0.00017106724,0.00008023364,0.00026565202],"domain_scores_gemma":[0.99830616,0.00020534656,0.00093642756,0.00011992725,0.00031394037,0.000118197786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014841343,0.00021235226,0.00081050117,0.00017235405,0.00007450181,0.0000052565842,0.00031931043,0.00028290343,0.00034270046],"category_scores_gemma":[0.00046485724,0.00016667567,0.0002987927,0.0002469468,0.0006657449,0.00013987959,0.00005804756,0.00030789958,0.000121429555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071900425,0.00015933771,0.0036473759,0.00006473911,0.0015308595,0.00039023577,0.0036933233,0.000012927219,0.96805584,0.0017256135,0.018262422,0.001738289],"study_design_scores_gemma":[0.0034813655,0.00048145457,0.0055094394,0.000031329742,0.00040527937,0.0016617121,0.0007583784,0.000004960062,0.98154366,0.0009317008,0.0050387396,0.00015198902],"about_ca_topic_score_codex":0.000007061751,"about_ca_topic_score_gemma":0.0000019469921,"teacher_disagreement_score":0.013487778,"about_ca_system_score_codex":0.00001974257,"about_ca_system_score_gemma":0.00026775704,"threshold_uncertainty_score":0.6796836},"labels":[],"label_agreement":null},{"id":"W3035497496","doi":"10.1016/j.jid.2020.03.051","title":"049 Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) both show upregulation of the IL-36, neutrophil chemokine, and innate pathways that are modulated by spesolimab, an anti-IL-36 receptor antibody, treatment","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"CXCL1; Downregulation and upregulation; Medicine; Psoriasis; Chemokine; Immunology; Generalized pustular psoriasis; Inflammation; Neutrophil elastase; Interleukin 8; Interleukin 23; Interleukin 17; Biology; Gene","score_opus":0.030604100208983635,"score_gpt":0.23253337003016994,"score_spread":0.2019292698211863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035497496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914,0.0038183946,0.000027896367,0.005434309,0.0003856992,0.0004216421,0.0007258662,0.000028951796,0.000017292183],"genre_scores_gemma":[0.9957555,0.0027993473,0.0004566908,0.00051915227,0.000080494654,0.000012039697,0.0003078848,0.000039329178,0.000029561106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710923,0.0010547268,0.0008335646,0.0004592108,0.00012851074,0.00041475988],"domain_scores_gemma":[0.99776036,0.00014636756,0.0013975753,0.00029040856,0.00022236451,0.00018292006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017505523,0.0005066717,0.0012495628,0.00017171727,0.00028605916,0.00003296097,0.00029269463,0.00046757216,0.000052547704],"category_scores_gemma":[0.00010434008,0.00032265365,0.00022482431,0.00030381526,0.0008610933,0.00032196016,0.000110884794,0.0003014218,0.0000049433156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007475948,0.0002364743,0.0860687,0.00006528327,0.001320951,0.00006142391,0.0023957614,0.000030816962,0.9063702,0.000112962894,0.0014251862,0.0011646347],"study_design_scores_gemma":[0.005331607,0.00064024824,0.17160241,0.00007855447,0.00067887886,0.00090862456,0.00061643624,0.00012651879,0.8172551,0.0002786971,0.0021874225,0.0002955116],"about_ca_topic_score_codex":0.000069027396,"about_ca_topic_score_gemma":0.000016178834,"teacher_disagreement_score":0.08911512,"about_ca_system_score_codex":0.000070420516,"about_ca_system_score_gemma":0.00012571587,"threshold_uncertainty_score":0.9999226},"labels":[],"label_agreement":null},{"id":"W3035644225","doi":"10.1177/1203475420917387","title":"Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Inflammatory bowel disease; Retrospective cohort study; Dermatology; Tumor necrosis factor alpha; Disease; Inflammatory Bowel Diseases; Gastroenterology; Internal medicine","score_opus":0.013504616959771724,"score_gpt":0.2294503513233525,"score_spread":0.21594573436358078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035644225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968228,0.0019605123,0.000007992597,0.00053483323,0.00021171407,0.00039901154,0.00002717811,0.00001172312,0.000024278695],"genre_scores_gemma":[0.9990015,0.000449609,0.000010424264,0.0001392632,0.00026824872,0.000018179819,0.000033911318,0.000015997848,0.00006283816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988588,0.00014211127,0.00054276735,0.00017488784,0.00009183441,0.00018960296],"domain_scores_gemma":[0.9987983,0.00047945027,0.0003538273,0.000071931434,0.00019855094,0.000097923636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020846991,0.00017047315,0.0004610383,0.00028043755,0.000082899365,0.0000064256014,0.000054363474,0.000066452856,0.00003207531],"category_scores_gemma":[0.00035537354,0.000112498026,0.00008215586,0.00018926486,0.000058726953,0.00008257675,0.000010651552,0.00014477542,0.000002916343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032843167,0.000439266,0.9866771,0.000053218664,0.00022564668,0.0014050825,0.0023787944,0.0000025916593,0.000103184,0.0000028377917,0.0034984588,0.0019295171],"study_design_scores_gemma":[0.004990614,0.0028794545,0.98923063,0.000101031066,0.0007025373,0.00023772079,0.0011899839,0.000003078303,0.000046969348,0.000018888273,0.00045313363,0.00014592799],"about_ca_topic_score_codex":0.0000075848616,"about_ca_topic_score_gemma":0.000021184886,"teacher_disagreement_score":0.0030453252,"about_ca_system_score_codex":0.000042973777,"about_ca_system_score_gemma":0.00013192958,"threshold_uncertainty_score":0.45875362},"labels":[],"label_agreement":null},{"id":"W3035833253","doi":"10.1016/j.jid.2020.03.597","title":"587 Investigation of omega-3 mechanisms involve in psoriatic plaque healing using a psoriatic skin model produced by tissue engineering","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Keratinocyte; Epidermis (zoology); Psoriasis; Filaggrin; Keratin; Phosphorylation; Kinase; Chemistry; Cell biology; Biochemistry; Dermatology; Cancer research; Biology; Medicine; Pathology; In vitro; Anatomy; Atopic dermatitis","score_opus":0.03262776870037184,"score_gpt":0.2419103992527898,"score_spread":0.20928263055241794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035833253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532206,0.0028816024,0.008953685,0.0020557474,0.00039831063,0.00032602754,0.000032823078,0.000022862685,0.0000068568697],"genre_scores_gemma":[0.98646253,0.00009553209,0.012858124,0.0004431405,0.000050658975,0.00001380476,0.000034126388,0.00003502002,0.000007058404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746543,0.0004922049,0.0012584337,0.0002943782,0.00010925854,0.00038028343],"domain_scores_gemma":[0.99816436,0.0002523038,0.0010853994,0.00015697055,0.00021610752,0.00012485166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035661968,0.0003260561,0.0009964628,0.00037971116,0.00006984217,0.000011250488,0.00027904013,0.00035281977,0.00001801202],"category_scores_gemma":[0.0006038505,0.0003049759,0.00012495751,0.00051479985,0.00020746466,0.00029878042,0.000058451456,0.00047326335,0.000010113019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013908402,0.000059246144,0.00042775666,0.00022204676,0.00033699643,0.0000414387,0.0058610193,0.00695186,0.983812,0.0016063298,0.00030721864,0.00023502173],"study_design_scores_gemma":[0.0026478106,0.00027137581,0.00019884344,0.00022259282,0.00020331917,0.0002711249,0.00037807395,0.012152583,0.9802959,0.0030350783,0.00007809584,0.0002452328],"about_ca_topic_score_codex":0.000045574587,"about_ca_topic_score_gemma":0.000008836866,"teacher_disagreement_score":0.0054829456,"about_ca_system_score_codex":0.00012702985,"about_ca_system_score_gemma":0.00044513334,"threshold_uncertainty_score":0.9999402},"labels":[],"label_agreement":null},{"id":"W3036157954","doi":"10.1016/j.jid.2020.03.516","title":"507 Alternative data presentation methods: Exploring waterfall and bubble plots in psoriasis biologic clinical trials","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Clinical trial; Cohort; Waterfall; Psoriasis; Electronic data capture; Raw data; Medical physics; Intensive care medicine; Statistics; Internal medicine; Mathematics","score_opus":0.5753422119208192,"score_gpt":0.46506609623412876,"score_spread":0.11027611568669049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036157954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864378,0.0051202746,0.0012062867,0.005625435,0.0011786957,0.00028966932,0.000062865525,0.000019909487,0.00005905545],"genre_scores_gemma":[0.9828143,0.0028385925,0.013181113,0.0007465342,0.00025414204,0.0000242216,0.00010377597,0.000020075116,0.000017240438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98845357,0.008911293,0.0018567935,0.00042334484,0.00005510955,0.00029987408],"domain_scores_gemma":[0.9943621,0.0038091526,0.0013160154,0.00023440187,0.00015680447,0.00012148936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036668654,0.00025098686,0.0014140771,0.00022478963,0.00007851462,0.000020567873,0.00050980167,0.000298361,0.000056927227],"category_scores_gemma":[0.008247063,0.00017872264,0.00014504658,0.00021698904,0.0005555199,0.0005410294,0.0002819732,0.00052837085,0.000040837138],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004564641,0.0006668528,0.13002749,0.0001553582,0.0058328602,0.00097195414,0.016687162,0.00007448227,0.65126187,0.0020448118,0.00918405,0.17852846],"study_design_scores_gemma":[0.010796192,0.0012915226,0.03440002,0.00013203485,0.0006814566,0.0009368007,0.0031188808,0.00019021398,0.93232864,0.0060868487,0.009632405,0.0004049738],"about_ca_topic_score_codex":0.00003818399,"about_ca_topic_score_gemma":0.000013889119,"teacher_disagreement_score":0.28106678,"about_ca_system_score_codex":0.000027353504,"about_ca_system_score_gemma":0.0001483832,"threshold_uncertainty_score":0.98731},"labels":[],"label_agreement":null},{"id":"W3036413731","doi":"10.1016/j.jid.2020.05.033","title":"LB940 Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Internal medicine; Plaque psoriasis; Dosing; Surgery; Dermatology; Secukinumab","score_opus":0.20735861842567138,"score_gpt":0.3404739827137998,"score_spread":0.13311536428812842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036413731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810771,0.009124883,0.00013562667,0.007655596,0.0015555808,0.00014157518,0.00015966273,0.000032686345,0.000117343305],"genre_scores_gemma":[0.99221486,0.0011852749,0.0047426154,0.0013640093,0.0002253204,0.000004534417,0.00013836141,0.00002777445,0.00009724348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629164,0.0017881254,0.0010511637,0.0004413226,0.00008349005,0.00034427093],"domain_scores_gemma":[0.9967179,0.0016191353,0.00084795686,0.00040825384,0.00019949768,0.0002072699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004653103,0.00028838674,0.0008750269,0.00014423692,0.00020310657,0.000022717495,0.000643435,0.0004179779,0.00011694145],"category_scores_gemma":[0.00253922,0.00022529862,0.00014354596,0.00016743554,0.0011166353,0.00035774527,0.0003950159,0.00061298296,0.0001423657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024780752,0.00087341445,0.015120762,0.00008289174,0.003136665,0.0022332256,0.0039133807,0.0000042116044,0.7758223,0.0005088451,0.15792832,0.015595241],"study_design_scores_gemma":[0.015148808,0.00318931,0.021356603,0.00009789019,0.00072663516,0.0036269722,0.0010650833,0.000018206056,0.8925979,0.00048220367,0.061271254,0.00041914743],"about_ca_topic_score_codex":0.000006248984,"about_ca_topic_score_gemma":0.0000057043135,"teacher_disagreement_score":0.116775595,"about_ca_system_score_codex":0.00002392869,"about_ca_system_score_gemma":0.00040014338,"threshold_uncertainty_score":0.91874105},"labels":[],"label_agreement":null},{"id":"W3036453179","doi":"10.1016/j.jid.2020.03.472","title":"464 Treatment patterns of psoriasis by medical providers and disease severity in US women","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Methotrexate; Adalimumab; Disease; Severity of illness; Systemic therapy; Internal medicine","score_opus":0.01825901099162532,"score_gpt":0.2389178000128636,"score_spread":0.22065878902123828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036453179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867965,0.0025303543,0.00002414856,0.010185307,0.00017530138,0.00015048758,0.00010713806,0.0000075586718,0.000023207904],"genre_scores_gemma":[0.99801964,0.0006172688,0.00005867798,0.001204447,0.000024219657,0.000018268389,0.000023437811,0.00001009929,0.000023965173],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828964,0.0005708214,0.00060543173,0.00019075649,0.000076248565,0.00026708868],"domain_scores_gemma":[0.998866,0.00023990247,0.0004163556,0.000090227906,0.00007204516,0.00031545275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013369376,0.00019931332,0.0006766854,0.000112496215,0.000041985502,0.000005231075,0.0001553642,0.00020090172,0.00017957448],"category_scores_gemma":[0.00059037795,0.00015055068,0.00009477791,0.00011597381,0.0004397424,0.00011950528,0.000046742978,0.00020221366,0.00000866833],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020926285,0.00081368594,0.9075824,0.00021029827,0.0016326437,0.001260946,0.014999779,0.000003982941,0.05242503,0.00028304255,0.006329435,0.012366113],"study_design_scores_gemma":[0.020285647,0.0023411715,0.45970005,0.00025289255,0.0005231091,0.0013340636,0.0040324107,0.000035681005,0.4939829,0.0017693287,0.015178333,0.00056439504],"about_ca_topic_score_codex":0.00008191906,"about_ca_topic_score_gemma":0.000029033577,"teacher_disagreement_score":0.44788235,"about_ca_system_score_codex":0.00008294241,"about_ca_system_score_gemma":0.00045167358,"threshold_uncertainty_score":0.61392784},"labels":[],"label_agreement":null},{"id":"W3036656871","doi":"10.1016/j.jid.2020.03.817","title":"802 Effects of cholera toxin and isoproterenol as cAMP stimulators for a psoriatic reconstructed skin model","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cholera toxin; Epidermis (zoology); Psoriasis; Toxin; Keratinocyte; Endocrinology; Biology; Internal medicine; Immunology; Medicine; In vitro; Microbiology; Biochemistry; Anatomy","score_opus":0.0207595475297777,"score_gpt":0.24201827497362827,"score_spread":0.22125872744385056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036656871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935492,0.0024352036,0.0012775693,0.001893853,0.00029753117,0.0004582775,0.00003801142,0.000013180109,0.000037144888],"genre_scores_gemma":[0.9943522,0.000075020616,0.0046516913,0.000800284,0.000037999427,0.000024170358,0.000012469939,0.000018434846,0.000027685528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985747,0.0002836075,0.0006568967,0.00020043235,0.00004294602,0.00024143136],"domain_scores_gemma":[0.9982881,0.00053056865,0.0007553781,0.00010606869,0.00021813344,0.00010176692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009395647,0.00022799068,0.0008069648,0.00015846035,0.00008319561,0.000007612486,0.00016692655,0.00028480423,0.000027375198],"category_scores_gemma":[0.00075660023,0.00018455759,0.0001631783,0.00013699588,0.00047354042,0.0001275779,0.000032830496,0.00023442731,0.000013637109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010926349,0.00014308366,0.0017533908,0.0004927146,0.0018940029,0.00007600841,0.010912875,0.0001362991,0.9697196,0.0021858045,0.001708373,0.009885196],"study_design_scores_gemma":[0.0064487704,0.000900742,0.0013606127,0.000120655175,0.00040228723,0.00079473766,0.00022597608,0.0005968246,0.98395395,0.004684164,0.00033376037,0.00017748874],"about_ca_topic_score_codex":0.000006323414,"about_ca_topic_score_gemma":0.0000017654621,"teacher_disagreement_score":0.014234363,"about_ca_system_score_codex":0.000022717655,"about_ca_system_score_gemma":0.00023546447,"threshold_uncertainty_score":0.752604},"labels":[],"label_agreement":null},{"id":"W3036832314","doi":"10.1016/j.jid.2020.03.814","title":"799 Acute IL-17A production by a 3D immunocompetent psoriatic skin substitute to study the interaction between epithelial and immune cells","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Ionomycin; Psoriasis; Immunology; Immune system; Cytokine; CD3; Interleukin 17; Pathogenesis; Chemokine; Medicine; Chemistry; CD8; Endocrinology; Stimulation","score_opus":0.025488164096758744,"score_gpt":0.2561584019631287,"score_spread":0.23067023786636998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036832314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875367,0.0012576086,0.00013564921,0.009280718,0.0010780995,0.00062202493,0.00004769609,0.000018989422,0.00002249532],"genre_scores_gemma":[0.998725,0.0001766371,0.00034185185,0.0004591809,0.00017537153,0.000030989173,0.00002467371,0.000017760836,0.000048519305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764055,0.00095885864,0.00077752676,0.00027510212,0.00007909019,0.00026885697],"domain_scores_gemma":[0.99863684,0.00023842865,0.00066846696,0.00018013494,0.00018778961,0.00008834724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031017346,0.0002679316,0.00065422384,0.00012702911,0.00027733576,0.000028589237,0.00028789495,0.00014153539,0.00003293155],"category_scores_gemma":[0.00018664787,0.00018045015,0.0001247837,0.0002505786,0.00031540848,0.00021699142,0.00010594504,0.0004724452,0.000111674184],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058400456,0.00020910584,0.0014448687,0.000013009855,0.003348065,0.00006094648,0.012545698,0.000012979908,0.96961987,0.000030282034,0.0034928657,0.00863833],"study_design_scores_gemma":[0.0021784292,0.0010665851,0.015572735,0.00002800177,0.001009834,0.00077289675,0.0023926676,0.0000027016317,0.9712296,0.00012697863,0.0054406794,0.00017886361],"about_ca_topic_score_codex":0.000027143116,"about_ca_topic_score_gemma":0.0000038711655,"teacher_disagreement_score":0.014127866,"about_ca_system_score_codex":0.00005054096,"about_ca_system_score_gemma":0.00008679628,"threshold_uncertainty_score":0.7358544},"labels":[],"label_agreement":null},{"id":"W3037060742","doi":"10.1111/bjd.19341","title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":206,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Interleukin 17; Internal medicine; Randomized controlled trial; Clinical endpoint; Confidence interval; Clinical trial; Dermatology; Psoriatic arthritis; Cytokine","score_opus":0.04242110571347812,"score_gpt":0.3147352210618506,"score_spread":0.27231411534837247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037060742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992528,0.0021242232,0.00023464512,0.0013753646,0.00080908043,0.0021358093,0.000671209,0.000018443761,0.000103227205],"genre_scores_gemma":[0.99706423,0.0011581415,0.00086425076,0.00036706452,0.00009351207,0.000031490286,0.00036452888,0.000038383147,0.000018421455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99280447,0.0024872231,0.0034328299,0.00063814555,0.00015366783,0.00048365],"domain_scores_gemma":[0.9947666,0.0026227485,0.0018007276,0.00028929565,0.0003191877,0.00020146286],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008677997,0.00039648224,0.003399917,0.00021641927,0.00016521412,0.000070434144,0.0006657612,0.00062429206,0.00014052892],"category_scores_gemma":[0.0018174329,0.00035761565,0.00023867263,0.00035659468,0.00035163158,0.00029595415,0.00024560533,0.0007537473,0.000017725808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9387372,0.0043780054,0.001401783,0.0000133326885,0.0019801178,0.0006785578,0.00090926973,0.000022409837,0.00007364639,0.000021151456,0.0028235796,0.048960954],"study_design_scores_gemma":[0.9838293,0.0032001748,0.007947286,0.00036623937,0.0007602341,0.001038974,0.00010700958,0.000018390821,0.00116796,0.000043131626,0.0011536762,0.00036761188],"about_ca_topic_score_codex":0.00026709572,"about_ca_topic_score_gemma":0.0001342383,"teacher_disagreement_score":0.048593342,"about_ca_system_score_codex":0.00004382219,"about_ca_system_score_gemma":0.000383516,"threshold_uncertainty_score":0.9998876},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3037406979","doi":"10.1177/1203475420936652","title":"Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Hôtel-Dieu de Québec; Amgen (Canada); Université de Montréal; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Formulary; Plaque psoriasis; Medical prescription; Health care; Medicare Part D; Psoriatic arthritis; Dermatology; Prescription drug; Family medicine; Pharmacology","score_opus":0.04132149990537026,"score_gpt":0.2755690531171162,"score_spread":0.23424755321174595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037406979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934785,0.0031664004,0.000061629755,0.00303594,0.000022214472,0.00019260713,0.000014464565,0.0000035492833,0.000024689924],"genre_scores_gemma":[0.99658084,0.0030415559,0.00003763991,0.0002536009,0.000019486626,0.000008505184,0.000032786353,0.00000756922,0.000018022098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873906,0.00029271992,0.00055772765,0.00017041442,0.00010488662,0.00013515796],"domain_scores_gemma":[0.9986233,0.00072774984,0.0003734364,0.00011098994,0.00011508253,0.000049404574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020499245,0.00015145446,0.00073903287,0.0005280154,0.000044122575,0.0000037942507,0.000054965607,0.000057155637,0.000016504926],"category_scores_gemma":[0.000045238667,0.000081797545,0.00005364346,0.00096204935,0.0001058653,0.000042853462,0.0000043322566,0.000073178584,7.990282e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030018207,0.00043138443,0.7972227,0.0001747409,0.00077845453,0.00044403112,0.12975007,0.002954945,0.0009383361,0.000015860056,0.00026163552,0.03700967],"study_design_scores_gemma":[0.036789045,0.030342285,0.66780597,0.008570531,0.008868127,0.0026805855,0.19084312,0.0074145594,0.03405534,0.00003856706,0.011105359,0.0014865407],"about_ca_topic_score_codex":0.0035209295,"about_ca_topic_score_gemma":0.026179435,"teacher_disagreement_score":0.12941672,"about_ca_system_score_codex":0.00004744069,"about_ca_system_score_gemma":0.00016531302,"threshold_uncertainty_score":0.99159026},"labels":[],"label_agreement":null},{"id":"W3037931538","doi":"10.1177/1203475420933174","title":"Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Bausch Health (Canada); Health Canada","funders":"","keywords":"Medicine; Ixekizumab; Secukinumab; Psoriasis Area and Severity Index; Etanercept; Ustekinumab; Adalimumab; Infliximab; Internal medicine; Psoriasis; Dermatology; Psoriatic arthritis; Disease","score_opus":0.10785962858652047,"score_gpt":0.3146747214384422,"score_spread":0.20681509285192173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037931538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013244514,0.9968527,0.000077943834,0.0011010962,0.0009268219,0.000544505,0.0002718733,0.0000083850055,0.00008426092],"genre_scores_gemma":[0.0012072215,0.99667126,0.0001537003,0.00043961845,0.00065597973,0.000032322423,0.00022535933,0.000046643716,0.00056789507],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653953,0.0005643814,0.0019109423,0.0003686783,0.00011997131,0.0004965204],"domain_scores_gemma":[0.99348485,0.004185734,0.0014472587,0.00029758,0.00028198093,0.0003025777],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009833368,0.0005564084,0.009368419,0.0011183094,0.00014865272,0.000013856397,0.0002554949,0.00051335344,0.00040510992],"category_scores_gemma":[0.00058416545,0.0003460363,0.0038649854,0.00084492785,0.00008571998,0.00003952032,0.00002713556,0.00036542336,0.000011811447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010736616,0.00006321479,0.000013061595,0.0016336502,0.3926475,0.0009489437,0.0003789432,0.00010415269,0.0000026583602,0.000031103416,0.069968775,0.53313434],"study_design_scores_gemma":[0.00042373218,0.00028809777,0.0000018065094,0.00072648405,0.3347399,0.0027353857,0.00003164658,9.3079353e-7,0.000001993521,0.000023447656,0.66082096,0.00020562859],"about_ca_topic_score_codex":0.0013478452,"about_ca_topic_score_gemma":0.0022931308,"teacher_disagreement_score":0.5908522,"about_ca_system_score_codex":0.00009010435,"about_ca_system_score_gemma":0.001202754,"threshold_uncertainty_score":0.99989915},"labels":[],"label_agreement":null},{"id":"W3038261526","doi":"","title":"Psoriasisis associated with elevated gut IL-1 and intestinal microbiome alterations: results of a cross-sectional study from Central Asia.","year":2020,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg","funders":"","keywords":"Microbiome; Gut microbiome; Cross-sectional study; Immunology; Medicine; Biology; Bioinformatics; Pathology","score_opus":0.017650526278611894,"score_gpt":0.23981715798345032,"score_spread":0.22216663170483844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038261526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452156,0.0022994545,0.0002795379,0.00016642269,0.0011834686,0.00049806683,0.0009073781,0.000070589755,0.000073512754],"genre_scores_gemma":[0.9972761,0.0000777421,0.0009689054,0.000044139684,0.0000375143,0.000049910683,0.0013461484,0.000022178048,0.00017735497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766207,0.00053918257,0.00070689234,0.00059753645,0.000052797735,0.00044149373],"domain_scores_gemma":[0.99901766,0.00024005272,0.0003270079,0.00024052236,0.00014164933,0.000033123903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021112307,0.00028918724,0.00060209323,0.00023276857,0.00015104486,0.00002795358,0.0002499262,0.00035240775,0.00007485452],"category_scores_gemma":[0.00045534217,0.0002605582,0.000071908624,0.0004593038,0.0004641015,0.000140908,0.00009657949,0.000327425,0.000017144497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005829367,0.00072070345,0.87184376,0.0000048743655,0.0021614274,0.000034930497,0.002226668,0.00001750089,0.11437116,0.000020438843,0.0008479905,0.0019211716],"study_design_scores_gemma":[0.013401257,0.0016213506,0.9674683,0.00003268148,0.00016644609,0.000023022982,0.0011054246,0.000022296537,0.015322178,0.00007393329,0.00051540096,0.00024770782],"about_ca_topic_score_codex":0.00047477524,"about_ca_topic_score_gemma":0.00016939573,"teacher_disagreement_score":0.09904898,"about_ca_system_score_codex":0.000114313756,"about_ca_system_score_gemma":0.000107833876,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W3042003151","doi":"10.1111/bjd.19393","title":"Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"UCB Pharma","keywords":"Certolizumab pegol; Medicine; Psoriasis; Plaque psoriasis; Term (time); Randomized controlled trial; Internal medicine; Dermatology; Adalimumab; Disease","score_opus":0.043120984841270325,"score_gpt":0.30675068317116083,"score_spread":0.2636296983298905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042003151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453619,0.047649927,0.00086873205,0.00255863,0.00083766296,0.0013273838,0.0013451104,0.00001579934,0.000034847544],"genre_scores_gemma":[0.9830454,0.0161204,0.00026961332,0.000038266127,0.0002455265,0.000043865646,0.00017956519,0.000024936757,0.000032452117],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955188,0.0015091395,0.0022647213,0.00029641663,0.00008049607,0.0003304396],"domain_scores_gemma":[0.99041253,0.0070372666,0.0020137166,0.00022489815,0.00022337135,0.00008819018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036850365,0.00029599748,0.0028803875,0.000120596895,0.00015139583,0.000025672987,0.00030686427,0.0002898196,0.00012663026],"category_scores_gemma":[0.0013606354,0.000212758,0.0009327285,0.0001116279,0.0004366082,0.000096837786,0.000035067802,0.00015937629,0.0000060579073],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7717557,0.0015968605,0.00067424786,0.00005328403,0.010060292,0.0012968958,0.0041256086,0.0000059081,0.010841883,0.000114163944,0.0025914833,0.19688368],"study_design_scores_gemma":[0.9056902,0.0015828675,0.0013826606,0.00017639718,0.0047284914,0.013533295,0.0003674463,0.000015638858,0.07033874,0.00012936995,0.001840886,0.00021404258],"about_ca_topic_score_codex":0.0002894659,"about_ca_topic_score_gemma":0.00006885928,"teacher_disagreement_score":0.19666964,"about_ca_system_score_codex":0.000028628874,"about_ca_system_score_gemma":0.00018659519,"threshold_uncertainty_score":0.86760193},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W3042065713","doi":"10.1016/j.jaad.2020.07.021","title":"Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study","year":2020,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Dermatrials Research; Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Discontinuation; Psoriasis; Retrospective cohort study; Scopus; Pandemic; Coronavirus disease 2019 (COVID-19); Disease; Internal medicine; Pediatrics; MEDLINE; Dermatology; Infectious disease (medical specialty)","score_opus":0.028700329493420856,"score_gpt":0.2849309258967448,"score_spread":0.2562305964033239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042065713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8239408,0.0016471576,0.0000018895333,0.17344022,0.00016976296,0.0006703272,0.00012195744,0.0000047752123,0.0000031287782],"genre_scores_gemma":[0.97438145,0.0033391365,0.0000112831285,0.022092126,0.00007474931,0.000026365129,0.000020316922,0.000019995705,0.0000345774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959193,0.0025359679,0.0008517982,0.00029199474,0.00007699416,0.00032393707],"domain_scores_gemma":[0.99722654,0.0004661501,0.0020092782,0.00016280534,0.000051616757,0.00008363704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018369158,0.00032818987,0.0011069367,0.00032023087,0.0001692628,0.0000070519054,0.0004494269,0.00026711298,0.000017862638],"category_scores_gemma":[0.00020818478,0.0001690479,0.00028780603,0.0002657804,0.0005381079,0.000062270105,0.000049823735,0.0008632269,0.0000012018066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020478847,0.00025063517,0.9843112,0.000025989064,0.0010494706,0.000070260925,0.0026528419,0.0000043614064,0.001834208,7.215669e-7,0.0021149223,0.005637453],"study_design_scores_gemma":[0.0064983773,0.00073228835,0.9757784,0.00006757944,0.00054513564,0.00014662571,0.00046767443,0.0000019920574,0.00071166485,0.000052295465,0.014818889,0.00017908802],"about_ca_topic_score_codex":0.0031174652,"about_ca_topic_score_gemma":0.0006225753,"teacher_disagreement_score":0.15134808,"about_ca_system_score_codex":0.00035769914,"about_ca_system_score_gemma":0.00026503965,"threshold_uncertainty_score":0.6893573},"labels":[],"label_agreement":null},{"id":"W3042196480","doi":"10.1136/annrheumdis-2020-eular.474","title":"OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Novartis Pharma; Celgene; Chugai Pharmaceutical; Pfizer","keywords":"Medicine; Sacroiliitis; BASDAI; Psoriatic arthritis; Axial spondyloarthritis; Internal medicine; Sacroiliac joint; Ankylosing spondylitis; Surgery; Nuclear medicine; Gastroenterology; Arthritis","score_opus":0.05550652916542601,"score_gpt":0.3145206718421891,"score_spread":0.2590141426767631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042196480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98941773,0.0010077666,0.000010954494,0.002659829,0.0002146271,0.0044814716,0.002118522,0.000024778776,0.00006434197],"genre_scores_gemma":[0.99863946,0.00022471856,0.000046284484,0.00025742454,0.000015241834,0.00023214774,0.00049390807,0.000029577668,0.00006125015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99671406,0.0009463962,0.0011331883,0.00051313045,0.0003151459,0.00037807375],"domain_scores_gemma":[0.9957377,0.0022485529,0.0009546182,0.00063069566,0.00032497552,0.00010349686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005090713,0.0004451348,0.0017113761,0.00020282848,0.00013158681,0.000019003315,0.0005941247,0.00007100118,0.0000663392],"category_scores_gemma":[0.00087413436,0.0002249461,0.00037666332,0.00045468507,0.000451212,0.00010681849,0.0001779423,0.00016338158,0.000031234817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96950233,0.0033888917,0.002597608,0.000049938986,0.007543475,0.0000061967885,0.00789028,0.0006242285,0.0005394462,0.000062485735,0.00046019876,0.0073349196],"study_design_scores_gemma":[0.9310082,0.0024751816,0.030951153,0.001771849,0.0016433971,8.3406906e-7,0.0019585013,0.000036787802,0.029664855,0.000104463456,0.00004321895,0.0003415632],"about_ca_topic_score_codex":0.00022163027,"about_ca_topic_score_gemma":0.00007154211,"teacher_disagreement_score":0.038494136,"about_ca_system_score_codex":0.000032333526,"about_ca_system_score_gemma":0.00014669291,"threshold_uncertainty_score":0.91730356},"labels":[],"label_agreement":null},{"id":"W3042207082","doi":"10.1136/annrheumdis-2020-eular.4736","title":"FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada; AbbVie; Celgene; Gilead Sciences; Galápagos; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Adalimumab; Secukinumab; Etanercept; Psoriasis; Psoriatic arthritis; Ustekinumab; Plaque psoriasis; Internal medicine; Psoriasis Area and Severity Index; Clinical endpoint; Dosing; Dermatology; Clinical trial; Gastroenterology; Rheumatoid arthritis","score_opus":0.09139180522912485,"score_gpt":0.3222439612649051,"score_spread":0.23085215603578027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042207082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990754,0.0048952457,0.0000011399388,0.0019181488,0.0005927805,0.0008062982,0.00090555585,0.000031688458,0.00009514388],"genre_scores_gemma":[0.99937034,0.00023503663,0.000007625124,0.00015966063,0.000020427937,0.000041033385,0.000115328105,0.000017685565,0.000032891312],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974849,0.0008308718,0.00092149584,0.0003241252,0.00016564857,0.0002729434],"domain_scores_gemma":[0.9955993,0.0030821268,0.00055407826,0.00067593326,0.000047467696,0.000041083764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002184869,0.0002744133,0.0008594584,0.000053047163,0.0001313158,0.000015718024,0.0006665379,0.00007768747,0.00009249818],"category_scores_gemma":[0.0016587429,0.00016033513,0.00033043927,0.00025450005,0.00015909775,0.000058189522,0.00014647398,0.00014580405,0.00009200521],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059652604,0.040473733,0.19745079,0.00021271002,0.01495389,0.000026905276,0.09678303,0.0012751133,0.00043781797,0.00061588356,0.02394389,0.56417364],"study_design_scores_gemma":[0.025903558,0.0021525605,0.95525664,0.00060786464,0.00062561536,3.9269506e-7,0.00968054,0.000043320015,0.0049220137,0.00035295164,0.00018283246,0.0002717201],"about_ca_topic_score_codex":0.0007634013,"about_ca_topic_score_gemma":0.00025322847,"teacher_disagreement_score":0.7578058,"about_ca_system_score_codex":0.0000132750665,"about_ca_system_score_gemma":0.00006831279,"threshold_uncertainty_score":0.65382767},"labels":[],"label_agreement":null},{"id":"W3042689359","doi":"10.1080/09546634.2020.1782817","title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development","keywords":"Medicine; Psoriasis; Internal medicine; Placebo; Clinical trial; Dermatology; Adalimumab; Gastroenterology; Surgery; Rheumatoid arthritis","score_opus":0.04617964588141407,"score_gpt":0.2791858588932267,"score_spread":0.23300621301181265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042689359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953486,0.0007997008,0.00006701467,0.0020344008,0.00021919714,0.0006967137,0.0005979817,0.000045514033,0.00019089766],"genre_scores_gemma":[0.9963555,0.00043186836,0.0021665944,0.0005359341,0.00007996146,0.000039290288,0.00018423938,0.000030563406,0.00017609543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967093,0.0008610656,0.0011966536,0.0005754862,0.00015724893,0.00050026295],"domain_scores_gemma":[0.9979755,0.0007739381,0.0005955462,0.0003285401,0.00014134822,0.0001851187],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014475019,0.00049985445,0.0014238381,0.00010724649,0.000108422064,0.000040319726,0.00025150977,0.00034573092,0.00009164812],"category_scores_gemma":[0.0001364555,0.00026955068,0.0002895886,0.00024721178,0.00014102926,0.00016488967,0.00004545708,0.00024356374,0.0001603864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20098029,0.0074255774,0.7461234,0.000005535631,0.0046007303,0.0048291255,0.0037308538,0.00021649773,0.00012123172,0.000050703642,0.0012721702,0.030643886],"study_design_scores_gemma":[0.11209108,0.04509685,0.8169099,0.00018605207,0.0012962321,0.00033733726,0.0009088079,0.0000049721925,0.0037048017,0.000094584226,0.018704232,0.0006651173],"about_ca_topic_score_codex":0.00008537079,"about_ca_topic_score_gemma":0.00006535228,"teacher_disagreement_score":0.088889204,"about_ca_system_score_codex":0.0003262148,"about_ca_system_score_gemma":0.0002139689,"threshold_uncertainty_score":0.9999757},"labels":[],"label_agreement":null},{"id":"W3042936806","doi":"10.1101/2020.07.13.20151340","title":"Biologic Drug Survival in Psoriasis: A Systematic Review &amp; Comparative Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"medRxiv","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Ustekinumab; Medicine; Secukinumab; Adalimumab; Etanercept; Infliximab; Ixekizumab; Hazard ratio; Internal medicine; Psoriatic arthritis; Discontinuation; Oncology; Confidence interval; Disease; Tumor necrosis factor alpha","score_opus":0.19947804222492582,"score_gpt":0.36182132404716905,"score_spread":0.16234328182224322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042936806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013195137,0.9949778,0.000010226786,0.00010704418,0.0005338603,0.003386359,0.0005039066,0.00011348283,0.00035416064],"genre_scores_gemma":[0.00010261789,0.99215764,0.000045571072,0.00012342168,0.000037504666,0.0025755845,0.0019390074,0.000043617176,0.002975035],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98694235,0.008761199,0.002394783,0.0011999902,0.00011923491,0.0005824588],"domain_scores_gemma":[0.9954429,0.0016651361,0.0014697006,0.0012617684,0.00009088848,0.00006960305],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002061998,0.0012026633,0.021649616,0.0006433393,0.00011895214,0.000027673686,0.0010407121,0.0005862081,0.001601114],"category_scores_gemma":[0.00040276963,0.00070186076,0.0073870714,0.0027914415,0.0001305976,0.00006080903,0.00018687644,0.00064149353,0.006212615],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014083045,0.0001979774,0.000039298346,0.48831066,0.5068085,0.00006325568,0.00025696045,3.5718443e-7,0.0000012922087,0.00009635864,0.0006288821,0.0035823246],"study_design_scores_gemma":[0.00018265645,0.000023387573,0.00000463057,0.02272719,0.6028428,0.000021992395,0.000025249119,6.922833e-8,0.0000014839268,0.000006581991,0.37370673,0.00045721245],"about_ca_topic_score_codex":0.00005758182,"about_ca_topic_score_gemma":0.0003874179,"teacher_disagreement_score":0.46558347,"about_ca_system_score_codex":0.00012635745,"about_ca_system_score_gemma":0.00016367361,"threshold_uncertainty_score":0.99954325},"labels":[],"label_agreement":null},{"id":"W3043299604","doi":"10.1016/j.jaad.2020.07.052","title":"Drugs associated with development of pityriasis rubra pilaris: A systematic review","year":2020,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Psoriasis Association","keywords":"Pityriasis rubra pilaris; Medicine; Dermatology; Palmoplantar keratoderma; Hyperkeratosis; Psoriasis","score_opus":0.02841740291168345,"score_gpt":0.29726308212343866,"score_spread":0.26884567921175523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043299604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000574718,0.99743605,0.000012443782,0.00076432596,0.0001633501,0.00093708944,0.000060730083,0.000011962091,0.0000393048],"genre_scores_gemma":[0.0017510157,0.9974242,0.00026264894,0.00037635892,0.000017165277,0.000046848225,0.000017311331,0.000043471096,0.00006099812],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9932306,0.0028365704,0.0031395333,0.00025119298,0.00019241606,0.0003496989],"domain_scores_gemma":[0.9834807,0.0009989444,0.015055653,0.00027202355,0.00013745126,0.000055218225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060433085,0.0005437823,0.008925077,0.00028642363,0.00009949262,0.0000042621887,0.0013522798,0.00040463524,0.000024070923],"category_scores_gemma":[0.0005711053,0.0002856728,0.0012460283,0.00088448735,0.0005903632,0.000057773726,0.00019137502,0.0009588683,0.000032719694],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022510301,0.0005421845,0.00012636256,0.7387221,0.038129304,0.000076281656,0.0011800362,2.1015498e-7,0.00012968283,0.00007626981,0.0042698844,0.21652259],"study_design_scores_gemma":[0.0013106852,0.00030743674,0.00010118612,0.6855168,0.042608175,0.008482993,0.00027785197,8.1821526e-8,0.0010349944,0.000014981025,0.25977707,0.00056774437],"about_ca_topic_score_codex":0.0000025451584,"about_ca_topic_score_gemma":6.492002e-7,"teacher_disagreement_score":0.25550717,"about_ca_system_score_codex":0.00014710015,"about_ca_system_score_gemma":0.00095059513,"threshold_uncertainty_score":0.9999595},"labels":[],"label_agreement":null},{"id":"W3043733200","doi":"10.1080/09546634.2020.1793891","title":"Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Secukinumab; Psoriasis Area and Severity Index; Psoriasis; Adalimumab; Dermatology; Adverse effect; Internal medicine; Psoriatic arthritis; Rheumatoid arthritis","score_opus":0.07257574718631102,"score_gpt":0.3027416133475172,"score_spread":0.23016586616120618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043733200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915764,0.0050266334,0.00003457484,0.002526361,0.0001441486,0.00046199927,0.00012617934,0.00000778085,0.00009597704],"genre_scores_gemma":[0.9972334,0.0021786103,0.00028402658,0.00015188567,0.000019088153,0.000054385902,0.000037664096,0.000009596177,0.00003132438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975766,0.00082550035,0.0009316991,0.0002464745,0.00011791508,0.00030183035],"domain_scores_gemma":[0.9984558,0.0007303369,0.00042601678,0.00023706006,0.00009370953,0.000057051395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016733371,0.000311289,0.001292479,0.00046333668,0.000055390643,0.00001142612,0.00025289264,0.00022566695,0.00026322724],"category_scores_gemma":[0.00004520118,0.00016361526,0.0005655388,0.00080722367,0.00008249319,0.000075004995,0.00001914523,0.0001100936,0.00001927545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15982257,0.028922724,0.38883433,0.000083666135,0.07015092,0.0033940137,0.17342772,0.02336476,0.072460465,0.00094984233,0.0009840024,0.07760498],"study_design_scores_gemma":[0.07465025,0.024528638,0.7205968,0.00010624999,0.010973137,0.00043337228,0.013952548,0.00026585397,0.13629493,0.00018077792,0.017085414,0.0009320117],"about_ca_topic_score_codex":0.000062174455,"about_ca_topic_score_gemma":0.00013818165,"teacher_disagreement_score":0.33176246,"about_ca_system_score_codex":0.00022850241,"about_ca_system_score_gemma":0.0000858726,"threshold_uncertainty_score":0.66720366},"labels":[],"label_agreement":null},{"id":"W3044282243","doi":"10.1016/j.jaad.2020.07.082","title":"Sex differences in the risk of diabetes mellitus among individuals with psoriasis: A retrospective cohort study in Québec, Canada","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Université de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Fonds de Recherche du Québec - Santé; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Diabetes mellitus; Comorbidity; Cohort study; Internal medicine; Cohort; Population; Concomitant; Scopus; Odds ratio; Retrospective cohort study; MEDLINE; Dermatology; Endocrinology; Environmental health","score_opus":0.01061704103209296,"score_gpt":0.2265440255837226,"score_spread":0.21592698455162965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044282243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231654,0.002106631,9.960262e-7,0.0050830585,0.00006833462,0.00035479723,0.00003775806,0.0000026983196,0.000029182553],"genre_scores_gemma":[0.99925023,0.00030757042,0.000016908829,0.0003767397,0.000017304945,0.000016569893,7.8706825e-7,0.000008390865,0.0000055209143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675906,0.0018864818,0.00074854126,0.00017773925,0.00016317399,0.00026497737],"domain_scores_gemma":[0.9971915,0.0007106011,0.0018975392,0.00013420034,0.000039586976,0.000026566695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040875535,0.00019081605,0.0012097844,0.00013203842,0.00006144589,0.0000037559266,0.0007563363,0.00009136837,0.000013802463],"category_scores_gemma":[0.0002070089,0.00009681353,0.000114017435,0.0005561307,0.00063950784,0.000058881236,0.00007075422,0.00067991565,6.605742e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018137894,0.00019772483,0.99344456,0.000008313083,0.0012627636,0.000015247269,0.0036202956,0.000010713798,0.00031666312,0.000008497652,0.00044692834,0.0004869251],"study_design_scores_gemma":[0.0015263321,0.00043722938,0.98648787,0.000033617765,0.0004638657,0.00007236465,0.00640706,0.000001980624,0.0043329066,0.000037452068,0.00010543921,0.00009388597],"about_ca_topic_score_codex":0.101023845,"about_ca_topic_score_gemma":0.11445973,"teacher_disagreement_score":0.013435884,"about_ca_system_score_codex":0.00007640299,"about_ca_system_score_gemma":0.00034928473,"threshold_uncertainty_score":0.90496254},"labels":[],"label_agreement":null},{"id":"W3044862537","doi":"10.3390/ijms21155215","title":"A Tissue-Engineered Human Psoriatic Skin Model to Investigate the Implication of cAMP in Psoriasis: Differential Impacts of Cholera Toxin and Isoproterenol on cAMP Levels of the Epidermis","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Psoriasis; Cholera toxin; Involucrin; Epidermis (zoology); Keratinocyte; Filaggrin; Microphthalmia-associated transcription factor; Human skin; Cyclase; Cancer research; Dermatology; Medicine; Biology; Cell culture; Endocrinology; Internal medicine; Receptor; Biochemistry; Atopic dermatitis; Anatomy; Tyrosinase","score_opus":0.03488644556130643,"score_gpt":0.2905475561987068,"score_spread":0.2556611106374004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044862537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951109,0.00040496365,0.0010870503,0.0029621164,0.00019244936,0.00017424603,0.000044100554,0.0000016970479,0.00002247314],"genre_scores_gemma":[0.99950427,0.000020822008,0.000256468,0.00017664529,0.000023936414,0.0000049562054,0.0000014809782,0.000004312195,0.000007084649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989578,0.00014386173,0.00047739485,0.00012826541,0.00018698319,0.00010566919],"domain_scores_gemma":[0.9991754,0.000074525975,0.00046609624,0.00010753344,0.0001474023,0.00002903662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003037589,0.00010196345,0.00022774175,0.00015199494,0.00004317288,0.000013194161,0.0005843712,0.000055464283,0.000019364625],"category_scores_gemma":[0.00020048139,0.000059171478,0.00008724532,0.00019492884,0.0001908664,0.00007032234,0.00007582732,0.00010316771,0.0000011293756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084057734,0.00006733327,0.00049682776,0.000008939409,0.00014264225,0.0000021096307,0.0034740868,0.0023001884,0.98567367,0.0008631694,0.00001598162,0.006870985],"study_design_scores_gemma":[0.0009776953,0.0003579898,0.042025745,0.00013021489,0.00004560734,0.0000226027,0.00014219103,0.00021050185,0.9551208,0.00089559186,0.000012619219,0.000058423782],"about_ca_topic_score_codex":0.000063153355,"about_ca_topic_score_gemma":0.000013570288,"teacher_disagreement_score":0.041528918,"about_ca_system_score_codex":0.00002136094,"about_ca_system_score_gemma":0.00009466807,"threshold_uncertainty_score":0.24129428},"labels":[],"label_agreement":null},{"id":"W3046003671","doi":"10.1111/dth.14092","title":"Successful use of lymphoplasma exchange in a patient with acute generalized pustular psoriasis of von Zumbusch","year":2020,"lang":"en","type":"article","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Pustular psoriasis; Generalized pustular psoriasis","score_opus":0.03027663742336438,"score_gpt":0.2303553223214944,"score_spread":0.20007868489813002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046003671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994169,0.004502993,0.000055218337,0.00045006847,0.00015299264,0.00044602138,0.00011796539,0.000047115373,0.000058642952],"genre_scores_gemma":[0.9956962,0.0030040473,0.00050979125,0.0005257927,0.00000812619,0.000081647464,0.00012675452,0.000019436522,0.000028218206],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985343,0.00035348465,0.000441406,0.00031334095,0.00006308289,0.00029438263],"domain_scores_gemma":[0.999216,0.00011391634,0.00029455006,0.00027047156,0.00007445908,0.000030609088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005675854,0.0002574308,0.00067509897,0.00012781727,0.000044049008,0.000007135631,0.0002020714,0.00024988316,0.00025962116],"category_scores_gemma":[0.00001629138,0.00018061468,0.00012694648,0.00037004513,0.00013106273,0.00011455121,0.00004362075,0.00008550488,0.000020820005],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01639585,0.0016425338,0.5129446,0.00016989278,0.003840367,0.001146438,0.012882441,0.00015701969,0.35642558,0.0004807325,0.0024784927,0.0914361],"study_design_scores_gemma":[0.014001548,0.0014137605,0.017053481,0.000051794003,0.00019466486,0.0004333935,0.0004451404,0.00004066991,0.95287174,0.00004904799,0.013029495,0.00041524807],"about_ca_topic_score_codex":0.00019248453,"about_ca_topic_score_gemma":0.000034607423,"teacher_disagreement_score":0.59644616,"about_ca_system_score_codex":0.000020206482,"about_ca_system_score_gemma":0.00005042814,"threshold_uncertainty_score":0.73652524},"labels":[],"label_agreement":null},{"id":"W3046622164","doi":"10.1111/1346-8138.15522","title":"Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence","year":2020,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Calcipotriol; Medicine; Betamethasone dipropionate; Psoriasis; Plaque psoriasis; Betamethasone; Body surface area; Patient satisfaction; Dermatology; Topical medication; Internal medicine; Surgery","score_opus":0.014072221703884653,"score_gpt":0.22440479733217383,"score_spread":0.2103325756282892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046622164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966714,0.0018978271,0.00006101792,0.00089768507,0.00020639486,0.000220074,0.000019834379,0.000005755949,0.00002002883],"genre_scores_gemma":[0.9994625,0.00030366308,0.000100216974,0.000100187324,0.000010337641,0.0000035549992,0.0000068351233,0.0000088362085,0.000003882885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873185,0.0004492122,0.0004737471,0.000109855595,0.0000586134,0.00017673164],"domain_scores_gemma":[0.99886554,0.00039352017,0.00050807616,0.00009583376,0.00010389077,0.00003313717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008124201,0.00014226229,0.00045407243,0.000096295444,0.00005927575,0.0000031263473,0.000098040786,0.00013658444,0.000045554913],"category_scores_gemma":[0.00008989764,0.000083313615,0.000051487546,0.00014637767,0.00015648169,0.00008255015,0.000043096377,0.00023578719,0.0000107722135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013887921,0.00042043612,0.8708205,0.00007937597,0.0008992713,0.0000922912,0.009724454,0.0001195112,0.025311813,0.00012456352,0.0004461039,0.07807375],"study_design_scores_gemma":[0.013865109,0.0017865796,0.9420423,0.000084600324,0.00039585546,0.00071755255,0.00056797557,0.000009442086,0.039948802,0.000057512632,0.00036703883,0.0001572416],"about_ca_topic_score_codex":0.000099480225,"about_ca_topic_score_gemma":0.000051028113,"teacher_disagreement_score":0.0779165,"about_ca_system_score_codex":0.0000274608,"about_ca_system_score_gemma":0.00008118973,"threshold_uncertainty_score":0.33974305},"labels":[],"label_agreement":null},{"id":"W3048014867","doi":"10.2147/ppa.s263843","title":"&lt;p&gt;Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey&lt;/p&gt;","year":2020,"lang":"en","type":"article","venue":"Patient Preference and Adherence","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Ministry of Science and Technology of the People's Republic of China; Central South University; Hunan Provincial Science and Technology Department; National Natural Science Foundation of China","keywords":"Medicine; Psoriasis; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Dermatology; Internal medicine; Virology; Disease; Outbreak","score_opus":0.07872068354811136,"score_gpt":0.2777774762262896,"score_spread":0.19905679267817827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048014867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461925,0.0024144296,0.000061540726,0.0006701712,0.00024720133,0.0011056964,0.00060403714,0.00008846604,0.0001892251],"genre_scores_gemma":[0.99768335,0.0005677985,0.00015080115,0.00086867774,0.000012052323,0.00034740733,0.000118853066,0.000021355576,0.00022971537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970763,0.0006595071,0.00077735604,0.00083777076,0.00013276142,0.0005163208],"domain_scores_gemma":[0.99760556,0.0009926412,0.00047607496,0.00050390325,0.00014562342,0.00027617143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023020977,0.0005030144,0.00074755994,0.00010655653,0.0003701941,0.000036430192,0.00029561238,0.0002128817,0.00033000458],"category_scores_gemma":[0.0008581671,0.0003317259,0.00013074621,0.00037326265,0.00027273918,0.00012507112,0.00019308286,0.00013965485,0.00008383362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018634725,0.00048601488,0.7458022,0.00013373308,0.000720417,0.00002769349,0.0053125625,0.000060405582,0.15914088,0.000118985816,0.0007649344,0.085568674],"study_design_scores_gemma":[0.009598942,0.006682588,0.87523836,0.00016723812,0.0005664031,0.000051395404,0.0005936824,0.000077476674,0.0794407,0.00012084049,0.026291095,0.0011712692],"about_ca_topic_score_codex":0.00048171202,"about_ca_topic_score_gemma":0.0005149973,"teacher_disagreement_score":0.12943615,"about_ca_system_score_codex":0.00007602191,"about_ca_system_score_gemma":0.00027712766,"threshold_uncertainty_score":0.99991345},"labels":[],"label_agreement":null},{"id":"W3048060477","doi":"10.1177/1203475420945234","title":"Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis","year":2020,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Coronavirus disease 2019 (COVID-19); Dermatology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Coronavirus; Respiratory system; Intensive care medicine; Internal medicine; Virology; Disease; Infectious disease (medical specialty); Outbreak","score_opus":0.07750544635517705,"score_gpt":0.28047939011601836,"score_spread":0.20297394376084132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048060477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.086448856,0.9125789,7.642917e-7,0.0000931417,0.0004866919,0.00029280432,0.00008422529,0.000004536976,0.000010107423],"genre_scores_gemma":[0.0040758606,0.99552524,0.000014819175,0.00019225426,0.000059972634,0.000005060813,0.00004586046,0.000021592927,0.00005935142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756145,0.00077541097,0.0011469852,0.00020763309,0.00010050636,0.0002080004],"domain_scores_gemma":[0.9947123,0.0035924178,0.001349276,0.00017609971,0.000117564705,0.000052342595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005178132,0.0003568295,0.003218556,0.00032526857,0.00006177338,0.000007811931,0.0001320707,0.00036232444,0.00004142779],"category_scores_gemma":[0.0003635395,0.00015816513,0.00026053365,0.00024058904,0.00055114314,0.00006698402,0.000047668473,0.0004667342,0.000002623142],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002527502,0.00009328165,0.0089905085,0.0009517393,0.0029157186,0.0022522644,0.00022315908,2.3647571e-7,0.000001961442,0.000010625631,0.0019835103,0.9800495],"study_design_scores_gemma":[0.0034022608,0.0014908032,0.001492028,0.007393224,0.0047700745,0.0131351715,0.000050795206,5.974674e-8,0.0000010374979,0.00001352703,0.96800536,0.00024564177],"about_ca_topic_score_codex":0.000019073894,"about_ca_topic_score_gemma":0.0000047382396,"teacher_disagreement_score":0.97980386,"about_ca_system_score_codex":0.000033766548,"about_ca_system_score_gemma":0.0002159438,"threshold_uncertainty_score":0.6449787},"labels":[],"label_agreement":null},{"id":"W3048560770","doi":"10.1136/annrheumdis-2020-eular.387","title":"FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Adverse effect; Discontinuation; Internal medicine; Placebo; Gastroenterology; Surgery; Arthritis; Pathology","score_opus":0.04106422336789942,"score_gpt":0.29787521990846044,"score_spread":0.256810996540561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048560770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98708475,0.0067639137,0.000023803663,0.0011114675,0.00021096932,0.0016198627,0.0029505016,0.000018290142,0.0002164618],"genre_scores_gemma":[0.99874717,0.00070527586,0.000043091135,0.00010833369,0.0000101140195,0.00007351023,0.00025098698,0.000015718144,0.000045796885],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99605566,0.0017200887,0.001615678,0.00022852798,0.00013776464,0.0002422783],"domain_scores_gemma":[0.99613684,0.0017683643,0.0013712178,0.0004907008,0.00020360535,0.000029288183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007084893,0.00025707445,0.0015290505,0.000058103942,0.00009796803,0.00000846195,0.0004456666,0.000082700106,0.00021395039],"category_scores_gemma":[0.0033115046,0.00012308816,0.00045835885,0.00036392116,0.00031840216,0.00010170734,0.000069774695,0.000099680685,0.000008952524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42886874,0.009682405,0.012560941,0.00068499945,0.0151855275,0.000004642712,0.020929378,0.0010124845,0.0017311659,0.0015137409,0.008161948,0.499664],"study_design_scores_gemma":[0.7771304,0.007853984,0.1183462,0.007007631,0.0054730237,0.000004211726,0.0056467033,0.00018673333,0.07196506,0.003191845,0.0020989273,0.0010952285],"about_ca_topic_score_codex":0.0002702873,"about_ca_topic_score_gemma":0.000047427,"teacher_disagreement_score":0.4985688,"about_ca_system_score_codex":0.000010719321,"about_ca_system_score_gemma":0.0001638012,"threshold_uncertainty_score":0.50193894},"labels":[],"label_agreement":null},{"id":"W3048577711","doi":"10.1212/nxi.0000000000000870","title":"Interleukin-26, preferentially produced by T <sub>H</sub> 17 lymphocytes, regulates CNS barrier function","year":2020,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Vlaamse regering; Centre de recherche du CHU Sainte-Justine; Multiple Sclerosis Society; Fonds de Recherche du Québec - Santé; Fonds Wetenschappelijk Onderzoek; Multiple Sclerosis Society of Canada","keywords":"Function (biology); Chemistry; Cell biology; Biology","score_opus":0.012176076734275058,"score_gpt":0.19114320554901484,"score_spread":0.17896712881473978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048577711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867055,0.0016585581,0.00011901304,0.005589325,0.0031972243,0.0010904007,0.000081049846,0.0012841726,0.0002747503],"genre_scores_gemma":[0.9943713,0.0005813546,0.000008891126,0.0034071223,0.0002305225,0.00017969709,0.00072588865,0.00017756756,0.00031767308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99437517,0.0015894512,0.0010830652,0.0017483067,0.00013798157,0.0010660548],"domain_scores_gemma":[0.9976845,0.00038824536,0.00065997615,0.00095367903,0.00019545096,0.000118189375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021724569,0.0008513474,0.0008712201,0.00032391155,0.0005724055,0.0000684705,0.00071200577,0.000993224,0.00035234424],"category_scores_gemma":[0.00043292472,0.00087160314,0.0003284391,0.00048552462,0.00052641914,0.0004961937,0.00034136508,0.0010320581,0.002250105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003908694,0.00017344873,0.0013973737,0.000030599782,0.0003811856,0.000059720358,0.0002715121,0.000077151264,0.9607567,0.00016576343,0.01137529,0.021402571],"study_design_scores_gemma":[0.004690427,0.0031713585,0.0398648,0.000012285356,0.00046950494,0.0002929203,0.000016546324,0.000101777456,0.9134015,0.00012234083,0.03725998,0.00059655093],"about_ca_topic_score_codex":0.0000117473055,"about_ca_topic_score_gemma":0.000014664473,"teacher_disagreement_score":0.047355182,"about_ca_system_score_codex":0.00005259419,"about_ca_system_score_gemma":0.00016709937,"threshold_uncertainty_score":0.9993735},"labels":[],"label_agreement":null},{"id":"W3048687053","doi":"10.1016/j.jaad.2020.08.032","title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec; Université Laval; Dalhousie University","funders":"Janssen Research and Development","keywords":"Medicine; Nested case-control study; Psoriasis; Systemic therapy; Risk assessment; Case-control study; Dermatology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.02685730341905348,"score_gpt":0.29734917634228203,"score_spread":0.27049187292322857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048687053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406976,0.0018531341,0.00009569154,0.003340676,0.00007826706,0.00034587138,0.00019051756,0.000008068578,0.00001799747],"genre_scores_gemma":[0.9991086,0.0005608971,0.00009162328,0.0001655512,0.000029426557,0.000019019879,0.00000608272,0.000012807883,0.000005979823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950098,0.003163658,0.001099594,0.0002733785,0.00014873315,0.00030488198],"domain_scores_gemma":[0.99453586,0.0011341234,0.0039160694,0.00026281952,0.0000985556,0.000052556046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059207133,0.00029578488,0.0017340026,0.00024410509,0.0001363457,0.000009886975,0.00046261735,0.00021298042,0.000011629304],"category_scores_gemma":[0.00022555265,0.00015599377,0.0005011873,0.0011705937,0.0006514264,0.000081628714,0.00004511557,0.00052059436,6.7951146e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011161326,0.00032280965,0.97138196,0.000026775091,0.017165704,0.0003642069,0.0013130546,0.00019808224,0.0062706755,0.00003528715,0.000083999,0.001721339],"study_design_scores_gemma":[0.0051399423,0.00072171877,0.960568,0.0000615021,0.01628883,0.011114603,0.002368498,0.00008060351,0.0034491627,0.000022893008,0.000028558972,0.00015570348],"about_ca_topic_score_codex":0.00046231944,"about_ca_topic_score_gemma":0.000103138605,"teacher_disagreement_score":0.010813951,"about_ca_system_score_codex":0.000115489536,"about_ca_system_score_gemma":0.00018179136,"threshold_uncertainty_score":0.6361241},"labels":[],"label_agreement":null},{"id":"W3049421987","doi":"10.1097/md.0000000000021565","title":"The association of serum vascular endothelial growth factor levels and psoriasis vulgaris","year":2020,"lang":"en","type":"article","venue":"Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Chongqing; China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Psoriasis; Medicine; Pathogenesis; Vascular endothelial growth factor; Angiogenesis; Microcirculation; Dermis; Dermatology; Physiology; Pathology; Immunology; Internal medicine; Bioinformatics; VEGF receptors; Biology","score_opus":0.02120056417281702,"score_gpt":0.23057971359314738,"score_spread":0.20937914942033037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049421987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98009956,0.006591458,0.000070534275,0.011138117,0.00093834585,0.00021716325,0.00021141312,0.000043284515,0.0006901301],"genre_scores_gemma":[0.9979479,0.00072880345,0.000010903047,0.00025814664,0.00018344412,0.0000073049277,0.00001704586,0.000008428012,0.00083802943],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992424,0.0001689437,0.00020370638,0.00015322323,0.000061091894,0.0001706395],"domain_scores_gemma":[0.9992009,0.00047210578,0.00013103969,0.00010676163,0.00006380043,0.00002539406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023327823,0.000111345194,0.0002608592,0.000025992815,0.0001335452,0.0000035079088,0.00010024075,0.00012854255,0.000317763],"category_scores_gemma":[0.0006415435,0.000065080654,0.00005417008,0.0000990618,0.000093501185,0.00002852411,0.00003063262,0.000094018586,0.00004110123],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035604785,0.00008608849,0.36597615,0.000085896754,0.00284293,0.0000075477165,0.009188795,3.4888708e-7,0.41150153,0.0016437536,0.010580651,0.19773027],"study_design_scores_gemma":[0.007619097,0.0007591145,0.68639594,0.000038316706,0.0006461361,0.000005738647,0.00062991306,0.0000037768023,0.17636026,0.0002471926,0.12710741,0.00018712154],"about_ca_topic_score_codex":0.00006208813,"about_ca_topic_score_gemma":0.000015332327,"teacher_disagreement_score":0.3204198,"about_ca_system_score_codex":0.000022322018,"about_ca_system_score_gemma":0.000018853332,"threshold_uncertainty_score":0.34792823},"labels":[],"label_agreement":null},{"id":"W3081597039","doi":"10.1093/cvr/cvaa257","title":"Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension","year":2020,"lang":"en","type":"review","venue":"Cardiovascular Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"Medicine; Interleukin 17; Immune system; Interleukin; Interleukin 23; Immunology; T cell; Cytokine; Bioinformatics; Biology","score_opus":0.10380854666261166,"score_gpt":0.33418314623045847,"score_spread":0.2303745995678468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081597039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002447241,0.99312186,0.0000023125428,0.000016718104,0.00034572542,0.0013742124,0.00014127958,0.000038699087,0.0025119372],"genre_scores_gemma":[0.010028658,0.98749197,0.000014611981,0.0000050370727,0.00008008384,0.00044571017,0.001034793,0.00008377126,0.00081536226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937498,0.0032559452,0.00092393963,0.00097247644,0.00027321844,0.0008246459],"domain_scores_gemma":[0.9975903,0.00079674646,0.00014063247,0.0011945034,0.00020357297,0.00007425836],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019911667,0.0005119729,0.003263418,0.0015688735,0.00010208957,0.000021781907,0.0007690479,0.0010769089,0.00018313482],"category_scores_gemma":[0.0004330027,0.00043378907,0.0023553337,0.0018094137,0.0002745462,0.00007620557,0.0004534958,0.0017494262,0.0015854831],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099862715,0.00031290346,0.000054598495,0.0022155603,0.0030620177,0.00047046496,0.00030483358,0.0000032018409,0.0016281157,0.000010709634,0.0010252368,0.9908125],"study_design_scores_gemma":[0.0016192948,0.00016534087,0.00010888662,0.0034867749,0.00072738307,0.0001806172,0.00037810698,0.0000018611139,0.0007950489,0.000010883258,0.992197,0.00032883653],"about_ca_topic_score_codex":0.00057135714,"about_ca_topic_score_gemma":0.0001503935,"teacher_disagreement_score":0.9911717,"about_ca_system_score_codex":0.0005083546,"about_ca_system_score_gemma":0.00057663687,"threshold_uncertainty_score":0.9998114},"labels":[],"label_agreement":null},{"id":"W3081835091","doi":"10.1111/ajd.13412","title":"Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology","year":2020,"lang":"en","type":"letter","venue":"Australasian Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis Area and Severity Index; Medicine; Erythema; Body surface area; Trunk; Psoriasis; Teledermatology; Dermatology; Physical therapy; Surgery; Health care; Telemedicine","score_opus":0.038129991427731456,"score_gpt":0.2737128985737642,"score_spread":0.23558290714603272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081835091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86929893,0.0017830192,0.0074838554,0.11946806,0.0011138796,0.00067614415,0.00014699038,0.000013861831,0.000015281377],"genre_scores_gemma":[0.9257814,0.0006551145,0.063208535,0.00927697,0.0002565603,0.000027829066,0.0004449432,0.00007762509,0.0002709814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739856,0.0005015912,0.0013660913,0.0003042488,0.00006890008,0.00036061395],"domain_scores_gemma":[0.99777174,0.0004573636,0.0014075213,0.00014814336,0.00016184791,0.000053395728],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013864085,0.0003552485,0.0015574618,0.00056066486,0.000051255105,0.00001282994,0.00019360843,0.0012261324,0.00003709408],"category_scores_gemma":[0.00011976575,0.00032482154,0.00018739775,0.0001407268,0.0001928318,0.00016467208,0.000070077534,0.0007108892,0.0000014196904],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057450803,0.00056689675,0.20518352,0.003384002,0.010247641,0.0062101358,0.009441288,0.000031258664,0.026240459,0.00017260712,0.63025975,0.10251738],"study_design_scores_gemma":[0.021760577,0.00087481976,0.043762058,0.0007504851,0.0032390582,0.08362172,0.0008768283,0.00002961273,0.35529417,0.0014107988,0.4871409,0.0012389763],"about_ca_topic_score_codex":0.00003646675,"about_ca_topic_score_gemma":0.000015322134,"teacher_disagreement_score":0.3290537,"about_ca_system_score_codex":0.000030669606,"about_ca_system_score_gemma":0.00043869705,"threshold_uncertainty_score":0.99992037},"labels":[],"label_agreement":null},{"id":"W3082025374","doi":"10.1177/1203475420952423","title":"A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis","year":2020,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Drug; Psoriasis; Concomitant; Intensive care medicine; Drug class; Approved drug; Drug interaction; Adverse effect; Pharmacology; Dermatology; Internal medicine","score_opus":0.07218258701567584,"score_gpt":0.33630488589300794,"score_spread":0.2641222988773321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082025374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012129275,0.9957913,0.0000021853477,0.0010813194,0.0010773201,0.0006759465,0.0000945914,0.0000039912643,0.000060429426],"genre_scores_gemma":[0.00054572755,0.9986229,0.000020031875,0.00019368112,0.00026031377,0.000048695427,0.00012398412,0.000017229127,0.00016747101],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968137,0.00085325405,0.0018706347,0.00019081413,0.00007430983,0.00019728471],"domain_scores_gemma":[0.9895139,0.008081254,0.0020105492,0.00021787458,0.00014148615,0.000034971185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009362285,0.00035633837,0.004087228,0.0004115802,0.00004819512,0.0000026821774,0.00019380893,0.00013057557,0.000101563586],"category_scores_gemma":[0.00044149894,0.00016728407,0.0011819574,0.00033056005,0.00016894563,0.00003106575,0.000011518599,0.00021253241,0.000003304467],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019305557,0.0003447217,0.00006267556,0.018007841,0.0014122362,0.00015071672,0.0016299789,3.3371506e-8,0.00002208383,0.000009489525,0.020230321,0.9579368],"study_design_scores_gemma":[0.00061835005,0.00061875023,0.0000027234712,0.055185813,0.0045695393,0.0028119464,0.0005881503,6.0195006e-8,0.000026408075,0.000021701822,0.93544114,0.00011540247],"about_ca_topic_score_codex":0.000037370537,"about_ca_topic_score_gemma":0.000013248545,"teacher_disagreement_score":0.9578214,"about_ca_system_score_codex":0.00006386,"about_ca_system_score_gemma":0.0002895482,"threshold_uncertainty_score":0.6821646},"labels":[],"label_agreement":null},{"id":"W3082286918","doi":"10.1016/j.jaad.2020.09.001","title":"National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Janssen Biotech; Ortho Dermatologics; Gilead Sciences; LEO Pharma; National Heart, Lung, and Blood Institute; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Mylan; Janssen Research and Development; Galderma; Almirall; UCB; University of Pennsylvania; Celgene; Novartis; AbbVie; Agency for Healthcare Research and Quality; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Sanofi; Merck; Allergan; AstraZeneca; Eli Lilly and Company; National Psoriasis Foundation; Pfizer; Samsung; Amgen","keywords":"Medicine; Task force; Psoriasis; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Foundation (evidence); Disease; Dermatology; Virology; Pathology; Infectious disease (medical specialty); Outbreak","score_opus":0.028539436760893468,"score_gpt":0.30323649867281544,"score_spread":0.27469706191192195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082286918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962044,0.0020349598,0.0014695929,0.033506077,0.00038539214,0.00040137506,0.00010235242,0.000012196017,0.000044073764],"genre_scores_gemma":[0.9970736,0.00077891303,0.00037518627,0.0015726968,0.00006800685,0.000015950704,0.000008761152,0.00001002352,0.00009687234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985918,0.00033950253,0.00061901484,0.00014259625,0.00012434107,0.00018276885],"domain_scores_gemma":[0.9976282,0.00044473828,0.001688482,0.00009924647,0.00008319742,0.000056138375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024077237,0.00013402053,0.0004205399,0.00008162874,0.00018628799,0.0000037142852,0.0005400244,0.00007106987,0.00003153927],"category_scores_gemma":[0.00030066186,0.00008345349,0.00029704516,0.00024293367,0.0003815992,0.00008476363,0.00010310348,0.00016839229,0.000008442974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04874,0.0012294939,0.38463515,0.0043677003,0.01774769,0.00006124383,0.005796891,0.006074388,0.3812516,0.019810759,0.076962,0.053323057],"study_design_scores_gemma":[0.03015713,0.0009528001,0.64243555,0.00050155167,0.0059848796,0.002033047,0.0038532338,0.0004722476,0.090950295,0.011701625,0.2100378,0.0009198575],"about_ca_topic_score_codex":0.000003944695,"about_ca_topic_score_gemma":4.8209677e-7,"teacher_disagreement_score":0.29030132,"about_ca_system_score_codex":0.00008809594,"about_ca_system_score_gemma":0.00014078245,"threshold_uncertainty_score":0.34031346},"labels":[],"label_agreement":null},{"id":"W3083570764","doi":"10.1177/1203475420952424","title":"Estimated Frequency of Psychodermatologic Conditions in Alberta, Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Faculty of Graduate Studies and Research, University of Alberta","keywords":"Medicine; Medical prescription; Atopic dermatitis; Hyperhidrosis; Psoriasis; Pharmacy; Dermatology; Family medicine","score_opus":0.03165719008305963,"score_gpt":0.25806320811006467,"score_spread":0.22640601802700505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083570764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98612803,0.0056105964,0.00000605897,0.0073147058,0.00045377013,0.000042211752,0.000012821206,0.000003303789,0.00042850693],"genre_scores_gemma":[0.99821174,0.0008068477,0.000023428802,0.0008509785,0.000030044825,8.176739e-7,0.00002200851,0.000004905449,0.000049252525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999067,0.00010529986,0.00056223205,0.00007996102,0.000046966925,0.0001385183],"domain_scores_gemma":[0.9984532,0.0010744847,0.00029660968,0.000055811764,0.000069875554,0.000049999526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010629466,0.00010135115,0.0005550545,0.00011638973,0.00003130785,0.0000012182254,0.000060045033,0.00008198588,0.00033772815],"category_scores_gemma":[0.000375562,0.00007057386,0.0000558637,0.00014490969,0.00009816057,0.000033225726,0.000005789993,0.000131955,0.0000027892806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006630441,0.00020235899,0.7781401,0.00017261527,0.00081745523,0.006053883,0.0019933186,0.000032650227,0.06338264,0.00027397397,0.13900617,0.009261759],"study_design_scores_gemma":[0.025912309,0.0059239874,0.57351476,0.0068313754,0.0042637787,0.20970234,0.011049169,0.00021057915,0.06801337,0.0066542826,0.08519448,0.00272955],"about_ca_topic_score_codex":0.051882867,"about_ca_topic_score_gemma":0.039060406,"teacher_disagreement_score":0.20462537,"about_ca_system_score_codex":0.000017079794,"about_ca_system_score_gemma":0.000272496,"threshold_uncertainty_score":0.97847426},"labels":[],"label_agreement":null},{"id":"W3084796437","doi":"10.25251/skin.4.supp.31","title":"Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Psoriasis; Randomized controlled trial; Dermatology; Surgery","score_opus":0.009909449047611192,"score_gpt":0.2376766184769342,"score_spread":0.227767169429323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084796437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928171,0.0019115893,0.0002687529,0.0006684618,0.00028157365,0.0038900916,0.00004080856,0.000007574823,0.00011402014],"genre_scores_gemma":[0.99834543,0.001237871,0.00010124127,0.00004633402,0.000062468804,0.000031077383,0.00005445095,0.000019161605,0.000101956866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967566,0.0010579416,0.0014053569,0.00023168948,0.00029715506,0.00025123276],"domain_scores_gemma":[0.9956487,0.0018675957,0.0018621403,0.00021153878,0.00034173467,0.000068284295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011367352,0.00030139828,0.0017391383,0.00023073696,0.00008389341,0.0000043264095,0.0002225884,0.00013023356,0.000036452664],"category_scores_gemma":[0.00061593606,0.00014702424,0.00013403269,0.0003049958,0.0004874848,0.00009146023,0.00004758532,0.0003007427,8.5472715e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534757,0.0024148342,0.0011730967,0.000058706635,0.004195041,0.00013806981,0.0049099675,0.0000501283,0.0009082785,0.0000137746,0.000032995267,0.032629386],"study_design_scores_gemma":[0.9712476,0.015129243,0.0040611033,0.000528928,0.0044307015,0.00011153766,0.00062900205,0.00005106002,0.0036284064,0.000018360988,0.00001838183,0.00014564182],"about_ca_topic_score_codex":0.00005696231,"about_ca_topic_score_gemma":0.000023472321,"teacher_disagreement_score":0.032483745,"about_ca_system_score_codex":0.00006263402,"about_ca_system_score_gemma":0.000066511326,"threshold_uncertainty_score":0.59954745},"labels":[],"label_agreement":null},{"id":"W3085117737","doi":"10.1016/j.jaad.2020.09.037","title":"Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Daiichi Sankyo Europe; Samsung; Sandoz; Janssen Pharmaceuticals; Sanofi Genzyme; Novartis; Merck Sharp and Dohme; Bausch Health; Allergan; Beiersdorf; Janssen Research and Development; Language Literacy and Culture, University of Maryland, Baltimore County; EMD Serono; Almirall; MorphoSys; Galderma; Bayer; Astellas Pharma; Daiichi-Sankyo; National Institute for Health and Care Research; LEO Pharma; UCB Pharma; Dermira; Galápagos; MedImmune; Janssen UK; Sanofi; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Ortho Dermatologics; Celgene; Johnson and Johnson; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Takeda Pharmaceutical Company; Amgen; Boehringer Ingelheim; Schering-Plough; AbbVie; Roche; Merck; GlaxoSmithKline; Incyte; Pfizer; Biogen; Asana Biosciences; Santen; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca","keywords":"Medicine; Betamethasone dipropionate; Randomized controlled trial; Psoriasis; Clinical endpoint; Internal medicine; Dermatology","score_opus":0.01794440259014538,"score_gpt":0.2784574218106345,"score_spread":0.2605130192204891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085117737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853948,0.0019960476,0.000016391165,0.011864413,0.000113858114,0.00039804427,0.000022729866,0.000008991865,0.0001847514],"genre_scores_gemma":[0.99730957,0.0013298927,0.00024057433,0.00079958356,0.00004054844,0.000009439659,0.0000036883398,0.000015554037,0.00025116676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99764466,0.0007629853,0.00091908075,0.0002671256,0.00012988542,0.00027624826],"domain_scores_gemma":[0.9978783,0.00046451393,0.0013917229,0.00013253072,0.000057423786,0.00007546877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020439383,0.00023687989,0.0010810732,0.00017750468,0.00006495428,0.00000533776,0.0003971411,0.00028062746,0.00016622496],"category_scores_gemma":[0.00013792058,0.00016145012,0.00022949651,0.00042041412,0.00047071412,0.00010976535,0.00020331776,0.00054573186,0.000015717329],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2398773,0.0035343063,0.13097218,0.00066327996,0.012192334,0.00066642533,0.0043199565,0.000041958472,0.5093024,0.0013216259,0.015671954,0.08143632],"study_design_scores_gemma":[0.052460577,0.0035812985,0.29515818,0.000616351,0.0021930602,0.002261009,0.0013918673,0.0000553505,0.6299906,0.00081674056,0.010856822,0.0006181749],"about_ca_topic_score_codex":0.000099228055,"about_ca_topic_score_gemma":0.0000012947329,"teacher_disagreement_score":0.18741672,"about_ca_system_score_codex":0.00004713475,"about_ca_system_score_gemma":0.00009285848,"threshold_uncertainty_score":0.6583745},"labels":[],"label_agreement":null},{"id":"W3085571220","doi":"10.25251/skin.4.supp.42","title":"Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"XBiotech; Kyowa Kirin Pharmaceutical Development; National Institutes of Health; Incyte; Dermira; Valeant Pharmaceuticals International; Celgene; Allergan; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Post-hoc analysis; Psoriasis; Post hoc; Medicine; Internal medicine; Dermatology","score_opus":0.040734554695007204,"score_gpt":0.31283860531457386,"score_spread":0.27210405061956666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085571220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76348555,0.23033534,0.000008093038,0.0049537835,0.00028417708,0.00016232485,0.0007452808,0.000006934009,0.000018502167],"genre_scores_gemma":[0.959379,0.03986433,0.00005640911,0.00032388172,0.000077694676,8.648072e-7,0.0002042423,0.000016364009,0.00007719647],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973196,0.0010196591,0.0008938123,0.0002702013,0.00019504369,0.00030171074],"domain_scores_gemma":[0.99547184,0.0028967415,0.00074410596,0.0006411221,0.00017877128,0.00006743776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010915023,0.0002576199,0.0012439217,0.00014872987,0.00013441575,0.000008091738,0.00080222706,0.0001167122,0.00019485816],"category_scores_gemma":[0.0013729332,0.00012656556,0.00011144579,0.0007697897,0.0005118694,0.00008810936,0.00020276284,0.0003936715,0.000011906249],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08276822,0.0024257991,0.012615088,0.0001493218,0.14616744,0.002755989,0.14297384,0.0011877159,0.40307644,0.000099231096,0.11939249,0.08638843],"study_design_scores_gemma":[0.15804851,0.036618613,0.110009395,0.002885924,0.21870674,0.011249167,0.19363247,0.0005743319,0.04503962,0.0005454126,0.22013123,0.0025586025],"about_ca_topic_score_codex":0.00044518762,"about_ca_topic_score_gemma":0.00019166183,"teacher_disagreement_score":0.35803682,"about_ca_system_score_codex":0.000027860659,"about_ca_system_score_gemma":0.00008056683,"threshold_uncertainty_score":0.51611936},"labels":[],"label_agreement":null},{"id":"W3086123339","doi":"10.25251/skin.4.supp.45","title":"Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain","funders":"UCB Pharma; Dermira","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Dermatology; Gastroenterology","score_opus":0.021227095897562276,"score_gpt":0.27338008013662973,"score_spread":0.25215298423906746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086123339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921414,0.0037438218,0.000022342234,0.00240933,0.00051678426,0.00089172827,0.00006661219,0.000013287142,0.0001946601],"genre_scores_gemma":[0.99858475,0.00080918474,0.00002635108,0.00017955595,0.00021701213,0.000006904437,0.000036206377,0.000039636318,0.0001004058],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960221,0.0011930882,0.0016898899,0.00029190225,0.00028412323,0.00051892037],"domain_scores_gemma":[0.9953949,0.0025531081,0.0014174209,0.00033577078,0.00015524692,0.00014358546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009052276,0.00045516767,0.0019878843,0.00039269295,0.00012292362,0.000010058904,0.00039918086,0.00026656137,0.00091718644],"category_scores_gemma":[0.0011741585,0.00024724012,0.00019784368,0.0004641253,0.0003212093,0.00013175444,0.00008149436,0.0005588165,0.000011555566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55466557,0.004780024,0.15668531,0.0002537322,0.005661899,0.004276026,0.024726951,0.0003879889,0.17033505,0.00004110762,0.00784704,0.07033929],"study_design_scores_gemma":[0.66506577,0.04214854,0.22870557,0.002436849,0.005612807,0.014042276,0.002641189,0.00012876363,0.035157997,0.0005380766,0.0021973206,0.0013248454],"about_ca_topic_score_codex":0.0003025172,"about_ca_topic_score_gemma":0.00040222678,"teacher_disagreement_score":0.13517705,"about_ca_system_score_codex":0.00018732263,"about_ca_system_score_gemma":0.0001954957,"threshold_uncertainty_score":0.999998},"labels":[],"label_agreement":null},{"id":"W3086665346","doi":"10.25251/skin.4.supp.32","title":"Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Surgery","score_opus":0.01589909687135234,"score_gpt":0.2637209916648256,"score_spread":0.24782189479347327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086665346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682,0.007065303,0.0008216535,0.001599894,0.0005705935,0.002829168,0.00008727854,0.000010025464,0.00019610733],"genre_scores_gemma":[0.9961609,0.0031358632,0.0001483053,0.00005263181,0.00014968251,0.000033371074,0.00007526746,0.000017525566,0.00022641431],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99662673,0.0011737603,0.0015300123,0.00021451274,0.00025519045,0.00019977457],"domain_scores_gemma":[0.99415326,0.0029453104,0.0023091563,0.00022429688,0.0003015595,0.00006638929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013957042,0.00028483378,0.0023397452,0.000152176,0.000095490905,0.0000049135115,0.00024716486,0.00014572628,0.00012092748],"category_scores_gemma":[0.00066290033,0.00013831585,0.00024483676,0.00021441109,0.00059575523,0.00006429791,0.000050114875,0.00026395704,0.0000014841706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94930816,0.0007600821,0.000029069517,0.000042552037,0.009478606,0.00021171922,0.004969739,0.000010999198,0.015541883,0.00004654543,0.00012883986,0.019471789],"study_design_scores_gemma":[0.95502853,0.008019251,0.00016614486,0.0004383769,0.009584313,0.00034680258,0.00082714134,0.000030682193,0.025254259,0.00013990542,0.000038034163,0.00012652636],"about_ca_topic_score_codex":0.000087426735,"about_ca_topic_score_gemma":0.000006829847,"teacher_disagreement_score":0.019345263,"about_ca_system_score_codex":0.000033676755,"about_ca_system_score_gemma":0.00006966603,"threshold_uncertainty_score":0.56403565},"labels":[],"label_agreement":null},{"id":"W3086988593","doi":"","title":"A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks","year":2019,"lang":"en","type":"article","venue":"Queensland's institutional digital repository (The University of Queensland)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Adalimumab; Psoriasis; Internal medicine; Ixekizumab; Enthesitis; BASDAI; Clinical endpoint; Concomitant; Dermatology; Secukinumab; Randomized controlled trial; Rheumatoid arthritis","score_opus":0.02620242542995411,"score_gpt":0.2701458427527925,"score_spread":0.24394341732283842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3086988593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947752,0.0005374518,0.00009750689,0.00007058283,0.00024050444,0.002309997,0.0004700671,0.000022272086,0.0014764428],"genre_scores_gemma":[0.99935085,0.000044231176,0.0001682735,0.000019016808,0.000009910673,0.000007486852,0.00022437131,0.000009580631,0.00016630947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809545,0.0004655683,0.0005165712,0.0005241823,0.00015337345,0.0002448732],"domain_scores_gemma":[0.99796045,0.001094739,0.00041440074,0.00030649008,0.00017678933,0.000047125428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016414834,0.00031856296,0.0012823914,0.00010789229,0.00032839752,0.000043832035,0.00032657926,0.00020042704,0.000022355634],"category_scores_gemma":[0.00011654816,0.00022096791,0.00008084651,0.00017694969,0.0006696341,0.00046155317,0.0002831584,0.00021984703,0.000019294168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13294,0.003464741,0.82940114,0.000022406752,0.0019936822,0.000035228037,0.005987246,0.000082198276,0.00011741635,0.00042485495,0.000024132665,0.02550696],"study_design_scores_gemma":[0.18862067,0.0017875454,0.80577075,0.00023343896,0.00029033734,0.0000105506115,0.0024755378,0.000012322854,0.00017373607,0.00011798578,0.00024180474,0.0002652797],"about_ca_topic_score_codex":0.002485675,"about_ca_topic_score_gemma":0.0007972555,"teacher_disagreement_score":0.055680685,"about_ca_system_score_codex":0.00009300612,"about_ca_system_score_gemma":0.00015063431,"threshold_uncertainty_score":0.90108097},"labels":[],"label_agreement":null},{"id":"W3088313763","doi":"10.3390/biom10101361","title":"IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis","year":2020,"lang":"en","type":"review","venue":"Biomolecules","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Commission; European Regional Development Fund; Sociedad Española de Nefrología; Ministerio de Ciencia e Innovación; Emissions Reduction Alberta; Instituto de Salud Carlos III; Comunidad de Madrid","keywords":"Medicine; Peritoneal dialysis; Mesothelial Cell; Inflammation; Immune system; Fibrosis; Transplantation; Peritoneum; Cytokine; Kidney disease; Immunology; Pathology; Internal medicine","score_opus":0.024739198672856694,"score_gpt":0.28592812045603644,"score_spread":0.26118892178317976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088313763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000121146906,0.99468714,0.00009221083,0.00006354815,0.0014419531,0.001200758,0.0020630744,0.0000896162,0.00024055724],"genre_scores_gemma":[0.00097046385,0.9900434,0.00014075184,0.00010954735,0.00022772554,0.00055949815,0.00699025,0.00009424484,0.00086411915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979953,0.00036872533,0.0004548245,0.0006830052,0.00006443348,0.00043371067],"domain_scores_gemma":[0.99911463,0.00014893517,0.00028970686,0.00033961123,0.00005849344,0.000048613252],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006923433,0.00060902734,0.0014295425,0.00019362461,0.00022126354,0.00003571691,0.00037071094,0.0006747446,0.00024125924],"category_scores_gemma":[0.000051212573,0.0004566966,0.0012522197,0.00021126696,0.00012974186,0.000025921907,0.00007496233,0.00015947517,0.0017460022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018578986,0.00035834668,0.0000042274323,0.0007138947,0.0023332566,0.000019859426,0.000046888472,4.163061e-8,0.00020088433,0.00021967514,0.00096343213,0.9949537],"study_design_scores_gemma":[0.0010843951,0.0010645279,0.000008819983,0.0004033092,0.0032223703,0.000014101495,0.000011085197,2.8816694e-7,0.0005715218,0.000058851874,0.99311066,0.000450058],"about_ca_topic_score_codex":0.00002193673,"about_ca_topic_score_gemma":0.0000020890736,"teacher_disagreement_score":0.9945036,"about_ca_system_score_codex":0.00007841241,"about_ca_system_score_gemma":0.00016689042,"threshold_uncertainty_score":0.99978846},"labels":[],"label_agreement":null},{"id":"W3088534458","doi":"10.1007/s12325-020-01497-6","title":"PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Dermira; National Institute for Health and Care Research; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Calcipotriol; Betamethasone dipropionate; Psoriasis; Discontinuation; Adverse effect; Randomized controlled trial; Maintenance therapy; Clinical trial; Internal medicine; Dermatology; Surgery; Chemotherapy","score_opus":0.07843577025216758,"score_gpt":0.32965928514946174,"score_spread":0.25122351489729416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088534458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840848,0.00743173,0.0056993663,0.00029478475,0.0005376243,0.0014575383,0.000030041172,0.000026721627,0.00043742763],"genre_scores_gemma":[0.98969114,0.006655772,0.0031391187,0.00013791012,0.00007886595,0.00016491652,0.000014932626,0.000020050573,0.00009732095],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980986,0.00043228897,0.0006916559,0.0004194487,0.00006523268,0.00029277412],"domain_scores_gemma":[0.9986513,0.0006784508,0.0003333226,0.00025064216,0.00005700395,0.000029235562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034628218,0.00022242284,0.00072780024,0.00007259533,0.000027870105,0.0000032445146,0.00027315217,0.00023176728,0.00005226018],"category_scores_gemma":[0.00016487241,0.00015945152,0.00012093045,0.0002831985,0.00031915176,0.00016643078,0.00002674402,0.00023412984,0.000003892066],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44869843,0.005166474,0.06514077,0.00004371663,0.0008257539,0.000042428364,0.0039021138,0.00042939206,0.026218299,0.0006631735,0.00008363868,0.4487858],"study_design_scores_gemma":[0.5786313,0.06823794,0.0886328,0.00045238913,0.00027515987,0.00003094524,0.0029168387,0.00013528472,0.23775744,0.0010252136,0.020626403,0.0012783087],"about_ca_topic_score_codex":0.000054877855,"about_ca_topic_score_gemma":0.00014909945,"teacher_disagreement_score":0.4475075,"about_ca_system_score_codex":0.00003528841,"about_ca_system_score_gemma":0.00011603744,"threshold_uncertainty_score":0.65022445},"labels":[],"label_agreement":null},{"id":"W3089697455","doi":"10.3390/genes11101155","title":"Transcriptome Profiling Analyses in Psoriasis: A Dynamic Contribution of Keratinocytes to the Pathogenesis","year":2020,"lang":"en","type":"review","venue":"Genes","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Université Laval","keywords":"Psoriasis; Transcriptome; Computational biology; Pathogenesis; Disease; Microarray; Biology; Gene expression profiling; RNA-Seq; Gene expression; Bioinformatics; Gene; Medicine; Immunology; Genetics; Pathology","score_opus":0.05627816000744975,"score_gpt":0.33603168784320664,"score_spread":0.2797535278357569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089697455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026078022,0.9941943,0.00010664837,0.00007646903,0.00075253326,0.00144865,0.00075114344,0.000043963963,0.000018478562],"genre_scores_gemma":[0.0060480325,0.9915708,0.00017966969,0.000030644598,0.0000887924,0.0006644059,0.0012427105,0.000043974494,0.00013101978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720335,0.0008769598,0.0008882648,0.00056617137,0.00006745519,0.00039780498],"domain_scores_gemma":[0.9988663,0.00023253621,0.0003371551,0.00044456264,0.00008628384,0.0000331626],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029942297,0.0005141719,0.0019166949,0.0003208209,0.00012760535,0.000018485265,0.0004695536,0.00047001944,0.0000500291],"category_scores_gemma":[0.0001151602,0.00033033302,0.0007063148,0.0008412631,0.00006485429,0.000032077933,0.0000742201,0.00019085291,0.00020327694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083547384,0.000078997386,0.000065306944,0.0008801551,0.0011209866,0.000012824293,0.0002328908,0.000009903385,0.021663308,0.000058612266,0.0000481613,0.9757453],"study_design_scores_gemma":[0.0008972381,0.00022960136,0.00028293935,0.001961654,0.0040193396,0.00005111638,0.00021097304,0.0000032594685,0.008864686,0.0000114535405,0.98295593,0.0005118008],"about_ca_topic_score_codex":0.00004357017,"about_ca_topic_score_gemma":0.00016012261,"teacher_disagreement_score":0.9829078,"about_ca_system_score_codex":0.00009144233,"about_ca_system_score_gemma":0.00024553636,"threshold_uncertainty_score":0.9999149},"labels":[],"label_agreement":null},{"id":"W3090475848","doi":"10.31557/apjcp.2020.21.9.2507","title":"Association between IL-27 Gene Polymorphisms and Cancer Susceptibility in Asian Population: A Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Asian Pacific Journal of Cancer Prevention","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Zahedan University of Medical Sciences","keywords":"Meta-analysis; Colorectal cancer; Allele; Internal medicine; Oncology; Genetic model; Breast cancer; Medicine; Cancer; Genotype; Bioinformatics; Genetics; Biology; Gene","score_opus":0.058475933046097474,"score_gpt":0.3362719500341228,"score_spread":0.2777960169880253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090475848","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005101545,0.9966155,0.00007350615,0.000668578,0.00068426,0.000534183,0.0007593668,0.000013430523,0.00014101976],"genre_scores_gemma":[0.027887674,0.9689815,0.00009312593,0.000007433334,0.00030065372,0.000088406145,0.0005802418,0.000034507513,0.0020264396],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956998,0.0016589185,0.0016275486,0.0004971893,0.00017875574,0.00033776526],"domain_scores_gemma":[0.99647653,0.00012924305,0.0029159891,0.00026570688,0.00013679675,0.000075738775],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011295999,0.00047909102,0.004035254,0.00066963193,0.00010315013,0.00004587861,0.00022984932,0.00070847984,0.0011367743],"category_scores_gemma":[0.000052581556,0.00037717307,0.0027604417,0.0009958923,0.00003931822,0.00022744568,0.00004372095,0.00057851465,0.00001960952],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003651805,0.00008201271,0.015637564,0.0003304592,0.17161664,0.00001197633,0.0002103621,0.0000014772213,0.0000145451,0.000006069455,0.00018297839,0.8118694],"study_design_scores_gemma":[0.0009950458,0.00021542187,0.02679713,0.00058032194,0.6339998,0.00003125383,0.00008444736,2.0293452e-7,0.000041611667,0.00021686452,0.33658165,0.00045624032],"about_ca_topic_score_codex":0.0003015241,"about_ca_topic_score_gemma":0.0013045712,"teacher_disagreement_score":0.81141317,"about_ca_system_score_codex":0.0008846878,"about_ca_system_score_gemma":0.00035002938,"threshold_uncertainty_score":0.99986804},"labels":[],"label_agreement":null},{"id":"W3090832537","doi":"10.3389/fimmu.2020.571319","title":"Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations","year":2020,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg","funders":"Ministry of Education and Science of the Republic of Kazakhstan","keywords":"Psoriasis; Firmicutes; Gut flora; Medicine; Immunology; Microbiome; Dysbiosis; Roseburia; Inflammatory bowel disease; Proinflammatory cytokine; Disease; Internal medicine; Inflammation; Biology; Bacteroides; Bioinformatics; Genetics","score_opus":0.013091986140653468,"score_gpt":0.21084150009212466,"score_spread":0.1977495139514712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090832537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789394,0.00673222,0.0011327264,0.0020843134,0.001164493,0.00035579855,0.00021232243,0.00014739232,0.00027682414],"genre_scores_gemma":[0.994938,0.00038142028,0.002153787,0.0007777406,0.000034800745,0.00006823887,0.00061091094,0.000036368318,0.000998727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983134,0.00030559694,0.0003557654,0.000502764,0.000028970879,0.00049349474],"domain_scores_gemma":[0.999398,0.000110940266,0.00015580998,0.0002216866,0.000078379635,0.000035184188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011669726,0.0003022123,0.00054231833,0.00024015606,0.00019112977,0.000022810602,0.0002280343,0.0003832852,0.00022937536],"category_scores_gemma":[0.00016041078,0.00027040642,0.00006367071,0.00050934585,0.00039811185,0.00011874078,0.000088710316,0.0003372079,0.00010755244],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00218427,0.0004680415,0.096491076,0.000024293908,0.0036489514,0.00014022076,0.005762702,0.0000067455903,0.8192737,0.00029839348,0.041262057,0.030439552],"study_design_scores_gemma":[0.046121962,0.0070109824,0.34803858,0.00045377188,0.001846834,0.00096844684,0.0056539187,0.0002990593,0.44838896,0.0012588323,0.13678718,0.0031714947],"about_ca_topic_score_codex":0.000060187547,"about_ca_topic_score_gemma":0.000034792745,"teacher_disagreement_score":0.37088475,"about_ca_system_score_codex":0.00008976473,"about_ca_system_score_gemma":0.00008378082,"threshold_uncertainty_score":0.9999748},"labels":[],"label_agreement":null},{"id":"W3091694826","doi":"10.1093/rheumatology/keaa559","title":"Comment on: The impact of smoking on prevalence of psoriasis and psoriatic arthritis: reply","year":2020,"lang":"en","type":"letter","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Arthritis; Internal medicine","score_opus":0.023971762607888348,"score_gpt":0.25108177260302683,"score_spread":0.22711000999513847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091694826","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32149708,0.024641573,0.00000788971,0.6438458,0.002297051,0.0020107082,0.0033712112,0.00012656447,0.0022021562],"genre_scores_gemma":[0.67695445,0.006491835,0.000047407204,0.31371412,0.0009894337,0.00018313453,0.0006182743,0.000102666214,0.00089869346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979669,0.00059639587,0.00050310156,0.00047607446,0.00011356869,0.0003439601],"domain_scores_gemma":[0.99769545,0.0009826744,0.00051517395,0.00073085405,0.00005510585,0.000020755333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024258834,0.00041583963,0.0007789323,0.0001097383,0.00012405768,0.000014398803,0.00039306778,0.00050366495,0.00041448738],"category_scores_gemma":[0.0001481956,0.00027485655,0.00037052293,0.0001341883,0.00020610323,0.000033103057,0.00010206157,0.0007801751,0.000056369456],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004860126,0.00018048691,0.0024534576,0.00038567118,0.0026943204,0.0000877502,0.00085691694,0.0000029813884,0.00091642997,0.00018281546,0.97357595,0.018177224],"study_design_scores_gemma":[0.010978261,0.011469716,0.0434766,0.005772026,0.0034705112,0.00017120146,0.0002371374,0.000008920619,0.043831225,0.0021315694,0.87661386,0.0018389537],"about_ca_topic_score_codex":0.00016360823,"about_ca_topic_score_gemma":0.0000016087104,"teacher_disagreement_score":0.35545737,"about_ca_system_score_codex":0.000060942828,"about_ca_system_score_gemma":0.00006655252,"threshold_uncertainty_score":0.9999704},"labels":[],"label_agreement":null},{"id":"W3092141337","doi":"10.1016/j.intimp.2020.107026","title":"Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway","year":2020,"lang":"en","type":"article","venue":"International Immunopharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Xunta de Galicia; Innovative Medicines Initiative; Debreceni Egyetem; Ministero dello Sviluppo Economico; Ministerio de Ciencia e Innovación; Ministerio de Economía y Competitividad; Novartis Pharma; Canada Foundation for Innovation; Ontario Ministry of Economic Development and Innovation; Ministerio de Ciencia, Innovación y Universidades; Wellcome Trust; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genome Canada; Boehringer Ingelheim; Janssen Pharmaceuticals; Merck KGaA; European Regional Development Fund; Meso Scale Diagnostics; AbbVie; Takeda Pharmaceutical Company; Pfizer","keywords":"Proinflammatory cytokine; Chemokine; Chemistry; Cytokine; Interleukin 17; Pharmacology; Drug discovery; Virtual screening; Immunology; Inflammation; Biology; Biochemistry; Receptor","score_opus":0.02488114799132078,"score_gpt":0.2705651862935972,"score_spread":0.24568403830227642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092141337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861276,0.0038289763,0.00018743282,0.0043109786,0.0037253264,0.00035229672,0.00026151142,0.00013294377,0.00107294],"genre_scores_gemma":[0.9948966,0.00044633925,0.00007304155,0.0024366053,0.00031947644,0.00010679183,0.00016824076,0.00003286736,0.0015200543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982688,0.00017428906,0.00068612513,0.00038307667,0.000105632316,0.00038207925],"domain_scores_gemma":[0.99872035,0.0005102109,0.0003873923,0.00017091971,0.00018080215,0.00003031634],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032596922,0.00029563773,0.00039153558,0.00008865168,0.00021186184,0.000029511768,0.00097879,0.00024447154,0.0012530643],"category_scores_gemma":[0.00013083268,0.00021093103,0.0002751886,0.00017488464,0.00041331662,0.00025837382,0.00035786082,0.00044531646,0.0003427251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012835041,0.00034481732,0.0012594356,0.0000105863155,0.0014423177,0.000027204642,0.0005615086,0.00010376572,0.98310226,0.0009106559,0.008827784,0.0021261487],"study_design_scores_gemma":[0.005446144,0.0002749176,0.0046629948,0.000012970864,0.00018790615,0.000043501263,0.00028174737,0.00013905129,0.88688624,0.000027939957,0.10177974,0.0002568615],"about_ca_topic_score_codex":0.000022093876,"about_ca_topic_score_gemma":9.774172e-7,"teacher_disagreement_score":0.09621604,"about_ca_system_score_codex":0.00006734052,"about_ca_system_score_gemma":0.00012687659,"threshold_uncertainty_score":0.9996599},"labels":[],"label_agreement":null},{"id":"W3092306676","doi":"10.7150/thno.47435","title":"IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8","year":2020,"lang":"en","type":"article","venue":"Theranostics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; Interleukin Foundation for Medical Research; Agencia Estatal de Investigación; National Institutes of Health; National Cancer Institute; Ministerio de Economía y Competitividad","keywords":"Experimental autoimmune encephalomyelitis; Multiple sclerosis; Immunology; Inflammation; Encephalomyelitis; Cytokine; Immune system; Receptor; Medicine; Biology; Internal medicine","score_opus":0.03332050038402508,"score_gpt":0.2609134369008505,"score_spread":0.22759293651682544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092306676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9514893,0.03913336,0.00044388836,0.0030428634,0.0022867932,0.0014442363,0.00024722563,0.00063250784,0.0012797841],"genre_scores_gemma":[0.99584925,0.000825893,0.00025918736,0.0021442978,0.00016526665,0.000119198616,0.00021176528,0.00009298172,0.00033218155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787104,0.0006260324,0.00040331853,0.00044120682,0.00008843058,0.0005699574],"domain_scores_gemma":[0.9986686,0.000697082,0.00012900353,0.0004322627,0.000036259145,0.000036779536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012928202,0.0004130494,0.0005223906,0.000033658773,0.00022274295,0.000033692057,0.00048228976,0.00027472762,0.00066263997],"category_scores_gemma":[0.0000604493,0.00029626497,0.00017064864,0.00026812454,0.000333953,0.00010456154,0.000112294474,0.00030071608,0.00067849865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005827724,0.00031537,0.00072583184,0.000027616521,0.00040511577,0.00003086456,0.0144684855,0.000015098684,0.9502005,0.0021507533,0.0019552347,0.029122356],"study_design_scores_gemma":[0.009370669,0.0017416304,0.051678978,0.00014915598,0.00031182356,0.000055312164,0.0030035821,0.000067102,0.57537776,0.0011619823,0.35606092,0.0010210735],"about_ca_topic_score_codex":0.00012843584,"about_ca_topic_score_gemma":0.000010277322,"teacher_disagreement_score":0.37482274,"about_ca_system_score_codex":0.00007765015,"about_ca_system_score_gemma":0.000057833917,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W3093065321","doi":"10.1136/annrheumdis-2020-eular.401","title":"SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 &amp; 2","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Internal medicine; Psoriasis; Clinical trial; Physical therapy; Concomitant; Clinical endpoint; Arthritis; Phases of clinical research; Rheumatology; Dermatology; Alternative medicine; Pathology","score_opus":0.12597946982937208,"score_gpt":0.3752623223085817,"score_spread":0.24928285247920962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093065321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831737,0.003029295,0.000017341692,0.00060917105,0.00043610035,0.0026065863,0.010085648,0.00003685011,0.00000526917],"genre_scores_gemma":[0.9965695,0.0005761918,0.000054211647,0.00023162107,0.000042656895,0.0005422208,0.0019174322,0.000031710242,0.00003445311],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99365133,0.0038693475,0.0013705029,0.000588966,0.00015634272,0.00036349884],"domain_scores_gemma":[0.9940017,0.0044188746,0.00069817994,0.0006783026,0.00008051586,0.00012242368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093645736,0.0004318434,0.0012902203,0.0000852731,0.000100642355,0.000028019032,0.00028737946,0.00018617517,0.00013898377],"category_scores_gemma":[0.0023921086,0.00023526797,0.0005286386,0.00016162588,0.0001479444,0.0001410577,0.00004712412,0.000102026934,0.00004538716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4736193,0.0124791,0.04098537,0.00007463121,0.0047512157,0.000008911811,0.0017327454,0.00010994881,0.00019570286,0.000016841634,0.0018632525,0.46416298],"study_design_scores_gemma":[0.08993195,0.019912612,0.8795034,0.0012663559,0.0015718999,5.914605e-7,0.00015176795,0.000015464873,0.006687068,0.00015781596,0.0003661613,0.0004348659],"about_ca_topic_score_codex":0.00010641438,"about_ca_topic_score_gemma":0.00010397179,"teacher_disagreement_score":0.8385181,"about_ca_system_score_codex":0.000047687285,"about_ca_system_score_gemma":0.00017628263,"threshold_uncertainty_score":0.95939493},"labels":[],"label_agreement":null},{"id":"W3093128632","doi":"10.3899/jrheum.190923","title":"Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry","year":2020,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Momenta Pharmaceuticals; Genentech; Novartis Pharmaceuticals Corporation; Celgene; Ortho Dermatologics; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Dactylitis; Dermatology; Nail (fastener); Enthesitis; Nail disease; Internal medicine; Physical therapy","score_opus":0.022867077797813336,"score_gpt":0.2416885815670069,"score_spread":0.21882150376919357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093128632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472926,0.04739505,0.00011920105,0.003761008,0.00050847826,0.0002367126,0.000664074,0.000012224758,0.000010630473],"genre_scores_gemma":[0.97290957,0.026806232,0.00004196358,0.000090098816,0.00003959369,0.000006686365,0.00006862046,0.000020296022,0.000016918786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701935,0.0015076264,0.0006961235,0.00026189984,0.00017252174,0.0003425054],"domain_scores_gemma":[0.9958842,0.0020466978,0.0012898936,0.00055908744,0.00013812003,0.0000820141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011542041,0.00026727509,0.00087943487,0.00007311858,0.000171083,0.000025497513,0.0006690047,0.00021302947,0.00014083163],"category_scores_gemma":[0.0014399533,0.00015746868,0.000116806536,0.0002383831,0.00027459374,0.00028745268,0.00014481039,0.00049930543,0.000019427694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01137961,0.00035359763,0.7823375,0.00005205904,0.0027505865,0.00006246926,0.0034131785,0.000054970424,0.0021344242,0.00006415123,0.008929251,0.18846819],"study_design_scores_gemma":[0.023692857,0.001895268,0.961583,0.001398495,0.0018360137,0.0018381968,0.002139024,0.00011159831,0.0014924131,0.001192352,0.002252377,0.00056840613],"about_ca_topic_score_codex":0.0012661143,"about_ca_topic_score_gemma":0.003290157,"teacher_disagreement_score":0.18789978,"about_ca_system_score_codex":0.00006619889,"about_ca_system_score_gemma":0.0003145982,"threshold_uncertainty_score":0.6421386},"labels":[],"label_agreement":null},{"id":"W3094048891","doi":"10.12788/cutis.0035","title":"Management of Psoriasis With Biologics in Clinical Practice: An Update for 2020","year":2020,"lang":"en","type":"article","venue":"Cutis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine; Clinical Practice; Family medicine","score_opus":0.04558443526944403,"score_gpt":0.32886666770001577,"score_spread":0.2832822324305717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094048891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910448,0.0023783012,0.000909974,0.002602761,0.00058245036,0.0007402659,0.00019036436,0.000062149,0.0014889052],"genre_scores_gemma":[0.9864733,0.0015410869,0.010854697,0.0005018191,0.00006645885,0.00006756106,0.0003201636,0.0000146724415,0.00016019438],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893683,0.00018326589,0.00034442445,0.00031681336,0.000021895286,0.00019675272],"domain_scores_gemma":[0.9994083,0.00016515171,0.00015742598,0.000194514,0.00004516736,0.000029426728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027327682,0.00012593623,0.00029614518,0.000025205498,0.000041752417,0.0000047726885,0.00016680361,0.00016853525,0.00010383704],"category_scores_gemma":[0.00006523665,0.000094719784,0.000075194584,0.00016191223,0.000089041976,0.000086745684,0.00004717601,0.000090849695,0.00008632169],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012486879,0.002371709,0.06557848,0.00021249146,0.0033407107,0.0003069069,0.0012051214,0.000025683456,0.0039077336,0.012066534,0.011637327,0.88686043],"study_design_scores_gemma":[0.025976202,0.012164701,0.17312148,0.00014018087,0.002230685,0.000078389574,0.0043219635,0.000052834574,0.023574416,0.0006875284,0.75669575,0.0009558948],"about_ca_topic_score_codex":0.000010802058,"about_ca_topic_score_gemma":0.000010013479,"teacher_disagreement_score":0.88590455,"about_ca_system_score_codex":0.000010712679,"about_ca_system_score_gemma":0.000023007191,"threshold_uncertainty_score":0.38625607},"labels":[],"label_agreement":null},{"id":"W3094082904","doi":"10.1080/09546634.2020.1840502","title":"Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data","year":2020,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Aprepitant; Psoriasis; Antihistamine; Refractory (planetary science); Psoriatic arthritis; Internal medicine; Dermatology; Apremilast; Gastroenterology; Anesthesia; Pharmacology; Chemotherapy; Antiemetic","score_opus":0.06610967567425224,"score_gpt":0.293384985865162,"score_spread":0.22727531019090974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094082904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988547,0.008279762,0.000040182385,0.0011875543,0.00065453723,0.00052964664,0.0001809358,0.00006137195,0.00051901187],"genre_scores_gemma":[0.99043405,0.00815488,0.00039134518,0.00014998726,0.00013131234,0.000017437178,0.00050165167,0.000024038312,0.00019531777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687624,0.00046436203,0.0013526261,0.00057766895,0.00013005476,0.0005990413],"domain_scores_gemma":[0.9976907,0.0005308488,0.0010134769,0.0005300091,0.00010448382,0.00013048829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024858996,0.00048328773,0.0012924833,0.0002643741,0.00014867536,0.00003655949,0.0006554142,0.00024352461,0.0001446037],"category_scores_gemma":[0.00017169137,0.00030811375,0.0002605307,0.0004665668,0.00019067776,0.0002982662,0.00021914806,0.0003056535,0.00012888735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005990606,0.00650834,0.91537213,0.00017619591,0.002277312,0.002535156,0.00068592385,0.00005333754,0.006177355,0.00034299033,0.0038475802,0.056033064],"study_design_scores_gemma":[0.0869794,0.021259634,0.73716027,0.00059053145,0.0020360372,0.00073937303,0.00046588163,0.00014635542,0.022938084,0.00026647592,0.12575024,0.0016677104],"about_ca_topic_score_codex":0.00007518378,"about_ca_topic_score_gemma":0.0003680848,"teacher_disagreement_score":0.17821187,"about_ca_system_score_codex":0.00058902276,"about_ca_system_score_gemma":0.0002719269,"threshold_uncertainty_score":0.9999371},"labels":[],"label_agreement":null},{"id":"W3094124122","doi":"10.1007/s40259-020-00451-w","title":"Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministère de l'Agriculture, des Pêcheries et de l'Alimentation; University of Calgary; Western University","funders":"","keywords":"Ustekinumab; Medicine; Interleukin 23; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Immunology; Inflammation; Immune system; Pathogenesis; Disease; Clinical trial; Interleukin 17; Internal medicine; Tumor necrosis factor alpha; Infliximab","score_opus":0.06456502656389661,"score_gpt":0.31679348668401647,"score_spread":0.25222846012011985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094124122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935011,0.0032147153,0.0000044836347,0.0009447747,0.0011383584,0.0003761364,0.0004461487,0.00005995662,0.00031428953],"genre_scores_gemma":[0.9984897,0.00033327102,0.000036425256,0.00028359523,0.00023378771,0.000030284546,0.00018155835,0.000015662996,0.00039575138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970355,0.0011531945,0.001162622,0.00035021568,0.000045390258,0.00025308604],"domain_scores_gemma":[0.99874014,0.00054843945,0.0003354576,0.0002498316,0.000028979253,0.00009717769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013538635,0.00019358449,0.0006224097,0.00009388576,0.000043560758,0.000007255415,0.00019123033,0.000288547,0.00025832545],"category_scores_gemma":[0.0011422848,0.00015870067,0.0003906072,0.00011947633,0.00017921856,0.000060380815,0.00008374306,0.00016621244,0.00068888406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033573264,0.00052425946,0.85069937,0.00011483186,0.0004976017,0.00007480324,0.0011862579,0.0000032185355,0.06332503,0.00034264463,0.020368038,0.05950662],"study_design_scores_gemma":[0.013431443,0.0005261569,0.7222704,0.00016814921,0.00054884807,0.0000031089025,0.0005552023,0.000010110654,0.084691174,0.00015666983,0.17702484,0.00061386556],"about_ca_topic_score_codex":0.000017096016,"about_ca_topic_score_gemma":0.000007759669,"teacher_disagreement_score":0.1566568,"about_ca_system_score_codex":0.00001891496,"about_ca_system_score_gemma":0.00015274431,"threshold_uncertainty_score":0.88544405},"labels":[],"label_agreement":null},{"id":"W3094350968","doi":"10.12788/cutis.0038","title":"Psoriasis in Patients of Color: Differences in Morphology, Clinical Presentation, and Treatment","year":2020,"lang":"en","type":"review","venue":"Cutis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Psychosocial; Presentation (obstetrics); Population; Disease; Pathology; Surgery","score_opus":0.09084426603029415,"score_gpt":0.3486491992218935,"score_spread":0.25780493319159936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094350968","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15550011,0.84273076,2.1714546e-7,0.000017692935,0.00059729855,0.0007592828,0.00030092365,0.000010668722,0.00008301905],"genre_scores_gemma":[0.016837565,0.9820693,0.000027014594,0.0000076263345,0.0000283361,0.0001770342,0.000631995,0.00001674081,0.0002043814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748737,0.00084253156,0.00093518867,0.0004809335,0.000028132717,0.00022586838],"domain_scores_gemma":[0.9988425,0.00054281513,0.00035937622,0.00020543567,0.000021862541,0.000028005114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012611087,0.00033042216,0.0020663135,0.00020725072,0.000028498844,0.0000050594317,0.00016102126,0.000633253,0.00010324084],"category_scores_gemma":[0.0000960098,0.00024320552,0.00023821245,0.00023815884,0.00020533841,0.00003271429,0.000076823664,0.00017845625,0.000079772],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008452584,0.00047474008,0.18347567,0.00029720296,0.000402892,0.000015774727,0.00016717949,1.133616e-8,5.3966016e-7,0.00002965497,0.00017550754,0.8148763],"study_design_scores_gemma":[0.0074827014,0.0020061054,0.37805262,0.0017660579,0.001702535,0.00001609722,0.00007007909,3.33413e-7,0.000020397834,0.000042012576,0.6083955,0.00044552409],"about_ca_topic_score_codex":0.00021612259,"about_ca_topic_score_gemma":0.00016155625,"teacher_disagreement_score":0.8144308,"about_ca_system_score_codex":0.00008487235,"about_ca_system_score_gemma":0.00012225802,"threshold_uncertainty_score":0.9917633},"labels":[],"label_agreement":null},{"id":"W3094600452","doi":"10.1177/0300060520966896","title":"Severe acitretin-induced diffuse idiopathic skeletal hyperostosis: a case report","year":2020,"lang":"en","type":"article","venue":"Journal of International Medical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Diffuse Idiopathic Skeletal Hyperostosis; Ossification; Hyperostosis; Enthesis; Heterotopic ossification; Surgery; Acitretin; Anterior longitudinal ligament; Radiography; Dermatology; Tendon; Psoriasis","score_opus":0.07456147593191383,"score_gpt":0.3610933965271541,"score_spread":0.2865319205952403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094600452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771126,0.0018600693,0.00006362559,0.01753569,0.0013832883,0.0001003272,0.000016296488,0.000015775537,0.0013136939],"genre_scores_gemma":[0.99773186,0.00036090525,0.000059801543,0.0003813688,0.00084485544,0.000009404031,0.00001632039,0.000015851758,0.0005796167],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972197,0.00061092863,0.00075040065,0.00024297286,0.00082584773,0.00035014868],"domain_scores_gemma":[0.9978086,0.00061913853,0.0002698628,0.00015068287,0.00087705377,0.00027468166],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002577307,0.00014244464,0.0003428145,0.00019003772,0.000154831,0.000035213467,0.0006039594,0.00031850653,0.0022252088],"category_scores_gemma":[0.010767718,0.000103855,0.00023234762,0.00024473044,0.00018974366,0.00014494198,0.00020244127,0.00131674,0.000368682],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027675312,0.0016278735,0.010248239,0.000068330926,0.0030662026,0.5416907,0.0022601183,0.0000017012586,0.17003803,0.0006418459,0.02103243,0.246557],"study_design_scores_gemma":[0.014826895,0.003373174,0.0063394695,0.00076081825,0.00024271918,0.80987626,0.002421869,0.00010284774,0.047810134,0.00030247666,0.11343221,0.0005110935],"about_ca_topic_score_codex":0.00004868942,"about_ca_topic_score_gemma":0.000012682902,"teacher_disagreement_score":0.2681856,"about_ca_system_score_codex":0.00011335524,"about_ca_system_score_gemma":0.000599593,"threshold_uncertainty_score":0.9986869},"labels":[],"label_agreement":null},{"id":"W3094618645","doi":"10.1016/j.jaad.2020.10.031","title":"Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Institute for Clinical Evaluative Sciences; North York General Hospital; Sunnybrook Health Science Centre; Women's College Hospital; University Health Network; University of Toronto; Health Sciences Centre","funders":"Canadian Rheumatology Association","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology","score_opus":0.024147865576726,"score_gpt":0.24328618507093408,"score_spread":0.2191383194942081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094618645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966136,0.0014234192,0.0000010779047,0.0016710005,0.00013459673,0.000097373835,0.00002817997,0.0000027309397,0.00002801054],"genre_scores_gemma":[0.9992023,0.00041423188,0.000029769606,0.00031646062,0.0000120597315,0.000003411794,0.000004536493,0.000008819102,0.000008376476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984315,0.00037444654,0.0006613464,0.00019483463,0.00008957414,0.00024828076],"domain_scores_gemma":[0.9988386,0.00012341663,0.00086091127,0.00009385083,0.000025443222,0.00005778509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010509833,0.00017948015,0.00082976394,0.0001441624,0.000045219625,0.000004734073,0.0001975425,0.00010732364,0.000039945968],"category_scores_gemma":[0.000032090684,0.00012495028,0.000060491937,0.00032002904,0.00049448654,0.00010015826,0.000065230204,0.0004916028,3.2350778e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030527235,0.00006657481,0.99088126,0.000008532589,0.0003237167,0.00004553591,0.0005557571,0.0000062059735,0.00015896968,0.000021056525,0.0004863402,0.007140748],"study_design_scores_gemma":[0.0030400692,0.00012520712,0.9947241,0.000043086387,0.00012610681,0.00017470233,0.00018647415,0.0000012727553,0.00071447046,0.000031448264,0.00071606966,0.000117020834],"about_ca_topic_score_codex":0.25834516,"about_ca_topic_score_gemma":0.71264535,"teacher_disagreement_score":0.45430022,"about_ca_system_score_codex":0.00010068707,"about_ca_system_score_gemma":0.0001701596,"threshold_uncertainty_score":0.7465936},"labels":[],"label_agreement":null},{"id":"W3094693153","doi":"10.1136/annrheumdis-2020-eular.3908","title":"OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Celgene; GlaxoSmithKline; Pfizer","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Psoriatic arthritis; Internal medicine; Tolerability; Adverse effect; Psoriasis; Arthritis; Immunology; Alternative medicine","score_opus":0.028727753255920856,"score_gpt":0.28895007390383304,"score_spread":0.2602223206479122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094693153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99287444,0.0016297034,0.0000053043145,0.00019520972,0.00013641894,0.0046391217,0.00048012292,0.000020460455,0.000019215968],"genre_scores_gemma":[0.9991301,0.0004085753,0.000018217888,0.000039575694,0.000009592477,0.00020110837,0.00015806628,0.00002344626,0.000011372455],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99732685,0.0007683401,0.0009898446,0.0004157558,0.00015126806,0.0003479315],"domain_scores_gemma":[0.9975119,0.0012845028,0.0006496013,0.00035978272,0.00011930267,0.000074885145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029318058,0.00037050204,0.0014862748,0.0001873924,0.00010180367,0.000017205099,0.0003366612,0.000105180174,0.0000731913],"category_scores_gemma":[0.0006024955,0.0002455293,0.00021819612,0.0003471335,0.00022632266,0.00017632828,0.00014932612,0.00016480348,0.000008673736],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8024287,0.010239233,0.113735475,0.00013354293,0.002470993,0.000012594478,0.0034214053,0.00018802563,0.00014941026,0.000026298881,0.000035680558,0.06715862],"study_design_scores_gemma":[0.5495859,0.0013382517,0.446248,0.0005170811,0.00035990225,0.0000013259954,0.00047238357,0.000036401838,0.0012264069,0.000026102718,0.000002540976,0.00018572985],"about_ca_topic_score_codex":0.00034567737,"about_ca_topic_score_gemma":0.00016661915,"teacher_disagreement_score":0.33251253,"about_ca_system_score_codex":0.00002123565,"about_ca_system_score_gemma":0.00012886699,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W3095186834","doi":"10.1177/2475530320970531","title":"A Description of Treatment Patterns of Psoriasis by Medical Providers and Disease Severity in US Women","year":2020,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"National Cancer Institute","keywords":"Psoriasis; Medicine; Dermatology; Disease; Severity of illness; Internal medicine","score_opus":0.01474809790695775,"score_gpt":0.22402350219118466,"score_spread":0.20927540428422692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095186834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846142,0.013209656,0.000116968855,0.0009345055,0.00060466066,0.00024746038,0.0002444334,0.000007666511,0.00002043552],"genre_scores_gemma":[0.97951627,0.020002807,0.00011706126,0.00012270949,0.00014368902,0.000021865633,0.000022276712,0.000016082795,0.00003722459],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979004,0.0003681156,0.0010097672,0.0002619386,0.00016241857,0.00029730733],"domain_scores_gemma":[0.9986254,0.00022163069,0.00062262994,0.00013789051,0.000100660785,0.00029177425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456463,0.00025911455,0.000908376,0.00015051731,0.0000625657,0.000017031936,0.00013370674,0.00021482921,0.00032666855],"category_scores_gemma":[0.00042780713,0.0002105343,0.00016350862,0.00015034493,0.00014034567,0.00022712912,0.000047298123,0.00015627992,0.000002412099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033837575,0.001053555,0.30190352,0.00032065666,0.0014244701,0.000118664975,0.012096857,0.000004974455,0.0057599465,0.00013702763,0.0016118676,0.6721847],"study_design_scores_gemma":[0.08577622,0.017303009,0.82937515,0.0024301193,0.0023021789,0.00047729202,0.0116299195,0.00019518567,0.019868623,0.002563392,0.026502607,0.0015763143],"about_ca_topic_score_codex":0.0003357286,"about_ca_topic_score_gemma":0.00010579877,"teacher_disagreement_score":0.6706084,"about_ca_system_score_codex":0.00009399298,"about_ca_system_score_gemma":0.00026105324,"threshold_uncertainty_score":0.858534},"labels":[],"label_agreement":null},{"id":"W3095480534","doi":"10.1016/j.jdcr.2020.10.032","title":"Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23","year":2020,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research; SKiN Health","funders":"","keywords":"Medicine; Immunosuppression; Psoriasis; Asymptomatic; Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Ustekinumab; Immunology; 2019-20 coronavirus outbreak; Clarithromycin; Intensive care medicine; Dermatology; Internal medicine; Infliximab; Virology; Disease; Infectious disease (medical specialty); Tumor necrosis factor alpha","score_opus":0.02001887036858501,"score_gpt":0.252190622638426,"score_spread":0.232171752269841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095480534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827206,0.00024020042,0.000035852143,0.000041142546,0.000706988,0.0003018483,0.000011200587,0.00007657021,0.00031414075],"genre_scores_gemma":[0.99960124,0.000028528657,0.00008245219,0.00006078589,0.000043040523,0.000045366578,0.000089274756,0.00001816387,0.000031160056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984756,0.00024195678,0.0006730095,0.00034890522,0.0000443683,0.00021613628],"domain_scores_gemma":[0.9992111,0.000045217934,0.00038855724,0.00027701462,0.000043588174,0.000034553526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020381286,0.0001803005,0.00036314965,0.00013440948,0.000061099825,0.00001008773,0.000029399247,0.00020141309,0.00009740317],"category_scores_gemma":[0.0001672057,0.00016502058,0.000109839115,0.00023796444,0.00004578115,0.00014821059,0.00005289105,0.00014034295,0.000040514566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000624393,0.0014477138,0.31992465,0.00030073122,0.00056084414,0.07944095,0.018164914,0.00010183122,0.3948131,0.000027073418,0.0016780199,0.18291578],"study_design_scores_gemma":[0.0024014092,0.0022884042,0.06338826,0.0003787115,0.00029377738,0.070793144,0.0004726591,0.00009259624,0.85508245,0.00014242753,0.0040533235,0.00061283563],"about_ca_topic_score_codex":0.00080419576,"about_ca_topic_score_gemma":0.00021608197,"teacher_disagreement_score":0.46026936,"about_ca_system_score_codex":0.0000838441,"about_ca_system_score_gemma":0.000059975388,"threshold_uncertainty_score":0.6729344},"labels":[],"label_agreement":null},{"id":"W3096200572","doi":"10.1097/md.0000000000023068","title":"Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis","year":2020,"lang":"en","type":"review","venue":"Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Meta-analysis; Odds ratio; Internal medicine; Publication bias; Confidence interval; Psoriasis; Dermatology","score_opus":0.03703850323584338,"score_gpt":0.3022718662212954,"score_spread":0.265233362985452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096200572","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011829167,0.9960137,0.000024184541,0.0004934592,0.0012504363,0.00050915073,0.0003240144,0.000045162396,0.00015699305],"genre_scores_gemma":[0.00037164675,0.99257994,0.00008064378,0.0000294007,0.00052213826,0.000057119545,0.004739512,0.000034975186,0.0015846074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795306,0.00059742713,0.0007729938,0.000381253,0.00007788111,0.00021736688],"domain_scores_gemma":[0.9984142,0.00044167115,0.0008336546,0.00020029834,0.00007214799,0.000038007074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044004867,0.00036171405,0.0021860683,0.00019896639,0.0000812462,0.000006018597,0.00016009535,0.00061539235,0.00049575133],"category_scores_gemma":[0.0003277509,0.00026206064,0.00021176327,0.000275254,0.00011062056,0.000036462756,0.000053928394,0.00024614087,0.00014179856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004252421,0.000023169781,0.00035390814,0.0018235455,0.0026077644,0.000007386861,0.00034814232,7.758199e-9,0.00024845352,0.000024004257,0.0074274587,0.9870936],"study_design_scores_gemma":[0.0018395686,0.00031772634,0.00015152317,0.0024212305,0.0068211923,0.0000167911,0.00005306282,9.078676e-8,0.0004010003,0.000016884454,0.98776555,0.00019535061],"about_ca_topic_score_codex":0.000115045346,"about_ca_topic_score_gemma":0.0000073398073,"teacher_disagreement_score":0.9868983,"about_ca_system_score_codex":0.00017341548,"about_ca_system_score_gemma":0.00008053439,"threshold_uncertainty_score":0.99998313},"labels":[],"label_agreement":null},{"id":"W3097601648","doi":"10.1016/j.jaad.2020.10.085","title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent","year":2020,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Mechanism of action; Aryl hydrocarbon receptor; Psoriasis; Mechanism (biology); Action (physics); Receptor; Hydrocarbon; Pharmacology; Dermatology; Biochemistry; Internal medicine; Organic chemistry; Epistemology; Chemistry","score_opus":0.0718099664436638,"score_gpt":0.3435358538899207,"score_spread":0.2717258874462569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097601648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022739654,0.97374815,0.000025190595,0.001968303,0.00037573976,0.0010216851,0.00008678407,0.0000033848808,0.000031134783],"genre_scores_gemma":[0.118675865,0.88091284,0.000120791934,0.00018034854,0.00003320334,0.000034045097,0.000006493824,0.000025876336,0.000010536927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99429876,0.0024324884,0.0025898418,0.00023027285,0.00019227754,0.0002563556],"domain_scores_gemma":[0.98735124,0.0008034879,0.011308434,0.0004220563,0.000092521244,0.000022277705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005532238,0.00044081616,0.00419759,0.00026868758,0.000049963313,0.0000013541766,0.0011742075,0.00039025367,0.00001787794],"category_scores_gemma":[0.0001276608,0.00021137601,0.0017577903,0.0009045528,0.0006309726,0.0000421879,0.00010343007,0.0006159584,0.0000010980546],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074617827,0.0024539565,0.0004450885,0.02724971,0.009726741,0.000008833712,0.002537429,0.000009253212,0.06543286,0.0016559798,0.00028534312,0.88944864],"study_design_scores_gemma":[0.008336842,0.0057916795,0.0017778631,0.1447213,0.03393228,0.009839133,0.0024414982,0.000016605298,0.24157743,0.0010329431,0.5494308,0.0011016323],"about_ca_topic_score_codex":0.000069877955,"about_ca_topic_score_gemma":0.0000030474282,"teacher_disagreement_score":0.88834697,"about_ca_system_score_codex":0.00012847062,"about_ca_system_score_gemma":0.00037683567,"threshold_uncertainty_score":0.8619664},"labels":[],"label_agreement":null},{"id":"W3100764894","doi":"10.1016/j.jaad.2020.11.013","title":"Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia; Dermatrials Research; Health Sciences Centre; Bausch Health (Canada); McMaster University; Women's College Hospital; Dalhousie University; Hospital for Sick Children; University of New Brunswick; University of Toronto; Sunnybrook Health Science Centre","funders":"Janssen Biotech; Takeda Canada; LEO Pharma; Eli Lilly and Company; Galderma; Dermira; UCB; Celgene; Regeneron Pharmaceuticals; Bausch Health; Novartis; Amgen; Pfizer; AbbVie; Merck","keywords":"Medicine; Psoriasis; Interleukin 17; Dermatology; Interleukin; Internal medicine; Cytokine","score_opus":0.009972853653798554,"score_gpt":0.23722944270815155,"score_spread":0.227256589054353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100764894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880826,0.0004918261,0.000026645275,0.010778752,0.00023421025,0.00029109127,0.00002762838,0.000011602851,0.000055649904],"genre_scores_gemma":[0.99797916,0.00008419171,0.00015814851,0.0016636797,0.00004556718,0.000007638275,0.0000037150573,0.000024459845,0.000033441895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978071,0.0006059366,0.00085329555,0.000250226,0.00011870508,0.0003647558],"domain_scores_gemma":[0.9981781,0.00016325343,0.0013378785,0.00014664703,0.00009507877,0.00007901483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101860904,0.00026786255,0.0011124931,0.00023396235,0.00007448979,0.000009554416,0.00072719075,0.00017720772,0.000041018287],"category_scores_gemma":[0.00011402814,0.00016960339,0.00020813441,0.0005830586,0.00035143495,0.00015900296,0.00016328062,0.00057670684,0.000026796024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094325105,0.0003307818,0.96489227,0.00004757234,0.00096518546,0.000026760652,0.0020389247,0.00024362103,0.003391857,0.000045899724,0.0049222647,0.013662336],"study_design_scores_gemma":[0.012693486,0.0016373869,0.910842,0.00032168976,0.0005124581,0.00061999727,0.0005679703,0.000011333144,0.06830268,0.00009697255,0.003908513,0.00048552194],"about_ca_topic_score_codex":0.000031752446,"about_ca_topic_score_gemma":0.000007990378,"teacher_disagreement_score":0.06491083,"about_ca_system_score_codex":0.00006762057,"about_ca_system_score_gemma":0.00010294813,"threshold_uncertainty_score":0.6916225},"labels":[],"label_agreement":null},{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","score_opus":0.019812991342659063,"score_gpt":0.25553552177184496,"score_spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102615618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924064,0.0018026248,0.00006381857,0.0023973002,0.00025204464,0.0028336295,0.00014358405,0.000010339652,0.00009023092],"genre_scores_gemma":[0.9989914,0.00045728715,0.000069169044,0.00024181342,0.00011354491,0.00001638755,0.000034678353,0.000023800305,0.00005193898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996741,0.0011402253,0.0013342858,0.00029680305,0.00021516933,0.00027254847],"domain_scores_gemma":[0.9956234,0.002913432,0.0008903405,0.00024474433,0.0002081436,0.00011990323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255164,0.00035452956,0.0019216154,0.00021426522,0.00013060428,0.000012024146,0.00024948892,0.00014659564,0.000058547885],"category_scores_gemma":[0.0006286766,0.00018030558,0.00008616728,0.00023880135,0.00025414565,0.00007756795,0.000069575246,0.00037673896,0.0000051312677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9652251,0.0010733558,0.0003466573,0.000011905389,0.0026267252,0.00018623167,0.022667997,0.00034236963,0.00053889654,0.0000036974743,0.00026601108,0.0067110276],"study_design_scores_gemma":[0.98176795,0.010273402,0.0007234898,0.00031678606,0.0025947134,0.0004092016,0.0029151281,0.000044930763,0.00060801714,0.000031180232,0.00012530774,0.00018989474],"about_ca_topic_score_codex":0.00022178139,"about_ca_topic_score_gemma":0.00014535544,"teacher_disagreement_score":0.019752868,"about_ca_system_score_codex":0.000039700848,"about_ca_system_score_gemma":0.000093878276,"threshold_uncertainty_score":0.73526484},"labels":[],"label_agreement":null},{"id":"W3103707355","doi":"10.1093/rheumatology/keaa589","title":"Systemic overexpression of interleukin-22 induces the negative immune-regulator SOCS3 and potently reduces experimental arthritis in mice","year":2020,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Arthritis Society; Dutch Arthritis Society","keywords":"Arthritis; Medicine; Spleen; Immune system; Immunology; Cytokine; SOCS3; Inflammation; Rheumatoid arthritis; Internal medicine; Cancer","score_opus":0.014840037155980142,"score_gpt":0.23409346938938422,"score_spread":0.21925343223340407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103707355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96935654,0.029568186,0.0000010036349,0.00026393318,0.00022604497,0.0003031349,0.00005958335,0.000024899473,0.00019668776],"genre_scores_gemma":[0.9993329,0.0003014543,0.000030847386,0.00008011803,0.000041651416,0.000045450546,0.000033507462,0.000013463522,0.00012057356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888957,0.00026776822,0.00033074623,0.0002713715,0.00004266941,0.00019790485],"domain_scores_gemma":[0.9995214,0.00012359975,0.00017149744,0.00013908079,0.000021875681,0.000022553299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010680346,0.00017644947,0.00034492224,0.000045604433,0.000101879814,0.000015247273,0.00019799006,0.00016636516,0.00009835658],"category_scores_gemma":[0.00003420558,0.00012645504,0.00007886213,0.0001103707,0.00017340409,0.00011578826,0.00013607806,0.00014680701,0.000028473885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034853804,0.0000799265,0.0009074078,0.000017400082,0.00012979786,0.0000062694667,0.008765201,0.000001895067,0.9846787,0.00008853353,0.0001804101,0.0047959243],"study_design_scores_gemma":[0.002183494,0.00024777537,0.009468503,0.00034194477,0.00002855337,0.00005020341,0.0075554624,0.0000042235315,0.9797744,0.00003415843,0.00017428037,0.00013700951],"about_ca_topic_score_codex":0.00019925646,"about_ca_topic_score_gemma":0.000007658634,"teacher_disagreement_score":0.029976407,"about_ca_system_score_codex":0.000027843455,"about_ca_system_score_gemma":0.00003012246,"threshold_uncertainty_score":0.51566863},"labels":[],"label_agreement":null},{"id":"W3103727622","doi":"10.25251/skin.4.supp.83","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Double blinded; Medicine; Randomized controlled trial; Placebo; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Alternative medicine; Pathology","score_opus":0.016129608752117178,"score_gpt":0.25199327768949914,"score_spread":0.23586366893738198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103727622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915243,0.0014236573,0.00022239813,0.002610014,0.00024482163,0.0060312594,0.000116173964,0.000017207645,0.00018202883],"genre_scores_gemma":[0.9988465,0.00032564098,0.00015561128,0.00025746707,0.00015051974,0.000053134525,0.000078275654,0.000037456957,0.00009544214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946034,0.002440937,0.0018896655,0.0003714657,0.00034083158,0.00035368538],"domain_scores_gemma":[0.99224067,0.005374141,0.001518222,0.00034264236,0.00038025656,0.0001440818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024144023,0.0004993215,0.0037129142,0.00026938764,0.0001505884,0.000015069692,0.00035419365,0.00016791366,0.00007327519],"category_scores_gemma":[0.0009585858,0.00022252467,0.00017305199,0.000341233,0.0005073912,0.00009598711,0.00005668477,0.0004993076,0.000004703052],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9653864,0.0016887916,0.000103014056,0.000012211632,0.0070738588,0.0003067539,0.021790316,0.000941129,0.00021740467,0.000009593879,0.00024518286,0.0022253701],"study_design_scores_gemma":[0.97598404,0.014153572,0.00008790965,0.00044476066,0.0057246946,0.00043856143,0.0022873096,0.00005449407,0.0005009716,0.000027885093,0.000051666786,0.00024416685],"about_ca_topic_score_codex":0.00047876596,"about_ca_topic_score_gemma":0.00022016809,"teacher_disagreement_score":0.019503007,"about_ca_system_score_codex":0.00005387553,"about_ca_system_score_gemma":0.00019108858,"threshold_uncertainty_score":0.9074293},"labels":[],"label_agreement":null},{"id":"W3106177555","doi":"10.25251/skin.4.supp.70","title":"Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Roflumilast; Dermatology; Psoriasis; Pediatrics; Internal medicine; COPD","score_opus":0.008240515777240696,"score_gpt":0.23637852521625272,"score_spread":0.22813800943901202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106177555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855826,0.012549203,0.0000150826445,0.0011120071,0.00015030804,0.0005180868,0.0000144786345,0.0000063843877,0.000051838328],"genre_scores_gemma":[0.99795234,0.0017080748,0.00001384113,0.000063026906,0.00018448912,0.0000064346987,0.000005789427,0.000017615821,0.000048390233],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984464,0.0003599968,0.0006578685,0.00019272034,0.00009339383,0.00024962839],"domain_scores_gemma":[0.998779,0.0004869201,0.00043422868,0.00015484144,0.000080179816,0.0000648413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044536262,0.00023413567,0.00074511586,0.00018882344,0.000055161825,0.000004195804,0.00020128195,0.00011995778,0.00009600231],"category_scores_gemma":[0.00014362029,0.0001296274,0.000036129655,0.0002597489,0.00029975723,0.000057729176,0.00004821036,0.00035989267,0.0000018651715],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06978778,0.002925785,0.03226615,0.00039432713,0.0030132364,0.0034069198,0.1614949,0.0002113026,0.5428095,0.000019208996,0.00052337465,0.18314752],"study_design_scores_gemma":[0.33527192,0.39843708,0.034422655,0.0068673887,0.006259864,0.03978924,0.116034165,0.0007867573,0.057837944,0.00020186654,0.0025025154,0.0015885953],"about_ca_topic_score_codex":0.0005161848,"about_ca_topic_score_gemma":0.00080560165,"teacher_disagreement_score":0.48497155,"about_ca_system_score_codex":0.000051497685,"about_ca_system_score_gemma":0.00010852639,"threshold_uncertainty_score":0.5286052},"labels":[],"label_agreement":null},{"id":"W3107214515","doi":"10.1016/j.jaad.2020.06.501","title":"18630 The influence of biologics on psoriasis comorbidities: A systematic review","year":2020,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Comorbidity; Internal medicine","score_opus":0.03897750591068198,"score_gpt":0.3234318766053687,"score_spread":0.2844543706946867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107214515","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017955864,0.99358356,0.0000013863847,0.0030921006,0.0003416404,0.0009941631,0.00014055126,0.000009607908,0.000041428288],"genre_scores_gemma":[0.004293538,0.9938965,0.00002596793,0.0016121841,0.00004673867,0.000047050904,0.0000063900948,0.000028061899,0.000043595865],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99243927,0.0041272016,0.0027276995,0.00023767653,0.00014764904,0.00032050317],"domain_scores_gemma":[0.9850366,0.0026948855,0.011662994,0.00045719687,0.000109506946,0.000038807488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005762982,0.00051823986,0.007071488,0.00021167239,0.00011177627,0.000004557175,0.0022824542,0.0004090104,0.00002389638],"category_scores_gemma":[0.0009733253,0.00022654243,0.0018456806,0.0007252107,0.0013897488,0.00004566959,0.00022768829,0.0012291103,0.000070698305],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000386836,0.00039312,0.00008792004,0.8413226,0.01660123,0.000095216696,0.00039445542,0.000006508222,0.00023204858,0.0014639867,0.018082,0.12093409],"study_design_scores_gemma":[0.0006617022,0.00074420735,0.00013060433,0.38347673,0.02300073,0.015636904,0.00021258398,1.4833904e-7,0.00034199472,0.00012196898,0.5752367,0.0004357248],"about_ca_topic_score_codex":0.000007398234,"about_ca_topic_score_gemma":3.2328123e-7,"teacher_disagreement_score":0.55715466,"about_ca_system_score_codex":0.00006988612,"about_ca_system_score_gemma":0.0003239097,"threshold_uncertainty_score":0.9238132},"labels":[],"label_agreement":null},{"id":"W3107299701","doi":"10.1016/j.jaad.2020.06.365","title":"16742 Depression as a risk factor for the development of psoriasis","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psoriasis; Medicine; Depression (economics); Psoriatic arthritis; Risk factor; Tumor necrosis factor alpha; Disease; Dermatology; Immunology; Internal medicine","score_opus":0.02880965044664332,"score_gpt":0.2897154125729932,"score_spread":0.2609057621263499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107299701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880596,0.003589639,0.0005644559,0.0071549737,0.00030465584,0.00021479656,0.000066353554,0.0000066357798,0.00003888132],"genre_scores_gemma":[0.9975468,0.00045769752,0.0013501046,0.0005391228,0.00004878419,0.0000080162445,9.647075e-7,0.000012364021,0.000036153415],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984558,0.00036405612,0.00076267734,0.00012703068,0.000075524804,0.00021489951],"domain_scores_gemma":[0.9966244,0.0008563707,0.0023042911,0.00011284645,0.00006705884,0.00003502686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015530385,0.00015660496,0.0006585597,0.00007209395,0.00016918643,0.0000025791787,0.00067821646,0.00013803005,0.000084590254],"category_scores_gemma":[0.00032616637,0.00008020723,0.0003480601,0.00019405864,0.00039520927,0.00004682158,0.00011639981,0.00033000877,0.000013244878],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005092688,0.0002595487,0.1135893,0.00009110363,0.0048335707,0.0000045473143,0.008332767,0.00004019947,0.2887102,0.00012407659,0.0052592345,0.57366276],"study_design_scores_gemma":[0.0025398156,0.0002581317,0.16125637,0.00004867737,0.0007342777,0.0005976373,0.0011194376,0.000007843301,0.78043264,0.00016563016,0.05269447,0.00014508807],"about_ca_topic_score_codex":0.0000074451223,"about_ca_topic_score_gemma":0.000001484522,"teacher_disagreement_score":0.5735177,"about_ca_system_score_codex":0.000018527902,"about_ca_system_score_gemma":0.0001540205,"threshold_uncertainty_score":0.3270756},"labels":[],"label_agreement":null},{"id":"W3107307654","doi":"10.1016/j.jaad.2020.06.225","title":"15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Dermatology; Plaque psoriasis; Interleukin 17; Internal medicine; Cytokine; Psoriatic arthritis","score_opus":0.017716807709537933,"score_gpt":0.232999873465712,"score_spread":0.21528306575617406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107307654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962177,0.00021935036,0.0000027938447,0.0028723893,0.00009224396,0.0004837583,0.00008915898,0.00000925355,0.000013331743],"genre_scores_gemma":[0.99902827,0.00006128164,0.000034253582,0.0007997378,0.000021673206,0.000010332157,0.000013572972,0.000018507668,0.0000124033495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791026,0.0007108151,0.0006545287,0.000270981,0.00014758545,0.00030585768],"domain_scores_gemma":[0.9981787,0.0002808189,0.001255386,0.00016548096,0.000060975584,0.00005861252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107757645,0.0002912892,0.0009874,0.00009558492,0.00017281987,0.000009962676,0.00053719623,0.000112185786,0.00003889307],"category_scores_gemma":[0.000031817883,0.00014896302,0.00009927029,0.00034915376,0.00060395704,0.000096610696,0.00021085495,0.00050817104,0.0000069103107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008925184,0.00069616217,0.98199403,0.0000071041136,0.0015098421,0.00002542628,0.0026271837,0.000009916834,0.0019354348,0.0000015234175,0.001304735,0.00096347235],"study_design_scores_gemma":[0.0124038225,0.0011683166,0.97839737,0.000047359896,0.00051111454,0.00021058807,0.0016456842,0.000010318108,0.004948171,0.000010348585,0.0004812932,0.00016558473],"about_ca_topic_score_codex":0.00034036915,"about_ca_topic_score_gemma":0.00010052375,"teacher_disagreement_score":0.003596617,"about_ca_system_score_codex":0.000084437284,"about_ca_system_score_gemma":0.00004929576,"threshold_uncertainty_score":0.6074536},"labels":[],"label_agreement":null},{"id":"W3108229751","doi":"10.1016/j.jaad.2020.06.335","title":"16392 Efficacy of tapinarof cream by body region in subjects with plaque psoriasis in a phase 2b randomized controlled study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Trunk; Psoriasis; Randomized controlled trial; Gastroenterology; Internal medicine; Atopic dermatitis; Post-hoc analysis; Plaque psoriasis; Dermatology","score_opus":0.01450576798681795,"score_gpt":0.2806347988607247,"score_spread":0.2661290308739067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108229751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885642,0.0026936512,0.00003575403,0.0073716543,0.00010179933,0.0011709055,0.000010210858,0.000007324221,0.00004448039],"genre_scores_gemma":[0.9987829,0.0006584518,0.00004611439,0.00041190232,0.000022215527,0.000035965302,0.0000025924076,0.000017593282,0.000022272763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99457204,0.0031621675,0.001617579,0.00022481715,0.00011081487,0.0003125941],"domain_scores_gemma":[0.9948409,0.0017273667,0.0031822708,0.00014394739,0.00005745202,0.00004806928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055010396,0.00027629963,0.003690231,0.00034729548,0.000040611732,0.000003483465,0.00053518236,0.00017982567,0.00001722569],"category_scores_gemma":[0.0006010305,0.0001601576,0.00044801136,0.00060611864,0.0007627151,0.000083851366,0.000066392815,0.00059605105,0.0000029534726],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8524706,0.004717914,0.05703755,0.00003797133,0.0033073188,0.00020201491,0.0034976716,0.00004198079,0.07499782,0.000071143666,0.0018947325,0.0017233201],"study_design_scores_gemma":[0.9062736,0.0031107722,0.013798136,0.00015606418,0.0013989635,0.001542412,0.0022942165,0.00002084422,0.070793234,0.000053909553,0.00032042924,0.00023739206],"about_ca_topic_score_codex":0.0001011205,"about_ca_topic_score_gemma":0.000009317543,"teacher_disagreement_score":0.053803064,"about_ca_system_score_codex":0.000039281676,"about_ca_system_score_gemma":0.00014000094,"threshold_uncertainty_score":0.6531037},"labels":[],"label_agreement":null},{"id":"W3108618187","doi":"10.1016/j.jaad.2020.06.667","title":"15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Skin cancer; Dermatology; Malignancy; Psoriasis; Incidence (geometry); Population; Cancer; Internal medicine","score_opus":0.03297475188691685,"score_gpt":0.2877946203099817,"score_spread":0.25481986842306487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108618187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869909,0.0012198101,0.000031240193,0.011122754,0.00011298394,0.0003567505,0.00015640205,0.0000036819936,0.000005465322],"genre_scores_gemma":[0.9976572,0.00022394767,0.0004346178,0.0016133068,0.00002977798,0.0000069263024,0.000010954012,0.000011153487,0.000012161138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978527,0.0010771152,0.00066046894,0.00015971217,0.00007219197,0.00017785377],"domain_scores_gemma":[0.99827456,0.00055053446,0.0009865208,0.0001100348,0.000044661447,0.000033707347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018041521,0.00015705964,0.00090464484,0.000058478294,0.00008639117,0.000008873076,0.00029690235,0.00009630416,0.000009977303],"category_scores_gemma":[0.00018924278,0.00007843422,0.00010094183,0.00029707234,0.0001902439,0.000073020994,0.00010062195,0.00021445194,0.0000024889532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044169393,0.00006383529,0.9780631,0.0000066718826,0.0007673683,0.0000035957542,0.002917483,0.0002404476,0.0055555427,0.000054399145,0.003295368,0.004615238],"study_design_scores_gemma":[0.0037265045,0.0002660516,0.98300093,0.0000552694,0.00039423173,0.00006612118,0.00039030804,0.0000118257985,0.010593812,0.0000876573,0.0013070188,0.00010027844],"about_ca_topic_score_codex":0.00063768827,"about_ca_topic_score_gemma":0.000073913,"teacher_disagreement_score":0.010666243,"about_ca_system_score_codex":0.00001604925,"about_ca_system_score_gemma":0.000028383301,"threshold_uncertainty_score":0.31984547},"labels":[],"label_agreement":null},{"id":"W3108746558","doi":"10.1016/j.jaad.2020.06.675","title":"15313 Gender differences in moderate to severe psoriasis: Analysis of the PSOLAR registry","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Disease; Longitudinal data; Dermatology; Demography; Internal medicine","score_opus":0.032568229207752826,"score_gpt":0.27092265866402504,"score_spread":0.23835442945627222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108746558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810475,0.0015760451,0.00006076081,0.01689395,0.00018494813,0.00011008894,0.000044769517,0.000004544133,0.00007737689],"genre_scores_gemma":[0.9975721,0.00026448982,0.00013291283,0.001940275,0.000025783163,0.0000033400622,0.0000011603476,0.00000886267,0.000051072377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978195,0.0008293508,0.00081066636,0.00018219982,0.000103013655,0.0002552762],"domain_scores_gemma":[0.9978749,0.00023417543,0.0015903261,0.00019983009,0.000055823955,0.000044927117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014669631,0.00018304097,0.0011706756,0.00024456074,0.00007115243,0.000004372767,0.0009793492,0.00016918668,0.000046270994],"category_scores_gemma":[0.00016546687,0.00010236299,0.00051879964,0.0012862307,0.00042376076,0.000058514262,0.00017470357,0.00047544006,0.0000063581547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021970503,0.00022785366,0.8925403,0.000048798465,0.00838503,0.000018433606,0.0037035788,0.0009820596,0.08376361,0.00037559442,0.0042084903,0.003549248],"study_design_scores_gemma":[0.0016980194,0.00015460973,0.9231831,0.000054851913,0.0029538732,0.00063207065,0.0015346867,0.000080650716,0.0676355,0.00035373506,0.0015061548,0.00021274229],"about_ca_topic_score_codex":0.000038632283,"about_ca_topic_score_gemma":0.000009800433,"teacher_disagreement_score":0.030642852,"about_ca_system_score_codex":0.000026548416,"about_ca_system_score_gemma":0.00009820062,"threshold_uncertainty_score":0.41742414},"labels":[],"label_agreement":null},{"id":"W3108752263","doi":"10.1016/j.jaad.2020.06.668","title":"15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Clinical trial; Plaque psoriasis; Internal medicine","score_opus":0.07814616633827731,"score_gpt":0.3506989008348348,"score_spread":0.2725527344965575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108752263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93304324,0.00040393852,0.00003807779,0.06556547,0.00023018182,0.00036598675,0.00033746092,0.000004838641,0.00001079035],"genre_scores_gemma":[0.9954419,0.00088059035,0.00022253788,0.003287818,0.00008974439,0.0000067705473,0.00001289587,0.000012461186,0.000045252687],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99449235,0.0032861952,0.0017053914,0.00023390856,0.00007315167,0.00020898951],"domain_scores_gemma":[0.9960996,0.0020249207,0.0015886216,0.00016570304,0.000049830167,0.00007134917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085831666,0.0001892204,0.0013658613,0.00012204649,0.000058599122,0.0000067365104,0.00041176417,0.00018766354,0.000015728205],"category_scores_gemma":[0.0013677444,0.000103736944,0.00028259773,0.00033268842,0.00025285606,0.000070616836,0.00010423827,0.00028681167,0.000011641407],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0809764,0.0006387669,0.07987705,0.000017911596,0.003931044,0.00004279806,0.01406411,0.00011803321,0.73075014,0.00010597941,0.0063058804,0.08317186],"study_design_scores_gemma":[0.019179668,0.0022513387,0.7059732,0.00017874557,0.001418312,0.00051140646,0.0022455337,0.000030599876,0.24282728,0.0001607277,0.024873171,0.00034997863],"about_ca_topic_score_codex":0.000091060996,"about_ca_topic_score_gemma":0.000016083217,"teacher_disagreement_score":0.6260962,"about_ca_system_score_codex":0.000035820718,"about_ca_system_score_gemma":0.00011677263,"threshold_uncertainty_score":0.42302698},"labels":[],"label_agreement":null},{"id":"W3108854688","doi":"10.1016/j.jaad.2020.06.152","title":"14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research","funders":"","keywords":"Medicine; Post-hoc analysis; Plaque psoriasis; Psoriasis; Internal medicine; Post hoc; Gastroenterology; Randomized controlled trial; Surgery; Dermatology","score_opus":0.03296586563614887,"score_gpt":0.30592894606983007,"score_spread":0.2729630804336812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108854688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991443,0.0011150051,0.000027470598,0.006219157,0.000073728595,0.0010465683,0.000052787953,0.0000062763943,0.000015999422],"genre_scores_gemma":[0.9992833,0.00019945922,0.00018206084,0.00023743502,0.000023541106,0.000041194675,0.0000013809674,0.00001802552,0.0000135873515],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955723,0.0022191354,0.0014324303,0.00031791974,0.00012311275,0.00033506897],"domain_scores_gemma":[0.99680287,0.0010637249,0.0017852876,0.00015541652,0.00012632932,0.00006636668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006189718,0.0002943593,0.0022891597,0.00047503255,0.00004934305,0.0000054010284,0.00036174714,0.00018326486,0.000016899143],"category_scores_gemma":[0.00030503247,0.00019347019,0.00021405154,0.0008492737,0.0009080431,0.00014732455,0.00015639122,0.0006466401,0.0000012722091],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8766328,0.0018978068,0.03030236,0.000106221705,0.0018354289,0.00010053121,0.010752571,0.0003498133,0.07578246,0.00004129626,0.00021099523,0.001987729],"study_design_scores_gemma":[0.48129237,0.0077367346,0.021911638,0.00031493144,0.000917649,0.003065344,0.0061216,0.00007764408,0.47787258,0.00017051479,0.000125595,0.0003934056],"about_ca_topic_score_codex":0.00030053008,"about_ca_topic_score_gemma":0.00015907486,"teacher_disagreement_score":0.40209013,"about_ca_system_score_codex":0.00011615727,"about_ca_system_score_gemma":0.00039050527,"threshold_uncertainty_score":0.78894854},"labels":[],"label_agreement":null},{"id":"W3109095351","doi":"10.1016/j.jaad.2020.06.747","title":"15953 Clearance of head involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.03844495734310572,"score_gpt":0.3170295103483425,"score_spread":0.27858455300523677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109095351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834044,0.0017759722,0.0000067844644,0.0142059745,0.00007378854,0.0004719303,0.000022217151,0.0000038939615,0.000035024612],"genre_scores_gemma":[0.9987307,0.00048500835,0.00009576119,0.0006294346,0.000019040275,0.000015805785,0.0000014796833,0.000011435371,0.000011311697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972761,0.0013087424,0.0008544023,0.00018611421,0.00011132543,0.0002632854],"domain_scores_gemma":[0.99812543,0.00033022775,0.001307692,0.00017812115,0.00003213228,0.00002637495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002519638,0.00020995998,0.00096083275,0.00015293607,0.00004996752,0.0000032543,0.000621411,0.00009461148,0.000014464844],"category_scores_gemma":[0.000042858694,0.000108664266,0.00016187989,0.00057327666,0.0004416483,0.00006782362,0.00005379509,0.00040148586,0.0000053631084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036862627,0.009976517,0.80230474,0.000086747365,0.0032025375,0.0004212129,0.044609345,0.0006792396,0.064077586,0.00023844594,0.0018926433,0.035648342],"study_design_scores_gemma":[0.05810924,0.016147058,0.69059557,0.00027983138,0.0011990528,0.0025971062,0.032580655,0.00002677281,0.18617515,0.00013674967,0.011661666,0.00049115764],"about_ca_topic_score_codex":0.00024885117,"about_ca_topic_score_gemma":0.00012385113,"teacher_disagreement_score":0.12209757,"about_ca_system_score_codex":0.00006741824,"about_ca_system_score_gemma":0.00012776343,"threshold_uncertainty_score":0.44312},"labels":[],"label_agreement":null},{"id":"W3110108782","doi":"10.1016/j.jaad.2020.06.677","title":"15328 Efficacy and safety of mirikizumab in patients with moderate to severe plaque psoriasis: 104-week results from a randomized phase 2 study","year":2020,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Internal medicine; Dermatology; Randomized controlled trial; Gastroenterology; Pathology; Alternative medicine","score_opus":0.01574543642778634,"score_gpt":0.2625358340282847,"score_spread":0.24679039760049834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110108782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919627,0.00048038817,0.00003488038,0.006426538,0.00009421046,0.00077595725,0.00019916153,0.000006390251,0.000019801908],"genre_scores_gemma":[0.9989465,0.00013408416,0.00032642638,0.0005327982,0.000019310928,0.000008016728,0.00000979382,0.00001521833,0.000007888503],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661964,0.0015202289,0.0012595978,0.00025412664,0.00010698467,0.00023943346],"domain_scores_gemma":[0.9968446,0.0010161165,0.0018470471,0.00014551112,0.000078501995,0.00006825807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002663853,0.00023939792,0.0018730481,0.00017538914,0.000059722817,0.0000044383833,0.00040205763,0.00012563918,0.000012336745],"category_scores_gemma":[0.0003804175,0.00014488792,0.00015910504,0.00034542233,0.000435049,0.00008318901,0.00011841297,0.00040042706,0.0000041785493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95814365,0.0018806836,0.020524833,0.000014101557,0.0024919382,0.000025895379,0.0071557066,0.00015435778,0.0023674287,0.000014132549,0.0005675061,0.0066597755],"study_design_scores_gemma":[0.7690431,0.0035095445,0.20956868,0.00017453326,0.001310535,0.00020622392,0.0015629295,0.000019648456,0.013802359,0.00007112555,0.00043109636,0.00030023136],"about_ca_topic_score_codex":0.00008534297,"about_ca_topic_score_gemma":0.0000067023134,"teacher_disagreement_score":0.18910055,"about_ca_system_score_codex":0.000025230054,"about_ca_system_score_gemma":0.0000850097,"threshold_uncertainty_score":0.5908358},"labels":[],"label_agreement":null},{"id":"W3110243001","doi":"10.1016/j.annder.2020.09.558","title":"Efficacité et tolérance du bimékizumab chez des patients présentant un psoriasis en plaques modéré à sévère : résultats de BE VIVID, une étude de phase 3 de 52 semaines, randomisée, en double aveugle, contrôlée versus ustékinumab et versus placebo","year":2020,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.046698313868817315,"score_gpt":0.3184699074482137,"score_spread":0.2717715935793964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110243001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94504684,0.019024093,0.0028866339,0.02583203,0.0022145389,0.0018046541,0.0015180652,0.0007752339,0.0008979258],"genre_scores_gemma":[0.95113176,0.03705897,0.0040696855,0.0051463097,0.00029075707,0.0006227145,0.0013165958,0.00017421175,0.00018902047],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9869669,0.006651533,0.0013772051,0.0015086852,0.0002765708,0.0032191016],"domain_scores_gemma":[0.9881917,0.009281428,0.0007455256,0.00082819443,0.00035366224,0.00059946073],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0021423614,0.0015489588,0.0021026072,0.0003173059,0.0007127802,0.00020757099,0.0015008763,0.0023699484,0.00025226493],"category_scores_gemma":[0.0047378773,0.0015363551,0.00084647693,0.00081826956,0.0011376509,0.0006317268,0.000610483,0.0015549015,0.00023877434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5527708,0.011515065,0.14499156,0.0018815876,0.019018346,0.015461315,0.09567685,0.008602338,0.026104882,0.0058684694,0.051987156,0.06612164],"study_design_scores_gemma":[0.5631566,0.0073746154,0.05043321,0.00094552164,0.00663776,0.003666637,0.008452218,0.0029801938,0.29164287,0.002002554,0.058221485,0.004486359],"about_ca_topic_score_codex":0.00080942485,"about_ca_topic_score_gemma":0.0014438431,"teacher_disagreement_score":0.26553798,"about_ca_system_score_codex":0.0013936155,"about_ca_system_score_gemma":0.0022589827,"threshold_uncertainty_score":0.9997259},"labels":[],"label_agreement":null},{"id":"W3110328268","doi":"10.2340/00015555-3700","title":"An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis","year":2020,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Samsung; LEO Pharma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Baxalta; Biogen; Celgene; Mylan; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Ustekinumab; Medicine; Dermatology Life Quality Index; Psoriasis; Quality of life (healthcare); Dermatology; Psoriasis Area and Severity Index; Physical therapy; Internal medicine; Psoriatic arthritis; Disease; Adalimumab; Nursing; Secukinumab","score_opus":0.025431780240483034,"score_gpt":0.2567801333372463,"score_spread":0.23134835309676327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110328268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984556,0.00047548205,0.00001888928,0.0003389745,0.00010241015,0.00031147248,0.000053184547,0.000057929865,0.00018606041],"genre_scores_gemma":[0.9989913,0.000057307152,0.00013792583,0.00049409847,0.0000064291635,0.000051865343,0.00022541564,0.000016361002,0.00001929621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997794,0.00037871042,0.0007457729,0.00058972475,0.00007375725,0.00041807553],"domain_scores_gemma":[0.9990514,0.00016859538,0.00026336985,0.00038991196,0.000044657165,0.00008207223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012421915,0.00032360447,0.0011775015,0.00038757524,0.00007889022,0.000021128066,0.00025370737,0.00032322528,0.00020889829],"category_scores_gemma":[0.000112705224,0.00027180306,0.00015420225,0.0009225393,0.0000821742,0.00017663998,0.0001538884,0.00019133597,0.000015433092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000947306,0.00040197352,0.9802093,0.00001662474,0.001244341,0.000099546174,0.002574186,0.002004746,0.0072070216,0.00005137858,0.000061270955,0.0051822956],"study_design_scores_gemma":[0.0037200567,0.00025796526,0.9843685,0.00002025768,0.0006647454,0.000023149469,0.0009159604,0.0017804607,0.0075598205,0.00004371195,0.0002673862,0.0003779583],"about_ca_topic_score_codex":0.0006020389,"about_ca_topic_score_gemma":0.0007805533,"teacher_disagreement_score":0.0048043374,"about_ca_system_score_codex":0.00005891728,"about_ca_system_score_gemma":0.000034513956,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W3111112701","doi":"10.1016/j.jval.2020.08.079","title":"PBI1 The Psoriasis Study of Health Outcomes (PSOHO) in Biologic-Naive and -Experienced Patients: Results from the First 217 Patients","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"","keywords":"Medicine; Secukinumab; Ixekizumab; Internal medicine; Psoriasis; Psoriatic arthritis; Plaque psoriasis; Cohort; Ustekinumab; Population; Observational study; Psoriasis Area and Severity Index; Interleukin 17; Arthritis; Dermatology; Adalimumab; Disease","score_opus":0.055678992256940826,"score_gpt":0.2791351838719384,"score_spread":0.22345619161499758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111112701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887175,0.001888122,9.025064e-7,0.006855769,0.0005389993,0.00159059,0.0003681142,0.000021134205,0.000018873972],"genre_scores_gemma":[0.99744916,0.00045835384,0.000019581541,0.0017899391,0.000019229135,0.000079807316,0.00016603984,0.000010948287,0.000006967892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632394,0.0017178269,0.0009928049,0.00048083154,0.00008152948,0.00040307743],"domain_scores_gemma":[0.9978588,0.00118285,0.00051044143,0.0003658265,0.000042640113,0.00003939364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007602558,0.00022697424,0.0005978009,0.000065195956,0.00038134944,0.000012056952,0.0003415471,0.00011848892,0.000013308961],"category_scores_gemma":[0.00056570466,0.00012328701,0.00005521619,0.0003503652,0.00015719411,0.000055025725,0.0001432832,0.00022659251,0.000013889957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005298682,0.0008882996,0.9063559,0.0000133886915,0.00006817621,8.247896e-7,0.07953469,0.000041507577,0.00000395766,0.000025926644,0.00027743104,0.012260039],"study_design_scores_gemma":[0.008538397,0.002310994,0.97742885,0.00005390919,0.000012096604,1.702654e-7,0.010544846,0.000010770865,0.00003208587,0.00004663476,0.00091265683,0.00010861289],"about_ca_topic_score_codex":0.034268934,"about_ca_topic_score_gemma":0.0021062603,"teacher_disagreement_score":0.071072936,"about_ca_system_score_codex":0.00010292275,"about_ca_system_score_gemma":0.00012039409,"threshold_uncertainty_score":0.97216195},"labels":[],"label_agreement":null},{"id":"W3113634853","doi":"10.1007/s13555-020-00472-x","title":"Two-Year US Pharmacovigilance Report on Brodalumab","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Pharmacovigilance; Adverse effect; Adverse Event Reporting System; Internal medicine","score_opus":0.023034592902739248,"score_gpt":0.27007475149976373,"score_spread":0.2470401585970245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113634853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835687,0.0068897144,0.000015436059,0.0030475957,0.00049456937,0.00016570788,0.00002052946,0.00011993221,0.0056777946],"genre_scores_gemma":[0.9929743,0.0017420832,0.0000394281,0.004789073,0.000061425475,0.00002542978,0.00009289773,0.000014265571,0.0002611118],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990499,0.00016241538,0.00019002236,0.00033272945,0.00002170243,0.00024324367],"domain_scores_gemma":[0.99961114,0.00008325002,0.00008122445,0.00016657633,0.000019917132,0.000037900183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005099305,0.00017615387,0.0002875938,0.000037074657,0.00016375478,0.0000078052335,0.000106744184,0.0001604815,0.00036510918],"category_scores_gemma":[0.000013765906,0.0001442704,0.00006517301,0.000076685814,0.00012691432,0.000045351473,0.000020916385,0.00015841419,0.000550923],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073094512,0.0006289038,0.6096835,0.000047017907,0.0024365664,0.00408869,0.0018721644,0.000007221232,0.22088571,0.017573278,0.024031075,0.11143638],"study_design_scores_gemma":[0.014350872,0.0004130354,0.03220194,0.000014073079,0.00009048002,0.0048777247,0.000109599634,0.000007781001,0.40970492,0.00046350627,0.5372794,0.00048660577],"about_ca_topic_score_codex":0.000009635707,"about_ca_topic_score_gemma":0.0000012989979,"teacher_disagreement_score":0.5774816,"about_ca_system_score_codex":0.0000049233213,"about_ca_system_score_gemma":0.0000241991,"threshold_uncertainty_score":0.7081184},"labels":[],"label_agreement":null},{"id":"W3114027606","doi":"10.15690/vsp.v19i6.2149","title":"Psoriasis Comorbidities in Childhood","year":2020,"lang":"en","type":"article","venue":"Вопросы современной педиатрии","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute","funders":"","keywords":"Psoriasis; Medicine; Disease; Metabolic syndrome; Comorbidity; Dermatology; Hyperkeratosis; Obesity; Pathogenesis; Pediatrics; Pathology","score_opus":0.023120112723486783,"score_gpt":0.22515984694195057,"score_spread":0.20203973421846377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114027606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97407234,0.0058932947,0.00004645063,0.0033624908,0.0013885356,0.00048404618,0.00017167536,0.00034852713,0.014232624],"genre_scores_gemma":[0.996277,0.00030583722,0.00014952943,0.0013358458,0.00023208027,0.00007792271,0.00025742556,0.00004395478,0.001320419],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99804574,0.00024142118,0.0004687652,0.00056095736,0.00007322645,0.0006098707],"domain_scores_gemma":[0.9992435,0.00016339128,0.00012257886,0.00035304716,0.000038858438,0.00007861353],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016894186,0.00036805237,0.00054584106,0.00015274652,0.00016504903,0.000029524084,0.00039616143,0.00033265643,0.0020527712],"category_scores_gemma":[0.0001266519,0.0003415272,0.00020402616,0.00043134426,0.00013393284,0.00016878774,0.00012546599,0.00033241033,0.0035040195],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025541228,0.0036170385,0.20661105,0.00027751978,0.0028359406,0.0007306962,0.040239435,0.00013613162,0.13777868,0.013898775,0.1557838,0.4355368],"study_design_scores_gemma":[0.01941024,0.0013503841,0.43649933,0.00016158722,0.0004924751,0.00016661346,0.0037399996,0.000026726711,0.15150847,0.0013846277,0.3832272,0.0020323559],"about_ca_topic_score_codex":0.00013821469,"about_ca_topic_score_gemma":0.00007038839,"teacher_disagreement_score":0.43350446,"about_ca_system_score_codex":0.000054814718,"about_ca_system_score_gemma":0.00008700042,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W3114059115","doi":"10.15690/vsp.v19i6.2153","title":"Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study","year":2020,"lang":"en","type":"article","venue":"Вопросы современной педиатрии","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Adverse effect; Retrospective cohort study; Dermatology; Pediatrics; Internal medicine; Disease; Adalimumab","score_opus":0.008354660051083838,"score_gpt":0.2140791517932174,"score_spread":0.20572449174213356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114059115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495476,0.00215318,0.000018682578,0.00021184726,0.00009021652,0.0018304314,0.00015912994,0.00007568771,0.0005060345],"genre_scores_gemma":[0.9989623,0.0005024115,0.00006588201,0.000080775004,0.000041093077,0.00007320769,0.0001468226,0.000038897117,0.000088602224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794984,0.00020971178,0.0005123674,0.00079255714,0.00010541894,0.000430121],"domain_scores_gemma":[0.99917066,0.000119526274,0.00022641655,0.00034903217,0.000057977693,0.00007638203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028234467,0.00041342588,0.0009002408,0.00015404767,0.0001687372,0.000019994059,0.00019047907,0.00025228818,0.00009554245],"category_scores_gemma":[0.000056115925,0.0003188657,0.000059539518,0.00036820862,0.00025998414,0.00016391644,0.00012834706,0.00030367167,0.000025535033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023686218,0.0004655994,0.9881971,0.000021266114,0.0012508183,0.000021851924,0.0024513032,0.0000058544924,0.0013263975,0.00017654937,0.00011614607,0.0035985282],"study_design_scores_gemma":[0.013572327,0.002287525,0.9804066,0.000049322098,0.00047401479,0.00013353971,0.00088815886,0.0000037722716,0.0016637543,0.000049262653,0.000115007795,0.0003567311],"about_ca_topic_score_codex":0.00021896753,"about_ca_topic_score_gemma":0.00023193703,"teacher_disagreement_score":0.011203705,"about_ca_system_score_codex":0.000063956424,"about_ca_system_score_gemma":0.000061684616,"threshold_uncertainty_score":0.9999263},"labels":[],"label_agreement":null},{"id":"W3115852192","doi":"10.1111/jdv.17092","title":"Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real‐world evidence study","year":2020,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology; Retrospective cohort study; Ustekinumab; Real world evidence; Internal medicine; Adalimumab; Disease","score_opus":0.01754378247948413,"score_gpt":0.2423139302186115,"score_spread":0.22477014773912737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115852192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97783154,0.0018970127,0.00001651988,0.018721024,0.00012879343,0.0011263744,0.000099968194,0.000013436433,0.00016530797],"genre_scores_gemma":[0.99350166,0.0008181613,0.00007670045,0.005328133,0.00008442787,0.000016734873,0.000011448182,0.000056360168,0.00010635887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99148864,0.0064274683,0.0009901872,0.0005648717,0.0001092003,0.0004196197],"domain_scores_gemma":[0.99710464,0.0008599312,0.0015795522,0.00024508854,0.00016078627,0.00004999555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000578876,0.000537298,0.0019748015,0.0004417637,0.00014064438,0.000007840331,0.00059069024,0.00058246474,0.000013001826],"category_scores_gemma":[0.00012489311,0.00031089116,0.00013478336,0.00036720352,0.0006731319,0.00011880549,0.00026965156,0.0016321229,0.0000037756536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013964829,0.00023524823,0.97793746,0.00022344849,0.002451576,0.00025843803,0.0010162598,0.000031098378,0.0002995205,0.0000274084,0.0028367196,0.0007180172],"study_design_scores_gemma":[0.008818447,0.001653942,0.9806098,0.0015409398,0.0012841581,0.0010459005,0.00006594433,6.4280687e-7,0.0016347447,0.000096572,0.0028734822,0.00037547617],"about_ca_topic_score_codex":0.00007924439,"about_ca_topic_score_gemma":0.00006540722,"teacher_disagreement_score":0.015670111,"about_ca_system_score_codex":0.00008535372,"about_ca_system_score_gemma":0.00008892744,"threshold_uncertainty_score":0.9999343},"labels":[],"label_agreement":null},{"id":"W3117991710","doi":"10.21115/jbes.v12.n3.p231-40","title":"Cost-effectiveness of moderate-to-severe psoriasis biologic treatments in Brazilian private healthcare system: cost-per-responder results derived from a network metanalysis","year":2020,"lang":"en","type":"article","venue":"Jornal Brasileiro de Economia da Saúde","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Summit Pacific College","funders":"","keywords":"Medicine; Number needed to treat; Cost effectiveness; Internal medicine; Relative risk; Confidence interval","score_opus":0.06111169584325908,"score_gpt":0.29192034338337686,"score_spread":0.23080864754011776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117991710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202055,0.0014873556,0.00044857807,0.00054434605,0.00054516166,0.001932513,0.0027051147,0.000112405345,0.00020395652],"genre_scores_gemma":[0.9960052,0.00014191782,0.001023019,0.0005039919,0.00015452546,0.0005684458,0.0014685955,0.000055863973,0.00007845652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943667,0.0023100001,0.0011931984,0.0011584788,0.0000680231,0.00090357184],"domain_scores_gemma":[0.9971577,0.0013092374,0.00055414793,0.00062954496,0.00009552154,0.00025386031],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077700237,0.0006295653,0.0017282709,0.00027904153,0.00023874508,0.000052633623,0.00053985836,0.0006281654,0.00020884657],"category_scores_gemma":[0.00021274609,0.0005650331,0.00044286373,0.0005613012,0.000105428175,0.00019657867,0.00016867822,0.00034442297,0.00045994442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062875874,0.0006632538,0.75696486,0.00030929295,0.0085338615,0.0002216523,0.0018840265,0.026498178,0.11767009,0.0004347206,0.00068460446,0.023259582],"study_design_scores_gemma":[0.016044905,0.0008772427,0.9147546,0.00033325705,0.001036639,0.0000373155,0.00041307177,0.0005969426,0.06361087,0.00015887871,0.0013311629,0.0008050892],"about_ca_topic_score_codex":0.0016853453,"about_ca_topic_score_gemma":0.0007761524,"teacher_disagreement_score":0.15778977,"about_ca_system_score_codex":0.00087544724,"about_ca_system_score_gemma":0.0002533934,"threshold_uncertainty_score":0.9996801},"labels":[],"label_agreement":null},{"id":"W3118633569","doi":"10.1111/jdv.17113","title":"Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study","year":2021,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Ortho Dermatologics","keywords":"Medicine; Lotion; Tolerability; Tazarotene; Psoriasis; Adverse effect; Dermatology; Irritation; Itching; Body surface area; Erythema; Internal medicine; Pharmacology; Immunology","score_opus":0.032725368470184174,"score_gpt":0.30031655855357614,"score_spread":0.26759119008339194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118633569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167156,0.0038644932,0.000096466974,0.003281502,0.0003893198,0.00049073336,0.000022240754,0.00000620578,0.00017745873],"genre_scores_gemma":[0.998616,0.0008237713,0.00012538729,0.00016241273,0.000029170276,0.00000502885,0.000013643489,0.000018609415,0.00020597538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526477,0.00310022,0.0010105312,0.00029888205,0.00006377047,0.0002618541],"domain_scores_gemma":[0.99860543,0.000263556,0.00079358416,0.00017345297,0.00011370097,0.000050298895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007326743,0.00023122324,0.0008364924,0.00024636032,0.00015454045,0.000010926896,0.0004551916,0.0002660256,0.00002722334],"category_scores_gemma":[0.00018875653,0.00017083036,0.000083375155,0.00023774897,0.00025819018,0.00017056474,0.0004393062,0.0004930107,0.0000062563113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024083616,0.013698451,0.69010556,0.0003105647,0.0034528123,0.001078845,0.0053501576,0.00023362327,0.1235423,0.003821234,0.0006393578,0.13368349],"study_design_scores_gemma":[0.057702698,0.0006822424,0.8701504,0.00031658207,0.00066281494,0.009543846,0.00025995186,0.000021555425,0.059257656,0.00057412684,0.00053822866,0.00028988483],"about_ca_topic_score_codex":0.000006391708,"about_ca_topic_score_gemma":0.000017196393,"teacher_disagreement_score":0.18004486,"about_ca_system_score_codex":0.000027959482,"about_ca_system_score_gemma":0.00008919323,"threshold_uncertainty_score":0.69662595},"labels":[],"label_agreement":null},{"id":"W3118855444","doi":"10.5114/dr.2020.101677","title":"Clinical features and the course of psoriasis in children","year":2020,"lang":"en","type":"article","venue":"Dermatology Review","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.022227938930160833,"score_gpt":0.2968165931671584,"score_spread":0.2745886542369976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118855444","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28617683,0.7008169,0.0000024369156,0.01212654,0.00013988123,0.00046707873,0.000021135547,0.000016521111,0.00023266634],"genre_scores_gemma":[0.7568175,0.23868474,0.000026420543,0.00433594,0.000019458072,0.000033810476,0.000049237766,0.0000066156113,0.000026253325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982201,0.00093512336,0.00047209594,0.0002058231,0.000014764423,0.00015210277],"domain_scores_gemma":[0.99924845,0.00035787656,0.00016181366,0.00019133509,0.000020610298,0.000019925332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003025825,0.0001316642,0.00082421687,0.000017184997,0.000040630337,0.0000019054706,0.00017808686,0.0001791227,0.00008569611],"category_scores_gemma":[0.00017116361,0.00007527841,0.00015412208,0.00012959185,0.00045105725,0.000023273145,0.000064592175,0.00019517307,0.000078756355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030834932,0.00014669767,0.8057354,0.0004802964,0.0009389556,0.000015608792,0.00031884815,6.517719e-8,0.00006468458,0.002872317,0.030494576,0.15862417],"study_design_scores_gemma":[0.0130050285,0.00012280165,0.92423975,0.0007403405,0.0015926573,0.0028218022,0.00007447749,0.0000013891494,0.0012441607,0.00023025568,0.05562342,0.00030388866],"about_ca_topic_score_codex":0.000012456217,"about_ca_topic_score_gemma":0.000006664588,"teacher_disagreement_score":0.4706407,"about_ca_system_score_codex":0.0000019016737,"about_ca_system_score_gemma":0.000028786806,"threshold_uncertainty_score":0.30697647},"labels":[],"label_agreement":null},{"id":"W3119727280","doi":"10.1016/j.jaad.2020.12.058","title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"National Institute of Allergy and Infectious Diseases; Sanofi Genzyme; Genentech; Agency for Healthcare Research and Quality; Bausch Health; Inozyme Pharma; National Psoriasis Foundation; Pfizer; Incyte; Mylan; Regeneron Pharmaceuticals; Castle Biosciences; National Heart, Lung, and Blood Institute; Sun Pharma; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Boston Scientific Corporation; University of Pennsylvania; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Sanofi; GlaxoSmithKline; Health Canada; Centers for Disease Control and Prevention; Celgene; Janssen Research and Development; EMD Serono; Galderma; Allergan; AstraZeneca; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Meiji Seika Pharma; Coherus Biosciences; Amgen","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Psoriasis; Pandemic; Disease; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Task force; Virology; Dermatology; Pathology; Infectious disease (medical specialty); Outbreak","score_opus":0.021404988142710114,"score_gpt":0.3234124267463879,"score_spread":0.3020074386036778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119727280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9333583,0.028995479,0.0036195128,0.031271484,0.00078034913,0.0014541214,0.00042313233,0.00003102989,0.000066582594],"genre_scores_gemma":[0.97556484,0.02043685,0.00054333766,0.0027725897,0.000054085416,0.000113733644,0.00006644489,0.00002120641,0.00042691428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972421,0.0008316113,0.0009819715,0.0003736241,0.00021721784,0.00035349792],"domain_scores_gemma":[0.99650854,0.0010361711,0.0018921377,0.00024788015,0.00008384109,0.00023143202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048061294,0.00028948727,0.00070271245,0.0003057236,0.00038443712,0.000013328168,0.00053061964,0.00009831994,0.00004932622],"category_scores_gemma":[0.000806589,0.00020201653,0.00029951174,0.00052220374,0.00041671467,0.00024017841,0.00021087489,0.00018812528,0.0000039054344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031062648,0.002237011,0.87019116,0.009450247,0.0103069255,0.0005392031,0.0021506525,0.009990221,0.005513813,0.015270816,0.010153369,0.033133913],"study_design_scores_gemma":[0.05134426,0.00037768437,0.73849815,0.00059597404,0.007846655,0.0017931663,0.0044402694,0.00033486742,0.002171135,0.039455768,0.15215003,0.0009920384],"about_ca_topic_score_codex":0.000020600197,"about_ca_topic_score_gemma":0.000015884703,"teacher_disagreement_score":0.14199667,"about_ca_system_score_codex":0.0005499296,"about_ca_system_score_gemma":0.0005235721,"threshold_uncertainty_score":0.8237995},"labels":[],"label_agreement":null},{"id":"W3119812808","doi":"10.25251/skin.5.supp.15","title":"Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Medicine; Adalimumab; Plaque psoriasis; Double blinded; Multicenter study; Randomized controlled trial; Psoriasis; Internal medicine; Dermatology; Pathology; Placebo; Alternative medicine","score_opus":0.02438267293933946,"score_gpt":0.2821770173124763,"score_spread":0.25779434437313686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119812808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917649,0.0020900248,0.000052488675,0.0015073696,0.002051014,0.0021284851,0.0002029833,0.000012919976,0.00018980233],"genre_scores_gemma":[0.99853307,0.0005756876,0.00008278493,0.00015601401,0.00027372054,0.00002077482,0.0001862478,0.000024931556,0.00014677031],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959202,0.0018220162,0.0013181795,0.0003270335,0.0002453655,0.00036724],"domain_scores_gemma":[0.9929818,0.005235908,0.00089219096,0.00034652132,0.00043375403,0.00010981146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010518273,0.00039498208,0.0019954783,0.0002131031,0.00018864873,0.00002056044,0.00025051687,0.00021493992,0.00013816492],"category_scores_gemma":[0.0009052262,0.00020954797,0.00016723893,0.0002579486,0.00022688622,0.000095792886,0.000053584925,0.00048489825,0.0000093618255],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9822502,0.0013561742,0.000013482362,0.0000045754437,0.003889935,0.00035104307,0.005616577,0.0003315484,0.0006247316,0.000009238737,0.0003727782,0.005179698],"study_design_scores_gemma":[0.98716,0.004643722,0.00013394932,0.000329196,0.0024352502,0.0003583305,0.0010381272,0.000032561282,0.0032180762,0.00002149828,0.00041020187,0.0002190669],"about_ca_topic_score_codex":0.00024376,"about_ca_topic_score_gemma":0.0003935746,"teacher_disagreement_score":0.006768156,"about_ca_system_score_codex":0.00014122277,"about_ca_system_score_gemma":0.0002567686,"threshold_uncertainty_score":0.85451186},"labels":[],"label_agreement":null},{"id":"W3120199534","doi":"10.25251/skin.5.supp.18","title":"Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; European Academy of Dermatology and Venereology","keywords":"Post-hoc analysis; Scalp; Medicine; Dermatology; Nail (fastener); Psoriasis; Post hoc; Dentistry; Internal medicine; Structural engineering; Engineering","score_opus":0.02446779732439922,"score_gpt":0.27520131174977336,"score_spread":0.2507335144253741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120199534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96360934,0.023785137,0.000665667,0.009790182,0.00074201764,0.0008144661,0.00054791785,0.0000072117587,0.00003804401],"genre_scores_gemma":[0.9851497,0.012328113,0.00028351546,0.00094039796,0.00053324114,0.00003721789,0.00018525225,0.000023344832,0.00051923475],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810433,0.00052046985,0.00067044835,0.00023531455,0.00018503734,0.0002844168],"domain_scores_gemma":[0.9955289,0.0030652208,0.0005399192,0.00048165984,0.00033195814,0.00005234331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046939842,0.000313614,0.0008935965,0.00008844387,0.00041348411,0.000017737042,0.000311134,0.00012684293,0.00036078654],"category_scores_gemma":[0.00009560064,0.000118443386,0.0002800132,0.00035430043,0.00027428006,0.00004909351,0.00003458877,0.00015406101,0.000002768678],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6853713,0.0030049523,0.00034358303,0.000038103015,0.064470865,0.0007643308,0.06418259,0.0012162961,0.029573614,0.00012859724,0.009241121,0.14166468],"study_design_scores_gemma":[0.38214722,0.12502676,0.0007865437,0.0007125029,0.108966514,0.012191459,0.059575383,0.0002004439,0.18415135,0.0013562009,0.12387398,0.0010116519],"about_ca_topic_score_codex":0.0007099506,"about_ca_topic_score_gemma":0.0015486904,"teacher_disagreement_score":0.30322406,"about_ca_system_score_codex":0.00008794812,"about_ca_system_score_gemma":0.00018952604,"threshold_uncertainty_score":0.4829981},"labels":[],"label_agreement":null},{"id":"W3120319462","doi":"10.25251/skin.5.supp.21","title":"Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Phase (matter); Dermatology; Internal medicine; Meta-analysis; Chemistry","score_opus":0.05098681300665635,"score_gpt":0.34998676432880144,"score_spread":0.2989999513221451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120319462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266547,0.0047029085,0.00025610498,0.0008449683,0.0005196907,0.00019446718,0.0007598831,0.00000348966,0.00005301426],"genre_scores_gemma":[0.9971928,0.0015480452,0.00019095904,0.0002011267,0.00012479494,6.76279e-7,0.0006047899,0.000011048997,0.00012575378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956467,0.0022414674,0.0015477263,0.00024021376,0.00014417444,0.00017971253],"domain_scores_gemma":[0.99509585,0.0030755168,0.00089812686,0.0005856468,0.00028012833,0.00006470248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029784578,0.00018270068,0.0016178187,0.00025814265,0.00006398266,0.0000056471295,0.00036097068,0.0001475418,0.00069992064],"category_scores_gemma":[0.001897697,0.00009331974,0.00012852854,0.00055211503,0.00014511503,0.00006300708,0.00010574374,0.0002590408,0.000004786091],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2352805,0.0052447976,0.123916596,0.00003788811,0.09449304,0.0014448822,0.0064987093,0.0007677189,0.009321412,0.000027597498,0.0074282135,0.51553863],"study_design_scores_gemma":[0.2751969,0.022442216,0.45234534,0.0024126763,0.21025015,0.0031154535,0.006780257,0.00078320195,0.012391777,0.00086171227,0.012049235,0.0013710809],"about_ca_topic_score_codex":0.00011014783,"about_ca_topic_score_gemma":0.00038103832,"teacher_disagreement_score":0.51416755,"about_ca_system_score_codex":0.000029981304,"about_ca_system_score_gemma":0.00014275654,"threshold_uncertainty_score":0.766364},"labels":[],"label_agreement":null},{"id":"W3120771989","doi":"10.25251/skin.5.supp.16","title":"Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; McMaster University","funders":"","keywords":"Ustekinumab; Plaque psoriasis; Medicine; Double blinded; Psoriasis; Internal medicine; Randomized controlled trial; Multicenter study; Dermatology; Pathology; Placebo; Disease; Alternative medicine","score_opus":0.03190225859256773,"score_gpt":0.2984405727850189,"score_spread":0.26653831419245116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120771989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888836,0.0022053719,0.00012339998,0.002646456,0.0040966715,0.0013790559,0.00052871223,0.000015252399,0.000121490055],"genre_scores_gemma":[0.99788135,0.0005807195,0.00009642528,0.00024500632,0.00057959516,0.00001449581,0.0002719466,0.00003458888,0.00029587757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595577,0.0014868454,0.0014263205,0.00031129294,0.00036483564,0.00045492445],"domain_scores_gemma":[0.9910256,0.006199824,0.001306662,0.0006624338,0.0007125935,0.000092885115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014460563,0.00040503463,0.0013981871,0.00008884984,0.0003419107,0.000024815565,0.00061411917,0.00023228448,0.00022363228],"category_scores_gemma":[0.0012581783,0.00018378904,0.0003139418,0.00032656404,0.0004527362,0.00009009501,0.00010703229,0.0005097665,0.000017400222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97170275,0.0012301006,0.000013880042,0.0000074583827,0.0035988844,0.00022315011,0.012056299,0.0003144739,0.0014009543,0.0000105264335,0.0014253998,0.0080160955],"study_design_scores_gemma":[0.9710951,0.004536327,0.000070195616,0.00033209848,0.002732539,0.0004963829,0.0023478558,0.00001153112,0.016080867,0.000024898369,0.002066207,0.00020601232],"about_ca_topic_score_codex":0.00028838043,"about_ca_topic_score_gemma":0.0003209525,"teacher_disagreement_score":0.014679913,"about_ca_system_score_codex":0.000094102405,"about_ca_system_score_gemma":0.00023004417,"threshold_uncertainty_score":0.74947},"labels":[],"label_agreement":null},{"id":"W3122132687","doi":"10.1007/s13555-021-00490-3","title":"Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Ustekinumab; Plaque psoriasis; Open label; Randomized controlled trial; Clinical trial; Dermatology; Gastroenterology; Disease; Adalimumab","score_opus":0.023874858612425512,"score_gpt":0.2783510814867329,"score_spread":0.2544762228743074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122132687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889077,0.009248866,0.000035205092,0.00023845785,0.0003046637,0.0008420582,0.00037094206,0.000018096429,0.000050936942],"genre_scores_gemma":[0.9959901,0.002400891,0.00008551885,0.00014905308,0.00002009978,0.00003639155,0.001240773,0.000017309158,0.00005984865],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99821866,0.00045376873,0.00045650572,0.0005531131,0.000037127145,0.00028085583],"domain_scores_gemma":[0.99904776,0.00033572348,0.00016329646,0.0003425874,0.00006943224,0.00004122831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010270791,0.0002519523,0.0006716722,0.00009790856,0.00016293387,0.000020050917,0.00014547409,0.00033753045,0.00007409655],"category_scores_gemma":[0.00003345767,0.00019678616,0.000029523137,0.00014718543,0.00013398712,0.00011940569,0.00009639097,0.00016054235,0.000011070509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8243502,0.0041953125,0.019983128,0.000015357173,0.00093505246,0.00018954353,0.0012909126,0.00000667159,0.0037771435,0.00010531069,0.00013003254,0.14502136],"study_design_scores_gemma":[0.76361126,0.002167144,0.20795822,0.00014404932,0.000121102494,0.000119303484,0.00003800021,0.000008326985,0.024685536,0.000103143524,0.0007094568,0.00033444667],"about_ca_topic_score_codex":0.000078263656,"about_ca_topic_score_gemma":0.00016639761,"teacher_disagreement_score":0.1879751,"about_ca_system_score_codex":0.000024636023,"about_ca_system_score_gemma":0.00012926453,"threshold_uncertainty_score":0.8024707},"labels":[],"label_agreement":null},{"id":"W3123269709","doi":"10.1159/000512688","title":"The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Skin Appendage Disorders","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriasis; Medicine; Quality of life (healthcare); Dermatology Life Quality Index; Adalimumab; Psoriasis Area and Severity Index; Patient-reported outcome; Nail (fastener); Dermatology; Severity of illness; Nail disease; Physical therapy; Disease; Internal medicine","score_opus":0.043366910476147214,"score_gpt":0.34812176838244996,"score_spread":0.30475485790630275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123269709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028250917,0.9958836,0.0000013921957,0.000021700474,0.00023783161,0.002590023,0.00057401217,0.000017102166,0.00039186288],"genre_scores_gemma":[0.0009602436,0.9975263,0.000004584912,0.0000090359945,0.00001154943,0.00023639924,0.00056214636,0.000041148043,0.00064862473],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9951042,0.002459528,0.0015245497,0.00047766382,0.00008744938,0.00034663055],"domain_scores_gemma":[0.99564934,0.0017566633,0.0014689699,0.0010129322,0.00007031881,0.00004177645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082539767,0.0006640223,0.0049044336,0.00011533809,0.00016884184,0.0000139156955,0.00034672904,0.0003757388,0.00017994521],"category_scores_gemma":[0.00060721743,0.00033872522,0.0021023462,0.0003354087,0.00023967966,0.000026355257,0.00007887343,0.00017268522,0.00007654589],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052371128,0.00041328633,0.000029573728,0.37797135,0.008567437,0.0000019908362,0.00015275308,1.6469713e-7,0.000001803483,0.0002454885,0.0004988459,0.6120649],"study_design_scores_gemma":[0.0037020836,0.0018406017,0.00021647435,0.76820093,0.02366765,0.0000567013,0.00078518206,2.0289598e-7,0.000038183538,0.00007283021,0.20014063,0.0012785225],"about_ca_topic_score_codex":0.0004503029,"about_ca_topic_score_gemma":0.000116266456,"teacher_disagreement_score":0.6107864,"about_ca_system_score_codex":0.00012720606,"about_ca_system_score_gemma":0.00040475343,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W3123676674","doi":"10.1007/s13555-021-00483-2","title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Biotech; Sun Pharma; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Medicine; Inflammation; Interleukin 17; Immunology; Interleukin 23; Immune system; Disease; Interleukin; Cytokine; Internal medicine","score_opus":0.04843329614868765,"score_gpt":0.32176808786269695,"score_spread":0.2733347917140093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123676674","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010084208,0.9887885,0.000007125356,0.00007371492,0.00034559198,0.00048994087,0.00012081926,0.000013984745,0.00007615549],"genre_scores_gemma":[0.005295291,0.9937899,0.000024067229,0.00010607962,0.000006866515,0.000099343066,0.0005141513,0.00001936129,0.0001449533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974239,0.0012257639,0.0007488558,0.00036398298,0.000031231717,0.00020627472],"domain_scores_gemma":[0.9985614,0.0004972803,0.00065220124,0.00019290479,0.00007658647,0.00001964466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002713171,0.0003843907,0.0026502563,0.00024931188,0.00007275563,0.000006305088,0.00010851119,0.0006961371,0.000108254004],"category_scores_gemma":[0.000060911665,0.00030323016,0.00019790352,0.00018687895,0.0003231642,0.000064993634,0.00007236247,0.00028885907,0.0000020969205],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012095454,0.00024065521,0.00018785933,0.018012289,0.0031901663,0.00005486889,0.002461113,5.2351226e-9,0.00022640142,0.001607884,0.0008418689,0.97305596],"study_design_scores_gemma":[0.008772879,0.0011002754,0.00054170936,0.17797822,0.0037303204,0.005602598,0.0038381836,8.033948e-7,0.0086287055,0.0020963,0.78625804,0.0014519499],"about_ca_topic_score_codex":0.000034744175,"about_ca_topic_score_gemma":0.000065159875,"teacher_disagreement_score":0.971604,"about_ca_system_score_codex":0.000025311501,"about_ca_system_score_gemma":0.00009312154,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W3123964245","doi":"10.1177/1203475421991126","title":"A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic","year":2021,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Pandemic; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Intensive care medicine; Dermatology; Disease; Pathology; Outbreak; Infectious disease (medical specialty)","score_opus":0.18335854161462845,"score_gpt":0.2790839199939615,"score_spread":0.09572537837933304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123964245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361813,0.0023701834,0.000021380136,0.0029665583,0.00085558416,0.00010377133,0.00004039823,0.0000045436254,0.000019460676],"genre_scores_gemma":[0.9968304,0.0016397504,0.0000025771767,0.0013731263,0.000051798113,0.0000013668063,0.000010380526,0.0000075525218,0.0000830271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978108,0.0012253316,0.00057839084,0.00011288001,0.00011117567,0.00016142156],"domain_scores_gemma":[0.98454803,0.014345112,0.0006994991,0.00024621774,0.00013081722,0.000030332558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000934307,0.00014542334,0.0004965967,0.000111188696,0.00023218401,0.000006383925,0.000121179764,0.0001105037,0.0001262338],"category_scores_gemma":[0.0035502403,0.000056310462,0.000181446,0.00024290555,0.00021675548,0.000021149244,0.000025594532,0.00022593862,7.964771e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047397474,0.0004396329,0.9130282,0.00015743708,0.0015023218,0.00037913816,0.0022675197,0.0006805625,0.048945155,0.00024160722,0.02290874,0.004709938],"study_design_scores_gemma":[0.017647812,0.009792029,0.7202067,0.006710465,0.0044137207,0.024950707,0.022143308,0.00010132028,0.13018918,0.0028653403,0.05938468,0.0015947298],"about_ca_topic_score_codex":0.000080073376,"about_ca_topic_score_gemma":0.000102721235,"teacher_disagreement_score":0.1928215,"about_ca_system_score_codex":0.00006609841,"about_ca_system_score_gemma":0.00022705548,"threshold_uncertainty_score":0.42502257},"labels":[],"label_agreement":null},{"id":"W3125468466","doi":"10.1503/cmaj.200517-f","title":"Psoriasis rupioïde touchant les mains","year":2021,"lang":"fr","type":"article","venue":"Canadian Medical Association Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Gynecology; Humanities; Philosophy; Dermatology","score_opus":0.012137714288541657,"score_gpt":0.22738119574500767,"score_spread":0.21524348145646602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125468466","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33596328,0.20382178,0.00030824947,0.3637487,0.0600974,0.00027011873,0.0014581863,0.00006633205,0.034265958],"genre_scores_gemma":[0.3990422,0.06752393,0.00085264194,0.03384265,0.02191643,0.00004199607,0.00081379066,0.0001603796,0.475806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960168,0.0014024889,0.00065425964,0.00032206508,0.0004012284,0.0012031697],"domain_scores_gemma":[0.9972287,0.00046232075,0.00031458677,0.00019067677,0.0006299768,0.0011737329],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015310356,0.00028463628,0.00048718552,0.00020261324,0.0009646001,0.00012351037,0.00029344484,0.0020879772,0.09323379],"category_scores_gemma":[0.0023159941,0.0002944025,0.00037542914,0.00036567336,0.00012291904,0.00014039084,0.000039710212,0.001496577,0.0032077539],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021585956,0.00017104454,0.023666555,0.000021292952,0.0019016961,0.0049283206,0.0006958382,0.0000019219312,0.00028142097,0.0033201084,0.377111,0.58787924],"study_design_scores_gemma":[0.0021858437,0.000077932025,0.015821245,0.00020813066,0.00037791836,0.0037147312,0.0012968755,0.000007781014,0.0009260978,0.00036076643,0.97472674,0.00029597103],"about_ca_topic_score_codex":0.0067981556,"about_ca_topic_score_gemma":0.15009905,"teacher_disagreement_score":0.5976157,"about_ca_system_score_codex":0.002145795,"about_ca_system_score_gemma":0.0080131525,"threshold_uncertainty_score":0.9999508},"labels":[],"label_agreement":null},{"id":"W3126208456","doi":"10.1177/1203475421993770","title":"Safety of Systemic Medications Among Older Adults With Psoriasis and Atopic Dermatitis: A Systematic Review of Observational Studies","year":2021,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Atopic dermatitis; Observational study; Psoriasis; Dermatology; Intensive care medicine; Internal medicine","score_opus":0.04658722715090995,"score_gpt":0.29965936341822225,"score_spread":0.2530721362673123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126208456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024180198,0.9962644,0.000009109917,0.0001940774,0.00042239384,0.00062938605,0.000042953725,0.0000046800697,0.000014991756],"genre_scores_gemma":[0.0015355095,0.9979755,0.000034377088,0.00010013829,0.00008125051,0.000038982547,0.000109698696,0.000017181195,0.000107330525],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960189,0.0008103284,0.0026432467,0.00018316416,0.00019451798,0.0001498743],"domain_scores_gemma":[0.9898647,0.005627189,0.0034855988,0.00024718235,0.00072507525,0.000050236456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091286,0.00032216703,0.0060258335,0.00030975018,0.000068810994,0.0000028281006,0.000115601375,0.00022263428,0.000058598343],"category_scores_gemma":[0.001571445,0.00017652402,0.00036807838,0.0002947841,0.0003421324,0.000060352297,0.00003003937,0.00021438206,7.924597e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001611294,0.000053996533,0.00055568153,0.94167024,0.0068453467,0.00024528976,0.0008427184,3.4868826e-8,7.116598e-7,0.000033138043,0.0022903325,0.04744638],"study_design_scores_gemma":[0.0004559277,0.000118791824,0.00011189411,0.9529455,0.017036673,0.022862434,0.0012820929,8.120315e-8,0.0000018046743,0.00000305686,0.005048645,0.00013315307],"about_ca_topic_score_codex":0.0000070032174,"about_ca_topic_score_gemma":0.0000049295304,"teacher_disagreement_score":0.04731323,"about_ca_system_score_codex":0.000042894077,"about_ca_system_score_gemma":0.0004350955,"threshold_uncertainty_score":0.71984404},"labels":[],"label_agreement":null},{"id":"W3126405891","doi":"10.1053/j.gastro.2021.02.002","title":"Ustekinumab for Ulcerative Colitis","year":2021,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Western University","funders":"","keywords":"Ustekinumab; Ulcerative colitis; Medicine; Interleukin 23; Immunology; Psoriasis; Immune system; Inflammatory bowel disease; Monoclonal antibody; Blockade; Disease; Antibody; Interleukin 17; Internal medicine; Tumor necrosis factor alpha; Receptor; Infliximab","score_opus":0.016748715377882247,"score_gpt":0.2418890760926198,"score_spread":0.22514036071473756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126405891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923259,0.00049391465,0.0026889106,0.000976876,0.0017497258,0.0002697454,0.00033709628,0.00006714077,0.0010906714],"genre_scores_gemma":[0.9904607,0.00004322324,0.00086348085,0.00092086394,0.00009080456,0.00019232485,0.00071045716,0.000017221195,0.006700901],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987625,0.00024673215,0.00019230435,0.0003247407,0.000014856986,0.00045889517],"domain_scores_gemma":[0.99948514,0.00010542602,0.000063726366,0.00021224021,0.00011050433,0.000022964305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008591167,0.00015195108,0.00028813924,0.000047898568,0.00013910803,0.000008992883,0.00010083975,0.0001605964,0.001110505],"category_scores_gemma":[0.000044168148,0.0001458229,0.00014647245,0.00004830089,0.00009690905,0.00003964444,0.00005178904,0.00008222487,0.000260805],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028254472,0.0027334385,0.25848863,0.00016223687,0.008387763,0.00061414996,0.003192216,0.000034194538,0.30707347,0.01793555,0.20728983,0.16583407],"study_design_scores_gemma":[0.03015144,0.0043540266,0.46561658,0.000044446304,0.0007799836,0.0026771931,0.0010126984,0.0000130335075,0.1902482,0.0019412454,0.30264276,0.00051838136],"about_ca_topic_score_codex":0.0000085155625,"about_ca_topic_score_gemma":0.00032636602,"teacher_disagreement_score":0.20712797,"about_ca_system_score_codex":0.000035678346,"about_ca_system_score_gemma":0.000042992426,"threshold_uncertainty_score":0.9998026},"labels":[],"label_agreement":null},{"id":"W3126713119","doi":"10.36849/jdd.5531","title":"Dermatologists’ Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey","year":2021,"lang":"en","type":"article","venue":"Journal of Drugs in Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Family medicine","score_opus":0.024400363767539287,"score_gpt":0.26039667061772676,"score_spread":0.23599630685018747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126713119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97063905,0.018664561,0.00004298185,0.0050322614,0.0022819145,0.00015043738,0.00007060875,0.000022606582,0.0030955772],"genre_scores_gemma":[0.99734956,0.0013523329,0.00019565276,0.00069548446,0.000058300506,0.000018832301,0.000053290998,0.000033129294,0.0002434196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951397,0.002578428,0.00096179446,0.00040920638,0.00012314173,0.0007877003],"domain_scores_gemma":[0.9970854,0.0012810952,0.0005303946,0.00046355676,0.0005341425,0.000105444866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094523444,0.000385015,0.00097372266,0.0005384117,0.00057230174,0.00008432306,0.0005319135,0.0005782208,0.0001926434],"category_scores_gemma":[0.00076713297,0.0002836855,0.00028330134,0.0004998973,0.00029595385,0.00018061587,0.000075918935,0.00092863245,0.00019948705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0138936145,0.004067472,0.62435275,0.00021879243,0.013003245,0.01778625,0.11320122,0.0067720395,0.0041419724,0.084454566,0.07012654,0.04798152],"study_design_scores_gemma":[0.042385895,0.001054521,0.49879247,0.0008975452,0.0018820225,0.08435516,0.081723996,0.000719626,0.24048589,0.012132094,0.031809483,0.0037613101],"about_ca_topic_score_codex":0.0060298718,"about_ca_topic_score_gemma":0.080759324,"teacher_disagreement_score":0.23634392,"about_ca_system_score_codex":0.00033129277,"about_ca_system_score_gemma":0.0015641653,"threshold_uncertainty_score":0.99996156},"labels":[],"label_agreement":null},{"id":"W3127388240","doi":"10.1016/j.jid.2021.01.005","title":"Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Secukinumab; Medicine; Psoriasis; Immunology; Dermatology; Mononuclear phagocyte system; Peripheral blood mononuclear cell; Phagocyte; Ustekinumab; Psoriatic arthritis; Tumor necrosis factor alpha; Immune system; Infliximab; Biology","score_opus":0.01136565606973122,"score_gpt":0.2072506532659993,"score_spread":0.1958849971962681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127388240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995508,0.003217506,0.000005292701,0.0006393399,0.00031174003,0.00020008915,0.000017110915,0.000016888798,0.000084021405],"genre_scores_gemma":[0.998394,0.00061368814,0.00056706654,0.000073470364,0.00005735403,0.00002806955,0.00002234975,0.000028671855,0.000215301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814737,0.0005949947,0.0005564519,0.00028548308,0.000067382585,0.0003483192],"domain_scores_gemma":[0.99885887,0.00014148634,0.00060277246,0.0001724576,0.00014715597,0.00007722895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007865681,0.00032925588,0.0007578764,0.00029072008,0.00013828107,0.000027314665,0.00012451623,0.00025131562,0.00015379119],"category_scores_gemma":[0.000043392225,0.00024055512,0.00008601151,0.0001643571,0.00043280548,0.00014969904,0.000058289752,0.00029018367,0.000019557765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018607693,0.00057876366,0.02207926,0.00019286101,0.0013916462,0.0029596668,0.01220008,0.000022855387,0.9562826,0.000350137,0.00009885395,0.001982479],"study_design_scores_gemma":[0.009487579,0.0006217257,0.03295157,0.00014140968,0.0002732548,0.004641764,0.001483037,0.0000059637805,0.9496254,0.00018624392,0.00035740528,0.00022468467],"about_ca_topic_score_codex":0.000017873886,"about_ca_topic_score_gemma":0.00023134705,"teacher_disagreement_score":0.010872314,"about_ca_system_score_codex":0.00011815228,"about_ca_system_score_gemma":0.00034008693,"threshold_uncertainty_score":0.9809553},"labels":[],"label_agreement":null},{"id":"W3128034858","doi":"10.1016/s0140-6736(21)00126-4","title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"UCB Pharma","keywords":"Medicine; Placebo; Psoriasis; Population; Dosing; Clinical trial; Psoriasis Area and Severity Index; Adverse effect; Internal medicine; Clinical endpoint; Randomized controlled trial; Tolerability; Plaque psoriasis; Physical therapy; Dermatology; Alternative medicine","score_opus":0.03975210694711809,"score_gpt":0.29805242783996005,"score_spread":0.25830032089284194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128034858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886853,0.0019470667,0.000045234123,0.0030269597,0.00083313463,0.0033957844,0.0002117517,0.0000749349,0.0017798034],"genre_scores_gemma":[0.99413365,0.0006113636,0.00016849289,0.00057745795,0.0004599862,0.00056909974,0.0003564498,0.000031065854,0.0030924405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974658,0.0008685233,0.00051729294,0.0005067902,0.00006924744,0.0005723727],"domain_scores_gemma":[0.99812305,0.0010233375,0.0001447661,0.0005802661,0.000068159636,0.000060442348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071778265,0.0003394466,0.0012526592,0.00010079472,0.00027237038,0.00006610219,0.00025721616,0.00025932005,0.0003087373],"category_scores_gemma":[0.00021235959,0.00022811051,0.00013491315,0.00024949425,0.00008084875,0.00008580892,0.00010041105,0.0002926937,0.00014126384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98185253,0.0006262511,0.00004581569,0.000012732636,0.000847896,0.000069442474,0.0016757665,0.00014438697,0.0048190095,0.0002459487,0.0017399464,0.0079203015],"study_design_scores_gemma":[0.9810914,0.00032237644,0.00010447379,0.000047857236,0.0004179659,0.000073226336,0.00023237812,0.00006535356,0.009459058,0.000040360108,0.0078595765,0.00028598093],"about_ca_topic_score_codex":0.00011354101,"about_ca_topic_score_gemma":0.00051812094,"teacher_disagreement_score":0.0076343208,"about_ca_system_score_codex":0.00006357722,"about_ca_system_score_gemma":0.0001543572,"threshold_uncertainty_score":0.93020767},"labels":[],"label_agreement":null},{"id":"W3128747576","doi":"10.1016/s0140-6736(21)00125-2","title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma","keywords":"Medicine; Ustekinumab; Psoriasis; Placebo; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Adverse effect; Clinical trial; Randomization; Dosing; Body surface area; Plaque psoriasis; Randomized controlled trial; Dermatology; Adalimumab; Disease; Pathology","score_opus":0.09074387936814433,"score_gpt":0.32995205412581574,"score_spread":0.23920817475767142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128747576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860102,0.0045018345,0.00008766007,0.0017296545,0.0010015746,0.0038490219,0.0026416287,0.000032482392,0.00014591966],"genre_scores_gemma":[0.9963093,0.0015539753,0.00017034935,0.00011226196,0.00041444422,0.00064416346,0.00036903776,0.000021791262,0.00040471845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844986,0.00039915583,0.00034317566,0.00040099458,0.000054220065,0.00035258368],"domain_scores_gemma":[0.99533814,0.003850193,0.0001865017,0.0004911805,0.00008810027,0.000045887333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017786546,0.00030952762,0.0010965102,0.000038599108,0.0003907067,0.000045114677,0.00017503167,0.00016992571,0.00012784699],"category_scores_gemma":[0.000077290904,0.00017325976,0.00015890923,0.00010618082,0.00012235489,0.00005327611,0.00005353759,0.000097066186,0.000025057212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9660681,0.0011916369,0.000014868753,0.000007722562,0.004339782,0.00000581468,0.0038983622,0.00007038213,0.004123049,0.000136939,0.0009362344,0.019207126],"study_design_scores_gemma":[0.93288755,0.0023682094,0.00021061391,0.000023313767,0.001998944,0.000009963113,0.001080306,0.00018125029,0.041905377,0.00002627638,0.019105162,0.00020304772],"about_ca_topic_score_codex":0.00016678713,"about_ca_topic_score_gemma":0.00045560885,"teacher_disagreement_score":0.037782326,"about_ca_system_score_codex":0.000072610914,"about_ca_system_score_gemma":0.00010224114,"threshold_uncertainty_score":0.70653284},"labels":[],"label_agreement":null},{"id":"W3129022701","doi":"10.1111/bjd.19866","title":"Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*","year":2021,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Mediprobe Research (Canada); University of Toronto","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Almirall; National Institute for Health and Care Research","keywords":"Medicine; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Etanercept; Adverse effect; Placebo; Psoriasis; Gastroenterology; Surgery; Dermatology; Rheumatoid arthritis; Pathology","score_opus":0.038113802512536245,"score_gpt":0.34746219059349354,"score_spread":0.30934838808095727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129022701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841092,0.014437159,0.00009200882,0.0002399572,0.00025133122,0.00054869015,0.00025794347,0.000005947022,0.000057711888],"genre_scores_gemma":[0.9955576,0.0032447828,0.0008358851,0.000046655638,0.000016316495,0.000005184913,0.000060896265,0.000019673947,0.00021302792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99042225,0.0062101334,0.0025629483,0.00037426464,0.00011858914,0.0003118397],"domain_scores_gemma":[0.9939816,0.0037283532,0.0014671966,0.00022166227,0.0005009219,0.00010025647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020863255,0.00025463593,0.003432671,0.00025447796,0.00011199327,0.00001902981,0.0001630118,0.00033505884,0.0001250852],"category_scores_gemma":[0.002548303,0.00022114276,0.0002994266,0.00027703983,0.0004277612,0.00012975548,0.00012796921,0.00031102062,0.0000030883205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92338705,0.0020402863,0.03555509,0.00006857568,0.0052730227,0.0010583948,0.0008696148,0.00015583095,0.0068885298,0.000038780225,0.0013967688,0.023268081],"study_design_scores_gemma":[0.88064593,0.0010025712,0.07346814,0.0007029428,0.0021701187,0.0045453063,0.00024109158,0.000012119095,0.03666042,0.00006870313,0.00017567888,0.00030695088],"about_ca_topic_score_codex":0.00010747004,"about_ca_topic_score_gemma":0.00013427493,"teacher_disagreement_score":0.04274107,"about_ca_system_score_codex":0.000031094816,"about_ca_system_score_gemma":0.00024419688,"threshold_uncertainty_score":0.901794},"labels":[],"label_agreement":null},{"id":"W3129403399","doi":"10.3899/jrheum.201681","title":"GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Medical physics; Medicine; Psoriasis; Systematic review; MEDLINE; Dermatology; Political science","score_opus":0.01753881109821294,"score_gpt":0.2534608218369046,"score_spread":0.23592201073869168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129403399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669621,0.019599292,0.00009316778,0.011094035,0.0018724592,0.00009743948,0.00015295515,0.000018732359,0.00010980474],"genre_scores_gemma":[0.9780215,0.02058359,0.00041899757,0.00040025747,0.000046898884,0.000008591112,0.00023038611,0.000018998468,0.00027078614],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970985,0.001846905,0.0005663762,0.00016175368,0.000045150107,0.00028130919],"domain_scores_gemma":[0.9976453,0.0012461704,0.0005053509,0.0003916918,0.00017777663,0.00003367048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058315985,0.00020115319,0.00044982968,0.000047516176,0.00045721416,0.00001798495,0.00040311101,0.00015935877,0.0007630503],"category_scores_gemma":[0.00012463742,0.00010372225,0.00019031335,0.00017182164,0.0001702598,0.00012932332,0.000066313536,0.0002404643,0.00016213779],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034681312,0.0023063296,0.28175136,0.000016138461,0.0133151915,0.0002455578,0.028561752,0.00008580684,0.04175211,0.0037536891,0.15017195,0.47457197],"study_design_scores_gemma":[0.020090135,0.0032331257,0.043154906,0.0004959339,0.0051726457,0.043370336,0.049838103,0.000023624929,0.08847408,0.014652127,0.73033226,0.0011627394],"about_ca_topic_score_codex":0.000497132,"about_ca_topic_score_gemma":0.0008308929,"teacher_disagreement_score":0.58016026,"about_ca_system_score_codex":0.000041154064,"about_ca_system_score_gemma":0.00015431603,"threshold_uncertainty_score":0.83548653},"labels":[],"label_agreement":null},{"id":"W3129416935","doi":"10.1016/j.jaad.2021.02.057","title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data","year":2021,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"AbbVie","keywords":"Medicine; Discontinuation; Etanercept; Adverse effect; Psoriasis; Internal medicine; Randomized controlled trial; Certolizumab pegol; Dermatology","score_opus":0.32446007850646374,"score_gpt":0.45548821782294396,"score_spread":0.13102813931648022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129416935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018194485,0.97429013,0.00009620363,0.00038795415,0.00030458847,0.0012561603,0.005457337,0.000003856603,0.000009282495],"genre_scores_gemma":[0.0074891355,0.9891336,0.0027784177,0.00007111825,0.00008287818,0.000048912512,0.00031110353,0.000020345993,0.00006446377],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923796,0.003168103,0.0034905388,0.00054398156,0.000086270666,0.00033149382],"domain_scores_gemma":[0.98515224,0.0045458395,0.009543741,0.0005247785,0.00016184634,0.00007156805],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.001190474,0.0005253632,0.015352272,0.0003369189,0.00012153431,0.0000066866387,0.00085181586,0.00064817304,0.00003247218],"category_scores_gemma":[0.00030796704,0.0002793094,0.0030195531,0.0007348305,0.00088878087,0.00006331328,0.00042326012,0.0005265625,7.941172e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033386584,0.00076169835,0.0008541209,0.00053021684,0.6871114,0.0000078043295,0.00022251203,0.00017143495,0.000010464066,0.00039651294,0.0016230043,0.27492428],"study_design_scores_gemma":[0.01546503,0.002561538,0.0005203603,0.00035974706,0.7534277,0.0008189548,0.0002048817,0.00004550526,0.0001330361,0.00013513443,0.22592144,0.0004066736],"about_ca_topic_score_codex":0.000040619227,"about_ca_topic_score_gemma":0.00002561374,"teacher_disagreement_score":0.2745176,"about_ca_system_score_codex":0.00003097541,"about_ca_system_score_gemma":0.0003402794,"threshold_uncertainty_score":0.9999659},"labels":[],"label_agreement":null},{"id":"W3130421808","doi":"10.3899/jrheum.201682","title":"GRAPPA 2019 Research Recipient Awards Report","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Arthritis; Plaque psoriasis; Internal medicine; Dermatology; Physical therapy","score_opus":0.04217793796792082,"score_gpt":0.3165473816117732,"score_spread":0.2743694436438524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130421808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747529,0.017926686,0.00008995686,0.0028898343,0.002855925,0.000072572286,0.000006855046,0.00001149553,0.0013937614],"genre_scores_gemma":[0.9879716,0.0049968567,0.0001082761,0.000046337023,0.000019269311,0.0000032755634,0.000022302225,0.000014346441,0.0068177315],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9969168,0.0017768833,0.00063970295,0.00014914956,0.0001145336,0.00040297644],"domain_scores_gemma":[0.99752253,0.00095478154,0.0003843924,0.00045841967,0.0006456255,0.000034263037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031340255,0.00012727412,0.00044669062,0.00018085819,0.0002963191,0.0000100213865,0.00037144864,0.00022544424,0.0006462804],"category_scores_gemma":[0.0005912607,0.00007823441,0.00017552752,0.00030486358,0.00031406048,0.00005770028,0.00013099433,0.00056291197,0.00042359612],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025004311,0.0013784489,0.32092455,0.000052192878,0.004195533,0.0029533012,0.004117854,0.000023419838,0.121026024,0.006789802,0.48967752,0.046360914],"study_design_scores_gemma":[0.0048363246,0.0011713285,0.03740051,0.00023635228,0.00051441946,0.43769985,0.0026558496,0.0000011415411,0.10185905,0.005713512,0.40755746,0.00035418244],"about_ca_topic_score_codex":0.00015021763,"about_ca_topic_score_gemma":0.00008121454,"teacher_disagreement_score":0.43474656,"about_ca_system_score_codex":0.00005113291,"about_ca_system_score_gemma":0.00041789946,"threshold_uncertainty_score":0.7076317},"labels":[],"label_agreement":null},{"id":"W3132376226","doi":"10.1007/s40259-020-00464-5","title":"Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen UK; Arthritis Society; Psoriasis Association","keywords":"Medicine; Nice; Specialty; Excellence; Equity (law); Alternative medicine; Health care; Family medicine; Intensive care medicine; Political science","score_opus":0.04720052022437258,"score_gpt":0.30890214784455794,"score_spread":0.26170162762018534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132376226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311763,0.00456163,0.00014933512,0.00024044412,0.0010140666,0.00025021916,0.00023930121,0.00010038566,0.00032699917],"genre_scores_gemma":[0.99615264,0.0009103371,0.0021821728,0.000107476444,0.000035728262,0.000017415667,0.0005083261,0.000018242758,0.00006765497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538726,0.0019570098,0.0011543217,0.0007967011,0.00005563441,0.00064909743],"domain_scores_gemma":[0.9980751,0.00072213594,0.00042669568,0.0005213159,0.00017748126,0.000077253106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012520752,0.00037755346,0.0009630266,0.00015985424,0.00017614491,0.00004694411,0.00031943506,0.0007172086,0.000101676706],"category_scores_gemma":[0.0011264433,0.0003166717,0.00017851933,0.0002503299,0.0015270474,0.00007271702,0.00027264023,0.00045373174,0.000023075989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006509694,0.0004283352,0.98270833,0.000029417228,0.00021311181,0.00020080294,0.00023836696,0.00003218169,0.007272831,0.0014368697,0.00023723328,0.0065515703],"study_design_scores_gemma":[0.005753619,0.0006271364,0.97571033,0.00019433125,0.0001023676,0.00084308395,0.001510526,0.00007614058,0.012708964,0.00018635152,0.0018787652,0.00040835756],"about_ca_topic_score_codex":0.00046821465,"about_ca_topic_score_gemma":0.0008292862,"teacher_disagreement_score":0.006997954,"about_ca_system_score_codex":0.00006049621,"about_ca_system_score_gemma":0.0001862914,"threshold_uncertainty_score":0.99992853},"labels":[],"label_agreement":null},{"id":"W3134284151","doi":"10.1016/j.jaad.2021.03.005","title":"The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof","year":2021,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Aryl hydrocarbon receptor; Psoriasis; Mechanism of action; Medicine; Mechanism (biology); Scopus; Receptor; Dermatology; MEDLINE; Internal medicine; Biochemistry; Biology; Transcription factor; In vitro","score_opus":0.05483533039360631,"score_gpt":0.30972760476677896,"score_spread":0.25489227437317263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134284151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86527973,0.012927103,0.000049833678,0.11973367,0.0015714791,0.00031465554,0.00007637815,0.000007674642,0.000039500956],"genre_scores_gemma":[0.9849306,0.009093556,0.00013277975,0.0052647903,0.00017533025,0.000008786073,0.000015159898,0.0000338587,0.00034514078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955592,0.001699443,0.0018031934,0.00029053545,0.00027546083,0.00037213627],"domain_scores_gemma":[0.9889159,0.001020475,0.009307888,0.00049023126,0.00023808781,0.000027385611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054879254,0.00034563936,0.0018161401,0.00025571976,0.00010235323,0.000004140985,0.0011141927,0.0007879846,0.000063573636],"category_scores_gemma":[0.0002239612,0.0002034489,0.0006742998,0.00030000845,0.0012161537,0.00014361975,0.000183219,0.0015165374,0.0000024284097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012923728,0.00020672112,0.0030524484,0.00035899822,0.0025690938,0.00006493864,0.0004582617,0.000012635383,0.9430588,0.0001082036,0.043363165,0.005454348],"study_design_scores_gemma":[0.0007247093,0.00062084285,0.0023582012,0.0006692014,0.000978469,0.0056430567,0.00044134277,0.0000018699186,0.9727818,0.0006577149,0.014922363,0.00020046734],"about_ca_topic_score_codex":0.00007861659,"about_ca_topic_score_gemma":0.0000051428055,"teacher_disagreement_score":0.11965089,"about_ca_system_score_codex":0.00006348071,"about_ca_system_score_gemma":0.00036560986,"threshold_uncertainty_score":0.82964057},"labels":[],"label_agreement":null},{"id":"W3134953187","doi":"10.1007/s13555-021-00504-0","title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Palmoplantar pustulosis; Medicine; Placebo; Clinical endpoint; Internal medicine; Gastroenterology; Psoriasis Area and Severity Index; Multicenter trial; Placebo-controlled study; Intention-to-treat analysis; Randomized controlled trial; Surgery; Double blind; Immunology; Multicenter study; Psoriasis; Pathology","score_opus":0.0211709192181169,"score_gpt":0.2831314459354729,"score_spread":0.261960526717356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134953187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921109,0.0043014702,0.000009125676,0.00014411104,0.00047059814,0.002674454,0.00014180581,0.000040748528,0.000106766776],"genre_scores_gemma":[0.99628776,0.0020816897,0.000052572384,0.00009545582,0.000017284077,0.0002275387,0.0011049509,0.000026485073,0.00010626328],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963755,0.0016538617,0.00086091354,0.0006073368,0.00006993374,0.00043243048],"domain_scores_gemma":[0.99846375,0.0005111119,0.0003888208,0.00042805276,0.0001584298,0.000049811904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044499454,0.00040513035,0.0017374711,0.0002622606,0.00015500344,0.000020605263,0.00019183027,0.00021149422,0.00012022473],"category_scores_gemma":[0.000040123534,0.00026289158,0.00012256938,0.00019341956,0.00029704982,0.00016169592,0.00004676998,0.00022340074,0.000023430046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8484531,0.014542703,0.123417534,0.000016701484,0.0024259763,0.00013472937,0.002076642,8.5439547e-7,0.006518432,0.000029726249,0.000025167086,0.0023584384],"study_design_scores_gemma":[0.9570782,0.0031834554,0.013567674,0.000061690014,0.00035460637,0.00008710238,0.00065415545,0.0000068912723,0.024433058,0.00000971768,0.00027243485,0.0002910006],"about_ca_topic_score_codex":0.00018790174,"about_ca_topic_score_gemma":0.00028063427,"teacher_disagreement_score":0.10984986,"about_ca_system_score_codex":0.00001691069,"about_ca_system_score_gemma":0.00006971257,"threshold_uncertainty_score":0.99998236},"labels":[],"label_agreement":null},{"id":"W3135198003","doi":"10.5114/ada.2021.104295","title":"The comparison of effectiveness of therapy withustekinumab and etanercept in psoriatic patients during48 weeks’ observation","year":2021,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Etanercept; Dermatology; Psoriasis; Internal medicine; Adalimumab; Disease; Tumor necrosis factor alpha","score_opus":0.01136577918615242,"score_gpt":0.2643022042613967,"score_spread":0.2529364250752443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135198003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93084544,0.06843906,0.000013552397,0.00007509947,0.0003461638,0.00017397228,0.0000043820323,0.0000053041326,0.000097033124],"genre_scores_gemma":[0.98538387,0.014429136,0.00005796773,0.000019636682,0.0000029899663,0.000037439582,0.00004744635,0.0000057616126,0.00001575484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818295,0.00093914696,0.0004298945,0.00022585402,0.000022979139,0.0001991496],"domain_scores_gemma":[0.9982137,0.0013755487,0.00019626619,0.00014716078,0.000058871425,0.000008449987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017517465,0.00013210662,0.0005181003,0.00007706361,0.00007351026,0.0000018184829,0.00008913127,0.00021550023,0.0000083855775],"category_scores_gemma":[0.00009763533,0.000099808836,0.000028527482,0.00014490561,0.00047386414,0.00008730549,0.000053054588,0.0001282598,0.0000012849441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086781953,0.00028163378,0.94699496,0.00011289453,0.00010355744,0.00001002723,0.0008003856,0.000024157853,0.0045600045,0.0019239719,0.0000031944044,0.044317413],"study_design_scores_gemma":[0.0052097198,0.00019616519,0.94767046,0.000083613166,0.00001971618,0.000059151254,0.000522468,0.000011667984,0.043397017,0.0016714149,0.0010575408,0.00010105492],"about_ca_topic_score_codex":0.00002242817,"about_ca_topic_score_gemma":0.00067366904,"teacher_disagreement_score":0.054538433,"about_ca_system_score_codex":0.0000115543835,"about_ca_system_score_gemma":0.000028844972,"threshold_uncertainty_score":0.40700862},"labels":[],"label_agreement":null},{"id":"W3135419536","doi":"10.1093/jcag/gwab002.185","title":"A187 ASSOCIATION OF IL-17 INHIBITOR TREATMENT WITH NEW OR WORSENING INFLAMMATORY BOWEL DISEASE: A CASE SERIES","year":2021,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Colonoscopy; Inflammatory bowel disease; Gastroenterology; Internal medicine; Infliximab; Golimumab; Secukinumab; Abdominal pain; Ascending colon; Hematochezia; Ustekinumab; Adalimumab; Ileitis; Psoriatic arthritis; Crohn's disease; Arthritis; Rheumatoid arthritis; Disease; Colorectal cancer; Cancer","score_opus":0.008231383511944287,"score_gpt":0.20297869385432585,"score_spread":0.19474731034238157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135419536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928278,0.00023862401,0.0000067159685,0.0057182517,0.000803219,0.00011962443,0.00023330442,0.0000045080806,0.00004795473],"genre_scores_gemma":[0.98584116,0.00009770432,0.00012312771,0.0001880179,0.00013462506,0.000004346192,0.00002583642,0.000013457302,0.013571711],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836093,0.0005298408,0.0005437589,0.00012282208,0.00010787196,0.00033475994],"domain_scores_gemma":[0.9974279,0.00015089787,0.0016892401,0.00016901699,0.00043822278,0.0001247679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037822194,0.00015915398,0.00043533382,0.00017098273,0.00015788156,0.000013333217,0.00012131854,0.0001994423,0.00017484598],"category_scores_gemma":[0.00030425045,0.00010814627,0.00023449361,0.00012193633,0.000049046437,0.00011882124,0.000021869437,0.00016628057,0.000003950745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019727298,0.00010931167,0.98356146,0.000013532244,0.0020650139,0.00065988145,0.0006419008,0.00008539679,0.0029476958,0.00001596088,0.0073698205,0.0005572962],"study_design_scores_gemma":[0.019909741,0.0052966527,0.90863836,0.00040707484,0.003516337,0.008105482,0.0012973626,0.0000050185754,0.019142604,0.00009974825,0.03327423,0.00030737754],"about_ca_topic_score_codex":0.0017705883,"about_ca_topic_score_gemma":0.4895031,"teacher_disagreement_score":0.4877325,"about_ca_system_score_codex":0.0016970092,"about_ca_system_score_gemma":0.0017119747,"threshold_uncertainty_score":0.51981217},"labels":[],"label_agreement":null},{"id":"W3135562600","doi":"10.1002/cti2.1262","title":"The IL‐27/IL‐27R axis is altered in CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes from multiple sclerosis patients","year":2021,"lang":"en","type":"article","venue":"Clinical & Translational Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Multiple Sclerosis Society of Canada","keywords":"Multiple sclerosis; CD8; Physics; Medicine; Immunology; Immune system","score_opus":0.051024306869859815,"score_gpt":0.27906458791006655,"score_spread":0.22804028104020674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135562600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97465646,0.019531073,0.000054380052,0.0022439477,0.001102191,0.00042984285,0.0017410587,0.00007180338,0.0001692626],"genre_scores_gemma":[0.98903316,0.0063008512,0.0004461081,0.0007698098,0.0001646709,0.00008429117,0.002441665,0.0000489309,0.0007104947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951453,0.0014392164,0.0014721188,0.001061975,0.0001251322,0.00075623335],"domain_scores_gemma":[0.9926508,0.0060945414,0.00024503184,0.0006896263,0.0002451577,0.00007482709],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000528983,0.0004956223,0.00089272443,0.00013218727,0.0005412357,0.000056849138,0.00046377393,0.0010274901,0.00091550493],"category_scores_gemma":[0.0006007209,0.00041025446,0.00044562036,0.00032759696,0.0009952162,0.00020444217,0.00016493855,0.0006196074,0.0006562842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003178949,0.0017800959,0.7688246,0.000016216118,0.0027447604,0.000022798691,0.002641722,0.00017107352,0.008363938,0.0004472704,0.0017166787,0.21009192],"study_design_scores_gemma":[0.02063104,0.0005315052,0.90863746,0.0001131673,0.0003687082,0.000023644721,0.00062044634,0.0006797888,0.006861915,0.0022511564,0.058635943,0.0006452096],"about_ca_topic_score_codex":0.0003271559,"about_ca_topic_score_gemma":0.00023783803,"teacher_disagreement_score":0.20944671,"about_ca_system_score_codex":0.00007839997,"about_ca_system_score_gemma":0.00029498065,"threshold_uncertainty_score":0.9999978},"labels":[],"label_agreement":null},{"id":"W3136746007","doi":"10.3899/jrheum.201673","title":"Pustular Psoriasis and Associated Musculoskeletal Disorders","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"LEO Pharma; Astellas Pharma; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Biogen; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Palmoplantar pustulosis; Pustulosis; Medicine; Dermatology; Psoriatic arthritis; Psoriasis; Hyperostosis; Pustular psoriasis; Synovitis; Generalized pustular psoriasis; Arthritis; Chronic recurrent multifocal osteomyelitis; SAPHO syndrome; Osteomyelitis; Osteitis; Immunology; Surgery","score_opus":0.008499229766004346,"score_gpt":0.23005451706212407,"score_spread":0.22155528729611973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136746007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98191464,0.015097169,0.000072289506,0.0014284971,0.0011675289,0.00004778946,0.000007266191,0.000012498735,0.0002523017],"genre_scores_gemma":[0.99195004,0.007523594,0.000043708384,0.00004819816,0.0000058593423,0.0000015355357,0.000013036614,0.000011217045,0.0004027954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845225,0.00079949293,0.00036260585,0.00010239047,0.000040560833,0.0002427081],"domain_scores_gemma":[0.998842,0.00053819234,0.0003160581,0.00016232472,0.00011683309,0.000024594268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005201584,0.0001376034,0.00040382487,0.00007213512,0.00018864733,0.000007724935,0.0001679642,0.00019983202,0.0002870605],"category_scores_gemma":[0.00034116907,0.00008904087,0.00015462229,0.00013674363,0.00019562042,0.000064576474,0.00006684208,0.00023792834,0.000046803765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009442583,0.000945701,0.76953596,0.000072164104,0.008111442,0.000086191605,0.0039489996,0.000020310777,0.035933904,0.0035817812,0.012506172,0.16431311],"study_design_scores_gemma":[0.04019829,0.003509386,0.69159776,0.00052921753,0.007974114,0.07669355,0.014081469,0.000024100591,0.03356166,0.016719643,0.11329675,0.0018140803],"about_ca_topic_score_codex":0.00006557195,"about_ca_topic_score_gemma":0.00020329774,"teacher_disagreement_score":0.16249903,"about_ca_system_score_codex":0.000020830328,"about_ca_system_score_gemma":0.000083739,"threshold_uncertainty_score":0.36309814},"labels":[],"label_agreement":null},{"id":"W3137009934","doi":"10.1016/j.nrl.2020.12.007","title":"Association between psoriasis and dementia: A systematic review","year":2021,"lang":"en","type":"review","venue":"Neurología","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Dementia; Medicine; Disease; Risk factor; Dermatology; Internal medicine","score_opus":0.032546395721346405,"score_gpt":0.2828716174126878,"score_spread":0.2503252216913414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137009934","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000014793815,0.9969714,0.0000016408867,0.000114046576,0.00084334286,0.001587167,0.00018754267,0.00007938006,0.000200633],"genre_scores_gemma":[0.0000070798806,0.9959807,0.000009466224,0.00028619234,0.00009449528,0.0004954873,0.0010269451,0.000046167454,0.002053513],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563444,0.0023478272,0.0009348931,0.00061372505,0.00007139062,0.00039772064],"domain_scores_gemma":[0.99731636,0.0011148606,0.0009490246,0.0005190014,0.000067208326,0.000033566128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006781081,0.0005132255,0.0040879184,0.00012785468,0.0001526395,0.000029524452,0.00026075984,0.0009153521,0.00023713175],"category_scores_gemma":[0.0006354072,0.00039081674,0.0006393135,0.00027028672,0.000031713163,0.000047464448,0.00015382076,0.00044300882,0.0006692538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000016247021,0.000044203534,0.00016810461,0.73636836,0.009089493,0.000033894903,0.000011937272,2.1150757e-9,9.4059783e-7,0.000019341847,0.006430828,0.24783128],"study_design_scores_gemma":[0.00026794773,0.00007934523,0.000024172601,0.1545041,0.073000506,0.000106214284,0.0000014915846,6.264767e-9,0.0000026431412,0.00000412896,0.77173775,0.00027168],"about_ca_topic_score_codex":0.000005559596,"about_ca_topic_score_gemma":0.0000030800684,"teacher_disagreement_score":0.76530695,"about_ca_system_score_codex":0.00007028114,"about_ca_system_score_gemma":0.00009478949,"threshold_uncertainty_score":0.9998544},"labels":[],"label_agreement":null},{"id":"W3137197107","doi":"10.1016/j.abdp.2019.04.005","title":"10.1016/j.abdp.2019.04.005","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Political science; Geography; Medicine; Art","score_opus":0.007002707580471679,"score_gpt":0.17883656964416433,"score_spread":0.17183386206369267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137197107","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008618982,0.0012907822,3.0239488e-7,0.00018518441,0.000011902425,0.00019392167,0.00008643476,0.00017411655,0.98943835],"genre_scores_gemma":[0.0008246538,0.000002648531,0.000039714334,0.000046118577,0.00007703528,0.000029232471,0.00019615122,0.00002277129,0.99876165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990736,0.00009710757,0.00017031986,0.0002743861,0.000028091321,0.00035648714],"domain_scores_gemma":[0.9995187,0.00006410113,0.000029382514,0.0003247777,0.00002126477,0.000041782867],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000096095006,0.00018788247,0.00022898531,0.00007528844,0.00013253298,0.000013362093,0.0002073765,0.00018567975,0.9977336],"category_scores_gemma":[0.000013716284,0.00016541778,0.000103524246,0.0001341708,0.000048849015,0.000058614543,0.000034198118,0.00008961059,0.9986662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002240046,0.00008495868,8.3616277e-7,0.0000016329876,0.00011907005,0.0000052867504,0.000022116237,0.00000327246,0.0027799879,0.0000013608668,0.332946,0.66381145],"study_design_scores_gemma":[0.0008009515,0.00021660978,0.00023017921,0.000010191633,0.000083001694,0.00003159263,0.0000012443204,7.554454e-7,0.0049833916,0.0000055881364,0.99343866,0.00019784071],"about_ca_topic_score_codex":0.000034632103,"about_ca_topic_score_gemma":4.6335865e-7,"teacher_disagreement_score":0.6636136,"about_ca_system_score_codex":0.000028110906,"about_ca_system_score_gemma":0.000026178703,"threshold_uncertainty_score":0.6745541},"labels":[],"label_agreement":null},{"id":"W3137718344","doi":"10.1111/dth.14944","title":"Investigation of prevalence of biologic use and discontinuation rates in moderate‐to‐severe psoriasis patients in Newfoundland and Labrador using real‐world data","year":2021,"lang":"en","type":"article","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Newfoundland and Labrador Centre for Applied Health Research","funders":"","keywords":"Discontinuation; Medicine; Psoriasis; Adverse effect; Retrospective cohort study; Internal medicine; Cohort; Pediatrics; Dermatology","score_opus":0.08056164782187028,"score_gpt":0.2902843453685043,"score_spread":0.209722697546634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137718344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99739873,0.0019888396,0.000009649547,0.0000784315,0.0000822111,0.0002768881,0.0001515564,0.000008205903,0.0000054738425],"genre_scores_gemma":[0.99542284,0.0035422365,0.00059808674,0.000061499384,0.0000030338347,0.000010172157,0.0003239121,0.000005564241,0.00003264093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874526,0.000437175,0.0003367689,0.00031174114,0.000026079344,0.00014298831],"domain_scores_gemma":[0.9992737,0.0002276919,0.00017630898,0.0002446308,0.00006325916,0.000014381273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016720277,0.00013158473,0.0003388096,0.00016198667,0.00003587349,0.000013054769,0.00010182196,0.000102243044,0.0000109444145],"category_scores_gemma":[0.000091891896,0.0001046796,0.000014832914,0.00029651215,0.00013011445,0.00024339523,0.00008274596,0.00005796131,7.3253807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028681185,0.0000853471,0.962996,0.000033946555,0.000039736384,0.000003474545,0.0006071604,0.0000091723705,0.028905774,0.00007391198,0.000010832281,0.0069478084],"study_design_scores_gemma":[0.0021913068,0.000079725396,0.9641081,0.00008168648,0.000020134821,0.000009151619,0.000083600295,0.00007811557,0.03298473,0.00024029522,0.000018612427,0.0001045608],"about_ca_topic_score_codex":0.0021926397,"about_ca_topic_score_gemma":0.0063763545,"teacher_disagreement_score":0.0068432475,"about_ca_system_score_codex":0.000020486399,"about_ca_system_score_gemma":0.000036483398,"threshold_uncertainty_score":0.42687103},"labels":[],"label_agreement":null},{"id":"W3137782610","doi":"10.3899/jrheum.201671","title":"Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting","year":2021,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Pandemic; Telehealth; Context (archaeology); Disease; Coronavirus disease 2019 (COVID-19); Telemedicine; Health care; Family medicine; Physical therapy; Dermatology; Infectious disease (medical specialty); Internal medicine","score_opus":0.020524030759491906,"score_gpt":0.2552063295272491,"score_spread":0.23468229876775717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137782610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9375692,0.052026402,0.000021423399,0.009112589,0.0009686271,0.00016857225,0.00009483851,0.0000060346983,0.00003230486],"genre_scores_gemma":[0.9791248,0.019591965,0.000023600353,0.0011737843,0.000025057703,0.0000073858632,0.000011183637,0.0000098343,0.00003241713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99485403,0.003933357,0.00071629765,0.00015043329,0.0000937943,0.00025207156],"domain_scores_gemma":[0.9934352,0.0053389687,0.0007259061,0.00036909065,0.00010411581,0.000026696627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017950748,0.00018134672,0.0005577485,0.000043485583,0.00038967901,0.000011830798,0.00059257954,0.00021347431,0.00011729684],"category_scores_gemma":[0.00111415,0.00007440912,0.00017596764,0.00025023962,0.00045421143,0.00006873271,0.00016427554,0.0005018954,0.0000074347986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015133123,0.00025892028,0.8544473,0.000038911105,0.0012380142,0.00006673849,0.054474674,0.000019910047,0.010110748,0.0007098861,0.017346343,0.05977526],"study_design_scores_gemma":[0.039569844,0.0014009449,0.38970223,0.0022622924,0.003076339,0.113006204,0.3274753,0.000030624433,0.013932149,0.019826476,0.08869089,0.0010266893],"about_ca_topic_score_codex":0.0011580236,"about_ca_topic_score_gemma":0.0024028088,"teacher_disagreement_score":0.46474504,"about_ca_system_score_codex":0.000029874729,"about_ca_system_score_gemma":0.0002731148,"threshold_uncertainty_score":0.3034316},"labels":[],"label_agreement":null},{"id":"W3138450947","doi":"10.2147/ptt.s303634","title":"Phosphodiesterase-4 Inhibition in Psoriasis","year":2021,"lang":"en","type":"review","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University; University of Toronto","funders":"","keywords":"Apremilast; Psoriasis; Roflumilast; Medicine; Phosphodiesterase; Pharmacology; Adenosine monophosphate; Phosphodiesterase inhibitor; Adverse effect; Adenosine; Atopic dermatitis; Cyclic adenosine monophosphate; Dermatology; Internal medicine; Enzyme; Chemistry; Psoriatic arthritis; Biochemistry","score_opus":0.03911721463802153,"score_gpt":0.2921043110875625,"score_spread":0.252987096449541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138450947","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010905308,0.9946741,0.0000049764685,0.00004037579,0.0025083164,0.0008268528,0.00022564974,0.00008707757,0.0005421075],"genre_scores_gemma":[0.0002346536,0.99603504,0.00008696439,0.00009857407,0.00025606144,0.00047165557,0.001654418,0.00009862721,0.001064005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653536,0.0007987046,0.00091180176,0.0010069903,0.000077532684,0.0006696323],"domain_scores_gemma":[0.9985594,0.00038743851,0.00038240105,0.00054221525,0.000067905574,0.000060641964],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004380324,0.0008937303,0.002688526,0.00041806843,0.00022969117,0.000077049815,0.00016429226,0.0010563323,0.0010182139],"category_scores_gemma":[0.000046130735,0.00069937966,0.0006662707,0.0004802562,0.00012787376,0.00014372412,0.0001015306,0.00047626405,0.0002479406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006583654,0.00033377064,0.0000426533,0.0006175156,0.0009648868,0.00009888205,0.0003173791,8.082051e-8,0.0000249939,0.00028708918,0.0011066158,0.9961403],"study_design_scores_gemma":[0.002892745,0.00013959996,0.0000527685,0.0027617323,0.0005083878,0.00014491724,0.00006816753,8.8922974e-8,0.000526188,0.00012165372,0.99208206,0.0007016826],"about_ca_topic_score_codex":0.0001249271,"about_ca_topic_score_gemma":0.00004244468,"teacher_disagreement_score":0.99543864,"about_ca_system_score_codex":0.000111373156,"about_ca_system_score_gemma":0.00017988753,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W3139309195","doi":"10.3389/fmed.2020.625755","title":"Biologic Drug Survival in Psoriasis: A Systematic Review &amp; Comparative Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Ustekinumab; Medicine; Secukinumab; Adalimumab; Etanercept; Infliximab; Ixekizumab; Hazard ratio; Internal medicine; Psoriatic arthritis; Discontinuation; Oncology; Confidence interval; Arthritis; Disease; Tumor necrosis factor alpha","score_opus":0.15586759853353974,"score_gpt":0.3686177466908827,"score_spread":0.21275014815734297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139309195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000018390369,0.993744,0.0001331105,0.0001682767,0.0024564632,0.0028832431,0.00017234262,0.000042141102,0.00039855295],"genre_scores_gemma":[0.000008501515,0.9875235,0.00037254294,0.00017527306,0.000062768275,0.001812964,0.004425939,0.00003359012,0.0055849054],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98693895,0.008399275,0.0027758158,0.0011092981,0.0001576072,0.000619034],"domain_scores_gemma":[0.9961883,0.0011091904,0.0012668923,0.0012694637,0.000110441295,0.00005572408],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036528877,0.0010642052,0.029520847,0.0015468935,0.000076890115,0.0000099501285,0.0007826168,0.0006788235,0.0013754424],"category_scores_gemma":[0.0006910164,0.0006141269,0.0033255757,0.003643272,0.00028865278,0.000052944386,0.00012048725,0.00079248997,0.00023646644],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021949128,0.0002853562,0.00009069103,0.47868603,0.4731337,0.00014626028,0.0007554597,0.0000012885813,2.8790052e-7,0.00005656322,0.035956156,0.010866221],"study_design_scores_gemma":[0.00058381696,0.000034512115,0.0000036337547,0.11441789,0.60209256,0.00002491651,0.00042278186,1.9856722e-7,2.7288368e-7,0.000016161131,0.28198516,0.0004180995],"about_ca_topic_score_codex":0.00017613971,"about_ca_topic_score_gemma":0.0005414795,"teacher_disagreement_score":0.36426815,"about_ca_system_score_codex":0.0002968562,"about_ca_system_score_gemma":0.00018599961,"threshold_uncertainty_score":0.999631},"labels":[],"label_agreement":null},{"id":"W3142156858","doi":"10.1016/j.mjafi.2020.12.019","title":"An observational study on ocular manifestations in patients of psoriasis in a tertiary care hospital in western India","year":2021,"lang":"en","type":"article","venue":"Medical Journal Armed Forces India","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Association of Faculties of Medicine of Canada","keywords":"Medicine; Blepharitis; Psoriasis; Dermatology; Uveitis; Observational study; Ophthalmology; Psoriatic arthritis; Internal medicine","score_opus":0.018964518889339733,"score_gpt":0.2845678064592643,"score_spread":0.2656032875699246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3142156858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840933,0.00038702134,0.000004173663,0.00010883175,0.00069665705,0.00028365006,0.00004194458,0.00000659662,0.00006181761],"genre_scores_gemma":[0.9992968,0.00007001698,0.00003326978,0.00014491116,0.000046921778,0.000039262122,0.0003357496,0.000012949366,0.000020155152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978655,0.00062694156,0.00068463146,0.00026138432,0.00024400197,0.0003175645],"domain_scores_gemma":[0.9992956,0.00019435355,0.0001788312,0.00016377486,0.00009526713,0.00007221035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003899845,0.00017403936,0.00032425145,0.0003914914,0.000070817616,0.000014066859,0.00026346778,0.00025832883,0.00024187216],"category_scores_gemma":[0.00025857755,0.00014978292,0.00007814689,0.00031362605,0.00007218633,0.000174728,0.00005048594,0.00052964315,0.000018473665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012216133,0.0029801147,0.9645669,0.000012519754,0.00010195742,0.0009519699,0.01678456,0.000013414561,0.000088329085,0.00001519865,0.000012182758,0.014350707],"study_design_scores_gemma":[0.007199836,0.0007235335,0.9842864,0.00019143842,0.000034729735,0.000029873861,0.006741101,0.0000016317781,0.00055041496,0.00006979113,0.00003171532,0.00013952723],"about_ca_topic_score_codex":0.000068394926,"about_ca_topic_score_gemma":0.0005837409,"teacher_disagreement_score":0.01971952,"about_ca_system_score_codex":0.0001433931,"about_ca_system_score_gemma":0.00028388604,"threshold_uncertainty_score":0.61079705},"labels":[],"label_agreement":null},{"id":"W3143775625","doi":"10.1007/s40257-021-00598-4","title":"Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Hamilton Health Sciences; University of Toronto; Lynde Centre for Dermatology; McMaster University","funders":"","keywords":"Medicine; Secukinumab; Ixekizumab; Ustekinumab; Psoriatic arthritis; Internal medicine; Retrospective cohort study; Psoriasis; Hazard ratio; Proportional hazards model; Oncology; Dermatology; Adalimumab; Confidence interval; Disease","score_opus":0.028362322672536147,"score_gpt":0.32671167242351506,"score_spread":0.29834934975097893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143775625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936275,0.0018101871,0.00013573395,0.0005925316,0.0027063517,0.0006584085,0.00037188662,0.000022452341,0.000074974814],"genre_scores_gemma":[0.9959959,0.002157049,0.00092245964,0.00011503502,0.0002070527,0.00004003397,0.000078163364,0.000038159553,0.00044616722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946505,0.0018729651,0.0022013483,0.00060119707,0.0001329188,0.0005411166],"domain_scores_gemma":[0.99372697,0.003151583,0.0019599413,0.0004160522,0.00059466,0.00015080377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009503806,0.00041818141,0.0027561544,0.00023880451,0.00018575253,0.00001775069,0.00026250567,0.0002881152,0.000049156963],"category_scores_gemma":[0.0014004408,0.00033156332,0.0006552505,0.00038421774,0.0011850533,0.00011773274,0.00009975457,0.00039274638,0.000021032636],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023023067,0.0038590236,0.9593765,0.000017158543,0.0050280555,0.00035115652,0.0010332717,0.000002615436,0.0005312237,0.000063469495,0.0008511617,0.026584035],"study_design_scores_gemma":[0.028407179,0.0053521655,0.9340799,0.00005644003,0.0034875611,0.0014756832,0.007579342,0.000019403366,0.0064153178,0.000053785425,0.012613181,0.0004600832],"about_ca_topic_score_codex":0.0001766648,"about_ca_topic_score_gemma":0.00042721993,"teacher_disagreement_score":0.02612395,"about_ca_system_score_codex":0.00009102833,"about_ca_system_score_gemma":0.00042421467,"threshold_uncertainty_score":0.99991363},"labels":[],"label_agreement":null},{"id":"W314487992","doi":"10.1038/ncomms8001","title":"Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci","year":2015,"lang":"en","type":"review","venue":"Nature Communications","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":199,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital; University of Toronto; Centre for Addiction and Mental Health","funders":"European Regional Development Fund; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Medical Research Council; National Institutes of Health; Exzellenzclusters Entzündungsforschung; Tartu Ülikool; Deutsche Forschungsgemeinschaft; Heinz Nixdorf Stiftung; National Institute for Health and Care Research; Bundesministerium für Bildung und Forschung; U.S. Department of Veterans Affairs; King's College London; Psoriasis Association; Wellcome Trust","keywords":"Genome-wide association study; Biology; Genetics; Psoriasis; Imputation (statistics); Genetic architecture; Genetic association; Computational biology; Disease; Meta-analysis; Human genetics; Population; Locus (genetics); Genome; Genotype; Evolutionary biology; Gene; Quantitative trait locus; Single-nucleotide polymorphism; Medicine; Immunology","score_opus":0.19268016184294515,"score_gpt":0.43548016074957124,"score_spread":0.2427999989066261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W314487992","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024732137,0.99713093,0.0000406139,0.00047403673,0.0002854855,0.0010243458,0.0005525372,0.00011925809,0.00034803792],"genre_scores_gemma":[0.0016817809,0.9833749,0.001134092,0.000057400168,0.00004994688,0.0005537069,0.006266166,0.00003599216,0.0068460493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957966,0.0019112803,0.00091816776,0.0009874151,0.00009312091,0.0002933666],"domain_scores_gemma":[0.9904347,0.0014202701,0.0008795109,0.006621252,0.00057364354,0.00007063679],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012205223,0.0006149479,0.0039370125,0.00047845757,0.00048459665,0.000046352976,0.0015355097,0.0016228895,0.00015971213],"category_scores_gemma":[0.0008654634,0.00045047817,0.002137836,0.0014236016,0.00038307367,0.00012999613,0.0008111518,0.0012679,0.00025827976],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012091457,0.00015171604,0.000010688639,0.00039878173,0.33514208,4.6018027e-7,0.00061288336,1.8053323e-7,0.000016613458,0.00065333757,0.013363832,0.64963734],"study_design_scores_gemma":[0.00018938907,0.000022861113,0.000049789312,0.00004773205,0.38444984,0.000008470078,0.00010924508,9.9824184e-8,0.00003609252,0.00019980337,0.6146276,0.00025905977],"about_ca_topic_score_codex":0.000137415,"about_ca_topic_score_gemma":0.002271661,"teacher_disagreement_score":0.6493783,"about_ca_system_score_codex":0.00022525883,"about_ca_system_score_gemma":0.0003047294,"threshold_uncertainty_score":0.9997947},"labels":[],"label_agreement":null},{"id":"W3152655764","doi":"10.1007/s13555-021-00518-8","title":"Psoriasis Prevalence and Severity by Expert Elicitation","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Université Laval; BC Children's Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; Dermatrials Research; Ottawa Hospital; Lynde Centre for Dermatology; University of Alberta; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Novartis Pharmaceuticals Canada; LEO Pharma; AbbVie","keywords":"Psoriasis; Medicine; Population; Confidence interval; Credible interval; Expert elicitation; Estimation; Body surface area; Epidemiology; Disease; Demography; Statistics; Internal medicine; Dermatology; Environmental health; Mathematics","score_opus":0.014126296446566627,"score_gpt":0.24875321946604367,"score_spread":0.23462692301947705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152655764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8636046,0.13463251,0.00004898813,0.0010561809,0.0002787181,0.0000780386,0.000027271544,0.00003697928,0.00023669546],"genre_scores_gemma":[0.9490857,0.049228095,0.000082396604,0.000880024,0.00001367535,0.00003272694,0.00010467124,0.000007740297,0.00056494627],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991822,0.0002461686,0.00012647017,0.00025576426,0.000015230227,0.00017414913],"domain_scores_gemma":[0.999635,0.0001413083,0.0000411314,0.00012852336,0.000034271463,0.000019783229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049955328,0.00012895328,0.00019713353,0.000028212151,0.000195396,0.000011106518,0.000045322704,0.00022368257,0.00022878424],"category_scores_gemma":[0.000015810405,0.000113021844,0.000030486732,0.00005674474,0.00014517449,0.00007655222,0.000021759231,0.000074418946,0.000032023057],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005010066,0.0003689441,0.17148231,0.000056811365,0.0008048026,0.000090128146,0.0034951053,4.5859558e-8,0.27792126,0.0020042988,0.014024165,0.52925116],"study_design_scores_gemma":[0.0055553243,0.00011327222,0.12977867,0.000026064537,0.00007784094,0.0024807886,0.00036166888,0.0000043505797,0.6152636,0.0020492636,0.24387452,0.00041466448],"about_ca_topic_score_codex":0.000015237387,"about_ca_topic_score_gemma":0.000005112402,"teacher_disagreement_score":0.5288365,"about_ca_system_score_codex":0.000004307691,"about_ca_system_score_gemma":0.000018536926,"threshold_uncertainty_score":0.4608897},"labels":[],"label_agreement":null},{"id":"W3152891451","doi":"10.1177/12034754211007852","title":"Response to Reader Comment on “Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis”","year":2021,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Bausch Health (Canada); Health Canada","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Meta-analysis; Dermatology; MEDLINE; Intensive care medicine; Internal medicine","score_opus":0.07801014899214326,"score_gpt":0.28375970306727,"score_spread":0.20574955407512674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152891451","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024947505,0.013891499,0.0001088007,0.9578685,0.0020147245,0.0006148701,0.00044317808,0.000010234935,0.00010065858],"genre_scores_gemma":[0.055232942,0.0009780428,0.00036683498,0.9329888,0.0026004247,0.00006818451,0.0007448289,0.000095031246,0.006924876],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960164,0.001230235,0.0014121198,0.00044969915,0.00021786953,0.0006736697],"domain_scores_gemma":[0.9904345,0.0075281756,0.00078891614,0.0004984018,0.00051404245,0.00023595623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018247496,0.0005270836,0.0040331697,0.0015300326,0.0001893221,0.000021564785,0.00023726083,0.00076866586,0.000609689],"category_scores_gemma":[0.0008504595,0.00036661283,0.0016588658,0.000572825,0.00007369847,0.000029963938,0.000030345898,0.000729878,0.000010494248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008367518,0.0000611785,0.00003474125,0.000046379875,0.0956,0.002918429,0.00064773654,0.0006226415,0.00014755661,0.0000038757594,0.89031017,0.0012397923],"study_design_scores_gemma":[0.0011253908,0.0011985278,0.00006316091,0.00026505577,0.090756536,0.0022941558,0.00017312325,0.0000014245395,0.00021259635,0.000030086685,0.9035387,0.00034121532],"about_ca_topic_score_codex":0.0023295577,"about_ca_topic_score_gemma":0.0022595753,"teacher_disagreement_score":0.030285437,"about_ca_system_score_codex":0.00016528343,"about_ca_system_score_gemma":0.00081076357,"threshold_uncertainty_score":0.9998786},"labels":[],"label_agreement":null},{"id":"W3153100789","doi":"10.1016/j.jid.2021.02.650","title":"621 Development of a tissue-engineered immunocompetent psoriatic skin model for the study of communication between T cells and pathological epithelial cells","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Psoriasis; Immune system; Chemokine; Immunology; Inflammation; CXCL1; Interleukin 17; Pathogenesis; CXCL10; Interleukin 8; Medicine; Pathological; Biology; Pathology","score_opus":0.041033423648411685,"score_gpt":0.2645101319945247,"score_spread":0.22347670834611305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153100789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917163,0.0034629803,0.0038397408,0.00030906292,0.00017651317,0.00042265197,0.000060854887,0.0000044313542,0.000007454184],"genre_scores_gemma":[0.9888248,0.00020036819,0.010817023,0.000029435048,0.000013153403,0.000030807983,0.000022701373,0.000010464325,0.000051283678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795437,0.00068193243,0.00097606314,0.00014223908,0.000064582295,0.0001807909],"domain_scores_gemma":[0.99739945,0.0010939386,0.0008293722,0.00024475236,0.00040079045,0.000031684056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044498272,0.00017813304,0.0007289491,0.00010323864,0.0001545501,0.0000061003484,0.00028464213,0.00017707738,0.000011835222],"category_scores_gemma":[0.00012520592,0.00011966222,0.000104714,0.000117949814,0.00032135486,0.000055086308,0.00011806176,0.00021579617,0.0000025472311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016542654,0.0005449611,0.00067683915,0.000054875836,0.0014096336,0.000013305477,0.014857647,0.0003184025,0.9757356,0.00020957922,0.00015744154,0.005856272],"study_design_scores_gemma":[0.0031919628,0.0003538989,0.012197346,0.00004190881,0.00049399206,0.00013970865,0.0025147118,0.00011062829,0.9798112,0.00076441607,0.0002728054,0.00010740807],"about_ca_topic_score_codex":0.0000054532866,"about_ca_topic_score_gemma":0.000013419977,"teacher_disagreement_score":0.0123429345,"about_ca_system_score_codex":0.00003111869,"about_ca_system_score_gemma":0.00025097321,"threshold_uncertainty_score":0.48796836},"labels":[],"label_agreement":null},{"id":"W3154018763","doi":"10.1186/s12974-021-02146-7","title":"STEAP4 expression in CNS resident cells promotes Th17 cell-induced autoimmune encephalomyelitis","year":2021,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; Case Western Reserve University; National Institutes of Health; School of Medicine, Case Western Reserve University; National Multiple Sclerosis Society","keywords":"Experimental autoimmune encephalomyelitis; Encephalomyelitis; Neurology; Multiple sclerosis; Immunology; Neuroscience; Medicine; Biology","score_opus":0.01733661683965507,"score_gpt":0.23442762863811098,"score_spread":0.2170910117984559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154018763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610615,0.0016437476,0.00003250157,0.00033915672,0.001225267,0.00014373999,0.00000499365,0.000016293736,0.00048817793],"genre_scores_gemma":[0.9980596,0.000452201,0.00025728377,0.00001071768,0.00009830928,0.0000050712974,0.000022008882,0.000015125889,0.0010797294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982847,0.0005125665,0.0006965065,0.00018258125,0.00009754144,0.00022610558],"domain_scores_gemma":[0.9988678,0.00017029313,0.0005427506,0.00021826166,0.00017441464,0.000026450056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003147347,0.00016058914,0.000314587,0.00020474907,0.00009848581,0.000032949698,0.00015571168,0.0001674332,0.00027911706],"category_scores_gemma":[0.000113147835,0.00013749505,0.0001453917,0.00018755201,0.000021901302,0.00031461124,0.00005024726,0.00028111425,0.00009382949],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012925851,0.0001229861,0.00056857883,0.000024515633,0.000027598904,0.00038416966,0.0011507875,0.000041313113,0.9858838,0.000011126026,0.0002688335,0.0113870585],"study_design_scores_gemma":[0.0017627623,0.00021325352,0.08569684,0.00015861158,0.000048197755,0.00027636805,0.00032629276,0.000006101558,0.9102915,0.00010908183,0.0010020318,0.00010897816],"about_ca_topic_score_codex":0.000011103059,"about_ca_topic_score_gemma":0.000015874148,"teacher_disagreement_score":0.08512826,"about_ca_system_score_codex":0.00006401695,"about_ca_system_score_gemma":0.0001691249,"threshold_uncertainty_score":0.56068856},"labels":[],"label_agreement":null},{"id":"W3154114083","doi":"10.2196/26673","title":"Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study","year":2021,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Syddansk Universitet; Odense Universitetshospital","keywords":"mHealth; Psoriasis; Participatory design; Citizen journalism; Smartphone app; Mobile apps; Medicine; Computer science; Internet privacy; World Wide Web; Engineering; Nursing; Dermatology; Operations management; Psychological intervention","score_opus":0.08091320830308568,"score_gpt":0.31330514492025524,"score_spread":0.23239193661716956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154114083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99691254,0.0004657292,0.00080841855,0.00002843775,0.00027131021,0.0013469855,0.00004162465,0.00007948579,0.000045484157],"genre_scores_gemma":[0.99098647,0.000022317638,0.0071595856,0.000041684278,0.000014387455,0.001128556,0.0005453844,0.000023896957,0.00007771824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775934,0.00068126014,0.0005097605,0.00050415704,0.000043169017,0.00050228694],"domain_scores_gemma":[0.99878234,0.0004532439,0.00021593616,0.00033978812,0.00015177573,0.000056942332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012571535,0.0002893298,0.0006409451,0.000103543345,0.00029429814,0.000007719225,0.00013818161,0.00027090948,0.00009022788],"category_scores_gemma":[0.000034349057,0.0002080065,0.00007206226,0.00014975923,0.000108115775,0.000070217764,0.000041132465,0.00006419198,0.000048011163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070816344,0.030670056,0.77632576,0.00019134901,0.004697797,0.00018642376,0.016154412,0.000023017335,0.008903703,0.0006973973,0.00032495012,0.15474352],"study_design_scores_gemma":[0.054838557,0.013353558,0.6651871,0.00007959041,0.0011309166,0.00028090982,0.008053738,0.00001426233,0.23844601,0.00019408567,0.017200122,0.0012211157],"about_ca_topic_score_codex":0.0000057296133,"about_ca_topic_score_gemma":0.00016488564,"teacher_disagreement_score":0.22954232,"about_ca_system_score_codex":0.00008825379,"about_ca_system_score_gemma":0.00055273797,"threshold_uncertainty_score":0.8482259},"labels":[],"label_agreement":null},{"id":"W3156084043","doi":"10.1016/s0140-6736(21)00440-2","title":"IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Placebo; Medicine; Dermatology; Psoriasis; Internal medicine; Pathology; Alternative medicine","score_opus":0.01441938214759182,"score_gpt":0.25062958684544784,"score_spread":0.23621020469785603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156084043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940517,0.0016835524,0.000012326245,0.0003523958,0.0006100323,0.0023124435,0.00010402561,0.00006938645,0.000804121],"genre_scores_gemma":[0.99755913,0.000097982454,0.00006327311,0.00020004311,0.00014365252,0.00050304155,0.00020522145,0.000027105765,0.0012005363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99749666,0.0010348473,0.00039712657,0.000426909,0.000088488836,0.0005559401],"domain_scores_gemma":[0.99853194,0.00048903236,0.00017163061,0.0006828265,0.000096486394,0.000028081757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005093872,0.00031441954,0.0010768585,0.00007702993,0.00021127026,0.000035320976,0.00032524456,0.00013845538,0.00037325633],"category_scores_gemma":[0.00015247676,0.00018419685,0.00012625365,0.00024537844,0.000073401665,0.00008591119,0.00007608674,0.00025418302,0.00026212278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72955865,0.012194016,0.22076413,0.000031476262,0.0044092117,0.00023479055,0.0071672867,0.00005129946,0.0029655898,0.000096245,0.0038029032,0.018724393],"study_design_scores_gemma":[0.9428602,0.0006469114,0.048275612,0.000054650365,0.0007365039,0.000011697466,0.0017314663,0.0000105030695,0.0030190889,0.00002394874,0.002317353,0.0003121011],"about_ca_topic_score_codex":0.00006619674,"about_ca_topic_score_gemma":0.00039386874,"teacher_disagreement_score":0.21330151,"about_ca_system_score_codex":0.000057081637,"about_ca_system_score_gemma":0.000095072515,"threshold_uncertainty_score":0.75113297},"labels":[],"label_agreement":null},{"id":"W3157445152","doi":"10.1093/rheumatology/keab247.166","title":"P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Internal medicine; Rheumatoid arthritis; Clinical endpoint; Psoriatic arthritis; Adverse effect; Certolizumab pegol; Placebo; Psoriasis Area and Severity Index; Randomized controlled trial; Tolerability; Physical therapy; Adalimumab; Immunology","score_opus":0.02011007499670484,"score_gpt":0.27409961464573496,"score_spread":0.2539895396490301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157445152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995085,0.00086723024,0.000022652583,0.00015864652,0.0001814653,0.0033117116,0.00018616184,0.00002460886,0.00016254898],"genre_scores_gemma":[0.9986925,0.0001233368,0.000067222485,0.000067804845,0.000023675831,0.00028030644,0.00031758877,0.000016246628,0.00041128002],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975364,0.0010387958,0.00051576743,0.00048300327,0.00006066555,0.00036535945],"domain_scores_gemma":[0.99821067,0.0011203153,0.00021936286,0.0002479687,0.00014093306,0.000060753722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064432574,0.00028742367,0.0010587487,0.00019729999,0.00012888499,0.000017947994,0.00010129481,0.00028216565,0.00010166395],"category_scores_gemma":[0.00038155913,0.00020857705,0.00009541243,0.00032963837,0.00013927637,0.00007610119,0.000076307166,0.00017137434,0.000010185418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9463715,0.0011008121,0.0010958986,0.000008407552,0.0008026005,0.000027031549,0.00077763275,0.0000021245708,0.027616281,0.000023558256,0.000023262826,0.022150889],"study_design_scores_gemma":[0.95289916,0.003897918,0.018543372,0.000050648825,0.00033392306,0.000008444066,0.00012198401,0.0000013355087,0.02311134,0.000010348448,0.0007845687,0.00023693375],"about_ca_topic_score_codex":0.000043406613,"about_ca_topic_score_gemma":0.000055208166,"teacher_disagreement_score":0.021913955,"about_ca_system_score_codex":0.000045368175,"about_ca_system_score_gemma":0.00016453436,"threshold_uncertainty_score":0.85055256},"labels":[],"label_agreement":null},{"id":"W3158473853","doi":"10.1093/rheumatology/keab247.190","title":"P195 Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adalimumab; Ixekizumab; Psoriatic arthritis; Clinical endpoint; Internal medicine; Post-hoc analysis; Concomitant; Psoriasis; Placebo; Randomized controlled trial; Arthritis; Rheumatoid arthritis; Secukinumab; Dermatology","score_opus":0.027160800824591363,"score_gpt":0.26121396583287154,"score_spread":0.2340531650082802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158473853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935903,0.001947106,0.000011499413,0.000074320385,0.00071720575,0.002490277,0.0008359144,0.00004384584,0.0002895639],"genre_scores_gemma":[0.9974386,0.00020357867,0.0008053955,0.00005107747,0.000037296377,0.00020243088,0.00090672984,0.00004680721,0.00030809408],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968268,0.0007945762,0.00078183535,0.00093119073,0.00015149686,0.0005140701],"domain_scores_gemma":[0.9979581,0.0007374978,0.00029555272,0.00069908204,0.00021732714,0.00009239217],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028623437,0.00043715612,0.001102599,0.00014250625,0.00018246417,0.00008192239,0.00036213457,0.00024751984,0.00007678555],"category_scores_gemma":[0.00050132204,0.00038347725,0.00006396248,0.00039099922,0.00007893167,0.00022919416,0.0002900321,0.00022551612,0.00006480587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73913133,0.025874365,0.05635208,0.00004386504,0.005225901,0.00023326155,0.018298803,0.00015780014,0.0017886867,0.000033329714,0.00041453112,0.15244608],"study_design_scores_gemma":[0.7883144,0.0025678203,0.20268396,0.00033043593,0.0007501686,0.000005970106,0.0017012908,0.000039663482,0.0027624625,0.000028515899,0.00026137865,0.0005539069],"about_ca_topic_score_codex":0.0011635703,"about_ca_topic_score_gemma":0.0031688877,"teacher_disagreement_score":0.15189217,"about_ca_system_score_codex":0.00008031434,"about_ca_system_score_gemma":0.00018254165,"threshold_uncertainty_score":0.9998617},"labels":[],"label_agreement":null},{"id":"W3159131528","doi":"10.1080/09546634.2021.1902925","title":"Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study","year":2021,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of British Columbia","funders":"","keywords":"Secukinumab; Medicine; Tolerability; Placebo; Psoriasis Area and Severity Index; Psoriasis; Bioequivalence; Randomized controlled trial; Clinical endpoint; Adverse effect; Internal medicine; Pharmacokinetics; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.023625956233543143,"score_gpt":0.2691566812626643,"score_spread":0.24553072502912116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159131528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992868,0.00071267545,0.000051179093,0.0008486011,0.0002020644,0.0051090247,0.00014072248,0.000025882837,0.000041862375],"genre_scores_gemma":[0.9989207,0.00007190505,0.0002749345,0.0000828172,0.000028454982,0.00046921684,0.000114096845,0.000019415787,0.000018484468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99518913,0.0022608053,0.001291594,0.00062090636,0.00022878154,0.0004087642],"domain_scores_gemma":[0.99585193,0.0025357623,0.000765473,0.000419679,0.0003107374,0.00011640848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006083559,0.0005290916,0.0021027161,0.000111424786,0.0002818576,0.00009964107,0.00015061526,0.00024165661,0.00006138479],"category_scores_gemma":[0.00027049318,0.0002447425,0.0002585384,0.00021277301,0.00013699982,0.00016997929,0.000093407085,0.0003425778,0.000006207189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8269011,0.0062041995,0.14883395,0.0000045365387,0.0037908552,0.00035108125,0.0057599046,0.0007568474,0.000036690923,0.000007868303,0.000013497049,0.007339481],"study_design_scores_gemma":[0.89652556,0.0075275186,0.09103356,0.00014719996,0.0015267758,0.00029247426,0.0017704759,0.000028679413,0.00079601543,0.00003171839,0.000037533155,0.00028247404],"about_ca_topic_score_codex":0.00028644683,"about_ca_topic_score_gemma":0.0014419312,"teacher_disagreement_score":0.06962448,"about_ca_system_score_codex":0.00031047701,"about_ca_system_score_gemma":0.00018914611,"threshold_uncertainty_score":0.9980309},"labels":[],"label_agreement":null},{"id":"W3161289930","doi":"10.3390/vaccines9050507","title":"The Adjuvants Polyphosphazene (PCEP) and a Combination of Curdlan Plus Leptin Promote a Th17-Type Immune Response to an Intramuscular Vaccine in Mice","year":2021,"lang":"en","type":"article","venue":"Vaccines","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Curdlan; Biology; Immune system; Cytokine; Immunology; Leptin; Endocrinology","score_opus":0.011025505478582356,"score_gpt":0.2494285181601458,"score_spread":0.23840301268156344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161289930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803005,0.017555509,0.000006785627,0.0012930373,0.00044507728,0.00033558733,0.00001572118,0.000027456417,0.000020338783],"genre_scores_gemma":[0.9980789,0.000624863,0.00013027785,0.000047244845,0.000019659725,0.000025754314,0.000081358274,0.000016929509,0.00097501307],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985806,0.00048633062,0.00034426802,0.00029021813,0.000036529636,0.00026210243],"domain_scores_gemma":[0.99917597,0.0002101644,0.00010138546,0.00033258478,0.00015071689,0.00002919058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054229115,0.00017342635,0.0003260024,0.000116287105,0.00014125522,0.000018313689,0.00016421385,0.0001414352,0.00006873463],"category_scores_gemma":[0.00030050307,0.00012757356,0.00004683625,0.0004336212,0.000017636281,0.00008391988,0.00009606217,0.00009958151,0.000027648006],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006702945,0.00028095976,0.0072163125,0.000020017851,0.0001556846,0.000027378868,0.0017187238,0.0000061491523,0.93376225,0.00012945363,0.00011019332,0.04986993],"study_design_scores_gemma":[0.005520646,0.0008005481,0.58985233,0.00007837765,0.0000864399,0.000070333415,0.0006357946,0.000022472259,0.3990203,0.00012347483,0.0036029022,0.00018634813],"about_ca_topic_score_codex":0.00025999636,"about_ca_topic_score_gemma":0.00064241677,"teacher_disagreement_score":0.58263606,"about_ca_system_score_codex":0.000033690885,"about_ca_system_score_gemma":0.00009606462,"threshold_uncertainty_score":0.5202299},"labels":[],"label_agreement":null},{"id":"W3161437439","doi":"10.1007/s13555-021-00550-8","title":"Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Psoriasis; Plaque psoriasis; Medicine; Quality of life (healthcare); Dermatology; Nursing","score_opus":0.01540259117287134,"score_gpt":0.23959682154864953,"score_spread":0.22419423037577818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161437439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913965,0.0076655447,0.00024444287,0.000103135564,0.000051310315,0.00035872348,0.00014485262,0.000012004943,0.000023523038],"genre_scores_gemma":[0.99888337,0.0005486944,0.00015553863,0.000055628352,0.000001438918,0.00006538907,0.00024971526,0.000011480981,0.000028750484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981416,0.0007727689,0.00062014116,0.00024695342,0.00004011532,0.00017844558],"domain_scores_gemma":[0.99926585,0.00009365346,0.00035419452,0.0001559887,0.000105901636,0.00002442923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011277257,0.0001812631,0.00076029915,0.00011557537,0.0000612711,0.0000020907294,0.000044773245,0.0002136407,0.000032880365],"category_scores_gemma":[0.000015833977,0.0001381455,0.000056072528,0.0001399049,0.00011044853,0.00006551044,0.000017972377,0.000095336225,0.0000012582219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026841844,0.0011322309,0.9497991,0.000061182225,0.001033263,0.0000057868,0.0071589174,0.0011894105,0.0027960637,0.00012149402,0.0000035078922,0.00985717],"study_design_scores_gemma":[0.029163588,0.002324835,0.9317725,0.000108736305,0.00008210611,0.000032297503,0.00037774132,0.00061436294,0.034961157,0.00028917988,0.000024194238,0.00024933505],"about_ca_topic_score_codex":0.00031399488,"about_ca_topic_score_gemma":0.00026188086,"teacher_disagreement_score":0.032165095,"about_ca_system_score_codex":0.000026521977,"about_ca_system_score_gemma":0.00018990388,"threshold_uncertainty_score":0.56334096},"labels":[],"label_agreement":null},{"id":"W3161550071","doi":"10.2196/28882","title":"An mHealth App to Support Patients With Psoriasis in Relation to Follow-up Consultations: Qualitative Study","year":2021,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"mHealth; Psoriasis; Relation (database); Medicine; Qualitative research; Psychology; Computer science; Psychiatry; Data mining; Psychological intervention; Sociology; Dermatology","score_opus":0.024036476784887437,"score_gpt":0.33278287904304754,"score_spread":0.3087464022581601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161550071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676824,0.0000747807,0.00013968747,0.0005462553,0.000547026,0.0014262134,0.000103690654,0.00007246035,0.00032165687],"genre_scores_gemma":[0.99656063,0.000004117024,0.00049326784,0.0005260057,0.000010411979,0.0007806453,0.0010185556,0.000022602417,0.0005837453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971995,0.0013043504,0.00047524445,0.0005437226,0.000065599976,0.00041158235],"domain_scores_gemma":[0.9988579,0.00030155462,0.00011971204,0.0003699968,0.00027012062,0.000080704274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018378027,0.00022626546,0.0004759076,0.0003189942,0.00016541772,0.000014400784,0.00014178579,0.00021551215,0.00021332304],"category_scores_gemma":[0.0001256531,0.0002050689,0.000040960997,0.0006626504,0.000045673576,0.00014574558,0.0000445251,0.00014587767,0.0007989238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026327937,0.0040372973,0.7279131,0.000034686018,0.00050623,0.00018910615,0.24427862,0.000022221411,0.0014610271,0.0011360623,0.003573439,0.014215418],"study_design_scores_gemma":[0.015077703,0.002437135,0.9198098,0.000031575502,0.00015066993,0.00008193187,0.054782785,8.7349144e-7,0.0023639582,0.00011251045,0.004719355,0.0004316554],"about_ca_topic_score_codex":0.000096787866,"about_ca_topic_score_gemma":0.00185207,"teacher_disagreement_score":0.19189675,"about_ca_system_score_codex":0.00008794331,"about_ca_system_score_gemma":0.00023431837,"threshold_uncertainty_score":0.9999791},"labels":[],"label_agreement":null},{"id":"W3162996590","doi":"10.23736/s2784-8671.21.06984-4","title":"Consensus on the place in therapy of biologics in the treatment of patients with chronic plaque psoriasis","year":2022,"lang":"en","type":"article","venue":"Italian Journal of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Imperial Oil (Canada)","funders":"","keywords":"Venereology; Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.017549441474369674,"score_gpt":0.2272106025553906,"score_spread":0.20966116108102092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162996590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895382,0.0076413997,9.329529e-7,0.0021783283,0.00027669952,0.00024039327,0.000050688188,0.0000017617539,0.000071607545],"genre_scores_gemma":[0.99873084,0.0010704006,0.000011419249,0.00010799087,0.000009843003,0.000028129058,0.000019486393,0.0000058152077,0.000016076081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976919,0.001471634,0.000457436,0.00012737616,0.000041866915,0.0002097844],"domain_scores_gemma":[0.9983393,0.0009863613,0.0004531724,0.00016942252,0.000041550164,0.000010173883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023738922,0.00015453169,0.0004923343,0.0002045289,0.000099217024,0.0000014207186,0.00022404717,0.00013824509,0.00009606254],"category_scores_gemma":[0.000022234099,0.00007589299,0.000081879945,0.00017567948,0.00045667906,0.000015144671,0.000018925912,0.00020600825,0.0000013621287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005156614,0.0014683009,0.9806945,0.000007677751,0.00048153597,0.00020188445,0.0029006135,0.00012150167,0.00050602504,0.0023240924,0.00023006313,0.0059072385],"study_design_scores_gemma":[0.029994484,0.016123988,0.90281206,0.000055118584,0.00019345511,0.004339185,0.004165144,0.0000062100967,0.018233212,0.0011577937,0.022608731,0.00031060347],"about_ca_topic_score_codex":0.00003210776,"about_ca_topic_score_gemma":0.00011523042,"teacher_disagreement_score":0.07788238,"about_ca_system_score_codex":0.000053073774,"about_ca_system_score_gemma":0.00011076772,"threshold_uncertainty_score":0.30948263},"labels":[],"label_agreement":null},{"id":"W3163968658","doi":"10.1136/annrheumdis-2021-eular.142","title":"POS1023 HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; University of Washington; Sorbonne Université; Memorial University of Newfoundland; University of Leeds; Janssen Scientific Affairs","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Internal medicine; Psoriasis Area and Severity Index; Discontinuation; BASDAI; Ankylosing spondylitis; Beck Depression Inventory; Rheumatoid arthritis; Psoriasis; Physical therapy; Immunology; Anxiety; Psychiatry","score_opus":0.05637795383459359,"score_gpt":0.30647568855226137,"score_spread":0.2500977347176678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163968658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99309635,0.0041321614,5.9131474e-7,0.00061862654,0.00025591816,0.0006987437,0.0011633416,0.000018321876,0.000015938931],"genre_scores_gemma":[0.9973717,0.0013160553,0.000012426259,0.00005070312,0.000010404374,0.000058523907,0.0009055547,0.000015367237,0.00025929522],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823445,0.0008071423,0.00026872125,0.0003649872,0.00009988281,0.00022482847],"domain_scores_gemma":[0.9981614,0.000549415,0.00024042967,0.00096536963,0.000057808767,0.000025611433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015303289,0.00023765575,0.0004756354,0.00005024116,0.0001660036,0.000052159547,0.00030192488,0.00003642798,0.000075657445],"category_scores_gemma":[0.0001279584,0.00010521385,0.000099583034,0.00017417801,0.00013914422,0.00015911084,0.00020177593,0.000052582443,0.000009110737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003158505,0.0015692146,0.9542209,0.00002142501,0.0015590843,0.0000061243595,0.0009582911,9.936143e-7,0.000015126847,0.000029971317,0.00041573175,0.040887307],"study_design_scores_gemma":[0.0041800058,0.00021863988,0.9928184,0.00020139561,0.00058430224,6.632119e-7,0.00094531267,0.0000036045892,0.00034965755,0.0005375232,0.000026912057,0.00013356397],"about_ca_topic_score_codex":0.00064520765,"about_ca_topic_score_gemma":0.0047651264,"teacher_disagreement_score":0.040753745,"about_ca_system_score_codex":0.000017026627,"about_ca_system_score_gemma":0.000056750505,"threshold_uncertainty_score":0.4290496},"labels":[],"label_agreement":null},{"id":"W3164028683","doi":"10.1136/annrheumdis-2021-eular.1002","title":"POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"LEO Pharma; Foundation for Research in Rheumatology; Genentech; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Psoriatic arthritis; Internal medicine; Psoriasis Area and Severity Index; Adverse effect; Gastroenterology; Arthritis; Dermatology; Pathology","score_opus":0.035888513442331606,"score_gpt":0.2916870868243451,"score_spread":0.25579857338201345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164028683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220324,0.0034047258,0.0000074762756,0.0006508726,0.00007954921,0.0009816835,0.0026180882,0.000019412317,0.000034939345],"genre_scores_gemma":[0.9990593,0.00033784477,0.00007377004,0.00012180113,0.000011000549,0.00004782392,0.00027361172,0.000018575185,0.000056255252],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99769217,0.0009796234,0.0005427584,0.00043150832,0.00009757403,0.00025636062],"domain_scores_gemma":[0.99794537,0.0009999336,0.00026132105,0.0005342385,0.00018735586,0.00007179733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002805069,0.00028036142,0.00062610424,0.000062382176,0.00020529244,0.00003075309,0.00022042541,0.00007899584,0.000021331867],"category_scores_gemma":[0.00042139014,0.0001681827,0.00006396048,0.0003084324,0.00020026557,0.00012624197,0.0001542647,0.00011110597,0.000002663276],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4802411,0.051476102,0.12755352,0.00058989244,0.014963181,0.00018283559,0.097705506,0.0043466752,0.033821788,0.0005069502,0.01138044,0.17723203],"study_design_scores_gemma":[0.08914719,0.0036185787,0.78247267,0.0027039493,0.0016363565,0.000053423733,0.01754366,0.00019451404,0.10104174,0.000641342,0.00015421187,0.0007923629],"about_ca_topic_score_codex":0.0006355223,"about_ca_topic_score_gemma":0.00095551735,"teacher_disagreement_score":0.65491915,"about_ca_system_score_codex":0.000013667903,"about_ca_system_score_gemma":0.00014099274,"threshold_uncertainty_score":0.68582916},"labels":[],"label_agreement":null},{"id":"W3164174907","doi":"10.1136/annrheumdis-2021-eular.900","title":"AB0531 THERAPIES FOR PERIPHERAL JOINT INVOLVEMENT IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Celgene; Biogen; Gilead Sciences; Chugai Pharmaceutical; Celltrion; Sanofi; Amgen; Pfizer; Samsung; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Leflunomide; Psoriatic arthritis; Systematic review; Internal medicine; Randomized controlled trial; Infliximab; Arthritis; Physical therapy; Rheumatoid arthritis; MEDLINE; Disease","score_opus":0.036532537979361644,"score_gpt":0.2765538748898031,"score_spread":0.24002133691044145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164174907","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11237259,0.88378173,0.000012287534,0.0018332871,0.00046007583,0.0012622015,0.00022198481,0.00002040653,0.0000354486],"genre_scores_gemma":[0.689235,0.30692646,0.00009105051,0.0015339789,0.000020307887,0.0010418402,0.00021339356,0.000023484405,0.00091449136],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981858,0.0005837619,0.0006822658,0.00021678398,0.0000729784,0.00025839152],"domain_scores_gemma":[0.9987373,0.0002526743,0.00030181103,0.0005136377,0.00017027388,0.00002435485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033919708,0.0002104855,0.0008042347,0.00005347274,0.000097765726,0.000026698623,0.00021547888,0.00007525575,0.00016514765],"category_scores_gemma":[0.0006041912,0.00013137226,0.0004748531,0.00025195995,0.000065872344,0.000085772685,0.00006113109,0.00006123754,0.000015903715],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044287846,0.004728903,0.0021915417,0.70675427,0.009420706,0.00006052161,0.012590877,0.000029773915,0.003210552,0.0076362714,0.04508533,0.2078484],"study_design_scores_gemma":[0.0058713327,0.00040194817,0.025088573,0.9339851,0.0018656648,0.00010176734,0.002673755,0.000027472262,0.016235093,0.011416114,0.0015484185,0.0007847391],"about_ca_topic_score_codex":0.00000828203,"about_ca_topic_score_gemma":0.000029613357,"teacher_disagreement_score":0.5768624,"about_ca_system_score_codex":0.000017454799,"about_ca_system_score_gemma":0.00010163812,"threshold_uncertainty_score":0.5357206},"labels":[],"label_agreement":null},{"id":"W3164503965","doi":"10.1136/annrheumdis-2021-eular.274","title":"POS0200 CLINICAL CHARACTERISTICS &amp; OUTCOMES ASSOCIATE WITH WORK PRODUCTIVITY IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Presenteeism; Internal medicine; Absenteeism; Golimumab; Placebo; Multivariate analysis; Physical therapy; Work productivity; Enthesitis; Arthritis; Productivity; Disease; Adalimumab","score_opus":0.0468209902511662,"score_gpt":0.2974974360181815,"score_spread":0.2506764457670153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164503965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963477,0.0007799426,0.0000030182753,0.0006293043,0.00065373274,0.0008378433,0.0007138309,0.000011960151,0.000022652066],"genre_scores_gemma":[0.9991633,0.00019157601,0.000030024172,0.000067694054,0.000011157267,0.000054433334,0.00008577822,0.000018784382,0.0003772092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974327,0.0011708281,0.00061654527,0.00033334983,0.0001703084,0.00027628004],"domain_scores_gemma":[0.99756527,0.00066952663,0.00077102514,0.0007527955,0.00021797617,0.00002342911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023849946,0.0002532317,0.0008294032,0.000030811432,0.00013730713,0.000015719976,0.0003127708,0.000082836654,0.00004831322],"category_scores_gemma":[0.0010604057,0.00012534765,0.0002518202,0.00040211252,0.0003204698,0.00014957628,0.00017203129,0.00015970242,0.000011632962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008467343,0.007597395,0.9530188,0.000046713587,0.0020556187,0.0000021539897,0.001364723,0.000004069785,0.0000036317358,0.000022127968,0.00017938824,0.03485869],"study_design_scores_gemma":[0.0028527668,0.0003656379,0.9938457,0.00068542926,0.0005228634,9.406151e-7,0.0004982615,7.357393e-8,0.0007056601,0.00033567694,0.00003152211,0.0001554875],"about_ca_topic_score_codex":0.0001038171,"about_ca_topic_score_gemma":0.0003800557,"teacher_disagreement_score":0.040826924,"about_ca_system_score_codex":0.000021060887,"about_ca_system_score_gemma":0.00021849436,"threshold_uncertainty_score":0.51115286},"labels":[],"label_agreement":null},{"id":"W3164564997","doi":"","title":"Bimekizumab for Moderate-to-Severe Plaque Psoriasis.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of Ottawa","funders":"","keywords":"Psoriasis; Plaque psoriasis; Medicine; Interleukin 17; Pathogenesis; Monoclonal antibody; Dermatology; Population; Interleukin 23; Disease; Immune system; Immunology; Interleukin; Monoclonal; Antibody; Cytokine; Pathology","score_opus":0.027616092672795113,"score_gpt":0.22669055711499092,"score_spread":0.19907446444219581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164564997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651693,0.0069969976,0.0014855372,0.0038285071,0.006069598,0.0028002951,0.00075292046,0.00034936037,0.01254745],"genre_scores_gemma":[0.9650887,0.000080716665,0.00049916183,0.00061624433,0.00015447172,0.0046631955,0.00041664427,0.000031822026,0.028448999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986951,0.00010297761,0.00020572933,0.00040800578,0.000028325247,0.0005598907],"domain_scores_gemma":[0.9993104,0.0001687828,0.000047394213,0.00030985402,0.00010470085,0.00005891736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015599506,0.00018795261,0.00029296108,0.00007698584,0.00018858313,0.000028275976,0.00014504515,0.00022753223,0.00020367038],"category_scores_gemma":[0.00013910393,0.00017254944,0.00015389362,0.0001741497,0.000026645854,0.000067479195,0.000060119517,0.000077521356,0.00037152081],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002232747,0.00041615608,0.0011890047,0.00004152969,0.0011958631,0.000041996773,0.0003580077,0.000049894075,0.007892686,0.003452647,0.050376024,0.93275344],"study_design_scores_gemma":[0.009580395,0.00010034396,0.07146624,0.000013900925,0.00037902064,0.00017792017,0.00016729916,0.000004902822,0.42809626,0.0016245769,0.4877308,0.0006583446],"about_ca_topic_score_codex":0.000015042133,"about_ca_topic_score_gemma":0.000048462305,"teacher_disagreement_score":0.9320951,"about_ca_system_score_codex":0.00006043512,"about_ca_system_score_gemma":0.00006932961,"threshold_uncertainty_score":0.70363617},"labels":[],"label_agreement":null},{"id":"W3164736687","doi":"10.1007/s13555-021-00548-2","title":"Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Clinical trial; Computer science; Dermatology; Psoriatic arthritis; Internal medicine; Secukinumab","score_opus":0.06649211576710885,"score_gpt":0.4084196808102532,"score_spread":0.34192756504314437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164736687","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.075038165,0.923693,0.000005963071,0.000017082844,0.0007271358,0.00037422258,0.00004303592,0.000012927531,0.00008849139],"genre_scores_gemma":[0.018262781,0.9808495,0.0000433082,0.0000126599025,0.00001361051,0.000035992318,0.00067374913,0.00002155172,0.00008681655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961728,0.0017418374,0.0013998505,0.00043838672,0.00003082992,0.00021628333],"domain_scores_gemma":[0.9974509,0.0014340489,0.0007237999,0.0003213261,0.000052202515,0.000017717899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024268252,0.0003000237,0.003082291,0.00027045127,0.000040254952,0.000002922576,0.00016283811,0.0011139639,0.00013069843],"category_scores_gemma":[0.00010722761,0.00024021773,0.0005708457,0.00031312782,0.00031232828,0.000035664125,0.000051715375,0.00030521405,0.000020171394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021565372,0.0005119456,0.0020278944,0.00064756116,0.0013660545,0.00004486662,0.00012859445,7.7795164e-8,0.000017241116,0.00019128992,0.000049279035,0.99479955],"study_design_scores_gemma":[0.020019164,0.0006464718,0.018654672,0.005807775,0.002583575,0.0020801243,0.0002400378,0.000004655742,0.0018415581,0.00021119165,0.9469465,0.0009642806],"about_ca_topic_score_codex":0.00002880769,"about_ca_topic_score_gemma":0.000013536689,"teacher_disagreement_score":0.9938353,"about_ca_system_score_codex":0.000010107738,"about_ca_system_score_gemma":0.00018540249,"threshold_uncertainty_score":0.9795795},"labels":[],"label_agreement":null},{"id":"W3164790330","doi":"10.1136/annrheumdis-2021-eular.244","title":"POS1026 GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Sanofi Genzyme; Memorial University of Newfoundland; University of Glasgow; University of Pennsylvania; Celgene; Amgen; Pfizer; University of Washington; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Presenteeism; Medicine; Absenteeism; Psoriatic arthritis; Placebo; Work productivity; Productivity; Physical therapy; Demography; Internal medicine; Arthritis; Psychology; Alternative medicine","score_opus":0.019028202810161956,"score_gpt":0.26527330304651725,"score_spread":0.2462451002363553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164790330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965828,0.0015089768,0.0000018160373,0.00024222763,0.0002019133,0.0011958362,0.00022985406,0.000009469175,0.000027083757],"genre_scores_gemma":[0.99948984,0.00019396779,0.000038646212,0.000013670204,0.000009188259,0.00008718121,0.00006794564,0.000012885469,0.00008664886],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984246,0.00040839447,0.0004661519,0.0003253905,0.00010223664,0.00027324024],"domain_scores_gemma":[0.9987947,0.0002116066,0.00039189693,0.00045579052,0.00012635696,0.0000196983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025299302,0.00019467568,0.00054426136,0.00007215335,0.000058978072,0.000011994289,0.0001444288,0.00008198984,0.000016364786],"category_scores_gemma":[0.00079929334,0.00013529697,0.00009827891,0.00047907987,0.00016123289,0.0001972889,0.00010695154,0.00008807059,0.0000019928657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2319438,0.021222765,0.20095478,0.00072189054,0.0015563131,0.000012935952,0.0032682638,0.000018195142,0.0004474949,0.000054481578,0.00077402854,0.53902507],"study_design_scores_gemma":[0.118375786,0.0013579405,0.8607748,0.0018001832,0.00019607403,5.1200124e-7,0.0004087035,0.0000012314587,0.016230708,0.0005977291,0.000021122456,0.00023522487],"about_ca_topic_score_codex":0.00014110639,"about_ca_topic_score_gemma":0.00008000997,"teacher_disagreement_score":0.65982,"about_ca_system_score_codex":0.00002071238,"about_ca_system_score_gemma":0.00016175273,"threshold_uncertainty_score":0.55172503},"labels":[],"label_agreement":null},{"id":"W3165137789","doi":"10.1111/bjd.20527","title":"Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab","year":2021,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Dermatology; Psoriasis; Eczematous dermatitis; Ustekinumab; Ixekizumab; Adverse effect; Population; Atopy; Etanercept; Allergy; Internal medicine; Secukinumab; Disease; Adalimumab; Immunology; Psoriatic arthritis","score_opus":0.010541554469904646,"score_gpt":0.20993748670632478,"score_spread":0.19939593223642013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165137789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898505,0.0034346003,0.000075530865,0.0040998873,0.0003069969,0.00051896105,0.0015404293,0.0000225921,0.00015046442],"genre_scores_gemma":[0.98401266,0.0032741588,0.0005260558,0.0029402215,0.00008423874,0.00006462028,0.0076885456,0.00011885181,0.001290638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99629176,0.0009781002,0.001421667,0.00058883545,0.00014367595,0.00057598],"domain_scores_gemma":[0.9974579,0.0002446675,0.0010964794,0.0003721135,0.0007494439,0.000079348065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000086896165,0.0006153028,0.0027284957,0.0014725275,0.00016717323,0.000043486318,0.00024431795,0.0011073804,0.0005257032],"category_scores_gemma":[0.00004645829,0.00050206116,0.00038609523,0.0013491249,0.0002089332,0.00015353801,0.000044847657,0.00092154014,0.00000676242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029169748,0.005177348,0.43039078,0.0005107538,0.15689364,0.056539636,0.0024719955,0.0017550007,0.0005201155,0.000016505632,0.1268068,0.18974769],"study_design_scores_gemma":[0.08546284,0.008681407,0.43137154,0.004617096,0.06751574,0.15510419,0.0024196897,0.000051842162,0.004875544,0.000022852597,0.23607883,0.0037984354],"about_ca_topic_score_codex":0.0014627161,"about_ca_topic_score_gemma":0.0026978229,"teacher_disagreement_score":0.18594925,"about_ca_system_score_codex":0.0003823111,"about_ca_system_score_gemma":0.00044801366,"threshold_uncertainty_score":0.9997431},"labels":[],"label_agreement":null},{"id":"W3165292399","doi":"10.32553/jbpr.v10i3.860","title":"A PROSPECTIVE STUDY OF DRUG UTILIZATION AND QUALITY OF LIFE IN PSORIASIS PATIENTS IN DERMATOLOGY DEPARTMENT OF A TERTIARY CARE TEACHING HOSPITAL","year":2021,"lang":"en","type":"article","venue":"Journal of Biomedical and Pharmaceutical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"New York Institute of Technology","funders":"","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Observational study; Tolerability; Quality of life (healthcare); Internal medicine; Psoriasis Area and Severity Index; Medical prescription; Prospective cohort study; Physical therapy; Dermatology; Adverse effect; Pharmacology","score_opus":0.07722557155622048,"score_gpt":0.41587360395175393,"score_spread":0.3386480323955334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165292399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886286,0.010686543,0.000004173852,0.0002185933,0.00011492078,0.0002914384,0.000034832246,0.0000011121643,0.000019749667],"genre_scores_gemma":[0.99881613,0.001094632,0.000037283895,0.00000820236,0.000011995724,0.000008348352,0.000014431778,0.00000406848,0.0000048875754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680555,0.0017742193,0.0008124933,0.00016453321,0.00023106161,0.00021215639],"domain_scores_gemma":[0.99855864,0.00076408265,0.00018757072,0.00007331834,0.0003329048,0.00008345457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012207361,0.000088858025,0.00049256097,0.0003121852,0.00004122139,0.0000034721409,0.00009197685,0.0001251187,0.00003172469],"category_scores_gemma":[0.0009113503,0.000066261964,0.000049358867,0.000277151,0.00034706146,0.000057019406,0.00013952346,0.00044502574,3.2422466e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011722777,0.0048329365,0.9460068,0.0002949903,0.00021712291,0.00003802597,0.0073253685,1.3097893e-7,0.005955772,0.000058402875,0.00003021535,0.034067985],"study_design_scores_gemma":[0.010592054,0.000957976,0.9602299,0.00015030688,0.00005550688,0.000011589956,0.008070826,0.000005523739,0.019639399,0.000078482735,0.00014884552,0.00005963255],"about_ca_topic_score_codex":0.00017410026,"about_ca_topic_score_gemma":0.00013090867,"teacher_disagreement_score":0.03400835,"about_ca_system_score_codex":0.000043878317,"about_ca_system_score_gemma":0.00016697485,"threshold_uncertainty_score":0.27020845},"labels":[],"label_agreement":null},{"id":"W3165320040","doi":"10.1136/annrheumdis-2021-eular.1555","title":"POS1043 NETAKIMAB REDUCES PSORIATIC ARTHRITIS ACTIVITY IN PATIENTS WITH OR WITHOUT AXIAL DISEASE: SUBANALYSIS OF THE PATERA STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharma; University of California, San Diego; LEO Pharma; University of Toronto; Genentech; Griffith University; Kyowa Hakko Kirin; University of Glasgow; Institut National de la Santé et de la Recherche Médicale; Université François-Rabelais; University of Oxford; Universitat Autònoma de Barcelona; Dermira; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; GlaxoSmithKline; University of Washington; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Ankylosing spondylitis; Placebo; Internal medicine; Tolerability; Rheumatoid arthritis; Gastroenterology; Psoriasis Area and Severity Index; Mallinckrodt; Psoriasis; Inflammatory arthritis; Immunology; Adverse effect; Pathology","score_opus":0.022554011389906793,"score_gpt":0.25972162051621844,"score_spread":0.23716760912631166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165320040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957779,0.0026694054,0.0000011482203,0.00026154373,0.00026619437,0.00059119734,0.0004074221,0.0000116619,0.000013549862],"genre_scores_gemma":[0.9993327,0.00022250952,0.0000062459976,0.000034577337,0.0000075966527,0.000060688813,0.00005090549,0.000015122673,0.0002696433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979412,0.00092177634,0.00042783035,0.00028256435,0.00017361535,0.000252991],"domain_scores_gemma":[0.99841875,0.00021378818,0.00042709187,0.0007303771,0.00017147065,0.000038539452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014204031,0.00022603542,0.000627787,0.00006982861,0.00014538282,0.000017468596,0.00036796427,0.00005082905,0.00022835354],"category_scores_gemma":[0.00034613593,0.00011229113,0.00028029576,0.0004762238,0.0001898732,0.00011933125,0.00014926358,0.00007744744,0.0000067422334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022860882,0.005149915,0.9074368,0.00009899939,0.0018575542,0.0000046369155,0.00084274006,0.000039518258,0.000099510515,0.000010128045,0.00015071621,0.08202343],"study_design_scores_gemma":[0.0032044293,0.0002447352,0.98897856,0.00051169586,0.0009135508,8.640323e-7,0.00042984943,0.0000068301138,0.0054586767,0.00009923961,0.000009472773,0.00014210097],"about_ca_topic_score_codex":0.0001956954,"about_ca_topic_score_gemma":0.000329752,"teacher_disagreement_score":0.08188133,"about_ca_system_score_codex":0.000014315716,"about_ca_system_score_gemma":0.00023788364,"threshold_uncertainty_score":0.45790994},"labels":[],"label_agreement":null},{"id":"W3165355211","doi":"10.1007/s40264-021-01065-z","title":"Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR","year":2021,"lang":"en","type":"review","venue":"Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University; Innovaderm (Canada)","funders":"Janssen Scientific Affairs; University of Pennsylvania","keywords":"Medicine; Term (time); Medical physics","score_opus":0.3266899675499887,"score_gpt":0.4281687764952196,"score_spread":0.10147880894523092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165355211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010140172,0.98821574,0.00011969554,0.000056027573,0.00020320418,0.00071608,0.00018290622,0.000018785748,0.00034739176],"genre_scores_gemma":[0.022848757,0.9744358,0.00014950306,0.000008878513,0.000043481086,0.00013074357,0.0020602401,0.000018968933,0.00030363633],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9889403,0.009298193,0.0008922404,0.0005401646,0.00010190538,0.00022717992],"domain_scores_gemma":[0.9934697,0.005438965,0.00059347623,0.00037249053,0.0001080842,0.000017275695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031839695,0.000329162,0.0014672,0.0002632473,0.00014412799,0.000014580095,0.00019954996,0.00044170587,0.00026587336],"category_scores_gemma":[0.0008971613,0.00022636355,0.00033751427,0.0007718392,0.0001562199,0.00006153118,0.00009699959,0.0005677466,0.000014068979],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011790547,0.000085475105,0.0022148155,0.0002015309,0.00051003194,0.000009398924,0.0004615412,0.000033019303,0.00022155377,0.000021795027,0.000010681028,0.9961122],"study_design_scores_gemma":[0.0064074085,0.00020176033,0.7317798,0.017867386,0.016596831,0.000106049345,0.0013983697,0.000071630835,0.0008289131,0.0003561296,0.22304747,0.0013382484],"about_ca_topic_score_codex":0.0013388818,"about_ca_topic_score_gemma":0.015876208,"teacher_disagreement_score":0.994774,"about_ca_system_score_codex":0.00023960459,"about_ca_system_score_gemma":0.000270094,"threshold_uncertainty_score":0.9230838},"labels":[],"label_agreement":null},{"id":"W3165364673","doi":"10.1136/annrheumdis-2021-eular.1390","title":"POS0405 GENETIC VARIANTS WITHIN PSORIATIC ARTHRITIS (PsA)-WEIGHTED GENES FBXL19 AND HLA-B*39 MAY SERVE AS A POTENTIAL LINK BETWEEN PsA AND OBESITY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Single-nucleotide polymorphism; Internal medicine; Body mass index; Oncology; Mendelian randomization; PTPN22; Population; Rheumatoid arthritis; Genotype; Genetics; Genetic variants; Gene","score_opus":0.020030026633281375,"score_gpt":0.25028087315060166,"score_spread":0.23025084651732028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165364673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927244,0.070307985,0.00001783481,0.0011016754,0.0004584702,0.00030839714,0.00047951893,0.00003840522,0.00004370879],"genre_scores_gemma":[0.9893141,0.009446407,0.00022285993,0.00015923269,0.000072170864,0.000025061656,0.00015777908,0.000022301123,0.00058009085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979452,0.00062871433,0.000546839,0.0004146437,0.000108924636,0.00035570635],"domain_scores_gemma":[0.99865484,0.00029214253,0.00030085558,0.0005091101,0.00014253242,0.000100545774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018949281,0.0003062754,0.00063644594,0.00007650202,0.0003231578,0.000055721015,0.00023894866,0.00019798802,0.00023692375],"category_scores_gemma":[0.00022720119,0.00023115243,0.00020844214,0.00018704274,0.00026360212,0.00011803817,0.00025349332,0.00010448915,0.00006403417],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040507107,0.0008312454,0.23410463,0.00078771013,0.0061173253,0.00013624411,0.0017023899,0.000021929247,0.004453529,0.0010464188,0.0010336109,0.7493599],"study_design_scores_gemma":[0.0022272598,0.00021660287,0.9683755,0.0006877456,0.0012323891,0.00017795083,0.0002465633,0.000027885222,0.017101455,0.00917164,0.00018925127,0.00034572865],"about_ca_topic_score_codex":0.00019726784,"about_ca_topic_score_gemma":0.000037533006,"teacher_disagreement_score":0.74901414,"about_ca_system_score_codex":0.000007845996,"about_ca_system_score_gemma":0.00016183087,"threshold_uncertainty_score":0.9426123},"labels":[],"label_agreement":null},{"id":"W3165446279","doi":"10.1186/s12931-021-01743-7","title":"RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma","year":2021,"lang":"en","type":"article","venue":"Respiratory Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Interleukin 17; Asthma; Medicine; RAR-related orphan receptor gamma; Immunology; Interleukin 4; Cytokine; Immune system; FOXP3","score_opus":0.03788640976864323,"score_gpt":0.3164845125374193,"score_spread":0.2785981027687761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165446279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869354,0.0060271523,0.000009086789,0.00024711827,0.00040487235,0.00052821625,0.00047265083,0.000090672926,0.0035266802],"genre_scores_gemma":[0.98077506,0.00036304988,0.000056319615,0.00033100948,0.00031539486,0.00008496687,0.00011778778,0.000066402274,0.017890038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99602115,0.0011022185,0.0004368187,0.0009939088,0.00028598015,0.001159909],"domain_scores_gemma":[0.998408,0.00028898462,0.0000777728,0.0007218974,0.0002827293,0.00022062381],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00095561444,0.000397506,0.00060080853,0.00046728962,0.0007384919,0.0001294705,0.00030440307,0.00049847533,0.0012666123],"category_scores_gemma":[0.0001804077,0.00037308686,0.00018376588,0.0005755782,0.0003069657,0.00020434617,0.00058098126,0.000643513,0.0005619808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007023908,0.00036380184,0.01591088,0.00007456181,0.0003305755,0.001203048,0.00037656765,0.000017472767,0.9358272,0.00008700607,0.022265805,0.02284068],"study_design_scores_gemma":[0.0054939324,0.001021826,0.046605263,0.00016705456,0.000105299005,0.00035391032,0.0009541415,0.0000052599953,0.49002674,0.0000378898,0.4545784,0.00065027305],"about_ca_topic_score_codex":0.00010486865,"about_ca_topic_score_gemma":0.00017425537,"teacher_disagreement_score":0.44580045,"about_ca_system_score_codex":0.00015815893,"about_ca_system_score_gemma":0.00042447803,"threshold_uncertainty_score":0.9998721},"labels":[],"label_agreement":null},{"id":"W3165793297","doi":"10.1136/annrheumdis-2021-eular.2695","title":"OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Keele University; University of California, San Diego; University of Toronto; University College Dublin; Singapore General Hospital; University of Leeds; Northwell Health; University of Pennsylvania; Cleveland Clinic; University of Washington","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Clinical endpoint; Rheumatology; Placebo; Psoriasis; Adverse effect; Randomized controlled trial; Gastroenterology; Arthritis; Immunology","score_opus":0.0822944902644143,"score_gpt":0.3282076787436841,"score_spread":0.24591318847926982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165793297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364407,0.007300047,0.000080607184,0.0014683716,0.00047923942,0.0033815089,0.0036179808,0.000018981815,0.000009187471],"genre_scores_gemma":[0.9966676,0.0020765027,0.00012874542,0.00017750893,0.000026703929,0.00039017713,0.00042146628,0.00001870259,0.000092553055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967057,0.0016663537,0.00084850274,0.00038268964,0.000109126035,0.0002876245],"domain_scores_gemma":[0.9882988,0.010107414,0.00072584965,0.0005693061,0.00025166027,0.000047015463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082314,0.00028801296,0.0010263787,0.00006461604,0.00033957945,0.000025848802,0.00034634685,0.0001127037,0.00006210252],"category_scores_gemma":[0.004114953,0.000139076,0.00027893143,0.0002738181,0.00039500807,0.00009801587,0.00014795245,0.00009055805,0.0000045362835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8019564,0.00135663,0.000027209386,0.000028427918,0.0019990753,0.0000011259278,0.0030949302,0.000018368482,0.00010962525,0.000051155286,0.00025343674,0.19110359],"study_design_scores_gemma":[0.9790414,0.0020835851,0.0051536798,0.001155648,0.0007524023,0.000001743661,0.0009152801,0.000006941902,0.009438484,0.0007765574,0.0004446715,0.00022961838],"about_ca_topic_score_codex":0.000109629385,"about_ca_topic_score_gemma":0.00005755821,"teacher_disagreement_score":0.19087397,"about_ca_system_score_codex":0.000016998405,"about_ca_system_score_gemma":0.00021606886,"threshold_uncertainty_score":0.5671355},"labels":[],"label_agreement":null},{"id":"W3167102770","doi":"10.1007/s13555-021-00560-6","title":"Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits","year":2021,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Psoriasis; Lotion; Tolerability; Medicine; Pharmacology; Dermatology; Clobetasol propionate; Active ingredient; Clinical trial; Adverse effect; Internal medicine","score_opus":0.050980535848023374,"score_gpt":0.3138735115390394,"score_spread":0.26289297569101605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167102770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016746318,0.9817422,0.000005660361,0.00015010816,0.00014909802,0.0011245684,0.000061423336,0.0000051556513,0.000015475027],"genre_scores_gemma":[0.016043492,0.983323,0.000024771367,0.00005090659,0.0000049495893,0.00024193365,0.0002794986,0.000011704965,0.000019776035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783486,0.0011302435,0.0005789286,0.0002785735,0.000038785674,0.0001386239],"domain_scores_gemma":[0.9987736,0.00036184248,0.000564017,0.00021401863,0.000076358905,0.000010167104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019266165,0.0003043105,0.0016891545,0.0001463477,0.00007511252,0.000003195239,0.000086512846,0.00040107802,0.000022456508],"category_scores_gemma":[0.00001115677,0.00017878119,0.00016547399,0.00017745189,0.00019620697,0.000035716603,0.000014032551,0.00010403069,5.4990966e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060682298,0.00041274907,0.00006658512,0.006584587,0.0010756629,0.0000052825458,0.0013555498,2.5033968e-8,0.00020263573,0.0038799988,0.0000070333836,0.9863492],"study_design_scores_gemma":[0.02599848,0.0083116675,0.004099228,0.11073631,0.013191244,0.0073038717,0.0039314376,0.000004431277,0.06848459,0.008409658,0.7474718,0.0020572771],"about_ca_topic_score_codex":0.000018700153,"about_ca_topic_score_gemma":0.000010467833,"teacher_disagreement_score":0.9842919,"about_ca_system_score_codex":0.000012698811,"about_ca_system_score_gemma":0.00006884255,"threshold_uncertainty_score":0.72904855},"labels":[],"label_agreement":null},{"id":"W3167895097","doi":"10.1097/der.0000000000000765","title":"Anti–Interleukin 23–Based Therapies May Shift Cutaneous Immune Responses: A Case of New-Onset Contact Dermatitis to Carbamates after Guselkumab for Psoriasis","year":2021,"lang":"en","type":"article","venue":"Dermatitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Immunology","score_opus":0.014076376872568045,"score_gpt":0.25418403555952057,"score_spread":0.24010765868695252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167895097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842103,0.0074372212,0.0006894833,0.002613471,0.0009133328,0.0006920402,0.003231935,0.00010948983,0.00010270386],"genre_scores_gemma":[0.99355125,0.00020221976,0.0019561057,0.0017697909,0.00004603946,0.00030474344,0.0006741044,0.000056973407,0.001438775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977922,0.0004551876,0.0007141973,0.00043981234,0.00006646297,0.0005321456],"domain_scores_gemma":[0.99794257,0.0009279545,0.0002197633,0.0006432494,0.00018693211,0.000079527555],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001452754,0.00041009585,0.0008095231,0.00025746922,0.0002115887,0.00006761977,0.00022879786,0.00030000234,0.0010942954],"category_scores_gemma":[0.00020244245,0.00039043083,0.0003910847,0.0002565478,0.00008679895,0.00013854078,0.00007606978,0.00012036665,0.00024507332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075644925,0.0030516395,0.12466065,0.0022892882,0.01497515,0.04351918,0.104708515,0.00007822679,0.3500166,0.001228112,0.19290504,0.15500313],"study_design_scores_gemma":[0.006406304,0.000647757,0.08928281,0.0004217145,0.0007035931,0.013868437,0.0017128811,0.0000139746135,0.8190133,0.00019003746,0.06696943,0.0007697734],"about_ca_topic_score_codex":0.0009905424,"about_ca_topic_score_gemma":0.001596366,"teacher_disagreement_score":0.4689967,"about_ca_system_score_codex":0.00008833876,"about_ca_system_score_gemma":0.00028190057,"threshold_uncertainty_score":0.99985474},"labels":[],"label_agreement":null},{"id":"W3173878348","doi":"10.1111/bjd.20595","title":"Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up","year":2021,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Psoriasis Area and Severity Index; Medicine; Dermatology Life Quality Index; Psoriasis; Discontinuation; Adverse effect; Internal medicine; Randomized controlled trial; Quality of life (healthcare); Dermatology; Surgery","score_opus":0.03393482954166807,"score_gpt":0.2914853224965989,"score_spread":0.2575504929549308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173878348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804001,0.01724858,0.00025502016,0.00021944035,0.00090174866,0.0005786125,0.0003731069,0.0000020489695,0.000021341268],"genre_scores_gemma":[0.9951794,0.004378894,0.00019627917,0.000027072618,0.00002199724,0.000017608274,0.000043585394,0.000013383517,0.00012174571],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796945,0.00050194195,0.0010510688,0.00020870735,0.000074077565,0.000194772],"domain_scores_gemma":[0.99749964,0.0008302384,0.0009415904,0.00032364397,0.0003749414,0.000029970413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020927894,0.00016115887,0.001307222,0.00016598799,0.00010505231,0.000013750629,0.00038300743,0.0002278622,0.00006092806],"category_scores_gemma":[0.00015643405,0.000119718316,0.00044715696,0.00033306621,0.00022578401,0.00006778471,0.0001230908,0.00010171658,5.6389126e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23444583,0.008663705,0.016660776,0.0002202747,0.048073307,0.0005663924,0.0060140137,0.00023884466,0.09956407,0.00041956326,0.002031388,0.58310187],"study_design_scores_gemma":[0.27710214,0.0047235307,0.26189318,0.0008567767,0.01970441,0.010894897,0.0013725501,0.00003528668,0.4216505,0.00020774145,0.0011340716,0.00042492797],"about_ca_topic_score_codex":0.000121418874,"about_ca_topic_score_gemma":0.0004636182,"teacher_disagreement_score":0.58267695,"about_ca_system_score_codex":0.000032706223,"about_ca_system_score_gemma":0.00021678583,"threshold_uncertainty_score":0.48819712},"labels":[],"label_agreement":null},{"id":"W3174239144","doi":"10.1111/jdv.17486","title":"Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial","year":2021,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Placebo; Randomized controlled trial; Etanercept; Internal medicine; Plaque psoriasis; Open label; Surgery; Psoriasis; Dermatology; Tumor necrosis factor alpha","score_opus":0.033942147230820445,"score_gpt":0.2879030609756602,"score_spread":0.25396091374483976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174239144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565496,0.028469797,0.00016099028,0.012739026,0.0008876371,0.00071817404,0.00030088922,0.0000047996878,0.00016909787],"genre_scores_gemma":[0.9893762,0.010144629,0.00011491214,0.000064861946,0.00018545486,0.0000069362245,0.000018420236,0.000015301543,0.0000733192],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953494,0.0029310966,0.0012357681,0.00020257865,0.000055437144,0.00022569907],"domain_scores_gemma":[0.99125737,0.0068648937,0.0015030055,0.0002559772,0.00008883053,0.000029913308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005948414,0.00022629173,0.0012266318,0.0000662433,0.00021039681,0.0000045337442,0.0003824654,0.00026638046,0.000030582953],"category_scores_gemma":[0.0006993899,0.00010252899,0.00048721244,0.00009442024,0.0011085863,0.000040254035,0.000090766094,0.00026413423,0.0000019049742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94804674,0.0010120021,0.0018308153,0.000027042166,0.0067628566,0.000060358256,0.002593029,0.000012825532,0.009668075,0.0020287333,0.0017603538,0.026197175],"study_design_scores_gemma":[0.9096748,0.00074352353,0.009953456,0.00010968427,0.0039719287,0.0040226807,0.00035098975,0.000014622789,0.055682313,0.0014263164,0.013900014,0.0001496316],"about_ca_topic_score_codex":0.000021071108,"about_ca_topic_score_gemma":0.000011440701,"teacher_disagreement_score":0.04601424,"about_ca_system_score_codex":0.000013887095,"about_ca_system_score_gemma":0.0000990729,"threshold_uncertainty_score":0.41810107},"labels":[],"label_agreement":null},{"id":"W3178933799","doi":"10.1177/12034754211029188","title":"A Useful Clinical Tool for Psoriasis","year":2021,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Medical physics; Intensive care medicine","score_opus":0.06534728644342147,"score_gpt":0.3023995970525296,"score_spread":0.23705231060910814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178933799","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19388486,0.10439733,0.0001567116,0.66861093,0.031807527,0.000522243,0.00018277977,0.000045392644,0.00039221955],"genre_scores_gemma":[0.013307556,0.06846825,0.00053151004,0.8316484,0.052675366,0.000043646472,0.0016276457,0.00023236185,0.031465232],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968091,0.00056303915,0.0017159474,0.00034028676,0.00013377525,0.00043785124],"domain_scores_gemma":[0.98856354,0.009492408,0.0011751154,0.00028863776,0.0004290732,0.000051246057],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013535229,0.0003923944,0.0022302463,0.00037855675,0.00012419983,0.000018449002,0.00017236642,0.0014390787,0.0006034018],"category_scores_gemma":[0.0018114821,0.00026784508,0.00095545215,0.000116307834,0.00026763172,0.00005434917,0.000031265496,0.0012691027,0.000016849886],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050002325,0.00006690957,0.002932166,0.0001552755,0.0020112835,0.0068377173,0.00009932804,7.042253e-8,0.00018438029,0.000002315267,0.93128705,0.055923454],"study_design_scores_gemma":[0.0014725925,0.0006686676,0.00023382124,0.00069610303,0.00198421,0.021811366,0.000084818836,1.8881998e-7,0.00013345593,0.000108722386,0.9725455,0.00026055388],"about_ca_topic_score_codex":0.0000073781393,"about_ca_topic_score_gemma":0.0000022962447,"teacher_disagreement_score":0.18057731,"about_ca_system_score_codex":0.000035610865,"about_ca_system_score_gemma":0.00042789563,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W3179238984","doi":"10.1007/s13555-021-00572-2","title":"The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score","year":2021,"lang":"en","type":"letter","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sanofi","keywords":"Psoriasis Area and Severity Index; Body surface area; Psoriasis; Plaque psoriasis; Medicine; Severity of illness; Measure (data warehouse); Dermatology; Internal medicine; Computer science; Data mining","score_opus":0.019194619574046435,"score_gpt":0.25204580214016575,"score_spread":0.2328511825661193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179238984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8270318,0.01540798,0.00003983492,0.15520987,0.0005362586,0.0013426414,0.00017590933,0.000058149213,0.00019758995],"genre_scores_gemma":[0.9472775,0.01752932,0.00026928057,0.030881805,0.00017204051,0.00070295675,0.001995586,0.00009199232,0.0010795473],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973525,0.00091159117,0.00050917343,0.000612868,0.00008268,0.0005312257],"domain_scores_gemma":[0.9981826,0.00073214585,0.00034696813,0.00060106657,0.00011220208,0.000025045756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00016397226,0.0004901809,0.0010067692,0.00017177011,0.0003056479,0.000028853307,0.00033038383,0.0014693023,0.000068406014],"category_scores_gemma":[0.000021981381,0.00029860678,0.00016627352,0.00022207866,0.0009020174,0.00007021826,0.0000677769,0.0011775512,0.0000035000617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064505036,0.0022768932,0.5051907,0.00093496306,0.011090964,0.0075411294,0.0042208275,0.0000042084903,0.00453227,0.0019205646,0.38891858,0.06691846],"study_design_scores_gemma":[0.02804429,0.0011870381,0.14741732,0.0016952271,0.0010927347,0.010140763,0.0014105912,0.00005957823,0.052677218,0.0032178417,0.7505365,0.002520881],"about_ca_topic_score_codex":0.00009153052,"about_ca_topic_score_gemma":0.00027116324,"teacher_disagreement_score":0.36161795,"about_ca_system_score_codex":0.000050612845,"about_ca_system_score_gemma":0.00049023627,"threshold_uncertainty_score":0.9999466},"labels":[],"label_agreement":null},{"id":"W3179812036","doi":"","title":"Adalimumab for Adult Patients with Plaque Psoriasis: A Review of Clinical Effectiveness [Internet]","year":2020,"lang":"en","type":"review","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Infliximab; Ixekizumab; Secukinumab; Dermatology; Ustekinumab; Acitretin; Immunology; Internal medicine; Psoriatic arthritis; Tumor necrosis factor alpha","score_opus":0.04600294077429645,"score_gpt":0.3451688572531583,"score_spread":0.29916591647886187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179812036","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026717054,0.99274963,0.00015487296,0.000021740801,0.0012239338,0.004451334,0.0008760872,0.0000703133,0.00042535324],"genre_scores_gemma":[0.000024582105,0.9944714,0.00024218547,0.00018819481,0.00010018839,0.0012153715,0.0031115275,0.00008231903,0.0005642557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99557626,0.0014755849,0.0016718396,0.0008448197,0.00007271151,0.00035876795],"domain_scores_gemma":[0.9957868,0.001931577,0.0011639468,0.0005331508,0.0005267782,0.00005777708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058112206,0.0007111121,0.0053418265,0.00009566762,0.000048201597,0.0000068192458,0.0004845126,0.0008197403,0.000317642],"category_scores_gemma":[0.000655399,0.00042395474,0.0016879713,0.000246382,0.00012981225,0.000052674324,0.00010415746,0.00033631764,0.00031702497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074960175,0.00041163486,0.00016070796,0.13571069,0.004238924,0.000003620343,0.000009250825,4.0722687e-9,9.302791e-8,0.00024276547,0.004181007,0.8542917],"study_design_scores_gemma":[0.0046252618,0.0014866533,0.000093836024,0.13942488,0.007815619,0.00001169744,0.0000028229056,4.8341096e-8,0.000021568158,0.0000048462102,0.8461128,0.0003999569],"about_ca_topic_score_codex":0.000027111637,"about_ca_topic_score_gemma":0.0000101812175,"teacher_disagreement_score":0.85389173,"about_ca_system_score_codex":0.000064107175,"about_ca_system_score_gemma":0.0004127263,"threshold_uncertainty_score":0.99982125},"labels":[],"label_agreement":null},{"id":"W3181628305","doi":"10.1016/j.jdin.2021.05.003","title":"Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study","year":2021,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Plaque psoriasis; Clinical trial; Retrospective cohort study; Drug; Dermatology; Internal medicine; Secukinumab; Surgery; Pharmacology; Psoriatic arthritis","score_opus":0.008285508891869377,"score_gpt":0.22919457058539144,"score_spread":0.22090906169352206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181628305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959425,0.00006152511,0.000006911918,0.000067107554,0.0013180947,0.00020965833,0.00013927829,0.00001643074,0.002238542],"genre_scores_gemma":[0.9971734,0.000009708802,0.000096159514,0.000016329463,0.000035172474,0.000027453212,0.00026263014,0.000012211705,0.0023668816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907845,0.00015623,0.00024544165,0.00027109552,0.000104079394,0.00014467954],"domain_scores_gemma":[0.9994055,0.000057592635,0.00010490528,0.00017766886,0.00024304856,0.000011279565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011146493,0.00012610978,0.00022413734,0.00011241111,0.000029960425,0.000009696762,0.0001563246,0.000065651955,0.0008672802],"category_scores_gemma":[0.00005617426,0.00010575088,0.00005610829,0.00012310584,0.000036847374,0.000091773145,0.00006811109,0.00011269018,0.0000917001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000993539,0.0023175976,0.9935382,0.0000029491184,0.000652192,0.000013271987,0.00095089717,0.000004142116,0.00034821525,0.00028710222,0.00027684958,0.0006150533],"study_design_scores_gemma":[0.011517344,0.00017856175,0.9825812,0.000028793253,0.00005055886,9.2889354e-7,0.0007537616,0.0000013671279,0.004073186,0.000025623587,0.0006835565,0.000105134844],"about_ca_topic_score_codex":0.00007906287,"about_ca_topic_score_gemma":0.00046621723,"teacher_disagreement_score":0.010957007,"about_ca_system_score_codex":0.000098523786,"about_ca_system_score_gemma":0.00004644888,"threshold_uncertainty_score":0.949611},"labels":[],"label_agreement":null},{"id":"W3181909995","doi":"10.4049/jimmunol.2100237","title":"SIGIRR Negatively Regulates IL-36–Driven Psoriasiform Inflammation and Neutrophil Infiltration in the Skin","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"National Children's Research Centre; Health Research Board","keywords":"Infiltration (HVAC); Inflammation; Immunology; Medicine; Materials science; Composite material","score_opus":0.012794409675786688,"score_gpt":0.22408680135646364,"score_spread":0.21129239168067696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181909995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769385,0.008256709,0.000028959208,0.0031169502,0.00049106235,0.00012565819,0.00000655263,0.0000068061227,0.00027346725],"genre_scores_gemma":[0.9965718,0.002955465,0.000070098286,0.000090631045,0.0001088353,0.0000053940003,0.000023479919,0.000008090635,0.00016624176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981523,0.0010355188,0.0004633046,0.000097634926,0.000047359277,0.00020387518],"domain_scores_gemma":[0.9986433,0.00059847813,0.00039148054,0.00021314886,0.00014535672,0.000008238074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066305965,0.00014394164,0.0002717771,0.000121596706,0.00018857159,0.000021317337,0.00025326596,0.00018657454,0.000062438165],"category_scores_gemma":[0.00013244175,0.00008083436,0.00007711592,0.00019645914,0.00021811767,0.00019790283,0.000050451446,0.00035087217,0.000027914733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010656029,0.000110065266,0.0014102011,0.000007929304,0.00057134056,0.000042139694,0.008843648,0.00007790549,0.9279928,0.001821033,0.00028035833,0.057776976],"study_design_scores_gemma":[0.0050022327,0.0009641645,0.47064874,0.00007728219,0.0003957448,0.00467315,0.006979277,0.000011205083,0.49378216,0.0049695373,0.012273897,0.00022260862],"about_ca_topic_score_codex":0.000033906825,"about_ca_topic_score_gemma":0.00011537601,"teacher_disagreement_score":0.46923855,"about_ca_system_score_codex":0.000039726838,"about_ca_system_score_gemma":0.000094727635,"threshold_uncertainty_score":0.32963294},"labels":[],"label_agreement":null},{"id":"W3184268904","doi":"10.1016/j.celrep.2021.109456","title":"Prostaglandin E2 amplifies IL-17 production by γδ T cells during barrier inflammation","year":2021,"lang":"en","type":"article","venue":"Cell Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; McGill University; McGill University Health Centre","funders":"Kenneth Rainin Foundation","keywords":"Inflammation; Eicosanoid; Biology; Immunology; Cytokine; Cell biology; Lipid signaling; Prostaglandin E2; Innate lymphoid cell; Barrier function; Innate immune system; Immune system; Endocrinology; Biochemistry","score_opus":0.008219759475309443,"score_gpt":0.2019434442290206,"score_spread":0.19372368475371116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184268904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262214,0.0022120243,0.000018953306,0.00022063969,0.0020516722,0.00026410967,0.000023858882,0.00009410789,0.0024925072],"genre_scores_gemma":[0.8357824,0.00017142115,0.000033017393,0.000008039823,0.00012029219,0.000049596176,0.00058629754,0.000016144953,0.16323277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988797,0.00009369716,0.00027978563,0.00044119242,0.00004717502,0.0002584611],"domain_scores_gemma":[0.9992471,0.000021282505,0.00022142369,0.00038723843,0.000096732896,0.000026277863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014911497,0.00017075254,0.00019672514,0.00005423306,0.00023678177,0.00003685654,0.000039461513,0.00019241992,0.0003941842],"category_scores_gemma":[0.00006496613,0.0001573063,0.00008240774,0.000113627946,0.000049194132,0.00013830187,0.000041264557,0.00010351173,0.000097675875],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003371558,0.000060901853,0.0047622914,0.000044944976,0.000069519374,0.00022983406,0.00035442872,0.00000763402,0.9783912,0.0000024442215,0.014511331,0.0015318055],"study_design_scores_gemma":[0.0002969004,0.000021360594,0.0023579216,0.000017210034,0.00006829046,0.00036251996,0.00014765306,1.5505692e-7,0.8871081,0.00004632924,0.10942055,0.00015300917],"about_ca_topic_score_codex":0.000009729614,"about_ca_topic_score_gemma":0.000011668123,"teacher_disagreement_score":0.16074027,"about_ca_system_score_codex":0.000049399423,"about_ca_system_score_gemma":0.000068844296,"threshold_uncertainty_score":0.6414765},"labels":[],"label_agreement":null},{"id":"W3185370894","doi":"10.3389/fgene.2021.685280","title":"From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases","year":2021,"lang":"en","type":"review","venue":"Frontiers in Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Society; University of Toronto; University Health Network","funders":"Fonds Wetenschappelijk Onderzoek","keywords":"Tyrosine kinase 2; Janus kinase; Medicine; Immunology; Tyrosine kinase; Psoriasis; Signal transduction; Psoriatic arthritis; Syk; Tofacitinib; Biology; Cancer research; Rheumatoid arthritis; Cytokine; Receptor; Cell biology; Internal medicine","score_opus":0.01011527430947435,"score_gpt":0.2548443808972049,"score_spread":0.24472910658773056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185370894","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03419904,0.9619516,0.000015288802,0.000012083291,0.0027915605,0.0005606696,0.00041440057,0.000025636018,0.000029686478],"genre_scores_gemma":[0.0018201314,0.99599147,0.0007292904,0.000010441579,0.000092848255,0.00010412516,0.0010040323,0.00004229338,0.00020537215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748474,0.0003548242,0.0006621683,0.00081476074,0.00007042154,0.0006130565],"domain_scores_gemma":[0.999188,0.0000974404,0.00018412675,0.00041217796,0.000043038868,0.00007523653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026899323,0.0004179895,0.0012874089,0.00063229905,0.00013016899,0.000048141137,0.00039983116,0.00047858607,0.00010991715],"category_scores_gemma":[0.00015734656,0.0004148538,0.00013936072,0.0009156615,0.0003724273,0.00007401173,0.00030653775,0.00034631448,0.000040877978],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015426902,0.000066037566,0.009824345,0.00053847727,0.0001321749,0.00023553683,0.00022445405,0.000009747361,0.00012472748,0.0000133788835,0.00095211854,0.9878636],"study_design_scores_gemma":[0.0014958137,0.000106475825,0.004693145,0.008386946,0.0006188836,0.00002510353,0.00015266355,0.0000059654935,0.00026694854,0.00009417963,0.98340917,0.00074473803],"about_ca_topic_score_codex":0.000046406854,"about_ca_topic_score_gemma":0.00006621196,"teacher_disagreement_score":0.98711884,"about_ca_system_score_codex":0.00042263008,"about_ca_system_score_gemma":0.0007949181,"threshold_uncertainty_score":0.9998303},"labels":[],"label_agreement":null},{"id":"W3185712937","doi":"10.2174/2666082217666210716145041","title":"Cognitive Functions Assessment in Psoriasis Patients: A Crosssectional Study in University Hospital","year":2021,"lang":"en","type":"article","venue":"Current Psychiatry Research and Reviews","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Montreal Cognitive Assessment; Psoriasis Area and Severity Index; Cognition; Systemic inflammation; Internal medicine; Disease; Severity of illness; Dermatology; Psychiatry; Cognitive impairment; Inflammation","score_opus":0.0739456826952547,"score_gpt":0.38040750176533333,"score_spread":0.30646181907007863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185712937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94437575,0.05147756,0.0000074213667,0.00018118719,0.0023074239,0.001015369,0.00009305355,0.000009527507,0.0005326836],"genre_scores_gemma":[0.98460007,0.013652018,0.000032555745,0.000008535962,0.00007995111,0.00011060091,0.00041397358,0.000008501994,0.0010938222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974686,0.0012898037,0.00030585733,0.00048518568,0.0000860152,0.00036452393],"domain_scores_gemma":[0.99937904,0.00014391732,0.000061939776,0.00016969234,0.0001997524,0.000045662102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007398228,0.00015224241,0.0003207054,0.00029039462,0.00030741945,0.000026391532,0.00009898283,0.00009362545,0.00029198691],"category_scores_gemma":[0.000109607296,0.0001315927,0.000084211235,0.0008447245,0.00013314602,0.00012290312,0.00012264893,0.00058422727,0.00013901314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013449584,0.0069003874,0.93413514,0.000055148153,0.00007308257,0.00000814919,0.00031039093,7.24355e-8,0.000014177041,0.0001441572,0.0022231152,0.056001667],"study_design_scores_gemma":[0.005331921,0.00072834844,0.9471999,0.00026737404,0.00004240123,0.0000029232453,0.0036552863,3.9915548e-7,0.000005807767,0.00010103332,0.042523034,0.00014159676],"about_ca_topic_score_codex":0.00004851386,"about_ca_topic_score_gemma":0.0013810418,"teacher_disagreement_score":0.05586007,"about_ca_system_score_codex":0.000117606345,"about_ca_system_score_gemma":0.00031704002,"threshold_uncertainty_score":0.5366194},"labels":[],"label_agreement":null},{"id":"W3186120662","doi":"10.2196/28149","title":"Impact of an eHealth Smartphone App on the Mental Health of Patients With Psoriasis: Prospective Randomized Controlled Intervention Study","year":2021,"lang":"en","type":"article","venue":"JMIR mhealth and uhealth","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"eHealth; mHealth; Mental health; Intervention (counseling); Randomized controlled trial; Smartphone app; Medicine; Telehealth; Telemedicine; Psychological intervention; Psychology; Physical therapy; Psychiatry; Internet privacy; Health care; Computer science","score_opus":0.015663392497773425,"score_gpt":0.3214313237189027,"score_spread":0.3057679312211293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186120662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933095,0.0031554627,0.00000985916,0.00040668153,0.00038481658,0.0062995143,0.000299198,0.00003308369,0.000080436155],"genre_scores_gemma":[0.9982232,0.00053299527,0.000037492737,0.000148088,0.00003192817,0.00049648935,0.00039469713,0.000024010391,0.00011110434],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99427295,0.003397128,0.0011693335,0.00047878563,0.00016456361,0.00051723025],"domain_scores_gemma":[0.9973848,0.0004927587,0.0012759068,0.00043426128,0.00026735145,0.00014494744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002111472,0.00033616263,0.0020409499,0.00017002426,0.00040595737,0.000011829685,0.00012770577,0.00012111263,0.00012635096],"category_scores_gemma":[0.00010108945,0.00017856646,0.0003259731,0.00030396908,0.00021186232,0.000087685825,0.00003812555,0.00025594936,0.0000056473664],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7087217,0.01759292,0.21997246,0.00053740887,0.0027933205,0.0000025563338,0.01239911,0.0000034440236,0.000057396614,0.000721875,0.00039879477,0.036799017],"study_design_scores_gemma":[0.36553615,0.011186955,0.62074673,0.000110966845,0.00023333033,0.000004889447,0.001875615,0.000004883328,0.00010989702,0.00006113137,0.00001110602,0.00011831742],"about_ca_topic_score_codex":0.00099579,"about_ca_topic_score_gemma":0.00043871297,"teacher_disagreement_score":0.4007743,"about_ca_system_score_codex":0.00022082026,"about_ca_system_score_gemma":0.00078278617,"threshold_uncertainty_score":0.7281729},"labels":[],"label_agreement":null},{"id":"W3187307731","doi":"10.1080/09546634.2021.1959501","title":"Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis","year":2021,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Probity Medical Research","funders":"LEO Pharma","keywords":"Medicine; Psoriasis; Clinical endpoint; Hazard ratio; Internal medicine; Adverse effect; Gastroenterology; Dermatology; Randomized controlled trial; Confidence interval","score_opus":0.023649579152604096,"score_gpt":0.2408794334713459,"score_spread":0.2172298543187418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187307731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968239,0.0018685759,0.00020686469,0.000324675,0.00007020214,0.00046121722,0.00004014491,0.000017219418,0.00018717718],"genre_scores_gemma":[0.99711096,0.0005022083,0.002126484,0.00002251234,0.000019272182,0.000032327214,0.00008556945,0.000016165226,0.00008450388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976946,0.00050711527,0.00079583685,0.00044324592,0.0001466415,0.00041256932],"domain_scores_gemma":[0.9975646,0.0012286308,0.00057445274,0.00026921404,0.00025549572,0.000107600856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009739659,0.00043934057,0.0013829983,0.00028513433,0.00014307814,0.000024419898,0.00011266534,0.00027393855,0.0000659251],"category_scores_gemma":[0.00009909239,0.00024100438,0.00026855836,0.00069926895,0.00017813753,0.00013560196,0.000041340012,0.00017717248,0.000003587891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007728624,0.0055268523,0.94498897,0.000017409855,0.011069398,0.0009738113,0.0005694187,0.00011426975,0.00024353986,0.0000498386,0.0000052039536,0.028712638],"study_design_scores_gemma":[0.02623902,0.011081551,0.9470949,0.000120206874,0.004604657,0.0006428228,0.0004123465,0.000007515305,0.00937751,0.00002592779,0.0001271626,0.00026635182],"about_ca_topic_score_codex":0.00007109541,"about_ca_topic_score_gemma":0.00033403453,"teacher_disagreement_score":0.028446287,"about_ca_system_score_codex":0.00044012518,"about_ca_system_score_gemma":0.00026982446,"threshold_uncertainty_score":0.9827874},"labels":[],"label_agreement":null},{"id":"W3187385535","doi":"10.1139/apnm-2021-0217","title":"Dietary Inflammatory Index in relation to psoriasis risk, cardiovascular risk factors, and clinical outcomes: a case-control study in psoriasis patients","year":2021,"lang":"en","type":"article","venue":"Applied Physiology Nutrition and Metabolism","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kermanshah University of Medical Sciences","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Odds ratio; Internal medicine; Confounding; Confidence interval; Disease; Logistic regression; Body mass index; Severity of illness; Gastroenterology; Immunology","score_opus":0.015834827931178318,"score_gpt":0.2516226903651741,"score_spread":0.23578786243399577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187385535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929876,0.0045247637,0.000011890193,0.000019367035,0.00075061613,0.0013707331,0.0002754228,0.000039119048,0.00002049947],"genre_scores_gemma":[0.9959322,0.003232605,0.00007241656,0.00009307605,0.00008274495,0.00036289968,0.00018993818,0.000023686194,0.000010430121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613607,0.0018472801,0.00074252405,0.00082432013,0.00006908052,0.00038070264],"domain_scores_gemma":[0.99855125,0.0006777648,0.00019776568,0.0004221784,0.0000730891,0.00007795508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072807947,0.000370535,0.0011756014,0.00031158442,0.00021309606,0.000014219044,0.000084716856,0.00052454113,0.000034291254],"category_scores_gemma":[0.0002322832,0.0003222972,0.00026321292,0.0003068344,0.00010620162,0.00010219081,0.0001000505,0.0005242651,0.00002422238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049609906,0.0016787539,0.9462231,0.000015766498,0.0018013624,0.00005567174,0.0011116328,0.000018241499,0.0006430936,0.000040035007,0.00002738366,0.04788886],"study_design_scores_gemma":[0.025141483,0.00006864208,0.97005755,0.000012290077,0.0010302854,0.000010842827,0.0013486452,0.0000032100613,0.00015085157,0.00034365544,0.0015386813,0.0002938622],"about_ca_topic_score_codex":0.0006343681,"about_ca_topic_score_gemma":0.0006887212,"teacher_disagreement_score":0.047594994,"about_ca_system_score_codex":0.000034087247,"about_ca_system_score_gemma":0.00003217753,"threshold_uncertainty_score":0.99992293},"labels":[],"label_agreement":null},{"id":"W3189146888","doi":"10.1007/s13555-021-00585-x","title":"Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"UCB Pharma; Janssen Pharmaceuticals; Manchester Biomedical Research Centre; Sanofi Genzyme; Allergan; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; National Institute for Health and Care Research; Inozyme Pharma; Pfizer; Incyte; Castle Biosciences; Dermira; Vertex Pharmaceuticals; Regeneron Pharmaceuticals; Celgene; Medac; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Plaque psoriasis; Betamethasone dipropionate; Medicine; Term (time); Psoriasis; Dermatology; Anesthesia; Physics","score_opus":0.014687963623217636,"score_gpt":0.24568417798942385,"score_spread":0.2309962143662062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189146888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620106,0.022724338,0.000034256947,0.00029617088,0.00015989313,0.00041039966,0.00011407395,0.000020452228,0.00003936715],"genre_scores_gemma":[0.98550403,0.013844318,0.00019926007,0.000023336786,0.000013484487,0.000083309795,0.00019418131,0.000015740161,0.00012233284],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864626,0.00039095964,0.00033283533,0.0003809371,0.00004109655,0.00020789298],"domain_scores_gemma":[0.9990376,0.00027194852,0.0002768344,0.00020002895,0.00017860637,0.00003497117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000057502453,0.0002515774,0.00063358113,0.000095289404,0.00012937041,0.000005647121,0.000048409467,0.00026177365,0.000053325377],"category_scores_gemma":[0.000031896136,0.00016869756,0.00006390115,0.00012532667,0.00042466706,0.0000701748,0.000026283118,0.000086195185,0.0000017220165],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011569866,0.0023618739,0.32855612,0.00008969524,0.0033814819,0.00032900803,0.0071672364,4.7393507e-7,0.23638348,0.00043401442,0.000024650768,0.4097021],"study_design_scores_gemma":[0.0044427086,0.0012945987,0.115296565,0.00006887751,0.00022655542,0.00080311496,0.00027948845,0.0000015695455,0.8767173,0.00010194091,0.0006052252,0.00016200352],"about_ca_topic_score_codex":0.000020896994,"about_ca_topic_score_gemma":0.000007653515,"teacher_disagreement_score":0.6403339,"about_ca_system_score_codex":0.000017219814,"about_ca_system_score_gemma":0.0001006591,"threshold_uncertainty_score":0.68792874},"labels":[],"label_agreement":null},{"id":"W3189225536","doi":"10.3389/fmed.2021.702776","title":"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab","year":2021,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University of Manitoba; McMaster University; Université de Sherbrooke; Université Laval; University of Ottawa","funders":"Fonds de Recherche du Québec - Santé; Sun Pharma","keywords":"Psoriasis; Medicine; Interleukin 23; Pathogenesis; Immunology; Disease; Immune system; Tumor necrosis factor alpha; Interleukin 17; Internal medicine","score_opus":0.03155439954830183,"score_gpt":0.29952822150077574,"score_spread":0.2679738219524739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189225536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014318101,0.99572146,0.000040481667,0.0006129821,0.00095919176,0.002203557,0.0000951881,0.000009756734,0.00021422282],"genre_scores_gemma":[0.00008880274,0.9982256,0.00031598113,0.00020646102,0.00009608981,0.00030662163,0.00038105785,0.00002936416,0.00034999277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722075,0.0011237384,0.00078011036,0.00047673553,0.000061231134,0.00033745263],"domain_scores_gemma":[0.9978467,0.0010532144,0.00060292025,0.00043721125,0.00004316042,0.00001678689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011713437,0.00042818306,0.0025134718,0.00016328877,0.00014147085,0.0000029834755,0.00036048557,0.0003284684,0.00003642702],"category_scores_gemma":[0.0008472674,0.00017809405,0.00027521997,0.00058915763,0.00031131125,0.000012868747,0.000077454744,0.00039420903,0.0000020971752],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001567967,0.00007171081,0.0002449094,0.008743188,0.00065465906,0.000007012172,0.00025110692,3.9439803e-7,0.0000022035194,0.000029583261,0.020729512,0.96910894],"study_design_scores_gemma":[0.003388309,0.00041474611,0.0001740831,0.15625368,0.0022920324,0.000031612613,0.0003147323,4.7665324e-7,0.000010095284,0.000016451897,0.8369,0.00020382104],"about_ca_topic_score_codex":0.000036666173,"about_ca_topic_score_gemma":0.00002087439,"teacher_disagreement_score":0.9689051,"about_ca_system_score_codex":0.00012632043,"about_ca_system_score_gemma":0.00012238121,"threshold_uncertainty_score":0.7262465},"labels":[],"label_agreement":null},{"id":"W3190122872","doi":"10.1080/09546634.2021.1959504","title":"Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study","year":2021,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Probity Medical Research; Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Plaque psoriasis; Dermatology; Psoriasis; Psoriatic arthritis","score_opus":0.03732038913152342,"score_gpt":0.2685031290800881,"score_spread":0.2311827399485647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190122872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976771,0.00062690565,0.0000066528187,0.0003178172,0.00040193307,0.0004647186,0.0003932542,0.00000667103,0.00010494431],"genre_scores_gemma":[0.99933845,0.00008984543,0.0002808744,0.000018284603,0.00003532816,0.00001700595,0.00018343017,0.0000097468255,0.000027019925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978351,0.00061064254,0.00095254806,0.00024942285,0.00013237771,0.00021990402],"domain_scores_gemma":[0.99765724,0.0011167892,0.000575623,0.0003528489,0.00025485925,0.00004265056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001267418,0.00024007929,0.00077190803,0.00009785557,0.000093882605,0.000010884246,0.00020295115,0.00016060646,0.0000875786],"category_scores_gemma":[0.00022386647,0.00012529324,0.00019376638,0.00028793784,0.00006216804,0.00007285207,0.00005230468,0.00014854709,0.000013279378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09192083,0.021554427,0.8593623,0.000008788436,0.0055437665,0.0006146199,0.0075751687,0.0026687463,0.0003917496,0.00011000152,0.00046844035,0.009781131],"study_design_scores_gemma":[0.070454255,0.0033231236,0.91458505,0.00008776645,0.00081461895,0.000054785232,0.0016529581,0.0000023707753,0.008450285,0.0000745603,0.00034262473,0.00015759305],"about_ca_topic_score_codex":0.00009019641,"about_ca_topic_score_gemma":0.00033889074,"teacher_disagreement_score":0.055222727,"about_ca_system_score_codex":0.00012705858,"about_ca_system_score_gemma":0.00014349709,"threshold_uncertainty_score":0.51093096},"labels":[],"label_agreement":null},{"id":"W3191495509","doi":"10.1016/j.jdin.2021.05.008","title":"Sex differences in factors associated with switch between systemic agents among individuals with psoriasis: A retrospective cohort study in Quebec, Canada","year":2021,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Université de Montréal; McGill University Health Centre; Impact; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Fonds de Recherche du Québec - Santé","keywords":"Psoriasis; Medicine; Scopus; Discontinuation; Retrospective cohort study; Ustekinumab; Cohort study; Cohort; Internal medicine; Dermatology; MEDLINE; Tumor necrosis factor alpha; Adalimumab","score_opus":0.019631417986888878,"score_gpt":0.2342398557399717,"score_spread":0.2146084377530828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3191495509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819565,0.00009133301,0.0000029711105,0.000048001177,0.0004263084,0.0004764215,0.00025580218,0.000023407982,0.0004801022],"genre_scores_gemma":[0.99450386,0.0000069928637,0.0000025266384,0.000014128976,0.000027989508,0.00013298157,0.0008307854,0.000015284737,0.0044654505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983272,0.0003661645,0.00035167942,0.0004537735,0.00022334751,0.00027783072],"domain_scores_gemma":[0.99925303,0.00021307361,0.00021127694,0.00015937208,0.00013786377,0.000025390818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021347604,0.0002394138,0.0005278697,0.00017463343,0.00006731974,0.000037610265,0.00023480639,0.0001485057,0.00023764677],"category_scores_gemma":[0.000104221916,0.0001789198,0.000033836783,0.00031538052,0.000046602527,0.00012778035,0.000057605354,0.00023705898,0.0000046522814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041503972,0.0003363064,0.9951546,0.0000026281004,0.0022986296,0.000101152335,0.0017615225,0.0000052275145,0.000049045473,0.000010170657,0.00012267637,0.000116547286],"study_design_scores_gemma":[0.003143693,0.000100258796,0.99153894,0.00016286102,0.00013181705,0.0000036997953,0.003927259,0.0000015828501,0.0007596955,0.000008119666,0.00001698796,0.00020510585],"about_ca_topic_score_codex":0.47023842,"about_ca_topic_score_gemma":0.96848303,"teacher_disagreement_score":0.4982446,"about_ca_system_score_codex":0.0010886403,"about_ca_system_score_gemma":0.00046492915,"threshold_uncertainty_score":0.7296138},"labels":[],"label_agreement":null},{"id":"W3192134537","doi":"10.1155/2021/5515868","title":"Associations between <i>ERAP1</i> Gene Polymorphisms and Psoriasis Susceptibility: A Meta‐Analysis of Case‐Control Studies","year":2021,"lang":"en","type":"review","venue":"BioMed Research International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cochrane Library; Psoriasis; Meta-analysis; Polymorphism (computer science); Gene; Genetics; Medicine; Biology; Internal medicine; Allele; Immunology","score_opus":0.2861055540488362,"score_gpt":0.4517824470985754,"score_spread":0.1656768930497392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192134537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044256568,0.97419405,0.000021275642,0.00030596895,0.00081837614,0.00060424523,0.023517078,0.000025729514,0.000070700844],"genre_scores_gemma":[0.002764032,0.9878244,0.00016721015,0.000012607438,0.00025471993,0.00033008654,0.0064642304,0.00003180514,0.0021509537],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994386,0.0028591733,0.0010866993,0.0008198375,0.00033561004,0.00051264476],"domain_scores_gemma":[0.9928088,0.0049898387,0.0005345132,0.00053278904,0.0010641993,0.000069863825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029510884,0.0004306121,0.0041922093,0.002425701,0.00033039114,0.000053509906,0.0004678813,0.0006050211,0.0008568715],"category_scores_gemma":[0.00084596046,0.0003235457,0.0022983195,0.0019307262,0.0005595246,0.00008287141,0.00035406937,0.00045867756,0.00004765438],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013884863,0.00017685734,0.00024475914,0.00021301761,0.77738523,0.00015384573,0.00015976586,1.7679648e-7,0.00009927558,0.00018043799,0.0011127712,0.22026],"study_design_scores_gemma":[0.0010828254,0.00013278349,0.00035807886,0.00023010456,0.58564144,0.00017459528,0.00013434853,8.4274626e-7,0.00022144265,0.00006643371,0.41155776,0.00039932277],"about_ca_topic_score_codex":0.00037155676,"about_ca_topic_score_gemma":0.00024999876,"teacher_disagreement_score":0.41044497,"about_ca_system_score_codex":0.00031919815,"about_ca_system_score_gemma":0.0003588856,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W3192809805","doi":"10.1016/j.jaad.2021.07.040","title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Bellus Health (Canada); Queen's University; University of British Columbia; Probity Medical Research","funders":"UCB; Celgene; Boehringer Ingelheim; Eli Lilly and Company; Amgen","keywords":"Apremilast; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Adverse effect; Body surface area; Internal medicine; Dermatology Life Quality Index; Nausea; Randomized controlled trial; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.016988566822548692,"score_gpt":0.2859902605222075,"score_spread":0.2690016936996588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192809805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514973,0.0010101463,0.000035272787,0.0016966981,0.00029154588,0.0016847765,0.00007679903,0.0000036233298,0.000051387015],"genre_scores_gemma":[0.9989388,0.00046122866,0.00035641165,0.00013062975,0.00002512927,0.000030856296,0.000010452801,0.000014928814,0.000031540123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995712,0.001713594,0.0019257403,0.00023654867,0.00012855277,0.00028360702],"domain_scores_gemma":[0.99477714,0.0015689465,0.0032190408,0.00019073243,0.00019091142,0.00005320053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006042885,0.0002568623,0.0026936983,0.00033678874,0.000054980857,0.0000040380205,0.0003339915,0.00019913379,0.0000100458365],"category_scores_gemma":[0.00043628737,0.0001556448,0.0003572815,0.00036687875,0.0006839319,0.00007856959,0.00010318954,0.00040825907,0.0000014066243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9850278,0.0017643006,0.0018234795,0.000027322785,0.0024142633,0.00000985856,0.00071450893,0.000088365516,0.006481487,0.000029893728,0.00013080704,0.0014879312],"study_design_scores_gemma":[0.93560517,0.000829788,0.0020568352,0.00020549915,0.0009921896,0.00014813639,0.00015772556,0.00000824273,0.05972211,0.000011514518,0.00014127628,0.00012153279],"about_ca_topic_score_codex":0.000029948686,"about_ca_topic_score_gemma":0.000008558494,"teacher_disagreement_score":0.053240623,"about_ca_system_score_codex":0.00002990215,"about_ca_system_score_gemma":0.00017630066,"threshold_uncertainty_score":0.6347011},"labels":[],"label_agreement":null},{"id":"W3193126242","doi":"10.1111/bcp.15034","title":"Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)","year":2021,"lang":"en","type":"article","venue":"British Journal of Clinical Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Medicine; Psoriasis Area and Severity Index; Population; Dosing; Pharmacokinetics; Pharmacology; Internal medicine; Dermatology","score_opus":0.02250769926121333,"score_gpt":0.31944736475063074,"score_spread":0.2969396654894174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193126242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931714,0.0047241114,0.00005121264,0.00018173132,0.001469627,0.00022883841,0.00012166947,0.000008986843,0.00004240874],"genre_scores_gemma":[0.99617654,0.0027305074,0.00031546704,0.00032847407,0.00019257501,0.000008528585,0.00015367685,0.000018596282,0.00007562818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962086,0.0013189907,0.001658951,0.00037536488,0.00011751136,0.00032056216],"domain_scores_gemma":[0.99746716,0.0010257018,0.00078279234,0.00011566813,0.00048842514,0.00012024909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076714926,0.00020301406,0.0013301979,0.0004942189,0.000077277466,0.000017806105,0.00018424864,0.0003021011,0.00064036896],"category_scores_gemma":[0.00034221268,0.00020013303,0.00031939847,0.0009978851,0.00010305401,0.00015376594,0.00007990571,0.0004988112,0.0000075396642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067920256,0.0026690383,0.611536,0.000026995816,0.005176478,0.0005259793,0.00014518871,0.0032061548,0.0011072247,0.0000048447496,0.0016443497,0.36716565],"study_design_scores_gemma":[0.02263333,0.00082480913,0.96982914,0.00005185261,0.004391774,0.00021212509,0.00003383313,0.000044187924,0.0011450112,0.000022517428,0.00060490955,0.00020648043],"about_ca_topic_score_codex":0.000072849245,"about_ca_topic_score_gemma":0.00015308656,"teacher_disagreement_score":0.36695918,"about_ca_system_score_codex":0.000041337666,"about_ca_system_score_gemma":0.00015372288,"threshold_uncertainty_score":0.8161188},"labels":[],"label_agreement":null},{"id":"W3194137308","doi":"10.1016/j.jaad.2021.06.356","title":"26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Dermatology; Plaque psoriasis; Clinical trial; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.01308272054913317,"score_gpt":0.27586255638548524,"score_spread":0.26277983583635206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194137308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459326,0.00096901064,0.000027193373,0.0038794982,0.00015191203,0.00029967862,0.000037974587,0.0000018588095,0.000039640247],"genre_scores_gemma":[0.9987552,0.00038367702,0.00028890412,0.00052242674,0.000018731791,0.0000065421273,0.000003619577,0.00000885701,0.000012039253],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997917,0.0008979455,0.0007144446,0.0001591441,0.00008223142,0.000229213],"domain_scores_gemma":[0.99837416,0.0005210024,0.0008741312,0.00014695583,0.00005887467,0.000024858346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021345858,0.00015792821,0.0007827964,0.00016739196,0.00005127454,0.000003267513,0.00034458248,0.00011280084,0.000009826941],"category_scores_gemma":[0.00013458468,0.00009008562,0.00009695497,0.00044015635,0.0003306921,0.00007180688,0.000071237104,0.00040204317,0.0000014990629],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5329689,0.0059706667,0.3579505,0.00010038593,0.0017444254,0.000115317736,0.0077058673,0.0007519471,0.03998041,0.00058826536,0.0018652807,0.050258026],"study_design_scores_gemma":[0.2200931,0.0027224317,0.66205865,0.00041935273,0.00047362427,0.0012077152,0.0012625369,0.0000069338516,0.1059283,0.00018378987,0.00528625,0.0003572829],"about_ca_topic_score_codex":0.000013722339,"about_ca_topic_score_gemma":0.000014836963,"teacher_disagreement_score":0.3128758,"about_ca_system_score_codex":0.000027376058,"about_ca_system_score_gemma":0.00009328213,"threshold_uncertainty_score":0.3673585},"labels":[],"label_agreement":null},{"id":"W3194232218","doi":"10.1016/j.jaad.2021.06.345","title":"25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"","keywords":"Medicine; Dermatology; Monoclonal; Interleukin 23; Psoriasis; Monoclonal antibody; Plaque psoriasis; Internal medicine; Pharmacology; Immunology; Interleukin 17; Antibody; Cytokine","score_opus":0.012845542329437395,"score_gpt":0.270598440928868,"score_spread":0.25775289859943057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194232218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973149,0.020909533,0.000004142538,0.0055180714,0.0001396834,0.00008615448,0.00004132601,0.000004418056,0.00014767182],"genre_scores_gemma":[0.9951485,0.0039811395,0.0002805389,0.0003175345,0.000016367489,0.0000013932319,0.0000037373673,0.000013434542,0.00023735708],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99810535,0.000657483,0.00069443055,0.0001952149,0.0000673057,0.00028019416],"domain_scores_gemma":[0.9982673,0.00046488742,0.0010290041,0.00014836581,0.000048885257,0.000041587155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001853361,0.00018166765,0.0008936212,0.00015104865,0.00006377745,0.000004769662,0.00028055935,0.00022064806,0.00005239872],"category_scores_gemma":[0.00013960034,0.00013290271,0.00014192384,0.00028308475,0.0008192348,0.000073129195,0.00013997448,0.00045618604,0.0000061512415],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002647821,0.0005937859,0.29173863,0.000080369646,0.0013069782,0.000088837834,0.001109749,0.000013078669,0.66129863,0.00030398308,0.019380195,0.021437915],"study_design_scores_gemma":[0.010019813,0.00041108677,0.5151012,0.00019709306,0.00050652894,0.009821576,0.0011620116,0.0000029134771,0.427102,0.00034071953,0.035030127,0.00030497223],"about_ca_topic_score_codex":0.000045747096,"about_ca_topic_score_gemma":0.0000041676008,"teacher_disagreement_score":0.23419668,"about_ca_system_score_codex":0.00002448695,"about_ca_system_score_gemma":0.00009339257,"threshold_uncertainty_score":0.54196155},"labels":[],"label_agreement":null},{"id":"W3194315489","doi":"10.1111/dth.15104","title":"Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review","year":2021,"lang":"en","type":"review","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; Sunnybrook Health Science Centre; University of Manitoba; Western University; University of Toronto; Dalhousie University; SKiN Health; Queen's University; St. Paul's Hospital; Memorial University of Newfoundland; Guenther Dermatology Research Centre; Probity Medical Research","funders":"","keywords":"Medicine; Intensive care medicine; Maintenance therapy; Psoriasis; Context (archaeology); Narrative review; Dermatology; Surgery","score_opus":0.07861494477628093,"score_gpt":0.345905914063979,"score_spread":0.2672909692876981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194315489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014386087,0.995782,0.0000150624965,0.00053298834,0.00087239814,0.002114213,0.00014157493,0.0000920769,0.00030583373],"genre_scores_gemma":[0.00018830887,0.9967406,0.00005499828,0.00016128391,0.00006968693,0.0013959947,0.0010911041,0.00004238905,0.00025567223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585253,0.0017217465,0.0010734462,0.0007693965,0.000074115815,0.0005087642],"domain_scores_gemma":[0.99805135,0.00040945836,0.0007584027,0.0006843751,0.00005159626,0.00004480911],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013260863,0.00088178506,0.004675411,0.00015590212,0.00016098641,0.000013882982,0.000370114,0.0008167865,0.0007921282],"category_scores_gemma":[0.000032564778,0.0005550516,0.0015678398,0.00039099006,0.00017481367,0.0000653691,0.000047119232,0.00024882978,0.00014647054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005099184,0.00068084453,0.000017743463,0.0035278355,0.005421393,0.00011945789,0.002331467,2.2472475e-8,0.0000018160102,0.00086972915,0.001001349,0.98597735],"study_design_scores_gemma":[0.0013471642,0.00047184678,0.000016127435,0.008505416,0.00204241,0.0005225235,0.00018764344,2.0976598e-8,0.00030105334,0.000121572855,0.98600113,0.00048310525],"about_ca_topic_score_codex":0.000019277317,"about_ca_topic_score_gemma":0.0000031108993,"teacher_disagreement_score":0.98549426,"about_ca_system_score_codex":0.00015752544,"about_ca_system_score_gemma":0.0003812263,"threshold_uncertainty_score":0.9996901},"labels":[],"label_agreement":null},{"id":"W3194367373","doi":"10.1016/j.jaad.2021.06.329","title":"25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Randomized controlled trial; Multicenter study; Internal medicine; Double blinded; Severity of illness; Dermatology; Surgery; Pathology; Placebo; Alternative medicine","score_opus":0.05329753619340438,"score_gpt":0.3557059412527911,"score_spread":0.3024084050593867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194367373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791808,0.0032301946,0.0006247443,0.012846917,0.0014739651,0.0012667307,0.0013333499,0.000020263114,0.000023018249],"genre_scores_gemma":[0.99558413,0.0008390923,0.0018391595,0.0012915243,0.00015637482,0.00006686361,0.00008174966,0.000036153004,0.00010496369],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99295694,0.0030687687,0.0027735448,0.0004458026,0.00014924114,0.0006056812],"domain_scores_gemma":[0.9893305,0.0055731875,0.0043225144,0.00035692117,0.0003050479,0.000111869755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011494777,0.00041538102,0.0033878859,0.00019700394,0.00025488867,0.000023895947,0.0006815012,0.00036940194,0.00004685781],"category_scores_gemma":[0.002231701,0.00027087415,0.001424831,0.0003991825,0.0004944192,0.00013328594,0.0002083553,0.0005194472,0.000027156222],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8579107,0.0012438713,0.000106704516,0.000019465893,0.0060775983,0.000052576182,0.002805934,0.00024297602,0.09121494,0.00006479397,0.005729103,0.034531344],"study_design_scores_gemma":[0.4884483,0.0002870332,0.0002534048,0.00011193419,0.0014296777,0.0009424174,0.00076977676,0.000026475303,0.501311,0.0002017416,0.0059685633,0.00024971124],"about_ca_topic_score_codex":0.000091585855,"about_ca_topic_score_gemma":0.000012726671,"teacher_disagreement_score":0.41009605,"about_ca_system_score_codex":0.000084870786,"about_ca_system_score_gemma":0.00023613936,"threshold_uncertainty_score":0.99997437},"labels":[],"label_agreement":null},{"id":"W3194398820","doi":"10.1177/12034754211038509","title":"Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature","year":2021,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Melanoma; Systemic therapy; Topical agents; Intensive care medicine; Cancer; Internal medicine; Cancer research","score_opus":0.040543521974702894,"score_gpt":0.2894559459481505,"score_spread":0.2489124239734476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194398820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007631231,0.99067134,0.0000048084635,0.00018279976,0.000984892,0.00040192227,0.00007474807,0.000003995781,0.000044279357],"genre_scores_gemma":[0.00076355704,0.99844664,0.00003307354,0.00013011116,0.00016615409,0.00001025407,0.000053280848,0.000028180357,0.0003687476],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99641275,0.0012434385,0.0017219161,0.00022507607,0.00017560799,0.000221182],"domain_scores_gemma":[0.9946866,0.0017640458,0.0026819103,0.00037265668,0.00043850334,0.000056272398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097093394,0.00041699593,0.00453908,0.00036738798,0.00007281246,0.0000060569887,0.00024118242,0.00033217587,0.000069773596],"category_scores_gemma":[0.00075685716,0.00018613564,0.00077480887,0.0006983001,0.0001064225,0.00003394734,0.00004670032,0.00039602863,0.000002377309],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020070808,0.000086901025,0.0010023009,0.12692022,0.0051762634,0.0014655791,0.0012057098,2.2838933e-7,0.00005802382,0.0000108383065,0.016136862,0.84773636],"study_design_scores_gemma":[0.00037532096,0.00025401026,0.000024147823,0.59831315,0.008401361,0.036825657,0.00012311272,5.5041354e-9,0.000061490784,0.0000020733303,0.35545805,0.00016160794],"about_ca_topic_score_codex":0.000011550724,"about_ca_topic_score_gemma":0.000003956304,"teacher_disagreement_score":0.8475748,"about_ca_system_score_codex":0.00006322313,"about_ca_system_score_gemma":0.0007119223,"threshold_uncertainty_score":0.75903916},"labels":[],"label_agreement":null},{"id":"W3194711549","doi":"10.1016/j.jaad.2021.06.336","title":"25983 Rates of individual and composite cardiovascular events through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Monoclonal; Clinical trial; Plaque psoriasis; Psoriasis; Internal medicine; Dermatology; Monoclonal antibody; Interleukin 23; Immunology; Antibody; Interleukin; Cytokine","score_opus":0.07598746161508962,"score_gpt":0.38961181960893976,"score_spread":0.31362435799385013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194711549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718929,0.026864706,0.000015938951,0.00076667167,0.000258978,0.00011356798,0.00007280805,0.0000018092678,0.000012606889],"genre_scores_gemma":[0.9957904,0.0035849109,0.0004345673,0.0001354244,0.000028008059,0.0000016326604,0.000005833962,0.000008733405,0.000010486498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99408513,0.0037610817,0.0017179905,0.00015060845,0.000108075204,0.00017714036],"domain_scores_gemma":[0.99616426,0.0012116631,0.0023639868,0.00016587372,0.000070954346,0.000023285196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001347306,0.00013439346,0.0021132089,0.00012633782,0.0000261079,0.0000018990993,0.0003546674,0.0002273384,0.000018579609],"category_scores_gemma":[0.0005190815,0.000098015546,0.00076118385,0.00026795335,0.0007008511,0.00006897678,0.00013731391,0.0004000011,0.0000015289612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004196047,0.0018398949,0.602154,0.00012371,0.016564453,0.00017063448,0.0019264707,0.0000377532,0.19887774,0.00016861707,0.0012003471,0.17274031],"study_design_scores_gemma":[0.015171687,0.00057114876,0.6033279,0.00018944297,0.0021074146,0.0041295146,0.0007409134,7.617534e-7,0.3697634,0.0004462268,0.0034006897,0.00015090239],"about_ca_topic_score_codex":0.000017571778,"about_ca_topic_score_gemma":0.0000011239601,"teacher_disagreement_score":0.1725894,"about_ca_system_score_codex":0.000010743743,"about_ca_system_score_gemma":0.00013272901,"threshold_uncertainty_score":0.39969578},"labels":[],"label_agreement":null},{"id":"W3194827476","doi":"","title":"Fatal COVID19 in pd patient on IL-23 Inhibitor","year":2021,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Hemodialysis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Intensive care medicine; Virology; Internal medicine; Disease; Outbreak","score_opus":0.014823346808316627,"score_gpt":0.24079999548185166,"score_spread":0.22597664867353504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194827476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881694,0.00035971042,0.000038990333,0.0005264172,0.002315106,0.00007740259,0.0002944364,0.00003203562,0.008186537],"genre_scores_gemma":[0.99418825,0.00007259435,0.000116597264,0.00040137846,0.00012362354,0.00004120927,0.0016978233,0.000010864826,0.003347687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897355,0.00013678722,0.0002743813,0.0003364087,0.00008531887,0.00019354076],"domain_scores_gemma":[0.9994777,0.00013931307,0.00007534823,0.0001997615,0.00008882905,0.000019062141],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00008541163,0.00014635472,0.00020490025,0.00018862028,0.000060280367,0.000020963009,0.00013839996,0.00014535133,0.0018285844],"category_scores_gemma":[0.00011240234,0.00013839662,0.00016014691,0.00016349195,0.00003990992,0.000067769484,0.00007846355,0.00012562433,0.0016468392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017844484,0.0042255963,0.10288658,0.000019441064,0.0030549553,0.00087056024,0.002806818,0.00051881437,0.48844942,0.008759271,0.034574643,0.35204944],"study_design_scores_gemma":[0.0044637774,0.00016449942,0.028439842,0.00006110679,0.00011315365,0.00007285772,0.00034719126,0.000053470845,0.8010861,0.00032754708,0.16448341,0.00038703054],"about_ca_topic_score_codex":0.000030454674,"about_ca_topic_score_gemma":0.00009964739,"teacher_disagreement_score":0.3516624,"about_ca_system_score_codex":0.00013994542,"about_ca_system_score_gemma":0.00006811429,"threshold_uncertainty_score":0.9991305},"labels":[],"label_agreement":null},{"id":"W3194908373","doi":"10.1016/j.jaad.2021.06.338","title":"25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Imputation (statistics); Internal medicine; Psoriasis Area and Severity Index; Dermatology; Monoclonal; Monoclonal antibody; Gastroenterology; Antibody; Immunology; Missing data; Statistics","score_opus":0.01708652485733887,"score_gpt":0.28061181591653966,"score_spread":0.2635252910592008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194908373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599236,0.0007559667,0.0011912961,0.001529149,0.00010069894,0.00027802814,0.00014475823,0.0000034197162,0.000004299094],"genre_scores_gemma":[0.99491835,0.00007029857,0.004596307,0.0003420279,0.000013141457,0.0000051267225,0.000023469818,0.00001493298,0.0000163394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981451,0.00049793825,0.0007682695,0.00024379056,0.00009415941,0.00025072708],"domain_scores_gemma":[0.9977855,0.0004887516,0.0013794459,0.00014932842,0.0001659557,0.000031008953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013717946,0.00019557193,0.0009954592,0.00023838771,0.00007570735,0.000007268988,0.00021299503,0.0001500493,0.000013163356],"category_scores_gemma":[0.00009232956,0.00013703013,0.00021038542,0.00060482,0.00017602036,0.00011875731,0.000085147454,0.00020983067,7.405919e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.077475265,0.0027855746,0.39144927,0.00013053743,0.03193426,0.00004572845,0.008932021,0.026428958,0.42457014,0.0001464172,0.0006659238,0.035435904],"study_design_scores_gemma":[0.018440867,0.0010655472,0.67721486,0.0001589824,0.005523513,0.00019125253,0.0013584391,0.00020503181,0.29477292,0.0005076856,0.00021792088,0.00034296798],"about_ca_topic_score_codex":0.00012026141,"about_ca_topic_score_gemma":0.000023779543,"teacher_disagreement_score":0.28576562,"about_ca_system_score_codex":0.00006566453,"about_ca_system_score_gemma":0.00014858646,"threshold_uncertainty_score":0.5587927},"labels":[],"label_agreement":null},{"id":"W3195123012","doi":"10.1016/j.jaad.2021.06.575","title":"27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Maintenance therapy; Complete response; Internal medicine; Clinical trial; Surgery; Chemotherapy","score_opus":0.023730521157013258,"score_gpt":0.2901031741811524,"score_spread":0.26637265302413915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195123012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221546,0.00034980083,0.00012841033,0.01591109,0.00048452365,0.0003292346,0.00054991315,0.000008986592,0.000022547767],"genre_scores_gemma":[0.9972421,0.000065418666,0.000991985,0.0014312676,0.00004115935,0.000011063975,0.000016628699,0.000022676519,0.00017769924],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955198,0.0023311584,0.0012924152,0.00032384798,0.00012877722,0.0004039787],"domain_scores_gemma":[0.9966561,0.0012173917,0.001569956,0.00029762986,0.00017452147,0.000084353014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006836523,0.00026028528,0.0014779271,0.00030015755,0.000078830526,0.0000107979195,0.0005447265,0.00020164384,0.000044906217],"category_scores_gemma":[0.0015243381,0.00016596829,0.00024164395,0.00060581666,0.00018548022,0.00009678285,0.000142344,0.00045656058,0.0000519235],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76194984,0.0013724881,0.052823476,0.000017346829,0.004292684,0.00031093424,0.003726974,0.0005906356,0.1140833,0.00013551272,0.03092985,0.029766973],"study_design_scores_gemma":[0.09412075,0.0024355834,0.555744,0.000662483,0.0011821348,0.0013742707,0.0015436583,0.000008213142,0.32764435,0.0007348164,0.013820338,0.000729387],"about_ca_topic_score_codex":0.00005127747,"about_ca_topic_score_gemma":0.00003970905,"teacher_disagreement_score":0.6678291,"about_ca_system_score_codex":0.00009772303,"about_ca_system_score_gemma":0.00030353575,"threshold_uncertainty_score":0.676799},"labels":[],"label_agreement":null},{"id":"W3195182578","doi":"10.3899/jrheum.210349","title":"Does Age Matter in Psoriatic Arthritis? A Narrative Review","year":2021,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Depression (economics); Disease; Arthritis; Population; Comorbidity; Risk factor; Narrative review; Internal medicine; Physical therapy; Dermatology; Intensive care medicine","score_opus":0.0224731958500889,"score_gpt":0.2936291892853882,"score_spread":0.27115599343529934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195182578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000530211,0.99575907,0.0000038616167,0.00044472824,0.0026599017,0.00045238822,0.00002254879,0.0000069116822,0.00012038117],"genre_scores_gemma":[0.000084307445,0.9985959,0.000028688673,0.000178953,0.000017040726,0.000039443774,0.000067035464,0.000032521344,0.00095611735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99362296,0.003965306,0.001747398,0.0002196937,0.00005820162,0.00038645827],"domain_scores_gemma":[0.9965575,0.0011713114,0.0017042639,0.00043838136,0.00010149663,0.000027091093],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011972173,0.00045282135,0.004324789,0.00024932745,0.00010358519,0.0000110903065,0.00060165266,0.0005161418,0.0018553635],"category_scores_gemma":[0.0002327466,0.00019734204,0.0007543757,0.00031865182,0.00020743674,0.000067977235,0.000108144544,0.00090342725,0.00059616123],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042486587,0.0001597784,0.00018489352,0.0107409675,0.0023520982,0.0003104059,0.0015130448,9.247344e-8,0.0000017861909,0.00010726864,0.02557067,0.9590165],"study_design_scores_gemma":[0.0008301654,0.00009262083,0.000013064639,0.11438972,0.0018444897,0.021690115,0.0002745129,6.4512946e-9,0.000002620439,0.0001047564,0.8605239,0.00023405004],"about_ca_topic_score_codex":0.000036989397,"about_ca_topic_score_gemma":0.0001389717,"teacher_disagreement_score":0.95878243,"about_ca_system_score_codex":0.00008312938,"about_ca_system_score_gemma":0.00036592945,"threshold_uncertainty_score":0.99905705},"labels":[],"label_agreement":null},{"id":"W3195227536","doi":"10.1016/j.jaad.2021.06.709","title":"28096 Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Work productivity; Psoriasis; Depression (economics); Quality of life (healthcare); Productivity; Placebo; Physical therapy; Anxiety; Adalimumab; Clinical trial; Alternative medicine; Internal medicine; Psychiatry; Dermatology; Nursing; Disease","score_opus":0.0458343997511304,"score_gpt":0.3228891366153647,"score_spread":0.2770547368642343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195227536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994009,0.0005780903,0.000008840898,0.0045883567,0.00014580277,0.000508886,0.00014981983,0.0000048824904,0.000006308807],"genre_scores_gemma":[0.9988115,0.00013127133,0.0006146598,0.00029650936,0.000030119772,0.000006173085,0.000049459468,0.000015372581,0.000044977078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99515355,0.002366789,0.001645168,0.00039931026,0.00012045274,0.00031471293],"domain_scores_gemma":[0.99679995,0.00039893566,0.0022298673,0.0003830736,0.00011656412,0.00007158714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074977445,0.00021493169,0.0016367583,0.00016600877,0.00005056244,0.000005590136,0.00041284537,0.0001812807,0.000014857365],"category_scores_gemma":[0.00040700068,0.00013609802,0.00009104019,0.0006111058,0.0003870356,0.000121596015,0.00023569062,0.00053469226,0.0000010394826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12235686,0.0010621616,0.8671328,0.000020628517,0.0010035706,0.000011539471,0.00022791524,0.00004486873,0.0006608338,0.000013373991,0.00034629164,0.007119168],"study_design_scores_gemma":[0.055290386,0.0012902713,0.9403211,0.000080977174,0.00014899363,0.000035707366,0.0002855857,0.000002886711,0.002278552,0.000040617186,0.000069267786,0.00015568164],"about_ca_topic_score_codex":0.00046211094,"about_ca_topic_score_gemma":0.00018173992,"teacher_disagreement_score":0.07318828,"about_ca_system_score_codex":0.00006733367,"about_ca_system_score_gemma":0.00043118582,"threshold_uncertainty_score":0.5549916},"labels":[],"label_agreement":null},{"id":"W3195417065","doi":"10.1016/j.jaad.2021.06.569","title":"27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Adalimumab; Plaque psoriasis; Psoriasis; Monoclonal antibody; Dermatology; Interleukin 17; Monoclonal; Internal medicine; Immunology; Antibody; Tumor necrosis factor alpha; Inflammation","score_opus":0.02062054342886212,"score_gpt":0.2772263132695126,"score_spread":0.2566057698406505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195417065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836671,0.00074295193,0.000040499686,0.013664779,0.00075873826,0.00047272627,0.0006111028,0.00001633699,0.000025765663],"genre_scores_gemma":[0.9975647,0.00019600184,0.00055869535,0.0013469952,0.00014933887,0.00001023382,0.00006572863,0.000037141683,0.000071190305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954666,0.0019994595,0.0013901313,0.00043928638,0.00020538886,0.0004991709],"domain_scores_gemma":[0.9943558,0.002844952,0.0021540446,0.00041335545,0.00015721096,0.00007463767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003220891,0.0003873119,0.0014976178,0.00017994521,0.0002366536,0.00003012214,0.00086804025,0.00030529153,0.00007310815],"category_scores_gemma":[0.0008771014,0.000209347,0.00030421757,0.0006542157,0.0002613311,0.00016427197,0.00021135312,0.0009988439,0.000013193088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83293885,0.0033843587,0.035982765,0.000013983055,0.00561481,0.0003661103,0.007607193,0.00043741098,0.01964853,0.00003114769,0.010565656,0.08340916],"study_design_scores_gemma":[0.54926604,0.003570053,0.3107077,0.0010271464,0.0025116573,0.0018093409,0.0036450527,0.000028940862,0.11123627,0.00029695206,0.014728156,0.0011727026],"about_ca_topic_score_codex":0.00060516613,"about_ca_topic_score_gemma":0.00019076517,"teacher_disagreement_score":0.28367284,"about_ca_system_score_codex":0.00010539809,"about_ca_system_score_gemma":0.00039350163,"threshold_uncertainty_score":0.8536923},"labels":[],"label_agreement":null},{"id":"W3195838575","doi":"10.1016/j.jaad.2021.06.275","title":"25597 Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Apremilast; Psoriasis; Psoriatic arthritis; Dermatology; Scalp; Nail (fastener); Plaque psoriasis; Nail disease; Arthritis; Internal medicine","score_opus":0.008278212771125748,"score_gpt":0.21812394385396022,"score_spread":0.20984573108283447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195838575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597836,0.0025258425,0.000016967784,0.0009451581,0.00010699716,0.0003457512,0.000036075282,0.0000042762845,0.000040595525],"genre_scores_gemma":[0.99769956,0.00088403776,0.0010203352,0.0002359391,0.000011139628,0.000025091118,0.0000042282973,0.00002392681,0.000095718206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981465,0.00043783974,0.0006627587,0.0003032498,0.00012141764,0.00032824863],"domain_scores_gemma":[0.9984949,0.00013497694,0.0010309241,0.0001697264,0.00010409316,0.00006533741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106699496,0.0003006782,0.001215793,0.00030491548,0.000044028846,0.000005253267,0.00017333828,0.00014019242,0.000010857962],"category_scores_gemma":[0.000029830584,0.00018201795,0.0000665622,0.00033020286,0.00051177246,0.00013242861,0.000071177805,0.00027756326,8.2034904e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011812053,0.0007107468,0.9376488,0.0000620171,0.0012288493,0.000048308848,0.002320363,0.00008348273,0.0032191474,0.000028809241,0.00014025472,0.042697165],"study_design_scores_gemma":[0.032516774,0.0035850033,0.9324177,0.00069011044,0.0006329824,0.002434371,0.0010711557,0.000009417734,0.025187071,0.00006430898,0.0009807299,0.00041039256],"about_ca_topic_score_codex":0.00018630645,"about_ca_topic_score_gemma":0.00035413087,"teacher_disagreement_score":0.042286772,"about_ca_system_score_codex":0.0002305083,"about_ca_system_score_gemma":0.00032699545,"threshold_uncertainty_score":0.74224764},"labels":[],"label_agreement":null},{"id":"W3195918713","doi":"10.1016/j.jaad.2021.06.592","title":"27454 Efficacy and safety of long-term risankizumab re-treatment following drug withdrawal: IMMhance trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Drug; Plaque psoriasis; Monoclonal; Dermatology; Internal medicine; Monoclonal antibody; Pharmacology; Antibody; Immunology","score_opus":0.01513750163859811,"score_gpt":0.2884609842801245,"score_spread":0.2733234826415264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195918713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829036,0.012498287,0.000020100937,0.00359732,0.0006544112,0.00021265584,0.000018868759,0.000007649731,0.00008710689],"genre_scores_gemma":[0.9966052,0.002686912,0.00021198035,0.00015336233,0.000058898313,0.0000043249524,0.0000047521885,0.00001638283,0.0002581488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768156,0.00080002635,0.00092765444,0.00021090031,0.000089086425,0.0002908022],"domain_scores_gemma":[0.9972909,0.0006029027,0.0018023753,0.00020933588,0.00005337995,0.00004109191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017397791,0.00023316703,0.0012394241,0.00012421721,0.00012674251,0.000005150955,0.00034462643,0.00015720459,0.000038353282],"category_scores_gemma":[0.00010766822,0.0001532785,0.0004900778,0.00026645476,0.0006108264,0.00008381535,0.00011894005,0.00031318373,0.0000048774996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09330125,0.0026446409,0.3486423,0.00014529297,0.013787166,0.00074345537,0.0034425252,0.000028244629,0.39117602,0.00033042885,0.0026240244,0.14313467],"study_design_scores_gemma":[0.07111026,0.0010715866,0.25667638,0.0003107628,0.002170007,0.008613229,0.000548177,8.383152e-7,0.6554464,0.0001246359,0.0036116012,0.00031611556],"about_ca_topic_score_codex":0.000017896757,"about_ca_topic_score_gemma":0.0000074399604,"teacher_disagreement_score":0.2642704,"about_ca_system_score_codex":0.00006022041,"about_ca_system_score_gemma":0.00019558746,"threshold_uncertainty_score":0.62505156},"labels":[],"label_agreement":null},{"id":"W3195936002","doi":"10.1111/pde.14712","title":"Paradoxical psoriasis in pediatric patients: A systematic review","year":2021,"lang":"en","type":"review","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Intensive care medicine","score_opus":0.023124726816623704,"score_gpt":0.28263996183998996,"score_spread":0.25951523502336626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195936002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006493454,0.99371177,0.0000037908271,0.000042913107,0.0025085015,0.0030588794,0.00016711988,0.00011763658,0.0003244515],"genre_scores_gemma":[0.000040216684,0.9947429,0.00002766183,0.00017903587,0.0002427049,0.0019803164,0.002288599,0.00009810071,0.00040048797],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99110055,0.0035506578,0.002988085,0.0011627419,0.00013704215,0.0010609508],"domain_scores_gemma":[0.99558866,0.0016848022,0.0013870122,0.0010943414,0.00015135988,0.000093829505],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045260432,0.0011075378,0.008610115,0.001015583,0.00013139476,0.000024909088,0.00084083504,0.0017737132,0.00043690525],"category_scores_gemma":[0.0011478679,0.00087291293,0.0014416256,0.0019714104,0.000066395194,0.000100032004,0.00028731587,0.0008848194,0.0041711982],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000062671024,0.00064533757,0.0020737322,0.95377696,0.0005509022,0.00039937426,0.000031534775,2.0034863e-8,5.646887e-9,0.000101894075,0.012573256,0.029840702],"study_design_scores_gemma":[0.0040836157,0.00015881771,0.00022699982,0.20312633,0.09750186,0.0033924703,0.000021340438,1.3117001e-7,7.8664544e-7,0.000028323935,0.68870884,0.0027504805],"about_ca_topic_score_codex":0.000009270299,"about_ca_topic_score_gemma":0.000009648416,"teacher_disagreement_score":0.75065064,"about_ca_system_score_codex":0.00019608845,"about_ca_system_score_gemma":0.0007411741,"threshold_uncertainty_score":0.9995222},"labels":[],"label_agreement":null},{"id":"W3196094841","doi":"10.1016/j.jaad.2021.06.439","title":"26549 Risk of malignancy associated with medication use in elderly patients with psoriasis","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Western University; University of Ottawa","funders":"","keywords":"Medicine; Malignancy; Internal medicine; Psoriasis; Etanercept; Relative risk; Retrospective cohort study; Psoriatic arthritis; Cancer; Dermatology; Rheumatoid arthritis; Confidence interval","score_opus":0.010843493977580242,"score_gpt":0.23392598948120422,"score_spread":0.22308249550362397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196094841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977778,0.0008288173,0.000027853133,0.0010632613,0.00011975369,0.00009813325,0.000052541855,0.0000040740997,0.000027761333],"genre_scores_gemma":[0.99904233,0.00044847868,0.00029739458,0.00012754629,0.000007875655,0.0000033016586,0.000012062754,0.000012183915,0.000048804814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979411,0.0009498605,0.00064093294,0.00013889422,0.000113633316,0.00021558793],"domain_scores_gemma":[0.99640965,0.00049866445,0.0027391678,0.00014451667,0.00018366784,0.00002429893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015950383,0.00014855246,0.00073627784,0.00017313974,0.000049450133,0.0000027211183,0.00028026834,0.0001597056,0.000027791086],"category_scores_gemma":[0.0003319508,0.00008731838,0.00012908646,0.0004971191,0.00049654354,0.00011531529,0.000041229352,0.00037348896,0.0000023567911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008129563,0.00041688787,0.9871891,0.00000962021,0.0011902711,0.000017195172,0.0002483001,0.000013979544,0.003946015,0.00004618437,0.0003431618,0.00576634],"study_design_scores_gemma":[0.003937671,0.00038613996,0.9512327,0.00018049461,0.000564735,0.00036219647,0.00019170897,6.743467e-7,0.04264335,0.00007197215,0.0003355703,0.00009280861],"about_ca_topic_score_codex":0.00005462764,"about_ca_topic_score_gemma":0.000051637002,"teacher_disagreement_score":0.038697336,"about_ca_system_score_codex":0.00004017386,"about_ca_system_score_gemma":0.00016228206,"threshold_uncertainty_score":0.356074},"labels":[],"label_agreement":null},{"id":"W3196193197","doi":"10.1016/j.jaad.2021.06.312","title":"25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Secukinumab; Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Nail (fastener); Nail disease; Arthritis; Randomized controlled trial; Clinical trial; Surgery; Internal medicine","score_opus":0.011418717243678102,"score_gpt":0.24256455179875466,"score_spread":0.23114583455507656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196193197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935585,0.0019236434,0.0000049263163,0.0038545658,0.00030666462,0.00022295289,0.00008806236,0.0000029753837,0.00003771066],"genre_scores_gemma":[0.9986389,0.0009020584,0.0002220485,0.00016008396,0.000037183763,0.0000047553726,0.000014177622,0.00001050213,0.000010272253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976184,0.0009405028,0.00094531616,0.00017964178,0.00009706081,0.00021907777],"domain_scores_gemma":[0.99727005,0.0010827003,0.0014014051,0.00016534509,0.000059810638,0.000020684649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002144734,0.0001551023,0.0006993645,0.00015854793,0.00006603685,0.0000059283034,0.00030373016,0.00011674709,0.000014020766],"category_scores_gemma":[0.00032809656,0.00009619263,0.00012271995,0.00037929745,0.00044176905,0.00008215038,0.00008503013,0.00041888625,0.0000018854616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19174372,0.0030909923,0.5291593,0.00006495826,0.0033100096,0.00038159016,0.011489971,0.00023067262,0.0035970274,0.0006680158,0.0016628923,0.25460085],"study_design_scores_gemma":[0.08731368,0.00032900268,0.9054629,0.00022814645,0.0002873267,0.00044068083,0.0011949122,0.0000027784597,0.003713037,0.0005411233,0.00035941915,0.00012698483],"about_ca_topic_score_codex":0.00014707103,"about_ca_topic_score_gemma":0.00009682118,"teacher_disagreement_score":0.37630358,"about_ca_system_score_codex":0.00003263944,"about_ca_system_score_gemma":0.000121935234,"threshold_uncertainty_score":0.39226216},"labels":[],"label_agreement":null},{"id":"W3196287952","doi":"10.1016/j.jaad.2021.06.532","title":"27078 Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&amp;2","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Plaque psoriasis; Quality of life (healthcare); Dermatology; Adalimumab; Randomized controlled trial; Clinical trial; Internal medicine; Disease; Nursing","score_opus":0.03653642598415063,"score_gpt":0.33865943086376954,"score_spread":0.3021230048796189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196287952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943094,0.0026982112,0.000005992797,0.001986396,0.000184853,0.0002635015,0.00054147944,0.0000038044257,0.000006344796],"genre_scores_gemma":[0.99865764,0.0009659843,0.00011112708,0.00012257198,0.0000079024785,0.000005155542,0.00010366043,0.000010468141,0.000015512416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467194,0.0026620638,0.0020042092,0.00024707918,0.00019370904,0.0002210269],"domain_scores_gemma":[0.9934018,0.0013141325,0.004719522,0.0002615878,0.0002520806,0.00005086604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048786064,0.00024718465,0.0026510383,0.00051867863,0.000046637837,0.0000016431635,0.00024899168,0.00017642324,0.00001535367],"category_scores_gemma":[0.00066754746,0.00014837425,0.00033679057,0.0010477932,0.0002515794,0.00005554985,0.000062359555,0.00025342303,0.0000019575325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13528548,0.0040259464,0.7535568,0.00015187931,0.05069136,0.00001476113,0.009377401,0.009374171,0.022696136,0.00003493027,0.00065737445,0.014133761],"study_design_scores_gemma":[0.038726293,0.005741005,0.8026804,0.00028240646,0.0034759783,0.000030408224,0.0009807897,0.000014302618,0.14768565,0.00006186742,0.000080435115,0.00024047327],"about_ca_topic_score_codex":0.00048484752,"about_ca_topic_score_gemma":0.00019781283,"teacher_disagreement_score":0.12498951,"about_ca_system_score_codex":0.00014952576,"about_ca_system_score_gemma":0.00022652594,"threshold_uncertainty_score":0.6050526},"labels":[],"label_agreement":null},{"id":"W3197610576","doi":"10.1177/2050313x211034925","title":"A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors","year":2021,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; University of Toronto; SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Adverse effect; Interleukin; Oral mucosa; Pathogenesis; Gastroenterology; Internal medicine; Cytokine; Pathology","score_opus":0.01635819641525202,"score_gpt":0.2815077235326276,"score_spread":0.2651495271173756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197610576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944908,0.0007127197,0.000013202781,0.00006882292,0.00051656796,0.0006033271,0.00003929775,0.000030251811,0.0035249812],"genre_scores_gemma":[0.9972552,0.000034072793,0.00013988338,0.00007307773,0.000026749356,0.000085623506,0.00046687608,0.000030356512,0.0018881287],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99705213,0.00043564348,0.0012060964,0.0007174924,0.00017764296,0.00041097938],"domain_scores_gemma":[0.99832153,0.00016523045,0.00051882025,0.0006833647,0.00016630304,0.00014477182],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009987155,0.00029124436,0.0007222366,0.00014236782,0.000117575495,0.000024179795,0.00010647477,0.000285545,0.0017733647],"category_scores_gemma":[0.00060132105,0.00021800547,0.00014331011,0.0004707015,0.00023479416,0.00012780448,0.0002196562,0.00032112512,0.000010589792],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031945168,0.00074093,0.06896384,0.00002283131,0.00030279852,0.8864788,0.00038717524,0.0000011134621,0.00063331134,0.0000018243858,0.0003964078,0.041751534],"study_design_scores_gemma":[0.0038959128,0.00028264298,0.0017627493,0.00037548353,0.00023157289,0.9608293,0.0004103815,0.0000012017412,0.030309314,0.000011914519,0.0016373808,0.00025212677],"about_ca_topic_score_codex":0.00462788,"about_ca_topic_score_gemma":0.0065643736,"teacher_disagreement_score":0.07435054,"about_ca_system_score_codex":0.00010624839,"about_ca_system_score_gemma":0.00056092656,"threshold_uncertainty_score":0.99913913},"labels":[],"label_agreement":null},{"id":"W3197965471","doi":"10.1101/2021.08.27.21262722","title":"Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: An Updated Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"LEO Pharma; Swedish Orphan Biovitrum; Bristol-Myers Squibb; Eli Lilly and Company; Galderma; Cilag; University of Manchester; British Association of Dermatologists; National Institute for Health and Care Research; Medical Research Council; Celgene; Sanofi; Pfizer; King's College London","keywords":"Medicine; Secukinumab; Adalimumab; Etanercept; Ixekizumab; Certolizumab pegol; Infliximab; Ustekinumab; Placebo; Internal medicine; Psoriasis; Anakinra; Odds ratio; Meta-analysis; Dermatology; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor alpha; Alternative medicine; Disease","score_opus":0.024563007532051446,"score_gpt":0.25576989783601,"score_spread":0.23120689030395855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197965471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278664,0.07006409,0.000013707894,0.00004172851,0.00011026227,0.0013939074,0.00044772387,0.000037991977,0.000024198433],"genre_scores_gemma":[0.99055284,0.006770027,0.00006400321,0.00009253367,0.0000032080245,0.00045226637,0.0019315049,0.00001993582,0.00011365929],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99588805,0.0024769471,0.0007131622,0.00065100106,0.00005990118,0.00021093147],"domain_scores_gemma":[0.9978284,0.00017550621,0.0007823192,0.0010049004,0.00018287837,0.000025981564],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064469763,0.000438267,0.003281567,0.00040180687,0.00008521878,0.000017936136,0.00022458554,0.0003948305,0.0005800585],"category_scores_gemma":[0.00011022704,0.00025614368,0.00064220803,0.0006345357,0.00009668005,0.000046205423,0.00011516267,0.00033495997,0.000013397483],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012125805,0.0014522066,0.48422748,0.014191655,0.4991107,0.0000070384804,0.0005959498,0.0000877393,0.000084018204,0.0000149126145,0.000011828566,0.000095213865],"study_design_scores_gemma":[0.00096258894,0.00059882755,0.22168308,0.0008049314,0.775102,0.000002941712,0.000088968474,0.0000010844531,0.00036088075,0.000021739661,0.000010017634,0.00036292366],"about_ca_topic_score_codex":0.00024735052,"about_ca_topic_score_gemma":0.0004957093,"teacher_disagreement_score":0.27599132,"about_ca_system_score_codex":0.000033650744,"about_ca_system_score_gemma":0.00004043945,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W3199368308","doi":"10.3390/life11101000","title":"Identification of IL-18 and Soluble Cell Adhesion Molecules in the Gingival Crevicular Fluid as Novel Biomarkers of Psoriasis","year":2021,"lang":"en","type":"article","venue":"Life","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"International Council for Canadian Studies","keywords":"Psoriasis; Medicine; Biomarker; Gastroenterology; Internal medicine; Psoriasis Area and Severity Index; Receiver operating characteristic; Dermatology","score_opus":0.01878262287630928,"score_gpt":0.24218491920406277,"score_spread":0.2234022963277535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199368308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900509,0.008760027,0.00007920228,0.000167167,0.00025915683,0.00012414808,0.000034336,0.0000071296454,0.00051793637],"genre_scores_gemma":[0.9988384,0.0005465137,0.00014047333,0.000055560344,0.000012054528,0.000012517409,0.000081113074,0.0000065927916,0.00030675848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991883,0.00017812764,0.00029052809,0.00018121355,0.000041904575,0.00011994253],"domain_scores_gemma":[0.99944395,0.00012556034,0.00012971909,0.0002364447,0.00005329897,0.000011055704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025910593,0.00009359494,0.00019100693,0.00006801266,0.00005067774,0.0000070493425,0.00010824284,0.00011602273,0.000103426435],"category_scores_gemma":[0.00010293425,0.000072245326,0.00007555887,0.00018258305,0.000072521376,0.000041118266,0.000038881786,0.000043387103,0.000022237986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008258527,0.00021853269,0.0032141476,0.000054784,0.00011794784,0.000003900333,0.00053094944,0.000002901532,0.9933097,0.0002874176,0.00040716788,0.0017699616],"study_design_scores_gemma":[0.0011701004,0.00006198443,0.0314755,0.000026182746,0.00013528673,0.0000135240625,0.0010234074,0.000010837349,0.9644956,0.00006967976,0.0014430927,0.00007478739],"about_ca_topic_score_codex":0.00009086148,"about_ca_topic_score_gemma":0.0000076022484,"teacher_disagreement_score":0.028814089,"about_ca_system_score_codex":0.000006992752,"about_ca_system_score_gemma":0.000043528133,"threshold_uncertainty_score":0.29460788},"labels":[],"label_agreement":null},{"id":"W3200438706","doi":"10.1016/j.actbio.2021.09.018","title":"Development of a 3D psoriatic skin model optimized for infiltration of IL-17A producing T cells: Focus on the crosstalk between T cells and psoriatic keratinocytes","year":2021,"lang":"en","type":"article","venue":"Acta Biomaterialia","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Psoriasis; Involucrin; Interleukin 22; Immunology; Filaggrin; Interleukin 8; Interleukin 17; Inflammation; Medicine; Cancer research; Biology; Cytokine; Cell culture; Keratinocyte; Interleukin; Atopic dermatitis","score_opus":0.02880285174383181,"score_gpt":0.24773321330523654,"score_spread":0.21893036156140472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200438706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970884,0.00020123043,0.0005444925,0.00012388808,0.000897063,0.00061605213,0.00048190643,0.000022785518,0.000024236113],"genre_scores_gemma":[0.9801659,0.000042471216,0.01903855,0.0000130288045,0.00006005026,0.00011618788,0.00029624955,0.00002091357,0.0002466747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859595,0.000177461,0.0005968211,0.00033260972,0.00005604767,0.00024113116],"domain_scores_gemma":[0.9989653,0.0002389556,0.000349645,0.00031948098,0.00010914202,0.000017471497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003779299,0.0002287076,0.00046701127,0.00006734458,0.00020334589,0.00004029063,0.00013220934,0.00018383985,0.000066255074],"category_scores_gemma":[0.00006981924,0.00016461225,0.000073550174,0.000107449276,0.000087947505,0.0000731943,0.00006381461,0.00003348207,0.0000081247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003283335,0.00012539,0.000035197172,0.00013707162,0.000443824,4.691266e-7,0.0032812664,0.000017895252,0.989457,0.00008258804,0.00025993751,0.005830997],"study_design_scores_gemma":[0.002198603,0.000130707,0.0005800361,0.00007972045,0.00024993275,0.0000018428726,0.00015841943,0.00009298415,0.995829,0.00017508553,0.00033621857,0.0001674409],"about_ca_topic_score_codex":0.000030821124,"about_ca_topic_score_gemma":0.000014714945,"teacher_disagreement_score":0.018494058,"about_ca_system_score_codex":0.000029732368,"about_ca_system_score_gemma":0.00016659526,"threshold_uncertainty_score":0.6712693},"labels":[],"label_agreement":null},{"id":"W3201090734","doi":"10.1111/jdv.17673","title":"Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A <i>post‐hoc</i> analysis of PSO‐LONG","year":2021,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"LEO Pharma","keywords":"Medicine; Dermatology Life Quality Index; Betamethasone dipropionate; Psoriasis; Post-hoc analysis; Quality of life (healthcare); Psychosocial; Post hoc; Randomized controlled trial; Physical therapy; Fixed-dose combination; Internal medicine; Dermatology","score_opus":0.013484148588341011,"score_gpt":0.23798337783838674,"score_spread":0.22449922925004573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201090734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970078,0.0013096625,0.000028135653,0.001085446,0.00007539238,0.0002188617,0.000025708492,0.0000031047857,0.0002459087],"genre_scores_gemma":[0.99930423,0.0003397356,0.00009233103,0.00019632444,0.0000050740714,0.0000036798172,0.000012583013,0.0000116872,0.000034336706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609053,0.0026901448,0.0007159373,0.00021569293,0.00009574815,0.0001919731],"domain_scores_gemma":[0.99759156,0.00065094675,0.0013763302,0.00015963725,0.00019282736,0.000028723256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034985912,0.0001886609,0.00080574735,0.00027961147,0.00010634664,0.0000035979403,0.00021259625,0.00015952259,0.0000126880595],"category_scores_gemma":[0.000102797974,0.00009918161,0.00012577759,0.00045878676,0.0005904181,0.00010746025,0.00015321554,0.00031863377,4.2854975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009558468,0.0007165142,0.9656101,0.00010492274,0.01020079,0.000040778978,0.0030564365,0.00006046715,0.0015172738,0.0006854395,0.00004580563,0.008402988],"study_design_scores_gemma":[0.0070050177,0.0004145161,0.9852683,0.00009257764,0.0018329093,0.00017409369,0.0016071874,0.0000027822537,0.0034021134,0.000048434915,0.000044123717,0.00010792096],"about_ca_topic_score_codex":0.00001127755,"about_ca_topic_score_gemma":0.000079799756,"teacher_disagreement_score":0.019658208,"about_ca_system_score_codex":0.000025814776,"about_ca_system_score_gemma":0.000073705654,"threshold_uncertainty_score":0.40445086},"labels":[],"label_agreement":null},{"id":"W3202361886","doi":"10.23736/s0392-0488.20.06789-9","title":"Successful ustekinumab treatment of severe refractory psoriasis vulgaris in a haemodialysis patient: a case report","year":2020,"lang":"it","type":"article","venue":"Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Ustekinumab; Medicine; Refractory (planetary science); Psoriasis; Dermatology; Plaque psoriasis; Internal medicine; Disease; Adalimumab","score_opus":0.025210853363352596,"score_gpt":0.24518058058685405,"score_spread":0.21996972722350144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202361886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95246625,0.030691525,0.00014895535,0.003323723,0.004232708,0.0036871003,0.0032486948,0.0009025208,0.0012985197],"genre_scores_gemma":[0.989152,0.0041171745,0.0006559687,0.0008775884,0.00031878403,0.0006330567,0.0030898538,0.00039740722,0.00075814454],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9788702,0.0042873994,0.007018361,0.0046113334,0.00089696905,0.0043157362],"domain_scores_gemma":[0.9871916,0.0021934162,0.0053889044,0.003279346,0.00105212,0.0008946253],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","insufficient_payload"],"category_scores_codex":[0.0007610328,0.004017699,0.007860547,0.0015008638,0.0014251586,0.00030993446,0.0023270433,0.005227509,0.0020529516],"category_scores_gemma":[0.0018788907,0.0037967998,0.0037623295,0.0053568548,0.0034885318,0.0010664391,0.0010915499,0.0018470816,0.0011949139],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030677237,0.009455159,0.60711753,0.0013414356,0.011895635,0.31025556,0.01410856,0.0005698058,0.007937099,0.00037748367,0.017851979,0.016022014],"study_design_scores_gemma":[0.054852463,0.012386732,0.070924185,0.002083778,0.028423803,0.5044536,0.07647435,0.001956536,0.18735644,0.00065528275,0.040964074,0.01946874],"about_ca_topic_score_codex":0.0028720368,"about_ca_topic_score_gemma":0.0011920676,"teacher_disagreement_score":0.5361934,"about_ca_system_score_codex":0.001507031,"about_ca_system_score_gemma":0.0019549998,"threshold_uncertainty_score":0.99987483},"labels":[],"label_agreement":null},{"id":"W3203965558","doi":"10.1186/s12876-021-01936-w","title":"Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis","year":2021,"lang":"en","type":"article","venue":"BMC Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Memorial University of Newfoundland","funders":"Memorial University of Newfoundland","keywords":"Ixekizumab; Medicine; Psoriasis; Plaque psoriasis; Inflammatory bowel disease; Crohn's disease; Ustekinumab; Internal medicine; Disease; Dermatology; Immunology; Adalimumab; Psoriatic arthritis; Secukinumab","score_opus":0.009895434265556044,"score_gpt":0.22699139402121732,"score_spread":0.21709595975566126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203965558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961419,0.0020106179,0.00011215873,0.0003129647,0.00046145992,0.0005000857,0.00032495288,0.00004247656,0.00009337233],"genre_scores_gemma":[0.9971716,0.00019732531,0.0005689263,0.0001691232,0.000052161493,0.0002495253,0.00066087727,0.000032495653,0.0008979961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789596,0.0005671075,0.0003742175,0.00045289463,0.00004018252,0.0006696566],"domain_scores_gemma":[0.99900895,0.00029799962,0.00024402264,0.00028085453,0.00014247348,0.000025678157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021393709,0.00027049365,0.000622458,0.00013594227,0.000103328275,0.000009210995,0.00018234081,0.00027495253,0.0001688638],"category_scores_gemma":[0.000060823513,0.00023607643,0.00017354237,0.00015976257,0.000116572,0.000057496636,0.000052476513,0.00017837968,0.000009390385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020101715,0.0012521101,0.9370451,0.000147076,0.0018743611,0.00011994027,0.0021794243,0.00020581977,0.01666398,0.00019365926,0.0048082387,0.015408563],"study_design_scores_gemma":[0.020020945,0.0014912543,0.9544417,0.000095767995,0.000121257224,0.00035698718,0.00051194715,0.0000049296964,0.02207918,0.00007252223,0.0006330939,0.00017036908],"about_ca_topic_score_codex":0.00016083293,"about_ca_topic_score_gemma":0.016975623,"teacher_disagreement_score":0.017396634,"about_ca_system_score_codex":0.00015638713,"about_ca_system_score_gemma":0.00023262805,"threshold_uncertainty_score":0.9626918},"labels":[],"label_agreement":null},{"id":"W3204650442","doi":"10.2196/28669","title":"Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study","year":2021,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"LEO Fondet; Novo Nordisk Fonden","keywords":"Psoriasis; Protocol (science); Medicine; Computer science; Alternative medicine; Pathology; Immunology","score_opus":0.16103112993875554,"score_gpt":0.4742601946541565,"score_spread":0.3132290647154009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204650442","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02181797,0.00008914924,0.00013589574,0.000022816912,0.000021859723,0.9773348,0.00037182987,0.00003954447,0.00016616474],"genre_scores_gemma":[0.075204454,9.954555e-7,0.00023778231,0.00000354721,0.000064701955,0.9240591,0.000018179895,0.00003260099,0.00037864986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99259305,0.0050131665,0.0006558316,0.0007692842,0.00013229622,0.00083637313],"domain_scores_gemma":[0.9971725,0.0010294927,0.00015090409,0.001004323,0.0005920864,0.000050699793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036320619,0.00026260907,0.0008212711,0.00034421342,0.00028258484,0.000025167423,0.00034455067,0.00039753687,0.00032088385],"category_scores_gemma":[0.000699289,0.00021616001,0.00043750176,0.00060857256,0.00022870666,0.00008593823,0.00017496862,0.00051056244,0.000069220645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017252238,0.02420082,0.31770647,0.0016150292,0.0082889,0.0027696446,0.0038528333,0.00009662916,0.047232445,0.00040034347,0.0026505524,0.5739341],"study_design_scores_gemma":[0.18931206,0.014921804,0.052481968,0.0012070874,0.00026310855,0.00057897094,0.0036904435,0.000041483538,0.16703711,0.0011954765,0.5683382,0.0009322501],"about_ca_topic_score_codex":0.0003421166,"about_ca_topic_score_gemma":0.00036676784,"teacher_disagreement_score":0.57300186,"about_ca_system_score_codex":0.00009163671,"about_ca_system_score_gemma":0.00032510082,"threshold_uncertainty_score":0.881475},"labels":[],"label_agreement":null},{"id":"W3205001914","doi":"10.1016/j.cjca.2021.07.150","title":"ANTI-INFLAMMATORY EFFECT OF BIOLOGIC THERAPY IN PATIENTS WITH PSORIATIC DISEASE COMPARED WITH TREATMENT WITH NON-BIOLOGIC DMARDS: A PROSPECTIVE COHORT FDG-PET STUDY","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Positron emission tomography; Prospective cohort study; Psoriasis; Fluorodeoxyglucose; Arthritis; Radiology; Immunology","score_opus":0.006333164992226694,"score_gpt":0.20205394239908678,"score_spread":0.19572077740686009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205001914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961992,0.0018464305,0.000013777518,0.000023409186,0.00030886574,0.0013323432,0.000122727,0.000008252566,0.00014502827],"genre_scores_gemma":[0.9994694,0.00014135607,0.000023618424,0.000014865185,0.00006115085,0.00010943705,0.0001278077,0.000023043842,0.000029330673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974021,0.0011747332,0.0004613866,0.00039979964,0.000067111134,0.0004948943],"domain_scores_gemma":[0.99847054,0.00022016837,0.00040527928,0.000365768,0.00036225747,0.00017595655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033934478,0.00040579654,0.0015361663,0.0003149835,0.00012184119,0.000010916466,0.0001991736,0.00013388191,0.000034508495],"category_scores_gemma":[0.00004415838,0.00021578129,0.00016878433,0.00029313035,0.00037474738,0.00006686486,0.000012247067,0.00020686573,0.000006628944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006436532,0.00016072638,0.98465306,0.000011497205,0.0044499384,0.0016396809,0.00026063787,0.00044161605,0.00022482174,0.000004324035,0.00002604158,0.001691142],"study_design_scores_gemma":[0.020176776,0.023219917,0.95401275,0.00007948082,0.00076812285,0.00019377127,0.0002514792,4.203825e-7,0.00085257855,0.0000061150704,0.00019778946,0.00024078981],"about_ca_topic_score_codex":0.000529681,"about_ca_topic_score_gemma":0.004257465,"teacher_disagreement_score":0.030640282,"about_ca_system_score_codex":0.00033179994,"about_ca_system_score_gemma":0.0013462551,"threshold_uncertainty_score":0.87993056},"labels":[],"label_agreement":null},{"id":"W3205723104","doi":"10.1016/j.jaad.2021.10.028","title":"Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review","year":2021,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Alberta Children's Hospital; Dermatrials Research; University of Calgary; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Dermatology; Pustular psoriasis; Psoriasis; Intensive care medicine","score_opus":0.11480744055827849,"score_gpt":0.3780322666719299,"score_spread":0.2632248261136514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205723104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006373225,0.99172074,0.000032235283,0.0005438273,0.0006825263,0.00056506303,0.00006214515,0.000009359322,0.000010902609],"genre_scores_gemma":[0.00066435547,0.9966355,0.0021066053,0.0003549707,0.00012676668,0.000019485264,0.000023648448,0.000038713588,0.000029939267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99205685,0.0044556116,0.0025108622,0.00038659913,0.00016216055,0.0004279226],"domain_scores_gemma":[0.9896871,0.0006271204,0.008949661,0.00050706085,0.00017117764,0.00005787781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007761919,0.0005568007,0.0054885074,0.0004815181,0.000102959326,0.000005801114,0.0015549158,0.0005167856,0.000111024754],"category_scores_gemma":[0.00017270687,0.00033906425,0.002097861,0.0012041818,0.00058886746,0.000114039845,0.00026287074,0.0007356202,0.000009871948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023281059,0.0005803119,0.0010985889,0.04002132,0.009155252,0.00024900705,0.000030841136,0.000016537027,0.0004057536,0.00030845322,0.0034360902,0.94446504],"study_design_scores_gemma":[0.0022700252,0.0005385523,0.00035365167,0.086519316,0.06778742,0.010133342,0.00012963836,0.0000018095358,0.0018142457,0.000066000575,0.8294148,0.000971187],"about_ca_topic_score_codex":0.000013861704,"about_ca_topic_score_gemma":1.9351815e-7,"teacher_disagreement_score":0.94349384,"about_ca_system_score_codex":0.0001086132,"about_ca_system_score_gemma":0.00050797866,"threshold_uncertainty_score":0.9999061},"labels":[],"label_agreement":null},{"id":"W3207173999","doi":"10.1016/j.jaci.2021.09.035","title":"Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis","year":2021,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Generalized pustular psoriasis; Pathogenesis; Inflammation; Lipocalin; Pathology; Internal medicine; Immunology; Dermatology","score_opus":0.017338053517136503,"score_gpt":0.26939227504837293,"score_spread":0.2520542215312364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207173999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8867276,0.11061404,0.00007963645,0.00037839147,0.0019479636,0.00011735925,0.0000070363913,0.000009906919,0.00011809013],"genre_scores_gemma":[0.9378113,0.06082953,0.0007823474,0.00024018827,0.00010780056,0.000008017691,0.00002019276,0.000026140373,0.00017449015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962446,0.0013957769,0.0014705559,0.00039532493,0.000079205296,0.0004145342],"domain_scores_gemma":[0.9977819,0.0008672569,0.0006887896,0.0003424244,0.00025092278,0.00006871971],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007721277,0.00030657035,0.0013210401,0.00023189827,0.00008425162,0.00001495603,0.00024154982,0.00081314,0.00012678048],"category_scores_gemma":[0.00070527906,0.0002607312,0.00040657926,0.00022659799,0.0004276069,0.00012216352,0.00019565957,0.00061390613,0.000011211304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005803728,0.0040723234,0.025491651,0.00015462092,0.024004448,0.0044924472,0.0011340244,0.000020549449,0.7314128,0.009682583,0.00050547207,0.19322535],"study_design_scores_gemma":[0.06478642,0.007106969,0.4005105,0.000710487,0.0026675714,0.0037286633,0.0015230521,0.000013784502,0.482272,0.008068285,0.027515607,0.0010966825],"about_ca_topic_score_codex":0.000035747104,"about_ca_topic_score_gemma":0.000052163177,"teacher_disagreement_score":0.37501884,"about_ca_system_score_codex":0.000028643033,"about_ca_system_score_gemma":0.00017775699,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W3207194448","doi":"10.1111/bjd.20818","title":"Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*","year":2021,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"AbbVie","keywords":"Psoriasis; Medicine; Plaque psoriasis; Term (time); Clinical trial; Dermatology; Pediatrics; Internal medicine","score_opus":0.02992038853060693,"score_gpt":0.2943077013034289,"score_spread":0.264387312772822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207194448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915959,0.005684704,0.0003740784,0.0003040778,0.0012722239,0.00024192907,0.0003670719,0.000009156098,0.00015086055],"genre_scores_gemma":[0.997556,0.0011679995,0.0006321269,0.00017690883,0.000079272264,0.000006427283,0.00026076942,0.000021872816,0.000098640965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99366844,0.003184637,0.002378134,0.00031910464,0.00009528611,0.0003543999],"domain_scores_gemma":[0.9967463,0.0014471461,0.0011032932,0.00023918643,0.00038145244,0.0000826315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008316404,0.00022003365,0.0020152729,0.0001698361,0.00008415032,0.000023244784,0.00027676538,0.0005258051,0.0006298947],"category_scores_gemma":[0.0009017866,0.0002068498,0.00036963733,0.00019274911,0.00013659045,0.00015122179,0.00008047641,0.0004796224,0.000033205655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014785622,0.0016226788,0.8669562,0.00002170877,0.0019753007,0.0040905047,0.00023423311,0.000023424083,0.00036802405,0.00002788603,0.0052398792,0.10465459],"study_design_scores_gemma":[0.03141611,0.00039027387,0.94951856,0.00048954884,0.0004348138,0.008644215,0.00007697649,5.259257e-7,0.0077192793,0.00012091178,0.0009434602,0.00024532803],"about_ca_topic_score_codex":0.000074280666,"about_ca_topic_score_gemma":0.00055417314,"teacher_disagreement_score":0.10440926,"about_ca_system_score_codex":0.00004913095,"about_ca_system_score_gemma":0.0004119961,"threshold_uncertainty_score":0.843509},"labels":[],"label_agreement":null},{"id":"W3207892227","doi":"10.12688/f1000research.19144.1","title":"Psoriatic arthritis","year":2019,"lang":"en","type":"preprint","venue":"F1000Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"Celgene; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Subclinical infection; Disease; Arthritis; Dermatology; Uveitis; Osteoporosis; Inflammatory arthritis; Pathology; Internal medicine; Immunology","score_opus":0.040624640126394364,"score_gpt":0.30307066775376895,"score_spread":0.26244602762737457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207892227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8444852,0.10129462,0.00016118432,0.00076188124,0.011909148,0.0026289704,0.0011228613,0.0004735559,0.037162576],"genre_scores_gemma":[0.92819357,0.006807598,0.00015791389,0.00007366129,0.00033086384,0.00038876693,0.0019638392,0.00008912995,0.061994646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731994,0.00061977614,0.00037185088,0.00075647485,0.0001470262,0.0007849093],"domain_scores_gemma":[0.9981799,0.00035755578,0.000116304815,0.0011367812,0.00015843139,0.000051035815],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006045292,0.00037328608,0.0006200493,0.00033777693,0.00016761615,0.00007278884,0.0008111105,0.0009980742,0.005898808],"category_scores_gemma":[0.00015115844,0.0003426843,0.00029562172,0.00016242053,0.00018027642,0.000048659764,0.0012403766,0.0011634234,0.027052792],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057427294,0.0006250258,0.010662356,0.0005197256,0.0025958044,0.00016418523,0.00085719774,0.00010225275,0.012774566,0.0018205068,0.17032902,0.7989751],"study_design_scores_gemma":[0.013544431,0.0012459769,0.10177175,0.0018149652,0.0006779862,0.00021867093,0.00048566403,0.00009490125,0.11258644,0.017049909,0.74752796,0.0029813377],"about_ca_topic_score_codex":0.00029904704,"about_ca_topic_score_gemma":0.00004403593,"teacher_disagreement_score":0.79599375,"about_ca_system_score_codex":0.00012410931,"about_ca_system_score_gemma":0.00044525132,"threshold_uncertainty_score":0.99990255},"labels":[],"label_agreement":null},{"id":"W3208995048","doi":"10.21272/eumj.2021;9(3):247-255","title":"THE RELATIONSHIP BETWEEN DECREASED COGNITIVE FUNCTIONS AND THE LEVEL OF PROINFLAMMATORY CYTOKINES IN PATIENTS WITH ALZHEIMER’S DISEASE, VASCULAR DEMENTIA, AND MILD COGNITIVE DISORDER","year":2021,"lang":"en","type":"article","venue":"Eastern Ukrainian Medical Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dementia; Neurocognitive; Proinflammatory cytokine; Montreal Cognitive Assessment; Context (archaeology); Medicine; Vascular dementia; Neuropsychology; Internal medicine; Cognition; Disease; Alzheimer's disease; Psychology; Inflammation; Pathology; Psychiatry; Biology","score_opus":0.03986900502889056,"score_gpt":0.25861892467914854,"score_spread":0.21874991965025797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208995048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98161036,0.016852526,0.00020487125,0.00073202315,0.000110556655,0.00030823803,0.00012351769,0.000005010589,0.000052877294],"genre_scores_gemma":[0.99943274,0.00016519679,0.000010967323,0.00007561011,0.000056134864,0.0000314013,0.00012999783,0.00001153701,0.00008639658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982366,0.0008512545,0.00033851212,0.00018254205,0.00017367327,0.00021742741],"domain_scores_gemma":[0.9975286,0.0019156892,0.00016870862,0.00009453863,0.00017370937,0.00011875058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061039993,0.00015020662,0.00023895872,0.000059185968,0.00045923065,0.000029672736,0.00008668599,0.00010534135,0.00007714315],"category_scores_gemma":[0.0010889429,0.000079850084,0.00007214802,0.00011922178,0.00079998974,0.00007560077,0.00006278523,0.0003376127,0.000008565786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011490632,0.00010782471,0.95590794,0.0000074660234,0.0013273695,0.000017127684,0.0011493377,7.8514056e-8,8.3362835e-7,0.000032782984,0.000007135297,0.040293016],"study_design_scores_gemma":[0.015202894,0.0000870175,0.981356,0.00034786202,0.0013340182,0.000023501376,0.001188025,0.0000020540715,0.000011376112,0.000105630876,0.00024459293,0.00009698943],"about_ca_topic_score_codex":0.000013366818,"about_ca_topic_score_gemma":0.00016755817,"teacher_disagreement_score":0.040196028,"about_ca_system_score_codex":0.0000067495457,"about_ca_system_score_gemma":0.00024325337,"threshold_uncertainty_score":0.35320774},"labels":[],"label_agreement":null},{"id":"W3209037189","doi":"10.1111/bjd.20813","title":"Risankizumab vs. fumaric acid esters: a direct comparison","year":2021,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Fumaric acid; Medicine; Dermatology; Chemistry; Organic chemistry","score_opus":0.018649059170808356,"score_gpt":0.23844152917481465,"score_spread":0.21979247000400629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209037189","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08191435,0.61664593,0.0002811481,0.26645702,0.024700044,0.0007002085,0.0007230097,0.00020153204,0.008376753],"genre_scores_gemma":[0.66351837,0.01919006,0.001139756,0.29500264,0.00513714,0.00009158685,0.0052159606,0.00039940438,0.010305098],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956191,0.0015359387,0.0014284744,0.00047749656,0.00013537737,0.00080359087],"domain_scores_gemma":[0.9973998,0.0004553549,0.0014165457,0.00037357296,0.0003033124,0.00005138165],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00016453907,0.0005153498,0.0023181993,0.00040141,0.0002490182,0.00011534123,0.00069884286,0.0023588915,0.0012679652],"category_scores_gemma":[0.00015226859,0.00056881964,0.00080643466,0.0002289066,0.00028855194,0.00016408815,0.00014719633,0.002864304,0.00033618486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017200744,0.00020067766,0.001847657,0.00010640992,0.002251068,0.055169478,0.00013378027,4.2123597e-7,0.00043452802,0.0000019976826,0.90059984,0.03908215],"study_design_scores_gemma":[0.0028378635,0.0001559231,0.0009725881,0.00047582327,0.0009512514,0.29392537,0.00006519103,2.8013102e-7,0.006174089,0.000023873414,0.6940229,0.00039486357],"about_ca_topic_score_codex":0.00009908556,"about_ca_topic_score_gemma":0.000080695434,"teacher_disagreement_score":0.59745586,"about_ca_system_score_codex":0.0001233364,"about_ca_system_score_gemma":0.00045343235,"threshold_uncertainty_score":0.99967635},"labels":[],"label_agreement":null},{"id":"W3210301357","doi":"","title":"② 乾癬におけるresident memory T細胞と制御性T細胞〜獲得免疫と自己免疫〜","year":2021,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.025825739234155994,"score_gpt":0.2780795696642436,"score_spread":0.2522538304300876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210301357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6084122,0.30644897,0.000055941036,0.011549494,0.024721127,0.0007019227,0.0005553213,0.00034473883,0.04721029],"genre_scores_gemma":[0.9059665,0.020602426,0.0001396961,0.0027013926,0.0014670752,0.000094822346,0.0008034584,0.000084393956,0.06814024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99598145,0.0010336948,0.0007390569,0.0009449504,0.00022775149,0.0010731164],"domain_scores_gemma":[0.9979975,0.00046136763,0.00025581956,0.00081642653,0.00020055212,0.00026831235],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005725868,0.000584823,0.0008428631,0.00016605335,0.0004765738,0.000049139988,0.00052474486,0.0006614176,0.05653317],"category_scores_gemma":[0.00030880875,0.00055717264,0.00045369362,0.0004201865,0.00039897775,0.00015326327,0.00035390552,0.0006773042,0.011829746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007917317,0.0020349612,0.0017053501,0.00030560594,0.0055424846,0.0048953667,0.0049679675,0.0000036956908,0.3506798,0.0002528809,0.29499978,0.33382037],"study_design_scores_gemma":[0.00765042,0.00017109903,0.003345619,0.00020285201,0.0018109566,0.0008858889,0.001231941,0.00001059712,0.51226336,0.000088681205,0.47169182,0.0006467581],"about_ca_topic_score_codex":0.000088414854,"about_ca_topic_score_gemma":0.000038803748,"teacher_disagreement_score":0.33317363,"about_ca_system_score_codex":0.0001385855,"about_ca_system_score_gemma":0.00072816043,"threshold_uncertainty_score":0.99968797},"labels":[],"label_agreement":null},{"id":"W3211156244","doi":"10.1007/s13555-021-00632-7","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Palmoplantar pustulosis; Medicine; Double blind; Placebo; Dermatology; Randomized controlled trial; Internal medicine; Psoriasis; Alternative medicine; Pathology","score_opus":0.02480674125765737,"score_gpt":0.29438390573820644,"score_spread":0.2695771644805491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211156244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775658,0.01847811,0.000019777328,0.0007594359,0.00014768308,0.0027705298,0.000017928834,0.000017452323,0.00022324713],"genre_scores_gemma":[0.9961294,0.0030496314,0.000017699134,0.00020530926,0.000010549287,0.00042077174,0.000042768683,0.000013390905,0.00011048839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971567,0.001695435,0.0004406253,0.00037280953,0.00004729874,0.00028715516],"domain_scores_gemma":[0.9980323,0.0014624322,0.00011366059,0.00028846724,0.00007056118,0.000032631597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074416754,0.0002645837,0.0011600188,0.00013784505,0.00021559646,0.00001448971,0.000116265364,0.00015236747,0.00008585246],"category_scores_gemma":[0.000045427947,0.00014829231,0.00008386746,0.00021681665,0.0002822367,0.00004257504,0.00004641802,0.00017092205,0.000012585128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9629876,0.0014520965,0.020034814,0.000010955426,0.0025325213,0.00017350426,0.005446983,0.0000039548595,0.0021304968,0.0002767669,0.00003201026,0.004918269],"study_design_scores_gemma":[0.97573084,0.0005096754,0.0035017808,0.000028820206,0.0005214951,0.00080315856,0.0013277022,0.000004677576,0.0169845,0.00007130093,0.00033770225,0.0001783655],"about_ca_topic_score_codex":0.00009951236,"about_ca_topic_score_gemma":0.00034907076,"teacher_disagreement_score":0.018563557,"about_ca_system_score_codex":0.000008095731,"about_ca_system_score_gemma":0.000073401585,"threshold_uncertainty_score":0.6047185},"labels":[],"label_agreement":null},{"id":"W3211379308","doi":"10.1111/1346-8138.16214","title":"Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis","year":2021,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Lynde Centre for Dermatology; Dalhousie University; University of New Brunswick; University of Toronto; Probity Medical Research; Government of New Brunswick; SKiN Health; Queen's University","funders":"AbbVie","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Term (time); Internal medicine","score_opus":0.015951654604163763,"score_gpt":0.23798223795868556,"score_spread":0.2220305833545218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211379308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99687445,0.0010967279,0.000020615056,0.0010732437,0.0003964804,0.00023900626,0.00015419132,0.0000065041477,0.00013876056],"genre_scores_gemma":[0.9987073,0.0008224264,0.00003794912,0.00009237345,0.000024777237,0.000008830137,0.00012831886,0.000017252154,0.0001607627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799114,0.0007299995,0.0005745437,0.00016121048,0.000051229654,0.00049189036],"domain_scores_gemma":[0.9987567,0.0002757551,0.0003639435,0.00032529782,0.00018893513,0.00008934409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012434238,0.00024646978,0.000704219,0.00034494855,0.0001182395,0.000007834797,0.00028747326,0.0002080379,0.00017514658],"category_scores_gemma":[0.000018814599,0.00014771748,0.000109616914,0.00025553553,0.00008705913,0.00006564877,0.000040869018,0.00020398453,0.00002676073],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010695677,0.00034869538,0.99134475,0.00001876012,0.00071872683,0.00043316832,0.0010210947,0.00012167029,0.0012632065,0.000091718175,0.00012613653,0.0034425217],"study_design_scores_gemma":[0.0084989,0.0009882827,0.9489159,0.0001298796,0.00037545455,0.0019378999,0.00017887529,0.0000020944344,0.03775368,0.000037606103,0.0009595128,0.00022193306],"about_ca_topic_score_codex":0.020501956,"about_ca_topic_score_gemma":0.5922409,"teacher_disagreement_score":0.571739,"about_ca_system_score_codex":0.00042593267,"about_ca_system_score_gemma":0.0009751847,"threshold_uncertainty_score":0.9860206},"labels":[],"label_agreement":null},{"id":"W3211411127","doi":"10.25251/skin.5.supp.39","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Plaque psoriasis; Pharmacology; Internal medicine; Dermatology; Pathology; Psoriatic arthritis","score_opus":0.050049962194994205,"score_gpt":0.33098603349030825,"score_spread":0.28093607129531406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211411127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98773485,0.0083157355,0.00003079715,0.0025113511,0.0007308512,0.00047069765,0.000086714965,0.0000072354624,0.0001117575],"genre_scores_gemma":[0.99556863,0.0036546695,0.00010702394,0.00028413505,0.0002066875,0.000010948574,0.00004589756,0.000019537727,0.00010247697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957256,0.0026103258,0.0009482902,0.00025030997,0.00015482875,0.0003106664],"domain_scores_gemma":[0.9965729,0.0023432826,0.00054009195,0.00025210553,0.00021975247,0.0000718495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002625236,0.0002919082,0.0009560025,0.00028825528,0.00014760916,0.000017248807,0.00020078754,0.0002327104,0.000075600656],"category_scores_gemma":[0.0012433222,0.00016836257,0.00007780107,0.00043559485,0.00022141995,0.00013271515,0.000044902463,0.0004979689,0.0000026405528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25621584,0.002662924,0.0014064142,0.00015802024,0.002022088,0.003252879,0.042442244,0.0004843229,0.566616,0.00017757012,0.009452563,0.115109116],"study_design_scores_gemma":[0.18263412,0.027850699,0.0045718444,0.0025042284,0.004297609,0.083501585,0.058385327,0.00013312708,0.6241031,0.0021326274,0.008751862,0.0011338544],"about_ca_topic_score_codex":0.00019524689,"about_ca_topic_score_gemma":0.0013059546,"teacher_disagreement_score":0.113975264,"about_ca_system_score_codex":0.000093353345,"about_ca_system_score_gemma":0.00019395283,"threshold_uncertainty_score":0.68656266},"labels":[],"label_agreement":null},{"id":"W3211829948","doi":"10.25251/skin.5.supp.48","title":"Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Adverse effect; Fixed-dose combination; Pharmacology","score_opus":0.006887610117860704,"score_gpt":0.23037279793076346,"score_spread":0.22348518781290275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211829948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969873,0.0016429061,0.00006186563,0.00068531296,0.00028582136,0.0002932687,0.0000064058554,0.0000028365241,0.00003430371],"genre_scores_gemma":[0.99785334,0.0018905691,0.00005572185,0.00004644559,0.00003161883,0.0000016732986,0.00003616937,0.000009264019,0.0000751721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985171,0.00033282986,0.0007483703,0.00013923817,0.0001111841,0.00015129706],"domain_scores_gemma":[0.99861175,0.0004828031,0.0005401791,0.00013016605,0.00020871607,0.000026381931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006684447,0.00014130885,0.00044394704,0.00013679988,0.000051263167,0.000003554873,0.000090428846,0.00011356291,0.00004543972],"category_scores_gemma":[0.00025911318,0.000080029495,0.00003123805,0.0001486889,0.00017351976,0.00005689802,0.00003697275,0.00023589778,8.112083e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017827168,0.0014727701,0.62584746,0.00011519823,0.0006224012,0.0003316921,0.003362929,0.000067503235,0.0236797,0.00007272187,0.000026090307,0.32657436],"study_design_scores_gemma":[0.020142844,0.0054028104,0.9642402,0.0007982306,0.00035661148,0.00073736656,0.00022287623,0.000005063989,0.007835651,0.00011527986,0.000032789278,0.000110272944],"about_ca_topic_score_codex":0.000027600458,"about_ca_topic_score_gemma":0.00009121052,"teacher_disagreement_score":0.33839273,"about_ca_system_score_codex":0.000054742002,"about_ca_system_score_gemma":0.00006425867,"threshold_uncertainty_score":0.3263508},"labels":[],"label_agreement":null},{"id":"W3211993606","doi":"10.1136/bmjopen-2020-047806","title":"Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Medicine; Epidemiology; Cross-sectional study; Psoriasis; Ambulatory; Environmental health; Public health; Family medicine; Dermatology; Pathology; Internal medicine","score_opus":0.2356404163545013,"score_gpt":0.42568634852945203,"score_spread":0.19004593217495072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211993606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954078,0.00042069986,0.00005314048,0.00035616485,0.00054061157,0.0019650168,0.00094141485,0.000012116526,0.00030304043],"genre_scores_gemma":[0.995848,0.0000699559,0.0005967631,0.00027447572,0.00006999686,0.00042198118,0.0007144673,0.000008547128,0.0019958257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793214,0.00070471957,0.0004678718,0.0006517535,0.000066727414,0.00017677598],"domain_scores_gemma":[0.9980518,0.00075265893,0.00016403869,0.00092068274,0.00007884236,0.000031946198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011151687,0.00015265551,0.0003770716,0.00007374474,0.00013414335,0.00003269963,0.0005722933,0.00019557933,0.0007845603],"category_scores_gemma":[0.00047421738,0.00012942935,0.00004022391,0.00013376678,0.00006340307,0.00017708896,0.00080624927,0.0001371785,0.00017524535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064366846,0.0008096565,0.9891081,0.000011149235,0.00025045927,0.000021422664,0.00036831363,0.000018924617,0.0035760358,0.00063526427,0.003866119,0.0006908832],"study_design_scores_gemma":[0.0018390337,0.00021591288,0.9958615,0.00004595,0.00006194556,0.00001565148,0.00010124903,0.0000109385155,0.00027473638,0.0004242479,0.001010171,0.00013870806],"about_ca_topic_score_codex":0.00086209597,"about_ca_topic_score_gemma":0.0005507929,"teacher_disagreement_score":0.006753352,"about_ca_system_score_codex":0.00003181046,"about_ca_system_score_gemma":0.00014800354,"threshold_uncertainty_score":0.8590385},"labels":[],"label_agreement":null},{"id":"W3212333063","doi":"10.25251/skin.5.supp.52","title":"Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Interim; Open label; Medicine; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Interim analysis; Clinical trial; Surgery; History","score_opus":0.02578579340508559,"score_gpt":0.280982458042791,"score_spread":0.2551966646377054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212333063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912731,0.0016604624,0.00003250443,0.0048737098,0.00096772925,0.0007727454,0.00029754746,0.0000058067058,0.00011640539],"genre_scores_gemma":[0.9954759,0.00055333995,0.000226129,0.00078242976,0.00014645312,0.000017083452,0.00006413401,0.000029007533,0.0027055102],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961419,0.0020940164,0.000942503,0.00031487647,0.00018586153,0.00032084138],"domain_scores_gemma":[0.9960536,0.0022483547,0.00063092995,0.00066743005,0.0003516791,0.000048001628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010115585,0.00029289856,0.0008468934,0.000110315035,0.000114116934,0.000018354756,0.0005081244,0.0001469661,0.00019019927],"category_scores_gemma":[0.0007740013,0.00013795902,0.000085841195,0.00033422088,0.00021514567,0.00011146612,0.00013581563,0.00028787096,0.000012802804],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96030205,0.0008000081,0.00013116655,0.0000024469512,0.0008325861,0.0010060389,0.0115194,0.00007075848,0.0066966317,0.00001078295,0.004411722,0.014216397],"study_design_scores_gemma":[0.789921,0.05468094,0.031876728,0.0049208784,0.002721223,0.0050659175,0.006015945,0.000012617303,0.055686224,0.0013302614,0.046904147,0.0008641569],"about_ca_topic_score_codex":0.0010573912,"about_ca_topic_score_gemma":0.0009834452,"teacher_disagreement_score":0.1703811,"about_ca_system_score_codex":0.00033260035,"about_ca_system_score_gemma":0.0003700863,"threshold_uncertainty_score":0.5625805},"labels":[],"label_agreement":null},{"id":"W3212399069","doi":"10.25251/skin.5.supp.49","title":"Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Lotion; Psoriasis; Medicine; Dermatology; Internal medicine; Pharmacology","score_opus":0.011908172349742327,"score_gpt":0.24588944887510455,"score_spread":0.23398127652536221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212399069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829442,0.014729377,0.00040594596,0.0012128549,0.00045756705,0.00016266447,0.000038026366,0.0000048279835,0.00004456285],"genre_scores_gemma":[0.9969101,0.00225402,0.000056463286,0.000046947247,0.00004490511,0.0000014803381,0.000065755674,0.000009979925,0.00061033666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860996,0.0004041212,0.0006210765,0.00011543149,0.00011754405,0.00013187827],"domain_scores_gemma":[0.9982478,0.00060238736,0.0006410067,0.00015569833,0.0003217567,0.000031335887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056174165,0.00015794543,0.0005383826,0.000099020705,0.00007642626,0.0000037148081,0.000105223684,0.00012640699,0.00016764268],"category_scores_gemma":[0.00027821944,0.00009029194,0.00006500276,0.00011139514,0.00028370306,0.000058269354,0.000027504131,0.00014965964,0.0000010835571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000759311,0.00039904716,0.029987147,0.00012623916,0.0012560292,0.00010904534,0.0010977965,0.000009186795,0.8323974,0.000121694284,0.00041819987,0.1333189],"study_design_scores_gemma":[0.012513999,0.0074727554,0.114031896,0.0008640971,0.0036248781,0.012103397,0.0010661198,0.000026006011,0.84678805,0.000924716,0.0002607178,0.0003233729],"about_ca_topic_score_codex":0.000022754592,"about_ca_topic_score_gemma":0.00001861647,"teacher_disagreement_score":0.13299553,"about_ca_system_score_codex":0.000017680875,"about_ca_system_score_gemma":0.000054728876,"threshold_uncertainty_score":0.36819983},"labels":[],"label_agreement":null},{"id":"W3212504077","doi":"10.25251/skin.5.supp.51","title":"Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Dermira; Tulane University; Celgene; Regeneron Pharmaceuticals; Bausch Health; Novartis; Amgen; Pfizer","keywords":"Ustekinumab; Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Pharmacology; Internal medicine; Tumor necrosis factor alpha; Adalimumab","score_opus":0.016614763979763615,"score_gpt":0.2994205924946756,"score_spread":0.282805828514912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212504077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9110542,0.08607382,0.000032789958,0.0011426008,0.0013316218,0.00015591923,0.00012593309,0.000008899544,0.0000742219],"genre_scores_gemma":[0.9915291,0.0070087896,0.000088502304,0.00012397932,0.00026482437,0.0000020886337,0.00008159992,0.00002152722,0.00087959063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701494,0.0008061534,0.0013931919,0.00021682298,0.00026165217,0.00030721095],"domain_scores_gemma":[0.9950235,0.0019191973,0.0014443275,0.00050137186,0.0010557695,0.000055872355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008927546,0.00030572835,0.0016637204,0.00041828232,0.00015080234,0.0000043882783,0.00039067102,0.00016101969,0.0006299298],"category_scores_gemma":[0.0009829394,0.00017909602,0.00049894257,0.00097152387,0.0005611218,0.000057492576,0.0000810657,0.00029551538,0.000008464118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016065536,0.0019872007,0.00086003484,0.00010251365,0.03812851,0.0006366907,0.011993747,0.000110958375,0.814668,0.00004212807,0.01026257,0.1051421],"study_design_scores_gemma":[0.058324564,0.019190744,0.0022556875,0.0010487139,0.06368402,0.010490914,0.01495014,0.000009395035,0.8188608,0.00013463864,0.010490101,0.0005602445],"about_ca_topic_score_codex":0.00005353682,"about_ca_topic_score_gemma":0.00007401161,"teacher_disagreement_score":0.104581855,"about_ca_system_score_codex":0.000082906925,"about_ca_system_score_gemma":0.00018524965,"threshold_uncertainty_score":0.73033243},"labels":[],"label_agreement":null},{"id":"W3212595479","doi":"10.25251/skin.5.supp.50","title":"Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Psoriasis; Medicine; Dermatology; Quality of life (healthcare); Intensive care medicine; Nursing","score_opus":0.01449934001659458,"score_gpt":0.2550851118258947,"score_spread":0.24058577180930013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212595479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547446,0.003495413,0.000003242683,0.00044371342,0.00017413375,0.00030138597,0.00002709513,0.000002428905,0.000078103985],"genre_scores_gemma":[0.9984646,0.001184101,0.00005206543,0.000060084614,0.000029018944,0.000009745112,0.000025682697,0.000012277882,0.00016242669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979581,0.00058023166,0.0008946153,0.00020306281,0.00013988452,0.00022410069],"domain_scores_gemma":[0.9987724,0.00026937664,0.00054712093,0.0002448224,0.00013287457,0.000033446246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005310158,0.00021377683,0.0006721224,0.00020648228,0.000026421394,0.0000034672164,0.00008970375,0.000105107494,0.000044388824],"category_scores_gemma":[0.00012668649,0.00010910817,0.00004189942,0.00027319408,0.00016524777,0.00006328012,0.00002417204,0.00018189123,0.0000016776177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10115456,0.0022993763,0.79670995,0.000060903927,0.0007845904,0.000510297,0.011492859,0.00007971934,0.002205799,0.0000069459825,0.000027554317,0.08466742],"study_design_scores_gemma":[0.039843634,0.007138128,0.9459407,0.0008467331,0.00019702691,0.0002526591,0.0017408755,0.0000015570354,0.0037948205,0.000031391588,0.000087802364,0.00012468669],"about_ca_topic_score_codex":0.0009442771,"about_ca_topic_score_gemma":0.0053796936,"teacher_disagreement_score":0.1492307,"about_ca_system_score_codex":0.00024047545,"about_ca_system_score_gemma":0.000107017564,"threshold_uncertainty_score":0.4449302},"labels":[],"label_agreement":null},{"id":"W3212995571","doi":"10.25251/skin.5.supp.35","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Extension (predicate logic); Aryl hydrocarbon receptor; Aryl; Psoriasis; Hydrocarbon; Medicine; Combinatorial chemistry; Pharmacology; Chemistry; Computer science; Dermatology; Organic chemistry; Physics; Biochemistry","score_opus":0.034237871899152575,"score_gpt":0.2839932816325126,"score_spread":0.24975540973336002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212995571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752696,0.017197339,0.00175599,0.0013644609,0.003757588,0.0005105709,0.000021949947,0.0000136901635,0.000108794746],"genre_scores_gemma":[0.9952649,0.0026252368,0.0003104121,0.00019521298,0.0008335171,0.000010347832,0.000046064044,0.00003249851,0.00068179454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979897,0.00030237145,0.0009870478,0.00021794371,0.00017946845,0.00032343043],"domain_scores_gemma":[0.996882,0.001279432,0.0010475346,0.00038403698,0.00035822974,0.000048720805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009608095,0.00026978605,0.000809952,0.00012896438,0.00018392566,0.000006155024,0.00030995437,0.00022472616,0.0001723606],"category_scores_gemma":[0.00046824932,0.00016151018,0.0002811085,0.00018806783,0.00020171152,0.000054041047,0.000047346948,0.0002968708,0.000005285599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042589862,0.0010181952,0.00014020607,0.000060927334,0.0013860792,0.00014062459,0.0021743232,0.00017575083,0.90067184,0.00005658485,0.00058115885,0.05100446],"study_design_scores_gemma":[0.21004614,0.02811305,0.0028231083,0.0041458225,0.0073152767,0.032223124,0.004041005,0.00028367236,0.7043846,0.0009623784,0.004832165,0.00082962605],"about_ca_topic_score_codex":0.000023925058,"about_ca_topic_score_gemma":0.000016337746,"teacher_disagreement_score":0.1962872,"about_ca_system_score_codex":0.00008018492,"about_ca_system_score_gemma":0.00018020615,"threshold_uncertainty_score":0.6586194},"labels":[],"label_agreement":null},{"id":"W3213232762","doi":"10.1016/j.jaad.2021.11.004","title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Janssen Research and Development","keywords":"Medicine; Adverse effect; Psoriasis; Placebo; Dermatology; Randomized controlled trial; Crossover study; Internal medicine","score_opus":0.03140226911436131,"score_gpt":0.3067322821856013,"score_spread":0.27533001307123994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213232762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950994,0.0015551326,0.00010450841,0.0017906347,0.000086159125,0.00051335135,0.00081701187,0.0000048529732,0.00002893017],"genre_scores_gemma":[0.9980839,0.00026418472,0.0011063456,0.0003317575,0.00001716499,0.000015011285,0.00002747072,0.000019721103,0.00013442842],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997152,0.0011935368,0.0010125445,0.00024581334,0.00014629636,0.00024985653],"domain_scores_gemma":[0.99624276,0.0008885932,0.0022907208,0.00026654438,0.00024586072,0.00006553759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021889455,0.00026380064,0.0019375465,0.00016107445,0.00008765948,0.000007781572,0.0002929746,0.00010879161,0.00006454142],"category_scores_gemma":[0.00015403006,0.00012417388,0.00023059777,0.00044574976,0.00056303496,0.000058085127,0.000075113574,0.00018301485,0.000002355279],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18560165,0.00395987,0.371637,0.0000952275,0.04647535,0.00022554483,0.00934605,0.00049430045,0.27896613,0.00015601952,0.003829588,0.099213295],"study_design_scores_gemma":[0.041942302,0.0072147083,0.2837574,0.00043613053,0.008708987,0.0011760276,0.004037969,0.0000039965757,0.6479008,0.000036540874,0.004355295,0.00042984265],"about_ca_topic_score_codex":0.00012801951,"about_ca_topic_score_gemma":0.00003393879,"teacher_disagreement_score":0.36893466,"about_ca_system_score_codex":0.000043602475,"about_ca_system_score_gemma":0.00023918474,"threshold_uncertainty_score":0.5063664},"labels":[],"label_agreement":null},{"id":"W3213530550","doi":"10.25251/skin.5.supp.53","title":"Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma","keywords":"Secukinumab; Medicine; Plaque psoriasis; Double blinded; Psoriasis; Dermatology; Randomized controlled trial; Multicenter study; Internal medicine; Psoriatic arthritis; Alternative medicine; Placebo; Pathology","score_opus":0.028914308113880276,"score_gpt":0.2928783056741451,"score_spread":0.2639639975602648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213530550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787636,0.002930787,0.000093953655,0.0029200283,0.004033685,0.0014096852,0.00061932806,0.000014561422,0.000101626],"genre_scores_gemma":[0.997697,0.00076864666,0.00010125011,0.00026168622,0.0005900377,0.000014672373,0.00031219414,0.000034800963,0.00021969479],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961094,0.001359679,0.001406105,0.00031249138,0.00034154748,0.00047077387],"domain_scores_gemma":[0.99221736,0.0051769605,0.0012337064,0.0006495718,0.0006161959,0.00010623005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001395673,0.00040358736,0.0013890193,0.00009335079,0.00033552016,0.000024777444,0.00059616903,0.00023008068,0.00021463889],"category_scores_gemma":[0.0011548343,0.00018485884,0.0003157891,0.00032444563,0.00044511314,0.00008455113,0.00009102323,0.0005166255,0.000016840908],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96759987,0.0011409341,0.000011699969,0.00000709427,0.0036454736,0.00033204615,0.014585853,0.0003087055,0.00119083,0.00001268461,0.0015855453,0.009579252],"study_design_scores_gemma":[0.97314954,0.0038775965,0.00007925436,0.00031978436,0.002530049,0.00062086276,0.0023679642,0.000015301319,0.014340823,0.000027784581,0.0024597794,0.00021125177],"about_ca_topic_score_codex":0.00034213538,"about_ca_topic_score_gemma":0.00035053724,"teacher_disagreement_score":0.013149993,"about_ca_system_score_codex":0.00010271323,"about_ca_system_score_gemma":0.00026174294,"threshold_uncertainty_score":0.7538325},"labels":[],"label_agreement":null},{"id":"W3213919372","doi":"10.25251/skin.5.supp.44","title":"Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia; Queen's University","funders":"","keywords":"Roflumilast; Open label; Plaque psoriasis; Medicine; Psoriasis; Dermatology; Adverse effect; Term (time); Pharmacology; Internal medicine; COPD","score_opus":0.016306808373359905,"score_gpt":0.2737719592662977,"score_spread":0.2574651508929378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213919372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922245,0.0057415487,0.000014418926,0.0004693222,0.00059232535,0.0006192983,0.00016897687,0.0000061914798,0.00016339654],"genre_scores_gemma":[0.99693316,0.0023351756,0.000034549703,0.000067451314,0.00016330133,0.00000382051,0.00016264887,0.00002322227,0.00027669145],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738836,0.00076314533,0.001097306,0.00028244202,0.00017793174,0.00029079395],"domain_scores_gemma":[0.9970258,0.001262745,0.00085545075,0.00043335548,0.0003588157,0.000063839274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005917135,0.00028779323,0.00091770705,0.00014307063,0.00013500324,0.000011695663,0.00046427772,0.00014630427,0.00015965161],"category_scores_gemma":[0.0004926518,0.00016122636,0.000044877797,0.0002767855,0.00026989364,0.00008639043,0.00013886037,0.00040198525,0.000006993916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36585155,0.09209711,0.12862214,0.0001377839,0.011279084,0.008752147,0.04234994,0.000090843474,0.044765636,0.00003494765,0.002067009,0.3039518],"study_design_scores_gemma":[0.52570325,0.06829153,0.36814076,0.0037453438,0.0045660306,0.005091564,0.0045338273,0.0000071673117,0.018478831,0.00004811021,0.00080108235,0.0005925102],"about_ca_topic_score_codex":0.00039601052,"about_ca_topic_score_gemma":0.0016778023,"teacher_disagreement_score":0.3033593,"about_ca_system_score_codex":0.00010756801,"about_ca_system_score_gemma":0.00024446473,"threshold_uncertainty_score":0.657462},"labels":[],"label_agreement":null},{"id":"W3214205933","doi":"10.1016/j.jdin.2021.09.007","title":"Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study","year":2021,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; McMaster University; Dermatrials Research; Probity Medical Research; Heritage Medical Research Clinic; SKiN Health; University of Calgary; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Randomized controlled trial; Psoriasis; Clinical trial; Internal medicine; Ustekinumab; Adverse effect; Secukinumab; Dermatology; Disease","score_opus":0.022814624718708126,"score_gpt":0.31984210289900583,"score_spread":0.29702747818029773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214205933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99209934,0.00020994127,0.00012733236,0.0009445999,0.0014762561,0.0010134905,0.0005227669,0.000011770669,0.003594502],"genre_scores_gemma":[0.9969871,0.00009783092,0.00077171286,0.00024675552,0.00008736983,0.00012711342,0.00033894042,0.000014339072,0.0013288262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984275,0.00027848018,0.00054469367,0.00045129837,0.000073864,0.00022415908],"domain_scores_gemma":[0.99856025,0.0006838343,0.00014564814,0.00018693955,0.00036606105,0.000057244313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005583234,0.00015313688,0.00036497432,0.00016401522,0.00008871788,0.000021112863,0.00014295994,0.00017918939,0.000395811],"category_scores_gemma":[0.0012471062,0.00014965546,0.00009102231,0.00011271363,0.000047555586,0.00011989719,0.00006690141,0.00017959782,0.00003548568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010899024,0.002978127,0.96507126,0.0000072420535,0.0027166747,0.00006688443,0.0014730662,0.000038176746,0.00025812938,0.0012767189,0.0019619332,0.013252777],"study_design_scores_gemma":[0.014154902,0.0004916485,0.97103447,0.000034571232,0.00018927154,0.000040876454,0.0008138504,0.000041968025,0.00071911083,0.00010200949,0.0122141,0.00016324584],"about_ca_topic_score_codex":0.0062192655,"about_ca_topic_score_gemma":0.03864851,"teacher_disagreement_score":0.03242924,"about_ca_system_score_codex":0.00033455057,"about_ca_system_score_gemma":0.00026493176,"threshold_uncertainty_score":0.97889364},"labels":[],"label_agreement":null},{"id":"W3214525563","doi":"10.1161/circ.144.suppl_1.9057","title":"Abstract 9057: Anti-inflammatory Effect of Biologic Therapy in Patients With Psoriatic Disease: A Prospective Cohort Fdg-pet Study","year":2021,"lang":"en","type":"article","venue":"Circulation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Heart Institute; Montreal Heart Institute; University of Ottawa","funders":"","keywords":"Medicine; Prospective cohort study; Disease; Psoriasis; Cohort; Internal medicine; Antibody therapy; Oncology; Dermatology; Immunology; Antibody","score_opus":0.006932721380092487,"score_gpt":0.2222319225107714,"score_spread":0.2152992011306789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214525563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975779,0.00072512124,0.0000031047098,0.0000040090376,0.00022144217,0.0013547293,0.000028138253,0.000030923376,0.0000546124],"genre_scores_gemma":[0.99946576,0.000025241097,0.000003309591,0.000003959942,0.000013439206,0.00012094239,0.0003451469,0.000011935581,0.000010240966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989213,0.00031985668,0.00023597447,0.0003089554,0.00005575247,0.00015819674],"domain_scores_gemma":[0.99938166,0.00011822666,0.00014721487,0.00024414473,0.00009335054,0.000015417902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020379199,0.00016572021,0.00031458953,0.00008547837,0.00006307761,0.0000066967555,0.000059177833,0.0000722423,0.00011911],"category_scores_gemma":[0.000054110038,0.000119743876,0.00006309649,0.0001951962,0.000045701494,0.000078628174,0.000013767068,0.00007583427,0.000030710296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075003336,0.00079436175,0.9870446,0.000020443023,0.0004283403,0.000024114546,0.00017053355,0.00006535459,0.005667298,0.000012585073,0.000001904605,0.0050204857],"study_design_scores_gemma":[0.0063373917,0.0004078195,0.9886502,0.00003410835,0.00012752145,0.0000011687721,0.000029471714,0.000001503242,0.0042567994,0.000024035413,0.0000035608753,0.00012643353],"about_ca_topic_score_codex":0.000015134677,"about_ca_topic_score_gemma":0.000020403231,"teacher_disagreement_score":0.0055873585,"about_ca_system_score_codex":0.000062283696,"about_ca_system_score_gemma":0.00005575364,"threshold_uncertainty_score":0.48830134},"labels":[],"label_agreement":null},{"id":"W3214549902","doi":"10.25251/skin.5.supp.38","title":"Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Domain (mathematical analysis); Dermatology; Mathematics; Mathematical analysis","score_opus":0.012569610244830129,"score_gpt":0.24920588041576186,"score_spread":0.23663627017093172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214549902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96800095,0.025278876,0.000033194596,0.0051474497,0.00072937406,0.00042810664,0.00029315706,0.000013818576,0.00007507443],"genre_scores_gemma":[0.9929716,0.0053581162,0.00021577503,0.00079595187,0.00030720132,0.0000110562205,0.00008419715,0.000032033866,0.00022408042],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971234,0.0010293144,0.00084710383,0.00037240252,0.00020848743,0.0004192675],"domain_scores_gemma":[0.99570906,0.0029506772,0.0005125427,0.00039690186,0.00033302288,0.00009778814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009594306,0.00041164027,0.0008657809,0.00014107773,0.0003575074,0.000028259243,0.00029320357,0.00018058119,0.00003364628],"category_scores_gemma":[0.0007894906,0.0001983731,0.000072178176,0.00027708703,0.00048869126,0.000119311335,0.00013753276,0.00044603818,0.0000053629137],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21188271,0.0031509704,0.045681648,0.00021529099,0.0222488,0.0051282644,0.18505026,0.00029710194,0.105237305,0.00042913022,0.023780607,0.3968979],"study_design_scores_gemma":[0.39386573,0.05748229,0.19391924,0.013524582,0.016928852,0.034655612,0.14948398,0.000057578673,0.091781795,0.021911241,0.021756459,0.004632632],"about_ca_topic_score_codex":0.00016664615,"about_ca_topic_score_gemma":0.0005121833,"teacher_disagreement_score":0.3922653,"about_ca_system_score_codex":0.00006953942,"about_ca_system_score_gemma":0.00012379832,"threshold_uncertainty_score":0.8089421},"labels":[],"label_agreement":null},{"id":"W3214576279","doi":"10.1111/bjd.20885","title":"Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting","year":2021,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; ABB (Canada); Surrey Memorial Hospital; SKiN Health; University of British Columbia; Queen's University; Probity Medical Research","funders":"AbbVie Canada","keywords":"Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Methotrexate; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Quality of life (healthcare); Patient satisfaction; Physical therapy; Clinical trial; Surgery; Dermatology; Disease","score_opus":0.010135586516618247,"score_gpt":0.24391609904802913,"score_spread":0.23378051253141088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214576279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902876,0.002565469,0.00007560337,0.00507106,0.0006869624,0.00082324515,0.0003519058,0.000015728852,0.00012242116],"genre_scores_gemma":[0.99281824,0.001030708,0.0026656247,0.002529846,0.00012152202,0.00007989671,0.0004772849,0.00010271456,0.00017416872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939809,0.003175969,0.0013978776,0.00061231415,0.00015086845,0.00068206666],"domain_scores_gemma":[0.9968223,0.0016572871,0.0008528589,0.00026021426,0.00033417606,0.000073149386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005827903,0.0005063147,0.0020804529,0.0019532773,0.00013324399,0.000042082556,0.00022295199,0.00070782274,0.000059262533],"category_scores_gemma":[0.00024036205,0.000513345,0.00020123083,0.0009149275,0.00008647981,0.000174123,0.000109441935,0.0008768829,0.0000057896145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019689947,0.0005010339,0.83547527,0.0005450424,0.0030094185,0.020940294,0.0013202508,0.0001732156,0.0019421235,0.000027971655,0.004217241,0.112158194],"study_design_scores_gemma":[0.018928515,0.0012610401,0.946418,0.004923925,0.0006407872,0.010503447,0.000173482,6.0543647e-7,0.0039421343,0.00001643987,0.012553773,0.0006378517],"about_ca_topic_score_codex":0.0014438959,"about_ca_topic_score_gemma":0.003646211,"teacher_disagreement_score":0.11152034,"about_ca_system_score_codex":0.0006627475,"about_ca_system_score_gemma":0.00036999525,"threshold_uncertainty_score":0.99973184},"labels":[],"label_agreement":null},{"id":"W3215006483","doi":"10.1111/jdv.17836","title":"Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial","year":2021,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis; Placebo; Sex organ; Quality of life (healthcare); Dosing; Internal medicine; Dermatology Life Quality Index; Secukinumab; Dermatology; Alternative medicine; Psoriatic arthritis","score_opus":0.03883039974010785,"score_gpt":0.3024456140539665,"score_spread":0.2636152143138587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215006483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598954,0.004294362,0.0000012620901,0.033372324,0.00055867125,0.001736599,0.00010248958,0.000005567889,0.000033366592],"genre_scores_gemma":[0.99259573,0.0004866311,0.000012033694,0.006471176,0.00014214304,0.00003140656,0.000052917654,0.00003734788,0.00017061297],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9755859,0.019548798,0.0037039784,0.00045306527,0.00015540542,0.0005528713],"domain_scores_gemma":[0.9926841,0.0023491725,0.0044874446,0.00021992013,0.00018050219,0.0000788202],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0031728733,0.00049042417,0.0034563756,0.00037817002,0.00017526481,0.000012405677,0.00049902307,0.0010751779,0.00001678752],"category_scores_gemma":[0.0024472885,0.00027088946,0.0006622532,0.00021422138,0.0008686674,0.000091785856,0.0002600543,0.0025340638,0.0000014664181],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91822946,0.0015404936,0.06359235,0.00026432026,0.0088597415,0.00019126225,0.0018193128,0.00006931094,0.00013829744,0.000011086314,0.003018768,0.0022656184],"study_design_scores_gemma":[0.95159554,0.001659889,0.043546345,0.00038545788,0.00094452646,0.0009806923,0.0003126416,0.000021948246,0.00007254774,0.000043593023,0.00011396383,0.00032282164],"about_ca_topic_score_codex":0.00007897414,"about_ca_topic_score_gemma":0.000039037404,"teacher_disagreement_score":0.033366136,"about_ca_system_score_codex":0.000100515696,"about_ca_system_score_gemma":0.00036637686,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W3215900435","doi":"10.1016/j.fander.2021.09.595","title":"Rapidité de la réponse clinique et amélioration du psoriasis avec le bimékizumab : résultats groupés des trois études de phase 3 multicentriques, randomisées en double aveugle BE VIVID, BE READY et BE SURE","year":2021,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Gynecology","score_opus":0.05618212659747289,"score_gpt":0.35143023719579164,"score_spread":0.29524811059831874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215900435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90068084,0.034591746,0.007603753,0.051887497,0.0010647499,0.0010845999,0.0013906525,0.00069050933,0.0010056612],"genre_scores_gemma":[0.86663145,0.1069063,0.012635546,0.008817099,0.00019172337,0.00055893953,0.0030860903,0.00014462403,0.001028219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.97558045,0.019161277,0.0014362793,0.0013484089,0.00020013374,0.0022734732],"domain_scores_gemma":[0.98431224,0.013018276,0.0007598654,0.001011586,0.00055109634,0.0003469508],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006017025,0.001220347,0.001834915,0.00044368888,0.0008401418,0.00037195196,0.00090609165,0.0030726679,0.0002945777],"category_scores_gemma":[0.006130674,0.0012352979,0.0008775273,0.0006830376,0.0014086294,0.00089750515,0.00045263697,0.0015606292,0.00009788096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07159793,0.02612172,0.15753633,0.0023336264,0.014740314,0.037239373,0.09375708,0.0026835012,0.29447076,0.07064431,0.17442389,0.05445117],"study_design_scores_gemma":[0.07238627,0.0015334979,0.024695165,0.0006423429,0.0030319886,0.015974985,0.010458351,0.0007163392,0.6434512,0.006168774,0.21843171,0.0025093534],"about_ca_topic_score_codex":0.0021811882,"about_ca_topic_score_gemma":0.0061901896,"teacher_disagreement_score":0.34898046,"about_ca_system_score_codex":0.00086155714,"about_ca_system_score_gemma":0.005733609,"threshold_uncertainty_score":0.99990296},"labels":[],"label_agreement":null},{"id":"W3216407054","doi":"10.1080/1744666x.2022.2008240","title":"TYK2 inhibition: changing the treatment landscape for psoriasis?","year":2021,"lang":"en","type":"article","venue":"Expert Review of Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; SKiN Health; Western University","funders":"","keywords":"Disease; Perspective (graphical); Immune system; MEDLINE; Insulin degludec","score_opus":0.06068640059237729,"score_gpt":0.37935824267752744,"score_spread":0.31867184208515015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216407054","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04441262,0.9436887,0.00016014409,0.005299702,0.004354332,0.0007333095,0.00006492143,0.000050066265,0.0012361885],"genre_scores_gemma":[0.03216826,0.95719373,0.00073212065,0.0031118286,0.0006935849,0.0007838758,0.0007061432,0.000033911,0.0045765573],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723417,0.0008217917,0.0011046685,0.00041230148,0.00003694994,0.000390099],"domain_scores_gemma":[0.9970212,0.0016777022,0.00038317713,0.00067561603,0.00022085363,0.000021464733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00078451924,0.00024582027,0.0011016311,0.00005093004,0.00020538186,0.000006420009,0.00019662827,0.00032874756,0.0013720647],"category_scores_gemma":[0.00066854735,0.00014776137,0.0008605729,0.00023037936,0.00025335522,0.00004474948,0.00007657794,0.00014783387,0.00023629813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056677446,0.0018105203,0.00064581435,0.0004831197,0.0038687957,0.000029235543,0.00082174607,1.8213557e-7,0.011681474,0.0039938963,0.021881647,0.9542168],"study_design_scores_gemma":[0.003879815,0.0009694634,0.0008151661,0.0011816847,0.00044996743,0.00009562219,0.00042749298,7.5989084e-7,0.044202883,0.00011823071,0.94766796,0.00019097845],"about_ca_topic_score_codex":0.0000056880504,"about_ca_topic_score_gemma":0.000008581294,"teacher_disagreement_score":0.9540258,"about_ca_system_score_codex":0.00002305777,"about_ca_system_score_gemma":0.00015363866,"threshold_uncertainty_score":0.9995408},"labels":[],"label_agreement":null},{"id":"W3216720515","doi":"10.1192/j.eurpsy.2021.1903","title":"Association between IL-17, IL-23 with neurocognitive scales in patients with Alzheimer’s disease","year":2021,"lang":"en","type":"article","venue":"European Psychiatry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Montreal Cognitive Assessment; Neurocognitive; Dementia; Pathogenesis; Disease; Medicine; Proinflammatory cytokine; Cognition; Internal medicine; Clinical Dementia Rating; Alzheimer's disease; Correlation; Mini–Mental State Examination; Psychology; Psychiatry; Inflammation","score_opus":0.010697618441010168,"score_gpt":0.21287799984136646,"score_spread":0.2021803814003563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216720515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913091,0.0017139455,0.000011076214,0.0004691889,0.0005277615,0.00026070944,0.000557734,0.00007421615,0.005076287],"genre_scores_gemma":[0.9961038,0.000028846674,0.00017284299,0.0003374785,0.0001326664,0.00001219582,0.0017942783,0.000052274845,0.0013655807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982287,0.0006715142,0.00023056383,0.0004483903,0.000080219375,0.00034060908],"domain_scores_gemma":[0.9993146,0.00008124863,0.00017155246,0.00025953283,0.00011563108,0.00005742288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013012388,0.00024245001,0.0002409488,0.0000850884,0.00014629152,0.000024830199,0.00012649718,0.000070162045,0.00008655213],"category_scores_gemma":[0.000028458067,0.00019241149,0.00006932499,0.00025547732,0.000051142262,0.00010849541,0.000051350242,0.00020310991,0.00064900133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050941546,0.00044791485,0.9908766,0.0000069397265,0.0007357175,0.00003771278,0.00015543547,0.0000020604332,0.000028606406,0.00002901495,0.0024117634,0.004758797],"study_design_scores_gemma":[0.0044500395,0.0002786416,0.9907507,0.00011825298,0.00069702626,0.0000018122731,0.00011560334,7.971014e-8,0.00017351736,0.000030155601,0.0031279535,0.00025623135],"about_ca_topic_score_codex":0.0000045711313,"about_ca_topic_score_gemma":0.00010625508,"teacher_disagreement_score":0.004794754,"about_ca_system_score_codex":0.00003338597,"about_ca_system_score_gemma":0.000093852635,"threshold_uncertainty_score":0.83418155},"labels":[],"label_agreement":null},{"id":"W3216761040","doi":"10.1016/j.jid.2021.07.190","title":"A Randomized Open-Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation","year":2021,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; York University; American Society of Pediatric Hematology/Oncology; Novartis; National Heart, Lung, and Blood Institute; Pfizer; National Psoriasis Foundation; Rheumatology Research Foundation; Dermatology Foundation; Institut National de la Santé et de la Recherche Médicale; American Society of Hematology; American Heart Association","keywords":"Psoriasis; Medicine; Inflammasome; Inflammation; Proinflammatory cytokine; Systemic inflammation; Immunology","score_opus":0.08824396700725706,"score_gpt":0.35191362475512117,"score_spread":0.2636696577478641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216761040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929853,0.0015027642,0.000118942495,0.001994678,0.0022744234,0.0008016589,0.000012305915,0.000007469384,0.00030245885],"genre_scores_gemma":[0.9952451,0.0016722395,0.0022568884,0.0003375822,0.00026772113,0.00007494299,0.000019801495,0.000020621812,0.00010510586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936581,0.0036567631,0.002055625,0.00026668518,0.00008958914,0.0002732372],"domain_scores_gemma":[0.9961527,0.0018664418,0.0011749851,0.0002611986,0.00046777303,0.00007691278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021219233,0.00023006,0.001860149,0.00031297456,0.00006653897,0.000021223745,0.00042292962,0.00036752786,0.00011737059],"category_scores_gemma":[0.0047053797,0.00018236839,0.00035704073,0.0003630547,0.00044663734,0.00021487534,0.00013084862,0.00037872087,0.000029351982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4209609,0.0009894462,0.00061805727,0.000019506047,0.0021346828,0.000191176,0.002096502,0.000014727516,0.55335534,0.0010969755,0.0005800646,0.017942628],"study_design_scores_gemma":[0.45454672,0.0004978839,0.00042497515,0.00007769393,0.00010918335,0.00022943076,0.00013779933,0.0000016608856,0.5412017,0.00076135644,0.0019108274,0.00010077616],"about_ca_topic_score_codex":0.000027865979,"about_ca_topic_score_gemma":0.000025853313,"teacher_disagreement_score":0.03358581,"about_ca_system_score_codex":0.000046712128,"about_ca_system_score_gemma":0.0007168765,"threshold_uncertainty_score":0.74367666},"labels":[],"label_agreement":null},{"id":"W3216792729","doi":"10.1177/12034754211061085","title":"Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis","year":2021,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Dermatology; Psoriasis Area and Severity Index; Receiver operating characteristic; Plaque psoriasis; Internal medicine","score_opus":0.024011355140502736,"score_gpt":0.2759709232084149,"score_spread":0.25195956806791214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216792729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.946413,0.047915272,0.0005727987,0.0017892763,0.0023498943,0.00018143654,0.00003128414,0.000008088959,0.00073894946],"genre_scores_gemma":[0.989174,0.008429313,0.000691966,0.00041199118,0.00039459477,0.0000060402404,0.00001921049,0.000014985587,0.0008579156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985403,0.0002450063,0.00073453586,0.00014151803,0.00012381768,0.00021483803],"domain_scores_gemma":[0.99712116,0.0017962427,0.0005405468,0.00019359335,0.00031089582,0.000037561782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000700925,0.0001554453,0.00074725837,0.000065361324,0.00014438752,0.000008499761,0.000102787795,0.0001319399,0.00046087123],"category_scores_gemma":[0.00073398324,0.00009633068,0.00032497474,0.000100054865,0.0001136149,0.0000822659,0.000031899082,0.0001266218,9.397376e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009067166,0.00033915497,0.045072757,0.00015697295,0.003056581,0.00068209035,0.0011234357,0.000010172884,0.05319362,0.00075012824,0.02954596,0.86516243],"study_design_scores_gemma":[0.031443484,0.0072693913,0.29083395,0.011586551,0.009757518,0.11283237,0.017912878,0.00007258234,0.105708316,0.0038723338,0.40677017,0.0019404568],"about_ca_topic_score_codex":0.00009484621,"about_ca_topic_score_gemma":0.00007501147,"teacher_disagreement_score":0.86322194,"about_ca_system_score_codex":0.000036364643,"about_ca_system_score_gemma":0.00028365286,"threshold_uncertainty_score":0.5046217},"labels":[],"label_agreement":null},{"id":"W3217403735","doi":"10.2147/jir.s341429","title":"A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS-CoV-2 Vaccines in Chinese Patients with Psoriasis","year":2021,"lang":"en","type":"article","venue":"Journal of Inflammation Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Ministry of Science and Technology of the People's Republic of China; National Natural Science Foundation of China","keywords":"Psoriasis; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Adverse effect; 2019-20 coronavirus outbreak; Virology; Immunology; Pharmacology; Internal medicine; Disease","score_opus":0.05517128062321538,"score_gpt":0.3414287193729892,"score_spread":0.28625743874977383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217403735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992261,0.00008457416,0.00003424911,0.00015498264,0.00015491764,0.00024341965,0.00005522304,0.0000034494165,0.0000431018],"genre_scores_gemma":[0.9995408,0.00006708665,0.00009464996,0.000004424805,0.000021387235,0.000011219554,0.0001786061,0.000008121345,0.00007369432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985936,0.00058510114,0.0004261004,0.00011763838,0.00012691326,0.00015064595],"domain_scores_gemma":[0.99670714,0.0013932453,0.0002930468,0.00011547977,0.0014758074,0.000015275373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011392141,0.000097088174,0.0002401761,0.0006060562,0.00009426668,0.000010501053,0.000072569936,0.00011301809,0.00002580841],"category_scores_gemma":[0.0016349903,0.00006678831,0.00005905278,0.00047467795,0.000028558294,0.00016217363,0.000013792469,0.00017158713,0.000002897783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027400905,0.00033451314,0.86907786,0.000048160367,0.00014695762,0.0000037251973,0.00025055502,0.00008189973,0.122530326,0.00003452968,0.0002404688,0.0045109405],"study_design_scores_gemma":[0.0061178436,0.00050676666,0.82776564,0.000075673386,0.000018308263,0.000001755369,0.00010491014,0.000019604367,0.16505507,0.000042499018,0.00024117903,0.00005076489],"about_ca_topic_score_codex":0.00007178584,"about_ca_topic_score_gemma":0.0008788274,"teacher_disagreement_score":0.042524733,"about_ca_system_score_codex":0.00007499996,"about_ca_system_score_gemma":0.00022032204,"threshold_uncertainty_score":0.2723548},"labels":[],"label_agreement":null},{"id":"W363749682","doi":"10.2165/00003495-200565090-00004","title":"Traditional and Newer Therapeutic Options for Psoriatic Arthritis","year":2005,"lang":"en","type":"review","venue":"Drugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Krembil Foundation","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Pathogenesis; Arthritis; Disease; Tumor necrosis factor alpha; Inflammatory arthritis; Inflammation; Immunology; Clinical trial; Dermatology; Intensive care medicine; Internal medicine","score_opus":0.06488033340554322,"score_gpt":0.29955361725219976,"score_spread":0.23467328384665653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W363749682","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012305937,0.996693,0.000040054503,0.000069459784,0.000935109,0.00071421964,0.001060473,0.000047573798,0.00042781766],"genre_scores_gemma":[0.000041871142,0.9928027,0.00021548432,0.00006240766,0.00034683233,0.0006679406,0.0025274095,0.000035479734,0.0032998899],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989493,0.00014290362,0.00031372232,0.00031847146,0.00002287147,0.00025276706],"domain_scores_gemma":[0.99921906,0.00041773266,0.00013240344,0.00018377464,0.000023809735,0.00002321771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011896736,0.0003019872,0.0008195656,0.000117596275,0.00019702064,0.000019614497,0.000111780944,0.00041505936,0.00046524472],"category_scores_gemma":[0.000010989693,0.00024498568,0.00037981954,0.00007618463,0.000083578954,0.000049065202,0.000011657732,0.00013861929,0.0003424091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007273794,0.000082083876,2.174397e-7,0.00037370477,0.0006190107,7.447734e-7,0.0000807486,3.685577e-8,0.0000022666286,0.004283887,0.0023305763,0.99221945],"study_design_scores_gemma":[0.00093286525,0.00007203807,0.00000918192,0.000856294,0.0014018583,0.000095272975,0.00001648995,1.9925322e-7,0.0000035033393,0.00055485003,0.9958164,0.00024105472],"about_ca_topic_score_codex":0.0000034559,"about_ca_topic_score_gemma":0.0000049291884,"teacher_disagreement_score":0.9934858,"about_ca_system_score_codex":0.00004265054,"about_ca_system_score_gemma":0.00010940789,"threshold_uncertainty_score":0.99902266},"labels":[],"label_agreement":null},{"id":"W4200186797","doi":"10.1177/24755303211062887","title":"Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study","year":2021,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Queen's University; Axdev Group (Canada)","funders":"Bristol-Myers Squibb","keywords":"Health care; Psoriasis; Face (sociological concept); Medicine; Dermatology; Nursing; Sociology; Political science","score_opus":0.023949479309775226,"score_gpt":0.2807003387961327,"score_spread":0.2567508594863575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200186797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93057483,0.064867124,0.000105941894,0.0011638985,0.0024151127,0.0005042669,0.0001977856,0.000025600433,0.00014542002],"genre_scores_gemma":[0.98101234,0.012598438,0.0057545025,0.000050639548,0.0003342762,0.00004007308,0.00008947009,0.0000454394,0.0000748297],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948966,0.0022039018,0.0014809764,0.0006647229,0.0002212848,0.000532531],"domain_scores_gemma":[0.9968505,0.001199245,0.0010108596,0.0004444919,0.0003711309,0.00012377181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012938866,0.00045850518,0.0012355752,0.00027079743,0.00025258047,0.00007590038,0.00021705366,0.0003125265,0.000070267786],"category_scores_gemma":[0.0006986462,0.00036491576,0.00018486609,0.0003473107,0.00008019197,0.00035533292,0.00008893723,0.0004538001,0.000012432737],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018104633,0.0015641872,0.03525002,0.00003225683,0.0012562481,0.00023510176,0.016302813,0.000010290712,0.000096615324,0.00005750845,0.00019174091,0.9431928],"study_design_scores_gemma":[0.0951997,0.008318273,0.77773976,0.0019076274,0.0012958572,0.00034858848,0.100122005,0.0000073056917,0.003682339,0.0012460685,0.008854346,0.0012781356],"about_ca_topic_score_codex":0.00048243685,"about_ca_topic_score_gemma":0.0021804776,"teacher_disagreement_score":0.9419146,"about_ca_system_score_codex":0.00010973064,"about_ca_system_score_gemma":0.00025251732,"threshold_uncertainty_score":0.99988025},"labels":[],"label_agreement":null},{"id":"W4200228656","doi":"10.1101/2021.12.05.21267219","title":"Machine Learning Model for Predicting Outcomes of Biologic Therapy in Psoriasis","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Ustekinumab; Medicine; Discontinuation; Adalimumab; Secukinumab; Psoriasis; Etanercept; Ixekizumab; Infliximab; Machine learning; Internal medicine; Artificial intelligence; Psoriatic arthritis; Computer science; Immunology; Disease; Tumor necrosis factor alpha","score_opus":0.04857536190293693,"score_gpt":0.28095376478926964,"score_spread":0.2323784028863327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200228656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837331,0.013236248,0.00093325396,0.00008162352,0.0010786228,0.00055596983,0.00020395052,0.000077372475,0.000099820914],"genre_scores_gemma":[0.9930511,0.0035386232,0.0010521734,0.000032368403,0.00003139045,0.00029195537,0.0009504888,0.000034573502,0.00101731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812686,0.00035827135,0.00056107534,0.00056247436,0.000037600304,0.00035372563],"domain_scores_gemma":[0.9987206,0.0004265902,0.00036228934,0.00038579275,0.00008881226,0.000015943957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005920536,0.0003608755,0.0009187781,0.00020976656,0.000090031535,0.000011331512,0.00031976888,0.0007125076,0.00009461013],"category_scores_gemma":[0.00030490788,0.00028250756,0.0003987078,0.00010784432,0.00007147668,0.00003112198,0.0002457429,0.0004845376,0.000005767221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021936597,0.0002260112,0.9489378,0.00007333935,0.00077757816,0.0000040161176,0.0009735354,0.003323922,0.024071291,0.00003724287,0.0000066615453,0.021349238],"study_design_scores_gemma":[0.012499095,0.00083131867,0.8471742,0.00045430195,0.00065526186,0.00001566509,0.0006047746,0.0219142,0.11231962,0.0013274411,0.0008472988,0.0013567727],"about_ca_topic_score_codex":0.00022972716,"about_ca_topic_score_gemma":0.00019904759,"teacher_disagreement_score":0.10176355,"about_ca_system_score_codex":0.000039255487,"about_ca_system_score_gemma":0.000104263985,"threshold_uncertainty_score":0.9999627},"labels":[],"label_agreement":null},{"id":"W4200232143","doi":"10.1007/s13555-021-00661-2","title":"Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line","year":2021,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"LEO Pharma; Bausch Health; Eisai; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Celgene; Sanofi; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Referral; Medicine; Health care; Clinical Practice; Multidisciplinary approach; Front line; Family medicine","score_opus":0.021628210300348567,"score_gpt":0.31553662836221386,"score_spread":0.2939084180618653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200232143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81257784,0.17154707,0.000024144858,0.014658118,0.0003871319,0.0001704428,0.000045142086,0.0000064250585,0.00058366585],"genre_scores_gemma":[0.9440085,0.053339135,0.00076732965,0.0015484088,0.000065637614,0.000040223924,0.00012802728,0.0000051459747,0.00009759038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980837,0.0012040146,0.00028970142,0.00023398268,0.00003697212,0.00015159069],"domain_scores_gemma":[0.9987419,0.0008248064,0.00011129917,0.00025110538,0.000058527603,0.000012333482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031657217,0.00013363984,0.00027175198,0.000023732604,0.00014436686,0.000013692265,0.00014610191,0.00017973862,0.00013686162],"category_scores_gemma":[0.00004295722,0.00007961256,0.00007222239,0.00012904315,0.0002761956,0.000056459863,0.0000472857,0.00013830815,0.000012057442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043176375,0.0045088483,0.5296879,0.000040160114,0.014165419,0.00035542046,0.025299897,0.0000029882924,0.0015891525,0.2560055,0.007792972,0.15623412],"study_design_scores_gemma":[0.011569539,0.00015955693,0.8150629,0.00004413551,0.0008312185,0.0012637413,0.038656205,0.0000048699694,0.001948617,0.013330333,0.11685921,0.00026966608],"about_ca_topic_score_codex":0.00012481379,"about_ca_topic_score_gemma":0.00006450832,"teacher_disagreement_score":0.28537503,"about_ca_system_score_codex":0.000009383106,"about_ca_system_score_gemma":0.00004941179,"threshold_uncertainty_score":0.3246506},"labels":[],"label_agreement":null},{"id":"W4200327046","doi":"10.1093/rheumatology/keab566","title":"Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","year":2021,"lang":"en","type":"erratum","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Ixekizumab; Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Plaque psoriasis; Clinical trial; Arthritis; Secukinumab; Internal medicine","score_opus":0.04789705385705851,"score_gpt":0.3017310206501115,"score_spread":0.253833966793053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200327046","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49449942,0.13668266,0.00011584039,0.00062433444,0.20902576,0.0061771,0.1484425,0.00022320944,0.0042091887],"genre_scores_gemma":[0.19751401,0.15117322,0.0033918568,0.0018515942,0.009971454,0.00080515613,0.5906743,0.00072046195,0.043897953],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916291,0.0031567286,0.002563285,0.0017115073,0.00023199625,0.00070738146],"domain_scores_gemma":[0.99542236,0.0011645817,0.0010934916,0.0018824997,0.0002961173,0.00014092521],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016885062,0.0007930175,0.0035161276,0.00024512337,0.00016802254,0.000062629486,0.0008966381,0.0021255452,0.0008575036],"category_scores_gemma":[0.0020042984,0.0007065539,0.00030523626,0.00033892272,0.00030106344,0.00022224839,0.00064138474,0.0011958458,0.0001549194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014001557,0.0019874687,0.016154988,0.0001629002,0.004224714,0.0003908283,0.00078022346,7.3084914e-7,0.00007786252,0.00032213973,0.49661258,0.46528402],"study_design_scores_gemma":[0.06003009,0.0024923554,0.17598769,0.0060060974,0.0023707263,0.000048199967,0.0004193628,0.0000053679637,0.0003534306,0.00022240911,0.7501608,0.0019034754],"about_ca_topic_score_codex":0.0021203654,"about_ca_topic_score_gemma":0.014531796,"teacher_disagreement_score":0.46338055,"about_ca_system_score_codex":0.00008443696,"about_ca_system_score_gemma":0.0006242971,"threshold_uncertainty_score":0.99953854},"labels":[],"label_agreement":null},{"id":"W4200540420","doi":"10.1177/12034754211067474","title":"Healthcare Use Among Psoriasis Patients: A Population-Based Study of Emergency Department and Inpatient Care","year":2021,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; University of Ottawa","funders":"Bausch Health","keywords":"Medicine; Emergency department; Health care; Psoriasis; Emergency medicine; Medical emergency; Dermatology; Nursing","score_opus":0.031207211495176183,"score_gpt":0.2609023113991909,"score_spread":0.2296950999040147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200540420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713094,0.016721891,0.0000010753915,0.008197226,0.0032713285,0.00037832197,0.000107585125,0.000007872904,0.000005246143],"genre_scores_gemma":[0.98755443,0.0025742913,0.00001192676,0.007783877,0.0005751644,0.000013986679,0.0013361094,0.000036967034,0.000113246395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970249,0.00068946136,0.0014349204,0.0003110172,0.00024745785,0.0002922586],"domain_scores_gemma":[0.99649256,0.0010274621,0.0014350155,0.00025815604,0.0007205468,0.00006625602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002002105,0.00038009995,0.0014683842,0.00053434854,0.000142428,0.000009330349,0.00008591548,0.0005093501,0.00014804747],"category_scores_gemma":[0.00032125774,0.00027609727,0.00022983576,0.00017381519,0.00005983415,0.00007483489,0.0000328813,0.0005878888,5.991396e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030140998,0.00032919602,0.87889796,0.00039819904,0.00091135554,0.0012763434,0.0019723617,0.0000023282694,0.000011369262,2.09794e-7,0.10556755,0.010331699],"study_design_scores_gemma":[0.0077831475,0.010146765,0.8606536,0.0035885307,0.0058900826,0.0008689375,0.007767775,0.0000011616476,0.00012691213,0.000023331906,0.102087595,0.0010621854],"about_ca_topic_score_codex":0.0007800618,"about_ca_topic_score_gemma":0.00028736502,"teacher_disagreement_score":0.0182444,"about_ca_system_score_codex":0.0000898008,"about_ca_system_score_gemma":0.00015106969,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W4200563961","doi":"10.1016/j.fander.2021.09.426","title":"Le sécukinumab : efficacité élevée, amélioration de la qualité de vie chez les patients atteints de psoriasis modéré à sévère: 3 ans de suivi dans l’étude PURE","year":2021,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University; Queen's University; Novartis (Canada); Probity Medical Research","funders":"","keywords":"Medicine; Humanities; Psoriasis; Gynecology; Philosophy; Dermatology","score_opus":0.025527404905284917,"score_gpt":0.2904123356480135,"score_spread":0.26488493074272856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200563961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96402955,0.01792515,0.007328538,0.0060840244,0.00085921754,0.0005765414,0.0007927282,0.0005298547,0.0018744225],"genre_scores_gemma":[0.97356695,0.015474133,0.004576228,0.0026774001,0.00019854035,0.00033456206,0.0014038116,0.00014551109,0.0016228465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98387605,0.009956906,0.0011986941,0.0013267507,0.00021627914,0.0034253276],"domain_scores_gemma":[0.99447083,0.0029453633,0.00065344514,0.001149911,0.00036391814,0.00041653178],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026666338,0.0011409865,0.0014084834,0.0003396648,0.0009800058,0.00023762649,0.001206758,0.00359673,0.00025746506],"category_scores_gemma":[0.0032172988,0.0012485195,0.00080941245,0.00079312385,0.0012963905,0.00043490046,0.00051855354,0.0015181544,0.00028516797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009172947,0.003660421,0.86201036,0.0005403062,0.0022035046,0.0036871491,0.010141697,0.0013436065,0.056561757,0.005775973,0.012119716,0.041038234],"study_design_scores_gemma":[0.006935613,0.0005292836,0.65912855,0.0004731015,0.0015005278,0.005173836,0.0060600704,0.00034154157,0.277386,0.0057379613,0.034997474,0.0017360616],"about_ca_topic_score_codex":0.0012396362,"about_ca_topic_score_gemma":0.003939226,"teacher_disagreement_score":0.22082426,"about_ca_system_score_codex":0.0014192213,"about_ca_system_score_gemma":0.0048648017,"threshold_uncertainty_score":0.99899644},"labels":[],"label_agreement":null},{"id":"W4200573446","doi":"10.1111/exd.14513","title":"Small plaque psoriasis re‐visited: A type of psoriasis mediated by a type‐I interferon pathway","year":2021,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Dermatology Foundation","keywords":"Psoriasis; Medicine; Interferon; Pathogenesis; Biopsy; Dermis; Immune system; Immunology; Pathology; Dermatology","score_opus":0.02890516046088391,"score_gpt":0.2618898721628442,"score_spread":0.2329847117019603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200573446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643591,0.029052582,0.000020629413,0.00031055073,0.0028635862,0.00022247389,0.00016822139,0.00012414425,0.0028787279],"genre_scores_gemma":[0.99559325,0.00045848277,0.00020631713,0.00030381305,0.000039731996,0.000048853104,0.0017527972,0.00004615101,0.001550588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977214,0.00052658207,0.00059632753,0.0005703185,0.00006211491,0.00052327616],"domain_scores_gemma":[0.9988196,0.0002529521,0.00021854622,0.00049739674,0.00014543084,0.000066092245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007980549,0.0003819175,0.00074847176,0.00015344727,0.00013138771,0.000013433182,0.00028909117,0.0005994309,0.0028616749],"category_scores_gemma":[0.00009580944,0.00036681278,0.00017783837,0.00042056138,0.00021126731,0.00008081889,0.00019340639,0.00021734131,0.000987148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012126229,0.0008542867,0.0023056287,0.000029031266,0.0008202465,0.00019793822,0.0016177623,7.2659424e-7,0.9694918,0.0005436361,0.021046538,0.0018797948],"study_design_scores_gemma":[0.003141972,0.0004625021,0.0003048833,0.00003402447,0.00009585187,0.0005181242,0.0016074049,0.0000028940137,0.9497275,0.00002512641,0.043765895,0.00031381933],"about_ca_topic_score_codex":0.00010924585,"about_ca_topic_score_gemma":0.000045400713,"teacher_disagreement_score":0.03123418,"about_ca_system_score_codex":0.00008344994,"about_ca_system_score_gemma":0.0001769214,"threshold_uncertainty_score":0.9998784},"labels":[],"label_agreement":null},{"id":"W4205675137","doi":"10.1007/s13555-021-00649-y","title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"LEO Pharma; Kyowa Hakko Kirin; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Quality of life (healthcare); Clinical trial; Medicine; Phase (matter); Quality (philosophy); Intensive care medicine; Internal medicine; Dermatology; Nursing; Philosophy; Physics","score_opus":0.08333823224810268,"score_gpt":0.36791601861026796,"score_spread":0.2845777863621653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205675137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265814,0.0051345835,0.0000093660865,0.0009018469,0.00058228814,0.00053176825,0.00008454337,0.000018505565,0.000078979574],"genre_scores_gemma":[0.9976459,0.0009086845,0.000042150314,0.0010292231,0.0000123984755,0.0002055869,0.00004504793,0.000010074412,0.00010090153],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99705684,0.0015869283,0.0007313209,0.0003335673,0.00003194119,0.00025940657],"domain_scores_gemma":[0.99904394,0.00059830904,0.00013241907,0.00017370743,0.000014120636,0.00003752294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006438378,0.00017280735,0.00082858594,0.00021815347,0.00012958632,0.000005170922,0.00011614629,0.00021026676,0.00014792834],"category_scores_gemma":[0.000089193505,0.00015252207,0.00007931253,0.00014837935,0.00014091781,0.000046185047,0.00007767589,0.0002515496,0.000007898563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17450081,0.002142766,0.7628941,0.000016534093,0.0004982258,0.000057844667,0.0025253715,0.000006466444,0.001261343,0.0024603875,0.00017341091,0.053462755],"study_design_scores_gemma":[0.6552362,0.0025000735,0.3201757,0.000019793311,0.000066128065,0.0002883469,0.0019072245,0.000020916881,0.0028481544,0.0033074312,0.01289237,0.00073765253],"about_ca_topic_score_codex":0.00011330212,"about_ca_topic_score_gemma":0.00013340337,"teacher_disagreement_score":0.4807354,"about_ca_system_score_codex":0.000008004579,"about_ca_system_score_gemma":0.000066749315,"threshold_uncertainty_score":0.62196696},"labels":[],"label_agreement":null},{"id":"W4206112747","doi":"10.1007/s13555-021-00679-6","title":"Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"Celgene; Eli Lilly and Company; AbbVie; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Body mass index; Psoriasis; Disease; Dermatology","score_opus":0.012722383655553214,"score_gpt":0.23173519781918517,"score_spread":0.21901281416363194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206112747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99599165,0.0026532596,0.000008184248,0.00012939016,0.00034884945,0.00063979777,0.00015881145,0.000020930598,0.000049139937],"genre_scores_gemma":[0.99924266,0.00008281694,0.000012167639,0.00013120993,0.00000782888,0.0001632071,0.00032465236,0.000014464794,0.000021011041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981612,0.0007969156,0.00030763622,0.00038981586,0.000071019684,0.0002734395],"domain_scores_gemma":[0.99901456,0.0004026257,0.00013585952,0.00039414607,0.000032713375,0.000020094789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012477778,0.00022341138,0.0005477542,0.00020561887,0.0003639394,0.000007799143,0.00026782937,0.00010426261,0.00043590588],"category_scores_gemma":[0.0000088266925,0.00015117596,0.00009618457,0.00063721696,0.00008819567,0.00004600537,0.000096648684,0.00020877166,0.000012180805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03866224,0.0018441774,0.93706775,0.000001317842,0.0060775587,0.000020060788,0.0062967553,0.00017205454,0.00007208074,0.00008355878,0.00011703413,0.009585401],"study_design_scores_gemma":[0.03825581,0.0009593727,0.9569266,0.0000025022846,0.00061360875,0.000005239763,0.0017193797,0.000006763326,0.0005038564,0.00004053147,0.00076961634,0.00019673519],"about_ca_topic_score_codex":0.00068008195,"about_ca_topic_score_gemma":0.00043795805,"teacher_disagreement_score":0.019858822,"about_ca_system_score_codex":0.000026387796,"about_ca_system_score_gemma":0.0000315368,"threshold_uncertainty_score":0.61647767},"labels":[],"label_agreement":null},{"id":"W4206267503","doi":"10.1007/s40257-021-00652-1","title":"Diagnosis of Generalized Pustular Psoriasis","year":2022,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"Boehringer Ingelheim","keywords":"Medicine; Disease; Generalized pustular psoriasis; Psoriasis; Differential diagnosis; Intensive care medicine; Dermatology; Pathology","score_opus":0.09468950018906415,"score_gpt":0.39441803776924406,"score_spread":0.2997285375801799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206267503","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056825127,0.9887922,0.0000139564,0.00016556472,0.004720571,0.00028512997,0.00014589228,0.000018542836,0.00017565831],"genre_scores_gemma":[0.001191806,0.99755967,0.00045101575,0.00015535441,0.00022794018,0.00008676101,0.0001379144,0.000066626555,0.000122904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9875503,0.0062769186,0.005075933,0.0004532228,0.00014087892,0.0005027023],"domain_scores_gemma":[0.98467195,0.0068942816,0.0075272364,0.00062711403,0.00016393368,0.00011550475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012921289,0.00057054515,0.009030437,0.0005645272,0.00011951706,0.0000073312135,0.0011215735,0.0006530124,0.0026216256],"category_scores_gemma":[0.0012922601,0.00042541948,0.0037791133,0.00063590857,0.0011271756,0.00006604601,0.0002460654,0.0013292625,0.00013616617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020477513,0.0005882592,0.0018096052,0.00058252894,0.005557115,0.00036501326,0.00004455364,4.1911704e-7,5.7920477e-7,0.00014203756,0.0046324143,0.9860727],"study_design_scores_gemma":[0.0019038253,0.0010866836,0.00010629416,0.0006740418,0.0065218317,0.0047901976,0.000108403176,5.6359546e-8,0.00002310971,0.000038750157,0.9844175,0.0003293355],"about_ca_topic_score_codex":0.00005239083,"about_ca_topic_score_gemma":0.0000039693605,"teacher_disagreement_score":0.98574334,"about_ca_system_score_codex":0.000057988596,"about_ca_system_score_gemma":0.0009942227,"threshold_uncertainty_score":0.99981976},"labels":[],"label_agreement":null},{"id":"W4206298574","doi":"10.1016/j.jval.2021.11.153","title":"POSC7 Work Productivity and Activity Impairment for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 AND CIMPASI-2)","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Certolizumab pegol; Medicine; Presenteeism; Absenteeism; Placebo; Psoriatic arthritis; Work productivity; Physical therapy; Internal medicine; Productivity; Arthritis; Disease; Adalimumab; Psychology","score_opus":0.04380790334745937,"score_gpt":0.289780443493676,"score_spread":0.2459725401462166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206298574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878432,0.00047214777,0.00009042472,0.002143952,0.00026505382,0.0042282464,0.0048726522,0.00007317419,0.000011129067],"genre_scores_gemma":[0.9976184,0.00005876914,0.0006932193,0.00003984768,0.000068057925,0.0006659891,0.0007174344,0.000048265472,0.000090067166],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99608576,0.0015577117,0.000575121,0.0010066881,0.00012589259,0.0006488174],"domain_scores_gemma":[0.9980359,0.0008648652,0.00043852732,0.00044977106,0.000073200936,0.00013772835],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073509756,0.00042011912,0.0010251947,0.0002263024,0.00062464527,0.000038148522,0.00012909913,0.000115208444,0.000030190815],"category_scores_gemma":[0.00015701566,0.00031631166,0.00006632763,0.0004072499,0.00007535383,0.00015272271,0.00011089787,0.0002635369,0.000003237146],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6096496,0.0065362845,0.23876712,0.0001680874,0.0015401581,0.00008833115,0.007993934,0.0028234306,0.0007828928,0.00007609301,0.0009883964,0.13058567],"study_design_scores_gemma":[0.42408532,0.05882428,0.49938795,0.0006730335,0.0010823527,0.00037178572,0.0011627532,0.0006368043,0.007238066,0.00084505917,0.0032040554,0.0024885712],"about_ca_topic_score_codex":0.008770434,"about_ca_topic_score_gemma":0.000983509,"teacher_disagreement_score":0.2606208,"about_ca_system_score_codex":0.0003778215,"about_ca_system_score_gemma":0.00031864713,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W4206853608","doi":"","title":"Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.","year":2021,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Probity Medical Research; Guenther Dermatology Research Centre; SKiN Health; Western University","funders":"","keywords":"Tazarotene; Lotion; Discontinuation; Dermatology; Medicine; Clobetasol propionate; Psoriasis; Adverse effect; Plaque psoriasis; Clinical trial; Internal medicine; Pharmacology","score_opus":0.022149532893674957,"score_gpt":0.21237256633207544,"score_spread":0.19022303343840047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206853608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98658484,0.005254783,0.00075267605,0.00238979,0.0020363,0.0018196793,0.00015998773,0.000126461,0.00087547395],"genre_scores_gemma":[0.98981297,0.00022881353,0.00021025387,0.0000968182,0.00005583204,0.0026131987,0.0008498715,0.000014884943,0.0061173458],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991339,0.00011893043,0.00016462256,0.00027853533,0.00002505018,0.00027895518],"domain_scores_gemma":[0.9995467,0.000108871776,0.0000708067,0.0001395407,0.00010797259,0.000026084455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018313712,0.00012731912,0.00018727442,0.000056247332,0.00016856691,0.000021156251,0.000053512507,0.00017849797,0.000039029994],"category_scores_gemma":[0.00012273763,0.00011485843,0.000066201224,0.000090358786,0.00004763201,0.00009185408,0.00003069326,0.000058738526,0.000024826011],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034483563,0.00036023243,0.0040684943,0.00006624609,0.00045150897,0.000009279226,0.00014246571,0.0000019276952,0.023982221,0.005745822,0.0027603712,0.9620666],"study_design_scores_gemma":[0.009095594,0.00010741229,0.53314424,0.000015768863,0.00032643368,0.00008746803,0.00007551255,0.0000115420935,0.39163536,0.0024756063,0.062697895,0.0003271683],"about_ca_topic_score_codex":0.000009721099,"about_ca_topic_score_gemma":0.00002029475,"teacher_disagreement_score":0.9617394,"about_ca_system_score_codex":0.000036419046,"about_ca_system_score_gemma":0.000026780232,"threshold_uncertainty_score":0.46837905},"labels":[],"label_agreement":null},{"id":"W4207027824","doi":"10.1016/j.genhosppsych.2022.01.006","title":"Associations between psoriasis and mental illness: an update for clinicians","year":2022,"lang":"en","type":"review","venue":"General Hospital Psychiatry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Canada Research Chairs; University of Toronto","funders":"Canadian Institutes of Health Research; University of Toronto; Department of Psychiatry, University of Toronto; Centre for Addiction and Mental Health Foundation; Physicians' Services Incorporated Foundation; Brain and Behavior Research Foundation","keywords":"Psoriasis; Suicidal ideation; Medicine; Anxiety; Psychiatry; Depression (economics); Schizophrenia (object-oriented programming); Population; Mental illness; MEDLINE; Mental health; Clinical psychology; Poison control; Dermatology; Suicide prevention; Emergency medicine","score_opus":0.037423570842602505,"score_gpt":0.3241172298628262,"score_spread":0.2866936590202237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207027824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050844923,0.96146256,0.000009684771,0.00020145447,0.013643597,0.0015378533,0.017774133,0.00012796857,0.00015826267],"genre_scores_gemma":[0.00007338502,0.957046,0.0008363285,0.00009827945,0.0014388676,0.0006343974,0.038540825,0.000118113356,0.0012138558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970949,0.0004409362,0.0008824294,0.0009122981,0.000072230636,0.0005971666],"domain_scores_gemma":[0.9985629,0.00018246142,0.0006465438,0.0005032548,0.00002907388,0.00007581356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037474243,0.000657628,0.0017824918,0.0002060992,0.0009758689,0.00004996492,0.00046224173,0.0007939869,0.00040921153],"category_scores_gemma":[0.000026828304,0.0005951474,0.00088273163,0.00023265413,0.00009692967,0.00014777436,0.00016920708,0.00041192202,0.00013860903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018422537,0.00038364224,0.001133161,0.0003851396,0.0020454943,9.101809e-7,0.00015716786,7.450944e-8,4.4493356e-7,0.0007025681,0.015830237,0.97934276],"study_design_scores_gemma":[0.0012857646,0.00087569596,0.00046459862,0.00015397064,0.0032574874,0.000009964913,0.00012691833,1.4291665e-7,0.0000014723997,0.0005277899,0.99251735,0.000778858],"about_ca_topic_score_codex":0.000048602215,"about_ca_topic_score_gemma":0.000050214276,"teacher_disagreement_score":0.9785639,"about_ca_system_score_codex":0.0001439911,"about_ca_system_score_gemma":0.000273268,"threshold_uncertainty_score":0.99965},"labels":[],"label_agreement":null},{"id":"W4210244593","doi":"10.1111/ijd.16064","title":"Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review","year":2022,"lang":"en","type":"review","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Women's College Hospital; University of Toronto; Hamilton Health Sciences","funders":"","keywords":"Palmoplantar pustulosis; Medicine; Adalimumab; Dermatology; Secukinumab; Psoriasis; Infliximab; Plaque psoriasis; Internal medicine; Psoriatic arthritis; Disease","score_opus":0.036628766732382724,"score_gpt":0.2838329310550962,"score_spread":0.2472041643227135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210244593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013292574,0.9966358,0.000012828358,0.00011347752,0.0010181117,0.0006681357,0.00016065901,0.000015716227,0.00004603725],"genre_scores_gemma":[0.0022609872,0.99667865,0.00012619833,0.00006344397,0.000024671608,0.00014314298,0.0005971856,0.000030403047,0.00007534253],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957677,0.0014230346,0.0020555276,0.00028175607,0.00020214774,0.00026980374],"domain_scores_gemma":[0.99480945,0.0011197248,0.0035496873,0.0002113076,0.0002731425,0.00003669793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045203898,0.00048688916,0.0036545256,0.0005360774,0.00012053496,0.000014742066,0.00081476825,0.0003720012,0.00029205723],"category_scores_gemma":[0.00030576318,0.0003013263,0.00046850523,0.00019417208,0.00015262289,0.00007659982,0.00015796737,0.00044903246,0.000016637523],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007197938,0.0017364915,0.0020540364,0.5896755,0.1408248,0.0076296707,0.0026373866,4.2188822e-7,0.00006068698,0.00042133336,0.0019418066,0.2522981],"study_design_scores_gemma":[0.002544622,0.00039615654,0.00007158858,0.37271068,0.01752705,0.11740573,0.00046335577,1.2252642e-7,0.0001266878,0.00003602275,0.48800474,0.0007132673],"about_ca_topic_score_codex":0.0000034713348,"about_ca_topic_score_gemma":0.000009268053,"teacher_disagreement_score":0.4860629,"about_ca_system_score_codex":0.00017627238,"about_ca_system_score_gemma":0.0005307454,"threshold_uncertainty_score":0.9999439},"labels":[],"label_agreement":null},{"id":"W4210244930","doi":"10.1053/j.gastro.2022.01.047","title":"Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study","year":2022,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Janssen Research and Development; Janssen Scientific Affairs","keywords":"Crohn's disease; Medicine; Phase (matter); Internal medicine; Gastroenterology; Disease; Dermatology; Physics","score_opus":0.03133859218263738,"score_gpt":0.27142821602654765,"score_spread":0.24008962384391028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210244930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051684,0.0017059948,0.000059784834,0.0015256376,0.0016976101,0.0013405342,0.0031166228,0.000029080174,0.00000789793],"genre_scores_gemma":[0.99689275,0.000111900896,0.000013020441,0.00012298394,0.00011871495,0.0012455994,0.0009802268,0.00001461228,0.000500217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828666,0.00066849485,0.00034242682,0.00034875178,0.000046470188,0.0003071756],"domain_scores_gemma":[0.99867475,0.0004885535,0.00021427244,0.00056824664,0.00003540554,0.000018762326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002321788,0.00018176534,0.00026889204,0.00004588042,0.0006079934,0.000006450996,0.00030807493,0.000043073363,0.00027976205],"category_scores_gemma":[0.000033407898,0.00010334178,0.00018783902,0.00006959674,0.00014459861,0.000025708301,0.00007479634,0.000093465365,0.000014599087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29175913,0.041135043,0.3820896,0.000009427674,0.013376084,0.00011897391,0.027477145,0.00056364003,0.020688692,0.00012878323,0.03702632,0.18562713],"study_design_scores_gemma":[0.042993177,0.017778948,0.8706033,0.0000028812703,0.0017229643,0.000026742407,0.004387678,0.000018723109,0.0012279437,0.000085114916,0.06103579,0.00011669045],"about_ca_topic_score_codex":0.00034677304,"about_ca_topic_score_gemma":0.00025408156,"teacher_disagreement_score":0.4885137,"about_ca_system_score_codex":0.000085346226,"about_ca_system_score_gemma":0.000033237844,"threshold_uncertainty_score":0.4676255},"labels":[],"label_agreement":null},{"id":"W4210430537","doi":"10.1016/j.jaad.2022.01.048","title":"Association of psoriasis with risk of COVID-19: A 2-sample Mendelian randomization study","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Project 211; National Key Research and Development Program of China","keywords":"Mendelian randomization; Medicine; Coronavirus disease 2019 (COVID-19); Psoriasis; 2019-20 coronavirus outbreak; Genome-wide association study; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Dermatology; Internal medicine; Single-nucleotide polymorphism; Genetics; Virology; Genotype; Disease; Genetic variants; Outbreak; Gene","score_opus":0.013703356770142191,"score_gpt":0.2737573127698547,"score_spread":0.26005395599971254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210430537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949393,0.0006249427,0.00034537705,0.0033908426,0.00020598782,0.00029186485,0.0001743046,0.0000056250333,0.00002173308],"genre_scores_gemma":[0.9991711,0.00027941715,0.00024938755,0.00019443884,0.000014377732,0.000013912199,0.0000056448016,0.000010627304,0.000061127284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596554,0.00271739,0.0008536435,0.00012142698,0.0001664603,0.00017553938],"domain_scores_gemma":[0.9927324,0.0012864161,0.005720106,0.00013256154,0.00009869649,0.00002978766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008407599,0.00013208418,0.000944672,0.00028277753,0.00017441764,0.0000015385381,0.00042605394,0.000077243545,0.0001270894],"category_scores_gemma":[0.0007475817,0.000087305154,0.00024461208,0.00053445244,0.00024583025,0.00005263624,0.000102460755,0.00035780424,9.0261904e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0092108045,0.0009289111,0.9593706,0.000028007391,0.005166288,0.0000053377566,0.0029070827,0.0015362918,0.015265236,0.00008647832,0.0030545737,0.0024403918],"study_design_scores_gemma":[0.12001428,0.00892158,0.5785003,0.00007806466,0.016662583,0.004227883,0.038478654,0.0000681326,0.19379584,0.002417591,0.0359905,0.0008446146],"about_ca_topic_score_codex":0.00027914456,"about_ca_topic_score_gemma":0.000018296161,"teacher_disagreement_score":0.3808703,"about_ca_system_score_codex":0.00012365426,"about_ca_system_score_gemma":0.00022342872,"threshold_uncertainty_score":0.3560201},"labels":[],"label_agreement":null},{"id":"W4210613042","doi":"10.25270/con.2022.02.00001","title":"Myocardial Infarction Associated With Psoriasis","year":2022,"lang":"en","type":"article","venue":"Consultant","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; The Scarborough Hospital","funders":"","keywords":"Psoriasis; Myocardial infarction; Medicine; Cardiology; Internal medicine; Dermatology","score_opus":0.013756553113042561,"score_gpt":0.21293807447244434,"score_spread":0.1991815213594018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210613042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99349576,0.0011987062,0.000014329175,0.00021563833,0.001429891,0.00022061287,0.00028006188,0.00014582984,0.0029991423],"genre_scores_gemma":[0.9959397,0.000030278567,0.000014310775,0.00015064525,0.00002802695,0.00015078032,0.00048750488,0.000014901675,0.0031838936],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904543,0.00028081806,0.00014496798,0.00022790182,0.000051424417,0.0002494349],"domain_scores_gemma":[0.9994863,0.00016591215,0.000092707895,0.0001761896,0.000062191604,0.000016680562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019361857,0.00013285832,0.00019525673,0.000077767,0.0005081083,0.000008650789,0.00011009779,0.00007713872,0.0013921892],"category_scores_gemma":[0.00009979925,0.000111252695,0.00006221037,0.0003066674,0.000077955294,0.000037451086,0.00006582659,0.00016613893,0.0001737721],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007409375,0.0026257338,0.20976761,0.000016669112,0.0139734605,0.00033016925,0.00650665,0.00034218878,0.37671036,0.005482514,0.057221506,0.31961375],"study_design_scores_gemma":[0.022415252,0.002346256,0.320631,0.00003230488,0.0015345298,0.00045284786,0.0024733536,0.000016653628,0.030283108,0.00026555674,0.61842644,0.001122707],"about_ca_topic_score_codex":0.000046740388,"about_ca_topic_score_gemma":0.000018654815,"teacher_disagreement_score":0.5612049,"about_ca_system_score_codex":0.000116141135,"about_ca_system_score_gemma":0.00009604842,"threshold_uncertainty_score":0.99952066},"labels":[],"label_agreement":null},{"id":"W4210662640","doi":"10.1136/bmjopen-2021-055538","title":"Prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis","year":2022,"lang":"en","type":"review","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fundamental Research Funds for Central Universities of the Central South University; National Natural Science Foundation of China","keywords":"Medicine; Psoriasis; Disease; Etiology; Thyroid disease; Autoimmune disease; Meta-analysis; Dermatology; Thyroid; Immunology; Internal medicine","score_opus":0.11934583781755294,"score_gpt":0.36201947959058794,"score_spread":0.24267364177303502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210662640","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016312301,0.98734933,0.0000011368579,0.000009926626,0.00016588306,0.009557868,0.0023102222,0.000018159333,0.00042436656],"genre_scores_gemma":[0.0004961606,0.9757971,0.00007061809,0.000018990857,0.00000875095,0.012135812,0.0032314733,0.000055187797,0.008185875],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9958088,0.0018437417,0.0010742169,0.00077533565,0.00014714828,0.00035079088],"domain_scores_gemma":[0.99694955,0.00031517624,0.0011368885,0.0015082422,0.000052579893,0.00003753179],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009110278,0.00056771596,0.0046906075,0.0005335624,0.00012074348,0.00002748711,0.0015620332,0.00022167558,0.009401461],"category_scores_gemma":[0.00009114957,0.00036533654,0.002033919,0.0012207574,0.00008793914,0.00014145493,0.00086994644,0.00027033643,0.00013027569],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020599668,0.0024255086,0.013127092,0.013010692,0.6290226,0.00006136178,0.00027239328,0.00002372009,2.9963027e-7,0.00010712091,0.00049002224,0.33939922],"study_design_scores_gemma":[0.0017635013,0.00029681026,0.015720189,0.00056563085,0.66129196,0.0000017905197,0.000011481824,1.2996874e-7,8.2230275e-7,0.000007846277,0.31981283,0.0005270028],"about_ca_topic_score_codex":0.00024325085,"about_ca_topic_score_gemma":0.000037463713,"teacher_disagreement_score":0.3388722,"about_ca_system_score_codex":0.00010184358,"about_ca_system_score_gemma":0.0005270281,"threshold_uncertainty_score":0.99987984},"labels":[],"label_agreement":null},{"id":"W4210758677","doi":"10.1111/1346-8138.16299","title":"Relationship between patient acceptable symptom state and disease scores in psoriasis","year":2022,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Medicine; Psoriasis Area and Severity Index; Confidence interval; Receiver operating characteristic; Odds ratio; Body surface area; Logistic regression; Internal medicine; Area under the curve; Body mass index; Gastroenterology; Dermatology","score_opus":0.021194445057553458,"score_gpt":0.24446302410896895,"score_spread":0.22326857905141548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210758677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976076,0.00786133,0.000019826812,0.0017299831,0.00039520033,0.000112670146,0.00004340791,0.000005514005,0.00007133929],"genre_scores_gemma":[0.99956256,0.00012256354,0.000018268422,0.00010541698,0.000014298815,0.000010320047,0.000014409142,0.000008183518,0.00014396574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821615,0.0010417694,0.0004022068,0.0000844362,0.000047843958,0.0002076142],"domain_scores_gemma":[0.99866843,0.000835236,0.00029008582,0.00013803071,0.000028059105,0.00004016767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025332128,0.000103292776,0.00026191503,0.00019611344,0.0002921125,0.0000060909033,0.00019026003,0.000044725035,0.00020670053],"category_scores_gemma":[0.00011967385,0.00007255869,0.000056856923,0.00015212607,0.00010047019,0.000084858206,0.00012603776,0.00030127983,0.000022396327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059262407,0.00007577173,0.9907339,0.000007868685,0.00011620622,0.00009131361,0.001650426,0.00007421807,0.0002206084,0.00021463339,0.0016180488,0.0046043703],"study_design_scores_gemma":[0.0020416246,0.00017123295,0.9868889,0.000010245978,0.00026751377,0.0015735717,0.00072890543,0.0000016716691,0.0009879492,0.0037037744,0.0035195597,0.000105048064],"about_ca_topic_score_codex":0.000024884333,"about_ca_topic_score_gemma":0.000011279706,"teacher_disagreement_score":0.009801846,"about_ca_system_score_codex":0.000042880365,"about_ca_system_score_gemma":0.00011753878,"threshold_uncertainty_score":0.29588574},"labels":[],"label_agreement":null},{"id":"W4211167150","doi":"10.1007/s40257-018-0353-x","title":"Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)","year":2018,"lang":"en","type":"erratum","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Etanercept; Plaque psoriasis; Psoriasis; Clinical trial; Randomized controlled trial; Internal medicine; Dermatology; Pharmacology; Psoriatic arthritis; Tumor necrosis factor alpha; Secukinumab","score_opus":0.045482967405203044,"score_gpt":0.40517980120416425,"score_spread":0.3596968337989612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211167150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712677,0.0015884832,0.0039546574,0.0019709002,0.019576242,0.0013005919,0.00014627274,0.000014572409,0.00018055445],"genre_scores_gemma":[0.9899853,0.0054645166,0.0013396671,0.0012502125,0.0009331929,0.000043101794,0.00016002964,0.00006535151,0.00075864815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9673917,0.020782435,0.009904513,0.0010786646,0.00019233604,0.0006502928],"domain_scores_gemma":[0.94941753,0.04418656,0.005091319,0.0005545316,0.00035471655,0.00039533374],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015850414,0.00073986646,0.013918008,0.0016811216,0.000112137815,0.00004152285,0.0005601415,0.0011985431,0.00017630312],"category_scores_gemma":[0.029365022,0.00059078576,0.0014301599,0.0009272443,0.0008028668,0.00014834973,0.0002565636,0.0022322105,0.00004223312],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6240871,0.0009055909,0.0039293594,0.000019648545,0.00441646,0.0002608327,0.0018163656,0.00010615455,0.00022281957,0.0000060910306,0.035440274,0.32878932],"study_design_scores_gemma":[0.9187284,0.009964659,0.025650488,0.0027977896,0.008542168,0.0015160159,0.0027102157,0.00094717153,0.00039177734,0.00035100678,0.02660923,0.0017910813],"about_ca_topic_score_codex":0.0019350005,"about_ca_topic_score_gemma":0.0023382455,"teacher_disagreement_score":0.32699823,"about_ca_system_score_codex":0.00011221241,"about_ca_system_score_gemma":0.00097509165,"threshold_uncertainty_score":0.99965435},"labels":[],"label_agreement":null},{"id":"W4211202219","doi":"10.1038/nrdp.2016.82","title":"Psoriasis","year":2016,"lang":"en","type":"review","venue":"Nature Reviews Disease Primers","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":897,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital","funders":"National Center for Research Resources; National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriasis; Dermatology; Medicine","score_opus":0.033100981365700666,"score_gpt":0.32818666279558745,"score_spread":0.2950856814298868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211202219","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.980027e-7,0.99107784,0.000004826863,0.00005387698,0.0038375515,0.0022859653,0.0007886274,0.00015326004,0.0017976819],"genre_scores_gemma":[0.0000010761677,0.9885454,0.00007363648,0.00015909516,0.00041347658,0.00078241667,0.0016590685,0.00011456853,0.008251264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569523,0.0013799446,0.0010377705,0.0010858547,0.00009005165,0.00071113004],"domain_scores_gemma":[0.9972446,0.00034856357,0.0008139517,0.0013366663,0.00006185736,0.00019434621],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048971706,0.0011251895,0.0035436146,0.00032052086,0.00020333845,0.000025895868,0.00081805844,0.0019380589,0.0026825652],"category_scores_gemma":[0.0004120217,0.0006411795,0.0028736142,0.00043511897,0.00015513337,0.000104051454,0.00016071925,0.0010018421,0.02010102],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003324424,0.000099207755,0.0000031647885,0.007703772,0.0011253105,0.000022556134,0.0000051708603,1.0062202e-9,0.000002088942,0.00027179028,0.032061484,0.9586722],"study_design_scores_gemma":[0.0005145532,0.000022240092,0.000009486189,0.02126803,0.007966112,0.000024004468,9.0718584e-7,2.0849664e-9,0.000005366776,0.000035290843,0.96944225,0.00071177975],"about_ca_topic_score_codex":0.0000018034066,"about_ca_topic_score_gemma":7.360585e-7,"teacher_disagreement_score":0.9579604,"about_ca_system_score_codex":0.00023598364,"about_ca_system_score_gemma":0.0005442978,"threshold_uncertainty_score":0.9996039},"labels":[],"label_agreement":null},{"id":"W4211211216","doi":"10.2139/ssrn.4029739","title":"Topical VX-509 Attenuates Psoriatic Inflammation Through the STAT3/FABP5 Pathway in Keratinocytes","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Inflammation; Psoriasis; Medicine; Pharmacology; Dermatology; Internal medicine","score_opus":0.011310481974382957,"score_gpt":0.22903921065528218,"score_spread":0.21772872868089924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211211216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98033524,0.015033988,0.00023353039,0.0028433942,0.00082406634,0.00024889855,0.00001321208,0.00003161018,0.0004360619],"genre_scores_gemma":[0.9955742,0.0013743923,0.000025615447,0.000118382355,0.00018794478,0.00008160559,0.00006845002,0.000015777532,0.0025536297],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99731773,0.0007269175,0.00037507588,0.00019985114,0.00008979286,0.0012906601],"domain_scores_gemma":[0.99939597,0.00019520166,0.0001776363,0.00018735699,0.00003143197,0.000012400029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009910448,0.00017482784,0.00021832512,0.0000775322,0.0007472141,0.00003207949,0.00031713347,0.00008689764,0.00039366024],"category_scores_gemma":[0.000059044425,0.00012318029,0.0001183951,0.00020717848,0.00005729374,0.00014692813,0.00008526636,0.0015115652,0.00009410859],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012096558,0.00059880666,0.020568093,0.000016456152,0.001697681,0.000060612347,0.010569132,0.0007606196,0.045895085,0.29867268,0.0011453319,0.6188058],"study_design_scores_gemma":[0.019428868,0.0052458057,0.023929987,0.00006327235,0.00050997466,0.004703044,0.04519716,0.00011278901,0.05806529,0.6121983,0.22899063,0.0015548583],"about_ca_topic_score_codex":0.00013281952,"about_ca_topic_score_gemma":0.00085017085,"teacher_disagreement_score":0.617251,"about_ca_system_score_codex":0.0006587554,"about_ca_system_score_gemma":0.00077814446,"threshold_uncertainty_score":0.6567083},"labels":[],"label_agreement":null},{"id":"W4212817779","doi":"10.3899/jrheum.211321","title":"Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis","year":2022,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Celgene; Sanofi; Pfizer; Eli Lilly and Company; Amgen","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Pathogenesis; Immunology; Rheumatoid arthritis; Microbiome; CD8; Bioinformatics; Antigen; Biology","score_opus":0.024055072620144977,"score_gpt":0.2623710373128638,"score_spread":0.23831596469271885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212817779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488954,0.048081975,0.00022572263,0.0005877022,0.0019656764,0.00010470848,0.00001287398,0.0000062666704,0.000119653145],"genre_scores_gemma":[0.9635291,0.036343552,0.000055863627,0.00002408562,0.0000038258795,0.000005608249,0.0000026092005,0.000008103728,0.00002721028],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.99801165,0.0008307908,0.00061314093,0.00012763124,0.00012088056,0.0002959023],"domain_scores_gemma":[0.9987163,0.00029840716,0.0006975114,0.00018555032,0.000081074,0.000021148478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001927272,0.000121239114,0.00045026888,0.0004042804,0.0004034524,0.0000042252946,0.00046525826,0.000058293223,0.00023936179],"category_scores_gemma":[0.00016291345,0.00008410853,0.00007928685,0.0006045588,0.00021695827,0.0001648871,0.00014098542,0.00025040668,0.000010441472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004604722,0.0012227006,0.30546197,0.000115352246,0.0005004529,0.00009496277,0.0103695905,0.0024514275,0.19728075,0.008657059,0.0013848442,0.46785614],"study_design_scores_gemma":[0.07058217,0.015155871,0.13201402,0.0033186686,0.0020423427,0.11528326,0.30327627,0.00024190062,0.22125249,0.059558444,0.07415669,0.003117895],"about_ca_topic_score_codex":0.000024357578,"about_ca_topic_score_gemma":0.000039818988,"teacher_disagreement_score":0.46473825,"about_ca_system_score_codex":0.00021203245,"about_ca_system_score_gemma":0.0002851304,"threshold_uncertainty_score":0.34298462},"labels":[],"label_agreement":null},{"id":"W4212893275","doi":"10.1016/j.jaad.2022.02.022","title":"Real-world experience with ustekinumab for the treatment of plaque psoriasis in pediatric patients: A retrospective, single-center chart review","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Probity Medical Research; Heritage Medical Research Clinic; Alberta Children's Hospital; University of Calgary; University of Toronto","funders":"","keywords":"Medicine; Ustekinumab; Plaque psoriasis; Psoriasis; Retrospective cohort study; Chart; Dermatology; Single Center; Clinical trial; Pediatrics; Surgery; Disease; Internal medicine","score_opus":0.021068995867963486,"score_gpt":0.2779999749853104,"score_spread":0.25693097911734697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212893275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858196,0.00921488,0.000006705018,0.0037942259,0.00033348982,0.0006693737,0.00009408053,0.00000450101,0.00006317251],"genre_scores_gemma":[0.98308337,0.016163746,0.00008815754,0.00035840497,0.000034691227,0.00014734405,0.0000053722624,0.000015409149,0.00010351392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812347,0.00054676674,0.00077508314,0.00017669465,0.000112828115,0.0002651417],"domain_scores_gemma":[0.9971646,0.00044065557,0.0021067834,0.00019089256,0.00007752798,0.000019539304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015033555,0.00018947716,0.00091116823,0.0002229921,0.00014811412,0.0000020760688,0.00050543377,0.000047572237,0.00007001154],"category_scores_gemma":[0.000044956538,0.00010128663,0.00030322094,0.0006460968,0.00035870462,0.000059706483,0.00006695843,0.00023346278,0.0000012693486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028422433,0.0019582298,0.9808046,0.000101354184,0.000655623,0.000008706153,0.0015762036,0.0000147184755,0.0012289574,0.00011278396,0.004009029,0.0066875434],"study_design_scores_gemma":[0.015829882,0.0065924837,0.87962395,0.00032492843,0.0019894724,0.0017140047,0.0014915073,0.000003364691,0.017364755,0.00008788948,0.07458064,0.0003971046],"about_ca_topic_score_codex":0.000044791483,"about_ca_topic_score_gemma":0.000021457497,"teacher_disagreement_score":0.101180635,"about_ca_system_score_codex":0.00023366723,"about_ca_system_score_gemma":0.0000860577,"threshold_uncertainty_score":0.4130349},"labels":[],"label_agreement":null},{"id":"W4212902690","doi":"10.3899/jrheum.211325","title":"Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis","year":2022,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"NIHR Cambridge Biomedical Research Centre; National Medical Research Council; Medical Research Council; National Institute for Health and Care Research","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Disease; Dermatology; Arthritis; Psoriasis Area and Severity Index; Internal medicine","score_opus":0.03804431943304894,"score_gpt":0.28618219629760966,"score_spread":0.24813787686456074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212902690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692768,0.023893107,0.000013771487,0.0031000054,0.0032649776,0.0003533136,0.00007516621,0.000007894944,0.000014976747],"genre_scores_gemma":[0.95172966,0.047883015,0.00003514686,0.00019699436,0.000015611537,0.000029320592,0.000014428213,0.000017163306,0.00007864052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99561495,0.0024788259,0.0012446605,0.0001781793,0.000114860595,0.00036854335],"domain_scores_gemma":[0.99100924,0.007529279,0.0009450637,0.00039699272,0.00008223338,0.000037187656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013801905,0.00022056376,0.00090091646,0.00020640893,0.00022868492,0.000007710683,0.0005562245,0.00013549071,0.0004250614],"category_scores_gemma":[0.0012962195,0.00013815193,0.0002757485,0.00028869923,0.00035817397,0.000107912805,0.00012939908,0.0006369429,0.000024931094],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12536371,0.003610609,0.36252686,0.0000704123,0.004172828,0.0002840705,0.007884615,0.0075830556,0.0012256508,0.004795213,0.0054821204,0.47700083],"study_design_scores_gemma":[0.2544863,0.025035635,0.38190418,0.0010635005,0.0019329067,0.005313975,0.010901342,0.00042412773,0.0014005721,0.013058313,0.3028185,0.0016606365],"about_ca_topic_score_codex":0.0003760463,"about_ca_topic_score_gemma":0.0008614141,"teacher_disagreement_score":0.47534022,"about_ca_system_score_codex":0.000082581864,"about_ca_system_score_gemma":0.0002295347,"threshold_uncertainty_score":0.56336725},"labels":[],"label_agreement":null},{"id":"W4212917769","doi":"10.3389/fphar.2022.810309","title":"Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada","year":2022,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; McGill University Health Centre","funders":"Fonds de Recherche du Québec - Santé; Galderma; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Psoriasis; Ustekinumab; Retrospective cohort study; Cohort; Gee; Cohort study; Proportional hazards model; Internal medicine; Adalimumab; Tumor necrosis factor alpha; Generalized estimating equation; Immunology","score_opus":0.009351260575528552,"score_gpt":0.2139926014064171,"score_spread":0.20464134083088856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212917769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462277,0.00053881796,0.000005731748,0.000029104518,0.002735053,0.0018574285,0.00018292488,0.000008574919,0.000019600999],"genre_scores_gemma":[0.998225,0.0000543241,0.0000040099994,0.000078403325,0.000012351827,0.0011254444,0.000094437695,0.000012727928,0.00039331382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99676156,0.0019101917,0.00042664973,0.00039960365,0.00012856472,0.0003734483],"domain_scores_gemma":[0.99939936,0.0001370878,0.00021477208,0.00020218095,0.000031500433,0.000015095482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040059345,0.00021381737,0.00061481906,0.00028630142,0.00010193624,0.0000061168025,0.00039350762,0.00007803102,0.00015510427],"category_scores_gemma":[0.000013852788,0.00015866668,0.000036497226,0.00037367392,0.00008036991,0.00007402481,0.000101635356,0.00038605998,5.865899e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006468823,0.0011935146,0.9880001,0.000011271104,0.0005159624,0.00013230438,0.006166843,0.00006473091,0.000073645555,0.0000018087866,0.002746517,0.00044642482],"study_design_scores_gemma":[0.0058877333,0.00035388762,0.9795495,0.000016401176,0.00016398657,0.0000031174495,0.01365725,0.0000061777932,0.00012484737,0.0000032969149,0.000079811354,0.00015397598],"about_ca_topic_score_codex":0.6537691,"about_ca_topic_score_gemma":0.8250792,"teacher_disagreement_score":0.1713101,"about_ca_system_score_codex":0.0009783271,"about_ca_system_score_gemma":0.00021539285,"threshold_uncertainty_score":0.6470239},"labels":[],"label_agreement":null},{"id":"W4213002005","doi":"10.2340/actadv.v102.1984","title":"Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis","year":2022,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Confidence interval; Psoriasis; Placebo; Post-hoc analysis; Randomized controlled trial; Clinical trial; Internal medicine; Psoriasis Area and Severity Index; Dermatology; Alternative medicine","score_opus":0.007000644510678062,"score_gpt":0.2045205424398759,"score_spread":0.19751989792919786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213002005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99844366,0.00012629204,0.000005335568,0.00028360804,0.00015119734,0.00048709847,0.00018829387,0.000033221313,0.00028127167],"genre_scores_gemma":[0.9985214,0.0000017560218,0.00020468797,0.00020262763,0.0000046123996,0.00013161545,0.00014051209,0.0000217572,0.00077102263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980421,0.00067543454,0.00041051768,0.00037146304,0.00011788125,0.00038257992],"domain_scores_gemma":[0.9990842,0.00023708228,0.000172855,0.0004021693,0.00006086055,0.000042879517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029351693,0.00023761862,0.00057816564,0.00030150876,0.00016879351,0.0000045068973,0.00037290546,0.00013108231,0.00085225183],"category_scores_gemma":[0.00009438056,0.00019475995,0.000118931464,0.0005300743,0.00007058082,0.00007352923,0.0002903989,0.00014430088,0.00011614494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1599669,0.0041180532,0.7097891,0.00006174414,0.0019950457,0.0003172481,0.0077439323,0.0060176114,0.09011812,0.000090022826,0.0066303965,0.0131518375],"study_design_scores_gemma":[0.017555786,0.0047728196,0.902797,0.00011127278,0.00029023955,0.00009029836,0.0007172331,0.000013990289,0.063977145,0.00008108906,0.008685059,0.00090806664],"about_ca_topic_score_codex":0.000039940187,"about_ca_topic_score_gemma":0.00000867539,"teacher_disagreement_score":0.1930079,"about_ca_system_score_codex":0.000097886485,"about_ca_system_score_gemma":0.00010214462,"threshold_uncertainty_score":0.933156},"labels":[],"label_agreement":null},{"id":"W4213031527","doi":"10.1007/s13555-022-00690-5","title":"Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research; Dermira; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer","keywords":"Psoriasis Area and Severity Index; Medicine; Psoriasis; Internal medicine; Placebo; Clinical trial; Randomized controlled trial; Ixekizumab; Gastroenterology; Dermatology","score_opus":0.0738873349008602,"score_gpt":0.3023967785833831,"score_spread":0.2285094436825229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213031527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883936,0.010562596,0.000014302453,0.00014086429,0.00009385533,0.0004364831,0.00029546543,0.000007137773,0.000055664004],"genre_scores_gemma":[0.99807626,0.0011431118,0.000079467114,0.00025951804,0.0000064623127,0.00015665582,0.00023115205,0.000006992898,0.000040370298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787146,0.0011866253,0.00041181926,0.000275932,0.000047636186,0.00020653063],"domain_scores_gemma":[0.9988591,0.00058627286,0.00022288195,0.00027303727,0.000044588218,0.00001411069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002304107,0.00018483214,0.0010392454,0.00013387618,0.00015130559,0.000002745618,0.00014657555,0.00014101907,0.00035564648],"category_scores_gemma":[0.0000056560934,0.000099023484,0.0003605839,0.00046679034,0.00013755978,0.000023542538,0.00002856161,0.000093968956,0.0000028380196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004792867,0.0016584157,0.91868335,0.0000021715116,0.062535174,0.0000054469583,0.0021472203,0.002247139,0.0000061683986,0.0011854332,0.000093508716,0.0066431244],"study_design_scores_gemma":[0.009838338,0.0032191311,0.9595038,0.0000013575094,0.020805262,0.000015484426,0.00034688276,0.000022074351,0.00043062956,0.0005596867,0.0050060796,0.0002512574],"about_ca_topic_score_codex":0.00006155449,"about_ca_topic_score_gemma":0.000066790635,"teacher_disagreement_score":0.041729916,"about_ca_system_score_codex":0.000010261645,"about_ca_system_score_gemma":0.000020691528,"threshold_uncertainty_score":0.40380606},"labels":[],"label_agreement":null},{"id":"W4213036915","doi":"10.3410/f.1109356.565387","title":"Faculty Opinions recommendation of A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.","year":2008,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Single-nucleotide polymorphism; Psoriatic arthritis; Psoriasis; Internal medicine; SNP; Medicine; Genetic association; Genotype; Immunology; Oncology; Biology; Genetics; Gene","score_opus":0.02539640739668107,"score_gpt":0.30443740753870263,"score_spread":0.27904100014202154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213036915","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013567913,0.011632766,0.0000065251597,0.039225172,0.0012790292,0.0017671562,0.9459181,0.000027798702,0.00000780777],"genre_scores_gemma":[0.00018880921,0.005028461,0.000059215374,0.0006281323,0.00016391384,0.0002106817,0.9911533,0.000022186412,0.0025453102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576646,0.000985134,0.0017480088,0.0006429518,0.0005299387,0.00032748556],"domain_scores_gemma":[0.9931821,0.00041688877,0.002420119,0.0010426745,0.0027753506,0.00016287212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093409815,0.0005115,0.0012686459,0.00040975257,0.0002951884,0.00005135898,0.0008150295,0.00070928223,0.00037592556],"category_scores_gemma":[0.007388699,0.00036621463,0.0005090805,0.0012172759,0.00021966438,0.00027295775,0.00034342398,0.00054839044,0.0000443888],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005901952,0.0011203784,0.00035412915,0.0022580514,0.0010021441,5.249398e-7,0.0006255921,8.225037e-8,0.0000034177435,0.000012904145,0.9889167,0.005647034],"study_design_scores_gemma":[0.0025305196,0.0002697289,0.0379802,0.0029171898,0.00095112115,0.0000099559675,0.00012490837,2.4133527e-7,0.000018810568,0.000024331093,0.9548906,0.000282363],"about_ca_topic_score_codex":0.00033596277,"about_ca_topic_score_gemma":0.000052019444,"teacher_disagreement_score":0.045235224,"about_ca_system_score_codex":0.00013492237,"about_ca_system_score_gemma":0.0004904158,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W4213057579","doi":"10.2196/33920","title":"The Importance of Exploring the Role of Anger in People With Psoriasis","year":2022,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Anger; Psoriasis; Psychology; Social psychology; Sociology; Medicine; Dermatology","score_opus":0.013409824189277237,"score_gpt":0.22202837874119538,"score_spread":0.20861855455191813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213057579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930382,0.005062959,0.0000010914358,0.0005210091,0.00025839792,0.00025702812,0.000022147793,0.000012909221,0.0008262907],"genre_scores_gemma":[0.99848366,0.00013563661,0.000010638634,0.000039526498,0.0000068664303,0.0011517605,0.000017354445,0.00000998177,0.00014456666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989716,0.00032571878,0.00027560428,0.00014894108,0.00004012932,0.00023802735],"domain_scores_gemma":[0.999108,0.00034279824,0.0001842803,0.0003324686,0.000025781837,0.000006639215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001439431,0.00010504526,0.00026640858,0.00006873527,0.00022470768,0.0000020503837,0.0002930134,0.00004966403,0.00014916736],"category_scores_gemma":[0.000012572026,0.00005975819,0.00006191239,0.0002797869,0.00016282404,0.00003784229,0.00011520294,0.00015434754,0.000009050225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006451123,0.00018662549,0.9677432,0.000014493465,0.00024369778,0.000016799806,0.0039929464,0.000018941539,0.009325887,0.005356093,0.0005796425,0.011876521],"study_design_scores_gemma":[0.0034240652,0.00045905355,0.722463,0.000018665893,0.00013703162,0.0010872753,0.016191008,0.000008900266,0.13949643,0.0010437638,0.115395576,0.00027518702],"about_ca_topic_score_codex":0.00008291476,"about_ca_topic_score_gemma":0.0006683423,"teacher_disagreement_score":0.2452802,"about_ca_system_score_codex":0.000021039023,"about_ca_system_score_gemma":0.00005914554,"threshold_uncertainty_score":0.24368681},"labels":[],"label_agreement":null},{"id":"W4213058992","doi":"10.1111/jdv.18010","title":"Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate‐to‐severe plaque psoriasis","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie","keywords":"Dermatology Life Quality Index; Medicine; Psoriasis Area and Severity Index; Ustekinumab; Post-hoc analysis; Psoriasis; Severity of illness; Internal medicine; Quality of life (healthcare); Dermatology; Disease; Adalimumab","score_opus":0.01953885691421686,"score_gpt":0.2453142887681741,"score_spread":0.22577543185395724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213058992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99466234,0.003172669,0.000035768135,0.0011543368,0.00013466788,0.0003448823,0.00044184682,0.0000084975445,0.000044999568],"genre_scores_gemma":[0.99872774,0.000744969,0.000075922246,0.0002859363,0.0000071679206,0.00000838248,0.00006729971,0.000022375138,0.00006019235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952302,0.0027008096,0.0012670285,0.00034788705,0.000121115954,0.0003329402],"domain_scores_gemma":[0.99705946,0.00025653228,0.0022122283,0.0002140773,0.00015450023,0.000103194616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006667183,0.00033771657,0.0015626868,0.00051372376,0.0003146844,0.0000058058467,0.00030990705,0.00020594442,0.00004856917],"category_scores_gemma":[0.000045747067,0.00021347374,0.00017000895,0.0005640884,0.0005612516,0.00011084392,0.00024222798,0.00046582715,4.4929016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017543795,0.0006425843,0.96008533,0.000104461964,0.009811283,0.000019902089,0.0016669657,0.00024794182,0.00059644645,0.00008054383,0.000106795655,0.009093949],"study_design_scores_gemma":[0.012808053,0.0014162938,0.9812541,0.00005535254,0.002021984,0.0006155282,0.00028153128,0.000020166068,0.0011636142,0.000040488656,0.000116078365,0.00020678192],"about_ca_topic_score_codex":0.0001851456,"about_ca_topic_score_gemma":0.000115547766,"teacher_disagreement_score":0.021168794,"about_ca_system_score_codex":0.000063901934,"about_ca_system_score_gemma":0.00015967332,"threshold_uncertainty_score":0.87052065},"labels":[],"label_agreement":null},{"id":"W4213192169","doi":"10.2340/actadv.v102.1993","title":"Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials","year":2022,"lang":"en","type":"review","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; LEO Pharma; Medac; XBiotech; Swedish Orphan Biovitrum; Fresenius Medical Care North America; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Samsung; Valeant Pharmaceuticals International; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Pfizer; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adverse effect; Ustekinumab; Placebo; Internal medicine; Adalimumab; Pathology","score_opus":0.2406111113496134,"score_gpt":0.4076051418125518,"score_spread":0.1669940304629384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213192169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017177111,0.9813552,0.0000056620706,0.00010115064,0.0022159808,0.0015203159,0.012438643,0.000111534195,0.00053382793],"genre_scores_gemma":[0.0019846018,0.94812286,0.00013936806,0.00011558628,0.00014823313,0.00030380028,0.04866868,0.00006410851,0.00045278276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9762552,0.016942471,0.0045174127,0.0015303399,0.00011985177,0.0006347269],"domain_scores_gemma":[0.98263973,0.012410918,0.0027044632,0.0021369024,0.00004149832,0.00006650349],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048927306,0.0009308838,0.0077336975,0.00041417178,0.00018000539,0.000021234298,0.0028170368,0.0021490972,0.008481857],"category_scores_gemma":[0.004207833,0.0006587176,0.0012897385,0.00066341873,0.00031738143,0.000145566,0.0015364301,0.001518121,0.00043357807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000990299,0.0008408547,0.00026516794,0.0005249487,0.005345156,0.00014521631,0.00008572515,4.6555186e-7,0.000022920614,0.000084792344,0.018288787,0.97340566],"study_design_scores_gemma":[0.003710992,0.00014337656,0.00027844906,0.0016490481,0.0049468656,0.00010645797,0.00015696113,0.000002324731,0.000035127276,0.0001232421,0.988252,0.00059518794],"about_ca_topic_score_codex":0.00054913,"about_ca_topic_score_gemma":0.00013985026,"teacher_disagreement_score":0.9728105,"about_ca_system_score_codex":0.00018976645,"about_ca_system_score_gemma":0.0008359919,"threshold_uncertainty_score":0.9995864},"labels":[],"label_agreement":null},{"id":"W4213328363","doi":"10.1007/s13555-022-00687-0","title":"A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; National Institute for Health and Care Research; Manchester Biomedical Research Centre; UCB","keywords":"Psoriasis; Medicine; Dermatology; Antifungal; Interleukin 17; Disease; Invasive candidiasis; Incidence (geometry); Intensive care medicine; Immunology; Immune system; Internal medicine; Fluconazole","score_opus":0.01712598439463311,"score_gpt":0.2629888597760026,"score_spread":0.2458628753813695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213328363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575806,0.0011259858,0.000051366897,0.0016683305,0.00030459362,0.0006109866,0.00006225125,0.000019567437,0.00039886578],"genre_scores_gemma":[0.9975954,0.0004362183,0.0006712501,0.0004422364,0.0000037404623,0.00033341994,0.00012202323,0.000015181048,0.00038051908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986652,0.00044541107,0.0002374218,0.00029332013,0.00006025816,0.00029837346],"domain_scores_gemma":[0.99946135,0.00012237496,0.00011755135,0.00025435945,0.000021176162,0.000023186103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016356533,0.00019604093,0.00033482464,0.00013723399,0.0002674474,0.000008590675,0.00016652403,0.000087565655,0.00032259867],"category_scores_gemma":[0.0000037779307,0.00012781988,0.000050472365,0.00019256255,0.00008667013,0.00007345039,0.00011072455,0.00014926383,0.0000129263935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005354952,0.0010947672,0.9359615,0.000014505395,0.0027646401,0.00013847495,0.0027342841,0.00001728743,0.00008553745,0.00055217685,0.0065065185,0.04477538],"study_design_scores_gemma":[0.018526629,0.0012534386,0.83595645,0.00004388467,0.00029443085,0.00031349837,0.0027193585,0.0000035077367,0.0080478685,0.00015989481,0.1322851,0.0003959363],"about_ca_topic_score_codex":0.00016268465,"about_ca_topic_score_gemma":0.00008724453,"teacher_disagreement_score":0.12577859,"about_ca_system_score_codex":0.000052459516,"about_ca_system_score_gemma":0.00002951235,"threshold_uncertainty_score":0.52123433},"labels":[],"label_agreement":null},{"id":"W4214807866","doi":"10.1111/jdv.18044","title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","year":2022,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"","keywords":"Psoriasis; Medicine; Metabolic syndrome; Disease; Comorbidity; Inflammation; Systemic inflammation; Dermatology; Bioinformatics; Intensive care medicine; Immunology; Internal medicine; Obesity","score_opus":0.05756281154694331,"score_gpt":0.3043400099104051,"score_spread":0.2467771983634618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214807866","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051902137,0.9919472,0.000015519923,0.0012974263,0.00058189314,0.0006400775,0.00014783711,0.000005611026,0.00017423394],"genre_scores_gemma":[0.012762275,0.9865505,0.0001451339,0.000053195457,0.000056031808,0.00006182874,0.000013566008,0.0000318288,0.00032561115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966575,0.001745615,0.001024138,0.0002761402,0.000037897138,0.00025872551],"domain_scores_gemma":[0.9968157,0.0012549707,0.0016137077,0.00025401966,0.000026797867,0.000034846813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004888494,0.00035508472,0.0018261261,0.00028314537,0.0003592091,0.0000054583975,0.0005135613,0.00029759403,0.000027982],"category_scores_gemma":[0.00003922011,0.00019089588,0.0005088159,0.00017392411,0.000679903,0.000039262708,0.00029872585,0.00031492853,0.0000017981318],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011409367,0.00014473905,0.0015672348,0.000900948,0.007214523,0.000015594833,0.00018410229,5.670775e-7,0.000013101658,0.005772817,0.00050389115,0.9835684],"study_design_scores_gemma":[0.0018397844,0.00012818072,0.013034887,0.00022684914,0.011725217,0.018196791,0.0000670552,1.5696723e-7,0.000054360826,0.00043706837,0.95414174,0.00014792231],"about_ca_topic_score_codex":0.0000027242306,"about_ca_topic_score_gemma":9.17122e-7,"teacher_disagreement_score":0.9834205,"about_ca_system_score_codex":0.000022699847,"about_ca_system_score_gemma":0.000046099845,"threshold_uncertainty_score":0.7784508},"labels":[],"label_agreement":null},{"id":"W4220680365","doi":"10.1111/apt.16883","title":"Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease","year":2022,"lang":"en","type":"review","venue":"Alimentary Pharmacology & Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Psoriasis; Medicine; Inflammatory bowel disease; Disease; Dermatology; Ulcerative colitis; Population; Crohn's disease; Ustekinumab; Immunology; Adalimumab; Internal medicine","score_opus":0.039079317589170416,"score_gpt":0.3201587357453049,"score_spread":0.28107941815613446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220680365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05686216,0.93843025,2.2923928e-7,0.00016285754,0.0010276829,0.002217639,0.001236551,0.000048379723,0.000014221118],"genre_scores_gemma":[0.0037096823,0.99011815,0.000016480455,0.0036021215,0.0000339318,0.0007385911,0.0016181474,0.000081406964,0.00008146335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955412,0.0017771818,0.0011297503,0.00074596977,0.00014357576,0.0006623018],"domain_scores_gemma":[0.9980454,0.0005420669,0.0007654464,0.00048303205,0.000054790693,0.00010928428],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000253885,0.0007747421,0.0018336814,0.0002407879,0.00019142037,0.000008989581,0.00062363717,0.00030871184,0.0042916914],"category_scores_gemma":[0.000001832747,0.00062302296,0.00046954822,0.00039696138,0.0004856933,0.00011094672,0.00020644351,0.00068084645,0.00017454097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007623505,0.010395858,0.046080794,0.03704008,0.085538104,0.0014994671,0.00058034004,0.0000043403534,0.0023302163,0.000043265383,0.0023283912,0.80653566],"study_design_scores_gemma":[0.0062257405,0.0010186876,0.0056968583,0.005449681,0.062158488,0.000091817354,0.000023942408,3.6801242e-7,0.0010361833,0.000019411487,0.917243,0.0010358486],"about_ca_topic_score_codex":0.00003581522,"about_ca_topic_score_gemma":0.000005037016,"teacher_disagreement_score":0.9149146,"about_ca_system_score_codex":0.00033332963,"about_ca_system_score_gemma":0.0006736556,"threshold_uncertainty_score":0.9996221},"labels":[],"label_agreement":null},{"id":"W4220709450","doi":"10.3899/jrheum.211328","title":"Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting","year":2022,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Physical therapy; Medical diagnosis; Reliability (semiconductor); Dermatology; Medical physics; Pathology","score_opus":0.030412585744745525,"score_gpt":0.2747126631756572,"score_spread":0.24430007743091164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220709450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827492,0.011549901,0.0000117293885,0.0031615915,0.0018990994,0.00014379447,0.000029002744,0.000004156133,0.00045151124],"genre_scores_gemma":[0.99883866,0.00057701295,0.000025964719,0.000051901854,0.000033436245,0.000009435766,0.0000090806425,0.00001319775,0.0004412904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939936,0.0046243262,0.0007118689,0.00013785159,0.0001856131,0.00034673754],"domain_scores_gemma":[0.99527305,0.0030972906,0.00090990047,0.00052776694,0.00017732091,0.000014694872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053332835,0.0001270763,0.00039423534,0.00009730545,0.0011440379,0.000007259323,0.0011557838,0.00010920585,0.0005315678],"category_scores_gemma":[0.00044430932,0.000059766873,0.00022967576,0.0004199977,0.00050073303,0.000037321275,0.0005637975,0.0009937666,0.000016561065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021939678,0.00040467476,0.8629521,0.000011417884,0.0028781092,0.00016546689,0.0239205,0.00018955051,0.018524447,0.0022799708,0.05225454,0.034225244],"study_design_scores_gemma":[0.010179888,0.002139164,0.33920094,0.0007475852,0.001831236,0.13722539,0.12934725,0.000018848648,0.037004683,0.019933198,0.32157105,0.00080075325],"about_ca_topic_score_codex":0.0011220821,"about_ca_topic_score_gemma":0.0002301922,"teacher_disagreement_score":0.52375114,"about_ca_system_score_codex":0.000050688563,"about_ca_system_score_gemma":0.00018178494,"threshold_uncertainty_score":0.87991303},"labels":[],"label_agreement":null},{"id":"W4220793238","doi":"10.1007/s13555-022-00704-2","title":"Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Nail (fastener); Secukinumab","score_opus":0.03272359154223959,"score_gpt":0.2870244712254104,"score_spread":0.25430087968317083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220793238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95923775,0.03687406,0.00010786276,0.0017424347,0.0005798298,0.0011555799,0.000223267,0.000043367265,0.000035827154],"genre_scores_gemma":[0.9920767,0.0052791717,0.0002337222,0.0014293693,0.000034010067,0.0006438663,0.00006689462,0.000027739177,0.00020855035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976515,0.0008303769,0.00048311902,0.00054890505,0.00003840227,0.00044766537],"domain_scores_gemma":[0.9984002,0.0011919173,0.00011100322,0.00019881997,0.000033880744,0.00006415132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046030647,0.00028672084,0.0009178186,0.00023312012,0.00055584504,0.000026171647,0.00011813307,0.00023954347,0.00010004028],"category_scores_gemma":[0.00014008723,0.00026801528,0.00007604052,0.00017869579,0.00010359791,0.00006316162,0.0000756391,0.00018892957,0.000016736394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013658836,0.0002258075,0.0015417708,0.00003065166,0.00039341082,0.0000943886,0.0037390422,0.00013320876,0.0018223851,0.00080269406,0.000569916,0.9769879],"study_design_scores_gemma":[0.19607131,0.00940714,0.08422063,0.00033335685,0.0006272578,0.01627119,0.0048634764,0.0015386307,0.05603919,0.024781484,0.60141706,0.0044292337],"about_ca_topic_score_codex":0.00009394474,"about_ca_topic_score_gemma":0.00023981175,"teacher_disagreement_score":0.9725587,"about_ca_system_score_codex":0.000023536168,"about_ca_system_score_gemma":0.00004256432,"threshold_uncertainty_score":0.99997723},"labels":[],"label_agreement":null},{"id":"W4220927294","doi":"10.1007/s13555-022-00707-z","title":"Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ustekinumab; Discontinuation; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Internal medicine; Disease; Infliximab","score_opus":0.02282714459850081,"score_gpt":0.23854891269022555,"score_spread":0.21572176809172475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220927294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980082,0.001145649,0.000002119106,0.00006233785,0.0000918834,0.0003648427,0.00013502981,0.000008925432,0.00018103386],"genre_scores_gemma":[0.9988956,0.0006399162,0.000006867219,0.00017230629,0.0000036223785,0.0001334299,0.000114731214,0.000006711443,0.000026814743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986653,0.00082762114,0.00015718429,0.00018365949,0.000023035582,0.00014321848],"domain_scores_gemma":[0.9994432,0.0002584628,0.00014121973,0.00013745442,0.000012781949,0.0000068953163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011487678,0.00014032103,0.00022845952,0.0000917671,0.00023057955,0.0000044075455,0.00007169323,0.000094322466,0.00008865375],"category_scores_gemma":[0.000006642824,0.00007599487,0.000029518105,0.00010493693,0.00018838269,0.000029150999,0.000015720627,0.000100643476,0.0000029394362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010136327,0.00046524883,0.97156745,0.0000010018982,0.00027389763,0.000004894363,0.0019908156,0.0000059025574,0.00010016512,0.0003625477,0.0000150201,0.024199432],"study_design_scores_gemma":[0.006755458,0.0016999004,0.98628664,0.000004344534,0.00006195666,0.000030036768,0.00046952034,0.000003001128,0.0017639276,0.00012248917,0.0027008543,0.00010185603],"about_ca_topic_score_codex":0.000292957,"about_ca_topic_score_gemma":0.00024875827,"teacher_disagreement_score":0.024097575,"about_ca_system_score_codex":0.000015208203,"about_ca_system_score_gemma":0.00001250971,"threshold_uncertainty_score":0.30989808},"labels":[],"label_agreement":null},{"id":"W4220947258","doi":"10.1111/jdv.18053","title":"Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trial","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"LEO Pharma","keywords":"Medicine; Psoriasis; Presenteeism; Work productivity; Productivity; Randomized controlled trial; Physical therapy; Dermatology Life Quality Index; Placebo; Quality of life (healthcare); Surgery; Dermatology; Nursing","score_opus":0.03014265511376589,"score_gpt":0.25739756277781395,"score_spread":0.22725490766404804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220947258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208695,0.0016574641,0.0000073762526,0.004214263,0.000884242,0.0007986691,0.000121027966,0.000005583215,0.00022444494],"genre_scores_gemma":[0.9995205,0.00013632615,0.0000131241195,0.00009931048,0.00009053203,0.00001478319,0.000030443229,0.000018035515,0.0000769602],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99013394,0.008153639,0.001087007,0.00023638319,0.00014520901,0.00024384097],"domain_scores_gemma":[0.994486,0.00248411,0.0025768827,0.00030923093,0.00011903393,0.000024761377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020644357,0.00024173528,0.00097647175,0.00014185834,0.00034768812,0.000004500008,0.0007293609,0.00017571874,0.000050633622],"category_scores_gemma":[0.0005008974,0.000108884684,0.00042060818,0.00027130972,0.0010354744,0.000073502655,0.000258496,0.00086873583,0.000003071574],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8910431,0.0012237243,0.098334365,0.000009597049,0.0026911597,0.000009840307,0.0012437988,0.00016052474,0.00039019278,0.0006546244,0.0019714818,0.0022675695],"study_design_scores_gemma":[0.5705479,0.0010045201,0.4200946,0.000075016826,0.001252503,0.00028936958,0.00016607149,0.0000019054544,0.0052602133,0.0006630492,0.00048501132,0.0001598728],"about_ca_topic_score_codex":0.000031121926,"about_ca_topic_score_gemma":0.0000033363538,"teacher_disagreement_score":0.32176024,"about_ca_system_score_codex":0.000031544307,"about_ca_system_score_gemma":0.000080346086,"threshold_uncertainty_score":0.44401884},"labels":[],"label_agreement":null},{"id":"W4220972015","doi":"10.1016/j.jid.2022.02.013","title":"Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR","year":2022,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Janssen Scientific Affairs; Perelman School of Medicine, University of Pennsylvania; University of Pennsylvania","keywords":"Psoriasis; Medicine; Observational study; Population; Dermatology; Quality of life (healthcare); Ethnic group; Dermatology Life Quality Index; Gerontology; Internal medicine; Environmental health","score_opus":0.011864615324939976,"score_gpt":0.2211621176771828,"score_spread":0.20929750235224281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220972015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231863,0.0019112484,0.000011381208,0.003952995,0.0005204036,0.00028102146,0.00095763954,0.000021099368,0.000025604466],"genre_scores_gemma":[0.9978795,0.00009946619,0.0002069173,0.00089056033,0.000013492333,0.00002530994,0.00081351254,0.000025018944,0.000046230492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954393,0.0023774498,0.0012169149,0.00034922193,0.00014018537,0.00047693888],"domain_scores_gemma":[0.9974477,0.0005002596,0.0015515027,0.00023790488,0.00015076535,0.00011185352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029427145,0.00030294262,0.0010966016,0.00032236156,0.00030889353,0.000007842705,0.00037018646,0.00010680132,0.000067354755],"category_scores_gemma":[0.00023760312,0.00024221392,0.00012473781,0.0007034766,0.00070129486,0.00014491609,0.00010208175,0.0009219611,0.000021713511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061450433,0.001350169,0.94460905,0.000012266178,0.0018492454,0.00030456015,0.0090555735,0.0001568919,0.0049778563,0.000027722906,0.02424632,0.0072653173],"study_design_scores_gemma":[0.015086064,0.001747699,0.96163726,0.000032039334,0.00014271,0.00028792652,0.0012912552,0.0000043662894,0.015494417,0.000093222894,0.0038691987,0.00031383173],"about_ca_topic_score_codex":0.0009883156,"about_ca_topic_score_gemma":0.0007842782,"teacher_disagreement_score":0.020377122,"about_ca_system_score_codex":0.0002777467,"about_ca_system_score_gemma":0.00033631388,"threshold_uncertainty_score":0.9877197},"labels":[],"label_agreement":null},{"id":"W4220973834","doi":"10.3899/jrheum.211331","title":"GRAPPA Treatment Recommendations: 2021 Update","year":2022,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Medicine; Psoriatic arthritis; MEDLINE; Psoriasis; Medical physics; Alternative medicine; Family medicine; Physical therapy; Pathology; Dermatology","score_opus":0.018501729752126682,"score_gpt":0.24866128633334256,"score_spread":0.23015955658121587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220973834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784993,0.011435211,0.00008956595,0.0068400973,0.0026611327,0.000123178,0.00004702705,0.000011104548,0.00029336615],"genre_scores_gemma":[0.99088126,0.007589861,0.00010121141,0.00013660143,0.000008445646,0.000021069449,0.000055539647,0.000011402894,0.0011946285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815696,0.0010787055,0.00042285706,0.00008792654,0.00003692416,0.00021663017],"domain_scores_gemma":[0.9989105,0.00036693487,0.0004365507,0.00021858723,0.000049891758,0.000017560129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005505874,0.00012969894,0.0003385181,0.00014502498,0.00052305724,0.000004690521,0.00031730346,0.000056848952,0.0055588027],"category_scores_gemma":[0.00002586698,0.000080171296,0.00015368528,0.00015071302,0.00009030147,0.000049476148,0.000081366255,0.00020794549,0.00023387394],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048077516,0.0024102298,0.11158718,0.000015076815,0.007975562,0.00009023296,0.008517033,0.00029758827,0.014970996,0.009853118,0.21162918,0.62784606],"study_design_scores_gemma":[0.0061230212,0.0021126324,0.0018114825,0.00001896964,0.0007290629,0.027853064,0.0037516584,0.000004066108,0.004616874,0.0023240244,0.9504185,0.00023668246],"about_ca_topic_score_codex":0.00010875214,"about_ca_topic_score_gemma":0.000035802434,"teacher_disagreement_score":0.73878926,"about_ca_system_score_codex":0.00009631161,"about_ca_system_score_gemma":0.00010120466,"threshold_uncertainty_score":0.99535024},"labels":[],"label_agreement":null},{"id":"W4220987608","doi":"10.1007/s13555-022-00703-3","title":"Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; TransCanada (Canada); Memorial University of Newfoundland; Barrie Urology Group; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Plaque psoriasis; Adalimumab; Psoriasis; Observational study; Medicine; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.11494625202222078,"score_gpt":0.2949359315501205,"score_spread":0.1799896795278997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220987608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948019,0.0011110973,0.000033180393,0.0006029257,0.00030005522,0.0013378651,0.0017571852,0.000009951548,0.000045855486],"genre_scores_gemma":[0.9977854,0.00011705101,0.000033338994,0.00037685927,0.000012844064,0.00078345765,0.00087299495,0.0000067653127,0.000011308163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962676,0.002630045,0.0004649993,0.0003456416,0.00005350555,0.00023821996],"domain_scores_gemma":[0.9979426,0.0016057115,0.00012502928,0.00024790154,0.00004164557,0.000037056478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003585622,0.00018691648,0.0006179531,0.00015790142,0.00023486806,0.0000037493144,0.00021761745,0.00010422198,0.00007376346],"category_scores_gemma":[0.000029984307,0.00013714483,0.000072369636,0.00019227831,0.000051270494,0.000025540185,0.000020378668,0.00008812178,0.000007512516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07811013,0.011175137,0.7189962,0.00009111281,0.0063469796,0.00039473118,0.08120281,0.01235872,0.06670417,0.009191112,0.0011854981,0.0142433625],"study_design_scores_gemma":[0.0145438,0.0017982083,0.9722742,0.0000368262,0.00007056842,0.0001346893,0.002182859,0.000038697715,0.0062232767,0.001337422,0.0011450219,0.00021445776],"about_ca_topic_score_codex":0.015826937,"about_ca_topic_score_gemma":0.006562362,"teacher_disagreement_score":0.25327793,"about_ca_system_score_codex":0.00010434187,"about_ca_system_score_gemma":0.00010587304,"threshold_uncertainty_score":0.99072677},"labels":[],"label_agreement":null},{"id":"W4221135275","doi":"10.1001/jamadermatol.2022.0434","title":"International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis","year":2022,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of Alberta; Queen's University; University of Manitoba; University of Calgary; Institute of Infection and Immunity; Memorial University of Newfoundland; Probity Medical Research; University of Toronto; Dalhousie University; University of British Columbia","funders":"Faculty of Medicine, Memorial University of Newfoundland; Medical Research Council; Sharda University; Centro Hospitalar Universitário do Porto; Kunming Medical University; Radboud Universitair Medisch Centrum; Memorial University of Newfoundland; Univerzita Komenského v Bratislave","keywords":"Medicine; Psoriasis; Venereology; Dosing; Regimen; Methotrexate; Family medicine; Dermatology; Internal medicine","score_opus":0.01876221773036976,"score_gpt":0.25330034944806784,"score_spread":0.23453813171769808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221135275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988225,0.000065299675,0.000004105956,0.0069366777,0.0010044997,0.0007392279,0.00006491929,0.00004120857,0.002919057],"genre_scores_gemma":[0.998057,0.0000025695042,0.00009095665,0.001006028,0.000019304485,0.0002682901,0.00011392581,0.000019324023,0.00042258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975008,0.0013997506,0.00029367732,0.00038581196,0.00009543679,0.0003245417],"domain_scores_gemma":[0.99885374,0.0005639543,0.00013472298,0.0003664173,0.00006024053,0.0000208994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003534304,0.00019456795,0.00030575425,0.0002723738,0.0003251864,0.000018677169,0.00037944704,0.00007760342,0.00054404297],"category_scores_gemma":[0.000107151056,0.00013533606,0.000048400452,0.00028650925,0.00006331465,0.000030833515,0.00022132734,0.0003199315,0.00015091071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011081607,0.004991404,0.9093963,0.000006246285,0.0019135083,0.00043394457,0.011645006,0.00021816354,0.0012877069,0.002381892,0.03000936,0.026634881],"study_design_scores_gemma":[0.024486607,0.0026488504,0.83359325,0.000031205054,0.00029389796,0.00047470853,0.011665379,0.00001353,0.005107084,0.00018092051,0.12080986,0.0006947269],"about_ca_topic_score_codex":0.00014677191,"about_ca_topic_score_gemma":0.000059103502,"teacher_disagreement_score":0.09080051,"about_ca_system_score_codex":0.00012244128,"about_ca_system_score_gemma":0.000044413075,"threshold_uncertainty_score":0.5956889},"labels":[],"label_agreement":null},{"id":"W4223411743","doi":"10.3389/fmed.2022.869912","title":"MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis","year":2022,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Shanghai Shenkang Hospital Development Center; Science and Technology Commission of Shanghai Municipality; Dalhousie University; National Natural Science Foundation of China","keywords":"Psoriasis; Methotrexate; Methylenetetrahydrofolate reductase; Psoriatic arthritis; Medicine; Genotype; Dermatology; Internal medicine; Gene; Genetics; Biology","score_opus":0.007515999397192705,"score_gpt":0.21337073828650885,"score_spread":0.20585473888931616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223411743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95257443,0.04479289,0.00024989355,0.0009666891,0.00085853314,0.00042165138,0.00004078727,0.000011858215,0.000083261104],"genre_scores_gemma":[0.9900074,0.008612123,0.00087375095,0.00010584312,0.000034858265,0.00009838344,0.00004208455,0.000011930186,0.00021363092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99787253,0.0012145474,0.00034370675,0.00025084466,0.00009376143,0.0002245937],"domain_scores_gemma":[0.99897134,0.00052709214,0.00029150167,0.00017221035,0.000019690204,0.00001813994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018024311,0.00015167048,0.0006346081,0.00023180593,0.00016933544,0.0000028135803,0.000105156745,0.000097741045,0.000079002544],"category_scores_gemma":[0.00032903528,0.00010065526,0.000027941049,0.00034717214,0.00030089676,0.000037331225,0.000060674924,0.00029364412,7.156198e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033512507,0.0001785747,0.8190326,0.000016677515,0.0006544556,0.00002524584,0.0073670405,0.000026695541,0.0024896236,0.00016429536,0.0023987233,0.16429482],"study_design_scores_gemma":[0.10412644,0.0016146098,0.8712284,0.00020181802,0.0010989428,0.00010427091,0.0051859985,0.00019501719,0.008208671,0.0029122701,0.004681571,0.0004419938],"about_ca_topic_score_codex":0.0011631713,"about_ca_topic_score_gemma":0.00014903308,"teacher_disagreement_score":0.16385284,"about_ca_system_score_codex":0.000104558545,"about_ca_system_score_gemma":0.00002698784,"threshold_uncertainty_score":0.41046023},"labels":[],"label_agreement":null},{"id":"W4223550633","doi":"10.1016/j.jaad.2022.04.006","title":"Associations of combined lifestyle and genetic risks with incident psoriasis: A prospective cohort study among UK Biobank participants of European ancestry","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; Medical Research Council; National Natural Science Foundation of China","keywords":"Medicine; Biobank; Hazard ratio; Psoriasis; Cohort study; Confidence interval; Population; Risk assessment; Prospective cohort study; Body mass index; Relative risk; Cohort; Lower risk; Demography; Internal medicine; Environmental health; Bioinformatics; Immunology","score_opus":0.0315458950562501,"score_gpt":0.2973487181065467,"score_spread":0.2658028230502966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223550633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812955,0.00095420226,0.0000044157323,0.0002925264,0.00013092812,0.00036894987,0.000065324966,0.0000050106783,0.000049073435],"genre_scores_gemma":[0.999679,0.00013329684,0.00007575172,0.000047760615,0.000013327067,0.000018781422,0.0000019464048,0.000012995504,0.000017120403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971451,0.0015591648,0.0007904853,0.00015540973,0.00013308284,0.00021675313],"domain_scores_gemma":[0.99632263,0.00022841142,0.0031854832,0.00014478699,0.00008791711,0.000030741496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038635958,0.00014548094,0.0008527727,0.00015652958,0.00015474806,0.0000025307852,0.0003795201,0.000047485057,0.000020718786],"category_scores_gemma":[0.000102744925,0.00010083918,0.00011996735,0.00034980557,0.0007316982,0.000042319254,0.00019402691,0.00036640934,8.54007e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005462752,0.0005772065,0.9887715,0.000007656051,0.0019025487,0.000022155875,0.0011669225,0.00006559159,0.0064445096,0.000016954024,0.00013102248,0.00034766176],"study_design_scores_gemma":[0.0024045247,0.0012020983,0.98261625,0.000020684161,0.0010524243,0.00057517504,0.0018598477,0.0000018493457,0.010116415,0.000047450074,0.000017607834,0.00008569439],"about_ca_topic_score_codex":0.00015930222,"about_ca_topic_score_gemma":0.000017712413,"teacher_disagreement_score":0.006155267,"about_ca_system_score_codex":0.000045250774,"about_ca_system_score_gemma":0.00009463408,"threshold_uncertainty_score":0.41121024},"labels":[],"label_agreement":null},{"id":"W4224236679","doi":"10.1007/s13555-022-00722-0","title":"Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"Janssen Canada; Sanofi Genzyme; Novartis Pharmaceuticals Canada; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Genentech; Coherus Biosciences; Pfizer; Incyte; Sun Pharma; Dermira; BC Children's Hospital; Regeneron Pharmaceuticals; Baxalta; Celgene; ViiV Healthcare; Amgen; Amgen Canada; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Psoriasis; Medicine; Population; Intensive care medicine; Life expectancy; Viral load; Immunology; Human immunodeficiency virus (HIV)","score_opus":0.04170993901513721,"score_gpt":0.26177482557682524,"score_spread":0.22006488656168804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224236679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95990425,0.03844959,0.00026269277,0.00016462321,0.00014411556,0.0007953182,0.0002548092,0.000020061774,0.0000045302645],"genre_scores_gemma":[0.99563587,0.0025608484,0.00027331573,0.00003797384,0.000006890711,0.0012870905,0.00012972998,0.000014932941,0.00005334866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861556,0.00052503566,0.00037120373,0.0002560606,0.000029966342,0.00020218002],"domain_scores_gemma":[0.99751294,0.0019603143,0.0002537012,0.0002190116,0.000041942007,0.000012113448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008173811,0.00020756159,0.0008514091,0.00014470692,0.00016396686,0.000003837465,0.00009660673,0.00012397899,0.000082769235],"category_scores_gemma":[0.000015345138,0.00014594526,0.000117851894,0.00010296771,0.00012461368,0.000055362394,0.000020246369,0.000040423434,8.018359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014839946,0.0014372992,0.8511564,0.000030785664,0.0015371196,0.000013647686,0.025457455,0.00012889043,0.09584318,0.00022382494,0.000017904655,0.00931351],"study_design_scores_gemma":[0.16934775,0.006612477,0.64408886,0.00049576757,0.00047741018,0.00035485384,0.022102932,0.0010781573,0.1520014,0.00034183773,0.0020159583,0.0010825853],"about_ca_topic_score_codex":0.0004345233,"about_ca_topic_score_gemma":0.00011536532,"teacher_disagreement_score":0.20706756,"about_ca_system_score_codex":0.00002907988,"about_ca_system_score_gemma":0.00008524785,"threshold_uncertainty_score":0.5951475},"labels":[],"label_agreement":null},{"id":"W4224327048","doi":"10.1111/jdv.18167","title":"Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5‐year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"National Institutes of Health; LEO Pharma; Eli Lilly and Company; AstraZeneca; Galderma; Cilag; Mylan; Alexion Pharmaceuticals; Merck; Simon Spies Fonden; Celgene; Pfizer; Samsung; National Psoriasis Foundation; Amgen","keywords":"Medicine; Post-hoc analysis; Concomitant; Post hoc; Psoriasis; Metabolic syndrome; Internal medicine; Oncology; Dermatology; Obesity","score_opus":0.013614150035106548,"score_gpt":0.22559881992687966,"score_spread":0.21198466989177311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224327048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96744233,0.030952957,0.0000052457976,0.00040441158,0.00021275353,0.00021840882,0.00064422813,0.000007929148,0.00011172259],"genre_scores_gemma":[0.995742,0.0037187773,0.00016414531,0.00017595265,0.000014054948,0.000001820572,0.00009775147,0.000026544696,0.000058907215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951654,0.0029195892,0.0009520544,0.0004723157,0.00012116469,0.00036944644],"domain_scores_gemma":[0.9965511,0.001731069,0.0012232093,0.00035495695,0.000061923034,0.000077734236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008539784,0.00032570804,0.0014331634,0.00043971027,0.00028858404,0.000010166638,0.0006542883,0.00024998354,0.000017729653],"category_scores_gemma":[0.00029276946,0.00023400353,0.000105355306,0.0004521865,0.0009956397,0.000169791,0.0010179887,0.0007413546,0.0000020791704],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011350613,0.00032242452,0.9863863,0.000034060602,0.005692435,0.00008422611,0.001234239,0.000087441076,0.002159044,0.00022720554,0.0006106357,0.0020268986],"study_design_scores_gemma":[0.010402893,0.0003152266,0.97666305,0.00004500268,0.0034911844,0.0012546693,0.00053554255,0.000015920941,0.00090677466,0.00006912246,0.0062183286,0.00008226519],"about_ca_topic_score_codex":0.000031874537,"about_ca_topic_score_gemma":0.000018933379,"teacher_disagreement_score":0.028299702,"about_ca_system_score_codex":0.000016642336,"about_ca_system_score_gemma":0.000055958484,"threshold_uncertainty_score":0.9542387},"labels":[],"label_agreement":null},{"id":"W4225261123","doi":"10.3390/cells11091513","title":"Alpha-Linolenic Acid Modulates T Cell Incorporation in a 3D Tissue-Engineered Psoriatic Skin Model","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Centre Hospitalier Universitaire de Québec; Canadian Institutes of Health Research; Université Laval","keywords":"Psoriasis; Eicosapentaenoic acid; HaCaT; Chemistry; Polyunsaturated fatty acid; Cytokine; Immunology; Cancer research; Biology; Medicine; Fatty acid; Biochemistry; In vitro","score_opus":0.011527347872826771,"score_gpt":0.2076302035504863,"score_spread":0.19610285567765953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225261123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248004,0.0044776644,0.0007511303,0.000061811224,0.0009986367,0.00037823938,0.0001057439,0.00007779647,0.0006689388],"genre_scores_gemma":[0.9932005,0.00010383845,0.00060988223,0.00005408062,0.000029407593,0.00014982693,0.00044445242,0.000026338732,0.005381703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988476,0.00018508629,0.0002881818,0.00031996614,0.00004876316,0.00031037087],"domain_scores_gemma":[0.9995176,0.000049805236,0.000106869826,0.00028622148,0.000019225592,0.00002027882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018436999,0.00019905025,0.00026130016,0.00018955232,0.00015827651,0.000010060741,0.00020589569,0.00014296424,0.0006066472],"category_scores_gemma":[0.0000055109595,0.00020603611,0.000069999616,0.00023781772,0.000026985465,0.000078054014,0.000102174185,0.00020614921,0.00046700946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011010634,0.0003705985,0.00014804436,0.000021061302,0.00006160607,0.000016073427,0.0010881897,0.03080711,0.9537628,0.00008940763,0.0012161267,0.012308834],"study_design_scores_gemma":[0.0028108787,0.0002181878,0.0005562583,0.000007540355,0.000095975716,0.000010724987,0.00013502938,0.008418589,0.98387134,0.0007606574,0.0027987352,0.00031606387],"about_ca_topic_score_codex":0.000049230923,"about_ca_topic_score_gemma":0.000018852563,"teacher_disagreement_score":0.030108519,"about_ca_system_score_codex":0.00011491031,"about_ca_system_score_gemma":0.000066614106,"threshold_uncertainty_score":0.8401909},"labels":[],"label_agreement":null},{"id":"W4225380775","doi":"10.1177/24755303221099848","title":"Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry","year":2022,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Janssen Scientific Affairs","keywords":"Psoriasis; Medicine; Longitudinal data; Dermatology; Demography","score_opus":0.021096602765689875,"score_gpt":0.25852365820692846,"score_spread":0.2374270554412386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225380775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98720473,0.009014828,0.00013039864,0.0007769663,0.0020837917,0.00032423678,0.0002579856,0.0000105183,0.00019653214],"genre_scores_gemma":[0.9958261,0.0029333553,0.0004746254,0.00010704002,0.00016287317,0.000059275655,0.00001599623,0.000021674572,0.00039903904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99643886,0.0010227038,0.001286384,0.0004702914,0.00033931178,0.000442463],"domain_scores_gemma":[0.9977611,0.0005208152,0.0010002463,0.00045314443,0.00015920847,0.00010550996],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014560525,0.00037530012,0.0014514301,0.00074221357,0.0005363588,0.00006290303,0.0004683654,0.00017853967,0.000496132],"category_scores_gemma":[0.00014248799,0.00028437143,0.00042930944,0.0012303618,0.00015752391,0.00018142858,0.00033274846,0.0005098415,0.000001773285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017436296,0.0010335802,0.6513197,0.000075238815,0.01062194,0.00010164724,0.00778692,0.0011060132,0.0018348796,0.0018651311,0.002154561,0.32035682],"study_design_scores_gemma":[0.00881867,0.0013321795,0.9735566,0.00020631253,0.004125374,0.00048896926,0.005869827,0.00019350478,0.0011200333,0.0013213414,0.0023704588,0.00059674354],"about_ca_topic_score_codex":0.00028280288,"about_ca_topic_score_gemma":0.0003844369,"teacher_disagreement_score":0.32223693,"about_ca_system_score_codex":0.00014947033,"about_ca_system_score_gemma":0.00022175566,"threshold_uncertainty_score":0.99996084},"labels":[],"label_agreement":null},{"id":"W4225383400","doi":"10.1111/bjd.21601","title":"Systemic treatments for psoriasis: not another network meta‐analysis!","year":2022,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Department of Medicine, University of Toronto; University of Toronto; Women's College Hospital","keywords":"Psoriasis; Meta-analysis; Medicine; MEDLINE; Dermatology; Intensive care medicine; Internal medicine; Biology","score_opus":0.04115178157844975,"score_gpt":0.2568427037830461,"score_spread":0.21569092220459632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225383400","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058883615,0.81278723,0.0018916754,0.15344658,0.016972525,0.0026002394,0.0054343604,0.00018655017,0.00079247385],"genre_scores_gemma":[0.17407429,0.033721656,0.003362884,0.68826777,0.011980475,0.0036834576,0.016354553,0.0011042136,0.067450695],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99499464,0.001772744,0.0015614344,0.00057371386,0.00015565855,0.00094179093],"domain_scores_gemma":[0.9962666,0.0009538802,0.0020364027,0.00044278003,0.00026252648,0.000037807982],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038400275,0.0006135229,0.0040380736,0.0005955893,0.00048667876,0.00006364306,0.00081034546,0.0015593567,0.0033882845],"category_scores_gemma":[0.000052127987,0.0006028533,0.004309103,0.00043354701,0.0001411542,0.00011730984,0.000100313344,0.0014069476,0.000078641926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033030112,0.0001018953,0.00013802601,0.00006222192,0.38164583,0.0063082883,0.00004284454,0.000031836178,0.000043423977,0.000009327953,0.60964215,0.0016438597],"study_design_scores_gemma":[0.0029890288,0.00022266996,0.00006873437,0.000037472168,0.35955352,0.09746815,0.00003186716,5.873831e-7,0.00028243545,0.000070604794,0.5389016,0.00037332298],"about_ca_topic_score_codex":0.0000918289,"about_ca_topic_score_gemma":0.00004481712,"teacher_disagreement_score":0.77906555,"about_ca_system_score_codex":0.00015151095,"about_ca_system_score_gemma":0.0002700953,"threshold_uncertainty_score":0.99973685},"labels":[],"label_agreement":null},{"id":"W4225852860","doi":"10.3899/jrheum.211336","title":"Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting","year":2022,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; General partnership; Session (web analytics); Terminology; Family medicine; Internal medicine; Medical physics; Dermatology; World Wide Web","score_opus":0.022383990800178395,"score_gpt":0.2690969690727759,"score_spread":0.24671297827259753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225852860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609793,0.009011108,0.0000020366597,0.001849224,0.0011955845,0.00019544084,0.000010394694,0.0000042847623,0.0016339947],"genre_scores_gemma":[0.99818426,0.00095359184,0.00004707313,0.000031840813,0.000018954595,0.00001390271,0.0000015591772,0.000011550909,0.0007372608],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755454,0.0012896071,0.00050814316,0.00010570308,0.00013620411,0.00040583115],"domain_scores_gemma":[0.9977053,0.000918268,0.00071981305,0.00015304222,0.0004878833,0.00001573338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038459678,0.000115198796,0.00039328498,0.00012585435,0.001064793,0.000006525321,0.0007664499,0.00009606568,0.00043096236],"category_scores_gemma":[0.0002320741,0.00006269831,0.00013480296,0.00087037665,0.00042841106,0.0000538058,0.0003862488,0.00073043385,0.000016105118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057680905,0.00064877945,0.5629592,0.00007257647,0.0036720987,0.000013329887,0.023745107,0.00071128836,0.12682812,0.02971317,0.2339004,0.011967827],"study_design_scores_gemma":[0.02209621,0.009988706,0.08816095,0.001331094,0.0026228807,0.04481834,0.1894664,0.00004268142,0.17440519,0.04959401,0.4160136,0.0014599537],"about_ca_topic_score_codex":0.000080905746,"about_ca_topic_score_gemma":0.000027923881,"teacher_disagreement_score":0.47479826,"about_ca_system_score_codex":0.000054643428,"about_ca_system_score_gemma":0.0002069907,"threshold_uncertainty_score":0.8189634},"labels":[],"label_agreement":null},{"id":"W4226175612","doi":"10.1177/2050313x221093453","title":"A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report","year":2022,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Pityriasis rubra pilaris; Acitretin; Medicine; Dermatology; Ustekinumab; Psoriasis; Disease; Adalimumab; Internal medicine","score_opus":0.014301478957419912,"score_gpt":0.25944790090490016,"score_spread":0.24514642194748026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226175612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694,0.0007349874,0.00003880533,0.00015412636,0.00020386653,0.0009464527,0.00019495074,0.000033065375,0.0007537485],"genre_scores_gemma":[0.998191,0.00003475216,0.00012260434,0.000047698875,0.000012429293,0.00025836486,0.00034446846,0.00002888276,0.0009598174],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99701977,0.00071505446,0.0010872394,0.00064295664,0.00022025515,0.00031475522],"domain_scores_gemma":[0.9975907,0.0002942535,0.0010983667,0.0006608864,0.00022470942,0.0001310499],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001566461,0.00028420094,0.0007840986,0.00019393282,0.00045786673,0.00002462311,0.00012381203,0.0002598693,0.0026847064],"category_scores_gemma":[0.00053837104,0.00022835787,0.000116232186,0.0004258,0.0003960461,0.000150926,0.00045139587,0.00034684784,0.00000196548],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069432135,0.00084675424,0.014874771,0.00007430203,0.00054596364,0.9514262,0.00093228964,8.7914185e-7,0.0009271227,0.000044076056,0.00023820718,0.02939508],"study_design_scores_gemma":[0.0037022235,0.0010471712,0.00054592424,0.000085009575,0.00070703827,0.9832267,0.0028396412,0.000014441405,0.007146024,0.000038850107,0.00041629554,0.00023067997],"about_ca_topic_score_codex":0.014019118,"about_ca_topic_score_gemma":0.002274411,"teacher_disagreement_score":0.031800468,"about_ca_system_score_codex":0.00008049829,"about_ca_system_score_gemma":0.00044066086,"threshold_uncertainty_score":0.998227},"labels":[],"label_agreement":null},{"id":"W4226441756","doi":"10.1161/circ.145.suppl_1.p185","title":"Abstract P185: Adverse Cardiovascular Events In Patients With Psoriasis And Psoriatic Arthritis","year":2022,"lang":"en","type":"article","venue":"Circulation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Berger (Canada)","funders":"","keywords":"Medicine; Adverse effect; Clinical trial; Psoriasis; Internal medicine; Psoriatic arthritis; Population; Disease; Dermatology","score_opus":0.008349172801963484,"score_gpt":0.18810144734723297,"score_spread":0.17975227454526949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226441756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963482,0.002590483,0.00001782211,0.000011844548,0.0004576705,0.0003844066,0.00004023417,0.000029325469,0.000120017896],"genre_scores_gemma":[0.99932086,0.00005237877,0.000018804623,0.00001533107,0.000017585937,0.00009637137,0.0004421284,0.000014729793,0.00002180857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990935,0.00016192123,0.00018865775,0.00027927515,0.00008659684,0.00019007054],"domain_scores_gemma":[0.9996348,0.000034133718,0.00007649329,0.00021171635,0.000026908958,0.000015953214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020397732,0.0001303361,0.00022359079,0.00013182234,0.0002133333,0.0000031809986,0.000059415303,0.00007224089,0.00025445642],"category_scores_gemma":[0.000015664567,0.00012934969,0.000084626474,0.00017359648,0.000024349261,0.000113580274,0.000035778678,0.00011129471,0.000039871673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018758579,0.00018740309,0.8721662,0.000010526975,0.00040294792,0.0000059111467,0.0003614539,0.001003406,0.00017241592,0.000036003235,0.000016301616,0.12544984],"study_design_scores_gemma":[0.0059029795,0.00006681786,0.99258476,0.000016606697,0.00010992499,0.0000068650343,0.00010236688,0.000004491547,0.00007401345,0.00008311908,0.0008999157,0.00014814718],"about_ca_topic_score_codex":0.00009580011,"about_ca_topic_score_gemma":0.000020519801,"teacher_disagreement_score":0.12530169,"about_ca_system_score_codex":0.000100766614,"about_ca_system_score_gemma":0.000025169995,"threshold_uncertainty_score":0.52747273},"labels":[],"label_agreement":null},{"id":"W4228997704","doi":"10.3390/biomedicines10051078","title":"Remodeling of the Dermal Extracellular Matrix in a Tissue-Engineered Psoriatic Skin Model by n-3 Polyunsaturated Fatty Acids","year":2022,"lang":"en","type":"article","venue":"Biomedicines","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Université Laval","keywords":"Extracellular matrix; Chemistry; Lipidome; Western blot; Polyunsaturated fatty acid; Molecular biology; Psoriasis; Biochemistry; Lipidomics; Fatty acid; Biology; Immunology; Gene","score_opus":0.012030307530929929,"score_gpt":0.2366965885511329,"score_spread":0.22466628102020297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4228997704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96059096,0.036520403,0.00076768734,0.0006191584,0.0009460575,0.000307759,0.00016808881,0.000040385727,0.00003949541],"genre_scores_gemma":[0.9958082,0.00008762167,0.0002065456,0.000034423363,0.00003179935,0.00004673242,0.00023912624,0.000018674771,0.0035268723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988398,0.00019045034,0.00037183758,0.00023183823,0.00008444446,0.00028165278],"domain_scores_gemma":[0.9994764,0.00006271054,0.00012551127,0.0002882214,0.000029837414,0.0000173363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023985028,0.00018159974,0.0003027355,0.00017271133,0.00016048166,0.0000034061375,0.00028732317,0.00012973763,0.00018737988],"category_scores_gemma":[0.000029185321,0.00012837458,0.00007532406,0.00052509096,0.00009790308,0.000038717357,0.000097279844,0.00018056894,0.000012260601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014358091,0.00015072364,0.00071926723,0.000022511287,0.000084760744,0.00000535356,0.0007455909,0.0010745708,0.9882039,0.00006544767,0.0017401349,0.0070441556],"study_design_scores_gemma":[0.014115002,0.0006411152,0.009739144,0.00018207793,0.00074727833,0.00027444243,0.0022822497,0.027734613,0.90061706,0.0005276196,0.042193703,0.0009457148],"about_ca_topic_score_codex":0.0001569598,"about_ca_topic_score_gemma":0.000008442228,"teacher_disagreement_score":0.087586865,"about_ca_system_score_codex":0.000059528855,"about_ca_system_score_gemma":0.00006899691,"threshold_uncertainty_score":0.5234963},"labels":[],"label_agreement":null},{"id":"W4228999540","doi":"10.25251/skin.6.supp.2","title":"Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&amp;2","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.009601773036925079,"score_gpt":0.19994825235826888,"score_spread":0.1903464793213438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4228999540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98333824,0.01165251,0.000023129884,0.00046773712,0.0021438804,0.00023441043,0.00011073937,0.00000975709,0.0020196233],"genre_scores_gemma":[0.9953852,0.00073403644,0.00006543863,0.00015439717,0.00011981176,0.000005039581,0.00007825754,0.000022816948,0.0034349724],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793786,0.0006813583,0.00073753606,0.00015270102,0.0002374805,0.00025306398],"domain_scores_gemma":[0.9981206,0.000563655,0.0008101009,0.00033957956,0.00013281182,0.000033230626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063181436,0.00020745044,0.00062756723,0.00023594136,0.00010662665,0.0000011806507,0.00045358727,0.00009041276,0.0031352458],"category_scores_gemma":[0.00011756806,0.00012176266,0.00010328426,0.00020278824,0.0002494853,0.00004268669,0.00007644762,0.00043652306,0.000018702314],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13741685,0.006956999,0.19474532,0.00019976769,0.01050995,0.0026170053,0.1093206,0.0014700925,0.12388317,0.00062930916,0.24377708,0.16847384],"study_design_scores_gemma":[0.056269873,0.014929494,0.12178607,0.0010691273,0.0043656835,0.005347392,0.0074473713,0.0000052176943,0.0039044947,0.0011838948,0.7826861,0.0010052891],"about_ca_topic_score_codex":0.000419025,"about_ca_topic_score_gemma":0.0001649809,"teacher_disagreement_score":0.538909,"about_ca_system_score_codex":0.00049232686,"about_ca_system_score_gemma":0.00021577098,"threshold_uncertainty_score":0.99777603},"labels":[],"label_agreement":null},{"id":"W4229010470","doi":"10.25251/skin.6.supp.1","title":"Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&amp;2 Phase 3 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Internal medicine; Dermatology","score_opus":0.03227119884599514,"score_gpt":0.29356994865446284,"score_spread":0.2612987498084677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229010470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978483,0.00053853006,0.000074133255,0.000108936365,0.0005927447,0.0006166799,0.0001838249,0.00000463084,0.000032263695],"genre_scores_gemma":[0.9990517,0.0005852855,0.000023989773,0.000022262751,0.000039260492,0.000029591698,0.00003147484,0.000014605167,0.00020183166],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794644,0.0008448453,0.00086261815,0.000113554546,0.0000636073,0.00016893983],"domain_scores_gemma":[0.9975516,0.0013114429,0.0008020763,0.00016687714,0.00013605597,0.00003193212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012703205,0.00014687706,0.00073404284,0.000602644,0.000099021185,0.0000022776262,0.0001386114,0.00007252007,0.0001964708],"category_scores_gemma":[0.00093526207,0.00009168268,0.000093754155,0.00047204294,0.00013020728,0.000034923607,0.00003912762,0.00025490072,0.000001254365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08629226,0.013857472,0.32162106,0.00025239398,0.007508897,0.0002585728,0.052977104,0.0043672267,0.16348995,0.0001000693,0.009017369,0.34025764],"study_design_scores_gemma":[0.32854906,0.22860281,0.22900875,0.0033569853,0.015056075,0.015422187,0.017052593,0.00004880444,0.11499319,0.0015884467,0.044602953,0.0017181465],"about_ca_topic_score_codex":0.00049089495,"about_ca_topic_score_gemma":0.0018913187,"teacher_disagreement_score":0.33853948,"about_ca_system_score_codex":0.000090579204,"about_ca_system_score_gemma":0.00006749863,"threshold_uncertainty_score":0.37387115},"labels":[],"label_agreement":null},{"id":"W4229026528","doi":"10.1177/24755303221099292","title":"Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options","year":2022,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Queen's University; Trent University; SKiN Health","funders":"","keywords":"Palmoplantar pustulosis; Demographics; Medicine; Dermatology; Psoriasis","score_opus":0.012586717045956684,"score_gpt":0.229988582291355,"score_spread":0.2174018652453983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229026528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94737923,0.049808312,0.00006721436,0.0004805789,0.0015696941,0.00021998397,0.00037091947,0.000009384886,0.00009465462],"genre_scores_gemma":[0.943176,0.055781644,0.00069451676,0.00007794064,0.00012318789,0.00003798111,0.00003308293,0.000015962965,0.00005969538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981133,0.00056956697,0.0007403266,0.00020568789,0.00013568395,0.00023544607],"domain_scores_gemma":[0.9983009,0.00050897314,0.0008058411,0.0001755087,0.00014213033,0.00006664056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047537065,0.00021821081,0.00055422104,0.00025814373,0.00040889293,0.000019926527,0.000104334475,0.00010007245,0.00029171194],"category_scores_gemma":[0.00009382092,0.00018242568,0.00019353091,0.00015415093,0.00007582728,0.00017404907,0.00008022833,0.00019580786,0.0000024412175],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014216241,0.0018324624,0.033165876,0.000041633957,0.0038091198,0.00020136766,0.008062064,0.00004653105,0.001793758,0.0021250136,0.0011786356,0.9463219],"study_design_scores_gemma":[0.055601265,0.04652765,0.16377804,0.0008707967,0.011008375,0.023419822,0.080375515,0.000043875032,0.01264359,0.0022878167,0.6013342,0.0021090438],"about_ca_topic_score_codex":0.000118439406,"about_ca_topic_score_gemma":0.000041514373,"teacher_disagreement_score":0.94421285,"about_ca_system_score_codex":0.00005574033,"about_ca_system_score_gemma":0.00007941126,"threshold_uncertainty_score":0.7439103},"labels":[],"label_agreement":null},{"id":"W4229034592","doi":"10.25251/skin.6.supp.4","title":"Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Pharmacology; Dermatology","score_opus":0.04009431060346913,"score_gpt":0.302258072534325,"score_spread":0.2621637619308559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229034592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787339,0.009517833,0.000037190166,0.008610722,0.0014623391,0.00079316116,0.000682736,0.000024491157,0.00013760371],"genre_scores_gemma":[0.99614704,0.0011969932,0.00010151868,0.0011955635,0.00067377125,0.000023454273,0.00019470787,0.000039644892,0.00042730512],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931063,0.0043248283,0.0014587925,0.00038345964,0.00025596304,0.0004706522],"domain_scores_gemma":[0.9937964,0.0044946675,0.0009225261,0.0004651191,0.00019848168,0.00012281151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004356343,0.00040636086,0.0011765301,0.00026266757,0.00064764556,0.000027309734,0.00058613444,0.000173298,0.00032263392],"category_scores_gemma":[0.0019395711,0.00022060618,0.00014597946,0.0005127887,0.00024715654,0.00011429358,0.00014323184,0.000908244,0.0000151881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30421194,0.0053113527,0.00030318083,0.0000236961,0.0037796437,0.0038019456,0.07836991,0.003346244,0.29877084,0.00016251233,0.10080077,0.20111795],"study_design_scores_gemma":[0.3430208,0.08532566,0.004715336,0.001957677,0.010158728,0.07143686,0.05474647,0.00029510073,0.22313529,0.007618408,0.19475791,0.002831766],"about_ca_topic_score_codex":0.0008022597,"about_ca_topic_score_gemma":0.00046511533,"teacher_disagreement_score":0.19828619,"about_ca_system_score_codex":0.00016973149,"about_ca_system_score_gemma":0.00024275859,"threshold_uncertainty_score":0.8996059},"labels":[],"label_agreement":null},{"id":"W4229043584","doi":"10.25251/skin.6.supp.5","title":"Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Term (time); Aryl hydrocarbon receptor; Psoriasis; Extension (predicate logic); Medicine; Aryl; Pharmacology; Dermatology; Chemistry; Computer science; Physics; Organic chemistry; Biochemistry","score_opus":0.0328903932308255,"score_gpt":0.27828189498316785,"score_spread":0.24539150175234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229043584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221064,0.010562613,0.0008771007,0.001179746,0.0042484943,0.0007874269,0.0000398056,0.000015646487,0.00007850619],"genre_scores_gemma":[0.99744236,0.0009343911,0.00013566317,0.00020207895,0.00062570453,0.000030997282,0.000046107813,0.000034617042,0.00054805324],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99787134,0.00039469305,0.0009681753,0.0002052606,0.00023378443,0.00032672178],"domain_scores_gemma":[0.99701256,0.0011644992,0.0012652794,0.00035104938,0.00016458401,0.000042013922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001463294,0.00025959266,0.0007390262,0.0001928631,0.00038067275,0.0000041747808,0.00046130214,0.00012772963,0.00030514642],"category_scores_gemma":[0.00023383292,0.00016052574,0.0002642987,0.0001968083,0.00018892482,0.000045714783,0.00008359493,0.00039879902,0.0000029615028],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10730298,0.0015424269,0.0001758881,0.000052242314,0.0015705348,0.00009253256,0.0044367802,0.0010924225,0.8263216,0.000072180446,0.0012685009,0.056071926],"study_design_scores_gemma":[0.48162487,0.14008334,0.004091523,0.0029753526,0.013438878,0.058846593,0.014269614,0.0011417711,0.25958875,0.0020150756,0.02008624,0.001837967],"about_ca_topic_score_codex":0.000042234504,"about_ca_topic_score_gemma":0.0000075867943,"teacher_disagreement_score":0.5667328,"about_ca_system_score_codex":0.00013624568,"about_ca_system_score_gemma":0.00012972698,"threshold_uncertainty_score":0.654605},"labels":[],"label_agreement":null},{"id":"W4229684386","doi":"10.1177/120347540500900607","title":"Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Efalizumab; Medicine; Adverse effect; Placebo; Psoriasis; Clinical trial; Incidence (geometry); Internal medicine; Dermatology; Plaque psoriasis; Pathology; Alternative medicine","score_opus":0.03849130579220388,"score_gpt":0.2978299855919772,"score_spread":0.2593386797997733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229684386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9307863,0.06636252,0.000008215125,0.0017320183,0.0006827379,0.00020126216,0.00007057619,0.000003813213,0.00015252932],"genre_scores_gemma":[0.8944171,0.10412179,0.00009349646,0.00068326964,0.000370876,0.0000018960675,0.00012596525,0.000014281871,0.00017132371],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974188,0.00032499616,0.0017315719,0.0001911868,0.0001297004,0.0002037424],"domain_scores_gemma":[0.9977032,0.00081564,0.00087338267,0.00031484582,0.00022673354,0.00006621002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014213766,0.00017024408,0.001443778,0.00018216229,0.00004363194,0.0000012782614,0.00016782485,0.00013743844,0.00024004692],"category_scores_gemma":[0.00048810185,0.000105000254,0.00010709872,0.00016674775,0.00012271998,0.00010351966,0.00005667024,0.00021385746,0.00000368305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026327685,0.0017245918,0.16680802,0.0021705653,0.0023901262,0.00037992798,0.00078299915,0.00008643086,0.00021013839,0.000028534792,0.14099766,0.65809333],"study_design_scores_gemma":[0.034675036,0.015566826,0.086945474,0.08631867,0.0037471578,0.0060331114,0.00035625213,0.000020935671,0.0014370639,0.000056375324,0.76377475,0.0010683434],"about_ca_topic_score_codex":0.000017655688,"about_ca_topic_score_gemma":0.000045917648,"teacher_disagreement_score":0.657025,"about_ca_system_score_codex":0.00003423366,"about_ca_system_score_gemma":0.00031499396,"threshold_uncertainty_score":0.4281786},"labels":[],"label_agreement":null},{"id":"W4233235381","doi":"10.3410/f.725820161.793510301","title":"Faculty Opinions recommendation of Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.","year":2015,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Secukinumab; Psoriatic arthritis; Interleukin 17; Psoriasis; Medicine; Dermatology; Plaque psoriasis; Internal medicine; Cytokine","score_opus":0.019490325432291025,"score_gpt":0.2931849874809953,"score_spread":0.2736946620487043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233235381","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012695628,0.00225934,0.0000052963633,0.012044148,0.0010469793,0.001416703,0.98305154,0.000018880906,0.000030170086],"genre_scores_gemma":[0.00055725663,0.00031413714,0.00013770816,0.00041660716,0.000060976035,0.00018861763,0.99807185,0.000021068685,0.00023176306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964021,0.00070127373,0.001621255,0.00052118703,0.00045069001,0.00030348802],"domain_scores_gemma":[0.9928465,0.00011321669,0.0018161804,0.0009389299,0.00420289,0.000082265324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009254368,0.00047128237,0.0011469494,0.0004895066,0.00009197258,0.000025970437,0.0006894198,0.00081329804,0.00038249133],"category_scores_gemma":[0.0019997102,0.00029919273,0.0003433459,0.001408851,0.0003431602,0.0002670164,0.0002507387,0.00065304834,0.00004836949],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012756759,0.0010301439,0.00010915749,0.0024044309,0.0002844627,2.1707216e-7,0.0001988609,6.907819e-8,0.0000032303828,0.00006295037,0.98608994,0.009688975],"study_design_scores_gemma":[0.004162836,0.0005087412,0.008082673,0.014228139,0.00024140952,0.000011528453,0.000037426486,2.244443e-7,0.00010601391,0.000023215993,0.9723304,0.00026737837],"about_ca_topic_score_codex":0.00008918012,"about_ca_topic_score_gemma":0.0000391273,"teacher_disagreement_score":0.015020339,"about_ca_system_score_codex":0.00015158998,"about_ca_system_score_gemma":0.00043644125,"threshold_uncertainty_score":0.999946},"labels":[],"label_agreement":null},{"id":"W4233727453","doi":"10.1177/120347540300700302","title":"Mycophenolate Mofetil (CellCept®) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial","year":2003,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Adverse effect; Nausea; Leukopenia; Clinical trial; Open label; Internal medicine; Dermatology; Surgery; Gastroenterology; Chemotherapy","score_opus":0.10015512159607844,"score_gpt":0.3576214980133305,"score_spread":0.25746637641725206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233727453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741678,0.0131238,0.00012961887,0.0006235086,0.009025016,0.00082761777,0.000021273085,0.000018994604,0.0020623328],"genre_scores_gemma":[0.9885683,0.0061842003,0.00056766445,0.00068884104,0.001072222,0.00003664392,0.000024674428,0.000042596348,0.0028148708],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997198,0.00057212927,0.0014323946,0.000308651,0.0000951847,0.00039366254],"domain_scores_gemma":[0.9959421,0.002626403,0.00082780584,0.00021661127,0.0002711535,0.00011588654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023622224,0.00027610603,0.0013342305,0.00021603447,0.00020914491,0.000027762666,0.00021812243,0.00021408105,0.00036024218],"category_scores_gemma":[0.0015441519,0.00018738378,0.0002607173,0.00014500738,0.00022144808,0.0001308626,0.00003578224,0.00031355157,0.000020342979],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34955937,0.009055562,0.038911298,0.00018773082,0.0069264667,0.0023270852,0.0016038686,0.0000019267268,0.01166779,0.002119882,0.2722061,0.30543292],"study_design_scores_gemma":[0.48113847,0.01566142,0.00046433916,0.0007793408,0.0022969637,0.021756297,0.0011733766,0.0000056552312,0.0028641801,0.0042839544,0.46880543,0.0007705752],"about_ca_topic_score_codex":0.000015123158,"about_ca_topic_score_gemma":0.0000075314356,"teacher_disagreement_score":0.30466235,"about_ca_system_score_codex":0.000037199545,"about_ca_system_score_gemma":0.00026833566,"threshold_uncertainty_score":0.76412886},"labels":[],"label_agreement":null},{"id":"W4234297760","doi":"10.32388/c29sds","title":"Palmoplantar Pustulosis","year":2020,"lang":"en","type":"article","venue":"Definitions","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Pustulosis; Palmoplantar pustulosis; Psoriasis; Dermatology; Medicine; PUVA therapy; Plaque psoriasis; Differential diagnosis; Pustular psoriasis; Pathology; Immunology; Arthritis","score_opus":0.07062480787154513,"score_gpt":0.23207030906005266,"score_spread":0.16144550118850753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234297760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8787041,0.0032056733,0.00027922902,0.006756525,0.0008318141,0.00024806397,0.0013789658,0.00045890454,0.108136766],"genre_scores_gemma":[0.99726933,0.00021261767,0.00017701506,0.0011625944,0.000047577618,0.00003733115,0.00074871915,0.000008887028,0.00033590023],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995306,0.000049215298,0.00010235943,0.00014906352,0.000013464749,0.00015529164],"domain_scores_gemma":[0.9997592,0.00007264841,0.00002512978,0.00010067383,0.000016068128,0.000026269672],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000020894262,0.00008756522,0.000113234884,0.000028453163,0.00016724243,0.0000070526166,0.000075693446,0.000086295106,0.0019205671],"category_scores_gemma":[0.000027941172,0.00007953581,0.00007603433,0.00011462994,0.000042394986,0.000033987904,0.000022563127,0.00007411229,0.008438407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005157244,0.0010349398,0.05405253,0.00007522258,0.002263427,0.00020798115,0.005439061,0.0000119999,0.29811373,0.10243834,0.4874178,0.048429243],"study_design_scores_gemma":[0.0066434285,0.00075949676,0.07882321,0.00004938795,0.0012215802,0.00029995153,0.0013931199,0.000007017209,0.17051286,0.0058532227,0.7333692,0.001067584],"about_ca_topic_score_codex":0.00001008815,"about_ca_topic_score_gemma":0.0000047728877,"teacher_disagreement_score":0.24595135,"about_ca_system_score_codex":0.000006943534,"about_ca_system_score_gemma":0.000016704393,"threshold_uncertainty_score":0.9989918},"labels":[],"label_agreement":null},{"id":"W4235484441","doi":"10.1503/cmaj.090631","title":"Psoriasis","year":2012,"lang":"en","type":"article","venue":"Canadian Medical Association Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Psoriasis; Scalp; Medicine; Dermatology; Population","score_opus":0.010578917518045771,"score_gpt":0.2244392672618003,"score_spread":0.21386034974375454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235484441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92794704,0.008671377,0.000052871284,0.014930565,0.016497444,0.00012707258,0.000072994204,0.000059058897,0.03164158],"genre_scores_gemma":[0.9901151,0.0001982603,0.000039600727,0.0031918075,0.0017764149,0.000005689411,0.00002946355,0.000010924547,0.0046327366],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986592,0.0002476711,0.00022597717,0.00007511167,0.00015823635,0.0006338321],"domain_scores_gemma":[0.9990362,0.00013569082,0.00011134996,0.000070815455,0.00010488938,0.0005410826],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012128336,0.000095607626,0.00015186085,0.00012399057,0.0003241866,0.000021426866,0.00014621067,0.0005178374,0.020651942],"category_scores_gemma":[0.0006672387,0.00008131054,0.0001001358,0.00012033919,0.000023248953,0.00013054658,0.000008782679,0.0004396597,0.004487094],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011245051,0.00006624637,0.31285137,0.0000016656564,0.000503019,0.000043037835,0.00053209875,1.3221019e-7,0.00020682135,0.0007082797,0.38201413,0.30306196],"study_design_scores_gemma":[0.0008872791,0.000019974808,0.09201365,0.000009005504,0.000055242024,0.0004370117,0.00018085132,3.2319707e-7,0.00038516277,0.00003872912,0.90587115,0.00010159022],"about_ca_topic_score_codex":0.00090376305,"about_ca_topic_score_gemma":0.0033403845,"teacher_disagreement_score":0.52385706,"about_ca_system_score_codex":0.00049992325,"about_ca_system_score_gemma":0.0006992967,"threshold_uncertainty_score":0.996288},"labels":[],"label_agreement":null},{"id":"W4236288139","doi":"10.2165/11633980-000000000-00000","title":"Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis","year":2012,"lang":"en","type":"article","venue":"Applied Health Economics and Health Policy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of British Columbia; Dermatrials Research; Lynde Centre for Dermatology; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Etanercept; Plaque psoriasis; Health care; Physical therapy; Population; Psoriasis; Internal medicine; Environmental health; Dermatology","score_opus":0.07707869048208142,"score_gpt":0.338362433317164,"score_spread":0.26128374283508254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236288139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90548825,0.0020139813,0.00021121024,0.083534166,0.0007120372,0.006561635,0.0012197968,0.0000782321,0.00018068065],"genre_scores_gemma":[0.97898585,0.0018001115,0.00080608117,0.015936991,0.0003794059,0.0009915753,0.0007925382,0.000055805638,0.00025167334],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977947,0.00010195035,0.0005546126,0.00054590753,0.000021850607,0.0009810036],"domain_scores_gemma":[0.9987748,0.0002631424,0.0003384334,0.00027534252,0.000040361825,0.00030790086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007540807,0.00030572969,0.0006967417,0.00021562148,0.000935191,0.000021868454,0.00008043311,0.00024206145,0.000003994236],"category_scores_gemma":[0.000037837457,0.00028985416,0.000059561324,0.00010312646,0.000045434703,0.00007223878,0.00004699125,0.00012175238,0.000016117088],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003583766,0.00067580555,0.062579945,0.0010079569,0.00019835992,1.895492e-8,0.0070848577,0.00005483733,0.000004052175,0.15630698,0.012013835,0.7564896],"study_design_scores_gemma":[0.01092438,0.0022984198,0.454167,0.00008453115,0.00004958903,0.0000043872915,0.0004547075,0.000016506783,0.00014986463,0.003060478,0.5280509,0.0007391965],"about_ca_topic_score_codex":0.00074376847,"about_ca_topic_score_gemma":0.0004740231,"teacher_disagreement_score":0.7557504,"about_ca_system_score_codex":0.00036915418,"about_ca_system_score_gemma":0.0003815699,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W4237839909","doi":"10.21203/rs.3.rs-147804/v1","title":"The Efficacy of Genetic Testing for Early Detection of Psoriatic Arthritis in Patients with Psoriasis","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; University of Toronto; Women's College Hospital","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology","score_opus":0.0346519232822373,"score_gpt":0.3000608877907852,"score_spread":0.2654089645085479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237839909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028724,0.0072472338,0.00007258679,0.000013702592,0.00042171264,0.001761082,0.00014440336,0.0000141965265,0.00003784329],"genre_scores_gemma":[0.99849033,0.000373503,0.0003898593,7.167825e-7,0.000046229274,0.00045199035,0.00015680591,0.000030680425,0.000059904585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99751884,0.000822371,0.00054519373,0.00043586182,0.00019023956,0.00048752423],"domain_scores_gemma":[0.9954212,0.0026517939,0.00028396846,0.00057928625,0.0010401516,0.000023615154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008413806,0.00020755036,0.00049719104,0.00028553267,0.00022708537,0.000031239793,0.00030850276,0.0003741443,0.0000160135],"category_scores_gemma":[0.0016115779,0.00015149002,0.00015351475,0.00048402994,0.00022825965,0.000032266813,0.00025124216,0.00048717269,0.0000052682763],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019671337,0.0006705291,0.333139,0.0006189194,0.000597088,0.0000041456374,0.00095781934,0.00009673191,0.0050382856,0.0000133784215,0.000012441331,0.6568845],"study_design_scores_gemma":[0.0050412714,0.001704617,0.9674039,0.0012057456,0.0000776675,0.0000011280887,0.0002684292,0.000007963335,0.02397355,0.000118495416,0.000051991352,0.00014522269],"about_ca_topic_score_codex":0.0006876729,"about_ca_topic_score_gemma":0.00056176167,"teacher_disagreement_score":0.6567393,"about_ca_system_score_codex":0.00009858419,"about_ca_system_score_gemma":0.0003082682,"threshold_uncertainty_score":0.61775833},"labels":[],"label_agreement":null},{"id":"W4239805270","doi":"10.1177/2475530318812244","title":"2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","year":2018,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Psoriatic arthritis; Guideline; Enthesitis; Internal medicine; Abatacept; Tofacitinib; Physical therapy; Intensive care medicine; Psoriasis; Disease; Dermatology; Rheumatoid arthritis; Rituximab; Pathology","score_opus":0.020224608349345873,"score_gpt":0.2757395728411959,"score_spread":0.25551496449185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239805270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93077195,0.043915812,0.007089688,0.0025052556,0.0120884,0.001526487,0.0017915985,0.000035915044,0.000274869],"genre_scores_gemma":[0.94411546,0.047261335,0.007167543,0.00007893216,0.00097437075,0.000078183686,0.00008036913,0.000042263757,0.00020153071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640536,0.00034672458,0.0022306344,0.0003369366,0.00025885462,0.00042146104],"domain_scores_gemma":[0.9941223,0.0016672073,0.0024023838,0.00035018462,0.0013817732,0.000076123],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012070942,0.00039594495,0.0013874132,0.0003495649,0.000400572,0.000020026191,0.00029816444,0.00022891065,0.0004162872],"category_scores_gemma":[0.0005969524,0.00028300012,0.00052192406,0.00039674915,0.00087909115,0.00021169752,0.00003370917,0.00010656851,0.000024961575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017370773,0.0009256836,0.0022101551,0.000044676817,0.0032709925,0.000004591507,0.0017689404,0.00000976891,0.0015023483,0.0050356346,0.017795919,0.9656942],"study_design_scores_gemma":[0.06811869,0.037280444,0.021362068,0.0011284513,0.0045557683,0.0019670585,0.007198901,0.00042602164,0.049757667,0.019597733,0.78712773,0.0014794903],"about_ca_topic_score_codex":0.00025069035,"about_ca_topic_score_gemma":0.00042446633,"teacher_disagreement_score":0.96421474,"about_ca_system_score_codex":0.000121629295,"about_ca_system_score_gemma":0.00034180304,"threshold_uncertainty_score":0.9999622},"labels":[],"label_agreement":null},{"id":"W4241417618","doi":"10.1007/978-1-349-94186-5_336","title":"Chronic Granulomatous Disorder (CGD) Society","year":2018,"lang":"en","type":"book-chapter","venue":"Palgrave Macmillan UK eBooks","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"College of Optometrists; Camargo Foundation; Chiang Ching-Kuo Foundation for International Scholarly Exchange; Royal Academy of Engineering; Government of Canada; Ciência sem Fronteiras; Australian Government","keywords":"Chronic granulomatous disease; Medicine; Dermatology; Immunology","score_opus":0.014704716477444296,"score_gpt":0.22202043815267408,"score_spread":0.2073157216752298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241417618","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025541768,0.040472925,0.000059660313,0.000041889463,0.00232878,0.00095826446,0.0008137365,0.0003926147,0.952378],"genre_scores_gemma":[0.839826,0.0011183348,0.00009176324,0.00014430312,0.00083877175,0.000089202316,0.0012106285,0.00020252557,0.15647846],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99739075,0.00007520315,0.00059607165,0.0009747162,0.00011558343,0.00084766146],"domain_scores_gemma":[0.99822766,0.0001279378,0.00038099784,0.00105221,0.0001306121,0.00008060803],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017160014,0.0010172669,0.0009917939,0.00015714898,0.0004530444,0.000035633297,0.00054106326,0.001549185,0.008765627],"category_scores_gemma":[0.000008416307,0.00088939583,0.0010474045,0.000022553671,0.0007251443,8.287986e-7,0.00025485374,0.00046835272,0.008070221],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004547959,0.00000823353,0.00087678013,0.0004761451,0.011264386,0.00019518286,0.0029664685,6.2665424e-7,0.013864296,0.5767243,0.007494535,0.38567427],"study_design_scores_gemma":[0.005449743,0.0010436168,0.00069440994,0.00044012113,0.0019483264,0.00035132098,0.00009541177,0.000002275398,0.007226064,0.62824297,0.35194737,0.0025583769],"about_ca_topic_score_codex":0.00006470442,"about_ca_topic_score_gemma":0.00033079437,"teacher_disagreement_score":0.8372718,"about_ca_system_score_codex":0.00019899268,"about_ca_system_score_gemma":0.00020307196,"threshold_uncertainty_score":0.99974704},"labels":[],"label_agreement":null},{"id":"W4241502642","doi":"10.1177/120347540400800503","title":"Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel","year":2004,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; University of Manitoba; Probity Medical Research; University of British Columbia; Lynde Centre for Dermatology; Queen Elizabeth II Health Sciences Centre; University Health Network; Western University; University of Toronto; Dalhousie University; University of Calgary; Innovaderm (Canada); Guenther Dermatology Research Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psoriasis; Quality of life (healthcare); Clinical trial; Intensive care medicine; Disease; Panel discussion; Dermatology; Internal medicine; Nursing","score_opus":0.04447640236346012,"score_gpt":0.2637940386200915,"score_spread":0.21931763625663137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241502642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888082,0.006248889,0.000019394902,0.002623114,0.001527907,0.0001769823,0.0000139203485,0.000005980038,0.00057562435],"genre_scores_gemma":[0.9971935,0.0016820603,0.00033230253,0.00051758037,0.000089690526,0.000004359083,0.000006362639,0.000011841215,0.00016231577],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838483,0.00020309121,0.0008468343,0.0001662815,0.00011698442,0.00028197136],"domain_scores_gemma":[0.9985348,0.00039398135,0.0005399782,0.00021143361,0.00021706501,0.00010274709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005505699,0.00021354429,0.0007564878,0.0003422811,0.00018522728,0.000005768444,0.00019195188,0.00018280756,0.00008644236],"category_scores_gemma":[0.0002451646,0.000121199315,0.00020368487,0.00026023615,0.0002421928,0.000026708514,0.000038780458,0.00018159885,0.0000038774597],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011207607,0.001515749,0.08037676,0.0011079202,0.016243804,0.007816627,0.055696618,0.0011858576,0.1498691,0.0031612068,0.06394992,0.60786885],"study_design_scores_gemma":[0.057329506,0.014910666,0.118808545,0.041870616,0.012494772,0.10305187,0.17503643,0.00006127335,0.32614905,0.027708935,0.117163174,0.005415159],"about_ca_topic_score_codex":0.011194399,"about_ca_topic_score_gemma":0.0052843057,"teacher_disagreement_score":0.60245365,"about_ca_system_score_codex":0.0001141394,"about_ca_system_score_gemma":0.0002944786,"threshold_uncertainty_score":0.9953901},"labels":[],"label_agreement":null},{"id":"W4241580772","doi":"10.25251/skin.4.supp.30","title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Medicine; Dermatology; Psoriasis; Baseline (sea); Phase (matter); Randomized controlled trial; Internal medicine; Biology; Physics","score_opus":0.01703836544243391,"score_gpt":0.27875486484144557,"score_spread":0.26171649939901165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241580772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95606244,0.036560565,0.00021334566,0.00504457,0.00039241332,0.0015495243,0.00016452323,0.0000058017326,0.0000068353875],"genre_scores_gemma":[0.97480243,0.024583131,0.000019206442,0.0001595197,0.00023202143,0.000017599505,0.000050523282,0.000015303965,0.00012026295],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980723,0.0007555825,0.00077555235,0.00014609739,0.000078191726,0.00017224887],"domain_scores_gemma":[0.99497575,0.0041639367,0.0005063724,0.00016697861,0.00011009173,0.0000768775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009728269,0.00022375629,0.00099724,0.00006574206,0.000119888035,0.0000049641294,0.00014889005,0.00006807105,0.00008641665],"category_scores_gemma":[0.00092275743,0.000099932055,0.00009281119,0.0001181801,0.00032828163,0.000023562501,0.00001912843,0.00012356772,0.0000014112582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8233168,0.004404357,0.0007694944,0.00006377052,0.002887898,0.00025075747,0.020280544,0.000012330181,0.008662681,0.000019613097,0.0023263264,0.13700543],"study_design_scores_gemma":[0.88764703,0.046674706,0.0028887424,0.0004052815,0.0136959,0.0015631687,0.0076107318,0.00041208684,0.0035756014,0.00011078407,0.03504036,0.00037560222],"about_ca_topic_score_codex":0.000042950378,"about_ca_topic_score_gemma":0.00001214775,"teacher_disagreement_score":0.13662983,"about_ca_system_score_codex":0.000027249125,"about_ca_system_score_gemma":0.000061252504,"threshold_uncertainty_score":0.4075111},"labels":[],"label_agreement":null},{"id":"W4241720996","doi":"10.3410/f.725715735.793510300","title":"Faculty Opinions recommendation of Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.","year":2015,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Secukinumab; Psoriatic arthritis; Psoriasis; Plaque psoriasis; Medicine; Dermatology; Randomized controlled trial; Internal medicine","score_opus":0.03299282898505208,"score_gpt":0.33792053066436434,"score_spread":0.30492770167931227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241720996","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000106272935,0.0071446663,0.000019534102,0.025001004,0.0016826554,0.002751663,0.963236,0.000037018566,0.000021222422],"genre_scores_gemma":[0.00043274896,0.0018146089,0.0001725732,0.00043282792,0.0004070322,0.00053766504,0.9959561,0.000027337204,0.00021909317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929358,0.003045573,0.0023098402,0.0008902017,0.00044974065,0.0003688469],"domain_scores_gemma":[0.9925452,0.0013626989,0.0026035043,0.0010444837,0.0023057074,0.00013840217],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038795439,0.0006813179,0.0027747273,0.0004376586,0.00017148197,0.0000856011,0.0006397165,0.0008263929,0.000098331904],"category_scores_gemma":[0.012465476,0.00039532027,0.0006268856,0.0011911417,0.0005226982,0.00034408667,0.00021548384,0.0008800301,0.00003308831],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0124691585,0.00087634946,0.0000011609656,0.00089084526,0.0010219262,6.961193e-7,0.0004556092,1.1855692e-7,0.000016967497,0.00009303953,0.9504399,0.033734243],"study_design_scores_gemma":[0.12495287,0.00047577632,0.00012437196,0.0067434413,0.0012701012,0.000025736728,0.00006620284,0.000005254115,0.00009945479,0.00014061424,0.8657512,0.00034498452],"about_ca_topic_score_codex":0.0005398078,"about_ca_topic_score_gemma":0.00011484742,"teacher_disagreement_score":0.1124837,"about_ca_system_score_codex":0.000111394045,"about_ca_system_score_gemma":0.00057015155,"threshold_uncertainty_score":0.99984986},"labels":[],"label_agreement":null},{"id":"W4241851203","doi":"10.3899/jrheum.180137","title":"Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting","year":2018,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Body surface area; Dermatology; Dermatology Life Quality Index; Physical therapy; Surgery","score_opus":0.042370381879727144,"score_gpt":0.29846606094704303,"score_spread":0.2560956790673159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241851203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884046,0.006234568,0.000028362312,0.0021305785,0.0020292606,0.00013077035,0.000015052472,0.000006405958,0.0010204035],"genre_scores_gemma":[0.99882,0.0006388101,0.000053051295,0.000049183902,0.00008207735,0.0000027401659,0.000004272548,0.000012347182,0.0003374936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623775,0.0024225467,0.000698007,0.00013614981,0.00013252957,0.0003730219],"domain_scores_gemma":[0.9954915,0.0025319713,0.00095279614,0.0006165942,0.0003892412,0.000017887585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004368232,0.00013912875,0.0004003012,0.000086654465,0.0007673868,0.000009757708,0.0011171491,0.00021081901,0.00012599684],"category_scores_gemma":[0.0006949128,0.000059235594,0.00019356975,0.00026756225,0.0013413063,0.000054176682,0.0002704622,0.00059709337,0.00005972603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021818306,0.00025708094,0.82913184,0.0000130523385,0.002710988,0.00007211879,0.022376357,0.000006184,0.023497956,0.0021891964,0.09095297,0.026610449],"study_design_scores_gemma":[0.00731971,0.0019590736,0.60920745,0.0016332255,0.0014287713,0.07967471,0.025510313,0.00000943238,0.10462038,0.018296273,0.14972557,0.0006150611],"about_ca_topic_score_codex":0.001123652,"about_ca_topic_score_gemma":0.0006870424,"teacher_disagreement_score":0.21992435,"about_ca_system_score_codex":0.000026189218,"about_ca_system_score_gemma":0.00014375879,"threshold_uncertainty_score":0.5902196},"labels":[],"label_agreement":null},{"id":"W4244921764","doi":"10.1007/978-3-540-29676-8_3243","title":"Pityriasis Alba","year":2009,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Pityriasis rosea; Pityriasis; Dermatology; Medicine","score_opus":0.020864639339998072,"score_gpt":0.22302970214268156,"score_spread":0.20216506280268348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244921764","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007918768,0.0077868104,0.0000104508235,0.0002472715,0.0008853889,0.00021822161,0.00012982902,0.00018880656,0.990454],"genre_scores_gemma":[0.002122133,0.0011081832,0.0001056809,0.00053037854,0.00013795707,0.000007838209,0.0006940386,0.000042272848,0.99525154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989193,0.000027520522,0.00028290198,0.0004377533,0.00003370672,0.0002988384],"domain_scores_gemma":[0.9992559,0.000072551615,0.00013159911,0.00046729855,0.000046595866,0.000026076203],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007711827,0.00043524074,0.00052708085,0.00015531505,0.00012407752,0.000012472938,0.00022738642,0.0010600152,0.021472722],"category_scores_gemma":[0.000007457327,0.0003573042,0.000337123,0.000015735422,0.00008740081,0.000035347082,0.000050848746,0.00025008654,0.017516064],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010428427,0.00006163194,0.000012465962,0.000009532148,0.0011148751,0.00004469434,0.000039507093,1.14448696e-7,0.0014878208,0.1441655,0.12568127,0.7272783],"study_design_scores_gemma":[0.00076475507,0.00016378684,0.00016764962,0.000038811613,0.00044245075,0.000054532087,0.0000032683581,2.880774e-8,0.0034075542,0.0073463116,0.98721164,0.00039920252],"about_ca_topic_score_codex":0.0000426013,"about_ca_topic_score_gemma":0.000053822187,"teacher_disagreement_score":0.86153036,"about_ca_system_score_codex":0.000051323193,"about_ca_system_score_gemma":0.000075530814,"threshold_uncertainty_score":0.9998879},"labels":[],"label_agreement":null},{"id":"W4247576793","doi":"10.1016/j.jaad.2018.05.959","title":"Real-world safety of secukinumab in patients with moderate to severe chronic plaque psoriasis in Latin America and Canada: Results from the PURE registry","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Secukinumab; Medicine; Plaque psoriasis; Latin Americans; Dermatology; Psoriasis; Family medicine; Environmental health; Psoriatic arthritis","score_opus":0.008009628017007464,"score_gpt":0.22717380278816046,"score_spread":0.219164174771153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247576793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901278,0.00026963057,0.0000041284065,0.008867,0.00012972344,0.00019129559,0.00028277762,0.0000024864996,0.00012515848],"genre_scores_gemma":[0.9989387,0.00027543423,0.00017417644,0.00049750664,0.000038470604,0.0000032101252,0.0000106270445,0.000011907896,0.000049997125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804544,0.0005723997,0.0008054889,0.0001980656,0.0000977986,0.00028078846],"domain_scores_gemma":[0.9976733,0.0005063743,0.0015001522,0.00021596729,0.00007048151,0.000033724045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012229917,0.00018481317,0.00076860026,0.00013936473,0.000075992895,0.000003127916,0.00046326438,0.000111165304,0.000013584149],"category_scores_gemma":[0.00009995343,0.000106298794,0.000060439306,0.00043296738,0.0006434464,0.000054208824,0.00010879287,0.00044233433,0.000001366309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026326679,0.00020549353,0.94161016,0.000021380505,0.00089638325,0.00002785633,0.002290917,0.0003142537,0.0033546812,0.00009077326,0.0110473735,0.013814067],"study_design_scores_gemma":[0.0054114903,0.000307834,0.98276657,0.00017684116,0.00010255658,0.00010011529,0.00035863934,0.000006807791,0.006885526,0.00006354993,0.0036880155,0.00013207088],"about_ca_topic_score_codex":0.09369874,"about_ca_topic_score_gemma":0.17856283,"teacher_disagreement_score":0.084864095,"about_ca_system_score_codex":0.0001860313,"about_ca_system_score_gemma":0.00047676955,"threshold_uncertainty_score":0.9123364},"labels":[],"label_agreement":null},{"id":"W4248095883","doi":"10.2310/7750.2009.00024","title":"Psoriasis Comorbidities","year":2009,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Guenther Dermatology Research Centre","funders":"Abbott Laboratories","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Comorbidity; Depression (economics); Diabetes mellitus; Metabolic syndrome; Disease; Anxiety; Hyperlipidemia; Intensive care medicine; Dermatology; Obesity; Internal medicine; Psychiatry","score_opus":0.06462970087758643,"score_gpt":0.3046525127310202,"score_spread":0.24002281185343374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248095883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024684376,0.99555665,0.000002710513,0.00021597413,0.0030560282,0.000124389,0.000023656772,0.000016124482,0.0007576435],"genre_scores_gemma":[0.000104322164,0.99626917,0.000014755194,0.00016184022,0.0009807396,0.0000030121478,0.00007606345,0.000028744249,0.0023613505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758345,0.00044472612,0.0013560002,0.00019851919,0.00010308537,0.00031424736],"domain_scores_gemma":[0.9955728,0.0027474684,0.0012722225,0.00021033043,0.00012311645,0.00007404635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006600586,0.0004503862,0.0037687807,0.0006886751,0.00011611148,0.000012229571,0.00017662946,0.0005202711,0.00046791314],"category_scores_gemma":[0.00032719682,0.00026825533,0.00077299646,0.00018715147,0.00021841077,0.00005867505,0.000020613192,0.0004955422,0.000050841907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057513404,0.00005001552,0.00001151193,0.0010696037,0.00097534084,0.0014249438,0.0001092656,2.1287198e-8,0.0000037502457,0.00001802503,0.09644238,0.8998376],"study_design_scores_gemma":[0.00030359736,0.00035432083,0.0000046014247,0.010729446,0.0036880327,0.043545276,0.00009682847,1.1657041e-8,0.000004875123,0.00007500156,0.94098175,0.00021624008],"about_ca_topic_score_codex":0.000012483629,"about_ca_topic_score_gemma":0.0000023748164,"teacher_disagreement_score":0.89962137,"about_ca_system_score_codex":0.00004994645,"about_ca_system_score_gemma":0.0003139779,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4248269869","doi":"10.1016/s0140-6736(08)60726-6","title":"Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1350,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research; Western University","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Clinical endpoint; Dosing; Internal medicine; Intention-to-treat analysis; Randomized controlled trial; Adverse effect; Gastroenterology; Immunology; Tumor necrosis factor alpha; Adalimumab","score_opus":0.03514495136420409,"score_gpt":0.26498338303827507,"score_spread":0.22983843167407098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248269869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428946,0.0005101135,0.0000059198724,0.000121340774,0.00042351364,0.0034202232,0.00033806454,0.000042511852,0.00084882684],"genre_scores_gemma":[0.9978784,0.00016058626,0.000060875678,0.00003851871,0.00024355488,0.00019739149,0.00095639646,0.000023644501,0.0004406745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976833,0.0005808079,0.0007807677,0.0004400572,0.00010033441,0.0004147274],"domain_scores_gemma":[0.9980275,0.0008700505,0.00044090825,0.00057098205,0.000058986807,0.000031547366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057484227,0.00033400787,0.0013980683,0.00013370065,0.00023820074,0.000015086768,0.00036940473,0.00022979754,0.00006515697],"category_scores_gemma":[0.000093118666,0.00020038242,0.00015030445,0.00014204385,0.00029519177,0.00008475603,0.000087315915,0.00027724684,0.00003060422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9828577,0.0009007076,0.009517956,0.0000067548294,0.001179865,0.000012824172,0.002614718,0.000012553104,0.0015942971,0.000031244253,0.00041954545,0.00085182337],"study_design_scores_gemma":[0.9228213,0.0012803972,0.073359035,0.000096919124,0.00034391854,0.000007659906,0.000059170052,0.000001982116,0.00138406,0.000026982554,0.00040599445,0.0002125673],"about_ca_topic_score_codex":0.0004406797,"about_ca_topic_score_gemma":0.00030008456,"teacher_disagreement_score":0.06384108,"about_ca_system_score_codex":0.000041465075,"about_ca_system_score_gemma":0.000068843234,"threshold_uncertainty_score":0.8171358},"labels":[],"label_agreement":null},{"id":"W4248283463","doi":"10.1016/j.jdcr.2018.07.021","title":"Eruptive lentiginosis in resolving psoriatic plaques","year":2018,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Dermatology; Ustekinumab; Treatment modality; Population; Melasma; Lentigo; Pathology; Surgery; Melanoma; Disease","score_opus":0.01965326381742274,"score_gpt":0.2638647818157378,"score_spread":0.24421151799831506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248283463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901484,0.0028605263,0.000017568744,0.000053713185,0.0016687216,0.00022432944,0.000010861185,0.00008991382,0.0049259267],"genre_scores_gemma":[0.9977524,0.000085054635,0.00013937593,0.000053534666,0.00014392218,0.000053507956,0.000041770054,0.000017237893,0.0017131645],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861676,0.00013611655,0.00043032158,0.0004126894,0.00003854588,0.00036556835],"domain_scores_gemma":[0.9991975,0.00011118318,0.00020444201,0.00039180307,0.00006770279,0.000027374203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035477398,0.0001901802,0.00029051476,0.0001786225,0.00018332672,0.000017744587,0.000043917025,0.00021770997,0.0005171978],"category_scores_gemma":[0.0001369518,0.00016826771,0.000097948796,0.0002016364,0.00012334608,0.00011653435,0.000056239616,0.00012020043,0.0002873699],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068282365,0.0011702473,0.30563015,0.00009607901,0.0014920151,0.34496483,0.010137278,0.000003551119,0.10788374,0.00058551185,0.014574343,0.21277943],"study_design_scores_gemma":[0.0037144783,0.0009754299,0.112301886,0.00038088972,0.0006584253,0.20739888,0.0015997337,0.000010429974,0.5782027,0.0015742765,0.09194774,0.0012351151],"about_ca_topic_score_codex":0.0007547006,"about_ca_topic_score_gemma":0.0007683419,"teacher_disagreement_score":0.47031897,"about_ca_system_score_codex":0.00008959016,"about_ca_system_score_gemma":0.00006311573,"threshold_uncertainty_score":0.6861758},"labels":[],"label_agreement":null},{"id":"W4249889268","doi":"10.1016/j.jaad.2004.10.749","title":"Etanercept improves symptoms of depression in patients with moderate to severe psoriasis","year":2005,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Etanercept; Psoriasis; Depression (economics); Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.006723590018332699,"score_gpt":0.23842215804445557,"score_spread":0.23169856802612288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249889268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740684,0.00053626864,0.000019982952,0.0016731718,0.00011786044,0.00015461161,0.000017585875,0.0000044273515,0.000069226575],"genre_scores_gemma":[0.9988739,0.000058525526,0.00055571,0.00041408968,0.000020678193,0.0000035876394,0.0000017791285,0.00001299496,0.00005872984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855655,0.00032776463,0.0006374265,0.00014348816,0.00008474362,0.00025003342],"domain_scores_gemma":[0.9984164,0.00013155185,0.0012069267,0.0001397874,0.000071479815,0.000033830373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009913943,0.00016819546,0.0007355343,0.00023976593,0.0000447013,0.0000022336826,0.0004194477,0.00014336286,0.00002436226],"category_scores_gemma":[0.000040524825,0.000098727716,0.00014083201,0.00028264744,0.00027116266,0.000108469314,0.000085697815,0.00029565446,0.000008833488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064926986,0.00052814337,0.81220186,0.000023525194,0.0007225657,0.000004034573,0.0008359471,0.00053891283,0.059684332,0.00003714879,0.00096939394,0.11796144],"study_design_scores_gemma":[0.004372419,0.0004904734,0.86416364,0.000106746294,0.00021260796,0.00044365067,0.00013087508,0.000005572332,0.12872928,0.000040087096,0.0011536018,0.00015104924],"about_ca_topic_score_codex":0.000016332911,"about_ca_topic_score_gemma":0.000005067876,"teacher_disagreement_score":0.11781039,"about_ca_system_score_codex":0.00003963791,"about_ca_system_score_gemma":0.000054881843,"threshold_uncertainty_score":0.40259996},"labels":[],"label_agreement":null},{"id":"W4249995199","doi":"10.1111/bjd.19509","title":"A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":117,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Dermatrials Research; Dalhousie University; Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis; Double blinded; Randomized controlled trial; Dermatology; Plaque psoriasis; Head (geology); Physical therapy; Internal medicine; Alternative medicine; Placebo; Psoriatic arthritis; Secukinumab; Pathology","score_opus":0.031101962779269417,"score_gpt":0.2690927002085634,"score_spread":0.237990737429294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249995199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916859,0.0029757489,0.0002556892,0.0023813143,0.0006110336,0.0016176885,0.00037671713,0.000023601751,0.00007225347],"genre_scores_gemma":[0.99811965,0.00028651624,0.0009519668,0.00032168854,0.0000621168,0.000034712226,0.00017421882,0.000032623433,0.000016528222],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99577886,0.0010997977,0.002024868,0.00048121923,0.00014716764,0.00046809195],"domain_scores_gemma":[0.99747133,0.0009117014,0.00091661606,0.00021511281,0.00030003628,0.00018519774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003230731,0.00035007027,0.002623731,0.00029626006,0.00013722504,0.000042930125,0.00034754322,0.00042873345,0.000043481756],"category_scores_gemma":[0.0005213563,0.0003234338,0.0001992221,0.00034732922,0.00017709825,0.00017636931,0.00010288288,0.00052570447,0.000031306296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9697051,0.001367308,0.0035589936,0.00002430175,0.0011443313,0.00038380254,0.0030806023,0.000160422,0.00010657016,0.000019538089,0.0020406037,0.018408438],"study_design_scores_gemma":[0.9677833,0.002403043,0.023372179,0.0005491926,0.0004887262,0.0013664743,0.00024377649,0.00001589586,0.0025072696,0.000038192673,0.0008807631,0.0003512344],"about_ca_topic_score_codex":0.00051341555,"about_ca_topic_score_gemma":0.00067761604,"teacher_disagreement_score":0.019813186,"about_ca_system_score_codex":0.00005771284,"about_ca_system_score_gemma":0.00024182656,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W4250120529","doi":"10.1177/120347540500900602","title":"Safe Psoriasis Control: A New Outcome Measure for the Composite Assessment of the Efficacy and Safety of Psoriasis Treatment","year":2005,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Clinical endpoint; Safety profile; Clinical trial; Patient-reported outcome; Quality of life (healthcare); Intensive care medicine; Adverse effect; Internal medicine; Dermatology","score_opus":0.03297616383954409,"score_gpt":0.2878567824449184,"score_spread":0.2548806186053743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250120529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94657415,0.036887657,0.00060838764,0.013352766,0.0016399029,0.0006438893,0.00006554444,0.0000078155535,0.00021987606],"genre_scores_gemma":[0.99429786,0.004426403,0.00017758463,0.00023835467,0.00037088248,0.0000047616054,0.000004807777,0.000013163999,0.00046615687],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822694,0.00026332482,0.0010241594,0.0001396902,0.00013446141,0.00021144173],"domain_scores_gemma":[0.99347,0.00519846,0.00086204254,0.0002290153,0.00018169181,0.00005880494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085533236,0.00022446702,0.0010770846,0.00013000207,0.00018025604,0.0000056038257,0.00013734592,0.00013623982,0.00007053933],"category_scores_gemma":[0.0002853732,0.0001009368,0.00035241427,0.000110196605,0.0002521259,0.000043311353,0.000018880497,0.00013717281,5.135023e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009381422,0.0007067506,0.17167921,0.00010721173,0.0072034886,0.00004187831,0.0022298957,0.00015350374,0.040882982,0.000278767,0.008978677,0.7583562],"study_design_scores_gemma":[0.069625504,0.007728015,0.53796816,0.0018804569,0.021631647,0.011633595,0.002127912,0.00012312405,0.020428965,0.00030525844,0.3256965,0.0008508572],"about_ca_topic_score_codex":0.00007221178,"about_ca_topic_score_gemma":0.000040075593,"teacher_disagreement_score":0.75750536,"about_ca_system_score_codex":0.00005470372,"about_ca_system_score_gemma":0.00019567783,"threshold_uncertainty_score":0.41160834},"labels":[],"label_agreement":null},{"id":"W4251759037","doi":"10.3410/f.1126869.589028","title":"Faculty Opinions recommendation of Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis.","year":2008,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Arthritis; Association (psychology); Dermatology; Genetic association; Computational biology; Genetics; Internal medicine; Biology; Gene; Genotype; Psychology; Single-nucleotide polymorphism","score_opus":0.0196902181524763,"score_gpt":0.2701292746775789,"score_spread":0.2504390565251026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251759037","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008073036,0.013011865,0.00004408204,0.01203079,0.0021652938,0.0022558516,0.97037506,0.000023890863,0.000012443103],"genre_scores_gemma":[0.00014511085,0.023841487,0.0006790602,0.0003209127,0.00022844887,0.00034930676,0.9737387,0.000031239597,0.0006657376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958335,0.000997049,0.0016026278,0.00067949627,0.00048460608,0.00040269154],"domain_scores_gemma":[0.9915335,0.00047406327,0.0030868964,0.0011242164,0.0036868714,0.00009445114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083875336,0.00056490937,0.0012556716,0.00023103406,0.00046509833,0.000054645003,0.0008518851,0.0010891183,0.00032676815],"category_scores_gemma":[0.0041660615,0.0003369071,0.0005894995,0.00091819617,0.00037535187,0.00019110656,0.00022536427,0.00070409366,0.000031346277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007081711,0.0003826635,0.00012234005,0.0012842449,0.00072718714,2.0484637e-7,0.00017302095,6.82689e-8,0.000026362137,0.000040972103,0.9427894,0.054382768],"study_design_scores_gemma":[0.0028161653,0.00036479984,0.027611908,0.0057714432,0.00040007266,0.000058061996,0.000026040667,8.954178e-7,0.00024847017,0.000020101399,0.9623645,0.00031754686],"about_ca_topic_score_codex":0.00009371069,"about_ca_topic_score_gemma":0.000031244548,"teacher_disagreement_score":0.05406522,"about_ca_system_score_codex":0.00012943357,"about_ca_system_score_gemma":0.0004501039,"threshold_uncertainty_score":0.99990827},"labels":[],"label_agreement":null},{"id":"W4252246894","doi":"10.3410/f.1119027.576013","title":"Faculty Opinions recommendation of Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.","year":2008,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Efalizumab; Psoriatic arthritis; Psoriasis; Dermatology; Medicine; Plaque psoriasis","score_opus":0.023230558681355182,"score_gpt":0.2986652763091375,"score_spread":0.27543471762778227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252246894","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014931141,0.0013676856,0.00001474944,0.014460223,0.00067043415,0.0028465951,0.9804569,0.00002115154,0.000012945429],"genre_scores_gemma":[0.00029660668,0.00071922416,0.00043995157,0.0006799668,0.00005130043,0.0006649344,0.99659,0.00002877859,0.00052921876],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99637485,0.00059431646,0.001661222,0.00063915976,0.00034586035,0.0003846234],"domain_scores_gemma":[0.99351716,0.00021308413,0.0014225376,0.0009958766,0.0037484115,0.000102929014],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005653192,0.0005500743,0.0014480205,0.00050980115,0.00017864797,0.000024385537,0.00082537445,0.00081642024,0.00018590545],"category_scores_gemma":[0.0022475827,0.000355297,0.00045625793,0.0015410352,0.00022634701,0.00018532749,0.0001688024,0.0004261334,0.000031505147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004961092,0.0010212096,0.00010985469,0.00232773,0.00046757536,2.5416742e-7,0.00018247559,5.0650186e-7,0.0000014695078,0.000026729607,0.9863667,0.008999379],"study_design_scores_gemma":[0.0058535696,0.0008139161,0.007719089,0.008744741,0.00031158637,0.000030357665,0.000017624814,9.3165085e-7,0.00014252556,0.000007952241,0.97601664,0.00034104649],"about_ca_topic_score_codex":0.000120130084,"about_ca_topic_score_gemma":0.00004381678,"teacher_disagreement_score":0.016133115,"about_ca_system_score_codex":0.000121949866,"about_ca_system_score_gemma":0.0004196846,"threshold_uncertainty_score":0.9998899},"labels":[],"label_agreement":null},{"id":"W4252916761","doi":"10.1016/j.jval.2017.08.2678","title":"Burden of Disease for Psoriasis In Argentina, Brazil, Colombia and Mexico","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Latin Americans; Population; Epidemiology; Depression (economics); Disease; MEDLINE; Anxiety; Psychological intervention; Family medicine; Environmental health; Dermatology; Psychiatry; Internal medicine","score_opus":0.039352777556383604,"score_gpt":0.3087343521731895,"score_spread":0.2693815746168059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252916761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907352,0.0062845927,0.000011030284,0.0015378046,0.000567245,0.0005869013,0.00016734227,0.000010521332,0.000099401426],"genre_scores_gemma":[0.99815017,0.0010091693,0.00018225185,0.000053729178,0.000030441828,0.00007417808,0.000047991627,0.000011067806,0.00044101843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892014,0.00017818461,0.00032750613,0.0002452729,0.000022785409,0.00030610085],"domain_scores_gemma":[0.99920744,0.00018064462,0.000223445,0.0003231741,0.00002107886,0.000044214787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051535666,0.00011308237,0.00032714597,0.000115243165,0.00018782134,0.000010034163,0.0001612583,0.00010833484,0.000030771545],"category_scores_gemma":[0.00020652005,0.00010812198,0.000054542706,0.00004481643,0.00010414421,0.00006326648,0.000051137915,0.000068439986,0.000010688812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030489727,0.0007728058,0.87754434,0.00092567544,0.00019255125,0.000021504808,0.0031058441,0.00018701302,0.0055225473,0.00793979,0.0024556615,0.09828329],"study_design_scores_gemma":[0.008845534,0.00056796276,0.9697359,0.00034101118,0.000058932095,0.0000054829297,0.00020367256,0.00019527308,0.004185201,0.0037887297,0.011826421,0.00024586607],"about_ca_topic_score_codex":0.0050097513,"about_ca_topic_score_gemma":0.00026499687,"teacher_disagreement_score":0.09803743,"about_ca_system_score_codex":0.000046627476,"about_ca_system_score_gemma":0.00014690132,"threshold_uncertainty_score":0.7573279},"labels":[],"label_agreement":null},{"id":"W4253191276","doi":"10.1016/j.jaad.2004.10.768","title":"Integrated analysis of 50 mg twice-weekly etanercept in patients with psoriasis from three phase 3 studies","year":2005,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Etanercept; Psoriasis; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.021549939789075098,"score_gpt":0.2945817627103043,"score_spread":0.2730318229212292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253191276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99373186,0.0035587242,0.00005263461,0.0022324268,0.0001401101,0.00012138844,0.00013330202,0.000006233863,0.000023298435],"genre_scores_gemma":[0.9984589,0.0004308533,0.00076396874,0.00026708067,0.000022863389,0.0000035711298,0.000018091065,0.000012477997,0.000022190346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978412,0.0005477405,0.001034707,0.0001902686,0.000113968206,0.00027214977],"domain_scores_gemma":[0.9968892,0.00044912854,0.002282934,0.00019382364,0.00015541486,0.000029504947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015885942,0.00023914076,0.0016560582,0.00066400773,0.00005391067,0.000002319374,0.00050481263,0.00016826406,0.000090985995],"category_scores_gemma":[0.000101746315,0.00013862949,0.00037216226,0.0011174261,0.0008436533,0.00011663955,0.00007773703,0.0004329956,0.0000073014858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046205088,0.0010247773,0.9170257,0.000008974497,0.017222665,0.000006786863,0.0011139226,0.0001253212,0.014909765,0.000033705008,0.000896776,0.043011133],"study_design_scores_gemma":[0.00821225,0.00072688924,0.95748395,0.000084005835,0.0061737895,0.00006953493,0.0012343401,0.000019691272,0.023337815,0.00006729313,0.0023931153,0.00019734354],"about_ca_topic_score_codex":0.000110983165,"about_ca_topic_score_gemma":0.00014945552,"teacher_disagreement_score":0.04281379,"about_ca_system_score_codex":0.000075867894,"about_ca_system_score_gemma":0.00007004838,"threshold_uncertainty_score":0.56531465},"labels":[],"label_agreement":null},{"id":"W4253404384","doi":"10.3899/jrheum.190124","title":"Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting","year":2019,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Delphi method; Clinical trial; Dermatology; Quality of life (healthcare); Delphi; Family medicine; Physical therapy; Internal medicine; Nursing","score_opus":0.024203206002217058,"score_gpt":0.2753478142646524,"score_spread":0.25114460826243534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253404384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868789,0.0077325837,0.000010117755,0.0023299851,0.0021759644,0.00018960012,0.000021583077,0.000005694299,0.00065557234],"genre_scores_gemma":[0.99811393,0.000707983,0.00003635688,0.000050680366,0.000026055699,0.0000026987889,0.0000052505943,0.000012922206,0.0010441061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632585,0.0023629963,0.0006960154,0.00013330775,0.0001366065,0.00034519727],"domain_scores_gemma":[0.9952296,0.0029804592,0.0008421743,0.00065948465,0.0002719071,0.000016344804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037088683,0.00013733059,0.0004412452,0.00007804783,0.00032330278,0.0000070748856,0.0010132835,0.00021803059,0.00029824252],"category_scores_gemma":[0.00040041303,0.000057018813,0.00021894166,0.0002653658,0.00058621657,0.000060525872,0.0002336435,0.00065420364,0.0001658793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014494758,0.00020278824,0.9025639,0.00001604382,0.0018882967,0.000027099753,0.007797915,0.00002553687,0.023327753,0.0010647506,0.051866602,0.009769827],"study_design_scores_gemma":[0.00985975,0.0018921156,0.6524564,0.0013822714,0.0012911031,0.05381303,0.03224763,0.000007857782,0.07157453,0.011884796,0.162949,0.00064152037],"about_ca_topic_score_codex":0.001193824,"about_ca_topic_score_gemma":0.00021735471,"teacher_disagreement_score":0.2501075,"about_ca_system_score_codex":0.000027903658,"about_ca_system_score_gemma":0.00015211268,"threshold_uncertainty_score":0.32655466},"labels":[],"label_agreement":null},{"id":"W4253623967","doi":"10.3410/f.11270956.12266054","title":"Faculty Opinions recommendation of Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Positron emission tomography; Fluorodeoxyglucose; Psoriasis; Radiology; Nuclear medicine; Computed tomography; Positron Emission Tomography-Computed Tomography; Tomography; Medical physics","score_opus":0.016441071813285784,"score_gpt":0.2655236862635466,"score_spread":0.24908261445026084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253623967","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051587652,0.0027531453,0.000018945893,0.004194595,0.0006103381,0.0043474184,0.9828575,0.0000522531,0.000007030929],"genre_scores_gemma":[0.00948642,0.00022219947,0.00017460626,0.00031533805,0.000040042374,0.0005563743,0.98905295,0.000034933953,0.00011716073],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514216,0.0014011447,0.0015275512,0.0009434365,0.00056930893,0.00041642386],"domain_scores_gemma":[0.994174,0.0001031723,0.0012598046,0.001177578,0.0031032164,0.00018223499],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011529801,0.00073627045,0.001274151,0.00085776555,0.00028652587,0.00008310301,0.00089846365,0.00024659556,0.000091377944],"category_scores_gemma":[0.0007888536,0.00047943307,0.00033085456,0.0022889143,0.00016488376,0.00035951158,0.00030394748,0.000652337,0.000021952543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005603425,0.002266319,0.00115173,0.0023674236,0.0009944878,8.9474463e-7,0.0003591573,3.5581024e-7,0.000056849127,0.000010654569,0.98879313,0.0034386723],"study_design_scores_gemma":[0.007038193,0.0026157037,0.045404468,0.013508744,0.001018586,0.000077619196,0.00009692159,0.0000012841654,0.0003044176,0.000010180229,0.92919326,0.000730597],"about_ca_topic_score_codex":0.00029215816,"about_ca_topic_score_gemma":0.000026133786,"teacher_disagreement_score":0.059599828,"about_ca_system_score_codex":0.00010920441,"about_ca_system_score_gemma":0.00021775778,"threshold_uncertainty_score":0.99976575},"labels":[],"label_agreement":null},{"id":"W4253753574","doi":"10.3410/f.1161683.623265","title":"Faculty Opinions recommendation of Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking.","year":2009,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Association (psychology); Psoriasis; Medicine; Dermatology; Psychology; Psychotherapist","score_opus":0.023694543154294888,"score_gpt":0.3044646949571302,"score_spread":0.2807701518028353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253753574","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000973069,0.010384884,0.000013165006,0.12491975,0.0009356574,0.0009230687,0.86274827,0.000035094457,0.00003035865],"genre_scores_gemma":[0.000089119705,0.003074545,0.00008668253,0.0023945246,0.00021818011,0.00013624613,0.9917683,0.00002120213,0.0022112194],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962061,0.0007570699,0.0014967755,0.0006661584,0.00046257876,0.0004112882],"domain_scores_gemma":[0.994615,0.00028243448,0.0020636881,0.0008845088,0.0020351473,0.00011919036],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00119563,0.0005534858,0.001224343,0.0003049237,0.0003200013,0.00008196666,0.00082136306,0.0015096696,0.00044623966],"category_scores_gemma":[0.0026929353,0.00039459308,0.00050085585,0.0010270664,0.00020529088,0.00025214689,0.00022071239,0.0008022666,0.000056174234],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014450413,0.0002181609,0.000049744718,0.0008717508,0.00071310997,1.0304701e-7,0.00011913472,8.135323e-9,0.000008599168,0.000039155686,0.954432,0.043533754],"study_design_scores_gemma":[0.0016547737,0.0001886369,0.004696865,0.0042852727,0.0007571366,0.000015814041,0.000012428121,3.9717966e-7,0.00018010175,0.000042192332,0.9878238,0.00034262415],"about_ca_topic_score_codex":0.000116813055,"about_ca_topic_score_gemma":0.00000475932,"teacher_disagreement_score":0.12901999,"about_ca_system_score_codex":0.00017127239,"about_ca_system_score_gemma":0.00023053365,"threshold_uncertainty_score":0.9998506},"labels":[],"label_agreement":null},{"id":"W4255177016","doi":"10.1177/247553031117a00208","title":"Abstracts from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Trainees Symposium","year":2011,"lang":"en","type":"article","venue":"Psoriasis Forum","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Library science; Family medicine; Miami; Biostatistics; Psoriasis; Presentation (obstetrics); Medical education; Dermatology; Internal medicine; Surgery; Epidemiology","score_opus":0.06269170541963497,"score_gpt":0.3054488009629336,"score_spread":0.2427570955432986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255177016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981769,0.011753527,0.00017205034,0.00087027316,0.0015898662,0.0012177636,0.0006105119,0.00006114396,0.0019558426],"genre_scores_gemma":[0.9926858,0.0043594455,0.0019739382,0.000059865535,0.0001548506,0.00039745704,0.00015377319,0.00003904398,0.00017583807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977105,0.00031837326,0.0005706777,0.00057540543,0.00012827321,0.0006967326],"domain_scores_gemma":[0.99770725,0.0013451367,0.00022223529,0.0004909186,0.00016539621,0.00006904886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011665854,0.0003125089,0.00054060074,0.00016530004,0.0005401982,0.00004080729,0.0003176809,0.00033530322,0.000117918324],"category_scores_gemma":[0.00013321017,0.00023016488,0.00015260885,0.00020784223,0.00051988073,0.00016590153,0.0001461491,0.00026825527,0.000013467415],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021350777,0.001946511,0.09372899,0.00022506219,0.0037043367,0.000016155,0.012388082,9.555772e-7,0.077219896,0.042235922,0.007996264,0.75840276],"study_design_scores_gemma":[0.017039193,0.004003126,0.8128368,0.0004682773,0.0010592826,0.00006723829,0.010923641,0.000022802324,0.07291949,0.043162446,0.036521148,0.00097653456],"about_ca_topic_score_codex":0.0010556215,"about_ca_topic_score_gemma":0.00064832147,"teacher_disagreement_score":0.7574262,"about_ca_system_score_codex":0.00003226755,"about_ca_system_score_gemma":0.00006465388,"threshold_uncertainty_score":0.93858516},"labels":[],"label_agreement":null},{"id":"W4255303081","doi":"10.4161/mabs.1.3.8593","title":"Ustekinumab","year":2009,"lang":"sw","type":"review","venue":"mAbs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Psoriasis; Food and drug administration; Dermatology; Biosimilar; Plaque psoriasis; Clinical trial; Disease; Internal medicine; Pharmacology; Adalimumab","score_opus":0.03684663513344908,"score_gpt":0.28531856196487343,"score_spread":0.24847192683142436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255303081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039534504,0.97996897,0.000007025983,0.00013487804,0.0033929073,0.0008061171,0.00028590948,0.000119965676,0.014888859],"genre_scores_gemma":[0.00057699636,0.9252562,0.000038410337,0.0001749306,0.00045297886,0.00008249633,0.0016548147,0.000064452346,0.07169872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656266,0.00078982726,0.000844913,0.0008759629,0.00006850867,0.0008581076],"domain_scores_gemma":[0.9981634,0.00025570826,0.00047756222,0.0009636188,0.00007126511,0.000068420704],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025884583,0.0010013826,0.0024129928,0.000275217,0.0003487563,0.000045676974,0.00062435266,0.0018326064,0.0061530275],"category_scores_gemma":[0.000051357998,0.0007730954,0.0012020333,0.00030189217,0.00015247948,0.00006609497,0.00012573846,0.00062282744,0.027711099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060805083,0.0003721337,0.000019391557,0.001273094,0.0013127762,0.00011780836,0.00006890568,6.67967e-8,0.000047421436,0.0005909288,0.013953084,0.9821836],"study_design_scores_gemma":[0.0015933973,0.00036169548,0.00019496736,0.0031339624,0.0035474573,0.0004056498,0.000022622751,8.2438895e-8,0.000111137786,0.00010063027,0.9898117,0.00071666704],"about_ca_topic_score_codex":0.000031697287,"about_ca_topic_score_gemma":0.000023586525,"teacher_disagreement_score":0.9814669,"about_ca_system_score_codex":0.000200573,"about_ca_system_score_gemma":0.00021321417,"threshold_uncertainty_score":0.999472},"labels":[],"label_agreement":null},{"id":"W4255692432","doi":"10.3410/f.2111958.1706056","title":"Faculty Opinions recommendation of Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Etanercept; Psoriasis; Medicine; Double blind; Dermatology; Internal medicine; Alternative medicine; Physical therapy; Tumor necrosis factor alpha; Placebo; Pathology","score_opus":0.05955004724702395,"score_gpt":0.3824235153982974,"score_spread":0.32287346815127344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255692432","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010171107,0.010464787,0.000017164497,0.012758176,0.0017586425,0.0062131565,0.96865386,0.000018712792,0.000013782829],"genre_scores_gemma":[0.0001505702,0.0028364842,0.0007769233,0.00009180591,0.0001613798,0.0009307444,0.9943935,0.000024187118,0.00063437154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99571896,0.000692897,0.0023260042,0.0006234851,0.00030750752,0.000331175],"domain_scores_gemma":[0.9922211,0.0007037636,0.0030324464,0.0011840538,0.0027471583,0.00011146906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010152325,0.00056428154,0.00216488,0.0003360741,0.00019358618,0.000032387237,0.0006738118,0.0010115736,0.00032709824],"category_scores_gemma":[0.0023339551,0.00036074495,0.0008618205,0.000650581,0.00047176532,0.00015024308,0.00013920304,0.00034061316,0.000008470837],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01075688,0.0023071337,0.000006711991,0.0033233336,0.0012122723,7.581341e-8,0.0005505299,1.3988927e-7,0.000076707904,0.00010204241,0.95738643,0.024277711],"study_design_scores_gemma":[0.14512548,0.00093253626,0.00007406994,0.003316914,0.0015757236,0.000009894347,0.000074749914,0.0000029293824,0.0011918197,0.000012075335,0.8474459,0.00023788189],"about_ca_topic_score_codex":0.00016600564,"about_ca_topic_score_gemma":0.00006882462,"teacher_disagreement_score":0.1343686,"about_ca_system_score_codex":0.000061571845,"about_ca_system_score_gemma":0.0003536128,"threshold_uncertainty_score":0.9998844},"labels":[],"label_agreement":null},{"id":"W4255728492","doi":"10.1016/j.jaad.2017.04.427","title":"Early real-world effectiveness of secukinumab in the treatment of psoriasis in Canada: Retrospective analysis of patient support program data","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Secukinumab; Medicine; Psoriasis; Dermatology; Retrospective cohort study; Family medicine; Surgery; Psoriatic arthritis","score_opus":0.022819028533895065,"score_gpt":0.3102219016915647,"score_spread":0.28740287315766966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255728492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981461,0.00046438034,0.000001045171,0.00047535842,0.00015838844,0.00036635247,0.0002684021,0.0000014503981,0.000118527365],"genre_scores_gemma":[0.9991446,0.0007250403,0.00005859724,0.000017549717,0.000008077665,0.0000147966875,0.000016132655,0.000008295847,0.0000069217394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996977,0.0013040086,0.001095065,0.0002104932,0.00015219486,0.0002612607],"domain_scores_gemma":[0.99456745,0.00064690737,0.0039910665,0.0006808099,0.00009322515,0.000020529242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045028547,0.00019523341,0.0017572739,0.0004912574,0.000061185805,0.0000030592262,0.0012992239,0.00010095817,0.000012902018],"category_scores_gemma":[0.000112464375,0.00011392072,0.00032233668,0.000720533,0.00074785925,0.000094104646,0.00012988734,0.00023938988,3.0353252e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013810423,0.0008498138,0.97527105,0.000031606054,0.0038020322,0.000030606952,0.0010158952,0.000029060764,0.0033759463,0.00010169603,0.00007259442,0.014038687],"study_design_scores_gemma":[0.0019061462,0.000850412,0.9532494,0.00006340927,0.001674303,0.000090489855,0.0005264187,0.0000055141227,0.04126081,0.000060524955,0.00023306528,0.000079510275],"about_ca_topic_score_codex":0.25015435,"about_ca_topic_score_gemma":0.12726243,"teacher_disagreement_score":0.1228919,"about_ca_system_score_codex":0.00027915576,"about_ca_system_score_gemma":0.00050023245,"threshold_uncertainty_score":0.88866276},"labels":[],"label_agreement":null},{"id":"W4256649559","doi":"10.1177/12034754040080s102","title":"Pathogenesis of Psoriasis and Current Challenges","year":2004,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Psoriasis; Pathogenesis; Dermatology; Current (fluid); Immunology","score_opus":0.04012616608098008,"score_gpt":0.2610578290259241,"score_spread":0.22093166294494404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256649559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7591935,0.23848683,0.000014703592,0.001177181,0.00096533104,0.000040554496,0.0000055116707,0.0000057091006,0.00011068693],"genre_scores_gemma":[0.8561136,0.14357065,0.000040996638,0.000044986213,0.00018213002,0.0000011015327,0.000003700844,0.0000090175545,0.000033800618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998942,0.00010915052,0.00056407746,0.00013062837,0.00007680723,0.00017733169],"domain_scores_gemma":[0.9986477,0.000653634,0.0004035502,0.00010773064,0.0001293445,0.000058025245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004566824,0.00015929523,0.0007024905,0.00028087827,0.000060683018,0.0000026689443,0.000059320373,0.0001168065,0.00005409147],"category_scores_gemma":[0.00021178156,0.00010592521,0.00012173584,0.00008179408,0.0002077488,0.000053121905,0.000018638795,0.00012259312,0.0000028418356],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063289853,0.0002567738,0.0076626022,0.00020558479,0.0005966381,0.00048552992,0.0023120872,0.0000025044094,0.04124133,0.0003386898,0.0012050256,0.9450603],"study_design_scores_gemma":[0.031452112,0.012418959,0.2513618,0.0114311855,0.009673449,0.17207393,0.017826714,0.0000024025162,0.11916259,0.016742345,0.3552026,0.0026519396],"about_ca_topic_score_codex":0.000015065512,"about_ca_topic_score_gemma":0.0000062735994,"teacher_disagreement_score":0.9424084,"about_ca_system_score_codex":0.000015620899,"about_ca_system_score_gemma":0.00008429406,"threshold_uncertainty_score":0.43195048},"labels":[],"label_agreement":null},{"id":"W4280641247","doi":"","title":"Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Probity Medical Research; Health Sciences Centre; University of Toronto; Women's College Hospital; McMaster University; Dermatrials Research; University of Calgary; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Lotion; Medicine; Dermatology; Psoriasis; Clobetasol propionate; Adverse effect; Corticosteroid; Plaque psoriasis; Clinical trial; Internal medicine; Pharmacology","score_opus":0.02237332925929329,"score_gpt":0.21572693557345554,"score_spread":0.19335360631416226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280641247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902118,0.0040570158,0.00012193814,0.001000518,0.0015596393,0.0022411689,0.0004770606,0.00010825549,0.00022261163],"genre_scores_gemma":[0.9857833,0.00009933235,0.00006163187,0.00026142361,0.00004171949,0.010391648,0.00037524969,0.000022949236,0.0029627495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99876046,0.00024831048,0.00021795335,0.0003234479,0.00004270718,0.00040714288],"domain_scores_gemma":[0.9994077,0.00022142369,0.0001164161,0.00017564397,0.00004124255,0.00003757086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023604669,0.00016652359,0.00022728078,0.00012086108,0.00047013434,0.00001873488,0.00011927344,0.000096154654,0.000115219154],"category_scores_gemma":[0.00008532266,0.00015429503,0.00008709368,0.0001066153,0.00006902409,0.00008580086,0.00011195072,0.00011083052,0.00002242131],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003473129,0.00041859192,0.0091660805,0.000054024218,0.0008966646,0.000028927763,0.0007299357,0.000016502107,0.014949125,0.0011952603,0.009463728,0.959608],"study_design_scores_gemma":[0.013248482,0.00046044248,0.48526865,0.000009195518,0.0007499357,0.00062054576,0.00061401754,0.000017983124,0.08613426,0.0010308378,0.4111327,0.00071297295],"about_ca_topic_score_codex":0.000018517385,"about_ca_topic_score_gemma":0.0000128731845,"teacher_disagreement_score":0.958895,"about_ca_system_score_codex":0.000082468345,"about_ca_system_score_gemma":0.00003299543,"threshold_uncertainty_score":0.6291969},"labels":[],"label_agreement":null},{"id":"W4281254501","doi":"10.1016/j.jdermsci.2022.05.006","title":"Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis","year":2022,"lang":"en","type":"article","venue":"Journal of Dermatological Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"HaCaT; Psoriasis; Tumor necrosis factor alpha; Pharmacology; Medicine; Inflammation; In vivo; Immunology; Cancer research; In vitro; Chemistry; Biology; Biochemistry","score_opus":0.01774181621701244,"score_gpt":0.24250351788502475,"score_spread":0.22476170166801232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281254501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990625,0.006286987,0.00004427796,0.0013760903,0.0009802474,0.000083564926,0.000015523112,0.00001943036,0.00056886615],"genre_scores_gemma":[0.9984706,0.0003151732,0.00038681857,0.0006576113,0.000022014568,0.0000071660447,0.0000036221231,0.000004147193,0.0001328623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861073,0.00025629357,0.0004232956,0.00020403358,0.00016602865,0.00033959773],"domain_scores_gemma":[0.9991927,0.00020122557,0.00031938707,0.00011610166,0.00009757846,0.00007299466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068838894,0.00013464633,0.00032215548,0.00018290167,0.0007512483,0.000037789534,0.00044570345,0.000073109055,0.000608504],"category_scores_gemma":[0.00014812598,0.000093460636,0.000095238334,0.00040192512,0.0004906668,0.00025674977,0.0002908705,0.00028431276,0.000044977314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007650136,0.0021769716,0.23118441,0.0000740393,0.00068040134,0.001989367,0.004449727,0.0001868712,0.44869196,0.0075292005,0.044576474,0.25769556],"study_design_scores_gemma":[0.00899611,0.0020318716,0.46217084,0.000082508464,0.0003841244,0.06342787,0.0027093792,0.000076019925,0.24020813,0.004483486,0.21444322,0.0009864257],"about_ca_topic_score_codex":0.000004628809,"about_ca_topic_score_gemma":0.0000017948782,"teacher_disagreement_score":0.25670913,"about_ca_system_score_codex":0.0000567717,"about_ca_system_score_gemma":0.000120211815,"threshold_uncertainty_score":0.66626924},"labels":[],"label_agreement":null},{"id":"W4281382713","doi":"10.1111/bjd.21677","title":"Biomarkers of systemic treatment response in people with psoriasis: a scoping review","year":2022,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Banting and Best Diabetes Centre, University of Toronto; Canadian Institutes of Health Research; Innovative Medicines Initiative; Astellas Pharma; Novo Nordisk; National Institute for Health and Care Research; Department of Medicine, University of Toronto; Psoriasis Association; Department of Health and Social Care; European Commission; Sanofi; Kidney Foundation of Canada; Merck Canada; University of Toronto; European Federation of Pharmaceutical Industries and Associations; AstraZeneca; Eli Lilly and Company; King's College London; Gilead Sciences; Vifor Pharma; Heart and Stroke Foundation of Canada; Amgen","keywords":"Psoriasis; Medicine; Intensive care medicine; Dermatology","score_opus":0.031994865585863876,"score_gpt":0.29623763703079387,"score_spread":0.26424277144492997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281382713","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002541265,0.9951535,0.000004604295,0.00004252883,0.0007178668,0.0013446921,0.00013097694,0.000013085628,0.000051518997],"genre_scores_gemma":[0.00077353214,0.99863774,0.000051451745,0.000020742591,0.000019876228,0.0002615003,0.000117632495,0.000051257783,0.00006629602],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99251324,0.0044034985,0.0022030394,0.00035328997,0.00009752526,0.00042943313],"domain_scores_gemma":[0.99580026,0.001261641,0.0024719883,0.00032743972,0.00009211403,0.00004656032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074871624,0.00046004582,0.0049335305,0.0006686396,0.00010796437,0.000011818192,0.00045871676,0.0004213636,0.00049233524],"category_scores_gemma":[0.00022726081,0.00039112204,0.0008269672,0.0006473108,0.00012759615,0.00008564324,0.000073239215,0.0004216133,0.00002292865],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013983414,0.00041577747,0.00019366333,0.050010968,0.0034604222,0.008052425,0.00015629389,3.9661626e-7,0.000009625703,0.0000032521518,0.0005317992,0.93576705],"study_design_scores_gemma":[0.0029894125,0.0006886319,0.000045237084,0.43930846,0.0036172916,0.42835593,0.00012978225,1.4969567e-8,0.000021075339,9.5019305e-7,0.124559455,0.00028376732],"about_ca_topic_score_codex":0.00011915221,"about_ca_topic_score_gemma":0.00019663872,"teacher_disagreement_score":0.9354833,"about_ca_system_score_codex":0.0003801759,"about_ca_system_score_gemma":0.0022869857,"threshold_uncertainty_score":0.9998541},"labels":[],"label_agreement":null},{"id":"W4281618980","doi":"10.53350/pjmhs22164742","title":"Impact of Covid-19 on Mental Health and Treatment Compliance in Psoriasis Patients","year":2022,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Psoriasis; Anxiety; Medicine; Depression (economics); Mental health; Coronavirus disease 2019 (COVID-19); Psychiatry; Internal medicine; Disease; Dermatology; Infectious disease (medical specialty)","score_opus":0.04845503265054533,"score_gpt":0.3219754697540616,"score_spread":0.27352043710351626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281618980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967811,0.0011957793,0.000001190917,0.0003065058,0.00022872075,0.00040246887,0.0006201184,0.00001899779,0.0004451197],"genre_scores_gemma":[0.99801433,0.00028584618,0.000022130534,0.00023436928,0.0000038617177,0.00006431162,0.00059371156,0.0000073048504,0.000774139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990469,0.00026655442,0.00020801454,0.000229217,0.000032883185,0.00021640837],"domain_scores_gemma":[0.99961656,0.000076638964,0.00010010992,0.00014609082,0.000007367793,0.000053231128],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000090675756,0.00014200667,0.00027807362,0.00012567476,0.00021441361,0.0000023387597,0.0000688366,0.000036300415,0.0009791917],"category_scores_gemma":[0.000011656838,0.000107784144,0.00008363155,0.0001214507,0.000044685785,0.000022103868,0.00004915609,0.000051956235,0.000020877025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027614143,0.0034463017,0.853489,0.000017309561,0.00046139912,0.0000039624374,0.0049904874,0.000047126643,0.0010531235,0.0002444417,0.005275892,0.12820953],"study_design_scores_gemma":[0.037691943,0.02958707,0.89271677,0.000028335886,0.000054072905,0.000036218473,0.0024206408,0.000014368701,0.0020063282,0.00011849098,0.03484615,0.00047958945],"about_ca_topic_score_codex":0.0022704673,"about_ca_topic_score_gemma":0.00016474488,"teacher_disagreement_score":0.12772994,"about_ca_system_score_codex":0.0007521166,"about_ca_system_score_gemma":0.00017508618,"threshold_uncertainty_score":0.9999341},"labels":[],"label_agreement":null},{"id":"W4281731899","doi":"10.1007/s13555-022-00743-9","title":"Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Adverse effect; Internal medicine; Discontinuation; Psoriasis; Incidence (geometry); Mace; Psoriatic arthritis; Gastroenterology; Pediatrics; Disease; Dermatology","score_opus":0.042917860359638765,"score_gpt":0.29590337731369254,"score_spread":0.2529855169540538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281731899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355304,0.0026860647,0.000017295268,0.00007138703,0.00030239785,0.00061679684,0.0026690704,0.000015693528,0.00006823395],"genre_scores_gemma":[0.9971169,0.00066163205,0.00013563398,0.00031688402,0.000010447529,0.00006573524,0.001647797,0.000019676854,0.000025285086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641466,0.0018666204,0.00089149026,0.00049451896,0.000084523315,0.00024816568],"domain_scores_gemma":[0.99798083,0.00082401745,0.0004676182,0.00061691063,0.00007732737,0.00003328416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042645444,0.00021921012,0.0010605855,0.00013840556,0.00011772709,0.00000441136,0.0003272802,0.00023557048,0.0006732741],"category_scores_gemma":[0.00007132087,0.00016405524,0.00006892947,0.00018667988,0.00018437099,0.00010082595,0.00015359862,0.00024050454,0.0000048430843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07342228,0.0015004717,0.82010657,0.000011128836,0.001755168,0.000043253574,0.001697537,0.000059338814,0.00023327502,0.00009970344,0.0013927602,0.0996785],"study_design_scores_gemma":[0.055195108,0.0028595575,0.9308409,0.0000702055,0.00026354034,0.00006535341,0.00073317904,0.00001409785,0.0023232854,0.00017470779,0.007049749,0.00041030245],"about_ca_topic_score_codex":0.00020757955,"about_ca_topic_score_gemma":0.00011683237,"teacher_disagreement_score":0.110734336,"about_ca_system_score_codex":0.000012278285,"about_ca_system_score_gemma":0.000086392,"threshold_uncertainty_score":0.7371879},"labels":[],"label_agreement":null},{"id":"W4281820548","doi":"10.7573/dic.2021-9-3","title":"Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour","year":2022,"lang":"en","type":"review","venue":"Drugs in Context","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Presentation (obstetrics); Ethnic group; Disease; Dermatology; Quality of life (healthcare); Epidemiology; Intensive care medicine; Pathology; Surgery; Nursing","score_opus":0.02359558653875514,"score_gpt":0.25511693170589916,"score_spread":0.231521345167144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281820548","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5177868,0.48095396,3.5445734e-7,0.000028405131,0.0001810834,0.0008873149,0.000117502146,0.00000549901,0.00003908649],"genre_scores_gemma":[0.28383738,0.71510905,0.000028215485,0.000029877308,0.0000057768957,0.0004957702,0.00033931402,0.000020049798,0.00013457108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976537,0.001033228,0.00046700487,0.0005220922,0.00004042917,0.00028352725],"domain_scores_gemma":[0.9987095,0.0007730246,0.00028469542,0.00019239825,0.000020143369,0.000020242307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017074739,0.00032755267,0.0015710719,0.0006103693,0.000041970477,0.000008606294,0.00017188866,0.00035143463,0.00006204908],"category_scores_gemma":[0.00007971508,0.00026078714,0.000062522195,0.0003846405,0.00012518835,0.000060232393,0.00016552604,0.00027608353,0.000005969626],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029746257,0.00019501975,0.05552048,0.0009761718,0.00014421763,0.000015660502,0.0020558145,4.823854e-8,0.0000023016175,0.000028512071,0.000037890703,0.9407264],"study_design_scores_gemma":[0.023269217,0.0020773746,0.66454977,0.007691006,0.0012500394,0.000050797305,0.0069273324,0.0000017472798,0.00006154183,0.0003753959,0.29187918,0.0018665914],"about_ca_topic_score_codex":0.0002655359,"about_ca_topic_score_gemma":0.0010282358,"teacher_disagreement_score":0.9388598,"about_ca_system_score_codex":0.00006627851,"about_ca_system_score_gemma":0.00004505861,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W4281872990","doi":"10.51731/cjht.2022.346","title":"Bimekizumab (Bimzelx)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Plaque psoriasis; Family medicine; Psoriasis; Intensive care medicine; Dermatology; Political science; Health care","score_opus":0.024982866814554368,"score_gpt":0.24319567992768074,"score_spread":0.21821281311312637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281872990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5559705,0.41393524,0.00005648045,0.02460512,0.003950167,0.0002862096,0.00020311598,0.00020042172,0.0007927682],"genre_scores_gemma":[0.99877185,0.00027355566,0.00009831702,0.00029052419,0.0000053515537,0.000015362393,0.0000160263,0.00001155255,0.00051748246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998727,0.00020096249,0.00042271265,0.00012462336,0.000041135172,0.0004835503],"domain_scores_gemma":[0.9992771,0.000056589808,0.0003627854,0.00022213455,0.0000555193,0.00002584018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005667607,0.00012016858,0.00032267362,0.0006797737,0.0009111831,0.000010409429,0.0004955717,0.00011305819,0.0006060093],"category_scores_gemma":[0.00011956236,0.00010678389,0.00010359255,0.0003297248,0.00016529755,0.00005593685,0.000048174945,0.00047849945,0.00005335099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003348629,0.000029204273,0.002735944,0.000010148356,0.00013446844,0.0001322216,0.0003334413,0.000013114826,0.00038110465,0.0013804412,0.020992268,0.97382414],"study_design_scores_gemma":[0.001007287,0.000846418,0.003952251,0.000019947829,0.000027757938,0.001469232,0.00539527,3.400202e-7,0.0024471355,0.0018552409,0.98283875,0.00014036617],"about_ca_topic_score_codex":0.0025903026,"about_ca_topic_score_gemma":0.0010446564,"teacher_disagreement_score":0.9736838,"about_ca_system_score_codex":0.00046179342,"about_ca_system_score_gemma":0.0020511472,"threshold_uncertainty_score":0.7008175},"labels":[],"label_agreement":null},{"id":"W4281877709","doi":"10.1007/s13555-022-00746-6","title":"Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Allergan; LEO Pharma; Bausch Health; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Valeant Pharmaceuticals International; Celgene; Amgen; Pfizer","keywords":"Medicine; Psoriasis; Dermatology; Ixekizumab; Secukinumab; Scalp; Psoriatic arthritis","score_opus":0.02688408479749728,"score_gpt":0.2961091200770096,"score_spread":0.26922503527951236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281877709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005097093,0.99278665,3.5704372e-7,0.00015639202,0.00040813044,0.0011188115,0.000080999846,0.0000145168815,0.00033707093],"genre_scores_gemma":[0.0024002423,0.99668044,0.000004997765,0.00022453313,0.000010324618,0.0003593159,0.00013645936,0.000028151459,0.00015554357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967432,0.0017287931,0.00079388416,0.00039009887,0.000054717126,0.00028933422],"domain_scores_gemma":[0.99845195,0.0004423641,0.0005503883,0.00049701065,0.000040709627,0.000017607901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022242921,0.00041985698,0.0021661464,0.0002180292,0.00017321816,0.0000024791766,0.00044598238,0.0003713944,0.000637496],"category_scores_gemma":[0.00003800664,0.0002555397,0.00043604907,0.0006468277,0.00020008703,0.000028687373,0.00012342981,0.00034991797,0.000013344948],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007309597,0.000188416,0.0002615401,0.006214837,0.0007608445,0.0000054307407,0.0025080813,8.066118e-8,0.00011340319,0.0003602823,0.00021578945,0.9892982],"study_design_scores_gemma":[0.0010144494,0.00009466398,0.0001901874,0.0077149207,0.0006221338,0.00034874285,0.0004881694,4.982681e-8,0.000752279,0.00009607882,0.988424,0.00025432318],"about_ca_topic_score_codex":0.00004718112,"about_ca_topic_score_gemma":0.000014138289,"teacher_disagreement_score":0.9890439,"about_ca_system_score_codex":0.00003260964,"about_ca_system_score_gemma":0.00014515837,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W4282582089","doi":"10.3390/pharmaceutics14061211","title":"Structural and Functional Validation of a Full-Thickness Self-Assembled Skin Equivalent for Disease Modeling","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Institute of Environmental Health Sciences; National Research Foundation of Korea","keywords":"Psoriasis; Basement membrane; Skin equivalent; In vitro; Chemistry; Parakeratosis; Human skin; Cell biology; Keratinocyte; Biomedical engineering; Biophysics; Dermatology; Biology; Medicine; Biochemistry","score_opus":0.0699500105873922,"score_gpt":0.31375911594639355,"score_spread":0.24380910535900135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282582089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306756,0.0022799873,0.0030795864,0.0001212499,0.0008582152,0.0003399321,0.00019737189,0.00004011816,0.000015966587],"genre_scores_gemma":[0.9989241,0.00008290945,0.00032938606,0.00005200454,0.000042314743,0.00013805642,0.00034366417,0.000012415117,0.00007520269],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992805,0.0001279141,0.00018319489,0.00018594963,0.00005088542,0.00017151822],"domain_scores_gemma":[0.9996351,0.00009655543,0.0000826387,0.00009450596,0.00006210034,0.000029087558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019012923,0.000112648035,0.00013999305,0.000065852735,0.00031023336,0.000006352534,0.00006585547,0.00003817072,0.00021535228],"category_scores_gemma":[0.000009677243,0.000110217974,0.000074439304,0.0000704973,0.000013451239,0.00005292732,0.000088205576,0.00008859417,0.0000031082905],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045697144,0.00039140508,0.0076793465,0.00027169866,0.0010654064,0.0000039500997,0.0013066372,0.026274344,0.9402994,0.0016500358,0.00023724254,0.01625082],"study_design_scores_gemma":[0.034549825,0.0009422321,0.0075587323,0.000047797515,0.0066664387,0.00040550038,0.0017978878,0.4742331,0.44893792,0.0054112906,0.017939469,0.0015098231],"about_ca_topic_score_codex":0.0000038758762,"about_ca_topic_score_gemma":5.0938434e-7,"teacher_disagreement_score":0.4913615,"about_ca_system_score_codex":0.000048095248,"about_ca_system_score_gemma":0.000065384615,"threshold_uncertainty_score":0.44945586},"labels":[],"label_agreement":null},{"id":"W4282585183","doi":"10.1016/j.jdin.2022.05.001","title":"Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review","year":2022,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada; University of Calgary; Dermatrials Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; Bausch Health (Canada); McMaster University; SKiN Health; Hospital for Sick Children; Probity Medical Research; University of Toronto; Dalhousie University","funders":"Bausch Health","keywords":"Tazarotene; Medicine; Psoriasis; Dermatology; Lotion; Plaque psoriasis; Psoriasis Area and Severity Index; Adverse effect; Clinical trial; Randomized controlled trial; Internal medicine; Pharmacology","score_opus":0.012175190223107788,"score_gpt":0.23932162333546617,"score_spread":0.22714643311235838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282585183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872958,0.00042758937,0.000011499127,0.0045270813,0.0011874718,0.0024488422,0.0013824877,0.00006800546,0.00265121],"genre_scores_gemma":[0.9872319,0.00031993992,0.00021938939,0.00085434853,0.00004120014,0.0014522232,0.0024515912,0.000039441184,0.00738993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982407,0.00022764578,0.000362912,0.00056428276,0.00018626692,0.0004181939],"domain_scores_gemma":[0.99924433,0.000036726957,0.00017978197,0.0002774091,0.00018066895,0.0000810789],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015419666,0.0003394378,0.00045944058,0.00047550173,0.00026161328,0.000023647555,0.0002472461,0.0000638562,0.0014026677],"category_scores_gemma":[0.000017903358,0.00024447145,0.00009736652,0.00031066997,0.000040371142,0.00014979148,0.000060395916,0.00019760108,0.00016255744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022104962,0.0009499377,0.98869795,0.000021633465,0.001222406,0.000046128516,0.0005086389,0.0001195534,0.00006621492,0.00043765004,0.0013891257,0.0043302597],"study_design_scores_gemma":[0.00839177,0.0010525248,0.9713393,0.00027619657,0.0001676289,0.000008709667,0.00004933213,0.000017628165,0.00047024718,0.000016518119,0.017872581,0.0003375744],"about_ca_topic_score_codex":0.024727076,"about_ca_topic_score_gemma":0.1104934,"teacher_disagreement_score":0.08576632,"about_ca_system_score_codex":0.002083892,"about_ca_system_score_gemma":0.00023283015,"threshold_uncertainty_score":0.99951017},"labels":[],"label_agreement":null},{"id":"W4282918298","doi":"10.1358/dot.2022.58.6.3400572","title":"Bimekizumab for psoriasis","year":2022,"lang":"en","type":"article","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Secukinumab; Psoriasis; Ustekinumab; Tolerability; Adalimumab; Adverse effect; Dermatology; Immunology; Immune system; Population; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis","score_opus":0.01460619210585043,"score_gpt":0.24055590479578004,"score_spread":0.2259497126899296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282918298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842106,0.004532663,0.00007271987,0.0006333242,0.0029047655,0.00052008004,0.000884968,0.00008648548,0.0061543854],"genre_scores_gemma":[0.98905003,0.000025149442,0.00024911162,0.00008338087,0.00003802028,0.0002419412,0.00028622747,0.00001543768,0.010010702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928176,0.00009855236,0.00018612458,0.00018969645,0.00003355436,0.00021028315],"domain_scores_gemma":[0.99945295,0.0001792435,0.00010134567,0.00022259801,0.000032944652,0.000010900402],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021383252,0.000105915235,0.00021596975,0.00009287397,0.0002504033,0.0000026599857,0.00020901019,0.000062259285,0.0016412139],"category_scores_gemma":[0.000025621372,0.00009942431,0.0001739207,0.000108000866,0.000043752294,0.000029928851,0.000090453075,0.00006765816,0.000076155615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027677051,0.001249591,0.0024915235,0.00008403315,0.0018227312,0.000006441995,0.0053352285,0.000074045034,0.23848842,0.014563572,0.12641488,0.60670185],"study_design_scores_gemma":[0.0050167744,0.0006074563,0.0017546918,0.000006671706,0.00025366378,0.000018205643,0.0012801595,0.000003923407,0.27484968,0.0011558349,0.7148029,0.0002500268],"about_ca_topic_score_codex":0.000048148533,"about_ca_topic_score_gemma":0.0000023469102,"teacher_disagreement_score":0.6064518,"about_ca_system_score_codex":0.000036198602,"about_ca_system_score_gemma":0.000041432486,"threshold_uncertainty_score":0.9992714},"labels":[],"label_agreement":null},{"id":"W4282945318","doi":"10.1111/jdv.18296","title":"Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence","year":2022,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Key Research and Development Program of China; Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China","keywords":"Medicine; Psoriasis; Observational study; Metabolic syndrome; Confidence interval; Population; Internal medicine; Meta-analysis; Publication bias; Subgroup analysis; Environmental health; Dermatology; Obesity","score_opus":0.04439570488320536,"score_gpt":0.31075612483327153,"score_spread":0.26636041995006615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282945318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1505919,0.84820664,0.0000015486312,0.00018293166,0.00051223737,0.00036626848,0.000059013382,0.00000249225,0.00007697164],"genre_scores_gemma":[0.26604813,0.7338316,0.000013992206,0.000037372156,0.000025651412,0.0000109189405,0.0000053338886,0.0000140407265,0.000012982199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888429,0.008873347,0.0014934149,0.00030622943,0.00012934057,0.00035474385],"domain_scores_gemma":[0.99635684,0.0009680919,0.0023393543,0.00027279978,0.000037139358,0.000025792668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755523,0.00038504045,0.001949427,0.00037605612,0.0000943542,0.0000038299513,0.0015576469,0.00027721585,0.00004844944],"category_scores_gemma":[0.00018163079,0.00020234751,0.00037570778,0.00061792205,0.00064975506,0.00010484656,0.00035962366,0.0011944389,0.0000065580275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003652216,0.00045286075,0.676256,0.0028938,0.00077735033,0.0001062348,0.00026172464,0.0000073246806,7.758431e-7,0.0007676601,0.00017258123,0.31793845],"study_design_scores_gemma":[0.0032625205,0.00018417285,0.72521704,0.0056870864,0.0034343959,0.01209832,0.000039624556,1.0901769e-7,0.0000058500896,0.00013899124,0.24964748,0.00028442146],"about_ca_topic_score_codex":0.00000515652,"about_ca_topic_score_gemma":0.000004103614,"teacher_disagreement_score":0.317654,"about_ca_system_score_codex":0.00004166637,"about_ca_system_score_gemma":0.00014323543,"threshold_uncertainty_score":0.8251492},"labels":[],"label_agreement":null},{"id":"W4282973374","doi":"10.1016/j.jaad.2022.06.019","title":"Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review","year":2022,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Women's College Hospital; University of Toronto","funders":"Canadian Dermatology Foundation","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Dermatologic agents; Intensive care medicine","score_opus":0.03896320573970135,"score_gpt":0.3143981676912017,"score_spread":0.27543496195150036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282973374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062796976,0.9913823,0.0000016328128,0.0005001793,0.00061816117,0.000906081,0.0002844001,0.0000084067515,0.000019144658],"genre_scores_gemma":[0.0040172916,0.9954411,0.00004866123,0.00029835472,0.00003635509,0.000081443795,0.00002625916,0.00002723756,0.00002333406],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897124,0.006354846,0.003151179,0.00029069834,0.00014778171,0.00034309173],"domain_scores_gemma":[0.9880078,0.0024138568,0.009111708,0.00039666778,0.000034329634,0.000035644312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007404923,0.00048461693,0.008247847,0.00038953204,0.000065252556,0.0000025375093,0.0017112432,0.00047426662,0.00022870442],"category_scores_gemma":[0.00059050653,0.0002669996,0.0018223581,0.0008213905,0.0007908373,0.000051496267,0.00026748766,0.0012868431,0.000013548806],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078261236,0.0017123307,0.0066443034,0.7027719,0.03264124,0.00018333757,0.0010365585,0.0000013204889,0.000245023,0.00019338407,0.007044354,0.24674362],"study_design_scores_gemma":[0.0020828468,0.00063852244,0.0014395794,0.2957642,0.029711666,0.011245967,0.0005271722,3.0360906e-7,0.00022653381,0.00031941268,0.6572209,0.000822883],"about_ca_topic_score_codex":0.00003764804,"about_ca_topic_score_gemma":0.000001577666,"teacher_disagreement_score":0.6501766,"about_ca_system_score_codex":0.00012902201,"about_ca_system_score_gemma":0.00030247617,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W4283454900","doi":"10.1016/j.jdin.2022.06.018","title":"Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis","year":2022,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Université de Montréal; McGill University Health Centre; Impact; Douglas Mental Health University Institute; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Réseau Québécois de Recherche sur les Médicaments","keywords":"Medicine; Discontinuation; Acitretin; Psoriasis; Depression (economics); Anxiety; Methotrexate; Ustekinumab; Adalimumab; Pediatrics; Internal medicine; Psychiatry; Rheumatoid arthritis; Dermatology","score_opus":0.007608735013366949,"score_gpt":0.21601015240745045,"score_spread":0.2084014173940835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283454900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530613,0.002671709,0.0000028557763,0.00003377353,0.0007854324,0.00025254264,0.0008357524,0.000026859769,0.00008491359],"genre_scores_gemma":[0.99788314,0.00018649534,0.000019174413,0.000027908496,0.000007477215,0.00005253413,0.001317462,0.000011330678,0.00049450144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912494,0.00020450387,0.00022772053,0.00022121804,0.0000897775,0.00013181017],"domain_scores_gemma":[0.99944216,0.00008767552,0.00023726135,0.000088436325,0.00012224415,0.000022241464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009645265,0.00011889442,0.0001992651,0.000093765484,0.000210391,0.00001339265,0.00008545346,0.00007033457,0.00012800546],"category_scores_gemma":[0.000040001614,0.000098988865,0.000034101955,0.00008090835,0.00005852605,0.00010449962,0.0000889684,0.000107453285,0.0000015184769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024937125,0.00013147958,0.9863335,0.0000108061595,0.0005747393,0.0000014952668,0.002710211,0.000010191472,0.00038696922,0.000059463913,0.0004223328,0.009109474],"study_design_scores_gemma":[0.0033137235,0.00024742147,0.9940219,0.00007556627,0.00006664773,0.000016316799,0.0010015159,0.0000045865986,0.00049448025,0.000004784678,0.000647463,0.000105604515],"about_ca_topic_score_codex":0.00051200733,"about_ca_topic_score_gemma":0.000103732316,"teacher_disagreement_score":0.009003869,"about_ca_system_score_codex":0.000263573,"about_ca_system_score_gemma":0.00004527676,"threshold_uncertainty_score":0.4036649},"labels":[],"label_agreement":null},{"id":"W4283587753","doi":"10.1136/annrheumdis-2022-eular.1762","title":"OP0027 ASSOCIATION BETWEEN BASELINE CARDIOVASCULAR RISK AND INCIDENCE RATES OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MALIGNANCIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS RECEIVING TOFACITINIB","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Pfizer (Canada)","funders":"","keywords":"Medicine; Internal medicine; Myocardial infarction; Mace; Tofacitinib; Psoriatic arthritis; Dyslipidemia; Coronary artery disease; Cohort; Psoriasis; Arthritis; Surgery; Rheumatoid arthritis; Cardiology; Gastroenterology; Disease; Percutaneous coronary intervention; Dermatology","score_opus":0.012796983464369202,"score_gpt":0.21770257480153446,"score_spread":0.20490559133716527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283587753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496526,0.048614323,0.000009317411,0.000039850824,0.00009972617,0.00043751945,0.0011343856,0.000008924205,0.0000033623287],"genre_scores_gemma":[0.9924136,0.0073535535,0.000034033248,0.000011363744,0.00000627642,0.00006689993,0.000084118015,0.000012480877,0.00001766666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997823,0.0011016808,0.00039405245,0.00026446892,0.00020584087,0.00021093788],"domain_scores_gemma":[0.998679,0.00050840236,0.0003591182,0.00032180457,0.000100241276,0.00003147883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010525576,0.00017879705,0.0006815656,0.00010570919,0.00022470209,0.0000068196973,0.00012484865,0.00005932576,0.00003149632],"category_scores_gemma":[0.00074350735,0.00013763718,0.00023570006,0.00020421972,0.000099987396,0.00013230501,0.00018669221,0.00008753327,7.7796966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117320786,0.000102993254,0.86237395,0.00012104064,0.003400242,8.947923e-7,0.00043510547,0.00012630584,0.0000042748898,0.0000054775783,0.00002902647,0.13328336],"study_design_scores_gemma":[0.0031897388,0.00015574486,0.9933407,0.00043547514,0.0014635212,0.000002096519,0.00041046445,0.0000053081894,0.0005218579,0.00025113774,0.000077832825,0.00014616421],"about_ca_topic_score_codex":0.0005213606,"about_ca_topic_score_gemma":0.000022194163,"teacher_disagreement_score":0.1331372,"about_ca_system_score_codex":0.00002416424,"about_ca_system_score_gemma":0.000038893966,"threshold_uncertainty_score":0.56126815},"labels":[],"label_agreement":null},{"id":"W4283590895","doi":"10.1136/annrheumdis-2022-eular.1753","title":"OP0249 CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH PSORIASIS AND SPONDYLOARTHRITIS: DATA FROM THE COVID-19 PsoProtect AND GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRIES","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McMaster University","funders":"Michael Smith Health Research BC","keywords":"Medicine; Internal medicine; Psoriatic arthritis; Comorbidity; Psoriasis; Epidemiology; Rheumatology; Hydroxychloroquine; Rheumatoid arthritis; Disease; Physical therapy; Immunology; Infectious disease (medical specialty); Coronavirus disease 2019 (COVID-19)","score_opus":0.05921945049366961,"score_gpt":0.30087400094580635,"score_spread":0.24165455045213674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283590895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661544,0.009484496,0.000023740378,0.009309089,0.00016441035,0.00069861975,0.01410473,0.000050715877,0.000009827761],"genre_scores_gemma":[0.99446887,0.001388696,0.000016947639,0.0022926785,0.000004714176,0.0001846626,0.0015291916,0.000018005654,0.00009622947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976351,0.0008932331,0.00047583494,0.0005019377,0.00015346399,0.0003404147],"domain_scores_gemma":[0.9966419,0.0015739944,0.0007359001,0.00090425217,0.000050741048,0.00009322181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043288685,0.00030417347,0.0007829114,0.0000348011,0.0006206205,0.000040709983,0.00066775817,0.0000810629,0.00011474898],"category_scores_gemma":[0.0025412,0.00018024776,0.00007081613,0.0003576465,0.0006409109,0.00013115659,0.00048984244,0.0001487493,0.0000028393013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019566538,0.00057779276,0.9806966,0.00012398607,0.0024125115,0.00004955877,0.00093955745,0.00002559832,0.000017373859,0.00023910501,0.00643812,0.0065231076],"study_design_scores_gemma":[0.004725632,0.0003110359,0.9878244,0.00023202438,0.0007177176,0.00014557647,0.002003918,0.000026465292,0.00003428349,0.0014294927,0.002211339,0.00033814032],"about_ca_topic_score_codex":0.0041204337,"about_ca_topic_score_gemma":0.0033066075,"teacher_disagreement_score":0.028314505,"about_ca_system_score_codex":0.00006310119,"about_ca_system_score_gemma":0.0005490584,"threshold_uncertainty_score":0.73502904},"labels":[],"label_agreement":null},{"id":"W4283591596","doi":"10.1016/j.jaad.2022.06.1171","title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Psoriasis; Clinical trial; Internal medicine; Open label; Surgery; Randomized controlled trial; Dermatology","score_opus":0.030047973570930392,"score_gpt":0.28341841874877,"score_spread":0.2533704451778396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283591596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98060066,0.006180185,0.000024942305,0.011470426,0.0005635424,0.0005849193,0.0005305002,0.0000044763765,0.00004036762],"genre_scores_gemma":[0.99560165,0.0038493625,0.00016943921,0.00014882421,0.000112483016,0.000023153709,0.000010632753,0.000013666006,0.000070774884],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975079,0.00094365416,0.0010535524,0.0001698414,0.00010313577,0.00022187289],"domain_scores_gemma":[0.99270326,0.0043325564,0.0026333798,0.00026334208,0.000046933408,0.00002052825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041202916,0.00017298298,0.000938813,0.00008752524,0.00030343686,0.0000030824672,0.00065966597,0.00010491197,0.00002902641],"category_scores_gemma":[0.00021314884,0.000090486385,0.00045092136,0.00019874546,0.00081167347,0.000034643017,0.00013415879,0.00030001075,9.497291e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72150385,0.0049986797,0.011645959,0.000045809185,0.01659208,0.000008989125,0.013169872,0.00055950665,0.08025638,0.0021394773,0.007759282,0.14132014],"study_design_scores_gemma":[0.28135425,0.01611558,0.20756966,0.00018305484,0.00825545,0.0013969415,0.012183495,0.000032051117,0.27053934,0.0015187949,0.20029603,0.000555366],"about_ca_topic_score_codex":0.00021768303,"about_ca_topic_score_gemma":0.0000066734283,"teacher_disagreement_score":0.44014958,"about_ca_system_score_codex":0.00005284518,"about_ca_system_score_gemma":0.000112301546,"threshold_uncertainty_score":0.36899278},"labels":[],"label_agreement":null},{"id":"W4283687598","doi":"10.1136/annrheumdis-2022-eular.1318","title":"AB0887 Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; Memorial University of Newfoundland; University of Glasgow; Janssen Scientific Affairs; Drexel University; Brigham and Women's Hospital; University of Rochester; Medical Center, University of Rochester; University of Pennsylvania; College of Medicine, Drexel University; University of Washington; York University","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Clinical endpoint; Population; Clinical trial; Oncology; Arthritis","score_opus":0.02649186919727261,"score_gpt":0.28875431326061024,"score_spread":0.26226244406333765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283687598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895292,0.0006069271,0.000032175474,0.00031861686,0.00029072788,0.008900805,0.00029394607,0.000025154575,0.0000024276446],"genre_scores_gemma":[0.99704355,0.00001257739,0.00002054406,0.00014078866,0.000004755351,0.0026753496,0.00004275241,0.000028464161,0.000031199317],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99192274,0.0062231976,0.00093786273,0.00032948918,0.00022255101,0.00036417722],"domain_scores_gemma":[0.9956387,0.003082207,0.0006393,0.00046880075,0.00009909431,0.000071849936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020108395,0.00033912068,0.0012754177,0.0003317741,0.00034027683,0.000036655503,0.00038095057,0.000031109408,0.00007992645],"category_scores_gemma":[0.0017756,0.00018872727,0.00035251252,0.00049060414,0.00016007993,0.00012269695,0.00027079595,0.000148592,0.000011846406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9655303,0.0024619251,0.005130796,0.00007391546,0.0013758686,0.0000060016405,0.007899587,0.000749517,0.0011996998,0.0000028172497,0.00007783833,0.015491736],"study_design_scores_gemma":[0.9493556,0.0060841646,0.010582937,0.001255071,0.0010125391,0.0000029102087,0.0013604894,0.00006817437,0.02996046,0.000036417317,0.000004372927,0.00027684038],"about_ca_topic_score_codex":0.00035648097,"about_ca_topic_score_gemma":0.000068067806,"teacher_disagreement_score":0.02876076,"about_ca_system_score_codex":0.000059728503,"about_ca_system_score_gemma":0.00008985882,"threshold_uncertainty_score":0.7696074},"labels":[],"label_agreement":null},{"id":"W4283687873","doi":"10.1136/annrheumdis-2022-eular.1158","title":"POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Memorial University of Newfoundland","funders":"Glenmark Pharmaceuticals; Celgene; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Univariate analysis; Arthritis; Multivariate analysis; Pathology; Alternative medicine","score_opus":0.015774657567564247,"score_gpt":0.24040266920247863,"score_spread":0.2246280116349144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283687873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954797,0.0032931499,0.0000032454323,0.00015825186,0.00020064574,0.00034820155,0.00049393065,0.000013394667,0.000009497092],"genre_scores_gemma":[0.99946207,0.00015827983,0.000023515151,0.00008679547,0.0000026529258,0.000072360024,0.00005716704,0.000015668076,0.00012150446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996614,0.0023557388,0.00049295154,0.00018144099,0.00011852114,0.00023734214],"domain_scores_gemma":[0.9980515,0.001029652,0.0003927304,0.00043116158,0.00007331753,0.000021614487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011341356,0.00015476688,0.00041601664,0.00013898505,0.00015019,0.000004134919,0.00031592324,0.00003768103,0.00042463362],"category_scores_gemma":[0.0011598119,0.0001085662,0.00013590412,0.00028425545,0.00010405081,0.00006449045,0.00013568003,0.00007274094,0.000006579622],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009775296,0.0022047474,0.52001095,0.00014817396,0.00040545364,0.0000059788154,0.0009805515,0.00016493502,0.00013793218,0.000018306582,0.0013874233,0.46476027],"study_design_scores_gemma":[0.003212581,0.0010080532,0.99212706,0.0006325577,0.00010402767,0.0000028627906,0.0003380338,0.000026992799,0.002089755,0.0001952026,0.00011122933,0.00015161606],"about_ca_topic_score_codex":0.00008956455,"about_ca_topic_score_gemma":0.000033600496,"teacher_disagreement_score":0.47211614,"about_ca_system_score_codex":0.000020002006,"about_ca_system_score_gemma":0.0001057656,"threshold_uncertainty_score":0.464944},"labels":[],"label_agreement":null},{"id":"W4283689520","doi":"10.1002/jvc2.42","title":"Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)","year":2022,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Dermatology Life Quality Index; Secukinumab; Medicine; Quality of life (healthcare); Psoriasis; Psoriasis Area and Severity Index; Family member; Dermatology; Family medicine; Physical therapy","score_opus":0.11054191353214776,"score_gpt":0.4128400528710501,"score_spread":0.3022981393389023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283689520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970133,0.003923257,0.00003939797,0.0015548912,0.0008195866,0.002033365,0.0007717591,0.000031282198,0.001125126],"genre_scores_gemma":[0.9974384,0.00036820796,0.00033606094,0.0011619565,0.000040023577,0.0003208239,0.00018136112,0.00002961835,0.00012356087],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9826445,0.012681886,0.00312697,0.0008515796,0.0003164062,0.000378688],"domain_scores_gemma":[0.9590673,0.035744216,0.003638569,0.0010825043,0.00036879117,0.00009862905],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008458131,0.00037341056,0.002001734,0.00009643025,0.0003463016,0.000023704539,0.0009118739,0.0003943044,0.00006363497],"category_scores_gemma":[0.015926603,0.00025721348,0.00022463615,0.00044701673,0.0006108271,0.0002905245,0.00072458555,0.0009584332,0.0000059504077],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7921751,0.023912646,0.09515207,0.00017591032,0.019074699,0.000046269975,0.022481157,0.000060678824,0.023585089,0.000986676,0.0067245946,0.015625086],"study_design_scores_gemma":[0.33791727,0.004760297,0.50360876,0.00004367725,0.003523855,0.000024826164,0.13674578,0.000034515833,0.0009109425,0.00028173835,0.011403285,0.0007450733],"about_ca_topic_score_codex":0.012315549,"about_ca_topic_score_gemma":0.0009724758,"teacher_disagreement_score":0.45425785,"about_ca_system_score_codex":0.000028296006,"about_ca_system_score_gemma":0.00072266586,"threshold_uncertainty_score":0.999988},"labels":[],"label_agreement":null},{"id":"W4283690623","doi":"10.1136/annrheumdis-2022-eular.219","title":"POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Adverse effect; Internal medicine; Population; Placebo; Golimumab; Randomized controlled trial; Surgery; Arthritis; Rheumatoid arthritis; Adalimumab; Pathology; Alternative medicine","score_opus":0.0590640130460358,"score_gpt":0.33362055878706526,"score_spread":0.27455654574102945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283690623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742574,0.0034097321,0.0000074300624,0.0002957848,0.0006419461,0.0014702235,0.0066739926,0.000020365012,0.00005478729],"genre_scores_gemma":[0.99709725,0.0018697957,0.000048744252,0.00012821854,0.000014761048,0.00019785417,0.0004952043,0.000019780346,0.00012836895],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99085426,0.0063538547,0.0019133858,0.00038638033,0.00020757683,0.00028451165],"domain_scores_gemma":[0.99074197,0.006502599,0.001964143,0.0006272222,0.00012551331,0.00003853159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019211998,0.00025740755,0.0022390853,0.000095665346,0.00015574667,0.000009652466,0.000474568,0.000113694565,0.0006621751],"category_scores_gemma":[0.0072684307,0.00015257862,0.00061768753,0.0003316392,0.00043638799,0.00013377193,0.00020461892,0.00015801692,0.0000116604115],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.705588,0.00416948,0.008691193,0.000049671202,0.006099307,0.000009449219,0.008045399,0.00012567596,0.000015791717,0.00014872561,0.00258141,0.2644759],"study_design_scores_gemma":[0.41787282,0.0013767623,0.5664758,0.0017947215,0.001666642,0.000001928925,0.0053285137,0.000014278075,0.0022342906,0.0024277957,0.00033332474,0.00047311932],"about_ca_topic_score_codex":0.00049143337,"about_ca_topic_score_gemma":0.00005771877,"teacher_disagreement_score":0.5577846,"about_ca_system_score_codex":0.000029621637,"about_ca_system_score_gemma":0.00021125311,"threshold_uncertainty_score":0.8701515},"labels":[],"label_agreement":null},{"id":"W4283691218","doi":"10.1136/annrheumdis-2022-eular.1185","title":"POS1023 LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Clinical trial; Disease; Internal medicine; Dermatology","score_opus":0.07345681402659911,"score_gpt":0.3533740556729263,"score_spread":0.2799172416463272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283691218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98280054,0.013630503,0.0000030790354,0.000109612716,0.00031654537,0.0008341762,0.002290599,0.000008984918,0.000005929237],"genre_scores_gemma":[0.99662,0.0026896899,0.000023551855,0.000029078006,0.0000060948637,0.00009291524,0.00049806514,0.000018287064,0.000022315797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932858,0.003557766,0.0022965006,0.0003729773,0.00019538612,0.00029161593],"domain_scores_gemma":[0.995144,0.00306171,0.0011507494,0.00051016314,0.000078935074,0.000054449505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001646273,0.00027948106,0.0017805018,0.0004094588,0.000072108196,0.0000082817405,0.00039842617,0.00010260058,0.00049897423],"category_scores_gemma":[0.0028118615,0.00019399803,0.00037008573,0.00069412135,0.0002788352,0.00011910697,0.00019524935,0.000194648,0.0000019052422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008906535,0.0025142834,0.91403174,0.00014324381,0.0009858613,0.000005507741,0.0004962978,0.0001627491,0.00003264949,0.00002207544,0.00014557953,0.07255345],"study_design_scores_gemma":[0.011020874,0.0003771015,0.98516357,0.0014458864,0.0005592882,4.1918065e-7,0.00030717166,0.000019218025,0.00032864904,0.0005944821,0.00000436962,0.00017894128],"about_ca_topic_score_codex":0.0008895168,"about_ca_topic_score_gemma":0.0003769714,"teacher_disagreement_score":0.07237451,"about_ca_system_score_codex":0.00004118702,"about_ca_system_score_gemma":0.00020345509,"threshold_uncertainty_score":0.791101},"labels":[],"label_agreement":null},{"id":"W4283695118","doi":"10.1136/annrheumdis-2022-eular.1862","title":"POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Medac; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Placebo; Internal medicine; Apremilast; Adverse effect; Clinical trial; Pharmacology; Gastroenterology; Arthritis; Dermatology; Pathology","score_opus":0.045903781331351916,"score_gpt":0.3313386473117772,"score_spread":0.2854348659804253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96261793,0.011786512,0.000002537491,0.00030762158,0.00060841034,0.0013379004,0.02329921,0.00002415053,0.000015703026],"genre_scores_gemma":[0.9958179,0.0021785817,0.000045882844,0.00011545315,0.000020151281,0.00026614594,0.0015073003,0.000025317077,0.000023243432],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920494,0.005176617,0.0017594965,0.00048433722,0.00017448163,0.00035567224],"domain_scores_gemma":[0.99533224,0.0028479085,0.0011125322,0.00052539527,0.00010739236,0.000074503805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021995804,0.00032474758,0.001461812,0.0002748489,0.00017730435,0.000023107432,0.00033482694,0.00013604463,0.00022104396],"category_scores_gemma":[0.004691349,0.00026695558,0.00026680334,0.0006513831,0.00022880199,0.00022678159,0.00012482896,0.00019080991,0.000003518879],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4237295,0.030552147,0.00089115556,0.00013459857,0.0023386213,0.000043700013,0.0050575985,0.00010870647,0.035741616,0.00014367167,0.0109985825,0.4902601],"study_design_scores_gemma":[0.6910001,0.011985168,0.007565103,0.0014110719,0.0014321203,0.000009883482,0.0049150316,0.00009432656,0.27478543,0.0043193647,0.0014522395,0.0010301388],"about_ca_topic_score_codex":0.0017301865,"about_ca_topic_score_gemma":0.00016129532,"teacher_disagreement_score":0.48922998,"about_ca_system_score_codex":0.00005141506,"about_ca_system_score_gemma":0.00033528736,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W4283695384","doi":"10.1136/annrheumdis-2022-eular.1291","title":"POS1026 PREDICTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT WEEK 56 IN PATIENTS WITH PSORIATIC ARTHRITIS WHO RECEIVED UPADACITINIB 15 MG ONCE DAILY: POOLED ANALYSIS OF TWO PHASE 3 STUDIES","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Internal medicine; Enthesitis; Logistic regression; Golimumab; Body mass index; Post-hoc analysis; Psoriasis Area and Severity Index; Psoriasis; Arthritis; Disease; Immunology; Adalimumab","score_opus":0.030330806761450613,"score_gpt":0.295746787816304,"score_spread":0.26541598105485337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835186,0.007117264,0.000010106992,0.00018427739,0.00018342446,0.0009857639,0.007981887,0.000013214152,0.00000548092],"genre_scores_gemma":[0.99831915,0.0005733403,0.000015271302,0.00004010747,0.0000043594537,0.0003162679,0.00055900664,0.000016675422,0.00015580856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979606,0.0006079235,0.0006285471,0.0003100363,0.00020174042,0.00029109593],"domain_scores_gemma":[0.9977437,0.0006342529,0.00085832557,0.0005230537,0.00018870433,0.000051918596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002829404,0.000248099,0.0009896854,0.00026400428,0.00022149131,0.0000041604717,0.00031949175,0.000030705614,0.00016353499],"category_scores_gemma":[0.0003347911,0.0001774978,0.00052252435,0.000563337,0.00025452845,0.00010336831,0.000224548,0.00006017454,9.120319e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03772502,0.023864336,0.7587056,0.0014170579,0.061322812,0.00000477663,0.004361418,0.0037324459,0.0013545972,0.00013602631,0.0022736036,0.105102286],"study_design_scores_gemma":[0.016944624,0.0020472785,0.96427715,0.0007990577,0.008768376,1.8940757e-7,0.000678572,0.00015591587,0.0057397196,0.00027386664,0.0000344688,0.00028080403],"about_ca_topic_score_codex":0.000085900065,"about_ca_topic_score_gemma":0.000110225905,"teacher_disagreement_score":0.2055715,"about_ca_system_score_codex":0.000057578516,"about_ca_system_score_gemma":0.000102845195,"threshold_uncertainty_score":0.723815},"labels":[],"label_agreement":null},{"id":"W4283695720","doi":"10.1136/annrheumdis-2022-eular.1386","title":"POS1031 EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; McGill University","funders":"Cilag; College of Medicine, Drexel University; Memorial University of Newfoundland; University of Glasgow; Janssen Scientific Affairs; School of Medicine, Kyorin University; McGill University; Drexel University","keywords":"Medicine; Internal medicine; Psoriatic arthritis; Regimen; Ustekinumab; Arthritis; Rheumatoid arthritis","score_opus":0.03273134540151599,"score_gpt":0.31839783121207516,"score_spread":0.28566648581055915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886422,0.00873595,5.432502e-7,0.00025057892,0.0006692822,0.00087711215,0.0007798157,0.000022877026,0.00002164157],"genre_scores_gemma":[0.9960727,0.0033296035,0.000013775034,0.000033781955,0.000008900998,0.00027023535,0.0001552076,0.000019696983,0.00009607198],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99562407,0.0027838894,0.00081764814,0.00031588334,0.00014675967,0.0003117597],"domain_scores_gemma":[0.9974449,0.0012634587,0.00066364236,0.0004879495,0.00009580585,0.000044207194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057032035,0.0002392829,0.00065001217,0.00025521638,0.00023002074,0.000007661102,0.00033768738,0.000096376454,0.00024179458],"category_scores_gemma":[0.0007452425,0.0001645481,0.00048948516,0.0004477023,0.00028574656,0.00009837872,0.00017502796,0.000121607605,0.0000099970885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009265657,0.005835707,0.38693947,0.000071491886,0.0015413098,0.0000057640973,0.0017351981,0.000044506647,0.00018531196,0.000015031691,0.00094631646,0.59341425],"study_design_scores_gemma":[0.0051754443,0.002358152,0.9832877,0.0007993898,0.00025989665,0.000003346452,0.00048983324,0.000013193608,0.007024557,0.00028002725,0.00014557964,0.00016287962],"about_ca_topic_score_codex":0.00007590825,"about_ca_topic_score_gemma":0.0000124750895,"teacher_disagreement_score":0.5963482,"about_ca_system_score_codex":0.000048243986,"about_ca_system_score_gemma":0.00018118661,"threshold_uncertainty_score":0.67100763},"labels":[],"label_agreement":null},{"id":"W4283695735","doi":"10.1136/annrheumdis-2022-eular.902","title":"POS1017 GUSELKUMAB PROVIDES CONTINUED IMPROVEMENT IN KEY DOMAINS OF PSORIATIC ARTHRITIS THROUGH 2 YEARS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; McGill University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Psoriatic arthritis; Dermatology; Psoriasis; Arthritis; Key (lock); Immunology","score_opus":0.02154011137893312,"score_gpt":0.25723012773835163,"score_spread":0.2356900163594185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283695735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679525,0.011148077,0.0000019343988,0.0003589089,0.0004417815,0.00053672557,0.00052353775,0.000018389894,0.00017538536],"genre_scores_gemma":[0.99843633,0.00079444645,0.000031186977,0.00012548122,0.000006331438,0.0001663906,0.000059795857,0.000013827348,0.00036622252],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985875,0.00034735026,0.00051259465,0.00018777768,0.00010769817,0.0002570811],"domain_scores_gemma":[0.9988979,0.00021246735,0.0003960112,0.00043609051,0.00004131858,0.000016193919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022314838,0.00014892932,0.00043532287,0.00007487269,0.00012427018,0.0000067473934,0.0003893156,0.000042544412,0.00044596646],"category_scores_gemma":[0.00017944876,0.000117709584,0.00024824246,0.00019855337,0.00015386762,0.000078805024,0.00021109634,0.00007815064,0.000014333887],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018009548,0.005805337,0.025251685,0.0006619035,0.0034776705,0.000027060694,0.012664515,0.00025568312,0.01833441,0.005829667,0.017335027,0.9085561],"study_design_scores_gemma":[0.019865876,0.0030483431,0.78570104,0.001919535,0.001108195,0.00003958436,0.008236413,0.000025298581,0.13022065,0.038729478,0.01002094,0.001084624],"about_ca_topic_score_codex":0.00042898813,"about_ca_topic_score_gemma":0.00006122466,"teacher_disagreement_score":0.9074715,"about_ca_system_score_codex":0.000022567843,"about_ca_system_score_gemma":0.00010414022,"threshold_uncertainty_score":0.488302},"labels":[],"label_agreement":null},{"id":"W4283696316","doi":"10.1136/annrheumdis-2022-eular.1902","title":"POS1042 IMPACT OF RISANKIZUMAB ON IMPROVING HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND REDUCING FATIGUE AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A POOLED ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Psoriatic arthritis; Quality of life (healthcare); Minimal clinically important difference; Physical therapy; Confidence interval; Internal medicine; Randomized controlled trial; WOMAC; Dermatology Life Quality Index; Arthritis; Osteoarthritis; Disease","score_opus":0.10256875464522701,"score_gpt":0.4046384005273311,"score_spread":0.30206964588210405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283696316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919231,0.004673519,0.0000075118874,0.000079329766,0.00017214548,0.0009994418,0.0021265978,0.000012183598,0.0000061556507],"genre_scores_gemma":[0.9995286,0.00014339796,0.000014907614,0.0000100826755,0.000005521512,0.000052252533,0.00022040417,0.00001444326,0.000010375454],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99131495,0.0057141217,0.0021743304,0.0003537144,0.00019864635,0.00024426734],"domain_scores_gemma":[0.99214786,0.0024471728,0.004532662,0.0006109528,0.00019255701,0.00006877315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029994221,0.00023669435,0.0022774246,0.0003044011,0.00017480995,0.000005537122,0.00023876336,0.000066472494,0.00014064739],"category_scores_gemma":[0.004129853,0.00015342196,0.0008932846,0.00089786,0.00037778245,0.00010280332,0.00014155736,0.0001571987,2.771763e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01616946,0.008387642,0.3784552,0.000300994,0.035031285,4.243423e-7,0.0021334735,0.0018433651,0.00024666078,0.00003746985,0.00011222232,0.5572818],"study_design_scores_gemma":[0.009318895,0.002430001,0.98220694,0.0005424537,0.0034455585,3.2191176e-7,0.0003325846,0.000037682417,0.0013686211,0.00017456946,1.3024336e-7,0.00014226623],"about_ca_topic_score_codex":0.0025447372,"about_ca_topic_score_gemma":0.000045177083,"teacher_disagreement_score":0.6037517,"about_ca_system_score_codex":0.000032800268,"about_ca_system_score_gemma":0.00033989307,"threshold_uncertainty_score":0.6256366},"labels":[],"label_agreement":null},{"id":"W4283697252","doi":"10.1136/annrheumdis-2022-eular.2138","title":"POS0938 MAINTENANCE OF RESPONSE TO BIMEKIZUMAB OVER 3 YEARS OF TREATMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POST HOC ANALYSES FROM THE BE AGILE STUDY AND ITS OPEN-LABEL EXTENSION","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"UCB Pharma; Novartis Pharma; Universitair Ziekenhuis Gent; Case Western Reserve University; Universiteit Leiden; Leids Universitair Medisch Centrum; Universiteit Gent; Second Military Medical University; Universität Bielefeld; University of Alberta","keywords":"Medicine; Ankylosing spondylitis; Post-hoc analysis; Post hoc; Internal medicine; Open label; Physical therapy; Clinical trial","score_opus":0.061566235882431083,"score_gpt":0.3267831128669879,"score_spread":0.2652168769845568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283697252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973566,0.0029973437,1.674804e-7,0.00023488751,0.000058725305,0.0010620888,0.0059023895,0.0000041434105,0.0000046053005],"genre_scores_gemma":[0.99949986,0.0000820122,0.000010292438,0.00010123288,0.000001212555,0.0000756514,0.00011941206,0.0000111388335,0.00009921093],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99824136,0.0009728606,0.00030239823,0.00022648851,0.000099219345,0.00015764753],"domain_scores_gemma":[0.99843276,0.00072739774,0.00030011972,0.0004091341,0.00010853126,0.000022051481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019963684,0.00014526425,0.00041717844,0.000092895934,0.00012569978,0.000008027022,0.0003198958,0.000023253664,0.00011593634],"category_scores_gemma":[0.00025120337,0.00008342617,0.00006336318,0.00026801287,0.00008595835,0.00008487629,0.00031822507,0.000041061114,0.0000012582218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3069843,0.03586028,0.29936025,0.000100801626,0.010033736,0.00003923614,0.042398926,0.00038936682,0.034847926,0.00010849647,0.0014053778,0.26847133],"study_design_scores_gemma":[0.005812864,0.004028333,0.9817235,0.0002370183,0.00035464042,9.2703016e-7,0.0036844637,0.0000034253017,0.0039464645,0.00005804735,0.00005692547,0.000093393246],"about_ca_topic_score_codex":0.0015735979,"about_ca_topic_score_gemma":0.00010077055,"teacher_disagreement_score":0.6823633,"about_ca_system_score_codex":0.00004137781,"about_ca_system_score_gemma":0.00010292329,"threshold_uncertainty_score":0.34020203},"labels":[],"label_agreement":null},{"id":"W4283697961","doi":"10.1136/annrheumdis-2022-eular.733","title":"AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Memorial University of Newfoundland","funders":"Amgen","keywords":"Medicine; Psoriatic arthritis; Visual analogue scale; Dactylitis; Dermatology Life Quality Index; Quality of life (healthcare); Internal medicine; Physical therapy; Placebo; Psoriasis; Arthritis; Enthesitis; Disease; Dermatology; Alternative medicine","score_opus":0.023741402733442288,"score_gpt":0.27098493470840657,"score_spread":0.2472435319749643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283697961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436146,0.0035003286,7.7323483e-7,0.00020680623,0.00013231655,0.00088575797,0.00088406453,0.000007871929,0.000020617377],"genre_scores_gemma":[0.9993933,0.00022036771,0.000010814699,0.000058692185,0.0000011617377,0.00009863491,0.0001496011,0.000012674652,0.000054749573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751234,0.00089401257,0.0009867027,0.00019719645,0.00015235499,0.00025740662],"domain_scores_gemma":[0.9981904,0.00030475686,0.0010618101,0.0003518667,0.00006997503,0.00002116901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003353933,0.00014834247,0.00068721443,0.00011042897,0.00006866939,0.0000028827312,0.0002686621,0.00004314691,0.00012364866],"category_scores_gemma":[0.00042472433,0.0001136451,0.00014066865,0.00037210018,0.00015945022,0.0001360867,0.0001505346,0.0000937259,0.0000014317259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010748503,0.010583169,0.5647463,0.0014220014,0.0025949855,0.000002331186,0.012374367,0.00062173104,0.0001746288,0.0013906282,0.0004715296,0.3948698],"study_design_scores_gemma":[0.0068649314,0.0007561618,0.98700076,0.0004487688,0.000042091026,1.6641884e-7,0.0023091456,0.0000021392452,0.00082372094,0.0016235358,0.000010781354,0.00011778684],"about_ca_topic_score_codex":0.004267136,"about_ca_topic_score_gemma":0.0002114795,"teacher_disagreement_score":0.42225444,"about_ca_system_score_codex":0.000053513795,"about_ca_system_score_gemma":0.00032226194,"threshold_uncertainty_score":0.64506614},"labels":[],"label_agreement":null},{"id":"W4283699051","doi":"10.1136/annrheumdis-2022-eular.174","title":"POS1014 IMPACT OF SERUM INTERLEUKIN 22 AS A BIOMARKER FOR THE DIFFERENTIAL USE OF MOLECULAR TARGETED DRUGS FOR PSORIATIC ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hôpitaux Universitaires de Genève; Memorial University of Newfoundland; University of Oxford; Université de Genève; University of Glasgow; Janssen Scientific Affairs; University of Washington","keywords":"Medicine; Psoriatic arthritis; Cohort; Biomarker; Internal medicine; Immunology; Tumor necrosis factor alpha; Psoriasis; Oncology; TNF inhibitor; Disease; Etanercept","score_opus":0.031905624823694925,"score_gpt":0.29081742926777204,"score_spread":0.25891180444407713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283699051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98418146,0.008115704,0.00013057138,0.00028433173,0.00044196198,0.0010381129,0.0057902164,0.0000119754495,0.0000056731697],"genre_scores_gemma":[0.9989338,0.0002746464,0.00002399403,0.000052994063,0.0000055048645,0.0003190383,0.00017819833,0.000021036114,0.00019078299],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986914,0.00034020716,0.00047309828,0.00016424159,0.000083751314,0.00024730718],"domain_scores_gemma":[0.99785364,0.00106314,0.00048241927,0.00045833059,0.00011966853,0.000022797716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001804581,0.0001835806,0.000462999,0.00008600737,0.00018782669,0.0000093571125,0.00040060774,0.000049267906,0.0007988228],"category_scores_gemma":[0.00042105702,0.00010839195,0.0010044264,0.00014470416,0.00016407794,0.00005427583,0.00015929244,0.000043368476,0.000002126043],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012395741,0.0046777753,0.007734409,0.0011728184,0.029835114,0.0000027305057,0.004541881,0.0006451957,0.104833126,0.0025153956,0.037590396,0.7940554],"study_design_scores_gemma":[0.019647505,0.0062132,0.52314883,0.0014385475,0.006215892,0.000040577062,0.0031980479,0.0016155929,0.416242,0.019447211,0.0017405788,0.001052012],"about_ca_topic_score_codex":0.00023022536,"about_ca_topic_score_gemma":0.000004657876,"teacher_disagreement_score":0.7930034,"about_ca_system_score_codex":0.000015121044,"about_ca_system_score_gemma":0.00011500681,"threshold_uncertainty_score":0.8746549},"labels":[],"label_agreement":null},{"id":"W4283699516","doi":"10.1136/annrheumdis-2022-eular.1775","title":"AB0896 Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Golimumab; Meta-analysis; Oncology; Secukinumab; Ustekinumab; Adverse effect; TNF inhibitor; Randomized controlled trial; Etanercept; Adalimumab; Arthritis; Rheumatoid arthritis","score_opus":0.05196865573754977,"score_gpt":0.308142508952681,"score_spread":0.25617385321513125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283699516","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19225344,0.8053774,0.0000070024794,0.00023462347,0.00009288271,0.0014565764,0.0005459824,0.000010517359,0.000021528735],"genre_scores_gemma":[0.9840118,0.01468522,0.000019450414,0.00021099427,0.0000022268516,0.0008804045,0.0001026317,0.000008203659,0.000079038204],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.995237,0.003523853,0.00068532024,0.00024643034,0.0000967262,0.00021066147],"domain_scores_gemma":[0.99768454,0.001216941,0.0004632389,0.0005079272,0.000097645876,0.000029705501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010401903,0.00022066005,0.002567785,0.00017338825,0.00013600444,0.000011476802,0.0003238883,0.000037415026,0.00021493393],"category_scores_gemma":[0.00023210631,0.00013739926,0.00081314094,0.0013068505,0.00007333294,0.000063134314,0.00019172017,0.00008423394,0.000006804034],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014168324,0.0029859354,0.0057620695,0.22728957,0.7292504,0.000021346174,0.006697163,0.0103424415,0.000193746,0.0037605094,0.008525027,0.0037549643],"study_design_scores_gemma":[0.003870458,0.0011832481,0.12537575,0.07967951,0.7776141,0.00007531001,0.0015810698,0.00006517351,0.002892163,0.0063149063,0.0001859864,0.001162282],"about_ca_topic_score_codex":0.000033062282,"about_ca_topic_score_gemma":0.00001838495,"teacher_disagreement_score":0.7917584,"about_ca_system_score_codex":0.000012305645,"about_ca_system_score_gemma":0.000038125323,"threshold_uncertainty_score":0.5602979},"labels":[],"label_agreement":null},{"id":"W4283701030","doi":"10.1136/annrheumdis-2022-eular.2030","title":"POS1044 GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Sun Pharma; University College Dublin; Celgene; Gilead Sciences; Pfizer Canada; Sanofi; Amgen; Pfizer; University of Washington; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Placebo; Psoriatic arthritis; Visual analogue scale; Internal medicine; Physical therapy; Ankylosing spondylitis; Arthritis; Alternative medicine","score_opus":0.03881296192731053,"score_gpt":0.31647508208758685,"score_spread":0.2776621201602763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283701030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857038,0.008136887,0.000003345616,0.00045829668,0.00029394255,0.004102693,0.0012564064,0.000012284338,0.00003232148],"genre_scores_gemma":[0.99768126,0.0011414384,0.000014566874,0.00012538572,0.000005790921,0.0007703993,0.00014454081,0.000012035037,0.00010458981],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886891,0.008526183,0.0021043832,0.00028403787,0.00015453121,0.00024173866],"domain_scores_gemma":[0.9894908,0.0080487,0.0019021593,0.0003732598,0.00014502357,0.00004004389],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0074664,0.00022493556,0.0024770584,0.00011720451,0.00015364416,0.00001080479,0.00020110836,0.00005973009,0.00012076928],"category_scores_gemma":[0.010047074,0.0001251617,0.0005929374,0.00013428077,0.000362908,0.00007182571,0.00011906022,0.00010899473,0.0000014003228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56572425,0.0051976326,0.0016510012,0.00010711949,0.004621272,0.0000016511995,0.00047957548,0.00002011117,0.000050180908,0.00009935696,0.00088527345,0.42116258],"study_design_scores_gemma":[0.9771527,0.0035175546,0.013089794,0.00065656553,0.0017421156,0.0000014084421,0.0010912817,0.00006638502,0.0014029678,0.0009909455,0.00007074315,0.00021752204],"about_ca_topic_score_codex":0.000154903,"about_ca_topic_score_gemma":0.00001889585,"teacher_disagreement_score":0.42094505,"about_ca_system_score_codex":0.00001854942,"about_ca_system_score_gemma":0.00017826904,"threshold_uncertainty_score":0.99829173},"labels":[],"label_agreement":null},{"id":"W4283702633","doi":"10.1136/annrheumdis-2022-eular.1377","title":"AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Placebo; Apremilast; Internal medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Clinical trial; Gastroenterology; Dermatology; Pathology","score_opus":0.08045805314873049,"score_gpt":0.3275665331738446,"score_spread":0.2471084800251141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283702633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749526,0.010353011,0.0000065694508,0.0032281843,0.00053102407,0.0013615234,0.009442264,0.00006107222,0.000063773216],"genre_scores_gemma":[0.9964696,0.001046138,0.00005953445,0.00086901523,0.00005677668,0.00028667407,0.0009235465,0.000040244257,0.0002484684],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99414974,0.0034143417,0.0010965969,0.0006411429,0.00018359607,0.0005145665],"domain_scores_gemma":[0.9957618,0.0025734904,0.00058218435,0.00083671254,0.00012937035,0.000116431394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013899836,0.00043755342,0.0010190693,0.00015822708,0.0006773366,0.000066217435,0.0006489975,0.0001322715,0.00021486841],"category_scores_gemma":[0.0020763213,0.0002837384,0.00031944935,0.0005299098,0.00019723232,0.00020705316,0.00035356623,0.00026213526,0.000028929813],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1386429,0.027041137,0.00349516,0.00021261655,0.007865703,0.00010614989,0.03287333,0.0035078342,0.024172466,0.0015914713,0.21263558,0.5478557],"study_design_scores_gemma":[0.2507801,0.01812401,0.24741592,0.00459819,0.008481087,0.00026836066,0.02781367,0.0008783383,0.364429,0.03837896,0.03282052,0.006011858],"about_ca_topic_score_codex":0.0015414429,"about_ca_topic_score_gemma":0.0002500434,"teacher_disagreement_score":0.5418438,"about_ca_system_score_codex":0.000048804228,"about_ca_system_score_gemma":0.00024713442,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W4283711666","doi":"10.1136/annrheumdis-2022-eular.1366","title":"AB0888 Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Toronto Western Hospital; Memorial University of Newfoundland","funders":"Memorial University of Newfoundland; University of Glasgow; Janssen Scientific Affairs","keywords":"Medicine; Presenteeism; Psoriatic arthritis; Absenteeism; Placebo; Work productivity; Internal medicine; Physical therapy; Productivity; Arthritis; Alternative medicine","score_opus":0.012512518441388414,"score_gpt":0.2318985414583646,"score_spread":0.21938602301697618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283711666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710613,0.0012810006,9.982522e-7,0.00015700405,0.0001319686,0.00093605963,0.00036083386,0.000008649071,0.0000173401],"genre_scores_gemma":[0.99957895,0.00010204639,0.000010487131,0.000016884933,0.000002790126,0.00016675962,0.000040393603,0.000013006988,0.00006866036],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986289,0.00045222376,0.00028226405,0.0002683009,0.000119564254,0.0002487215],"domain_scores_gemma":[0.99905217,0.00020086847,0.0003473831,0.00033994857,0.000044806988,0.00001484198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001719377,0.00016115709,0.0004180377,0.000092588365,0.00009371631,0.000007158917,0.00019647263,0.000036741963,0.000036746704],"category_scores_gemma":[0.00021291978,0.00012207779,0.000075753196,0.00037242245,0.00018244938,0.00025770874,0.00021770992,0.00010667705,8.7093593e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004521921,0.0035991124,0.38255358,0.00020140092,0.0005671613,0.0000024716471,0.0029445924,0.000064137996,0.00018470077,0.00006666385,0.00011725444,0.605177],"study_design_scores_gemma":[0.0036804075,0.00045096784,0.989952,0.0002466553,0.000074385935,4.1561884e-7,0.0006612837,8.6907227e-7,0.003937829,0.0008471776,0.000018438981,0.00012953502],"about_ca_topic_score_codex":0.0005331045,"about_ca_topic_score_gemma":0.000116396586,"teacher_disagreement_score":0.60739845,"about_ca_system_score_codex":0.000043711,"about_ca_system_score_gemma":0.0001205762,"threshold_uncertainty_score":0.4978188},"labels":[],"label_agreement":null},{"id":"W4283713497","doi":"10.1111/jdv.18376","title":"Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>)","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"UCB Pharma; Sanofi Genzyme; LEO Pharma; Biogen; Celgene; Sanofi; Pfizer; Eli Lilly and Company","keywords":"Medicine; Secukinumab; Ustekinumab; Psoriasis; Ixekizumab; Psoriatic arthritis; Psoriasis Area and Severity Index; Observational study; Cohort; Clinical endpoint; Internal medicine; Dermatology Life Quality Index; Cohort study; Clinical trial; Physical therapy; Adalimumab; Dermatology; Disease","score_opus":0.1047750623908989,"score_gpt":0.3722308858027155,"score_spread":0.2674558234118166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283713497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946853,0.0017419875,0.00002236031,0.0015069817,0.0012944852,0.0003120025,0.00011865085,0.0000060647058,0.0003121749],"genre_scores_gemma":[0.99864286,0.00026498942,0.00027463763,0.00068875705,0.000031388798,0.000007057061,0.0000530529,0.000012285421,0.000024948928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97900665,0.018441312,0.0019159277,0.00027691363,0.00013602302,0.00022319646],"domain_scores_gemma":[0.9912633,0.005357327,0.0030459468,0.00018819259,0.00011162918,0.000033636974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003765991,0.00021897313,0.0015635487,0.00025096716,0.0001550291,0.0000025580232,0.00080139114,0.00019028553,0.000018300287],"category_scores_gemma":[0.0006867031,0.00015367664,0.00023954612,0.00016494142,0.0004818066,0.00017560515,0.0004668287,0.0008585646,0.0000017801997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095548487,0.0032480834,0.98775065,0.00002270792,0.0018595314,0.000027198837,0.001577654,0.00012843256,0.001638152,0.0005602738,0.00021682052,0.0020150186],"study_design_scores_gemma":[0.0064380295,0.00073458685,0.98673344,0.00002494588,0.00024732202,0.00045810052,0.0017958533,0.000002553998,0.00086078193,0.00040265932,0.002236569,0.000065163505],"about_ca_topic_score_codex":0.00004624626,"about_ca_topic_score_gemma":0.000008616271,"teacher_disagreement_score":0.013083985,"about_ca_system_score_codex":0.000050998056,"about_ca_system_score_gemma":0.00014171428,"threshold_uncertainty_score":0.6266751},"labels":[],"label_agreement":null},{"id":"W4283837126","doi":"10.1093/rheumatology/keac385","title":"IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3","year":2022,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Academy of Finland; Yrjö Jahnssonin Säätiö","keywords":"Proinflammatory cytokine; Cell biology; Transcription factor; Tumor necrosis factor alpha; Chemokine; NFKB1; Cancer research; Medicine; Immunology; Biology; Inflammation; Biochemistry","score_opus":0.007873888901257522,"score_gpt":0.21254731792294768,"score_spread":0.20467342902169017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283837126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811053,0.0007472758,0.000038278085,0.000033662986,0.00050245965,0.00027119467,0.0001197365,0.000022945573,0.00015391211],"genre_scores_gemma":[0.9994121,0.000055409575,0.00010037813,0.000007638815,0.000032546475,0.00007480861,0.00010244058,0.000014276012,0.00020036532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987616,0.0002945313,0.00037549814,0.00027142506,0.000089197805,0.00020773223],"domain_scores_gemma":[0.9994159,0.000115114366,0.00020475629,0.00020475357,0.000035053614,0.00002447009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024140514,0.00014885033,0.00032323424,0.00018207704,0.000094670635,0.0000027654835,0.00013877274,0.00016798069,0.00025540876],"category_scores_gemma":[0.000048546513,0.0001391765,0.000059345162,0.00013881543,0.00012172955,0.000067448746,0.00019263812,0.00019334115,0.000010434507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007050825,0.00028891186,0.016408771,0.00005934571,0.000095612704,0.000023886623,0.001235068,0.000052076517,0.9724054,0.00023004378,0.0001380413,0.008357804],"study_design_scores_gemma":[0.004395739,0.0008935482,0.11495439,0.00010155401,0.00012531763,0.00008473529,0.00092903705,0.000015777832,0.8763092,0.0004920983,0.0013829969,0.00031558357],"about_ca_topic_score_codex":0.00007882346,"about_ca_topic_score_gemma":0.000038035127,"teacher_disagreement_score":0.09854562,"about_ca_system_score_codex":0.000055483015,"about_ca_system_score_gemma":0.000066045766,"threshold_uncertainty_score":0.5675453},"labels":[],"label_agreement":null},{"id":"W4284879785","doi":"10.2196/32593","title":"A German Smartphone-Based Self-management Tool for Psoriasis: Community-Driven Development and Evaluation of Quality-of-Life Effects","year":2022,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Usability; Psoriasis; Quality of life (healthcare); Self-management; Medicine; The Internet; Dermatology Life Quality Index; Psychology; World Wide Web; Computer science; Nursing","score_opus":0.09858262510111789,"score_gpt":0.40895810921528053,"score_spread":0.31037548411416266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284879785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621594,0.0006154987,0.000120992845,0.00005990456,0.00016666864,0.002265869,0.00010288209,0.000026036283,0.00042623797],"genre_scores_gemma":[0.99491334,0.000017687471,0.0006196026,0.000025113313,0.000006563196,0.003968597,0.00035053972,0.000012653617,0.00008592762],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99340385,0.0052401195,0.000484483,0.0001686755,0.0003643279,0.00033855237],"domain_scores_gemma":[0.9971642,0.0018626127,0.00022223483,0.0003195821,0.00040419202,0.000027173981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00737111,0.00014431681,0.00035196383,0.00041582674,0.0009766585,0.000009421881,0.00027346512,0.00007869774,0.000089528294],"category_scores_gemma":[0.00013698472,0.00013222724,0.00008766393,0.0003389064,0.00013664257,0.00009306862,0.0003252642,0.0003107557,0.00001549938],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011756765,0.012031654,0.0161494,0.011289493,0.009132093,0.000003337481,0.2655028,0.0003173482,0.06172621,0.013809354,0.008175751,0.5901058],"study_design_scores_gemma":[0.058067635,0.006451665,0.53805065,0.00049247197,0.0006859429,0.0000072080047,0.027582109,0.0009862559,0.3326582,0.002019881,0.031955253,0.001042703],"about_ca_topic_score_codex":0.000034512363,"about_ca_topic_score_gemma":0.000015410535,"teacher_disagreement_score":0.5890631,"about_ca_system_score_codex":0.0002469325,"about_ca_system_score_gemma":0.00030393878,"threshold_uncertainty_score":0.75117666},"labels":[],"label_agreement":null},{"id":"W4284976524","doi":"10.2196/39399","title":"Using a Digital Approach to Improving Mental Health in Adults With Self-reported Psoriasis: An Analysis of Real-world User Data","year":2022,"lang":"en","type":"article","venue":"Iproceedings","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Mental health; Anxiety; Embarrassment; Mental distress; Psychiatry; Psoriasis; Medicine; Distress; Feeling; Clinical psychology; Psychology; Social psychology","score_opus":0.039366860893119866,"score_gpt":0.2841051667084579,"score_spread":0.24473830581533806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284976524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975012,0.00017699775,0.000056711488,0.00006712631,0.00012571091,0.00054528227,0.0008377159,0.00009289615,0.0005963543],"genre_scores_gemma":[0.9940779,0.000016760392,0.0024242841,0.000081997234,0.000021888878,0.00005793718,0.0031307405,0.0000298429,0.00015864421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981118,0.00005647076,0.0005159025,0.00077361707,0.000112707035,0.00042954262],"domain_scores_gemma":[0.999008,0.00002201595,0.00038346747,0.00046133462,0.0000625232,0.00006267031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048140087,0.00023625622,0.0005857836,0.00088297843,0.00030580186,0.00003345386,0.00041037542,0.00006130755,0.0000447513],"category_scores_gemma":[0.00001763452,0.00021481572,0.00007402619,0.0021669078,0.000038998634,0.0004828365,0.00039769485,0.00016585064,0.0000021245387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072908057,0.006532357,0.84404373,0.00028061334,0.014378516,0.000031805263,0.055658467,0.0007487496,0.030055393,0.00063042477,0.0012525629,0.039096586],"study_design_scores_gemma":[0.048952878,0.01070495,0.6828221,0.00070528185,0.019931229,0.0011416422,0.15575965,0.036979113,0.013210884,0.00006646306,0.023763757,0.005962044],"about_ca_topic_score_codex":0.004311629,"about_ca_topic_score_gemma":0.000758928,"teacher_disagreement_score":0.16122161,"about_ca_system_score_codex":0.0002832276,"about_ca_system_score_gemma":0.00018736733,"threshold_uncertainty_score":0.8759931},"labels":[],"label_agreement":null},{"id":"W4284989117","doi":"10.1016/j.jaad.2022.07.002","title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":347,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Manchester Biomedical Research Centre; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Apremilast; Placebo; Psoriasis; Double blinded; Randomized controlled trial; Plaque psoriasis; Internal medicine; Dermatology; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.03301569140574727,"score_gpt":0.30046359644093135,"score_spread":0.26744790503518406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284989117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741471,0.0031241663,0.000023234137,0.01919961,0.00085834,0.0021230872,0.00032417016,0.0000130858625,0.00018720665],"genre_scores_gemma":[0.9977323,0.000981346,0.00014472954,0.0007606777,0.00011920981,0.00012791404,0.000017876144,0.000024404279,0.00009158666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9933926,0.0039402074,0.0016539617,0.00039083237,0.00016970588,0.00045271066],"domain_scores_gemma":[0.9899014,0.0076055606,0.0021083453,0.00025343092,0.000048087182,0.00008313402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015142448,0.00037095728,0.0022162825,0.00027147593,0.00042447684,0.000021699248,0.0007061337,0.00021617784,0.000044544508],"category_scores_gemma":[0.00075145456,0.00022664705,0.00037169404,0.0003583996,0.0007495539,0.00010377258,0.0003688646,0.0011390959,0.000005195683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98748267,0.00037852282,0.00009244896,0.000004417894,0.0018813454,0.000027973927,0.0015871375,0.00036618096,0.0021985818,0.00017015067,0.0016272722,0.0041833087],"study_design_scores_gemma":[0.9872305,0.0008413755,0.0002890777,0.000043727698,0.0009847229,0.0013686516,0.0013759988,0.000047389458,0.0026560505,0.0001652624,0.004765731,0.00023152414],"about_ca_topic_score_codex":0.00018876563,"about_ca_topic_score_gemma":0.000032425545,"teacher_disagreement_score":0.023585156,"about_ca_system_score_codex":0.00008590978,"about_ca_system_score_gemma":0.0001846693,"threshold_uncertainty_score":0.9242399},"labels":[],"label_agreement":null},{"id":"W4285077251","doi":"10.1177/12034754221111111","title":"Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies","year":2022,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Lynde Centre for Dermatology; Probity Medical Research; Health Sciences Centre; McMaster University; Women's College Hospital; Dalhousie University; University of New Brunswick; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Psoriasis; Candida albicans; Disease; Immunology; Intensive care medicine; Interleukin 17; Dermatology; Inflammation; Internal medicine","score_opus":0.04173631516893615,"score_gpt":0.3021026750872646,"score_spread":0.26036635991832846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285077251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003461714,0.9946789,0.000001524769,0.0006004984,0.00073529594,0.00029586567,0.000016959551,0.000009736226,0.00019951293],"genre_scores_gemma":[0.000456284,0.9987192,0.000016328853,0.00045268677,0.00011815978,0.000016361551,0.000040762534,0.000029145873,0.00015105783],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976347,0.0007811649,0.0009488611,0.00026043487,0.000114643924,0.00026020585],"domain_scores_gemma":[0.9953092,0.0033845722,0.0010025243,0.0001809843,0.00007256628,0.00005019405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010271239,0.00036000414,0.0024221493,0.0005640808,0.00017731133,0.000011848317,0.00006927171,0.00017005765,0.00034993197],"category_scores_gemma":[0.00061738386,0.0002162482,0.00020169366,0.0003224545,0.00013312545,0.00009318669,0.000035870115,0.0007187954,0.0000032025541],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015879478,0.00024994148,0.007546177,0.004990628,0.001235613,0.0008202397,0.00012728185,1.9810876e-7,4.3543437e-7,0.0000077487775,0.014715438,0.9701475],"study_design_scores_gemma":[0.0005845812,0.0008510251,0.0007482803,0.034694735,0.00292837,0.01078247,0.000055206896,2.327875e-8,1.6331128e-7,0.000008627349,0.9491299,0.0002166211],"about_ca_topic_score_codex":0.000011423145,"about_ca_topic_score_gemma":0.000006162545,"teacher_disagreement_score":0.9699309,"about_ca_system_score_codex":0.00007751723,"about_ca_system_score_gemma":0.00018086225,"threshold_uncertainty_score":0.88183457},"labels":[],"label_agreement":null},{"id":"W4285908235","doi":"10.1016/j.jid.2022.05.080","title":"026 Bioactivity of alpha-linolenic acid on T cell adhesion in a psoriatic skin model produced by tissue-engineering","year":2022,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Psoriasis; Immunology; Chemokine; Epidermis (zoology); Immune system; Keratinocyte; Chemistry; Medicine; Biochemistry; In vitro; Anatomy","score_opus":0.016614121872239544,"score_gpt":0.22851282389805627,"score_spread":0.21189870202581673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285908235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498975,0.003440617,0.00012144516,0.00065584044,0.00045789313,0.00020684989,0.00006195256,0.000012365952,0.000053263055],"genre_scores_gemma":[0.9992246,0.000084435495,0.00041430094,0.00011260419,0.0000155439,0.000028992135,0.000024846873,0.000020785053,0.00007387114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99804807,0.00064160686,0.0006779834,0.00023265873,0.00009585487,0.00030381032],"domain_scores_gemma":[0.998733,0.00022641207,0.0007177749,0.00019472923,0.000082676925,0.000045422825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031088226,0.00023270822,0.0006742579,0.00043806163,0.000098274926,0.0000036422268,0.00027800776,0.00016700497,0.00006164708],"category_scores_gemma":[0.0001560971,0.00021001336,0.00013064862,0.00030099077,0.00014994528,0.000118170596,0.00008647042,0.00057135505,0.000015382464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000337022,0.00052409945,0.0005430379,0.000046558776,0.00017432953,0.00005907899,0.0011672218,0.0015308656,0.99298126,0.00025010025,0.001686308,0.00070012326],"study_design_scores_gemma":[0.0025549761,0.000657624,0.000993272,0.000041406183,0.00009306201,0.00033251406,0.0002056966,0.00027776402,0.9937876,0.0003841352,0.0005054741,0.00016649973],"about_ca_topic_score_codex":0.000017407594,"about_ca_topic_score_gemma":0.0000033372223,"teacher_disagreement_score":0.004234847,"about_ca_system_score_codex":0.00013977489,"about_ca_system_score_gemma":0.00019090727,"threshold_uncertainty_score":0.8564096},"labels":[],"label_agreement":null},{"id":"W4286110999","doi":"10.1080/14740338.2022.2103536","title":"Safety and tolerability of spesolimab in patients with ulcerative colitis","year":2022,"lang":"en","type":"article","venue":"Expert Opinion on Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Boehringer Ingelheim","keywords":"Medicine; Tolerability; Ulcerative colitis; Adverse effect; Intensive care medicine; Internal medicine; Gastroenterology; Disease","score_opus":0.009818968218653348,"score_gpt":0.23554349803142818,"score_spread":0.22572452981277483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286110999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342144,0.0014351379,0.000012905935,0.00056461827,0.00083401235,0.00068048766,0.00066901144,0.000032028376,0.0023503362],"genre_scores_gemma":[0.9985211,0.00039074206,0.000052900188,0.00013887676,0.000015965454,0.00006068808,0.00053019205,0.000012838905,0.00027669518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844825,0.0005680185,0.00033980235,0.00034715008,0.00007504214,0.00022175955],"domain_scores_gemma":[0.99937934,0.00018794762,0.00012251678,0.00024744959,0.000041021038,0.000021724081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002561048,0.00017589769,0.00036567196,0.00009075939,0.00024711026,0.0000032612124,0.000110563364,0.000061499064,0.0007797341],"category_scores_gemma":[0.000019958623,0.00014643792,0.000048553873,0.00015792156,0.00012404719,0.000059550064,0.0001043597,0.00016087701,0.000010943955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09987021,0.006441468,0.5878582,0.00004838502,0.00073548243,0.000009944728,0.03094836,0.00035005275,0.0005922557,0.008066001,0.0038105268,0.26126912],"study_design_scores_gemma":[0.008325857,0.00083699875,0.9210948,0.000029549397,0.000004332939,0.0000033372164,0.0008851117,0.0000034083346,0.0014942366,0.00003188625,0.06709475,0.00019576814],"about_ca_topic_score_codex":0.000174946,"about_ca_topic_score_gemma":0.00005452255,"teacher_disagreement_score":0.33323658,"about_ca_system_score_codex":0.00016417353,"about_ca_system_score_gemma":0.00005082038,"threshold_uncertainty_score":0.8537542},"labels":[],"label_agreement":null},{"id":"W4286607682","doi":"10.46747/cfp.6702e59","title":"La glucosamine et la chondroïtine sont-elles des remèdes naturels pour l’arthrose?","year":2021,"lang":"fr","type":"article","venue":"Canadian Family Physician","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"College of Family Physicians of Canada; Queen's University","funders":"","keywords":"Gynecology; Medicine; Philosophy; Humanities","score_opus":0.018358171748217668,"score_gpt":0.2445343000185682,"score_spread":0.22617612827035055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286607682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5183242,0.28009146,0.00002296345,0.0047999066,0.0028192217,0.00026625625,0.0018752556,0.00008542762,0.19171529],"genre_scores_gemma":[0.86699295,0.012026208,0.0008851726,0.032159526,0.0007947039,0.000057505582,0.0022226423,0.00016901917,0.08469226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961045,0.0013809091,0.00035952142,0.00072841725,0.000073940144,0.0013527485],"domain_scores_gemma":[0.9981741,0.000506082,0.00013677649,0.0005983694,0.00021052793,0.0003741926],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033748837,0.00060095894,0.0006719992,0.000214669,0.00051625527,0.00011877282,0.0003239005,0.0010226434,0.00017024008],"category_scores_gemma":[0.000080279206,0.000663536,0.00037261014,0.0005179513,0.000721609,0.00022730978,0.0000780189,0.0007235117,0.0014488011],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009099628,0.00067858404,0.0011051157,0.00020231093,0.0019850947,0.0031150095,0.0010205925,0.000019535333,0.22034897,0.033391707,0.065782756,0.67225933],"study_design_scores_gemma":[0.0023457892,0.000119817465,0.040878978,0.0005776105,0.0004952358,0.00014382655,0.0019259291,0.0000045821757,0.033646416,0.002365713,0.9167423,0.00075378775],"about_ca_topic_score_codex":0.012623357,"about_ca_topic_score_gemma":0.15658271,"teacher_disagreement_score":0.85095954,"about_ca_system_score_codex":0.00037942,"about_ca_system_score_gemma":0.002360789,"threshold_uncertainty_score":0.9995816},"labels":[],"label_agreement":null},{"id":"W4287219390","doi":"10.1080/09546634.2022.2095330","title":"Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis","year":2022,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"LEO Pharma","keywords":"Medicine; Betamethasone dipropionate; Calcipotriol; Plaque psoriasis; Dermatology; Betamethasone; Psoriasis; Randomized controlled trial; Surgery; Internal medicine","score_opus":0.12532798555622987,"score_gpt":0.36141883211665476,"score_spread":0.2360908465604249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287219390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843289,0.0129341185,0.00017171114,0.0004477465,0.00031214484,0.0012420636,0.000539623,0.000007913112,0.000015726913],"genre_scores_gemma":[0.99746984,0.001467615,0.00070170296,0.000008189334,0.000014299837,0.00018415283,0.000072155635,0.000011403943,0.000070638496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967072,0.00091171847,0.0018385655,0.00018559098,0.00012005823,0.00023683789],"domain_scores_gemma":[0.9915473,0.0063245436,0.0017883842,0.00020812893,0.00009653334,0.000035108045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005831233,0.00027684387,0.0023927612,0.00029145592,0.00019208834,0.000005364113,0.00017859666,0.0001637016,0.00010623668],"category_scores_gemma":[0.00019322034,0.00014145058,0.0007493566,0.00020521546,0.00013899479,0.00004924674,0.00004225377,0.00011165884,7.000134e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023234831,0.04404607,0.6190874,0.00017943826,0.019407373,0.00009341636,0.02423804,0.006760005,0.023081783,0.0022533475,0.00020061393,0.23741768],"study_design_scores_gemma":[0.08892735,0.029571882,0.5845673,0.00013864908,0.00798622,0.0004990439,0.0063930396,0.0001687361,0.27448684,0.0018223862,0.004938331,0.00050020573],"about_ca_topic_score_codex":0.00013673428,"about_ca_topic_score_gemma":0.000047616726,"teacher_disagreement_score":0.25140503,"about_ca_system_score_codex":0.00024111247,"about_ca_system_score_gemma":0.00011572139,"threshold_uncertainty_score":0.57681876},"labels":[],"label_agreement":null},{"id":"W4287911138","doi":"","title":"Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment.","year":2020,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dermatology; Ultraviolet radiation; Psoriasis; Chemistry","score_opus":0.027528197637793028,"score_gpt":0.2761547131615667,"score_spread":0.24862651552377368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287911138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96551585,0.0076232725,0.00065598695,0.017340051,0.0009905435,0.0050152335,0.0019837439,0.00045246148,0.0004228402],"genre_scores_gemma":[0.9854797,0.0003120883,0.0002977564,0.003048419,0.00007576727,0.0093801925,0.0006194379,0.000034105193,0.0007525369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984795,0.00016634226,0.00030118393,0.00042696914,0.000034088534,0.00059193076],"domain_scores_gemma":[0.9992667,0.00019859459,0.00017512054,0.00021787894,0.00006686302,0.000074845535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021872885,0.00022500593,0.00042739208,0.00017274838,0.0002697178,0.00001692731,0.00021614062,0.00026218253,0.00019728135],"category_scores_gemma":[0.00007067418,0.00020463641,0.000145863,0.00029753285,0.00015640951,0.000066431065,0.000021835926,0.00015596539,0.0000611607],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005225604,0.001405574,0.022169339,0.00021077697,0.0038762884,0.000042505253,0.0029632554,0.0000057619027,0.18214068,0.0093486,0.08853613,0.6840755],"study_design_scores_gemma":[0.0258025,0.001969539,0.2823687,0.00003939706,0.00029470064,0.00014618332,0.0025026558,0.000008047706,0.22548473,0.002949539,0.45730495,0.0011290782],"about_ca_topic_score_codex":0.000016688098,"about_ca_topic_score_gemma":0.000010373001,"teacher_disagreement_score":0.6829464,"about_ca_system_score_codex":0.00008733246,"about_ca_system_score_gemma":0.00013149877,"threshold_uncertainty_score":0.8344831},"labels":[],"label_agreement":null},{"id":"W4287981427","doi":"10.3389/fimmu.2022.953714","title":"MiR-365-3p is a negative regulator in IL-17-mediated asthmatic inflammation","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Natural Science Basic Research Program of Shaanxi Province; National Natural Science Foundation of China","keywords":"Inflammation; microRNA; Pathogenesis; Proinflammatory cytokine; Immunology; Mediator; Cytokine; House dust mite; Medicine; Interleukin 13; Interleukin; Biology; Allergy; Cell biology; Gene; Allergen; Genetics","score_opus":0.007939465462285541,"score_gpt":0.2058659748097622,"score_spread":0.19792650934747666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287981427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869258,0.007131154,0.000104752195,0.0006996035,0.0033444248,0.0006391739,0.00016973802,0.0000835682,0.00090178126],"genre_scores_gemma":[0.9930865,0.00023709949,0.0009879937,0.00024311052,0.00003197042,0.0007013157,0.0007176733,0.00003888173,0.0039554103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99735147,0.0009340132,0.0005967692,0.0004633435,0.00006327732,0.0005911227],"domain_scores_gemma":[0.9991017,0.00018327875,0.00024703008,0.0004160159,0.000034877125,0.000017102786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039421525,0.00028505598,0.0005910789,0.0008045805,0.00022607377,0.00000912345,0.00038588114,0.00034482282,0.0013572382],"category_scores_gemma":[0.00013374651,0.00030402452,0.000113180206,0.0007407212,0.00024062158,0.0001450698,0.00021023635,0.0005439338,0.00021068304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010093129,0.0023666327,0.18922128,0.00012609048,0.00486707,0.0005192583,0.05407155,0.0005471518,0.33640447,0.0027965142,0.1473641,0.25162277],"study_design_scores_gemma":[0.03558996,0.0024393287,0.51576155,0.00015606702,0.00029973584,0.00035319277,0.02453061,0.0006169636,0.093417786,0.015679156,0.30904114,0.002114485],"about_ca_topic_score_codex":0.0001866015,"about_ca_topic_score_gemma":0.000078384866,"teacher_disagreement_score":0.3265403,"about_ca_system_score_codex":0.0004894632,"about_ca_system_score_gemma":0.00012951843,"threshold_uncertainty_score":0.9999412},"labels":[],"label_agreement":null},{"id":"W4288967947","doi":"10.5539/gjhs.v14n8p51","title":"Obstructive Sleep Apnea Screening in Psoriasis Using the STOP-Bang Questionnaire: A Cross-Sectional Study","year":2022,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Obstructive sleep apnea; Body mass index; Sleep apnea; Internal medicine; Cross-sectional study; Psoriasis Area and Severity Index; Physical therapy; Pathology; Dermatology","score_opus":0.039088588304195704,"score_gpt":0.33953330338574367,"score_spread":0.30044471508154796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288967947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992083,0.0030810868,0.00069931743,0.00018745573,0.003640471,0.0002504361,0.00002548111,0.000009419507,0.000023308387],"genre_scores_gemma":[0.99941194,0.000008773973,0.0003722248,0.00010679993,0.0000760592,0.0000087917015,0.000001443059,0.0000037673426,0.00001018031],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977809,0.0005674937,0.00065906416,0.00025640405,0.00029388402,0.00044224132],"domain_scores_gemma":[0.9989433,0.000058652284,0.0006107299,0.00016129932,0.00018052,0.000045481684],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.003864809,0.00012463305,0.0002520683,0.00018910499,0.0020638015,0.00005355671,0.00059799117,0.00003739831,0.000048262216],"category_scores_gemma":[0.00010171299,0.0000921018,0.00008812836,0.0011758641,0.00036828066,0.00029122047,0.00018766864,0.00035280676,0.000003600633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025755423,0.00021445961,0.9728001,0.0000025022339,0.00005017424,0.000016856435,0.00061469746,0.0046635102,0.00038363435,0.00012178376,0.000015633452,0.020859143],"study_design_scores_gemma":[0.0014949542,0.0004706143,0.99296373,0.00001244804,0.000018166138,0.0016812603,0.0028854501,0.00008816543,0.00006118668,0.0001484163,0.00009614828,0.0000794552],"about_ca_topic_score_codex":0.0007287048,"about_ca_topic_score_gemma":0.000048253543,"teacher_disagreement_score":0.020779688,"about_ca_system_score_codex":0.0007704789,"about_ca_system_score_gemma":0.0007648918,"threshold_uncertainty_score":0.9992354},"labels":[],"label_agreement":null},{"id":"W4289594701","doi":"10.1111/jdv.18474","title":"Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance","year":2022,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Research and Development","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Logistic regression; Dermatology Life Quality Index; Odds ratio; Body mass index; Severity of illness; Confidence interval; Gastroenterology; Dermatology","score_opus":0.014595092351164303,"score_gpt":0.24012915341881164,"score_spread":0.22553406106764734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289594701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280447,0.0015198763,0.000071200746,0.0044941762,0.00031882763,0.00043360304,0.00030381224,0.0000127836065,0.00004123936],"genre_scores_gemma":[0.9979405,0.00025029245,0.0005181561,0.0011346143,0.000042530395,0.000020112602,0.00002203985,0.000023445482,0.00004834492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930128,0.005295964,0.0007521119,0.00041935436,0.00012456287,0.00039521625],"domain_scores_gemma":[0.99871194,0.0004242427,0.00043486824,0.00019794154,0.00006529107,0.00016571449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009852361,0.00035756588,0.00085980835,0.00027471897,0.0003623281,0.000012074871,0.00035611165,0.0001729867,0.000032175165],"category_scores_gemma":[0.00017826621,0.00024941826,0.00008754986,0.00028162633,0.00043086958,0.0001056396,0.0004192769,0.0004899487,0.0000024380922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019099988,0.0005313317,0.97122216,0.000027073902,0.0007147619,0.00015716591,0.0006206072,0.00034472856,0.00084674644,0.00013657908,0.0012687547,0.0050301277],"study_design_scores_gemma":[0.011672173,0.0008473542,0.97736037,0.000075309465,0.0003230572,0.0022727954,0.00012554556,0.000082983,0.00052015507,0.00017297569,0.006297354,0.00024990918],"about_ca_topic_score_codex":0.000033904744,"about_ca_topic_score_gemma":0.000033784003,"teacher_disagreement_score":0.007427816,"about_ca_system_score_codex":0.00012449386,"about_ca_system_score_gemma":0.00014590661,"threshold_uncertainty_score":0.9999958},"labels":[],"label_agreement":null},{"id":"W4289711724","doi":"10.1002/jvc2.41","title":"Depression, anxiety and adjustment disorder among patients with psoriasis receiving systemic agents: A retrospective cohort study in Quebec, Canada","year":2022,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Centre Hospitalier de l’Université de Montréal; McGill University; Université de Montréal; McGill University Health Centre","funders":"Réseau Québécois de Recherche sur les Médicaments","keywords":"Medicine; Psoriasis; Cohort; Anxiety; Depression (economics); Retrospective cohort study; Incidence (geometry); Cohort study; Physical therapy; Internal medicine; Psychiatry","score_opus":0.012436844183961668,"score_gpt":0.27726689039907987,"score_spread":0.2648300462151182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289711724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442977,0.0016666299,0.000006162864,0.00013250184,0.0015062356,0.0017624693,0.00006695485,0.000035857145,0.00039344636],"genre_scores_gemma":[0.99748975,0.00031531576,0.00003534543,0.00024308318,0.00003460897,0.00052702375,0.00012722271,0.000028434488,0.0011991998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954612,0.0023967992,0.0007475457,0.0008005892,0.00023382345,0.0003599904],"domain_scores_gemma":[0.9972665,0.0015115992,0.00055380614,0.00045474627,0.00015262712,0.00006077382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013834296,0.0002671407,0.00059130404,0.00007008485,0.00039019034,0.00001865053,0.00020462484,0.00013753591,0.00028809183],"category_scores_gemma":[0.0014923905,0.00021666252,0.00005918732,0.0002978577,0.000081455684,0.0003225565,0.00028544714,0.00069178216,0.000009517132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012791761,0.0024561293,0.97844106,0.000008562717,0.00080421794,0.0000395643,0.00053541706,0.000030038129,0.0000032437367,0.0000034113825,0.0021768464,0.014222311],"study_design_scores_gemma":[0.006195247,0.00046780074,0.98192227,0.000031013125,0.0005915777,0.000014754055,0.0046705715,0.000004057807,0.000002333017,0.0000022374963,0.005844018,0.00025414792],"about_ca_topic_score_codex":0.61177695,"about_ca_topic_score_gemma":0.7855047,"teacher_disagreement_score":0.17372775,"about_ca_system_score_codex":0.00065437896,"about_ca_system_score_gemma":0.00029476496,"threshold_uncertainty_score":0.88352406},"labels":[],"label_agreement":null},{"id":"W4289856259","doi":"10.1038/s41392-022-01059-y","title":"Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study","year":2022,"lang":"en","type":"article","venue":"Signal Transduction and Targeted Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Medicine; Umbilical cord; Mesenchymal stem cell; Peripheral blood mononuclear cell; Adverse effect; Immune system; Immunology; Transplantation; Interleukin 17; Internal medicine; Psoriasis Area and Severity Index; Biomarker; Gastroenterology; Pathology; In vitro","score_opus":0.048788719943454704,"score_gpt":0.2857586974476647,"score_spread":0.23696997750420998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289856259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282676,0.003436649,0.00025595204,0.00013756237,0.0014195609,0.0014497214,0.00027280388,0.00014221092,0.00005877341],"genre_scores_gemma":[0.9975167,0.00007063749,0.000041083335,0.00009709893,0.00013104995,0.00062082947,0.00018247639,0.000035537178,0.0013045985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812686,0.000531434,0.0003567775,0.0005354399,0.00008481933,0.0003646917],"domain_scores_gemma":[0.9995201,0.00008055465,0.00010365782,0.00019303983,0.000053637552,0.000048996084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003559982,0.0002819907,0.0003797147,0.00015551149,0.0010337565,0.00002589084,0.00015135195,0.0001218759,0.0034383945],"category_scores_gemma":[0.0000011507258,0.0002584921,0.00020587769,0.00020957831,0.00010294152,0.00008321343,0.000016450287,0.00022522939,0.000012543973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005158063,0.007988072,0.00017342888,0.000008523435,0.0008462526,0.000008014965,0.0025531533,0.000012142196,0.8520115,0.00014737553,0.00041801046,0.13067546],"study_design_scores_gemma":[0.050466966,0.044519164,0.0007407421,0.000007729232,0.00047173616,0.00010683755,0.010648237,0.000015214104,0.8134506,0.00057214353,0.07823739,0.00076325884],"about_ca_topic_score_codex":0.00003558248,"about_ca_topic_score_gemma":0.000010463743,"teacher_disagreement_score":0.1299122,"about_ca_system_score_codex":0.000050252358,"about_ca_system_score_gemma":0.000034098983,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4290546013","doi":"10.1177/12034754221117736","title":"Real World Studies of Psoriasis and Mental Illness in Newfoundland and Labrador","year":2022,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Newfoundland and Labrador Centre for Applied Health Research; Memorial University of Newfoundland","funders":"Janssen Biotech","keywords":"Psoriasis; Medicine; Depression (economics); Anxiety; Mental health; Psychiatry; Population; Mental illness; Medical record; Internal medicine; Dermatology; Environmental health","score_opus":0.028884657634886172,"score_gpt":0.2768904523419157,"score_spread":0.24800579470702955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290546013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9530409,0.044825777,2.3745253e-7,0.0010085263,0.0009168126,0.00006183778,0.000012259948,0.000003370464,0.00013026122],"genre_scores_gemma":[0.9713668,0.027870009,0.000011988125,0.00009101476,0.00007844785,0.0000030017045,0.0000070050346,0.0000072411785,0.00056449557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894893,0.00022038286,0.0004883757,0.00011876985,0.0000748389,0.0001486851],"domain_scores_gemma":[0.998447,0.0011233311,0.00029025075,0.00006184076,0.0000450087,0.00003254047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006348552,0.00012523813,0.00068967434,0.0004196654,0.00014613832,0.0000031545026,0.00004235698,0.00004033183,0.000109897526],"category_scores_gemma":[0.00009786839,0.00008879564,0.000047763693,0.00016301233,0.0002509641,0.00005025782,0.000056451394,0.00015859459,2.3407155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003170464,0.00024248198,0.7536681,0.00016528374,0.0013708111,0.0017479272,0.015614565,0.0000026665448,0.01889221,0.0001443769,0.010589329,0.19439174],"study_design_scores_gemma":[0.029361712,0.00874482,0.4930622,0.0022082261,0.003168978,0.10123855,0.1412733,0.000015906067,0.0045005917,0.0030825457,0.21160285,0.001740322],"about_ca_topic_score_codex":0.00041206088,"about_ca_topic_score_gemma":0.00047403402,"teacher_disagreement_score":0.26060596,"about_ca_system_score_codex":0.000046177305,"about_ca_system_score_gemma":0.000045068427,"threshold_uncertainty_score":0.36209813},"labels":[],"label_agreement":null},{"id":"W4290994087","doi":"10.1136/annrheumdis-2022-eular.2468","title":"POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Secukinumab; Placebo; Oncology; Arthritis; Immunology; Pathology","score_opus":0.03291885164253951,"score_gpt":0.3062609298272585,"score_spread":0.273342078184719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290994087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905597,0.0039253426,0.0000056990298,0.0015138856,0.0006439873,0.0013194919,0.0019738856,0.00003976635,0.000018248915],"genre_scores_gemma":[0.99801886,0.00023534786,0.00004853487,0.0005896136,0.00003364613,0.00059710845,0.00032567998,0.000027621543,0.00012359527],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99565303,0.0025493011,0.0007830443,0.0004111038,0.00014888305,0.0004546503],"domain_scores_gemma":[0.9984447,0.0006521792,0.0002570055,0.0005009679,0.00006818425,0.00007698324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009740264,0.00028119414,0.0006071607,0.0004691814,0.00021228666,0.000019476289,0.00040591808,0.0000830417,0.00060062367],"category_scores_gemma":[0.0011574825,0.00023051583,0.00021917764,0.0008087528,0.0001291961,0.00015882021,0.00018939178,0.00015740201,0.00002217508],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2561756,0.018902222,0.018019453,0.0001590759,0.0014028444,0.00012702386,0.0041615157,0.0001893263,0.0077880844,0.000081511724,0.026786178,0.66620713],"study_design_scores_gemma":[0.48736313,0.029568642,0.34028727,0.0038561092,0.0015162821,0.0001458764,0.0068584997,0.0004892069,0.11390516,0.0050765495,0.008008935,0.0029243268],"about_ca_topic_score_codex":0.00046990943,"about_ca_topic_score_gemma":0.0002523528,"teacher_disagreement_score":0.6632828,"about_ca_system_score_codex":0.000062918756,"about_ca_system_score_gemma":0.00025789934,"threshold_uncertainty_score":0.94001627},"labels":[],"label_agreement":null},{"id":"W4290996954","doi":"10.1136/annrheumdis-2022-eular.1070","title":"POS0082 A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Calgary","funders":"UCB Pharma; Regeneron Pharmaceuticals; Celgene; Gilead Sciences; Sanofi; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Secukinumab; Psoriasis; Dermatology; Disease","score_opus":0.047744164237551144,"score_gpt":0.28385856135729,"score_spread":0.23611439711973883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290996954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9081118,0.07641184,0.000016460675,0.0030508074,0.00043370388,0.00082994247,0.011107901,0.000022349248,0.000015207757],"genre_scores_gemma":[0.9919083,0.0065691303,0.00006858194,0.00025976732,0.000020477793,0.00032249032,0.0005858654,0.000020362508,0.00024498487],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983653,0.00037371085,0.00052046595,0.00035591156,0.00009421868,0.0002904078],"domain_scores_gemma":[0.99719125,0.0018750728,0.000404277,0.0004451778,0.000049543443,0.000034683348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002478491,0.00028639383,0.000611791,0.000044702192,0.0008749028,0.000039355575,0.0002394528,0.00003935785,0.000030130219],"category_scores_gemma":[0.00035255754,0.0001632457,0.00025459504,0.00009123662,0.00029519538,0.0001067307,0.00035127587,0.000068299654,0.0000029851512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023355335,0.011063802,0.014613388,0.00066183653,0.057870224,0.000025130586,0.09650815,0.000570129,0.012766859,0.007450501,0.038830906,0.7362837],"study_design_scores_gemma":[0.07875883,0.00652713,0.7522577,0.0030183801,0.010243677,0.00012619069,0.04803384,0.000394623,0.049570337,0.036617577,0.012332936,0.0021188082],"about_ca_topic_score_codex":0.00051167887,"about_ca_topic_score_gemma":0.00007557017,"teacher_disagreement_score":0.7376443,"about_ca_system_score_codex":0.000037525213,"about_ca_system_score_gemma":0.00006757619,"threshold_uncertainty_score":0.6729134},"labels":[],"label_agreement":null},{"id":"W4291116994","doi":"10.1016/j.jcmgh.2022.08.001","title":"Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis","year":2022,"lang":"en","type":"article","venue":"Cellular and Molecular Gastroenterology and Hepatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Fatty liver; Alcoholic liver disease; Disease; Fibrosis; Medicine; Liver fibrosis; Receptor; Internal medicine; Cirrhosis","score_opus":0.0054671744771272405,"score_gpt":0.18784262720451028,"score_spread":0.18237545272738304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291116994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902458,0.00839509,0.00024195071,0.00012413153,0.00024354308,0.00046977968,0.00020274326,0.000027036795,0.000049887753],"genre_scores_gemma":[0.9987862,0.0003387712,0.00008718815,0.00018346733,0.00000804497,0.00021717517,0.0002471588,0.000026112015,0.000105882405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974325,0.0009361808,0.0004275668,0.00061655,0.00005699385,0.0005302489],"domain_scores_gemma":[0.99938875,0.00006401156,0.00018501894,0.000256026,0.000031625237,0.00007457827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003012441,0.000299016,0.0006248516,0.00028793165,0.0002597703,0.000005607233,0.00017854964,0.00025104624,0.00038361846],"category_scores_gemma":[0.000016119882,0.000313953,0.00014296721,0.00011289552,0.00034786,0.00004428494,0.00033711985,0.00042005937,0.00001211015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015188723,0.00026931727,0.33851275,0.000032166805,0.00036060222,0.0001995645,0.00075910764,0.000029702733,0.6557987,0.0002625624,0.000014061374,0.0022426194],"study_design_scores_gemma":[0.013451959,0.0040725796,0.09446816,0.000055635886,0.0009626908,0.0008810894,0.0015718032,0.00057342515,0.87989867,0.0019164222,0.0013680791,0.0007794848],"about_ca_topic_score_codex":0.00025307178,"about_ca_topic_score_gemma":0.00004335529,"teacher_disagreement_score":0.24404459,"about_ca_system_score_codex":0.000046131867,"about_ca_system_score_gemma":0.00003785137,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W4291186573","doi":"10.1136/annrheumdis-2022-eular.4363","title":"OP0031 SEROLOGICAL COLLAGEN BIOMARKERS CAN DIFFERENTIATE PATIENTS WITH PSORIASIS FROM PSORIATIC ARTHRITIS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Serology; Dermatology; Arthritis; Immunology; Pathology; Antibody","score_opus":0.018792380497803518,"score_gpt":0.2218333245832943,"score_spread":0.20304094408549078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291186573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903885,0.0043686065,0.0000031291459,0.00046353805,0.00082685327,0.000497463,0.0033348163,0.000048685557,0.00006837639],"genre_scores_gemma":[0.9982631,0.0003307783,0.000018062978,0.00023963494,0.000011456292,0.00018440891,0.0007294301,0.000021960523,0.0002011547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804133,0.00072243955,0.00039043126,0.0003224195,0.0001685259,0.00035485215],"domain_scores_gemma":[0.99867064,0.00031205488,0.00035289617,0.0005356696,0.00007501353,0.000053734817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010949974,0.00025859405,0.00048650824,0.0000761684,0.00049895124,0.00001842087,0.0005159627,0.00006802606,0.0022786022],"category_scores_gemma":[0.00011977009,0.00016404809,0.00026113042,0.0002603612,0.00018880732,0.00005386987,0.00028341654,0.000071030285,0.00003301806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004156515,0.0046560173,0.55322766,0.00010418246,0.01125179,0.000014061946,0.00210125,0.00011722811,0.00029735328,0.00026753158,0.02036705,0.40343937],"study_design_scores_gemma":[0.0042660176,0.0005165096,0.9902465,0.00012538263,0.0006677064,0.0000025652955,0.0005421329,0.000005509945,0.0014647975,0.0012667036,0.00061497814,0.00028120406],"about_ca_topic_score_codex":0.0003546689,"about_ca_topic_score_gemma":0.00005887106,"teacher_disagreement_score":0.43701884,"about_ca_system_score_codex":0.000025514299,"about_ca_system_score_gemma":0.000078938116,"threshold_uncertainty_score":0.99863344},"labels":[],"label_agreement":null},{"id":"W4292116273","doi":"10.1111/j.1468-3083.2007.02245.x","title":"Abstracts of Invited Speakers","year":2007,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Citation; Library science; Information retrieval; Computer science","score_opus":0.018751402987448543,"score_gpt":0.24921331421339607,"score_spread":0.23046191122594753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292116273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98857933,0.0054193847,0.000035916695,0.002421775,0.00057488773,0.00005939367,0.000006051611,0.000005565482,0.0028976812],"genre_scores_gemma":[0.9988927,0.00036855944,0.00014217128,0.0003957884,0.00005459155,1.4471078e-7,0.0000017003362,0.000011496649,0.0001328172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794203,0.0007736995,0.0008838168,0.00011275941,0.000040439405,0.0002472716],"domain_scores_gemma":[0.99827707,0.0003516973,0.0011777236,0.00010746509,0.000052556774,0.000033471315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008957347,0.00014269911,0.00048740662,0.00021067339,0.000074595555,0.0000012369356,0.0003750439,0.0002712338,0.000027569344],"category_scores_gemma":[0.00013191732,0.00009404651,0.00017460246,0.00012652647,0.0007123065,0.00005564609,0.00011014141,0.00042526203,0.000013882949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016408825,0.00037536316,0.55123514,0.00010506543,0.001753847,0.00025801087,0.0011394966,0.000026386297,0.3990013,0.0025669145,0.006900762,0.034996837],"study_design_scores_gemma":[0.00213498,0.000057461755,0.6914433,0.000057821057,0.0002765415,0.009309481,0.000117433825,2.7498888e-7,0.27755076,0.00047672377,0.018477837,0.000097342956],"about_ca_topic_score_codex":0.000003199289,"about_ca_topic_score_gemma":0.00000226146,"teacher_disagreement_score":0.1402082,"about_ca_system_score_codex":0.000009116708,"about_ca_system_score_gemma":0.000020875468,"threshold_uncertainty_score":0.38351056},"labels":[],"label_agreement":null},{"id":"W4292324125","doi":"10.1007/s40257-022-00722-y","title":"Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study","year":2022,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Secukinumab; Hazard ratio; Internal medicine; Ixekizumab; Retrospective cohort study; Discontinuation; Proportional hazards model; Psoriasis; Cohort; Confidence interval; Psoriatic arthritis; Immunology; Arthritis","score_opus":0.025827744074120234,"score_gpt":0.3257116528310061,"score_spread":0.29988390875688586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292324125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930485,0.0028711846,0.00008235168,0.00048552893,0.0024104316,0.00085748546,0.0002191746,0.000008913659,0.000016412429],"genre_scores_gemma":[0.997946,0.0014749767,0.00019486598,0.000054823176,0.00009262361,0.00009038046,0.00001759376,0.000020607551,0.00010810512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550074,0.0017750604,0.0019701875,0.00031956658,0.00012693134,0.00030750473],"domain_scores_gemma":[0.99290293,0.004136733,0.0023304757,0.00031700468,0.00025711034,0.000055763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012570388,0.00025152645,0.0018158752,0.00019163864,0.00020623008,0.0000055870264,0.00034051016,0.00008981841,0.00005409728],"category_scores_gemma":[0.00044435041,0.0001660011,0.0004965927,0.0003010143,0.0011450911,0.00004807404,0.000099248275,0.00030903678,0.0000023568678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004305875,0.0044840113,0.94568974,0.00000880952,0.004581537,0.000053087893,0.00256386,0.00001394592,0.00019584077,0.000059114318,0.000573078,0.0374711],"study_design_scores_gemma":[0.02447042,0.019039232,0.9012396,0.00002448555,0.0035917899,0.0008933472,0.029399961,0.000051377363,0.001909196,0.00004744059,0.019026786,0.00030639037],"about_ca_topic_score_codex":0.00033181856,"about_ca_topic_score_gemma":0.00017575818,"teacher_disagreement_score":0.044450164,"about_ca_system_score_codex":0.00008537156,"about_ca_system_score_gemma":0.00018485708,"threshold_uncertainty_score":0.6769329},"labels":[],"label_agreement":null},{"id":"W4293216296","doi":"10.1002/jmv.28085","title":"Clinical characteristics and outcomes of patients with COVID‐19 and psoriasis","year":2022,"lang":"en","type":"review","venue":"Journal of Medical Virology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Medicine; Psoriasis; Internal medicine; Confidence interval; Coronavirus disease 2019 (COVID-19); Case fatality rate; Systemic therapy; Relative risk; Disease; Epidemiology; Immunology; Infectious disease (medical specialty); Cancer","score_opus":0.05229286459059651,"score_gpt":0.35158811131510587,"score_spread":0.29929524672450936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293216296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04252737,0.95508057,0.000014725177,0.0003025614,0.001631674,0.00021284916,0.00020862417,0.000005896334,0.000015751932],"genre_scores_gemma":[0.00068607385,0.9985774,0.000056491583,0.0003202954,0.000108498636,0.000009756748,0.00014231305,0.000022359141,0.0000767871],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962893,0.0014449828,0.0015578438,0.00026609402,0.00020314049,0.00023865116],"domain_scores_gemma":[0.99464893,0.0030912065,0.001805446,0.00019218943,0.000052155203,0.00021007781],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015598241,0.00031165537,0.0031388137,0.0002388042,0.00009392231,0.0000048216843,0.00035639084,0.0009988425,0.0017805859],"category_scores_gemma":[0.0019320386,0.00018130757,0.00034229382,0.00008968464,0.00067685626,0.00003213301,0.0002239686,0.0010375706,0.000006206858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035603126,0.0004005143,0.08199667,0.00085632433,0.0023552103,0.00011753945,0.000050389084,4.0873958e-9,8.028614e-8,0.00006088832,0.00048736273,0.913319],"study_design_scores_gemma":[0.0036633632,0.0017638347,0.056289334,0.0002577045,0.0031435331,0.00054278196,0.000016206839,3.7623032e-8,6.336548e-8,0.000018080427,0.93416196,0.00014309757],"about_ca_topic_score_codex":0.000005857739,"about_ca_topic_score_gemma":0.0000035412359,"teacher_disagreement_score":0.9336746,"about_ca_system_score_codex":0.000037681453,"about_ca_system_score_gemma":0.00059161556,"threshold_uncertainty_score":0.9991319},"labels":[],"label_agreement":null},{"id":"W4293242071","doi":"10.1007/s13555-022-00790-2","title":"Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"LEO Pharma; Bausch Health; Castle Biosciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Helsinn; Celgene; Biogen; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer","keywords":"Medicine; Psoriasis; Concomitant; Metabolic syndrome; Internal medicine; Exacerbation; Comorbidity; Observational study; Dermatology; Obesity","score_opus":0.035528050407611284,"score_gpt":0.3204511661888236,"score_spread":0.2849231157812123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293242071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04886608,0.9487095,2.677886e-7,0.000029538596,0.0002912821,0.001809504,0.00020893935,0.000017788016,0.0000670937],"genre_scores_gemma":[0.0022700033,0.99642634,0.00001966839,0.000110548535,0.000005177181,0.00025712556,0.00081887684,0.000032290493,0.000059961734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956705,0.0023025048,0.0010866593,0.0005844896,0.000049040606,0.0003068311],"domain_scores_gemma":[0.997907,0.0009953113,0.0006655677,0.00036237156,0.000030481651,0.000039299077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003086841,0.00053801906,0.003967004,0.00020209777,0.00017070041,0.0000039418883,0.00018755299,0.0005130129,0.0003205712],"category_scores_gemma":[0.000039222592,0.0003472211,0.00025961472,0.0002882919,0.00040097762,0.000052872976,0.00007647287,0.000412311,0.000012184265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007780989,0.00076069875,0.018417958,0.0015912456,0.005392236,0.00007140284,0.00027476344,5.738189e-9,7.67773e-8,0.00010665147,0.000085316366,0.97252154],"study_design_scores_gemma":[0.013976111,0.000877158,0.03237196,0.0042863064,0.0029845992,0.0007704711,0.000032409473,1.2968431e-8,0.0000017484092,0.000014004794,0.9442946,0.00039062704],"about_ca_topic_score_codex":0.000012450481,"about_ca_topic_score_gemma":0.0000046314226,"teacher_disagreement_score":0.9721309,"about_ca_system_score_codex":0.000022720846,"about_ca_system_score_gemma":0.00013640229,"threshold_uncertainty_score":0.99989796},"labels":[],"label_agreement":null},{"id":"W4293277077","doi":"","title":"VTAMA<sup>®</sup> (Tapinarof) Cream* for Plaque Psoriasis.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.02534833257288067,"score_gpt":0.22000446137334095,"score_spread":0.1946561288004603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293277077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97258735,0.0073789307,0.0001439437,0.0023183168,0.003766463,0.0035907507,0.0013012358,0.0004296381,0.00848337],"genre_scores_gemma":[0.95448405,0.000082884726,0.00009529487,0.0004518928,0.00020251515,0.01901992,0.0007949673,0.00004552092,0.024822932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813193,0.00027619707,0.00029639623,0.00047126625,0.0000593241,0.0007648608],"domain_scores_gemma":[0.99911124,0.00029409316,0.0001148454,0.0003859876,0.00004142659,0.00005243881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005092038,0.0002508403,0.0003556627,0.00016037258,0.00068967906,0.000018984187,0.0003666165,0.00017032294,0.00089583726],"category_scores_gemma":[0.000094865536,0.00024190497,0.00025147686,0.00020748166,0.00007505063,0.00008209187,0.00017131853,0.00020016491,0.00016142605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032450496,0.0016488907,0.0058008037,0.000058782487,0.001878463,0.000039024486,0.0015414838,0.0003129334,0.0016793278,0.0054323194,0.16176777,0.81659514],"study_design_scores_gemma":[0.0060757888,0.0003400528,0.026826054,0.0000026946411,0.00032169023,0.00010680713,0.0006752539,0.000012598533,0.008902463,0.00086481974,0.9554317,0.00044004718],"about_ca_topic_score_codex":0.000052440104,"about_ca_topic_score_gemma":0.0000070273372,"teacher_disagreement_score":0.81615514,"about_ca_system_score_codex":0.00014611632,"about_ca_system_score_gemma":0.000050086044,"threshold_uncertainty_score":0.98645985},"labels":[],"label_agreement":null},{"id":"W4293512004","doi":"10.1016/j.ad.2022.07.021","title":"Quality of Life and Body Region Affected by Psoriasis: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Actas Dermo-Sifiliográficas","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of Ottawa","funders":"","keywords":"Psoriasis; Quality (philosophy); Medicine; Dermatology; Philosophy; Epistemology","score_opus":0.06349842011389552,"score_gpt":0.3180910418121217,"score_spread":0.2545926216982262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293512004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011099065,0.9936414,0.0000056817917,0.00004463496,0.0006904875,0.004239854,0.0007501366,0.00015576309,0.0003610867],"genre_scores_gemma":[0.0004433616,0.9930074,0.00001381835,0.00014870956,0.000039956583,0.0017560858,0.003411384,0.00010694962,0.0010723044],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899437,0.005684328,0.0025038521,0.001070025,0.00019276155,0.00060534326],"domain_scores_gemma":[0.9937028,0.0020186699,0.0025051706,0.0015731106,0.0000849432,0.00011526958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013876925,0.0010286535,0.0071259756,0.00047718227,0.00029709915,0.0000281534,0.00075154623,0.00086822774,0.00078456267],"category_scores_gemma":[0.0013738399,0.00079449563,0.0014195803,0.0011010466,0.00022552552,0.00010746756,0.0003007647,0.00064317964,0.0001806505],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005767838,0.00045749103,0.000008727697,0.8687285,0.004881719,0.000032313572,0.00006604356,3.838789e-9,0.000080077836,0.00010357299,0.029271416,0.09631243],"study_design_scores_gemma":[0.0013638255,0.00029506287,0.000026275444,0.16506621,0.01677427,0.0006240197,0.00009307205,9.775897e-8,0.000028039229,0.0000143981315,0.8146451,0.0010695904],"about_ca_topic_score_codex":0.00007924276,"about_ca_topic_score_gemma":0.000004928951,"teacher_disagreement_score":0.78537375,"about_ca_system_score_codex":0.00012561108,"about_ca_system_score_gemma":0.000260325,"threshold_uncertainty_score":0.9994506},"labels":[],"label_agreement":null},{"id":"W4294031210","doi":"10.1186/s12974-022-02572-1","title":"IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes","year":2022,"lang":"en","type":"article","venue":"Journal of Neuroinflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Multiple Sclerosis Society of Canada; University of Washington","keywords":"Immune system; Neurology; Neuroimmunology; Neuroscience; Immunology; Neuroinflammation; Astrocyte; Medicine; Biology; Psychology; Inflammation; Central nervous system","score_opus":0.02298743070490122,"score_gpt":0.23895693101706836,"score_spread":0.21596950031216713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294031210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651754,0.002877732,0.0000013964453,0.00013908038,0.0002123676,0.00013925745,0.00002178506,0.000009309214,0.000081532686],"genre_scores_gemma":[0.99966973,0.00008331537,0.0000026674113,0.000008942764,0.000055062854,0.0000060692682,0.000011865974,0.0000114566665,0.00015088361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888885,0.00035829953,0.0004565635,0.000094662886,0.00006904989,0.00013256042],"domain_scores_gemma":[0.9990603,0.00010077801,0.00063175877,0.00012478947,0.00007038263,0.000011993681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035713933,0.00015411389,0.00027939465,0.00015269623,0.0004319156,0.000021712636,0.00020435583,0.000039305767,0.00012940165],"category_scores_gemma":[0.000028894994,0.000080178404,0.00017431569,0.000075790245,0.00009202158,0.00012987154,0.00006397143,0.00017173267,0.0000039055008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052485307,0.000086995526,0.00072213943,0.000011677599,0.00021962098,0.000004480152,0.0016146809,0.00014917477,0.9926297,0.00008493042,0.000073032315,0.003878719],"study_design_scores_gemma":[0.001577093,0.0023022364,0.053363897,0.00005093551,0.0000871231,0.0003476282,0.0010263934,0.000016440661,0.9406988,0.00009459463,0.00034925225,0.00008558149],"about_ca_topic_score_codex":0.000021137857,"about_ca_topic_score_gemma":0.0000042652478,"teacher_disagreement_score":0.052641757,"about_ca_system_score_codex":0.000065454624,"about_ca_system_score_gemma":0.000046246307,"threshold_uncertainty_score":0.33219892},"labels":[],"label_agreement":null},{"id":"W4295254586","doi":"10.1016/j.jaad.2022.06.348","title":"34039 Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Medicine; Lotion; Psoriasis; Dermatology; Post-hoc analysis; Open label; Adverse effect; Pharmacology; Internal medicine","score_opus":0.04740504003006497,"score_gpt":0.3188376131538056,"score_spread":0.27143257312374064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295254586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99812037,0.00034407267,0.000023758796,0.00059173076,0.00006584605,0.0008197271,0.000031671534,0.0000012855371,0.0000015285585],"genre_scores_gemma":[0.99944574,0.0001395606,0.00027597926,0.00003026011,0.0000027091291,0.00006323079,0.0000026204982,0.000008492951,0.000031390486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811375,0.00067612267,0.00078420347,0.0001517422,0.00008207228,0.00019209723],"domain_scores_gemma":[0.9978462,0.00021524906,0.0017496273,0.000110727015,0.0000626829,0.000015510934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022208391,0.00012234032,0.0008067351,0.00020118202,0.000049526014,0.0000021591766,0.00031954542,0.000062292514,0.0000046632954],"category_scores_gemma":[0.00007488199,0.00008297204,0.000056769422,0.00028969973,0.00031343786,0.00012158831,0.0001334474,0.00019124696,1.03637475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009821125,0.0053003985,0.9284271,0.000073429415,0.00061872654,0.000016984104,0.0017462886,0.000088893554,0.033181693,0.00011499626,0.000018006322,0.020592337],"study_design_scores_gemma":[0.015078898,0.002642973,0.9391315,0.00010895681,0.00023958873,0.0002954603,0.0006163887,0.000022645814,0.04171175,0.00007147097,0.000011728013,0.00006867064],"about_ca_topic_score_codex":0.00013802905,"about_ca_topic_score_gemma":0.00006340406,"teacher_disagreement_score":0.020523667,"about_ca_system_score_codex":0.000056116125,"about_ca_system_score_gemma":0.00006517398,"threshold_uncertainty_score":0.33835015},"labels":[],"label_agreement":null},{"id":"W4295255311","doi":"10.1016/j.jaad.2022.06.680","title":"33354 Efficacy of apremilast in patients with mild to moderate psoriasis assessed by the physician global assessment and body surface area composite tool: Post hoc analysis from ADVANCE","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Apremilast; Post-hoc analysis; Post hoc; Body surface area; Psoriasis; Internal medicine; Gastroenterology; Randomized controlled trial; Immunology","score_opus":0.007718523954101549,"score_gpt":0.2608112989600135,"score_spread":0.25309277500591193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295255311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950667,0.0011372041,0.00010974043,0.0026511324,0.00010639186,0.00023628965,0.0006686507,0.0000046726655,0.000019230842],"genre_scores_gemma":[0.99853855,0.00008489343,0.00048004417,0.00082533463,0.0000071080735,0.000006368373,0.00003893998,0.000011026197,0.000007718823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771214,0.000969049,0.0006447342,0.00023555182,0.000168956,0.00026957676],"domain_scores_gemma":[0.9977301,0.00043899787,0.0015015178,0.00021311703,0.0000833663,0.000032938115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015945146,0.00022224714,0.0010268801,0.00012567035,0.00017671089,0.000008880727,0.0005918177,0.00006550407,0.000014943647],"category_scores_gemma":[0.000017049357,0.00013819156,0.00020976237,0.00091490935,0.00034283777,0.000087475884,0.00021902256,0.00040149697,7.480351e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007136776,0.00094726845,0.9368482,0.0000074145387,0.004039946,0.0000050979565,0.00034884326,0.005507773,0.0400859,0.000041520532,0.00072301785,0.004308231],"study_design_scores_gemma":[0.0040812227,0.0005885445,0.984491,0.000025471594,0.0012597245,0.000045611658,0.0004375797,0.000054635355,0.008342723,0.000037704085,0.00047495659,0.00016083836],"about_ca_topic_score_codex":0.00015074576,"about_ca_topic_score_gemma":0.000013043165,"teacher_disagreement_score":0.047642775,"about_ca_system_score_codex":0.000115848736,"about_ca_system_score_gemma":0.0000827332,"threshold_uncertainty_score":0.5635289},"labels":[],"label_agreement":null},{"id":"W4295255312","doi":"10.1016/j.jaad.2022.06.593","title":"32805 Analysis of time to second relapse confirms the superiority of long-term proactive management with Cal/BD foam vs reactive management of psoriasis","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Randomization; Post-hoc analysis; Betamethasone dipropionate; Internal medicine; Psoriasis; Randomized controlled trial; Gastroenterology; Surgery; Dermatology","score_opus":0.010540934019017125,"score_gpt":0.25395623991958066,"score_spread":0.24341530590056354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295255312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608296,0.0005973938,0.000055714936,0.0018013564,0.00011464987,0.000530344,0.00019635685,0.000004880992,0.0006163524],"genre_scores_gemma":[0.99874806,0.00020886048,0.00026637618,0.00018327934,0.000008422036,0.00003507454,0.000008779969,0.000016119382,0.0005250355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973067,0.00094728905,0.0009899015,0.00024668407,0.0002207552,0.00028868034],"domain_scores_gemma":[0.99641407,0.0003312867,0.0027371242,0.00036501145,0.00011524346,0.000037240505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042234518,0.00024072059,0.0014597715,0.00055136916,0.00013751809,0.0000025560282,0.00092468713,0.00008858427,0.00051064027],"category_scores_gemma":[0.000016173077,0.00014669844,0.0005314818,0.00127123,0.0008488568,0.000070854505,0.00039981926,0.00043383468,0.000004672984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037047062,0.004102433,0.54626834,0.00064685877,0.22986822,0.0003509902,0.01045415,0.0011899368,0.13102126,0.0021559556,0.004622499,0.032272287],"study_design_scores_gemma":[0.0027055473,0.001349396,0.8229191,0.000097060016,0.013965568,0.0010180289,0.004970249,0.000007022027,0.15109505,0.00006542566,0.0015655303,0.00024204263],"about_ca_topic_score_codex":0.0000477153,"about_ca_topic_score_gemma":0.00000765091,"teacher_disagreement_score":0.27665076,"about_ca_system_score_codex":0.000097196265,"about_ca_system_score_gemma":0.000059957638,"threshold_uncertainty_score":0.59821886},"labels":[],"label_agreement":null},{"id":"W4295257226","doi":"10.1016/j.jaad.2022.06.863","title":"34615 Tapinarof cream 1% once daily for plaque psoriasis: Dermatology Life Quality Index and local tolerability scores from a long-term extension trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Tolerability; Psoriasis; Plaque psoriasis; Dermatology; Quality of life (healthcare); Psoriasis Area and Severity Index; Term (time); Index (typography); Internal medicine; Adverse effect","score_opus":0.0342122122168233,"score_gpt":0.31389656540569266,"score_spread":0.27968435318886936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295257226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818365,0.006075304,0.0008330903,0.009378893,0.0010868354,0.0005618022,0.00019940549,0.000019523579,0.000008619295],"genre_scores_gemma":[0.99778944,0.0003992736,0.00019903855,0.0013648135,0.00011278733,0.00006683711,0.000021392356,0.000024099962,0.000022288796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99479115,0.0026292484,0.0015223,0.00042480716,0.00016145113,0.00047105184],"domain_scores_gemma":[0.99480945,0.0018335239,0.0028403618,0.0003185079,0.000103875915,0.0000942642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005530413,0.0003268746,0.0017237792,0.00022122085,0.00043831844,0.000009618218,0.0008007086,0.00029846997,0.000085373256],"category_scores_gemma":[0.00044976216,0.00024564628,0.00048814647,0.0002626943,0.0015538301,0.0001328667,0.00042979175,0.00089485897,0.0000034390248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28314567,0.0031650711,0.58076113,0.00018761678,0.0043900004,0.00013422106,0.0020256762,0.00019265119,0.06375935,0.0008321979,0.009812388,0.051594008],"study_design_scores_gemma":[0.078298174,0.0027322953,0.84959775,0.00011404774,0.0014711153,0.0115781,0.0025683378,0.000050445487,0.04360135,0.002975667,0.006287443,0.000725284],"about_ca_topic_score_codex":0.00018612186,"about_ca_topic_score_gemma":0.000020466412,"teacher_disagreement_score":0.26883662,"about_ca_system_score_codex":0.00010154368,"about_ca_system_score_gemma":0.00032882948,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W4295257253","doi":"10.1016/j.jaad.2022.06.465","title":"35098 Secukinumab versus guselkumab in the treatment of ustekinumab-resistant psoriatic plaques: 16-week randomized, open-label, multicenter ARROW study","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Dalhousie University","funders":"","keywords":"Medicine; Secukinumab; Ustekinumab; Psoriasis; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Dermatology; Gastroenterology; Randomized controlled trial; Disease; Psoriatic arthritis","score_opus":0.042380024080505466,"score_gpt":0.3190129473043446,"score_spread":0.27663292322383914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295257253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98970354,0.004988728,0.0000045025968,0.0028761681,0.0008529716,0.001352023,0.000066611174,0.000005971402,0.0001494683],"genre_scores_gemma":[0.9985428,0.00077066565,0.00008419341,0.00028946841,0.000033045562,0.00014824509,0.000006412128,0.000022069198,0.0001031264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99247646,0.005116123,0.0015241528,0.00025946842,0.00022151446,0.00040226785],"domain_scores_gemma":[0.9943329,0.0022110834,0.0030088746,0.00035847354,0.00005848367,0.00003019414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086135947,0.0003268047,0.0020072388,0.00032836694,0.0002605645,0.000013565608,0.0017608497,0.00009950306,0.00013890413],"category_scores_gemma":[0.00015295357,0.00018183234,0.0004146046,0.0005236239,0.00073505007,0.000105825005,0.0002556251,0.0005306588,0.000007638152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84129155,0.03681168,0.020331077,0.000076075514,0.016355999,0.00040720013,0.035950292,0.00021786065,0.022794466,0.0009410101,0.0053616636,0.01946114],"study_design_scores_gemma":[0.8668791,0.016286323,0.014800921,0.00010663045,0.0057951943,0.003250286,0.045736846,0.000026294912,0.021876877,0.0005261852,0.024106393,0.00060893653],"about_ca_topic_score_codex":0.00039229353,"about_ca_topic_score_gemma":0.00006927809,"teacher_disagreement_score":0.025587576,"about_ca_system_score_codex":0.00029371015,"about_ca_system_score_gemma":0.0001569058,"threshold_uncertainty_score":0.7414908},"labels":[],"label_agreement":null},{"id":"W4295257805","doi":"10.1016/j.jaad.2022.06.314","title":"34223 Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: A multicenter retrospective cohort study","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Discontinuation; Incidence (geometry); Population; Retrospective cohort study; Internal medicine; Dermatology; Psoriatic arthritis; Environmental health","score_opus":0.010656211458400924,"score_gpt":0.2650077681667486,"score_spread":0.2543515567083477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295257805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780357,0.00023235097,0.0000026784267,0.0011970864,0.00013446913,0.0005615611,0.00004650892,0.000004336599,0.000017445553],"genre_scores_gemma":[0.99943894,0.000052838484,0.000053460742,0.00038857717,0.0000064817827,0.00003394801,0.00000176814,0.000010703846,0.000013308476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977778,0.0010624619,0.00058815937,0.00020379161,0.0001649257,0.00020284967],"domain_scores_gemma":[0.99781173,0.00032042517,0.0016454906,0.00012687131,0.00005981555,0.000035636425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003283318,0.00015967742,0.0008043502,0.00029148438,0.00012161865,0.0000020934024,0.00038941932,0.000059767393,0.000037738966],"category_scores_gemma":[0.00019155472,0.00010466061,0.00009999411,0.00040283802,0.00050851284,0.000058628302,0.00019229003,0.00048668584,0.0000010100882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003799043,0.0011698324,0.991406,0.000011953526,0.0006742257,0.000012702493,0.0013122829,0.000034047414,0.00065991585,0.000017907812,0.00028434285,0.00061774725],"study_design_scores_gemma":[0.0049867034,0.0017623442,0.9888249,0.00002208691,0.00028459937,0.00022515106,0.0012610435,0.000001212339,0.0023311279,0.000029555693,0.00018082191,0.00009044589],"about_ca_topic_score_codex":0.00009800399,"about_ca_topic_score_gemma":0.000012197743,"teacher_disagreement_score":0.002581091,"about_ca_system_score_codex":0.00017274126,"about_ca_system_score_gemma":0.00010133675,"threshold_uncertainty_score":0.42679358},"labels":[],"label_agreement":null},{"id":"W4295259494","doi":"10.1016/j.jaad.2022.06.303","title":"33950 Impact of psoriasis in special areas on patient quality-of-life outcomes and depression screening: Findings from the multinational UPLIFT survey","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Multinational corporation; Psoriasis; Depression (economics); Quality of life (healthcare); Psychiatry; Dermatology; Nursing","score_opus":0.03977499198604127,"score_gpt":0.32593808936542107,"score_spread":0.2861630973793798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295259494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707144,0.00076178793,0.000006902432,0.0013821542,0.0002759925,0.00012028102,0.00036444326,0.0000019431932,0.0000150387095],"genre_scores_gemma":[0.99952936,0.00008955999,0.00006704902,0.00024821586,0.000030912,0.000003956412,0.000014957001,0.000008334239,0.0000076266074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649656,0.0021274514,0.0009072543,0.00013781602,0.00015616984,0.0001747497],"domain_scores_gemma":[0.99479705,0.00286845,0.002130138,0.000123957,0.00005477136,0.00002563484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055377756,0.00015323033,0.00082913256,0.00019373879,0.0001259808,0.0000022791492,0.00043857642,0.000090399015,0.00010851747],"category_scores_gemma":[0.00081327854,0.00008622692,0.00030599238,0.00025083908,0.00041292017,0.00004530616,0.00021134247,0.0004593919,8.89916e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002857382,0.00025280623,0.9843451,0.0000035125872,0.0006099206,0.0000019109682,0.0007877973,0.00011996927,0.004536111,0.000053691554,0.0012537647,0.005178083],"study_design_scores_gemma":[0.00237298,0.00020192869,0.99012524,0.00002353882,0.00007095048,0.00008397583,0.00059370376,0.0000042604493,0.0061483323,0.00010278959,0.00019674694,0.0000755565],"about_ca_topic_score_codex":0.0008864944,"about_ca_topic_score_gemma":0.000027794296,"teacher_disagreement_score":0.005780186,"about_ca_system_score_codex":0.000043711178,"about_ca_system_score_gemma":0.000100396675,"threshold_uncertainty_score":0.3516232},"labels":[],"label_agreement":null},{"id":"W4295260246","doi":"10.1016/j.jaad.2022.06.248","title":"33007 Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.03116722314343098,"score_gpt":0.314117501322825,"score_spread":0.28295027817939405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295260246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993033,0.005795376,0.000007595242,0.0028787337,0.00032801105,0.00090898026,0.0001280158,0.0000030884435,0.000019858004],"genre_scores_gemma":[0.99916536,0.00049010303,0.0000311144,0.00016553952,0.00002910666,0.00007149894,0.000003265571,0.000013041525,0.000030985542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686897,0.0014998798,0.0010053252,0.0001600639,0.00014819075,0.00031755053],"domain_scores_gemma":[0.9951566,0.0024062945,0.0020741362,0.00029610144,0.000052279047,0.000014616069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044715425,0.00019892331,0.00091076776,0.0001262161,0.0002381081,0.0000035246144,0.0009257218,0.00007148229,0.000030995772],"category_scores_gemma":[0.00008406883,0.000095514864,0.0004877641,0.00036835068,0.0006644607,0.000032012438,0.00014011013,0.00030806608,0.0000012962889],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039883006,0.02917446,0.48134255,0.000098703895,0.011309258,0.0001033571,0.15639812,0.002004302,0.09874431,0.00067604415,0.007315092,0.17295079],"study_design_scores_gemma":[0.017118946,0.010637025,0.7543402,0.00003325908,0.0014542586,0.0021440324,0.057764888,0.000010649923,0.11760034,0.00018091749,0.038463432,0.00025205387],"about_ca_topic_score_codex":0.00008013685,"about_ca_topic_score_gemma":0.000019336867,"teacher_disagreement_score":0.27299765,"about_ca_system_score_codex":0.00006748141,"about_ca_system_score_gemma":0.00006993662,"threshold_uncertainty_score":0.3894983},"labels":[],"label_agreement":null},{"id":"W4295807681","doi":"10.1016/j.jaad.2022.08.061","title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":279,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Cilag; LEO Pharma; Eli Lilly and Company; Bristol-Myers Squibb; Galderma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Biogen; Celgene; Amgen; Pfizer","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Adverse effect; Psoriasis Area and Severity Index; Internal medicine; Randomized controlled trial; Gastroenterology; Dermatology Life Quality Index; Clinical trial; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.051617200701128164,"score_gpt":0.3402775865708558,"score_spread":0.2886603858697276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295807681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880842,0.0018179226,0.000018619585,0.005185552,0.00088347145,0.0033522963,0.00060186145,0.000008297433,0.000047763508],"genre_scores_gemma":[0.99869084,0.000261157,0.00035925425,0.00017381218,0.00013055053,0.0003087683,0.00003533513,0.000018826406,0.00002145844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493814,0.0028190932,0.0014227893,0.00031289537,0.00019983128,0.00030723165],"domain_scores_gemma":[0.9932207,0.004296341,0.0021099558,0.00019199915,0.00013054968,0.000050496652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022983523,0.0002574859,0.0013544052,0.00022612808,0.00024972437,0.000012829707,0.0004291002,0.0001817319,0.000035399942],"category_scores_gemma":[0.0008024819,0.00016844198,0.00026884582,0.00031914597,0.0005586058,0.00009557917,0.00019766718,0.0005569015,8.3740076e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95437634,0.0005435612,0.00007830486,0.000012211683,0.0012145452,0.0000021331564,0.0017421042,0.00030316296,0.0030473277,0.0000644193,0.001178012,0.037437905],"study_design_scores_gemma":[0.9729749,0.0016460933,0.0005669021,0.000055024513,0.0014704036,0.00036686528,0.0014924745,0.0001453072,0.017134907,0.00026664106,0.0036977287,0.00018277112],"about_ca_topic_score_codex":0.00006119365,"about_ca_topic_score_gemma":0.00003682646,"teacher_disagreement_score":0.03725513,"about_ca_system_score_codex":0.00008444149,"about_ca_system_score_gemma":0.00022066857,"threshold_uncertainty_score":0.6868865},"labels":[],"label_agreement":null},{"id":"W4295993138","doi":"10.1016/j.jid.2022.05.1094","title":"Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non‒Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis","year":2022,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Rockefeller University; UCB; Regeneron Pharmaceuticals","keywords":"Palmoplantar pustulosis; Psoriasis; Medicine; Inflammation; Dermatology; Immunology","score_opus":0.022693330817818595,"score_gpt":0.2557233201740332,"score_spread":0.2330299893562146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295993138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876689,0.008251269,0.00001550435,0.00092121284,0.0023647714,0.00044634458,0.0001403711,0.000016265496,0.00017539166],"genre_scores_gemma":[0.998859,0.000460785,0.000110329165,0.00027806684,0.000079925434,0.000052279607,0.000052268653,0.000036568283,0.0000708145],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947939,0.0022047262,0.0017327406,0.00041676065,0.00026152385,0.0005903481],"domain_scores_gemma":[0.9966478,0.0006804407,0.0018728118,0.0004651423,0.00022488504,0.000108922104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089753844,0.00046967986,0.0015132063,0.0006209323,0.0005226408,0.000016903281,0.0008101728,0.00040082142,0.00015205788],"category_scores_gemma":[0.0003495704,0.00037158077,0.00033445805,0.00061964686,0.0009608557,0.00020412833,0.0003946033,0.0012503141,0.000018241599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006763016,0.0007120264,0.7949305,0.00017420377,0.0018010611,0.00047762992,0.014882911,0.00026306722,0.17256016,0.0010316235,0.0097694695,0.0027210135],"study_design_scores_gemma":[0.008806341,0.00063231756,0.32772657,0.0002016322,0.00096024084,0.006797463,0.011321329,0.000031966832,0.6232556,0.0014216279,0.018236073,0.0006088225],"about_ca_topic_score_codex":0.00011506112,"about_ca_topic_score_gemma":0.0001062081,"teacher_disagreement_score":0.46720397,"about_ca_system_score_codex":0.00018255034,"about_ca_system_score_gemma":0.00051513966,"threshold_uncertainty_score":0.99987364},"labels":[],"label_agreement":null},{"id":"W4296164535","doi":"10.1016/j.jaad.2022.09.006","title":"Disparities in psoriasis clinical trials: A cross-sectional analysis","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Cross-sectional study; Psoriasis; Dermatology; Clinical trial; MEDLINE; Internal medicine; Pathology","score_opus":0.08554311277228233,"score_gpt":0.4083347676896008,"score_spread":0.3227916549173185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296164535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923606,0.002798451,0.000030372403,0.0035072912,0.0010418766,0.000103853825,0.000090786474,0.0000064667383,0.000060306073],"genre_scores_gemma":[0.9985957,0.00044187732,0.00009284846,0.00057402917,0.000073676354,0.00001469421,0.0000066162875,0.000009182777,0.000191354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99112666,0.006061833,0.0022060294,0.00019515444,0.00013143693,0.0002788969],"domain_scores_gemma":[0.99400955,0.0023070658,0.003452186,0.00015247916,0.000047393558,0.00003131294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031480861,0.00015661612,0.0016959977,0.00060931157,0.00019655451,0.0000075762655,0.00073154457,0.0001558658,0.00035184674],"category_scores_gemma":[0.0008279596,0.00010813291,0.0013945198,0.001046304,0.00085190334,0.000072106486,0.00022394341,0.0009804068,0.0000072562257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016458044,0.00029184407,0.9873705,0.000004671641,0.0036070836,0.000015983112,0.00007044625,0.00027829173,0.0014252056,0.00030652108,0.0015176642,0.003465972],"study_design_scores_gemma":[0.0023272922,0.00016082854,0.9855549,0.0000040046057,0.0010679279,0.0016206688,0.00017503656,0.000009829771,0.0016202022,0.00049087306,0.0068665966,0.00010184176],"about_ca_topic_score_codex":0.000096886746,"about_ca_topic_score_gemma":0.000009256854,"teacher_disagreement_score":0.006235126,"about_ca_system_score_codex":0.00007639516,"about_ca_system_score_gemma":0.00014666254,"threshold_uncertainty_score":0.44095322},"labels":[],"label_agreement":null},{"id":"W4296312509","doi":"10.3390/cells11182904","title":"Gene Profiling of a 3D Psoriatic Skin Model Enriched in T Cells: Downregulation of PTPRM Promotes Keratinocyte Proliferation through Excessive ERK1/2 Signaling","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université Laval; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Psoriasis; Dermis; Keratinocyte; Effector; Pathogenesis; Epidermis (zoology); Biology; Immune system; Downregulation and upregulation; Signal transduction; Cell biology; Immunology; Cancer research; Gene; Genetics; Cell culture; Anatomy","score_opus":0.020686607069611347,"score_gpt":0.23868108519545111,"score_spread":0.21799447812583977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296312509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994846,0.0015831364,0.0021930905,0.000015498681,0.00026097122,0.0008386545,0.00008819662,0.000023989393,0.00015046341],"genre_scores_gemma":[0.9914792,0.000040830102,0.0075664073,0.000014895241,0.000029069446,0.0002038467,0.0003351466,0.000019574272,0.00031100528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984382,0.00034950016,0.0005731182,0.00031739858,0.000085933105,0.00023586857],"domain_scores_gemma":[0.99913394,0.000116151445,0.00042617304,0.00022652397,0.00008668897,0.000010499877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034076674,0.00018807611,0.00038845892,0.00014015725,0.00014443503,0.0000070620345,0.00014993838,0.00013862655,0.00015469703],"category_scores_gemma":[0.00001914102,0.00018142973,0.00008623005,0.00027965484,0.000052626012,0.0001228102,0.00007429669,0.00014617543,0.000009341506],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024592422,0.00034040777,0.00033864166,0.0000879147,0.000108148,0.000002318124,0.004754393,0.053380128,0.9381076,0.0001399103,0.000014906291,0.0024797115],"study_design_scores_gemma":[0.0017470054,0.00021127427,0.0002616408,0.00002421584,0.00011478916,0.0000033562121,0.0003387769,0.009363625,0.9871687,0.00059570017,0.000011377204,0.00015951996],"about_ca_topic_score_codex":0.000047380207,"about_ca_topic_score_gemma":0.000007973847,"teacher_disagreement_score":0.049061123,"about_ca_system_score_codex":0.0000818175,"about_ca_system_score_gemma":0.00013934873,"threshold_uncertainty_score":0.739849},"labels":[],"label_agreement":null},{"id":"W4296330112","doi":"10.2340/actadv.v102.2269","title":"Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3","year":2022,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Bausch Health; Simon Spies Fonden; Dermira; Regeneron Pharmaceuticals; Biogen; Celgene; Mylan; Janssen Pharmaceuticals; Gilead Sciences; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Samsung; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Medicine; Ixekizumab; Nail (fastener); Dermatology; Post-hoc analysis; Nail disease; Psoriasis Area and Severity Index; Internal medicine; Psoriatic arthritis; Secukinumab","score_opus":0.012020243841556392,"score_gpt":0.2182900166107102,"score_spread":0.20626977276915381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296330112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310386,0.00415763,0.00006524387,0.00046927272,0.000249148,0.00023186821,0.0006682018,0.00010785145,0.00094694213],"genre_scores_gemma":[0.9962277,0.00020600563,0.00045285132,0.00030965335,0.000023935467,0.00011309391,0.001956339,0.000020720274,0.0006897491],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979866,0.0006019244,0.00038362163,0.0004831986,0.00012530324,0.00041931242],"domain_scores_gemma":[0.99869084,0.00025656234,0.00033942782,0.00058828684,0.00009776085,0.000027089727],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001571738,0.00026538124,0.0006167948,0.00022903387,0.00036538646,0.000011564308,0.0003956598,0.00020095914,0.0023112965],"category_scores_gemma":[0.000042547243,0.00021829175,0.00029822736,0.0009603195,0.00017585885,0.00012570727,0.00034916284,0.0002137266,0.000057496447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08109889,0.008358346,0.2433034,0.00017448228,0.09026883,0.0027829488,0.033517685,0.008218878,0.27131307,0.010728977,0.07254956,0.17768495],"study_design_scores_gemma":[0.02753665,0.008527884,0.49677306,0.00006482995,0.018691707,0.0005874708,0.029783849,0.00013050552,0.06847999,0.004244115,0.3421525,0.0030274405],"about_ca_topic_score_codex":0.0018157888,"about_ca_topic_score_gemma":0.00021289318,"teacher_disagreement_score":0.26960295,"about_ca_system_score_codex":0.00013845696,"about_ca_system_score_gemma":0.00011544696,"threshold_uncertainty_score":0.9986007},"labels":[],"label_agreement":null},{"id":"W4296799947","doi":"10.1001/jama.2022.15632","title":"Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Amgen","keywords":"Medicine; Roflumilast; Psoriasis; Discontinuation; Randomized controlled trial; Clinical trial; Randomization; Intertriginous; Clinical endpoint; Internal medicine; Dermatology; COPD; Disease","score_opus":0.007924494824205035,"score_gpt":0.23107526180017052,"score_spread":0.22315076697596548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296799947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904154,0.002628509,0.0000024727049,0.00024404303,0.0012343617,0.00033446448,0.00024946756,0.0000853994,0.0048058815],"genre_scores_gemma":[0.9956794,0.00012369087,0.0000057777684,0.000102127065,0.0001478098,0.00021058717,0.00024816554,0.000028064576,0.003454422],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823576,0.0007336141,0.0002543908,0.0003437391,0.00007559243,0.00035692623],"domain_scores_gemma":[0.99879396,0.00059819437,0.0001407066,0.00041296778,0.000027418757,0.000026741382],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043362132,0.0002297149,0.00041468622,0.00013875825,0.00032537724,0.000009366424,0.0002858278,0.00018354482,0.0027834896],"category_scores_gemma":[0.000077324315,0.00019725208,0.00021666844,0.00021336137,0.00008445435,0.000056221765,0.00014316075,0.0002934871,0.0005842924],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011936966,0.0021854541,0.012173665,0.00018007921,0.00135829,0.00007617881,0.0007911309,0.00023060002,0.3524319,0.0008336768,0.038915478,0.57888657],"study_design_scores_gemma":[0.011976982,0.023593405,0.013029161,0.0000489932,0.00032140303,0.000056875862,0.00013535874,0.000009695178,0.8392511,0.00003226403,0.11122488,0.00031989874],"about_ca_topic_score_codex":0.00013791016,"about_ca_topic_score_gemma":0.000012763563,"teacher_disagreement_score":0.5785667,"about_ca_system_score_codex":0.00018400063,"about_ca_system_score_gemma":0.00007183872,"threshold_uncertainty_score":0.9981281},"labels":[],"label_agreement":null},{"id":"W4296807013","doi":"10.1371/journal.pone.0274841","title":"Interleukin-17, a salivary biomarker for COVID-19 severity","year":2022,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"King Saud University","keywords":"Saliva; Biomarker; Medicine; Severity of illness; Coronavirus disease 2019 (COVID-19); Comorbidity; Immunology; Internal medicine; Gastroenterology; Disease; Biology","score_opus":0.08014899427008353,"score_gpt":0.26777557157056675,"score_spread":0.1876265773004832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296807013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922688,0.0022452662,0.00011516715,0.0015057931,0.00039289022,0.00072435365,0.0010994724,0.00018390638,0.0014643364],"genre_scores_gemma":[0.97821605,0.000041512572,0.00055055914,0.0018317661,0.000043886746,0.0008853011,0.0011267767,0.000025578383,0.017278576],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989758,0.00021791868,0.00018054912,0.00029829986,0.000045192457,0.00028222657],"domain_scores_gemma":[0.9993331,0.00026023627,0.00007564224,0.00026471034,0.000026275244,0.00004007904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025001896,0.00014401608,0.0002581791,0.000097409546,0.00044733981,0.000007830152,0.00021534637,0.000093682895,0.0038445583],"category_scores_gemma":[0.000104407394,0.00014258592,0.00012135631,0.00012488107,0.000062635714,0.00004009062,0.00016929327,0.000113215145,0.00017423982],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049599917,0.008784467,0.027337393,0.00026036004,0.006940049,0.000058837817,0.0023754975,0.000003226064,0.80587155,0.0006735858,0.12900841,0.013726615],"study_design_scores_gemma":[0.018691624,0.0025475551,0.024961004,0.00006736487,0.00290952,0.00020508342,0.0014032525,0.00007131254,0.22500587,0.0029669213,0.7197325,0.0014379683],"about_ca_topic_score_codex":0.000074666925,"about_ca_topic_score_gemma":0.000024326791,"teacher_disagreement_score":0.5907241,"about_ca_system_score_codex":0.00016337949,"about_ca_system_score_gemma":0.000106160674,"threshold_uncertainty_score":0.9970661},"labels":[],"label_agreement":null},{"id":"W4297103102","doi":"10.1186/s41927-022-00287-7","title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"BMC Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada Research Chairs; Queen's University","funders":"Queen's University","keywords":"Medicine; Tofacitinib; Internal medicine; Placebo; Psoriatic arthritis; Psoriasis; Observational study; Odds ratio; Randomized controlled trial; Adverse effect; Meta-analysis; Physical therapy; Arthritis; Dermatology; Rheumatoid arthritis; Alternative medicine; Pathology","score_opus":0.061150871927385234,"score_gpt":0.3015846058255981,"score_spread":0.24043373389821288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297103102","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000714423,0.99526113,0.0000024533235,0.00003117953,0.0001098945,0.0035365415,0.00030910704,0.000011710014,0.00002354904],"genre_scores_gemma":[0.0009322598,0.9970831,0.00004501227,0.0000134365155,0.0000025316492,0.001582681,0.0002492352,0.00002405218,0.00006764338],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926345,0.004268218,0.0021248653,0.000607969,0.0000739157,0.00029058373],"domain_scores_gemma":[0.9937238,0.004047795,0.0014450894,0.0007278212,0.000027987957,0.000027468115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010396566,0.0006113607,0.011859745,0.00053035945,0.00012823826,0.000008785596,0.00024050134,0.00038391817,0.00026197554],"category_scores_gemma":[0.0002686247,0.00034545787,0.0013001225,0.0007288503,0.00031329933,0.000033457625,0.000091579685,0.0001609459,0.000005828663],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001000926,0.0007669055,0.00020027545,0.65138716,0.2437699,0.000016599393,0.0015893108,3.0102038e-7,2.9649755e-7,0.00082415843,0.00004866928,0.10129634],"study_design_scores_gemma":[0.0023039654,0.0005672473,0.00006445365,0.011712672,0.9511307,0.0009140518,0.000269325,2.2754277e-7,0.0000017695426,0.000026478041,0.032647297,0.00036184356],"about_ca_topic_score_codex":0.00018398523,"about_ca_topic_score_gemma":0.00023297561,"teacher_disagreement_score":0.7073608,"about_ca_system_score_codex":0.000043622254,"about_ca_system_score_gemma":0.00010080727,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W4297878627","doi":"10.1007/s13555-022-00811-0","title":"Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bell (Canada); EVERSANA (Canada); Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Institute for Energy Training; Women's College Hospital; University of Toronto","funders":"Janssen Canada","keywords":"Psoriasis; Medicine; Ethnic group; Incidence (geometry); Family medicine; Dermatology","score_opus":0.015535834025596386,"score_gpt":0.23544727240543967,"score_spread":0.21991143837984328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297878627","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34298667,0.6563606,1.8869216e-7,0.000094588766,0.000076309974,0.00038774635,0.000073425545,0.0000036037545,0.000016842476],"genre_scores_gemma":[0.02611705,0.97305787,0.0000047671033,0.0001334685,0.0000028378831,0.0002084628,0.0004291974,0.000015606032,0.000030770116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980233,0.0010929233,0.00036841462,0.0002585353,0.000025499574,0.0002313659],"domain_scores_gemma":[0.99829036,0.0013162011,0.00020548097,0.00016151625,0.000010899553,0.000015514584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018697587,0.00027668948,0.0013860438,0.00026560843,0.00010253624,0.000005085425,0.000118586024,0.00021465324,0.00007511857],"category_scores_gemma":[0.00001121625,0.00016223038,0.000042122705,0.00039382165,0.00029933295,0.000021470438,0.0000519298,0.00027342478,5.1073886e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021289343,0.00014247892,0.048763692,0.0013699959,0.0019502109,0.00015714108,0.003470686,0.000002421371,0.000001842318,0.0012721835,0.0002007883,0.9405396],"study_design_scores_gemma":[0.011158785,0.00013947781,0.0067396862,0.0003535617,0.00041698737,0.0014752169,0.0015092462,0.000005130968,0.00003298581,0.00013864406,0.9776719,0.00035832817],"about_ca_topic_score_codex":0.41637444,"about_ca_topic_score_gemma":0.6159803,"teacher_disagreement_score":0.9774712,"about_ca_system_score_codex":0.000041769177,"about_ca_system_score_gemma":0.00033949086,"threshold_uncertainty_score":0.6615563},"labels":[],"label_agreement":null},{"id":"W4298840351","doi":"","title":"Immunosupportive therapies in aging","year":2007,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.15991840174731015,"score_gpt":0.5010806955849536,"score_spread":0.34116229383764346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298840351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9032529,0.08952005,0.00009201729,0.00008342447,0.0010048911,0.00033001142,0.00003059851,0.000033905413,0.0056522284],"genre_scores_gemma":[0.98864466,0.009677201,0.00007567405,0.00015985566,0.00006577332,0.000024253544,0.00004029444,0.000034778328,0.0012775112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776,0.00033179522,0.00084918947,0.0003753835,0.00011375281,0.0005698742],"domain_scores_gemma":[0.99835086,0.00048162282,0.00060226966,0.00037390928,0.00013595569,0.000055388813],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018325254,0.000317311,0.00071489584,0.0009456899,0.00023149187,0.00020239942,0.0014828315,0.00021483742,0.011745168],"category_scores_gemma":[0.00010852726,0.00027026932,0.00020075236,0.000729359,0.00018023014,0.0010374326,0.00042217728,0.00036341822,0.00011312311],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042604253,0.00026607313,0.5274931,0.00001309077,0.00048370915,0.00007672565,0.00085609424,0.0000034743932,0.3804382,0.00007182948,0.002698869,0.08717278],"study_design_scores_gemma":[0.0011550421,0.000013778092,0.7665724,0.0001533068,0.000069895934,0.000029045843,0.0004548258,2.4491263e-7,0.22025463,0.0012508528,0.00978461,0.00026137475],"about_ca_topic_score_codex":0.0010037982,"about_ca_topic_score_gemma":0.00021327708,"teacher_disagreement_score":0.23907928,"about_ca_system_score_codex":0.00010348835,"about_ca_system_score_gemma":0.00009354491,"threshold_uncertainty_score":0.99997497},"labels":[],"label_agreement":null},{"id":"W4298850272","doi":"","title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","year":2015,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Etanercept; Tofacitinib; Medicine; Placebo; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Tumor necrosis factor alpha; Rheumatoid arthritis; Pathology","score_opus":0.03580989490834927,"score_gpt":0.28363052357678364,"score_spread":0.24782062866843438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298850272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96935004,0.0017222145,0.0046757013,0.0017875403,0.0031153918,0.004521222,0.00088977494,0.00029942804,0.013638709],"genre_scores_gemma":[0.978685,0.00083629217,0.0023107468,0.000055163604,0.000121824814,0.0015123484,0.0038203984,0.00009112488,0.0125671085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98867077,0.0080587445,0.0010310538,0.0012777552,0.0001989618,0.00076270744],"domain_scores_gemma":[0.9937196,0.0023697973,0.0005703225,0.0020754784,0.0010603076,0.0002045457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053905393,0.00074025156,0.0012584492,0.0004110941,0.0003480577,0.00022004146,0.0012528154,0.001134628,0.0011025327],"category_scores_gemma":[0.0021900462,0.00069182937,0.00040703607,0.00046406858,0.00021991876,0.00015019166,0.0009836382,0.0010289539,0.0004384642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76061165,0.0058178375,0.00020171017,0.000337117,0.0019592978,0.000091547336,0.025372228,0.0006723615,0.01305397,0.0013517857,0.007285199,0.18324532],"study_design_scores_gemma":[0.87735784,0.000045840578,0.00016641294,0.0018728714,0.00061151484,0.000031317326,0.00047102149,0.001665657,0.08875344,0.00042935458,0.026938023,0.0016567144],"about_ca_topic_score_codex":0.0013406064,"about_ca_topic_score_gemma":0.0075194133,"teacher_disagreement_score":0.1815886,"about_ca_system_score_codex":0.00067565934,"about_ca_system_score_gemma":0.0019567043,"threshold_uncertainty_score":0.9998106},"labels":[],"label_agreement":null},{"id":"W4300022276","doi":"10.17615/c1qn-1p61","title":"Genome-wide asociation analysis identifies three psoriasis susceptibility loci","year":2021,"lang":"en","type":"article","venue":"UNC Libraries","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institutes of Health; Canadian Institutes of Health Research; U.S. Department of Veterans Affairs; Bundesministerium für Forschung und Technologie; Krembil Foundation; Bundesministerium für Bildung und Forschung","keywords":"Genetics; Psoriasis; Biology; Computational biology; Genome; Evolutionary biology; Gene","score_opus":0.018449416056041064,"score_gpt":0.2244909516153828,"score_spread":0.20604153555934174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300022276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334783,0.010173521,0.0016223043,0.00065373763,0.000854575,0.00015624496,0.0001613258,0.0002203285,0.0028101208],"genre_scores_gemma":[0.9837229,0.00008066197,0.0008945529,0.0001606949,0.00010511932,0.000030183923,0.0029767605,0.000019832074,0.012009253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984008,0.00029667138,0.0003617519,0.0005079321,0.00007218516,0.00036065406],"domain_scores_gemma":[0.9987323,0.00039153878,0.00015005603,0.0005585717,0.00013635088,0.000031131443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002118078,0.00023700116,0.00048229663,0.00017401845,0.0004027463,0.00014721644,0.00020858757,0.00030309008,0.0053318804],"category_scores_gemma":[0.00027975455,0.00021896929,0.0004093868,0.0009125859,0.00019070528,0.00046310766,0.00014396649,0.00013077106,0.0005943233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016920734,0.00031160912,0.9338352,0.000034778892,0.008496539,0.000032588003,0.0019322295,0.000030317537,0.029890746,0.014149611,0.0030310487,0.008086127],"study_design_scores_gemma":[0.0008272537,0.00004005694,0.8508672,0.000004747318,0.0020976008,0.000003312724,0.000870782,0.0000024736005,0.11175776,0.0257526,0.0074850223,0.00029118248],"about_ca_topic_score_codex":0.00008828769,"about_ca_topic_score_gemma":0.0013355517,"teacher_disagreement_score":0.08296799,"about_ca_system_score_codex":0.00005858614,"about_ca_system_score_gemma":0.00015708378,"threshold_uncertainty_score":0.9955774},"labels":[],"label_agreement":null},{"id":"W4300793612","doi":"","title":"Psoriasis in children","year":2016,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Dermatology; Medicine","score_opus":0.1322892639360899,"score_gpt":0.4689617836532141,"score_spread":0.3366725197171242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300793612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651606,0.030137392,0.00004203019,0.00018525792,0.0010070914,0.00042881965,0.00013892094,0.000040904357,0.0028589973],"genre_scores_gemma":[0.98329544,0.014225016,0.000046568537,0.00011240124,0.0001132787,0.00006071894,0.000032610325,0.0000400141,0.0020739776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976548,0.0004802951,0.000737068,0.00048737437,0.00012039789,0.0005200447],"domain_scores_gemma":[0.99841446,0.0003767508,0.0005010218,0.0005183333,0.00011186073,0.0000775795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008122449,0.0003433134,0.00077830313,0.0008177813,0.00017709691,0.00016365017,0.0019826472,0.00027317437,0.022241434],"category_scores_gemma":[0.00020409389,0.00023465151,0.00022865138,0.0006250448,0.00017051818,0.0011580014,0.00056872505,0.00021473235,0.00040262585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026756496,0.00023934586,0.64939225,0.000005377685,0.00043316532,0.000010631902,0.000052456086,0.0000011423913,0.21831477,0.00006664552,0.012013698,0.11920295],"study_design_scores_gemma":[0.0023009526,0.000014303695,0.84123576,0.00019596325,0.00011154021,0.00003819631,0.00001529773,9.3633965e-8,0.1473958,0.001607195,0.00678702,0.00029790238],"about_ca_topic_score_codex":0.00076596753,"about_ca_topic_score_gemma":0.00008289863,"teacher_disagreement_score":0.19184348,"about_ca_system_score_codex":0.00010382406,"about_ca_system_score_gemma":0.00010233002,"threshold_uncertainty_score":0.97865236},"labels":[],"label_agreement":null},{"id":"W4301764150","doi":"10.1136/annrheumdis-2022-eular.892","title":"POS0074 IMMUNOLOGICAL DIFFERENCES BETWEEN PsA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Cilag; University of Oxford; Janssen Scientific Affairs; Memorial University of Newfoundland; Drexel University; College of Medicine, Drexel University; University of Washington","keywords":"Medicine; TNF inhibitor; Tumor necrosis factor alpha; Rheumatoid arthritis; Cytokine; Internal medicine; Psoriatic arthritis; Adalimumab; Immunology; Oncology","score_opus":0.03738201722601285,"score_gpt":0.2635972635267192,"score_spread":0.22621524630070633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301764150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880023,0.0020819376,0.000001259694,0.0013630314,0.00048128483,0.00088075217,0.0071120993,0.00006245837,0.000014899916],"genre_scores_gemma":[0.998233,0.00014805843,0.000006998019,0.00042005297,0.000022351544,0.00024667187,0.00010738508,0.000036123634,0.00077932613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962646,0.0014904845,0.0007605499,0.0005872416,0.0002576718,0.0006394707],"domain_scores_gemma":[0.9972545,0.0011688843,0.00067333906,0.00059269654,0.0001598469,0.00015076318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023535655,0.0005107526,0.0010470927,0.00024808798,0.0008809795,0.000072193325,0.000699082,0.00011613242,0.00044276065],"category_scores_gemma":[0.0010325289,0.00035331896,0.00041615634,0.0003353136,0.00039393204,0.00017503444,0.0009543563,0.0002586896,0.00004237434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037068368,0.0010107243,0.9302527,0.00012547648,0.0011404373,0.000008369496,0.0033953092,0.0000030263338,0.0022027688,0.000022432718,0.0051957387,0.052936234],"study_design_scores_gemma":[0.00155477,0.0011303698,0.9791331,0.0004514338,0.00021739208,0.000003361368,0.0011706142,0.0000022527915,0.015140832,0.00028179656,0.00049809663,0.00041594316],"about_ca_topic_score_codex":0.00033759285,"about_ca_topic_score_gemma":0.00001294777,"teacher_disagreement_score":0.05252029,"about_ca_system_score_codex":0.00007457319,"about_ca_system_score_gemma":0.000105586,"threshold_uncertainty_score":0.9998919},"labels":[],"label_agreement":null},{"id":"W4302218624","doi":"","title":"Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study","year":2014,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Disease; Medicine; Ethnography; Dermatology; Physical therapy; Internal medicine; History","score_opus":0.10002786603633301,"score_gpt":0.43127011312588454,"score_spread":0.3312422470895515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4302218624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564093,0.0019346536,0.000030275762,0.00005408941,0.0005534051,0.0014042062,0.00009553936,0.000058485548,0.00022839839],"genre_scores_gemma":[0.9990882,0.0002097512,0.00006415524,0.00015606593,0.000039099486,0.00016996409,0.00008105712,0.000052393196,0.00013926574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970039,0.0007860302,0.00079493236,0.00072551216,0.00024766463,0.0004419596],"domain_scores_gemma":[0.9976461,0.00018426722,0.0007456579,0.0007571178,0.00036284214,0.00030399236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005573883,0.0004775021,0.00092089735,0.0006962693,0.00047336236,0.00042194774,0.00091997196,0.00013796872,0.0007846398],"category_scores_gemma":[0.00017740668,0.00034746286,0.00014250036,0.00056016364,0.00013727436,0.0012659377,0.00049706124,0.00023466471,0.000010879483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023807513,0.0010644845,0.94725156,0.000016452746,0.0013756389,0.000027506692,0.001340097,0.00011944427,0.0007984533,0.0000039175366,0.0008557958,0.0447659],"study_design_scores_gemma":[0.0036987977,0.00023332417,0.9927318,0.00012277221,0.0006263426,0.0000032274434,0.00038701962,0.0000047824487,0.000797284,0.00023809422,0.00067385705,0.0004827088],"about_ca_topic_score_codex":0.0011021106,"about_ca_topic_score_gemma":0.00018626859,"teacher_disagreement_score":0.045480233,"about_ca_system_score_codex":0.000035020756,"about_ca_system_score_gemma":0.000055330245,"threshold_uncertainty_score":0.9998977},"labels":[],"label_agreement":null},{"id":"W4304687870","doi":"10.1007/s13555-022-00824-9","title":"Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma","keywords":"Betamethasone dipropionate; Lotion; Calcipotriol; Tazarotene; Medicine; Dermatology; Psoriasis; Plaque psoriasis; Pharmacology","score_opus":0.05013840468471775,"score_gpt":0.3084369931753386,"score_spread":0.2582985884906209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304687870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97835654,0.018710634,0.000104966355,0.0005245494,0.00046788025,0.001588451,0.00021036342,0.000024080222,0.000012547966],"genre_scores_gemma":[0.9953985,0.00349615,0.000068151465,0.00003649403,0.000009868956,0.00044206998,0.00048944243,0.000016837788,0.000042490246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980978,0.00072064885,0.000507938,0.00032739295,0.00006351193,0.00028274953],"domain_scores_gemma":[0.99832916,0.0010614566,0.00031444727,0.00023759335,0.000037878825,0.000019433961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021702566,0.0002735512,0.00091901363,0.00019113334,0.0003597159,0.0000059983804,0.00016697479,0.00021699147,0.000047078647],"category_scores_gemma":[0.000013422788,0.0001848406,0.0001357351,0.00016100761,0.00023656205,0.00004778779,0.000038704922,0.00015173928,0.0000016159039],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05911,0.004893324,0.44023883,0.00022684838,0.005043241,0.000082496525,0.043020226,0.00033915095,0.015599744,0.0028352146,0.000056220026,0.4285547],"study_design_scores_gemma":[0.09423242,0.004706908,0.8262433,0.000041221934,0.00074584025,0.00031517225,0.0019822877,0.00007464071,0.068501666,0.00039582633,0.002263509,0.0004972141],"about_ca_topic_score_codex":0.00015208623,"about_ca_topic_score_gemma":0.00013937126,"teacher_disagreement_score":0.4280575,"about_ca_system_score_codex":0.0000728339,"about_ca_system_score_gemma":0.00006598725,"threshold_uncertainty_score":0.7537581},"labels":[],"label_agreement":null},{"id":"W4304890405","doi":"10.1111/dth.15931","title":"Tapinarof for the treatment of psoriasis","year":2022,"lang":"en","type":"review","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research","funders":"","keywords":"Medicine; Psoriasis; Adverse effect; Dermatology; Folliculitis; Clinical trial; Tachyphylaxis; Upper respiratory tract infection; Clinical endpoint; Safety profile; Internal medicine","score_opus":0.11391123600145421,"score_gpt":0.33283784176012154,"score_spread":0.21892660575866735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304890405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008548252,0.9947847,0.0000169371,0.00007250397,0.0018582238,0.002348955,0.0005968034,0.000068159134,0.0001681959],"genre_scores_gemma":[0.000031273987,0.99355793,0.000036207046,0.000055569006,0.00006191706,0.0039438247,0.00096275157,0.00004541822,0.0013051372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980494,0.00054967194,0.0005912622,0.00040160617,0.000040263403,0.00036780295],"domain_scores_gemma":[0.99658656,0.0021504352,0.00054000434,0.00068436563,0.00002486122,0.000013758628],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014791655,0.0005276899,0.0019256271,0.00013304062,0.00039988157,0.000009050782,0.00053577014,0.00044275742,0.0015804261],"category_scores_gemma":[0.000016191047,0.0002649041,0.0014521622,0.00021667189,0.00015398841,0.000019800784,0.000029500921,0.0001165245,0.00008771602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012800598,0.00050777954,0.000007793027,0.00039093292,0.0031748035,0.0000065706126,0.0002446454,1.8605012e-7,0.000003966164,0.00027372502,0.0025919988,0.9926696],"study_design_scores_gemma":[0.0018056699,0.0009046386,0.0000047092853,0.00009889949,0.0015369031,0.0001962032,0.00009321016,1.1403375e-7,0.00023115728,0.00006467462,0.99481714,0.00024669405],"about_ca_topic_score_codex":0.00002174441,"about_ca_topic_score_gemma":0.000002369607,"teacher_disagreement_score":0.9924229,"about_ca_system_score_codex":0.00010058356,"about_ca_system_score_gemma":0.00013609532,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4306174538","doi":"10.1002/jmv.28196","title":"Back Cover Image, Volume 94, Number 12, December 2022","year":2022,"lang":"en","type":"paratext","venue":"Journal of Medical Virology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Cover (algebra); Coronavirus disease 2019 (COVID-19); Image (mathematics); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Volume (thermodynamics); Virology; Medicine; Internal medicine; Artificial intelligence; Computer science; Engineering; Physics","score_opus":0.013813280990821863,"score_gpt":0.27400871798889126,"score_spread":0.2601954369980694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306174538","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11476192,0.09499925,0.000860064,0.017923176,0.1170779,0.0009267312,0.0015546842,0.0000498727,0.6518464],"genre_scores_gemma":[0.0031375433,0.017886154,0.00015586456,0.0035150265,0.0021010458,0.000039621635,0.0010891061,0.00011963736,0.971956],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949671,0.0017556658,0.001428408,0.0005236011,0.00049879437,0.00082639925],"domain_scores_gemma":[0.9971542,0.00066509267,0.0013183247,0.0004806847,0.00015664814,0.00022506398],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0014993497,0.00058481167,0.0017505287,0.00030414358,0.00024154414,0.000022855222,0.0013424129,0.002573079,0.8956739],"category_scores_gemma":[0.00035495925,0.00046725982,0.0008257197,0.00019437562,0.00061740034,0.00011791968,0.0005295132,0.0033449198,0.19509344],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011159795,0.0005522908,0.0003936828,0.00004496163,0.0022507943,0.0007529261,0.000089999274,0.000005872286,0.0018268359,0.000028669367,0.98604614,0.006891872],"study_design_scores_gemma":[0.005075752,0.00085293065,0.0008172658,0.000058407022,0.0006894532,0.006357429,0.00004162943,0.000002652046,0.00025666674,0.000042685224,0.985426,0.0003791416],"about_ca_topic_score_codex":0.000054003514,"about_ca_topic_score_gemma":0.000024300452,"teacher_disagreement_score":0.7005805,"about_ca_system_score_codex":0.00020970001,"about_ca_system_score_gemma":0.0011450443,"threshold_uncertainty_score":0.9997779},"labels":[],"label_agreement":null},{"id":"W4307427140","doi":"10.18553/jmcp.2022.28.11.1213","title":"COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data","year":2022,"lang":"en","type":"article","venue":"Journal of Managed Care & Specialty Pharmacy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Coronavirus disease 2019 (COVID-19); Pharmacy; Medicine; 2019-20 coronavirus outbreak; MEDLINE; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Pandemic; Psoriasis; Family medicine; Virology; Dermatology; Disease; Internal medicine; Infectious disease (medical specialty); Political science","score_opus":0.09957264582041192,"score_gpt":0.3783236926464389,"score_spread":0.27875104682602697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307427140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98046774,0.013230606,0.00058070006,0.0011282436,0.0015617427,0.00059138867,0.0023013172,0.000025226207,0.00011305166],"genre_scores_gemma":[0.99554145,0.0016033627,0.00055553345,0.0011035015,0.00027913143,0.000045777324,0.0006921645,0.000016867209,0.00016222692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780107,0.00073398586,0.00066512986,0.00039132274,0.00013925435,0.00026924512],"domain_scores_gemma":[0.9981054,0.000431893,0.0006790154,0.00041193224,0.00023408183,0.00013765336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001233119,0.00022243301,0.0006488604,0.00078636856,0.0005044479,0.00002933794,0.0009759555,0.000041585266,0.0016249812],"category_scores_gemma":[0.00022406982,0.00019056369,0.0002605725,0.00072401145,0.00008757773,0.00024403268,0.000308398,0.00024235889,0.0000038366456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015012586,0.0014035531,0.12382832,0.00028921288,0.024714276,0.00014778256,0.024338594,0.0025903087,0.117132105,0.0009243524,0.025261063,0.66435784],"study_design_scores_gemma":[0.017123748,0.0021556532,0.024899222,0.000018695217,0.01249515,0.0001175374,0.021726198,0.00014973461,0.011863556,0.00047737433,0.90831614,0.0006569707],"about_ca_topic_score_codex":0.00021207752,"about_ca_topic_score_gemma":0.0003730078,"teacher_disagreement_score":0.8830551,"about_ca_system_score_codex":0.00016933828,"about_ca_system_score_gemma":0.0002970765,"threshold_uncertainty_score":0.99928766},"labels":[],"label_agreement":null},{"id":"W4307723138","doi":"10.1016/j.jaad.2022.10.041","title":"Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Bellus Health (Canada); Queen's University; University of British Columbia; Probity Medical Research","funders":"Manitoba Beekeepers' Association; Amgen","keywords":"Apremilast; Medicine; Psoriasis; Randomized controlled trial; Phase (matter); Extension (predicate logic); Internal medicine; Dermatology; Psoriatic arthritis","score_opus":0.01600549215371726,"score_gpt":0.2848892945368695,"score_spread":0.26888380238315224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307723138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916448,0.000908885,0.000038560873,0.0053760214,0.00053547637,0.0010479934,0.00043452784,0.000002981957,0.000010755228],"genre_scores_gemma":[0.9989119,0.0002072317,0.00016343291,0.0006227004,0.00002859184,0.000020080342,0.000008921934,0.0000135432465,0.000023569513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99570304,0.0024067187,0.0012560181,0.00023073294,0.00016618606,0.00023728509],"domain_scores_gemma":[0.99530447,0.0018648877,0.0024097357,0.00029599838,0.000086872096,0.00003801385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066199177,0.00020715958,0.0013466957,0.00015502314,0.00018499536,0.0000027532637,0.0006726159,0.000082704064,0.000016833234],"category_scores_gemma":[0.0006414962,0.00010096142,0.00025047964,0.0004898133,0.0006712676,0.00005519953,0.00027907995,0.0004967936,9.970952e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9681927,0.00083526754,0.002087458,0.0000049265423,0.00067903043,0.000002549218,0.0019513578,0.00029106226,0.015247935,0.00002026342,0.0010122149,0.009675235],"study_design_scores_gemma":[0.9217539,0.0020583628,0.02711047,0.0001616821,0.00081529043,0.00014217685,0.0007352294,0.000011189537,0.04442465,0.000094417,0.0025167253,0.00017595291],"about_ca_topic_score_codex":0.00007186068,"about_ca_topic_score_gemma":0.0000055753553,"teacher_disagreement_score":0.046438847,"about_ca_system_score_codex":0.00003894315,"about_ca_system_score_gemma":0.000094319556,"threshold_uncertainty_score":0.41170874},"labels":[],"label_agreement":null},{"id":"W4307851580","doi":"10.1007/s13555-022-00840-9","title":"A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians","year":2022,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Psoriasis; Intensive care medicine; Food and drug administration; Limiting; Modalities; Drug; Disease; First line; Pharmacology; Internal medicine; Dermatology","score_opus":0.1323058363091473,"score_gpt":0.40444072710116097,"score_spread":0.2721348907920137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307851580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075185514,0.9933428,0.0000011406115,0.00018053017,0.002720062,0.0026539622,0.00024845713,0.000020596462,0.00008058973],"genre_scores_gemma":[0.00003664904,0.996985,0.000016050471,0.0009992992,0.000090698784,0.0010596506,0.0007151917,0.000032729775,0.00006471628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943714,0.0033253157,0.001478726,0.00049325154,0.000029780107,0.00030152278],"domain_scores_gemma":[0.99719626,0.001344293,0.0008092671,0.00060411403,0.000024383533,0.000021659143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011688916,0.00036234077,0.0026878496,0.00012215541,0.00017147367,0.0000045705533,0.00051735656,0.0007868854,0.00041566356],"category_scores_gemma":[0.00013891661,0.00022064963,0.0009283184,0.00022836748,0.00021394608,0.000037753634,0.00008454472,0.00050606194,0.000015785903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027240172,0.00050651265,0.00013530364,0.005073996,0.0007593258,0.000005582137,0.00003956444,4.9942637e-9,1.1532619e-7,0.00028347154,0.0027278895,0.9877442],"study_design_scores_gemma":[0.01992209,0.00046425837,0.000017634438,0.0037285667,0.00088205584,0.00021690749,0.000017600387,9.021097e-8,0.0000024119847,0.00014748321,0.9743959,0.0002050349],"about_ca_topic_score_codex":0.0000057950774,"about_ca_topic_score_gemma":0.000019461719,"teacher_disagreement_score":0.9875392,"about_ca_system_score_codex":0.000010104676,"about_ca_system_score_gemma":0.00028790536,"threshold_uncertainty_score":0.8997831},"labels":[],"label_agreement":null},{"id":"W4307973407","doi":"10.3899/jrheum.220313","title":"Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations","year":2022,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Cilag; UCB Pharma; InflaRx; LEO Pharma; Incyte; Celgene; Eli Lilly and Company; Arthritis Australia; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Medicine; Acitretin; Dermatology; Psoriasis; Psoriatic arthritis; Pimecrolimus; Tofacitinib; Apremilast; Tazarotene; Dactylitis; Population; Nail disease; Surgery; Internal medicine; Tacrolimus; Enthesitis; Rheumatoid arthritis","score_opus":0.016442733135205036,"score_gpt":0.26560544450493245,"score_spread":0.24916271136972742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307973407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033574346,0.9944972,0.000002037309,0.00020199917,0.00061779434,0.0010929276,0.00019475246,0.0000052230666,0.000030678773],"genre_scores_gemma":[0.00060829025,0.9973356,0.000037729034,0.000030486764,0.0000047711,0.0001186763,0.0017428453,0.000024788178,0.00009680362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961997,0.0019476516,0.0013133349,0.00017574095,0.000091473485,0.0002720923],"domain_scores_gemma":[0.99718624,0.00031125246,0.0017927329,0.00058278255,0.00008951853,0.000037496622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000696788,0.00038829877,0.0016867708,0.0002658625,0.00021828589,0.000010832342,0.0005919424,0.00013796144,0.00081359776],"category_scores_gemma":[0.00002339849,0.00017931277,0.00035341634,0.0005885369,0.000113713206,0.0001285403,0.000096423195,0.00044889378,0.000016370732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027508044,0.0004590216,0.0007034457,0.002445669,0.0024232653,0.000033501186,0.0003327667,0.0000014851365,1.2407066e-8,0.00015311669,0.00067374867,0.9924989],"study_design_scores_gemma":[0.0027854608,0.00083441596,0.00043163833,0.04884856,0.005443376,0.0007911643,0.00018679029,1.3268591e-7,2.5066961e-7,0.00004177042,0.9404102,0.00022624528],"about_ca_topic_score_codex":0.000023782552,"about_ca_topic_score_gemma":0.00003312276,"teacher_disagreement_score":0.9922726,"about_ca_system_score_codex":0.00013178286,"about_ca_system_score_gemma":0.00020128982,"threshold_uncertainty_score":0.8908325},"labels":[],"label_agreement":null},{"id":"W4308580112","doi":"10.1016/j.ad.2022.07.025","title":"[Artículo traducido] Calidad de vida y región corporal afectada por la psoriasis: una revisión sistemática","year":2022,"lang":"es","type":"review","venue":"Actas Dermo-Sifiliográficas","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of Ottawa","funders":"","keywords":"Psoriasis; Quality of life (healthcare); Web of science; Population; Medicine; MEDLINE; Dermatology; Biology; Meta-analysis; Pathology; Environmental health; Nursing","score_opus":0.04407894958129648,"score_gpt":0.30153554395703264,"score_spread":0.25745659437573615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308580112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006343614,0.96785456,0.000038752583,0.00060674583,0.0043375366,0.0034987223,0.0029600349,0.0006505846,0.013709438],"genre_scores_gemma":[0.03347134,0.94631934,0.0003978575,0.000510858,0.0010830414,0.0017509112,0.0073361057,0.0005678214,0.008562713],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97877926,0.01061665,0.0035115853,0.0034765285,0.00059286266,0.0030231343],"domain_scores_gemma":[0.98704046,0.005638315,0.002868849,0.0036458364,0.00020990615,0.00059666036],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0034302264,0.0031914036,0.006686592,0.001649652,0.0017931095,0.0004513142,0.0026626128,0.0034967964,0.014976617],"category_scores_gemma":[0.0011576149,0.0029627613,0.004758499,0.0028667424,0.0010646275,0.00038645856,0.00083887955,0.0031666558,0.0027212922],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015898673,0.0032000332,0.0012763499,0.0205862,0.015934676,0.005774639,0.0009938795,0.000004730414,0.0019181638,0.00346313,0.110467434,0.8347909],"study_design_scores_gemma":[0.0032463374,0.00094727677,0.00092782895,0.0064972,0.01274629,0.0063917106,0.00043149883,0.0000036114632,0.0006524186,0.00023638552,0.96517843,0.0027410039],"about_ca_topic_score_codex":0.00057852414,"about_ca_topic_score_gemma":0.000088257286,"teacher_disagreement_score":0.854711,"about_ca_system_score_codex":0.0010639015,"about_ca_system_score_gemma":0.0018982801,"threshold_uncertainty_score":0.9995064},"labels":[],"label_agreement":null},{"id":"W4308834973","doi":"10.1007/s40257-022-00739-3","title":"Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial","year":2022,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"","keywords":"Medicine; Roflumilast; Psoriasis; Psoriasis Area and Severity Index; Eczema Area and Severity Index; Erythema; Dermatology; Dermatology Life Quality Index; Severity of illness; Body surface area; Dose-ranging study; Randomized controlled trial; Post-hoc analysis; Physical therapy; Internal medicine; Atopic dermatitis; Placebo; Double blind; Pathology; COPD","score_opus":0.011840739231970945,"score_gpt":0.30982363626329584,"score_spread":0.2979828970313249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308834973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996357,0.0011007407,0.0000070128917,0.00048781524,0.0012903932,0.0006260084,0.00006465868,0.000015435282,0.00005092459],"genre_scores_gemma":[0.9993088,0.000358798,0.00003277515,0.000113378504,0.000037010894,0.000057000118,0.000045226032,0.000030614785,0.00001640177],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923365,0.0034845578,0.0030998604,0.00042717654,0.00020165645,0.00045024086],"domain_scores_gemma":[0.9915325,0.004216567,0.0036236148,0.0003783105,0.00014580988,0.00010319042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012266727,0.0003801913,0.0028787265,0.0004313293,0.00010309271,0.00000433171,0.00037407837,0.00027467698,0.0001745956],"category_scores_gemma":[0.00073262776,0.00027162497,0.00048699608,0.00049135805,0.0010128274,0.00008092773,0.0001269581,0.0009437828,0.0000068297304],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26516223,0.0044365823,0.5885671,0.000057297806,0.0033298503,0.0010105249,0.0006582483,0.000047765854,0.00071745116,0.000032028034,0.00013885026,0.13584207],"study_design_scores_gemma":[0.60258275,0.17075595,0.18480077,0.0005318514,0.0029686105,0.009296326,0.0014534938,0.000039456558,0.024802675,0.0000626068,0.0018381529,0.0008673282],"about_ca_topic_score_codex":0.00016212088,"about_ca_topic_score_gemma":0.00004111376,"teacher_disagreement_score":0.40376633,"about_ca_system_score_codex":0.00006665466,"about_ca_system_score_gemma":0.00034688067,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W4309245215","doi":"10.30498/ijb.2022.276921.3012","title":"The <i>HLA rs9267649</i> and <i>CYP24A1 rs2248359</i> Variants are Associated with Multiple Sclerosis: A Study on Iranian Population.","year":2022,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SGS (Canada)","funders":"","keywords":"Multiple sclerosis; Allele; Genotype; Medicine; Internal medicine; Vitamin D and neurology; Population; Expanded Disability Status Scale; Genetics; Biology; Immunology; Gene","score_opus":0.03292506493897867,"score_gpt":0.19513850226511262,"score_spread":0.16221343732613394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309245215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995739,0.0011168615,0.0000011239011,0.00036416578,0.000541102,0.0015769707,0.00021908712,0.00011293907,0.0003287731],"genre_scores_gemma":[0.9941766,0.000029350245,0.0000023371535,0.0002620407,0.000025297231,0.0036292262,0.000109710134,0.000029654753,0.0017357644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980451,0.0007178351,0.00023371627,0.00040645397,0.000106034924,0.0004908458],"domain_scores_gemma":[0.99895686,0.00042208546,0.00021055153,0.0003355746,0.00003457863,0.000040366715],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0006510003,0.00022502923,0.00027470163,0.000072560055,0.001561643,0.000049928185,0.0002232164,0.000082129714,0.000024040899],"category_scores_gemma":[0.0001437572,0.00015307302,0.000056569035,0.00027869217,0.0000681582,0.00006451887,0.00012310299,0.00023571854,0.000015129463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011981945,0.0013972138,0.94295305,0.000002848365,0.0011277659,0.00002653697,0.0008548865,0.000021565698,0.00029272036,0.00005160156,0.0015199528,0.050553635],"study_design_scores_gemma":[0.005044311,0.00029976582,0.9908866,0.000008412747,0.00020383595,0.000012862379,0.0014942776,0.0000016374757,0.0001417273,0.000023927309,0.0016884821,0.00019414634],"about_ca_topic_score_codex":0.0001635919,"about_ca_topic_score_gemma":0.00052254624,"teacher_disagreement_score":0.050359488,"about_ca_system_score_codex":0.00010901713,"about_ca_system_score_gemma":0.00001621692,"threshold_uncertainty_score":0.9997382},"labels":[],"label_agreement":null},{"id":"W4309247569","doi":"10.1007/s13555-022-00843-6","title":"Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; LEO Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Janssen Pharmaceuticals; Gilead Sciences; Union Chimique Belge; Sanofi; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Psoriatic arthritis; Body mass index; Odds ratio; Body surface area; Internal medicine; Visual analogue scale; Confidence interval; Physical therapy; Dermatology","score_opus":0.017252792669996294,"score_gpt":0.22538397874167568,"score_spread":0.20813118607167938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309247569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952228,0.0024562548,0.000007700203,0.0007582852,0.0005327712,0.00043926836,0.00045423995,0.000030618026,0.000098073164],"genre_scores_gemma":[0.9973909,0.00078995625,0.00006713016,0.0008021147,0.000009863205,0.00016228911,0.00067360635,0.000017917728,0.00008621786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980992,0.00072310254,0.00039949318,0.00039327363,0.00005567695,0.00032926933],"domain_scores_gemma":[0.9986868,0.00047110615,0.00029686632,0.00046367146,0.00005959499,0.00002195309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010912836,0.00028623716,0.0006642449,0.000105260064,0.00034536837,0.000010760772,0.00033908995,0.00020655862,0.000278045],"category_scores_gemma":[0.00003238072,0.00017747011,0.00010448827,0.00023373247,0.00031642144,0.00007880435,0.00009521224,0.00028343074,0.000014531527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015009387,0.0004054793,0.9886982,0.000004668867,0.00073119503,0.000023201766,0.0013554832,0.000003105259,0.00047880996,0.00019784435,0.0008709902,0.0057301093],"study_design_scores_gemma":[0.008397324,0.00031324843,0.9850094,0.000013161805,0.00010074023,0.00006443267,0.00088584895,0.000002497382,0.001257189,0.00015646168,0.003585278,0.00021446466],"about_ca_topic_score_codex":0.00061127654,"about_ca_topic_score_gemma":0.0005141759,"teacher_disagreement_score":0.006896385,"about_ca_system_score_codex":0.000023399343,"about_ca_system_score_gemma":0.000039269325,"threshold_uncertainty_score":0.7237021},"labels":[],"label_agreement":null},{"id":"W4309313322","doi":"10.25251/skin.6.supp.47","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Medicine; Psoriasis; Internal medicine; Gastroenterology; Dermatology; Pharmacology","score_opus":0.023743141155382914,"score_gpt":0.29033300301102205,"score_spread":0.26658986185563915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988092,0.00467635,0.000016299931,0.004319676,0.001161053,0.0014353665,0.00013813663,0.000016696664,0.00014440887],"genre_scores_gemma":[0.99741435,0.00056300795,0.00003630246,0.00077039056,0.00037701483,0.0000980427,0.00011670865,0.000035129528,0.0005890485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99524224,0.0027072905,0.0009627983,0.00031121715,0.0002540719,0.000522355],"domain_scores_gemma":[0.9978817,0.0010714306,0.00047009552,0.00038833203,0.00010362774,0.000084804735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016373715,0.00040270278,0.0008405928,0.0003634678,0.00043837036,0.000018315071,0.0005996686,0.00014596713,0.00035316372],"category_scores_gemma":[0.00023652342,0.00021817471,0.00014459273,0.0006566188,0.00014883584,0.000095174924,0.000059928378,0.0006942473,0.000015966401],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59164435,0.020917438,0.00019461715,0.00001986759,0.0014865927,0.004722721,0.07276827,0.0022815347,0.10910726,0.00009036378,0.03461926,0.16214772],"study_design_scores_gemma":[0.57763606,0.16964345,0.0004954166,0.00039912772,0.0026426252,0.039799407,0.029819317,0.00008820867,0.066760235,0.0008283017,0.11067553,0.0012123291],"about_ca_topic_score_codex":0.00061933714,"about_ca_topic_score_gemma":0.00053312496,"teacher_disagreement_score":0.16093539,"about_ca_system_score_codex":0.00047583468,"about_ca_system_score_gemma":0.0003337882,"threshold_uncertainty_score":0.88969064},"labels":[],"label_agreement":null},{"id":"W4309313508","doi":"10.25251/skin.6.supp.72","title":"Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Plaque psoriasis; Medicine; Psoriasis; Clinical trial; Pooled analysis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.05224517280317597,"score_gpt":0.3519867857175708,"score_spread":0.29974161291439483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309313508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722385,0.0014565598,0.000022546432,0.00016461768,0.0003056836,0.0003291975,0.00048674786,0.0000021854555,0.000008611796],"genre_scores_gemma":[0.9986297,0.0009037106,0.000034544013,0.000036599118,0.000039662227,0.0000050477693,0.00031197447,0.000008223121,0.00003057316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962072,0.00215126,0.00123634,0.00017124315,0.000106827676,0.00012716105],"domain_scores_gemma":[0.9967508,0.001897618,0.00093093136,0.00031646033,0.00007364242,0.000030596693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022653139,0.00013791035,0.0012596496,0.00052645145,0.000042641183,0.0000022920287,0.00020361286,0.000075483396,0.000285777],"category_scores_gemma":[0.00047392354,0.00007925216,0.000089090616,0.0005392276,0.00009235352,0.000046268728,0.000070676295,0.00018426639,8.606301e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16127144,0.005832577,0.52977675,0.000020488058,0.02725873,0.0003245379,0.010949467,0.008912057,0.006952492,0.00000832244,0.00089729996,0.24779584],"study_design_scores_gemma":[0.15564106,0.053423423,0.7371771,0.0005496392,0.039878417,0.000623462,0.0036682996,0.0008723104,0.005343643,0.0003722209,0.0019027244,0.00054772536],"about_ca_topic_score_codex":0.0014337421,"about_ca_topic_score_gemma":0.00094275863,"teacher_disagreement_score":0.24724811,"about_ca_system_score_codex":0.00009329552,"about_ca_system_score_gemma":0.000114313705,"threshold_uncertainty_score":0.3231809},"labels":[],"label_agreement":null},{"id":"W4309316023","doi":"10.25251/skin.6.supp.67","title":"Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Pooled analysis; Psoriasis; Clinical trial; Medicine; Dermatology; Internal medicine; Meta-analysis","score_opus":0.05999239470806655,"score_gpt":0.3657157579674115,"score_spread":0.30572336325934496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309316023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921739,0.005604554,0.00010484885,0.00033901408,0.00064193184,0.0003158437,0.00077708875,0.0000050901153,0.00003769553],"genre_scores_gemma":[0.9977575,0.0012024199,0.00010060661,0.00013506273,0.00011870045,0.0000020998568,0.00059940264,0.000014158647,0.000070082024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942977,0.0034581348,0.001589687,0.00025017827,0.0002050468,0.00019927333],"domain_scores_gemma":[0.99376404,0.0040694666,0.0014537426,0.00056621665,0.000108772256,0.000037740472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003876375,0.00019178497,0.0015844628,0.00026333364,0.00013146333,0.000004561403,0.0005600238,0.00008606263,0.0007855361],"category_scores_gemma":[0.0008989283,0.00010656876,0.00013820881,0.00051914324,0.00027331954,0.00007666419,0.00017874615,0.00044756426,0.00000274762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43663695,0.008690389,0.04642828,0.000021495742,0.09413091,0.0012750438,0.024146868,0.0052742576,0.0036114538,0.00006953206,0.007939227,0.37177557],"study_design_scores_gemma":[0.49356747,0.039070316,0.27135062,0.000795167,0.16580237,0.001704159,0.0106188925,0.0014970984,0.0015829914,0.0015803602,0.011158049,0.0012725078],"about_ca_topic_score_codex":0.00033641208,"about_ca_topic_score_gemma":0.000098215925,"teacher_disagreement_score":0.37050307,"about_ca_system_score_codex":0.000046859175,"about_ca_system_score_gemma":0.00010944539,"threshold_uncertainty_score":0.8601069},"labels":[],"label_agreement":null},{"id":"W4309317622","doi":"10.25251/skin.6.supp.66","title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plaque psoriasis; Clinical trial; Pooled analysis; Psoriasis; Internal medicine; Dermatology; Meta-analysis","score_opus":0.0520842969948615,"score_gpt":0.34155571863602985,"score_spread":0.28947142164116835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961836,0.0012236913,0.00006861441,0.00041157324,0.0003830167,0.0004953457,0.001220112,0.0000022290046,0.000011857093],"genre_scores_gemma":[0.999023,0.00042165213,0.00008357816,0.00007965424,0.000042688644,0.000004930433,0.00028456133,0.0000108133345,0.00004908949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962757,0.001654257,0.0015223384,0.00022430802,0.00015093907,0.00017242643],"domain_scores_gemma":[0.99643683,0.0021228513,0.000820723,0.00048389478,0.00008068474,0.000054998243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026068897,0.00016812932,0.0015845819,0.00053991046,0.00004823912,0.0000022365386,0.0003995809,0.00008038556,0.0004012007],"category_scores_gemma":[0.0005276514,0.000096840675,0.000109024666,0.0006255794,0.00008753959,0.000037026628,0.00013257223,0.00020047564,0.0000016262418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36047593,0.0042577446,0.17557369,0.000016148548,0.032901224,0.00049808976,0.017459705,0.008910816,0.0037763126,0.000014721262,0.0013534208,0.39476222],"study_design_scores_gemma":[0.22481945,0.07463846,0.6283895,0.00082230766,0.053445935,0.00070163887,0.008557209,0.0007836918,0.002378857,0.00047042864,0.004139927,0.00085258327],"about_ca_topic_score_codex":0.001052433,"about_ca_topic_score_gemma":0.002229926,"teacher_disagreement_score":0.4528158,"about_ca_system_score_codex":0.00012984156,"about_ca_system_score_gemma":0.00014895311,"threshold_uncertainty_score":0.43928662},"labels":[],"label_agreement":null},{"id":"W4309317789","doi":"10.25251/skin.6.supp.70","title":"Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Secukinumab; Plaque psoriasis; Post-hoc analysis; Medicine; Post hoc; Psoriasis; Dermatology; Physical therapy; Internal medicine","score_opus":0.015508266964146407,"score_gpt":0.2422494022651389,"score_spread":0.22674113530099252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98869914,0.0016198726,0.000008924415,0.005709999,0.0018448912,0.0008086045,0.0011995432,0.000009992086,0.000099011944],"genre_scores_gemma":[0.99802417,0.0002613158,0.00008083895,0.00065212656,0.00020307538,0.00001373625,0.00014839685,0.000030935294,0.0005854056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964428,0.001615003,0.0009550958,0.0002586472,0.00034410952,0.00038432988],"domain_scores_gemma":[0.9957498,0.0024964677,0.00089248526,0.0005124837,0.00029656582,0.000052228017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013812331,0.0002809059,0.00077697175,0.00014212911,0.00031350338,0.000006884281,0.0005873544,0.00011818132,0.000414063],"category_scores_gemma":[0.00084814476,0.00014987976,0.00012587375,0.00032392528,0.00021602988,0.00007026169,0.00014150952,0.0005176961,0.00001443889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9668945,0.0006701606,0.000039801173,0.0000032719188,0.0010001439,0.0003754385,0.014845729,0.00042421598,0.003425969,0.000011616296,0.008785756,0.0035234012],"study_design_scores_gemma":[0.8385379,0.096738555,0.002522148,0.00068217266,0.0020611193,0.0022255236,0.015282777,0.000010511316,0.0066269757,0.00018778778,0.0345204,0.00060414645],"about_ca_topic_score_codex":0.00044358772,"about_ca_topic_score_gemma":0.0002262329,"teacher_disagreement_score":0.12835662,"about_ca_system_score_codex":0.00036015842,"about_ca_system_score_gemma":0.00026601387,"threshold_uncertainty_score":0.611192},"labels":[],"label_agreement":null},{"id":"W4309317888","doi":"10.25251/skin.6.supp.45","title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec","funders":"XBiotech; Bristol-Myers Squibb","keywords":"Apremilast; Plaque psoriasis; Placebo; Medicine; Psoriasis; Tyrosine-kinase inhibitor; Body surface area; Internal medicine; Pharmacology; Dermatology; Pathology; Psoriatic arthritis; Alternative medicine","score_opus":0.03984404570829199,"score_gpt":0.3064452367381327,"score_spread":0.2666011910298407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309317888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077195,0.00645587,0.000025176518,0.0014500371,0.0004056958,0.0006476088,0.00017442893,0.0000061418195,0.000063102205],"genre_scores_gemma":[0.99812776,0.0012986085,0.000050992858,0.00027700578,0.00006730104,0.000019402294,0.00007456063,0.000016369831,0.00006800497],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995013,0.0030747654,0.0010903685,0.0002676285,0.00023197896,0.00032226025],"domain_scores_gemma":[0.99659663,0.0022333404,0.00067969435,0.0002825589,0.00013924028,0.00006850524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046238666,0.00029594867,0.0012368337,0.0005886096,0.00023486429,0.0000135894015,0.00032816335,0.00011541627,0.0001557864],"category_scores_gemma":[0.000481857,0.00017170032,0.0001131345,0.0010394608,0.00019101809,0.000085494445,0.00009422665,0.00049206323,6.7699875e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35061324,0.005118311,0.01018104,0.00010838054,0.014437792,0.0020821667,0.11605135,0.032135885,0.4357758,0.00022467844,0.008770233,0.024501145],"study_design_scores_gemma":[0.3672185,0.10288684,0.0138748,0.001556657,0.05000778,0.019333545,0.24015199,0.0039497497,0.18275486,0.0018910888,0.013525844,0.0028483598],"about_ca_topic_score_codex":0.00052597723,"about_ca_topic_score_gemma":0.0013677629,"teacher_disagreement_score":0.2530209,"about_ca_system_score_codex":0.0001500522,"about_ca_system_score_gemma":0.000121704805,"threshold_uncertainty_score":0.70017356},"labels":[],"label_agreement":null},{"id":"W4309319190","doi":"10.25251/skin.6.supp.65","title":"Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Open label; Psoriasis; Medicine; Extension (predicate logic); Internal medicine; Dermatology; Randomized controlled trial; Computer science","score_opus":0.02902341705181288,"score_gpt":0.2578144856618625,"score_spread":0.2287910686100496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309319190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893557,0.0011810854,0.00002375372,0.0066938256,0.0011491474,0.0010036036,0.0004435516,0.000006980243,0.00014237472],"genre_scores_gemma":[0.99605125,0.00018555958,0.00011198763,0.00088390097,0.00010889575,0.000015748252,0.0000750954,0.000031374715,0.0025361744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583346,0.002235568,0.00095066824,0.00029446444,0.00034113202,0.00034471956],"domain_scores_gemma":[0.9953974,0.002783674,0.00091118057,0.0006468034,0.00021851055,0.000042430645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022690573,0.0002599645,0.00076438393,0.00014407751,0.0003758663,0.000010211057,0.0009878527,0.000117992844,0.00032121572],"category_scores_gemma":[0.00078005594,0.0001291839,0.00007147555,0.00043707044,0.00024006773,0.00009267813,0.0003582316,0.00050733367,0.000010046971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95362437,0.0005862732,0.00018643864,0.0000021447986,0.00048206773,0.00039279545,0.007996605,0.00039853918,0.0038697014,0.000021877606,0.027912544,0.004526641],"study_design_scores_gemma":[0.7719385,0.06323104,0.058361452,0.001663389,0.0019923383,0.005819486,0.0058721346,0.00002952478,0.011243013,0.003196271,0.075705,0.00094786787],"about_ca_topic_score_codex":0.00093200407,"about_ca_topic_score_gemma":0.0007388687,"teacher_disagreement_score":0.1816859,"about_ca_system_score_codex":0.0003342432,"about_ca_system_score_gemma":0.00022964725,"threshold_uncertainty_score":0.52679664},"labels":[],"label_agreement":null},{"id":"W4309477704","doi":"10.1016/j.jid.2022.09.408","title":"395 Defining Paradoxical Psoriasis and Deep Tissue Immune Cell Profiling","year":2022,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Immune system; Immunology; Flow cytometry; Pathology; Tumor necrosis factor alpha","score_opus":0.01678178767423258,"score_gpt":0.2395630229586395,"score_spread":0.2227812352844069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309477704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97029346,0.026857797,0.00010229332,0.0010805901,0.000933337,0.00013967871,0.00002691306,0.000020133835,0.0005457727],"genre_scores_gemma":[0.9965874,0.0002108085,0.0026159245,0.00030945917,0.000035325742,0.000027124093,0.00003991841,0.000020490023,0.00015356923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770695,0.0009474415,0.00069278927,0.00022144841,0.000077437144,0.00035392374],"domain_scores_gemma":[0.99858695,0.00042768655,0.0006601499,0.00014786166,0.00010548214,0.00007187731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036849795,0.00022534674,0.00063610415,0.00024993042,0.0004745666,0.0000130039925,0.00025159362,0.0001697956,0.00028278373],"category_scores_gemma":[0.0001644163,0.00019664086,0.00012656984,0.00020833287,0.00044455985,0.00012218792,0.00017754905,0.0006106564,0.0000518578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053557026,0.00032396519,0.012212583,0.000054761902,0.00074546214,0.0007763467,0.0038177967,0.000058429316,0.9639633,0.006273724,0.0015451423,0.009692897],"study_design_scores_gemma":[0.0029692089,0.00059523823,0.0048716855,0.000016191692,0.0002657883,0.009781606,0.0023296352,0.000010373864,0.96548986,0.002259131,0.011177654,0.00023359997],"about_ca_topic_score_codex":0.000011396141,"about_ca_topic_score_gemma":0.0000024310323,"teacher_disagreement_score":0.026646988,"about_ca_system_score_codex":0.000060506874,"about_ca_system_score_gemma":0.00018090973,"threshold_uncertainty_score":0.80187815},"labels":[],"label_agreement":null},{"id":"W4309681771","doi":"10.25251/skin.6.supp.68","title":"Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension","year":2022,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Open label; Plaque psoriasis; Medicine; Term (time); Randomized controlled trial; Psoriasis; Extension (predicate logic); Internal medicine; Dermatology; Computer science; Physics","score_opus":0.01666533154652453,"score_gpt":0.24956503916923573,"score_spread":0.2328997076227112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309681771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97513086,0.007907648,0.000028140017,0.01123293,0.001029036,0.004460794,0.00012385336,0.0000071005134,0.000079669786],"genre_scores_gemma":[0.99655074,0.0016974363,0.00003050354,0.0011212825,0.00017573989,0.00005554478,0.00007316717,0.000023011877,0.00027256864],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493784,0.0032459514,0.0010158197,0.0002691983,0.00026142216,0.00026975133],"domain_scores_gemma":[0.99090034,0.007698048,0.0008253155,0.00040457436,0.00013067492,0.0000410245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034924622,0.00029381353,0.0016694674,0.00007386219,0.00058933167,0.000033162014,0.0005642364,0.000111486275,0.00011170787],"category_scores_gemma":[0.0008361199,0.00010858305,0.00009249958,0.00017989897,0.000517386,0.00007934593,0.00023630435,0.0005724932,0.0000015230195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9846197,0.00032245764,0.0001318704,0.0000020064012,0.001672179,0.00015747601,0.0068565137,0.00014133452,0.000079543686,0.00004690743,0.0014129351,0.0045570857],"study_design_scores_gemma":[0.9883619,0.0024730535,0.0045301463,0.00018722824,0.001922901,0.001074063,0.00043569264,0.000017147788,0.000029556168,0.00036956748,0.00045032086,0.00014844048],"about_ca_topic_score_codex":0.000542568,"about_ca_topic_score_gemma":0.00038867394,"teacher_disagreement_score":0.021419916,"about_ca_system_score_codex":0.00005938215,"about_ca_system_score_gemma":0.00011172337,"threshold_uncertainty_score":0.45327222},"labels":[],"label_agreement":null},{"id":"W4310237092","doi":"10.1177/12034754221139265","title":"Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial","year":2022,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thornhill Medical (Canada); University of Manitoba; University of British Columbia; SKiN Health; University of Toronto; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Surgery; Intensive care medicine","score_opus":0.033442255828664134,"score_gpt":0.2608987251390295,"score_spread":0.22745646931036537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310237092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428099,0.0065831025,0.0000016944797,0.047512464,0.0020624162,0.00056541106,0.00015900159,0.0000026647108,0.00030338773],"genre_scores_gemma":[0.967527,0.014028555,0.000008589125,0.014613419,0.0017798479,0.00005836616,0.0007226618,0.000036692665,0.0012249198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971219,0.0007904767,0.00130164,0.00021669001,0.00021642142,0.00035287888],"domain_scores_gemma":[0.9965298,0.0017781932,0.0012058993,0.00025349614,0.00018646133,0.000046105866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005601678,0.00030174112,0.0017559872,0.001511024,0.00009254494,0.000004530264,0.00020720312,0.0003966279,0.0004808435],"category_scores_gemma":[0.0002486401,0.0001702118,0.00049314817,0.00045087456,0.00021537452,0.00003881358,0.000012358727,0.00057178567,7.413182e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068423174,0.0027624585,0.01707569,0.00017281243,0.009271352,0.015769236,0.009979735,0.000003365112,0.00012458333,0.000012304188,0.747224,0.12918133],"study_design_scores_gemma":[0.09006982,0.017648261,0.0025166092,0.0005355711,0.0070291464,0.0039861565,0.0027137534,0.0000013016123,0.00043769178,0.00007827512,0.8744795,0.0005039446],"about_ca_topic_score_codex":0.015916482,"about_ca_topic_score_gemma":0.004454503,"teacher_disagreement_score":0.12867737,"about_ca_system_score_codex":0.00019831127,"about_ca_system_score_gemma":0.00048635824,"threshold_uncertainty_score":0.9906366},"labels":[],"label_agreement":null},{"id":"W4310275920","doi":"10.1007/s13555-022-00853-4","title":"Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); SKiN Health; Memorial University of Newfoundland","funders":"Eli Lilly Canada; Eli Lilly and Company","keywords":"Ixekizumab; Plaque psoriasis; Persistence (discontinuity); Medicine; Psoriasis; Physical therapy; Dermatology; Psoriatic arthritis; Engineering; Secukinumab","score_opus":0.022458528999022054,"score_gpt":0.23913844214158805,"score_spread":0.216679913142566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310275920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964233,0.001208425,4.572514e-7,0.0009545324,0.00008431528,0.00079142174,0.00006477591,0.000012600742,0.00046015036],"genre_scores_gemma":[0.99689436,0.00015859243,0.000046519508,0.00031978887,0.0000028469951,0.0024506967,0.000097630866,0.00000868886,0.000020880483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866635,0.00044337328,0.00023458048,0.00025184697,0.000038628474,0.00036520392],"domain_scores_gemma":[0.999605,0.00009463547,0.000071232,0.00017796729,0.000020462094,0.000030707168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009039701,0.00016340087,0.00028692276,0.00017419455,0.00031079614,0.000007210044,0.00012465716,0.000097277276,0.00014287306],"category_scores_gemma":[0.0000046187583,0.00010886018,0.00003842365,0.00022774044,0.00009299546,0.000034505945,0.00001815335,0.00013132398,0.0000048611832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00880306,0.0018431584,0.44399402,0.000025626512,0.00046367338,0.00082375825,0.107865036,0.0003960059,0.00015249605,0.0009490327,0.00018058381,0.43450356],"study_design_scores_gemma":[0.08351503,0.03453686,0.6364966,0.00021607323,0.0003592495,0.012710164,0.08268448,0.0005486406,0.034344435,0.0006759032,0.1115935,0.0023190354],"about_ca_topic_score_codex":0.01705564,"about_ca_topic_score_gemma":0.10597512,"teacher_disagreement_score":0.43218452,"about_ca_system_score_codex":0.00008383618,"about_ca_system_score_gemma":0.00018324312,"threshold_uncertainty_score":0.98948985},"labels":[],"label_agreement":null},{"id":"W4310774826","doi":"10.1177/12034754221143085","title":"Under-Reporting of COVID-19 Infections in Psoriasis Patients on Biologics","year":2022,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; Western University","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Psoriasis; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Dermatology; MEDLINE; Intensive care medicine; Virology; Internal medicine; Infectious disease (medical specialty); Disease; Outbreak","score_opus":0.05994475969096214,"score_gpt":0.2931847772105055,"score_spread":0.23324001751954337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310774826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8591479,0.0058412007,0.000011017067,0.12810357,0.0060402015,0.0002297814,0.000089124645,0.000019719502,0.0005174736],"genre_scores_gemma":[0.7189497,0.012300167,0.00002001276,0.2636596,0.0021326998,0.000023173157,0.0011613254,0.00007759426,0.0016757563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963719,0.0006280657,0.0023063887,0.00023550207,0.00015781522,0.00030028497],"domain_scores_gemma":[0.9907953,0.0045534633,0.0042694923,0.00019086948,0.00014209103,0.000048747734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012829304,0.0002928703,0.001516719,0.0011378838,0.00014492871,0.000004220353,0.00012447678,0.00060822075,0.0009005591],"category_scores_gemma":[0.0041538295,0.00020447298,0.0003204932,0.00028095537,0.00019854259,0.00003191948,0.00004104728,0.0012765513,0.000003421561],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006009674,0.00034783088,0.11298027,0.00019011185,0.0008145997,0.0042971047,0.0005076476,0.000041458912,0.00025572866,0.0000083116975,0.8691639,0.010792108],"study_design_scores_gemma":[0.0019164379,0.0028992235,0.002525746,0.000442751,0.0006385863,0.00843348,0.0005395663,2.6851922e-7,0.000103191356,0.0004445759,0.9817418,0.00031436048],"about_ca_topic_score_codex":0.0001950501,"about_ca_topic_score_gemma":0.00002153857,"teacher_disagreement_score":0.14019825,"about_ca_system_score_codex":0.00018054094,"about_ca_system_score_gemma":0.00040571953,"threshold_uncertainty_score":0.9860491},"labels":[],"label_agreement":null},{"id":"W4310942033","doi":"10.1007/s13555-022-00865-0","title":"Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Internal medicine","score_opus":0.010904188158029003,"score_gpt":0.21603245469819568,"score_spread":0.20512826654016666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310942033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037814,0.008001879,0.0000296566,0.00017190588,0.00023394317,0.000907219,0.0001236352,0.000032014246,0.00012160709],"genre_scores_gemma":[0.9972843,0.0014970711,0.000022922583,0.00019967742,0.000011407371,0.0004821128,0.00045109144,0.000028213251,0.000023221479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664134,0.0021936113,0.0003047052,0.0004206423,0.00009684907,0.0003428768],"domain_scores_gemma":[0.99836606,0.0008311065,0.0002492512,0.000461187,0.0000717014,0.000020722262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055379514,0.0003224561,0.0005865212,0.00016630514,0.00039362497,0.000010431118,0.00033635716,0.00018964098,0.00015818716],"category_scores_gemma":[0.000013368903,0.00018952311,0.00007735449,0.00038458526,0.00045025468,0.00009361059,0.000041110965,0.00033955686,0.000003678248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013013783,0.0010517972,0.9658841,0.00004822143,0.0009178784,0.00008227585,0.0014023804,0.000021857233,0.000676364,0.00060426415,0.0002283728,0.016068734],"study_design_scores_gemma":[0.024638422,0.0016788756,0.94909304,0.000079672915,0.0001245754,0.00043562186,0.0007439931,0.0000020264845,0.01776705,0.00023660215,0.0048183887,0.00038171612],"about_ca_topic_score_codex":0.00015525857,"about_ca_topic_score_gemma":0.000049441718,"teacher_disagreement_score":0.017090684,"about_ca_system_score_codex":0.000024542718,"about_ca_system_score_gemma":0.0000709279,"threshold_uncertainty_score":0.77285284},"labels":[],"label_agreement":null},{"id":"W4311115017","doi":"10.1007/s13555-022-00849-0","title":"Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Novartis (Canada); Probity Medical Research","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Clinical trial; Latin Americans; Observational study; Population; Dermatology Life Quality Index; Dermatology; Internal medicine; Psoriatic arthritis; Environmental health","score_opus":0.01111867910410766,"score_gpt":0.2270354545668102,"score_spread":0.21591677546270255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311115017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658066,0.0019503884,0.00003237475,0.00021838113,0.00011733963,0.00047696443,0.00051720825,0.000019476742,0.00008718943],"genre_scores_gemma":[0.9986935,0.00041107144,0.000060857354,0.00013903304,0.0000041411718,0.000096699274,0.00055077556,0.000014962819,0.000028957744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984916,0.000627917,0.000204304,0.00040966994,0.000037092308,0.00022945003],"domain_scores_gemma":[0.999237,0.0002054373,0.00012641399,0.00038341124,0.00002317307,0.000024583616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014552462,0.00018836293,0.00046109813,0.00010847501,0.0002173872,0.0000055266096,0.00020507298,0.00009841434,0.00004284725],"category_scores_gemma":[0.000009844552,0.00015438623,0.000019041125,0.00016139759,0.00017607839,0.00007017308,0.00016638242,0.00017967114,0.0000021455692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024162678,0.0004551964,0.9064622,0.000045021272,0.0006446293,0.000052672232,0.0016956558,0.000065240245,0.00093182054,0.00039929536,0.0002220563,0.064863525],"study_design_scores_gemma":[0.015813023,0.00084465975,0.97281003,0.00004043281,0.000060370872,0.00021791422,0.0005517676,0.00001711803,0.003448955,0.00021309762,0.0056552785,0.00032734254],"about_ca_topic_score_codex":0.0001709784,"about_ca_topic_score_gemma":0.00016735915,"teacher_disagreement_score":0.06634783,"about_ca_system_score_codex":0.00001884617,"about_ca_system_score_gemma":0.000043861608,"threshold_uncertainty_score":0.62956876},"labels":[],"label_agreement":null},{"id":"W4311220073","doi":"10.1007/s13555-022-00861-4","title":"Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Sun Pharma; Valeant Pharmaceuticals International; Case Western Reserve University; XBiotech; Celgene; Incyte; Dermira; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Certolizumab pegol; Medicine; Plaque psoriasis; Psoriasis; Term (time); Quality of life (healthcare); Internal medicine; Dermatology; Adalimumab; Disease","score_opus":0.03323950638803691,"score_gpt":0.28825304511501404,"score_spread":0.25501353872697713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311220073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790267,0.018320482,0.0000045424317,0.00082801044,0.00013715732,0.0009560548,0.0006517068,0.000051536852,0.000023813931],"genre_scores_gemma":[0.9967496,0.0019180087,0.000023095601,0.00008490822,0.0000075760872,0.0001333729,0.0010348486,0.000025289715,0.000023319912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968801,0.0013221022,0.0008134637,0.0005241375,0.00007647837,0.0003837288],"domain_scores_gemma":[0.9983326,0.00065676606,0.000561277,0.00031725425,0.00007260929,0.000059454724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016745653,0.0003497409,0.001266146,0.00019971502,0.00037512474,0.000007973679,0.00013187809,0.00016608599,0.00009214835],"category_scores_gemma":[0.0000369356,0.00024750634,0.000065628,0.00023695854,0.00041228265,0.00008811443,0.00005896448,0.00026198817,0.0000030709098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2028315,0.0009204362,0.7809758,0.000024717006,0.0023757252,0.00008998753,0.0030055346,0.0000026823745,0.00016866668,0.000073813426,0.000059179692,0.009471931],"study_design_scores_gemma":[0.39482534,0.0019280099,0.6008879,0.000043772685,0.00012417114,0.00018277437,0.00052921585,0.0000027139379,0.0009779573,0.00012194653,0.000060782924,0.00031542467],"about_ca_topic_score_codex":0.0011674643,"about_ca_topic_score_gemma":0.000831215,"teacher_disagreement_score":0.19199385,"about_ca_system_score_codex":0.0000411859,"about_ca_system_score_gemma":0.000103728744,"threshold_uncertainty_score":0.99999774},"labels":[],"label_agreement":null},{"id":"W4311326697","doi":"10.1007/s00403-022-02498-x","title":"The HLA-Cw*06 allele may predict the response to methotrexate (MTX) treatment in Chinese arthritis-free psoriasis patients","year":2022,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Methotrexate; Arthritis; Internal medicine; Genotyping; Gastroenterology; Allele; Psoriasis Area and Severity Index; Genotype; Immunology; Dermatology; Genetics; Biology","score_opus":0.03469587581490305,"score_gpt":0.320985606318352,"score_spread":0.28628973050344897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311326697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857276,0.004008709,0.000006021726,0.00625075,0.0001800117,0.0012813868,0.00037572937,0.00003524426,0.0021345643],"genre_scores_gemma":[0.9940929,0.0013280398,0.00012533562,0.000094133284,0.00001715833,0.0013232274,0.0001469231,0.000019700588,0.0028525784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98864263,0.00908138,0.00054311,0.000509383,0.0003062649,0.00091720873],"domain_scores_gemma":[0.987663,0.011109701,0.000105117804,0.0009822398,0.000059826387,0.00008016393],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0019319801,0.00026769735,0.0004687073,0.00032374708,0.001377774,0.000030683004,0.0014545654,0.0001019454,0.00024569695],"category_scores_gemma":[0.0023374327,0.0001364849,0.00023846242,0.0006799833,0.00071325246,0.00004457531,0.0013167654,0.00055250747,0.0001238093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04106903,0.0045357323,0.5084725,0.000025831245,0.001134772,0.00038256883,0.010738631,0.00012725235,0.027549079,0.003790834,0.0141241215,0.38804966],"study_design_scores_gemma":[0.008246864,0.0028004209,0.8247772,0.000025539019,0.000032739095,0.00008997257,0.0014726925,0.000021649694,0.007969909,0.0054418575,0.14885761,0.00026354945],"about_ca_topic_score_codex":0.00018224992,"about_ca_topic_score_gemma":0.00023493652,"teacher_disagreement_score":0.38778612,"about_ca_system_score_codex":0.00008927008,"about_ca_system_score_gemma":0.00015124222,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W4311335052","doi":"10.1016/j.jval.2022.09.968","title":"EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Epidemiology; Incidence (geometry); Inpatient care; Emergency medicine; Medical emergency; Family medicine; Health care; Internal medicine","score_opus":0.0815685335182627,"score_gpt":0.3247590854359011,"score_spread":0.2431905519176384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311335052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395055,0.0019961605,0.0000010177365,0.000112758644,0.0008680165,0.001847838,0.0011945617,0.000018019246,0.000011101978],"genre_scores_gemma":[0.99765956,0.0009520218,0.000053461376,0.00013544431,0.000011228674,0.00032655417,0.000835698,0.000020234665,0.0000058210767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942791,0.0035772747,0.0011119052,0.00044349738,0.000060676288,0.00052756735],"domain_scores_gemma":[0.9980676,0.00062478724,0.0005911993,0.0005212438,0.000048128444,0.00014702081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015508526,0.0002664684,0.0006850678,0.00027867683,0.0006047357,0.0000039339266,0.00026181192,0.00015300063,0.00008362064],"category_scores_gemma":[0.00016605193,0.00025033817,0.00005729299,0.0001438358,0.00015166108,0.00006810742,0.00023971987,0.00047383938,0.0000050891526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025500348,0.00076861144,0.98702013,0.00010858909,0.00045542436,0.000008643849,0.008449776,0.0014346349,6.660695e-7,0.000028317087,0.00010658803,0.0013636238],"study_design_scores_gemma":[0.0034279134,0.0073633925,0.9797133,0.000032575907,0.00021742456,0.0000026147989,0.008330881,0.0001389075,0.0000049864243,0.00007245981,0.00044840458,0.0002471158],"about_ca_topic_score_codex":0.6749937,"about_ca_topic_score_gemma":0.48437715,"teacher_disagreement_score":0.19061658,"about_ca_system_score_codex":0.0006825062,"about_ca_system_score_gemma":0.00045561205,"threshold_uncertainty_score":0.9999949},"labels":[],"label_agreement":null},{"id":"W4311352505","doi":"10.1016/j.jval.2022.09.2427","title":"SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bausch Health (Canada); Health Canada","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Tazarotene; Dermatology; Calcipotriol; Lotion; Betamethasone dipropionate; Clobetasol propionate; Pharmacology","score_opus":0.02600185905838446,"score_gpt":0.24841278352575952,"score_spread":0.22241092446737507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311352505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975998,0.0005622984,0.00006948103,0.00039217394,0.00038397525,0.00042973753,0.0005490816,0.000007727381,0.000005757278],"genre_scores_gemma":[0.99854445,0.000053709045,0.00013248724,0.00018904296,0.0000070994856,0.00017802125,0.0008805647,0.000008008391,0.0000066149273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982911,0.00066092197,0.0005396904,0.00019130638,0.00006243838,0.00025457324],"domain_scores_gemma":[0.9990218,0.00051066483,0.0002792077,0.00012994102,0.000041696738,0.00001664848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043556307,0.000105455976,0.00040267457,0.00042443082,0.00014805401,0.000002464395,0.00010662779,0.000059255715,0.000069179354],"category_scores_gemma":[0.000054455082,0.0001090209,0.00008736657,0.00066317327,0.000020742444,0.000021447575,0.00002202522,0.00013556819,2.84343e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026799765,0.00035733756,0.98405635,0.000064646425,0.00018888527,0.0000016150339,0.0005846897,0.0006690852,0.000040124803,0.00044147158,0.000028712408,0.013299103],"study_design_scores_gemma":[0.0028379925,0.0003791934,0.9946388,0.00001841619,0.00007192422,3.2438652e-7,0.000306345,0.00094780594,0.00015496786,0.00015913573,0.00038871964,0.000096393596],"about_ca_topic_score_codex":0.40031314,"about_ca_topic_score_gemma":0.2523913,"teacher_disagreement_score":0.14792185,"about_ca_system_score_codex":0.00050753617,"about_ca_system_score_gemma":0.0007454485,"threshold_uncertainty_score":0.7612506},"labels":[],"label_agreement":null},{"id":"W4311384535","doi":"10.1016/j.fander.2022.09.573","title":"Efficacité de bimékizumab sur 2 ans sur l’atteinte unguéale et le cuir chevelu chez les patients atteints de psoriasis en plaques modéré à sévère qui sont passés d’adalimumab, d’ustékinumab ou de sécukinumab au bimékizumab : résultats des phases 3/3b","year":2022,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine","score_opus":0.03905135766138814,"score_gpt":0.28985766473379243,"score_spread":0.2508063070724043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311384535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95292884,0.027617121,0.0018360646,0.009014452,0.0016125237,0.0013842211,0.0036347876,0.001095206,0.0008767889],"genre_scores_gemma":[0.97355753,0.01387367,0.0026115915,0.002703615,0.00023755331,0.001253543,0.0020794875,0.00033114228,0.00335189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9794617,0.009926309,0.002009007,0.0022389288,0.0005090062,0.005855028],"domain_scores_gemma":[0.99087495,0.0050576944,0.0012322273,0.0016187623,0.00057680707,0.000639575],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.003433199,0.002172912,0.0025018386,0.00094672485,0.0024682505,0.00028858165,0.0027170088,0.002546872,0.001033973],"category_scores_gemma":[0.0034595828,0.0023297179,0.0013861136,0.0011199301,0.0019363615,0.0008971579,0.0016025599,0.0026612866,0.0003059836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076565314,0.011955751,0.7103916,0.0011955511,0.007090861,0.0067542493,0.032207265,0.0070878244,0.016446788,0.0025516404,0.035381816,0.16128017],"study_design_scores_gemma":[0.046855528,0.0055352254,0.4825816,0.0015749792,0.0045104343,0.016646262,0.04225074,0.0018632594,0.22675204,0.007780787,0.15616708,0.0074820714],"about_ca_topic_score_codex":0.011903649,"about_ca_topic_score_gemma":0.009174074,"teacher_disagreement_score":0.22780997,"about_ca_system_score_codex":0.0054747323,"about_ca_system_score_gemma":0.0080817845,"threshold_uncertainty_score":0.99987924},"labels":[],"label_agreement":null},{"id":"W4311395722","doi":"10.1016/j.fander.2022.09.571","title":"Tolérance de l’ixékizumab chez les patients adultes atteints de psoriasis modéré à sévère : données issues de 15 essais cliniques avec plus de 18 000 patients-années d’exposition","year":2022,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.04045004868718295,"score_gpt":0.29797712659984266,"score_spread":0.2575270779126597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311395722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95324785,0.03229739,0.001040313,0.007301016,0.0015793627,0.0010575145,0.002028013,0.0007477869,0.0007007514],"genre_scores_gemma":[0.95971864,0.026887376,0.005000937,0.003633512,0.00026537018,0.0011521517,0.0018801987,0.000164288,0.0012975179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9858284,0.007422251,0.0014936231,0.001479115,0.0003193883,0.003457213],"domain_scores_gemma":[0.9951955,0.0019184056,0.0010137233,0.0010544701,0.00047015137,0.00034776147],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019412339,0.0013312132,0.0016596029,0.0005246817,0.0018395359,0.00019986884,0.0017283101,0.0020165902,0.0011784318],"category_scores_gemma":[0.0017251786,0.0014375633,0.0008708824,0.00060418784,0.0013009069,0.0006032072,0.00094349444,0.0016568794,0.00022237774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002776283,0.0029742827,0.8708706,0.0005182312,0.0015734644,0.0011163162,0.015266904,0.0015065953,0.0015167408,0.00068775093,0.0531236,0.048069257],"study_design_scores_gemma":[0.015508801,0.0046361163,0.723942,0.0011840014,0.002803872,0.003060103,0.011619221,0.0017064698,0.1422764,0.011619203,0.07779084,0.00385301],"about_ca_topic_score_codex":0.0023067116,"about_ca_topic_score_gemma":0.00078652764,"teacher_disagreement_score":0.14692861,"about_ca_system_score_codex":0.0028801656,"about_ca_system_score_gemma":0.0018380838,"threshold_uncertainty_score":0.9999439},"labels":[],"label_agreement":null},{"id":"W4311396406","doi":"10.1016/j.fander.2022.09.569","title":"Efficacité et tolérance du bimékizumab sur deux ans chez des patients atteints de psoriasis modéré : analyse des données groupées de cinq essais cliniques de phase 3/3b","year":2022,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine","score_opus":0.0661665785595895,"score_gpt":0.3175181770245034,"score_spread":0.2513515984649139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311396406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95551366,0.03208134,0.004764025,0.0028431057,0.0010282019,0.00083643175,0.001569203,0.0007451062,0.0006189394],"genre_scores_gemma":[0.93851846,0.04571299,0.00953786,0.003397483,0.00013162615,0.00084024965,0.0010113901,0.00015748503,0.00069243636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9842768,0.008917609,0.0014845595,0.0015236174,0.00025523725,0.0035421823],"domain_scores_gemma":[0.9938771,0.0032976114,0.00084001257,0.001166129,0.00039227953,0.00042683852],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0031168002,0.0013555463,0.0017941435,0.0006971176,0.001782783,0.00018817878,0.0018432505,0.0015649016,0.0006331048],"category_scores_gemma":[0.002065546,0.0014197035,0.0010780721,0.0011111723,0.0021616225,0.0006756516,0.0009385987,0.0015451399,0.00015913726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032009694,0.005877729,0.8483698,0.0006339712,0.003110192,0.0032848888,0.012524596,0.0012389238,0.006219026,0.00068524305,0.009112367,0.105742306],"study_design_scores_gemma":[0.020104276,0.003457661,0.782719,0.00073672796,0.003865423,0.007804476,0.009350012,0.000976658,0.13047658,0.015073882,0.022407215,0.0030280738],"about_ca_topic_score_codex":0.0015469843,"about_ca_topic_score_gemma":0.0017455665,"teacher_disagreement_score":0.12425755,"about_ca_system_score_codex":0.0019896186,"about_ca_system_score_gemma":0.0017084968,"threshold_uncertainty_score":0.99991953},"labels":[],"label_agreement":null},{"id":"W4311476820","doi":"10.1007/s12325-022-02379-9","title":"Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Eli Lilly and Company","keywords":"Medicine; Plaque psoriasis; Psoriasis; Rheumatology; Internal medicine; Dermatology; Physical therapy","score_opus":0.026024946539772983,"score_gpt":0.299438510484854,"score_spread":0.273413563945081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311476820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942229,0.002433609,0.0000053448816,0.000015319745,0.0002924714,0.0014969032,0.0013935234,0.000017139464,0.00012280402],"genre_scores_gemma":[0.9985988,0.00037286986,0.000054398246,0.000025242281,0.000009065392,0.0004168578,0.00047072928,0.000014427272,0.000037598333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99664825,0.0020426426,0.00046947302,0.0004489262,0.00008612226,0.0003046085],"domain_scores_gemma":[0.99745154,0.0017829866,0.00033671848,0.00035602882,0.00006036487,0.000012354979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007612837,0.00024500236,0.0006436917,0.000094328825,0.00023848009,0.000004358904,0.0003563867,0.00006219227,0.000023653038],"category_scores_gemma":[0.000023107961,0.0001584675,0.000055517296,0.00048652876,0.00013984609,0.00011070071,0.0001571454,0.00021013002,0.0000025478764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05920292,0.001777749,0.9063263,0.000007733811,0.00031472597,0.0000050885264,0.01942586,0.005056649,0.0030882992,0.00002357559,0.000007851796,0.004763281],"study_design_scores_gemma":[0.01642218,0.0028650973,0.9541235,0.00006352239,0.000020913274,6.177208e-7,0.0053785425,0.0000041397743,0.020294428,0.00021429652,0.00041343123,0.00019932816],"about_ca_topic_score_codex":0.001310308,"about_ca_topic_score_gemma":0.011433878,"teacher_disagreement_score":0.047797237,"about_ca_system_score_codex":0.00015158701,"about_ca_system_score_gemma":0.00003324878,"threshold_uncertainty_score":0.64621174},"labels":[],"label_agreement":null},{"id":"W4311491456","doi":"10.1186/s12950-022-00323-w","title":"Combination of IL-17A/F and TNF-α uniquely alters the bronchial epithelial cell proteome to enhance proteins that augment neutrophil migration","year":2022,"lang":"en","type":"article","venue":"Journal of Inflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba","funders":"Children's Hospital Research Institute of Manitoba; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Reseau canadien de recherche respiratoire; Research Manitoba","keywords":"Tumor necrosis factor alpha; Chemokine; Immunology; Inflammation; Cytokine; Interleukin 8; Interleukin 17; Lipocalin; Medicine; Cell biology; Biology; Internal medicine","score_opus":0.009426494568626004,"score_gpt":0.22240630298490235,"score_spread":0.21297980841627634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311491456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527234,0.00024848155,0.00048556304,0.0028016446,0.00038362708,0.0007303899,0.000026747812,0.0000067765627,0.00004443674],"genre_scores_gemma":[0.9992692,0.00007181119,0.00023140835,0.000044166558,0.000058332633,0.00008301343,0.00003199611,0.0000073127485,0.00020276429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989208,0.0003724825,0.00038751998,0.000096038544,0.00011156195,0.00011162511],"domain_scores_gemma":[0.9990578,0.000055872668,0.0006487793,0.000105300554,0.00011489435,0.000017301712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005836698,0.000102073354,0.00016902527,0.0001470627,0.00022751244,0.000014503729,0.00013099021,0.000053291264,0.000050309995],"category_scores_gemma":[0.000024743058,0.000074120115,0.0000701966,0.000112332746,0.000037801907,0.00016072651,0.00004403351,0.00015660416,0.000005569163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007017872,0.00010290913,0.00043125174,0.000020764128,0.0000675968,0.0000021107173,0.0022243438,0.00037291856,0.97377414,0.00020228127,0.0001600241,0.021939889],"study_design_scores_gemma":[0.0011717218,0.0013550066,0.014855837,0.000025917734,0.000077831435,0.000041231066,0.00036923413,0.000018311022,0.97810954,0.00036863613,0.0035249186,0.000081822225],"about_ca_topic_score_codex":0.000037293423,"about_ca_topic_score_gemma":0.000023649985,"teacher_disagreement_score":0.021858066,"about_ca_system_score_codex":0.000100201854,"about_ca_system_score_gemma":0.000069492744,"threshold_uncertainty_score":0.30225307},"labels":[],"label_agreement":null},{"id":"W4311580809","doi":"10.1177/12034754221141680","title":"Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway","year":2022,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of British Columbia; SKiN Health; University of Alberta; University of Calgary; University of Toronto; Dalhousie University; Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Janus kinase; Psoriasis; Medicine; Tyrosine kinase 2; Tofacitinib; JAK-STAT signaling pathway; STAT protein; stat; Pharmacology; Tyrosine kinase; Immunology; Cancer research; Signal transduction; Cytokine; Internal medicine; STAT3; Receptor; Biology; Rheumatoid arthritis","score_opus":0.09426026995532921,"score_gpt":0.33817197679327643,"score_spread":0.24391170683794722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311580809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004516712,0.9909553,0.0000022842407,0.0022309595,0.0016640823,0.00035231482,0.00010210699,0.0000065770023,0.00016964262],"genre_scores_gemma":[0.007103039,0.991785,0.0000037074708,0.0003176497,0.0003841178,0.000039083316,0.000104881976,0.000029270803,0.0002332363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949642,0.002225877,0.0021276346,0.00024576279,0.00015091203,0.0002856197],"domain_scores_gemma":[0.9775147,0.02008566,0.0018457182,0.0004058551,0.00008066387,0.00006740242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033094997,0.00033658734,0.0021596956,0.00032413204,0.0002495877,0.000008275346,0.00036568474,0.00021523895,0.0005725924],"category_scores_gemma":[0.0024936309,0.00015004075,0.0008497333,0.00037832424,0.00031781287,0.00002842554,0.000065592336,0.00085474155,0.000009380449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015983175,0.00021706965,0.0006829,0.0005569712,0.0007453526,0.000354281,0.00022775022,6.943383e-7,0.0000066874286,0.00019041717,0.0113106035,0.9855474],"study_design_scores_gemma":[0.0003018526,0.00026586725,0.00016654962,0.0030513157,0.0010813288,0.0012602449,0.00028336054,2.020466e-7,0.0000023134967,0.00018243787,0.9932636,0.00014090474],"about_ca_topic_score_codex":0.000011762555,"about_ca_topic_score_gemma":0.000004950779,"teacher_disagreement_score":0.9854065,"about_ca_system_score_codex":0.00006515153,"about_ca_system_score_gemma":0.00071081345,"threshold_uncertainty_score":0.62694854},"labels":[],"label_agreement":null},{"id":"W4311985041","doi":"10.1016/j.rhum.2022.10.043","title":"Le bimékizumab améliore la qualité de vie chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo","year":2022,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Gynecology","score_opus":0.01843174179693413,"score_gpt":0.26705319449555076,"score_spread":0.24862145269861663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311985041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96969825,0.018358748,0.002755164,0.0036686847,0.0009222577,0.0019975065,0.0018153668,0.000386885,0.00039714074],"genre_scores_gemma":[0.979116,0.012002351,0.001540894,0.00080079003,0.0003477745,0.0018603668,0.001462245,0.00019079659,0.0026787776],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98259467,0.012279313,0.001588344,0.0011257943,0.00017555039,0.0022363067],"domain_scores_gemma":[0.99383175,0.0035480007,0.0012019224,0.0008180602,0.00024516188,0.0003550994],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00470209,0.0011945312,0.00202808,0.00048437127,0.0021046358,0.00017017801,0.001052413,0.0013804911,0.00093525206],"category_scores_gemma":[0.0016735385,0.0012746458,0.00071271183,0.0004710956,0.0009270658,0.00038450686,0.00046303272,0.0012251145,0.00010374892],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03904607,0.012729749,0.10374026,0.002665283,0.009225063,0.0024581505,0.09312919,0.0007472755,0.15607698,0.06328096,0.012920922,0.5039801],"study_design_scores_gemma":[0.32051724,0.007807633,0.11996555,0.0056727002,0.0066773403,0.010896488,0.014972088,0.002265756,0.22347575,0.01690956,0.26294807,0.007891818],"about_ca_topic_score_codex":0.0057451488,"about_ca_topic_score_gemma":0.0026287676,"teacher_disagreement_score":0.49608827,"about_ca_system_score_codex":0.0018527224,"about_ca_system_score_gemma":0.002912992,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W4312163186","doi":"10.1007/s13555-022-00870-3","title":"Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Novartis (Canada); SKiN Health; University of British Columbia; Ottawa Hospital; Lynde Centre for Dermatology; University of Toronto; University of Ottawa; Probity Medical Research; Queen's University","funders":"Novartis Pharmaceuticals Canada","keywords":"Secukinumab; Medicine; Psoriasis; Erythema; Plaque psoriasis; Observational study; Psoriasis Area and Severity Index; Body surface area; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.0072825027337107915,"score_gpt":0.2210104133937281,"score_spread":0.2137279106600173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312163186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626756,0.0018377524,0.000041908745,0.00047576005,0.0002534023,0.0006415657,0.00041891722,0.00002517867,0.000037948044],"genre_scores_gemma":[0.99876416,0.0001437814,0.000005730045,0.00019283187,0.000008016589,0.0002839411,0.0005366204,0.000018115019,0.000046810976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797267,0.0010900428,0.00021757011,0.0003451925,0.000050637762,0.00032390823],"domain_scores_gemma":[0.9988957,0.00055760954,0.000119353695,0.00035907305,0.00004603531,0.00002224868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012902149,0.00023119884,0.00045793748,0.000058411886,0.00047491945,0.000009586745,0.00024043786,0.00017823273,0.00007376861],"category_scores_gemma":[0.000012572639,0.00014866646,0.00006141586,0.000173635,0.00016669794,0.000043897904,0.00014262952,0.00026450565,0.000003566167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027344303,0.0009266358,0.9577873,0.0000263919,0.001051321,0.000055166533,0.0041863313,0.00005770278,0.0018994485,0.001993181,0.0003719196,0.004300334],"study_design_scores_gemma":[0.020403497,0.0005540985,0.96157604,0.00003991724,0.00006447782,0.00009826581,0.0016154358,0.0000046608793,0.011804573,0.0020185802,0.0015179302,0.0003024982],"about_ca_topic_score_codex":0.00016664788,"about_ca_topic_score_gemma":0.00009752561,"teacher_disagreement_score":0.009905124,"about_ca_system_score_codex":0.000040455558,"about_ca_system_score_gemma":0.000042262986,"threshold_uncertainty_score":0.6062442},"labels":[],"label_agreement":null},{"id":"W4312181886","doi":"10.1136/bmjopen-2022-063650","title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","year":2022,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Women's College Hospital; University of Toronto","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Population; Internal medicine; Placebo; Arthritis; Cohort; Randomized controlled trial; Surgery; Dermatology; Pathology","score_opus":0.03715669250452593,"score_gpt":0.33726301411545756,"score_spread":0.30010632161093165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312181886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63983047,0.00012652356,0.0000013622761,0.000021789892,0.00027845296,0.35912138,0.00015849824,0.000018007038,0.00044350282],"genre_scores_gemma":[0.6000978,0.000017256974,0.00010228138,0.000007665012,0.000039526483,0.3987114,0.00014588417,0.000029679468,0.0008485264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931572,0.0033392215,0.001958859,0.0007265646,0.00020390464,0.00061422517],"domain_scores_gemma":[0.9961262,0.0015632564,0.0016103704,0.0005284825,0.00012462931,0.00004707769],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036036377,0.0004135158,0.0019950494,0.00041749445,0.00026770885,0.000026014923,0.00062347326,0.00027422156,0.00086189323],"category_scores_gemma":[0.00090515346,0.00038498678,0.00044045315,0.0006606237,0.0001063817,0.00017026885,0.000787255,0.00043714355,0.000036300346],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9390795,0.0040157163,0.038467772,0.00007572042,0.0013751342,0.000038656417,0.0046298075,0.00035225967,0.0053045847,0.000010047335,0.00018629093,0.0064644734],"study_design_scores_gemma":[0.9620843,0.0011083479,0.004957251,0.00030795773,0.0004335154,0.000018708506,0.001157393,0.00006623375,0.028889515,0.000010840787,0.0005996112,0.0003663383],"about_ca_topic_score_codex":0.0021582148,"about_ca_topic_score_gemma":0.003867181,"teacher_disagreement_score":0.039732724,"about_ca_system_score_codex":0.00033769407,"about_ca_system_score_gemma":0.00053239445,"threshold_uncertainty_score":0.9998602},"labels":[],"label_agreement":null},{"id":"W4312379893","doi":"10.33590/emjdermatol/10310097","title":"Lingual Pustular Psoriasis and Acrodermatitis Continua of Hallopeau Successfully Treated with Adalimumab: A Rare Case Report and Review of Oral Psoriasis","year":2018,"lang":"en","type":"article","venue":"EMJ Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Generalized pustular psoriasis; Adalimumab; Pustular psoriasis; Acrodermatitis; Tongue; Pathology; Disease","score_opus":0.013259088387648714,"score_gpt":0.2586710524694921,"score_spread":0.2454119640818434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312379893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95536864,0.042533036,0.000030162088,0.00042861557,0.00020599473,0.00048420636,0.00014080857,0.00005467404,0.00075389555],"genre_scores_gemma":[0.9938499,0.0047336766,0.0006446711,0.00018522517,0.000029649336,0.000047444522,0.00016301018,0.00003110158,0.0003153483],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9977521,0.0004467466,0.00085402373,0.00049237395,0.000063772655,0.00039102914],"domain_scores_gemma":[0.9983189,0.00018416534,0.0006114094,0.00041787376,0.00040886787,0.000058782025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002451646,0.0003536851,0.0012263476,0.00017435788,0.00018103812,0.000010179081,0.00014513034,0.00035096542,0.00026381543],"category_scores_gemma":[0.00014787796,0.0002789033,0.00010125707,0.00025763328,0.0009284388,0.00013138393,0.00011570681,0.00013535986,0.000015693955],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005209603,0.0016587465,0.4273458,0.014735469,0.012935309,0.26846623,0.010997151,5.44042e-7,0.023294307,0.0016941684,0.027461762,0.20620091],"study_design_scores_gemma":[0.008581514,0.0010485434,0.010258501,0.0020925535,0.0023497273,0.74808395,0.00078424084,0.0000029096873,0.20161936,0.00005503643,0.024475778,0.000647909],"about_ca_topic_score_codex":0.00096856325,"about_ca_topic_score_gemma":0.00073088397,"teacher_disagreement_score":0.4796177,"about_ca_system_score_codex":0.000016208967,"about_ca_system_score_gemma":0.00012713954,"threshold_uncertainty_score":0.9999663},"labels":[],"label_agreement":null},{"id":"W4312851191","doi":"10.1161/atvb.42.suppl_1.485","title":"Abstract 485: Platelet Aggregation Is Increased In Psoriasis And Associated With Biomarkers Of Vascular Health","year":2022,"lang":"en","type":"article","venue":"Arteriosclerosis Thrombosis and Vascular Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Berger (Canada)","funders":"","keywords":"Medicine; Psoriasis; Internal medicine; Pulse wave velocity; Platelet; Arterial stiffness; Platelet activation; Arachidonic acid; C-reactive protein; Aspirin; Biomarker; Adenosine diphosphate; Inflammation; Cardiology; Gastroenterology; Immunology; Platelet aggregation; Blood pressure; Biochemistry; Chemistry","score_opus":0.024484059487759068,"score_gpt":0.24810064863109127,"score_spread":0.2236165891433322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312851191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966512,0.0021761574,0.000011142558,0.00025846888,0.00014897862,0.0004057744,0.00028523133,0.000033372064,0.000029719102],"genre_scores_gemma":[0.99448156,0.004503022,0.00007031258,0.00028210212,0.000008012678,0.00011311571,0.0005156117,0.000023889634,0.0000023852572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978567,0.0006499803,0.00046795871,0.0005423045,0.00006795032,0.00041511454],"domain_scores_gemma":[0.9991378,0.00016465322,0.0003189656,0.000290845,0.000038323724,0.000049416638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008269412,0.00028115988,0.00072572817,0.00025630233,0.0003643066,0.000013085372,0.00013472297,0.00020418668,0.0003179915],"category_scores_gemma":[0.00002945317,0.0002443557,0.00013882903,0.0003317434,0.0002705351,0.000080185884,0.000119738375,0.00016953112,0.0000040250125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010782261,0.00090520683,0.78808296,0.00007169001,0.00433462,4.88117e-7,0.0026510004,0.000004957897,0.17648745,0.00019406574,0.0003210573,0.026838703],"study_design_scores_gemma":[0.0047594807,0.0008871917,0.9898515,0.00007950467,0.00014557596,0.0000017159928,0.0005597001,0.00000834838,0.0021642938,0.00004432417,0.0012432686,0.0002550921],"about_ca_topic_score_codex":0.0016245596,"about_ca_topic_score_gemma":0.00034367244,"teacher_disagreement_score":0.20176856,"about_ca_system_score_codex":0.00008373201,"about_ca_system_score_gemma":0.00006766937,"threshold_uncertainty_score":0.9964536},"labels":[],"label_agreement":null},{"id":"W4313339834","doi":"10.1007/s13555-022-00879-8","title":"Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Janssen Biotech","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.012117338014736839,"score_gpt":0.23112417089595352,"score_spread":0.2190068328812167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313339834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949924,0.0028001068,0.000010966566,0.00011517585,0.00028248917,0.001086579,0.00017551587,0.00002392252,0.0005128728],"genre_scores_gemma":[0.9975092,0.001558012,0.000027974564,0.0001303855,0.00000863117,0.00046701723,0.00021918277,0.000026445252,0.000053188975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968575,0.0018912443,0.00041953244,0.00039913852,0.00009772458,0.000334859],"domain_scores_gemma":[0.9983415,0.000777231,0.00029158086,0.00049089006,0.000074134914,0.000024635076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043891053,0.00030618004,0.00074059464,0.00026635884,0.0002924709,0.0000075846306,0.00037859814,0.00018336008,0.00011943342],"category_scores_gemma":[0.000013518299,0.00020709062,0.00010744202,0.00041943789,0.00028679147,0.00008507462,0.00006080734,0.00026978002,0.0000030949764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021424279,0.0012078917,0.95636916,0.00006077267,0.0011102383,0.00003654704,0.0031526661,0.000133461,0.0021744526,0.001541722,0.00033335589,0.012455479],"study_design_scores_gemma":[0.016532628,0.0009989343,0.94492394,0.00006037946,0.00009084128,0.00008468932,0.0005313162,0.0000037026232,0.03396612,0.00057000015,0.0019089076,0.0003285224],"about_ca_topic_score_codex":0.0006900384,"about_ca_topic_score_gemma":0.00023244477,"teacher_disagreement_score":0.031791665,"about_ca_system_score_codex":0.000033076536,"about_ca_system_score_gemma":0.00006775565,"threshold_uncertainty_score":0.844491},"labels":[],"label_agreement":null},{"id":"W4313359213","doi":"10.4049/jimmunol.200.supp.43.19","title":"Soluble TIR-8 neutralizes anti-inflammatory effects of IL-37 in Crohn disease patients","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cytokine; Immune system; Peripheral blood mononuclear cell; Receptor; Inflammation; Immunology; Secretion; Tumor necrosis factor alpha; Chemistry; Pharmacology; Biology; Endocrinology; In vitro; Biochemistry","score_opus":0.007695307237237442,"score_gpt":0.22052697332168095,"score_spread":0.2128316660844435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313359213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98658305,0.010529658,0.0000074019463,0.00011612328,0.002462339,0.00018703964,0.000009377175,0.000009530152,0.00009549952],"genre_scores_gemma":[0.99811584,0.0014169484,0.000017802093,0.000054854725,0.00006439297,0.0000040974246,0.000007794801,0.000014776826,0.00030351063],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982991,0.0006724197,0.0005438557,0.00010755657,0.00004681809,0.0003302087],"domain_scores_gemma":[0.99861157,0.00036634575,0.0005149297,0.00029636337,0.00018666945,0.000024133638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037011987,0.00017609147,0.00043394926,0.00018004289,0.00011669966,0.0000041758453,0.00042659655,0.0001729638,0.00012683947],"category_scores_gemma":[0.00013995545,0.000114105955,0.00014483057,0.00014258409,0.0005502555,0.000113424256,0.00009272682,0.00023609737,0.00012347398],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008116136,0.0015265318,0.28955147,0.00010758697,0.001947421,0.00014050843,0.0028557815,0.000009416909,0.66150194,0.00043018616,0.0028618795,0.030951176],"study_design_scores_gemma":[0.004055441,0.0008134591,0.82879543,0.00010330015,0.00023940772,0.00003689041,0.00007259156,4.5155113e-7,0.16342102,0.00021901602,0.00213577,0.000107206295],"about_ca_topic_score_codex":0.000035592435,"about_ca_topic_score_gemma":0.000016896094,"teacher_disagreement_score":0.539244,"about_ca_system_score_codex":0.00004016058,"about_ca_system_score_gemma":0.00010196941,"threshold_uncertainty_score":0.46531057},"labels":[],"label_agreement":null},{"id":"W4313365920","doi":"10.4049/jimmunol.202.supp.182.38","title":"The impact of IL-27 on human T cells is altered in multiple sclerosis patients","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Multiple sclerosis; CD8; Experimental autoimmune encephalomyelitis; Cytotoxic T cell; Cytokine; Immunology; Interleukin; Chemistry; Biology; In vitro; Immune system; Biochemistry","score_opus":0.03493399797395726,"score_gpt":0.25670933409088703,"score_spread":0.22177533611692976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313365920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959097,0.0022765289,8.07889e-7,0.00009485014,0.0012444105,0.00020578202,0.00004638665,0.0000039817774,0.00021755227],"genre_scores_gemma":[0.9984318,0.00097165466,0.0000042272736,0.00003535143,0.000022437758,0.0000018720414,0.000008103941,0.000013244671,0.000511302],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983551,0.00063243305,0.0005532312,0.00009916276,0.00004828962,0.0003117649],"domain_scores_gemma":[0.9981842,0.00066696905,0.00062988827,0.00038798834,0.00011951682,0.000011412379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005169304,0.0001734906,0.00040138944,0.00015161005,0.00015008966,0.000006156029,0.00053304085,0.0001803303,0.00027067604],"category_scores_gemma":[0.000045707526,0.0000845431,0.00023402162,0.0001271886,0.0002096566,0.000058758207,0.00007156645,0.0003464117,0.00025863375],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002615115,0.00046984002,0.06601255,0.0000029259613,0.0010364965,9.605046e-7,0.0012074218,0.00004547074,0.91736215,0.000027640472,0.0018516562,0.009367754],"study_design_scores_gemma":[0.0064592324,0.0037325302,0.65440005,0.00007563964,0.00008912702,0.000022335862,0.0003245789,0.0000015307684,0.33384883,0.00012612136,0.0008080875,0.00011191501],"about_ca_topic_score_codex":0.00026515545,"about_ca_topic_score_gemma":0.000025779033,"teacher_disagreement_score":0.58838755,"about_ca_system_score_codex":0.00008918331,"about_ca_system_score_gemma":0.000054571123,"threshold_uncertainty_score":0.34475675},"labels":[],"label_agreement":null},{"id":"W4313382209","doi":"10.4049/jimmunol.198.supp.201.2","title":"The impact of IL-27 on human T cells is altered in multiple sclerosis patients","year":2017,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunology; Multiple sclerosis; CD8; Experimental autoimmune encephalomyelitis; C-C chemokine receptor type 7; T cell; Cytokine; Immune system; Cytotoxic T cell; Biology; Medicine; Chemokine; Chemokine receptor; In vitro","score_opus":0.055952317097251,"score_gpt":0.28326431079080155,"score_spread":0.22731199369355054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313382209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963052,0.0018229659,0.0000011418342,0.0001899794,0.0012239194,0.00014567551,0.000055996617,0.000003271118,0.00025182276],"genre_scores_gemma":[0.9981818,0.0013834804,0.00000495219,0.0000230597,0.000035693614,0.000002230264,0.0000051465145,0.000012257547,0.00035137817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985189,0.00050962355,0.0005202731,0.000095625786,0.000045401022,0.0003102109],"domain_scores_gemma":[0.99766237,0.00047624655,0.0010724902,0.00064479053,0.00013102946,0.000013057589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005811845,0.00017348715,0.000387551,0.00011551899,0.00062912697,0.000016797485,0.0009460168,0.00018054397,0.00010732229],"category_scores_gemma":[0.00013641917,0.0000846842,0.00023595172,0.000046717378,0.00048728034,0.00008607264,0.000117368065,0.00034111788,0.00008266584],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030380914,0.000587617,0.071227066,0.0000026331384,0.001396369,0.0000027904593,0.0013515247,0.000016498432,0.89327794,0.000035285568,0.0030620676,0.02600211],"study_design_scores_gemma":[0.004576688,0.0019083174,0.73942685,0.000059104885,0.00008416248,0.000017021843,0.00013988011,7.57727e-7,0.253023,0.00015782284,0.0005247381,0.00008162706],"about_ca_topic_score_codex":0.0005536046,"about_ca_topic_score_gemma":0.00007557568,"teacher_disagreement_score":0.6681998,"about_ca_system_score_codex":0.00007585089,"about_ca_system_score_gemma":0.00005357383,"threshold_uncertainty_score":0.48387998},"labels":[],"label_agreement":null},{"id":"W4313402716","doi":"10.1002/jvc2.92","title":"Development of rapid, reliable and novel severity measures for psoriasis and eczema","year":2022,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Newfoundland and Labrador Centre for Applied Health Research","funders":"","keywords":"Psoriasis Area and Severity Index; Psoriasis; Body surface area; Eczema Area and Severity Index; Medicine; Dermatology; Clinical Practice; Severity of illness; Gestalt psychology; Correlation; Atopic dermatitis; Psychology; Internal medicine; Physical therapy; Mathematics","score_opus":0.0855241493805185,"score_gpt":0.35114722522836356,"score_spread":0.26562307584784506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313402716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818715,0.0088361325,0.0014697185,0.0021235542,0.0023160211,0.00095703144,0.00020790935,0.00007059815,0.002147559],"genre_scores_gemma":[0.92103845,0.0010686588,0.0742979,0.0009817701,0.0001031605,0.00028354206,0.00013173957,0.000033851396,0.0020609382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984853,0.00025176915,0.00061123417,0.0003738241,0.000066973145,0.0002108814],"domain_scores_gemma":[0.99640465,0.0028966414,0.00035303307,0.0002047776,0.00010429975,0.000036574864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026870985,0.00014131393,0.00038279616,0.0000472303,0.00043621834,0.000009553443,0.00011386218,0.00015893928,0.000115934046],"category_scores_gemma":[0.0018596099,0.00012937763,0.00008246899,0.000080837344,0.00012228885,0.00014259505,0.00019934376,0.00024161467,0.000011080936],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008793746,0.0034294426,0.01066421,0.00013110833,0.0024681946,0.000008234957,0.0018081893,0.000004750466,0.025269048,0.0023278554,0.009491786,0.93560344],"study_design_scores_gemma":[0.004544606,0.0005571912,0.018896779,0.000009288283,0.0004513494,0.00006886214,0.0011416922,0.00000674435,0.003664194,0.00015359548,0.9703146,0.00019106855],"about_ca_topic_score_codex":0.000030288962,"about_ca_topic_score_gemma":0.000011805761,"teacher_disagreement_score":0.9608228,"about_ca_system_score_codex":0.000025950838,"about_ca_system_score_gemma":0.00014147958,"threshold_uncertainty_score":0.52758664},"labels":[],"label_agreement":null},{"id":"W4313575311","doi":"10.1111/jdv.18851","title":"Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management","year":2023,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Boehringer Ingelheim","keywords":"Medicine; Psoriasis; Delphi method; Disease; Generalized pustular psoriasis; Intensive care medicine; Disease management; Delphi; MEDLINE; Dermatology; Pathology; Artificial intelligence","score_opus":0.09660565050261666,"score_gpt":0.3754584025731065,"score_spread":0.2788527520704898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313575311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018539958,0.97609603,0.0000015110576,0.0025251722,0.0016813097,0.00061998167,0.00023890156,0.00002632097,0.0002708199],"genre_scores_gemma":[0.008921406,0.9899529,0.000065481676,0.0003130913,0.0002230421,0.0000347323,0.00002724179,0.000051419935,0.0004106751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901387,0.006852526,0.0019452454,0.0005138059,0.00008478594,0.00046494056],"domain_scores_gemma":[0.996291,0.0010454939,0.0021101509,0.00033066532,0.00004295311,0.00017974338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008875987,0.0006271118,0.0028066614,0.00022096517,0.00022117436,0.000011009767,0.00061695237,0.0007204044,0.000019420873],"category_scores_gemma":[0.00020409041,0.00037701256,0.0009848686,0.00021267858,0.0010211082,0.000027669592,0.0003716898,0.00063319784,0.00008860207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011277087,0.00096017227,0.031913877,0.002306087,0.017728545,0.0023263015,0.000060746654,0.000004011182,0.0000012235779,0.008424244,0.02281197,0.9123351],"study_design_scores_gemma":[0.0057907375,0.00025706258,0.015776549,0.003232884,0.0167542,0.00732767,0.00003275611,4.2214305e-7,0.000008794259,0.00095341756,0.949462,0.00040350697],"about_ca_topic_score_codex":0.0000025194786,"about_ca_topic_score_gemma":0.0000019200515,"teacher_disagreement_score":0.92665005,"about_ca_system_score_codex":0.00006478486,"about_ca_system_score_gemma":0.00017332842,"threshold_uncertainty_score":0.99986815},"labels":[],"label_agreement":null},{"id":"W4313728090","doi":"10.1093/bjd/ljac040","title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","year":2022,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Placebo; Randomized controlled trial; Psoriasis; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis","score_opus":0.022812531839389194,"score_gpt":0.28525301356138516,"score_spread":0.26244048172199597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313728090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97608745,0.022021398,0.000020730608,0.00038244718,0.00040307947,0.00065697986,0.00037503228,0.0000030011327,0.000049864302],"genre_scores_gemma":[0.9952868,0.0044683884,0.00009227094,0.000030506208,0.000017136666,0.000014335373,0.000028793813,0.00000980446,0.000051968902],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956059,0.0024367347,0.001527741,0.00018578203,0.000070570495,0.00017330235],"domain_scores_gemma":[0.99720377,0.0012484104,0.0012358265,0.00017223474,0.0001156213,0.000024119949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001006505,0.00015308303,0.0019389876,0.00015339482,0.00010849666,0.000004731567,0.00015790558,0.00016371068,0.00007441736],"category_scores_gemma":[0.0007014187,0.00011485769,0.00030320341,0.00018990386,0.00023915019,0.000054759803,0.00009869594,0.00018448314,3.4143446e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73625684,0.0031100318,0.008951915,0.00014493238,0.004313329,0.0011074679,0.010785902,0.00004683848,0.09250187,0.0002301674,0.0016531043,0.14089762],"study_design_scores_gemma":[0.8651841,0.0015209354,0.034579195,0.00050758524,0.0015215119,0.021816265,0.0006040492,0.0000012596981,0.07290551,0.00019060019,0.0009758615,0.00019308462],"about_ca_topic_score_codex":0.0001736459,"about_ca_topic_score_gemma":0.000083681385,"teacher_disagreement_score":0.14070454,"about_ca_system_score_codex":0.000035909678,"about_ca_system_score_gemma":0.00012338796,"threshold_uncertainty_score":0.46837607},"labels":[],"label_agreement":null},{"id":"W4313729039","doi":"10.1093/bjd/ljac021","title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Cilag; LEO Pharma; Novo Nordisk; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer","keywords":"Open label; Randomized controlled trial; Plaque psoriasis; Medicine; Term (time); Psoriasis; Extension (predicate logic); Surgery; Dermatology; Computer science","score_opus":0.018578486234398846,"score_gpt":0.2485509443510118,"score_spread":0.22997245811661296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313729039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412544,0.0065347976,0.000014809999,0.0034776828,0.0011327779,0.0040799,0.0005874691,0.000011145158,0.00003595768],"genre_scores_gemma":[0.9956694,0.003361646,0.00005366881,0.000401384,0.00011426043,0.000077401324,0.00024759234,0.00002236804,0.00005224432],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936463,0.0041116965,0.0014326357,0.00035208263,0.00014415597,0.00031313222],"domain_scores_gemma":[0.98848915,0.010033341,0.00096003094,0.00031366583,0.000167648,0.000036191323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014326578,0.0002622871,0.0022261825,0.00007063031,0.000330044,0.00011345688,0.00052548,0.0003239291,0.00003002436],"category_scores_gemma":[0.0014013036,0.00013286364,0.00019782802,0.00020448577,0.00059823773,0.00017234372,0.00020236212,0.0004329348,0.0000039973315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9859824,0.00039965517,0.00028858244,0.0000018652851,0.0019273557,0.00023391529,0.0022246584,0.000007688957,0.000028516424,0.000061623876,0.0027926671,0.0060510584],"study_design_scores_gemma":[0.976956,0.00040305976,0.019760678,0.00021820245,0.00096634234,0.0005529902,0.0002625092,0.000010281208,0.00008295648,0.00027620807,0.00035507852,0.00015566763],"about_ca_topic_score_codex":0.0011154249,"about_ca_topic_score_gemma":0.00050139247,"teacher_disagreement_score":0.019472096,"about_ca_system_score_codex":0.000019502388,"about_ca_system_score_gemma":0.00016561116,"threshold_uncertainty_score":0.5418022},"labels":[],"label_agreement":null},{"id":"W4316927819","doi":"10.1007/s13555-022-00883-y","title":"Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Celgene; Eisai; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Kyowa Hakko Kirin; LEO Pharma; Torii Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Plaque psoriasis; Placebo; Medicine; Psoriasis; Dermatology; Internal medicine; Alternative medicine; Pathology; Disease","score_opus":0.013551954605158692,"score_gpt":0.2571772653719167,"score_spread":0.24362531076675803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316927819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951366,0.0026287101,6.349018e-7,0.00032721728,0.00014132584,0.0015916849,0.000047221976,0.000058871985,0.000067733636],"genre_scores_gemma":[0.9976501,0.0017913553,0.0000057233124,0.00011384278,0.0000070546002,0.00022538076,0.000121328325,0.000019929414,0.000065313674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981421,0.00060782087,0.00036215672,0.00046001145,0.00003833619,0.00038954683],"domain_scores_gemma":[0.9990157,0.00063839596,0.0000970757,0.00018994175,0.000022450047,0.000036449565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023636673,0.00029988165,0.0007560062,0.00040066926,0.0001847838,0.000016233469,0.00008479497,0.00027795768,0.00003844541],"category_scores_gemma":[0.000028097773,0.00021903573,0.000029082648,0.00030078183,0.00019179087,0.00010112853,0.000047751626,0.00019181604,0.000025212134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11219616,0.0029660694,0.81512725,0.000023528526,0.0010953569,0.00036543002,0.016743347,0.0000028802356,0.0006288161,0.00007963297,0.000099786914,0.050671723],"study_design_scores_gemma":[0.39790073,0.0012936855,0.5965061,0.000033189448,0.000109578745,0.00017047265,0.0021165037,0.000019008465,0.0003858252,0.00005512389,0.0010705219,0.00033925398],"about_ca_topic_score_codex":0.00010396999,"about_ca_topic_score_gemma":0.00041435234,"teacher_disagreement_score":0.28570458,"about_ca_system_score_codex":0.00001528205,"about_ca_system_score_gemma":0.000028226714,"threshold_uncertainty_score":0.8932018},"labels":[],"label_agreement":null},{"id":"W4317476907","doi":"10.1016/j.annder.2022.11.008","title":"Burden of visible [face and hands] skin diseases: Results from a large international survey","year":2023,"lang":"en","type":"article","venue":"Annales de Dermatologie et de Vénéréologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Population; Quality of life (healthcare); Gerontology; Family medicine; Demography; Psychology; Environmental health; Pathology","score_opus":0.04436557739400973,"score_gpt":0.3134011537846806,"score_spread":0.2690355763906709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317476907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897221,0.0030940804,0.00013457116,0.0016251673,0.0004050989,0.000155929,0.004090407,0.00026145094,0.00051120046],"genre_scores_gemma":[0.9910248,0.0035804294,0.0001349217,0.00024460242,0.000029254921,0.00003485217,0.004341446,0.00001781149,0.0005918992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782836,0.00072820584,0.00039718588,0.00042970938,0.0000597849,0.0005567291],"domain_scores_gemma":[0.99720854,0.0021206369,0.0001875214,0.00034795122,0.00008477249,0.000050607443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006817731,0.00023141077,0.00041691397,0.00021299231,0.00011218206,0.000029798211,0.00042813967,0.00036687183,0.00007375235],"category_scores_gemma":[0.0015369246,0.00020407446,0.00012045362,0.0002634035,0.00019160862,0.00011710386,0.00031440717,0.00017243781,0.00026210284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019524542,0.0003116222,0.8927584,0.000040466373,0.0012990485,0.0004356424,0.0024040525,0.00012228775,0.0086334795,0.00037255735,0.081040226,0.010629728],"study_design_scores_gemma":[0.0044313655,0.00012485152,0.9577583,0.0000536155,0.00012138151,0.00008431164,0.00092863524,0.00018528971,0.02343787,0.0011452303,0.011435004,0.00029412998],"about_ca_topic_score_codex":0.00076197955,"about_ca_topic_score_gemma":0.00021661083,"teacher_disagreement_score":0.069605224,"about_ca_system_score_codex":0.000042673902,"about_ca_system_score_gemma":0.00019429336,"threshold_uncertainty_score":0.83219147},"labels":[],"label_agreement":null},{"id":"W4317646773","doi":"10.1093/bjd/ljac052","title":"Does bimekizumab stand the test of time for psoriasis?","year":2022,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Psoriasis; Test (biology); Medicine; Dermatology; Biology","score_opus":0.010099609438465305,"score_gpt":0.21994090026958446,"score_spread":0.20984129083111916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317646773","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057675354,0.21538626,0.00020570646,0.68916875,0.023200836,0.002498554,0.010264949,0.000103637816,0.0014959367],"genre_scores_gemma":[0.3123258,0.10515415,0.0032910306,0.4312062,0.020479588,0.0015129865,0.009461122,0.0015862385,0.11498287],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99739015,0.0006862313,0.001061548,0.00026474308,0.00010907921,0.00048825747],"domain_scores_gemma":[0.9952234,0.0027229956,0.0014447521,0.00029843784,0.0002905197,0.000019914049],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000299511,0.00030659794,0.0012098267,0.00022775993,0.00034647054,0.000036136676,0.00080786255,0.00089483825,0.0020321952],"category_scores_gemma":[0.00040588016,0.00020336224,0.00064850884,0.00013254328,0.0003536557,0.00009513949,0.00011139941,0.0013313324,0.0000406251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034622833,0.00014664132,0.0002298559,0.000121121324,0.0015608644,0.00259731,0.00009900882,5.1271184e-7,0.0010044186,0.0000056079966,0.9731721,0.020716306],"study_design_scores_gemma":[0.0037600484,0.00042196014,0.00019125079,0.00021124959,0.0010388392,0.074703194,0.000099349345,3.0490682e-7,0.0060022287,0.00039273466,0.9129374,0.00024142029],"about_ca_topic_score_codex":0.00003681874,"about_ca_topic_score_gemma":0.0000131632705,"teacher_disagreement_score":0.25796255,"about_ca_system_score_codex":0.00006427039,"about_ca_system_score_gemma":0.0003939959,"threshold_uncertainty_score":0.9988801},"labels":[],"label_agreement":null},{"id":"W4317830684","doi":"10.33425/2690-537x.1025","title":"Mannitol Cream for Itchy Psoriasis, a Case Report","year":2022,"lang":"en","type":"article","venue":"Dermatology Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Psoriasis; Scalp; Medicine; Dermatology; Mannitol; Scratching; Chemistry; Materials science","score_opus":0.07441067575893305,"score_gpt":0.36370019410856236,"score_spread":0.2892895183496293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317830684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818421,0.0052582514,0.00010224273,0.0029072568,0.0020055745,0.0014202961,0.00035683627,0.0001666827,0.0059407833],"genre_scores_gemma":[0.9853482,0.00003722151,0.00016271073,0.00013349806,0.00007890466,0.0028234744,0.0008093463,0.000039037313,0.010567572],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9964853,0.0013737638,0.00043097697,0.00061214634,0.00011783337,0.0009799652],"domain_scores_gemma":[0.9978358,0.001104782,0.00010584769,0.0006653465,0.0002314139,0.000056785688],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001353952,0.00020264275,0.00041926064,0.00048226365,0.0020983024,0.00002000382,0.00040324536,0.0002643056,0.0015334457],"category_scores_gemma":[0.00031009788,0.00019794157,0.00019012518,0.0004446934,0.00031411854,0.00006396216,0.0004162958,0.0006257238,0.00045590315],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033438655,0.0027955307,0.021176813,0.0001743626,0.0021781106,0.392783,0.0026706392,0.000010838835,0.018237518,0.007945916,0.50053376,0.04814963],"study_design_scores_gemma":[0.0029850514,0.00039755474,0.00046378007,0.000003883871,0.00009193645,0.5434991,0.002110724,0.000011282229,0.019867191,0.0009924545,0.42934364,0.00023341834],"about_ca_topic_score_codex":0.00021086347,"about_ca_topic_score_gemma":0.000060000904,"teacher_disagreement_score":0.1507161,"about_ca_system_score_codex":0.00011230944,"about_ca_system_score_gemma":0.00024208112,"threshold_uncertainty_score":0.9993793},"labels":[],"label_agreement":null},{"id":"W4318754522","doi":"10.1016/j.jaad.2022.12.046","title":"Machine learning model for predicting outcomes of biologic therapy in psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bispebjerg Hospital; Alberta Innovates; Aalborg Universitetshospital; Gentofte Hospital; Aalborg Universitet; Odense Universitetshospital; University of Alberta","keywords":"Medicine; Secukinumab; Ustekinumab; Discontinuation; Scopus; Psoriasis; Adalimumab; Dermatology; Biosimilar; Internal medicine; MEDLINE; Psoriatic arthritis; Tumor necrosis factor alpha","score_opus":0.03867615573282402,"score_gpt":0.3070818252715341,"score_spread":0.2684056695387101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318754522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947703,0.0017178286,0.00010341587,0.0029678182,0.00021214763,0.00015691268,0.00003730622,0.000015239328,0.000019060184],"genre_scores_gemma":[0.9969283,0.0023815956,0.00034538447,0.00017416282,0.000015237555,0.0000096478525,0.000004885844,0.000013203702,0.00012759022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998384,0.0004181035,0.0007514049,0.00012242414,0.000048430764,0.00027564072],"domain_scores_gemma":[0.99746025,0.00079587,0.0015962479,0.000088682646,0.000043636315,0.000015290794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038803296,0.00015009903,0.00088027614,0.00033944863,0.00007150003,0.0000014880666,0.00043298013,0.00016246378,0.000007728392],"category_scores_gemma":[0.0002818928,0.000090109716,0.00034276998,0.00039115973,0.0003400543,0.000049060494,0.00007309828,0.00035577794,0.0000032746646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074527785,0.000096557254,0.9095805,0.000017124843,0.00064395205,0.0000027741196,0.00048669003,0.0014981547,0.06920681,0.00014581089,0.00026007765,0.017316261],"study_design_scores_gemma":[0.008629477,0.00095180306,0.8504876,0.00009459787,0.00035287053,0.00082237757,0.00090125826,0.0044209454,0.12862259,0.0023213963,0.0020897584,0.000305321],"about_ca_topic_score_codex":0.000029137087,"about_ca_topic_score_gemma":0.0000041574604,"teacher_disagreement_score":0.059415773,"about_ca_system_score_codex":0.000018871358,"about_ca_system_score_gemma":0.000053105658,"threshold_uncertainty_score":0.36745676},"labels":[],"label_agreement":null},{"id":"W4318816060","doi":"10.5114/ada.2022.124418","title":"Drug-related psoriasis","year":2023,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Drug; Pharmacology","score_opus":0.00843275138301883,"score_gpt":0.24812294075821376,"score_spread":0.23969018937519493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318816060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95480746,0.036190227,0.000010257858,0.0016243806,0.0020569363,0.00017445793,0.0000126255445,0.00025598513,0.004867663],"genre_scores_gemma":[0.98053324,0.016716458,0.000049841314,0.00019008447,0.000016664368,0.00008918571,0.00015434636,0.00001715373,0.002233023],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982236,0.00034898333,0.00037912838,0.00044779998,0.000021275639,0.0005792327],"domain_scores_gemma":[0.9991148,0.00052050344,0.00009404086,0.00022286661,0.000020622672,0.000027163689],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015259026,0.0002284765,0.00046548044,0.00035867235,0.00017295085,0.0000040109103,0.00018832111,0.00040262027,0.00030026902],"category_scores_gemma":[0.000070028786,0.0002081778,0.00006380082,0.00042901552,0.00044314927,0.00016716907,0.00011810025,0.00023675806,0.0013622582],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009203834,0.0004242947,0.5161603,0.00014112474,0.0009681277,0.0020751648,0.0037853515,0.00017228613,0.006801257,0.059630092,0.01480312,0.39411852],"study_design_scores_gemma":[0.01502172,0.00022781934,0.24858448,0.000090027315,0.00019675517,0.0053092735,0.0020231009,0.00008980648,0.017750802,0.05072895,0.65868086,0.0012964081],"about_ca_topic_score_codex":0.000018632121,"about_ca_topic_score_gemma":0.00031291557,"teacher_disagreement_score":0.64387774,"about_ca_system_score_codex":0.000013967242,"about_ca_system_score_gemma":0.0000254057,"threshold_uncertainty_score":0.9994153},"labels":[],"label_agreement":null},{"id":"W4319066240","doi":"10.1016/j.jaad.2023.01.029","title":"Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Sanofi Genzyme; LEO Pharma; Bausch Health; Simon Spies Fonden; LEO Fondet; Coloplast; Mylan; Horizon Therapeutics; UCB Pharma; Kongelig Hofbuntmager Aage Bangs Fond; Regeneron Pharmaceuticals; Sanofi; Galderma; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Samsung; National Psoriasis Foundation; Amgen","keywords":"Medicine; Discontinuation; Psoriasis; Cohort study; Cohort; Dermatology; MEDLINE; Internal medicine; Pediatrics","score_opus":0.016527922586928024,"score_gpt":0.2864238922055715,"score_spread":0.2698959696186435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319066240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584806,0.0005657563,0.0000065005966,0.0030198495,0.00017282933,0.0003560675,0.000011639411,0.000007837831,0.000011433795],"genre_scores_gemma":[0.99946946,0.0002442072,0.00010480767,0.000092930204,0.000016910988,0.000032415053,0.0000019453541,0.000007050729,0.000030257781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983725,0.0005924039,0.0006565921,0.00014007985,0.00006911141,0.00016934244],"domain_scores_gemma":[0.9986742,0.00031090694,0.0008541226,0.000081418446,0.00005850048,0.000020830186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004172571,0.0001215138,0.0006510408,0.00035679856,0.000042009593,0.0000028842026,0.00021807953,0.0001090741,0.0000071648424],"category_scores_gemma":[0.0002827097,0.00007607115,0.00009732671,0.00063780276,0.00024635385,0.00006668636,0.00008347952,0.00018567064,0.0000033040317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058117334,0.00019044701,0.96492666,0.000010186055,0.00026098953,0.000011801667,0.0012346616,0.00000558751,0.026221678,0.000021026224,0.0002641804,0.006271602],"study_design_scores_gemma":[0.0008252043,0.00031451415,0.9611069,0.00005408029,0.00015571021,0.00025735787,0.0013589123,0.000001251778,0.035447598,0.00012941565,0.00028100755,0.000068057336],"about_ca_topic_score_codex":0.000033875585,"about_ca_topic_score_gemma":0.000017378066,"teacher_disagreement_score":0.009225919,"about_ca_system_score_codex":0.000019261865,"about_ca_system_score_gemma":0.000040383668,"threshold_uncertainty_score":0.31020913},"labels":[],"label_agreement":null},{"id":"W4319317601","doi":"10.1177/2050313x231152054","title":"Case of resolution of plaque psoriasis following treatment with rifampicin for latent tuberculosis: A case report","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Rifampicin; Psoriasis; Tuberculosis; Latent tuberculosis; Dermatology; Mycobacterium tuberculosis; Disease; Plaque psoriasis; Surgery; Internal medicine; Pathology","score_opus":0.034788008357876626,"score_gpt":0.3063371460235567,"score_spread":0.2715491376656801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319317601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535805,0.001273732,0.00015800007,0.00017815286,0.00077242294,0.0016782903,0.00017371953,0.000064453234,0.00034319414],"genre_scores_gemma":[0.9967323,0.00014196306,0.00047364255,0.000017490167,0.00005059983,0.0005836082,0.0005003867,0.00003753242,0.001462464],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972783,0.00026517568,0.0011917878,0.0006590816,0.00015046872,0.0004552023],"domain_scores_gemma":[0.99787825,0.00045687275,0.0006440659,0.00076480367,0.00011865113,0.00013737031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00183386,0.0003154394,0.00087855035,0.00019633259,0.00029655907,0.0000151645545,0.00008981796,0.00041166623,0.00028274464],"category_scores_gemma":[0.00047312796,0.0002241835,0.00035526717,0.00042398216,0.00015274841,0.00012053838,0.00014110252,0.00012212331,0.0000102938875],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005596626,0.00044121838,0.0021890837,0.000075005155,0.0016125245,0.95117855,0.0007702359,0.0000087324215,0.001111203,0.0000147406945,0.00048347286,0.041555546],"study_design_scores_gemma":[0.003828735,0.0012480045,0.00013700503,0.00026825906,0.0014393885,0.97178984,0.0011652774,0.000030813284,0.01819722,0.000048039874,0.0016190651,0.00022834948],"about_ca_topic_score_codex":0.010001813,"about_ca_topic_score_gemma":0.0037260856,"teacher_disagreement_score":0.041327197,"about_ca_system_score_codex":0.00012061707,"about_ca_system_score_gemma":0.00044785766,"threshold_uncertainty_score":0.9965907},"labels":[],"label_agreement":null},{"id":"W4319349919","doi":"10.1177/1759720x221149965","title":"Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Musculoskeletal Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Tofacitinib; Psoriasis; Psoriatic arthritis; Adverse effect; Incidence (geometry); Internal medicine; Dermatology; Rheumatoid arthritis; Oncology","score_opus":0.0075525746487717805,"score_gpt":0.23502665101708697,"score_spread":0.22747407636831518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319349919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89920765,0.09969763,0.00008972574,0.000018258994,0.0001146958,0.0005226126,0.00031377637,0.000030537176,0.000005108896],"genre_scores_gemma":[0.95944726,0.040132582,0.00007770423,0.000007681262,0.000021691741,0.000093396106,0.00018142606,0.00002203643,0.000016208178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784905,0.00075847347,0.0003772978,0.0004814284,0.00017378211,0.0003599835],"domain_scores_gemma":[0.9989896,0.00042331323,0.000174246,0.00028381756,0.00006993294,0.000059089216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097026245,0.0002717843,0.0006685666,0.00022471257,0.000116560645,0.000007721454,0.000085714506,0.00012416966,0.0000140556085],"category_scores_gemma":[0.0002705438,0.00023756345,0.00018237595,0.00041658175,0.00015634304,0.00035235213,0.00007506983,0.00013759338,0.00000573226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018535937,0.000046126406,0.6832282,0.00012901537,0.00097127917,0.0000058579926,0.00017134972,0.00013262336,0.000012124745,0.000007485253,4.7413047e-7,0.3151101],"study_design_scores_gemma":[0.0060293972,0.00013544816,0.9908059,0.000325127,0.0011870438,6.553486e-7,0.00021229411,0.000014173901,0.00008379233,0.0006482882,0.00029711993,0.0002607601],"about_ca_topic_score_codex":0.000111046545,"about_ca_topic_score_gemma":0.00007448579,"teacher_disagreement_score":0.31484935,"about_ca_system_score_codex":0.00005655696,"about_ca_system_score_gemma":0.000030896583,"threshold_uncertainty_score":0.96875566},"labels":[],"label_agreement":null},{"id":"W4319460830","doi":"10.1093/bjd/ljac089","title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials","year":2022,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Ustekinumab; Medicine; Secukinumab; Adalimumab; Psoriasis Area and Severity Index; Discontinuation; Adverse effect; Psoriasis; Dermatology; Dermatology Life Quality Index; Clinical trial; Internal medicine; Psoriatic arthritis; Disease","score_opus":0.019078634734313493,"score_gpt":0.25183596524701773,"score_spread":0.23275733051270425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319460830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889496,0.0033874938,0.0001216379,0.00052391837,0.0010104503,0.00078152184,0.0051268814,0.000032166143,0.00006635954],"genre_scores_gemma":[0.9972557,0.0005021853,0.00036479428,0.0002615778,0.00008698929,0.000044585504,0.0013025344,0.000050763243,0.00013086536],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99418026,0.0023227888,0.0020685438,0.0006380536,0.00019915616,0.0005911719],"domain_scores_gemma":[0.99625635,0.0018667041,0.0012123516,0.00033434428,0.00019346077,0.00013676759],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006100926,0.00042244562,0.0020889712,0.00040026542,0.00047935455,0.00007088016,0.00046657783,0.00036794503,0.0010075581],"category_scores_gemma":[0.0005185634,0.0003835199,0.00018562627,0.0003765441,0.000120316305,0.00025328062,0.00022479659,0.0007498106,0.000020038662],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7160042,0.004843947,0.011493927,0.000021876645,0.005081038,0.010483064,0.0058141933,0.00044317413,0.0015682941,0.000029696348,0.013954379,0.23026225],"study_design_scores_gemma":[0.8077281,0.0046679457,0.12984252,0.0008290449,0.0018435708,0.020853547,0.002244698,0.00003648723,0.008158283,0.00034883426,0.021852076,0.0015948748],"about_ca_topic_score_codex":0.0015843275,"about_ca_topic_score_gemma":0.0009816628,"teacher_disagreement_score":0.22866736,"about_ca_system_score_codex":0.00021120696,"about_ca_system_score_gemma":0.00041408415,"threshold_uncertainty_score":0.99990565},"labels":[],"label_agreement":null},{"id":"W4320012155","doi":"10.1016/j.jdcr.2023.01.015","title":"Use of risankizumab in two HIV-positive patients with psoriasis","year":2023,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Human immunodeficiency virus (HIV); Population; Clinical trial; Immunology; Internal medicine","score_opus":0.019154129086747577,"score_gpt":0.2502033833799579,"score_spread":0.23104925429321033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320012155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998443,0.00015119041,0.000006038574,0.000020040421,0.0004707409,0.00033616458,0.0001298437,0.00007057892,0.0003724111],"genre_scores_gemma":[0.9980389,0.000024296702,0.0000899363,0.000014827863,0.000016106964,0.000049709168,0.0006090768,0.000021161955,0.0011359788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987211,0.0001475828,0.00041857403,0.00035181365,0.00005862729,0.000302301],"domain_scores_gemma":[0.9990444,0.00018968446,0.00027026297,0.0003791592,0.00009188003,0.000024579624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001695059,0.00018648406,0.00034043734,0.000244915,0.00007936973,0.000008543198,0.00003162977,0.00011661311,0.000105749],"category_scores_gemma":[0.00007663158,0.00014740964,0.00008623545,0.00044443627,0.000079705926,0.00013137244,0.00005051701,0.00009965406,0.00009464836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008279639,0.0006880806,0.87355876,0.00002716666,0.0006595345,0.082548894,0.0013132733,0.00007254874,0.0021377942,0.00008151497,0.002217065,0.035867415],"study_design_scores_gemma":[0.006077607,0.00049592915,0.9117203,0.0001501729,0.0004590972,0.015142418,0.0003326205,0.000004740878,0.060226724,0.00014574234,0.0047034435,0.0005412071],"about_ca_topic_score_codex":0.00090473925,"about_ca_topic_score_gemma":0.0002953013,"teacher_disagreement_score":0.067406476,"about_ca_system_score_codex":0.00005594509,"about_ca_system_score_gemma":0.000057569046,"threshold_uncertainty_score":0.60111904},"labels":[],"label_agreement":null},{"id":"W4320166268","doi":"10.21608/ejmm.2023.282660","title":"Correlation between Serum Level of Interleukin-6 and Osteoarthritis Disease Activity and Disability in Beni-Suef University Hospital","year":2019,"lang":"en","type":"article","venue":"The Egyptian Journal of Medical Microbiology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Osteoarthritis; Correlation; Gastroenterology; Disease; Internal medicine; Pathology; Mathematics; Alternative medicine","score_opus":0.01554854360029961,"score_gpt":0.22636890872367663,"score_spread":0.210820365123377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320166268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994983,0.0013770721,0.00005728165,0.002729494,0.0004738223,0.00015529168,0.00020670105,0.0000035068572,0.00001379301],"genre_scores_gemma":[0.9995771,0.00023417154,0.0000149782,0.000023804947,0.000035285826,2.9906673e-7,0.000018506633,0.0000049538994,0.00009091264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872947,0.0006009741,0.0002869642,0.0001634362,0.000037173413,0.00018197953],"domain_scores_gemma":[0.999037,0.0004744263,0.0002459765,0.000136531,0.000037651418,0.00006839333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067738676,0.00012422352,0.00039985837,0.00006661842,0.000051384846,0.0000034305751,0.00019314104,0.00025686467,0.00022534233],"category_scores_gemma":[0.000118939715,0.00008681499,0.00008043993,0.000075906275,0.0007667632,0.000086581254,0.0001367179,0.0003713384,0.0000108523345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011718603,0.00020413063,0.860146,0.000038759506,0.00021662931,0.000039807685,0.0008725276,0.0000012061325,0.020709863,0.00009897448,0.00007065257,0.116429575],"study_design_scores_gemma":[0.0040959013,0.0009166114,0.9915498,0.00013730227,0.0001245503,0.00018728651,0.00038095828,0.0000023210243,0.0016873872,0.000107120046,0.00070835656,0.00010239998],"about_ca_topic_score_codex":0.00007339189,"about_ca_topic_score_gemma":0.00011815186,"teacher_disagreement_score":0.13140379,"about_ca_system_score_codex":0.000043364813,"about_ca_system_score_gemma":0.00008192383,"threshold_uncertainty_score":0.35402125},"labels":[],"label_agreement":null},{"id":"W4320498120","doi":"10.2147/ccid.s401934","title":"Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study","year":2023,"lang":"en","type":"article","venue":"Clinical Cosmetic and Investigational Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Erythrocyte sedimentation rate; Depression (economics); Medicine; Internal medicine; Anxiety; C-reactive protein; Odds ratio; Cross-sectional study; Gastroenterology; Immunology; Psychiatry; Inflammation; Pathology","score_opus":0.03590907105159643,"score_gpt":0.32892308296583456,"score_spread":0.29301401191423815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320498120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981364,0.00038836908,0.00001848899,0.00028677162,0.00028182348,0.00072840584,0.000024115223,0.00007790997,0.000057716377],"genre_scores_gemma":[0.9988172,0.000041665447,0.00009129195,0.00016024352,0.000028200622,0.00025893017,0.00036938422,0.000014961019,0.00021814143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977558,0.000762091,0.0006386408,0.000528636,0.00006341607,0.00025137022],"domain_scores_gemma":[0.99835956,0.0011538111,0.00020274981,0.00012450389,0.000095923104,0.00006347133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055434,0.00022006802,0.00040184188,0.00020039143,0.00023040498,0.000028034356,0.000075735166,0.0003049308,0.000040860803],"category_scores_gemma":[0.0004434465,0.00016378953,0.000039756575,0.0003768664,0.0006730449,0.00017054389,0.000077677876,0.0002957275,0.00010274425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008407627,0.0002493825,0.9940767,0.000015548685,0.00021869387,0.00004396098,0.00023848895,0.000014137769,0.0035149853,0.00032596895,0.00007383121,0.00038752498],"study_design_scores_gemma":[0.0067898436,0.00039198436,0.98731685,0.000032781732,0.00006500898,0.00019049279,0.00020182559,0.00019762007,0.0014515733,0.0031475504,0.00003926778,0.00017520608],"about_ca_topic_score_codex":0.00004516386,"about_ca_topic_score_gemma":0.000043276785,"teacher_disagreement_score":0.006759869,"about_ca_system_score_codex":0.000019981566,"about_ca_system_score_gemma":0.00011410975,"threshold_uncertainty_score":0.66791433},"labels":[],"label_agreement":null},{"id":"W4320912957","doi":"10.1136/bmjopen-2021-060536","title":"Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"Cilag; Janssen Pharmaceuticals; Principia Biopharma; LEO Pharma; Medac; Radboud Universiteit; Argenx; Radboud Universitair Medisch Centrum; Incyte; Dermira; UCB Pharma; Regeneron Pharmaceuticals; Pfizer; Hexal AG; Celgene; Biogen; Sanofi; Amgen; Les Laboratories Pierre Fabre; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Observational study; Quality of life (healthcare); Psoriasis Area and Severity Index; Internal medicine; Dermatology; Nursing","score_opus":0.10625489157699053,"score_gpt":0.4272371488332586,"score_spread":0.32098225725626806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320912957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.762752,0.0000023818764,0.0000015881621,0.00004751108,0.0000656279,0.23628317,0.000036475732,0.000025670857,0.000785608],"genre_scores_gemma":[0.80902123,8.904835e-8,0.000108736094,0.000023791545,0.000011509577,0.19038013,0.00026749852,0.000019550424,0.00016746293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972561,0.0009734306,0.0008069217,0.00050929683,0.00016690623,0.0002873716],"domain_scores_gemma":[0.998514,0.00035390747,0.000480759,0.00036979697,0.00026632854,0.000015205101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011436158,0.00023046855,0.0004394797,0.00038904627,0.0002365109,0.00003329655,0.00029791016,0.00008035609,0.00006506449],"category_scores_gemma":[0.0001930391,0.00018615316,0.0000716145,0.0012576462,0.000060292805,0.0001671141,0.0002731804,0.00016568766,0.00001934254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031407187,0.0036723095,0.9718547,0.000024129344,0.00045828344,0.00015355035,0.016264953,0.0006813829,0.0019036795,0.000066625544,0.000028144428,0.0017515416],"study_design_scores_gemma":[0.020256918,0.0009539293,0.9638267,0.00017587155,0.00013688326,0.000003955323,0.009509574,0.00040832272,0.004435881,0.000060987357,0.000026667287,0.00020427644],"about_ca_topic_score_codex":0.0042113513,"about_ca_topic_score_gemma":0.002822182,"teacher_disagreement_score":0.046269268,"about_ca_system_score_codex":0.000333857,"about_ca_system_score_gemma":0.00054102606,"threshold_uncertainty_score":0.75911057},"labels":[],"label_agreement":null},{"id":"W4321132006","doi":"10.33590/emjdermatol/10314045","title":"Latest Highlights from Guselkumab in Psoriasis from EADV 2019","year":2019,"lang":"en","type":"article","venue":"EMJ Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriasis; Tolerability; Clinical trial; Dermatology; Secukinumab; Ustekinumab; Venereology; Internal medicine; Adverse effect; Psoriatic arthritis; Adalimumab; Tumor necrosis factor alpha","score_opus":0.00900181662433231,"score_gpt":0.215701605695829,"score_spread":0.2066997890714967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321132006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98408216,0.0074915523,0.000007889249,0.0013872243,0.0038614615,0.0003115556,0.0003150808,0.00014225213,0.0024008157],"genre_scores_gemma":[0.9950954,0.0002578745,0.00018097085,0.00031844183,0.00007936348,0.00004103316,0.0016336672,0.000035227604,0.002358077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782413,0.000393638,0.00049316976,0.00064347486,0.00004456997,0.00060103775],"domain_scores_gemma":[0.99855953,0.0005719671,0.00015699037,0.0006376771,0.000034382934,0.00003947069],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000057126876,0.0003471605,0.00074652274,0.00021449724,0.00008313267,0.00001584603,0.0003917934,0.0007359217,0.0044167703],"category_scores_gemma":[0.000027592067,0.00030890608,0.00014332314,0.00018570552,0.00009736308,0.00014237015,0.00011426128,0.00026377634,0.027568806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012657773,0.0010288282,0.77293855,0.000025161802,0.0019166849,0.0011221688,0.002920974,0.000011638699,0.13933684,0.003988081,0.06635969,0.009085586],"study_design_scores_gemma":[0.014569529,0.00016475622,0.48382184,0.00009434247,0.0003429893,0.00042809325,0.00039581698,0.000013422007,0.23062456,0.0027152377,0.26579496,0.0010344391],"about_ca_topic_score_codex":0.0036036395,"about_ca_topic_score_gemma":0.0010156567,"teacher_disagreement_score":0.28911674,"about_ca_system_score_codex":0.000060013706,"about_ca_system_score_gemma":0.0000790188,"threshold_uncertainty_score":0.9999363},"labels":[],"label_agreement":null},{"id":"W4321446264","doi":"10.1001/jama.2022.22649","title":"Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply","year":2023,"lang":"en","type":"letter","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Family medicine; Otorhinolaryngology; Psychiatry","score_opus":0.015373634309027658,"score_gpt":0.22952680323163208,"score_spread":0.21415316892260441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321446264","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18785112,0.030544274,0.00001285129,0.7517478,0.014304917,0.0017627273,0.0028602376,0.0016293492,0.009286769],"genre_scores_gemma":[0.044155546,0.010936113,0.000104856495,0.5741563,0.026107278,0.0010497465,0.016388182,0.0007834186,0.32631856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972746,0.00035091897,0.0004610641,0.00093956856,0.000092859445,0.0008809949],"domain_scores_gemma":[0.99824697,0.00062395405,0.00024656713,0.0007555359,0.00008292462,0.00004402627],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023381351,0.00063984696,0.0008402242,0.0002826602,0.00032086004,0.00009374187,0.00041826873,0.0022764553,0.0009123853],"category_scores_gemma":[0.00010888901,0.00057787646,0.00028103674,0.00022731845,0.0002487006,0.00013066172,0.00022578512,0.0014864051,0.0057982053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019257072,0.00010211607,0.00035374757,0.0001406928,0.0009128949,0.00040119316,0.00015573266,5.123332e-7,0.003332843,0.000023796358,0.9620773,0.032306593],"study_design_scores_gemma":[0.0036536213,0.0007538158,0.0051385583,0.00017512866,0.0004835141,0.0001413413,0.000033457425,0.000001700935,0.008263888,0.00010389802,0.9806659,0.00058517326],"about_ca_topic_score_codex":0.00042792602,"about_ca_topic_score_gemma":0.000100845326,"teacher_disagreement_score":0.3170318,"about_ca_system_score_codex":0.00018703511,"about_ca_system_score_gemma":0.00019637114,"threshold_uncertainty_score":0.9996673},"labels":[],"label_agreement":null},{"id":"W4321614222","doi":"10.2196/42421","title":"The Differentially Expressed Genes Responsible for the Development of T Helper 9 Cells From T Helper 2 Cells in Various Disease States: Immuno-Interactomics Study","year":2023,"lang":"en","type":"article","venue":"JMIR Bioinformatics and Biotechnology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University Grants Commission","keywords":"Immunology; Disease; Medicine; Interleukin 22; Interleukin; Cytokine; Internal medicine","score_opus":0.014853106114999435,"score_gpt":0.2454852363028882,"score_spread":0.23063213018788878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321614222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496526,0.0013351804,0.0006230344,0.00051728805,0.00059466297,0.0014615583,0.0004141195,0.000082968865,0.0000059561335],"genre_scores_gemma":[0.9949279,0.0026803212,0.0010974491,0.000045065666,0.000014226769,0.0005149283,0.0002653102,0.000022994009,0.00043181123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985245,0.000085136075,0.0006937644,0.00022310296,0.0000573894,0.0004161386],"domain_scores_gemma":[0.9983784,0.00080295163,0.00023356614,0.00051129994,0.000050633436,0.000023150591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036885694,0.00025397085,0.00033996685,0.00023160437,0.00041733115,0.000047007772,0.0004630725,0.00029895495,0.000017907108],"category_scores_gemma":[0.000030244602,0.00014224544,0.00008611155,0.00025871347,0.0002333469,0.000059513175,0.0003340428,0.00017891031,0.00005855117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002698823,0.0007665101,0.0016223099,0.00010332364,0.0011648426,0.0000075409216,0.015789106,0.00004053104,0.70765376,0.00023500492,0.00095090526,0.26896736],"study_design_scores_gemma":[0.0058176783,0.00062076695,0.019912452,0.00008952748,0.00024568118,0.0000024339738,0.022344546,0.0027764996,0.9009826,0.0007772618,0.045913912,0.0005166236],"about_ca_topic_score_codex":0.000047570098,"about_ca_topic_score_gemma":0.0003427037,"teacher_disagreement_score":0.26845074,"about_ca_system_score_codex":0.000030784977,"about_ca_system_score_gemma":0.00012882877,"threshold_uncertainty_score":0.58006006},"labels":[],"label_agreement":null},{"id":"W4322620768","doi":"10.1111/jdv.18999","title":"Psychometric validation of the generalized pustular psoriasis physician global assessment (<scp>GPPGA</scp>) and generalized pustular psoriasis area and severity index (<scp>GPPASI</scp>)","year":2023,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; Pfizer; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Medicine; Intraclass correlation; Convergent validity; Confirmatory factor analysis; Generalized pustular psoriasis; Psoriasis; Reliability (semiconductor); Severity of illness; Correlation; Internal medicine; Psychometrics; Physical therapy; Dermatology; Clinical psychology; Internal consistency; Statistics; Structural equation modeling","score_opus":0.02415150028357699,"score_gpt":0.27141775719606487,"score_spread":0.24726625691248788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322620768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876308,0.0080876015,0.000079285186,0.0016810249,0.0014158329,0.00032838323,0.00007745732,0.00003096975,0.0006686705],"genre_scores_gemma":[0.99372596,0.0050835065,0.00019965226,0.00047797614,0.00016328941,0.000008539944,0.000019059473,0.000034920206,0.0002871064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994113,0.003513988,0.0011535402,0.0004588227,0.00019131825,0.0005693323],"domain_scores_gemma":[0.9970376,0.00067771855,0.0016940732,0.00035004038,0.00014290653,0.000097689204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012368952,0.00045425555,0.0011889733,0.00044351158,0.00046075767,0.000022755823,0.0007386725,0.0006022829,0.0000073844194],"category_scores_gemma":[0.00048248342,0.00030321747,0.00037568517,0.0010169504,0.0010020689,0.00018415827,0.0005610511,0.0007037357,0.000007970358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016955347,0.00030070695,0.9360812,0.00013877316,0.0025852497,0.00003957782,0.00066217827,0.00010803301,0.03595699,0.0020002634,0.010106019,0.011851461],"study_design_scores_gemma":[0.0067711785,0.00010864569,0.928581,0.000088500885,0.0012637835,0.0027306117,0.00037497535,0.000049666443,0.043415498,0.003346577,0.013135051,0.00013452742],"about_ca_topic_score_codex":0.000019381496,"about_ca_topic_score_gemma":0.0000037948744,"teacher_disagreement_score":0.011716933,"about_ca_system_score_codex":0.000047971665,"about_ca_system_score_gemma":0.00008816141,"threshold_uncertainty_score":0.999942},"labels":[],"label_agreement":null},{"id":"W4322765827","doi":"10.1016/j.jaad.2023.02.040","title":"Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Medac; Bausch Health; Eisai; Celltrion; XBiotech; InflaRx; Pfizer; Biogen; Incyte; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Novocure; Valeant Pharmaceuticals International; Springworks Therapeutics; Castle Biosciences; Therakos; Celgene; Sanofi; LEO Pharma; Ortho Dermatologics; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; Boehringer Ingelheim; Amgen; Meiji Seika Pharma","keywords":"Medicine; Generalized pustular psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Placebo; Pustular psoriasis; Internal medicine; Alternative medicine; Pathology","score_opus":0.01630509240174297,"score_gpt":0.3020979104907079,"score_spread":0.2857928180889649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322765827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989588,0.0031555337,0.00003595521,0.003335711,0.00024907073,0.0035337713,0.000066855544,0.000011567886,0.00002350337],"genre_scores_gemma":[0.99675477,0.0020047089,0.0003964866,0.00024185577,0.000060628336,0.00046804413,0.000014633264,0.000024460762,0.000034391214],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9939379,0.0034284631,0.0015058626,0.00034394153,0.00021551295,0.00056829106],"domain_scores_gemma":[0.99602425,0.0013466673,0.00219889,0.0002838622,0.0001076535,0.000038664708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012799675,0.00044669118,0.0031827732,0.00044867233,0.00014467238,0.000016675936,0.00060246006,0.00016856793,0.0000075086755],"category_scores_gemma":[0.00016347141,0.0002289705,0.00062019227,0.000813529,0.0006851617,0.000098118464,0.00009383559,0.00019622492,9.899485e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69988465,0.0057607526,0.19715866,0.00016535383,0.019215759,0.00022491578,0.006710435,0.00066512596,0.027612695,0.0012004339,0.000969235,0.040431987],"study_design_scores_gemma":[0.87844294,0.0035648511,0.08578562,0.000100418714,0.0043755975,0.00040266037,0.011538486,0.0002399239,0.013666889,0.0010084943,0.0004589625,0.00041512895],"about_ca_topic_score_codex":0.00033517406,"about_ca_topic_score_gemma":0.00008089356,"teacher_disagreement_score":0.17855833,"about_ca_system_score_codex":0.0001673351,"about_ca_system_score_gemma":0.00020037217,"threshold_uncertainty_score":0.93371457},"labels":[],"label_agreement":null},{"id":"W4323652381","doi":"10.1093/bjd/ljad060","title":"Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Intertriginous; Medicine; Roflumilast; Psoriasis; Dermatology; Post-hoc analysis; Randomized controlled trial; Discontinuation; Reactogenicity; Internal medicine; Immunology; Disease; COPD","score_opus":0.009377737268086021,"score_gpt":0.226653947008203,"score_spread":0.21727620974011697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769274,0.019637702,0.00043591592,0.00029118374,0.000409109,0.0017632712,0.0004838376,0.000024367564,0.000027212216],"genre_scores_gemma":[0.9899084,0.0092165405,0.00015038459,0.00003981876,0.00007043253,0.00014494744,0.0003789447,0.000019619416,0.00007090322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99735737,0.0006859538,0.0012450778,0.00029186686,0.00007264089,0.00034710963],"domain_scores_gemma":[0.99613243,0.0024243305,0.0009853963,0.00013818029,0.00025568446,0.000063977895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004770982,0.00026233215,0.0031717448,0.0005446352,0.00017766374,0.00003682597,0.00016640621,0.00029880868,0.00008066116],"category_scores_gemma":[0.00038454094,0.00021161296,0.0005968026,0.00031304837,0.00039163098,0.00010596251,0.00005356547,0.00018687667,0.000002913018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9598912,0.00035753628,0.00078096637,0.000034511428,0.020119967,0.0003478444,0.0005138738,0.0000085866495,0.0016596533,0.00003518505,0.00038912566,0.015861556],"study_design_scores_gemma":[0.9815028,0.001880874,0.0021340498,0.00020107513,0.008552678,0.0026803485,0.00026937772,0.000039225295,0.0016717449,0.00007666669,0.0007849786,0.00020618708],"about_ca_topic_score_codex":0.00027185472,"about_ca_topic_score_gemma":0.00084481057,"teacher_disagreement_score":0.021611601,"about_ca_system_score_codex":0.000037272624,"about_ca_system_score_gemma":0.00020994089,"threshold_uncertainty_score":0.8629326},"labels":[],"label_agreement":null},{"id":"W4323874616","doi":"10.3899/jrheum.120828","title":"Psoriasis and Psoriatic Arthritis in Peruvian Aborigines: A Report from the GRAPPA 2011 Annual Meeting","year":2012,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Methotrexate; Arthritis; Disease; Family history; Dermatology; Internal medicine","score_opus":0.010546186641329003,"score_gpt":0.2307066968665265,"score_spread":0.2201605102251975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323874616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354623,0.060844578,0.000028335915,0.0011558578,0.0022416664,0.00012776806,0.00002492292,0.0000111693225,0.00010338955],"genre_scores_gemma":[0.9897414,0.009871861,0.00012295872,0.00007671538,0.000065384935,0.000007905155,0.000011212838,0.000015120356,0.000087451175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977328,0.0008928625,0.0007718025,0.00012723194,0.000060752634,0.00041453185],"domain_scores_gemma":[0.9976296,0.0013062608,0.00065304263,0.0002851768,0.00008568916,0.000040242037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017479265,0.0001986181,0.00055911974,0.00011047537,0.00020328835,0.000009583537,0.00029465108,0.00020527978,0.00019893904],"category_scores_gemma":[0.00028908433,0.00010808216,0.000108313514,0.00012039201,0.00024197059,0.00018116184,0.00006183898,0.0003552497,0.00007862406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045320016,0.00014474051,0.9447691,0.000007804637,0.00063928287,0.000043776497,0.011164792,0.0000019865172,0.0009568346,0.00032016297,0.005582733,0.035915595],"study_design_scores_gemma":[0.009753591,0.00043256945,0.8370605,0.0004916498,0.0010416071,0.07153776,0.016337877,0.0000037339596,0.0023482183,0.002301067,0.058111303,0.00058013404],"about_ca_topic_score_codex":0.0020448235,"about_ca_topic_score_gemma":0.0006789604,"teacher_disagreement_score":0.1077086,"about_ca_system_score_codex":0.000024765981,"about_ca_system_score_gemma":0.000073440446,"threshold_uncertainty_score":0.44074628},"labels":[],"label_agreement":null},{"id":"W4324057437","doi":"10.25251/skin.7.supp.117","title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Medicine; Placebo; Apremilast; Psoriasis; Internal medicine; Plaque psoriasis; Tolerability; Randomized controlled trial; Clinical trial; Gastroenterology; Dermatology; Adverse effect; Psoriatic arthritis; Pathology","score_opus":0.030488021619105438,"score_gpt":0.3025046343398302,"score_spread":0.27201661272072475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903418,0.0025764315,0.000013028584,0.0044271927,0.0010914343,0.0013167984,0.00007750705,0.000032677617,0.0001231327],"genre_scores_gemma":[0.9964483,0.0015011514,0.00003391101,0.0005402934,0.00043449676,0.00005505331,0.00013501421,0.000040530595,0.00081125647],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961737,0.0017022875,0.0009957314,0.00031703786,0.00021180177,0.0005994383],"domain_scores_gemma":[0.9978109,0.001173486,0.00040005115,0.00040068247,0.000118413016,0.00009648483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014140436,0.00043321657,0.0008778998,0.0004629414,0.00023132413,0.000024825187,0.00053119945,0.0002324771,0.00012262347],"category_scores_gemma":[0.0003113875,0.00022384408,0.00014117888,0.0009842534,0.00016003495,0.000117230586,0.000042739415,0.0004588077,0.00007506144],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42043638,0.011945726,0.00029659047,0.000041300053,0.0015591837,0.006010541,0.051947244,0.00094027835,0.23025727,0.000042849526,0.047457315,0.22906531],"study_design_scores_gemma":[0.6298103,0.1344578,0.0020982348,0.0012581454,0.0029683423,0.027177233,0.016939737,0.00015783978,0.10398148,0.0007917529,0.07879012,0.0015690344],"about_ca_topic_score_codex":0.00039075024,"about_ca_topic_score_gemma":0.0005976993,"teacher_disagreement_score":0.22749627,"about_ca_system_score_codex":0.00024447413,"about_ca_system_score_gemma":0.00023560128,"threshold_uncertainty_score":0.91280967},"labels":[],"label_agreement":null},{"id":"W4324057475","doi":"10.25251/skin.7.supp.109","title":"Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Galderma; Celgene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Amgen","keywords":"Apremilast; Plaque psoriasis; Medicine; Randomized controlled trial; Psoriasis; Dermatology; Physical therapy; Internal medicine; Psoriatic arthritis","score_opus":0.010800901179962612,"score_gpt":0.24335464792855624,"score_spread":0.23255374674859364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944587,0.0014218577,0.000026953123,0.0007136359,0.00057906023,0.0022933795,0.0002722178,0.000016704249,0.00021753258],"genre_scores_gemma":[0.997888,0.0013101188,0.000026474445,0.000053530242,0.00020873209,0.000018300416,0.00010336682,0.000022499467,0.00036894743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957234,0.0015895889,0.0018479575,0.0002760559,0.0002453207,0.00031767067],"domain_scores_gemma":[0.99182063,0.0062928954,0.0012141395,0.00031726528,0.00027783462,0.00007722182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002990355,0.00032363107,0.0020310746,0.00047303294,0.00012122504,0.0000076086862,0.00028340722,0.000134312,0.000026579786],"category_scores_gemma":[0.002292912,0.00015598504,0.00012106547,0.00051086064,0.00016398676,0.00005424637,0.000060318594,0.00033838148,0.000013052683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9771059,0.0013855216,0.00082688784,0.000010232152,0.001536276,0.000251505,0.012163868,0.0007178791,0.0003000907,0.0000015736172,0.0012459215,0.00445434],"study_design_scores_gemma":[0.9812711,0.0072955904,0.0052878736,0.00033082292,0.0028789642,0.00024312496,0.0020578238,0.000024684156,0.00025730996,0.00006957666,0.000101222715,0.00018190942],"about_ca_topic_score_codex":0.00024976765,"about_ca_topic_score_gemma":0.00023449554,"teacher_disagreement_score":0.010106045,"about_ca_system_score_codex":0.00005708333,"about_ca_system_score_gemma":0.000099933015,"threshold_uncertainty_score":0.63608855},"labels":[],"label_agreement":null},{"id":"W4324057607","doi":"10.25251/skin.7.supp.110","title":"Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"","keywords":"Apremilast; Psoriasis; Placebo; Double blind; Medicine; Randomized controlled trial; Dermatology; Internal medicine; Alternative medicine; Psoriatic arthritis; Pathology","score_opus":0.015637138701321746,"score_gpt":0.2629802931701529,"score_spread":0.24734315446883118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324057607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398226,0.00212751,0.000010890721,0.0007828507,0.00058980717,0.0022000433,0.00010871154,0.000010641018,0.00018728508],"genre_scores_gemma":[0.9988401,0.0005906253,0.000007961251,0.00002903052,0.0001836099,0.000016061895,0.000086926666,0.00001832675,0.00022734223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968362,0.0012828686,0.0012089193,0.0001870207,0.00022374894,0.00026127492],"domain_scores_gemma":[0.992066,0.006494504,0.0009074122,0.00033765342,0.00015432523,0.000040101197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027127622,0.00026651274,0.0012637379,0.00018821412,0.00016660293,0.00000765534,0.00036320076,0.000107278735,0.00005831091],"category_scores_gemma":[0.00074185606,0.00010350749,0.0001173553,0.0003190206,0.00048744984,0.000053524447,0.000064760236,0.00034848595,0.000009325664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9761477,0.0008253544,0.00179835,0.0000036159927,0.0025992368,0.000110637804,0.010999195,0.00009621784,0.0002893666,0.0000051498887,0.00049967575,0.00662546],"study_design_scores_gemma":[0.9816991,0.003480316,0.006222317,0.00023136595,0.0026538076,0.00022469182,0.004989219,0.0000074173704,0.00020778435,0.000041171465,0.00012997435,0.00011282422],"about_ca_topic_score_codex":0.00021526212,"about_ca_topic_score_gemma":0.0002038531,"teacher_disagreement_score":0.006512636,"about_ca_system_score_codex":0.000028146585,"about_ca_system_score_gemma":0.000058733676,"threshold_uncertainty_score":0.4220913},"labels":[],"label_agreement":null},{"id":"W4324142027","doi":"10.1016/j.joca.2023.01.340","title":"Developing And Characterizing An Osteochondral-Synovial Model For Evaluating Psoriatic Arthritis Therapies","year":2023,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Dexamethasone; Stage (stratigraphy); Arthritis; Internal medicine; Biology","score_opus":0.04375011734200865,"score_gpt":0.28421146374143946,"score_spread":0.24046134639943081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324142027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906505,0.009008905,0.00017889771,0.0003086228,0.0005157021,0.00048984,0.00019771102,0.00016559711,0.00006964901],"genre_scores_gemma":[0.99529684,0.0019982115,0.0009936808,0.00016549931,0.00009230031,0.00030492485,0.000408968,0.000038537455,0.00070102036],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860275,0.00013080321,0.00030033855,0.0004482258,0.000051602176,0.0004662584],"domain_scores_gemma":[0.9994839,0.00013583347,0.00009290168,0.00018103082,0.000059392267,0.000046981182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003999999,0.00024344596,0.00036153375,0.00011587029,0.0005735939,0.000094871066,0.00007948589,0.00018485503,0.000031080854],"category_scores_gemma":[0.000052120944,0.0002386478,0.0000700974,0.00012356383,0.000107192376,0.00028033045,0.000067555105,0.000090844886,0.000034297136],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010893816,0.0000125255065,0.0003713783,0.000029765391,0.000019825766,0.00000733192,0.0027895297,0.0000023687505,0.46769598,0.0007496611,0.000050875078,0.5281618],"study_design_scores_gemma":[0.061585676,0.010240927,0.025206823,0.0023200882,0.0010866872,0.001064419,0.012620548,0.0055490527,0.8274616,0.022473855,0.0250981,0.005292213],"about_ca_topic_score_codex":0.0000063953134,"about_ca_topic_score_gemma":0.00013993854,"teacher_disagreement_score":0.5228696,"about_ca_system_score_codex":0.000016384069,"about_ca_system_score_gemma":0.00005890323,"threshold_uncertainty_score":0.9731775},"labels":[],"label_agreement":null},{"id":"W4327547032","doi":"10.1080/14737167.2023.2190514","title":"Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods","year":2023,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); University of Toronto","funders":"","keywords":"Plaque psoriasis; Psoriasis; Medicine; Intensive care medicine; Dermatology","score_opus":0.06564973707451045,"score_gpt":0.4520642311900215,"score_spread":0.38641449411551104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327547032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96766096,0.023733726,0.00002499363,0.003853858,0.00017968625,0.0038212908,0.0006691237,0.000011709578,0.000044644672],"genre_scores_gemma":[0.852393,0.1407664,0.0015430679,0.00034463394,0.000024833373,0.0033922913,0.00010210281,0.000041837433,0.0013918801],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984138,0.00030727446,0.0004963946,0.00033919513,0.000046905425,0.00039644854],"domain_scores_gemma":[0.9979047,0.0014428432,0.00015215247,0.0002930635,0.00017468998,0.00003255772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010594635,0.00020576277,0.0008528269,0.0001655514,0.0001391573,0.0000077893665,0.00029241267,0.00010752889,0.00013398685],"category_scores_gemma":[0.00014059736,0.00011442492,0.00020557658,0.00019591322,0.00028385915,0.00004694507,0.00010821648,0.00007378863,0.000009984966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057226166,0.002808458,0.34384146,0.010765076,0.0078760665,0.000012065694,0.022904556,0.00043461905,0.20655972,0.0049939156,0.058893386,0.2836845],"study_design_scores_gemma":[0.056346804,0.008561978,0.12038856,0.0055446876,0.00045395392,0.00004314174,0.005080239,0.0006911095,0.29568782,0.0006808263,0.50509316,0.0014277505],"about_ca_topic_score_codex":0.000093786046,"about_ca_topic_score_gemma":0.00010354062,"teacher_disagreement_score":0.44619974,"about_ca_system_score_codex":0.00011761388,"about_ca_system_score_gemma":0.00013623342,"threshold_uncertainty_score":0.4666113},"labels":[],"label_agreement":null},{"id":"W4327676480","doi":"10.1007/s13555-023-00910-6","title":"Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Secukinumab; Medicine; Discontinuation; Ixekizumab; Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Ustekinumab; Cohort; Dermatology; Internal medicine; Pediatrics; Rheumatoid arthritis","score_opus":0.022863082856469093,"score_gpt":0.2595506901935598,"score_spread":0.2366876073370907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260306,0.004602685,0.000024312041,0.0013620653,0.0003872999,0.0005328695,0.000039782677,0.00011375995,0.00033414582],"genre_scores_gemma":[0.99430877,0.003496233,0.000008755855,0.0010742742,0.000037972357,0.00024685622,0.00012874613,0.000025396059,0.0006729692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980422,0.0006317752,0.0002964505,0.00040272117,0.000056839697,0.00056997756],"domain_scores_gemma":[0.9988195,0.0006239052,0.00010469572,0.00039102166,0.000034433913,0.000026452848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024690983,0.00032021262,0.00049312174,0.00022488977,0.00035101213,0.000029589526,0.00031717712,0.00036200986,0.00040664742],"category_scores_gemma":[0.000015590937,0.00017413913,0.00007975085,0.00044908878,0.00032831184,0.00010664897,0.000026742724,0.0002534491,0.0004665547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0105105555,0.0005080045,0.8232662,0.000044435164,0.0016743344,0.0022601623,0.005215241,0.000005302801,0.0021691138,0.0019982255,0.0023925686,0.14995584],"study_design_scores_gemma":[0.024211746,0.0005677844,0.9513234,0.000040691815,0.00014857181,0.0042983256,0.00049322937,0.000006555815,0.0052100983,0.00026723117,0.012993217,0.00043914735],"about_ca_topic_score_codex":0.0000818535,"about_ca_topic_score_gemma":0.0009613914,"teacher_disagreement_score":0.1495167,"about_ca_system_score_codex":0.000014743032,"about_ca_system_score_gemma":0.00006764934,"threshold_uncertainty_score":0.7101188},"labels":[],"label_agreement":null},{"id":"W4327676963","doi":"10.1007/s13555-023-00905-3","title":"Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lynde Centre for Dermatology; University of Toronto; University of Alberta; BC Children's Hospital; Dalhousie University; SKiN Health; McMaster University; Juravinski Cancer Centre; BC Cancer Agency; Dermatrials Research; Ottawa Hospital; Probity Medical Research; University of British Columbia; University of Ottawa","funders":"Sun Pharma; AbbVie; AbbVie Canada; LEO Pharma; Janssen Canada; Novartis; Amgen Canada; Amgen","keywords":"Psoriasis; Medicine; Systemic therapy; Malignancy; Population; Intensive care medicine; Immunosuppression; Disease; Cancer; Dermatology; Internal medicine; Breast cancer","score_opus":0.05779641493854979,"score_gpt":0.26736302212177254,"score_spread":0.20956660718322276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327676963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98168653,0.017219158,0.00002319229,0.000035766734,0.00015055588,0.0005492365,0.00030342344,0.00002763878,0.0000044692547],"genre_scores_gemma":[0.9966992,0.0024462936,0.00011582709,0.000011711774,0.000004526017,0.00023266552,0.0004128849,0.000014245636,0.00006266001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989294,0.00022355831,0.00039076936,0.0002341453,0.000028752118,0.00019337158],"domain_scores_gemma":[0.9987976,0.00059245754,0.0002821904,0.00022634154,0.00008815588,0.000013264157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040860912,0.00020724714,0.00069961796,0.0002190831,0.000034041142,0.0000012475386,0.00007861405,0.00020895775,0.000017604547],"category_scores_gemma":[0.000010990455,0.00014425357,0.00009070053,0.00011685782,0.00025724174,0.00006212421,0.000009310802,0.000024413519,0.0000017747549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006673797,0.0010149494,0.9061264,0.000044184944,0.00082583254,0.0000069734706,0.008468111,0.000012415163,0.06603456,0.000037062182,0.00006282305,0.010692906],"study_design_scores_gemma":[0.021269409,0.0018964919,0.8385762,0.00022782884,0.00012589908,0.000005909269,0.00053159014,0.00006453043,0.13665108,0.000054889326,0.000371398,0.00022476622],"about_ca_topic_score_codex":0.00048943044,"about_ca_topic_score_gemma":0.00004609494,"teacher_disagreement_score":0.07061651,"about_ca_system_score_codex":0.00004756929,"about_ca_system_score_gemma":0.00009158756,"threshold_uncertainty_score":0.58824897},"labels":[],"label_agreement":null},{"id":"W4328049279","doi":"10.1177/12034754231163541","title":"Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion","year":2023,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; SKiN Health; Western University","funders":"","keywords":"Tazarotene; Medicine; Lotion; Dermatology; Plaque psoriasis; Psoriasis; Single Center; Surgery; Pharmacology","score_opus":0.034228860852436774,"score_gpt":0.2556790706645644,"score_spread":0.22145020981212765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328049279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95458204,0.0063648177,0.000023369355,0.037148412,0.0014917981,0.0002832395,0.0000339819,0.000030104295,0.00004223938],"genre_scores_gemma":[0.9444681,0.02388634,0.00011203596,0.023301944,0.0035744826,0.00006823678,0.00082604715,0.0001719081,0.0035909493],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99780494,0.00031582772,0.0008765572,0.0003748962,0.00016628118,0.00046151452],"domain_scores_gemma":[0.9973124,0.001584337,0.0007396314,0.00018269596,0.00012322386,0.000057711084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035848218,0.0004328855,0.0012420155,0.00069396844,0.0001301009,0.000022082766,0.00011763965,0.00061397115,0.00009116866],"category_scores_gemma":[0.00023659892,0.00027432325,0.00013281962,0.00020355522,0.00029340826,0.00012487127,0.000035627094,0.0009025114,0.000008039621],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026798707,0.00022249178,0.65338504,0.0007233388,0.0014918261,0.05310852,0.00428554,0.0000052529713,0.0051683057,0.0000012260746,0.15790665,0.12102194],"study_design_scores_gemma":[0.035619482,0.008646558,0.24116082,0.039301384,0.0046668723,0.32997617,0.0041643963,0.000035723355,0.008082883,0.00013287953,0.32372576,0.0044870665],"about_ca_topic_score_codex":0.0001111389,"about_ca_topic_score_gemma":0.000108566855,"teacher_disagreement_score":0.4122242,"about_ca_system_score_codex":0.00006822896,"about_ca_system_score_gemma":0.00010684566,"threshold_uncertainty_score":0.9999709},"labels":[],"label_agreement":null},{"id":"W4328052704","doi":"10.1093/bjd/ljad081","title":"Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Probity Medical Research","funders":"Janssen Research and Development; St Vincent's Hospital Melbourne; Pusan National University Hospital; Humboldt-Universität zu Berlin; Janssen Scientific Affairs; Freie Universität Berlin; Pusan National University; Berlin Institute of Health; University of Melbourne","keywords":"Medicine; Malignancy; Psoriasis; Dermatology; Skin cancer; Breast cancer; Cancer; Population; Family history; Internal medicine","score_opus":0.01635308347776333,"score_gpt":0.21098835684000225,"score_spread":0.19463527336223893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328052704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974866,0.00855692,0.000010328577,0.00019727647,0.00039871718,0.00023054148,0.0005579671,0.0000094771285,0.00029013932],"genre_scores_gemma":[0.9978854,0.0015834128,0.000133821,0.000029655646,0.000021595837,0.0000050770054,0.00011465371,0.000014852755,0.00021154743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997519,0.00090158416,0.0010764534,0.00018529005,0.000087075576,0.00023057483],"domain_scores_gemma":[0.9974671,0.0010602578,0.0010895994,0.00018679924,0.00017146154,0.00002481038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060474005,0.0001514668,0.000972881,0.00017217975,0.00004783683,0.0000051308793,0.00021165035,0.0002005797,0.00006517692],"category_scores_gemma":[0.00037478234,0.000106264546,0.00010573939,0.00019110288,0.00030703098,0.00009388399,0.000044412718,0.0002035966,0.0000065877402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055308487,0.0012180706,0.80585873,0.00011822281,0.0047059576,0.0026009197,0.0058128964,0.000020566109,0.0036457747,0.00023519715,0.046579536,0.073895626],"study_design_scores_gemma":[0.03968105,0.0006944353,0.9462624,0.00068958034,0.0005848186,0.0017124888,0.00047426642,5.202773e-7,0.0033029427,0.00008251835,0.0063225594,0.00019240048],"about_ca_topic_score_codex":0.000381581,"about_ca_topic_score_gemma":0.00037107745,"teacher_disagreement_score":0.14040367,"about_ca_system_score_codex":0.000052291667,"about_ca_system_score_gemma":0.0002165365,"threshold_uncertainty_score":0.43333423},"labels":[],"label_agreement":null},{"id":"W4328092607","doi":"10.1177/24755303231155118","title":"Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry","year":2023,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.025627111057160066,"score_gpt":0.2648293605340589,"score_spread":0.23920224947689886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328092607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910579,0.004017847,0.00006999125,0.0002108473,0.0033340347,0.0005067437,0.00010978517,0.00002787968,0.00066501356],"genre_scores_gemma":[0.9884551,0.008696916,0.0020167872,0.000065324864,0.0003522546,0.000070731934,0.00014069791,0.00003801235,0.00016415531],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958352,0.00070566754,0.0020308425,0.0004003622,0.00041427885,0.0006136858],"domain_scores_gemma":[0.9966789,0.000985556,0.001442952,0.0004808098,0.00032332222,0.00008849128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026723263,0.00044782835,0.0011308148,0.00054439536,0.0003531816,0.00008719303,0.0005951316,0.0003715814,0.00021780154],"category_scores_gemma":[0.0004537453,0.00032478347,0.0003616065,0.00083538226,0.00021829183,0.00041462612,0.000127157,0.00045944515,0.000050005165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003278776,0.0007369166,0.08166509,0.00010484897,0.0011134149,0.00007727539,0.007439038,0.000011274898,0.00083050947,0.0007950849,0.008187368,0.8987113],"study_design_scores_gemma":[0.011443969,0.00072969287,0.94819254,0.0006801541,0.0004938286,0.00008874577,0.0052772597,0.000007058911,0.0028599119,0.00065321254,0.029058255,0.0005153895],"about_ca_topic_score_codex":0.00006710579,"about_ca_topic_score_gemma":0.00019172576,"teacher_disagreement_score":0.8981959,"about_ca_system_score_codex":0.00011657207,"about_ca_system_score_gemma":0.0002942946,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4328130008","doi":"10.1002/jvc2.126","title":"Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)","year":2023,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"Eli Lilly and Company; American Academy of Dermatology","keywords":"Ixekizumab; Psoriasis; Medicine; Placebo; Randomized controlled trial; Sex organ; Quality of life (healthcare); Internal medicine; Physical therapy; Dermatology; Secukinumab; Nursing","score_opus":0.04441120760223758,"score_gpt":0.35471659182364396,"score_spread":0.31030538422140636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328130008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99338406,0.00012331683,0.000043451415,0.0005643842,0.0012828822,0.0039197817,0.00011470153,0.00016105158,0.00040638968],"genre_scores_gemma":[0.9946037,0.00024031269,0.0009883457,0.00042076322,0.00033979662,0.0008274175,0.0004318252,0.00007817923,0.002069649],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9915978,0.0032997467,0.0025305422,0.001357837,0.0002575175,0.0009565974],"domain_scores_gemma":[0.9920995,0.0058980193,0.0008178216,0.000732004,0.00027944281,0.00017316078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033581308,0.0005946853,0.0019494744,0.00036610887,0.00021535986,0.00006994593,0.00037353727,0.0007363422,0.00012139857],"category_scores_gemma":[0.0052247737,0.0004286141,0.00038265515,0.0010117893,0.00028444012,0.00060733047,0.00018547637,0.0011866157,0.00067706354],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92404413,0.00908234,0.024853688,0.000018703011,0.0011809312,0.0003172036,0.00026133668,0.00012880223,0.0000994203,0.00002127251,0.0003041909,0.03968799],"study_design_scores_gemma":[0.9395476,0.011385594,0.045516558,0.0000980045,0.0007632874,0.000017429747,0.00022900273,0.000097450175,0.00046015996,0.000025017345,0.0011884804,0.00067139696],"about_ca_topic_score_codex":0.0003967134,"about_ca_topic_score_gemma":0.00031976894,"teacher_disagreement_score":0.039016597,"about_ca_system_score_codex":0.0001820549,"about_ca_system_score_gemma":0.0002592466,"threshold_uncertainty_score":0.99981654},"labels":[],"label_agreement":null},{"id":"W4360597205","doi":"10.1177/2050313x231160937","title":"Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Acrodermatitis; Medicine; Dermatology; Psoriasis; Pustular psoriasis; Generalized pustular psoriasis; Pathology","score_opus":0.018348178932203158,"score_gpt":0.28254103401229974,"score_spread":0.2641928550800966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360597205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898268,0.0008990162,0.000040506962,0.00030533623,0.000371892,0.00080635335,0.00009657912,0.00016190145,0.007491587],"genre_scores_gemma":[0.9880985,0.00011758605,0.00012288264,0.00007008689,0.00003791614,0.00016195887,0.00068859954,0.000040579154,0.010661881],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972558,0.00031898942,0.0010590296,0.0006544106,0.0001990603,0.00051270594],"domain_scores_gemma":[0.9979587,0.00025704195,0.0006295411,0.0008312612,0.00015869165,0.00016476231],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014777116,0.00031204132,0.0007798856,0.00016748463,0.0002971321,0.000046606874,0.0001910276,0.0003987739,0.0036544164],"category_scores_gemma":[0.00046930273,0.00022493696,0.00013853543,0.0006157922,0.0003547143,0.00019971412,0.00033200983,0.0002398711,0.00014816181],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016282432,0.0001729716,0.009302936,0.00003892546,0.0005696912,0.9284925,0.00032682696,7.220714e-7,0.00065976556,0.000009544006,0.0037219347,0.05654138],"study_design_scores_gemma":[0.0019851695,0.00023494494,0.0019385691,0.0002110579,0.00032526656,0.96940637,0.0005067274,0.0000036148733,0.011387885,0.000023413797,0.013709693,0.00026729426],"about_ca_topic_score_codex":0.0088535305,"about_ca_topic_score_gemma":0.0036274695,"teacher_disagreement_score":0.056274086,"about_ca_system_score_codex":0.00004186011,"about_ca_system_score_gemma":0.00044667433,"threshold_uncertainty_score":0.9977466},"labels":[],"label_agreement":null},{"id":"W4360599620","doi":"","title":"Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Allergan; Bausch Health; Ortho Dermatologics; Amgen","keywords":"Medicine; Tazarotene; Psoriasis; Dermatology; Lotion; Post-hoc analysis; Quality of life (healthcare); Clinical trial; Internal medicine; Pharmacology","score_opus":0.042892927643780845,"score_gpt":0.22713115050683544,"score_spread":0.18423822286305458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360599620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663587,0.02714044,0.0000047188873,0.0035057804,0.0007957367,0.0013449687,0.00012673432,0.00022659246,0.0004963133],"genre_scores_gemma":[0.98907083,0.005100171,0.000004666928,0.00003369441,0.000029028077,0.0027797748,0.0006187132,0.000019479585,0.0023436563],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987241,0.00021878815,0.00021216551,0.0003747456,0.000050980696,0.00041924024],"domain_scores_gemma":[0.9995113,0.00012546276,0.00007712863,0.00019916857,0.000028472576,0.00005848486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003101825,0.00017529688,0.00021842888,0.00019503704,0.000106966094,0.000017035247,0.00010798218,0.00014738376,0.000035002126],"category_scores_gemma":[0.00015617958,0.00015566636,0.00004719872,0.00023058701,0.00006182769,0.00013317207,0.00005298984,0.00009700195,0.00016418095],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028188227,0.00040776635,0.015158336,0.000110789704,0.00018956943,0.000029539975,0.0002921535,0.000005276647,0.0017787345,0.00081122346,0.0032897417,0.977645],"study_design_scores_gemma":[0.0030036806,0.000035723544,0.98752016,0.000021705511,0.00008184432,0.0000037711286,0.000066529494,0.000017976974,0.0027140635,0.00087704073,0.0054606195,0.00019690269],"about_ca_topic_score_codex":0.0000219091,"about_ca_topic_score_gemma":0.000028086572,"teacher_disagreement_score":0.9774481,"about_ca_system_score_codex":0.000046859863,"about_ca_system_score_gemma":0.000017156179,"threshold_uncertainty_score":0.63478905},"labels":[],"label_agreement":null},{"id":"W4361009497","doi":"10.1093/bjd/ljad035","title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Plaque psoriasis; Body surface area; Open label; Imputation (statistics); Randomized controlled trial; Internal medicine; Surgery; Dermatology; Missing data","score_opus":0.028912431949101897,"score_gpt":0.2601819524444339,"score_spread":0.23126952049533198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361009497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484813,0.0009713498,0.00002186893,0.0019240984,0.0009808064,0.00058300165,0.00060055614,0.000015840487,0.000054331238],"genre_scores_gemma":[0.99851,0.0003925722,0.00032071274,0.00032901435,0.000035695153,0.000019067891,0.00015484648,0.000025181804,0.00021293308],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970341,0.0012130509,0.0009257738,0.0003204939,0.00011201498,0.00039457463],"domain_scores_gemma":[0.99786544,0.0009656269,0.0005755977,0.0003099726,0.0002466234,0.00003672792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005243446,0.00018793825,0.00073094555,0.00014930339,0.00014185849,0.000038762293,0.0006212646,0.0002825158,0.000036132467],"category_scores_gemma":[0.00057894184,0.00014635769,0.00007969567,0.0004348013,0.0001564488,0.0002430975,0.00016821972,0.0003357624,0.000054935055],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8900876,0.0013032513,0.0042441096,0.0000072098355,0.0007780871,0.0038497704,0.00205404,0.0000700324,0.0013135364,0.000064973196,0.07505962,0.021167796],"study_design_scores_gemma":[0.466191,0.0021468608,0.50600815,0.0010580417,0.00026203803,0.0055407956,0.00066037686,0.0000060845696,0.0057756975,0.0006539559,0.011235071,0.00046195998],"about_ca_topic_score_codex":0.0006237868,"about_ca_topic_score_gemma":0.00037268948,"teacher_disagreement_score":0.501764,"about_ca_system_score_codex":0.00005150484,"about_ca_system_score_gemma":0.0002610268,"threshold_uncertainty_score":0.59682935},"labels":[],"label_agreement":null},{"id":"W4361798956","doi":"10.1177/2050313x231164207","title":"Plaque psoriasis and morphea in a patient on ustekinumab: A case report","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; Western University","funders":"","keywords":"Morphea; Ustekinumab; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Dermatologic agents; Pathology; Disease; Lichen sclerosus; Adalimumab; Antibiotics","score_opus":0.024458452073896367,"score_gpt":0.28972154595567085,"score_spread":0.2652630938817745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361798956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416184,0.00065046485,0.0000045806037,0.0005994309,0.0010472239,0.0008042093,0.000032484688,0.000085786865,0.0026139969],"genre_scores_gemma":[0.99711555,0.0001687565,0.00003632922,0.0002666747,0.000049311057,0.00027880658,0.00020652595,0.000028604753,0.0018494193],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9974079,0.00034202426,0.0008437171,0.0007634348,0.00015747375,0.00048543667],"domain_scores_gemma":[0.9985461,0.00035828652,0.00026683047,0.0006267239,0.00003408967,0.00016796235],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015454206,0.000270697,0.0005163399,0.00022045684,0.0002410982,0.000042655578,0.000090044756,0.00044253562,0.0016315967],"category_scores_gemma":[0.0009161552,0.00021858141,0.000088492074,0.0004257915,0.00014013851,0.000106109495,0.00035045,0.00033620224,0.00016872895],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015130098,0.00019643278,0.0019742174,0.000015681584,0.00011349353,0.8817948,0.0005525466,0.000001410393,0.00012476165,0.00002122737,0.002695345,0.11235875],"study_design_scores_gemma":[0.0015306587,0.00026109934,0.0010094782,0.00016518534,0.00007759401,0.9761333,0.0007541024,0.00000812883,0.0014825647,0.00012333384,0.018212695,0.00024184823],"about_ca_topic_score_codex":0.0038702807,"about_ca_topic_score_gemma":0.0019797725,"teacher_disagreement_score":0.112116896,"about_ca_system_score_codex":0.00007798626,"about_ca_system_score_gemma":0.00024372917,"threshold_uncertainty_score":0.99928105},"labels":[],"label_agreement":null},{"id":"W4361799381","doi":"10.1177/2050313x231160927","title":"Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Pityriasis rubra pilaris; Medicine; Dermatology; Erythroderma; Palmoplantar keratoderma; Isotretinoin; Etiology; Pathology; Hyperkeratosis; Acne; Psoriasis","score_opus":0.033866238340658786,"score_gpt":0.3119742168593051,"score_spread":0.2781079785186463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361799381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204856,0.0004609364,0.00012655514,0.0019611565,0.000903441,0.0017580041,0.0001792811,0.00025274704,0.0023093394],"genre_scores_gemma":[0.97785884,0.00010868297,0.00036130985,0.0004955888,0.00013780876,0.000908471,0.00058095274,0.00006457496,0.019483797],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9962614,0.0005641372,0.00096885016,0.0011430949,0.00025865535,0.00080382],"domain_scores_gemma":[0.99726903,0.000534018,0.00037663712,0.0012400957,0.0001425729,0.00043762822],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020024201,0.0004623569,0.0008183191,0.00024109709,0.0006256976,0.00010033559,0.00018275641,0.00044807373,0.003562733],"category_scores_gemma":[0.0012056765,0.00032644975,0.00019127471,0.0007761168,0.00019755744,0.00016512335,0.00040934057,0.00024043465,0.0007104361],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008005517,0.00030647972,0.0013055195,0.000009077297,0.0007163106,0.880344,0.00095336244,0.0000021089843,0.00077738636,0.000012600156,0.004728448,0.11004421],"study_design_scores_gemma":[0.0018945294,0.0012430412,0.0006307828,0.00010367667,0.00044989644,0.8700151,0.000966169,0.0000016758116,0.009711096,0.00003485569,0.11457625,0.00037291614],"about_ca_topic_score_codex":0.006916335,"about_ca_topic_score_gemma":0.00632976,"teacher_disagreement_score":0.1098478,"about_ca_system_score_codex":0.00016892898,"about_ca_system_score_gemma":0.0013444623,"threshold_uncertainty_score":0.99991876},"labels":[],"label_agreement":null},{"id":"W4362474184","doi":"10.3389/fimmu.2023.1191228","title":"Editorial: IL-27 in health and disease","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Immunity; Immunology; Disease; Immune system; Internal medicine","score_opus":0.00786849824476392,"score_gpt":0.24155753187417478,"score_spread":0.23368903362941085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362474184","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005538355,0.07699382,0.000015072435,0.00043169985,0.9205848,0.00047197475,0.0007613874,0.00013914662,0.000048286598],"genre_scores_gemma":[0.00009757082,0.04689701,0.00017075487,0.0000575304,0.93816155,0.000297217,0.0058444864,0.0001494566,0.008324407],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960129,0.000972487,0.00084621867,0.0009729562,0.00010908855,0.0010862948],"domain_scores_gemma":[0.99798703,0.0008807792,0.00035264157,0.00060870906,0.000067043045,0.0001037877],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00073485903,0.0005852634,0.0013862568,0.001066078,0.00013397,0.00002338471,0.0005057829,0.0025112114,0.000034728975],"category_scores_gemma":[0.0022788006,0.00060029986,0.00014561041,0.00045142169,0.00043083483,0.00009370345,0.00027328206,0.0015468944,0.0002855938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014315053,0.00015199787,0.0026873425,0.00013438257,0.00041760263,0.000056499463,0.00040872497,0.0000012903665,0.00004191431,0.000037166825,0.9822046,0.012426973],"study_design_scores_gemma":[0.0041409954,0.00030537797,0.0008273359,0.00027651404,0.000059927082,0.0000015240291,0.00032044208,7.92744e-7,0.000008050423,0.0011110993,0.99249536,0.00045255746],"about_ca_topic_score_codex":0.0009569864,"about_ca_topic_score_gemma":0.00029488464,"teacher_disagreement_score":0.030096812,"about_ca_system_score_codex":0.000495114,"about_ca_system_score_gemma":0.0014234721,"threshold_uncertainty_score":0.9996448},"labels":[],"label_agreement":null},{"id":"W4362520762","doi":"10.1111/jdv.19089","title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial","year":2023,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Adalimumab; Methotrexate; Activities of daily living; Randomization; Randomized controlled trial; Internal medicine; Psoriasis; Clinical trial; Physical therapy; Surgery; Rheumatoid arthritis; Dermatology","score_opus":0.06056539793169732,"score_gpt":0.29344964174290106,"score_spread":0.23288424381120373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362520762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898473,0.0044849785,0.000045856184,0.002301479,0.001747175,0.0010205577,0.000028764125,0.000019346164,0.00050451263],"genre_scores_gemma":[0.99798447,0.0014105896,0.00017545444,0.000076329445,0.0000839632,0.000016684537,0.00001972809,0.000033677556,0.00019908257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.991302,0.00629042,0.0016023895,0.0003153291,0.000110060835,0.00037977006],"domain_scores_gemma":[0.9948566,0.002664314,0.0019815832,0.00037749487,0.00008039532,0.00003963075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002870675,0.0003188482,0.0026143824,0.0004958674,0.00010434528,0.000006218918,0.0009785085,0.0003792536,0.000037656708],"category_scores_gemma":[0.00064129906,0.00018505845,0.0004090016,0.0003876469,0.00089781,0.00012859063,0.00027163982,0.00054035726,0.000012360151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98458004,0.00026841144,0.0029167053,0.000024801515,0.00409352,0.000066624634,0.00041463948,0.000028705608,0.0042858324,0.00085146446,0.00041907057,0.0020501975],"study_design_scores_gemma":[0.9893311,0.0006270643,0.0018531557,0.000108050015,0.0015489908,0.0005339822,0.00015653248,0.000030412024,0.004247624,0.00074699905,0.0006420668,0.0001739668],"about_ca_topic_score_codex":0.0000106141515,"about_ca_topic_score_gemma":0.000031463922,"teacher_disagreement_score":0.00813716,"about_ca_system_score_codex":0.000018016146,"about_ca_system_score_gemma":0.00011120617,"threshold_uncertainty_score":0.7546465},"labels":[],"label_agreement":null},{"id":"W4362521454","doi":"10.1177/12034754231167140","title":"Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab","year":2023,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Eczematous dermatitis; Adverse effect; Contact dermatitis; Immunology; Allergy; Pharmacology","score_opus":0.022622180389454388,"score_gpt":0.25160926302089415,"score_spread":0.22898708263143977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362521454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964168,0.00047452038,0.000018095121,0.0011051152,0.0011009908,0.00016696037,0.0000028298618,0.0000291973,0.0006854725],"genre_scores_gemma":[0.9977613,0.0012696751,0.00004954852,0.0002334743,0.00010962904,0.000008903436,0.00001534918,0.00001862973,0.00053345953],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99862504,0.00013485046,0.0006316432,0.00018125305,0.000121613215,0.00030561147],"domain_scores_gemma":[0.9987533,0.00065884914,0.0002756828,0.0001524684,0.0000910696,0.000068597066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052135723,0.000179712,0.0005716523,0.0009699334,0.00011707587,0.0000094361885,0.00008624619,0.00009835653,0.00007496942],"category_scores_gemma":[0.00015752712,0.00012045218,0.000080602484,0.00055854494,0.0000306893,0.00008262861,0.000027587666,0.00019764258,0.00004696602],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005140253,0.00080966187,0.1489243,0.00029192213,0.0024167015,0.010812562,0.0067808395,0.00009662223,0.014396292,0.00016123107,0.055669807,0.7544998],"study_design_scores_gemma":[0.028393934,0.0096401675,0.66391385,0.009444175,0.0032558949,0.031217674,0.02237714,0.000021353035,0.007173835,0.0015068516,0.22079843,0.0022566875],"about_ca_topic_score_codex":0.000086069704,"about_ca_topic_score_gemma":0.00004669954,"teacher_disagreement_score":0.7522431,"about_ca_system_score_codex":0.00006207413,"about_ca_system_score_gemma":0.000044245382,"threshold_uncertainty_score":0.49118975},"labels":[],"label_agreement":null},{"id":"W4362578693","doi":"10.1016/j.jaad.2023.03.035","title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Janssen Research and Development; LEO Pharma; Sun Pharma; Argenx; Janssen Scientific Affairs; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Malignancy; Psoriasis; Skin cancer; Population; Dermatology; Incidence (geometry); Epidemiology; Cancer registry; Basal cell carcinoma; Cancer; Surgery; Internal medicine; Basal cell","score_opus":0.024262026976789353,"score_gpt":0.27236752075920756,"score_spread":0.2481054937824182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362578693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573404,0.0006872269,0.0000059632894,0.0026472046,0.00013821096,0.00038469402,0.00035785435,0.000011895714,0.0000329063],"genre_scores_gemma":[0.9988584,0.00045101508,0.00017815379,0.00029719778,0.000020454208,0.000009985155,0.000026860047,0.000023549372,0.00013440513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99693924,0.0013157616,0.0010537063,0.00024612527,0.00012593101,0.00031925927],"domain_scores_gemma":[0.99613136,0.0015584358,0.0019617418,0.00022867577,0.00008775325,0.000032056323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004346538,0.00024300268,0.0013899724,0.0002315524,0.000087221655,0.000008629198,0.0004721763,0.0001735388,0.0000136211365],"category_scores_gemma":[0.000373007,0.00012410159,0.00016944791,0.0008744147,0.00047705363,0.00011553321,0.00009905814,0.0003203449,0.000009809117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081296265,0.0004915433,0.8575506,0.000032655673,0.006408316,0.00009548857,0.0063169855,0.00028628125,0.021876901,0.00014008486,0.009472998,0.01603187],"study_design_scores_gemma":[0.020816933,0.0007520107,0.9302201,0.00027370066,0.0009242404,0.00015082894,0.00082463573,0.0000028722347,0.04487918,0.00022567315,0.00071983004,0.00020994998],"about_ca_topic_score_codex":0.0002722736,"about_ca_topic_score_gemma":0.00003096241,"teacher_disagreement_score":0.072669536,"about_ca_system_score_codex":0.000026196461,"about_ca_system_score_gemma":0.000083120896,"threshold_uncertainty_score":0.50607157},"labels":[],"label_agreement":null},{"id":"W4362604277","doi":"10.7759/cureus.37174","title":"Psoriasis Patients Treated With Methotrexate Have an Increased Risk of Nonmelanoma Skin Cancer: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Cureus","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Skin cancer; Methotrexate; Dermatology; Odds ratio; Confidence interval; Meta-analysis; Cancer; Internal medicine","score_opus":0.06684059923037729,"score_gpt":0.3226970721257062,"score_spread":0.2558564728953289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362604277","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033192895,0.99004465,0.0000031309276,0.0000027097335,0.000058356785,0.0032382484,0.006194611,0.000072084105,0.000054259894],"genre_scores_gemma":[0.00012554802,0.9929678,0.00006895979,0.000018831975,0.0000120150125,0.0022986208,0.003143505,0.00009234234,0.0012724083],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9932249,0.0039300625,0.0014431746,0.00088912033,0.000112483714,0.00040021667],"domain_scores_gemma":[0.99538314,0.0007159899,0.0023466875,0.0012585352,0.00021300734,0.00008265648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086535496,0.0009394072,0.0125204185,0.00043164467,0.00014671692,0.000020094103,0.00045134188,0.00057084934,0.00055777316],"category_scores_gemma":[0.00018312357,0.00052425795,0.0023676367,0.0011036186,0.00012450824,0.00009046371,0.00009197004,0.0002468641,0.00009063614],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030836156,0.00023045397,0.00043537578,0.29612672,0.69534636,0.0000114264985,0.00007692288,3.162304e-7,2.626979e-7,0.0000049322357,0.000069817,0.0076665776],"study_design_scores_gemma":[0.0006077935,0.00027583385,0.00019254924,0.012903707,0.981865,0.00001207689,0.000017167122,3.3663432e-7,0.000011858117,0.0000020636285,0.0036206176,0.0004910137],"about_ca_topic_score_codex":0.0038495902,"about_ca_topic_score_gemma":0.0013024366,"teacher_disagreement_score":0.28651863,"about_ca_system_score_codex":0.0001059407,"about_ca_system_score_gemma":0.00011570669,"threshold_uncertainty_score":0.9997209},"labels":[],"label_agreement":null},{"id":"W4362635350","doi":"10.1016/j.jdin.2023.02.018","title":"National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine","year":2023,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Allergan; Genentech; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Regeneron Pharmaceuticals; Mylan; Dermira; Sun Pharma; Valeant Pharmaceuticals International; Argenx; Helsinn; National Psoriasis Foundation; Pfizer; Biogen; Novartis; Celgene; Pediatric Dermatology Research Alliance; Sanofi; GlaxoSmithKline; Galderma; Myriad Genetics; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Amgen","keywords":"Teledermatology; Psoriatic arthritis; Telemedicine; Medicine; Psoriasis; Disease; Task force; Medical emergency; Intensive care medicine; Dermatology; Health care; Pathology","score_opus":0.01909266219769858,"score_gpt":0.2884515160791992,"score_spread":0.26935885388150066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362635350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79511046,0.0044662855,0.09448281,0.021372125,0.041497145,0.006687072,0.0035240662,0.0010922529,0.031767756],"genre_scores_gemma":[0.9673652,0.0003222437,0.00118352,0.00021908821,0.00056578126,0.00055416155,0.005628642,0.000027668786,0.024133662],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99867356,0.000046835266,0.00049397413,0.0003217976,0.00021736714,0.00024646355],"domain_scores_gemma":[0.9989832,0.00023106394,0.00023823272,0.00017901309,0.00033329823,0.000035170804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046229988,0.0001776679,0.00022650516,0.0002935506,0.000115314644,0.000008522067,0.000281869,0.00008025663,0.0007034946],"category_scores_gemma":[0.00017258525,0.00015820467,0.00014054003,0.00027432406,0.000087071334,0.00012076443,0.00006832542,0.000057979465,0.00036045548],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004649093,0.0012881075,0.023599492,0.00082817086,0.008281255,0.000050544204,0.0008694828,0.0006117199,0.046232987,0.1157088,0.16834915,0.6295312],"study_design_scores_gemma":[0.030186234,0.00086856313,0.48358265,0.00077587896,0.0014589619,0.00003359279,0.00060326123,0.0060811355,0.015975744,0.045597322,0.41386965,0.0009670303],"about_ca_topic_score_codex":0.00001149841,"about_ca_topic_score_gemma":0.000005440705,"teacher_disagreement_score":0.6285642,"about_ca_system_score_codex":0.00011628755,"about_ca_system_score_gemma":0.00005784082,"threshold_uncertainty_score":0.7702772},"labels":[],"label_agreement":null},{"id":"W4362657980","doi":"10.1093/bjd/ljad115","title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Psoriasis; Clinical trial; Dermatology; Internal medicine","score_opus":0.0560023929324294,"score_gpt":0.35370666446939775,"score_spread":0.2977042715369683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362657980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996666,0.00083778036,0.00007545071,0.00011580554,0.0004659432,0.0008784732,0.00093973696,0.000014829689,0.0000059631357],"genre_scores_gemma":[0.9988566,0.0002737995,0.0004641092,0.00005206581,0.000026629707,0.000054275035,0.00016951996,0.000032860647,0.00007011528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632037,0.000974725,0.0017990925,0.00032051935,0.00012621935,0.0004590945],"domain_scores_gemma":[0.9974864,0.00078851776,0.0010114881,0.00023732547,0.0003826651,0.0000936098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006138986,0.00023774162,0.0018688795,0.0003230761,0.00007240776,0.000014776957,0.00024914273,0.00032130737,0.00002735899],"category_scores_gemma":[0.0004081234,0.00020206529,0.00036195177,0.0004656867,0.00012477068,0.000107207175,0.00005505898,0.00015474147,0.000010263936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08998701,0.0021265137,0.5822415,0.00007866248,0.0079804985,0.0010697893,0.008770766,0.0016703788,0.00095963385,0.000009411811,0.0020457937,0.30306005],"study_design_scores_gemma":[0.046584565,0.006411454,0.9325779,0.0005650073,0.0009552148,0.001314613,0.0026950345,0.0000023692453,0.007981755,0.000021156653,0.0005692982,0.00032160996],"about_ca_topic_score_codex":0.00013239283,"about_ca_topic_score_gemma":0.0004300286,"teacher_disagreement_score":0.35033643,"about_ca_system_score_codex":0.00006143352,"about_ca_system_score_gemma":0.00023688834,"threshold_uncertainty_score":0.8239984},"labels":[],"label_agreement":null},{"id":"W4362697966","doi":"10.1177/1721727x231160361","title":"The case-control study on relationship between the serum concentration of IL-7 and the pathogenesis of psoriasis: ampere systematic review and meta-Analysis","year":2023,"lang":"en","type":"article","venue":"European Journal of Inflammation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Pathogenesis; Internal medicine; Psoriasis; Medicine; Gastroenterology; Strictly standardized mean difference; Significant difference; Immunology","score_opus":0.048824851379855795,"score_gpt":0.26655545910680123,"score_spread":0.21773060772694544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362697966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645532,0.0321071,0.00007306227,0.0018266964,0.00006650588,0.0012266067,0.00008986976,0.000010342655,0.00004662529],"genre_scores_gemma":[0.9987781,0.0010655454,0.0000043909286,0.000024741534,0.00002712073,0.000017884402,0.000006382219,0.00000854625,0.0000672677],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9916794,0.0069108154,0.0011175543,0.00010115823,0.00009349379,0.00009758753],"domain_scores_gemma":[0.99470574,0.0032658654,0.0015032165,0.00029775343,0.00021329949,0.0000141067385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007760004,0.00013507831,0.00086754543,0.00009433035,0.0003558525,0.000025932506,0.00016821372,0.000029794975,0.000007765753],"category_scores_gemma":[0.000951453,0.00005430669,0.00036061116,0.00038311034,0.00014798011,0.00008116652,0.000024407653,0.00012145859,0.000009278221],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002185724,0.00028976146,0.16375533,0.018043563,0.75023407,0.00040664934,0.03751553,0.0008773734,0.0049369964,0.0068890164,0.00056592067,0.014300103],"study_design_scores_gemma":[0.0024809856,0.00033360114,0.5349764,0.00029290494,0.45806628,0.00013058081,0.0032139523,0.000014654105,0.00032655438,0.00006533956,0.000009517959,0.00008919382],"about_ca_topic_score_codex":0.0000033331721,"about_ca_topic_score_gemma":0.000008915343,"teacher_disagreement_score":0.3712211,"about_ca_system_score_codex":0.0000091122465,"about_ca_system_score_gemma":0.00001520525,"threshold_uncertainty_score":0.27369657},"labels":[],"label_agreement":null},{"id":"W4363679264","doi":"10.35541/cjd.20220378","title":"Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study","year":2023,"lang":"en","type":"article","venue":"Chinese Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; McNemar's test; Internal medicine; Gastroenterology; Psoriasis; Dermatology","score_opus":0.010230247080248892,"score_gpt":0.2562492842267369,"score_spread":0.24601903714648798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4363679264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971468,0.00039638093,0.00000276991,0.000074450836,0.0013513967,0.00074180716,0.000030681036,0.00003818367,0.00021755842],"genre_scores_gemma":[0.9994748,0.00014848093,0.000023022872,0.000009134053,0.000057570513,0.000051285613,0.00006953456,0.000037685608,0.00012849127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976832,0.00053512707,0.0008925444,0.00032251267,0.00012180111,0.0004447842],"domain_scores_gemma":[0.99850494,0.00034573034,0.0005332495,0.00034087064,0.00021964812,0.000055592038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012339941,0.0004569062,0.0014126546,0.0010543002,0.00009003088,0.00001061939,0.00027451466,0.0001874463,0.00003117871],"category_scores_gemma":[0.00010938517,0.00026264836,0.00025088983,0.0010261683,0.00012647477,0.00017511482,0.000073167466,0.00023856,0.000032856122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021796254,0.0054411534,0.98054063,0.000053831056,0.0015693428,0.0011869062,0.003662082,0.00000482231,0.0023147129,0.000006975983,0.00008247129,0.0029574235],"study_design_scores_gemma":[0.019605065,0.003221682,0.9739745,0.00011846999,0.0003099441,0.0004949038,0.00018747308,0.0000010596274,0.0017894006,0.00006765958,0.000024455216,0.00020536268],"about_ca_topic_score_codex":0.000046099023,"about_ca_topic_score_gemma":0.0008148586,"teacher_disagreement_score":0.01742544,"about_ca_system_score_codex":0.0002513147,"about_ca_system_score_gemma":0.00010013987,"threshold_uncertainty_score":0.9999826},"labels":[],"label_agreement":null},{"id":"W4365517559","doi":"10.1016/j.jdin.2023.03.012","title":"The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics","year":2023,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Calgary Laboratory Services; McMaster University; Programs for Assessment of Technology in Health Research Institute; St. Joseph’s Healthcare Hamilton; Impact","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Valeant Pharmaceuticals International; Sun Pharma; Regeneron Pharmaceuticals; McMaster University; Dermira; Hamilton Health Sciences; Edwards Lifesciences; Amgen; Boehringer Ingelheim; Novo Nordisk; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Pfizer; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Incidence (geometry); Emergency department; Psoriasis; Population; Medical prescription; Emergency medicine; Outpatient visits; Pediatrics; Health care; Environmental health; Psychiatry; Dermatology","score_opus":0.02433677021105333,"score_gpt":0.27712072940797117,"score_spread":0.2527839591969178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365517559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99682164,0.00016403884,0.000004039379,0.00025643,0.0014914728,0.0006952064,0.00043360668,0.000047466277,0.000086122964],"genre_scores_gemma":[0.99499696,0.00003304576,0.000025982454,0.000051256535,0.000031697266,0.00023727663,0.004044648,0.000020071406,0.00055908307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840426,0.00055964134,0.00043995923,0.00020283704,0.00014192874,0.00025138885],"domain_scores_gemma":[0.99876654,0.00031727858,0.0002769304,0.00028843715,0.00030634337,0.00004445323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032280953,0.00018686004,0.00022743178,0.00021258627,0.00057332224,0.0000200869,0.0002860755,0.00012939234,0.00009717591],"category_scores_gemma":[0.00021149774,0.00012549142,0.00006823395,0.00026278268,0.000043197724,0.000044757653,0.0000486218,0.00016265878,0.000017183422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067329156,0.0008720886,0.984796,0.000012189814,0.0016013347,0.000009541291,0.0048697456,0.0012080687,0.000027581973,0.000062489125,0.0010469375,0.0048207273],"study_design_scores_gemma":[0.00953886,0.0029569839,0.97318214,0.000046812016,0.00034364485,5.84755e-7,0.006202955,0.00041490537,0.0002399132,0.00004604171,0.0067240917,0.00030308642],"about_ca_topic_score_codex":0.04010085,"about_ca_topic_score_gemma":0.12828603,"teacher_disagreement_score":0.088185176,"about_ca_system_score_codex":0.00021298716,"about_ca_system_score_gemma":0.00019055937,"threshold_uncertainty_score":0.9662912},"labels":[],"label_agreement":null},{"id":"W4365520309","doi":"10.1016/j.jaad.2022.08.017","title":"Investigating the risk of malignancy in elderly patients with psoriasis: A population-based retrospective matched cohort study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Ottawa; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Malignancy; Cohort; Cohort study; Population; Dermatology; Internal medicine; Environmental health","score_opus":0.010555768877568528,"score_gpt":0.25381484978135854,"score_spread":0.24325908090379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365520309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980745,0.00016988665,0.0000044920707,0.0010812033,0.00015541431,0.00045826417,0.000032713884,0.000010513415,0.00001306097],"genre_scores_gemma":[0.9997072,0.000041195388,0.00009480396,0.0000921718,0.000012937044,0.000018856379,0.000005533761,0.000014985279,0.000012309673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973952,0.0012502087,0.00080647296,0.00016231381,0.00014428205,0.00024152113],"domain_scores_gemma":[0.9964695,0.0005162037,0.0027093121,0.0001857963,0.000099646524,0.000019531524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046094673,0.00017218423,0.0008239534,0.00026448208,0.00011731338,0.000003430026,0.00045242457,0.00010425768,0.0000095650785],"category_scores_gemma":[0.00029146386,0.00009170371,0.00016259769,0.0009348084,0.00041152383,0.00006258906,0.00005760268,0.00045310514,0.000004771527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029282263,0.0002257102,0.99596107,0.00000950385,0.0007692307,0.0000036581316,0.0007269341,0.00014328846,0.000753223,0.000024842571,0.00012873451,0.0009609716],"study_design_scores_gemma":[0.0027155422,0.0004646849,0.991963,0.00007699437,0.0004567188,0.000044241533,0.0010129401,0.0000065892978,0.0028542406,0.000307587,0.000010553824,0.000086852844],"about_ca_topic_score_codex":0.0003370408,"about_ca_topic_score_gemma":0.000043808293,"teacher_disagreement_score":0.003998026,"about_ca_system_score_codex":0.00005380135,"about_ca_system_score_gemma":0.00008681937,"threshold_uncertainty_score":0.37395686},"labels":[],"label_agreement":null},{"id":"W4365813762","doi":"10.1016/j.jdin.2023.04.002","title":"The burden of palmoplantar pustulosis: A Canadian population-based study of inpatient care, emergency departments, and outpatient clinics","year":2023,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Calgary Laboratory Services; McMaster University; Impact; University of Calgary; St. Joseph’s Healthcare Hamilton; Programs for Assessment of Technology in Health Research Institute","funders":"Sanofi Genzyme; LEO Pharma; Galderma; Regeneron Pharmaceuticals; Hamilton Health Sciences; Pfizer; McMaster University; Boehringer Ingelheim; Valeant Pharmaceuticals International; Sanofi","keywords":"Medicine; Palmoplantar pustulosis; Emergency department; Emergency medicine; Cohort; Incidence (geometry); Medical prescription; Diagnosis code; Population; Psoriasis; Internal medicine; Environmental health; Dermatology","score_opus":0.016941856386418007,"score_gpt":0.27174787540389067,"score_spread":0.2548060190174727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365813762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968711,0.0004906326,8.63579e-7,0.00009886571,0.0015795064,0.00032008695,0.00038592416,0.000012424178,0.00024058373],"genre_scores_gemma":[0.99850327,0.00011022997,0.000008116259,0.00000866393,0.000028928165,0.00006475118,0.00091130246,0.0000070006913,0.0003577443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991624,0.00009550864,0.00037368934,0.00015111774,0.000078546145,0.00013876216],"domain_scores_gemma":[0.999413,0.000110056375,0.00017171697,0.0001471637,0.00013544336,0.000022624736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011999752,0.0000941199,0.00013495299,0.00016065144,0.0001366234,0.0000043594428,0.00015572204,0.00007003854,0.000092191956],"category_scores_gemma":[0.000057424062,0.000071002316,0.000052564887,0.000112746035,0.00002196996,0.0000252013,0.000038104645,0.0000516988,0.000022734635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001273948,0.00015736553,0.9869892,0.000009372687,0.0004592743,0.000002279417,0.002979667,0.00019958869,0.00007887042,0.00010185842,0.0006329945,0.008262153],"study_design_scores_gemma":[0.0016810088,0.0005560248,0.98673004,0.00001647169,0.00011489216,9.4596976e-7,0.004862183,0.00011524578,0.0004536313,0.000055565,0.0053144004,0.00009958943],"about_ca_topic_score_codex":0.032850977,"about_ca_topic_score_gemma":0.035204727,"teacher_disagreement_score":0.008162564,"about_ca_system_score_codex":0.00006427416,"about_ca_system_score_gemma":0.000064419786,"threshold_uncertainty_score":0.9824003},"labels":[],"label_agreement":null},{"id":"W4366172733","doi":"10.1016/j.jid.2023.03.588","title":"581 Ixekizumab reduces key IL-17 and IL-23 pathway genes more rapidly than guselkumab: 4-week results from IXORA-R","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Psoriasis; Medicine; Interleukin 17; Cytokine; Inflammation; Secukinumab; Transcriptome; Internal medicine; Endocrinology; Immunology; Gene expression; Biology; Gene; Genetics","score_opus":0.036592871730999635,"score_gpt":0.2519173928078544,"score_spread":0.2153245210768548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366172733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98210245,0.008423217,0.000008823358,0.006507893,0.0012764538,0.00019774906,0.001013678,0.00009028536,0.00037946415],"genre_scores_gemma":[0.99477684,0.0020473183,0.0007869761,0.0004507586,0.00019789982,0.000019313587,0.00056329876,0.00004411398,0.0011134652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967826,0.0009156836,0.0011131209,0.00047835553,0.00012078174,0.000589441],"domain_scores_gemma":[0.99716413,0.00096537964,0.0010596965,0.00032866636,0.00032186086,0.00016028754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041615037,0.00044725367,0.0010122799,0.0005043177,0.00034995176,0.000039857805,0.0004266663,0.00054329936,0.00007287576],"category_scores_gemma":[0.00062274095,0.00035270883,0.00024171111,0.00044436462,0.0010980549,0.00030268115,0.00015361155,0.0004935437,0.000310408],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021611631,0.00032487133,0.003631414,0.00004311133,0.0032804573,0.0021001026,0.017074086,0.000026478236,0.8536482,0.00056938914,0.09339248,0.023748256],"study_design_scores_gemma":[0.0056664366,0.0005343894,0.057346214,0.00013134175,0.00032227547,0.0021687222,0.0034899234,0.00001036144,0.8959026,0.0031209067,0.030894121,0.00041273516],"about_ca_topic_score_codex":0.00008731869,"about_ca_topic_score_gemma":0.000058378042,"teacher_disagreement_score":0.062498353,"about_ca_system_score_codex":0.00005517099,"about_ca_system_score_gemma":0.00036701965,"threshold_uncertainty_score":0.9998925},"labels":[],"label_agreement":null},{"id":"W4366452142","doi":"10.1093/bjd/ljad071","title":"The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Psoriasis; Generalized pustular psoriasis; Erythema; Dermatology; Disease; Severity of illness; Pustular psoriasis; Internal medicine","score_opus":0.030948719773450945,"score_gpt":0.3016663221667482,"score_spread":0.2707176023932973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366452142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931168,0.004838798,0.00014076778,0.0004697426,0.0008233376,0.00036208448,0.00019328295,0.000016381488,0.000038793372],"genre_scores_gemma":[0.9969871,0.0027094798,0.00012098642,0.000014909359,0.000056144014,0.000015533566,0.00006309439,0.000012895029,0.000019857862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974504,0.0011946317,0.00068100926,0.00021940973,0.0001767108,0.00027785316],"domain_scores_gemma":[0.998406,0.00021769853,0.0007955933,0.00023190008,0.00029356655,0.000055265897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042432407,0.0001819844,0.0006722267,0.00010563045,0.00025357696,0.000029519431,0.0002530403,0.00012602548,0.000015401292],"category_scores_gemma":[0.00004844812,0.00015778896,0.00018633423,0.00033222855,0.00019294402,0.00013329001,0.000098236844,0.00021197248,0.0000023565085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027188093,0.008753519,0.4756864,0.00013208622,0.0049611907,0.0020074379,0.0004325633,0.000091515685,0.04995671,0.0008148741,0.004669835,0.44977504],"study_design_scores_gemma":[0.007682906,0.0005596889,0.9829962,0.00011890616,0.0006828308,0.0016279455,0.0010438432,0.000017234563,0.0042280974,0.00034983153,0.000531306,0.00016116252],"about_ca_topic_score_codex":0.00007680304,"about_ca_topic_score_gemma":0.00010906326,"teacher_disagreement_score":0.50730985,"about_ca_system_score_codex":0.00007296692,"about_ca_system_score_gemma":0.00024413392,"threshold_uncertainty_score":0.6434447},"labels":[],"label_agreement":null},{"id":"W4366602777","doi":"10.1177/12034754231168851","title":"Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch","year":2023,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bausch Health (Canada); Health Canada","funders":"Bausch Health","keywords":"Medicine; Secukinumab; Ixekizumab; Plaque psoriasis; Psoriasis; Retrospective cohort study; Internal medicine; Pediatrics; Dermatology; Psoriatic arthritis","score_opus":0.03111706119373028,"score_gpt":0.2720828407684413,"score_spread":0.24096577957471102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366602777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900066,0.0035657242,0.0000018798925,0.0032053853,0.002494234,0.00014899591,0.000055755467,0.000028578606,0.0004927966],"genre_scores_gemma":[0.98639286,0.0046512187,0.000022719287,0.00065663276,0.0004184173,0.000015604477,0.00008939479,0.000024263765,0.0077289203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985658,0.00010803278,0.000572416,0.00019617149,0.000087920955,0.0004696722],"domain_scores_gemma":[0.9977724,0.0014454854,0.00027141342,0.00016018117,0.00018326334,0.00016726463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005512279,0.00018665165,0.0006331035,0.0008072601,0.00023001396,0.000009741121,0.00012324651,0.00016034463,0.00040294413],"category_scores_gemma":[0.00039634653,0.00014205872,0.00018271124,0.00032596616,0.0001556506,0.000070449154,0.00002101577,0.0001405185,0.0000487168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046011163,0.00013148399,0.082165636,0.00016519363,0.0016628428,0.009498962,0.0151163805,0.000010960073,0.048328634,0.00037520978,0.67745155,0.16049205],"study_design_scores_gemma":[0.004192809,0.0014766259,0.058183894,0.0006533339,0.0006506233,0.017242862,0.005367908,0.000008401704,0.0047665816,0.000341739,0.9065017,0.00061348174],"about_ca_topic_score_codex":0.008623774,"about_ca_topic_score_gemma":0.023958892,"teacher_disagreement_score":0.2290502,"about_ca_system_score_codex":0.00012803207,"about_ca_system_score_gemma":0.00034223296,"threshold_uncertainty_score":0.9979779},"labels":[],"label_agreement":null},{"id":"W4366817818","doi":"10.1016/j.jaad.2023.04.031","title":"Management of adult generalized pustular psoriasis using biologics: A systematic review","year":2023,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; SKiN Health; Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Dermatrials Research; Women's College Hospital; McMaster University; University of Toronto; University of Calgary; Western University","funders":"","keywords":"Medicine; Dermatology; Generalized pustular psoriasis; Psoriasis; Pustular psoriasis","score_opus":0.06246607280875774,"score_gpt":0.35067533315529137,"score_spread":0.2882092603465336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366817818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010506328,0.99651414,0.000014870879,0.00035015697,0.0006289653,0.0013074501,0.000096408214,0.000016416932,0.000020964686],"genre_scores_gemma":[0.00017493949,0.9987858,0.00052455865,0.00021391234,0.000038509475,0.00005340062,0.000013619284,0.00005028991,0.00014498639],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925328,0.00312697,0.003472978,0.0002939815,0.00015092986,0.00042233375],"domain_scores_gemma":[0.98653036,0.0005491405,0.012280466,0.00045641535,0.00014429721,0.00003933273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000610568,0.00055505574,0.008226208,0.00048106647,0.00008944251,0.0000041460626,0.0015975236,0.00047207487,0.000024657395],"category_scores_gemma":[0.00023547115,0.00030576493,0.0023403699,0.0010583362,0.00063834485,0.00004781059,0.00033821576,0.0006319048,0.000049167877],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009026087,0.0001640455,0.000035956735,0.9309246,0.021690901,0.00012672572,0.00004472427,0.000001948413,0.0001277838,0.0006072287,0.001748509,0.044437308],"study_design_scores_gemma":[0.0015180965,0.00019623444,0.000022735385,0.83060896,0.077875786,0.016203433,0.00022693853,0.0000011083165,0.00049981935,0.00018528641,0.0720378,0.0006237844],"about_ca_topic_score_codex":0.000014831366,"about_ca_topic_score_gemma":2.870399e-7,"teacher_disagreement_score":0.10031564,"about_ca_system_score_codex":0.00010408266,"about_ca_system_score_gemma":0.0001577291,"threshold_uncertainty_score":0.99993944},"labels":[],"label_agreement":null},{"id":"W4366832236","doi":"10.1093/rheumatology/kead104.227","title":"P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis","year":2023,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Sun Pharma; Gilead Sciences; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Allergan; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Ixekizumab; Ankylosing spondylitis; Psoriasis; Internal medicine; Adverse effect; Axial spondyloarthritis; Incidence (geometry); Arthritis; Dermatology; Secukinumab; Sacroiliitis","score_opus":0.007313710049564699,"score_gpt":0.21258174128141552,"score_spread":0.20526803123185083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366832236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529314,0.0025570071,0.000005910741,0.00006219998,0.00065392605,0.0004628496,0.00042717287,0.00008559248,0.00045221933],"genre_scores_gemma":[0.99604005,0.0023990362,0.00004854886,0.000040673505,0.00005298879,0.000061214385,0.0010717075,0.000031097203,0.0002546698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984093,0.00019632478,0.00043455084,0.0004119105,0.000088391345,0.00045953522],"domain_scores_gemma":[0.99926573,0.0001456856,0.00014567279,0.00031462748,0.00008840008,0.00003989503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016423826,0.00026428973,0.0005156691,0.00019846919,0.00013131999,0.000015801957,0.00015499961,0.0002634508,0.00015341469],"category_scores_gemma":[0.000047485788,0.00023718552,0.000076673314,0.00036873773,0.00019475486,0.00015080262,0.000083811734,0.00015852974,0.00017744717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030562382,0.0005355562,0.52339494,0.00010203912,0.00044748085,0.000121393634,0.0014905072,0.0000041789763,0.0010720188,0.0020737096,0.0002480083,0.46745396],"study_design_scores_gemma":[0.016407404,0.00059425016,0.9789423,0.00036035295,0.00009118444,0.000026282909,0.00008219467,0.0000010890486,0.0024527258,0.00013811959,0.00059939444,0.00030473238],"about_ca_topic_score_codex":0.0002410286,"about_ca_topic_score_gemma":0.002025432,"teacher_disagreement_score":0.46714923,"about_ca_system_score_codex":0.000035802022,"about_ca_system_score_gemma":0.000041608997,"threshold_uncertainty_score":0.9672145},"labels":[],"label_agreement":null},{"id":"W4367183667","doi":"10.1177/24755303231173376","title":"Scarring Alopecia in Tumor Necrosis Factor-α Antagonists-Induced Scalp Psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Scalp; Medicine; Psoriasis; Dermatology; Tumor necrosis factor α; Scarring alopecia; Tumor necrosis factor alpha; Necrosis; Pathology; Internal medicine","score_opus":0.023177698944721745,"score_gpt":0.25614420054646037,"score_spread":0.23296650160173862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367183667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871707,0.005885758,0.000019373438,0.00045290502,0.005646414,0.00028810004,0.000100169455,0.00007514618,0.00036141177],"genre_scores_gemma":[0.9903953,0.008043374,0.00028131972,0.000092966366,0.0007566023,0.00002816312,0.00002894129,0.000056683828,0.00031663856],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966228,0.00044266036,0.0014181219,0.00047714924,0.00023118325,0.0008081024],"domain_scores_gemma":[0.9980722,0.00053164636,0.0006971148,0.000350531,0.00019459671,0.00015391537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010810425,0.00047890304,0.0011801983,0.00084324286,0.00035793643,0.00011681731,0.00037031324,0.00034883968,0.00046790318],"category_scores_gemma":[0.00037892253,0.00042382753,0.00039611137,0.00090056803,0.00012232646,0.0004401382,0.00012801845,0.00046766797,0.0002631391],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006754111,0.00035697027,0.037843544,0.00007306795,0.0010548914,0.0005780926,0.0036247578,0.000013289136,0.036618583,0.0005094121,0.0046589207,0.91399306],"study_design_scores_gemma":[0.039886463,0.0027299698,0.8057351,0.0018348269,0.00094339,0.0020931556,0.005303009,0.0000668519,0.09186117,0.0038996015,0.04343554,0.002210932],"about_ca_topic_score_codex":0.00019831074,"about_ca_topic_score_gemma":0.00028140005,"teacher_disagreement_score":0.91178215,"about_ca_system_score_codex":0.00012888471,"about_ca_system_score_gemma":0.00018008487,"threshold_uncertainty_score":0.99982136},"labels":[],"label_agreement":null},{"id":"W4372336289","doi":"10.1111/jdv.19161","title":"Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks","year":2023,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.060568958796291525,"score_gpt":0.3297519327588512,"score_spread":0.26918297396255964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4372336289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98752105,0.0024058241,0.0000030648096,0.008217367,0.0010950571,0.00043478372,0.000097465185,0.000011381131,0.0002140109],"genre_scores_gemma":[0.99762326,0.0012426677,0.00004281359,0.00094153127,0.00006806282,0.000004087469,0.000018317836,0.00002111924,0.000038147136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98799807,0.008450447,0.0027346693,0.0003272759,0.00013589596,0.0003536626],"domain_scores_gemma":[0.9915801,0.004757486,0.003220718,0.0003601236,0.000049686074,0.000031860054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028825516,0.0002928431,0.0015637093,0.00017753508,0.00021945365,0.000005958104,0.0006946915,0.0002494504,0.000030343093],"category_scores_gemma":[0.00043651712,0.00014868063,0.00031516416,0.00025924822,0.00064684486,0.00009312096,0.00040614442,0.00086307025,0.0000032844318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035732298,0.000445003,0.95647717,0.000018783767,0.0023737766,0.00004096212,0.006961631,0.000005796691,0.0008568807,0.00010029694,0.0009890392,0.03137335],"study_design_scores_gemma":[0.005483987,0.0003703637,0.9857413,0.00006554129,0.0006299408,0.000096517615,0.004762939,0.0000022331067,0.0011145845,0.00094281323,0.0006696369,0.00012013756],"about_ca_topic_score_codex":0.0006185916,"about_ca_topic_score_gemma":0.0001915685,"teacher_disagreement_score":0.031253215,"about_ca_system_score_codex":0.000014650227,"about_ca_system_score_gemma":0.00009407102,"threshold_uncertainty_score":0.606302},"labels":[],"label_agreement":null},{"id":"W4375855360","doi":"10.2217/imt-2023-0062","title":"Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology","score_opus":0.01778521998774822,"score_gpt":0.26715033747022876,"score_spread":0.24936511748248053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375855360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920935,0.0053975517,0.000012106691,0.000118494645,0.000412332,0.00083134166,0.00021411532,0.00026340934,0.0006571356],"genre_scores_gemma":[0.98824066,0.0017315914,0.00012489638,0.00003354687,0.000060197402,0.0003176058,0.00040258485,0.00006253612,0.0090264045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845594,0.00028123174,0.00035538356,0.0003934523,0.000074870935,0.0004391473],"domain_scores_gemma":[0.9989144,0.00025977707,0.00016033293,0.00059748575,0.00004496247,0.00002301295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015790449,0.00035744946,0.0005639017,0.00024967862,0.0001781051,0.000014647292,0.00022594674,0.00018542631,0.0003521155],"category_scores_gemma":[0.0000071274553,0.00025078896,0.00017756253,0.0004573494,0.00012527952,0.00007034725,0.000021452937,0.00007826335,0.0005316535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009170914,0.004034135,0.059411567,0.000028595345,0.0071291737,0.00041713292,0.036844198,0.000014822195,0.470347,0.00035211042,0.0013869388,0.41086343],"study_design_scores_gemma":[0.07113162,0.021589007,0.17758341,0.00015074993,0.00083083863,0.00024559553,0.025809253,0.000008495618,0.60064846,0.00010019133,0.100452036,0.0014503209],"about_ca_topic_score_codex":0.0006552352,"about_ca_topic_score_gemma":0.0002115085,"teacher_disagreement_score":0.4094131,"about_ca_system_score_codex":0.00007470354,"about_ca_system_score_gemma":0.00007849951,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4376057337","doi":"10.1016/bs.acc.2023.03.006","title":"Autoantibodies in psoriatic disease","year":2023,"lang":"en","type":"review","venue":"Advances in clinical chemistry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Krembil Foundation; Pfizer","keywords":"Psoriatic arthritis; Psoriasis; Autoantibody; Medicine; Disease; Immunology; Autoimmune disease; Rheumatoid arthritis; Rheumatoid factor; Dermatology; Antibody; Internal medicine","score_opus":0.09231080845502614,"score_gpt":0.43402219871327385,"score_spread":0.3417113902582477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376057337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033778235,0.9965443,5.327511e-7,0.000014246105,0.0015569994,0.00031652054,0.00018441949,0.000098172044,0.00094701955],"genre_scores_gemma":[0.00009066696,0.99387866,0.000023393615,0.000013805139,0.00020370296,0.00024155503,0.00081742863,0.000048468708,0.004682345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680877,0.00031394718,0.0015989015,0.0007707675,0.00004626839,0.00046135913],"domain_scores_gemma":[0.9963283,0.0026280463,0.0004186747,0.0005559717,0.000016003394,0.00005300784],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058019714,0.0004564731,0.002071496,0.000084694846,0.000040870862,0.000009007056,0.00047725,0.0008373964,0.00018468272],"category_scores_gemma":[0.0013994572,0.0003732133,0.0006438246,0.0003798,0.0002377565,0.00008061995,0.00016754257,0.0008288148,0.0010573287],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004681946,0.0002464296,0.0017961522,0.011340217,0.00016780895,0.00016764505,0.000008093593,0.0000011871475,6.0842757e-7,0.000016915783,0.0001555072,0.98605263],"study_design_scores_gemma":[0.00089798763,0.00001763355,0.0003475531,0.011037687,0.0005232989,0.0000061502933,0.000012771373,3.7579403e-7,0.0000066818952,0.0005162063,0.98622864,0.0004049832],"about_ca_topic_score_codex":0.0000051940524,"about_ca_topic_score_gemma":0.000022618804,"teacher_disagreement_score":0.98607314,"about_ca_system_score_codex":0.00009369927,"about_ca_system_score_gemma":0.00026920158,"threshold_uncertainty_score":0.99987197},"labels":[],"label_agreement":null},{"id":"W4376599888","doi":"10.3389/fmed.2023.1020523","title":"Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measure","year":2023,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jikei University School of Medicine; Clalit Health Services; Alopecia UK; Cardiff University; Yale University","keywords":"Measure (data warehouse); Content (measure theory); Content validity; Medicine; Psychology; Computer science; Clinical psychology; Psychometrics; Data mining; Mathematics","score_opus":0.18469322014107525,"score_gpt":0.3385301396709762,"score_spread":0.15383691952990097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376599888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390025,0.014624129,0.000043677326,0.00028851966,0.00061247445,0.00044412597,0.000050331473,0.000015042347,0.000021479336],"genre_scores_gemma":[0.999375,0.00047899116,0.000051661722,0.000011426913,0.000008963651,0.000008322858,0.000020128426,0.000004390279,0.000041132706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985492,0.00041604263,0.000547315,0.00021529676,0.000101605794,0.00017051883],"domain_scores_gemma":[0.9988939,0.0002854657,0.00031237627,0.000373671,0.0000995225,0.000035073703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041602174,0.0001343138,0.00068614207,0.00010235876,0.000030378735,8.3949493e-7,0.00018069387,0.0001278937,0.000110928886],"category_scores_gemma":[0.0019197266,0.00007156258,0.00015808754,0.00037972658,0.00068899605,0.000045187513,0.00011300239,0.0000909921,5.8854016e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070336735,0.00013956419,0.96703905,0.00008059998,0.00023067817,0.0000041374706,0.00077071076,0.000002405741,0.013136588,0.0000035457542,0.0053237746,0.012565578],"study_design_scores_gemma":[0.0017961243,0.0004729178,0.9883877,0.00028994592,0.00027312504,0.000011676104,0.0006861787,0.0000042979177,0.0075257616,0.00048604375,0.0000109493385,0.000055255085],"about_ca_topic_score_codex":0.00051326957,"about_ca_topic_score_gemma":0.000029413219,"teacher_disagreement_score":0.021348676,"about_ca_system_score_codex":0.000044021264,"about_ca_system_score_gemma":0.00012755506,"threshold_uncertainty_score":0.29182371},"labels":[],"label_agreement":null},{"id":"W4377939923","doi":"10.1136/bmjopen-2022-067504","title":"Value in psoriasis (IRIS) trial: implementing value-based healthcare in psoriasis management – a 1-year prospective clinical study to evaluate feasibility and value creation","year":2023,"lang":"en","type":"article","venue":"BMJ Open","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Guenther Dermatology Research Centre","funders":"Vlaamse regering; Cilag; Fonds Wetenschappelijk Onderzoek; Novartis","keywords":"Medicine; Psoriasis; Value (mathematics); Health care; Clinical trial; IRIS (biosensor); Alternative medicine; Family medicine; Dermatology; Internal medicine; Pathology; Statistics","score_opus":0.16342922339548846,"score_gpt":0.46744252273048487,"score_spread":0.30401329933499643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377939923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961997,0.0001136348,0.000015998112,0.00091772986,0.00096975005,0.034925412,0.00009601515,0.00009965675,0.0008648023],"genre_scores_gemma":[0.9911367,0.000059940532,0.00079932925,0.0002029139,0.00009953973,0.006789966,0.00019051372,0.00004628964,0.0006747863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917977,0.0043374687,0.0014915488,0.0013569423,0.00021496041,0.00080139434],"domain_scores_gemma":[0.99799716,0.0006228632,0.00032486502,0.00085407187,0.00011150691,0.0000895513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013931448,0.00039015958,0.0009921067,0.00054034207,0.00030018197,0.00011431153,0.0005404617,0.00022777246,0.00010410508],"category_scores_gemma":[0.00064375834,0.0003647626,0.00014997444,0.0013633221,0.0000652879,0.00019956932,0.0008899502,0.00027741137,0.00026904565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040437095,0.0023938925,0.9242199,0.00010257837,0.0005467799,0.00007200191,0.0032258746,0.00017783468,0.00005860977,0.0009895468,0.0006375445,0.027138308],"study_design_scores_gemma":[0.10107379,0.0026975907,0.88726676,0.00019914785,0.0003024592,0.0000020748648,0.0061630844,0.00010241922,0.00023482305,0.0011000893,0.00044577164,0.0004119874],"about_ca_topic_score_codex":0.0042179553,"about_ca_topic_score_gemma":0.0042646453,"teacher_disagreement_score":0.060636695,"about_ca_system_score_codex":0.00043800127,"about_ca_system_score_gemma":0.00028240238,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W4378211370","doi":"10.1016/j.jaci.2023.03.035","title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease","year":2023,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Academy of Medical Sciences; National Institute for Health and Care Research","keywords":"Biology; Interleukin 17; Chromatin immunoprecipitation; Chromatin; Cytokine; Interleukin 22; Interleukin; Immunology; Gene isoform; Cell biology; Gene expression; Gene; Genetics; Promoter","score_opus":0.020759049773160655,"score_gpt":0.2885082067921432,"score_spread":0.2677491570189825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378211370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99126947,0.004766727,0.00041021247,0.0014536062,0.0018866812,0.00012397733,0.00004991812,0.000018066012,0.000021359572],"genre_scores_gemma":[0.9916776,0.0074725333,0.00005641062,0.00007540392,0.000096703,0.0000047631115,0.00004970682,0.00001191181,0.000555008],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980849,0.00043041818,0.00096364826,0.00021108847,0.000047181416,0.00026273896],"domain_scores_gemma":[0.9982644,0.0008528313,0.0004651073,0.00017880871,0.00016461525,0.00007424474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041413083,0.0001691333,0.00065085274,0.00022218519,0.00012420374,0.000010387522,0.00014887602,0.00031132068,0.00017929958],"category_scores_gemma":[0.00041349855,0.0001312837,0.00019017987,0.00016288382,0.00032284055,0.00008051425,0.00012222832,0.0002401806,0.000042952117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028649304,0.0021380123,0.06232654,0.00008242571,0.026352601,0.00014588721,0.0008115827,0.000039207425,0.3207586,0.009649589,0.007321742,0.5417245],"study_design_scores_gemma":[0.0055630826,0.0015871061,0.97352314,0.000074527336,0.0004970457,0.000039557715,0.00014767167,0.000019168949,0.003147127,0.004396996,0.010853481,0.0001510992],"about_ca_topic_score_codex":0.0000138480345,"about_ca_topic_score_gemma":0.000024216333,"teacher_disagreement_score":0.9111966,"about_ca_system_score_codex":0.000015265516,"about_ca_system_score_gemma":0.000066924826,"threshold_uncertainty_score":0.5353594},"labels":[],"label_agreement":null},{"id":"W4378473515","doi":"10.1016/j.jdin.2023.05.006","title":"Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class","year":2023,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Probity Medical Research; SKiN Health; Dermatrials Research; Sunnybrook Health Science Centre; Health Sciences Centre; University of Calgary; University of Toronto","funders":"","keywords":"Medicine; Interleukin 23; Psoriasis; Plaque psoriasis; Dermatology; Multicenter study; Interleukin 17; Internal medicine; Randomized controlled trial; Cytokine","score_opus":0.008630439969146362,"score_gpt":0.24539974113766488,"score_spread":0.23676930116851852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378473515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977686,0.00002103469,0.000005218013,0.00005825453,0.0008511708,0.0009719031,0.000100666184,0.00002503734,0.0001981477],"genre_scores_gemma":[0.9995406,0.000024246896,0.00002384467,0.000007185669,0.00002475055,0.00011589072,0.00012371471,0.000020636486,0.00011908563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981442,0.0005495284,0.00057470147,0.0003857134,0.00014558628,0.00020026499],"domain_scores_gemma":[0.9988515,0.0004167466,0.00034738262,0.00022255466,0.00014791793,0.000013939406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059856544,0.00021496828,0.00043882628,0.0005043072,0.00007628003,0.00001696381,0.00024288024,0.00011006189,0.00003351862],"category_scores_gemma":[0.00012130876,0.0001491518,0.000054333203,0.00049034395,0.00010580631,0.00015560804,0.00015807815,0.00026655348,0.0000108522345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008937159,0.001054929,0.97626626,0.000021147027,0.00064382405,0.000007218611,0.009407645,0.000080094935,0.0015813835,0.00022623806,0.000026844706,0.0017472364],"study_design_scores_gemma":[0.017762506,0.0006187144,0.97470564,0.0003149325,0.000059508387,8.820948e-7,0.001899219,0.000059196267,0.004342071,0.000076225144,0.000026835181,0.00013425136],"about_ca_topic_score_codex":0.0012441092,"about_ca_topic_score_gemma":0.008200225,"teacher_disagreement_score":0.008825348,"about_ca_system_score_codex":0.00031645782,"about_ca_system_score_gemma":0.000050756586,"threshold_uncertainty_score":0.60822344},"labels":[],"label_agreement":null},{"id":"W4378530731","doi":"10.1080/1744666x.2023.2219897","title":"Topical roflumilast for the treatment of psoriasis","year":2023,"lang":"en","type":"review","venue":"Expert Review of Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of Ottawa","funders":"","keywords":"Roflumilast; Medicine; Intertriginous; Adverse effect; Psoriasis; Clinical trial; Apremilast; Discontinuation; Quality of life (healthcare); Dermatology; Intensive care medicine; Pharmacology; Internal medicine; Disease; COPD","score_opus":0.17833703146497726,"score_gpt":0.4633252691026638,"score_spread":0.28498823763768655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378530731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008111363,0.98915577,0.00002845285,0.0002871621,0.007090371,0.002929335,0.00032578307,0.000055327684,0.00011966381],"genre_scores_gemma":[8.784373e-7,0.9935742,0.00016021023,0.00011013186,0.00053986325,0.0019850673,0.00065380946,0.000073341995,0.0029024938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931212,0.001594079,0.004019156,0.00069746724,0.00006814169,0.000499956],"domain_scores_gemma":[0.98466367,0.011723969,0.0019333309,0.0014511313,0.00019609512,0.00003182816],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010664503,0.00067278405,0.0074257366,0.00013037444,0.00012530031,0.0000040473456,0.0009261983,0.0013410501,0.00051716826],"category_scores_gemma":[0.0014381421,0.0003531526,0.004901537,0.00034755826,0.00079989,0.00002686384,0.0001310838,0.0003113933,0.0004973523],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011788219,0.00075720216,0.0000050287285,0.01318168,0.008670662,0.0000031082511,0.000045477707,6.68053e-9,0.0000048943953,0.0003479843,0.0072233733,0.9696427],"study_design_scores_gemma":[0.0014921031,0.002132403,0.00003145969,0.024395786,0.005572089,0.000026696107,0.000021008447,7.019008e-8,0.000063314415,0.000022513048,0.96597916,0.00026339584],"about_ca_topic_score_codex":0.000056976787,"about_ca_topic_score_gemma":0.000010634398,"teacher_disagreement_score":0.9693793,"about_ca_system_score_codex":0.00006126178,"about_ca_system_score_gemma":0.00039814197,"threshold_uncertainty_score":0.9999554},"labels":[],"label_agreement":null},{"id":"W4378905320","doi":"10.3389/fgene.2023.1141010","title":"A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort","year":2023,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Nexus Clinical Research (Canada)","funders":"","keywords":"Psoriasis; Genome-wide association study; Single-nucleotide polymorphism; Population; Medicine; Cohort; Human leukocyte antigen; Genetic predisposition; Disease; Immunology; Genetics; Biology; Internal medicine; Genotype; Gene","score_opus":0.017485364304060044,"score_gpt":0.2866489268318449,"score_spread":0.26916356252778484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378905320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871145,0.0052994047,0.002308904,0.00030529016,0.0030986336,0.0010570536,0.00060839445,0.00008309751,0.00012476003],"genre_scores_gemma":[0.9773836,0.012728559,0.007596883,0.00015612587,0.00026805096,0.00035938525,0.00042622216,0.00004787957,0.0010332677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969109,0.0006414615,0.00088447484,0.0007309516,0.00009264482,0.00073953794],"domain_scores_gemma":[0.9987782,0.00030307766,0.00018584348,0.00049922813,0.000109290944,0.00012435131],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009506726,0.00034272342,0.0007894728,0.0004911408,0.00023895435,0.000039388786,0.00025909278,0.0005631743,0.00005347426],"category_scores_gemma":[0.0004967239,0.0003439607,0.00014953504,0.00091428397,0.00022920448,0.000049760773,0.00014856773,0.0003315152,0.00026556235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035361527,0.00016916062,0.9411151,0.000015245173,0.00038233446,0.000032218722,0.0006175692,0.00024880265,0.00051835977,0.000016939364,0.017556028,0.038974646],"study_design_scores_gemma":[0.004456427,0.00031286778,0.9820606,0.000060290386,0.00037215452,0.000008914837,0.00028268533,0.00016080031,0.00034567533,0.0015607828,0.010006071,0.00037274],"about_ca_topic_score_codex":0.00035058425,"about_ca_topic_score_gemma":0.0014074575,"teacher_disagreement_score":0.04094551,"about_ca_system_score_codex":0.000178736,"about_ca_system_score_gemma":0.00012203455,"threshold_uncertainty_score":0.99990124},"labels":[],"label_agreement":null},{"id":"W4379094806","doi":"10.1007/s40265-023-01882-9","title":"Targeting IL-23 for IBD: Rationale and Progress to Date","year":2023,"lang":"en","type":"review","venue":"Drugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Western University","funders":"","keywords":"Medicine; Ustekinumab; Ulcerative colitis; Interleukin 23; Inflammatory bowel disease; Crohn's disease; Psoriasis; Disease; Immunology; Clinical trial; Internal medicine; Gastroenterology; Immune system; Interleukin 17; Adalimumab","score_opus":0.05452225443549843,"score_gpt":0.3243609393276801,"score_spread":0.2698386848921817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379094806","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056909346,0.9959768,0.00001276689,0.000074879004,0.0008003207,0.0016402636,0.0012509549,0.00009185705,0.0000952365],"genre_scores_gemma":[0.0000038665585,0.9770507,0.00036301816,0.000029636829,0.0001638895,0.0014851785,0.007584984,0.000051314986,0.013267378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888366,0.00011425939,0.00030401893,0.00039149422,0.000022602053,0.00028393135],"domain_scores_gemma":[0.9993008,0.00032660403,0.0001370784,0.00017287553,0.00003772749,0.000024930374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002576456,0.0002642424,0.0007625739,0.00012962695,0.00018082662,0.000022628066,0.00014953988,0.0002858509,0.00004114837],"category_scores_gemma":[0.00005786286,0.00020705776,0.00021796471,0.00014662194,0.0000435743,0.0000305655,0.00009381342,0.000090723,0.0012706202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017684197,0.0000259081,0.0000035691257,0.0027483818,0.0006332298,0.0000028094005,0.00026606876,8.9848186e-8,0.000017685263,0.0002722093,0.018704247,0.9773081],"study_design_scores_gemma":[0.00032627155,0.00004565091,0.0000021656185,0.0010856349,0.0006791825,0.0000100436,0.000048485395,2.225266e-7,0.000034136156,0.000027861033,0.9975251,0.00021525325],"about_ca_topic_score_codex":0.0000036433403,"about_ca_topic_score_gemma":0.00000229856,"teacher_disagreement_score":0.97882086,"about_ca_system_score_codex":0.000019438416,"about_ca_system_score_gemma":0.00008223098,"threshold_uncertainty_score":0.999507},"labels":[],"label_agreement":null},{"id":"W4379376915","doi":"10.1111/exd.14828","title":"Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The <scp>ARROW</scp> study","year":2023,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Dalhousie University","funders":"Novartis Pharma","keywords":"Secukinumab; Ustekinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Refractory (planetary science); Clinical endpoint; Dermatology; Internal medicine; Interleukin 23; Randomized controlled trial; Gastroenterology; Interleukin 17; Psoriatic arthritis; Disease; Cytokine; Adalimumab","score_opus":0.041021473843430745,"score_gpt":0.28637726171925326,"score_spread":0.24535578787582252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379376915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907236,0.0046880324,0.0000030041474,0.0002016324,0.0015594158,0.0009375885,0.000060902268,0.00009566364,0.00173017],"genre_scores_gemma":[0.9990568,0.000056229692,0.000011282221,0.00008352091,0.00003416897,0.00036101713,0.00019327385,0.000024080146,0.00017961995],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.9970448,0.0012992301,0.0005760981,0.00038888465,0.00012294325,0.0005680408],"domain_scores_gemma":[0.99781305,0.0013126845,0.00021593609,0.00060764985,0.00003164539,0.000019045943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003800792,0.0002978027,0.0004910075,0.00021709221,0.00037130676,0.000019280831,0.0006338222,0.00021551864,0.00007378743],"category_scores_gemma":[0.00009967777,0.00019222428,0.00014730179,0.00055640197,0.0003227848,0.00007928469,0.00017369428,0.00024046506,0.0005708931],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047477274,0.007541602,0.022583297,0.00014157749,0.0040948014,0.0015048345,0.2455999,0.00012352398,0.613675,0.021706043,0.07617459,0.0021071201],"study_design_scores_gemma":[0.0485847,0.004668466,0.15615247,0.000106097905,0.0007430299,0.0011295752,0.40675834,0.0001617975,0.31691384,0.00053253834,0.0636845,0.00056462456],"about_ca_topic_score_codex":0.00031179434,"about_ca_topic_score_gemma":0.00029863502,"teacher_disagreement_score":0.29676113,"about_ca_system_score_codex":0.00009893524,"about_ca_system_score_gemma":0.00006348641,"threshold_uncertainty_score":0.7838679},"labels":[],"label_agreement":null},{"id":"W4379510689","doi":"10.1136/annrheumdis-2023-eular.5053","title":"POS0882 SCREENING/REFERRAL STRATEGIES FOR THE EARLY RECOGNITION OF PSA AMONG PATIENTS WITH PSORIASIS: RESULTS OF A GRAPPA SURVEY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"Medicine; Psoriasis; Referral; Family medicine; Dermatology","score_opus":0.081827927108435,"score_gpt":0.2851397575585802,"score_spread":0.20331183045014517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379510689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99340796,0.00072513695,0.00002340452,0.00008324848,0.00020228427,0.0006157585,0.0048673213,0.000024521521,0.00005033708],"genre_scores_gemma":[0.9987109,0.0002118989,0.000019926403,0.000010924824,0.000005674429,0.00007842415,0.0008073854,0.000014297521,0.00014060184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987412,0.00032631474,0.00045678584,0.00016296687,0.00009702369,0.00021572589],"domain_scores_gemma":[0.9975505,0.0011438366,0.0005582,0.00037822445,0.00035094426,0.00001828701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041948617,0.0001573232,0.000346677,0.00009208304,0.00013136695,0.000010920698,0.00030642803,0.000072597,0.000019214838],"category_scores_gemma":[0.00044164166,0.00008254072,0.00022577659,0.00033188192,0.00030934383,0.00012571637,0.00005317163,0.000042892712,0.0000066518483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019773154,0.0018952225,0.6451657,0.00076582993,0.008684512,7.2824605e-7,0.003842093,0.00026092108,0.00031055056,0.0002930121,0.018573092,0.3004352],"study_design_scores_gemma":[0.0025045113,0.0004750105,0.9914787,0.00045424904,0.0003955424,1.9018485e-7,0.00067750376,0.000007731351,0.002859164,0.0010344305,0.000015433781,0.00009754063],"about_ca_topic_score_codex":0.0011253891,"about_ca_topic_score_gemma":0.00018966201,"teacher_disagreement_score":0.346313,"about_ca_system_score_codex":0.0000024923456,"about_ca_system_score_gemma":0.000062843435,"threshold_uncertainty_score":0.3365913},"labels":[],"label_agreement":null},{"id":"W4379517577","doi":"10.1136/annrheumdis-2023-eular.5841","title":"POS0867 B-CELL SUBSETS IN PERIPHERAL BLOOD ACROSS DISEASE PHASES OF PSORIATIC ARTHRITIS AND THEIR CORRELATION WITH SYNOVIAL TISSUE FEATURES","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Ottawa","keywords":"Psoriatic arthritis; Medicine; Immunoglobulin D; Psoriasis; B cell; Immunology; Antibody; Rheumatoid arthritis; Pathology; Rheumatology; Arthritis; Synovial fluid; Internal medicine; Osteoarthritis","score_opus":0.015551575462803066,"score_gpt":0.2602851051236385,"score_spread":0.24473352966083545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379517577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97429425,0.02401625,0.0000035548787,0.00022317498,0.00019584855,0.00033933268,0.00086691766,0.000032196385,0.000028492439],"genre_scores_gemma":[0.99674386,0.0025937012,0.0000063155044,0.000029366709,0.000010289095,0.000042592863,0.0001809813,0.000015163484,0.0003777291],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99897885,0.00019459485,0.000300649,0.00019823184,0.00006332538,0.0002643617],"domain_scores_gemma":[0.99909955,0.0003060359,0.00021513416,0.00028325876,0.000053172353,0.0000428366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012008146,0.0001938358,0.0003741984,0.00007333925,0.000121177414,0.000014127873,0.00016655012,0.000069357695,0.00006279593],"category_scores_gemma":[0.0001431644,0.00011945095,0.00010660146,0.00026511482,0.00026958363,0.00010159914,0.000066794135,0.000058620033,0.000008172193],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048220335,0.005173942,0.23821533,0.0014504435,0.0022198027,0.00006737939,0.01494634,0.0008534522,0.009270583,0.00046036718,0.0048267078,0.7176936],"study_design_scores_gemma":[0.0056563243,0.00047025454,0.9504482,0.0014918124,0.00035010715,0.00001984842,0.0015471667,0.000044057,0.038407132,0.0011966452,0.000075365664,0.00029309935],"about_ca_topic_score_codex":0.0001259692,"about_ca_topic_score_gemma":0.00009514467,"teacher_disagreement_score":0.71740055,"about_ca_system_score_codex":0.0000043958785,"about_ca_system_score_gemma":0.000063315885,"threshold_uncertainty_score":0.48710686},"labels":[],"label_agreement":null},{"id":"W4379518346","doi":"10.1136/annrheumdis-2023-eular.5653","title":"POS0026 THE INDEPENDENT INFLUENCE OF SEX ON THE DISEASE IMPACT DOMAINS IN PSORIATIC ARTHRITIS IS MODEST, ONCE CONFOUNDERS ARE TAKEN INTO ACCOUNT","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; University of Leeds; University of Glasgow; Janssen Scientific Affairs; School of Medicine, Kyorin University; McGill University; Leeds Biomedical Research Centre; University of Washington","keywords":"Medicine; Psoriatic arthritis; Confounding; Disease; Arthritis; Internal medicine","score_opus":0.033794001180524405,"score_gpt":0.2945953375326547,"score_spread":0.2608013363521303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379518346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120915,0.003932142,0.0000016004215,0.0035118908,0.00014786003,0.00061142014,0.00049610983,0.000029485282,0.000060355695],"genre_scores_gemma":[0.99674696,0.002282847,9.897202e-7,0.00063388335,0.000009620176,0.00011354038,0.000031363044,0.000017727452,0.0001630562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819815,0.00051600544,0.000486305,0.00024505836,0.00019694184,0.00035756],"domain_scores_gemma":[0.99741244,0.0011602939,0.00042776857,0.0008634414,0.000085895306,0.000050130366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043137674,0.0002568228,0.00041528424,0.000111025074,0.00025511766,0.00002844737,0.000749959,0.00008113696,0.00014633953],"category_scores_gemma":[0.00061967,0.00012611586,0.0003519299,0.0004292979,0.00041928396,0.000120731995,0.000166786,0.00013642864,0.000112206675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051630144,0.004774288,0.5824549,0.0014956502,0.009906102,0.0001011533,0.041776136,0.048363477,0.0028890555,0.010899918,0.039283127,0.25289318],"study_design_scores_gemma":[0.0011650476,0.00011963739,0.9777473,0.0012508353,0.00018800684,0.0000032822454,0.0026520789,0.00016097614,0.0018057842,0.014621306,0.00008558983,0.00020016027],"about_ca_topic_score_codex":0.0006783704,"about_ca_topic_score_gemma":0.00011426592,"teacher_disagreement_score":0.3952924,"about_ca_system_score_codex":0.00003855247,"about_ca_system_score_gemma":0.00019390856,"threshold_uncertainty_score":0.51428556},"labels":[],"label_agreement":null},{"id":"W4379522315","doi":"10.1136/annrheumdis-2023-eular.199","title":"OP0271 INCIDENCE OF PSORIATIC ARTHRITIS AND PREVALENCE OF UNDIAGNOSED CASES IN A UK PRIMARY CARE POPULATION FOLLOWED PROSPECTIVELY FOR 2 YEARS - RESULTS FROM THE TUDOR RANDOMIZED CLINICAL TRIAL","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institutes of Health; National Institute for Health and Care Research; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Medizinische Universität Wien; Alan Turing Institute; Pfizer; Programme Grants for Applied Research; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Incidence (geometry); Population; Psoriasis; Rheumatology; Physical therapy; Physical examination; Pediatrics; Internal medicine; Epidemiology; Disease; Dermatology; Environmental health","score_opus":0.054167073910616224,"score_gpt":0.3338601235531854,"score_spread":0.2796930496425692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379522315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98250693,0.012708785,0.0000021891651,0.00011185385,0.00046648175,0.0021699877,0.0020161238,0.000012120386,0.00000552481],"genre_scores_gemma":[0.99369705,0.005714664,0.00003269282,0.000017241136,0.000016734031,0.000229035,0.00023610167,0.000007929705,0.000048528243],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976824,0.0009600393,0.0009228244,0.00021254405,0.00008243479,0.00013974191],"domain_scores_gemma":[0.9882434,0.010677237,0.0006800512,0.00031021642,0.00007356804,0.000015523572],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010285333,0.00011941508,0.00072802417,0.000058641857,0.00005889068,0.000005825746,0.00021592718,0.000085841704,0.000009172021],"category_scores_gemma":[0.0088409465,0.00007350739,0.00034092503,0.00017956494,0.00028679438,0.00005500204,0.000079783546,0.000045733766,0.0000017539575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5911704,0.0009023618,0.15244792,0.0009297494,0.0017736508,0.000007185596,0.005037457,0.00003854163,0.00015321534,0.00024785716,0.001299214,0.2459925],"study_design_scores_gemma":[0.1609467,0.0003018018,0.8337451,0.0015008494,0.00041468182,7.2624465e-7,0.0002774414,0.00001208028,0.0004340203,0.0022910282,0.0000025258114,0.00007300714],"about_ca_topic_score_codex":0.00097376195,"about_ca_topic_score_gemma":0.00016859238,"teacher_disagreement_score":0.68129724,"about_ca_system_score_codex":0.000009355711,"about_ca_system_score_gemma":0.00010007985,"threshold_uncertainty_score":0.999508},"labels":[],"label_agreement":null},{"id":"W4379523580","doi":"10.1136/annrheumdis-2023-eular.464","title":"POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McGill University; Memorial University of Newfoundland","funders":"University of Toronto; University of Glasgow; Sorbonne Université; University of Washington; University of Occupational and Environmental Health; University of Rochester; Jikei University School of Medicine; Icahn School of Medicine at Mount Sinai","keywords":"Medicine; Internal medicine; Psoriatic arthritis; Logistic regression; Ankylosing spondylitis; Rheumatoid arthritis","score_opus":0.022426293072336366,"score_gpt":0.2883421436897537,"score_spread":0.26591585061741735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379523580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894831,0.008330048,0.0000010181678,0.00060495647,0.00024743064,0.00052138796,0.0004971868,0.000047220237,0.0002676564],"genre_scores_gemma":[0.99701774,0.0023938864,0.000014085808,0.00008557353,0.000017791694,0.00011121821,0.00017036451,0.000011880286,0.00017748335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985992,0.0002886709,0.00043291305,0.00025415779,0.00010811905,0.00031694476],"domain_scores_gemma":[0.9991873,0.00022741899,0.00019163651,0.00032000046,0.00003108913,0.00004256929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009661064,0.00024713392,0.0004967054,0.00008189322,0.00014744257,0.000022600292,0.00016123032,0.000071214614,0.00006631614],"category_scores_gemma":[0.00004121506,0.00016686947,0.00018141423,0.00027873614,0.00015482094,0.00010594301,0.00015184638,0.00003947097,0.00009579087],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008071942,0.0006395803,0.10769471,0.0001085021,0.0011352048,0.000006240044,0.002005521,0.000015021434,0.00016008942,0.0004700829,0.00127326,0.8864111],"study_design_scores_gemma":[0.0017840931,0.0004699753,0.98956084,0.00061833794,0.00024596404,0.0000011763894,0.00038209092,0.000017916687,0.0015077959,0.0045485236,0.00065561244,0.00020768472],"about_ca_topic_score_codex":0.0003338521,"about_ca_topic_score_gemma":0.00007769626,"teacher_disagreement_score":0.8862034,"about_ca_system_score_codex":0.00007876109,"about_ca_system_score_gemma":0.00009040033,"threshold_uncertainty_score":0.6804739},"labels":[],"label_agreement":null},{"id":"W4379534383","doi":"10.1136/annrheumdis-2023-eular.2985","title":"POS0227 SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Griffith University; University of Leeds; University of Oxford; Janssen Scientific Affairs; Celgene; McGill University; Gilead Sciences; Brigham and Women's Hospital; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Double blind; Post-hoc analysis; Placebo; Arthritis; Internal medicine; Dermatology; Pathology; Alternative medicine","score_opus":0.03736903366541654,"score_gpt":0.34420621260855694,"score_spread":0.3068371789431404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379534383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698193,0.023127299,0.000016913124,0.00090620725,0.00060236384,0.0042189513,0.0011859018,0.00011289659,0.000010189052],"genre_scores_gemma":[0.9964937,0.001144372,0.000031006828,0.000062498904,0.000015536605,0.0009571124,0.0003369972,0.000038494116,0.0009203069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99370575,0.0035345876,0.0013586945,0.0005786935,0.0002478406,0.00057443825],"domain_scores_gemma":[0.9952541,0.0029219554,0.00057350233,0.0010314365,0.00013497492,0.00008401313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002386237,0.0004226694,0.002035045,0.00088145403,0.00019144826,0.000074956115,0.00069106114,0.00016991317,0.00070221466],"category_scores_gemma":[0.0012779321,0.00031105036,0.0013296662,0.0020380171,0.00017427301,0.00020197878,0.00021928536,0.000121393314,0.0005283163],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9513983,0.0024599973,0.0008684398,0.000031272557,0.023887731,0.0000813485,0.0050737616,0.00031854332,0.0012070349,0.000031823398,0.0008268207,0.013814919],"study_design_scores_gemma":[0.9495979,0.0007252679,0.031821664,0.00041471425,0.0090902,0.0000033815684,0.00572322,0.0001190709,0.001127032,0.00081194047,0.00007385799,0.000491753],"about_ca_topic_score_codex":0.0011183004,"about_ca_topic_score_gemma":0.00034669082,"teacher_disagreement_score":0.030953223,"about_ca_system_score_codex":0.000034976576,"about_ca_system_score_gemma":0.00015177843,"threshold_uncertainty_score":0.99993414},"labels":[],"label_agreement":null},{"id":"W4379600190","doi":"10.1093/bjd/ljad182","title":"Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research; Calgary Laboratory Services; SKiN Health","funders":"","keywords":"Scalp; Tolerability; Roflumilast; Medicine; Psoriasis; Randomized controlled trial; Clinical endpoint; Adverse effect; Randomization; Dermatology; Surgery; Internal medicine","score_opus":0.02527273897059209,"score_gpt":0.2932965594720684,"score_spread":0.26802382050147633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379600190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764458,0.017938333,0.00021908102,0.0007492943,0.0019507038,0.0024100794,0.000071478826,0.0000795418,0.00013567026],"genre_scores_gemma":[0.996322,0.0020648027,0.00007780895,0.00009947475,0.00019221926,0.00047262976,0.00006996711,0.000042564385,0.0006585739],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99645513,0.0010301411,0.0013978911,0.0003830449,0.00010005412,0.0006337468],"domain_scores_gemma":[0.99718523,0.0014426088,0.00074664946,0.00019853415,0.0003251462,0.00010183689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011973458,0.0003311599,0.0022660946,0.00045952434,0.0004295536,0.0000862042,0.00032651037,0.0003866617,0.00008558742],"category_scores_gemma":[0.00043900064,0.00030667827,0.0006218095,0.00028714605,0.00030169953,0.00022648508,0.00008677015,0.00035131586,0.0000882437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.905835,0.0025448222,0.0030397784,0.00005924967,0.0071022604,0.0035954127,0.0010946394,0.000003340398,0.0052274354,0.00017828727,0.013629221,0.057690606],"study_design_scores_gemma":[0.9659086,0.000859902,0.0009105184,0.00010138603,0.0020883007,0.022641495,0.0011753787,0.000030279252,0.0032089923,0.000267186,0.0025126848,0.00029526715],"about_ca_topic_score_codex":0.000059396156,"about_ca_topic_score_gemma":0.0000853771,"teacher_disagreement_score":0.060073663,"about_ca_system_score_codex":0.00003109815,"about_ca_system_score_gemma":0.00016860053,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W4379647448","doi":"10.1136/annrheumdis-2023-eular.958","title":"AB1156 METABOLIC DISORDERS AND ABNORMAL DIETARY PATTERNS AND THEIR ASSOCIATION WITH PSORIATIC ARTHRITIS ACTIVITY: THE DIETARY INTERVENTION IN PSA (DIPSA) STUDY","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriatic arthritis; Dash; Internal medicine; Overweight; Physical therapy; Body mass index; Mediterranean diet; Obesity; Metabolic syndrome; Randomized controlled trial; Disease","score_opus":0.014113832197185256,"score_gpt":0.23365883004836754,"score_spread":0.21954499785118228,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379647448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950333,0.0034135554,0.000019869398,0.0004970257,0.0002747048,0.00054562546,0.000046549056,0.00007643239,0.00009290705],"genre_scores_gemma":[0.9946132,0.0045453957,0.0000034399777,0.000033373133,0.000022563358,0.00013961674,0.00008331385,0.000014148073,0.00054494996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871314,0.00048044522,0.00018845104,0.0002878906,0.000043783908,0.0002862804],"domain_scores_gemma":[0.99943274,0.00027046454,0.00010159491,0.00016409,0.000015080772,0.000016037515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004964676,0.00020154427,0.00030216962,0.00013248458,0.00019924121,0.000030791587,0.00007566393,0.00011111711,0.000055954904],"category_scores_gemma":[0.000023963015,0.000120581506,0.000059952854,0.00022248368,0.00004676726,0.00019852514,0.000087815926,0.00016352614,0.000023917743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014282293,0.00027481435,0.5781423,0.000008990318,0.0005922239,0.000004185762,0.0020652397,0.000001400458,0.00038652794,0.000009709296,0.000050955223,0.41832086],"study_design_scores_gemma":[0.003215889,0.00051670294,0.9909313,0.000029237577,0.00015345652,0.000007865333,0.0040165936,0.000025700094,0.000649327,0.00011364497,0.00019088587,0.00014943155],"about_ca_topic_score_codex":0.0016704628,"about_ca_topic_score_gemma":0.024862587,"teacher_disagreement_score":0.4181714,"about_ca_system_score_codex":0.000022189624,"about_ca_system_score_gemma":0.000009461349,"threshold_uncertainty_score":0.9929311},"labels":[],"label_agreement":null},{"id":"W4379647467","doi":"10.1136/annrheumdis-2023-eular.555","title":"AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Dactylitis; Enthesitis; Internal medicine; Psoriatic arthritis; Placebo; BASDAI; Physical therapy; Arthritis; Pathology","score_opus":0.0447157044069695,"score_gpt":0.3523626437271072,"score_spread":0.3076469393201377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379647467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994158,0.0032670093,0.0000451849,0.000108979424,0.00009335102,0.001544901,0.0007241945,0.000025054818,0.000033311284],"genre_scores_gemma":[0.9960412,0.0031473148,0.000017002832,0.000014860686,0.00000575541,0.00031548762,0.00029461348,0.000014753137,0.00014903206],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974206,0.00094487175,0.0010338037,0.0002110473,0.00015628131,0.00023339217],"domain_scores_gemma":[0.99555933,0.0023615991,0.001241173,0.00048060014,0.00032774688,0.000029523162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001196144,0.0002572788,0.0018761082,0.0005792607,0.000103510596,0.000006015036,0.00021913314,0.00005929741,0.0002108333],"category_scores_gemma":[0.0006918007,0.00014421476,0.0013052112,0.0008308305,0.00034113997,0.00007890155,0.00004278443,0.000048128313,0.0000091544935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7345143,0.0032747465,0.0015452787,0.0005182851,0.14976367,0.0000033906085,0.004640931,0.0062086796,0.0062919534,0.00045283063,0.00057345896,0.09221247],"study_design_scores_gemma":[0.934636,0.0025529133,0.011489096,0.0013650537,0.034711752,0.000001904253,0.004223679,0.0011333103,0.00839591,0.0012026129,7.0526124e-7,0.00028707553],"about_ca_topic_score_codex":0.00033601356,"about_ca_topic_score_gemma":0.00008737485,"teacher_disagreement_score":0.20012169,"about_ca_system_score_codex":0.000020814228,"about_ca_system_score_gemma":0.00010384672,"threshold_uncertainty_score":0.5880908},"labels":[],"label_agreement":null},{"id":"W4379647494","doi":"10.1136/annrheumdis-2023-eular.3472","title":"AB1159 THE SPANISH VERSION OF THE PURE-4 QUESTIONNAIRE USE FOR PSORIATIC ARTHRITIS SCREENING AFTER 1 YEAR OF FOLLOW-UP IN PATIENTS WITH PSORIASIS","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Arthritis; Family medicine; Physical therapy; Internal medicine","score_opus":0.010378725192201458,"score_gpt":0.20353573602066322,"score_spread":0.19315701082846176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379647494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820715,0.00021222136,0.000056451605,0.00011332168,0.00065103255,0.00055920176,0.00013803167,0.00002604577,0.00003652953],"genre_scores_gemma":[0.99873763,0.000062551335,0.00012864155,0.00002729823,0.000014886571,0.000081794315,0.000077104174,0.00001464657,0.00085543667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999183,0.00014150077,0.00023718401,0.00017358322,0.00006326102,0.00020148465],"domain_scores_gemma":[0.99930614,0.00017999622,0.00012304427,0.00028738548,0.00009433225,0.000009124568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018480059,0.00012560966,0.00021818312,0.00008035658,0.000098984674,0.0000071782397,0.00015415213,0.00012491894,0.00008144905],"category_scores_gemma":[0.000107545326,0.00006803143,0.00012546513,0.00030985125,0.00009703926,0.000092816554,0.000060622802,0.000067206674,0.000027506854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023055573,0.00014413142,0.95870525,0.00003689419,0.00031937222,8.697692e-7,0.0007667528,0.00001623238,0.0005843854,0.00034686216,0.0018964853,0.03487718],"study_design_scores_gemma":[0.006774682,0.0002742447,0.9855184,0.00024130206,0.00012832216,5.6271637e-7,0.00024224262,0.0000036681909,0.005908757,0.00008247534,0.0007304119,0.00009493269],"about_ca_topic_score_codex":0.00017787116,"about_ca_topic_score_gemma":0.0005846362,"teacher_disagreement_score":0.03478225,"about_ca_system_score_codex":0.000017367483,"about_ca_system_score_gemma":0.00002900658,"threshold_uncertainty_score":0.27742413},"labels":[],"label_agreement":null},{"id":"W4379649269","doi":"10.1136/annrheumdis-2023-eular.45","title":"POS1527 EFFECTS OF APREMILAST ON CHANGES IN CARDIOMETABOLIC PARAMETERS BY DIABETES AND OBESITY STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"LEO Pharma; Incyte; IC Design Education Center; Regeneron Pharmaceuticals; Sanofi; Pfizer","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Body mass index; Diabetes mellitus; Placebo; Gastroenterology; Apremilast; Population; Obesity; Arthritis; Endocrinology; Pathology","score_opus":0.008808702312123926,"score_gpt":0.2121055439803363,"score_spread":0.20329684166821238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99167114,0.0073371837,8.462895e-8,0.000058919635,0.0001472373,0.00043526298,0.00032813303,0.000014113453,0.000007922075],"genre_scores_gemma":[0.9969883,0.0027966269,0.0000029906412,0.000034969173,0.0000015445655,0.00006270892,0.0000839868,0.00001022523,0.00001867151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989836,0.0002859012,0.00020351361,0.00016719577,0.000070672,0.0002891006],"domain_scores_gemma":[0.9990356,0.00054213795,0.00014328488,0.0002267684,0.000025739484,0.00002645891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010566858,0.00015025976,0.00046663967,0.00019938864,0.000034958714,0.000004847586,0.000110513465,0.0000553248,0.0000062477684],"category_scores_gemma":[0.0002496439,0.000099793586,0.00006451705,0.00037574183,0.00012959084,0.000043419775,0.000052659554,0.00004461406,0.0000067036476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017086597,0.00048654922,0.87269443,0.00030588708,0.00034934733,7.946582e-7,0.00043952244,0.00001847056,0.00020476275,0.000012488379,0.00035371212,0.12496316],"study_design_scores_gemma":[0.0023013283,0.00034804473,0.9834132,0.0009538497,0.000084590305,7.3413005e-8,0.000081538004,0.0000021500377,0.012565735,0.0001406815,0.000010506271,0.00009830215],"about_ca_topic_score_codex":0.000116704556,"about_ca_topic_score_gemma":0.000053895852,"teacher_disagreement_score":0.124864854,"about_ca_system_score_codex":0.000007649136,"about_ca_system_score_gemma":0.000017242459,"threshold_uncertainty_score":0.40694642},"labels":[],"label_agreement":null},{"id":"W4379649312","doi":"10.1136/annrheumdis-2023-eular.4556","title":"POS1607 BIOLOGICS THERAPIES FOR PSORIASIS DECREASE FUTURE RISK FOR DEVELOPING PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; University Health Network Foundation; Krembil Foundation; Arthritis Society; National Psoriasis Foundation","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Ustekinumab; Arthritis; Immunology; Adalimumab; Rheumatoid arthritis","score_opus":0.045186304967485644,"score_gpt":0.2937621905716569,"score_spread":0.24857588560417126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615194,0.028630441,0.00035122567,0.0028468978,0.002134123,0.0013280641,0.0030079759,0.0001645529,0.000017274388],"genre_scores_gemma":[0.9725345,0.024170268,0.00080909085,0.0003515253,0.00015346738,0.00081159873,0.000645785,0.00004115761,0.00048262737],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854106,0.00024862375,0.0004406786,0.00027745392,0.000054459048,0.00043772836],"domain_scores_gemma":[0.9975998,0.0013871448,0.00037979375,0.00041607203,0.00017468493,0.000042546802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039159477,0.00025719925,0.0004877965,0.000113088616,0.00048182483,0.000021249496,0.00039103406,0.00016291843,0.00006187773],"category_scores_gemma":[0.001456757,0.00016430992,0.0005571088,0.00029141188,0.00013741906,0.000076345714,0.00007570003,0.000050554754,0.000052639043],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075170846,0.0002379229,0.0038832477,0.00034101502,0.0026172572,7.4297793e-7,0.0010153591,0.00001651539,0.00029245895,0.0053246706,0.030192297,0.9553268],"study_design_scores_gemma":[0.01959268,0.0018379,0.52314514,0.002649036,0.0038573886,0.000026304633,0.010227513,0.00018511563,0.05777478,0.28889504,0.08958656,0.0022225112],"about_ca_topic_score_codex":0.000031871623,"about_ca_topic_score_gemma":0.000022128486,"teacher_disagreement_score":0.9531043,"about_ca_system_score_codex":0.000011640582,"about_ca_system_score_gemma":0.000141416,"threshold_uncertainty_score":0.67003644},"labels":[],"label_agreement":null},{"id":"W4379649390","doi":"10.1136/annrheumdis-2023-eular.2581","title":"POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psoriatic arthritis; Enthesitis; Psoriasis; Internal medicine; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Post-hoc analysis; Arthritis; Placebo; Dermatology; Gastroenterology; Pathology","score_opus":0.019944587159781375,"score_gpt":0.28119453567197605,"score_spread":0.2612499485121947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598783,0.0020807735,6.996708e-7,0.00007691537,0.000037515354,0.00074499374,0.0010315622,0.00003565095,0.000004052374],"genre_scores_gemma":[0.9989142,0.00060241594,0.000007750811,0.000015204745,0.0000025222823,0.000084115236,0.00010916637,0.00002566598,0.00023899614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726534,0.0013623206,0.00052173686,0.00033020903,0.00018109704,0.0003392842],"domain_scores_gemma":[0.9978599,0.00095943897,0.00048325918,0.0004915319,0.00016696256,0.000038923845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036819474,0.00025593102,0.0007898273,0.0004383229,0.000115006726,0.000026848806,0.00024775474,0.00008536792,0.000044249045],"category_scores_gemma":[0.000341316,0.00017552034,0.00019774595,0.0012923094,0.00023112328,0.00017010389,0.00007839493,0.00007135369,0.000014909302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02136096,0.002833142,0.9078224,0.000041402818,0.007041806,0.00005824522,0.0065408316,0.0000059507456,0.00010337666,0.0000034273858,0.000035024852,0.05415349],"study_design_scores_gemma":[0.008937105,0.0050168703,0.98172265,0.0004614303,0.0019809229,0.0000025435634,0.00054477586,8.6786747e-7,0.0011203289,0.000021570842,0.0000019452877,0.0001890161],"about_ca_topic_score_codex":0.0009419576,"about_ca_topic_score_gemma":0.00038034393,"teacher_disagreement_score":0.07390028,"about_ca_system_score_codex":0.00002137526,"about_ca_system_score_gemma":0.00008637942,"threshold_uncertainty_score":0.7157512},"labels":[],"label_agreement":null},{"id":"W4379649489","doi":"10.1136/annrheumdis-2023-eular.2513","title":"POS1539 SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGICS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Leeds Biomedical Research Centre; University of Leeds; Genentech; Griffith University; Janssen Scientific Affairs; McGill University; University of Ottawa; Celgene; Gilead Sciences; University of Washington; Eli Lilly and Company; GlaxoSmithKline; Ottawa Hospital Research Institute; Amgen","keywords":"Medicine; Psoriatic arthritis; Adverse effect; Internal medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Rheumatology; Ustekinumab; Clinical endpoint; Tolerability; Randomized controlled trial; Gastroenterology; Adalimumab; Arthritis; Rheumatoid arthritis; Immunology","score_opus":0.02439458694575209,"score_gpt":0.2758261132775698,"score_spread":0.2514315263318177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949457,0.0013450029,7.4007664e-7,0.00062426337,0.00007904393,0.00088944443,0.0020888592,0.000020221527,0.000006746305],"genre_scores_gemma":[0.9990057,0.0006903982,0.000010165203,0.000054208824,0.0000043985387,0.000024717367,0.00015415685,0.000009659547,0.000046617242],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981109,0.00090215175,0.00044928124,0.00024960304,0.00007370275,0.00021439065],"domain_scores_gemma":[0.99703777,0.002249669,0.00022285989,0.00037563636,0.000080762075,0.00003330831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005326354,0.00016473359,0.00039411816,0.0000916697,0.00011216364,0.000010746813,0.00020041992,0.000052854906,0.00002018004],"category_scores_gemma":[0.001955722,0.00008770229,0.000048771137,0.00042012928,0.00016998127,0.000045690107,0.00013212468,0.000058937298,0.000015744688],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10430887,0.003753066,0.24868749,0.000049900522,0.0017361477,0.0000078228395,0.013475646,0.00005100339,0.00031456712,0.00005744631,0.0014068139,0.6261512],"study_design_scores_gemma":[0.01465438,0.0016492688,0.9811858,0.00039468752,0.00012699897,4.263581e-7,0.001150832,0.0000029533712,0.00048975303,0.00015900408,0.00007872936,0.000107189284],"about_ca_topic_score_codex":0.00024448452,"about_ca_topic_score_gemma":0.00006315291,"teacher_disagreement_score":0.7324983,"about_ca_system_score_codex":0.0000057717175,"about_ca_system_score_gemma":0.000047381902,"threshold_uncertainty_score":0.35763958},"labels":[],"label_agreement":null},{"id":"W4379649641","doi":"10.1136/annrheumdis-2023-eular.2523","title":"POS1522 CHANGES IN SERUM CYTOKINES BY WEEK 24 CORRELATE WITH LONG-TERM EFFICACY OF GUSELKUMAB THROUGH 2-YEARS IN BIO-NAÏVE ADULTS WITH PSA","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Sun Pharma; Genentech; Celgene; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Psoriasis; Psoriasis Area and Severity Index; Immunology; Biomarker; Arthritis; Cytokine; Gastroenterology; C-reactive protein; Placebo; Inflammation; Pathology","score_opus":0.027363049130723238,"score_gpt":0.26097349458910146,"score_spread":0.23361044545837822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933648,0.004789139,0.000001170154,0.00063410396,0.0001705788,0.00048838987,0.0004741315,0.00004256223,0.000035104153],"genre_scores_gemma":[0.99645823,0.0027660823,0.000008889594,0.000055808432,0.0000048527604,0.00005818141,0.0001996948,0.000025252699,0.0004229931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987357,0.00020416074,0.00034022616,0.0002662005,0.00009222136,0.00036143782],"domain_scores_gemma":[0.9988574,0.00036493927,0.00028656423,0.0004139277,0.000052743613,0.000024459263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011334022,0.00023666788,0.0005050889,0.00016112385,0.000049809794,0.000007788837,0.00033033258,0.000103131075,0.00008353456],"category_scores_gemma":[0.0000870405,0.00014556487,0.000101317135,0.00062237843,0.00025448608,0.000098287775,0.00008953793,0.000086040396,0.000043670563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070420364,0.0032115902,0.9122804,0.0009041191,0.0019911616,0.00007750548,0.00736642,0.00024527882,0.0010395761,0.00010524838,0.004089745,0.061646964],"study_design_scores_gemma":[0.004311871,0.0006141726,0.9826728,0.002472084,0.0001839567,0.000009946279,0.0005276411,0.0000044856706,0.008889152,0.00009291061,0.000026890604,0.00019406981],"about_ca_topic_score_codex":0.0002998065,"about_ca_topic_score_gemma":0.0006392311,"teacher_disagreement_score":0.07039247,"about_ca_system_score_codex":0.000011614906,"about_ca_system_score_gemma":0.000060550254,"threshold_uncertainty_score":0.59359634},"labels":[],"label_agreement":null},{"id":"W4379649688","doi":"10.1136/annrheumdis-2023-eular.1917","title":"POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"UCB Pharma; Sun Pharma; National Institute for Health and Care Research; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Dermatology; Disease; Internal medicine","score_opus":0.05197030421202719,"score_gpt":0.35482728047167206,"score_spread":0.30285697625964486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379649688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369514,0.003991961,0.00004281355,0.00004637455,0.0005186256,0.0004592748,0.0011505065,0.00008309554,0.00001221955],"genre_scores_gemma":[0.99191743,0.006741939,0.00016702927,0.000021600965,0.000018442279,0.0000538339,0.00094195316,0.000021219552,0.00011656933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683136,0.00074268423,0.0012328259,0.00061407115,0.00011982579,0.0004592208],"domain_scores_gemma":[0.9979455,0.0007498006,0.00043807706,0.00053340767,0.00024276675,0.000090435555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007839623,0.00035190402,0.0014504492,0.000545734,0.00014826277,0.000010373167,0.0001859767,0.00021184384,0.00018220404],"category_scores_gemma":[0.0003234682,0.00025624927,0.00027579925,0.0020834191,0.000610604,0.0001838393,0.00014230287,0.0001439665,0.000017349825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008758662,0.0033765153,0.5583584,0.00015215158,0.0143351685,0.00015379972,0.011626123,0.0002472338,0.0006834593,0.00038697268,0.00025864693,0.4016629],"study_design_scores_gemma":[0.03104331,0.004414023,0.91280293,0.00039505173,0.008800039,0.000009722471,0.037769623,0.00045823035,0.002809128,0.00013333141,0.0005915847,0.0007730078],"about_ca_topic_score_codex":0.00060173584,"about_ca_topic_score_gemma":0.00567632,"teacher_disagreement_score":0.40088987,"about_ca_system_score_codex":0.0000544602,"about_ca_system_score_gemma":0.00008420741,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4379650502","doi":"10.1136/annrheumdis-2023-eular.1709","title":"AB1086 COVID-19–RELATED ADVERSE EVENTS IN THE PHASE 3 POETYK TRIALS OF THE ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Janssen Research and Development; Universidade Federal de Uberlândia; McGill University; Bristol-Myers Squibb; University of Washington; Monash University","keywords":"Medicine; Adverse effect; Psoriasis; Allosteric regulation; Plaque psoriasis; Coronavirus disease 2019 (COVID-19); Tyrosine kinase; Dermatology; Virology; Internal medicine; Receptor","score_opus":0.05191540164228455,"score_gpt":0.31396138099783727,"score_spread":0.26204597935555274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379650502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431443,0.00044715698,0.000002309517,0.0020525632,0.00031254487,0.0015275208,0.0012925594,0.000024230989,0.000026673288],"genre_scores_gemma":[0.99873614,0.00015819214,0.0000069618504,0.0005455069,0.0000060065167,0.00015404621,0.00023630922,0.00001992292,0.00013691578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963316,0.0019204227,0.00094427314,0.00027527582,0.00017779903,0.0003506367],"domain_scores_gemma":[0.9976781,0.0009705294,0.00057806005,0.00063796405,0.000078170386,0.0000571826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010280827,0.00027412066,0.0006830613,0.00020045259,0.0001614054,0.000006042794,0.00059790886,0.00011967221,0.00013585118],"category_scores_gemma":[0.0015750481,0.0001332348,0.00030892435,0.0010002886,0.00013684593,0.000100241494,0.00016509344,0.0001095039,0.00003951941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06329708,0.02464245,0.72142804,0.001766726,0.0076072165,0.000066156856,0.036768712,0.013203242,0.0036643688,0.0011872031,0.021635408,0.10473342],"study_design_scores_gemma":[0.033579633,0.00085298077,0.94726485,0.0016716954,0.00075577263,0.0000073518445,0.0017002774,0.000043801814,0.010472854,0.0028945808,0.00027521214,0.00048098966],"about_ca_topic_score_codex":0.00020851176,"about_ca_topic_score_gemma":0.00007379594,"teacher_disagreement_score":0.22583684,"about_ca_system_score_codex":0.00003205766,"about_ca_system_score_gemma":0.00017694345,"threshold_uncertainty_score":0.54331577},"labels":[],"label_agreement":null},{"id":"W4379794110","doi":"10.1136/annrheumdis-2023-eular.515","title":"AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; McGill University","funders":"Bundesministerium für Bildung und Forschung; Janssen Scientific Affairs; Jazz Pharmaceuticals; Celgene; Novavax; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Psoriatic arthritis; Quality of life (healthcare); Visual analogue scale; Dermatology Life Quality Index; Physical therapy; Psoriasis; Internal medicine; Ustekinumab; Placebo; Disease; Dermatology; Adalimumab; Alternative medicine","score_opus":0.03441002239376385,"score_gpt":0.3097852246297757,"score_spread":0.27537520223601186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379794110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906066,0.006965913,0.0000028424724,0.0010110624,0.00031831843,0.00082091615,0.00022375966,0.00003787585,0.000012717255],"genre_scores_gemma":[0.9955112,0.004049728,0.000012285812,0.00020268133,0.0000058048436,0.00008363893,0.00003596687,0.000015461252,0.0000832305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99719155,0.00057332247,0.0015112187,0.0003192099,0.00010448124,0.00030022732],"domain_scores_gemma":[0.9972382,0.0013373727,0.0007563452,0.00046326497,0.000117984804,0.00008678407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069799146,0.00021047295,0.0007728422,0.0001228893,0.00008696905,0.0000130228955,0.00017004716,0.00009625766,0.000031190688],"category_scores_gemma":[0.0042050844,0.00014042301,0.00027329059,0.00018525163,0.00041184726,0.000089646266,0.00015563736,0.00008088945,0.0000052967353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011396725,0.0006793295,0.5975273,0.0002275378,0.0011212326,0.000014583478,0.00038158405,0.0000035454495,0.0000640669,0.00015622814,0.0004782022,0.39820668],"study_design_scores_gemma":[0.005912512,0.0004652581,0.98908806,0.00049314846,0.00039684164,0.0000018739726,0.0005565403,0.00004829372,0.00016322288,0.0026690038,0.000056435587,0.00014883009],"about_ca_topic_score_codex":0.00006154977,"about_ca_topic_score_gemma":0.000011375385,"teacher_disagreement_score":0.39805788,"about_ca_system_score_codex":0.0000053924978,"about_ca_system_score_gemma":0.00013155934,"threshold_uncertainty_score":0.57262844},"labels":[],"label_agreement":null},{"id":"W4379794924","doi":"10.1136/annrheumdis-2023-eular.2516","title":"AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Saskatchewan","funders":"","keywords":"Dactylitis; Medicine; Psoriatic arthritis; Dermatology Life Quality Index; Enthesitis; Quality of life (healthcare); Internal medicine; Population; Physical therapy; Clinical endpoint; Visual analogue scale; Clinical trial; Arthritis; Disease","score_opus":0.058408884931000146,"score_gpt":0.3587095173051938,"score_spread":0.30030063237419363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379794924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947929,0.0025338116,0.000001105707,0.00006639853,0.00012368601,0.0011200439,0.0013309321,0.000026141573,0.0000049769596],"genre_scores_gemma":[0.9982499,0.0012561881,0.000005587939,0.000026434256,0.000002879968,0.00005777092,0.00034404846,0.000016167918,0.000041054696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959263,0.0011350622,0.00215238,0.00029663945,0.00021147831,0.00027811198],"domain_scores_gemma":[0.99665016,0.0006529883,0.0017399393,0.00065085304,0.00025106355,0.00005499376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067106367,0.00020853111,0.0014940553,0.00024691722,0.00004745334,0.000004245836,0.00032505044,0.00010560655,0.000112014066],"category_scores_gemma":[0.00058343774,0.00014819755,0.00050168706,0.0010641703,0.00027342624,0.00008782137,0.00009830503,0.000079696954,0.0000107397855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003649506,0.009807083,0.9123126,0.0002529752,0.00983753,0.0000023886703,0.0025553512,0.000017874287,0.00006241025,0.00001650196,0.0000595176,0.06142624],"study_design_scores_gemma":[0.011572458,0.007452204,0.9782743,0.0004922594,0.0011093444,1.5961736e-7,0.0005219135,0.0000035556889,0.00039111672,0.00006910666,3.3283334e-7,0.00011326638],"about_ca_topic_score_codex":0.0038458076,"about_ca_topic_score_gemma":0.0004038758,"teacher_disagreement_score":0.06596167,"about_ca_system_score_codex":0.000015324,"about_ca_system_score_gemma":0.00019979637,"threshold_uncertainty_score":0.60433203},"labels":[],"label_agreement":null},{"id":"W4379795143","doi":"10.1136/annrheumdis-2023-eular.1533","title":"AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Manchester Biomedical Research Centre; Sanofi Genzyme; LEO Pharma; Astellas Pharma; Eisai; University of Glasgow; Genentech; University of Oxford; National Institute for Health and Care Research; Glenmark Pharmaceuticals; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Pfizer; Icahn School of Medicine at Mount Sinai; Biogen; University of Rochester; Incyte; Prothena; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Galderma; University of Manchester; XBiotech; Brigham and Women's Hospital; Kyowa Hakko Kirin; Sanofi; Celgene; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Johns Hopkins University; Amgen","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology","score_opus":0.04608898550564392,"score_gpt":0.31764476655338014,"score_spread":0.2715557810477362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379795143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864662,0.0040950985,4.8625014e-7,0.0028268164,0.00056383613,0.0006613369,0.0049371663,0.00015646496,0.0002925543],"genre_scores_gemma":[0.99672955,0.0016206733,0.000022078024,0.00023521039,0.000039051683,0.00019213697,0.00073917187,0.000023632363,0.00039852218],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980086,0.00061990676,0.0005585711,0.00030687178,0.000102696446,0.0004033536],"domain_scores_gemma":[0.99768317,0.0011365515,0.00028577205,0.0007675666,0.00008643637,0.00004048551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004404391,0.00023358336,0.00038034236,0.000086960164,0.00019213148,0.000026897795,0.0006088147,0.00013779543,0.00013837116],"category_scores_gemma":[0.0009076447,0.00013583113,0.00024020256,0.00062092434,0.0002479041,0.00009580373,0.0001383534,0.00012973347,0.0004798298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064670932,0.0055114324,0.022548225,0.00020323729,0.003660222,0.000045940564,0.0063959034,0.00007620096,0.002339956,0.0019117177,0.29930398,0.6515361],"study_design_scores_gemma":[0.029974217,0.0009276437,0.84229964,0.0024917743,0.0011531791,0.000006701703,0.0069948267,0.0000793612,0.04259832,0.010145092,0.06227562,0.0010536356],"about_ca_topic_score_codex":0.00031906023,"about_ca_topic_score_gemma":0.00009546504,"teacher_disagreement_score":0.8197514,"about_ca_system_score_codex":0.000011914366,"about_ca_system_score_gemma":0.00013993059,"threshold_uncertainty_score":0.6167401},"labels":[],"label_agreement":null},{"id":"W4379797691","doi":"10.1136/annrheumdis-2023-eular.3412","title":"AB1105 LONG-TERM SAFETY OF IXEKIZUMAB TREATMENT IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: A POST-HOC ANALYSIS OF END-OF-STUDY PROGRAM DATA RELATING TO MAJOR ADVERSE CARDIOVASCULAR EVENTS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Memorial University of Newfoundland","funders":"Agencia Estatal de Investigación; Sanofi Genzyme; Bausch Health; Sanofi; Kyowa Hakko Kirin; Celltrion; Galderma; XBiotech; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Castle Biosciences; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Helsinn; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Helsinn Therapeutics; Amgen","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Psoriasis; Post-hoc analysis; Arthritis; Adverse effect; Dermatology; Internal medicine; Secukinumab","score_opus":0.028858596229654143,"score_gpt":0.2903887033458657,"score_spread":0.26153010711621155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379797691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98859024,0.0033927436,0.000002854197,0.000033602533,0.0002226801,0.0024396745,0.0052746735,0.000034535842,0.0000089926725],"genre_scores_gemma":[0.9960039,0.0015424284,0.0000839334,0.0000066352977,0.000008102414,0.00024061036,0.0020377333,0.000027171613,0.00004944802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968734,0.00071396213,0.0012038964,0.00049934647,0.0003149368,0.00039447795],"domain_scores_gemma":[0.99695355,0.00039357095,0.0006872991,0.0015836643,0.00032042566,0.00006146741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041729436,0.00034395495,0.0015093928,0.0005468962,0.00010048108,0.0000052703663,0.0006233419,0.00010441221,0.00010048737],"category_scores_gemma":[0.00055711775,0.00022507542,0.0006883605,0.0016995826,0.00015019224,0.00016143156,0.0002885815,0.00006133332,0.000012189887],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061651664,0.005226774,0.4194433,0.00024239295,0.023646966,0.000016809774,0.0018035667,0.00035179433,0.000013011019,0.000009391084,0.000028672752,0.54305214],"study_design_scores_gemma":[0.009938043,0.0032987061,0.97678196,0.0014609356,0.006974129,0.0000018849347,0.0009677835,0.000016884605,0.00031581116,0.0000103388975,0.000016242586,0.00021728249],"about_ca_topic_score_codex":0.0011526693,"about_ca_topic_score_gemma":0.002132996,"teacher_disagreement_score":0.55733865,"about_ca_system_score_codex":0.000036324975,"about_ca_system_score_gemma":0.00019710748,"threshold_uncertainty_score":0.91783094},"labels":[],"label_agreement":null},{"id":"W4379797826","doi":"10.1136/annrheumdis-2023-eular.3238","title":"AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Sanofi Genzyme; Bausch Health; Agencia Estatal de Investigación; Memorial University of Newfoundland; Sanofi; Kyowa Hakko Kirin; Celltrion; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Castle Biosciences; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Helsinn; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Galderma; XBiotech; Brigham and Women's Hospital; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Helsinn Therapeutics; Amgen","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Internal medicine; Placebo; Rheumatology; Ustekinumab; Clinical endpoint; Post-hoc analysis; Randomized controlled trial; Psoriasis; Enthesitis; Arthritis; Physical therapy; Disease; Immunology; Adalimumab; Pathology; Alternative medicine","score_opus":0.01370864123754903,"score_gpt":0.2778400634311458,"score_spread":0.26413142219359675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379797826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107724,0.0002317476,0.000043648033,0.000018720519,0.00014897021,0.00523648,0.0031509672,0.00007684447,0.00001540022],"genre_scores_gemma":[0.9973033,0.00015958655,0.000006840015,0.000010472043,0.000014156829,0.0008154822,0.001335735,0.000031093346,0.00032334778],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963117,0.0013205033,0.0010657938,0.00059466314,0.00019000875,0.0005172881],"domain_scores_gemma":[0.9968884,0.0013574627,0.00078571367,0.00052795804,0.00035184433,0.000088650355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012541352,0.00042982784,0.0028383366,0.00081029494,0.00012723365,0.000017675025,0.00019383754,0.0001677401,0.0002819645],"category_scores_gemma":[0.000276935,0.00031906512,0.0005872241,0.0013833678,0.0002222647,0.000112357346,0.00008638037,0.00013946505,0.000037333142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8430857,0.0068724165,0.12248705,0.000015235556,0.018378424,0.00007309196,0.0014527999,0.00008565138,0.0013198985,0.0000071953436,0.0000065472204,0.0062160045],"study_design_scores_gemma":[0.72685164,0.0020550792,0.2622252,0.000031833028,0.0071963565,4.331462e-7,0.00032159674,0.0002306785,0.00085682713,0.0000013224,0.00000277583,0.00022625257],"about_ca_topic_score_codex":0.00062792434,"about_ca_topic_score_gemma":0.002452785,"teacher_disagreement_score":0.13973816,"about_ca_system_score_codex":0.00017313345,"about_ca_system_score_gemma":0.00010232689,"threshold_uncertainty_score":0.99992615},"labels":[],"label_agreement":null},{"id":"W4379800822","doi":"10.1136/annrheumdis-2023-eular.1426","title":"AB1110 EXPLORING LEVELS OF PROTEIN BIOMARKERS IN RESPONSE TO TREATMENT FOR PSORIASIS AND PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; University of Toronto; Krembil Foundation","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; CXCL10; MMP3; Internal medicine; Arthritis; Gastroenterology; Immunology; Chemokine; Inflammation","score_opus":0.07503542969847594,"score_gpt":0.28256518830602984,"score_spread":0.2075297586075539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379800822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964068,0.0010967281,0.000046743942,0.00046219036,0.0003525015,0.0012736382,0.00020344077,0.00008329217,0.000074677504],"genre_scores_gemma":[0.9950494,0.00029607015,0.00086667103,0.000013796016,0.000018570856,0.0016150407,0.00003105255,0.000021099891,0.0020883032],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987524,0.00019908823,0.00033144545,0.00033442848,0.000028808152,0.0003538225],"domain_scores_gemma":[0.99919933,0.0004623186,0.000057384947,0.00021613509,0.000030796626,0.000034036206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048560745,0.00019217686,0.0003699087,0.00044735603,0.00008045256,0.000008180747,0.000077648896,0.00012248717,0.00009596348],"category_scores_gemma":[0.0001814956,0.00016260502,0.00009075529,0.00041116084,0.000044198525,0.00007694467,0.000039217928,0.00002749179,0.00010505932],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943793,0.00012803386,0.0010871681,0.000025980886,0.00044943916,0.000011642287,0.001660866,0.0000037615616,0.41467592,0.0002434239,0.00011116483,0.57765883],"study_design_scores_gemma":[0.014852463,0.002872794,0.13285826,0.0002527703,0.00011743329,0.000013825997,0.0021270276,0.000008824223,0.8332974,0.0004786138,0.012682389,0.0004382365],"about_ca_topic_score_codex":0.0001654948,"about_ca_topic_score_gemma":0.0002723651,"teacher_disagreement_score":0.57722056,"about_ca_system_score_codex":0.00007024823,"about_ca_system_score_gemma":0.00005221555,"threshold_uncertainty_score":0.66308403},"labels":[],"label_agreement":null},{"id":"W4379802255","doi":"10.1136/annrheumdis-2023-eular.3015","title":"AB1103 UPADACITINIB REAL-LIFE EFFICACY AND SAFETY IN PSORIATIC ARTHRITIS: RESULTS AT 24 WEEKS OF A MULTICENTRIC ITALIAN STUDY (UP-REAL)","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Brigham and Women's Hospital; McGill University; Drexel University; College of Medicine, Drexel University; University of Washington; Université de Genève; University of Glasgow; Janssen Scientific Affairs","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology","score_opus":0.0435757214384568,"score_gpt":0.2966996287833561,"score_spread":0.2531239073448993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379802255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922614,0.0046872776,2.5459076e-7,0.00042420777,0.00050776737,0.0009772669,0.00087130646,0.000056089168,0.00021443523],"genre_scores_gemma":[0.98794657,0.010861178,0.000003916048,0.000025864267,0.000010571086,0.000059472783,0.00016665332,0.000019648587,0.0009061023],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976133,0.00063805823,0.00090782915,0.0003360097,0.00012172714,0.00038303752],"domain_scores_gemma":[0.9976649,0.0011713597,0.00044910877,0.0005736765,0.000072158364,0.00006877944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004929926,0.00024519127,0.0006680605,0.00021602486,0.00016348065,0.000010302245,0.00029378105,0.00010516855,0.000070588205],"category_scores_gemma":[0.0012337675,0.00017803295,0.00017821079,0.00054532365,0.00020098737,0.000078096564,0.00022199495,0.00007376017,0.00008453367],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023375731,0.012674947,0.29928464,0.0017737058,0.007829446,0.000096787786,0.038775746,0.0003744428,0.0021954721,0.0011201068,0.02445325,0.5880457],"study_design_scores_gemma":[0.011021457,0.00039211908,0.9831342,0.00079182955,0.00031154364,0.0000037987209,0.0027848214,0.000027201875,0.0010477519,0.00017861906,0.00010840751,0.0001982295],"about_ca_topic_score_codex":0.00082365406,"about_ca_topic_score_gemma":0.00034930903,"teacher_disagreement_score":0.6838496,"about_ca_system_score_codex":0.00001910307,"about_ca_system_score_gemma":0.00008231081,"threshold_uncertainty_score":0.72599727},"labels":[],"label_agreement":null},{"id":"W4380149197","doi":"10.1016/j.jval.2023.03.2280","title":"SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Medicine; Meta-analysis; Systematic review; Internal medicine; Arthritis; Oncology; MEDLINE; Biology","score_opus":0.049348241419072084,"score_gpt":0.28872810596136006,"score_spread":0.239379864542288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149197","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4866217,0.51072097,0.0000051574975,0.000071054244,0.00009854083,0.001867343,0.0005815667,0.000023614493,0.000010019522],"genre_scores_gemma":[0.978869,0.019484999,0.00010319087,0.00005230633,0.0000064417945,0.00025307643,0.0011988244,0.000010752524,0.00002140979],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.99373096,0.0045755445,0.0009010473,0.0004145326,0.000070531656,0.00030737178],"domain_scores_gemma":[0.99717706,0.001901432,0.00046608955,0.0003573693,0.00006973163,0.000028307139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001965625,0.0002299398,0.0028171318,0.00032366056,0.0000610821,0.000008787322,0.00010166227,0.00012270115,0.000011807756],"category_scores_gemma":[0.00011882429,0.00015485348,0.00019741514,0.0022764567,0.000045872366,0.000062736,0.000032117325,0.00015754727,0.00001988528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01191118,0.0029666948,0.19686833,0.30399638,0.42477703,0.00016907435,0.028026294,0.025197117,0.00004608577,0.0014711677,0.0011924624,0.003378194],"study_design_scores_gemma":[0.015149216,0.0013904094,0.83034503,0.08385826,0.06773216,0.000006592015,0.00021080066,0.00014833249,0.00007606196,0.00051253184,0.000022205582,0.00054838735],"about_ca_topic_score_codex":0.0011084216,"about_ca_topic_score_gemma":0.00034909387,"teacher_disagreement_score":0.63347673,"about_ca_system_score_codex":0.000063352934,"about_ca_system_score_gemma":0.000062209285,"threshold_uncertainty_score":0.6314742},"labels":[],"label_agreement":null},{"id":"W4380149593","doi":"10.1016/j.jval.2023.03.719","title":"EE418 Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health; Bausch Health (Canada); Health Canada","funders":"","keywords":"Tazarotene; Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.026973085544685683,"score_gpt":0.28754943763129465,"score_spread":0.26057635208660895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380149593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383914,0.00057511474,0.00020475402,0.00018890797,0.0001185631,0.002508169,0.0025350717,0.000021736847,0.000008536373],"genre_scores_gemma":[0.9984082,0.00008382845,0.00032824805,0.000061524,0.000004910783,0.0004158694,0.00066418987,0.000019533865,0.0000137262705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981673,0.00046762827,0.00050624774,0.00040446312,0.00007470846,0.00037969492],"domain_scores_gemma":[0.9986546,0.0005232028,0.00017412679,0.00024845146,0.00033670233,0.00006288314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003826265,0.00020247871,0.0010571298,0.00081038766,0.00008430897,0.0000047990943,0.00011385966,0.00012814393,0.000009283546],"category_scores_gemma":[0.00012687499,0.00017572241,0.00008481286,0.0013655963,0.000046382986,0.000041093106,0.00004461083,0.00007742242,0.0000038256458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020302722,0.00030114755,0.8378775,0.00091230305,0.0011878564,0.000003921337,0.009001224,0.11023468,0.00067426945,0.00014804961,0.00009562977,0.019260658],"study_design_scores_gemma":[0.012614167,0.0027682793,0.97222465,0.0006569848,0.00037286014,9.519315e-7,0.0014562603,0.0006576269,0.0086251255,0.00002929099,0.00029061834,0.0003032039],"about_ca_topic_score_codex":0.045002617,"about_ca_topic_score_gemma":0.056316208,"teacher_disagreement_score":0.1343471,"about_ca_system_score_codex":0.00030299815,"about_ca_system_score_gemma":0.00036704398,"threshold_uncertainty_score":0.9613568},"labels":[],"label_agreement":null},{"id":"W4380422753","doi":"10.1177/03000605231175547","title":"Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?","year":2023,"lang":"en","type":"review","venue":"Journal of International Medical Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; McMaster University","funders":"","keywords":"Medicine; Psoriasis; Narrative review; Biologic Agents; Intensive care medicine; Immunology; Rheumatoid arthritis","score_opus":0.25892662480568884,"score_gpt":0.4807571631060314,"score_spread":0.22183053830034255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380422753","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047685808,0.9882583,0.000026964412,0.00069139444,0.008967482,0.0008702596,0.00051858637,0.000043999786,0.00014613167],"genre_scores_gemma":[0.00020943687,0.99180067,0.0000594995,0.00006894147,0.0013282545,0.0002919102,0.00031315567,0.00010242685,0.0058257002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99393845,0.0016990479,0.0021108985,0.0004916238,0.000954414,0.0008055561],"domain_scores_gemma":[0.9908777,0.005718925,0.0014408153,0.00042310503,0.0013656502,0.00017379125],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0067904918,0.0004891455,0.0021720836,0.0012942891,0.00028323228,0.00008148385,0.002710475,0.0013416853,0.002327907],"category_scores_gemma":[0.013860762,0.0002744001,0.0014126113,0.00042061534,0.00031806054,0.00013170253,0.00053381594,0.0019248477,0.0013298868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091544737,0.0004483119,0.00003125944,0.001796783,0.007990003,0.00042657842,0.000075728014,3.1691113e-7,0.000015226145,0.00024640598,0.026833389,0.96122056],"study_design_scores_gemma":[0.00213535,0.0006548867,0.00021432436,0.021456927,0.00055225595,0.00078310206,0.00011529909,0.0000015077984,0.000030296278,0.000515532,0.97329116,0.00024934384],"about_ca_topic_score_codex":0.000041869473,"about_ca_topic_score_gemma":0.000030450241,"teacher_disagreement_score":0.9609712,"about_ca_system_score_codex":0.0005072556,"about_ca_system_score_gemma":0.0016275683,"threshold_uncertainty_score":0.9999708},"labels":[],"label_agreement":null},{"id":"W4380536337","doi":"10.37766/inplasy2023.6.0040","title":"Risk for HBV reactivation in psoriasis patients treated with cytokine inhibitors: A Systematic Review and Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Population; Meta-analysis; Hepatitis B; Cytokine; Internal medicine; Hepatitis B virus; Randomized controlled trial; Clinical trial; Immunology; Relative risk; Confidence interval; Virus; Environmental health","score_opus":0.06280383660663721,"score_gpt":0.30192272932934505,"score_spread":0.23911889272270784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380536337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000428724,0.9906718,0.00001438928,0.0000155866,0.000048036094,0.007600972,0.001467723,0.00009635078,0.000042254207],"genre_scores_gemma":[0.000039587216,0.9848364,0.000056065,0.000028499055,0.000011480677,0.0064964565,0.0051442375,0.00006952735,0.0033177354],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960698,0.0012231756,0.0014931133,0.00079437473,0.000070466114,0.00034907815],"domain_scores_gemma":[0.99665153,0.0011340667,0.0014002363,0.00062306144,0.0001601506,0.00003097297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082677265,0.000754372,0.009433907,0.00087640464,0.00011560688,0.00002421228,0.00018152494,0.000530523,0.00011591254],"category_scores_gemma":[0.00035198772,0.0003989391,0.0019153471,0.0018756295,0.000043132626,0.000098319164,0.000049215785,0.00019834736,0.00011235205],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037833943,0.00020651377,0.00010809621,0.5269306,0.46235654,0.0000031549848,0.000033179276,1.3801863e-7,2.6178228e-7,0.000016308315,0.00032577757,0.009981616],"study_design_scores_gemma":[0.0008369133,0.000189251,0.000028557744,0.01977573,0.9674712,0.0000055790556,0.00001138566,1.5476307e-7,0.000007251249,0.0000043476443,0.011257035,0.0004126133],"about_ca_topic_score_codex":0.0002887502,"about_ca_topic_score_gemma":0.00030611557,"teacher_disagreement_score":0.5071548,"about_ca_system_score_codex":0.00012280289,"about_ca_system_score_gemma":0.000055512075,"threshold_uncertainty_score":0.9998462},"labels":[],"label_agreement":null},{"id":"W4380686487","doi":"10.1177/2050313x231180775","title":"Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Medicine; Acrodermatitis; Dermatology; Malignancy; Psoriatic arthritis; Generalized pustular psoriasis; Psoriasis; Internal medicine; Pathology; Alternative medicine","score_opus":0.02134483614009477,"score_gpt":0.2945751951857203,"score_spread":0.27323035904562554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380686487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284595,0.0016175209,0.000032261934,0.00019610154,0.00038630716,0.00082094956,0.0001183664,0.000063222484,0.0039193467],"genre_scores_gemma":[0.992914,0.00030890992,0.00016191609,0.000021511665,0.000030944168,0.0001491378,0.00041489105,0.000028906992,0.0059697707],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99762654,0.00023584499,0.0010688151,0.0005119581,0.00017557453,0.0003812467],"domain_scores_gemma":[0.9979759,0.00025276293,0.00073968974,0.00078191387,0.00012995776,0.00011977259],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081644795,0.0002733127,0.0008653341,0.00013345407,0.0001658459,0.00001847793,0.00013271451,0.0002931336,0.0023076138],"category_scores_gemma":[0.00021717868,0.00018804401,0.00016115779,0.00037881974,0.0003489152,0.00013035677,0.00017895523,0.0001002769,0.000047026027],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016992197,0.00039455105,0.009604103,0.000043620905,0.0006914418,0.8845692,0.00082988077,9.396015e-7,0.0005500661,0.0000099281815,0.0007894622,0.10234685],"study_design_scores_gemma":[0.0024851358,0.00065288827,0.0014513925,0.00018170713,0.00039012745,0.9573375,0.00085252326,0.0000024403007,0.023543525,0.000024978133,0.012880622,0.000197188],"about_ca_topic_score_codex":0.008200242,"about_ca_topic_score_gemma":0.0036390263,"teacher_disagreement_score":0.102149665,"about_ca_system_score_codex":0.00005338018,"about_ca_system_score_gemma":0.0004574725,"threshold_uncertainty_score":0.9986044},"labels":[],"label_agreement":null},{"id":"W4380988690","doi":"10.1177/2050313x231181035","title":"The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature","year":2023,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Psoriasis; Medicine; Immune system; Cancer; Melanoma; Adverse effect; Interleukin; Skin cancer; Immunology; Dermatology; Oncology; Internal medicine; Cytokine; Cancer research","score_opus":0.012930162217498955,"score_gpt":0.25611668063662985,"score_spread":0.2431865184191309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380988690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717984,0.025442192,5.646366e-8,0.0007160415,0.00045066557,0.0013952096,0.00016590118,0.000012273694,0.00001923062],"genre_scores_gemma":[0.98999304,0.009152873,0.000005408424,0.00005497376,0.000009680885,0.00017824293,0.00012631401,0.000021170981,0.00045832465],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977579,0.0004724291,0.00097648776,0.0003841188,0.00014236227,0.0002667134],"domain_scores_gemma":[0.9985156,0.0002659743,0.0005493771,0.00047299775,0.000121658726,0.000074389776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008383459,0.00025910378,0.0006248433,0.000090312635,0.00022101696,0.000034894845,0.00011767195,0.00027414554,0.00005627656],"category_scores_gemma":[0.00081296643,0.00013393292,0.00009527525,0.0007839478,0.00030416314,0.0002113632,0.00047727348,0.00032744935,0.0000011390214],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054128654,0.00082956534,0.049340658,0.0021875212,0.002022114,0.077036075,0.015433799,0.0000010720515,0.024722503,0.0000091402735,0.0034958818,0.8195088],"study_design_scores_gemma":[0.020222478,0.0042849393,0.15877248,0.09988507,0.002628356,0.1754791,0.00640946,0.000002098638,0.5139926,0.000084481544,0.016250513,0.0019884277],"about_ca_topic_score_codex":0.0022450276,"about_ca_topic_score_gemma":0.0009473567,"teacher_disagreement_score":0.8175204,"about_ca_system_score_codex":0.00006290794,"about_ca_system_score_gemma":0.00016334494,"threshold_uncertainty_score":0.5461626},"labels":[],"label_agreement":null},{"id":"W4381113775","doi":"10.1007/s12325-023-02568-0","title":"Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sun Pharma; Sanofi Genzyme; Incyte; Eli Lilly and Company; Ortho Dermatologics; Purdue Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Purdue University","keywords":"Medicine; Adverse effect; Psoriasis; Clinical trial; Psoriatic arthritis; Internal medicine; Dermatology; Population; Intensive care medicine","score_opus":0.03196367031395327,"score_gpt":0.3203321296975279,"score_spread":0.28836845938357464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381113775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033684584,0.9914299,0.00002216982,0.00003694221,0.0007077092,0.005771376,0.0016352277,0.00002413336,0.00003568385],"genre_scores_gemma":[0.00006259737,0.9954963,0.00010041296,0.000035269735,0.000044896646,0.0027750619,0.0009877024,0.000061472434,0.00043633915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780464,0.0003931604,0.0009282633,0.0004790265,0.00007377167,0.00032114564],"domain_scores_gemma":[0.9974259,0.0011514223,0.000747751,0.0005134723,0.00014152964,0.000019926456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021296441,0.00056700973,0.0023446355,0.00016164877,0.00012047814,0.0000037045645,0.00032111013,0.00026406668,0.000035127116],"category_scores_gemma":[0.00003115852,0.00028576778,0.0004969886,0.00054567034,0.00013278745,0.00008994339,0.00002066391,0.00010876596,0.000023319479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002030217,0.00049452175,0.000055558354,0.0038218773,0.0018882175,9.957583e-7,0.0011839588,0.00002207281,0.0000010819045,0.000056838468,0.00018119096,0.99026346],"study_design_scores_gemma":[0.004210701,0.002336392,0.000032603282,0.016811403,0.0007977275,0.000001966712,0.00013574043,1.1571314e-7,0.00014391408,0.000058511123,0.97516185,0.0003090586],"about_ca_topic_score_codex":0.000017602033,"about_ca_topic_score_gemma":0.00010338895,"teacher_disagreement_score":0.9899544,"about_ca_system_score_codex":0.00014181873,"about_ca_system_score_gemma":0.00017063678,"threshold_uncertainty_score":0.99995947},"labels":[],"label_agreement":null},{"id":"W4382025359","doi":"10.1093/bjd/ljad113.105","title":"P77 Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"European League Against Rheumatism; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Apremilast; Internal medicine; Plaque psoriasis; Randomized controlled trial; Gastroenterology; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.029527391441481896,"score_gpt":0.29683082332800753,"score_spread":0.2673034318865256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382025359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949221,0.0030261434,0.00007820351,0.00039879367,0.0005742065,0.0006513421,0.00028361377,0.00002836386,0.00003721201],"genre_scores_gemma":[0.9973935,0.0019899302,0.00017927239,0.00014059889,0.00005911747,0.000058743713,0.00010899053,0.000033158547,0.0000367045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568075,0.0014607066,0.0016338758,0.00048605577,0.00011687484,0.00062171434],"domain_scores_gemma":[0.99837047,0.00046549394,0.00065435946,0.00018239078,0.00018707862,0.00014023356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012953022,0.00037457788,0.0017950424,0.00081129797,0.00014410015,0.00005230555,0.00023564734,0.00040940492,0.000043904383],"category_scores_gemma":[0.00028650876,0.0004004954,0.00013606338,0.0005955687,0.00019825833,0.00038777798,0.00016778025,0.00050208886,0.000005303395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15089643,0.0070605422,0.41232836,0.00044250244,0.0036877575,0.01587239,0.010305249,0.00070634374,0.12437156,0.00018676482,0.008929032,0.26521307],"study_design_scores_gemma":[0.29571462,0.003853408,0.5072001,0.0020073443,0.0010391196,0.07129917,0.003502309,0.0005837455,0.110123925,0.0015954422,0.0012094142,0.0018713946],"about_ca_topic_score_codex":0.0006189841,"about_ca_topic_score_gemma":0.003910419,"teacher_disagreement_score":0.2633417,"about_ca_system_score_codex":0.000094334886,"about_ca_system_score_gemma":0.00021275171,"threshold_uncertainty_score":0.9998447},"labels":[],"label_agreement":null},{"id":"W4382025379","doi":"10.1093/bjd/ljad113.366","title":"PS14 Bimekizumab response up to 3 years in patients with moderate-to-severe plaque psoriasis who responded at week 16: post hoc results from the BE BRIGHT open-label extension trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Dermatology Life Quality Index; Medicine; Plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis; Quality of life (healthcare); Open label; Randomized controlled trial; Internal medicine; Dermatology","score_opus":0.027861972868238737,"score_gpt":0.25728290783648694,"score_spread":0.2294209349682482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382025379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900678,0.0007508584,0.000006826651,0.005173248,0.0017071211,0.0010014849,0.0012140779,0.000032938347,0.000045663273],"genre_scores_gemma":[0.99565136,0.00022652044,0.00014235344,0.0011975731,0.00006969892,0.00004184443,0.00047655244,0.000051505074,0.0021425688],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99540055,0.0022206528,0.0010366733,0.000544807,0.00017609709,0.0006211946],"domain_scores_gemma":[0.997123,0.0014987387,0.00045700234,0.00045353486,0.00034276262,0.000124966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079669914,0.00029954268,0.0009051706,0.0004386207,0.00037334356,0.00011217786,0.00082372525,0.00042894942,0.00011934749],"category_scores_gemma":[0.0009648376,0.00025009352,0.000110653906,0.00068057707,0.00011697214,0.00025608175,0.00040145576,0.00043130683,0.00036881355],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87014914,0.00052727613,0.0012367696,0.0000027214392,0.0004338971,0.0033860053,0.0015968601,0.000022677965,0.0018632424,0.000009951071,0.103190914,0.017580573],"study_design_scores_gemma":[0.43861538,0.0053937845,0.49762166,0.00073079474,0.00029923953,0.008273533,0.00065310515,0.00000346915,0.0065062353,0.00013486364,0.041016184,0.0007517516],"about_ca_topic_score_codex":0.0006615148,"about_ca_topic_score_gemma":0.0019102189,"teacher_disagreement_score":0.4963849,"about_ca_system_score_codex":0.00020846687,"about_ca_system_score_gemma":0.00036365906,"threshold_uncertainty_score":0.9999951},"labels":[],"label_agreement":null},{"id":"W4382538536","doi":"10.3389/fmed.2023.1185523","title":"Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)","year":2023,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Psoriasis; Secukinumab; Ustekinumab; Dermatology; Internal medicine; Adalimumab; Physical therapy; Psoriatic arthritis; Disease","score_opus":0.07985886528838769,"score_gpt":0.2968431272682186,"score_spread":0.2169842619798309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382538536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389154,0.00040252402,0.00043896658,0.00035649454,0.0015662352,0.0021639366,0.0011392779,0.000017792006,0.00002323581],"genre_scores_gemma":[0.99684227,0.00008681263,0.0005671836,0.00007597912,0.000075821496,0.00017800847,0.0021169062,0.000011400924,0.00004559675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979141,0.0007033384,0.0006162029,0.00039434302,0.000117397976,0.0002546208],"domain_scores_gemma":[0.99752825,0.0016910463,0.00034790928,0.0002530497,0.0001527932,0.000026944856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010702491,0.00023486295,0.0011277413,0.00019147444,0.00016334522,0.0000032385726,0.00019356748,0.000105157545,0.000009609469],"category_scores_gemma":[0.00029501834,0.00013448934,0.000043801334,0.00039162723,0.00020575587,0.000049706297,0.000059851678,0.00009759656,0.0000013293451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011647847,0.000795396,0.96270704,0.000037693822,0.0011135014,7.142666e-7,0.011737632,0.00015182441,0.00005874709,0.000051127292,0.0063548796,0.0053435904],"study_design_scores_gemma":[0.023189286,0.0039964444,0.96093917,0.00018529479,0.0001689825,1.1099531e-7,0.010269051,0.000019591022,0.00018155687,0.00065373565,0.0002713828,0.00012538893],"about_ca_topic_score_codex":0.0006288148,"about_ca_topic_score_gemma":0.00049782346,"teacher_disagreement_score":0.011541439,"about_ca_system_score_codex":0.000066319124,"about_ca_system_score_gemma":0.00006110698,"threshold_uncertainty_score":0.54843163},"labels":[],"label_agreement":null},{"id":"W4383217265","doi":"10.1186/s13223-023-00811-5","title":"Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report","year":2023,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Anhui Provincial Key Research and Development Plan","keywords":"Secukinumab; Prurigo nodularis; Dermatology; Medicine; Psoriasis; Psoriatic arthritis","score_opus":0.02673404086387889,"score_gpt":0.2990843650991519,"score_spread":0.27235032423527306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383217265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991401,0.0056022243,0.000007051856,0.00030081047,0.0017986397,0.0002713605,0.000076940654,0.00019334779,0.00034860565],"genre_scores_gemma":[0.9859021,0.0070127714,0.00007164498,0.000023968905,0.000097675234,0.00009142834,0.00036183296,0.000035150264,0.006403432],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99696225,0.0005535674,0.0011250098,0.00072354084,0.000045869154,0.00058976735],"domain_scores_gemma":[0.9981253,0.000614441,0.0003899585,0.00072221516,0.000090672365,0.000057413654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003689177,0.00036599315,0.0009076066,0.00022475113,0.00030546385,0.000010750732,0.00016475399,0.000768211,0.00043207602],"category_scores_gemma":[0.00017227806,0.00030395118,0.00040247268,0.00030265222,0.00054366,0.00007292028,0.00016034729,0.00021129264,0.00044476808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010812935,0.008316925,0.08974857,0.00010812345,0.05033258,0.22210035,0.0050315196,0.000016957349,0.045807026,0.0021116612,0.002856429,0.5627569],"study_design_scores_gemma":[0.025716195,0.006838031,0.6686173,0.00009170924,0.0007033003,0.14824891,0.0024918066,0.000014941844,0.028894015,0.00055522117,0.11674456,0.0010839748],"about_ca_topic_score_codex":0.00054811785,"about_ca_topic_score_gemma":0.00041519784,"teacher_disagreement_score":0.57886875,"about_ca_system_score_codex":0.000044017583,"about_ca_system_score_gemma":0.00009507341,"threshold_uncertainty_score":0.9999413},"labels":[],"label_agreement":null},{"id":"W4383302158","doi":"10.1007/s13555-023-00950-y","title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel","year":2023,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; University of Alberta; BC Children's Hospital; Toronto General Hospital; McMaster University; SKiN Health; Probity Medical Research; University of British Columbia; University Health Network; Ottawa Hospital; Dermatrials Research; University of Ottawa; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Multidisciplinary approach; Inference; Human immunodeficiency virus (HIV); Medicine; Intensive care medicine; Computer science; Dermatology; Artificial intelligence; Family medicine; Sociology","score_opus":0.03847214964924443,"score_gpt":0.2729562787058102,"score_spread":0.23448412905656574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383302158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94110787,0.046673797,0.00055717607,0.00019035923,0.008746734,0.0020059743,0.0006193852,0.000074188436,0.000024497778],"genre_scores_gemma":[0.97282445,0.018849513,0.00018054889,0.00003907016,0.00006778177,0.0019098212,0.0010235672,0.000058628713,0.0050465884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803287,0.0005017068,0.00062221516,0.00048316325,0.00004345615,0.00031656164],"domain_scores_gemma":[0.99539536,0.0036212585,0.00048706905,0.00035084,0.000121327146,0.000024147686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000092901246,0.00045834813,0.0018139912,0.00037548435,0.0001206476,0.000009874149,0.00013417038,0.00068638666,0.000028162573],"category_scores_gemma":[0.000083333885,0.00032138452,0.0002223249,0.00019716838,0.00014026738,0.00006221088,0.000020459067,0.00010864724,0.0000066288867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053532157,0.003518099,0.7328339,0.0005050301,0.012499611,0.000072306226,0.07313572,0.00017228987,0.04755322,0.00008707406,0.031174082,0.044916496],"study_design_scores_gemma":[0.15631694,0.010558727,0.7280222,0.012267852,0.0017223787,0.00033334046,0.013796464,0.0016585769,0.048411854,0.00016726714,0.023790147,0.002954222],"about_ca_topic_score_codex":0.0014823352,"about_ca_topic_score_gemma":0.001438273,"teacher_disagreement_score":0.10278478,"about_ca_system_score_codex":0.000054567965,"about_ca_system_score_gemma":0.00022452051,"threshold_uncertainty_score":0.9999238},"labels":[],"label_agreement":null},{"id":"W4383556506","doi":"10.3899/jrheum.2023-0511","title":"Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?","year":2023,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Interleukin 17; Interleukin 22; Plaque psoriasis; Arthritis; Interleukin 23; Population; Interleukin; Biologic Agents; Immunology; Internal medicine; Rheumatoid arthritis; Cytokine","score_opus":0.01463089372991201,"score_gpt":0.24345867285993106,"score_spread":0.22882777913001906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383556506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992589,0.0008276178,0.000027291375,0.0042411904,0.0017694838,0.00037249722,0.00008384553,0.000033717166,0.000055338456],"genre_scores_gemma":[0.9975937,0.0014930343,0.00016158604,0.00047613686,0.000023017448,0.000029888748,0.000040900297,0.00003948244,0.00014225261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715,0.0007009035,0.0010672486,0.00033756054,0.00010343787,0.0006408467],"domain_scores_gemma":[0.99783295,0.0010337385,0.00044415944,0.00035644404,0.00023010957,0.00010260823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051230885,0.0003714336,0.0010404072,0.00063952984,0.00019468086,0.00002444352,0.00038538745,0.00039408822,0.00010661527],"category_scores_gemma":[0.00023832278,0.00025261135,0.00010485958,0.00065794925,0.00014168982,0.00015568471,0.00017432927,0.00043666075,0.0004919108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0327989,0.00056636607,0.80532694,0.00009158649,0.0018332205,0.00012681415,0.015437019,0.00016332307,0.00056035595,0.000114933726,0.054718796,0.08826175],"study_design_scores_gemma":[0.26150587,0.026496809,0.5903708,0.0047780424,0.00363304,0.022995926,0.01229236,0.0001481471,0.027239937,0.0038229208,0.041673057,0.005043132],"about_ca_topic_score_codex":0.00014024535,"about_ca_topic_score_gemma":0.0011079306,"teacher_disagreement_score":0.22870696,"about_ca_system_score_codex":0.00007402197,"about_ca_system_score_gemma":0.00010510968,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W4383683701","doi":"10.58931/cibdt.2023.1s0510","title":"Targeting IL23p19 using risankizumab for the management of moderate-to-severely active Crohn's disease","year":2023,"lang":"en","type":"article","venue":"Canadian IBD Today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Ustekinumab; Medicine; Interleukin 23; Crohn's disease; Psoriasis; Inflammatory bowel disease; Monoclonal antibody; Immunology; Ulcerative colitis; Monoclonal; Disease; Internal medicine; Interleukin 17; Antibody; Inflammation; Adalimumab","score_opus":0.027281064687976257,"score_gpt":0.2513715419572027,"score_spread":0.22409047726922643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383683701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921082,0.0014420789,0.0005016875,0.0008379775,0.0012871189,0.0013055177,0.001513706,0.00006357498,0.0009401071],"genre_scores_gemma":[0.9951995,0.00006882801,0.0002072336,0.00019023086,0.000045146047,0.00015335581,0.00023941846,0.00002719763,0.0038690965],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99897593,0.000060271035,0.00017061585,0.0002655393,0.000031390846,0.0004962745],"domain_scores_gemma":[0.9993841,0.00012967203,0.0000595683,0.00025964645,0.000052177304,0.00011483794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014796734,0.00015822233,0.0001796638,0.00017701375,0.00047905964,0.000015736443,0.00021514836,0.00008853921,0.00019147679],"category_scores_gemma":[0.000025786621,0.00012750315,0.0001074351,0.00028705283,0.000057676047,0.000048516078,0.000045297485,0.00006254737,0.0001862582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017091988,0.00043944633,0.005479998,0.0010617588,0.01827676,0.0021127274,0.015056469,0.04562481,0.022528954,0.024190618,0.17727953,0.67085695],"study_design_scores_gemma":[0.007904549,0.00024301825,0.65395266,0.00042881604,0.0029135374,0.00001544645,0.0057364204,0.0041410155,0.022803694,0.0024959857,0.29774752,0.0016173242],"about_ca_topic_score_codex":0.008602603,"about_ca_topic_score_gemma":0.0038338583,"teacher_disagreement_score":0.66923964,"about_ca_system_score_codex":0.00017446147,"about_ca_system_score_gemma":0.00021790045,"threshold_uncertainty_score":0.9979992},"labels":[],"label_agreement":null},{"id":"W4383817237","doi":"10.1016/j.humimm.2023.06.007","title":"The β2-adrenergic receptor agonist terbutaline upregulates T helper-17 cells in a protein kinase A-dependent manner","year":2023,"lang":"en","type":"article","venue":"Human Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"RAR-related orphan receptor gamma; Rolipram; Terbutaline; CREB; CD28; Endocrinology; Peripheral blood mononuclear cell; Biology; Internal medicine; Chemistry; Molecular biology; T cell; Immunology; FOXP3; Phosphodiesterase; Medicine; Immune system; Biochemistry","score_opus":0.015758795856121537,"score_gpt":0.2352076637682899,"score_spread":0.21944886791216836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383817237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899731,0.0061729895,0.0000015664186,0.00061818975,0.0013235284,0.0006273411,0.00008974844,0.0002744547,0.0009190745],"genre_scores_gemma":[0.91190165,0.0004709315,0.000019778197,0.000051477262,0.000083002255,0.0005237223,0.00063965074,0.000049989434,0.086259775],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973435,0.0005576208,0.0005545614,0.0005714881,0.000056783054,0.00091608637],"domain_scores_gemma":[0.99884844,0.00016569156,0.00017851453,0.0007289167,0.00005241527,0.000026040188],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00045599704,0.00038431198,0.0004510566,0.0002881676,0.0008303117,0.00004759002,0.00058812613,0.00047933325,0.0009705234],"category_scores_gemma":[0.00003272937,0.00028494583,0.00017860431,0.0003668984,0.00064836093,0.00007536784,0.00029035218,0.00036485022,0.0037584098],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034978404,0.00022426735,0.00036788592,0.000011498607,0.00036549132,0.00008162413,0.0005645798,0.000019246398,0.98360914,0.0021355571,0.0042943857,0.007976545],"study_design_scores_gemma":[0.004853106,0.00064856577,0.015406981,0.000090709626,0.00009162976,0.000062917046,0.0011104394,0.0000056392514,0.83771414,0.0012680875,0.13812318,0.0006246089],"about_ca_topic_score_codex":0.00034630363,"about_ca_topic_score_gemma":0.0006643941,"teacher_disagreement_score":0.145895,"about_ca_system_score_codex":0.00010971252,"about_ca_system_score_gemma":0.00005326381,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W4384407667","doi":"10.3899/jrheum.2023-0528","title":"Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting","year":2023,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Quality of life (healthcare); Physical therapy; Epidemiology; Musculoskeletal disease; Disease; Patient-reported outcome; Internal medicine; Dermatology; Nursing","score_opus":0.02892868685115529,"score_gpt":0.2890171572003298,"score_spread":0.2600884703491745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384407667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781734,0.009350492,0.0000058050164,0.009916546,0.0018533443,0.00022151055,0.00006584612,0.000015171436,0.0003979098],"genre_scores_gemma":[0.99493295,0.0019652047,0.000007733686,0.00008684004,0.00004432875,0.000011339901,0.000019804369,0.00002064354,0.0029111763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994337,0.0039264956,0.00084151205,0.0001785702,0.00021848718,0.0004979232],"domain_scores_gemma":[0.9915014,0.006447412,0.00090973865,0.00084268284,0.00027686724,0.00002189062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068089105,0.00018037025,0.00046601056,0.00010912298,0.0011353643,0.0000119324095,0.0014101383,0.0002288592,0.00031707893],"category_scores_gemma":[0.00088541,0.00006809582,0.0003099156,0.00069111626,0.0011141577,0.000053687123,0.0006441078,0.0008437696,0.00020441758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024356958,0.00020257728,0.5862293,0.00002102681,0.003882568,0.00016370381,0.02205361,0.00011419372,0.032463696,0.0011938771,0.3237068,0.027532944],"study_design_scores_gemma":[0.0062808236,0.0008742838,0.63983047,0.0007733466,0.001525049,0.058843672,0.046482034,0.000015538672,0.04769941,0.013262411,0.1838287,0.0005842396],"about_ca_topic_score_codex":0.0018611918,"about_ca_topic_score_gemma":0.0014408858,"teacher_disagreement_score":0.1398781,"about_ca_system_score_codex":0.000051056824,"about_ca_system_score_gemma":0.00016614793,"threshold_uncertainty_score":0.87324196},"labels":[],"label_agreement":null},{"id":"W4384469487","doi":"10.25251/skin.7.supp.219","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Placebo; Plaque psoriasis; Internal medicine; Psoriasis; Population; Gastroenterology; Dermatology; Pathology","score_opus":0.02762875616616525,"score_gpt":0.29977164924700356,"score_spread":0.27214289308083833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384469487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98524386,0.0071038553,0.00004121132,0.006263094,0.00042281224,0.00066673843,0.0002278764,0.000020423087,0.000010109066],"genre_scores_gemma":[0.99177164,0.006591602,0.000030731808,0.0010186034,0.000249623,0.00001883396,0.00018137107,0.000029898216,0.00010771597],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954245,0.0026265392,0.0010845545,0.00028494408,0.00015929398,0.00042014674],"domain_scores_gemma":[0.99678767,0.0021780846,0.00045949104,0.00027414665,0.00012532099,0.00017531366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039750584,0.000351746,0.00097029906,0.00049906265,0.00019828462,0.000030218967,0.0002913064,0.00016402271,0.00004427435],"category_scores_gemma":[0.0019065809,0.00019136487,0.000079503894,0.00079452124,0.00023422367,0.00011117066,0.000053220698,0.00045109913,0.000007257758],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12615818,0.0052328855,0.015375122,0.00028157808,0.0018693183,0.008512589,0.027849246,0.00018990715,0.3957217,0.00010957678,0.05936283,0.3593371],"study_design_scores_gemma":[0.3932481,0.076402225,0.21505828,0.010951271,0.019967774,0.0884439,0.02936964,0.0027912795,0.04959937,0.008777356,0.09859626,0.006794528],"about_ca_topic_score_codex":0.00007184596,"about_ca_topic_score_gemma":0.00012228914,"teacher_disagreement_score":0.35254255,"about_ca_system_score_codex":0.00003716978,"about_ca_system_score_gemma":0.00011337225,"threshold_uncertainty_score":0.7803633},"labels":[],"label_agreement":null},{"id":"W4384570149","doi":"10.5114/ada.2023.128984","title":"Successful treatment of a child’s generalized pustularpsoriasis with adalimumab in combination with low-doseacitretin","year":2023,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Acitretin; Medicine; Adalimumab; Psoriasis; Dermatology; Generalized pustular psoriasis; Pustular psoriasis; Internal medicine","score_opus":0.006658486745655127,"score_gpt":0.23616107379965418,"score_spread":0.22950258705399904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384570149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871142,0.010717223,0.000029716262,0.0009792644,0.00021765177,0.00038407493,0.000017840666,0.000059191178,0.0004808224],"genre_scores_gemma":[0.98845226,0.01072851,0.00013127108,0.000060475082,0.000008514089,0.00023538325,0.00024153772,0.000018879124,0.00012314548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827486,0.0003868281,0.00038654212,0.0004494779,0.00003792886,0.00046436267],"domain_scores_gemma":[0.9992586,0.00028194624,0.00017132136,0.00022754967,0.000037351245,0.000023233695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000851337,0.0002844854,0.0007189971,0.00047589614,0.00009444954,0.000003663995,0.00012974694,0.00029286556,0.000057905203],"category_scores_gemma":[0.000016297425,0.00020712573,0.000042830718,0.0005102393,0.00046689928,0.00015404008,0.000035536967,0.00011468773,0.000024296176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005815983,0.001331509,0.93220824,0.00011459449,0.00056824955,0.0010859147,0.0020815625,0.000471686,0.0013463695,0.005777904,0.000052795443,0.04914517],"study_design_scores_gemma":[0.11414202,0.0065611517,0.7372384,0.0005025773,0.00044291557,0.005389684,0.0034623344,0.00022772602,0.09017234,0.0035538548,0.036694564,0.0016124088],"about_ca_topic_score_codex":0.00012490408,"about_ca_topic_score_gemma":0.003609123,"teacher_disagreement_score":0.19496983,"about_ca_system_score_codex":0.00003830614,"about_ca_system_score_gemma":0.00004736054,"threshold_uncertainty_score":0.84463423},"labels":[],"label_agreement":null},{"id":"W4384571895","doi":"10.5114/ada.2023.129514","title":"Rapid response of spesolimab in biologics-failure patientwith generalized pustular psoriasis flare","year":2023,"lang":"en","type":"article","venue":"Advances in Dermatology and Allergology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Flare; Generalized pustular psoriasis","score_opus":0.012809343719670246,"score_gpt":0.24986228890682666,"score_spread":0.23705294518715642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384571895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680344,0.029919626,0.000009850297,0.0007869239,0.00070078246,0.00027943746,0.00004222623,0.00007239277,0.00015436501],"genre_scores_gemma":[0.9848907,0.014233227,0.0002535903,0.00012065633,0.000013573155,0.00011305884,0.00021494496,0.0000167731,0.00014346576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687797,0.0013157869,0.00061920035,0.0005281535,0.000032890748,0.00062597066],"domain_scores_gemma":[0.9985739,0.00084447686,0.00020356865,0.00030777193,0.000042909334,0.00002735716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038879833,0.0002950344,0.000813405,0.0006626416,0.000094485156,0.000002942032,0.00025171493,0.0006346905,0.00017822107],"category_scores_gemma":[0.00024820297,0.0002521821,0.00008674154,0.00060105475,0.00054744596,0.00013980865,0.00015762122,0.0002511878,0.00009582494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0115427235,0.0005734139,0.88935477,0.00015123168,0.00046923006,0.0010771821,0.0027019135,0.00031133497,0.033936713,0.004178683,0.0014253057,0.05427749],"study_design_scores_gemma":[0.027694972,0.0014610883,0.75793815,0.00017759993,0.0001523711,0.0014779035,0.0031319882,0.000097069686,0.059747692,0.007360527,0.13951948,0.0012411352],"about_ca_topic_score_codex":0.000031117408,"about_ca_topic_score_gemma":0.00057779555,"teacher_disagreement_score":0.13809417,"about_ca_system_score_codex":0.000025434567,"about_ca_system_score_gemma":0.00005579161,"threshold_uncertainty_score":0.999993},"labels":[],"label_agreement":null},{"id":"W4385188822","doi":"10.1111/cch.13152","title":"Attachment style and children and young people with chronic dermatological conditions","year":2023,"lang":"en","type":"article","venue":"Child Care Health and Development","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Prince Edward Island","funders":"","keywords":"Psychosocial; Attachment theory; Population; Dermatological diseases; Strengths and Difficulties Questionnaire; Psychology; Clinical psychology; Insecure attachment; Attachment measures; Medicine; Developmental psychology; Psychiatry; Mental health; Dermatology","score_opus":0.010625046215962136,"score_gpt":0.2505315806697854,"score_spread":0.2399065344538233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385188822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97297287,0.025503693,0.00001470365,0.00063492276,0.00012295805,0.00041300306,0.00006609818,0.00010385644,0.00016788895],"genre_scores_gemma":[0.99459255,0.003207942,0.00012794622,0.00028843136,0.000016607923,0.000101294405,0.0015364828,0.000009784,0.00011895941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905455,0.00005899853,0.00017518959,0.00031748944,0.00003525717,0.00035852878],"domain_scores_gemma":[0.9996931,0.00003122331,0.0000530961,0.0000919779,0.000020339336,0.0001102844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006945317,0.00017107946,0.00024986232,0.000083348925,0.000755719,0.000018673773,0.000038316484,0.00009697104,0.000028232938],"category_scores_gemma":[0.0000038205226,0.00012721939,0.00001297708,0.00010006646,0.00008890583,0.000036106776,0.0000746303,0.000096128955,0.00004295268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056371664,0.00004473165,0.9105455,0.00012627263,0.0002121936,0.000009835248,0.008296217,4.240149e-7,0.000021611553,0.00018218941,0.0018556744,0.07864894],"study_design_scores_gemma":[0.001827414,0.00018095713,0.9903748,0.000064173684,0.000018915174,0.0005658408,0.00093708135,5.5295453e-7,0.00022490529,0.0000044408307,0.0056371917,0.0001637274],"about_ca_topic_score_codex":0.00006258109,"about_ca_topic_score_gemma":0.0005213829,"teacher_disagreement_score":0.07982926,"about_ca_system_score_codex":0.00006540868,"about_ca_system_score_gemma":0.00021399735,"threshold_uncertainty_score":0.5812456},"labels":[],"label_agreement":null},{"id":"W4385221284","doi":"10.55788/6d568baa","title":"Medicom Conference Report The 6th IFPA World Psoriasis and Psoriatic Arthritis Congress","year":2021,"lang":"en","type":"paratext","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Pfizer","keywords":"Psoriatic arthritis; Psoriasis; Dermatology; Medicine; Arthritis; Computer science; Internal medicine","score_opus":0.023516875404718442,"score_gpt":0.25847753675870283,"score_spread":0.23496066135398438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385221284","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020274004,0.34081203,0.0003391308,0.0047875918,0.077145465,0.0020360257,0.0012220688,0.00025452525,0.55312914],"genre_scores_gemma":[0.07432157,0.030899541,0.00008782464,0.00044269598,0.0006340062,0.00028215392,0.0041479543,0.00006642051,0.88911784],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673766,0.0006563878,0.0008497097,0.0009938478,0.00012496808,0.00063741405],"domain_scores_gemma":[0.9973614,0.00071789604,0.00053618214,0.001064377,0.00024740378,0.00007270872],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00047830355,0.00069864345,0.0012547732,0.00019956479,0.00048258304,0.00017638836,0.00045725645,0.00083433365,0.04295949],"category_scores_gemma":[0.00015400654,0.00046585812,0.00027166246,0.0003044724,0.00054761197,0.00010711337,0.00028386543,0.00069369137,0.004676753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010486034,0.00015459323,0.00022534329,0.00008954937,0.002783404,0.00057982636,0.00039181058,8.3910703e-7,0.00057654426,0.0010153848,0.8177715,0.17630635],"study_design_scores_gemma":[0.0024596378,0.00009557514,0.00054256566,0.00047681728,0.0007569187,0.0016407244,0.0005481358,0.0000011421158,0.0062023406,0.0001285861,0.98649055,0.0006569962],"about_ca_topic_score_codex":0.00043679785,"about_ca_topic_score_gemma":0.0017945912,"teacher_disagreement_score":0.33598867,"about_ca_system_score_codex":0.000053167438,"about_ca_system_score_gemma":0.00048412103,"threshold_uncertainty_score":0.9997793},"labels":[],"label_agreement":null},{"id":"W4385230266","doi":"10.1093/bjd/ljad252","title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Dermatrials Research; Probity Medical Research; University of British Columbia","funders":"National Institutes of Health; AbbVie; Boehringer Ingelheim","keywords":"Apremilast; Medicine; Psoriasis Area and Severity Index; Psoriasis; Randomized controlled trial; Internal medicine; Secukinumab; Clinical endpoint; Dermatology; Psoriatic arthritis","score_opus":0.06904877460295726,"score_gpt":0.35285259864049323,"score_spread":0.28380382403753596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385230266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96927977,0.024267368,0.0010034663,0.00031077358,0.00040682126,0.003762066,0.00094100874,0.000017672859,0.000011059456],"genre_scores_gemma":[0.99068564,0.00802209,0.00044821197,0.000014849969,0.00004546489,0.00049384456,0.00021125114,0.000032041673,0.000046602992],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686503,0.0007885367,0.0015820501,0.00034142847,0.00008523093,0.0003377014],"domain_scores_gemma":[0.99373186,0.0039842455,0.0015619892,0.00026269004,0.00041946265,0.000039739596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005673844,0.00028723874,0.0023049111,0.00018553736,0.0002824727,0.00005284523,0.00039047396,0.00024157901,0.0000073081865],"category_scores_gemma":[0.00014142256,0.0001953368,0.00020768405,0.00018883415,0.00023150991,0.00013281449,0.000038445134,0.00012404396,0.0000016793181],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.870071,0.00830485,0.001868859,0.000085477535,0.010946317,0.00021765077,0.009775544,0.00010791708,0.005703421,0.0000325407,0.002604377,0.090282075],"study_design_scores_gemma":[0.92168427,0.0074672275,0.0004825285,0.00047635558,0.0020608762,0.003945193,0.007111386,0.00077917124,0.055087186,0.00012745759,0.00053282664,0.00024551878],"about_ca_topic_score_codex":0.0004941481,"about_ca_topic_score_gemma":0.00031285782,"teacher_disagreement_score":0.090036556,"about_ca_system_score_codex":0.00003586645,"about_ca_system_score_gemma":0.00018867424,"threshold_uncertainty_score":0.79656035},"labels":[],"label_agreement":null},{"id":"W4385254189","doi":"10.55788/d80fe177","title":"Low COVID-19 risk for patients with psoriasis on biologic treatment","year":2021,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriasis; Coronavirus disease 2019 (COVID-19); Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Internal medicine; Dermatology; Virology; Disease","score_opus":0.022006166950102827,"score_gpt":0.2525935284479755,"score_spread":0.23058736149787268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385254189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951645,0.00052673917,0.0004459369,0.00024500635,0.00066998164,0.0006531063,0.00085566984,0.00013158697,0.0013074882],"genre_scores_gemma":[0.9853754,0.00039144626,0.000761748,0.0006609369,0.00004981539,0.0003311572,0.0022847727,0.000022498283,0.010122238],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877435,0.00020004319,0.00017684222,0.00048076772,0.000026658476,0.000341356],"domain_scores_gemma":[0.99891305,0.00050000986,0.00009955803,0.00034606433,0.000084301595,0.000056995563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007141715,0.0002636583,0.00031662785,0.00006568541,0.00031864774,0.000012500903,0.00008849653,0.0002135589,0.0011483224],"category_scores_gemma":[0.0001466284,0.00015622714,0.00016400435,0.00012401599,0.000066059794,0.000031203035,0.0000202907,0.00005022129,0.0004183922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008292691,0.009409838,0.58338475,0.000053862135,0.004907802,0.00005274471,0.00076009944,0.00007746677,0.0046764687,0.0024089203,0.011764169,0.3742112],"study_design_scores_gemma":[0.06444616,0.020747425,0.16025841,0.000043077092,0.0019033322,0.00003157943,0.0006877579,0.0000040948075,0.33578175,0.0009420488,0.41381478,0.0013395917],"about_ca_topic_score_codex":0.00007677613,"about_ca_topic_score_gemma":0.00015966293,"teacher_disagreement_score":0.42312634,"about_ca_system_score_codex":0.00017050785,"about_ca_system_score_gemma":0.0001531459,"threshold_uncertainty_score":0.99976474},"labels":[],"label_agreement":null},{"id":"W4385429790","doi":"10.1007/s13555-023-00977-1","title":"Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; Kyowa Hakko Kirin","keywords":"Adalimumab; Plaque psoriasis; Psoriasis; Term (time); Medicine; Internal medicine; Matching (statistics); Dermatology; Pathology; Disease; Physics","score_opus":0.05121365840193167,"score_gpt":0.3044505649306275,"score_spread":0.25323690652869585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385429790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558663,0.002047661,0.00008030337,0.00042212574,0.0009523144,0.0006178854,0.00015844435,0.00006137221,0.00007325064],"genre_scores_gemma":[0.9990534,0.0004110052,0.000045667686,0.00007709053,0.000016942598,0.000078374265,0.00015573167,0.000019527868,0.00014225577],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987884,0.00026246815,0.00035987847,0.00025494077,0.00003574046,0.00029852838],"domain_scores_gemma":[0.9986819,0.00076700374,0.00019188754,0.00027603516,0.00005943511,0.000023710787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011461735,0.00020332697,0.0005890766,0.00013923422,0.00022783995,0.0000056249037,0.00022505729,0.0003060966,0.00004050647],"category_scores_gemma":[0.000025537733,0.00014752934,0.00014855752,0.00024768856,0.00014979472,0.000035894845,0.000057046094,0.000109116256,0.00002463645],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07919064,0.0017512953,0.3976277,0.00047454698,0.00951055,0.000035150722,0.03284756,0.00042744,0.15798151,0.0068654804,0.0049967375,0.30829138],"study_design_scores_gemma":[0.025519753,0.0005428435,0.27503207,0.00008543893,0.00029153438,0.000117448995,0.00056813145,0.000025981819,0.69546485,0.000603306,0.001395491,0.00035311593],"about_ca_topic_score_codex":0.000027504064,"about_ca_topic_score_gemma":0.00007802419,"teacher_disagreement_score":0.53748333,"about_ca_system_score_codex":0.000008865352,"about_ca_system_score_gemma":0.000045067078,"threshold_uncertainty_score":0.6016072},"labels":[],"label_agreement":null},{"id":"W4385456057","doi":"10.3899/jrheum.2023-0535","title":"Novel Insights From Basic Science in Psoriatic Disease at the GRAPPA 2022 Annual Meeting","year":2023,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Regeneron Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriatic arthritis; Positron emission tomography; Psoriasis; Medical physics; Biomarker; Disease; Radiology; Dermatology; Internal medicine","score_opus":0.013815183984063934,"score_gpt":0.23534572573936421,"score_spread":0.2215305417553003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385456057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964506,0.006523064,0.000014555715,0.0014951816,0.0020566583,0.00011384255,0.00004198315,0.000017260583,0.00009239022],"genre_scores_gemma":[0.99780667,0.0017622794,0.000013256842,0.00007727874,0.000013915754,0.0000065585077,0.000013772451,0.000010682674,0.00029561186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983858,0.0005071973,0.0004759795,0.0001652937,0.00010404207,0.0003616804],"domain_scores_gemma":[0.99781966,0.0013507933,0.0003907179,0.00030751128,0.00009023331,0.000041081224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011040332,0.00015250353,0.00033734684,0.00029227452,0.0005162536,0.000010031042,0.00070669,0.000088055895,0.00015474849],"category_scores_gemma":[0.00042840393,0.00007886405,0.000103548184,0.0007249161,0.0006372308,0.00014693197,0.00023092331,0.00027340386,0.00041617226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052803834,0.0007537358,0.55626905,0.000049651182,0.0013820624,0.00019480204,0.030945553,0.0011543357,0.35617706,0.00433452,0.018125404,0.025333453],"study_design_scores_gemma":[0.010488655,0.0004481866,0.9432425,0.0004264834,0.0008454765,0.0028864285,0.00724572,0.00021554707,0.01364355,0.0063088043,0.0136434715,0.00060520467],"about_ca_topic_score_codex":0.00039688282,"about_ca_topic_score_gemma":0.00036448246,"teacher_disagreement_score":0.38697344,"about_ca_system_score_codex":0.000072262636,"about_ca_system_score_gemma":0.00021611336,"threshold_uncertainty_score":0.53491914},"labels":[],"label_agreement":null},{"id":"W4385499551","doi":"10.54660/.ijmrge.2023.4.4.531-543","title":"Improve psoriasis symptoms with strategies to manage nutrition","year":2023,"lang":"en","type":"article","venue":"International Journal of Multidisciplinary Research and Growth Evaluation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Population; Clinical trial; Randomized controlled trial; Vitamin D and neurology; Weight loss; Micronutrient; Disease; Internal medicine; Dermatology; Obesity; Environmental health; Pathology","score_opus":0.06295765053594404,"score_gpt":0.38733702523900987,"score_spread":0.3243793747030658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385499551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950003,0.0006096553,0.00021366768,0.0022382545,0.0008028833,0.00045845093,0.000044259745,0.000021457288,0.00061109243],"genre_scores_gemma":[0.99826294,0.00044666472,0.00023443156,0.000008664602,0.0002598977,0.00009321788,0.00014083854,0.000012402013,0.0005409585],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983667,0.00033353263,0.00030388992,0.0002159745,0.000515515,0.0002643998],"domain_scores_gemma":[0.99740213,0.00031800187,0.00013148502,0.000101966885,0.0019864922,0.000059900773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021835573,0.00012020408,0.00016531594,0.0009161158,0.00020628273,0.00009297155,0.00027433786,0.000094166564,0.00009105526],"category_scores_gemma":[0.00017267323,0.00008917905,0.000055314264,0.00041162266,0.00011567291,0.0004383081,0.00013387711,0.00021097441,0.00015409975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018803816,0.0021589592,0.04084468,0.00016184716,0.0041132346,0.00056425686,0.011008578,0.00038351852,0.3708168,0.00693315,0.0065174387,0.53769374],"study_design_scores_gemma":[0.020514399,0.009760411,0.85548943,0.00072447496,0.00032831563,0.00055731536,0.010930042,0.00075763505,0.06818292,0.029964488,0.0022688406,0.0005217045],"about_ca_topic_score_codex":0.000030055544,"about_ca_topic_score_gemma":0.000024572646,"teacher_disagreement_score":0.81464475,"about_ca_system_score_codex":0.00012747476,"about_ca_system_score_gemma":0.00013473295,"threshold_uncertainty_score":0.36366162},"labels":[],"label_agreement":null},{"id":"W4385612755","doi":"10.1016/j.jaad.2023.07.1024","title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Sanofi Genzyme; Celltrion; Eisai; Bristol-Myers Squibb; Samsung; AbbVie Canada; Coherus Biosciences; Mitsubishi Tanabe Pharma Corporation; Pfizer; Incyte; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Dermira; Sun Pharma; Helsinn; Celgene; AbbVie; Sanofi; Amgen; Meiji Seika Pharma; EMD Serono; Galderma; Ortho Dermatologics; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Discontinuation; Adverse effect; Dermatology Life Quality Index; Internal medicine; Placebo; Randomized controlled trial; Severity of illness; Interim analysis; Surgery; Dermatology","score_opus":0.051637281120511344,"score_gpt":0.3408411507546446,"score_spread":0.28920386963413325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385612755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949655,0.0011515826,0.000095858304,0.002123611,0.00059490744,0.00083755475,0.00022115372,0.0000035729015,0.0000062724307],"genre_scores_gemma":[0.99804574,0.0015539479,0.00009254782,0.000098321514,0.00002281225,0.000019410107,0.0000069718444,0.000016286933,0.0001439418],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99764735,0.0006114265,0.0011791394,0.00021067183,0.00011177421,0.00023967058],"domain_scores_gemma":[0.99592465,0.0014000181,0.0021513028,0.0003602324,0.00012698294,0.00003681439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034527603,0.00020661937,0.0016777818,0.00037859296,0.00009535924,0.0000045393385,0.0008959574,0.0001728309,0.000014392904],"category_scores_gemma":[0.00018892236,0.00011198422,0.00056665915,0.0009232324,0.0005086872,0.000049209753,0.0002563948,0.00015180405,0.0000015722802],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44422704,0.002935236,0.029464073,0.00016379956,0.04089943,0.000013595125,0.012784911,0.0017497462,0.29056445,0.00038321223,0.0030556004,0.17375891],"study_design_scores_gemma":[0.101002395,0.0058504203,0.52846354,0.00038574063,0.014390294,0.00036598957,0.0023771527,0.000119026874,0.34531036,0.00012872997,0.0012547994,0.00035157794],"about_ca_topic_score_codex":0.000097068434,"about_ca_topic_score_gemma":0.000029545148,"teacher_disagreement_score":0.49899945,"about_ca_system_score_codex":0.00004462028,"about_ca_system_score_gemma":0.000114426606,"threshold_uncertainty_score":0.4566584},"labels":[],"label_agreement":null},{"id":"W4385632390","doi":"10.1111/exd.14595","title":"Issue Information","year":2023,"lang":"en","type":"paratext","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leibniz-Gemeinschaft; Szegedi Tudományegyetem; Universitätsklinikum Köln; Paracelsus Medizinische Privatuniversität; Humanitas University; Rheinische Friedrich-Wilhelms-Universität Bonn; Université de Bordeaux; Peking University First Hospital; Universität Wien; Radboud Universitair Medisch Centrum; Medizinische Universität Wien; Technische Universität München; Universitätsklinikum Regensburg; Chinese Academy of Medical Sciences; Zhejiang University; Université de Toulouse; Thammasat University; Universidad de Murcia; University of California, San Diego; Johns Hopkins University; Universität zu Lübeck; Imperial College London; University of Toronto; Eidgenössische Technische Hochschule Zürich; Hebrew University of Jerusalem; King's College London; Albert-Ludwigs-Universität Freiburg; York University; Universiteit Leiden; Universität Heidelberg; Karl-Franzens-Universität Graz; University of California, Irvine; University of Leeds; Westfälische Wilhelms-Universität Münster; University of Hull; China Agricultural University; University of Queensland; Universität zu Köln; Northwestern University; Centre Hospitalier Universitaire Vaudois; Universidad de Las Palmas de Gran Canaria; Peking University; Fourth Military Medical University; Harvard University; Queen Mary University of London; Helsingin Yliopisto; Peking Union Medical College; Xiamen University; University of Miami; Yonsei University; University of Southern California; Shenzhen University; Radboud Universiteit; Medizinische Universität Graz; University of Pennsylvania; Philipps-Universität Marburg","keywords":"Citation; Computer science; Citation impact; Information retrieval; World Wide Web; Internet privacy; Library science","score_opus":0.014868328905723573,"score_gpt":0.27306534455317527,"score_spread":0.2581970156474517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385632390","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03241891,0.0771537,0.00006436396,0.0011166538,0.120817944,0.0017026928,0.0018777204,0.00090455235,0.76394343],"genre_scores_gemma":[0.14038351,0.0015609614,0.000081067046,0.001315866,0.00047848318,0.00090362394,0.03579272,0.00014823329,0.8193355],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824935,0.00022700433,0.00054333225,0.00035245722,0.00005139593,0.00057643896],"domain_scores_gemma":[0.99914956,0.00010108307,0.00025970183,0.00041201775,0.00004102966,0.000036592377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004502905,0.0004852004,0.0007110501,0.00036726653,0.00023719156,0.00003197279,0.00035406384,0.0012434416,0.026291048],"category_scores_gemma":[0.000014221461,0.00046059475,0.00021710782,0.00018334288,0.00018450589,0.000226135,0.00020069878,0.0003212705,0.73334503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099695324,0.00009139307,0.000011951699,0.000046865753,0.00043447933,0.000025723532,0.0007750362,0.0000012558451,0.009291919,0.0001525857,0.9862474,0.0028216937],"study_design_scores_gemma":[0.0011383076,0.00007001515,0.00004013698,0.000027706334,0.000049387996,0.00035703584,0.00049218076,5.0993657e-7,0.25323835,0.0000053208305,0.7442623,0.00031878927],"about_ca_topic_score_codex":0.000116057316,"about_ca_topic_score_gemma":0.000004403351,"teacher_disagreement_score":0.70705396,"about_ca_system_score_codex":0.00010666221,"about_ca_system_score_gemma":0.00011928998,"threshold_uncertainty_score":0.9997846},"labels":[],"label_agreement":null},{"id":"W4385717019","doi":"10.1177/12034754231191458","title":"The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study","year":2023,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Sudbury; Probity Medical Research; NOSM University; Queen's University; Ottawa Hospital","funders":"AbbVie Canada","keywords":"Medicine; Psoriasis; Interleukin 23; Internal medicine; Retrospective cohort study; Interleukin 17; Dermatology; Cytokine","score_opus":0.01404381453959699,"score_gpt":0.2515057131252639,"score_spread":0.23746189858566688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385717019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966208,0.0013491109,0.000004475217,0.00021609366,0.0013594845,0.0003468183,0.000007659328,0.000013906292,0.0000816663],"genre_scores_gemma":[0.99933136,0.00043142273,0.0000044286994,0.000025956833,0.00006635988,0.000013835524,0.000009055546,0.00001687859,0.00010072366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976791,0.00094579486,0.0007144472,0.00019581089,0.00016690101,0.00029794563],"domain_scores_gemma":[0.99545985,0.003800259,0.00031709604,0.00017916782,0.00019915933,0.000044454577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022983004,0.00019963512,0.00092431146,0.00048469706,0.00018116392,0.00001038209,0.00013734987,0.00012240792,0.000017528952],"category_scores_gemma":[0.0013725589,0.0001182795,0.00018966146,0.00061566476,0.00007959973,0.00007927734,0.000043258347,0.0002382838,0.000008259216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010571677,0.0006019399,0.9494697,0.000064989166,0.002018489,0.001288058,0.005058461,0.000061070416,0.0037981023,0.000029558638,0.004677479,0.022360513],"study_design_scores_gemma":[0.012306963,0.0046992386,0.9640743,0.0014037576,0.0008739977,0.0009252734,0.010928369,0.0000055736286,0.0018897008,0.0009659065,0.0015287257,0.00039819226],"about_ca_topic_score_codex":0.00007453113,"about_ca_topic_score_gemma":0.00009332192,"teacher_disagreement_score":0.021962322,"about_ca_system_score_codex":0.00008654308,"about_ca_system_score_gemma":0.00009050525,"threshold_uncertainty_score":0.48232982},"labels":[],"label_agreement":null},{"id":"W4385778731","doi":"10.1177/12034754231191509","title":"Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2023,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Alberta; Dermatrials Research; Health Sciences Centre; Sunnybrook Health Science Centre; Memorial University of Newfoundland; Guenther Dermatology Research Centre; University of British Columbia; Probity Medical Research; University of Calgary; Innovaderm (Canada); Vancouver Coastal Health; Vancouver Coastal Health Research Institute","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs; Université Laval","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Population; Internal medicine; Subgroup analysis; Disease; Comorbidity; Demographics; Demography; Confidence interval; Dermatology","score_opus":0.03307455217286389,"score_gpt":0.2666509725247371,"score_spread":0.23357642035187318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385778731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957971,0.001298477,0.0000024670849,0.001958757,0.00068984414,0.00006265513,0.00003566095,0.0000031484567,0.0001519109],"genre_scores_gemma":[0.99241436,0.0070937863,0.000012097422,0.00018233896,0.00012009747,0.000001482038,0.00006743808,0.000006401448,0.00010200949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988561,0.0002204325,0.00054052216,0.00009790802,0.00008540059,0.00019961625],"domain_scores_gemma":[0.9981669,0.0012271127,0.00031808912,0.000110536406,0.00012471016,0.00005263853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011610397,0.00011468728,0.0004677961,0.0006917199,0.00007718156,0.0000066132943,0.00007938038,0.00010229043,0.000057510955],"category_scores_gemma":[0.00040401876,0.00006908453,0.000059326412,0.0003436315,0.00012336628,0.0000406673,0.000012181197,0.00018340816,0.0000021997248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018149972,0.00007672528,0.9262346,0.000045026358,0.00016969637,0.0010946,0.0007282984,3.6135216e-7,0.0005703594,0.000023545483,0.01981637,0.051058907],"study_design_scores_gemma":[0.0008835191,0.00034597266,0.97894543,0.00024505157,0.00020920551,0.0018248972,0.0008136173,0.0000036508136,0.00006569509,0.000042846408,0.016530575,0.00008951404],"about_ca_topic_score_codex":0.0028736403,"about_ca_topic_score_gemma":0.0019485421,"teacher_disagreement_score":0.052710846,"about_ca_system_score_codex":0.00002560401,"about_ca_system_score_gemma":0.00016687257,"threshold_uncertainty_score":0.43441036},"labels":[],"label_agreement":null},{"id":"W4385797942","doi":"10.1111/ddg.15121_g","title":"Schulungsangebot korreliert mit stärkerer Verbesserung und höherer Adhärenz bei Psoriasis‐Patienten, die auf Ixekizumab ansprechen","year":2023,"lang":"de","type":"letter","venue":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Ixekizumab; Psoriasis; Medicine; Psychology; Dermatology","score_opus":0.031866775845977295,"score_gpt":0.2755889316506393,"score_spread":0.243722155804662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385797942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11923493,0.72699594,0.00096815755,0.0835994,0.053862974,0.0048529822,0.0026787275,0.002076094,0.0057308017],"genre_scores_gemma":[0.17364456,0.35230762,0.010197776,0.13557486,0.038796257,0.003678092,0.02788132,0.007162927,0.25075656],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771797,0.0057587572,0.005279331,0.003938091,0.0015058349,0.006338298],"domain_scores_gemma":[0.9864707,0.0030669726,0.0040902863,0.0034944264,0.0018331129,0.001044509],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0022054838,0.005025427,0.0059233992,0.0026250363,0.0036582001,0.0012753356,0.0051137945,0.01130357,0.0035332374],"category_scores_gemma":[0.00091141753,0.004399769,0.0036747397,0.0016994764,0.0017967197,0.0015113634,0.0018917951,0.01408761,0.044549316],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030226007,0.0016280059,0.023102738,0.0013045816,0.06924517,0.016868867,0.004048057,0.00007849354,0.0022200549,0.00007409311,0.8557001,0.022707276],"study_design_scores_gemma":[0.012967765,0.0010993469,0.0068573034,0.0022322007,0.029075656,0.0047360705,0.00096920406,0.00009727081,0.013001873,0.0007477675,0.92311627,0.0050992747],"about_ca_topic_score_codex":0.00044043807,"about_ca_topic_score_gemma":0.00013629308,"teacher_disagreement_score":0.3746883,"about_ca_system_score_codex":0.0010784387,"about_ca_system_score_gemma":0.0017018287,"threshold_uncertainty_score":0.99976146},"labels":[],"label_agreement":null},{"id":"W4385798576","doi":"10.1080/09546634.2023.2245081","title":"Fixed-combination halobetasol propionate and tazarotene topical lotion decreases TNF-α and IL-17A levels in psoriatic lesions","year":2023,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Medicine; Lotion; Tazarotene; Dermatology; Psoriasis; Clobetasol propionate; Pharmacology","score_opus":0.04533301504517874,"score_gpt":0.27711150266847906,"score_spread":0.23177848762330033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385798576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946926,0.0030009544,0.00003471303,0.0016525073,0.00027200542,0.00024854465,0.000023645867,0.000028914328,0.00004610604],"genre_scores_gemma":[0.9971383,0.0022999428,0.0002353832,0.000035392175,0.000024379824,0.000028562763,0.000039242113,0.0000066587563,0.00019211655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99879915,0.0002968257,0.00042955356,0.0001850879,0.000059058148,0.00023034964],"domain_scores_gemma":[0.9992807,0.0003402104,0.00018226942,0.00008732482,0.000051034367,0.000058474758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014574353,0.00018167516,0.00043180076,0.0002034801,0.00012981446,0.000020079744,0.000062270425,0.00020377872,0.000050263978],"category_scores_gemma":[0.00013683623,0.00011309182,0.00009318499,0.00016023836,0.00008864793,0.00011741817,0.000037919184,0.000110384084,0.00003630716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069029676,0.0027245877,0.3359316,0.000078506,0.0009351757,0.0016893959,0.0007944479,0.000027707003,0.01650482,0.004886733,0.00052070623,0.635216],"study_design_scores_gemma":[0.0062388116,0.00109099,0.97137046,0.00009498787,0.00023189487,0.0016708955,0.0001655956,0.000040059636,0.014287028,0.0033425682,0.0013054821,0.0001612474],"about_ca_topic_score_codex":0.000013262945,"about_ca_topic_score_gemma":0.000011835094,"teacher_disagreement_score":0.63543886,"about_ca_system_score_codex":0.000080993275,"about_ca_system_score_gemma":0.00004180764,"threshold_uncertainty_score":0.46117505},"labels":[],"label_agreement":null},{"id":"W4385988552","doi":"10.1016/j.jlr.2023.100428","title":"Eicosapentaenoic acid reduces the proportion of IL-17A–producing T cells in a 3D psoriatic skin model","year":2023,"lang":"en","type":"article","venue":"Journal of Lipid Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Psoriasis; Eicosapentaenoic acid; STAT protein; Chemistry; FOXP3; Immunology; Biology; Cell biology; Cancer research; Medicine; Signal transduction; Polyunsaturated fatty acid; Biochemistry; Fatty acid; STAT3; Immune system","score_opus":0.07072322292242546,"score_gpt":0.34193400848374556,"score_spread":0.2712107855613201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385988552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965139,0.0013684904,0.00001563689,0.0008314239,0.00080354017,0.00028040275,0.000012569428,0.000009025521,0.00016498663],"genre_scores_gemma":[0.9967376,0.0013463232,0.00013381797,0.000008308971,0.000246363,0.000017630497,0.000008955542,0.000014869499,0.0014861546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997702,0.0007671368,0.0006401788,0.00018808787,0.00027204645,0.0004305617],"domain_scores_gemma":[0.99878526,0.00030025735,0.00031411584,0.00025676168,0.0003156311,0.000027977998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048214076,0.00011631513,0.0003269934,0.00067057216,0.00017478393,0.000018923216,0.00040437127,0.00014141639,0.00010293849],"category_scores_gemma":[0.0002763255,0.0000710939,0.0001381944,0.00087707455,0.00017359981,0.00013305689,0.00010880536,0.00057831604,0.00014698412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048246837,0.00027475317,0.0013690881,0.000048437876,0.00018718302,0.000022211369,0.0027296746,0.0007993077,0.9443492,0.000034646255,0.003526039,0.046176933],"study_design_scores_gemma":[0.0015854705,0.00053105206,0.012796085,0.00017831691,0.00005589533,0.000057042078,0.001235009,0.00031011063,0.9814307,0.0003784389,0.0013427517,0.00009909902],"about_ca_topic_score_codex":0.00003050253,"about_ca_topic_score_gemma":0.000015238248,"teacher_disagreement_score":0.046077833,"about_ca_system_score_codex":0.0000920557,"about_ca_system_score_gemma":0.00032222955,"threshold_uncertainty_score":0.2899125},"labels":[],"label_agreement":null},{"id":"W4386042284","doi":"10.1016/s2665-9913(23)00120-0","title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","year":2023,"lang":"en","type":"article","venue":"The Lancet Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Probity Medical Research; University of Toronto","funders":"Eli Lilly and Company","keywords":"Secukinumab; Medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Plaque psoriasis; Adverse effect; Surgery; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.05122242741578401,"score_gpt":0.3182541849661377,"score_spread":0.2670317575503537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386042284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412787,0.0018303007,0.0000041575827,0.00065870036,0.00037227932,0.0026612403,0.0001420066,0.000038815306,0.00016465706],"genre_scores_gemma":[0.99565166,0.0038425848,0.000022444283,0.000016837754,0.000015639522,0.0002781105,0.00008939569,0.000017360451,0.00006595861],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99768776,0.00085144857,0.00056397956,0.0003896898,0.00006316505,0.0004439749],"domain_scores_gemma":[0.9965748,0.002613563,0.00021445678,0.0005289094,0.000039067178,0.000029180372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060013216,0.00030158935,0.0011471974,0.0001904253,0.00018695628,0.000012302959,0.0002860014,0.00018665356,0.00004200122],"category_scores_gemma":[0.00008205627,0.00017421624,0.00009397571,0.00035588443,0.00022701117,0.000040492778,0.0000762737,0.00012694857,0.000060056682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91981804,0.0024920125,0.008330701,0.00005258063,0.0018642603,0.0000381368,0.040678646,0.00013179416,0.00049062184,0.0004639158,0.0002994189,0.025339866],"study_design_scores_gemma":[0.964978,0.0029240476,0.018000405,0.000056650486,0.0006797685,0.00014953454,0.008049775,0.00009276745,0.0029293003,0.000053609616,0.0018144394,0.0002716922],"about_ca_topic_score_codex":0.000467567,"about_ca_topic_score_gemma":0.0009573863,"teacher_disagreement_score":0.045159962,"about_ca_system_score_codex":0.000036983038,"about_ca_system_score_gemma":0.000051421663,"threshold_uncertainty_score":0.7104332},"labels":[],"label_agreement":null},{"id":"W4386128682","doi":"10.2139/ssrn.4546761","title":"A Machine Learning Model to Predict Psoriasis Incidence Based on Neighborhood Characteristics: A Populational Study from Quebec, Canada","year":2023,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Sherbrooke; Centre de Recherche Dermatologique du Québec Métropolitain; Memorial University of Newfoundland; McGill University","funders":"","keywords":"Incidence (geometry); Demography; Psoriasis; Geography; Medicine; Data science; Computer science; Sociology; Mathematics","score_opus":0.01749366667287063,"score_gpt":0.2412264252976255,"score_spread":0.22373275862475486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386128682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98647004,0.0015557616,0.006279661,0.00095997716,0.0025231193,0.0008217879,0.0012226345,0.0001292028,0.00003781964],"genre_scores_gemma":[0.9921053,0.00039271524,0.000055779972,0.00016308762,0.00040651404,0.00013619468,0.0025009369,0.00008804211,0.0041514463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956247,0.0006558209,0.0007287653,0.0008030142,0.0002939265,0.0018937618],"domain_scores_gemma":[0.99840605,0.00031296595,0.000537594,0.00048136534,0.00015996966,0.000102056285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009872495,0.0006038229,0.00076215196,0.00034574448,0.00051286444,0.00007939881,0.0006800095,0.00041046177,0.00015491212],"category_scores_gemma":[0.00033711875,0.0005549075,0.00023487149,0.00018384715,0.000024434568,0.000060562845,0.00028412137,0.004259094,0.00011705693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004414695,0.0014888053,0.7862349,0.00003424289,0.0074699386,0.00021146846,0.0013538018,0.14461763,0.0008477063,0.00082996837,0.00096399453,0.05153281],"study_design_scores_gemma":[0.016820382,0.0043385956,0.8345759,0.001122266,0.004594362,0.0001579818,0.0037136443,0.086715974,0.00026845335,0.042672165,0.0010747414,0.00394553],"about_ca_topic_score_codex":0.6211173,"about_ca_topic_score_gemma":0.94274986,"teacher_disagreement_score":0.3216326,"about_ca_system_score_codex":0.0034488896,"about_ca_system_score_gemma":0.012999203,"threshold_uncertainty_score":0.99969023},"labels":[],"label_agreement":null},{"id":"W4386162778","doi":"10.51731/cjht.2023.720","title":"Deucravacitinib (Sotyktu)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Clinical trial; Intensive care medicine; Internal medicine","score_opus":0.036647230691082354,"score_gpt":0.2688750822448455,"score_spread":0.23222785155376316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386162778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83149487,0.13896401,0.000056168832,0.024767889,0.0030084457,0.00024184212,0.00011606246,0.0005385595,0.00081214827],"genre_scores_gemma":[0.9978706,0.001123359,0.00008191259,0.00016586199,0.000008778894,0.0000062117233,0.00002283914,0.000012808298,0.00070761406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871194,0.00009853462,0.0004355144,0.00012322767,0.000029911991,0.0006008445],"domain_scores_gemma":[0.9993048,0.00009145722,0.00027624457,0.00020948687,0.00008497133,0.000033066364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058636384,0.00012867426,0.00033531783,0.0008856433,0.0003578232,0.000014605036,0.00037148214,0.000250816,0.000107310516],"category_scores_gemma":[0.00031522664,0.000106064734,0.00009829624,0.00053093414,0.00021280562,0.00006898389,0.000020562695,0.00028051634,0.00056880247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014245831,0.000009501449,0.006449139,0.00002153846,0.0001290324,0.00016180552,0.00029156407,0.0000031939687,0.0007578463,0.0011570491,0.0370073,0.9539978],"study_design_scores_gemma":[0.0011412047,0.0005125467,0.041119214,0.00013340161,0.000034980578,0.00061739434,0.0046711857,6.22956e-7,0.009102233,0.0039808247,0.938476,0.0002103859],"about_ca_topic_score_codex":0.001332967,"about_ca_topic_score_gemma":0.0017946393,"teacher_disagreement_score":0.9537874,"about_ca_system_score_codex":0.00014399835,"about_ca_system_score_gemma":0.0012908201,"threshold_uncertainty_score":0.7310995},"labels":[],"label_agreement":null},{"id":"W4386163009","doi":"10.1016/j.jdin.2023.08.011","title":"Neighborhood characteristics and the risk of psoriasis: A systematic review","year":2023,"lang":"en","type":"review","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; McGill University Health Centre; McGill University","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.030631956435638312,"score_gpt":0.2946133798668182,"score_spread":0.26398142343117986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386163009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000028597317,0.99498534,0.000008240168,0.00007405555,0.0017918685,0.0014158002,0.0011193432,0.000037457037,0.0005650521],"genre_scores_gemma":[0.00001716353,0.99375975,0.000007486676,0.00005900449,0.00011254338,0.00063787727,0.00080185354,0.000031750977,0.0045725843],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974549,0.0009453213,0.0010938966,0.00027172835,0.00008221142,0.00015196184],"domain_scores_gemma":[0.99671465,0.0013715253,0.001400252,0.00038994133,0.00011000555,0.000013650379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094300223,0.00032225373,0.0023888026,0.00013598759,0.00007550149,0.000018075329,0.0004952678,0.0002569267,0.00017572573],"category_scores_gemma":[0.001198332,0.00016998453,0.0006525342,0.00015509638,0.00014874397,0.00003438025,0.00014594547,0.00025393718,0.0006781516],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004810334,0.000082486906,0.000033778608,0.7904827,0.0139088,0.000007836565,0.000105550185,8.8208365e-9,3.0230146e-7,0.0064715235,0.002451507,0.18640739],"study_design_scores_gemma":[0.0015663253,0.000045738205,0.00004293279,0.58131987,0.030808916,0.00025605402,0.0000212921,0.0000017740657,0.000001095521,0.00027453323,0.38533273,0.0003287433],"about_ca_topic_score_codex":0.000012092364,"about_ca_topic_score_gemma":0.0000017588087,"teacher_disagreement_score":0.38288125,"about_ca_system_score_codex":0.000040116433,"about_ca_system_score_gemma":0.00007436666,"threshold_uncertainty_score":0.8716493},"labels":[],"label_agreement":null},{"id":"W4386193192","doi":"10.1016/j.jaad.2023.08.057","title":"Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review","year":2023,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Pityriasis rubra pilaris; Medicine; Dermatology; Secukinumab; Scopus; MEDLINE; Psoriasis","score_opus":0.15731246814195635,"score_gpt":0.39652969027962864,"score_spread":0.2392172221376723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386193192","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023299614,0.99411994,0.00003837828,0.0020599316,0.0005317123,0.0026719908,0.00030590035,0.00003639301,0.0000027368117],"genre_scores_gemma":[0.00022754737,0.9980672,0.0003032409,0.0005227935,0.0000789129,0.00053156,0.000054844946,0.00005756855,0.0001563256],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920826,0.0042617843,0.0026874465,0.00038176635,0.00010232966,0.00048407665],"domain_scores_gemma":[0.98726636,0.0036526246,0.008341052,0.00053804036,0.00013255962,0.00006937348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086514145,0.00064754795,0.0074719074,0.0005152426,0.0002093756,0.000011541057,0.0014912706,0.0005589253,0.000025350815],"category_scores_gemma":[0.0009938107,0.00033330626,0.0028883847,0.00076916756,0.0006367948,0.00012213155,0.00009510237,0.0005272439,0.00009100582],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003395199,0.0009201798,0.000088301334,0.81952006,0.016225452,0.00004961069,0.000103346836,0.000005083454,0.0002323232,0.00039444832,0.005663377,0.15645832],"study_design_scores_gemma":[0.0016771681,0.002210046,0.000055807788,0.69296396,0.076928005,0.008221288,0.00015076861,0.0000017459586,0.00046068354,0.0001719835,0.21637113,0.00078743196],"about_ca_topic_score_codex":0.000012979382,"about_ca_topic_score_gemma":0.0000017818279,"teacher_disagreement_score":0.21070775,"about_ca_system_score_codex":0.0002380145,"about_ca_system_score_gemma":0.0006536111,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W4386201054","doi":"","title":"SOTYKTU<sup>TM</sup> (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Psoriasis; Internal medicine; Dosing; Placebo; Regimen; Acne; Dermatology; Gastroenterology; Pathology","score_opus":0.0318056957942081,"score_gpt":0.23216353631710127,"score_spread":0.20035784052289318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386201054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94247884,0.011764698,0.0019194015,0.010076302,0.006942862,0.013404915,0.0019417711,0.0010179932,0.01045321],"genre_scores_gemma":[0.92567176,0.0034250563,0.0003193733,0.00048113006,0.00029374924,0.008972878,0.0007308254,0.00007223621,0.060033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822813,0.00009758543,0.00040397345,0.00040987856,0.00007635466,0.00078406633],"domain_scores_gemma":[0.9988359,0.00036639112,0.00015734119,0.00052444736,0.000066637454,0.000049246726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040795517,0.0002704307,0.00036265145,0.0001401596,0.00024059687,0.00002097857,0.0004387627,0.0002013966,0.00016240707],"category_scores_gemma":[0.000055178174,0.00019395792,0.00026958904,0.00039457227,0.00009173495,0.00007908242,0.00014483044,0.00010606427,0.0004009761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010074243,0.00022722772,0.0008170102,0.00020000814,0.004410074,0.000032448806,0.00090210035,0.00015758269,0.0006505717,0.0059686243,0.13141206,0.85421485],"study_design_scores_gemma":[0.015873661,0.00020371741,0.12877038,0.00009147707,0.0023671812,0.000040927025,0.002888287,0.00008471826,0.030561918,0.0020367117,0.81632197,0.00075902557],"about_ca_topic_score_codex":0.0001301149,"about_ca_topic_score_gemma":0.00002560981,"teacher_disagreement_score":0.85345584,"about_ca_system_score_codex":0.000053331827,"about_ca_system_score_gemma":0.000036562087,"threshold_uncertainty_score":0.7909374},"labels":[],"label_agreement":null},{"id":"W4386332794","doi":"10.1007/s13555-023-01007-w","title":"Causal Associations Between Gut Microbiota and Psoriasis: A Mendelian Randomization Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Mendelian randomization; Psoriasis; Odds ratio; Medicine; Internal medicine; Genome-wide association study; Observational study; Genetics; Single-nucleotide polymorphism; Biology; Dermatology; Gene; Genotype","score_opus":0.02638600789472362,"score_gpt":0.2723551934737127,"score_spread":0.24596918557898906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438184,0.0035573533,0.00001773829,0.00079298357,0.00037410008,0.0004900778,0.00011667978,0.00015517528,0.000114073635],"genre_scores_gemma":[0.9967711,0.0020694856,0.000014543487,0.00011316772,0.000036728914,0.00006858646,0.00052218226,0.000015805615,0.00038840566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986538,0.0004833358,0.0002620544,0.0002976547,0.000023195857,0.00027990094],"domain_scores_gemma":[0.9993703,0.00032126863,0.00009826943,0.00014976219,0.000034610937,0.000025785837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023745002,0.00018527087,0.00042235572,0.00019697084,0.0004311816,0.000020836476,0.00007763793,0.00027845136,0.000049632323],"category_scores_gemma":[0.00002647613,0.00015617377,0.000047284822,0.00023436558,0.00010311227,0.00007139888,0.000039408213,0.00011132288,0.00013821373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006340065,0.00031799282,0.89083344,0.000009235664,0.0029309609,0.0000460885,0.0054887254,6.8815615e-7,0.029011298,0.0005262466,0.0036326596,0.06656867],"study_design_scores_gemma":[0.024641609,0.0002020869,0.9581766,0.000008043464,0.0003051155,0.00011640689,0.0008657676,0.000003345118,0.006060004,0.0006796699,0.008638441,0.00030291564],"about_ca_topic_score_codex":0.00005566128,"about_ca_topic_score_gemma":0.000039283437,"teacher_disagreement_score":0.06734317,"about_ca_system_score_codex":0.000009477402,"about_ca_system_score_gemma":0.000022289696,"threshold_uncertainty_score":0.63685817},"labels":[],"label_agreement":null},{"id":"W4386370870","doi":"10.3899/jrheum.2023-0500","title":"Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis","year":2023,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Immunology; Disease; Dermatology; Internal medicine","score_opus":0.02380100647479459,"score_gpt":0.2568516698577709,"score_spread":0.23305066338297634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386370870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698765,0.010986087,0.000043816955,0.001406798,0.00043114708,0.000054562584,0.0000073262095,0.0000056015915,0.00007698556],"genre_scores_gemma":[0.96445405,0.035454847,0.00001754259,0.000014752264,0.0000024824571,8.509137e-7,0.0000013285063,0.0000048323127,0.000049308754],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9991913,0.0002546201,0.0003031363,0.00006440852,0.000023233146,0.00016329372],"domain_scores_gemma":[0.99872404,0.0008982754,0.00027579375,0.0000648044,0.000024653385,0.000012453129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005135793,0.00008750167,0.00037374682,0.0002042185,0.0000734248,0.0000031635952,0.000091540605,0.00009029958,0.0000079072515],"category_scores_gemma":[0.00012284718,0.00005604824,0.000034873974,0.0001232265,0.0001520046,0.00006802045,0.000040145802,0.00011256891,0.000005202713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004220669,0.000099892546,0.9231279,0.00021730663,0.0011927311,0.000049379618,0.011374508,0.00007847262,0.023727557,0.010859157,0.003068659,0.021983793],"study_design_scores_gemma":[0.08198264,0.006161281,0.3397697,0.0023713543,0.0025899909,0.03992865,0.34665605,0.00013933283,0.043281578,0.116124265,0.019355569,0.0016395685],"about_ca_topic_score_codex":0.00006746713,"about_ca_topic_score_gemma":0.00015446106,"teacher_disagreement_score":0.58335817,"about_ca_system_score_codex":0.000018228551,"about_ca_system_score_gemma":0.00002551753,"threshold_uncertainty_score":0.2285581},"labels":[],"label_agreement":null},{"id":"W4386640130","doi":"10.1016/j.clim.2023.109771","title":"Architecture of skin inflammation in psoriasis revealed by spatial transcriptomics","year":2023,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Arthritis Network; Institute of Musculoskeletal Health and Arthritis; Arthritis Society; Mitacs; Canadian Dermatology Foundation","keywords":"Psoriasis; Inflammation; Dermis; Innate immune system; Papillary dermis; Transcriptome; Biology; Chemokine; Cytokine; Immunology; Skin repair; Reticular Dermis; Proinflammatory cytokine; Medicine; Immune system; Pathology; Wound healing; Gene expression; Genetics; Gene","score_opus":0.025365306986128596,"score_gpt":0.2942631373311596,"score_spread":0.268897830345031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386640130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465436,0.0016378993,0.00018383365,0.0006778958,0.002037629,0.00030280245,0.0001058481,0.00010504131,0.00029470085],"genre_scores_gemma":[0.9963427,0.0015560862,0.00007990576,0.00005405841,0.00008456444,0.000053992957,0.0006850775,0.000023150807,0.001120455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997287,0.0008232182,0.0010570417,0.00038682792,0.000034967998,0.0004109929],"domain_scores_gemma":[0.9984605,0.00083689205,0.00025166964,0.00038165008,0.0000497006,0.000019621559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007124622,0.00020901358,0.00067176705,0.00026367034,0.000059359405,0.000004087722,0.00030517697,0.0008274349,0.00033878593],"category_scores_gemma":[0.00037532183,0.00019021795,0.00025283181,0.00041525997,0.00038687428,0.000046386456,0.000068376794,0.00043988595,0.0005569133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017089158,0.00035409915,0.038757034,0.000025886793,0.00078775367,0.00001558718,0.00076766574,0.000014623988,0.37472108,0.00029179594,0.0027728581,0.5797827],"study_design_scores_gemma":[0.017427525,0.0015143356,0.72065103,0.00010483466,0.0003629088,0.000036914218,0.00038190358,0.000024845123,0.19739324,0.0027147317,0.05877329,0.0006144647],"about_ca_topic_score_codex":0.0002096507,"about_ca_topic_score_gemma":0.00023338426,"teacher_disagreement_score":0.68189394,"about_ca_system_score_codex":0.000028350818,"about_ca_system_score_gemma":0.00006368473,"threshold_uncertainty_score":0.77568626},"labels":[],"label_agreement":null},{"id":"W4386884687","doi":"10.1007/s13555-023-01002-1","title":"Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Adverse effect; Palmoplantar pustulosis; Internal medicine; Dosing; Confidence interval; Randomized controlled trial; Gastroenterology; Psoriasis; Dermatology","score_opus":0.022892398002283324,"score_gpt":0.27479690215286845,"score_spread":0.25190450415058513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386884687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926296,0.0018851076,0.00000692845,0.00017260374,0.00023763174,0.004809033,0.000049503204,0.00009939772,0.000110233545],"genre_scores_gemma":[0.9979586,0.0009709055,0.000015388025,0.00014205594,0.0000148174295,0.00050004805,0.0002454929,0.000030400082,0.00012229128],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99778694,0.00051114033,0.00047252083,0.00058497,0.00006053607,0.00058389583],"domain_scores_gemma":[0.99902886,0.00046637547,0.0001372201,0.00024977393,0.000044199987,0.00007356958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027930998,0.0004103677,0.00097049476,0.00040708258,0.0004094502,0.000033852473,0.0001394824,0.00027955347,0.000060600534],"category_scores_gemma":[0.000018879431,0.00029595802,0.0000630286,0.00031674816,0.00010571174,0.00011790521,0.000059036905,0.00022732113,0.000102714075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7897075,0.0021869834,0.19188935,0.000013669036,0.0015182134,0.00015897943,0.0041232407,0.000030042791,0.00023895245,0.0000302086,0.000062713036,0.01004017],"study_design_scores_gemma":[0.8992212,0.0007524099,0.09760282,0.000037398102,0.00022635059,0.00009403713,0.00074195507,0.000034662233,0.0006470351,0.000013877354,0.00027287597,0.0003553737],"about_ca_topic_score_codex":0.00004034152,"about_ca_topic_score_gemma":0.00009396478,"teacher_disagreement_score":0.10951372,"about_ca_system_score_codex":0.000021357971,"about_ca_system_score_gemma":0.00003563237,"threshold_uncertainty_score":0.9999493},"labels":[],"label_agreement":null},{"id":"W4386886964","doi":"10.1016/j.jaad.2023.08.097","title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.018688156576502652,"score_gpt":0.2841982089956106,"score_spread":0.26551005241910797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386886964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997988,0.0002627401,0.000021641908,0.0008718638,0.00036343018,0.00034843353,0.000055133223,0.000011090354,0.00007766832],"genre_scores_gemma":[0.9994084,0.00019291644,0.00018269487,0.00010703976,0.000026378233,0.000009931076,0.0000059634895,0.000025606427,0.000041072777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686974,0.0015752439,0.00080456043,0.00021802819,0.00014904134,0.00038339783],"domain_scores_gemma":[0.9967864,0.0009882485,0.0017791827,0.00029169113,0.00011795791,0.00003647914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005001134,0.00025200238,0.001144721,0.00046441072,0.00013135583,0.00000551978,0.0007361883,0.0001558975,0.000013671744],"category_scores_gemma":[0.00014201266,0.00014092418,0.00025104676,0.00147255,0.00063849066,0.00009543199,0.00015703875,0.00048136697,0.00000899522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0140422,0.0003575114,0.9572116,0.00014564556,0.0018040098,0.000026553496,0.00062139006,0.001986555,0.016176367,0.00033289226,0.0015085248,0.0057867374],"study_design_scores_gemma":[0.0047789435,0.00030831137,0.9468436,0.00036250445,0.00051366386,0.00037786685,0.00032797927,0.000012424597,0.04561583,0.00028943378,0.0003748955,0.00019453306],"about_ca_topic_score_codex":0.0002080665,"about_ca_topic_score_gemma":0.00001698487,"teacher_disagreement_score":0.029439464,"about_ca_system_score_codex":0.000106667496,"about_ca_system_score_gemma":0.0001527273,"threshold_uncertainty_score":0.57467216},"labels":[],"label_agreement":null},{"id":"W4386944194","doi":"","title":"Topical Roflumilast for Plaque Psoriasis.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Roflumilast; Tolerability; Intertriginous; Medicine; Psoriasis; Dermatology; Plaque psoriasis; Clinical trial; Pharmacology; Adverse effect; Internal medicine; COPD; Disease","score_opus":0.03490502611062755,"score_gpt":0.2358435961882837,"score_spread":0.20093857007765617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386944194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833469,0.0011261591,0.000131965,0.0026284165,0.0054085823,0.0016500233,0.00021171515,0.00060586556,0.0048904093],"genre_scores_gemma":[0.9644026,0.000108724744,0.00004540118,0.00015834416,0.00025423843,0.005275619,0.00036612232,0.000020574756,0.029368369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990418,0.00005457936,0.00015316947,0.00024165837,0.000021021682,0.0004877822],"domain_scores_gemma":[0.99951535,0.00021323159,0.000035012967,0.00018150329,0.000024834344,0.000030038404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019369354,0.00012150296,0.00018559641,0.00009105967,0.00013471035,0.000010951371,0.00013578417,0.00018968683,0.0000793584],"category_scores_gemma":[0.00010059287,0.000103710445,0.0001258707,0.00016281586,0.000045182947,0.00004206643,0.000040340976,0.000061049184,0.0007432436],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003867844,0.00011011349,0.007402893,0.000023614786,0.0004113822,0.0000102427175,0.00015893638,0.0000019716115,0.0023438018,0.0030058648,0.11542139,0.870723],"study_design_scores_gemma":[0.002790621,0.000053815034,0.43690744,0.0000029833407,0.0001023462,0.000011979644,0.00006157691,0.0000016367744,0.030078026,0.00065931014,0.52913904,0.00019119059],"about_ca_topic_score_codex":0.000010079066,"about_ca_topic_score_gemma":0.000015129988,"teacher_disagreement_score":0.8705318,"about_ca_system_score_codex":0.000026013036,"about_ca_system_score_gemma":0.00001450453,"threshold_uncertainty_score":0.95531404},"labels":[],"label_agreement":null},{"id":"W4386955537","doi":"10.1038/s41419-023-06134-y","title":"Depletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-κB signaling in keratinocyte","year":2023,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Keratinocyte; Imiquimod; Cancer research; Apoptosis; Downregulation and upregulation; Immunology; Medicine; Biology; Cell culture; Biochemistry; Genetics","score_opus":0.016665718748192615,"score_gpt":0.22912000295041346,"score_spread":0.21245428420222084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386955537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478024,0.0042704926,0.000085829764,0.00008947351,0.0002783267,0.00022217662,0.000057669426,0.0000681455,0.00014765875],"genre_scores_gemma":[0.99872804,0.00030132054,0.00011801819,0.000082867904,0.00003968687,0.00004748789,0.00051406387,0.000016121683,0.00015241261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989149,0.00016582065,0.0003043983,0.0002660869,0.000039442795,0.00030935358],"domain_scores_gemma":[0.9994746,0.00015517745,0.00010569515,0.00014326922,0.00003543217,0.00008582957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016615923,0.00017520279,0.00025121224,0.0001595472,0.00014138904,0.000014365212,0.00007689938,0.00011048937,0.00009804791],"category_scores_gemma":[0.000095499665,0.00016211224,0.000081613514,0.00019332903,0.000031327818,0.00008400716,0.000045928915,0.00007773994,0.00014040274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027969386,0.00021367252,0.2345354,0.00029704583,0.00009967101,0.00010498,0.00080794253,0.00008654555,0.74215245,0.000067251734,0.0006879639,0.020667369],"study_design_scores_gemma":[0.006712015,0.00022980335,0.3598985,0.00023182404,0.00049582263,0.000008836942,0.00062830263,0.0016171897,0.6272118,0.0018552315,0.00040086743,0.0007097756],"about_ca_topic_score_codex":0.000101924445,"about_ca_topic_score_gemma":0.00001027988,"teacher_disagreement_score":0.12536311,"about_ca_system_score_codex":0.000020141724,"about_ca_system_score_gemma":0.0000627984,"threshold_uncertainty_score":0.6610745},"labels":[],"label_agreement":null},{"id":"W4386979770","doi":"10.1093/bjd/ljad347","title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Institute for Health and Care Research; Psoriasis Association","keywords":"Psoriasis; Medicine; Dermatology; Association (psychology); Dermatologic agents; Plaque psoriasis; MEDLINE; Family medicine; Psychology; Psychotherapist; Political science","score_opus":0.03792392213837212,"score_gpt":0.3033003803270341,"score_spread":0.26537645818866196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386979770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9530592,0.034376238,0.0020773255,0.0052646673,0.003126047,0.0010376986,0.00089922163,0.00009599133,0.00006361694],"genre_scores_gemma":[0.959185,0.03202527,0.0049352623,0.0008229795,0.00026818528,0.00032837965,0.0010723027,0.000064791806,0.0012978513],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738264,0.0003984854,0.0013631277,0.00024459788,0.0000727332,0.0005384422],"domain_scores_gemma":[0.9959762,0.0011572847,0.0014125608,0.00013931189,0.0012775174,0.00003713223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080204045,0.00020068743,0.0010005188,0.00024433262,0.00018390623,0.000036501446,0.00035963967,0.0005535032,0.00015791872],"category_scores_gemma":[0.0022930067,0.00021719588,0.0005139455,0.0002954913,0.00011396718,0.00014559875,0.000041311545,0.00015352297,0.00003815176],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086604455,0.0004071825,0.01953309,0.00021519925,0.002591044,0.00043884641,0.0001274757,0.000016237731,0.0126736965,0.00023208505,0.7197376,0.24316148],"study_design_scores_gemma":[0.066357,0.002151551,0.0736757,0.0013931585,0.0020060788,0.13758492,0.0012819279,0.00015134575,0.12214023,0.017329037,0.57422954,0.0016995326],"about_ca_topic_score_codex":0.00006249496,"about_ca_topic_score_gemma":0.00017282648,"teacher_disagreement_score":0.24146195,"about_ca_system_score_codex":0.000050266135,"about_ca_system_score_gemma":0.00016944451,"threshold_uncertainty_score":0.8856991},"labels":[],"label_agreement":null},{"id":"W4387014163","doi":"10.1016/j.jaad.2023.07.429","title":"43322 A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; McMaster University; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Palmoplantar pustulosis; Epidemiology; Psoriasis; Emergency department; Outpatient visits; Emergency medicine; Population; Outpatient clinic; Family medicine; Dermatology; Internal medicine; Health care; Environmental health; Psychiatry","score_opus":0.02239707966958353,"score_gpt":0.299034380869453,"score_spread":0.27663730119986946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978917,0.00010091644,1.7036426e-7,0.0010020155,0.00022615626,0.000598532,0.00017289852,0.0000034788807,0.000004080166],"genre_scores_gemma":[0.99963254,0.0001880488,0.000025345837,0.00007246158,0.0000050186663,0.000017607414,0.000017485525,0.000012491558,0.000028993989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965332,0.001782143,0.001142874,0.00013193795,0.00012199663,0.00028785414],"domain_scores_gemma":[0.997421,0.00044373077,0.0017810125,0.00023239478,0.00007792075,0.000043888336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039774898,0.0001738619,0.00074384676,0.00040884805,0.00010701599,0.0000018316682,0.0006136521,0.00014683334,0.000037977523],"category_scores_gemma":[0.00035050247,0.00010205234,0.00013579341,0.0007556542,0.00023522618,0.000048285954,0.00010713286,0.000386348,0.0000019571225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011540047,0.0007404797,0.99508685,0.000087149514,0.00022426773,0.00000619327,0.0018536549,0.00016337656,0.00009222879,0.0000013165483,0.00022825348,0.00036224717],"study_design_scores_gemma":[0.003912642,0.0012545402,0.99222857,0.000117069016,0.00020836225,0.000010500563,0.0013386651,0.00002354628,0.00069547474,0.000023436216,0.00008551744,0.000101675425],"about_ca_topic_score_codex":0.023081882,"about_ca_topic_score_gemma":0.007383733,"teacher_disagreement_score":0.015698148,"about_ca_system_score_codex":0.00008226949,"about_ca_system_score_gemma":0.0002346955,"threshold_uncertainty_score":0.9834235},"labels":[],"label_agreement":null},{"id":"W4387014235","doi":"10.1016/j.jaad.2023.07.428","title":"43266 A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Epidemiology; Outpatient visits; Emergency department; Outpatient clinic; Emergency medicine; Population; Generalized pustular psoriasis; Family medicine; Pediatrics; Dermatology; Internal medicine; Environmental health; Health care; Psychiatry","score_opus":0.023984480276759933,"score_gpt":0.30333473389030036,"score_spread":0.27935025361354043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976003,0.00015851915,4.234711e-7,0.0010562756,0.00032730645,0.0007220037,0.00012691836,0.000004499761,0.0000037330362],"genre_scores_gemma":[0.99952704,0.00021851795,0.000059401686,0.00008445158,0.000008055483,0.00002451479,0.000017681266,0.000016474052,0.00004385977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99558663,0.0024195693,0.0013575389,0.00015706418,0.00014861539,0.00033057661],"domain_scores_gemma":[0.9971251,0.0003761164,0.0020495115,0.0002889119,0.00010886451,0.000051520492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005089325,0.00020516667,0.00089982664,0.00047485917,0.00011898673,0.0000024654548,0.00070199196,0.00017805278,0.000046254627],"category_scores_gemma":[0.00048580143,0.00012216394,0.00017941953,0.0009283315,0.0002570949,0.00005714675,0.000121752346,0.00039555423,0.0000019162842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013823841,0.00079549383,0.9943022,0.00008389825,0.0002890485,0.0000061432966,0.0018249571,0.00040902582,0.00015550628,0.0000028618642,0.00025975722,0.000488735],"study_design_scores_gemma":[0.0072016534,0.0012193441,0.98886025,0.00010162978,0.0002666324,0.000008349622,0.0010278164,0.00004874257,0.0009258185,0.000039299593,0.00017482025,0.00012561638],"about_ca_topic_score_codex":0.024852239,"about_ca_topic_score_gemma":0.0056144428,"teacher_disagreement_score":0.019237796,"about_ca_system_score_codex":0.000097539225,"about_ca_system_score_gemma":0.00028500773,"threshold_uncertainty_score":0.98164135},"labels":[],"label_agreement":null},{"id":"W4387014319","doi":"10.1016/j.jaad.2023.07.430","title":"44100 A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; McMaster University; University of Toronto; University of Calgary","funders":"","keywords":"Medicine; Incidence (geometry); Psoriasis; Outpatient visits; Emergency department; Generalized pustular psoriasis; Emergency medicine; Population; Outpatient clinic; Pediatrics; Family medicine; Dermatology; Health care; Internal medicine; Environmental health; Psychiatry","score_opus":0.023270365545776335,"score_gpt":0.30472914957633035,"score_spread":0.281458784030554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754167,0.000113964765,6.326643e-7,0.0012281063,0.0003667564,0.0006543234,0.00008741369,0.000004359076,0.0000027947715],"genre_scores_gemma":[0.999583,0.00015306851,0.00006515408,0.000119763725,0.000008038625,0.000021885551,0.000017417311,0.0000162104,0.000015459258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99566275,0.0023142556,0.0013912173,0.00015015673,0.0001523025,0.00032930897],"domain_scores_gemma":[0.9970707,0.0004057375,0.0020827004,0.00027932276,0.00010914456,0.00005234894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052613404,0.0002024576,0.0009393074,0.0005237586,0.00012504063,0.0000025055253,0.0007006151,0.00018162408,0.000022953076],"category_scores_gemma":[0.0005093128,0.000120595374,0.00017351472,0.0010490696,0.00026236346,0.000061557956,0.0001322102,0.00044737422,0.0000014856518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012204358,0.00067988137,0.9943344,0.00004056184,0.0002646211,0.00000873418,0.0020140011,0.000566011,0.00018283259,0.0000041066305,0.00016598955,0.00051842973],"study_design_scores_gemma":[0.006856446,0.0010797549,0.988919,0.00008398551,0.00020916051,0.000010581701,0.001481253,0.000058319092,0.0010086219,0.0000544265,0.00011497518,0.00012345782],"about_ca_topic_score_codex":0.052941132,"about_ca_topic_score_gemma":0.012960711,"teacher_disagreement_score":0.03998042,"about_ca_system_score_codex":0.00011107085,"about_ca_system_score_gemma":0.0003282818,"threshold_uncertainty_score":0.95336545},"labels":[],"label_agreement":null},{"id":"W4387014395","doi":"10.1016/j.jaad.2023.07.333","title":"44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University; University of British Columbia","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Biologic Agents; Dermatology; Internal medicine; Disease","score_opus":0.016472015054450798,"score_gpt":0.2740454491434924,"score_spread":0.2575734340890416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966241,0.00023686739,0.000018869174,0.0020502685,0.00032028518,0.0005922609,0.00010749166,0.000021296923,0.000028574841],"genre_scores_gemma":[0.99886227,0.00015037779,0.0003186832,0.0004155821,0.000029916613,0.000035718764,0.000019388483,0.0000271366,0.00014090791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979853,0.0004275145,0.0007200786,0.00027088233,0.00009077505,0.0005054683],"domain_scores_gemma":[0.9979953,0.0005793753,0.0011254345,0.0001832616,0.00006499817,0.000051624927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015037703,0.0002910644,0.0010210073,0.00045384452,0.00013855474,0.000006334623,0.0005470805,0.00024697813,0.000036249494],"category_scores_gemma":[0.00011288901,0.00017237381,0.0002774154,0.000664079,0.00026478356,0.00009250067,0.00010710565,0.00032197515,0.00004269951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028307717,0.0014748749,0.90544295,0.000048779028,0.003356562,0.000035051286,0.0009736571,0.0005504213,0.010195214,0.00018455782,0.008751978,0.04067824],"study_design_scores_gemma":[0.015327952,0.0011932182,0.9665681,0.00008138077,0.0003921124,0.00025524772,0.0001283089,0.0000073637793,0.013442056,0.00024260707,0.0021268139,0.00023483818],"about_ca_topic_score_codex":0.000023834587,"about_ca_topic_score_gemma":0.0000052167793,"teacher_disagreement_score":0.061125156,"about_ca_system_score_codex":0.00010093645,"about_ca_system_score_gemma":0.00010023346,"threshold_uncertainty_score":0.70292},"labels":[],"label_agreement":null},{"id":"W4387014407","doi":"10.1016/j.jaad.2023.07.431","title":"44118 A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Impact; University of Calgary; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Incidence (geometry); Outpatient visits; Emergency department; Emergency medicine; Outpatient clinic; Community hospital; Population; Medical emergency; Family medicine; Pediatrics; Environmental health; Health care; Nursing; Internal medicine","score_opus":0.022064892522852757,"score_gpt":0.3003822051454872,"score_spread":0.2783173126226344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978809,0.00008171702,3.0291568e-7,0.0011193969,0.00026682662,0.0005298566,0.00011430657,0.0000034999948,0.0000032038972],"genre_scores_gemma":[0.999673,0.00013014532,0.00003184103,0.00010569474,0.0000048958823,0.000015278947,0.000016941312,0.000012239766,0.000009968785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996585,0.0016871057,0.0011836917,0.00012828448,0.00012306022,0.0002928499],"domain_scores_gemma":[0.9973009,0.00048059586,0.0018652065,0.0002271696,0.000080857564,0.000045243014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040271785,0.00017390223,0.00080416765,0.0004634475,0.0001111865,0.0000018222054,0.0006212574,0.0001585299,0.00001706576],"category_scores_gemma":[0.0003911752,0.00010218989,0.00013246902,0.00085639185,0.0002583093,0.000052420935,0.00011407377,0.00044405274,0.0000016427347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001075979,0.00062278274,0.99514437,0.00004352485,0.00020079028,0.000009981143,0.00198344,0.00025790336,0.00010057239,0.0000018418644,0.00015697179,0.000401872],"study_design_scores_gemma":[0.004037427,0.0011224615,0.99172693,0.000102715436,0.00016599603,0.000016588843,0.0018695953,0.000033198143,0.0007220184,0.000030247913,0.00007064023,0.000102158],"about_ca_topic_score_codex":0.049769484,"about_ca_topic_score_gemma":0.017354913,"teacher_disagreement_score":0.03241457,"about_ca_system_score_codex":0.000093653674,"about_ca_system_score_gemma":0.00027707746,"threshold_uncertainty_score":0.9684449},"labels":[],"label_agreement":null},{"id":"W4387014730","doi":"10.1016/j.jaad.2023.07.221","title":"44094 Impact of Risankizumab on Nail Psoriasis and Enthesitis Among Psoriatic Arthritis Patients with High Nail Symptom Burden","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Enthesitis; Dactylitis; Arthritis; Internal medicine","score_opus":0.007079896877637167,"score_gpt":0.2400602803463201,"score_spread":0.23298038346868294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973591,0.0009331863,0.0000025243064,0.0010533188,0.00029335916,0.00019343288,0.00010959362,0.000017487167,0.000037989113],"genre_scores_gemma":[0.9982267,0.0014921858,0.000060199054,0.000078796176,0.00004908925,0.000007029244,0.00000981341,0.000026695145,0.000049515464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788207,0.0006009787,0.0007612474,0.0002117045,0.00015523833,0.00038875648],"domain_scores_gemma":[0.9970313,0.0005956511,0.0020287018,0.00019893369,0.00008753143,0.000057934736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016668212,0.0002804692,0.0011359999,0.00040023623,0.00012436562,0.000006936842,0.0004332785,0.00020558148,0.000060156304],"category_scores_gemma":[0.000120466364,0.00017236607,0.00033389704,0.00050692656,0.0009502103,0.000118130105,0.000098302764,0.00039187228,0.000022032193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035411164,0.0004052652,0.79249346,0.000064301435,0.0053209327,0.00005932758,0.0015442359,0.00013405248,0.0053394292,0.00018095187,0.006494422,0.18442248],"study_design_scores_gemma":[0.004679084,0.001224417,0.97724026,0.00021306534,0.00044795385,0.0006196745,0.00022817963,0.0000026973219,0.014637791,0.00020463357,0.0003227368,0.00017952365],"about_ca_topic_score_codex":0.00021329857,"about_ca_topic_score_gemma":0.0000048642337,"teacher_disagreement_score":0.18474676,"about_ca_system_score_codex":0.000061170875,"about_ca_system_score_gemma":0.00009350977,"threshold_uncertainty_score":0.7028884},"labels":[],"label_agreement":null},{"id":"W4387014783","doi":"10.1016/j.jaad.2023.07.240","title":"43113 Ixekizumab improves fatigue, an important patient-reported outcome in psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Outcome (game theory); Dermatology; Psoriatic arthritis; Secukinumab","score_opus":0.03769193699997926,"score_gpt":0.31077275355054135,"score_spread":0.2730808165505621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417645,0.00086058513,0.0000040910095,0.0039253337,0.0007579718,0.00016947385,0.000022972468,0.00002859202,0.00005455084],"genre_scores_gemma":[0.9988337,0.0004414089,0.00012434839,0.00043682934,0.000032757875,0.000009393256,0.000008426355,0.00002237702,0.000090749694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969014,0.0006136657,0.0016950313,0.00022235297,0.00011277684,0.00045478006],"domain_scores_gemma":[0.9964282,0.0002596483,0.0029543592,0.00024507902,0.00006095946,0.000051784664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003278023,0.00023937722,0.0010258344,0.000524541,0.00009351533,0.00000579999,0.0006090132,0.00022568258,0.000034700377],"category_scores_gemma":[0.00023594551,0.00015871212,0.0003427226,0.00083456724,0.0004990494,0.00015903551,0.00012870356,0.00053157395,0.000021865664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010911687,0.0004226696,0.73197687,0.000031465814,0.0012478953,0.00028150738,0.0012817774,0.000030077725,0.16455546,0.00023738356,0.0032284134,0.09561533],"study_design_scores_gemma":[0.002786041,0.00046734695,0.90217525,0.00004276766,0.0003496712,0.004803691,0.0014941953,0.0000137357,0.082159266,0.00064304087,0.004807921,0.00025709518],"about_ca_topic_score_codex":0.00007986911,"about_ca_topic_score_gemma":0.000010048038,"teacher_disagreement_score":0.17019837,"about_ca_system_score_codex":0.000052255567,"about_ca_system_score_gemma":0.00011603481,"threshold_uncertainty_score":0.6472092},"labels":[],"label_agreement":null},{"id":"W4387014784","doi":"10.1016/j.jaad.2023.07.241","title":"43335 Ixekizumab reduces IL-17 and IL-23 pathway genes more rapidly than guselkumab: 4-week results from IXORA-R","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Interleukin 17; Plaque psoriasis; Interleukin 23; Blockade; Dermatology; Immunology; Internal medicine; Secukinumab; Cytokine; Psoriatic arthritis","score_opus":0.024997677638711146,"score_gpt":0.2703099281402654,"score_spread":0.24531225050155425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387014784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745061,0.006478343,0.000003821357,0.017459307,0.0006527472,0.00014575466,0.0005925928,0.000043389693,0.000117972035],"genre_scores_gemma":[0.9938556,0.0044992585,0.00024804435,0.00048745243,0.00013490957,0.0000066763255,0.00004451044,0.000030712716,0.00069283036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972626,0.00075352984,0.0010302151,0.00033591068,0.00012751193,0.00049020763],"domain_scores_gemma":[0.99677235,0.00080013106,0.0020131913,0.0002653068,0.000076520526,0.00007249178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031057835,0.00032195865,0.0010979458,0.00034946878,0.00022876427,0.0000135673035,0.0007776147,0.00031396738,0.000024687082],"category_scores_gemma":[0.00020733739,0.00021566529,0.00034491997,0.0005345805,0.0012518355,0.00014347103,0.00023497501,0.00054701505,0.0000713475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056535983,0.00041713403,0.01591568,0.00003712832,0.0039946586,0.0002712346,0.0045203576,0.00004191226,0.74740285,0.00016632954,0.08015919,0.14141995],"study_design_scores_gemma":[0.0062018116,0.0006094474,0.24765478,0.00016701665,0.00075764424,0.0049158973,0.0037543331,0.000011844666,0.6528006,0.0010389339,0.08159159,0.00049610704],"about_ca_topic_score_codex":0.00008865336,"about_ca_topic_score_gemma":0.000006743762,"teacher_disagreement_score":0.2317391,"about_ca_system_score_codex":0.000032858574,"about_ca_system_score_gemma":0.00013898095,"threshold_uncertainty_score":0.87945753},"labels":[],"label_agreement":null},{"id":"W4387015031","doi":"10.1016/j.jaad.2023.07.093","title":"43758 Bimekizumab safety and tolerability in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in five phase 3/3b clinical trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma","keywords":"Medicine; Plaque psoriasis; Tolerability; Psoriasis; Clinical trial; Pooled analysis; Safety profile; Dermatology; Adverse effect; Internal medicine; Meta-analysis","score_opus":0.07382226389681977,"score_gpt":0.3803119089144869,"score_spread":0.3064896450176671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624974,0.0002365482,0.00003632396,0.0015411844,0.00013759529,0.0004469262,0.001344586,0.000004129871,0.0000029878593],"genre_scores_gemma":[0.99920183,0.00032433856,0.00023602534,0.00012533554,0.000011987013,0.000006577889,0.000073562434,0.000009983735,0.000010331751],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526477,0.0020283123,0.0020385797,0.00033058962,0.00009547893,0.00024230075],"domain_scores_gemma":[0.99557894,0.0019810412,0.00191436,0.0003986619,0.00006671493,0.000060261693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011156963,0.00019477315,0.0026972373,0.0006727698,0.000026913785,0.0000029601745,0.0005566407,0.00018739938,0.000024073604],"category_scores_gemma":[0.00063926156,0.00012770611,0.00026132044,0.0012360935,0.00029965935,0.00008448753,0.00021973919,0.00024606043,0.0000039876936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0454613,0.00093405874,0.88706934,0.000011651657,0.008159965,0.0000139986805,0.0015461323,0.0009943835,0.0015933466,0.000012129646,0.0003108768,0.053892788],"study_design_scores_gemma":[0.014217739,0.0011359667,0.9791093,0.000069483096,0.0023314403,0.000015551384,0.00040069732,0.00013372471,0.0022219298,0.00009100064,0.0001490543,0.0001241115],"about_ca_topic_score_codex":0.00063106295,"about_ca_topic_score_gemma":0.0004023865,"teacher_disagreement_score":0.092039935,"about_ca_system_score_codex":0.000075460455,"about_ca_system_score_gemma":0.00016598596,"threshold_uncertainty_score":0.5207704},"labels":[],"label_agreement":null},{"id":"W4387015096","doi":"10.1016/j.jaad.2023.07.145","title":"43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Plaque psoriasis; Placebo; Psoriasis; Apremilast; Internal medicine; Pharmacology; Clinical trial; Dermatology; Pathology","score_opus":0.030909819029725366,"score_gpt":0.31949963247556634,"score_spread":0.288589813445841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981593,0.002496989,0.000020798932,0.014928865,0.00015626711,0.0004700986,0.00031627086,0.000014794845,0.0000028756904],"genre_scores_gemma":[0.99504316,0.002779984,0.00009879069,0.0019133106,0.00005167916,0.00002651004,0.00004494571,0.00002404726,0.000017564278],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946067,0.0033375486,0.0012010005,0.00031617458,0.00010456711,0.00043404792],"domain_scores_gemma":[0.9973206,0.0012084886,0.0010962401,0.00018271536,0.000057493253,0.00013446657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013477145,0.00031570182,0.0013206744,0.0005734349,0.00013552404,0.000023707285,0.00042049782,0.00018830702,0.000008049912],"category_scores_gemma":[0.0009046253,0.00020061826,0.0001591322,0.0010620502,0.00046246484,0.00016374947,0.00011251762,0.0005651076,0.0000044327217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052976545,0.004682809,0.29062578,0.00023642607,0.0018522684,0.00077204587,0.0051229442,0.00007928403,0.47298366,0.0002977422,0.031907108,0.1384634],"study_design_scores_gemma":[0.0498859,0.0031215048,0.8683198,0.00068161706,0.0021157092,0.0071489266,0.0025403546,0.00036669022,0.047586083,0.001458178,0.015427681,0.0013475571],"about_ca_topic_score_codex":0.000040243372,"about_ca_topic_score_gemma":0.000016432285,"teacher_disagreement_score":0.57769406,"about_ca_system_score_codex":0.000027401038,"about_ca_system_score_gemma":0.00012426195,"threshold_uncertainty_score":0.81809753},"labels":[],"label_agreement":null},{"id":"W4387015569","doi":"10.1016/j.jaad.2023.07.941","title":"43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Quality of life (healthcare); Health related quality of life; Clinical trial; Dermatology; Internal medicine; Disease; Nursing","score_opus":0.04126863102983205,"score_gpt":0.31267627200400705,"score_spread":0.271407640974175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955986,0.0007314239,0.0000010968778,0.0027102013,0.00005126624,0.00040334254,0.00046873777,0.0000040977893,0.0000311987],"genre_scores_gemma":[0.99917895,0.000576943,0.000034786346,0.000121093464,0.000011559981,0.000008109244,0.000010978849,0.000011871293,0.000045727076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965252,0.001910902,0.0010726379,0.00018265792,0.000091255,0.00021732113],"domain_scores_gemma":[0.99512154,0.0022425202,0.0023208787,0.00021621288,0.00006116277,0.000037670554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006485088,0.00021437937,0.0012999356,0.000141652,0.00008642323,0.0000051181805,0.00028173975,0.00012467039,0.000010367351],"category_scores_gemma":[0.0002999835,0.00008176414,0.00017545161,0.00039223893,0.0005405395,0.000050961087,0.00006585099,0.00023441571,0.0000022685028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06299582,0.00056674774,0.9023276,0.000019346642,0.0059439344,0.00000956204,0.00800337,0.0012038795,0.0071734777,0.000055438784,0.0011384534,0.010562358],"study_design_scores_gemma":[0.011873536,0.0019253091,0.9771294,0.00011311516,0.00036606775,0.00011885865,0.0011003606,0.000006482853,0.0071140807,0.00008611666,0.0000630442,0.00010362132],"about_ca_topic_score_codex":0.0011607922,"about_ca_topic_score_gemma":0.00006524969,"teacher_disagreement_score":0.074801795,"about_ca_system_score_codex":0.00004666453,"about_ca_system_score_gemma":0.00013278234,"threshold_uncertainty_score":0.3334245},"labels":[],"label_agreement":null},{"id":"W4387015668","doi":"10.1016/j.jaad.2023.07.837","title":"43359 Post hoc Analysis of Long-term Efficacy of Brodalumab in Early vs Late Responders With Psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Medicine; Post-hoc analysis; Psoriasis; Post hoc; Ixekizumab; Dermatology; Internal medicine; Pharmacology; Secukinumab","score_opus":0.015075996549449753,"score_gpt":0.27917989123261255,"score_spread":0.2641038946831628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963832,0.0008547478,0.0000073001197,0.002398383,0.0001329791,0.00013116935,0.000053476375,0.000009801954,0.000028976587],"genre_scores_gemma":[0.99896085,0.00068441016,0.00007035218,0.00012061864,0.0000117188065,0.000002024458,0.00000961844,0.0000174078,0.00012298398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974306,0.0008232704,0.0010646182,0.0001973301,0.0001341791,0.00034998823],"domain_scores_gemma":[0.9963321,0.0007642515,0.0025045008,0.00025144985,0.000112517206,0.000035169713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003406964,0.00021402354,0.0015546451,0.001527522,0.000050516122,0.0000029265736,0.0006792342,0.00020736252,0.000035062],"category_scores_gemma":[0.00012348207,0.00014145317,0.0005464733,0.0026281078,0.0009623865,0.00008909644,0.000105695806,0.00040536077,0.000010603152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012506281,0.00031470467,0.8777842,0.00004630298,0.0085404,0.00008674218,0.0016132472,0.0003463692,0.08962896,0.00006351748,0.0002536745,0.008815593],"study_design_scores_gemma":[0.0032087492,0.00068462227,0.9439417,0.00008619762,0.0022564242,0.00039186812,0.00026408612,0.0000040920154,0.048960026,0.000018153863,0.00006415807,0.00011990194],"about_ca_topic_score_codex":0.00010116085,"about_ca_topic_score_gemma":0.000033277895,"teacher_disagreement_score":0.066157505,"about_ca_system_score_codex":0.000038606864,"about_ca_system_score_gemma":0.00013106137,"threshold_uncertainty_score":0.5768293},"labels":[],"label_agreement":null},{"id":"W4387015750","doi":"10.1016/j.jaad.2023.07.739","title":"42664 Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Itching; Psoriasis; Dermatology; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Severity of illness; Clinical trial; Internal medicine","score_opus":0.028238009921756554,"score_gpt":0.28616639389567144,"score_spread":0.2579283839739149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110496,0.00017320715,0.000004938903,0.0077543235,0.00015355174,0.00074851105,0.000046420468,0.0000060564666,0.00000804491],"genre_scores_gemma":[0.9992315,0.00006575122,0.00001907442,0.0005995576,0.000019877149,0.00003634334,0.00000900763,0.000012981778,0.0000058641876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972501,0.0011387955,0.0009071305,0.00022538808,0.00013387027,0.0003447374],"domain_scores_gemma":[0.99759406,0.0011124301,0.0010597045,0.00016782238,0.000027314629,0.000038654656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005370288,0.00021701056,0.00067764695,0.00043509074,0.00015025631,0.000015239097,0.00034366336,0.00017868275,0.0000021825883],"category_scores_gemma":[0.00027308054,0.00011634047,0.0000759591,0.0008093083,0.00027533568,0.00015277782,0.00011371742,0.0007296884,9.498009e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012929709,0.00020231618,0.97255987,0.0000088259,0.00027552358,0.000020080832,0.0034474612,0.000051768955,0.00008397634,0.000025890351,0.0001987294,0.010195833],"study_design_scores_gemma":[0.03358062,0.00049919926,0.9634493,0.00008034498,0.00014737045,0.00018776343,0.0011116305,0.000014648693,0.000277505,0.0003895446,0.00012929534,0.00013277252],"about_ca_topic_score_codex":0.00018220187,"about_ca_topic_score_gemma":0.00007078757,"teacher_disagreement_score":0.02065091,"about_ca_system_score_codex":0.000058414964,"about_ca_system_score_gemma":0.00008376923,"threshold_uncertainty_score":0.47442266},"labels":[],"label_agreement":null},{"id":"W4387015862","doi":"10.1016/j.jaad.2023.07.764","title":"42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Memorial University of Newfoundland","funders":"","keywords":"Ixekizumab; Medicine; Psoriatic arthritis; Psoriasis; Mace; Adverse effect; Dermatology; Arthritis; Axial spondyloarthritis; Secukinumab; Enthesitis; Post-hoc analysis; Internal medicine; Sacroiliitis","score_opus":0.01717214329732582,"score_gpt":0.2868384428223365,"score_spread":0.2696662995250107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996123,0.0016174273,0.000008207172,0.00022077373,0.00021638274,0.0010845088,0.000711376,0.000012663159,0.000005659172],"genre_scores_gemma":[0.9979959,0.0013107898,0.00042495632,0.000023772098,0.000019944573,0.000037199727,0.00014679672,0.000024944422,0.00001569853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99586,0.0012454836,0.0018032456,0.00037831377,0.000294304,0.00041865467],"domain_scores_gemma":[0.99616045,0.00040285787,0.002507384,0.0006371528,0.00023298044,0.00005915721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000449615,0.00032360217,0.0024279777,0.001025174,0.00007769131,0.0000024059561,0.00084118225,0.00017893163,0.00003187976],"category_scores_gemma":[0.00027302385,0.00021219115,0.0006897132,0.002214082,0.00039871884,0.00015271617,0.00027322516,0.00027556173,0.000004800318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011363163,0.0020618779,0.7483179,0.00005955211,0.021624839,0.00009745521,0.0016490901,0.0002161248,0.00047199693,0.000006666186,0.000027523307,0.2141038],"study_design_scores_gemma":[0.013835303,0.004395708,0.9709129,0.00035932066,0.00674777,0.00025845005,0.0012911598,0.000006487533,0.0018648403,0.0000042259785,0.00012844398,0.00019543892],"about_ca_topic_score_codex":0.0003436935,"about_ca_topic_score_gemma":0.00042240167,"teacher_disagreement_score":0.22259495,"about_ca_system_score_codex":0.00008923395,"about_ca_system_score_gemma":0.00022847568,"threshold_uncertainty_score":0.8652904},"labels":[],"label_agreement":null},{"id":"W4387015875","doi":"10.1016/j.jaad.2023.07.491","title":"42163 Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Medicine; Apremilast; Psoriasis; Plaque psoriasis; Dermatology; Placebo; Randomized controlled trial; Internal medicine; Psoriatic arthritis; Alternative medicine; Pathology","score_opus":0.02033938590694062,"score_gpt":0.27960522576656005,"score_spread":0.25926583985961943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99077845,0.0006087283,0.000015712016,0.0057355156,0.00028796488,0.002368119,0.00013729976,0.00001618868,0.000052046773],"genre_scores_gemma":[0.99885654,0.00050991547,0.000046705627,0.00030930454,0.000088368855,0.00007562858,0.000026815032,0.000023628068,0.00006310682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954373,0.0021762769,0.0014527892,0.00034344112,0.0001676009,0.00042254417],"domain_scores_gemma":[0.9940211,0.0036147067,0.0019594936,0.0002459762,0.000092004775,0.000066675115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010110792,0.00034370838,0.0019642154,0.00037808352,0.00020462084,0.00001744003,0.00063600007,0.00017528601,0.00001210754],"category_scores_gemma":[0.00041805342,0.00017260057,0.00024432386,0.0007661092,0.00038185186,0.00011042955,0.00018241699,0.00066863047,0.000020296315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96120256,0.0010135025,0.029582793,0.0000061277724,0.0017683349,0.000021883248,0.0025202795,0.00039302366,0.00013089347,0.000011172878,0.0014737352,0.0018756787],"study_design_scores_gemma":[0.9404048,0.00074550736,0.05476905,0.000057950834,0.0016030589,0.00015992063,0.0011510353,0.000015120865,0.00060267124,0.00005748083,0.00021657262,0.00021686353],"about_ca_topic_score_codex":0.0001139718,"about_ca_topic_score_gemma":0.00005082197,"teacher_disagreement_score":0.025186257,"about_ca_system_score_codex":0.000053925054,"about_ca_system_score_gemma":0.0001246953,"threshold_uncertainty_score":0.7038447},"labels":[],"label_agreement":null},{"id":"W4387015984","doi":"10.1016/j.jaad.2023.07.760","title":"44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Ustekinumab; Quality of life (healthcare); Psoriasis; Dermatology; Scalp; Internal medicine; Disease; Nursing","score_opus":0.016258537470750428,"score_gpt":0.27352683714822457,"score_spread":0.2572682996774741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99486667,0.00022024378,0.000009375245,0.0040269955,0.00023764624,0.00045557992,0.0001664128,0.000008574657,0.000008532024],"genre_scores_gemma":[0.9989396,0.00008287702,0.00008568914,0.0007677893,0.000020378004,0.000017575212,0.000015748154,0.000018949371,0.000051427207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754936,0.00050263864,0.0010983561,0.00029587638,0.00014634841,0.0004074457],"domain_scores_gemma":[0.99813396,0.00037327726,0.0010527361,0.00022350221,0.00010500188,0.00011150288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022005457,0.00026244082,0.0012372189,0.00056813285,0.000051299783,0.000005913093,0.0004990976,0.00017488122,0.000023817347],"category_scores_gemma":[0.0002242639,0.00017391631,0.00012609798,0.0008847899,0.00019889724,0.00007230075,0.00025610309,0.00032864156,0.000023183065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005994201,0.0002942738,0.9452632,0.000031611595,0.00035071184,0.00000957258,0.0015699521,0.000028254053,0.033021785,0.00001095704,0.00046324966,0.012962194],"study_design_scores_gemma":[0.0054477085,0.0007936782,0.9710396,0.00013773191,0.00011654461,0.00003080531,0.00063384935,2.8216917e-7,0.021550642,0.000016004597,0.000060325507,0.00017281553],"about_ca_topic_score_codex":0.00094447954,"about_ca_topic_score_gemma":0.00030250472,"teacher_disagreement_score":0.025776377,"about_ca_system_score_codex":0.000101994265,"about_ca_system_score_gemma":0.000095396026,"threshold_uncertainty_score":0.70921016},"labels":[],"label_agreement":null},{"id":"W4387015996","doi":"10.1016/j.jaad.2023.07.635","title":"43250 Efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups: Analysis From ESTEEM 1 and ESTEEM 2","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Amgen","keywords":"Apremilast; Medicine; Psoriasis; Plaque psoriasis; Obesity; Internal medicine; Dermatology","score_opus":0.009579686812385016,"score_gpt":0.25252133280181693,"score_spread":0.2429416459894319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387015996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765265,0.0006071405,0.000022458407,0.0012657522,0.00010326839,0.00016856837,0.00015986332,0.0000091506245,0.000011163646],"genre_scores_gemma":[0.9991186,0.0004043927,0.00025242748,0.00014438087,0.000016320639,0.0000045932065,0.000016698123,0.000016522607,0.00002605133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998116,0.00044143756,0.0007321155,0.00026211882,0.000103889965,0.00034443973],"domain_scores_gemma":[0.9979365,0.00063786336,0.0011242899,0.00017561883,0.00006637465,0.0000593716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017104932,0.00023576956,0.0012342487,0.00037680473,0.000091740905,0.000007950647,0.00035647023,0.00020115996,0.000012355482],"category_scores_gemma":[0.00007280932,0.0001538279,0.0001705979,0.0011382553,0.0005578041,0.00010801539,0.0001783732,0.00034024598,0.000005308209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037639914,0.00020253053,0.982544,0.000017665427,0.0024938672,0.00001214775,0.0013560979,0.00024482285,0.0032780292,0.000021471857,0.00025966467,0.0058057215],"study_design_scores_gemma":[0.004936484,0.00027183644,0.9821228,0.000068470275,0.0008682197,0.00012800009,0.00046992878,0.000021052772,0.0106880125,0.00006414495,0.00020529501,0.00015576059],"about_ca_topic_score_codex":0.000110142086,"about_ca_topic_score_gemma":0.000047389643,"teacher_disagreement_score":0.0074099833,"about_ca_system_score_codex":0.000028507484,"about_ca_system_score_gemma":0.000042820146,"threshold_uncertainty_score":0.627292},"labels":[],"label_agreement":null},{"id":"W4387016013","doi":"10.1016/j.jaad.2023.07.815","title":"42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; Dalhousie University; Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Eclipse; Clinical trial; Internal medicine; Astronomy; Pathology; Alternative medicine","score_opus":0.07612226255220515,"score_gpt":0.381308500926952,"score_spread":0.30518623837474684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387016013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9508689,0.0023536566,0.000008242025,0.045370806,0.00087279244,0.00036705012,0.000090105605,0.000010888544,0.00005758057],"genre_scores_gemma":[0.99237853,0.00400808,0.00002900951,0.0030957044,0.00035477168,0.000017393913,0.0000099531435,0.000015108908,0.00009142847],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99412805,0.0034485443,0.0017092086,0.00023149449,0.000117843425,0.00036488438],"domain_scores_gemma":[0.9913541,0.0058745355,0.0024161134,0.00029130233,0.000029312534,0.000034609388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032811551,0.00023387463,0.0012395725,0.00014322555,0.00022682948,0.000016334618,0.0009727728,0.00026503124,0.000055060034],"category_scores_gemma":[0.0009378283,0.00010672662,0.0004844591,0.000362465,0.00092053815,0.00008168129,0.00020190632,0.0008942262,0.00004023911],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009696038,0.0021145889,0.29983732,0.000056487206,0.005548714,0.00032000267,0.0071390066,0.000014696357,0.066701025,0.0008916169,0.26791134,0.33976915],"study_design_scores_gemma":[0.028008616,0.0019772109,0.5856055,0.00020830409,0.0024159125,0.0025357713,0.0061705397,0.00003174656,0.023417136,0.0033916996,0.34574,0.00049757445],"about_ca_topic_score_codex":0.000089641304,"about_ca_topic_score_gemma":0.000041933876,"teacher_disagreement_score":0.3392716,"about_ca_system_score_codex":0.000028362918,"about_ca_system_score_gemma":0.00008120565,"threshold_uncertainty_score":0.43521854},"labels":[],"label_agreement":null},{"id":"W4387016059","doi":"10.1016/j.jaad.2023.07.877","title":"44007 Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Clinical trial; Internal medicine","score_opus":0.058643317489252667,"score_gpt":0.37469207841959,"score_spread":0.31604876093033735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387016059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921909,0.0043669874,0.000053184413,0.00196134,0.0008600391,0.00031821174,0.00022218349,0.000021237649,0.0000059265776],"genre_scores_gemma":[0.99491173,0.004520792,0.00014554682,0.00021333294,0.00008984276,0.000009236202,0.000060403454,0.000024883147,0.000024246334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924747,0.00429187,0.0023598531,0.0003244903,0.00015645116,0.00039265465],"domain_scores_gemma":[0.9936627,0.002731998,0.0031781713,0.00023912409,0.00008790171,0.00010009638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001138829,0.0003225546,0.002331472,0.00047101633,0.000099819794,0.000013696478,0.0005418911,0.00024693398,0.00008683068],"category_scores_gemma":[0.0014728945,0.00019279467,0.0005020925,0.0007818145,0.00086655584,0.00015183614,0.00015369851,0.0007092539,0.000024643221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077381246,0.00033911882,0.84192103,0.000021845814,0.0024528448,0.00005189727,0.00019072088,0.000009630547,0.00030905634,0.000019290668,0.0009820188,0.14596441],"study_design_scores_gemma":[0.010156257,0.0003677587,0.9858311,0.00033788956,0.001271169,0.00009953691,0.00017817723,0.000008118838,0.000993674,0.00024388812,0.00032128376,0.00019117579],"about_ca_topic_score_codex":0.00006560599,"about_ca_topic_score_gemma":0.000029029345,"teacher_disagreement_score":0.14577323,"about_ca_system_score_codex":0.000060017377,"about_ca_system_score_gemma":0.00016392073,"threshold_uncertainty_score":0.7861939},"labels":[],"label_agreement":null},{"id":"W4387016067","doi":"10.1016/j.jaad.2023.07.813","title":"41824 Palmoplantar psoriasis complete clearance is achieved rapidly and sustained with ixekizumab treatment in adult and pediatric patients with moderate-to-severe plaque psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ixekizumab; Plaque psoriasis; Psoriasis; Psoriasis Area and Severity Index; Post-hoc analysis; Population; Internal medicine; Dermatology; Gastroenterology; Psoriatic arthritis; Secukinumab","score_opus":0.010124645004568441,"score_gpt":0.23311386049575591,"score_spread":0.22298921549118747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387016067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362457,0.00052225415,0.0000085910115,0.005198001,0.00009697873,0.00038216988,0.00013629436,0.000015983398,0.000015179634],"genre_scores_gemma":[0.99731,0.0017853327,0.00024833294,0.00050827104,0.000030578827,0.00001874514,0.000010733325,0.000026838106,0.00006116599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981469,0.0004299527,0.0005645203,0.00030528926,0.00011116484,0.0004421851],"domain_scores_gemma":[0.99850017,0.00032051,0.00084742805,0.00015469569,0.000101025595,0.0000761884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009999861,0.00032327886,0.0010094894,0.00043779978,0.00015688162,0.0000109596,0.00026692182,0.00015839073,0.000008590822],"category_scores_gemma":[0.000034962522,0.00019012652,0.000093601986,0.00069609337,0.00037168275,0.00011407264,0.00008280788,0.00030383858,0.0000094024335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020689838,0.00029217332,0.9620211,0.00007019535,0.0010661389,0.00008060604,0.0024166454,0.00009334229,0.0005637854,0.000065568005,0.001291091,0.011349512],"study_design_scores_gemma":[0.013851849,0.0015249723,0.97812665,0.00007898316,0.0005695541,0.0012896289,0.0010880223,0.000018189545,0.0023646755,0.00007367194,0.00071196293,0.00030182637],"about_ca_topic_score_codex":0.000086752865,"about_ca_topic_score_gemma":0.000032977954,"teacher_disagreement_score":0.01610556,"about_ca_system_score_codex":0.000065592256,"about_ca_system_score_gemma":0.000106603984,"threshold_uncertainty_score":0.7753135},"labels":[],"label_agreement":null},{"id":"W4387016096","doi":"10.1016/j.jaad.2023.07.773","title":"42307 Matching-adjusted indirect comparison of efficacy of ixekizumab versus secukinumab through 1 year in pediatric patients with severe plaque psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Probity Medical Research; Calgary Laboratory Services; Sunnybrook Health Science Centre; SKiN Health; University of Calgary","funders":"","keywords":"Ixekizumab; Secukinumab; Medicine; Etanercept; Psoriasis; Dermatology; Plaque psoriasis; Placebo; Clinical trial; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis; Pathology; Alternative medicine","score_opus":0.025012510889219176,"score_gpt":0.28816546072793786,"score_spread":0.2631529498387187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387016096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981001,0.00057482865,0.0000045473494,0.0005086275,0.00043491027,0.00019056983,0.00006292283,0.000012825775,0.00011064462],"genre_scores_gemma":[0.9993439,0.00033743266,0.00020489156,0.000029059018,0.000028256798,0.000003209017,0.000014549307,0.00002098665,0.00001773402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977623,0.0005679111,0.0010164939,0.0001742909,0.000155807,0.0003231738],"domain_scores_gemma":[0.9962673,0.00076467945,0.002679578,0.00017474954,0.00008862074,0.000025042507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015468204,0.00021865236,0.0013021751,0.0004450499,0.00005484571,0.0000020619325,0.00056801265,0.00023023087,0.000025004276],"category_scores_gemma":[0.00011458199,0.00014895327,0.00024284425,0.0011229026,0.00040259006,0.000098058204,0.00012111645,0.0005146687,0.000016528043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012600841,0.00088677765,0.9688385,0.0001308175,0.0014809505,0.000014741389,0.0040619746,0.0003889774,0.0017569684,0.00012553793,0.0026846873,0.0070291944],"study_design_scores_gemma":[0.012994247,0.00076651416,0.9602506,0.00009555388,0.0006464084,0.00014252632,0.0012447652,0.0000019160739,0.02319604,0.00009067264,0.00039380492,0.00017691228],"about_ca_topic_score_codex":0.000055376047,"about_ca_topic_score_gemma":0.000011682562,"teacher_disagreement_score":0.021439072,"about_ca_system_score_codex":0.00005119659,"about_ca_system_score_gemma":0.00013474318,"threshold_uncertainty_score":0.6074138},"labels":[],"label_agreement":null},{"id":"W4387026142","doi":"10.1016/j.jaad.2023.07.676","title":"43341 Fixed-Combination Halobetasol Propionate and Tazarotene Topical Lotion Decreases Interleukin-17A Levels in Psoriasis","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"Bausch Health; Ortho Dermatologics","keywords":"Tazarotene; Psoriasis; Medicine; Lotion; Dermatology; Interleukin 17; Tolerability; Proinflammatory cytokine; Interleukin; Pharmacology; Adverse effect; Immunology; Inflammation; Cytokine","score_opus":0.02367842836896941,"score_gpt":0.28439644556160626,"score_spread":0.2607180171926369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387026142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989295,0.0008617304,0.000029302204,0.009263009,0.00035368188,0.00014106196,0.00001164247,0.0000141312485,0.000030461282],"genre_scores_gemma":[0.9989491,0.00053813134,0.00011879624,0.00021295848,0.00002974901,0.000007718266,0.000004818417,0.0000097408,0.00012898452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838716,0.00056431646,0.0005904456,0.00014978099,0.00006945241,0.00023883009],"domain_scores_gemma":[0.9987202,0.00032437738,0.0007860157,0.000091136775,0.00004916288,0.000029098557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021093879,0.00014513198,0.00054848316,0.00034718172,0.00006971801,0.000005590065,0.0002850298,0.0001634992,0.000028728598],"category_scores_gemma":[0.00021993127,0.00009890949,0.0001457568,0.00040009434,0.0004188067,0.00011196167,0.00010591268,0.000337183,0.00002119709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014657364,0.0005933131,0.45122522,0.00010971922,0.0010839436,0.00012184137,0.0011453073,0.000038605463,0.28081706,0.003572729,0.0039250627,0.25590146],"study_design_scores_gemma":[0.002314425,0.00022728466,0.8491419,0.000102403916,0.00015565283,0.0024978623,0.00027221744,0.000019693773,0.1411772,0.0019131195,0.0020512764,0.00012693787],"about_ca_topic_score_codex":0.000033881384,"about_ca_topic_score_gemma":0.000006411372,"teacher_disagreement_score":0.3979167,"about_ca_system_score_codex":0.00004418527,"about_ca_system_score_gemma":0.0000577742,"threshold_uncertainty_score":0.4033412},"labels":[],"label_agreement":null},{"id":"W4387026281","doi":"10.1016/j.jaad.2023.07.759","title":"42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; GDI Integrated Facility Services (Canada); Montreal General Hospital; Krembil Foundation; Toronto Western Hospital","funders":"","keywords":"Medicine; Post-hoc analysis; Placebo; Double blind; Post hoc; Term (time); Internal medicine; Oncology; Alternative medicine; Pathology","score_opus":0.02617833358952999,"score_gpt":0.3171300572902101,"score_spread":0.2909517237006801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387026281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673206,0.0013095076,0.000023151408,0.00022717542,0.000100577265,0.0015002417,0.0000963196,0.0000067097917,0.000004235406],"genre_scores_gemma":[0.9980616,0.00176806,0.000038672664,0.000016901138,0.000008457073,0.000052621923,0.00003135439,0.000013094482,0.000009266262],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962466,0.0013797296,0.0017372917,0.00024438425,0.00014908258,0.00024294498],"domain_scores_gemma":[0.9939758,0.0013190858,0.0043076146,0.00022953874,0.00014106274,0.000026909227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004943722,0.00025138247,0.0027131268,0.0008132213,0.000048734466,0.000004587258,0.0003320652,0.00015510176,0.000010882701],"category_scores_gemma":[0.00018203727,0.00015413095,0.0005080426,0.0009733075,0.00077259674,0.00009414897,0.000053056094,0.00019580693,0.0000023271655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7361623,0.0038486922,0.22234298,0.000028257304,0.014290589,0.000020070753,0.003469924,0.00018368868,0.006747465,0.000033598135,0.0000085413585,0.0128639005],"study_design_scores_gemma":[0.5549361,0.0039848774,0.42270964,0.000084144915,0.0038635356,0.00003395085,0.0005466618,0.0000054325274,0.013688613,0.000024687035,0.0000018048905,0.00012051045],"about_ca_topic_score_codex":0.00011869286,"about_ca_topic_score_gemma":0.00002891079,"teacher_disagreement_score":0.20036666,"about_ca_system_score_codex":0.000043465763,"about_ca_system_score_gemma":0.000070713126,"threshold_uncertainty_score":0.62852776},"labels":[],"label_agreement":null},{"id":"W4387026331","doi":"10.1016/j.jaad.2023.07.514","title":"43744 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"UCB Pharma","keywords":"Medicine; Psoriatic arthritis; Tolerability; Placebo; Internal medicine; Psoriasis; Multicenter trial; Randomized controlled trial; Multicenter study; Gastroenterology; Arthritis; Surgery; Dermatology; Adverse effect; Pathology; Alternative medicine","score_opus":0.015716327021604214,"score_gpt":0.2906388282815742,"score_spread":0.27492250125997003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387026331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956039,0.002607174,0.000009964939,0.00034025422,0.000079070975,0.0012349242,0.00011048756,0.0000064195096,0.000007771177],"genre_scores_gemma":[0.9968651,0.0028737905,0.000100338875,0.000040884457,0.000004739599,0.00006450804,0.000026772399,0.000013185981,0.000010713932],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99587595,0.0020230613,0.001384908,0.00024034898,0.00018157701,0.00029413146],"domain_scores_gemma":[0.9946104,0.0012362308,0.0038059899,0.00017202321,0.00013394616,0.00004138521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005762921,0.00025810458,0.0028178953,0.0013806515,0.00007998006,0.0000035586093,0.00033677905,0.00013585408,0.000028031907],"category_scores_gemma":[0.00018972377,0.00015360772,0.00045439025,0.0014334526,0.0011271724,0.00010152992,0.00014225925,0.00031144675,9.144683e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6118386,0.004925228,0.30773425,0.000069342495,0.027551394,0.000033956065,0.004433217,0.000114596536,0.0031590823,0.000023866232,0.00019000439,0.039926507],"study_design_scores_gemma":[0.720615,0.0029711013,0.24792624,0.0003812846,0.009268745,0.000105516054,0.004295384,0.00012380746,0.01396737,0.000026246322,0.00006295235,0.00025631097],"about_ca_topic_score_codex":0.000118259566,"about_ca_topic_score_gemma":0.000074524265,"teacher_disagreement_score":0.10877649,"about_ca_system_score_codex":0.00005008407,"about_ca_system_score_gemma":0.00005732933,"threshold_uncertainty_score":0.6263941},"labels":[],"label_agreement":null},{"id":"W4387026372","doi":"10.1016/j.jaad.2023.07.634","title":"40665 Efficacy of Apremilast in Patients With Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results From the Phase 3 DISCREET Trial","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Dermatology; Body surface area; Clinical trial; Randomized controlled trial; Internal medicine; Psoriatic arthritis","score_opus":0.01914038285220168,"score_gpt":0.270290612974961,"score_spread":0.2511502301227593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387026372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501944,0.00024720363,0.0000126978375,0.0031394172,0.00039940633,0.00048623097,0.000647864,0.000012956407,0.00003479371],"genre_scores_gemma":[0.9994443,0.00009420029,0.00009128343,0.0001783615,0.00005451839,0.000005916133,0.00006202257,0.00002230172,0.000047090147],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99713784,0.000912642,0.0011245062,0.00025967997,0.00016899635,0.0003963099],"domain_scores_gemma":[0.99645936,0.0013453034,0.0017539856,0.00029138871,0.000099837525,0.00005010532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031273524,0.00026744147,0.0010401298,0.00018240557,0.000110651825,0.0000073995557,0.0008392651,0.00018851728,0.000016203949],"category_scores_gemma":[0.00037933752,0.00014422508,0.0002467423,0.0008500135,0.0005282831,0.00010545751,0.00016619303,0.0005269424,0.00002038972],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70421726,0.0030458437,0.2233538,0.000020196454,0.0036959222,0.000057532558,0.0038215392,0.0018247826,0.034846947,0.000064599444,0.016967028,0.008084532],"study_design_scores_gemma":[0.21333836,0.0025057103,0.74175775,0.00022377988,0.00087200163,0.0002335754,0.0012271709,0.00003625004,0.037892856,0.0001365055,0.0013647268,0.00041133247],"about_ca_topic_score_codex":0.00011708541,"about_ca_topic_score_gemma":0.000017655198,"teacher_disagreement_score":0.51840395,"about_ca_system_score_codex":0.000040729607,"about_ca_system_score_gemma":0.0001239796,"threshold_uncertainty_score":0.5881328},"labels":[],"label_agreement":null},{"id":"W4387193454","doi":"10.1007/978-3-031-34459-6_4","title":"Computer-Aided Diagnosis Based on DenseNet201 Architecture for Psoriasis Classification","year":2023,"lang":"en","type":"book-chapter","venue":"EAI/Springer Innovations in Communication and Computing","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec en Abitibi-Témiscamingue","funders":"","keywords":"Psoriasis; Dermatology; Medicine; Rosacea; Convolutional neural network; Artificial intelligence; Skin lesion; Lesion; Computer science; Pathology","score_opus":0.06435460303473974,"score_gpt":0.2838353960371278,"score_spread":0.2194807930023881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387193454","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20940463,0.022489533,0.2487007,0.053186476,0.021865597,0.026991446,0.0031490165,0.007726953,0.40648565],"genre_scores_gemma":[0.9059948,0.0016626581,0.035602983,0.0017483245,0.00049874117,0.0009531259,0.0074532963,0.00034795207,0.045738157],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807525,0.00016138106,0.00078438566,0.0005886519,0.000083102575,0.0003072485],"domain_scores_gemma":[0.9961509,0.0020026702,0.00052798,0.0010481618,0.0002464673,0.000023813669],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006634332,0.0004268248,0.00049977505,0.0009042303,0.00059425994,0.000068760404,0.0004740015,0.00059676985,0.000051187235],"category_scores_gemma":[0.000118510616,0.00045442287,0.0001432781,0.00029773818,0.00016452311,0.00004354539,0.00021313976,0.0006179451,0.000100069265],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015451692,0.00023592838,0.0025087653,0.0001255328,0.00037337092,0.0000022082622,0.00058800785,0.0013828065,0.00031774928,0.19830252,0.004161207,0.7918474],"study_design_scores_gemma":[0.016074857,0.0011847282,0.13566203,0.006483909,0.0009641441,0.000039929382,0.00036799663,0.035614174,0.002294778,0.043632243,0.7533356,0.0043455944],"about_ca_topic_score_codex":0.000024021774,"about_ca_topic_score_gemma":0.00009685676,"teacher_disagreement_score":0.7875018,"about_ca_system_score_codex":0.00013168398,"about_ca_system_score_gemma":0.00008435072,"threshold_uncertainty_score":0.9997907},"labels":[],"label_agreement":null},{"id":"W4387340332","doi":"10.1016/j.jdcr.2023.09.024","title":"Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab","year":2023,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Pityriasis rubra pilaris; Medicine; Dermatology; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Vaccination; Virology; Psoriasis; Internal medicine; Disease","score_opus":0.025306599804552972,"score_gpt":0.26857324875238675,"score_spread":0.24326664894783379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387340332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959755,0.00075180706,0.00004575335,0.0001088645,0.00084295275,0.00043738293,0.000028393175,0.0006243666,0.0011849613],"genre_scores_gemma":[0.996575,0.000063661006,0.00006633289,0.000053529202,0.00005185119,0.00012175469,0.00063767185,0.000053736436,0.0023764747],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981118,0.00017779917,0.00047707296,0.0006400146,0.00008111255,0.0005121877],"domain_scores_gemma":[0.9988699,0.00011987096,0.00028968372,0.00061094045,0.00008054527,0.000029043544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036926457,0.00034103237,0.00046268248,0.00033939513,0.0004346556,0.00004074663,0.000059414542,0.00032804353,0.0001143532],"category_scores_gemma":[0.00007429481,0.0002769174,0.0002448934,0.00076358474,0.00003430103,0.00021256154,0.000057405203,0.0001567015,0.00044804934],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000450181,0.0004935692,0.052272428,0.00006300405,0.0030154178,0.44258183,0.001343917,0.000018160701,0.40072793,0.00004696352,0.010935282,0.088051334],"study_design_scores_gemma":[0.0035476347,0.00047259906,0.0334256,0.00008384675,0.0013868546,0.13514124,0.0005106034,0.000017443092,0.81656814,0.00016290192,0.007904542,0.00077859947],"about_ca_topic_score_codex":0.0007051189,"about_ca_topic_score_gemma":0.00025041457,"teacher_disagreement_score":0.41584024,"about_ca_system_score_codex":0.000121400764,"about_ca_system_score_gemma":0.00010067746,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W4387358894","doi":"10.1101/2023.10.04.23296543","title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","year":2023,"lang":"en","type":"preprint","venue":"medRxiv","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Memorial University of Newfoundland; University Health Network; Nexus Clinical Research (Canada)","funders":"Norwegian Institute of Public Health; Faculty of Medicine and Health, University of Sydney; Medical Research Council; NIHR BioResource; Manchester Biomedical Research Centre; University of California, San Francisco; Multiple Sclerosis Society of Western Australia; National Institutes of Health; Heinz Nixdorf Stiftung; Versus Arthritis; St. Olavs Hospital Universitetssykehuset i Trondheim; Norges Forskningsråd; Krembil Foundation; Institute of Psychiatry, Psychology and Neuroscience, King’s College London; Deutsches Zentrum für Neurodegenerative Erkrankungen; Helse Midt-Norge; Deutsche Forschungsgemeinschaft; European Commission; King's College London; U.S. Department of Veterans Affairs; Helene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust; University of Toronto; Eesti Teadusagentuur; European Federation of Pharmaceutical Industries and Associations; NIHR Cambridge Biomedical Research Centre; Maudsley Charity; Multiple Sclerosis Society; Pfizer; National Psoriasis Foundation; LEO Fondet; Stiftelsen Kristian Gerhard Jebsen; NIHR Maudsley Biomedical Research Centre; Norges Teknisk-Naturvitenskapelige Universitet; A. Alfred Taubman Medical Research Institute; Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet; Michael J. Fox Foundation for Parkinson's Research; European Regional Development Fund; Bundesministerium für Bildung und Forschung; National Institute for Health and Care Research","keywords":"Psoriasis; Genome-wide association study; Epigenetics; Biology; Disease; Transcriptome; Genetics; Genetic predisposition; Allele; Single-nucleotide polymorphism; Immunology; Medicine; Genotype; Gene; Gene expression; Internal medicine","score_opus":0.09510250165322937,"score_gpt":0.3091345521932678,"score_spread":0.21403205054003843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387358894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9373778,0.05765086,0.000956686,0.0006527036,0.0013455135,0.0006385655,0.0011247058,0.00022191541,0.000031215026],"genre_scores_gemma":[0.9929309,0.0009353063,0.00024100556,0.000043031716,0.000046073812,0.00009829947,0.0008234563,0.00005254972,0.0048293867],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968064,0.0007644333,0.0007693435,0.0010643611,0.00013270455,0.00046276665],"domain_scores_gemma":[0.9973923,0.00061504846,0.0005988432,0.0011536278,0.00012405863,0.00011613395],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010303536,0.0005987815,0.0021715332,0.00060457084,0.00018809225,0.00004626239,0.00045542832,0.0005010928,0.001715195],"category_scores_gemma":[0.0002222118,0.0004627893,0.0022151065,0.0004499706,0.00017464897,0.000055464152,0.00057103817,0.00034073496,0.00008092986],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005920414,0.00038213204,0.046425596,0.0004344653,0.8652625,0.00004452644,0.0033810104,0.00060290325,0.07551486,0.0006089911,0.00034005535,0.00641089],"study_design_scores_gemma":[0.0008489906,0.000092307375,0.22948067,0.000023055962,0.7139808,0.0000025326253,0.00055659877,0.0000670226,0.03189865,0.022056898,0.00021857944,0.0007739149],"about_ca_topic_score_codex":0.0016517121,"about_ca_topic_score_gemma":0.0014326911,"teacher_disagreement_score":0.18305507,"about_ca_system_score_codex":0.000041463332,"about_ca_system_score_gemma":0.00015862333,"threshold_uncertainty_score":0.9997824},"labels":[],"label_agreement":null},{"id":"W4387439333","doi":"10.1111/jdv.19266","title":"Patient prioritisation of impact items to develop the <scp>patient‐reported</scp> impact of dermatological diseases (<scp>PRIDD</scp>) measure: European Delphi data","year":2023,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Arthritis Patient Alliance","funders":"","keywords":"Medicine; Delphi method; Dermatological diseases; Family medicine; Descriptive statistics; Disease; Qualitative research; Dermatology; Pathology","score_opus":0.048175646124691995,"score_gpt":0.29129264488163537,"score_spread":0.24311699875694337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387439333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112934,0.0065924325,0.000049251346,0.000567166,0.0005619255,0.00032297382,0.0002898001,0.000029508998,0.00045761102],"genre_scores_gemma":[0.99874556,0.0007894968,0.00007111435,0.00016335101,0.00006262508,0.0000028954378,0.00008215024,0.00003790198,0.00004492576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99258286,0.004607506,0.0017074983,0.00036984403,0.00018123146,0.0005510865],"domain_scores_gemma":[0.9951072,0.0016416581,0.002306531,0.0005304683,0.00028985567,0.00012433079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011595436,0.00037815497,0.0010039228,0.0003821618,0.00024678383,0.000010192377,0.0012099703,0.00029838117,0.00001062192],"category_scores_gemma":[0.0031051014,0.0002146497,0.00038366413,0.0007362365,0.0008059067,0.00017517358,0.00095748855,0.0005811146,0.000039265353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020414386,0.00036464067,0.9103605,0.00007039104,0.0028158524,0.00030546312,0.0028061937,0.00023698594,0.0329336,0.00016494335,0.033348493,0.01638875],"study_design_scores_gemma":[0.0015305183,0.00028980817,0.97036237,0.00012805368,0.0006554629,0.008486593,0.0004776287,0.00001290786,0.012560124,0.00019399515,0.0052271,0.00007546137],"about_ca_topic_score_codex":0.000013464817,"about_ca_topic_score_gemma":0.000002507278,"teacher_disagreement_score":0.060001805,"about_ca_system_score_codex":0.000040331528,"about_ca_system_score_gemma":0.00022620085,"threshold_uncertainty_score":0.875316},"labels":[],"label_agreement":null},{"id":"W4387666949","doi":"10.1016/j.jaad.2023.10.020","title":"Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"Amgen","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Dermatology; Psoriatic arthritis; Pathology; Alternative medicine","score_opus":0.01753623319444852,"score_gpt":0.2776379369077473,"score_spread":0.26010170371329877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387666949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99542,0.00033528684,0.000022689765,0.0016161677,0.0002947789,0.002006187,0.00022908987,0.000011081739,0.00006474573],"genre_scores_gemma":[0.9993881,0.00019349265,0.0001306674,0.000082616396,0.000048454698,0.00004845482,0.000034236633,0.000019521733,0.00005443319],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964497,0.0012100324,0.0015947123,0.0002646889,0.0001425826,0.00033829032],"domain_scores_gemma":[0.99549013,0.0019394953,0.0022420685,0.00018458503,0.00008244019,0.00006126749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056410657,0.00028138788,0.0023410842,0.00043803873,0.000086311644,0.0000067163055,0.00042652417,0.00020939171,0.000011303922],"category_scores_gemma":[0.00038860418,0.00016184653,0.0003268395,0.0005073305,0.0006313167,0.00010548959,0.0001283429,0.0004332563,0.000007991097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99077487,0.000598458,0.0019209661,0.000007077854,0.0021427278,0.0000100648085,0.0007276662,0.0001911041,0.0011920363,0.000025000387,0.00030651916,0.0021034803],"study_design_scores_gemma":[0.9879854,0.00078529684,0.006266257,0.00009764788,0.0008750174,0.00009178814,0.00020300127,0.00001745459,0.0033693223,0.00006199962,0.00008655729,0.00016027519],"about_ca_topic_score_codex":0.00006202411,"about_ca_topic_score_gemma":0.0000102010945,"teacher_disagreement_score":0.004345291,"about_ca_system_score_codex":0.00003122199,"about_ca_system_score_gemma":0.00011053196,"threshold_uncertainty_score":0.65999097},"labels":[],"label_agreement":null},{"id":"W4387738167","doi":"10.3390/ijms242015299","title":"Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis","year":2023,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Research Centre of Canada; University of Toronto; Discovery Centre; University Health Network","funders":"Canadian Institutes of Health Research; Krembil Foundation; University of Toronto; Pfizer","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Metabolomics; Disease; Arthritis; Dermatology; Internal medicine; Bioinformatics; Biology","score_opus":0.011035575802308777,"score_gpt":0.2440878314822167,"score_spread":0.23305225567990792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387738167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829286,0.0004966858,0.00008580531,0.00022465651,0.00073038414,0.00007996315,0.00003373646,0.000011315905,0.000044565164],"genre_scores_gemma":[0.9997181,0.00008908192,0.00007340351,0.000033091208,0.000012536672,0.0000041024705,0.000017777264,0.000006421183,0.0000454273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989804,0.00019303655,0.00020237717,0.00016314202,0.00026741726,0.00019359753],"domain_scores_gemma":[0.9993622,0.00008995205,0.0002884846,0.00006154343,0.0001670937,0.000030756008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048742144,0.000107752676,0.00017453864,0.00039500915,0.000077827026,0.000050317336,0.00033731098,0.000040561663,0.000048516842],"category_scores_gemma":[0.000104272105,0.00007524462,0.00007068994,0.00040960975,0.00014727662,0.0002935783,0.000040677907,0.000103912564,0.000018059205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033496546,0.000711034,0.85448146,0.0000063507096,0.0021158464,0.000913475,0.0004699053,0.0011695963,0.010787365,0.0001581482,0.000105386236,0.12573178],"study_design_scores_gemma":[0.0034617174,0.00027642315,0.98759824,0.00017255297,0.00006369403,0.000010489227,0.000091053065,0.000012008976,0.008012872,0.00017112259,0.000026823422,0.000102973776],"about_ca_topic_score_codex":0.000018373148,"about_ca_topic_score_gemma":0.000051214316,"teacher_disagreement_score":0.13311681,"about_ca_system_score_codex":0.00006455157,"about_ca_system_score_gemma":0.0001437683,"threshold_uncertainty_score":0.30683866},"labels":[],"label_agreement":null},{"id":"W4387775654","doi":"10.7573/dic.2023-8-2","title":"Childhood guttate psoriasis: an updated review","year":2023,"lang":"en","type":"review","venue":"Drugs in Context","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.046436631851284854,"score_gpt":0.32066376356562215,"score_spread":0.2742271317143373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387775654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051789535,0.9936845,3.7509267e-7,0.00006018938,0.0023457701,0.0017899043,0.0005566264,0.00031100705,0.001199886],"genre_scores_gemma":[0.000035648503,0.9830089,0.000010578635,0.00029947274,0.0001402362,0.0006903969,0.009103165,0.00014549066,0.006566096],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955344,0.0013859777,0.0013092232,0.0009818109,0.00007160557,0.00071693433],"domain_scores_gemma":[0.9979672,0.000300489,0.00054972386,0.0010593026,0.000063953536,0.00005937537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00086011854,0.00084907137,0.0033292118,0.0004323168,0.00014031415,0.000026767657,0.0008379877,0.00090210635,0.0012854988],"category_scores_gemma":[0.00010614605,0.0006768896,0.0007664591,0.0008933696,0.00010503298,0.00012986225,0.00016665402,0.00069699145,0.013785766],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000107574,0.00019605903,0.0000028137172,0.0055836425,0.0009376239,0.000035657496,0.0003111593,1.8014443e-8,5.532006e-7,0.00015185084,0.013507375,0.9792625],"study_design_scores_gemma":[0.0010531344,0.00007829732,0.000021346403,0.039409406,0.0021968065,0.000062791005,0.00011626491,4.202789e-8,0.000005076527,0.000043489144,0.95639074,0.00062259985],"about_ca_topic_score_codex":0.00012486248,"about_ca_topic_score_gemma":0.0001788422,"teacher_disagreement_score":0.9786399,"about_ca_system_score_codex":0.00014319055,"about_ca_system_score_gemma":0.0003316887,"threshold_uncertainty_score":0.9996275},"labels":[],"label_agreement":null},{"id":"W4388042291","doi":"10.1007/s40264-023-01361-w","title":"Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis","year":2023,"lang":"en","type":"article","venue":"Drug Safety","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Janssen Pharmaceuticals; National Institute for Health and Care Research; Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Placebo; Population; Adverse effect; Internal medicine; Psoriasis Area and Severity Index; Incidence (geometry); Concomitant; Body surface area; Dermatology; Pathology","score_opus":0.02649699749345453,"score_gpt":0.3186145722983213,"score_spread":0.2921175748048668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994475,0.0035039256,0.000018159286,0.000052300576,0.00043713895,0.0005959608,0.0008588034,0.0000478198,0.000010891729],"genre_scores_gemma":[0.9916481,0.005762197,0.000058901936,0.000013535058,0.000019916028,0.00005077411,0.0023003686,0.000023649183,0.000122564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965191,0.0008896749,0.0014563923,0.00059695094,0.0001258871,0.0004119925],"domain_scores_gemma":[0.99806696,0.00068202225,0.00047071016,0.0005276481,0.00018119239,0.00007146371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001073626,0.00034560333,0.0015395453,0.0008688774,0.000121404475,0.000005319316,0.0002208094,0.00019180507,0.00011738341],"category_scores_gemma":[0.000296732,0.0002769596,0.00021479998,0.0021221072,0.00037162917,0.0001782037,0.00013069191,0.00021162067,0.000007686106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009335031,0.002675143,0.77490413,0.00008070825,0.0048855944,0.000028751057,0.0035266632,0.00010153538,0.00004492383,0.000056936475,0.000045120047,0.20431545],"study_design_scores_gemma":[0.025270728,0.00087506423,0.97001326,0.0003320662,0.0020796433,5.5453086e-7,0.0008324746,0.00005933367,0.00015975545,0.00004202764,0.00005914149,0.0002759303],"about_ca_topic_score_codex":0.0001888577,"about_ca_topic_score_gemma":0.0025303855,"teacher_disagreement_score":0.20403953,"about_ca_system_score_codex":0.00009089476,"about_ca_system_score_gemma":0.00011405384,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W4388160039","doi":"10.1016/j.jinf.2023.10.015","title":"The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of Infection","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"","keywords":"Dupilumab; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Betacoronavirus; Meta-analysis; MEDLINE; Coronavirus; Virology; Immunology; Internal medicine; Biology","score_opus":0.11683544105944844,"score_gpt":0.40782406301648555,"score_spread":0.2909886219570371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388160039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035177194,0.96253043,0.000017386637,0.000036903508,0.0013273116,0.00079015194,0.00007200792,0.000016551943,0.000032058582],"genre_scores_gemma":[0.006105686,0.99331355,0.0000035066819,0.000018989163,0.00003909597,0.000052008614,0.000075719545,0.000025508902,0.00036591932],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99530345,0.0027927223,0.0014498312,0.00018647357,0.00010371316,0.00016383607],"domain_scores_gemma":[0.99101675,0.006279804,0.0022994885,0.00027786917,0.00009087502,0.000035210196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002576944,0.00030475893,0.003934785,0.00073372305,0.00010629842,0.000012170127,0.00015188364,0.00039793397,0.00007125788],"category_scores_gemma":[0.0015205286,0.00012239708,0.0044561466,0.0007306786,0.000080934886,0.00004331465,0.000026446212,0.0005157646,0.00005672004],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009495897,0.00037942448,0.29229736,0.00071885716,0.50083804,0.000014654989,0.000018580753,0.00003909603,6.700147e-8,0.00000823419,0.00025856396,0.20447752],"study_design_scores_gemma":[0.004010154,0.0076845954,0.10543771,0.0003224846,0.687667,0.00002108493,0.0000025392687,6.7370806e-8,0.0000034968778,0.000008332396,0.1946285,0.0002140225],"about_ca_topic_score_codex":0.00008677085,"about_ca_topic_score_gemma":0.00019796946,"teacher_disagreement_score":0.2042635,"about_ca_system_score_codex":0.00015043643,"about_ca_system_score_gemma":0.0001648214,"threshold_uncertainty_score":0.49912083},"labels":[],"label_agreement":null},{"id":"W4388224263","doi":"10.51731/cjht.2023.773","title":"Roflumilast (Zoryve)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Roflumilast; Reimbursement; Intertriginous; Medicine; Psoriasis; Plaque psoriasis; Family medicine; Dermatology; Internal medicine; Political science; COPD; Health care; Disease","score_opus":0.0316320951458392,"score_gpt":0.26019278478805236,"score_spread":0.22856068964221316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388224263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8071661,0.16291462,0.000042733813,0.024941333,0.0034263853,0.00022891696,0.00009730275,0.0005145056,0.000668103],"genre_scores_gemma":[0.9976356,0.001167145,0.00005058968,0.00014630625,0.000008750919,0.000005705421,0.00001809902,0.000012530707,0.000955274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987855,0.00009205686,0.0004056801,0.00011908492,0.000028523009,0.00056914124],"domain_scores_gemma":[0.9993534,0.0000750077,0.00025533742,0.00020558551,0.00007933229,0.000031326996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053561316,0.00012412104,0.00032455058,0.0008689578,0.00035605062,0.000013193752,0.0003553576,0.0002388988,0.00009870905],"category_scores_gemma":[0.00025002277,0.000102079954,0.00009549656,0.0005229805,0.00020959227,0.00006927709,0.000021208336,0.00027672548,0.00059137854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014722137,0.00001121722,0.00790758,0.000023651257,0.00013899237,0.00016406023,0.00036358263,0.000004412763,0.0011891876,0.0006852302,0.05986591,0.9296315],"study_design_scores_gemma":[0.0009920844,0.00046931268,0.04494511,0.00012345616,0.000031461674,0.00048336003,0.0044607944,5.341826e-7,0.009701954,0.0021364726,0.93646586,0.00018962035],"about_ca_topic_score_codex":0.0013541053,"about_ca_topic_score_gemma":0.0019547495,"teacher_disagreement_score":0.9294418,"about_ca_system_score_codex":0.00016020793,"about_ca_system_score_gemma":0.001250651,"threshold_uncertainty_score":0.76011723},"labels":[],"label_agreement":null},{"id":"W4388242982","doi":"10.1093/oso/9780199231225.003.0004","title":"What causes psoriatic arthritis","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Arthritis; Medicine; Dermatology; Disease; Psoriasis; Immunology; Internal medicine","score_opus":0.02359056393276141,"score_gpt":0.22156674485721067,"score_spread":0.19797618092444927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388242982","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011234448,0.25850314,0.000006346437,0.0001807156,0.009031459,0.0004658871,0.00013989468,0.00031347683,0.73023564],"genre_scores_gemma":[0.002175766,0.17746067,0.000035377645,0.00019940412,0.00017612055,0.000022266006,0.0006056998,0.000057367655,0.81926733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987613,0.000036384263,0.00035769766,0.00046697888,0.00004515073,0.00033247878],"domain_scores_gemma":[0.9991595,0.00012442382,0.00015960677,0.00046739232,0.0000589017,0.000030144474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000049385093,0.00047712636,0.00063901406,0.00015841403,0.00019149945,0.000032341362,0.00018416053,0.0009595014,0.014075643],"category_scores_gemma":[0.000009956984,0.00040985108,0.000308916,0.000018054665,0.00018124189,0.00016335236,0.00006577621,0.00024957184,0.015836157],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001209547,0.00009758829,0.000032740576,0.000030842326,0.0027082122,0.00037477323,0.0004621586,2.9552592e-7,0.0006233772,0.024717964,0.19185199,0.7789791],"study_design_scores_gemma":[0.0012749936,0.00015618718,0.00007021231,0.00026819823,0.0002679282,0.0004893321,0.0000337566,3.138153e-8,0.0031105094,0.0012259373,0.9925944,0.00050846394],"about_ca_topic_score_codex":0.000027735212,"about_ca_topic_score_gemma":0.00016046989,"teacher_disagreement_score":0.80074245,"about_ca_system_score_codex":0.00004959249,"about_ca_system_score_gemma":0.00008733563,"threshold_uncertainty_score":0.9998353},"labels":[],"label_agreement":null},{"id":"W4388243011","doi":"10.1093/oso/9780199231225.003.0002","title":"The relationship between psoriasis and psoriatic arthritis","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Dermatology; Medicine; Scalp","score_opus":0.04057552965542605,"score_gpt":0.23760253655699842,"score_spread":0.19702700690157238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388243011","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011515615,0.17644776,0.000031515097,0.00090754905,0.0026915642,0.00093177706,0.00037111389,0.000303196,0.8067999],"genre_scores_gemma":[0.11462602,0.023679072,0.000058550708,0.00004457974,0.000298869,0.000033353193,0.00040863882,0.000056200777,0.8607947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987105,0.00008967076,0.0004318823,0.00040243566,0.000054617314,0.00031090603],"domain_scores_gemma":[0.9970426,0.00221681,0.00020547927,0.000451245,0.000047966878,0.00003591375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018285803,0.0003937839,0.0004816185,0.000108428765,0.0009242203,0.000029573466,0.00018894441,0.0008525001,0.00049745064],"category_scores_gemma":[0.00011591991,0.0002729597,0.00019094883,0.0000282562,0.00036138052,0.000052486746,0.00008004441,0.00038993158,0.0018998923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092699935,0.000019014255,0.014511864,0.000020311341,0.0016762785,0.000026876463,0.00032806039,6.208421e-8,0.000014918046,0.1667295,0.05511751,0.7614629],"study_design_scores_gemma":[0.0016725892,0.00015079965,0.04922839,0.00011306735,0.00053172617,0.0001382062,0.000023310038,4.3510084e-8,0.00013330058,0.016886877,0.930632,0.0004896745],"about_ca_topic_score_codex":0.000025365984,"about_ca_topic_score_gemma":0.00008676998,"teacher_disagreement_score":0.8755145,"about_ca_system_score_codex":0.000039306855,"about_ca_system_score_gemma":0.00006623453,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W4388243017","doi":"10.1093/oso/9780199231225.003.0012","title":"A team approach","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Arthritis; Rheumatology; Disease; Population; Inflammatory arthritis; Internal medicine","score_opus":0.026830757985641263,"score_gpt":0.21059904032919918,"score_spread":0.1837682823435579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388243017","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044340246,0.011555298,0.000034233824,0.000015928827,0.0005403183,0.00025238807,0.00007386243,0.0001690782,0.9873146],"genre_scores_gemma":[0.0016452243,0.002068034,0.00029085908,0.00013157542,0.00010052441,0.000022854036,0.0009876195,0.000049919938,0.9947034],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990822,0.000021103102,0.0002182737,0.00040401056,0.000028223923,0.00024620284],"domain_scores_gemma":[0.99941957,0.000041382165,0.0000978522,0.00038958222,0.000032020238,0.000019600158],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004256979,0.00036733053,0.00044954623,0.00012300961,0.0001359955,0.0000049751998,0.00018430952,0.00094521214,0.003847305],"category_scores_gemma":[0.000003689465,0.00028619642,0.00026961043,0.0000129985365,0.00014659672,0.000023750448,0.00006080581,0.00024802197,0.009375511],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001263929,0.00014692808,0.000030420932,0.000025502608,0.0018519898,0.000023357734,0.00023176974,3.339876e-7,0.00068219873,0.04519522,0.8696172,0.08206867],"study_design_scores_gemma":[0.000720691,0.0000803053,0.000031574764,0.000015701842,0.00019971734,0.0002919699,0.000008092558,1.4850005e-7,0.0007356683,0.00030092217,0.99728674,0.00032845244],"about_ca_topic_score_codex":0.000019124069,"about_ca_topic_score_gemma":0.000003585148,"teacher_disagreement_score":0.12766953,"about_ca_system_score_codex":0.00003833823,"about_ca_system_score_gemma":0.000062025545,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W4388243036","doi":"10.1093/oso/9780199231225.003.0001","title":"What is psoriatic arthritis?","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Dermatology; Medicine; Scalp; Nail (fastener); Arthritis; Internal medicine; Materials science","score_opus":0.020215587060612817,"score_gpt":0.21949108790929298,"score_spread":0.19927550084868015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388243036","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037704277,0.22856094,0.0000066163307,0.00031228602,0.0062157866,0.00037359283,0.00012596615,0.00019841612,0.76382935],"genre_scores_gemma":[0.0010629628,0.17447253,0.00004201293,0.000573908,0.00015759088,0.000018400144,0.00047299545,0.0000547267,0.82314485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987178,0.00002962554,0.00036288056,0.00050684327,0.000047933343,0.00033495028],"domain_scores_gemma":[0.99914634,0.000087327266,0.00016297447,0.0005144976,0.000058305275,0.0000305799],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000052988205,0.00047874477,0.0006286048,0.00014765908,0.0001815654,0.00003200845,0.00020233644,0.0010748395,0.026952574],"category_scores_gemma":[0.000004328322,0.0004166563,0.0003616601,0.00001807863,0.00016159672,0.00015843826,0.00006746351,0.00026794657,0.027190795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007129842,0.000055391272,0.000007850993,0.000016625447,0.0014861244,0.00012485372,0.00045186194,5.1171885e-8,0.00024246698,0.011433356,0.24226017,0.74384993],"study_design_scores_gemma":[0.0013594257,0.00013565188,0.000030962277,0.00022910685,0.00022093816,0.00027499069,0.00002815833,5.929043e-8,0.003037574,0.0018688223,0.9923399,0.00047442442],"about_ca_topic_score_codex":0.000015429288,"about_ca_topic_score_gemma":0.000031760097,"teacher_disagreement_score":0.7500797,"about_ca_system_score_codex":0.000046120887,"about_ca_system_score_gemma":0.00007598753,"threshold_uncertainty_score":0.9998285},"labels":[],"label_agreement":null},{"id":"W4388414981","doi":"10.1016/j.jid.2023.09.142","title":"134 Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto; Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Immunology; Chemokine; Inflammation","score_opus":0.04010102263558514,"score_gpt":0.29311015860070605,"score_spread":0.2530091359651209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388414981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943194,0.0002827103,0.000034335248,0.004359139,0.0006864132,0.00020272931,0.000044751694,0.00003468488,0.000035848065],"genre_scores_gemma":[0.9990759,0.000083376515,0.00017556133,0.00010409037,0.000058191432,0.000011287402,0.000029859553,0.000015847301,0.0004458683],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996527,0.0018882096,0.0010656894,0.0001817912,0.00008630465,0.00025098192],"domain_scores_gemma":[0.99716234,0.00084440573,0.0012189946,0.00017107461,0.0005316055,0.00007156143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011477139,0.00017464742,0.0007072691,0.00049506605,0.0000958025,0.000006131431,0.00018140768,0.00035836286,0.000031793497],"category_scores_gemma":[0.0015731252,0.00013344889,0.00015428737,0.0006043868,0.0004224704,0.000121667545,0.000038232803,0.00028969257,0.00016460117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028344318,0.000077799996,0.00813523,0.00002300458,0.0012740358,0.00015336146,0.0037364282,0.00006711826,0.9758355,0.000059486967,0.006961997,0.0008416015],"study_design_scores_gemma":[0.0029586274,0.0010469492,0.062448323,0.0003681895,0.00031490187,0.0033255734,0.0013972418,0.0000061114806,0.9266512,0.00029792558,0.0010344695,0.00015052769],"about_ca_topic_score_codex":0.000007894449,"about_ca_topic_score_gemma":0.0000060307157,"teacher_disagreement_score":0.054313093,"about_ca_system_score_codex":0.00007247557,"about_ca_system_score_gemma":0.0003721402,"threshold_uncertainty_score":0.5441888},"labels":[],"label_agreement":null},{"id":"W4388415168","doi":"10.1016/j.jid.2023.09.086","title":"78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; McMaster University; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dose-ranging study; Plaque psoriasis; Dermatology; Scalp; Placebo; Internal medicine; Double blind; Pathology","score_opus":0.03336834155924129,"score_gpt":0.29784082373116344,"score_spread":0.26447248217192215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388415168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926648,0.0022060005,0.000580719,0.0008896593,0.0010097747,0.0022638324,0.00032410224,0.00003330549,0.000027792783],"genre_scores_gemma":[0.9972524,0.00019496374,0.0018093121,0.00014668226,0.00007078942,0.000218475,0.000059243892,0.000042060376,0.0002060468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99444145,0.0026535552,0.0018464423,0.0004207075,0.0001469819,0.0004908687],"domain_scores_gemma":[0.9917805,0.0057387636,0.0015366734,0.00029729915,0.0005136278,0.00013313188],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013558598,0.00046764544,0.0032935287,0.00093647867,0.00021018813,0.000022236994,0.00034181803,0.00038955364,0.00005609059],"category_scores_gemma":[0.0026909392,0.00035427595,0.0005549871,0.00035627815,0.00059153984,0.00022153545,0.00010961174,0.0003092804,0.000015897158],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8537699,0.0014820956,0.0014587383,0.000070748174,0.010261388,0.0001470266,0.014510436,0.0002934104,0.11052264,0.00036940756,0.0046050684,0.0025091304],"study_design_scores_gemma":[0.81979716,0.0018907876,0.0026710434,0.00022096999,0.0029261184,0.00029157416,0.0041458365,0.00029341519,0.16423328,0.0028349156,0.00030101294,0.00039385873],"about_ca_topic_score_codex":0.00015256683,"about_ca_topic_score_gemma":0.000051458068,"teacher_disagreement_score":0.053710636,"about_ca_system_score_codex":0.00004874724,"about_ca_system_score_gemma":0.00030242873,"threshold_uncertainty_score":0.9998909},"labels":[],"label_agreement":null},{"id":"W4388415534","doi":"10.1016/j.jid.2023.09.085","title":"77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Medicine; Placebo; Pharmacodynamics; Internal medicine; Gastroenterology; Randomized controlled trial; Plaque psoriasis; Pharmacokinetics; Immunology; Pathology","score_opus":0.03767727716746607,"score_gpt":0.28898607577991736,"score_spread":0.2513087986124513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388415534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488896,0.0007707201,0.0000061175306,0.0010327415,0.0016889275,0.0010276135,0.0005132985,0.00004123336,0.000030359439],"genre_scores_gemma":[0.999258,0.00008571378,0.000044565066,0.000055376564,0.00006608862,0.00009251727,0.00025762437,0.00003174023,0.000108380125],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99436253,0.0035195511,0.0010689679,0.00040385625,0.00014999442,0.00049507],"domain_scores_gemma":[0.99580234,0.0025412668,0.0010110651,0.00035406643,0.00020897751,0.00008225417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068024365,0.0004317627,0.0008882489,0.00044976425,0.0002412643,0.000026125468,0.00043076059,0.00025314928,0.000029955847],"category_scores_gemma":[0.00044022815,0.00025816113,0.00014151164,0.0005211053,0.00039812003,0.00023933066,0.00006867146,0.0004632359,0.00012604232],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5735839,0.006829395,0.2184919,0.000026401602,0.016944513,0.003008289,0.06424973,0.00051843846,0.098116,0.000064770684,0.010573763,0.007592899],"study_design_scores_gemma":[0.39376593,0.012330415,0.45648208,0.00042965842,0.00230144,0.00034431124,0.03582328,0.000050975614,0.09611497,0.00009083415,0.0014494566,0.00081666134],"about_ca_topic_score_codex":0.00018948848,"about_ca_topic_score_gemma":0.00022076949,"teacher_disagreement_score":0.23799019,"about_ca_system_score_codex":0.00034022186,"about_ca_system_score_gemma":0.00046420487,"threshold_uncertainty_score":0.99998707},"labels":[],"label_agreement":null},{"id":"W4388456111","doi":"10.1016/j.jaad.2023.08.103","title":"Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","year":2023,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"American Academy of Dermatology","keywords":"Medicine; Atopic dermatitis; Dermatology; Executive summary; MEDLINE; Intensive care medicine","score_opus":0.015995978812012614,"score_gpt":0.28062449977625,"score_spread":0.2646285209642374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388456111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697842,0.02640175,0.000026935506,0.003254157,0.000097263095,0.0003623465,0.000044673434,0.000004268308,0.000024401948],"genre_scores_gemma":[0.9804498,0.019029798,0.0002785322,0.00015064767,0.000009158827,0.000022144714,0.0000022326376,0.000009588494,0.000048122656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891055,0.00020275942,0.00058798597,0.000091018934,0.000053569125,0.00015409414],"domain_scores_gemma":[0.99830854,0.000334413,0.0011463447,0.000106094245,0.0000956945,0.000008936965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013192212,0.00012062679,0.0006139293,0.0001511036,0.000050769548,0.0000013799514,0.00030970204,0.00007261711,0.0000026089137],"category_scores_gemma":[0.000011199646,0.00006197368,0.00012651147,0.00027247044,0.000503377,0.000039939678,0.000046168545,0.0001098122,4.0930703e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009170826,0.00031270023,0.6736293,0.004552128,0.016072018,0.00007626217,0.045039833,0.00026300832,0.05973046,0.0036071134,0.011010661,0.17653571],"study_design_scores_gemma":[0.01620177,0.0013854483,0.67655295,0.0049734744,0.0014807244,0.0039556995,0.10409092,0.000034291417,0.17532468,0.00064358977,0.014957051,0.00039938104],"about_ca_topic_score_codex":0.000048815735,"about_ca_topic_score_gemma":0.000013534254,"teacher_disagreement_score":0.17613633,"about_ca_system_score_codex":0.000014497663,"about_ca_system_score_gemma":0.000031658048,"threshold_uncertainty_score":0.25272134},"labels":[],"label_agreement":null},{"id":"W4388493104","doi":"10.15690/vsp.v22i5.2635","title":"TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case","year":2023,"lang":"en","type":"article","venue":"Вопросы современной педиатрии","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute","funders":"","keywords":"Medicine; Infliximab; Ulcerative colitis; Psoriasis; Calprotectin; Dermatology; Adalimumab; Exacerbation; Inflammatory bowel disease; Adverse effect; Scalp; Disease; Internal medicine","score_opus":0.047530034069574845,"score_gpt":0.30327861470077105,"score_spread":0.2557485806311962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388493104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475694,0.00075446104,0.000011405045,0.00044218573,0.0017683526,0.00094620005,0.000120276265,0.00027296713,0.00092722906],"genre_scores_gemma":[0.9967879,0.00058018585,0.000115800336,0.0002358209,0.00034577958,0.00022849881,0.00017800214,0.000065968336,0.0014620625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99621254,0.00092729495,0.0008876982,0.0009626501,0.00011645887,0.0008933392],"domain_scores_gemma":[0.9983754,0.00059355935,0.00023600826,0.00054531754,0.00011378692,0.00013592487],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009673811,0.00053068105,0.0008887812,0.00040511065,0.00034701015,0.000059633225,0.0002097264,0.0005857092,0.00019237465],"category_scores_gemma":[0.00020116358,0.0004401899,0.0001635279,0.0008786818,0.00026843534,0.00021040814,0.00017037179,0.0005587395,0.0009878188],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007462131,0.0023450735,0.18274038,0.00027974445,0.0023557895,0.01621775,0.007162275,0.000020848676,0.0052629304,0.0019203306,0.021836957,0.7523958],"study_design_scores_gemma":[0.021539116,0.0019657025,0.9422635,0.00049196417,0.0006065433,0.0026214246,0.0039746943,0.000038807335,0.010058642,0.00028789858,0.014820305,0.0013314085],"about_ca_topic_score_codex":0.0003426562,"about_ca_topic_score_gemma":0.0032264516,"teacher_disagreement_score":0.7595231,"about_ca_system_score_codex":0.00012930474,"about_ca_system_score_gemma":0.00019632168,"threshold_uncertainty_score":0.999805},"labels":[],"label_agreement":null},{"id":"W4388568066","doi":"10.1177/12034754231211341","title":"Elderly Onset Generalized Pustular Psoriasis: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; McMaster University; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Dermatology; Psoriasis; Generalized pustular psoriasis","score_opus":0.06840368282860947,"score_gpt":0.31718839573684027,"score_spread":0.2487847129082308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388568066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000785301,0.99579805,0.0000027837868,0.00030546967,0.0027985375,0.00088551594,0.000041158215,0.000042949297,0.000047004527],"genre_scores_gemma":[0.000007059709,0.9959091,0.0000107253145,0.00035431128,0.0004269913,0.00006455445,0.00016627664,0.00007557216,0.0029853887],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9941178,0.0017135809,0.003199634,0.00032472936,0.00020257126,0.00044170208],"domain_scores_gemma":[0.99211264,0.004233851,0.00285044,0.00046114856,0.0002251844,0.00011671596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025005324,0.00066758913,0.009365041,0.0008190381,0.00013609017,0.000017058113,0.00031414622,0.0005690482,0.00025962054],"category_scores_gemma":[0.0021092938,0.00037763367,0.0014762653,0.00051426655,0.00015260471,0.00005890247,0.000044588935,0.00057219504,0.00021350327],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045711797,0.000055310706,0.0000027260498,0.71783715,0.005450507,0.004000208,0.000080537495,2.1470324e-8,0.0000022603238,0.00000822242,0.09861421,0.17390317],"study_design_scores_gemma":[0.00028065912,0.0002165545,1.7796609e-7,0.5235577,0.021626323,0.043601263,0.00004592122,2.7223653e-8,6.296113e-7,0.00002085878,0.41042686,0.00022298924],"about_ca_topic_score_codex":0.000016390239,"about_ca_topic_score_gemma":0.0000035249177,"teacher_disagreement_score":0.31181264,"about_ca_system_score_codex":0.00007497248,"about_ca_system_score_gemma":0.00046696057,"threshold_uncertainty_score":0.99986756},"labels":[],"label_agreement":null},{"id":"W4388578674","doi":"","title":"ZORYVE<sup>TM</sup> (Roflumilast) Cream: A Topical Phosphodiesterase-4 Inhibitor for the Treatment of Psoriasis.","year":2023,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Medicine; Roflumilast; Adverse effect; Psoriasis; Dermatology; Nausea; Diarrhea; Dysgeusia; Internal medicine; COPD","score_opus":0.0339059670102131,"score_gpt":0.24009192839600052,"score_spread":0.20618596138578743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388578674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877303,0.006418592,0.000036523772,0.0009805474,0.0016941946,0.0021566073,0.0003463081,0.00017735198,0.00045956328],"genre_scores_gemma":[0.9712806,0.0018202462,0.000057687925,0.00010008248,0.0003670505,0.009372495,0.00025702253,0.000036053952,0.016708815],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984845,0.000116638366,0.0003645747,0.00035914782,0.000053336677,0.0006218011],"domain_scores_gemma":[0.9983815,0.0009796914,0.00010684308,0.0004292155,0.000058455513,0.000044272794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002402277,0.00026321123,0.00042493758,0.00010421945,0.00023962083,0.000016542363,0.00021356209,0.0002273974,0.00010029256],"category_scores_gemma":[0.00010532637,0.00016721079,0.0003467367,0.00024195298,0.00016175595,0.000050397815,0.00004347529,0.00006119955,0.00017152105],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015360215,0.0011900271,0.0069364314,0.000044823242,0.0017680598,0.000013953039,0.0023174596,0.000023278328,0.0017021315,0.00046836506,0.020210173,0.9637893],"study_design_scores_gemma":[0.0088247815,0.0009776284,0.14453888,0.0000144886335,0.00081268686,0.000020930118,0.0008540891,0.000021141837,0.12853816,0.000245014,0.71479553,0.0003566612],"about_ca_topic_score_codex":0.00007579982,"about_ca_topic_score_gemma":0.00003197862,"teacher_disagreement_score":0.9634326,"about_ca_system_score_codex":0.00009109156,"about_ca_system_score_gemma":0.000037169968,"threshold_uncertainty_score":0.6818658},"labels":[],"label_agreement":null},{"id":"W4388586208","doi":"10.1093/bjd/ljad429","title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials","year":2023,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; LEO Pharma; Sun Pharma; Eisai; National Institute for Health and Care Research; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Discontinuation; Adverse effect; Psoriasis; Incidence (geometry); Internal medicine; Plaque psoriasis; Gastroenterology; Dermatology","score_opus":0.06127394202515896,"score_gpt":0.32844693045013756,"score_spread":0.2671729884249786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388586208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08987184,0.89904827,0.00006259134,0.000054225315,0.0015387584,0.0035196245,0.005866043,0.000020358433,0.000018300965],"genre_scores_gemma":[0.01254883,0.9824972,0.0002065107,0.000032396063,0.00006967348,0.00019964851,0.0042327964,0.00008630766,0.00012660984],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98963565,0.004982242,0.0040705306,0.00065117434,0.00012135911,0.00053905696],"domain_scores_gemma":[0.9939734,0.003041857,0.002111167,0.000615198,0.00015108772,0.000107317195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001318874,0.00057345786,0.010787849,0.0011530956,0.000057467918,0.000031820633,0.0008786675,0.0008042734,0.00018011824],"category_scores_gemma":[0.0010573184,0.00048238755,0.0007013626,0.00061987515,0.00010555341,0.00016009579,0.0002082972,0.0004543422,0.00013233215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17094977,0.0010319925,0.00007857908,0.00031918322,0.007886634,0.002170968,0.0003826898,0.000011961877,0.0000025437512,0.0000068668687,0.0014135026,0.8157453],"study_design_scores_gemma":[0.87315315,0.00096798845,0.00034901104,0.020308308,0.009179994,0.004074418,0.00013078026,0.0000020754226,0.00005211462,0.00006428121,0.09088277,0.0008351338],"about_ca_topic_score_codex":0.0013421678,"about_ca_topic_score_gemma":0.0015248241,"teacher_disagreement_score":0.8149102,"about_ca_system_score_codex":0.0003139139,"about_ca_system_score_gemma":0.0011266455,"threshold_uncertainty_score":0.9997628},"labels":[],"label_agreement":null},{"id":"W4388625669","doi":"10.25251/skin.7.supp.240","title":"Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Plaque psoriasis; Adverse effect; Apremilast; Internal medicine; Randomized controlled trial; Dosing; Dermatology; Psoriatic arthritis","score_opus":0.03578117792347708,"score_gpt":0.304577256432096,"score_spread":0.2687960785086189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97146195,0.013539832,0.0000132649,0.012695688,0.0011831011,0.00038537168,0.00026955732,0.000024203051,0.0004270347],"genre_scores_gemma":[0.97491425,0.02340287,0.000029472903,0.00030193978,0.00061782624,0.0000026568948,0.00009468864,0.000021149652,0.0006151367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964567,0.0016579207,0.0012231419,0.00021052263,0.00013081258,0.0003209392],"domain_scores_gemma":[0.98837084,0.010500765,0.0006853243,0.00030728264,0.00007754109,0.000058244077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045923274,0.000249482,0.000877875,0.0001726254,0.00024144872,0.000013633471,0.00031452242,0.00020772459,0.00014878648],"category_scores_gemma":[0.0033296645,0.00011631626,0.000101563994,0.0003003699,0.00040525346,0.000050671537,0.00006923864,0.00045828093,0.000040438463],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.150755,0.0007928194,0.0018885055,0.000047329482,0.005110452,0.0031405604,0.054332487,0.000090243375,0.105702035,0.00060085324,0.09038245,0.58715725],"study_design_scores_gemma":[0.3591653,0.014126272,0.061298408,0.0041147172,0.009595711,0.037848715,0.041336223,0.000070910755,0.033187293,0.00915143,0.42852706,0.0015779437],"about_ca_topic_score_codex":0.00021060607,"about_ca_topic_score_gemma":0.00014012904,"teacher_disagreement_score":0.58557934,"about_ca_system_score_codex":0.000031407468,"about_ca_system_score_gemma":0.00006994304,"threshold_uncertainty_score":0.47432396},"labels":[],"label_agreement":null},{"id":"W4388625690","doi":"10.25251/skin.7.supp.239","title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Apremilast; Medicine; Psoriasis; Placebo; Psoriasis Area and Severity Index; Internal medicine; Gastroenterology; Randomization; Randomized controlled trial; Plaque psoriasis; Pharmacology; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.02818460525731643,"score_gpt":0.30724518295219083,"score_spread":0.2790605776948744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902143,0.0012415367,0.00001424977,0.0055715763,0.0018092251,0.00082699396,0.0000538504,0.00003249001,0.00023578785],"genre_scores_gemma":[0.99642557,0.0007521456,0.000032941196,0.0013021571,0.00046281822,0.00003249295,0.00006196412,0.00003903381,0.00089087075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99630535,0.001459584,0.0010725339,0.0002908222,0.00025317367,0.00061855774],"domain_scores_gemma":[0.9978124,0.0011035771,0.00043486233,0.00042393338,0.00013745141,0.000087809916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020774726,0.00040861344,0.00091775693,0.00057807734,0.0002065257,0.00002571829,0.0006370804,0.0002752011,0.00020315444],"category_scores_gemma":[0.0004553294,0.00021406673,0.00015854412,0.0009850978,0.00016461257,0.0001607817,0.0000708068,0.000709793,0.00006427762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49620166,0.007073758,0.0052163675,0.000110699264,0.0031532305,0.014739481,0.06854842,0.0026127794,0.17763256,0.00028345207,0.100853115,0.123574495],"study_design_scores_gemma":[0.7043308,0.07007825,0.042664606,0.002140155,0.003976422,0.041734684,0.02545769,0.00051273505,0.031009682,0.0055769286,0.069619775,0.00289828],"about_ca_topic_score_codex":0.00036683894,"about_ca_topic_score_gemma":0.001044987,"teacher_disagreement_score":0.20812914,"about_ca_system_score_codex":0.00013941196,"about_ca_system_score_gemma":0.00018130364,"threshold_uncertainty_score":0.8729388},"labels":[],"label_agreement":null},{"id":"W4388625988","doi":"10.25251/skin.7.supp.254","title":"Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Medicine; Double blind; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Randomized controlled trial; Placebo-controlled study; Double blind study; Internal medicine; Alternative medicine; Pathology; Psoriatic arthritis","score_opus":0.017666931991307977,"score_gpt":0.2602192344788104,"score_spread":0.24255230248750242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388625988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913584,0.0017636871,0.000036148816,0.0020673282,0.0008338368,0.003624635,0.00008802125,0.000024295969,0.00020367464],"genre_scores_gemma":[0.9975478,0.001178234,0.000012505598,0.00014774634,0.00044262607,0.000051298957,0.00008627725,0.00002950534,0.0005040156],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99613,0.0016335923,0.0012795394,0.0002993179,0.00026212333,0.00039545583],"domain_scores_gemma":[0.9915262,0.007034663,0.0007726141,0.0003741299,0.00020998945,0.00008241393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003155552,0.0003751835,0.001410337,0.0003117681,0.00030063916,0.000021318228,0.00042736542,0.00014494956,0.00005928901],"category_scores_gemma":[0.0008800704,0.00015714187,0.00011480552,0.00053414993,0.00017509199,0.000069149464,0.00008104365,0.00051712035,0.00004057656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9768241,0.0009190974,0.0011127695,0.000005263616,0.0015481502,0.00021146983,0.012645379,0.0009611091,0.00006742055,0.000003029689,0.0016397964,0.004062392],"study_design_scores_gemma":[0.9873233,0.0037499347,0.0020496803,0.00017497371,0.0030699342,0.00035315086,0.0027190251,0.000021806056,0.00008835235,0.000060098835,0.0001951437,0.00019459493],"about_ca_topic_score_codex":0.00023633549,"about_ca_topic_score_gemma":0.00043805037,"teacher_disagreement_score":0.010499181,"about_ca_system_score_codex":0.000075231175,"about_ca_system_score_gemma":0.00011011598,"threshold_uncertainty_score":0.64080596},"labels":[],"label_agreement":null},{"id":"W4388626014","doi":"10.25251/skin.7.supp.236","title":"Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto; Dalhousie University; Probity Medical Research","funders":"Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Minimal clinically important difference; Medicine; Quality of life (healthcare); Adalimumab; Psoriasis; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Placebo; Randomization; Physical therapy; Surgery; Dermatology; Disease; Pathology","score_opus":0.015940636727592213,"score_gpt":0.26762430941817744,"score_spread":0.2516836726905852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996524,0.0011656153,0.0000024808874,0.001640514,0.00017516392,0.00025951097,0.000025155063,0.000008941766,0.00019864747],"genre_scores_gemma":[0.9958423,0.00090218976,0.00004670416,0.00009696511,0.000051870058,0.0000065572845,0.000014950493,0.000014095554,0.0030243704],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99806386,0.00033740257,0.001063202,0.00013815619,0.00010764132,0.00028971417],"domain_scores_gemma":[0.998009,0.0011591521,0.00048237105,0.00023888817,0.00006552984,0.000045021385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091700867,0.00019116563,0.0007079929,0.00034549335,0.000033758595,0.0000018410906,0.00027214948,0.000111960966,0.00039436683],"category_scores_gemma":[0.00026273666,0.00009191303,0.00007588906,0.00044827818,0.00021383929,0.000016920832,0.000031309282,0.00019150713,0.00010060812],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074651584,0.0039850404,0.2683896,0.00010572476,0.0035453818,0.02743063,0.052263897,0.0005092402,0.40439376,0.000033563618,0.013382528,0.15130903],"study_design_scores_gemma":[0.04902955,0.111997254,0.70851195,0.004628877,0.0030161985,0.055078816,0.009929539,0.000106731204,0.04314523,0.0007250833,0.012667482,0.0011633122],"about_ca_topic_score_codex":0.00014331288,"about_ca_topic_score_gemma":0.0004005527,"teacher_disagreement_score":0.4401223,"about_ca_system_score_codex":0.00008135793,"about_ca_system_score_gemma":0.00015847398,"threshold_uncertainty_score":0.43180403},"labels":[],"label_agreement":null},{"id":"W4388626067","doi":"10.25251/skin.7.supp.257","title":"Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; Glenmark Pharmaceuticals; LEO Pharma; Incyte; Dermira; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Apremilast; Psoriasis; Randomized controlled trial; Body surface area; Plaque psoriasis; Internal medicine; Gastroenterology; Dermatology","score_opus":0.013720690003934744,"score_gpt":0.2400699069863114,"score_spread":0.22634921698237664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967873,0.0012560368,0.000014833587,0.0008088922,0.00033202767,0.00054679974,0.00016830007,0.000010180267,0.00007562233],"genre_scores_gemma":[0.99861246,0.0009951862,0.00002497523,0.000045014243,0.0001392669,0.0000029435146,0.000109838285,0.00001668818,0.00005363664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981773,0.00055783865,0.0006999462,0.00017843996,0.00015717269,0.00022932747],"domain_scores_gemma":[0.99699,0.001977714,0.0006148679,0.00026095434,0.0001144789,0.00004194221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007230632,0.0002258707,0.0006428069,0.0001181411,0.0001644959,0.00000722432,0.00021201979,0.00010199294,0.00002276175],"category_scores_gemma":[0.00016069869,0.00009468616,0.000034293174,0.00023848203,0.0004477934,0.000049041355,0.000040537332,0.00030410266,0.0000021922742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9542851,0.000512567,0.0018927158,0.0000116011815,0.0013400977,0.0001880152,0.016540037,0.00032445716,0.0015165095,0.000008744134,0.0011241534,0.02225602],"study_design_scores_gemma":[0.9005765,0.021452434,0.060026556,0.0017545951,0.0026300051,0.0015998578,0.005959832,0.000101281774,0.003918255,0.0002178095,0.0013602242,0.0004026496],"about_ca_topic_score_codex":0.0001898281,"about_ca_topic_score_gemma":0.00022721362,"teacher_disagreement_score":0.05813384,"about_ca_system_score_codex":0.000028044513,"about_ca_system_score_gemma":0.000065332955,"threshold_uncertainty_score":0.38611895},"labels":[],"label_agreement":null},{"id":"W4388626102","doi":"10.25251/skin.7.supp.246","title":"Flare Frequency and Duration in Patients with Generalized Pustular Psoriasis (GPP)","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Flare; Psoriasis; Erythema; Generalized pustular psoriasis; Sepsis; Pediatrics; Dermatology; Internal medicine","score_opus":0.008628953416183355,"score_gpt":0.21938818921263625,"score_spread":0.2107592357964529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388626102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952218,0.0027055405,0.000012763978,0.0010935953,0.0006396739,0.00017518774,0.000007939282,0.000013500059,0.00012998532],"genre_scores_gemma":[0.9981599,0.0011219345,0.00004725784,0.000087757464,0.000121542456,0.0000026661935,0.00004578016,0.000013244024,0.00039994062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989039,0.0002835786,0.00040775264,0.00009920251,0.000106273495,0.000199316],"domain_scores_gemma":[0.99919844,0.00021707924,0.00028534836,0.00014583784,0.00012677521,0.000026499181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047242583,0.00014337833,0.0003247092,0.00021183328,0.00011025699,0.000004486129,0.00013941524,0.00010212978,0.0001549563],"category_scores_gemma":[0.00014170159,0.0000716583,0.000033845216,0.00029524148,0.00013371218,0.000060148235,0.000019064435,0.00017633443,0.000023994016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011806223,0.0006479561,0.69739366,0.00012438143,0.00306523,0.0020917186,0.021166062,0.00023551652,0.09640268,0.00050107384,0.018275337,0.14829017],"study_design_scores_gemma":[0.03881378,0.008661794,0.91682655,0.0009097826,0.0022189105,0.006987388,0.0034774994,0.000019438608,0.011567297,0.002690392,0.0071893753,0.00063782005],"about_ca_topic_score_codex":0.00007581354,"about_ca_topic_score_gemma":0.00008389338,"teacher_disagreement_score":0.21943288,"about_ca_system_score_codex":0.000037305817,"about_ca_system_score_gemma":0.000036671034,"threshold_uncertainty_score":0.2922141},"labels":[],"label_agreement":null},{"id":"W4388627102","doi":"10.25251/skin.7.supp.255","title":"Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"Amgen","keywords":"Apremilast; Psoriasis; Body surface area; Medicine; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.016358601469401518,"score_gpt":0.24945393813424263,"score_spread":0.2330953366648411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959295,0.00063063565,0.000022854041,0.0010409406,0.0011532467,0.0006725329,0.0003953199,0.000015996719,0.00013900863],"genre_scores_gemma":[0.998834,0.00018205267,0.000021899275,0.00007042078,0.00028169018,0.000003241986,0.00025848576,0.000024978008,0.00032323386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766093,0.000608536,0.0009236144,0.00020738727,0.00025281575,0.00034668634],"domain_scores_gemma":[0.996222,0.0024814324,0.00062669575,0.00043003043,0.00018246232,0.000057369092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009175367,0.0002713863,0.00066932495,0.00013444145,0.00015005842,0.000008021379,0.0005330419,0.00014497846,0.00010093694],"category_scores_gemma":[0.00067508325,0.00012048215,0.00011382752,0.00048301942,0.00022804053,0.00006041739,0.00006641811,0.00036530782,0.00003456892],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94279945,0.0015626211,0.0041621765,0.000009150834,0.0018049126,0.00033731194,0.012061474,0.0026980771,0.011819803,0.000009407008,0.012840092,0.009895515],"study_design_scores_gemma":[0.8630683,0.031362295,0.074197166,0.0016083763,0.0035436952,0.0011562092,0.0069417176,0.00011426498,0.01378497,0.00033917997,0.003085522,0.000798303],"about_ca_topic_score_codex":0.00023681995,"about_ca_topic_score_gemma":0.00014879818,"teacher_disagreement_score":0.07973115,"about_ca_system_score_codex":0.000052959353,"about_ca_system_score_gemma":0.00009258661,"threshold_uncertainty_score":0.49131197},"labels":[],"label_agreement":null},{"id":"W4388627217","doi":"10.25251/skin.7.supp.237","title":"PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McMaster University; Dalhousie University; Probity Medical Research","funders":"Amgen","keywords":"Medicine; Placebo; Clinical trial; Interquartile range; Internal medicine","score_opus":0.06724673980502993,"score_gpt":0.35733990167381413,"score_spread":0.2900931618687842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665389,0.008425148,0.00001773041,0.020832146,0.0032307568,0.0005776609,0.000059968177,0.00001612271,0.00030157928],"genre_scores_gemma":[0.9839822,0.011167676,0.000007067263,0.0015444598,0.0023952078,0.000010721827,0.000044646207,0.000018643284,0.0008293542],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953229,0.0025034186,0.0014752169,0.00018993484,0.00018082601,0.00032771795],"domain_scores_gemma":[0.98654836,0.012026713,0.0008729109,0.0004475827,0.00006367478,0.00004075712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011514389,0.00024389598,0.00082417665,0.00010624383,0.00033209173,0.000019344201,0.0006266251,0.00021474202,0.00040900428],"category_scores_gemma":[0.002144985,0.000090775924,0.0002168527,0.00022719707,0.00040755043,0.000046397596,0.00008228464,0.00066761725,0.00007453901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013697786,0.001301117,0.00576492,0.00003467038,0.0033005225,0.0027699796,0.028866896,0.000019561367,0.028828233,0.00017594048,0.3210238,0.5942166],"study_design_scores_gemma":[0.07269132,0.019029805,0.027852885,0.001157044,0.0077959253,0.010631874,0.02592444,0.00006603242,0.0059917993,0.007062823,0.8210792,0.00071683316],"about_ca_topic_score_codex":0.0001687097,"about_ca_topic_score_gemma":0.000390876,"teacher_disagreement_score":0.5934998,"about_ca_system_score_codex":0.00003784146,"about_ca_system_score_gemma":0.00006645382,"threshold_uncertainty_score":0.447831},"labels":[],"label_agreement":null},{"id":"W4388627467","doi":"10.25251/skin.7.supp.251","title":"Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Probity Medical Research; Queen's University","funders":"","keywords":"Roflumilast; Tolerability; Dermatology; Seborrheic dermatitis; Medicine; Atopic dermatitis; Psoriasis; Apremilast; Internal medicine; Adverse effect","score_opus":0.014233596826854404,"score_gpt":0.2521682519196282,"score_spread":0.2379346550927738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546784,0.0029118112,0.00001902853,0.00094030704,0.00029657554,0.00030533303,0.000030138293,0.0000069111406,0.000022072618],"genre_scores_gemma":[0.99897623,0.0007478158,0.000022731801,0.00017227941,0.0000275311,0.0000040375417,0.00002791561,0.000008367884,0.000013101453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752384,0.000985219,0.0010569483,0.000120471865,0.00011111829,0.00020241615],"domain_scores_gemma":[0.9982689,0.0009407672,0.00049086974,0.00013834199,0.00009964778,0.000061470084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077325664,0.00016487254,0.0008050663,0.0002170679,0.000054162083,0.000003888813,0.000106502026,0.0001305446,0.000060315444],"category_scores_gemma":[0.00076362945,0.000091750386,0.000036958132,0.0003021919,0.00049033994,0.00006303087,0.00003490938,0.00022186135,0.0000021850547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018390322,0.00062253576,0.75904375,0.00016409044,0.00047505944,0.00042873947,0.01422463,0.000054576507,0.003457832,0.00004937126,0.002369861,0.21727054],"study_design_scores_gemma":[0.027558342,0.0047201896,0.94606197,0.0010030587,0.00043235798,0.0017773302,0.0031680942,0.00003774064,0.01312029,0.00066061446,0.0012329653,0.00022704148],"about_ca_topic_score_codex":0.00014535493,"about_ca_topic_score_gemma":0.0002031287,"teacher_disagreement_score":0.21704349,"about_ca_system_score_codex":0.000044366294,"about_ca_system_score_gemma":0.000082191764,"threshold_uncertainty_score":0.3741472},"labels":[],"label_agreement":null},{"id":"W4388627499","doi":"10.25251/skin.7.supp.241","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2023,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Bristol-Myers Squibb","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Clinical endpoint; Apremilast; Clinical trial; Internal medicine; Randomized controlled trial; Tolerability; Adverse effect; Gastroenterology; Dermatology; Psoriatic arthritis","score_opus":0.03370635970462376,"score_gpt":0.3210922749445532,"score_spread":0.28738591523992946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388627499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988863,0.0063137654,0.000005830953,0.0037128201,0.00062780274,0.00029051414,0.000038176262,0.00000728826,0.0001408326],"genre_scores_gemma":[0.99388856,0.0051800027,0.000016369167,0.00026091005,0.00013586911,0.000005909298,0.000008569813,0.000013799116,0.0004900212],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99563336,0.0027691128,0.0010307999,0.00012862807,0.00014019498,0.00029789738],"domain_scores_gemma":[0.99347043,0.0055596135,0.00062627485,0.00025551522,0.0000622656,0.000025877289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008589252,0.00017496024,0.0007661364,0.00040149342,0.00005512532,0.000004732276,0.00036285628,0.00015928375,0.00015591679],"category_scores_gemma":[0.0024614714,0.00008612783,0.00010953536,0.0004965267,0.00032974742,0.00004441391,0.000034497552,0.0003708861,0.00001646522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15977752,0.0012769533,0.0057407357,0.00012514413,0.0019067776,0.011073366,0.077103004,0.00012142765,0.4949413,0.00091921753,0.07286288,0.17415167],"study_design_scores_gemma":[0.22223976,0.027862068,0.27570346,0.007194477,0.0047808564,0.09992779,0.08342546,0.00008154492,0.066117525,0.016815102,0.19423513,0.001616825],"about_ca_topic_score_codex":0.000095055264,"about_ca_topic_score_gemma":0.00011656438,"teacher_disagreement_score":0.42882377,"about_ca_system_score_codex":0.000039044724,"about_ca_system_score_gemma":0.00009433217,"threshold_uncertainty_score":0.3512191},"labels":[],"label_agreement":null},{"id":"W4388760077","doi":"10.1016/j.fander.2023.09.604","title":"Efficacité du risankizumab chez les patients psoriasiques naïfs de biothérapies ou précédemment traités par biothérapies participant à l’étude VALUE, étude internationale observationnelle post-AMM","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; McMaster University","funders":"","keywords":"Gynecology; Medicine","score_opus":0.0750319714604807,"score_gpt":0.3035546028163506,"score_spread":0.22852263135586992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388760077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94314766,0.01887184,0.0004366636,0.031314988,0.002473674,0.0010695944,0.0012042893,0.0011237366,0.0003575764],"genre_scores_gemma":[0.94778347,0.04191022,0.0022520681,0.003098057,0.00026178177,0.00076592027,0.0023052935,0.00012956822,0.0014936097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914213,0.002846539,0.001527564,0.0012668087,0.0003023169,0.0026354927],"domain_scores_gemma":[0.99469084,0.0029994056,0.00076111016,0.0008135361,0.0004678318,0.00026726312],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017525457,0.0011690006,0.0013546267,0.00066810334,0.0009035652,0.00021387798,0.0013676819,0.0018774037,0.00043073107],"category_scores_gemma":[0.002582376,0.0011244162,0.0007702591,0.00084135163,0.0013018553,0.0005237336,0.00065080397,0.0008831339,0.00087389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013257124,0.0036481922,0.84877175,0.000580691,0.0053130435,0.0010013115,0.015876114,0.0013559387,0.012915107,0.0122455675,0.06646478,0.030501813],"study_design_scores_gemma":[0.004813709,0.0009694885,0.89184034,0.00041404754,0.0009582019,0.0004089691,0.0033447098,0.00047868307,0.04713517,0.003805371,0.044571325,0.001259969],"about_ca_topic_score_codex":0.0007348783,"about_ca_topic_score_gemma":0.0010221256,"teacher_disagreement_score":0.04306863,"about_ca_system_score_codex":0.00057730405,"about_ca_system_score_gemma":0.0008288221,"threshold_uncertainty_score":0.99990404},"labels":[],"label_agreement":null},{"id":"W4388760087","doi":"10.1016/j.fander.2023.09.594","title":"Bimékizumab : efficacité à 3 ans dans les zones à fort impact dans le psoriasis en plaques modéré à sévère : résultats regroupés de cinq essais de phase 3/3b","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.046654488169707735,"score_gpt":0.3462948439593266,"score_spread":0.29964035578961884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388760087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94965315,0.021762986,0.009507269,0.010943047,0.0014030078,0.0009449145,0.0024063068,0.00178433,0.0015950013],"genre_scores_gemma":[0.94960946,0.039749835,0.0027749168,0.00065677025,0.00033593454,0.00051572867,0.0018224162,0.00021315238,0.0043218103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98789924,0.004672623,0.0013763555,0.0015896996,0.00022436891,0.0042377175],"domain_scores_gemma":[0.993112,0.0041042226,0.0006454681,0.0014349739,0.00022930038,0.00047400006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022035055,0.0015941977,0.0019235786,0.00085868407,0.0012799733,0.00019933634,0.0018099275,0.0033251555,0.00025717073],"category_scores_gemma":[0.0020057198,0.0015139824,0.0013235293,0.0014090809,0.0015414327,0.0006347211,0.0006163722,0.0014790851,0.00072194566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005410776,0.004795757,0.47096053,0.0011130678,0.008996773,0.019688351,0.053517632,0.008173109,0.13328716,0.005827817,0.09559325,0.19263579],"study_design_scores_gemma":[0.023785478,0.004059655,0.4706172,0.0011634285,0.00432268,0.024010262,0.05437781,0.0056807203,0.3333353,0.01201045,0.061656736,0.004980254],"about_ca_topic_score_codex":0.0041734264,"about_ca_topic_score_gemma":0.0028914693,"teacher_disagreement_score":0.20004816,"about_ca_system_score_codex":0.0014619775,"about_ca_system_score_gemma":0.0028100433,"threshold_uncertainty_score":0.9996806},"labels":[],"label_agreement":null},{"id":"W4388760156","doi":"10.1016/j.fander.2023.09.602","title":"Efficacité et tolérance à long terme du risankizumab (RZB) dans le traitement du psoriasis en plaques modéré à sévère: résultats de l’étude d’extension en ouvert LIMMitless, analyse intermédiaire jusqu’à 5 ans de suivi","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.025899537737894048,"score_gpt":0.2920214323253194,"score_spread":0.26612189458742536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388760156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547972,0.013470192,0.0065958844,0.019969182,0.0017496225,0.0008611806,0.0007547863,0.0011706998,0.0006312704],"genre_scores_gemma":[0.9374218,0.054456003,0.001606584,0.003140918,0.00026808635,0.00041223073,0.0010979807,0.00016283464,0.0014335425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98712826,0.0062266532,0.0013934602,0.0016337206,0.00024379669,0.0033741312],"domain_scores_gemma":[0.99375933,0.0038047882,0.0006167767,0.0012232827,0.00021979296,0.0003760468],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0030447925,0.0013663721,0.0018072176,0.00070773455,0.0008306526,0.00018761284,0.0017254347,0.0024385029,0.00013061393],"category_scores_gemma":[0.0021166257,0.0013549774,0.0010043584,0.0009949341,0.0009961771,0.0006200455,0.0008198489,0.0013928288,0.0006956226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024108079,0.0032632404,0.72832936,0.0008404039,0.0056197313,0.020418465,0.041521173,0.010891203,0.048720624,0.002994576,0.06503765,0.06995278],"study_design_scores_gemma":[0.0072785197,0.0009242506,0.8567299,0.0008869451,0.0020666244,0.008277269,0.012377447,0.005184202,0.08029182,0.0015047534,0.022422269,0.0020559866],"about_ca_topic_score_codex":0.0015050373,"about_ca_topic_score_gemma":0.006770205,"teacher_disagreement_score":0.12840056,"about_ca_system_score_codex":0.0013436794,"about_ca_system_score_gemma":0.0017783501,"threshold_uncertainty_score":0.9999087},"labels":[],"label_agreement":null},{"id":"W4388760185","doi":"10.1016/j.fander.2023.09.598","title":"Caractéristiques à l’inclusion et résultats intermédiaires du mNAPSI à 12 mois de patients atteints de psoriasis en plaques modéré à sévère et de psoriasis unguéal concomitant sous traitement biologique dans l’étude Psoriasis Study of Health Outcomes","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Medicine; Gynecology; Psoriasis; Dermatology","score_opus":0.03725992586016077,"score_gpt":0.33452345495382213,"score_spread":0.2972635290936614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388760185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96846646,0.0080128955,0.0019214407,0.013388847,0.002127739,0.0023018478,0.0024876432,0.0010166679,0.0002764574],"genre_scores_gemma":[0.94206357,0.04760249,0.002958329,0.004540588,0.00014275212,0.0007789904,0.0014448989,0.00018428956,0.00028406983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97329485,0.018280154,0.0027944287,0.0017283901,0.00040192262,0.0035002464],"domain_scores_gemma":[0.9885093,0.0075558755,0.0017780986,0.001285844,0.00042573648,0.00044515423],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0072061843,0.0017540954,0.0031708556,0.0009885121,0.0011589479,0.00014579175,0.002046948,0.0025391285,0.00009893829],"category_scores_gemma":[0.0049599735,0.00160931,0.0010020015,0.00080729095,0.0008832244,0.00052536343,0.0022683833,0.0016232124,0.00010512093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020115927,0.0054089967,0.8454504,0.0005417761,0.0046181465,0.0014806655,0.084514715,0.0013961471,0.0026748076,0.0010045625,0.012462043,0.038436122],"study_design_scores_gemma":[0.009356779,0.0044495477,0.9315748,0.0006752181,0.0013391699,0.000643661,0.02468645,0.00031275625,0.017442806,0.0024710037,0.005507776,0.0015400198],"about_ca_topic_score_codex":0.009513504,"about_ca_topic_score_gemma":0.011890908,"teacher_disagreement_score":0.08612439,"about_ca_system_score_codex":0.0028048374,"about_ca_system_score_gemma":0.003159922,"threshold_uncertainty_score":0.9995205},"labels":[],"label_agreement":null},{"id":"W4388781925","doi":"10.1016/j.fander.2023.09.593","title":"Bimékizumab : réponse jusqu’à 3 ans chez les patients atteints de psoriasis en plaques qui ont arrêté et repris le traitement","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Humanities; Medicine; Gynecology; Art","score_opus":0.043166654020153926,"score_gpt":0.3060494385778065,"score_spread":0.26288278455765257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388781925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518458,0.01006613,0.00070364313,0.030921973,0.00213853,0.0009177385,0.0011575669,0.0011251353,0.0011234498],"genre_scores_gemma":[0.9601174,0.026024023,0.0018697061,0.004051027,0.0001603513,0.0005439818,0.0017919241,0.0001455259,0.0052960683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874248,0.0066947322,0.0013290282,0.0014620443,0.00022376531,0.0028656384],"domain_scores_gemma":[0.99423724,0.0034264913,0.00062964816,0.0011888206,0.00023589838,0.00028188378],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002792448,0.001162728,0.0014383327,0.0006933013,0.0007332511,0.00014863248,0.0012787523,0.0024087485,0.00048069988],"category_scores_gemma":[0.0023044324,0.0011685702,0.00081560377,0.00079217704,0.00094497914,0.00043355871,0.0007204516,0.0012005764,0.0017935192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001980854,0.0031507986,0.642895,0.00063698867,0.0039563994,0.002503778,0.0220147,0.0005721264,0.012404183,0.0031059808,0.18805806,0.11872111],"study_design_scores_gemma":[0.007575134,0.0012498496,0.70281374,0.0005951886,0.0011759282,0.0011210043,0.010815504,0.00016150094,0.10804291,0.00420311,0.16028075,0.0019653938],"about_ca_topic_score_codex":0.002416207,"about_ca_topic_score_gemma":0.0018748859,"teacher_disagreement_score":0.116755724,"about_ca_system_score_codex":0.0009225743,"about_ca_system_score_gemma":0.0018460116,"threshold_uncertainty_score":0.9990764},"labels":[],"label_agreement":null},{"id":"W4388781995","doi":"10.1016/j.fander.2023.09.588","title":"Résultats groupés des essais de phase 3 DERMIS-1 et DERMIS-2 relatifs à l’efficacité et à l’innocuité de l’application uniquotidienne de la crème de roflumilast à 0,3 % pour le traitement du psoriasis en plaques chronique","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Institute of Technology; Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.03339195297663466,"score_gpt":0.33374785406320895,"score_spread":0.3003559010865743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388781995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91096264,0.01760075,0.04225318,0.024428576,0.00027956846,0.0009932674,0.000500835,0.0015002519,0.0014809419],"genre_scores_gemma":[0.9106713,0.07003227,0.012773931,0.0032630372,0.00014290048,0.0010423388,0.00085335446,0.00019873692,0.0010221545],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98573464,0.0086344695,0.0011487625,0.0012752798,0.00015033901,0.00305653],"domain_scores_gemma":[0.9913715,0.0065781334,0.0005885204,0.0008092421,0.00021518901,0.00043742222],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0049273022,0.0011389727,0.0012257729,0.000571684,0.00085867976,0.00021810879,0.001030719,0.0026672808,0.00008679078],"category_scores_gemma":[0.0027307344,0.0012201704,0.00050265226,0.00083028304,0.001420207,0.000549675,0.00046732128,0.0014486762,0.00026398525],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025421046,0.0067666997,0.25181127,0.0016933217,0.0050774375,0.007852238,0.05312352,0.006177654,0.32904088,0.06264203,0.07902873,0.1942441],"study_design_scores_gemma":[0.01683908,0.0014449132,0.41756463,0.00093959394,0.0022074773,0.02090231,0.0122969635,0.008167174,0.36676198,0.057780556,0.09202567,0.0030696641],"about_ca_topic_score_codex":0.0018680929,"about_ca_topic_score_gemma":0.0016025843,"teacher_disagreement_score":0.19117443,"about_ca_system_score_codex":0.0016480433,"about_ca_system_score_gemma":0.0034360276,"threshold_uncertainty_score":0.9990248},"labels":[],"label_agreement":null},{"id":"W4388782034","doi":"10.1016/j.fander.2023.09.587","title":"Durabilité de l’efficacité et de l’innocuité de la crème de roflumilast à 0,3 % chez des adultes atteints de psoriasis en plaques chronique lors d’un essai de phase 2 sur l’innocuité, mené en mode ouvert pendant 52 semaines","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research","funders":"","keywords":"Medicine; Gynecology","score_opus":0.024780387748744047,"score_gpt":0.33069987167446985,"score_spread":0.3059194839257258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388782034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605379,0.015922043,0.0070990287,0.0106931925,0.000686894,0.0010847047,0.0013284913,0.0019974713,0.0006502423],"genre_scores_gemma":[0.9205576,0.06367177,0.008378828,0.0033097034,0.00035184924,0.0010509168,0.00074323866,0.00033126932,0.0016047946],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9743537,0.016138949,0.0016822999,0.0018121344,0.00027436283,0.0057385736],"domain_scores_gemma":[0.98526865,0.011530956,0.000745292,0.0013850552,0.00037020032,0.00069986447],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.008178028,0.0019092239,0.0022164327,0.00085171615,0.0011047333,0.0003123696,0.0022366652,0.0042685736,0.00043410712],"category_scores_gemma":[0.007559645,0.0019402204,0.0010857035,0.0011535764,0.002413977,0.0007040581,0.000895686,0.0022998578,0.00042103193],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027898408,0.004467509,0.55824494,0.0017075734,0.005010956,0.012448652,0.037443906,0.0041075223,0.28789198,0.004752639,0.0352556,0.045878876],"study_design_scores_gemma":[0.010722287,0.001226195,0.17298181,0.0011747892,0.0019613996,0.017083248,0.0085742455,0.0030351805,0.7424531,0.017859584,0.020116685,0.0028114782],"about_ca_topic_score_codex":0.0036311047,"about_ca_topic_score_gemma":0.0027921314,"teacher_disagreement_score":0.4545611,"about_ca_system_score_codex":0.0036901615,"about_ca_system_score_gemma":0.0054730247,"threshold_uncertainty_score":0.99936515},"labels":[],"label_agreement":null},{"id":"W4388782071","doi":"10.1016/j.fander.2023.09.585","title":"Réponse au bimékizumab jusqu’à 3 ans de traitement chez des patients atteints de psoriasis en plaques modéré à sévère ayant répondu après 16 semaines : résultats de l’extension en ouvert de BE RADIANT","year":2023,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Gynecology; Humanities; Philosophy","score_opus":0.05435886473077953,"score_gpt":0.30096336973428495,"score_spread":0.24660450500350542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388782071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647411,0.012618089,0.0020961454,0.01504636,0.0016175854,0.0011215793,0.0015003111,0.001006106,0.000252686],"genre_scores_gemma":[0.9449796,0.04003105,0.004800221,0.005320754,0.0002886869,0.00060888386,0.0013528542,0.00020239998,0.0024155232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9845634,0.007247698,0.001421884,0.0015541606,0.0002771381,0.004935709],"domain_scores_gemma":[0.99288255,0.0044314074,0.00060848636,0.0011114421,0.0003390392,0.00062709657],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003445838,0.0015140753,0.0017194821,0.00092299265,0.0011324086,0.00016424297,0.0014988325,0.0030065281,0.00027546243],"category_scores_gemma":[0.0040704436,0.0014711531,0.0008863603,0.00103862,0.0012669442,0.0005501201,0.00071096426,0.0012571475,0.0005706147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038136877,0.0036083874,0.68225557,0.0013310593,0.004357904,0.009604433,0.056766085,0.0027351095,0.05293161,0.0011442195,0.08520125,0.09625072],"study_design_scores_gemma":[0.009380285,0.0015534142,0.7740614,0.0011610882,0.0021997206,0.0056839176,0.013180664,0.0016417317,0.13905811,0.005818233,0.043849993,0.0024114768],"about_ca_topic_score_codex":0.0032275452,"about_ca_topic_score_gemma":0.004650615,"teacher_disagreement_score":0.09383924,"about_ca_system_score_codex":0.0049870694,"about_ca_system_score_gemma":0.0038998849,"threshold_uncertainty_score":0.9997608},"labels":[],"label_agreement":null},{"id":"W4388819057","doi":"10.1016/j.jid.2023.10.022","title":"Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cilag; LEO Pharma; Swedish Orphan Biovitrum; Radboud Universitair Medisch Centrum; Universiteit Gent; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Universitair Ziekenhuis Gent; Celgene; Nierstichting; Amgen; ZonMw; Baxalta; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Radboud Universiteit; Sanofi; Pfizer","keywords":"Adalimumab; Psoriasis; Methotrexate; Pharmacodynamics; Medicine; Pharmacology; Pharmacokinetics; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.04469804818054609,"score_gpt":0.32321774761789573,"score_spread":0.27851969943734967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388819057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942042,0.002395421,0.000069587964,0.0020447753,0.00092175143,0.00024036106,0.000044443594,0.000024525263,0.00005490537],"genre_scores_gemma":[0.99920905,0.00040123466,0.000060684382,0.0001775131,0.000022335867,0.000022778053,0.00002106922,0.000025021023,0.00006032267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99363285,0.0047986927,0.0008658568,0.00021259204,0.0001000842,0.00038989392],"domain_scores_gemma":[0.99570173,0.0033203405,0.00063657213,0.00018463419,0.00011109083,0.000045639048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019219946,0.00027988848,0.00077487656,0.00059762225,0.00012593504,0.000007547715,0.0003825639,0.00020557284,0.000046643552],"category_scores_gemma":[0.00076938054,0.00017843311,0.00023355112,0.00066348707,0.00037447424,0.00010248903,0.000061602455,0.00054000574,0.000080926555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007650669,0.000058531896,0.0021310276,0.000045711055,0.0007191018,0.00019797722,0.0012259324,0.0042268527,0.97795707,0.00006605233,0.0028107055,0.0029103458],"study_design_scores_gemma":[0.006119807,0.0008389765,0.002170007,0.00013899614,0.00031279802,0.00040035447,0.0003241433,0.0027607346,0.986049,0.00016270841,0.0005625106,0.00015999355],"about_ca_topic_score_codex":0.000027432821,"about_ca_topic_score_gemma":0.0000055358732,"teacher_disagreement_score":0.008091878,"about_ca_system_score_codex":0.00006460175,"about_ca_system_score_gemma":0.00010973587,"threshold_uncertainty_score":0.7276291},"labels":[],"label_agreement":null},{"id":"W4388979729","doi":"10.1016/j.jaad.2023.10.066","title":"Risk of infections among patients with psoriasis on Janus kinase inhibitor treatment: A systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; McMaster University; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Meta-analysis; Psoriasis; Janus kinase; Janus kinase inhibitor; Tofacitinib; Randomized controlled trial; Dermatology; Incidence (geometry); Clinical trial; Systematic review; Internal medicine; MEDLINE","score_opus":0.03849742366906728,"score_gpt":0.3089216441822099,"score_spread":0.27042422051314263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388979729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068527893,0.9908862,0.0000021074852,0.00017751951,0.00009709168,0.0013289881,0.0006323963,0.000010618202,0.0000122727015],"genre_scores_gemma":[0.006329784,0.9932197,0.000022754264,0.000067210254,0.000012444146,0.00013641847,0.000024108283,0.000037911817,0.00014969261],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9938677,0.0033032026,0.002124631,0.00029904846,0.00013425219,0.00027118705],"domain_scores_gemma":[0.98710674,0.0014837165,0.010823303,0.00040751515,0.00012562644,0.00005309345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003421663,0.00057346676,0.011748989,0.000906962,0.00012530202,0.0000057321167,0.00045932014,0.00031308952,0.000030183526],"category_scores_gemma":[0.0003021596,0.0002601412,0.0038320238,0.0015459938,0.0006822284,0.00006273027,0.000085286905,0.0005401829,0.000017728795],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011282339,0.00072746904,0.0038613174,0.11642477,0.87197953,0.000016756892,0.00009919409,0.000004128606,0.0000010262045,0.00002606085,0.00034510696,0.0064017903],"study_design_scores_gemma":[0.0007010085,0.0006102463,0.0010043279,0.011208177,0.9819051,0.00038643173,0.00002198387,6.610346e-8,0.00003376092,0.000008940281,0.0039086435,0.0002112882],"about_ca_topic_score_codex":0.00006634336,"about_ca_topic_score_gemma":0.00001309138,"teacher_disagreement_score":0.10992557,"about_ca_system_score_codex":0.00008360189,"about_ca_system_score_gemma":0.00011264674,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4389030365","doi":"10.1038/s41392-023-01655-6","title":"Signaling pathways and targeted therapies for psoriasis","year":2023,"lang":"en","type":"review","venue":"Signal Transduction and Targeted Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":360,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Disease; Mechanism (biology); Medicine; Epigenetics; Pathogenesis; Bioinformatics; Intensive care medicine; Immunology; Biology; Pathology; Genetics","score_opus":0.08059675380004618,"score_gpt":0.2949508710315138,"score_spread":0.21435411723146763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389030365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016171759,0.9938353,0.00026845757,0.000051682702,0.0014243167,0.0016379969,0.00081854966,0.0003264332,0.000020093326],"genre_scores_gemma":[0.0011472586,0.9950963,0.00020086036,0.00003945047,0.00032876967,0.00068026193,0.0016468472,0.00014126855,0.0007189457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974711,0.00047226177,0.0006534433,0.00080842315,0.000065505024,0.0005292721],"domain_scores_gemma":[0.9988667,0.00048699143,0.00027313863,0.00022762144,0.000080972844,0.00006457816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043764524,0.00075123465,0.0016062986,0.0003974921,0.00054472964,0.000061135455,0.00016683275,0.0008607189,0.0005852537],"category_scores_gemma":[0.000012486308,0.0005718656,0.000611955,0.0003608765,0.00020562766,0.0001146538,0.000014247132,0.00032966028,0.000059176604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028911134,0.000095091564,0.0000033395133,0.0014620668,0.0033356352,0.000003865139,0.00091891526,4.808255e-7,0.008507605,0.00030857197,0.00018161105,0.9848937],"study_design_scores_gemma":[0.0031684856,0.00059148984,0.000017351926,0.001029265,0.0012910429,0.00006718508,0.0003257493,0.0000012180658,0.0052205464,0.0011012476,0.98641205,0.0007743478],"about_ca_topic_score_codex":0.000020332815,"about_ca_topic_score_gemma":0.000004688184,"teacher_disagreement_score":0.98623043,"about_ca_system_score_codex":0.00003288289,"about_ca_system_score_gemma":0.000109816145,"threshold_uncertainty_score":0.9996733},"labels":[],"label_agreement":null},{"id":"W4389107934","doi":"10.1016/j.jid.2023.10.031","title":"Association of the Complement System with Subclinical Atherosclerosis in Psoriasis: Findings from an Observational Cohort Study","year":2023,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Social Fund; Almirall; Instituto de Salud Carlos III; Junta de Comunidades de Castilla-La Mancha; Canada Foundation for Innovation; Celgene; National Psoriasis Foundation; European Commission; European Regional Development Fund; LEO Pharma Research Foundation; Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Disease; Pathological; Inflammation; Population; Complement system; Immune system; Subclinical infection; Immunology; Internal medicine","score_opus":0.08029310834559579,"score_gpt":0.3000716085454343,"score_spread":0.21977850019983852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389107934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974718,0.000053811982,0.000007978871,0.0014349387,0.000545995,0.00037243037,0.000076803495,0.000015938424,0.000020264013],"genre_scores_gemma":[0.99960285,0.0000128639595,0.00009686216,0.00010654149,0.000028716062,0.00003264934,0.000058158697,0.000011325149,0.000050019822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970473,0.0014811148,0.0009122507,0.0001839593,0.00015884194,0.00021655402],"domain_scores_gemma":[0.9976767,0.00082562165,0.0010059275,0.0001832919,0.00027718875,0.000031295247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009434764,0.00015590012,0.0006327419,0.00015746505,0.0001155969,0.000008656454,0.0002984667,0.00018149684,0.00003556356],"category_scores_gemma":[0.00028253184,0.0000995262,0.0001087971,0.00044076156,0.0001855324,0.00012855935,0.000055582488,0.0002706957,0.000022415454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016080898,0.00028259843,0.9797802,0.000008564911,0.0010783003,0.000013948636,0.002086898,0.00003967526,0.015263563,0.00030593065,0.0009503029,0.000029212259],"study_design_scores_gemma":[0.0035268355,0.00034941532,0.9596664,0.000100838246,0.00030194133,0.000033121985,0.003409145,0.000014739705,0.03229205,0.00014089062,0.00007800428,0.00008663422],"about_ca_topic_score_codex":0.00018816364,"about_ca_topic_score_gemma":0.0005882819,"teacher_disagreement_score":0.020113813,"about_ca_system_score_codex":0.00018183728,"about_ca_system_score_gemma":0.00019639335,"threshold_uncertainty_score":0.40585607},"labels":[],"label_agreement":null},{"id":"W4389118364","doi":"10.1016/j.rhum.2023.10.170","title":"Différences selon le sexe sur les perceptions de l’impact du rhumatisme psoriasique, sa gestion et les interactions avec les médecins : résultats d’une enquête internationale auprès des patients","year":2023,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Women's College Hospital","funders":"","keywords":"Humanities; Medicine; Gynecology; Political science; Art","score_opus":0.03510156864617668,"score_gpt":0.27132906727778666,"score_spread":0.23622749863160997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389118364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98152673,0.004610753,0.0021514923,0.005532557,0.0023912357,0.0006902188,0.0019378627,0.00039040152,0.0007687728],"genre_scores_gemma":[0.95844996,0.016787892,0.0008345032,0.000047959766,0.00044676833,0.0002833817,0.0035562632,0.00009455003,0.019498732],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995824,0.0015406955,0.0009230119,0.0007207313,0.00015887884,0.00083272625],"domain_scores_gemma":[0.9967971,0.0016126415,0.00054460944,0.00043102622,0.0004686475,0.00014598123],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006479609,0.00068900397,0.00073831994,0.0005977154,0.0017580901,0.00018198394,0.0004722397,0.00079408195,0.0030845637],"category_scores_gemma":[0.00077605987,0.00069609255,0.00049377023,0.00063986634,0.0005651587,0.00088046805,0.00020605397,0.0007457117,0.0012264756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019656609,0.001972949,0.40239486,0.00042611777,0.0015360678,0.00007103881,0.049535166,0.0012787746,0.008541847,0.006194249,0.0096295085,0.51822287],"study_design_scores_gemma":[0.00255818,0.00045334437,0.9757404,0.0017723385,0.0004423798,0.00026800408,0.0018322181,0.0012676638,0.0005368895,0.0013649714,0.01309907,0.00066459284],"about_ca_topic_score_codex":0.011203174,"about_ca_topic_score_gemma":0.017369736,"teacher_disagreement_score":0.5733455,"about_ca_system_score_codex":0.00059662876,"about_ca_system_score_gemma":0.00022705433,"threshold_uncertainty_score":0.9995512},"labels":[],"label_agreement":null},{"id":"W4389123463","doi":"10.1016/j.rhum.2023.10.277","title":"L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST","year":2023,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology; Psoriatic arthritis; Rheumatoid arthritis; Internal medicine","score_opus":0.01719837325032472,"score_gpt":0.24194328697886955,"score_spread":0.22474491372854483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389123463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815759,0.0069742114,0.0011375488,0.0030724364,0.0023043246,0.0017582981,0.0011525861,0.0005003232,0.0015243822],"genre_scores_gemma":[0.9756096,0.008643742,0.0011084223,0.00045301937,0.00059306924,0.0006182679,0.0017137486,0.0002073262,0.011052812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930756,0.0016866855,0.0014243394,0.0011237855,0.00020155993,0.0024879915],"domain_scores_gemma":[0.9964986,0.00091532164,0.00074889336,0.0010297431,0.00040987597,0.00039758204],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014484525,0.0011178213,0.0015816968,0.0005459805,0.0013795302,0.00016948057,0.00080921553,0.0014965417,0.001271718],"category_scores_gemma":[0.0005401135,0.0011718121,0.00074451003,0.0010693249,0.0008766307,0.0006310597,0.00041861495,0.00072334916,0.0028996605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001857449,0.0026075244,0.5364372,0.0027112968,0.004644672,0.0011841125,0.03612878,0.0006657587,0.007286332,0.011557699,0.013536743,0.38138244],"study_design_scores_gemma":[0.021419704,0.0015996736,0.888223,0.004014497,0.003274022,0.0012195889,0.0017951244,0.0031820459,0.015529556,0.009026637,0.04823783,0.0024783397],"about_ca_topic_score_codex":0.0006493903,"about_ca_topic_score_gemma":0.002734317,"teacher_disagreement_score":0.3789041,"about_ca_system_score_codex":0.0012698898,"about_ca_system_score_gemma":0.00043798448,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W4389123606","doi":"10.1016/j.rhum.2023.10.252","title":"Étude observationnelle prospective de 24 mois de la persistance du traitement chez des patients atteints de rhumatisme psoriasique (PRO-SPIRIT) – conception de l’étude et caractéristiques des patients à l’inclusion (échantillon complet)","year":2023,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gynecology","score_opus":0.024045330774733847,"score_gpt":0.25862563883500567,"score_spread":0.23458030806027183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389123606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858222,0.004222678,0.0049653216,0.0010871768,0.000813496,0.0016139961,0.0008690277,0.00032531377,0.0002807744],"genre_scores_gemma":[0.9795457,0.010299611,0.0062164473,0.0003619655,0.00028527627,0.00059795595,0.0017029411,0.00013523869,0.0008548545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938783,0.0026449966,0.0009785661,0.0008711216,0.00021892304,0.0014080834],"domain_scores_gemma":[0.9973923,0.00073410524,0.0006904322,0.00044845036,0.00052191067,0.00021280146],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0018245345,0.0007761263,0.0008907528,0.00026679804,0.0018446351,0.00013725583,0.0005338878,0.00092856423,0.00048854493],"category_scores_gemma":[0.00064502005,0.00086702185,0.0003738935,0.0005567752,0.0010068638,0.00058613624,0.00048509648,0.0005585332,0.0002088649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045678276,0.0020571558,0.7666911,0.0011374233,0.0008098957,0.00008308504,0.1624835,0.00043975157,0.01472717,0.0043082847,0.0020655212,0.04474036],"study_design_scores_gemma":[0.0054853586,0.0009185656,0.9709442,0.0022035406,0.000502651,0.0000655627,0.001835608,0.0011660343,0.0089719575,0.0050543044,0.0020498459,0.00080233667],"about_ca_topic_score_codex":0.0024124326,"about_ca_topic_score_gemma":0.0030048543,"teacher_disagreement_score":0.20425317,"about_ca_system_score_codex":0.0033747975,"about_ca_system_score_gemma":0.0003090554,"threshold_uncertainty_score":0.99945486},"labels":[],"label_agreement":null},{"id":"W4389123611","doi":"10.1016/j.rhum.2023.10.259","title":"Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)","year":2023,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GDI Integrated Facility Services (Canada)","funders":"","keywords":"Medicine; Gynecology; Psoriatic arthritis; Psoriasis; Dermatology","score_opus":0.03609629910853289,"score_gpt":0.30111003270566544,"score_spread":0.26501373359713254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389123611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810549,0.004887138,0.0037275373,0.0033267154,0.0014819705,0.00302359,0.0018584194,0.000525177,0.00011457557],"genre_scores_gemma":[0.9778611,0.013858636,0.0022163074,0.00032543446,0.00032273153,0.0012952227,0.0026468555,0.00020191316,0.0012717963],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886244,0.005975623,0.0020074295,0.0013261402,0.00023441382,0.0018320027],"domain_scores_gemma":[0.99452597,0.0022214134,0.0011312095,0.0010912855,0.0006193418,0.00041077723],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021216276,0.00117965,0.0016892139,0.0006071553,0.001899909,0.00022156815,0.0008210706,0.0011657435,0.0010410999],"category_scores_gemma":[0.0013853519,0.0012469311,0.0005750709,0.0009917447,0.0010158507,0.00077023375,0.00026089954,0.0007774594,0.00110257],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053956322,0.011048239,0.015570908,0.0009723471,0.0041167843,0.00061554456,0.16925003,0.0005058149,0.08489486,0.0026108983,0.0053163553,0.6997026],"study_design_scores_gemma":[0.16094418,0.013960328,0.48384067,0.0058334908,0.00742331,0.0007910274,0.015808685,0.0051569375,0.25851357,0.013254475,0.027913492,0.006559838],"about_ca_topic_score_codex":0.001958426,"about_ca_topic_score_gemma":0.0011751188,"teacher_disagreement_score":0.6931428,"about_ca_system_score_codex":0.0008190244,"about_ca_system_score_gemma":0.00065677235,"threshold_uncertainty_score":0.9998721},"labels":[],"label_agreement":null},{"id":"W4389243779","doi":"10.1182/blood-2023-190975","title":"Interleukin-17A Directly Signals to Bone Marrow-Derived Hematopoietic Stem and Progenitor Cells to Promote Their Expansion and Differentiation in Vitro","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Haematopoiesis; Progenitor cell; Bone marrow; Biology; Clonogenic assay; Immunology; Stem cell; Cell biology; Stromal cell; CD34; Cancer research; Cell","score_opus":0.013809833714926544,"score_gpt":0.21550681438149294,"score_spread":0.20169698066656638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772,0.0009905087,0.000014572254,0.00014826677,0.00021328042,0.00075986696,0.00004271984,0.000099237186,0.00001156169],"genre_scores_gemma":[0.9991816,0.00006633978,0.00010087178,0.000040552848,0.000021385513,0.00018417317,0.00005787292,0.000020991769,0.00032621296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989643,0.00013762077,0.00022093738,0.00036026153,0.000031865304,0.00028503494],"domain_scores_gemma":[0.9996459,0.00007056006,0.000049754868,0.00016007795,0.000023153005,0.00005054342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014276728,0.0001937809,0.00030169473,0.00020890847,0.00008368771,0.000029464378,0.00007181087,0.00013427592,0.000017969114],"category_scores_gemma":[0.00001141205,0.00015685876,0.00004058496,0.00022025684,0.000023235854,0.000054203658,0.00011282152,0.00006417217,0.00010230191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020957139,0.00019981519,0.0016206367,0.00003750961,0.00009567169,0.000016128197,0.004598508,3.3271095e-7,0.9691735,0.0000011189403,0.000034585908,0.024012642],"study_design_scores_gemma":[0.0017528486,0.0002383366,0.018367467,0.00008243442,0.00007923751,0.00002344135,0.0005608808,0.0000026765779,0.97858936,0.000016679425,0.00011870507,0.00016790807],"about_ca_topic_score_codex":0.000018522827,"about_ca_topic_score_gemma":0.000030096959,"teacher_disagreement_score":0.023844734,"about_ca_system_score_codex":0.000014699343,"about_ca_system_score_gemma":0.000013599701,"threshold_uncertainty_score":0.6396514},"labels":[],"label_agreement":null},{"id":"W4389440549","doi":"10.1212/wnl.92.15_supplement.s12.002","title":"A Mouse Model of Meningeal Inflammation and Subpial Demyelination Identifies an IL-17-mediated Mechanism of Cortical Injury that is Inhibited by Siponimod Therapy (S12.002)","year":2019,"lang":"en","type":"article","venue":"Neurology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Neuroscience; Inflammation; Medicine; Mechanism (biology); Psychology; Immunology; Philosophy","score_opus":0.016509839569379937,"score_gpt":0.23115110422364218,"score_spread":0.21464126465426225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389440549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851537,0.00022200569,0.00015450698,0.00020503097,0.00021179488,0.00033234095,0.00028214522,0.000043474804,0.00003333374],"genre_scores_gemma":[0.9988952,0.000282484,0.000031030613,0.00019614439,0.000013912163,0.000021469894,0.0003595858,0.000018762736,0.00018139405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986991,0.00034321714,0.00035753023,0.00031854835,0.000061974126,0.00021957626],"domain_scores_gemma":[0.9992646,0.00015882937,0.0002480095,0.00021426841,0.00009030322,0.000023993325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020595567,0.00017758438,0.0003605425,0.00016918004,0.000058962258,0.000006165255,0.000114545124,0.00045382456,0.00012173592],"category_scores_gemma":[0.000028579278,0.0001620897,0.000057916055,0.00008326629,0.00014519985,0.00016025042,0.000048519603,0.00016629267,0.000020965199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002390677,0.00013372334,0.0026377076,0.000011511916,0.00013252877,6.959295e-7,0.00096134207,0.000015507965,0.9895592,0.00048094493,0.000078571415,0.0035976216],"study_design_scores_gemma":[0.002509572,0.0019017162,0.003362522,0.0000033336214,0.00008019306,0.0000075902212,0.000029000772,0.0021537903,0.9891258,0.0006202236,0.000079142825,0.00012715424],"about_ca_topic_score_codex":0.00006696007,"about_ca_topic_score_gemma":0.00002274008,"teacher_disagreement_score":0.0034704672,"about_ca_system_score_codex":0.0000074230725,"about_ca_system_score_gemma":0.000032406402,"threshold_uncertainty_score":0.66098255},"labels":[],"label_agreement":null},{"id":"W4389471935","doi":"10.1093/bjd/ljad487","title":"Further refinement of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure using classical test theory and item response theory","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Jikei University School of Medicine; Clalit Health Services; University of Leeds; Cardiff University; Yale University","keywords":"Rasch model; Patient-reported outcome; Item response theory; Classical test theory; Cronbach's alpha; Exploratory factor analysis; Confirmatory factor analysis; Differential item functioning; Clinical psychology; Psychometrics; Reliability (semiconductor); Medicine; Structural equation modeling; Psychology; Quality of life (healthcare); Statistics; Developmental psychology","score_opus":0.01913950425351802,"score_gpt":0.25884221246329886,"score_spread":0.23970270820978085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389471935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812157,0.010904002,0.000033954242,0.00026813635,0.0003001268,0.00015795523,0.00016494413,0.000018470419,0.000030814303],"genre_scores_gemma":[0.99954796,0.00029380812,0.000027394955,0.00004050542,0.000013456274,0.000004231031,0.000011083759,0.000016547398,0.00004499172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995849,0.0026957672,0.00087171985,0.00017420315,0.00010258064,0.00030670996],"domain_scores_gemma":[0.996178,0.002475739,0.00086064264,0.00021333389,0.00021857813,0.000053732972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062989694,0.00018511988,0.00067405024,0.00017302504,0.00014350175,0.000010281566,0.00022440289,0.0002664888,0.00013095285],"category_scores_gemma":[0.0022151577,0.00012770887,0.00039601154,0.0002635703,0.0006068486,0.00007094455,0.0001273681,0.00023978336,0.000004433328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010848855,0.0010776209,0.7575053,0.00006845542,0.0027448658,0.0041180844,0.00085102016,0.00001641626,0.1775792,0.00042631815,0.002792225,0.04197166],"study_design_scores_gemma":[0.0034200656,0.00037547812,0.88074654,0.0003238499,0.00072560535,0.087848105,0.0006572033,0.0000051443744,0.024223115,0.0012853048,0.00021435568,0.00017522072],"about_ca_topic_score_codex":0.000010770295,"about_ca_topic_score_gemma":0.00000540838,"teacher_disagreement_score":0.15335608,"about_ca_system_score_codex":0.000036311365,"about_ca_system_score_gemma":0.00027571214,"threshold_uncertainty_score":0.5207817},"labels":[],"label_agreement":null},{"id":"W4389521645","doi":"10.1111/jdv.19652","title":"An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis","year":2023,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Delphi method; Facilitator; Psoriasis; Delphi; MEDLINE; Disease; Family medicine; Intensive care medicine; Pathology; Dermatology; Artificial intelligence","score_opus":0.06629232433920085,"score_gpt":0.3118911905439097,"score_spread":0.24559886620470883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389521645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5569105,0.0012862639,0.0005150921,0.43584275,0.0035957592,0.0006211897,0.0008815486,0.000032854223,0.00031401552],"genre_scores_gemma":[0.9651307,0.0012722329,0.0017589235,0.030122135,0.0010386657,0.000025120486,0.0003557941,0.000079557314,0.00021688605],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995878,0.0019951293,0.0014397118,0.00032054016,0.000081858474,0.00028478663],"domain_scores_gemma":[0.99646103,0.0010070413,0.0020204678,0.00024720005,0.00020977505,0.000054477638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080555346,0.00027663936,0.0008271155,0.00040054676,0.00010972324,0.0000057165435,0.00080781314,0.0008047165,0.000014824071],"category_scores_gemma":[0.0005664833,0.00020469149,0.00037107666,0.00011915734,0.00047773635,0.000050835595,0.0001432657,0.00089549884,0.000025840829],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026287504,0.0016733322,0.07778982,0.0014483148,0.011638582,0.00072093745,0.0018977531,0.0003233537,0.039640322,0.014982752,0.7884393,0.035158034],"study_design_scores_gemma":[0.030254446,0.0020345266,0.27138436,0.0018625314,0.011215642,0.013676877,0.00033436058,0.00010499806,0.01952,0.058255266,0.5891635,0.0021934893],"about_ca_topic_score_codex":0.0000031554523,"about_ca_topic_score_gemma":0.0000010516679,"teacher_disagreement_score":0.40822014,"about_ca_system_score_codex":0.000022350676,"about_ca_system_score_gemma":0.0001089721,"threshold_uncertainty_score":0.8347076},"labels":[],"label_agreement":null},{"id":"W4389951300","doi":"10.1111/cts.13682","title":"Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis","year":2023,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly and Company; Galderma; Incyte; Bausch Health; Arbor Pharmaceuticals; Regeneron Pharmaceuticals; Genentech; Coherus Biosciences; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Plaque psoriasis; Medicine; Psoriasis; Pharmacokinetics; MEDLINE; Dermatology; Intensive care medicine; Internal medicine; Pharmacology; Biology","score_opus":0.10099290635001242,"score_gpt":0.40301874581812447,"score_spread":0.30202583946811207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389951300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949322,0.0039971545,0.0000073319975,0.00042381973,0.00023049187,0.00017249618,0.00021614636,0.000011376524,0.000008988103],"genre_scores_gemma":[0.9954941,0.0043167137,0.00006111831,0.000029057612,0.0000249384,0.0000057533452,0.00005656644,0.000003067192,0.000008633651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899745,0.00007925794,0.00033699107,0.0003154276,0.00006268961,0.00020818894],"domain_scores_gemma":[0.9988844,0.00089452113,0.00006509283,0.000061400635,0.000043653225,0.0000509486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043725246,0.00009127094,0.00024675674,0.000070238675,0.00013890209,0.0000050520357,0.00005828473,0.00005371046,0.000018101158],"category_scores_gemma":[0.000077957375,0.00006353905,0.00001792541,0.00024029295,0.0014713147,0.000080772676,0.000033127104,0.00007482832,0.000003733244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003055212,0.00048881635,0.8270885,0.00002517826,0.00014484423,0.000003920032,0.0008661716,0.000014378171,0.0012206918,0.0002260895,0.00001339464,0.16685282],"study_design_scores_gemma":[0.01468721,0.0006420492,0.98325473,0.000046443925,0.00007321783,6.653178e-7,0.000037903104,0.00006908033,0.0005504847,0.00025859402,0.0003026514,0.000076944445],"about_ca_topic_score_codex":0.00002941373,"about_ca_topic_score_gemma":0.00007716377,"teacher_disagreement_score":0.16677587,"about_ca_system_score_codex":0.000005531973,"about_ca_system_score_gemma":0.000075984346,"threshold_uncertainty_score":0.54211205},"labels":[],"label_agreement":null},{"id":"W4389958397","doi":"10.1161/circ.148.suppl_1.15758","title":"Abstract 15758: Platelet Aggregation is Elevated in Psoriasis and Associated With Cardiovascular Risk","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Berger (Canada)","funders":"","keywords":"Medicine; Psoriasis; Aspirin; Platelet; Internal medicine; Pulse wave velocity; Arachidonic acid; Adenosine diphosphate; Platelet activation; Gastroenterology; Cardiology; Endocrinology; Immunology; Platelet aggregation; Biochemistry; Blood pressure","score_opus":0.017742877276035456,"score_gpt":0.2187882033316497,"score_spread":0.20104532605561423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389958397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978902,0.0012897425,0.00002814566,0.000032273023,0.00017236266,0.00025728042,0.000056095032,0.00013579802,0.00013812292],"genre_scores_gemma":[0.9985952,0.00035849633,0.0000074990653,0.000011675492,0.000018892326,0.00003141672,0.0008982348,0.000017047223,0.00006158111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99908906,0.00014547935,0.0001930478,0.000290231,0.000060434933,0.00022173315],"domain_scores_gemma":[0.9995101,0.00012111796,0.00011258595,0.00019140584,0.0000500003,0.000014798699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041787536,0.00014174338,0.00023563695,0.0002053842,0.00013637674,0.00001564089,0.000043618937,0.00024986398,0.00006940281],"category_scores_gemma":[0.00009966975,0.00012821385,0.00007925365,0.0005168971,0.00003915769,0.000120370445,0.00001197483,0.00011301712,0.0001883731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013778191,0.00007386081,0.7835617,0.00001758181,0.0016966225,0.000034118963,0.0013223982,0.0013282856,0.011505093,0.000031817697,0.00020283934,0.20008788],"study_design_scores_gemma":[0.0025130394,0.000023230863,0.98765624,0.000047496193,0.00017486117,0.000006332136,0.00008237073,0.00014571664,0.00863512,0.00017858442,0.0003838054,0.0001532139],"about_ca_topic_score_codex":0.0002232294,"about_ca_topic_score_gemma":0.00007750838,"teacher_disagreement_score":0.2040945,"about_ca_system_score_codex":0.00006725608,"about_ca_system_score_gemma":0.000022646125,"threshold_uncertainty_score":0.522841},"labels":[],"label_agreement":null},{"id":"W4389992582","doi":"10.1001/jamadermatol.2023.5058","title":"Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary","year":2023,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Placebo; Apremilast; Clinical trial; Psoriasis; Physical therapy; Randomized controlled trial; Internal medicine; Dermatology; Alternative medicine; Psoriatic arthritis","score_opus":0.03765485234694558,"score_gpt":0.26191168464697917,"score_spread":0.2242568323000336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389992582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96506214,0.014932849,0.00028768083,0.013973609,0.0031120277,0.0011330973,0.00022294502,0.000434756,0.00084091735],"genre_scores_gemma":[0.9958192,0.0010646983,0.000033942542,0.00092214096,0.0001803168,0.00082837173,0.00023683603,0.000030340238,0.00088411523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869955,0.00020570162,0.0002232569,0.00032952667,0.000029042176,0.00051291403],"domain_scores_gemma":[0.997953,0.0015811506,0.000085514555,0.00030908777,0.00004381994,0.000027433092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002611183,0.0002147323,0.00033510968,0.00014286854,0.0004364607,0.00002683567,0.00023641542,0.00041676866,0.00009995901],"category_scores_gemma":[0.00011608863,0.00014742467,0.000121131285,0.00022060983,0.00021328256,0.0001119424,0.00012829775,0.00013803584,0.0004996235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010169428,0.00023208099,0.15717578,0.00019529476,0.003408807,0.00022878067,0.008996352,0.0000041803,0.03313715,0.032319613,0.15780315,0.60548186],"study_design_scores_gemma":[0.011763767,0.0005544132,0.17483371,0.00006407944,0.0013365842,0.0027694334,0.0020831842,0.00028012143,0.041764077,0.004082941,0.75944847,0.0010192386],"about_ca_topic_score_codex":0.000040748888,"about_ca_topic_score_gemma":0.00004399432,"teacher_disagreement_score":0.6044626,"about_ca_system_score_codex":0.000013545483,"about_ca_system_score_gemma":0.00002606828,"threshold_uncertainty_score":0.6421816},"labels":[],"label_agreement":null},{"id":"W4390124513","doi":"10.1016/j.jval.2023.09.2695","title":"PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bausch Health (Canada); Health Canada; Covenant Health; University of Toronto; SKiN Health; University of British Columbia","funders":"","keywords":"Plaque psoriasis; Baseline (sea); Medicine; Psoriasis; Dermatology; Political science","score_opus":0.034849143537404266,"score_gpt":0.282796456769974,"score_spread":0.24794731323256974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390124513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955672,0.0002287781,1.7004687e-7,0.0009793276,0.0001522153,0.0011799906,0.0018306567,0.000023949326,0.000037707785],"genre_scores_gemma":[0.99726874,0.0004097027,0.000026631895,0.00015480432,0.000037720663,0.00004526284,0.0020135383,0.000018671819,0.000024947138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606264,0.002318283,0.0007251363,0.00040456152,0.000088386565,0.00040098734],"domain_scores_gemma":[0.9972732,0.0018493546,0.00028997014,0.00045292894,0.00008119077,0.000053362215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017115589,0.00019998885,0.0004423748,0.00027745168,0.00026684016,0.000014083471,0.0002116672,0.00013277128,0.0000053606905],"category_scores_gemma":[0.00016803472,0.00010742374,0.00003685538,0.0009537072,0.0001466908,0.000029064653,0.000026154383,0.00032833,0.0000058520086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014033437,0.0002680329,0.9820571,0.0000147608,0.00013694358,0.000030423364,0.00638554,0.00001659199,6.743769e-7,0.000012441928,0.00015913234,0.0095150005],"study_design_scores_gemma":[0.0068239085,0.0011408604,0.9884959,0.00014388586,0.00009445585,0.0000011902625,0.002796884,0.00001883635,0.0000042088363,0.0000062254376,0.00036339302,0.00011027227],"about_ca_topic_score_codex":0.66057307,"about_ca_topic_score_gemma":0.85946846,"teacher_disagreement_score":0.1988954,"about_ca_system_score_codex":0.0001067808,"about_ca_system_score_gemma":0.00047144035,"threshold_uncertainty_score":0.43806127},"labels":[],"label_agreement":null},{"id":"W4390176123","doi":"10.3390/pharmaceutics16010023","title":"Phosphodiesterase-4 Inhibition in the Management of Psoriasis","year":2023,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; SKiN Health; Queen's University; Okanagan University College; Probity Medical Research; University of British Columbia, Okanagan Campus","funders":"","keywords":"Apremilast; Psoriasis; Medicine; Roflumilast; Adverse effect; Clinical trial; Dermatology; Atopic dermatitis; Phosphodiesterase; Intensive care medicine; Pharmacology; Internal medicine; Psoriatic arthritis; Pulmonary disease","score_opus":0.1536761483398357,"score_gpt":0.38847593063403263,"score_spread":0.23479978229419693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390176123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017291865,0.99644303,0.0000028925,0.000022998109,0.0011173468,0.0009258605,0.00021915029,0.000046082918,0.0010497436],"genre_scores_gemma":[0.00017087845,0.9977654,0.000029101608,0.000040783038,0.000042536303,0.0003181007,0.0006236985,0.000037044556,0.00097244646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983216,0.00044367262,0.0005920312,0.0002794437,0.00006017757,0.00030305336],"domain_scores_gemma":[0.9990511,0.00029319807,0.00027818012,0.00034663407,0.000019957457,0.00001094477],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005188269,0.00032703872,0.000844997,0.00019851743,0.000069037524,0.000010103206,0.0002503462,0.00026935115,0.0001069625],"category_scores_gemma":[0.0000056238523,0.00021739396,0.00033911644,0.0005647047,0.00007336096,0.0000309571,0.000107271226,0.00029396528,0.0008587247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021385771,0.00016347146,0.0000054334205,0.010082309,0.0013296654,0.000105121464,0.00026376438,5.1078655e-7,0.00000554396,0.0003767566,0.0009313898,0.98671466],"study_design_scores_gemma":[0.00085270137,0.0000244465,0.000011812234,0.004463896,0.0037692296,0.000038852228,0.0001517048,2.3754424e-7,0.0003503914,0.0000561786,0.9900821,0.00019848337],"about_ca_topic_score_codex":0.000010687,"about_ca_topic_score_gemma":0.000005020476,"teacher_disagreement_score":0.9891507,"about_ca_system_score_codex":0.000063467065,"about_ca_system_score_gemma":0.00003555059,"threshold_uncertainty_score":0.99991924},"labels":[],"label_agreement":null},{"id":"W4390241019","doi":"10.4103/jdds.jdds_8_23","title":"A 60-week Real-world Experience with Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Including Patients with Malignancy: A Retrospective Study from Ontario, Canada","year":2023,"lang":"en","type":"article","venue":"Journal of Dermatology & Dermatologic Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Plaque psoriasis; Medicine; Malignancy; Psoriasis; Dermatology; Retrospective cohort study; Surgery; Internal medicine","score_opus":0.01933725643659487,"score_gpt":0.22185554865235785,"score_spread":0.20251829221576298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390241019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765015,0.00011083661,0.000009958575,0.00032752808,0.0008198886,0.00081925653,0.000095710435,0.00007058539,0.00009611172],"genre_scores_gemma":[0.9990838,0.000025511992,0.00011393871,0.0002683264,0.000016999285,0.00013870645,0.00021320503,0.000055135555,0.00008435898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958645,0.0007436669,0.0012836491,0.00071884075,0.00039093246,0.0009984078],"domain_scores_gemma":[0.9968249,0.00086960424,0.0011058393,0.00049706566,0.00054789864,0.0001546558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020807884,0.00067132653,0.0019803275,0.001012829,0.00039153273,0.00004276026,0.00044298492,0.00028298452,0.00013092945],"category_scores_gemma":[0.00010456462,0.00045029723,0.00012692779,0.0014001764,0.00017240283,0.00043368322,0.00014529919,0.0006260625,0.000028525772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008532948,0.0012896864,0.9751224,0.000013369862,0.0013087351,0.0054369494,0.0043501626,0.00011421234,0.000008249891,0.000005705797,0.003635432,0.00018215043],"study_design_scores_gemma":[0.009448941,0.00063606096,0.98568255,0.00028268725,0.000290203,0.0005132212,0.0017405198,0.00000163725,0.0005909898,0.000029900839,0.00021002526,0.000573257],"about_ca_topic_score_codex":0.15569879,"about_ca_topic_score_gemma":0.76564604,"teacher_disagreement_score":0.6099472,"about_ca_system_score_codex":0.0009004017,"about_ca_system_score_gemma":0.0015662726,"threshold_uncertainty_score":0.9997949},"labels":[],"label_agreement":null},{"id":"W4390412107","doi":"10.1177/12034754231220929","title":"GLP-1R Agonists in Psoriasis Patients","year":2023,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.02811205639716055,"score_gpt":0.24750337079653267,"score_spread":0.21939131439937212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390412107","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6616332,0.022258116,0.0000022247139,0.2946339,0.020137055,0.00032492317,0.00010609565,0.000059927534,0.0008445755],"genre_scores_gemma":[0.2842069,0.085828386,0.000065796965,0.5558869,0.025640784,0.00005179531,0.0036732466,0.0005629852,0.04408319],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974501,0.00038521976,0.0012035866,0.00028069562,0.00018625039,0.0004941223],"domain_scores_gemma":[0.9959752,0.0026755813,0.00086547993,0.00021910323,0.0002169044,0.00004772979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006000704,0.00039936323,0.0015869671,0.0010773818,0.0000868039,0.0000126833875,0.00018618882,0.0010119998,0.00028950218],"category_scores_gemma":[0.0006960729,0.00028155037,0.0003117403,0.00027761082,0.00019619931,0.0000615957,0.00003817645,0.0012883168,0.000099769844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027340357,0.00006776293,0.011431301,0.00011372164,0.0005610949,0.0106714135,0.00033373077,3.5492e-7,0.0001262107,8.0592775e-7,0.94321585,0.033204377],"study_design_scores_gemma":[0.0018248996,0.00055350503,0.0039880304,0.0012354112,0.0005981908,0.0045131664,0.00011556705,1.8310246e-7,0.00013345142,0.00017178587,0.9865182,0.00034758705],"about_ca_topic_score_codex":0.00008973109,"about_ca_topic_score_gemma":0.00002068829,"teacher_disagreement_score":0.3774263,"about_ca_system_score_codex":0.0000964149,"about_ca_system_score_gemma":0.00019535088,"threshold_uncertainty_score":0.99996364},"labels":[],"label_agreement":null},{"id":"W4390412258","doi":"10.1177/12034754231217205","title":"Real-World Experience Using Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis From a Single Outpatient Dermatology Clinic","year":2023,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Dermatology; Psoriasis; Outpatient clinic; Internal medicine","score_opus":0.08852433049438385,"score_gpt":0.3099063616180642,"score_spread":0.22138203112368032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390412258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9079879,0.016791184,0.00013925355,0.06491562,0.009065405,0.0007106306,0.0003013452,0.00003044984,0.000058221478],"genre_scores_gemma":[0.74585575,0.10143602,0.0014793527,0.11086622,0.018541912,0.00037262472,0.0018217444,0.000619914,0.019006481],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997258,0.0003386444,0.0014499712,0.00034864733,0.00014810388,0.00045662795],"domain_scores_gemma":[0.9888494,0.009235656,0.0012346983,0.00035906077,0.00026431252,0.000056882538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022722055,0.00044306964,0.0019550158,0.000611648,0.00020888724,0.00001293346,0.00020590304,0.00060336525,0.00020022075],"category_scores_gemma":[0.00026373912,0.0002567266,0.0005247732,0.00024096461,0.0002717942,0.00004308561,0.00002792877,0.0003564866,0.000013717406],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073403157,0.0006042689,0.0034272356,0.00019444058,0.0063757855,0.005324409,0.011614527,0.000043415603,0.0050693243,0.0000021125365,0.86861575,0.09138841],"study_design_scores_gemma":[0.004964403,0.0050165053,0.0003713798,0.0016256233,0.00580806,0.00780841,0.0024836329,0.000057344005,0.0073733763,0.00025877514,0.96347755,0.00075490924],"about_ca_topic_score_codex":0.00068604614,"about_ca_topic_score_gemma":0.00009321038,"teacher_disagreement_score":0.16213216,"about_ca_system_score_codex":0.00015540002,"about_ca_system_score_gemma":0.00024085416,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W4390429175","doi":"10.1016/j.nrleng.2023.12.005","title":"Association between psoriasis and dementia: A systematic review","year":2023,"lang":"en","type":"review","venue":"Neurología (English Edition)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Dementia; Medicine; Disease; Risk factor; Systematic review; MEDLINE; Dermatology; Internal medicine","score_opus":0.031659274840521084,"score_gpt":0.2729269409548085,"score_spread":0.24126766611428743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390429175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000113369515,0.99011505,0.0000022643658,0.00011186359,0.0054694833,0.0025439174,0.0010010867,0.0004435749,0.00030144403],"genre_scores_gemma":[0.0000070233455,0.9910636,0.000005741823,0.00021030188,0.0011780668,0.0016100492,0.0040194993,0.000095986026,0.0018097622],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99528176,0.0019201456,0.0013094926,0.0007824217,0.00014318166,0.00056299416],"domain_scores_gemma":[0.99556565,0.0022937597,0.0013131116,0.0005649131,0.00020444785,0.000058124155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010974667,0.00067057635,0.0036477626,0.00030421617,0.00028910983,0.0000536084,0.00037662179,0.0012027924,0.00021535343],"category_scores_gemma":[0.0024685578,0.00054668286,0.0006800575,0.0005340617,0.0000632673,0.00016359717,0.00016846137,0.0006715596,0.0021379949],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000005106293,0.00007077363,0.00010012573,0.8393928,0.009923781,0.000034247732,0.000049992992,1.3865439e-8,2.470879e-7,0.00005105837,0.08537237,0.064999476],"study_design_scores_gemma":[0.00044967263,0.00013607519,0.00006250272,0.12947634,0.057674747,0.000030805637,0.0000062699733,1.9725121e-8,0.0000013784348,0.000035318575,0.8117093,0.000417562],"about_ca_topic_score_codex":0.0000059880767,"about_ca_topic_score_gemma":0.0000060708726,"teacher_disagreement_score":0.72633696,"about_ca_system_score_codex":0.000120610996,"about_ca_system_score_gemma":0.000103994265,"threshold_uncertainty_score":0.99969846},"labels":[],"label_agreement":null},{"id":"W4390580814","doi":"10.1177/12034754231223159","title":"Updates on Pityriasis Rubra Pilaris: A Scoping Review","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pityriasis rubra pilaris; Dermatology; Etiology; Disease; Adverse effect; Psoriasis; Malignancy; Clinical trial; Filaggrin; Pityriasis rosea; Pathogenesis; Intensive care medicine; Bioinformatics; Immunology; Pathology; Internal medicine; Atopic dermatitis","score_opus":0.07429927513453184,"score_gpt":0.34554737351072473,"score_spread":0.2712480983761929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390580814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045779998,0.9952345,0.0000013350145,0.000667714,0.0032836816,0.0004165637,0.000026813648,0.00002798867,0.00029560598],"genre_scores_gemma":[0.000017881235,0.99756634,0.000008548074,0.00073962245,0.00070063997,0.000016079792,0.000100322555,0.000053246404,0.0007973419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675995,0.0005813322,0.0018344569,0.00033713214,0.0001383851,0.00034872268],"domain_scores_gemma":[0.9955401,0.002763608,0.0012053516,0.0002914723,0.00011170221,0.00008776825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012619663,0.00058528787,0.004836754,0.0007376262,0.00010912231,0.000020508085,0.0001998543,0.0004494548,0.000583296],"category_scores_gemma":[0.0006939615,0.00032238447,0.0010474072,0.00034303914,0.00015956703,0.000056793106,0.00004745707,0.00078454945,0.00025361686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043793843,0.000053263946,0.0000036596034,0.072351806,0.001660191,0.0023801604,0.000056443005,1.16299566e-8,0.0000034238856,0.000012948462,0.11482366,0.8086106],"study_design_scores_gemma":[0.000105549385,0.00022405872,1.7471991e-7,0.45384228,0.007479118,0.017021552,0.000017786553,8.557018e-9,0.0000027444976,0.000017323977,0.52112687,0.00016253449],"about_ca_topic_score_codex":0.0000057555,"about_ca_topic_score_gemma":0.0000018563741,"teacher_disagreement_score":0.8084481,"about_ca_system_score_codex":0.00006235931,"about_ca_system_score_gemma":0.00056585146,"threshold_uncertainty_score":0.9999228},"labels":[],"label_agreement":null},{"id":"W4390614285","doi":"10.1111/jdv.19748","title":"Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (<scp>LIMMitless</scp> trial)","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Dermatology; Body mass index; Severity of illness; Randomized controlled trial; Subgroup analysis; Gastroenterology; Surgery; Meta-analysis","score_opus":0.041608995851492636,"score_gpt":0.3131399310294778,"score_spread":0.27153093517798516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390614285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97462946,0.020614097,0.0010814054,0.0017944002,0.00087601395,0.00050188357,0.00041326645,0.000017265076,0.00007223114],"genre_scores_gemma":[0.99461186,0.0043010926,0.0002093923,0.00015875627,0.00016881416,0.00001803016,0.00008024566,0.000034082466,0.0004177395],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996957,0.0013874954,0.0009865257,0.00030533868,0.000057881654,0.00030574657],"domain_scores_gemma":[0.9973313,0.0016745051,0.00067023176,0.00017156382,0.000070463706,0.000081903636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036739395,0.00031145482,0.0008466681,0.0002101158,0.00018604868,0.000016956768,0.0002895333,0.00025063215,0.000017823679],"category_scores_gemma":[0.0003218643,0.0002085813,0.00029679073,0.00014431415,0.0003426626,0.0001245663,0.000094115974,0.00027604366,0.0000088649795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16950873,0.011405565,0.22531058,0.004977692,0.05168854,0.0027892836,0.02444175,0.0005386818,0.12919703,0.020751338,0.080898784,0.27849203],"study_design_scores_gemma":[0.20517182,0.004198629,0.5450219,0.002172232,0.0303952,0.022516716,0.000982718,0.00038693284,0.13307184,0.006427621,0.048335634,0.001318765],"about_ca_topic_score_codex":0.0000050346694,"about_ca_topic_score_gemma":0.0000025517647,"teacher_disagreement_score":0.3197113,"about_ca_system_score_codex":0.000032972726,"about_ca_system_score_gemma":0.00009931911,"threshold_uncertainty_score":0.85056984},"labels":[],"label_agreement":null},{"id":"W4390753055","doi":"10.7759/cureus.52099","title":"Psoriasis and Metabolic Disorders: A Comprehensive Meta-Analysis of Million Adults Worldwide","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Adiponectin; Metabolic syndrome; Dyslipidemia; Medicine; Insulin resistance; Adipokine; Diabetes mellitus; Obesity; Type 2 diabetes; Internal medicine; Bioinformatics; Immunology; Endocrinology; Biology","score_opus":0.03487491858780694,"score_gpt":0.27385660392389083,"score_spread":0.23898168533608388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390753055","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47124633,0.52682936,0.00007475204,0.0002373684,0.000533481,0.00019924501,0.0003445547,0.00007685823,0.00045803175],"genre_scores_gemma":[0.9908937,0.007425076,0.00015409652,0.000050317038,0.000023044528,0.000061548,0.00023849974,0.000016912314,0.0011367727],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9988501,0.00018954747,0.000297181,0.00040080008,0.000042893025,0.0002194567],"domain_scores_gemma":[0.9992085,0.00031646132,0.00007773725,0.00031546789,0.000056876757,0.000024932328],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010465386,0.00023182137,0.00095104816,0.00035826862,0.000073841904,0.000017676603,0.0001238802,0.00015465457,0.0011151901],"category_scores_gemma":[0.000021686474,0.00016727895,0.0008736065,0.00076938415,0.00011899679,0.0000948113,0.000058452206,0.0000904442,0.00008860755],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000332943,0.00031582083,0.002083648,0.000116097486,0.88034916,0.000016610442,0.0033957586,0.000030532923,0.018420495,0.0054026623,0.0019115235,0.08762474],"study_design_scores_gemma":[0.001392958,0.00021535762,0.032622702,0.00002218689,0.80429417,0.000016601061,0.0007978867,0.00008305743,0.021033868,0.000700812,0.13832335,0.0004970747],"about_ca_topic_score_codex":0.00043912648,"about_ca_topic_score_gemma":0.0006849232,"teacher_disagreement_score":0.5196474,"about_ca_system_score_codex":0.000010596393,"about_ca_system_score_gemma":0.000018927896,"threshold_uncertainty_score":0.99979794},"labels":[],"label_agreement":null},{"id":"W4390790402","doi":"10.1111/jdv.19701","title":"Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase <scp>III</scp> studies","year":2024,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland; Pfizer (Canada); Probity Medical Research; University of Toronto","funders":"Medical Research Council; Manchester Biomedical Research Centre; LEO Pharma; Sun Pharma; Bausch Health; Astellas Pharma; National Institute for Health and Care Research; Valeant Pharmaceuticals International; Amgen; Pfizer; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Discontinuation; Internal medicine; Psoriatic arthritis; Janus kinase inhibitor; Placebo; Adverse effect; Psoriasis; Randomized controlled trial; Physical therapy; Rheumatoid arthritis; Dermatology; Alternative medicine","score_opus":0.018156013562432686,"score_gpt":0.2660924596037756,"score_spread":0.2479364460413429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390790402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92981774,0.05999953,0.000002974848,0.008991281,0.0007694584,0.00022344259,0.000104449406,0.0000075951307,0.00008351362],"genre_scores_gemma":[0.98876315,0.005697156,0.000040741845,0.0051891874,0.00006512555,0.000004123216,0.000053414835,0.000034544017,0.00015256437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947487,0.0023660758,0.001984855,0.00038270428,0.00018271722,0.00033492155],"domain_scores_gemma":[0.9955002,0.0015874257,0.0025180622,0.00020608268,0.00013807022,0.00005014986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006665193,0.00042379528,0.0026031043,0.0009846904,0.000056582445,0.0000028412,0.00032656794,0.00075157784,0.000017561342],"category_scores_gemma":[0.00058664795,0.0002691528,0.00033967735,0.00029935714,0.0017016013,0.000066252396,0.00028466678,0.0013742168,0.0000010419128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017458819,0.0009909159,0.8407133,0.00074265106,0.07109754,0.0014163115,0.007177326,0.000008924928,0.00022644374,0.00019002207,0.043094937,0.03259571],"study_design_scores_gemma":[0.07530597,0.0013401415,0.77920943,0.0027126656,0.053231414,0.0061559677,0.0008314026,0.000013260866,0.0017369447,0.00053663057,0.07826245,0.0006637223],"about_ca_topic_score_codex":0.000010869847,"about_ca_topic_score_gemma":0.000010842341,"teacher_disagreement_score":0.07356009,"about_ca_system_score_codex":0.00005394601,"about_ca_system_score_gemma":0.00014350346,"threshold_uncertainty_score":0.99997604},"labels":[],"label_agreement":null},{"id":"W4390885433","doi":"10.3390/pharmaceutics16010111","title":"Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents","year":2024,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; University of Ottawa","funders":"Samsung; LEO Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Galderma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Biogen; Celgene; Mylan; Sanofi; Amgen; Pfizer","keywords":"Psoriasis; Pipeline (software); Medicine; Intensive care medicine; Dermatology; Computer science","score_opus":0.1729825846414711,"score_gpt":0.43467081833998206,"score_spread":0.26168823369851096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390885433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000043902037,0.9943711,0.000022390146,0.000115053466,0.0020514634,0.0021522436,0.0011651542,0.00003467834,0.00008350629],"genre_scores_gemma":[0.000013298893,0.9955424,0.00008014456,0.00006547659,0.00012432266,0.000672262,0.0005543476,0.00006167064,0.0028860539],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810857,0.00031106576,0.0009125822,0.00031652016,0.000057143898,0.00029414654],"domain_scores_gemma":[0.9983607,0.00054159184,0.0005366844,0.0004374755,0.00010426352,0.000019305096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039138968,0.00050682016,0.0019397709,0.00012701543,0.000089613735,0.0000064987175,0.00032792796,0.0002237183,0.00036452635],"category_scores_gemma":[0.000030320565,0.0002632486,0.0013987389,0.00028763493,0.000121810124,0.000022372475,0.00004280988,0.00013062336,0.00009344176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036378788,0.00026398778,0.0000012635506,0.06473848,0.0062573575,0.0000022066877,0.00027429676,1.2224426e-7,0.000010354849,0.000058071444,0.007916862,0.9204406],"study_design_scores_gemma":[0.00083075935,0.00015453574,2.1467521e-7,0.026211206,0.039150734,0.000017573284,0.00003418537,0.0000027571577,0.0004925059,0.00001920756,0.93289703,0.00018929728],"about_ca_topic_score_codex":0.000010460541,"about_ca_topic_score_gemma":0.0000024895894,"teacher_disagreement_score":0.92498016,"about_ca_system_score_codex":0.000072723866,"about_ca_system_score_gemma":0.00014903494,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W4390905440","doi":"10.25251/skin.8.supp.305","title":"Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Manchester Biomedical Research Centre; Galderma; Meiji Seika Pharma; Astellas Pharma; Celltrion; Eisai; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Pfizer; Biogen; Incyte; Genentech; Torii Pharmaceutical; Dalhousie University; Castle Biosciences; Sun Pharma; Dermira; Universität zu Lübeck; Regeneron Pharmaceuticals; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Celgene; Yale University; Sanofi; Amgen; LEO Pharma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Tolerability; Plaque psoriasis; Medicine; Term (time); Pooled analysis; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis; Physics","score_opus":0.01961196471794321,"score_gpt":0.29877832102755414,"score_spread":0.27916635630961095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390905440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97123027,0.022919819,0.0007064163,0.0031665633,0.0012303129,0.00038441198,0.00022506085,0.000021933092,0.00011523994],"genre_scores_gemma":[0.9955836,0.003012193,0.000062442625,0.00018489618,0.0003767633,0.000004862038,0.000077865705,0.00001890232,0.0006784853],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963932,0.0015290771,0.0013310425,0.00030366232,0.00013998795,0.0003030546],"domain_scores_gemma":[0.9963096,0.0027684132,0.00037351015,0.00033382658,0.00012446716,0.0000902006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025086734,0.00030120867,0.0015514833,0.000523536,0.00012506712,0.00002684867,0.00028573364,0.00022468276,0.0011994074],"category_scores_gemma":[0.0006378078,0.00016595196,0.0002754641,0.00063662697,0.00015673196,0.000087044784,0.00005548027,0.00043624738,0.000040700153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16418763,0.0016845841,0.010310795,0.0002168282,0.06506763,0.008295439,0.053837854,0.004234194,0.090410024,0.0001979818,0.0075231665,0.5940339],"study_design_scores_gemma":[0.23607317,0.0374241,0.15067454,0.012713721,0.29177672,0.06296548,0.023685714,0.0028543596,0.13616192,0.017780988,0.021966416,0.0059228875],"about_ca_topic_score_codex":0.00030333098,"about_ca_topic_score_gemma":0.00048149878,"teacher_disagreement_score":0.588111,"about_ca_system_score_codex":0.00014213292,"about_ca_system_score_gemma":0.00012785704,"threshold_uncertainty_score":0.99971366},"labels":[],"label_agreement":null},{"id":"W4390933743","doi":"10.25251/skin.8.supp.307","title":"Bimekizumab Efficacy Through 3 Years in Patients with Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma","keywords":"Medicine; Dermatology Life Quality Index; Plaque psoriasis; Psoriasis Area and Severity Index; Discontinuation; Psoriasis; Adverse effect; Internal medicine; Clinical trial; Dosing; Dermatology","score_opus":0.009459164200808652,"score_gpt":0.24160882969120187,"score_spread":0.23214966549039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390933743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062014,0.0062416587,0.00026540476,0.0014098936,0.0009734728,0.00026547193,0.00007304577,0.00002369675,0.00012723966],"genre_scores_gemma":[0.9982303,0.00044872906,0.00007763478,0.00031783295,0.0002131213,0.000003268291,0.00011996703,0.00002886409,0.000560284],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982861,0.00035608548,0.0005943806,0.00025100622,0.0001922002,0.00032018134],"domain_scores_gemma":[0.99867386,0.00060258125,0.00022561185,0.00032622323,0.00011605797,0.00005568967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002867918,0.00027442907,0.0007299388,0.00041091064,0.0000876901,0.000021799686,0.00036388027,0.00016651419,0.000783715],"category_scores_gemma":[0.00005804343,0.00014549623,0.0001640197,0.0008081953,0.00012197224,0.00010135613,0.000041434116,0.00039034412,0.00007778065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11475514,0.0040562134,0.1865273,0.00018866127,0.1364403,0.020637505,0.11655134,0.014820095,0.012286921,0.0002436647,0.02837931,0.36511356],"study_design_scores_gemma":[0.029290626,0.006289527,0.9038136,0.0027085666,0.03757318,0.003978443,0.0010443588,0.000055235712,0.007836238,0.0006694019,0.0056425016,0.0010983029],"about_ca_topic_score_codex":0.00028265943,"about_ca_topic_score_gemma":0.00033099353,"teacher_disagreement_score":0.7172863,"about_ca_system_score_codex":0.00012348613,"about_ca_system_score_gemma":0.000095560405,"threshold_uncertainty_score":0.85811293},"labels":[],"label_agreement":null},{"id":"W4390955842","doi":"10.1111/exd.15011","title":"The impacts of biologic treatment on metabolic profiling in psoriasis","year":2024,"lang":"en","type":"article","venue":"Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Fundamental Research Funds for Central Universities of the Central South University; Fundamental Research Funds for the Central Universities; Central South University; National Natural Science Foundation of China","keywords":"Psoriasis; Metabolome; Internal medicine; Medicine; Resistin; Adalimumab; Lysophosphatidylcholine; Metabolite; Endocrinology; Lysophosphatidylethanolamine; Gastroenterology; Chemistry; Adipokine; Disease; Immunology; Leptin; Phospholipid; Obesity; Phosphatidylcholine; Biochemistry","score_opus":0.0214783976311967,"score_gpt":0.29080796783226875,"score_spread":0.26932957020107207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390955842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8940485,0.10245828,0.0000013731928,0.00022701321,0.0015002816,0.00031177385,0.000029586008,0.00006845605,0.0013547039],"genre_scores_gemma":[0.9979267,0.0014240725,0.000034995785,0.000042051146,0.00002737305,0.00019910569,0.0000684878,0.000016399828,0.00026078112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99860615,0.0003095153,0.00035383107,0.00030953152,0.000028178318,0.00039281067],"domain_scores_gemma":[0.99928373,0.00037469287,0.00006172436,0.00024956337,0.000010341525,0.000019933515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000939212,0.00023860834,0.00038669864,0.00017543386,0.00012666298,0.000014324386,0.00015943979,0.0002063657,0.00010427211],"category_scores_gemma":[0.000019369225,0.0001376064,0.00016032376,0.00019762394,0.00020164312,0.000047990907,0.000041580606,0.000101869366,0.0004065594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069227436,0.0007230504,0.014017004,0.00001889065,0.00081997836,0.00017335525,0.001665491,0.0000031086424,0.91216916,0.042209905,0.00043540058,0.027072359],"study_design_scores_gemma":[0.0012674852,0.00040879849,0.0031009624,0.000024404175,0.000043687436,0.00023825481,0.00058285653,0.0000052770583,0.9780243,0.000112234986,0.01606715,0.00012455905],"about_ca_topic_score_codex":0.00013354994,"about_ca_topic_score_gemma":0.00005249332,"teacher_disagreement_score":0.1038782,"about_ca_system_score_codex":0.000085095126,"about_ca_system_score_gemma":0.00007106589,"threshold_uncertainty_score":0.5611426},"labels":[],"label_agreement":null},{"id":"W4391033331","doi":"10.25251/skin.8.supp.356","title":"Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"Amgen","keywords":"Apremilast; Psoriasis; Medicine; Dermatology; Intensive care medicine; Psoriatic arthritis","score_opus":0.016159876219574692,"score_gpt":0.26458304217604783,"score_spread":0.24842316595647315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98216033,0.013588518,0.000004389459,0.00082160695,0.0021672717,0.0010119337,0.000017510913,0.0000030192039,0.00022544825],"genre_scores_gemma":[0.9940328,0.00456297,0.0000037485333,0.0000314982,0.001139596,0.000028613993,0.0000068773247,0.000012413804,0.00018147081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982678,0.0005165453,0.0007193505,0.00012879765,0.00013359384,0.00023391002],"domain_scores_gemma":[0.99695325,0.002523997,0.00023152465,0.00021822278,0.000060360013,0.000012670551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010786337,0.0001863882,0.00044773848,0.0003158835,0.000063094565,0.0000062348217,0.0003633993,0.00008821027,0.00007959972],"category_scores_gemma":[0.00016713688,0.000071287905,0.00012175811,0.00044488252,0.00010398538,0.000031411266,0.000015161362,0.0002174626,0.000007434712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009792855,0.007916933,0.5081796,0.00009859255,0.0012764335,0.0010954841,0.17052923,0.00026444643,0.0004802467,0.00009692386,0.0059902915,0.29427895],"study_design_scores_gemma":[0.035176694,0.033281058,0.85222197,0.0006304631,0.0049971007,0.0022032817,0.04401857,0.00003805735,0.0012681358,0.001298454,0.024441654,0.00042459645],"about_ca_topic_score_codex":0.00020944793,"about_ca_topic_score_gemma":0.0017821066,"teacher_disagreement_score":0.3440423,"about_ca_system_score_codex":0.000135197,"about_ca_system_score_gemma":0.000077247816,"threshold_uncertainty_score":0.29070362},"labels":[],"label_agreement":null},{"id":"W4391033341","doi":"10.25251/skin.8.supp.355","title":"Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Queen's University; University of British Columbia","funders":"","keywords":"Dermis; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Pathology","score_opus":0.01578545855335113,"score_gpt":0.2696607524575266,"score_spread":0.25387529390417546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456333,0.051520836,0.000020977064,0.0011499213,0.00094932545,0.00054688146,0.00009626042,0.000020555297,0.000061976076],"genre_scores_gemma":[0.9954877,0.003744757,0.00002786724,0.00018127587,0.00027873367,0.00001237517,0.00004599818,0.000034128407,0.00018717595],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99664026,0.0013966975,0.0010804352,0.00027157666,0.00022124372,0.00038978033],"domain_scores_gemma":[0.9965102,0.002525461,0.00052181666,0.0002256477,0.00012362463,0.000093266004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001743376,0.00036376138,0.000980594,0.00042300043,0.00017333071,0.00003272657,0.00021180822,0.00022835589,0.00019013112],"category_scores_gemma":[0.00063569675,0.00018616498,0.0000892422,0.00025748584,0.0004022906,0.00011895063,0.000058214577,0.0004914159,0.000009274026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05176244,0.0024362616,0.013861218,0.00028737288,0.0070042745,0.00370229,0.023112178,0.000024665364,0.014818999,0.000086505985,0.0101566,0.8727472],"study_design_scores_gemma":[0.26969975,0.21234165,0.124432765,0.01816307,0.034908082,0.10992289,0.018928178,0.00006187358,0.06945104,0.0025923215,0.13607588,0.0034224829],"about_ca_topic_score_codex":0.000050293875,"about_ca_topic_score_gemma":0.00010468967,"teacher_disagreement_score":0.8693247,"about_ca_system_score_codex":0.000121255376,"about_ca_system_score_gemma":0.000280455,"threshold_uncertainty_score":0.75915873},"labels":[],"label_agreement":null},{"id":"W4391069389","doi":"10.1016/j.jdin.2023.12.012","title":"Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40","year":2024,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Dalhousie University","funders":"Janssen Pharmaceuticals; Janssen Research and Development","keywords":"Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Medicine; Index (typography); Matching (statistics); Internal medicine; Dermatology; Pathology","score_opus":0.034856489659063856,"score_gpt":0.2734170693552344,"score_spread":0.23856057969617056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391069389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953599,0.0005129929,0.00015099213,0.0002760851,0.0017355521,0.0005102651,0.0011749982,0.000054173917,0.0002250518],"genre_scores_gemma":[0.99797183,0.000034471468,0.00039071738,0.000089175344,0.00008467532,0.00015252057,0.0011313268,0.00002726196,0.00011803621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839586,0.00018157624,0.0004664349,0.0005339676,0.00014841977,0.00027375703],"domain_scores_gemma":[0.99925023,0.00031666085,0.00010068393,0.00019127253,0.000093010305,0.0000481472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018719626,0.00028488395,0.00049460365,0.00060301676,0.000046716057,0.00003813556,0.00023554865,0.00024388827,0.00040424976],"category_scores_gemma":[0.000055072447,0.00025426745,0.0000556711,0.00036191967,0.000036286205,0.00022632106,0.0001282066,0.0002646455,0.00007312421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0502076,0.001872463,0.825987,0.00005468452,0.001627936,0.000040830095,0.015317047,0.0006474991,0.0003813702,0.00019636536,0.0011903543,0.102476865],"study_design_scores_gemma":[0.013164695,0.0007771362,0.97967476,0.00047785614,0.00011958549,0.0000035356825,0.00055789336,0.0010108488,0.0022452935,0.00016453727,0.0013841526,0.00041968582],"about_ca_topic_score_codex":0.0029164448,"about_ca_topic_score_gemma":0.0050996765,"teacher_disagreement_score":0.15368779,"about_ca_system_score_codex":0.00024535018,"about_ca_system_score_gemma":0.00006402737,"threshold_uncertainty_score":0.99999094},"labels":[],"label_agreement":null},{"id":"W4391115649","doi":"10.1016/j.jaad.2023.11.068","title":"Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"LEO Pharma; European Academy of Dermatology and Venereology; Bristol-Myers Squibb; Eli Lilly and Company; Galderma; Incyte; Regeneron Pharmaceuticals; Les Laboratories Pierre Fabre; Celgene; Sanofi; Amgen; Pfizer","keywords":"Medicine; Apremilast; Plaque psoriasis; Randomized controlled trial; Psoriasis; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.009041776613370692,"score_gpt":0.23924886932093425,"score_spread":0.23020709270756357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391115649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923149,0.0033173214,0.000047858462,0.0021434228,0.0004972157,0.0014356856,0.00014583748,0.000009576539,0.00008819276],"genre_scores_gemma":[0.9985154,0.000984373,0.0001856457,0.0001272711,0.000082700826,0.000030105064,0.000010836213,0.000018451381,0.00004520355],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99605495,0.0015656766,0.0017184963,0.00026450478,0.00012477628,0.00027159957],"domain_scores_gemma":[0.994578,0.0033783268,0.0017800068,0.0001391313,0.00007581781,0.000048723974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057650125,0.00026949873,0.002657849,0.00044133668,0.000053443968,0.00000910743,0.00034571576,0.00021353849,0.000014259259],"category_scores_gemma":[0.00057735445,0.00014701237,0.00037282179,0.0004195897,0.0004355318,0.00009254254,0.00008296084,0.0005223821,0.0000051996944],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9900748,0.00040637288,0.00411564,0.000022805241,0.0017510209,0.0000117385225,0.0006612274,0.00008420108,0.00045684705,0.00005608244,0.00051187864,0.0018473756],"study_design_scores_gemma":[0.97507024,0.0007002853,0.019671783,0.00020421344,0.001701839,0.00016733677,0.000101111444,0.000014710043,0.0017737783,0.00019115079,0.00023117037,0.00017239832],"about_ca_topic_score_codex":0.000054359665,"about_ca_topic_score_gemma":0.000007726427,"teacher_disagreement_score":0.015556142,"about_ca_system_score_codex":0.000047000078,"about_ca_system_score_gemma":0.00018100273,"threshold_uncertainty_score":0.59949905},"labels":[],"label_agreement":null},{"id":"W4391116418","doi":"10.1002/art.42803","title":"Modulation of Interleukin‐23 Signaling With Guselkumab in <scp>Biologic‐Naive</scp> Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis","year":2024,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; National Institute for Health and Care Research; Janssen Research and Development; Janssen Scientific Affairs; Yale University","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Biomarker; Interleukin 23; Adalimumab; Tumor necrosis factor alpha; Etanercept; Rheumatology; Psoriasis Area and Severity Index; Rheumatoid arthritis; Psoriasis; Oncology; Interleukin; Immunology; Gastroenterology; Cytokine","score_opus":0.012469301578252082,"score_gpt":0.22002556835298862,"score_spread":0.20755626677473654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391116418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184704,0.0053903884,0.00009561043,0.00006182097,0.0014100894,0.0006433317,0.0002524741,0.0001657635,0.00013348021],"genre_scores_gemma":[0.99777955,0.0011682014,0.00021503604,0.000020960308,0.000015135677,0.00017561052,0.0004942376,0.000060383725,0.00007087042],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970095,0.0005420748,0.0007650515,0.0008223212,0.0001164068,0.0007446414],"domain_scores_gemma":[0.9976895,0.0014102915,0.00034250127,0.00033603795,0.00016398673,0.000057725545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018047873,0.0005032327,0.0009540945,0.0005660167,0.0001705152,0.00004205216,0.00023012894,0.00039228436,0.00010770721],"category_scores_gemma":[0.00026535717,0.00041631042,0.00014333724,0.0005807349,0.00048864074,0.00037837672,0.00008119514,0.00038772347,0.00018501165],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013008646,0.0016311768,0.19516823,0.00041285015,0.0041943933,0.000805219,0.02430563,0.00028864565,0.049474232,0.004000926,0.00087588374,0.70583415],"study_design_scores_gemma":[0.11127752,0.028455442,0.37297356,0.013024244,0.0007371249,0.0015927694,0.01487796,0.0002784381,0.44732243,0.002445024,0.004634947,0.0023805338],"about_ca_topic_score_codex":0.00036819247,"about_ca_topic_score_gemma":0.0016141029,"teacher_disagreement_score":0.70345366,"about_ca_system_score_codex":0.00016638164,"about_ca_system_score_gemma":0.00019696676,"threshold_uncertainty_score":0.9998289},"labels":[],"label_agreement":null},{"id":"W4391173592","doi":"10.1186/s42358-024-00351-5","title":"Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis","year":2024,"lang":"en","type":"article","venue":"Advances in Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"WOMAC; Osteoarthritis; Medicine; Internal medicine; Visual analogue scale; Body mass index; Pathogenesis; Gastroenterology; Interleukin; Cytokine; Physical therapy; Pathology","score_opus":0.003921897435031126,"score_gpt":0.21654894330379118,"score_spread":0.21262704586876005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391173592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372082,0.061650556,0.000009314498,0.000014136198,0.00042628124,0.00019627792,0.00018566681,0.000023946188,0.0002856492],"genre_scores_gemma":[0.99826497,0.0013992666,0.00007241128,0.000007008512,0.0000017998705,0.000057706136,0.00013819727,0.000012553248,0.000046106485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989251,0.00012583564,0.0004007694,0.00028007268,0.000032798496,0.0002354112],"domain_scores_gemma":[0.99943036,0.00022028369,0.00010010967,0.00019447408,0.00003866517,0.000016082884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059585644,0.00016278765,0.0004511759,0.00023979788,0.000017316257,0.0000024169115,0.00013259603,0.00012027278,0.00007029816],"category_scores_gemma":[0.00003735534,0.00013395525,0.000056926743,0.00024155404,0.00025865718,0.00018457309,0.00005371253,0.000113554015,0.00001856393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011831339,0.0002564482,0.89108723,0.00019919162,0.000065013,0.000022084638,0.0006686158,0.000022086864,0.0009776672,0.0008861754,0.000013673685,0.1046187],"study_design_scores_gemma":[0.004959237,0.0007987942,0.9761517,0.0011608746,0.000063727544,0.00002440775,0.0005260379,0.000009845214,0.004080476,0.0023274652,0.009596105,0.00030132194],"about_ca_topic_score_codex":0.00010065383,"about_ca_topic_score_gemma":0.00052804674,"teacher_disagreement_score":0.104317375,"about_ca_system_score_codex":0.000025569943,"about_ca_system_score_gemma":0.000057734615,"threshold_uncertainty_score":0.5462537},"labels":[],"label_agreement":null},{"id":"W4391227055","doi":"10.1111/ajd.14213","title":"Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study","year":2024,"lang":"en","type":"article","venue":"Australasian Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Dermatology; MEDLINE; Surgery","score_opus":0.01414682398966192,"score_gpt":0.2661754164603716,"score_spread":0.2520285924707097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391227055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551356,0.0018206246,0.000019082187,0.00052050076,0.0012907191,0.00032125492,0.000018788967,0.000041495066,0.00045397464],"genre_scores_gemma":[0.9992214,0.00022458685,0.00010193233,0.000021167714,0.000056099256,0.000024853622,0.0000105158815,0.000026631971,0.0003128548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978011,0.00051358336,0.000730867,0.00036280282,0.00008879534,0.0005028335],"domain_scores_gemma":[0.9991498,0.00016167696,0.00026394578,0.00023662156,0.000099727215,0.00008823372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017962696,0.0003137812,0.0007188011,0.00045674018,0.000091755865,0.00004366096,0.0002992271,0.00024311579,0.00025082752],"category_scores_gemma":[0.00005752684,0.00022693293,0.00013525244,0.00043691669,0.00018801916,0.00033238204,0.00003327906,0.0005183801,0.00014376185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013777274,0.0007281386,0.9498846,0.000043268003,0.0015120652,0.014966354,0.024394758,0.000008961383,0.004348615,0.00031707154,0.0007592165,0.0016592509],"study_design_scores_gemma":[0.01044207,0.0018675824,0.8988586,0.00044375163,0.00085943844,0.027184838,0.043367084,0.000007331698,0.014736352,0.0001205828,0.001513608,0.00059875293],"about_ca_topic_score_codex":0.0000906789,"about_ca_topic_score_gemma":0.0002531367,"teacher_disagreement_score":0.051025968,"about_ca_system_score_codex":0.00011112353,"about_ca_system_score_gemma":0.00024103545,"threshold_uncertainty_score":0.9254056},"labels":[],"label_agreement":null},{"id":"W4391263782","doi":"","title":"Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; Probity Medical Research; Health Sciences Centre; University of Toronto; Women's College Hospital; McMaster University; Dermatrials Research; University of Calgary; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Generalized pustular psoriasis; Psoriasis; Medicine; Interleukin 1 receptor antagonist; Pathogenesis; Interleukin; Immunology; Disease; Dermatology; Clinical trial; Receptor antagonist; Immune system; Antagonist; Receptor; Internal medicine; Cytokine","score_opus":0.019154706476155765,"score_gpt":0.22491242295884184,"score_spread":0.20575771648268606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391263782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878678,0.003829393,0.00012788852,0.0003818727,0.0049130255,0.0017090036,0.00047412142,0.00017469535,0.0005222196],"genre_scores_gemma":[0.99018896,0.00014225928,0.0002670681,0.00018574268,0.00025992774,0.0051295133,0.00063461397,0.000048984217,0.0031429066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982551,0.000086095366,0.00042188913,0.00052493234,0.0000509405,0.0006610836],"domain_scores_gemma":[0.9993955,0.00016227564,0.00006341444,0.00024582524,0.000090168745,0.000042849817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024438658,0.00028448796,0.000368576,0.00031397186,0.00008341912,0.000055411743,0.00020458101,0.00029123644,0.000070087626],"category_scores_gemma":[0.00018013864,0.0002397452,0.00024517797,0.00027101865,0.0000640306,0.00015065688,0.00007336795,0.00014661257,0.00012767383],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025330374,0.0013492053,0.012385754,0.00030020365,0.0014912836,0.000032700704,0.0017951652,0.000006500444,0.01369369,0.003025517,0.023361342,0.9400256],"study_design_scores_gemma":[0.03768925,0.0005213434,0.3003201,0.0002649404,0.0013209573,0.000045951132,0.00042680462,0.00008251547,0.21457252,0.0009157188,0.4421574,0.0016825229],"about_ca_topic_score_codex":0.000106178566,"about_ca_topic_score_gemma":0.00017374287,"teacher_disagreement_score":0.93834305,"about_ca_system_score_codex":0.00015998234,"about_ca_system_score_gemma":0.000037193786,"threshold_uncertainty_score":0.97765255},"labels":[],"label_agreement":null},{"id":"W4391281248","doi":"10.1111/jdv.19811","title":"Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (<scp>COMFORT</scp>‐1)","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Apremilast; Placebo; Medicine; Psoriasis Area and Severity Index; Population; Clinical endpoint; Randomized controlled trial; Psoriasis; Placebo-controlled study; Internal medicine; Anesthesia; Gastroenterology; Dermatology; Double blind; Psoriatic arthritis; Pathology","score_opus":0.03853453511229285,"score_gpt":0.3225671857400922,"score_spread":0.28403265062779937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391281248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713525,0.023919174,0.000038531034,0.00190787,0.0017253292,0.00036811837,0.00007554646,0.000012315348,0.00060057925],"genre_scores_gemma":[0.9921834,0.00717363,0.00011419659,0.00012372066,0.00021412532,0.0000027150343,0.0000128082565,0.000018680523,0.00015672075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99065304,0.0063720723,0.002336422,0.0003122961,0.000057752462,0.00026844468],"domain_scores_gemma":[0.9911017,0.007472119,0.0011820671,0.00016298275,0.00003146119,0.00004970741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028061913,0.00023972773,0.0015874505,0.000274121,0.00007531169,0.0000070267706,0.0003964573,0.00052614044,0.000011480328],"category_scores_gemma":[0.001748601,0.00015256715,0.00037677938,0.00013686015,0.0011474363,0.00009518814,0.00019336397,0.00092377677,0.00000884009],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9009341,0.0013750411,0.014071956,0.00012840805,0.005548879,0.000561448,0.004002589,0.000017840233,0.010090627,0.0036757991,0.0052771424,0.05431616],"study_design_scores_gemma":[0.9360328,0.00044055987,0.025824511,0.0005027215,0.0017386578,0.0031447755,0.00015709983,0.000027149046,0.011071348,0.0022490125,0.018679736,0.00013164694],"about_ca_topic_score_codex":0.0000120063405,"about_ca_topic_score_gemma":0.0000039867277,"teacher_disagreement_score":0.05418451,"about_ca_system_score_codex":0.000011883185,"about_ca_system_score_gemma":0.00008046414,"threshold_uncertainty_score":0.6221508},"labels":[],"label_agreement":null},{"id":"W4391290415","doi":"10.1016/j.jaad.2024.01.025","title":"Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study","year":2024,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dermatrials Research; Bausch Health (Canada); Université de Montréal; SKiN Health; University of Calgary; Innovaderm (Canada); Probity Medical Research; Calgary Laboratory Services; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Multicenter study; Open label; Psoriasis; Dermatology; Internal medicine; Clinical trial; Randomized controlled trial","score_opus":0.035794806361481725,"score_gpt":0.3299326365636837,"score_spread":0.29413783020220197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391290415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89964443,0.008100977,0.0000046363452,0.08984882,0.0005952511,0.0014714326,0.00030808971,0.00001000704,0.000016369138],"genre_scores_gemma":[0.9743618,0.0012860777,0.00026536675,0.02360077,0.000139337,0.00008308629,0.00002127974,0.00006355436,0.00017872675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942646,0.0023430348,0.0021561126,0.00051805965,0.00016848759,0.0005496858],"domain_scores_gemma":[0.9950899,0.00077996636,0.003475527,0.00047336917,0.00013955457,0.000041706968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039344418,0.0006173954,0.003141666,0.0008347943,0.00005426026,0.000015432086,0.002188266,0.00091400056,0.00007609936],"category_scores_gemma":[0.0001339311,0.000389968,0.00051156705,0.00069466216,0.00071246235,0.00011169097,0.00056906714,0.0022545794,0.00002391508],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10854656,0.029024335,0.046020165,0.0012154101,0.03231681,0.0024593477,0.011624122,0.00009198474,0.10471077,0.000029035735,0.6075698,0.056391664],"study_design_scores_gemma":[0.29510102,0.02605137,0.046750292,0.006257673,0.0126327695,0.018496145,0.0039761914,0.000030856463,0.192524,0.0008847663,0.393356,0.0039389282],"about_ca_topic_score_codex":0.00013240872,"about_ca_topic_score_gemma":0.000014377172,"teacher_disagreement_score":0.21421379,"about_ca_system_score_codex":0.00008977882,"about_ca_system_score_gemma":0.00025992724,"threshold_uncertainty_score":0.9998552},"labels":[],"label_agreement":null},{"id":"W4391294622","doi":"10.2196/48749","title":"Risk Factors Associated With Burden of Disease of Psoriasis From 1990 to 2019: Epidemiological Analysis","year":2024,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Epidemiology; Psoriasis; Disease; Medicine; Environmental health; Dermatology; Internal medicine","score_opus":0.020167536914723467,"score_gpt":0.2714101367464955,"score_spread":0.25124259983177205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391294622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923179,0.003979555,0.0002612917,0.00033765423,0.00033204688,0.00029478632,0.0022774274,0.00010439108,0.00009491459],"genre_scores_gemma":[0.99792594,0.0001267277,0.00006250882,0.000031601397,0.000021095808,0.00006462884,0.0015028585,0.000017503933,0.0002471481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768716,0.00083237444,0.0005672199,0.0004924534,0.000055834793,0.00036498354],"domain_scores_gemma":[0.9973849,0.001789367,0.0002626971,0.00040492258,0.00007598888,0.00008209849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015461206,0.00028729023,0.0011346391,0.0004401205,0.000068803754,0.000005868753,0.00025649983,0.00041317305,0.0006970659],"category_scores_gemma":[0.00032166205,0.00019159584,0.00043292707,0.0008366591,0.00022585166,0.00005075851,0.00007918841,0.00018435923,0.00012951661],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008963155,0.00034500012,0.9645627,0.000036614878,0.017862823,0.000078734076,0.0014238061,0.00039442207,0.005585334,0.00047405905,0.0058058333,0.0025343641],"study_design_scores_gemma":[0.0011812504,0.00028404008,0.9734135,0.00008509345,0.007015914,0.0000047018752,0.00024629693,0.000100537654,0.013268919,0.00041934653,0.003633937,0.00034644146],"about_ca_topic_score_codex":0.0010426447,"about_ca_topic_score_gemma":0.00012379671,"teacher_disagreement_score":0.010846908,"about_ca_system_score_codex":0.00003597527,"about_ca_system_score_gemma":0.000080643826,"threshold_uncertainty_score":0.7813052},"labels":[],"label_agreement":null},{"id":"W4391317995","doi":"10.1080/15569527.2024.2310243","title":"Understanding the impact of risankizumab on keratinocyte-derived IL-23A in a novel organotypic 3D skin model containing IL-23A responsive and IL-17A producing γδ-T-cells","year":2024,"lang":"en","type":"article","venue":"Cutaneous and Ocular Toxicology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Interleukin 17; Interleukin 23; Human skin; Psoriasis; Interleukin 4; Interleukin 6; Stimulation; Interleukin; Chemistry; Immunology; Cancer research; Cytokine; Medicine; Internal medicine; Biology","score_opus":0.03951695273424896,"score_gpt":0.26727644809862106,"score_spread":0.2277594953643721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391317995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99318504,0.003957804,0.0012473229,0.00019161245,0.0003450357,0.0005883171,0.00019557854,0.000052080413,0.00023718651],"genre_scores_gemma":[0.99870414,0.00044384602,0.00022877018,0.00010193834,0.000041974476,0.000030917043,0.000039412866,0.00004139663,0.00036758895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980138,0.00035617247,0.00040937043,0.0006539035,0.00005359262,0.00051313674],"domain_scores_gemma":[0.99861854,0.00084788795,0.00012907729,0.00031986146,0.000040721323,0.00004389191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037177617,0.0003669863,0.00059216097,0.00027196933,0.00029745628,0.00005145208,0.00014830047,0.00042510434,0.00008018995],"category_scores_gemma":[0.00013438772,0.00025864274,0.00013527597,0.00022661831,0.0003663231,0.000065059234,0.00011293536,0.00039480388,0.000016886248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021732321,0.00019361022,0.0005233911,0.00005459185,0.00076506817,0.00039468936,0.0092910705,0.003225066,0.97655123,0.0014953173,0.000100949255,0.0052317884],"study_design_scores_gemma":[0.021274075,0.019612286,0.011411712,0.0015385557,0.0023589714,0.0143854525,0.014411483,0.06677905,0.8343662,0.008924313,0.001659548,0.003278335],"about_ca_topic_score_codex":0.00012454436,"about_ca_topic_score_gemma":0.0001744192,"teacher_disagreement_score":0.142185,"about_ca_system_score_codex":0.00032580298,"about_ca_system_score_gemma":0.00032593528,"threshold_uncertainty_score":0.9999866},"labels":[],"label_agreement":null},{"id":"W4391479168","doi":"10.23736/s2532-1285.23.00180-5","title":"Erythrodermic psoriasis","year":2024,"lang":"en","type":"article","venue":"Italian Journal of Emergency Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Psoriasis; Dermatology; Medicine","score_opus":0.040988062108008094,"score_gpt":0.31026065078270293,"score_spread":0.26927258867469483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391479168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66328,0.2506285,0.0003940875,0.0052240244,0.069283776,0.000143461,0.000029693832,0.0000820594,0.01093441],"genre_scores_gemma":[0.9762612,0.0043593375,0.00004360968,0.000037177462,0.0013852895,0.0000030871795,0.000021931392,0.000025264193,0.0178631],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862105,0.00011835008,0.00075025315,0.00016983683,0.00008525524,0.0002552438],"domain_scores_gemma":[0.9993795,0.00007993697,0.00017831137,0.00017221544,0.00013430705,0.000055688703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048491478,0.00019145547,0.000382548,0.00030454295,0.00007455601,0.0000036772494,0.00021759338,0.0001312172,0.01732449],"category_scores_gemma":[0.00013717676,0.00012497704,0.0002493361,0.00033817586,0.000092137125,0.00015817162,0.00001658758,0.00022679973,0.0005778006],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024518048,0.00016789643,0.0041402886,0.00014098891,0.0025859126,0.000451708,0.003297331,0.0000037916045,0.14301938,0.0016814074,0.75115055,0.09311555],"study_design_scores_gemma":[0.0030530647,0.0022287362,0.009207277,0.0010141118,0.0019479289,0.0017794686,0.0015335542,0.0000051654974,0.017917573,0.003603317,0.9572766,0.00043321226],"about_ca_topic_score_codex":0.000015168686,"about_ca_topic_score_gemma":0.000005590197,"teacher_disagreement_score":0.31298122,"about_ca_system_score_codex":0.00003719519,"about_ca_system_score_gemma":0.000072121715,"threshold_uncertainty_score":0.9835738},"labels":[],"label_agreement":null},{"id":"W4391618252","doi":"10.1056/nejmoa2308713","title":"An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Innovaderm (Canada); Dermatrials Research; Probity Medical Research","funders":"Janssen Research and Development","keywords":"Interleukin 1 receptor antagonist; Psoriasis; Receptor antagonist; Interleukin 23; Medicine; Antagonist; Cytokine; Immune system; Monoclonal antibody; Immunology; Receptor; Peptide; Interleukin; Pharmacology; Antibody; Internal medicine; Chemistry; Biochemistry","score_opus":0.021741809512331015,"score_gpt":0.2879754072596409,"score_spread":0.26623359774730987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391618252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94614625,0.023303488,0.0036482725,0.008588384,0.017030329,0.00030953586,0.000118725446,0.00009111646,0.00076392555],"genre_scores_gemma":[0.98793215,0.00090298895,0.00087574054,0.00023553146,0.005323168,0.000006260101,0.0002060855,0.000032645432,0.0044854633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987936,0.00016416881,0.00050522,0.00019597905,0.000071891176,0.00026916547],"domain_scores_gemma":[0.9990671,0.00040600268,0.00015578716,0.00015499629,0.000109914836,0.00010618605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080164796,0.00021283767,0.0004999611,0.0002481471,0.000099333,0.000025274052,0.00023067475,0.00015932898,0.0008594255],"category_scores_gemma":[0.000119453376,0.0001327269,0.000158737,0.00012564631,0.000116978226,0.00016332901,0.000012959302,0.0002674996,0.00008692111],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031546587,0.00012528864,0.0009702994,0.000059808248,0.0010772011,0.00013795975,0.00278627,0.000005118881,0.18418555,0.0008631383,0.17109023,0.6355445],"study_design_scores_gemma":[0.03493088,0.004615544,0.0006127034,0.00043933545,0.00075043505,0.0015694906,0.0005500386,0.0000114356235,0.028107785,0.000699916,0.9275217,0.00019073815],"about_ca_topic_score_codex":0.000069496455,"about_ca_topic_score_gemma":0.00007337638,"teacher_disagreement_score":0.75643146,"about_ca_system_score_codex":0.00006164596,"about_ca_system_score_gemma":0.00017592504,"threshold_uncertainty_score":0.94101065},"labels":[],"label_agreement":null},{"id":"W4391647210","doi":"10.2340/actadv.v104.12623","title":"Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis","year":2024,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Kyowa Hakko Kirin; Celltrion; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Baxalta; Celgene; Gilead Sciences; Genentech; Coherus Biosciences; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Betamethasone dipropionate; Calcipotriol; Dermatology; Medicine; Psoriasis; Betamethasone; Immunology","score_opus":0.05872298193760503,"score_gpt":0.3251873466800769,"score_spread":0.2664643647424719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391647210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453616,0.0038476477,0.00009300971,0.0003141117,0.00019247601,0.0006988801,0.00021821553,0.000054320615,0.000045179513],"genre_scores_gemma":[0.99927366,0.0001010366,0.00018083007,0.000031443393,0.0000067277006,0.000092213864,0.0002696849,0.000018919864,0.000025460346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949169,0.0027346886,0.0014725443,0.000416966,0.00009694853,0.00036196114],"domain_scores_gemma":[0.9954157,0.0036095849,0.00054875243,0.00030393287,0.000078703735,0.000043353666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010667414,0.00029977973,0.001679594,0.0006548827,0.0000745777,0.000011661912,0.0001932126,0.00052360934,0.000093022136],"category_scores_gemma":[0.00088438415,0.00021649137,0.00013710358,0.0005880071,0.0002446612,0.00015071605,0.00011583494,0.0002918335,0.000007018865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013441284,0.0009943557,0.9659653,0.00021424008,0.00058368896,0.000025492147,0.00410384,0.00010893405,0.00660277,0.0004998805,0.00007859989,0.007381661],"study_design_scores_gemma":[0.0069722156,0.0003913318,0.9765571,0.00018956584,0.00020509215,0.000021386819,0.0005103603,0.0000545493,0.014130351,0.0004718212,0.00024567443,0.00025059682],"about_ca_topic_score_codex":0.0004241279,"about_ca_topic_score_gemma":0.00031558154,"teacher_disagreement_score":0.010591801,"about_ca_system_score_codex":0.00007745559,"about_ca_system_score_gemma":0.00019739803,"threshold_uncertainty_score":0.8828262},"labels":[],"label_agreement":null},{"id":"W4391680495","doi":"10.1111/jdv.19830","title":"Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy–Fatigue and <scp>pain‐Visual</scp> Analogue Scale in patients with generalized pustular psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Boehringer Ingelheim","keywords":"Visual analogue scale; Cronbach's alpha; Medicine; Intraclass correlation; Convergent validity; Physical therapy; Population; Psychometrics; Clinical psychology; Internal consistency","score_opus":0.015881056557061346,"score_gpt":0.25699040019336483,"score_spread":0.24110934363630349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391680495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98698443,0.010932333,0.00020605636,0.0006006395,0.00089273497,0.00023828328,0.000027379974,0.0000071290924,0.00011101665],"genre_scores_gemma":[0.9977389,0.001921492,0.00008114251,0.00008950999,0.0000686881,0.000005380884,0.000015836307,0.000022200713,0.00005685778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957906,0.0027116307,0.00085947046,0.00025629532,0.00013061569,0.00025141396],"domain_scores_gemma":[0.99828273,0.00053243636,0.0008754376,0.00016354572,0.00011411213,0.000031747957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010272573,0.00024114696,0.0006849389,0.000555086,0.00013243643,0.000007448419,0.0003450912,0.00029661716,0.000020406527],"category_scores_gemma":[0.00009171616,0.00013705592,0.00019550268,0.0006757519,0.00066043035,0.000121409255,0.00012246783,0.00047352555,0.0000011107292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023026431,0.0003646985,0.9714158,0.00012161833,0.0010389409,0.000002874501,0.00032475792,0.00014830196,0.0074005225,0.00038339794,0.0005392132,0.018029599],"study_design_scores_gemma":[0.004875467,0.00023992301,0.9635476,0.00020056448,0.0003922236,0.00034386027,0.00007164702,0.000033274988,0.028577622,0.00020658845,0.0014256907,0.00008552472],"about_ca_topic_score_codex":0.0000073074702,"about_ca_topic_score_gemma":0.0000045675197,"teacher_disagreement_score":0.0211771,"about_ca_system_score_codex":0.00004093167,"about_ca_system_score_gemma":0.00010255964,"threshold_uncertainty_score":0.5588978},"labels":[],"label_agreement":null},{"id":"W4391689991","doi":"10.1007/s13555-023-01075-y","title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McMaster University; Dermatrials Research; Probity Medical Research; University of British Columbia; SKiN Health","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Ixekizumab; Plaque psoriasis; Psoriasis; Medicine; Interleukin 17; Interleukin 23; Antagonist; Interleukin; Interleukin 1 receptor antagonist; Pharmacology; Internal medicine; Receptor antagonist; Dermatology; Secukinumab; Cytokine; Receptor","score_opus":0.017409283018732104,"score_gpt":0.2538951513793576,"score_spread":0.2364858683606255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391689991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956142,0.0018424309,0.000043643333,0.00080131495,0.0004270067,0.0007928323,0.00012558661,0.00014385578,0.00020915858],"genre_scores_gemma":[0.9985375,0.0003820099,0.00008728774,0.00022875011,0.000027089192,0.00008805083,0.00017434263,0.000053811265,0.00042118717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792075,0.0003824041,0.00034652947,0.0007591812,0.00006296165,0.0005281675],"domain_scores_gemma":[0.9990179,0.00044023772,0.00007576987,0.00029371332,0.00008235219,0.000090014255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000094357136,0.0004850643,0.0006386692,0.0005353168,0.00030269622,0.00008828437,0.00014801598,0.00033816832,0.00003238552],"category_scores_gemma":[0.000020129679,0.00035034347,0.00005801043,0.00041304482,0.00020635272,0.00023264723,0.000066677094,0.0002763531,0.00006383161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4134415,0.0011903408,0.49394187,0.00011133706,0.0063528586,0.0017146455,0.018814169,0.000073068455,0.010531745,0.0028299114,0.002381679,0.048616875],"study_design_scores_gemma":[0.16258593,0.02165585,0.51179254,0.0023924236,0.0013686569,0.0043769786,0.0075945873,0.0002144499,0.24427299,0.0007504926,0.038058814,0.0049363],"about_ca_topic_score_codex":0.0001607745,"about_ca_topic_score_gemma":0.00021836911,"teacher_disagreement_score":0.25085557,"about_ca_system_score_codex":0.00009573392,"about_ca_system_score_gemma":0.00009565398,"threshold_uncertainty_score":0.99989486},"labels":[],"label_agreement":null},{"id":"W4391942083","doi":"10.1007/s13555-024-01097-0","title":"Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Placebo; Medicine; Psoriasis; Pharmacodynamics; Proinflammatory cytokine; Pharmacokinetics; Psoriasis Area and Severity Index; Internal medicine; Pharmacology; Randomized controlled trial; Gastroenterology; Inflammation; Immunology; Pathology","score_opus":0.020706768672432423,"score_gpt":0.2805420094087598,"score_spread":0.25983524073632736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391942083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96280277,0.031911157,0.000032714706,0.00025567831,0.0007771063,0.003948284,0.000012244702,0.00008026775,0.00017976282],"genre_scores_gemma":[0.9962919,0.0016019574,0.000023618884,0.00002651049,0.00004230303,0.0017341365,0.00007261258,0.000022581147,0.00018438704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99736804,0.0011998842,0.00067471166,0.0004078174,0.00003819714,0.0003113541],"domain_scores_gemma":[0.9988127,0.00076278375,0.00017944256,0.00018511752,0.000038868897,0.000021137908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006287186,0.00029112154,0.0010398502,0.00037413815,0.0001078791,0.000025229801,0.00009079138,0.0003097302,0.00022300593],"category_scores_gemma":[0.000040969884,0.00021710593,0.00019585708,0.0001745816,0.00017735087,0.00016015691,0.00003313226,0.00030084146,0.000076393226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8710142,0.0008535858,0.0011335333,0.000098236625,0.0022405596,0.00015723046,0.0047211186,0.0000041958347,0.10406558,0.0008308204,0.000054144646,0.014826828],"study_design_scores_gemma":[0.83854425,0.00027879616,0.000050322753,0.0002823797,0.00017911053,0.0001054106,0.0008383013,0.00009484693,0.15863891,0.00012762818,0.0006506187,0.00020941766],"about_ca_topic_score_codex":0.00016015721,"about_ca_topic_score_gemma":0.00014103715,"teacher_disagreement_score":0.054573327,"about_ca_system_score_codex":0.00005152348,"about_ca_system_score_gemma":0.00008886693,"threshold_uncertainty_score":0.8853323},"labels":[],"label_agreement":null},{"id":"W4391953210","doi":"10.1016/j.jaad.2024.01.078","title":"Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: A real-world case-control study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta","funders":"Alberta Innovates; Canadian Dermatology Foundation; Scottish Rock Garden Club; TD Bank","keywords":"Medicine; Psoriasis; Comorbidity; Intensive care medicine; Dermatology; Internal medicine","score_opus":0.03545970573030689,"score_gpt":0.3308789436656919,"score_spread":0.29541923793538505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391953210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963681,0.0010247147,0.0000035074106,0.0005258596,0.00016180566,0.00048685225,0.001371902,0.000013619504,0.000043603133],"genre_scores_gemma":[0.9990908,0.00068498374,0.000017438211,0.000093347175,0.000017248332,0.000014194546,0.000011727543,0.000019965053,0.00005032791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970199,0.0013102753,0.0010085925,0.0002374725,0.000114412585,0.00030938318],"domain_scores_gemma":[0.9966693,0.0009067434,0.002033057,0.00022648239,0.00011977713,0.00004461918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015985928,0.00034125065,0.001443871,0.00030418063,0.00006932913,0.0000055832684,0.00033948183,0.00014278176,0.00010389904],"category_scores_gemma":[0.000053205138,0.00017512639,0.00050796644,0.0004285495,0.0008420111,0.00009234349,0.00004213916,0.00030289442,0.0000050009244],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061521227,0.0025782103,0.93279374,0.000036008234,0.04108472,0.00022827851,0.0027587304,0.00005233409,0.0074980133,0.000057586934,0.0026518924,0.0041083833],"study_design_scores_gemma":[0.0084610265,0.009886552,0.9177278,0.00012989102,0.00684692,0.00094480475,0.0011605567,0.00000923888,0.054257046,0.0001115392,0.00020000961,0.00026456462],"about_ca_topic_score_codex":0.00087633246,"about_ca_topic_score_gemma":0.0000874981,"teacher_disagreement_score":0.04675903,"about_ca_system_score_codex":0.00011392007,"about_ca_system_score_gemma":0.00014532395,"threshold_uncertainty_score":0.7141447},"labels":[],"label_agreement":null},{"id":"W4392131776","doi":"10.1016/j.jdin.2024.02.012","title":"Use of sulfasalazine for psoriasis: An evidence-based review","year":2024,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Sulfasalazine; Psoriasis; Dermatology; Medicine; Internal medicine; Ulcerative colitis","score_opus":0.10391569836576713,"score_gpt":0.3337567303739795,"score_spread":0.22984103200821238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392131776","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39682287,0.53978145,0.006895396,0.019381993,0.027756725,0.0029741402,0.0035215078,0.0006834345,0.002182513],"genre_scores_gemma":[0.95757085,0.017288864,0.0033215475,0.0015856987,0.00052110106,0.0004943057,0.0026323742,0.00005140897,0.016533827],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992523,0.00007778368,0.000269844,0.00023109984,0.000048738075,0.000120232566],"domain_scores_gemma":[0.9991055,0.00047929666,0.000066990455,0.00017382846,0.00016025301,0.000014111497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024401535,0.00011383735,0.00018569843,0.000112866306,0.00003088022,0.000021374553,0.00018093355,0.00008843204,0.001125024],"category_scores_gemma":[0.0002805126,0.00009158044,0.00017243675,0.00009095542,0.000043927063,0.00032065163,0.000018978193,0.00005556477,0.00016270093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014067243,0.00080000557,0.0049858764,0.001995046,0.0027247465,0.000023954244,0.00021505496,0.000036036843,0.18003432,0.036075104,0.1757171,0.595986],"study_design_scores_gemma":[0.0013713371,0.0006010612,0.006312712,0.0067293956,0.00064838177,0.0000332918,0.000016848155,0.00039283754,0.10037045,0.00047103473,0.88274825,0.00030438264],"about_ca_topic_score_codex":0.000022192358,"about_ca_topic_score_gemma":0.000007859933,"teacher_disagreement_score":0.7070312,"about_ca_system_score_codex":0.00003938627,"about_ca_system_score_gemma":0.00008522273,"threshold_uncertainty_score":0.9997881},"labels":[],"label_agreement":null},{"id":"W4392219630","doi":"10.1016/j.jaad.2023.12.070","title":"Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Vaccination; Delphi; Family medicine; Immunology","score_opus":0.030577084136270468,"score_gpt":0.3157510814859053,"score_spread":0.28517399734963483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392219630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9051187,0.009330511,0.00040091662,0.08339664,0.0010942632,0.00040910282,0.00023312889,0.000009615845,0.0000070957253],"genre_scores_gemma":[0.9928679,0.0047495216,0.0015013386,0.0006767574,0.00012944675,0.000034782654,0.000016116806,0.000011414421,0.000012757937],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99827766,0.00060614053,0.00068806624,0.00016443046,0.0001033926,0.00016028546],"domain_scores_gemma":[0.9944675,0.004291891,0.00097156916,0.00007762265,0.00017094625,0.00002045561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005975037,0.00014501553,0.00045809688,0.000100636906,0.00026091305,0.000015742433,0.00030344777,0.00018817426,0.000027860095],"category_scores_gemma":[0.0013170382,0.00007594626,0.00020566644,0.00020055752,0.00053164735,0.00007614848,0.00007070189,0.00024902215,7.205939e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017750859,0.00015555922,0.016502487,0.000112548485,0.0032727483,0.0000010658844,0.0035908783,0.0000060814746,0.0074547166,0.0063774055,0.019253436,0.941498],"study_design_scores_gemma":[0.024038808,0.0018030639,0.6257617,0.002550208,0.0043017934,0.0058156257,0.0143418405,0.0015855117,0.054003116,0.11662728,0.14818583,0.0009852464],"about_ca_topic_score_codex":0.00004030866,"about_ca_topic_score_gemma":0.00004173796,"teacher_disagreement_score":0.9405127,"about_ca_system_score_codex":0.00003229743,"about_ca_system_score_gemma":0.00015132621,"threshold_uncertainty_score":0.30969983},"labels":[],"label_agreement":null},{"id":"W4392453816","doi":"10.1016/j.jaad.2024.02.040","title":"Psoriasis and non-Hodgkin’s lymphoma in a diverse sample of U.S. adults: a propensity matched case-control study","year":2024,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Lymphoma; Hodgkin lymphoma; Scopus; Psoriasis; Internal medicine; Oncology; Dermatology; MEDLINE","score_opus":0.016808118772618064,"score_gpt":0.25925037272467427,"score_spread":0.2424422539520562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392453816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91971594,0.0028512632,0.0000069693892,0.07571532,0.0006184754,0.0006430286,0.00042960976,0.000008544996,0.000010837738],"genre_scores_gemma":[0.9813232,0.000415903,0.00013202529,0.01785811,0.00016113064,0.000019913341,0.000005351837,0.00003794287,0.000046466612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963279,0.0014232153,0.0013318893,0.000360625,0.00013134869,0.00042501636],"domain_scores_gemma":[0.9959309,0.0009906112,0.0026811692,0.00027060384,0.00009608741,0.00003061359],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038108244,0.00043066576,0.0025005685,0.0006055336,0.000076522694,0.000008761343,0.00064721785,0.00068205793,0.000035685713],"category_scores_gemma":[0.00016760602,0.0002808645,0.00045950603,0.00040689777,0.000871748,0.000081717306,0.00027097788,0.0013647586,0.000011374884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01176969,0.0020531828,0.5198248,0.0014137208,0.020159114,0.023184791,0.01171241,0.0000079006595,0.007220682,0.000014703631,0.33084336,0.07179566],"study_design_scores_gemma":[0.044293217,0.0041196337,0.6068869,0.002061595,0.0161636,0.23735255,0.013051248,0.000017428478,0.012530105,0.0006968281,0.06111941,0.0017074582],"about_ca_topic_score_codex":0.00087786186,"about_ca_topic_score_gemma":0.00006697709,"teacher_disagreement_score":0.26972395,"about_ca_system_score_codex":0.00008939795,"about_ca_system_score_gemma":0.0001839483,"threshold_uncertainty_score":0.99996436},"labels":[],"label_agreement":null},{"id":"W4392455278","doi":"10.1016/j.jaad.2024.02.042","title":"Use of biologic treatment in psoriasis patients with HIV: A systematic review","year":2024,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Human immunodeficiency virus (HIV); Dermatology; Biologic Agents; Intensive care medicine; MEDLINE; Immunology; Internal medicine; Disease","score_opus":0.04516504020753033,"score_gpt":0.31305596098121624,"score_spread":0.2678909207736859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392455278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005727116,0.99204296,8.480359e-7,0.00034937504,0.00026122917,0.0013963416,0.0002074569,0.0000074292034,0.000007247568],"genre_scores_gemma":[0.001777791,0.99772286,0.00007961395,0.00014193085,0.000014550196,0.00007976489,0.000025527133,0.00003538392,0.00012256516],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99446714,0.0023377077,0.0024945918,0.0002720005,0.00010342201,0.0003251447],"domain_scores_gemma":[0.9921425,0.0008521802,0.0065558394,0.00033849876,0.000078937264,0.000032060412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022884611,0.0005582971,0.0072929957,0.0005719461,0.000032595228,0.000004834087,0.00072879146,0.00036792515,0.000016431053],"category_scores_gemma":[0.00021154578,0.00023990637,0.0013238244,0.00083672785,0.00056466385,0.00006921659,0.00011486427,0.0005717316,0.000041903608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048207035,0.0014034334,0.008337537,0.83825904,0.020068048,0.00012436508,0.00021283067,0.0000013268672,0.000023718378,0.00011856504,0.004118794,0.12685025],"study_design_scores_gemma":[0.0019637214,0.0012646555,0.0009971746,0.70990974,0.061387032,0.006614026,0.00004949165,1.3870051e-7,0.0001448444,0.000025791005,0.21704823,0.0005951498],"about_ca_topic_score_codex":0.000024881336,"about_ca_topic_score_gemma":0.0000037080163,"teacher_disagreement_score":0.21292944,"about_ca_system_score_codex":0.00017811547,"about_ca_system_score_gemma":0.00028556204,"threshold_uncertainty_score":0.97830975},"labels":[],"label_agreement":null},{"id":"W4392551856","doi":"10.1111/jdv.19925","title":"Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (<scp>POETYK PSO</scp>‐1 and <scp>PSO</scp>‐2)","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Placebo; Tolerability; Adverse effect; Discontinuation; Internal medicine; Apremilast; Psoriasis; Incidence (geometry); Population; Gastroenterology; Dermatology; Psoriatic arthritis; Pathology","score_opus":0.02740083357130022,"score_gpt":0.29529768643913734,"score_spread":0.2678968528678371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392551856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95671433,0.03817935,0.00013681024,0.002642207,0.0010637715,0.00037115952,0.00021414013,0.000031929783,0.000646315],"genre_scores_gemma":[0.9941762,0.0041955137,0.00021129544,0.0007242218,0.00025340493,0.000006328398,0.000021220296,0.00004368605,0.000368094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912112,0.0056973584,0.0018160923,0.0006095057,0.00009268137,0.0005731725],"domain_scores_gemma":[0.99440783,0.004308775,0.0008299592,0.0002441436,0.000062935585,0.00014634425],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023108895,0.00048849225,0.0017942424,0.0004111278,0.0002510719,0.00003786211,0.00047904474,0.00065965136,0.000035733698],"category_scores_gemma":[0.0012718766,0.00034736042,0.0002859276,0.00025551885,0.0007160577,0.00023754658,0.0003758891,0.0012038641,0.000027603788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011136796,0.0019700667,0.49205506,0.0008681043,0.014200438,0.0024738526,0.019251062,0.00040437587,0.25084764,0.014017903,0.036529075,0.15624563],"study_design_scores_gemma":[0.07591724,0.0010497178,0.5371831,0.0015244047,0.0057555484,0.035402305,0.0020748607,0.00043415083,0.13037604,0.02837887,0.18109342,0.00081031903],"about_ca_topic_score_codex":0.00003269702,"about_ca_topic_score_gemma":0.000024388391,"teacher_disagreement_score":0.15543531,"about_ca_system_score_codex":0.00004290111,"about_ca_system_score_gemma":0.00011116675,"threshold_uncertainty_score":0.99989784},"labels":[],"label_agreement":null},{"id":"W4392644075","doi":"10.1038/s41366-024-01508-4","title":"Serum IL-36β levels are associated with Insulin sensitivity in paediatric patients with obesity","year":2024,"lang":"en","type":"article","venue":"International Journal of Obesity","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Irish Research eLibrary","keywords":"Medicine; Obesity; Cytokine; Context (archaeology); Insulin sensitivity; Inflammation; Insulin resistance; Disease; Internal medicine; Cohort; Insulin; Interleukin 6; Endocrinology; Systemic inflammation; Proinflammatory cytokine; Immunology; Biology","score_opus":0.01113349917554244,"score_gpt":0.22293351472533202,"score_spread":0.21180001554978958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392644075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971397,0.0006373434,0.00013816066,0.00023728296,0.0011792516,0.00011194103,0.00044590965,0.000027523198,0.00008291218],"genre_scores_gemma":[0.99943143,0.00005154595,0.00006635324,0.000056130113,0.000109341156,0.0000018377625,0.00006602307,0.000014298883,0.00020306541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879915,0.0002575928,0.0003313122,0.00020276131,0.00019797112,0.0002112006],"domain_scores_gemma":[0.99879056,0.00026245866,0.00031281397,0.00008974415,0.000510523,0.000033927554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050315575,0.00018794439,0.0003145607,0.00033678426,0.000060298815,0.00004283957,0.00018727871,0.00015881144,0.000099695535],"category_scores_gemma":[0.00011634371,0.00013141026,0.00010805363,0.00026007468,0.000062931016,0.00030239453,0.000054900476,0.0003766144,0.000058187055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004869621,0.0009323357,0.9897305,0.0000077744235,0.0010152723,0.00081646384,0.00022739466,0.00005783213,0.0003259654,0.000038483828,0.00021427177,0.0061467797],"study_design_scores_gemma":[0.002948616,0.00026341216,0.99368775,0.00027571112,0.00013426677,0.000119061144,0.000044435154,0.000009410321,0.0020273135,0.000108402965,0.00022901369,0.00015258885],"about_ca_topic_score_codex":0.0000365859,"about_ca_topic_score_gemma":0.00043693703,"teacher_disagreement_score":0.005994191,"about_ca_system_score_codex":0.00028312116,"about_ca_system_score_gemma":0.00016323976,"threshold_uncertainty_score":0.5358755},"labels":[],"label_agreement":null},{"id":"W4392885723","doi":"10.1002/ski2.359","title":"Clinical Course, Treatment and Management of Generalised Pustular Psoriasis from a United Kingdom Extension of a Global Delphi Panel","year":2024,"lang":"en","type":"article","venue":"Skin Health and Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Boehringer Ingelheim","keywords":"Delphi method; Delphi; Medicine; Psoriasis; Disease; Disease management; Family medicine; Dermatology; Pathology; Artificial intelligence; Computer science","score_opus":0.07689513207981939,"score_gpt":0.35394319526819734,"score_spread":0.27704806318837794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392885723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9165556,0.08062516,0.000037982507,0.00061500823,0.0005106218,0.00040510352,0.0011969802,0.000034805616,0.000018750261],"genre_scores_gemma":[0.9855948,0.012976276,0.00029528147,0.00022605686,0.00004988558,0.00003569055,0.0007515952,0.000010307803,0.00006011118],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985715,0.00027369548,0.00046086035,0.00040915498,0.000043867898,0.00024093405],"domain_scores_gemma":[0.99921006,0.00012622091,0.000114871604,0.0002577822,0.00003497362,0.00025611825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017451968,0.00018836734,0.0004067931,0.000059257403,0.00008785192,0.000009443048,0.000056030563,0.00011053771,0.00003764013],"category_scores_gemma":[0.000019068546,0.00014427565,0.00012864245,0.00018097127,0.00014983187,0.000033469307,0.000050919476,0.00004290968,0.000007633151],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007568879,0.002750218,0.32072634,0.0016921642,0.0039401003,0.00035814027,0.0007881819,0.000009952116,0.00035380156,0.011647536,0.0044470364,0.6457177],"study_design_scores_gemma":[0.011974083,0.0016313967,0.95789784,0.00094896456,0.0028672037,0.000017185872,0.0006359708,0.00020873346,0.00019171672,0.0020712083,0.021167323,0.00038834757],"about_ca_topic_score_codex":0.001417165,"about_ca_topic_score_gemma":0.0000356189,"teacher_disagreement_score":0.6453293,"about_ca_system_score_codex":0.000043498225,"about_ca_system_score_gemma":0.00022527885,"threshold_uncertainty_score":0.58833903},"labels":[],"label_agreement":null},{"id":"W4392926834","doi":"10.1007/s40257-024-00854-3","title":"Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada","year":2024,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal General Hospital; Memorial University of Newfoundland; Centre de Recherche Dermatologique du Québec Métropolitain; McGill University Health Centre; McGill University; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Incidence (geometry); Demography; Context (archaeology); Socioeconomic status; Environmental health; Gerontology; Population; Geography; Dermatology","score_opus":0.03423073616569131,"score_gpt":0.3359677600582995,"score_spread":0.30173702389260815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392926834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99078345,0.00229028,0.00026824736,0.003598179,0.002706211,0.00016972734,0.00013301289,0.000017462675,0.00003342697],"genre_scores_gemma":[0.9989357,0.00005004229,0.00009095037,0.0004206404,0.00014555134,0.000008827958,0.00006214183,0.000020210695,0.0002659618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99573725,0.0018943974,0.001611987,0.0003015257,0.0001808546,0.00027396012],"domain_scores_gemma":[0.9939848,0.004685447,0.0008161964,0.00025207712,0.0001676716,0.00009379249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063663203,0.0002182946,0.0010000531,0.00015717845,0.00013641601,0.000015433581,0.0004350895,0.000121533085,0.0005246266],"category_scores_gemma":[0.0009449497,0.00014317974,0.0003227511,0.00037085556,0.00035157506,0.00007095367,0.000109114466,0.00054674933,0.000043868466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010381031,0.00023850612,0.93073773,0.0000058599267,0.0016084904,0.0002829942,0.00043099816,0.00012914804,0.0005291853,0.000020164776,0.0035008562,0.061477978],"study_design_scores_gemma":[0.0017836405,0.0008662003,0.98480284,0.00006455991,0.0006922344,0.00019561822,0.00091134437,0.00006251427,0.0008918185,0.000029842662,0.009541556,0.00015784687],"about_ca_topic_score_codex":0.23286033,"about_ca_topic_score_gemma":0.639477,"teacher_disagreement_score":0.4066167,"about_ca_system_score_codex":0.00009323531,"about_ca_system_score_gemma":0.0012440482,"threshold_uncertainty_score":0.7722481},"labels":[],"label_agreement":null},{"id":"W4392926895","doi":"10.25251/skin.8.supp.366","title":"Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Particle swarm optimization; Phase (matter); Dermatology; Mathematics; Physics; Mathematical optimization","score_opus":0.02849553644203048,"score_gpt":0.301655482586512,"score_spread":0.2731599461444815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392926895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8950501,0.086507514,0.000044881348,0.01497755,0.0019891222,0.00040655799,0.000319852,0.000023647022,0.0006807839],"genre_scores_gemma":[0.97289145,0.025352119,0.00004413996,0.00027805433,0.0008023664,0.0000021690546,0.000054895994,0.000021789387,0.00055300194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967134,0.001467316,0.0011990019,0.00022829835,0.00011981493,0.0002721782],"domain_scores_gemma":[0.9888685,0.010327005,0.00041611496,0.00027105893,0.000062744766,0.00005460837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039096256,0.00025826754,0.0008153857,0.00015031357,0.00018034654,0.000025691143,0.00027551223,0.00020819964,0.00021626441],"category_scores_gemma":[0.0020500359,0.00011549633,0.00011301428,0.0002030617,0.00040512686,0.00006383422,0.000052523574,0.00055951,0.000025133197],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08996267,0.00058880355,0.0004083042,0.000070549235,0.005307163,0.0034291581,0.04356042,0.000030656996,0.074778534,0.0011499943,0.051168162,0.7295456],"study_design_scores_gemma":[0.16185194,0.010940854,0.0091052465,0.006753835,0.010919311,0.060424253,0.019031484,0.00007513928,0.026382208,0.008433201,0.6849084,0.0011741271],"about_ca_topic_score_codex":0.00019771502,"about_ca_topic_score_gemma":0.00011818077,"teacher_disagreement_score":0.72837144,"about_ca_system_score_codex":0.000040812203,"about_ca_system_score_gemma":0.00009412847,"threshold_uncertainty_score":0.47098038},"labels":[],"label_agreement":null},{"id":"W4392927062","doi":"10.25251/skin.8.supp.364","title":"Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Dermatology","score_opus":0.03951776206723881,"score_gpt":0.32725086810167403,"score_spread":0.28773310603443525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392927062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215634,0.06747816,0.000052558946,0.008279389,0.0014538149,0.00042005238,0.00002482645,0.000015277074,0.00071255665],"genre_scores_gemma":[0.9902506,0.008429262,0.000021850372,0.0003920304,0.00045414848,0.000008169615,0.00001456463,0.000019737954,0.0004096519],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99621093,0.0020468342,0.0010981277,0.00018318564,0.00013165933,0.00032928155],"domain_scores_gemma":[0.99465007,0.0047115167,0.00031428738,0.00023521688,0.000053651114,0.000035267043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049756435,0.00026033496,0.00083339284,0.0003510672,0.000113281465,0.000026884154,0.00036455557,0.00019572847,0.00022985319],"category_scores_gemma":[0.0007578882,0.00011614488,0.00013439155,0.00034339272,0.00025627165,0.00007753465,0.000028146671,0.0006587436,0.00002965545],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02908408,0.002181832,0.00036374343,0.00022547,0.003373427,0.014356547,0.07768668,0.0003039649,0.12912051,0.0027290983,0.034404073,0.70617056],"study_design_scores_gemma":[0.15982187,0.021719694,0.0042974423,0.010524471,0.011332063,0.3306966,0.036294334,0.000633708,0.07798438,0.024874575,0.3196969,0.002123933],"about_ca_topic_score_codex":0.00007817256,"about_ca_topic_score_gemma":0.00011725312,"teacher_disagreement_score":0.7040466,"about_ca_system_score_codex":0.00005095349,"about_ca_system_score_gemma":0.00011361688,"threshold_uncertainty_score":0.47362506},"labels":[],"label_agreement":null},{"id":"W4392928302","doi":"10.25251/skin.8.supp.361","title":"Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Pfizer Pharmaceuticals; Sanofi Genzyme; Regeneron Pharmaceuticals; Meiji Seika Pharma; Eli Lilly and Company; Bristol-Myers Squibb; LEO Pharma; Incyte; Amgen","keywords":"Placebo; Psoriasis; Dermatology Life Quality Index; Medicine; Generalized pustular psoriasis; Quality of life (healthcare); Placebo group; Index (typography); Physical therapy; Dermatology; Alternative medicine; Pathology","score_opus":0.03282687181193359,"score_gpt":0.25589317684163365,"score_spread":0.22306630502970007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392928302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584212,0.037054658,0.000030080248,0.0020932185,0.0017571285,0.00047319513,0.00007730797,0.0000109021985,0.00008231396],"genre_scores_gemma":[0.9969479,0.0022913155,0.0000111098825,0.00013640875,0.0004371744,0.0000050606745,0.000016174385,0.00001798182,0.00013688044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941201,0.0037811482,0.0014172645,0.00019079719,0.0002533152,0.00023736812],"domain_scores_gemma":[0.99227583,0.006297177,0.0008269866,0.00042592626,0.00013687444,0.000037171896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056044096,0.00024457154,0.0008153479,0.00013990901,0.00012732642,0.000010049525,0.0005097691,0.00021582087,0.000067899695],"category_scores_gemma":[0.0032292777,0.000100958845,0.00019706132,0.00034639865,0.0005475969,0.00004293547,0.00008151695,0.0004616589,0.0000020606055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5475665,0.0009170436,0.0350294,0.0003416088,0.011693173,0.00033032606,0.04091898,0.0008132154,0.29317915,0.0006566895,0.009940256,0.058613706],"study_design_scores_gemma":[0.62074953,0.012650407,0.17440186,0.016472766,0.012841817,0.004451707,0.020735499,0.000556871,0.11724167,0.0068686237,0.011374197,0.0016550272],"about_ca_topic_score_codex":0.0024781371,"about_ca_topic_score_gemma":0.0007700765,"teacher_disagreement_score":0.17593747,"about_ca_system_score_codex":0.000051937448,"about_ca_system_score_gemma":0.00014904566,"threshold_uncertainty_score":0.41169822},"labels":[],"label_agreement":null},{"id":"W4393064608","doi":"10.1016/j.jaad.2024.03.008","title":"Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis","year":2024,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Perioperative; Dermatology; Complication; Plaque psoriasis; Arthritis; Intensive care medicine; Surgery; Immunology","score_opus":0.03593636161910609,"score_gpt":0.3250930398090816,"score_spread":0.28915667818997554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393064608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16995546,0.8265921,0.0000058664195,0.0014083437,0.0011078999,0.00070652243,0.00018715452,0.000004332014,0.000032299755],"genre_scores_gemma":[0.15172796,0.847739,0.00013136562,0.00017303802,0.000089575,0.00003775876,0.000019659929,0.000031951517,0.00004970683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951992,0.0015678406,0.0022527955,0.00028918637,0.00045083175,0.00024012108],"domain_scores_gemma":[0.9950681,0.00052248815,0.0038569926,0.00026382023,0.00025724916,0.000031364012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005382671,0.00040730322,0.0022817687,0.000237704,0.000106872605,0.000010168153,0.0011317335,0.00034427101,0.000054287964],"category_scores_gemma":[0.00018652702,0.00018676482,0.00058902183,0.0006065594,0.0010970943,0.00007974455,0.0003497825,0.00075935636,0.00000875639],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011211226,0.0004809974,0.010392953,0.0038748598,0.018948885,0.000029078457,0.0011687089,0.000014744131,0.000031560012,0.0010415008,0.0039649117,0.9589307],"study_design_scores_gemma":[0.027833775,0.0020859712,0.18350326,0.1745123,0.039553694,0.012476706,0.0042446265,0.000025199288,0.00050458865,0.0011510507,0.5519388,0.0021700845],"about_ca_topic_score_codex":0.000039597984,"about_ca_topic_score_gemma":0.00000795545,"teacher_disagreement_score":0.9567606,"about_ca_system_score_codex":0.0001449286,"about_ca_system_score_gemma":0.00046512496,"threshold_uncertainty_score":0.76160485},"labels":[],"label_agreement":null},{"id":"W4393282627","doi":"10.1016/j.jaad.2024.03.025","title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sun Pharma; Amgen","keywords":"Medicine; Scalp; Placebo; Dermatology; Multicenter study; Psoriasis; Plaque psoriasis; Adverse effect; Double blind; Randomized controlled trial; Surgery; Internal medicine; Pathology","score_opus":0.025329845663090534,"score_gpt":0.3236869785360868,"score_spread":0.29835713287299626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98129725,0.00982185,0.00017180532,0.0043474655,0.0005293316,0.0036682305,0.00013627515,0.0000063630737,0.000021419186],"genre_scores_gemma":[0.9976175,0.0018726755,0.00012257398,0.00007685833,0.00004287307,0.00012867143,0.0000019774357,0.000021651547,0.00011523375],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99661964,0.0012229834,0.0015289016,0.00022659783,0.00012559809,0.00027626634],"domain_scores_gemma":[0.99349254,0.0041267197,0.0019424915,0.0002821011,0.000117636715,0.00003849579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005934703,0.00030704393,0.0023047,0.0002340526,0.00015143653,0.000007835965,0.00060250657,0.00016418277,0.00001827598],"category_scores_gemma":[0.00015855243,0.00013425687,0.0009346434,0.00030931144,0.0010266487,0.00006148525,0.000098117,0.00026070213,0.0000016363177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9540686,0.0021853724,0.0007640161,0.000068314876,0.010667621,0.0000046151017,0.0035312911,0.00028459128,0.011249644,0.00020248718,0.00028377198,0.01668965],"study_design_scores_gemma":[0.88879204,0.0019379713,0.00097322365,0.00019846798,0.0068915035,0.000783087,0.0015186733,0.000214506,0.09704224,0.00009091488,0.001396334,0.00016104525],"about_ca_topic_score_codex":0.00007528582,"about_ca_topic_score_gemma":0.000011264267,"teacher_disagreement_score":0.08579259,"about_ca_system_score_codex":0.000051725467,"about_ca_system_score_gemma":0.00015623031,"threshold_uncertainty_score":0.5474836},"labels":[],"label_agreement":null},{"id":"W4393321344","doi":"10.1016/j.jaad.2024.03.030","title":"Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); SKiN Health; Surrey Memorial Hospital; Trent University; Western University; Probity Medical Research","funders":"","keywords":"Medicine; Open label; Psoriasis; Plaque psoriasis; Dermatology; Adverse effect; Term (time); Safety profile; Roflumilast; Clinical trial; Internal medicine; Pulmonary disease","score_opus":0.01780337476514756,"score_gpt":0.3083348050804826,"score_spread":0.29053143031533507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393321344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503524,0.012714222,0.00006222105,0.0009961141,0.000444355,0.00062899856,0.00006137702,0.000008870633,0.000048608348],"genre_scores_gemma":[0.99711704,0.0026422327,0.00005595241,0.000049240938,0.00005731167,0.000021888032,0.0000066397074,0.000022628297,0.000027082586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997198,0.0012715629,0.000869977,0.00026648902,0.000079949124,0.00031401176],"domain_scores_gemma":[0.9977772,0.0009370942,0.0010367302,0.0001588561,0.000048517628,0.00004158041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005009139,0.00025833448,0.0013081682,0.00031875964,0.00006819362,0.000011918331,0.00063281937,0.00022228547,0.000022840666],"category_scores_gemma":[0.00006773626,0.00016085146,0.00014166748,0.00046120767,0.0009120311,0.00019752752,0.00018298755,0.0006011375,0.000004749587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70522004,0.007394296,0.054349866,0.0016175925,0.0060388194,0.00049230806,0.0013905441,0.000027505186,0.13161832,0.0010943615,0.0005224438,0.09023391],"study_design_scores_gemma":[0.40911922,0.022863343,0.25637624,0.0072882283,0.0022121083,0.020736668,0.0004110548,0.00002720486,0.27792004,0.0002915826,0.0020335417,0.0007207847],"about_ca_topic_score_codex":0.00006594398,"about_ca_topic_score_gemma":0.000028860899,"teacher_disagreement_score":0.29610083,"about_ca_system_score_codex":0.000097139666,"about_ca_system_score_gemma":0.00033285917,"threshold_uncertainty_score":0.6559332},"labels":[],"label_agreement":null},{"id":"W4393408471","doi":"10.1016/j.jdcr.2024.03.015","title":"Anti-TNF alpha-induced paradoxical psoriasis treated with topical roflumilast 0.3%","year":2024,"lang":"en","type":"article","venue":"JAAD Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Cégep de Rivière-du-Loup","funders":"","keywords":"Medicine; Roflumilast; Psoriasis; Tumor necrosis factor alpha; Dermatology; Adalimumab; Alpha (finance); Infliximab; Immunology; Internal medicine; Surgery","score_opus":0.019473412436894842,"score_gpt":0.25529883654510976,"score_spread":0.23582542410821491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393408471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916495,0.0037059211,0.00004294162,0.00020853958,0.001561137,0.000308507,0.000029607314,0.00039825297,0.00209557],"genre_scores_gemma":[0.99590665,0.00007539059,0.00006502254,0.00004925544,0.00020797407,0.0000850568,0.00016674344,0.000041536674,0.0034023675],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980852,0.00015189014,0.00046732553,0.0007322593,0.00007851018,0.0004847941],"domain_scores_gemma":[0.9990972,0.0001430425,0.0000973253,0.00053317286,0.00004846911,0.00008078481],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002000783,0.00035027417,0.0004946554,0.0001482824,0.00020917154,0.000060430797,0.000055996807,0.0004126993,0.0007113599],"category_scores_gemma":[0.000034691377,0.0002465086,0.00021383211,0.0002772955,0.000099910285,0.00012145386,0.000044497385,0.0002632953,0.0004196939],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032208077,0.0005521885,0.01980909,0.00007974255,0.001990598,0.73888016,0.00040830867,0.000002758071,0.074297525,0.00040555405,0.005635787,0.1576162],"study_design_scores_gemma":[0.0017223648,0.0009801496,0.019278351,0.00017187478,0.0013161042,0.57638294,0.00020655418,0.000013730656,0.30713043,0.000098467804,0.09189865,0.0008003832],"about_ca_topic_score_codex":0.00025913824,"about_ca_topic_score_gemma":0.00006526613,"teacher_disagreement_score":0.23283291,"about_ca_system_score_codex":0.000073906485,"about_ca_system_score_gemma":0.00012838628,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4393544960","doi":"10.5281/zenodo.3782581","title":"Psoriasis is associated with elevated gut IL-1α and intestinal microbiome alterations","year":2020,"lang":"en","type":"dataset","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg","funders":"","keywords":"Gut microbiome; Psoriasis; Microbiome; Intestinal Microbiome; Biology; Microbiology; Immunology; Genetics","score_opus":0.03148261132962222,"score_gpt":0.24277689719383316,"score_spread":0.21129428586421095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393544960","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027736335,0.0010022125,1.3736815e-7,0.00013485641,0.00019604403,0.0004169264,0.99781847,0.00011733713,0.000036649835],"genre_scores_gemma":[0.00034524174,0.00005556362,0.000019240048,0.00048626558,0.000101876525,0.0002631685,0.9978329,0.000038937247,0.0008568162],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983364,0.00018995031,0.00033178963,0.00066359126,0.000055578887,0.00042271204],"domain_scores_gemma":[0.99871606,0.0003019886,0.0003367424,0.000394633,0.000185572,0.00006498777],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003900767,0.00054310175,0.00060841185,0.00017802118,0.00029654475,0.00008517924,0.00033454676,0.00072953495,0.0976471],"category_scores_gemma":[0.00065081066,0.00045930987,0.00011770051,0.0003545991,0.000040770323,0.00008836118,0.0001820499,0.00047596227,0.011526662],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009062129,0.00011009906,0.0000072316952,0.00010340124,0.0010572647,0.00009311578,0.00006838444,1.3499152e-7,0.0029326056,2.784991e-7,0.99498224,0.00055463426],"study_design_scores_gemma":[0.0015366058,0.00036120383,0.00046263676,0.0014910372,0.00055768905,0.00014406607,0.000016331755,7.075738e-7,0.0044698897,0.000002599731,0.99043864,0.00051857054],"about_ca_topic_score_codex":0.000042459233,"about_ca_topic_score_gemma":0.00012400758,"teacher_disagreement_score":0.086120434,"about_ca_system_score_codex":0.000072792885,"about_ca_system_score_gemma":0.00018735895,"threshold_uncertainty_score":0.99978584},"labels":[],"label_agreement":null},{"id":"W4393698749","doi":"10.5281/zenodo.3782580","title":"Psoriasis is associated with elevated gut IL-1α and intestinal microbiome alterations","year":2020,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg","funders":"","keywords":"Psoriasis; Microbiome; Gut microbiome; Intestinal Microbiome; Immunology; Biology; Genetics","score_opus":0.029516716455636065,"score_gpt":0.23299163892011593,"score_spread":0.20347492246447987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393698749","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032884711,0.00026724814,0.000048391772,0.00049105764,0.00019699708,0.0005163485,0.99405193,0.0004358085,0.0007037261],"genre_scores_gemma":[0.0043849666,0.00031577097,0.000044688783,0.00025717815,0.000084765576,2.4438125e-7,0.9933067,0.0006298097,0.00097590714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781305,0.00061395107,0.00033735277,0.00068820507,0.00010400429,0.00044343452],"domain_scores_gemma":[0.998642,0.000075576594,0.0002595594,0.00045946433,0.00046482834,0.000098541976],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00027575635,0.00036716493,0.00040253287,0.0003116172,0.001968633,0.00041911253,0.000717259,0.00032420474,0.01199077],"category_scores_gemma":[0.0005683599,0.00034050675,0.000070937196,0.0006062872,0.00029953613,0.0001302536,0.0007161945,0.00051056925,0.014716934],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019729813,0.00019129885,0.0000012333936,0.0000497162,0.0007041083,0.000042236912,0.000286991,5.5506877e-7,0.018698605,0.000022452954,0.9730748,0.006730695],"study_design_scores_gemma":[0.0015716112,0.00068963616,0.00017964758,0.00011183192,0.00034905146,0.00034223392,0.00007419117,0.000002627829,0.0020255076,0.000010250722,0.99428934,0.00035407385],"about_ca_topic_score_codex":0.000043487194,"about_ca_topic_score_gemma":0.000003579568,"teacher_disagreement_score":0.021214526,"about_ca_system_score_codex":0.0001349721,"about_ca_system_score_gemma":0.000015087796,"threshold_uncertainty_score":0.9999047},"labels":[],"label_agreement":null},{"id":"W4394064121","doi":"10.1016/j.jdin.2023.12.014","title":"Association between the disease severity and quality of life of patients with psoriasis in a tertiary government hospital in the Philippines: A retrospective cross-sectional study","year":2024,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Cross-sectional study; Psoriasis; Medicine; Association (psychology); Retrospective cohort study; Government (linguistics); Disease; Tertiary care; Family medicine; Internal medicine; Psychology; Dermatology; Pathology","score_opus":0.012173049817423941,"score_gpt":0.26624728184013063,"score_spread":0.2540742320227067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394064121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767125,0.00017936669,0.0000049020578,0.00031326734,0.0003784044,0.000387259,0.00097273773,0.0000060780985,0.00008673457],"genre_scores_gemma":[0.99962014,0.000011711659,0.0000032865466,0.000020324633,0.000049458886,0.00006816418,0.00011030638,0.0000043279165,0.00011228228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988939,0.00025816288,0.0003392145,0.00019301866,0.00022900595,0.000086695996],"domain_scores_gemma":[0.9992718,0.00037966683,0.00015849658,0.00010209555,0.0000793811,0.000008567297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006369154,0.00009182729,0.00014726323,0.00004796854,0.000040902014,0.000020597712,0.000144467,0.00005761939,0.00006129534],"category_scores_gemma":[0.00025971435,0.00005348111,0.000053535943,0.00011604063,0.00006641811,0.000109827,0.00004998563,0.00012514078,0.000002523996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003936499,0.000731939,0.9960531,0.000011483668,0.000653533,9.2691084e-7,0.0015038986,0.0000020752673,0.000016829235,0.00015939293,0.0000321843,0.00044099387],"study_design_scores_gemma":[0.001776125,0.00013467453,0.9974437,0.000017905171,0.00005120664,1.211356e-7,0.00027701524,0.000004086776,0.00003050371,0.00016562214,0.000041988722,0.00005710018],"about_ca_topic_score_codex":0.0002444378,"about_ca_topic_score_gemma":0.00017716798,"teacher_disagreement_score":0.0019488875,"about_ca_system_score_codex":0.00022905982,"about_ca_system_score_gemma":0.00004008954,"threshold_uncertainty_score":0.21808964},"labels":[],"label_agreement":null},{"id":"W4394124706","doi":"10.6084/m9.figshare.20430464","title":"Additional file 1 of Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Psoriasis; Human skin; Medicine; Dermatology; Biology; Genetics","score_opus":0.025548966975111626,"score_gpt":0.2449501931510394,"score_spread":0.21940122617592778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394124706","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021417665,0.00012597335,7.836409e-9,0.0000075764137,0.00029365075,0.00029128537,0.9970999,0.000010185586,0.00002967707],"genre_scores_gemma":[0.0015480847,0.000007333111,0.000013872525,0.000027909491,0.00009341417,0.0007101765,0.99711627,0.000013837811,0.00046909138],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985044,0.00039482952,0.00046667148,0.00034006048,0.00009456859,0.0001994489],"domain_scores_gemma":[0.99745584,0.0015437019,0.0005143476,0.000405912,0.00006106868,0.000019146066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002510512,0.0002578169,0.00043249916,0.000117432064,0.00015931572,0.0000083169825,0.0005345714,0.00048096967,0.99619925],"category_scores_gemma":[0.00043268825,0.00021456929,0.00023815047,0.00019447583,0.000051059513,0.000036792,0.00023434435,0.00037196296,0.0007471317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007353888,0.00023185503,9.256178e-7,0.000064905485,0.00013601522,0.000012025318,0.000047742145,0.0000016997119,0.0056339884,3.4663535e-7,0.99354935,0.0002476034],"study_design_scores_gemma":[0.000496094,0.00015123481,0.0066105756,0.0007098709,0.00009511648,0.0000062447125,0.000096769996,2.2233189e-7,0.022892922,0.0000149207835,0.96873295,0.0001930589],"about_ca_topic_score_codex":0.00020389962,"about_ca_topic_score_gemma":0.0009779799,"teacher_disagreement_score":0.9954521,"about_ca_system_score_codex":0.00006113584,"about_ca_system_score_gemma":0.0003061449,"threshold_uncertainty_score":0.9603116},"labels":[],"label_agreement":null},{"id":"W4394133670","doi":"10.6084/m9.figshare.19374860","title":"Supplementary Material for: Psoriasis and Dry Eye Disease: A Systematic Review and Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Psoriasis; Disease; Medicine; Dermatology; Internal medicine","score_opus":0.09753470224149803,"score_gpt":0.3266648643490312,"score_spread":0.22913016210753318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394133670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.1397112e-8,0.5077768,5.1434135e-8,0.000016433794,0.00005250188,0.00229253,0.4898374,0.000018139654,0.000006094827],"genre_scores_gemma":[2.1882973e-7,0.52785,0.000009894039,0.000085992055,0.000017573626,0.011730019,0.45898747,0.000028773786,0.0012900968],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971247,0.0008985422,0.0008463606,0.0007271413,0.000064653206,0.00033861044],"domain_scores_gemma":[0.9980271,0.0005941549,0.00062612933,0.00065097515,0.000034891345,0.00006677128],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023286535,0.00065219076,0.0063388604,0.00025007018,0.0002845624,0.00005038958,0.00031760178,0.00022570892,0.61714023],"category_scores_gemma":[0.00027297012,0.00044964414,0.0024560622,0.00031527647,0.000015125935,0.00005237532,0.00032267722,0.00014206699,0.00014364086],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009011083,0.000029686682,5.4376926e-7,0.7680779,0.20497742,0.000010194665,0.00001068468,7.756338e-9,3.3588872e-8,0.0000027621804,0.023035258,0.0038464856],"study_design_scores_gemma":[0.00010983698,0.000022636366,7.254852e-7,0.011809462,0.48330268,0.0000030796039,0.000004063446,2.109912e-8,3.2258595e-7,0.0000015172591,0.5045299,0.00021574747],"about_ca_topic_score_codex":0.000009063177,"about_ca_topic_score_gemma":0.000012444166,"teacher_disagreement_score":0.75626844,"about_ca_system_score_codex":0.00005805899,"about_ca_system_score_gemma":0.00008837177,"threshold_uncertainty_score":0.99979556},"labels":[],"label_agreement":null},{"id":"W4394225431","doi":"10.6084/m9.figshare.20430482","title":"Additional file 7 of Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Psoriasis; Medicine; Human skin; Administration (probate law); Immunology; Biology; Genetics; Political science","score_opus":0.025188782288911214,"score_gpt":0.24479286729549804,"score_spread":0.21960408500658682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394225431","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021563799,0.00012698396,7.912927e-9,0.000007570943,0.0002938775,0.0002914408,0.99708384,0.000010187818,0.000029723304],"genre_scores_gemma":[0.0015810897,0.000007443388,0.000013725862,0.000027928161,0.00009353449,0.0006969173,0.9971002,0.000013834131,0.00046536],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985042,0.000394648,0.00046701933,0.0003400278,0.0000945877,0.00019948557],"domain_scores_gemma":[0.9974691,0.0015307957,0.0005144684,0.0004054894,0.00006096805,0.00001914916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000025124975,0.00025784128,0.0004327126,0.00011744993,0.00015938832,0.000008337921,0.0005344911,0.0004809801,0.99599236],"category_scores_gemma":[0.00042425017,0.00021457986,0.00023817157,0.00019444495,0.000051079063,0.00003682811,0.00023429727,0.00037195213,0.00073700596],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007358597,0.00023192287,9.251033e-7,0.00006603365,0.0001359517,0.000012204988,0.000047834965,0.0000017003125,0.005619238,3.5582414e-7,0.99355763,0.00025259025],"study_design_scores_gemma":[0.0005008253,0.00015188946,0.006582353,0.00071765983,0.00009509043,0.0000062547833,0.000096674776,2.234869e-7,0.023180494,0.000015110961,0.9684601,0.00019332778],"about_ca_topic_score_codex":0.00020623008,"about_ca_topic_score_gemma":0.0009918492,"teacher_disagreement_score":0.99525535,"about_ca_system_score_codex":0.000061164064,"about_ca_system_score_gemma":0.0003056359,"threshold_uncertainty_score":0.9472966},"labels":[],"label_agreement":null},{"id":"W4394520922","doi":"10.6084/m9.figshare.21970847","title":"Datasets for \"A Partitioned 88-Loci Psoriasis Genetic Risk Score Reveals HLA and Non-HLA Contributions to Clinical Phenotypes in a Newfoundland Psoriasis Cohort\"","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Cohort; Human leukocyte antigen; Phenotype; Genetics; Medicine; Biology; Immunology; Gene; Internal medicine; Antigen","score_opus":0.044004253596410955,"score_gpt":0.33241353456930633,"score_spread":0.28840928097289537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394520922","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034628338,0.0022356438,0.0000046343866,0.00011365877,0.0012289246,0.0027046662,0.9901541,0.00008862647,0.0000069319562],"genre_scores_gemma":[0.0004198417,0.0013510054,0.00011788594,0.00020379045,0.0006746299,0.003955968,0.9929032,0.000064327876,0.00030937014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603605,0.00060634676,0.0011335439,0.0012663658,0.0001076494,0.00085004297],"domain_scores_gemma":[0.9958043,0.0021608535,0.00056167645,0.0010616272,0.00023529977,0.00017626109],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00054263236,0.00066618837,0.001330108,0.00038527552,0.0004692662,0.0001002724,0.00056615344,0.0014255258,0.0073382463],"category_scores_gemma":[0.005879671,0.0006351091,0.00032594733,0.00046635786,0.000060617378,0.00010004213,0.00037912972,0.000578045,0.012139679],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004637831,0.00022350987,0.0049184733,0.0002320469,0.0009761465,0.000045941415,0.000028593999,0.00000618673,0.000014260869,9.174602e-7,0.98941857,0.003671546],"study_design_scores_gemma":[0.0040713586,0.00038815665,0.13442576,0.0010585507,0.0010981733,0.000016800934,0.000018228699,0.0000022891784,0.000026580248,0.00008655873,0.85819405,0.000613465],"about_ca_topic_score_codex":0.0011898562,"about_ca_topic_score_gemma":0.010840165,"teacher_disagreement_score":0.13122451,"about_ca_system_score_codex":0.0001725105,"about_ca_system_score_gemma":0.0002578633,"threshold_uncertainty_score":0.99987084},"labels":[],"label_agreement":null},{"id":"W4394529982","doi":"10.6084/m9.figshare.20430479","title":"Additional file 6 of Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Psoriasis; Medicine; Human skin; Administration (probate law); Immunology; Biology; Political science; Genetics","score_opus":0.025158345614139172,"score_gpt":0.24471867671739936,"score_spread":0.21956033110326018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394529982","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021434168,0.00012726455,7.920608e-9,0.0000075746175,0.00029385823,0.00029186154,0.99709576,0.000010186718,0.00003008202],"genre_scores_gemma":[0.0015876262,0.000007419853,0.000013724747,0.000027927488,0.00009352762,0.00069829565,0.99708956,0.000013832645,0.0004680678],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850416,0.00039475257,0.00046702145,0.0003399996,0.000094586845,0.00019947044],"domain_scores_gemma":[0.99746794,0.001531996,0.0005144973,0.00040547768,0.000060971928,0.000019148354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000025126277,0.00025782658,0.00043270335,0.00011744005,0.0001593588,0.000008337666,0.0005344796,0.00048096874,0.9960144],"category_scores_gemma":[0.0004284968,0.00021456913,0.00023816725,0.0001944538,0.000051074778,0.000036826827,0.00023429016,0.00037194844,0.0007370725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007394266,0.00023296072,9.237379e-7,0.000065496075,0.0001359494,0.0000121995645,0.000047910744,0.0000016752647,0.0055981916,3.596472e-7,0.99357927,0.0002511094],"study_design_scores_gemma":[0.0005009222,0.00015161067,0.0066650333,0.00071053643,0.00009506144,0.000006249581,0.00009685148,2.2074352e-7,0.022931574,0.000015112207,0.9686336,0.0001932624],"about_ca_topic_score_codex":0.00020812324,"about_ca_topic_score_gemma":0.001007724,"teacher_disagreement_score":0.99527735,"about_ca_system_score_codex":0.00006107985,"about_ca_system_score_gemma":0.00030559135,"threshold_uncertainty_score":0.94738215},"labels":[],"label_agreement":null},{"id":"W4394748593","doi":"10.1093/bjd/ljae069","title":"Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada; Newcastle upon Tyne Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Psoriasis Association; American Institute of Mathematics","keywords":"Methotrexate; Psoriasis; Medicine; Cumulative dose; Fibrosis; Internal medicine; Dermatology; Liver fibrosis; Gastroenterology","score_opus":0.015903414195897782,"score_gpt":0.22267481643709014,"score_spread":0.20677140224119236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394748593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020624,0.008342407,0.00008625172,0.0001353096,0.00047448298,0.00021041889,0.00017347024,0.000020174202,0.00035123416],"genre_scores_gemma":[0.99827003,0.00023088994,0.0003935691,0.00015421008,0.000012497682,0.000010822873,0.00004356935,0.000027982182,0.0008564245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982,0.00050591835,0.0005890499,0.00026797605,0.0001052543,0.00033179225],"domain_scores_gemma":[0.9988197,0.0003270784,0.00035549552,0.00012128944,0.00032570865,0.000050746396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016331542,0.00022220485,0.00076231273,0.00038457045,0.000047803092,0.000016524758,0.00017796183,0.0002789987,0.00028250433],"category_scores_gemma":[0.00008379233,0.00019319437,0.00013672744,0.00028954333,0.00015147273,0.0002338669,0.000037579364,0.00033398368,0.000029592216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056181222,0.0063066455,0.4775055,0.0007126938,0.023703076,0.023485448,0.030521138,0.00057898497,0.009136838,0.00042046636,0.09112843,0.28031954],"study_design_scores_gemma":[0.03084509,0.0027916871,0.91524583,0.0036360417,0.0019173626,0.01284004,0.00026866986,0.000081208986,0.022759797,0.00012379949,0.008452141,0.0010383306],"about_ca_topic_score_codex":0.0001952272,"about_ca_topic_score_gemma":0.0002220346,"teacher_disagreement_score":0.43774033,"about_ca_system_score_codex":0.00028121198,"about_ca_system_score_gemma":0.0003360806,"threshold_uncertainty_score":0.7878238},"labels":[],"label_agreement":null},{"id":"W4394808579","doi":"10.1111/jdv.19978","title":"Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients","year":2024,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Centre for Addiction and Mental Health; Women's College Hospital; University of Toronto; McGill University Health Centre","funders":"","keywords":"Context (archaeology); Excellence; Library science; Medicine; Center of excellence; Gerontology; Family medicine; History; Political science; Archaeology","score_opus":0.02479109202086943,"score_gpt":0.24426489398196366,"score_spread":0.21947380196109423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394808579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94495815,0.022730883,8.5802395e-7,0.03153133,0.00036079763,0.00029143496,0.00005093929,0.0000023175157,0.00007329254],"genre_scores_gemma":[0.98579305,0.009596278,0.000023463457,0.0044046585,0.00007910941,0.0000048708985,0.00002487866,0.000015566337,0.000058113812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946754,0.0037400147,0.0010373215,0.0002597009,0.000043074248,0.00024449712],"domain_scores_gemma":[0.99794006,0.0008908854,0.0009900883,0.00013538024,0.000029608416,0.000013977512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005022535,0.00030150363,0.0010652982,0.0003628881,0.00004685556,0.0000036897643,0.00033491294,0.0007740045,0.000012609672],"category_scores_gemma":[0.00005874499,0.00015607642,0.00017085961,0.00013085194,0.001136539,0.000029231438,0.00010655042,0.00078516896,0.0000019904512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012182757,0.00048668683,0.94888794,0.00029646236,0.001502117,0.0003828216,0.004663978,0.0000039511483,0.010397594,0.0003463533,0.009262143,0.022551663],"study_design_scores_gemma":[0.008086951,0.0007534555,0.9237081,0.0004686199,0.0007517606,0.0029557992,0.00036468904,0.0000020872835,0.01759052,0.0023055393,0.042678617,0.00033389978],"about_ca_topic_score_codex":0.000020809684,"about_ca_topic_score_gemma":0.000026658021,"teacher_disagreement_score":0.04083492,"about_ca_system_score_codex":0.000022430357,"about_ca_system_score_gemma":0.000028275344,"threshold_uncertainty_score":0.63646114},"labels":[],"label_agreement":null},{"id":"W4394990011","doi":"10.1016/j.jaad.2024.04.027","title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study","year":2024,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Dermatrials Research; SKiN Health; University of Calgary; Women's College Hospital; McMaster University; University of Toronto","funders":"Women's College Hospital","keywords":"Medicine; Multicenter study; Plaque psoriasis; Retrospective cohort study; Psoriasis; Dermatology; Surgery","score_opus":0.014456860253421104,"score_gpt":0.2766678771711971,"score_spread":0.26221101691777604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394990011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9258874,0.0006491931,0.000015563011,0.07047189,0.0012997951,0.0011303277,0.00043996863,0.00001858949,0.000087289736],"genre_scores_gemma":[0.9798061,0.00024327617,0.00025665702,0.018591987,0.00028691287,0.00009544338,0.000033088927,0.00007764294,0.00060884183],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9966551,0.00074541493,0.0014124424,0.00044501113,0.00023247604,0.00050956337],"domain_scores_gemma":[0.9943426,0.0004922587,0.004292998,0.00033732268,0.00050177507,0.000033008608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013797446,0.0005170758,0.002079645,0.00062445196,0.00010999868,0.000010038746,0.001051941,0.00047169658,0.000036504753],"category_scores_gemma":[0.00013912361,0.00030963804,0.00063121377,0.00052106654,0.0010677831,0.0001093729,0.00016686197,0.0017026012,0.000010812699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0113809975,0.002429489,0.340155,0.00044964816,0.014531441,0.00016896981,0.006077507,0.0000028135569,0.0013919588,0.0000838586,0.62046105,0.0028672607],"study_design_scores_gemma":[0.0481385,0.016064025,0.58312905,0.0034469503,0.020082735,0.0032938796,0.009750954,0.000006333775,0.0669045,0.00088409765,0.24569583,0.002603158],"about_ca_topic_score_codex":0.00017620294,"about_ca_topic_score_gemma":0.000033750708,"teacher_disagreement_score":0.37476522,"about_ca_system_score_codex":0.00021424037,"about_ca_system_score_gemma":0.00018135022,"threshold_uncertainty_score":0.99993557},"labels":[],"label_agreement":null},{"id":"W4394999927","doi":"10.1007/s13555-024-01147-7","title":"Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Quality of life (healthcare); Psoriasis; Scalp; Dermatology; Physical therapy; Psoriatic arthritis; Nursing","score_opus":0.02612450247803453,"score_gpt":0.28405261176407526,"score_spread":0.2579281092860407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394999927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049914,0.008660461,0.000007203694,0.00009283561,0.0001761516,0.0003818517,0.00012794012,0.000025211622,0.00002921457],"genre_scores_gemma":[0.99818057,0.0015049464,0.000030782976,0.000116464435,0.0000022833485,0.000020532469,0.00010541026,0.000013840317,0.000025180878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983147,0.00038367455,0.00070225523,0.00034353216,0.00004349221,0.00021235266],"domain_scores_gemma":[0.9992068,0.00030258406,0.00023828463,0.00016708621,0.000055949542,0.000029338711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014107242,0.000193001,0.00069002167,0.00008291717,0.000054143315,0.000007726555,0.000058019228,0.00025710888,0.000016824088],"category_scores_gemma":[0.000036066445,0.00014325576,0.000056934976,0.00012579537,0.0006887666,0.000108192515,0.000045409848,0.00013345639,0.0000012564849],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019974294,0.00037037308,0.94978124,0.0000581948,0.0009618988,0.000014905163,0.00077412615,7.484621e-8,0.0006286322,0.00014945587,0.00008345371,0.045180194],"study_design_scores_gemma":[0.009097947,0.00044592124,0.98784506,0.000038869526,0.00006160502,0.000006007892,0.00022291008,0.0000028931095,0.0015907845,0.00017544597,0.0003719331,0.00014062854],"about_ca_topic_score_codex":0.0004227735,"about_ca_topic_score_gemma":0.00005079075,"teacher_disagreement_score":0.045039564,"about_ca_system_score_codex":0.0000054335965,"about_ca_system_score_gemma":0.000027792514,"threshold_uncertainty_score":0.58418006},"labels":[],"label_agreement":null},{"id":"W4395071654","doi":"10.1001/jamadermatol.2024.0594","title":"Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders","year":2024,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Alberta Children's Hospital; Hospital for Sick Children","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Mental health; Psychiatry; MEDLINE","score_opus":0.005849112952734974,"score_gpt":0.256111285155037,"score_spread":0.250262172202302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395071654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8897897,0.10754346,0.00019506864,0.0012697696,0.00061477255,0.00021096916,0.00009422972,0.00006649864,0.00021552137],"genre_scores_gemma":[0.99065876,0.008784289,0.000024804203,0.000027687069,0.000037365175,0.000014049358,0.0003325173,0.000012969316,0.00010757887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991214,0.00017231332,0.00024303525,0.00019989556,0.000019267294,0.00024407374],"domain_scores_gemma":[0.99967605,0.000103833794,0.000078067766,0.000107612344,0.000012063642,0.000022371229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006794256,0.00013661268,0.0002666444,0.00019904623,0.000090234455,0.000012267887,0.00006523953,0.00017972055,0.0002072463],"category_scores_gemma":[0.000011840471,0.000109483226,0.00009240971,0.00018245212,0.00008525108,0.000096881435,0.00003512817,0.00009460688,0.000103140155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032325267,0.00056603743,0.41035512,0.0019807217,0.0019370351,0.000032154476,0.005822998,0.00004037232,0.013469278,0.0074675907,0.08797839,0.47002703],"study_design_scores_gemma":[0.013247003,0.0025199607,0.8983107,0.0003000495,0.0006399716,0.0044130003,0.00063961203,0.0014529815,0.015207384,0.0021882325,0.05986627,0.0012148346],"about_ca_topic_score_codex":0.00013917964,"about_ca_topic_score_gemma":0.00011257754,"teacher_disagreement_score":0.48795557,"about_ca_system_score_codex":0.00008020465,"about_ca_system_score_gemma":0.000222287,"threshold_uncertainty_score":0.44645965},"labels":[],"label_agreement":null},{"id":"W4395084838","doi":"10.1093/rheumatology/keae163.293","title":"E066 Baseline characteristics of patients initiating ixekizumab, secukinumab or a tumour necrosis factor inhibitor by country in the 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment - PRO-SPIRIT","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Medac; Celgene; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Biogen; GlaxoSmithKline","keywords":"Secukinumab; Medicine; Ixekizumab; Psoriatic arthritis; Observational study; Internal medicine; Arthritis; Persistence (discontinuity); Dermatology; Oncology; Physical therapy","score_opus":0.0429452569140167,"score_gpt":0.26130575234286313,"score_spread":0.21836049542884645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395084838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927424,0.001353102,0.0000050431513,0.000050150964,0.00040338247,0.0013164664,0.004076538,0.000021329872,0.000031586824],"genre_scores_gemma":[0.99848294,0.0001421123,0.000052403375,0.00002002663,0.000042800766,0.00027279076,0.0008360196,0.00002062535,0.00013026119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981899,0.00032401312,0.0007578924,0.0003447743,0.00014224315,0.00024117345],"domain_scores_gemma":[0.99873245,0.00046650457,0.00034268745,0.00024111752,0.00020065701,0.00001656771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023072095,0.0002594714,0.000579038,0.000111347144,0.0000879157,0.000020526053,0.00018854551,0.00014080555,0.00009920547],"category_scores_gemma":[0.00019669611,0.00017612151,0.000113218135,0.00037997318,0.00009630527,0.00014553395,0.000044883887,0.00013856216,0.0000065837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031600078,0.012779264,0.8328785,0.00053395,0.0018884303,0.000055592995,0.06111405,0.000006146362,0.025169542,0.00012976675,0.00048909953,0.061795667],"study_design_scores_gemma":[0.009459824,0.008002349,0.9594324,0.0006098078,0.0005047739,0.000009860733,0.005273834,0.000071393704,0.015428174,0.0000342872,0.00083745416,0.00033579234],"about_ca_topic_score_codex":0.00039378883,"about_ca_topic_score_gemma":0.0003783334,"teacher_disagreement_score":0.12655397,"about_ca_system_score_codex":0.00016830432,"about_ca_system_score_gemma":0.0002005391,"threshold_uncertainty_score":0.71820265},"labels":[],"label_agreement":null},{"id":"W4395450174","doi":"10.1016/j.jaad.2024.03.048","title":"Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Calgary Laboratory Services; Dermatrials Research; Sunnybrook Health Science Centre; University of British Columbia; University of Calgary; University of Toronto","funders":"Department of Medicine, University of Toronto; Temerty Faculty of Medicine, University of Toronto; National Institutes of Health; UCB; University of Toronto; GlaxoSmithKline; Women's College Hospital; Universidade do Porto; Faculty of Medicine, University of British Columbia; Eli Lilly and Company","keywords":"Medicine; Plaque psoriasis; Retrospective cohort study; Psoriasis; Cohort study; Multicenter study; Cohort; Internal medicine; Dermatology; Pediatrics; Randomized controlled trial","score_opus":0.005299296752437013,"score_gpt":0.2599715143050303,"score_spread":0.2546722175525933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395450174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982328,0.00020364621,0.0000070881847,0.00049830327,0.00042424173,0.00042160528,0.000056347293,0.0000068087074,0.00014916658],"genre_scores_gemma":[0.9994845,0.00035210716,0.0000654434,0.000030824656,0.000019565074,0.000012510843,0.0000032464943,0.00001374334,0.000018099458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822146,0.000706298,0.0005914831,0.000199517,0.000114306546,0.0001669348],"domain_scores_gemma":[0.99862945,0.00039467664,0.0007443418,0.000098256874,0.00011412851,0.000019154995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002527185,0.00016512799,0.00075142446,0.00035945795,0.000037347476,0.0000050409167,0.00028515668,0.00008451239,0.0000190697],"category_scores_gemma":[0.00007026049,0.00010197514,0.00011563283,0.0003370251,0.00042757206,0.00010985524,0.000089664754,0.00041109594,0.0000025752586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005486549,0.0004427754,0.9886164,0.00003139737,0.0019459357,0.000017770375,0.0005992166,0.0000058127407,0.0010836291,0.00025087286,0.00008522791,0.0014344334],"study_design_scores_gemma":[0.0054786853,0.0003808259,0.988067,0.00024210721,0.00035502255,0.0001481364,0.00037578645,0.000003259306,0.0047003846,0.000055512293,0.00010501195,0.00008832247],"about_ca_topic_score_codex":0.00016987481,"about_ca_topic_score_gemma":0.000049847524,"teacher_disagreement_score":0.0036167556,"about_ca_system_score_codex":0.0001286297,"about_ca_system_score_gemma":0.00005761591,"threshold_uncertainty_score":0.41584256},"labels":[],"label_agreement":null},{"id":"W4396546585","doi":"10.1001/jamadermatol.2024.0915","title":"International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council","year":2024,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Delphi method; Voting; Psoriasis; Delphi; Dermatology; MEDLINE; Intensive care medicine; Computer science; Artificial intelligence","score_opus":0.04830633618579252,"score_gpt":0.26979698467900626,"score_spread":0.22149064849321373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396546585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9134057,0.01909489,0.000752032,0.039626073,0.02029582,0.0005947644,0.0029960843,0.000239867,0.0029947727],"genre_scores_gemma":[0.99050725,0.002365613,0.0016420588,0.0014957895,0.0007555354,0.0004385634,0.0022437964,0.00003818521,0.00051321066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852234,0.00023899233,0.00038561877,0.0004666094,0.000095925374,0.00029053277],"domain_scores_gemma":[0.99561125,0.003809614,0.00009218106,0.00022556173,0.00023342353,0.000027943028],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028490284,0.00024555705,0.0003083444,0.00009036739,0.00021287808,0.00017420079,0.0003208495,0.0003702102,0.0010086336],"category_scores_gemma":[0.0011630235,0.0001869812,0.00015511074,0.00007952935,0.00020684955,0.00011193475,0.00011074457,0.00016764061,0.0002709107],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019761748,0.00029663308,0.011759158,0.00008929857,0.006759408,0.00045240042,0.0031041591,0.0000040217365,0.056767885,0.05380911,0.7575872,0.107394546],"study_design_scores_gemma":[0.0055802492,0.00005771524,0.0059024133,0.000074770534,0.0007837035,0.0013447976,0.00033875494,0.00030787857,0.010981239,0.009178282,0.9651306,0.00031955738],"about_ca_topic_score_codex":0.00023581,"about_ca_topic_score_gemma":0.00010628992,"teacher_disagreement_score":0.20754343,"about_ca_system_score_codex":0.00012922559,"about_ca_system_score_gemma":0.00017247738,"threshold_uncertainty_score":0.9999046},"labels":[],"label_agreement":null},{"id":"W4396603568","doi":"10.1093/ced/llae152","title":"Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial","year":2024,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Placebo; Adverse effect; Clinical endpoint; Internal medicine; Interleukin 17; Randomized controlled trial; Gastroenterology; Dermatology; Cytokine; Pathology","score_opus":0.02979389415664884,"score_gpt":0.3533725789174983,"score_spread":0.32357868476084944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396603568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601191,0.031084308,0.000020204605,0.00068439846,0.0048004454,0.0021276406,0.000023910903,0.0001493658,0.0009906065],"genre_scores_gemma":[0.9962516,0.0013889738,0.00010318793,0.0002985151,0.0002894945,0.0009171055,0.00010868886,0.000029800658,0.00061262987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99477285,0.0018535632,0.0019128412,0.00088420726,0.00005867909,0.00051787443],"domain_scores_gemma":[0.9964374,0.002956658,0.00018648204,0.00028203343,0.000025298716,0.00011214129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012112219,0.00041329014,0.0023615547,0.00017414453,0.00017251258,0.00003224669,0.00018496306,0.00074988033,0.00041053045],"category_scores_gemma":[0.00029556727,0.00026200738,0.0006208189,0.00014647856,0.001351754,0.00012586114,0.00014722366,0.00053779705,0.00026403865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9733345,0.0036345297,0.0005560921,0.00002703914,0.0012817293,0.0005871112,0.0007399089,1.598328e-7,0.0001851275,0.0013208487,0.0014279308,0.016905008],"study_design_scores_gemma":[0.9850585,0.0044920268,0.000048460028,0.00017163043,0.0004317933,0.00059553544,0.0005267434,0.00010766852,0.002513657,0.0001357464,0.0055951937,0.00032304734],"about_ca_topic_score_codex":0.000034258752,"about_ca_topic_score_gemma":0.000025466034,"teacher_disagreement_score":0.036132485,"about_ca_system_score_codex":0.000019370691,"about_ca_system_score_gemma":0.00014533848,"threshold_uncertainty_score":0.9999832},"labels":[],"label_agreement":null},{"id":"W4396683134","doi":"10.5114/dr.2023.136325","title":"Betamethasone dipropionate and calcipotriol foam as an adjuvant therapy in patients with severe psoriasis treated with biologic drugs","year":2023,"lang":"en","type":"article","venue":"Dermatology Review","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Calcipotriol; Betamethasone dipropionate; Medicine; Psoriasis; Dermatology; Adjuvant; Plaque psoriasis; Betamethasone; Adjuvant therapy; Surgery; Internal medicine; Chemotherapy","score_opus":0.016635030883337776,"score_gpt":0.2527709223160972,"score_spread":0.23613589143275943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396683134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265475,0.071455196,8.001593e-7,0.0004830462,0.00008207745,0.0010888034,0.00006103525,0.00015111813,0.00013039359],"genre_scores_gemma":[0.9203819,0.07690435,0.00004577003,0.0007501613,0.0000074880213,0.00032246474,0.0013422542,0.000033798835,0.00021182657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977303,0.0007535011,0.00037996337,0.00058370084,0.000051335377,0.0005012008],"domain_scores_gemma":[0.99910945,0.00017706805,0.00018245449,0.00039255797,0.00008563607,0.00005281342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018682996,0.00038982398,0.0010024621,0.00019633204,0.00014967684,0.000008910746,0.00018702091,0.00029822564,0.00016810605],"category_scores_gemma":[0.00003112517,0.00022652301,0.00006711468,0.00064983155,0.00022888053,0.00012636014,0.0000487276,0.00019447907,0.00037155236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010354227,0.00038615553,0.77374417,0.00028920345,0.00061929476,0.00014035731,0.00033030182,4.778077e-7,0.0001433549,0.00010691113,0.00053428835,0.22267006],"study_design_scores_gemma":[0.020595003,0.0031590594,0.9426797,0.0016492632,0.0007152984,0.00092289835,0.00018413783,0.0000021246135,0.0023145576,0.00016282019,0.026568498,0.001046651],"about_ca_topic_score_codex":0.00007601439,"about_ca_topic_score_gemma":0.000037328842,"teacher_disagreement_score":0.2216234,"about_ca_system_score_codex":0.000025026282,"about_ca_system_score_gemma":0.000053040047,"threshold_uncertainty_score":0.92373407},"labels":[],"label_agreement":null},{"id":"W4396813342","doi":"10.1007/s13555-024-01164-6","title":"Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie; Biogen; Amgen","keywords":"Medicine; Psoriasis; Term (time); Chart; Pediatrics; Intensive care medicine; Dermatology; Statistics; Mathematics","score_opus":0.012119976135845978,"score_gpt":0.28454329913593046,"score_spread":0.2724233230000845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396813342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259854,0.015635254,0.00006996856,0.0001100015,0.00054125645,0.0007005353,0.00013846808,0.00007161394,0.00013435334],"genre_scores_gemma":[0.98781765,0.010660122,0.0000113351125,0.00014015874,0.000024793768,0.00016873791,0.0011185828,0.000020430565,0.000038182592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977532,0.0009962174,0.0003719194,0.00054517953,0.00011268438,0.00022082336],"domain_scores_gemma":[0.99906915,0.00034386697,0.00009722119,0.00033579802,0.00009058002,0.000063405205],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029379578,0.00027225373,0.0007872325,0.0003525444,0.000109485525,0.000019875008,0.00026035684,0.00020314351,0.0009546879],"category_scores_gemma":[0.000013827957,0.00019111413,0.00012582852,0.0004567736,0.00014757727,0.0001797008,0.000047758273,0.00017637217,0.000031759562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021394824,0.0008277791,0.95101506,0.00009508773,0.010092742,0.00010261987,0.000484046,0.0000015365238,0.000051435734,0.00009445333,0.000044965473,0.03505079],"study_design_scores_gemma":[0.0040658466,0.00035288007,0.99226266,0.0004753722,0.0012170841,0.000020612508,0.000023970835,0.000012130838,0.0011564138,0.000042339067,0.00015936012,0.00021132821],"about_ca_topic_score_codex":0.00028158026,"about_ca_topic_score_gemma":0.0004671187,"teacher_disagreement_score":0.0412476,"about_ca_system_score_codex":0.000021616466,"about_ca_system_score_gemma":0.00005348992,"threshold_uncertainty_score":0.9999586},"labels":[],"label_agreement":null},{"id":"W4396863912","doi":"10.1080/07853890.2024.2341252","title":"Health-related quality of life in patients with generalized pustular psoriasis – a Swedish register study","year":2024,"lang":"en","type":"article","venue":"Annals of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Portugal; Janssen Australia; Cilag; AbbVie Canada; LEO Pharma; Eli Lilly and Company; Boehringer Ingelheim","keywords":"Register (sociolinguistics); Medicine; Psoriasis; Generalized pustular psoriasis; Quality (philosophy); Quality of life (healthcare); Dermatology; Nursing; Philosophy","score_opus":0.07560737225451337,"score_gpt":0.3388023238483301,"score_spread":0.26319495159381673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396863912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97566533,0.018947998,0.0000035154849,0.003985146,0.0005789184,0.00054628926,0.000049187875,0.000030928477,0.00019270371],"genre_scores_gemma":[0.9985086,0.00030861524,0.00001267001,0.00030752303,0.000032035845,0.000024184325,0.00018698648,0.000015955493,0.00060348364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976965,0.0006383243,0.0009851236,0.0003017157,0.00012528182,0.0002530225],"domain_scores_gemma":[0.9989946,0.00017319735,0.00031001453,0.00033776715,0.00014194153,0.000042510073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262875,0.00018403564,0.00095609215,0.00025359163,0.000033392585,0.000002169072,0.0001377608,0.000109828434,0.00027025462],"category_scores_gemma":[0.00019876339,0.00011956646,0.00007903501,0.00041539507,0.00020271757,0.00005782375,0.000031372478,0.00013229268,0.000015431568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005337024,0.0027700632,0.9170347,0.0004705361,0.0030791601,0.000025597283,0.008650313,0.0000058232595,0.00097585685,0.00059432467,0.022523621,0.03853301],"study_design_scores_gemma":[0.016120423,0.0040394785,0.9757471,0.00054604333,0.00015886656,0.0000020225725,0.00075866294,9.64537e-7,0.0005636694,0.00013228091,0.0017692774,0.00016118212],"about_ca_topic_score_codex":0.0028750305,"about_ca_topic_score_gemma":0.00029928764,"teacher_disagreement_score":0.058712456,"about_ca_system_score_codex":0.00001446714,"about_ca_system_score_gemma":0.00009156226,"threshold_uncertainty_score":0.48757786},"labels":[],"label_agreement":null},{"id":"W4396928451","doi":"10.1080/09546634.2024.2349658","title":"Comparative analysis of persistence and remission with guselkumab <i>versus</i> secukinumab and ixekizumab in the United States","year":2024,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Biotech","keywords":"Secukinumab; Ixekizumab; Medicine; Persistence (discontinuity); Dermatology; Immunology; Psoriasis; Psoriatic arthritis","score_opus":0.051451101065958495,"score_gpt":0.28894458342242774,"score_spread":0.23749348235646925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396928451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985207,0.013855408,0.000016993126,0.0005633761,0.00005439479,0.00010774055,0.000033575063,0.0000072146645,0.00015429554],"genre_scores_gemma":[0.997068,0.0026754509,0.00013259123,0.000029780063,0.0000042922225,0.000005651523,0.000052823885,0.0000026913635,0.00002874835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990429,0.00029371682,0.0003125257,0.00015184045,0.000060104303,0.00013888071],"domain_scores_gemma":[0.9990222,0.0006560733,0.00014855154,0.00009492084,0.000052811058,0.000025464968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013443823,0.00016130015,0.0005520829,0.00031491558,0.00007161418,0.000023533237,0.00008261875,0.00009243492,0.00002826111],"category_scores_gemma":[0.000011156298,0.00006976773,0.00011966734,0.0005603289,0.00018461121,0.00006607173,0.00001701107,0.00011276437,0.000001553795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053898472,0.0104337735,0.40210545,0.00054986874,0.14415783,0.012621547,0.2114585,0.0031440242,0.020529307,0.006177322,0.003681305,0.1312426],"study_design_scores_gemma":[0.052853096,0.02955439,0.6232283,0.0014164408,0.05285825,0.01600788,0.09457597,0.0028380507,0.064607546,0.00080264185,0.059777874,0.0014795372],"about_ca_topic_score_codex":0.000028397317,"about_ca_topic_score_gemma":0.00003141524,"teacher_disagreement_score":0.22112288,"about_ca_system_score_codex":0.00005515677,"about_ca_system_score_gemma":0.000034104327,"threshold_uncertainty_score":0.28450453},"labels":[],"label_agreement":null},{"id":"W4398204520","doi":"10.3390/ijms25115639","title":"Antiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes","year":2024,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Chicoutimi; Université de Montréal; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Phloretin; Psoriasis; Tumor necrosis factor alpha; Monocyte; Interleukin; Immunology; Inflammation; Chemistry; Pharmacology; Chemokine; Cytokine; Biology; Biochemistry","score_opus":0.005191327589135749,"score_gpt":0.23400496255453135,"score_spread":0.2288136349653956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398204520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692805,0.029772878,0.000035181263,0.00026102964,0.00052500097,0.00007872541,0.000008952878,0.0000015214023,0.00003624375],"genre_scores_gemma":[0.9989621,0.00081825064,0.00015571085,0.000026883785,0.000015638787,0.0000012238536,4.1301135e-7,0.000002183037,0.000017611972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993946,0.00012538563,0.00022427907,0.00010108531,0.000088276785,0.00006638412],"domain_scores_gemma":[0.9995392,0.00019939037,0.00014530196,0.00003220684,0.000073392395,0.000010516196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027268694,0.00007297925,0.00016183176,0.00012238402,0.000032764303,0.00002805448,0.00013951,0.00004785964,0.0000052074515],"category_scores_gemma":[0.00006852085,0.00004262333,0.000039366187,0.00008743392,0.00046602933,0.0000951233,0.000051031362,0.00007656755,3.0558067e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032801297,0.00002781664,0.01610608,0.00003930644,0.00019923176,0.000038463942,0.0017128272,0.000009368147,0.9753926,0.001578322,0.000011865926,0.004851353],"study_design_scores_gemma":[0.00072071096,0.00014977393,0.0467295,0.00040536502,0.00005658354,0.00014962755,0.0002954481,0.00003203356,0.9508639,0.0005081821,0.000040197017,0.000048660877],"about_ca_topic_score_codex":0.000009807245,"about_ca_topic_score_gemma":0.0000039266124,"teacher_disagreement_score":0.03062342,"about_ca_system_score_codex":0.000007828411,"about_ca_system_score_gemma":0.00006181263,"threshold_uncertainty_score":0.17381291},"labels":[],"label_agreement":null},{"id":"W4398767077","doi":"10.1007/s00403-024-02972-8","title":"Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients","year":2024,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Systemic inflammation; Inflammation; Medicine; Disease; Systemic disease; Dermatology; Severity of illness; Immunology; Internal medicine","score_opus":0.03338663623549444,"score_gpt":0.3051791125048093,"score_spread":0.27179247626931485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398767077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922111,0.006157904,0.000007930646,0.0002925276,0.00015568094,0.0009056464,0.00003834329,0.0000073868905,0.00022346035],"genre_scores_gemma":[0.9992413,0.0005938368,0.0000149025145,0.000002897101,0.000004199668,0.000100494115,0.000023758013,0.0000047807484,0.000013821526],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949441,0.0038757955,0.00044725076,0.00020583122,0.0003260376,0.00020097813],"domain_scores_gemma":[0.99783856,0.0016217405,0.00011745264,0.000257747,0.00014050481,0.000024004601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019422374,0.00010131899,0.00024280879,0.00021000345,0.00008885719,0.000009584593,0.00025481594,0.000089099965,0.000020071371],"category_scores_gemma":[0.001374117,0.000052886127,0.0001411569,0.00024067888,0.0012867784,0.000060129318,0.00020639742,0.00017405728,0.0000063233297],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007916942,0.0005809059,0.40762126,0.0013938206,0.0016353634,0.000023412149,0.006087277,0.0002500086,0.07859005,0.00984211,0.00008629117,0.48597255],"study_design_scores_gemma":[0.003785886,0.00008212685,0.949048,0.00054118555,0.00029339475,0.000019498744,0.00058161124,0.0017563648,0.029047253,0.014743203,0.000016704811,0.000084777304],"about_ca_topic_score_codex":0.00006967121,"about_ca_topic_score_gemma":0.00000961974,"teacher_disagreement_score":0.5414267,"about_ca_system_score_codex":0.000025100439,"about_ca_system_score_gemma":0.00018163167,"threshold_uncertainty_score":0.47411886},"labels":[],"label_agreement":null},{"id":"W4398794394","doi":"","title":"Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psoriasis; Term (time); Medicine; Dermatology; Intensive care medicine; Physics","score_opus":0.027362643742625252,"score_gpt":0.2504426109148005,"score_spread":0.22307996717217526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398794394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97478855,0.022555463,0.0000024916976,0.00012765845,0.0007433605,0.00064499024,0.000043305416,0.000025803336,0.0010683858],"genre_scores_gemma":[0.9974095,0.00077291374,0.0000048640654,0.000009195413,0.000045271725,0.0005844016,0.00006363783,0.000009670329,0.0011004962],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991308,0.00015247847,0.0002556903,0.00018707485,0.00003317854,0.00024076803],"domain_scores_gemma":[0.9993252,0.00033520337,0.000052237618,0.00026413257,0.000013279367,0.000009923218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016883349,0.00013166358,0.00025589424,0.00013277467,0.000024703944,0.000007082067,0.00015606439,0.00011244777,0.000072737275],"category_scores_gemma":[0.000017846123,0.00007779615,0.00016514822,0.000221496,0.00008951841,0.000033901684,0.0000112896,0.000046447665,0.000047687085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000301916,0.0010341548,0.02267301,0.000040908148,0.0005362935,0.000031799773,0.001913504,0.0000011618096,0.0012062549,0.00040128155,0.00019531116,0.9716644],"study_design_scores_gemma":[0.0022361104,0.00019296486,0.947925,0.000019668825,0.00025170183,0.000021896363,0.00004748026,2.0167413e-7,0.044377156,0.000041016556,0.0048091672,0.00007768228],"about_ca_topic_score_codex":0.000056223293,"about_ca_topic_score_gemma":0.000044924196,"teacher_disagreement_score":0.9715867,"about_ca_system_score_codex":0.000048716687,"about_ca_system_score_gemma":0.000024102466,"threshold_uncertainty_score":0.3172435},"labels":[],"label_agreement":null},{"id":"W4399010251","doi":"10.1016/j.ejogrb.2024.05.029","title":"Phlegmasia cerulea dolens – A rare presentation of ovarian malignancy","year":2024,"lang":"en","type":"letter","venue":"European Journal of Obstetrics & Gynecology and Reproductive Biology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Royal Victoria Hospital; McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Presentation (obstetrics); Malignancy; Ovarian cancer; Surgery; Internal medicine; Cancer","score_opus":0.02320338587983017,"score_gpt":0.24536915748564556,"score_spread":0.22216577160581538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399010251","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26408285,0.4307493,0.00034116386,0.20880151,0.082921274,0.001769149,0.001261922,0.00016663532,0.009906194],"genre_scores_gemma":[0.9029268,0.016083531,0.0018173584,0.03713069,0.010486482,0.000037481426,0.0021875293,0.00046212634,0.028868003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99367976,0.0034634657,0.0013227788,0.00091668323,0.000075959215,0.0005413558],"domain_scores_gemma":[0.99519724,0.001954094,0.0016728134,0.00057885284,0.0005550819,0.00004190792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013015872,0.0005393609,0.0012495406,0.0010905653,0.00015649383,0.000018405337,0.00051547866,0.0010274792,0.0002666233],"category_scores_gemma":[0.0024996263,0.00041005775,0.00041909158,0.00048082395,0.0008093762,0.0001353029,0.00024233968,0.002007522,0.00018212399],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009332993,0.0006209142,0.0117459325,0.00085516175,0.011212643,0.011299849,0.0034863853,0.000005499815,0.043777097,0.0012074186,0.7512062,0.16364959],"study_design_scores_gemma":[0.0025524048,0.0026248586,0.01620115,0.00019402117,0.0016696592,0.002307262,0.0002269426,1.8971699e-7,0.0053084968,0.00089278945,0.96754295,0.00047928866],"about_ca_topic_score_codex":0.0000063444336,"about_ca_topic_score_gemma":8.353916e-7,"teacher_disagreement_score":0.63884395,"about_ca_system_score_codex":0.000095622556,"about_ca_system_score_gemma":0.00021005512,"threshold_uncertainty_score":0.99983513},"labels":[],"label_agreement":null},{"id":"W4399034169","doi":"10.1080/09546634.2024.2350227","title":"Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)","year":2024,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology; Psoriasis Area and Severity Index","score_opus":0.02965685294977767,"score_gpt":0.28558827444117285,"score_spread":0.2559314214913952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399034169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957227,0.0008283318,0.0000041656467,0.0023666685,0.00018690841,0.0007865368,0.00007871023,0.000010661607,0.000015310303],"genre_scores_gemma":[0.9990613,0.0006045784,0.00007880342,0.00005132722,0.000007934623,0.000049401835,0.000037377034,0.000009208257,0.00010010887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959277,0.002350063,0.0010835001,0.0002453271,0.00014012269,0.0002532665],"domain_scores_gemma":[0.9973608,0.0016672001,0.00067586236,0.00016189626,0.000089022484,0.000045179444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010497668,0.00024695473,0.00081677083,0.00037601375,0.00010948058,0.000021659711,0.00011964183,0.00012714895,0.0000178145],"category_scores_gemma":[0.00023655273,0.00012319992,0.000114780545,0.00035012458,0.00003966603,0.00011632605,0.000036032714,0.00014089131,0.0000029684766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010910445,0.0029310535,0.9783278,0.00002783983,0.0006352889,0.000063993095,0.0032445143,0.00009646716,0.00007031979,0.00002640779,0.00008957225,0.0035762733],"study_design_scores_gemma":[0.006658432,0.0041567227,0.9872164,0.00013582125,0.00023601418,0.000012128562,0.0009423903,0.0000055308005,0.00036518226,0.000079686375,0.00007969572,0.00011197398],"about_ca_topic_score_codex":0.00013070804,"about_ca_topic_score_gemma":0.0010057618,"teacher_disagreement_score":0.008888597,"about_ca_system_score_codex":0.0005363872,"about_ca_system_score_gemma":0.0001107848,"threshold_uncertainty_score":0.50239474},"labels":[],"label_agreement":null},{"id":"W4399355196","doi":"10.3389/fimmu.2024.1398120","title":"Granzyme K mediates IL-23-dependent inflammation and keratinocyte proliferation in psoriasis","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; International Collaboration On Repair Discoveries; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research; Arthritis Society","keywords":"Psoriasis; Keratinocyte; Inflammation; Imiquimod; Immunology; Granzyme A; Granzyme; Medicine; Granzyme B; S100A8; Desquamation; Immune system; T cell; Biology; Pathology; CD8; In vitro","score_opus":0.008475149812280307,"score_gpt":0.21815786541662938,"score_spread":0.20968271560434906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399355196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371621,0.055433176,0.00045155964,0.0005999503,0.0054383776,0.00044998416,0.00003509748,0.00011447632,0.0003152791],"genre_scores_gemma":[0.9932494,0.0041609723,0.0006529049,0.000025275356,0.00009244988,0.00023815091,0.00037694164,0.00002443236,0.0011794483],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983216,0.00036714337,0.00045135472,0.0004392128,0.00003830727,0.00038241394],"domain_scores_gemma":[0.9995875,0.00011406886,0.000063876185,0.00019517499,0.000025305255,0.000014124201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003665174,0.00023739539,0.00038360394,0.0006559009,0.00008792141,0.000042825486,0.00013249628,0.00046430403,0.000070169765],"category_scores_gemma":[0.00007379968,0.0002197465,0.000052661933,0.0002908902,0.00015790734,0.0002538516,0.00005974824,0.0003158567,0.00014611211],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014716762,0.00023920686,0.14990674,0.00015658572,0.001197581,0.00023228196,0.008993979,0.00006261031,0.2548753,0.0057070316,0.004695148,0.57246184],"study_design_scores_gemma":[0.019268319,0.0013937674,0.3208494,0.0006054869,0.0005367252,0.0005541096,0.0042333417,0.0014298026,0.5586472,0.020430204,0.07004927,0.0020023691],"about_ca_topic_score_codex":0.000084014595,"about_ca_topic_score_gemma":0.00027724853,"teacher_disagreement_score":0.5704595,"about_ca_system_score_codex":0.00014849682,"about_ca_system_score_gemma":0.000074361276,"threshold_uncertainty_score":0.8961002},"labels":[],"label_agreement":null},{"id":"W4399364549","doi":"10.1016/j.xjidi.2024.100287","title":"Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy","year":2024,"lang":"en","type":"article","venue":"JID Innovations","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Dalhousie University","funders":"Johnson and Johnson","keywords":"Adalimumab; Medicine; Psoriasis; Interleukin 23; Tumor necrosis factor alpha; Internal medicine; Interleukin 17; Blockade; Cytokine; Gastroenterology; Oncology; Immunology; Receptor","score_opus":0.009707073364754354,"score_gpt":0.22531583082946632,"score_spread":0.21560875746471198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399364549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560225,0.0020587537,0.000013659992,0.0005328123,0.0006214587,0.00053289736,0.00023970765,0.00017623129,0.00022222598],"genre_scores_gemma":[0.99796027,0.000050402297,0.000066571825,0.000037448062,0.000014995612,0.00015884706,0.00095223996,0.00003147638,0.00072772865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879736,0.00009005823,0.00033323324,0.00043139586,0.000064726155,0.00028324523],"domain_scores_gemma":[0.9994967,0.00007305237,0.00007057808,0.00023914895,0.000092264076,0.000028264603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014763244,0.00023674089,0.00022021036,0.00050251506,0.00019085253,0.000046603167,0.000114367765,0.00015120137,0.00012934391],"category_scores_gemma":[0.000035165303,0.00018569273,0.00004436191,0.0013237695,0.00011219862,0.00020907138,0.00004634644,0.0001506858,0.0000744429],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00385215,0.0039951378,0.7876433,0.00024006693,0.01178717,0.00018893757,0.010495086,0.000015305186,0.036166437,0.074722774,0.005493488,0.06540015],"study_design_scores_gemma":[0.0046799616,0.0003165173,0.987908,0.00021472063,0.00048607492,0.000007760864,0.00068910007,0.000020879328,0.0033768564,0.0009892372,0.0009137466,0.0003971619],"about_ca_topic_score_codex":0.000054217744,"about_ca_topic_score_gemma":0.000055235556,"teacher_disagreement_score":0.20026469,"about_ca_system_score_codex":0.0000707351,"about_ca_system_score_gemma":0.00010350237,"threshold_uncertainty_score":0.75723296},"labels":[],"label_agreement":null},{"id":"W4399366132","doi":"10.1016/j.anai.2024.05.014","title":"A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology","year":2024,"lang":"en","type":"review","venue":"Annals of Allergy Asthma & Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; McMaster University; St. Joseph’s Healthcare Hamilton; Impact","funders":"National Institute of Allergy and Infectious Diseases; National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; National Institutes of Health","keywords":"Dupilumab; Medicine; Atopic dermatitis; Asthma; Vaccination; Contraindication; Clinical trial; Dermatology; Immunology; Intensive care medicine; Internal medicine; Alternative medicine; Pathology","score_opus":0.04779944257150254,"score_gpt":0.2977367533677531,"score_spread":0.2499373107962506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399366132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031869415,0.9642398,5.574798e-7,0.0013197665,0.0003258041,0.0016983992,0.00050176197,0.000013370569,0.00003114764],"genre_scores_gemma":[0.009312557,0.98981506,0.000028740134,0.0002641779,0.00000769488,0.00021861422,0.00022170939,0.00004855087,0.000082897466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99356985,0.0032975837,0.0021607764,0.0005210334,0.00007915533,0.00037161127],"domain_scores_gemma":[0.99447626,0.0015320015,0.002831949,0.0007955825,0.0003472476,0.000016968204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006359102,0.00060171087,0.0036923746,0.00045494846,0.00009724394,0.0000056888557,0.0004267456,0.0004901558,0.00007992385],"category_scores_gemma":[0.00058614137,0.00035965026,0.00052296364,0.00061819004,0.0007652354,0.000074849275,0.00035394914,0.0004108655,0.000007212891],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00409562,0.0034336806,0.000050224924,0.28907508,0.07702173,0.000028752236,0.0026644864,0.000002963449,0.0038460547,0.008064246,0.010539852,0.60117733],"study_design_scores_gemma":[0.0033453808,0.005945158,0.0087133655,0.37927315,0.0012782912,0.0005401986,0.00095371023,0.000002433082,0.0012925911,0.00015966709,0.59728974,0.0012063092],"about_ca_topic_score_codex":0.00039300753,"about_ca_topic_score_gemma":0.00023219752,"teacher_disagreement_score":0.599971,"about_ca_system_score_codex":0.000042076965,"about_ca_system_score_gemma":0.00013567666,"threshold_uncertainty_score":0.99988556},"labels":[],"label_agreement":null},{"id":"W4399443863","doi":"10.1111/ijd.17236","title":"Disparities and barriers to the access of biologics in moderate‐to‐severe adult psoriasis","year":2024,"lang":"en","type":"review","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Memorial University of Newfoundland; University of British Columbia","funders":"","keywords":"Medicine; Psychosocial; MEDLINE; Psoriasis; Socioeconomic status; Comorbidity; Health equity; Family medicine; Intensive care medicine; Environmental health; Population; Dermatology; Public health; Psychiatry; Nursing","score_opus":0.034359763336793886,"score_gpt":0.3341019655923975,"score_spread":0.29974220225560366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399443863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050575687,0.9864021,0.00004473072,0.0037647304,0.0040561734,0.00027878743,0.00027151365,0.0000075735575,0.00011685226],"genre_scores_gemma":[0.038796972,0.960511,0.000064208834,0.00026217743,0.000106691776,0.000041322783,0.000047545105,0.000019695948,0.00015032853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814993,0.00038008648,0.0009566531,0.00022295982,0.00007636351,0.00021397998],"domain_scores_gemma":[0.9986798,0.0003856259,0.00044421898,0.00014507046,0.00028650177,0.000058786736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012626489,0.0002866505,0.001216156,0.0007191263,0.000043913966,0.00004653857,0.00096081564,0.00039565572,0.00006348149],"category_scores_gemma":[0.00038511967,0.00016590206,0.0002983586,0.00020920562,0.00011210011,0.000091224356,0.00031184568,0.00039774456,0.000053170934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008404377,0.00014078333,0.003132157,0.0017174261,0.0065643685,0.0014033332,0.0011586841,0.000021924476,0.00002716793,0.0065882555,0.016597936,0.96180755],"study_design_scores_gemma":[0.0010409174,0.00014806568,0.00016408243,0.0047924076,0.0013156561,0.024138639,0.00020300873,0.0000018600301,0.00020661272,0.0010119106,0.9666416,0.0003352386],"about_ca_topic_score_codex":0.00004970132,"about_ca_topic_score_gemma":0.000112483554,"teacher_disagreement_score":0.9614723,"about_ca_system_score_codex":0.00007715066,"about_ca_system_score_gemma":0.00034481965,"threshold_uncertainty_score":0.676529},"labels":[],"label_agreement":null},{"id":"W4399463057","doi":"10.1007/s00403-024-03122-w","title":"Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry","year":2024,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dartmouth General Hospital; University Health Network; Ottawa Hospital; University of Ottawa; Queen's University; Novartis (Canada); Probity Medical Research; University of British Columbia; SKiN Health; University of Calgary; Lynde Centre for Dermatology; University of Toronto","funders":"Novartis Pharmaceuticals Canada","keywords":"Secukinumab; Plaque psoriasis; Psoriasis; Medicine; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.03869639536747959,"score_gpt":0.30720947858515446,"score_spread":0.26851308321767486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399463057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463516,0.0030946245,0.000117331925,0.00040535998,0.00006140361,0.0005433913,0.0007353804,0.000016745296,0.00039058688],"genre_scores_gemma":[0.9990929,0.00024335837,0.00019985183,0.000011938955,0.000007912142,0.000031304226,0.00038071093,0.000010774738,0.000021294067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785995,0.0009627694,0.00025638888,0.000475936,0.00011668539,0.00032826624],"domain_scores_gemma":[0.9955896,0.0037406166,0.00003943506,0.00055535795,0.00004138639,0.000033567914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044597904,0.00014774386,0.00035362993,0.00012789184,0.00013099477,0.000024800529,0.0005660248,0.00013314524,0.000029403678],"category_scores_gemma":[0.00021864349,0.00008249751,0.000035795973,0.0002745654,0.00047628733,0.00009272423,0.000600138,0.00037819776,0.000013879942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030347697,0.0007412335,0.8504188,0.0005897247,0.0012689139,0.00014097984,0.0032321152,0.00007220572,0.011101518,0.0047972295,0.0007319325,0.09655767],"study_design_scores_gemma":[0.002953993,0.00028886506,0.9801846,0.00093224586,0.000048087586,0.00002213633,0.00025254054,0.000083180836,0.011741163,0.0027647798,0.0005884674,0.00013992336],"about_ca_topic_score_codex":0.00015088891,"about_ca_topic_score_gemma":0.00007669453,"teacher_disagreement_score":0.12976584,"about_ca_system_score_codex":0.000014038434,"about_ca_system_score_gemma":0.00008860123,"threshold_uncertainty_score":0.33641508},"labels":[],"label_agreement":null},{"id":"W4399482982","doi":"10.1136/annrheumdis-2024-eular.245","title":"AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Psoriasis; Medicine; Placebo; Psoriasis Area and Severity Index; Psoriatic arthritis; Apremilast; Internal medicine; Clinical endpoint; Clinical trial; Plaque psoriasis; Randomized controlled trial; Dermatology","score_opus":0.025947630980426926,"score_gpt":0.28446363461567886,"score_spread":0.25851600363525196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399482982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826047,0.015504721,0.000003661545,0.00053343753,0.0005622712,0.00018875726,0.00040673162,0.000028772762,0.00016697255],"genre_scores_gemma":[0.99767953,0.0010389506,0.000014221702,0.00007246786,0.000008227668,0.000029892251,0.000016793201,0.000014300122,0.0011255853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987796,0.00037548912,0.0003802723,0.00018002825,0.00005960432,0.00022502829],"domain_scores_gemma":[0.9988044,0.00065857026,0.000120511286,0.00036215887,0.00003457973,0.000019772846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003406729,0.00013686315,0.00031194088,0.00014140872,0.00002860267,0.000008847988,0.0002765498,0.00008791702,0.00032354653],"category_scores_gemma":[0.00038811637,0.00009360795,0.00024671204,0.00025662902,0.0001732396,0.00007520255,0.00006953912,0.00007111484,0.00008343596],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018701114,0.00318105,0.053249914,0.0026296657,0.006136595,0.00017176058,0.010144004,0.0002080891,0.03193416,0.023896994,0.15631697,0.6934297],"study_design_scores_gemma":[0.0017480167,0.00019349132,0.9547659,0.0032055746,0.0002654175,0.000017332673,0.00046064192,0.000028978437,0.028129885,0.0056730825,0.0052650026,0.00024665223],"about_ca_topic_score_codex":0.00010396342,"about_ca_topic_score_gemma":0.000018937977,"teacher_disagreement_score":0.901516,"about_ca_system_score_codex":0.000012787381,"about_ca_system_score_gemma":0.000119373886,"threshold_uncertainty_score":0.38172215},"labels":[],"label_agreement":null},{"id":"W4399527455","doi":"10.1111/jdv.20143","title":"Age affects drug survival rates of interleukin (<scp>IL</scp>)‐17 and <scp>IL</scp>‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto; McMaster University","funders":"","keywords":"Psoriasis; Medicine; Plaque psoriasis; Drug; Pharmacology; Immunology","score_opus":0.010134738420319046,"score_gpt":0.2337633874384789,"score_spread":0.22362864901815988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399527455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906733,0.0067474544,0.000006004877,0.00023120885,0.0012464969,0.00057031424,0.00022736701,0.000022848715,0.00027497212],"genre_scores_gemma":[0.99854654,0.00086199725,0.00007469885,0.000056398578,0.00010340041,0.00000643898,0.00003971125,0.000043091895,0.00026769814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944872,0.0032291936,0.0011435602,0.0005372937,0.00014155883,0.00046114362],"domain_scores_gemma":[0.996402,0.0021272653,0.0010766883,0.00022777212,0.0000946439,0.0000715946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011253457,0.00042979262,0.0012180469,0.0004805273,0.00013749293,0.000020801011,0.0004912122,0.00039884137,0.0000030550536],"category_scores_gemma":[0.0007133957,0.0002874951,0.00015372963,0.00035396274,0.00072893745,0.0001903572,0.00032394016,0.001061162,0.000009636816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006461137,0.00068556226,0.9876002,0.00005997108,0.0017925435,0.0003411162,0.0037971532,0.000012015833,0.0021994745,0.00006542665,0.002176967,0.0006234688],"study_design_scores_gemma":[0.011514687,0.0002957985,0.97259355,0.00032736902,0.0007502757,0.00036118276,0.001073458,0.000010603501,0.011209196,0.00007212382,0.0016945805,0.00009719037],"about_ca_topic_score_codex":0.00006586435,"about_ca_topic_score_gemma":0.00011159207,"teacher_disagreement_score":0.015006652,"about_ca_system_score_codex":0.00005687819,"about_ca_system_score_gemma":0.00006244193,"threshold_uncertainty_score":0.99995774},"labels":[],"label_agreement":null},{"id":"W4399696611","doi":"10.1016/j.jaad.2024.05.085","title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; McMaster University; Dermatrials Research; Probity Medical Research; SKiN Health; University of Calgary; University of Toronto","funders":"LEO Pharma; Bausch Health; Women's College Hospital; Sanofi Genzyme; Incyte; Astellas Pharma; Mylan; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Baxalta; Celgene; Coherus Biosciences; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Multicenter study; Plaque psoriasis; Psoriasis; Retrospective cohort study; Dermatology; Internal medicine; Randomized controlled trial","score_opus":0.013227376201327848,"score_gpt":0.2844077789418028,"score_spread":0.27118040274047495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399696611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970328,0.00049215363,0.000042345473,0.0011888469,0.00055505784,0.0005273446,0.000089740366,0.0000144593605,0.00005722389],"genre_scores_gemma":[0.9991297,0.00015216124,0.00036659712,0.0001336594,0.000038152004,0.0000367482,0.00000320803,0.000023817558,0.00011595792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998189,0.00037068123,0.0007904813,0.0002409931,0.00011758027,0.00029132035],"domain_scores_gemma":[0.9978906,0.00033305792,0.0013094594,0.00017209123,0.0002630371,0.000031736778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120915494,0.00022667735,0.00089544314,0.00031653026,0.00008752819,0.0000067247133,0.0004944933,0.00010149339,0.000021894462],"category_scores_gemma":[0.00010960522,0.00013316136,0.0002790137,0.00046016005,0.000630228,0.00013646764,0.00007724128,0.00035175603,0.000005242171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009701122,0.0022937485,0.94980663,0.000111526744,0.0046201837,0.000030370982,0.009359971,0.0000072928037,0.0125837475,0.00063922425,0.0031388507,0.0077073225],"study_design_scores_gemma":[0.009759498,0.0032064107,0.9007217,0.0003618201,0.00145449,0.00041106125,0.005089984,0.000012391134,0.07666906,0.00019070077,0.001822015,0.00030086053],"about_ca_topic_score_codex":0.00009634754,"about_ca_topic_score_gemma":0.00002784028,"teacher_disagreement_score":0.06408531,"about_ca_system_score_codex":0.00008219488,"about_ca_system_score_gemma":0.00009962257,"threshold_uncertainty_score":0.54301625},"labels":[],"label_agreement":null},{"id":"W4399859737","doi":"10.3390/jcm13123610","title":"Clinical Characteristics of Cutaneous Pain in Psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu","keywords":"Medicine; Dermatology; Psoriasis","score_opus":0.05640134037805995,"score_gpt":0.3831316661863876,"score_spread":0.32673032580832767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399859737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97377783,0.010661172,0.00019663756,0.0022928948,0.012148241,0.0001044188,0.000017245613,0.00001598085,0.0007855904],"genre_scores_gemma":[0.9904306,0.0067091426,0.00022348482,0.00028923454,0.0017143609,0.000001309902,0.000012720887,0.000015401756,0.0006037319],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946155,0.0012661665,0.0036076522,0.00020099875,0.00010222441,0.0002074483],"domain_scores_gemma":[0.99135715,0.0074340412,0.00077885186,0.00020029687,0.00015526457,0.00007438114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008250679,0.00015895121,0.0014282905,0.00023063726,0.000018706683,0.000003935759,0.00023857271,0.00043944942,0.00070021575],"category_scores_gemma":[0.007441807,0.00009948301,0.00044292054,0.00022416972,0.0003863654,0.00005154658,0.00003083989,0.0008171781,0.00006981903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010995342,0.0004306365,0.13719249,0.000068523,0.0006117891,0.00081988494,0.0001424084,2.519665e-7,0.00083343784,0.0001375396,0.006534344,0.85212916],"study_design_scores_gemma":[0.013587659,0.020043075,0.5863548,0.004694147,0.0020330881,0.0017913436,0.0004474725,0.00005393785,0.00068357895,0.0018069855,0.36810428,0.00039961864],"about_ca_topic_score_codex":0.000011916976,"about_ca_topic_score_gemma":0.0000064443657,"teacher_disagreement_score":0.8517295,"about_ca_system_score_codex":0.000020349831,"about_ca_system_score_gemma":0.00019302139,"threshold_uncertainty_score":0.8909076},"labels":[],"label_agreement":null},{"id":"W4399993154","doi":"10.1016/j.jid.2024.05.020","title":"Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB Pharma; Sun Pharma; LEO Pharma; Dermira; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Quality of life (healthcare); Scopus; Adalimumab; Disease; Dermatology; Clearance; Internal medicine; MEDLINE; Nursing","score_opus":0.020263487030241837,"score_gpt":0.23439375105751387,"score_spread":0.21413026402727203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958358,0.0032074454,0.00002227655,0.00046914155,0.0001290142,0.00021073715,0.00006668471,0.00001600182,0.000042901243],"genre_scores_gemma":[0.9980431,0.00016116096,0.0014766492,0.00010984196,0.000023206487,0.00001663582,0.000060361224,0.000025011883,0.000084037834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813545,0.0005882824,0.0005661127,0.0003010727,0.000094428215,0.00031464588],"domain_scores_gemma":[0.99906105,0.0003715929,0.0002656127,0.00012238005,0.00012344908,0.00005589773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016018492,0.00027134002,0.0006166222,0.00050186564,0.00008007782,0.000020603256,0.00014367826,0.00022402324,0.00006713217],"category_scores_gemma":[0.000064025364,0.00015976968,0.000042906206,0.00038725612,0.00050405686,0.00025698764,0.000040897354,0.0004057252,0.0000151810855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03608971,0.0014454867,0.6770158,0.00034247976,0.0019193758,0.0087398,0.009598007,0.00016424686,0.24849136,0.0006374597,0.0049354504,0.010620826],"study_design_scores_gemma":[0.012683763,0.0013301625,0.6540499,0.0010218191,0.00014418158,0.0022827557,0.0003931616,0.000010534597,0.32639694,0.00021318014,0.0011744003,0.0002992286],"about_ca_topic_score_codex":0.000042686268,"about_ca_topic_score_gemma":0.00028129428,"teacher_disagreement_score":0.07790559,"about_ca_system_score_codex":0.00008030494,"about_ca_system_score_gemma":0.0002496105,"threshold_uncertainty_score":0.65152186},"labels":[],"label_agreement":null},{"id":"W4400017087","doi":"10.1007/s13555-024-01204-1","title":"Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; Guenther Dermatology Research Centre; Probity Medical Research; Innovaderm (Canada); Dermatrials Research; Dalhousie University","funders":"Bausch Health; Amgen","keywords":"Psoriasis; Tazarotene; Medicine; Lotion; Plaque psoriasis; Dermatology; Session (web analytics); Panel discussion; Consensus conference; Expert opinion; Dermatologic agents; Medical physics; Intensive care medicine; Pharmacology; Internal medicine; Computer science; World Wide Web; Business","score_opus":0.05041861591236199,"score_gpt":0.25564226531527123,"score_spread":0.20522364940290924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400017087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96335024,0.01933906,0.0000758253,0.014941936,0.0011550206,0.00071843615,0.0002573409,0.000056340865,0.00010580676],"genre_scores_gemma":[0.99620783,0.002213319,0.0000618381,0.00074891857,0.000027313736,0.00017326022,0.00012918578,0.000015703818,0.0004226098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99916524,0.00019618706,0.00017126871,0.0002161067,0.000016736176,0.00023445078],"domain_scores_gemma":[0.9990502,0.0006790335,0.000038687824,0.00016635032,0.000040739647,0.000025007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076871685,0.00015340326,0.0002146252,0.00012624678,0.0002210907,0.000016091572,0.000074940755,0.00026831086,0.00009881785],"category_scores_gemma":[0.000024844738,0.00009444977,0.00008424871,0.00007435965,0.0001763896,0.000032863394,0.000006858296,0.000096680014,0.000038677194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003505829,0.00041281735,0.008232092,0.00014011348,0.0050900253,0.00022580208,0.0045730113,0.000017785756,0.108560115,0.18617408,0.09614046,0.5869279],"study_design_scores_gemma":[0.0021840553,0.00029467198,0.0026285185,0.00007526209,0.00008162564,0.0006430588,0.00012922626,0.00010313145,0.24620374,0.0015869038,0.74582016,0.00024962806],"about_ca_topic_score_codex":0.0029342887,"about_ca_topic_score_gemma":0.0019260213,"teacher_disagreement_score":0.6496797,"about_ca_system_score_codex":0.000019764331,"about_ca_system_score_gemma":0.00010555624,"threshold_uncertainty_score":0.44357863},"labels":[],"label_agreement":null},{"id":"W4400030395","doi":"10.1093/bjd/ljae267","title":"Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Arthritis Patient Alliance","funders":"Jikei University School of Medicine; Clalit Health Services; University of Leeds; Cardiff University; Yale University","keywords":"Patient-reported outcome; Intraclass correlation; Construct validity; Criterion validity; Physical therapy; Medicine; Interpretability; Ceiling effect; Reliability (semiconductor); Convergent validity; Content validity; Quality of life (healthcare); Psychology; Clinical psychology; Psychometrics; Internal consistency; Pathology; Alternative medicine; Nursing; Computer science","score_opus":0.035422669925068366,"score_gpt":0.23313437663996328,"score_spread":0.1977117067148949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400030395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84788674,0.15115474,0.00003285102,0.0001661823,0.00050532544,0.00015309862,0.000050026563,0.000012129279,0.00003890025],"genre_scores_gemma":[0.99944663,0.00049707195,0.000011809443,0.000013789742,0.0000091411075,0.0000058868654,0.000002334845,0.000008924059,0.000004393223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809825,0.00060162664,0.0008285163,0.0001581279,0.00011585375,0.00019762498],"domain_scores_gemma":[0.998963,0.00007640895,0.00040538068,0.00015702349,0.00036184106,0.000036333444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019181074,0.00015171892,0.00059496914,0.00008650727,0.00007342243,0.000016699862,0.00018550275,0.00017374502,0.000051775387],"category_scores_gemma":[0.0004189777,0.00009454056,0.00042046965,0.00012286226,0.00047079774,0.000107639586,0.00008305841,0.00021901079,0.0000018386412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011638217,0.0008690708,0.74018824,0.0005065392,0.004726626,0.0011321924,0.00095393707,0.0000060374414,0.12550282,0.000061107494,0.002099128,0.122790456],"study_design_scores_gemma":[0.002097942,0.00042965604,0.7008688,0.0022363556,0.0012498063,0.13175127,0.00028807373,0.000009050659,0.16017818,0.00031737535,0.00035318732,0.000220318],"about_ca_topic_score_codex":0.000062233004,"about_ca_topic_score_gemma":0.000022702117,"teacher_disagreement_score":0.1515599,"about_ca_system_score_codex":0.000048609036,"about_ca_system_score_gemma":0.00033092027,"threshold_uncertainty_score":0.38552523},"labels":[],"label_agreement":null},{"id":"W4400078729","doi":"10.1007/s13555-024-01210-3","title":"Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"UCB Pharma; National Institute for Health and Care Research","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Clinical Practice; Medical physics; Dermatology; Internal medicine; Physical therapy; Adalimumab","score_opus":0.05889889606803407,"score_gpt":0.34748839995163283,"score_spread":0.2885895038835988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400078729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9444726,0.04127626,0.000023977254,0.011181435,0.0012227799,0.0012475351,0.00034062497,0.000040294944,0.00019446654],"genre_scores_gemma":[0.9763187,0.02285626,0.000057009565,0.00010225424,0.00012423733,0.00023152854,0.00014223169,0.000015741476,0.00015201021],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793535,0.00084806536,0.00056196214,0.00038265152,0.0000342818,0.00023767832],"domain_scores_gemma":[0.99144197,0.00799647,0.00012736415,0.00037989306,0.000039465947,0.000014813214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025885264,0.0002024578,0.00044948942,0.000052690517,0.00019609406,0.000019296886,0.000150937,0.00027878978,0.000047950372],"category_scores_gemma":[0.00010185316,0.000103739214,0.00015433946,0.000117873395,0.00022168296,0.000059549166,0.000020275798,0.00015996276,0.000035062087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0539162,0.010053929,0.16479956,0.000020841466,0.01502743,0.0006079146,0.045548778,0.000002791364,0.00075408485,0.0066254283,0.0053855632,0.6972575],"study_design_scores_gemma":[0.08329524,0.0064471015,0.34231442,0.00008350126,0.0022672603,0.0012461002,0.013311363,0.000094226794,0.008626486,0.0023461084,0.5393799,0.000588316],"about_ca_topic_score_codex":0.0007202636,"about_ca_topic_score_gemma":0.00040352822,"teacher_disagreement_score":0.69666916,"about_ca_system_score_codex":0.000018390845,"about_ca_system_score_gemma":0.00007216285,"threshold_uncertainty_score":0.42303625},"labels":[],"label_agreement":null},{"id":"W4400102092","doi":"10.1016/j.xjidi.2024.100297","title":"Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy","year":2024,"lang":"en","type":"article","venue":"JID Innovations","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Janssen Research and Development; Jeannette Rankin Foundation; Visual Communications","keywords":"Secukinumab; Medicine; Psoriasis; Dermatology; Pharmacodynamics; Term (time); Psoriatic arthritis; Internal medicine; Pharmacokinetics","score_opus":0.014815042105985986,"score_gpt":0.27559970155415003,"score_spread":0.26078465944816404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400102092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905482,0.0007932378,0.0001998349,0.0001463305,0.006641137,0.0006752415,0.00020003933,0.0003716373,0.00042434878],"genre_scores_gemma":[0.99528587,0.00006448739,0.000022187849,0.000046707275,0.00022040655,0.00016734272,0.003133779,0.00006099919,0.0009981927],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983656,0.00019487987,0.00034150196,0.00057765254,0.00009056435,0.00042981745],"domain_scores_gemma":[0.9989828,0.00039345323,0.0001038269,0.00040683732,0.00007342328,0.00003965254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000104419574,0.00038948358,0.00031734072,0.0003863536,0.00035885695,0.00008358124,0.00023054818,0.0002275842,0.0006073823],"category_scores_gemma":[0.00002634735,0.00030898713,0.0000974629,0.00096800615,0.00010826496,0.00019096762,0.00003841472,0.00031809352,0.00079751614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012019957,0.0053578224,0.01184633,0.0003480365,0.019909548,0.00032633927,0.0028294008,0.00003841851,0.4815003,0.0057524405,0.017947588,0.44212383],"study_design_scores_gemma":[0.09585759,0.013323859,0.6734441,0.0011896961,0.009843544,0.00025020546,0.00031351848,0.00087028503,0.18750153,0.00016645,0.013476963,0.0037622873],"about_ca_topic_score_codex":0.000019905192,"about_ca_topic_score_gemma":0.000050443177,"teacher_disagreement_score":0.6615977,"about_ca_system_score_codex":0.0001649466,"about_ca_system_score_gemma":0.00009422728,"threshold_uncertainty_score":0.99998045},"labels":[],"label_agreement":null},{"id":"W4400125623","doi":"10.1093/bjd/ljae090.057","title":"P030 Implementing the Edmonton Obesity Staging System: a cross-sectional study of the prevalence and management of obesity in a systemic therapies clinic","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Overweight; Obesity; Body mass index; Psoriasis; Cross-sectional study; Population; Hidradenitis suppurativa; Incidence (geometry); Internal medicine; Dermatology; Environmental health; Pathology; Disease","score_opus":0.018026244068118973,"score_gpt":0.2790227932212983,"score_spread":0.2609965491531793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400125623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521057,0.046649672,0.000014881569,0.0000314719,0.000677466,0.00042161372,0.000028753917,0.000009100192,0.00006134218],"genre_scores_gemma":[0.99755645,0.0022821561,0.000010469555,0.0000048341544,0.00001654411,0.00001537039,0.0000011741654,0.0000074346062,0.00010556279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780345,0.0008135819,0.00091478915,0.00017403,0.00008554192,0.00020861615],"domain_scores_gemma":[0.9990221,0.0002559118,0.00047240272,0.00014841449,0.0000906909,0.000010459016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009622531,0.00011300584,0.00038746142,0.000098440534,0.00019559277,0.00003514408,0.0002945149,0.00009506234,0.000026356245],"category_scores_gemma":[0.00001690327,0.00007945996,0.00012904,0.00016207348,0.00015854792,0.00011367588,0.00015215384,0.00023603582,0.0000022932488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008682973,0.00025085386,0.9928436,0.0014507961,0.0008964984,0.00035186636,0.0014054081,0.0000020763166,0.0008889858,0.00016929762,0.000032939133,0.0016208461],"study_design_scores_gemma":[0.0016585236,0.00008993559,0.9753069,0.0013370061,0.0002805397,0.016763361,0.00377989,0.000003439248,0.00064114266,0.000034191715,0.000042647112,0.00006241264],"about_ca_topic_score_codex":0.00022745828,"about_ca_topic_score_gemma":0.00021166027,"teacher_disagreement_score":0.045450754,"about_ca_system_score_codex":0.000047199326,"about_ca_system_score_gemma":0.000055842058,"threshold_uncertainty_score":0.3240283},"labels":[],"label_agreement":null},{"id":"W4400125754","doi":"10.1093/bjd/ljae090.072","title":"P045 An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Delphi method; Facilitator; Medicine; Psoriasis; Disease; Likert scale; Delphi; Family medicine; Intensive care medicine; Psychology; Pathology; Dermatology; Computer science; Artificial intelligence","score_opus":0.0435485983189179,"score_gpt":0.30582179960449596,"score_spread":0.2622732012855781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400125754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98287255,0.00423258,0.0070168907,0.0022716764,0.0024792838,0.00029337776,0.0006372086,0.000034915975,0.00016152672],"genre_scores_gemma":[0.9931054,0.00089673226,0.005347381,0.00012430608,0.00012139655,0.000040182018,0.00030827717,0.00001992633,0.000036374688],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9983569,0.0002396637,0.00091217895,0.00023033378,0.000058966412,0.00020197376],"domain_scores_gemma":[0.99867547,0.0004250523,0.00031834657,0.00013263934,0.00036820726,0.00008030513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003001954,0.00012892213,0.00038652026,0.00024206887,0.00007436179,0.00003381497,0.00023602803,0.00020286391,0.00007263527],"category_scores_gemma":[0.00042356816,0.00013649875,0.00023206252,0.000109301065,0.000100516234,0.00012335887,0.000027713968,0.00015692503,0.000039571052],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025718303,0.0044044782,0.013858626,0.00062757195,0.005855737,0.0039131427,0.001887603,0.00016938329,0.081432074,0.05454333,0.021544604,0.78604513],"study_design_scores_gemma":[0.07413397,0.009533729,0.21813196,0.0064132116,0.010335701,0.28482142,0.0027603763,0.0014213161,0.112050086,0.14275262,0.13369831,0.003947303],"about_ca_topic_score_codex":0.00002222096,"about_ca_topic_score_gemma":0.000023749868,"teacher_disagreement_score":0.7820978,"about_ca_system_score_codex":0.00003346185,"about_ca_system_score_gemma":0.0002339109,"threshold_uncertainty_score":0.5566258},"labels":[],"label_agreement":null},{"id":"W4400131739","doi":"10.5114/dr.2024.140793","title":"Association of serum calcium level and serum uric acid level in psoriasis and its correlation with severity of psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology Review","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Uric acid; Medicine; Calcium; Internal medicine; Dermatology; Gastroenterology","score_opus":0.036470582103257564,"score_gpt":0.2700298545042479,"score_spread":0.2335592724009903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400131739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.660444,0.3367289,0.00006334132,0.0013776366,0.00039236335,0.00043459702,0.00041816023,0.000029585268,0.00011141536],"genre_scores_gemma":[0.948763,0.050476793,0.00008022145,0.00010238838,0.000009535077,0.00003885738,0.000073513285,0.000014486907,0.00044118176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984242,0.00043584543,0.000530923,0.00031411313,0.00005192559,0.00024301339],"domain_scores_gemma":[0.9991965,0.00026580848,0.00026467288,0.00015649758,0.000094124895,0.000022389077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037981645,0.00021574568,0.00079809566,0.00016946216,0.000053320582,0.0000054654993,0.000080549915,0.00035725426,0.00009873479],"category_scores_gemma":[0.00011163446,0.0001743643,0.00007395903,0.00037565254,0.0000739831,0.0001504424,0.000050761446,0.0001815701,0.00003207681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018867978,0.00024353217,0.80010074,0.011927026,0.0019520415,0.00006923728,0.0012089463,0.0000013800177,0.0055113467,0.0018003236,0.0026143603,0.17438236],"study_design_scores_gemma":[0.0032859384,0.00019796655,0.9350032,0.0042116162,0.002235781,0.0013509557,0.000105991145,0.00005628042,0.04368241,0.00019933397,0.009194558,0.00047595135],"about_ca_topic_score_codex":0.000027862285,"about_ca_topic_score_gemma":0.00011475079,"teacher_disagreement_score":0.28831902,"about_ca_system_score_codex":0.00004502755,"about_ca_system_score_gemma":0.00007619622,"threshold_uncertainty_score":0.711037},"labels":[],"label_agreement":null},{"id":"W4400174824","doi":"10.1080/09546634.2024.2371045","title":"Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials","year":2024,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Placebo; Psoriasis; Apremilast; Plaque psoriasis; Onset of action; Internal medicine; Clinical trial; Randomized controlled trial; Gastroenterology; Dermatology; Pathology","score_opus":0.08820321456382156,"score_gpt":0.3608091798270552,"score_spread":0.2726059652632336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400174824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98682326,0.01157617,0.00008200319,0.00063642574,0.00044493692,0.00020405912,0.00017693029,0.000010439786,0.00004579374],"genre_scores_gemma":[0.99564517,0.003894025,0.00028893753,0.000013586951,0.000018825907,0.000013494819,0.000013620759,0.000006993915,0.000105336374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99731755,0.0011967198,0.0010916167,0.00015893536,0.000053756965,0.00018142154],"domain_scores_gemma":[0.9973081,0.0019898226,0.0004928438,0.0001126335,0.00006292805,0.00003370012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009903593,0.00018295209,0.0010336242,0.00030224444,0.000029723911,0.000008543383,0.000080085854,0.000228018,0.0001262852],"category_scores_gemma":[0.0004250929,0.00010611034,0.0003013723,0.00016454075,0.00013336953,0.00008778274,0.000016897618,0.000121060126,0.0000088999395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10210231,0.006575477,0.030948468,0.00028432388,0.005266714,0.004242591,0.0026566107,0.000025732272,0.50161,0.0011299772,0.002187631,0.34297016],"study_design_scores_gemma":[0.028506808,0.008470643,0.045674402,0.0007321682,0.001243388,0.008657923,0.0010505542,0.000017146156,0.8934204,0.0012339812,0.010725836,0.00026674953],"about_ca_topic_score_codex":0.000011897069,"about_ca_topic_score_gemma":0.00000583788,"teacher_disagreement_score":0.3918104,"about_ca_system_score_codex":0.00009509503,"about_ca_system_score_gemma":0.000117913936,"threshold_uncertainty_score":0.4327054},"labels":[],"label_agreement":null},{"id":"W4400257813","doi":"10.1038/s41598-024-65902-8","title":"Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study","year":2024,"lang":"en","type":"article","venue":"Scientific Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Natural Science Foundation of Hubei Province; National Natural Science Foundation of China","keywords":"Secukinumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology; Acanthosis; Papillary dermis; Dermis; Parakeratosis; Interleukin 17; Pathology; Internal medicine; Psoriatic arthritis; Inflammation; Hyperkeratosis","score_opus":0.08090264144576709,"score_gpt":0.3606922976402409,"score_spread":0.2797896561944738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400257813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96913296,0.0019482339,0.00041555718,0.00007943709,0.026924508,0.001049396,0.00009296493,0.0002768823,0.00008008516],"genre_scores_gemma":[0.989791,0.000013768535,0.0003160856,0.00003128152,0.00020201654,0.00019776079,0.0015623306,0.000051411254,0.007834348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672544,0.00022595111,0.0007306542,0.0015452937,0.00016173643,0.0006108961],"domain_scores_gemma":[0.9984157,0.0001236341,0.00025757204,0.0009055077,0.00022080606,0.0000767454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228809,0.00037020186,0.0004480623,0.00028900945,0.000905641,0.00045107838,0.00030191048,0.00023159999,0.0002639626],"category_scores_gemma":[0.000053651816,0.0003210908,0.00024367127,0.0004396143,0.00025697175,0.00057831296,0.00006128998,0.00018736061,0.00007138175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038753092,0.0006013562,0.035001207,0.000049384675,0.00056236767,0.00030765784,0.0020679336,0.000011039397,0.95614976,0.00024909456,0.0007152364,0.0038974523],"study_design_scores_gemma":[0.0037800835,0.0013201814,0.106582835,0.00018683814,0.00073880417,0.0012351,0.0013802428,0.00017252869,0.8475625,0.0034662143,0.03253914,0.0010355294],"about_ca_topic_score_codex":0.000048301386,"about_ca_topic_score_gemma":0.00018823858,"teacher_disagreement_score":0.10858724,"about_ca_system_score_codex":0.00012496117,"about_ca_system_score_gemma":0.0003712205,"threshold_uncertainty_score":0.9999241},"labels":[],"label_agreement":null},{"id":"W4400408268","doi":"10.3390/pharmaceutics16070908","title":"New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors","year":2024,"lang":"en","type":"review","venue":"Pharmaceutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Generalized pustular psoriasis; Psoriasis; Medicine; Receptor; Focus (optics); Pharmacology; Immunology; Computational biology; Dermatology; Biology; Internal medicine; Physics","score_opus":0.08596871339989337,"score_gpt":0.3750268089323546,"score_spread":0.28905809553246126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400408268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014529617,0.9887373,0.000024417384,0.0001505679,0.0073243445,0.0019366607,0.0012695822,0.00019799564,0.00021385138],"genre_scores_gemma":[0.000021422937,0.9843533,0.00053688633,0.000059950387,0.00087727944,0.00057800364,0.0013412739,0.0001745894,0.0120572895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973457,0.0003089404,0.00071533286,0.000892381,0.00007384054,0.000663807],"domain_scores_gemma":[0.99889535,0.00025748942,0.0002962563,0.0003866614,0.000039995026,0.00012425317],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023042539,0.00096314726,0.0016986484,0.00037876694,0.00025561967,0.00006408455,0.00026170348,0.00075196516,0.00024936823],"category_scores_gemma":[0.00003343052,0.0007246399,0.00082974165,0.00029687167,0.000059385526,0.00006352092,0.00012425266,0.00042498723,0.0010227957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017101066,0.00011732933,0.0000026979678,0.0024053196,0.0060006143,0.0000146792645,0.00015607945,2.1220848e-7,0.00022080804,0.00021125918,0.028115327,0.9625847],"study_design_scores_gemma":[0.0030224742,0.00021832704,3.0330543e-7,0.0022917679,0.027074113,0.00004456331,0.000019414434,0.0000016085454,0.0036131346,0.00015598025,0.9629485,0.00060984056],"about_ca_topic_score_codex":0.000025556417,"about_ca_topic_score_gemma":0.000003332368,"teacher_disagreement_score":0.9619748,"about_ca_system_score_codex":0.00022646431,"about_ca_system_score_gemma":0.00023507087,"threshold_uncertainty_score":0.999755},"labels":[],"label_agreement":null},{"id":"W4400413883","doi":"10.15690/pf.v21i3.2764","title":"Potential Effects of Some Factors on Psoriasis Course in Children","year":2024,"lang":"en","type":"article","venue":"Педиатрическая фармакология","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute","funders":"","keywords":"Psoriasis; Medicine; Atopic dermatitis; Disease; Dermatology; Intensive care medicine; Immunology; Pathology","score_opus":0.005900161937061945,"score_gpt":0.2261345748586597,"score_spread":0.22023441292159776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400413883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98177624,0.013475841,0.000023020852,0.00009811577,0.003380461,0.00047861206,0.000134049,0.00017661501,0.00045704],"genre_scores_gemma":[0.997631,0.0003515014,0.000023069095,0.0000519712,0.00016162243,0.00004611734,0.00026404287,0.000047608108,0.0014230596],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99820644,0.00023003801,0.00039529792,0.0005486127,0.00009363528,0.0005259953],"domain_scores_gemma":[0.9991477,0.00029623453,0.00008438413,0.000402493,0.000025162974,0.000044035773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016949998,0.0003801719,0.00051595876,0.00038418197,0.00008611605,0.000024558469,0.00027509566,0.00040844857,0.0003036173],"category_scores_gemma":[0.0000482877,0.0003097716,0.00029965854,0.0003378563,0.00013671847,0.00015801794,0.00006717423,0.00031451133,0.00076913857],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017722112,0.0051609096,0.24967891,0.00073770795,0.007681519,0.00059486565,0.0035724335,0.00018753509,0.3810288,0.021260988,0.011779287,0.31654483],"study_design_scores_gemma":[0.0034094034,0.0009203485,0.6876614,0.00039990677,0.0006238815,0.000047373047,0.00008994452,0.000014278514,0.30419537,0.0007535217,0.0013622456,0.00052231393],"about_ca_topic_score_codex":0.00017823448,"about_ca_topic_score_gemma":0.000016586702,"teacher_disagreement_score":0.4379825,"about_ca_system_score_codex":0.00007081687,"about_ca_system_score_gemma":0.000093998504,"threshold_uncertainty_score":0.99993545},"labels":[],"label_agreement":null},{"id":"W4400552116","doi":"10.1016/j.jdrv.2024.06.007","title":"The efficacy and safety of switching between interleukin inhibitors in psoriasis therapy: A systematic review","year":2024,"lang":"en","type":"review","venue":"JAAD reviews.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Interleukin; Intensive care medicine; Dermatology; Immunology; Cytokine","score_opus":0.04529209523574395,"score_gpt":0.32365232003474476,"score_spread":0.2783602247990008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400552116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017019824,0.9917945,0.0000014007429,0.000067757464,0.000898548,0.007017288,0.00006263975,0.0000379101,0.00010292561],"genre_scores_gemma":[0.00001962579,0.998096,0.000011284724,0.000037101057,0.00010558199,0.0009994647,0.00014304438,0.00006696602,0.00052097166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925788,0.0031517697,0.0031872601,0.00060775434,0.00007534285,0.00039906957],"domain_scores_gemma":[0.99584246,0.0018127376,0.001365403,0.0009104347,0.00003489453,0.00003407267],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003712292,0.0007908632,0.006849858,0.00024600036,0.00014163447,0.000036610647,0.0006005834,0.000508999,0.000025321788],"category_scores_gemma":[0.0006454775,0.00036987528,0.00121329,0.0007105589,0.00011117562,0.000053469335,0.00020983338,0.0006950111,0.00051632803],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000063595157,0.000020399388,0.0000031819575,0.42970583,0.0007665174,0.0000029232667,0.00009828264,7.692306e-10,8.447835e-7,0.000026377538,0.00060923793,0.56876004],"study_design_scores_gemma":[0.00025844772,0.000045104633,0.000003040317,0.47685662,0.0057704975,0.000030609765,0.000007951416,7.0639694e-9,0.0000019826882,0.000008710682,0.51683426,0.00018279515],"about_ca_topic_score_codex":0.000023777544,"about_ca_topic_score_gemma":0.000016628763,"teacher_disagreement_score":0.56857723,"about_ca_system_score_codex":0.00012628947,"about_ca_system_score_gemma":0.00012816502,"threshold_uncertainty_score":0.9998753},"labels":[],"label_agreement":null},{"id":"W4400654569","doi":"10.3899/jrheum.2024-0445","title":"GRAPPA 2023 Annual Meeting Report: Hot Topic Session on Measurement of Musculoskeletal Symptoms in Psoriatic Disease","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Workgroup; Physical therapy; Disease; Enthesitis; Quality of life (healthcare); Musculoskeletal disease; Internal medicine; Dermatology","score_opus":0.013208300992010256,"score_gpt":0.25549442710018244,"score_spread":0.24228612610817218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400654569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785136,0.018070819,0.00005168106,0.0006272412,0.0024597517,0.0001265902,0.000012435006,0.000013600115,0.00012426256],"genre_scores_gemma":[0.99875087,0.0010256247,0.000015613869,0.000012333652,0.000017398337,0.000005481832,0.000007671727,0.000011981706,0.00015302091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980594,0.00066761323,0.0007624624,0.00014613765,0.00012550464,0.00023890879],"domain_scores_gemma":[0.998827,0.000399889,0.00039985048,0.00022600005,0.00011481474,0.0000324923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014568721,0.00016389172,0.00044191096,0.0002695229,0.00007059371,0.0000053612243,0.00021579803,0.00012925979,0.00009866532],"category_scores_gemma":[0.00030551682,0.000097647695,0.00020409892,0.0001950438,0.00010858041,0.000069655136,0.000043693148,0.00027938164,0.000042627053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119401,0.002902901,0.55142146,0.0021529943,0.0091174655,0.0031119133,0.010662535,0.0007972883,0.08261903,0.007851557,0.02110469,0.29631808],"study_design_scores_gemma":[0.025323832,0.0087060705,0.80372983,0.021177733,0.007378561,0.04068688,0.0076179467,0.00020171501,0.037457824,0.009760668,0.035685696,0.0022732338],"about_ca_topic_score_codex":0.00010584831,"about_ca_topic_score_gemma":0.00005636142,"teacher_disagreement_score":0.29404485,"about_ca_system_score_codex":0.00006883065,"about_ca_system_score_gemma":0.00017560998,"threshold_uncertainty_score":0.39819574},"labels":[],"label_agreement":null},{"id":"W4400654581","doi":"10.3899/jrheum.2024-0362","title":"Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis","year":2024,"lang":"en","type":"review","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Mental health; Depression (economics); Medicine; Anxiety; Mood; Quality of life (healthcare); Affect (linguistics); Disease; Psychiatry; Mood disorders; Psychology; Internal medicine; Dermatology; Nursing","score_opus":0.021057913927491824,"score_gpt":0.2746241748676947,"score_spread":0.25356626094020285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400654581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018082282,0.98004234,0.0000066492726,0.000093951196,0.0013805813,0.00029648264,0.000029618757,0.0000132607365,0.000054831373],"genre_scores_gemma":[0.002856313,0.9967422,0.00007526183,0.000012029138,0.000026277728,0.000022534334,0.000020227055,0.000035184534,0.00020999396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734634,0.0010747687,0.0009795085,0.00021838445,0.00006197593,0.00031901695],"domain_scores_gemma":[0.9981513,0.00069359376,0.00080819195,0.00027426783,0.000042435666,0.00003018132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078725273,0.0003964218,0.0021214904,0.00046188498,0.000091793285,0.000021690214,0.00037636756,0.00057669583,0.00008652295],"category_scores_gemma":[0.0000819447,0.00019332292,0.00022072419,0.0002497375,0.0001917971,0.00007021654,0.00011626083,0.00078557973,0.00010229285],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007710239,0.00005165243,0.0026356524,0.0014578592,0.0015889617,0.000045113462,0.0005985844,2.2143634e-7,7.3199686e-7,0.00012555333,0.0011476212,0.99227095],"study_design_scores_gemma":[0.0025147004,0.00046854556,0.00037096997,0.027565481,0.005653422,0.0498507,0.00023298031,1.5297509e-7,0.000011025827,0.00041140016,0.91254824,0.0003723613],"about_ca_topic_score_codex":0.00005853451,"about_ca_topic_score_gemma":0.000110580106,"teacher_disagreement_score":0.9918986,"about_ca_system_score_codex":0.000046688096,"about_ca_system_score_gemma":0.00022664046,"threshold_uncertainty_score":0.78834796},"labels":[],"label_agreement":null},{"id":"W4400654710","doi":"10.3899/jrheum.2024-0327","title":"Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Workgroup; Quality of life (healthcare); Physical therapy; Rheumatology; Internal medicine; Family medicine; Dermatology; Nursing","score_opus":0.012648866641685881,"score_gpt":0.24553926434639034,"score_spread":0.23289039770470446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400654710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665148,0.01999874,0.00007653826,0.008284598,0.0042240084,0.00017977702,0.000023986737,0.000016752547,0.00068080245],"genre_scores_gemma":[0.9978237,0.00091123534,0.000053908934,0.000103875194,0.000031767937,0.000005144131,0.0000027086703,0.000015990985,0.001051665],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780774,0.00086337345,0.00079919986,0.00013641878,0.0000923693,0.0003009176],"domain_scores_gemma":[0.9978711,0.001019435,0.000555639,0.00038511917,0.00014625158,0.000022448054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024351638,0.00016522815,0.00040683537,0.00010848336,0.00028506864,0.00001147097,0.0006477155,0.00014071715,0.000091856054],"category_scores_gemma":[0.000469662,0.000069262365,0.00027056658,0.00032450818,0.00020906425,0.00005217768,0.00018988005,0.0003783302,0.00009681747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028582457,0.0005376499,0.26900163,0.00037729743,0.012279321,0.00062176364,0.05293051,0.001625355,0.15367104,0.008092098,0.39772344,0.10028163],"study_design_scores_gemma":[0.00364592,0.0014306084,0.043532282,0.0039026197,0.0036632484,0.2251138,0.02357363,0.000047504167,0.124689244,0.0032302728,0.5662897,0.0008811551],"about_ca_topic_score_codex":0.00031840283,"about_ca_topic_score_gemma":0.00021303124,"teacher_disagreement_score":0.22546935,"about_ca_system_score_codex":0.00003170492,"about_ca_system_score_gemma":0.00014958151,"threshold_uncertainty_score":0.28244373},"labels":[],"label_agreement":null},{"id":"W4400654813","doi":"10.3899/jrheum.2024-0317","title":"Debate at the GRAPPA 2023 Annual Meeting: Should Methotrexate Be the First Systemic Therapy in Psoriatic Disease?","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriatic arthritis; Systemic therapy; Medicine; Psoriasis; Tolerability; Methotrexate; Clinical trial; Disease; Internal medicine; Intensive care medicine; Dermatology; Adverse effect","score_opus":0.025712371341353357,"score_gpt":0.26650385624015027,"score_spread":0.24079148489879693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400654813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84357893,0.13851225,0.000023342907,0.0148909995,0.0025302793,0.00028950843,0.000045503384,0.000025000403,0.000104166356],"genre_scores_gemma":[0.97371215,0.024725787,0.000005236245,0.00031858493,0.000029234398,0.000030341811,0.000009436122,0.000028173974,0.0011410738],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966652,0.0018973378,0.00071634003,0.0001903451,0.00010059172,0.00043020447],"domain_scores_gemma":[0.9960782,0.003004999,0.00037684257,0.00042692374,0.00008032872,0.0000327075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002490716,0.00027368008,0.00052179274,0.0001656915,0.00045434167,0.00002797735,0.0007775537,0.00018644122,0.00023749187],"category_scores_gemma":[0.00016640946,0.00010977686,0.00028903983,0.00035528207,0.00037271393,0.00008750821,0.00012188366,0.0005306167,0.0002044891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020415574,0.0010904463,0.3810021,0.0008889046,0.02204834,0.0010445397,0.089957036,0.0023093508,0.021498358,0.011205725,0.3183031,0.1302365],"study_design_scores_gemma":[0.020755105,0.0028990817,0.11701841,0.0051971315,0.006636948,0.0980099,0.021868823,0.00051868946,0.011638095,0.012785619,0.7003644,0.0023078048],"about_ca_topic_score_codex":0.00029437174,"about_ca_topic_score_gemma":0.0006374975,"teacher_disagreement_score":0.38206127,"about_ca_system_score_codex":0.00008382268,"about_ca_system_score_gemma":0.0001368597,"threshold_uncertainty_score":0.44765705},"labels":[],"label_agreement":null},{"id":"W4400654945","doi":"10.3899/jrheum.2024-0230","title":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Alternative medicine; Dermatology; Rheumatology; Family medicine; Disease; Medical physics; Internal medicine; Physical therapy; Pathology","score_opus":0.03677734071924004,"score_gpt":0.3203543070989098,"score_spread":0.2835769663796697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400654945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85175896,0.14512748,0.00011014517,0.0016196611,0.0010272796,0.00022745275,0.000028135204,0.000008247027,0.00009262122],"genre_scores_gemma":[0.9180383,0.081531085,0.00016060595,0.00000799335,0.000015118931,0.000012020906,0.0000045864235,0.000011699837,0.00021857841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842757,0.00065282016,0.0004234768,0.00013214127,0.00006738802,0.0002966186],"domain_scores_gemma":[0.9955092,0.003939826,0.00019143998,0.00014429842,0.00018840726,0.000026841102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022664997,0.0001268437,0.00037711204,0.0001786698,0.00041700984,0.000030126785,0.0002227252,0.00014557231,0.000027314005],"category_scores_gemma":[0.0001276941,0.000068228,0.00008149157,0.00013820243,0.0005156683,0.00010055427,0.00007832654,0.00031948218,0.000004890817],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035178994,0.00047780274,0.047130287,0.0007728949,0.007764606,0.000049503666,0.007506957,0.000005204021,0.051457442,0.14217563,0.034752466,0.70438933],"study_design_scores_gemma":[0.045900732,0.035146445,0.17311801,0.005802767,0.0052989344,0.05805449,0.04463937,0.0012029447,0.072450615,0.18152648,0.374737,0.002122205],"about_ca_topic_score_codex":0.00004655523,"about_ca_topic_score_gemma":0.00007856308,"teacher_disagreement_score":0.7022671,"about_ca_system_score_codex":0.000020897758,"about_ca_system_score_gemma":0.00011757494,"threshold_uncertainty_score":0.32073447},"labels":[],"label_agreement":null},{"id":"W4400655074","doi":"10.3899/jrheum.2024-0459","title":"Advancing Basic and Translational Science: Highlights From the Basic Science Workshop at the GRAPPA 2023 Annual Meeting","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Rheumatology Research Foundation; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Psoriatic arthritis; Translational science; Psoriasis; Medicine; Translational research; Plaque psoriasis; Medical physics; Dermatology; Pathology","score_opus":0.010472436577305283,"score_gpt":0.24622524105408405,"score_spread":0.23575280447677877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400655074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94541025,0.040969882,0.00008907972,0.01095241,0.002209463,0.000108861335,0.000033337194,0.000015688436,0.00021104647],"genre_scores_gemma":[0.99711865,0.002314531,0.00005619063,0.00010715674,0.000034694665,0.0000031954664,0.0000037680163,0.000009230944,0.0003525552],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840647,0.00038572747,0.0003963294,0.00022954542,0.00016564135,0.00041628507],"domain_scores_gemma":[0.9962835,0.003086846,0.00020648004,0.00024463877,0.00014254231,0.00003602082],"candidate_categories":["sts"],"consensus_categories":["sts"],"category_scores_codex":[0.0032133544,0.00016245767,0.00025707763,0.00016755222,0.0017255312,0.000060496364,0.00076449127,0.00009054295,0.00022541126],"category_scores_gemma":[0.00022714288,0.000068512425,0.00009325321,0.0006701362,0.0028597708,0.00030387836,0.00014980689,0.00035049074,0.00010158521],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002637626,0.00025203175,0.1508172,0.00007338864,0.002683517,0.00010309214,0.08191611,0.00069750956,0.5013441,0.030365692,0.044565555,0.18454418],"study_design_scores_gemma":[0.012127367,0.0014164867,0.3763928,0.0036474077,0.0046522715,0.07136418,0.042528883,0.001232954,0.16253224,0.034415282,0.28747496,0.0022151384],"about_ca_topic_score_codex":0.00011483602,"about_ca_topic_score_gemma":0.0002247725,"teacher_disagreement_score":0.33881184,"about_ca_system_score_codex":0.00004759404,"about_ca_system_score_gemma":0.0004181149,"threshold_uncertainty_score":0.99985385},"labels":[],"label_agreement":null},{"id":"W4400825519","doi":"10.1016/j.jid.2024.06.1111","title":"LB938 JNJ-77242113, a targeted oral peptide that binds the interleukin (IL)-23 receptor, inhibits IL-23 signaling in the skin of psoriasis (PsO) patients","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Interleukin 23; Receptor; Interleukin 17; Peptide; Interleukin; Medicine; Immunology; Chemistry; Immune system; Cytokine; Internal medicine; Biochemistry","score_opus":0.026541796889218733,"score_gpt":0.24906874082181338,"score_spread":0.22252694393259465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400825519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900918,0.0041385293,0.00003763144,0.00327045,0.001747284,0.00035648444,0.00015880704,0.000023576888,0.00017542807],"genre_scores_gemma":[0.99837875,0.00023635951,0.0002935339,0.00063256314,0.000088997986,0.00003433952,0.00012979441,0.000034549015,0.00017110957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953673,0.0023263192,0.0012777438,0.00032585213,0.00018711247,0.0005156871],"domain_scores_gemma":[0.9971242,0.0013471695,0.0008767247,0.0002933593,0.0002993308,0.00005919669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010561647,0.00041416517,0.0008556498,0.0005732318,0.00019105193,0.000047485697,0.0007186163,0.00041868477,0.00014816828],"category_scores_gemma":[0.00051542645,0.00023486036,0.0004088345,0.00073679903,0.0009879556,0.00030626528,0.0001211817,0.0009531767,0.00017294026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012944281,0.00088044803,0.049349405,0.00022814481,0.003587397,0.00035005854,0.047345538,0.000048587277,0.83425605,0.0029509768,0.050282788,0.009426193],"study_design_scores_gemma":[0.0031312148,0.00076480035,0.009888915,0.0005399303,0.00042326472,0.0009412111,0.005014482,0.000016959215,0.9639269,0.002381227,0.012642556,0.000328509],"about_ca_topic_score_codex":0.00006565195,"about_ca_topic_score_gemma":0.000105223706,"teacher_disagreement_score":0.12967089,"about_ca_system_score_codex":0.000119006625,"about_ca_system_score_gemma":0.0003173295,"threshold_uncertainty_score":0.95773274},"labels":[],"label_agreement":null},{"id":"W4400826274","doi":"10.1016/j.jid.2024.06.139","title":"123 Association of systemic therapies with serious infections among older adults with psoriatic disease","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Disease; Association (psychology); Dermatology; Internal medicine; Psychology","score_opus":0.005980469127664733,"score_gpt":0.2091896262953035,"score_spread":0.20320915716763877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400826274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889916,0.00919995,0.00014104787,0.0007953996,0.0005093086,0.00023638149,0.000029653716,0.000033997872,0.000062656436],"genre_scores_gemma":[0.999232,0.00033548125,0.00009714807,0.000044569384,0.000039623737,0.000028551009,0.000020403826,0.000019772397,0.00018247866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863726,0.00046033558,0.00045795966,0.00015705617,0.00007974837,0.00020766008],"domain_scores_gemma":[0.998465,0.00037484418,0.000646729,0.00011939131,0.00033646208,0.000057576337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015602821,0.00019484741,0.00048413407,0.00027119947,0.00009423021,0.000016659314,0.000103633174,0.00016683273,0.00004414506],"category_scores_gemma":[0.00010598609,0.00012131445,0.00011337956,0.00028656857,0.00034079814,0.00027167803,0.0000132218665,0.00026141613,0.000029927496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017817524,0.0006714233,0.893505,0.0013223588,0.0134807825,0.0010807482,0.031126363,0.00016004448,0.04849014,0.0022069272,0.003419895,0.0027546112],"study_design_scores_gemma":[0.0116465185,0.0022305183,0.7978038,0.0076470086,0.004121751,0.008422838,0.0076179,0.00004012385,0.15739255,0.0010989677,0.0012800095,0.0006979846],"about_ca_topic_score_codex":0.000020407408,"about_ca_topic_score_gemma":0.00006067113,"teacher_disagreement_score":0.10890241,"about_ca_system_score_codex":0.00010667894,"about_ca_system_score_gemma":0.00037467078,"threshold_uncertainty_score":0.49470598},"labels":[],"label_agreement":null},{"id":"W4400930442","doi":"10.25251/skin.8.supp.407","title":"Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Psoriasis; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Dermatology","score_opus":0.026229748451744,"score_gpt":0.3182034868212671,"score_spread":0.2919737383695231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572073,0.0374004,0.000020947635,0.0038686497,0.0009664361,0.00028340914,0.000043238153,0.000006756716,0.00020285195],"genre_scores_gemma":[0.9927265,0.006268368,0.00002622938,0.00025705117,0.00018986793,0.0000052791193,0.000005441361,0.000015649615,0.00050558196],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958524,0.002553649,0.0010444468,0.00014736764,0.00013548252,0.00026664068],"domain_scores_gemma":[0.9938738,0.0054052263,0.00040326308,0.00023893573,0.000052649884,0.000026136408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076051448,0.0001912781,0.00074403017,0.000367786,0.000044119322,0.00000962663,0.00033152514,0.00016430015,0.00022211722],"category_scores_gemma":[0.001475128,0.00009114335,0.0001309999,0.00035393136,0.0003406305,0.00006013452,0.000028261162,0.00046870732,0.000010674478],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1283812,0.0012691531,0.0014591363,0.00024470143,0.0027859025,0.016450379,0.082558624,0.000059411508,0.43969405,0.0022764148,0.050548434,0.2742726],"study_design_scores_gemma":[0.13548604,0.027942928,0.0507914,0.015794951,0.00760968,0.20405072,0.045094293,0.00012796489,0.067388386,0.020504858,0.42356715,0.0016416289],"about_ca_topic_score_codex":0.00009070288,"about_ca_topic_score_gemma":0.00010031597,"teacher_disagreement_score":0.3730187,"about_ca_system_score_codex":0.000052443276,"about_ca_system_score_gemma":0.00012994728,"threshold_uncertainty_score":0.3716718},"labels":[],"label_agreement":null},{"id":"W4400930587","doi":"10.25251/skin.8.supp.404","title":"Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Eisai; Torii Pharmaceutical; Amgen","keywords":"Tolerability; Plaque psoriasis; Medicine; Pooled analysis; Clinical trial; Psoriasis; Internal medicine; Dermatology; Adverse effect; Meta-analysis","score_opus":0.04438970228239314,"score_gpt":0.36332345056434967,"score_spread":0.31893374828195653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674905,0.009103838,0.00022502754,0.0021178585,0.0011070066,0.00047551777,0.00017323007,0.00000832678,0.000040134444],"genre_scores_gemma":[0.9966228,0.0026346392,0.00008333599,0.00013006158,0.00018830199,0.0000065431022,0.000028496002,0.000012845461,0.00029297185],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99495953,0.0023437154,0.002082133,0.00027839662,0.00010100213,0.00023519041],"domain_scores_gemma":[0.99465275,0.0045098774,0.00036727558,0.0003046471,0.000073426825,0.000092018694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043326216,0.00022516135,0.0019108228,0.0006020461,0.000035878675,0.0000090176845,0.00020372328,0.00020679332,0.00035599997],"category_scores_gemma":[0.0010860768,0.00012956184,0.00028942214,0.0007063832,0.000113835165,0.0000423479,0.000039168677,0.00027878387,0.000016334725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08619968,0.0010913806,0.005285228,0.000035390683,0.015024476,0.001452608,0.02913528,0.0037953744,0.02181058,0.000039646417,0.0011190076,0.83501136],"study_design_scores_gemma":[0.30943283,0.11155191,0.19460365,0.009793641,0.1516821,0.014752631,0.033496886,0.0043291952,0.078377545,0.010958499,0.07696679,0.004054312],"about_ca_topic_score_codex":0.0010527915,"about_ca_topic_score_gemma":0.0014294458,"teacher_disagreement_score":0.83095706,"about_ca_system_score_codex":0.00021278944,"about_ca_system_score_gemma":0.00019425746,"threshold_uncertainty_score":0.52833784},"labels":[],"label_agreement":null},{"id":"W4400930719","doi":"10.25251/skin.8.supp.409","title":"Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Dermatology Life Quality Index; Placebo; Medicine; Psoriasis Area and Severity Index; Psoriasis; Clinical endpoint; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Dermatology; Pathology","score_opus":0.030731104938953067,"score_gpt":0.2982840636318148,"score_spread":0.2675529586928617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96153605,0.031529795,0.000074516436,0.0033661164,0.0026418748,0.0005717252,0.00019996129,0.000017029104,0.000062910636],"genre_scores_gemma":[0.9967071,0.001600457,0.00004503345,0.0006306636,0.00064971595,0.000005599582,0.00024394278,0.00002996268,0.000087529115],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99411273,0.0030782234,0.0017460876,0.00033860953,0.00034813513,0.00037622105],"domain_scores_gemma":[0.99392945,0.0037590778,0.001014309,0.0009959032,0.00021906468,0.00008217199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024715476,0.00035003727,0.0012947744,0.00017110797,0.00014042646,0.00001772282,0.0011918332,0.00029390698,0.000568485],"category_scores_gemma":[0.002247029,0.00015726943,0.00016386296,0.00027661864,0.0006815437,0.0001276616,0.00018424087,0.0006542641,0.00003668778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65786743,0.0033263278,0.19863026,0.00041171597,0.017817311,0.000572481,0.01977551,0.00009805585,0.02575832,0.0006907509,0.039319273,0.035732534],"study_design_scores_gemma":[0.47795254,0.014335848,0.42617998,0.0024162924,0.009530802,0.0034789536,0.011603653,0.00009829199,0.005958863,0.0039027345,0.0427099,0.0018321621],"about_ca_topic_score_codex":0.0024850867,"about_ca_topic_score_gemma":0.00060668413,"teacher_disagreement_score":0.2275497,"about_ca_system_score_codex":0.000056640256,"about_ca_system_score_gemma":0.0005649784,"threshold_uncertainty_score":0.6413261},"labels":[],"label_agreement":null},{"id":"W4400930743","doi":"10.25251/skin.8.supp.406","title":"Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Dermira; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Computer science; Dermatology","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400930743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8924461,0.08914056,0.000054727967,0.014738859,0.0021131418,0.0004323636,0.0003472713,0.000025511505,0.0007014679],"genre_scores_gemma":[0.9712721,0.026832925,0.000046404748,0.0002812829,0.00084491493,0.0000023573039,0.000057386416,0.000023533383,0.0006391099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965476,0.0015483623,0.0012459973,0.00024195432,0.0001275815,0.00028853395],"domain_scores_gemma":[0.9891089,0.010038125,0.00044096337,0.00028814148,0.00006518677,0.00005865321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004107199,0.0002734667,0.0008538619,0.00016036286,0.00019050369,0.000027804497,0.0002891888,0.0002150057,0.00021708489],"category_scores_gemma":[0.0019523544,0.0001235148,0.00012264025,0.00021574167,0.00041948972,0.00006928897,0.000056340064,0.0005816698,0.000026858057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09416894,0.0006348892,0.00038843526,0.000075879056,0.005905161,0.0037269345,0.046236135,0.000035357243,0.07761314,0.0011438659,0.04859599,0.7214753],"study_design_scores_gemma":[0.16115947,0.010309008,0.008601205,0.006697407,0.011123861,0.05758612,0.016285181,0.0000826999,0.025795413,0.008297715,0.69287574,0.0011861885],"about_ca_topic_score_codex":0.00020040224,"about_ca_topic_score_gemma":0.0001222922,"teacher_disagreement_score":0.7202891,"about_ca_system_score_codex":0.000042764827,"about_ca_system_score_gemma":0.00009701909,"threshold_uncertainty_score":0.5036787},"labels":[],"label_agreement":null},{"id":"W4400934629","doi":"10.1186/s13223-024-00907-6","title":"Association of psoriasis with allergic multimorbidity of asthma, rhinitis, and eczema among adolescents: a cross-sectional study","year":2024,"lang":"en","type":"article","venue":"Allergy Asthma and Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Kuwait University; Kuwait Foundation for the Advancement of Sciences","keywords":"Medicine; Cross-sectional study; Psoriasis; Multimorbidity; Asthma; Dermatology; Association (psychology); Comorbidity; Immunology; Internal medicine; Psychology; Pathology","score_opus":0.021251509356516776,"score_gpt":0.2991631527425861,"score_spread":0.27791164338606933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400934629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018943,0.0077808653,0.000024954206,0.00005074367,0.0013384807,0.00030609075,0.000072443225,0.000058632093,0.00017835388],"genre_scores_gemma":[0.9953609,0.003276363,0.000059430044,0.00001726804,0.0000693779,0.00003311283,0.00008226039,0.000023643664,0.0010776046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731565,0.00069756777,0.0009568647,0.0006086561,0.00009153338,0.0003297054],"domain_scores_gemma":[0.99832803,0.0007975462,0.00038280716,0.00026861377,0.00018433933,0.000038657607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008234924,0.000277746,0.00069368485,0.00015316642,0.00014251136,0.000027422348,0.00016178138,0.0006666048,0.00031971402],"category_scores_gemma":[0.00017803784,0.00022429053,0.00018420265,0.00017751078,0.0006836133,0.0001550702,0.00014998768,0.000429928,0.000033184773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014043481,0.0013057861,0.9747189,0.000047628935,0.0067599663,0.000029609477,0.0003335092,0.000003207764,0.0012289335,0.00017674002,0.00008996374,0.013901353],"study_design_scores_gemma":[0.0051994836,0.0024962882,0.9885424,0.00009773426,0.0001413306,0.00005446446,0.0002523675,0.00001447192,0.00049624534,0.0000707445,0.0024332474,0.00020126216],"about_ca_topic_score_codex":0.0005002563,"about_ca_topic_score_gemma":0.00079530285,"teacher_disagreement_score":0.013823406,"about_ca_system_score_codex":0.00003665755,"about_ca_system_score_gemma":0.0000759049,"threshold_uncertainty_score":0.9146303},"labels":[],"label_agreement":null},{"id":"W4400973275","doi":"10.3390/brainsci14080747","title":"Do Psoriasis and Atopic Dermatitis Affect Memory, Attention, Stress and Emotions?","year":2024,"lang":"en","type":"article","venue":"Brain Sciences","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Affect (linguistics); Psoriasis; Dermatology; Medicine; Psychology; Communication","score_opus":0.021483713016897783,"score_gpt":0.27457114656375636,"score_spread":0.2530874335468586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400973275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97515076,0.020239651,0.000051515126,0.0021724983,0.00091655715,0.00012098,0.00004070336,0.000072776435,0.0012345475],"genre_scores_gemma":[0.99721575,0.00049268786,0.00010698976,0.00009926985,0.000045497032,0.000015445337,0.000014570473,0.00000422856,0.0020055391],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992142,0.0001393693,0.00011128141,0.0003154742,0.000038165745,0.0001815561],"domain_scores_gemma":[0.9995531,0.00029899683,0.000023653314,0.0000898634,0.0000132559935,0.000021148999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031145537,0.00010558718,0.000120995224,0.00012615362,0.0003908697,0.00014074524,0.000092118215,0.00007876118,0.0001767663],"category_scores_gemma":[0.00005036617,0.000079078935,0.00003765813,0.00022147426,0.00044305364,0.00018947938,0.000049905455,0.000049506463,0.00008453153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007900005,0.00009441668,0.14676932,0.00025825694,0.00036484248,0.000044955093,0.0032380251,0.0000025504057,0.018147407,0.015704067,0.019146776,0.7962215],"study_design_scores_gemma":[0.00090456253,0.00024191251,0.9684767,0.0003111599,0.00014575268,0.0003204213,0.001659604,0.00003388015,0.008927889,0.002471104,0.016184526,0.00032246605],"about_ca_topic_score_codex":0.00005023987,"about_ca_topic_score_gemma":0.00005719233,"teacher_disagreement_score":0.8217074,"about_ca_system_score_codex":0.00000837353,"about_ca_system_score_gemma":0.00002989603,"threshold_uncertainty_score":0.32247454},"labels":[],"label_agreement":null},{"id":"W4401114827","doi":"10.1007/s13555-024-01224-x","title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Incyte; Dermira; Celgene; Sanofi; Amgen; Pfizer","keywords":"Randomized controlled trial; Psoriasis; Medicine; Phase (matter); Physical therapy; Internal medicine; Dermatology; Physics","score_opus":0.020853798424552844,"score_gpt":0.27203108451029606,"score_spread":0.2511772860857432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401114827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98138314,0.01343988,0.000033967102,0.0020922276,0.0007281677,0.0016102635,0.0005553217,0.00008689366,0.00007011697],"genre_scores_gemma":[0.99667984,0.0014039688,0.00009048688,0.0008781576,0.000023376479,0.00025184912,0.0005226233,0.000026287331,0.00012343352],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966857,0.0014425634,0.00087249966,0.00058996957,0.000050623377,0.00035864871],"domain_scores_gemma":[0.99653316,0.002821037,0.00022130896,0.00031945566,0.000058159476,0.000046856818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006196848,0.00038249488,0.0012926256,0.00015107704,0.00021957811,0.00006781032,0.00012007179,0.0003213153,0.00004175435],"category_scores_gemma":[0.0002944996,0.00020040256,0.00013804724,0.00015714428,0.00024086445,0.00013423483,0.000043355336,0.00021479907,0.000023754572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68263835,0.00080989435,0.030747037,0.000018523915,0.0072873933,0.00016598034,0.010577014,0.0000021552178,0.0018488652,0.00066112244,0.0011744705,0.2640692],"study_design_scores_gemma":[0.9227992,0.0013687013,0.042208508,0.00019632961,0.0010499797,0.000230814,0.00068591005,0.00005043291,0.015851226,0.004076422,0.010549503,0.0009329241],"about_ca_topic_score_codex":0.00021974146,"about_ca_topic_score_gemma":0.00007190921,"teacher_disagreement_score":0.2631363,"about_ca_system_score_codex":0.000011785167,"about_ca_system_score_gemma":0.000055032324,"threshold_uncertainty_score":0.8172179},"labels":[],"label_agreement":null},{"id":"W4401123996","doi":"10.7573/dic.2024-5-6","title":"New and emerging oral therapies for psoriasis","year":2024,"lang":"en","type":"review","venue":"Drugs in Context","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Amgen","keywords":"Medicine; Apremilast; Psoriasis; Adverse effect; Acitretin; Methotrexate; Pharmacology; Clinical trial; Intensive care medicine; Dermatology; Immunology; Internal medicine","score_opus":0.04510012189573023,"score_gpt":0.3263494329327066,"score_spread":0.28124931103697637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401123996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000740639,0.9959613,0.00001933129,0.00008625498,0.0025253769,0.0007656373,0.00017701677,0.000064695974,0.00032633953],"genre_scores_gemma":[0.00018694898,0.9840304,0.00013999242,0.000034985947,0.00015708299,0.00028663545,0.00027604165,0.000059672708,0.014828225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985485,0.00016838135,0.0004335447,0.00049216906,0.000022118962,0.00033525212],"domain_scores_gemma":[0.9991968,0.00040398908,0.00012165702,0.00023640058,0.00001789565,0.000023249822],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025139906,0.00044030702,0.0013458155,0.000274853,0.000081843544,0.000037197042,0.00019317729,0.00050877256,0.00018957972],"category_scores_gemma":[0.000031366617,0.00031865705,0.00040534904,0.00017919921,0.00005571561,0.000048076934,0.00007506951,0.00024158807,0.00035747813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026478288,0.000017166945,0.000005056123,0.0018298031,0.0009723072,0.000003613869,0.0014271335,4.6407256e-9,0.0000026826558,0.0011941013,0.008098942,0.9864227],"study_design_scores_gemma":[0.00093463983,0.000054542124,0.0000025155205,0.0030340685,0.0017505769,0.000021353782,0.00040494106,1.403108e-7,0.000011892553,0.00035720732,0.9931227,0.00030545413],"about_ca_topic_score_codex":0.00012993606,"about_ca_topic_score_gemma":0.00015167738,"teacher_disagreement_score":0.98611724,"about_ca_system_score_codex":0.000059664948,"about_ca_system_score_gemma":0.00015988464,"threshold_uncertainty_score":0.99992657},"labels":[],"label_agreement":null},{"id":"W4401195165","doi":"10.1177/12034754241266187","title":"Management of Guttate Psoriasis: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Calcipotriol; Dermatology; Psoriasis; MEDLINE; Cochrane Library; Ultraviolet therapy; Randomized controlled trial; Surgery","score_opus":0.045503651313513714,"score_gpt":0.3108583456931412,"score_spread":0.2653546943796275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401195165","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012938041,0.9964998,0.000002430012,0.00014926406,0.002312388,0.0006383137,0.000021166114,0.000013430866,0.00035030363],"genre_scores_gemma":[0.00002071023,0.9969055,0.000014476017,0.000085526044,0.00015163189,0.000028845137,0.00003884542,0.000037829046,0.002716605],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960447,0.00058625854,0.002744119,0.00022663012,0.00014939802,0.00024887925],"domain_scores_gemma":[0.99617285,0.0012190958,0.002097254,0.00032199948,0.00013269951,0.000056081637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015838519,0.00046908777,0.0067098327,0.00059288455,0.000041097275,0.0000070026003,0.00021956261,0.00026476692,0.00014732512],"category_scores_gemma":[0.00019027592,0.00024400691,0.0011604913,0.00035893844,0.00012685228,0.000035549176,0.00004980911,0.00035780173,0.00008093552],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019173984,0.000035945177,3.714989e-7,0.71512556,0.0062209293,0.003144878,0.000051612147,6.3840164e-9,7.235842e-7,0.0000291329,0.0214685,0.25390318],"study_design_scores_gemma":[0.00011457931,0.00011474952,7.983184e-8,0.60432976,0.049538013,0.020172404,0.00006867395,1.3147019e-8,7.186885e-7,0.000023205424,0.32551813,0.000119687524],"about_ca_topic_score_codex":0.0000030863089,"about_ca_topic_score_gemma":3.3956553e-7,"teacher_disagreement_score":0.30404964,"about_ca_system_score_codex":0.000048001737,"about_ca_system_score_gemma":0.0001537947,"threshold_uncertainty_score":0.99503124},"labels":[],"label_agreement":null},{"id":"W4401219495","doi":"10.3899/jrheum.2024-0664","title":"Unintended Consequences of Immune Therapy for Immune-Mediated Diseases: Paradoxical Psoriasis and Dupilumab-Associated Musculoskeletal Syndrome","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Dupilumab; Unintended consequences; Arthritis; Immune system; Immunology; Plaque psoriasis; Atopic dermatitis","score_opus":0.012126522535737679,"score_gpt":0.25540098549334744,"score_spread":0.24327446295760977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9113542,0.085609816,0.00006822691,0.0011504907,0.0013703615,0.00025590268,0.00014441782,0.000033164855,0.00001343504],"genre_scores_gemma":[0.9864064,0.013344361,0.000029993324,0.000017674356,0.0000057164157,0.000016307029,0.000063163956,0.000021704096,0.00009470411],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99784136,0.0006922408,0.0009031146,0.0001654961,0.0000645593,0.00033323033],"domain_scores_gemma":[0.99712986,0.0019481059,0.00052554056,0.00019330195,0.00016424533,0.000038945964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080284465,0.00023901643,0.0008863851,0.00020962502,0.00016152799,0.000014276119,0.00033452394,0.00027950612,0.0001499611],"category_scores_gemma":[0.00038381704,0.00014196053,0.00040194925,0.00020826618,0.0013039142,0.00010290129,0.000045012002,0.0002602586,0.000019118774],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02291369,0.0031585486,0.08440956,0.0010522616,0.049339563,0.00040863518,0.012629672,0.000022424825,0.68414444,0.028717062,0.004823378,0.10838077],"study_design_scores_gemma":[0.09628268,0.038299114,0.49473435,0.0056074723,0.0164329,0.13861394,0.020476962,0.00029697505,0.104599535,0.064781934,0.01602563,0.003848497],"about_ca_topic_score_codex":0.00014480375,"about_ca_topic_score_gemma":0.00001175586,"teacher_disagreement_score":0.5795449,"about_ca_system_score_codex":0.00003774032,"about_ca_system_score_gemma":0.00022031018,"threshold_uncertainty_score":0.57889825},"labels":[],"label_agreement":null},{"id":"W4401219509","doi":"10.3899/jrheum.2024-0655","title":"GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"XBiotech; Sanofi; Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Body surface area; Internal medicine; Surgery","score_opus":0.04032703183123507,"score_gpt":0.2846430544685096,"score_spread":0.24431602263727456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9533024,0.029149354,0.0021803242,0.007642789,0.007048583,0.00032867322,0.000106391584,0.00007848847,0.00016302362],"genre_scores_gemma":[0.99514574,0.0035240627,0.00023601344,0.00033639045,0.000042914762,0.000017904384,0.000036373294,0.000031705604,0.00062886847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981877,0.0004329951,0.00069691404,0.00019510895,0.000054774944,0.00043245684],"domain_scores_gemma":[0.99735725,0.0018791127,0.00032114238,0.0002783894,0.00013100065,0.000033101172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001327016,0.0002676337,0.000637235,0.00025617608,0.00021598095,0.00002555343,0.0005120485,0.00039506427,0.0002948916],"category_scores_gemma":[0.0001714392,0.00015022962,0.00041723752,0.00018646546,0.00028711357,0.00012168224,0.000060007063,0.00038707233,0.00013827591],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011867009,0.0012825493,0.054609116,0.00083014864,0.019975677,0.00015911937,0.018127082,0.000071762355,0.20276451,0.09038119,0.51486385,0.08506801],"study_design_scores_gemma":[0.015612876,0.0060933176,0.002632232,0.001053687,0.004580716,0.045386523,0.0048462143,0.00013089995,0.08784717,0.03615952,0.7942408,0.0014160447],"about_ca_topic_score_codex":0.000053068405,"about_ca_topic_score_gemma":0.00005704804,"teacher_disagreement_score":0.27937695,"about_ca_system_score_codex":0.00004627586,"about_ca_system_score_gemma":0.00012694199,"threshold_uncertainty_score":0.6126186},"labels":[],"label_agreement":null},{"id":"W4401219522","doi":"10.3899/jrheum.2024-0621","title":"Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; University of Pennsylvania; National Psoriasis Foundation; Samsung; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Celgene; Rheumatology Research Foundation; Gilead Sciences; Sanofi; Eli Lilly and Company; Pfizer; Amgen","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Breakout; Dermatology; Rheumatology; Multidisciplinary approach; Disease; Session (web analytics); Enthesitis; Family medicine; Physical therapy; Internal medicine","score_opus":0.008005670118887242,"score_gpt":0.242216829679492,"score_spread":0.23421115956060476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95617485,0.04194092,0.0003752882,0.0005220371,0.0005647142,0.00032813204,0.00007449778,0.0000069572834,0.0000125905],"genre_scores_gemma":[0.99701184,0.00278478,0.00011269655,0.000008357225,0.0000024101278,0.000008543939,0.000031195224,0.000010597922,0.000029573057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988731,0.00025268292,0.0005591283,0.00011930922,0.000055207292,0.00014057691],"domain_scores_gemma":[0.9976991,0.0011565574,0.00060151174,0.00019062207,0.00032819802,0.000024040037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032471432,0.00014135406,0.00044705288,0.00009312218,0.00012292447,0.000009667403,0.00013690464,0.00011744533,0.000011500167],"category_scores_gemma":[0.00019664541,0.00006527683,0.00006025426,0.00012024739,0.00044830734,0.00008854903,0.00004386077,0.000101977814,0.0000013881485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002694699,0.0000818601,0.9794266,0.0007011264,0.0008917071,0.000016253294,0.002745958,0.000014493575,0.00028519248,0.0014118194,0.0008680096,0.010862283],"study_design_scores_gemma":[0.010135982,0.0018387119,0.95394224,0.0018727817,0.0035646087,0.013117955,0.005583533,0.00008619208,0.0040741162,0.0012829558,0.004079842,0.00042110553],"about_ca_topic_score_codex":0.00005820461,"about_ca_topic_score_gemma":0.000069920796,"teacher_disagreement_score":0.040836982,"about_ca_system_score_codex":0.000016543348,"about_ca_system_score_gemma":0.0001708395,"threshold_uncertainty_score":0.26619118},"labels":[],"label_agreement":null},{"id":"W4401231162","doi":"10.1136/annrheumdis-2024-eular.307","title":"AB0402 HIGHER LEVELS OF HIGH-SENSITIVITY CRP IS ASSOCIATED WITH FUTURE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS: A PROSPECTIVE COHORT STUDY","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Toronto; University Health Network; Arthritis Society; Women's College Hospital; Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Prospective cohort study; Cohort; Dermatology; Internal medicine","score_opus":0.02266674959650849,"score_gpt":0.2609871561671661,"score_spread":0.23832040657065762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401231162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969716,0.007867494,0.000007660055,0.0001724285,0.0005871319,0.0010020869,0.0005712878,0.000034325272,0.000060415463],"genre_scores_gemma":[0.9992374,0.00021098707,0.000042590324,0.00002088932,0.000014643269,0.00012865076,0.00003132658,0.000021391104,0.00029210703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980409,0.00050772785,0.00067694456,0.00032053466,0.00017640325,0.0002774589],"domain_scores_gemma":[0.99864364,0.00039744223,0.00037525466,0.00037279763,0.00018554846,0.000025297852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000556364,0.00025988818,0.00085481256,0.00014586825,0.000085688494,0.000010751616,0.00018121062,0.00011684945,0.00023969715],"category_scores_gemma":[0.00014888546,0.00016678374,0.00017598148,0.000492891,0.00015876767,0.00010240882,0.00008613079,0.00010341417,0.000013783793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012448789,0.008866948,0.6909697,0.000894234,0.022807086,0.000054425367,0.020710602,0.0000379516,0.0010122422,0.0013997211,0.0018602085,0.25014198],"study_design_scores_gemma":[0.0017896475,0.00026090175,0.97755593,0.0018769116,0.00053839147,0.000002909517,0.0008063551,0.0000026172095,0.01618379,0.00079018436,0.000018444242,0.00017393274],"about_ca_topic_score_codex":0.00018598832,"about_ca_topic_score_gemma":0.0003240399,"teacher_disagreement_score":0.2865862,"about_ca_system_score_codex":0.000041191328,"about_ca_system_score_gemma":0.00025752772,"threshold_uncertainty_score":0.68012434},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4401232044","doi":"10.1136/annrheumdis-2024-eular.2938","title":"POS0983 POOLED ANALYSIS OF THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES TO LONGITUDINALLY EVALUATE THE NOVEL PSORIATIC ARTHRITIS 5-THERMOMETER SCALE (PSA-5TS) DOMAINS DURING GUSELKUMAB TREATMENT","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital","funders":"","keywords":"Psoriatic arthritis; Placebo; Medicine; Double blind; Thermometer; Dermatology; Psoriasis; Physics; Pathology","score_opus":0.0667616839851884,"score_gpt":0.3449086537650987,"score_spread":0.2781469697799103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401232044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.933298,0.060744785,0.00014884243,0.0014048927,0.00062020007,0.003087428,0.0005655048,0.000061730316,0.00006861868],"genre_scores_gemma":[0.9930444,0.004690297,0.000029501549,0.000055751807,0.00003278013,0.0013465286,0.00006408482,0.00003432106,0.0007023321],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99680555,0.0007564674,0.0012317116,0.000489278,0.00024519645,0.0004717919],"domain_scores_gemma":[0.99584657,0.0024953282,0.00041240503,0.0009176701,0.00025988216,0.00006812838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001124781,0.00051207177,0.0025088678,0.00054789224,0.0003482041,0.000062285,0.0005255945,0.000107309344,0.00033338804],"category_scores_gemma":[0.00046633338,0.00024851898,0.002335088,0.0010156145,0.00042609288,0.00012518646,0.00016812615,0.00008603808,0.00007987494],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4965943,0.003159698,0.00037820401,0.00038470564,0.41550985,0.000013916201,0.0053933603,0.0015397753,0.0050143683,0.00062773714,0.00033317396,0.0710509],"study_design_scores_gemma":[0.78076434,0.00086594926,0.0070073204,0.001912184,0.18243153,0.000022714767,0.00097101677,0.0008738801,0.023147263,0.001348214,0.00003949836,0.0006160937],"about_ca_topic_score_codex":0.00016710626,"about_ca_topic_score_gemma":0.00039327735,"teacher_disagreement_score":0.28417,"about_ca_system_score_codex":0.00006539527,"about_ca_system_score_gemma":0.00013434398,"threshold_uncertainty_score":0.9999967},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W4401280614","doi":"","title":"Spevigo® (Spesolimab-Sbzo) Injection for the Treatment of Generalized Pustular Psoriasis.","year":2024,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mediprobe Research (Canada); University of Toronto","funders":"","keywords":"Generalized pustular psoriasis; Pustular psoriasis; Dermatology; Medicine; Psoriasis","score_opus":0.03269183141872107,"score_gpt":0.24813056683321072,"score_spread":0.21543873541448966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401280614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82262176,0.15786299,0.0007697429,0.0011611442,0.011032397,0.0043544504,0.00038147706,0.00029859587,0.0015174713],"genre_scores_gemma":[0.97738314,0.0030852393,0.00008691935,0.000040802173,0.00038498425,0.005697457,0.00017340308,0.000032139986,0.013115906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989706,0.00009824073,0.0002525613,0.0002863122,0.000033085762,0.00035915064],"domain_scores_gemma":[0.99927783,0.0003211411,0.00006122532,0.00028073366,0.000039287093,0.00001980337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021543466,0.00019308325,0.00028007058,0.00010669098,0.00014521877,0.000024621517,0.000121694786,0.00015900041,0.000099498524],"category_scores_gemma":[0.000026319422,0.00011569431,0.00032073088,0.0001833405,0.00008142511,0.000056277968,0.000013566607,0.00004342632,0.000065571396],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043070002,0.00028440478,0.00059621054,0.00003445585,0.0018906851,0.0000039047927,0.0005025657,0.000018699007,0.0028411318,0.0017735756,0.0034949712,0.9881287],"study_design_scores_gemma":[0.0041922177,0.00066008524,0.030734325,0.000012454079,0.001704246,0.00005195627,0.0001471332,0.000038828133,0.116485454,0.0006635753,0.84506553,0.00024417613],"about_ca_topic_score_codex":0.00013044682,"about_ca_topic_score_gemma":0.00004130482,"teacher_disagreement_score":0.9878845,"about_ca_system_score_codex":0.00010803769,"about_ca_system_score_gemma":0.000029631328,"threshold_uncertainty_score":0.47178772},"labels":[],"label_agreement":null},{"id":"W4401339443","doi":"10.1177/12034754241269160","title":"Unraveling the Connection: A Systematic Review of HPV in Individuals With Psoriasis","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Connection (principal bundle); Dermatology; Systematic review; MEDLINE","score_opus":0.04240401310491918,"score_gpt":0.298552426697327,"score_spread":0.2561484135924078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401339443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008011484,0.99774253,0.0000023759656,0.00035293144,0.0010802967,0.0005778228,0.000016150878,0.000006469647,0.0001413211],"genre_scores_gemma":[0.00019560386,0.99909526,0.000006165661,0.00016193013,0.00018840127,0.000027053422,0.000024424746,0.000026031285,0.0002751392],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99642473,0.00091596093,0.0021343196,0.00017934416,0.00014652604,0.000199142],"domain_scores_gemma":[0.99370486,0.004062421,0.0018120242,0.00024115374,0.00014766124,0.00003185494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002613157,0.00036048915,0.004894099,0.00060346123,0.000052685496,0.000008737176,0.00017496341,0.0002532738,0.00016892923],"category_scores_gemma":[0.00085244287,0.0001457313,0.0005185409,0.0005388954,0.00016347412,0.00003372028,0.000025292698,0.00051832094,0.000012762163],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002585635,0.000038559057,0.000021846208,0.8351037,0.0032559962,0.0007411894,0.00031207065,6.74968e-8,6.904472e-7,0.000022246697,0.0052278996,0.15524991],"study_design_scores_gemma":[0.00019621199,0.00021650524,0.0000013608222,0.77966064,0.019513959,0.039479516,0.00027591694,4.134809e-8,0.0000015025911,0.000016960914,0.16050884,0.00012856288],"about_ca_topic_score_codex":0.00001286099,"about_ca_topic_score_gemma":0.0000051029106,"teacher_disagreement_score":0.15528095,"about_ca_system_score_codex":0.000047249003,"about_ca_system_score_gemma":0.0003819125,"threshold_uncertainty_score":0.594275},"labels":[],"label_agreement":null},{"id":"W4401420454","doi":"10.1080/07853890.2024.2386524","title":"Health-related quality of life in patients with palmoplantar pustulosis – a Swedish register study","year":2024,"lang":"en","type":"article","venue":"Annals of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Portugal; Janssen Australia; AbbVie Canada; LEO Pharma; Boehringer Ingelheim","keywords":"Palmoplantar pustulosis; Medicine; Quality of life (healthcare); Register (sociolinguistics); Dermatology; Psoriasis; Nursing","score_opus":0.07317423778520586,"score_gpt":0.33348111550503723,"score_spread":0.26030687771983135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401420454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827238,0.012547516,0.0000011056659,0.003581946,0.00036186542,0.00041500962,0.00007228793,0.000022700013,0.00027381658],"genre_scores_gemma":[0.99886966,0.00025975358,0.0000035877144,0.0002549781,0.000017874692,0.000014520416,0.00018840304,0.000010704955,0.0003805384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982958,0.00039226792,0.0007693857,0.00024028547,0.000094098556,0.00020816494],"domain_scores_gemma":[0.99916816,0.00021532773,0.00024067884,0.00025091303,0.00009112239,0.00003382088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009221089,0.00014567183,0.0007354812,0.00020240017,0.000027027223,0.0000014152005,0.00010861319,0.00008424064,0.000197745],"category_scores_gemma":[0.00012561816,0.00009239962,0.00005209425,0.000308553,0.00017852003,0.000045471403,0.000024970792,0.00012360817,0.000017433593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019652192,0.001192605,0.96781886,0.00025893058,0.0010316627,0.00001224103,0.004325769,7.79452e-7,0.00020352696,0.000090377194,0.0108937025,0.01220633],"study_design_scores_gemma":[0.005973862,0.0033822863,0.98812777,0.0005779985,0.00008478428,0.0000020120801,0.00083596207,2.5853356e-7,0.00025387053,0.000045624605,0.00062453706,0.0000910613],"about_ca_topic_score_codex":0.0025233903,"about_ca_topic_score_gemma":0.00042106176,"teacher_disagreement_score":0.020308886,"about_ca_system_score_codex":0.000010652752,"about_ca_system_score_gemma":0.00006825409,"threshold_uncertainty_score":0.3814628},"labels":[],"label_agreement":null},{"id":"W4401442020","doi":"10.2196/54762","title":"Development, Feasibility, and Acceptability of the Electronic Patient Benefit Index for Psoriasis in Clinical Practice: Mixed Methods Study","year":2024,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universitätsklinikum Hamburg-Eppendorf; Deutsche Forschungsgemeinschaft","keywords":"Psoriasis; Clinical Practice; Index (typography); Medicine; Medical physics; Computer science; Family medicine; Dermatology; World Wide Web","score_opus":0.039425778978181086,"score_gpt":0.398307853839227,"score_spread":0.35888207486104595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401442020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990357,0.00570965,0.00018765975,0.00035853588,0.001295171,0.0019134011,0.000018524299,0.000040777413,0.00011931553],"genre_scores_gemma":[0.9974387,0.00007902043,0.0017163561,0.00006565861,0.00001286907,0.0006057662,0.000017358429,0.00001632978,0.000047887857],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99649864,0.001571263,0.0009269298,0.000553897,0.000042945197,0.00040633488],"domain_scores_gemma":[0.9971182,0.0021723704,0.00019519574,0.0004119014,0.000080614285,0.00002173772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013290787,0.00021359212,0.0005622661,0.000124048,0.00011803478,0.0000137076695,0.00022619976,0.0003840482,0.00007239517],"category_scores_gemma":[0.0005091059,0.0001496791,0.0001609101,0.00027753206,0.00019749098,0.00010217591,0.00023701273,0.00033583722,0.000010708531],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007244405,0.001605016,0.4911222,0.00010427347,0.00071024825,0.0000071201166,0.003156968,5.2670987e-7,0.00043345566,0.0012832659,0.0002478294,0.5006046],"study_design_scores_gemma":[0.0030408439,0.00039088915,0.9120273,0.000016071828,0.00024219656,0.00020059229,0.0025807517,0.000011710546,0.008443856,0.0012586914,0.07158864,0.0001984619],"about_ca_topic_score_codex":0.000028197503,"about_ca_topic_score_gemma":0.0005845225,"teacher_disagreement_score":0.5004062,"about_ca_system_score_codex":0.00010197238,"about_ca_system_score_gemma":0.00032222067,"threshold_uncertainty_score":0.6103737},"labels":[],"label_agreement":null},{"id":"W4401699847","doi":"10.3390/jcm13164890","title":"Psychological Aspects of Cutaneous Pain in Psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.06570828772364722,"score_gpt":0.39395964980763903,"score_spread":0.3282513620839918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401699847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598995,0.021808058,0.00014506698,0.003766627,0.007070667,0.00010260823,0.000005797264,0.000019411604,0.0071822777],"genre_scores_gemma":[0.99596626,0.0025217177,0.0001515951,0.0002518787,0.0007464344,0.0000013946994,0.000004188659,0.0000096030035,0.00034696187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970004,0.00079045026,0.0017420728,0.00018638611,0.0000906885,0.00019002343],"domain_scores_gemma":[0.99568635,0.0036353595,0.00037747825,0.00015996526,0.00008771006,0.000053161188],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038361722,0.00013608031,0.00091812573,0.00023634029,0.000016082447,0.000002877875,0.00020920877,0.00034137774,0.0011246778],"category_scores_gemma":[0.0033884216,0.00007823225,0.0002882277,0.00026675768,0.00028395868,0.000041952157,0.000019266769,0.00059105706,0.00006429764],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015298205,0.0007489475,0.01346975,0.00005940123,0.0005964181,0.002009866,0.00025715432,0.0000023844466,0.0075274957,0.0014250454,0.012071739,0.960302],"study_design_scores_gemma":[0.0433564,0.08658806,0.36045325,0.009439165,0.0032727723,0.014383154,0.0016552494,0.00006791569,0.0104771815,0.048984453,0.42026427,0.0010581252],"about_ca_topic_score_codex":0.000010042036,"about_ca_topic_score_gemma":0.00000868459,"teacher_disagreement_score":0.95924383,"about_ca_system_score_codex":0.000020063546,"about_ca_system_score_gemma":0.000070714836,"threshold_uncertainty_score":0.9997884},"labels":[],"label_agreement":null},{"id":"W4401723588","doi":"10.1001/jamadermatol.2024.2701","title":"Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis","year":2024,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Innovaderm (Canada); University of Toronto; Lynde Centre for Dermatology; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Tolerability; Randomized controlled trial; Placebo; Internal medicine; Clinical endpoint; Body surface area; Adverse effect; Clinical trial; Dermatology; Pathology","score_opus":0.011759113868737328,"score_gpt":0.23438298106143812,"score_spread":0.2226238671927008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401723588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97985166,0.010194298,0.00011960817,0.003116164,0.0011230037,0.00026458217,0.000084335545,0.00025965963,0.0049866657],"genre_scores_gemma":[0.99774355,0.0002498391,0.00012330335,0.0003789054,0.00007662308,0.00012316114,0.00048055494,0.00003379982,0.0007902729],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844414,0.0002644898,0.00033242843,0.0004476816,0.00003849029,0.0004727669],"domain_scores_gemma":[0.9993804,0.00024794615,0.00006067128,0.00023988087,0.000042019088,0.000029071867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011709039,0.000260229,0.00039478487,0.0003357983,0.00010111358,0.000045133707,0.00010728605,0.0004995027,0.0006030315],"category_scores_gemma":[0.000038149356,0.0002091824,0.00009237779,0.00043067255,0.00017917692,0.00020710118,0.000045664758,0.0003102651,0.0014326583],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039236234,0.0018470725,0.09822945,0.0009130766,0.002500865,0.018554024,0.006932303,0.000031074396,0.26708037,0.10344452,0.086313196,0.41023043],"study_design_scores_gemma":[0.018199114,0.0007066178,0.06154835,0.00083091337,0.0006808925,0.014235863,0.0011842164,0.00006859118,0.5498841,0.003186624,0.34803817,0.0014365503],"about_ca_topic_score_codex":0.00009024273,"about_ca_topic_score_gemma":0.00016298777,"teacher_disagreement_score":0.40879387,"about_ca_system_score_codex":0.0000694471,"about_ca_system_score_gemma":0.00010700622,"threshold_uncertainty_score":0.9993448},"labels":[],"label_agreement":null},{"id":"W4401794058","doi":"10.1007/s40261-024-01368-w","title":"Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad Autónoma de Madrid","keywords":"Roflumilast; Medicine; Psoriasis; Randomized controlled trial; Adverse effect; Food and drug administration; Dermatology; Meta-analysis; Safety profile; Intensive care medicine; Pharmacology; Internal medicine; Pulmonary disease","score_opus":0.19724499704418705,"score_gpt":0.41843696655347923,"score_spread":0.22119196950929218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401794058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011768086,0.98227865,0.000036622685,0.00022052706,0.00025028732,0.016418597,0.0006591525,0.000010877189,0.0000076238475],"genre_scores_gemma":[0.00020065556,0.99475193,0.00007556626,0.000031213793,0.000031844367,0.0037660757,0.00036866489,0.000017533996,0.0007565194],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98067474,0.011088092,0.0075814696,0.00044599653,0.000077987424,0.00013171433],"domain_scores_gemma":[0.9290509,0.06570489,0.0045230254,0.00051813805,0.00016486028,0.000038184295],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.01334039,0.00047555895,0.043419216,0.00023372192,0.0000563098,0.000009715873,0.00016823008,0.00042876974,0.000045006913],"category_scores_gemma":[0.013111982,0.0001838446,0.012996809,0.00036482472,0.0008038736,0.000021200965,0.00003386052,0.00011849384,0.0000032445284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054862034,0.00019549234,0.0000012314214,0.22719872,0.7547982,2.5895918e-7,0.00019425648,2.8158806e-7,0.0000016113249,0.00082166237,0.00007143819,0.011230679],"study_design_scores_gemma":[0.050163005,0.00022796693,0.0000033344897,0.013249136,0.9338495,0.0000020012794,0.00001878688,0.000006421818,0.000013363727,0.00009923445,0.0022499969,0.000117261065],"about_ca_topic_score_codex":0.000020649957,"about_ca_topic_score_gemma":0.000009617428,"teacher_disagreement_score":0.21394958,"about_ca_system_score_codex":0.000022885984,"about_ca_system_score_gemma":0.00014434542,"threshold_uncertainty_score":0.9968878},"labels":[],"label_agreement":null},{"id":"W4401802229","doi":"10.1007/s13555-024-01250-9","title":"Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Dermatology Life Quality Index; Adalimumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Anxiety; Placebo; Depression (economics); Internal medicine; Mediation; Dermatology; Psychiatry; Pathology; Disease","score_opus":0.00909996769524771,"score_gpt":0.2415113970875818,"score_spread":0.23241142939233408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401802229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873066,0.012094392,0.000016632475,0.00005517681,0.00008071288,0.00029573438,0.00007114302,0.000022256934,0.00005735562],"genre_scores_gemma":[0.99771225,0.0020650127,0.000013733949,0.000047926118,0.000003793651,0.000044421562,0.00009509036,0.000009211457,0.000008545332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986072,0.00061069155,0.00028344165,0.00031428135,0.00004034426,0.00014402601],"domain_scores_gemma":[0.9991742,0.00053396437,0.00009724838,0.00013681712,0.000028934322,0.00002885423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023242147,0.00017995673,0.00067192415,0.0003499046,0.000058495098,0.000007634233,0.000046394907,0.00023388767,0.000015351341],"category_scores_gemma":[0.00003472374,0.00011902705,0.00004713521,0.00030487712,0.0000995513,0.000062864936,0.000020805684,0.00008731287,0.0000016150373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064719496,0.00010818762,0.96539605,0.00008190909,0.0018007861,0.0000020841017,0.0010259342,0.000013580749,0.0012074447,0.000058970658,0.00001883008,0.023814265],"study_design_scores_gemma":[0.0061725364,0.00048193897,0.9391347,0.00005632367,0.00024122997,0.000007139647,0.000024769599,0.000018060726,0.05360195,0.00003967591,0.000070656235,0.00015097196],"about_ca_topic_score_codex":0.00008121153,"about_ca_topic_score_gemma":0.00008676948,"teacher_disagreement_score":0.052394506,"about_ca_system_score_codex":0.0000069753605,"about_ca_system_score_gemma":0.000021367363,"threshold_uncertainty_score":0.4853782},"labels":[],"label_agreement":null},{"id":"W4401835086","doi":"10.1093/ced/llae348","title":"Predicting psoriasis severity using machine learning: a systematic review","year":2024,"lang":"en","type":"review","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of British Columbia; McMaster University Medical Centre; Queen's University; McMaster University; Trillium Health Centre; University of Toronto","funders":"","keywords":"Psoriasis; Psoriasis Area and Severity Index; Medicine; MEDLINE; Scopus; Systematic review; Machine learning; Artificial intelligence; Prospective cohort study; Clinical trial; Medical physics; Dermatology; Computer science; Surgery; Internal medicine","score_opus":0.08241320948198344,"score_gpt":0.38834135722012914,"score_spread":0.3059281477381457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401835086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052022847,0.99505043,0.0000016082168,0.000034517165,0.0024060013,0.0015410638,0.00010021296,0.00019606929,0.00014985816],"genre_scores_gemma":[0.00042956477,0.99762625,0.000042413056,0.00016674446,0.00010073346,0.00033015257,0.00047198063,0.000075629374,0.00075653923],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9938002,0.0024777004,0.0022458152,0.0009204362,0.000057489535,0.0004983592],"domain_scores_gemma":[0.99805087,0.00073021994,0.00066022953,0.00043377065,0.000028639439,0.00009627017],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053653313,0.0007777411,0.00561633,0.00014783021,0.00027765657,0.00003462402,0.00031469963,0.001181636,0.00018589923],"category_scores_gemma":[0.00030527488,0.0005251837,0.0012096362,0.00022437966,0.00042580543,0.00006777359,0.00044812614,0.0010229299,0.001039004],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003417883,0.00034428452,0.0002533373,0.9707502,0.004204114,0.00032716678,0.000103318554,1.3885862e-8,0.000008091802,0.00009843672,0.0007822387,0.02309462],"study_design_scores_gemma":[0.0011269426,0.00025062024,0.0000013030929,0.48115805,0.033360112,0.015339752,0.000106563304,0.000024424755,0.00007488724,0.0000192784,0.46757135,0.0009667357],"about_ca_topic_score_codex":0.00003747033,"about_ca_topic_score_gemma":0.0000033029078,"teacher_disagreement_score":0.48959216,"about_ca_system_score_codex":0.00005980815,"about_ca_system_score_gemma":0.00014617488,"threshold_uncertainty_score":0.9997388},"labels":[],"label_agreement":null},{"id":"W4401840934","doi":"10.1016/j.jaad.2024.07.1515","title":"Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Women's College Hospital; Dermatrials Research; Probity Medical Research; SKiN Health; University of Calgary; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Multicenter study; Retrospective cohort study; Dermatology; Interleukin; Internal medicine; Cytokine; Randomized controlled trial","score_opus":0.011097755775325135,"score_gpt":0.28089732347365287,"score_spread":0.26979956769832775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401840934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990997,0.0037628005,0.000029178584,0.0039968453,0.00043091257,0.00064377626,0.0000799604,0.000009923209,0.000049591436],"genre_scores_gemma":[0.9967649,0.0018255413,0.00055295025,0.0006224623,0.000038399634,0.00005671638,0.000004708064,0.000022551707,0.00011178232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795794,0.00033537994,0.0010382378,0.00025719454,0.00010985557,0.00030138364],"domain_scores_gemma":[0.9980753,0.00032777342,0.001189339,0.0001716472,0.00019485933,0.00004105701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016316697,0.00023633036,0.0010735784,0.00040604622,0.00004620776,0.0000055412474,0.00047262007,0.00011266066,0.00003051997],"category_scores_gemma":[0.0001820777,0.00014475033,0.00030048736,0.0006673602,0.00039351295,0.00013678297,0.000090573245,0.00038242538,0.0000052382948],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019369623,0.0025557766,0.78174305,0.0023221204,0.0043531093,0.00007898096,0.014293109,0.000017426146,0.03982224,0.0007133526,0.04424304,0.09048816],"study_design_scores_gemma":[0.015263258,0.0062740836,0.57364684,0.020020884,0.002008612,0.0012276685,0.0023230065,0.0000065162476,0.35469368,0.00023204491,0.023387318,0.00091606844],"about_ca_topic_score_codex":0.00008581562,"about_ca_topic_score_gemma":0.00006149427,"teacher_disagreement_score":0.31487146,"about_ca_system_score_codex":0.00017880429,"about_ca_system_score_gemma":0.00010947028,"threshold_uncertainty_score":0.5902747},"labels":[],"label_agreement":null},{"id":"W4401865195","doi":"10.37723/jumdc.v15i3.1002","title":"Determination of Knowledge of Patients Regarding Psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of University Medical & Dental College","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.010402083865329242,"score_gpt":0.2362609749221771,"score_spread":0.22585889105684787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401865195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946362,0.0017311132,0.00013272792,0.00006057004,0.0017001939,0.000063126616,0.00010298948,0.0000073402207,0.001565748],"genre_scores_gemma":[0.998261,0.0002356048,0.00009389133,0.0000041415656,0.000041690022,7.1013176e-8,0.0000120270915,0.000004806264,0.0013467837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991934,0.00020511897,0.00029652595,0.00008740222,0.000113535345,0.00010406476],"domain_scores_gemma":[0.99923915,0.00028988672,0.00019550572,0.00006230516,0.00016684149,0.00004628677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037305476,0.00008209736,0.00027979515,0.00031436744,0.000054340475,0.0000021488715,0.00020513004,0.00018099866,0.00039690064],"category_scores_gemma":[0.00015353438,0.000069684946,0.00022812406,0.00026108543,0.00013025782,0.00015632522,0.00006737743,0.00016977922,0.000018918588],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012110217,0.0069120545,0.17231844,0.0014254963,0.0061045033,0.0027309153,0.008319053,0.0000028254035,0.05219345,0.009712888,0.043750804,0.68441933],"study_design_scores_gemma":[0.048254266,0.008540063,0.27243206,0.005801267,0.0063752322,0.0016084615,0.014885767,0.00019173075,0.26395604,0.00064163096,0.37615046,0.0011630029],"about_ca_topic_score_codex":0.000009944639,"about_ca_topic_score_gemma":0.0000200109,"teacher_disagreement_score":0.6832563,"about_ca_system_score_codex":0.000114406765,"about_ca_system_score_gemma":0.00019209628,"threshold_uncertainty_score":0.4345784},"labels":[],"label_agreement":null},{"id":"W4402034013","doi":"10.1016/j.jaad.2024.07.1521","title":"A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"AbbVie; Amgen","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis; Randomized controlled trial; Pustular psoriasis; Palmoplantar pustulosis; Surgery","score_opus":0.014854132486827355,"score_gpt":0.29709449608560323,"score_spread":0.28224036359877586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402034013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595046,0.0009108568,0.00008426784,0.0016707419,0.00012979543,0.0011927066,0.00004080026,0.000006103949,0.000014266196],"genre_scores_gemma":[0.99921733,0.00026743725,0.00021953351,0.00021181958,0.000016094127,0.000030328996,0.000005240482,0.00001904277,0.0000131672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968671,0.001486304,0.0009656388,0.00023808121,0.00017418199,0.0002686928],"domain_scores_gemma":[0.9974416,0.0011709458,0.0010716204,0.00017368275,0.000106432744,0.00003571249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006713421,0.00026077224,0.0013489487,0.00026087588,0.00011681104,0.000010006637,0.00037439071,0.000094191855,0.00001258326],"category_scores_gemma":[0.00012337415,0.00011984171,0.00015641665,0.00043434475,0.0005612037,0.000083118975,0.00010115439,0.0004813844,0.0000021176716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.825241,0.0025487703,0.12041353,0.00014364542,0.008625979,0.00008764709,0.015261642,0.0011881532,0.0042452933,0.00012841064,0.00030032662,0.021815559],"study_design_scores_gemma":[0.82161266,0.009682987,0.13231757,0.0013976691,0.005950223,0.0025172804,0.0072798827,0.00055857643,0.017724808,0.00014549264,0.00019799663,0.00061485],"about_ca_topic_score_codex":0.00010677322,"about_ca_topic_score_gemma":0.000021487383,"teacher_disagreement_score":0.021200709,"about_ca_system_score_codex":0.00005033672,"about_ca_system_score_gemma":0.00015199532,"threshold_uncertainty_score":0.4887003},"labels":[],"label_agreement":null},{"id":"W4402103592","doi":"10.1016/j.jaad.2024.07.391","title":"50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Scalp; Dermatology; Psoriasis; Plaque psoriasis","score_opus":0.01816836815974643,"score_gpt":0.27052522720317956,"score_spread":0.25235685904343313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931791,0.0023513536,0.00005801553,0.003550758,0.00030932736,0.00038275443,0.00009732117,0.000017184962,0.000054172473],"genre_scores_gemma":[0.99819416,0.0009449383,0.0003427004,0.00030879746,0.000028013423,0.00002541221,0.0000036156011,0.0000347106,0.00011763192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969978,0.0006759,0.001179836,0.00038477112,0.00015802475,0.0006036858],"domain_scores_gemma":[0.99809676,0.00047017293,0.0010378176,0.00020012131,0.000093674935,0.00010147197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036726534,0.00034765605,0.0012950464,0.0004340998,0.00011842258,0.000016168306,0.00049989193,0.00027852267,0.000049772607],"category_scores_gemma":[0.00007917226,0.00022910895,0.00019035352,0.00086759817,0.00081968226,0.0001668719,0.00015968364,0.0005451523,0.000019519892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034051888,0.0013313823,0.17844424,0.00046968868,0.005650669,0.00024753145,0.002342349,0.0007412975,0.70761395,0.00051786285,0.005780585,0.06280859],"study_design_scores_gemma":[0.008024179,0.0015060744,0.22634257,0.0008377355,0.0011621807,0.0035382814,0.0011889071,0.00021164301,0.75441355,0.00035551557,0.0018730555,0.00054629723],"about_ca_topic_score_codex":0.00014935412,"about_ca_topic_score_gemma":0.00006778454,"teacher_disagreement_score":0.06226229,"about_ca_system_score_codex":0.00014609446,"about_ca_system_score_gemma":0.00024416397,"threshold_uncertainty_score":0.93427914},"labels":[],"label_agreement":null},{"id":"W4402103643","doi":"10.1016/j.jaad.2024.07.390","title":"54203 VISIBLE: Clearance and Symptom Improvement With Guselkumab at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.01351958969289073,"score_gpt":0.2601794413498324,"score_spread":0.24665985165694165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930317,0.0024773425,0.000039767147,0.003985505,0.00013177606,0.00024317487,0.000037019145,0.000009076474,0.00004466478],"genre_scores_gemma":[0.9985608,0.0006542149,0.00025690507,0.00035230748,0.000016320606,0.000017526083,0.0000011585911,0.000022237236,0.00011855418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983496,0.00029160926,0.0006420747,0.00023675627,0.000097725206,0.0003822014],"domain_scores_gemma":[0.99878424,0.0002762515,0.0006966805,0.00013911295,0.000050028884,0.00005370418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017984076,0.00022465769,0.00087761326,0.00026071435,0.00006810316,0.000007915824,0.00030213554,0.00013817681,0.000027452368],"category_scores_gemma":[0.000023389057,0.00013040562,0.000094756266,0.0004467984,0.0005557602,0.000105820356,0.0001043511,0.00034485722,0.000008728536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081607796,0.0017698595,0.26636243,0.00087535364,0.010919668,0.00046647695,0.007338613,0.0021070316,0.5580817,0.0016155937,0.008967,0.0598885],"study_design_scores_gemma":[0.009661276,0.004467954,0.24141555,0.0011465999,0.0012106327,0.007573059,0.0013187453,0.00009361746,0.7276579,0.0002442541,0.004684071,0.0005263413],"about_ca_topic_score_codex":0.00006820996,"about_ca_topic_score_gemma":0.000066023014,"teacher_disagreement_score":0.16957623,"about_ca_system_score_codex":0.000098177785,"about_ca_system_score_gemma":0.00015432779,"threshold_uncertainty_score":0.5317787},"labels":[],"label_agreement":null},{"id":"W4402103671","doi":"10.1016/j.jaad.2024.07.354","title":"51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Dermatology; Placebo; Psoriasis; Randomized controlled trial; Internal medicine; Pathology; Alternative medicine","score_opus":0.0147021214546543,"score_gpt":0.28329756275677676,"score_spread":0.26859544130212243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766138,0.009270728,0.00012211008,0.010489494,0.001078678,0.0022109556,0.00016488315,0.000009875011,0.000039485698],"genre_scores_gemma":[0.99833935,0.00088428176,0.00014286896,0.0002081183,0.00010870719,0.00011811116,0.000014985285,0.000022359782,0.00016122717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938646,0.003620679,0.0017958453,0.00025295117,0.0001518131,0.0003141023],"domain_scores_gemma":[0.9917037,0.0057012006,0.002180821,0.0002880761,0.00010442157,0.000021821215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016260424,0.00027858093,0.001842258,0.00021912403,0.0001499111,0.00001666554,0.00087395083,0.00018466557,0.00003104954],"category_scores_gemma":[0.0011298073,0.00012451022,0.0010007521,0.00038647492,0.0006743137,0.000095131654,0.00011864019,0.00049529783,0.00000592551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8679205,0.0022994627,0.038742363,0.00006882826,0.02112609,0.000027634249,0.014462846,0.00038009573,0.0066102287,0.0004313528,0.013778183,0.034152396],"study_design_scores_gemma":[0.89330584,0.0012497823,0.06154443,0.00044173063,0.010208958,0.0004100898,0.008385704,0.00028111314,0.0147015145,0.002333789,0.0066997064,0.00043734408],"about_ca_topic_score_codex":0.0001349219,"about_ca_topic_score_gemma":0.00005712859,"teacher_disagreement_score":0.033715054,"about_ca_system_score_codex":0.00005094129,"about_ca_system_score_gemma":0.00012277628,"threshold_uncertainty_score":0.50773793},"labels":[],"label_agreement":null},{"id":"W4402103827","doi":"10.1016/j.jaad.2024.07.151","title":"51454 Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Medicine; Apremilast; Plaque psoriasis; Psoriasis; Randomized controlled trial; Dermatology; Internal medicine; Psoriatic arthritis","score_opus":0.009500319463457446,"score_gpt":0.23983626522577003,"score_spread":0.2303359457623126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885732,0.0039968807,0.000030327976,0.005017235,0.00058188435,0.0015723342,0.00014996975,0.000009014794,0.000069145455],"genre_scores_gemma":[0.998224,0.0012276957,0.00012276624,0.00021859886,0.00010824256,0.00003175124,0.000008905901,0.00001812176,0.000039885304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956985,0.0020207607,0.0016197705,0.0002523133,0.00013359138,0.00027504325],"domain_scores_gemma":[0.9924874,0.0054951366,0.0017291184,0.00017148112,0.000076597156,0.000040324783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075215485,0.0002687219,0.0023033936,0.00026378132,0.0000813818,0.000011506997,0.00046680775,0.00020317009,0.000011273572],"category_scores_gemma":[0.00073620677,0.00012465136,0.00037312772,0.00040926246,0.00055979314,0.00008586703,0.00009940174,0.00059970375,0.000005721596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98775226,0.00030211607,0.0058460925,0.0000156377,0.001699102,0.000009200913,0.0010677712,0.0001127196,0.00037200042,0.00007194138,0.00086172106,0.0018894451],"study_design_scores_gemma":[0.95782846,0.00059147837,0.037163075,0.00018947035,0.0018376189,0.0001618937,0.00017391863,0.00001977096,0.0012999538,0.00018528676,0.00037975496,0.00016929948],"about_ca_topic_score_codex":0.00005571457,"about_ca_topic_score_gemma":0.000009183764,"teacher_disagreement_score":0.03131698,"about_ca_system_score_codex":0.00003374296,"about_ca_system_score_gemma":0.00018076306,"threshold_uncertainty_score":0.5083135},"labels":[],"label_agreement":null},{"id":"W4402103833","doi":"10.1016/j.jaad.2024.07.158","title":"50251 Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; University of British Columbia","funders":"","keywords":"Medicine; Apremilast; Dermatology; Scalp; Psoriasis; Nail (fastener)","score_opus":0.018038362342502633,"score_gpt":0.2926226818215649,"score_spread":0.2745843194790623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951015,0.0021940751,0.000014781743,0.0010947448,0.0010287433,0.00036805889,0.00013962305,0.00001605361,0.000042409403],"genre_scores_gemma":[0.99947804,0.00018112668,0.0000732587,0.00009318932,0.000079510944,0.000008206076,0.00000855934,0.000026663078,0.000051425683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747604,0.0009076864,0.0008837395,0.00024988689,0.00017051517,0.0003121228],"domain_scores_gemma":[0.99631,0.0018949092,0.0013854052,0.00028711857,0.00008159172,0.000040985175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019702874,0.0002829574,0.0009592059,0.00017147932,0.0001442784,0.000011979876,0.0008881145,0.00015717183,0.000120332115],"category_scores_gemma":[0.0001488953,0.00013096433,0.00034059043,0.0005442926,0.0011770609,0.00012776325,0.00015419871,0.0006271146,0.00001882295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07650608,0.0063938685,0.67190534,0.00006920125,0.024048977,0.00017373999,0.007581001,0.00005107994,0.009911632,0.00007127023,0.0143840965,0.18890372],"study_design_scores_gemma":[0.0335027,0.0038616988,0.92023176,0.00030382193,0.0049703494,0.00045827855,0.0031954865,0.0000075789494,0.028265456,0.000045698464,0.004827763,0.00032943705],"about_ca_topic_score_codex":0.00012455498,"about_ca_topic_score_gemma":0.00001823921,"teacher_disagreement_score":0.24832639,"about_ca_system_score_codex":0.000052058404,"about_ca_system_score_gemma":0.00015265636,"threshold_uncertainty_score":0.5340571},"labels":[],"label_agreement":null},{"id":"W4402103895","doi":"10.1016/j.jaad.2024.07.246","title":"53833 Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial For up to 6 Years of Follow-up","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Amgen","keywords":"Medicine; Open label; Interim; Plaque psoriasis; Interim analysis; Term (time); Psoriasis; Adverse effect; Clinical trial; Dermatology; Surgery; Internal medicine","score_opus":0.052514300129946345,"score_gpt":0.3445210261402866,"score_spread":0.2920067260103403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988701,0.004363864,0.0005141933,0.0032708358,0.00068763184,0.0011024206,0.0013516302,0.0000034235932,0.0000050306808],"genre_scores_gemma":[0.99753654,0.001824441,0.00031408115,0.000103404884,0.000046146142,0.000029156383,0.00002662765,0.00001813754,0.000101480524],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975878,0.00047979952,0.0013639263,0.0002623946,0.00009261381,0.00021346835],"domain_scores_gemma":[0.9937276,0.0040936633,0.0016779673,0.00033543564,0.0001309509,0.00003433203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041201417,0.00021406855,0.0016206413,0.00027086382,0.00008204784,0.000008625299,0.0007631573,0.00017844996,0.000010575532],"category_scores_gemma":[0.00027668703,0.00011357356,0.0005827669,0.00049587764,0.00042596896,0.000057432837,0.0001516403,0.0001478363,7.9568474e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67388296,0.0015161405,0.0019474995,0.00010142694,0.035814706,0.000007939192,0.011488268,0.00053824804,0.10272752,0.0003097757,0.003607267,0.16805823],"study_design_scores_gemma":[0.26120183,0.015306552,0.17193078,0.0012611302,0.04100615,0.00043680778,0.004567918,0.0005216034,0.4953844,0.00043501268,0.007281454,0.0006663777],"about_ca_topic_score_codex":0.00019995944,"about_ca_topic_score_gemma":0.000046854035,"teacher_disagreement_score":0.41268116,"about_ca_system_score_codex":0.0000460195,"about_ca_system_score_gemma":0.00012915302,"threshold_uncertainty_score":0.46313953},"labels":[],"label_agreement":null},{"id":"W4402103969","doi":"10.1016/j.jaad.2024.07.118","title":"52766 Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: Results at Months 6 and 12 from the PSoHO study in real-world settings","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology; Comparative effectiveness research; Internal medicine; Alternative medicine; Pathology","score_opus":0.020455203739226772,"score_gpt":0.2988374757253141,"score_spread":0.27838227198608734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402103969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672747,0.0011839832,0.0000055642954,0.00074105896,0.00018056858,0.00058587233,0.00053377525,0.000007500163,0.000034191366],"genre_scores_gemma":[0.9995892,0.00019645317,0.00006700592,0.0000711628,0.000014529005,0.000014335259,0.000015922848,0.000013308777,0.000018067978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965337,0.001908264,0.0008990503,0.000278937,0.000103156526,0.000276886],"domain_scores_gemma":[0.9959204,0.0024770347,0.0012906111,0.00018834727,0.00009307271,0.000030543168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000558793,0.00025316453,0.0012633471,0.00016475531,0.00010651731,0.0000068875715,0.00047242598,0.00014062648,0.0000033585302],"category_scores_gemma":[0.00008277853,0.00013056317,0.0001367715,0.0004748803,0.0008062025,0.000088737805,0.00022506915,0.00045230633,0.000001926523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023458501,0.00046465718,0.95409036,0.000054182092,0.0017678544,0.00001553126,0.008506768,0.00018633349,0.010015982,0.000048364956,0.0004216916,0.0009697992],"study_design_scores_gemma":[0.004411098,0.0008865508,0.9512929,0.00031107065,0.0002967173,0.000084421656,0.002276482,0.0000074906684,0.039990418,0.00012550133,0.0001858985,0.00013148424],"about_ca_topic_score_codex":0.0005038447,"about_ca_topic_score_gemma":0.0003946469,"teacher_disagreement_score":0.029974435,"about_ca_system_score_codex":0.00006931964,"about_ca_system_score_gemma":0.000063312604,"threshold_uncertainty_score":0.5324212},"labels":[],"label_agreement":null},{"id":"W4402104003","doi":"10.1016/j.jaad.2024.07.060","title":"54494 A systematic review and meta-analysis exploring the risk of infections with janus kinase inhibitor treatment for plaque psoriasis","year":2024,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Janus kinase; Dermatology; Psoriasis; Janus kinase inhibitor; Meta-analysis; Tofacitinib; Internal medicine","score_opus":0.08442853812902106,"score_gpt":0.33801477917347983,"score_spread":0.25358624104445876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007992776,0.99543405,0.000028383181,0.0013099189,0.00016730311,0.0017525567,0.00049431657,0.000008509178,0.000005694286],"genre_scores_gemma":[0.002877857,0.9959624,0.000103509345,0.00008470193,0.00003165268,0.00076436374,0.0000089908435,0.000035123794,0.00013142337],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99502045,0.0023691088,0.0019612662,0.00028746386,0.000093208815,0.00026850967],"domain_scores_gemma":[0.9912904,0.0019673058,0.006202998,0.00040005523,0.00009981767,0.00003946236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053451024,0.00055667176,0.009822614,0.00056314253,0.0001627196,0.000010420912,0.00051642925,0.00020418143,0.000014219986],"category_scores_gemma":[0.00019733884,0.00020817509,0.004942591,0.0010913684,0.00058874185,0.0000690685,0.00009532234,0.0005488583,0.0000060799716],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107983244,0.0002314966,0.00005713705,0.17487498,0.8140552,0.000013131567,0.00024948313,0.000004636072,0.000008135963,0.00013529422,0.0006171182,0.009645409],"study_design_scores_gemma":[0.00037039342,0.00037855384,0.000010812025,0.0095777605,0.947647,0.0035185008,0.00009823116,2.1426871e-7,0.00016393716,0.00002616165,0.03803627,0.00017218044],"about_ca_topic_score_codex":0.000043882676,"about_ca_topic_score_gemma":0.00001549112,"teacher_disagreement_score":0.16529721,"about_ca_system_score_codex":0.00008770407,"about_ca_system_score_gemma":0.00019234292,"threshold_uncertainty_score":0.8489134},"labels":[],"label_agreement":null},{"id":"W4402104070","doi":"10.1016/j.jaad.2024.07.102","title":"52661 Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open label extension phase 3 trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Plaque psoriasis; Open label; Psoriasis; Dermatology; Clinical trial; Internal medicine; Surgery","score_opus":0.048074770986853956,"score_gpt":0.32704431435357145,"score_spread":0.2789695433667175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95253754,0.0020394877,0.000048474412,0.043835957,0.00047390978,0.00053257326,0.00043204165,0.000010539264,0.000089461995],"genre_scores_gemma":[0.9970323,0.00057640346,0.0005609643,0.00121653,0.000059903272,0.000014853708,0.000009874158,0.00002577487,0.00050339865],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962049,0.0018863139,0.0010828985,0.0003390116,0.00013379689,0.0003530556],"domain_scores_gemma":[0.99634737,0.0020092265,0.0011772697,0.00032935184,0.000090915106,0.00004585084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007582628,0.00025724457,0.0010276352,0.00029813836,0.000116122654,0.000024082548,0.0011296882,0.00020337758,0.000028714936],"category_scores_gemma":[0.00045354577,0.00013287885,0.000170502,0.00066735793,0.0006421783,0.00018303347,0.00022625679,0.0006702881,0.000013533572],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8732957,0.00071970373,0.0003607641,0.000017644385,0.0015287418,0.00022490845,0.002343489,0.00007599469,0.06114116,0.00052185444,0.049048588,0.010721455],"study_design_scores_gemma":[0.4037518,0.010053769,0.01901377,0.0033410615,0.0022988524,0.012232704,0.008816694,0.00009115438,0.4207331,0.0039169122,0.114547834,0.001202362],"about_ca_topic_score_codex":0.00038736404,"about_ca_topic_score_gemma":0.000060081908,"teacher_disagreement_score":0.4695439,"about_ca_system_score_codex":0.00009215592,"about_ca_system_score_gemma":0.00043962648,"threshold_uncertainty_score":0.5418642},"labels":[],"label_agreement":null},{"id":"W4402104163","doi":"10.1016/j.jaad.2024.07.873","title":"51782 Generalized pustular psoriasis (GPP) continues to adversely impact quality of life between flares, as per Dermatology Life Quality Index scores: Baseline data from the Effisayil 2 trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Psoriasis; Dermatology; Psoriasis Area and Severity Index; Index (typography); Generalized pustular psoriasis; Baseline (sea)","score_opus":0.0769125939771212,"score_gpt":0.38047616063847883,"score_spread":0.30356356666135764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95877135,0.014910362,0.00031555456,0.022600763,0.0011861946,0.000528406,0.0016271414,0.000033734854,0.000026481777],"genre_scores_gemma":[0.9958115,0.0010379396,0.00027540978,0.0020845341,0.00052571885,0.000013178969,0.00015352521,0.000041424526,0.00005677645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98854756,0.007161361,0.0028095297,0.00055189506,0.000322216,0.0006074431],"domain_scores_gemma":[0.9899767,0.0057333736,0.0029449838,0.0009604573,0.00018891963,0.00019555417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020780156,0.0004990911,0.0027888457,0.0003167193,0.00019834373,0.00002784245,0.002636878,0.0005332298,0.0003296095],"category_scores_gemma":[0.003937059,0.00028823112,0.0009505265,0.00061272416,0.0012773557,0.00023902036,0.00071011897,0.0010826087,0.000092939736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08107432,0.0008261741,0.6529953,0.00019116688,0.023147184,0.00006489175,0.0028742983,0.00007889372,0.06547145,0.00061875244,0.1579686,0.01468898],"study_design_scores_gemma":[0.06107136,0.0012494487,0.75775534,0.0004740921,0.0060045505,0.0015812431,0.0034870657,0.00005194081,0.044112198,0.0014731498,0.12141812,0.0013215243],"about_ca_topic_score_codex":0.0028076512,"about_ca_topic_score_gemma":0.0000872594,"teacher_disagreement_score":0.10476001,"about_ca_system_score_codex":0.00007351807,"about_ca_system_score_gemma":0.00092050806,"threshold_uncertainty_score":0.99995697},"labels":[],"label_agreement":null},{"id":"W4402104210","doi":"10.1016/j.jaad.2024.07.1145","title":"52846 Proportion of the US psoriasis population impacted by common warnings for moderate-to-severe plaque psoriasis treatment","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Population; Environmental health","score_opus":0.014926408223219252,"score_gpt":0.2871291933056586,"score_spread":0.27220278508243934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875125,0.00193999,0.00009046048,0.008945647,0.0007684441,0.000505494,0.00020116147,0.000018724184,0.0000175501],"genre_scores_gemma":[0.9988818,0.0003549824,0.00015729143,0.00024358866,0.000060676604,0.000028071572,0.000025376943,0.000026298781,0.00022186844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979621,0.00051629054,0.0009078874,0.00020294746,0.00010800963,0.000302749],"domain_scores_gemma":[0.9978632,0.00032403303,0.0015011777,0.00018488821,0.000085596905,0.00004114362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018944324,0.0002531983,0.0008813477,0.00020641628,0.0001657964,0.000010635748,0.00041967662,0.00024159071,0.00002154342],"category_scores_gemma":[0.000091996655,0.00013792352,0.00053794024,0.00042010762,0.00025809553,0.00011903293,0.00006137208,0.00029253904,0.0000059581025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010678372,0.0010401779,0.22776039,0.00029463452,0.0076826345,0.000015055875,0.00411542,0.00089838466,0.57856363,0.000969306,0.04407485,0.12390717],"study_design_scores_gemma":[0.004775897,0.0015018217,0.18608557,0.0003511882,0.0025895261,0.0036532895,0.00035084612,0.00018901733,0.76846385,0.0013886287,0.03023548,0.00041490677],"about_ca_topic_score_codex":0.00021032129,"about_ca_topic_score_gemma":0.000011974598,"teacher_disagreement_score":0.18990023,"about_ca_system_score_codex":0.0001660462,"about_ca_system_score_gemma":0.00012388232,"threshold_uncertainty_score":0.5624358},"labels":[],"label_agreement":null},{"id":"W4402104221","doi":"10.1016/j.jaad.2024.07.1168","title":"53838 Real-world drug survival of risankizumab at a tertiary care psoriasis clinic in Toronto, Canada","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tertiary care; Psoriasis; Drug; Family medicine; Dermatology; Pharmacology","score_opus":0.01150235615120707,"score_gpt":0.28798463942477204,"score_spread":0.27648228327356494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9694441,0.024413854,0.0000010489576,0.0032821468,0.0016317192,0.0001221408,0.000092522474,0.000009313169,0.0010031853],"genre_scores_gemma":[0.99641335,0.0025217838,0.000057206955,0.0002218068,0.00006268848,0.000004559419,0.000006195229,0.000020688869,0.00069171336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732095,0.0008649835,0.0011394102,0.00020717569,0.00011976378,0.00034770256],"domain_scores_gemma":[0.9978563,0.00074588496,0.0011170262,0.00019087644,0.00004985838,0.00004004606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022805932,0.00022505435,0.0010448615,0.00019659464,0.00006302684,0.000003307454,0.00061178836,0.00014136585,0.00028761718],"category_scores_gemma":[0.000052247055,0.0001549705,0.00036506748,0.00033254814,0.00045922486,0.00009242871,0.00015768626,0.00047171113,0.0000100398265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002250532,0.0002513758,0.8539479,0.00038415092,0.0032833843,0.00032466106,0.0035461392,0.00001783814,0.032065038,0.00041528302,0.055569813,0.047943912],"study_design_scores_gemma":[0.003220656,0.00016847251,0.83074385,0.000459443,0.0010152317,0.002412464,0.0052922177,0.0000040066857,0.107994966,0.00018094605,0.048108663,0.00039910126],"about_ca_topic_score_codex":0.1491936,"about_ca_topic_score_gemma":0.32512885,"teacher_disagreement_score":0.17593525,"about_ca_system_score_codex":0.0006233435,"about_ca_system_score_gemma":0.0006366734,"threshold_uncertainty_score":0.856472},"labels":[],"label_agreement":null},{"id":"W4402104227","doi":"10.1016/j.jaad.2024.07.572","title":"52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dermatrials Research","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Internal medicine; Clinical trial; Pooled analysis; Dermatology; Meta-analysis","score_opus":0.04094490572478248,"score_gpt":0.377095401805439,"score_spread":0.3361504960806565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957644,0.0011923889,0.00012611499,0.0012985723,0.00041954045,0.00044590177,0.00074014626,0.000008552317,0.000004437634],"genre_scores_gemma":[0.9990605,0.00028751823,0.00033791212,0.00017554953,0.000041009793,0.000012959137,0.000026130525,0.00002111949,0.00003729925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948985,0.0020566045,0.0022459,0.00032828565,0.00012728297,0.0003434301],"domain_scores_gemma":[0.9956018,0.0020085035,0.0019357257,0.00026937216,0.00009736813,0.0000872443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075887295,0.00027396763,0.0028250546,0.0005889726,0.000039060582,0.000008591554,0.00051246653,0.00025553623,0.000048952053],"category_scores_gemma":[0.00035619788,0.00017144423,0.00086575054,0.0012346345,0.00034531526,0.000081779195,0.00010118934,0.00034733268,0.000014518681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11132989,0.0053780046,0.431356,0.00008175943,0.071440704,0.00014694093,0.013337564,0.003040143,0.039376207,0.000102652666,0.0022415156,0.32216862],"study_design_scores_gemma":[0.03860752,0.0053510997,0.82697564,0.00040654145,0.013815374,0.00020099017,0.0013697022,0.000061014274,0.10956047,0.0001453915,0.002979193,0.00052703795],"about_ca_topic_score_codex":0.0002574724,"about_ca_topic_score_gemma":0.000051231775,"teacher_disagreement_score":0.39561966,"about_ca_system_score_codex":0.00010568575,"about_ca_system_score_gemma":0.00021566928,"threshold_uncertainty_score":0.6991293},"labels":[],"label_agreement":null},{"id":"W4402104239","doi":"10.1016/j.jaad.2024.07.1181","title":"52876 Relationships Among Abrocitinib Treatment, Itch, Skin Clearance, Anxiety, and Depression: A Mediation Modeling Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Probity Medical Research; SKiN Health; Queen's University; University of Alberta","funders":"","keywords":"Medicine; Anxiety; Depression (economics); Mediation; Dermatology; Clinical psychology; Psychiatry","score_opus":0.023296933604207846,"score_gpt":0.28211666060480134,"score_spread":0.25881972700059347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841567,0.012993924,0.00063929183,0.0017237543,0.00022943609,0.00009523024,0.000020711903,0.000017795524,0.00012311626],"genre_scores_gemma":[0.99534196,0.004169622,0.00023367527,0.00007031339,0.00006464952,0.0000064777264,0.0000070662813,0.000012601597,0.00009365268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838287,0.0005784306,0.00058754784,0.00018632963,0.00006608518,0.00019874185],"domain_scores_gemma":[0.99876165,0.00037768087,0.0006719211,0.00011098063,0.00004206626,0.00003568673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019604093,0.00016673259,0.00063864666,0.0004202637,0.00015945974,0.000012246231,0.00020378375,0.00019388205,0.000024561901],"category_scores_gemma":[0.00007369694,0.000105018975,0.00038247538,0.0007013323,0.00033677515,0.00016012554,0.00004769892,0.00038904173,0.000008720679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000580018,0.00012291971,0.92021036,0.000038205133,0.007180971,0.000023876353,0.0020689503,0.001557235,0.010491909,0.00030765467,0.0010069658,0.056410916],"study_design_scores_gemma":[0.0034030597,0.0001823078,0.9268885,0.00023228556,0.010364901,0.0054558767,0.0020250482,0.00867501,0.03332918,0.0018854605,0.0070796465,0.00047867448],"about_ca_topic_score_codex":0.00003925539,"about_ca_topic_score_gemma":0.000012596867,"teacher_disagreement_score":0.055932242,"about_ca_system_score_codex":0.000043051812,"about_ca_system_score_gemma":0.000056064455,"threshold_uncertainty_score":0.42825496},"labels":[],"label_agreement":null},{"id":"W4402104274","doi":"10.1016/j.jaad.2024.07.1256","title":"51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Dermatology Life Quality Index; Dermatology; Psoriasis; Quality of life (healthcare); Generalized pustular psoriasis; Psoriasis Area and Severity Index; Index (typography)","score_opus":0.03684672638143557,"score_gpt":0.319830949425381,"score_spread":0.28298422304394544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97699773,0.011675626,0.000046314424,0.009282301,0.001057206,0.00052258384,0.00037813766,0.000017858956,0.000022216223],"genre_scores_gemma":[0.9972577,0.00083963684,0.00018903866,0.0014173343,0.00015562362,0.000012624531,0.0000764469,0.000033559703,0.000018040575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99204385,0.004363992,0.0023240969,0.000483089,0.00028282087,0.0005021638],"domain_scores_gemma":[0.99374914,0.002324682,0.0029411705,0.0007727683,0.0001261639,0.000086064865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009650149,0.0004066224,0.0021410447,0.00027094228,0.00012704295,0.000020177882,0.0020350935,0.0004205878,0.000105972744],"category_scores_gemma":[0.0012094638,0.00022333214,0.00042714397,0.0005160003,0.0016325562,0.00025159685,0.00048549703,0.0010404722,0.000028107652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10079427,0.0013483799,0.86047757,0.00016232222,0.0067596133,0.00002502709,0.0014169437,0.00002076176,0.013092454,0.00077229075,0.009269528,0.005860863],"study_design_scores_gemma":[0.056765907,0.0006154847,0.9253629,0.00017519628,0.0010823986,0.00032082395,0.00095343223,0.000016457296,0.0064522554,0.00069853076,0.0071114823,0.000445164],"about_ca_topic_score_codex":0.001262382,"about_ca_topic_score_gemma":0.00009106342,"teacher_disagreement_score":0.06488532,"about_ca_system_score_codex":0.00005441144,"about_ca_system_score_gemma":0.0007210107,"threshold_uncertainty_score":0.9107221},"labels":[],"label_agreement":null},{"id":"W4402104290","doi":"10.1016/j.jaad.2024.07.777","title":"52826 Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results of a multicenter, randomized, double-blind, placebo-controlled clinical study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Scalp; Dermatology; Placebo; Psoriasis; Plaque psoriasis; Multicenter study; Double blind; Clinical trial; Pilot trial; Randomized controlled trial; Surgery; Internal medicine; Pathology","score_opus":0.039577097497548536,"score_gpt":0.34175244887346773,"score_spread":0.3021753513759192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850381,0.006021985,0.00008257751,0.0045411983,0.0006475407,0.0033940873,0.00023825844,0.000005694539,0.000030539773],"genre_scores_gemma":[0.99675786,0.002723747,0.0001864758,0.00006254796,0.000049741066,0.00007584853,0.0000027625106,0.000021307345,0.000119699405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994224,0.002200619,0.0028633475,0.00027884185,0.0001534048,0.0002797557],"domain_scores_gemma":[0.9866545,0.009312944,0.0034466076,0.00035807802,0.00018369894,0.00004414183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001341419,0.0003146894,0.0031213688,0.00023036175,0.00011492532,0.0000056725876,0.0006994792,0.0002424908,0.000008990934],"category_scores_gemma":[0.0005142356,0.00014054734,0.0012040709,0.00034542472,0.0015182025,0.000055261116,0.0001296412,0.00034705788,0.0000012520577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9643242,0.0025215345,0.0022421486,0.00007367924,0.011317373,0.0000037459558,0.0026837653,0.00025317143,0.0039457968,0.00012745519,0.000424419,0.012082755],"study_design_scores_gemma":[0.9194223,0.003683331,0.0077229436,0.0003225622,0.007824872,0.00047095804,0.0016363946,0.00021082217,0.057291806,0.00009565706,0.0011394765,0.00017882483],"about_ca_topic_score_codex":0.000110852285,"about_ca_topic_score_gemma":0.000019423542,"teacher_disagreement_score":0.05334601,"about_ca_system_score_codex":0.000040359366,"about_ca_system_score_gemma":0.0002252819,"threshold_uncertainty_score":0.57313544},"labels":[],"label_agreement":null},{"id":"W4402104411","doi":"10.1016/j.jaad.2024.07.1234","title":"51582 Simultaneous Genital Skin Clearance and Patient Reported Outcome Responses at Weeks 24 and 52 in Patients with Moderate-to-Severe Genital Psoriasis Treated with Ixekizumab: an analysis of the Phase 3 Clinical Trial IXORA-Q","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Medicine; Ixekizumab; Psoriasis; Sex organ; Dermatology; Psoriatic arthritis","score_opus":0.027475813929519508,"score_gpt":0.3195392359290998,"score_spread":0.29206342199958024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99777484,0.00075424695,0.0000075941866,0.0006620548,0.00019231375,0.00044089524,0.00015263737,0.000010024038,0.000005423679],"genre_scores_gemma":[0.99951994,0.00008106424,0.000115774106,0.00017160962,0.000016264707,0.000007398102,0.000007908414,0.000022235912,0.000057829344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656516,0.001257332,0.0013736943,0.00036192653,0.00015769743,0.00028419853],"domain_scores_gemma":[0.99731946,0.0008035837,0.0014363675,0.00025488378,0.000110766814,0.00007496289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025270798,0.00027900407,0.0013368241,0.0004417654,0.000119202654,0.0000141013525,0.00028487458,0.00021491137,0.000012503825],"category_scores_gemma":[0.00024269831,0.0001444064,0.00027649925,0.0008864616,0.0009024235,0.00011585325,0.000121936944,0.00047650113,0.0000011356901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26044172,0.00095693,0.70643175,0.000019331681,0.0055591837,0.0001719698,0.000983582,0.00036832335,0.0010080386,0.000005976848,0.00006914406,0.02398402],"study_design_scores_gemma":[0.043585386,0.007693948,0.932441,0.00010477679,0.0059356466,0.0026148695,0.0005315782,0.000309794,0.006019291,0.000014611988,0.0003874898,0.00036163273],"about_ca_topic_score_codex":0.00005614494,"about_ca_topic_score_gemma":0.000047478516,"teacher_disagreement_score":0.2260092,"about_ca_system_score_codex":0.000060020728,"about_ca_system_score_gemma":0.0001059087,"threshold_uncertainty_score":0.5888722},"labels":[],"label_agreement":null},{"id":"W4402104414","doi":"10.1016/j.jaad.2024.07.1187","title":"50793 Response to therapy in skin of colour participants with moderate-to-severe psoriasis and atopic dermatitis: a systematic review","year":2024,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Université Laval; Queen's University","funders":"","keywords":"Medicine; Atopic dermatitis; Dermatology; Psoriasis","score_opus":0.036899782706698823,"score_gpt":0.33328899403685036,"score_spread":0.29638921133015156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104414","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06891316,0.926388,0.0000037100149,0.0029908014,0.0001458269,0.0014808171,0.00006464746,0.0000066532098,0.0000063275284],"genre_scores_gemma":[0.044088382,0.9543394,0.000114959774,0.0011689012,0.000013689406,0.00014833362,0.0000018458377,0.00003798508,0.00008654239],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9936081,0.0035191244,0.0020716926,0.0002783754,0.00012416481,0.00039852253],"domain_scores_gemma":[0.9957536,0.001101574,0.0026933586,0.000296131,0.000076724784,0.00007862984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076336035,0.00045699344,0.005609921,0.00059636624,0.000047359288,0.000008714306,0.00070753344,0.00029004703,0.000012850658],"category_scores_gemma":[0.0003837889,0.00024159685,0.00050225493,0.00093864196,0.00029932128,0.000055819353,0.00014836137,0.0006067012,0.00003188977],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004652497,0.0006290631,0.0008907171,0.7861637,0.016667143,0.0004390799,0.003323964,0.000012180974,0.0003422999,0.00017921328,0.010958097,0.17574203],"study_design_scores_gemma":[0.0031696383,0.001644949,0.0019581143,0.8271274,0.01867288,0.03255881,0.00045179148,0.0000010079126,0.0010253335,0.000098447425,0.112418994,0.00087260944],"about_ca_topic_score_codex":0.000015981574,"about_ca_topic_score_gemma":0.0000069779467,"teacher_disagreement_score":0.17486942,"about_ca_system_score_codex":0.00008739774,"about_ca_system_score_gemma":0.00038331686,"threshold_uncertainty_score":0.9852033},"labels":[],"label_agreement":null},{"id":"W4402104460","doi":"10.1016/j.jaad.2024.07.1218","title":"51675 Safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement: changes in PPASI and PASI from Phase 3b IMMprint trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.008949594487291372,"score_gpt":0.24881062640019588,"score_spread":0.2398610319129045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959894,0.0012051396,0.000028773215,0.0019538687,0.00015173423,0.0004891899,0.00016646998,0.000005265497,0.000010153466],"genre_scores_gemma":[0.9981958,0.0012919605,0.00023809161,0.00019255446,0.000027487436,0.00001268859,0.00001723151,0.000018277824,0.0000058953965],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99830693,0.00037753888,0.0006741927,0.00027085413,0.000098690136,0.00027176784],"domain_scores_gemma":[0.9987162,0.00039278684,0.0006711798,0.00012630639,0.0000456497,0.000047909645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014465493,0.0002512184,0.0010076399,0.00037030794,0.000049418668,0.000008335261,0.00024057865,0.00016859829,0.000013355202],"category_scores_gemma":[0.00003597849,0.00015212905,0.00007133401,0.0003352169,0.0003906588,0.00009007566,0.0000972755,0.00045250423,0.000001269439],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50741756,0.0024006872,0.39190865,0.00025812114,0.003949724,0.0002672346,0.00984119,0.00018678662,0.018608216,0.00021085622,0.00032855597,0.06462244],"study_design_scores_gemma":[0.29311252,0.0072261095,0.58302116,0.002117933,0.0015427589,0.0014895343,0.0026039782,0.00008683655,0.10613704,0.00026087486,0.0016263884,0.0007748877],"about_ca_topic_score_codex":0.0002521482,"about_ca_topic_score_gemma":0.00015461762,"teacher_disagreement_score":0.21430506,"about_ca_system_score_codex":0.00005098387,"about_ca_system_score_gemma":0.00009080193,"threshold_uncertainty_score":0.6203643},"labels":[],"label_agreement":null},{"id":"W4402104479","doi":"10.1016/j.jaad.2024.07.993","title":"53822 Longitudinal evaluation of the psoriasis epidemiology screening tool (PEST) in patients with moderate to severe psoriasis: Results from the PURE Registry","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Trent University; University of Ottawa; Probity Medical Research; Queen's University; Novartis (Canada); University of British Columbia","funders":"","keywords":"Medicine; Psoriasis; Epidemiology; Dermatology; Internal medicine","score_opus":0.04261913830304342,"score_gpt":0.30112543028913374,"score_spread":0.2585062919860903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402104479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765155,0.002896898,0.000091547256,0.019127516,0.0006868308,0.00041177234,0.00021616924,0.000008808708,0.0000449806],"genre_scores_gemma":[0.99860275,0.00012996737,0.00041700946,0.0006672402,0.00009474982,0.000016376485,0.000013820409,0.000019739604,0.00003837222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946918,0.0030764819,0.0012929484,0.00033284375,0.00023504464,0.00037087014],"domain_scores_gemma":[0.9953245,0.00210912,0.0019220279,0.00041105426,0.00020190096,0.00003139556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015485756,0.00027499493,0.0009795481,0.00016876942,0.00015106442,0.000009024546,0.00096821494,0.00026270823,0.000023676068],"category_scores_gemma":[0.0014472364,0.00012782308,0.00032612527,0.000708852,0.0006232004,0.00012976796,0.00019003749,0.00083435373,0.00000787259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008832981,0.00019713167,0.93253314,0.000026197606,0.0023566766,0.000008681889,0.0014316323,0.0038518212,0.001332554,0.00022126926,0.008606144,0.040601753],"study_design_scores_gemma":[0.0041240924,0.00020826278,0.9881571,0.0004017714,0.0010162462,0.0004442433,0.00036320515,0.00010158246,0.0029628042,0.0009665151,0.0010881562,0.00016601382],"about_ca_topic_score_codex":0.00014429697,"about_ca_topic_score_gemma":0.000040429513,"teacher_disagreement_score":0.05562395,"about_ca_system_score_codex":0.00009739969,"about_ca_system_score_gemma":0.0002549099,"threshold_uncertainty_score":0.5212474},"labels":[],"label_agreement":null},{"id":"W4402106714","doi":"10.1016/j.jaad.2024.07.1217","title":"51652 Safety and efficacy of risankizumab in adult patients with moderate to severe plaque psoriasis with non-pustular palmoplantar involvement: change in DLQI and achievement of DLQI 0/1 results from the Phase 3b IMMprint trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Dermatology","score_opus":0.014224999667186742,"score_gpt":0.26278382014051127,"score_spread":0.24855882047332453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402106714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942469,0.00097113516,0.000016887536,0.0034849087,0.00013294995,0.0007315448,0.00040443562,0.0000032289615,0.000007984761],"genre_scores_gemma":[0.99834377,0.0011521402,0.00017048567,0.0002482333,0.000028230059,0.000015561967,0.000023007788,0.0000144694,0.0000040847085],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979017,0.0005050183,0.00096495915,0.00025701645,0.0001231525,0.00024815698],"domain_scores_gemma":[0.99818414,0.00057288393,0.0009794163,0.00017051151,0.00005474917,0.00003828028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002868105,0.00023322424,0.0009182711,0.00024228978,0.00005318043,0.000006190604,0.00030276872,0.00013358495,0.0000058839164],"category_scores_gemma":[0.000052462507,0.00012415093,0.00008569808,0.00034295776,0.00041288236,0.000093335635,0.00013228034,0.00042857628,7.293136e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69344956,0.0024258974,0.21999252,0.00018337807,0.0036969872,0.0001025377,0.022542851,0.00019412325,0.009661165,0.00021049583,0.00030704492,0.04723347],"study_design_scores_gemma":[0.23915279,0.0056025595,0.69761926,0.0018732963,0.0011234041,0.00044387885,0.0024171812,0.00008375601,0.050277647,0.00012298446,0.0008359637,0.00044727017],"about_ca_topic_score_codex":0.00074880617,"about_ca_topic_score_gemma":0.0001652702,"teacher_disagreement_score":0.47762677,"about_ca_system_score_codex":0.000048500635,"about_ca_system_score_gemma":0.00008462609,"threshold_uncertainty_score":0.50627285},"labels":[],"label_agreement":null},{"id":"W4402106721","doi":"10.1016/j.jaad.2024.07.657","title":"50250 Comparing the Effect of Risankizumab versus Apremilast on Psoriasis Symptoms, Treatment Satisfaction, and Health-Related Quality of Life from the Phase 4 IMMpulse Study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Dermatrials Research","funders":"","keywords":"Apremilast; Medicine; Psoriasis; Quality of life (healthcare); Dermatology; Nursing","score_opus":0.04434144673981586,"score_gpt":0.35219063475214474,"score_spread":0.30784918801232886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402106721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97991025,0.013718793,0.000003542857,0.00507358,0.0007680148,0.0004127568,0.000083144885,0.000010843906,0.000019068366],"genre_scores_gemma":[0.9990133,0.000818482,0.000008629479,0.0000825483,0.000040288065,0.000010208741,0.0000041213343,0.0000136029785,0.000008803377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952172,0.0030243995,0.0012239758,0.00019756162,0.00011924981,0.00021760343],"domain_scores_gemma":[0.9940257,0.0037073188,0.0019514704,0.00024907646,0.000029632725,0.00003680117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067938527,0.00024600167,0.0013507555,0.00011885625,0.0001809577,0.0000070221345,0.0003469244,0.00012069696,0.00002362972],"category_scores_gemma":[0.0001436041,0.00011204589,0.00034324036,0.00028873462,0.0007509976,0.000050655806,0.00008047649,0.00046175648,0.0000048254733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025344314,0.00092529214,0.7961537,0.00009516223,0.016906373,0.000011361815,0.0065012043,0.00008667079,0.015644573,0.0002546542,0.0021942512,0.1358824],"study_design_scores_gemma":[0.017206402,0.0070363306,0.9450595,0.00017515032,0.0018820823,0.00032762237,0.002230152,0.000019983168,0.025310481,0.000065929926,0.00053885276,0.00014753222],"about_ca_topic_score_codex":0.0015983995,"about_ca_topic_score_gemma":0.000065103006,"teacher_disagreement_score":0.14890574,"about_ca_system_score_codex":0.00009278627,"about_ca_system_score_gemma":0.00011667434,"threshold_uncertainty_score":0.45690987},"labels":[],"label_agreement":null},{"id":"W4402106889","doi":"10.1016/j.jaad.2024.07.605","title":"54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Interleukin 17; Interleukin; Longitudinal data; Internal medicine; Immunology; Cytokine; Data mining","score_opus":0.032508828523076315,"score_gpt":0.3090880432453111,"score_spread":0.2765792147222348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402106889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99200886,0.0018365998,0.000047797883,0.004068811,0.0008810365,0.00022948092,0.00085467973,0.000015923772,0.000056816552],"genre_scores_gemma":[0.9974651,0.001367193,0.0005439572,0.00018133123,0.00017473147,0.000006468601,0.00007663842,0.00002929751,0.00015528114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973813,0.0006796847,0.0010922708,0.00035798235,0.00018070229,0.00030805252],"domain_scores_gemma":[0.9960869,0.001124514,0.002058572,0.000569157,0.00011388742,0.000046995607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003151555,0.00031002544,0.0010603892,0.0001894857,0.00013292045,0.000031029795,0.0012573745,0.00017321312,0.000078037796],"category_scores_gemma":[0.00013548014,0.00015457699,0.00017884372,0.00041414853,0.0010963096,0.00024533205,0.00048249602,0.0007408465,0.0000044248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046509067,0.00050597446,0.9021997,0.00012926666,0.006090062,0.000073150564,0.00080441654,0.0000015810979,0.0059479997,0.00017666833,0.044340488,0.035079814],"study_design_scores_gemma":[0.0024171085,0.00047976672,0.968191,0.00063540676,0.0022539352,0.0007652891,0.00037626282,0.00001167233,0.007428779,0.00009148365,0.01711699,0.0002322645],"about_ca_topic_score_codex":0.00023036965,"about_ca_topic_score_gemma":0.00006310377,"teacher_disagreement_score":0.06599137,"about_ca_system_score_codex":0.000073625095,"about_ca_system_score_gemma":0.00027727042,"threshold_uncertainty_score":0.6303467},"labels":[],"label_agreement":null},{"id":"W4402106939","doi":"10.1016/j.jaad.2024.07.1099","title":"53817 Patient-reported outcomes with roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Scalp; Psoriasis; Dermatology; Roflumilast; Clinical trial; Pathology; Internal medicine; Surgery","score_opus":0.011292007441371238,"score_gpt":0.27422218211305005,"score_spread":0.2629301746716788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402106939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462587,0.0012258977,0.000005206785,0.0032830825,0.00039175682,0.00040678302,0.000021661428,0.00000773417,0.000032021642],"genre_scores_gemma":[0.99942404,0.00012986414,0.00005169732,0.00031710044,0.00002404006,0.000017078057,0.000004244908,0.000015543425,0.0000163671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979802,0.0006660543,0.00074635004,0.00019765165,0.0001248657,0.0002849097],"domain_scores_gemma":[0.99835193,0.0005592031,0.0008806408,0.000144732,0.00003724241,0.000026239519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021557772,0.00022187132,0.00078453537,0.00032293284,0.00006213142,0.000012828931,0.0003169326,0.00012679638,0.000011842983],"category_scores_gemma":[0.000097887256,0.00009981844,0.00013412297,0.00049312937,0.0005573897,0.00012363179,0.000046522688,0.00056342507,0.0000029492846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037990216,0.0011499886,0.9234345,0.000025561283,0.0014317627,0.0001471818,0.0015332807,0.000004112059,0.001310849,0.000055936813,0.0010696908,0.031846948],"study_design_scores_gemma":[0.0678274,0.0031871244,0.9146126,0.00020851425,0.0007596151,0.0021936602,0.0009782962,0.0000033169292,0.0052941246,0.00008712048,0.004590941,0.00025731124],"about_ca_topic_score_codex":0.00003879025,"about_ca_topic_score_gemma":0.000015535885,"teacher_disagreement_score":0.031589635,"about_ca_system_score_codex":0.000037926293,"about_ca_system_score_gemma":0.00010416234,"threshold_uncertainty_score":0.40704778},"labels":[],"label_agreement":null},{"id":"W4402107731","doi":"10.1016/j.jaad.2024.07.577","title":"52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Tolerability; Plaque psoriasis; Clinical trial; Dermatology; Psoriasis; Pooled analysis; Adverse effect; Internal medicine; Meta-analysis","score_opus":0.05068970887569089,"score_gpt":0.384595949770265,"score_spread":0.3339062408945741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402107731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899178,0.0031005435,0.000110601766,0.0058301217,0.00039061747,0.00035895486,0.00027394682,0.000006922332,0.000010457872],"genre_scores_gemma":[0.9981191,0.0011661232,0.00029923927,0.00030368858,0.00003847562,0.000011260293,0.000007738032,0.000011824988,0.000042520107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9937561,0.0031823795,0.0023826195,0.0003365489,0.000071027374,0.0002713033],"domain_scores_gemma":[0.99624914,0.0024088665,0.0010172913,0.00021090465,0.000035766818,0.00007803469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013947823,0.00022239728,0.0027320245,0.00074545335,0.000028584835,0.000008216783,0.0003323009,0.0002589765,0.000055315795],"category_scores_gemma":[0.00052434794,0.00015227582,0.0006175077,0.001041419,0.00026467873,0.000073770265,0.000097420765,0.00039240645,0.000010000231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06564944,0.002021163,0.24922062,0.00006608508,0.026124045,0.00023324242,0.008942883,0.0024662649,0.059662115,0.00023728696,0.0013715324,0.5840053],"study_design_scores_gemma":[0.03422489,0.0035714346,0.85639656,0.00052239915,0.012659514,0.0010974554,0.0024304101,0.00050446525,0.07502674,0.0015542898,0.011233087,0.0007787695],"about_ca_topic_score_codex":0.0005319894,"about_ca_topic_score_gemma":0.00015700953,"teacher_disagreement_score":0.6071759,"about_ca_system_score_codex":0.00015260947,"about_ca_system_score_gemma":0.00022604913,"threshold_uncertainty_score":0.6209628},"labels":[],"label_agreement":null},{"id":"W4402109144","doi":"10.1016/j.jaad.2024.07.762","title":"49513 Effectiveness and Persistence of Brodalumab in Patients with Plaque Psoriasis in the Canadian Real-World Setting: 3-Month Follow-up Results from the CARE Study","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; University of Calgary; Vancouver Coastal Health Research Institute; Ontario Tech University; Vancouver Coastal Health; Lakeridge Health; Queen's University; University of British Columbia; Guenther Dermatology Research Centre; Health Canada; University of Manitoba; Bausch Health (Canada)","funders":"","keywords":"Medicine; Persistence (discontinuity); Plaque psoriasis; Psoriasis; Dermatology; Intensive care medicine","score_opus":0.012580726689783444,"score_gpt":0.2546101748891541,"score_spread":0.24202944819937067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402109144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940819,0.0016805892,2.8156566e-7,0.0033108566,0.00025303,0.00042249792,0.00014931046,0.000003200598,0.00009834248],"genre_scores_gemma":[0.9996883,0.000106531086,0.0000164672,0.00013258395,0.00001732309,0.0000103566435,0.000007656647,0.000011109604,0.000009636923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697983,0.0018854501,0.0005607586,0.00021058887,0.00010934196,0.0002540494],"domain_scores_gemma":[0.9975556,0.001569244,0.00059608807,0.00019409807,0.000059212714,0.00002574891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048188312,0.00017887248,0.0006072268,0.0002680285,0.00012778769,0.000011700834,0.00057969335,0.00010511449,0.00000331228],"category_scores_gemma":[0.00012568683,0.00008622421,0.000118887205,0.0005728318,0.00051002664,0.000070939386,0.000060241164,0.00057315914,0.0000011820968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024272976,0.00011576084,0.9759304,0.000022669703,0.00053585647,0.000044864926,0.014475583,0.000016843904,0.00019379266,0.00003681168,0.000281816,0.0059183254],"study_design_scores_gemma":[0.004287486,0.00038251767,0.98463637,0.00022816796,0.00033041593,0.00010866201,0.008474402,0.0000012893664,0.0009947583,0.00004119422,0.00042613907,0.00008859059],"about_ca_topic_score_codex":0.04455224,"about_ca_topic_score_gemma":0.10145271,"teacher_disagreement_score":0.056900468,"about_ca_system_score_codex":0.00013234906,"about_ca_system_score_gemma":0.0002587913,"threshold_uncertainty_score":0.9618102},"labels":[],"label_agreement":null},{"id":"W4402111034","doi":"10.1016/j.jaad.2024.07.576","title":"52687 Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Dermatology Life Quality Index; Medicine; Dermatology; Psoriasis; Plaque psoriasis; Psoriasis Area and Severity Index; Quality of life (healthcare); Index (typography); World Wide Web","score_opus":0.014524148749033659,"score_gpt":0.26530608994801835,"score_spread":0.25078194119898467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402111034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828941,0.001313561,0.0002737405,0.014130529,0.0006892756,0.0005199189,0.00007977618,0.000030521776,0.0000685517],"genre_scores_gemma":[0.9977146,0.00012027542,0.00018302925,0.0017987835,0.000061688464,0.000030821804,0.0000058880387,0.000041120682,0.000043820255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99688816,0.0005641301,0.0012687617,0.00042739802,0.00019187204,0.0006596889],"domain_scores_gemma":[0.9981173,0.00041316097,0.0009226022,0.00027793323,0.000120404635,0.00014857276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022660266,0.00040611002,0.0013483437,0.00071405503,0.00012260479,0.000023837889,0.00073985505,0.00029759126,0.000036971185],"category_scores_gemma":[0.00012944781,0.00027240065,0.0002247364,0.00086487574,0.00030438724,0.0001683485,0.0002185472,0.00080412324,0.000056162582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022366716,0.0015402612,0.7955694,0.00054806843,0.008023169,0.0006251106,0.007326428,0.0057947743,0.084577754,0.0027502144,0.0070021893,0.0638759],"study_design_scores_gemma":[0.012602581,0.0014876517,0.84265816,0.00080193003,0.0008237837,0.006309095,0.0012213176,0.00009953181,0.12250175,0.0019920676,0.008145298,0.0013568188],"about_ca_topic_score_codex":0.00045175344,"about_ca_topic_score_gemma":0.00022587251,"teacher_disagreement_score":0.06251908,"about_ca_system_score_codex":0.00018789741,"about_ca_system_score_gemma":0.00029159247,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4402304947","doi":"10.1371/journal.pone.0307234","title":"Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective","year":2024,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Hospital for Sick Children; University of Toronto","keywords":"Medicine; Biosimilar; Cost-effectiveness analysis; Secukinumab; Psoriasis; Time horizon; Cost effectiveness; Cost–benefit analysis; Intensive care medicine; Internal medicine; Risk analysis (engineering); Psoriatic arthritis; Mathematics; Immunology","score_opus":0.09499177941432033,"score_gpt":0.31382537133681965,"score_spread":0.21883359192249932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402304947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871247,0.005408225,0.0007396749,0.0001747334,0.0004189457,0.0025654032,0.003083119,0.00023674013,0.00024850428],"genre_scores_gemma":[0.9961381,0.00009591229,0.00036907312,0.000022254086,0.00006494424,0.0017698779,0.0008829574,0.000033922912,0.0006229446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979534,0.00048211528,0.00035208964,0.0007064041,0.00007194076,0.00043402662],"domain_scores_gemma":[0.99885786,0.00034452486,0.000101947735,0.00034765736,0.00028970905,0.00005828276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026687598,0.00032384857,0.0010016137,0.0006278161,0.00018173292,0.000027796508,0.00017008156,0.0003185668,0.00007090435],"category_scores_gemma":[0.000044374912,0.00026502027,0.0004531572,0.000934554,0.00005924985,0.0000782993,0.000048932696,0.00010721161,0.00013846562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014403872,0.006811445,0.037097696,0.0033575604,0.34341896,0.00010279247,0.007162602,0.0008457859,0.54086655,0.032833084,0.000108897286,0.012990788],"study_design_scores_gemma":[0.012205739,0.0064532594,0.056409474,0.0031207872,0.11642994,0.000049606442,0.0074098716,0.0030542836,0.7921173,0.00081139023,0.00019100911,0.0017473366],"about_ca_topic_score_codex":0.0005827682,"about_ca_topic_score_gemma":0.00015481559,"teacher_disagreement_score":0.25125077,"about_ca_system_score_codex":0.000629965,"about_ca_system_score_gemma":0.00011911625,"threshold_uncertainty_score":0.9999802},"labels":[],"label_agreement":null},{"id":"W4402311632","doi":"10.1111/jdv.20310","title":"Considerations for defining and diagnosing generalized pustular psoriasis","year":2024,"lang":"en","type":"review","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain; Sunnybrook Health Science Centre; Dermatrials Research; Health Sciences Centre; Ottawa Hospital; University of Ottawa; Women's College Hospital; Queen's University; University of British Columbia; Probity Medical Research; University of Toronto; Hospital for Sick Children; McMaster University; SKiN Health; University of Calgary","funders":"Boehringer Ingelheim","keywords":"Medicine; Generalized pustular psoriasis; Dermatology; Psoriasis; Erythema; Pustular psoriasis; Disease; Pathology","score_opus":0.06326976682797841,"score_gpt":0.32032572746090765,"score_spread":0.25705596063292924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402311632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030424353,0.9936304,0.000018147284,0.0013091946,0.0014337687,0.0002946546,0.0000854272,0.0000126178875,0.00017334998],"genre_scores_gemma":[0.010762165,0.98813856,0.0005188327,0.0001751142,0.00015541387,0.00001388894,0.000013472707,0.000048636914,0.00017392571],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959383,0.0023028853,0.0011577591,0.00028053223,0.000033032895,0.00028750542],"domain_scores_gemma":[0.99700224,0.0015953502,0.0011842554,0.00013260687,0.000047169964,0.000038351416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006385342,0.00036978457,0.0018312394,0.00032672787,0.00026572682,0.000015975755,0.00027751728,0.0006320631,0.000017750215],"category_scores_gemma":[0.00038775962,0.00022640135,0.0005774468,0.00011024831,0.00055886427,0.000057832287,0.00023326115,0.00073040876,0.000017027454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018914472,0.00017481516,0.001690037,0.009418035,0.011023134,0.00032228619,0.0007924926,0.0000031744405,0.00029509002,0.04256519,0.034481976,0.89904463],"study_design_scores_gemma":[0.0016210098,0.000047613416,0.00017483463,0.0027247763,0.010920198,0.036764346,0.00002788255,9.115435e-7,0.0002735569,0.0034708807,0.9437075,0.00026644277],"about_ca_topic_score_codex":0.0000011670489,"about_ca_topic_score_gemma":0.0000010149079,"teacher_disagreement_score":0.9092256,"about_ca_system_score_codex":0.000019235198,"about_ca_system_score_gemma":0.00011570044,"threshold_uncertainty_score":0.92323786},"labels":[],"label_agreement":null},{"id":"W4402497013","doi":"10.1007/s13555-024-01264-3","title":"Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses","year":2024,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health; Ortho Dermatologics","keywords":"Post-hoc analysis; Medicine; Psoriasis; Post hoc; Dermatology; Internal medicine","score_opus":0.03730252384487797,"score_gpt":0.3197305289108256,"score_spread":0.2824280050659476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402497013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14357425,0.8540852,9.113755e-7,0.000016999193,0.00011647731,0.0013639244,0.0008241227,0.000012613954,0.000005476149],"genre_scores_gemma":[0.0043189093,0.99411434,0.00003859243,0.000012093084,0.00000674521,0.00017192723,0.0012772026,0.000031587493,0.000028604738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982071,0.00045358212,0.0006534341,0.0004272327,0.000029669161,0.00022900761],"domain_scores_gemma":[0.9984694,0.00065487274,0.00050790247,0.00027800782,0.000067769855,0.000022034274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008687811,0.00049189536,0.0026891502,0.00031287267,0.00006160829,0.0000045582506,0.00010849718,0.00045642562,0.00002898703],"category_scores_gemma":[0.000033242217,0.00027146417,0.00037648363,0.00023175718,0.00021244076,0.00003426631,0.00002340377,0.00010721533,0.0000041440267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076739036,0.00053135806,0.009915843,0.01809578,0.007245931,0.0000052048745,0.00030003587,1.9184924e-8,0.00000282382,0.00005701757,0.00010802534,0.96297055],"study_design_scores_gemma":[0.021721061,0.004603592,0.012343975,0.04101651,0.024618056,0.0001672872,0.000092438415,1.3436538e-7,0.00043137494,0.00005264634,0.8939918,0.0009610937],"about_ca_topic_score_codex":0.00007092853,"about_ca_topic_score_gemma":0.000040222854,"teacher_disagreement_score":0.9620095,"about_ca_system_score_codex":0.000022686869,"about_ca_system_score_gemma":0.000102788516,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4402580541","doi":"10.1007/s13555-024-01258-1","title":"Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; LEO Pharma; UCB Pharma; Regeneron Pharmaceuticals; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Ortho Dermatologics; Janssen Pharmaceuticals; UCB US; Gilead Sciences; Sanofi; Pfizer; Genentech; National Psoriasis Foundation; Amgen","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Disease; Arthritis; Internal medicine","score_opus":0.0255114006844872,"score_gpt":0.27182321956590577,"score_spread":0.24631181888141856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402580541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9174111,0.08102127,0.00000979934,0.00023411778,0.00041611533,0.00041623297,0.00042127242,0.00004680231,0.000023307446],"genre_scores_gemma":[0.9357885,0.06383186,0.000016403823,0.000060066675,0.000029652296,0.000035970985,0.00019477437,0.000021585578,0.000021148335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983142,0.00049475016,0.00039216137,0.00045694277,0.00006490659,0.00027704512],"domain_scores_gemma":[0.9974219,0.001781164,0.00024081179,0.0004431115,0.000061494575,0.000051488983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013459839,0.00036356173,0.00062754867,0.00013830258,0.00018340722,0.000022923294,0.00020533561,0.00020910252,0.00014315954],"category_scores_gemma":[0.000058390448,0.00018640762,0.00018202302,0.00023648098,0.00041801328,0.0001221994,0.00003173124,0.00020250476,0.0000070886404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003670449,0.00024368573,0.8889262,0.000026865062,0.0017569843,0.000013827818,0.0011334971,0.0000010166005,0.0013594921,0.00045635502,0.00028143974,0.102130175],"study_design_scores_gemma":[0.0028275936,0.0008904197,0.988948,0.0003330981,0.0001671076,0.0000085787215,0.00007683282,0.000002649592,0.0050472617,0.0009235206,0.00055716076,0.00021780936],"about_ca_topic_score_codex":0.0006329541,"about_ca_topic_score_gemma":0.00006158212,"teacher_disagreement_score":0.101912364,"about_ca_system_score_codex":0.00001886652,"about_ca_system_score_gemma":0.000092604285,"threshold_uncertainty_score":0.7601482},"labels":[],"label_agreement":null},{"id":"W4402722894","doi":"10.1016/j.bbih.2024.100862","title":"Circulating Interleukin-17A is associated with executive function in middle aged adults with and without type 2 diabetes","year":2024,"lang":"en","type":"article","venue":"Brain Behavior & Immunity - Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Service Executive; Wellcome Trust; Meath Foundation; Canadian Institute for Theoretical Astrophysics","keywords":"Type 2 diabetes; Diabetes mellitus; Medicine; Interleukin 1β; Interleukin; Internal medicine; Psychology; Endocrinology; Cytokine","score_opus":0.029770268324475754,"score_gpt":0.2694341864330144,"score_spread":0.23966391810853865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402722894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932331,0.00519371,0.0000072605003,0.00024520818,0.0003099466,0.00066477543,0.00008708984,0.00016747943,0.00009144253],"genre_scores_gemma":[0.9975666,0.000085645705,0.00004712017,0.0003138402,0.000014215294,0.000103212515,0.00065579143,0.000044371904,0.0011692111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807286,0.00063638174,0.00031518994,0.0004100514,0.000062941595,0.0005025797],"domain_scores_gemma":[0.999213,0.0002601114,0.00014429401,0.00026488423,0.000068109584,0.0000495927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000543849,0.0002927231,0.00043857636,0.00023032718,0.0003285968,0.000045379922,0.00010430923,0.00022089366,0.000102794824],"category_scores_gemma":[0.000053210322,0.00023076762,0.000045686753,0.0004922902,0.00015846196,0.00016825796,0.000048923936,0.0005221841,0.000031791926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016651676,0.00086083973,0.87669164,0.0002610868,0.0007773323,0.00009659317,0.028593648,0.0000017072472,0.021666285,0.00004136125,0.0008269594,0.0685174],"study_design_scores_gemma":[0.0037281173,0.0026249387,0.98546857,0.0019633353,0.0002592719,0.00009118679,0.0033352806,0.0000132130435,0.0017364483,0.000017954706,0.00038374704,0.00037793917],"about_ca_topic_score_codex":0.0015463688,"about_ca_topic_score_gemma":0.002412098,"teacher_disagreement_score":0.10877695,"about_ca_system_score_codex":0.00023970098,"about_ca_system_score_gemma":0.00023332938,"threshold_uncertainty_score":0.9410431},"labels":[],"label_agreement":null},{"id":"W4402938707","doi":"10.1007/s13555-024-01271-4","title":"Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study","year":2024,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; University of Toronto","funders":"","keywords":"Certolizumab pegol; Plaque psoriasis; Medicine; Psoriasis; Medical physics; Dermatology; Internal medicine; Adalimumab","score_opus":0.04964615182662028,"score_gpt":0.33680599483069884,"score_spread":0.28715984300407854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402938707","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24783187,0.44950867,0.000037346857,0.044292837,0.23376748,0.010782394,0.0051587536,0.0002697888,0.008350859],"genre_scores_gemma":[0.738027,0.22143546,0.000048951046,0.0002997514,0.0021182527,0.001212595,0.0032677418,0.00010180225,0.03348845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963415,0.0014630755,0.0010331472,0.0007292852,0.0000673214,0.00036564807],"domain_scores_gemma":[0.9902483,0.008415079,0.00049078,0.0007200258,0.00010247454,0.000023303879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031730754,0.00047641058,0.0011073912,0.00010939161,0.00033353805,0.000030537933,0.00028804585,0.0012289601,0.00008209819],"category_scores_gemma":[0.00022526673,0.0002585032,0.00034666283,0.00017756151,0.00036114096,0.00005193043,0.00004643259,0.00073483057,0.00006783346],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033278022,0.0062353313,0.011215249,0.000024840916,0.015332726,0.00039185255,0.014705095,8.4254395e-7,0.000016284039,0.00034184434,0.75801706,0.16044088],"study_design_scores_gemma":[0.020597925,0.0024424344,0.020599157,0.00008375518,0.0018927896,0.00063840917,0.0036301117,0.000017136279,0.0002214459,0.00027311707,0.9493022,0.00030153152],"about_ca_topic_score_codex":0.0015735246,"about_ca_topic_score_gemma":0.0017017359,"teacher_disagreement_score":0.49019513,"about_ca_system_score_codex":0.00005178913,"about_ca_system_score_gemma":0.00025444248,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4403035793","doi":"10.3899/jrheum.2024-0589","title":"The 1st GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis – 1º Encontro Internacional do GRAPPA sobre Psoríase e Artrite Psoriásica","year":2024,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Dermatology; Arthritis; Internal medicine","score_opus":0.008756480773554886,"score_gpt":0.23205853056477865,"score_spread":0.22330204979122376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403035793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92189276,0.058509357,0.00016343666,0.007119573,0.011039276,0.00021917725,0.000061544,0.000054647164,0.0009402345],"genre_scores_gemma":[0.95268494,0.04652652,0.00006146097,0.00012722079,0.00012764016,0.000017270158,0.000014286212,0.000029296903,0.0004113398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974642,0.00077528507,0.0008845366,0.00026925743,0.00016159739,0.0004451652],"domain_scores_gemma":[0.9961371,0.0028830124,0.00047255075,0.00028834827,0.00015989844,0.000059114132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015588489,0.00032685493,0.0005500417,0.00030902636,0.00053392735,0.00012132047,0.00062627194,0.00023433407,0.00015800216],"category_scores_gemma":[0.00037772828,0.00018260948,0.0003086177,0.00019037194,0.00045507855,0.00016327066,0.00012231272,0.00067562424,0.00018685524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004675857,0.00031508552,0.0063410136,0.000060520175,0.0062631685,0.00024333414,0.0037651476,0.00002381956,0.0052616843,0.049533285,0.029823044,0.89369404],"study_design_scores_gemma":[0.025446419,0.0052503087,0.008637587,0.0051341,0.0029730622,0.115725696,0.0084815,0.00041340795,0.010284337,0.05940509,0.7563676,0.0018808887],"about_ca_topic_score_codex":0.00006575425,"about_ca_topic_score_gemma":0.00013567678,"teacher_disagreement_score":0.89181316,"about_ca_system_score_codex":0.00006074994,"about_ca_system_score_gemma":0.00010860285,"threshold_uncertainty_score":0.74465984},"labels":[],"label_agreement":null},{"id":"W4403061875","doi":"10.1007/s13555-024-01268-z","title":"A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"AbbVie","keywords":"Post-hoc analysis; Ethnic group; Medicine; Psoriasis; Post hoc; Descriptive statistics; Internal medicine; Dermatology; Political science; Statistics; Mathematics","score_opus":0.026430391181251064,"score_gpt":0.2666626916384742,"score_spread":0.24023230045722316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403061875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97601026,0.02321988,0.00006949279,0.0001305609,0.00009730454,0.00024715572,0.0001689479,0.00001569675,0.000040673513],"genre_scores_gemma":[0.9968406,0.002823022,0.00014549003,0.000049063787,0.0000028553443,0.00001737619,0.0000995421,0.000007768583,0.0000142692015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991248,0.00017570761,0.0002560349,0.00026274545,0.000024998824,0.00015565896],"domain_scores_gemma":[0.99959296,0.00016350587,0.000064705964,0.0001155385,0.000039545976,0.000023714034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006204666,0.00015421947,0.0004675276,0.00044578582,0.000092974515,0.0000063482616,0.00004170076,0.00018158696,0.000049832088],"category_scores_gemma":[0.000008634758,0.00011678118,0.000050102728,0.00045064455,0.00019694249,0.000070711656,0.00003103232,0.00009138542,0.0000018345978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040954288,0.00082053064,0.27869067,0.00012489432,0.011879554,0.00015899746,0.06595326,0.0002462437,0.017196054,0.008366488,0.000073378134,0.57553566],"study_design_scores_gemma":[0.009894083,0.0011978038,0.9767042,0.000108305154,0.0016434552,0.0002649779,0.0018986942,0.00018563966,0.0066963737,0.0003730028,0.0006705754,0.00036291862],"about_ca_topic_score_codex":0.0001656488,"about_ca_topic_score_gemma":0.0005396131,"teacher_disagreement_score":0.69801354,"about_ca_system_score_codex":0.0000100348625,"about_ca_system_score_gemma":0.000028425684,"threshold_uncertainty_score":0.47621983},"labels":[],"label_agreement":null},{"id":"W4403269358","doi":"10.3389/fimmu.2024.1446424","title":"The β2-adrenergic biased agonist nebivolol inhibits the development of Th17 and the response of memory Th17 cells in an NF-κB-dependent manner","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University","funders":"Fonds de recherche du Québec – Nature et technologies; Natural Sciences and Engineering Research Council of Canada","keywords":"Nebivolol; CREB; Flow cytometry; CD28; Cell biology; Peripheral blood mononuclear cell; Biology; Chemistry; T cell; Molecular biology; Endocrinology; Immunology; Transcription factor; Immune system; Biochemistry; Gene; In vitro","score_opus":0.010811004223605189,"score_gpt":0.22264341133549848,"score_spread":0.21183240711189327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403269358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9321151,0.063714415,0.00006877363,0.00059371104,0.0027645961,0.00050112745,0.000030903862,0.000024600455,0.00018677302],"genre_scores_gemma":[0.9960575,0.0015080635,0.00024830084,0.00004506845,0.000017080167,0.00015055152,0.000031323525,0.000023560813,0.0019185556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963165,0.0020745024,0.0007216033,0.0003799831,0.00006630812,0.00044110933],"domain_scores_gemma":[0.9981114,0.0010497234,0.00019152935,0.0005889726,0.00004496003,0.000013385422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002214153,0.00027040867,0.0005141268,0.00029370934,0.00030591688,0.000027197539,0.0005896389,0.00034105746,0.000029921213],"category_scores_gemma":[0.000098939716,0.00013973052,0.000109135784,0.00032923336,0.0015530912,0.00007505816,0.00021276738,0.0004013584,0.000018405257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035160046,0.0006222584,0.007853077,0.000102489066,0.002741863,0.000081443446,0.042616084,0.0001349707,0.7257187,0.0032815882,0.0031765727,0.1785109],"study_design_scores_gemma":[0.009116958,0.0005010214,0.04353895,0.00020738668,0.00025627864,0.000076396725,0.017217884,0.000094106,0.91291326,0.0012993211,0.0143439565,0.000434477],"about_ca_topic_score_codex":0.00015105358,"about_ca_topic_score_gemma":0.0005634905,"teacher_disagreement_score":0.18719457,"about_ca_system_score_codex":0.0000932642,"about_ca_system_score_gemma":0.00027070357,"threshold_uncertainty_score":0.572243},"labels":[],"label_agreement":null},{"id":"W4403287791","doi":"10.1080/09546634.2024.2414048","title":"A systematic review of recent randomized controlled trials for palmoplantar pustulosis","year":2024,"lang":"en","type":"review","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; McMaster University","funders":"","keywords":"Palmoplantar pustulosis; Medicine; Randomized controlled trial; Dermatology; Quality of life (healthcare); Incidence (geometry); Psoriasis; Intensive care medicine; Surgery","score_opus":0.13774116053334678,"score_gpt":0.38436744412217355,"score_spread":0.24662628358882677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403287791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004568714,0.9820999,0.000029870662,0.00023922478,0.0016414818,0.01524942,0.0005728971,0.000024790255,0.00013783788],"genre_scores_gemma":[0.000009996761,0.99490225,0.00018481918,0.000058270805,0.0000874933,0.003908372,0.0003194425,0.000039367205,0.00048996275],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97968894,0.009802849,0.009621818,0.0003553903,0.00015489207,0.00037612917],"domain_scores_gemma":[0.9714525,0.018263875,0.009443616,0.0003938196,0.00037260918,0.00007360071],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.007316333,0.0009879987,0.052242022,0.00045243432,0.00007622178,0.000027923823,0.00039416293,0.00077816367,0.00037996095],"category_scores_gemma":[0.008177545,0.0003617471,0.017802965,0.00024437936,0.00013719263,0.00004001097,0.000042235493,0.00026735093,0.0001212676],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018623771,0.00081367925,2.6040908e-7,0.83566076,0.09290244,0.00023038742,0.000035211273,3.6384428e-8,0.0000018126436,0.00021160748,0.0024912637,0.049028788],"study_design_scores_gemma":[0.1068115,0.0005180901,1.629689e-8,0.4868042,0.28109834,0.003150832,0.00001635713,1.3967518e-7,0.00003386987,0.00009345682,0.12125359,0.00021961993],"about_ca_topic_score_codex":0.000001248978,"about_ca_topic_score_gemma":3.2430333e-7,"teacher_disagreement_score":0.34885657,"about_ca_system_score_codex":0.00030165698,"about_ca_system_score_gemma":0.00047343105,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W4403312673","doi":"10.1016/j.jid.2024.08.039","title":"Imaging Mass Cytometry in Psoriatic Disease Reveals Immune Profile Heterogeneity in Skin and Synovial Tissue","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Women's College Hospital","funders":"Canadian Institutes of Health Research; Women's College Hospital; Ontario Institute for Cancer Research; Canadian Dermatology Foundation; Fluidigm; Canada Research Chairs; Government of Ontario; AbbVie","keywords":"Mass cytometry; Pathology; Immune system; Flow cytometry; Cytometry; Psoriasis; Medicine; Dermatology; Biology; Immunology","score_opus":0.014326953822097366,"score_gpt":0.2690512714840729,"score_spread":0.2547243176619755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403312673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561998,0.040871292,0.00009309967,0.0017012734,0.0007950846,0.00021161103,0.00003945364,0.000016675387,0.00007168895],"genre_scores_gemma":[0.9988911,0.00032735834,0.0004622338,0.00013504284,0.000050503626,0.000022211325,0.000023990146,0.00001908601,0.000068483845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776703,0.00076707476,0.00079868984,0.00026210793,0.000055263423,0.00034984917],"domain_scores_gemma":[0.99908996,0.00037458792,0.0002541862,0.00013703395,0.000063554464,0.000080681435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004369112,0.00023311967,0.0006295356,0.0007830787,0.000055272096,0.000027688564,0.00016722505,0.00016261294,0.000069300004],"category_scores_gemma":[0.000324574,0.00019461827,0.000098140794,0.00043933507,0.0004315548,0.00026500522,0.000059297476,0.00043201138,0.000060133985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042211765,0.00019970325,0.16793883,0.00036598806,0.00044328597,0.0051550395,0.0017273183,0.0000079980755,0.80986357,0.0012168217,0.0008881285,0.011771223],"study_design_scores_gemma":[0.0031378446,0.00014375849,0.41689175,0.0007144811,0.00021405263,0.0031649407,0.00037816356,0.000071232986,0.5668477,0.0069343033,0.0011603397,0.00034146372],"about_ca_topic_score_codex":0.000029769633,"about_ca_topic_score_gemma":0.00002276289,"teacher_disagreement_score":0.24895293,"about_ca_system_score_codex":0.00010828306,"about_ca_system_score_gemma":0.0002290666,"threshold_uncertainty_score":0.7936303},"labels":[],"label_agreement":null},{"id":"W4403372072","doi":"10.1111/hdi.13185","title":"Plaque psoriasis with renal dysfunction successfully treated with ixekizumab","year":2024,"lang":"en","type":"article","venue":"Hemodialysis International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Ixekizumab; Medicine; Psoriasis; Plaque psoriasis; Dermatology; Kidney disease; Albuminuria; Population; Internal medicine; Psoriatic arthritis; Secukinumab","score_opus":0.01028283717054639,"score_gpt":0.2252702332144827,"score_spread":0.2149873960439363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403372072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770387,0.0008377777,0.003756563,0.00079178956,0.0013488298,0.0002250369,0.00020696901,0.0003914628,0.014737707],"genre_scores_gemma":[0.98562396,0.000088703055,0.00031478013,0.000059353453,0.0002603744,0.000121458615,0.0014763778,0.00003490563,0.012020073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987302,0.00009845044,0.00024709347,0.0005233205,0.00013565266,0.00026528994],"domain_scores_gemma":[0.9993727,0.0001311347,0.00007988953,0.00023304622,0.00015182403,0.00003141011],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012785569,0.00027696544,0.00026990537,0.0003775526,0.00014962339,0.00010969308,0.00021418519,0.00018136785,0.0026527643],"category_scores_gemma":[0.000013588955,0.00018583513,0.00014141134,0.00038327026,0.00011264254,0.00026596806,0.000031430474,0.00017452573,0.00081019505],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01932779,0.0015228633,0.08606698,0.000112117,0.039050467,0.0013656882,0.0020832978,0.001586128,0.083242185,0.015413365,0.035021782,0.71520734],"study_design_scores_gemma":[0.021251852,0.0024504852,0.055470604,0.00075194443,0.006040017,0.0024040516,0.0005323844,0.0014420719,0.41000906,0.00055502803,0.4968614,0.002231123],"about_ca_topic_score_codex":0.00018008634,"about_ca_topic_score_gemma":0.00020666048,"teacher_disagreement_score":0.7129762,"about_ca_system_score_codex":0.00017137389,"about_ca_system_score_gemma":0.00011113792,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W4403421806","doi":"10.1101/2024.10.11.617865","title":"CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Interleukin 17; Pathology; Joint (building); Medicine; Inflammation; Immunology; Engineering; Structural engineering","score_opus":0.009758743319346914,"score_gpt":0.21390913596563335,"score_spread":0.20415039264628643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403421806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561921,0.03490036,0.000046205765,0.00017490881,0.005181577,0.0012235325,0.0018944469,0.00034729994,0.000039599217],"genre_scores_gemma":[0.9972326,0.0008442339,0.00037182868,0.00005919187,0.0003940656,0.0003538117,0.000005711837,0.0001942268,0.0005443233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995916,0.00049569015,0.0010542735,0.001457105,0.0001861428,0.0008907632],"domain_scores_gemma":[0.99736804,0.00017862784,0.00063701905,0.0014552488,0.00024279839,0.00011826752],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065044785,0.00092489406,0.0014164558,0.0007809022,0.00014250552,0.00009509726,0.0007912394,0.0015564446,0.0006421392],"category_scores_gemma":[0.00011632856,0.0009786368,0.0002968453,0.0005993539,0.00032745465,0.00008727173,0.0010049416,0.0011451646,0.0014620009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002192046,0.00031806692,0.0014241033,0.00087584055,0.00063238165,0.00064958306,0.000116636766,0.00003066054,0.9937697,0.00012303049,0.0016999899,0.0001408057],"study_design_scores_gemma":[0.0017078746,0.00016624719,0.016809193,0.0014896881,0.00052761106,3.6604428e-7,0.000032961616,0.000002861429,0.96060777,0.000008282713,0.017754097,0.0008930613],"about_ca_topic_score_codex":0.0008123882,"about_ca_topic_score_gemma":0.00013259298,"teacher_disagreement_score":0.04104054,"about_ca_system_score_codex":0.0002941236,"about_ca_system_score_gemma":0.00056817685,"threshold_uncertainty_score":0.99973977},"labels":[],"label_agreement":null},{"id":"W4403512247","doi":"10.3389/fimmu.2024.1452788","title":"Circulating IL-17F, but not IL-17A, is elevated in severe COVID-19 and leads to an ERK1/2 and p38 MAPK-dependent increase in ICAM-1 cell surface expression and neutrophil adhesion on endothelial cells","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mila - Quebec Artificial Intelligence Institute; Children’s Health Research Institute; McGill University Health Centre; Lawson Health Research Institute; Western University; McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Lung Association; Fonds de Recherche du Québec - Santé; Public Health Agency; Public Health Agency of Canada","keywords":"p38 mitogen-activated protein kinases; Interleukin 17; ICAM-1; Coronavirus disease 2019 (COVID-19); MAPK/ERK pathway; Expression (computer science); Cell biology; Immunology; Medicine; Inflammation; Biology; Signal transduction; Internal medicine; Computer science; Cell adhesion molecule","score_opus":0.013114789338410418,"score_gpt":0.2356485607071494,"score_spread":0.22253377136873898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403512247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987913,0.00941419,0.000044013046,0.0003260357,0.0011395777,0.0005928008,0.00042898048,0.000069440815,0.000071974],"genre_scores_gemma":[0.9957308,0.002096538,0.00070201646,0.0003870595,0.00002561805,0.000047728496,0.00011218784,0.000042664404,0.0008553509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709547,0.0007797792,0.0004954253,0.00096485246,0.00006245891,0.00060202146],"domain_scores_gemma":[0.99914116,0.00030114758,0.00009325267,0.0003498299,0.000018978888,0.00009564261],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004587189,0.00040951397,0.0006257343,0.0006513903,0.00014788585,0.000042704447,0.00019118136,0.00067222683,0.00007341476],"category_scores_gemma":[0.000074326665,0.0003924432,0.00004623432,0.00028372247,0.00020683598,0.00017563076,0.00021696903,0.0005472371,0.00003521901],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002316465,0.000202499,0.034384795,0.00009669579,0.00006168241,0.00035965157,0.0030722956,0.000082917526,0.95220387,0.000025017502,0.00058177416,0.0066123665],"study_design_scores_gemma":[0.012377685,0.0015790971,0.05666704,0.00039923706,0.00011689869,0.0003014446,0.0027726889,0.00025229104,0.91918457,0.000531125,0.0048191864,0.0009987579],"about_ca_topic_score_codex":0.0014257178,"about_ca_topic_score_gemma":0.00020237337,"teacher_disagreement_score":0.033019293,"about_ca_system_score_codex":0.0002591954,"about_ca_system_score_gemma":0.00011944718,"threshold_uncertainty_score":0.9998527},"labels":[],"label_agreement":null},{"id":"W4403565426","doi":"10.1093/ced/llae449","title":"Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","year":2024,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Portugal; Janssen Australia; Cilag; Bristol-Myers Squibb Canada; Samsung; AbbVie Canada; LEO Pharma; National Institute for Health and Care Research; British Association of Dermatologists; Almirall; Boehringer Ingelheim España; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Medicine; Suicidal ideation; Comorbidity; Population; Depression (economics); Psychiatry; Incidence (geometry); Suicide attempt; Poison control; Suicide prevention; Emergency medicine; Dermatology; Environmental health","score_opus":0.01856670141786635,"score_gpt":0.27652505990569826,"score_spread":0.2579583584878319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403565426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845965,0.009991359,0.0000057466464,0.00036864475,0.00031047582,0.0002850569,0.0005165714,0.00002026895,0.000042257634],"genre_scores_gemma":[0.9988247,0.0007115357,0.000090975904,0.00013934984,0.000010327565,0.000017170114,0.00015993846,0.000009121629,0.0000368582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798054,0.0006139361,0.00072359276,0.00042707403,0.00003977215,0.00021511645],"domain_scores_gemma":[0.998343,0.0011671814,0.0002290924,0.00018370844,0.000043540666,0.000033470507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003249332,0.00017113952,0.0005767375,0.000037701575,0.00012341369,0.000034178618,0.00009316395,0.00036029177,0.0000070422457],"category_scores_gemma":[0.00022394297,0.000118760414,0.000059745013,0.000093022965,0.00044877923,0.00007595401,0.0001402303,0.00018904598,0.000004280807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021670472,0.00020292771,0.9913271,0.000016247997,0.0003896463,0.000013190183,0.0006430308,0.0000013199372,0.0004215529,0.00006204518,0.00040808305,0.0043478264],"study_design_scores_gemma":[0.0052402816,0.00032672557,0.9843727,0.000110720306,0.00012173251,0.000054144,0.00034595391,0.000012967367,0.008724587,0.00025787458,0.00027566656,0.00015668388],"about_ca_topic_score_codex":0.0017145016,"about_ca_topic_score_gemma":0.0004230143,"teacher_disagreement_score":0.010365103,"about_ca_system_score_codex":0.000018533223,"about_ca_system_score_gemma":0.000026331529,"threshold_uncertainty_score":0.48429093},"labels":[],"label_agreement":null},{"id":"W4403623250","doi":"10.1093/bjd/ljae406","title":"Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Discontinuation; Internal medicine; Psoriasis Area and Severity Index; Adverse effect; Psoriasis; Placebo; Plaque psoriasis; Randomized controlled trial; Clinical trial; Gastroenterology; Dermatology; Pathology","score_opus":0.014479805038292212,"score_gpt":0.2706572667441224,"score_spread":0.25617746170583017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403623250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925267,0.0039530345,0.0004364172,0.00023841218,0.0014788721,0.0009516961,0.0003384069,0.00003591494,0.000040553972],"genre_scores_gemma":[0.9984708,0.00028704345,0.00047747485,0.00011797019,0.00019502318,0.000058093185,0.00031523223,0.000041442385,0.000036940837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995158,0.0023525148,0.0014044729,0.0005200458,0.00009757444,0.00046737873],"domain_scores_gemma":[0.99874884,0.0003846774,0.0003970419,0.00015239566,0.00016107966,0.00015594276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068944256,0.00035145538,0.0017975338,0.0003385094,0.0001445918,0.00012467732,0.00019812214,0.00048041387,0.00007498942],"category_scores_gemma":[0.0002491788,0.00029909637,0.00023415907,0.00025019347,0.00027066018,0.0003292178,0.00006464767,0.0006546783,0.000018197226],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9169119,0.0017882456,0.011289996,0.000020899752,0.001543663,0.0043658344,0.0022076291,0.0000047721282,0.00021074276,0.00002691051,0.0008840832,0.060745347],"study_design_scores_gemma":[0.9738365,0.0033965618,0.009358883,0.00048694556,0.0008506554,0.009617456,0.00032002278,0.00005196771,0.0010696725,0.00027062267,0.0002993515,0.0004413536],"about_ca_topic_score_codex":0.00022132875,"about_ca_topic_score_gemma":0.00037609518,"teacher_disagreement_score":0.060303994,"about_ca_system_score_codex":0.000054261196,"about_ca_system_score_gemma":0.0003228049,"threshold_uncertainty_score":0.9999461},"labels":[],"label_agreement":null},{"id":"W4403714904","doi":"10.1016/s0140-6736(24)01750-1","title":"IL-23 inhibition for chronic inflammatory disease","year":2024,"lang":"en","type":"review","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine","score_opus":0.05136192180307113,"score_gpt":0.30841394628549335,"score_spread":0.2570520244824222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403714904","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047529265,0.99488246,0.0000062706386,0.00019580725,0.0014405304,0.0009663216,0.0020853542,0.00013550156,0.00024020846],"genre_scores_gemma":[0.000073267955,0.98811555,0.0000037741781,0.000050084356,0.001654746,0.0009427982,0.0030815913,0.000046417797,0.006031794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988762,0.00019454505,0.00025761605,0.0002880578,0.000020904454,0.00036267997],"domain_scores_gemma":[0.9991558,0.00016590094,0.00012368863,0.0005216756,0.000015420024,0.000017488148],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000247446,0.00030365423,0.00096369523,0.000066365734,0.00013596087,0.000023318386,0.00024949538,0.00026363452,0.00010147251],"category_scores_gemma":[0.000026863263,0.00016621826,0.0004926185,0.00009167204,0.00008502005,0.000027456186,0.000076559554,0.0002501744,0.0038785895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069318856,0.000022206405,0.0000017287296,0.012809131,0.0009464548,0.000015524629,0.00003607785,1.2864797e-7,0.000012547962,0.0032533605,0.0956659,0.88716763],"study_design_scores_gemma":[0.0005198548,0.000037867827,0.000007111571,0.003935446,0.0038976169,0.00001645098,0.0000032238197,2.1040455e-7,0.000010678344,0.00071028195,0.99067295,0.00018833493],"about_ca_topic_score_codex":0.0000015169197,"about_ca_topic_score_gemma":0.000008025451,"teacher_disagreement_score":0.895007,"about_ca_system_score_codex":0.00012162072,"about_ca_system_score_gemma":0.00028304532,"threshold_uncertainty_score":0.996897},"labels":[],"label_agreement":null},{"id":"W4403725800","doi":"10.14309/01.ajg.0001034252.80967.08","title":"S1221 Risankizumab Sustains Remission and Improves Anti-TNF-Induced Psoriasiform Dermatitis in Well Controlled Crohn's Disease Patients Switched From Anti-TNF Therapy","year":2024,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Crohn's disease; Psoriasis; Tumor necrosis factor alpha; Disease; Crohn disease; Immunology; Dermatology; Internal medicine","score_opus":0.007678182778310022,"score_gpt":0.23188035503884386,"score_spread":0.22420217226053382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403725800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304867,0.0033817608,0.000050942348,0.0019757606,0.0010212783,0.0004092596,0.00006229307,0.000027346536,0.000022714848],"genre_scores_gemma":[0.9966665,0.0023696083,0.000046817277,0.000648058,0.00013138732,0.000019303996,0.000042721374,0.000032448857,0.000043160675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973944,0.0008887033,0.0007558396,0.00032173563,0.00009362758,0.00054570823],"domain_scores_gemma":[0.9984788,0.00037561634,0.000644561,0.00029539168,0.00010271838,0.000102961494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003911493,0.0003461887,0.0011284158,0.00031401237,0.0001454322,0.000050996812,0.0003643376,0.000098338496,0.00009574292],"category_scores_gemma":[0.000074175645,0.00021196403,0.0002792716,0.00017812246,0.00037340695,0.0001821445,0.000087047265,0.0004436634,0.000020409969],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092830256,0.0014951869,0.5695064,0.000042604872,0.0041735563,0.0013052551,0.004108285,0.000018794963,0.0975144,0.000027079815,0.0016073316,0.22737084],"study_design_scores_gemma":[0.01938852,0.004359586,0.9718499,0.000116663316,0.00037709167,0.00015634893,0.00090697623,0.00003807298,0.001605599,0.00022448528,0.0008126142,0.00016413616],"about_ca_topic_score_codex":0.00020494481,"about_ca_topic_score_gemma":0.00003463146,"teacher_disagreement_score":0.40234348,"about_ca_system_score_codex":0.00008962903,"about_ca_system_score_gemma":0.000110502784,"threshold_uncertainty_score":0.8643642},"labels":[],"label_agreement":null},{"id":"W4403771309","doi":"10.1177/12034754241291042","title":"Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study","year":2024,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Multicenter study; Retrospective cohort study; Dermatology; Surgery; Randomized controlled trial","score_opus":0.015423066840535751,"score_gpt":0.2580412507964065,"score_spread":0.24261818395587076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403771309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795684,0.0019995389,0.000011990155,0.013906876,0.0027053626,0.0013872385,0.0002978305,0.000014660839,0.000108093525],"genre_scores_gemma":[0.98873407,0.0022576929,0.000033494674,0.0071907793,0.00084807875,0.000065067296,0.00016412938,0.00007911702,0.00062760164],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9969965,0.00063424854,0.0013035339,0.00048184706,0.00018025072,0.00040362446],"domain_scores_gemma":[0.99523294,0.0032321173,0.00068429945,0.00021368402,0.0005773514,0.00005959865],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079658726,0.0004939335,0.0022037323,0.0011832641,0.00009142426,0.000016115424,0.00013121273,0.0005156342,0.000042547133],"category_scores_gemma":[0.00053346495,0.00034723416,0.00026374924,0.00028661414,0.00014598948,0.0000828494,0.00005635306,0.00091840676,0.0000035499827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072411634,0.0024021736,0.2892921,0.003277627,0.009863552,0.008393282,0.010726697,0.000017972092,0.0007803162,0.000023563533,0.5667209,0.036090184],"study_design_scores_gemma":[0.12136299,0.05084923,0.53242743,0.050671156,0.022903008,0.010690989,0.0076762303,0.000049164668,0.003120213,0.0020423424,0.192844,0.005363268],"about_ca_topic_score_codex":0.00032677688,"about_ca_topic_score_gemma":0.00024965932,"teacher_disagreement_score":0.3738769,"about_ca_system_score_codex":0.00022729255,"about_ca_system_score_gemma":0.00015183166,"threshold_uncertainty_score":0.99989796},"labels":[],"label_agreement":null},{"id":"W4403781950","doi":"10.1177/12034754241293085","title":"Biologic Therapy in Psoriasis Patients with Renal Disease: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Western University; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Disease; Intensive care medicine; Pathology","score_opus":0.03772883245980959,"score_gpt":0.28724022947861355,"score_spread":0.24951139701880395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403781950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005485802,0.9973952,5.2321235e-7,0.00016015788,0.00094373,0.00087336265,0.000040233586,0.00001367326,0.000024537147],"genre_scores_gemma":[0.00014862746,0.9988985,0.000003180639,0.00022522945,0.00015309054,0.000050540606,0.00016133717,0.000036159134,0.0003233209],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9965768,0.00090568216,0.0018045419,0.00028609612,0.00013661187,0.00029030454],"domain_scores_gemma":[0.99658966,0.0016359254,0.0012891336,0.00026507053,0.00013547184,0.0000847502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009791375,0.0005276152,0.0052037826,0.0006882247,0.000048034057,0.000011201924,0.00018017004,0.00026763923,0.0001351074],"category_scores_gemma":[0.00051429064,0.00022631664,0.00061096647,0.0004297768,0.00014011106,0.00004616502,0.00002313625,0.00046842085,0.00003602647],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030405325,0.00019426279,0.00030609948,0.62240785,0.003152454,0.0030655088,0.000072045834,2.5263924e-8,5.2274e-7,0.000005465301,0.012265812,0.3582259],"study_design_scores_gemma":[0.00045704842,0.0005057968,0.000017898861,0.7455995,0.011002032,0.0032293096,0.000013290726,1.5774278e-8,1.2101911e-7,0.000014483109,0.23893324,0.00022726973],"about_ca_topic_score_codex":0.0000037193586,"about_ca_topic_score_gemma":0.0000018775271,"teacher_disagreement_score":0.35799864,"about_ca_system_score_codex":0.000072248025,"about_ca_system_score_gemma":0.00033960442,"threshold_uncertainty_score":0.92289245},"labels":[],"label_agreement":null},{"id":"W4403835469","doi":"10.3390/jcm13216424","title":"Psychopathological Profile of Patients with Moderate-to-Severe Plaque Psoriasis and Its Correlation to DLQI: Results from a Prospective, Monocentric Clinical Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alexithymia; Medicine; Psoriasis; Psychopathology; Depression (economics); Somatization; Toronto Alexithymia Scale; Anxiety; Prospective cohort study; Internal medicine; Quality of life (healthcare); Clinical psychology; Psychiatry; Dermatology","score_opus":0.04979345570235808,"score_gpt":0.3581833950861125,"score_spread":0.3083899393837544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403835469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992751,0.0012884085,0.00031970278,0.00096982275,0.0031981547,0.0010178948,0.00019700317,0.00002291226,0.000235107],"genre_scores_gemma":[0.99817425,0.00028033857,0.00048577372,0.00016456738,0.0005512024,0.000015665777,0.00004772631,0.000018153112,0.00026233093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958654,0.000777666,0.0024153488,0.0005211334,0.00019960298,0.00022086868],"domain_scores_gemma":[0.99579144,0.002646994,0.00065990025,0.00022097655,0.00049726095,0.00018344175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002166051,0.0002391553,0.001223996,0.00022981176,0.00006324213,0.000011304761,0.00018902443,0.0003383749,0.00014028186],"category_scores_gemma":[0.0036016286,0.00013377173,0.00013792048,0.00043016433,0.000118580356,0.00011399322,0.00006449125,0.0006480732,0.000063333755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06482169,0.0033042538,0.8277294,0.000021450232,0.0013105136,0.00016584166,0.0014518659,0.000041381394,0.00012753143,0.0000381008,0.005375233,0.09561274],"study_design_scores_gemma":[0.022560373,0.020361848,0.95418113,0.0004655494,0.00077879743,0.000024666111,0.0002193701,0.000041647676,0.000093711555,0.000118765,0.0010027799,0.00015134978],"about_ca_topic_score_codex":0.000012028619,"about_ca_topic_score_gemma":0.000009665867,"teacher_disagreement_score":0.12645175,"about_ca_system_score_codex":0.000029622468,"about_ca_system_score_gemma":0.00012501124,"threshold_uncertainty_score":0.5455053},"labels":[],"label_agreement":null},{"id":"W4403930682","doi":"10.1016/j.jdrv.2024.10.006","title":"Biologic therapy in psoriasis patients with current or previous solid tumor malignancy: A systematic review","year":2024,"lang":"en","type":"review","venue":"JAAD reviews.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Sunnybrook Health Science Centre; Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Malignancy; Psoriasis; Medicine; Solid tumor; Dermatology; Oncology; Internal medicine; Cancer","score_opus":0.05839418549580727,"score_gpt":0.33360669992747594,"score_spread":0.27521251443166866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403930682","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010639992,0.9792366,0.00000121565,0.000014805991,0.0018930312,0.018283563,0.00034288506,0.00013824849,0.00007903661],"genre_scores_gemma":[0.000002232873,0.9862385,0.000033233304,0.00018544651,0.000091641676,0.010595117,0.0014778574,0.0001378961,0.001238081],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99118185,0.003375983,0.0031644588,0.0013280369,0.00012462244,0.0008250407],"domain_scores_gemma":[0.99622345,0.00033096722,0.0018392259,0.0014295095,0.00010894233,0.000067892404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013929365,0.0016382111,0.010734128,0.00043510378,0.000112354,0.000047985348,0.0009116551,0.0005299122,0.00046902802],"category_scores_gemma":[0.00038694777,0.0007087408,0.0016516383,0.0013643167,0.00011563454,0.0000918451,0.00016808657,0.00078766304,0.007017368],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021714113,0.00026108045,0.000010188262,0.51446867,0.0006787343,0.000031218733,0.000028726161,2.0240964e-9,5.88568e-8,0.0000073230963,0.0027011372,0.48179114],"study_design_scores_gemma":[0.0005095645,0.00031647366,0.0000036375438,0.492435,0.007710557,0.00007638605,0.0000015085968,7.816188e-9,4.0542218e-7,0.0000039604456,0.49846423,0.0004782437],"about_ca_topic_score_codex":0.000007755359,"about_ca_topic_score_gemma":0.000017575301,"teacher_disagreement_score":0.4957631,"about_ca_system_score_codex":0.00028791756,"about_ca_system_score_gemma":0.00040161735,"threshold_uncertainty_score":0.99963653},"labels":[],"label_agreement":null},{"id":"W4404338206","doi":"10.55788/dd95332d","title":"Psoriatic arthritis - Treatment advances in biologic therapies","year":2024,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriatic arthritis; Medicine; Arthritis; Dermatology; Intensive care medicine; Immunology","score_opus":0.015587868448666614,"score_gpt":0.25558674360924355,"score_spread":0.23999887516057694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404338206","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4950082,0.4964608,0.000040558305,0.00028817452,0.0013595067,0.00019537617,0.00003075731,0.00021680395,0.0063998057],"genre_scores_gemma":[0.9370675,0.057197824,0.000107397784,0.000040231294,0.000041828618,0.00011931175,0.00007427401,0.000009669921,0.0053419527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99918467,0.0001125022,0.00017310036,0.00027383037,0.000012616626,0.0002433112],"domain_scores_gemma":[0.99966955,0.00016656841,0.000016469066,0.00013075845,0.0000071573954,0.000009502928],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00007846894,0.00016903022,0.00022664778,0.00012793428,0.000053129417,0.000018394683,0.00006655084,0.00012706958,0.0016051038],"category_scores_gemma":[0.000007722933,0.00010506358,0.000091691785,0.0001583682,0.000060544404,0.00011698639,0.000012042338,0.00005033336,0.0014337586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041164833,0.0001199785,0.0024712028,0.000008126557,0.00018066897,0.000042354088,0.0005475345,0.0000014184284,0.006967542,0.0050655846,0.00016810873,0.9843863],"study_design_scores_gemma":[0.0039763823,0.0014060251,0.013185598,0.000204018,0.000121710276,0.00012296096,0.00095131184,0.000011992155,0.06774567,0.0079000415,0.90381974,0.00055457494],"about_ca_topic_score_codex":0.00007513854,"about_ca_topic_score_gemma":0.00041837074,"teacher_disagreement_score":0.98383176,"about_ca_system_score_codex":0.00005779568,"about_ca_system_score_gemma":0.000028502707,"threshold_uncertainty_score":0.99934375},"labels":[],"label_agreement":null},{"id":"W4404348106","doi":"10.1016/j.fander.2024.09.421","title":"Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variations des scores PPASI et PASI dans l’étude de phase 3b IMMprint","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine","score_opus":0.02443032720509079,"score_gpt":0.3039294134537753,"score_spread":0.27949908624868447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451367,0.030744696,0.010293038,0.007695288,0.0014090582,0.0009503396,0.0022665088,0.0009877128,0.00051661284],"genre_scores_gemma":[0.9380431,0.05215229,0.0055393865,0.0014937171,0.00022101539,0.0006492033,0.0012967614,0.0001626919,0.00044182796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98986125,0.0045724954,0.0013109203,0.0015163651,0.00023607028,0.00250288],"domain_scores_gemma":[0.99245393,0.0055271704,0.0004941526,0.00092149724,0.00031066337,0.0002925855],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016664579,0.0014173158,0.0014356921,0.0005794443,0.00086238736,0.00043158382,0.0014029029,0.0019371256,0.00027226502],"category_scores_gemma":[0.0025660566,0.0013327588,0.00079309905,0.0005980104,0.0014823406,0.0007916439,0.00061812083,0.0014589109,0.0003817105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018618077,0.0043320907,0.81026065,0.0013738608,0.004443118,0.003906755,0.037125833,0.0012311819,0.018924532,0.0075951423,0.011310935,0.0976341],"study_design_scores_gemma":[0.007889806,0.0016896097,0.75875896,0.0031652004,0.002407492,0.0047340347,0.004497963,0.0018515991,0.19410768,0.007110778,0.011551172,0.002235697],"about_ca_topic_score_codex":0.0017981511,"about_ca_topic_score_gemma":0.0038422956,"teacher_disagreement_score":0.17518315,"about_ca_system_score_codex":0.0009947618,"about_ca_system_score_gemma":0.0014517248,"threshold_uncertainty_score":0.9998577},"labels":[],"label_agreement":null},{"id":"W4404348123","doi":"10.1016/j.fander.2024.09.442","title":"Taux de maintien comparatif de l’acitrétine, du méthotrexate et de la ciclosporine dans le psoriasis sévère de l’enfant. Analyse en vie courante de la cohorte internationale multicentrique ACMé","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Humanities; Physics; Medicine; Philosophy","score_opus":0.019600238088196012,"score_gpt":0.3227156066364479,"score_spread":0.3031153685482519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92663884,0.027358746,0.02645924,0.010660137,0.0009820297,0.00058710034,0.00092994253,0.000673341,0.0057106065],"genre_scores_gemma":[0.93267345,0.047582116,0.012703763,0.002395369,0.00025044166,0.00027886647,0.0007463452,0.00013261933,0.0032370226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9849043,0.010224084,0.0010917406,0.0010943433,0.00017525209,0.0025103027],"domain_scores_gemma":[0.9898808,0.008329732,0.00045660496,0.000766838,0.00020174123,0.0003642623],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005419422,0.00103884,0.001317264,0.00056347577,0.0004728953,0.00036554932,0.0013986914,0.0021180802,0.00032065326],"category_scores_gemma":[0.0023934373,0.0010459776,0.0008086854,0.0006422902,0.0013450993,0.00044114,0.0004785026,0.0017717491,0.0002902732],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013127533,0.0017449273,0.81327736,0.0006235507,0.006156104,0.018330093,0.012669633,0.004781342,0.06671651,0.029098814,0.037887264,0.007401633],"study_design_scores_gemma":[0.0068963426,0.0004619905,0.48090723,0.0011453391,0.0036502501,0.03842871,0.007006963,0.021022765,0.17491433,0.010728479,0.25257918,0.0022584237],"about_ca_topic_score_codex":0.0027791515,"about_ca_topic_score_gemma":0.0015482814,"teacher_disagreement_score":0.33237013,"about_ca_system_score_codex":0.0019183791,"about_ca_system_score_gemma":0.0045576757,"threshold_uncertainty_score":0.99919903},"labels":[],"label_agreement":null},{"id":"W4404348132","doi":"10.1016/j.fander.2024.09.412","title":"Exposition systémique et profil d’innocuité du delgocitinib en crème chez les adultes atteints d’eczéma chronique des mains modéré à sévère dans l’essai de phase 3 DELTA-2","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Exposition (narrative); Medicine; Physics; Art","score_opus":0.03538888529153732,"score_gpt":0.32231086234007833,"score_spread":0.286921977048541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88848144,0.06227506,0.027678695,0.013527234,0.0012531421,0.0011833974,0.0021492415,0.0013614713,0.0020903219],"genre_scores_gemma":[0.94988483,0.036549523,0.005336689,0.0023286333,0.00033892874,0.001094404,0.0021175037,0.00019104373,0.002158417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9870172,0.0074035046,0.0012471393,0.0014682048,0.0001658228,0.0026980948],"domain_scores_gemma":[0.9953338,0.002829387,0.00040604267,0.0008437356,0.00030311232,0.00028391214],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0028064062,0.0013419669,0.0013528258,0.0005374433,0.0008297241,0.00034847987,0.0011352949,0.003083468,0.00054740725],"category_scores_gemma":[0.0011274131,0.0013005098,0.0008026518,0.00066155696,0.0017813053,0.0008457109,0.00047619652,0.0016962546,0.00062592747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034343551,0.0070023825,0.18570274,0.007952214,0.010172101,0.03803416,0.04347805,0.0014096791,0.3371741,0.102730066,0.074898414,0.18801177],"study_design_scores_gemma":[0.009989187,0.0033084385,0.048591707,0.005796406,0.003415099,0.04228366,0.010519195,0.0032144983,0.80155903,0.02086982,0.0465593,0.0038936585],"about_ca_topic_score_codex":0.0011269371,"about_ca_topic_score_gemma":0.0014742474,"teacher_disagreement_score":0.46438494,"about_ca_system_score_codex":0.0016649654,"about_ca_system_score_gemma":0.0023025507,"threshold_uncertainty_score":0.9999331},"labels":[],"label_agreement":null},{"id":"W4404348158","doi":"10.1016/j.fander.2024.09.420","title":"Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variation du DLQI et obtention d’un score DLQI 0/1 dans l’étude de phase 3b IMMprint","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Dermatology","score_opus":0.019934522623145236,"score_gpt":0.2834417695246986,"score_spread":0.26350724690155336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558116,0.01780424,0.011632671,0.00894827,0.0020462633,0.0010517105,0.0014791334,0.0009202047,0.0003058801],"genre_scores_gemma":[0.9499488,0.042770784,0.0025709353,0.0013759176,0.00027864933,0.0005261413,0.0020932003,0.00015029497,0.00028529807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9901934,0.0045646518,0.0013358032,0.0015449414,0.00025857217,0.0021026295],"domain_scores_gemma":[0.9947256,0.0032711714,0.00062425784,0.00083179626,0.0003114694,0.00023570925],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019385745,0.0013379303,0.0013487245,0.00055436045,0.00069820834,0.00037170955,0.0011655644,0.0021170746,0.00028679226],"category_scores_gemma":[0.0018290695,0.0012838526,0.0007910593,0.00053277815,0.00076249556,0.0008456048,0.00052956137,0.0013645715,0.00039722762],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028139907,0.0047351616,0.7863812,0.0013968733,0.004393792,0.0041471906,0.03221883,0.0011830435,0.038885448,0.0051757596,0.007840152,0.11082857],"study_design_scores_gemma":[0.008280443,0.0014504866,0.8057063,0.0023439932,0.0021079476,0.004246834,0.0030398762,0.0030570196,0.15904032,0.0033490325,0.005585453,0.0017923093],"about_ca_topic_score_codex":0.0013734653,"about_ca_topic_score_gemma":0.0014537455,"teacher_disagreement_score":0.120154865,"about_ca_system_score_codex":0.0009923859,"about_ca_system_score_gemma":0.000989332,"threshold_uncertainty_score":0.9999372},"labels":[],"label_agreement":null},{"id":"W4404348172","doi":"10.1016/j.fander.2024.09.401","title":"Le deucravacitinib dans le psoriasis en plaques : résultats de tolérance et d’efficacité à 4 ans dans les essais de phase 3 POETYK PSO-1, PSO-2 et dans l’étude LTE","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.03495025854855219,"score_gpt":0.3280996918584198,"score_spread":0.29314943330986765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8497267,0.05131981,0.05047761,0.030014232,0.0017036622,0.00090827997,0.0028794757,0.0016912109,0.011279034],"genre_scores_gemma":[0.93553364,0.0478468,0.0069709904,0.0034176225,0.00022032387,0.0005564171,0.0014972824,0.00024477462,0.0037121149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9853906,0.007411679,0.001518365,0.0019701226,0.00024557716,0.0034636466],"domain_scores_gemma":[0.9927246,0.004794565,0.0004897833,0.0013514782,0.00021271559,0.00042684734],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002881724,0.0016421012,0.0018049084,0.0005812916,0.0010699886,0.00041400816,0.0019418189,0.0030026517,0.00016586036],"category_scores_gemma":[0.0015808946,0.00169885,0.001117163,0.0009464499,0.001888653,0.0009194374,0.00058623985,0.0022154218,0.00046628612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003013363,0.007860004,0.15046468,0.0019392116,0.00890234,0.022564624,0.10224903,0.0028328497,0.41293204,0.15641618,0.054574408,0.07625129],"study_design_scores_gemma":[0.012735721,0.0018725991,0.09274892,0.0018225643,0.003001734,0.021290034,0.032305118,0.0017102592,0.56993824,0.012970945,0.24573378,0.0038700663],"about_ca_topic_score_codex":0.0038679491,"about_ca_topic_score_gemma":0.011163382,"teacher_disagreement_score":0.19115938,"about_ca_system_score_codex":0.0009093996,"about_ca_system_score_gemma":0.004872536,"threshold_uncertainty_score":0.9996326},"labels":[],"label_agreement":null},{"id":"W4404348284","doi":"10.1016/j.fander.2024.09.426","title":"Efficacité du risankizumab versus aprémilast chez les patients atteints de psoriasis du cuir chevelu ou unguéal d’après l’étude de phase IV IMMpulse","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; British Columbia Institute of Technology","funders":"","keywords":"Medicine","score_opus":0.05028453823184583,"score_gpt":0.30809599920157105,"score_spread":0.25781146096972524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405508,0.037490886,0.0017078161,0.0091390135,0.0060444833,0.0008448672,0.0013083897,0.0010744926,0.0018392316],"genre_scores_gemma":[0.96698534,0.026045423,0.0014254667,0.0014337713,0.0006040228,0.00035867587,0.0013030241,0.00020212155,0.0016421238],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898997,0.0032913012,0.0013645884,0.0017017595,0.00024783995,0.0034948164],"domain_scores_gemma":[0.9942139,0.0035408812,0.00047376374,0.0010670441,0.000269539,0.00043487293],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0016240191,0.0015617969,0.0015866272,0.0006296175,0.0008490336,0.00030033028,0.0015410272,0.0030975777,0.00095609325],"category_scores_gemma":[0.0021797682,0.001547642,0.001119472,0.0008208201,0.0015253376,0.0005239787,0.00069971516,0.0017437707,0.00199452],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012738734,0.009244041,0.4035514,0.001698903,0.011552536,0.015519077,0.011129649,0.0005717774,0.015775306,0.0064152293,0.11373998,0.3980634],"study_design_scores_gemma":[0.05571758,0.005720624,0.2648448,0.0019733058,0.008425535,0.010175406,0.0047147204,0.0024003624,0.16385967,0.003128458,0.47297615,0.006063394],"about_ca_topic_score_codex":0.00052027276,"about_ca_topic_score_gemma":0.00038018357,"teacher_disagreement_score":0.392,"about_ca_system_score_codex":0.0016003784,"about_ca_system_score_gemma":0.0018472866,"threshold_uncertainty_score":0.99995714},"labels":[],"label_agreement":null},{"id":"W4404348297","doi":"10.1016/j.fander.2024.09.408","title":"Efficacité et sécurité d’emploi du delgocitinib en crème à 36 semaines chez les adultes atteints d’eczéma chronique des mains : résultats de l’essai d’extension de phase 3 DELTA-3","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Queen's University; Probity Medical Research","funders":"","keywords":"Medicine; Political science; Gynecology","score_opus":0.039708450997348314,"score_gpt":0.32956398251736047,"score_spread":0.28985553152001214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8798444,0.08432832,0.008108585,0.022036908,0.0012065098,0.00087340636,0.0014446788,0.0014188563,0.00073828537],"genre_scores_gemma":[0.9175106,0.066948995,0.0063220966,0.004311661,0.00039243308,0.00047645424,0.0013656507,0.00022420703,0.0024478673],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9869304,0.006368404,0.001344826,0.0016912535,0.00019670185,0.0034684204],"domain_scores_gemma":[0.9916808,0.0061441143,0.00041651874,0.0009556453,0.00039027043,0.00041262756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0032546239,0.0015409351,0.0016301208,0.00061503856,0.0009621074,0.00035054437,0.0012540256,0.0031695697,0.00061394915],"category_scores_gemma":[0.0032399117,0.0014587333,0.000966796,0.0007875531,0.0020886306,0.0006576706,0.0006290502,0.0018303475,0.0007571519],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004812905,0.0073707984,0.19888428,0.004778632,0.008437758,0.040179353,0.029611815,0.001714331,0.2687608,0.027971564,0.12154063,0.28593713],"study_design_scores_gemma":[0.016184699,0.003327696,0.1608838,0.006349669,0.004680681,0.0514451,0.006925883,0.0043135947,0.4864648,0.028727142,0.22539227,0.0053046714],"about_ca_topic_score_codex":0.0010913583,"about_ca_topic_score_gemma":0.0012950681,"teacher_disagreement_score":0.28063247,"about_ca_system_score_codex":0.0009846465,"about_ca_system_score_gemma":0.0023149326,"threshold_uncertainty_score":0.9997339},"labels":[],"label_agreement":null},{"id":"W4404348481","doi":"10.1016/j.fander.2024.09.398","title":"Étude de phase 2b, d’extension à long terme évaluant l’efficacité de JNJ-77242113 par voie orale pour le traitement du psoriasis en plaques modéré à sévère : FRONTIER-2","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); St. Thomas Hospital","funders":"","keywords":"Medicine","score_opus":0.04153619193215417,"score_gpt":0.3142858026905817,"score_spread":0.2727496107584275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8298162,0.12507942,0.015699102,0.023483457,0.0028243007,0.0009030609,0.00075762585,0.0010212016,0.00041560153],"genre_scores_gemma":[0.93812454,0.047253292,0.0076733534,0.0025985588,0.00049268734,0.0004314711,0.00072822435,0.00018005197,0.0025178378],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.989292,0.004204766,0.0013726915,0.0016821781,0.00022146812,0.003226884],"domain_scores_gemma":[0.99554324,0.002354906,0.0004081755,0.001091717,0.00020841815,0.00039355454],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0024753253,0.0013849775,0.0016828021,0.00063000293,0.000726352,0.0003233181,0.0012863481,0.002501769,0.00045274774],"category_scores_gemma":[0.0010489144,0.0013173444,0.0010723062,0.0005496256,0.0008890062,0.0006244901,0.00054517813,0.0014211241,0.0009124298],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004043087,0.008634394,0.13466151,0.0021480697,0.0096989125,0.044409104,0.01636817,0.0030973698,0.15662466,0.0042815707,0.3025862,0.31344694],"study_design_scores_gemma":[0.020672712,0.0034546684,0.21221687,0.00331183,0.0070831887,0.033860907,0.008735449,0.023853982,0.44687414,0.013811023,0.22089301,0.0052322233],"about_ca_topic_score_codex":0.00076731795,"about_ca_topic_score_gemma":0.00074851996,"teacher_disagreement_score":0.30821472,"about_ca_system_score_codex":0.0010803406,"about_ca_system_score_gemma":0.0028208185,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W4404348533","doi":"10.1016/j.fander.2024.09.425","title":"Efficacité à long terme du bimékizumab chez des patients atteints de psoriasis en plaques modéré à sévère insuffisamment répondeurs à l’adalimumab, l’ustékinumab, ou sécukinumab : résultats de BE RADIANT et BE BRIGHT jusqu’à 4 ans de traitement","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine","score_opus":0.03821770672519788,"score_gpt":0.30129247800424447,"score_spread":0.2630747712790466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9226632,0.036167897,0.0033784222,0.029627973,0.0023571008,0.0014601578,0.002516875,0.0010975492,0.0007308108],"genre_scores_gemma":[0.94015944,0.0439901,0.0031716267,0.0075396975,0.00030330018,0.00071573537,0.0017329027,0.00027062304,0.0021165528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9852672,0.0058033853,0.0018042887,0.002058749,0.00039466284,0.0046717194],"domain_scores_gemma":[0.9938282,0.0034356557,0.00058514625,0.0011867762,0.00028924862,0.0006750244],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026289795,0.001951666,0.0018990356,0.0009570962,0.0009162797,0.00050718035,0.0017943053,0.0029323695,0.0006557565],"category_scores_gemma":[0.0013287761,0.0018917498,0.0011582548,0.0009211599,0.0015815644,0.0008514218,0.0006932674,0.0018914544,0.00038542412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004453332,0.008972446,0.46489033,0.0035739674,0.012087826,0.025170622,0.0724688,0.0026579655,0.010512893,0.008497686,0.08624629,0.30046785],"study_design_scores_gemma":[0.016535126,0.0029460972,0.6406942,0.0030557269,0.004720669,0.013763156,0.0061821262,0.001984195,0.11137378,0.0064166947,0.18781744,0.004510799],"about_ca_topic_score_codex":0.0011106532,"about_ca_topic_score_gemma":0.0021053157,"teacher_disagreement_score":0.29595703,"about_ca_system_score_codex":0.0039915526,"about_ca_system_score_gemma":0.0030410374,"threshold_uncertainty_score":0.999832},"labels":[],"label_agreement":null},{"id":"W4404348625","doi":"10.1016/j.fander.2024.09.224","title":"Considérations pour l’interprétation et la comparaison de l’efficacité à long terme des études portant sur le traitement du psoriasis modéré à sévère à l’aide d’agents biologiques","year":2024,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); University of British Columbia; Centre de Recherche Industrielle du Québec; Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research; Innovaderm (Canada); Queen's University; Dalhousie University","funders":"","keywords":"Humanities; Philosophy","score_opus":0.08389457695979986,"score_gpt":0.3350492700994809,"score_spread":0.25115469313968103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404348625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92765445,0.038352802,0.010624562,0.017128235,0.0013117557,0.00070780405,0.0007485852,0.000933477,0.0025383574],"genre_scores_gemma":[0.9629971,0.026464773,0.0053228377,0.0022470276,0.000119973236,0.00033459347,0.0009038883,0.000092561895,0.0015172876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917578,0.0042222277,0.0011476859,0.0010564051,0.00012748828,0.0016884062],"domain_scores_gemma":[0.9949502,0.0037039274,0.00036602162,0.0005618293,0.00022335869,0.00019466504],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019794118,0.00092431926,0.0010820233,0.00049138913,0.0005439513,0.00035345342,0.00070538523,0.0015414229,0.0003106098],"category_scores_gemma":[0.0010824973,0.00087147544,0.00065313344,0.0004445811,0.0011687601,0.00063385477,0.00026940843,0.0009132413,0.00037856845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001490051,0.006069927,0.54059505,0.0023013684,0.009889083,0.015497693,0.019662017,0.0053952234,0.03958913,0.14166765,0.08611327,0.13172954],"study_design_scores_gemma":[0.0070874076,0.0017027857,0.63525254,0.0034078725,0.0031937067,0.021578986,0.01198365,0.009074781,0.120009534,0.025800025,0.15751167,0.0033970252],"about_ca_topic_score_codex":0.0007688666,"about_ca_topic_score_gemma":0.0026328142,"teacher_disagreement_score":0.12833253,"about_ca_system_score_codex":0.0005533708,"about_ca_system_score_gemma":0.0026516342,"threshold_uncertainty_score":0.9997548},"labels":[],"label_agreement":null},{"id":"W4404368241","doi":"10.1016/j.jaad.2024.10.076","title":"FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Cilag; Galderma; Janssen Research and Development; Pfizer Pharmaceuticals; LEO Pharma; Bausch Health; Basilea Pharmaceutica; Glenmark Pharmaceuticals; Actelion Pharmaceuticals; Pfizer; Biogen; Incyte; IC Design Education Center; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Dermira; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Plaque psoriasis; Term (time); Dose-ranging study; Dermatology; Psoriasis; Extension (predicate logic); Internal medicine; Pathology","score_opus":0.03348407815273174,"score_gpt":0.3308613464931109,"score_spread":0.29737726834037914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404368241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836789,0.010485405,0.0006989638,0.0033739647,0.00086246285,0.0007772589,0.00010269575,0.000012470611,0.000007911189],"genre_scores_gemma":[0.99798715,0.0012909989,0.0002975805,0.00014287085,0.000060553702,0.000040858173,0.0000042702727,0.000028669152,0.00014704476],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775827,0.00049930793,0.0010372342,0.0002514294,0.000109281886,0.0003445059],"domain_scores_gemma":[0.9976493,0.00077992835,0.0011305592,0.0002733936,0.00012348946,0.000043295717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023478214,0.00029327325,0.0013057141,0.00033858226,0.00015270947,0.000008818906,0.0005530673,0.00016061887,0.0000327629],"category_scores_gemma":[0.0000529532,0.00015761731,0.0005695866,0.00039394977,0.00039994804,0.00008880531,0.00006888625,0.00023681,0.0000057465672],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04064921,0.0134098,0.07665616,0.00039563823,0.03184204,0.00027014661,0.024072316,0.0010998971,0.37169924,0.00045620732,0.0139219565,0.4255274],"study_design_scores_gemma":[0.066056654,0.025442995,0.1836969,0.0010040044,0.019111386,0.013668567,0.013178056,0.0006583345,0.6536078,0.00090028485,0.02135707,0.0013179781],"about_ca_topic_score_codex":0.00006737151,"about_ca_topic_score_gemma":0.00001401142,"teacher_disagreement_score":0.42420942,"about_ca_system_score_codex":0.000067453344,"about_ca_system_score_gemma":0.00012957398,"threshold_uncertainty_score":0.6427447},"labels":[],"label_agreement":null},{"id":"W4404385910","doi":"10.1016/j.jdin.2024.09.015","title":"Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensus","year":2024,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Memorial University of Newfoundland; University of Calgary; University of Saskatchewan; Hospital for Sick Children; Probity Medical Research; University of British Columbia; Saskatchewan Science Centre; Lynde Centre for Dermatology; Medical Council of Canada; University of Alberta; Dalhousie University; University of Toronto; Health Sciences Centre; PROTO Manufacturing (Canada); University Health Network; Women's College Hospital","funders":"LEO Pharma; Bausch Health; Eli Lilly and Company; Galderma; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Meiji Seika Pharma","keywords":"Psoriasis; Delphi; Delphi method; Dermatology; Consensus conference; Medicine; Computer science; Internal medicine; Artificial intelligence","score_opus":0.009803807793513282,"score_gpt":0.22437530820748175,"score_spread":0.21457150041396847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404385910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910226,0.0005570074,0.000011318581,0.00032360374,0.0007937662,0.00018868608,0.00019972704,0.000008216139,0.0068951137],"genre_scores_gemma":[0.99857146,0.000030498144,0.00037751344,0.000023898954,0.000010686476,0.000023153998,0.00011129336,0.000006502861,0.0008449923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994949,0.000036879013,0.00018198053,0.00012292454,0.00004779185,0.00011550243],"domain_scores_gemma":[0.9997214,0.00006574754,0.000048859834,0.00009577729,0.00005836243,0.000009874255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010145925,0.000076045806,0.000103215985,0.00017012608,0.000025518446,0.000006375372,0.00014615194,0.000053393134,0.00026552484],"category_scores_gemma":[0.000004741456,0.000050775245,0.000043098953,0.000118664895,0.00006730391,0.00002320217,0.00002594113,0.000055993965,0.000027744776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049192086,0.0017575187,0.45391995,0.00041026575,0.022796392,0.0002756909,0.013941356,0.0018238778,0.0024435318,0.13685332,0.013185213,0.34767368],"study_design_scores_gemma":[0.008004554,0.00048712632,0.9295221,0.0007757159,0.0004676593,0.000020051355,0.0016865084,0.00024337783,0.010384454,0.00035629713,0.047699906,0.00035223522],"about_ca_topic_score_codex":0.0040254756,"about_ca_topic_score_gemma":0.0060151634,"teacher_disagreement_score":0.47560218,"about_ca_system_score_codex":0.000084075866,"about_ca_system_score_gemma":0.00005962885,"threshold_uncertainty_score":0.60853416},"labels":[],"label_agreement":null},{"id":"W4404455104","doi":"10.25251/skin.8.supp.423","title":"Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Bristol-Myers Squibb","keywords":"Plaque psoriasis; Psoriasis; Medicine; Phase (matter); Dermatology; Computer science; Physics","score_opus":0.02818014222467983,"score_gpt":0.30170471001867927,"score_spread":0.2735245677939994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8924461,0.08914056,0.000054727967,0.014738859,0.0021131418,0.0004323636,0.0003472713,0.000025511505,0.0007014679],"genre_scores_gemma":[0.9712721,0.026832925,0.000046404748,0.0002812829,0.00084491493,0.0000023573039,0.000057386416,0.000023533383,0.0006391099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965476,0.0015483623,0.0012459973,0.00024195432,0.0001275815,0.00028853395],"domain_scores_gemma":[0.9891089,0.010038125,0.00044096337,0.00028814148,0.00006518677,0.00005865321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004107199,0.0002734667,0.0008538619,0.00016036286,0.00019050369,0.000027804497,0.0002891888,0.0002150057,0.00021708489],"category_scores_gemma":[0.0019523544,0.0001235148,0.00012264025,0.00021574167,0.00041948972,0.00006928897,0.000056340064,0.0005816698,0.000026858057],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09416894,0.0006348892,0.00038843526,0.000075879056,0.005905161,0.0037269345,0.046236135,0.000035357243,0.07761314,0.0011438659,0.04859599,0.7214753],"study_design_scores_gemma":[0.16115947,0.010309008,0.008601205,0.006697407,0.011123861,0.05758612,0.016285181,0.0000826999,0.025795413,0.008297715,0.69287574,0.0011861885],"about_ca_topic_score_codex":0.00020040224,"about_ca_topic_score_gemma":0.0001222922,"teacher_disagreement_score":0.7202891,"about_ca_system_score_codex":0.000042764827,"about_ca_system_score_gemma":0.00009701909,"threshold_uncertainty_score":0.5036787},"labels":[],"label_agreement":null},{"id":"W4404455128","doi":"10.25251/skin.8.supp.432","title":"Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.013005384212936908,"score_gpt":0.25876436658693264,"score_spread":0.24575898237399574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063344,0.008810038,0.00002129602,0.007587417,0.0019855162,0.00029223567,0.00019109859,0.000028030025,0.00045092386],"genre_scores_gemma":[0.9969088,0.0010980443,0.000050854986,0.00026633043,0.0004848573,0.0000034309526,0.000087361645,0.000033182056,0.0010671259],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975285,0.00064455025,0.0009583967,0.00028033173,0.00016024757,0.00042800253],"domain_scores_gemma":[0.99750406,0.0017447383,0.0002366418,0.00034774587,0.00008263349,0.00008420974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093030283,0.0003239757,0.00076618604,0.00054615526,0.0000759395,0.000021367265,0.00041854373,0.0002586551,0.0005476684],"category_scores_gemma":[0.00043998717,0.00017620971,0.0001444021,0.0005317,0.00010586287,0.00008883786,0.000049358292,0.0006584743,0.00016115991],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21904378,0.002855582,0.002631211,0.00013301212,0.011743093,0.04124756,0.095452264,0.024700157,0.1612021,0.00065235223,0.16631562,0.27402326],"study_design_scores_gemma":[0.2406944,0.027473785,0.22933392,0.030088043,0.012570453,0.12883048,0.015601317,0.00094794,0.18080649,0.02197705,0.10645976,0.0052163745],"about_ca_topic_score_codex":0.001962231,"about_ca_topic_score_gemma":0.00072433084,"teacher_disagreement_score":0.2688069,"about_ca_system_score_codex":0.00026108717,"about_ca_system_score_gemma":0.00021485824,"threshold_uncertainty_score":0.71856236},"labels":[],"label_agreement":null},{"id":"W4404455203","doi":"10.25251/skin.8.supp.434","title":"Bimekizumab Clinical Efficacy in Important Body Regions and Health-related Quality of Life in Patients with Plaque Psoriasis: Data from Four Phase 3/3b Comparator-controlled Trial Periods","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"LEO Pharma; Case Western Reserve University; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sun Pharma; Biogen","keywords":"Plaque psoriasis; Psoriasis; Quality of life (healthcare); Medicine; Clinical trial; Phase (matter); Physical therapy; Physical medicine and rehabilitation; Internal medicine; Dermatology; Nursing; Physics","score_opus":0.08402653805773325,"score_gpt":0.3715673497894008,"score_spread":0.28754081173166757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96962136,0.02533631,0.000014860731,0.0022570358,0.0016584235,0.00095193734,0.00012826982,0.000011589667,0.000020204145],"genre_scores_gemma":[0.99724084,0.0021890025,0.000027730683,0.000097314485,0.00021976154,0.0000042787847,0.00016991067,0.000018309756,0.000032839333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99411374,0.0020809246,0.0030637863,0.00028925322,0.0001792246,0.00027304617],"domain_scores_gemma":[0.9949843,0.0029600875,0.0013633049,0.0005080034,0.0000901741,0.00009412065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041395156,0.00025260125,0.0019003997,0.00025896746,0.00007737744,0.000008744028,0.00041971367,0.00022201441,0.0001291894],"category_scores_gemma":[0.0009144846,0.00013086715,0.000118528114,0.00028553102,0.0003628272,0.00008240009,0.00006423222,0.0006871062,0.0000048578063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90901923,0.004974779,0.05990712,0.000062673345,0.0047560176,0.00068580895,0.0044067334,0.000015192844,0.00047182452,0.00011042429,0.0055969423,0.009993224],"study_design_scores_gemma":[0.86715317,0.014593159,0.1120128,0.0014498126,0.0014434868,0.0008271023,0.0010013147,0.000120306046,0.000034721626,0.00025932328,0.00082558003,0.00027919674],"about_ca_topic_score_codex":0.00088897906,"about_ca_topic_score_gemma":0.0006909854,"teacher_disagreement_score":0.052105684,"about_ca_system_score_codex":0.00006441331,"about_ca_system_score_gemma":0.00054514105,"threshold_uncertainty_score":0.5336607},"labels":[],"label_agreement":null},{"id":"W4404455251","doi":"10.25251/skin.8.supp.431","title":"Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research; Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.009632729964742385,"score_gpt":0.23137510540230313,"score_spread":0.22174237543756076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850898,0.012954018,0.0000015512886,0.0006772806,0.00047882038,0.0002695226,0.00040829074,0.0000051141656,0.000115609975],"genre_scores_gemma":[0.99394476,0.0054338537,0.000017953467,0.000051827756,0.00009012901,0.0000037226998,0.00007868849,0.00001688691,0.000362202],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886775,0.00020083322,0.0004689593,0.0001801278,0.00006746909,0.00021483959],"domain_scores_gemma":[0.99903053,0.00050221424,0.00017499023,0.0001719895,0.00004065432,0.00007959486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016989611,0.00020954922,0.00047092504,0.00031346444,0.000051708153,0.000009297513,0.000076622324,0.00012775151,0.00012865009],"category_scores_gemma":[0.000047409147,0.00011025747,0.000052598658,0.00013670983,0.00021169169,0.00005481251,0.000012047011,0.00012590046,0.0000048699208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046208546,0.000578075,0.035040293,0.000034145563,0.0047394126,0.0026599264,0.051637407,0.000036044097,0.0018281986,0.000020646592,0.0009478778,0.8562694],"study_design_scores_gemma":[0.04851959,0.019150428,0.86307126,0.002552192,0.0038554305,0.0030807278,0.0011744541,0.00003612514,0.0013138048,0.00009809636,0.056733478,0.0004144211],"about_ca_topic_score_codex":0.040828623,"about_ca_topic_score_gemma":0.045282535,"teacher_disagreement_score":0.855855,"about_ca_system_score_codex":0.00037136278,"about_ca_system_score_gemma":0.00015676631,"threshold_uncertainty_score":0.9721386},"labels":[],"label_agreement":null},{"id":"W4404455270","doi":"10.25251/skin.8.supp.441","title":"Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Body surface area; Dermatology; Internal medicine","score_opus":0.024201131398376464,"score_gpt":0.29140096923614606,"score_spread":0.26719983783776957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266745,0.0100242905,0.000038295377,0.002703925,0.0033236952,0.0007684004,0.00004160515,0.000029853774,0.00040247152],"genre_scores_gemma":[0.99657524,0.0014843396,0.000063866595,0.00022450753,0.00052329653,0.000018367537,0.00003487131,0.000036834448,0.00103869],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969674,0.0008725886,0.0011098622,0.00031623032,0.00021239901,0.00052154844],"domain_scores_gemma":[0.998248,0.0009954771,0.00030817368,0.00021851048,0.00014623538,0.00008360824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016294536,0.00037642298,0.00091319083,0.00049251626,0.00012509656,0.000026679303,0.00036843965,0.0002817053,0.0003775522],"category_scores_gemma":[0.00031583942,0.00023083636,0.00015898955,0.00076796935,0.00017422685,0.00012395975,0.00005755348,0.00078262156,0.000048980844],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34839046,0.0037216127,0.0007231846,0.00015696343,0.0034689761,0.008103637,0.050031573,0.0029076228,0.46473432,0.00019401558,0.06018542,0.057382222],"study_design_scores_gemma":[0.42611095,0.0477872,0.0005164749,0.0083447555,0.003775673,0.03321459,0.022895133,0.0008973479,0.40298983,0.005336687,0.045866407,0.002264947],"about_ca_topic_score_codex":0.00028839055,"about_ca_topic_score_gemma":0.00046279185,"teacher_disagreement_score":0.07772048,"about_ca_system_score_codex":0.00036688842,"about_ca_system_score_gemma":0.00038964555,"threshold_uncertainty_score":0.9413234},"labels":[],"label_agreement":null},{"id":"W4404455273","doi":"10.25251/skin.8.supp.433","title":"Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Ustekinumab; Secukinumab; Medicine; Plaque psoriasis; Adalimumab; Dermatology; Psoriasis; Internal medicine; Tumor necrosis factor alpha; Psoriatic arthritis","score_opus":0.011477805515059185,"score_gpt":0.2361622407124037,"score_spread":0.2246844351973445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915391,0.00366996,0.000045058514,0.0012685816,0.0013518966,0.0005589383,0.0015300356,0.000018353418,0.000018064986],"genre_scores_gemma":[0.99820626,0.00045361102,0.00015461903,0.00020838699,0.00029497172,0.000009291325,0.00023294351,0.00004771383,0.0003922235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977522,0.0003418972,0.00088495197,0.00042429022,0.0002311593,0.00036550435],"domain_scores_gemma":[0.9974734,0.0015793428,0.0003000104,0.0004137458,0.00009215152,0.00014130728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021999588,0.00040589698,0.0009086444,0.00032556304,0.000081908074,0.00003062039,0.00024667743,0.00020936476,0.00040668683],"category_scores_gemma":[0.00010694928,0.00021915595,0.00010839005,0.00026296222,0.00009908102,0.00010493095,0.00007276938,0.00030923844,0.00002121979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36929646,0.0014016976,0.012226159,0.00005288143,0.010037093,0.011319463,0.17566569,0.001131,0.013825521,0.000006252948,0.0026645316,0.40237325],"study_design_scores_gemma":[0.11228654,0.022813728,0.80354065,0.010021028,0.007670859,0.004606312,0.0037083656,0.00009960439,0.029114429,0.00022780806,0.0041781436,0.0017325573],"about_ca_topic_score_codex":0.0039740223,"about_ca_topic_score_gemma":0.002459218,"teacher_disagreement_score":0.7913145,"about_ca_system_score_codex":0.000255703,"about_ca_system_score_gemma":0.00016689065,"threshold_uncertainty_score":0.893692},"labels":[],"label_agreement":null},{"id":"W4404455301","doi":"10.25251/skin.8.supp.442","title":"Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Lynde Centre for Dermatology; SKiN Health","funders":"","keywords":"Plaque psoriasis; Medicine; Internal medicine; Psoriasis; Dermatology; Pharmacology","score_opus":0.022981120971243156,"score_gpt":0.29019544373035705,"score_spread":0.2672143227591139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404455301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571896,0.0021632863,0.000013863831,0.00026120766,0.00093877775,0.0006851751,0.00017990601,0.0000066196453,0.000032183936],"genre_scores_gemma":[0.9994044,0.00022849234,0.00007269185,0.000051730156,0.00012798172,0.000014938691,0.00006848243,0.000019776235,0.000011524525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997268,0.0014052859,0.000630403,0.00017893949,0.00032025942,0.00019706863],"domain_scores_gemma":[0.9981575,0.0006531016,0.0004205782,0.0001757046,0.0005557499,0.000037381353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018107949,0.0002006171,0.0006415111,0.00042132658,0.00003539213,0.00000510828,0.00017487883,0.00017380237,0.00012924834],"category_scores_gemma":[0.00037788312,0.0001181757,0.00004886659,0.0005303831,0.00014630334,0.0000951351,0.000015906211,0.00029362927,0.0000029067485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56224984,0.0058705066,0.0054521756,0.00011632872,0.004871972,0.00034100463,0.065145,0.0035554706,0.106542215,0.000027491224,0.002264399,0.24356359],"study_design_scores_gemma":[0.514628,0.09621874,0.009053204,0.0054342505,0.009004376,0.00049294037,0.01136818,0.0006897303,0.34923863,0.0022821908,0.0006348947,0.00095486746],"about_ca_topic_score_codex":0.00028844774,"about_ca_topic_score_gemma":0.0008953603,"teacher_disagreement_score":0.2426964,"about_ca_system_score_codex":0.0001834588,"about_ca_system_score_gemma":0.000380808,"threshold_uncertainty_score":0.48190653},"labels":[],"label_agreement":null},{"id":"W4404529073","doi":"10.1016/j.jdrv.2024.11.003","title":"Terminology, classification systems, and evaluation tools to describe skin of color in psoriasis and other dermatological conditions","year":2024,"lang":"en","type":"article","venue":"JAAD reviews.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; University Health Network; Probity Medical Research; University of Alberta; Women's College Hospital","funders":"Janssen Pharmaceuticals; Bausch Health; Astellas Pharma; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Baxalta; Celgene; Janssen Canada; Sanofi; Amgen; Pfizer; Coherus Biosciences; Galderma; Eli Lilly and Company","keywords":"Terminology; Psoriasis; Dermatology; Dermatological diseases; Medicine; Linguistics","score_opus":0.1236370795134621,"score_gpt":0.3502070533460283,"score_spread":0.22656997383256622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404529073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8769235,0.1206611,0.000033139408,0.00032289972,0.00038807653,0.0011563468,0.00011058642,0.000027047712,0.00037728625],"genre_scores_gemma":[0.99463123,0.004277396,0.00011516588,0.00009411668,0.000018741477,0.00057567126,0.000107601496,0.000007853302,0.00017224539],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859226,0.00056469114,0.0004062011,0.00026888296,0.00002766481,0.000140301],"domain_scores_gemma":[0.99949455,0.00022335717,0.00007950959,0.00014866056,0.000034784076,0.000019149027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062219374,0.00012675223,0.000380657,0.00015281473,0.00004904763,0.00002253804,0.00005828642,0.00020165795,0.00010076184],"category_scores_gemma":[0.00014781687,0.00009278529,0.00004430112,0.00017056169,0.00010059512,0.000075500015,0.000027554745,0.000074158714,0.00015412518],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012388451,0.00026948686,0.030869998,0.00100691,0.00033837755,0.000016982558,0.0021470655,0.0000039157662,0.08150644,0.02035476,0.010948371,0.85241383],"study_design_scores_gemma":[0.0024567307,0.00037143962,0.39190304,0.0016704641,0.0010375914,0.00065476936,0.00087144715,0.00032460206,0.006178258,0.00050921005,0.59352297,0.0004994698],"about_ca_topic_score_codex":0.000037383037,"about_ca_topic_score_gemma":0.000040286806,"teacher_disagreement_score":0.85191435,"about_ca_system_score_codex":0.000038970647,"about_ca_system_score_gemma":0.000032051536,"threshold_uncertainty_score":0.37836742},"labels":[],"label_agreement":null},{"id":"W4404627081","doi":"10.1007/s13555-024-01295-w","title":"Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; XBiotech; National Institute for Health and Care Research; Sanofi; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Scalp; Medicine; Dermatology; Randomized controlled trial; Psoriasis; Internal medicine; Surgery","score_opus":0.016499543770947603,"score_gpt":0.29786979812062464,"score_spread":0.28137025434967705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404627081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87906563,0.11848074,0.000037356756,0.00042034974,0.00047985898,0.0011137946,0.0002754609,0.00007171978,0.000055072967],"genre_scores_gemma":[0.97812206,0.020605719,0.00003205975,0.000110713925,0.000044062785,0.0002317589,0.0007687825,0.000021520626,0.000063301915],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936269,0.004115977,0.001173711,0.00060475105,0.000048754737,0.00042991608],"domain_scores_gemma":[0.99227595,0.0071576103,0.00022863134,0.00025893285,0.000024963698,0.000053906242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016998494,0.00045270368,0.004852151,0.0011091499,0.000107475375,0.00006370834,0.00012959093,0.00059594784,0.0008674418],"category_scores_gemma":[0.00034158817,0.00028446366,0.00076471624,0.000576591,0.00028193314,0.00011492391,0.000027420705,0.00028353013,0.000055758308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72244644,0.0017286151,0.06436556,0.000032224307,0.063480206,0.0010596301,0.0033907583,0.000014795983,0.009077313,0.0016042507,0.00038128495,0.13241895],"study_design_scores_gemma":[0.9422317,0.00017102879,0.041476157,0.00010235011,0.0059034126,0.00018471379,0.00019343654,0.0002476537,0.006218907,0.0022296626,0.0005513813,0.00048956036],"about_ca_topic_score_codex":0.0009544567,"about_ca_topic_score_gemma":0.00022189712,"teacher_disagreement_score":0.21978532,"about_ca_system_score_codex":0.00003008424,"about_ca_system_score_gemma":0.00007298441,"threshold_uncertainty_score":0.9999608},"labels":[],"label_agreement":null},{"id":"W4404705928","doi":"10.2196/64277","title":"Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Randomized controlled trial; Medicine; Protocol (science); Psoriasis; Clinical trial; Family medicine; Alternative medicine; Internal medicine; Dermatology; World Wide Web; Computer science; Pathology","score_opus":0.10700056596691157,"score_gpt":0.4733596442193852,"score_spread":0.3663590782524736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404705928","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01277762,0.0000052069067,0.000006053049,0.000097621516,0.00008585554,0.98607147,0.0001264122,0.000062474595,0.0007672693],"genre_scores_gemma":[0.019122703,1.485507e-7,0.000014855173,0.0000064813116,0.0001763055,0.97878355,0.000036025987,0.000041750944,0.0018181663],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952955,0.002673668,0.00064809906,0.00045323087,0.00031663058,0.00061284896],"domain_scores_gemma":[0.99585634,0.002904785,0.0002083902,0.00057412026,0.00041019195,0.000046186524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002745829,0.00031402378,0.0011568444,0.00027554296,0.00027873492,0.00007877492,0.00047820655,0.00026347564,0.00048117156],"category_scores_gemma":[0.0007255031,0.00012714206,0.0010251594,0.0003955148,0.0004841569,0.00009646337,0.00008405079,0.00042603293,0.00006827411],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98072916,0.0020654863,0.00020706079,0.0002759811,0.0015895462,0.0000017692106,0.00030967637,0.0000012802323,0.0005105743,0.00028459087,0.008685027,0.0053398726],"study_design_scores_gemma":[0.957928,0.020047238,0.00046870438,0.0017975027,0.000055423934,8.51556e-7,0.000010067181,0.000008983779,0.0017920786,0.00029544733,0.017451096,0.00014459115],"about_ca_topic_score_codex":0.000016142621,"about_ca_topic_score_gemma":0.0000048736256,"teacher_disagreement_score":0.02280112,"about_ca_system_score_codex":0.000119432756,"about_ca_system_score_gemma":0.0005388008,"threshold_uncertainty_score":0.52684915},"labels":[],"label_agreement":null},{"id":"W4404730948","doi":"10.1016/j.rhum.2024.10.190","title":"Caractéristiques des patients atteints de rhumatisme psoriasique traités par Guselkumab ou par un inhibiteur de l’IL-17 : résultats de l’étude observationnelle multicentrique PsABIOnd en cours","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Multicenter study; Gynecology; Internal medicine; Randomized controlled trial","score_opus":0.017934061269767845,"score_gpt":0.2478929328931664,"score_spread":0.22995887162339856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404730948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9464312,0.03855428,0.0046316497,0.004029774,0.002222991,0.0013318132,0.001933461,0.00045258406,0.0004122518],"genre_scores_gemma":[0.9651667,0.019517811,0.007853091,0.00045080762,0.0007411011,0.00038596534,0.0014860841,0.000214347,0.0041840803],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99305004,0.0024446845,0.001392878,0.001129557,0.0001719979,0.001810865],"domain_scores_gemma":[0.99644536,0.0016943646,0.00048055698,0.00068818557,0.00035356832,0.00033797044],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014358946,0.0010498697,0.0011227949,0.0003369478,0.0008745539,0.00026231073,0.0006704951,0.0017088219,0.0015386711],"category_scores_gemma":[0.00072123826,0.0011325463,0.00053300196,0.00054449897,0.0005502827,0.0007306245,0.0001969577,0.001026387,0.00080935785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008957738,0.004726259,0.19939718,0.0055149584,0.0060827937,0.0018595012,0.15909028,0.0006096667,0.053643957,0.013683791,0.033069756,0.5214261],"study_design_scores_gemma":[0.009283063,0.0013500708,0.8098448,0.008605042,0.003352786,0.001443319,0.0017565736,0.003285472,0.108688526,0.009662681,0.039966676,0.0027610145],"about_ca_topic_score_codex":0.0010924152,"about_ca_topic_score_gemma":0.0009666547,"teacher_disagreement_score":0.6104476,"about_ca_system_score_codex":0.0016668397,"about_ca_system_score_gemma":0.00062391814,"threshold_uncertainty_score":0.99996865},"labels":[],"label_agreement":null},{"id":"W4404731466","doi":"10.1016/j.rhum.2024.10.193","title":"Le guselkumab et les inhibiteurs de l’IL-17 améliorent de manière similaire l’impact perçu par les patients atteints de rhumatisme psoriasique : résultats intermédiaires à 6 mois de l’étude de cohorte observationnelle PsABIOnd","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Gynecology","score_opus":0.018349887375833016,"score_gpt":0.25536210548209903,"score_spread":0.23701221810626602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404731466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577276,0.02633762,0.004665435,0.006437926,0.0011671823,0.0009812707,0.0017842202,0.0003911766,0.00050753605],"genre_scores_gemma":[0.9771708,0.01377884,0.002637381,0.00054177444,0.0004605477,0.00034935193,0.0014277141,0.0002247627,0.00340881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99364465,0.0020675496,0.0012024221,0.0010561711,0.00017243189,0.001856765],"domain_scores_gemma":[0.9972785,0.0009448622,0.0004707763,0.0007220444,0.00022915188,0.00035465232],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012971549,0.0010629811,0.0010801645,0.00042609955,0.0010552522,0.00032101595,0.00074770383,0.0015121632,0.0010307698],"category_scores_gemma":[0.0005057657,0.001115134,0.00073896465,0.00047235194,0.0005186203,0.00062373356,0.000301713,0.0011023192,0.00029816717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006518338,0.0026382296,0.49087065,0.002759427,0.004567658,0.0010252809,0.06871665,0.003019855,0.02435236,0.014176974,0.055071242,0.33214983],"study_design_scores_gemma":[0.005157577,0.0012976819,0.92493385,0.0077514173,0.0019696953,0.001497517,0.002615946,0.004428151,0.021983555,0.0049620275,0.02143158,0.0019709866],"about_ca_topic_score_codex":0.005563495,"about_ca_topic_score_gemma":0.005047503,"teacher_disagreement_score":0.4340632,"about_ca_system_score_codex":0.00178863,"about_ca_system_score_gemma":0.001238216,"threshold_uncertainty_score":0.9998824},"labels":[],"label_agreement":null},{"id":"W4404731829","doi":"10.1016/j.rhum.2024.10.192","title":"Le guselkumab et les inhibiteurs de l’IL-17 ont une persistance et une efficacité comparables dans le rhumastisme psoriasique : résultats intermédiaires à 6 mois de l’étude de cohorte observationnelle PsABIOnd","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Memorial University of Newfoundland","funders":"","keywords":"Medicine","score_opus":0.02110061837054618,"score_gpt":0.24880348399372063,"score_spread":0.22770286562317443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404731829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8769395,0.05973403,0.025774539,0.03088045,0.001503459,0.00077834044,0.0012348228,0.00043528457,0.0027196119],"genre_scores_gemma":[0.9678489,0.011212979,0.0036428284,0.000536393,0.000258208,0.00023243375,0.0009735502,0.0001521369,0.015142562],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99508303,0.0016675653,0.00097454817,0.0009867118,0.0001183035,0.0011698578],"domain_scores_gemma":[0.9975579,0.0011323884,0.00033795193,0.00063182716,0.00015169877,0.00018825338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012023594,0.000794455,0.0010150224,0.00026569868,0.00088652305,0.00024232526,0.0005988227,0.00094454974,0.00022834647],"category_scores_gemma":[0.0002085626,0.00089428236,0.00049621356,0.00068723893,0.00067805283,0.0005047562,0.0001783658,0.00091420277,0.00022356908],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008902606,0.0029610363,0.02272219,0.002766427,0.00497702,0.0013616494,0.15616728,0.014082292,0.14063783,0.55006737,0.04352447,0.059842158],"study_design_scores_gemma":[0.01543531,0.0020136395,0.53109723,0.01923741,0.004199635,0.0052799513,0.027737072,0.014846962,0.07404279,0.022052908,0.279148,0.0049090856],"about_ca_topic_score_codex":0.011196411,"about_ca_topic_score_gemma":0.027682066,"teacher_disagreement_score":0.5280145,"about_ca_system_score_codex":0.0006519723,"about_ca_system_score_gemma":0.0010875035,"threshold_uncertainty_score":0.9993508},"labels":[],"label_agreement":null},{"id":"W4404731907","doi":"10.1016/j.rhum.2024.10.061","title":"L’aprémilast améliore l’état des patients atteints de rhumatisme psoriasique récent de forme oligoarticulaire : résultats à 48 semaines de l’étude FOREMOST","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.013740008810551589,"score_gpt":0.23973034511077704,"score_spread":0.22599033630022544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404731907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9346801,0.049774025,0.0038494465,0.0034002075,0.0044508907,0.0011877789,0.001104428,0.0004371252,0.0011160073],"genre_scores_gemma":[0.9713585,0.012006763,0.0037255979,0.00043411,0.0009298126,0.00038132936,0.0008922308,0.00023611731,0.0100355735],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99422306,0.0009772318,0.0011848601,0.0010480729,0.00017228018,0.0023945007],"domain_scores_gemma":[0.9976932,0.0006026702,0.00033507036,0.00071572483,0.00026540912,0.00038792225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00089349574,0.0010658532,0.0011036859,0.000382477,0.0009683805,0.00027756437,0.0006409117,0.0012858602,0.0013570789],"category_scores_gemma":[0.0003515573,0.0010820745,0.000664375,0.0006442973,0.00071798946,0.00063607894,0.0002840213,0.0007394657,0.0023829879],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042055288,0.0017734915,0.06763973,0.0057135355,0.0031522983,0.0014649916,0.04693564,0.00024724694,0.014473543,0.0173913,0.024501763,0.8162859],"study_design_scores_gemma":[0.019415606,0.0036903778,0.5630952,0.03619916,0.008669935,0.010675479,0.0045857914,0.008773901,0.07166402,0.06221534,0.20413508,0.006880104],"about_ca_topic_score_codex":0.0005784401,"about_ca_topic_score_gemma":0.0015560125,"teacher_disagreement_score":0.8094058,"about_ca_system_score_codex":0.001961827,"about_ca_system_score_gemma":0.00056504994,"threshold_uncertainty_score":0.9995558},"labels":[],"label_agreement":null},{"id":"W4404731910","doi":"10.1016/j.rhum.2024.10.066","title":"Impact du rhumatisme psoriasique récent oligoarticulaire selon le questionnaire PSAID-12 (Psoriatic Arthritis Impact of Disease 12-items) dans l’étude FOREMOST de l’aprémilast","year":2024,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Medicine; Dermatology; Gynecology; Arthritis; Psoriasis; Internal medicine","score_opus":0.0101921915250581,"score_gpt":0.24523050277509814,"score_spread":0.23503831125004004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404731910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.844578,0.14119954,0.0023384427,0.0028226178,0.004355345,0.0013250699,0.0026669663,0.00036253067,0.0003514515],"genre_scores_gemma":[0.9733737,0.0220131,0.00031838124,0.000058410187,0.0011822369,0.00025415706,0.0010936118,0.0002146904,0.001491675],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9939582,0.0014544653,0.0016261023,0.0011295481,0.00022016875,0.0016115409],"domain_scores_gemma":[0.9970395,0.0005010541,0.00059538556,0.0010883493,0.00021594767,0.00055974384],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008713997,0.0012200796,0.0015998903,0.00047481575,0.00074820383,0.0002251232,0.00059055735,0.0009812497,0.001433222],"category_scores_gemma":[0.00040317906,0.0011708335,0.0017152607,0.0005709534,0.00064693886,0.00087371044,0.00020806673,0.0006779222,0.000753175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020964756,0.0057916217,0.24048226,0.0085338615,0.014224416,0.0035787062,0.05015663,0.00562359,0.025871942,0.046477627,0.027750019,0.5694128],"study_design_scores_gemma":[0.0076303934,0.0031635137,0.9379573,0.021538284,0.0035605298,0.0029483612,0.00055308733,0.008155342,0.002826781,0.0042246687,0.0051515093,0.0022902396],"about_ca_topic_score_codex":0.0048161037,"about_ca_topic_score_gemma":0.0031624576,"teacher_disagreement_score":0.697475,"about_ca_system_score_codex":0.0015010481,"about_ca_system_score_gemma":0.0017454914,"threshold_uncertainty_score":0.9994796},"labels":[],"label_agreement":null},{"id":"W4404755298","doi":"10.1001/jamadermatol.2024.4688","title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years","year":2024,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Randomized controlled trial; Psoriasis Area and Severity Index; Placebo; Clinical trial; Plaque psoriasis; Adverse effect; Internal medicine; Physical therapy; Surgery; Dermatology; Alternative medicine","score_opus":0.014891991540232768,"score_gpt":0.2600149887870187,"score_spread":0.2451229972467859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404755298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927215,0.0017872634,0.00081778166,0.0023235844,0.0009899725,0.00061382406,0.00029523685,0.000058052457,0.00039278902],"genre_scores_gemma":[0.9976809,0.000114479255,0.0005577723,0.0003729885,0.00003064744,0.00010030027,0.00009969214,0.000022766726,0.001020466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987837,0.00013473048,0.00035121158,0.0003680282,0.00002093366,0.0003414085],"domain_scores_gemma":[0.9991262,0.0005783115,0.0000354842,0.00018188795,0.00003533701,0.00004279944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012996873,0.00016999047,0.0004441933,0.00030040657,0.000047941754,0.000017406088,0.00012542318,0.00032902224,0.00008987407],"category_scores_gemma":[0.00010749623,0.00016257366,0.000075914075,0.00021816223,0.000048488204,0.00006235686,0.00007333052,0.000111476096,0.00019564111],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026530655,0.00044688865,0.012583784,0.0007623077,0.002159572,0.0005436699,0.024655012,0.00040948467,0.094406046,0.040861983,0.0627444,0.7338962],"study_design_scores_gemma":[0.03010153,0.0010176142,0.11015389,0.0006014918,0.00055447285,0.0031356267,0.0012829311,0.00025192378,0.22702558,0.0020808817,0.6223922,0.0014018695],"about_ca_topic_score_codex":0.000054716453,"about_ca_topic_score_gemma":0.00011826589,"teacher_disagreement_score":0.7324943,"about_ca_system_score_codex":0.00003036563,"about_ca_system_score_gemma":0.000072179224,"threshold_uncertainty_score":0.6629562},"labels":[],"label_agreement":null},{"id":"W4404826455","doi":"10.1111/jdv.20456","title":"AI versus dermatologist performance in psoriasis body surface area assessment: A ground truth‐validated, anatomical segment‐based comparative study (AI <scp>PASS</scp>)","year":2024,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Body surface area; Dermatology; Ground truth; Artificial intelligence; Surgery","score_opus":0.04213087454373087,"score_gpt":0.3059883763534948,"score_spread":0.2638575018097639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404826455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91093206,0.006306962,0.000018602814,0.07762621,0.0034760577,0.0005256526,0.00011165715,0.000040104565,0.00096267473],"genre_scores_gemma":[0.97931844,0.0004658852,0.00006291283,0.019412806,0.00027263144,0.0000126710665,0.00009489665,0.00007123098,0.0002884971],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98931825,0.007069444,0.0018613773,0.00070261286,0.00020094212,0.0008473659],"domain_scores_gemma":[0.9956338,0.00209778,0.0016814233,0.00039359348,0.00012660306,0.00006679053],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0009665202,0.00082459784,0.0022401519,0.0006929178,0.00027746716,0.000048558202,0.0013224926,0.0016259949,0.00003705861],"category_scores_gemma":[0.00012306869,0.0005908893,0.00048294262,0.0004575541,0.0012505146,0.00021267065,0.0004749098,0.00575387,0.000077301534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020630409,0.0018696737,0.38589078,0.000763956,0.010610242,0.0062013054,0.0019601465,0.00034709988,0.0025745702,0.0005712166,0.58654743,0.00060052786],"study_design_scores_gemma":[0.049058035,0.0017917732,0.28420484,0.0014396204,0.010592714,0.032046996,0.0021768848,0.00049456034,0.021807808,0.000787236,0.5940563,0.0015432573],"about_ca_topic_score_codex":0.0000107018805,"about_ca_topic_score_gemma":0.000006547865,"teacher_disagreement_score":0.10168594,"about_ca_system_score_codex":0.00015637788,"about_ca_system_score_gemma":0.00028394436,"threshold_uncertainty_score":0.9996701},"labels":[],"label_agreement":null},{"id":"W4405112380","doi":"10.1111/1346-8138.17570","title":"Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient‐reported outcomes in the <scp>POETYK PSO</scp>‐4 study","year":2024,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Dermatology Life Quality Index; Psoriasis; Generalized pustular psoriasis; Quality of life (healthcare); Plaque psoriasis; Dermatology; Psoriasis Area and Severity Index; Severity of illness; Population; Internal medicine","score_opus":0.017935574336227438,"score_gpt":0.2577610967137909,"score_spread":0.23982552237756344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405112380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929622,0.004112726,0.0000059187414,0.0007090095,0.0011909045,0.0008559242,0.000020677526,0.000030636613,0.000112008864],"genre_scores_gemma":[0.99905574,0.00027155678,0.000032254364,0.000285481,0.000029933439,0.000058119673,0.000029596244,0.00003456775,0.0002027362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956322,0.0021487453,0.0012101515,0.00027840902,0.00018084444,0.0005497001],"domain_scores_gemma":[0.9972318,0.001643987,0.00051641243,0.0004541628,0.00012035921,0.00003330472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006432515,0.0003901336,0.0008836462,0.00048898987,0.00016043043,0.000039744507,0.0005905909,0.000257101,0.00006021018],"category_scores_gemma":[0.0002367632,0.00017380732,0.00016232881,0.000588975,0.00019122822,0.00020729496,0.00007986935,0.00065068144,0.000054049404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014652358,0.0026569385,0.9390376,0.00004336109,0.0025139574,0.004166392,0.04366203,0.000052066032,0.00046709104,0.000048582464,0.0033464532,0.002540259],"study_design_scores_gemma":[0.028830014,0.0029048044,0.8920083,0.00025560084,0.002263717,0.023451496,0.041820575,0.00001838218,0.001885521,0.00031402317,0.0058990717,0.0003485048],"about_ca_topic_score_codex":0.00014911704,"about_ca_topic_score_gemma":0.00076718925,"teacher_disagreement_score":0.047029343,"about_ca_system_score_codex":0.000068619214,"about_ca_system_score_gemma":0.00018956498,"threshold_uncertainty_score":0.7087657},"labels":[],"label_agreement":null},{"id":"W4405128635","doi":"10.33667/2078-5631-2024-25-52-57","title":"Psoriasis and oncology: is there a way out?","year":2024,"lang":"en","type":"article","venue":"Medical alphabet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Medicine; Psoriatic arthritis; Basal cell carcinoma; Dermatology; Systemic therapy; Cancer; Skin cancer; Internal medicine; Oncology; Basal cell","score_opus":0.020087846918555596,"score_gpt":0.2817367936957297,"score_spread":0.2616489467771741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405128635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8378685,0.11816519,0.00010771189,0.016958304,0.0060819187,0.0002744521,0.00014782109,0.00041230448,0.019983802],"genre_scores_gemma":[0.9803376,0.0025942316,0.00007281745,0.0013046726,0.00027859243,0.00005831748,0.00007759649,0.000024754052,0.015251396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988148,0.000165787,0.00021967907,0.00038253164,0.00007977909,0.00033742937],"domain_scores_gemma":[0.9993209,0.0003685487,0.000024205354,0.00018179943,0.000017421788,0.000087116],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000379458,0.00018942507,0.00030937488,0.00007787749,0.00011129872,0.000022354683,0.00016850686,0.0005315497,0.01047905],"category_scores_gemma":[0.00009228104,0.00013022638,0.00010423591,0.00010845879,0.00025198614,0.000055918725,0.000093272494,0.0002885778,0.0034759361],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000074872856,0.00014815482,0.0035820852,0.00005070007,0.0007514657,0.00027223324,0.0016498495,8.814329e-9,0.002107176,0.0011085294,0.11144289,0.878812],"study_design_scores_gemma":[0.001449385,0.00029295404,0.004810551,0.00009969946,0.0002286956,0.00013904709,0.00013815888,0.000009505061,0.0074327653,0.0007787457,0.98444,0.00018048866],"about_ca_topic_score_codex":0.00003413867,"about_ca_topic_score_gemma":0.00004526629,"teacher_disagreement_score":0.87863153,"about_ca_system_score_codex":0.000043117812,"about_ca_system_score_gemma":0.0001220461,"threshold_uncertainty_score":0.99729997},"labels":[],"label_agreement":null},{"id":"W4405229307","doi":"10.1093/bjd/ljae360.126","title":"P96 Effectiveness and safety of bimekizumab for adult patients with plaque psoriasis: an interim analysis of 2-year data from a real-world, multicentre, retrospective study","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Interim analysis; Plaque psoriasis; Interim; Psoriasis; Retrospective cohort study; Dermatology; Internal medicine; Clinical trial; History","score_opus":0.01386349948587046,"score_gpt":0.27420053712202475,"score_spread":0.2603370376361543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405229307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305177,0.0023938054,0.00039874436,0.000022420252,0.00044821727,0.0005222213,0.0031251782,0.000014430957,0.000023221293],"genre_scores_gemma":[0.9983161,0.0005509021,0.00037866837,0.0000069548373,0.000023078921,0.000013586404,0.0006812627,0.000021821157,0.000007633333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785775,0.00070196966,0.0007415136,0.0004036474,0.00008133429,0.00021380163],"domain_scores_gemma":[0.9979684,0.00058392447,0.0004935092,0.0003285865,0.0005843555,0.000041260242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025737743,0.00019507886,0.0011552927,0.00047814412,0.0000843642,0.000023636821,0.0003349898,0.0001552579,0.000056531513],"category_scores_gemma":[0.00015883567,0.00017326004,0.00015047516,0.00045169925,0.00018286784,0.00028952534,0.000105868516,0.0001869571,0.0000016046685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013156164,0.0021140159,0.92769676,0.0001281598,0.026641782,0.0003555784,0.0013888124,0.0000052705486,0.0009608797,0.00010731208,0.00019361451,0.027251625],"study_design_scores_gemma":[0.012907446,0.0012208816,0.9732274,0.00045047284,0.007778647,0.00033991996,0.0012001911,0.000052394527,0.00253578,0.00005588597,0.0000575681,0.00017342063],"about_ca_topic_score_codex":0.0011732093,"about_ca_topic_score_gemma":0.004724821,"teacher_disagreement_score":0.04553061,"about_ca_system_score_codex":0.000054423304,"about_ca_system_score_gemma":0.00009962228,"threshold_uncertainty_score":0.7065339},"labels":[],"label_agreement":null},{"id":"W4405229326","doi":"10.1093/bjd/ljae360.064","title":"P34 The incidence and prevalence of psoriasis in Newfoundland and Labrador, Canada","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Incidence (geometry); Medicine; Geography; Demography; Epidemiology; Dermatology; Pathology; Sociology","score_opus":0.007111329557458947,"score_gpt":0.2156186800416515,"score_spread":0.20850735048419256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405229326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8410278,0.15758987,0.000009794875,0.0007100993,0.00051316613,0.000054545406,0.000026678588,0.0000031217019,0.00006492942],"genre_scores_gemma":[0.9878476,0.011882232,0.000033215536,0.00006130035,0.000019342693,0.0000024214987,0.0000015670608,0.0000055140194,0.00014680627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991242,0.0002184529,0.00034777663,0.000115795076,0.000037381687,0.00015638469],"domain_scores_gemma":[0.99934345,0.00040913673,0.00011545313,0.00006543654,0.000046119876,0.000020424128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016438006,0.00008379091,0.00026841988,0.00007515038,0.000060292125,0.000019941748,0.00012755895,0.00009948201,0.00004785578],"category_scores_gemma":[0.0000853438,0.00006808936,0.00003176775,0.00010300014,0.00019017483,0.00010144493,0.000042445852,0.0002002461,0.0000013193686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002180859,0.00008159159,0.69982326,0.0005206279,0.00052760006,0.006661995,0.0011458411,0.000002165883,0.004453349,0.00078881474,0.005996759,0.27977988],"study_design_scores_gemma":[0.0016164238,0.000097573306,0.796236,0.00066966197,0.00022075945,0.18938744,0.00027080777,0.0000072278553,0.0025565552,0.0003867039,0.00841337,0.0001374796],"about_ca_topic_score_codex":0.097167745,"about_ca_topic_score_gemma":0.36104456,"teacher_disagreement_score":0.2796424,"about_ca_system_score_codex":0.00003319489,"about_ca_system_score_gemma":0.0002959665,"threshold_uncertainty_score":0.9088443},"labels":[],"label_agreement":null},{"id":"W4405229705","doi":"10.1093/bjd/ljae360.145","title":"P115 Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-23 inhibitors: a 52-week multicentre retrospective review","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Women's College Hospital; McMaster University","keywords":"Medicine; Discontinuation; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Adverse effect; Plaque psoriasis; Body surface area; Gastroenterology; Interleukin 17; Retrospective cohort study; Dermatology; Cytokine","score_opus":0.008607231824469994,"score_gpt":0.24633820757110672,"score_spread":0.23773097574663674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405229705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717377,0.02525788,0.000068072055,0.0005525863,0.00121774,0.0008751581,0.0001817615,0.00002503485,0.00008409229],"genre_scores_gemma":[0.9928004,0.005998874,0.00064976054,0.00015404062,0.000055954657,0.00010326404,0.000056890247,0.0000325186,0.0001482873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782616,0.00027365316,0.0010525578,0.00035208176,0.00009707277,0.00039845658],"domain_scores_gemma":[0.998539,0.0002648499,0.00042690328,0.00017519378,0.0005305571,0.00006351178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014906169,0.00024659344,0.000944606,0.00038804047,0.00007308932,0.000025233185,0.00027339833,0.00019561817,0.0000767389],"category_scores_gemma":[0.00028741048,0.00022332784,0.00022190824,0.00048472808,0.00012350861,0.00023426795,0.000054913235,0.0003012405,0.000022416132],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011117625,0.0042725164,0.41707426,0.004470915,0.0035442698,0.0067294524,0.01772723,0.0000073989427,0.0051117986,0.0005842921,0.05281428,0.47654596],"study_design_scores_gemma":[0.06399168,0.010573634,0.58232427,0.10569769,0.002996426,0.039601758,0.005240607,0.000010874935,0.15132253,0.00031757928,0.035334524,0.002588414],"about_ca_topic_score_codex":0.00018949537,"about_ca_topic_score_gemma":0.0015909777,"teacher_disagreement_score":0.47395754,"about_ca_system_score_codex":0.00017057887,"about_ca_system_score_gemma":0.00018944948,"threshold_uncertainty_score":0.91070443},"labels":[],"label_agreement":null},{"id":"W4405229751","doi":"10.1093/bjd/ljae360.045","title":"P15 Evaluating risankizumab for moderate-to-severe plaque psoriasis: real-world outcomes from an international study","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis Area and Severity Index; Ustekinumab; Psoriasis; Plaque psoriasis; Adalimumab; Adverse effect; Internal medicine; Randomized controlled trial; Severity of illness; Dermatology; Disease","score_opus":0.04039434091804939,"score_gpt":0.33980244830136674,"score_spread":0.29940810738331736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405229751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888813,0.0027573337,0.00058274704,0.00096753467,0.005498978,0.00046784448,0.00038449027,0.00007000358,0.0003898007],"genre_scores_gemma":[0.9973105,0.00024590088,0.0011591329,0.0001879632,0.0002585477,0.00007496193,0.00018012177,0.000039532082,0.00054332556],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977729,0.000522522,0.0008600894,0.00038331875,0.00010945903,0.0003517262],"domain_scores_gemma":[0.9986203,0.0006298276,0.00024537474,0.00018741624,0.00024702464,0.0000700649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003716369,0.00023675148,0.00069114845,0.00036749087,0.00021295254,0.00015409039,0.00046169353,0.00020412322,0.0004936963],"category_scores_gemma":[0.00017354141,0.0002359018,0.00025090514,0.00014533017,0.000046411977,0.00039933948,0.000072223665,0.00031508028,0.000089330635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007374597,0.002990557,0.26951528,0.00007085938,0.014763283,0.008996738,0.005760507,0.00030664625,0.006014719,0.0010235669,0.028824156,0.6543591],"study_design_scores_gemma":[0.064556405,0.0048659625,0.7603733,0.001644708,0.0057386816,0.08844484,0.008270427,0.0010756153,0.020014318,0.0082149925,0.034283172,0.002517596],"about_ca_topic_score_codex":0.00061153714,"about_ca_topic_score_gemma":0.001456037,"teacher_disagreement_score":0.65184146,"about_ca_system_score_codex":0.00010443038,"about_ca_system_score_gemma":0.000225521,"threshold_uncertainty_score":0.9619796},"labels":[],"label_agreement":null},{"id":"W4405257802","doi":"10.1177/2050313x241304954","title":"Anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis: A case report","year":2024,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Tumor necrosis factor alpha; Psoriasis; Alpha (finance); Dermatology; Internal medicine; Surgery","score_opus":0.03163363856852824,"score_gpt":0.31090258074192334,"score_spread":0.2792689421733951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405257802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98180383,0.006014491,0.000071431874,0.00042738786,0.007911555,0.0010207627,0.0001324817,0.00035120454,0.002266864],"genre_scores_gemma":[0.99251693,0.00010868935,0.00014838284,0.00023406146,0.0005581479,0.00023124492,0.00029810067,0.000086981505,0.0058174543],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9956601,0.00039025297,0.0014648484,0.0013962181,0.00029671562,0.00079181814],"domain_scores_gemma":[0.99766254,0.00034968174,0.00036614315,0.0011540956,0.00011515291,0.0003523683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019347119,0.0005585009,0.00094968977,0.00022289524,0.0005345064,0.000232553,0.00024962917,0.00075138087,0.0070996904],"category_scores_gemma":[0.0012352183,0.000439821,0.00039608259,0.00054415787,0.00019937159,0.00040204698,0.000558566,0.0007537103,0.00056182855],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005425963,0.00025464437,0.00044766243,0.00006759544,0.0006320281,0.8704894,0.00046379483,1.0799375e-7,0.007274687,0.000015172687,0.0030881201,0.1172125],"study_design_scores_gemma":[0.00091725116,0.00019001862,0.00019481128,0.00036535633,0.00036859102,0.8972674,0.00024435518,0.000009359822,0.03480523,0.000049963437,0.065118626,0.00046904682],"about_ca_topic_score_codex":0.003977307,"about_ca_topic_score_gemma":0.0005052003,"teacher_disagreement_score":0.11674345,"about_ca_system_score_codex":0.00019650349,"about_ca_system_score_gemma":0.0015454686,"threshold_uncertainty_score":0.99980533},"labels":[],"label_agreement":null},{"id":"W4405277067","doi":"10.1001/jamadermatol.2024.5103","title":"Improving Diversity in a Novel Psoriasis Study","year":2024,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Allergan; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Galderma; Incyte; L'Oreal USA; Sanofi; Amgen; Pfizer; Concert Pharmaceuticals","keywords":"Medicine; Psoriasis; Ethnic group; Dermatology; Clinical trial; Scalp; Quality of life (healthcare); Population; Food and drug administration; Socioeconomic status; Internal medicine; Environmental health","score_opus":0.02387171806912441,"score_gpt":0.24916309798963773,"score_spread":0.22529137992051332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405277067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925189,0.003303625,0.00017430917,0.00049552874,0.0019718783,0.0003258106,0.000035842702,0.00018542298,0.0009886543],"genre_scores_gemma":[0.9989567,0.00002248269,0.00006310015,0.0001065204,0.00003926525,0.000048684065,0.000038144044,0.000015213274,0.0007099185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867624,0.00020198723,0.00026437704,0.00043200352,0.000032905227,0.0003925083],"domain_scores_gemma":[0.9994224,0.0002483689,0.00004275534,0.00024175936,0.000024094867,0.000020630441],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017474256,0.00019519428,0.00034359854,0.00031908197,0.00018961453,0.000033150056,0.00023525402,0.00032475716,0.00022574443],"category_scores_gemma":[0.000057086094,0.00017409686,0.00009761749,0.00029726638,0.00007152108,0.00016934027,0.0003668471,0.00027448256,0.0008262552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006760141,0.0025381541,0.6986464,0.00017703178,0.0016242687,0.003140793,0.019206475,0.000005348432,0.054867294,0.004294885,0.004154306,0.21066901],"study_design_scores_gemma":[0.03366817,0.001054218,0.82481813,0.00019893299,0.0016722757,0.0065434794,0.0116684865,0.0003630432,0.04827037,0.0009132051,0.06885341,0.0019762677],"about_ca_topic_score_codex":0.0008053377,"about_ca_topic_score_gemma":0.00046239328,"teacher_disagreement_score":0.20869274,"about_ca_system_score_codex":0.00009018042,"about_ca_system_score_gemma":0.00010217954,"threshold_uncertainty_score":0.9999517},"labels":[],"label_agreement":null},{"id":"W4405396550","doi":"10.1177/12034754241302827","title":"Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Guenther Dermatology Research Centre; Probity Medical Research; Regional Municipality of Niagara; McMaster University","funders":"Sun Pharma; University of Waterloo","keywords":"Medicine; Plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Gastroenterology; Dermatology","score_opus":0.018219129996391997,"score_gpt":0.2561311935522911,"score_spread":0.23791206355589908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405396550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897445,0.007104108,0.000044327986,0.0005828888,0.002042583,0.0001805041,0.000040202187,0.0000064483697,0.00025446125],"genre_scores_gemma":[0.9980842,0.001319575,0.000028486395,0.000072205476,0.00012851722,0.0000088293755,0.000017703293,0.00001603404,0.00032445192],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874747,0.00020775662,0.0005887419,0.00015659927,0.000073427,0.00022602372],"domain_scores_gemma":[0.9951153,0.004482486,0.00014520413,0.00009271134,0.00011094692,0.000053377407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069750834,0.00016102578,0.0008135076,0.00048356826,0.000040000446,0.0000052449595,0.00007139925,0.00008443659,0.00006819204],"category_scores_gemma":[0.00018097779,0.00011258505,0.00011197592,0.00025230637,0.000044294535,0.000050442053,0.000011928761,0.00014839372,0.0000015870519],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058190208,0.0005355352,0.11976185,0.0053313817,0.006630467,0.0146982,0.004273342,0.0012289191,0.16345203,0.0016022748,0.15145053,0.47284526],"study_design_scores_gemma":[0.036648765,0.010479202,0.16840942,0.051377576,0.007167998,0.071589045,0.0074043656,0.0005552662,0.38714102,0.009899645,0.24520962,0.004118082],"about_ca_topic_score_codex":0.09927707,"about_ca_topic_score_gemma":0.13636903,"teacher_disagreement_score":0.46872717,"about_ca_system_score_codex":0.00020285569,"about_ca_system_score_gemma":0.0010658125,"threshold_uncertainty_score":0.90672094},"labels":[],"label_agreement":null},{"id":"W4405467033","doi":"10.1016/s0140-6736(24)01927-5","title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Western University","funders":"Janssen Research and Development","keywords":"Medicine; Ulcerative colitis; Placebo; Internal medicine; Population; Maintenance therapy; Gastroenterology; Intention-to-treat analysis; Surgery; Clinical trial; Chemotherapy; Pathology","score_opus":0.042768513126206845,"score_gpt":0.2988047411565045,"score_spread":0.2560362280302977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405467033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936321,0.001696188,0.00003328241,0.0011537956,0.0004428371,0.002247651,0.00014603332,0.000059430047,0.0005887106],"genre_scores_gemma":[0.9971789,0.00028564557,0.000032455508,0.00016183335,0.00010163973,0.0008069679,0.00006478171,0.000016952257,0.0013508274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99877375,0.0003106075,0.00021506431,0.00033117324,0.000045884637,0.00032352665],"domain_scores_gemma":[0.99930304,0.00032846053,0.00006568832,0.00019118394,0.00009145806,0.000020172274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032298954,0.00022681667,0.000690898,0.00010368831,0.00017876075,0.00004612722,0.00010861859,0.000099154655,0.000033264852],"category_scores_gemma":[0.000047807716,0.00012456231,0.000047290592,0.00019071529,0.00011758648,0.00015039007,0.000041126554,0.00020233287,0.00006476364],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9746021,0.00015992693,0.00010972299,0.000022848808,0.0016919652,0.000012194525,0.006435754,0.000033336928,0.0001686526,0.00044155537,0.0018288384,0.014493092],"study_design_scores_gemma":[0.96253395,0.0011596074,0.024001122,0.00028307913,0.0004592233,0.000021248432,0.0015145772,0.000028343025,0.0070327995,0.0004928754,0.0021114934,0.00036166018],"about_ca_topic_score_codex":0.00005378249,"about_ca_topic_score_gemma":0.00030395022,"teacher_disagreement_score":0.023891399,"about_ca_system_score_codex":0.000106092426,"about_ca_system_score_gemma":0.00004884031,"threshold_uncertainty_score":0.5079504},"labels":[],"label_agreement":null},{"id":"W4405652357","doi":"10.1155/dth/8724445","title":"Real‐World Guselkumab Response and Drug Survival in Australian Patients With Psoriasis: Results From the Australasian Psoriasis Registry","year":2024,"lang":"en","type":"article","venue":"Dermatologic Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; LEO Pharma; Argenx; Amryt Pharma; Incyte; Dermira; Genentech; Valeant Pharmaceuticals International; UCB Pharma; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Medicine; Psoriasis; Dermatology; Drug; Plaque psoriasis; Complete response; Dermatologic agents; Internal medicine; Pharmacology; Chemotherapy; Antibiotics","score_opus":0.01931454918454005,"score_gpt":0.25026035074008024,"score_spread":0.23094580155554018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405652357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805964,0.0025693204,0.0000011430227,0.0061771814,0.001242751,0.00053218944,0.0007047251,0.0002258275,0.00048719853],"genre_scores_gemma":[0.9944319,0.0012716419,0.00008230246,0.00017327267,0.000070946466,0.000085118576,0.00056260126,0.000038202143,0.003284015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967548,0.0013049846,0.00053247093,0.00075286673,0.00010348266,0.00055138924],"domain_scores_gemma":[0.99756956,0.0015036613,0.00015235879,0.0006804458,0.000044667664,0.000049283808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059484417,0.00044509323,0.000501444,0.00019086401,0.00024668235,0.00011350158,0.00040420966,0.00030946877,0.00014014753],"category_scores_gemma":[0.000071443785,0.00026309793,0.00011112689,0.0005050691,0.00030608752,0.00016755902,0.000051923147,0.00042761702,0.0001316854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056406587,0.0010517167,0.7505088,0.00004885488,0.002980891,0.00091210427,0.015657427,0.00001149943,0.003561622,0.0014064059,0.07009536,0.09735877],"study_design_scores_gemma":[0.009603758,0.00019959171,0.8819885,0.0001687042,0.0001267517,0.0000384081,0.0011281138,0.0000012143079,0.005361722,0.00035592206,0.100580916,0.00044637214],"about_ca_topic_score_codex":0.0014786163,"about_ca_topic_score_gemma":0.0015520956,"teacher_disagreement_score":0.13147977,"about_ca_system_score_codex":0.00007992856,"about_ca_system_score_gemma":0.00010047323,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4405665962","doi":"10.1093/bjd/ljae502","title":"Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Calgary Laboratory Services; SKiN Health; University of Calgary","funders":"Janssen Research and Development; LEO Pharma; Janssen Scientific Affairs; Celgene; Amgen; Pfizer; Eli Lilly and Company; Language Literacy and Culture, University of Maryland, Baltimore County","keywords":"Medicine; Placebo; Psoriasis; Internal medicine; Randomized controlled trial; Psoriasis Area and Severity Index; Dermatology; Pathology","score_opus":0.011350609452663618,"score_gpt":0.2568854939495789,"score_spread":0.24553488449691527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405665962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972839,0.016987275,0.000101195015,0.00051955745,0.0013484195,0.007804542,0.0003492036,0.000010347327,0.00004045425],"genre_scores_gemma":[0.9970031,0.0017297118,0.000045985114,0.000023125282,0.00005152813,0.00095667614,0.000023616163,0.00002030418,0.00014596125],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99618775,0.0014645389,0.0017163033,0.00023793938,0.000093895156,0.0002995907],"domain_scores_gemma":[0.9958518,0.002906668,0.0007119016,0.00023014199,0.00027088256,0.000028619672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007275687,0.00023677971,0.0016902979,0.00028150636,0.00014236518,0.000023808863,0.0003282375,0.00019819486,0.000027251823],"category_scores_gemma":[0.000516744,0.00013734208,0.0006744296,0.0002998494,0.00014097826,0.00008537607,0.00003581031,0.00017517475,0.000003769848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91143763,0.0065521523,0.0010766318,0.00006312195,0.0056106327,0.0002700163,0.0057560885,0.00017135951,0.0004102891,0.00005264576,0.0023363526,0.06626306],"study_design_scores_gemma":[0.9813832,0.0020924387,0.00063821144,0.00018606255,0.0021431244,0.0015287435,0.00077079,0.000086134496,0.009401518,0.00012264367,0.0014882276,0.00015892608],"about_ca_topic_score_codex":0.00019492154,"about_ca_topic_score_gemma":0.0002840683,"teacher_disagreement_score":0.06994552,"about_ca_system_score_codex":0.000079329,"about_ca_system_score_gemma":0.0002598148,"threshold_uncertainty_score":0.56006473},"labels":[],"label_agreement":null},{"id":"W4405695730","doi":"10.1016/j.jaad.2024.12.018","title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sun Pharma; Amgen","keywords":"Medicine; Scalp; Randomized controlled trial; Placebo; Double blind; Dermatology; Psoriasis; Adverse effect; Surgery; Internal medicine; Pathology; Alternative medicine","score_opus":0.02970217914875858,"score_gpt":0.31243469179696925,"score_spread":0.2827325126482107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405695730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776169,0.008185344,0.00015866652,0.008944169,0.0008713434,0.0035154365,0.0006562309,0.0000073287156,0.00004459239],"genre_scores_gemma":[0.99680465,0.0025029199,0.00019474818,0.00008493651,0.0001106888,0.000119576376,0.00001009366,0.000021994585,0.00015040374],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99602467,0.0013298132,0.0019650266,0.00026278268,0.00013496703,0.00028276027],"domain_scores_gemma":[0.98887795,0.008030754,0.00262895,0.00031134978,0.00010817659,0.000042830627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006722444,0.00032021423,0.0026272458,0.00021984678,0.0001478502,0.000008657743,0.0006168394,0.00026000608,0.000021098349],"category_scores_gemma":[0.00034056438,0.00014218253,0.0011844346,0.0003123327,0.0011676224,0.00006267761,0.00008238369,0.0003016178,0.0000019199308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96537536,0.00093429146,0.000022357122,0.000026798127,0.0076220185,0.0000031810737,0.001719852,0.00020502583,0.010683384,0.00023500204,0.00067484216,0.012497881],"study_design_scores_gemma":[0.8940446,0.0015155892,0.00011022454,0.0001523144,0.0041849082,0.00031908418,0.0002724251,0.00010569268,0.09675523,0.00027218,0.0021495954,0.000118176074],"about_ca_topic_score_codex":0.00013862531,"about_ca_topic_score_gemma":0.000010289506,"teacher_disagreement_score":0.08607184,"about_ca_system_score_codex":0.000053335712,"about_ca_system_score_gemma":0.0002598688,"threshold_uncertainty_score":0.5798035},"labels":[],"label_agreement":null},{"id":"W4405763927","doi":"10.3389/fpsyt.2024.1499714","title":"Stigma and psychological health in psoriasis patients based on the dual-factor model of mental health: the chain mediating roles of social appearance anxiety and alexithymia","year":2024,"lang":"en","type":"article","venue":"Frontiers in Psychiatry","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; Guangzhou University; Guangzhou University of Chinese Medicine","keywords":"Alexithymia; Anxiety; Mental health; Toronto Alexithymia Scale; Clinical psychology; Psoriasis; Stigma (botany); Psychiatry; Structural equation modeling; Medicine; Social stigma; Psychology; Hospital Anxiety and Depression Scale; Family medicine","score_opus":0.016210856991905474,"score_gpt":0.26190502548450745,"score_spread":0.24569416849260198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405763927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968346,0.019501517,0.00017682284,0.008494991,0.0024753714,0.00047291047,0.00045870867,0.00001506378,0.000058621506],"genre_scores_gemma":[0.99721813,0.0011722277,0.0009235897,0.0005426192,0.000037626534,0.000029542744,0.000049147748,0.000011994714,0.00001509769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985655,0.0004143146,0.00039952766,0.00029717476,0.000063149986,0.0002603137],"domain_scores_gemma":[0.99960214,0.00006633687,0.00016264732,0.00014013339,0.000009085276,0.000019659119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048677123,0.00016702194,0.00034547359,0.00012170636,0.00017165342,0.000007376836,0.000111763125,0.00015259511,0.0000066633693],"category_scores_gemma":[0.000015618987,0.000102422346,0.00006651208,0.00019310115,0.00022877166,0.000033837558,0.000029348543,0.00024470862,7.1668285e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013331242,0.0010187378,0.74155754,0.00032521796,0.00021829714,3.396126e-7,0.013442176,0.000092932285,0.00029513848,0.0018393631,0.026734097,0.21314305],"study_design_scores_gemma":[0.00672442,0.0010323542,0.97688943,0.00086050434,0.00003731391,0.0000033430779,0.0041422504,0.006967155,0.00022833176,0.0022191305,0.00056190375,0.00033386325],"about_ca_topic_score_codex":0.0000309761,"about_ca_topic_score_gemma":0.00008961208,"teacher_disagreement_score":0.2353319,"about_ca_system_score_codex":0.000048562637,"about_ca_system_score_gemma":0.00009215472,"threshold_uncertainty_score":0.41766623},"labels":[],"label_agreement":null},{"id":"W4406091194","doi":"10.58931/cpct.2024.2334","title":"The Spectrum of Management for Psoriasis: From the Known to New Alternatives","year":2024,"lang":"en","type":"article","venue":"Canadian Primary Care Today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Psoriasis; Spectrum (functional analysis); Broad spectrum; Business; Medicine; Dermatology; Physics; Chemistry","score_opus":0.010787238504128408,"score_gpt":0.22442362978658736,"score_spread":0.21363639128245895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091194","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25547296,0.5180934,0.0011451922,0.056788377,0.030582175,0.006329527,0.009560164,0.00033580977,0.12169235],"genre_scores_gemma":[0.9117706,0.0017465835,0.0006441184,0.002781142,0.0010033465,0.0003936779,0.0013829614,0.000083797975,0.08019381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990979,0.000074381016,0.00017196168,0.00027296323,0.000034320758,0.00034849276],"domain_scores_gemma":[0.99913704,0.00035630827,0.000029131084,0.00037558802,0.000027831846,0.00007412149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113704875,0.00015691806,0.00016213515,0.00008459206,0.00025558047,0.000046500034,0.00042776033,0.00008134057,0.00018750268],"category_scores_gemma":[0.00001468346,0.00009387741,0.000142028,0.0001465581,0.00006345239,0.000037831414,0.000049320646,0.00007917721,0.000266779],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113917624,0.000007248998,0.00029763256,0.000039635885,0.001218571,0.000020160056,0.0038122234,0.0000036224565,0.00076253543,0.008876794,0.21945791,0.76538974],"study_design_scores_gemma":[0.00045330625,0.00008675308,0.009432352,0.000079364654,0.00022967413,0.0000027767044,0.0008964568,3.2327662e-7,0.005977856,0.0013252833,0.98138845,0.00012737724],"about_ca_topic_score_codex":0.023011377,"about_ca_topic_score_gemma":0.1154385,"teacher_disagreement_score":0.76526237,"about_ca_system_score_codex":0.0003028951,"about_ca_system_score_gemma":0.0004392893,"threshold_uncertainty_score":0.98349446},"labels":[],"label_agreement":null},{"id":"W4406390250","doi":"10.1016/s1541-9800(06)71447-8","title":"10.1016/s1541-9800(06)71447-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.007694644796840554,"score_gpt":0.17832657484973904,"score_spread":0.17063193005289848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406390250","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013441486,0.0009894866,3.140101e-7,0.00016072005,0.000008290621,0.00020297628,0.00007812713,0.00017776707,0.9849408],"genre_scores_gemma":[0.0014275896,0.0000022752688,0.0000360877,0.000046978384,0.000075811826,0.00004086692,0.00024370926,0.000024229445,0.9981024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900013,0.00010653076,0.00018384994,0.00029593712,0.000030983636,0.00038258222],"domain_scores_gemma":[0.9994905,0.00006689641,0.00003048292,0.00033667643,0.000027958158,0.000047471487],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000102697224,0.00020252349,0.0002457939,0.000081887265,0.00015126073,0.000014826266,0.00021615622,0.0001956543,0.99803543],"category_scores_gemma":[0.000016665967,0.00017979277,0.00010881398,0.00015578131,0.00005347896,0.000060058686,0.00003560953,0.00009729241,0.999028],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021928351,0.000107401494,0.0000016086019,0.0000024988904,0.00014320026,0.00000798878,0.00003118962,0.0000040896466,0.0030708371,0.0000013828898,0.35186505,0.64454544],"study_design_scores_gemma":[0.0008767516,0.00020702001,0.0002920706,0.000011344148,0.000090157395,0.00003531318,0.0000016948151,0.0000010525627,0.004855978,0.0000065417016,0.9934093,0.00021278868],"about_ca_topic_score_codex":0.000026764861,"about_ca_topic_score_gemma":4.323593e-7,"teacher_disagreement_score":0.64433265,"about_ca_system_score_codex":0.000030830008,"about_ca_system_score_gemma":0.00002769698,"threshold_uncertainty_score":0.73317367},"labels":[],"label_agreement":null},{"id":"W4406414697","doi":"10.1016/s1541-9800(06)71120-6","title":"10.1016/s1541-9800(06)71120-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Efalizumab; Psoriasis; Medicine; Dermatology; Plaque psoriasis","score_opus":0.007705152374564535,"score_gpt":0.1785500064759325,"score_spread":0.17084485410136796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406414697","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011341565,0.0010665641,3.3642178e-7,0.00017006596,0.000008168666,0.00020281384,0.00007280724,0.00017734597,0.98696035],"genre_scores_gemma":[0.0014624848,0.0000024517676,0.000036741796,0.00004719593,0.00007594382,0.000040833642,0.00023328348,0.000024216535,0.99807686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989993,0.00010777194,0.00018344901,0.0002963856,0.000030889474,0.00038218993],"domain_scores_gemma":[0.9994903,0.000066778564,0.000030404723,0.0003372405,0.000027809392,0.00004743472],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010276968,0.00020242872,0.00024565918,0.0000805122,0.00015110907,0.000014513191,0.00021601142,0.00019652995,0.9979789],"category_scores_gemma":[0.0000164201,0.0001797401,0.00010863303,0.00015205375,0.000053343312,0.000060048773,0.000035559402,0.00009751128,0.99902517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021603775,0.0001074676,0.0000013852773,0.0000024971537,0.00014484115,0.000007911846,0.00003218645,0.0000044255894,0.0027656595,0.0000013776245,0.34600592,0.6507103],"study_design_scores_gemma":[0.0008732423,0.00020820525,0.0002506912,0.000011316835,0.00008702689,0.000034529417,0.000001859375,0.0000011241046,0.0045613805,0.0000068328554,0.993751,0.00021282658],"about_ca_topic_score_codex":0.000025234534,"about_ca_topic_score_gemma":4.5927575e-7,"teacher_disagreement_score":0.65049744,"about_ca_system_score_codex":0.000030754283,"about_ca_system_score_gemma":0.00002746938,"threshold_uncertainty_score":0.7329589},"labels":[],"label_agreement":null},{"id":"W4406423125","doi":"10.1016/s1541-9800(07)70433-7","title":"10.1016/s1541-9800(07)70433-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Comorbidity; Dermatology; Intensive care medicine; Internal medicine","score_opus":0.00779096717195882,"score_gpt":0.17898293806200113,"score_spread":0.17119197089004232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406423125","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009229131,0.0011720711,3.0760773e-7,0.00016500568,0.000011602918,0.00020014468,0.00007434259,0.00017576807,0.98897165],"genre_scores_gemma":[0.0013798276,0.0000021146336,0.000039498762,0.000046063044,0.00007645932,0.000040903535,0.00017829608,0.000024170819,0.9982127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990043,0.000107175845,0.00018356564,0.00029521578,0.000030758303,0.00037896037],"domain_scores_gemma":[0.9994911,0.000068088186,0.000031171447,0.0003352425,0.000028010456,0.00004641449],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010255257,0.00020187788,0.00024456478,0.00007681921,0.0001517115,0.000014276992,0.00021564482,0.00019470166,0.998678],"category_scores_gemma":[0.000016594991,0.00017917133,0.00010637321,0.00014143102,0.00005365671,0.00005892473,0.000035410412,0.00009703287,0.99923444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027166097,0.00010646103,0.0000010167669,0.0000024091305,0.00016545565,0.000008667481,0.000029588135,0.000003623644,0.002649267,0.0000013919148,0.27650404,0.72025645],"study_design_scores_gemma":[0.000863603,0.0002345959,0.00022134997,0.000011353831,0.00010700467,0.00003685974,0.0000015333677,9.4973876e-7,0.004983546,0.0000071187264,0.9933198,0.00021224676],"about_ca_topic_score_codex":0.00003119945,"about_ca_topic_score_gemma":4.6175788e-7,"teacher_disagreement_score":0.7200442,"about_ca_system_score_codex":0.00003089801,"about_ca_system_score_gemma":0.000027581937,"threshold_uncertainty_score":0.7306395},"labels":[],"label_agreement":null},{"id":"W4406426034","doi":"10.1093/ced/llaf031","title":"Comment on ‘The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis’: risk of cancer recurrence with biologics in psoriasis","year":2025,"lang":"en","type":"review","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Psoriasis; Malignancy; Dermatology; Meta-analysis; Oncology; Cancer; Tumor necrosis factor α; Internal medicine; Tumor necrosis factor alpha; Risk factor","score_opus":0.05683523775342269,"score_gpt":0.34385046433145244,"score_spread":0.28701522657802975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406426034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15485844,0.8411681,0.0000012276877,0.00007237017,0.000058753867,0.0027586373,0.0010638166,0.000010449379,0.000008191724],"genre_scores_gemma":[0.1575534,0.8407887,0.000023242972,0.00013804625,0.0000030354815,0.0012072893,0.00024631122,0.000019970394,0.000019973939],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99244887,0.0040864795,0.0021494995,0.00084990304,0.00009596481,0.00036929306],"domain_scores_gemma":[0.99489444,0.0022084382,0.0021312323,0.0006162599,0.00009649763,0.000053113756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047245895,0.00078685663,0.008800964,0.00035676363,0.00010012572,0.000010882616,0.00031889149,0.00055961,0.00007469934],"category_scores_gemma":[0.00013531017,0.00034786118,0.0007784714,0.00083396514,0.00073510985,0.000047128,0.00014036919,0.0005085972,0.0000033912968],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011953368,0.0023992911,0.7573231,0.09889557,0.13636112,0.000030581392,0.00019657619,6.7714984e-7,6.955353e-7,0.000047807844,0.00006693419,0.003482292],"study_design_scores_gemma":[0.007930477,0.0034523448,0.044855054,0.08022966,0.8613618,0.000047981724,0.00015207804,3.9472826e-7,0.0005923634,0.0000075480875,0.00027535154,0.0010949291],"about_ca_topic_score_codex":0.00039551308,"about_ca_topic_score_gemma":0.00036079678,"teacher_disagreement_score":0.7250007,"about_ca_system_score_codex":0.000054602355,"about_ca_system_score_gemma":0.00011185237,"threshold_uncertainty_score":0.99989736},"labels":[],"label_agreement":null},{"id":"W4406510104","doi":"10.1016/j.yspm.2012.09.014","title":"10.1016/j.yspm.2012.09.014","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Association (psychology); Physical activity; Environmental health; Physical therapy; Dermatology","score_opus":0.007760607068071075,"score_gpt":0.17977334986702795,"score_spread":0.17201274279895687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406510104","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008410256,0.0013504701,4.236815e-7,0.00016731,0.000012058512,0.00018743609,0.00006277672,0.00016770218,0.98964155],"genre_scores_gemma":[0.0008615283,0.0000022302681,0.000035592933,0.000037939088,0.000077078774,0.000035485027,0.00015628591,0.000022786438,0.9987711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906653,0.00010522773,0.00016951888,0.00027011376,0.000027871974,0.00036073066],"domain_scores_gemma":[0.9995202,0.00006425154,0.000029260413,0.0003171399,0.000025035446,0.00004412951],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000100232464,0.00018795374,0.00023098529,0.00007520168,0.00013775118,0.000013013046,0.000198824,0.00018538996,0.9981181],"category_scores_gemma":[0.000012883965,0.00016433361,0.00009896123,0.00013055131,0.000049740604,0.000073891686,0.00003229909,0.0000890317,0.99875355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022855596,0.000089778936,8.273568e-7,0.000002016207,0.0001246738,0.000005570317,0.00002336881,0.0000027036738,0.0029592002,0.0000013562143,0.25412622,0.7424357],"study_design_scores_gemma":[0.0007953285,0.00022068684,0.00020199345,0.000010070173,0.00008682634,0.000031461204,0.000001268201,7.814357e-7,0.004638066,0.0000057558277,0.99381036,0.0001973795],"about_ca_topic_score_codex":0.00002443453,"about_ca_topic_score_gemma":5.878468e-7,"teacher_disagreement_score":0.74223834,"about_ca_system_score_codex":0.000025921801,"about_ca_system_score_gemma":0.00002334296,"threshold_uncertainty_score":0.67013305},"labels":[],"label_agreement":null},{"id":"W4406545921","doi":"10.1016/s1541-9800(12)70379-4","title":"10.1016/s1541-9800(12)70379-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Morning; Psoriasis; Morning stiffness; Medicine; Dermatology; Arthritis; Internal medicine; Psoriatic arthritis","score_opus":0.00813424435936368,"score_gpt":0.17666581626306285,"score_spread":0.16853157190369916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545921","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008091856,0.0008552821,3.154261e-7,0.00017786857,0.000011414632,0.00020277349,0.00006883809,0.00017418602,0.9904175],"genre_scores_gemma":[0.0011765781,0.0000023979114,0.000037744183,0.000048455764,0.000077169345,0.000040066287,0.00018092827,0.000024202316,0.99841243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900264,0.00010711163,0.00018374351,0.00029545778,0.000030823623,0.0003802538],"domain_scores_gemma":[0.9994915,0.000070771464,0.0000310272,0.00033618076,0.000024033658,0.000046472465],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010174838,0.00020240016,0.00024495178,0.00008069767,0.00015132791,0.000014544348,0.00021576244,0.0001930175,0.99824786],"category_scores_gemma":[0.000016833383,0.00017961641,0.00010746731,0.0001239392,0.000053448064,0.000060000264,0.000035578705,0.00009619585,0.9986181],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028349733,0.00010333139,0.0000013059955,0.0000023523396,0.00014012156,0.000008112813,0.000030217856,0.0000035094558,0.0029831722,0.0000013182494,0.2889855,0.70745754],"study_design_scores_gemma":[0.00088814285,0.00024698515,0.00026841252,0.000011436922,0.00009057744,0.000035077213,0.0000015864808,9.2832136e-7,0.005168621,0.0000069276334,0.9930689,0.00021242142],"about_ca_topic_score_codex":0.00003137747,"about_ca_topic_score_gemma":8.1064695e-7,"teacher_disagreement_score":0.7072451,"about_ca_system_score_codex":0.000031101317,"about_ca_system_score_gemma":0.000027024793,"threshold_uncertainty_score":0.7324545},"labels":[],"label_agreement":null},{"id":"W4406545973","doi":"10.1016/s1541-9800(12)70261-2","title":"10.1016/s1541-9800(12)70261-2","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Psychology","score_opus":0.008234726655050595,"score_gpt":0.17696709853427073,"score_spread":0.16873237187922013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406545973","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008289027,0.0008713856,3.2684622e-7,0.00015227834,0.000011379376,0.00020024605,0.00006878972,0.0001743773,0.99023217],"genre_scores_gemma":[0.0012249816,0.0000023997004,0.00003913824,0.000047100544,0.00007614453,0.000039391205,0.00018114418,0.000024504583,0.9983652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990063,0.000106233725,0.00018321261,0.00029467995,0.000030675994,0.00037892134],"domain_scores_gemma":[0.9994967,0.00006678957,0.00003099358,0.00033553367,0.000023882407,0.000046100246],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010084689,0.00020193803,0.00024456638,0.00008068533,0.00015161044,0.000014540736,0.00021561388,0.0001912478,0.99833035],"category_scores_gemma":[0.00001584107,0.00017923638,0.000107217405,0.00012337812,0.000053588,0.00005992653,0.00003516941,0.00009594574,0.99867284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028476745,0.00010303774,0.0000012964528,0.000002363338,0.00013973536,0.0000079151005,0.000032136064,0.0000033180413,0.0030108602,0.0000012531211,0.28293926,0.71347404],"study_design_scores_gemma":[0.000883014,0.0002468127,0.00025758942,0.000011344725,0.00009039494,0.00003486994,0.0000016526739,9.641267e-7,0.0049851453,0.0000068815757,0.99326926,0.00021209307],"about_ca_topic_score_codex":0.000032263328,"about_ca_topic_score_gemma":8.0244916e-7,"teacher_disagreement_score":0.71326196,"about_ca_system_score_codex":0.00003077246,"about_ca_system_score_gemma":0.000026279375,"threshold_uncertainty_score":0.7309047},"labels":[],"label_agreement":null},{"id":"W4406546674","doi":"10.1016/s1541-9800(08)70631-8","title":"10.1016/s1541-9800(08)70631-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Intensive care medicine; Dermatology","score_opus":0.00766920548401004,"score_gpt":0.178416645865975,"score_spread":0.17074744038196496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406546674","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0111866975,0.000906723,2.8630964e-7,0.00016453976,0.000011220759,0.00019877973,0.0000700291,0.0001740415,0.9872877],"genre_scores_gemma":[0.0013655422,0.0000024584685,0.00003725225,0.000047225665,0.00008152207,0.000040840638,0.00018305572,0.000024270561,0.9982178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990042,0.00010614557,0.00018414727,0.0002948502,0.00003061782,0.00038004166],"domain_scores_gemma":[0.9994918,0.00006617704,0.00003107898,0.0003366906,0.000027669254,0.000046544134],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010198379,0.00020243406,0.0002468188,0.000084373925,0.00015102491,0.000014708791,0.00021828456,0.00019561884,0.99845916],"category_scores_gemma":[0.000016079986,0.00017976548,0.00010858375,0.00016004962,0.00005408557,0.000059774247,0.000037237784,0.000096814445,0.99897707],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002636294,0.00010317851,0.0000011093299,0.0000023515233,0.0001378349,0.0000075701496,0.000035495606,0.000003511218,0.00283769,0.0000012764473,0.2811221,0.71548426],"study_design_scores_gemma":[0.0009049298,0.00023078712,0.00023432975,0.0000111064655,0.00008805397,0.00003495696,0.000001834878,9.91877e-7,0.005228384,0.0000069339826,0.9930455,0.00021216056],"about_ca_topic_score_codex":0.000033885535,"about_ca_topic_score_gemma":5.78123e-7,"teacher_disagreement_score":0.71527207,"about_ca_system_score_codex":0.000031099124,"about_ca_system_score_gemma":0.000027304182,"threshold_uncertainty_score":0.7330623},"labels":[],"label_agreement":null},{"id":"W4406546684","doi":"10.1016/s1541-9800(08)70430-7","title":"10.1016/s1541-9800(08)70430-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Skin cancer; Medicine; Oncology; Internal medicine; Cancer; Dermatology","score_opus":0.0076657092603585235,"score_gpt":0.1783964484242583,"score_spread":0.17073073916389978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406546684","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0100013,0.0010154584,3.1200733e-7,0.00016621478,0.000011775094,0.00020103047,0.00007282536,0.00017563718,0.98835546],"genre_scores_gemma":[0.0013474828,0.0000022812364,0.000040116294,0.000046054043,0.00007779621,0.00004082806,0.00018003448,0.000024254981,0.9982411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989977,0.000108144304,0.00018465899,0.00029712883,0.000030946107,0.00038143806],"domain_scores_gemma":[0.99948967,0.00006710712,0.000031207765,0.00033742,0.000027957301,0.000046624235],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010339365,0.0002029723,0.0002463548,0.00008189859,0.00015239687,0.000014592114,0.00021703867,0.00019558835,0.9984132],"category_scores_gemma":[0.000016325195,0.00018012003,0.00010889077,0.0001565,0.00005401691,0.000059072183,0.000035604855,0.000097545395,0.9989705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002593304,0.00010480663,0.0000010178143,0.000002386331,0.00013946625,0.000008136099,0.000030485106,0.0000037420873,0.0029761214,0.0000014386183,0.28439432,0.71207875],"study_design_scores_gemma":[0.00090439187,0.00023296436,0.0002210226,0.0000113705055,0.00009023728,0.000034855093,0.0000017462322,0.0000010243087,0.0055516306,0.000006954756,0.99273074,0.00021307173],"about_ca_topic_score_codex":0.000028947868,"about_ca_topic_score_gemma":4.88483e-7,"teacher_disagreement_score":0.71186566,"about_ca_system_score_codex":0.000031065392,"about_ca_system_score_gemma":0.000027226934,"threshold_uncertainty_score":0.73450816},"labels":[],"label_agreement":null},{"id":"W4406550392","doi":"10.1016/s1541-9800(05)70521-4","title":"10.1016/s1541-9800(05)70521-4","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Methotrexate; Medicine; Dermatology; Psoriasis; Arthritis; Internal medicine","score_opus":0.007784401176313781,"score_gpt":0.17906964259692904,"score_spread":0.17128524142061524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550392","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010603762,0.00094907434,2.983019e-7,0.00018230003,0.000013598294,0.00020245297,0.00007364386,0.00017673938,0.98779815],"genre_scores_gemma":[0.0013854421,0.000002152775,0.00003806052,0.00005393993,0.000077578035,0.000038056383,0.00018612723,0.000023985214,0.99819463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900264,0.00010556509,0.00018320451,0.0002953151,0.000030770352,0.00038250332],"domain_scores_gemma":[0.99949193,0.000067132045,0.000030966094,0.00033572162,0.000027480854,0.00004677802],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010174823,0.00020251074,0.00024510696,0.00008187876,0.00015132636,0.000014625843,0.0002159162,0.00019459949,0.99823606],"category_scores_gemma":[0.000016091199,0.00017952337,0.000108573404,0.00015475793,0.000053526044,0.00006012326,0.00003504492,0.00009632689,0.99865144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002510853,0.00009819177,7.8869266e-7,0.0000022192678,0.00012878398,0.000009340211,0.000029774383,0.0000033478518,0.0028828501,0.0000012313767,0.3284985,0.66809386],"study_design_scores_gemma":[0.00090262864,0.00026158124,0.00019681455,0.00001132359,0.000089874746,0.000044845918,0.0000018162436,9.862995e-7,0.0056872154,0.0000069664716,0.9925841,0.00021181942],"about_ca_topic_score_codex":0.000032073258,"about_ca_topic_score_gemma":5.470915e-7,"teacher_disagreement_score":0.667882,"about_ca_system_score_codex":0.000031039588,"about_ca_system_score_gemma":0.000026998003,"threshold_uncertainty_score":0.7320751},"labels":[],"label_agreement":null},{"id":"W4406550627","doi":"10.1016/s1541-9800(10)70140-x","title":"10.1016/s1541-9800(10)70140-x","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Adalimumab; Psoriasis; Medicine; Dermatology; Internal medicine; Tumor necrosis factor alpha","score_opus":0.007883848485110553,"score_gpt":0.17863708875819678,"score_spread":0.17075324027308622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550627","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073089725,0.0010216692,2.6500817e-7,0.00015959762,0.000010800517,0.0001969375,0.0000764793,0.00017589345,0.9910494],"genre_scores_gemma":[0.0009942184,0.000002237853,0.000037014295,0.000041311403,0.000081237675,0.0000427037,0.00021972947,0.0000253234,0.9985562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998964,0.00011318475,0.00019128426,0.00030858532,0.000032347856,0.00039060786],"domain_scores_gemma":[0.999462,0.00007200756,0.000033520533,0.00035206502,0.000032391952,0.000048025588],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000108071195,0.00021230793,0.00025625248,0.00008074538,0.00015936437,0.00001543698,0.00022432726,0.00020906227,0.9990857],"category_scores_gemma":[0.000018822351,0.00018862615,0.00011720935,0.00015686333,0.000056296238,0.000061017337,0.0000378956,0.00009300693,0.99919516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032625764,0.00010251669,5.7296523e-7,0.000002449744,0.00013838819,0.000007172824,0.000025718566,0.0000033680988,0.0024939259,0.0000010331592,0.41464826,0.58225036],"study_design_scores_gemma":[0.00092496944,0.0002769968,0.00016578234,0.000011410192,0.00009679837,0.000030983858,0.0000017226411,0.0000011661709,0.005187611,0.0000064353485,0.99307454,0.00022157235],"about_ca_topic_score_codex":0.00002626064,"about_ca_topic_score_gemma":5.2920063e-7,"teacher_disagreement_score":0.58202875,"about_ca_system_score_codex":0.000032310443,"about_ca_system_score_gemma":0.000028812452,"threshold_uncertainty_score":0.7691951},"labels":[],"label_agreement":null},{"id":"W4406550672","doi":"10.1016/s1541-9800(10)70251-9","title":"10.1016/s1541-9800(10)70251-9","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Disease; Medicine; Dermatology; Internal medicine","score_opus":0.007889150981310357,"score_gpt":0.17900411334788366,"score_spread":0.1711149623665733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550672","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008101123,0.0010258476,2.6910854e-7,0.00015825592,0.000010900398,0.0002014672,0.00007945766,0.00017715411,0.9902455],"genre_scores_gemma":[0.0009199074,0.0000021311769,0.00003740851,0.00004093941,0.00007943155,0.000043369037,0.00021998759,0.00002508584,0.9986317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895287,0.00011478471,0.00019411242,0.00031106643,0.00003249996,0.0003946641],"domain_scores_gemma":[0.9994551,0.00007404854,0.00003375685,0.00035572256,0.00003298086,0.00004841307],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010775707,0.00021438999,0.00025929598,0.00008630872,0.00016147527,0.00001595921,0.00022852533,0.00020942552,0.9991554],"category_scores_gemma":[0.000019662259,0.0001906142,0.000115425726,0.00015970279,0.000057825306,0.00006232813,0.000038568935,0.00009308816,0.99921364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033222706,0.00010593575,6.1695545e-7,0.0000024939504,0.00014092925,0.000007727218,0.00002679457,0.0000032879213,0.002487848,0.0000011084035,0.40072465,0.5961664],"study_design_scores_gemma":[0.00094182283,0.00026917833,0.0001757873,0.000011868962,0.00009788304,0.000031043084,0.0000017057774,0.0000011629492,0.005196781,0.0000062599215,0.99304366,0.00022285256],"about_ca_topic_score_codex":0.000027466023,"about_ca_topic_score_gemma":5.4516283e-7,"teacher_disagreement_score":0.5959435,"about_ca_system_score_codex":0.00003344467,"about_ca_system_score_gemma":0.00003114551,"threshold_uncertainty_score":0.77730215},"labels":[],"label_agreement":null},{"id":"W4406555042","doi":"10.1016/s1634-6939(14)56172-8","title":"10.1016/s1634-6939(14)56172-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology","score_opus":0.007492838130364001,"score_gpt":0.17730863832456717,"score_spread":0.16981580019420317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406555042","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008358916,0.0010012501,3.2738959e-7,0.00016506854,0.00001258382,0.00020630781,0.00007105431,0.00017808993,0.9900064],"genre_scores_gemma":[0.0012360555,0.0000022253018,0.00003783075,0.000046939414,0.00007731759,0.000042991232,0.00017602519,0.000024033785,0.9983566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899787,0.00010754749,0.00018409449,0.00029725832,0.00003171485,0.0003815065],"domain_scores_gemma":[0.9994862,0.00006753152,0.00003110837,0.00033731607,0.0000311996,0.00004661042],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010474101,0.00020294663,0.0002457101,0.00008177947,0.00015245953,0.0000147134215,0.00021633443,0.00020079045,0.9981628],"category_scores_gemma":[0.00001695417,0.00018011317,0.00010868143,0.00015624044,0.000054700668,0.00006037958,0.000035515066,0.00009983502,0.99865305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000276788,0.00010238924,9.3143035e-7,0.0000023588298,0.00013619136,0.000007865904,0.000028936596,0.0000035141072,0.0025817521,0.0000013599057,0.29037863,0.70647925],"study_design_scores_gemma":[0.00090910774,0.00023602543,0.00019871075,0.000011388728,0.0000899684,0.000035397676,0.0000015443999,8.1434126e-7,0.0052797794,0.0000065205313,0.9930176,0.0002131498],"about_ca_topic_score_codex":0.000026971014,"about_ca_topic_score_gemma":4.978248e-7,"teacher_disagreement_score":0.7062661,"about_ca_system_score_codex":0.000030658386,"about_ca_system_score_gemma":0.000027042031,"threshold_uncertainty_score":0.7344802},"labels":[],"label_agreement":null},{"id":"W4406564229","doi":"10.1016/j.abdp.2024.07.031","title":"10.1016/j.abdp.2024.07.031","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Humanities; Philosophy","score_opus":0.007954313526716968,"score_gpt":0.18150631800698286,"score_spread":0.1735520044802659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406564229","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007836486,0.0010584602,2.6135353e-7,0.00016067931,0.000016642754,0.00018284128,0.000068859226,0.00016243737,0.9905133],"genre_scores_gemma":[0.00093846954,0.0000022677407,0.00003246647,0.000043654807,0.00007834965,0.000038434515,0.00013190696,0.00002337311,0.99871105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990727,0.000096635136,0.0001700051,0.0002809665,0.000028283006,0.000351417],"domain_scores_gemma":[0.9995301,0.000064528125,0.0000271539,0.00031133133,0.000024655908,0.000042256852],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009488735,0.00018832163,0.00022877118,0.000075320255,0.0001331678,0.000013957683,0.00019532478,0.00018121317,0.99888533],"category_scores_gemma":[0.000014857352,0.00016658366,0.000105680636,0.00014305107,0.00004729879,0.000052373747,0.00003400466,0.000096957534,0.999136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022746924,0.00008603841,0.0000011154615,0.0000022763766,0.00013417339,0.000007419841,0.000026784877,0.0000035495766,0.0020231204,0.0000010904331,0.33099988,0.6664871],"study_design_scores_gemma":[0.0007378232,0.00022360118,0.00016899523,0.000011379406,0.00009173526,0.00003335742,0.0000019162476,0.0000010402589,0.0038667875,0.000006105819,0.99466074,0.00019654911],"about_ca_topic_score_codex":0.000030133231,"about_ca_topic_score_gemma":4.4552516e-7,"teacher_disagreement_score":0.6662905,"about_ca_system_score_codex":0.000028852426,"about_ca_system_score_gemma":0.000026438789,"threshold_uncertainty_score":0.6793085},"labels":[],"label_agreement":null},{"id":"W4406577405","doi":"10.1016/s1544-8800(12)70328-7","title":"10.1016/s1544-8800(12)70328-7","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Disease; Internal medicine","score_opus":0.008162975977635345,"score_gpt":0.17684780733867872,"score_spread":0.16868483136104337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406577405","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008849312,0.00072120415,3.429521e-7,0.0001565318,0.000011545477,0.0002014838,0.000066048706,0.00017265484,0.9898209],"genre_scores_gemma":[0.0012507053,0.000002204344,0.000041008112,0.000040999275,0.00007857044,0.00003932976,0.00016342007,0.000024091874,0.9983597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990089,0.00010633309,0.00018291557,0.0002937599,0.000030449219,0.0003776728],"domain_scores_gemma":[0.9995003,0.00006726033,0.000030147028,0.00033250492,0.000023672163,0.00004611115],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00009811568,0.00020124165,0.00024433684,0.00007882908,0.0001559563,0.000014913984,0.0002109142,0.00019269637,0.99830526],"category_scores_gemma":[0.00001521583,0.00017882996,0.000107076485,0.000117965654,0.000053456606,0.00005820206,0.000035022476,0.00009596473,0.9987633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002842803,0.000100546255,0.0000011470539,0.0000022875738,0.00013451686,0.000007901747,0.000029127046,0.000004062721,0.0029834018,0.0000012799873,0.26527253,0.73117894],"study_design_scores_gemma":[0.0008658842,0.00024787502,0.0003525397,0.000010872976,0.000090041045,0.00003575998,0.0000015966967,0.0000010787476,0.0049896324,0.0000058285214,0.99318755,0.00021137296],"about_ca_topic_score_codex":0.00004244145,"about_ca_topic_score_gemma":0.0000010390955,"teacher_disagreement_score":0.7309675,"about_ca_system_score_codex":0.00003091505,"about_ca_system_score_gemma":0.000027092357,"threshold_uncertainty_score":0.7292474},"labels":[],"label_agreement":null},{"id":"W4406579345","doi":"10.1016/s1541-9800(11)70540-3","title":"10.1016/s1541-9800(11)70540-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Dermatology; Computer science","score_opus":0.007572300314115722,"score_gpt":0.17780663513476394,"score_spread":0.17023433482064823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579345","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014830598,0.00090800243,3.2779442e-7,0.00018555883,0.000012494568,0.00020494561,0.000072056486,0.00017818612,0.9836078],"genre_scores_gemma":[0.0015108662,0.0000019514778,0.000042241074,0.000046344554,0.000077701916,0.000040494142,0.0001825501,0.000023959059,0.9980739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999004,0.00010846699,0.00018301315,0.00029602734,0.00003082265,0.00037765838],"domain_scores_gemma":[0.99948376,0.00007243439,0.000030981013,0.0003400809,0.000027296657,0.00004543978],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001037104,0.00020134609,0.00024310853,0.00008053694,0.00015125786,0.000014877029,0.00022304541,0.00019504143,0.9983057],"category_scores_gemma":[0.000016232625,0.00017895323,0.00010748386,0.00015301914,0.000054858483,0.000059375365,0.000036370107,0.00008354161,0.99844086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002136407,0.0001086597,0.0000023137302,0.000002586139,0.00011989432,0.000008200104,0.0000311321,0.0000041906164,0.002543561,0.0000016157032,0.3073819,0.6895823],"study_design_scores_gemma":[0.0008551182,0.00019405698,0.00029096304,0.000011092009,0.00009074512,0.000034651934,0.0000017748922,0.0000010338354,0.0052290224,0.0000063016005,0.99307364,0.00021162126],"about_ca_topic_score_codex":0.000041663145,"about_ca_topic_score_gemma":0.0000010836419,"teacher_disagreement_score":0.6893707,"about_ca_system_score_codex":0.000030188987,"about_ca_system_score_gemma":0.000026244992,"threshold_uncertainty_score":0.7297501},"labels":[],"label_agreement":null},{"id":"W4406579467","doi":"10.1016/s1541-9800(07)70372-1","title":"10.1016/s1541-9800(07)70372-1","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Efalizumab; Clearance; Psoriasis; Foot (prosody); Medicine; Dermatology; Plaque psoriasis; Art","score_opus":0.007813739838801098,"score_gpt":0.1793674420697206,"score_spread":0.1715537022309195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579467","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010295126,0.0010281723,3.103179e-7,0.00016531255,0.000011534395,0.00020163058,0.00007391973,0.0001757696,0.9880482],"genre_scores_gemma":[0.0013448178,0.000002351621,0.000038735918,0.000047199257,0.000077568264,0.000040275405,0.0001783415,0.00002421583,0.9982465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99899983,0.00010754411,0.00018415964,0.00029668157,0.000030894516,0.00038087976],"domain_scores_gemma":[0.9994893,0.00006756357,0.00003111772,0.00033749046,0.000027926475,0.00004658665],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010293077,0.00020269591,0.00024599046,0.00007750644,0.00015290629,0.000014684228,0.00021669418,0.00019533245,0.9987648],"category_scores_gemma":[0.000016330017,0.00017991055,0.000108880224,0.0001397875,0.000054007236,0.000060322684,0.000035577483,0.00009712823,0.9992829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027242277,0.000106788946,0.0000010035565,0.0000024053172,0.00014186233,0.000008653628,0.000030527972,0.000003608695,0.0027662755,0.0000013389596,0.29280376,0.70386136],"study_design_scores_gemma":[0.0008805449,0.00023603832,0.0002115299,0.000011223955,0.00009043138,0.00003688645,0.0000016914696,9.395921e-7,0.005158274,0.000007231501,0.99315226,0.00021296558],"about_ca_topic_score_codex":0.000030374329,"about_ca_topic_score_gemma":4.6740496e-7,"teacher_disagreement_score":0.7036484,"about_ca_system_score_codex":0.00003107469,"about_ca_system_score_gemma":0.000027478998,"threshold_uncertainty_score":0.7336539},"labels":[],"label_agreement":null},{"id":"W4406579897","doi":"10.1016/s1541-9800(07)70431-3","title":"10.1016/s1541-9800(07)70431-3","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Medicine; Tumor necrosis factor alpha; Dermatology; Internal medicine","score_opus":0.007804115216786446,"score_gpt":0.17911520535756942,"score_spread":0.17131109014078297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406579897","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010145739,0.0009433371,3.0159197e-7,0.00015894958,0.000011586609,0.00019946983,0.00006891674,0.00017510292,0.98829657],"genre_scores_gemma":[0.001307629,0.0000023232244,0.000038716124,0.000046989237,0.00007715836,0.00004094811,0.00018034427,0.00002421916,0.99828166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990038,0.00010569613,0.00018379845,0.00029732753,0.000030764346,0.000378569],"domain_scores_gemma":[0.99948865,0.00006714742,0.000031091684,0.00033858724,0.000028021952,0.000046503126],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000102211656,0.00020233769,0.0002461358,0.000077343946,0.0001514368,0.000014695656,0.00021815901,0.00019496508,0.99869496],"category_scores_gemma":[0.000016505941,0.00017966368,0.00010678056,0.00014229723,0.00005383555,0.00006016424,0.00003711914,0.00009671613,0.99925894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002717892,0.00010510239,0.0000011566075,0.0000023711718,0.00013961882,0.000008345955,0.000029008646,0.0000034116963,0.0024982877,0.0000013547741,0.28026977,0.7166698],"study_design_scores_gemma":[0.00088290573,0.00023381875,0.00024047933,0.00001120317,0.00009023512,0.000036802838,0.0000016647874,9.632332e-7,0.004894871,0.0000075977127,0.99338675,0.00021271195],"about_ca_topic_score_codex":0.000033084292,"about_ca_topic_score_gemma":4.922769e-7,"teacher_disagreement_score":0.71645707,"about_ca_system_score_codex":0.00003093657,"about_ca_system_score_gemma":0.00002754055,"threshold_uncertainty_score":0.73264724},"labels":[],"label_agreement":null},{"id":"W4406620870","doi":"10.1016/j.jaad.2024.12.034","title":"Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Women's College Hospital; Dermatrials Research; Probity Medical Research; SKiN Health; University of Calgary; University of Toronto","funders":"Women's College Hospital","keywords":"Medicine; Plaque psoriasis; Psoriasis; Multicenter study; Interleukin; Retrospective cohort study; Dermatology; Interleukin 17; Internal medicine; Cytokine; Randomized controlled trial","score_opus":0.00941404489685831,"score_gpt":0.28059734968477007,"score_spread":0.27118330478791175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406620870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262744,0.0015676534,0.00002953092,0.0045717508,0.00033059894,0.00074002106,0.000054097665,0.0000061645774,0.000072714894],"genre_scores_gemma":[0.99656844,0.0012771476,0.0007768572,0.0011436812,0.000018676086,0.000061736624,0.0000035449025,0.000013891618,0.00013602627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790376,0.0003781731,0.00109333,0.00023675124,0.00009060098,0.00029736408],"domain_scores_gemma":[0.99744844,0.0003113474,0.001739078,0.0002018451,0.00026652412,0.000032783686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014951125,0.00022904754,0.001195085,0.00042778355,0.000059149217,0.0000032014932,0.0005548835,0.000119909455,0.00001544961],"category_scores_gemma":[0.00028105406,0.00014596366,0.0002629796,0.00071687106,0.0004239651,0.00010256901,0.000113223374,0.00033448503,0.0000021742765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011489248,0.0013829368,0.9274086,0.00059042434,0.0015307222,0.000011463224,0.0035735203,0.000008525282,0.015868507,0.00029895722,0.0136686815,0.024168454],"study_design_scores_gemma":[0.011755904,0.0019715058,0.7754947,0.0063546896,0.0007928966,0.00014987624,0.0010585986,0.000001447052,0.19647922,0.00009812206,0.005503136,0.00033990556],"about_ca_topic_score_codex":0.0000930632,"about_ca_topic_score_gemma":0.00007151641,"teacher_disagreement_score":0.1806107,"about_ca_system_score_codex":0.00014200069,"about_ca_system_score_gemma":0.0001198707,"threshold_uncertainty_score":0.59522253},"labels":[],"label_agreement":null},{"id":"W4406662629","doi":"10.1016/j.jid.2024.12.025","title":"Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Boehringer Ingelheim","keywords":"Plaque psoriasis; Psoriasis; Dermatology; Medicine; Randomized controlled trial; RAR-related orphan receptor gamma; Pharmacology; Internal medicine; Immunology","score_opus":0.0297421741863885,"score_gpt":0.3041298550137833,"score_spread":0.2743876808273948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406662629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897327,0.0010616932,0.001816073,0.0030949172,0.0025763388,0.0013192776,0.0001430457,0.00002224745,0.00023372602],"genre_scores_gemma":[0.9946992,0.000084128726,0.003675317,0.00070210977,0.00012000867,0.00014491421,0.00008937937,0.000022205379,0.00046274278],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99617356,0.0015373554,0.0015262566,0.00029788332,0.00007283542,0.00039208346],"domain_scores_gemma":[0.9968712,0.0010986978,0.0010123495,0.0002567572,0.00065375905,0.00010729032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008858484,0.00034980392,0.002035568,0.00066146743,0.00027377065,0.000015124097,0.0003597997,0.00048866426,0.00006404711],"category_scores_gemma":[0.00135128,0.0002684607,0.0005395406,0.00033719375,0.0007097287,0.00024898362,0.00007923973,0.0003003723,0.000010587595],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8108936,0.0018785645,0.000028435066,0.000055581135,0.0025093968,0.000031492167,0.0018886732,0.00004563254,0.15943676,0.007181809,0.0119831925,0.0040668827],"study_design_scores_gemma":[0.5100893,0.0024075054,0.00000857868,0.00007132939,0.00057904195,0.00018034883,0.0002383779,0.000024320494,0.47770828,0.0058105276,0.0027372264,0.00014516556],"about_ca_topic_score_codex":0.000024354498,"about_ca_topic_score_gemma":0.000025744865,"teacher_disagreement_score":0.31827152,"about_ca_system_score_codex":0.0000639524,"about_ca_system_score_gemma":0.0006907709,"threshold_uncertainty_score":0.99997675},"labels":[],"label_agreement":null},{"id":"W4406699579","doi":"10.1093/ecco-jcc/jjae190.1148","title":"P0974 Risk factors for anti-TNFα induced paradoxical psoriasis in Inflammatory Bowel Disease and association with an IL-23 receptor polymorphism: A retrospective study","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Inflammatory bowel disease; Psoriasis; Tumor necrosis factor alpha; Crohn's disease; Immunology; Disease; Internal medicine; Gastroenterology","score_opus":0.010214536008457759,"score_gpt":0.2449327321271428,"score_spread":0.23471819611868505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406699579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978376,0.00089587324,0.000013148357,0.00014807432,0.00040761926,0.00046135535,0.0002063387,0.000010037614,0.000019962235],"genre_scores_gemma":[0.99918246,0.0003897977,0.00003414113,0.000027199145,0.00006807854,0.0000325665,0.000016884163,0.000010750105,0.0002381346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877244,0.0003056217,0.0003841736,0.0002240541,0.00007209179,0.00024162233],"domain_scores_gemma":[0.9990699,0.00020445015,0.00039286222,0.00010874631,0.00014978119,0.00007420607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043867668,0.00018059256,0.00042413926,0.00021895845,0.00020926048,0.000054128603,0.00008019501,0.000183178,0.000018067034],"category_scores_gemma":[0.00020197738,0.0001370186,0.000078665435,0.00012531303,0.00005257761,0.00020992837,0.000023996092,0.0002250031,9.888337e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006052826,0.0004995661,0.98656166,0.000013792119,0.0007621703,0.00003058485,0.0012971763,7.033761e-7,0.0005385556,0.00019142534,0.00018196726,0.003869557],"study_design_scores_gemma":[0.0054886686,0.0014795839,0.9887336,0.00006177187,0.0005220172,0.000007741872,0.0018474015,0.0000020928944,0.0010385975,0.0004087797,0.0002686278,0.00014113351],"about_ca_topic_score_codex":0.0001195195,"about_ca_topic_score_gemma":0.00016873037,"teacher_disagreement_score":0.0037284237,"about_ca_system_score_codex":0.00015760904,"about_ca_system_score_gemma":0.00014797007,"threshold_uncertainty_score":0.5587456},"labels":[],"label_agreement":null},{"id":"W4406733220","doi":"10.1093/bjd/ljae491","title":"Global Delphi consensus on treatment goals for generalized pustular psoriasis","year":2025,"lang":"en","type":"review","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University","funders":"Boehringer Ingelheim España; Biogen; Amgen","keywords":"Medicine; Delphi method; Disease; Intensive care medicine; Delphi; Psoriasis; Physical therapy; Dermatology; Internal medicine","score_opus":0.039593174392979484,"score_gpt":0.3227014374868438,"score_spread":0.28310826309386433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406733220","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005150548,0.9913554,0.000083923485,0.00019326844,0.004236395,0.001129469,0.0020520876,0.000037410286,0.00039695753],"genre_scores_gemma":[0.00016477736,0.9969308,0.00053370936,0.0001016157,0.00020976143,0.00020355123,0.0005547516,0.00004242805,0.0012586194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99576956,0.0012347755,0.0017627627,0.00049690995,0.00007000178,0.0006659852],"domain_scores_gemma":[0.99666715,0.0012231112,0.0014028805,0.0003455483,0.00027926295,0.0000820607],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002035427,0.0007114918,0.00439646,0.00035861132,0.00027982597,0.000049590464,0.0005068948,0.0013409512,0.00013050578],"category_scores_gemma":[0.00033231912,0.00061710645,0.0022399807,0.00028355667,0.00017639436,0.00003576395,0.000057039044,0.00027549165,0.00008712186],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036656237,0.0004487516,0.000019325225,0.0016805058,0.005679861,0.0027343507,0.000013999,9.888595e-7,0.0000019267873,0.00040547617,0.037110873,0.9515374],"study_design_scores_gemma":[0.006813791,0.0004691196,0.0000113436245,0.0058970526,0.008636708,0.10318701,0.00001929901,1.0169534e-7,0.00007115078,0.00017728706,0.87433064,0.00038647052],"about_ca_topic_score_codex":0.00006626426,"about_ca_topic_score_gemma":0.00008577221,"teacher_disagreement_score":0.9511509,"about_ca_system_score_codex":0.0004446349,"about_ca_system_score_gemma":0.0012829531,"threshold_uncertainty_score":0.99995553},"labels":[],"label_agreement":null},{"id":"W4406808042","doi":"10.2147/dddt.s504485","title":"Tanshinone I Ameliorates Psoriasis-Like Dermatitis by Suppressing Inflammation and Regulating Keratinocyte Differentiation","year":2025,"lang":"en","type":"article","venue":"Drug Design Development and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Natural Science Foundation of China","keywords":"Psoriasis; Keratinocyte; Inflammation; Medicine; Dermatology; Immunology; Biology; Cell culture; Genetics","score_opus":0.014999870614813655,"score_gpt":0.22261221925640662,"score_spread":0.20761234864159298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406808042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97490746,0.017079845,0.006809377,0.00028781887,0.00034555368,0.00036276138,0.0000061057112,0.00008432162,0.000116730684],"genre_scores_gemma":[0.9903379,0.0021539375,0.003996307,0.00011086228,0.000022486247,0.00008884572,0.00034806252,0.000014624573,0.002926972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888194,0.00025599022,0.0003171629,0.0002811353,0.000042566662,0.00022122495],"domain_scores_gemma":[0.99951965,0.0001814668,0.00012526284,0.00010749266,0.000046410136,0.000019695282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023782601,0.00022864444,0.00024077538,0.00013712909,0.0005351911,0.00011299914,0.00006875086,0.00013811332,0.000047014943],"category_scores_gemma":[0.00001180193,0.00019731374,0.00002378085,0.00013569882,0.00006125739,0.0002025062,0.00003064424,0.00008019386,0.000009638963],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013750473,0.000041183626,0.00834161,0.000024532197,0.00034097888,0.0000011115051,0.0034850321,0.0000021611656,0.2771702,0.00012352048,0.0021451262,0.70818704],"study_design_scores_gemma":[0.0029404676,0.000025264215,0.038251687,0.00010450798,0.00004727606,0.0000055968567,0.00022204057,0.000058900754,0.93901426,0.0003762099,0.018686974,0.00026681842],"about_ca_topic_score_codex":0.000011788244,"about_ca_topic_score_gemma":0.0000071842956,"teacher_disagreement_score":0.7079202,"about_ca_system_score_codex":0.000029382836,"about_ca_system_score_gemma":0.00005180073,"threshold_uncertainty_score":0.8046221},"labels":[],"label_agreement":null},{"id":"W4406822184","doi":"10.1093/bjd/ljaf032","title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Cilag; Manchester Biomedical Research Centre; Sanofi Genzyme; Genentech; Medac; L'Oreal USA; Bausch Health; Celltrion; Astellas Pharma; National Institute for Health and Care Research; Pfizer; Biogen; Incyte; Castle Biosciences; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Sanofi; Amgen; Meiji Seika Pharma; Les Laboratories Pierre Fabre; Galderma; LEO Pharma; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Secukinumab; Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Interleukin 17; Plaque psoriasis; Open label; Dosing; Clinical trial; Internal medicine; Dermatology; Psoriatic arthritis; Cytokine","score_opus":0.02186603706440261,"score_gpt":0.27622659060136234,"score_spread":0.25436055353695974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406822184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98954844,0.006127162,0.00007712068,0.0018172706,0.0009961581,0.0009231199,0.000425403,0.000011308958,0.00007401007],"genre_scores_gemma":[0.9978005,0.000987124,0.00025375362,0.0005472451,0.000043877928,0.000018141249,0.00025116798,0.000018416198,0.00007975055],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766314,0.000663816,0.00084987155,0.0003896879,0.000072921575,0.00036057644],"domain_scores_gemma":[0.9987246,0.00045332106,0.00035888245,0.00027449793,0.00013876236,0.00004995686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021315247,0.00023090362,0.0007662705,0.0001252965,0.0002893479,0.00010666617,0.00045996738,0.0003102206,0.000038927068],"category_scores_gemma":[0.00022592969,0.0001871634,0.000059739476,0.00022589412,0.00016958712,0.00026410192,0.0001686972,0.0004043309,0.000011172732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7341068,0.004965193,0.013096737,0.000015710573,0.0018016805,0.0049267067,0.0024345051,0.000020486013,0.00043624124,0.00009214018,0.012178216,0.2259256],"study_design_scores_gemma":[0.66255796,0.0014302832,0.32590988,0.0008297872,0.00041821031,0.0050712726,0.00018516435,0.000002577448,0.00069738936,0.00008527817,0.0024896788,0.00032249372],"about_ca_topic_score_codex":0.0003013693,"about_ca_topic_score_gemma":0.0004647188,"teacher_disagreement_score":0.31281316,"about_ca_system_score_codex":0.000063908854,"about_ca_system_score_gemma":0.00027652367,"threshold_uncertainty_score":0.7632302},"labels":[],"label_agreement":null},{"id":"W4407059329","doi":"10.1177/2050313x251317763","title":"Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases","year":2025,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Ixekizumab; Adverse effect; Acitretin; Refractory (planetary science); Plaque psoriasis; Palmoplantar pustulosis; Ustekinumab; Secukinumab; Internal medicine; Adalimumab; Psoriatic arthritis","score_opus":0.02305846496369153,"score_gpt":0.32817955878473093,"score_spread":0.3051210938210394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407059329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982414,0.0019033222,0.00020213093,0.0010807496,0.002095639,0.0010699737,0.00016031225,0.000059540696,0.011014307],"genre_scores_gemma":[0.98615175,0.000110262874,0.0004914614,0.0005926603,0.000066337845,0.00020335495,0.00029600653,0.000021261165,0.012066886],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9969964,0.0004703055,0.0011789434,0.0007405579,0.00017357053,0.00044021526],"domain_scores_gemma":[0.99731505,0.000986418,0.0004139061,0.00095771154,0.00016085658,0.00016607043],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019266119,0.00029303113,0.0007873314,0.00025187084,0.000248291,0.00002977154,0.00025724215,0.0003760043,0.0032216322],"category_scores_gemma":[0.003921161,0.0002419295,0.00018353463,0.00047452498,0.00019730501,0.000098151744,0.00052824337,0.00025961647,0.0000691173],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009747861,0.00027602454,0.00442399,0.00003896315,0.0006345225,0.91215444,0.00031509425,9.0143345e-7,0.003822116,0.00019091625,0.016171921,0.060996335],"study_design_scores_gemma":[0.0023102937,0.00029320832,0.0015002297,0.0005737352,0.0004980158,0.79718816,0.0006447795,5.1690853e-7,0.07952721,0.0003756747,0.11675218,0.00033600727],"about_ca_topic_score_codex":0.004099659,"about_ca_topic_score_gemma":0.0015507463,"teacher_disagreement_score":0.11496627,"about_ca_system_score_codex":0.00007113312,"about_ca_system_score_gemma":0.0010492189,"threshold_uncertainty_score":0.99768955},"labels":[],"label_agreement":null},{"id":"W4407134354","doi":"10.1007/s13555-025-01342-0","title":"Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto; Lynde Centre for Dermatology","funders":"AbbVie","keywords":"Observational study; Interim; Medicine; Psoriasis; Interim analysis; Value (mathematics); Dermatology; Internal medicine; Clinical trial; Political science; Statistics; Mathematics","score_opus":0.013512419789648596,"score_gpt":0.26710814172110503,"score_spread":0.2535957219314564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407134354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969101,0.0010746572,0.000025820787,0.00012998944,0.00018567308,0.0011309764,0.00022237083,0.000023859213,0.00029657627],"genre_scores_gemma":[0.9992558,0.000050037885,0.00003717491,0.00014274774,0.0000049832906,0.00019964905,0.0002599781,0.000007902385,0.00004172707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724996,0.0016871879,0.00033139365,0.00044746615,0.000052976557,0.00023100794],"domain_scores_gemma":[0.9983276,0.0010901024,0.00013640252,0.00028779704,0.000142257,0.000015811742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003173958,0.0002467477,0.00063237135,0.00017488665,0.00024221493,0.000011748039,0.00019059778,0.00015191553,0.00004095366],"category_scores_gemma":[0.00004526904,0.00016258872,0.00008948306,0.00079943397,0.0001264242,0.000056766807,0.00009379622,0.00011856661,0.000004708437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02626128,0.00074949156,0.9634211,0.000009514888,0.0054277442,0.0000065396357,0.0009011652,0.00009031899,0.00019032432,0.0005853541,0.00001875602,0.0023383764],"study_design_scores_gemma":[0.0096628405,0.00024583007,0.98710924,0.000055166372,0.0004873308,0.0000021357214,0.00031453162,0.000014216673,0.0015328635,0.00040491667,0.000022381122,0.00014852207],"about_ca_topic_score_codex":0.0017501139,"about_ca_topic_score_gemma":0.003039141,"teacher_disagreement_score":0.023688128,"about_ca_system_score_codex":0.00010771987,"about_ca_system_score_gemma":0.00006550622,"threshold_uncertainty_score":0.6630176},"labels":[],"label_agreement":null},{"id":"W4407240390","doi":"10.36469/jheor.2025.127820","title":"Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Retrospective cohort study; Medicine; Drug; Cohort; Internal medicine; Dermatology; Pharmacology","score_opus":0.03267356853526875,"score_gpt":0.36064143991909187,"score_spread":0.3279678713838231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407240390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854684,0.010137387,0.0000022294041,0.0028193041,0.00068657595,0.00046395676,0.000025739782,0.000004590932,0.0003918009],"genre_scores_gemma":[0.9828412,0.015243088,0.000044067332,0.00018431908,0.00002645418,0.000013764565,0.0000021540184,0.00000739104,0.0016375659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982196,0.0005797618,0.00058520446,0.00023281651,0.000047813166,0.00033478995],"domain_scores_gemma":[0.9989212,0.0004446637,0.00023178107,0.00017253235,0.00017651498,0.000053297073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039358158,0.00012564962,0.0007060804,0.0003950986,0.00043257832,0.00004308397,0.00014574644,0.00008320775,0.000019528823],"category_scores_gemma":[0.00014034196,0.00009862794,0.00006977206,0.0001385794,0.00013016358,0.00011118125,0.00011587907,0.00040730825,0.0000058869728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019004689,0.0001844159,0.948332,0.000025806852,0.0005882831,0.000004736028,0.00086785085,5.1162374e-7,0.0000093360295,0.00036098986,0.0007821895,0.04865385],"study_design_scores_gemma":[0.002562725,0.0003650317,0.9890712,0.000024841751,0.000028150149,0.000026903706,0.0013925477,0.000002025659,0.000047847174,0.0007910286,0.005619743,0.00006796206],"about_ca_topic_score_codex":0.00046608073,"about_ca_topic_score_gemma":0.00035605737,"teacher_disagreement_score":0.048585888,"about_ca_system_score_codex":0.00023429103,"about_ca_system_score_gemma":0.0003421527,"threshold_uncertainty_score":0.40219307},"labels":[],"label_agreement":null},{"id":"W4407253168","doi":"10.36469/001c.127820","title":"Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Cohort; Medical prescription; Prescription drug; Family medicine; Internal medicine; Dermatology; Pharmacology","score_opus":0.03267356853526875,"score_gpt":0.36064143991909187,"score_spread":0.3279678713838231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407253168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854684,0.010137387,0.0000022294041,0.0028193041,0.00068657595,0.00046395676,0.000025739782,0.000004590932,0.0003918009],"genre_scores_gemma":[0.9828412,0.015243088,0.000044067332,0.00018431908,0.00002645418,0.000013764565,0.0000021540184,0.00000739104,0.0016375659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982196,0.0005797618,0.00058520446,0.00023281651,0.000047813166,0.00033478995],"domain_scores_gemma":[0.9989212,0.0004446637,0.00023178107,0.00017253235,0.00017651498,0.000053297073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039358158,0.00012564962,0.0007060804,0.0003950986,0.00043257832,0.00004308397,0.00014574644,0.00008320775,0.000019528823],"category_scores_gemma":[0.00014034196,0.00009862794,0.00006977206,0.0001385794,0.00013016358,0.00011118125,0.00011587907,0.00040730825,0.0000058869728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019004689,0.0001844159,0.948332,0.000025806852,0.0005882831,0.000004736028,0.00086785085,5.1162374e-7,0.0000093360295,0.00036098986,0.0007821895,0.04865385],"study_design_scores_gemma":[0.002562725,0.0003650317,0.9890712,0.000024841751,0.000028150149,0.000026903706,0.0013925477,0.000002025659,0.000047847174,0.0007910286,0.005619743,0.00006796206],"about_ca_topic_score_codex":0.00046608073,"about_ca_topic_score_gemma":0.00035605737,"teacher_disagreement_score":0.048585888,"about_ca_system_score_codex":0.00023429103,"about_ca_system_score_gemma":0.0003421527,"threshold_uncertainty_score":0.40219307},"labels":[],"label_agreement":null},{"id":"W4407265706","doi":"10.1093/ced/llae549","title":"Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China","year":2025,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Chemoprophylaxis; Medicine; Internal medicine; Regimen; Latent tuberculosis; Psoriasis; Incidence (geometry); Tuberculosis; Gastroenterology; Adverse effect; Interleukin 17; Surgery; Immunology; Mycobacterium tuberculosis; Cytokine; Pathology","score_opus":0.01076373423060541,"score_gpt":0.28223566418141655,"score_spread":0.27147192995081115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407265706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972186,0.00084019825,0.0000015039426,0.00020237503,0.0004235128,0.00095235946,0.000023632267,0.000025061521,0.00031274732],"genre_scores_gemma":[0.99950284,0.00006736326,0.00004161614,0.00007304809,0.0000088842435,0.000088423745,0.00004669628,0.000015112938,0.00015599528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762595,0.0005262567,0.0008681187,0.0005846255,0.000054557862,0.00034048647],"domain_scores_gemma":[0.99936146,0.0001374003,0.00017431691,0.00024454383,0.00004416488,0.000038115348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015495693,0.00030750534,0.0010176441,0.0002178998,0.000075309166,0.000007697079,0.00011380839,0.0002871175,0.00006949021],"category_scores_gemma":[0.0000367283,0.00019428445,0.00007476264,0.00033033494,0.00047443743,0.000089185465,0.0001510503,0.00028471815,0.000010564971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012095235,0.005276795,0.97734463,0.000020130314,0.0005576682,0.000082084756,0.00274698,9.665018e-7,0.0001765425,0.00007983183,0.00007152665,0.0015476339],"study_design_scores_gemma":[0.025423614,0.002028267,0.96058244,0.00022093806,0.00013406211,0.000037559388,0.0034692998,0.000003007547,0.007783027,0.000021522144,0.000075964934,0.00022028612],"about_ca_topic_score_codex":0.00030032662,"about_ca_topic_score_gemma":0.0013369047,"teacher_disagreement_score":0.016762154,"about_ca_system_score_codex":0.000077414225,"about_ca_system_score_gemma":0.000075127056,"threshold_uncertainty_score":0.792269},"labels":[],"label_agreement":null},{"id":"W4407358806","doi":"10.1080/09546634.2025.2464107","title":"Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study","year":2025,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Roflumilast; Psoriasis; Prospective cohort study; Cohort; Cohort study; Dermatology; Internal medicine; COPD","score_opus":0.03453545310000239,"score_gpt":0.30395596781091644,"score_spread":0.26942051471091405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407358806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949474,0.002441044,0.00016733466,0.00057401916,0.0018390507,0.0020874704,0.00006164804,0.000062297375,0.003272417],"genre_scores_gemma":[0.9938397,0.0003656051,0.0005519678,0.00008314627,0.00006485867,0.0004344186,0.000027349804,0.000014653637,0.0046183183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790347,0.00038983638,0.00083573797,0.00036679313,0.00008130314,0.0004228446],"domain_scores_gemma":[0.998528,0.0004776201,0.00042234184,0.0002696493,0.0002454212,0.00005698969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030785575,0.00037576107,0.0011439341,0.0003155407,0.00028635215,0.000033589196,0.00024448446,0.00020902108,0.000118948854],"category_scores_gemma":[0.00009356908,0.00023042587,0.0005130505,0.00032320962,0.0001101433,0.00010318116,0.000049231556,0.00016816723,0.00005785946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025879722,0.0075875167,0.96615463,0.000014094575,0.0062073213,0.00025280917,0.00031104972,0.0000053965423,0.0006107588,0.0012789103,0.0050862124,0.009903338],"study_design_scores_gemma":[0.018786063,0.0056147096,0.93693775,0.00006602526,0.003133881,0.00032601308,0.0009459649,0.0000022820814,0.018218042,0.0015479104,0.014130211,0.00029116962],"about_ca_topic_score_codex":0.00004735863,"about_ca_topic_score_gemma":0.00014194341,"teacher_disagreement_score":0.029216895,"about_ca_system_score_codex":0.00041218303,"about_ca_system_score_gemma":0.00017246713,"threshold_uncertainty_score":0.9396494},"labels":[],"label_agreement":null},{"id":"W4407588454","doi":"10.1016/j.jaad.2024.11.083","title":"Response to Potestio et al., “Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review”","year":2025,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Women's College Hospital; Dermatrials Research; Probity Medical Research; SKiN Health; University of Calgary; University of Toronto","funders":"Women's College Hospital","keywords":"Medicine; Plaque psoriasis; Psoriasis; Multicenter study; Dermatology; Interleukin; Interleukin 17; Internal medicine; Cytokine; Randomized controlled trial","score_opus":0.0120106946450387,"score_gpt":0.2884723279994982,"score_spread":0.2764616333544595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407588454","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3958715,0.0003674974,0.000022733682,0.6017575,0.0004354977,0.001242954,0.00026908904,0.0000074650334,0.000025756888],"genre_scores_gemma":[0.30485976,0.0008570043,0.00084667024,0.692719,0.000067857436,0.00022384548,0.00003208668,0.000046718455,0.00034707057],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954732,0.0017216434,0.0016007817,0.0004852138,0.0002279804,0.0004911578],"domain_scores_gemma":[0.9947601,0.001411734,0.0029837256,0.00040751672,0.00038245012,0.000054455246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039935333,0.0005099777,0.0020501183,0.0010407955,0.00007312149,0.000007257719,0.00095317466,0.00034190988,0.000020276431],"category_scores_gemma":[0.0008168786,0.00033869827,0.00044718187,0.00074443273,0.00035235888,0.0000822801,0.00020778723,0.0014185292,0.0000053390722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024234582,0.0005892879,0.018865172,0.00021255546,0.00086071575,0.000035829336,0.0012937288,0.0000071264394,0.001348056,0.000011944103,0.9496059,0.002935114],"study_design_scores_gemma":[0.01165992,0.007865027,0.09646499,0.017014442,0.0009722092,0.00029063885,0.00040238586,4.3629635e-7,0.045753866,0.000028888766,0.8187853,0.0007619123],"about_ca_topic_score_codex":0.00016068101,"about_ca_topic_score_gemma":0.000043160864,"teacher_disagreement_score":0.1308206,"about_ca_system_score_codex":0.0005222514,"about_ca_system_score_gemma":0.00023863812,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W4407590686","doi":"10.1007/s11845-025-03875-x","title":"Exploring the association between psoriasis and subclinical atherosclerosis defined by carotid intima-media thickness (CIMT) in patients with psoriasis vulgaris: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Irish Journal of Medical Science (1971 -)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Toronto General Hospital; Dalhousie University","funders":"","keywords":"Intima-media thickness; Psoriasis; Meta-analysis; Medicine; Internal medicine; Subclinical infection; Plaque psoriasis; Association (psychology); Cardiology; Dermatology; Carotid arteries; Psychology","score_opus":0.1457095673219179,"score_gpt":0.3446701094500892,"score_spread":0.1989605421281713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407590686","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003739352,0.99358094,0.00004111346,0.0007779587,0.000461929,0.0011848267,0.0001880225,0.000012845457,0.000012987642],"genre_scores_gemma":[0.00288254,0.9964474,0.0000694568,0.00017350781,0.000051936047,0.0002394215,0.000056695622,0.000019539935,0.000059515864],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923242,0.0027641437,0.0024728638,0.0006812266,0.0011691548,0.00058841443],"domain_scores_gemma":[0.9894142,0.006825529,0.002585822,0.0004953101,0.00046144615,0.00021767146],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01432598,0.00058832084,0.007432705,0.00067008525,0.00033647593,0.00013602547,0.0013511427,0.00060956425,0.00008912417],"category_scores_gemma":[0.010007093,0.00028727393,0.0011800444,0.002900739,0.0006045145,0.00040564005,0.00030287428,0.0012434607,0.000009701409],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001220187,0.0015363477,0.070090406,0.2682441,0.4180611,0.000028056087,0.0017843005,6.834512e-7,0.0000011788818,0.00004665029,0.0046233786,0.23546179],"study_design_scores_gemma":[0.0018511122,0.00024415608,0.011758122,0.043034673,0.9391992,0.000025280677,0.00011643576,1.8281524e-7,0.0000034602876,0.000007403483,0.0032745465,0.00048542462],"about_ca_topic_score_codex":0.000077216064,"about_ca_topic_score_gemma":0.000044230484,"teacher_disagreement_score":0.5211381,"about_ca_system_score_codex":0.00031542458,"about_ca_system_score_gemma":0.0006772956,"threshold_uncertainty_score":0.9999579},"labels":[],"label_agreement":null},{"id":"W4407771126","doi":"10.1080/vjbm-2024-0012","title":"Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study","year":2025,"lang":"en","type":"article","venue":"Video Journal of Biomedicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Generalized pustular psoriasis; Psoriasis; Medicine; Dermatology; Pustular psoriasis","score_opus":0.015312262566978192,"score_gpt":0.2747713921648219,"score_spread":0.2594591295978437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407771126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804977,0.015935788,0.0003070318,0.0012226355,0.0008273191,0.0011307232,0.000034801957,0.000004262232,0.000039718994],"genre_scores_gemma":[0.99766546,0.0009808457,0.0001219547,0.00003767126,0.00007192013,0.000056873843,0.000014307339,0.000010387032,0.0010405675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840444,0.00037038498,0.0007650968,0.00015739466,0.00010667165,0.00019600788],"domain_scores_gemma":[0.99828947,0.00055820856,0.0006171948,0.00033457702,0.00018460627,0.00001595138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000778191,0.00019425145,0.0007023567,0.00034776356,0.00010151333,0.0000044599497,0.00030135826,0.000099445824,0.000041228803],"category_scores_gemma":[0.0000910227,0.00008486474,0.000264696,0.000626014,0.00016782188,0.00004947708,0.000043707518,0.00009731879,7.116518e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02513301,0.009551684,0.3573886,0.000329217,0.015955962,0.00004190151,0.011695032,0.00019713548,0.39751154,0.00019227949,0.006086679,0.17591697],"study_design_scores_gemma":[0.08965451,0.020081054,0.5476342,0.0018884083,0.009168221,0.0001598937,0.011278635,0.000025811822,0.3067337,0.00041844448,0.012652675,0.0003044767],"about_ca_topic_score_codex":0.00041115843,"about_ca_topic_score_gemma":0.0008107977,"teacher_disagreement_score":0.19024558,"about_ca_system_score_codex":0.00009430487,"about_ca_system_score_gemma":0.00021742244,"threshold_uncertainty_score":0.34606835},"labels":[],"label_agreement":null},{"id":"W4407859111","doi":"10.1111/jdv.20555","title":"Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis","year":2025,"lang":"en","type":"letter","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); University of British Columbia; Probity Medical Research; Centre de Recherche Dermatologique du Québec Métropolitain; Innovaderm (Canada); Queen's University; Dalhousie University","funders":"Janssen Canada","keywords":"Medicine; Plaque psoriasis; Psoriasis; Term (time); Dermatology; Dermatologic agents; Intensive care medicine; Astronomy","score_opus":0.049031501153527966,"score_gpt":0.3131835518266548,"score_spread":0.26415205067312686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407859111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.870398,0.020180615,0.00001700658,0.1079076,0.000925458,0.00039201765,0.000020983396,0.000008729442,0.00014960118],"genre_scores_gemma":[0.97968805,0.0029235177,0.00011048567,0.016755724,0.00017790278,0.000007694432,0.000017261087,0.000025970077,0.00029339906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954422,0.0024740016,0.0011815925,0.0003967776,0.000037713748,0.00046768202],"domain_scores_gemma":[0.9975671,0.0013079306,0.0008917073,0.00014678048,0.000057856472,0.000028612156],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006171158,0.0004021037,0.0015450686,0.0007178393,0.00014816875,0.000008936348,0.00055072975,0.0010199466,0.000004209667],"category_scores_gemma":[0.0003655078,0.0002714609,0.00019712556,0.00017139835,0.00042644027,0.00006130919,0.0004748145,0.0017099921,0.0000024153094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005375648,0.00031213992,0.83829635,0.0015294946,0.0030014552,0.0010011697,0.0034435699,0.00018627224,0.007625063,0.00017573671,0.11929289,0.019760206],"study_design_scores_gemma":[0.036251515,0.00072344515,0.83122605,0.012571585,0.0025774888,0.027931497,0.0006417674,0.00006912448,0.02364189,0.003216212,0.05918474,0.0019647127],"about_ca_topic_score_codex":0.0000051128745,"about_ca_topic_score_gemma":0.000012649593,"teacher_disagreement_score":0.109290056,"about_ca_system_score_codex":0.00006033283,"about_ca_system_score_gemma":0.00006215855,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4407892408","doi":"10.18203/issn.2455-4529.intjresdermatol20250424","title":"Prevalence and patterns of comorbidities in psoriasis: a cross-sectional study from Bangladesh","year":2025,"lang":"en","type":"article","venue":"International Journal of Research in Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Cross-sectional study; Dermatology; Medicine; Environmental health; Pathology","score_opus":0.05213512745380675,"score_gpt":0.3888326839418514,"score_spread":0.3366975564880446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407892408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944342,0.0034915837,0.000013226298,0.00039142292,0.0012433082,0.0001504807,0.00007961673,0.000003406616,0.00019280612],"genre_scores_gemma":[0.9989565,0.0007170092,0.000026271302,0.000020118805,0.000038897728,0.000019284062,0.000012394112,0.000004135946,0.00020541335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797916,0.0007863242,0.0006838163,0.00017448439,0.0001734615,0.00020276554],"domain_scores_gemma":[0.99806994,0.0011969064,0.0001721265,0.00010806632,0.00043690458,0.00001605358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083892065,0.00009269036,0.00028757076,0.0011892258,0.00003758475,0.000025017627,0.00047628966,0.00015395411,0.00016688569],"category_scores_gemma":[0.0002516454,0.00008252426,0.00005641644,0.00016839075,0.00023250068,0.00014313539,0.0001692692,0.00042642406,0.000007033381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009334774,0.0005593339,0.9939332,0.000030023179,0.00040988688,0.00041866672,0.0005700145,0.000005750515,0.0012408353,0.0005518835,0.00008784459,0.0012591005],"study_design_scores_gemma":[0.004398333,0.0001374786,0.98644495,0.00020029888,0.000012668868,0.00031445693,0.00074737205,0.000003488511,0.005879008,0.0015714144,0.00024159897,0.000048944774],"about_ca_topic_score_codex":0.00073989574,"about_ca_topic_score_gemma":0.00045633735,"teacher_disagreement_score":0.007488246,"about_ca_system_score_codex":0.00010115231,"about_ca_system_score_gemma":0.00018964117,"threshold_uncertainty_score":0.3365242},"labels":[],"label_agreement":null},{"id":"W4408033278","doi":"10.1038/s41467-025-56719-8","title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","year":2025,"lang":"en","type":"review","venue":"Nature Communications","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; Memorial University of Newfoundland; University Health Network; Nexus Clinical Research (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Environmental Health Sciences; Norwegian Institute of Public Health; Faculty of Medicine and Health, University of Sydney; Medical Research Council; NIHR Cambridge Biomedical Research Centre; NIHR BioResource; Manchester Biomedical Research Centre; U.S. Department of Health and Human Services; University of California, San Francisco; Stiftelsen Kristian Gerhard Jebsen; National Institutes of Health; Heinz Nixdorf Stiftung; National Institute of Allergy and Infectious Diseases; Versus Arthritis; St. Olavs Hospital Universitetssykehuset i Trondheim; Innovative Medicines Initiative; LEO Pharma Research Foundation; Norges Forskningsråd; National Institute of General Medical Sciences; Bundesministerium für Bildung und Forschung; Institute of Psychiatry, Psychology and Neuroscience, King’s College London; Deutsches Zentrum für Neurodegenerative Erkrankungen; Krembil Foundation; Guy's and St Thomas' Charity; Helse Midt-Norge; Deutsche Forschungsgemeinschaft; European Regional Development Fund; King's College London; European Commission; National Institute for Health and Care Research; Multiple Sclerosis Society of Western Australia; U.S. Department of Veterans Affairs; Helene Morgan Babcock and Alfred Babcock Memorial Scholarship Trust; University of Toronto; Psoriasis Association; Eesti Teadusagentuur; European Federation of Pharmaceutical Industries and Associations; Maudsley Charity; Multiple Sclerosis Society; Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet; Pfizer; Michael J. Fox Foundation for Parkinson's Research; National Psoriasis Foundation; LEO Fondet; NIHR Maudsley Biomedical Research Centre; Norges Teknisk-Naturvitenskapelige Universitet; A. Alfred Taubman Medical Research Institute","keywords":"Psoriasis; Genome-wide association study; Epigenetics; Biology; Transcriptome; Disease; Genetic predisposition; Genetics; Computational biology; Single-nucleotide polymorphism; Medicine; Bioinformatics; Immunology; Gene; Genotype; Gene expression; Pathology","score_opus":0.0917651674618361,"score_gpt":0.3712135813371258,"score_spread":0.2794484138752897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408033278","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008267,0.99700165,0.00006809079,0.00032510937,0.0002436813,0.0007088025,0.0014185254,0.00006270392,0.00016315453],"genre_scores_gemma":[0.00545662,0.987309,0.00071860035,0.000057215675,0.000012418935,0.00016871294,0.0036164569,0.000024905503,0.0026361078],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967217,0.0015896896,0.0008046014,0.0005403101,0.00007414615,0.00026954082],"domain_scores_gemma":[0.99337107,0.0025517787,0.00069134537,0.0031546433,0.00016618517,0.00006497031],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005605326,0.0005305635,0.003240947,0.0007176394,0.00041829795,0.00003463103,0.001334284,0.0009935277,0.0004470821],"category_scores_gemma":[0.00034188168,0.00038687242,0.0030001788,0.001162715,0.00021375218,0.00006594916,0.00057321263,0.00086991675,0.000016265652],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035394492,0.00035424987,0.000037891845,0.002028776,0.51191646,0.0000011764681,0.00035802412,0.0000016135554,0.00006595797,0.0073233414,0.0007441077,0.47713304],"study_design_scores_gemma":[0.00018924732,0.000018327426,0.00017197317,0.00019316556,0.72271764,0.0000020554276,0.000078599565,0.0000013940895,0.00002964293,0.0009755581,0.27532142,0.00030099953],"about_ca_topic_score_codex":0.00020609496,"about_ca_topic_score_gemma":0.0017189451,"teacher_disagreement_score":0.47683203,"about_ca_system_score_codex":0.00006344805,"about_ca_system_score_gemma":0.0004069103,"threshold_uncertainty_score":0.9998583},"labels":[],"label_agreement":null},{"id":"W4408191973","doi":"10.1007/s13555-024-01317-7","title":"Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2025,"lang":"en","type":"erratum","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Randomized controlled trial; Medicine; Internal medicine; Dermatology","score_opus":0.01633031962578176,"score_gpt":0.26834044493712034,"score_spread":0.2520101253113386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408191973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577735,0.01057435,0.00004926014,0.0020991233,0.022559516,0.0044254838,0.001776316,0.00009934851,0.0006430818],"genre_scores_gemma":[0.9417209,0.009468563,0.00019626602,0.006042255,0.0002618297,0.001955104,0.0126872305,0.00012520886,0.027542634],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942859,0.002646369,0.0014625003,0.0009985681,0.00008447904,0.0005221958],"domain_scores_gemma":[0.9947075,0.003653859,0.000792496,0.00059244374,0.00018006792,0.00007359856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071741955,0.0007695085,0.002888912,0.00035669503,0.00039560956,0.000070385024,0.00023422555,0.0010281443,0.000038784663],"category_scores_gemma":[0.0012418908,0.00045008192,0.00024162883,0.00026366918,0.00022630373,0.00010076529,0.00009552299,0.0006533193,0.00001703204],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66294235,0.0008127802,0.006246528,0.000020024341,0.006792792,0.000048217644,0.004014223,0.000002198907,0.00012506067,0.00003748854,0.18857798,0.13038033],"study_design_scores_gemma":[0.8597168,0.0020037736,0.02586019,0.0006835145,0.0020256448,0.00011802189,0.0005766364,0.000022208806,0.0030410895,0.000799265,0.10366493,0.0014879557],"about_ca_topic_score_codex":0.00082494476,"about_ca_topic_score_gemma":0.0005117313,"teacher_disagreement_score":0.1967744,"about_ca_system_score_codex":0.000035550103,"about_ca_system_score_gemma":0.00019773473,"threshold_uncertainty_score":0.9997951},"labels":[],"label_agreement":null},{"id":"W4408225227","doi":"10.58931/cdt.2024.54130","title":"Paradoxical Psoriasis Induced by TNF Inhibitors and Beyond: A Review","year":2024,"lang":"en","type":"review","venue":"Canadian dermatology today.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Psoriasis; Tumor necrosis factor alpha; Medicine; Dermatology; Immunology","score_opus":0.024480933984058696,"score_gpt":0.27774168759544426,"score_spread":0.25326075361138556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408225227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059111666,0.990984,2.5982425e-7,0.0018334389,0.003096052,0.0010566637,0.0010429381,0.00012004024,0.0018074467],"genre_scores_gemma":[0.00012776941,0.9932863,0.000009987075,0.0016949765,0.00009761147,0.0004794048,0.0022734916,0.00011044492,0.0019199923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608225,0.0007782291,0.0009969905,0.0010387792,0.00005189547,0.0010518698],"domain_scores_gemma":[0.9984279,0.0002555488,0.00025678577,0.0006501951,0.000041580224,0.00036794363],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020765135,0.00096782984,0.0031505614,0.0006340652,0.000280401,0.000041664232,0.00045555976,0.002259793,0.0005941995],"category_scores_gemma":[0.00010830179,0.0007817584,0.0006270722,0.00053502485,0.00028317206,0.00007428807,0.00011739025,0.0010074574,0.0040729237],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000022440338,0.00001684562,0.0000045222387,0.008433223,0.00087913126,0.00031816956,0.000030126386,2.905769e-10,0.000002541419,0.0003064579,0.38311213,0.6068946],"study_design_scores_gemma":[0.00031338877,0.00004300584,0.0000020543748,0.009761075,0.005977291,0.004601452,0.000013342682,3.7388904e-8,0.000019548683,0.00006453134,0.97852534,0.00067892723],"about_ca_topic_score_codex":0.0029806455,"about_ca_topic_score_gemma":0.0070223478,"teacher_disagreement_score":0.60621566,"about_ca_system_score_codex":0.00027998516,"about_ca_system_score_gemma":0.001370908,"threshold_uncertainty_score":0.9994633},"labels":[],"label_agreement":null},{"id":"W4408245591","doi":"10.1111/jdv.20553","title":"Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Adverse effect; Discontinuation; Psoriasis; Placebo; Clinical trial; Internal medicine; Incidence (geometry); Cumulative incidence; Randomized controlled trial; Dosing; Dermatology; Cohort","score_opus":0.03773991648713579,"score_gpt":0.2932539044022475,"score_spread":0.2555139879151117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408245591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96767443,0.025326036,0.000078794685,0.0046116346,0.0010603277,0.00035613062,0.00012932741,0.000017549428,0.00074576074],"genre_scores_gemma":[0.9855116,0.01273063,0.00012297535,0.0008363288,0.00017558767,0.0000031250026,0.000026155909,0.00002570856,0.0005678827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990583,0.0066235554,0.0017593203,0.00047421924,0.00007773567,0.00048216485],"domain_scores_gemma":[0.9883443,0.009711054,0.001492514,0.00030456937,0.00007303675,0.0000745368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027532734,0.00039627662,0.0013825209,0.0002980046,0.000381832,0.000021262138,0.00060627534,0.00064455636,0.0000071797076],"category_scores_gemma":[0.004116245,0.00024303836,0.0002458967,0.00023737586,0.0010569309,0.00012945445,0.00042534244,0.0010750929,0.000012385858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014786296,0.0019572787,0.6513002,0.00027329146,0.00840662,0.0014041953,0.011174082,0.000051676514,0.09409842,0.0071666637,0.064131096,0.14525022],"study_design_scores_gemma":[0.038829096,0.00020018332,0.88800937,0.0005273191,0.0014343964,0.005336502,0.00064749585,0.000008067411,0.020075163,0.0018033882,0.043001134,0.000127875],"about_ca_topic_score_codex":0.000012409117,"about_ca_topic_score_gemma":0.000015836655,"teacher_disagreement_score":0.2367092,"about_ca_system_score_codex":0.00002270492,"about_ca_system_score_gemma":0.0000833555,"threshold_uncertainty_score":0.99108166},"labels":[],"label_agreement":null},{"id":"W4408338425","doi":"10.1111/1346-8138.17685","title":"Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 <scp>POETYK PSO</scp> ‐1, <scp>PSO</scp> ‐4, and <scp>LTE</scp> trials","year":2025,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Adverse effect; Placebo; Clinical trial; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Incidence (geometry); Dermatology","score_opus":0.022217816757435237,"score_gpt":0.2900349899425235,"score_spread":0.2678171731850883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408338425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805208,0.015521078,0.000025815432,0.00071313273,0.0010207399,0.00091624015,0.00007974143,0.000021422986,0.0011810255],"genre_scores_gemma":[0.9893399,0.009395655,0.00006702058,0.000677083,0.00007701844,0.000035325425,0.00006007578,0.00003267626,0.00031527274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99146944,0.0050322674,0.0020358437,0.0004290341,0.00015384157,0.0008795973],"domain_scores_gemma":[0.98336965,0.014955169,0.0010193576,0.00047130114,0.00011914964,0.000065385255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027163674,0.0005324824,0.0017462334,0.0006923053,0.0002487374,0.000051377665,0.0007677691,0.00073835545,0.0000106530915],"category_scores_gemma":[0.0043994533,0.0003511866,0.00023628844,0.0007631961,0.00052913494,0.00030188498,0.00020550135,0.0010704815,0.000037033933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005439688,0.012426605,0.5476132,0.00059670495,0.0060978592,0.0034803234,0.2741171,0.0002007395,0.021502793,0.004838312,0.069760896,0.05392574],"study_design_scores_gemma":[0.13544779,0.0017991491,0.6679168,0.0009912488,0.0021339548,0.008480445,0.048910048,0.00002911155,0.020257378,0.0051850188,0.10855697,0.00029212242],"about_ca_topic_score_codex":0.00020706213,"about_ca_topic_score_gemma":0.00039892062,"teacher_disagreement_score":0.22520708,"about_ca_system_score_codex":0.00009403208,"about_ca_system_score_gemma":0.00022362657,"threshold_uncertainty_score":0.999894},"labels":[],"label_agreement":null},{"id":"W4408379574","doi":"10.3389/fimmu.2025.1532852","title":"Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"CD64; Immunology; Flow cytometry; Monocyte; Monoclonal antibody; Cytokine; Medicine; Antibody","score_opus":0.01183224122948081,"score_gpt":0.23869898618001878,"score_spread":0.22686674495053796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408379574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95006675,0.017574294,0.012248617,0.00070359604,0.017244264,0.00115353,0.00015925376,0.00018915729,0.00066056784],"genre_scores_gemma":[0.9596873,0.0012084069,0.01876646,0.00042526526,0.0001693771,0.0006065457,0.00043703595,0.0000796171,0.018620027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967835,0.0003359062,0.00073399633,0.00096666947,0.000044154578,0.0011357806],"domain_scores_gemma":[0.9987827,0.00030045855,0.00020805912,0.0005797655,0.00009703428,0.000031983483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058542227,0.00046637154,0.00087456056,0.0010805174,0.0005097855,0.000040314266,0.00064226077,0.0006234132,0.000057849324],"category_scores_gemma":[0.00017602653,0.00047554693,0.0002456613,0.0007359734,0.00019370773,0.00017912994,0.00018059535,0.00037679655,0.00022284279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074976304,0.00014967976,0.0024812322,0.000059760383,0.000895281,0.000011194707,0.0015849539,0.00008987426,0.9304469,0.00041006407,0.009286544,0.053834736],"study_design_scores_gemma":[0.002689935,0.00036662474,0.0015049151,0.00022780277,0.00022721803,0.000011969756,0.0022360566,0.000008972851,0.9384471,0.0008065713,0.052973833,0.0004989776],"about_ca_topic_score_codex":0.00018606709,"about_ca_topic_score_gemma":0.000079920894,"teacher_disagreement_score":0.05333576,"about_ca_system_score_codex":0.00029176695,"about_ca_system_score_gemma":0.00016985087,"threshold_uncertainty_score":0.9997696},"labels":[],"label_agreement":null},{"id":"W4408463370","doi":"10.1007/s43440-025-00710-z","title":"Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis","year":2025,"lang":"en","type":"article","venue":"Pharmacological Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Atorvastatin; Psoriasis; Medicine; Pharmacology; Inflammation; Expression (computer science); Immunology; Internal medicine; Computer science","score_opus":0.008600467219242364,"score_gpt":0.24706145686412695,"score_spread":0.23846098964488457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408463370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986084,0.00037887954,0.00000941095,0.00008161129,0.0003204537,0.00040735942,0.000021438133,0.000029254968,0.00014318612],"genre_scores_gemma":[0.9995183,0.00005033285,0.000014121532,0.00010916764,0.0000045409583,0.00008167878,0.000068635236,0.0000068867334,0.00014636414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878705,0.00029874744,0.00036889155,0.00027558563,0.00005779832,0.00021195716],"domain_scores_gemma":[0.99925876,0.00024375608,0.00025097484,0.00014647782,0.0000827406,0.000017323324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026158773,0.00016412634,0.0002730074,0.00007641475,0.00008590657,0.0000074355476,0.00008850865,0.00013291951,0.0001199328],"category_scores_gemma":[0.00013552107,0.00009249033,0.000047477115,0.00016111223,0.00012550928,0.000049034286,0.0001048086,0.00013816077,0.0000018418274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030501044,0.00028075985,0.88353544,0.000015671321,0.00018453586,0.00010532534,0.00009104321,0.000009654989,0.112803146,0.000013414919,0.00019634113,0.002459649],"study_design_scores_gemma":[0.0017000455,0.00009490959,0.76341194,0.000065482294,0.00014206141,0.0000023897346,0.000033656546,7.9644724e-7,0.23426221,0.00007107519,0.00013270832,0.00008271791],"about_ca_topic_score_codex":0.000032843505,"about_ca_topic_score_gemma":0.000016639222,"teacher_disagreement_score":0.12145907,"about_ca_system_score_codex":0.000028079292,"about_ca_system_score_gemma":0.000031924326,"threshold_uncertainty_score":0.3771646},"labels":[],"label_agreement":null},{"id":"W4408493853","doi":"10.25251/skin.10.supp.538","title":"Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Incyte; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Malignancy; Medicine; Dermatology; Internal medicine","score_opus":0.00954215173484367,"score_gpt":0.23473512960486337,"score_spread":0.22519297787001968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408493853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853442,0.011523853,0.00000534284,0.00032336958,0.00082503626,0.00064956356,0.000020621172,0.0000056063454,0.0013024171],"genre_scores_gemma":[0.99761367,0.00081284216,0.0000778302,0.0001190873,0.000041920634,0.000036409365,0.00001671378,0.000012610804,0.0012689445],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99799496,0.00057759054,0.00084269844,0.00014577636,0.00016185905,0.00027713698],"domain_scores_gemma":[0.9982504,0.00064602576,0.0005873718,0.00033329052,0.00016252638,0.000020389343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005891553,0.00022662352,0.0006918066,0.00036728242,0.00002578115,0.0000019709385,0.0003622993,0.00014739117,0.00012548723],"category_scores_gemma":[0.00012979924,0.000112468486,0.00014260091,0.0003410825,0.00040098478,0.00003827057,0.00002372686,0.00021908082,0.0000033675178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03155309,0.0048065446,0.29878008,0.00021447075,0.00278318,0.001101968,0.05097702,0.00002214457,0.0046538063,0.00022523329,0.0051015015,0.599781],"study_design_scores_gemma":[0.060714975,0.024876678,0.8217933,0.0041472213,0.0047779595,0.0021720398,0.007848782,0.0000041823614,0.006522725,0.0009441058,0.06560462,0.00059339945],"about_ca_topic_score_codex":0.0003421505,"about_ca_topic_score_gemma":0.0007138712,"teacher_disagreement_score":0.59918755,"about_ca_system_score_codex":0.00025317757,"about_ca_system_score_gemma":0.00027756835,"threshold_uncertainty_score":0.45863318},"labels":[],"label_agreement":null},{"id":"W4408497907","doi":"10.25251/skin.10.supp.534","title":"Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Toxoid; Tetanus; Medicine; Immune system; Plaque psoriasis; Immunology; Psoriasis; Microbiology; Vaccination; Biology","score_opus":0.009630359305753027,"score_gpt":0.2599379885476756,"score_spread":0.25030762924192257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408497907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97214234,0.016599573,0.000012354691,0.009528228,0.0008091487,0.00057426025,0.000012888378,0.000004029514,0.0003172027],"genre_scores_gemma":[0.9957299,0.0034375347,0.00002298795,0.00029487538,0.00010250368,0.000008398088,0.0000028839136,0.000008289494,0.00039260625],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997094,0.0014738708,0.0009551041,0.00014296727,0.00009146214,0.00024260044],"domain_scores_gemma":[0.99592113,0.0033665989,0.00033905098,0.0002637153,0.00008342373,0.00002609203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032623278,0.00020153307,0.00068006717,0.0004236344,0.00010073098,0.0000061687774,0.00034018268,0.00015265902,0.000042705244],"category_scores_gemma":[0.0011109632,0.00010125152,0.000066076944,0.00040560905,0.00018854438,0.000038914346,0.00006187257,0.00035186214,0.0000020264251],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5853014,0.00041994455,0.0031304872,0.00006804496,0.0007316995,0.00072504627,0.019697377,0.00003382014,0.31300855,0.0003082366,0.0012940357,0.07528135],"study_design_scores_gemma":[0.35877055,0.028620388,0.3884337,0.0056083845,0.0037151957,0.042479213,0.0460433,0.000014443444,0.07301505,0.006525914,0.04572731,0.0010465613],"about_ca_topic_score_codex":0.00013117996,"about_ca_topic_score_gemma":0.00021574242,"teacher_disagreement_score":0.3853032,"about_ca_system_score_codex":0.000041653435,"about_ca_system_score_gemma":0.0001070396,"threshold_uncertainty_score":0.41289172},"labels":[],"label_agreement":null},{"id":"W4408498262","doi":"10.25251/skin.10.supp.526","title":"Bimekizumab Maintenance of Response at Every Visit Over 4 Years in Patients with Psoriasis Achieving Clear Skin at Week 16: Results from Four Phase 3 Trials","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Psoriasis; Medicine; Phase (matter); Dermatology; Internal medicine; Chemistry","score_opus":0.016137967611291333,"score_gpt":0.26463942600066387,"score_spread":0.24850145838937254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936361,0.0035477672,0.00003037582,0.0010577452,0.0009887244,0.00033645693,0.00019463937,0.00000882606,0.0001993912],"genre_scores_gemma":[0.9955181,0.0007620569,0.00006899034,0.00020811796,0.000112776426,0.0000017214379,0.00005208072,0.000021535843,0.0032546478],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960922,0.0018211545,0.0013170303,0.00023340891,0.00021109568,0.00032508565],"domain_scores_gemma":[0.99383456,0.0041741175,0.0013095287,0.0004350351,0.00020401116,0.00004274455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029955392,0.00025783578,0.0010934663,0.0003170184,0.00013518828,0.00000483754,0.0003898292,0.00020694917,0.0005948227],"category_scores_gemma":[0.0025846905,0.00014744906,0.00018776236,0.0002996723,0.00027360392,0.00006137391,0.0001068006,0.0003155572,0.000033804165],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8287718,0.0009303121,0.0056813704,0.000023936953,0.0024819726,0.00067916536,0.0057848967,0.00009306699,0.035965335,0.000004328786,0.044859532,0.07472427],"study_design_scores_gemma":[0.30528098,0.033095364,0.51167697,0.00765902,0.0068859872,0.0025112503,0.0032688084,0.0000150397345,0.050172355,0.00062326033,0.07779035,0.0010205943],"about_ca_topic_score_codex":0.00025216799,"about_ca_topic_score_gemma":0.00026134253,"teacher_disagreement_score":0.52349085,"about_ca_system_score_codex":0.00035127994,"about_ca_system_score_gemma":0.00012882928,"threshold_uncertainty_score":0.65128917},"labels":[],"label_agreement":null},{"id":"W4408498282","doi":"10.25251/skin.10.supp.531","title":"Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry","year":2025,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology; Term (time)","score_opus":0.01039560788878543,"score_gpt":0.25438247411742243,"score_spread":0.243986866228637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408498282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98453826,0.012018103,0.000059358892,0.00056520477,0.0017231343,0.00049916474,0.000024687268,0.000010381949,0.00056168786],"genre_scores_gemma":[0.99635535,0.0030180104,0.000009426678,0.00021197872,0.00012372567,0.000013578736,0.00002239612,0.000016066542,0.00022947598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962303,0.0023265332,0.00080598,0.00018530327,0.00014687088,0.0003049951],"domain_scores_gemma":[0.9952751,0.0031984942,0.0008003358,0.0004889206,0.00021686542,0.000020289493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002046535,0.00030316965,0.00082548324,0.00027554116,0.00015469153,0.000007895324,0.00084304705,0.0002753013,0.00016070955],"category_scores_gemma":[0.00048622454,0.0001367815,0.0002046565,0.00042817154,0.0007082586,0.000056846085,0.000051820614,0.00043517357,0.000008785193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012348028,0.0011087199,0.91552913,0.00033074807,0.0034143534,0.0002389741,0.0065370826,0.000040328177,0.0152392285,0.00039530854,0.0033054547,0.041512627],"study_design_scores_gemma":[0.00947065,0.0030169706,0.95578176,0.002346335,0.0016541474,0.0011391311,0.001661201,6.419689e-7,0.02180943,0.0012376765,0.0016320007,0.00025004725],"about_ca_topic_score_codex":0.00021851496,"about_ca_topic_score_gemma":0.00012759744,"teacher_disagreement_score":0.04126258,"about_ca_system_score_codex":0.00008690794,"about_ca_system_score_gemma":0.00007988335,"threshold_uncertainty_score":0.5577788},"labels":[],"label_agreement":null},{"id":"W4408520764","doi":"10.1186/s12348-025-00486-6","title":"Ocular complications in psoriatic patients: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Ophthalmic Inflammation and Infection","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blepharitis; Episcleritis; Psoriasis; Meibomian gland; Dermatology; Population; Odds ratio; Meta-analysis; Ophthalmology; Uveitis; Internal medicine; Eyelid; Scleritis","score_opus":0.0419328596628178,"score_gpt":0.3184768132066199,"score_spread":0.2765439535438021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408520764","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018568113,0.9980533,0.000053168435,0.000048964655,0.00014711592,0.0013168405,0.000032857617,0.000007451034,0.00015462875],"genre_scores_gemma":[0.00045930187,0.9988488,0.000025677671,0.000025041683,0.00001157979,0.00018526817,0.00017577938,0.000008632144,0.00025990495],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99699694,0.000974365,0.0016574464,0.00019307235,0.000059567654,0.000118592165],"domain_scores_gemma":[0.9973533,0.00032029033,0.0018475344,0.00021918012,0.00023690621,0.000022791506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078684895,0.00029807782,0.003910874,0.0010749984,0.00009455875,0.00003145234,0.000088584675,0.0002745699,0.00010033305],"category_scores_gemma":[0.00032409336,0.00019812431,0.0011051373,0.0007477249,0.000032294392,0.00019577118,0.00003123487,0.00025050694,0.000018161043],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000825024,0.00016681121,0.0001346014,0.79547244,0.1683135,0.0000057524308,0.00009481943,0.0000035568376,0.0000014915056,0.00022511727,0.000087306325,0.035486337],"study_design_scores_gemma":[0.00047565333,0.000092983915,0.00041815412,0.027126553,0.9612449,0.0002782327,0.0000056871677,0.0000010328039,0.0000019248957,0.000041959378,0.010107468,0.0002054762],"about_ca_topic_score_codex":0.000015233969,"about_ca_topic_score_gemma":0.0000065289173,"teacher_disagreement_score":0.7929314,"about_ca_system_score_codex":0.00010163874,"about_ca_system_score_gemma":0.00007724287,"threshold_uncertainty_score":0.8079275},"labels":[],"label_agreement":null},{"id":"W4408552243","doi":"10.1007/s13555-025-01369-3","title":"Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; University of Calgary; McMaster University; Lynde Centre for Dermatology; Dalhousie University; University of Toronto; Probity Medical Research; Bausch Health (Canada); Health Canada","funders":"","keywords":"Plaque psoriasis; Medicine; Psoriasis; Retrospective cohort study; Cohort; Dermatology; Internal medicine","score_opus":0.012138154383044289,"score_gpt":0.2727859351044288,"score_spread":0.2606477807213845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408552243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398315,0.0012256609,0.000023535402,0.0021190764,0.00032393803,0.00058059406,0.000143699,0.0000134066595,0.0015869405],"genre_scores_gemma":[0.9977102,0.00045666887,0.000037089583,0.00092013297,0.0000070210585,0.0001846189,0.00015149366,0.0000058076457,0.00052695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989684,0.00024182237,0.00023609742,0.00026044768,0.00002189713,0.00027132122],"domain_scores_gemma":[0.9993207,0.00030332757,0.00006378372,0.00024211538,0.00005008816,0.000019979238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028540601,0.00013032807,0.000460664,0.00083206384,0.00017921293,0.000009614933,0.00017014409,0.00020705171,0.00004675523],"category_scores_gemma":[0.000028383922,0.00010252107,0.000116709154,0.0009128276,0.00010718887,0.000023218328,0.000012659534,0.000103298225,0.0000053774384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004371547,0.00004830899,0.9648538,0.000005897079,0.0032463137,0.000010617208,0.002763343,0.0000034256745,0.00048161406,0.016736668,0.0028120782,0.008600776],"study_design_scores_gemma":[0.0016570352,0.000048295155,0.9767947,0.000008399526,0.00046913174,0.000010010487,0.0002532015,0.0000065808426,0.0029099404,0.0009122875,0.01683163,0.00009874464],"about_ca_topic_score_codex":0.03603107,"about_ca_topic_score_gemma":0.37831986,"teacher_disagreement_score":0.3422888,"about_ca_system_score_codex":0.000060079445,"about_ca_system_score_gemma":0.00012725267,"threshold_uncertainty_score":0.97038805},"labels":[],"label_agreement":null},{"id":"W4408648268","doi":"10.2147/jir.s500822","title":"FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression","year":2025,"lang":"en","type":"article","venue":"Journal of Inflammation Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Plaque psoriasis; Psoriasis; FLI1; Disease; Medicine; Cancer research; Immunology; Internal medicine; Biology; Genetics; Gene; Transcription factor","score_opus":0.04246175484200099,"score_gpt":0.35333552601208823,"score_spread":0.31087377117008724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408648268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844826,0.0066797705,0.000018447601,0.0038482076,0.00033964863,0.00023338581,0.0000070105198,0.000011845562,0.00041341883],"genre_scores_gemma":[0.99737173,0.0014195686,0.000039457344,0.000015615664,0.00011874882,0.000023639917,0.000025847734,0.0000056197728,0.000979798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998612,0.0005241985,0.00038653202,0.00013063927,0.00013641047,0.00021025258],"domain_scores_gemma":[0.9987128,0.00033583754,0.00018301858,0.00009651597,0.0006238584,0.0000479805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012801585,0.00009772328,0.00017607037,0.00061593216,0.00029119608,0.0000492825,0.00010313287,0.0001489168,0.00010248132],"category_scores_gemma":[0.00055559626,0.00007220301,0.000061250896,0.00031969135,0.0000855026,0.00029430416,0.00006867198,0.00031623663,0.00006320708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018510341,0.00016601643,0.009223828,0.00015192752,0.00031537501,0.000066393586,0.00058367813,0.000010031071,0.75001985,0.0031461082,0.004095474,0.2303703],"study_design_scores_gemma":[0.003450431,0.0003332608,0.086528346,0.0008389603,0.00011528012,0.00003674245,0.00048202492,0.000027693693,0.89530766,0.002636696,0.010106804,0.00013609008],"about_ca_topic_score_codex":0.0000032749674,"about_ca_topic_score_gemma":0.0000034757559,"teacher_disagreement_score":0.2302342,"about_ca_system_score_codex":0.00006289223,"about_ca_system_score_gemma":0.00020288909,"threshold_uncertainty_score":0.29443532},"labels":[],"label_agreement":null},{"id":"W4408665420","doi":"10.1007/s43678-025-00883-9","title":"Just the facts: diagnosis and management of generalized pustular psoriasis","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Emergency Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; SKiN Health; University of Calgary; Probity Medical Research; Health Sciences Centre; Queen's University; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Dermatology; Psoriasis; Intensive care medicine","score_opus":0.061855463108095546,"score_gpt":0.3083934521219404,"score_spread":0.24653798901384488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408665420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.821061,0.15273258,0.00007489706,0.007725109,0.013394987,0.00030038392,0.00003680115,0.0000050489866,0.004669174],"genre_scores_gemma":[0.957377,0.037295457,0.000054906715,0.00016202322,0.00015447695,0.00001899443,0.000014627948,0.000009776012,0.0049127196],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891293,0.00013530506,0.00056069193,0.000115579576,0.000044741366,0.00023074853],"domain_scores_gemma":[0.9992793,0.00006496682,0.0002297798,0.0001979633,0.00014212483,0.000085821666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041328382,0.00014083115,0.00034111645,0.00027120244,0.00017518147,0.0000020482435,0.00024613953,0.000091674796,0.002602613],"category_scores_gemma":[0.00009063305,0.00008608492,0.00010154251,0.0003124944,0.00017296724,0.000040632327,0.00001667913,0.000114173046,0.0000060707252],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029751434,0.00014304215,0.21638496,0.0004751787,0.009128949,0.00021617752,0.0042056246,0.00002033071,0.005931204,0.016606377,0.586955,0.15963565],"study_design_scores_gemma":[0.0050283964,0.000489183,0.19670855,0.0007616537,0.0033397889,0.000032068805,0.0038834268,0.0000012464535,0.004643066,0.0011201127,0.7837745,0.00021804105],"about_ca_topic_score_codex":0.0033738983,"about_ca_topic_score_gemma":0.0039061185,"teacher_disagreement_score":0.19681948,"about_ca_system_score_codex":0.000041362266,"about_ca_system_score_gemma":0.00013388133,"threshold_uncertainty_score":0.99830914},"labels":[],"label_agreement":null},{"id":"W4408743360","doi":"10.1016/j.reval.2025.104322","title":"Efficacité et sécurité d’emploi du delgocitinib en crème à 36 semaines chez les adultes atteints d’eczéma chronique des mains : résultats de l’essai d’extension de phase 3 DELTA-3","year":2025,"lang":"fr","type":"article","venue":"Revue française d'allergologie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Medicine; Political science","score_opus":0.02283368543696768,"score_gpt":0.2849292337771474,"score_spread":0.26209554834017973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408743360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9064696,0.07278413,0.0047377367,0.009939806,0.0017334338,0.0011668971,0.0010573606,0.0005521899,0.0015588492],"genre_scores_gemma":[0.93412155,0.041941434,0.0038907484,0.0013032135,0.00065829227,0.00048382368,0.001089973,0.0001565044,0.016354464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99183035,0.003060229,0.0012419543,0.0015257794,0.00012090737,0.0022208],"domain_scores_gemma":[0.99483263,0.002917268,0.00044381365,0.0010602516,0.0004881274,0.00025788695],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018215379,0.0012759846,0.0016044957,0.0004793471,0.0012165036,0.000099475816,0.001022857,0.0025850246,0.0011382179],"category_scores_gemma":[0.0022910426,0.0012777231,0.0008144834,0.0007639969,0.0014341413,0.00031506483,0.0005039998,0.0011549958,0.00046606423],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080087315,0.010264111,0.08395316,0.0034457194,0.006914094,0.0039342493,0.019549549,0.0018203249,0.29760912,0.014961707,0.031904966,0.5176343],"study_design_scores_gemma":[0.04642742,0.003921238,0.27972755,0.0103776315,0.0044215885,0.0025876218,0.003074308,0.0013684903,0.21696627,0.0072854157,0.4191722,0.0046702716],"about_ca_topic_score_codex":0.0023994865,"about_ca_topic_score_gemma":0.003102216,"teacher_disagreement_score":0.512964,"about_ca_system_score_codex":0.0005866009,"about_ca_system_score_gemma":0.0010387183,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W4408751164","doi":"10.1016/j.jdin.2025.02.002","title":"Skin pain characteristics in psoriasis and psoriatic arthritis: A cross-sectional study","year":2025,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of British Columbia; University Health Network; Queen's University; University of Toronto","funders":"Eli Lilly and Company; Amgen","keywords":"Psoriasis; Psoriatic arthritis; Medicine; Dermatology; Cross-sectional study; Pathology","score_opus":0.011612790939755799,"score_gpt":0.2751944309710452,"score_spread":0.26358164003128937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408751164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938263,0.00070543884,0.00010538303,0.00014572617,0.0031601298,0.00026668288,0.00009686442,0.00003764062,0.0016558083],"genre_scores_gemma":[0.99451447,0.00013664215,0.000059965136,0.00015143675,0.00011497577,0.0001308509,0.00019507243,0.000008012657,0.004688564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987672,0.00023398138,0.00043045392,0.00032554398,0.000059968588,0.00018284384],"domain_scores_gemma":[0.99942243,0.000261779,0.00009030387,0.00013225577,0.00007975034,0.00001345464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006435234,0.00015297806,0.00021777819,0.0002828413,0.0001051233,0.00006501881,0.0001675562,0.0001523024,0.00051434635],"category_scores_gemma":[0.00027968714,0.00015154653,0.000059726943,0.00013462831,0.00006771498,0.00010226003,0.00007978386,0.00014986609,0.000100556426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022133507,0.000521724,0.8910074,0.0000056338295,0.00036612633,0.000013839806,0.00026915286,0.0000010436149,0.00034522652,0.0013668119,0.00033191202,0.105549775],"study_design_scores_gemma":[0.0037448967,0.00010653507,0.9892962,0.00003481342,0.000021652475,0.000013700751,0.00015537758,0.000031895903,0.00028124297,0.00059025135,0.005602493,0.000120936274],"about_ca_topic_score_codex":0.000114114686,"about_ca_topic_score_gemma":0.00016692845,"teacher_disagreement_score":0.10542884,"about_ca_system_score_codex":0.00009328066,"about_ca_system_score_gemma":0.00005203237,"threshold_uncertainty_score":0.61798877},"labels":[],"label_agreement":null},{"id":"W4408872339","doi":"10.2147/ptt.s506624","title":"Treatment With Schistosoma Japonicum Peptide SJMHE1 and SJMHE1-Loaded Hydrogel for the Mitigation of Psoriasis","year":2025,"lang":"en","type":"article","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Magna International (Canada)","funders":"","keywords":"Schistosoma japonicum; Peptide; Psoriasis; Self-healing hydrogels; Chemistry; Nanotechnology; Materials science; Biophysics; Schistosomiasis; Biology; Helminths; Immunology; Biochemistry; Polymer chemistry","score_opus":0.012705350246925198,"score_gpt":0.23957663121609887,"score_spread":0.22687128096917367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408872339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9134565,0.08243531,0.00031964728,0.0010799051,0.0006824025,0.0011617793,0.00014036472,0.000054771008,0.0006693074],"genre_scores_gemma":[0.9778373,0.019084526,0.00041297762,0.00012974846,0.00007158191,0.00042593514,0.00009763668,0.000024924135,0.0019153692],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876386,0.00010473105,0.0003187588,0.0004330778,0.00005010247,0.00032947588],"domain_scores_gemma":[0.9986267,0.0007342741,0.00017756953,0.00034036287,0.00008955614,0.000031522504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017219978,0.0003428861,0.00048444688,0.00012860655,0.0005011715,0.000026750784,0.00013549604,0.00019696756,0.0000390663],"category_scores_gemma":[0.000027798806,0.00019806906,0.00014994098,0.0001609489,0.00028457277,0.00008634535,0.00002490317,0.0000745245,0.0000044539693],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049969526,0.00069033843,0.008786265,0.000051845644,0.005060158,0.0000031916672,0.0023909505,0.0000040503137,0.10571883,0.009279856,0.0007404068,0.86227715],"study_design_scores_gemma":[0.03128439,0.0036471563,0.023320979,0.00011114737,0.0014964724,0.00004930014,0.0012375674,0.00006801251,0.62512296,0.003583947,0.30943406,0.00064402015],"about_ca_topic_score_codex":0.00018969981,"about_ca_topic_score_gemma":0.00006179183,"teacher_disagreement_score":0.8616331,"about_ca_system_score_codex":0.00004259213,"about_ca_system_score_gemma":0.00008040494,"threshold_uncertainty_score":0.8077022},"labels":[],"label_agreement":null},{"id":"W4408884560","doi":"10.1097/asw.0000000000000243","title":"Cutaneous Psoriasis: Clinical Aspects and Treatments","year":2025,"lang":"en","type":"review","venue":"Advances in Skin & Wound Care","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Dermatology; Nurse practitioners; Continuing education; Wound care; Disease; Physician assistants; Skin care; MEDLINE; Intensive care medicine; Nursing; Health care; Internal medicine","score_opus":0.022760285365530087,"score_gpt":0.35252068746210186,"score_spread":0.32976040209657176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408884560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019565775,0.98550665,0.000001927346,0.0000046120176,0.0038320671,0.0010321452,0.00032878024,0.000067009416,0.009031173],"genre_scores_gemma":[0.0004951048,0.9944905,0.000072998766,0.000030073117,0.00016424462,0.00038231997,0.0009736799,0.000042085838,0.0033489754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697334,0.00066694425,0.00091775693,0.00087093294,0.000058264064,0.00051274226],"domain_scores_gemma":[0.9978188,0.001140713,0.00033996598,0.0006051949,0.00005292592,0.00004235357],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012920385,0.0007160418,0.0023480132,0.0002777963,0.00016827146,0.000028732527,0.00037223153,0.0010348466,0.00010375209],"category_scores_gemma":[0.00011558444,0.00056498946,0.00056308246,0.0003551426,0.00022885334,0.00012363399,0.00016648234,0.0004992591,0.00022240235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005099011,0.00013193727,0.00037932556,0.004086895,0.00063010806,0.00017781189,0.00019854128,3.2483894e-7,7.630234e-8,0.00020013809,0.00010950074,0.99403435],"study_design_scores_gemma":[0.001331959,0.00026270963,0.00004247695,0.006357571,0.0024087587,0.0003073866,0.00036656045,1.3691055e-8,0.0000046535233,0.00022945882,0.98822826,0.0004602158],"about_ca_topic_score_codex":0.000026695729,"about_ca_topic_score_gemma":0.00027180125,"teacher_disagreement_score":0.99357414,"about_ca_system_score_codex":0.00026214478,"about_ca_system_score_gemma":0.00030938757,"threshold_uncertainty_score":0.99968016},"labels":[],"label_agreement":null},{"id":"W4408921411","doi":"10.1093/ndt/gfaf047","title":"Psoriasis associates with increased risk for kidney transplant rejection","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine","funders":"","keywords":"Medicine; Psoriasis; Hazard ratio; Dialysis; Internal medicine; Cohort; Proportional hazards model; Transplantation; Retrospective cohort study; Kidney disease; Kidney transplantation; Dermatology; Confidence interval","score_opus":0.00715180875968092,"score_gpt":0.22347592459523022,"score_spread":0.2163241158355493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408921411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750983,0.00053385156,0.02016385,0.00047604603,0.00069819833,0.00072881626,0.0012765005,0.00023275557,0.00079165044],"genre_scores_gemma":[0.99108464,0.0014792389,0.0005684526,0.00070195226,0.000064031374,0.00051199854,0.005075416,0.00002219073,0.0004920928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816483,0.00049532397,0.00037871767,0.0005077375,0.000047637597,0.00040577532],"domain_scores_gemma":[0.9986957,0.0007209148,0.00020205106,0.00022989987,0.00011442224,0.000037057707],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039488365,0.00029527862,0.00049094594,0.00037984533,0.00049248786,0.00001909242,0.00014763988,0.00050994963,0.0001158502],"category_scores_gemma":[0.000054011365,0.0002473091,0.00024202192,0.00041332594,0.00012088468,0.00012447429,0.0000038974827,0.00017284372,0.00004990302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036268547,0.0013265454,0.4760981,0.000416891,0.018492367,0.00003624926,0.004718133,0.00029454994,0.37882385,0.0028573864,0.0071662427,0.07350116],"study_design_scores_gemma":[0.039760806,0.0015265628,0.52567387,0.00019081334,0.030670615,0.00008315098,0.00022234373,0.00012564141,0.37250075,0.0018994429,0.0263438,0.0010022436],"about_ca_topic_score_codex":0.00061720563,"about_ca_topic_score_gemma":0.0011372479,"teacher_disagreement_score":0.07249892,"about_ca_system_score_codex":0.00006745916,"about_ca_system_score_gemma":0.00013919052,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W4409039284","doi":"10.1007/s13555-025-01366-6","title":"Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"UCB","keywords":"Medicine; Adverse effect; Syringe; Injection site; Discontinuation; Anesthesia; Pharmacokinetics; Adalimumab; Placebo; Bioequivalence; Self-administration; Surgery; Pharmacology; Internal medicine; Rheumatoid arthritis","score_opus":0.022848295447719286,"score_gpt":0.2676768045114574,"score_spread":0.24482850906373813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409039284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97644216,0.020537745,0.000990043,0.0004818493,0.0006080767,0.00036807868,0.000064508975,0.00006627712,0.00044128488],"genre_scores_gemma":[0.9969982,0.0019459939,0.0002889813,0.00012804978,0.000012944645,0.000074254065,0.00006250905,0.000009745389,0.0004793295],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919564,0.000117010255,0.0002421452,0.0002368125,0.000010938606,0.00019747893],"domain_scores_gemma":[0.9994729,0.00024583106,0.000085542575,0.0001443482,0.000036007343,0.000015344564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007875781,0.0001537934,0.00032286881,0.00015608808,0.0002661325,0.0000087198,0.00006133164,0.0002593177,0.000031925927],"category_scores_gemma":[0.000016917853,0.00013538275,0.00006889286,0.00009663201,0.00018104484,0.000056358433,0.00002993154,0.000070822985,0.0000038885846],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058895196,0.00064178964,0.029675256,0.0002493601,0.0020830606,0.00001518272,0.001690349,0.0000020889559,0.4611652,0.021063114,0.0004348337,0.47709024],"study_design_scores_gemma":[0.029844262,0.0021482343,0.14915435,0.00028811273,0.00068789517,0.002259232,0.00086134195,0.00016542552,0.5715961,0.005031945,0.2370679,0.00089523883],"about_ca_topic_score_codex":0.000019095829,"about_ca_topic_score_gemma":0.000021180178,"teacher_disagreement_score":0.476195,"about_ca_system_score_codex":0.000012420204,"about_ca_system_score_gemma":0.0000348725,"threshold_uncertainty_score":0.55207485},"labels":[],"label_agreement":null},{"id":"W4409244071","doi":"10.1016/j.cell.2025.03.006","title":"Brain-wide mapping of immune receptors uncovers a neuromodulatory role of IL-17E and the receptor IL-17RB","year":2025,"lang":"en","type":"article","venue":"Cell","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Eye Institute; National Institute of Mental Health; National Cancer Institute; Simons Center for the Social Brain, Massachusetts Institute of Technology; Marcus Foundation; Japan Society for the Promotion of Science; Simons Foundation Autism Research Initiative; Burroughs Wellcome Fund; Yamada Science Foundation","keywords":"Biology; Receptor; Immune system; Neuroscience; Cell biology; Immunology; Genetics","score_opus":0.006262460109715539,"score_gpt":0.1909150819360685,"score_spread":0.18465262182635295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409244071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815384,0.010716632,0.000015100151,0.0004385793,0.00094048394,0.0002556339,0.00006121096,0.000023086652,0.0060108732],"genre_scores_gemma":[0.9916333,0.0005598044,0.00005814559,0.00018614497,0.000012670464,0.000015912845,0.000042900054,0.000011344198,0.0074798022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894536,0.0002786458,0.00033815083,0.00021754169,0.000028675398,0.00019165268],"domain_scores_gemma":[0.9985386,0.0008967703,0.00018810012,0.00031966585,0.000044761062,0.00001209582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029333547,0.00015603597,0.000367535,0.00011221836,0.00010305924,0.00000455741,0.00018540524,0.0001597286,0.00017186638],"category_scores_gemma":[0.00014414501,0.00011479587,0.00015614503,0.00019691337,0.00035524883,0.000037418566,0.000100508056,0.00011872593,0.00003761894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046445403,0.00010372222,0.005173919,0.000070309485,0.00030731043,5.9067185e-7,0.0012961458,0.0000050933436,0.97411215,0.0005611545,0.0046906993,0.013214439],"study_design_scores_gemma":[0.0033820833,0.000081563994,0.007895918,0.000058997342,0.00012147176,0.0000016409408,0.0009971322,0.0000024234112,0.82619333,0.00035475907,0.16080135,0.00010934931],"about_ca_topic_score_codex":0.000115141986,"about_ca_topic_score_gemma":0.00000521781,"teacher_disagreement_score":0.15611064,"about_ca_system_score_codex":0.000019183704,"about_ca_system_score_gemma":0.00005894818,"threshold_uncertainty_score":0.46812397},"labels":[],"label_agreement":null},{"id":"W4409291081","doi":"10.58931/cdt.2025.6s01138","title":"A Review of the Network Meta-Analysis and Psoriasis Management","year":2025,"lang":"en","type":"review","venue":"Canadian dermatology today.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"Canadian Institutes of Health Research","keywords":"Meta-analysis; Psoriasis; Medicine; Dermatology; Internal medicine","score_opus":0.04439206216578415,"score_gpt":0.28573449819481805,"score_spread":0.2413424360290339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409291081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.8911617e-7,0.99199075,0.000004387097,0.000662913,0.00069426105,0.0012204255,0.00053949544,0.000018402476,0.004868952],"genre_scores_gemma":[0.000008100053,0.9908644,0.000057983285,0.001762587,0.000015833077,0.0004922217,0.00046002478,0.00002146141,0.0063173696],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641764,0.0014165345,0.0009290198,0.0005918251,0.000039101426,0.00060588145],"domain_scores_gemma":[0.99772936,0.00042393524,0.00052853354,0.0011699464,0.00006307903,0.00008515989],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003117644,0.00057500985,0.0054069874,0.00049898954,0.00027801335,0.000009512375,0.000717549,0.00072146003,0.0011932891],"category_scores_gemma":[0.0000570312,0.00035940637,0.0033290617,0.0017975391,0.00025035677,0.000023839764,0.00019331156,0.00030451381,0.00009593769],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000023249481,0.000017271112,0.000061906365,0.0637854,0.43063813,0.000058879537,0.000012120008,1.9226327e-7,1.2308266e-8,0.0017923821,0.09815802,0.40547338],"study_design_scores_gemma":[0.000080099795,0.000002989371,0.000018800885,0.0037384636,0.415798,0.00012651035,0.0000023404596,1.5123685e-8,7.328826e-7,0.000029996825,0.5800502,0.00015185575],"about_ca_topic_score_codex":0.0029149568,"about_ca_topic_score_gemma":0.025483852,"teacher_disagreement_score":0.48189217,"about_ca_system_score_codex":0.000095877585,"about_ca_system_score_gemma":0.0006035719,"threshold_uncertainty_score":0.9998858},"labels":[],"label_agreement":null},{"id":"W4409326368","doi":"10.1089/derm.2025.0022","title":"No Evidence of Paradoxical Atopy in Psoriasis Treated with Biologics: A Retrospective Cohort Study","year":2025,"lang":"en","type":"letter","venue":"Dermatitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Atopy; Psoriasis; Retrospective cohort study; Dermatology; Cohort; Internal medicine; Immunopathology","score_opus":0.017477742297826053,"score_gpt":0.25108801470207714,"score_spread":0.23361027240425108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409326368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9411165,0.0056909886,0.000027627004,0.04037887,0.0015622654,0.0046168864,0.0010528213,0.00023938414,0.005314625],"genre_scores_gemma":[0.94232804,0.00132487,0.00013090717,0.04522003,0.00036487635,0.0010771408,0.0015516399,0.000052267238,0.007950251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971486,0.00089422765,0.0006480623,0.000733135,0.00011307145,0.00046291525],"domain_scores_gemma":[0.9981691,0.0005928496,0.00035339844,0.0006631142,0.00020666764,0.000014861285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024283747,0.0005321195,0.0014214459,0.0003789248,0.000093292314,0.000017526818,0.00040243732,0.0011728309,0.00046066465],"category_scores_gemma":[0.00016198707,0.00038619246,0.00018732264,0.00050144235,0.00023170991,0.000094194365,0.00009073927,0.0008763451,0.00025287477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013723748,0.00025257646,0.6999561,0.00009690691,0.0013094783,0.00050708157,0.00018960376,3.416342e-7,0.00007992949,0.0000073250903,0.2968802,0.00058319495],"study_design_scores_gemma":[0.0028116729,0.0017772944,0.9296822,0.000998235,0.0010251466,0.00007415864,0.000081035156,0.0000010236288,0.0019332776,0.000044757075,0.061021715,0.0005494659],"about_ca_topic_score_codex":0.0013920154,"about_ca_topic_score_gemma":0.00021369936,"teacher_disagreement_score":0.23585847,"about_ca_system_score_codex":0.00021845441,"about_ca_system_score_gemma":0.00013108487,"threshold_uncertainty_score":0.999859},"labels":[],"label_agreement":null},{"id":"W4409448141","doi":"10.1007/s40257-025-00944-w","title":"Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Pharmacotherapy; Dermatology; MEDLINE; Intensive care medicine; Family medicine; Internal medicine","score_opus":0.02826216597991016,"score_gpt":0.35803172884862633,"score_spread":0.32976956286871617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409448141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98493844,0.00028930354,0.00020228807,0.011561361,0.001900176,0.00018750541,0.000058917016,0.000008690052,0.0008533173],"genre_scores_gemma":[0.99837756,0.00014846682,0.00038737978,0.0007155516,0.00012072314,0.000009200668,0.000016371581,0.000007975019,0.00021677183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968991,0.0010674346,0.0014948763,0.00024482037,0.00008784243,0.00020592457],"domain_scores_gemma":[0.99463147,0.0036754808,0.0010114807,0.0003520585,0.000284356,0.000045183846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006580398,0.0001604736,0.0009772669,0.00013271694,0.000070015754,0.000009028644,0.0006645782,0.000101809965,0.0000518934],"category_scores_gemma":[0.0010006978,0.00009316437,0.0002178864,0.0003358224,0.0004165699,0.000047753016,0.00010588012,0.0003207121,0.000051739935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018453928,0.0012188801,0.7512834,0.0000029044136,0.007273185,0.0001295866,0.0051691425,0.000074632975,0.00040370677,0.00030922197,0.015361209,0.2003202],"study_design_scores_gemma":[0.012988328,0.003159896,0.89627296,0.000104736,0.0010190951,0.00022687811,0.02656264,0.000003613972,0.00089681667,0.00012329494,0.058453295,0.0001884619],"about_ca_topic_score_codex":0.00045784368,"about_ca_topic_score_gemma":0.00020635728,"teacher_disagreement_score":0.20013173,"about_ca_system_score_codex":0.000015147435,"about_ca_system_score_gemma":0.00026415545,"threshold_uncertainty_score":0.37991327},"labels":[],"label_agreement":null},{"id":"W4409567485","doi":"10.1016/j.clinthera.2025.03.005","title":"A Canadian Real-World Study of Fixed-DOSE combination of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for the Treatment of Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SKiN Health; McMaster University; Bausch Health (Canada); Probity Medical Research; Dermatrials Research","funders":"Bausch Health","keywords":"Tazarotene; Medicine; Lotion; Dermatology; Psoriasis; Plaque psoriasis; Pharmacology","score_opus":0.07841509737631215,"score_gpt":0.3605263565612945,"score_spread":0.28211125918498237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409567485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938634,0.00090247084,0.0002470347,0.00084789377,0.0010108354,0.0026139428,0.00026484163,0.000018252944,0.00023132307],"genre_scores_gemma":[0.9960683,0.0012703241,0.00012879603,0.000101826954,0.000026289823,0.00022908395,0.00010532903,0.000016204292,0.002053862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981253,0.0004148081,0.0008720478,0.0002944814,0.000054066226,0.0002392561],"domain_scores_gemma":[0.997612,0.0012769538,0.0003116593,0.00048124162,0.000282516,0.0000356412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004236345,0.00020705377,0.0006372368,0.00020452886,0.00015673702,0.0000061078285,0.00023305653,0.00023902136,0.00003073454],"category_scores_gemma":[0.000049386334,0.00014022345,0.00024861956,0.00033439754,0.00012438698,0.000028759223,0.000022587876,0.00008855771,0.0000051259185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012142482,0.018318594,0.14464343,0.00014507057,0.01155463,0.00000355081,0.004174928,0.00090437196,0.007960862,0.007250845,0.00045259862,0.79244864],"study_design_scores_gemma":[0.06569952,0.03269693,0.7149728,0.00035257378,0.008652156,0.000004021694,0.0028776175,0.0016012106,0.13282311,0.0050363685,0.034395546,0.0008881589],"about_ca_topic_score_codex":0.00964389,"about_ca_topic_score_gemma":0.043800656,"teacher_disagreement_score":0.7915605,"about_ca_system_score_codex":0.00013616703,"about_ca_system_score_gemma":0.00031153567,"threshold_uncertainty_score":0.996951},"labels":[],"label_agreement":null},{"id":"W4409645248","doi":"10.5863/1551-6776-30.2.152","title":"Systematic Review of Adverse Events of IL-1 and IL-6 Inhibitor Use in Pediatrics","year":2025,"lang":"en","type":"article","venue":"The Journal of Pediatric Pharmacology and Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Anakinra; Adverse effect; Canakinumab; Population; Rash; Incidence (geometry); Tocilizumab; Internal medicine; Pediatrics; Intensive care medicine","score_opus":0.019630249918588777,"score_gpt":0.28954195739979294,"score_spread":0.2699117074812042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409645248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7639061,0.23496966,0.000016690532,0.00014201144,0.00061345927,0.00030777478,0.00002942825,0.0000024341819,0.000012406974],"genre_scores_gemma":[0.68208706,0.3174274,0.000021908172,0.00030999785,0.00005098801,0.0000036691358,0.000001688907,0.0000046334717,0.000092657414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806166,0.000821928,0.0008346664,0.00008096492,0.00005022033,0.00015055944],"domain_scores_gemma":[0.99777806,0.0011636366,0.0007863653,0.00010741615,0.00014731385,0.000017212538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012057152,0.00014227376,0.00064655504,0.000271645,0.000053238356,7.9680643e-7,0.00017357602,0.00014468064,0.000018352699],"category_scores_gemma":[0.00007813501,0.000089665264,0.000095233096,0.00032994951,0.00011268593,0.00007872449,0.000059148428,0.00024020544,0.0000015591679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065122796,0.0033893269,0.52078575,0.33135343,0.010304225,0.000083376726,0.004882071,0.000031690204,0.11468026,0.0006680357,0.0032340381,0.0040755365],"study_design_scores_gemma":[0.085365064,0.008155536,0.3813954,0.06079956,0.2962169,0.002070628,0.0044743405,0.000069518675,0.15019171,0.004944688,0.003792666,0.0025239717],"about_ca_topic_score_codex":0.000005348565,"about_ca_topic_score_gemma":0.000002058594,"teacher_disagreement_score":0.2859127,"about_ca_system_score_codex":0.000019381338,"about_ca_system_score_gemma":0.00011411463,"threshold_uncertainty_score":0.36564434},"labels":[],"label_agreement":null},{"id":"W4409777208","doi":"10.1016/j.jaad.2025.04.038","title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Sanofi Genzyme; Union Chimique Belge; Sanofi; UCB; Bright Research Group","keywords":"Medicine; Open label; Psoriasis; Dermatology; Plaque psoriasis; Extension (predicate logic); Clinical trial; Surgery; Internal medicine","score_opus":0.02517035636229951,"score_gpt":0.2934647518648225,"score_spread":0.268294395502523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409777208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98254687,0.00081366755,0.000029028626,0.015210997,0.00033665673,0.0007433005,0.00022794011,0.0000049334462,0.00008662663],"genre_scores_gemma":[0.99760926,0.00036253422,0.00067464955,0.0012652153,0.000020712143,0.0000069792945,0.000012786243,0.0000113540145,0.000036537927],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99704015,0.00118253,0.001098056,0.00031064113,0.000104266335,0.00026436552],"domain_scores_gemma":[0.99692935,0.0012295609,0.0013938112,0.00033020406,0.00009360886,0.000023462542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032060238,0.00022380766,0.0010926903,0.00008568101,0.00013501891,0.0000104744095,0.0007964803,0.00021358626,0.000008415686],"category_scores_gemma":[0.00030218103,0.00012371248,0.000107485735,0.00044324005,0.0006719366,0.00017504458,0.00032048847,0.0005110241,0.0000021036637],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88655454,0.0031375715,0.052508254,0.00003453984,0.003183681,0.000023267774,0.0059373896,0.00021060082,0.005275668,0.00086982775,0.013968319,0.028296355],"study_design_scores_gemma":[0.1556248,0.0011050329,0.81931394,0.00037916025,0.0005979383,0.00014853741,0.00048964954,0.0000037029824,0.014545536,0.0015347225,0.0060112183,0.00024573255],"about_ca_topic_score_codex":0.0005929503,"about_ca_topic_score_gemma":0.000036694266,"teacher_disagreement_score":0.7668057,"about_ca_system_score_codex":0.00005792566,"about_ca_system_score_gemma":0.00018054424,"threshold_uncertainty_score":0.5044849},"labels":[],"label_agreement":null},{"id":"W4409867655","doi":"10.1093/rheumatology/keaf142.115","title":"P075 Efficacy of methotrexate for symptomatic relief in patients with osteoarthritis: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Meta-analysis; Medicine; Osteoarthritis; Methotrexate; Systematic review; Internal medicine; Physical therapy; Alternative medicine; MEDLINE; Pathology; Political science","score_opus":0.029055698523128493,"score_gpt":0.29156837026000015,"score_spread":0.26251267173687165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409867655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047587568,0.99173164,0.000019211257,0.0000124505095,0.000045669643,0.007005697,0.0010426232,0.000026480822,0.00006865989],"genre_scores_gemma":[0.00005258149,0.99403995,0.00030349818,0.00004657594,0.0000032988273,0.0027463653,0.001384343,0.00003454946,0.0013888167],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962163,0.0013724625,0.0014388434,0.0005876106,0.0000696766,0.00031511456],"domain_scores_gemma":[0.9964117,0.0015788429,0.0010492636,0.0008156105,0.00011882017,0.000025768677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071264594,0.000594845,0.010729544,0.0005489533,0.00006205738,0.000013560332,0.00031034066,0.000388073,0.000067084875],"category_scores_gemma":[0.00032503504,0.000363653,0.0019426444,0.0009889973,0.000067386325,0.000038798873,0.00007855283,0.00016056541,0.000020845382],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003479939,0.00022436005,0.00001864861,0.7918488,0.19537377,0.0000026788011,0.000044285796,4.0163607e-7,1.221315e-7,0.00004318258,0.00004166088,0.012367279],"study_design_scores_gemma":[0.0016731304,0.00022999411,0.00003777911,0.0822196,0.91187996,0.0000049214805,0.0000040552436,9.872126e-8,0.0000017456002,0.0000058387054,0.0036329264,0.00030994497],"about_ca_topic_score_codex":0.000013954895,"about_ca_topic_score_gemma":0.000025440495,"teacher_disagreement_score":0.7165062,"about_ca_system_score_codex":0.000042359352,"about_ca_system_score_gemma":0.00009946399,"threshold_uncertainty_score":0.99988157},"labels":[],"label_agreement":null},{"id":"W4409867727","doi":"10.1093/rheumatology/keaf142.204","title":"P167 Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis outcomes: 6-month interim results of the PsABIOnd observational cohort study","year":2025,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Eli Lilly and Company","keywords":"Psoriatic arthritis; Interim; Medicine; Observational study; Cohort; Persistence (discontinuity); Internal medicine; Cohort study; Interim analysis; Physical therapy; Oncology; Arthritis; Randomized controlled trial","score_opus":0.03190475894723931,"score_gpt":0.2700578155658881,"score_spread":0.23815305661864877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409867727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950795,0.0026602808,0.000002402896,0.0002062123,0.0004688786,0.0011116919,0.00015686634,0.000017399147,0.0002967545],"genre_scores_gemma":[0.99871397,0.00021073032,0.000025772993,0.00002917887,0.000008436497,0.00016349253,0.00006414727,0.0000070074684,0.0007772606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856067,0.0004502642,0.00036381866,0.00037862523,0.00005260133,0.00019404083],"domain_scores_gemma":[0.999054,0.0004644111,0.000115980205,0.00030406468,0.000045935696,0.000015622114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000370085,0.00021399956,0.0005257275,0.000096002914,0.00016157835,0.000018622448,0.00012748824,0.000122018544,0.000009645242],"category_scores_gemma":[0.0000852803,0.0001486263,0.00008026937,0.00020684933,0.00016479813,0.00008016765,0.000098675715,0.00009124423,0.0000032399385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005914005,0.00075957825,0.98877186,0.00002648863,0.00061291247,0.0000050016397,0.0012427944,0.000012253212,0.0022615094,0.000087471926,0.00010730663,0.005521413],"study_design_scores_gemma":[0.008494175,0.0005286107,0.98460424,0.00019344909,0.00021201822,0.0000058719024,0.00072841765,0.000008866443,0.004483063,0.00007674,0.00054218346,0.0001223436],"about_ca_topic_score_codex":0.0006481929,"about_ca_topic_score_gemma":0.0015017597,"teacher_disagreement_score":0.007902774,"about_ca_system_score_codex":0.00011091975,"about_ca_system_score_gemma":0.00005964182,"threshold_uncertainty_score":0.6060805},"labels":[],"label_agreement":null},{"id":"W4409867809","doi":"10.1093/rheumatology/keaf142.325","title":"E090 Guselkumab and IL-17 inhibitors improve patient-perceived impact of psoriatic arthritis similarly: 6-month interim results of the PsABIOnd observational cohort study","year":2025,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Interim; Medicine; Observational study; Cohort; Psoriasis; Cohort study; Interim analysis; Dermatology; Physical therapy; Internal medicine; Randomized controlled trial","score_opus":0.015870450783844987,"score_gpt":0.25685846016270997,"score_spread":0.24098800937886497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409867809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548817,0.0013333911,0.0000021007165,0.0000987022,0.0007965208,0.0009540167,0.00087484077,0.000021821505,0.0004304399],"genre_scores_gemma":[0.99892616,0.00011924356,0.00003246667,0.000038278653,0.000023799648,0.0000594155,0.00017152759,0.000011554095,0.0006175381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984669,0.00028016072,0.00061111955,0.00034104605,0.00007891759,0.00022185137],"domain_scores_gemma":[0.9988786,0.00018009746,0.00030594398,0.00046408208,0.00015162432,0.00001964092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024706527,0.00022526731,0.0004757679,0.00009712647,0.00013752434,0.0000138628175,0.00020454341,0.00018827338,0.000048514838],"category_scores_gemma":[0.00020391485,0.00015756521,0.00019728891,0.00023558245,0.00017933831,0.00010388543,0.00015854379,0.00014394353,0.000004856671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001809422,0.0014391519,0.807528,0.00003583666,0.0021493158,0.000004428489,0.0038624932,0.000018085935,0.14153461,0.00006558839,0.004457124,0.037095934],"study_design_scores_gemma":[0.005298534,0.0012448851,0.97513264,0.00012352008,0.000291158,0.0000032813787,0.00050215493,0.0000072201556,0.016631896,0.00011107359,0.00051434955,0.00013929211],"about_ca_topic_score_codex":0.0006506149,"about_ca_topic_score_gemma":0.00026773376,"teacher_disagreement_score":0.16760463,"about_ca_system_score_codex":0.00007056154,"about_ca_system_score_gemma":0.00013008711,"threshold_uncertainty_score":0.64253235},"labels":[],"label_agreement":null},{"id":"W4410133096","doi":"10.5826/dpc.1502a4793","title":"Biologic and Non-Biologic Therapies for Scalp Psoriasis: A Network Meta-analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Dermatology Practical & Conceptual","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"McMaster University","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Scalp; Psoriasis; Dermatology; MEDLINE; Surgery; Pathology","score_opus":0.17594316472836974,"score_gpt":0.4018495761515475,"score_spread":0.22590641142317774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410133096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004906459,0.98724926,0.001436702,0.0005241431,0.0011295143,0.008216549,0.00097538676,0.000084153995,0.00033525165],"genre_scores_gemma":[0.0017826,0.9853493,0.0011284584,0.00033551472,0.00010018906,0.008415047,0.0019284462,0.000033396893,0.0009270646],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9685419,0.024342524,0.004978953,0.0011927923,0.000083357154,0.00086048257],"domain_scores_gemma":[0.85883266,0.13613918,0.004057384,0.0006349487,0.0002748682,0.000060941613],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0086017735,0.0013045622,0.061272033,0.00084733154,0.00031395725,0.000040549134,0.00048160512,0.0029020407,0.0009981714],"category_scores_gemma":[0.01918081,0.0006667703,0.020327762,0.00084195356,0.0025164362,0.00009412895,0.00021242604,0.0006150797,0.000045213874],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034912083,0.00025735257,0.000009789788,0.00090585847,0.90605545,0.000021302774,0.00013067794,0.0000013572749,0.0000072736116,0.018033966,0.0014678111,0.03819705],"study_design_scores_gemma":[0.07536252,0.00014940066,0.0000012480674,0.00015286618,0.7243967,0.00009448723,0.00013412572,0.000005359633,0.000013703045,0.000444447,0.1988111,0.0004340226],"about_ca_topic_score_codex":0.000014106951,"about_ca_topic_score_gemma":0.000010762714,"teacher_disagreement_score":0.19734329,"about_ca_system_score_codex":0.000032420216,"about_ca_system_score_gemma":0.0005266796,"threshold_uncertainty_score":0.9999706},"labels":[],"label_agreement":null},{"id":"W4410156931","doi":"10.1001/jamadermatol.2025.1136","title":"Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body","year":2025,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Probity Medical Research; Western University; SKiN Health; Queen's University","funders":"Pfizer; Eli Lilly and Company; Sun Pharma; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Scalp; Tolerability; Randomized controlled trial; Psoriasis; Clinical endpoint; Randomization; Adverse effect; Roflumilast; Internal medicine; Physical therapy; Dermatology","score_opus":0.008634013456365299,"score_gpt":0.23688500562185918,"score_spread":0.22825099216549388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410156931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820396,0.006941103,0.0004581051,0.0046408772,0.0018752676,0.0005014385,0.00010178268,0.000040552928,0.0034012778],"genre_scores_gemma":[0.9969832,0.00011375762,0.0001090277,0.00044805728,0.000018386652,0.00009308359,0.000029762941,0.0000083096875,0.0021964647],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907804,0.00017008507,0.00026491555,0.00022146787,0.0000158798,0.0002496232],"domain_scores_gemma":[0.9991081,0.00042233733,0.00010346018,0.00028843433,0.00006670539,0.000010972576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008582137,0.00014103828,0.00034282307,0.000096038086,0.00018722542,0.000007893537,0.00020863047,0.000343722,0.000039870545],"category_scores_gemma":[0.0001374776,0.000098357144,0.00012956651,0.0001463496,0.00025931472,0.000042362968,0.00011049787,0.00009503784,0.000020045421],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017616979,0.0006098866,0.3091819,0.0005333845,0.0028840885,0.000013513633,0.0009453508,0.0000021324063,0.23799026,0.12165206,0.14484484,0.17958088],"study_design_scores_gemma":[0.0068063103,0.00008809852,0.16706204,0.00006854923,0.0005462774,0.00028617188,0.0002561736,0.000014390686,0.59497553,0.0033073016,0.22638872,0.00020042712],"about_ca_topic_score_codex":0.000025951545,"about_ca_topic_score_gemma":0.000027784889,"teacher_disagreement_score":0.35698527,"about_ca_system_score_codex":0.000012558138,"about_ca_system_score_gemma":0.000071813396,"threshold_uncertainty_score":0.4010888},"labels":[],"label_agreement":null},{"id":"W4410290285","doi":"10.1093/ecco-jcc/jjaf080","title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis","year":2025,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Medac; Bristol-Myers Squibb Canada; Nordic Pharma Group; Eisai; Celltrion; Kissei; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celltrion Healthcare; Astellas Pharma; Mylan; Biogen; EA Pharma Co., Ltd.; Gilead Sciences; Seres Therapeutics; Amgen; Kyorin Pharmaceutical; Pfizer","keywords":"Medicine; Ulcerative colitis; Inflammatory bowel disease; Clinical endpoint; Placebo; Internal medicine; Gastroenterology; Randomized controlled trial; Adverse effect; Colitis; Phases of clinical research; Crohn's disease; Clinical trial; Psoriasis; Immunology; Disease; Pathology","score_opus":0.01266118477218858,"score_gpt":0.26125967470157774,"score_spread":0.24859848992938915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410290285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825934,0.015226583,0.000007034506,0.00027014816,0.00022322436,0.00071063376,0.0008732569,0.00000699142,0.00008872858],"genre_scores_gemma":[0.9929048,0.0064766356,0.000034566623,0.00010356366,0.000034098975,0.000037685364,0.000086166336,0.000009837411,0.00031268218],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99798346,0.000603906,0.0007844706,0.0002919871,0.00007081049,0.00026537702],"domain_scores_gemma":[0.9981887,0.0010746255,0.00033387062,0.00012691045,0.00015916672,0.00011673377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043928673,0.00025254142,0.00084584963,0.0002495627,0.00016593807,0.00004326465,0.00007259479,0.000098165256,0.000019312294],"category_scores_gemma":[0.00047609885,0.00018524751,0.000071661656,0.00009413028,0.00055144454,0.00019864309,0.00006601827,0.00019246056,8.5554615e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90326214,0.00071919255,0.072444774,0.00007915936,0.0011455165,0.0007919814,0.0023319402,0.0000036202619,0.0000073529422,0.00030732516,0.00031541765,0.018591573],"study_design_scores_gemma":[0.2562666,0.0002010166,0.7410042,0.00066494127,0.00038654334,0.000004636326,0.00033702972,0.0000026973414,0.00002372987,0.0005883362,0.000383649,0.00013661625],"about_ca_topic_score_codex":0.00007215233,"about_ca_topic_score_gemma":0.00031885185,"teacher_disagreement_score":0.66855943,"about_ca_system_score_codex":0.00007000428,"about_ca_system_score_gemma":0.00017631082,"threshold_uncertainty_score":0.75541747},"labels":[],"label_agreement":null},{"id":"W4410353018","doi":"10.1002/jvc2.70043","title":"Genital Psoriasis: Shining Light on This Hidden Disease","year":2025,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Psoriasis; Dermatology; Sex organ; Disease; Medicine; Pathology; Biology","score_opus":0.03847842700681338,"score_gpt":0.35995346204993933,"score_spread":0.32147503504312597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410353018","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44906375,0.019246906,0.00018599948,0.052065652,0.023223791,0.0012433359,0.000170226,0.00079349516,0.45400685],"genre_scores_gemma":[0.9401328,0.000790389,0.00082136126,0.0075130844,0.0005146317,0.00008979585,0.00013901011,0.000034638597,0.049964294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969223,0.0011455462,0.00076047465,0.0006700999,0.00008629802,0.00041527214],"domain_scores_gemma":[0.99214864,0.0066399644,0.00029453906,0.00069116725,0.00013051149,0.0000951935],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010123684,0.00028714453,0.00045255787,0.00012453501,0.00033434454,0.000050475992,0.00036259103,0.00044767238,0.00094530405],"category_scores_gemma":[0.010081085,0.00023808474,0.0003594404,0.00025153474,0.00012654506,0.00034462288,0.00015072044,0.00069287705,0.007219406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014154821,0.005384664,0.019871946,0.00005784592,0.0040543256,0.00051748846,0.0004545057,0.000002503879,0.001929645,0.021779522,0.23038569,0.701407],"study_design_scores_gemma":[0.0038300764,0.00044340125,0.035904743,0.00009643562,0.0016776898,0.000013991074,0.00028156018,0.00000390595,0.0010581384,0.0008458253,0.95550215,0.0003420771],"about_ca_topic_score_codex":0.000029158295,"about_ca_topic_score_gemma":0.0000058599285,"teacher_disagreement_score":0.7251165,"about_ca_system_score_codex":0.000056638833,"about_ca_system_score_gemma":0.00023052203,"threshold_uncertainty_score":0.999968},"labels":[],"label_agreement":null},{"id":"W4410431250","doi":"10.1093/skinhd/vzaf021","title":"Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis","year":2025,"lang":"en","type":"article","venue":"Skin Health and Disease","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Portugal; Janssen Australia; Cilag; UCB Pharma; Merck Sharp and Dohme; Sandoz Canada; UCB Pharma France; LEO Pharma; Almirall; AMGEN Germany; Boehringer Ingelheim España; Celgene; AbbVie Canada; British Microcirculation Society; Amgen; Pfizer; Eli Lilly and Company","keywords":"Plaque psoriasis; Medicine; Psoriasis; Dermatology; Internal medicine","score_opus":0.007288268913860756,"score_gpt":0.23623122013397094,"score_spread":0.22894295122011019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410431250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584657,0.002749323,0.000014243786,0.00012965921,0.000075487515,0.0005210768,0.00048058777,0.000025418549,0.00015763589],"genre_scores_gemma":[0.9979132,0.00046004957,0.000021407865,0.00009620502,0.0000071950176,0.00009124109,0.0008995416,0.000009304968,0.00050189544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887073,0.00020364518,0.00026454488,0.00034113383,0.000040295403,0.00027967468],"domain_scores_gemma":[0.9992945,0.00008254685,0.00013981391,0.00029426554,0.000042019437,0.00014684444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000066633234,0.00021280006,0.00049173593,0.00031196588,0.00009899623,0.0000063076704,0.000061730476,0.00008269052,0.000044339846],"category_scores_gemma":[0.0000139037775,0.00013772013,0.00007624551,0.0006049932,0.00010803349,0.000037027206,0.000009649193,0.000046225035,0.0000015995946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009660464,0.00077521923,0.9810558,0.000062978834,0.0017514603,0.000004710536,0.00022966808,0.000017731456,0.000004713797,0.000050816416,0.00008191996,0.006304501],"study_design_scores_gemma":[0.009859007,0.0012803554,0.9868948,0.000067337845,0.00084145105,1.8105851e-7,0.00013634595,0.0000029144908,0.0001729563,0.00001176933,0.0006126699,0.00012019688],"about_ca_topic_score_codex":0.0018437376,"about_ca_topic_score_gemma":0.0007932604,"teacher_disagreement_score":0.006184304,"about_ca_system_score_codex":0.00012406727,"about_ca_system_score_gemma":0.0005595586,"threshold_uncertainty_score":0.5616064},"labels":[],"label_agreement":null},{"id":"W4410455633","doi":"10.1177/12034754251339106","title":"Outcomes of Isolated Nail Psoriasis Treatment With Roflumilast 0.3% Cream: A Case Series of 7 Patients","year":2025,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Roflumilast; Dermatology; Psoriasis; Nail (fastener); Series (stratigraphy); Internal medicine; COPD","score_opus":0.01464097484935083,"score_gpt":0.23806699879020776,"score_spread":0.22342602394085692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410455633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929161,0.0056786067,0.0000139039985,0.00037567504,0.00061220495,0.00010490257,0.000034284396,0.000007302149,0.00025703094],"genre_scores_gemma":[0.9959036,0.0026023136,0.000033502292,0.000059330436,0.000025162699,0.000002514244,0.000017720946,0.000008980689,0.0013468746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872893,0.00013506545,0.00077376305,0.00012111385,0.000069768364,0.00017136379],"domain_scores_gemma":[0.9980036,0.0009055967,0.00059510727,0.00014743976,0.00031129603,0.00003697404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018125933,0.0002051455,0.0011087966,0.00038941775,0.00007260307,0.000002627634,0.000053979347,0.00012902626,0.00010719752],"category_scores_gemma":[0.00013230254,0.000114452334,0.00016453993,0.00019935796,0.00024644684,0.00006475449,0.000013565404,0.00008331662,9.567052e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008431133,0.0014247136,0.8544012,0.00016619277,0.005809391,0.0047234986,0.0020982581,0.000003126143,0.004059184,0.000029773519,0.004257323,0.11459624],"study_design_scores_gemma":[0.06469268,0.08839963,0.3273395,0.00704148,0.026218746,0.22365274,0.02264317,0.000009257736,0.14846408,0.0006014193,0.08887116,0.002066156],"about_ca_topic_score_codex":0.0001426889,"about_ca_topic_score_gemma":0.000059848328,"teacher_disagreement_score":0.5270617,"about_ca_system_score_codex":0.000031455646,"about_ca_system_score_gemma":0.00014433003,"threshold_uncertainty_score":0.46672305},"labels":[],"label_agreement":null},{"id":"W4410589534","doi":"10.1177/17562848251335824","title":"MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Amgen","keywords":"Medicine; Internal medicine; Randomized controlled trial; Psoriasis; Cohort study; Systematic review; Cohort; Observational study; Clinical trial; Relative risk; MEDLINE; Immunology; Confidence interval","score_opus":0.014594544777399226,"score_gpt":0.26961400377438827,"score_spread":0.255019458996989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410589534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057594496,0.9950349,0.00003143833,0.000030555584,0.0005543602,0.003477554,0.00020670239,0.00004664577,0.000041917458],"genre_scores_gemma":[0.00044302212,0.996783,0.0001477011,0.00034791193,0.000027929036,0.0013355135,0.00034284362,0.000055108925,0.0005169317],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9947517,0.002038319,0.0014228415,0.00090476597,0.0000854411,0.0007969216],"domain_scores_gemma":[0.997526,0.00090331153,0.00082186155,0.0006516571,0.000059693248,0.000037487098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049756235,0.0008745992,0.004329675,0.0005799079,0.00008790367,0.000015862895,0.00046608475,0.00051309826,0.000101888145],"category_scores_gemma":[0.00011165005,0.00056257925,0.00026744776,0.000507468,0.00024964826,0.00020618961,0.00018150148,0.0005363949,0.000044155637],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001264767,0.0004290773,0.0057127066,0.53618234,0.0011028942,0.000034621786,0.0001452387,6.7803603e-7,5.399613e-7,0.000012695573,0.00006108802,0.45505336],"study_design_scores_gemma":[0.0055111563,0.0024965368,0.0009565564,0.8846411,0.007314656,0.00014282223,0.000057729547,3.535189e-7,0.0000030015415,0.00003066175,0.098162495,0.0006829101],"about_ca_topic_score_codex":0.000010770357,"about_ca_topic_score_gemma":0.0003212769,"teacher_disagreement_score":0.45437044,"about_ca_system_score_codex":0.00022135903,"about_ca_system_score_gemma":0.00009836473,"threshold_uncertainty_score":0.99968255},"labels":[],"label_agreement":null},{"id":"W4410706661","doi":"10.1093/ced/llaf215","title":"Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis","year":2025,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"Manchester Biomedical Research Centre; Bristol-Myers Squibb Canada; Samsung; LEO Pharma; Sun Pharma; Celgene; Teva Pharmaceutical Industries; National Institute for Health and Care Research; XBiotech; Celltrion; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Placebo; Medicine; Psoriasis Area and Severity Index; Plaque psoriasis; Erythema; Psoriasis; Desquamation; Internal medicine; Severity of illness; Clinical trial; Surgery; Gastroenterology; Dermatology; Pathology","score_opus":0.04650189664611037,"score_gpt":0.35105570569781197,"score_spread":0.3045538090517016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410706661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974109,0.0010781479,0.000020028052,0.00021118368,0.000321424,0.0006653599,0.00016855822,0.000011967177,0.000112413094],"genre_scores_gemma":[0.9992758,0.00015832878,0.00013610635,0.0002177989,0.000005172412,0.00006459392,0.000100848556,0.000009749005,0.00003162249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970751,0.00073640584,0.0013761921,0.00047868153,0.000046302546,0.00028732332],"domain_scores_gemma":[0.99853534,0.00087453384,0.00028584764,0.00019576903,0.000044419572,0.00006410394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039370175,0.00028670157,0.0017830115,0.0002590398,0.000066208064,0.000007974684,0.00010891405,0.00029992216,0.000033378303],"category_scores_gemma":[0.00013681318,0.000221711,0.00008911824,0.00016091332,0.00044889154,0.000088968955,0.00018236165,0.00017109732,0.0000016390841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015427091,0.0019294537,0.97229934,0.00003994478,0.00045734242,0.000013470323,0.00063812995,0.0000020261455,0.0013889596,0.00021349399,0.00007362968,0.007517128],"study_design_scores_gemma":[0.07996192,0.00056033203,0.8877878,0.0001262939,0.00013326605,0.000025160964,0.00056010176,0.000023228138,0.030201359,0.0002526027,0.00011356292,0.0002543818],"about_ca_topic_score_codex":0.00031509416,"about_ca_topic_score_gemma":0.00017917641,"teacher_disagreement_score":0.08451153,"about_ca_system_score_codex":0.00001709178,"about_ca_system_score_gemma":0.000043450178,"threshold_uncertainty_score":0.9041112},"labels":[],"label_agreement":null},{"id":"W4410711514","doi":"10.1016/j.jaad.2025.05.1412","title":"The association between bariatric surgery and improvement in psoriasis: A systematic review","year":2025,"lang":"en","type":"review","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Queen's University; McMaster University","funders":"","keywords":"Medicine; Psoriasis; Dermatology; MEDLINE; Association (psychology); Surgery; General surgery","score_opus":0.02028919796348273,"score_gpt":0.2997666705720775,"score_spread":0.2794774726085948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410711514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004032478,0.99581003,0.0000013179406,0.002291601,0.00048884476,0.00094496156,0.000036281148,0.0000047343497,0.00001899502],"genre_scores_gemma":[0.00081459404,0.9985801,0.0000075518537,0.00025098448,0.00004582856,0.00007346709,0.0000054303637,0.0000144454125,0.00020759678],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99310046,0.003568614,0.0026764085,0.00019104528,0.00011720021,0.0003462847],"domain_scores_gemma":[0.98299724,0.0076749236,0.009009872,0.00022929578,0.00006434689,0.000024342218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018700141,0.0003414229,0.0054852525,0.0004139392,0.00012653564,0.000010365981,0.000734835,0.00039597254,0.0000029700273],"category_scores_gemma":[0.0016527312,0.00016849875,0.0010608135,0.00082160806,0.00019651638,0.000048167858,0.00017302285,0.0008451989,0.00000799917],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044502947,0.00007991202,0.004174467,0.5167047,0.008461667,0.000010664264,0.00004489003,4.632674e-8,0.000006175159,0.000094043855,0.008341617,0.46203735],"study_design_scores_gemma":[0.0010957763,0.00013136379,0.0026293453,0.5927724,0.053926643,0.0022872447,0.00011178255,6.720193e-8,0.00007177339,0.00019551006,0.34624484,0.00053324597],"about_ca_topic_score_codex":0.000012249655,"about_ca_topic_score_gemma":0.0000020681464,"teacher_disagreement_score":0.4615041,"about_ca_system_score_codex":0.0002272788,"about_ca_system_score_gemma":0.00043688144,"threshold_uncertainty_score":0.687118},"labels":[],"label_agreement":null},{"id":"W4410850742","doi":"10.1007/s13555-025-01434-x","title":"Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Brampton Civic Hospital; Nova Chemicals (Canada); Bayer (Canada); Probity Medical Research; Calgary Laboratory Services; SKiN Health; University of Calgary","funders":"Sun Pharma","keywords":"Medicine; Plaque psoriasis; Psoriasis; Retrospective cohort study; Dermatology; Internal medicine","score_opus":0.007483775893738951,"score_gpt":0.22781465538256276,"score_spread":0.22033087948882382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410850742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410737,0.0018866675,0.000017969433,0.0018466391,0.00017659628,0.0010059426,0.00035220676,0.000048387705,0.0005582209],"genre_scores_gemma":[0.99672765,0.0008296923,0.000045483932,0.00095124403,0.000009420128,0.0006984262,0.0006018826,0.0000117718155,0.00012443853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984983,0.00028368967,0.0002524428,0.0004973138,0.00003309757,0.00043514365],"domain_scores_gemma":[0.99935687,0.000115131465,0.000069392016,0.0003505353,0.00005396817,0.00005411747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004614285,0.00029650985,0.0005242489,0.0003223574,0.0003669295,0.00003300918,0.00014542209,0.0003065965,0.00017263816],"category_scores_gemma":[0.00000519071,0.0001817052,0.000099044424,0.0004999954,0.00010668167,0.0000488144,0.000020148023,0.00015403662,0.000026917776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002765031,0.00033968937,0.88544816,0.0000030880328,0.0043193107,0.0001438431,0.005437316,0.000014922367,0.000014738495,0.00042351775,0.00023011216,0.1008603],"study_design_scores_gemma":[0.009359379,0.0009080181,0.9727921,0.000053759322,0.0005718905,0.00009188119,0.0009254827,0.000028146173,0.0034284214,0.00028738423,0.0112278415,0.00032571942],"about_ca_topic_score_codex":0.098503344,"about_ca_topic_score_gemma":0.6515349,"teacher_disagreement_score":0.55303156,"about_ca_system_score_codex":0.00016981839,"about_ca_system_score_gemma":0.00023954565,"threshold_uncertainty_score":0.9074998},"labels":[],"label_agreement":null},{"id":"W4410932188","doi":"10.2196/69026","title":"Representation of Psoriasis on the Web for Patients With Skin of Color","year":2025,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Psoriasis; Dermatology; Representation (politics); Medicine; Computer science; World Wide Web; Political science","score_opus":0.011611355965961015,"score_gpt":0.26009884871987576,"score_spread":0.24848749275391474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410932188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643147,0.00014610088,0.00004024158,0.0006472146,0.00032437674,0.0008163859,0.00009168236,0.00001429991,0.0014882127],"genre_scores_gemma":[0.9988457,0.000018085206,0.00006926826,0.00010775732,0.0000046197642,0.00033442353,0.00012022717,0.000006260488,0.00049368094],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999255,0.00016833383,0.0002474302,0.0001612389,0.000022992754,0.00014502413],"domain_scores_gemma":[0.998726,0.00071877195,0.00017967545,0.00025065424,0.000119714554,0.0000051738275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004485077,0.00010395225,0.0003082563,0.000115759176,0.00007197616,0.0000016826201,0.00013637333,0.00015958537,0.000058367878],"category_scores_gemma":[0.000060491584,0.000063972286,0.00008676466,0.00020294962,0.00015711471,0.0000219806,0.000023775228,0.000048021047,0.000015445428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013183295,0.0032336577,0.7417583,0.00038444786,0.0036673078,0.0000048009438,0.0016147282,0.000015433796,0.037099365,0.08717811,0.07054012,0.04132044],"study_design_scores_gemma":[0.011866527,0.0009904305,0.33600023,0.00010115462,0.00042099712,0.00001279693,0.0004568866,0.000010965318,0.6259101,0.0007896785,0.023249969,0.00019027876],"about_ca_topic_score_codex":0.000010405419,"about_ca_topic_score_gemma":0.000018401026,"teacher_disagreement_score":0.58881074,"about_ca_system_score_codex":0.000011153414,"about_ca_system_score_gemma":0.00005612566,"threshold_uncertainty_score":0.2608714},"labels":[],"label_agreement":null},{"id":"W4411048402","doi":"10.1016/j.jdin.2025.04.011","title":"Bimekizumab for psoriasis treatment: A Canadian real-world multicenter study","year":2025,"lang":"en","type":"article","venue":"JAAD International","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; SKiN Health; Ottawa Hospital; Saskatoon City Hospital; Children's Hospital of Eastern Ontario; University of Ottawa; Probity Medical Research; Dalhousie University; CARE Canada; University of Saskatchewan; Greenfield Research (Canada); Saskatchewan Science Centre; Western University","funders":"UCB","keywords":"Psoriasis; Medicine; Dermatology; Family medicine","score_opus":0.021849464680074135,"score_gpt":0.2986767522979553,"score_spread":0.27682728761788117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411048402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8735884,0.00046810418,0.00009107112,0.0020363696,0.0088042095,0.0018886804,0.0010753843,0.00013240606,0.11191539],"genre_scores_gemma":[0.87091917,0.000045019166,0.00012347553,0.0001647513,0.00010905947,0.00045444502,0.0005305692,0.0000124461685,0.12764104],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999026,0.00007078259,0.00024923726,0.00033201269,0.000032517284,0.0002894683],"domain_scores_gemma":[0.9994142,0.00015929808,0.000060657603,0.00021898981,0.00011338993,0.000033436416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000094532414,0.0001900653,0.00021264012,0.0005098695,0.00020828641,0.00003274805,0.00023870813,0.00010049321,0.0009510888],"category_scores_gemma":[0.000040864037,0.00016248204,0.000155062,0.00014494377,0.000033120185,0.00007165468,0.000028262211,0.000052964755,0.00031604696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002457465,0.003540126,0.55156946,0.000015508804,0.0106379455,0.000043740987,0.002551695,0.000012967918,0.0024544925,0.017983846,0.047440812,0.36129192],"study_design_scores_gemma":[0.016272694,0.00062879495,0.24773142,0.00003711367,0.00057357154,0.000003473687,0.0006701678,0.000070277056,0.00859761,0.00038668927,0.72471803,0.00031018927],"about_ca_topic_score_codex":0.05770177,"about_ca_topic_score_gemma":0.2634331,"teacher_disagreement_score":0.6772772,"about_ca_system_score_codex":0.0005717486,"about_ca_system_score_gemma":0.00020155078,"threshold_uncertainty_score":0.99996215},"labels":[],"label_agreement":null},{"id":"W4411242481","doi":"10.1111/pde.16007","title":"The Association of Psoriasis and Bacterial Infections in Pediatric Patients: A Retrospective Review","year":2025,"lang":"en","type":"review","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Pediatric Dermatology Research Alliance","keywords":"Medicine; Psoriasis; Retrospective cohort study; Dermatology; Association (psychology); Pediatrics; Internal medicine","score_opus":0.008796552380245884,"score_gpt":0.2578746923082784,"score_spread":0.24907813992803254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411242481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009269961,0.994039,8.286111e-7,0.0000634674,0.0029371888,0.0011795775,0.00025240262,0.000032390504,0.00056816096],"genre_scores_gemma":[0.00023171044,0.9981891,0.0000049938026,0.000016794254,0.0001649286,0.00043938388,0.00046287786,0.00001980978,0.00047038405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99646854,0.0014007898,0.0011876293,0.00045105576,0.00006416912,0.00042779706],"domain_scores_gemma":[0.9957345,0.0024932527,0.0012329875,0.000338164,0.0001792481,0.000021809847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043534333,0.00040841836,0.0021071783,0.000548676,0.00019870118,0.000012962989,0.00025992838,0.0008928154,0.00004913347],"category_scores_gemma":[0.0016646825,0.00029450827,0.00038370086,0.0011903826,0.00005627949,0.00006328734,0.0001616456,0.00044148462,0.00008432172],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055492317,0.0006077521,0.34696582,0.050218802,0.00094388594,0.000008941782,0.0000754784,1.8007572e-8,1.1506344e-7,0.00042360125,0.0336857,0.5670144],"study_design_scores_gemma":[0.0018798007,0.000103959945,0.01643893,0.0016648397,0.01033009,0.000054384556,0.0000040088294,1.5625035e-8,7.8625686e-7,0.000058024372,0.9690853,0.00037985423],"about_ca_topic_score_codex":0.000024402603,"about_ca_topic_score_gemma":0.00008672624,"teacher_disagreement_score":0.9353996,"about_ca_system_score_codex":0.00024686777,"about_ca_system_score_gemma":0.0004979,"threshold_uncertainty_score":0.9999507},"labels":[],"label_agreement":null},{"id":"W4411394482","doi":"10.1016/j.ard.2025.05.117","title":"OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Double blind; Multicenter study; Internal medicine; Arthritis; Randomized controlled trial; Dermatology; Alternative medicine; Pathology","score_opus":0.023921558269499748,"score_gpt":0.2943720277713867,"score_spread":0.27045046950188695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411394482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98748606,0.0053849863,0.000028838649,0.00020644593,0.00039360215,0.0059306743,0.0004954012,0.000019058409,0.000054944067],"genre_scores_gemma":[0.9986688,0.0005057954,0.000031544463,0.000076381955,0.000005684869,0.00042373996,0.000108167056,0.000015137111,0.00016477627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974018,0.00087007065,0.0009742383,0.00034425498,0.00011700027,0.0002926698],"domain_scores_gemma":[0.9971105,0.0017497315,0.00043722367,0.00050237513,0.00014569316,0.00005450917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043060572,0.000310616,0.0015113222,0.00022136829,0.00011944825,0.000019419002,0.00031672695,0.000083053565,0.00010734824],"category_scores_gemma":[0.0006481216,0.00019339853,0.00024315456,0.00026766208,0.0002128492,0.000091094436,0.00013918019,0.00008463724,0.000013121541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9040136,0.006856874,0.02168572,0.00007732795,0.0039989613,0.0000015682941,0.002176357,0.000025562715,0.000019251434,0.00007649129,0.00015611282,0.060912214],"study_design_scores_gemma":[0.9094125,0.0007155572,0.08530017,0.0013915581,0.0013472899,2.7286418e-7,0.0008800604,0.000012028908,0.0005810672,0.00016485606,0.000015228371,0.000179421],"about_ca_topic_score_codex":0.00048246866,"about_ca_topic_score_gemma":0.00014029158,"teacher_disagreement_score":0.06361445,"about_ca_system_score_codex":0.000013632744,"about_ca_system_score_gemma":0.00008839816,"threshold_uncertainty_score":0.78865635},"labels":[],"label_agreement":null},{"id":"W4411410187","doi":"10.1016/j.ard.2025.06.1445","title":"ABS0902 DEUCRAVACITINIB IN PLAQUE PSORIASIS: IMMUNE RESPONSE TO AND SAFETY OF PNEUMOCOCCUS AND TETANUS TOXOID VACCINES IN THE POETYK LTE TRIAL","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Toxoid; Tetanus; Immune system; Immunology; Psoriasis; Plaque psoriasis; Vaccination","score_opus":0.021205998693083126,"score_gpt":0.28544844599958175,"score_spread":0.2642424473064986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411410187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98227143,0.0128187025,0.000001668194,0.0034037728,0.00025920218,0.00091014797,0.00017658153,0.000008872731,0.00014961955],"genre_scores_gemma":[0.997704,0.0017225953,0.000009875417,0.0001790992,0.0000064445017,0.00010183727,0.000011649128,0.000006847644,0.00025760537],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99790204,0.0009869298,0.0006213559,0.00020934491,0.000054340086,0.0002259965],"domain_scores_gemma":[0.997616,0.0017120114,0.00018294128,0.00042446595,0.000044199765,0.000020359817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088260847,0.00018415411,0.00051015295,0.00021393089,0.00009148679,0.000012846128,0.00032585723,0.00009667375,0.000028437606],"category_scores_gemma":[0.0010743769,0.00010970464,0.00012562827,0.0003523356,0.00012569716,0.00006004879,0.0001363364,0.00008150617,0.0000038454705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4764269,0.0038660874,0.06489194,0.0010769963,0.0025494383,0.000026734691,0.013611506,0.00008068057,0.031407073,0.0041770195,0.0038112411,0.3980744],"study_design_scores_gemma":[0.019032042,0.0004000308,0.96557516,0.000944869,0.0002096533,0.0000075779544,0.0015399846,0.0000031740508,0.0093008615,0.0023328643,0.0004975773,0.00015620196],"about_ca_topic_score_codex":0.00020687988,"about_ca_topic_score_gemma":0.000100260826,"teacher_disagreement_score":0.9006832,"about_ca_system_score_codex":0.000009084877,"about_ca_system_score_gemma":0.000088584165,"threshold_uncertainty_score":0.44736254},"labels":[],"label_agreement":null},{"id":"W4411410510","doi":"10.1016/j.ard.2025.06.1399","title":"ABS0774 PUSTULAR PSORIASIS IS LINKED TO A SEVERE DISEASE PHENOTYPE IN PSORIATIC ARTHRITIS","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Krembil Foundation; Toronto Western Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Pustular psoriasis; Disease; Arthritis; Immunology; Pathology","score_opus":0.02199290902070357,"score_gpt":0.27500821185692814,"score_spread":0.2530153028362246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411410510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675239,0.024662923,0.000017924584,0.00491175,0.0011028368,0.0007523262,0.0004622023,0.00005163889,0.0005145487],"genre_scores_gemma":[0.99434257,0.0016537384,0.00003280649,0.0014667867,0.000017426604,0.00015244295,0.000048686856,0.000017021084,0.0022685006],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983438,0.00029457005,0.00053342077,0.00034151645,0.00009271915,0.00039392966],"domain_scores_gemma":[0.998609,0.00029347936,0.00015968544,0.0007579203,0.000099949255,0.000079947866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017867988,0.00026404354,0.0005231334,0.0002219469,0.00015078425,0.000022355676,0.0005067096,0.00011099458,0.0005561534],"category_scores_gemma":[0.00068032625,0.00019866391,0.0003402476,0.0005837538,0.000106315056,0.00009104717,0.00018887426,0.00009166512,0.00027757723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014398174,0.0019680818,0.051030565,0.00066677347,0.0021159363,0.000016098058,0.0022453996,0.0001759155,0.0003203702,0.0033413188,0.058131218,0.8785485],"study_design_scores_gemma":[0.0038370378,0.00010987588,0.96163595,0.0028547568,0.00068920257,0.0000022382349,0.0004370764,0.000023992423,0.0018406761,0.02131709,0.00679647,0.00045565993],"about_ca_topic_score_codex":0.00018494077,"about_ca_topic_score_gemma":0.00004558762,"teacher_disagreement_score":0.9106054,"about_ca_system_score_codex":0.00002553705,"about_ca_system_score_gemma":0.00019980648,"threshold_uncertainty_score":0.8101279},"labels":[],"label_agreement":null},{"id":"W4411410596","doi":"10.1016/j.ard.2025.06.1258","title":"ABS0448 ZASOCITINIB (TAK-279), AN ORAL, ALLOSTERIC, SELECTIVE TYK2 INHIBITOR, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: EFFICACY ANALYSIS BY BASELINE CHARACTERISTICS FROM A RANDOMISED PHASE 2B TRIAL","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Internal medicine; Randomized controlled trial; Clinical trial; Pharmacology; Dermatology","score_opus":0.028502580437707144,"score_gpt":0.314214772876351,"score_spread":0.2857121924386439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411410596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107504,0.0019038523,0.0002092031,0.00061784126,0.00060302543,0.0014792967,0.0039916956,0.00005842447,0.000061651066],"genre_scores_gemma":[0.9956993,0.00049212895,0.000055009295,0.00056391564,0.0000418684,0.00028072653,0.0023478048,0.000025158213,0.0004940786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963648,0.0015011748,0.0010246044,0.0005517376,0.000120759825,0.00043694183],"domain_scores_gemma":[0.9972266,0.0013434674,0.0004587443,0.000670499,0.00020493027,0.00009578055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004925153,0.00042417322,0.0013614726,0.0003425359,0.00020589212,0.000060598253,0.0005115069,0.0002341417,0.0003875562],"category_scores_gemma":[0.0012152803,0.00031817498,0.0005964681,0.0009838624,0.00012541651,0.00016659807,0.00011936803,0.0001579686,0.000041298827],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6960182,0.01970816,0.0041262712,0.00017505253,0.025724446,0.000017665287,0.003173984,0.00038301133,0.009716042,0.000088920955,0.038885344,0.20198289],"study_design_scores_gemma":[0.8376994,0.0024727618,0.04981393,0.0016764981,0.017945554,0.000003422256,0.001272224,0.0020229337,0.081126474,0.0018961593,0.002157439,0.0019131756],"about_ca_topic_score_codex":0.0004889391,"about_ca_topic_score_gemma":0.000104921186,"teacher_disagreement_score":0.20006971,"about_ca_system_score_codex":0.00004418941,"about_ca_system_score_gemma":0.00024437677,"threshold_uncertainty_score":0.99992704},"labels":[],"label_agreement":null},{"id":"W4411411094","doi":"10.1016/j.ard.2025.06.426","title":"POS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Interleukin 23; Randomized controlled trial; Internal medicine; Dermatology; Gastroenterology; Interleukin; Cytokine","score_opus":0.06217196332027962,"score_gpt":0.323081874671518,"score_spread":0.26090991135123837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411411094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9620087,0.013339871,0.00021210434,0.005709274,0.0023291472,0.01383401,0.0022141007,0.00004074744,0.00031204105],"genre_scores_gemma":[0.98982245,0.0016799497,0.000047533023,0.00022555912,0.00004815127,0.0032193928,0.0001268197,0.00003077684,0.0047993506],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956701,0.0017580221,0.0013970187,0.0004641309,0.00019765788,0.00051310175],"domain_scores_gemma":[0.99069846,0.0064916303,0.0012730415,0.0011268036,0.00037228255,0.000037759735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095435296,0.0005615646,0.001979098,0.00012513726,0.0005710729,0.000045691853,0.0011341167,0.00021798137,0.00007834008],"category_scores_gemma":[0.0011132592,0.0002262411,0.0021131642,0.00042300476,0.00065524684,0.00011431339,0.00014561674,0.00014831404,0.000010543145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9590601,0.0034791888,0.000029839648,0.000073160794,0.013884192,2.942983e-7,0.0035176247,0.00046892455,0.0005924401,0.0007454303,0.01095217,0.0071966606],"study_design_scores_gemma":[0.8852986,0.0016328436,0.00007433923,0.0005344554,0.0050544306,0.0000030239314,0.0013612354,0.00022028293,0.102559544,0.001779634,0.001247581,0.00023403017],"about_ca_topic_score_codex":0.0005541664,"about_ca_topic_score_gemma":0.00017350038,"teacher_disagreement_score":0.101967104,"about_ca_system_score_codex":0.00006498686,"about_ca_system_score_gemma":0.00050336716,"threshold_uncertainty_score":0.9225844},"labels":[],"label_agreement":null},{"id":"W4411413719","doi":"10.1001/jamadermatol.2025.1625","title":"Defining On-Treatment Remission in Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Western Hospital; Dalhousie University; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Delphi method; Psoriasis Area and Severity Index; Delphi; Family medicine; MEDLINE; Physical therapy; Dermatology","score_opus":0.011329736024911885,"score_gpt":0.2573055058001082,"score_spread":0.2459757697751963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411413719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95461744,0.0054367715,0.00003745003,0.0046600862,0.0016364739,0.00029112143,0.00003093262,0.00012857893,0.033161156],"genre_scores_gemma":[0.9951463,0.00044439427,0.00012840553,0.00068734156,0.000016125327,0.00012013064,0.0001658662,0.000013301454,0.003278144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845207,0.0003306305,0.00035387432,0.00040672556,0.000022757478,0.0004339314],"domain_scores_gemma":[0.99897444,0.0005488789,0.00008020337,0.0003489846,0.000025180547,0.000022282606],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008434741,0.00026506034,0.00047956023,0.00039765,0.00015048397,0.000014402603,0.00017126097,0.00057343487,0.00022545784],"category_scores_gemma":[0.00010120248,0.00020913569,0.00011611162,0.00027269818,0.00007523983,0.00005727548,0.00005398075,0.00019041018,0.0010275964],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030508586,0.0017408886,0.27457938,0.00007866446,0.0012207516,0.0009961108,0.0015873669,0.00004428531,0.023436131,0.10377433,0.04259457,0.54689664],"study_design_scores_gemma":[0.016322052,0.00038297096,0.079578295,0.00028663274,0.00023145585,0.00062264997,0.00047432067,0.000018414854,0.41740888,0.0022093188,0.48193964,0.00052536064],"about_ca_topic_score_codex":0.00014227588,"about_ca_topic_score_gemma":0.000119400116,"teacher_disagreement_score":0.5463713,"about_ca_system_score_codex":0.00017897807,"about_ca_system_score_gemma":0.0001482621,"threshold_uncertainty_score":0.9997502},"labels":[],"label_agreement":null},{"id":"W4411421315","doi":"10.1016/j.ard.2025.05.118","title":"OP0096 Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Double blind; Internal medicine; Placebo-controlled study; Randomized controlled trial; Arthritis; Physical therapy; Immunology; Alternative medicine; Pathology","score_opus":0.05849382257027811,"score_gpt":0.37139902831729904,"score_spread":0.3129052057470209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411421315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870086,0.003312856,0.000021063755,0.0009899046,0.0007503484,0.0041234666,0.0036537312,0.000024929583,0.000115145296],"genre_scores_gemma":[0.99751765,0.0014986184,0.00003746338,0.00012960828,0.000039380557,0.0004140827,0.00018488061,0.00001763346,0.00016066169],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99501026,0.0020096903,0.00199077,0.00045382624,0.00013999124,0.00039549443],"domain_scores_gemma":[0.97836345,0.019576056,0.0012656756,0.0006298706,0.00011389548,0.000051066672],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021636654,0.0004188987,0.002400469,0.00017711786,0.00020738838,0.00003263444,0.00041936318,0.00023596984,0.000038210976],"category_scores_gemma":[0.008883831,0.0002161778,0.0015277693,0.00023966664,0.0005748466,0.00011322573,0.00016092032,0.00024109083,0.00000963088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93721277,0.003467983,0.000657252,0.000025797302,0.006353874,0.000002257162,0.00069916906,0.00004561045,0.000215179,0.00024771862,0.00044667115,0.050625723],"study_design_scores_gemma":[0.98458624,0.0005365007,0.0075862883,0.0013645062,0.0012089667,0.0000012973856,0.00050571526,0.00012547862,0.002476355,0.0013995817,0.000009042157,0.00020005673],"about_ca_topic_score_codex":0.001163565,"about_ca_topic_score_gemma":0.00013250494,"teacher_disagreement_score":0.050425667,"about_ca_system_score_codex":0.000027361673,"about_ca_system_score_gemma":0.0003091677,"threshold_uncertainty_score":0.99946475},"labels":[],"label_agreement":null},{"id":"W4411627913","doi":"10.1001/jamadermatol.2025.1849","title":"Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones","year":2025,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto; University of British Columbia","funders":"LEO Pharma; Glenmark Pharmaceuticals; Incyte; Kiniksa Pharmaceuticals; Dermira; Sun Pharma; Regeneron Pharmaceuticals; L'Oreal USA; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; Biogen; GlaxoSmithKline","keywords":"Medicine; Scalp; Psoriasis; Dermatology Life Quality Index; Dermatology; Quality of life (healthcare); Adverse effect; Clinical endpoint; Placebo; Randomized controlled trial; Clinical trial; Internal medicine; Pathology","score_opus":0.016996194663880623,"score_gpt":0.28824732129078134,"score_spread":0.2712511266269007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411627913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890747,0.0024581272,0.0024592218,0.009341229,0.0027820999,0.00090450334,0.0003930093,0.00021596528,0.0025383935],"genre_scores_gemma":[0.9856642,0.00009141978,0.0008931133,0.003938502,0.00006611042,0.0005618308,0.0003448449,0.00003077862,0.00840919],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978807,0.00022974175,0.00044681114,0.0005814001,0.000030788375,0.0008305533],"domain_scores_gemma":[0.9987718,0.00045796964,0.000097727716,0.00047714735,0.000146314,0.00004904179],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015749403,0.00033787178,0.0006533874,0.00018294637,0.00037992885,0.00005427249,0.00039104398,0.0007184757,0.00013794558],"category_scores_gemma":[0.00013826443,0.00030921036,0.00022782791,0.0002472018,0.00010736608,0.00012401532,0.00017804856,0.00016413908,0.0007670752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0106015075,0.001115549,0.01050555,0.00039516506,0.005667236,0.00015783058,0.0064555886,0.00015837494,0.06263652,0.029482052,0.46555817,0.40726647],"study_design_scores_gemma":[0.010602085,0.00016090016,0.0077961152,0.000056244884,0.000378428,0.00066615036,0.00060205755,0.000041402436,0.34382686,0.0023249455,0.63295424,0.00059058395],"about_ca_topic_score_codex":0.00008077665,"about_ca_topic_score_gemma":0.00020576932,"teacher_disagreement_score":0.40667588,"about_ca_system_score_codex":0.000065930995,"about_ca_system_score_gemma":0.00010760553,"threshold_uncertainty_score":0.999936},"labels":[],"label_agreement":null},{"id":"W4411627919","doi":"10.1001/jamadermatol.2025.1836","title":"Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones","year":2025,"lang":"en","type":"article","venue":"JAMA Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Probity Medical Research; University of Toronto","funders":"Sun Pharma; LEO Pharma; Galderma; Incyte; Regeneron Pharmaceuticals; L'Oreal USA; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Randomized controlled trial; Dermatology; Placebo; Adverse effect; Internal medicine; Physical therapy; Pathology; Alternative medicine","score_opus":0.017583188025831392,"score_gpt":0.2887633835104765,"score_spread":0.2711801954846451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411627919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897714,0.0024476196,0.0023489702,0.009177778,0.0028231537,0.00088159397,0.0003865899,0.00020985484,0.002747291],"genre_scores_gemma":[0.98491347,0.00008963071,0.00083392387,0.003990715,0.00006133818,0.00055759447,0.00033703368,0.000028492683,0.009187774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998039,0.00020756677,0.0004135392,0.00053847494,0.000027231787,0.0007741749],"domain_scores_gemma":[0.998845,0.00043482165,0.000091756694,0.00044992758,0.00013569633,0.000042820953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014289662,0.0003141934,0.0006060295,0.00016986656,0.00034798015,0.00004851831,0.0003642911,0.00065845886,0.00013399725],"category_scores_gemma":[0.00012938408,0.00028817466,0.00020870051,0.00022543083,0.000090768204,0.000114852315,0.00016064574,0.0001505048,0.0007088526],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010666195,0.0010457931,0.009257524,0.0003797869,0.005938292,0.00015941955,0.007553073,0.00015728008,0.06613595,0.035086494,0.5059861,0.35763407],"study_design_scores_gemma":[0.009474147,0.00014123996,0.005648554,0.00004335502,0.00032298776,0.00056593993,0.00057530095,0.000029189843,0.31031337,0.0020828908,0.6702999,0.0005031443],"about_ca_topic_score_codex":0.00007722537,"about_ca_topic_score_gemma":0.00019317766,"teacher_disagreement_score":0.35713091,"about_ca_system_score_codex":0.00006009812,"about_ca_system_score_gemma":0.00010257714,"threshold_uncertainty_score":0.999957},"labels":[],"label_agreement":null},{"id":"W4411703573","doi":"10.3389/fimmu.2025.1604332","title":"IL-36/IL-36R signaling promotes CD4+ T cell-dependent colitis via pro-inflammatory cytokine production","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Cytokine; Immunology; Mesenteric lymph nodes; Inflammatory bowel disease; T cell; Immune system; Tumor necrosis factor alpha; Biology; Interleukin 10; Colitis; Medicine; Internal medicine; Disease","score_opus":0.00704335342174887,"score_gpt":0.20685485906151818,"score_spread":0.19981150563976932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411703573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644338,0.01648247,0.0022031728,0.00064580084,0.013135069,0.0013754935,0.0000895856,0.00026289228,0.0013717476],"genre_scores_gemma":[0.9824527,0.0007142407,0.001514185,0.000088087916,0.000110207584,0.00048070372,0.00030651988,0.000043618205,0.014289742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970448,0.00059940276,0.0006775074,0.0008062686,0.000060457798,0.0008115672],"domain_scores_gemma":[0.99892014,0.00008312844,0.00024410187,0.0006084452,0.000120875935,0.00002332495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004627463,0.00043156743,0.00071072933,0.00069352216,0.00032089325,0.000016859405,0.00043520587,0.0007331992,0.00012589036],"category_scores_gemma":[0.00009140266,0.00043092147,0.00015836905,0.00044820667,0.0003805036,0.0001724764,0.00016678886,0.00052447483,0.00019809032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022258637,0.000734722,0.034518026,0.00014854994,0.0016385516,0.00008088852,0.0010647003,0.000056718527,0.88373256,0.00030685167,0.0070023285,0.068490244],"study_design_scores_gemma":[0.0039010977,0.00035037752,0.031233208,0.00014209992,0.00031241184,0.00008723462,0.00090450625,0.000011676661,0.92737955,0.0017305439,0.033426784,0.0005204819],"about_ca_topic_score_codex":0.00011536679,"about_ca_topic_score_gemma":0.000059934206,"teacher_disagreement_score":0.06796976,"about_ca_system_score_codex":0.0003629797,"about_ca_system_score_gemma":0.00021690181,"threshold_uncertainty_score":0.9998143},"labels":[],"label_agreement":null},{"id":"W4411872561","doi":"10.1172/jci188530","title":"Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Psoriasis; Inflammation; Generalized pustular psoriasis; Medicine; Pustular psoriasis; Immunology; Receptor; Dermatology; Internal medicine","score_opus":0.032138088779788146,"score_gpt":0.30661382459766606,"score_spread":0.27447573581787793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411872561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924337,0.0024666172,0.00011112304,0.003717614,0.0009615709,0.00021590477,0.0000120513305,0.000015296942,0.000066110224],"genre_scores_gemma":[0.9928516,0.0014797003,0.0037341327,0.00031557592,0.00057567115,0.000013999408,0.00009108603,0.000013844542,0.00092435064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997488,0.0010011197,0.0010800824,0.00017702568,0.00008846066,0.00016527763],"domain_scores_gemma":[0.9979147,0.0008166442,0.0008562413,0.00014219816,0.00022827313,0.00004195864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018511643,0.00015407447,0.0004038356,0.000104286504,0.00022758919,0.000043627417,0.0001615784,0.000241863,0.000043121076],"category_scores_gemma":[0.0012836859,0.00009068446,0.00011382624,0.00017264503,0.00030889988,0.00022981278,0.000040780626,0.00032212757,0.0000132172545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005486777,0.00031882268,0.38153508,0.00014487332,0.0040662778,0.000022356062,0.0022247727,0.0003031989,0.42936575,0.0025579582,0.03378565,0.14018849],"study_design_scores_gemma":[0.016344672,0.001687606,0.29854563,0.00097605115,0.0022614736,0.00008481056,0.0011378634,0.00010916725,0.6149073,0.01085701,0.05259016,0.0004982379],"about_ca_topic_score_codex":0.00001556618,"about_ca_topic_score_gemma":0.000008812893,"teacher_disagreement_score":0.18554156,"about_ca_system_score_codex":0.000023374752,"about_ca_system_score_gemma":0.0001790163,"threshold_uncertainty_score":0.3698005},"labels":[],"label_agreement":null},{"id":"W4411884100","doi":"10.3899/jrheum.2025-0314.tour2b","title":"Exploring Causal Relationships of Depression and Psoriatic Disease (Psoriatic Arthritis and Psoriasis) Through Mendelian Randomization","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Mendelian randomization; Medicine; Genome-wide association study; Psoriasis; Odds ratio; Genetic association; Linkage disequilibrium; Single-nucleotide polymorphism; Causality (physics); Depression (economics); Minor allele frequency; Internal medicine; Genetics; Dermatology; Biology; Genetic variants","score_opus":0.03800318299959907,"score_gpt":0.24844091927445355,"score_spread":0.2104377362748545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411884100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9549483,0.041111328,0.001966232,0.00055878994,0.0011474935,0.00018609184,0.000008507949,0.000011356423,0.00006190467],"genre_scores_gemma":[0.955868,0.043818668,0.00020877087,0.000017691189,0.000008677748,0.000012694998,0.0000075905077,0.000008720735,0.00004920492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802405,0.0009741856,0.0006558768,0.00012716255,0.000048230322,0.00017050217],"domain_scores_gemma":[0.997897,0.0013052762,0.0004884662,0.00017765646,0.00010175125,0.000029836803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076278887,0.00015220382,0.0005211829,0.0001798909,0.0002765307,0.000008805334,0.0001216256,0.00011760717,0.000024614115],"category_scores_gemma":[0.0006423454,0.00010233725,0.00006778005,0.0001639971,0.0001872753,0.0002517588,0.000059480073,0.00021300666,0.0000037867298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016796429,0.00046588772,0.6220344,0.00049099134,0.0036390445,0.000019456638,0.01357597,0.0002950331,0.0067083146,0.027478194,0.0014230715,0.3070732],"study_design_scores_gemma":[0.12755041,0.0012935079,0.7280168,0.0069225193,0.009485732,0.0054966933,0.010932391,0.00035939956,0.028180528,0.07592063,0.0045969095,0.0012444914],"about_ca_topic_score_codex":0.00007299797,"about_ca_topic_score_gemma":0.00004167325,"teacher_disagreement_score":0.30582872,"about_ca_system_score_codex":0.000018210738,"about_ca_system_score_gemma":0.000080599224,"threshold_uncertainty_score":0.4173192},"labels":[],"label_agreement":null},{"id":"W4411884404","doi":"10.3899/jrheum.2025-0314.workshop3e_02","title":"Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto Western Hospital; Krembil Foundation; University of Toronto","funders":"","keywords":"Medicine; Apremilast; Psoriatic arthritis; Internal medicine; Cohort; Tofacitinib; Weight change; Psoriasis; Weight loss; Weight gain; Arthritis; Obesity; Body weight; Dermatology; Rheumatoid arthritis","score_opus":0.01740584931891728,"score_gpt":0.2365642367306112,"score_spread":0.2191583874116939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411884404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712945,0.025326537,0.00012796983,0.00034447966,0.0025404266,0.00006269879,0.0000015515806,0.000008505934,0.0002933142],"genre_scores_gemma":[0.988502,0.011209431,0.00006082226,0.000023741066,0.0000061615874,0.000007684652,0.0000024864867,0.000007726044,0.00017991915],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983883,0.0005661423,0.00067086617,0.00009198713,0.00003604437,0.00024668613],"domain_scores_gemma":[0.998316,0.0010425309,0.00038557133,0.00018367267,0.000059608374,0.000012615929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005799084,0.00014248503,0.00061600085,0.0005804172,0.000073010444,0.0000029549058,0.00027538478,0.00012869894,0.00005372623],"category_scores_gemma":[0.00012918354,0.000095971496,0.00013700008,0.00037096156,0.000117920834,0.00009471753,0.00004895549,0.00025557014,0.000016814307],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015693839,0.000455992,0.072395936,0.00023145568,0.001991549,0.000040395444,0.009699197,0.000062940424,0.025039114,0.006320528,0.001079213,0.8811143],"study_design_scores_gemma":[0.05425841,0.002488304,0.2419553,0.009947493,0.002585991,0.0067210034,0.0078821825,0.000041540614,0.65277934,0.010548658,0.009716484,0.0010752957],"about_ca_topic_score_codex":0.00012578815,"about_ca_topic_score_gemma":0.000057712616,"teacher_disagreement_score":0.880039,"about_ca_system_score_codex":0.00003428746,"about_ca_system_score_gemma":0.00006329489,"threshold_uncertainty_score":0.3913604},"labels":[],"label_agreement":null},{"id":"W4411964459","doi":"10.1007/s40257-025-00959-3","title":"Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Psoriasis; Disease; Pharmacotherapy; Systematic review; Duration (music); MEDLINE; Clinical trial; Internal medicine; Dermatology","score_opus":0.10144247819161838,"score_gpt":0.45203061981818654,"score_spread":0.35058814162656815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411964459","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003716684,0.9927359,0.000065723536,0.00048546604,0.0026821594,0.0034388308,0.00016148624,0.000019110372,0.000039635375],"genre_scores_gemma":[0.0005115111,0.9973562,0.00008986187,0.0010707597,0.00009408536,0.00034251664,0.00034759493,0.00003246148,0.00015502602],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.96895576,0.01835489,0.011591775,0.00051854434,0.00013057221,0.00044843717],"domain_scores_gemma":[0.978762,0.010695564,0.009251308,0.00068384747,0.00038589962,0.00022143914],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0046663308,0.0006297768,0.018176565,0.0009216352,0.00006894332,0.000016366203,0.0007649245,0.00048782444,0.000114932045],"category_scores_gemma":[0.028420774,0.0004188727,0.002808147,0.0011766352,0.0002327992,0.0000943751,0.00011202959,0.0008302448,0.00023596025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013945886,0.0011492039,0.00013326082,0.17151006,0.002564744,0.00016270288,0.000024382358,6.6319e-8,5.2045493e-8,0.000022851498,0.0039344025,0.81910366],"study_design_scores_gemma":[0.011057898,0.001457405,0.000114351606,0.6097221,0.032418385,0.0002921016,0.000030918924,1.7583888e-7,7.3731616e-7,0.000017428809,0.3443527,0.00053578726],"about_ca_topic_score_codex":0.000008020944,"about_ca_topic_score_gemma":0.0000042645506,"teacher_disagreement_score":0.8185679,"about_ca_system_score_codex":0.00011519728,"about_ca_system_score_gemma":0.0013515303,"threshold_uncertainty_score":0.9998263},"labels":[],"label_agreement":null},{"id":"W4412157154","doi":"10.11817/j.issn.1672-7347.2024.240663","title":"TMAO promotes disorders of lipid metabolism in psoriasis.","year":2025,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Psoriasis; Lipid metabolism; Lipid Metabolism Disorder; Metabolism; Chemistry; Medicine; Biochemistry; Dermatology; Cholesterol; Blood lipids","score_opus":0.011388630595972393,"score_gpt":0.21401889726673526,"score_spread":0.20263026667076287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412157154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699788,0.010268455,0.00001700775,0.00068964297,0.0019212846,0.0008408881,0.000031706913,0.00005497072,0.016197246],"genre_scores_gemma":[0.9936217,0.00033964362,0.0000340546,0.000049112972,0.000023627908,0.0009939173,0.000031599855,0.000007641753,0.0048986995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990214,0.00014359519,0.00026057032,0.00022022986,0.00002100041,0.00033320373],"domain_scores_gemma":[0.999571,0.00011223482,0.00006957817,0.00021344222,0.000021343532,0.00001235809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024866458,0.00013402317,0.00031254027,0.00023913491,0.00004144737,0.000004752331,0.00016828706,0.00016639045,0.0000725075],"category_scores_gemma":[0.0001208458,0.00011443091,0.00009987549,0.00034093886,0.0000853836,0.000056078647,0.00005124012,0.00008778202,0.000027407043],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025916973,0.00047355285,0.058821477,0.000043218788,0.00047859564,0.0000011551795,0.00027708116,0.0000019092897,0.0035358628,0.0036860418,0.0014249063,0.930997],"study_design_scores_gemma":[0.002432504,0.000013110225,0.8895601,0.000011709379,0.000119351644,9.604265e-7,0.000064769214,3.537523e-7,0.058267955,0.0012369448,0.048174176,0.000118045784],"about_ca_topic_score_codex":0.0001225259,"about_ca_topic_score_gemma":0.0001604709,"teacher_disagreement_score":0.930879,"about_ca_system_score_codex":0.000021006788,"about_ca_system_score_gemma":0.000029307263,"threshold_uncertainty_score":0.4666357},"labels":[],"label_agreement":null},{"id":"W4412422999","doi":"10.1080/09546634.2025.2523373","title":"The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial","year":2025,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research; Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Foot (prosody); Clinical trial; Physical therapy; Dermatology; Measure (data warehouse); Physical medicine and rehabilitation; Surgery; Internal medicine; Data mining","score_opus":0.06067050228900951,"score_gpt":0.34320144719193957,"score_spread":0.28253094490293007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412422999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98118645,0.0142662665,0.000016191021,0.0022542775,0.0011359783,0.00048768922,0.00030861507,0.000010703567,0.00033380045],"genre_scores_gemma":[0.992476,0.006773297,0.0002468345,0.000119704884,0.00006735386,0.000028931518,0.00003530787,0.0000064851365,0.0002460835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967081,0.00087925,0.0016875132,0.00032543682,0.00009750562,0.0003021733],"domain_scores_gemma":[0.9967375,0.0019856442,0.00074614596,0.00032336375,0.00014949816,0.00005788494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008237703,0.0002723902,0.0010694348,0.0001146591,0.00023463502,0.000030378858,0.0002382965,0.0004686637,0.00004160399],"category_scores_gemma":[0.00067542546,0.00014310359,0.00044612976,0.00020244073,0.00033623373,0.00007434292,0.00006313642,0.00028759195,0.000008862399],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59288925,0.0131041715,0.077753596,0.0000359397,0.0059461566,0.000607861,0.0018755727,0.0000030292672,0.0013979346,0.00020224265,0.010941393,0.29524285],"study_design_scores_gemma":[0.7812441,0.012051567,0.06994463,0.0009563694,0.0023924191,0.00041472176,0.001285907,0.000024458112,0.05035933,0.003173403,0.077663586,0.0004894915],"about_ca_topic_score_codex":0.00012098012,"about_ca_topic_score_gemma":0.000066523135,"teacher_disagreement_score":0.29475334,"about_ca_system_score_codex":0.00009911034,"about_ca_system_score_gemma":0.00019650614,"threshold_uncertainty_score":0.5835595},"labels":[],"label_agreement":null},{"id":"W4412454913","doi":"10.1016/j.jaad.2025.07.013","title":"Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Plaque psoriasis; Placebo; Dose-ranging study; STRIDE; Dermatology; Psoriasis; Randomized controlled trial; Internal medicine; Pathology; Double blind; Physical medicine and rehabilitation","score_opus":0.014979457793060856,"score_gpt":0.26939739043571403,"score_spread":0.25441793264265317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412454913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954963,0.0003433835,0.00010046426,0.0014515951,0.00020348236,0.002135724,0.00014998701,0.000013924149,0.000105160725],"genre_scores_gemma":[0.9991184,0.000059274484,0.00034184987,0.0002555195,0.000019446545,0.00008331451,0.000033219578,0.000023327892,0.00006567906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956088,0.0017855461,0.0016310229,0.00037101234,0.00018584293,0.00041774055],"domain_scores_gemma":[0.9957829,0.001041623,0.0026736874,0.00022952208,0.00022246793,0.0000497757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005355535,0.00039846517,0.0026457442,0.00081660325,0.000119436496,0.000013356982,0.0004364317,0.0002179152,0.000009568548],"category_scores_gemma":[0.00014088512,0.00023530399,0.00025909257,0.00084704254,0.00044470327,0.00020073821,0.00010621726,0.0006390098,0.0000037645607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9661636,0.002873848,0.020659707,0.000015373773,0.0044283057,0.00003223428,0.0008036936,0.00058002357,0.001992125,0.00003168391,0.0004430631,0.0019763806],"study_design_scores_gemma":[0.95862186,0.002534286,0.016080715,0.0003146758,0.001882779,0.00016347576,0.0007600826,0.000021553567,0.019181032,0.000099412864,0.00007367614,0.00026647013],"about_ca_topic_score_codex":0.0003603323,"about_ca_topic_score_gemma":0.00010628269,"teacher_disagreement_score":0.017188907,"about_ca_system_score_codex":0.000112451286,"about_ca_system_score_gemma":0.0002315669,"threshold_uncertainty_score":0.9595418},"labels":[],"label_agreement":null},{"id":"W4412492282","doi":"10.1007/s13555-025-01463-6","title":"Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; University of Saskatchewan; EVERSANA (Canada); Western University; University of Toronto; Dalhousie University; Dermatrials Research; Probity Medical Research; McMaster University","funders":"LEO Pharma; Bausch Health; Astellas Pharma; Mylan; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Valeant Pharmaceuticals International; Janssen Canada; Sanofi; Amgen; Pfizer; Meiji Seika Pharma; Galderma; Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Onset of action; Psoriasis; Confidence interval; Meta-analysis; Dermatology; Psoriatic arthritis","score_opus":0.031940586587068345,"score_gpt":0.2905279435827251,"score_spread":0.25858735699565677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492282","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21318367,0.78418905,0.000056037115,0.0009802204,0.00007856481,0.0013132761,0.00016137233,0.000020913016,0.000016905895],"genre_scores_gemma":[0.8626239,0.13243555,0.00038508215,0.0017788664,0.000006298371,0.0008715381,0.0006949912,0.0000119738015,0.0011918024],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99843377,0.00062632776,0.0004096247,0.0003111205,0.0000136382605,0.0002055201],"domain_scores_gemma":[0.99918395,0.0003988618,0.00015530738,0.00018907685,0.00005311703,0.000019690513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026288786,0.0002265546,0.0016572376,0.00025616479,0.00010953391,0.000008328577,0.00006548434,0.00030404888,0.00005683643],"category_scores_gemma":[0.000041054223,0.00014907731,0.00021083614,0.00053664466,0.000083443476,0.000044056884,0.000022244427,0.00006904837,0.000004802398],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045763403,0.0012181855,0.05117368,0.02677538,0.86752385,0.000078058016,0.002644463,0.000028513123,0.015373687,0.0019984785,0.0094930995,0.019116294],"study_design_scores_gemma":[0.026196329,0.0023114919,0.08099029,0.0054609138,0.8168547,0.0012940322,0.0005223971,0.00017866239,0.042141493,0.007702518,0.014054642,0.0022925364],"about_ca_topic_score_codex":0.0000068342883,"about_ca_topic_score_gemma":0.000012632347,"teacher_disagreement_score":0.6517535,"about_ca_system_score_codex":0.000007888487,"about_ca_system_score_gemma":0.00001368282,"threshold_uncertainty_score":0.60791963},"labels":[],"label_agreement":null},{"id":"W4412509907","doi":"10.1111/jdv.20809","title":"Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; McMaster University; Juravinski Cancer Centre; BC Children's Hospital; Vancouver General Hospital; Probity Medical Research; University of British Columbia; BC Cancer Agency; Hôtel-Dieu de Québec; Krembil Foundation; Research Canada; Ottawa Hospital; University Health Network; University of Toronto; Blackberry (Canada); University of Ottawa","funders":"Janssen Pharmaceuticals; Eli Lilly Canada; Sanofi Genzyme; Amgen Canada; Janssen Canada; University of Texas MD Anderson Cancer Center; Sun Pharma; EMD Serono; Galderma; Seagen; Novartis Pharmaceuticals Canada; MacroGenics; Pfizer; Incyte; BeiGene; Melanoma Research Alliance; Queen Mary University of London; Clovis Oncology; BC Children's Hospital; Astellas Pharma; Eisai; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; National Center for Advancing Translational Sciences; Les Laboratories Pierre Fabre; Therakos; Amgen; Ariad Pharmaceuticals; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Bausch Health; L'Oreal USA; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Sanofi; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Inference; Dermatology; Artificial intelligence","score_opus":0.025928135575957047,"score_gpt":0.2768369650984526,"score_spread":0.2509088295224956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412509907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96724737,0.02799956,0.00009125791,0.002163616,0.0012042547,0.00016836262,0.000012199205,0.000011096824,0.0011022837],"genre_scores_gemma":[0.9986074,0.00085879775,0.00008649585,0.000104033825,0.000054948672,0.000004225229,0.000002775355,0.000012562477,0.00026876933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629784,0.0018857738,0.0013133341,0.00019435426,0.0000455647,0.00026311443],"domain_scores_gemma":[0.9978714,0.00039900708,0.0013840217,0.00022241024,0.00009666555,0.00002647662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004564127,0.00024913406,0.00094055216,0.00029376693,0.00012654562,0.000003163594,0.0004533295,0.0003545094,0.00002038487],"category_scores_gemma":[0.00015185447,0.00016030861,0.00036301583,0.00020382954,0.00048197142,0.000054454194,0.000110099536,0.0002908904,0.000010488005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012625026,0.0005701871,0.19918475,0.0002372804,0.0019962022,0.00005441083,0.0005592987,0.000037230046,0.7665487,0.0026760714,0.00037155312,0.026501829],"study_design_scores_gemma":[0.006668368,0.00024030785,0.17697683,0.00053457863,0.0008099631,0.0021611333,0.00013391815,0.000006712841,0.80826664,0.0004265092,0.0036155304,0.00015952742],"about_ca_topic_score_codex":0.000009452443,"about_ca_topic_score_gemma":0.0000014489309,"teacher_disagreement_score":0.041717935,"about_ca_system_score_codex":0.000044592314,"about_ca_system_score_gemma":0.00014761843,"threshold_uncertainty_score":0.6537196},"labels":[],"label_agreement":null},{"id":"W4412645286","doi":"10.3389/fimmu.2025.1610499","title":"All-cause and cause-specific mortality in psoriasis patients: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Beijing University of Chinese Medicine","keywords":"Medicine; Internal medicine; Publication bias; Hazard ratio; Cochrane Library; Meta-analysis; Funnel plot; Psoriasis; Subgroup analysis; Mortality rate; Cohort study; Confidence interval; Immunology","score_opus":0.06435560254565842,"score_gpt":0.3089981480268375,"score_spread":0.24464254548117909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412645286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006375073,0.9947857,0.000024957426,0.000048928392,0.000951185,0.0034794805,0.000529806,0.000042523567,0.00007361691],"genre_scores_gemma":[0.000030626576,0.99526566,0.0001287609,0.00013053155,0.0000063664265,0.0020886546,0.0011779187,0.000039815637,0.001131661],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99227846,0.0035486482,0.0021865135,0.0012369294,0.000068825975,0.00068061135],"domain_scores_gemma":[0.9971059,0.00057535083,0.00090616074,0.0013004703,0.0000769566,0.00003515725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096435094,0.0010052008,0.013610391,0.0018846854,0.00009910517,0.000029969666,0.0005507028,0.001276296,0.00017530112],"category_scores_gemma":[0.0002892809,0.0007523546,0.0014779496,0.0015933589,0.00034204265,0.000115697454,0.00031683475,0.00068915554,0.00003843292],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031597527,0.00031348175,0.0012484998,0.3019912,0.678906,0.000051697498,0.00014061795,1.0078403e-7,1.771062e-7,0.00013942129,0.0018141088,0.015363061],"study_design_scores_gemma":[0.0009666138,0.00006590533,0.00048637958,0.012223864,0.91789365,0.000024653591,0.00006495741,8.46353e-8,5.4797135e-7,0.000053072436,0.06760707,0.00061319285],"about_ca_topic_score_codex":0.000119188495,"about_ca_topic_score_gemma":0.0001944468,"teacher_disagreement_score":0.28976732,"about_ca_system_score_codex":0.0002688527,"about_ca_system_score_gemma":0.000114956754,"threshold_uncertainty_score":0.99949276},"labels":[],"label_agreement":null},{"id":"W4412683700","doi":"10.3389/fimmu.2025.1614466","title":"Hemopexin and HO-1 induction during acute colitis in mice is dependent on interleukin-22","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Hemopexin; Colitis; Interleukin 11; Medicine; Interleukin; Immunology; Interleukin 6; Inflammation; Biology; Cytokine; Biochemistry; Enzyme","score_opus":0.0066109963469607085,"score_gpt":0.22030549321518825,"score_spread":0.21369449686822753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412683700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360205,0.009903683,0.00005415981,0.00048953603,0.004259235,0.000297458,0.000034408804,0.000039601393,0.0013198529],"genre_scores_gemma":[0.98976696,0.0023216016,0.00023475528,0.00021416516,0.000015760621,0.000101644044,0.000056511217,0.000014578006,0.0072740256],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984453,0.00027847898,0.0003450708,0.00047208153,0.00002285264,0.00043622966],"domain_scores_gemma":[0.99958205,0.00005309676,0.000081764156,0.0002514113,0.000020408115,0.000011243572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014122206,0.00023197258,0.0004351117,0.00076330215,0.00011076304,0.000011831456,0.00020579297,0.00048811446,0.00008899263],"category_scores_gemma":[0.000029974984,0.00023906748,0.000056064207,0.00028766465,0.0001927047,0.00009391931,0.00013182755,0.00040165932,0.00005515796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009510791,0.0009080775,0.28321695,0.00008877745,0.0034114707,0.0003209407,0.0044785435,0.0000070430037,0.45013076,0.0019111425,0.009595624,0.23641989],"study_design_scores_gemma":[0.009673018,0.00038149196,0.6671351,0.00022026525,0.00014681328,0.0001638531,0.0021565836,0.0000034069847,0.3083441,0.0015142965,0.009853508,0.00040757787],"about_ca_topic_score_codex":0.00028007754,"about_ca_topic_score_gemma":0.0001545193,"teacher_disagreement_score":0.38391814,"about_ca_system_score_codex":0.00031490295,"about_ca_system_score_gemma":0.000051343333,"threshold_uncertainty_score":0.9748889},"labels":[],"label_agreement":null},{"id":"W4412725353","doi":"10.1093/ced/llaf343","title":"Systematic review of the use of the Dermatology Life Quality Index in routine clinical practice: evidence from 287 articles across 56 countries","year":2025,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cardiff University","keywords":"Medicine; Dermatology Life Quality Index; Observational study; MEDLINE; CINAHL; Clinical Practice; Quality of life (healthcare); Scopus; Systematic review; Clinical trial; Psychological intervention; Family medicine; Disease; Pathology; Psychiatry","score_opus":0.105362007760588,"score_gpt":0.43188971601933807,"score_spread":0.32652770825875005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412725353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8314713,0.16186832,0.000011811489,0.0048649036,0.0010368426,0.000666023,0.000048146176,0.000012114798,0.000020517216],"genre_scores_gemma":[0.98434836,0.010297865,0.000050236966,0.0051447973,0.000012564862,0.00007000384,0.000008359699,0.000006706654,0.00006111959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9909766,0.0054851985,0.00278759,0.0003892932,0.000077364726,0.00028396753],"domain_scores_gemma":[0.98852855,0.009636897,0.0009615155,0.0007202098,0.000117689735,0.000035162793],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0011255874,0.00021556954,0.0015867873,0.000027718006,0.00014863175,0.000011365079,0.00045060398,0.00047897547,0.000051076226],"category_scores_gemma":[0.0093203485,0.00012096899,0.00042457043,0.00022549464,0.002025648,0.00015626596,0.0005509188,0.00035187282,0.00002101488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009552087,0.0009158641,0.9821307,0.010571542,0.0009291733,0.0000128386955,0.00074677117,4.647026e-7,0.0008727234,0.00095747155,0.0016580806,0.00024916462],"study_design_scores_gemma":[0.0074742967,0.00017933406,0.8682409,0.058753137,0.0016331753,0.0003809015,0.0037159007,0.000028026843,0.056262247,0.0002767568,0.0026231667,0.0004321511],"about_ca_topic_score_codex":0.000353452,"about_ca_topic_score_gemma":0.000091417125,"teacher_disagreement_score":0.15287703,"about_ca_system_score_codex":0.000017790977,"about_ca_system_score_gemma":0.00018914888,"threshold_uncertainty_score":0.99902457},"labels":[],"label_agreement":null},{"id":"W4412725534","doi":"10.1093/ced/llaf342","title":"Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study","year":2025,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Probity Medical Research; Calgary Laboratory Services; SKiN Health; Dermatrials Research; University of Calgary; University of Saskatchewan; Women's College Hospital; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Multicenter study; Drug; Dermatology; Retrospective cohort study; Internal medicine; Pharmacology; Randomized controlled trial","score_opus":0.024256738932433606,"score_gpt":0.3479182734764593,"score_spread":0.3236615345440257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412725534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912311,0.00086003955,0.000015916798,0.00046183105,0.003732274,0.0006680599,0.00009068717,0.000044962057,0.0028951266],"genre_scores_gemma":[0.9972029,0.00012916054,0.00014841725,0.0000737895,0.000054588672,0.00013078557,0.00009630689,0.000011031232,0.002153025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983108,0.0003131865,0.00065808045,0.00044612185,0.000035720783,0.00023607438],"domain_scores_gemma":[0.99907225,0.00045122995,0.00015961862,0.00020760037,0.000078811936,0.000030470834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018572362,0.00019460885,0.00063805486,0.0001319168,0.0001293198,0.0000093177105,0.00020330786,0.00018640065,0.00013768992],"category_scores_gemma":[0.0000862909,0.00016840317,0.00017948206,0.00010221413,0.00033579778,0.000056477013,0.00016070128,0.00014018473,0.00002976488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005448016,0.0037466497,0.96607035,0.00002606608,0.0021117271,0.000020550224,0.0015047869,4.047946e-7,0.004614635,0.009826287,0.0043331594,0.0022973618],"study_design_scores_gemma":[0.06823888,0.001434263,0.67500263,0.00012834051,0.00092409685,0.000058839054,0.024076948,0.0000326035,0.2081813,0.0017014251,0.019468216,0.00075248186],"about_ca_topic_score_codex":0.0001334452,"about_ca_topic_score_gemma":0.00021531458,"teacher_disagreement_score":0.29106775,"about_ca_system_score_codex":0.000037126687,"about_ca_system_score_gemma":0.00005685625,"threshold_uncertainty_score":0.68672824},"labels":[],"label_agreement":null},{"id":"W4412727529","doi":"10.1007/s40257-025-00964-6","title":"Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Probity Medical Research; University of Toronto","funders":"AbbVie","keywords":"Medicine; Psoriasis Area and Severity Index; Psoriasis; Discontinuation; Adverse effect; Internal medicine; Dermatology Life Quality Index; Randomized controlled trial; Severity of illness; Dermatology","score_opus":0.07167977802277621,"score_gpt":0.40167062400092113,"score_spread":0.32999084597814493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121964,0.0010362419,0.0010819952,0.003736325,0.0017069855,0.000672035,0.00012092101,0.000015918204,0.0004099254],"genre_scores_gemma":[0.99654555,0.0009457966,0.0009194133,0.00092495506,0.00010810798,0.000013453077,0.0000447264,0.000019928724,0.0004780487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994607,0.0015926429,0.0027283803,0.00054912356,0.00008608732,0.00043678135],"domain_scores_gemma":[0.9944307,0.0033437242,0.0012480951,0.00049387466,0.00029548162,0.00018810689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009554332,0.00034108604,0.002340765,0.00036570197,0.0001734477,0.0000283543,0.000661622,0.00035640819,0.00004363986],"category_scores_gemma":[0.0015420992,0.00026722552,0.00025596115,0.0004354996,0.0005245924,0.00012629456,0.0003030591,0.0004883174,0.000048760743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5703167,0.003106238,0.001756772,0.000017855498,0.0008047708,0.0002587838,0.00021042473,0.000024603325,0.0009126122,0.00016731229,0.0035246906,0.41889927],"study_design_scores_gemma":[0.87173617,0.030809745,0.06404888,0.0008330743,0.0023196386,0.0032348717,0.0003992503,0.000022082153,0.01266008,0.0001928912,0.012914403,0.00082891405],"about_ca_topic_score_codex":0.000054454442,"about_ca_topic_score_gemma":0.000027528664,"teacher_disagreement_score":0.41807035,"about_ca_system_score_codex":0.000040487856,"about_ca_system_score_gemma":0.00050348986,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W4412743752","doi":"10.1093/bjd/ljaf305","title":"Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"Amgen","keywords":"Apremilast; Medicine; Placebo; Psoriasis; Randomized controlled trial; Internal medicine; Dermatology; Psoriatic arthritis; Alternative medicine; Pathology","score_opus":0.006006601279841326,"score_gpt":0.2054851770162141,"score_spread":0.1994785757363728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412743752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866888,0.008817162,0.00012773614,0.0007507276,0.00097449136,0.0021712095,0.00019558758,0.000008889904,0.0002653987],"genre_scores_gemma":[0.9980593,0.0014061959,0.00013239031,0.00013306974,0.000052136165,0.000061523104,0.00006915708,0.000011545463,0.0000747229],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99593127,0.0018618448,0.0015873294,0.00025540162,0.00007941156,0.00028474745],"domain_scores_gemma":[0.9945497,0.0042088637,0.00080665265,0.00017027113,0.00022756391,0.000036964742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067268725,0.00022342303,0.002063409,0.00023399353,0.0001339327,0.00002629021,0.00026274833,0.00029998485,0.000022472159],"category_scores_gemma":[0.0014014553,0.00015152912,0.00023642926,0.00023946729,0.00020772885,0.00008919036,0.000066654306,0.00035276628,0.0000046709893],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98308605,0.0006334491,0.004045205,0.000008013524,0.0015406578,0.0001285719,0.0003845514,0.000043844637,0.000043080865,0.00004675671,0.0011096109,0.008930192],"study_design_scores_gemma":[0.97601646,0.00029259623,0.021044966,0.00031051852,0.00082353555,0.0005366318,0.00010684225,0.0000047017493,0.0003466994,0.000137616,0.00024227239,0.00013715861],"about_ca_topic_score_codex":0.00018586572,"about_ca_topic_score_gemma":0.00022891643,"teacher_disagreement_score":0.01699976,"about_ca_system_score_codex":0.000031290645,"about_ca_system_score_gemma":0.00023756016,"threshold_uncertainty_score":0.61791784},"labels":[],"label_agreement":null},{"id":"W4412994049","doi":"10.3899/jrheum.2025-0241","title":"Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Disease; Rheumatology; Immunology; Artificial intelligence; Internal medicine; Computer science","score_opus":0.032949957683551426,"score_gpt":0.2541643336301533,"score_spread":0.22121437594660187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883011,0.009859676,0.00019952068,0.00056742906,0.0007855122,0.0001191861,0.0000018038781,0.0000037833631,0.00016199905],"genre_scores_gemma":[0.99449724,0.005358552,0.000042041538,0.00003135442,0.000005618692,0.000009751888,9.0796635e-7,0.0000028724908,0.0000516862],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99892,0.00038733316,0.0004588213,0.000066210625,0.000033044656,0.00013457172],"domain_scores_gemma":[0.999169,0.0004104914,0.0002146559,0.00016770803,0.000030794545,0.000007385115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005162477,0.00008975673,0.00026194236,0.0001348337,0.00007700893,0.0000047121785,0.00028754314,0.00005553093,0.000025180114],"category_scores_gemma":[0.00003527718,0.00005003262,0.00005589603,0.00012145355,0.00017097186,0.000054182492,0.000061914325,0.00013388167,0.000006061838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026306068,0.0005541404,0.12468501,0.00063578185,0.0026788325,0.000072974224,0.013294141,0.0001757308,0.0014508845,0.1287509,0.00043143413,0.72463953],"study_design_scores_gemma":[0.005727244,0.0013005591,0.7147276,0.0031661412,0.0045556994,0.0033473095,0.10977896,0.000056397304,0.039269563,0.112251595,0.0050627626,0.00075618306],"about_ca_topic_score_codex":0.000026705791,"about_ca_topic_score_gemma":0.000029184564,"teacher_disagreement_score":0.7238834,"about_ca_system_score_codex":0.00001412131,"about_ca_system_score_gemma":0.000031169722,"threshold_uncertainty_score":0.2040271},"labels":[],"label_agreement":null},{"id":"W4412994065","doi":"10.3899/jrheum.2025-0235","title":"MHC-I-opathy: A Unified Concept for the Etiology of Several Major Histocompatibility Complex–Associated Conditions Including Psoriasis and Psoriatic Arthritis","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunology; Major histocompatibility complex; MHC class I; Psoriasis; Human leukocyte antigen; CD8; Psoriatic arthritis; Autoimmunity; Medicine; Immune system; Biology; Antigen","score_opus":0.027776892102192884,"score_gpt":0.2825042519607211,"score_spread":0.25472735985852824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98658097,0.006953512,0.0021179407,0.0021904188,0.0013132715,0.0005674597,0.00018052183,0.000016886874,0.0000790018],"genre_scores_gemma":[0.9982141,0.0012907966,0.00012557195,0.00013733833,0.0000083884825,0.000031164534,0.000044433174,0.000009231916,0.00013892667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754184,0.001113432,0.00086983986,0.00014766949,0.000041088315,0.00028614167],"domain_scores_gemma":[0.9939777,0.004608365,0.00087327335,0.00022163219,0.00029873193,0.000020266893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011607666,0.00018885484,0.00081826915,0.0001516152,0.0005401195,0.0000071012882,0.0003516749,0.00020880814,0.00011390373],"category_scores_gemma":[0.0007120382,0.000116649426,0.00018648131,0.0001828846,0.00082258566,0.000057363868,0.00009100015,0.00025320583,0.000003692826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02055605,0.0036350251,0.32842106,0.00073158095,0.039480355,0.000029547646,0.03996789,0.0011406728,0.10226493,0.2053822,0.11103782,0.14735287],"study_design_scores_gemma":[0.08215094,0.0052146656,0.75714505,0.0014594374,0.009658845,0.008181743,0.0145531045,0.0011275291,0.015983786,0.082514904,0.020652423,0.0013575642],"about_ca_topic_score_codex":0.000297024,"about_ca_topic_score_gemma":0.00039833607,"teacher_disagreement_score":0.42872402,"about_ca_system_score_codex":0.00007222881,"about_ca_system_score_gemma":0.00017680254,"threshold_uncertainty_score":0.47568256},"labels":[],"label_agreement":null},{"id":"W4412994192","doi":"10.3899/jrheum.2025-0265","title":"GRAPPA 2024: Key Project Advances","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Medicine; Presentation (obstetrics); Psoriasis; Key (lock); Session (web analytics); Medical education; Dermatology; Surgery; World Wide Web; Computer science","score_opus":0.011905343779138064,"score_gpt":0.2612103445679139,"score_spread":0.24930500078877585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93203866,0.05746204,0.00037742028,0.0012679872,0.0040637883,0.00014651704,0.0000073330384,0.000019026775,0.004617225],"genre_scores_gemma":[0.98434454,0.010379433,0.00011793968,0.000120935634,0.000006778091,0.00000543358,0.000003843141,0.00000709201,0.005014026],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987975,0.0004545094,0.00040790197,0.00008557349,0.000027226602,0.00022733184],"domain_scores_gemma":[0.9989166,0.00048777455,0.0003072631,0.00018628182,0.000092922994,0.000009130204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004686433,0.00013165029,0.0003893789,0.00020313894,0.00016976694,0.0000054408906,0.0003626736,0.0001427905,0.00019527801],"category_scores_gemma":[0.0001004169,0.00007403596,0.00013188767,0.00022168021,0.00020545,0.00007840281,0.00004983411,0.00023697341,0.00009870403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055770283,0.00070481154,0.42964333,0.00019253715,0.0056886347,0.000044987173,0.0042166035,0.00003261692,0.025591264,0.025693834,0.2388976,0.26371673],"study_design_scores_gemma":[0.007884917,0.0010701418,0.015131749,0.00041721482,0.0013396776,0.013696609,0.0032753802,0.00000347474,0.025580771,0.010171785,0.9210276,0.00040070215],"about_ca_topic_score_codex":0.000071251765,"about_ca_topic_score_gemma":0.000063855616,"teacher_disagreement_score":0.68213,"about_ca_system_score_codex":0.000020210748,"about_ca_system_score_gemma":0.00015375258,"threshold_uncertainty_score":0.3019099},"labels":[],"label_agreement":null},{"id":"W4412994291","doi":"10.3899/jrheum.2025-0264","title":"Challenges and Opportunities in Psoriatic Disease: An Integrated View of the Future","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Disease; Quality of life (healthcare); Intensive care medicine; Enthesitis; Disease burden; Population; Comorbidity; Physical therapy; Dermatology; Internal medicine","score_opus":0.029328868236405025,"score_gpt":0.25449502737127105,"score_spread":0.22516615913486604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77116716,0.2230305,0.0000057346465,0.0047727968,0.0008338417,0.00007203477,0.0000056620606,0.0000034451325,0.00010885148],"genre_scores_gemma":[0.87432224,0.12544006,0.000008295202,0.00006808557,0.000003911466,0.000002358196,0.0000024220838,0.0000037472103,0.00014886151],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99848646,0.0009450433,0.0003573474,0.000065005355,0.000023534065,0.00012261362],"domain_scores_gemma":[0.99919546,0.00026369002,0.00025944816,0.00019944184,0.000067198576,0.000014779968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004940534,0.00010489891,0.0003607567,0.00011483631,0.00006564375,0.0000024671713,0.00027699425,0.000108984736,0.000032106058],"category_scores_gemma":[0.00005187895,0.00005022217,0.000059676495,0.00007641508,0.00022207538,0.00005374805,0.000047901103,0.00018583142,0.0000013996079],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015892233,0.000352954,0.053467516,0.00025286176,0.0009636123,0.000011576462,0.0052962564,0.0000064165574,0.0008653676,0.040535294,0.0008436066,0.8958153],"study_design_scores_gemma":[0.008543601,0.0008400519,0.8307048,0.002395299,0.0016676089,0.0033567136,0.031715963,0.000015948464,0.0019253357,0.01874583,0.099692166,0.00039668326],"about_ca_topic_score_codex":0.000028658358,"about_ca_topic_score_gemma":0.00030523541,"teacher_disagreement_score":0.89541864,"about_ca_system_score_codex":0.000013179147,"about_ca_system_score_gemma":0.00014392516,"threshold_uncertainty_score":0.20480007},"labels":[],"label_agreement":null},{"id":"W4412994313","doi":"10.3899/jrheum.2025-0233","title":"Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Prom; Patient-reported outcome; Adalimumab; Physical therapy; Hidradenitis suppurativa; Clinical trial; Epidemiology; Disease; Internal medicine; Quality of life (healthcare); Nursing","score_opus":0.009631742804992216,"score_gpt":0.24360003567311542,"score_spread":0.2339682928681232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412994313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740351,0.008636525,0.0000859323,0.011744715,0.0038917838,0.00020412565,0.000013189898,0.00000891068,0.0013797282],"genre_scores_gemma":[0.9968893,0.00060179946,0.00009644964,0.00024494343,0.000014382507,0.0000054025877,0.0000016629684,0.000009156094,0.0021369283],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977185,0.0009523523,0.000845089,0.0001243636,0.000073753785,0.00028595133],"domain_scores_gemma":[0.99729127,0.0010794,0.00082693406,0.0005764946,0.00020872055,0.000017170185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021501924,0.0001596467,0.0004550222,0.000118853975,0.00035859394,0.000006402276,0.0009549383,0.00014563047,0.00006457744],"category_scores_gemma":[0.0011381601,0.00006936577,0.0002389079,0.0003430575,0.00022473872,0.000035741923,0.00032661573,0.0003451857,0.000028230797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021741828,0.00038026005,0.65997237,0.000113808186,0.005369674,0.000072608804,0.013435713,0.0006510559,0.046832073,0.0039738137,0.23126788,0.035756573],"study_design_scores_gemma":[0.008252879,0.0012213159,0.16705497,0.0036301329,0.004734862,0.0738401,0.03285814,0.000014776769,0.20900469,0.0073928563,0.49110633,0.00088895916],"about_ca_topic_score_codex":0.00031081718,"about_ca_topic_score_gemma":0.00025040095,"teacher_disagreement_score":0.4929174,"about_ca_system_score_codex":0.000032289754,"about_ca_system_score_gemma":0.00017260741,"threshold_uncertainty_score":0.2828654},"labels":[],"label_agreement":null},{"id":"W4413100346","doi":"10.1177/12034754251364849","title":"Drug-Induced Generalized Pustular Psoriasis: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University; Université de Montréal; Université de Sherbrooke","funders":"","keywords":"Medicine; Dermatology; Psoriasis; Generalized pustular psoriasis","score_opus":0.04207553581591404,"score_gpt":0.30402160160873287,"score_spread":0.2619460657928188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413100346","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052185806,0.9948354,0.0000025805266,0.00038245707,0.0034699873,0.0010016096,0.000018375591,0.000024153436,0.00021325365],"genre_scores_gemma":[0.000015146193,0.99487174,0.0000118957705,0.00061655906,0.00037879255,0.000063221014,0.00009039648,0.00003830449,0.0039139763],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99407995,0.0019137992,0.0030958117,0.0003347805,0.00017569518,0.00039997857],"domain_scores_gemma":[0.9921292,0.0043398915,0.0026675065,0.00048826812,0.0002765683,0.0000985498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021178534,0.0006932648,0.009960693,0.00087715744,0.00013759048,0.000015013679,0.000334641,0.0005017775,0.00022158888],"category_scores_gemma":[0.0021680086,0.0003938752,0.0015418378,0.0004894359,0.00010096757,0.000059342496,0.000052606105,0.0005795337,0.000045423385],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036013025,0.00006278564,0.0000016997403,0.72233284,0.0036372468,0.0014554778,0.00006673299,9.36597e-9,0.0000076232673,0.000015036853,0.05678364,0.21560091],"study_design_scores_gemma":[0.00032477058,0.00008141124,8.567821e-8,0.5829347,0.025015809,0.016718796,0.000039959963,1.70235e-8,0.00000344523,0.00001265533,0.37465322,0.00021512907],"about_ca_topic_score_codex":0.000015089238,"about_ca_topic_score_gemma":0.000002908269,"teacher_disagreement_score":0.31786957,"about_ca_system_score_codex":0.00009096265,"about_ca_system_score_gemma":0.000733053,"threshold_uncertainty_score":0.9998513},"labels":[],"label_agreement":null},{"id":"W4413257463","doi":"10.1016/j.clinthera.2025.06.020","title":"Prevalence of Three Prominent Corticosteroid Side Effects in a Large Asthma Population by Age, Sex and ICD-10 Asthma Severity with Recommendations for Screening","year":2025,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Asthma; Corticosteroid; Population; Pediatrics; Immunology; Internal medicine; Environmental health","score_opus":0.048640265147797894,"score_gpt":0.34437235694332896,"score_spread":0.29573209179553106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413257463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868649,0.0020857428,0.009369789,0.00038920454,0.00019317384,0.0008821146,0.00014273245,0.000025107782,0.000047212616],"genre_scores_gemma":[0.9953793,0.00027706134,0.0026751712,0.0002751518,0.000012465377,0.00009077969,0.00023085855,0.000011333394,0.0010478477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987574,0.00026777256,0.00046629287,0.0002802535,0.000025802348,0.00020243597],"domain_scores_gemma":[0.99849445,0.001074737,0.00017304768,0.00019953524,0.00004133564,0.000016906964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048515486,0.000141394,0.00033494178,0.00005369577,0.00008879135,0.0000090586655,0.00009245098,0.00021312425,0.000014252179],"category_scores_gemma":[0.00008299193,0.000115344505,0.000070163405,0.00009242734,0.00009093983,0.000051738713,0.000047162768,0.00014009063,0.0000015925691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011672854,0.0005676878,0.6131481,0.00019669654,0.00044673253,0.0000016014931,0.00012498297,0.0000016524871,0.0030514752,0.00015789714,0.0001261882,0.3810097],"study_design_scores_gemma":[0.005915609,0.001072737,0.9817172,0.00026787084,0.00023732877,0.00000323584,0.00003483228,0.00022869495,0.003483774,0.00052444165,0.0063565616,0.00015770675],"about_ca_topic_score_codex":0.00001472464,"about_ca_topic_score_gemma":0.00014501771,"teacher_disagreement_score":0.38085198,"about_ca_system_score_codex":0.000017399825,"about_ca_system_score_gemma":0.000024716484,"threshold_uncertainty_score":0.47036123},"labels":[],"label_agreement":null},{"id":"W4413258261","doi":"10.3899/jrheum.2025-0531","title":"What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Glycemic; Psoriatic arthritis; Insulin resistance; Type 2 diabetes; Psoriasis; Diabetes mellitus; Immunology; Endocrinology","score_opus":0.012529024327697568,"score_gpt":0.27239832294186167,"score_spread":0.2598692986141641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413258261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95303744,0.026766958,0.00030459493,0.0091048675,0.009830006,0.00018527712,0.00000694111,0.000027218108,0.0007367135],"genre_scores_gemma":[0.9741837,0.015783114,0.00012541813,0.0013242691,0.000017324252,0.000007642449,0.000008674179,0.000016966653,0.008532922],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979762,0.0006464879,0.00076599413,0.00015719706,0.000044448192,0.000409676],"domain_scores_gemma":[0.99810225,0.0008803587,0.00042160097,0.0003774992,0.00017695136,0.000041365158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000834035,0.000220176,0.000674532,0.00027858128,0.00027028608,0.000031114803,0.0006271192,0.00028258975,0.00020209218],"category_scores_gemma":[0.00018214538,0.00014253777,0.00023443058,0.0002755683,0.00020699755,0.00014542819,0.00011830923,0.00035466554,0.0006163984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007656937,0.00095590134,0.14903551,0.00011285247,0.0061332486,0.000076800236,0.009570623,0.00013675321,0.046157792,0.0063559273,0.53673023,0.2370774],"study_design_scores_gemma":[0.007711298,0.0013466165,0.02758949,0.0014825444,0.0014082632,0.0075989077,0.008725111,0.000004624149,0.019935964,0.0018602939,0.9217953,0.0005415672],"about_ca_topic_score_codex":0.000112775095,"about_ca_topic_score_gemma":0.000261888,"teacher_disagreement_score":0.38506508,"about_ca_system_score_codex":0.00005386148,"about_ca_system_score_gemma":0.00021580921,"threshold_uncertainty_score":0.792276},"labels":[],"label_agreement":null},{"id":"W4413270055","doi":"10.1016/j.jid.2025.06.1598","title":"Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Psoriasis; Medicine; Interleukin 17; Dermatology; Internal medicine; Cytokine","score_opus":0.026181843175732463,"score_gpt":0.26069599878349436,"score_spread":0.2345141556077619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413270055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943338,0.0022199068,0.00042825294,0.0014274876,0.00025506612,0.00020738681,0.0006977533,0.000009957376,0.0004204109],"genre_scores_gemma":[0.998095,0.00009850523,0.00095856824,0.00048406015,0.000010200464,0.0000138234755,0.00026139154,0.000008202354,0.000070293754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970744,0.0010589536,0.0011813472,0.00034015102,0.00007313396,0.0002720175],"domain_scores_gemma":[0.9979214,0.0006414187,0.0007706126,0.00021595923,0.0003810121,0.000069606685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029889165,0.00027954535,0.0013992444,0.0012920131,0.00008474049,0.000014356749,0.00014576505,0.00033634593,0.00002077131],"category_scores_gemma":[0.00034627388,0.00024192099,0.0002084867,0.001178673,0.00044609353,0.00016085086,0.00007969374,0.0003318798,0.000014999263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004662341,0.0006106669,0.0063825445,0.000035333243,0.010172877,0.00050460297,0.011322696,0.002119614,0.957417,0.0034778002,0.002131949,0.0011625427],"study_design_scores_gemma":[0.0055233086,0.00027545425,0.03910189,0.00019412144,0.0013142595,0.00010007814,0.0016558601,0.00009674806,0.9460077,0.0051583694,0.00036702713,0.00020512637],"about_ca_topic_score_codex":0.00014874619,"about_ca_topic_score_gemma":0.0002934027,"teacher_disagreement_score":0.032719348,"about_ca_system_score_codex":0.00007311868,"about_ca_system_score_gemma":0.00027025634,"threshold_uncertainty_score":0.9865252},"labels":[],"label_agreement":null},{"id":"W4413289306","doi":"10.1002/acr.25634","title":"Reply","year":2025,"lang":"en","type":"letter","venue":"Arthritis Care & Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arthritis Society; Toronto Western Hospital; University of Toronto; University Health Network; University of Waterloo; Women's College Hospital","funders":"Department of Medicine, University of Toronto; Krembil Foundation","keywords":"Psoriatic arthritis; Psoriasis; Medicine; Prospective cohort study; Cohort; C-reactive protein; Association (psychology); Dermatology; Cohort study; Internal medicine; Psychology; Inflammation","score_opus":0.03844215814878605,"score_gpt":0.31720286785489205,"score_spread":0.278760709706106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413289306","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023245497,0.29073527,0.0000031635423,0.5718734,0.0048352666,0.0014240394,0.0016585422,0.00033543544,0.1268103],"genre_scores_gemma":[0.022535628,0.018805576,0.000080503174,0.5518578,0.0040247655,0.0011950077,0.015779153,0.0001638076,0.38555774],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961853,0.0012442832,0.00033881827,0.0008775163,0.00020281936,0.0011512485],"domain_scores_gemma":[0.9975612,0.0007183154,0.00005880893,0.0010669497,0.0005694656,0.000025238774],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00043799917,0.00034621978,0.00054453785,0.0006160302,0.0005892351,0.00007472988,0.0006454588,0.0015414301,0.0018698149],"category_scores_gemma":[0.00016350631,0.00033574295,0.0002934311,0.00043489292,0.00039743693,0.000057835074,0.00034137786,0.0030055533,0.0050368058],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028653749,0.000016259397,0.00012146331,0.00008560778,0.00020955541,0.0008883637,0.00039309578,2.186837e-8,0.0002644927,0.000049007205,0.73052245,0.267421],"study_design_scores_gemma":[0.0012824989,0.00019016379,0.00013789203,0.00042048524,0.00004166925,0.00006548613,0.00039611067,1.4506264e-8,0.004450853,0.00015647805,0.99258167,0.00027669538],"about_ca_topic_score_codex":0.00077826064,"about_ca_topic_score_gemma":0.00016932121,"teacher_disagreement_score":0.27192968,"about_ca_system_score_codex":0.00019041178,"about_ca_system_score_gemma":0.00048983295,"threshold_uncertainty_score":0.99990946},"labels":[],"label_agreement":null},{"id":"W4413744809","doi":"10.1111/pde.70013","title":"Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2–11 Years","year":2025,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"","keywords":"Medicine; Roflumilast; Plaque psoriasis; Pharmacokinetics; Dermatology; Psoriasis; Intensive care medicine; Pharmacology; Internal medicine; COPD","score_opus":0.03145613138158878,"score_gpt":0.31600082874628377,"score_spread":0.284544697364695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413744809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819442,0.016417312,0.00012091807,0.0001397778,0.00039362014,0.00068155385,0.0002598216,0.000014858136,0.000027930986],"genre_scores_gemma":[0.9742244,0.024903733,0.00048094674,0.000025597132,0.000037758957,0.00006727602,0.000055810277,0.000013580536,0.0001909058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979431,0.0002835763,0.0010573898,0.00037640467,0.000038295304,0.00030125584],"domain_scores_gemma":[0.9975429,0.0016655199,0.0004055219,0.0002668792,0.000090515845,0.000028648268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020092182,0.00022761346,0.0010246736,0.00034097242,0.000047006164,0.0000030796473,0.00020012027,0.00036396718,0.000025385669],"category_scores_gemma":[0.00011857595,0.0001966521,0.00017328236,0.00032390706,0.00021026902,0.00006140399,0.00007295993,0.00007524664,0.0000029975001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005180274,0.0009954958,0.97733533,0.00015324696,0.000557925,0.000008616188,0.00041650643,0.000032001306,0.0017377895,0.0001830444,0.00035740534,0.013042361],"study_design_scores_gemma":[0.013518749,0.001126919,0.9495907,0.00007296164,0.0012950987,0.000054059212,0.000048280577,0.000022844059,0.03375132,0.00012893174,0.00019848367,0.00019166197],"about_ca_topic_score_codex":0.00033481035,"about_ca_topic_score_gemma":0.00014585648,"teacher_disagreement_score":0.03201353,"about_ca_system_score_codex":0.000027174669,"about_ca_system_score_gemma":0.00019332021,"threshold_uncertainty_score":0.801924},"labels":[],"label_agreement":null},{"id":"W4413786495","doi":"10.1093/bjd/ljaf327","title":"SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; Dalhousie University; Innovaderm (Canada)","funders":"Johnson and Johnson; Dermira; Celgene; Teva Pharmaceutical Industries; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Intertriginous; Body surface area; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Dermatology; Disease; Pathology","score_opus":0.038585348085449125,"score_gpt":0.3233213397615486,"score_spread":0.2847359916760995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413786495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756859,0.018622195,0.0015298007,0.0010521426,0.0012805123,0.001126593,0.000611803,0.000017351927,0.0000737334],"genre_scores_gemma":[0.9820467,0.016822016,0.00044400012,0.00007827738,0.00010859604,0.0000223782,0.0001770371,0.000019927453,0.00028102662],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969809,0.00064036873,0.0015073619,0.00036718338,0.00007514114,0.00042903287],"domain_scores_gemma":[0.99633884,0.0021488632,0.0008956937,0.00031091267,0.00025156865,0.000054131186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042101,0.0003218705,0.0013182627,0.00009245239,0.00034264755,0.000042570904,0.00022786815,0.00032461312,0.000044606702],"category_scores_gemma":[0.00015638726,0.0002193325,0.000420885,0.00016825572,0.00037341643,0.00013286967,0.000034242097,0.0002227764,0.0000036431384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81356645,0.015529911,0.0027912196,0.00007474444,0.015761744,0.0010042788,0.0012682211,0.00024217175,0.0022289308,0.00032844575,0.013639462,0.13356441],"study_design_scores_gemma":[0.87088746,0.025153572,0.011526672,0.0005875594,0.004609667,0.008014377,0.000474519,0.00005573629,0.060897112,0.0005066585,0.016774762,0.0005119217],"about_ca_topic_score_codex":0.00028050793,"about_ca_topic_score_gemma":0.0003423722,"teacher_disagreement_score":0.1330525,"about_ca_system_score_codex":0.00012784563,"about_ca_system_score_gemma":0.0003718281,"threshold_uncertainty_score":0.894412},"labels":[],"label_agreement":null},{"id":"W4413818658","doi":"10.58931/crt.2025.2262","title":"IL-17 Inhibition vs IL-23 Inhibition for Psoriatic Arthritis: An Ongoing Debate","year":2025,"lang":"en","type":"article","venue":"Canadian rheumatology today.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Krembil Foundation","funders":"Canadian Institutes of Health Research; Krembil Foundation; Arthritis Society; National Psoriasis Foundation","keywords":"Psoriatic arthritis; Medicine; Arthritis; Pharmacology; Internal medicine","score_opus":0.010393807326044047,"score_gpt":0.22697272929628248,"score_spread":0.21657892197023842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413818658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870623,0.004210029,0.00044501858,0.0018679035,0.0025973916,0.00084047596,0.000847509,0.00018406454,0.0019453298],"genre_scores_gemma":[0.9920097,0.00047005882,0.00024167326,0.0010674887,0.000032078962,0.00042547574,0.002934055,0.00003569382,0.0027837947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997737,0.00026411813,0.0005238971,0.0005880344,0.000029775883,0.00085718674],"domain_scores_gemma":[0.9989381,0.0002303414,0.00014996245,0.0004078646,0.00012740814,0.0001463566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029619044,0.00033470767,0.0005747959,0.0006265803,0.00070958684,0.00004061525,0.00015064629,0.0007103911,0.00032202955],"category_scores_gemma":[0.00017392114,0.00036840062,0.00015936527,0.0002795038,0.00020093395,0.0002236657,0.000028788501,0.0002083596,0.00041607293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017826213,0.0007924838,0.039581403,0.0006453688,0.002903607,0.0004698247,0.003504013,0.00006234004,0.034388952,0.16900459,0.28337818,0.4634866],"study_design_scores_gemma":[0.042671986,0.0026309628,0.0523767,0.0036583685,0.001505933,0.0030159885,0.0030667232,0.00024685997,0.18770747,0.046333004,0.65280974,0.0039762612],"about_ca_topic_score_codex":0.010062167,"about_ca_topic_score_gemma":0.19357175,"teacher_disagreement_score":0.45951036,"about_ca_system_score_codex":0.00027202923,"about_ca_system_score_gemma":0.000695042,"threshold_uncertainty_score":0.9998768},"labels":[],"label_agreement":null},{"id":"W4413870593","doi":"10.1016/j.jaad.2025.05.1192","title":"63736 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Dalhousie University; Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Psoriasis; Body surface area; Dermatology; Internal medicine","score_opus":0.016471736223666805,"score_gpt":0.2625292127327814,"score_spread":0.2460574765091146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413870593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875382,0.0034481431,0.00008858597,0.007962517,0.0003800415,0.00031081706,0.00008034254,0.000010493558,0.00018084886],"genre_scores_gemma":[0.9978519,0.0011708617,0.00024854913,0.0004383069,0.00006964431,0.0000061658634,0.0000028566476,0.000015770673,0.00019592592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738765,0.0007412324,0.0010109271,0.00025263833,0.00014291053,0.00046464303],"domain_scores_gemma":[0.9968157,0.00062429125,0.002071055,0.0002853719,0.00016736408,0.00003622783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035250714,0.00031600543,0.0011820573,0.000113790746,0.00025853244,0.0000152188595,0.0008168168,0.00017723274,0.00004966304],"category_scores_gemma":[0.00006804823,0.00017260495,0.00038403575,0.0004869915,0.0020853803,0.000088770634,0.00013281533,0.00055217615,0.0000085056145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02218774,0.0013857872,0.2716281,0.00023662623,0.009032229,0.00008998503,0.0027645046,0.001183276,0.670291,0.0022407337,0.012489158,0.0064708455],"study_design_scores_gemma":[0.005833942,0.00073916494,0.12714076,0.00037068655,0.0012808645,0.0016366318,0.0038441762,0.00005878677,0.8557538,0.00066289137,0.0023222032,0.00035610795],"about_ca_topic_score_codex":0.000045974153,"about_ca_topic_score_gemma":0.000039368082,"teacher_disagreement_score":0.18546277,"about_ca_system_score_codex":0.000066307475,"about_ca_system_score_gemma":0.00023264738,"threshold_uncertainty_score":0.7683671},"labels":[],"label_agreement":null},{"id":"W4413870807","doi":"10.1016/j.jaad.2025.05.1122","title":"62697 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin clearance from the RePhlect Registry","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Probity Medical Research; SKiN Health; Queen's University","funders":"","keywords":"Medicine; Plaque psoriasis; Psoriasis; Dermatology","score_opus":0.006789472635826107,"score_gpt":0.2592353245623932,"score_spread":0.25244585192656704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413870807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99734145,0.0011575595,0.00003782789,0.000832136,0.00014201606,0.0002120823,0.00010284257,0.0000041238413,0.00016997795],"genre_scores_gemma":[0.99936914,0.00032372298,0.000107223175,0.0001323399,0.000009458558,0.000007689746,0.000010843597,0.000009733192,0.000029825836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966467,0.0018495643,0.0009562143,0.00020867573,0.000105862164,0.00023299144],"domain_scores_gemma":[0.9952092,0.0017106805,0.002610922,0.00033432653,0.00011804181,0.000016820337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040463117,0.00020064646,0.0014941349,0.00049985456,0.00006060818,0.000002737375,0.0007416269,0.00015929095,0.0000124540475],"category_scores_gemma":[0.0001581158,0.00011425368,0.00040143548,0.0018161512,0.00089131494,0.000060100818,0.000089415276,0.0004551512,7.970546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008585996,0.00032223304,0.97461057,0.00004320958,0.006480418,0.0000045906827,0.00026291676,0.00015132633,0.0057815104,0.000264552,0.00029518225,0.0031975117],"study_design_scores_gemma":[0.0029912551,0.00017302176,0.9353578,0.00033309343,0.002213754,0.000018159988,0.00017891359,0.0000034148682,0.05824093,0.0001777262,0.00022593907,0.00008597219],"about_ca_topic_score_codex":0.0008912362,"about_ca_topic_score_gemma":0.0002287797,"teacher_disagreement_score":0.052459422,"about_ca_system_score_codex":0.000057920057,"about_ca_system_score_gemma":0.0001456409,"threshold_uncertainty_score":0.465913},"labels":[],"label_agreement":null},{"id":"W4413870850","doi":"10.1016/j.jaad.2025.05.857","title":"63549 Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of a phase 3, randomized, placebo-controlled study","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; University of Calgary","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Placebo; Psoriasis; Randomized controlled trial; Internal medicine; Alternative medicine; Pathology","score_opus":0.013769705088917773,"score_gpt":0.2986567653505907,"score_spread":0.28488706026167293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413870850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907961,0.002816457,0.0000948378,0.002985602,0.00042665566,0.0026866107,0.00014018432,0.0000043367218,0.000049251885],"genre_scores_gemma":[0.9977116,0.0016651534,0.00012637027,0.0001342476,0.000029912899,0.00018181452,0.000003974304,0.000012178234,0.00013473023],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583554,0.00161359,0.0019560328,0.00020959157,0.00009668186,0.0002885352],"domain_scores_gemma":[0.9921979,0.004496346,0.0028610749,0.00024368343,0.00017516596,0.000025833455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006465706,0.0002706222,0.0025711104,0.0005573476,0.000094121875,0.0000036521185,0.0005810099,0.00016172063,0.0000065920512],"category_scores_gemma":[0.00065679144,0.00013920252,0.00073212973,0.0005451789,0.00035997477,0.000052169285,0.000058360987,0.00020524894,0.0000015632238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.954913,0.0060653696,0.016337939,0.0000402556,0.005163311,0.000004208047,0.0026028838,0.00040959133,0.0011363624,0.00010416338,0.0017684336,0.0114544565],"study_design_scores_gemma":[0.9583313,0.0029763242,0.010611626,0.000060015347,0.004708703,0.00006150805,0.0012501639,0.00005582213,0.020769877,0.00023631661,0.0007757506,0.00016260758],"about_ca_topic_score_codex":0.00008058865,"about_ca_topic_score_gemma":0.00002125499,"teacher_disagreement_score":0.019633515,"about_ca_system_score_codex":0.00007946462,"about_ca_system_score_gemma":0.00019549586,"threshold_uncertainty_score":0.5676514},"labels":[],"label_agreement":null},{"id":"W4413870882","doi":"10.1016/j.jaad.2025.05.834","title":"64510 Flare burden in generalized pustular psoriasis (GPP): analysis of pre-trial historical experience of patients enrolled in EFFISAYIL® 2","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Generalized pustular psoriasis; Flare; Psoriasis; Pustular psoriasis; Dermatology","score_opus":0.01133503957624771,"score_gpt":0.2836634516875507,"score_spread":0.272328412111303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413870882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955965,0.0024688684,0.000023833458,0.0010281024,0.0005422149,0.0002750393,0.000022050253,0.0000034403297,0.000039913346],"genre_scores_gemma":[0.99910736,0.00046357437,0.00017701797,0.000091213864,0.000018759147,0.000015465728,0.000005649517,0.00000776447,0.000113212125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99642116,0.0012010877,0.0017382443,0.0002154981,0.00013675969,0.00028727818],"domain_scores_gemma":[0.9968609,0.0004704451,0.0023048772,0.0002301333,0.00010801529,0.000025619394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028494102,0.00021066844,0.0020695997,0.0013151137,0.00003859412,0.0000018886251,0.0007627135,0.00028535107,0.0000455755],"category_scores_gemma":[0.0003678361,0.0001512021,0.0006313912,0.001955495,0.00044107353,0.0000699866,0.00014778871,0.00037968904,8.3372896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03746558,0.0012400921,0.88666266,0.000055542372,0.0045591057,0.000015328158,0.003274897,0.00050359574,0.059119843,0.00014659397,0.0008973421,0.0060594394],"study_design_scores_gemma":[0.048951384,0.000534992,0.8475264,0.00013471587,0.002961127,0.000046311787,0.0006700102,0.00004575576,0.09581529,0.00016281719,0.0028881314,0.0002631176],"about_ca_topic_score_codex":0.00048172456,"about_ca_topic_score_gemma":0.000034491262,"teacher_disagreement_score":0.03913629,"about_ca_system_score_codex":0.00019608147,"about_ca_system_score_gemma":0.00014157398,"threshold_uncertainty_score":0.6165843},"labels":[],"label_agreement":null},{"id":"W4413871122","doi":"10.1016/j.jaad.2025.05.966","title":"64587 Longitudinal Psychological Impact of Psoriasis: A Comparative Study between Adults and Children","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"","keywords":"Medicine; Psoriasis; Longitudinal study; Clinical psychology; Dermatology; Pathology","score_opus":0.029771633809812764,"score_gpt":0.36033988368432934,"score_spread":0.3305682498745166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413871122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601847,0.0025759023,0.000014070837,0.0008576855,0.00013443572,0.00026915068,0.0000465169,0.0000062412028,0.000077518],"genre_scores_gemma":[0.99961275,0.00019250024,0.00007813619,0.000053020216,0.00002834637,0.000003956593,0.0000021717701,0.0000054653956,0.00002366736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978212,0.0008539662,0.000818779,0.00019904731,0.00006573844,0.00024126023],"domain_scores_gemma":[0.99776727,0.0004208636,0.0015490367,0.00015509035,0.00007543952,0.000032291828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019734797,0.0002158256,0.0013214654,0.00027266028,0.00009025651,0.0000036367887,0.00052479474,0.00016178901,0.000020359732],"category_scores_gemma":[0.000063478416,0.00012426413,0.00036331528,0.00040746696,0.0009502848,0.000062126,0.00013717794,0.00046548262,0.0000036852487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018453245,0.0005714229,0.9833304,0.000007709767,0.0036084354,0.0000044877834,0.00058555003,0.0000031706318,0.002745391,0.00005109275,0.0012523682,0.005994606],"study_design_scores_gemma":[0.0036297739,0.0012346227,0.98577017,0.00006509152,0.0007815122,0.0010248367,0.00056048046,3.7691683e-7,0.0066282596,0.00017582843,0.000037541788,0.000091513655],"about_ca_topic_score_codex":0.00006778288,"about_ca_topic_score_gemma":0.0000027272938,"teacher_disagreement_score":0.005903092,"about_ca_system_score_codex":0.00002901541,"about_ca_system_score_gemma":0.000060282666,"threshold_uncertainty_score":0.50673443},"labels":[],"label_agreement":null},{"id":"W4413871244","doi":"10.1016/j.jaad.2025.05.313","title":"62396 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin pain, itch, and fatigue from the RePhlect Registry","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Queen's University; Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.008740750792603981,"score_gpt":0.2625338765884431,"score_spread":0.2537931257958391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413871244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716663,0.0012843955,0.00008286092,0.0009640282,0.00008751605,0.00022041168,0.00009658581,0.000003627641,0.0000939456],"genre_scores_gemma":[0.9992742,0.00038461367,0.00012097807,0.00016485293,0.000007623829,0.000008416645,0.0000141101955,0.000008779407,0.000016402553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960088,0.0025946028,0.0008862328,0.00020584003,0.00009211306,0.00021239016],"domain_scores_gemma":[0.99456793,0.002772083,0.002254075,0.00027348462,0.00011284438,0.00001957607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063843094,0.00020194039,0.0014101423,0.0005085542,0.000062961255,0.0000031852496,0.0005163306,0.00015931287,0.000008606688],"category_scores_gemma":[0.00027151528,0.00011407889,0.00028243588,0.0013827549,0.0008889156,0.000055830158,0.000092560644,0.00038860796,2.0543965e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039776857,0.00022637383,0.9802611,0.000050387272,0.0057746563,0.000004046097,0.0003250946,0.000058229612,0.0042307037,0.00019641338,0.00028096372,0.004614338],"study_design_scores_gemma":[0.0028284101,0.00017693659,0.9593758,0.00033056427,0.0022463726,0.00001828353,0.00033555698,0.0000058636883,0.03424621,0.00020477445,0.00014132632,0.00008992593],"about_ca_topic_score_codex":0.0010333197,"about_ca_topic_score_gemma":0.00026922146,"teacher_disagreement_score":0.030015508,"about_ca_system_score_codex":0.0000443001,"about_ca_system_score_gemma":0.00011813242,"threshold_uncertainty_score":0.4652002},"labels":[],"label_agreement":null},{"id":"W4413871270","doi":"10.1016/j.jaad.2025.05.556","title":"62934 Body Mass Index and Weight as Cardiometabolic Outcomes in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis Treated With Apremilast: 16-Week Results From the SPROUT Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Apremilast; Plaque psoriasis; Body mass index; Randomized controlled trial; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Dermatology","score_opus":0.0059502749653910355,"score_gpt":0.23229439759222614,"score_spread":0.22634412262683512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413871270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091166,0.0014902524,0.000045016503,0.0050338465,0.0003164413,0.0018806579,0.00010262415,0.000010869814,0.00020862046],"genre_scores_gemma":[0.99818414,0.00073760754,0.00008076404,0.00059642666,0.00005746141,0.000096209355,0.000011354067,0.000018974615,0.00021704866],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954328,0.0023554023,0.0013550251,0.00031820752,0.0001661896,0.00037239288],"domain_scores_gemma":[0.99434954,0.0031873025,0.0020473525,0.00023933304,0.00012496591,0.000051483723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005043883,0.00039154693,0.003472551,0.0005314638,0.00014554766,0.000018013065,0.000538994,0.00024878333,0.000009326693],"category_scores_gemma":[0.00055080815,0.00017001315,0.0004119449,0.0007255095,0.0005633286,0.000098871424,0.00009037568,0.00061318564,0.000004122549],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7071793,0.00023275313,0.28791013,0.00000459596,0.0033855482,0.000008657297,0.00016210851,0.0000563571,0.00008689568,0.000035166748,0.00031259298,0.0006258897],"study_design_scores_gemma":[0.7705407,0.00036070962,0.22460261,0.000056363013,0.0026191003,0.00008382172,0.00013668349,0.0000063853945,0.0009997832,0.00017729342,0.00023873738,0.00017782471],"about_ca_topic_score_codex":0.00026343483,"about_ca_topic_score_gemma":0.000022569435,"teacher_disagreement_score":0.06336138,"about_ca_system_score_codex":0.000059089823,"about_ca_system_score_gemma":0.0002308506,"threshold_uncertainty_score":0.6932936},"labels":[],"label_agreement":null},{"id":"W4413871446","doi":"10.1016/j.jaad.2025.05.544","title":"62020 Bimekizumab efficacy in patients with plaque psoriasis: A post hoc stratification by weight over 4 years in BE BRIGHT","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Medicine; Plaque psoriasis; Post-hoc analysis; Psoriasis; Post hoc; Stratification (seeds); Dermatology; Internal medicine","score_opus":0.005397165505638845,"score_gpt":0.2401147297499204,"score_spread":0.23471756424428156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413871446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208325,0.0013038295,0.000004769488,0.006074156,0.00019927215,0.00020634424,0.000041933457,0.000005577871,0.000080866],"genre_scores_gemma":[0.9989174,0.00024569427,0.000073394294,0.00064533803,0.000009639215,0.0000056583485,0.000016208824,0.000010362637,0.000076319615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983123,0.0005021607,0.0006760608,0.00018030584,0.00007665501,0.00025255178],"domain_scores_gemma":[0.99863714,0.00024012294,0.0009147956,0.00014338385,0.000043765096,0.000020801384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011237497,0.00017131233,0.0006294215,0.0003781721,0.000041242343,0.000005351575,0.00044449887,0.00019022977,0.000037677633],"category_scores_gemma":[0.000048943126,0.00011557929,0.0001180689,0.0005851386,0.00036878444,0.000106227766,0.000049731483,0.00046555474,0.000006464773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432686,0.0019601847,0.910763,0.000036631118,0.001204243,0.000029070285,0.0009079156,0.00002045477,0.027384331,0.0008610079,0.01621596,0.031184481],"study_design_scores_gemma":[0.0068003014,0.00022574623,0.9675145,0.0001022077,0.00013806245,0.000090178866,0.00010897506,8.778293e-7,0.018714221,0.000082207145,0.006105771,0.00011695816],"about_ca_topic_score_codex":0.00006053559,"about_ca_topic_score_gemma":0.000021228867,"teacher_disagreement_score":0.05675146,"about_ca_system_score_codex":0.00008245455,"about_ca_system_score_gemma":0.0001420679,"threshold_uncertainty_score":0.47131866},"labels":[],"label_agreement":null},{"id":"W4413871680","doi":"10.1016/j.jaad.2025.05.541","title":"62275 Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Probity Medical Research; Dermatrials Research","funders":"","keywords":"Medicine; Plaque psoriasis; Dermatology; Psoriasis","score_opus":0.006009678061953932,"score_gpt":0.23114932568880706,"score_spread":0.22513964762685312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413871680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904777,0.00071865006,0.000005245959,0.008412006,0.00010145713,0.0001946212,0.00002074073,0.0000015816667,0.00006799007],"genre_scores_gemma":[0.99772227,0.00026868787,0.00009778777,0.0018739761,0.000005458323,0.000003418269,0.0000013562998,0.0000053698286,0.000021705298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878174,0.0004470689,0.00038400246,0.00012843299,0.00005530563,0.0002034522],"domain_scores_gemma":[0.9991908,0.00032872733,0.00034778338,0.00009505388,0.000021739073,0.000015871741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010680551,0.00012841549,0.00049102877,0.00012533902,0.000062108105,0.000004710838,0.00027380057,0.00008630288,0.000003294634],"category_scores_gemma":[0.000044192504,0.00007338812,0.00003198182,0.00029614594,0.00024186945,0.00005461159,0.0000721801,0.00032905294,5.13304e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007820763,0.00020551143,0.9698276,0.000023643599,0.00056821166,0.000038301325,0.0016020025,0.00021753149,0.0003828316,0.000381415,0.0032623368,0.015669843],"study_design_scores_gemma":[0.00463312,0.000121301644,0.98957974,0.00007380311,0.000092743445,0.00035590777,0.0002972327,0.0000010820613,0.0008600141,0.0001010284,0.0038022238,0.00008183232],"about_ca_topic_score_codex":0.013320307,"about_ca_topic_score_gemma":0.01099349,"teacher_disagreement_score":0.019752102,"about_ca_system_score_codex":0.000056671397,"about_ca_system_score_gemma":0.0001813876,"threshold_uncertainty_score":0.9932501},"labels":[],"label_agreement":null},{"id":"W4413875724","doi":"10.1016/j.jaad.2025.05.165","title":"62986 Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 2-year results from the SPROUT extension trial","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital; University of Alberta","funders":"","keywords":"Medicine; Apremilast; Psoriasis; Dermatology; Plaque psoriasis; Internal medicine; Psoriatic arthritis","score_opus":0.01031342340016822,"score_gpt":0.2454803991084882,"score_spread":0.23516697570832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413875724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937731,0.00086432096,0.000016619431,0.004405805,0.0003272907,0.00043331512,0.00010902845,0.000004441116,0.00006604857],"genre_scores_gemma":[0.9987666,0.0005955872,0.00019215826,0.00034870353,0.000047150814,0.000004344858,0.000007176674,0.000009569496,0.000028707105],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99781555,0.00073256233,0.00092162244,0.00021608507,0.00008982447,0.00022434816],"domain_scores_gemma":[0.9972332,0.0011595255,0.0012959795,0.0001995052,0.00008468955,0.000027076629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002499315,0.0001875014,0.0008119081,0.00020954241,0.000092320566,0.000004473256,0.000443313,0.00018245785,0.000004858174],"category_scores_gemma":[0.0003396656,0.00010015865,0.00011721675,0.00045087127,0.00033121757,0.00006116484,0.00014220006,0.00046134615,0.0000031538266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.555778,0.0008834854,0.41832733,0.00003390958,0.0011860253,0.0000106945945,0.0014864369,0.0003143349,0.003670565,0.00018753014,0.005688668,0.01243299],"study_design_scores_gemma":[0.07267532,0.00053383096,0.91926694,0.00017350812,0.00054276205,0.00006739016,0.00027440538,0.0000027843869,0.00534903,0.00015391986,0.0008258296,0.00013428717],"about_ca_topic_score_codex":0.00005875755,"about_ca_topic_score_gemma":0.000012052082,"teacher_disagreement_score":0.5009396,"about_ca_system_score_codex":0.00003118934,"about_ca_system_score_gemma":0.00012938608,"threshold_uncertainty_score":0.40843514},"labels":[],"label_agreement":null},{"id":"W4413877979","doi":"10.3899/jrheum.2025-0606","title":"Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Psoriasis; Psoriatic arthritis; Dermatology; Seborrheic dermatitis; Dermatology Life Quality Index; Pityriasis rubra pilaris; Clinical Practice; Disease; Acne; Physical therapy; Internal medicine","score_opus":0.02163719922571343,"score_gpt":0.29125749096446885,"score_spread":0.2696202917387554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413877979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9199856,0.06352719,0.0010125169,0.012368961,0.0024782633,0.00039030885,0.00011788679,0.000010504302,0.00010878043],"genre_scores_gemma":[0.972996,0.026013868,0.00052697654,0.00015830217,0.000012324387,0.00006304444,0.0000073980605,0.000011156866,0.0002109281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979367,0.0008234127,0.000740771,0.00015501007,0.00005904668,0.00028503843],"domain_scores_gemma":[0.98053944,0.018081706,0.0007213791,0.00045151488,0.00019013819,0.00001583983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016237942,0.00020664511,0.0006415935,0.00009596441,0.00048792336,0.000016251814,0.0008490588,0.00022225219,0.000081048114],"category_scores_gemma":[0.0010916712,0.00009107396,0.00023428486,0.00021450107,0.0005954693,0.000057858873,0.00021794773,0.00037873,0.0000031147247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014173476,0.00027045258,0.7703642,0.00006868301,0.0068431967,0.0000030649715,0.0039924034,0.00005505791,0.0007553098,0.007254499,0.07898262,0.12999313],"study_design_scores_gemma":[0.025189502,0.0017216465,0.6139356,0.0034363365,0.014021916,0.0043383837,0.073200844,0.00022219642,0.014097658,0.042782508,0.20591883,0.0011345771],"about_ca_topic_score_codex":0.00061776827,"about_ca_topic_score_gemma":0.00038642608,"teacher_disagreement_score":0.15642864,"about_ca_system_score_codex":0.000024410776,"about_ca_system_score_gemma":0.00015145655,"threshold_uncertainty_score":0.37527615},"labels":[],"label_agreement":null},{"id":"W4413897076","doi":"10.1016/j.jaad.2025.05.537","title":"63312 Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from BE BRIGHT and BE RADIANT","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Psoriatic arthritis; Psoriasis; Dermatology; Arthritis; Internal medicine","score_opus":0.012250122327350637,"score_gpt":0.27517079298144587,"score_spread":0.26292067065409525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413897076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913353,0.0029811433,0.0003067556,0.0029843866,0.0002853677,0.0011168994,0.0009782561,0.000009305393,0.0000026287526],"genre_scores_gemma":[0.99462366,0.0018794119,0.0030911488,0.00024175433,0.000036591744,0.00003524657,0.000053476968,0.000021881433,0.00001681959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978664,0.00045322254,0.00087001064,0.0003410693,0.000086305365,0.0003830069],"domain_scores_gemma":[0.99635947,0.0019734034,0.0013563433,0.00014617936,0.00009461128,0.000069976384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020666765,0.00028459975,0.0010743262,0.00036364,0.00021845757,0.000018751934,0.00026564073,0.00021261798,0.0000044220824],"category_scores_gemma":[0.0006072908,0.0001771729,0.00015384816,0.0003112212,0.00039312599,0.00012950499,0.00008822112,0.00030522217,4.0566854e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033965804,0.00055805326,0.49031514,0.000053557764,0.002508003,0.000015122881,0.0020725445,0.000011004867,0.00053500576,0.00006511639,0.00095565367,0.468945],"study_design_scores_gemma":[0.02558768,0.0013406768,0.95772195,0.0009902234,0.00068219716,0.00009609512,0.00034451374,0.000004923118,0.012516303,0.00008700866,0.0004143219,0.00021408242],"about_ca_topic_score_codex":0.00009124935,"about_ca_topic_score_gemma":0.00006523112,"teacher_disagreement_score":0.46873093,"about_ca_system_score_codex":0.00004466086,"about_ca_system_score_gemma":0.00009592286,"threshold_uncertainty_score":0.72249013},"labels":[],"label_agreement":null},{"id":"W4413912343","doi":"10.1021/acsptsci.5c00361","title":"Toward Long-Acting Psoriasis Therapy with Phloretin-Loaded Microneedle Patches: Insights from <i>In Vitro</i> Patient-Derived Skin Models","year":2025,"lang":"en","type":"article","venue":"ACS Pharmacology & Translational Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Chicoutimi; Université de Montréal; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Université Laval","keywords":"Psoriasis; Phloretin; In vitro; Medicine; Chemistry; Dermatology; Pharmacology; Biochemistry","score_opus":0.024363822441302477,"score_gpt":0.2613500801609772,"score_spread":0.23698625771967474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413912343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076086,0.0046448465,0.0011452541,0.0008358307,0.0010182274,0.00055716175,0.00008406538,0.000071652736,0.0008821129],"genre_scores_gemma":[0.9976394,0.00024880038,0.0007196912,0.0009548332,0.000042827327,0.00014446139,0.00018558688,0.000014949538,0.00004941523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788857,0.00024090646,0.00040971627,0.0007627763,0.0001346978,0.00056335994],"domain_scores_gemma":[0.9990596,0.00042607088,0.00014402953,0.00018786677,0.00013313838,0.00004929672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019720197,0.0003238318,0.00038009824,0.0003293051,0.00045869284,0.000031832602,0.0004972738,0.00022731665,0.00019664958],"category_scores_gemma":[0.000007975548,0.0002657883,0.0000912059,0.0009253808,0.00077414577,0.0004922805,0.000048683603,0.00028501524,0.00003998225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001870426,0.000343258,0.0012284617,0.00000459942,0.00025934115,0.000015869713,0.0044415086,0.00042197751,0.9513153,0.00010496211,0.00005577991,0.039938517],"study_design_scores_gemma":[0.0056062154,0.00011306493,0.008532984,0.000025135538,0.00011645488,0.000006681914,0.00037986686,0.0001084064,0.98333186,0.0008869749,0.00061788387,0.0002744833],"about_ca_topic_score_codex":0.0003167167,"about_ca_topic_score_gemma":0.000058523307,"teacher_disagreement_score":0.039664034,"about_ca_system_score_codex":0.000100552475,"about_ca_system_score_gemma":0.00046408075,"threshold_uncertainty_score":0.99997944},"labels":[],"label_agreement":null},{"id":"W4414003437","doi":"10.2147/ptt.s532112","title":"Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023","year":2025,"lang":"en","type":"article","venue":"Psoriasis Targets and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"China Academy of Chinese Medical Sciences; State Administration of Traditional Chinese Medicine of the People's Republic of China; National Natural Science Foundation of China","keywords":"Epidemiology; Psoriasis; Medicine; Dermatology; Environmental health; Pathology","score_opus":0.034549987230702156,"score_gpt":0.28825905247573247,"score_spread":0.25370906524503034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414003437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96092176,0.037048183,0.000096749056,0.00032351,0.0007385553,0.00015871394,0.0003695659,0.000021490456,0.00032145943],"genre_scores_gemma":[0.99463457,0.00338994,0.00048708494,0.00030885634,0.000035469686,0.000040726463,0.00053658447,0.000012260268,0.00055451074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778503,0.000575962,0.0007238309,0.00053726725,0.00003880551,0.0003390929],"domain_scores_gemma":[0.998638,0.0005442461,0.00021526811,0.00047021033,0.000090166934,0.00004216002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005763113,0.00026524212,0.0013007886,0.0012705125,0.00006984868,0.0000022489291,0.00021354247,0.0003362044,0.0005339908],"category_scores_gemma":[0.00008477968,0.00021041432,0.0002545155,0.0012770134,0.0001104576,0.000069036585,0.000049201408,0.00010014436,0.000008351531],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001831621,0.00078246836,0.59282595,0.00000722737,0.004694364,0.0000034152854,0.0007720344,0.00010920916,0.03851391,0.0010757376,0.00063818623,0.35874587],"study_design_scores_gemma":[0.00344458,0.00039315468,0.9662702,0.000027876424,0.00090305123,7.0182404e-7,0.00027605286,0.000058452042,0.022494178,0.00090622855,0.0050184317,0.00020709119],"about_ca_topic_score_codex":0.004716311,"about_ca_topic_score_gemma":0.0010423362,"teacher_disagreement_score":0.37344423,"about_ca_system_score_codex":0.000022592369,"about_ca_system_score_gemma":0.000030815077,"threshold_uncertainty_score":0.8580447},"labels":[],"label_agreement":null},{"id":"W4414015732","doi":"10.11159/icbes25.181","title":"Comparing 3D-Modeling Algorithms to Enhance Remote Diagnosis Accuracy of Psoriasis","year":2025,"lang":"en","type":"article","venue":"Proceedings of the World Congress on Electrical Engineering and Computer Systems and Science","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science; Psoriasis; Artificial intelligence; Algorithm; Dermatology; Medicine","score_opus":0.011739934233724313,"score_gpt":0.24486634918371397,"score_spread":0.23312641494998965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414015732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99292445,0.0023431885,0.002491551,0.0001237504,0.0016366141,0.0002567798,0.00000220409,0.000037050675,0.00018439941],"genre_scores_gemma":[0.9987706,0.00009721898,0.00074484234,0.00002481592,0.00003562321,0.000017296592,1.7705375e-7,0.000005005818,0.00030441085],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990357,0.00000874465,0.0002791412,0.00032959503,0.00008439012,0.00026241172],"domain_scores_gemma":[0.99942136,0.00018266143,0.00010096023,0.00010892108,0.00014964791,0.000036449645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032408387,0.0001505342,0.00034370294,0.0003236787,0.00017273636,0.0000563772,0.00036104038,0.000048306094,4.177172e-7],"category_scores_gemma":[0.00010277404,0.00010798136,0.000042406245,0.00095639087,0.000089490866,0.0000870599,0.00017898338,0.00012455382,5.725575e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036991105,0.0003382785,0.03544706,0.0010769876,0.00065428304,0.0000018545603,0.00084887026,0.02675812,0.17846382,0.041388184,0.0012372868,0.7134153],"study_design_scores_gemma":[0.0006610762,0.00024557696,0.007370465,0.00182636,0.00009755206,0.00001616891,0.00002321758,0.80239683,0.18554866,0.000040390336,0.0014709237,0.00030275795],"about_ca_topic_score_codex":0.000072267576,"about_ca_topic_score_gemma":0.0000015721384,"teacher_disagreement_score":0.77563876,"about_ca_system_score_codex":0.000029048819,"about_ca_system_score_gemma":0.000024659947,"threshold_uncertainty_score":0.4403352},"labels":[],"label_agreement":null},{"id":"W4414081119","doi":"10.1097/cm9.0000000000003682","title":"Efficacy and safety of secukinumab in Chinese patients with psoriasis: Update of six-year real-world data and a meta-analysis","year":2025,"lang":"en","type":"article","venue":"Chinese Medical Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Secukinumab; Tolerability; Clinical trial; Adverse effect; Disease; Discontinuation; Systematic review; Psoriasis; Population","score_opus":0.01659620635519069,"score_gpt":0.2897583277501739,"score_spread":0.2731621213949832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414081119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99511683,0.0035046877,0.00007116784,0.00051925133,0.00012392472,0.00016525603,0.0002520807,0.000007535141,0.00023928306],"genre_scores_gemma":[0.99828845,0.0010371922,0.00020389668,0.00006319843,0.000021071968,0.0000041403155,0.00025435054,0.000008864251,0.000118820615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818707,0.00038761538,0.000709492,0.00033108346,0.0001669553,0.00021781216],"domain_scores_gemma":[0.99860036,0.00043157753,0.00033812033,0.00045225254,0.000099972414,0.000077710676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008929705,0.00024561264,0.0014006307,0.0005733417,0.00008691211,0.000011464657,0.0003979202,0.00013417481,0.00047451942],"category_scores_gemma":[0.0004067805,0.00012961702,0.0001757778,0.0011054314,0.00034076624,0.00011117396,0.00026697386,0.00033360385,0.000001979085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028667108,0.000578351,0.92605793,0.00004177268,0.059065208,0.000023127575,0.00028044774,0.0000047813037,0.000058299083,0.00009111482,0.00013196257,0.010800306],"study_design_scores_gemma":[0.009033677,0.0001281043,0.9541169,0.000027074284,0.036086686,0.000015477472,0.0000353028,0.00001673582,0.000036728066,0.0001627453,0.00022253391,0.00011804077],"about_ca_topic_score_codex":0.0001483739,"about_ca_topic_score_gemma":0.0014778693,"teacher_disagreement_score":0.028058978,"about_ca_system_score_codex":0.000017047078,"about_ca_system_score_gemma":0.00011889662,"threshold_uncertainty_score":0.5285629},"labels":[],"label_agreement":null},{"id":"W4414165728","doi":"10.1109/access.2025.3607989","title":"Classification of Psoriasis Using Vision Transformer: A Deep Learning-Based Approach","year":2025,"lang":"en","type":"article","venue":"IEEE Access","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of the Fraser Valley","funders":"","keywords":"Psoriasis; Convolutional neural network; Pattern recognition (psychology); Deep learning; Skin lesion; Feature extraction; Dermatological diseases; Reliability (semiconductor)","score_opus":0.03645217943522331,"score_gpt":0.31348575514450006,"score_spread":0.2770335757092767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414165728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91738904,0.0014391067,0.076918855,0.00005828781,0.0007872382,0.0002928406,0.000012592468,0.00006913776,0.0030328857],"genre_scores_gemma":[0.99913096,0.00005794427,0.0002608019,0.000033397464,0.000019027351,0.000034714136,0.000106858046,0.000011022914,0.0003452973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99902374,0.0001912743,0.00027831976,0.00026976247,0.000037021822,0.00019986364],"domain_scores_gemma":[0.99945587,0.00010832248,0.00012932507,0.00021637724,0.000078317855,0.000011804315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001763015,0.0001494852,0.00026097172,0.0002353762,0.00017740279,0.000020782605,0.0002664394,0.00024072966,0.00007650712],"category_scores_gemma":[0.000021452384,0.00013067843,0.00012785368,0.00040154543,0.00009180122,0.00015202361,0.000011320583,0.00012486862,0.000017379578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000820968,0.00074336026,0.034287214,0.00019655465,0.00049272325,0.0000013092697,0.0003308425,0.003731862,0.733588,0.00037923534,0.00024506528,0.2251829],"study_design_scores_gemma":[0.005118924,0.00021229417,0.08595261,0.00013151312,0.0007528343,0.0000055318474,0.0002585088,0.0061728507,0.8956255,0.00018118671,0.005233663,0.0003546235],"about_ca_topic_score_codex":0.00009466557,"about_ca_topic_score_gemma":0.000017663657,"teacher_disagreement_score":0.22482829,"about_ca_system_score_codex":0.000045049903,"about_ca_system_score_gemma":0.000072670584,"threshold_uncertainty_score":0.53289115},"labels":[],"label_agreement":null},{"id":"W4414179164","doi":"10.3899/jrheum.2025-0811","title":"How to Manage Cardiovascular Disease in Psoriatic Disease: Evidence and Time Management in Clinic","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Disease; Arthritis; Risk assessment; Risk factor; Comorbidity; Disease management","score_opus":0.015085694292015062,"score_gpt":0.24936695786317264,"score_spread":0.23428126357115758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414179164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066179,0.08876042,0.00013703202,0.0036281955,0.00046325344,0.00031032652,0.0000034970356,0.00000671891,0.00007267258],"genre_scores_gemma":[0.98352414,0.014770478,0.000055008364,0.000097809134,0.0000031659258,0.000017376655,0.0000019469276,0.0000067396113,0.0015233544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983505,0.00079221145,0.00039241198,0.00016977754,0.00005059064,0.0002444889],"domain_scores_gemma":[0.9989592,0.0004924196,0.000121714234,0.00035269064,0.000028169787,0.000045798617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010757151,0.00014337379,0.0004874643,0.00038309256,0.0000577559,0.000013142859,0.00031120976,0.00006950208,0.00003721199],"category_scores_gemma":[0.0002403662,0.00009934899,0.00014527662,0.0002773493,0.00009045052,0.00009235085,0.00013776652,0.00016049844,0.00007171614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00904728,0.0006618004,0.8040411,0.0006412837,0.0082383845,0.00089131464,0.0015802342,0.0006331455,0.00033979808,0.0022537678,0.0041566784,0.1675152],"study_design_scores_gemma":[0.0058865864,0.00020184825,0.9691823,0.0018717553,0.0030351034,0.00024287791,0.00048053623,0.00004289953,0.00007602183,0.004147367,0.014520785,0.00031191556],"about_ca_topic_score_codex":0.000054691474,"about_ca_topic_score_gemma":0.00002573808,"teacher_disagreement_score":0.16720329,"about_ca_system_score_codex":0.000046990346,"about_ca_system_score_gemma":0.000042897216,"threshold_uncertainty_score":0.40513343},"labels":[],"label_agreement":null},{"id":"W4414305229","doi":"10.1111/apt.70377","title":"<scp>IL23</scp> Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease","year":2025,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; Academic Medical Organization of Southwestern Ontario","keywords":"Inflammatory bowel disease; Psoriasis; Ulcerative colitis; Crohn's disease; Necrosis; Disease; Inflammatory Bowel Diseases; Risk stratification; Receptor","score_opus":0.022700917845449923,"score_gpt":0.28127084809036224,"score_spread":0.2585699302449123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414305229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98311925,0.009454581,0.0000069939138,0.0016413266,0.003961252,0.00082246755,0.000751288,0.000109879715,0.00013297211],"genre_scores_gemma":[0.9897004,0.0023092614,0.00004732736,0.006050215,0.00011263705,0.0001838163,0.0002734046,0.000046760204,0.0012761749],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99685603,0.0007059335,0.0008328778,0.000691456,0.00011150099,0.00080220844],"domain_scores_gemma":[0.99848163,0.0006116289,0.00029382991,0.00042544096,0.00007551869,0.00011197293],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022387672,0.0005528943,0.000686133,0.00046445307,0.00021057557,0.000016505985,0.00056293583,0.00051729666,0.0009282488],"category_scores_gemma":[0.000003042929,0.0005314988,0.0003291056,0.0003957732,0.0003665293,0.00016915858,0.00019047513,0.00045328232,0.00017748552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065800693,0.0011898632,0.2087427,0.00005087137,0.0088391295,0.000029028095,0.0011667563,0.0000039139136,0.77377224,0.00006184947,0.0039260066,0.0015596221],"study_design_scores_gemma":[0.007098765,0.00026743163,0.24217013,0.000061028684,0.005199704,0.0000050495005,0.0002652002,0.000019502499,0.7330478,0.00015350436,0.011500072,0.00021183332],"about_ca_topic_score_codex":0.000099943376,"about_ca_topic_score_gemma":0.000009127821,"teacher_disagreement_score":0.04072447,"about_ca_system_score_codex":0.00018530358,"about_ca_system_score_gemma":0.00031327602,"threshold_uncertainty_score":0.99998504},"labels":[],"label_agreement":null},{"id":"W4414335360","doi":"10.1016/s0140-6736(25)01576-4","title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 &amp; 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; Probity Medical Research; Dermatrials Research; Innovaderm (Canada)","funders":"Johnson and Johnson","keywords":"Plaque psoriasis; Placebo; Clinical trial; Psoriasis; Oral cavity; Oral administration","score_opus":0.06560107486122974,"score_gpt":0.34489048298240754,"score_spread":0.2792894081211778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414335360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862863,0.0045937165,0.0003245744,0.0012597694,0.00082290836,0.004984213,0.00033886672,0.0001204326,0.0012692455],"genre_scores_gemma":[0.9942221,0.00071087555,0.00044637235,0.00049790804,0.0001881176,0.0021229563,0.0000977503,0.000040952655,0.0016729713],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99334,0.0033695211,0.0011502793,0.00086531456,0.00012942903,0.0011454554],"domain_scores_gemma":[0.99420065,0.004314002,0.00052994105,0.0007210814,0.00011128651,0.00012301344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030141163,0.000747387,0.004812234,0.00026622627,0.00047158817,0.00014858085,0.00044957135,0.00030623397,0.00017034683],"category_scores_gemma":[0.0012400635,0.00046254916,0.0002712601,0.00036565762,0.000336099,0.00025825412,0.00012311983,0.00049701106,0.000081478334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9683786,0.00038795406,0.0018130991,0.000027055483,0.0025985616,0.000025625008,0.0012567703,0.00053021987,0.0106187025,0.00051120546,0.0018146228,0.012037597],"study_design_scores_gemma":[0.9817966,0.0007873278,0.0011868894,0.00019351435,0.0020679056,0.000028276761,0.0005113258,0.0003302888,0.008419399,0.00035449714,0.0037169282,0.0006070446],"about_ca_topic_score_codex":0.00021823459,"about_ca_topic_score_gemma":0.0025522746,"teacher_disagreement_score":0.013418015,"about_ca_system_score_codex":0.0001345757,"about_ca_system_score_gemma":0.00029581002,"threshold_uncertainty_score":0.9997826},"labels":[],"label_agreement":null},{"id":"W4414371190","doi":"10.1007/s13555-025-01533-9","title":"Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Narrative review; Psoriasis; Biologic Agents; Mechanism (biology); Observational study; Action (physics)","score_opus":0.015095661325495979,"score_gpt":0.25821738763741076,"score_spread":0.24312172631191478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414371190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96478724,0.03301349,0.000038062633,0.001329278,0.00030507735,0.00035149846,0.000025658586,0.000040570638,0.00010909458],"genre_scores_gemma":[0.9821238,0.016433528,0.000052631993,0.0007982469,0.000007835723,0.00013526365,0.000032936292,0.000009694348,0.00040607445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981493,0.00095054245,0.00030381302,0.00033423898,0.000016383903,0.00024575187],"domain_scores_gemma":[0.9992978,0.0003307594,0.00010161041,0.00021516328,0.000037927715,0.000016738952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028185316,0.00023045254,0.0004561065,0.0003278581,0.000100016354,0.000007334003,0.00009606962,0.0005921605,0.00035794594],"category_scores_gemma":[0.000023537947,0.00018016092,0.00006622735,0.00018478472,0.00022014257,0.000073633455,0.00003159599,0.00018657149,0.000012414612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042232037,0.0005354051,0.02976144,0.000057407375,0.0012029704,0.0001012732,0.0020994006,2.2380533e-7,0.72000235,0.011111694,0.00026931395,0.19262646],"study_design_scores_gemma":[0.013673879,0.001170096,0.10291422,0.00006798573,0.000053847943,0.00065535796,0.00067500665,0.0000033325057,0.83530605,0.016928473,0.028211571,0.00034017692],"about_ca_topic_score_codex":0.000031212614,"about_ca_topic_score_gemma":0.0000814205,"teacher_disagreement_score":0.19228628,"about_ca_system_score_codex":0.000012240663,"about_ca_system_score_gemma":0.00006704857,"threshold_uncertainty_score":0.73467493},"labels":[],"label_agreement":null},{"id":"W4414394245","doi":"10.3390/ph18091422","title":"Tracing Five Decades of Psoriasis Pharmacotherapy: A Large-Scale Bibliometric Investigation with AI-Guided Terminology Normalization","year":2025,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Terminology; Citation; Normalization (sociology); Citation impact; Bibliometrics; Citation analysis; Scopus; Alliance; Psoriasis","score_opus":0.040435010012030065,"score_gpt":0.3493872740884505,"score_spread":0.3089522640764204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414394245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869169,0.006016493,0.0039449707,0.0008161453,0.00055668363,0.0005273625,0.00009177522,0.00012400927,0.0010056491],"genre_scores_gemma":[0.99584913,0.0009333629,0.00050114613,0.0011648464,0.000036775593,0.00010033145,0.00013300397,0.000020660062,0.0012607368],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982434,0.00037873082,0.00048547256,0.00037739566,0.00007368464,0.00044131585],"domain_scores_gemma":[0.9990114,0.0003335543,0.00018702121,0.00021784929,0.00020271115,0.000047470578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040778457,0.00025165046,0.00043405744,0.006081792,0.00017885632,0.00001915539,0.00021198603,0.0002404482,0.0005118175],"category_scores_gemma":[0.00007109551,0.00020741332,0.00010261677,0.010455007,0.0002157847,0.00021379186,0.00004775575,0.00019092682,0.00006186198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011208678,0.00065454864,0.21592893,0.00024404319,0.001713398,0.0000110393885,0.0017809797,0.000105457555,0.6580085,0.0009836347,0.0050302767,0.114418305],"study_design_scores_gemma":[0.00633603,0.0001266351,0.021627046,0.000084050225,0.0007226526,0.00002790446,0.00015169095,0.0002523944,0.95770687,0.00025760697,0.012488334,0.00021879267],"about_ca_topic_score_codex":0.000029793015,"about_ca_topic_score_gemma":0.000011974172,"teacher_disagreement_score":0.29969832,"about_ca_system_score_codex":0.000049434315,"about_ca_system_score_gemma":0.000114017595,"threshold_uncertainty_score":0.845807},"labels":[{"model":"gemma","categories":["bibliometrics"],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["bibliometrics"],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W4414418254","doi":"10.1007/s12325-025-03363-9","title":"IL-17C as a Driver of Inflammation in Psoriasis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Psoriasis; Autocrine signalling; Inflammation; Rheumatology; Psoriatic arthritis; Mechanism of action; Ustekinumab; Cytokine","score_opus":0.019473864995041102,"score_gpt":0.3204962230484371,"score_spread":0.301022358053396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414418254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011111641,0.99520296,0.000004592462,0.000008696896,0.00093381177,0.00067706575,0.00006177553,0.000020617676,0.0019793033],"genre_scores_gemma":[0.00018719798,0.9980718,0.000059213653,0.000011956506,0.000036783058,0.00028379058,0.00026242682,0.000016942753,0.0010698985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983345,0.00042335212,0.0006410459,0.00033471143,0.000033599747,0.0002327874],"domain_scores_gemma":[0.9988222,0.0004860404,0.00033551207,0.00032112823,0.000027838623,0.0000072904495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020095201,0.00032171552,0.001284963,0.00050241046,0.000028124437,0.000003833082,0.00028749648,0.00047356618,0.00020431685],"category_scores_gemma":[0.000052098112,0.00025450863,0.00026025926,0.0005383715,0.00008130538,0.00014410744,0.00003382934,0.00021125226,0.00010550092],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009459895,0.000085806314,0.00014901745,0.0012327833,0.00017418728,0.000005960707,0.00018811866,0.0000023481102,0.00005825012,0.0005812001,0.000016812943,0.9974109],"study_design_scores_gemma":[0.0014421409,0.0001007812,0.00006135047,0.004728458,0.00010651919,0.0000056341705,0.000024747033,5.148998e-8,0.00085231144,0.00084702356,0.99162334,0.0002076512],"about_ca_topic_score_codex":0.000042729513,"about_ca_topic_score_gemma":0.00011810727,"teacher_disagreement_score":0.9972033,"about_ca_system_score_codex":0.000086172986,"about_ca_system_score_gemma":0.00016518423,"threshold_uncertainty_score":0.9999907},"labels":[],"label_agreement":null},{"id":"W4414737278","doi":"10.3899/jrheum.2025-0446","title":"Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriatic arthritis; Psoriasis; Mace; Adverse effect; Inflammatory arthritis; Immunotherapy; Secukinumab; Risk factor","score_opus":0.010148287452128996,"score_gpt":0.24594920822091254,"score_spread":0.23580092076878353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414737278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772912,0.020920288,0.0001683238,0.000195177,0.00096299394,0.00031881095,0.000119419376,0.0000061924034,0.000017559005],"genre_scores_gemma":[0.96747905,0.031953357,0.00018434279,0.00001680585,0.000006778822,0.00001439394,0.000008222242,0.00000876057,0.00032828044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827224,0.000748993,0.00062515633,0.00010451044,0.000044838747,0.00020423954],"domain_scores_gemma":[0.9958172,0.0023008287,0.0014367728,0.00015278258,0.00028033296,0.000012122214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004645,0.00015385712,0.0007943847,0.00016437758,0.000121333316,0.000001659314,0.00019567659,0.00024276577,0.00004357561],"category_scores_gemma":[0.00057166425,0.00008543563,0.0001674804,0.00017130966,0.00008573255,0.0000615964,0.000025936364,0.00014663761,0.0000030029546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007862529,0.00023697143,0.91934526,0.00011627436,0.0088900495,7.439638e-7,0.00087731105,0.00001386291,0.017330827,0.0005180367,0.0005975768,0.04421056],"study_design_scores_gemma":[0.039433487,0.0060736174,0.819954,0.0012620327,0.005159769,0.0005161089,0.0016675513,0.0000081716635,0.11808918,0.002324631,0.0050495686,0.0004619005],"about_ca_topic_score_codex":0.0001747316,"about_ca_topic_score_gemma":0.0001386769,"teacher_disagreement_score":0.10075835,"about_ca_system_score_codex":0.00004193322,"about_ca_system_score_gemma":0.00012528275,"threshold_uncertainty_score":0.3483964},"labels":[],"label_agreement":null},{"id":"W4414849140","doi":"10.1038/s41591-025-03971-6","title":"Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"Cilag; Regeneron Pharmaceuticals; National Institutes of Health; Gilead Sciences; LEO Pharma; University of Pennsylvania; Swedish Orphan Biovitrum; Medac; Galderma; XBiotech; Sun Pharma; Amgen; Rheumatology Research Foundation; Sanofi; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Versus Arthritis; Celgene; National Psoriasis Foundation; Pfizer; Biogen; Pacira BioSciences; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Psoriatic arthritis; Clinical endpoint; Confidence interval; Odds ratio; Randomized controlled trial; Placebo; Adalimumab","score_opus":0.009939838097560674,"score_gpt":0.3030443671438675,"score_spread":0.29310452904630685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414849140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89648074,0.06067132,0.0023469627,0.00465517,0.01628874,0.01416225,0.00054801494,0.00041455255,0.0044322237],"genre_scores_gemma":[0.98858994,0.00068856124,0.00031845638,0.0010195139,0.0014577449,0.0023686457,0.0012696796,0.000043369837,0.004244075],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99656904,0.0009974979,0.0009522955,0.000710903,0.00012222776,0.00064806745],"domain_scores_gemma":[0.9954445,0.0033773608,0.00044254618,0.00041087242,0.00025531827,0.0000694451],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002062511,0.0005317778,0.0024252704,0.00043891967,0.00045020453,0.000020745445,0.00028039629,0.0010921779,0.00034852145],"category_scores_gemma":[0.0040438273,0.0003675101,0.000524997,0.000352222,0.00034294464,0.000148751,0.000042877888,0.000746493,0.0000334281],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78673196,0.0005958531,0.0000011911751,0.000038656177,0.0019960117,0.000019042307,0.00066677626,6.633218e-7,0.027844472,0.002268832,0.0040674843,0.17576909],"study_design_scores_gemma":[0.9406463,0.0017206568,0.000005073681,0.00042438734,0.0022816309,0.000024122177,0.00067958067,0.000058692876,0.041373577,0.0017115955,0.010774265,0.00030013383],"about_ca_topic_score_codex":0.00004145908,"about_ca_topic_score_gemma":0.000062277606,"teacher_disagreement_score":0.17546895,"about_ca_system_score_codex":0.000103404214,"about_ca_system_score_gemma":0.0002418584,"threshold_uncertainty_score":0.9998777},"labels":[],"label_agreement":null},{"id":"W4414866676","doi":"10.1016/j.jaad.2025.10.005","title":"Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Plaque psoriasis; STRIDE; Allosteric regulation; Adverse effect; Psoriasis; Phases of clinical research","score_opus":0.01926189088015886,"score_gpt":0.2876578508778589,"score_spread":0.26839595999770005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414866676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940925,0.0005463861,0.000009415517,0.0039893626,0.00020426014,0.00087575894,0.00025017338,0.0000036807203,0.000028440152],"genre_scores_gemma":[0.99926305,0.00009729851,0.00014944021,0.00041693062,0.000011735485,0.000008281322,0.0000075851412,0.00001326971,0.000032381395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99658644,0.0015874569,0.0011532829,0.000288281,0.00012871085,0.00025580084],"domain_scores_gemma":[0.9968037,0.000856733,0.0018465499,0.0003051557,0.00015816405,0.000029675472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003457651,0.0002520111,0.0011306519,0.00017219852,0.00016774345,0.000010069513,0.0009113574,0.0001464982,0.0000035055427],"category_scores_gemma":[0.00030709946,0.00012610237,0.00010013799,0.0006837739,0.00058751076,0.000112468486,0.00043303065,0.00052374613,8.268692e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31466833,0.015323318,0.5326683,0.00004838837,0.0060925605,0.0000316161,0.01133825,0.0003601965,0.075089484,0.00012907552,0.004328716,0.039921794],"study_design_scores_gemma":[0.060839087,0.0025928577,0.8976072,0.00036583346,0.0007267262,0.0001414322,0.0017838704,0.000008476681,0.03519621,0.00007828465,0.00048287518,0.00017716491],"about_ca_topic_score_codex":0.00027969858,"about_ca_topic_score_gemma":0.000057712772,"teacher_disagreement_score":0.3649389,"about_ca_system_score_codex":0.000052889685,"about_ca_system_score_gemma":0.00024343496,"threshold_uncertainty_score":0.51423055},"labels":[],"label_agreement":null},{"id":"W4414927188","doi":"10.1007/s13555-025-01557-1","title":"Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dermatrials Research","funders":"Manchester Biomedical Research Centre; Allergan; LEO Pharma; National Institute for Health and Care Research; Incyte; Sun Pharma; Regeneron Pharmaceuticals; UCB; Celgene; Biogen; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Clinical trial; Post-hoc analysis; Psoriasis; Post hoc; Phases of clinical research","score_opus":0.04833259873561692,"score_gpt":0.38336368143340194,"score_spread":0.33503108269778503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414927188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496874,0.04809548,0.000064683285,0.0007051978,0.0006870462,0.00032219916,0.00018925114,0.000033633376,0.00021509042],"genre_scores_gemma":[0.98635024,0.0123346,0.000025904124,0.0004830742,0.000011686136,0.000037489423,0.00053468347,0.000008600781,0.00021370867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957644,0.002339615,0.001158721,0.00041421666,0.000026529731,0.00029652924],"domain_scores_gemma":[0.99666834,0.0026003793,0.00031171448,0.0003349718,0.000057420046,0.000027156304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011856436,0.00023899476,0.0016532083,0.00066797744,0.00010578904,0.000008537461,0.00019269869,0.00062221504,0.00030977276],"category_scores_gemma":[0.00024111016,0.00018859498,0.00044332058,0.0007846897,0.00032701954,0.00005450143,0.000033639815,0.00019966741,0.000022434237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014392286,0.0048493203,0.13355222,0.000022250988,0.020889994,0.00004629478,0.00071759813,0.0000011633686,0.046173926,0.0026275753,0.004314039,0.7724133],"study_design_scores_gemma":[0.20222284,0.0029291739,0.39091635,0.00012349257,0.012189018,0.00013213599,0.0009982203,0.00009582216,0.24201187,0.0011899613,0.14583279,0.0013583265],"about_ca_topic_score_codex":0.00008156445,"about_ca_topic_score_gemma":0.000057666817,"teacher_disagreement_score":0.771055,"about_ca_system_score_codex":0.0000111767085,"about_ca_system_score_gemma":0.00006622292,"threshold_uncertainty_score":0.769068},"labels":[],"label_agreement":null},{"id":"W4414973762","doi":"10.1007/s13555-025-01535-7","title":"Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Centre de Recherche Dermatologique du Québec Métropolitain; Centre de Recherche Industrielle du Québec; Women's College Hospital; Hospital for Sick Children; Dermatrials Research; Health Sciences Centre; Ottawa Hospital; McGill University; University of Ottawa; Sunnybrook Health Science Centre; Quest University Canada; Queen's University; Probity Medical Research; University of British Columbia; McMaster University; SKiN Health; University of Calgary; Lynde Centre for Dermatology; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Generalized pustular psoriasis; Psoriasis; Narrative review; Biologic Agents; Plaque psoriasis; Pathogenesis","score_opus":0.04927849051615285,"score_gpt":0.3358533445554728,"score_spread":0.2865748540393199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414973762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042580326,0.9950783,0.00003897334,0.0005248407,0.00081714924,0.0026567958,0.0003385575,0.00009277422,0.00041000717],"genre_scores_gemma":[0.00001682423,0.9928637,0.0003738465,0.0009421027,0.000052976717,0.0026749992,0.0013704917,0.000034510875,0.0016705131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697083,0.0011667168,0.0007969996,0.0006261326,0.000025061425,0.00041423764],"domain_scores_gemma":[0.9970163,0.0020264261,0.0004164662,0.00040235044,0.000106925065,0.000031521606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021370806,0.0006375432,0.002888358,0.00022874528,0.0007162974,0.000023023684,0.00016069716,0.0009018076,0.00033967625],"category_scores_gemma":[0.00020702867,0.00047522606,0.0006759812,0.00020458452,0.00019311898,0.00005930991,0.00004150954,0.00025273085,0.000044100176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055900888,0.00010822653,0.0000081773915,0.012302419,0.0035437217,0.000026296717,0.00038295446,2.2856003e-8,0.000010434947,0.0039014812,0.020830281,0.95883006],"study_design_scores_gemma":[0.002378743,0.000070109294,0.0000011031709,0.0089500835,0.0025257186,0.0009520085,0.000040229334,2.0072173e-7,0.00012415752,0.0009422409,0.98360646,0.00040892742],"about_ca_topic_score_codex":0.000010619243,"about_ca_topic_score_gemma":0.000010912728,"teacher_disagreement_score":0.9627762,"about_ca_system_score_codex":0.000027306547,"about_ca_system_score_gemma":0.00034176503,"threshold_uncertainty_score":0.9997699},"labels":[],"label_agreement":null},{"id":"W4414986289","doi":"10.1093/qjmed/hcaf233","title":"Deconstruction of immune-mediated skin diseases defines six inflammatory subtypes","year":2025,"lang":"en","type":"article","venue":"QJM","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Natural Science Foundation of Hubei Province; National Natural Science Foundation of China","keywords":"Disease; Deconstruction (building); Inflammatory response; Skin lesion; Psoriasis","score_opus":0.005202532675526823,"score_gpt":0.21224635740814887,"score_spread":0.20704382473262206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414986289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98086333,0.01649899,0.000011482594,0.00005081605,0.00097173965,0.000105893494,0.00007379711,0.000060622337,0.0013633011],"genre_scores_gemma":[0.99732876,0.00018954926,0.000032046024,0.000018623641,0.00001772149,0.000021434409,0.0002106217,0.000005886114,0.0021753442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993832,0.000080595,0.0002362981,0.00014302027,0.000015637599,0.0001412429],"domain_scores_gemma":[0.9995196,0.00015261493,0.00009012367,0.00018224331,0.000045944063,0.000009511538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050966977,0.00010990655,0.00020244515,0.00013060382,0.000078045574,0.0000040266655,0.00009413833,0.00013809469,0.00027043725],"category_scores_gemma":[0.00007321952,0.000095102245,0.00010468557,0.00014057943,0.0001280542,0.00004783234,0.000031371117,0.0000478332,0.00019414634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004620037,0.00021359012,0.65894425,0.00009445681,0.00083781563,0.000005603273,0.0001458378,0.0000041512026,0.24997368,0.005540899,0.0024598264,0.08131788],"study_design_scores_gemma":[0.0015975882,0.00005162371,0.77678424,0.000055271314,0.00025040857,0.000008383511,0.00013214216,0.0000011754597,0.20756213,0.0004669768,0.012957697,0.000132388],"about_ca_topic_score_codex":0.00005746502,"about_ca_topic_score_gemma":0.000036523776,"teacher_disagreement_score":0.11783996,"about_ca_system_score_codex":0.000017086006,"about_ca_system_score_gemma":0.00007096108,"threshold_uncertainty_score":0.3878157},"labels":[],"label_agreement":null},{"id":"W4415095336","doi":"10.1093/bjd/ljaf394","title":"Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival – a retrospective registry study","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; UCB Pharma; Merck Sharp and Dohme; Sandoz Canada; UCB Pharma France; LEO Pharma; Boehringer Ingelheim España; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Concomitant; Ustekinumab; Comorbidity; Psoriatic arthritis; Psoriasis; Retrospective cohort study; Risk factor; Disease","score_opus":0.027414595998122626,"score_gpt":0.2692421529409907,"score_spread":0.24182755694286806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415095336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735015,0.023233028,0.000019205538,0.0003698053,0.0015821819,0.000733704,0.00035770625,0.000020639785,0.00018220747],"genre_scores_gemma":[0.96627766,0.033322908,0.00001437208,0.000022049546,0.000048575042,0.00010054572,0.000045911052,0.000014651411,0.00015330916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981487,0.0005181673,0.0006004553,0.00035664265,0.00006148977,0.00031459183],"domain_scores_gemma":[0.9965353,0.0025289648,0.00048702743,0.00018676609,0.000214274,0.000047673428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014089646,0.00026223864,0.00089638325,0.00022653583,0.00023359864,0.000026388805,0.00015935538,0.00018435408,0.000013540753],"category_scores_gemma":[0.0009039033,0.00023849784,0.00015623568,0.00008351834,0.00014668083,0.00009931866,0.000045335943,0.00017123054,0.0000032389862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003410607,0.0028134924,0.9074303,0.000097117896,0.004027122,0.0024712891,0.0043788524,5.950938e-7,0.00035663237,0.00026895685,0.001242421,0.07350264],"study_design_scores_gemma":[0.0036866094,0.0034577579,0.9812649,0.00078082544,0.0008012797,0.0020239083,0.004010206,4.515563e-7,0.0030730302,0.0001404723,0.00057992904,0.00018066427],"about_ca_topic_score_codex":0.00014602674,"about_ca_topic_score_gemma":0.0005922568,"teacher_disagreement_score":0.07383459,"about_ca_system_score_codex":0.00020530098,"about_ca_system_score_gemma":0.00013458388,"threshold_uncertainty_score":0.972566},"labels":[],"label_agreement":null},{"id":"W4415280763","doi":"10.1111/jdv.70108","title":"Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Retrospective cohort study; Methotrexate; Drug; Acitretin; Survival analysis; Cohort; Cohort study","score_opus":0.016116479903800333,"score_gpt":0.2724736230258559,"score_spread":0.2563571431220556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415280763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920233,0.0040557617,0.000033860855,0.00073830935,0.0020861593,0.000298977,0.000050295832,0.000007827533,0.0007055301],"genre_scores_gemma":[0.9986361,0.00058490963,0.000056214005,0.00005416035,0.00008964631,0.000005631539,0.0000056586846,0.000011656183,0.00055600394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969306,0.001869436,0.0007630271,0.0002008843,0.000050869516,0.0001851849],"domain_scores_gemma":[0.9985114,0.00026595363,0.00092736917,0.00014624414,0.00012760457,0.000021463477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006335741,0.00017820505,0.0006625821,0.00028263932,0.00012253219,0.0000033861415,0.0005680328,0.00018082763,0.000012365382],"category_scores_gemma":[0.00013077185,0.000120546014,0.00020625281,0.00014689018,0.00023952802,0.00010054261,0.00014431747,0.00026258855,0.0000027639571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011143363,0.0005863475,0.982535,0.00003945617,0.003219496,0.000015592927,0.00092194957,0.000011070522,0.0044049495,0.0020722873,0.0006284844,0.004451055],"study_design_scores_gemma":[0.010300264,0.00023912518,0.9740377,0.000107401334,0.0020645868,0.0021980691,0.0014078862,0.0000032128528,0.007342952,0.0012699723,0.0008817211,0.0001471259],"about_ca_topic_score_codex":0.0000046277246,"about_ca_topic_score_gemma":0.000003674814,"teacher_disagreement_score":0.009185927,"about_ca_system_score_codex":0.000036981393,"about_ca_system_score_gemma":0.00005883079,"threshold_uncertainty_score":0.49157238},"labels":[],"label_agreement":null},{"id":"W4415478490","doi":"10.2196/75727","title":"Evaluating the Body Roundness Index as a Novel Digital Biomarker for Psoriasis Risk Prediction: Cross-Sectional Study","year":2025,"lang":"en","type":"article","venue":"JMIR Medical Informatics","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Psoriasis; Biomarker; Roundness (object); Body mass index; Risk assessment; Precision medicine; Personalized medicine","score_opus":0.04361475041346888,"score_gpt":0.36955690019686027,"score_spread":0.3259421497833914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415478490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879128,0.00013487761,0.0048836973,0.000093205614,0.0027251844,0.0015442694,0.00041212767,0.00012284568,0.0021710028],"genre_scores_gemma":[0.9956371,0.000012915621,0.00007975003,0.00022487972,0.0001428519,0.00096837204,0.000365564,0.000012035532,0.0025564935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981157,0.000102087455,0.00094308826,0.00019868274,0.00027849717,0.00036191507],"domain_scores_gemma":[0.99810714,0.0009761814,0.00028298632,0.0003666708,0.00021560493,0.000051437437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013742828,0.00023924303,0.0002825472,0.00014038033,0.0008016239,0.00018823665,0.0004159798,0.00044746388,0.00031699732],"category_scores_gemma":[0.0010084166,0.0001553213,0.00019304923,0.0003392886,0.00027519802,0.0003550146,0.00018138079,0.00034908822,0.00015539769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016595557,0.0018812829,0.8480843,0.00010390134,0.0028835041,0.0000018754223,0.0046611573,0.00002910867,0.00011659188,0.0005906406,0.0029670538,0.13702108],"study_design_scores_gemma":[0.015327606,0.0013273855,0.9531861,0.00007748311,0.00040225222,0.000091151465,0.005751077,0.0062890006,0.00014828947,0.00060609035,0.016486676,0.0003068723],"about_ca_topic_score_codex":0.00003539496,"about_ca_topic_score_gemma":0.000010161129,"teacher_disagreement_score":0.13671422,"about_ca_system_score_codex":0.000094384406,"about_ca_system_score_gemma":0.00038729326,"threshold_uncertainty_score":0.63338184},"labels":[],"label_agreement":null},{"id":"W4415481589","doi":"10.1021/acsomega.5c03831","title":"Vine Tea Combined with a Lidocaine Microneedle Patch for Enhanced Treatment of Psoriasis","year":2025,"lang":"en","type":"article","venue":"ACS Omega","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Innovation-Driven Project of Central South University; Hunan Provincial Science and Technology Department; Ministry of Education of the People's Republic of China","keywords":"Lidocaine; Psoriasis; Vine; Therapeutic effect; Medicinal herbs; Phytotherapy","score_opus":0.011417470334032218,"score_gpt":0.2440993490827565,"score_spread":0.23268187874872426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415481589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927305,0.0035748144,0.000463757,0.00035423186,0.00048842985,0.0008057926,0.00017350708,0.00006375431,0.001345212],"genre_scores_gemma":[0.97889775,0.0003829075,0.00054662226,0.000061243445,0.000028399741,0.00039671775,0.00035945224,0.000018524304,0.019308366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990101,0.00005896226,0.0002803272,0.00031158992,0.00002451765,0.00031450432],"domain_scores_gemma":[0.9991307,0.000256221,0.000119704084,0.0003655212,0.00010995727,0.000017892344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006942282,0.00025069396,0.0005136199,0.00015004147,0.0001272447,0.000005532187,0.00014032947,0.00017983794,0.000033754262],"category_scores_gemma":[0.00002508194,0.00017910931,0.00013302494,0.00025950585,0.00009722355,0.0000442354,0.000024492598,0.000038210812,0.00003626993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008296513,0.0023768686,0.005002802,0.00010060246,0.003375489,0.000007745063,0.0011821786,0.00000471448,0.85916024,0.0009719426,0.0044070752,0.11511381],"study_design_scores_gemma":[0.013604706,0.0036667804,0.0027649985,0.00005525755,0.0005682465,0.000005707522,0.00021919346,8.9987e-7,0.9445233,0.00017662838,0.034232736,0.00018159562],"about_ca_topic_score_codex":0.00016207236,"about_ca_topic_score_gemma":0.00015314638,"teacher_disagreement_score":0.11493222,"about_ca_system_score_codex":0.00007806335,"about_ca_system_score_gemma":0.0000976226,"threshold_uncertainty_score":0.7303866},"labels":[],"label_agreement":null},{"id":"W4415494179","doi":"10.1007/s13555-025-01562-4","title":"Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trent University; University of British Columbia; SKiN Health; Queen's University; Probity Medical Research; University of Toronto","funders":"LEO Pharma; Bausch Health; Sanofi Genzyme; Incyte; Castle Biosciences; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Helsinn; Celgene; Celltrion; Valeant Pharmaceuticals International; Sanofi; Amgen; Helsinn Therapeutics; Meiji Seika Pharma; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company","keywords":"Dermis; Clinical trial; Roflumilast; Plaque psoriasis; Phases of clinical research","score_opus":0.015043720830515493,"score_gpt":0.25846577537987603,"score_spread":0.24342205454936053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415494179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670809,0.029255401,0.000025827641,0.0018553848,0.00045656302,0.0007578988,0.00029154788,0.000046465557,0.00023000585],"genre_scores_gemma":[0.9927793,0.0054932465,0.000016505448,0.00077025074,0.00003852449,0.0001251272,0.0005947182,0.0000145933145,0.0001677228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99744356,0.001046831,0.00060785934,0.0004922235,0.00003645176,0.0003731068],"domain_scores_gemma":[0.9978405,0.001502749,0.00022596444,0.0003570008,0.000045257166,0.000028486005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036044422,0.00032558164,0.0008286387,0.00013078161,0.00033652145,0.000027321928,0.00018005758,0.00043591214,0.00006728068],"category_scores_gemma":[0.00008843766,0.00019663869,0.00007514082,0.00018328657,0.000323612,0.00009138967,0.000046884008,0.00024122033,0.00001557691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06714163,0.0034316075,0.41186342,0.000030811818,0.006404309,0.00010545986,0.0039775604,0.0000021642638,0.0049545784,0.0016599938,0.0074552526,0.4929732],"study_design_scores_gemma":[0.2794332,0.0015031273,0.60539985,0.00025028843,0.0008141322,0.00008378567,0.00058595266,0.000009221396,0.047592927,0.0018179932,0.06181068,0.0006988249],"about_ca_topic_score_codex":0.00034294615,"about_ca_topic_score_gemma":0.00048738494,"teacher_disagreement_score":0.4922744,"about_ca_system_score_codex":0.00002734293,"about_ca_system_score_gemma":0.0001160465,"threshold_uncertainty_score":0.80186933},"labels":[],"label_agreement":null},{"id":"W4415531191","doi":"10.1177/24755303251382878","title":"Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis","year":2025,"lang":"en","type":"review","venue":"Journal of Psoriasis and Psoriatic Arthritis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Pharmacovigilance; Psoriasis; Adverse effect; Safety profile; Incidence (geometry)","score_opus":0.04714031260971944,"score_gpt":0.32902946341031025,"score_spread":0.2818891508005908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415531191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002764951,0.99162704,0.00015309431,0.000108082044,0.005405091,0.0015251068,0.00069504505,0.000012021377,0.00019805339],"genre_scores_gemma":[0.0005890179,0.99577045,0.0007020054,0.000008664907,0.00081166043,0.00015556376,0.00005578025,0.000047881156,0.0018589454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949267,0.00081623264,0.0031275225,0.00046493128,0.00019508411,0.00046950867],"domain_scores_gemma":[0.986543,0.008558039,0.00358909,0.00072785554,0.00051006995,0.000071947354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012961398,0.000751668,0.0046312856,0.0006506419,0.0003111817,0.000030754156,0.00059170194,0.0005739557,0.00023342804],"category_scores_gemma":[0.0005292008,0.0004600077,0.0022940682,0.0006048826,0.00030178708,0.00015829534,0.000067958776,0.000257051,0.0000075307616],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078855536,0.00045494136,0.0000358858,0.0046511013,0.006009102,0.0000082309725,0.0005319363,0.0000016051083,0.0000122327365,0.0008395405,0.0015873159,0.9850795],"study_design_scores_gemma":[0.005961405,0.0033350869,0.00020070517,0.029508537,0.016203672,0.00012920315,0.00019993176,9.3914724e-7,0.00033606915,0.00030071585,0.94339937,0.00042438772],"about_ca_topic_score_codex":0.00025677317,"about_ca_topic_score_gemma":0.00025981886,"teacher_disagreement_score":0.98465514,"about_ca_system_score_codex":0.00022212719,"about_ca_system_score_gemma":0.0009508338,"threshold_uncertainty_score":0.9997852},"labels":[],"label_agreement":null},{"id":"W4415679158","doi":"10.1016/j.jaad.2025.10.112","title":"Response to Childs et al., “The four ‘D’s of psoriasis disparities in patients with skin of color: A Letter to the Editor”","year":2025,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University of Toronto","funders":"","keywords":"Psoriasis; MEDLINE; Severity of illness; Immunopathology","score_opus":0.008155249931565807,"score_gpt":0.2466855314604971,"score_spread":0.2385302815289313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415679158","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.422406,0.00026524428,0.000008094351,0.57558674,0.001194869,0.00034183156,0.00018022706,0.0000025460104,0.00001443723],"genre_scores_gemma":[0.4053111,0.00012645761,0.00015181166,0.593511,0.00049163844,0.00003801722,0.000011083914,0.000030726915,0.0003281617],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99487174,0.0030665086,0.0011531527,0.00024571942,0.00023851592,0.0004243688],"domain_scores_gemma":[0.9950416,0.0019820263,0.002374683,0.0004202543,0.00015678782,0.00002461358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065920467,0.00036224467,0.001513776,0.00056394737,0.00009144347,0.0000065418362,0.0015576226,0.00046729637,0.000016465274],"category_scores_gemma":[0.000355885,0.00017765586,0.0004036819,0.000618563,0.0008774853,0.000054049928,0.00030077228,0.0018148406,0.000006862641],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064206305,0.00012666042,0.024090094,0.00003403819,0.0011783447,0.000012282009,0.00053669384,0.00003120748,0.00059736316,0.000010075904,0.96618986,0.0007727452],"study_design_scores_gemma":[0.001757416,0.0006205262,0.18719098,0.00030625114,0.00043760682,0.00020635252,0.000089575355,1.4963686e-7,0.0040872362,0.000019044757,0.80511886,0.00016601016],"about_ca_topic_score_codex":0.00011533887,"about_ca_topic_score_gemma":0.000022563094,"teacher_disagreement_score":0.16310088,"about_ca_system_score_codex":0.00007046618,"about_ca_system_score_gemma":0.00023629186,"threshold_uncertainty_score":0.788468},"labels":[],"label_agreement":null},{"id":"W4415854073","doi":"10.1093/bjd/ljaf404","title":"Psoriasis at high-impact sites: shifting the paradigm","year":2025,"lang":"en","type":"letter","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada","keywords":"Psoriasis; MEDLINE; Immunopathology; Disease","score_opus":0.014956436982895206,"score_gpt":0.24276929069415865,"score_spread":0.22781285371126345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415854073","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.217944,0.13426457,0.0000919833,0.63282055,0.011346344,0.00062766275,0.00096155546,0.0001058575,0.0018374962],"genre_scores_gemma":[0.58584374,0.014215027,0.00023560695,0.3724448,0.005611905,0.000082066974,0.0028763649,0.00022366317,0.018466832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960496,0.0014176472,0.0011822801,0.0003859026,0.00012209374,0.0008424975],"domain_scores_gemma":[0.9966212,0.0014441097,0.0012790859,0.00043448506,0.00018233206,0.00003880624],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0002799644,0.00051059504,0.0014878564,0.00034485833,0.0006017137,0.00009138874,0.0009927691,0.0019604617,0.0012476415],"category_scores_gemma":[0.0002587567,0.00040498757,0.0009383728,0.00025365583,0.00034608154,0.00012545989,0.00020124692,0.0024935328,0.00032401487],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015784353,0.000060144237,0.0020287908,0.00006150838,0.0029189116,0.013631436,0.00011034939,0.0000018274975,0.00015994466,0.000024237177,0.9648589,0.015986132],"study_design_scores_gemma":[0.0027224822,0.000116574214,0.00403168,0.00041982523,0.0014382947,0.20570658,0.00003173707,2.8712373e-7,0.0016416763,0.00041497502,0.7830909,0.00038499074],"about_ca_topic_score_codex":0.00023116035,"about_ca_topic_score_gemma":0.00011347525,"teacher_disagreement_score":0.36789972,"about_ca_system_score_codex":0.00022392257,"about_ca_system_score_gemma":0.00041496762,"threshold_uncertainty_score":0.9998402},"labels":[],"label_agreement":null},{"id":"W4415937993","doi":"10.1056/evidoa2500155","title":"Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites","year":2025,"lang":"en","type":"article","venue":"NEJM Evidence","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; University of Toronto; Probity Medical Research; Innovaderm (Canada); SKiN Health","funders":"","keywords":"Psoriasis; Placebo; Scalp; Peptide; Adverse effect; Oral cavity","score_opus":0.03823424837231556,"score_gpt":0.30680545054545894,"score_spread":0.2685712021731434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415937993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683734,0.02743799,0.00083077815,0.0006558071,0.0016034461,0.00057508016,0.00011027576,0.00019166122,0.0002215171],"genre_scores_gemma":[0.990079,0.0006371326,0.001191919,0.00031127915,0.000091374604,0.00016826447,0.00017323226,0.0000204218,0.0073274006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841726,0.00020306246,0.00032717263,0.00047692333,0.000045642715,0.0005299466],"domain_scores_gemma":[0.99817896,0.0010879545,0.00012366932,0.00042680942,0.0001485015,0.000034089895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032287475,0.00029576063,0.00043925605,0.00020414086,0.00033568838,0.000047772002,0.0003532832,0.0002821144,0.00048578397],"category_scores_gemma":[0.00080347806,0.00024516677,0.00027638822,0.00036255654,0.00010569966,0.00030846745,0.000093959185,0.0001486003,0.00031858182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013051813,0.00019818622,0.09555423,0.000120730765,0.0011904249,0.000009908136,0.00043442872,0.000038914975,0.77972513,0.0025815987,0.057166487,0.06167476],"study_design_scores_gemma":[0.005947601,0.0011280259,0.34173837,0.0009784304,0.0014376212,0.000024424897,0.0003253918,0.00007242053,0.60656786,0.0039522867,0.036850408,0.0009771738],"about_ca_topic_score_codex":0.0003824078,"about_ca_topic_score_gemma":0.00014598976,"teacher_disagreement_score":0.24618414,"about_ca_system_score_codex":0.00013873262,"about_ca_system_score_gemma":0.00016681386,"threshold_uncertainty_score":0.9997611},"labels":[],"label_agreement":null},{"id":"W4415992105","doi":"10.1056/nejmoa2504187","title":"Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Probity Medical Research; Innovaderm (Canada)","funders":"Johnson and Johnson","keywords":"Plaque psoriasis; Placebo; Psoriasis; Incidence (geometry); Peptide; Clinical trial","score_opus":0.011700493432505944,"score_gpt":0.2596216156414172,"score_spread":0.24792112220891127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415992105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816838,0.011734814,0.00041153328,0.0035103254,0.0021918104,0.00019490931,0.000008672335,0.0000073100964,0.00025685132],"genre_scores_gemma":[0.99717087,0.0012646732,0.0001626371,0.00023777131,0.0004288092,0.0000032445694,0.000012317747,0.0000060294637,0.000713629],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99919415,0.00010386228,0.0003740935,0.00011659885,0.000034904897,0.00017637902],"domain_scores_gemma":[0.9994675,0.00020210777,0.00014417652,0.00007911357,0.0000698084,0.000037291906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004229395,0.0001240176,0.00040115713,0.00026981704,0.000043206892,0.0000033911615,0.00010071349,0.00012451784,0.000045786222],"category_scores_gemma":[0.00020423772,0.00008227679,0.0000498694,0.000115979725,0.00006515373,0.000049027254,0.000015351903,0.0001638896,0.0000023360883],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009910597,0.00014681366,0.106488675,0.00010566482,0.00031615648,0.00004248943,0.0011642451,0.0000026715331,0.0074922093,0.00041246475,0.013990143,0.8599279],"study_design_scores_gemma":[0.46642423,0.0032633713,0.30688724,0.0051285317,0.00081137073,0.0005561524,0.00069420825,0.000009485732,0.009175715,0.0028992705,0.20387049,0.00027993644],"about_ca_topic_score_codex":0.000101095,"about_ca_topic_score_gemma":0.00017370732,"teacher_disagreement_score":0.8596479,"about_ca_system_score_codex":0.000028006549,"about_ca_system_score_gemma":0.000078075915,"threshold_uncertainty_score":0.33551502},"labels":[],"label_agreement":null},{"id":"W4416059012","doi":"10.1177/12034754251386789","title":"Psychological Comorbidities in Palmoplantar Psoriasis and Psoriatic Arthritis: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; University of Ottawa; Western University; McGill University","funders":"","keywords":"Psoriasis; Depression (economics); Anxiety; Comorbidity; Psoriatic arthritis; Disease; Mood; Mood disorders; Mental health","score_opus":0.04380723597667255,"score_gpt":0.3148584980859353,"score_spread":0.2710512621092628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416059012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030741977,0.9969724,0.0000013630311,0.00021508567,0.0016483025,0.00067197054,0.00003173414,0.000012064694,0.00013966681],"genre_scores_gemma":[0.00014936035,0.99879575,0.000009216921,0.00038423197,0.00016626842,0.00004708656,0.00005940319,0.000017776501,0.00037090675],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955308,0.0013316488,0.0024203681,0.0002939434,0.000111945425,0.00031129917],"domain_scores_gemma":[0.9922424,0.006003663,0.001346398,0.00025567928,0.000085302345,0.00006655711],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015598353,0.00049636175,0.007242265,0.0007459159,0.00007675642,0.000013350243,0.00017285276,0.00047112507,0.00013415697],"category_scores_gemma":[0.0016822922,0.00029028082,0.00049539836,0.00031264598,0.00020771386,0.0000517153,0.000037476442,0.0005579133,0.000011920111],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005147566,0.000083565814,0.000022268858,0.54592144,0.0008737994,0.0030241183,0.00010538591,6.5517924e-9,3.8627692e-7,0.000019700983,0.012489158,0.4374087],"study_design_scores_gemma":[0.0005331141,0.00023172838,0.00000477136,0.8301874,0.006609682,0.06239803,0.00012745293,2.4295733e-8,2.520495e-7,0.0000673802,0.09960894,0.00023125984],"about_ca_topic_score_codex":0.000010450867,"about_ca_topic_score_gemma":0.000009083035,"teacher_disagreement_score":0.43717742,"about_ca_system_score_codex":0.000046496094,"about_ca_system_score_gemma":0.0001770738,"threshold_uncertainty_score":0.99995494},"labels":[],"label_agreement":null},{"id":"W4416073030","doi":"10.1016/j.jid.2025.09.209","title":"204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Apex (geometry); Psoriatic arthritis; Phases of clinical research; Arthritis; Clinical trial","score_opus":0.03494254464096976,"score_gpt":0.31178737523046046,"score_spread":0.2768448305894907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416073030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763787,0.00036140994,0.00001798672,0.00078854995,0.00018857817,0.0007193246,0.00009273917,0.0000073414735,0.00018622058],"genre_scores_gemma":[0.99941784,0.000013433523,0.00039305456,0.00006856554,0.000009072412,0.000032271884,0.000017571641,0.000010983586,0.000037191436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99714696,0.0013286798,0.00085535063,0.00024739924,0.00011086909,0.00031071162],"domain_scores_gemma":[0.99744385,0.00035761483,0.0014463817,0.00022081248,0.00050183653,0.000029515828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023694134,0.00025852487,0.000799388,0.00024625784,0.00013494046,0.0000057685147,0.00020840092,0.00018212035,0.000008490125],"category_scores_gemma":[0.00027676823,0.00014041465,0.000087305925,0.00073368975,0.0011543238,0.0002668634,0.00006942083,0.0004688574,0.0000011815707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04910354,0.005812042,0.22880854,0.00019134831,0.0063156653,0.0005637477,0.07409033,0.00018067811,0.62955135,0.0011955594,0.0013765839,0.002810643],"study_design_scores_gemma":[0.0164266,0.0030118716,0.1850518,0.0005250653,0.00045112913,0.00025237084,0.006217633,0.0000051372012,0.78704816,0.000874823,0.000024118739,0.00011128126],"about_ca_topic_score_codex":0.000068540416,"about_ca_topic_score_gemma":0.00041352882,"teacher_disagreement_score":0.15749685,"about_ca_system_score_codex":0.00008854199,"about_ca_system_score_gemma":0.0005917195,"threshold_uncertainty_score":0.57259434},"labels":[],"label_agreement":null},{"id":"W4416073032","doi":"10.1016/j.jid.2025.09.124","title":"106 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health; Dalhousie University; Probity Medical Research; University of Toronto","funders":"","keywords":"Psoriasis; Body surface area; Range (aeronautics); Body surface; Surface (topology)","score_opus":0.022381257960863734,"score_gpt":0.24594412967453644,"score_spread":0.2235628717136727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416073032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915796,0.0038727135,0.00018923414,0.0027706313,0.00061769044,0.00037240004,0.000095928866,0.00001673502,0.0004850887],"genre_scores_gemma":[0.99832815,0.00038416998,0.0005369416,0.00033351025,0.00007954326,0.000012576843,0.000019403686,0.000016977492,0.00028870566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99731356,0.00078590977,0.0009840794,0.0003055586,0.00012014418,0.0004907457],"domain_scores_gemma":[0.9973007,0.00068223337,0.0010618833,0.00031474186,0.000579042,0.00006138774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042149477,0.00037773376,0.0010029471,0.0001373247,0.00034125865,0.000034312936,0.00043163094,0.00025459504,0.00010933275],"category_scores_gemma":[0.00015719153,0.0002342914,0.0002519442,0.0003791677,0.0019954399,0.00015287855,0.000077516816,0.00044638044,0.000024920988],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0086020185,0.0009915074,0.06647306,0.00023530087,0.006855819,0.00046806273,0.006497038,0.00075269945,0.88868254,0.006375167,0.012990122,0.0010766654],"study_design_scores_gemma":[0.004804901,0.0005849187,0.024184685,0.00028706738,0.00051712996,0.0006780328,0.0032246292,0.000043346925,0.9630589,0.0016104884,0.0007560053,0.00024989404],"about_ca_topic_score_codex":0.000037338617,"about_ca_topic_score_gemma":0.00022816798,"teacher_disagreement_score":0.07437636,"about_ca_system_score_codex":0.00009267317,"about_ca_system_score_gemma":0.00052028906,"threshold_uncertainty_score":0.95541257},"labels":[],"label_agreement":null},{"id":"W4416073163","doi":"10.1016/j.jid.2025.09.207","title":"202 Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From the Phase 3 ICONIC-LEAD Study","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Phases of clinical research; Phase (matter); Subgroup analysis; Clinical trial; Adverse effect","score_opus":0.03476346858085435,"score_gpt":0.30226955515078396,"score_spread":0.26750608656992964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416073163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994506,0.002975009,0.00042022864,0.0011062764,0.00024749886,0.00058900146,0.000109141874,0.000009852381,0.0000370179],"genre_scores_gemma":[0.9988337,0.000078974,0.00049376773,0.00047523112,0.00001890988,0.000020437232,0.000026490898,0.000014730722,0.000037754053],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972819,0.0010118426,0.0009635147,0.000326325,0.00008722291,0.0003291793],"domain_scores_gemma":[0.9982918,0.0004686421,0.0006298988,0.00026654775,0.00027928417,0.000063826716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028215538,0.0003356788,0.0010954564,0.00038028223,0.00015799396,0.0000188415,0.0003592029,0.00022089238,0.000021591597],"category_scores_gemma":[0.00030581414,0.00021215857,0.00010802952,0.00056967273,0.0005265075,0.00015464665,0.00010329122,0.0004894412,0.0000070186575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03215048,0.0055502704,0.427973,0.00007527678,0.0070017953,0.00035673656,0.0103309965,0.00050905,0.51158535,0.00041197022,0.0018718571,0.002183182],"study_design_scores_gemma":[0.06078503,0.0017734047,0.60507876,0.0010663655,0.0014384238,0.00041612427,0.0065286607,0.000051457926,0.3218523,0.00037855707,0.0002582167,0.0003727187],"about_ca_topic_score_codex":0.00036378755,"about_ca_topic_score_gemma":0.00092299306,"teacher_disagreement_score":0.18973309,"about_ca_system_score_codex":0.00006563118,"about_ca_system_score_gemma":0.00036847458,"threshold_uncertainty_score":0.86515754},"labels":[],"label_agreement":null},{"id":"W4416086287","doi":"10.1016/j.jid.2025.09.114","title":"96 Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra: Subgroup Analyses of the Phase 3, ICONIC-LEAD Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada); Probity Medical Research","funders":"","keywords":"Plaque psoriasis; Psoriasis; Phase (matter); Clinical trial; Phases of clinical research","score_opus":0.04934797501773737,"score_gpt":0.3293090466391395,"score_spread":0.27996107162140216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416086287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092424,0.0069274683,0.00007313328,0.0008838623,0.00061723957,0.00036912455,0.000099077006,0.000009673859,0.00009620634],"genre_scores_gemma":[0.9989114,0.00039232604,0.00036783988,0.00007616498,0.00004714507,0.000017539667,0.000031849882,0.000013914518,0.00014185745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725574,0.0010500292,0.0010736446,0.00021743528,0.000090927526,0.000312241],"domain_scores_gemma":[0.99667037,0.0008951315,0.0016506774,0.00034460967,0.00039208654,0.000047155772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017298922,0.0003488691,0.0013841572,0.0004595704,0.00015152509,0.000009868503,0.00034867923,0.0002950277,0.00009173082],"category_scores_gemma":[0.00029339828,0.00018637282,0.000538927,0.00051063293,0.00113235,0.00014978538,0.000046945614,0.00021829209,0.0000050037797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022704361,0.0017666072,0.025910659,0.000057483412,0.00891956,0.00006872586,0.0017811214,0.00006330037,0.93369424,0.0021300178,0.0012440383,0.0016598536],"study_design_scores_gemma":[0.055980276,0.0033197075,0.00860722,0.00015372469,0.001819196,0.00032473492,0.00053844467,0.000004949912,0.92787504,0.0009836724,0.00025844714,0.00013460909],"about_ca_topic_score_codex":0.00022667221,"about_ca_topic_score_gemma":0.00008654574,"teacher_disagreement_score":0.033275917,"about_ca_system_score_codex":0.00015163532,"about_ca_system_score_gemma":0.0007959064,"threshold_uncertainty_score":0.76000637},"labels":[],"label_agreement":null},{"id":"W4416140151","doi":"10.25251/9zz14r68","title":"Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health","funders":"Janssen Pharmaceuticals; Genentech; LEO Pharma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Chugai Pharmaceutical; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Apremilast; Clinical trial; Plaque psoriasis; MEDLINE","score_opus":0.023430808397990298,"score_gpt":0.30673503431089494,"score_spread":0.28330422591290466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673543,0.019824445,0.0002351789,0.0019310201,0.005585479,0.0033253513,0.0003389384,0.000018634948,0.0013866624],"genre_scores_gemma":[0.9920229,0.0042129625,0.000050019393,0.0001991033,0.0005400679,0.00006730007,0.0000352486,0.000045575074,0.0028268707],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899557,0.006123679,0.0023326904,0.00054637546,0.00035844647,0.00068309007],"domain_scores_gemma":[0.9670509,0.028607277,0.0024240592,0.001058109,0.00077698624,0.00008262916],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042425003,0.00082578504,0.003171089,0.00036084166,0.0009239906,0.000019300483,0.0014501177,0.00036339124,0.00035525317],"category_scores_gemma":[0.0009680059,0.0004220958,0.0007026067,0.00073504745,0.0012898927,0.00009074008,0.00022921195,0.0008883021,0.00001758068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4696588,0.0068102907,0.20869611,0.00090069027,0.07661888,0.00078383787,0.097639434,0.0015418725,0.07062661,0.0008526981,0.033889674,0.03198112],"study_design_scores_gemma":[0.053669754,0.021957232,0.70118904,0.008704624,0.028343273,0.0017284336,0.03240651,0.00006768951,0.13774578,0.0025542576,0.010607007,0.0010264044],"about_ca_topic_score_codex":0.0015122634,"about_ca_topic_score_gemma":0.0032459348,"teacher_disagreement_score":0.4924929,"about_ca_system_score_codex":0.00040056556,"about_ca_system_score_gemma":0.00039191922,"threshold_uncertainty_score":0.9998231},"labels":[],"label_agreement":null},{"id":"W4416140478","doi":"10.25251/ta5v8k92","title":"Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"","keywords":"Incidence (geometry); Adverse effect; Esophageal candidiasis; Nystatin; Oral microbiology; Mycosis","score_opus":0.01726677270135445,"score_gpt":0.2932623388721411,"score_spread":0.27599556617078663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828088,0.011141828,0.000030304005,0.0020495085,0.0023214743,0.0007973734,0.0007722102,0.000004674088,0.00007381559],"genre_scores_gemma":[0.99471235,0.0037990313,0.00015630217,0.00024541168,0.00010313515,0.000007048849,0.000043549633,0.000025608142,0.0009075525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959537,0.0009411846,0.001988375,0.00035587972,0.0002894111,0.00047145705],"domain_scores_gemma":[0.99490273,0.0021397967,0.0013555078,0.0005224768,0.0009712551,0.00010825767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009425841,0.00047183703,0.0019814232,0.00078936183,0.00012981708,0.000007821153,0.00058861147,0.000267431,0.00011080791],"category_scores_gemma":[0.0012460568,0.0002888943,0.00015780228,0.00093176885,0.000448891,0.00009456672,0.00014479064,0.00043650263,0.000009427698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6105742,0.0027079682,0.005856889,0.0002247102,0.022300927,0.0008366566,0.16812791,0.0061489493,0.008216543,0.000032585605,0.018938959,0.1560337],"study_design_scores_gemma":[0.3753806,0.09700625,0.07512892,0.036788892,0.025995305,0.0014517781,0.13837902,0.00008753737,0.24012938,0.00215082,0.005176177,0.0023253341],"about_ca_topic_score_codex":0.0017828252,"about_ca_topic_score_gemma":0.0012089147,"teacher_disagreement_score":0.23519361,"about_ca_system_score_codex":0.00022855261,"about_ca_system_score_gemma":0.0004446494,"threshold_uncertainty_score":0.9999563},"labels":[],"label_agreement":null},{"id":"W4416140920","doi":"10.25251/2q1bnf78","title":"Real-World Effectiveness of Guselkumab in Patients With Psoriasis: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Psoriasis Area and Severity Index; Body surface area; Severity of illness; Longitudinal study; Disease; Clinical trial","score_opus":0.017512896759632787,"score_gpt":0.29013079450370094,"score_spread":0.27261789774406814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97332495,0.020103445,0.00017039373,0.0014047698,0.0030583756,0.00088152906,0.00034903883,0.00000764088,0.0006998503],"genre_scores_gemma":[0.98798865,0.010995021,0.0001125479,0.00007165789,0.00032727007,0.000007105576,0.00015574617,0.00003304348,0.00030898367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932193,0.0036681106,0.0016278605,0.0005506338,0.00041527467,0.00051877525],"domain_scores_gemma":[0.98781216,0.00801238,0.0018515685,0.0017484159,0.0005017724,0.00007367311],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003932822,0.0006040293,0.0017156734,0.00038946889,0.00037654466,0.000027111597,0.0017905191,0.00033091282,0.0002429473],"category_scores_gemma":[0.0005336707,0.00029609835,0.00013290235,0.000857467,0.0013209763,0.0001903949,0.00046105002,0.001126858,0.0000031604811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038581427,0.001495945,0.9121489,0.0003518717,0.009927388,0.0003458825,0.0016751953,0.000068944704,0.0015448102,0.00024607516,0.0032904376,0.03032312],"study_design_scores_gemma":[0.018076265,0.0032693776,0.9584311,0.0067280955,0.008299079,0.00045665196,0.0015383313,0.000014316765,0.0011521004,0.00063714286,0.0011114875,0.00028600314],"about_ca_topic_score_codex":0.0022169647,"about_ca_topic_score_gemma":0.0016389233,"teacher_disagreement_score":0.046282247,"about_ca_system_score_codex":0.0002993138,"about_ca_system_score_gemma":0.00068693527,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W4416141358","doi":"10.25251/m10xva58","title":"Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study","year":2025,"lang":"","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer","keywords":"Interim analysis; Concomitant; Post-hoc analysis; Psoriatic arthritis; Propensity score matching; Psoriasis; Observational study; Interim","score_opus":0.007972802628403415,"score_gpt":0.24529220213115632,"score_spread":0.2373193995027529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416141358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844942,0.012140987,0.000037359776,0.00014673822,0.0017559752,0.0010253642,0.0002274869,0.000004577738,0.00016727638],"genre_scores_gemma":[0.9969549,0.0024509602,0.00002021087,0.000040750758,0.00008012026,0.000011487038,0.00001437011,0.00002432092,0.00040284253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936027,0.003209134,0.002180789,0.00031210078,0.0003178172,0.00037745858],"domain_scores_gemma":[0.9941167,0.0011599569,0.0030303963,0.0009942466,0.00064000656,0.00005869025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001250625,0.0005521441,0.0025199878,0.00066286145,0.00016528342,0.000006112748,0.00083189376,0.00024581482,0.0005408079],"category_scores_gemma":[0.0002025315,0.00024198415,0.0006051136,0.0011939999,0.0014714384,0.00007344475,0.00012254821,0.00034051447,9.718656e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024772977,0.0074220677,0.851837,0.0000830921,0.057167444,0.00007956008,0.029768776,0.0008860963,0.0011281068,0.000038384882,0.000063187494,0.026753306],"study_design_scores_gemma":[0.01931004,0.042591214,0.8393778,0.0022555494,0.068917125,0.00011994159,0.020747596,0.00006410005,0.0059268246,0.00017686647,0.00016023632,0.00035271107],"about_ca_topic_score_codex":0.0015217501,"about_ca_topic_score_gemma":0.002956045,"teacher_disagreement_score":0.035169143,"about_ca_system_score_codex":0.0001910218,"about_ca_system_score_gemma":0.00026068886,"threshold_uncertainty_score":0.98678267},"labels":[],"label_agreement":null},{"id":"W4416160337","doi":"10.1016/j.fander.2025.09.620","title":"ICONIC-TOTAL : résultats d’un essai de phase 3 avec icotrokinra, peptide oral ciblé bloquant sélectivement le récepteur de l’interleukine-23 dans le traitement des localisations difficiles à traiter et à fort impact du psoriasis en plaque","year":2025,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Innovaderm (Canada)","funders":"","keywords":"Hemoglobin s; Adult-onset Still's disease; Oral tolerance","score_opus":0.026980745088678443,"score_gpt":0.3207848583639703,"score_spread":0.2938041132752919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416160337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90409136,0.0093815485,0.06789312,0.013604596,0.00093090406,0.001095043,0.0015479482,0.00043876254,0.0010167061],"genre_scores_gemma":[0.9813246,0.007562864,0.0043380912,0.002604306,0.00010932716,0.0007656149,0.0013129702,0.000107742475,0.001874499],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98916316,0.005107146,0.0014299527,0.0012934116,0.00017235454,0.0028339964],"domain_scores_gemma":[0.99571615,0.0023472968,0.0005198395,0.0008460532,0.00025723982,0.00031339243],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0020965345,0.0013158927,0.001534877,0.00068905595,0.0010694831,0.00024464732,0.0010829683,0.0015336496,0.0003607045],"category_scores_gemma":[0.00085866597,0.0012598542,0.0011652927,0.00067943014,0.0014864868,0.000567197,0.00044398173,0.0011321807,0.00011812862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075014955,0.029263405,0.29808664,0.0013574511,0.02429968,0.0071981503,0.09210354,0.02288218,0.2748662,0.05597068,0.07700281,0.10946778],"study_design_scores_gemma":[0.03210565,0.0035646134,0.4039331,0.0011201235,0.0039231987,0.009267775,0.027287995,0.0066677066,0.47098115,0.01613983,0.02198455,0.0030242996],"about_ca_topic_score_codex":0.0029319262,"about_ca_topic_score_gemma":0.0040122047,"teacher_disagreement_score":0.19611496,"about_ca_system_score_codex":0.0021202131,"about_ca_system_score_gemma":0.0041699656,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W4416160559","doi":"10.1016/j.fander.2025.09.597","title":"Icotrokinra, peptide oral ciblé bloquant sélectivement le récepteur de l’interleukine-23, pour le traitement du psoriasis en plaque modéré à sévère: résultats jusqu’à la semaine 24 de l’essai de phase 3 ICONIC-LEAD","year":2025,"lang":"fr","type":"article","venue":"Annales de Dermatologie et de Vénéréologie - FMC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Psoriasis; Plaque psoriasis; Chemotherapy; Clinical Practice","score_opus":0.031026146048491927,"score_gpt":0.3170725155833248,"score_spread":0.28604636953483287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416160559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8809357,0.025207749,0.03584357,0.04933057,0.0019191157,0.0012823358,0.00086237415,0.00067381945,0.003944727],"genre_scores_gemma":[0.95253575,0.019838644,0.0096992105,0.0064348867,0.00023672184,0.00087093737,0.0006887106,0.00014604986,0.009549062],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.985384,0.0074191554,0.0016219172,0.0016591325,0.0002032699,0.0037125298],"domain_scores_gemma":[0.9939965,0.0035188405,0.0006873602,0.0011209873,0.00031190444,0.00036442743],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0033411789,0.0015372656,0.0019465866,0.00081589434,0.00087973336,0.0002460151,0.0016892544,0.0024239582,0.0002754818],"category_scores_gemma":[0.0015934844,0.0015948098,0.0010583071,0.0008000781,0.0011159469,0.0004552361,0.00071419263,0.0017321183,0.00035696948],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090041375,0.02105482,0.080922976,0.0018226325,0.015146177,0.0144382445,0.016064601,0.007072931,0.21612415,0.07048112,0.48309758,0.064770624],"study_design_scores_gemma":[0.047622763,0.0028238408,0.037593015,0.0015570369,0.004346239,0.011532326,0.016793523,0.008490947,0.54870534,0.026088614,0.2909469,0.003499432],"about_ca_topic_score_codex":0.0020637494,"about_ca_topic_score_gemma":0.001983614,"teacher_disagreement_score":0.33258122,"about_ca_system_score_codex":0.0022625173,"about_ca_system_score_gemma":0.0071046622,"threshold_uncertainty_score":0.9997376},"labels":[],"label_agreement":null},{"id":"W4416176977","doi":"10.1159/000548953","title":"New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report","year":2025,"lang":"en","type":"article","venue":"Case Reports in Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Secukinumab; Ulcerative colitis; Family history; Medical history; Inflammatory bowel disease; Inflammatory Bowel Diseases; Past medical history; Vedolizumab","score_opus":0.010141953651631624,"score_gpt":0.2537386555168467,"score_spread":0.2435967018652151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416176977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940072,0.0005417849,0.00075922534,0.00035093,0.0023898215,0.000467521,0.00007326206,0.000076266195,0.0013340072],"genre_scores_gemma":[0.99489254,0.000016985377,0.00034239926,0.0005491367,0.00005853762,0.00029721888,0.0002592267,0.000017992834,0.0035659943],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972602,0.00047784674,0.00094261975,0.00069949136,0.000035134275,0.00058466714],"domain_scores_gemma":[0.9987413,0.00012715255,0.00032894994,0.00064098387,0.00010557177,0.000056007735],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041779588,0.00031549248,0.00053635595,0.00038173897,0.00015389409,0.000020660475,0.000055269174,0.00035785942,0.00093571574],"category_scores_gemma":[0.00015498955,0.00031259732,0.00015627872,0.00022023403,0.00016856162,0.00011332806,0.00012221007,0.0002934875,0.000036520752],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013200336,0.00012905529,0.18064402,0.000013466846,0.00027832805,0.8110225,0.00041626423,0.0000038088363,0.000059973558,0.000037021837,0.003694089,0.0023814042],"study_design_scores_gemma":[0.002035848,0.00026354377,0.069339834,0.00004262971,0.00017265754,0.92300916,0.00030046757,0.0000014189201,0.00077871594,0.00029059208,0.0036341422,0.00013098496],"about_ca_topic_score_codex":0.000599218,"about_ca_topic_score_gemma":0.0076908446,"teacher_disagreement_score":0.11198662,"about_ca_system_score_codex":0.00018684418,"about_ca_system_score_gemma":0.00023815241,"threshold_uncertainty_score":0.9999776},"labels":[],"label_agreement":null},{"id":"W4416217165","doi":"10.1016/s2468-1253(25)00296-1","title":"Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial","year":2025,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Pharmacokinetics; Tumor necrosis factor alpha; Clinical trial; Adverse effect; Randomized controlled trial","score_opus":0.030365556437741237,"score_gpt":0.3073341946590808,"score_spread":0.27696863822133955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416217165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514204,0.0008601305,0.0000451503,0.00048406533,0.00044835612,0.002810476,0.00015778816,0.000016095859,0.00003591588],"genre_scores_gemma":[0.9985913,0.00043515753,0.000035838835,0.00028294415,0.00004023469,0.00045531077,0.00010920281,0.000016774855,0.00003323484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99608546,0.0014515609,0.0010928112,0.00057615014,0.00005137863,0.00074263016],"domain_scores_gemma":[0.99857914,0.00049826584,0.00046266228,0.00030139065,0.000096806005,0.00006175553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007908536,0.00036890103,0.0019626603,0.0003917213,0.00014910218,0.000010687806,0.0001986699,0.00029035733,0.000027670085],"category_scores_gemma":[0.000030444393,0.00027113396,0.00007112012,0.00016221058,0.0010906004,0.00007295236,0.00012924809,0.00035989398,9.804797e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6552752,0.0009813086,0.3409885,0.000049658596,0.00047800044,0.000012950887,0.00065177056,0.00000482911,0.00033581414,0.00009971653,0.00005064224,0.0010715817],"study_design_scores_gemma":[0.9150369,0.008378481,0.074859366,0.00007722124,0.0004105849,0.00003099889,0.00022844404,0.00009303521,0.0005019299,0.00005942252,0.00019189095,0.00013172069],"about_ca_topic_score_codex":0.0001953886,"about_ca_topic_score_gemma":0.013436111,"teacher_disagreement_score":0.26612914,"about_ca_system_score_codex":0.00005408329,"about_ca_system_score_gemma":0.00007354653,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W4416228555","doi":"10.1111/jdv.70147","title":"From reactive to predictive: Advancing biologic dosing in dermatology","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Fonds Wetenschappelijk Onderzoek; British Skin Foundation","keywords":"Dosing; Therapeutic drug monitoring; Pharmacogenomics; Drug; Population; Adverse effect; Precision medicine; Pharmacokinetics","score_opus":0.012088244179375979,"score_gpt":0.2627130128702634,"score_spread":0.2506247686908874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416228555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98149824,0.0076404437,0.00027155085,0.0075611332,0.0009753075,0.00018077332,0.000017120174,0.000012164184,0.0018432523],"genre_scores_gemma":[0.9982995,0.0003505783,0.00028008106,0.0008902318,0.00004997896,0.0000045330926,0.000003521718,0.000010805336,0.00011078648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961718,0.0024020963,0.0007914541,0.00025332186,0.00002979727,0.00035154124],"domain_scores_gemma":[0.99850047,0.0007151414,0.0005608344,0.00014265713,0.000046552515,0.000034364508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039526157,0.00020978956,0.0007327291,0.00043365132,0.0001222279,0.0000033598649,0.0005048055,0.00037471723,0.000019918945],"category_scores_gemma":[0.0003199454,0.00014564158,0.0001392512,0.00028089463,0.00045404668,0.00008668516,0.0003060287,0.0006456543,0.000017180932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019075378,0.0002372013,0.7526202,0.000041935727,0.0010407245,0.00024379333,0.0012588667,0.00007555167,0.21352506,0.002119749,0.0031510058,0.023778386],"study_design_scores_gemma":[0.0050366833,0.000097594406,0.742266,0.00040553903,0.00048302644,0.0062325317,0.00065667677,0.000009428037,0.21419778,0.0070509925,0.023300666,0.00026310276],"about_ca_topic_score_codex":0.000016779806,"about_ca_topic_score_gemma":0.000009461254,"teacher_disagreement_score":0.023515284,"about_ca_system_score_codex":0.000042890788,"about_ca_system_score_gemma":0.00006545516,"threshold_uncertainty_score":0.5939091},"labels":[],"label_agreement":null},{"id":"W4416276818","doi":"10.1111/jdv.70202","title":"The risk and prevalence of hepatic diseases in psoriasis: A systematic review and meta‐analysis","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Health Services; Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Observational study; Odds ratio; Epidemiology; Fatty liver; Liver disease; Meta-analysis; Confidence interval; Hepatitis C","score_opus":0.01393929777026235,"score_gpt":0.25878505994304346,"score_spread":0.24484576217278112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416276818","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29551125,0.7013367,0.000014148025,0.0027387913,0.00007114496,0.00023331,0.000021914193,0.0000025410582,0.00007025273],"genre_scores_gemma":[0.88097095,0.118547454,0.000017460421,0.00024020013,0.0000036410431,0.0000065175227,4.2784143e-7,0.00000415618,0.00020919589],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99421024,0.0045707007,0.00089262676,0.00014307712,0.000032089993,0.00015126143],"domain_scores_gemma":[0.99752325,0.0011911212,0.0010655193,0.00016086864,0.000039590654,0.00001962617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000986767,0.00015179972,0.0014192984,0.00019818381,0.00013105643,0.0000033978126,0.0003253558,0.000113995695,0.000008111382],"category_scores_gemma":[0.0004446129,0.00007503289,0.00030261534,0.00025822638,0.0006510003,0.000045259956,0.00016373437,0.00027318476,8.6006e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034599242,0.00019573845,0.81128484,0.05793251,0.12453303,0.000030400515,0.00045025177,0.000009347749,0.00039195453,0.0035869027,0.0004022988,0.00083676015],"study_design_scores_gemma":[0.0014174897,0.000047056114,0.4218518,0.0020094514,0.5702876,0.0013215925,0.00010311595,0.0000062743707,0.000944498,0.0017169835,0.00016320749,0.00013089685],"about_ca_topic_score_codex":0.0000048297024,"about_ca_topic_score_gemma":0.0000062772287,"teacher_disagreement_score":0.5854597,"about_ca_system_score_codex":0.0000053223266,"about_ca_system_score_gemma":0.000023277686,"threshold_uncertainty_score":0.30597526},"labels":[],"label_agreement":null},{"id":"W4416355999","doi":"10.1016/j.jid.2025.10.604","title":"Systemic therapies for psoriatic disease and serious adverse events in older adults: A population-based cohort study","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Institute for Clinical Evaluative Sciences; University of Toronto; Public Health Ontario; Women's College Hospital","funders":"Janssen Pharmaceuticals; Canadian Institutes of Health Research; Health Canada; Canadian Dermatology Foundation; Eczema Society of Canada; National Eczema Association; Ontario Ministry of Health and Long-Term Care; Indigenous Services Canada; Institute for Clinical Evaluative Sciences; AbbVie; Pfizer; Physicians' Services Incorporated Foundation; Eli Lilly and Company","keywords":"Adverse effect; Cohort study; Cohort; Disease; Retrospective cohort study; MEDLINE","score_opus":0.008634222398904311,"score_gpt":0.2502328108467892,"score_spread":0.2415985884478849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416355999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932287,0.004304801,0.00007972563,0.0005899079,0.0004934652,0.0012623462,0.000024801599,0.000010966424,0.000005287717],"genre_scores_gemma":[0.9993369,0.000052427884,0.00011148564,0.00023121275,0.000012746257,0.00016557174,0.00003563731,0.000009598569,0.00004443182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835414,0.00060731464,0.00061213865,0.00019411577,0.000039423743,0.00019286886],"domain_scores_gemma":[0.9988353,0.00042542408,0.00041117443,0.00012980352,0.00015619671,0.000042094664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024103599,0.00018471105,0.0005632987,0.00035557858,0.00010568302,0.0000030699625,0.00012077888,0.00012570286,0.000010790356],"category_scores_gemma":[0.00029129343,0.00014629918,0.000098707314,0.00016850475,0.00010913238,0.00011046723,0.00001907076,0.00013278265,0.0000033197996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095649826,0.0003647837,0.9946963,0.00014156866,0.0008095279,0.000042400065,0.0014555898,0.000027813574,0.0007996342,0.0001790516,0.00008181916,0.00044501884],"study_design_scores_gemma":[0.009197329,0.00016530715,0.9855742,0.00043001954,0.0004649719,0.00008707973,0.0018135202,0.000027849337,0.0013327847,0.00076578907,0.000025228854,0.000115917035],"about_ca_topic_score_codex":0.00005834833,"about_ca_topic_score_gemma":0.00008730392,"teacher_disagreement_score":0.00912209,"about_ca_system_score_codex":0.00008122204,"about_ca_system_score_gemma":0.00023556451,"threshold_uncertainty_score":0.5965907},"labels":[],"label_agreement":null},{"id":"W4416448599","doi":"10.1093/jimmun/vkaf283.2705","title":"IL-27: An Antiviral Cytokine or Cell Traffic Controller? 9282","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Cytokine; Immune system; A549 cell; Function (biology); RNA; Viral infection; Cell function","score_opus":0.012347112261364864,"score_gpt":0.24067900991193125,"score_spread":0.22833189765056638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804973,0.014483088,0.00012433887,0.000830164,0.0026891013,0.00018911451,0.000023404342,0.00003148085,0.0011320041],"genre_scores_gemma":[0.9888108,0.0018414096,0.000059890932,0.00025805115,0.00007710405,0.000004268337,0.000011319426,0.00001469265,0.008922515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99784577,0.0009816332,0.0005892578,0.0001476179,0.00003815513,0.0003975871],"domain_scores_gemma":[0.99859446,0.00051520613,0.00041682358,0.00032558435,0.00013191796,0.000016033126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007174665,0.00023813912,0.00061837834,0.0002704609,0.0002474336,0.000013711387,0.00063703675,0.0003014393,0.00026644272],"category_scores_gemma":[0.00007614853,0.00013049018,0.00020442728,0.000249423,0.00031989842,0.00012735117,0.00007209972,0.00045937122,0.00016970023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014946047,0.0008237114,0.0004153587,0.000012334855,0.002274973,0.00007248149,0.0010719795,0.00004366256,0.87263733,0.00035677032,0.004898762,0.10244659],"study_design_scores_gemma":[0.056624085,0.013003701,0.037414744,0.00023196767,0.004268997,0.0040011727,0.0062658405,0.00004282861,0.6411248,0.001004858,0.23508605,0.0009309519],"about_ca_topic_score_codex":0.00001949288,"about_ca_topic_score_gemma":0.000030591258,"teacher_disagreement_score":0.23151253,"about_ca_system_score_codex":0.00005456842,"about_ca_system_score_gemma":0.00018328962,"threshold_uncertainty_score":0.5321235},"labels":[],"label_agreement":null},{"id":"W4416449186","doi":"10.1093/jimmun/vkaf283.1505","title":"Soluble CD14 through GABA production by monocytes promotes Th17 differentiation and innate lymphoid cells 3740","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"CD14; Innate immune system; Inflammation; Monocyte; Macrophage; Immune system; Secretion; Cytokine","score_opus":0.0111211597494356,"score_gpt":0.22730496956166293,"score_spread":0.21618380981222735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9415205,0.05347447,0.00024797127,0.0016494284,0.0026791592,0.00019421919,0.000008759373,0.000021771988,0.00020369203],"genre_scores_gemma":[0.98585683,0.009936954,0.00007477223,0.000080564125,0.000047020116,0.0000075452826,0.000019454328,0.000010745436,0.003966093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869674,0.0004716402,0.0004011961,0.00014806687,0.000032323616,0.00025000164],"domain_scores_gemma":[0.99906176,0.00018961831,0.0003895784,0.00021997032,0.00013111976,0.000007933235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003849363,0.00018011387,0.00033309235,0.000118712844,0.00029748204,0.000016724869,0.000237677,0.00020707645,0.000060530725],"category_scores_gemma":[0.000074980795,0.00011450314,0.00007790759,0.00014809147,0.0002475644,0.00018079292,0.00008667748,0.00022997068,0.000029575727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007076136,0.00018246402,0.0012694977,0.000013778083,0.0010634302,0.0000011482538,0.0009394658,0.000003143669,0.9722571,0.00018894416,0.00505457,0.018318878],"study_design_scores_gemma":[0.0018337081,0.00038444495,0.005702917,0.00005571114,0.0004379554,0.00026336728,0.00043053893,0.0000022834308,0.9789923,0.001750564,0.010034027,0.00011221131],"about_ca_topic_score_codex":0.00005654597,"about_ca_topic_score_gemma":0.000011508738,"teacher_disagreement_score":0.044336323,"about_ca_system_score_codex":0.00006053568,"about_ca_system_score_gemma":0.0000665493,"threshold_uncertainty_score":0.46693024},"labels":[],"label_agreement":null},{"id":"W4416454404","doi":"10.1007/978-3-031-93616-6_21","title":"Psoriasis","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriasis; Drug; Drug class; Class (philosophy); MEDLINE","score_opus":0.017796730177639136,"score_gpt":0.2282258580923756,"score_spread":0.21042912791473647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416454404","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022768796,0.009279756,0.000027218855,0.00013789748,0.002512898,0.00020805334,0.00017577804,0.00018647629,0.98744917],"genre_scores_gemma":[0.0005451182,0.00104165,0.00009468591,0.00022577173,0.000095256764,0.0000175322,0.00066290476,0.000028664814,0.9972884],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904674,0.000022777174,0.0002595094,0.00040793006,0.000025218907,0.00023779647],"domain_scores_gemma":[0.99926114,0.000123153,0.00009563708,0.00045184305,0.000052758314,0.000015494516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006365206,0.0003749781,0.00047371787,0.00019718125,0.00011551357,0.000009833268,0.00021803757,0.0009891585,0.022027008],"category_scores_gemma":[0.000011557613,0.00031127786,0.00030858885,0.00002039567,0.00008191293,0.000023291152,0.00009215248,0.00022686651,0.009638558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008597049,0.000029988452,0.000018899655,0.000026017138,0.001685496,0.000018363298,0.000024589812,5.345556e-8,0.00043120215,0.38561943,0.29394093,0.31811905],"study_design_scores_gemma":[0.00073253276,0.000055561137,0.000033393866,0.00007352268,0.0005668589,0.000013337628,0.0000047698977,4.005101e-8,0.002911312,0.005136997,0.9901734,0.00029826854],"about_ca_topic_score_codex":0.00002192424,"about_ca_topic_score_gemma":0.000029660965,"teacher_disagreement_score":0.6962325,"about_ca_system_score_codex":0.000050353457,"about_ca_system_score_gemma":0.000097547025,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W4416573257","doi":"10.1007/s13555-025-01573-1","title":"Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Royal College of Physicians of Ireland; LEO Pharma; Galderma; AbbVie; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Psoriasis; Health care; Multinational corporation; Clinical Practice; Health professionals; Infographic","score_opus":0.02146915936222471,"score_gpt":0.30855008643268034,"score_spread":0.2870809270704556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416573257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882223,0.016460488,0.000016046995,0.0035561512,0.00022610983,0.00062348536,0.0001417822,0.000019033134,0.00013469919],"genre_scores_gemma":[0.99593586,0.0024614062,0.0001305034,0.0009227453,0.0000026621924,0.00013133754,0.0001578566,0.00000854555,0.00024911377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984048,0.00064327335,0.00034109046,0.00032699786,0.000041515003,0.0002423374],"domain_scores_gemma":[0.9989551,0.00058535085,0.00015154007,0.00015963097,0.000120587974,0.0000278188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026041156,0.00020200916,0.0004905152,0.00021403452,0.00016465512,0.0000058229984,0.00007545034,0.00022947282,0.00007953742],"category_scores_gemma":[0.00002316207,0.00015643013,0.000033446366,0.0002681347,0.00020503647,0.000060246904,0.000046791152,0.00011608831,0.000004067763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022672936,0.00060789695,0.9714447,0.00010267963,0.0014555816,0.000014829563,0.0027603256,7.4182554e-7,0.00008745831,0.004071517,0.001012033,0.016174939],"study_design_scores_gemma":[0.00908739,0.00011864481,0.9859185,0.0000981761,0.000073588344,0.000042781794,0.0010302528,0.000011443546,0.002397127,0.00077071204,0.00031168334,0.00013970559],"about_ca_topic_score_codex":0.00052157906,"about_ca_topic_score_gemma":0.0006721411,"teacher_disagreement_score":0.017113624,"about_ca_system_score_codex":0.000011848335,"about_ca_system_score_gemma":0.00012573764,"threshold_uncertainty_score":0.6379036},"labels":[],"label_agreement":null},{"id":"W4416586053","doi":"10.1016/j.jid.2025.10.101","title":"097 Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23–receptor","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology; Probity Medical Research; Innovaderm (Canada); SKiN Health","funders":"","keywords":"Plaque psoriasis; Scalp; Psoriasis; Peptide; Open label; Clinical trial","score_opus":0.03614814502020658,"score_gpt":0.28958660663370195,"score_spread":0.25343846161349537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416586053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944846,0.0006661186,0.0011843328,0.001261476,0.00038662474,0.0009435053,0.0009850856,0.000040270104,0.00004800098],"genre_scores_gemma":[0.9937971,0.000050482668,0.004968555,0.0003753459,0.00010146064,0.000060625447,0.0004931572,0.000035087003,0.00011814492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99449295,0.0029434431,0.0013334999,0.0005096331,0.00015665035,0.00056381477],"domain_scores_gemma":[0.9933932,0.0028734605,0.0019349244,0.00034495568,0.001332327,0.00012115688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006216838,0.00060017646,0.0014793604,0.00071640045,0.0004045189,0.00004777966,0.0005029194,0.00043192273,0.00004682844],"category_scores_gemma":[0.0020877756,0.00035656083,0.00019596053,0.0015187681,0.00082601036,0.00044240511,0.00008934038,0.0006655418,0.000016610296],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09817558,0.0009793029,0.003214467,0.000016049198,0.003527468,0.00007101191,0.011635863,0.00030698217,0.8752788,0.0003391683,0.0051097907,0.001345531],"study_design_scores_gemma":[0.06537599,0.00502876,0.010251153,0.00027180222,0.0006471687,0.00016023757,0.0022650256,0.000027110835,0.91500574,0.000505502,0.00014143733,0.00032006635],"about_ca_topic_score_codex":0.0004947377,"about_ca_topic_score_gemma":0.00016684021,"teacher_disagreement_score":0.039726958,"about_ca_system_score_codex":0.00024016295,"about_ca_system_score_gemma":0.0011248053,"threshold_uncertainty_score":0.99988866},"labels":[],"label_agreement":null},{"id":"W4416586055","doi":"10.1016/j.jid.2025.10.004","title":"002 Transcriptomic and degradomic analyses support roles for Granzyme K in inflammation, proliferation and pruritus in psoriasis","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Psoriasis; Granzyme A; Granzyme B; Transcriptome; Serine protease; Granzyme; Proteases; Receptor","score_opus":0.029286180450529657,"score_gpt":0.29306479279619096,"score_spread":0.2637786123456613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416586055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99136794,0.0052856873,0.00019039752,0.0025667727,0.00018611447,0.000330859,0.000014982079,0.000006369064,0.000050872044],"genre_scores_gemma":[0.99851507,0.00053325586,0.0006242868,0.00018461574,0.000016344215,0.000046350033,0.000027594302,0.000006507687,0.000045946996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847645,0.000372447,0.00075863325,0.00016925891,0.000024635907,0.00019858372],"domain_scores_gemma":[0.9992032,0.0002898465,0.00029275648,0.00006701005,0.000114667346,0.00003249178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003124194,0.00016536,0.00055398856,0.0007127034,0.00007382098,0.000015292835,0.00008149783,0.00022550335,0.000009157339],"category_scores_gemma":[0.0003074184,0.00013865145,0.00006632823,0.00020989518,0.00030530756,0.00020900684,0.000013787353,0.00017166231,0.0000013548212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015255433,0.0001895351,0.22171894,0.0002192283,0.00084047625,0.00007737586,0.0061767125,0.000035237972,0.7436795,0.01104103,0.0010282247,0.013468166],"study_design_scores_gemma":[0.009268689,0.0001944567,0.14986166,0.00015136617,0.00027190018,0.00057711685,0.00085647625,0.000048111848,0.82426125,0.013553497,0.00079347804,0.00016198255],"about_ca_topic_score_codex":0.00001691029,"about_ca_topic_score_gemma":0.00043402973,"teacher_disagreement_score":0.08058173,"about_ca_system_score_codex":0.00004381169,"about_ca_system_score_gemma":0.0002364338,"threshold_uncertainty_score":0.5654042},"labels":[],"label_agreement":null},{"id":"W4416586312","doi":"10.1016/j.jid.2025.10.095","title":"091 Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23–receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the Phase 3, 
randomized, double-blind, placebo-controlled ICONIC-LEAD trial","year":2025,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; Innovaderm (Canada)","funders":"","keywords":"Plaque psoriasis; Placebo; Peptide; Phases of clinical research; Oral administration; Phase (matter)","score_opus":0.050761066550392586,"score_gpt":0.3029761348135224,"score_spread":0.25221506826312984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416586312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96995527,0.006059205,0.0010243837,0.011645985,0.0033626084,0.0072606793,0.000349404,0.000019559604,0.00032288698],"genre_scores_gemma":[0.9954328,0.0005966996,0.00054733607,0.0005156487,0.00012219902,0.0011370252,0.000052381853,0.000029593743,0.0015663282],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993813,0.0030171825,0.0020599235,0.00040884767,0.00016006354,0.00054102053],"domain_scores_gemma":[0.98907256,0.007044406,0.002527445,0.00052240724,0.0007782123,0.0000549532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011855583,0.00058976695,0.0027386989,0.00028618117,0.0005218827,0.00003528147,0.0008675004,0.00047088234,0.000038919246],"category_scores_gemma":[0.0011954001,0.0002662164,0.0014842926,0.0004883304,0.0016036102,0.00016488048,0.00008709062,0.0004903504,0.000008966283],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94237477,0.001366992,0.000041362633,0.00002397252,0.013048482,0.0000072484663,0.0088217305,0.00025837182,0.020802278,0.0018325142,0.010856916,0.000565345],"study_design_scores_gemma":[0.5644473,0.0016849331,0.000013208247,0.00010488951,0.002274734,0.00012522809,0.0013740852,0.00006332928,0.42493975,0.001404452,0.0034290047,0.00013907533],"about_ca_topic_score_codex":0.00014930099,"about_ca_topic_score_gemma":0.00021921055,"teacher_disagreement_score":0.40413746,"about_ca_system_score_codex":0.00020341366,"about_ca_system_score_gemma":0.0011222704,"threshold_uncertainty_score":0.999979},"labels":[],"label_agreement":null},{"id":"W4416592825","doi":"10.1038/s41584-025-01326-6","title":"The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","year":2025,"lang":"en","type":"article","venue":"Nature Reviews Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Psoriasis; Disease; Obesity; Weight loss; Adipose tissue; Psoriatic arthritis","score_opus":0.008710767588091002,"score_gpt":0.2634033998550797,"score_spread":0.2546926322669887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416592825","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12904216,0.86503077,0.00048864266,0.0021822741,0.0016341752,0.000966453,0.000007264572,0.00005625908,0.0005920281],"genre_scores_gemma":[0.8893481,0.109763235,0.00005472758,0.00011802703,0.0000062442286,0.0001948101,0.00003937348,0.000008099337,0.00046738872],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824375,0.00072069117,0.00043100404,0.00029183278,0.000026120122,0.00028659074],"domain_scores_gemma":[0.99900377,0.0004744836,0.00014865186,0.00032423675,0.000032029297,0.00001681886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053266046,0.00021458861,0.0004979248,0.000121088,0.00025596455,0.000031264128,0.00020546751,0.00044493168,0.000056251505],"category_scores_gemma":[0.00015841571,0.00013270752,0.00009295834,0.00024685374,0.00012119178,0.00006165825,0.000052496765,0.00036939603,0.00009190772],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018197749,0.00006777598,0.006056638,0.0003410524,0.0002641313,0.000006314046,0.00018354421,0.0000012980132,0.0015472558,0.5349651,0.0008003512,0.4555846],"study_design_scores_gemma":[0.0054828557,0.00018017605,0.15146978,0.001535151,0.00089671876,0.0001627775,0.0011011165,0.00009331313,0.0030013062,0.2608085,0.5743862,0.000882142],"about_ca_topic_score_codex":0.000018710318,"about_ca_topic_score_gemma":0.00019725627,"teacher_disagreement_score":0.76030594,"about_ca_system_score_codex":0.000035980676,"about_ca_system_score_gemma":0.00009748606,"threshold_uncertainty_score":0.5411656},"labels":[],"label_agreement":null},{"id":"W4416635811","doi":"10.1183/13993003.congress-2025.pa4589","title":"Positive feedback loops as potential contributors to Interleukin-17A-driven synergistic potentiation of inflammatory response and corticosteroid insensitivity","year":2025,"lang":"","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Institute for Research in Immunology and Cancer; McGill University","funders":"","keywords":"Tumor necrosis factor alpha; Downregulation and upregulation; Corticosteroid; Long-term potentiation; Glucocorticoid receptor; Inflammation; Glucocorticoid; Chromosomal translocation; Gene expression","score_opus":0.0051359358954322235,"score_gpt":0.22804505453767243,"score_spread":0.2229091186422402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416635811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98913085,0.0019701533,0.0031025773,0.0010831659,0.0022885443,0.0012298649,0.0005448711,0.00006306003,0.0005868815],"genre_scores_gemma":[0.9908929,0.00024846726,0.00007505536,0.00044614694,0.00004596116,0.00003344669,0.00016097465,0.000029616469,0.00806742],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9951145,0.0020861258,0.0011087382,0.00088351086,0.00011629366,0.0006908451],"domain_scores_gemma":[0.99714714,0.0011020922,0.00047624425,0.0005496579,0.0005837501,0.00014111988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007016941,0.0006172761,0.0010508356,0.00070935785,0.00039214588,0.00007181089,0.000239121,0.0007527079,0.000416957],"category_scores_gemma":[0.0008042317,0.0006154398,0.00029305022,0.0004588801,0.00054787187,0.00020680332,0.00047282496,0.00030839178,0.00026065807],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035623893,0.000625419,0.010360032,0.00011500784,0.003073929,0.00027285382,0.0011827481,0.000055107175,0.9111931,0.0009889891,0.00046671537,0.036042236],"study_design_scores_gemma":[0.006558085,0.0019130661,0.52552474,0.0005842286,0.0016407948,0.00014344949,0.001001123,0.0000915571,0.46147603,0.0001541192,0.0003511879,0.0005616132],"about_ca_topic_score_codex":0.00033799227,"about_ca_topic_score_gemma":0.00017410227,"teacher_disagreement_score":0.51516473,"about_ca_system_score_codex":0.00028379136,"about_ca_system_score_gemma":0.0004753495,"threshold_uncertainty_score":0.9996297},"labels":[],"label_agreement":null},{"id":"W4416723040","doi":"10.3390/ph18121802","title":"Myricetin Attenuates IMQ-Induced Psoriatic Inflammation Through Multi-Target Modulation: Evidence from Network Pharmacology and Experimental Validation","year":2025,"lang":"en","type":"article","venue":"Pharmaceuticals","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Natural Science Foundation of Hubei Province","keywords":"Myricetin; Psoriasis; Imiquimod; myr; Adverse effect; Inflammation; Keratinocyte; Cytokine","score_opus":0.07301498526053818,"score_gpt":0.37189500035324125,"score_spread":0.29888001509270307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416723040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735209,0.019258548,0.00261126,0.0013060126,0.0023331766,0.00067205593,0.000023987814,0.00012713352,0.00014695192],"genre_scores_gemma":[0.9955931,0.00066273025,0.0023899768,0.00038657483,0.00028474172,0.00019640483,0.00020817836,0.000015081264,0.00026325695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809265,0.0005973036,0.00042786117,0.0004595392,0.000053129843,0.00036952132],"domain_scores_gemma":[0.99874306,0.00083839294,0.00014552464,0.00017520845,0.00006273877,0.00003505267],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031045044,0.0002592576,0.00033751436,0.00006704425,0.00030207096,0.000036112684,0.00015121567,0.00022597966,0.00097352464],"category_scores_gemma":[0.00008657578,0.0002450602,0.000072414376,0.00022742107,0.000097179865,0.00034419433,0.000112443035,0.00017597132,0.00024754426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038969438,0.00014796344,0.008687806,0.000023578648,0.00054483104,0.000003868632,0.00077901775,0.00028729733,0.97135204,0.00009684988,0.0013289494,0.016358074],"study_design_scores_gemma":[0.003478734,0.000054267883,0.008699572,0.00007817202,0.000435031,0.0000034578777,0.00010241449,0.0019727414,0.9814043,0.00056045013,0.0029874537,0.00022340515],"about_ca_topic_score_codex":0.000059088383,"about_ca_topic_score_gemma":0.0000021550231,"teacher_disagreement_score":0.022072181,"about_ca_system_score_codex":0.000080501086,"about_ca_system_score_gemma":0.00004469784,"threshold_uncertainty_score":0.99993974},"labels":[],"label_agreement":null},{"id":"W4416773282","doi":"10.1111/jdv.70166","title":"Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Amgen","keywords":"Apremilast; Palmoplantar pustulosis; Phase (matter); MEDLINE; Clinical trial","score_opus":0.00941797863843805,"score_gpt":0.24421294682497138,"score_spread":0.23479496818653334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416773282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920236,0.0040718424,0.00001074392,0.0015501543,0.00065856165,0.0003626703,0.000012413296,0.000005913029,0.0013041199],"genre_scores_gemma":[0.99901634,0.00037243887,0.00002973279,0.00029815035,0.000033360448,0.0000060755283,0.0000068431355,0.000009907684,0.00022717472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99568504,0.0030252307,0.00083242863,0.00017052871,0.000042089152,0.0002446798],"domain_scores_gemma":[0.99852604,0.00057341903,0.0007128135,0.000117377975,0.000047217385,0.000023136283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068898493,0.00019674742,0.00095415144,0.0003076448,0.000095334464,0.000003513961,0.00037776693,0.00024892608,0.000019025805],"category_scores_gemma":[0.0001906713,0.00011121049,0.00018506475,0.0001817468,0.00072399346,0.0000677658,0.000121132354,0.000501086,0.0000084073945],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7305668,0.0013089794,0.254865,0.00008033029,0.0020777832,0.000096844946,0.00096857396,0.000011146354,0.001469906,0.0010661789,0.0019573485,0.0055311313],"study_design_scores_gemma":[0.93050164,0.00020578028,0.058808897,0.0002525038,0.0010342797,0.0013951317,0.00013973504,0.0000022894644,0.0038414309,0.00042715683,0.003218963,0.00017221982],"about_ca_topic_score_codex":0.000004114061,"about_ca_topic_score_gemma":0.0000035352803,"teacher_disagreement_score":0.19993484,"about_ca_system_score_codex":0.000015665542,"about_ca_system_score_gemma":0.000048206744,"threshold_uncertainty_score":0.4535032},"labels":[],"label_agreement":null},{"id":"W4416833331","doi":"10.1542/gr.54-6-71","title":"Exploring the Role of Infection in Pediatric Psoriasis","year":2025,"lang":"en","type":"article","venue":"AAP Grand Rounds","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Retrospective cohort study; Microbiological culture; Medical record; Referral; Tertiary referral hospital","score_opus":0.024150773661558718,"score_gpt":0.23600053205193622,"score_spread":0.2118497583903775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416833331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775095,0.0053968746,0.00001768179,0.000066193046,0.0012754103,0.00011939536,0.0000041708317,0.000025596506,0.00534376],"genre_scores_gemma":[0.9957372,0.003129741,0.0000060060406,0.000015478488,0.000050340706,0.00007833866,0.000016204487,0.0000050795434,0.00096161466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935853,0.00012009187,0.00019523501,0.0001412814,0.000020162604,0.00016467764],"domain_scores_gemma":[0.99959457,0.00015164592,0.00005019055,0.0001738327,0.000024408102,0.0000053795607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019093187,0.000100200545,0.00016658739,0.00020348476,0.00013318834,0.0000072798607,0.000085607484,0.000086614076,0.000026293254],"category_scores_gemma":[0.00002685857,0.0000676255,0.00008960748,0.00046714506,0.00003956884,0.0000995269,0.00003379119,0.00010010802,0.000032219665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019543455,0.00017511434,0.8640976,0.000023850813,0.00016935973,0.0000010535979,0.0008738154,0.000013351319,0.0049329754,0.0025541692,0.00018637229,0.12677692],"study_design_scores_gemma":[0.0017342553,0.00006543171,0.9492475,0.000018749344,0.00021107862,0.0000031126515,0.00013931509,0.0000015422676,0.031450085,0.0015412065,0.015492904,0.00009483383],"about_ca_topic_score_codex":0.00062002457,"about_ca_topic_score_gemma":0.00037625435,"teacher_disagreement_score":0.12668209,"about_ca_system_score_codex":0.000024495956,"about_ca_system_score_gemma":0.000030669325,"threshold_uncertainty_score":0.2757688},"labels":[],"label_agreement":null},{"id":"W4416839048","doi":"10.3389/fimmu.2025.1691163","title":"Estradiol enhances B cell humoral immune responses against genital herpes simplex virus type 2 in mice through an IL-17 dependant pathway","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"Herpes simplex virus; Immune system; Antibody; Humoral immunity; Immunization; B cell; Genital herpes; Nasal administration","score_opus":0.013483843740557366,"score_gpt":0.24716895564983601,"score_spread":0.23368511190927865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416839048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404635,0.051484395,0.00021257823,0.00011399606,0.0048285704,0.00043672792,0.00015805302,0.000101272504,0.002200913],"genre_scores_gemma":[0.9891206,0.0042131576,0.002167099,0.00016754176,0.00003642195,0.00010074854,0.00047801583,0.000035028264,0.0036813598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99659103,0.0010276103,0.00073458505,0.00071489176,0.000045094792,0.0008867899],"domain_scores_gemma":[0.99894774,0.00021462707,0.00019362876,0.0005649501,0.000058179598,0.000020868005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003467016,0.00046452472,0.0008576836,0.0005605992,0.00023060277,0.00002616622,0.00066415436,0.0007262237,0.0001237938],"category_scores_gemma":[0.00009288628,0.00045539255,0.00015314843,0.00061634206,0.00049657613,0.00034030908,0.0001505728,0.00046673365,0.000108157816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052960184,0.0010383232,0.007872966,0.000027987096,0.00057026866,0.00024378474,0.002201671,0.000021091584,0.88524127,0.00034766103,0.0018156761,0.09532326],"study_design_scores_gemma":[0.0058664456,0.0007138483,0.040815096,0.00007757381,0.00009510268,0.00003843766,0.004246511,0.000010664153,0.8384098,0.0008814562,0.10820492,0.00064015156],"about_ca_topic_score_codex":0.00073404046,"about_ca_topic_score_gemma":0.0008139182,"teacher_disagreement_score":0.10638925,"about_ca_system_score_codex":0.00022460397,"about_ca_system_score_gemma":0.0003387287,"threshold_uncertainty_score":0.9997898},"labels":[],"label_agreement":null},{"id":"W4416872177","doi":"10.1016/j.rhum.2025.10.136","title":"Le Guselkumab et les inhibiteurs de l’IL-17 présentent une persistance de traitement et une efficacité comparable dans le rhumatisme psoriasique : résultats à 12 mois de l’étude observationnelle PsABIOnd","year":2025,"lang":"fr","type":"article","venue":"Revue du Rhumatisme","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Psoriatic arthritis; Immunopathology; Connective tissue disease; Multicenter study; Tumor necrosis factor α","score_opus":0.022978125725869068,"score_gpt":0.25162883993215607,"score_spread":0.228650714206287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416872177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85430396,0.024191082,0.049176436,0.062412214,0.0014184229,0.0015344697,0.00092150865,0.00027946653,0.0057624322],"genre_scores_gemma":[0.9525385,0.0075414777,0.0075308047,0.0013158742,0.00013722341,0.00041260087,0.0010702399,0.00010141075,0.029351892],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9944574,0.0019243977,0.0012164,0.0009439893,0.00013731616,0.0013204946],"domain_scores_gemma":[0.9975402,0.0007618165,0.0005570537,0.0007596296,0.0002068934,0.00017440182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013597924,0.0008065565,0.0011319414,0.00028065048,0.0012260752,0.00014498798,0.00065637234,0.0009078365,0.0002238287],"category_scores_gemma":[0.00019968113,0.000937378,0.00048793448,0.00075330515,0.00050372345,0.00039485178,0.00018665942,0.0007565607,0.00011068915],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010132388,0.006462736,0.027352884,0.0024491416,0.0043508313,0.00025852668,0.094723135,0.020835342,0.14512032,0.61628807,0.05155478,0.029591033],"study_design_scores_gemma":[0.032698754,0.0015363143,0.5674566,0.011308232,0.0035007782,0.0011256988,0.03497867,0.0065402132,0.09404266,0.021058565,0.22202523,0.0037282796],"about_ca_topic_score_codex":0.00921569,"about_ca_topic_score_gemma":0.02173221,"teacher_disagreement_score":0.59522945,"about_ca_system_score_codex":0.0008380635,"about_ca_system_score_gemma":0.0011157758,"threshold_uncertainty_score":0.9993077},"labels":[],"label_agreement":null},{"id":"W4416875636","doi":"10.58931/cdt.2025.64149","title":"Drug Survival of Biologics for Psoriasis in Canada: Real-World Patterns and Implications","year":2025,"lang":"","type":"article","venue":"Canadian dermatology today.","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Drug; Clinical Practice; Drug class; Survival analysis; Biologic Agents; Drug development; Ustekinumab","score_opus":0.016207043140835136,"score_gpt":0.24518481291965138,"score_spread":0.22897776977881626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416875636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651483,0.008872902,0.000037095066,0.012639202,0.0031193725,0.0011653923,0.005338156,0.000016758604,0.0036627974],"genre_scores_gemma":[0.99346846,0.0027316937,0.000049007256,0.0006735698,0.000026754784,0.0002371208,0.0005165365,0.000022957647,0.002273888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967091,0.0004927906,0.00096138444,0.0007045594,0.000027848331,0.0011043205],"domain_scores_gemma":[0.9975985,0.0011661926,0.00027253898,0.00059651106,0.00016710708,0.00019911148],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022680614,0.000450849,0.0011432624,0.0009995118,0.00036706642,0.000012267408,0.0004504367,0.0005455139,0.00022776815],"category_scores_gemma":[0.00012875414,0.00048461027,0.0001413387,0.000631655,0.00035073032,0.00005795627,0.00008757886,0.0002797474,0.000006777536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011751227,0.000056104054,0.9477406,0.00018902509,0.0006524895,0.000041716503,0.00021580388,0.0000029885841,0.00018508738,0.018924547,0.011033409,0.020840708],"study_design_scores_gemma":[0.0028408335,0.000044333494,0.9458537,0.00013562904,0.00045246162,0.00005813356,0.0009858281,0.000014065909,0.0030296522,0.0011881777,0.04495576,0.00044143398],"about_ca_topic_score_codex":0.9926256,"about_ca_topic_score_gemma":0.99994355,"teacher_disagreement_score":0.033922352,"about_ca_system_score_codex":0.0011014902,"about_ca_system_score_gemma":0.009163236,"threshold_uncertainty_score":0.99976057},"labels":[],"label_agreement":null},{"id":"W4416888475","doi":"10.7759/cureus.98267","title":"Navigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Pityriasis rubra pilaris; Refractory (planetary science); Biopsy; Omalizumab; Dermabrasion; Medical history; Skin biopsy","score_opus":0.02289762037373282,"score_gpt":0.28397588176576677,"score_spread":0.26107826139203394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416888475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97987473,0.018921798,0.000011816995,0.00028540424,0.00018145,0.0003714207,0.00008954856,0.000027071721,0.0002367788],"genre_scores_gemma":[0.9964369,0.0029996813,0.00015197606,0.000037085465,0.000014798212,0.0001042175,0.00005544733,0.000008806959,0.00019112152],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989519,0.00020296656,0.000339614,0.00028460126,0.000027611095,0.00019327652],"domain_scores_gemma":[0.99876195,0.0004593989,0.00026691976,0.00041402935,0.00008396273,0.000013731935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002022904,0.0002084176,0.00040310776,0.00003032556,0.00019749555,0.000008545437,0.00010288214,0.00016972741,0.000069997885],"category_scores_gemma":[0.000044272467,0.00011071833,0.00009947387,0.00019402865,0.0003121027,0.000042994805,0.000044236163,0.00009971114,0.000002126677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001566239,0.0020379983,0.47205126,0.00007978193,0.00737289,0.0045154328,0.007152248,0.0000057730376,0.1275462,0.0005835122,0.00047690936,0.37661174],"study_design_scores_gemma":[0.0072405585,0.0038064218,0.05107567,0.0002456977,0.0013673237,0.00916308,0.0048459144,0.0000026261341,0.9160899,0.00021108893,0.005565436,0.00038629316],"about_ca_topic_score_codex":0.0025613466,"about_ca_topic_score_gemma":0.00037917608,"teacher_disagreement_score":0.7885437,"about_ca_system_score_codex":0.000033581528,"about_ca_system_score_gemma":0.00007749735,"threshold_uncertainty_score":0.45149624},"labels":[],"label_agreement":null},{"id":"W4417103507","doi":"10.1007/s13555-025-01595-9","title":"Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"UCB Pharma","keywords":"MEDLINE; Population; Feature (linguistics); Component (thermodynamics)","score_opus":0.020032016934352907,"score_gpt":0.2725003341250734,"score_spread":0.2524683171907205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417103507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266786,0.006527773,0.0000022649238,0.0077153775,0.0007134827,0.00042097183,0.00095628784,0.000087050495,0.00090893515],"genre_scores_gemma":[0.99116516,0.0039419113,0.000030160247,0.0031479765,0.000015244638,0.00005625259,0.001189123,0.000021304273,0.00043284058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770117,0.00052896864,0.0006067138,0.0006495242,0.00005174456,0.00046187176],"domain_scores_gemma":[0.99811274,0.0011024321,0.00021412226,0.00047743157,0.000045816818,0.000047479876],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001632101,0.0004310929,0.00081795966,0.00032933053,0.0002547642,0.000025489475,0.00015236401,0.0007159608,0.000113854294],"category_scores_gemma":[0.00008406837,0.00031464838,0.00012636586,0.00018754131,0.00026075437,0.00010690558,0.000054567863,0.00030441262,0.0000136228755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023455705,0.0016287647,0.8740781,0.000024677935,0.0072595915,0.00073447666,0.0054843593,0.0000030921767,0.007281956,0.00377881,0.026606437,0.049664017],"study_design_scores_gemma":[0.036304016,0.0006671809,0.7729953,0.00009135274,0.00031661175,0.0003634508,0.00059485633,0.000005619763,0.07805888,0.0020237686,0.10783635,0.00074260944],"about_ca_topic_score_codex":0.001345959,"about_ca_topic_score_gemma":0.0003913822,"teacher_disagreement_score":0.10108282,"about_ca_system_score_codex":0.00003373492,"about_ca_system_score_gemma":0.00009197693,"threshold_uncertainty_score":0.99993056},"labels":[],"label_agreement":null},{"id":"W4417114041","doi":"10.1111/jdv.70228","title":"Global burden of major depressive disorder attributable to psoriasis, 2000–2021","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McGill University","funders":"","keywords":"Major depressive disorder; MEDLINE; Depression (economics); Comorbidity; Young adult","score_opus":0.010423259482284007,"score_gpt":0.25494764604090075,"score_spread":0.24452438655861675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417114041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95928186,0.027106574,0.00033529414,0.00888809,0.0010810251,0.00016318542,0.00006079948,0.0000067182996,0.003076461],"genre_scores_gemma":[0.99790573,0.0006155197,0.00015165018,0.0003128945,0.00006714558,0.0000021387987,0.0000036447996,0.000009147719,0.00093213294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728817,0.001397537,0.0007667793,0.00019763446,0.00004576855,0.00030413206],"domain_scores_gemma":[0.9987731,0.0002444473,0.0006710615,0.00017524019,0.00009770865,0.000038421455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034727604,0.00019801651,0.00073860545,0.00018517867,0.0001469988,0.0000034974723,0.0006169701,0.00030745775,0.000081534265],"category_scores_gemma":[0.00020333954,0.00013669432,0.00021126072,0.00031933203,0.00043005953,0.000060793653,0.0003510157,0.00030193813,0.000022940125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002028644,0.00037756184,0.8652312,0.0001565913,0.0036939094,0.00009873357,0.0007369914,0.00033033016,0.038202528,0.011335807,0.0230438,0.054763883],"study_design_scores_gemma":[0.013110123,0.00021066118,0.6593204,0.00049258536,0.0024558122,0.007675469,0.00049238215,0.00000626774,0.13124344,0.0057395278,0.17878707,0.00046624182],"about_ca_topic_score_codex":0.00002282175,"about_ca_topic_score_gemma":0.000005789012,"teacher_disagreement_score":0.2059108,"about_ca_system_score_codex":0.000027319405,"about_ca_system_score_gemma":0.0001041385,"threshold_uncertainty_score":0.55742323},"labels":[],"label_agreement":null},{"id":"W4417135034","doi":"10.1021/acsnanomed.5c00077","title":"Immunopathology to Nanotherapeutics: Redefining Psoriasis Management in Autoimmune Disease","year":2025,"lang":"en","type":"article","venue":"ACS Nano Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Immunopathology; Autoimmune disease; Psoriasis; Connective tissue disease; Disease; Autoimmunity","score_opus":0.01653236656323344,"score_gpt":0.27209662704095994,"score_spread":0.2555642604777265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417135034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9158335,0.04523353,0.0002918808,0.011177924,0.0055147666,0.0011028544,0.000027199721,0.00024188106,0.020576518],"genre_scores_gemma":[0.9756474,0.0012542641,0.00024994067,0.0028746559,0.000045242345,0.00023699619,0.00012852492,0.000023940143,0.019539049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981785,0.00023752749,0.00051820744,0.00049703283,0.000058219368,0.00051050313],"domain_scores_gemma":[0.9990224,0.00017477671,0.00008376815,0.00063784746,0.0000425907,0.00003861803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046888975,0.00028963198,0.00051688316,0.0006753183,0.00015978506,0.000006968826,0.0003681112,0.00018079783,0.00032722653],"category_scores_gemma":[0.00010450835,0.00024016008,0.0000700537,0.0007362876,0.0001562009,0.00004440485,0.00016077035,0.00015099143,0.0003660235],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022362715,0.00049595244,0.0122618945,0.00010341442,0.0010880247,0.00032175065,0.0020924138,0.00001771256,0.25513482,0.014428279,0.006819297,0.70500016],"study_design_scores_gemma":[0.020894753,0.0008300569,0.442626,0.0015114142,0.0014558432,0.000036851896,0.0017678958,0.000003898192,0.03908227,0.0032136447,0.48775032,0.0008270624],"about_ca_topic_score_codex":0.000105002175,"about_ca_topic_score_gemma":0.000025000643,"teacher_disagreement_score":0.7041731,"about_ca_system_score_codex":0.00012048368,"about_ca_system_score_gemma":0.000057977748,"threshold_uncertainty_score":0.97934437},"labels":[],"label_agreement":null},{"id":"W4417166614","doi":"10.2196/80113","title":"A Mobile App to Enhance Awareness of Vaccination in Adults With Psoriasis and Atopic Dermatitis: Development and Preliminary Evaluation Study","year":2025,"lang":"en","type":"article","venue":"JMIR Formative Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Vaccination; Psoriasis; Mobile apps; Immunization; mHealth; Atopic dermatitis","score_opus":0.02551256048485681,"score_gpt":0.37317466135925886,"score_spread":0.3476621008744021,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417166614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562085,0.0016856844,0.00008378007,0.000034944507,0.000050532213,0.0022049283,0.0000074291684,0.0000104969995,0.00030136522],"genre_scores_gemma":[0.9968534,0.00008098724,0.000100467456,0.000005839214,0.000002656597,0.0027452528,0.00003424767,0.0000042168112,0.0001728996],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987133,0.0005043975,0.00024449264,0.00021872336,0.000117089745,0.00020197367],"domain_scores_gemma":[0.9993408,0.00018100964,0.000051771603,0.00013075283,0.00027899476,0.000016683192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087002147,0.00010393435,0.0001940162,0.00044922333,0.00016664686,0.000012018467,0.000084099185,0.00007598508,0.000021862097],"category_scores_gemma":[0.000039526123,0.00008278573,0.000009097672,0.0004785751,0.000043381384,0.00016252816,0.00011879039,0.00011048992,0.000009951153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089123385,0.00079591636,0.10147964,0.00035034702,0.00017319332,0.00000238439,0.10449708,0.0000077796,0.00044595296,0.00006392823,0.0001533542,0.7911392],"study_design_scores_gemma":[0.002898413,0.0015241978,0.9327055,0.00034301373,0.000019114696,0.0000027626554,0.0137884235,0.0000405482,0.048311137,0.000057689434,0.00022430492,0.00008489475],"about_ca_topic_score_codex":0.00007390353,"about_ca_topic_score_gemma":0.00031665855,"teacher_disagreement_score":0.8312259,"about_ca_system_score_codex":0.000108555054,"about_ca_system_score_gemma":0.00015877369,"threshold_uncertainty_score":0.3375904},"labels":[],"label_agreement":null},{"id":"W4417196083","doi":"10.1111/jdv.70110","title":"Results from the 32‐week, phase 3 <scp>DISCREET</scp> study of apremilast in patients with moderate to severe genital psoriasis","year":2025,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Lynde Centre for Dermatology; Probity Medical Research; Guenther Dermatology Research Centre","funders":"Amgen","keywords":"Apremilast; Psoriasis; Sex organ; MEDLINE; Severity of illness; Plaque psoriasis","score_opus":0.01513872788205899,"score_gpt":0.24218543233240727,"score_spread":0.22704670445034827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417196083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958992,0.001145746,0.000020797419,0.001249475,0.00038477738,0.0003260291,0.000116021125,0.0000055868786,0.00085234764],"genre_scores_gemma":[0.99928886,0.000065998734,0.00005645349,0.00030752827,0.000034558812,0.000002949718,0.000010941236,0.000013712134,0.00021901382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962062,0.0022802707,0.00092067133,0.00025265015,0.00006879715,0.00027138888],"domain_scores_gemma":[0.9980187,0.0008702414,0.0007569317,0.00023357183,0.00008841502,0.00003214738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045788477,0.00022871248,0.0006737826,0.00021215084,0.00015096374,0.0000053309586,0.00064265967,0.00021178393,0.0000054919237],"category_scores_gemma":[0.00028798633,0.00012695818,0.00010569943,0.00026980197,0.00031180563,0.000076759745,0.0002837061,0.0005345389,0.000006647088],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00941902,0.002803466,0.96202016,0.000021677974,0.0023989317,0.000061352584,0.0055193463,0.0002835196,0.0026730595,0.00022490404,0.0057488475,0.008825723],"study_design_scores_gemma":[0.029647924,0.00063554215,0.9563603,0.00013732695,0.00068281376,0.00024988272,0.0013255546,0.000004453313,0.008284174,0.00025631813,0.0023198219,0.00009589647],"about_ca_topic_score_codex":0.000025082325,"about_ca_topic_score_gemma":0.000037293157,"teacher_disagreement_score":0.020228904,"about_ca_system_score_codex":0.000017304052,"about_ca_system_score_gemma":0.000050262497,"threshold_uncertainty_score":0.5177204},"labels":[],"label_agreement":null},{"id":"W4417231960","doi":"10.1177/2050313x251387391","title":"Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: A case report","year":2025,"lang":"en","type":"article","venue":"SAGE Open Medical Case Reports","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Psoriasis; Refractory (planetary science); Biologic Agents; Complete response; Etanercept; Adverse effect","score_opus":0.011796230676581579,"score_gpt":0.2697094448080454,"score_spread":0.2579132141314638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417231960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919519,0.0028935352,0.000048339814,0.00012703233,0.00039637735,0.0011002976,0.000021047059,0.000035295536,0.003426212],"genre_scores_gemma":[0.9978075,0.0001506409,0.00019562332,0.000112290174,0.000020735144,0.00021727325,0.00008437695,0.000019587886,0.0013919666],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9972207,0.0003717379,0.0012234575,0.0006448541,0.00015172425,0.00038753237],"domain_scores_gemma":[0.9980924,0.00033097496,0.0006132608,0.00070745236,0.00016589783,0.000090012014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008877763,0.00028074667,0.000776974,0.0002540021,0.0001469762,0.000021980568,0.00012143471,0.00035480838,0.00060071424],"category_scores_gemma":[0.0011025005,0.00020778306,0.00011288147,0.00078293966,0.00018512023,0.000111275556,0.00019361093,0.0002798645,0.0000116176225],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047124585,0.00047583028,0.019332418,0.00008492369,0.00023147323,0.91371423,0.00041999144,0.0000019646338,0.00007294129,0.000014172442,0.0003231034,0.064857684],"study_design_scores_gemma":[0.0029054347,0.00037832875,0.006723346,0.00043584744,0.0005648325,0.98272747,0.00089635083,0.0000053944186,0.004104523,0.00007168134,0.00092979457,0.0002570137],"about_ca_topic_score_codex":0.002803675,"about_ca_topic_score_gemma":0.0012679803,"teacher_disagreement_score":0.0690132,"about_ca_system_score_codex":0.000070337024,"about_ca_system_score_gemma":0.000598362,"threshold_uncertainty_score":0.8473147},"labels":[],"label_agreement":null},{"id":"W4417274052","doi":"10.1080/09546634.2025.2588072","title":"What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor?","year":2025,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Drug; Enzyme inhibitor; Chemotherapy; Clinical trial","score_opus":0.023824284592163847,"score_gpt":0.2812734661010952,"score_spread":0.25744918150893137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417274052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97693026,0.0054877503,0.00011071167,0.012992337,0.003069784,0.001106758,0.00016575576,0.00005771021,0.00007890478],"genre_scores_gemma":[0.99083036,0.0012610747,0.0011413995,0.004886348,0.00046757635,0.00029111927,0.00003202592,0.000046367928,0.0010437444],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99609405,0.0009184804,0.0012811655,0.00068177725,0.00020345463,0.0008210632],"domain_scores_gemma":[0.99835575,0.00037481188,0.00037235397,0.0005488151,0.00017337585,0.00017490114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046097487,0.0007361234,0.0011845859,0.00053078536,0.00033955436,0.00026691213,0.00052842236,0.00065636716,0.0007151312],"category_scores_gemma":[0.000055419405,0.00039225852,0.0005772563,0.0005827153,0.0001173689,0.00067043485,0.00018262936,0.00055855396,0.00025040662],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04304145,0.010739449,0.032241564,0.00010637324,0.0078080758,0.0056138667,0.03477109,0.00025821174,0.2830047,0.000240317,0.036749557,0.54542536],"study_design_scores_gemma":[0.02332109,0.008256729,0.022798223,0.0010356371,0.00081287883,0.0022484437,0.010446192,0.000008904783,0.6142631,0.00036037274,0.31515175,0.0012966571],"about_ca_topic_score_codex":0.000028620867,"about_ca_topic_score_gemma":0.00021033894,"teacher_disagreement_score":0.54412866,"about_ca_system_score_codex":0.00045101534,"about_ca_system_score_gemma":0.00035315464,"threshold_uncertainty_score":0.99985296},"labels":[],"label_agreement":null},{"id":"W4417289733","doi":"10.1007/s13555-025-01583-z","title":"Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial","year":2025,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Amgen","keywords":"Apremilast; Placebo; Palmoplantar pustulosis; Randomized controlled trial; Quality of life (healthcare); Clinical trial","score_opus":0.023753988291548504,"score_gpt":0.2986026229296635,"score_spread":0.274848634638115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417289733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842568,0.013158533,0.000003200141,0.00020381437,0.0003012724,0.0011057949,0.000042803564,0.000019674173,0.0009080931],"genre_scores_gemma":[0.9965092,0.0026285702,0.000011279751,0.000095144926,0.000008039586,0.00023140974,0.00020913046,0.000007782644,0.00029942516],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977953,0.0012320515,0.0003596658,0.00026727834,0.000041328058,0.00030441288],"domain_scores_gemma":[0.99858975,0.0010152917,0.00008915478,0.00021059261,0.00007852988,0.000016684988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047166547,0.00017024654,0.0007117679,0.0004013611,0.00012694311,0.0000055964483,0.0001347303,0.00028516827,0.000049618604],"category_scores_gemma":[0.000058339996,0.00011524691,0.00007349175,0.00028614418,0.0006719246,0.00005563256,0.000034718953,0.00021416452,0.000012246949],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93948543,0.0015298511,0.047365557,0.00003806693,0.00084087666,0.000030179615,0.0012110362,1.862095e-7,0.0007198406,0.00053350575,0.0006614809,0.007583959],"study_design_scores_gemma":[0.9830319,0.00047504462,0.004742054,0.00011496537,0.000084108935,0.000028513468,0.0003181163,0.0000015979319,0.008170881,0.0004954403,0.0024036241,0.00013369921],"about_ca_topic_score_codex":0.000092624214,"about_ca_topic_score_gemma":0.000044980363,"teacher_disagreement_score":0.043546494,"about_ca_system_score_codex":0.000010487535,"about_ca_system_score_gemma":0.00006207995,"threshold_uncertainty_score":0.46996328},"labels":[],"label_agreement":null},{"id":"W4417314564","doi":"10.1080/14712598.2025.2604057","title":"Cell population data as predictive biomarkers for biologic therapy response in psoriasis","year":2025,"lang":"en","type":"article","venue":"Expert Opinion on Biological Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; Natural Science Foundation of Hunan Province; National Natural Science Foundation of China","keywords":"Psoriasis; Population; Biological response modifiers; Biologic Agents; Biomarker; Clinical trial; Cell; Cell therapy","score_opus":0.0950750619438016,"score_gpt":0.3562980083849614,"score_spread":0.2612229464411598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417314564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280724,0.064493425,0.00025631333,0.0016533437,0.0028554266,0.0016222236,0.0003263018,0.00018855518,0.0005320019],"genre_scores_gemma":[0.8927256,0.10195133,0.00027587297,0.0015502597,0.00010219224,0.00048610303,0.0027185716,0.000016147227,0.00017395697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970172,0.0012163215,0.00041865138,0.000884916,0.000040004725,0.00042292586],"domain_scores_gemma":[0.9976561,0.0014379328,0.00013452103,0.00070091226,0.00004343504,0.000027118083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084590033,0.00035400543,0.00044494955,0.0002753024,0.00022522948,0.000019438747,0.0006110625,0.00068493624,0.0002654652],"category_scores_gemma":[0.00024347103,0.00022795709,0.00016063181,0.00034714703,0.00014297901,0.000083057836,0.00008964769,0.00014801625,0.00007203327],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1877029,0.0021868846,0.019897657,0.0000026273005,0.0007304092,0.000003797561,0.00042961325,0.000008815793,0.2724393,0.0011749276,0.012792483,0.5026306],"study_design_scores_gemma":[0.015003366,0.0087138545,0.2091535,0.00006607953,0.000002081241,0.00000328964,0.00046087822,0.00003295954,0.07207527,0.0023500684,0.69160223,0.0005364047],"about_ca_topic_score_codex":0.00013550672,"about_ca_topic_score_gemma":0.0000022810393,"teacher_disagreement_score":0.67880976,"about_ca_system_score_codex":0.00009383844,"about_ca_system_score_gemma":0.000055857363,"threshold_uncertainty_score":0.92958206},"labels":[],"label_agreement":null},{"id":"W4417324635","doi":"10.3899/jrheum.2025-1216","title":"Interdependent Cardiometabolic and Psoriatic Disease: An Intriguing Process That Calls for Far More Integrative Intervention","year":2025,"lang":"en","type":"editorial","venue":"The Journal of Rheumatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; National Research Foundation","keywords":"Psoriatic arthritis; Psoriasis; Multimorbidity; Intervention (counseling); Interdependence; Disease; Comorbidity; Arthritis","score_opus":0.010693621496685377,"score_gpt":0.2929196037908915,"score_spread":0.2822259822942061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417324635","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2297728,0.072233856,0.003963541,0.0003965321,0.6920046,0.0009069783,0.00064726494,0.000040519823,0.00003389265],"genre_scores_gemma":[0.9384955,0.02849218,0.00015503864,0.00006357025,0.029068872,0.00020154119,0.001454464,0.00012583476,0.0019430023],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99699,0.0013733996,0.0008521326,0.00029904276,0.00012732264,0.00035810328],"domain_scores_gemma":[0.99607664,0.0017178098,0.0012631565,0.0003284101,0.0005516396,0.00006234613],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015298323,0.00044795085,0.0013337118,0.00047795975,0.00023907839,0.000040505318,0.0007112605,0.00065479765,0.00003274661],"category_scores_gemma":[0.001212767,0.00027209095,0.0004232569,0.00013043503,0.00027045503,0.00017420886,0.00013838206,0.00083944056,0.0000061297646],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01473132,0.0009121101,0.006103293,0.0025520588,0.017348701,0.00004518565,0.016877417,0.000034338085,0.00020749476,0.00061563804,0.5899579,0.35061455],"study_design_scores_gemma":[0.035992686,0.004514445,0.0044147777,0.0107017085,0.028829947,0.0029751218,0.025631007,0.00007977539,0.0024204126,0.008433421,0.87360674,0.0023999703],"about_ca_topic_score_codex":0.00014995443,"about_ca_topic_score_gemma":0.00013373584,"teacher_disagreement_score":0.7087227,"about_ca_system_score_codex":0.00010670522,"about_ca_system_score_gemma":0.0003471516,"threshold_uncertainty_score":0.9999731},"labels":[],"label_agreement":null},{"id":"W4417358255","doi":"10.1080/09546634.2025.2598183","title":"Tildrakizumab in real-world Chinese psoriasis: efficacy-safety profiles from a 28-week retrospective cohort with geriatric, late-onset and metabolic syndrome stratification","year":2025,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Psoriasis; Retrospective cohort study; Metabolic syndrome; Cohort; Cohort study; Plaque psoriasis","score_opus":0.01267823375081535,"score_gpt":0.2569125784295141,"score_spread":0.24423434467869876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417358255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910837,0.006568621,0.000027208744,0.0005327218,0.00028680288,0.0006787079,0.00015511838,0.0000395094,0.0006276305],"genre_scores_gemma":[0.9948151,0.0039310995,0.00054683373,0.000030174744,0.000022670132,0.000076696786,0.0001541685,0.000012384283,0.00041086267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979004,0.0004809409,0.0008039452,0.00040499415,0.000094246265,0.00031545688],"domain_scores_gemma":[0.99863535,0.0004500992,0.00048264902,0.00026946093,0.00010615644,0.000056288143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020409032,0.00038798316,0.0012207207,0.00037756393,0.00016475492,0.00003892829,0.00017019629,0.00025582706,0.00011527296],"category_scores_gemma":[0.00006675869,0.00021972672,0.00017907015,0.00053952227,0.00014712352,0.00014859668,0.000037229187,0.00024139295,0.000021107697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026387423,0.0016774829,0.98561364,0.000008860488,0.002372533,0.0005741399,0.0002395874,0.0000129148075,0.0006164245,0.00035119985,0.0000742197,0.005820261],"study_design_scores_gemma":[0.007690534,0.0007478402,0.9851891,0.00008207974,0.00090271886,0.00065140566,0.00009049972,0.0000041462067,0.003384883,0.00079682766,0.00026808959,0.00019188953],"about_ca_topic_score_codex":0.00023159033,"about_ca_topic_score_gemma":0.00027034996,"teacher_disagreement_score":0.0056283716,"about_ca_system_score_codex":0.00027831792,"about_ca_system_score_gemma":0.00015947109,"threshold_uncertainty_score":0.8960195},"labels":[],"label_agreement":null},{"id":"W4417419156","doi":"10.1093/ced/llaf534","title":"Clinical phenotypes of 504 patients with pustular psoriasis from Europe and Egypt: a multicentre observational study","year":2025,"lang":"en","type":"article","venue":"Clinical and Experimental Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Academy of Dermatology and Venereology; LEO Pharma; Galderma; Celgene; Universität Zürich; Eli Lilly and Company","keywords":"Observational study; Psoriasis; Pustular psoriasis; Clinical phenotype; Phenotype; Generalized pustular psoriasis","score_opus":0.04518781083832319,"score_gpt":0.3337583247291255,"score_spread":0.2885705138908023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417419156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938946,0.004312004,0.000013474369,0.00016206157,0.00085833244,0.00043155928,0.000064784435,0.000027472342,0.0002357419],"genre_scores_gemma":[0.99886405,0.00015904741,0.00026981914,0.00031471872,0.00002733295,0.000028500368,0.00017740678,0.000010551598,0.00014854864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978134,0.0006141562,0.0008161767,0.000507962,0.00004273784,0.00020554624],"domain_scores_gemma":[0.99861765,0.0008329376,0.00018033477,0.00023140674,0.00008961505,0.000048082624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014329796,0.00021381078,0.0007005906,0.000052330357,0.0001348804,0.000009707879,0.00013331357,0.00026302517,0.000116953874],"category_scores_gemma":[0.0001296049,0.00015812513,0.000082023915,0.0001055543,0.0006389615,0.00007000392,0.0002005426,0.0001725977,0.00003093134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018531831,0.0034396427,0.98450166,0.000009685154,0.0009527664,0.000013756871,0.0003458197,1.7396425e-7,0.0002939717,0.00031954338,0.00043587538,0.007833928],"study_design_scores_gemma":[0.013906858,0.00071690104,0.9789993,0.000029952133,0.0003390242,0.000004975258,0.0007404222,0.0000055140486,0.002304748,0.00007035126,0.0027254685,0.00015645492],"about_ca_topic_score_codex":0.00007151204,"about_ca_topic_score_gemma":0.000023995413,"teacher_disagreement_score":0.012053675,"about_ca_system_score_codex":0.000005709141,"about_ca_system_score_gemma":0.000051240822,"threshold_uncertainty_score":0.64481556},"labels":[],"label_agreement":null},{"id":"W4417420457","doi":"10.1186/s13073-025-01561-2","title":"Genetic liability to psoriasis predicts severe disease outcomes","year":2025,"lang":"en","type":"article","venue":"Genome Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; Nexus Clinical Research (Canada); Memorial University of Newfoundland; University Health Network","funders":"Janssen Biotech; Faculty of Medicine and Health, University of Sydney; Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet; Medical School, University of Michigan; National Institutes of Health; King's College London; Business Finland; Norges Forskningsråd; Genentech; King's Health Partners; National Institute for Health and Care Research; Maze Therapeutics; British Association of Dermatologists; Wellcome Trust; Sanofi; Norges Teknisk-Naturvitenskapelige Universitet; Eesti Teadusagentuur; European Federation of Pharmaceutical Industries and Associations; School of Public Health, University of Michigan; Novartis Pharma; European Commission; Norwegian Institute of Public Health; Celgene; Pfizer; Biogen; Helse Midt-Norge; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca","keywords":"Psoriasis; Disease; Epidemiology; Human genetics; Risk stratification; Genetic predisposition; Liability; Severity of illness","score_opus":0.012679283905301408,"score_gpt":0.25149439015395936,"score_spread":0.23881510624865795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417420457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730165,0.010004383,0.0003447296,0.0077130822,0.002885153,0.00077594776,0.00015336178,0.00016769234,0.0049391524],"genre_scores_gemma":[0.97015595,0.00015513295,0.00015660639,0.0018732917,0.00014752778,0.0001396816,0.00015281656,0.000015402831,0.027203556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984985,0.00016360758,0.00036844137,0.0004922254,0.00006393682,0.00041331365],"domain_scores_gemma":[0.99887824,0.0001988358,0.000055403198,0.00067130366,0.000076661,0.00011954711],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023196403,0.0002724437,0.0004883159,0.00022378206,0.00017734208,0.000005759292,0.0003029805,0.00013912095,0.0016408269],"category_scores_gemma":[0.00037481278,0.00019577058,0.000110559085,0.00035843308,0.0001586032,0.000029368612,0.00012357181,0.00011211955,0.0007612653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011646515,0.0005377413,0.80887187,0.0002143561,0.0015799784,0.000074930846,0.0016336599,0.00006245587,0.02351254,0.00067725574,0.02483451,0.13683605],"study_design_scores_gemma":[0.002421612,0.00017172171,0.8804695,0.000050459545,0.0004704268,0.0000044734225,0.00009756069,6.7745e-7,0.0002866684,0.00049286475,0.11537052,0.00016353263],"about_ca_topic_score_codex":0.00008887574,"about_ca_topic_score_gemma":0.000026618816,"teacher_disagreement_score":0.13667251,"about_ca_system_score_codex":0.00009349665,"about_ca_system_score_gemma":0.00010719186,"threshold_uncertainty_score":0.9992718},"labels":[],"label_agreement":null},{"id":"W4417452897","doi":"10.1177/12034754251404475","title":"Predominance of Palmoplantar Psoriasis in Inuit Patients from Ungava Bay, Nunavik","year":2025,"lang":"en","type":"letter","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Nunavik Regional Board of Health and Social Services; Université Laval; McGill University Health Centre; Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Institute of Indigenous Peoples' Health; LEO Fondet","keywords":"Psoriasis; MEDLINE; Sun exposure; Epidemiology; Young adult","score_opus":0.014012885915805346,"score_gpt":0.22616590212779542,"score_spread":0.21215301621199006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417452897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491995,0.020585448,0.0000021523717,0.024621986,0.004617636,0.0001907418,0.00053070683,0.000008025564,0.00024380296],"genre_scores_gemma":[0.8913323,0.032332793,0.00007559765,0.066397786,0.0032866865,0.000013117523,0.0013411404,0.000078074336,0.005142459],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973666,0.00040250097,0.0014337467,0.000286667,0.0001653297,0.00034513665],"domain_scores_gemma":[0.99479526,0.0034498114,0.0012444576,0.00026131127,0.00021711469,0.000032066266],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003785586,0.00038690714,0.00195351,0.00076583494,0.000047631227,0.0000056278413,0.0002282655,0.0009561719,0.00041322422],"category_scores_gemma":[0.0004426173,0.00028107694,0.0002877642,0.00020841858,0.00021518482,0.000059137223,0.00004364222,0.0010523853,0.0000067393808],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012855426,0.00016613025,0.082340844,0.00025652134,0.0011000275,0.004416998,0.001420756,9.425186e-7,0.0005372625,8.4341724e-7,0.8642418,0.044232354],"study_design_scores_gemma":[0.009294144,0.0015788124,0.038342033,0.014461512,0.0041024135,0.00397811,0.00055283244,0.0000012945554,0.0039005212,0.0008169274,0.92189264,0.0010787845],"about_ca_topic_score_codex":0.00055217795,"about_ca_topic_score_gemma":0.00009877242,"teacher_disagreement_score":0.05786716,"about_ca_system_score_codex":0.000094915085,"about_ca_system_score_gemma":0.0003661171,"threshold_uncertainty_score":0.9999641},"labels":[],"label_agreement":null},{"id":"W4417479565","doi":"10.1016/j.jval.2025.09.2561","title":"PCR88 Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Depression (economics); Anxiety; Comorbidity; Disease; Mental health; Psychiatric comorbidity; Dermatological diseases","score_opus":0.03386724474695558,"score_gpt":0.3262418296832556,"score_spread":0.29237458493630003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577093,0.0027613873,0.0000028784527,0.00024822625,0.00043039594,0.0004950941,0.00024596782,0.000010938346,0.000034207824],"genre_scores_gemma":[0.9989613,0.00045026664,0.000031429376,0.00022683915,0.000009722382,0.000040480125,0.00025685155,0.000006915936,0.000016184542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981712,0.0004988402,0.0008524265,0.00021556058,0.000039515184,0.00022243337],"domain_scores_gemma":[0.9987875,0.00045314035,0.00045016457,0.00023735205,0.000040069062,0.000031761465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041737332,0.00012941976,0.0003801676,0.00015999032,0.0001033259,0.000005351998,0.000073101684,0.00007976741,0.00002183191],"category_scores_gemma":[0.00016663897,0.00008493227,0.000052790278,0.00026743818,0.00014098463,0.000047645954,0.000026910684,0.00016763339,0.0000017018519],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006834324,0.00040654998,0.9919949,0.00005084576,0.000083712664,0.000005368404,0.00036549073,0.000016797447,0.0000013778349,0.00028773106,0.00016908879,0.005934711],"study_design_scores_gemma":[0.0026148397,0.0003806635,0.9961664,0.00017444606,0.000036432284,0.0000015162752,0.00020265939,0.000016817858,0.0000064914443,0.00020714395,0.000120698096,0.00007185674],"about_ca_topic_score_codex":0.00055915385,"about_ca_topic_score_gemma":0.00006578438,"teacher_disagreement_score":0.0058628544,"about_ca_system_score_codex":0.000047341833,"about_ca_system_score_gemma":0.00036417088,"threshold_uncertainty_score":0.34634376},"labels":[],"label_agreement":null},{"id":"W4417479800","doi":"10.1016/j.jval.2025.09.1841","title":"HTA56 Beyond the Surface: Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Reimbursement; Health technology; Technology assessment; Risk assessment; MEDLINE","score_opus":0.022669601554001044,"score_gpt":0.3114611157838242,"score_spread":0.28879151422982313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93618435,0.018560411,0.0006796001,0.04222863,0.00025657553,0.0018950686,0.00004475924,0.000074433854,0.00007619395],"genre_scores_gemma":[0.9913111,0.004688168,0.0024854986,0.0007937292,0.0000039684246,0.00031333728,0.000060827853,0.000012281622,0.00033111664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998385,0.0004106277,0.00043291252,0.00032112485,0.00003320999,0.0004171154],"domain_scores_gemma":[0.9989839,0.00056286296,0.00016675319,0.00023402025,0.000025922209,0.000026523127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006484655,0.0001797909,0.0003620478,0.00016812742,0.00055315305,0.000014542564,0.00010462325,0.00014632281,0.000010494945],"category_scores_gemma":[0.000030328045,0.00011042337,0.000023800636,0.00026465327,0.0002935076,0.000035150635,0.000063586944,0.00020286445,0.0000018630436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011109394,0.0009768119,0.6229498,0.0014881003,0.000820997,0.00003169128,0.0027506892,0.00086058275,0.00074132223,0.1933975,0.0029490688,0.17192253],"study_design_scores_gemma":[0.009606096,0.0024932614,0.9420159,0.00050245784,0.00014066759,0.0002686076,0.0075578718,0.00068590406,0.00018621692,0.011588575,0.024532141,0.0004222871],"about_ca_topic_score_codex":0.00039025184,"about_ca_topic_score_gemma":0.0006558678,"teacher_disagreement_score":0.31906617,"about_ca_system_score_codex":0.00014727096,"about_ca_system_score_gemma":0.00068027055,"threshold_uncertainty_score":0.45029342},"labels":[],"label_agreement":null},{"id":"W4417480189","doi":"10.1016/j.jval.2025.09.316","title":"CO215 Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body: Improvements in Patient-Reported Outcomes and Quality of Life","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Probity Medical Research","funders":"","keywords":"Roflumilast; Quality of life (healthcare); Scalp; Psoriasis; Apremilast","score_opus":0.022511249125088943,"score_gpt":0.2719900967506689,"score_spread":0.24947884762557992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973505,0.0014095639,0.0000012580626,0.00018257945,0.0002498482,0.0006989333,0.000060592814,0.0000050600156,0.000041647152],"genre_scores_gemma":[0.9995842,0.00015591712,0.00003272088,0.00013569393,0.0000013680153,0.000026614422,0.000018854736,0.000005808519,0.000038852773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981199,0.00053660007,0.0008169767,0.00024319981,0.000057890735,0.00022544996],"domain_scores_gemma":[0.9990757,0.0002500739,0.0003770172,0.00023653111,0.000040368897,0.000020292267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000512748,0.00013647809,0.0005158899,0.00019659796,0.000042885877,0.0000025502163,0.00007897874,0.0001163641,0.0000040007176],"category_scores_gemma":[0.00022503569,0.00009260959,0.000031276144,0.00032153973,0.00011671362,0.00004220441,0.000080411555,0.00011585424,3.00852e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005352671,0.00049376296,0.9868246,0.00015783157,0.00009208561,3.7791864e-7,0.0006465198,0.000008201878,0.00031010737,0.00014631823,0.000011648716,0.010773296],"study_design_scores_gemma":[0.0073488546,0.0002799863,0.9906335,0.00019481711,0.000015970105,1.9160568e-7,0.00021515157,0.0000034899235,0.001122784,0.000084991414,0.00003188693,0.00006835984],"about_ca_topic_score_codex":0.012362301,"about_ca_topic_score_gemma":0.0013219177,"teacher_disagreement_score":0.011040384,"about_ca_system_score_codex":0.00006824632,"about_ca_system_score_gemma":0.00019202745,"threshold_uncertainty_score":0.9942145},"labels":[],"label_agreement":null},{"id":"W4417480624","doi":"10.1016/j.jval.2025.09.3438","title":"MSR155 New Developments in the Psychometric Testing of the Patient-Reported Impact of Dermatological Diseases (PRIDD) Questionnaire: Responsiveness and Minimally Important Change","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Reliability (semiconductor); Psychometric testing; Dermatological diseases; Measure (data warehouse); Test (biology); Selection (genetic algorithm)","score_opus":0.06838099945994429,"score_gpt":0.31892377081317025,"score_spread":0.25054277135322595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790849,0.019666813,0.0000023212046,0.0004095944,0.00020502749,0.0005705228,0.000031927844,0.000008727007,0.000020160447],"genre_scores_gemma":[0.9992389,0.00043655216,0.00011486135,0.0001369423,0.000004600476,0.000039869876,0.000013018047,0.000004146857,0.00001110594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803054,0.0008231052,0.0006673978,0.00019417077,0.000052381547,0.00023242089],"domain_scores_gemma":[0.99869585,0.00064824213,0.00037902358,0.00021074775,0.00004487127,0.000021257662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048445546,0.00012818721,0.00032024333,0.00030937523,0.000082232735,0.0000038865373,0.00015663895,0.00010047108,0.0000036528168],"category_scores_gemma":[0.0010452758,0.000071134105,0.00006074063,0.0013365473,0.0000824052,0.000034170724,0.000054027358,0.00010366258,5.2362475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028395062,0.00023523817,0.9733398,0.00007552692,0.000058410056,0.000008948204,0.0008611138,0.000007809492,0.0005842547,0.00009130044,0.000054087828,0.024399573],"study_design_scores_gemma":[0.0010077143,0.00019208071,0.99738765,0.00045876892,0.000025220055,0.0000523253,0.00009782583,0.000006298911,0.00040677717,0.00026292272,0.00004540095,0.000057009205],"about_ca_topic_score_codex":0.003639305,"about_ca_topic_score_gemma":0.0000933245,"teacher_disagreement_score":0.024342563,"about_ca_system_score_codex":0.00008540217,"about_ca_system_score_gemma":0.00076803507,"threshold_uncertainty_score":0.5501565},"labels":[],"label_agreement":null},{"id":"W4417524860","doi":"10.1111/ijd.70223","title":"Medical Phototherapy Malpractice and Legal Precedents in North America (1983–2025)","year":2025,"lang":"en","type":"article","venue":"International Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; McGill University","funders":"","keywords":"Malpractice; Cornerstone; Medical malpractice; Delegation; Licensure; Inclusion (mineral); Patient advocacy; Relevance (law)","score_opus":0.009000515059193366,"score_gpt":0.29106699581843704,"score_spread":0.2820664807592437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417524860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793532,0.0034030818,0.00023316752,0.012213448,0.0025814904,0.000062045976,0.0000070905357,0.000007761577,0.0021387036],"genre_scores_gemma":[0.99641865,0.001854784,0.00012058298,0.0008295264,0.000038263825,0.0000051949323,0.000016037267,0.0000048605416,0.0007120996],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898857,0.00021799534,0.0004368711,0.00012072392,0.00008641014,0.00014940203],"domain_scores_gemma":[0.9992049,0.00033214258,0.00023529875,0.000066451976,0.00013613753,0.000025087027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000068143745,0.00010480019,0.00027045535,0.0003521127,0.000031883435,0.00001651628,0.0003255781,0.00015642258,0.0003832042],"category_scores_gemma":[0.00019936418,0.00008834237,0.000065810134,0.000115300354,0.00011554964,0.00015379295,0.000059149745,0.00025865133,0.00003965815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032367532,0.0010009874,0.78652066,0.000020220323,0.0030868514,0.007956791,0.0006492059,0.000006954641,0.0060567777,0.0030950499,0.0054246187,0.18294512],"study_design_scores_gemma":[0.016928015,0.00026666318,0.29487595,0.0002254348,0.00021897796,0.06450637,0.0005772482,0.00004303349,0.015454816,0.00059078255,0.6059766,0.0003361515],"about_ca_topic_score_codex":0.00006071659,"about_ca_topic_score_gemma":0.00024009083,"teacher_disagreement_score":0.60055196,"about_ca_system_score_codex":0.000045155215,"about_ca_system_score_gemma":0.00020687179,"threshold_uncertainty_score":0.41958174},"labels":[],"label_agreement":null},{"id":"W4417539245","doi":"10.1172/jci.insight.193563","title":"Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis","year":2025,"lang":"en","type":"article","venue":"JCI Insight","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Johnson and Johnson","keywords":"Pharmacodynamics; Psoriasis; Placebo; Inflammation; S100A8; Psoriasis Area and Severity Index; Receptor; Transcriptome","score_opus":0.012817402481136499,"score_gpt":0.2700984760454655,"score_spread":0.257281073564329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417539245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977739,0.00048452883,0.000008659545,0.000049528182,0.00025448258,0.0009169241,0.00008513981,0.00003126284,0.00039561387],"genre_scores_gemma":[0.9984908,0.000028314404,0.000022483187,0.000059030044,0.000007757939,0.00010042552,0.00005378737,0.000014100738,0.0012232962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986602,0.00033769006,0.0003217133,0.0003668704,0.000052535353,0.0002609911],"domain_scores_gemma":[0.99936175,0.00016947009,0.00009675551,0.00022977726,0.00011602172,0.00002624629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010611184,0.00022845659,0.0004118072,0.0005091477,0.00012329932,0.000016857843,0.00014019386,0.00013775202,0.000047093246],"category_scores_gemma":[0.000043322747,0.00017570742,0.000031128973,0.00048172043,0.000058891597,0.00013009243,0.00008276797,0.0001353337,0.0000093287845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081674576,0.016170355,0.7233104,0.000098499666,0.0023524906,0.00009300357,0.02098384,0.000050972594,0.093285196,0.00038483055,0.0003119328,0.061283913],"study_design_scores_gemma":[0.05909783,0.0043296623,0.89309496,0.00009083132,0.00043585186,0.0000019182928,0.0019666145,0.000008024803,0.039618842,0.000057916623,0.00090065756,0.00039691923],"about_ca_topic_score_codex":0.00019543363,"about_ca_topic_score_gemma":0.00018193175,"teacher_disagreement_score":0.16978453,"about_ca_system_score_codex":0.000054565317,"about_ca_system_score_gemma":0.000084743224,"threshold_uncertainty_score":0.71651405},"labels":[],"label_agreement":null},{"id":"W48128272","doi":"10.2165/00128071-200607040-00006","title":"The Role of Antimalarials in the Exacerbation of Psoriasis","year":2006,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Psoriasis; Exacerbation; Pharmacotherapy; Dermatology; Intensive care medicine; Immunology; Internal medicine","score_opus":0.04442707188023524,"score_gpt":0.37156793728451737,"score_spread":0.3271408654042821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48128272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00979927,0.98812807,0.000011607898,0.00021942823,0.0010418,0.00027317807,0.000036302445,0.0000031378613,0.0004872316],"genre_scores_gemma":[0.053929854,0.94573545,0.0000896295,0.00003151687,0.00012682896,0.000012293166,0.000030236606,0.000017383793,0.000026820997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98923105,0.006058827,0.004137261,0.00019123532,0.00009742046,0.00028417754],"domain_scores_gemma":[0.98223627,0.010666292,0.006479391,0.00042623805,0.00017143728,0.0000203504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002515484,0.00027822226,0.0039353515,0.0002142698,0.00006893559,0.000006508067,0.0008849315,0.0004713547,0.000023913524],"category_scores_gemma":[0.000925957,0.00013604295,0.0013067409,0.00039805804,0.0012732961,0.00004289527,0.000056110443,0.0006738153,0.000020835594],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016349541,0.00027741122,0.0026882386,0.0001550814,0.0009093349,0.000021292522,0.00006166756,4.912493e-7,0.0000074519335,0.0007352249,0.00052885525,0.99445146],"study_design_scores_gemma":[0.0009672733,0.0006171769,0.0021352526,0.0007257889,0.001896489,0.0012201364,0.0003428731,2.1226153e-7,0.00007866329,0.00026528706,0.9916228,0.0001280175],"about_ca_topic_score_codex":0.00008950165,"about_ca_topic_score_gemma":0.000024893272,"teacher_disagreement_score":0.99432343,"about_ca_system_score_codex":0.000015311809,"about_ca_system_score_gemma":0.00048909674,"threshold_uncertainty_score":0.5547671},"labels":[],"label_agreement":null},{"id":"W57200028","doi":"10.2310/7750.2013.13059","title":"Efficacy of Topical Calcineurin Inhibitors in Psoriasis","year":2014,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Astellas Pharma","keywords":"Pimecrolimus; Calcineurin; Medicine; Psoriasis; Tacrolimus; Dermatology; Intertriginous; Atopic dermatitis; Surgery; Internal medicine; Transplantation; Disease","score_opus":0.04264389161723615,"score_gpt":0.305402320997544,"score_spread":0.26275842938030786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W57200028","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0301439,0.9674103,0.0000026499085,0.00009864737,0.0020196328,0.00014692903,0.0000055436612,0.000005601765,0.00016676937],"genre_scores_gemma":[0.0063734637,0.9926257,0.000008977155,0.000033634176,0.0006233728,0.0000030266342,0.000024441179,0.000023187891,0.0002841665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99700636,0.00058046775,0.0018573434,0.00020003607,0.00009841276,0.0002573578],"domain_scores_gemma":[0.99449694,0.003975617,0.0011930632,0.0001964954,0.00007589993,0.00006198959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076840824,0.00034186972,0.0037122113,0.0007730317,0.000032817265,0.0000031971222,0.00015088408,0.00050842145,0.00011873436],"category_scores_gemma":[0.0008033158,0.00020837432,0.0006263762,0.00024316765,0.00020560165,0.000027883421,0.000031452088,0.00047411837,0.000009472609],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018439496,0.00013242432,0.00064329174,0.0021301166,0.00047187327,0.0007969956,0.00023622956,1.6831929e-7,0.000039939627,0.000014941808,0.004009089,0.9913405],"study_design_scores_gemma":[0.0010923363,0.00046971746,0.0001734758,0.015032612,0.001682156,0.010702063,0.00007570427,5.8737147e-8,0.000048341677,0.000016875896,0.9705105,0.0001961998],"about_ca_topic_score_codex":0.000059930928,"about_ca_topic_score_gemma":0.000015740146,"teacher_disagreement_score":0.99114436,"about_ca_system_score_codex":0.000047334983,"about_ca_system_score_gemma":0.00024203389,"threshold_uncertainty_score":0.8497258},"labels":[],"label_agreement":null},{"id":"W649722205","doi":"10.71781/28928","title":"Caractérisation d'une nouvelle cytokine composite formée de CLF et de la sous-unité p28 de l'IL-27","year":2007,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Molecular biology; Biology","score_opus":0.005967762789336881,"score_gpt":0.20690448015322777,"score_spread":0.20093671736389088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W649722205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383901,0.01940165,0.0019039293,0.00028390792,0.001636832,0.00049009715,0.0004186548,0.00016098286,0.03731384],"genre_scores_gemma":[0.9391504,0.0034958322,0.0016936823,0.0002878955,0.00025579025,0.000039644317,0.0041301586,0.00006979349,0.050876804],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963818,0.0010288385,0.0005957902,0.0007157914,0.00023729354,0.0010404636],"domain_scores_gemma":[0.9976704,0.0006785838,0.00062917225,0.0004487639,0.00028729558,0.00028578096],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00084598165,0.00075027294,0.00068586384,0.00053500145,0.005977532,0.00006869144,0.00049350166,0.0019643758,0.00012047613],"category_scores_gemma":[0.000081564496,0.0008880104,0.000560579,0.0004393012,0.0005168099,0.00036084463,0.00013931144,0.0009363744,0.0002078946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063544256,0.0012934889,0.122145325,0.000309608,0.0027758917,0.0043514594,0.09180043,0.0035928623,0.7304082,0.017981974,0.0017510965,0.017235225],"study_design_scores_gemma":[0.0063624787,0.0005200309,0.5253523,0.00060431426,0.0030266151,0.006808512,0.041858558,0.00046768738,0.29437342,0.0005562694,0.11857066,0.0014991295],"about_ca_topic_score_codex":0.08698214,"about_ca_topic_score_gemma":0.01744941,"teacher_disagreement_score":0.4360348,"about_ca_system_score_codex":0.008746368,"about_ca_system_score_gemma":0.003445799,"threshold_uncertainty_score":0.99935704},"labels":[],"label_agreement":null},{"id":"W6888998214","doi":"10.25384/sage.6269429","title":"Supplemental Material, PROPEL_Manuscript_Supplementary_File_3 – Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys","year":2018,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Alternative medicine; MEDLINE; New england","score_opus":0.0492316871027142,"score_gpt":0.26204201794078114,"score_spread":0.21281033083806694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6888998214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463145,0.005230356,0.0000075632397,0.00068607694,0.0029703435,0.0007686278,0.04357867,0.000019668074,0.00042420608],"genre_scores_gemma":[0.9689175,0.0007698658,0.00012509612,0.0002669285,0.00045832866,0.000042393553,0.029229585,0.000018760036,0.00017152878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704516,0.0012838588,0.00051425153,0.0005205463,0.00010822206,0.0005279838],"domain_scores_gemma":[0.99868435,0.00009827805,0.0001454359,0.000906075,0.00008636254,0.000079524456],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004567989,0.00026908406,0.00030936796,0.00012612931,0.00048621223,0.00013490932,0.0013090684,0.00016942798,0.031428352],"category_scores_gemma":[0.00006629449,0.000167679,0.00004886294,0.0001803089,0.00017561475,0.00044539294,0.00043829752,0.00022883817,0.00038838945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001835622,0.00024989902,0.6578089,0.000009149877,0.00045148292,0.000033128155,0.0030605597,6.827262e-8,0.0031782214,0.000006570071,0.049059793,0.28595865],"study_design_scores_gemma":[0.0026448593,0.00036409413,0.8346544,0.0001546737,0.00014549885,0.0000069435573,0.0017483555,7.7947686e-7,0.009185559,0.00011450212,0.15068738,0.0002929618],"about_ca_topic_score_codex":0.24148273,"about_ca_topic_score_gemma":0.70596474,"teacher_disagreement_score":0.464482,"about_ca_system_score_codex":0.00014523992,"about_ca_system_score_gemma":0.00023994321,"threshold_uncertainty_score":0.96945703},"labels":[],"label_agreement":null},{"id":"W6893078417","doi":"10.5281/zenodo.13028844","title":"inclusive education in canada","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Inclusion (mineral); Work (physics); Curriculum; Higher education; Government (linguistics)","score_opus":0.013671196025313703,"score_gpt":0.23387272353814975,"score_spread":0.22020152751283606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893078417","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007361794,0.0061777933,0.000009938186,0.00025574185,0.0010636154,0.0004084291,0.0007836877,0.00038750962,0.9901771],"genre_scores_gemma":[0.032285463,0.00058219855,0.00002869961,0.00015091007,0.00021903579,1.7351338e-7,0.010907649,0.006302432,0.94952345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99887973,0.00025523728,0.00016618214,0.0003730763,0.00006306427,0.00026272665],"domain_scores_gemma":[0.99949294,0.000010489917,0.00008271903,0.00030351346,0.000076006676,0.000034324992],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013135101,0.0001735648,0.00018456294,0.0003717107,0.0002876677,0.00008276553,0.00048147506,0.00016237501,0.05901563],"category_scores_gemma":[0.00007749867,0.00017517278,0.000035696045,0.00028692573,0.00005518829,0.000029945712,0.0005121767,0.000253031,0.03764852],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016908783,0.00005285858,0.0000026131345,0.000060028487,0.00009720887,0.000014083101,0.00016338931,3.634177e-7,0.00038389178,0.00047608995,0.82492286,0.17380969],"study_design_scores_gemma":[0.00031084873,0.00003654741,0.00012068922,0.00014258343,0.000038363327,0.000058641344,0.00029895437,5.4978864e-7,0.0001752163,0.00006470583,0.99858797,0.00016493486],"about_ca_topic_score_codex":0.19112742,"about_ca_topic_score_gemma":0.03639926,"teacher_disagreement_score":0.17366509,"about_ca_system_score_codex":0.00064024184,"about_ca_system_score_gemma":0.00012299094,"threshold_uncertainty_score":0.98118395},"labels":[],"label_agreement":null},{"id":"W6901931951","doi":"10.6084/m9.figshare.21213405.v1","title":"Additional file 3 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; Adverse effect; MEDLINE; Psoriasis Area and Severity Index; Systematic review","score_opus":0.03312777320106693,"score_gpt":0.24359043375636424,"score_spread":0.2104626605552973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901931951","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000753816,0.18174528,1.3257804e-8,0.00003144866,0.000006078896,0.0006807455,0.8167352,0.0000031902164,0.00004422303],"genre_scores_gemma":[0.118129395,0.004635872,0.0000555061,0.00008468216,0.000010466708,0.0072921314,0.86928314,0.00001491568,0.0004938991],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986315,0.000531901,0.0004936761,0.00018520461,0.000061316205,0.00009644379],"domain_scores_gemma":[0.9970409,0.0023112649,0.0003828213,0.00021362398,0.000040035393,0.000011305735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107555534,0.00014339953,0.001239763,0.0001288788,0.00007684424,0.000003087691,0.00007893223,0.000049807102,0.72241825],"category_scores_gemma":[0.00043205827,0.000091527734,0.00027186165,0.00033636566,0.000029749304,0.000027990161,0.000044503842,0.000044702752,0.000010328519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021391847,0.0016118393,0.000030465571,0.050363522,0.1249614,0.000018749704,0.0033967167,0.000007955411,0.000048946196,0.000035654743,0.81406343,0.005247379],"study_design_scores_gemma":[0.011200505,0.0050218017,0.019469643,0.028976101,0.73344696,0.00034556887,0.003575947,0.000012102763,0.0011637531,0.000102082624,0.19558437,0.0011011469],"about_ca_topic_score_codex":0.000016266384,"about_ca_topic_score_gemma":0.000029845474,"teacher_disagreement_score":0.72240794,"about_ca_system_score_codex":0.000014770287,"about_ca_system_score_gemma":0.000025335183,"threshold_uncertainty_score":0.37323928},"labels":[],"label_agreement":null},{"id":"W6902078021","doi":"10.6084/m9.figshare.21213408.v1","title":"Additional file 4 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Rheumatology; Clinical trial; Funnel plot; MEDLINE","score_opus":0.03335381116452071,"score_gpt":0.24392920008810992,"score_spread":0.2105753889235892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902078021","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000750578,0.18217903,1.3330071e-8,0.00003139227,0.0000060295683,0.0006811488,0.8163045,0.0000031934976,0.00004411327],"genre_scores_gemma":[0.12034429,0.004622947,0.000055404485,0.00008452776,0.000010344517,0.00727229,0.86711794,0.000014870831,0.00047735867],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99863136,0.00053183915,0.00049383315,0.00018522108,0.00006131278,0.00009645352],"domain_scores_gemma":[0.99703753,0.0023151909,0.0003828749,0.00021372216,0.000039373237,0.000011306144],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010763231,0.00014340841,0.001240023,0.00012893211,0.00007687824,0.0000030891517,0.00007898385,0.000049810846,0.719399],"category_scores_gemma":[0.00042668628,0.000091543196,0.00027188036,0.00033632747,0.000029754056,0.0000279938,0.00004451893,0.000044701523,0.00001014084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021743747,0.001624079,0.000030744115,0.0503717,0.12585448,0.000018941999,0.0034240452,0.000007912807,0.00004862362,0.0000370701,0.81308377,0.0052812053],"study_design_scores_gemma":[0.011186134,0.00510925,0.019596204,0.029102672,0.7397865,0.00034953922,0.0035936537,0.000012167334,0.0011450305,0.000103234655,0.18891175,0.0011038318],"about_ca_topic_score_codex":0.00001613793,"about_ca_topic_score_gemma":0.000029954303,"teacher_disagreement_score":0.71938884,"about_ca_system_score_codex":0.000014719748,"about_ca_system_score_gemma":0.00002525075,"threshold_uncertainty_score":0.3733023},"labels":[],"label_agreement":null},{"id":"W6902193390","doi":"10.6084/m9.figshare.14903805","title":"Additional file 1 of Is there a relationship between psoriasis and hepatitis C? A meta-analysis and bioinformatics investigation","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Hepatitis C; Hepatitis; Scale (ratio); MEDLINE","score_opus":0.09400553198284621,"score_gpt":0.2559643101166442,"score_spread":0.161958778133798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902193390","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034329467,0.0019832146,0.0000010316973,0.00007463777,0.000006345618,0.00007107343,0.99397427,0.000016117212,0.00044038196],"genre_scores_gemma":[0.03772495,0.000011316645,0.0013025852,0.000068277805,0.00001298865,0.00026242272,0.9588964,0.0000060430098,0.0017150283],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99937695,0.000104765124,0.00022640478,0.00015546264,0.000039124967,0.000097289325],"domain_scores_gemma":[0.9971242,0.002413596,0.00017256053,0.00015295071,0.000112188565,0.000024482413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000026010857,0.000114687056,0.00036574894,0.00011039136,0.00011353121,0.00001677724,0.000043259188,0.00016139675,0.9670489],"category_scores_gemma":[0.0011408835,0.00009836616,0.0002183813,0.0003469113,0.000025106734,0.00011108649,0.000050435217,0.000068037756,0.00051104685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000024655576,0.000009303049,0.008204996,0.000052977903,0.0160531,0.0000015215473,0.00026273905,1.5105289e-7,0.0000065758854,0.0000073875603,0.9737416,0.001657217],"study_design_scores_gemma":[0.00034785582,0.000046327626,0.8107981,0.0001221094,0.0296383,0.000015326212,0.000111153415,0.000012689916,0.0026105265,0.00030744943,0.15578312,0.00020704842],"about_ca_topic_score_codex":0.000016730579,"about_ca_topic_score_gemma":0.00006179371,"teacher_disagreement_score":0.96653783,"about_ca_system_score_codex":0.000007906284,"about_ca_system_score_gemma":0.000058429472,"threshold_uncertainty_score":0.6568644},"labels":[],"label_agreement":null},{"id":"W6907747433","doi":"10.25384/sage.21637917.v1","title":"Table S1 - Supplemental material for Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Phase (matter); Clinical trial; Randomized controlled trial; Phases of clinical research","score_opus":0.035455857461962365,"score_gpt":0.2667180342736325,"score_spread":0.23126217681167013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907747433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55757403,0.00008964667,1.8817353e-7,0.000048319314,0.00024899386,0.0014685218,0.44044384,0.0000044052153,0.00012203427],"genre_scores_gemma":[0.742194,0.0000051086013,0.000009344309,0.000016323584,0.00004041181,0.0024186494,0.25508484,0.000007886283,0.00022341897],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988554,0.00020498053,0.00034403123,0.00022679423,0.000059179685,0.000309595],"domain_scores_gemma":[0.999418,0.00011389423,0.00018087435,0.00020839238,0.000057348036,0.000021497934],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006766773,0.0001504387,0.00035457037,0.00022933484,0.00017808503,0.0000071448812,0.00021898006,0.00007840293,0.083338834],"category_scores_gemma":[0.00005648749,0.000110519606,0.0001745766,0.00030387487,0.000014524481,0.000046375422,0.000034974626,0.00004893975,0.00001807173],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2606005,0.029073143,0.017271947,0.0003264153,0.008799798,0.00013897005,0.02362387,0.000074781776,0.0065404247,0.0005390038,0.5374708,0.11554031],"study_design_scores_gemma":[0.43335164,0.017458506,0.013633156,0.00012018019,0.001212578,0.000017425009,0.0045145545,0.000019734294,0.15638584,0.00005875246,0.37257528,0.0006523822],"about_ca_topic_score_codex":0.01730303,"about_ca_topic_score_gemma":0.027579783,"teacher_disagreement_score":0.185359,"about_ca_system_score_codex":0.00018587883,"about_ca_system_score_gemma":0.00017446071,"threshold_uncertainty_score":0.99016434},"labels":[],"label_agreement":null},{"id":"W6907794718","doi":"10.25384/sage.21637917","title":"Table S1 - Supplemental material for Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial","year":2022,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Phase (matter); Clinical trial; Randomized controlled trial; Phases of clinical research","score_opus":0.04939179670754684,"score_gpt":0.304208136136497,"score_spread":0.25481633942895016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907794718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932027,0.0013358885,0.000026204918,0.00026389564,0.00083359086,0.0014143381,0.064046666,0.0000033493448,0.00004908698],"genre_scores_gemma":[0.98457074,0.00078417425,0.00007335261,0.000030113033,0.000099236866,0.00032993976,0.013900671,0.000011060152,0.00020071893],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981945,0.0004619401,0.0005974378,0.00028238696,0.00009598591,0.00036774867],"domain_scores_gemma":[0.99890214,0.00013238538,0.00034252647,0.0005420686,0.000047832014,0.00003307049],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054638565,0.00016472682,0.00047605936,0.00034154236,0.0002682754,0.0000162604,0.0006028239,0.0000725879,0.005994433],"category_scores_gemma":[0.000048143098,0.00011461014,0.00013898568,0.00036941108,0.000054708,0.00013994804,0.00010299486,0.0000902286,0.0000025837776],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21727818,0.026100015,0.06979027,0.00007056476,0.012021251,0.00019630388,0.013560671,0.00003364897,0.022953335,0.00015789701,0.035953883,0.60188395],"study_design_scores_gemma":[0.69106305,0.019936103,0.029806027,0.00015710421,0.0053415373,0.000118061194,0.014080749,0.000054103348,0.1039723,0.0003036694,0.13426019,0.00090711133],"about_ca_topic_score_codex":0.043341517,"about_ca_topic_score_gemma":0.051661264,"teacher_disagreement_score":0.6009769,"about_ca_system_score_codex":0.00017236605,"about_ca_system_score_gemma":0.00022433567,"threshold_uncertainty_score":0.99491423},"labels":[],"label_agreement":null},{"id":"W6907815510","doi":"10.25384/sage.23936488.v1","title":"Supplementary material - Supplemental material for Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Baseline (sea); Longitudinal study; Longitudinal data; Patient registry","score_opus":0.03309775399995401,"score_gpt":0.2704184383989424,"score_spread":0.2373206843989884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907815510","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45427904,0.000006585132,6.499922e-8,0.0001188626,0.00035157063,0.00037572216,0.5448429,0.000007465773,0.000017757366],"genre_scores_gemma":[0.49558744,0.000010350922,0.000030969975,0.000035462555,0.00007394799,0.0002591995,0.50396204,0.000009706403,0.000030895386],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9988653,0.00013233296,0.00032931392,0.00024484663,0.000052618285,0.00037559067],"domain_scores_gemma":[0.99945027,0.00014185792,0.00012424521,0.00019722382,0.00005561645,0.000030782314],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018900498,0.000175174,0.00023811014,0.00024882136,0.00015469537,0.000035438374,0.0002025175,0.00013083128,0.095567554],"category_scores_gemma":[0.00007322099,0.000141042,0.000058512014,0.0001953044,0.000017810635,0.000057742305,0.00007526254,0.00006556856,0.000047193917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005273544,0.00023396124,0.14548293,0.00028677448,0.00024122719,0.000041333198,0.00046383333,2.6258897e-7,0.0033987402,0.00003566302,0.8412763,0.008011656],"study_design_scores_gemma":[0.0030089854,0.00033178696,0.8018122,0.00015398522,0.00009754825,0.000010357584,0.00030291072,0.0000040685313,0.009423998,0.000011731017,0.18462643,0.00021602082],"about_ca_topic_score_codex":0.00831891,"about_ca_topic_score_gemma":0.018236812,"teacher_disagreement_score":0.6566498,"about_ca_system_score_codex":0.00006495478,"about_ca_system_score_gemma":0.00010395042,"threshold_uncertainty_score":0.99967784},"labels":[],"label_agreement":null},{"id":"W6920818354","doi":"10.6084/m9.figshare.21213396","title":"Additional file 1 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; Table (database); Disease; MEDLINE; Safety profile","score_opus":0.03365386989534743,"score_gpt":0.24391347036419583,"score_spread":0.2102596004688484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920818354","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007490163,0.18111089,1.3192688e-8,0.000031583666,0.0000060283887,0.0006808235,0.81737447,0.0000031941486,0.000043996446],"genre_scores_gemma":[0.11607756,0.004540545,0.000055633733,0.000084050414,0.000010276511,0.0073542,0.8713814,0.000014795131,0.00048152078],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986311,0.00053235464,0.0004934804,0.00018527597,0.00006130502,0.0000964502],"domain_scores_gemma":[0.9970228,0.0023294892,0.00038276194,0.00021390532,0.000039724084,0.000011306416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107598775,0.00014341745,0.0012396508,0.00012891699,0.000076850105,0.0000030820745,0.0000789763,0.00004981086,0.7268291],"category_scores_gemma":[0.00043216118,0.000091548434,0.00027187704,0.00033647637,0.000029747427,0.000027971068,0.0000445324,0.00004471086,0.000010229343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020715203,0.0015698326,0.000029623337,0.048304047,0.121740244,0.000018060226,0.003306642,0.000007742622,0.00004754488,0.000034904566,0.81969154,0.005042691],"study_design_scores_gemma":[0.011038751,0.005016241,0.01952839,0.0289625,0.7373318,0.00034763836,0.003582637,0.000012057299,0.0011391143,0.00010157963,0.19184084,0.0010984557],"about_ca_topic_score_codex":0.000016104319,"about_ca_topic_score_gemma":0.000029666702,"teacher_disagreement_score":0.7268189,"about_ca_system_score_codex":0.000014718492,"about_ca_system_score_gemma":0.00002532276,"threshold_uncertainty_score":0.37332368},"labels":[],"label_agreement":null},{"id":"W6920979346","doi":"10.6084/m9.figshare.21213402.v1","title":"Additional file 2 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; MEDLINE; Disease; Systematic review; Table (database)","score_opus":0.032641922512182724,"score_gpt":0.24345831430751305,"score_spread":0.21081639179533032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920979346","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007435524,0.18285967,1.2925418e-8,0.000031396805,0.000006050937,0.000678823,0.81563246,0.0000031890731,0.000044814475],"genre_scores_gemma":[0.11440687,0.0046423655,0.00005451996,0.00008399655,0.000010403058,0.0072253975,0.8730791,0.000014766754,0.00048258473],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99863124,0.0005321967,0.0004936755,0.0001851541,0.00006129162,0.00009641908],"domain_scores_gemma":[0.99705166,0.002300626,0.00038324035,0.00021354845,0.00003964719,0.000011305186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010708214,0.00014337734,0.0012399174,0.00012884277,0.00007685506,0.0000030879555,0.00007893765,0.000049811115,0.7234956],"category_scores_gemma":[0.00042757322,0.000091522124,0.00027183082,0.00033624645,0.000029747067,0.00002798792,0.000044526892,0.00004470181,0.00001013332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020829521,0.0015856366,0.000029093988,0.04919079,0.12300298,0.000018685665,0.003343367,0.000007855861,0.000046571666,0.00003581117,0.81731105,0.005219845],"study_design_scores_gemma":[0.011066081,0.0049993317,0.019184213,0.028547771,0.73245645,0.00034709118,0.0035379797,0.000011944239,0.0011288971,0.00010193057,0.19752575,0.0010925714],"about_ca_topic_score_codex":0.00001624693,"about_ca_topic_score_gemma":0.00002982103,"teacher_disagreement_score":0.72348547,"about_ca_system_score_codex":0.0000147222,"about_ca_system_score_gemma":0.000025223646,"threshold_uncertainty_score":0.3732164},"labels":[],"label_agreement":null},{"id":"W6921066252","doi":"10.6084/m9.figshare.22607563.v1","title":"Additional file 1 of Combination of IL-17A/F and TNF-α uniquely alters the bronchial epithelial cell proteome to enhance proteins that augment neutrophil migration","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital Research Institute of Manitoba; University of Manitoba","funders":"","keywords":"Augment; Proteome; Epithelium; Cell; Transcriptome; Cell culture","score_opus":0.019130057710281433,"score_gpt":0.22715201986181566,"score_spread":0.20802196215153423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921066252","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07698928,0.000047301557,5.7796683e-7,0.0002255354,0.00004363924,0.0008125882,0.9217072,0.000028576265,0.00014530422],"genre_scores_gemma":[0.19666411,0.0000060166553,0.00007476331,0.000043458094,0.00002672342,0.0027531956,0.798702,0.000010757399,0.0017189834],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993683,0.00010638502,0.0001559331,0.00017157532,0.000056036497,0.00014175559],"domain_scores_gemma":[0.99926996,0.00034071773,0.00016006223,0.00013836788,0.000075439275,0.000015441794],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00003674642,0.00011062601,0.00013691882,0.00007658353,0.00010125184,0.000006809776,0.000113102345,0.00009636482,0.4742722],"category_scores_gemma":[0.00015939049,0.00008432224,0.00005669614,0.00015560228,0.000023243221,0.00005762956,0.000058854086,0.00006356295,0.0008023957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009122325,0.00007917233,0.000005021344,0.00006775842,0.00003883071,0.0000010004911,0.00028299825,0.0000049566397,0.076613046,0.00000743145,0.9179507,0.0048578787],"study_design_scores_gemma":[0.0004829522,0.00049333234,0.019628948,0.0005774261,0.000020851274,0.0000031771917,0.00007800903,0.000009263401,0.6742345,0.00007488823,0.30426645,0.00013016544],"about_ca_topic_score_codex":0.000020048785,"about_ca_topic_score_gemma":0.000035406214,"teacher_disagreement_score":0.61368424,"about_ca_system_score_codex":0.000019975576,"about_ca_system_score_gemma":0.000057946436,"threshold_uncertainty_score":0.9999756},"labels":[],"label_agreement":null},{"id":"W6927423988","doi":"10.3205/18dgrh176","title":"5 years of Secukinumab – high sustained efficacy and favorable safety in psoriasis patients with psoriatic arthritis at baseline","year":2019,"lang":"en","type":"article","venue":"German Medical Science (German Research Foundation)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"XLV Diagnostics (Canada); Probity Medical Research; Innovaderm (Canada)","funders":"","keywords":"Secukinumab; Psoriatic arthritis; Psoriasis; Monoclonal antibody; Arthritis; Adverse effect; Clinical trial","score_opus":0.013144099965031221,"score_gpt":0.30246002887089424,"score_spread":0.289315928905863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6927423988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791205,0.00019840882,0.000019362515,0.00038856405,0.00032134535,0.00071493664,0.0000239679,0.000024168567,0.0003971805],"genre_scores_gemma":[0.9982937,0.00028369622,0.00009400413,0.000045000532,0.00003465952,0.000030267132,0.0002949518,0.000013979284,0.0009097328],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966964,0.0005614166,0.00046569292,0.0006041119,0.0008561764,0.0008161914],"domain_scores_gemma":[0.9980235,0.0008730283,0.00012474683,0.0004319411,0.00037418905,0.00017258455],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038502784,0.00016941031,0.00037759868,0.0005438384,0.00037258814,0.000042196796,0.000485214,0.00017518277,0.0041218232],"category_scores_gemma":[0.001021422,0.00014026895,0.000040265586,0.0013271364,0.0015010256,0.0003886025,0.00032518312,0.00034795492,0.00074369187],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023567346,0.0011695136,0.09095649,0.00012738438,0.00016687001,0.000065704044,0.002087131,0.000009342967,0.0046716575,0.007592271,0.00042285616,0.89037406],"study_design_scores_gemma":[0.017458169,0.00097567297,0.9685192,0.00029883106,0.000030646454,0.00001957357,0.00019583432,0.00008927689,0.002250773,0.0006040287,0.009213062,0.00034489264],"about_ca_topic_score_codex":0.0002842642,"about_ca_topic_score_gemma":0.0003012649,"teacher_disagreement_score":0.89002913,"about_ca_system_score_codex":0.0003028985,"about_ca_system_score_gemma":0.0006627341,"threshold_uncertainty_score":0.99678856},"labels":[],"label_agreement":null},{"id":"W6928864489","doi":"10.3897/zookeys.186.2947.maps41-44","title":"Maps 41-44 from: Brunke A, Klimaszewski J, Dorval J, Bourdon C, Paiero S, Marshall S (2012) New species and distributional records of Aleocharinae (Coleoptera, Staphylinidae) from Ontario, Canada, with a checklist of recorded species. ZooKeys 186: 119-206. https://doi.org/10.3897/zookeys.186.2947","year":2012,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Checklist; Distribution (mathematics); Pace; Fauna; Taxonomy (biology)","score_opus":0.023470815852185696,"score_gpt":0.2019457866448087,"score_spread":0.178474970792623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928864489","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13332328,0.0042991363,0.00021399005,0.00026603183,0.00081254175,0.0011853749,0.008744685,0.00030798808,0.85084695],"genre_scores_gemma":[0.06908401,0.0007148023,0.00035009556,0.000037190897,0.00048674233,5.724009e-7,0.03569665,0.0012885673,0.8923414],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99683625,0.000509722,0.00069546857,0.0008806129,0.0003372884,0.0007406384],"domain_scores_gemma":[0.99768496,0.00010901619,0.0007841318,0.00083477923,0.00035506513,0.00023207405],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003358641,0.00062137574,0.0009232053,0.0003044547,0.0005996738,0.00012488448,0.0009334034,0.0004979726,0.5933062],"category_scores_gemma":[0.00013451568,0.00059235847,0.000160142,0.00029673637,0.0005634076,0.00017777004,0.00076504727,0.0006505807,0.006363394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014534965,0.00045040133,0.007994769,0.0001273034,0.0016465642,0.000032535663,0.0007576929,6.111915e-7,0.0042379573,0.00053142896,0.97375315,0.009014093],"study_design_scores_gemma":[0.0023419515,0.00044637066,0.11814625,0.00032479066,0.00028395976,0.0000061642413,0.00019805718,5.5883885e-7,0.0020962418,0.00004436996,0.87560725,0.00050403527],"about_ca_topic_score_codex":0.5795656,"about_ca_topic_score_gemma":0.102756284,"teacher_disagreement_score":0.5869428,"about_ca_system_score_codex":0.00053163624,"about_ca_system_score_gemma":0.0002108379,"threshold_uncertainty_score":0.9996528},"labels":[],"label_agreement":null},{"id":"W6928952041","doi":"10.4224/21243245","title":"BIM: going beyond the design suite","year":2012,"lang":"en","type":"other","venue":"NPARC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"","score_opus":0.02412074109201296,"score_gpt":0.232366494419167,"score_spread":0.20824575332715406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6928952041","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009491962,0.020021051,0.0003493603,0.00019526186,0.0024316243,0.00044359002,0.000106012754,0.00019837415,0.9761598],"genre_scores_gemma":[0.003734522,0.0005928245,0.0008176282,0.0001935152,0.00041374392,0.00007744918,0.00018244886,0.00023328335,0.99375457],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988924,0.0003035882,0.0001333458,0.00023424975,0.000030619703,0.00040578927],"domain_scores_gemma":[0.999209,0.00019549982,0.00013082827,0.00043468358,0.000010556533,0.00001942078],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022253653,0.00027673627,0.00028972677,0.00010781643,0.00013165169,0.000012225503,0.00029041793,0.0005386944,0.028988047],"category_scores_gemma":[0.000016427008,0.00017076859,0.00012175487,0.00008619507,0.000125867,0.000020349386,0.000060270184,0.00019288684,0.010428308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003539456,0.00005372166,0.00021775458,0.000012901428,0.0006028857,0.00000479692,0.00012248573,6.9861706e-8,0.01875278,0.0017665967,0.91439795,0.06403266],"study_design_scores_gemma":[0.00049475813,0.000037872782,0.00014802096,0.00003369979,0.00031567737,0.000026824053,0.00001673957,1.4661599e-7,0.0058854357,0.00054442935,0.9922863,0.00021008767],"about_ca_topic_score_codex":0.000022869537,"about_ca_topic_score_gemma":0.000020017831,"teacher_disagreement_score":0.077888355,"about_ca_system_score_codex":0.000022138183,"about_ca_system_score_gemma":0.000040788815,"threshold_uncertainty_score":0.9903422},"labels":[],"label_agreement":null},{"id":"W6929501048","doi":"10.5061/dryad.cz8w9gj2c","title":"Data for: Feedback between coevolution and epidemiology can help or hinder the maintenance of genetic variation in host-parasite models","year":2020,"lang":"en","type":"dataset","venue":"Warwick Research Archive Portal (University of Warwick)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"Science and Engineering Research Council","keywords":"Coevolution; Population; Population genetics; Genetic variation; Frequency-dependent selection; Genetic drift; Genetic model; Fixation (population genetics)","score_opus":0.12940828768194382,"score_gpt":0.32092113961779006,"score_spread":0.19151285193584625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929501048","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017800145,0.0011581541,0.0023843474,0.0010431949,0.00012420352,0.0012676689,0.9761754,0.000012027682,0.00003480571],"genre_scores_gemma":[0.059278525,0.004905218,0.001536123,0.000037350947,0.00008290133,0.0000091520715,0.93378156,0.000022324866,0.0003468531],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9958214,0.0018325306,0.0005456186,0.0009062818,0.00016079421,0.0007333552],"domain_scores_gemma":[0.9951546,0.0028789816,0.000563151,0.0010992399,0.00020638536,0.00009761663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001918805,0.00031809017,0.0010200335,0.00047067634,0.0003666544,0.000006179648,0.0015134355,0.00052251073,0.00012317317],"category_scores_gemma":[0.00083104614,0.0002665311,0.00014411629,0.00038233545,0.001467335,0.00015889268,0.0011998274,0.00084150303,0.00003822253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021881068,0.00017041748,0.0047053164,0.00041699677,0.0010143263,0.00006012608,0.0014586444,0.00003707424,0.00076407875,0.00022708507,0.98667324,0.0022845864],"study_design_scores_gemma":[0.009812336,0.0031418456,0.594134,0.0007788664,0.0017047334,0.000096846765,0.0068143005,0.0015837565,0.000061400475,0.01059274,0.37014836,0.0011308278],"about_ca_topic_score_codex":0.012425342,"about_ca_topic_score_gemma":0.020821597,"teacher_disagreement_score":0.6165249,"about_ca_system_score_codex":0.00006928309,"about_ca_system_score_gemma":0.0006365923,"threshold_uncertainty_score":0.99997866},"labels":[],"label_agreement":null},{"id":"W6929857511","doi":"10.5281/zenodo.11816670","title":"math foundations 30 textbook pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mathematical proof; Curriculum; Key (lock); Set (abstract data type); Line (geometry); Tangent; Elementary mathematics","score_opus":0.02981858196057255,"score_gpt":0.2476695370486894,"score_spread":0.21785095508811686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929857511","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059410875,0.0027682346,0.0002518249,0.00016099898,0.00071425945,0.000509769,0.00095781346,0.0015005426,0.99307716],"genre_scores_gemma":[0.0019302506,0.00041563148,0.000042690463,0.000052775864,0.0002500304,2.6524032e-7,0.008705808,0.0057372996,0.9828653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854535,0.00027395692,0.00020384094,0.00051641616,0.000077559336,0.00038286654],"domain_scores_gemma":[0.9992141,0.00001574013,0.00011211542,0.0005025976,0.00010300419,0.00005243474],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022741666,0.00025321863,0.00023550997,0.00041748869,0.0008038217,0.00032458777,0.0006493821,0.00030699046,0.37429628],"category_scores_gemma":[0.00009656654,0.0002425638,0.00010853245,0.00025888951,0.00019209032,0.000052479416,0.0006000709,0.00030218743,0.71975803],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016399625,0.00008384167,3.6886658e-7,0.00007511297,0.00040266302,0.000016388796,0.00018249868,2.6152034e-7,0.0007533756,0.004535899,0.91447926,0.07945394],"study_design_scores_gemma":[0.00043703898,0.00009539642,0.00003591871,0.00009367991,0.00015057759,0.00011301009,0.0000687292,0.0000015784854,0.00012728877,0.00013356442,0.99851364,0.00022955413],"about_ca_topic_score_codex":0.000025435049,"about_ca_topic_score_gemma":0.0000010402522,"teacher_disagreement_score":0.34546173,"about_ca_system_score_codex":0.00011067545,"about_ca_system_score_gemma":0.0000060203456,"threshold_uncertainty_score":0.9891465},"labels":[],"label_agreement":null},{"id":"W6929905408","doi":"10.5064/f6aktdbi/xbbpsy","title":"Hahn-Goldberg_Caregiving_Follow up patient interview guide.pdf","year":2018,"lang":"en","type":"dataset","venue":"Syracuse University Qualitative Data Repository","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Interview; Semi-structured interview; Data collection; MEDLINE","score_opus":0.05090652658378006,"score_gpt":0.3027433119779743,"score_spread":0.2518367853941943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929905408","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010073297,0.0024005217,0.000028949551,0.0000930766,0.0068325982,0.0004836973,0.9875139,0.00011806398,0.0015218877],"genre_scores_gemma":[0.00010339594,0.0007154121,0.00015622228,0.00014594398,0.00015001459,0.000005311939,0.959203,0.000033062162,0.03948763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99271095,0.0042892206,0.0006660917,0.0015357791,0.00018831792,0.0006096614],"domain_scores_gemma":[0.994611,0.0008041687,0.0008867063,0.0031912846,0.00040005552,0.00010674051],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009030228,0.0007676739,0.0009902244,0.00043689596,0.00076142524,0.00006147271,0.0025922044,0.0009478779,0.0013757441],"category_scores_gemma":[0.00029862564,0.00076079904,0.00036316304,0.00032136377,0.0008016986,0.00052497926,0.0021846034,0.00059875933,0.005142694],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027002406,0.00028852074,0.0000059016434,0.00015423779,0.0024933072,0.0003910325,0.0036805372,7.343995e-8,0.00038478343,0.000025301297,0.9906187,0.0016875567],"study_design_scores_gemma":[0.0013604099,0.00046428427,0.000022591817,0.00046726526,0.0015581365,0.00010714611,0.00956055,2.4950623e-7,0.00078046985,0.0000116317315,0.98488694,0.00078032404],"about_ca_topic_score_codex":0.003399715,"about_ca_topic_score_gemma":0.00073897775,"teacher_disagreement_score":0.037965745,"about_ca_system_score_codex":0.0005366548,"about_ca_system_score_gemma":0.00044800068,"threshold_uncertainty_score":0.9995371},"labels":[],"label_agreement":null},{"id":"W6930015468","doi":"10.5281/zenodo.12420064","title":"les racines du sous developpement en haiti pdf","year":2024,"lang":"fr","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); West indies; Biological evolution; Zea mays","score_opus":0.028584145270630273,"score_gpt":0.23980900915368303,"score_spread":0.21122486388305275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930015468","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002981068,0.010509031,0.00080242887,0.0024188429,0.0018531972,0.00085888326,0.0009890763,0.0009103451,0.97867715],"genre_scores_gemma":[0.031349886,0.0032640593,0.00023960455,0.00012574288,0.00077721797,3.2045193e-7,0.006504986,0.0052417074,0.95249647],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680984,0.0011163774,0.0004381276,0.0008334539,0.00013785543,0.00066431955],"domain_scores_gemma":[0.99883485,0.000063323416,0.00018118614,0.00048812001,0.00032364257,0.00010890809],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005891234,0.00049058185,0.0004433279,0.00047755765,0.0017657728,0.00045083868,0.001019055,0.0005711441,0.5402142],"category_scores_gemma":[0.00035856946,0.0004781799,0.00018243278,0.00042273165,0.0003559712,0.000088473425,0.0013600758,0.00051629014,0.56227964],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012055186,0.00025088058,0.000008536531,0.00033192773,0.0010797357,0.000114846116,0.0019951155,0.0000039529796,0.0049239867,0.0057813697,0.63062733,0.35476178],"study_design_scores_gemma":[0.0009906025,0.0003532807,0.00042216107,0.00032771542,0.0003420882,0.00049631024,0.0004412605,0.00000707584,0.0014474833,0.00013541034,0.99457514,0.0004614802],"about_ca_topic_score_codex":0.00008762646,"about_ca_topic_score_gemma":0.0000059572217,"teacher_disagreement_score":0.3639478,"about_ca_system_score_codex":0.00040274946,"about_ca_system_score_gemma":0.000013342446,"threshold_uncertainty_score":0.999767},"labels":[],"label_agreement":null},{"id":"W6930326860","doi":"10.5281/zenodo.12032191","title":"quran para 16 pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dysgeusia; TSG101; Subpoena; Pretext; Filter (signal processing)","score_opus":0.032577308473223286,"score_gpt":0.24507222263734663,"score_spread":0.21249491416412333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930326860","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009747922,0.005480066,0.00013144166,0.00019318685,0.0007268057,0.00039083703,0.0008527824,0.001529038,0.9905984],"genre_scores_gemma":[0.0050571356,0.0006291149,0.000032900847,0.00006524796,0.00025855034,1.0088881e-7,0.008776138,0.006799421,0.9783814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984143,0.00036170665,0.00020191522,0.00054752006,0.00007856999,0.000396038],"domain_scores_gemma":[0.9992256,0.000014253219,0.00010670283,0.0005120412,0.00008721309,0.0000541802],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023520549,0.00027171738,0.00027237914,0.0003984058,0.0006080365,0.00023692928,0.0007150071,0.00035880203,0.40004554],"category_scores_gemma":[0.00009020147,0.00025477848,0.00012054745,0.00029804272,0.00018130036,0.00004337476,0.0005731968,0.00033240084,0.6311163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040958188,0.000078095414,3.8000528e-7,0.00008854159,0.00042205487,0.000023886498,0.00020662833,1.0886724e-7,0.0020358383,0.00084382726,0.9183678,0.07789188],"study_design_scores_gemma":[0.00058114884,0.00013964169,0.000019433095,0.0001241756,0.0001343096,0.00014284095,0.00009463468,3.7294802e-7,0.00055514585,0.000100348116,0.99785364,0.00025429088],"about_ca_topic_score_codex":0.000045434663,"about_ca_topic_score_gemma":0.000001888582,"teacher_disagreement_score":0.2310707,"about_ca_system_score_codex":0.00011263755,"about_ca_system_score_gemma":0.0000041290614,"threshold_uncertainty_score":0.99999046},"labels":[],"label_agreement":null},{"id":"W6930463257","doi":"10.5281/zenodo.12319189","title":"time series analysis questions and answers pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Series (stratigraphy); Time series; Simple (philosophy); Order of integration (calculus); Sequence (biology); Moving average; Plot (graphics)","score_opus":0.014350599189814208,"score_gpt":0.22507060723014014,"score_spread":0.21072000804032592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930463257","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032619684,0.0056879986,0.00010241395,0.00029893513,0.00024056042,0.00030254843,0.0015377166,0.0012333565,0.99027026],"genre_scores_gemma":[0.0019211263,0.0009019926,0.00007137347,0.000026797425,0.00008534474,8.2548176e-8,0.008037665,0.0026429999,0.9863126],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987974,0.00029962393,0.00015225745,0.00044752215,0.000053596603,0.0002496112],"domain_scores_gemma":[0.9994394,0.000011798245,0.00007824067,0.0003441979,0.00007967474,0.0000466475],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018897274,0.00020395458,0.00027238386,0.00066898286,0.0006005807,0.00021928834,0.00032424257,0.00024248134,0.20028357],"category_scores_gemma":[0.00007486797,0.00019575661,0.00010042477,0.000585582,0.00028892606,0.000058426805,0.00039941035,0.000195211,0.20425062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030708074,0.00004748801,0.0000017889716,0.000053164353,0.0021624865,0.000015607464,0.0002922837,9.910364e-7,0.001349204,0.0005745609,0.97608274,0.019389002],"study_design_scores_gemma":[0.0002383574,0.00010854904,0.00008536931,0.0000488765,0.00092035,0.00007605943,0.0000908672,0.00000244115,0.000103971775,0.000044041662,0.99809307,0.00018803775],"about_ca_topic_score_codex":0.000039347662,"about_ca_topic_score_gemma":0.000003093778,"teacher_disagreement_score":0.022010364,"about_ca_system_score_codex":0.00004743868,"about_ca_system_score_gemma":0.000002934099,"threshold_uncertainty_score":0.80044746},"labels":[],"label_agreement":null},{"id":"W6930642580","doi":"10.5281/zenodo.14206107","title":"Trichoderma viridistromatis E. Tarafder & F. H. Tian 2024, sp. nov.","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Apex (geometry); Conidium; Ascocarp; Holotype; Hypocreales","score_opus":0.02776479526830328,"score_gpt":0.24065685113394894,"score_spread":0.21289205586564566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930642580","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3623506,0.02170714,0.008164208,0.0055844863,0.0052046976,0.0019996525,0.0038357335,0.0072950013,0.5838585],"genre_scores_gemma":[0.9617415,0.00034493805,0.0001192636,0.00011530652,0.00019213959,1.6994667e-7,0.005244242,0.0010940216,0.031148395],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985405,0.00033026238,0.00022681737,0.0004331311,0.000082308565,0.00038695324],"domain_scores_gemma":[0.99937576,0.000040816463,0.000043319298,0.0003496285,0.00013120844,0.00005923982],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032317906,0.00017869113,0.00016810842,0.0002481909,0.0012590117,0.00038876417,0.0005202925,0.00013059788,0.055878237],"category_scores_gemma":[0.000115349314,0.00016735888,0.00009781403,0.00050033815,0.00013365476,0.00019103037,0.00037940632,0.00024137714,0.073802784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070414026,0.00011120894,0.0000066904463,0.000056439036,0.00028472987,0.00006104793,0.0007555771,0.000004237233,0.046418488,0.0019686252,0.60309935,0.34716317],"study_design_scores_gemma":[0.0005724773,0.00015275179,0.0007525736,0.000039631563,0.00007439068,0.00033084027,0.00014901292,0.0000427144,0.005017315,0.00009062479,0.9925964,0.00018128601],"about_ca_topic_score_codex":0.00002042053,"about_ca_topic_score_gemma":5.2241455e-7,"teacher_disagreement_score":0.5993909,"about_ca_system_score_codex":0.000102733444,"about_ca_system_score_gemma":0.00000578373,"threshold_uncertainty_score":0.9683428},"labels":[],"label_agreement":null},{"id":"W6931246440","doi":"10.5281/zenodo.6586599","title":"MOBY Phantom Mouse Maps","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Imaging phantom; Monte Carlo method; Attenuation; Medical imaging","score_opus":0.026227511518820683,"score_gpt":0.229208718500507,"score_spread":0.2029812069816863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931246440","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046187782,0.0026418744,0.00005758566,0.00012225687,0.0005242606,0.00057000533,0.0039673955,0.0019930303,0.9896617],"genre_scores_gemma":[0.0022552728,0.0007662453,0.000051249528,0.0000969964,0.0001822301,2.3335342e-7,0.038224652,0.008303788,0.9501193],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980922,0.00062437804,0.00020228035,0.0005406764,0.00010838943,0.0004321302],"domain_scores_gemma":[0.9990553,0.000018606315,0.00016785096,0.00062027964,0.00008310678,0.000054826018],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000282354,0.00026855714,0.0002803042,0.00042854378,0.0015390037,0.00014737617,0.0010367706,0.00025361762,0.50170285],"category_scores_gemma":[0.00010550731,0.00027633944,0.00010808502,0.00031203197,0.00015467823,0.00005052516,0.0011322043,0.0003607022,0.067469485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068708556,0.0001732508,0.0000015203899,0.000036519716,0.00035104822,0.000021073038,0.00023954293,0.0000011978257,0.0046466077,0.0006496867,0.93487376,0.058937088],"study_design_scores_gemma":[0.0010273037,0.00019383986,0.000014062138,0.000017701355,0.00007895146,0.0001146764,0.00016155968,6.045869e-7,0.00085971464,0.00001988854,0.99724096,0.00027073533],"about_ca_topic_score_codex":0.000071808165,"about_ca_topic_score_gemma":0.0000012454069,"teacher_disagreement_score":0.43423337,"about_ca_system_score_codex":0.0001501701,"about_ca_system_score_gemma":0.0000048967395,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W6931338871","doi":"10.5281/zenodo.5679898","title":"Arachnoscelis Karny 1911","year":2013,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stridulation; Mandible (arthropod mouthpart); Orthoptera; Vein; Margin (machine learning)","score_opus":0.025990301850501912,"score_gpt":0.22038807946082936,"score_spread":0.19439777761032745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931338871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6280955,0.0014900224,0.00069968565,0.0017486055,0.0007400096,0.0011720282,0.00038581647,0.0022939348,0.36337438],"genre_scores_gemma":[0.9867799,0.00010630663,0.000104792896,0.00015415114,0.00007524926,1.5605423e-7,0.0025667895,0.0006707003,0.0095419185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876374,0.00029420978,0.00018553922,0.00032335674,0.00006149555,0.00037167402],"domain_scores_gemma":[0.999204,0.000025724119,0.00007041535,0.0003815775,0.00026272133,0.000055606582],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022165039,0.00014206249,0.00014432166,0.00015436547,0.0015872662,0.0002334579,0.0005915268,0.00012064373,0.06874158],"category_scores_gemma":[0.00018229318,0.0001326779,0.00006388346,0.00026173826,0.00014740843,0.00019054604,0.00043812612,0.00017629689,0.14352755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052877225,0.00020891998,0.00003117893,0.000017985141,0.00015356326,0.0000067789033,0.00066429994,0.0000026630773,0.10542867,0.0020045084,0.4108944,0.48053414],"study_design_scores_gemma":[0.00078876346,0.0001838856,0.003796628,0.000010512491,0.000029067867,0.000107965956,0.00020024262,0.0000067359106,0.00938468,0.00017881354,0.98515075,0.00016195794],"about_ca_topic_score_codex":0.00005614386,"about_ca_topic_score_gemma":2.618491e-7,"teacher_disagreement_score":0.57425636,"about_ca_system_score_codex":0.00006048834,"about_ca_system_score_gemma":0.0000021130254,"threshold_uncertainty_score":0.9997125},"labels":[],"label_agreement":null},{"id":"W6931398632","doi":"10.5281/zenodo.5283415","title":"Biologically-relevant transfer learning improves transcription factor binding prediction: TF binding matrices","year":2021,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Transcription factor; Binding site; Transcription (linguistics); Transfer of learning; DNA-binding protein; Plasma protein binding","score_opus":0.0349022198829428,"score_gpt":0.23248834112538833,"score_spread":0.1975861212424455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931398632","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17202434,0.023790708,0.0037357688,0.00060391554,0.004999765,0.0033304521,0.010346792,0.009744004,0.77142423],"genre_scores_gemma":[0.25399747,0.013579236,0.0002748898,0.000073285984,0.0009705842,0.0000012719945,0.07656457,0.010400279,0.6441384],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974892,0.00078601786,0.00035282536,0.0007305622,0.000120688936,0.00052067655],"domain_scores_gemma":[0.9992894,0.000040273357,0.00014163733,0.00031331895,0.0001443104,0.00007105916],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030827336,0.00036627363,0.00040117349,0.0005511535,0.0016451614,0.00029967836,0.0005776312,0.0005902327,0.09134714],"category_scores_gemma":[0.0001418475,0.0003344873,0.00018860248,0.0004717078,0.0001673028,0.000097743155,0.00022127447,0.00056692405,0.0074866577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014547915,0.00021717974,0.000024856477,0.00022592137,0.0008408191,0.00003081215,0.00076015625,0.0000033871374,0.7299648,0.00022874537,0.11621355,0.15134431],"study_design_scores_gemma":[0.0010380882,0.0003624255,0.00029762258,0.00021724627,0.00014093822,0.000110772606,0.0003382239,0.0000034645147,0.00611561,0.0000039068964,0.991047,0.000324658],"about_ca_topic_score_codex":0.000027709357,"about_ca_topic_score_gemma":0.0000012124527,"teacher_disagreement_score":0.87483346,"about_ca_system_score_codex":0.0001355032,"about_ca_system_score_gemma":0.000007706383,"threshold_uncertainty_score":0.9999107},"labels":[],"label_agreement":null},{"id":"W6931503809","doi":"10.5281/zenodo.5940695","title":"Grotea perplexa Slobodchikoff 1970","year":2019,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Simple eye in invertebrates; Ovipositor; Scutellum; Seta; Apex (geometry); Dorsum; Cephalothorax","score_opus":0.024289518174916865,"score_gpt":0.22520158010360272,"score_spread":0.20091206192868585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931503809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72720724,0.0007529624,0.0002446198,0.000527868,0.0007207277,0.0007218629,0.00033970704,0.0011128581,0.26837215],"genre_scores_gemma":[0.9802981,0.00008926625,0.00006626702,0.000116433024,0.000073372896,5.4561347e-8,0.0029234514,0.00070135726,0.015731681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985896,0.000369464,0.00018639925,0.00039068746,0.00007574512,0.00038814265],"domain_scores_gemma":[0.9992073,0.000027675784,0.00007357401,0.00046206132,0.00017909912,0.000050251536],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033291418,0.00015655432,0.00017552456,0.00015974144,0.0011977368,0.00015826453,0.00064958417,0.00012772046,0.06528321],"category_scores_gemma":[0.00011972745,0.00014936941,0.00008206451,0.00026395472,0.00010642483,0.00014847686,0.0005184356,0.00019996164,0.13585292],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004508244,0.0004505959,0.00021149214,0.00007297057,0.00046121856,0.000021215299,0.002063399,0.000017563789,0.33600992,0.010080118,0.25074822,0.39941245],"study_design_scores_gemma":[0.0012396082,0.00028672098,0.0031950753,0.000016468655,0.000031430456,0.00014822226,0.00020865737,0.000007109121,0.0069805756,0.00007872425,0.98762697,0.00018041364],"about_ca_topic_score_codex":0.000019947005,"about_ca_topic_score_gemma":2.392532e-7,"teacher_disagreement_score":0.73687875,"about_ca_system_score_codex":0.000076844604,"about_ca_system_score_gemma":0.0000034060806,"threshold_uncertainty_score":0.93557125},"labels":[],"label_agreement":null},{"id":"W6931920942","doi":"10.5281/zenodo.7875180","title":"FIGURES 206–213 in Morphological and molecular characterization of twenty-five new Diploneis species (Bacillariophyta) from Lake Tanganyika and its surrounding areas","year":2023,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Museum of Nature","funders":"","keywords":"Raphe; Scale (ratio); Raphe nuclei; Terminal (telecommunication); Morphology (biology)","score_opus":0.02925150804241293,"score_gpt":0.225586333805522,"score_spread":0.19633482576310907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931920942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9015557,0.008457872,0.0003793043,0.00039048752,0.00069746736,0.0015021242,0.008804876,0.0014375295,0.07677462],"genre_scores_gemma":[0.573826,0.012134281,0.0001151731,0.00010390819,0.0003427536,6.177328e-7,0.033592734,0.0074453936,0.3724391],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986545,0.00033320484,0.00022831379,0.0004473302,0.00008162176,0.00025503358],"domain_scores_gemma":[0.99943525,0.00004264539,0.00018407535,0.00021192877,0.000074535776,0.000051565454],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00016502985,0.00021994894,0.0003482548,0.00034687028,0.0002535009,0.00009924058,0.00026827003,0.00029673826,0.009258892],"category_scores_gemma":[0.00026284342,0.00021517967,0.000042604795,0.0002832691,0.0001319637,0.00007284347,0.00044533782,0.00019206567,0.0010575842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040054158,0.000272849,0.0006786798,0.00020596327,0.0008902782,0.00024508333,0.0019152917,0.0000016520592,0.76534766,0.0015664173,0.16842037,0.06005523],"study_design_scores_gemma":[0.0015545517,0.00020103039,0.029166346,0.0002785972,0.000106779764,0.000064502674,0.00014229683,0.000003829961,0.008228977,0.000057034667,0.9598686,0.0003274539],"about_ca_topic_score_codex":0.00012474923,"about_ca_topic_score_gemma":0.0000302258,"teacher_disagreement_score":0.79144824,"about_ca_system_score_codex":0.00003986056,"about_ca_system_score_gemma":0.000004614514,"threshold_uncertainty_score":0.9997202},"labels":[],"label_agreement":null},{"id":"W6939517333","doi":"10.6084/m9.figshare.17066218.v1","title":"Additional file 1 of Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Skin cancer; Biological response modifiers; Cancer; Quality (philosophy); Table (database); Systemic therapy; MEDLINE","score_opus":0.03345248937027258,"score_gpt":0.25479762862860333,"score_spread":0.22134513925833077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939517333","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010571501,0.12791677,2.9339263e-8,0.000007975576,0.0000031671457,0.00015892492,0.86129713,0.0000054173665,0.000039092363],"genre_scores_gemma":[0.10296085,0.0027470232,0.000020578613,0.000058511807,0.000005883384,0.0017778814,0.8922523,0.000006118416,0.00017083621],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991176,0.00029609515,0.0002557597,0.00020020058,0.000028606137,0.00010171523],"domain_scores_gemma":[0.9984747,0.0009579013,0.00026402393,0.00019164306,0.000096827054,0.000014900354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000026527787,0.0001297067,0.0008773362,0.00006610154,0.000027695745,0.0000022676747,0.00008013433,0.00010312412,0.96493787],"category_scores_gemma":[0.00016878641,0.00008070308,0.0003068225,0.00028560634,0.000024387118,0.000027021952,0.000034814097,0.00006658174,0.0000767025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117543015,0.0002078819,0.006591435,0.00069679477,0.06469894,0.000034424607,0.00008671748,0.0000073189753,0.00013585092,0.0000010307804,0.92432016,0.003101885],"study_design_scores_gemma":[0.0018300838,0.000318621,0.78089756,0.003347364,0.0731504,0.000059853635,0.00014705086,0.0000032803957,0.0023633146,0.000012823611,0.13737722,0.0004924289],"about_ca_topic_score_codex":0.000025532345,"about_ca_topic_score_gemma":0.00020595614,"teacher_disagreement_score":0.9648612,"about_ca_system_score_codex":0.000011573039,"about_ca_system_score_gemma":0.00008546418,"threshold_uncertainty_score":0.32909763},"labels":[],"label_agreement":null},{"id":"W6945328885","doi":"10.25384/sage.6269429.v1","title":"Supplemental Material, PROPEL_Manuscript_Supplementary_File_3 – Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys","year":2018,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Alternative medicine; MEDLINE; New england","score_opus":0.03291563446482829,"score_gpt":0.22487072839090194,"score_spread":0.19195509392607366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945328885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56157935,0.0003136768,4.550761e-8,0.00012716815,0.0009165944,0.00078576675,0.43501186,0.000028981041,0.0012365708],"genre_scores_gemma":[0.62139946,0.0000034534132,0.000013417315,0.0001362677,0.00016698606,0.0002794298,0.37783077,0.00001198688,0.00015824486],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9981763,0.0005879603,0.00029545103,0.0004188183,0.00006712667,0.0004543856],"domain_scores_gemma":[0.9993376,0.000087669054,0.00007547659,0.0003361783,0.00010922396,0.00005386217],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00005307756,0.0002521269,0.00022762343,0.00008378175,0.00033090275,0.00006368796,0.00046605736,0.00018815012,0.38617906],"category_scores_gemma":[0.000085974054,0.00016538176,0.000062205705,0.00014751605,0.00004564062,0.00015039713,0.00014625298,0.00012933608,0.003758263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001645153,0.00021889475,0.18278244,0.000037984246,0.0002667734,0.000020414676,0.004543684,1.2149754e-7,0.0007656882,0.000021113936,0.76611584,0.045062542],"study_design_scores_gemma":[0.0014284039,0.00032307088,0.56028765,0.00013480763,0.000031797223,0.0000010810077,0.00056960667,2.616072e-7,0.016017158,0.000024322779,0.42094904,0.00023281883],"about_ca_topic_score_codex":0.105367,"about_ca_topic_score_gemma":0.5588108,"teacher_disagreement_score":0.4534438,"about_ca_system_score_codex":0.00015975119,"about_ca_system_score_gemma":0.00018923513,"threshold_uncertainty_score":0.99701744},"labels":[],"label_agreement":null},{"id":"W6945457039","doi":"10.25384/sage.23936488","title":"Supplementary material - Supplemental material for Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","year":2023,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Baseline (sea); Longitudinal study; Longitudinal data; Patient registry","score_opus":0.04633291922529723,"score_gpt":0.3070974362151962,"score_spread":0.26076451698989894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945457039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68259144,0.00011117199,0.0000091983675,0.00061952655,0.0011606719,0.00038723668,0.31510758,0.0000055612095,0.00000763213],"genre_scores_gemma":[0.8460684,0.0019796204,0.00029525612,0.00008077512,0.00022936666,0.000048185335,0.15124223,0.000017210536,0.000038958882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983116,0.00029469532,0.0005636792,0.00030620862,0.000084557745,0.0004393091],"domain_scores_gemma":[0.99900013,0.00015794273,0.00023236619,0.0005177861,0.0000457696,0.000045977045],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014309471,0.00018957308,0.0003203027,0.00035887447,0.00023110725,0.00007520494,0.0005595727,0.00011947227,0.006618606],"category_scores_gemma":[0.00005837001,0.00014441292,0.000047099187,0.00023606159,0.000066731795,0.00017016058,0.00021929835,0.00011726984,0.000006317465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000842697,0.0003941636,0.80224144,0.00010059999,0.00059595075,0.00009701728,0.00048491193,2.2248184e-7,0.019238977,0.000017326434,0.09723826,0.07874844],"study_design_scores_gemma":[0.004363958,0.00030428337,0.94433624,0.00013105561,0.00029568438,0.000048509988,0.0007382586,0.000008611702,0.0042806044,0.000043969114,0.04522696,0.00022187876],"about_ca_topic_score_codex":0.020925896,"about_ca_topic_score_gemma":0.036185116,"teacher_disagreement_score":0.16386536,"about_ca_system_score_codex":0.00006177496,"about_ca_system_score_gemma":0.00013396719,"threshold_uncertainty_score":0.99428946},"labels":[],"label_agreement":null},{"id":"W6945659601","doi":"10.25384/sage.21637920","title":"Table S2 - Supplemental material for Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial","year":2022,"lang":"en","type":"article","venue":"Sage Journals Data","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Table (database); Phase (matter); Clinical trial; Randomized controlled trial; Phases of clinical research","score_opus":0.04939179670754684,"score_gpt":0.304208136136497,"score_spread":0.25481633942895016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945659601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9367906,0.0015191872,0.00002753029,0.0002669009,0.0008351908,0.0014143474,0.059095405,0.0000033520528,0.000047484013],"genre_scores_gemma":[0.98793346,0.00077589444,0.00007247561,0.00002981667,0.00009816435,0.00032559747,0.010549214,0.000010911787,0.00020444652],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981834,0.0004720579,0.0005978111,0.00028257293,0.000096115546,0.00036799855],"domain_scores_gemma":[0.9989042,0.000133585,0.00034276652,0.0005384775,0.000047862326,0.00003308425],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006207969,0.00016478055,0.00047701318,0.00034176654,0.0002685563,0.000016275266,0.0006033993,0.000072614996,0.0045920117],"category_scores_gemma":[0.000048122834,0.00011462811,0.00013904879,0.00036977415,0.000054732216,0.00014002428,0.00010306497,0.00009028016,0.0000016282285],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21360525,0.025629995,0.06982385,0.00006985246,0.011809036,0.00019280097,0.013481455,0.00003328833,0.022511503,0.00013308942,0.028079135,0.61463076],"study_design_scores_gemma":[0.69600093,0.020117609,0.04072115,0.00015868476,0.005379671,0.000118952,0.014282495,0.000055492797,0.09400966,0.00026749514,0.12797453,0.0009133615],"about_ca_topic_score_codex":0.042604472,"about_ca_topic_score_gemma":0.051559597,"teacher_disagreement_score":0.6137174,"about_ca_system_score_codex":0.0001725492,"about_ca_system_score_gemma":0.00022524668,"threshold_uncertainty_score":0.9963179},"labels":[],"label_agreement":null},{"id":"W6949579781","doi":"10.5281/zenodo.16574828","title":"Perspectives and Insights on Anti-Psoriatic Drugs (D05): From Development to New Drug Submission (NDS) Application to Health Canada","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Drug; Biosimilar; Drug development; Quality (philosophy); Drug approval; Biological drugs; Access to medicines","score_opus":0.01270710395029315,"score_gpt":0.23111579399188453,"score_spread":0.21840869004159139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949579781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738737,0.0018478131,0.0028570513,0.009466562,0.00035352114,0.0012683519,0.00018922024,0.00035108958,0.0097927395],"genre_scores_gemma":[0.9939131,0.00011439861,0.00035316905,0.00076455745,0.000038405396,3.062143e-7,0.0012708771,0.00019790596,0.0033472902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987841,0.00023480588,0.00019732525,0.0004489399,0.00008438463,0.00025040883],"domain_scores_gemma":[0.9993768,0.000038140675,0.000057711928,0.0002675382,0.00013048797,0.000129363],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016709774,0.0001420104,0.0001753665,0.00020619776,0.001355695,0.00009654516,0.0003230186,0.000048610906,0.000719785],"category_scores_gemma":[0.00011502623,0.00013495001,0.0000168144,0.00038532066,0.000024927305,0.000048376016,0.00033974124,0.00010850008,0.0018804646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002245359,0.0001397207,0.000017960483,0.000023145369,0.00014258504,0.0000020714656,0.023762964,0.00002027004,0.011244396,0.0016353929,0.25238937,0.7103976],"study_design_scores_gemma":[0.0007341953,0.00009719795,0.009476905,0.000059845366,0.000013741999,0.0000027572792,0.0021414144,0.000003443067,0.007850157,0.00006785739,0.9794125,0.00014001403],"about_ca_topic_score_codex":0.016252626,"about_ca_topic_score_gemma":0.001238412,"teacher_disagreement_score":0.72702307,"about_ca_system_score_codex":0.00041295233,"about_ca_system_score_gemma":0.0000728135,"threshold_uncertainty_score":0.9999444},"labels":[],"label_agreement":null},{"id":"W6955259767","doi":"10.58079/razr","title":"Colloque - De retour de la guerre. Femmes, Autochtones et minorités ethniques : regards croisés","year":2013,"lang":"fr","type":"article","venue":"OpenEdition (OpenEdition)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Vetting; Settlement (finance); TSG101","score_opus":0.030575224336628355,"score_gpt":0.29338272592213155,"score_spread":0.2628075015855032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6955259767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41563618,0.067722626,0.0051504704,0.31047156,0.01635426,0.006014214,0.00437355,0.0013012603,0.17297588],"genre_scores_gemma":[0.6647403,0.014472529,0.01082933,0.04611461,0.002381726,0.003159873,0.007917345,0.0002042374,0.25018],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930318,0.0036384072,0.0009059847,0.000934394,0.00020594845,0.0012834754],"domain_scores_gemma":[0.9970922,0.00091472507,0.0004830498,0.0007194602,0.00048242224,0.00030813096],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018380802,0.0008060553,0.00086073705,0.0002929146,0.0008037994,0.00044528802,0.00066548435,0.0018729629,0.017628403],"category_scores_gemma":[0.00039688114,0.00084789516,0.00044263212,0.00042115315,0.0007274763,0.0067151003,0.00019865685,0.0008602569,0.0050086947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062669313,0.0021789076,0.0031683042,0.00026274147,0.0012956904,0.00040230498,0.0018673767,0.000045994322,0.052789204,0.14155115,0.70613825,0.08967339],"study_design_scores_gemma":[0.0052819685,0.0012902702,0.2574017,0.0009706933,0.001048897,0.0013961532,0.00117812,0.00004865789,0.101112574,0.026642293,0.60197073,0.0016579229],"about_ca_topic_score_codex":0.005746545,"about_ca_topic_score_gemma":0.0021340938,"teacher_disagreement_score":0.26435694,"about_ca_system_score_codex":0.00057757983,"about_ca_system_score_gemma":0.0008089788,"threshold_uncertainty_score":0.9994228},"labels":[],"label_agreement":null},{"id":"W6957862375","doi":"10.6084/m9.figshare.17066218","title":"Additional file 1 of Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Skin cancer; Biological response modifiers; Cancer; Quality (philosophy); Table (database); Systemic therapy; MEDLINE","score_opus":0.03345248937027258,"score_gpt":0.25479762862860333,"score_spread":0.22134513925833077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6957862375","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010571501,0.12791677,2.9339263e-8,0.000007975576,0.0000031671457,0.00015892492,0.86129713,0.0000054173665,0.000039092363],"genre_scores_gemma":[0.10296085,0.0027470232,0.000020578613,0.000058511807,0.000005883384,0.0017778814,0.8922523,0.000006118416,0.00017083621],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9991176,0.00029609515,0.0002557597,0.00020020058,0.000028606137,0.00010171523],"domain_scores_gemma":[0.9984747,0.0009579013,0.00026402393,0.00019164306,0.000096827054,0.000014900354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000026527787,0.0001297067,0.0008773362,0.00006610154,0.000027695745,0.0000022676747,0.00008013433,0.00010312412,0.96493787],"category_scores_gemma":[0.00016878641,0.00008070308,0.0003068225,0.00028560634,0.000024387118,0.000027021952,0.000034814097,0.00006658174,0.0000767025],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117543015,0.0002078819,0.006591435,0.00069679477,0.06469894,0.000034424607,0.00008671748,0.0000073189753,0.00013585092,0.0000010307804,0.92432016,0.003101885],"study_design_scores_gemma":[0.0018300838,0.000318621,0.78089756,0.003347364,0.0731504,0.000059853635,0.00014705086,0.0000032803957,0.0023633146,0.000012823611,0.13737722,0.0004924289],"about_ca_topic_score_codex":0.000025532345,"about_ca_topic_score_gemma":0.00020595614,"teacher_disagreement_score":0.9648612,"about_ca_system_score_codex":0.000011573039,"about_ca_system_score_gemma":0.00008546418,"threshold_uncertainty_score":0.32909763},"labels":[],"label_agreement":null},{"id":"W6977135659","doi":"10.6084/m9.figshare.21213402","title":"Additional file 2 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; MEDLINE; Disease; Systematic review; Table (database)","score_opus":0.032641922512182724,"score_gpt":0.24345831430751305,"score_spread":0.21081639179533032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977135659","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007435524,0.18285967,1.2925418e-8,0.000031396805,0.000006050937,0.000678823,0.81563246,0.0000031890731,0.000044814475],"genre_scores_gemma":[0.11440687,0.0046423655,0.00005451996,0.00008399655,0.000010403058,0.0072253975,0.8730791,0.000014766754,0.00048258473],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99863124,0.0005321967,0.0004936755,0.0001851541,0.00006129162,0.00009641908],"domain_scores_gemma":[0.99705166,0.002300626,0.00038324035,0.00021354845,0.00003964719,0.000011305186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010708214,0.00014337734,0.0012399174,0.00012884277,0.00007685506,0.0000030879555,0.00007893765,0.000049811115,0.7234956],"category_scores_gemma":[0.00042757322,0.000091522124,0.00027183082,0.00033624645,0.000029747067,0.00002798792,0.000044526892,0.00004470181,0.00001013332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020829521,0.0015856366,0.000029093988,0.04919079,0.12300298,0.000018685665,0.003343367,0.000007855861,0.000046571666,0.00003581117,0.81731105,0.005219845],"study_design_scores_gemma":[0.011066081,0.0049993317,0.019184213,0.028547771,0.73245645,0.00034709118,0.0035379797,0.000011944239,0.0011288971,0.00010193057,0.19752575,0.0010925714],"about_ca_topic_score_codex":0.00001624693,"about_ca_topic_score_gemma":0.00002982103,"teacher_disagreement_score":0.72348547,"about_ca_system_score_codex":0.0000147222,"about_ca_system_score_gemma":0.000025223646,"threshold_uncertainty_score":0.3732164},"labels":[],"label_agreement":null},{"id":"W6977198659","doi":"10.6084/m9.figshare.21213396.v1","title":"Additional file 1 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; Table (database); Disease; MEDLINE; Safety profile","score_opus":0.03365386989534743,"score_gpt":0.24391347036419583,"score_spread":0.2102596004688484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977198659","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007490163,0.18111089,1.3192688e-8,0.000031583666,0.0000060283887,0.0006808235,0.81737447,0.0000031941486,0.000043996446],"genre_scores_gemma":[0.11607756,0.004540545,0.000055633733,0.000084050414,0.000010276511,0.0073542,0.8713814,0.000014795131,0.00048152078],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986311,0.00053235464,0.0004934804,0.00018527597,0.00006130502,0.0000964502],"domain_scores_gemma":[0.9970228,0.0023294892,0.00038276194,0.00021390532,0.000039724084,0.000011306416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107598775,0.00014341745,0.0012396508,0.00012891699,0.000076850105,0.0000030820745,0.0000789763,0.00004981086,0.7268291],"category_scores_gemma":[0.00043216118,0.000091548434,0.00027187704,0.00033647637,0.000029747427,0.000027971068,0.0000445324,0.00004471086,0.000010229343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020715203,0.0015698326,0.000029623337,0.048304047,0.121740244,0.000018060226,0.003306642,0.000007742622,0.00004754488,0.000034904566,0.81969154,0.005042691],"study_design_scores_gemma":[0.011038751,0.005016241,0.01952839,0.0289625,0.7373318,0.00034763836,0.003582637,0.000012057299,0.0011391143,0.00010157963,0.19184084,0.0010984557],"about_ca_topic_score_codex":0.000016104319,"about_ca_topic_score_gemma":0.000029666702,"teacher_disagreement_score":0.7268189,"about_ca_system_score_codex":0.000014718492,"about_ca_system_score_gemma":0.00002532276,"threshold_uncertainty_score":0.37332368},"labels":[],"label_agreement":null},{"id":"W6977342807","doi":"10.6084/m9.figshare.21213405","title":"Additional file 3 of Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Psoriasis; Clinical trial; Adverse effect; MEDLINE; Psoriasis Area and Severity Index; Systematic review","score_opus":0.03312777320106693,"score_gpt":0.24359043375636424,"score_spread":0.2104626605552973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977342807","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000753816,0.18174528,1.3257804e-8,0.00003144866,0.000006078896,0.0006807455,0.8167352,0.0000031902164,0.00004422303],"genre_scores_gemma":[0.118129395,0.004635872,0.0000555061,0.00008468216,0.000010466708,0.0072921314,0.86928314,0.00001491568,0.0004938991],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9986315,0.000531901,0.0004936761,0.00018520461,0.000061316205,0.00009644379],"domain_scores_gemma":[0.9970409,0.0023112649,0.0003828213,0.00021362398,0.000040035393,0.000011305735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107555534,0.00014339953,0.001239763,0.0001288788,0.00007684424,0.000003087691,0.00007893223,0.000049807102,0.72241825],"category_scores_gemma":[0.00043205827,0.000091527734,0.00027186165,0.00033636566,0.000029749304,0.000027990161,0.000044503842,0.000044702752,0.000010328519],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021391847,0.0016118393,0.000030465571,0.050363522,0.1249614,0.000018749704,0.0033967167,0.000007955411,0.000048946196,0.000035654743,0.81406343,0.005247379],"study_design_scores_gemma":[0.011200505,0.0050218017,0.019469643,0.028976101,0.73344696,0.00034556887,0.003575947,0.000012102763,0.0011637531,0.000102082624,0.19558437,0.0011011469],"about_ca_topic_score_codex":0.000016266384,"about_ca_topic_score_gemma":0.000029845474,"teacher_disagreement_score":0.72240794,"about_ca_system_score_codex":0.000014770287,"about_ca_system_score_gemma":0.000025335183,"threshold_uncertainty_score":0.37323928},"labels":[],"label_agreement":null},{"id":"W6980099666","doi":"","title":"19) ATP. Toronto 2004. Final. Federer Roddick Russian","year":2004,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Work (physics); State (computer science); Focus (optics)","score_opus":0.008334408091932961,"score_gpt":0.1934449702177483,"score_spread":0.18511056212581536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6980099666","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000504666,0.013385571,3.7146108e-7,0.0001672415,0.0009682584,0.0005166552,0.0004346803,0.00026054986,0.9842162],"genre_scores_gemma":[0.00062639825,0.0010265171,0.0003174486,0.00030466245,0.00018612205,0.000036443234,0.0012121235,0.00014212045,0.99614817],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836737,0.00010636222,0.0006265017,0.00030831597,0.00011970374,0.00047174576],"domain_scores_gemma":[0.9987302,0.00006724898,0.000568574,0.00049911154,0.000058172813,0.00007668508],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013580118,0.000524099,0.00062476407,0.00006479272,0.00015056305,0.000033764827,0.00036915127,0.0010339902,0.6862478],"category_scores_gemma":[0.00004538861,0.0004795028,0.0002915285,0.000006788321,0.00017497134,3.650056e-7,0.000079333426,0.00022743344,0.055075727],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020088865,0.00011601035,0.0000065285203,0.0002237277,0.00042604352,0.000025531024,0.00023127656,0.000024077706,0.000002738103,0.00006223374,0.990117,0.008563944],"study_design_scores_gemma":[0.0020743986,0.0002177268,0.000039467206,0.0002536041,0.00022096073,0.00015807216,0.00011086189,1.2459647e-7,0.000092002054,0.000007996763,0.996355,0.00046980797],"about_ca_topic_score_codex":0.028719697,"about_ca_topic_score_gemma":0.00871792,"teacher_disagreement_score":0.63117206,"about_ca_system_score_codex":0.00019762242,"about_ca_system_score_gemma":0.00009758428,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W6981001980","doi":"","title":"Delia Méndez Montesinos. The Ingenious Simpleton. Upending Imposed Ideologies through Brief Comic Theatre. New York, Toronto, Plymouth, UK: lanham, Boulder, 2014.","year":2014,"lang":"en","type":"other","venue":"Redalyc (Universidad Autónoma del Estado de México)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ideology; Comics; Context (archaeology); Culture theory","score_opus":0.020157807556835515,"score_gpt":0.23788184773287444,"score_spread":0.2177240401760389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981001980","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080522805,0.2302014,0.007897427,0.0017104121,0.006913886,0.0035843693,0.0014606831,0.0031755136,0.6645335],"genre_scores_gemma":[0.3648217,0.004931018,0.00197695,0.0008136879,0.00087812514,0.000054277698,0.0014410956,0.00087363477,0.6242095],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955902,0.0007701179,0.00062662613,0.0012735693,0.00018860422,0.0015508557],"domain_scores_gemma":[0.9966664,0.00056539977,0.00083612226,0.0017081213,0.00006388485,0.00016008776],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003721399,0.0012689524,0.0014537325,0.0003389932,0.0007023795,0.00013615862,0.0016914741,0.0021142755,0.006489766],"category_scores_gemma":[0.000048628623,0.0010657463,0.00075041153,0.00029919663,0.0005662726,0.00023247991,0.00047351985,0.00076763536,0.0012290947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054507505,0.00018327832,0.0038725913,0.0000888776,0.003190065,0.00024337965,0.0028669988,0.000028937393,0.004600779,0.003980326,0.91833967,0.062060025],"study_design_scores_gemma":[0.010301483,0.0007537118,0.005460187,0.00054502446,0.0033580041,0.0011519231,0.009030774,0.000113315444,0.0023211949,0.0012941677,0.9628027,0.0028675308],"about_ca_topic_score_codex":0.056558013,"about_ca_topic_score_gemma":0.014915185,"teacher_disagreement_score":0.28429887,"about_ca_system_score_codex":0.00081548176,"about_ca_system_score_gemma":0.00059196854,"threshold_uncertainty_score":0.99954855},"labels":[],"label_agreement":null},{"id":"W6981524551","doi":"","title":"Energy-aware resource allocation in multi-user OFDM systems","year":2013,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; McGill University","keywords":"Orthogonal frequency-division multiplexing; Subcarrier; Transmitter power output; Resource allocation; Telecommunications link; Spectral efficiency; Wireless; Base station; Wireless broadband","score_opus":0.01956970068829257,"score_gpt":0.2339871102703181,"score_spread":0.21441740958202554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981524551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664343,0.0071333162,0.0000010539927,0.000011517465,0.0039675916,0.0011600881,0.0012778509,0.00036178797,0.019652467],"genre_scores_gemma":[0.8168005,0.00055167906,0.000051030172,0.00009043429,0.00004019235,0.0008305104,0.0118261855,0.00019729916,0.16961217],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952212,0.0011323323,0.0011637552,0.0013326008,0.0001985724,0.0009515384],"domain_scores_gemma":[0.99757886,0.00027773785,0.0007216174,0.0009724918,0.0003311861,0.000118112446],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057170447,0.0010100749,0.0011110465,0.0007426551,0.00074995746,0.00007183187,0.00074402115,0.002440459,0.000469926],"category_scores_gemma":[0.00013549923,0.0010050023,0.00036904513,0.00053385564,0.00006740663,0.0004700773,0.000103609906,0.0010653175,0.002175677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013429039,0.0019084349,0.0006177757,0.00087930186,0.002407675,0.00017329799,0.00009681361,0.00009466196,0.48274365,0.057673965,0.00038835066,0.45167318],"study_design_scores_gemma":[0.00742435,0.00035656383,0.00676913,0.0015761162,0.0009036177,0.000099704,0.0020256718,0.0000385955,0.2769942,0.0005221721,0.7005755,0.002714432],"about_ca_topic_score_codex":0.0032899193,"about_ca_topic_score_gemma":0.0038640294,"teacher_disagreement_score":0.7001871,"about_ca_system_score_codex":0.00070888374,"about_ca_system_score_gemma":0.000072609895,"threshold_uncertainty_score":0.99924004},"labels":[],"label_agreement":null},{"id":"W6987591403","doi":"","title":"Taming psoriatic keratinocytes - PTH's uses go up another notch.: J.Cell Biochem.","year":2004,"lang":"en","type":"article","venue":"NPARC","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"MEDLINE; Psoriasis; Melanoma; Monoclonal antibody","score_opus":0.017182039660980336,"score_gpt":0.22669904047383094,"score_spread":0.2095170008128506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6987591403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788471,0.0023243306,0.00019262989,0.00030451833,0.0014460362,0.0002288904,0.000043858945,0.000153496,0.016459182],"genre_scores_gemma":[0.986161,0.00015963567,0.0017249726,0.00029906374,0.00011776158,0.000043689823,0.00008945758,0.00003305961,0.011371384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889916,0.00008691195,0.00023379321,0.0003353276,0.000043143544,0.00040166013],"domain_scores_gemma":[0.99941957,0.000102705126,0.000096990705,0.000319257,0.00003799773,0.000023507077],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010482293,0.0002475017,0.0002733728,0.00008721304,0.0002115472,0.00002672658,0.000190103,0.00024038057,0.0014931221],"category_scores_gemma":[0.000033383272,0.00020998482,0.00012245924,0.00013551851,0.00009909802,0.000087066765,0.00004839573,0.00012322688,0.002354475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006425316,0.0002014799,0.0013739857,0.000021252365,0.00018770088,0.000008824485,0.0012505886,0.0000046365335,0.9757065,0.00066417974,0.0028710477,0.017645514],"study_design_scores_gemma":[0.0033267445,0.0001449168,0.0021844846,0.00003687039,0.00014474738,0.000018936296,0.00027800584,0.0000010158011,0.97670853,0.0012281835,0.015640989,0.00028655177],"about_ca_topic_score_codex":0.00004651952,"about_ca_topic_score_gemma":0.000015223866,"teacher_disagreement_score":0.017358962,"about_ca_system_score_codex":0.00006399222,"about_ca_system_score_gemma":0.000076169024,"threshold_uncertainty_score":0.9994196},"labels":[],"label_agreement":null},{"id":"W6990739938","doi":"","title":"The effects of interleukin-17A on T helper 2 responses in allergic airways disease","year":2015,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"Ovalbumin; Sensitization; Bronchoalveolar lavage; Cytokine; Immunoglobulin E; Immune system; Allergy; Adjuvant; Airway","score_opus":0.014315773266779712,"score_gpt":0.24785459781451963,"score_spread":0.23353882454773991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6990739938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97318906,0.009732854,4.2141677e-9,0.000019119296,0.0039291107,0.0009134209,0.00086007384,0.000099473036,0.011256891],"genre_scores_gemma":[0.96254927,0.001620744,0.000008275401,0.00008275346,0.000026890459,0.00037282944,0.0014966123,0.00011998054,0.03372263],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957489,0.0016220447,0.0008197638,0.0008640382,0.0002264231,0.0007188771],"domain_scores_gemma":[0.9962579,0.0018518483,0.000526965,0.00097031717,0.00025322204,0.00013977454],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008973787,0.00077933556,0.0008352052,0.00048532741,0.00066664215,0.000027792525,0.00077867607,0.0008982078,0.000115911826],"category_scores_gemma":[0.002171212,0.0005920618,0.00045325697,0.0003536571,0.00014679787,0.00018120534,0.000113189,0.0010181826,0.0007384348],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03618783,0.0020285582,0.00072132173,0.0009693237,0.002167474,0.0005683528,0.00015593618,0.000011854087,0.31718186,0.026742486,0.00026673885,0.61299825],"study_design_scores_gemma":[0.011593609,0.002818253,0.057626754,0.003551965,0.001455604,0.00003284596,0.00095159275,0.000001113394,0.6755234,0.016749728,0.22748667,0.0022084524],"about_ca_topic_score_codex":0.00016072871,"about_ca_topic_score_gemma":0.0013930016,"teacher_disagreement_score":0.61078984,"about_ca_system_score_codex":0.00047212353,"about_ca_system_score_gemma":0.0001507751,"threshold_uncertainty_score":0.9996531},"labels":[],"label_agreement":null},{"id":"W6991987418","doi":"","title":"IPSA's 70th Anniversary in Paris - Welcome Address","year":2019,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Delegate; Politics; Futures studies; Section (typography); Fourth World","score_opus":0.007252608396017035,"score_gpt":0.18638698238423365,"score_spread":0.1791343739882166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6991987418","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033819166,0.0033000477,6.5960926e-8,0.000068814545,0.0010073376,0.00051641325,0.0004319999,0.00012420349,0.9942129],"genre_scores_gemma":[0.0026719267,0.0010022182,0.00007550807,0.00010007126,0.00006680662,0.000018514758,0.00086733437,0.00009457992,0.99510306],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986429,0.0001497941,0.00050812925,0.00024884395,0.00008774795,0.0003625523],"domain_scores_gemma":[0.998937,0.000120375014,0.00044905415,0.00041138034,0.000049889535,0.000032293392],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014711857,0.00037517518,0.00059582933,0.00017585937,0.00004403415,0.000014768555,0.0003203668,0.00087236136,0.36669078],"category_scores_gemma":[0.000028271676,0.00035898155,0.00018165093,0.000011152151,0.00012084543,2.489542e-7,0.000094350224,0.0002868251,0.05975581],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002231986,0.00009169727,0.00008357188,0.00023537662,0.00023957124,0.00002925452,0.00015950213,0.000040639825,0.000003136954,0.000012062337,0.9956384,0.0032436189],"study_design_scores_gemma":[0.0018354806,0.00014628487,0.0001870066,0.00025891213,0.0001026574,0.000051017032,0.00013393692,7.0816185e-7,0.000052391384,0.0000017479683,0.99688166,0.00034817174],"about_ca_topic_score_codex":0.006766081,"about_ca_topic_score_gemma":0.0011982959,"teacher_disagreement_score":0.30693498,"about_ca_system_score_codex":0.000056381123,"about_ca_system_score_gemma":0.000038821974,"threshold_uncertainty_score":0.9998862},"labels":[],"label_agreement":null},{"id":"W6996239565","doi":"","title":"Renewables could supply nearly a quarter of Africa's energy by 2030 - report","year":2015,"lang":"en","type":"other","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Renewable energy; Energy supply; Energy (signal processing); Mains electricity; Electricity","score_opus":0.013836153658862945,"score_gpt":0.22273690389921422,"score_spread":0.20890075024035126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996239565","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014712087,0.02767921,0.000056651676,0.00008783253,0.0010262728,0.0001547528,0.0010919269,0.000186706,0.9695695],"genre_scores_gemma":[0.0027343268,0.00048634477,0.00014848284,0.000036731682,0.000091119735,0.000045323162,0.0035958935,0.00018556934,0.9926762],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855113,0.00014018844,0.00043970067,0.00045312868,0.00006631466,0.00034953485],"domain_scores_gemma":[0.99879956,0.000041961743,0.00041431375,0.000631236,0.00007267914,0.00004024512],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015877817,0.00037710613,0.0006965063,0.00019059904,0.00003415288,0.000009052344,0.00023728775,0.001043229,0.017772757],"category_scores_gemma":[0.00001946911,0.00029076176,0.00015663441,0.000127079,0.00015205228,0.00002743289,0.000048952992,0.00007934311,0.00032774312],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072302064,0.00017692888,0.0002516396,0.000015356012,0.0009039638,0.00005639874,0.000078729754,5.7439394e-8,0.009847771,0.00011921671,0.9868885,0.0015891221],"study_design_scores_gemma":[0.0009986938,0.00021779508,0.000013905424,0.000053414802,0.000270484,0.000111492074,0.000069173206,7.842742e-8,0.009250676,0.00007649668,0.98863953,0.00029828525],"about_ca_topic_score_codex":0.0057932315,"about_ca_topic_score_gemma":0.0011728939,"teacher_disagreement_score":0.027192865,"about_ca_system_score_codex":0.000028844574,"about_ca_system_score_gemma":0.00016289059,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W7010493639","doi":"","title":"Interleukin-27 Modulates Monocyte and Macrophage Toll-Like Receptor Responses to Bacterial and Viral Components","year":2019,"lang":"en","type":"dissertation","venue":"QSpace (Queen's University Library)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"TLR7; TLR5; Innate immune system; TLR4; Proinflammatory cytokine; Pattern recognition receptor; Immune system; Cytokine; CD14; Acquired immune system","score_opus":0.007903785856952662,"score_gpt":0.1946775252129383,"score_spread":0.18677373935598562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7010493639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934263,0.0004399783,0.0000025388943,0.0015067144,0.0024597966,0.0005551288,0.00067644473,0.00014319218,0.0007898937],"genre_scores_gemma":[0.5139484,0.0010758248,0.00031648506,0.000063152664,0.000048693706,0.0000023043535,0.0043501183,0.000054531938,0.4801405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830323,0.0003705209,0.00018520589,0.00070349453,0.00005202798,0.00038550468],"domain_scores_gemma":[0.99920374,0.00015535997,0.0001758496,0.00033121897,0.000030911757,0.00010294521],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000038991435,0.00048346835,0.00060176116,0.00046521227,0.00024455262,0.00008035965,0.00030224433,0.00067914254,0.00069889263],"category_scores_gemma":[0.000013159668,0.0005111038,0.00012882244,0.00014331809,0.00009342246,0.0005535143,0.00025650166,0.00027538856,0.00040740674],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13779673,0.0010043455,0.076536044,0.0011378084,0.0064752246,0.00092143705,0.016914302,0.0000063872676,0.32587317,0.0011957631,0.39677146,0.035367344],"study_design_scores_gemma":[0.0069315494,0.0013850486,0.16619222,0.00054482784,0.00080774276,0.0000084297135,0.0037689717,0.0000012038072,0.14893933,0.00004352369,0.6696514,0.0017257511],"about_ca_topic_score_codex":0.001085267,"about_ca_topic_score_gemma":0.000039289105,"teacher_disagreement_score":0.4794779,"about_ca_system_score_codex":0.00006972362,"about_ca_system_score_gemma":0.00009541917,"threshold_uncertainty_score":0.99973404},"labels":[],"label_agreement":null},{"id":"W7014796246","doi":"","title":"Qualità di vita e alessitimia nel trattamento con antidepressivi.","year":2013,"lang":"it","type":"dissertation","venue":"IrInSubria (University of Insubria)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Studio; Context (archaeology); Depression (economics); Rating scale","score_opus":0.023920902393123698,"score_gpt":0.23912297139425295,"score_spread":0.21520206900112926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7014796246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800537,0.005479562,0.00014777092,0.00022897792,0.0034834384,0.0012913417,0.0013238488,0.00017150071,0.007819818],"genre_scores_gemma":[0.9284753,0.0038565844,0.00023614243,0.000057032634,0.0001987892,0.000009104764,0.0071218717,0.00011518898,0.05992997],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99513793,0.0010224599,0.0008950784,0.0015101138,0.00030733767,0.0011270798],"domain_scores_gemma":[0.99584854,0.00034533066,0.001713623,0.0012705212,0.0005904064,0.00023160015],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003945952,0.0011823195,0.002108544,0.0007385856,0.0009450333,0.00007488749,0.0014110506,0.0023134456,0.0054394123],"category_scores_gemma":[0.000074396514,0.0014794415,0.0010506922,0.00055164564,0.00068748783,0.00070900714,0.00027887206,0.00080047606,0.003063337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006719701,0.003552651,0.025116567,0.0018287426,0.011020035,0.0005880156,0.026225181,0.0000308036,0.8158056,0.003485567,0.019029722,0.08659742],"study_design_scores_gemma":[0.020203106,0.0015143799,0.84045583,0.0022609823,0.0059545967,0.00012949809,0.042910144,0.000100310506,0.057389125,0.00025059265,0.025295468,0.0035359706],"about_ca_topic_score_codex":0.006673416,"about_ca_topic_score_gemma":0.001000879,"teacher_disagreement_score":0.81533927,"about_ca_system_score_codex":0.00026633288,"about_ca_system_score_gemma":0.00049332203,"threshold_uncertainty_score":0.99994123},"labels":[],"label_agreement":null},{"id":"W7018952585","doi":"","title":"Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany &amp;ndash; Methodology and Outcomes of Claims Data Analysis","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Generalized pustular psoriasis; Epidemiology; Psoriasis; Health care; Incidence (geometry); German; Disease; Generalized estimating equation","score_opus":0.46421160367894937,"score_gpt":0.5958894105916251,"score_spread":0.13167780691267578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7018952585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7811177,0.21630606,0.0007577551,0.00048720904,0.00041865263,0.00037696157,0.0004077582,0.0000101526175,0.000117802934],"genre_scores_gemma":[0.9396161,0.0547756,0.0044371453,0.00040534936,0.000019199042,0.000031799653,0.0004084909,0.000020977886,0.00028535476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933858,0.0036146492,0.0017546852,0.000715488,0.000079644895,0.00044975826],"domain_scores_gemma":[0.99502367,0.0022872286,0.0014113425,0.0010202471,0.00018330479,0.00007418055],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0049967277,0.00035162675,0.0031772447,0.0019780851,0.00016022447,0.000026682439,0.0016111757,0.0003607692,0.00093183946],"category_scores_gemma":[0.0007964357,0.00029146066,0.0002474343,0.0012706964,0.0004219292,0.00041364456,0.0014824377,0.00028582878,0.0000014862926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004236453,0.00016695671,0.9368454,0.00017284536,0.005036387,0.000003960912,0.0005384535,0.00003260043,0.020604748,0.0004608637,0.0019052367,0.033808865],"study_design_scores_gemma":[0.002008702,0.000022702283,0.986046,0.00009952578,0.0015323804,0.000007577706,0.00022830638,0.000006686764,0.0052145096,0.0022851238,0.0023421491,0.00020633005],"about_ca_topic_score_codex":0.0072786584,"about_ca_topic_score_gemma":0.0024708782,"teacher_disagreement_score":0.16153046,"about_ca_system_score_codex":0.00006285474,"about_ca_system_score_gemma":0.00020070786,"threshold_uncertainty_score":0.99998146},"labels":[],"label_agreement":null},{"id":"W7019913529","doi":"","title":"Independent and Interdependent Immunoregulatory Effects of IL-27, IFN-β, and IL-10 in the Suppression of Human Th17 Cells and Murine Experimental Autoimmune Encephalomyelitis","year":2013,"lang":"en","type":"article","venue":"Research Portal (Queen's University Belfast)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nucleofection; Gestational period; TSG101; Dysgeusia; Liquation; Emperipolesis; Diafiltration; Triacetin; Durvalumab","score_opus":0.010211832943889528,"score_gpt":0.24875061089039613,"score_spread":0.2385387779465066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019913529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99712205,0.0012730287,9.2711e-7,0.000077649915,0.00008010274,0.000615069,0.000054316653,0.000011693835,0.0007651449],"genre_scores_gemma":[0.99714124,0.00052895886,0.000013916792,0.0000033949702,0.000008870566,0.000006468911,0.000052237392,0.000010355805,0.002234539],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980915,0.00081251597,0.00023402325,0.0003368248,0.00016562428,0.000359474],"domain_scores_gemma":[0.9991668,0.0002817845,0.00011489912,0.00029743818,0.000088888984,0.000050180402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004933246,0.00018754721,0.00033015996,0.00032558673,0.00025674942,0.000018660203,0.00027990507,0.00018341064,0.00040320787],"category_scores_gemma":[0.000018194114,0.0001516964,0.00006169002,0.00014403727,0.00078334636,0.00022241034,0.0005851988,0.0003064005,0.000011410839],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023010201,0.0004452644,0.012714787,0.00014004098,0.00019418437,0.00016216333,0.004111504,2.6084842e-7,0.9771802,0.0006121554,0.00055745186,0.0036519284],"study_design_scores_gemma":[0.0029589727,0.00088805537,0.6316601,0.00016831834,0.00004076837,0.000026357255,0.008894551,7.6472026e-7,0.35464954,0.00006020711,0.00050489086,0.00014747727],"about_ca_topic_score_codex":0.0034339419,"about_ca_topic_score_gemma":0.000039023605,"teacher_disagreement_score":0.6225306,"about_ca_system_score_codex":0.000044094075,"about_ca_system_score_gemma":0.00003998707,"threshold_uncertainty_score":0.61859995},"labels":[],"label_agreement":null},{"id":"W7025088558","doi":"","title":"Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment &amp;ndash; Large-Scale Claims Data Analysis","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Services and Policy Research","funders":"","keywords":"Psoriasis; Population; Disease; Health care; Systemic therapy; Alternative medicine; Disease management; Health services; Epidemiology","score_opus":0.2838091649716806,"score_gpt":0.5161528603209563,"score_spread":0.23234369534927568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7025088558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93956643,0.05859174,0.00025406285,0.00003771733,0.00038395857,0.00037278398,0.0006045898,0.0000150278465,0.00017366825],"genre_scores_gemma":[0.9310678,0.0680943,0.00023947207,0.000022270006,0.00003369143,0.000036062185,0.00040213458,0.000010290262,0.00009393885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750245,0.0006412011,0.0007632354,0.0006740369,0.00007734874,0.00034175857],"domain_scores_gemma":[0.99817896,0.0005789029,0.0004297394,0.00060206733,0.00014560873,0.00006470948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010368342,0.00032430657,0.0011206239,0.00093350676,0.0002112876,0.00012705104,0.000930602,0.00037455835,0.00086942245],"category_scores_gemma":[0.00018189101,0.00024179636,0.00011739946,0.0014939534,0.00023314358,0.00051260676,0.0009135108,0.00018074598,0.00000436943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044816322,0.0005196067,0.86700654,0.000015671525,0.0013883346,0.0000067810643,0.00017624209,0.000008224621,0.08699234,0.000020116902,0.00028630026,0.043131687],"study_design_scores_gemma":[0.0018016576,0.000040826875,0.954512,0.00015115147,0.00068292924,0.000002552881,0.00026122096,0.000019491781,0.03949311,0.00020352464,0.002614469,0.00021709649],"about_ca_topic_score_codex":0.00042486846,"about_ca_topic_score_gemma":0.00034772858,"teacher_disagreement_score":0.08750544,"about_ca_system_score_codex":0.0001041877,"about_ca_system_score_gemma":0.00008650329,"threshold_uncertainty_score":0.9860169},"labels":[],"label_agreement":null},{"id":"W7027913292","doi":"","title":"Effect of Apremilast and Etanercept on Pruritus and Health-Related Quality of Life in Patients With Moderate to Severe Plaque Psoriasis : Results From the LIBERATE Study","year":2016,"lang":"en","type":"article","venue":"Open Repository and Bibliography (University of Liège)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Apremilast; Plaque psoriasis; Etanercept; Psoriasis; Psoriatic arthritis; Tolerability; Itching; Immune system; Adverse effect; Disease","score_opus":0.01838783965494643,"score_gpt":0.23250360916316495,"score_spread":0.21411576950821853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027913292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979944,0.00041248545,0.0000019435602,0.00022887398,0.000057012876,0.0008467667,0.00029571087,0.000006537269,0.00015625586],"genre_scores_gemma":[0.99942696,0.00040281998,0.000032400407,0.0000140657485,0.0000028761026,0.0000016274023,0.000018530665,0.0000049244786,0.00009581828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814093,0.0010199054,0.00030519892,0.0003429903,0.00006226369,0.00012869443],"domain_scores_gemma":[0.99875975,0.0005281829,0.00035337437,0.00024663095,0.00006279575,0.000049241215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006960541,0.00015143762,0.0005223704,0.0008853465,0.00020609131,0.000014091898,0.00017273163,0.00011315425,0.000006671016],"category_scores_gemma":[0.0000022822887,0.000092738424,0.000046581823,0.0012676659,0.00019668863,0.00016772031,0.00015110173,0.000075280885,5.188652e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022815555,0.00035770223,0.9697014,0.000026087815,0.0005356236,0.0000030675317,0.0023437284,0.000002018257,0.0017070669,0.0000072548537,0.00028053753,0.0022199384],"study_design_scores_gemma":[0.014044695,0.0036710058,0.9796384,0.00021284845,0.00011098599,0.0000011439835,0.0006058843,2.57286e-7,0.0015893325,0.00000836747,0.0000075127905,0.00010956971],"about_ca_topic_score_codex":0.010702662,"about_ca_topic_score_gemma":0.00039154492,"teacher_disagreement_score":0.010311117,"about_ca_system_score_codex":0.00000611763,"about_ca_system_score_gemma":0.00002371857,"threshold_uncertainty_score":0.99588513},"labels":[],"label_agreement":null},{"id":"W7032898845","doi":"","title":"Oil and gas should be the tie that binds Mexico, U.S. and Canada","year":2021,"lang":"en","type":"other","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fossil fuel; Petroleum; Work (physics); Production (economics)","score_opus":0.027746772454405686,"score_gpt":0.22730629197208957,"score_spread":0.1995595195176839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7032898845","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034764092,0.09473074,0.0000018240521,0.0033022836,0.0012667404,0.000059909627,0.00027881542,0.000057013625,0.89682627],"genre_scores_gemma":[0.0038797446,0.007841989,0.000021721264,0.0010529284,0.00006061461,0.000021841059,0.00039009762,0.00009200659,0.9866391],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992119,0.000107762615,0.00009566822,0.00031351257,0.000034106015,0.00023703836],"domain_scores_gemma":[0.9995195,0.00010290605,0.00006414068,0.0002789048,0.000009939563,0.000024569094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006067966,0.00026611568,0.00031589146,0.000050877235,0.00012247753,0.000018571645,0.00011270434,0.00043071917,0.011743476],"category_scores_gemma":[0.000007874443,0.00015849758,0.00004196517,0.000040921557,0.00013743633,0.000008703156,0.00009196541,0.00015245032,0.000012750535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013353905,0.000019954674,0.0022039285,0.00003355622,0.0008191414,0.000032191398,0.000045758316,1.7548507e-8,0.00044383516,0.00033090424,0.8987184,0.09733893],"study_design_scores_gemma":[0.00041491163,0.000024287452,0.0006729452,0.000043307988,0.0001964202,0.00008004811,0.00019824454,1.3765124e-7,0.0014729088,0.000008919358,0.9966919,0.00019597186],"about_ca_topic_score_codex":0.45816836,"about_ca_topic_score_gemma":0.8802013,"teacher_disagreement_score":0.4220329,"about_ca_system_score_codex":0.000023108227,"about_ca_system_score_gemma":0.0001890888,"threshold_uncertainty_score":0.98915994},"labels":[],"label_agreement":null},{"id":"W7043536851","doi":"","title":"Systemic agent use and mental health outcomes among patients with psoriasis","year":2023,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University Health Centre; Réseau Québécois de Recherche sur les Médicaments; McGill University","keywords":"Psoriasis; Mental health; MEDLINE; Quality of life (healthcare); Comorbidity; Medication adherence","score_opus":0.017556971517235547,"score_gpt":0.23473702226520088,"score_spread":0.21718005074796534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7043536851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864726,0.0010575595,1.6784817e-8,0.000011197633,0.0041979183,0.0016175719,0.005642757,0.00038464266,0.00061572256],"genre_scores_gemma":[0.9616893,0.0010890077,0.00005077219,0.00010571079,0.00001628532,0.00029769595,0.01621432,0.00024565696,0.020291258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995922,0.0006911527,0.0009245626,0.0012612198,0.00026227956,0.0009387495],"domain_scores_gemma":[0.99774015,0.0002925737,0.000860526,0.0006871959,0.00023160204,0.00018793909],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00044330538,0.0010293666,0.0013314851,0.0005093942,0.0016113113,0.00008613367,0.000371779,0.000962146,0.00011929856],"category_scores_gemma":[0.00017972995,0.0008558633,0.00031577007,0.00038267885,0.00010345956,0.00055195135,0.00012405781,0.00076152466,0.0006180718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037318785,0.0018054496,0.5602791,0.0018456192,0.011756551,0.00013196454,0.00040029644,0.000006355776,0.0070696096,0.0035995797,0.0003239835,0.40904963],"study_design_scores_gemma":[0.007821372,0.00080297515,0.9725053,0.0012742004,0.00084996433,0.000032375683,0.0009918724,2.9364122e-7,0.0048073404,0.00014122913,0.00928144,0.001491659],"about_ca_topic_score_codex":0.0015243983,"about_ca_topic_score_gemma":0.0041244626,"teacher_disagreement_score":0.4122262,"about_ca_system_score_codex":0.0006556321,"about_ca_system_score_gemma":0.00006603552,"threshold_uncertainty_score":0.99968845},"labels":[],"label_agreement":null},{"id":"W7065654929","doi":"","title":"FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Plaque psoriasis; Psoriasis; FLI1; Transcription factor; ETS1; Apremilast; Disease","score_opus":0.13413976111358966,"score_gpt":0.4868572810333079,"score_spread":0.3527175199197182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7065654929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8940835,0.102778725,0.000013794075,0.0004751146,0.0009814433,0.00055218843,0.00012785515,0.000048970927,0.0009383923],"genre_scores_gemma":[0.9807948,0.01762588,0.00003332423,0.00016825843,0.00007373204,0.00012706793,0.00013061753,0.000023965713,0.001022392],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980091,0.00044454483,0.0005830381,0.0004908593,0.000116164636,0.0003562862],"domain_scores_gemma":[0.9986316,0.00031624525,0.00045993537,0.00028734232,0.00019871729,0.000106158644],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005523461,0.0003374118,0.00060810265,0.0007086595,0.0004712555,0.00035262993,0.0007055757,0.00024144321,0.0023468535],"category_scores_gemma":[0.00023600354,0.0002749321,0.00014596035,0.00060925575,0.00014116053,0.0011961681,0.0006237828,0.0002714366,0.000046610337],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013117403,0.0005194313,0.24306071,0.00015460677,0.0007013163,0.000048609523,0.000160151,0.0000045047523,0.62610215,0.00033118663,0.017289318,0.11031631],"study_design_scores_gemma":[0.0016255789,0.000018223409,0.5290295,0.00094746443,0.0003808987,0.000010267225,0.00006602826,0.0000030529027,0.45938247,0.0026631001,0.005571119,0.00030230865],"about_ca_topic_score_codex":0.00009588265,"about_ca_topic_score_gemma":0.000016774844,"teacher_disagreement_score":0.28596878,"about_ca_system_score_codex":0.000056522524,"about_ca_system_score_gemma":0.00014997432,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W7066823106","doi":"","title":"Interleukin-17A signalling in murine hematopoietic stem and progenitor cells promotes proliferation and monocytic-biased differentiation","year":2025,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Haematopoiesis; Progenitor cell; Stem cell; Signalling; Progenitor; Endothelial stem cell","score_opus":0.016133029268669843,"score_gpt":0.22395390110853367,"score_spread":0.2078208718398638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7066823106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934862,0.0026628547,5.8284496e-7,0.000009975089,0.0010026006,0.0016578723,0.0003902657,0.00013012862,0.00065950636],"genre_scores_gemma":[0.9913615,0.00047197926,0.000107516855,0.00002341665,0.000023070874,0.0004530541,0.0020586974,0.0000722373,0.005428512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970337,0.0005172984,0.00083695893,0.0009990318,0.000115852505,0.0004971481],"domain_scores_gemma":[0.9987531,0.00026938028,0.00043045147,0.00031110318,0.00016574442,0.00007024358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038931618,0.00069696794,0.0008189427,0.00055627554,0.0005547711,0.00009070378,0.00020985569,0.0009811098,0.000058745012],"category_scores_gemma":[0.000091686634,0.0006834415,0.00014504054,0.0002765827,0.000046024285,0.00032575944,0.00009020009,0.0006887342,0.00004402422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010061574,0.00049606146,0.00093590753,0.0014244638,0.0006844838,0.000035761004,0.0001581242,0.000004794621,0.8251351,0.002275192,0.0000016848893,0.16784225],"study_design_scores_gemma":[0.0030888794,0.00029182064,0.0034434577,0.0011111674,0.0006259075,0.00002725267,0.00039892402,0.000037989463,0.9884586,0.0013774327,0.00044681042,0.0006917652],"about_ca_topic_score_codex":0.00008364878,"about_ca_topic_score_gemma":0.00081575644,"teacher_disagreement_score":0.16715048,"about_ca_system_score_codex":0.0002969345,"about_ca_system_score_gemma":0.00006229968,"threshold_uncertainty_score":0.99956167},"labels":[],"label_agreement":null},{"id":"W7084262131","doi":"","title":"Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epidemiology; Observational study; Agency (philosophy); Public health; Disease; Strengthening the reporting of observational studies in epidemiology","score_opus":0.2328801090056408,"score_gpt":0.5061967469177504,"score_spread":0.2733166379121096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084262131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95604455,0.041074444,0.00010798376,0.00016519713,0.00084635866,0.00020874296,0.00054465514,0.000013833123,0.0009942353],"genre_scores_gemma":[0.994704,0.0034243928,0.00022893475,0.00023693833,0.00003172529,0.000035153007,0.0003815163,0.000017662056,0.00093967555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960339,0.0013383721,0.001560234,0.0005770186,0.000094618605,0.0003958663],"domain_scores_gemma":[0.9968253,0.0012053031,0.00091401784,0.0007248108,0.00025517767,0.00007543859],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015761026,0.0003196325,0.002273965,0.0039904905,0.000093834824,0.000019037527,0.0016102284,0.0003675838,0.008018469],"category_scores_gemma":[0.0004955099,0.0002735876,0.00044871282,0.0036186322,0.000154308,0.0004493978,0.0004792793,0.00023116382,0.000015419288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009313902,0.0005584694,0.76473206,0.000013210237,0.003203905,0.000009324077,0.00012217945,0.00044856686,0.17862172,0.00007145484,0.0065510436,0.04473669],"study_design_scores_gemma":[0.0011756277,0.000037318052,0.9422263,0.00017093166,0.0019266024,0.0000015106177,0.00013283109,0.000028662667,0.05202844,0.0009106978,0.0011518477,0.00020923534],"about_ca_topic_score_codex":0.014535613,"about_ca_topic_score_gemma":0.002393938,"teacher_disagreement_score":0.17749426,"about_ca_system_score_codex":0.000070615286,"about_ca_system_score_gemma":0.00010006811,"threshold_uncertainty_score":0.9999716},"labels":[],"label_agreement":null},{"id":"W7084677491","doi":"10.1055/s-0045-1802034","title":"Abwasserbasierte Epidemiologie von Drogenrückständen. Erkenntnisse aus 10 Jahren Forschung und in Begleitung der Einführung des Cannabisgesetzes","year":2025,"lang":"de","type":"article","venue":"Das Gesundheitswesen","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"McGill University","keywords":"Disease; Epidemiology; Etiology; Quality of life (healthcare); MEDLINE","score_opus":0.030858738065889037,"score_gpt":0.3299003491996664,"score_spread":0.29904161113377736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084677491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62411624,0.35869193,0.00015002953,0.0029640142,0.004475329,0.0016179859,0.00061873964,0.00032140102,0.0070443037],"genre_scores_gemma":[0.91978705,0.021553287,0.0008007994,0.0007785545,0.0005674269,0.0005283965,0.0024207856,0.00017470703,0.053388994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910026,0.0021725078,0.0019035895,0.00196282,0.00018180585,0.0027766821],"domain_scores_gemma":[0.99519116,0.0020850482,0.0005698486,0.0016115922,0.00029030396,0.00025203812],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0019875998,0.0014591384,0.002125875,0.0011082087,0.0010371873,0.00016635544,0.001384282,0.0022816428,0.0011313308],"category_scores_gemma":[0.0015833237,0.0013937808,0.0007358217,0.0015998178,0.001080297,0.00050369184,0.00076030585,0.0011811242,0.0025228097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045935586,0.002187123,0.5952503,0.0011626856,0.018869495,0.0011772566,0.0030413507,0.00029839214,0.041585602,0.007841254,0.073644936,0.25034803],"study_design_scores_gemma":[0.011244886,0.0009035501,0.4750417,0.0018355374,0.0060237916,0.000087261884,0.0016698267,0.00021862009,0.049405586,0.008048377,0.4425975,0.0029233738],"about_ca_topic_score_codex":0.0040069944,"about_ca_topic_score_gemma":0.006102964,"teacher_disagreement_score":0.36895257,"about_ca_system_score_codex":0.00081577594,"about_ca_system_score_gemma":0.00093480776,"threshold_uncertainty_score":0.9998158},"labels":[],"label_agreement":null},{"id":"W7093292492","doi":"10.6084/m9.figshare.30416065.v2","title":"Design, Synthesis and Characterization of 2,3-Derivatives of 4,5,6,7-Tetrahydrobenzothiophene Modulators of RORγt and Evaluation of Their Inhibitory Effect on Th17 Response In Vitro and In Vivo","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scope (computer science); Intellectual property; In vitro; In vivo; Drug discovery; Commons; Property (philosophy)","score_opus":0.026177286167802526,"score_gpt":0.2546060051388784,"score_spread":0.22842871897107586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093292492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97045684,0.0052051544,0.0000014945997,0.000014368313,0.000055414832,0.0009868857,0.023253167,0.0000041103362,0.00002256235],"genre_scores_gemma":[0.9985663,0.00022303319,0.000015093215,0.000004288396,0.000004761826,0.00014539585,0.0010138736,0.000013935514,0.000013278444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960087,0.0026796828,0.0006820098,0.00036898235,0.0000879515,0.00017270895],"domain_scores_gemma":[0.9961632,0.0028678058,0.000558785,0.00023351601,0.0001591644,0.000017525337],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010779712,0.00028297782,0.0008334971,0.0007080577,0.000041030136,0.0000046241003,0.00008948375,0.00040744923,0.0009503383],"category_scores_gemma":[0.0014855693,0.00025661848,0.00006210957,0.0003963209,0.000118757845,0.00012282107,0.00008693331,0.000111324465,6.475405e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012656935,0.00026600293,0.0029308503,0.0011071883,0.00023777956,9.731398e-7,0.0017650487,0.00003241878,0.9541953,0.0000025465768,0.000008138772,0.026796807],"study_design_scores_gemma":[0.0019824465,0.00060077244,0.28186592,0.0047932947,0.00012506974,0.0000011106638,0.000104085215,0.0003573878,0.710043,0.000019062758,0.000004088313,0.000103741884],"about_ca_topic_score_codex":0.000014584683,"about_ca_topic_score_gemma":0.0000054308343,"teacher_disagreement_score":0.27893507,"about_ca_system_score_codex":0.000050174545,"about_ca_system_score_gemma":0.00015859082,"threshold_uncertainty_score":0.9999886},"labels":[],"label_agreement":null},{"id":"W7093308358","doi":"10.6084/m9.figshare.30434146","title":"Targeting Th17 Cells Through Inhibition of the Nuclear Receptor (NR) Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) in Highly Sensitized Renal Transplant Patients (HSP)","year":2019,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RAR-related orphan receptor gamma; Retinoic acid; Nuclear receptor; Retinoic acid receptor; Orphan receptor; Receptor; Nephrology; Transplantation","score_opus":0.012358165368427904,"score_gpt":0.21938202341392854,"score_spread":0.20702385804550064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093308358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384265,0.0018684056,0.000002813655,0.0003189967,0.008008999,0.005564281,0.004474013,0.00001761476,0.041318376],"genre_scores_gemma":[0.74859244,0.004904208,0.0035337256,0.00018558752,0.00038434542,0.00012744263,0.010874493,0.000842309,0.23055544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9906653,0.0034134882,0.002373254,0.0019570836,0.0003120964,0.001278772],"domain_scores_gemma":[0.99546236,0.0003023477,0.0025712426,0.0013056248,0.0002580244,0.00010040901],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0011959589,0.0014287025,0.0022772304,0.0003431602,0.0005198324,0.00011812018,0.0014103728,0.0031156319,0.08879765],"category_scores_gemma":[0.0001091427,0.001135682,0.000704806,0.0008124715,0.00067545613,0.0003987332,0.00059005024,0.0013534323,0.01938557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050469674,0.0013412684,0.0008816372,0.00012245114,0.0013702569,0.000013630358,0.00961534,0.000011218383,0.93106997,0.000024162944,0.034729294,0.015773773],"study_design_scores_gemma":[0.01356835,0.0008646486,0.00025977363,0.0033411114,0.0007189449,0.000010793325,0.0006017574,0.000003146947,0.6000184,0.000009099056,0.37940562,0.0011983777],"about_ca_topic_score_codex":0.00040084185,"about_ca_topic_score_gemma":0.000113585076,"teacher_disagreement_score":0.34467632,"about_ca_system_score_codex":0.00041094722,"about_ca_system_score_gemma":0.00041318574,"threshold_uncertainty_score":0.9998463},"labels":[],"label_agreement":null},{"id":"W7093311543","doi":"10.6084/m9.figshare.30422329","title":"Tetrahydro-benzothiophene ROR gamma t Inverse Agonists to Target Th17 in a Sensitized Skin Allograft Mouse Model","year":2023,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Inverse agonist; Tacrolimus; RAR-related orphan receptor gamma; Agonist; Transplantation; Retinoic acid; Receptor","score_opus":0.03445454277291356,"score_gpt":0.28196779920810444,"score_spread":0.2475132564351909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093311543","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79802644,0.0022988028,0.00015621702,0.0010456524,0.00405348,0.009406614,0.006135402,0.00010119559,0.17877617],"genre_scores_gemma":[0.061419524,0.0008340207,0.014278455,0.000370848,0.00023660959,0.0005031324,0.0012459552,0.0010318417,0.9200796],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932705,0.00093435403,0.0013567002,0.0024550431,0.00017917456,0.0018042246],"domain_scores_gemma":[0.9970942,0.00030411678,0.0005799721,0.0016176928,0.0001039953,0.00029999088],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0010265659,0.0015754432,0.0024282106,0.0011738655,0.00036377273,0.00024305862,0.0017211109,0.002625751,0.027659548],"category_scores_gemma":[0.00017086444,0.0015814982,0.0005827161,0.0009265225,0.0003333433,0.00024139602,0.0012040882,0.0008617728,0.03764156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0126936,0.005483907,0.0013895176,0.00021541385,0.009670097,0.005790975,0.023330843,0.007310222,0.5031091,0.00009715996,0.083595484,0.34731367],"study_design_scores_gemma":[0.020655788,0.0011024944,0.0005149781,0.0010491285,0.0015916708,0.0002210959,0.0014098315,0.0015808094,0.18677257,0.00016422746,0.78032136,0.0046160333],"about_ca_topic_score_codex":0.0018388317,"about_ca_topic_score_gemma":0.026953911,"teacher_disagreement_score":0.74130344,"about_ca_system_score_codex":0.00041322949,"about_ca_system_score_gemma":0.00076933106,"threshold_uncertainty_score":0.99969935},"labels":[],"label_agreement":null},{"id":"W7093313295","doi":"10.6084/m9.figshare.30434146.v1","title":"Targeting Th17 Cells Through Inhibition of the Nuclear Receptor (NR) Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) in Highly Sensitized Renal Transplant Patients (HSP)","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"RAR-related orphan receptor gamma; Retinoic acid; Nuclear receptor; Retinoic acid receptor; Orphan receptor; Receptor; Nephrology; Transplantation","score_opus":0.010092224183289252,"score_gpt":0.19989681721990618,"score_spread":0.18980459303661693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093313295","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11286472,0.008373639,9.586116e-7,0.0004073188,0.007312739,0.0054468345,0.8357543,0.00033007856,0.02950946],"genre_scores_gemma":[0.23797889,0.0027875789,0.00043982296,0.00045011035,0.00051086105,0.0004484941,0.6693027,0.0007385716,0.08734296],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920145,0.0026323895,0.0021085374,0.0016701324,0.0003090923,0.0012652988],"domain_scores_gemma":[0.9958629,0.0004489368,0.0020910816,0.0010636966,0.00043993813,0.00009344282],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0003315281,0.0014641496,0.001880261,0.0004516847,0.0005863446,0.000056665067,0.0008810681,0.0035411287,0.5544132],"category_scores_gemma":[0.0006033956,0.0012149363,0.0009500254,0.0011095224,0.0001981706,0.00022445817,0.0003963254,0.0015575944,0.014541154],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018337877,0.00081813947,0.00015087589,0.00076903024,0.0011134666,0.000016455306,0.0029291718,0.000009619119,0.3659164,0.000025047244,0.62337184,0.0030462067],"study_design_scores_gemma":[0.00899669,0.00051955256,0.00045132043,0.026836863,0.00051480887,0.000006403628,0.0002111033,0.000004147634,0.4488732,0.000017163326,0.512257,0.0013118088],"about_ca_topic_score_codex":0.00013148673,"about_ca_topic_score_gemma":0.000053487394,"teacher_disagreement_score":0.53987205,"about_ca_system_score_codex":0.00045283657,"about_ca_system_score_gemma":0.00047446863,"threshold_uncertainty_score":0.9998108},"labels":[],"label_agreement":null},{"id":"W7093320159","doi":"10.6084/m9.figshare.30422329.v1","title":"Tetrahydro-benzothiophene ROR gamma t Inverse Agonists to Target Th17 in a Sensitized Skin Allograft Mouse Model","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tacrolimus; Transplantation; Infiltration (HVAC); Organ transplantation; RAR-related orphan receptor gamma; In vivo","score_opus":0.020987649529194113,"score_gpt":0.24521279932391643,"score_spread":0.22422514979472233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093320159","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043539936,0.00734776,0.000021519038,0.0003986573,0.001153189,0.004080685,0.86754346,0.0004079983,0.11469273],"genre_scores_gemma":[0.01578646,0.00024147851,0.0016033562,0.0015819715,0.00027389536,0.0013970209,0.28000402,0.00043498294,0.6986768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940552,0.00075020175,0.0011660275,0.0020986537,0.00017711945,0.0017527619],"domain_scores_gemma":[0.99709463,0.0003677117,0.0005294782,0.0015293699,0.00022088757,0.00025792976],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00019042548,0.0017316132,0.002135479,0.0014719293,0.00032419348,0.00010421716,0.0010730475,0.0033736604,0.43390933],"category_scores_gemma":[0.0007989438,0.0017979831,0.00085452,0.0008762605,0.00006792285,0.00012951023,0.0007126353,0.0010774793,0.03268075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014473744,0.0011015347,0.00004953489,0.0008603535,0.0020092952,0.0008844391,0.0014592105,0.0018382985,0.020557953,0.000038197333,0.9601651,0.009588742],"study_design_scores_gemma":[0.008515451,0.00040739207,0.00030493637,0.0068150186,0.0005734408,0.0000789163,0.00017704257,0.0012331879,0.054559372,0.00011212228,0.92427635,0.002946758],"about_ca_topic_score_codex":0.00030557837,"about_ca_topic_score_gemma":0.002304269,"teacher_disagreement_score":0.58753943,"about_ca_system_score_codex":0.00042966095,"about_ca_system_score_gemma":0.0011628277,"threshold_uncertainty_score":0.999543},"labels":[],"label_agreement":null},{"id":"W7093330864","doi":"10.6084/m9.figshare.30433699.v1","title":"RORγt: A Potential Drug Target in Transplantation","year":2025,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Transplantation; Drug; Clinical trial; Retinoic acid; Secretion; RAR-related orphan receptor gamma; Antibody","score_opus":0.013453663775490475,"score_gpt":0.26023327527462836,"score_spread":0.24677961149913788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093330864","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07356727,0.010680559,0.00024195982,0.00039447608,0.0050602057,0.0029665367,0.003118851,0.000005340483,0.9039648],"genre_scores_gemma":[0.10595424,0.0022812008,0.0015594925,0.00004555554,0.000114882285,0.00009914586,0.0029779493,0.00008048331,0.8868871],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970955,0.00065964874,0.00063085405,0.0009864374,0.000053544198,0.00057398895],"domain_scores_gemma":[0.9990981,0.00009195949,0.00028925852,0.00044462786,0.000037595404,0.000038425493],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00036907522,0.00059518765,0.00089904154,0.0004964178,0.00017986393,0.00010171247,0.0008580219,0.0010947156,0.20232019],"category_scores_gemma":[0.000013455431,0.00058839255,0.00022940597,0.00029388748,0.00013247285,0.000140606,0.00015571248,0.00039589405,0.010604677],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054024286,0.002111286,0.0033499927,0.00022507156,0.0027373617,0.0012305492,0.0056256186,0.000054089778,0.019387376,0.000112147056,0.017684778,0.9420793],"study_design_scores_gemma":[0.015754852,0.00023985268,0.0077513275,0.0012915555,0.0020853546,0.00009908807,0.0006387146,0.000010694616,0.047579303,0.00017141143,0.92308885,0.0012890259],"about_ca_topic_score_codex":0.0008542335,"about_ca_topic_score_gemma":0.0030476486,"teacher_disagreement_score":0.9407903,"about_ca_system_score_codex":0.000091935275,"about_ca_system_score_gemma":0.00057346857,"threshold_uncertainty_score":0.99965674},"labels":[],"label_agreement":null},{"id":"W7093353126","doi":"10.6084/m9.figshare.30416065","title":"Design, Synthesis and Characterization of 2,3-Derivatives of 4,5,6,7-Tetrahydrobenzothiophene Modulators of RORγt and Evaluation of Their Inhibitory Effect on Th17 Response In Vitro and In Vivo","year":2024,"lang":"","type":"dissertation","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scope (computer science); Intellectual property; In vitro; In vivo; Drug discovery; Commons; Property (philosophy)","score_opus":0.027188117544807308,"score_gpt":0.262201400746085,"score_spread":0.23501328320127768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093353126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9469837,0.007987162,3.5277776e-7,0.0000049618775,0.000115066454,0.0013727805,0.04351383,0.00000641079,0.000015730895],"genre_scores_gemma":[0.9857072,0.00037294437,0.00001154489,0.0000018629743,0.000010295324,0.000331496,0.013502352,0.000040660896,0.000021633947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954905,0.002599363,0.0009787438,0.00056859665,0.00015573626,0.00020709263],"domain_scores_gemma":[0.9957664,0.0027320243,0.0009801597,0.0002555476,0.0002398635,0.000026005839],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011728929,0.00048119377,0.0012175112,0.0010790864,0.000043517557,0.000008384688,0.00010959356,0.0008012076,0.0012210113],"category_scores_gemma":[0.001366913,0.00043376622,0.00010800263,0.0004277331,0.00009323524,0.00014581763,0.000058544803,0.00021340328,0.000002164339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01719531,0.00023326099,0.0004984369,0.0035098023,0.00037483548,0.0000024550125,0.0068784817,0.000031833384,0.9503765,0.0000014602762,0.0000056776225,0.02089191],"study_design_scores_gemma":[0.0015578042,0.0010019988,0.16570859,0.012210668,0.00032077037,0.0000029431128,0.00044505595,0.00044453813,0.8180683,0.000021168955,0.0000029227795,0.00021519621],"about_ca_topic_score_codex":0.000023274368,"about_ca_topic_score_gemma":0.000015509288,"teacher_disagreement_score":0.16521016,"about_ca_system_score_codex":0.00006495939,"about_ca_system_score_gemma":0.0002146887,"threshold_uncertainty_score":0.9998114},"labels":[],"label_agreement":null},{"id":"W7093368910","doi":"10.6084/m9.figshare.30422329.v2","title":"Tetrahydro-benzothiophene ROR gamma t Inverse Agonists to Target Th17 in a Sensitized Skin Allograft Mouse Model","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Inverse agonist; Tacrolimus; RAR-related orphan receptor gamma; Agonist; Transplantation; Retinoic acid; Receptor","score_opus":0.020987649529194113,"score_gpt":0.24521279932391643,"score_spread":0.22422514979472233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093368910","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043539936,0.00734776,0.000021519038,0.0003986573,0.001153189,0.004080685,0.86754346,0.0004079983,0.11469273],"genre_scores_gemma":[0.01578646,0.00024147851,0.0016033562,0.0015819715,0.00027389536,0.0013970209,0.28000402,0.00043498294,0.6986768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940552,0.00075020175,0.0011660275,0.0020986537,0.00017711945,0.0017527619],"domain_scores_gemma":[0.99709463,0.0003677117,0.0005294782,0.0015293699,0.00022088757,0.00025792976],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00019042548,0.0017316132,0.002135479,0.0014719293,0.00032419348,0.00010421716,0.0010730475,0.0033736604,0.43390933],"category_scores_gemma":[0.0007989438,0.0017979831,0.00085452,0.0008762605,0.00006792285,0.00012951023,0.0007126353,0.0010774793,0.03268075],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014473744,0.0011015347,0.00004953489,0.0008603535,0.0020092952,0.0008844391,0.0014592105,0.0018382985,0.020557953,0.000038197333,0.9601651,0.009588742],"study_design_scores_gemma":[0.008515451,0.00040739207,0.00030493637,0.0068150186,0.0005734408,0.0000789163,0.00017704257,0.0012331879,0.054559372,0.00011212228,0.92427635,0.002946758],"about_ca_topic_score_codex":0.00030557837,"about_ca_topic_score_gemma":0.002304269,"teacher_disagreement_score":0.58753943,"about_ca_system_score_codex":0.00042966095,"about_ca_system_score_gemma":0.0011628277,"threshold_uncertainty_score":0.999543},"labels":[],"label_agreement":null},{"id":"W7093779862","doi":"","title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.","year":2005,"lang":"en","type":"other","venue":"Radboud Repository (Radboud University)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Etanercept; Placebo; Psoriasis; Psoriasis Area and Severity Index; Randomized controlled trial; Clinical endpoint","score_opus":0.00472114109832029,"score_gpt":0.22195973130267643,"score_spread":0.21723859020435615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7093779862","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5537465,0.053193346,0.00004989524,0.00004289716,0.011320665,0.015663015,0.00042526776,0.00031570002,0.3652427],"genre_scores_gemma":[0.4525539,0.0065602423,0.00006865821,0.000002687168,0.00063797325,0.000060461392,0.00024716769,0.00017361043,0.5396953],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948858,0.0028592225,0.0010390198,0.0006858783,0.0001363742,0.0003937169],"domain_scores_gemma":[0.9971822,0.0007072231,0.001415937,0.000560122,0.00006476086,0.000069759764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068745506,0.0006603663,0.0042654234,0.0009634791,0.00013393912,0.0000151092745,0.0003546114,0.001192256,0.0002707206],"category_scores_gemma":[0.00009687739,0.00055452506,0.0007734702,0.0004908024,0.00086536794,0.00007065191,0.00010626574,0.00026873508,0.000009587682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98280257,0.0012518945,0.000024494426,0.00010039016,0.0048118825,0.00012663344,0.00017654708,0.0000473475,0.0022894908,0.00087030476,0.0032652372,0.004233189],"study_design_scores_gemma":[0.9503502,0.0014031508,0.00002566745,0.0003110101,0.004597495,0.0001089512,0.00010738841,0.0000073421934,0.0007101639,0.0000018670219,0.04197765,0.00039907364],"about_ca_topic_score_codex":0.0009896668,"about_ca_topic_score_gemma":0.00003244615,"teacher_disagreement_score":0.17445262,"about_ca_system_score_codex":0.00022193354,"about_ca_system_score_gemma":0.0002490046,"threshold_uncertainty_score":0.99969065},"labels":[],"label_agreement":null},{"id":"W7094939986","doi":"10.6084/m9.figshare.30418093.v2","title":"Identification of Novel Modulators of RORγt by Rational Drug Design and Molecular Docking","year":2025,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Cytokine; Rational design; Drug; Transplant rejection; Retinoic acid; Agonist; Docking (animal); FOXP3; Inverse agonist","score_opus":0.02138042511582294,"score_gpt":0.27023747302336376,"score_spread":0.24885704790754082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094939986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8222483,0.045255437,0.07585031,0.00026310483,0.0023630408,0.0063812523,0.004687462,0.0000052329515,0.04294587],"genre_scores_gemma":[0.8191381,0.00048706617,0.004663225,0.000013608685,0.000020052563,0.00005684139,0.0007959504,0.000064072694,0.17476109],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979945,0.00033307934,0.00077970745,0.00061462907,0.00007051771,0.00020755586],"domain_scores_gemma":[0.9983291,0.00018563197,0.0009139184,0.00041372748,0.00013319553,0.000024442747],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005501512,0.00034576992,0.00068929454,0.00024151815,0.00011194824,0.000040283547,0.0004716103,0.0005256926,0.0055430653],"category_scores_gemma":[0.00005334858,0.00035126603,0.0001211583,0.00018869675,0.00024627935,0.000099763936,0.00020723404,0.00012005696,0.000070247625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003168235,0.0006044012,0.0002403179,0.00006693086,0.0016052327,0.0000018948305,0.0004869858,0.00019477382,0.924041,0.0003142852,0.002180037,0.06994737],"study_design_scores_gemma":[0.0030015197,0.00008816396,0.0003209905,0.0003235546,0.00096282177,0.000006155348,0.00013443825,0.00017580108,0.9782284,0.00006653986,0.016371569,0.00032005276],"about_ca_topic_score_codex":0.000103298844,"about_ca_topic_score_gemma":0.000010909666,"teacher_disagreement_score":0.13181522,"about_ca_system_score_codex":0.00003300872,"about_ca_system_score_gemma":0.00031579193,"threshold_uncertainty_score":0.9998939},"labels":[],"label_agreement":null},{"id":"W7094941679","doi":"10.6084/m9.figshare.30422875","title":"A Novel RORγt Inverse Agonist to Target Th17 in Sensitized Skin Allograft Mouse Model","year":2023,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tacrolimus; Colchicine; Transplantation; Agonist; Retinoic acid; Immunohistochemistry; Immunosuppression","score_opus":0.04242547981911037,"score_gpt":0.2832840437043145,"score_spread":0.2408585638852041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094941679","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5227539,0.0024226878,0.0013714918,0.0019406097,0.0071210456,0.015695276,0.020041853,0.00013212918,0.42852104],"genre_scores_gemma":[0.014253753,0.0004516513,0.025254399,0.0003701783,0.00017099273,0.00035916088,0.001400553,0.00078653,0.9569528],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99500805,0.0004649383,0.0010458279,0.0019681863,0.0001219918,0.001390984],"domain_scores_gemma":[0.9977261,0.00022284902,0.00046557692,0.0012920204,0.00008760034,0.00020589613],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008239493,0.0012304989,0.0019069792,0.00087707065,0.00032674245,0.00020713663,0.0014139235,0.0020751809,0.01997031],"category_scores_gemma":[0.00012674616,0.0012321331,0.00045545894,0.0007024856,0.00029969838,0.00018265734,0.0012336565,0.00066185574,0.03357712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008760275,0.005446653,0.00091144245,0.000107099026,0.0071135997,0.0018188256,0.016207071,0.0045271073,0.64937013,0.00009820928,0.081378154,0.22426143],"study_design_scores_gemma":[0.019456638,0.0006839826,0.00043073721,0.0006991837,0.0012821741,0.00017909122,0.0015903758,0.0011379924,0.08189391,0.000059168917,0.8892131,0.0033736653],"about_ca_topic_score_codex":0.002574649,"about_ca_topic_score_gemma":0.035699353,"teacher_disagreement_score":0.8078349,"about_ca_system_score_codex":0.000315884,"about_ca_system_score_gemma":0.0007023346,"threshold_uncertainty_score":0.9992203},"labels":[],"label_agreement":null},{"id":"W7094948017","doi":"10.6084/m9.figshare.30418093","title":"Identification of Novel Modulators of RORγt by Rational Drug Design and Molecular Docking","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Cytokine; Rational design; Drug; Transplant rejection; Retinoic acid; Agonist; Docking (animal); FOXP3; Inverse agonist","score_opus":0.019846795687820135,"score_gpt":0.2401772659566197,"score_spread":0.22033047026879957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094948017","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006067643,0.065982714,0.0023467883,0.000065478955,0.00065838854,0.0021350568,0.9176276,0.000048954473,0.005067419],"genre_scores_gemma":[0.60459626,0.00031525662,0.00044225206,0.0000541305,0.00006028208,0.00037032357,0.31692636,0.00015470848,0.077080406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982794,0.00023329174,0.00066315575,0.00051951245,0.00008173729,0.00022291661],"domain_scores_gemma":[0.99820983,0.00027667085,0.0008980294,0.00037240627,0.00021811736,0.000024955078],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011878084,0.00037473833,0.00058224413,0.0002788134,0.00009654913,0.00001586272,0.00026576227,0.0006530294,0.09558147],"category_scores_gemma":[0.00028738892,0.00039179428,0.00017872466,0.00020474024,0.000050923703,0.00006182064,0.000111395595,0.00014492913,0.00018067485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002003287,0.000641481,0.00007268328,0.0013452868,0.002219798,0.0000038047542,0.00033106696,0.00045228965,0.6246302,0.0003341895,0.35900718,0.01076168],"study_design_scores_gemma":[0.0027108684,0.000094034636,0.0007549636,0.0041187694,0.00064000644,0.000008158433,0.000053951382,0.000408804,0.9474153,0.00006691651,0.043200575,0.0005276683],"about_ca_topic_score_codex":0.00001813548,"about_ca_topic_score_gemma":0.0000023351486,"teacher_disagreement_score":0.6007012,"about_ca_system_score_codex":0.00003480858,"about_ca_system_score_gemma":0.00024071657,"threshold_uncertainty_score":0.9998534},"labels":[],"label_agreement":null},{"id":"W7094948080","doi":"10.6084/m9.figshare.30422119.v1","title":"In Vitro DMPK Assessment and Solubility Evaluation of 2,3-Derivatives of 4,5,6,7-Tetrahydro-benzothiophene Modulators of RORγt","year":2025,"lang":"","type":"other","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fluorescence anisotropy; Microsome; Lipophilicity; In vitro; Nuclear receptor; Receptor; Solubility; Drug; In vivo","score_opus":0.04792475420467565,"score_gpt":0.3508782526549182,"score_spread":0.30295349845024255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094948080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92700815,0.0066765686,0.000042420368,0.000043399075,0.0006461338,0.0023919323,0.0008846911,8.2545677e-7,0.062305853],"genre_scores_gemma":[0.9823967,0.00046216353,0.0022974554,0.0000041565263,0.000017049446,0.000071060625,0.0002332637,0.000040711984,0.014477434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955249,0.0016715855,0.0013989863,0.00086665346,0.00020384887,0.0003340272],"domain_scores_gemma":[0.99703413,0.00040757592,0.0014147074,0.0007645341,0.0003461772,0.000032846066],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002341927,0.00051768054,0.0018210863,0.0005361889,0.000064524196,0.000013400498,0.0005636285,0.0009137991,0.019335452],"category_scores_gemma":[0.00016142202,0.00049656036,0.00020827055,0.0004214258,0.0006210465,0.00016638775,0.00044629353,0.0002500551,0.000016725877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013391348,0.0021271412,0.008460692,0.00035603464,0.0022159847,0.0000021458357,0.0017195138,0.00006194766,0.65910316,0.00013020518,0.000074052805,0.32441],"study_design_scores_gemma":[0.007685831,0.0005174622,0.06334797,0.0007598701,0.0017564674,0.0000025158263,0.0008151389,0.00019524473,0.92282426,0.0006034201,0.0010785846,0.00041324648],"about_ca_topic_score_codex":0.00082935643,"about_ca_topic_score_gemma":0.0002523377,"teacher_disagreement_score":0.32399675,"about_ca_system_score_codex":0.0001713917,"about_ca_system_score_gemma":0.0013192157,"threshold_uncertainty_score":0.9997486},"labels":[],"label_agreement":null},{"id":"W7094949535","doi":"10.6084/m9.figshare.30422119","title":"In Vitro DMPK Assessment and Solubility Evaluation of 2,3-Derivatives of 4,5,6,7-Tetrahydro-benzothiophene Modulators of RORγt","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fluorescence anisotropy; Microsome; Lipophilicity; In vitro; Nuclear receptor; Receptor; Solubility; Drug; In vivo","score_opus":0.04309598469439304,"score_gpt":0.3168242129199905,"score_spread":0.2737282282255975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094949535","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30409557,0.04511007,0.000007775926,0.00005637659,0.00094935694,0.004120125,0.60176855,0.000030063946,0.04386211],"genre_scores_gemma":[0.9567223,0.0001896958,0.00016106715,0.000009032345,0.000029186533,0.0002448683,0.038716547,0.00005613422,0.0038711291],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962944,0.0011944022,0.001193977,0.0007330119,0.00023219128,0.00035202684],"domain_scores_gemma":[0.99676853,0.000579049,0.0013824725,0.0006897691,0.0005471543,0.00003299884],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000570751,0.00055167824,0.0015483386,0.00061540795,0.00005560339,0.0000055941314,0.0003299093,0.001111315,0.22809352],"category_scores_gemma":[0.0007528579,0.0005437518,0.00029642365,0.0004538398,0.00014400361,0.00010675658,0.00024843388,0.00029517803,0.000039513896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002164098,0.0054854467,0.007176974,0.013885598,0.0073171686,0.0000102325885,0.0029882577,0.0003271696,0.7678001,0.0003463251,0.022010244,0.17048837],"study_design_scores_gemma":[0.0071412707,0.00054830045,0.14575875,0.008070626,0.0012303508,0.0000033475758,0.0003592849,0.0004244693,0.8325219,0.0006324857,0.002646167,0.00066305225],"about_ca_topic_score_codex":0.00016906206,"about_ca_topic_score_gemma":0.00006276465,"teacher_disagreement_score":0.65262675,"about_ca_system_score_codex":0.00017972894,"about_ca_system_score_gemma":0.0010319066,"threshold_uncertainty_score":0.9997014},"labels":[],"label_agreement":null},{"id":"W7094949938","doi":"10.6084/m9.figshare.30421933.v2","title":"Dose–Response Evaluation of Novel RORγt Inhibitors by Low-Throughput TR-FRET and Phenotypic Assays","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Coactivator; Retinoic acid; Fluorescence anisotropy; Transplantation; Phenotype; Receptor; Kidney transplantation; Antibody; Fluorescence","score_opus":0.036121415297520415,"score_gpt":0.27789679647865906,"score_spread":0.24177538118113864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094949938","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012630661,0.081410386,0.0000074172194,0.00012532804,0.0015754048,0.00251427,0.87028414,0.00009249426,0.031359896],"genre_scores_gemma":[0.2074955,0.0005354041,0.00011298296,0.00021491532,0.00042886668,0.0012286564,0.5531505,0.00036245465,0.23647076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995615,0.0014994122,0.0008492639,0.0011436867,0.00025654907,0.0006361032],"domain_scores_gemma":[0.9966917,0.000986711,0.0009023974,0.00082733884,0.0005157531,0.00007609737],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007123392,0.0009260393,0.0011555683,0.00046088448,0.00025865645,0.00004312711,0.00045061053,0.0022242113,0.5069466],"category_scores_gemma":[0.0019956923,0.00091000926,0.00035254587,0.00041194743,0.00011099823,0.0001258583,0.0003173677,0.0004552751,0.0025523466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023297209,0.00096884364,0.00006662159,0.0007811936,0.001964403,0.000005509842,0.0004991424,0.000009131282,0.030310694,0.000017784178,0.88582367,0.07722331],"study_design_scores_gemma":[0.029436825,0.0011626317,0.00939585,0.017633697,0.0044332794,0.00003231187,0.0003071971,0.00015109428,0.066345476,0.00008893418,0.86884344,0.0021692968],"about_ca_topic_score_codex":0.000059816746,"about_ca_topic_score_gemma":0.000058631264,"teacher_disagreement_score":0.5043943,"about_ca_system_score_codex":0.00022798491,"about_ca_system_score_gemma":0.001154293,"threshold_uncertainty_score":0.99933505},"labels":[],"label_agreement":null},{"id":"W7094952053","doi":"10.6084/m9.figshare.30422527.v2","title":"A Novel 2,3-Derivative of 4,5,6,7-Tetrahydrobenzothiophene RORγt Inverse Agonist to Target Th17 Rejection in a Sensitized Mouse Skin Allograft Model","year":2025,"lang":"","type":"other","venue":"Figshare","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tacrolimus; Immunopharmacology; Agonist; Inverse agonist; Transplantation; Immune system; RAR-related orphan receptor gamma; Splenocyte; Retinoic acid","score_opus":0.025179609676123326,"score_gpt":0.247459464340729,"score_spread":0.22227985466460567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7094952053","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071496125,0.0027205902,0.0003715309,0.0001910806,0.00090828055,0.004380141,0.9159684,0.00025030738,0.068060026],"genre_scores_gemma":[0.08171484,0.00029483112,0.008550618,0.001090788,0.0002880219,0.0019737908,0.38398963,0.0006549384,0.52144253],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99555016,0.00049231114,0.0012041269,0.0015594969,0.00016161914,0.0010323081],"domain_scores_gemma":[0.9972094,0.00035823768,0.0008791419,0.0010568633,0.00036509504,0.0001312176],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00018407535,0.001269791,0.001959666,0.001524767,0.00023521626,0.000043213247,0.0006576517,0.0024275675,0.14235131],"category_scores_gemma":[0.0009865328,0.0013495246,0.00068718777,0.0011939874,0.00008626877,0.00013224223,0.0004963666,0.0008118227,0.0027154824],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039315,0.00355074,0.000047106376,0.0020348527,0.004312181,0.00023376962,0.006756239,0.008905073,0.4694335,0.00014773656,0.4950627,0.0055846325],"study_design_scores_gemma":[0.032547753,0.0019875518,0.0014655739,0.027356664,0.0015675906,0.00018915914,0.0019127271,0.006198622,0.5782881,0.00026025635,0.3422594,0.0059666466],"about_ca_topic_score_codex":0.00082688156,"about_ca_topic_score_gemma":0.0024026516,"teacher_disagreement_score":0.5319788,"about_ca_system_score_codex":0.00041314543,"about_ca_system_score_gemma":0.0010529318,"threshold_uncertainty_score":0.9988954},"labels":[],"label_agreement":null},{"id":"W7098216591","doi":"","title":"Correspondence to","year":2016,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Protocol (science); Presentation (obstetrics); Key (lock); Focus (optics); Subject (documents)","score_opus":0.01800500610670531,"score_gpt":0.24268075202110684,"score_spread":0.22467574591440154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098216591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96938795,0.00030122144,0.0018525602,0.0013088201,0.0010080577,0.00011437665,0.000018931572,0.00011881328,0.025889263],"genre_scores_gemma":[0.7482884,0.000010030676,0.000121688885,0.00025565785,0.000013260711,0.000013347766,0.0000020430741,0.000003494832,0.2512921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996105,0.000035568843,0.00006278173,0.00013109864,0.000009426886,0.00015065636],"domain_scores_gemma":[0.99971503,0.00009670486,0.0000104097235,0.0001464272,0.000016029266,0.000015401432],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00005268276,0.000060282422,0.00006967017,0.000041436553,0.0000413093,0.0000022109205,0.0000906864,0.000057233,0.011092518],"category_scores_gemma":[0.00003571278,0.000031062515,0.00002886676,0.00005576828,0.000022727183,0.000030935345,0.000028273547,0.00001216895,0.048442822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012393644,0.000023633662,0.0054688244,3.526267e-7,0.000031724834,0.000002981658,0.000045206558,2.8597826e-8,0.7208738,0.0016040697,0.040316682,0.23150879],"study_design_scores_gemma":[0.00080084783,0.0001331522,0.0337469,0.000011486708,0.000014983866,0.000018934043,0.000018452685,1.7119161e-8,0.5722494,0.00013658773,0.39276323,0.00010598825],"about_ca_topic_score_codex":0.000013534825,"about_ca_topic_score_gemma":0.000014005077,"teacher_disagreement_score":0.35244656,"about_ca_system_score_codex":0.000013032475,"about_ca_system_score_gemma":0.000012447902,"threshold_uncertainty_score":0.9898115},"labels":[],"label_agreement":null},{"id":"W7098478258","doi":"","title":"Economic Group","year":2004,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Investment (military); Econometric model; Sensitivity (control systems); Interest rate; Business cycle; Real gross domestic product","score_opus":0.011778203098606926,"score_gpt":0.21649318007850546,"score_spread":0.20471497697989854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7098478258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96262765,0.0008530154,0.00015533897,0.00020617762,0.0008217841,0.00006864686,0.000010404828,0.00010115376,0.03515584],"genre_scores_gemma":[0.99410254,0.00004358394,0.00021625214,0.00010914576,0.000028586266,0.000009955356,0.00005487111,0.0000055142777,0.005429537],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965024,0.000014520337,0.00007520929,0.00012008398,0.0000038042594,0.00013616926],"domain_scores_gemma":[0.99984455,0.000014239681,0.000016130922,0.00011402431,0.0000028614027,0.000008175649],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000033708915,0.00006883784,0.000083602514,0.000028312224,0.000059927523,0.000004169132,0.00006473097,0.00008062275,0.0020882618],"category_scores_gemma":[0.0000016567204,0.000054417444,0.000049951657,0.000016232583,0.000030276513,0.000038945578,0.000015573098,0.00002899449,0.0113795735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003141543,0.0006158209,0.020343918,0.000010463642,0.0011460823,0.000034004825,0.000619068,0.00008876319,0.38498247,0.3533621,0.011955384,0.22652775],"study_design_scores_gemma":[0.0120564755,0.0005448441,0.08775407,0.000016102196,0.00018315598,0.00020090843,0.00025287337,4.4683335e-7,0.5913928,0.010079557,0.2968933,0.0006254527],"about_ca_topic_score_codex":0.00015743783,"about_ca_topic_score_gemma":0.00015615282,"teacher_disagreement_score":0.34328258,"about_ca_system_score_codex":0.00004278231,"about_ca_system_score_gemma":0.000017441998,"threshold_uncertainty_score":0.99882394},"labels":[],"label_agreement":null},{"id":"W7099102912","doi":"","title":"Windsor Combined Sewer Overflow Treatability Study with Chemical Coagulation","year":2014,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Settling; Sewage; Coagulation; Sewage treatment; Windsor; Wastewater","score_opus":0.012346178399421053,"score_gpt":0.22671085833915297,"score_spread":0.2143646799397319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099102912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504334,0.000032186654,0.00016105312,0.00006532783,0.00017136682,0.00040175288,0.0000091314705,0.00012058754,0.0039952393],"genre_scores_gemma":[0.9970626,7.9340884e-7,0.00012092434,0.000046280602,0.000032756005,0.00004164531,0.00015937709,0.00001171731,0.0025238993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907947,0.00019035913,0.00016556775,0.00031493473,0.00004019862,0.00020944767],"domain_scores_gemma":[0.9993805,0.00014270458,0.000047072113,0.0003590942,0.000048660037,0.000021947464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019905623,0.00017231259,0.0002577002,0.000035914938,0.00010811843,0.000011270198,0.00010382923,0.00013083786,0.00085353735],"category_scores_gemma":[0.00002890954,0.00011331586,0.00005078351,0.000093980576,0.00007905135,0.00006543471,0.000031757616,0.00007306307,0.0003220137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020716838,0.0022487273,0.91775906,0.0000071335667,0.00048530044,0.0000021819105,0.000443452,0.0000045426264,0.059751272,0.00043631648,0.00072720717,0.016063126],"study_design_scores_gemma":[0.013075044,0.0024665084,0.833622,0.0000080902455,0.00039041444,0.000014154726,0.00038616415,0.000030660358,0.14780322,0.00013526312,0.0017162167,0.00035226275],"about_ca_topic_score_codex":0.00009351414,"about_ca_topic_score_gemma":0.00006301661,"teacher_disagreement_score":0.088051945,"about_ca_system_score_codex":0.000029504612,"about_ca_system_score_gemma":0.000017658262,"threshold_uncertainty_score":0.9345636},"labels":[],"label_agreement":null},{"id":"W7099863632","doi":"","title":"GENDER IDENTITY Disorders Edited by","year":2014,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Section (typography); Identity (music); Permission; Authorization; Payment","score_opus":0.011704271896535298,"score_gpt":0.23041461615658232,"score_spread":0.218710344260047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7099863632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88362575,0.0025275138,0.010163387,0.00050915824,0.0033809945,0.0002299182,0.000051242652,0.00033833057,0.09917373],"genre_scores_gemma":[0.9863972,0.00009178402,0.00006655388,0.00023534613,0.000047543166,0.000013261095,0.00022522866,0.00000915489,0.012913902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993848,0.00010188347,0.000104706676,0.00018182215,0.000019943425,0.00020683916],"domain_scores_gemma":[0.99970824,0.000058478392,0.000029628565,0.00017414706,0.000014403739,0.000015086123],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00011030985,0.0001068904,0.00012043887,0.000037492377,0.00011462128,0.000010188108,0.0001200613,0.00013872604,0.0023019344],"category_scores_gemma":[0.000023328013,0.00008453587,0.00006582298,0.00007494337,0.000053770225,0.00010748992,0.000031748335,0.000054858367,0.00225251],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012243216,0.00057293364,0.06234053,0.00001775144,0.0007947902,8.6548795e-7,0.00032579098,0.0000015711879,0.2507045,0.020336311,0.5031577,0.16162483],"study_design_scores_gemma":[0.003301377,0.00015343474,0.05609525,0.0000037914642,0.00017484497,0.000008445728,0.00013211857,0.0000078687035,0.054001767,0.0040336004,0.88167953,0.00040794356],"about_ca_topic_score_codex":0.00010786411,"about_ca_topic_score_gemma":0.000100036916,"teacher_disagreement_score":0.37852186,"about_ca_system_score_codex":0.0000102596305,"about_ca_system_score_gemma":0.000006982411,"threshold_uncertainty_score":0.9986101},"labels":[],"label_agreement":null},{"id":"W7104430847","doi":"","title":"Multidisciplinary Management of Psoriasis: Integrating Diet, Exercise, Psychological Support, and Sleep Interventions","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child, Adolescent and Family Mental Health","funders":"","keywords":"Multidisciplinary approach; Psoriasis; Context (archaeology); Psychological intervention; Mental health; Quality of life (healthcare); Disease; MEDLINE; Translational research","score_opus":0.1733110566153459,"score_gpt":0.5212749571244897,"score_spread":0.3479639005091438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104430847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8791488,0.08224866,0.00057120604,0.00010903501,0.0014184893,0.000841318,0.00009125113,0.000058610916,0.035512645],"genre_scores_gemma":[0.9756485,0.01722251,0.00076210813,0.000027630816,0.000017522647,0.00011906999,0.000045535166,0.000026030784,0.006131085],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980055,0.00027339061,0.0008908828,0.00045181287,0.000081213366,0.0002972132],"domain_scores_gemma":[0.998701,0.00017092333,0.000572734,0.00040197352,0.00010136582,0.000051997806],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006731538,0.00029082483,0.00076033996,0.00065399846,0.00024340955,0.0001229644,0.001131918,0.0001889281,0.0073670205],"category_scores_gemma":[0.00004776905,0.00023456992,0.0003208609,0.0005787252,0.00022528159,0.00042056153,0.0011264082,0.00023290933,0.00002895054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022232481,0.002527944,0.3601825,0.0006935452,0.0038326136,0.00008921262,0.00039867137,0.000009535612,0.061933428,0.0021823216,0.025748814,0.5401782],"study_design_scores_gemma":[0.0024531335,0.0000983517,0.96397424,0.0025761046,0.0011466942,0.000016909727,0.0007370484,0.0000042021106,0.022986025,0.003325686,0.002356505,0.00032509235],"about_ca_topic_score_codex":0.00009631107,"about_ca_topic_score_gemma":0.000027476095,"teacher_disagreement_score":0.6037918,"about_ca_system_score_codex":0.000032622713,"about_ca_system_score_gemma":0.000017383878,"threshold_uncertainty_score":0.9935404},"labels":[],"label_agreement":null},{"id":"W7108071130","doi":"10.2139/ssrn.5797402","title":"Scan Psoriasis: A Vision Transformer-Based Psoriasis Detection and Clinical Classification","year":2025,"lang":"","type":"preprint","venue":"SSRN Electronic Journal","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada); University of Toronto","funders":"","keywords":"Interpretability; Discriminative model; Convolutional neural network; Pattern recognition (psychology); Binary classification; Binary decision diagram; Classifier (UML); Psoriasis","score_opus":0.021028858417397732,"score_gpt":0.30098150444922617,"score_spread":0.27995264603182846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108071130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82720965,0.07802997,0.06597964,0.0034825907,0.01979867,0.002982572,0.00033984566,0.0002790364,0.0018980238],"genre_scores_gemma":[0.8191786,0.17581382,0.00014580984,0.00011813411,0.0009696918,0.00012758638,0.00021916916,0.00007387994,0.0033533156],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9869866,0.0033360852,0.002857325,0.0019762435,0.00029812922,0.0045456607],"domain_scores_gemma":[0.99566376,0.00084796787,0.001717874,0.0010000721,0.00052699435,0.00024331393],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0078052464,0.0013963849,0.0019018053,0.0011382472,0.0018710896,0.00024717912,0.00092893903,0.0036769467,0.0002091251],"category_scores_gemma":[0.00030918556,0.0013160427,0.0017322566,0.0006567195,0.0006343665,0.00034762712,0.00014392807,0.010111,0.00014697571],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006513926,0.0013594456,0.003397615,0.00015009771,0.006691621,0.000006508338,0.0002479197,0.000025651048,0.006438031,0.003300015,0.000062542436,0.97180665],"study_design_scores_gemma":[0.15884292,0.053420212,0.2615757,0.008405879,0.079637334,0.0064716237,0.022810588,0.005906659,0.05706451,0.21776018,0.114039175,0.014065233],"about_ca_topic_score_codex":0.0003074488,"about_ca_topic_score_gemma":0.0044813016,"teacher_disagreement_score":0.9577414,"about_ca_system_score_codex":0.003108616,"about_ca_system_score_gemma":0.011014544,"threshold_uncertainty_score":0.99987864},"labels":[],"label_agreement":null},{"id":"W7108442680","doi":"10.2196/71468","title":"Identifying Over- and Underfunded Diseases by Comparing National Institutes of Health Funding for Skin Disease Research With US Skin Disease Burden According to 2021 Global Burden of Disease Data: Cross-Sectional Analysis","year":2025,"lang":"en","type":"article","venue":"JMIR Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Burden of disease; Disease burden; Disease; Public health; Quality-adjusted life year; Disability-adjusted life year","score_opus":0.09546766742555163,"score_gpt":0.41839561364994404,"score_spread":0.3229279462243924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108442680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98274654,0.008318108,0.0026619555,0.00071116834,0.00032111167,0.00090960454,0.0042553996,0.000029767445,0.00004632519],"genre_scores_gemma":[0.99449664,0.000105840576,0.00012467276,0.000054984957,0.000058708312,0.00025616938,0.0047315476,0.000013944037,0.00015749354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721503,0.00046265073,0.0006876528,0.0008330584,0.00022227419,0.00057931413],"domain_scores_gemma":[0.9979658,0.00064210914,0.00028765269,0.00053922384,0.00032009525,0.00024509936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041489935,0.0002738588,0.0007501913,0.0006975207,0.0006454254,0.0000846376,0.00050299236,0.00011663144,0.000032721877],"category_scores_gemma":[0.0003255271,0.0002611315,0.0001831539,0.0011523688,0.0005073628,0.00031532045,0.00054774794,0.00012960762,0.0000051575057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036387462,0.0003096464,0.9873429,0.0006293256,0.0021044598,0.000013162796,0.000083698025,0.0007131438,0.00049392984,0.0023867735,0.0011786362,0.0011055649],"study_design_scores_gemma":[0.0028807952,0.000050337272,0.99262476,0.0001676616,0.00075648515,0.0000055952237,0.00027270598,0.0004090402,0.00025797996,0.0010559908,0.0012923735,0.00022629448],"about_ca_topic_score_codex":0.00059871055,"about_ca_topic_score_gemma":0.00019033966,"teacher_disagreement_score":0.011750079,"about_ca_system_score_codex":0.0002389441,"about_ca_system_score_gemma":0.0011012842,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W7112546252","doi":"","title":"Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: a population-based cohort study","year":2021,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Concordance; Psoriasis; Record linkage; Cancer; Cohort; Cohort study; Medical record","score_opus":0.03746643819822834,"score_gpt":0.28567782250916934,"score_spread":0.248211384310941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112546252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981108,0.0006839103,0.000010221264,0.000046451398,0.00006349692,0.0010437784,0.000028532557,0.00000586838,0.000006954711],"genre_scores_gemma":[0.99944586,0.00027667367,0.00012825723,0.000005260775,0.000006364776,0.00003026182,0.00008320867,0.000008401854,0.000015712527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988764,0.00035670737,0.00012435093,0.00034568008,0.000082597755,0.00021429968],"domain_scores_gemma":[0.9993779,0.00022920227,0.00006502877,0.00016358477,0.00014086707,0.000023411236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040387828,0.00010767187,0.00026602804,0.00011848923,0.00018063394,0.000006801432,0.00008218646,0.00006694501,0.0000067673027],"category_scores_gemma":[0.00003785192,0.00009411062,0.000020125322,0.00015993709,0.0001249171,0.00013453575,0.00010220871,0.00013172346,3.9576773e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000598693,0.00023748408,0.9811592,0.000102965336,0.00013912917,0.000005067101,0.008399678,0.0000031703876,0.00004418267,0.0000018466546,0.0000041759317,0.009304384],"study_design_scores_gemma":[0.0052918177,0.00033239726,0.98046315,0.00021807959,0.000074243944,4.576904e-7,0.0133963125,0.00000961183,0.00007849318,0.000014587512,0.000019896383,0.00010097805],"about_ca_topic_score_codex":0.0009753676,"about_ca_topic_score_gemma":0.0013543428,"teacher_disagreement_score":0.009203405,"about_ca_system_score_codex":0.0001948918,"about_ca_system_score_gemma":0.0000879527,"threshold_uncertainty_score":0.383772},"labels":[],"label_agreement":null},{"id":"W7114942062","doi":"","title":"Recommendations for the long-term treatment of psoriasis with infliximab: A dermatology expert group consensus","year":2008,"lang":"en","type":"article","venue":"Research at the University of Copenhagen (University of Copenhagen)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Infliximab; Psoriasis; Expert opinion; Delphi method; Delphi; Alternative medicine; MEDLINE","score_opus":0.08280508335510837,"score_gpt":0.29048926432756667,"score_spread":0.20768418097245828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7114942062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96568817,0.020752028,0.0011173015,0.00268012,0.0001377104,0.001961378,0.00042142117,0.000033145316,0.0072087063],"genre_scores_gemma":[0.85508394,0.0037578025,0.00055452326,0.000012724572,0.000010732735,0.0000023060766,0.00018889668,0.000015607588,0.14037344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979776,0.00082616456,0.00020599947,0.0003613178,0.00016117748,0.00046772847],"domain_scores_gemma":[0.996687,0.0018205766,0.0002907405,0.0006737395,0.0004630889,0.00006487885],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003797242,0.00022168392,0.00056152104,0.000183258,0.0019950084,0.000005104141,0.00081150624,0.00019756147,0.058240455],"category_scores_gemma":[0.00003381049,0.00017015083,0.00028944755,0.00045459895,0.0021585026,0.00012938317,0.00025731127,0.00013576944,0.0034070485],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012498181,0.0012707869,0.00042721946,0.00009172474,0.0040291776,0.00026461133,0.018206311,0.000019955578,0.026362427,0.00030004393,0.90782046,0.0287091],"study_design_scores_gemma":[0.013960609,0.0025951988,0.03527099,0.000099924575,0.00078652176,0.00030051442,0.01594253,0.000023804765,0.056635283,0.0000043290906,0.8740401,0.00034016135],"about_ca_topic_score_codex":0.0015314168,"about_ca_topic_score_gemma":0.0020951726,"teacher_disagreement_score":0.13316473,"about_ca_system_score_codex":0.00021335298,"about_ca_system_score_gemma":0.00031385967,"threshold_uncertainty_score":0.99930423},"labels":[],"label_agreement":null},{"id":"W7115808992","doi":"","title":"Investigating the Role of Interleukin 17 in HIV and TB Infections","year":2024,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Proinflammatory cytokine; Tuberculosis; Cytokine; Disease; Human immunodeficiency virus (HIV); Interleukin 17; Viral load; Antiretroviral therapy; Lung","score_opus":0.008866036990350873,"score_gpt":0.19881120278765158,"score_spread":0.1899451657973007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115808992","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59507084,0.004242801,0.0000020335685,0.000045310833,0.0004519605,0.00021289621,0.00005738551,0.0000397157,0.39987704],"genre_scores_gemma":[0.35182977,0.00013143255,0.000024559482,0.000013487621,0.000019603085,0.0000033185681,0.0003494053,0.000019847075,0.6476086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999264,0.00013411079,0.00016305194,0.00025566167,0.00002378654,0.00015937614],"domain_scores_gemma":[0.9996152,0.00009298539,0.00011334105,0.00013668166,0.000027128739,0.000014643248],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006015282,0.00019394288,0.00024045832,0.00021536658,0.00009978336,0.000015943644,0.00016120957,0.0003037443,0.0066969027],"category_scores_gemma":[0.00001187574,0.00016257005,0.00008827504,0.00033100828,0.00009546574,0.00006823279,0.00006894627,0.00030270123,0.00007783165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024057963,0.00019010229,0.055249434,0.00032122503,0.0012614927,0.00004416477,0.018724525,0.000018806206,0.041345857,0.00715551,0.0017980316,0.87365025],"study_design_scores_gemma":[0.0021673492,0.0002519406,0.024107583,0.0011864391,0.0012216145,0.00003215533,0.057828795,0.00002999119,0.027611503,0.0015402245,0.8834234,0.000598988],"about_ca_topic_score_codex":0.0004144964,"about_ca_topic_score_gemma":0.0051996848,"teacher_disagreement_score":0.88162535,"about_ca_system_score_codex":0.000054892316,"about_ca_system_score_gemma":0.00006346299,"threshold_uncertainty_score":0.99421114},"labels":[],"label_agreement":null},{"id":"W7116677603","doi":"10.58931/cibdt.2025.3348","title":"Is IL-23 the Winner? Lessons from Inflammatory Bowel Disease (IBD) and Psoriasis (PsO)","year":2025,"lang":"","type":"article","venue":"Canadian IBD Today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Inflammatory bowel disease; Psoriasis; Ulcerative colitis; Disease; Crohn's disease; Inflammatory Bowel Diseases; Clinical trial; Pathogenesis","score_opus":0.013215833767124718,"score_gpt":0.23253063664412862,"score_spread":0.21931480287700392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116677603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8161738,0.10511735,0.000018208497,0.04989427,0.008102584,0.0012056464,0.012334092,0.000089006084,0.007065058],"genre_scores_gemma":[0.9479179,0.005216249,0.000016069938,0.0052689123,0.00039569745,0.0001609426,0.00051731954,0.00005954571,0.04044736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610895,0.0006863734,0.00064431963,0.0011408249,0.0000883634,0.0013311475],"domain_scores_gemma":[0.9969838,0.0005781053,0.00019819033,0.0014107013,0.0001298283,0.00069935643],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003406235,0.0007640882,0.0006482227,0.00049808156,0.0018678198,0.00018725429,0.000781953,0.00087702373,0.0031725655],"category_scores_gemma":[0.00018933926,0.000654354,0.0003796473,0.00044075496,0.00091225107,0.00018529418,0.00019877247,0.00057913206,0.0010644364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013118652,0.0003227723,0.27567157,0.0002597958,0.009595701,0.0009168205,0.01032226,0.000013541721,0.0030744688,0.01883537,0.39527023,0.28440562],"study_design_scores_gemma":[0.0024858394,0.000058167858,0.43442893,0.00026891145,0.0020173823,0.000008395679,0.0009800531,0.000020106696,0.0018344399,0.0024381534,0.5547833,0.0006763032],"about_ca_topic_score_codex":0.07051594,"about_ca_topic_score_gemma":0.189716,"teacher_disagreement_score":0.2837293,"about_ca_system_score_codex":0.0004737107,"about_ca_system_score_gemma":0.002734318,"threshold_uncertainty_score":0.99971336},"labels":[],"label_agreement":null},{"id":"W7117150585","doi":"10.1016/j.jaad.2025.12.066","title":"Biologic therapy and risk of paradoxical eczema in psoriasis: A propensity-matched cohort analysis of tumor necrosis factor-α and interleukin 17 inhibitors using TriNetX","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Interleukin 17; Tumor necrosis factor alpha; Immunopathology; Interleukin; Cohort; Cohort study; Necrosis","score_opus":0.0256706818352078,"score_gpt":0.28643143368582524,"score_spread":0.2607607518506174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117150585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949857,0.003958458,0.000018922385,0.0006730424,0.00010569005,0.00020247014,0.000043821066,0.0000036375725,0.000008243087],"genre_scores_gemma":[0.99638784,0.0032507363,0.00021002782,0.00012117455,0.000008577508,0.00000327512,0.0000016670011,0.0000061905644,0.000010526209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974486,0.0010008616,0.0010801362,0.0002011907,0.00005703359,0.00021214235],"domain_scores_gemma":[0.99707687,0.00052858895,0.0021663513,0.00013976988,0.00006306418,0.00002535024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003497416,0.00020823609,0.0018938207,0.00077304646,0.000053370735,0.000003932212,0.0002900623,0.00018719755,0.000010491152],"category_scores_gemma":[0.00015347922,0.00012539225,0.00033377885,0.0009459236,0.0010885799,0.000060078655,0.00012902022,0.00036950238,1.8171501e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012465202,0.00016119456,0.8554413,0.000021149002,0.0047215126,0.0000047074677,0.0003081902,0.000020384461,0.13333395,0.000025111793,0.000057920108,0.0046580913],"study_design_scores_gemma":[0.0017751775,0.0002002125,0.8425014,0.00008239217,0.0018746753,0.00024776696,0.0002800438,0.000033343644,0.15268826,0.00012401657,0.000099531535,0.000093148425],"about_ca_topic_score_codex":0.00024746286,"about_ca_topic_score_gemma":0.000016403059,"teacher_disagreement_score":0.01935431,"about_ca_system_score_codex":0.00003199356,"about_ca_system_score_gemma":0.00007795725,"threshold_uncertainty_score":0.5113348},"labels":[],"label_agreement":null},{"id":"W7117298190","doi":"10.1177/12034754251409046","title":"Oral JAK and TYK2 Inhibitors in the Management of Nail Psoriasis: An Evidence-Based Review","year":2025,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Health Sciences Centre; Women's College Hospital; University of British Columbia; University of Toronto; Sunnybrook Health Science Centre; University of Windsor; Western University","funders":"","keywords":"Nail disease; Ruxolitinib; Nail (fastener); Oral cavity; Onycholysis","score_opus":0.04210655244168275,"score_gpt":0.29475050866724284,"score_spread":0.2526439562255601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117298190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6518541,0.34194258,0.0000062209615,0.005211799,0.00057124475,0.00014831236,0.0000015385946,0.0000035567218,0.00026064017],"genre_scores_gemma":[0.83637744,0.16187993,0.000036272675,0.0015054372,0.000049758317,0.0000045398024,0.0000044671006,0.000004174907,0.00013797653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986141,0.00040872427,0.00063683046,0.00011693033,0.00008204958,0.00014139511],"domain_scores_gemma":[0.9984125,0.0010547279,0.00028293376,0.0001487552,0.00007814672,0.000022934357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016546474,0.00012909304,0.00059844065,0.00025078893,0.00005371879,0.0000049090563,0.00010569378,0.00007819511,0.00005047726],"category_scores_gemma":[0.00015578557,0.00007131444,0.00008923841,0.00025310196,0.0001544553,0.00007681122,0.000015550595,0.00014234045,9.815894e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015150133,0.00038456527,0.03808405,0.0030467864,0.001015544,0.0018484427,0.0008620142,0.0000022834354,0.0025264635,0.00032137806,0.047304742,0.90308875],"study_design_scores_gemma":[0.01837651,0.008181047,0.15871924,0.32802215,0.01753949,0.01994886,0.02296268,0.000018221204,0.011009917,0.0027442926,0.41090554,0.0015720613],"about_ca_topic_score_codex":0.00003173648,"about_ca_topic_score_gemma":0.00001115327,"teacher_disagreement_score":0.9015167,"about_ca_system_score_codex":0.000015071392,"about_ca_system_score_gemma":0.000073462856,"threshold_uncertainty_score":0.29081184},"labels":[],"label_agreement":null},{"id":"W7117357993","doi":"10.1080/2162402x.2025.2604877","title":"IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells","year":2025,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Associazione Italiana per la Ricerca sul Cancro; Fondazione Umberto Veronesi; Ministero della Salute","keywords":"Inflammasome; Immune system; Tumor microenvironment; Regulator; Cytokine; Inflammation; Mechanism (biology); Transcription factor; Signal transduction; Innate immune system","score_opus":0.009705949025675373,"score_gpt":0.23826926724224454,"score_spread":0.22856331821656917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117357993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96568197,0.02692895,0.0012666357,0.0012229492,0.0015872561,0.000667043,0.0007076249,0.00007988275,0.0018576925],"genre_scores_gemma":[0.98571754,0.00033884982,0.00009068677,0.00018118811,0.000024406352,0.00009477167,0.00006914387,0.000023882692,0.013459549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980594,0.00036449364,0.0005835074,0.00045104325,0.000037503953,0.0005040851],"domain_scores_gemma":[0.9981988,0.00074619905,0.000305947,0.0006477786,0.00008397332,0.00001728268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039513168,0.00034730133,0.000831481,0.00015163187,0.00032675735,0.000011928396,0.00048385715,0.00041563815,0.00034939527],"category_scores_gemma":[0.00006320366,0.0002520419,0.00018861027,0.00020561695,0.0006304077,0.000055872468,0.00040282492,0.00031816453,0.00028826192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067689636,0.00017285191,0.0011094785,0.000029141009,0.0020097825,0.0000052242267,0.0003791389,9.883762e-7,0.97860783,0.0057010124,0.00039766057,0.010910009],"study_design_scores_gemma":[0.008300054,0.0006591913,0.021319844,0.000088119166,0.0008907865,0.00008390852,0.0005729052,0.0000020282434,0.9341816,0.0009329905,0.032686252,0.0002823788],"about_ca_topic_score_codex":0.00035743215,"about_ca_topic_score_gemma":0.00007740295,"teacher_disagreement_score":0.044426274,"about_ca_system_score_codex":0.000098096665,"about_ca_system_score_gemma":0.00010197099,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W7117359151","doi":"10.1177/12034754251403190","title":"Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis","year":2025,"lang":"en","type":"article","venue":"Journal of Cutaneous Medicine and Surgery","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; McMaster University; Université Laval; Quest University Canada; SKiN Health; University of British Columbia; Research Canada; Ottawa Hospital; Probity Medical Research; Dermatrials Research; University of Ottawa","funders":"AbbVie Canada","keywords":"Psoriasis; Anxiety; Quality of life (healthcare); Disease; Life course approach; MEDLINE; Harm","score_opus":0.03247588591210198,"score_gpt":0.2551598854625542,"score_spread":0.2226839995504522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117359151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99116814,0.004225155,0.000027436881,0.0023209972,0.0009681387,0.00011971428,0.0000086367,0.000005114056,0.0011566458],"genre_scores_gemma":[0.9985942,0.00054015726,0.000009305777,0.000532202,0.000046596444,0.000001563291,0.000015017164,0.0000069990597,0.00025394023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989484,0.00012994472,0.00044006208,0.000115853356,0.00006777009,0.0002979563],"domain_scores_gemma":[0.9987769,0.0007243706,0.00020649117,0.00008151156,0.00010180849,0.00010888358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041531026,0.00014642127,0.00051200646,0.00060811994,0.0001058115,0.000006524694,0.00005541987,0.00011065285,0.0001229257],"category_scores_gemma":[0.00018544587,0.000094842224,0.000059613638,0.00023989643,0.000121661025,0.000060552476,0.000008016791,0.00016565203,0.0000023574175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012092249,0.00018932257,0.9678085,0.000028796278,0.00091024244,0.00062094344,0.0010844745,0.000014542119,0.000048839687,0.00023265515,0.020081986,0.0077704773],"study_design_scores_gemma":[0.014934203,0.0026434264,0.9302834,0.0032078605,0.0021088966,0.0014052397,0.008913615,0.000014615671,0.00023662332,0.0013130368,0.034286384,0.00065267325],"about_ca_topic_score_codex":0.0057216287,"about_ca_topic_score_gemma":0.012781491,"teacher_disagreement_score":0.03752507,"about_ca_system_score_codex":0.00021606326,"about_ca_system_score_gemma":0.00067335315,"threshold_uncertainty_score":0.8649429},"labels":[],"label_agreement":null},{"id":"W7117452601","doi":"10.1080/09546634.2025.2592448","title":"A novel nomogram based on clinical features and laboratory parameters to predict biologic-refractory psoriasis patients","year":2025,"lang":"en","type":"article","venue":"Journal of Dermatological Treatment","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Nomogram; Psoriasis; Predictive value of tests; Clinical trial","score_opus":0.030167742732322405,"score_gpt":0.3003088606808256,"score_spread":0.27014111794850315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117452601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949087,0.0015144907,0.00021025118,0.0009708609,0.0014158988,0.000428859,0.0001935263,0.00004059521,0.00031680753],"genre_scores_gemma":[0.9960751,0.00032796015,0.0019027889,0.0014420232,0.00003489687,0.00004126562,0.000044544013,0.000009561637,0.00012187368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979551,0.0005032888,0.0007632067,0.00036113273,0.00007864804,0.00033866597],"domain_scores_gemma":[0.9979794,0.0011276947,0.00035181886,0.0002574191,0.00016328767,0.000120383054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002734472,0.00034625694,0.0008244671,0.0002871661,0.00015579321,0.000028488897,0.00020462806,0.0004797978,0.00003483012],"category_scores_gemma":[0.0004370108,0.00019976402,0.00034910633,0.00023239732,0.00017708393,0.000056665147,0.000047984948,0.00025980093,0.00003411559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004266023,0.00874423,0.85272217,0.000017489818,0.0019669342,0.00013601438,0.00007367607,0.000048565566,0.0017489846,0.00016711962,0.007544634,0.122564144],"study_design_scores_gemma":[0.014317838,0.010775765,0.93913215,0.0001381912,0.0007241258,0.00008386137,0.00008028774,0.00000431903,0.0075186254,0.00007814367,0.026856748,0.00028996225],"about_ca_topic_score_codex":0.0000069550406,"about_ca_topic_score_gemma":0.000004059661,"teacher_disagreement_score":0.12227418,"about_ca_system_score_codex":0.00014167462,"about_ca_system_score_gemma":0.000125319,"threshold_uncertainty_score":0.81461406},"labels":[],"label_agreement":null},{"id":"W7117484199","doi":"10.1093/pnasnexus/pgaf406","title":"Soluble CD14 promotes Th17 expansion and differentiation through gamma-aminobutyric acid and expands non-canonical innate lymphoid cells","year":2025,"lang":"en","type":"article","venue":"PNAS Nexus","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Glycomics Centre; Northern Alberta Institute of Technology; Women and Children’s Health Research Institute; University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; Canada Foundation for Innovation","keywords":"Innate lymphoid cell; CD14; Chemokine; Innate immune system; Cytokine; Immune system; Peripheral blood mononuclear cell; Cellular differentiation; Transcription factor","score_opus":0.012825534796724483,"score_gpt":0.23741551834155897,"score_spread":0.22458998354483448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117484199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98557097,0.010474601,0.00043602262,0.00018963433,0.001132496,0.0003387748,0.000024270097,0.0000727215,0.0017605311],"genre_scores_gemma":[0.9937365,0.0011293448,0.00015124957,0.000109973684,0.00003941085,0.00006741761,0.00013765291,0.000015673188,0.0046127643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987447,0.00012900193,0.00026635703,0.00045725665,0.00004017937,0.00036246443],"domain_scores_gemma":[0.99944305,0.00013350253,0.00009206702,0.0002578361,0.00004421632,0.00002933844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001146283,0.00026399185,0.00035754166,0.00010284601,0.0003035916,0.00004727131,0.000114095914,0.0003115736,0.00008153402],"category_scores_gemma":[0.000027926777,0.00021694544,0.00006551466,0.0001596402,0.00013898546,0.00016375295,0.00015577087,0.00011962816,0.000058176513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002499073,0.0002527716,0.016115878,0.00007719995,0.00031216917,0.000007820869,0.0012530877,9.420702e-7,0.9388014,0.000400336,0.0010596488,0.041468833],"study_design_scores_gemma":[0.0041722194,0.00027136604,0.044294756,0.000088429726,0.00033815982,0.000033826716,0.00019293044,0.000063434316,0.94493175,0.001080733,0.0042260457,0.00030635245],"about_ca_topic_score_codex":0.00010076364,"about_ca_topic_score_gemma":0.000034212248,"teacher_disagreement_score":0.04116248,"about_ca_system_score_codex":0.000042400607,"about_ca_system_score_gemma":0.00007500619,"threshold_uncertainty_score":0.8846778},"labels":[],"label_agreement":null},{"id":"W7117568617","doi":"10.64898/2025.12.29.696811","title":"Pre-Human Immunodeficiency Virus (HIV) infection Th17 CD4 <sup>+</sup> T cells as predictors of early HIV disease progression","year":2025,"lang":"","type":"article","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Cohort; Peripheral blood mononuclear cell; Cd4 t cell; Hazard ratio; Human immunodeficiency virus (HIV); T cell; Cohort study; Immunopathology; Immune system; Cytotoxic T cell","score_opus":0.007190728947215859,"score_gpt":0.2258522495259725,"score_spread":0.21866152057875662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117568617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798746,0.014185779,0.00022085734,0.00007121212,0.0024520496,0.001775132,0.0009597421,0.00036887274,0.00009176115],"genre_scores_gemma":[0.99676085,0.0019706425,0.000108301734,0.000054009175,0.00018810714,0.00032608828,0.0000058811966,0.00011654359,0.00046957293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946724,0.000930037,0.001387627,0.0015111691,0.00027219742,0.0012265339],"domain_scores_gemma":[0.9963277,0.00017958201,0.00085599464,0.0017963918,0.0005853264,0.000254985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072022266,0.0010664458,0.0010798991,0.0008436155,0.0011378847,0.00014866437,0.00074790977,0.0010861715,0.00056159595],"category_scores_gemma":[0.00020592535,0.0010635153,0.0005490356,0.00156474,0.00078577956,0.00052956026,0.00039552656,0.00066178356,0.0005519881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012296393,0.0020988865,0.2596256,0.00045216567,0.0010863524,0.000040468916,0.00012173069,0.00007353117,0.7340413,0.0007321671,0.00045340453,0.000044778284],"study_design_scores_gemma":[0.0025796948,0.0005961861,0.4378072,0.0009843815,0.0013330757,3.3203772e-8,0.000008918926,0.00005448287,0.5511917,0.000002809596,0.004804761,0.00063674216],"about_ca_topic_score_codex":0.00024067124,"about_ca_topic_score_gemma":0.000002675058,"teacher_disagreement_score":0.18284957,"about_ca_system_score_codex":0.00035961455,"about_ca_system_score_gemma":0.0011658084,"threshold_uncertainty_score":0.9991815},"labels":[],"label_agreement":null},{"id":"W7117888279","doi":"10.1136/flgastro-2025-103405","title":"Secukinumab-induced ulcerative colitis in a patient with psoriasis successfully treated with risankizumab","year":2025,"lang":"en","type":"article","venue":"Frontline Gastroenterology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Secukinumab; Psoriasis; Ulcerative colitis; Inflammatory bowel disease; Mesalazine; Ustekinumab; Ankylosing spondylitis; Colonoscopy","score_opus":0.006874119642387327,"score_gpt":0.21564630154049705,"score_spread":0.20877218189810973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117888279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589545,0.00022289298,0.00042600214,0.0005318097,0.00039015763,0.000737019,0.00014607093,0.00011146665,0.0015391068],"genre_scores_gemma":[0.99725306,0.000029003422,0.0003754867,0.0004577881,0.000029911555,0.00041219834,0.00041185936,0.000031816566,0.0009988548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973398,0.0005901508,0.00048184785,0.00070449745,0.000059155467,0.00082457485],"domain_scores_gemma":[0.99910593,0.00009579796,0.00020000737,0.00042569436,0.00012854234,0.000044013203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011205058,0.00047100807,0.00077682774,0.00043081568,0.00015631306,0.000020600271,0.0002459736,0.00028945206,0.00030064315],"category_scores_gemma":[0.000018879318,0.00034643104,0.00008991236,0.0003488957,0.0002038154,0.0001137215,0.00007989154,0.00032660953,0.00005867064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086827084,0.0020724682,0.8590095,0.00005172591,0.0039812643,0.0011691563,0.0018443379,0.00012685511,0.0048640035,0.00039443173,0.0033930398,0.036266144],"study_design_scores_gemma":[0.05419348,0.01927323,0.881488,0.0003726267,0.0010780493,0.0010160761,0.0016216214,0.000045039604,0.03336429,0.000106584914,0.0067485096,0.00069245],"about_ca_topic_score_codex":0.0010101075,"about_ca_topic_score_gemma":0.016199768,"teacher_disagreement_score":0.035573695,"about_ca_system_score_codex":0.00022465503,"about_ca_system_score_gemma":0.00012462056,"threshold_uncertainty_score":0.9998988},"labels":[],"label_agreement":null},{"id":"W7119257833","doi":"","title":"Association of periodontitis and psoriasis: a systematic review and meta-analysis","year":2022,"lang":"en","type":"article","venue":"LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Periodontitis; Odds ratio; Psoriasis; Retrospective cohort study; Prospective cohort study; Periodontal disease; Epidemiology; Odds","score_opus":0.023314585467464163,"score_gpt":0.23928376864365467,"score_spread":0.21596918317619052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7119257833","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14914872,0.75913703,0.00059836655,0.059486922,0.0016515832,0.0063688434,0.0027126404,0.000649871,0.020246029],"genre_scores_gemma":[0.9944033,0.0021764117,0.00022444985,0.00024119,0.000018583316,0.0008137103,0.0002298415,0.000017878878,0.0018746483],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99704516,0.0012779175,0.0006849326,0.00046272692,0.00021417976,0.000315067],"domain_scores_gemma":[0.9983736,0.00031903887,0.0006647553,0.0003717896,0.00019813354,0.0000726576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011305239,0.00027991636,0.0015366692,0.000358325,0.0005978669,0.000040754625,0.00023988589,0.0002066135,0.00029949244],"category_scores_gemma":[0.00036996437,0.00023873674,0.00053247996,0.00066644273,0.000015332465,0.00014316534,0.0002105654,0.00025719043,0.0000037999641],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003974219,0.0016932623,0.0041074078,0.03675471,0.48493347,0.00012629655,0.005564085,0.0000399531,0.006610571,0.4560019,0.0034266936,0.00034422384],"study_design_scores_gemma":[0.0023393463,0.00026614807,0.0057542818,0.00035714664,0.7451771,0.0014585784,0.0009916318,0.000018584737,0.0009912053,0.00015090518,0.24168904,0.00080602977],"about_ca_topic_score_codex":0.000003328759,"about_ca_topic_score_gemma":0.000078045756,"teacher_disagreement_score":0.84525454,"about_ca_system_score_codex":0.00024584436,"about_ca_system_score_gemma":0.00010540239,"threshold_uncertainty_score":0.9735402},"labels":[],"label_agreement":null},{"id":"W7120526647","doi":"","title":"Preventive and therapeutic effect of anti IL-17 in experimental model of pulmonary lesion induced by elastase in C57Bl6 mice","year":2019,"lang":"pt","type":"dissertation","venue":"Digital Library of Theses and Dissertations  (Universidade de São Paulo)","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Elastase; Therapeutic effect; In vitro; Enzyme inhibitor; Pancreatic elastase","score_opus":0.01220157735849658,"score_gpt":0.24058888506060683,"score_spread":0.22838730770211024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7120526647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903757,0.0058051916,0.000006304784,0.000019405847,0.00005663808,0.00068207196,0.0021777528,0.000010366,0.00086655153],"genre_scores_gemma":[0.9924383,0.00041531192,0.000019007057,0.000005362784,0.0000019598508,0.000016365027,0.0043489034,0.000034992034,0.0027198023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985451,0.00023426814,0.00046684066,0.00041865834,0.00007166058,0.00026347372],"domain_scores_gemma":[0.9987974,0.0004872764,0.00045111557,0.00019073924,0.000026106512,0.000047338843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007420395,0.00039767465,0.00078979525,0.00060305285,0.00007059807,0.000024708717,0.00020919235,0.00044629665,0.00004380091],"category_scores_gemma":[0.000017121445,0.00038825432,0.00018221232,0.000336992,0.00012426516,0.0008766881,0.0000691004,0.00018549428,0.0000024225137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057037263,0.001491692,0.068118796,0.00076417654,0.00051484193,0.000014724813,0.012829714,0.00009517559,0.89714974,0.00043092793,0.000011553457,0.012874913],"study_design_scores_gemma":[0.004218355,0.0018071498,0.14519937,0.0013112342,0.0004165914,0.000010868917,0.08638346,0.0015283941,0.75832003,0.00022802835,0.000005896337,0.0005705921],"about_ca_topic_score_codex":0.00010694139,"about_ca_topic_score_gemma":0.000023908173,"teacher_disagreement_score":0.1388297,"about_ca_system_score_codex":0.00002135271,"about_ca_system_score_gemma":0.000107417254,"threshold_uncertainty_score":0.99985695},"labels":[],"label_agreement":null},{"id":"W7125907176","doi":"10.2196/83697","title":"Efficacy and Safety of HuaShiXiaoYin Decoction Combined With Secukinumab In Moderate To Severe Plaque Psoriasis: A Study Protocol For a Randomized Controlled Trial (Preprint)","year":2025,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Randomized controlled trial; Secukinumab; Decoction; Protocol (science); Randomization; Clinical trial","score_opus":0.06734971314389039,"score_gpt":0.4474853152126152,"score_spread":0.3801356020687248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7125907176","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.105609804,0.0000024779395,0.00015460285,0.00016805579,0.000017858734,0.89356613,0.000013594006,0.000044915752,0.00042252784],"genre_scores_gemma":[0.079082385,3.6577148e-7,0.00013798218,0.000011611611,0.00002042485,0.9192273,0.000010847456,0.000021678543,0.0014874208],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935375,0.003992554,0.0010373608,0.00069667416,0.00016871515,0.00056718255],"domain_scores_gemma":[0.99596894,0.002808363,0.00023395946,0.00050862436,0.00042694397,0.000053195734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005431335,0.00032094994,0.0018368186,0.00065648824,0.0002770364,0.00006577972,0.0003027969,0.00027189677,0.000080045524],"category_scores_gemma":[0.00088803936,0.00021492226,0.00018156922,0.0005912403,0.00019229724,0.00010221003,0.00018794778,0.00037451624,0.000011714104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9838207,0.0056208004,0.00044230925,0.00031620276,0.00094494753,0.0000053625067,0.0013924353,0.00004618947,0.0014379579,0.00058005034,0.00030559482,0.0050874837],"study_design_scores_gemma":[0.97866,0.011702916,0.0006833769,0.0013862079,0.000046475543,0.0000025619345,0.0003917874,0.000039178147,0.0044327728,0.00046585468,0.001995743,0.00019310963],"about_ca_topic_score_codex":0.0000656171,"about_ca_topic_score_gemma":0.00025957124,"teacher_disagreement_score":0.026527422,"about_ca_system_score_codex":0.00013481824,"about_ca_system_score_gemma":0.0005045854,"threshold_uncertainty_score":0.87642753},"labels":[],"label_agreement":null},{"id":"W7133091752","doi":"","title":"More than Skin Deep: The Cutaneous Microbiome of Psoriasis and Psoriatic Arthritis","year":2023,"lang":"","type":"dissertation","venue":"TSpace","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Psoriatic arthritis; Microbiome; Exacerbation; Disease; Pathogenesis","score_opus":0.012479349131263142,"score_gpt":0.2753534334287793,"score_spread":0.2628740842975162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133091752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339047,0.05776524,0.000012717368,0.00052245206,0.005664715,0.0012218572,0.00032231724,0.00011148758,0.00047452928],"genre_scores_gemma":[0.90528035,0.04668198,0.00009964656,0.00006018476,0.00029757796,0.00020113116,0.0026365328,0.00018894678,0.04455362],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961235,0.00066987966,0.0010264086,0.0010687407,0.00015725818,0.0009541997],"domain_scores_gemma":[0.9965966,0.001042218,0.0010151926,0.0010138517,0.00024269831,0.00008947947],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003983411,0.0010407874,0.0015335904,0.00046488005,0.00074913393,0.00006603761,0.00064360624,0.0015478797,0.000686537],"category_scores_gemma":[0.00019374142,0.00083745806,0.00058455777,0.0008014836,0.0006680342,0.00007432057,0.00016566485,0.0006158826,0.0009207471],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033249648,0.0007667914,0.0011548946,0.0012830198,0.009645567,0.00034812646,0.1925854,0.000023603176,0.17386839,0.0003995119,0.003120197,0.61347955],"study_design_scores_gemma":[0.019618426,0.004166786,0.067748904,0.0049201366,0.015037265,0.0038221981,0.33949184,0.000077847784,0.5078411,0.0011937199,0.030620482,0.0054612537],"about_ca_topic_score_codex":0.0017092852,"about_ca_topic_score_gemma":0.0025983392,"teacher_disagreement_score":0.6080183,"about_ca_system_score_codex":0.000082964216,"about_ca_system_score_gemma":0.00022422055,"threshold_uncertainty_score":0.9998571},"labels":[],"label_agreement":null},{"id":"W7133213073","doi":"10.2310/6620.2010.00008i","title":"T Cells in Skin Health and Disease","year":2010,"lang":"en","type":"article","venue":"Dermatitis","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"","score_opus":0.008088203823309064,"score_gpt":0.2252439463890834,"score_spread":0.21715574256577433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133213073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994132,0.0024016106,0.000009510236,0.002119356,0.0005765919,0.00012092007,0.0000815814,0.000025539035,0.000532888],"genre_scores_gemma":[0.99716824,0.00031014156,0.0001098365,0.0017177033,0.000017017757,0.000017640074,0.00009738852,0.0000057197635,0.00055629225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995366,0.000063026084,0.000112116155,0.00011555067,0.0000108745635,0.00016187514],"domain_scores_gemma":[0.9997504,0.00003714473,0.000031151227,0.000117477925,0.000005868666,0.000058000533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000053205615,0.0000730442,0.00011330638,0.0000561914,0.00006422531,0.000007784286,0.00004672834,0.000060620347,0.00023875892],"category_scores_gemma":[0.000016210539,0.000066084256,0.000021724176,0.000046092693,0.000047773567,0.000045791192,0.000019462466,0.00009004617,0.00027787677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005765808,0.00048702813,0.27711844,0.00016320117,0.00012909931,0.00013392922,0.0052165184,0.0000011060163,0.04384876,0.004246127,0.13263081,0.53596735],"study_design_scores_gemma":[0.001852339,0.00005004505,0.7304418,0.000028435212,0.000016362284,0.000046464233,0.00010503548,0.0000054344823,0.014960176,0.00064979534,0.25165796,0.00018612664],"about_ca_topic_score_codex":0.00015234984,"about_ca_topic_score_gemma":0.0003826492,"teacher_disagreement_score":0.5357812,"about_ca_system_score_codex":0.000007231297,"about_ca_system_score_gemma":0.000053584234,"threshold_uncertainty_score":0.35716364},"labels":[],"label_agreement":null},{"id":"W7157266704","doi":"10.31083/ph.2021.1694","title":"&amp;quot;Gut-skin&amp;quot;axis: understanding psoriasis from the gut","year":2021,"lang":"en","type":"article","venue":"˜Die œPharmazie","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"Natural Science Foundation of Heilongjiang Province; Heilongjiang University","keywords":"Psoriasis; Pathogenesis; Mechanism (biology); Western medicine; Traditional Chinese medicine; Perspective (graphical); Large intestine","score_opus":0.08252809288389087,"score_gpt":0.2880196666683364,"score_spread":0.20549157378444552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7157266704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8909308,0.07096432,0.0020439187,0.004710448,0.01206624,0.0007932608,0.001589053,0.00063533644,0.016266676],"genre_scores_gemma":[0.9622152,0.004847224,0.0006179146,0.001671579,0.0010323653,0.00011603952,0.0025728869,0.00011138438,0.026815398],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685925,0.0006845696,0.0005523064,0.0008566899,0.00014741115,0.000899781],"domain_scores_gemma":[0.99754757,0.0009780538,0.00023051293,0.0010287695,0.000120761724,0.00009433509],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038678912,0.00055909797,0.0006265977,0.0001134117,0.0009036588,0.00011248053,0.0006159937,0.0004609776,0.007898005],"category_scores_gemma":[0.00014912504,0.00043500084,0.00045685237,0.00039741636,0.0002719404,0.00019741223,0.00031064614,0.00050012436,0.005759135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001307492,0.0011899482,0.01972425,0.00007204863,0.008407812,0.00030521292,0.010708991,0.000029927503,0.51844406,0.0034320604,0.36790574,0.068472475],"study_design_scores_gemma":[0.0058156783,0.00006686685,0.0071920604,0.00010634799,0.0013398507,0.00013110443,0.002665386,0.0000028475565,0.05094662,0.0031546673,0.927725,0.0008535418],"about_ca_topic_score_codex":0.00039851124,"about_ca_topic_score_gemma":0.0014933468,"teacher_disagreement_score":0.5598193,"about_ca_system_score_codex":0.00028290963,"about_ca_system_score_gemma":0.00019526435,"threshold_uncertainty_score":0.99981016},"labels":[],"label_agreement":null},{"id":"W7162127907","doi":"10.82308/44327","title":"Systemic agent use and mental health outcomes among patients with psoriasis","year":2023,"lang":"en","type":"dissertation","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Ustekinumab; Discontinuation; Cohort; Depression (economics); Rheumatoid arthritis; Retrospective cohort study; Cohort study","score_opus":0.016331188144654257,"score_gpt":0.24746667896838948,"score_spread":0.23113549082373522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7162127907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941117,0.0011579074,8.2674586e-7,0.000027362596,0.0029585562,0.0009530473,0.00042190676,0.0001833801,0.00018528054],"genre_scores_gemma":[0.8782701,0.000911975,0.0000332051,0.00006169949,0.000018527164,0.0001498586,0.0251472,0.00008338626,0.09532407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984889,0.00016268204,0.00038762082,0.00050277147,0.00007483031,0.00038321275],"domain_scores_gemma":[0.99919474,0.00010271835,0.00031321507,0.00026893936,0.00007133639,0.000049046637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009832264,0.00043238833,0.0006703306,0.00021599802,0.00029652016,0.000042565505,0.00011192072,0.00038806992,0.00013770297],"category_scores_gemma":[0.000018947536,0.00029650808,0.00011338223,0.00012105292,0.000044492834,0.000118106866,0.000027891214,0.00015274384,0.00029046345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039050877,0.00016459798,0.97600645,0.00018499554,0.0016888082,0.0000039872284,0.001919214,2.3350303e-7,0.0000689026,0.000034228757,0.0060700653,0.013468031],"study_design_scores_gemma":[0.0028650968,0.00027174497,0.99353015,0.00025893544,0.00021863802,0.0000036048973,0.001646486,1.373119e-7,0.00021371375,0.000002589596,0.0006674215,0.00032146848],"about_ca_topic_score_codex":0.001538487,"about_ca_topic_score_gemma":0.0035961322,"teacher_disagreement_score":0.11584166,"about_ca_system_score_codex":0.00011100357,"about_ca_system_score_gemma":0.00007599915,"threshold_uncertainty_score":0.9999487},"labels":[],"label_agreement":null},{"id":"W72872560","doi":"","title":"An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.","year":2011,"lang":"en","type":"article","venue":"PubMed","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Psoriasis; Plaque psoriasis; Clinical trial; Internal medicine; Dermatology; Disease; Tumor necrosis factor alpha","score_opus":0.06942821123408488,"score_gpt":0.2916433299972708,"score_spread":0.2222151187631859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W72872560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861471,0.00006166199,0.0000032966664,0.00017020063,0.0001321804,0.013071509,0.00021660562,0.000011938347,0.00018550537],"genre_scores_gemma":[0.9936804,0.000024110253,0.0000453815,0.0001416817,0.000010022018,0.005735223,0.00003154352,0.000025125057,0.0003064883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99572486,0.0025178536,0.0005455656,0.000623032,0.00012118723,0.0004674809],"domain_scores_gemma":[0.9985681,0.00032771795,0.00011661414,0.00077203254,0.00012926906,0.00008627495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018488119,0.00031884844,0.0006226486,0.00022286209,0.00014899354,0.00002664024,0.00056719326,0.00008057091,0.000026679498],"category_scores_gemma":[0.00011812044,0.00019202422,0.000025196317,0.00035640414,0.00007290093,0.00014950674,0.00012822417,0.000095751915,0.000013071816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26293406,0.02596887,0.487032,0.0000045589854,0.0007624246,0.00001339925,0.12718362,0.00009361075,0.0011902576,0.00005264704,0.0000328771,0.09473168],"study_design_scores_gemma":[0.018236388,0.024833707,0.9486658,0.000014613431,0.0002243879,0.0000022227173,0.0025105616,0.0000031650989,0.005241712,0.000020755808,0.00003756514,0.0002091084],"about_ca_topic_score_codex":0.0026859469,"about_ca_topic_score_gemma":0.004781223,"teacher_disagreement_score":0.46163383,"about_ca_system_score_codex":0.00019334382,"about_ca_system_score_gemma":0.00005485497,"threshold_uncertainty_score":0.7830521},"labels":[],"label_agreement":null},{"id":"W750040606","doi":"","title":"Ustekinumab in the treatment of psoriasis","year":2015,"lang":"en","type":"article","venue":"Journal of symptoms and signs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ustekinumab; Medicine; Psoriatic arthritis; Psoriasis; Placebo; Randomized controlled trial; Clinical trial; Secukinumab; Dermatology; Internal medicine; Disease; Adalimumab; Pathology; Alternative medicine","score_opus":0.034403699488213695,"score_gpt":0.25994316459705097,"score_spread":0.22553946510883727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W750040606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988424,0.010306809,0.000012704156,0.00017437548,0.00040309865,0.00007940966,0.000008021091,0.0000020406399,0.0005895193],"genre_scores_gemma":[0.99861556,0.0009623774,0.00003956484,0.000024835226,0.00006997875,0.0000032825465,0.0000030772665,0.0000042742076,0.00027706035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993216,0.00015048594,0.0002964987,0.000066316796,0.000044647855,0.00012047835],"domain_scores_gemma":[0.9994921,0.00013360278,0.00018992844,0.000099877514,0.00006279983,0.000021661524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028911702,0.00009689758,0.00027828699,0.000104289764,0.000030915908,0.000007499039,0.00009820557,0.00008838052,0.00004224051],"category_scores_gemma":[0.00001731537,0.00005042732,0.000099242454,0.000089504465,0.000060812865,0.00005776648,0.0000062195527,0.000054054522,0.00000777567],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032694093,0.005130761,0.23942935,0.000031919844,0.00257674,0.00030743587,0.062109906,0.00006276042,0.07437033,0.0022774644,0.006670271,0.60376364],"study_design_scores_gemma":[0.078863196,0.061139215,0.32688376,0.00035634812,0.0029016621,0.004425447,0.032024734,0.000012618824,0.11525349,0.0040021166,0.3730975,0.0010398795],"about_ca_topic_score_codex":0.000052504485,"about_ca_topic_score_gemma":0.000017528333,"teacher_disagreement_score":0.6027238,"about_ca_system_score_codex":0.00003630366,"about_ca_system_score_gemma":0.0000541181,"threshold_uncertainty_score":0.20563664},"labels":[],"label_agreement":null},{"id":"W823422456","doi":"10.1056/nejmoa1501646","title":"A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":298,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Placebo; Adalimumab; Internal medicine; Clinical endpoint; Randomization; Gastroenterology; Plaque psoriasis; Surgery; Randomized controlled trial; Dermatology; Tumor necrosis factor alpha; Pathology","score_opus":0.07114551676151244,"score_gpt":0.32843984908404084,"score_spread":0.2572943323225284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W823422456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97659695,0.0074494164,0.0008762436,0.0022137826,0.011616333,0.00038091047,0.00004287697,0.000014206034,0.000809254],"genre_scores_gemma":[0.9946369,0.00038969697,0.00041668434,0.00004601846,0.0037106671,0.000006391284,0.00005121215,0.000015972379,0.0007264933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99874294,0.0001859731,0.00063939946,0.00011657868,0.00011076433,0.00020434993],"domain_scores_gemma":[0.998239,0.0006796461,0.00053106656,0.00016207623,0.00027822837,0.00011002682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010717914,0.0001627709,0.00065407413,0.00019220935,0.000041510466,0.000002879645,0.00018850915,0.00015749906,0.00016142562],"category_scores_gemma":[0.0008820172,0.00010478037,0.00015237286,0.00011022339,0.00010044453,0.00007152436,0.000013845856,0.00014704326,0.000008600085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57019967,0.000699604,0.000029648481,0.000015268068,0.0011388968,0.000032226664,0.0019173467,0.0000061636592,0.0118929595,0.00024009372,0.045837477,0.36799067],"study_design_scores_gemma":[0.7795992,0.027731694,0.000009601558,0.00007335061,0.0008513324,0.00017666185,0.00035777525,0.0000013141171,0.0118970545,0.00036756904,0.1788536,0.00008085017],"about_ca_topic_score_codex":0.00006813944,"about_ca_topic_score_gemma":0.000027297476,"teacher_disagreement_score":0.36790982,"about_ca_system_score_codex":0.000047655027,"about_ca_system_score_gemma":0.0003345462,"threshold_uncertainty_score":0.42728195},"labels":[],"label_agreement":null},{"id":"W83713607","doi":"10.2165/11587890-000000000-00000","title":"The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis","year":2011,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Western University","funders":"Allergan; Genentech; LEO Pharma; Medac; Mitsubishi Tanabe Pharma Corporation; Cilag; Astellas Pharma; Novo Nordisk; Incyte; University of Connecticut; Abbott Laboratories; Zalicus; Biogen; Celgene; Amgen; Pfizer; Galderma; Eli Lilly and Company; GlaxoSmithKline; Eisai","keywords":"Adalimumab; Medicine; Adverse effect; Psoriasis; Placebo; Population; Clinical trial; Internal medicine; Dosing; Incidence (geometry); Dermatology; Pathology; Disease","score_opus":0.07252126911291348,"score_gpt":0.3763919246789039,"score_spread":0.30387065556599047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W83713607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014674985,0.9819727,0.000038245027,0.00023736198,0.0021411069,0.00057894556,0.00008823605,0.000010657847,0.00025778526],"genre_scores_gemma":[0.013737376,0.98548573,0.00014673443,0.00008372801,0.00011353831,0.000043988737,0.000036955702,0.000046401547,0.00030556988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99071527,0.0037898044,0.004416958,0.00042198127,0.00007148864,0.00058450195],"domain_scores_gemma":[0.9908939,0.0044602435,0.0036741442,0.0006515959,0.0001889813,0.00013113924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009068361,0.0005862849,0.0061750384,0.00034931322,0.00011895713,0.000010318662,0.0008674484,0.0006195624,0.00010939341],"category_scores_gemma":[0.00037925987,0.0003300969,0.0017913596,0.00041989106,0.0008151295,0.00005765078,0.00012718102,0.0007079658,0.00019000642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020239097,0.0005075529,0.0033851818,0.00018322625,0.0031502307,0.00023870947,0.00015186812,9.518718e-7,3.9922324e-7,0.00013753207,0.00018725597,0.9900332],"study_design_scores_gemma":[0.0041859304,0.003072632,0.0034500365,0.0021664912,0.0032783705,0.0058135143,0.000112607544,1.4048885e-7,0.000027415668,0.00004821555,0.9774058,0.00043887034],"about_ca_topic_score_codex":0.00009337554,"about_ca_topic_score_gemma":0.00020367722,"teacher_disagreement_score":0.98959434,"about_ca_system_score_codex":0.00012175771,"about_ca_system_score_gemma":0.0011125811,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W839775831","doi":"10.1007/s40257-015-0141-9","title":"23rd World Congress of Dermatology: Vancouver, Canada, June 8–13, 2015","year":2015,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dermatology; Pharmacotherapy; Family medicine; Internal medicine","score_opus":0.03432645344616939,"score_gpt":0.3251040620749621,"score_spread":0.2907776086287927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W839775831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96406543,0.0050772117,0.00010056675,0.007425639,0.021730788,0.00014847054,0.00006014591,0.0000236063,0.0013681183],"genre_scores_gemma":[0.99601424,0.00022887973,0.00048713898,0.00085077464,0.0001146344,0.0000042085517,0.0000176799,0.000024181027,0.0022582365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511176,0.0015204626,0.0024156831,0.0002775581,0.00014354374,0.0005310061],"domain_scores_gemma":[0.99464446,0.0015829736,0.002483943,0.00039223573,0.00064354687,0.00025284232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005315555,0.0002974251,0.002237646,0.00026884367,0.00006410708,0.0000049076625,0.0006002064,0.00025198126,0.0001534988],"category_scores_gemma":[0.0008512698,0.00023702733,0.00037569457,0.0003920346,0.0014666343,0.00011371658,0.00010411458,0.0006117523,0.000064023014],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015651163,0.00041279962,0.22259037,0.000015167662,0.001391063,0.0012574715,0.00009607875,0.000009899776,0.0001549417,0.00022069144,0.74814105,0.024145365],"study_design_scores_gemma":[0.011775189,0.0010142614,0.022977049,0.000090504385,0.00086679077,0.011800716,0.0014333305,0.000008008006,0.010739469,0.0003494652,0.93842953,0.00051566056],"about_ca_topic_score_codex":0.015937801,"about_ca_topic_score_gemma":0.25056624,"teacher_disagreement_score":0.23462845,"about_ca_system_score_codex":0.00006109633,"about_ca_system_score_gemma":0.0024172426,"threshold_uncertainty_score":0.9906151},"labels":[],"label_agreement":null},{"id":"W856372086","doi":"10.71781/30603","title":"Effects of interleukin-27 on human CD8 T Cells","year":2008,"lang":"en","type":"dissertation","venue":"Open MIND","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interleukin 15; Interleukin; Immunology; Biology; Cytokine","score_opus":0.02610087053106895,"score_gpt":0.2967005766449282,"score_spread":0.27059970611385925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W856372086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93843246,0.0012446318,1.7958862e-7,0.000002651814,0.0021075231,0.00062431645,0.00007989625,0.0000022389188,0.057506096],"genre_scores_gemma":[0.7354185,0.00019836485,0.00006078211,0.000010824007,0.00004259441,0.0000483662,0.004170407,0.000035022127,0.26001516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893314,0.00014497942,0.0002942106,0.0003840189,0.00003463845,0.00020899856],"domain_scores_gemma":[0.99921656,0.00014340066,0.00028634668,0.0002913867,0.00004551222,0.000016782751],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006884359,0.00029144215,0.0005332797,0.00014209498,0.00012349573,0.00001587048,0.0004792741,0.0005548198,0.0024610881],"category_scores_gemma":[0.000014527152,0.00025433072,0.0001453421,0.000079271704,0.000048093625,0.000043278986,0.000045482037,0.00019469825,0.0031899798],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005839379,0.0004509044,0.00005069397,0.000070292626,0.0005967409,0.00005168325,0.0021434866,2.901422e-7,0.893402,0.00001386584,0.0054252134,0.09721092],"study_design_scores_gemma":[0.0015641957,0.0005187606,0.0018200054,0.0003125757,0.00029476747,0.000005561755,0.00017823926,1.7314203e-8,0.9524151,0.000008002802,0.042661265,0.00022149144],"about_ca_topic_score_codex":0.00010271239,"about_ca_topic_score_gemma":0.00019019823,"teacher_disagreement_score":0.20301399,"about_ca_system_score_codex":0.00003427376,"about_ca_system_score_gemma":0.000080511774,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W89469982","doi":"10.2165/11539360-000000000-00000","title":"Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Psoriasis; Quality of life (healthcare); Pharmacotherapy; Placebo; Intensive care medicine; Internal medicine; Physical therapy; Alternative medicine; Dermatology; Disease","score_opus":0.050805862688002475,"score_gpt":0.3349130731399031,"score_spread":0.2841072104519006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W89469982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707586,0.0006700379,0.0000016580044,0.00029037727,0.0013906076,0.00045580196,0.000039226958,0.0000219097,0.000054510478],"genre_scores_gemma":[0.9992701,0.0003751786,0.0001228642,0.000067606656,0.000028160637,0.00001596823,0.00008256309,0.000013235448,0.000024327917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616045,0.0018921682,0.0013453441,0.0003102083,0.00007802518,0.00021378073],"domain_scores_gemma":[0.99078965,0.007651804,0.0011374151,0.00027163315,0.000058042,0.0000914372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022741554,0.00018037228,0.0007241764,0.00017426962,0.0000615877,0.000002940691,0.00010659723,0.00039130516,0.000015902897],"category_scores_gemma":[0.0056575104,0.00015519967,0.00014203733,0.00021115418,0.0004606158,0.00005164837,0.000031257707,0.0004933684,0.000016833912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028584788,0.0016881563,0.7600203,0.0007690403,0.0014515258,0.0000042047604,0.0059940554,0.00014771099,0.13494815,0.008842175,0.00035035558,0.057199504],"study_design_scores_gemma":[0.019213125,0.0017058294,0.8329498,0.0004432156,0.00015018659,6.819697e-7,0.00013303226,0.000022423703,0.14412963,0.0010492093,0.00003154788,0.00017128458],"about_ca_topic_score_codex":0.0011766966,"about_ca_topic_score_gemma":0.0004890598,"teacher_disagreement_score":0.072929494,"about_ca_system_score_codex":0.000035413013,"about_ca_system_score_gemma":0.00018343473,"threshold_uncertainty_score":0.67729765},"labels":[],"label_agreement":null}]}